NCT Number,Study Title,Study URL,Study Status,Conditions,Interventions,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Start Date,Primary Completion Date,Completion Date,Locations
NCT04447937,Immunodeficiency in MS,https://beta.clinicaltrials.gov/study/NCT04447937,UNKNOWN,"Multiple Sclerosis|Hypogammaglobulinemia|Immunodeficiency|Infection, Bacterial",OTHER: No Interventions,Advanced Neurosciences Institute,Novel Pharmaceutics Institute,ALL,"ADULT, OLDER_ADULT",,1500,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-06-29,2021-01-30,2021-07-30,"Advanced Neurosciences Institute, Franklin, Tennessee, 37064, United States"
NCT00942214,Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment,https://beta.clinicaltrials.gov/study/NCT00942214,COMPLETED,Multiple Sclerosis,DRUG: Natalizumab,"University Hospital, Toulouse",,ALL,ADULT,PHASE4,300,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2009-06,2011-02,2011-03,"service de neurologie, hôpital Purpan, Toulouse, 31059, France"
NCT05562414,Transient and Immediate Motor Effects of Exercise in Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05562414,RECRUITING,"Multiple Sclerosis, Chronic Progressive|High-Intensity Interval Training|Motor Symptoms",BEHAVIORAL: HIIT|BEHAVIORAL: MCT,Klinik Valens,,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-10-01,2023-04-01,2023-04-01,"Klinik Valens, Valens rehabilitation clinic, Valens, Sankt Gallen, 7317, Switzerland"
NCT05090033,Characterizing the Use of Ofatumumab in a Real World Setting,https://beta.clinicaltrials.gov/study/NCT05090033,RECRUITING,Relapsing Multiple Sclerosis,OTHER: ofatumumab,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",,3500,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-12-08,2025-06-30,2025-06-30,"Novartis Investigative Site, Concord, New South Wales, 2139, Australia|Novartis Investigative Site, Southport, Queensland, 4222, Australia|Novartis Investigative Site, Box Hill, Victoria, 3128, Australia|Novartis Investigative Site, Melbourne, Victoria, 3004, Australia|Novartis Investigative Site, Nedlands, Western Australia, 6009, Australia|Novartis Investigative Site, Heidelberg, 3084, Australia"
NCT00883337,A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00883337,COMPLETED,Multiple Sclerosis,DRUG: Interferon β-1a|DRUG: Teriflunomide,Sanofi,,ALL,"ADULT, OLDER_ADULT",PHASE3,324,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2009-04,2011-09,2015-05,"Investigational Site Number 056003, Bruxelles, 1070, Belgium|Investigational Site Number 056001, Gent, 9000, Belgium|Investigational Site Number 056002, Hasselt, B-3590, Belgium|Investigational Site Number 124002, London, N6A 5A5, Canada|Investigational Site Number 124003, Lévis, G6V 3Z1, Canada|Investigational Site Number 124004, St. John'S, A1B 3V6, Canada|Investigational Site Number 203004, Jihlava, 58633, Czech Republic|Investigational Site Number 203003, Praha 10, 10034, Czech Republic|Investigational Site Number 203002, Praha 2, 12808, Czech Republic|Investigational Site Number 250003, Bordeaux Cedex, 33076, France|Investigational Site Number 250005, Clermont Ferrand Cedex 1, 63003, France|Investigational Site Number 250004, Lille Cedex, 59037, France|Investigational Site Number 250001, Montpellier Cedex 5, 34000, France|Investigational Site Number 250002, Strasbourg Cedex, 67091, France|Investigational Site Number 276003, Bad Mergentheim, 97980, Germany|Investigational Site Number 276011, Berlin, 10117, Germany|Investigational Site Number 276012, Berlin, 12099, Germany|Investigational Site Number 276001, Bochum, 44791, Germany|Investigational Site Number 276005, Dresden, 01307, Germany|Investigational Site Number 276007, Erbach, 64711, Germany|Investigational Site Number 276006, Essen, 45138, Germany|Investigational Site Number 276004, Halle/Saale, 06120, Germany|Investigational Site Number 276010, Hannover, 30559, Germany|Investigational Site Number 276009, Mainz, 55131, Germany|Investigational Site Number 276002, Münster, 48149, Germany|Investigational Site Number 300001, Athens, 11527, Greece|Investigational Site Number 300002, Thessaloniki, Greece|Investigational Site Number 348001, Budapest, 1083, Hungary|Investigational Site Number 348005, Budapest, 1096, Hungary|Investigational Site Number 348003, Budapest, 1106, Hungary|Investigational Site Number 348002, Esztergom, 2500, Hungary|Investigational Site Number 348007, Kecskemét, 6000, Hungary|Investigational Site Number 348004, Veszprém, 8200, Hungary|Investigational Site Number 380010, Ancona, 60020, Italy|Investigational Site Number 380005, Bari, 70124, Italy|Investigational Site Number 380008, Cagliari, 09126, Italy|Investigational Site Number 380003, Cefalù, 90015, Italy|Investigational Site Number 380007, Genova, 16132, Italy|Investigational Site Number 380001, Milano, 20132, Italy|Investigational Site Number 380004, Pavia, 27100, Italy|Investigational Site Number 380002, Roma, 00185, Italy|Investigational Site Number 380006, Torino, 10126, Italy|Investigational Site Number 616002, Bialystok, 15-276, Poland|Investigational Site Number 616004, Gdansk, 80-803, Poland|Investigational Site Number 616003, Lublin, 20-718, Poland|Investigational Site Number 616001, Warszawa, 02-957, Poland|Investigational Site Number 724007, Barcelona, 08036, Spain|Investigational Site Number 724001, Bilbao, 48013, Spain|Investigational Site Number 724002, Majadahonda, 28222, Spain|Investigational Site Number 724003, Murcia, 30120, Spain|Investigational Site Number 756002, St. Gallen, 9007, Switzerland|Investigational Site Number 788002, Monastir, 5000, Tunisia|Investigational Site Number 826002, London, SW17 0QT, United Kingdom|Investigational Site Number 826003, Plymouth, PL6 5BX, United Kingdom"
NCT01018537,NARCOMS Registry: A Multiple Sclerosis Registry,https://beta.clinicaltrials.gov/study/NCT01018537,RECRUITING,Multiple Sclerosis,,University of Texas Southwestern Medical Center,Consortium of Multiple Sclerosis Centers,ALL,"ADULT, OLDER_ADULT",,50000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,1996-01,2050-12,2050-12,"UT Southwestern Medical Center, Dallas, Texas, 75390-8806, United States"
NCT03249714,Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab,https://beta.clinicaltrials.gov/study/NCT03249714,COMPLETED,Relapsing Multiple Sclerosis,DRUG: Ofatumumab|DRUG: Matching placebo of ofatumumab,Novartis Pharmaceuticals,,ALL,ADULT,PHASE2,64,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-03-15,2019-12-26,2020-07-29,"Novartis Investigative Site, Toon-city, Ehime, 791-0295, Japan|Novartis Investigative Site, Fukuoka city, Fukuoka, 812-8582, Japan|Novartis Investigative Site, Sapporo city, Hokkaido, 063-0005, Japan|Novartis Investigative Site, Morioka, Iwate, 020-8505, Japan|Novartis Investigative Site, Sendai city, Miyagi, 980 8574, Japan|Novartis Investigative Site, Sendai city, Miyagi, 983 8512, Japan|Novartis Investigative Site, Kawagoe, Saitama, 350 8550, Japan|Novartis Investigative Site, Kodaira, Tokyo, 187-8551, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, 160 8582, Japan|Novartis Investigative Site, Chiba, 260 8677, Japan|Novartis Investigative Site, Niigata, 951 8520, Japan|Novartis Investigative Site, Osaka, 556-0016, Japan|Novartis Investigative Site, Kazan, 420021, Russian Federation|Novartis Investigative Site, Novosibirsk, 630007, Russian Federation"
NCT02833714,Teriflunomide's Therapeutic Mechanisms of Action in Patients With Relapsing Remitting Multiple Sclerosis.,https://beta.clinicaltrials.gov/study/NCT02833714,TERMINATED,RELAPSING REMITTING MULTIPLE SCLEROSIS,,"University of North Carolina, Chapel Hill","Genzyme, a Sanofi Company",ALL,ADULT,,26,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-01,2016-12-21,2016-12-21,"University of North Carolina, Chapel Hill, North Carolina, 27599, United States"
NCT04132037,An Observational Study on Intermittent Self Catheterisation Discontinuation Factors in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT04132037,UNKNOWN,Multiple Sclerosis,OTHER: data record,"University Hospital, Toulouse",French Association for Research on Multiple Sclerosis,ALL,"ADULT, OLDER_ADULT",,225,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-06-26,2021-12,2022-12,"UHToulouse, Toulouse, 31059, France"
NCT05809414,Amantadine and Transcranial Magnetic Stimulation for Treating Fatigue in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05809414,RECRUITING,Multiple Sclerosis|Fatigue,DEVICE: Transcranial Magnetic Stimulation|DRUG: Amantadine Hydrochloride 100 mg (milligrams) Oral Capsule,"Hospital San Carlos, Madrid",,ALL,"ADULT, OLDER_ADULT",PHASE3,144,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-11-28,2024-07-15,2025-02-28,"Hospital Puerta del Mar, Cadiz, 11009, Spain|Hospital General Gregorio Marañon, Madrid, 28007, Spain|Hospital Clínico San Carlos, Madrid, 28040, Spain|Hospitalario Universitario Nuestra Señora de la Candelaria, Santa Cruz De Tenerife, 38010, Spain"
NCT00168714,Pregnancy Exposure Registry for Avonex (Interferon Beta-1a),https://beta.clinicaltrials.gov/study/NCT00168714,COMPLETED,Prenatal Exposure Delayed Effects|Multiple Sclerosis|Pregnancy,DRUG: BG9418 (interferon beta-1a),Biogen,,FEMALE,"CHILD, ADULT, OLDER_ADULT",,329,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2004-02,2011-09,2011-09,"Kendle, Wilmington, North Carolina, 28405, United States"
NCT03166007,Abdominal Massage for Bowel Dysfunction,https://beta.clinicaltrials.gov/study/NCT03166007,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Abdominal massage|BEHAVIORAL: Optimised bowel care,Glasgow Caledonian University,,ALL,"ADULT, OLDER_ADULT",NA,191,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2014-06,2017-01,2017-03,"Glasgow Caledonian University - NMAHP RU, Glasgow, Glasgow city of, G4 0BA, United Kingdom"
NCT01803867,An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01803867,COMPLETED,Multiple Sclerosis,DRUG: rHIgM22,Acorda Therapeutics,PRA Health Sciences,ALL,"ADULT, OLDER_ADULT",PHASE1,72,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-03,2014-10,2015-01,"Acorda Investigational Site, Long Beach, California, 90806, United States|Acorda Investigational Site, Palo Alto, California, 04158, United States|Acorda Investigational Site, Sacramento, California, 95817, United States|Acorda Investigational Site, Stanford, California, 94305-5235, United States|Acorda Investigational Site, Aurora, Colorado, 80045, United States|Acorda Investigational Site, Centennial, Colorado, 80112, United States|Acorda Investigational Site, Indianapolis, Indiana, 46202, United States|Acorda Investigational Site, Kansas City, Kansas, 66160, United States|Acorda Investigational Site, Baltimore, Maryland, 22125, United States|Acorda Investigational Site, St. Louis, Missouri, 63131, United States|Acorda Investigational Site, Rochester, New York, 14642, United States|Acorda Investigational Site, Providence, Rhode Island, 02905, United States|Acorda Investigational Site, Knoxville, Tennessee, 37920, United States|Acorda Investigational Site, Dallas, Texas, 75390-9036, United States|Acorda Investigational Site, Burlington, Vermont, 05401, United States|Acorda Investigational Site, Seattle, Washington, 98101, United States|Acorda Investigational Site, Seattle, Washington, 98122, United States"
NCT04300543,MicroRNA-150 and microRNA-155 in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04300543,UNKNOWN,Multiple Sclerosis,,Assiut University,,ALL,"ADULT, OLDER_ADULT",,140,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-04,2021-04,2021-10,
NCT02727907,Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02727907,COMPLETED,Multiple Sclerosis,DRUG: BCD-033 (interferon beta 1a)|DRUG: Rebif (interferon beta 1a)|DRUG: Placebo,Biocad,,ALL,ADULT,PHASE2|PHASE3,163,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2015-02-12,2016-11-21,2017-08-11,"Scientific neurology center, RAS, Moscow, Russian Federation"
NCT00619307,Transition to Rebif New Formulation,https://beta.clinicaltrials.gov/study/NCT00619307,COMPLETED,Relapsing Multiple Sclerosis,DRUG: Rebif New Formulation + prophylactic Ibuprofen|DRUG: Rebif New Formulation + ibuprofen PRN,"Merck KGaA, Darmstadt, Germany",,ALL,ADULT,PHASE3,117,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2007-07,2008-04,2008-04,"Local Medical Information, Paris, France|Local Medical Information, Munich, Germany"
NCT00668343,Simvastatin in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Using Avonex Compared to Placebo,https://beta.clinicaltrials.gov/study/NCT00668343,COMPLETED,Relapsing Remitting Multiple Sclerosis,DRUG: simvastatin|DRUG: placebo,Tehran University of Medical Sciences,,ALL,"CHILD, ADULT",PHASE3,80,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2005-04,2008-03,2009-03,"Sanaz Ahmadi, Tehran, 0098, Iran, Islamic Republic of"
NCT01201707,Evaluation of Angioplasty in the Treatment of Chronic Cerebrospinal Venous Insufficiency (CCSVI) in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01201707,TERMINATED,Multiple Sclerosis,PROCEDURE: Angioplasty|OTHER: Observation,"Community Care Physicians, P.C.",,ALL,ADULT,NA,18,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2010-08,2013-09,2013-09,"Albany Medical Center, Albany, New York, 12208, United States|Image Care Latham, Latham, New York, 12110, United States"
NCT02609607,Treating Anorectal Dysfunction in MS,https://beta.clinicaltrials.gov/study/NCT02609607,TERMINATED,Constipation|Fecal Incontinence|Multiple Sclerosis,DRUG: Bisacodyl|OTHER: Placebo,David Levinthal,Consortium of Multiple Sclerosis Centers,ALL,"ADULT, OLDER_ADULT",PHASE2,11,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2016-06,2018-11,2018-12,"University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, 15213, United States"
NCT01864707,Acupuncture or MBSR for Patients With Fatigue and MS,https://beta.clinicaltrials.gov/study/NCT01864707,COMPLETED,Fatigue|Multiple Sclerosis,OTHER: Usual care + acupuncture|OTHER: usual care+mbsr|OTHER: usual care,"Charite University, Berlin, Germany",,ALL,"ADULT, OLDER_ADULT",NA,104,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2013-04,2015-06,2015-10,"The NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, Berlin, 10117, Germany"
NCT00755807,Duloxetine for Multiple Sclerosis Pain,https://beta.clinicaltrials.gov/study/NCT00755807,COMPLETED,Multiple Sclerosis,DRUG: Duloxetine Hydrochloride (HCI)|DRUG: Placebo,Eli Lilly and Company,,ALL,"ADULT, OLDER_ADULT",PHASE3,239,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2008-10,2010-08,2010-11,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, Alabama, 35294, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Phoenix, Arizona, 85018, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tucson, Arizona, 85741, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aurora, Colorado, 80045, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Denver, Colorado, 80204, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bradenton, Florida, 34205, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lenexa, Kansas, 66214, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roseville, Michigan, 48066, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St Louis, Missouri, 63141, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charlotte, North Carolina, 28207, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bismarck, North Dakota, 58501, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Akron, Ohio, 44320, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cincinnati, Ohio, 45219, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oklahoma City, Oklahoma, 73109, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Portland, Oregon, 97225, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Allentown, Pennsylvania, 18102, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Melsbroek, 1820, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Winnipeg, Manitoba, R3A 1R9, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greenfield Park, Quebec, J4V 2J2, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lublin, 20-090, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Szczecin, 70-215, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wroclaw, 50-556, Poland"
NCT05007483,Efficacy of Diet on Quality of Life in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05007483,RECRUITING,"Multiple Sclerosis, Relapsing-Remitting",DIETARY_SUPPLEMENT: BodyBio Balance Oil|DIETARY_SUPPLEMENT: Kirunal Fish Oil|DIETARY_SUPPLEMENT: BodyBio PC|BEHAVIORAL: Modified Paleolithic Elimination diet|BEHAVIORAL: Time Restricted Olive Oil Based (TROO) Ketogenic Diet|BEHAVIORAL: Usual diet with Dietary Guidelines for Americans Diet information,Terry L. Wahls,,ALL,"ADULT, OLDER_ADULT",NA,156,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2022-02-10,2025-03-01,2026-03-01,"Univeristy of Iowa, Iowa City, Iowa, 52246, United States"
NCT05242133,Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05242133,COMPLETED,Relapsing Remitting Multiple Sclerosis (RRMS),DRUG: Pegylated interferon beta-1a|DRUG: Interferon Beta-1A Prefilled Syringe,Cinnagen,,ALL,ADULT,PHASE3,168,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2017-12-20,2022-04-27,2022-04-27,"Sina Hospital, Tehran, Iran, Islamic Republic of"
NCT01704183,Effect of Fingolimod on the Cardiac Autonomic Regulation in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01704183,COMPLETED,Relapse-remitting Multiple Sclerosis,,Kuopio University Hospital,,ALL,"ADULT, OLDER_ADULT",,27,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-12,2014-03,2014-03,"Neuro Center, Kuopio University Hospital, Kuopio, Finland|Department of Neurology, Mikkeli Central Hospital, Mikkeli, Finland"
NCT00617383,AT RISK FOR MS - Clinical Conversion of Female Monozygotic Twins Discordant for CIS/MS,https://beta.clinicaltrials.gov/study/NCT00617383,COMPLETED,Multiple Sclerosis|Clinically Isolated Syndrome,,"The University of Texas Health Science Center, Houston",National Multiple Sclerosis Society,FEMALE,"CHILD, ADULT",,3,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2008-02,2010-12,2010-12,"University of Texas - Houston, Houston, Texas, 77030, United States"
NCT03785483,Implementation Intention for Physical Activity in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03785483,UNKNOWN,Motivation|Mindfulness,BEHAVIORAL: Motivation,University of Paris 5 - Rene Descartes,CeRSM|COMUE|Poissy-Saint Germain Hospital|Hôpital Raymond Poincaré|Paris West University Nanterre La Défense|Cite Sep,ALL,"ADULT, OLDER_ADULT",NA,45,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2018-12-30,2019-06-15,2019-06-30,"Hôpital Raymond-Poincaré, Garches, 92380, France|CHU Poissy Saint germain, Poissy, 78300, France"
NCT05062083,PET Imaging of Cyclooxygenase-2 in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05062083,RECRUITING,Multiple Sclerosis,DRUG: 11C-MCI|DRUG: 11C-PS13,National Institute of Mental Health (NIMH),University of Maryland,ALL,"ADULT, OLDER_ADULT",PHASE2,16,NIH,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-06-07,2025-04-11,2025-04-11,"National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States"
NCT02644083,Tecfidera and MRI for Brain Energy in MS,https://beta.clinicaltrials.gov/study/NCT02644083,TERMINATED,Multiple Sclerosis,DRUG: Dimethyl fumarate,Oregon Health and Science University,Biogen,ALL,ADULT,,4,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-02,2018-07,2018-07,"Oregon Health & Science University, Portland, Oregon, 97239, United States"
NCT03424733,Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects,https://beta.clinicaltrials.gov/study/NCT03424733,UNKNOWN,Multiple Sclerosis,DRUG: Plegridy|DRUG: Prednisone|DRUG: Tylenol Pill,"Holy Name Medical Center, Inc.",Biogen,ALL,"ADULT, OLDER_ADULT",PHASE4,50,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: PREVENTION,2017-09-25,2020-05-01,2020-05-31,"Holy Name Medical Center, Teaneck, New Jersey, 07666, United States"
NCT02769767,"Polymorphisms of Interleukins, Glypican, and Human Leukocyte Antigen Genes and Treatment Response in Multiple Sclerosis.",https://beta.clinicaltrials.gov/study/NCT02769767,UNKNOWN,"Multiple Sclerosis, Relapsing-Remitting","GENETIC: Polymorphism of Interleukins, Glypican, and Human Leukocyte Antigen Genes.",Instituto Jalisciense de Cancerologia,Instituto Mexicano del Seguro Social|University of Guadalajara,ALL,"ADULT, OLDER_ADULT",,500,OTHER_GOV,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-08,2016-12,2016-12,"Instituto Jalisciense de Cancerología, Guadalajara, Jalisco, 44280, Mexico"
NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,https://beta.clinicaltrials.gov/study/NCT02496767,COMPLETED,Amyotrophic Lateral Sclerosis,DRUG: Tirasemtiv|DRUG: Placebo tablets,Cytokinetics,,ALL,"ADULT, OLDER_ADULT",PHASE3,744,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2015-09-03,2017-03-09,2017-09-27,"St. Joseph's Hospital & Medical Center - Barrow Neurology Clinics, Phoenix, Arizona, 85013, United States|University of California San Diego, La Jolla, California, 92093, United States|Cedars-Sinai Medical Center, Los Angeles, California, 90048, United States|University of California, Irvine, Orange, California, 92868, United States|University of California Davis Medical Center, Sacramento, California, 95817, United States|Forbes Norris MDA/ALS Research Center, San Francisco, California, 94115, United States|Stanford Hospital and Clinics, Stanford, California, 94305, United States|University of Colorado Hospital Anschutz Outpatient Pavilion, Aurora, Colorado, 80045, United States|Hospital for Special Care, New Britain, Connecticut, 06053, United States|George Washington University Medical Center, Washington, District of Columbia, 20037, United States|Mayo Clinic, Jacksonville, Florida, 32224, United States|University of Miami, Miami, Florida, 33136, United States|Carol and Frank Morsini Center for Advanced Health Care - University of South Florida, Tampa, Florida, 33612, United States|The Emory Clinic, Atlanta, Georgia, 30322, United States|Georgia Regents University, Augusta, Georgia, 30912, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, 60611, United States|Indiana University, Indianapolis, Indiana, 46202, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, 52242, United States|University of Kansas Medical Center, Kansas City, Kansas, 66160, United States|Johns Hopkins University, Baltimore, Maryland, 21287, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, 01655, United States|University of Michigan Hospital and Health System, Ann Arbor, Michigan, 48109, United States|Henry Ford Health System, Detroit, Michigan, 48202, United States|Hennepin County Medical Center, Minneapolis, Minnesota, 55415, United States|Saint Louis University, Saint Louis, Missouri, 63104, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, 63110, United States|Neurology Associates, Lincoln, Nebraska, 68506, United States|Dartmouth Hitchcock Medical Center Dept of Neurology, Lebanon, New Hampshire, 03756, United States|Hospital for Special Surgery, New York, New York, 10021, United States|Neurological Institute Columbia University Medical Center, New York, New York, 10032, United States|SUNY Upstate Medical University, Syracuse, New York, 13210, United States|Neurosciences Institute: Neurology - Charlotte, Charlotte, North Carolina, 28207, United States|Duke Neurological Disorders Clinic, Durham, North Carolina, 27705, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, 27157, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, 43221, United States|Providence Brain and Spine Institute ALS Center, Portland, Oregon, 97213, United States|Oregon Health and Science Center, Portland, Oregon, 97239, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, 17033, United States|The Penn Comprehensive Neuroscience Center, Philadelphia, Pennsylvania, 19107, United States|Temple University School of Medicine, Philadelphia, Pennsylvania, 19140, United States|Vanderbilt University Medical Center, Nashville, Tennessee, 37232, United States|Texas Neurology, Dallas, Texas, 75214, United States|Baylor College of Medicine, Houston, Texas, 77030, United States|University of Texas Health Science Center, San Antonio, Texas, 78229, United States|University of Virgina Health System, Charlottesville, Virginia, 22908, United States|University of Washington Medical Center, Seattle, Washington, 98195, United States|West Virginia University Department of Neurology, Morgantown, West Virginia, 26506, United States|Froedtert Memorial Lutheran Hospital, Department of Neurology, Milwaukee, Wisconsin, 53226, United States|UZ Leuven - Campus Gasthuisberg, Leuven, Vlaams Brabant, 3000, Belgium|University of Calgary, Calgary, Alberta, T3M 1M4, Canada|Edmonton Kaye Clinic, Edmonton, Alberta, T6G 1Z1, Canada|Stan Cassidy Centre for Rehabilitation, Fredericton, New Brunswick, E3B OC7, Canada|QE II Health Sciences Centre, NHI Site, Halifax, Nova Scotia, B3H 1V7, Canada|McMaster University Medical Centre, Hamilton, Ontario, L8N 4K1, Canada|London Health Sciences Centre, London, Ontario, N6A 5A5, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, M4N 3M5, Canada|Notre-Dame Hospital/CHUM, Montreal, Quebec, H2L 4M1, Canada|Montreal Neurological Institute and Hospital, Montreal, Quebec, H3A 2B4, Canada|CHU de Quebec - Universite Laval Hopital de l'Enfant-Jesus, Quebec, G1J 1Z4, Canada|Hopital R. Salengro, CHRU Lille, Lille Cedex, 59037, France|CHU Dupuytren, Limoges cedex, 87042, France|Hopital de la Timone, Marseille, 13005, France|Hopital Gui de Chauliac, Montpellier, 34295, France|CHU de Nice - Hopital Pasteur 2, Nice Cedex 1, 06001, France|Hopital de la Salpetriere, Paris, 75651, France|Bretonneau University Hospital, Tours Cedex 9, 37044, France|University of Ulm, Department of Neurology, Ulm, Baden-Wuerttemberg, 89081, Germany|Hannover Medical School, Department of Neurology, Hannover, Lower Saxony, 30625, Germany|Charite Campus Virchow-Klinikum, Neurology Department, Berlin, 13353, Germany|Clinical Research Centre, Beaumont Hospital, Dublin, Dublin 9, Ireland|IRCCS Istituto Auxologico Italiano - U.O. Neurologia, Milan, 20149, Italy|Centro Clinico NEMO - Fondazione Serena Onlus, ASST Grande Ospedale Metropolitano Niguarda, Milan, 20162, Italy|Dipartimento di Neuroscienze ""Rita Levi Moltalcini"" A.O.U. Citta della Salute e della Scienza di Torino P.O. ""Molinette"", Torino, 10126, Italy|University Medical Center Utrecht, Utrecht, 3584 CX, Netherlands|Hospital Santa Maria-Centro Hospitalar Lisboa Norte, Lisboa, 1649-035, Portugal|Hospital San Rafael, Madrid, 28016, Spain|Derriford Hospital, Plymouth, Devon, PL6 8DH, United Kingdom|Walton Centre for Neurology and Neurosurgery, Liverpool, L9 7LJ, United Kingdom|Clinical Research Centre, Royal London Hospital, London, E1 2AT, United Kingdom|Kings College Hospital, London, SE59RS, United Kingdom"
NCT02293967,Mass Balance Study of MT-1303,https://beta.clinicaltrials.gov/study/NCT02293967,COMPLETED,Relapsing-remitting Multiple Sclerosis,DRUG: MT-1303,Mitsubishi Tanabe Pharma Corporation,,MALE,"ADULT, OLDER_ADULT",PHASE1,8,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-09,2014-12,2014-12,"Investigational site, Ruddington, Nottingham, United Kingdom"
NCT01911767,Biogen Multiple Sclerosis Pregnancy Exposure Registry,https://beta.clinicaltrials.gov/study/NCT01911767,COMPLETED,Multiple Sclerosis|Exposure During Pregnancy,DRUG: Dimethyl fumarate|DRUG: Peginterferon beta-1a,Biogen,,FEMALE,"CHILD, ADULT, OLDER_ADULT",,408,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-10-30,2022-02-10,2022-02-10,"Research Site, Cambridge, Massachusetts, 02139-1955, United States|Research Site, Box Hill, Victoria, 3128, Australia|Research Site, Cambridge, Massachusetts, 02139-1955, Canada|Research Site, Bron CEDEX, Cedex, 69677, France|Research Site, Bochum, Nordrhein Wesfalen, 44791, Germany|Research Site, Dublin, D04 T6F4, Ireland|Research Site, Firenze, 50134, Italy|Research Site, Genova, 16132, Italy|Research Site, Milano, 20132, Italy|Research Site, Palermo, 90146, Italy|Research Site, Roma, 00152, Italy|Research Site, Białystok, 15-276, Poland|Research Site, Madrid, 28034, Spain|Research Site, Malaga, 29010, Spain|Research Site, Salford, Greater Manchester, M6 8HD, United Kingdom"
NCT02143167,Resistance Training and Amino Pyridine in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02143167,COMPLETED,Multiple Sclerosis,DRUG: SR-fampridine|DRUG: Placebo,University of Southern Denmark,Region of Southern Denmark|Biogen,ALL,ADULT,PHASE4,40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-05,2015-01,2015-01,"Sydvestjysk Sygehus, Esbjerg, 6700, Denmark|Odense University Hospital, Odense, 5000, Denmark|Sygehus Sønderjylland, Sønderborg, 6400, Denmark|Sygehus Lillebælt, Vejle, 7100, Denmark"
NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,https://beta.clinicaltrials.gov/study/NCT00459667,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting","DRUG: Interferon beta-1b (Betaseron, BAY86-5046)|DRUG: Interferon beta-1b (Betaseron, BAY86-5046)|DRUG: Interferon beta-1b (Betaseron, BAY86-5046)",Bayer,,ALL,ADULT,PHASE3,1420,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,2007-05,2008-03,2008-03,"Birmingham, Alabama, 35294-7340, United States|Cullman, Alabama, 35058, United States|Phoenix, Arizona, 85013, United States|Tucson, Arizona, 85741, United States|Berkeley, California, 94705, United States|La Jolla, California, 92037, United States|Sacramento, California, 95817, United States|San Francisco, California, 94117, United States|Fort Collins, Colorado, 80528, United States|Newark, Delaware, 19713, United States|Washington, District of Columbia, 20037, United States|Maitland, Florida, 32751, United States|Miami, Florida, 33136, United States|Tampa, Florida, 33606, United States|Tampa, Florida, 33609, United States|Atlanta, Georgia, 30309-1465, United States|Augusta, Georgia, 30912, United States|Chicago, Illinois, 60637, United States|Fort Wayne, Indiana, 46805, United States|Indianapolis, Indiana, 46202, United States|Des Moines, Iowa, 50314, United States|Kansas City, Kansas, 66160, United States|Louisville, Kentucky, 40202, United States|Shreveport, Louisiana, 71130, United States|Detroit, Michigan, 48202, United States|Duluth, Minnesota, 55805, United States|St. Louis, Missouri, 63110, United States|Henderson, Nevada, 89052, United States|Reno, Nevada, 89509, United States|Newark, New Jersey, 07103, United States|Albuquerque, New Mexico, 87131-5281, United States|Mineola, New York, 11501, United States|Rochester, New York, 14642, United States|Stony Brook, New York, 11794, United States|Charlotte, North Carolina, 28207, United States|Durham, North Carolina, 27710, United States|Winston-Salem, North Carolina, 27157, United States|Cincinnati, Ohio, 45219, United States|Columbus, Ohio, 43210, United States|Tualatin, Oregon, 97062, United States|Philadelphia, Pennsylvania, 19104, United States|Pittsburgh, Pennsylvania, 15213, United States|Providence, Rhode Island, 02905, United States|Charleston, South Carolina, 29425, United States|Nashville, Tennessee, 37205, United States|Houston, Texas, 77030, United States|San Antonio, Texas, 78229, United States|Fairfax, Virginia, 22031, United States|Seattle, Washington, 98101, United States|Tacoma, Washington, 98405, United States|Milwaukee, Wisconsin, 53215, United States|Buenos Aires, Ciudad Auton. de Buenos Aires, C1117ABE, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, C1280AEB, Argentina|Cordoba, Córdoba, X5000HGX, Argentina|Rosario, Santa Fe, S2000ZBL, Argentina|Rosario, Santa Fe, Argentina|Buenos Aires, C1416CRJ, Argentina|Kogarah, New South Wales, 2217, Australia|Fitzroy, Victoria, 3065, Australia|Parkville, Victoria, 3050, Australia|Nedlands, Western Australia, 6009, Australia|Liverpool, NSW 2170, Australia|Wyoming, NSW 2250, Australia|St Poelten, Niederösterreich, A-3100, Austria|Graz, 8036, Austria|Innsbruck, 6020, Austria|Linz, 4020, Austria|Brussel, 1090, Belgium|Leuven, 3000, Belgium|Melsbroek, 1820, Belgium|Curitiba, Parana, 80240-340, Brazil|Recife, Pernambuco, 52010-040, Brazil|Porto Alegre, Rio Grande do Sul, 90035-001, Brazil|Campinas, Sao Paulo, 13081- 970, Brazil|Rio de Janeiro, 21941-590, Brazil|Sao Paulo, 01221-020, Brazil|Sao Paulo, 04039-032, Brazil|Sao Paulo, 05403-900, Brazil|Calgary, Alberta, T2N 2T9, Canada|Vancouver, British Columbia, V6T 2B5, Canada|Halifax, Nova Scotia, B3H 2Y9, Canada|London, Ontario, N6A 5A5, Canada|Mississauga, Ontario, L5B 1B8, Canada|Nepean, Ontario, K2G 6E2, Canada|Ottawa, Ontario, K1H 8L6, Canada|Toronto, Ontario, M5B 1W8, Canada|Greenfield Park, Quebec, J4V 2H1, Canada|Hull, Quebec, J8Y 1W7, Canada|Montreal, Quebec, H2L 4M1, Canada|Montreal, Quebec, H3A 2B4, Canada|Aarhus, 8000, Denmark|Oulu, 90029, Finland|Tampere, 33521, Finland|Rennes, Bretagne, 35038, France|Bordeaux, Gironde, 33076, France|Clermont ferrand, 63003, France|Dijon, 21033, France|Lille, 59037, France|Nancy, 54035, France|Nantes, 44093, France|Nice, 06000, France|Nimes, 30029, France|Toulouse, 31059, France|Heidelberg, Baden-Württemberg, 69120, Germany|Bayreuth, Bayern, 95445, Germany|Regensburg, Bayern, 93053, Germany|Hennigsdorf, Brandenburg, 16761, Germany|Gießen, Hessen, 35392, Germany|Marburg, Hessen, 35039, Germany|Offenbach, Hessen, 63069, Germany|Greifswald, Mecklenburg-Vorpommern, 17475, Germany|Göttingen, Niedersachsen, 37099, Germany|Hannover, Niedersachsen, 30559, Germany|Hannover, Niedersachsen, 30625, Germany|Düsseldorf, Nordrhein-Westfalen, 40225, Germany|Essen, Nordrhein-Westfalen, 45117, Germany|Münster, Nordrhein-Westfalen, 48149, Germany|Halle, Sachsen-Anhalt, 06120, Germany|Dresden, Sachsen, 01307, Germany|Leipzig, Sachsen, 04129, Germany|Berlin, 13347, Germany|Berlin, 13585, Germany|Hamburg, 20099, Germany|Hamburg, 20246, Germany|Athens, Attica, 11527, Greece|Thessaloniki, 54636, Greece|Budapest, 1076, Hungary|Budapest, 1145, Hungary|Györ, 9024, Hungary|Miskolc, 3501, Hungary|Pecs, 7623, Hungary|Zalaegerszeg-Pozva, H-8900, Hungary|Cork, Ireland|Dublin, 4, Ireland|Dublin, 9, Ireland|Dublin, Ireland|Ashkelon, 78278, Israel|Haifa, 31048, Israel|Jerusalem, 91120, Israel|Tel Hashomer, 52621, Israel|Tel-Aviv, 64239, Israel|Zerifin, 70300, Israel|Orbassano, Torino, 10043, Italy|Bari, 70122, Italy|Firenze, 50134, Italy|Milano, 20132, Italy|Padova, 35128, Italy|Roma, 00189, Italy|Riga, LV-1015, Latvia|Breda, 4819 EV, Netherlands|Nijmegen, 6533 PA, Netherlands|Sittard, 6131 BK, Netherlands|Bergen, N-5021, Norway|Gdansk, 80-803, Poland|Katowice, 40752, Poland|Lodz, 90153, Poland|Poznan, 61848, Poland|Warszawa, 02097, Poland|Warszawa, 02957, Poland|Wroclaw, 50420, Poland|Moskva, 117049, Russian Federation|Moskva, 118089, Russian Federation|Moskva, 123367, Russian Federation|Moskva, 127018, Russian Federation|Moskva, 129110, Russian Federation|Nizhy Novgorod, 603076, Russian Federation|Novosibirsk, 630007, Russian Federation|Sankt-Peterburg, 197022, Russian Federation|St. Petersburg, 194044, Russian Federation|St. Petersburg, 197376, Russian Federation|Yaroslavl, 150039, Russian Federation|Ljubljana, SI-1525, Slovenia|Maribor, 2000, Slovenia|L'Hospitalet de Llobregat, Barcelona, 08907, Spain|Malaga, 29010, Spain|Sevilla, 41071, Spain|Stockholm, 182 88, Sweden|Uppsala, 751 85, Sweden|Bern, 3010, Switzerland|St. Gallen, 9007, Switzerland|Donetsk, 83003, Ukraine|Kharkiv, 61068, Ukraine|Kiev, 03110, Ukraine|Lviv, 79000, Ukraine"
NCT05735067,The Impact of Interferon Beta 1a on Egyptian Relapse-Remitting Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT05735067,RECRUITING,Multiple Sclerosis,OTHER: Blood sample collection,German University in Cairo,,ALL,ADULT,NA,110,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2022-02-01,2023-05-01,2023-06-30,"Nasser Institute for Research and Treatment, Cairo, 1053, Egypt"
NCT02881567,Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab,https://beta.clinicaltrials.gov/study/NCT02881567,TERMINATED,Relapsing-Remitting Multiple Sclerosis (RRMS),DRUG: Daclizumab,Biogen,AbbVie,ALL,ADULT,PHASE3,41,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2017-04-18,2018-09-12,2018-09-12,"Research Site, Tampa, Florida, 33612, United States|Research Site, Des Moines, Iowa, 50314, United States|Research Site, Milwaukee, Wisconsin, 53501, United States|Research Site, Edmonton, Alberta, T6G 2G3, Canada|Research Site, Muenchen, Bayern, 81675, Germany|Research Site, Potsdam, Brandenburg, 14471, Germany|Research Site, Dresden, Sachsen, 01307, Germany|Research Site, Hamburg, 20249, Germany|Research Site, Pozzilli, Isernia, 86077, Italy|Research Site, Napoli, 80131, Italy|Research Site, Guaynabo, 00968, Puerto Rico"
NCT00525343,Avonex 15 Year Long Term Follow-up Study,https://beta.clinicaltrials.gov/study/NCT00525343,COMPLETED,Multiple Sclerosis,,Biogen,,ALL,"ADULT, OLDER_ADULT",,122,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2007-03,,2008-09,"Georgetown University Medical Center, Washington, District of Columbia, 20007, United States|Jocab's Neurological Institute, Buffalo, New York, 14203, United States|Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States|Oregon Health and Science University, Portland, Oregon, 97239, United States"
NCT00104143,A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis.,https://beta.clinicaltrials.gov/study/NCT00104143,WITHDRAWN,Multiple Sclerosis,DRUG: A4I Antagonist,Hoffmann-La Roche,,ALL,ADULT,PHASE2,0,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,2007-10,,,"Sofia, 1113, Bulgaria|Sofia, 1309, Bulgaria|Sofia, 1527, Bulgaria|Sofia, 1606, Bulgaria|Edmonton, Alberta, T6G 2G3, Canada|Vancouver, British Columbia, V6T 2B5, Canada|London, Ontario, N6A 5A5, Canada|Greenfield Park, Quebec, J4V 2H1, Canada|Hull, Quebec, J8Y 1W7, Canada|Hradec Kralove, 500 05, Czech Republic|Ostrava, Czech Republic|Praha, 845 15, Czech Republic|Marburg, 35033, Germany|Regensburg, 93053, Germany|Tübingen, 72076, Germany|ULM, 89081, Germany|Gdansk, 80-952, Poland|Lodz, 90-153, Poland|Lublin, 20-954, Poland|Szczecin, 71-242, Poland|Warszawa, 02-957, Poland|Moscow, 117997, Russian Federation|Moscow, 123367, Russian Federation|Nizhny Novgorod, 603076, Russian Federation|St Petersburg, 194044, Russian Federation|St Petersburg, 197089, Russian Federation|Banska Bystrica, 975 17, Slovakia|Bratislava, 813 69, Slovakia|Kosice, 041 66, Slovakia|Nitra, 949 01, Slovakia|Barcelona, 08035, Spain|Barcelona, 08907, Spain|Madrid, 28040, Spain|Malaga, 29010, Spain|Sevilla, 41071, Spain|Liverpool, L9 1AE, United Kingdom|Newcastle Upon Tyne, NE1 4LP, United Kingdom|Nottingham, NG7 2UH, United Kingdom|Sheffield, S10 2JF, United Kingdom"
NCT03829267,eFIT: An Internet-based Intervention to Increase Physical Activity in Persons With MS,https://beta.clinicaltrials.gov/study/NCT03829267,COMPLETED,Multiple Sclerosis,BEHAVIORAL: eFIT Intervention|BEHAVIORAL: eJournal Intervention|BEHAVIORAL: Treatment as usual,Columbia University,,ALL,"ADULT, OLDER_ADULT",NA,44,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2019-04-26,2020-04-13,2020-04-13,"Columbia University Multiple Sclerosis Clinical Care and Research, New York, New York, 10032, United States"
NCT05532943,Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05532943,RECRUITING,Multiple Sclerosis,BIOLOGICAL: Allogeneic umbilical cord mesenchymal stem cells|BIOLOGICAL: Control group,"Ever Supreme Bio Technology Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,41,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-06-30,2026-12-31,2026-12-31,"China Medical University Hospital, Taichung, Non-US, 404, Taiwan"
NCT05849467,Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy,https://beta.clinicaltrials.gov/study/NCT05849467,NOT_YET_RECRUITING,Multiple Sclerosis|Progressive Multifocal Leukoencephalopathy,DRUG: 89 Zr-Df-crefmirlimab,National Institute of Neurological Disorders and Stroke (NINDS),,ALL,"ADULT, OLDER_ADULT",PHASE1,10,NIH,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-05-19,2023-12-31,2023-12-31,"National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States"
NCT02634567,Attention/Working Memory Rehabilitation in Multiple Sclerosis: A Pilot Project Using Cogmed Working Memory Training,https://beta.clinicaltrials.gov/study/NCT02634567,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Cogmed Working Memory Training (CWMT),London Health Sciences Centre,,ALL,ADULT,NA,31,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2016-04,2018-11,2018-12,"London Health Sciences Centre, London, Ontario, N6A 5A5, Canada"
NCT04303143,Hypnosis and Direct Autonomic Experience Influence on Chronic Symptoms,https://beta.clinicaltrials.gov/study/NCT04303143,UNKNOWN,"Restless Legs Syndrome|Multiple Sclerosis|Trauma, Psychological|Chronic Disease|Trauma",BEHAVIORAL: Self-Hypnosis|BEHAVIORAL: Direct Autonomic Experience Control,Inner Group Inc.,,ALL,"CHILD, ADULT, OLDER_ADULT",,20,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-03,2021-05,2021-07,
NCT04997343,Neurophysiological Assessment in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04997343,NOT_YET_RECRUITING,Multiple Sclerosis|Demyelinating Disease|Inflammatory Disease,OTHER: Neurophysiological assessment|OTHER: clinical assessment,University of Roma La Sapienza,,ALL,"ADULT, OLDER_ADULT",NA,128,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2021-10,2023-07-01,2023-09-01,
NCT01436643,Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression,https://beta.clinicaltrials.gov/study/NCT01436643,TERMINATED,Depression|Relapsing-remitting Multiple Sclerosis,DRUG: Venlafaxine|DRUG: Fluoxetine|DRUG: Citalopram|DRUG: Fingolimod,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE4,54,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2011-11,2013-09,2013-09,"Novartis Investigative Site, Achim, 28832, Germany|Novartis Investigative Site, Altenholz-Stift, 24161, Germany|Novartis Investigative Site, Aschaffenburg, 63739, Germany|Novartis Investigative Site, Bad Honnef, 53604, Germany|Novartis Investigative Site, Baesweiler, 52499, Germany|Novartis Investigative Site, Berlin, 12621, Germany|Novartis Investigative Site, Bielefeld, 33602, Germany|Novartis Investigative Site, Bielefeld, 33647, Germany|Novartis Investigative Site, Bochum, 44787, Germany|Novartis Investigative Site, Bremerhaven, 27574, Germany|Novartis Investigative Site, Butzbach, 35510, Germany|Novartis Investigative Site, Grevenbroich, 41515, Germany|Novartis Investigative Site, Heidenheim, 89518, Germany|Novartis Investigative Site, Klingenmünster, 76889, Germany|Novartis Investigative Site, Leipzig, 04275, Germany|Novartis Investigative Site, Merzig, 66663, Germany|Novartis Investigative Site, Nienburg, 31582, Germany|Novartis Investigative Site, Oberhausen, 46045, Germany|Novartis Investigative Site, Oldenburg, 26122, Germany|Novartis Investigative Site, Potsdam, 14471, Germany|Novartis Investigative Site, Schwalmstadt-Treysa, 34613, Germany|Novartis Investigative Site, Stadtroda, 07646, Germany|Novartis Investigative Site, Tübingen, 72076, Germany|Novartis Investigative Site, Weil am Rhein, 79576, Germany|Novartis Investigative Site, Zwickau, 08060, Germany"
NCT04096443,Oral FMT (Fecal Microbial Transplant) in Subjects With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04096443,RECRUITING,Multiple Sclerosis,BIOLOGICAL: Fecal microbial transplant (FMT),Griffin Hospital,"Yale-Griffin Prevention Research Center|Multiple Sclerosis Treatment Center, Derby, Connecticut",ALL,ADULT,EARLY_PHASE1,15,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2019-10-28,2023-12-30,2023-12-30,"Griffin Hospital, Derby, Connecticut, 06418, United States"
NCT00735007,12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.,https://beta.clinicaltrials.gov/study/NCT00735007,COMPLETED,Multiple Sclerosis,DRUG: Rebif® New Formulation (RNF) using RebiSmartTM,EMD Serono,,ALL,"ADULT, OLDER_ADULT",PHASE3,106,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2008-07,2009-01,,"US Local Medical Information, Rockland, Massachusetts, 02370, United States|Canada, Local Medical Information, Ontario, British Columbia, Quebec, Canada|Germany, Local Medical Information, Hamburg, Ulm, Berlin, Erbach, Germany|Italy, Local Medical Information, Chieti & Roma, Italy|Spain, Local Medical Information, Barcelona & Madrid, Spain|Sweden, Local Medical Information, Sweden, Sweden"
NCT04744207,A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis,https://beta.clinicaltrials.gov/study/NCT04744207,COMPLETED,Systemic Sclerosis,DRUG: GS-248|DRUG: Placebo,Gesynta Pharma AB,Ergomed,ALL,"ADULT, OLDER_ADULT",PHASE2,69,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-12-29,2022-06-15,2022-06-15,"Investigator site, Gent, Belgium|Investigator Site, Nijmegen, Netherlands|Investigator site, Gdańsk, Poland|Investigator Site, Kraków, Poland|Investigator site, Lublin, Poland|Investigator site, Bath, United Kingdom|Investigator site, Cambridge, United Kingdom|Investigator Site, Dundee, United Kingdom|Investigator site, Leeds, United Kingdom|Investigator Site, Liverpool, United Kingdom|Investigator Site, London, United Kingdom|Investigator site, Manchester, United Kingdom"
NCT01201343,Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT01201343,COMPLETED,"Multiple Sclerosis, Relapsing, Remitting",DRUG: Interferon beta-1a,"Merck KGaA, Darmstadt, Germany","Merck Serono S.A.S, France",ALL,"ADULT, OLDER_ADULT",PHASE4,79,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2005-01,2010-07,2010-07,
NCT02790307,Transcutaneous Tibial Nerve Stimulation of Patients With Overactive Bladder (OAB) Syndrome,https://beta.clinicaltrials.gov/study/NCT02790307,COMPLETED,Overactive Bladder|Multiple Sclerosis,DEVICE: The Geko,"University College, London",,,"CHILD, ADULT, OLDER_ADULT",PHASE2,48,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2013-01,2013-09,2013-12,"National Hospital for Neurology and Neurosurgery, London, United Kingdom"
NCT02454907,The Use of Technology to Improve MS Clinical Trials and Patient Care,https://beta.clinicaltrials.gov/study/NCT02454907,RECRUITING,Multiple Sclerosis,OTHER: Communication with the clinic,Johns Hopkins University,,ALL,"ADULT, OLDER_ADULT",NA,150,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: DIAGNOSTIC",2018-07-31,2024-12-31,2024-12-31,"Johns Hopkins University, Baltimore, Maryland, 21287, United States"
NCT05301907,Survey Among Healthcare Professionals and MS Patients to Assess Their Understanding of RMP Materials,https://beta.clinicaltrials.gov/study/NCT05301907,RECRUITING,Multiple Sclerosis,,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",,310,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-12-02,2024-09-30,2024-09-30,"Novartis Investigative Site, Basel, Switzerland"
NCT04120207,"An Eight-week RCT of Home-based Pilates for Symptoms of Anxiety, Depression, and Fatigue Among People With MS",https://beta.clinicaltrials.gov/study/NCT04120207,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Home-based Pilates|OTHER: Delayed-start Pilates,University of Limerick,,ALL,"ADULT, OLDER_ADULT",NA,63,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2019-01-01,2019-08-28,2019-08-28,"University of Limerick, Limerick, V94 T9PX, Ireland"
NCT04480307,Clinical Trial Assessing Temelimab Following Rituximab Treatment in Patients With Relapsing Forms of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04480307,COMPLETED,Multiple Sclerosis,DRUG: temelimab 18 mg/kg|DRUG: temelimab 36 mg/kg|DRUG: temelimab 54 mg/kg|DRUG: Placebo,GeNeuro Innovation SAS,,ALL,ADULT,PHASE2,41,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-06-17,2022-01-24,2022-01-24,"Center for Neurology, Academic Specialist Center, Stockholm, 113 65, Sweden"
NCT00501943,Neuroprotection With Riluzole Patients With Early Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00501943,COMPLETED,Multiple Sclerosis,DRUG: Avonex (Interferon beta 1a)|DRUG: Riluzole|DRUG: Placebo,"University of California, San Francisco",National Multiple Sclerosis Society|Oregon Health and Science University,ALL,ADULT,PHASE2,43,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2006-07,2012-10,2012-10,"UCSF MS Center , 675 Nelson Rising Lane, Suite 221, San Francisco, California, 94158, United States"
NCT05123443,Longitudinal Assessment of Iron Rims in MS Lesions,https://beta.clinicaltrials.gov/study/NCT05123443,NOT_YET_RECRUITING,Multiple Sclerosis,BIOLOGICAL: Blood sample provided|DIAGNOSTIC_TEST: 7-T MRI scan,Nottingham University Hospitals NHS Trust,Johns Hopkins University,ALL,"CHILD, ADULT, OLDER_ADULT",,100,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-01-01,2022-06-30,2022-09-30,
NCT05795907,Single & Multiple Ascending Dose Study of SAR443820 in Healthy Adult Participants,https://beta.clinicaltrials.gov/study/NCT05795907,COMPLETED,Amyotrophic Lateral Sclerosis (Healthy Volunteers),DRUG: SAR443820|DRUG: Placebo,Sanofi,,ALL,ADULT,PHASE1,84,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-11-30,2021-07-20,2021-07-20,"Prism Research-Site Number:8400001, Saint Paul, Minnesota, 55144, United States"
NCT05412043,"Fatigability in Persons With Multiple Sclerosis: Inputs From Cognition, Walking and Coordination",https://beta.clinicaltrials.gov/study/NCT05412043,RECRUITING,Multiple Sclerosis,"BEHAVIORAL: Dance therapy|OTHER: Psychometric properties (Validity, Reliability) of interlimb coordination- and cognitive-fatigability",Hasselt University,Revalidatie & MS Centrum Overpelt|National MS Center Melsbroek,ALL,"ADULT, OLDER_ADULT",NA,90,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2021-09-01,2022-09-30,2022-09-30,"Noorderhart Revalidatie & MS centrum, Overpelt, 3900, Belgium|National MS Center Melsbroek, Overpelt, Belgium"
NCT03401307,Central and Peripheral Nervous System Changes as Markers of Disease Progression in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03401307,COMPLETED,Multiple Sclerosis|Neurodegeneration|Central Nervous System Lesion|Peripheral Nervous System Problem|Neurologic Deficits|Drug Effect|Genetic Disease|Neurophysiologic Abnormality,,University of Southern Denmark,Region of Southern Denmark,ALL,"ADULT, OLDER_ADULT",,49,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-08-01,2020-06-20,2020-12-01,"Department of Neurology (Skleroseklinikken), Sygehus Sønderjylland, Sønderborg, Jylland, 6400, Denmark"
NCT01442233,Plasma Exchanges in Multiple Sclerosis (MS) Relapses,https://beta.clinicaltrials.gov/study/NCT01442233,COMPLETED,"Multiple Sclerosis|Multiple Sclerosis, Acute Relapsing",PROCEDURE: plasma exchange|PROCEDURE: sham exchanges procedure,"University Hospital, Bordeaux",,ALL,"ADULT, OLDER_ADULT",PHASE3,38,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2012-03-08,2017-09-21,2017-09-21,"Service de Neurologie - Hôpital Pellegrin - CHU de Bordeaux, Bordeaux, 33000, France|Service de neurologie - CHU de Clermont-Ferrand, Clermont-Ferrand, France|Service de Neurologie - CHRU de Lille, Lille, 59000, France|Service de Neurologie - CHU de nancy, Nancy, 54000, France|Service de neurologie - CHU de Nantes, Nantes, 44000, France|Service de Neurologie - CHU de Starsbourg, Strasbourg, 67000, France"
NCT02936037,Effect of MD1003 in Progressive Multiple Sclerosis (SPI2),https://beta.clinicaltrials.gov/study/NCT02936037,TERMINATED,Multiple Sclerosis,DRUG: MD1003 100mg capsule|DRUG: PLACEBO,MedDay Pharmaceuticals SA,,ALL,"ADULT, OLDER_ADULT",PHASE3,642,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-12,2019-11-15,2020-04-23,"Barrow Neurology Clinics (BNC), Phoenix, Arizona, 85013, United States|Mayo Clinic Scottsdale, Scottsdale, Arizona, 85259, United States|Jordan Research And Education Institute Of Alta Bates Summit, Berkeley, California, 94705, United States|Neuro-Pain Medical Center, Fresno, California, 93710, United States|University of Southern California Keck School of Medicine, Los Angeles, California, 90033, United States|MS Center of California, Newport Beach, California, 92663, United States|UC Davis Health System, Sacramento, California, 95817, United States|UCSF Multiple Sclerosis Center, San Francisco, California, 94158, United States|University of Colorado Denver, Aurora, Colorado, 80045, United States|Yale New Haven Hospital, North Haven, Connecticut, 06473, United States|Nova Clinical Research, LLC, Bradenton, Florida, 34209, United States|University of Miami Miller School of Medicine, Miami, Florida, 33136, United States|University of South Florida - Neurology, Tampa, Florida, 33612, United States|Northwestern University - Feinberg School of Medicine, Chicago, Illinois, 60611, United States|University of Chicago Medical Center-Duchossois Center for Advanced Medicine (DCAM), Chicago, Illinois, 60637, United States|University of Kansas Medical Center, Kansas City, Kansas, 66160, United States|Rowe Neurology Institute, Lenexa, Kansas, 66214, United States|Ochsner Health System, New Orleans, Louisiana, 70121, United States|The Johns Hopkins Outpatient Center, Baltimore, Maryland, 21287, United States|Harvard Medical School - Brigham and Women's Hospital - Center for Neurologic Diseases, Boston, Massachusetts, 02115, United States|Wayne State University - Comp Clinic and MS Center, Detroit, Michigan, 48201, United States|Minneapolis Clinic of Neurology, LTD, Golden Valley, Minnesota, 55422, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|Holy Name Hospital, Teaneck, New Jersey, 07666, United States|The University of New Mexico - Multiple Sclerosis Specialty Clinic, Albuquerque, New Mexico, 87131, United States|UBMD Neurology, Buffalo, New York, 14203, United States|Mount Sinai School of Medicine - Corinne Goldsmith Dickinson Center for MS, New York, New York, 10029, United States|Columbia University Medical Center, New York, New York, 10032, United States|University of Rochester Medical Center, Rochester, New York, 14642, United States|State University of New York (SUNY), Stony Brook, New York, 11794, United States|Raleigh Neurology Associates, P.A., Raleigh, North Carolina, 27607, United States|Cleveland Clinic Mellen Center for MS, Cleveland, Ohio, 44195, United States|Providence Multiple Sclerosis Center, Portland, Oregon, 97225, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, 19107, United States|New Orleans Center for Clinical Research, Knoxville, Tennessee, 37920, United States|Vanderbilt Comprehensive Multiple Sclerosis Center, Nashville, Tennessee, 37215, United States|University of Texas Southwestern Medical Center, Dallas, Texas, 75390, United States|Central Texas Neurology Consultants, Round Rock, Texas, 78681, United States|University of Virginia Health System, Charlottesville, Virginia, 22903, United States|Virginia Mason Medical Center, Seattle, Washington, 98101, United States|Brain and Mind Centre/University of Sydney, Sydney, New South Wales, 2050, Australia|Austin Hospital, Heidelberg, Victoria, 3084, Australia|The Royal Melbourne Hospital, Parkville, Victoria, 3050, Australia|UZ Antwerpen, Edegem, Antwerpen, 2650, Belgium|Jessa Ziekenhuis - Campus Virga Jesse, Hasselt, Limburg, 3500, Belgium|UZ Gent, Halle, Oost-Vlaanderen, 9000, Belgium|Burnaby Hospital, Burnaby, British Columbia, V5G 2X6, Canada|Vancouver Hospital and Health Sciences Centre, Vancouver, British Columbia, V6T 2B5, Canada|Hôpital universitaire Dr George L-Dumont university Hospital, Moncton, New Brunswick, E1C 2Z3, Canada|Nova Scotia Rehabilitation Center, Halifax, Nova Scotia, B3H 4K4, Canada|Ottawa Hospital General Campus, Ottawa, Ontario, ON K1H 8L6, Canada|St. Michael's Hospital, Toronto, Ontario, M5B 1W8, Canada|Montreal Neurologic Institute, Montreal, Quebec, H3A 2B4, Canada|Hopital de Notre Dame, Montréal, Quebec, H2L 4M1, Canada|doc. MUDr. Radomir Talab, CSc., neurologie, Hradec Králové, 500 03, Czechia|Nemocnice Jihlava, Jihlava, 586 33, Czechia|Vseobecna fakultni nemocnice v Praze, Praha, 128 21, Czechia|Fakultni nemocnice v Motole, Praha, 150 06, Czechia|Nemocnice Teplice, Teplice, 415 29, Czechia|Universitätsklinikum Leipzig A.ö.R. - Klinik und Poliklinik, Leipzig, Sachsen, 04103, Germany|Fachkrankenhaus Hubertusburg, Wermsdorf, Sachsen, 04779, Germany|Caritas Krankenhaus, Bad Mergentheim, 97980, Germany|Charité - Universitätsmedizin Berlin / NeuroCure Clinical Research Center, Berlin, 10117, Germany|Heinrich-Heine-Universität Düsseldorf, Dusseldorf, 40225, Germany|Neuro Centrum Science GmbH, Erbach, 64711, Germany|MultipEL Studies Institut für klinische Studien GbR, Hamburg, 22179, Germany|Ludwig-Maximilians Universität München, München, 81377, Germany|Neuropoint GmbH, Ulm, 89073, Germany|Poliklinik für Neurologie Universitätsklinikum Ulm, Ulm, 89081, Germany|Valeomed Kft, Esztergom, 2500, Hungary|Ospedale San Raffaele, IRCCS, Milano, 20132, Italy|AO S.Andrea, Università degli Studi di Roma La Sapienza, Roma, 00189, Italy|Nasz Lekarz Ośrodek Badań Klinicznych, Bydgoszcz, 85-794, Poland|COPERNICUS PL sp z o.o.,Szpital im. M.Kopernika Oddział Neurologiczny, Gdansk, 80-803, Poland|Twoja Przychodnia Centrum Medyczne Nowa Sol, Nowa Sol, 67-100, Poland|Centrum Medyczne Pratia Warszawa, Warszawa, 01-868, Poland|Hospital Santa Caterina, Salt, Girona, 17190, Spain|Hostipal Universitario Quirónsalud Madrid, Pozuelo de Alarcón, Madrid, 28223, Spain|Servicio de Neurología Hospital Vithas Nisa Aljarafe, Castilleja de la Cuesta, Sevilla, 41950, Spain|Hospital del Mar Servicio de Neurología, Barcelona, 08003, Spain|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital Clínico San Carlos, Madrid, 28040, Spain|Hospital Regional Universitario de Málaga, Malaga, 29010, Spain|Sahlgrenska Universitetssjukhus - MS Center forskningsenheten, Göteborg, 413 45, Sweden|Karolinska University Hospital - Neurologmottagningen, Stockholm, 171 76, Sweden|Ondokuz Mayis University Medical Faculty, Samsun, 55139, Turkey|The University of Edinburgh, Edinburgh, EH16 4SB, United Kingdom|Institute of Neurological Sciences, Glasgow, G51 4TF, United Kingdom|Barts And The London School Of Medicine And Dentistry Institute, London, E1 2AT, United Kingdom|University College London Institute of Neurology / National Hospital for Neurology & Neurosurgery, London, WC1N 3BG, United Kingdom|Tyne Hospitals NHS Foundation, Newcastle upon Tyne, NE1 4LP, United Kingdom|Salford Royal Hospital, Salford, M6 8HD, United Kingdom"
NCT04819737,Spinal Cord Lesion Detection in Multiple Sclerosis Using Novel MRI Sequences,https://beta.clinicaltrials.gov/study/NCT04819737,NOT_YET_RECRUITING,Multiple Sclerosis (MS),PROCEDURE: SC MRI|OTHER: patient questionnaire,"University Hospital, Basel, Switzerland",Freie Akademische Gesellschaft Basel,ALL,"ADULT, OLDER_ADULT",NA,10,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-07,2022-12,2022-12,"University Hospital Basel, Department of Neurology, Basel, 4031, Switzerland"
NCT00616733,12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT00616733,COMPLETED,Multiple Sclerosis,DRUG: CS-0777 tablets|DRUG: CS-0777 tablets|DRUG: CS-0777 tablets,"Daiichi Sankyo, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1,25,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2008-03,2010-09,2010-09,"Denver, Colorado, United States|Port Orange, Florida, United States|Lenexa, Kansas, United States|Billings, Montana, United States|Philadelphia, Pennsylvania, United States"
NCT01431937,Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers,https://beta.clinicaltrials.gov/study/NCT01431937,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: GSK2018682|DRUG: Placebo,GlaxoSmithKline,,ALL,ADULT,PHASE1,40,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2010-10-10,2011-03-29,2011-03-29,"GSK Investigational Site, Randwick, New South Wales, 2031, Australia|GSK Investigational Site, Adelaide, South Australia, 5000, Australia|GSK Investigational Site, Nedlands, Western Australia, 6009, Australia"
NCT02308137,Domperidone in Secondary Progressive Multiple Sclerosis (SPMS),https://beta.clinicaltrials.gov/study/NCT02308137,COMPLETED,"Multiple Sclerosis, Secondary Progressive",DRUG: Domperidone,University of Calgary,Alberta Innovates Health Solutions,ALL,ADULT,PHASE2,64,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-02,2020-01-03,2020-01-03,"Calgary MS Clinic at Foothills Medical Centre, Calgary, Alberta, T2N 2T9, Canada"
NCT02096133,Vitamin D3 and the Stress-axis in MS,https://beta.clinicaltrials.gov/study/NCT02096133,TERMINATED,Multiple Sclerosis,DRUG: Cholecalciferol|OTHER: Placebo comparator,Academic MS Center Limburg,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,54,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2014-10-13,2016-11-07,2016-11-07,"Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Academic MS Center Limburg, Orbis Medical Center, Sittard-Geleen, 6162 BG, Netherlands"
NCT02220933,Effect of MD1003 in Spinal Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02220933,UNKNOWN,Multiple Sclerosis,DRUG: MD1003 100mg capsule|DRUG: Placebo,MedDay Pharmaceuticals SA,,ALL,"ADULT, OLDER_ADULT",PHASE3,144,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-10,2016-01,2018-01,"Hopital Pellegrin, Bordeaux, 33000, France|Hopital de la cote de Nacre, Caen, 14000, France|Hopital Gabriel Montpied, Clermont Ferrand, 63000, France|Hopital general du Bocage, Dijon, 21000, France|Hopital Pierre Wertheimer, Lyon, 69000, France|Hopital de la Timone, Marseille, 13000, France|Hopital Gui de Chauliac, Montpellier, 34000, France|Hopital Central, Nancy, 54000, France|Hopital Nord Laennec, Nantes, 44000, France|Hopital Pasteur, Nice, 06000, France|Groupe hospitalier la Pitié-Salpêtrière, Paris, 75013, France|Fondation Rothschild, Paris, 75019, France|Centre hospitalier Intercommunal Poissy/Saint-Germain-en-Laye, Poissy, 78300, France|Hopital Maison Blanche, Reims, 51000, France|Hopital Pontchaillou, Rennes, 35000, France|Hopital Hautepierre, Strasbourg, 67000, France|Hopital Purpan, Toulouse, 31000, France"
NCT02834533,Role of Virtual Reality in MS Rehabilitation,https://beta.clinicaltrials.gov/study/NCT02834533,COMPLETED,Multiple Sclerosis Relapse,DEVICE: Lokomat,"IRCCS Centro Neurolesi ""Bonino-Pulejo""",,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2014-01,2014-08,2015-01,
NCT00963833,Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00963833,COMPLETED,Multiple Sclerosis,"DRUG: Interferon beta-1b (Betaseron, BAY86-5046)",Bayer,,ALL,CHILD,,68,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2009-12-17,2016-04-12,2016-09-01,"Many Locations, Austria|Many Locations, Belgium|Many Locations, Finland|Many Locations, Germany|Many Locations, Israel|Many Locations, United Kingdom"
NCT05357833,Novel Imaging Markers in SPMS,https://beta.clinicaltrials.gov/study/NCT05357833,RECRUITING,"Secondary Progressive Multiple Sclerosis|Multiple Sclerosis, Secondary Progressive|Multiple Sclerosis",DRUG: Ferumoxytol infusion|DRUG: Gadoteridol|DIAGNOSTIC_TEST: MRI Brain and Cervical Spine,University of Utah,,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,10,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-06-01,2023-05-31,2023-05-31,"University of Utah Health Imaging and Neurosciences Center, Salt Lake City, Utah, 84108, United States"
NCT05590533,Turkish Version of F-2-MS,https://beta.clinicaltrials.gov/study/NCT05590533,NOT_YET_RECRUITING,Cultural Adaptation|Reliability|Validity|Multiple Sclerosis|Fatigue,"OTHER: Cultural adaptation, reliability and validity",Pamukkale University,,ALL,"ADULT, OLDER_ADULT",,180,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-11,2023-04,2023-05,
NCT00338637,Measuring the Balance Improvement on Multiple Sclerosis Patients After a Short Training Period With an APOS (All Phase Of Step Cycle) Kit,https://beta.clinicaltrials.gov/study/NCT00338637,UNKNOWN,Multiple Sclerosis|Balance|Cerebelar Impairment,DEVICE: APOS shoe kit,Sheba Medical Center,,ALL,"ADULT, OLDER_ADULT",PHASE2,30,OTHER_GOV,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,2006-04,,2006-10,"Sheba Medical Center, Ramat Gan, Israel"
NCT01216137,Effects of Vestibular Rehabilitation on MS-related Fatigue: a Randomized Control Trial,https://beta.clinicaltrials.gov/study/NCT01216137,COMPLETED,Multiple Sclerosis|Fatigue|Balance|Dizziness,OTHER: Exercise: Vestibular Rehabilitation|OTHER: Exercise,"University of Colorado, Denver",National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",NA,38,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2007-01,2010-07,2010-10,
NCT00641537,CLARITY Extension Study,https://beta.clinicaltrials.gov/study/NCT00641537,COMPLETED,Relapsing-Remitting Multiple Sclerosis,DRUG: Cladribine|DRUG: Placebo|DRUG: Cladribine|DRUG: Cladribine|DRUG: Placebo,"EMD Serono Research & Development Institute, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE3,867,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2008-02-29,2011-12-31,2011-12-31,"Research Site, Boulder, Colorado, United States|Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Northbrook, Illinois, United States|Research Site, Baltimore, Maryland, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Henderson, Nevada, United States|Research Site, Newark, New Jersey, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Columbus, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Medford, Oregon, United States|Research Site, Seattle, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, Charleston, West Virginia, United States|Research Site, Camperdown, Australia|Research Site, Melbourne, Australia|Research Site, Victoria, Australia|Research Site, Linz, Austria|Research Site, Diepenbeek, Belgium|Research Site, Esneux, Belgium|Research Site, Recife, Brazil|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Ruse, Bulgaria|Research Site, Shuman, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Zagora, Bulgaria|Research Site, Burnaby, Canada|Research Site, Greenfield Park, Canada|Research Site, Ottawa, Canada|Research Site, Quebec, Canada|Research Site, Karlovac, Croatia|Research Site, Sisak, Croatia|Research Site, Split, Croatia|Research Site, Hradec Králové, Czechia|Research Site, Olomouc, Czechia|Research Site, Praha, Czechia|Research Site, Copenhagen, Denmark|Research Site, Tallinn, Estonia|Research Site, Tartu, Estonia|Research Site, Oulu, Finland|Research Site, Turku, Finland|Research Site, Clermont-Ferrand, France|Research Site, Lille, France|Research Site, Nancy, France|Research Site, Nimes, France|Research Site, Paris, France|Research Site, Rennes, France|Research Site, Saint Herblain, France|Research Site, Bochum, Germany|Research Site, Frankfurt, Germany|Research Site, Giessen, Germany|Research Site, Hannover, Germany|Research Site, Regensburg, Germany|Research Site, Rostock, Germany|Research Site, Athens, Greece|Research Site, Bari, Italy|Research Site, Cagliari, Italy|Research Site, Catania, Italy|Research Site, Firenze, Italy|Research Site, Genova, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Padova, Italy|Research Site, Roma, Italy|Research Site, Riga, Latvia|Research Site, Beirut, Lebanon|Research Site, Beyrouth, Lebanon|Research Site, Kaunas, Lithuania|Research Site, Casablanca, Morocco|Research Site, Fes, Morocco|Research Site, Rabat, Morocco|Research Site, Sittard- Geleen, Netherlands|Research Site, Gdansk, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Poznan, Poland|Research Site, Warszawy, Poland|Research Site, Lisboa, Portugal|Research Site, Ekaterinburg, Russian Federation|Research Site, Kaluga, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Kursk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Rostov-on-Don, Russian Federation|Research Site, Samara, Russian Federation|Reseach Site, Saratov, Russian Federation|Research Site, St-Petersburg, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Vladimir, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Riyadh, Saudi Arabia|Research Site, Belgrade, Serbia|Research Site, Lausanne, Switzerland|Research Site, St. Gallen, Switzerland|Research Site, Monastir, Tunisia|Research Site, Sfax, Tunisia|Research Site, Tunis, Tunisia|Research Site, Bursa, Turkey|Research Site, Izmir, Turkey|Research Site, Kharkov, Ukraine|Research Site, Kiev, Ukraine|Research Site, Lviv, Ukraine|Research Site, Vinnitsa, Ukraine|Research Site, Hull, United Kingdom|Research Site, London, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Oxford, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Stoke-on-Trent, United Kingdom"
NCT01184833,Evaluation of Risk Factors for Early Termination of Injection Treatment With Betaferon in Patients Suffering From Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01184833,COMPLETED,Multiple Sclerosis,"DRUG: Interferon beta-1b (Betaseron, BAY86-5046)",Bayer,,ALL,"ADULT, OLDER_ADULT",,852,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2008-09,,2011-08,"Many Locations, Poland"
NCT02633033,Observational Registry of Acthar Gel for Participants With Multiple Sclerosis Relapse,https://beta.clinicaltrials.gov/study/NCT02633033,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",,Mallinckrodt,Mallinckrodt ARD Inc.,ALL,"ADULT, OLDER_ADULT",,160,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-11-24,2019-05-09,2019-05-09,"Alabama Neurology Associates, Homewood, Alabama, 35209, United States|Territory Neurology & Research Institute, Tucson, Arizona, 85704, United States|Colorado Springs Neurological Associates, Colorado Springs, Colorado, 80907, United States|Advanced Neurosciences Research, Fort Collins, Colorado, 80528, United States|Associated Neurologists of Southern Connecticut, Fairfield, Connecticut, 06824, United States|MedStar Health, Washington, District of Columbia, 20007, United States|Emery Neuroscience Center, Lighthouse Point, Florida, 33064, United States|Neurology Associates, Maitland, Florida, 32751, United States|Cordova Research Institute, Miami, Florida, 33155, United States|Collier Neurologic Specialists, Naples, Florida, 34102, United States|Florida Neurological Center, Ocala, Florida, 34471, United States|Neurological Services of Orlando, Orlando, Florida, 32806, United States|Neurology Associates of Ormond Beach, Ormond Beach, Florida, 32174, United States|Negroski, Sutherland and Hanes Neurology, Sarasota, Florida, 34239, United States|Infinity Clinical Research, Sunrise, Florida, 33351, United States|Columbus Research & Wellness Institute, Columbus, Georgia, 31904, United States|Neurology of Central Georgia, Macon, Georgia, 31210, United States|Meridian Clinical Research, Savannah, Georgia, 31406, United States|College Park Family Care Center, Overland Park, Kansas, 66212, United States|University System of Maryland, Baltimore, Maryland, 21201, United States|International Neurorehabilitation Institute, Lutherville, Maryland, 21093, United States|Neurology Center of New England, Foxboro, Massachusetts, 02035, United States|Milford Regional Medical Center, Hopedale, Massachusetts, 01747, United States|Detroit Clinical Research Center, Farmington Hills, Michigan, 48334, United States|CentraState Medical Center, Freehold, New Jersey, 07728, United States|Strotira, Inc., New York, New York, 11714, United States|Alpha Neurology, Staten Island, New York, 10306, United States|Five Towns Neurology, Woodmere, New York, 11598, United States|Braunstein Neurology, Mooresville, North Carolina, 28117, United States|The Toledo Clinic, Toledo, Ohio, 43623, United States|Oak Clinic for Multiple Sclerosis, Uniontown, Ohio, 44685, United States|Optimum Neurology, Bala-Cynwyd, Pennsylvania, 19004, United States|Irene Greenhouse MD, Jamison, Pennsylvania, 18929, United States|Neurology and Stroke Associates, Lititz, Pennsylvania, 17543, United States|D. Gary Kolva, MD, Neurology, West Reading, Pennsylvania, 19610, United States|Colonial Healthcare, Sumter, South Carolina, 29150, United States|Ogden Clinic, Ogden, Utah, 84403, United States|Dominion Neurological Services, Richmond, Virginia, 23226, United States"
NCT05188937,Validity and Reliability of the Dual-task Questionnaire,https://beta.clinicaltrials.gov/study/NCT05188937,COMPLETED,Multiple Sclerosis,PROCEDURE: validity and reliability study,Gazi University,,ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-02-01,2021-10-01,2022-05-05,"Gazi University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Ankara, Turkey"
NCT03797937,Microbiome Benchmarking to Identify Perturbations in Multiple Sclerosis II,https://beta.clinicaltrials.gov/study/NCT03797937,COMPLETED,Multiple Sclerosis,OTHER: Magnetic resonance imaging (MRI),National MS Center Melsbroek,,ALL,ADULT,NA,250,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2018-11-01,2021-11-01,2022-05-01,"Universitair Ziekenhuis Brussel, Jette, Brussel, 1090, Belgium|Nationaal Multiple Sclerose Centrum Melsbroek, Melsbroek, Vlaams-Brabant, 1820, Belgium"
NCT00906737,Effects of Targeted Lower Extremity Joint Training on Multiple Sclerosis (MS) Gait Abnormalities,https://beta.clinicaltrials.gov/study/NCT00906737,COMPLETED,Multiple Sclerosis,DEVICE: Ankle-bot|OTHER: Conventional focused ankle therapy,Mount Sinai Rehabilitation Hospital,,ALL,"ADULT, OLDER_ADULT",NA,18,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2009-04,2012-04,2012-04,"Mandell Center for Multiple Sclerosis at Mount Sinai Rehabilitation Hospital, Hartford, Connecticut, 06112, United States"
NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",https://beta.clinicaltrials.gov/study/NCT03650114,RECRUITING,Relapsing Multiple Sclerosis,"BIOLOGICAL: Ofatumumab|BIOLOGICAL: Tetanus toxoid (TT) containing vaccine (Td, Tdap)|BIOLOGICAL: 13-valent pneumococcal conjugate vaccine (13-PCV)|BIOLOGICAL: 23-valent pneumococcal polysaccharide vaccine (23-PPV)|BIOLOGICAL: Seasonal Quadrivalent influenza vaccine|BIOLOGICAL: Keyhole limpet hemocyanin (KLH) neo-antigen",Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,2060,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-12-28,2030-03-13,2030-03-14,"Novartis Investigative Site, Birmingham, Alabama, 35233-0271, United States|Novartis Investigative Site, Cullman, Alabama, 35058, United States|Novartis Investigative Site, Phoenix, Arizona, 85013, United States|Novartis Investigative Site, Fullerton, California, 92835, United States|Novartis Investigative Site, Sacramento, California, 95817, United States|Novartis Investigative Site, Aurora, Colorado, 80045, United States|Novartis Investigative Site, Basalt, Colorado, 81621, United States|Novartis Investigative Site, Boulder, Colorado, 80301, United States|Novartis Investigative Site, Colorado Springs, Colorado, 80907, United States|Novartis Investigative Site, Denver, Colorado, 80210, United States|Novartis Investigative Site, Fort Collins, Colorado, 80528, United States|Novartis Investigative Site, Fort Collins, Colorado, 80528, United States|Novartis Investigative Site, Newark, Delaware, 19713, United States|Novartis Investigative Site, Washington, District of Columbia, 20007, United States|Novartis Investigative Site, Atlantis, Florida, 33462-6608, United States|Novartis Investigative Site, Bradenton, Florida, 34205, United States|Novartis Investigative Site, Delray Beach, Florida, 33445, United States|Novartis Investigative Site, Maitland, Florida, 32751, United States|Novartis Investigative Site, Miami, Florida, 33032, United States|Novartis Investigative Site, Miami, Florida, 33136, United States|Novartis Investigative Site, Naples, Florida, 34102, United States|Novartis Investigative Site, Oldsmar, Florida, 34677, United States|Novartis Investigative Site, Ormond Beach, Florida, 32174, United States|Novartis Investigative Site, Pensacola, Florida, 32514, United States|Novartis Investigative Site, Port Charlotte, Florida, 33952, United States|Novartis Investigative Site, Sarasota, Florida, 34243, United States|Novartis Investigative Site, Sunrise, Florida, 33351, United States|Novartis Investigative Site, Tallahassee, Florida, 32312, United States|Novartis Investigative Site, Tampa, Florida, 33603, United States|Novartis Investigative Site, Tampa, Florida, 33609, United States|Novartis Investigative Site, Tampa, Florida, 33612, United States|Novartis Investigative Site, West Palm Beach, Florida, 33407, United States|Novartis Investigative Site, Savannah, Georgia, 31406, United States|Novartis Investigative Site, Suwanee, Georgia, 30024, United States|Novartis Investigative Site, Honolulu, Hawaii, 96817, United States|Novartis Investigative Site, Chicago, Illinois, 60612, United States|Novartis Investigative Site, Northbrook, Illinois, 60062, United States|Novartis Investigative Site, Indianapolis, Indiana, 46256, United States|Novartis Investigative Site, Des Moines, Iowa, 50314-2611, United States|Novartis Investigative Site, Kansas City, Kansas, 66160, United States|Novartis Investigative Site, Overland Park, Kansas, 66210, United States|Novartis Investigative Site, Alexandria, Louisiana, 71301, United States|Novartis Investigative Site, Baton Rouge, Louisiana, 70810, United States|Novartis Investigative Site, Wellesley, Massachusetts, 02481, United States|Novartis Investigative Site, Detroit, Michigan, 48201, United States|Novartis Investigative Site, Detroit, Michigan, 48202, United States|Novartis Investigative Site, Golden Valley, Minnesota, 55422, United States|Novartis Investigative Site, Chesterfield, Missouri, 63017, United States|Novartis Investigative Site, Ozark, Missouri, 65721, United States|Novartis Investigative Site, Saint Louis, Missouri, 63110, United States|Novartis Investigative Site, Billings, Montana, 59101, United States|Novartis Investigative Site, Great Falls, Montana, 59405, United States|Novartis Investigative Site, Las Vegas, Nevada, 89106, United States|Novartis Investigative Site, Albuquerque, New Mexico, 87131-0001, United States|Novartis Investigative Site, Latham, New York, 12110, United States|Novartis Investigative Site, Asheville, North Carolina, 28806, United States|Novartis Investigative Site, Charlotte, North Carolina, 28204, United States|Novartis Investigative Site, Greensboro, North Carolina, 27405, United States|Novartis Investigative Site, Raleigh, North Carolina, 27607, United States|Novartis Investigative Site, Winston-Salem, North Carolina, 27103, United States|Novartis Investigative Site, Akron, Ohio, 44320, United States|Novartis Investigative Site, Cleveland, Ohio, 44195, United States|Novartis Investigative Site, Columbus, Ohio, 43214, United States|Novartis Investigative Site, Westerville, Ohio, 43082, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, 73104, United States|Novartis Investigative Site, Portland, Oregon, 97225, United States|Novartis Investigative Site, Willow Grove, Pennsylvania, 19090, United States|Novartis Investigative Site, Greer, South Carolina, 29650, United States|Novartis Investigative Site, Spartanburg, South Carolina, 29303, United States|Novartis Investigative Site, Spartanburg, South Carolina, 29303, United States|Novartis Investigative Site, Cordova, Tennessee, 38018, United States|Novartis Investigative Site, Johnson City, Tennessee, 37604, United States|Novartis Investigative Site, Knoxville, Tennessee, 37920, United States|Novartis Investigative Site, Knoxville, Tennessee, 37922, United States|Novartis Investigative Site, El Paso, Texas, 79935, United States|Novartis Investigative Site, Houston, Texas, 77074, United States|Novartis Investigative Site, Lubbock, Texas, 79410, United States|Novartis Investigative Site, Round Rock, Texas, 78681, United States|Novartis Investigative Site, San Antonio, Texas, 78258, United States|Novartis Investigative Site, Sherman, Texas, 75092, United States|Novartis Investigative Site, Salt Lake City, Utah, 84103, United States|Novartis Investigative Site, Salt Lake City, Utah, 84132, United States|Novartis Investigative Site, Virginia Beach, Virginia, 23456, United States|Novartis Investigative Site, Kirkland, Washington, 98034, United States|Novartis Investigative Site, Tacoma, Washington, 98405, United States|Novartis Investigative Site, Green Bay, Wisconsin, 54311, United States|Novartis Investigative Site, Madison, Wisconsin, 53792, United States|Novartis Investigative Site, Milwaukee, Wisconsin, 53215, United States|Novartis Investigative Site, Rosario, Santa Fe, S2000BZL, Argentina|Novartis Investigative Site, Rosario, Santa Fe, S2000DSW, Argentina|Novartis Investigative Site, Buenos Aires, 1061, Argentina|Novartis Investigative Site, Cordoba, X5004CDT, Argentina|Novartis Investigative Site, Tucuman, 4000, Argentina|Novartis Investigative Site, Liverpool, New South Wales, 2170, Australia|Novartis Investigative Site, New Lambton Heights, New South Wales, 2305, Australia|Novartis Investigative Site, St Leonards, New South Wales, 2065, Australia|Novartis Investigative Site, Vienna, 1090, Austria|Novartis Investigative Site, Wien, 1010, Austria|Novartis Investigative Site, Edegem, Antwerpen, 2650, Belgium|Novartis Investigative Site, Brasschaat, 2930, Belgium|Novartis Investigative Site, Brugge, 8000, Belgium|Novartis Investigative Site, Bruxelles, 1200, Belgium|Novartis Investigative Site, Gent, 9000, Belgium|Novartis Investigative Site, Pleven, 5800, Bulgaria|Novartis Investigative Site, Sofia, 1113, Bulgaria|Novartis Investigative Site, Sofia, 1309, Bulgaria|Novartis Investigative Site, Sofia, 1413, Bulgaria|Novartis Investigative Site, Sofia, 1431, Bulgaria|Novartis Investigative Site, London, Ontario, N6A 5A5, Canada|Novartis Investigative Site, Ottawa, Ontario, K1H 8L6, Canada|Novartis Investigative Site, Toronto, Ontario, M4N 3M5, Canada|Novartis Investigative Site, Gatineau, Quebec, J9J 0A5, Canada|Novartis Investigative Site, Greenfield Park, Quebec, J4V 2J2, Canada|Novartis Investigative Site, Montreal, Quebec, H3A 2B4, Canada|Novartis Investigative Site, Quebec, G1J 1Z4, Canada|Novartis Investigative Site, Rijeka, HRV, 51000, Croatia|Novartis Investigative Site, Osijek, 31000, Croatia|Novartis Investigative Site, Zagreb, 10000, Croatia|Novartis Investigative Site, Zagreb, 10000, Croatia|Novartis Investigative Site, Brno, Czech Republic, 656 91, Czechia|Novartis Investigative Site, Havirov, Czech Republic, 736 01, Czechia|Novartis Investigative Site, Teplice, Czech Republic, 415 01, Czechia|Novartis Investigative Site, Hradec Kralove, CZE, 500 05, Czechia|Novartis Investigative Site, Olomouc, CZE, 775 20, Czechia|Novartis Investigative Site, JIhlava, 586 01, Czechia|Novartis Investigative Site, Ostrava-Poruba, 708 52, Czechia|Novartis Investigative Site, Pardubice, 532 03, Czechia|Novartis Investigative Site, Praha 10, 100 34, Czechia|Novartis Investigative Site, Praha 4, 140 59, Czechia|Novartis Investigative Site, Praha 5, 150 06, Czechia|Novartis Investigative Site, Copenhagen, DK-2100, Denmark|Novartis Investigative Site, Odense C, 5000, Denmark|Novartis Investigative Site, Tallinn, 10617, Estonia|Novartis Investigative Site, Tartu, 51014, Estonia|Novartis Investigative Site, Tampere, 33100, Finland|Novartis Investigative Site, Turku, 20520, Finland|Novartis Investigative Site, Nice, Cedex1, 06001, France|Novartis Investigative Site, Lille Cedex, 59037, France|Novartis Investigative Site, Montpellier, 34295, France|Novartis Investigative Site, Nantes Cedex 1, 44093, France|Novartis Investigative Site, Nimes, 30029, France|Novartis Investigative Site, Paris Cedex 13, 75651, France|Novartis Investigative Site, Strasbourg, 67098, France|Novartis Investigative Site, Barsinghausen, 30890, Germany|Novartis Investigative Site, Bayreuth, 95445, Germany|Novartis Investigative Site, Bielefeld, D 33647, Germany|Novartis Investigative Site, Bochum, 44791, Germany|Novartis Investigative Site, Dresden, 01307, Germany|Novartis Investigative Site, Essen, 45147, Germany|Novartis Investigative Site, Hamburg, 22179, Germany|Novartis Investigative Site, Hannover, 30625, Germany|Novartis Investigative Site, Heidelberg, 69120, Germany|Novartis Investigative Site, Koln, 50935, Germany|Novartis Investigative Site, Leipzig, 04103, Germany|Novartis Investigative Site, Marburg, 35043, Germany|Novartis Investigative Site, Minden, 32429, Germany|Novartis Investigative Site, Muenchen, 80377, Germany|Novartis Investigative Site, Muenchen, 81377, Germany|Novartis Investigative Site, Neuburg an der Donau, 86633, Germany|Novartis Investigative Site, Potsdam, 14471, Germany|Novartis Investigative Site, Siegen, 57076, Germany|Novartis Investigative Site, Ulm, 89073, Germany|Novartis Investigative Site, Unterhaching, 82008, Germany|Novartis Investigative Site, Athens, GR, 115 25, Greece|Novartis Investigative Site, Thessaloniki, GR 54636, Greece|Novartis Investigative Site, Budapest, HUN, 1135, Hungary|Novartis Investigative Site, Budapest, HUN, 1204, Hungary|Novartis Investigative Site, Esztergom, HUN, 2500, Hungary|Novartis Investigative Site, Budapest, 1106, Hungary|Novartis Investigative Site, Kistarcsa, 2143, Hungary|Novartis Investigative Site, Pecs, 7623, Hungary|Novartis Investigative Site, Szeged, 6725, Hungary|Novartis Investigative Site, New Delhi, Delhi, 110 060, India|Novartis Investigative Site, New Delhi, Delhi, 110017, India|Novartis Investigative Site, Kochi, Kerala, 682 026, India|Novartis Investigative Site, Mumbai, Maharashtra, 400008, India|Novartis Investigative Site, Pune, Maharashtra, 411004, India|Novartis Investigative Site, Chandigarh, Punjab, 160012, India|Novartis Investigative Site, Hyderabad, Telangana, 500082, India|Novartis Investigative Site, Howrah, West Bengal, 711103, India|Novartis Investigative Site, Mangalore, 575018, India|Novartis Investigative Site, Ashkelon, 78278, Israel|Novartis Investigative Site, Haifa, 3109601, Israel|Novartis Investigative Site, Sefad, 13100, Israel|Novartis Investigative Site, Tel Aviv, 6423906, Israel|Novartis Investigative Site, Toon-city, Ehime, 791-0295, Japan|Novartis Investigative Site, Sapporo city, Hokkaido, 063-0005, Japan|Novartis Investigative Site, Morioka, Iwate, 020-8505, Japan|Novartis Investigative Site, Sendai city, Miyagi, 980 8574, Japan|Novartis Investigative Site, Sendai city, Miyagi, 983 8512, Japan|Novartis Investigative Site, Kawagoe, Saitama, 350 8550, Japan|Novartis Investigative Site, Kodaira, Tokyo, 187-8551, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, 160 8582, Japan|Novartis Investigative Site, Chiba, 260 8677, Japan|Novartis Investigative Site, Niigata, 951 8520, Japan|Novartis Investigative Site, Osaka, 556-0016, Japan|Novartis Investigative Site, Riga, LV, LV-1005, Latvia|Novartis Investigative Site, Riga, LV 1002, Latvia|Novartis Investigative Site, Riga, LV-1038, Latvia|Novartis Investigative Site, Kaunas, LTU, LT 50161, Lithuania|Novartis Investigative Site, Vilnius, LT-08661, Lithuania|Novartis Investigative Site, Mexico, Distrito Federal, 03100, Mexico|Novartis Investigative Site, Chihuahua, 31238, Mexico|Novartis Investigative Site, Amsterdam, 1081 HV, Netherlands|Novartis Investigative Site, Rotterdam, 3015 CE, Netherlands|Novartis Investigative Site, Sittard-Geleen, 6162 BG, Netherlands|Novartis Investigative Site, Drammen, 1086, Norway|Novartis Investigative Site, Cercado De Lima, Lima, 01, Peru|Novartis Investigative Site, San Isidro, Lima, 27, Peru|Novartis Investigative Site, Lima, LIMA 13, Peru|Novartis Investigative Site, Bydgoszcz, Woj Kujawsko-pomorskie, 85-796, Poland|Novartis Investigative Site, Gdansk, 80 952, Poland|Novartis Investigative Site, Gdansk, 80-462, Poland|Novartis Investigative Site, Gdansk, 80-803, Poland|Novartis Investigative Site, Glogow, 36-060, Poland|Novartis Investigative Site, Katowice, 40 571, Poland|Novartis Investigative Site, Kielce, 25 726, Poland|Novartis Investigative Site, Lodz, 90 324, Poland|Novartis Investigative Site, Rzeszow, 35 055, Poland|Novartis Investigative Site, Warszawa, 02 957, Poland|Novartis Investigative Site, Wroclaw, 51-685, Poland|Novartis Investigative Site, Zabrze, 41-800, Poland|Novartis Investigative Site, Matosinhos, Porto, 4454509, Portugal|Novartis Investigative Site, Braga, 4710243, Portugal|Novartis Investigative Site, Coimbra, 3000 075, Portugal|Novartis Investigative Site, Lisboa, 1169-050, Portugal|Novartis Investigative Site, Lisboa, 1500 650, Portugal|Novartis Investigative Site, Loures, 2674514, Portugal|Novartis Investigative Site, Porto, 4099-001, Portugal|Novartis Investigative Site, Santa Maria da Feira, 4520 211, Portugal|Novartis Investigative Site, Ekaterinburg, 620109, Russian Federation|Novartis Investigative Site, Kazan, 420043, Russian Federation|Novartis Investigative Site, Kemerovo, 650066, Russian Federation|Novartis Investigative Site, Krasnoyarsk, 660049, Russian Federation|Novartis Investigative Site, Moscow, 125367, Russian Federation|Novartis Investigative Site, Moscow, 127015, Russian Federation|Novartis Investigative Site, Nizhny Novgorod, 603137, Russian Federation|Novartis Investigative Site, Nizhny Novgorod, 603155, Russian Federation|Novartis Investigative Site, Novosibirsk, 630007, Russian Federation|Novartis Investigative Site, Novosibirsk, 630087, Russian Federation|Novartis Investigative Site, Saint Petersburg, 194044, Russian Federation|Novartis Investigative Site, Saint Petersburg, 197022, Russian Federation|Novartis Investigative Site, Saransk, 430032, Russian Federation|Novartis Investigative Site, Sestroretsk, 197706, Russian Federation|Novartis Investigative Site, St Petersburg, 190000, Russian Federation|Novartis Investigative Site, St. Petersburg, 197376, Russian Federation|Novartis Investigative Site, Tyumen, 625000, Russian Federation|Novartis Investigative Site, Banska Bystrica, 975 17, Slovakia|Novartis Investigative Site, Bratislava, 813 69, Slovakia|Novartis Investigative Site, Bratislava, 82606, Slovakia|Novartis Investigative Site, Bratislava, 83305, Slovakia|Novartis Investigative Site, Martin, 036 59, Slovakia|Novartis Investigative Site, Nitra, 94901, Slovakia|Novartis Investigative Site, Trnava, 917 75, Slovakia|Novartis Investigative Site, Pretoria, 0041, South Africa|Novartis Investigative Site, Rosebank, 2196, South Africa|Novartis Investigative Site, Cadiz, Andalucia, 11009, Spain|Novartis Investigative Site, Malaga, Andalucia, 29010, Spain|Novartis Investigative Site, Sevilla, Andalucia, 41017, Spain|Novartis Investigative Site, Barcelona, Cataluna, 08026, Spain|Novartis Investigative Site, Salt, Cataluna, 17190, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08003, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08035, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08036, Spain|Novartis Investigative Site, L Hospitalet De Llobregat, Catalunya, 08907, Spain|Novartis Investigative Site, Pozuelo de Alarcon, Madrid, 28223, Spain|Novartis Investigative Site, El Palmar, Murcia, 30120, Spain|Novartis Investigative Site, San Sebastian, Pais Vasco, 20080, Spain|Novartis Investigative Site, Castilleja de la Cuesta, Sevilla, 41950, Spain|Novartis Investigative Site, Baracaldo, Vizcaya, 48903, Spain|Novartis Investigative Site, Madrid, 28006, Spain|Novartis Investigative Site, Madrid, 28034, Spain|Novartis Investigative Site, Madrid, 28040, Spain|Novartis Investigative Site, Madrid, 28222, Spain|Novartis Investigative Site, Valencia, 46026, Spain|Novartis Investigative Site, Goeteborg, 413 45, Sweden|Novartis Investigative Site, Stockholm, 102 35, Sweden|Novartis Investigative Site, Basel, 4031, Switzerland|Novartis Investigative Site, Lugano, 6900, Switzerland|Novartis Investigative Site, Tainan, 70403, Taiwan|Novartis Investigative Site, Khon Kaen, THA, 40002, Thailand|Novartis Investigative Site, Sancaktepe, Istanbul, 34785, Turkey|Novartis Investigative Site, Haseki / Istanbul, 34096, Turkey|Novartis Investigative Site, Istanbul, 34147, Turkey|Novartis Investigative Site, Izmir, 35040, Turkey|Novartis Investigative Site, Izmir, 35340, Turkey|Novartis Investigative Site, Kocaeli, 41380, Turkey|Novartis Investigative Site, Mersin, 33079, Turkey|Novartis Investigative Site, Samsun, 55139, Turkey|Novartis Investigative Site, Trabzon, 61080, Turkey|Novartis Investigative Site, Luton, Beds, LU4 0DZ, United Kingdom|Novartis Investigative Site, Headington, Oxfordshire, OX3 9DU, United Kingdom|Novartis Investigative Site, Sheffield, South Yorkshire, S10 2JF, United Kingdom|Novartis Investigative Site, Glasgow, G51 4TF, United Kingdom|Novartis Investigative Site, London, E1 1BB, United Kingdom|Novartis Investigative Site, London, SW17 0QT, United Kingdom"
NCT01871337,Exercises for Urinary Incontinence(UI) of Women With Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT01871337,COMPLETED,Urinary Incontinence;|Multiple Sclerosis,BEHAVIORAL: Paula method,Hadassah Medical Organization,,FEMALE,"ADULT, OLDER_ADULT",NA,12,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-02,2015-09,2015-09,"Hadassah University Hospital, Jerusalem, 91120, Israel|Hadassah Hospital, Jerusalem, Israel"
NCT04237337,Drugs for the Treatment of Multiple Sclerosis and Risk of Cancer: a Pharmacovigilance Analysis in Vigibase,https://beta.clinicaltrials.gov/study/NCT04237337,UNKNOWN,Multiple Sclerosis|Malignant Tumor,OTHER: Exposure to MS drugs,"University Hospital, Caen",,ALL,"CHILD, ADULT, OLDER_ADULT",,200000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-01,2020-02,2020-03,
NCT00004814,"Phase III Randomized, Double-Blind, Placebo-Controlled Study of Copolymer 1 for Relapsing-Remitting Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT00004814,COMPLETED,Multiple Sclerosis,DRUG: copolymer 1,National Center for Research Resources (NCRR),University of Maryland,ALL,ADULT,PHASE3,250,NIH,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: |Masking: |Primary Purpose: TREATMENT,1991-10,,,
NCT03774914,LEMTRADA Pregnancy Registry in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03774914,TERMINATED,Multiple Sclerosis,DRUG: Alemtuzumab (GZ402673),"Genzyme, a Sanofi Company",,FEMALE,ADULT,,42,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-09-01,2021-11-22,2021-11-22,"Investigational Site Number :840999, New York, New York, 00000, United States|Investigational Site Number :036001, Box Hill, Victoria, 3128, Australia|Investigational Site Number :040-001, Linz, Austria|Investigational Site Number :56, Charleroi, 6000, Belgium|Investigational Site Number :124999, Canada, Canada|Investigational Site Number :208001, Aarhus C, 8000, Denmark|Investigational Site Number :276001, Bochum, 44791, Germany|Investigational Site Number :380001, Gallarate (VA), 21013, Italy|Investigational Site Number :528999, Netherlands, Netherlands|Investigational Site Number :724999, Spain, Spain|Investigational Site Number :752001, Göteborg, 41345, Sweden|Investigational Site Number :756001, Zürich, 8091, Switzerland|Investigational Site Number :826-001, Salford, M6 8HD, United Kingdom"
NCT00142714,Effects of Spinal Cord Injury on Female Sexual Response,https://beta.clinicaltrials.gov/study/NCT00142714,UNKNOWN,Female Sexual Dysfunction|Multiple Sclerosis|Spinal Cord Injury,PROCEDURE: Sympathetic manipulation on sexual arousal in women,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),,FEMALE,ADULT,NA,70,NIH,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: ECT,2003-08,,2005-06,"The University of Alabama at Birmingham, Birmingham, Alabama, 35233, United States"
NCT01080014,Correlation Between Multiple Sclerosis Functional Composite (MSFC) and Expanded Disability Status Scale (EDSS) in Patients With Multiple Sclerosis (MS) in Argentina,https://beta.clinicaltrials.gov/study/NCT01080014,COMPLETED,Multiple Sclerosis,,"Merck KGaA, Darmstadt, Germany",,ALL,"ADULT, OLDER_ADULT",,252,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2008-08,2013-04,2013-04,"Dr. Roberto Rosa, Buenos Aires, Argentina"
NCT01572714,Examining the Effects of a Telehealth Self-management Intervention in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01572714,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Social Support Program|BEHAVIORAL: Physical Activity Program|BEHAVIORAL: Physical Activity Plus Fatigue Management Education Program,Case Western Reserve University,National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",NA,208,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2011-07,2017-02,2017-02,"Case Western Reserve University, Cleveland, Ohio, 44106, United States"
NCT01305837,Cyclic Oral Methylprednisolone Trial in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01305837,COMPLETED,Progressive Multiple Sclerosis,DRUG: methylprednisolone,"Rigshospitalet, Denmark",,ALL,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-04,2013-07,2013-07,"Scleroseklinikken, Rigshospitalet, Copenhagen, 2100, Denmark"
NCT01532037,Self Help for Fatigue in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01532037,COMPLETED,Multiple Sclerosis|Fatigue,OTHER: Cognitive behavioural therapy based self help|OTHER: Treatment as usual,University of Edinburgh,,ALL,"ADULT, OLDER_ADULT",NA,73,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,2012-06,2014-05,2014-05,"Fife Rehabilitation Service, Leven, Scotland, KY8 5RR, United Kingdom|NHS Fife, Leven, Scotland, KY8 5RR, United Kingdom"
NCT02962414,Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment,https://beta.clinicaltrials.gov/study/NCT02962414,ACTIVE_NOT_RECRUITING,Tuberous Sclerosis Complex,DRUG: everolimus,Novartis Pharmaceuticals,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,206,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2017-06-08,2027-08-04,2027-08-13,"TGen/APNNA SC, Phoenix, Arizona, 85012, United States|David Geffen School of Medicine at UCLA, Los Angeles, California, 90005-1752, United States|UCSF Benioff Children s Hospital, Oakland, California, 94609, United States|Rady Children s Hospital SC, San Diego, California, 92123, United States|University of Colorado School of Medicine, Aurora, Colorado, 80045, United States|Connecticut Childrens Medical Center, Hartford, Connecticut, 06106, United States|University of Chicago Medical Center, Chicago, Illinois, 60637, United States|Minnesota Epilepsy Group, Saint Paul, Minnesota, 55102, United States|Atlantic Health Systems, Morristown, New Jersey, 07962, United States|Cinn Children Hosp Medical Center SC-2, Cincinnati, Ohio, 45229-3039, United States|Oregon Health and Science Univ, Portland, Oregon, 97239, United States|Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States|Texas Scottish Rite Hospital for Children SC, Dallas, Texas, 75219, United States|Texas Children s Hospital SC-2, Houston, Texas, 77030, United States|Novartis Investigative Site, Randwick, New South Wales, 2130, Australia|Novartis Investigative Site, Nedlands, Western Australia, 6009, Australia|Novartis Investigative Site, Jette, Brussel, 1090, Belgium|Novartis Investigative Site, Bruxelles, 1200, Belgium|Novartis Investigative Site, Gent, 9000, Belgium|Novartis Investigative Site, Leuven, 3000, Belgium|Novartis Investigative Site, Vancouver, British Columbia, V6H 3V4, Canada|Novartis Investigative Site, Cali, Valle Del Cauca, 760012, Colombia|Novartis Investigative Site, Amiens, 80054, France|Novartis Investigative Site, Bron Cedex, 69677, France|Novartis Investigative Site, Lille Cedex, 59037, France|Novartis Investigative Site, Marseille Cedex 05, 13885, France|Novartis Investigative Site, Strasbourg Cedex, F 67098, France|Novartis Investigative Site, Budapest, 1145, Hungary|Novartis Investigative Site, Bari, BA, 70124, Italy|Novartis Investigative Site, Bologna, BO, 40139, Italy|Novartis Investigative Site, Pavia, PV, 27100, Italy|Novartis Investigative Site, Roma, RM, 00161, Italy|Novartis Investigative Site, Siena, SI, 53100, Italy|Novartis Investigative Site, Okayama-city, Okayama, 700-8558, Japan|Novartis Investigative Site, Suita, Osaka, 565 0871, Japan|Novartis Investigative Site, Shizuoka-city, Shizuoka, 420-8688, Japan|Novartis Investigative Site, Osaka, 534-0021, Japan|Novartis Investigative Site, Seoul, 03080, Korea, Republic of|Novartis Investigative Site, Seoul, 03722, Korea, Republic of|Novartis Investigative Site, Seoul, 06351, Korea, Republic of|Novartis Investigative Site, Guadalajara, Jalisco, 44280, Mexico|Novartis Investigative Site, Warszawa, 04 730, Poland|Novartis Investigative Site, Samara, Samara Region, 443095, Russian Federation|Novartis Investigative Site, Voronezh, Voronezh Region, 394024, Russian Federation|Novartis Investigative Site, Moscow, 119991, Russian Federation|Novartis Investigative Site, Moscow, 127412, Russian Federation|Novartis Investigative Site, Sevilla, Andalucia, 41013, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08035, Spain|Novartis Investigative Site, San Sebastian, Pais Vasco, 20080, Spain|Novartis Investigative Site, Madrid, 28009, Spain|Novartis Investigative Site, Madrid, 28041, Spain|Novartis Investigative Site, Valencia, 46026, Spain|Novartis Investigative Site, Kaohsiung City, 83301, Taiwan|Novartis Investigative Site, Tainan, 70403, Taiwan|Novartis Investigative Site, Taipei, 10002, Taiwan|Novartis Investigative Site, Bangkok, 10330, Thailand|Novartis Investigative Site, Bangkok, 10400, Thailand|Novartis Investigative Site, Bangkok, 10700, Thailand|Novartis Investigative Site, Ankara, 06500, Turkey|Novartis Investigative Site, Istanbul, 34093, Turkey|Novartis Investigative Site, Edgbaston, Birmingham, B15 2TH, United Kingdom|Novartis Investigative Site, Cambridge, Cambrigdeshire, CB2 0QQ, United Kingdom|Novartis Investigative Site, Buckinghamshire, SL9 0RJ, United Kingdom|Novartis Investigative Site, Liverpool, L12 2AP, United Kingdom|Novartis Investigative Site, London, SW17 0QT, United Kingdom|Novartis Investigative Site, London, WC1N 3JH, United Kingdom|Novartis Investigative Site, Sheffield, S10 2TH, United Kingdom|Novartis Investigative Site, York, YO31 7EX, United Kingdom"
NCT02655614,"A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis",https://beta.clinicaltrials.gov/study/NCT02655614,COMPLETED,Amyotrophic Lateral Sclerosis,DRUG: GDC-0134|DRUG: Placebo|DRUG: Rabeprazole|DRUG: Midazolam|DRUG: Caffeine,"Genentech, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1,54,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2016-05-31,2020-03-16,2020-03-16,"Forbes Norris Mda/als Ctr; Research Center, San Francisco, California, 94115, United States|Mayo Clinic Hospital - Florida, Jacksonville, Florida, 32224, United States|University of Miami Miller School of Medicine, Miami, Florida, 33136, United States|The Emory ALS Clinic, Atlanta, Georgia, 30322, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, 21205, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Wake Research Associates, Raleigh, North Carolina, 27612, United States|New Orleans Center for Clinical Research, Knoxville, Tennessee, 37920, United States|MUCH - Montreal Neurological Institute & Hospital, Montreal, Quebec, H3A 2B4, Canada|UMC Utrecht, Utrecht, 3508 GA, Netherlands"
NCT04121637,To Investigate the Effect of Aerobic Exercise on Neurophysiological Values and Functionality in Individuals With Multiple Sclerosis.,https://beta.clinicaltrials.gov/study/NCT04121637,UNKNOWN,"Multiple Sclerosis, Relapsing-Remitting|FNDC5|Irisin Hormone|Aerobic Exercise|EMG: Axonal Abnormality",OTHER: Aerobic Exercise|OTHER: Frenkel coordination exercises,Firat University,Pamukkale University,ALL,"ADULT, OLDER_ADULT",NA,22,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-10-21,2020-01-01,2020-06-01,
NCT03926637,Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03926637,TERMINATED,Multiple Sclerosis,OTHER: Multiple Sclerosis Performance Test (MSPT),Biogen,,ALL,"CHILD, ADULT, OLDER_ADULT",,3073,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-06-17,2022-12-05,2022-12-05,"Research Site, Berkeley, California, 94705, United States|Research Site, Los Angeles, California, 90033-5310, United States|Research Site, Aurora, Colorado, 80045, United States|Research Site, Washington, District of Columbia, 20007, United States|Research Site, Atlanta, Georgia, 30309, United States|Research Site, Atlanta, Georgia, 30327, United States|Research Site, Chicago, Illinois, 60008, United States|Research Site, Boston, Massachusetts, 02215, United States|Research Site, Farmington Hills, Michigan, 48334, United States|Research Site, Owosso, Michigan, 48867, United States|Research Site, Saint Louis, Missouri, 63131, United States|Research Site, Teaneck, New Jersey, 07666, United States|Research Site, Buffalo, New York, 14202, United States|Research Site, Durham, North Carolina, 27710, United States|Research Site, Oklahoma City, Oklahoma, 73104, United States|Research Site, Portland, Oregon, 97225, United States|Research Site, Philadelphia, Pennsylvania, 19104, United States|Research Site, Pittsburgh, Pennsylvania, 15212, United States|Research Site, Dallas, Texas, 75390-8806, United States|Research Site, Salt Lake City, Utah, 84103, United States|Research Site, Seattle, Washington, 98122, United States|Research Site, Spokane, Washington, 99208, United States|Research Site, Prague, 12000, Czechia|Research Site, Strasbourg, 67200, France|Research Site, Bari, 70124, Italy|Research Site, Catania, 95123, Italy|Research Site, Milano, 20132, Italy|Research Site, Orbassano, 10043, Italy|Research Site, Roma, 00185, Italy|Research Site, Basel, 4031, Switzerland|Research Site, Bern, 3010, Switzerland|Research Site, Camberley, GU16 7UJ, United Kingdom|Research Site, Oxford, OX3 9DU, United Kingdom"
NCT01624714,Study of Alemtuzumab in Treatment Refractory MS Subjects/Alemtuzumab Naive & Alemtuzumab Experienced Subjects,https://beta.clinicaltrials.gov/study/NCT01624714,UNKNOWN,Multiple Sclerosis,DRUG: Alemtuzumab|DRUG: Alemtuzumab immunotherapy,"Samuel Forrester Hunter, MD, PhD",,ALL,"ADULT, OLDER_ADULT",PHASE1,60,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2012-09,2017-04,2017-09,"Advanced Neurosciences Institute, Franklin, Tennessee, 37064, United States"
NCT04027114,Individualized Physiotherapy and Activity Coaching for Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04027114,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Individualized behavioural physical activity intervention,University of Saskatchewan,Saskatchewan Health Research Foundation (SHRF)|Saskatchewan Centre for Patient-Oriented Research,ALL,"ADULT, OLDER_ADULT",NA,120,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2019-07-12,2021-01-15,2021-06-21,"University of Saskatchewan, Saskatoon, Saskatchewan, S7N 2Z4, Canada"
NCT02810314,Default Mode Network in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02810314,UNKNOWN,Multiple Sclerosis,BEHAVIORAL: neuropsychological battery|OTHER: resting state functional magnetic resonance image (rs-fMRI),Hospital General Universitario Gregorio Marañon,,ALL,ADULT,NA,64,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2017-05-01,2021-10,2021-12,"Hospital General Universitario Gregorio Marañón, Madrid, 28007, Spain"
NCT01466114,Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition,https://beta.clinicaltrials.gov/study/NCT01466114,UNKNOWN,Relapsing-remitting Multiple Sclerosis|Secondary-progressive Multiple Sclerosis|Primary-progressive Multiple Sclerosis,DRUG: estriol|OTHER: Placebo|DRUG: Norethindrone|OTHER: Progestin Placebo,"University of California, Los Angeles",,FEMALE,ADULT,PHASE2,64,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-10,2021-12,2022-04,"University of California Los Angeles, Los Angeles, California, 90095, United States|The University of Colorado Denver, Aurora, Colorado, 80045, United States|The University of New Mexico, Albuquerque, New Mexico, 87131, United States|The University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States"
NCT05493514,Clinical and Instrumental Treatment's Predictors in Subjects With Neurological Diseases Using G-EO Robotic System,https://beta.clinicaltrials.gov/study/NCT05493514,RECRUITING,Multiple Sclerosis|Stroke|Parkinson Disease|Acquired Brain Injury,DEVICE: Robotic Assisted Gait Training with G-EO system,Fondazione Don Carlo Gnocchi Onlus,,ALL,"ADULT, OLDER_ADULT",,260,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-05-13,2027-04-01,2027-04-01,"Don Gnocchi Foundation, Milan, 20148, Italy"
NCT05796037,An Observational Study of Patients Living With Chronic Neurological Diseases,https://beta.clinicaltrials.gov/study/NCT05796037,NOT_YET_RECRUITING,Neurological Diseases or Conditions|Dementia of Alzheimer Type|Alzheimer Disease|Mild Cognitive Impairment|Parkinson Disease|Multiple Sclerosis,,"Target PharmaSolutions, Inc.",,ALL,"ADULT, OLDER_ADULT",,1500000,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-05-24,2038-12-31,2038-12-31,
NCT00262314,"Prospective, Open-label Tolerability and Safety Monitoring Study of Novantrone in a Selected Cohort of Multiple Sclerosis Patients",https://beta.clinicaltrials.gov/study/NCT00262314,COMPLETED,Multiple Sclerosis,,EMD Serono,,ALL,"ADULT, OLDER_ADULT",,509,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2000-10,2008-01,2008-09,"Registrat Inc, Lexington, Kentucky, 40504-3276, United States"
NCT04635033,Intermittent Hypoxia Intervention in MS Patients,https://beta.clinicaltrials.gov/study/NCT04635033,COMPLETED,Multiple Sclerosis,,Universitätsklinikum Hamburg-Eppendorf,,ALL,ADULT,,12,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-09-19,2019-10-10,2019-10-10,"Universitätsklinikum Hamburg-Eppendorf, INIMS, Hamburg, Germany"
NCT02903537,Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS),https://beta.clinicaltrials.gov/study/NCT02903537,UNKNOWN,"Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis, Chronic Progressive",DRUG: Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3)|DRUG: Interferon-beta,Fundació Institut Germans Trias i Pujol,"Clinica Universidad de Navarra, Universidad de Navarra",ALL,ADULT,PHASE1,16,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2017-07-06,2021-12,2021-12,"Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, 08916, Spain|Clínica Universidad de Navarra, Pamplona, Navarra, 31008, Spain"
NCT05772637,Clinical and Urodynamic Assessment of Bladder Sensation in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05772637,NOT_YET_RECRUITING,Overactive Bladder,PROCEDURE: Repeated cystometries with bladder sensations assessment,Assistance Publique - Hôpitaux de Paris,,ALL,"ADULT, OLDER_ADULT",NA,113,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-03-15,2025-03-15,2025-03-15,"Hôpital TENON, Paris, Choisir Une Région, 75020, France"
NCT04750733,Impact of Core Performance on Functional Parameters in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04750733,COMPLETED,Multiple Sclerosis,OTHER: Assessment,Istanbul University - Cerrahpasa (IUC),,ALL,"ADULT, OLDER_ADULT",,50,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-02-20,2022-07-01,2022-07-05,"Istanbul University-Cerrahpasa, Istanbul, 34147, Turkey"
NCT00544037,BENEFIT Extension Study,https://beta.clinicaltrials.gov/study/NCT00544037,COMPLETED,Multiple Sclerosis,"DRUG: Interferon beta-1b (Betaseron, BAY86-5046)",Bayer,,ALL,ADULT,,283,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2007-09,2011-01,2011-01,"Many Locations, Austria|Many Locations, Belgium|Many Locations, Canada|Many Locations, Czech Republic|Many Locations, Denmark|Many Locations, Finland|Many Locations, France|Many Locations, Germany|Many Locations, Hungary|Many Locations, Israel|Many Locations, Italy|Many Locations, Netherlands|Many Locations, Norway|Many Locations, Poland|Many Locations, Slovenia|Many Locations, Spain|Many Locations, Sweden|Many Locations, Switzerland"
NCT01075737,An Observational Study to Assess the Quality of Life of the Patients With Multiple Sclerosis and Their Caregivers,https://beta.clinicaltrials.gov/study/NCT01075737,COMPLETED,Multiple Sclerosis,,"Merck KGaA, Darmstadt, Germany",,ALL,"ADULT, OLDER_ADULT",,141,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2008-08,2011-03,2012-03,"25 de Mayo 138, Capital, Pcia. de, Santiago del Estero, G4200AWD, Argentina"
NCT02005237,Exercise in Multiple Sclerosis: Effects on Cognitive Function and Brain Connectivity,https://beta.clinicaltrials.gov/study/NCT02005237,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Aerobic Exercise,Universitätsklinikum Hamburg-Eppendorf,German Federal Ministry of Education and Research,ALL,"ADULT, OLDER_ADULT",NA,68,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-12,2016-05,2016-11,"University Hospital Hamburg-Eppendorf, Hamburg, 20241, Germany"
NCT00970333,Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological Conditions,https://beta.clinicaltrials.gov/study/NCT00970333,COMPLETED,Alzheimer Disease|Parkinson Disease|Multiple Sclerosis,DRUG: [18F]-FEPPA,Institute for Neurodegenerative Disorders,,ALL,"ADULT, OLDER_ADULT",PHASE1,3,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2009-08,2010-10,2010-10,"Instiute for Neurodegenerative Disorders, New Haven, Connecticut, 06510, United States"
NCT02977533,A Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02977533,COMPLETED,Progressive Multiple Sclerosis,DRUG: GZ402668|DRUG: Placebo|DRUG: Acyclovir,Sanofi,,ALL,"ADULT, OLDER_ADULT",PHASE1,20,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-12-01,2018-05-16,2018-05-16,"Investigational Site Number 276001, Berlin, 10117, Germany"
NCT04033133,Cerebral Blood Flow and tDCS,https://beta.clinicaltrials.gov/study/NCT04033133,COMPLETED,Multiple Sclerosis,DEVICE: tDCS,University of Iowa,,ALL,"ADULT, OLDER_ADULT",NA,3,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2019-12-20,2020-08-15,2020-08-15,"Department of Health and Human Physiology, Iowa City, Iowa, 52242, United States"
NCT02123537,Treating Foot Drop in People With Multiple Sclerosis Using Electrical Stimulation,https://beta.clinicaltrials.gov/study/NCT02123537,COMPLETED,Multiple Sclerosis|Foot Drop,DEVICE: Bioness L300 Foot Drop System,University of Manitoba,Riverview Health Centre Foundation,ALL,"ADULT, OLDER_ADULT",NA,10,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-06,2016-07,2016-07,"Rehabilitation Hospital, Health Sciences Centre, Winnipeg, Manitoba, R3A 1M4, Canada"
NCT04950933,The Treatment of Amyotrophic Lateral Sclerosis With Huollingshengji Granules,https://beta.clinicaltrials.gov/study/NCT04950933,RECRUITING,Amyotrophic Lateral Sclerosis,DRUG: Huolingshengji Granules|DRUG: Riluzole tablet,Peking University Third Hospital,The Second Hospital of Hebei Medical University,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,144,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-06-01,2021-12-31,2022-12-31,"Peking University Third Hospital, Beijin, China"
NCT03872583,Understanding Magnetic Resonance Imaging in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03872583,ACTIVE_NOT_RECRUITING,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting|Clinically Isolated Syndrome",OTHER: Understanding MRI in MS (website)|OTHER: Control website,Universitätsklinikum Hamburg-Eppendorf,Sanofi,ALL,"ADULT, OLDER_ADULT",NA,120,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2019-03-15,2022-12-01,2023-07,"University Medical Centre Hamburg-Eppendorf, Hamburg, 20246, Germany"
NCT00630383,Immunoregulation by Controlled Parasite Exposure in Multiple Sclerosis.,https://beta.clinicaltrials.gov/study/NCT00630383,WITHDRAWN,Multiple Sclerosis,BIOLOGICAL: Live Hookworm Larvae|OTHER: Histamine,University of Nottingham,,ALL,ADULT,PHASE2,0,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2008-02,2008-05,2008-05,"Nottingham University Hospital NHS Trust, Nottingham, Nottinghamshire, NG7 2UH, United Kingdom"
NCT03177083,Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy,https://beta.clinicaltrials.gov/study/NCT03177083,COMPLETED,Relapsing Remitting Multiple Sclerosis,DRUG: peginterferon beta-1a|DRUG: interferon beta-1a|DRUG: interferon beta-1b,Biogen,,ALL,"ADULT, OLDER_ADULT",PHASE4,80,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2017-01-30,2020-10-26,2020-10-26,"Hospital Fernando Fonseca, Amadora, 2720-276, Portugal|Hospital de Braga, Braga, 4710-243, Portugal|Centro Hospitalar Cova da Beira, Covilhã, 6200-251, Portugal|Hospital Evora, Evora, 7000-811, Portugal|Hospital Dr. Nelio Mendonça, Funchal, 9004-514, Portugal|Hospital da Senhora da Oliveira, Guimaraes, 4835-044, Portugal|Centro Hospitalar de Leiria, Leiria, 2410-197, Portugal|Hospital Egas Moniz, Lisboa, 1349-019, Portugal|Hospital da Luz, Lisboa, 1500-650, Portugal|Centro Hospitalar Lisboa Norte - Hosp Santa Maria, Lisboa, 1649-035, Portugal|Hospital Beatriz Ângelo, EPE, Loures, 2674-514, Portugal|ULS Matosinhos, Matosinhos, 4464-513, Portugal|Hospital Santo Antonio, Porto, 4099-001, Portugal|Hospital de Sao Sebastiao, Santa Maria da Feira, 4520-211, Portugal|Hospital Viana do Castelo, Viana do Castelo, 4904-858, Portugal"
NCT01763983,Effects of Cognitive Behavioural Therapy and Exercise on Stress and Cognitive Deficits in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01763983,COMPLETED,"Multiple Sclerosis|Cognitive Deficits|Stress, Psychological",BEHAVIORAL: Cognitive Behavioural Therapy|BEHAVIORAL: Aerobic Exercise,Sunnybrook Health Sciences Centre,Multiple Sclerosis Society of Canada,ALL,ADULT,NA,173,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2013-01,2016-10,2016-10,"Sunnybrook Health Sciences Centre, Toronto, Ontario, M4N 3M5, Canada"
NCT01158183,Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01158183,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: BAY86-5046_Interferon-beta-1b,Bayer,,ALL,"ADULT, OLDER_ADULT",,226,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2007-07,2009-09,2009-09,"Many Locations, Alabama, United States|Many Locations, California, United States|Many Locations, Colorado, United States|Many Locations, Florida, United States|Many Locations, Illinois, United States|Many Locations, Iowa, United States|Many Locations, Kansas, United States|Many Locations, Louisiana, United States|Many Locations, Maine, United States|Many Locations, Massachusetts, United States|Many Locations, Michigan, United States|Many Locations, Missouri, United States|Many Locations, Nevada, United States|Many Locations, New Hampshire, United States|Many Locations, New Jersey, United States|Many Locations, New York, United States|Many Locations, North Carolina, United States|Many Locations, North Dakota, United States|Many Locations, Ohio, United States|Many Locations, Oregon, United States|Many Locations, Pennsylvania, United States|Many Locations, Rhode Island, United States|Many Locations, Tennessee, United States|Many Locations, Texas, United States|Many Locations, Virginia, United States|Many Locations, Washington, United States|Many Locations, Wisconsin, United States"
NCT04764383,Histaminergic Basis of Fatigue in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04764383,WITHDRAWN,Multiple Sclerosis,DRUG: L-Histidine|DRUG: Placebo|DRUG: Lodosyn,University of Miami,,ALL,ADULT,PHASE2,0,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-01-01,2022-10-30,2022-10-30,"University of Miami, Miami, Florida, 33136, United States"
NCT01952483,Effect of Vitamin D Replacement on Immune Function and Cognition in MS Patients,https://beta.clinicaltrials.gov/study/NCT01952483,COMPLETED,Multiple Sclerosis (MS),,American University of Beirut Medical Center,,ALL,"ADULT, OLDER_ADULT",,108,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-08,2017-05-01,2017-06-30,"AUBMC Multiple Sclerosis Center, Beirut, Riad El Solh, 11-0236, Lebanon"
NCT02524483,Influence of High-Dosage Physical Therapy on the Balance and Mobility of Individuals With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02524483,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Therapeutic Challenge Program|BEHAVIORAL: Therapeutic Exercise Program,University of Nebraska,,ALL,"ADULT, OLDER_ADULT",NA,32,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2014-10,2015-06,2015-06,
NCT02423083,Oral Guanabenz for Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02423083,TERMINATED,"Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis",DRUG: Guanabenz,National Institute of Neurological Disorders and Stroke (NINDS),,ALL,ADULT,PHASE1,2,NIH,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-04-21,2017-10-30,2017-10-30,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States"
NCT04157283,Sexual Dysfunction in Patients With Relapsing Remitting Multiple Sclerosis and Associated Comorbidities,https://beta.clinicaltrials.gov/study/NCT04157283,UNKNOWN,Multiple Sclerosis|Sexual Dysfunction,"DIAGNOSTIC_TEST: MRI brain, visual evoked potential, Cerebrospinal Fluid, Sexual dysfunction measure, Depressive symptoms assessment and Multiple Sclerosis Quality of Life-54(MSQOL-54)",Mansoura University Hospital,,ALL,ADULT,,120,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-11-05,2020-05-05,2020-06-01,"Mansoura University Hospital, Mansoura, Dakahlia, 35516, Egypt"
NCT05558683,Effect of the Vojta Therapy in Patients Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05558683,NOT_YET_RECRUITING,Multiple Sclerosis,OTHER: Randomized clinical trial.,Aymara Abreu Corrales,University of Salamanca,ALL,"ADULT, OLDER_ADULT",NA,25,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-12-01,2023-06-01,2023-12-01,
NCT05104983,Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study,https://beta.clinicaltrials.gov/study/NCT05104983,RECRUITING,Tuberous Sclerosis Complex|Epilepsy,DRUG: Sirolimus|DRUG: Placebo,Darcy Krueger,,ALL,CHILD,PHASE2,64,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-10-13,2025-06-30,2026-06-30,"University of Alabama at Birmingham, Birmingham, Alabama, 35294, United States|University of California at Los Angeles, Los Angeles, California, 90095, United States|Stanford University, Palo Alto, California, 94304, United States|Boston Children's Hospital, Boston, Massachusetts, 02115, United States|Washington University -- St. Louis, Saint Louis, Missouri, 63110, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 27510, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 45229, United States|University of Texas HSC at Houston, Houston, Texas, 77030, United States"
NCT03215433,Study of Biomarkers of the Response to Biotine,https://beta.clinicaltrials.gov/study/NCT03215433,COMPLETED,Multiple Sclerosis|Biotine,,Centre Hospitalier Universitaire Dijon,,ALL,"ADULT, OLDER_ADULT",,25,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-12-08,2019-01-23,2019-01-23,"CHU Dijon Bourgogne, Dijon, 21079, France"
NCT05243407,Sensing Physical Activity to Evaluate and Monitor a Routine Aftercare Program (SensE-M),https://beta.clinicaltrials.gov/study/NCT05243407,COMPLETED,Disease With a Risk for Chronicity,,University of Zurich,Kliniken Valens,ALL,"ADULT, OLDER_ADULT",,23,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-02-21,2022-08-30,2022-08-30,"Kliniken Valens, Valens, Switzerland"
NCT02720107,Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01),https://beta.clinicaltrials.gov/study/NCT02720107,COMPLETED,Relapsing-remitting Multiple Sclerosis,DRUG: fingolimod,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE4,133,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2016-05-12,2016-11-14,2016-11-14,"Novartis Investigative Site, Ostfildern, Baden-Wuerttemberg, 73760, Germany|Novartis Investigative Site, Altenholz-Stift, 24161, Germany|Novartis Investigative Site, Aschaffenburg, 63739, Germany|Novartis Investigative Site, Berlin, 10713, Germany|Novartis Investigative Site, Berlin, 12163, Germany|Novartis Investigative Site, Berlin, 13347, Germany|Novartis Investigative Site, Boblingen, 71032, Germany|Novartis Investigative Site, Celle, 29223, Germany|Novartis Investigative Site, Dortmund, 44137, Germany|Novartis Investigative Site, Dresden, 01307, Germany|Novartis Investigative Site, Erbach, 64711, Germany|Novartis Investigative Site, Frankfurt, 60313, Germany|Novartis Investigative Site, Göttingen, 37073, Germany|Novartis Investigative Site, Jena, 07740, Germany|Novartis Investigative Site, Kiel, 24105, Germany|Novartis Investigative Site, Klingenmünster, 76889, Germany|Novartis Investigative Site, Lappersdorf, 93138, Germany|Novartis Investigative Site, Leverkusen, 51375, Germany|Novartis Investigative Site, Mönchengladbach, 41239, Germany|Novartis Investigative Site, München, 81829, Germany|Novartis Investigative Site, Neuburg an der Donau, 86633, Germany|Novartis Investigative Site, Siegen, 57076, Germany|Novartis Investigative Site, Singen, 78224, Germany|Novartis Investigative Site, Troisdorf, 53844, Germany|Novartis Investigative Site, Ulm, 89073, Germany|Novartis Investigative Site, Unterhaching, 82008, Germany"
NCT04917705,Search for Diagnostic and Prognostic Biomarkers in Systemic Sclerosis and Inflammatory Myopathies,https://beta.clinicaltrials.gov/study/NCT04917705,RECRUITING,Systemic Sclerosis|Inflammatory Myopathies,OTHER: Collection of biological samples,"University Hospital, Strasbourg, France",,ALL,"ADULT, OLDER_ADULT",NA,55,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2021-11-25,2023-06,2028-06,"University Hospital of Hautepierre, Strasbourg, Bas-Rhin, 67000, France"
NCT04625049,Does Microglial Activation Promote Lesion Growth and Progression Among Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT04625049,ENROLLING_BY_INVITATION,Multiple Sclerosis,,Turku University Hospital,,ALL,"ADULT, OLDER_ADULT",,100,OTHER_GOV,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-04-01,2030-11,2031-11,"Turku PET Centre, Turku, Finland Proper, 20520, Finland"
NCT01428505,[18F]PBR111 and Microglial Activation in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01428505,TERMINATED,Multiple Sclerosis,RADIATION: [18F]PBR111,GlaxoSmithKline,,ALL,"ADULT, OLDER_ADULT",PHASE2,50,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2011-07,2013-03,2013-03,"GSK Investigational Site, London, W12 0NN, United Kingdom"
NCT03608605,Advanced MRI Sequences in Multiple Sclerosis and Its Mimics,https://beta.clinicaltrials.gov/study/NCT03608605,UNKNOWN,Multiple Sclerosis,DEVICE: MRI,Assiut University,,ALL,ADULT,,70,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-09-01,2020-04-01,2020-07-01,
NCT01091727,Intravesical Injection of Botulinum Toxin A Versus Saline for Neurogenic Detrusor Overactivity,https://beta.clinicaltrials.gov/study/NCT01091727,COMPLETED,Neurogenic Detrusor Overactivity,DRUG: Botulinum toxin A,Sunnybrook Health Sciences Centre,ethica Clinical Research Inc.,ALL,"ADULT, OLDER_ADULT",PHASE3,57,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2006-10,2009-04,2009-04,"Sunnybrook Health Sciences Centre, Toronto, Ontario, M4N 3M5, Canada"
NCT00207727,A Safety and Efficacy Study of CNTO1275 in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00207727,COMPLETED,Multiple Sclerosis,DRUG: CNTO 1275,"Centocor, Inc.",Centocor BV,ALL,"ADULT, OLDER_ADULT",PHASE2,249,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,2004-07,2006-03,2006-08,
NCT04907305,Next-Gen MS: Feed-forward PRO Data for MS Research,https://beta.clinicaltrials.gov/study/NCT04907305,RECRUITING,Multiple Sclerosis (MS),,"EMD Serono Research & Development Institute, Inc.",,ALL,"ADULT, OLDER_ADULT",,2000,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-11-02,2026-04-30,2026-04-30,"Alabama Neurology Associates, Birmingham, Alabama, 35209, United States|Georgetown University, Washington, District of Columbia, 20057, United States|Atlanta Neuroscience Institute, Atlanta, Georgia, 30327, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States|The Memorial Hospital, d.b.a Memorial Healthcare, Owosso, Michigan, 48867, United States|Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, 73104, United States|The University of Texas of Austin, Austin, Texas, 78759, United States|The University of Texas Health Science Center, San Antonio, Texas, 78229, United States"
NCT05779449,Targeting the Gut Dysbiosis to Treat Inflammation-driven Synaptopathy in MS,https://beta.clinicaltrials.gov/study/NCT05779449,NOT_YET_RECRUITING,Patient Participation,DIETARY_SUPPLEMENT: Prebiotics and Probiotics supplementation|DIETARY_SUPPLEMENT: Placebo supplementation|PROCEDURE: peripheral blood withdrawal|PROCEDURE: Transcranial Magnetic Stimulation (TMS),Neuromed IRCCS,I.R.C.C.S. Fondazione Santa Lucia,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2023-05-02,2024-11-02,2026-05-01,"IRCCS INM-Neuromed, Pozzilli, Isernia, 86077, Italy"
NCT02771652,"Effect of an Internet-based At-home Physical Training Protocol on Quality of Life, Fatigue, Functional Performance, Aerobic Capacity and Muscle Strength in Multiple Sclerosis Patients",https://beta.clinicaltrials.gov/study/NCT02771652,COMPLETED,Multiple Sclerosis,BEHAVIORAL: e-training|OTHER: Control,University of Erlangen-Nürnberg,Caritas-Krankenhaus Bad Mergentheim,ALL,"ADULT, OLDER_ADULT",NA,126,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2010-02,2011-06,2011-11,
NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04035005,RECRUITING,"Multiple Sclerosis, Primary Progressive",DRUG: Ocrelizumab|DRUG: Placebo,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE3,1000,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2019-08-12,2026-08-20,2028-04-04,"HonorHealth Neurology, Scottsdale, Arizona, 85251, United States|Multiple Sclerosis Center of California, Newport Beach, California, 92663, United States|SC3 Research Group, Inc, Pasadena, California, 91105, United States|Georgetown University Medical Center, Washington, District of Columbia, 20007, United States|SFM Clinical Research, LLC, Boca Raton, Florida, 33487, United States|MS and Neuromuscular Center of Excellence, Clearwater, Florida, 33761, United States|Neurological Services of Orlando, Orlando, Florida, 32806, United States|Vero Neurology, Vero Beach, Florida, 32960, United States|University of Kansas Medical Center, Kansas City, Kansas, 66160, United States|Michigan Neurology Associates P.C., Clinton Township, Michigan, 48035, United States|Henry Ford Hospital, Detroit, Michigan, 48202, United States|University of Nebraska Medical Center, Omaha, Nebraska, 68198-0600, United States|Dent Neurological Institute, Amherst, New York, 14226, United States|The Boster Center for MS, Columbus, Ohio, 43235, United States|Columbus Neuroscience, Columbus, Ohio, 43801, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, 19107, United States|Albert Einstein Medical Center, Philadelphia, Pennsylvania, 19141, United States|Premier Neurology, Greer, South Carolina, 29650, United States|Maxine Mesinger MS Clinic/Baylor College of Medicine; Neurology, Houston, Texas, 77030, United States|Meridian Clinical Research, Norfolk, Virginia, 23502, United States|Center for Neurological Disorders, Milwaukee, Wisconsin, 53215, United States|Brain and Mind Research Institute, Camperdown, New South Wales, 2050, Australia|John Hunter Hospital, New Lambton, New South Wales, 2305, Australia|Austin Hospital, Heidelberg, Victoria, 3084, Australia|Royal Melbourne Hospital, Parkville, Victoria, 3050, Australia|Kepler Universitatsklinikum Linz, Linz, 4021, Austria|Cliniques Universitaires St-Luc, Bruxelles, 1200, Belgium|UZ Antwerpen PIN, Edegem, 2650, Belgium|CHU Tivoli, La Louvière, 7100, Belgium|MS & Neurologisch Revalidatie Centrum, Overpelt, 3900, Belgium|Military Medical Academy HBAT, Pleven, 5800, Bulgaria|Multiprofile Hospital For Active Treatment Avis Medica, Pleven, 5800, Bulgaria|Multiprofile Hospital for Active Treatment of Neurology and Psychiatry Sv. Naum EAD, Sofia, 1113, Bulgaria|University of Alberta, Edmonton, Alberta, T6G 2G3, Canada|Dalhousie Multiple Sclerosis Research Unit, Halifax, Nova Scotia, B3H 4K4, Canada|London Health Sciences Centre, London, Ontario, N6A 4L6, Canada|Ottawa Hospital, Ottawa, Ontario, K1H 8L6, Canada|University of Toronto, Toronto, Ontario, M5G 1Z6, Canada|Clinique Neuro Outaouais, Gatineau, Quebec, J8Y 1W2, Canada|Recherche Sepmus Inc., Greenfield Park, Quebec, J4V 2J2, Canada|Clinica Colsanitas S.A. sede Clinica Universitaria Colombia, Bogota, 111321, Colombia|Instituto Neurologico de Colombia INDEC, Medellin, Colombia|Clinical Hospital Centre Osijek, Osijek, 31000, Croatia|General Hospital Varazdin, Varazdin, 42000, Croatia|Clinical Hospital Sestre Milosrdnice, Zagreb, 10000, Croatia|University Hospital Center Zagreb, Zagreb, 10000, Croatia|Ain Shams University Hospital, Cairo, 11566, Egypt|CHU Amiens Hopital Sud; Neurologie, Amiens Cedex1, 80054, France|Centre Hospitalier Universitaire de Bordeaux Hopital Pellegrin, Bordeaux, 33076, France|Hopital Pierre Wertheimer, Cedex, 69677, France|Centre Hospitalier Universitaire de Clermont Ferrand, Clermont-ferrand, 63000, France|Centre Hospitalier de Colmar - Hopital Louis Pasteur; Service de Neurologie, Colmar, 68024, France|Hopitaux de La Timone, Marseille, 13385, France|CHU Gui de Chauliac, Montpellier, 34000, France|CHRU Nancy, Nancy, 54035, France|Hopital Guillaume Et Rene Laennec, Nantes, 44805, France|CHU de Nimes - Hopital Universitaire Caremeau, Nimes, 30900, France|Hopital Civil, Strasbourg, 67091, France|Pineo Medical Ecosystem LTD, Tbilisi, 0114, Georgia|Tbilisi State Medical University, Tbilisi, 0141, Georgia|Khechinashvili University Hospital, Tbilisi, 179, Georgia|Medizinische Hochschule Hannover, Hannover, 30625, Germany|Bacs-Kiskun Megyei Korhaz, Kecskemet, 6000, Hungary|Szent Borbala Korhaz, Tatabánya, 2800, Hungary|Saint Vincent's University Hospital, Dublin, Dublin 4, Ireland|AOU dell Universita degli Studi della Campania Luigi Vanvitelli Piazza Luigi Miraglia 2, Napoli, Campania, 80131, Italy|Fondazione PTV Policlinico Tor Vergata, Rome, Lazio, 00133, Italy|Azienda Ospedaliera Sant'andrea, Rome, Lazio, 00189, Italy|Ospedale Policlinico San Martino, Genova, Liguria, 16132, Italy|Ospedale San Raffaele S.r.l. - PPDS, Milano, Lombardia, 20132, Italy|Fondazione Istituto Neurologico Mondino IRCCS, Pavia, Lombardia, 27100, Italy|Azienda Sanitaria Ospedaliera S Luigi Gonzaga, Orbassano, Piemonte, 10043, Italy|Fondazione Istituto G. Giglio di Cefalu, Cefalù, Sicilia, 90015, Italy|Saint George University Medical Hospital, Achrafieh, Lebanon|American University of Beirut - Medical Center, Beirut, 1107 2020, Lebanon|Hotel Dieu de France, Beirut, Lebanon|Grupo Medico Camino, DF, Mexico CITY (federal District), Mexico|Centro de Diagnostico Neurofisiologico S.C, Mexico City, Mexico CITY (federal District), 01600, Mexico|Unidad de Investigacion en Salud de Chihuahua, Mexico City, Mexico CITY (federal District), 14390, Mexico|Clinical Research Institute, Tlalnepantla de Baz, Mexico CITY (federal District), 54055, Mexico|Neurociencias Estudios Clinicos S.C., Culiacán, Sinaloa, 80020, Mexico|Scientia Investigacion Clinica S.C., Chihuahua, 31203, Mexico|Hospital Angeles Chihuahua, Chihuahua, 31238, Mexico|Instituto de Investigationes Clinicas para la Salud AC, Durango, 34000, Mexico|Clinical Associates in Research Therapeutics of Americas-Mexico CARTA-MEX, Monterrey, 64050, Mexico|CHU Mohammed VI, Marrakech, 40080, Morocco|Hopital Militaire d'Instruction Mohamed V, Rabat, 10100, Morocco|New Zealand Clinical Research - Christchurch, Christchurch, 8011, New Zealand|Dunedin Hospital, Dunedin, New Zealand|Waikato Hospital; Neurology, Hamilton, 3240, New Zealand|Wellington Hospital; Department of Neurology, Wellington, 6021, New Zealand|Uniwersytecki Szpital Kliniczny w Bialymstoku Marii Sklodowskiej Curie 24a, Bia?ystok, 15-276, Poland|Neurocentrum Bydgoszcz sp z o.o, Bydgoszcz, 85-796, Poland|COPERNICUS Podmiot Leczniczy Sp. z o. o. Szpital im. M. Kopernika; Oddzia? Neurologiczny, Gdansk, 80-803, Poland|M.A. - LEK A. M. Maciejowscy SC. Centrum Terapii SM, Katowice, 40-571, Poland|RESMEDICA Spolka z o.o., Kielce, 25-726, Poland|SP ZOZ Szpital Uniwersytecki w Krakowie; Oddzial Kliniczny Kliniki Neurologii, Kraków, 31-503, Poland|Centrum Neurologii Krzysztof Selmaj, Lodz, 90-324, Poland|Rejdak Konrad Indywidualna Praktyka Lekarska dr hab. Konrad Rejdak, Lublin, 20-605, Poland|Wojewodzki Szpital Specjalistyczny, Olsztyn, 10-561, Poland|Clinical Research Center Sp z o o, Poznan, 61-731, Poland|Wojewódzki Szpital Specjalistyczny Nr 3, Rybnik, 44-200, Poland|Centrum Medyczne ""MEDYK"", Rzeszow, 35-055, Poland|EUROMEDIS Sp z o o, Szczecin, 70-111, Poland|Centrum Medyczne NeuroProtect Zablocinska 10, Warsaw, 01-684, Poland|Instytut Psychiatrii i Neurologii II Klinika Neurologiczna, Warszawa, 02-957, Poland|Przychodnia EuroMediCare, Wroc?aw, 50-220, Poland|Hospital Garcia de Orta, Almada, 2801-915, Portugal|Hospital de Braga, Braga, 4710-243, Portugal|Hospital Beatriz Angelo, Loures, 2674-514, Portugal|Hospital de Santo Antonio, Porto, 4099-001, Portugal|Campus Neurologico Senior, Torres Vedras, 2560-280, Portugal|Colentina Clinical Hospital, Bucharest, 020125, Romania|Emergency University Hospital, Bucharest, 050098, Romania|SC Clubul Sanatatii SRL, Campulung, 115100, Romania|County Hospital Caracal, Caracal, 235200, Romania|Cai Ferate Clinical Hospital, Constan?a, 900123, Romania|Spitalul Municipal Dr.Alexandru Simionescu Hunedoara, Hunedoara, 331057, Romania|Targu Mures Clinical Emergency County Hospital, Targu Mures, 540100, Romania|State Healthcare Institution Territorial Clinical Hospital, Barnaul, Altaj, 656024, Russian Federation|Kuvatov Republican Clinical Hospital, UFA, Baskortostan, 450005, Russian Federation|Krasnoyarsk State Medical Academy, Krasnoyarsk, Krasnojarsk, 660049, Russian Federation|Research Center of Neurology of RAMS, Moscow, Moskovskaja Oblast, 125367, Russian Federation|City Clinical Hospital #24, Moscow, Moskovskaja Oblast, 127015, Russian Federation|Moscow Regional Research Clinical Institute Na Mfvladimirskiy, Moscow, Moskovskaja Oblast, 129110, Russian Federation|City Out Patient Clinic For Rehabilitation Treatment #7, Moskva, Moskovskaja Oblast, 105005, Russian Federation|City Clinical Hospital #15 n.a. N.F. Filatov, Moskva, Moskovskaja Oblast, 111539, Russian Federation|Neftyanik Medical and Sanitary Unit, Tumen, Moskovskaja Oblast, 625000, Russian Federation|City Clinical Hospital #12, Nizhny Novgorod, Niznij Novgorod, 603003, Russian Federation|Nizhegorodskaya Regional Clinical Hospital n.a. Semashko, Nizhny Novgorod, Niznij Novgorod, 603126, Russian Federation|MEDIS Limited Liability Company, Nizhny Novgorod, Niznij Novgorod, 603137, Russian Federation|City Center of MS Treatment based on Saint-Petersburg City Clinical Hospital #31, Sankt-peterburg, Sankt Petersburg, 197110, Russian Federation|City Hospital #40 of Kurortniy Administrative District, St. Petersburg, Sankt Petersburg, 197706, Russian Federation|Yaroslavl Clinical Hospital #8, Yaroslavl, Sankt Petersburg, 150030, Russian Federation|City Clinical Hospital #4, Saransk, Saratov, 430032, Russian Federation|Sverdlovsk Regional Clinical Hospital 1, Yekaterinburg, Sverdlovsk, 620102, Russian Federation|Vertebronevrologiya LLC, Kazan, Tatarstan, 420047, Russian Federation|Ulyanovsk Regional Clinical Hospital, Ulyanovsk, Uljanovsk, 432063, Russian Federation|Belgorod Regional Clinical Hospital, Belgorod, 308007, Russian Federation|Kemerovo Regional Clinical Hospital, Kemerovo, 650066, Russian Federation|Kirov State Medical Academy, Kirov, 610027, Russian Federation|SBHI of Nizhny Novgorod region City Clinical Hospital #3; neurology department, Nizniy Novgorod, 603155, Russian Federation|FSBIH Siberian Regional Medical Centre of FMBA of Russia, Novosibirsk, 630007, Russian Federation|Perm SMA n.a. academ. E.A. Vagner, Perm, 614990, Russian Federation|Siberian State Medical University of Roszdrav, Tomsk, 634050, Russian Federation|Regional State Budget Institution of Healthcare Tver Regional Clinical Hospital, Tver, Russian Federation|Clinical Center of Serbia, Belgrade, 11000, Serbia|Military Medical Academy, Belgrade, 11040, Serbia|Clinical Center Kragujevac, Kragujevac, 34000, Serbia|Clinical Center Nis, NIS, 18000, Serbia|Clinical Centre of Vojvodina, Nova Sad, 21000, Serbia|General Hospital Uzice, Uzice, 31000, Serbia|Clinical Hospital Centre Zemun, Zemun, 11080, Serbia|Hospital Universitario Puerta de Hierro - Majadahonda, Majadahonda, Madrid, 28220, Spain|Hospital Universitario Quironsalud Madrid, Pozuelo de Alarcón, Madrid, 28223, Spain|Complejo Hospitalario Universitario de Vigo, Vigo, Pontevedra, 36204, Spain|Hospital Universitario Virgen Macarena, Seville, Sevilla, 41071, Spain|Hospital Universitario Cruces, Barakaldo, Vizcaya, 48903, Spain|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital Clinic de Barcelona, Barcelona, 08036, Spain|Hospital General de Castellon, Castellon, 12004, Spain|Hospital Universitario Ramon y Cajal, Madrid, 28034, Spain|Hospital Universitario HM Sanchinarro-CIOCC, Madrid, 28050, Spain|Hospital Regional Universitario Carlos Haya, Malaga, 29010, Spain|Hospital Universitario Virgen de La Arrixaca, Murcia, 30120, Spain|Complejo Asistencial Universitario de Salamanca ? H. Clinico, Salamanca, 37007, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, 46026, Spain|Hopital Razi, Mannouba, 2010, Tunisia|Fattouma Bourguiba University Hospital, Monastir, 5000, Tunisia|Hospital Habib Bourguiba, Sfax, 3029, Tunisia|Military Hospital of Tunis, Tunis, 1008, Tunisia|Medical Center Dopomoga Plus, Kyiv, Chernihiv Governorate, 02123, Ukraine|Medical Centre of PE First Private Clinic, Zhytomir, Crimean Regional Governmenta, 10008, Ukraine|LLC Medical Center INET 09, Zaporizhzhia, Katerynoslav Governorate, 69035, Ukraine|Municipal Non-profit Enterprise Zaporizhzhya Regional Hospital Zaporizhzhya Regional Council, Zaporizhzhia, Katerynoslav Governorate, 69600, Ukraine|Zaporizhia City Multispecialty Clinical Hospital #9, Zaporizhzhye, Katerynoslav Governorate, 69063, Ukraine|Communal Non-commercial Enterprise of Kharkiv Regional Council Regional Clinical Hospital, Kharkiv, Kharkiv Governorate, 61058, Ukraine|Communal noncommercial enterprise of Lviv Regional Council Lviv Regional Clinical Hospital, Lviv, Kharkiv Governorate, 79010, Ukraine|LLC Medical Center Family Medicine Clinic, Dnipro, Kherson Governorate, 49600, Ukraine|Municipal Non-profit Enterprise Kherson City Clinical Hospital named after Ye.Ye. Karabelesh, Kherson, Kherson Governorate, 73000, Ukraine|ME Dnipropetrovsk Regional Clinical Hospital n.a. I.I Mechnykov Dnipropetrovsk Regional Council, Dnipro, KIEV Governorate, 49005, Ukraine|Treatment and Diagnostic Center of LLC MRT Elit, Kropyvnytskyi, KIEV Governorate, 25005, Ukraine|Medical Center of LLC Medical Clinic Blagomed, Kyiv, KIEV Governorate, 01001, Ukraine|Communal Non-Commercial Enterprise Clinical Hospital #15 of the Podilskyi District ofthe Kyiv City, Kyiv, KIEV Governorate, 04080, Ukraine|LLC Smart Medical Center, Kyiv, KIEV Governorate, 04212, Ukraine|Municipal NPE Regional Clinical Center of Neurosurgery and Neurology of Transcarpathian RC, Uzhhorod, KIEV Governorate, 88018, Ukraine|Medical Clinical Research Center of Medical Center LLC Health Clinic; Department of General Therapy, Vinnytsia, Podolia Governorate, 21009, Ukraine|Medical Center Salutem, Vinnytsia, Podolia Governorate, 21050, Ukraine|Treatment and diagnostic Center Neuro Global of LLC Neuro Global, Krykhivtsi, Polissya Okruha, 76493, Ukraine|Kyiv City Clinical Hospital #4, Kyiv, 03110, Ukraine|Municipal Institution of Kyiv Regional Council Kyiv Regional Clinical Hospital, Kyiv, 04107, Ukraine|Volyn Regional Clinical Hospital, Lutsk, 43024, Ukraine|University Hospital of Wales, Cardiff, CF14 4XW, United Kingdom|Queen Elizabeth University Hospital - PPDS, Glasgow, G51 4TF, United Kingdom|Raigmore Hospital - PPDS; Highland Clinical Research Facility Center For Health Science, Inverness, IV2 3JH, United Kingdom|Walton Centre For Neurology and Neurosurgery, Liverpool, L9 7LJ, United Kingdom|The Royal London Hospital, London, E1 1FR, United Kingdom|The National Hospital for Neurology & Neurosurgery, London, WC1N 3BG, United Kingdom|University of Nottingham, Nottingham, NG7 2UH, United Kingdom|Peninsula College of Medicine and Dentistry, Plymouth, PL6 8BX, United Kingdom|Salford Royal Hospital, Salford, M6 8HD, United Kingdom|Royal Hallamshire Hospital, Sheffield, S10 2JF, United Kingdom|Morriston Hospital, Swansea, SA6 6NL, United Kingdom"
NCT04971005,Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial,https://beta.clinicaltrials.gov/study/NCT04971005,TERMINATED,Relapsing-Remitting Multiple Sclerosis,DRUG: Autologous Hematopoietic Stem Cell Transplantation|DRUG: Ocrelizumab|DRUG: Alemtuzumab,Universitätsklinikum Hamburg-Eppendorf,Neovii Biotech|Clinical Trial Center North (CTC North GmbH & Co. KG),ALL,ADULT,PHASE2,1,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-08-27,2022-02-04,2022-02-04,"Universitätsklinikum Hamburg-Eppendorf, Hamburg, 20246, Germany|Universitätsklinikum Mannheim, Mannheim, 68167, Germany"
NCT04178005,Cladribine Tablets After Treatment With Natalizumab (CLADRINA),https://beta.clinicaltrials.gov/study/NCT04178005,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,DRUG: Cladribine,University of Texas Southwestern Medical Center,EMD Serono,ALL,ADULT,PHASE4,40,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-02-19,2024-08-30,2024-12,"UT Southwestern Medical center, Dallas, Texas, 75390, United States"
NCT03589105,"A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting",https://beta.clinicaltrials.gov/study/NCT03589105,COMPLETED,Multiple Sclerosis,DRUG: Ocrelizumab 300 mg|DRUG: Ocrelizumab 600 mg,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE4,423,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-08-06,2021-02-15,2021-02-15,"Centre hospitalier d'Agen; Neurologie, Agen, 47923, France|CHU Amiens Hopital Sud; Neurologie, Amiens Cedex1, 80054, France|CHU Angers, Batiement Larrey 2, Neurologie, Angers Cedex 9, 49933, France|CHU de Besancon Hopital Jean Minjoz; Service de Neurologie, Besançon, 25030, France|Groupe Hospitalier Pellegrin; Service de neurochirurgie B, Bordeaux, 33076, France|CHU Brest Hopital La Cavale Blanche; Neurologie, Brest, 29609, France|Hopital Pierre Wertheimer; Neurologie D, Bron, 69677, France|Hopital Cote De Nacre; Unite Neurologie Generale, Caen, 14033, France|CH Jean Rougier; Neurologie, Cahors, 46005, France|Ch De Calais; Hopital De Jour, Calais Cedex, 62107, France|CHMS Site Chambery; Neurologie, CHAMBERY Cedex, 73011, France|CHU Hopital Gabriel Montpied; Service de Neurologie, Clermont Ferrand, 63003, France|Hôpital General - Service de neurologie; Service de neurologie, Dijon Cedex, 21079, France|CH de Gonesse; Neurologie, Gonesse, 95503, France|CHU de Grenoble; Neurologie, La Tronche, 38700, France|Centre hospitalier Andre Mignot; Neurologie, Le Chesnay Cedex, 78157, France|CH Le Mans; Neurologie, Le Mans, 72037, France|Centre hospitalier de Libourne Hopital Robert Boulin; Neurologie, Libourne Cedex, 33505, France|CH St Vincent de Paul, Lille, 59000, France|Hopital Roger Salengro; Service de Neurologie, Lille, France|CHU Dupruytren - Limoges; Neurologie, Limoges, 87042, France|Hopital européen de Marseille; Neurologie, Marseille, 13003, France|CHU de la Timone - Hopital d Adultes; Service de Neurologie, Marseille, 13005, France|Fondation Hopital Saint Joseph; Neurologie, Marseille, 13285, France|Gh De Meaux; Neurologie, Meaux, 77104, France|Centre hospitalier Annecy Genevois Site St Julien; Neurologie, Metz Tessy, 74370, France|Centre hospitalier de Montlucon; Neurologie, Montlucon, 03100, France|Hopital Gui de Chauliac; Neurologie, Montpellier, 34295, France|Centre hospitalier de Mulhouse Hopital Emile Muller; Neurologie, Mulhouse Cedex 1, 68070, France|Hopital Central - CHU de Nancy; Service de Neurologie, Nancy, 54035, France|Hôpital Guillaume et René Laënnec; Service Neurologie, Nantes, 44805, France|Hôpital Pasteur; Service de Neurologie, Nice, 06002, France|CHU de Nîmes Hopital Caremeau; Service de Neurologie, Nimes, 30900, France|Groupe Hospitalier Paris Saint Joseph; Service de Neurologie et Neurovasculaire, Paris, 75014, France|Fondation Rothschild; Service de Neurologie, Paris, 75019, France|Hopital Saint Antoine; Neurologie, Paris, 75571, France|CHU Poitiers - La Milétrie; Neurologie, Poitiers, 86021, France|Centre Hospitalier de Cornouaille; Neurologie, Quimper, 29000, France|Hopital Pontchaillou, Rennes, 35033, France|Hôpital Charles Nicolle; Service de Neurologie, Rouen, 76031, France|CHU Saint Etienne - Hôpital Nord; Neurologie, Saint-priest-en-jarez, 42270, France|Hopital Civil de Strasbourg; Service de Neurologie, Strasbourg, 67091, France|Hopital Foch; Neurologie, Suresnes, 92151, France|HIA de Toulon hôpital militaire; Neurologie, Toulon, 83041, France|Centre hospitalier Guy Chatiliez de Tourcoing; Neurologie, Tourcoing Cedex, 59208, France|Centre hospitalier de Valence; Neurologie, Valence Cedex 9, 26953, France"
NCT05212805,Promoting Aerobic Training in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05212805,RECRUITING,Multiple Sclerosis,BEHAVIORAL: Aerobic exercise|BEHAVIORAL: Task-oriented upper-limb training|BEHAVIORAL: Sport events participation,Fondazione Italiana Sclerosi Multipla,Universita degli Studi di Genova|University Grenoble Alps,ALL,"ADULT, OLDER_ADULT",NA,62,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2018-01-01,2023-06-24,2023-12-25,"Italian Multiple Sclerosis Association and Foundation, Genoa, GE, 16149, Italy"
NCT01058005,"Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT01058005,TERMINATED,Relapsing Remitting Multiple Sclerosis,DRUG: BG00002 (natalizumab)|DRUG: interferon beta-1a|DRUG: glatiramer acetate,Biogen,Elan Pharmaceuticals,ALL,ADULT,PHASE3,84,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: ",2010-03,2012-04,2012-04,"Research Site, Cullman, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, Fort Collins, Colorado, United States|Research Site, Maitland, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Lexington, Kentucky, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Detroit, Michigan, United States|Research Site, Patchogue, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Akron, Ohio, United States|Research Site, Franklin, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Round Rock, Texas, United States|Research Site, Norfolk, Virginia, United States|Research Site, Kirkland, Washington, United States|Research Site, Morgantown, West Virginia, United States|Research Site, Fitzroy, Victoria, Australia|Research Site, Gatineau, Quebec, Canada|Research Site, Pardubice, Czech Republic|Research Site, Tampere, Finland|Research Site, Strasbourg, Bas-Rhin, France|Research Site, Esztergom, Komárom-Esztergom, Hungary|Research Site, Budapest, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Catania, Italy|Research Site, Napoli, Italy|Research Site, Rome, Italy|Research Site, Riga, Latvia|Research Site, Lódz, Lodzkie, Poland|Research Site, Bialystok, Podlaskie, Poland|Research Site, Gdansk, Pomorskie, Poland|Research Site, Ljubljana, Slovenia|Research Site, Alicante, Spain|Research Site, Barcelona, Spain|Research Site, Girona, Spain|Research Site, Madrid, Spain|Research Site, Santa Cruz de Tenerife, Spain|Research Site, Sevilla, Spain|Research Site, Molndal, Sweden"
NCT00296205,Phase II High-Dose Cyclophosphamide for Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00296205,WITHDRAWN,Multiple Sclerosis,DRUG: Cyclophosphamide,Stony Brook University,,ALL,"ADULT, OLDER_ADULT",PHASE2,25,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2003-10,,2006-02,"Stony Brook University Hospital, Stony Brook, New York, 11794-8174, United States"
NCT03147105,Armergometry to Improve Mobility in MS,https://beta.clinicaltrials.gov/study/NCT03147105,UNKNOWN,Multiple Sclerosis,BEHAVIORAL: arm ergometry,Universitätsklinikum Hamburg-Eppendorf,Deutsche Multiple Sklerose Gesellschaft Hamburg,ALL,ADULT,NA,50,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2017-05-01,2018-07-01,2018-12-31,"Universitätsklinikum Hamburg-Eppendorf, Hamburg, 20246, Germany"
NCT02576717,"A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT02576717,COMPLETED,Multiple Sclerosis,DRUG: RPC1063,Celgene,,ALL,ADULT,PHASE3,2350,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-10-16,2023-01-05,2023-01-05,
NCT04855617,Symptom Burden in Patients Treated With Ocrelizumab for Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04855617,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,DRUG: Ocrelizumab,NYU Langone Health,"Genentech, Inc.",ALL,"ADULT, OLDER_ADULT",,122,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-10-26,2023-05-30,2023-05-30,"Elliot Lewis Center for Multiple Sclerosis Care, Wellesley, Massachusetts, 02481, United States|NYU Langone Health Multiple Sclerosis Comprehensive Care Center (NYULH MSCCC), New York, New York, 10016, United States"
NCT04322149,Multiple Doses of AT-1501-A201 in Adults With ALS,https://beta.clinicaltrials.gov/study/NCT04322149,COMPLETED,Amyotrophic Lateral Sclerosis,DRUG: AT-1501,"Anelixis Therapeutics, LLC",,ALL,"ADULT, OLDER_ADULT",PHASE2,54,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-10-16,2022-03-24,2022-03-24,"Barrows Neurological Institute, Phoenix, Arizona, 85013, United States|University of California Irvine, Orange, California, 92868, United States|California Pacific Medical Center, San Francisco, California, 94109, United States|Augusta University, Augusta, Georgia, 30912, United States|University of Indiana, Indianapolis, Indiana, 46202, United States|The University of Kansas Medical Center, Kansas City, Kansas, 66160, United States|Johns Hopkins University Medical Center, Baltimore, Maryland, 21287, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Hospital for Special Surgery (HSS), New York, New York, 10021, United States|Providence Brain & Spine Institute, Portland, Oregon, 97213, United States|Texas Neurology, P.A., Dallas, Texas, 75206, United States|Houston Methodist Neurological Institute, Houston, Texas, 77030, United States|Montreal Neurological Institute and Hospital, Montreal, H3A 2B4, Canada"
NCT00548405,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two",https://beta.clinicaltrials.gov/study/NCT00548405,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",BIOLOGICAL: Alemtuzumab 12 mg|BIOLOGICAL: Alemtuzumab 24 mg|BIOLOGICAL: Interferon beta-1a,"Genzyme, a Sanofi Company",Bayer,ALL,ADULT,PHASE3,840,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2007-10,2011-09,2011-09,"North Central Neurology Associates, P.C., Cullman, Alabama, United States|Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Hope Research Institute, Phoenix, Arizona, United States|Mayo Clinic Arizona, Department of Neurology, Scottsdale, Arizona, United States|Northwest NeuroSpecialists, PLLC, Tucson, Arizona, United States|East Bay Physicians Medical Group/Sutter East Bay Medical Foundation, Berkeley, California, United States|Neurology Center of North Orange County, La Habra, California, United States|Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, California, United States|Neuro-Therapeutics Inc., Pasadena, California, United States|Neuro-Therapeutics, Inc, Pasadena, California, United States|University of California, Davis Medical Center, Sacramento, California, United States|Stanford University School of Medicine, Stanford, California, United States|University of Colorado Hospital, Anschutz Outpatient Pavilioin, Aurora, Colorado, United States|Neurological Consultants, Denver, Colorado, United States|Advanced Neurosciences Research, Fort Collins, Colorado, United States|Yale University, New Haven, Connecticut, United States|George Washington University Medical Faculty Associates, Washington, District of Columbia, United States|University of Florida Neuroscience Institute, Jacksonville, Florida, United States|Neurology Associates, P.A., Maitland, Florida, United States|Neurological Associates, Pompano Beach, Florida, United States|Negroski, Stein, Sutherland and Hanes Neurology, Sarasota, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|University of South Florida, Department of Neurology, Tampa, Florida, United States|Emory University, Department of Neurology, Atlanta, Georgia, United States|Shepherd Center, Inc., Atlanta, Georgia, United States|Idaho Falls Multiple Sclerosis Center, PLLC, Idaho Falls, Idaho, United States|University of Chicago Medical Center, Department of Neurology, Chicago, Illinois, United States|Consultants in Neurology, Ltd, Northbrook, Illinois, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, United States|Indiana University School of Medicine, Department of Neurology, Indianapolis, Indiana, United States|Josephson Wallack Munshower Neurology P.C., Indianapolis, Indiana, United States|Iowa Health Physicians, Des Moines, Iowa, United States|Ruan Neurology Clinic and Research Center, Des Moines, Iowa, United States|University of Kansas Medical Center, Department of Neurology, Kansas City, Kansas, United States|MidAmerica Neuroscience Institute, Lenexa, Kansas, United States|Associates in Neurology, PSC, Lexington, Kentucky, United States|University of Louisville Research Foundation, Louisville, Kentucky, United States|Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States|Caritas St. Elizabeth's Medical Center, Boston, Massachusetts, United States|Partners Multiple Sclerosis Center/Brigham and Women's Hospital, Boston, Massachusetts, United States|Springfield Neurology Associates, LLC, Springfield, Massachusetts, United States|UMass Memorial Medical Center, Worcester, Massachusetts, United States|University of Michigan Department of Neurology, Ann Arbor, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Wayne State University, School of Medicine, Department of Neurology, Detroit, Michigan, United States|Spectrum Health Medical Group, Neurology (Previously known as Michigan Medical P.C., Neurology), Grand Rapids, Michigan, United States|Michigan Neurology Associates, P.C., St. Clair Shores, Michigan, United States|Northern Michigan Neurology, Traverse City, Michigan, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Neurology Consultants of Kansas City, Inc., Kansas City, Missouri, United States|Montana Neurobehavioral Specialists, Missoula, Montana, United States|University of Nevada School of Medicine, Las Vegas, Nevada, United States|Renown Institute for Neurosciences / Renown regional Medical Center, Reno, Nevada, United States|Dartmouth-Hitchcock Medical Center, Norris Cotton Cancer Center, Lebanon, New Hampshire, United States|MS Center at Holy Name Hospital, Teaneck, New Jersey, United States|University of New Mexico, Health Sciences Center, MS Specialty Clinic, Alburquerque, New Mexico, United States|Empire Neurology, PC, Latham, New York, United States|Winthrop University Hospital, Clinical Trials Center, Mineola, New York, United States|Mount Sinai School of Medicine, Corinne Goldsmith Dickinson Center for Multiple Sclerosis, New York, New York, United States|Comprehensive Multiple Sclerosis Care Center at South Shore Neurologic Associates, P.C., Patchogue, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|SUNY Upstate Medical University, Department of Neurology, Syracuse, New York, United States|University of North Carolina-Chapel Hill, Department of Neurology, Chapel Hill, North Carolina, United States|Wake Forest University Health Science, Department of Neurology, Winston-Salem, North Carolina, United States|Cleveland Clinic Foundation, Mellen Center, Cleveland, Ohio, United States|Neurology Specialists, Inc., Dayton, Ohio, United States|Oak Clinic for Multiple Sclerosis, Uniontown, Ohio, United States|MS Center of Oklahoma, Oklahoma City, Oklahoma, United States|Lehigh Valley Hospital, Neuroscience and Pain Research, Allentown, Pennsylvania, United States|Northshore Clinical Associates, Erie, Pennsylvania, United States|University of Pittsburgh, Kaufmann Medical Building, Pittsburgh, Pennsylvania, United States|The Neurology Foundation, Inc., Providence, Rhode Island, United States|Neurology Clinic, P.C., Cordova, Tennessee, United States|Advanced Neurosciences Institute, Franklin, Tennessee, United States|Biomedical Research Alliance of NY, LLC, Franklin, Tennessee, United States|Hope Neurology PC, Knoxville, Tennessee, United States|Vanderbilt Multiple Sclerosis Center, Nashville, Tennessee, United States|Clinical Center for Multiple Sclerosis, Dallas, Texas, United States|Central Texas Neurology, Round Rock, Texas, United States|Integra Clinical Research, San Antonio, Texas, United States|Neurology Center of San Antonio, San Antonio, Texas, United States|MS Center of Greater Washington, P.C., Vienna, Virginia, United States|Swedish Neuroscience Institute, Seattle, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Rockwood Clinical Research Center, Spokane, Washington, United States|DIABAID, Buenos Aires, Argentina|Westmead Hospital, Westmead, New South Wales, Australia|The Wesley Research Institute, Auchenflower, Queensland, 4066, Australia|Griffith School of Medicine, Gold Coast Campus, Griffith University, Southport, Queensland, Australia|Clinical Cognitive Research Unit/Clinical Trials, The Queen Elizabeth Hospital, Neurology Department, Woodville South, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, 7000, Australia|St. Vincent's Hospital, MS Education & Research, Department of Clinical Neurosciences, Fitzroy, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Royal Melbourne Hospital, Department of Neurology, Parkville, Victoria, 3050, Australia|Concord Repatriation General Hospital, Neurosciences Department, Concord, Australia|Southern Neurology, Kogarah, Australia|Liverpool Hospital, Neurology Department, Liverpool, 2170, Australia|AKH Wien, Universitätsklinikum für Neurologie, Wien, Austria|Cliniques Universitaires Saint-Luc, Neurology, Brussel, Belgium|CHU Ourthe Amblève, Neurology, Esneux, Belgium|University Hospital Leuven, Campus Gasthuisberg, Neurology, Leuven, Belgium|Hospital da Restauracao, Recife, PE, Brazil|Hospital Sao Lucas PUC-RS, Porto Alegre, RS, Brazil|Hospital de Clínicas USP, Sao Paulo, Brazil|Irmandade da Santa Casa de Misericordia de Sao Paulo, Sao Paulo, Brazil|UBC Hospital, Vancouver, British Columbia, Canada|Multiple Sclerosis Clinic, Connell 7, Kingston General Hospital, Kingston, Ontario, Canada|London Health Sciences Centre- University Hospital, London, Ontario, Canada|The Ottawa Hospital, General Campus, Ottawa, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Centre de Sante et de Services Sociaux de Gatineau-Hull Hospital, Gatineau, Quebec, Canada|Clinique Neuro rive-sud, Recherche sepmus inc, Greenfield park, Quebec, Canada|Hospital Maisonneuve-Rosemont, Montreal, Quebec, Canada|Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada|Clinical Hospital Centre Rijeka, Clinic for Neurology, Rijeka, Croatia|General Hospital Varazdin, Department of neurology, Varazdin, Croatia|Clinical Hospital Centre Zagreb, Zagreb, Croatia|Clinical Hospital Sestre Milosrdnice, Zagreb, Croatia|General Hospital "" Sveti Duh"", Department of neurology, Zagreb, Croatia|MS Center, Department of Neurology, Hradec Kralove, Czech Republic|St. Anne's University Hospital Brno, Pekarska, Czech Republic|Department of Neurology 1st Faculty of Medicine and General Teaching Hospital, MS Center, Praha 2, Czech Republic|Krajska zdravotni a.s. - Hospital Teplice, Teplice, Czech Republic|Århus Universitetshospital, Scleroseklinikken, Århus Sygehus, Aarhus, Denmark|Scleroseklinikken, Rigshospitalet, København, Denmark|Odense University Hospital, Odense, Denmark|CHU Clermont-Ferrand, Hôpital Gabriel Montpied, Clermont-Ferrand, France|Hôpital General, Service de Neurologie, Dijon Cedex, France|Hospital Roger Salengro, Lille Cedex, France|Hôpital Pitié Salpétrière, Service de Neurologie, Paris, France|Sevice de Neurologie, Rennes Cedex, France|Hôpital Civil, Departement de Neurologie, Strasbourg Cedex, France|Krankenhaus Hohe Warte, Betriebsstätte der Bayreuth, Bayreuth, Germany|Judisches Krankenhaus Berlin, Berlin, Germany|Neurologisches Fachzentrum Berlin, Berlin, Germany|Neurologische Universitätsklinik Bonn, Bonn, Germany|Multiple Sklerose Zentrum am, Zentrum für klinische Neurowissenschaften, Neurologische Uniklinik Dresden, Dresden, Germany|Asklepios Klinic Barmbek, Hamburg, Germany|Medizinische Hochshule Hannover, Hannover, Germany|Oberhavelkliniken Hennigsdorf, Hennigsdorf, Germany|Klinikum Ingolstadt, Neurologische Klinik, Ingolstadt, Germany|Klinikum Rechts der Isar, Klinik für Neurologie, Muenchen, Germany|Klinik und Poliklinik fur Neurologie der Universitat Rockstock, Rostock, Germany|Universitatsklinik Ulm, Ulm, Germany|Fachkrankenhaus Hubertusburg, Wermsdorf, Germany|Hadassah Medical Center Ein Karem, Jerusalem, Israel|Tel Aviv Sourasky Medical Center, Department of Neurology, Tel Aviv, Israel|Sheba Medical Centre, Tel Hashomer, Israel|Ospedale Binaghi - Centro Sclerosi Multipla, Cagliari, Italy|Ospedale S. Antonio Abate di Gallarate, Gallarate, Italy|Università di Genova Dipartimento di Neuroscienze Oftalmologia e Genetica, Genova, Italy|Ospedale Civile di Brescia c/o Ospedale Richiedei, Centro di riferimento per la Sclerosi Multiple, Montichiari, Italy|Ospedale San Luigi di Orbassano, Orbassano, Italy|Azienda Ospedaliera Sant'Andrea Neurologia, Roma, Italy|Hospital Medica Sur CIF-BIOTEC, Delegacion, Tlalpan, Mexico|Unidad de Investigación en Salud de Chihuahua, S.C., Chihuahua, Mexico|Hospital Angeles del Pedregal; Camino a Santa Teresa, Mexico City, Mexico|Jeroen Bosch Ziekenhuis, Hertogenbosch, Netherlands|Orbis Medisch Centrum, Department of Neurology, Sittard, Netherlands|Independent Public Healthcare Facility, Norbert Barlicki University Hospital No. 1 of the Medical University of Lodz, Lodz, Poland|Independent Public Teaching Hospital No. 4 in Lublin, Lublin, Poland|Heliodor Swiecicki Teaching Hospital of the Poznan, University of Medical Sciences, Poznan, Poland|Research Medical Complex ""Your Health"" Ltd, Kazan, Russian Federation|Institution of the Russian Academy of Medical Sciences, ""Neurology Scientific Center under RAMS"", Moscow, Russian Federation|Moscow State Medical Institution City Clinical Hospital #11, Moscow City Center for Multiple Sclerosis, Moscow, Russian Federation|Moscow State Public Medical Institution, City Clinical Hospital #11, Moscow, Russian Federation|Municipal Treatment and Prevention Institution, ""City Hospital #33"", Nizhniy Novgorod, Russian Federation|Federal State Institution: Siberian District Medical Center, Novosibirsk, Russian Federation|State Medical Institution, ""Samara Regional Clinical Hospital n.a. M.I. Kalinin"", Samara, Russian Federation|Institution of the Russian Academy of Sciences, ""Institute of the Human Brain n.a. N.P. Bekhtereva within the Russian Academy of Sciences"", St. Petersburg, Russian Federation|St. Petersburg Pavlov State Medical University, Department of Neurology and Neurosurgery with a Clinic, St. Petersburg, Russian Federation|St.Petersburg State Medical Institution, ""City Multispecialty Hospital #2"", St. Petersburg, Russian Federation|St.Petersburg State Medical Institution, ""Nikolayevskaya Hospital"", St. Petersburg, Russian Federation|Clinic of Neurology, Clinical Centre of Serbia, Belgrade, Serbia|Military Medical Academy, Belgrade, Serbia|Clinical Centre of Kragujevac, Kragujevac, Serbia|Clinical Centre Vojvodina Institute of Neurology, Novi Sad, Serbia|Servicio de Neurología Hospital Vall d'Hebron Paseo de Vall d'Hebron, Barcelona, Spain|Servicio de Neurología Hospital Clínico San Carlos, Madrid, Spain|Servicio de Neurología Hospital Carlos Haya, Malaga, Spain|Servicio de Neurología Hospital Virgen de la Macarena, Sevilla, Spain|Sahlgrenska University Hospital, Neurologkliniken, Gothenburg, Sweden|Norrlands Universitets sjukhus, Umea, Sweden|Institute of Neurology, Psychiatry and Narcology under the Academy of Medical Sciences of Ukraine, Kharkov, Ukraine|Kyiv Municipal Clinical Hospital #4, Department of Demyelinating Diseases of the Nervous System, Kyiv, Ukraine|Danylo Halytsky Lviv National Medical University, Department of Neurology, Lviv, Ukraine|Department Of Neurosciences, Addenbrookes Hospital, Cambridge, England, United Kingdom|Centre for Neuroscience & Trauma, Blizard Institute of Cell and Molecular Science Barts and The London School of Medicine and Dentistry, London, England, United Kingdom|Frenchay Hospital, Bristol, United Kingdom|Salford Royal NHS Foundation Trust, Clinical Trials Unit, Salford, United Kingdom|Department of Neurology Glossop Road, Royal Hallamshire Hospital, Sheffield, United Kingdom"
NCT02398149,Characterizing Upper Extremity Function in Individuals With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02398149,COMPLETED,Multiple Sclerosis,,Mount Sinai Rehabilitation Hospital,National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",,267,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-10,2016-10,2016-10,"Mandell Center for Multiple Sclerosis at the Mount Sinai Rehabilitation Hospital, Hartford, Connecticut, 06112, United States"
NCT05742152,Reliability and Validity of Outcome Measures for Pain in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05742152,NOT_YET_RECRUITING,Pain,,Hasselt University,,ALL,"ADULT, OLDER_ADULT",,50,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-03,2023-05,2023-05,
NCT04147052,iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04147052,COMPLETED,Multiple Sclerosis,BEHAVIORAL: iSLEEPms,Johns Hopkins University,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),ALL,"ADULT, OLDER_ADULT",NA,90,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-09-03,2022-04-20,2022-04-20,"Johns Hopkins University School of Medicine, Baltimore, Maryland, 21211, United States"
NCT02746705,Pilot Study of Transcranial Direct Current Stimulation (tDCS),https://beta.clinicaltrials.gov/study/NCT02746705,COMPLETED,Multiple Sclerosis,DEVICE: Transcranial Direct Current Stimulation (tDCS)|DEVICE: Sham Transcranial Direct Current Stimulation|BEHAVIORAL: Cognitive Training Program,NYU Langone Health,Stony Brook University,ALL,"ADULT, OLDER_ADULT",NA,31,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2016-04,2018-09-30,2018-09-30,"New York University Langone Medical Center, New York, New York, 10016, United States"
NCT01051349,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01051349,COMPLETED,Relapsing-Remitting Multiple Sclerosis,BIOLOGICAL: BIIB019 (Daclizumab)|BIOLOGICAL: trivalent seasonal influenza vaccine,Biogen,AbbVie,ALL,ADULT,PHASE2,410,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2010-03-31,2016-08-25,2016-08-25,"Research Site, Brno, 625 00, Czechia|Research Site, Brno, 656 91, Czechia|Research Site, Hradec Kralove, 500 02, Czechia|Research Site, Prague, 100 34, Czechia|Research Site, Teplice, 415 29, Czechia|Research Site, Bayreuth, 95445, Germany|Research Site, Erlangen, 91054, Germany|Research Site, Marburg, 35043, Germany|Research Site, Rostock, 18147, Germany|Research Site, Budapest, 1076, Hungary|Research Site, Budapest, 1083, Hungary|Research Site, Budapest, 1115, Hungary|Research Site, Budapest, 1125, Hungary|Research Site, Budapest, 1134, Hungary|Research Site, Debrecen, 4032, Hungary|Research Site, Esztergom, 2500, Hungary|Research Site, Gyor, 9024, Hungary|Research Site, Kecskemet, 6000, Hungary|Research Site, Miskolc, 3526, Hungary|Research Site, Miskolc, 3533, Hungary|Research Site, Nyiregyhaza, 4400, Hungary|Research Site, Siofok, 8600, Hungary|Research Site, Bangalore, 560034, India|Research Site, Hyderabad, 500082, India|Research Site, Kolkata, 700068, India|Research Site, Mumbai, 400012, India|Research Site, Rajasthan, 302021, India|Research Site, Bialystok, 15-276, Poland|Research Site, Bialystok, 15-420, Poland|Research Site, Gdansk, 80-803, Poland|Research Site, Katowice, 40-749, Poland|Research Site, Katowice, 40-752, Poland|Research Site, Krakow, 31-505, Poland|Research Site, Lodz, 93-121, Poland|Research Site, Lublin, 20954, Poland|Research Site, Warsaw, 02-957, Poland|Research Site, Warszawa, 02-097, Poland|Research Site, Kazan, 420021, Russian Federation|Research Site, Krasnoyarsk, 660049, Russian Federation|Research Site, Moscow, 107150, Russian Federation|Research Site, Moscow, 115682, Russian Federation|Research Site, Moscow, 6127018, Russian Federation|Research Site, Nizhniy Novgorod, 603076, Russian Federation|Research Site, Novosibirsk, 630087, Russian Federation|Research Site, Omsk, 644033, Russian Federation|Research Site, Samara, 443095, Russian Federation|Research Site, Smolensk, 214018, Russian Federation|Research Site, St Petersburg, 194291, Russian Federation|Research Site, Ufa, 450005, Russian Federation|Research Site, Yaroskavi, 150030, Russian Federation|Research Site, Chernivtsi, 58018, Ukraine|Research Site, Dnipropetrovsk, 49027, Ukraine|Research Site, Donetsk, 83003, Ukraine|Research Site, Kharkiv, 61068, Ukraine|Research Site, Kiev, 03110, Ukraine|Research Site, Kiev, 2125, Ukraine|Research Site, Kyiv, 03110, Ukraine|Research Site, Poltava, 36024, Ukraine|Research Site, Zaporizhia, 69035, Ukraine|Research Site, Zaporizhia, 69600, Ukraine|Research Site, London, SE59RF, United Kingdom|Research Site, Nottingham, NG72UH, United Kingdom|Research Site, Plymouth, PL68DH, United Kingdom|Research Site, Sheffield, S102JF, United Kingdom|Research Site, Stoke-on-Trent, ST47LN, United Kingdom"
NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00803049,COMPLETED,Multiple Sclerosis,DRUG: Teriflunomide (HMR1726),Sanofi,,ALL,ADULT,PHASE3,742,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2006-10,2015-12,2015-12,"Investigational Site Number 1032, Maitland, Florida, 32761, United States|Investigational Site Number 1038, Ft. Wayne, Indiana, 63104, United States|Investigational Site Number 1033, Detroit, Michigan, 48201, United States|Investigational Site Number 1037, Allentown, Pennsylvania, 18103, United States|Investigational Site Number 1603, Graz, 8036, Austria|Investigational Site Number 1604, Innsbruck, 6020, Austria|Investigational Site Number 1601, Wien, 1010, Austria|Investigational Site Number 1602, Wien, 1090, Austria|Investigational Site Number 1208, Calgary, T2N 2T9, Canada|Investigational Site Number 1212, Gatineau, J9J 0A5, Canada|Investigational Site Number 1205, Greenfield Park, J4V 2J2, Canada|Investigational Site Number 1201, Halifax, B3H 1V7, Canada|Investigational Site Number 1206, London, N6A 5A5, Canada|Investigational Site Number 1203, Montreal, H2L 4M1, Canada|Investigational Site Number 1204, Ottawa, K1H 8L6, Canada|Investigational Site Number 1202, Quebec, G1J 1Z4, Canada|Investigational Site Number 1211, St. John'S, A1B 3V6, Canada|Investigational Site Number 1209, Toronto, M5B 1W8, Canada|Investigational Site Number 1210, Vancouver, V6T 2B5, Canada|Investigational Site Number 1207, Winnipeg, R3A 1R9, Canada|Investigational Site Number 3804, Santiago, 750-0710, Chile|Investigational Site Number 3802, Santiago, 760-0746, Chile|Investigational Site Number 3803, Santiago, 890-0085, Chile|Investigational Site Number 3801, Santiago, Chile|Investigational Site Number 3805, Viña Del Mar, Chile|Investigational Site Number 4101, Olomouc, 77520, Czech Republic|Investigational Site Number 4801, Glostrup, 2600, Denmark|Investigational Site Number 4804, Sønderborg, 6400, Denmark|Investigational Site Number 4802, Vejle, 7100, Denmark|Investigational Site Number 1502, Tallinn, 10617, Estonia|Investigational Site Number 1501, Tartu, 50406, Estonia|Investigational Site Number 2203, Helsinki, 00100, Finland|Investigational Site Number 2206, Pori, 28100, Finland|Investigational Site Number 2201, Tampere, 33100, Finland|Investigational Site Number 2202, Turku, 20520, Finland|Investigational Site Number 2415, Besancon, 25030, France|Investigational Site Number 2403, Clermont Ferrand Cedex 1, 63003, France|Investigational Site Number 2408, Dijon, 21079, France|Investigational Site Number 2413, Lille Cedex, 59020, France|Investigational Site Number 2404, Limoges Cedex, 87042, France|Investigational Site Number 2401, Lyon Cedex 03, 69394, France|Investigational Site Number 2409, Marseille, 13005, France|Investigational Site Number 2402, Montpellier Cedex 5, 34000, France|Investigational Site Number 2405, Nancy Cedex, 54036, France|Investigational Site Number 2414, Nantes Cedex 01, 44093, France|Investigational Site Number 2407, Nice Cedex, 06002, France|Investigational Site Number 2410, Paris Cedex 12, 75571, France|Investigational Site Number 2406, Rennes Cedex, 35033, France|Investigational Site Number 2411, Toulouse, 31059, France|Investigational Site Number 2011, Berlin, 10785, Germany|Investigational Site Number 2001, Berlin, 13347, Germany|Investigational Site Number 2000, Bochum, 44791, Germany|Investigational Site Number 2012, Erbach, 64711, Germany|Investigational Site Number 2004, Essen, 45122, Germany|Investigational Site Number 2005, Gießen, 35385, Germany|Investigational Site Number 2007, Hannover, 30625, Germany|Investigational Site Number 2008, Münster, 48149, Germany|Investigational Site Number 2010, Offenbach, 63069, Germany|Investigational Site Number 2009, Rostock, 18055, Germany|Investigational Site Number 2003, Wiesbaden, 65191, Germany|Investigational Site Number 2819, Bari, 70124, Italy|Investigational Site Number 2827, Fidenza, 43036, Italy|Investigational Site Number 2803, Firenze, 50134, Italy|Investigational Site Number 2814, Gallarate, 21013, Italy|Investigational Site Number 2808, Milano, 20132, Italy|Investigational Site Number 2812, Padova, 35128, Italy|Investigational Site Number 2809, Pavia, 27100, Italy|Investigational Site Number 2813, Roma, 00152, Italy|Investigational Site Number 2824, Roma, 00185, Italy|Investigational Site Number 4602, 'S Hertogenbosch, 5223 GZ, Netherlands|Investigational Site Number 4605, Breda, 4818 CK, Netherlands|Investigational Site Number 4601, Nijmegen, 6525 GC, Netherlands|Investigational Site Number 4604, Sittard-Geleen, 6162 BG, Netherlands|Investigational Site Number 3601, Oslo, 0407, Norway|Investigational Site Number 3604, Tønsberg, 3116, Norway|Investigational Site Number 3008, Bialystok, 15-276, Poland|Investigational Site Number 3009, Bialystok, 15-402, Poland|Investigational Site Number 3007, Gdansk, 80-803, Poland|Investigational Site Number 3005, Lodz, 90-153, Poland|Investigational Site Number 3006, Lublin, 20-718, Poland|Investigational Site Number 3004, Lublin, 20-954, Poland|Investigational Site Number 3001, Poznan, 60-355, Poland|Investigational Site Number 3002, Warszawa, 02-097, Poland|Investigational Site Number 3003, Warszawa, 02-957, Poland|Investigational Site Number 4201, Coimbra, 3000-075, Portugal|Investigational Site Number 4203, Lisboa, 1169-050, Portugal|Investigational Site Number 3203, Moscow, 119049, Russian Federation|Investigational Site Number 3205, Moscow, 125015, Russian Federation|Investigational Site Number 3207, Nizhny Novgorod, 603076, Russian Federation|Investigational Site Number 3208, Novosibirsk, 630087, Russian Federation|Investigational Site Number 3201, St-Petersburg, 194044, Russian Federation|Investigational Site Number 3202, St-Petersburg, 197089, Russian Federation|Investigational Site Number 3206, St-Petersburg, 197376, Russian Federation|Investigational Site Number 3401, Stockholm, 171 76, Sweden|Investigational Site Number 1802, Basel, 4031, Switzerland|Investigational Site Number 5003, Izmir, 35340, Turkey|Investigational Site Number 5006, Izmir, 35380, Turkey|Investigational Site Number 5005, Kocaeli, 41380, Turkey|Investigational Site Number 5001, Sihhiye / Ankara, 06100, Turkey|Investigational Site Number 3504, Dnipropetrovsk, 49027, Ukraine|Investigational Site Number 3505, Ivano-Frankovsk, 76008, Ukraine|Investigational Site Number 3506, Kharkiv, 61018, Ukraine|Investigational Site Number 3510, Kharkiv, 61178, Ukraine|Investigational Site Number 3508, Lviv, 79010, Ukraine|Investigational Site Number 3502, Odessa, 65025, Ukraine|Investigational Site Number 3509, Uzhgorod, 88018, Ukraine|Investigational Site Number 3507, Vinnitsa, 21005, Ukraine|Investigational Site Number 3501, Zaporizhzhya, 69600, Ukraine|Investigational Site Number 2604, Dundee, DD1 9SY, United Kingdom|Investigational Site Number 2607, London, E1 1BB, United Kingdom|Investigational Site Number 2608, London, SW17 0QT, United Kingdom|Investigational Site Number 2600, Newcastle Upon Tyne, NE1 4LP, United Kingdom|Investigational Site Number 2601, Nottingham, NG7 2UH, United Kingdom|Investigational Site Number 2609, Plymouth, PL6 8BX, United Kingdom|Investigational Site Number 2606, Sheffield, S10 2JF, United Kingdom|Investigational Site Number 2602, Stoke On Trent, ST4 7LN, United Kingdom"
NCT01377805,Head Circumference Growth in Children Who Develop Multiple Sclerosis Later in Life,https://beta.clinicaltrials.gov/study/NCT01377805,WITHDRAWN,Multiple Sclerosis,,Genetic Disease Investigators,,ALL,"CHILD, ADULT, OLDER_ADULT",,0,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-06,2011-11,2011-11,"Total Eye Care, Colleyville, Texas, 76034, United States"
NCT05275049,Neuromodulation in MS Using Translingual Stimulation,https://beta.clinicaltrials.gov/study/NCT05275049,ENROLLING_BY_INVITATION,Multiple Sclerosis,COMBINATION_PRODUCT: PT plus translingual stimulation device|COMBINATION_PRODUCT: PT plus translingual stimulation control device,University of Saskatchewan,Memorial University of Newfoundland,ALL,"ADULT, OLDER_ADULT",NA,52,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-07-05,2022-07-05,2022-12-01,"Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, A1A 1E5, Canada|University of Saskatchewan, Saskatoon, Saskatchewan, S7N 2Z4, Canada"
NCT00662649,Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00662649,COMPLETED,Multiple Sclerosis,DRUG: Fingolimod 0.5 mg|DRUG: Fingolimod 1.25 mg,Novartis,,ALL,ADULT,PHASE3,920,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2008-02,2011-06,2011-06,"Novartis Investigative Site, Chatswood, Australia|Novartis Investigative Site, Fitzroy, 3065, Australia|Austin Health, Department of Neurology, Heidelberg, Australia|Novartis Investigative Site, North Gosford, Australia|Novartis Investigative Site, Woodville, Australia|Novartis Investigative Site, Brugge, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Charleroi, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Overpelt, Belgium|Novartis Investigative Site, Sijsele - Damme, Belgium|Novartis Investigative Site, Sint-Truiden, Belgium|Novartis Investigative Site, Halifax, Canada|Novartis Investigative Site, Kingston, Canada|Novartis Investigative Site, London, Canada|Novartis Investigative Site, Montreal, Canada|Novartis Investigative Site, Nepean, Canada|Novartis Investigative Site, Regina, Canada|Novartis Investigative Site, Toronto, Canada|Novartis Investigative Site, Vancouver, Canada|Novartis Investigative Site, Brno, Czech Republic|Novartis Investigative Site, Olomouc, Czech Republic|Novartis Investigative Site, Ostrava-Poruba, Czech Republic|Novartis Investigative Site, Pardubice, Czech Republic|Novartis Investigative Site, Plzen - Lochotin, Czech Republic|Novartis Investigative Site, Prague 5, Czech Republic|Novartis Investigative Site, Praha 2, Czech Republic|Novartis Investigative Site, Rychnov nad Kneznou, Czech Republic|Novartis Investigative Site, Teplice, Czech Republic|Novartis Investigative Site, Talinn, Estonia|Novartis Investigative Site, Helsinki, Finland|Novartis Investigative Site, Tampere, Finland|Novartis Investigative Site, Turku, Finland|Novartis Investigative Site, Clermont Ferrand Cedex, France|Novartis Investigative Site, Dijon, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Marseille cedex 05, France|Novartis Investigative Site, Montpellier cedex 5, France|Novartis Investigative Site, Nantes, France|Novartis Investigative Site, Paris Cedex 13, France|Novartis Investigative Site, Rennes, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Duesseldorf, Germany|Novartis Investigative Site, Gießen, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Magdeburg, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Muenster, Germany|Novartis Investigative Site, Regensburg, Germany|Novartis Investigative Site, Stuttgart, Germany|Novartis Investigative Site, Tübingen, Germany|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Miskolc, Hungary|Novartis Investigative Site, Szekesfehervar, Hungary|Novartis Investigative Site, Dublin 4, Ireland|Novaratis Investigative Site, Ashkelon, Israel|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Safed, Israel|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Nieuwegein, Netherlands|Novartis Investigative Site, Nijmegen, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Sittard, Netherlands|Novartis Investigative Site, Tilburg, Netherlands|Novartis Investigative Site, Bialystok, Poland|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Katowice, Poland|Novartis Investigative Site, Lodz, Poland|Novartis Investigative Site, Poznan, Poland|Novartis Investigative Site, Warsaw, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Craiova, Romania|Novartis Investigative Site, Lasi, Romania|Novartis Investigative Site, Tg. Mures, Romania|Novartis Investigative Site, Kazan, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigational Site, Bratislava, Slovakia|Novartis Investigative Site, Martin, Slovakia|Novartis Investigational Site, Zilina, Slovakia|Novartis Investigational Site, Cape Town, South Africa|Novartis Investigational Site, Rosebank, South Africa|Novartis Investigational Site, Umhlanga, South Africa|Novartis Investigational Site, Göteborg, Sweden|Novartis Investigational Site, Stockholm, Sweden|Novartis Investigative Site, Lausanne, Switzerland|Novartis Investigative Site, Zuerich, Switzerland|Novartis Investigational Site, Ankara, Turkey|Novartis Investigational Site, Bursa, Turkey|Novartis Investigational Site, Cerrahpasa/Istanbul, Turkey|Novartis Investigational Site, Gaziantep, Turkey|Novartis Investigational Site, Istanbul, Turkey|Novartis Investigational Site, Izmir, Turkey|Novartis Investigational Site, Mersin, Turkey|Novartis Investigational Site, Yenisehir/Izmir, Turkey|Novartis Investigative Site, Bristol, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Newcastle Upon Tyne, United Kingdom|Novartis Investigative Site, Nottingham, United Kingdom|Novartis Investigative Site, Sheffield, United Kingdom"
NCT02097849,Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.,https://beta.clinicaltrials.gov/study/NCT02097849,COMPLETED,Relapsing Forms of Multiple Sclerosis,DRUG: dimethyl fumarate|BIOLOGICAL: tetanus diphtheria toxoids vaccine|BIOLOGICAL: 23-valent pneumococcal polysaccharide vaccine|BIOLOGICAL: meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent)|DRUG: non-pegylated interferon,Biogen,,ALL,ADULT,PHASE2,71,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2015-02-28,2016-05-02,2016-05-02,"Research Site, Gilbert, Arizona, 85234, United States|Research Site, Thornton, Colorado, 80233, United States|Research Site, Fort Lauderdale, Florida, 33312, United States|Research Site, Sarasota, Florida, 34243, United States|Research Site, Indianapolis, Indiana, 46202, United States|Research Site, Lexington, Kentucky, 40513, United States|Research Site, Auburn, Maine, 04210, United States|Research Site, New York, New York, 10016, United States|Research Site, Charlotte, North Carolina, 28203, United States|Research Site, Akron, Ohio, 44320, United States|Research Site, Cleveland, Ohio, 44195, United States|Research Site, Dayton, Ohio, 45417, United States|Research Site, Round Rock, Texas, 78761, United States|Research Site, San Antonio, Texas, 78258, United States"
NCT00939549,High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00939549,WITHDRAWN,Relapsing Remitting Multiple Sclerosis,DRUG: Cyclophosphamide/Glatiramer acetate,Johns Hopkins University,,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2010-11,2010-11,2010-11,"Johns Hopkins Hospital Multiple Sclerosis Center, Baltimore, Maryland, 21287, United States"
NCT04390126,COVID-19 Related Lockdown Effects On Chronic Diseases,https://beta.clinicaltrials.gov/study/NCT04390126,UNKNOWN,Chronic Coronary Syndrome|Heart Failure|AMD and Macular Edema|Chronic Respiratory Failure|Hemophilia|Malignant Hemopathy|Multiple Sclerosis|Horton's Disease,OTHER: life questionnaires|OTHER: questionnaire,Centre Hospitalier Universitaire Dijon,,ALL,"CHILD, ADULT, OLDER_ADULT",,1200,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-04-20,2021-05-07,2021-11-07,"CHU Dijon Bourgogne, Dijon, 21079, France"
NCT03516526,Towards Personalized Dosing of Natalizumab in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03516526,COMPLETED,Multiple Sclerosis,DRUG: Natalizumab,"Amsterdam UMC, location VUmc",Prothya Biosolutions|Erasmus Medical Center|St. Antonius Hospital|OLVG|Rijnstate Hospital,ALL,"ADULT, OLDER_ADULT",PHASE4,61,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-11-03,2019-06-21,2019-07-01,"OLVG, Amsterdam, Netherlands|VU medical center, Amsterdam, Netherlands|Rijnstate Hospital, Arnhem, Netherlands|Erasmus medical center, Rotterdam, Netherlands|St. Antonius Hospital, Utrecht, Netherlands"
NCT02149706,"A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT02149706,UNKNOWN,Multiple Sclerosis,BIOLOGICAL: NeuroVax|BIOLOGICAL: IFA Incomplete Freund's Adjuvant,"Immune Response BioPharma, Inc.",cro,ALL,"ADULT, OLDER_ADULT",PHASE2,150,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-03-09,2022-03-09,2022-03-09,"CRO, San Diego, California, 92129, United States"
NCT03541226,"Clinical Monitoring, MRI and Neuro-Ophthalmology of a Cohort of Patients With a Clinically Isolated Syndrome (CIS)",https://beta.clinicaltrials.gov/study/NCT03541226,UNKNOWN,Clinically Isolated Syndrome|Multiple Sclerosis,,"University Hospital, Lille",,ALL,ADULT,,134,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-09,2021-09,2021-09,"Hôpital Roger Salengro, CHRU de Lille, Lille, France"
NCT05170126,A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring,https://beta.clinicaltrials.gov/study/NCT05170126,RECRUITING,Multiple Sclerosis,,Bristol-Myers Squibb,,FEMALE,"CHILD, ADULT, OLDER_ADULT",,1182,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-01-14,2031-06-30,2031-06-30,"Evidera, Bethesda, Maryland, 20814, United States"
NCT04009005,Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04009005,ACTIVE_NOT_RECRUITING,Clinically Isolated Syndrome|Relapsing Remitting Multiple Sclerosis,BEHAVIORAL: Therapeutic diet and lifestyle,Terry L. Wahls,,ALL,ADULT,NA,44,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-05-01,2022-08-01,2027-01-01,"University of Iowa, Iowa City, Iowa, 52246, United States"
NCT02142205,"Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)",https://beta.clinicaltrials.gov/study/NCT02142205,COMPLETED,Relapsing-Remitting Multiple Sclerosis,BIOLOGICAL: BG00002,Biogen,,ALL,ADULT,PHASE4,100,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2012-05,2013-12,2013-12,"Research Site, Belgorod, Russian Federation|Research Site, Kaluga, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Kursk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Rostov-on-Don, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Smolensk, Russian Federation"
NCT03121105,Pathologic-MRI Findings in Atypical IIDD,https://beta.clinicaltrials.gov/study/NCT03121105,COMPLETED,Idiopathic Inflammatory Demyelinating Disorders of the Central Nervous System,,"University Hospital, Montpellier","University Hospital, Strasbourg, France|Rennes University Hospital|University Hospital, Bordeaux|University Hospital, Limoges|Hospices Civils de Lyon|Centre Hospitalier Universitaire de Nīmes|Colmar Hospital|Perpignan Hospital",ALL,"ADULT, OLDER_ADULT",,25,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-01-01,2017-12-01,2017-12-31,
NCT04140305,Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063),https://beta.clinicaltrials.gov/study/NCT04140305,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,DRUG: RPC-1063,Celgene,,ALL,"ADULT, OLDER_ADULT",PHASE3,250,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-01-16,2026-01-27,2026-04-27,"Local Institution - 123, Birmingham, Alabama, 35209, United States|Local Institution - 136, Cullman, Alabama, 35058, United States|Local Institution - 153, Mobile, Alabama, 36617, United States|Local Institution - 162, Phoenix, Arizona, 85018, United States|Local Institution - 128, Pasadena, California, 91105, United States|Local Institution - 164, Sacramento, California, 95817, United States|Local Institution - 107, Aurora, Colorado, 80045, United States|Local Institution - 102, Colorado Springs, Colorado, 80907, United States|Local Institution - 144, Fort Collins, Colorado, 80528, United States|Local Institution - 109, Washington, District of Columbia, 20007, United States|Local Institution - 140, Boca Raton, Florida, 33428, United States|Local Institution - 158, Vero Beach, Florida, 32960-4818, United States|Local Institution - 114, Savannah, Georgia, 31406, United States|Northwest Neurology, Ltd, Hoffman Estates, Illinois, 60169, United States|Local Institution - 108, Northbrook, Illinois, 60062, United States|Local Institution - 148, Fort Wayne, Indiana, 46825-1603, United States|Local Institution - 126, Ames, Iowa, 50010, United States|Local Institution - 173, Kansas City, Kansas, 66160, United States|Local Institution - 133, Alexandria, Louisiana, 71301, United States|Local Institution - 152, Detroit, Michigan, 48201, United States|Local Institution - 112, Detroit, Michigan, 48202, United States|Local Institution - 122, Saint Louis, Missouri, 63110, United States|Local Institution - 143, Saint Louis, Missouri, 63131, United States|Advanced Neurology Specialists, Great Falls, Montana, 59405, United States|Local Institution - 149, Teaneck, New Jersey, 07666, United States|Dent Neurologic Institute, Amherst, New York, 14226, United States|Local Institution - 137, Buffalo, New York, 14202, United States|Local Institution - 160, East Setauket, New York, 11733-3528, United States|Local Institution - 130, New York, New York, 10016, United States|Local Institution - 121, New York, New York, 10021, United States|Local Institution - 146, Patchogue, New York, 11772, United States|Local Institution - 131, Chapel Hill, North Carolina, 27514, United States|Local Institution - 106, Greensboro, North Carolina, 27405, United States|Local Institution - 170, Mooresville, North Carolina, 28117, United States|Raleigh Neurology Associates PA, Raleigh, North Carolina, 27607, United States|Local Institution - 174, Cincinnati, Ohio, 45219, United States|Local Institution - 171, Cleveland, Ohio, 44106, United States|UC Health, LLC, Dayton, Ohio, 45417, United States|Local Institution - 157, Oklahoma City, Oklahoma, 73104, United States|Local Institution - 159, Philadelphia, Pennsylvania, 19107, United States|Local Institution - 169, Philadelphia, Pennsylvania, 19140, United States|University of Pittsburgh Medical Center Magee Womens Hospital, Pittsburgh, Pennsylvania, 15213, United States|Local Institution - 125, Franklin, Tennessee, 37064, United States|Local Institution - 119, Knoxville, Tennessee, 37922, United States|Baylor Research Institute - Dallas Clinical Trials Office, Dallas, Texas, 75246, United States|Local Institution - 113, Round Rock, Texas, 78681, United States|Local Institution - 101, San Antonio, Texas, 78259, United States|Local Institution - 103, Norfolk, Virginia, 23502, United States|Local Institution - 141, Kirkland, Washington, 98034, United States|Local Institution - 168, Seattle, Washington, 98101, United States|Local Institution - 172, Spokane, Washington, 99202, United States|Local Institution - 124, Tacoma, Washington, 98405, United States|Local Institution - 156, Huntington, West Virginia, 25701, United States|Local Institution - 150, Morgantown, West Virginia, 26506, United States|Local Institution - 167, Madison, Wisconsin, 53792, United States|Local Institution - 147, Milwaukee, Wisconsin, 53226, United States|Local Institution - 203, London, Ontario, N6G 2V4, Canada|Local Institution - 204, Ottawa, Ontario, K1H 8L6, Canada|Local Institution - 206, Montreal, Quebec, H2X 0A9, Canada|Local Institution - 207, Halifax, B3R 1V9, Canada|Local Institution - 166, Guaynabo, 00968, Puerto Rico"
NCT00497952,Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00497952,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,BIOLOGICAL: hematopoetic stem cell infusion,Talaris Therapeutics Inc.,,ALL,ADULT,PHASE1|PHASE2,3,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-07,2024-12,2024-12,
NCT02201849,"A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults",https://beta.clinicaltrials.gov/study/NCT02201849,COMPLETED,Multiple Sclerosis,DRUG: Study Drug|DRUG: Active Control|DRUG: Placebo,Biogen,,ALL,ADULT,PHASE1,104,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-07,2014-12,2014-12,"Alkermes Investigational Site, Austin, Texas, United States"
NCT00645749,Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00645749,COMPLETED,Relapsing Remitting Multiple Sclerosis,BIOLOGICAL: Helminth ova,"University of Wisconsin, Madison",National Multiple Sclerosis Society,ALL,ADULT,PHASE1,17,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2008-07,2015-08-13,2015-08-13,"University of Wisconsin Hospital and Clinics, Madison, Wisconsin, 53972, United States"
NCT01464905,Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS),https://beta.clinicaltrials.gov/study/NCT01464905,UNKNOWN,Relapsing Remitting Multiple Sclerosis,BIOLOGICAL: NU100|BIOLOGICAL: Placebo|BIOLOGICAL: rhIFN beta-1b,Nuron Biotech Inc.,,ALL,ADULT,PHASE3,500,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-10,2013-12,2014-12,"Minsk, Belarus|Sofia, Bulgaria|Zagreb, Croatia|Tbilisi, Georgia|Budapest, Hungary|Rome, Italy|Beirut, Lebanon|Warsaw, Poland|Moscow, Russian Federation|Belgrade, Serbia|Barcelona, Spain|Kiev, Ukraine"
NCT02038049,A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02038049,TERMINATED,Relapse Remitting Multiple Sclerosis,DRUG: VAY736|DRUG: Placebo,Novartis Pharmaceuticals,,ALL,ADULT,PHASE2,8,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-12-20,2015-05-05,2018-09-13,"Novartis Investigative Site, Long Beach, California, 90806, United States|Novartis Investigative Site, San Diego, California, 92103, United States|Novartis Investigative Site, Hradec Kralove, 501 03, Czechia|Novartis Investigative Site, Kharkiv, 61068, Ukraine|Novartis Investigative Site, Lviv, 79010, Ukraine"
NCT01720849,"Efficiency of 4-aminopyridin (Fampyra) on Gait, Vision, Cognition, Fatigue and Micturation in Patients With Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT01720849,UNKNOWN,Multiple Sclerosis|EDSS 4-7,DRUG: Fampyra,Vestre Viken Hospital Trust,,ALL,"ADULT, OLDER_ADULT",,50,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-12,2016-05,,"Vestre Viken Helseforetak, Drammen, 3004, Norway"
NCT02325505,"Characterization of Patients With Tuberous Sclerosis Complex, Lymphangioleiomyomatosis and Angiomyolipoma",https://beta.clinicaltrials.gov/study/NCT02325505,COMPLETED,Tuberous Sclerosis|Lymphangioleiomyomatosis|Angiomyolipoma,,InCor Heart Institute,Novartis,ALL,"CHILD, ADULT, OLDER_ADULT",,200,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-04,2021-04,2022-08,"InCor Heart Institute, Sao Paulo, 05303900, Brazil|InCor Heart Institute, Research Center, Sao Paulo, 05403900, Brazil|InCor Heart Institute, Sao Paulo, 05403900, Brazil"
NCT02887352,French Adaptation of the California Card Sorting Task (CCST) in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02887352,COMPLETED,Multiple Sclerosis,OTHER: assessment of problem-solving ability,Fondation Ophtalmologique Adolphe de Rothschild,,ALL,"ADULT, OLDER_ADULT",,48,NETWORK,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-03,2020-01,2020-01,"Fondation Ophtalmologique Adolphe de Rothschild, Paris, 75019, France"
NCT02364505,A Telemedicine Mindfulness-based Intervention for People With Multiple Sclerosis and Their Caregivers,https://beta.clinicaltrials.gov/study/NCT02364505,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Telemedicine mindfulness-based intervention|BEHAVIORAL: Psycho-education intervention,Fondazione Don Carlo Gnocchi Onlus,Catholic University of the Sacred Heart,ALL,"ADULT, OLDER_ADULT",NA,156,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2014-09,2016-11,2016-12,"Francesco Pagnini, Milan, Mi, 20871, Italy"
NCT01786005,Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity,https://beta.clinicaltrials.gov/study/NCT01786005,UNKNOWN,"Spasticity, Multiple Sclerosis, Stroke, Trauma",DEVICE: Transcranial magnetic stimulation,Russian Academy of Medical Sciences,,ALL,"ADULT, OLDER_ADULT",PHASE4,60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2013-02,2015-09,2015-12,"Research center of neurology RAMS, Moscow, Volokolamskoe shosse, 80, 125367, Russian Federation"
NCT01663649,Effectiveness of Web-based Treatment for Depression in Patients With Neurologic Disorders,https://beta.clinicaltrials.gov/study/NCT01663649,COMPLETED,Depression,BEHAVIORAL: Deprexis|BEHAVIORAL: Wait-list,Universitätsklinikum Hamburg-Eppendorf,Epilepsy Centre Alsterdorf,ALL,"ADULT, OLDER_ADULT",NA,180,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2012-06,2013-12,2014-02,"University Medical Center Hamburg-Eppendorf - Neurology, Hamburg, 20246, Germany|Epilepsy Centre Alsterdorf, Hamburg, 22337, Germany"
NCT05832515,AHSCT With Fludarabine and Cyclophosphamide Based Conditioning Regimes in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05832515,RECRUITING,Multiple Sclerosis,DRUG: Fludarabine Phosphate for Injection,St. Petersburg State Pavlov Medical University,,ALL,"ADULT, OLDER_ADULT",PHASE1,200,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-10-01,2025-10-01,2026-12-01,"First Pavlov State Medical University of St. Petersburg, Saint Petersburg, 197022, Russian Federation"
NCT02117050,RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate,https://beta.clinicaltrials.gov/study/NCT02117050,TERMINATED,Multiple Sclerosis,DRUG: Rebif®,EMD Serono,,ALL,"ADULT, OLDER_ADULT",PHASE4,1,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-06,2015-04,2015-04,"Call EMD Serono Medical Information for information on recruiting sites, Boston, Massachusetts, United States"
NCT01824550,Home Exercise Intervention in Persons With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01824550,COMPLETED,Multiple Sclerosis,OTHER: home-based exercise training condition,University of Illinois at Chicago,,ALL,"ADULT, OLDER_ADULT",NA,59,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2012-11-13,2017-09-07,2018-09-07,"University of Illinois at Chicago, Chicago, Illinois, 60612, United States"
NCT02544750,"An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)",https://beta.clinicaltrials.gov/study/NCT02544750,COMPLETED,Tuberous Sclerosis Complex|Seizures,DRUG: GWP42003-P,Jazz Pharmaceuticals,GW Pharmaceuticals,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,199,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-08-31,2021-06-11,2021-06-11,"Massachusetts General Hospital, Boston, Massachusetts, 02114, United States"
NCT03216915,Effects of Fingolimod on Heart Rhythm and Heart Rate Variability in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03216915,UNKNOWN,Multiple Sclerosis,DRUG: Gilenya®; Novartis Pharmaceuticals Corporation,Universitätsklinikum Hamburg-Eppendorf,,ALL,"ADULT, OLDER_ADULT",,100,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-06-01,2019-12-31,2020-12-31,"University Medical Hospital Hamburg-Eppendorf, Hamburg, 20246, Germany"
NCT03933215,A Study of Suboptimally Controlled Participants Previously Taking Injectable DMDs for RMS (CLICK-MS),https://beta.clinicaltrials.gov/study/NCT03933215,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,DRUG: Cladribine Tablets,"EMD Serono Research & Development Institute, Inc.","Merck KGaA, Darmstadt, Germany",ALL,"ADULT, OLDER_ADULT",,100,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-05-21,2026-02-21,2026-02-21,"University of Arkansas for Medical Sciences, Little Rock, Arkansas, 72205, United States|HCA Research Institute, Englewood, Colorado, 80113, United States|Advanced Neurosciences Research, Fort Collins, Colorado, 80528, United States|Prairie Education & Research, Springfield, Illinois, 62702, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, 46804, United States|College Park Family Care Center, Overland Park, Kansas, 66212, United States|The Elliot Lewis Center for Multiple Sclerosis Care, LLC, Wellesley, Massachusetts, 02481, United States|UMASS - Neurology, Worcester, Massachusetts, 01655, United States|Henry Ford Health System, Detroit, Michigan, 48202, United States|Memorial Healthcare, Owosso, Michigan, 48867, United States|Minneapolis Clinic of Neurology - Neurology, Minneapolis, Minnesota, 55422, United States|Neurology Center of Las Vegas, Las Vegas, Nevada, 89128, United States|The Charlotte-Mecklenburg Hospital Authority - Carolinas Healthcare System, Charlotte, North Carolina, 28203, United States|Guilford Neurologic Associates, Greensboro, North Carolina, 27405, United States|Temple University Hospital - Cardiology, Philadelphia, Pennsylvania, 19140, United States|Central Texas Neurology Consultants, Round Rock, Texas, 78681, United States|Neurology Center of San Antonio, San Antonio, Texas, 78258, United States|Fletcher Allen Health Care, Inc. - Hematology/Oncology Unit, Burlington, Vermont, 05401, United States|Blacksburg Neurology, PC, Christiansburg, Virginia, 24073, United States|Neurological Associates, Richmond, Virginia, 23229, United States|Sentara Ambulatory Care Center, Virginia Beach, Virginia, 23456, United States|MS Center of Evergreen, Kirkland, Washington, 98034, United States"
NCT05122559,Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05122559,RECRUITING,"Multiple Sclerosis|Multiple Sclerosis, Primary Progressive|Multiple Sclerosis, Secondary Progressive",DRUG: N-acetyl cysteine|DRUG: Placebo,"Emmanuelle Waubant, MD PhD",United States Department of Defense,ALL,"ADULT, OLDER_ADULT",PHASE2,98,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-02-16,2025-02,2025-02,"University of California, San Francisco, San Francisco, California, 94158, United States"
NCT02010554,Development of a Talk Therapy Protocol to Help Patients Make Treatment Decisions in MS,https://beta.clinicaltrials.gov/study/NCT02010554,COMPLETED,Relapsing-remitting Multiple Sclerosis,BEHAVIORAL: Brief Education|BEHAVIORAL: Motivational Interviewing-Cognitive Behavioral Therapy,"University of Missouri, Kansas City",,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2013-12,2015-03,2015-09,"University of Missouri-Kansas City, Kansas City, Missouri, 64110, United States|Kessler Rehabilitation Institute, West Orange, New Jersey, 07052, United States"
NCT03536559,Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03536559,TERMINATED,"Relapsing Remitting Multiple Sclerosis|Optic Neuropathy|Optic; Neuritis, With Demyelination",DRUG: CNM-Au8|DRUG: Placebo,Clene Nanomedicine,Clene Australia Pty Ltd,ALL,ADULT,PHASE2,73,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-11-23,2022-04-27,2022-07-12,"UT Southwestern Medical Center, Dallas, Texas, 75390, United States|John Hunter Hospital, New Lambton Heights, New South Wales, 2305, Australia|Sydney Brain Mind Centre, Sydney, New South Wales, Australia|Princess Alexandria Hospital, Woolloongabba, Queensland, 4102, Australia|Menzies Institute for Medical Research, Hobart, Tasmania, 7000, Australia|Alfred Health, Melbourne, Victoria, 3004, Australia|University of British Columbia, Vancouver, British Columbia, V6T 1Z3, Canada"
NCT04585659,Qigong for Multiple Sclerosis: A Feasibility Study,https://beta.clinicaltrials.gov/study/NCT04585659,COMPLETED,Multiple Sclerosis,OTHER: Qigong,National University of Natural Medicine,,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2017-02-01,2018-03-16,2018-03-16,"National University of Natural Medicine, Helfgott Research Institute, Portland, Oregon, 97201, United States"
NCT03060759,Light Therapy as Treatment for Fatigue in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03060759,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DEVICE: Light Therapy box,Massachusetts General Hospital,,ALL,"ADULT, OLDER_ADULT",NA,35,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2017-04-01,2019-06-30,2019-11-04,"Massachusetts General Hospital, Boston, Massachusetts, 02114, United States"
NCT01532154,Fampridine Pregnancy Exposure Registry,https://beta.clinicaltrials.gov/study/NCT01532154,TERMINATED,Multiple Sclerosis|Pregnancy,DRUG: Fampridine,Biogen,,FEMALE,"CHILD, ADULT, OLDER_ADULT",,1,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-08,2016-02,2016-02,"Hopital Pitie Salpetriere, Paris, 75013, France"
NCT05060354,COVID-19 Vaccine Response in Treated MS Patients,https://beta.clinicaltrials.gov/study/NCT05060354,RECRUITING,Multiple Sclerosis|Healthy,OTHER: Blood draw,Brigham and Women's Hospital,,ALL,"ADULT, OLDER_ADULT",,200,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-06-01,2023-06-01,2023-10-31,"Brigham MS Center, Boston, Massachusetts, 02115, United States"
NCT04175054,Comparison of Vigorous Versus Low Intensity Cool Room Treadmill Training in People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04175054,NOT_YET_RECRUITING,Multiple Sclerosis|Neurological Rehabilitation|Exercise|Neuronal Plasticity|Cooling,OTHER: Body-weight supported treadmill training in a room cooled to 16°C,Memorial University of Newfoundland,Multiple Sclerosis Society of Canada,ALL,"ADULT, OLDER_ADULT",NA,70,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-11,2025-02,2025-02,"Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, A1A 1E5, Canada"
NCT01031459,Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.,https://beta.clinicaltrials.gov/study/NCT01031459,COMPLETED,Multiple Sclerosis,"DRUG: Betaseron (Interferon beta-1b, BAY86-5046)",Bayer,,ALL,"ADULT, OLDER_ADULT",,176,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-01,2010-12,2010-12,"Birmingham, Alabama, 35249, United States|Tucson, Arizona, 85741-3537, United States|San Francisco, California, 94117, United States|Chicago, Illinois, 60637-1470, United States|Baltimore, Maryland, 21201, United States|Philadelphia, Pennsylvania, 19107, United States|Vancouver, British Columbia, V6T 2B5, Canada|London, Ontario, N6A 5A5, Canada|Montreal, Quebec, H2L 4M1, Canada|Montreal, Quebec, H3A 2B4, Canada"
NCT04025554,Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04025554,RECRUITING,Multiple Sclerosis,DRUG: Anakinra,National Institute of Neurological Disorders and Stroke (NINDS),,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,10,NIH,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2019-10-25,2023-12-31,2023-12-31,"National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States"
NCT00202254,Multiple Sclerosis Rehabilitation Study,https://beta.clinicaltrials.gov/study/NCT00202254,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Physiotherapy|BEHAVIORAL: Occupational therapy|BEHAVIORAL: Speech pathology,Melbourne Health,,ALL,ADULT,NA,100,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2004-12,2005-12,2005-12,
NCT02057159,"A Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT02057159,UNKNOWN,Secondary Progress Multiple Sclerosis|Multiple Sclerosis,BIOLOGICAL: NeuroVax|BIOLOGICAL: IFA Placebo,"Immune Response BioPharma, Inc.",cro,ALL,ADULT,PHASE2|PHASE3,200,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-03-09,2023-03-09,2023-03-09,"CRO, San Diego, California, 92129, United States"
NCT02340754,Mindfulness-based Stress Reduction for Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02340754,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Mindfulness-based Stress Reduction|BEHAVIORAL: MS Education Control,National University of Natural Medicine,National Institutes of Health (NIH)|National Center for Complementary and Integrative Health (NCCIH),ALL,"ADULT, OLDER_ADULT",NA,67,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2015-05,2017-05-30,2017-05-30,"National College of Natural Medicine, Portland, Oregon, 97201, United States"
NCT04853654,Investigation of the Effects of Selective Exercise Training in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04853654,COMPLETED,Multiple Sclerosis|Exercise,OTHER: exercise,Sanko University,,ALL,ADULT,NA,33,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-09-15,2020-04-15,2020-06-15,"Zekiye İpek Katırcı Kırmacı, Gaziantep, Turkey"
NCT02660359,Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2,https://beta.clinicaltrials.gov/study/NCT02660359,TERMINATED,Urinary Incontinence|Overactive Bladder,BIOLOGICAL: Botulinum toxin type A|BIOLOGICAL: Botulinum toxin type A|DRUG: Placebo|DRUG: Placebo,Ipsen,,ALL,"ADULT, OLDER_ADULT",PHASE3,258,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2016-07-08,2018-11-09,2019-07-04,"Instituto Urológico Buenos Aires, Buenos Aires, 1060, Argentina|Centro de Urologia, Buenos Aires, C1120AAS, Argentina|Centro Urológico Profesor Bengió, Córdoba, X5000, Argentina|Hospital Privado - Centro Médico de Córdoba, Córdoba, X5016KEH, Argentina|Instituto Médico Rodriguez Alfici, Godoy Cruz, M5501AAP, Argentina|Prince of Wales Hospital (POWH), Sydney, 2031, Australia|Westmead Hospital, Westmead, 2145, Australia|Antwerp University hospital, Antwerp, Belgium|Hôpital Erasme, Brussels, 1070, Belgium|Ourthe-Amblève, Esneux, 4130, Belgium|Universidade Estadual de Campinas - Cidade Universitária Zeferino Vaz, Campinas, 13083-970, Brazil|Hospital de Clinicas, Federal University of Paraná, Curitiba, 80060-900, Brazil|Hospital São Vicente de Paulo, Passo Fundo, 99010-080, Brazil|Santa Casa de Misericórdia de Porto Alegre - Hospital Santa Clara, Porto Alegre, 90020-090, Brazil|Hospital Moinhos de Vento, Pôrto Alegre, 90560-030, Brazil|Hospital São Lucas da PUCRS, Pôrto Alegre, 90610-000, Brazil|Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, Ribeirao Preto, 14048-900, Brazil|Faculdade de Medicina do ABC, Santo André, 09060-650, Brazil|Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, 05422-970, Brazil|Hospital Alemão Oswaldo Cruz, São Paulo, 01323-020, Brazil|Clínica Uromed, Santiago, 7500787, Chile|Hospital del Trabajador, Santiago, 7501241, Chile|Clínica Las Condes, Santiago, 7591046, Chile|Solano & Terront Servicios Medicos LTDA- Unidad Integral de Endocrinologia, Bogotá, 110221, Colombia|Fundación Valle del Lili, Cali, 760032, Colombia|Centro Medico Imbanaco, Cali, 760042, Colombia|Asociacion IPS Medicos Internistas de Caldas, Manizales, 170004, Colombia|Centro de Investigaciones Clinicas - CIC, Medellin, 5001000, Colombia|Hôpital Raymond-Poincaré, Garches, France|Centre Hospitalier Régional Universitaire de Lille (CHRU) - Hôpital Claude Huriez, Lille Cedex, France|Hôpital de la Conception, Marseille CEDEX 5, France|Groupe Hospitalo-Universitaire Pierre Caremau, Nimes Cedex 9, France|Hopital de la Source, Orleans, France|Hôpital Tenon, Paris Cedex 20, France|Hopital Pitie-Salpetriere, Paris, France|Centre Hospitalier Lyon-Sud, Pierre-Bénite, France|CHU de Rennes - Hôpital Pontchaillou, Rennes, France|CHU de ROUEN - Hôpital Charles Nicolle, Rouen Cedex, France|Hôpital Rangueil, Toulouse Cedex 9, France|Universitätsklinikum Bonn Klinik und Poliklinik für Urologie, Bonn, 53127, Germany|Kliniken Maria Hilf GmbH - Krankenhaus St. Franziskus, Monchengladbach, Germany|Universitätsklinikum Münster, Münster, 48149, Germany|Rambam Medical Center, Haifa, 31096, Israel|Carmel Medical Center, Haifa, 34362, Israel|Meir Medical Center, Kfar Saba, 44281, Israel|Rabin Medical Center - Davidoff Center, Petah Tikva, 49100, Israel|The Chaim Sheba Medical Center, Ramat Gan, 52621, Israel|Estetines Chirurgijos Centas, UAB, Kaunas, 49476, Lithuania|Vilnius University Hospital Santariskiu Klinikos, Vilnius, 8661, Lithuania|Centro Medico Puerta de Hierro - Colima, Colima, 28018, Mexico|Clinstile, S.A. de C.V., Cuauhtémoc, 06700, Mexico|Hospital Universitario ""Dr. José Eleuterio González"", Monterrey, 64460, Mexico|Consultorio Privado, Zapopan, 45040, Mexico|Clínica San Pablo Surco, Lima, 15023, Peru|Clinica Good Hope, Lima, Lima18, Peru|Clinica Internacional Sede Lima, Lima, Lima1, Peru|Clínica Anglo Americana, Lima, Lima27, Peru|Instituto de Ginecología y Reproducción, Lima, Lima33, Peru|Unidad de Investigación de la Clínica Internacional Sede San Borja, Lima, Lima41, Peru|Scientific research institute of urology and interventional radiology n. a. N. A. Lopatkin, Moscow, 105425, Russian Federation|Ministry of healthcare of the Russian Federation, Moscow, 129226, Russian Federation|Penza Regional Clinical Hospital n.a. N.N.Burdenko, Penza, 440026, Russian Federation|Rostov State Medical University, Rostov-on-Don, 344022, Russian Federation|St. Petersburg Research Institute of Phthisiopulmonology, Saint Petersburg, 194064, Russian Federation|Pavlov First Saint Petersburg State Medical University, Saint Petersburg, 197089, Russian Federation|City Hospital No. 40, Saint Petersburg, 197706, Russian Federation|Hospital Orkli, Saint Petersburg, Russian Federation|Complexo Hospitalario Universitario A Coruña, A Coruña, Spain|Fundacio Puigvert, Barcelona, 08025, Spain|Fundació GAEM, Barcelona, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital Universitari i Politècnic La Fe, Valencia, Spain|Municipal Healthcare Institution ""Regional Clinical Center of Urology and Nephrology n.a. V.I. Shapoval"", Urology Department, Kharkiv, 61037, Ukraine|Kiev City Clinical Hospital No. 3, Kiev, 02125, Ukraine|NHS Grampian - Aberdeen Royal Infirmary, Aberdeen, AB25 2ZN, United Kingdom|Bedford Hospital, Bedford, MK42 9DJ, United Kingdom|National Hospital for Neurology and Neurosurgery - UCL, London, WC1N 3BG, United Kingdom|Sheffield Teaching Hospitals NHS Foundation Trust - Royal Hallamshire Hospital, Sheffield, S10 2JF, United Kingdom|Royal National Orthopaedic Hospital Trust, Stanmore, HA7 4LP, United Kingdom|The Mid Yorkshire Hospitals NHS Trust - Pinderfields Hospital, Wakefield, WF1 4DG, United Kingdom"
NCT01719159,Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01719159,COMPLETED,Progressive Multiple Sclerosis,DRUG: Rituximab,Anders Svenningsson,"Västerbotten County Council, Sweden",ALL,"ADULT, OLDER_ADULT",PHASE2,23,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2009-11,2016-06,2016-06,"Department of neurology, Umeå University Hospital, Umeå, 901 85, Sweden|Dept of neurology, Uppsala University Hospital, Uppsala, SE-751 85, Sweden"
NCT04633759,Low Load Resistance Training Using Blood Flow Restriction for People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04633759,COMPLETED,Multiple Sclerosis,OTHER: Blood Flow Restriction Exercise,"University of Colorado, Denver",Consortium of Multiple Sclerosis Centers,ALL,"ADULT, OLDER_ADULT",NA,15,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-02-19,2022-10-05,2022-10-05,"University of Colorado, Aurora, Colorado, 80045, United States"
NCT02343159,Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients.,https://beta.clinicaltrials.gov/study/NCT02343159,TERMINATED,Multiple Sclerosis,DRUG: dimethyl fumarate|DEVICE: Medication Event Monitoring System (MEMS)|BEHAVIORAL: Adherence counseling,Biogen,,ALL,"ADULT, OLDER_ADULT",PHASE4,84,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2015-02-28,2016-04-15,2016-04-15,"Research Site, Homewood, Alabama, 35209, United States|Research Site, Pheonix, Arizona, 85018, United States|Research Site, Carlsbad, California, 92011, United States|Research Site, Los Angeles, California, 90095, United States|Research Site, Panorama City, California, 91402, United States|Research Site, Sacramento, California, 95816, United States|Research Site, Aurora, Colorado, 80045, United States|Research Site, Colorado Springs, Colorado, 80907, United States|Research Site, Fairfield, Connecticut, 06824, United States|Research Site, Gainesville, Florida, 32607, United States|Research Site, Ormond Beach, Florida, 32174, United States|Research Site, Tampa, Florida, 33612, United States|Research Site, Vero Beach, Florida, 32960, United States|Research Site, Merrillville, Indiana, 46410, United States|Research Site, Wichita, Kansas, 67214, United States|Research Site, Lexington, Kentucky, 40513, United States|Research Site, Auburn, Maine, 04210, United States|Research Site, Boston, Massachusetts, 02135, United States|Research Site, St. Louis, Missouri, 63141, United States|Research Site, Akron, Ohio, 44320, United States|Research Site, Columbus, Ohio, 43221, United States|Research Site, Sandusky, Ohio, 44870, United States|Research Site, Toledo, Ohio, 43623, United States|Research Site, Bend, Oregon, 97701, United States|Research Site, Portland, Oregon, 97225, United States|Research Site, Hodges, South Carolina, 29653-9181, United States|Research Site, Mt. Pleasant, South Carolina, 29464, United States|Research Site, Round Rock, Texas, 78681, United States|Research Site, Winchester, Virginia, 22601, United States"
NCT01910259,MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial,https://beta.clinicaltrials.gov/study/NCT01910259,COMPLETED,Secondary Progressive Multiple Sclerosis,DRUG: Amiloride|DRUG: Riluzole|DRUG: Fluoxetine|DRUG: Placebo,"University College, London","Medical Research Council|National Institute for Health Research, United Kingdom|National Multiple Sclerosis Society|University of Edinburgh|Queen Mary University of London|Keele University|University of Sheffield|University of Leeds|University of Warwick",ALL,"ADULT, OLDER_ADULT",PHASE2,445,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-12-18,2018-06-14,2018-07-04,"Anne Rowling Regenerative Neurology Clinic, Royal Infirmary of Edinburgh, Edinburgh, EH16 4SA, United Kingdom|Gartnavel Royal Hospital, 1055 Great Western Road, Glasgow, G12 OXH, United Kingdom|Brighton and Sussex University Hospitals, Haywards Heath, RH16 4EX, United Kingdom|St James's University Hospital, Leeds, LS9 7TF, United Kingdom|The Walton Centre, Liverpool, L9 7LJ, United Kingdom|The National hospital for Neurology and Neurosurgery, University College London, London, WC1N 3BG, United Kingdom|The Royal Victoria Infirmary, Newcastle, NE1 4LP, United Kingdom|Queens Medical Centre, Nottingham, NG7 2UH, United Kingdom|John Radcliffe Hospital, Oxford University Hospitals NHS Trust, Oxford, OX3 9DU, United Kingdom|Derriford Hospital, Plymouth, PL6 8DH, United Kingdom|Royal Hallamshire Hospital, Sheffield, S10 2JF, United Kingdom|University Hospital of North Staffordshire, Stoke-on-Trent, ST4 7LN, United Kingdom|Royal Cornwall Hospital, Truro, TR1 3LJ, United Kingdom"
NCT00146159,Study Evaluating Mitoxantrone in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00146159,TERMINATED,Secondary Progressive Multiple Sclerosis,DRUG: Mitoxantrone,Wyeth is now a wholly owned subsidiary of Pfizer,,ALL,ADULT,PHASE3,336,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2005-03,2007-09,,"Berg, D-82335, Germany|Berlin, D-13347, Germany|Düsseldorf, D-40225, Germany|Düsseldorf, D-40479, Germany|Gießen, D-35385, Germany|Marburg, D-35039, Germany|Wiesbaden, D-65191, Germany"
NCT03269175,BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies,https://beta.clinicaltrials.gov/study/NCT03269175,COMPLETED,Multiple Sclerosis,OTHER: Brain MRI|OTHER: Blood sampling,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE4,261,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2017-09-29,2018-05-24,2018-05-24,"Medizinische Universität Graz, Graz, Steiermark, 8036, Austria|Landeskrankenhaus - Universitätskliniken Innsbruck, Innsbruck, 6020, Austria|CU Saint-Luc/UZ St-Luc, Bruxelles - Brussel, 1200, Belgium|UZ Gent, Gent, 9000, Belgium|UZ Leuven Gasthuisberg, Leuven, 3000, Belgium|CHU de Liège, Liege, 4000, Belgium|Ottawa Hospital-General Campus, Ottawa, Ontario, K1H 8L6, Canada|CHUM - Hopital Hotel-Dieu, Montreal, Quebec, H2X 0A9, Canada|Montreal Neurological Hospital, Montreal, Quebec, H3A 2B4, Canada|Fakultni nemocnice Brno, Brno, 625 00, Czechia|Fakultni Nemocnice Hradec Kralove, Hradec Kralove, 500 05, Czechia|Fakultni nemocnice Ostrava, Ostrava-Poruba, 708 52, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, 121 11, Czechia|Amtssygehuset Glostrup, Glostrup, DK-2600, Denmark|Tampereen yliopistollinen sairaala, keskussairaala, Tampere, 33521, Finland|Terveystalo Turku, Turku, 20100, Finland|Hôpital Pellegrin - Bordeaux, Bordeaux, 33000, France|Hopital general, Dijon, 21033, France|Hopital Roger Salengro, Lille, 59037, France|Hôpital Pasteur - Nice, Nice, 06200, France|Hôpital Pontchaillou, Rennes Cedex, 35033, France|Klinikum der Universität München Grosshadern, München, Bayern, 81377, Germany|Bezirksklinikum, Regensburg, Bayern, 93053, Germany|Krankenhaus Hennigsdorf, Hennigsdorf, Brandenburg, 16761, Germany|Universitätsklinik Gießen und Marburg GmbH, Marburg, Hessen, 35043, Germany|Sana Klinikum Offenbach GmbH, Offenbach, Hessen, 63069, Germany|Universitätsmedizin der Georg-August-Universität Göttingen, Goettingen, Niedersachsen, 37075, Germany|Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Nordrhein-Westfalen, 40225, Germany|Städt. Krankenhaus Martha-Maria Halle-Dölau gGmbH, Halle, Sachsen-Anhalt, 06120, Germany|HELIOS Klinikum Erfurt GmbH, Erfurt, Thüringen, 99089, Germany|Universitätsklinikum Charite zu Berlin, Berlin, 10117, Germany|Peterfy Sandor utcai Korhaz - Rendelointezet, Budapest, 1076, Hungary|Uzsoki Utcai Korhaz, Budapest, 1145, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, 4012, Hungary|Szent-Gyorgyi Albert Orvostudomanyi Egyetem, Szeged, 6720, Hungary|Hadassah Hebrew University Hospital Ein Kerem, Jerusalem, Israel|Ospedale San Raffaele, Milano, Lombardia, 20132, Italy|IRCCS Ist Neurologico Nazionale C.Mondino, Pavia, Lombardia, 27100, Italy|ASST Valle Olona, Varese, Lombardia, 21013, Italy|A.O.U. San Luigi Gonzaga, Torino, Piemonte, 10043, Italy|A.O.U. Città della Salute e della Scienza di Torino, Torino, Toscana, 10126, Italy|Helse Bergen HF Haukeland universitetssjukehus, Bergen, 5021, Norway|10 Wojskowy Szpital Kliniczny z Poliklinika SPZOZ, Bydgoszcz, 85-681, Poland|Szpital Uniwersytecki w Krakowie, Krakow, 30-503, Poland|Szpital im. N. Barlickiego, Lodz, 90-153, Poland|Samodzielny Publiczny Szpital Kliniczny nr 4, Lublin, 20-090, Poland|Uniwersytecki Szpital Kliniczny im. J. Mikulicza-Radeckiego, Wroclaw, 50-556, Poland|Instituto Português de Oncologia Francisco Gentil - Coimbra, Coimbra, 3000-075, Portugal|Hospital Universitario Virgen de la Macarena, Sevilla, Andalucía, 41071, Spain|Ciutat Sanitària i Universitària de Bellvitge, L'Hospitalet de Llobregat, Barcelona, 08907, Spain|Ciutat Sanitària i Universitaria de la Vall d'Hebron, Barcelona, 08035, Spain|Hospital Clínic i Provincial de Barcelona, Barcelona, 08036, Spain|Hospital Regional de Málaga, Malaga, 29010, Spain|Hospital Universitari i Politècnic La Fe, Valencia, 46026, Spain|Sahlgrenska Universitetssjukhuset, Göteborg, 413 45, Sweden|Universitätsspital Basel, Basel, Basel-Stadt, 4031, Switzerland|Inselspital Universitätsspital Bern, Bern, 3010, Switzerland|Royal Hallamshire Hospital, Sheffield, South Yorkshire, S10 2JF, United Kingdom|Aberdeen Royal Infirmary, Aberdeen, AB25 2ZN, United Kingdom|Ninewells Hospital, Dundee, DD1 9SY, United Kingdom|Charing Cross Hospital, London, United Kingdom"
NCT04120675,Efficacy of Early Harvest Olive Oil in Cognition of Primary (PPMS) or Secondary (SPMS) Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04120675,COMPLETED,Progressive Multiple Sclerosis,DIETARY_SUPPLEMENT: Early Harvest Extra Virgin Olive Oil,Aristotle University Of Thessaloniki,"Greek Alzheimer's Association and Related Disorders|Ellis-Farm, Eliama Daily Value Gold (ellis-farm.com)",ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2018-11-09,2021-06-01,2021-06-06,"A' Department of Neurology,Aristotle University of Thessaloniki (AUTH), Thessaloniki, Macedonia, 546 36, Greece"
NCT03658668,Combined Effect of Transcranial Direct Current Stimulation (tDCS) and Physical Activity on Gait and Functional Mobility in Participants With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03658668,RECRUITING,Multiple Sclerosis,DEVICE: active tDCS|DEVICE: sham tDCS|OTHER: Physical Activity (PA),NYU Langone Health,,ALL,"ADULT, OLDER_ADULT",NA,80,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2018-10-03,2023-06-01,2023-06-01,"New York University School of Medicine, New York, New York, 10016, United States"
NCT00702468,Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00702468,COMPLETED,Spasticity|Multiple Sclerosis,DRUG: Sativex|DRUG: Placebo,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,36,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2007-11,2009-01,2009-01,"James Paget University Hospital NHS Foundation Trust, Gorleston on Sea, Norfolk, NR31 6LA, United Kingdom"
NCT05633459,A Study Evaluating the Safety and Tolerability of QRL-201 in ALS,https://beta.clinicaltrials.gov/study/NCT05633459,RECRUITING,Amyotrophic Lateral Sclerosis,DRUG: QRL-201 - Dose 1|DRUG: QRL-201 - Dose 2|DRUG: QRL-201 - Dose 3|DRUG: QRL-201 - Dose 4|DRUG: QRL-201 - Dose 5|DRUG: QRL-201 - Dose 6|DRUG: QRL-201 - Dose 7|DRUG: QRL-201- Dose 8,QurAlis Corporation,,ALL,"ADULT, OLDER_ADULT",PHASE1,64,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-12-16,2025-05-06,2025-05-06,"University of Calgary, Calgary, Alberta, T2N 1N4, Canada|CHUM - Hopital Notre-Dame, Montréal, Quebec, H2L 4M1, Canada|Montreal Neurological Institute-Hospital, Montréal, Quebec, H3A 2B4, Canada"
NCT03670459,Forty Five Patients With Multiple Sclerosis Recieved Vestibular Rehabilitation and Balance Training,https://beta.clinicaltrials.gov/study/NCT03670459,COMPLETED,Neurologic Disorder,OTHER: Cawthorne Cooksey exercises|OTHER: Vestibular habituation exercises|OTHER: Balance exercises,October 6 University,,ALL,ADULT,NA,45,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,2017-12-31,2018-07-21,2018-09-04,"October 6 University, Giza, 12511, Egypt"
NCT00927108,Rajavtihi Neuronal Adult Stem Cells Project,https://beta.clinicaltrials.gov/study/NCT00927108,WITHDRAWN,Alzheimer's Disease|Parkinson's Disease|Multiple Sclerosis,OTHER: Progenitor Stem Cell Culture,Rajavithi Hospital,Rajavithi Biomolecular Research Center,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER_GOV,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2009-07,2011-12,2011-12,"Rajavithi Hospital, Bangkok, 10140, Thailand"
NCT05819008,Remote Neuropsychological Assessment of Patients With Neurological Disorders and Injuries,https://beta.clinicaltrials.gov/study/NCT05819008,RECRUITING,Traumatic Brain Injury|Stroke|Multiple Sclerosis|Parkinson Disease|Epilepsy|Brain Tumor,DIAGNOSTIC_TEST: Neuropsychological Assessment,Umeå University,"Västerbotten County Council, Sweden",ALL,"ADULT, OLDER_ADULT",,350,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-03-10,2025-12-31,2025-12-31,"Umeå University Hospital, Umeå, 90185, Sweden"
NCT04662008,Offering Support and Electronic Resources for Care Partners of Those With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04662008,COMPLETED,Multiple Sclerosis|Caregivers,BEHAVIORAL: Tele-coaching|BEHAVIORAL: Website,Case Western Reserve University,,ALL,"ADULT, OLDER_ADULT",NA,151,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-03-10,2022-03-07,2022-03-07,"Case Western Reserve University, Cleveland, Ohio, 44124, United States"
NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),https://beta.clinicaltrials.gov/study/NCT00813709,COMPLETED,Multiple Sclerosis|Clinically Isolated Syndrome,DRUG: RNF|DRUG: RNF|DRUG: RNF|DRUG: Placebo,"Merck KGaA, Darmstadt, Germany",,ALL,"ADULT, OLDER_ADULT",PHASE3,402,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2008-12,2011-08,2013-09,"Research Site, Mendoza, Argentina|Research Site, Graz, Austria|Research Site, Brugge, Belgium|Research Site, Leuven, Belgium|Research Site, Pleven, Bulgaria|Research Site, Rousse, Bulgaria|Research Site, Shumen, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Ontario, Canada|Research Site, Victoria British Columbia, Canada|Research Site, Karlovac, Croatia|Research Site, Osijek, Croatia|Research Site, Rijeka, Croatia|Research Site, Split, Croatia|Research Site, Zagreb, Croatia|Research Site, Hradec Kralove, Czech Republic|Research Site, Olomouc, Czech Republic|Research Site, Prague, Czech Republic|Research Site, Tallinn, Estonia|Research Site, Tartu, Estonia|Research Site, Oulu, Finland|Research Site, Paris, France|Research Site, Poissy Cedex, France|Research Site, Hannover, Germany|Research Site, Henningsforf, Germany|Research Site, Athens, Greece|Research Site, Safed, Israel|Research Site, Tel-Hashomer, Israel|Research Site, Milano, Italy|Research Site, Padova, Italy|Research Site, Riga, Latvia|Research Site, Beirut, Lebanon|Research Site, Rabat, Morocco|Research Site, Bialystok, Poland|Research Site, Lodz, Poland|Research Site, Warsaw, Poland|Research Site, Wroclaw, Poland|Research Site, Lisbon, Portugal|Research Site, Bucharest, Romania|Research Site, Iasi, Romania|Research Site, Targu-Mures, Romania|Research Site, Timisoara, Romania|Research Site, Ekaterinburg, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Samara, Russian Federation|Research Site, Saratov, Russian Federation|Reserch Site, Belgrade, Serbia|Research Site, Nis, Serbia|Research Site, Presov, Slovakia|Research Site, Barcelona, Spain|Research Site, Bilbao, Spain|Research Site, Madrid, Spain|Research Site, Seville, Spain"
NCT01171209,REsPonse to Interferon-Alpha in InterfeRon-β Neutralizing Antibody Positive Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT01171209,COMPLETED,Multiple Sclerosis,DRUG: Interferon-beta and human leukocyte Interferon-α,Melinda Magyari,University of Copenhagen,ALL,ADULT,PHASE2,10,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2010-07,2011-06,2011-08,
NCT01500408,Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers,https://beta.clinicaltrials.gov/study/NCT01500408,COMPLETED,Multiple Sclerosis,"DRUG: Interferon beta-1a (current approved manufacturing process invloving FBS)|DRUG: Interferon beta-1a (new process, manufactured without FBS)",Biogen,,ALL,ADULT,PHASE1,110,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: ",2012-01,2012-04,2012-04,"Research Site, St. Paul, Minnesota, United States"
NCT02201108,"Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT02201108,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,DRUG: Teriflunomide|DRUG: Placebo,"Genzyme, a Sanofi Company",,ALL,CHILD,PHASE3,166,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-07-16,2019-10-25,2025-06-25,"Investigational Site Number :840003, Cullman, Alabama, 35058, United States|Investigational Site Number :840012, Tampa, Florida, 33609-4052, United States|Investigational Site Number :840002, Boston, Massachusetts, 02114, United States|Investigational Site Number :840004, Raleigh, North Carolina, 27607, United States|Investigational Site Number :056002, Gent, 9000, Belgium|Investigational Site Number :056001, Leuven, 3000, Belgium|Investigational Site Number :100001, Sofia, 1113, Bulgaria|Investigational Site Number :124001, Calgary, Alberta, T3B 6A8, Canada|Investigational Site Number :156001, Beijing, 100034, China|Investigational Site Number :156002, Beijing, 100045, China|Investigational Site Number :156010, Beijing, 100730, China|Investigational Site Number :156006, Changchun, 130021, China|Investigational Site Number :156007, Changsha, 410011, China|Investigational Site Number :156008, Chengdu, 610041, China|Investigational Site Number :156005, Chongqing, 400014, China|Investigational Site Number :156012, Guangzhou, 510630, China|Investigational Site Number :156003, Shanghai, 200092, China|Investigational Site Number :156004, Shanghai, 201102, China|Investigational Site Number :156011, Shijiazhuang, 050000, China|Investigational Site Number :156009, Taiyuan, 030001, China|Investigational Site Number :233001, Tallinn, 10617, Estonia|Investigational Site Number :250001, Le Kremlin Bicetre, 94270, France|Investigational Site Number :250002, Lyon Cedex 03, 69394, France|Investigational Site Number :250003, Rennes Cedex, 35033, France|Investigational Site Number :250005, Toulouse, 31059, France|Investigational Site Number :300002, Athens, 115 27, Greece|Investigational Site Number :300001, Thessaloniki, 54642, Greece|Investigational Site Number :376001, Jerusalem, 91120, Israel|Investigational Site Number :376003, Tel HaShomer, 52621, Israel|Investigational Site Number :422001, Beirut, Lebanon|Investigational Site Number :440001, Kaunas, 50161, Lithuania|Investigational Site Number :504004, FES, Morocco|Investigational Site Number :504005, Marrakech, 40000, Morocco|Investigational Site Number :528001, Rotterdam, 3015 CN, Netherlands|Investigational Site Number :620001, Coimbra, 3000-075, Portugal|Investigational Site Number :643001, Moscow, 127566, Russian Federation|Investigational Site Number :643003, Nizhny Novgorod, 603155, Russian Federation|Investigational Site Number :643004, Novosibirsk, 630087, Russian Federation|Investigational Site Number :643005, Saint-Petersburg, 197022, Russian Federation|Investigational Site Number :643002, Saint-Petersburg, 197110, Russian Federation|Investigational Site Number :688002, Belgrade, 11000, Serbia|Investigational Site Number :724002, Murcia, 30120, Spain|Investigational Site Number :788001, La Manouba, 2020, Tunisia|Investigational Site Number :788002, Sfax, 3029, Tunisia|Investigational Site Number :788004, Sfax, 3029, Tunisia|Investigational Site Number :792002, Ankara, 06100, Turkey|Investigational Site Number :792001, Ankara, 06500, Turkey|Investigational Site Number :792006, Istanbul, 34390, Turkey|Investigational Site Number :792003, Istanbul, 34688, Turkey|Investigational Site Number :792008, Izmir, 35210, Turkey|Investigational Site Number :792007, İzmir, Turkey|Investigational Site Number :804001, Kharkiv, 61068, Ukraine|Investigational Site Number :804002, Kharkiv, 61068, Ukraine|Investigational Site Number :826001, London, London, City Of, SE1 7EH, United Kingdom|Investigational Site Number :826003, Birmingham, B4 6NH, United Kingdom"
NCT02137109,Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri,https://beta.clinicaltrials.gov/study/NCT02137109,COMPLETED,Multiple Sclerosis,DRUG: natalizumab,Biogen,,ALL,"CHILD, ADULT",,400,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-03,2015-10,2015-10,
NCT00917839,The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00917839,UNKNOWN,Relapsing-Remitting Multiple Sclerosis,DRUG: lamotrigine,Cantonal Hospital of St. Gallen,,ALL,ADULT,PHASE2,88,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-06,2010-12,2011-12,"Cantonal Hospital St. Gallen, St. Gallen, 9007, Switzerland"
NCT03268239,Contrast-enhanced 3D T1-weighted Gradient-echo Versus Spin-echo 3 Tesla MR Sequences in the Detection of Active Multiple Sclerosis Lesions,https://beta.clinicaltrials.gov/study/NCT03268239,COMPLETED,Magnetic Resonance Imaging|Central Nervous System|Brain|Multiple Sclerosis|Demyelinating Diseases,DEVICE: Additional MRI sequences,Fondation Ophtalmologique Adolphe de Rothschild,,ALL,"ADULT, OLDER_ADULT",NA,180,NETWORK,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2017-08-02,2021-04-26,2021-04-26,"Fondation Ophtalmologique A. de Rothschild, Paris, 75019, France"
NCT00648908,"Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial",https://beta.clinicaltrials.gov/study/NCT00648908,COMPLETED,Multiple Sclerosis,DRUG: Fampridine-SR,Acorda Therapeutics,,ALL,"ADULT, OLDER_ADULT",PHASE3,269,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2006-06,2011-01,2011-04,"Barrow Neurology Clinic, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, 85013, United States|USC, Keck School of Medicine Health Care Consultation Center, Los Angeles, California, 90033, United States|UC Davis, Sacramento, California, 95817, United States|Shepherd Center, Atlanta, Georgia, 30309, United States|University of Chicago, Chicago, Illinois, 60637, United States|Indiana University MS Center, Indianapolis, Indiana, 46202, United States|Maryland Center for MS, Baltimore, Maryland, 21201, United States|Wayne State University, Department of Neurology, Detroit, Michigan, 48201, United States|The Schapiro Center for MS, Golden Valley, Minnesota, 55422, United States|Washington University School of Medicine, Div. of Rehab/Neurology, St. Louis, Missouri, 63110, United States|Advanced Neurology Specialists, Great Falls, Montana, 59405, United States|Gimbel MS Center at Holy Name Hospital, Teaneck, New Jersey, 07666, United States|Maimonides MS Care Center, Brooklyn, New York, 11219, United States|Corinne Goldsmith Dickinson Center for MS, New York, New York, 10029, United States|University of Rochester, Rochester, New York, 14642, United States|SUNY Stony Brook, Stony Brook, New York, 11794, United States|CMC - Neuroscience & Spine Institute, Division of Neurology, Charlotte, North Carolina, 28207, United States|Raleigh Neurology Associates, Raleigh, North Carolina, 27607, United States|Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States|Ohio State University MS Center, Columbus, Ohio, 43221, United States|Oregon Health & Science University, MS Center of Oregon, UHS-42, Portland, Oregon, 97239, United States|Thomas Jefferson University Physicians, Philadelphia, Pennsylvania, 19107, United States|Allegheny General Hospital, Allegheny Neurological Associates, Pittsburgh, Pennsylvania, 15212, United States|University of Texas-Houston, Houston, Texas, 77030, United States|Neurological Research Center, Inc., Bennington, Vermont, 05201, United States|Fletcher Allen Health Care, Burlington, Vermont, 05401, United States|MS Center at Evergreen, Kirkland, Washington, 98034, United States|Foothills Medical Center, Calgary, Alberta, T2N 2T9, Canada|University of British Columbia, Vancouver Coastal Health Research Institute, Vancouver, British Columbia, V6T 2B5, Canada|River Valley Health c/o Stan Cassidy Centre for Rehabilitation, Fredericton, New Brunswick, E3B 0C7, Canada|QEII Health Sciences Centre, Nova Scotia Rehabilitation Centre Site, Halifax, Nova Scotia, B3H 4K4, Canada|Ottawa Hospital General Campus, Ottawa, Ontario, K1H 8L6, Canada"
NCT01092208,Studies of Autistic Patients: Gene Networks and Clinical Subtypes,https://beta.clinicaltrials.gov/study/NCT01092208,TERMINATED,Autism|Tuberous Sclerosis,,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),,MALE,"CHILD, ADULT",,11,NIH,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-03-17,,2013-09-24,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States"
NCT05090709,MS Spinal Mobilisation Study,https://beta.clinicaltrials.gov/study/NCT05090709,COMPLETED,Multiple Sclerosis,OTHER: Spinal Mobilisation Intervention|OTHER: General Massage,Edinburgh Napier University,Scottish Hospital Endowments Research Trust|Pacla Medical Ltd,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,2018-10-01,2019-04-01,2019-04-01,"Edinburgh Napier University, Edinburgh, County, EH11 4BN, United Kingdom"
NCT04818008,The Use of Arabic Otago Exercise Program in People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04818008,RECRUITING,Multiple Sclerosis,OTHER: Otago Exercise Program,University of Jordan,,ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-04-01,2022-12,2022-12,"University of Jordan, Amman, 11942, Jordan|University of Jordan, Amman, 11942, Jordan"
NCT04486209,Non-invasive Spinal Cord Stimulation for Spasticity Control and Augmentation of Voluntary Motor Control in Individuals With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04486209,COMPLETED,Multiple Sclerosis,DEVICE: transcutaneous spinal cord stimulation,Medical University of Vienna,"Neurological Center, Otto Wagner Hospital",ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,15,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2017-12-27,2020-07-02,2020-07-02,"Medical University of Vienna, Vienna, 1090, Austria"
NCT05627609,Sunlight-mediated Inter-organ Leukocyte Exchange,https://beta.clinicaltrials.gov/study/NCT05627609,COMPLETED,Multiple Sclerosis,DEVICE: 311 nm narrowband UVB irradiation,University Hospital Muenster,,ALL,ADULT,NA,18,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2022-11-21,2023-04-14,2023-04-14,"University Hospital Muenster, Muenster, NRW, 48149, Germany"
NCT05815108,Epstein Barr Virus Infection in Patients With Radiologically Isolated Syndrome,https://beta.clinicaltrials.gov/study/NCT05815108,RECRUITING,Multiple Sclerosis|Radiologically Isolated Syndrome|Epstein-Barr Virus,OTHER: NO INTERVENTION,Centre Hospitalier Universitaire de Nice,,ALL,"CHILD, ADULT, OLDER_ADULT",,160,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-03-15,2023-04-15,2023-04-15,"Nice University Hospital, Nice, 06000, France"
NCT03339908,Regional Non-comparative Prospective Study of the Impact of Gamma Knife Radiosurgery on Tremor in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03339908,COMPLETED,Multiple Sclerosis,DEVICE: Thalamotomy by gamma Knife radiosurgery,Assistance Publique Hopitaux De Marseille,,ALL,"ADULT, OLDER_ADULT",NA,7,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2017-10-23,2021-01-20,2023-04-04,"Assistance Publique Hôpitaux de Marseille, Marseille, 13354, France"
NCT02767609,Measuring Cerebral Blood Flow Using Pseudo-continuous Arterial Spin Labeling Perfusion Magnetic Resonance Imaging,https://beta.clinicaltrials.gov/study/NCT02767609,COMPLETED,Traumatic Brain Injury|Multiple Sclerosis|Alzheimer's Disease|Tumor,DEVICE: Magnetic Resonance Imaging,Loma Linda University,,ALL,"ADULT, OLDER_ADULT",NA,1,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2014-05,2017-03-03,2017-03-03,
NCT04635709,Effect of Behavioral Therapy Versus Interferential Current on Bladder Dysfunction in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04635709,COMPLETED,Bladder Dysfunction on Patients With Multiple Sclerosis,DEVICE: biofeedback training and interferential therapy,Taibah University,,MALE,ADULT,PHASE1,50,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2019-02-15,2020-04-01,2020-04-01,"Taibah University, Medina, 42353, Saudi Arabia"
NCT00958009,"The Multicenter, Open-label, Single-use Autoinjector Convenience Study",https://beta.clinicaltrials.gov/study/NCT00958009,COMPLETED,Multiple Sclerosis,DEVICE: Rebidose®,EMD Serono,,ALL,"ADULT, OLDER_ADULT",PHASE3,109,INDUSTRY,INTERVENTIONAL,"Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: ",2009-10,2010-04,2010-06,"EMD Serono, Inc., Rockland, Massachusetts, 02370, United States"
NCT04621708,Pilot Study of the Safety and Tolerability of L-DLPFC iTBS rTMS for MDD in MS,https://beta.clinicaltrials.gov/study/NCT04621708,RECRUITING,Multiple Sclerosis|Major Depressive Disorder,DEVICE: Repetitive transcranial magnetic stimulation,Sunnybrook Health Sciences Centre,,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-04-30,2024-04-30,2024-04-30,"Sunnybrook Health Sciences Centre, Toronto, Ontario, M4N 3M5, Canada"
NCT05712408,"Examining the Impact of an Online, Non-restrictive Diet Among Persons With Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT05712408,RECRUITING,Multiple Sclerosis,BEHAVIORAL: 800g Challenge,"University of North Texas, Denton, TX",,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,15,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2023-01-01,2023-05-01,2023-05-01,"University of North Texas, Denton, Texas, 76203, United States"
NCT05029609,Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS,https://beta.clinicaltrials.gov/study/NCT05029609,WITHDRAWN,Primary Progressive Multiple Sclerosis|Secondary Progressive Multiple Sclerosis|Multiple Sclerosis,DRUG: Intranasal Foralumab Solution|DRUG: Placebo,Tiziana Life Sciences LTD,,ALL,"ADULT, OLDER_ADULT",PHASE1,0,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-10,2022-11,2022-12,
NCT01233245,BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program,https://beta.clinicaltrials.gov/study/NCT01233245,COMPLETED,Relapsing Remitting MS (RRMS)|Secondary Progressive MS (SPMS),"DRUG: Interferon beta-1b (Betaseron, BAY86-5046)",Bayer,,ALL,"ADULT, OLDER_ADULT",,1077,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2004-04,2009-06,2009-06,"Many Locations, Czech Republic|Many Locations, France|Many Locations, Germany|Many Locations, Iran, Islamic Republic of|Many Locations, Israel|Many Locations, Italy|Many Locations, Jordan|Many Locations, Korea, Republic of|Many Locations, Lebanon|Many Locations, Netherlands|Many Locations, Portugal|Many Locations, Saudi Arabia|Many Locations, Spain|Many Locations, Taiwan|Many Locations, Turkey"
NCT03816345,"Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer",https://beta.clinicaltrials.gov/study/NCT03816345,RECRUITING,Advanced Malignant Solid Neoplasm|Autoimmune Disease|Crohn Disease|Dermatomyositis|Hematopoietic and Lymphoid Cell Neoplasm|Inflammatory Bowel Disease|Metastatic Malignant Solid Neoplasm|Multiple Sclerosis|Psoriasis|Psoriatic Arthritis|Rheumatoid Arthritis|Sjogren Syndrome|Systemic Lupus Erythematosus|Systemic Scleroderma|Ulcerative Colitis|Unresectable Malignant Solid Neoplasm,PROCEDURE: Biospecimen Collection|BIOLOGICAL: Nivolumab,National Cancer Institute (NCI),,ALL,"ADULT, OLDER_ADULT",PHASE1,300,NIH,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2019-04-04,2023-08-31,2023-08-31,"University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, 35233, United States|Stanford Cancer Institute Palo Alto, Palo Alto, California, 94304, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, 95817, United States|Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, 06510, United States|Yale University, New Haven, Connecticut, 06520, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, 30322, United States|Northwestern University, Chicago, Illinois, 60611, United States|University of Kansas Clinical Research Center, Fairway, Kansas, 66205, United States|HaysMed University of Kansas Health System, Hays, Kansas, 67601, United States|University of Kansas Cancer Center, Kansas City, Kansas, 66160, United States|Lawrence Memorial Hospital, Lawrence, Kansas, 66044, United States|Olathe Health Cancer Center, Olathe, Kansas, 66061, United States|University of Kansas Cancer Center-Overland Park, Overland Park, Kansas, 66210, United States|University of Kansas Hospital-Indian Creek Campus, Overland Park, Kansas, 66211, United States|Ascension Via Christi - Pittsburg, Pittsburg, Kansas, 66762, United States|Salina Regional Health Center, Salina, Kansas, 67401, United States|University of Kansas Health System Saint Francis Campus, Topeka, Kansas, 66606, United States|University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, 66205, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, 21287, United States|National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, 20892, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, 02114, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, 48201, United States|Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, 63141, United States|Truman Medical Centers, Kansas City, Missouri, 64108, United States|University of Kansas Cancer Center - North, Kansas City, Missouri, 64154, United States|University of Kansas Cancer Center - Lee's Summit, Lee's Summit, Missouri, 64064, United States|University of Kansas Cancer Center at North Kansas City Hospital, North Kansas City, Missouri, 64116, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|Siteman Cancer Center-South County, Saint Louis, Missouri, 63129, United States|Siteman Cancer Center at Christian Hospital, Saint Louis, Missouri, 63136, United States|Siteman Cancer Center at Saint Peters Hospital, Saint Peters, Missouri, 63376, United States|NYU Winthrop Hospital, Mineola, New York, 11501, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, 10016, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, 10032, United States|NYP/Weill Cornell Medical Center, New York, New York, 10065, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, 43210, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, 19107, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, 15232, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, 75390, United States|UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth, Texas, 76104, United States|M D Anderson Cancer Center, Houston, Texas, 77030, United States|UT Southwestern Clinical Center at Richardson/Plano, Richardson, Texas, 75080, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, 84112, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, 23298, United States|University Health Network-Princess Margaret Hospital, Toronto, Ontario, M5G 2M9, Canada"
NCT00418145,Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis Attacks,https://beta.clinicaltrials.gov/study/NCT00418145,TERMINATED,Multiple Sclerosis,DRUG: megadose oral methylprednisolone|DRUG: IV methylprednisolone,Fred Lublin,National Multiple Sclerosis Society|Pfizer,ALL,ADULT,PHASE3,16,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2003-09,2013-10,2013-10,"University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey, 08901, United States|Maimonides Medical Center, Brooklyn, New York, 11219, United States|The Jacobs Neurological Institute, Buffalo, New York, 14203, United States|Hospital For Joint Diseases, New York, New York, 10003, United States|St. Luke's Roosevelt, New York, New York, 10019, United States|Icahn School of Medicine at Mount Sinai, New York, New York, 10029, United States|Columbia University Medical Center, New York, New York, 10032, United States|NY Presbyterian Hospital-Cornell University New York, New York, New York, 10065, United States|University of Rochester, Rochester, New York, 14627, United States|University of Vermont, Burlington, Burlington, Vermont, 05405, United States"
NCT02521545,Single-Dose Study of a New Formulation of BIIB061,https://beta.clinicaltrials.gov/study/NCT02521545,COMPLETED,Multiple Sclerosis,DRUG: BIIB061,Biogen,,ALL,ADULT,PHASE1,8,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-07,2015-08,2015-08,"Research Site, Madison, Wisconsin, 53704, United States"
NCT01428726,A Phase IIa Study of NT-KO-003 for Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01428726,COMPLETED,Relapsing Remitting Multiple Sclerosis,DRUG: NT-KO-003,Neurotec Pharma,"Advancell - Advanced In Vitro Cell Technologies, S.A.",ALL,ADULT,PHASE2,99,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-06,2014-01,2014-01,"Charité Universitätsmedizin, Berlin, Germany|Klinik und Poliklinik für Neurologie, Münster, Germany|Neurologisches Studienzentrum an der Stiftung Deutsche Klinik für Diagnostik GmbH, Wiesbaden, Germany|Hospital Germans Trias i Pujol, Badalona, Spain|Hospital Clinic i Provincial, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Vall d'Hebrón, Barcelona, Spain|Hospital Universitari Josep Trueta, Girona, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital Universitario Puerta del Hierro, Madrid, Spain|Hospital Regional Universitario Carlos Haya, Málaga, Spain|Complexo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain|Hospital Universitario La Fe, Valencia, Spain|Hospital Xeral Vigo, Vigo, Spain"
NCT00483652,Study of Fampridine-SR Tablets in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT00483652,COMPLETED,Multiple Sclerosis,DRUG: Fampridine-SR|DRUG: Placebo,Acorda Therapeutics,,ALL,"ADULT, OLDER_ADULT",PHASE3,240,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2007-05,2008-02,2008-05,"Barrow Neurology Clinic, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, 85013, United States|HOPE Research Institute, Phoenix, Arizona, 85050, United States|Neurological Associates, Fayetteville, Arkansas, 72703, United States|Alta Bates Summit Medical Center - Research and Education Institute, Berkeley, California, 94705, United States|USC, Keck School of Medicine Health Care Consultation Center, Los Angeles, California, 90033, United States|UC Davis, Sacramento, California, 95817, United States|Yale University MS Center, New Haven, Connecticut, 06510, United States|Shepherd Center, Atlanta, Georgia, 30309, United States|Consultants in Neurology, Ltd., Northbrook, Illinois, 60062, United States|Indiana University MS Center, Indianapolis, Indiana, 46202, United States|Associates in Neurology, PSC, Lexington, Kentucky, 40503, United States|Maryland Center for MS, Baltimore, Maryland, 21201, United States|Lahey Clinic, Lexington, Massachusetts, 02421, United States|The Schapiro Center for MS, Golden Valley, Minnesota, 55422, United States|Washington University School of Medicine, St. Louis, Missouri, 63110, United States|Advanced Neurology Specialists, Great Falls, Montana, 59405, United States|UMDNJ, Newark, New Jersey, 07103, United States|Gimbel MS Center at Holy Name Hospital, Teaneck, New Jersey, 07666, United States|Jacobs Neurological Institute Buffalo General Hospital, Buffalo, New York, 14203, United States|Corinne Goldsmith Dickinson Center for MS, New York, New York, 10029, United States|Columbia University Multiple Sclerosis Clinical Care Center, New York, New York, 10032, United States|University of Rochester, Rochester, New York, 14642, United States|SUNY Stony Brook, Stony Brook, New York, 11794, United States|CMC - Neuroscience & Spine Institute, Division of Neurology, Charlotte, North Carolina, 28207, United States|Raleigh Neurology Associates, Raleigh, North Carolina, 27607, United States|Wake Forest University, Dept of Neurology, M.S. Research, Winston-Salem, North Carolina, 27157, United States|The Center for Neurological Services, Bismarck, North Dakota, 58501, United States|Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States|Ohio State University MS Center, Columbus, Ohio, 43221, United States|Oregon Health & Science University, MS Center of Oregon, UHS-42, Portland, Oregon, 97239, United States|Thomas Jefferson University Physicians, Philadelphia, Pennsylvania, 19107, United States|Neurological Research Center, Inc., Bennington, Vermont, 05201, United States|Fletcher Allen Health Care, Burlington, Vermont, 05401, United States|MS Center at Evergreen, Kirkland, Washington, 98034, United States|CAMC Health Education & Research Institute, Charleston, West Virginia, 25304, United States|Center for Neurological Disorders of Aurora, St. Luke's Medical Center, Milwaukee, Wisconsin, 53215, United States|Foothills Medical Center, Calgary, Alberta, T2N 2T9, Canada|University of British Columbia, Vancouver Coastal Health Research Institute, Vancouver, British Columbia, V6T 2B5, Canada|River Valley Health c/o Stan Cassidy Centre for Rehabilitation, Fredericton, New Brunswick, E3B 0C7, Canada|QEII Health Sciences Centre, Nova Scotia Rehabilitation Centre Site, Halifax, Nova Scotia, B3H 4K4, Canada"
NCT01144052,Natalizumab De-escalation With Interferon Beta-1b,https://beta.clinicaltrials.gov/study/NCT01144052,COMPLETED,Relapsing-remitting Multiple Sclerosis,DRUG: interferon beta-1b|DRUG: Natalizumab,Claudio Gobbi,"Ospedale Civico, Lugano",ALL,ADULT,PHASE4,19,OTHER_GOV,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2010-06,2011-11,2011-11,"Neurocenter of Southern Switzerland, Ospedale Civico Lugano, Lugano, Ticino, 6900, Switzerland"
NCT00947752,Safety of New Formulation of Glatiramer Acetate,https://beta.clinicaltrials.gov/study/NCT00947752,COMPLETED,Relapsing Remitting Multiple Sclerosis,DRUG: Glatiramer Acetate|DRUG: Experimental Glatiramer Acetate,"Teva Branded Pharmaceutical Products R&D, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE3,147,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2009-07,2009-09,2009-11,
NCT01582126,Group Balance Training for People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01582126,COMPLETED,Multiple Sclerosis,OTHER: Group balance training,Örebro County Council,Uppsala-Örebro Regional Research Council|Norrbacka-Eugenia Foundation,ALL,"ADULT, OLDER_ADULT",NA,87,OTHER_GOV,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2012-08,2013-07,2013-07,"Mälarsjukhuset, Eskilstuna, 63188, Sweden|Karlstad hospital, Karlstad, Sweden|Rörelse och hälsa neuro, Linköping, Sweden|Primärvård Mjölby, Mjölby, Sweden|Nyköpings hospital, Nyköping, Sweden|Västerås hospital, Västerås, 72189, Sweden|University Hospital Örebro, Örebro, 70185, Sweden"
NCT00869726,A Study for Patients With Secondary Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00869726,COMPLETED,Secondary Progressive Multiple Sclerosis,DRUG: dirucotide|DRUG: Placebo,Eli Lilly and Company,BioMS Technology Corp.,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,596,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2004-12,2009-05,2009-05,"St. Michaels Hospital, Toronto, Ontario, M5B 1W8, Canada|Copenhagen University Hospital, Kobenhavn, 2100, Denmark|West Tallinn Central Hospital, Tallinn, 10617, Estonia|Terveystalo Turku Kuvantaminen, Turku, 20101, Finland|Heinrich Heine Universitaets, Duesseldorf, 40225, Germany|Vecmilgravis Hospital, Riga, 1015, Latvia|Maaslandziekenhuis, Sittard, 6131 BK, Netherlands|Hospital Duran I Reynals, Barcelona, 08907, Spain|Karolinska Universitetssjukhus, Stockholm, 14186, Sweden|Walton Hospital, Liverpool, L97LJ, United Kingdom"
NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,https://beta.clinicaltrials.gov/study/NCT00288626,COMPLETED,Relapsing-Remitting Multiple Sclerosis,"DRUG: Granulocyte-colony stimulating factor (G-CSF) and prednisone|DRUG: Carmustine, etoposide, cytarabine, and melphalan (BEAM)|PROCEDURE: Autologous hematopoietic stem cell transplant",National Institute of Allergy and Infectious Diseases (NIAID),Immune Tolerance Network (ITN),ALL,ADULT,PHASE2,25,NIH,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2006-07,2015-11,2015-11,"Ohio State University School of Medicine, Columbus, Ohio, 43210, United States|Baylor College of Medicine, Houston, Texas, 77030, United States|M.D. Anderson Cancer Center; Transplant site, please contact Baylor College of Medicine, Houston, Texas, 77230-1402, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, 98109-1024, United States"
NCT01600716,Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT01600716,COMPLETED,Urinary Incontinence|Multiple Sclerosis|Neurogenic Bladder,BIOLOGICAL: OnabotulinumtoxinA|DRUG: Placebo (Normal Saline),Allergan,,ALL,"ADULT, OLDER_ADULT",PHASE3,144,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-06-13,2014-04-04,2015-03-27,"Mountlake Terrace, Washington, United States|Liege, Belgium|Victoria, British Columbia, Canada|Kitchener, Ontario, Canada|Olomouc, Czechia|Garches, France|Marseille, France|Warsaw, Poland|Porto, Portugal|St. Petersburg, Russian Federation"
NCT01070316,Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC),https://beta.clinicaltrials.gov/study/NCT01070316,COMPLETED,Epilepsy|Tuberous Sclerosis Complex,DRUG: Everolimus,"Children's Hospital Medical Center, Cincinnati",Novartis,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1|PHASE2,20,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2010-01,2016-04,2016-04,"Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 45229, United States|Baylor College of Medicine, Houston, Texas, 77030, United States"
NCT00300716,Trial of Memantine for Cognitive Impairment in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00300716,COMPLETED,Multiple Sclerosis|Cognition Disorders,DRUG: Memantine,Oregon Health and Science University,Forest Laboratories|University of Southern California|University of Texas Southwestern Medical Center|MS-Hub Seattle,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,82,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,2004-04,2009-01,2009-01,"USC, Los Angeles, California, 90033, United States|OHSU, Portland, Oregon, 97201, United States|UT Southwestern, Dallas, Texas, 75390-9036, United States|MS Hub, Seattle, Washington, 98101, United States"
NCT05746845,Implication of 5-HT7 Receptor in Inflammatory Mechanisms in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05746845,RECRUITING,Healthy|Multiple Sclerosis,BIOLOGICAL: Blood sample,Centre Hospitalier Régional d'Orléans,,ALL,ADULT,,120,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-03-06,2025-03,2025-03,"CHR Orléans, Orléans, 45067, France"
NCT03808545,Activity and Balanced Eating to Reduce Comorbidities and Symptoms of MS,https://beta.clinicaltrials.gov/study/NCT03808545,TERMINATED,Multiple Sclerosis,BEHAVIORAL: Behavioral Intervention for Physical Activity in Multiple Sclerosis (BIPAMS)|BEHAVIORAL: BIPAMS + Diet,University of Alabama at Birmingham,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),ALL,"ADULT, OLDER_ADULT",NA,11,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2019-02-26,2020-03-19,2020-03-19,"Lakeshore Foundation, Birmingham, Alabama, 35209, United States"
NCT01226745,Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS),https://beta.clinicaltrials.gov/study/NCT01226745,TERMINATED,Multiple Sclerosis,DRUG: ONO-4641|DRUG: ONO-4641|DRUG: ONO-4641|DRUG: ONO-4641|DRUG: ONO-4641|DRUG: ONO-4641,EMD Serono,"Merck KGaA, Darmstadt, Germany|Ono Pharmaceutical Co. Ltd",ALL,ADULT,PHASE2,340,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2010-10,2015-01,2015-01,"Tucson Clinical Site 133, Tucson, Arizona, 85705, United States|Aurora Clinical Site 132, Aurora, Colorado, 80045, United States|Fort Collins Clinical Site 123, Fort Collins, Colorado, 80528, United States|Fairfield Clinical Site 110, Fairfield, Connecticut, 06824, United States|Ormond Beach Clinical Site 129, Ormond Beach, Florida, 32174, United States|Sarasota Clinical Site 116, Sarasota, Florida, 34243, United States|Northbrook Clinical Site 135, Northbrook, Illinois, 60062, United States|Fort Wayne Clinical Site 111, Fort Wayne, Indiana, 46805, United States|Indianapolis Clinical Site 121, Indianapolis, Indiana, 46202, United States|Detroit Clinical Site 104, Detroit, Michigan, 48202, United States|Farmington Hills Clinical Site 126, Farmington Hills, Michigan, 48334, United States|Lebanon Clinical Site 115, Lebanon, New Hampshire, 03756, United States|Albuquerque Clinical Site 106, Albuquerque, New Mexico, 87131, United States|Rochester Clinical Site 108, Rochester, New York, 14642, United States|Charlotte Clinical Site 125, Charlotte, North Carolina, 28201, United States|Raleigh Clinical Site 103, Raleigh, North Carolina, 27607, United States|Akron Clinical Site 112, Akron, Ohio, 44320, United States|Philadelphia Clinical Site 120, Philadelphia, Pennsylvania, 19104, United States|Knoxville Clinical Site 134, Knoxville, Tennessee, 37934, United States|Round Rock Clinical Site 107, Round Rock, Texas, 78681, United States|Brugge Clinical Site 203, Brugge, 8000, Belgium|La Louviere Clinical Site 201, La Louviere, 8000, Belgium|Vancouver Clinical Site 131, Vancouver, British Columbia, V6T 2B5, Canada|Gatineau Clinical Site 114, Gatineau, Quebec, Canada|Greenfield park Clinical Site 109, Greenfield Park, Quebec, J4V2J2, Canada|Montreal Clinical Site 101, Montreal, Quebec, H1T2M4, Canada|Montreal Clinical Site 102, Montreal, H9X3Z9, Canada|Olomouc Clinical Site 212, Olomouc, 775 20, Czech Republic|Pardubice Clinical Site 211, Pardubice, 53203, Czech Republic|Praha 5 Clinical Site 213, Praha 5, 15006, Czech Republic|Glessen Clinical Site 221, Glessen, 35385, Germany|Leipzig Clinical Site 229, Leipzig, 04103, Germany|Marburg Clinical Site 228, Marburg, 35033, Germany|Tubingen Clinical Site 226, Tubingen, 72076, Germany|Athens Clinical Site 243, Athens, 115 29, Greece|Kanto Region Clinical Site 404, Kanto, Japan|Kanto Region Clinical Site 405, Kanto, Japan|Kanto Region Clinical Site 406, Kanto, Japan|Kanto Region Clinical Site 409, Kanto, Japan|Kinki Region Clinical Site 401, Kinki, Japan|Kinki Region Clinical Site 407, Kinki, Japan|Kinki Region Clinical Site 408, Kinki, Japan|Tohoku Region Clinical Site 403, Tohoku, Japan|Tohoku Region Clinical Site 410, Tohoku, Japan|Bialystok Clinical Site 305, Bialystok, 15-402, Poland|Czeladz Clinical Site 303, Czeladz, 41-250, Poland|Gdansk Clinical Site 302, Gdansk, 80-803, Poland|Katowice Clinical Site 309, Katowice, 40-594, Poland|Krakow Clinical Site 307, Krakow, 31-530, Poland|Lodz Clinical Site 306, Lodz, 90-153, Poland|Plewiska Clinical Site 304, Plewiska, 62-064, Poland|Warszawa Clinical Site 308, Warszawa, 04-749, Poland|Kazan Clinical Site 333, Kazan, 420103, Russian Federation|Moscow Clinical Site 332, Moscow, 107150, Russian Federation|Moscow Clinical Site 330, Moscow, 121356, Russian Federation|Nizhniy Novgorod Clinical Site 321, Nizhniy Novgorod, 107150, Russian Federation|Novosibirsk Clinical Site 324, Novosibirsk, 630091, Russian Federation|Samara Clinical Site 329, Samara, 443095, Russian Federation|St. Petersburg Clinical Site 325, St. Petersburg, 194354, Russian Federation|Ufa Clinical Site 326, Ufa, 450005, Russian Federation|Barcelona Clinical Site 252, Barcelona, 08025, Spain|Barcelona Clinical Site 253, Barcelona, 08025, Spain|Bilbao Clinical Site 255, Bilbao, 48013, Spain|Girona Clinical Site 254, Girona, 17007, Spain|Hospitalet de Llobregat Clinical Site 251, Hospitalet de Llobregat, 08907, Spain|Sevilla Clinical Site 256, Sevilla, 41071, Spain|Dnipropetrovsk Clinical Site 341, Dnipropetrovsk, 49027, Ukraine|Kyiv Clinical Site 344, Kyiv, 03110, Ukraine|Lviv Clinical Site 343, Lviv, 03110, Ukraine|Vinnytsya Clinical Site 342, Vinnytsya, 21005, Ukraine"
NCT04595045,Botulinum Toxin in Patients With Spastic Lower Limb Paresis Associated With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04595045,COMPLETED,Multiple Sclerosis,DRUG: Botulinum toxin type A infiltrations,Aránzazu Vázquez Doce,,ALL,"ADULT, OLDER_ADULT",PHASE3,84,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2019-01-24,2022-07-28,2022-07-28,"Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, 28220, Spain|Hospital Universitario de la Princesa, Madrid, 28006, Spain"
NCT02651545,Effects of Teriflunomide (Aubagio) on Cognitive and Vocational Outcomes in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02651545,COMPLETED,Multiple Sclerosis,,State University of New York at Buffalo,,ALL,ADULT,,60,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-02,2020-11-30,2020-11-30,"Buffalo General Hospital, D3, Buffalo, New York, 14203, United States"
NCT04082468,VALIDATE: Factor VIII Trending for MS Relapse,https://beta.clinicaltrials.gov/study/NCT04082468,WITHDRAWN,Multiple Sclerosis,DIAGNOSTIC_TEST: Blood sample collection for coagulation profile,"St. Joseph's Hospital and Medical Center, Phoenix",,ALL,"ADULT, OLDER_ADULT",,0,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-08-13,2021-12-01,2022-03-01,"Barrow Neurological Institute, Phoenix, Arizona, 85013, United States"
NCT03468868,Comparative Effectiveness Study Telerehab Versus Conventional,https://beta.clinicaltrials.gov/study/NCT03468868,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,BEHAVIORAL: Exercise program for people with MS,"Shepherd Center, Atlanta GA","University of Alabama at Birmingham|University of North Carolina, Chapel Hill|University of Georgia|The Cleveland Clinic|University of Colorado, Denver|Marquette University|Accelerated Cure Project for Multiple Sclerosis|Patient-Centered Outcomes Research Institute|Tanner Foundation for Multiple Sclerosis|Massachusetts General Hospital",ALL,"ADULT, OLDER_ADULT",NA,400,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2018-07-23,2023-12-30,2024-08-31,"The Tanner Center for Multiple Sclerosis, Birmingham, Alabama, 35209, United States|University of Alabama, Birmingham, Alabama, 35209, United States|University of Colorado, Denver, Colorado, 80045, United States|University of Georgia, Athens, Georgia, 30602, United States|Shepherd Center, Atlanta, Georgia, 30309, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|University of North Carolina, Raleigh, North Carolina, 27599, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|Marquette University, Milwaukee, Wisconsin, 53233, United States"
NCT00525668,Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study),https://beta.clinicaltrials.gov/study/NCT00525668,COMPLETED,Relapsing-remitting Multiple Sclerosis,DRUG: epigallocatechin-gallate (Sunphenon)|DRUG: placebo,"Charite University, Berlin, Germany",,ALL,ADULT,PHASE1|PHASE2,120,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2007-09,2012-11,2012-11,"NeuroCure Clinical Research Center, Charite University, Berlin, Berlin, 10117, Germany|Outpatient Clinic for Neuroimmunology at the ECRC, Charite University, Berlin, Berlin, 13125, Germany"
NCT00242268,A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00242268,UNKNOWN,Relapsing Remitting Multiple Sclerosis,DRUG: Simvastatin,"Alabama Neurology Associates, PC",Biogen,ALL,ADULT,PHASE3,30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,2005-10,,,"Alabama Neurology Associates, Birmingham, Alabama, 35209, United States"
NCT04758468,Effects of Telerehabilitation-Based Pelvic Floor Muscle Training in People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04758468,COMPLETED,Multiple Sclerosis|Urinary Incontinence,BEHAVIORAL: Telerehabilitation-based pelvic floor muscle training|BEHAVIORAL: Home-based pelvic floor muscle training,Dokuz Eylul University,Izmir Katip Celebi University,ALL,"ADULT, OLDER_ADULT",NA,45,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-02-18,2021-11-15,2021-11-15,"Dokuz Eylul University Hospital, MS Outpatient Clinic, Izmir, Inciralti, 35340, Turkey"
NCT02440516,Standardized Ambulatory Neurorehabilitation Program for Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02440516,COMPLETED,Multiple Sclerosis,OTHER: Early treatment group|OTHER: Late treatment group,"University Hospital Inselspital, Berne",,ALL,"ADULT, OLDER_ADULT",NA,65,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2016-02,2019-02-26,2019-02-26,"Department of Neurology, Bern University Hospital, Bern, 3010, Switzerland|Department of Neurology, Cantonal hospital Luzern, Luzern, 6000, Switzerland"
NCT05000216,COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders,https://beta.clinicaltrials.gov/study/NCT05000216,ACTIVE_NOT_RECRUITING,Rheumatoid Arthritis (RA)|Systemic Lupus Erythematosus (SLE)|Pemphigus Vulgaris|Multiple Sclerosis (MS)|Systemic Sclerosis (SSc)|Pediatric SLE|Juvenile Idiopathic Arthritis (JIA)|Juvenile Dermatomyositis (JDM)|Pediatric-Onset Multiple Sclerosis (POMS),"BIOLOGICAL: Moderna mRNA-1273|BIOLOGICAL: BNT162b2|BIOLOGICAL: Ad26.COV2.S|DRUG: Continue IS (MMF or MPA)|DRUG: Continue IS (MTX)|BIOLOGICAL: Continue IS (B cell depletion therapy)|BIOLOGICAL: Monovalent [B.1.351] CoV2 preS dTM-AS03|DRUG: Withhold IS (MMF or MPA)|DRUG: Withhold IS (MTX)|DRUG: Withhold IS (B cell depletion therapy)|BIOLOGICAL: Moderna mRNA-1273, Bivalent|BIOLOGICAL: BNT162b2, Bivalent",National Institute of Allergy and Infectious Diseases (NIAID),"Autoimmunity Centers of Excellence|Rho Federal Systems Division, Inc.",ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,2340,NIH,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-08-13,2023-12,2024-11,"UCLA Medical Center: Division of Rheumatology, Los Angeles, California, 90095, United States|Yale University School of Medicine: Rheumatology, Allergy & Immunology, New Haven, Connecticut, 06519, United States|The Emory Clinic: Division of Rheumatology, Atlanta, Georgia, 30322, United States|Indiana University Medical Center, Riley Hospital for Children, Indianapolis, Indiana, 46202, United States|Massachusetts General Hospital: Rheumatology, Allergy and Immunology, Center for Immunology and Inflammatory Diseases, Boston, Massachusetts, 02114, United States|Boston Children's Hospital: Department of Pediatrics, Rheumatology Program, Boston, Massachusetts, 02115, United States|Brigham & Women's Hospital: Department of Medicine, Rheumatology, Immunology, Boston, Massachusetts, 02115, United States|University of Michigan Health System: Department of Internal Medicine, Division of Rheumatology, Ann Arbor, Michigan, 48109, United States|Washington University School of Medicine in St. Louis: Division of Rheumatology, Saint Louis, Missouri, 63110, United States|Feinstein Institute for Medical Research: Center for Autoimmune and Musculoskeletal Diseases, Manhasset, New York, 11030, United States|Feinstein Institute for Medical Research, Manhasset, New York, 11030, United States|New York University Langone Medical Center: Department of Medicine, Division of Rheumatology, New York, New York, 10016, United States|Hospital for Special Surgery, New York, New York, 10021, United States|Columbia University Irving Medical Center: Department of Neurology, Multiple Sclerosis Center, New York, New York, 10032, United States|University of Rochester Medical Center, Rochester, New York, 14642, United States|Stony Brook University Hospital, Stony Brook, New York, 11794-8111, United States|University of North Carolina Children's Hospital, Chapel Hill, North Carolina, 27599, United States|Duke University Medical Center: Division of Rheumatology and Immunology, Durham, North Carolina, 27710, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|Nationwide Children's Hopspital, Columbus, Ohio, 43205, United States|Oklahoma Children's Hospital-Pediatrics Specialties Clinic, Oklahoma City, Oklahoma, 73104, United States|Oklahoma Medical Research Foundation: Arthritis and Clinical Immunology Research Program, Oklahoma City, Oklahoma, 73104, United States|Temple Health: Rheumatology, Philadelphia, Pennsylvania, 19104, United States|University of Pennsylvania Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, 19104, United States|Medical University of South Carolina, Nexus Research Center, Charleston, South Carolina, 29425, United States|Medical University of South Carolina, Shawn Jenkins Children's Hospital, Charleston, South Carolina, 29425, United States|UT Southwestern (Peds), Dallas, Texas, 75325, United States|University of Texas Houston Medical School: Division of Rheumatology and Clinical Immunogenetics, Houston, Texas, 77030, United States|Benaroya Research Institute at Virginia Mason: Internal Medicine, Seattle, Washington, 98101, United States"
NCT01395316,Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01395316,COMPLETED,Multiple Sclerosis,DRUG: Alemtuzumab,University of Chicago,"Genzyme, a Sanofi Company",ALL,ADULT,PHASE4,8,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-06,2015-10,2017-07,
NCT00509145,Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS),https://beta.clinicaltrials.gov/study/NCT00509145,COMPLETED,Multiple Sclerosis,DRUG: Laquinimod|OTHER: Placebo,"Teva Branded Pharmaceutical Products R&D, Inc.",,ALL,ADULT,PHASE3,1106,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2007-11-13,2010-11-08,2010-11-08,"Teva Investigational Site 1076, Phoenix, Arizona, 85004, United States|Teva Investigational Site 1090, Centennial, Colorado, 80112, United States|Teva Investigational Site 1088, Fort Collins, Colorado, 80528, United States|Teva Investigational Site 1094, New Haven, Connecticut, 06520-8018, United States|Teva Investigational Site 1102, Northbrook, Illinois, 60062, United States|Teva Investigational Site 1081, Fort Wayne, Indiana, 46805, United States|Teva Investigational Site 1083, Des Moines, Iowa, 50314, United States|Teva Investigational Site 1086, Kansas City, Kansas, 66160, United States|Teva Investigational Site 1101, Lexington, Kentucky, 40513, United States|Teva Investigational Site 1096, Farmington Hills, Michigan, 48334, United States|Teva Investigational Site 1093, Minneapolis, Minnesota, 55414, United States|Teva Investigational Site 1098, Saint Louis, Missouri, 63104, United States|Teva Investigational Site 1082, New York, New York, 10003, United States|Teva Investigational Site 1079, Rochester, New York, 14642, United States|Teva Investigational Site 1073, Winston-Salem, North Carolina, 27157, United States|Teva Investigational Site 1097, Fargo, North Dakota, 58103, United States|Teva Investigational Site 1084, Dayton, Ohio, 45417, United States|Teva Investigational Site 1092, Oklahoma City, Oklahoma, 73120, United States|Teva Investigational Site 1100, Hershey, Pennsylvania, 17033-0850, United States|Teva Investigational Site 1087, Philadelphia, Pennsylvania, 19104, United States|Teva Investigational Site 1075, Lubbock, Texas, 79410, United States|Teva Investigational Site 1078, San Antonio, Texas, 78231, United States|Teva Investigational Site 1085, Milwaukee, Wisconsin, 53215, United States|Teva Investigational Site 3300, Klagenfurt, 9020, Austria|Teva Investigational Site 3303, Linz, A-4021, Austria|Teva Investigational Site 3302, Sankt Polten, 3100, Austria|Teva Investigational Site 3301, Villach, 9500, Austria|Teva Investigational Site 5901, Pleven, 5800, Bulgaria|Teva Investigational Site 5904, Sofia, 1113, Bulgaria|Teva Investigational Site 5903, Sofia, 1309, Bulgaria|Teva Investigational Site 5900, Sofia, 1606, Bulgaria|Teva Investigational Site 5905, Sofia, 1606, Bulgaria|Teva Investigational Site 5902, Varna, 9010, Bulgaria|Teva Investigational Site 1132, Halifax, Nova Scotia, B3M 0A6, Canada|Teva Investigational Site 1126, London, Ontario, N6A 5A5, Canada|Teva Investigational Site 1128, Ottawa, Ontario, K2G 6E2, Canada|Teva Investigational Site 1134, Toronto, Ontario, M4N 3M5, Canada|Teva Investigational Site 1130, Greenfield Park, Quebec, J4V 2J2, Canada|Teva Investigational Site 1129, Montreal, Quebec, H1T 2M4, Canada|Teva Investigational Site 1131, Sherbrooke, Quebec, J1H 5N4, Canada|Teva Investigational Site 5417, Olomouc, 779 00, Czechia|Teva Investigational Site 5416, Ostrava - poruba, 708 52, Czechia|Teva Investigational Site 5504, Tallinn, EE-10617, Estonia|Teva Investigational Site 5505, Tartu, EE-51014, Estonia|Teva Investigational Site 3525, Besancon, 25030, France|Teva Investigational Site 3527, Bron Cedex, 69677, France|Teva Investigational Site 3526, Clermont-Ferrand Cedex 1, 63003, France|Teva Investigational Site 3524, Lille Cedex, 59037, France|Teva Investigational Site 3528, Marseille Cedex 5, 13385, France|Teva Investigational Site 3529, Rennes Cedex 9, 35033, France|Teva Investigational Site 8100, Tbilisi, 0112, Georgia|Teva Investigational Site 8101, Tbilisi, 0179, Georgia|Teva Investigational Site 3247, Bayreuth, 95445, Germany|Teva Investigational Site 3241, Berlin, 10713, Germany|Teva Investigational Site 3238, Berlin, 13347, Germany|Teva Investigational Site 3248, Bochum, 44791, Germany|Teva Investigational Site 3245, Dresden, 01307, Germany|Teva Investigational Site 3237, Emden, 26721, Germany|Teva Investigational Site 3242, Erbach, 64711, Germany|Teva Investigational Site 3240, Erfurt, 99089, Germany|Teva Investigational Site 3249, Freiburg, 79106, Germany|Teva Investigational Site 3236, Hamburg, 20246, Germany|Teva Investigational Site 3246, Hamburg, 22417, Germany|Teva Investigational Site 3239, Hannover, 30559, Germany|Teva Investigational Site 3243, Heidelberg, 69120, Germany|Teva Investigational Site 3251, Munster, 48149, Germany|Teva Investigational Site 3250, Trier, 54292, Germany|Teva Investigational Site 3244, Ulm, 89081, Germany|Teva Investigational Site 5115, Budapest, H-1145, Hungary|Teva Investigational Site 5114, Debrecen, 4043, Hungary|Teva Investigational Site 5116, Miskolc, 3526, Hungary|Teva Investigational Site 5117, Veszprem, H-8200, Hungary|Teva Investigational Site 8034, Haifa, 31048, Israel|Teva Investigational Site 8031, Haifa, 3436212, Israel|Teva Investigational Site 8030, Jerusalem, 9112001, Israel|Teva Investigational Site 8033, Ramat Gan, 5262160, Israel|Teva Investigational Site 8032, Tel Aviv, 78278, Israel|Teva Investigational Site 3044, Catania, 95122, Italy|Teva Investigational Site 3045, Fidenza, 43036, Italy|Teva Investigational Site 3042, Gallarate, 21013, Italy|Teva Investigational Site 3046, Grosseto, 58100, Italy|Teva Investigational Site 3047, Milano, 20122, Italy|Teva Investigational Site 3038, Milano, 20132, Italy|Teva Investigational Site 555, Milano, 20132, Italy|Teva Investigational Site 3039, Milano, 20148, Italy|Teva Investigational Site 3041, Palermo, 90146, Italy|Teva Investigational Site 3040, Rome, 00133, Italy|Teva Investigational Site 5604, Riga, 1015, Latvia|Teva Investigational Site 5704, Kaunas, 50009, Lithuania|Teva Investigational Site 5705, Siauliai, 76231, Lithuania|Teva Investigational Site 3809, Groesbeek, 6561 KE, Netherlands|Teva Investigational Site 3810, Nieuwegein, 3430 EM, Netherlands|Teva Investigational Site 3811, Tilburg, 5022 GC, Netherlands|Teva Investigational Site 5322, Czestochowa, 42-200, Poland|Teva Investigational Site 5320, Gorzow Wielkopolski, 66-400, Poland|Teva Investigational Site 5316, Katowice, 40-752, Poland|Teva Investigational Site 5318, Kielce, 25-736, Poland|Teva Investigational Site 5319, Konskie, 26-200, Poland|Teva Investigational Site 5317, Krakow, 31-826, Poland|Teva Investigational Site 5315, Lodz, 90-153, Poland|Teva Investigational Site 5325, Warszawa, 04-749, Poland|Teva Investigational Site 5208, Bucharest, 011461, Romania|Teva Investigational Site 5210, Cluj-Napoca, 400437, Romania|Teva Investigational Site 5212, Constanta, 900123, Romania|Teva Investigational Site 5211, Targu-Mures, 540136, Romania|Teva Investigational Site 5209, Timisoara, 300736, Romania|Teva Investigational Site 5029, Ekaterinburg, 620102, Russian Federation|Teva Investigational Site 5031, Kemerovo, 650066, Russian Federation|Teva Investigational Site 5021, Moscow, 127018, Russian Federation|Teva Investigational Site 5028, Nizhny Novgorod, 603126, Russian Federation|Teva Investigational Site 5027, Novosibirsk, 630087, Russian Federation|Teva Investigational Site 5030, Perm, 614990, Russian Federation|Teva Investigational Site 5022, Saint Petersburg, 197022, Russian Federation|Teva Investigational Site 5026, Saint-Petersburg, 191025, Russian Federation|Teva Investigational Site 5025, St. Petersburg, 194044, Russian Federation|Teva Investigational Site 5024, St. Petersburg, 194354, Russian Federation|Teva Investigational Site 5023, St. Petersburg, 197376, Russian Federation|Teva Investigational Site 6100, Belgrade, 11000, Serbia|Teva Investigational Site 6102, Nis, 18 000, Serbia|Teva Investigational Site 3132, Barcelona, 08035, Spain|Teva Investigational Site 3134, Barcelona, 08036, Spain|Teva Investigational Site 3144, Barcelona, 08041, Spain|Teva Investigational Site 3140, Beade-Vigo, 36312, Spain|Teva Investigational Site 3142, Getafe, 28905, Spain|Teva Investigational Site 3136, Girona, 17007, Spain|Teva Investigational Site 3135, Lleida, 25198, Spain|Teva Investigational Site 3133, Madrid, 28040, Spain|Teva Investigational Site 3146, Madrid, 28046, Spain|Teva Investigational Site 3137, Murcia, 30120, Spain|Teva Investigational Site 3138, Pontevedra, 36001, Spain|Teva Investigational Site 3139, Santiago de Compostela, 15706, Spain|Teva Investigational Site 3143, Valencia, 46010, Spain|Teva Investigational Site 4204, Stockholm, 14186, Sweden|Teva Investigational Site 4205, Stockholm, 17176, Sweden|Teva Investigational Site 4206, Stockholm, 18288, Sweden|Teva Investigational Site 8201, Izmir, 35340, Turkey|Teva Investigational Site 5803, Dnipropetrovsk, 49027, Ukraine|Teva Investigational Site 5802, Kyiv, 03110, Ukraine|Teva Investigational Site 5804, Kyiv, 03115, Ukraine|Teva Investigational Site 5800, Lviv, 79010, Ukraine|Teva Investigational Site 5801, Vinnytsya, 21005, Ukraine|Teva Investigational Site 3425, Liverpool, L9 7LJ, United Kingdom|Teva Investigational Site 3424, London, E1 2AT, United Kingdom|Teva Investigational Site 3422, Sheffield, S10 2JF, United Kingdom"
NCT02481882,Baseline Cortical Haemodynamics in MS,https://beta.clinicaltrials.gov/study/NCT02481882,UNKNOWN,Multiple Sclerosis,DEVICE: Magnetic Resonance Imaging|DRUG: Prohance (Gadoteridol),University of Nottingham,,ALL,"ADULT, OLDER_ADULT",NA,80,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2017-01,2019-10,2019-10,"Queen's Medical Centre, Nottingham, Nottinghamshire, NG7 2RD, United Kingdom"
NCT02849782,Short and Long Term Multiple Outcomes in Persons With Multiple Sclerosis Treated by Fampridine.,https://beta.clinicaltrials.gov/study/NCT02849782,COMPLETED,Multiple Sclerosis,DRUG: Fampridine,Centre Hospitalier Universitaire de Besancon,,ALL,"ADULT, OLDER_ADULT",PHASE4,89,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-02-04,2019-03-01,2019-03-01,"CHU Jean Minjoz, Besancon, 25030, France"
NCT02040116,Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases,https://beta.clinicaltrials.gov/study/NCT02040116,COMPLETED,Multiple Sclerosis,DRUG: Rituximab Infusion,Wake Forest University Health Sciences,,ALL,"ADULT, OLDER_ADULT",PHASE4,19,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-02,2014-08,2014-08,"Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, 27157, United States"
NCT00859482,Differential Immune Effects of Natalizumab,https://beta.clinicaltrials.gov/study/NCT00859482,COMPLETED,"Multiple Sclerosis, Relapsing Remitting",,Cantonal Hospital of St. Gallen,,ALL,"ADULT, OLDER_ADULT",,27,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2006-07,2007-07,2007-07,
NCT00468182,Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00468182,COMPLETED,Multiple Sclerosis,DRUG: Interferon-beta 1b (Betaseron),"Rutgers, The State University of New Jersey",Bayer,ALL,ADULT,,24,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2007-04,2011-12,2011-12,"Rutgers-RWJMS, New Brunswick, New Jersey, 08901, United States"
NCT03783416,SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03783416,RECRUITING,Relapsing Remitting Multiple Sclerosis|Primary Progressive Multiple Sclerosis|Secondary Progressive Multiple Sclerosis,DRUG: Ixazomib (NINLARO®) capsules / Matching placebo capsules,Queen Mary University of London,"Takeda Pharmaceuticals International, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE1,72,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2020-08-20,2023-08-20,2023-08-20,"Royal London Hospital, Barts Health NHS Foundation Trust, London, Greater London, E1 1BB, United Kingdom"
NCT01405820,"Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)",https://beta.clinicaltrials.gov/study/NCT01405820,COMPLETED,Relapsing-Remitting Multiple Sclerosis,DRUG: natalizumab IV|DRUG: natalizumab SC|DRUG: IV Placebo|DRUG: SC Placebo,Biogen,,ALL,ADULT,PHASE2,290,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2011-08,2014-04,2014-10,"Research Site, Brasschaat, Belgium|Research Site, Liege, Belgium|Research Site, Overpelt, Belgium|Research Site, Wilrijk, Belgium|Research Site, Amiens cedex 1, France|Research Site, Besançon Cedex, France|Research Site, Bron cedex, France|Research Site, Lille Cedex, France|Research Site, Montpellier, France|Research Site, Nantes Cedex 01, France|Research Site, Nice cedex, France|Research Site, Paris Cedex, France|Research Site, Rennes Cedex 9, France|Research Site, Strasbourg, France|Research Site, Toulouse cedex 9, France|Research Site, Andernach, Germany|Research Site, Bamberg, Germany|Research Site, Berlin, Germany|Research Site, Bochum, Germany|Research Site, Bonn, Germany|Research Site, Dresden, Germany|Research Site, Emmendingen, Germany|Research Site, Erbach, Germany|Research Site, Erlangen, Germany|Research Site, Frankfurt, Germany|Research Site, Freiburg, Germany|Research Site, Heidelberg, Germany|Research Site, Jena, Germany|Research Site, Mainz, Germany|Research Site, Marburg, Germany|Research Site, München, Germany|Research Site, Neuburg, Germany|Research Site, Regensburg, Germany|Research Site, Tuebingen, Germany|Research Site, Ulm, Germany|Research Site, Wermsdorf, Germany|Research Site, Bari, Italy|Research Site, Catania, Italy|Research Site, Cefalù, Italy|Research Site, Chieti, Italy|Research Site, Firenze, Italy|Research Site, Gallarate, Italy|Research Site, L'Aquila, Italy|Research Site, Milano, Italy|Research Site, Montichiari, Italy|Research Site, Napoli, Italy|Research Site, Orbassano, Italy|Research Site, Padova, Italy|Research Site, Palermo, Italy|Research Site, Pavia, Italy|Research Site, Pozzilli, Italy|Research Site, Roma, Italy|Research Site, Sassari, Italy|Research Site, Torino, Italy|Research Site, Barcelona, Spain|Research Site, Girona, Spain|Research Site, Lleida, Spain|Research Site, Malaga, Spain|Research Site, Murcia, Spain|Research Site, Oviedo, Spain|Research Site, Pamplona, Spain|Research Site, San Sebastian, Spain|Research Site, Santa Cruz de Tenerife, Spain|Research Site, Sevilla, Spain"
NCT02490982,Teriflunomide Observational Effectiveness Study,https://beta.clinicaltrials.gov/study/NCT02490982,COMPLETED,Relapsing Remitting Multiple Sclerosis,DRUG: Teriflunomide,Centre hospitalier de l'Université de Montréal (CHUM),"Genzyme, a Sanofi Company|Montreal Neurological Institute and Hospital",ALL,"ADULT, OLDER_ADULT",,106,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-11,2018-12,2021-06-28,"CHUM, Montréal, Quebec, H2L 4M1, Canada"
NCT02533882,Lakeshore Examination of Activity and Disability Exercise Response Study,https://beta.clinicaltrials.gov/study/NCT02533882,COMPLETED,Multiple Sclerosis|Stroke,BEHAVIORAL: Movement to Music|BEHAVIORAL: Adapted Yoga,University of Alabama at Birmingham,Lakeshore Foundation,ALL,"ADULT, OLDER_ADULT",NA,180,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2014-12,2019-07-15,2019-08-30,"Lakeshore Foundation, Birmingham, Alabama, 35209, United States"
NCT01517282,Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01517282,COMPLETED,Multiple Sclerosis,BIOLOGICAL: MOR103|OTHER: Placebo,MorphoSys AG,,ALL,ADULT,PHASE1|PHASE2,32,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2012-01,2014-01,2014-02,"Morphosys Investigative Site, Berlin, Germany|Morphosys Investigative Site, Gdansk, Poland|Morphosys Investigative Site, Poznan, Poland|Morhosys Investigative Site, Manchester, United Kingdom|MorphoSys Investigative Site, Nottingham, United Kingdom"
NCT04932616,Tele-Assessment and Face-to-Face Evaluation of Functional Gait Assessment in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04932616,RECRUITING,Multiple Sclerosis,,Istanbul University - Cerrahpasa (IUC),,ALL,"ADULT, OLDER_ADULT",,32,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-01-26,2021-07-01,2021-08-01,"Memorial Sisli Hospital, Neurology Clinic, Istanbul, Sisli, 34384, Turkey"
NCT05304520,A Study for Tysabri Participant Preference,https://beta.clinicaltrials.gov/study/NCT05304520,RECRUITING,Relapsing-Remitting Multiple Sclerosis (RRMS),DRUG: Natalizumab,Biogen,,ALL,"ADULT, OLDER_ADULT",,500,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-10-12,2023-12-01,2023-12-01,"Neurozentrum am Königsplatz Augsburg; Dres. Müller und Schmid, Augsburg, Germany|Praxis Dr. Schöll, Bad Homburg, Germany|Caritas Krankenhaus Bad Mergentheim, Bad Mergentheim, Germany|Neurologische Praxis Dr. med. Boris-Alexander Kallmann, Bamberg, Germany|Marianne-Strauß-Klinik Starnberg, Berg, Germany|Neurologie am Mexikoplatz, Berlin, Germany|Neurologie im Tempelhofer Hafen Berlin, Berlin, Germany|Neurologisches Facharztzentrum Dr. Masri & Kollegen, Berlin, Germany|NFZB Neurologisches Facharztzentrum Berlin, Berlin, Germany|Praxis für Neurologie/Dr. med. Martin Delf, Berlin, Germany|Katholisches Klinikum Bochum gGmbH, Bochum, Germany|Praxis Dres. Kausch/Lippert, Bogen, Germany|Neurologische Studiengesellschaft Bonn GbR, Bonn, Germany|MVZ Daun GmbH, Daun, Germany|Neurologie Dillingen, Dillingen, Germany|Gemeinschaftspraxis für Neurologie, Düsseldorf, Germany|Praxis Dr. Hartmann, Eltville, Germany|Neuro Centrum science GmbH, Erbach, Germany|Universitätsklinikum Erlangen, Neurolische Klinik, Erlangen, Germany|med.ring GmbH, Essen, Germany|NeuroDot GmbH, Grevenbroich, Germany|GP Dr. med. Wolfgang Klostermann/ Dr. med. Samir Al-Boutros, Hagen, Germany|Krankenhaus Martha-Maria Halle-Dölau; Klinik für Neurologie, Halle (Saale), Germany|Universitätsklinikum Jena, Hans-Berger-Klinik für Neurologie, Jena, Germany|Praxis Dr. Fischer, Lappersdorf, Germany|Neurokomm - Gesellschaft für Studien und Kommunikation, Mannheim, Germany|NPS Neurologisch Psychiatrische Studiengesellschaft, Mannheim, Germany|GP Neurologie am Preußenmuseum/ Martina Lorenz/ Dr. med. Birgit Erker, Minden, Germany|Landesklinkum Mistelbach-Gänserndorf, Abteilung Neurologie, Mistelbach, Germany|Hygieia Pharmakologisches Studienzentrum Chemnitz GmbH, Außenstelle Mittweida, Mittweida, Germany|Amperklinikum München Haar, München, Germany|CODAST, München, Germany|Neurologie Neu-Ulm, Neu-Ulm, Germany|Bergmann.Consult, Neuburg, Germany|Neurozentrum Prien, Prien am Chiemsee, Germany|EMSA, Singen, Germany|NeuroSinsheim, Sinsheim, Germany|Nervenfachärztliche GP, Ulm, Germany|Neuropraxis München Süd, Unterhaching, Germany|Praxis Dr. Krause, Wolfratshausen, Germany"
NCT01808482,"A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS)",https://beta.clinicaltrials.gov/study/NCT01808482,TERMINATED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Part A: 100 mg/mL GSK2618960|DRUG: Part A: matching placebo|DRUG: Part B: Dose of GSK2618960 decided from Part A|DRUG: Part B: matching placebo|DRUG: Part C: Dose of GSK2618960 decided from Part A and B,GlaxoSmithKline,,MALE,ADULT,PHASE1,16,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2013-03-13,2013-08-06,2013-08-06,"GSK Investigational Site, Cambridge, CB2 2GG, United Kingdom"
NCT05605782,"A Post-Authorization, Long-term Study of Ozanimod Real-world Safety",https://beta.clinicaltrials.gov/study/NCT05605782,ACTIVE_NOT_RECRUITING,"Multiple Sclerosis, Relapsing-Remitting",,Bristol-Myers Squibb,,ALL,"ADULT, OLDER_ADULT",,9000,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-06-30,2032-12-31,2032-12-31,"Evidera, Bethesda, Maryland, 20814, United States"
NCT00537082,Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT00537082,COMPLETED,Multiple Sclerosis,DRUG: FTY720|DRUG: Placebo,Novartis,Mitsubishi Tanabe Pharma Corporation,ALL,ADULT,PHASE2,171,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2007-09,2010-02,,"Novartis Investigative site, Sapporo-shi, Hokkaido, Japan|Novartis Investigative Site, Chiba, 276-8524, Japan|Novartis Investigative Site, Ehime, 791-0295, Japan|Novartis Investigative Site, Fukuoka, 807-8555, Japan|Novartis Investigative Site, Gunma, 371-8511, Japan|Novartis Investigative Site, Hyogo, 650-0017, Japan|Novartis Investigative Site, Ibaraki, 305-8576, Japan|Novartis, Iwate, 020-8505, Japan|Novartis Investigative Site, Kanagawa, 259-1193, Japan|Novartis Investigative Site, Kyoto, 604-8453, Japan|Novartis Investigative Site, Kyoto, 616-8255, Japan|Novartis Investigative Site, Niigata, 951-8520, Japan|Novartis Investigative Site, Osaka, 556-0016, Japan|Novartis Investigative Site, Osaka, 589-8511, Japan|Novartis Investigative Site, Tochigi, 329-0498, Japan|Novartis Investigative Site, Tokyo, 145-0065, Japan|Novartis Investigative Site, Tokyo, 162-8666, Japan|Novartis Investigative Site, Wakayama, 641-8510, Japan"
NCT04239820,Effect of Cladribine Treatment on Microglial Activation in the CNS,https://beta.clinicaltrials.gov/study/NCT04239820,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,RADIATION: Imaging,Turku University Hospital,,ALL,ADULT,,15,OTHER_GOV,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-01-10,2023-08,2024-06,"Turku PET Centre, Turku, Finland Proper, 20520, Finland"
NCT03122652,"Randomized, Double-blinded Study of Treatment:Teriflunomide, in Radiologically Isolated Syndrome",https://beta.clinicaltrials.gov/study/NCT03122652,COMPLETED,Multiple Sclerosis,DRUG: Teriflunomide 14 MG Oral Tablet [Aubagio]|DRUG: Placebo Oral Tablet,Centre Hospitalier Universitaire de Nice,"Genzyme, a Sanofi Company",ALL,"ADULT, OLDER_ADULT",PHASE3,125,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-09-25,2019-02-05,2022-10-04,"CHU de Bordeaux, Bordeaux, 33000, France|CHU de Caen, Caen, France|CHU de Clermont-Ferrand, Clermont-Ferrand, France|CHU de Grenoble, Grenoble, France|CHRU de Lille, Lille, 59000, France|Hospices Civils de Lyon, Lyon, 69677, France|CHRU de Montpellier, Montpellier, 34000, France|CHU de Nantes, Nantes, France|CHU de Nice, Nice, 06000, France|CHU de Nîmes, Nîmes, France|APHP - Hôpital La Pitié Salpêtrière, Paris, 75013, France|CHU de Rennes, Rennes, 35000, France|CHU de Rouen, Rouen, France|CHU de Strasbourg, Strasbourg, 67000, France|CHU de Toulouse, Toulouse, 31000, France|Inselspital Bern, Bern, 3010, Switzerland|Hacettepe University, Ankara, Turkey|Mustafa Kemal University, Antakya, Turkey|Uludag University School of Medicine, Bursa, Turkey|Istanbul University, Istanbul, Turkey|Ege University Medical Faculty, İzmir, 35100, Turkey|Kocaeli University School of Medicine, Kocaeli, Turkey|Ondokuz Mayis University, Faculty of Medicine, Samsun, Turkey"
NCT00988052,"A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course",https://beta.clinicaltrials.gov/study/NCT00988052,TERMINATED,Relapsing Multiple Sclerosis,DRUG: Laquinimod,"Teva Branded Pharmaceutical Products R&D, Inc.",,ALL,ADULT,PHASE3,839,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2009-11-10,2017-07-01,2017-07-01,"Teva Investigational Site 1076, Phoenix, Arizona, 85004, United States|Teva Investigational Site 1090, Centennial, Colorado, 80112, United States|Teva Investigational Site 1088, Fort Collins, Colorado, 80528, United States|Teva Investigational Site 1102, Northbrook, Illinois, 60062, United States|Teva Investigational Site 1081, Fort Wayne, Indiana, 46845, United States|Teva Investigational Site 1083, Des Moines, Iowa, 50314, United States|Teva Investigational Site 1086, Kansas City, Kansas, 66103, United States|Teva Investigational Site 1101, Lexington, Kentucky, 40513, United States|Teva Investigational Site 1096, Farmington Hills, Michigan, 48334, United States|Teva Investigational Site 1093, Minneapolis, Minnesota, 55414, United States|Teva Investigational Site 1098, Saint Louis, Missouri, 63104, United States|Teva Investigational Site 1082, New York, New York, 10016, United States|Teva Investigational Site 1073, Winston-Salem, North Carolina, 27157, United States|Teva Investigational Site 1097, Fargo, North Dakota, 58103, United States|Teva Investigational Site 1084, Dayton, Ohio, 45417, United States|Teva Investigational Site 1092, Oklahoma City, Oklahoma, 73120, United States|Teva Investigational Site 1100, Hershey, Pennsylvania, 17033-0850, United States|Teva Investigational Site 1075, Lubbock, Texas, 79410, United States|Teva Investigational Site 1078, San Antonio, Texas, 78231, United States|Teva Investigational Site 1085, Milwaukee, Wisconsin, 53215, United States|Teva Investigational Site 3300, Klagenfurt, 9020, Austria|Teva Investigational Site 3303, Linz, A-4021, Austria|Teva Investigational Site 3302, Sankt Polten, 3100, Austria|Teva Investigational Site 5901, Pleven, 5800, Bulgaria|Teva Investigational Site 5904, Sofia, 1113, Bulgaria|Teva Investigational Site 5903, Sofia, 1309, Bulgaria|Teva Investigational Site 5900, Sofia, 1606, Bulgaria|Teva Investigational Site 5905, Sofia, 1606, Bulgaria|Teva Investigational Site 5902, Varna, 9010, Bulgaria|Teva Investigational Site 1132, Bedford, Nova Scotia, B4A 1A9, Canada|Teva Investigational Site 1126, London, Ontario, N6A 5A5, Canada|Teva Investigational Site 1128, Ottawa, Ontario, K2G 6E2, Canada|Teva Investigational Site 1134, Toronto, Ontario, M4N 3M5, Canada|Teva Investigational Site 1130, Greenfield Park, Quebec, J4V 2J2, Canada|Teva Investigational Site 1129, Montreal, Quebec, H1T 2M4, Canada|Teva Investigational Site 1131, Sherbrooke, Quebec, J1H 5N4, Canada|Teva Investigational Site 5417, Olomouc, 779 00, Czechia|Teva Investigational Site 5416, Ostrava - poruba, 708 52, Czechia|Teva Investigational Site 5504, Tallinn, EE-10617, Estonia|Teva Investigational Site 5505, Tartu, EE-51014, Estonia|Teva Investigational Site 3525, Besancon, 25030, France|Teva Investigational Site 3527, Bron Cedex, 69677, France|Teva Investigational Site 3526, Clermont-Ferrand Cedex 1, 63003, France|Teva Investigational Site 3524, Lille Cedex, 59037, France|Teva Investigational Site 3528, Marseille Cedex 5, 13385, France|Teva Investigational Site 3529, Rennes Cedex 9, 35033, France|Teva Investigational Site 8100, Tbilisi, 0112, Georgia|Teva Investigational Site 8101, Tbilisi, 0179, Georgia|Teva Investigational Site 3247, Bayreuth, 95445, Germany|Teva Investigational Site 3241, Berlin, 10713, Germany|Teva Investigational Site 3238, Berlin, 13347, Germany|Teva Investigational Site 3248, Bochum, 44791, Germany|Teva Investigational Site 3245, Dresden, 01307, Germany|Teva Investigational Site 3237, Emden, 26721, Germany|Teva Investigational Site 3242, Erbach, 64711, Germany|Teva Investigational Site 3240, Erfurt, 99089, Germany|Teva Investigational Site 3249, Freiburg, 79106, Germany|Teva Investigational Site 3236, Hamburg, 20246, Germany|Teva Investigational Site 3246, Hamburg, 22417, Germany|Teva Investigational Site 3239, Hannover, 30171, Germany|Teva Investigational Site 3243, Heidelberg, 69120, Germany|Teva Investigational Site 3251, Munster, 48149, Germany|Teva Investigational Site 3250, Trier, 54292, Germany|Teva Investigational Site 3244, Ulm, 89081, Germany|Teva Investigational Site 5115, Budapest, H-1145, Hungary|Teva Investigational Site 5114, Debrecen, 4043, Hungary|Teva Investigational Site 5116, Miskolc, 3526, Hungary|Teva Investigational Site 5117, Veszprem, H-8200, Hungary|Teva Investigational Site 8031, Haifa, 3436212, Israel|Teva Investigational Site 8030, Jerusalem, 9112001, Israel|Teva Investigational Site 8033, Ramat Gan, 5262160, Israel|Teva Investigational Site 8032, Tel Aviv, 78278, Israel|Teva Investigational Site 3044, Catania, 95124, Italy|Teva Investigational Site 3045, Fidenza, 43036, Italy|Teva Investigational Site 3042, Gallarate, 21013, Italy|Teva Investigational Site 3046, Grosseto, 58100, Italy|Teva Investigational Site 3038, Milano, 20132, Italy|Teva Investigational Site 555, Milano, 20132, Italy|Teva Investigational Site 3039, Milano, 20148, Italy|Teva Investigational Site 3041, Palermo, 90146, Italy|Teva Investigational Site 3040, Rome, 00133, Italy|Teva Investigational Site 5704, Kaunas, 50009, Lithuania|Teva Investigational Site 5705, Siauliai, 76231, Lithuania|Teva Investigational Site 3810, Nieuwegein, 3430 EM, Netherlands|Teva Investigational Site 3809, Nijmegen, 6525 GC, Netherlands|Teva Investigational Site 5322, Czestochowa, 42-280, Poland|Teva Investigational Site 5320, Gorzow Wielkopolski, 66-400, Poland|Teva Investigational Site 5316, Katowice, 40-752, Poland|Teva Investigational Site 5318, Kielce, 25-726, Poland|Teva Investigational Site 5319, Konskie, 26-200, Poland|Teva Investigational Site 5317, Krakow, 31-826, Poland|Teva Investigational Site 5315, Lodz, 90-153, Poland|Teva Investigational Site 5325, Warszawa, 04-749, Poland|Teva Investigational Site 5208, Bucharest, 011461, Romania|Teva Investigational Site 5210, Cluj-Napoca, 400437, Romania|Teva Investigational Site 5212, Constanta, 900123, Romania|Teva Investigational Site 5211, Targu-Mures, 540136, Romania|Teva Investigational Site 5209, Timisoara, 300736, Romania|Teva Investigational Site 5029, Ekaterinburg, 620102, Russian Federation|Teva Investigational Site 5021, Moscow, 127015, Russian Federation|Teva Investigational Site 5028, Nizhny Novgorod, 603126, Russian Federation|Teva Investigational Site 5027, Novosibirsk, 630087, Russian Federation|Teva Investigational Site 5030, Perm, 614990, Russian Federation|Teva Investigational Site 5022, Saint Petersburg, 197022, Russian Federation|Teva Investigational Site 5025, St. Petersburg, 194044, Russian Federation|Teva Investigational Site 5024, St. Petersburg, 194354, Russian Federation|Teva Investigational Site 5023, St. Petersburg, 197376, Russian Federation|Teva Investigational Site 5026, St.Petersburg, 191186, Russian Federation|Teva Investigational Site 6100, Belgrade, 11000, Serbia|Teva Investigational Site 6102, Nis, 18 000, Serbia|Teva Investigational Site 3132, Barcelona, 08035, Spain|Teva Investigational Site 3134, Barcelona, 08036, Spain|Teva Investigational Site 3144, Barcelona, 08041, Spain|Teva Investigational Site 3140, Beade-Pontevedra, 36312, Spain|Teva Investigational Site 3142, Getafe, 28905, Spain|Teva Investigational Site 3135, Lleida, 25198, Spain|Teva Investigational Site 3133, Madrid, 28040, Spain|Teva Investigational Site 3146, Madrid, 28046, Spain|Teva Investigational Site 3137, Murcia, 30120, Spain|Teva Investigational Site 3138, Pontevedra, 36001, Spain|Teva Investigational Site 3136, Salt, 17190, Spain|Teva Investigational Site 3139, Santiago de Compostela, 15706, Spain|Teva Investigational Site 3143, Valencia, 46010, Spain|Teva Investigational Site 4204, Stockholm, 14186, Sweden|Teva Investigational Site 4205, Stockholm, 17176, Sweden|Teva Investigational Site 4206, Stockholm, 18288, Sweden|Teva Investigational Site 8201, Izmir, 35340, Turkey|Teva Investigational Site 5803, Dnipropetrovsk, 49027, Ukraine|Teva Investigational Site 5802, Kyiv, 03110, Ukraine|Teva Investigational Site 5804, Kyiv, 03115, Ukraine|Teva Investigational Site 5800, Lviv, 79010, Ukraine|Teva Investigational Site 5801, Vinnytsya, 21005, Ukraine|Teva Investigational Site 3425, Liverpool, L9 7LJ, United Kingdom|Teva Investigational Site 3424, London, E1 2AT, United Kingdom|Teva Investigational Site 3422, Sheffield, S10 2JF, United Kingdom"
NCT00391352,fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls,https://beta.clinicaltrials.gov/study/NCT00391352,COMPLETED,Relapsing-Remitting Multiple Sclerosis,DRUG: IFN-β-1a (Rebif®),Waukesha Memorial Hospital,The Cleveland Clinic,ALL,"ADULT, OLDER_ADULT",,21,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2008-02,2012-08,2012-08,"Waukesha Memorial Hospital ProHealth Care, Waukesha, Wisconsin, 53188, United States"
NCT03326505,Allogenic Mesenchymal Stem Cells And Physical Therapy for MS Treatment,https://beta.clinicaltrials.gov/study/NCT03326505,COMPLETED,Multiple Sclerosis,BIOLOGICAL: Umbilical cord derived Mesenchymal Stem Cells|OTHER: Supervised physical therapy,University of Jordan,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2017-09-25,2020-01-25,2020-02-20,"Cell Therapy Center, University of Jordan, Amman, 11942, Jordan|Cell Therapy Center, Amman, 11942, Jordan"
NCT05533905,DECISIve - DiagnosE Using the Central veIn SIgn v1.0,https://beta.clinicaltrials.gov/study/NCT05533905,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,DIAGNOSTIC_TEST: Lumbar puncture|DIAGNOSTIC_TEST: MRI,Nottingham University Hospitals NHS Trust,,ALL,"ADULT, OLDER_ADULT",,115,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-12-09,2023-11-06,2023-11-06,"NUH NHS Trust, Nottingham, NG7 2UH, United Kingdom"
NCT03942952,PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes.,https://beta.clinicaltrials.gov/study/NCT03942952,ACTIVE_NOT_RECRUITING,"Multiple Sclerosis, Relapsing-Remitting|Neuromyelitis Optica|Acute Disseminated Encephalomyelitis|Transverse Myelitis",,University of Texas Southwestern Medical Center,,ALL,"CHILD, ADULT",,160,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-10-22,2023-05-31,2024-05-31,"University Texas Southwestern, Dallas, Texas, 75390, United States"
NCT05811949,Effects of Dimethyl Fumarate on Cognitive Performance and Brain Abnormalities in Multiple Sclerosis.,https://beta.clinicaltrials.gov/study/NCT05811949,RECRUITING,Multiple Sclerosis,DRUG: Dimethyl Fumarate 240 MG [Tecfidera],"IRCCS Centro Neurolesi ""Bonino-Pulejo""",,ALL,"ADULT, OLDER_ADULT",,52,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-02-24,2022-10-11,2025-02,"IRCCS Centro Neurolesi ""Bonino-Pulejo"", Messina, 98124, Italy"
NCT04998305,TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps,https://beta.clinicaltrials.gov/study/NCT04998305,RECRUITING,Amyotrophic Lateral Sclerosis|Muscle Cramp,DRUG: TJ-68|DRUG: Placebo,Hiroshi Mitsumoto,"Tsumura & Co., Tokyo, Japan",ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,26,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-09-30,2023-10,2023-10,"Mayo Clinic, Jacksonville, Florida, 32224, United States|Columbia University Irving Medical Center, New York, New York, 10032, United States"
NCT02975349,A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02975349,ACTIVE_NOT_RECRUITING,Relapsing-remitting Multiple Sclerosis,DRUG: Evobrutinib|DRUG: Evobrutinib|DRUG: Evobrutinib|DRUG: Placebo|DRUG: Tecfidera|DRUG: Evobrutinib,"EMD Serono Research & Development Institute, Inc.","Merck KGaA, Darmstadt, Germany",ALL,"ADULT, OLDER_ADULT",PHASE2,267,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-03-07,2018-01-24,2025-02-15,"Research Site, Blagoevgrad, 2700, Bulgaria|Research Site, Dupnitsa, 2600, Bulgaria|Research Site 1, Pleven, 5800, Bulgaria|Research Site 2, Pleven, 5800, Bulgaria|Research Site, Ruse, 7002, Bulgaria|Research Site, Sofia, 1142, Bulgaria|Research Site, Sofia, 1309, Bulgaria|Research Site, Sofia, 1336, Bulgaria|Research Site, Sofia, 1407, Bulgaria|Research Site, Sofia, 1431, Bulgaria|Research Site, Sofia, 1606, Bulgaria|Research Site, Sofia, 1797, Bulgaria|Research Site, Brno, 656 91, Czechia|Research Site, Hradec Kralove, 500 05, Czechia|Research Site, Hradec Kralove, 50003, Czechia|Research Site, Jihlava, 58633, Czechia|Research Site, Prague 5, 150 06, Czechia|Research Site, Teplice, 41529, Czechia|Research Site, Bydgoszcz, 85-654, Poland|Research Site, Katowice, 40-595, Poland|Research Site, Katowice, 40-650, Poland|Research Site, Lodz, 90-324, Poland|Research Site, Lublin, 20-605, Poland|Research Site, Oswiecim, 32-600, Poland|Research Site, Plewiska, 62-064, Poland|Research Site, Poznan, 61-853, Poland|Research Site, Rzeszow, 35-055, Poland|Research Site, Warszawa, 01-697, Poland|Research Site, Kazan, 420021, Russian Federation|Research Site, Krasnoyarsk, 660037, Russian Federation|Research Site, Krasnoyarsk, 660049, Russian Federation|Research Site, Moscow, 129128, Russian Federation|Research Site, Novosibirsk, 630102, Russian Federation|Research Site, Perm, 614000, Russian Federation|Research Site, Saransk, 430032, Russian Federation|Research Site, Belgrade, 11000, Serbia|Research Site, Kragujevac, 34000, Serbia|Research Site, Nis, 18000, Serbia|Research Site, Uzice, 31000, Serbia|Research Site, Banska Bystrica, 97404, Slovakia|Research Site, Bratislava, 85101, Slovakia|Research Site, Dubnica nad Vahom, 01841, Slovakia|Research Site, A Coruña, 15006, Spain|Research Site, Barcelona, 08003, Spain|Research Site, Barcelona, 08035, Spain|Research Site, Chernivtsi, 58018, Ukraine|Research Site, Ivano-Frankivsk, 76008, Ukraine|Research Site, Kharkiv, 61058, Ukraine|Research Site, Kharkiv, 61068, Ukraine|Research Site, Kharkiv, 61103, Ukraine|Research Site, Kyiv, 01601, Ukraine|Research Site, Kyiv, 03110, Ukraine|Research Site, Lviv, 79010, Ukraine|Research Site, Poltava, 36011, Ukraine|Research Site, Zaporizhzhia, 69035, Ukraine|Research Site, Zaporizhzhia, 69600, Ukraine"
NCT00881205,Rivastigmine in Multiple Sclerosis Patients With Cognitive Impairment,https://beta.clinicaltrials.gov/study/NCT00881205,TERMINATED,Multiple Sclerosis|Cognitive Impairment,DRUG: Rivastigmine transdermal patch|DRUG: Placebo,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE4,86,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-04,2011-01,2011-01,"Novartis Investigative Site, Aachen, 52062, Germany|Novartis Investigative Site, Aalen, 73430, Germany|Novartis Investigative Site, Abensberg, 93326, Germany|Novartis Investigative Site, Achim, 28832, Germany|Novartis Investigative Site, Alzenau, 63755, Germany|Novartis Investigative Site, Aschaffenburg, 63739, Germany|Novartis Investigative Site, Bad Mergentheim, 97980, Germany|Novartis Investigative Site, Bayreuth, 95445, Germany|Novartis Investigative Site, Berlin, 10178, Germany|Novartis Investigative SIte, Berlin, 10713, Germany|Novartis Investigative Site, Berlin, 12103, Germany|Novartis Investigative Site, Berlin, 13347, Germany|Novartis Investigative Site, Bochum, 44892, Germany|Novartis Investigative Site, Böblingen, 71034, Germany|Novartis Investigative Site, Düsseldorf, 40211, Germany|Novartis Investigative Site, Eisenach, 99817, Germany|Novartis Investigative Site, Ellwangen, 73479, Germany|Novartis Investigative Site, Erbach, 64711, Germany|Novartis Investigative Site, Erlangen, 91054, Germany|Novartis Investigative Site, Essen, 45122, Germany|Novartis Investigative Site, Essen, 45138, Germany|Novartis Investigative Site, Giessen, 35385, Germany|Novartis Investigative Site, Göttingen, 37075, Germany|Novartis Investigative Site, Hamburg, 20354, Germany|Novartis Investigative Site, Hamburg, 22083, Germany|Novartis Investigational Site, Hamburg, 22179, Germany|Novartis Investigative Site, Hannover, 30623, Germany|Novartis Investigative Site, Itzehoe, 25524, Germany|Novartis Investigative Site, Kaltenkirchen, 24568, Germany|Novartis Investigative Site, Koeln, 51109, Germany|Novartis Investigative Site, Krefeld, 47798, Germany|Novartis Investigative Site, Lappersdorf, 93138, Germany|Novartis Investigative Site, Leipzig, 04103, Germany|Novartis Investigative Site, Leipzig, 04157, Germany|Novartis Investigative Site, Ludwigshafen, 67059, Germany|Novartis Investigative Site, Lüneburg, 21335, Germany|Novartis Investigative Site, Neu-Ulm, 89231, Germany|Novartis Investigative Site, Neuburg, 86633, Germany|Novartis Investigative Site, Oldenburg, 26122, Germany|Novartis Investigative Site, Osnabruck, 49078, Germany|Novartis Investigative Site, Rostock, 18147, Germany|Novartis Investigative Site, Stade, 21682, Germany|Novartis Investigative Site, Stuttgart, 70182, Germany|Novartis Investigative Site, Stuttgart, 70191, Germany|Novartis Investigative Site, Ulm, 89073, Germany|Novartis Investigative Site, Unterhaching, 82008, Germany|Novartis Investigative Site, Viernheim, 69518, Germany|Novartis Investigative Site, Wiesbaden, 65183, Germany|Novartis Investigative Site, Wolfratshausen, 82515, Germany"
NCT01464749,Task-oriented Circuit Class Training in Multiple Sclerosis Subjects,https://beta.clinicaltrials.gov/study/NCT01464749,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Task-oriented circuit class training|BEHAVIORAL: usual care,University Hospital of Ferrara,Università degli Studi di Ferrara,ALL,"ADULT, OLDER_ADULT",NA,24,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2011-05,2012-05,2013-10,"Physical Medicine and Rehabilitation Department Ferrara, Ferrara, Emilia Romagna, 44100, Italy"
NCT04150549,FMT for MS Patients,https://beta.clinicaltrials.gov/study/NCT04150549,NOT_YET_RECRUITING,Multiple Sclerosis,BIOLOGICAL: Fecal Microbial Transplants|BIOLOGICAL: Fecal Microbial Transplants,Lawson Health Research Institute,,ALL,ADULT,PHASE2,34,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2023-06,2025-05,2025-08,
NCT02795052,Neurologic Stem Cell Treatment Study,https://beta.clinicaltrials.gov/study/NCT02795052,RECRUITING,Neurologic Disorders|Nervous System Diseases|Neurodegenerative Diseases|Neurological Disorders|Stroke|Traumatic Brain Injury|Cadasil|Chronic Traumatic Encephalopathy|Cerebral Infarction|Cerebral Ischemia|Cerebral Stroke|Cerebral Hemorrhage|Parkinson|Multi-System Degeneration|MSA - Multiple System Atrophy|Progressive Supranuclear Palsy|ALS|Amyotrophic Lateral Sclerosis|Neuropathy|Diabetic Neuropathies|Alzheimer Disease|Dementia|Frontotemporal Dementia|Lewy Body Disease|Cognitive Impairment|Lewy Body Variant of Alzheimer Disease,PROCEDURE: Intravenous and Intranasal BMSC,MD Stem Cells,,ALL,"ADULT, OLDER_ADULT",NA,500,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-06,2023-07,2024-07,"MD Stem Cells, Westport, Connecticut, 06880, United States|MD Stem Cells, Coral Springs, Florida, 33065, United States|Medcare Orthopaedics & Spine Hospital, Dubai, United Arab Emirates"
NCT05809505,Feasibility and Safety of the 360-degree Turn Test Delivered Via Telehealth,https://beta.clinicaltrials.gov/study/NCT05809505,NOT_YET_RECRUITING,Multiple Sclerosis,DIAGNOSTIC_TEST: 360-degree Turn Test|OTHER: Expanded Disability Status Scale|OTHER: Perceived Exertion,Uskudar State Hospital,,ALL,"ADULT, OLDER_ADULT",NA,50,OTHER_GOV,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-12-01,2024-12-01,2025-01-01,
NCT00377949,"Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients",https://beta.clinicaltrials.gov/study/NCT00377949,COMPLETED,Systemic Sclerosis|Scleroderma|Pulmonary Hypertension|Pulmonary Arterial Hypertension,,Georgetown University,Gilead Sciences,ALL,"ADULT, OLDER_ADULT",,602,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2005-02,2016-01,,"UCLA Medical Center, Los Angeles, California, 90095, United States|Stanford University, Stanford, California, 94305, United States|National Jewish Medical and Research Center, Denver, Colorado, 80206, United States|Georgetown University Medical Center, Washington, District of Columbia, 20007, United States|Northwestern University, Chicago, Illinois, 60611, United States|University of Chicago, Chicago, Illinois, 60637, United States|Louisiana State University Health Science Center, New Orleans, Louisiana, 70112, United States|John Hopkins University Medical Center, Baltimore, Maryland, 21224, United States|Tufts Medical Center, Boston, Massachusetts, 02111, United States|Boston University Medical School, Boston, Massachusetts, 02118, United States|University of Massachussetts Memorial Medical Center, Worcester, Massachusetts, 01605, United States|University of Michigan-Scleroderma Program, Ann Arbor, Michigan, 48109, United States|Hennepin County Medical Center, Minneapolis, Minnesota, 55415, United States|University of Minnesota, Minneapolis, Minnesota, 55455, United States|University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey, 08903, United States|Center for Rheumatology, Albany, New York, 12206, United States|North Shore Long Island Jewish Medical Center, New Hyde Park, New York, 11040, United States|Hospital for Special Surgery, New York, New York, 10021, United States|Cornell University, New York, New York, 10065, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, 15261, United States|Medical University of South Carolina, Charleston, South Carolina, 29425, United States|The University of Texas Health Science Center, Houston, Texas, 77030, United States|University of Utah, Salt Lake City, Utah, 84132, United States|The Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States"
NCT04667949,Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients,https://beta.clinicaltrials.gov/study/NCT04667949,RECRUITING,Relapsing Multiple Sclerosis (RMS),DRUG: Fingolimod 0.5mg,Novartis Pharmaceuticals,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE4,100,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-02-20,2025-03-28,2025-03-28,"Novartis Investigative Site, Beijing, Beijing, 100000, China|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Guangzhou, Guangdong, 510623, China|Novartis Investigative Site, Guangzhou, Guangdong, 510630, China|Novartis Investigative Site, Zhengzhou, Henan, 450052, China|Novartis Investigative Site, Wuhan, Hubei, 430030, China|Novartis Investigative Site, Suzhou, Jiangsu, 215004, China|Novartis Investigative Site, Changchun, Jilin, 130021, China|Novartis Investigative Site, Chengdu, Sichuan, 610041, China|Novartis Investigative Site, Wenzhou, Zhejiang, 325000, China|Novartis Investigative Site, Beijing, 100028, China|Novartis Investigative Site, Guang Zhou, 510260, China|Novartis Investigative Site, Shanghai, 200040, China"
NCT00794352,Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System,https://beta.clinicaltrials.gov/study/NCT00794352,RECRUITING,Central Nervous System Disease|Multiple Sclerosis,,National Institute of Allergy and Infectious Diseases (NIAID),,ALL,"CHILD, ADULT, OLDER_ADULT",,2400,NIH,OBSERVATIONAL,Observational Model: |Time Perspective: p,2008-10-01,,,"National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States"
NCT05837949,Multiple Sclerosis Falls Insight Track,https://beta.clinicaltrials.gov/study/NCT05837949,RECRUITING,Multiple Sclerosis,BEHAVIORAL: MS FIT: Falls Insight Track,"University of California, San Francisco",National Institutes of Health (NIH)|National Library of Medicine (NLM),ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2023-04-12,2026-04-12,2026-04-12,"University of California, San Francisco, San Francisco, California, 94158, United States"
NCT03652805,A Study of IPL344 in the Treatment of ALS Patients,https://beta.clinicaltrials.gov/study/NCT03652805,UNKNOWN,Amyotrophic Lateral Sclerosis,DRUG: IPL344,Immunity Pharma Ltd.,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,15,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-08-01,2022-07-15,2022-08-15,"Hadassah Medical Center -Motor Neuron Disease Clinic, Jerusalem, Israel"
NCT01730209,Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex,https://beta.clinicaltrials.gov/study/NCT01730209,UNKNOWN,Tuberous Sclerosis Complex|TSC Related Cognitive Disability|TSC Related Autism|TSC Related Learning Problems,DRUG: Everolimus|DRUG: Placebo,Erasmus Medical Center,Utrecht University,ALL,CHILD,PHASE2|PHASE3,60,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-11,2015-11,2016-11,"Erasmus Medical Center, Rotterdam, Netherlands"
NCT02081508,Consolidation & Interference in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02081508,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Interference onset,Kessler Foundation,,ALL,"ADULT, OLDER_ADULT",NA,39,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2014-03,2015-05,2015-05,"Kessler Foundation, West Orange, New Jersey, 07052, United States"
NCT04593927,Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients,https://beta.clinicaltrials.gov/study/NCT04593927,RECRUITING,Secondary Progressive Multiple Sclerosis (SPMS),DRUG: Mayzent,Novartis Pharmaceuticals,,ALL,"CHILD, ADULT, OLDER_ADULT",,330,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-10-28,2025-02-28,2025-02-28,"Novartis Investigative Site, Anjo, Aichi, 446-8602, Japan|Novartis Investigative Site, Hekinan, Aichi, 447-0084, Japan|Novartis Investigative Site, Ichinomiya, Aichi, 491-0041, Japan|Novartis Investigative Site, Kariya, Aichi, 448-0852, Japan|Novartis Investigative Site, Kasugai, Aichi, 487-0031, Japan|Novartis Investigative Site, Nagakute-city, Aichi, 480-1195, Japan|Novartis Investigative Site, Nagoya, Aichi, 451-8511, Japan|Novartis Investigative Site, Nagoya, Aichi, 453-0815, Japan|Novartis Investigative Site, Nagoya, Aichi, 454-0012, Japan|Novartis Investigative Site, Nagoya, Aichi, 455-8530, Japan|Novartis Investigative Site, Nagoya, Aichi, 466 8560, Japan|Novartis Investigative Site, Seto-city, Aichi, 489-8642, Japan|Novartis Investigative Site, Toyoake city, Aichi, 470 1192, Japan|Novartis Investigative Site, Toyohashi, Aichi, 441-8570, Japan|Novartis Investigative Site, Hachinohe, Aomori, 039-1104, Japan|Novartis Investigative Site, Hirosaki, Aomori, 036 8563, Japan|Novartis Investigative Site, Ichihara-city, Chiba, 299-0111, Japan|Novartis Investigative Site, Ichikawa, Chiba, 272-8513, Japan|Novartis Investigative Site, Matsudo-city, Chiba, 270-2251, Japan|Novartis Investigative Site, Narita, Chiba, 286-8523, Japan|Novartis Investigative Site, Urayasu, Chiba, 279-0021, Japan|Novartis Investigative Site, Yachiyo-city, Chiba, 276-8524, Japan|Novartis Investigative Site, Niihama, Ehime, 792-8543, Japan|Novartis Investigative Site, Toon-city, Ehime, 791-0295, Japan|Novartis Investigative Site, Fukuoka city, Fukuoka, 812-8582, Japan|Novartis Investigative Site, Fukuoka city, Fukuoka, 814 0180, Japan|Novartis Investigative Site, Kitakyushu-city, Fukuoka, 802-8517, Japan|Novartis Investigative Site, Kitakyushu-city, Fukuoka, 806-8501, Japan|Novartis Investigative Site, Kitakyushu-city, Fukuoka, 807-8556, Japan|Novartis Investigative Site, Kurume city, Fukuoka, 830-0011, Japan|Novartis Investigative Site, Omuta, Fukuoka, 836-8566, Japan|Novartis Investigative Site, Tagawa, Fukuoka, 825-0004, Japan|Novartis Investigative Site, Fukushima city, Fukushima, 960 1295, Japan|Novartis Investigative Site, Gifu shi, Gifu, 500 8513, Japan|Novartis Investigative Site, Gifu-city, Gifu, 501-1194, Japan|Novartis Investigative Site, Isesaki, Gunma, 372-0817, Japan|Novartis Investigative Site, Maebashi city, Gunma, 371 8511, Japan|Novartis Investigative Site, Maebashi, Gunma, 371-0847, Japan|Novartis Investigative Site, Ota, Gunma, 373-8585, Japan|Novartis Investigative Site, Fukuyama, Hiroshima, 720-0825, Japan|Novartis Investigative Site, Higashihiroshima, Hiroshima, 739-0041, Japan|Novartis Investigative Site, Hiroshima City, Hiroshima, 734-8551, Japan|Novartis Investigative Site, Hiroshima-city, Hiroshima, 730-8518, Japan|Novartis Investigative Site, Hiroshima-city, Hiroshima, 734-8530, Japan|Novartis Investigative Site, Kure-city, Hiroshima, 737-0023, Japan|Novartis Investigative Site, Asahikawa, Hokkaido, 070-8530, Japan|Novartis Investigative Site, Hakodate, Hokkaido, 041-0821, Japan|Novartis Investigative Site, Iwamizawa-city, Hokkaido, 068-0007, Japan|Novartis Investigative Site, Kitami, Hokkaido, 090-0837, Japan|Novartis Investigative Site, Kushiro, Hokkaido, 085-0052, Japan|Novartis Investigative Site, Muroran, Hokkaido, 050-0082, Japan|Novartis Investigative Site, Obihiro, Hokkaido, 080-0024, Japan|Novartis Investigative Site, Rumoi, Hokkaido, 077-0007, Japan|Novartis Investigative Site, Sapporo city, Hokkaido, 060 8648, Japan|Novartis Investigative Site, Sapporo city, Hokkaido, 063-0005, Japan|Novartis Investigative Site, Sapporo-city, Hokkaido, 060-8543, Japan|Novartis Investigative Site, Sapporo, Hokkaido, 060-0807, Japan|Novartis Investigative Site, Sapporo, Hokkaido, 065-0021, Japan|Novartis Investigative Site, Wakkanai, Hokkaido, 097-0022, Japan|Novartis Investigative Site, Ako-city, Hyogo, 678-0239, Japan|Novartis Investigative Site, Awaji, Hyogo, 672-8501, Japan|Novartis Investigative Site, Itami, Hyogo, 664-8533, Japan|Novartis Investigative Site, Kakogawa-shi, Hyogo, 675-8611, Japan|Novartis Investigative Site, Kobe-shi, Hyogo, 650-0017, Japan|Novartis Investigative Site, Kobe, Hyogo, 650-0044, Japan|Novartis Investigative Site, Nishinomiya, Hyogo, 663 8501, Japan|Novartis Investigative Site, Toyooka, Hyogo, 668-8501, Japan|Novartis Investigative Site, Hitachi-city, Ibaraki, 317-0077, Japan|Novartis Investigative Site, Hitachinaka, Ibaraki, 312-0057, Japan|Novartis Investigative Site, Toride-city, Ibaraki, 302-0022, Japan|Novartis Investigative Site, Tsuchiura, Ibaraki, 300-0028, Japan|Novartis Investigative Site, Tsukuba city, Ibaraki, 305-8576, Japan|Novartis Investigative Site, Tsukuba, Ibaraki, 305-8558, Japan|Novartis Investigative Site, Kanazawa, Ishikawa, 920-0853, Japan|Novartis Investigative Site, Hanamaki, Iwate, 025-0082, Japan|Novartis Investigative Site, Ichinoseki, Iwate, 021-0871, Japan|Novartis Investigative Site, Kita-gun, Kagawa, 761-0793, Japan|Novartis Investigative Site, Takamatsu city, Kagawa, 760 8557, Japan|Novartis Investigative Site, Kagoshima city, Kagoshima, 890 8520, Japan|Novartis Investigative Site, Oshima, Kagoshima, 891-7101, Japan|Novartis Investigative Site, Satsuma Sendai, Kagoshima, 895-0061, Japan|Novartis Investigative Site, Ashigarakami, Kanagawa, 258-0003, Japan|Novartis Investigative Site, Atsugi-city, Kanagawa, 243-0121, Japan|Novartis Investigative Site, Hiratsuka, Kanagawa, 254-0065, Japan|Novartis Investigative Site, Isehara, Kanagawa, 259-1193, Japan|Novartis Investigative Site, Kawasaki-city, Kanagawa, 216-8511, Japan|Novartis Investigative Site, Naka-gun, Kanagawa, 259-0198, Japan|Novartis Investigative Site, Sagamihara-city, Kanagawa, 252-0375, Japan|Novartis Investigative Site, Yokohama city, Kanagawa, 232 0024, Japan|Novartis Investigative Site, Yokohama-city, Kanagawa, 227-8501, Japan|Novartis Investigative Site, Yokohama-city, Kanagawa, 236 0037, Japan|Novartis Investigative Site, Yokohama-city, Kanagawa, 236-0004, Japan|Novartis Investigative Site, Yokohama, Kanagawa, 221-0821, Japan|Novartis Investigative Site, Yokohama, Kanagawa, 245-8575, Japan|Novartis Investigative Site, Yokosuka-city, Kanagawa, 238-8558, Japan|Novartis Investigative Site, Nankoku city, Kochi, 783 8505, Japan|Novartis Investigative Site, Kumamoto City, Kumamoto, 860-8556, Japan|Novartis Investigative Site, Kyoto-city, Kyoto, 616-8255, Japan|Novartis Investigative Site, Suzuka, Mie, 513-8505, Japan|Novartis Investigative Site, Tsu-city, Mie, 514-8507, Japan|Novartis Investigative Site, Kesennuma, Miyagi, 988-0085, Japan|Novartis Investigative Site, Sendai city, Miyagi, 980 8574, Japan|Novartis Investigative Site, Miyakonojo, Miyazaki, 885-0055, Japan|Novartis Investigative Site, Chiisagata, Nagano, 386-0603, Japan|Novartis Investigative Site, Iida, Nagano, 395-8502, Japan|Novartis Investigative Site, Ina, Nagano, 396-0033, Japan|Novartis Investigative Site, Kitaazumi, Nagano, 399-8601, Japan|Novartis Investigative Site, Matsumoto-city, Nagano, 390-8621, Japan|Novartis Investigative Site, Matsumoto, Nagano, 390-8648, Japan|Novartis Investigative Site, Nagano-city, Nagano, 380-8582, Japan|Novartis Investigative Site, Saku, Nagano, 384-0301, Japan|Novartis Investigative Site, Suwa, Nagano, 392-8510, Japan|Novartis Investigative Site, Ueda-city, Nagano, 386-8610, Japan|Novartis Investigative Site, Iki-city, Nagasaki, 811-5135, Japan|Novartis Investigative Site, Sasebo, Nagasaki, 857-8511, Japan|Novartis Investigative Site, Ikoma, Nara, 630-0243, Japan|Novartis Investigative Site, Kashihara city, Nara, 634 8522, Japan|Novartis Investigative Site, Tenri, Nara, 632-8552, Japan|Novartis Investigative Site, Nagaoka, Niigata, 940-2085, Japan|Novartis Investigative Site, Nagaoka, Niigata, 940-8653, Japan|Novartis Investigative Site, Niigata-city, Niigata, 950-1197, Japan|Novartis Investigative Site, Shibata, Niigata, 957-8588, Japan|Novartis Investigative Site, Tsubame, Niigata, 959-1228, Japan|Novartis Investigative Site, Tsubame, Niigata, 959-1284, Japan|Novartis Investigative Site, Beppu, Oita, 874-0011, Japan|Novartis Investigative Site, Oita-city, Oita, 870-0192, Japan|Novartis Investigative Site, Usa, Oita, 879-0231, Japan|Novartis Investigative Site, Yufu, Oita, 879-5593, Japan|Novartis Investigative Site, Okayama-city, Okayama, 700-8558, Japan|Novartis Investigative Site, Okayama-city, Okayama, 700-8607, Japan|Novartis Investigative Site, Tsuyama, Okayama, 708-0841, Japan|Novartis Investigative Site, Ginowan, Okinawa, 901-2214, Japan|Novartis Investigative Site, Fujiidera, Osaka, 583-0014, Japan|Novartis Investigative Site, Higashiosaka, Osaka, 578-8588, Japan|Novartis Investigative Site, Osaka Sayama, Osaka, 589 8511, Japan|Novartis Investigative Site, Osaka-city, Osaka, 543-8555, Japan|Novartis Investigative Site, Sakai-city, Osaka, 593-8304, Japan|Novartis Investigative Site, Sakai, Osaka, 592-8555, Japan|Novartis Investigative Site, Suita, Osaka, 565 0871, Japan|Novartis Investigative Site, Takatsuki-city, Osaka, 569-8686, Japan|Novartis Investigative Site, Saga-city, Saga, 849-8501, Japan|Novartis Investigative Site, Ageo-city, Saitama, 362-8588, Japan|Novartis Investigative Site, Iruma-gun, Saitama, 350-0495, Japan|Novartis Investigative Site, Kawagoe, Saitama, 350 8550, Japan|Novartis Investigative Site, Koshigaya-city, Saitama, 343-8555, Japan|Novartis Investigative Site, Koshigaya, Saitama, 343-8577, Japan|Novartis Investigative Site, Tokorozawa city, Saitama, 359 8513, Japan|Novartis Investigative Site, Wako-city, Saitama, 351-0102, Japan|Novartis Investigative Site, Ohtsu-city, Shiga, 520-2192, Japan|Novartis Investigative Site, Omihachiman, Shiga, 523-0082, Japan|Novartis Investigative Site, Izumo-city, Shimane, 693 8501, Japan|Novartis Investigative Site, Fuji city, Shizuoka, 416-0955, Japan|Novartis Investigative Site, Hamamatsu-city, Shizuoka, 431-3192, Japan|Novartis Investigative Site, Izunokuni, Shizuoka, 410-2295, Japan|Novartis Investigative Site, Nasushiobara, Tochigi, 329-2763, Japan|Novartis Investigative Site, Oyama, Tochigi, 323-0827, Japan|Novartis Investigative Site, Sano, Tochigi, 327-8511, Japan|Novartis Investigative Site, Shimotsuga Gun, Tochigi, 321-0293, Japan|Novartis Investigative Site, Shimotsuke, Tochigi, 329-0498, Japan|Novartis Investigative Site, Adachi-ku, Tokyo, 121-0061, Japan|Novartis Investigative Site, Adachi, Tokyo, 123-0864, Japan|Novartis Investigative Site, Bunkyo ku, Tokyo, 113 8655, Japan|Novartis Investigative Site, Bunkyo ku, Tokyo, 113-8431, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, 113-8519, Japan|Novartis Investigative Site, Edogawa, Tokyo, 134-0086, Japan|Novartis Investigative Site, Fuchu, Tokyo, 183-0042, Japan|Novartis Investigative Site, Fuchu, Tokyo, 183-8524, Japan|Novartis Investigative Site, Hachioji-city, Tokyo, 192-0032, Japan|Novartis Investigative Site, Hachioji-city, Tokyo, 193-0944, Japan|Novartis Investigative Site, Itabashi ku, Tokyo, 173 8606, Japan|Novartis Investigative Site, Kodaira, Tokyo, 187-8551, Japan|Novartis Investigative Site, Meguro, Tokyo, 153-8515, Japan|Novartis Investigative Site, Minato-ku, Tokyo, 108-8329, Japan|Novartis Investigative Site, Nakano, Tokyo, 164-8607, Japan|Novartis Investigative Site, Nerima-ku, Tokyo, 113-0033, Japan|Novartis Investigative Site, Ota-ku, Tokyo, 143 8541, Japan|Novartis Investigative Site, Ota-ku, Tokyo, 145-0065, Japan|Novartis Investigative Site, Ota, Tokyo, 146-0092, Japan|Novartis Investigative Site, Shinagawa-ku, Tokyo, 142-8666, Japan|Novartis Investigative Site, Shinjuku ku, Tokyo, 162 8666, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, 160 8582, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, 160-0023, Japan|Novartis Investigative Site, Suginami, Tokyo, 166-0001, Japan|Novartis Investigative Site, Sumida-ku, Tokyo, 130-8575, Japan|Novartis Investigative Site, Kurayoshi, Tottori, 682-0863, Japan|Novartis Investigative Site, Toyama-city, Toyama, 930-0194, Japan|Novartis Investigative Site, Sakata-city, Yamagata, 998-8501, Japan|Novartis Investigative Site, Hofu, Yamaguchi, 747-8511, Japan|Novartis Investigative Site, Shimonoseki, Yamaguchi, 750-0061, Japan|Novartis Investigative Site, Shunan-city, Yamaguchi, 745-8522, Japan|Novartis Investigative Site, Ube, Yamaguchi, 755-8505, Japan|Novartis Investigative Site, Akita, 010-1495, Japan|Novartis Investigative Site, Aomori, 030 8553, Japan|Novartis Investigative Site, Chiba, 260 8677, Japan|Novartis Investigative Site, Fukui, 918-8501, Japan|Novartis Investigative Site, Fukui, 918-8503, Japan|Novartis Investigative Site, Fukuoka, 810-0022, Japan|Novartis Investigative Site, Gifu, 500-8717, Japan|Novartis Investigative Site, Gifu, 501-3144, Japan|Novartis Investigative Site, Hiroshima, 730-0004, Japan|Novartis Investigative Site, Hiroshima, 731-3168, Japan|Novartis Investigative Site, Kagoshima, 890-0008, Japan|Novartis Investigative Site, Kagoshima, 890-0067, Japan|Novartis Investigative Site, Kagoshima, 890-8760, Japan|Novartis Investigative Site, Kochi, 781-0011, Japan|Novartis Investigative Site, Kumamoto, 862-0970, Japan|Novartis Investigative Site, Kyoto, 603-8041, Japan|Novartis Investigative Site, Kyoto, 616-8144, Japan|Novartis Investigative Site, Nagasaki, 850-0835, Japan|Novartis Investigative Site, Nagasaki, 850-8555, Japan|Novartis Investigative Site, Niigata, 951 8520, Japan|Novartis Investigative Site, Oita, 870-8511, Japan|Novartis Investigative Site, Okayama, 700-8557, Japan|Novartis Investigative Site, Osaka, 545-8586, Japan|Novartis Investigative Site, Osaka, 556-0016, Japan|Novartis Investigative Site, Saga, 840-8571, Japan|Novartis Investigative Site, Saitama, 330 8503, Japan|Novartis Investigative Site, Shizuoka, 420-0853, Japan|Novartis Investigative Site, Tokushima, 770-0852, Japan|Novartis Investigative Site, Tokushima, 770-8503, Japan|Novartis Investigative Site, Yamagata, 990 9585, Japan"
NCT03436927,Comparison of Two Different Virtual Reality Methods in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03436927,COMPLETED,Multiple Sclerosis,OTHER: Nintendo Wii Fit Balance exercises|OTHER: Balance Trainer Balance Exercises,Biruni University,Istanbul University,ALL,ADULT,NA,51,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-07-15,2017-07-15,2017-07-15,
NCT03302806,Study to Assess Effect and Safety of High Dose of Biotin (Qizenday®) in Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03302806,COMPLETED,Progressive Multiple Sclerosis,OTHER: Non interventional Study,Nantes University Hospital,,ALL,"ADULT, OLDER_ADULT",,103,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-06-29,2017-10-04,2018-10-24,"Nantes University Hospital, Nantes, 44093, France"
NCT01074827,Improving Gait in Multiple Sclerosis (MS) - Strength Training or Treadmill Walking?,https://beta.clinicaltrials.gov/study/NCT01074827,COMPLETED,Multiple Sclerosis,OTHER: Strength training and treadmill training,St. Olavs Hospital,Norwegian University of Science and Technology|Helse Midt-Norge,ALL,"ADULT, OLDER_ADULT",NA,28,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2010-03,2011-04,2011-04,"St. Olavs Hospital, Trondheim, 7006, Norway"
NCT02193906,Neuropsychological Profile of a Patient's Group With Multiple Sclerosis and Effect of a Cognitive Rehabilitation Program,https://beta.clinicaltrials.gov/study/NCT02193906,UNKNOWN,Cognitive Dysfunction,OTHER: Cognitive training|OTHER: Placebo task,Aveiro University,,ALL,"ADULT, OLDER_ADULT",NA,75,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2012-12,2013-06,2014-12,
NCT00451204,A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS),https://beta.clinicaltrials.gov/study/NCT00451204,COMPLETED,Relapsing Remitting Multiple Sclerosis,DRUG: Estriol|DRUG: Placebo|DRUG: Copaxone,"University of California, Los Angeles","Washington University School of Medicine|University of Texas Southwestern Medical Center|Ohio State University|University of Medicine and Dentistry of New Jersey|University of Chicago|University of Utah|Johns Hopkins University|University of Kansas Medical Center|University of Minnesota|Mayo Clinic|University of Colorado, Denver|University of New Mexico|University of Pennsylvania|Dartmouth-Hitchcock Medical Center|National Multiple Sclerosis Society|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS)",FEMALE,ADULT,PHASE2,158,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2007-03,2014-07,2014-07,"Mayo Clinic, Scottsdale, Arizona, 85259, United States|University of California, Los Angeles, Los Angeles, California, 90095, United States|University of Colorado, Aurora, Colorado, 80045, United States|University of Chicago, Chicago, Illinois, 60637, United States|University of Kansas, Kansas City, Kansas, 66160, United States|Johns Hopkins University, Baltimore, Maryland, 21287-6965, United States|University of Minnesota, Minneapolis, Minnesota, 55455, United States|Washington University, Saint Louis, Missouri, 63110, United States|Dartmouth Medical School, Lebanon, New Hampshire, 03765, United States|UMDNJ-Robert Wood Johnson Medical Center, New Brunswick, New Jersey, 08901, United States|University of New Mexico, Albuquerque, New Mexico, 87131, United States|Ohio State University, Columbus, Ohio, 43221, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|University of Texas Southwestern, Dallas, Texas, 75390-8575, United States|Western Institute for Biomedical Research, Salt Lake City, Utah, 84158, United States|Montreal Neurological Institute, Montreal, Canada"
NCT03456206,"Chronic Inflammatory Disease, Lifestyle and Risk of Disease",https://beta.clinicaltrials.gov/study/NCT03456206,UNKNOWN,"Autoimmune Diseases|Inflammatory Bowel Diseases|Crohn Disease (CD)|Ulcerative Colitis (UC)|Arthritis, Rheumatoid (RA)|Spondylarthropathies|Arthritis, Psoriatic (PsA)|Psoriasis (PsO)|Multiple Sclerosis (MS)",OTHER: Intake of red and processed meat and fibres|OTHER: Lifestyle factors independently or combined,University of Southern Denmark,Hospital of Southern Jutland|Odense Patient Data Explorative Network|University of Aarhus|Danish Cancer Society,ALL,ADULT,,57053,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-11-10,2020-09-01,2023-05-01,"University of Southern Denmark, Odense, 5230, Denmark"
NCT03889327,Intervention to Reduce Perceived Cognitive Impairment in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03889327,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Neuropsychological Feedback & Psychoeducation (Cognition)|BEHAVIORAL: Psychoeducation (Health),"University of Missouri, Kansas City",University of Kansas,ALL,"ADULT, OLDER_ADULT",NA,51,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-03-26,2019-08-15,2019-09-01,"University of Kansas Department of Neurology, Kansas City, Kansas, 66160, United States"
NCT03135327,Clinical Applications of Advanced Ophthalmic Imaging,https://beta.clinicaltrials.gov/study/NCT03135327,RECRUITING,Multiple Sclerosis|Dry Eye Syndromes|Diabetic Retinopathy|Presbyopia|Myopia|Dementia,DIETARY_SUPPLEMENT: Ocufolin,University of Miami,,ALL,"ADULT, OLDER_ADULT",NA,5000,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2007-01-01,2025-12-31,2025-12-31,"Bascom Palmer Eye Institute, Miami, Florida, 33136, United States"
NCT02836327,Multimodel Magnetic Resonance Imaging (MRI)of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders,https://beta.clinicaltrials.gov/study/NCT02836327,UNKNOWN,Multiple Sclerosis|Neuromyelitis Optica Spectrum Disorders,OTHER: Magnetic Resonance Imaging,Chinese PLA General Hospital,,ALL,ADULT,,300,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-09,2019-09,2021-09,"Chinese PLA General Hospital, Beijing, Beijing, 100853, China"
NCT02702804,High Intensity Interval Training for People With Mild Multiple Sclerosis: A Feasibility Study,https://beta.clinicaltrials.gov/study/NCT02702804,COMPLETED,Multiple Sclerosis,OTHER: High Intensity Interval Training,Sheffield Teaching Hospitals NHS Foundation Trust,Sheffield Hallam University,ALL,"ADULT, OLDER_ADULT",NA,11,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-04-21,2017-11,2017-11-08,"Sheffield Hallam University, Sheffield, South Yorkshire, S10 2BP, United Kingdom|Royal Hallamshire Hospital, Sheffield, S10 2JF, United Kingdom"
NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),https://beta.clinicaltrials.gov/study/NCT04410991,ACTIVE_NOT_RECRUITING,Relapsing Multiple Sclerosis,DRUG: Tolebrutinib|DRUG: Teriflunomide HMR1726|DRUG: Placebo to match Tolebrutinib|DRUG: Placebo to match Teriflunomide,Sanofi,,ALL,ADULT,PHASE3,900,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-06-11,2023-08,2023-08,"North Central Neurology Associates, PC-Site Number:8400009, Cullman, Alabama, 35058, United States|Center for Neurology and Spine-Site Number:8400089, Phoenix, Arizona, 84018, United States|Arcadia Neurology Center-Site Number:8400070, Arcadia, California, 91006, United States|Multiple Sclerosis Center of California-Site Number:8400135, Newport Beach, California, 92663, United States|Harbor UCLA-Site Number:8400088, Torrance, California, 90502, United States|Mountain Neurological Research Center, Inc.-Site Number:8400128, Basalt, Colorado, 81621, United States|Advanced Neurosciences Research-Site Number:8400025, Fort Collins, Colorado, 80528, United States|South Florida Neurology Associates-Site Number:8400029, Boca Raton, Florida, 33487, United States|University of Florida Health-Site Number:8400159, Gainesville, Florida, 32608, United States|Neurology Associates, PA-Site Number:8400004, Maitland, Florida, 32761, United States|University of Miami-Site Number:8400063, Miami, Florida, 33136, United States|Infinity Clinical Research-Site Number:8400008, Sunrise, Florida, 33351, United States|University of South Florida-Site Number:8400006, Tampa, Florida, 33612, United States|Meridian Clinical Research-Site Number:8400003, Savannah, Georgia, 31406, United States|Consultants In Neurology-Site Number:8400011, Northbrook, Illinois, 60062, United States|Prairie Education and Research Cooperative-Site Number:8400071, Springfield, Illinois, 62701, United States|Fort Wayne Neurological Center-Site Number:8400039, Fort Wayne, Indiana, 46804, United States|CHI Saint Joseph Medical Group Neurology-Site Number:8400110, Lexington, Kentucky, 40509, United States|University of Kentucky-Site Number:8400106, Lexington, Kentucky, 40536, United States|Norton Neurology MS Services-Site Number:8400127, Louisville, Kentucky, 40207, United States|The NeuroMedical Center-Site Number:8400057, Baton Rouge, Louisiana, 70810, United States|International Neurorehabilitation Institute-Site Number:8400034, Lutherville-Timonium, Maryland, 21093, United States|Wayne State University-Site Number:8400046, Detroit, Michigan, 48201, United States|Minneapolis Clinic of Neurology-Site Number:8400051, Minneapolis, Minnesota, 55422, United States|Saint Luke's Hospital-Site Number:8400153, Kansas City, Missouri, 64111, United States|West Omaha Family Physicians-Site Number:8400139, Omaha, Nebraska, 68130, United States|University Of Nebraska-Site Number:8400129, Omaha, Nebraska, 68198, United States|Hackensack University Hospital-Site Number:8400047, Hackensack, New Jersey, 07601, United States|University of New Mexico-Site Number:8400032, Albuquerque, New Mexico, 87131, United States|South Shore Neurologic Associates-Site Number:8400100, Patchogue, New York, 11772, United States|Novant Health Multiple Sclerosis Care Center - South Park-Site Number:8400120, Charlotte, North Carolina, 28210, United States|Meridian Clinical Research, LLC-Site Number:8400005, Raleigh, North Carolina, 27607, United States|Sanford Brain & Spine Center-Site Number:8400126, Fargo, North Dakota, 58103, United States|Dayton Center for Neurological Disorders-Site Number:8400081, Centerville, Ohio, 45459, United States|Jefferson Neurology Associates-Site Number:8400016, Philadelphia, Pennsylvania, 19107, United States|Premier Neurology-Site Number:8400069, Greer, South Carolina, 29650, United States|Advanced Neuroscience Center-Site Number:8400035, Franklin, Tennessee, 37064, United States|Sibyl Wray, MD, Neurology, PC-Site Number:8400007, Knoxville, Tennessee, 37922, United States|Mt Olympus Medical Research-Site Number:8400163, Katy, Texas, 77450, United States|Neurology Center of San Antonio-Site Number:8400036, San Antonio, Texas, 78258, United States|Texas Institute for Neuroogical Disorders-Sherman-Site Number:8400151, Sherman, Texas, 75092, United States|Neurological Associates-Site Number:8400097, Richmond, Virginia, 23229, United States|Wheaton Franciscan Healthcare-Site Number:8400022, Milwaukee, Wisconsin, 53215, United States|Investigational Site Number :0320004, Caba, Buenos Aires, C1023AAB, Argentina|Investigational Site Number :0320002, Capital Federal, Buenos Aires, 1012, Argentina|Investigational Site Number :0320001, Caba, Ciudad De Buenos Aires, C1061, Argentina|Investigational Site Number :0320003, Rosario, Santa Fe, 2000, Argentina|Investigational Site Number :0320005, San Miguel de Tucuman, T4000AXL, Argentina|Investigational Site Number :0560005, Brugge, B-8000, Belgium|Investigational Site Number :0560004, Gent, 9000, Belgium|Investigational Site Number :0560002, Mons, 7000, Belgium|Investigational Site Number :0560001, Pelt, 3900, Belgium|Investigational Site Number :0760001, Porto Alegre, Rio Grande Do Sul, 90610-000, Brazil|Investigational Site Number :0760002, Curitiba, 81210-310, Brazil|Investigational Site Number :0760007, Sao Paulo, 01228-000, Brazil|Investigational Site Number :1240002, Edmonton, Alberta, T6G 2C8, Canada|Investigational Site Number :1240014, London, Ontario, N6A 5A5, Canada|Investigational Site Number :1240005, Greenfield Park, Quebec, J4V 2J2, Canada|Investigational Site Number :1240006, Gatineau, J8Y1W2, Canada|Investigational Site Number :1240021, Quebec, G1W 4R4, Canada|Investigational Site Number :1520002, Santiago, Reg Metropolitana De Santiago, 7650568, Chile|Investigational Site Number :1520005, Santiago, Reg Metropolitana De Santiago, 833-0024, Chile|Investigational Site Number :1520001, Santiago, Reg Metropolitana De Santiago, 8380456, Chile|Investigational Site Number :1520003, Santiago, Reg Metropolitana De Santiago, 8431657, Chile|Investigational Site Number :1520006, Concepción, Chile|Investigational Site Number :1520004, Valdivia, 5110683, Chile|Investigational Site Number :1910001, Zagreb, 10000, Croatia|Investigational Site Number :1910002, Zagreb, 10000, Croatia|Investigational Site Number :1910003, Zagreb, 10000, Croatia|Investigational Site Number :2030002, Brno, 65691, Czechia|Investigational Site Number :2030011, Hradec Kralove, 50005, Czechia|Investigational Site Number :2030001, Jihlava, 58633, Czechia|Investigational Site Number :2030008, Praha 10, 10034, Czechia|Investigational Site Number :2030005, Praha 5 - Motol, 15006, Czechia|Investigational Site Number :2500019, Besancon, 25000, France|Investigational Site Number :2500018, Bordeaux, France|Investigational Site Number :2500011, Bron, 69500, France|Investigational Site Number :2500005, Clermont Ferrand, 63003, France|Investigational Site Number :2500006, Montpellier, 34295, France|Investigational Site Number :2500010, Nantes, 44093, France|Investigational Site Number :2500002, Nice, 06002, France|Investigational Site Number :2500017, Nimes, 30029, France|Investigational Site Number :2500007, Paris, 75019, France|Investigational Site Number :2500004, Poissy, 78300, France|Investigational Site Number :2500003, Rennes, 35033, France|Investigational Site Number :2500001, Strasbourg, 67098, France|Investigational Site Number :2760005, Bayreuth, 95445, Germany|Investigational Site Number :2760015, Berlin, 10713, Germany|Investigational Site Number :2760014, Berlin, 12099, Germany|Investigational Site Number :2760020, Bochum, 44791, Germany|Investigational Site Number :2760012, Essen, 45147, Germany|Investigational Site Number :2760003, Würzburg, 97070, Germany|Investigational Site Number :3000001, Athens, 115 28, Greece|Investigational Site Number :3000006, Athens, 11535, Greece|Investigational Site Number :3000002, Athens, 12462, Greece|Investigational Site Number :3000007, Athens, 15125, Greece|Investigational Site Number :3000009, Athens, Greece|Investigational Site Number :3000004, Larissa, 41110, Greece|Investigational Site Number :3000003, Thessaloniki, 546 36, Greece|Investigational Site Number :3480105, Budapest, 1135, Hungary|Investigational Site Number :3480102, Budapest, 1145, Hungary|Investigational Site Number :3480106, Kaposvár, 7400, Hungary|Investigational Site Number :3480103, Tatabánya, 2800, Hungary|Investigational Site Number :3560005, Chandigarh, 160012, India|Investigational Site Number :3560007, Gurgaon, 122001, India|Investigational Site Number :3560008, Gurgaon, 122002, India|Investigational Site Number :3560002, New Delhi, 110060, India|Investigational Site Number :3560004, Thiruvananthapuram, 695004, India|Investigational Site Number :3760002, Ashkelon, 78278, Israel|Investigational Site Number :3760003, Haifa, 31096, Israel|Investigational Site Number :3760006, Rehovot, 76100, Israel|Investigational Site Number :3760004, Safed, 13100, Israel|Investigational Site Number :3760001, Tel HaShomer, 52621, Israel|Investigational Site Number :4100001, Goyang-si, Gyeonggi-do, 10408, Korea, Republic of|Investigational Site Number :4100003, Seoul, Seoul-teukbyeolsi, 03080, Korea, Republic of|Investigational Site Number :4100006, Seoul, Seoul-teukbyeolsi, 03722, Korea, Republic of|Investigational Site Number :4100002, Seoul, Seoul-teukbyeolsi, 06351, Korea, Republic of|Investigational Site Number :4280002, Riga, LV-1002, Latvia|Investigational Site Number :4280003, Riga, LV-1005, Latvia|Investigational Site Number :5280001, Amsterdam, 1081 GN, Netherlands|Investigational Site Number :5780002, Namsos, 7800, Norway|Investigational Site Number :5780001, Oslo, 0450, Norway|Investigational Site Number :6200001, Braga, 4710-243, Portugal|Investigational Site Number :6200005, Coimbra, 3000-075, Portugal|Investigational Site Number :6200011, Lisboa, 1162-050, Portugal|Investigational Site Number :6200006, Lisboa, 1649-035, Portugal|Investigational Site Number :6200002, Matosinhos, 4464-513, Portugal|Investigational Site Number :6200010, Porto, 4099-001, Portugal|Investigational Site Number :6200004, Santa Maria da Feira, 4520-211, Portugal|San Juan MS Center-Site Number:8400015, Guaynabo, 00969, Puerto Rico|Investigational Site Number :6430006, Barnaul, 656024, Russian Federation|Investigational Site Number :6430013, Bryansk, 241033, Russian Federation|Investigational Site Number :6430012, Ekaterinburg, 620102, Russian Federation|Investigational Site Number :6430001, Kazan, 420021, Russian Federation|Investigational Site Number :6430010, Kirov, 610998, Russian Federation|Investigational Site Number :6430007, Moscow, 117997, Russian Federation|Investigational Site Number :6430005, Moscow, 127015, Russian Federation|Investigational Site Number :6430003, Novosibirsk, 630087, Russian Federation|Investigational Site Number :6430014, Saint-Petersburg, 192242, Russian Federation|Investigational Site Number :6430002, Saint-Petersburg, 197110, Russian Federation|Investigational Site Number :6430011, Saransk, 430032, Russian Federation|Investigational Site Number :6430004, St-Petersburg, 197022, Russian Federation|Investigational Site Number :6880001, Belgrade, 11000, Serbia|Investigational Site Number :6880003, Belgrade, 11000, Serbia|Investigational Site Number :6880006, Belgrade, 11000, Serbia|Investigational Site Number :6880002, Kragujevac, 34000, Serbia|Investigational Site Number :6880004, Nis, 18000, Serbia|Investigational Site Number :6880005, Novi Sad, 21000, Serbia|Investigational Site Number :7030001, Bratislava, 82606, Slovakia|Investigational Site Number :7030002, Martin, 03659, Slovakia|Investigational Site Number :7030004, Nitra, 950 01, Slovakia|Investigational Site Number :7240011, Sevilla, Andalucia, 41009, Spain|Investigational Site Number :7240006, Barcelona, Barcelona [Barcelona], 08036, Spain|Investigational Site Number :7240009, Barakaldo, Bizkaia, 48903, Spain|Investigational Site Number :7240004, Salt, Girona [Gerona], 17190, Spain|Investigational Site Number :7240013, Las Palmas de Gran Canaria, Las Palmas, 35010, Spain|Investigational Site Number :7240007, Hospitalet de Llobregat, 08907, Spain|Investigational Site Number :7240008, La Coruña, 15006, Spain|Investigational Site Number :7240005, Lleida, 25198, Spain|Investigational Site Number :7240003, Madrid, 28007, Spain|Investigational Site Number :7240001, Madrid, 28034, Spain|Investigational Site Number :7240002, Madrid, 28040, Spain|Investigational Site Number :7240010, Málaga, 29010, Spain|Investigational Site Number :7240012, Pozuelo De Alarcón, 28223, Spain|Investigational Site Number :7560003, Aarau, 5001, Switzerland|Investigational Site Number :7560002, Bern, 3010, Switzerland|Investigational Site Number :7560004, Lugano, 6903, Switzerland|Investigational Site Number :7920002, Ankara, 06100, Turkey|Investigational Site Number :7920005, Besevler / Ankara, 06500, Turkey|Investigational Site Number :7920006, Istanbul, 34896, Turkey|Investigational Site Number :7920004, Kuttahta, 43100, Turkey|Investigational Site Number :7920001, Samsun, Turkey|Investigational Site Number :7920003, Trabzon, 61080, Turkey|Investigational Site Number :8040020, Chernihiv, 14029, Ukraine|Investigational Site Number :8040002, Chernivtsi, 58000, Ukraine|Investigational Site Number :8040019, Chernivtsi, 58023, Ukraine|Investigational Site Number :8040005, Dnipro, 49005, Ukraine|Investigational Site Number :8040022, Kharkiv, 61103, Ukraine|Investigational Site Number :8040018, Kharkiv, 61166, Ukraine|Investigational Site Number :8040007, Kyiv, 02091, Ukraine|Investigational Site Number :8040006, Lviv, 79013, Ukraine|Investigational Site Number :8040003, Vinnytsia, 21050, Ukraine|Investigational Site Number :8260003, Exeter, Devon, EX2 5DW, United Kingdom|Investigational Site Number :8260016, Canterbury, Kent, CT1 3NG, United Kingdom|Investigational Site Number :8260009, Bristol, BS10 5NB, United Kingdom"
NCT03996291,Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03996291,ACTIVE_NOT_RECRUITING,Relapsing Multiple Sclerosis,DRUG: Tolebrutinib,Sanofi,,ALL,ADULT,PHASE2,125,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2019-09-23,2024-11-29,2024-11-29,"Investigational Site Number 8400005, Cullman, Alabama, 35058, United States|Investigational Site Number 8400002, Maitland, Florida, 32761, United States|Investigational Site Number 8400009, Tampa, Florida, 33612, United States|Investigational Site Number 8400007, Savannah, Georgia, 31406, United States|Investigational Site Number 8400001, Northbrook, Illinois, 60062, United States|Investigational Site Number 8400008, Dayton, Ohio, 45417, United States|Investigational Site Number 8400006, Westerville, Ohio, 43081, United States|Investigational Site Number 8400003, Knoxville, Tennessee, 37922, United States|Investigational Site Number 1240001, Greenfield Park, J4V 2J2, Canada|Investigational Site Number 1240003, Vancouver, V6T 2B5, Canada|Investigational Site Number 2030007, Brno, 62500, Czechia|Investigational Site Number 2030004, Hradec Kralove, 50005, Czechia|Investigational Site Number 2030003, Jihlava, 58633, Czechia|Investigational Site Number 2030005, Ostrava - Poruba, 70852, Czechia|Investigational Site Number 2030006, Pardubice, 53203, Czechia|Investigational Site Number 2030001, Praha 2, 12808, Czechia|Investigational Site Number 2030002, Praha 5 - Motol, 15006, Czechia|Investigational Site Number 2330001, Tallinn, 11315, Estonia|Investigational Site Number 2500004, Nancy Cedex, 54035, France|Investigational Site Number 5280001, Amsterdam, 1081 HV, Netherlands|Investigational Site Number 6430006, Kazan, 420021, Russian Federation|Investigational Site Number 6430003, Moscow, 125367, Russian Federation|Investigational Site Number 6430001, Saint-Petersburg, 197110, Russian Federation|Investigational Site Number 6430005, St-Petersburg, 194044, Russian Federation|Investigational Site Number 6430007, Tyumen, 625000, Russian Federation|Investigational Site Number 7240002, Barcelona, 08035, Spain|Investigational Site Number 7240001, Madrid, 28007, Spain|Investigational Site Number 7240004, Murcia, 30120, Spain|Investigational Site Number 7240005, Salt, 17190, Spain|Investigational Site Number 7240003, Sevilla, 41071, Spain|Investigational Site Number 8040002, Chernivtsi, 58018, Ukraine|Investigational Site Number 8040005, Dnipro, 49005, Ukraine|Investigational Site Number 8040001, Lviv, 79010, Ukraine|Investigational Site Number 8040006, Lviv, 79013, Ukraine|Investigational Site Number 8040009, Odesa, 65025, Ukraine|Investigational Site Number 8040003, Vinnytsya, 21005, Ukraine|Investigational Site Number 8040007, Zhytomyr, 10002, Ukraine"
NCT02457091,Project Get Fit With MS: Guidelines for Exercise Training and Fitness Outcomes in MS,https://beta.clinicaltrials.gov/study/NCT02457091,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Resistance exercise|BEHAVIORAL: Stretching exercise,University of Illinois at Urbana-Champaign,,ALL,ADULT,PHASE2,32,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2013-10,2014-09,2014-12,"University of Illinois at Urbana-Champaign, Urbana-Champaign, Illinois, 61801, United States"
NCT02493491,Neurogenic Dysphonia/Dysphagia Registry,https://beta.clinicaltrials.gov/study/NCT02493491,TERMINATED,Neurogenic Dysphonia|Neurogenic Dysphagia,,"Merz North America, Inc.",HealthCore-NERI|Cmed Clinical Services,ALL,"ADULT, OLDER_ADULT",,146,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-06,2016-08,2016-09,"Merz Clinical Site, LaJolla, California, 92037, United States|Merz Clinical Site, Sacramento, California, 95817, United States|Merz Clinical Site, Augusta, Georgia, 30912, United States|Merz Clinical Site, Boston, Massachusetts, 02115, United States|Merz Clinical Site, Burlington, Massachusetts, 01805, United States|Merz Clinical Site 0010334, New York, New York, 10016, United States|Merz Clinical Site 0010068, New York, New York, 10019, United States|Merz Clinical Site 0010333, Sleepy Hollow, New York, 10591, United States|Merz Clinical Site, Durham, North Carolina, 27710, United States|Merz Clinical Site 0010332, Pittsburgh, Pennsylvania, 15219, United States|Merz Clinical Site, Houston, Texas, 77030, United States|Merz Clinical Site, Norfolk, Virginia, 23507, United States"
NCT04759391,Effects of Digital Pelvic Floor Muscle Training in Patients With Multiple Sclerosis Having Lower Urinary Tract Symptoms,https://beta.clinicaltrials.gov/study/NCT04759391,UNKNOWN,Lower Urinary Tract Symptoms,OTHER: Exercise|OTHER: Lifestyle recommendations,Ataturk Training and Research Hospital,,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-02,2021-06,2021-07,"Ankara Yildirim Beyazit University, Ankara, Turkey"
NCT04141891,Advancing Understanding of Transportation Options,https://beta.clinicaltrials.gov/study/NCT04141891,ACTIVE_NOT_RECRUITING,Diabetic Retinopathy|Macular Degeneration|Glaucoma|Retinitis Pigmentosa|Vision Disorders|Acute Coronary Syndrome|Implantable Defibrillator User|Congestive Heart Failure|Hypertrophic Obstructive Cardiomyopathy|Orthostatic Hypotension|Syncope|Presyncope|Narcolepsy|Dementia|Multiple Sclerosis|Parkinson Disease|Brain Injuries|Spinal Cord Injuries|Stroke|Vertigo|Dizziness|Seizures|Substance Use|Insulin Dependent Diabetes Mellitus|Arthritis|Foot--Abnormalities|Chronic Obstructive Pulmonary Disease|Obstructive Sleep Apnea|End Stage Renal Disease|Sleep Apnea|Insomnia|Restless Legs Syndrome,BEHAVIORAL: Driving Decision Aid|BEHAVIORAL: Older Drivers Website,"University of Colorado, Denver",National Institute on Aging (NIA),ALL,"ADULT, OLDER_ADULT",NA,530,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH,2019-12-12,2023-08-01,2023-08-01,"University of California, San Diego, La Jolla, California, 92037, United States|CU Anschutz Medical Center, Aurora, Colorado, 80045, United States|Indiana University, Indianapolis, Indiana, 46202, United States"
NCT04171908,Semi-inmersive Virtual Reality on Upper Limb in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04171908,UNKNOWN,Multiple Sclerosis|Treatment Adherence|Upper Extremity Paresis,OTHER: Conventional therapy|OTHER: Nintendo Switch Joy-Con,Universidad Rey Juan Carlos,,ALL,"ADULT, OLDER_ADULT",NA,15,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-11-12,2021-06-11,2021-07-11,"Roberto Cano de la Cuerda, Alcorcón, Madrid, 28922, Spain"
NCT01994109,Efficacy and Safety Study of MYOBLOC® Followed by Open-Label Multiple-Treatment With MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects,https://beta.clinicaltrials.gov/study/NCT01994109,COMPLETED,Sialorrhea,DRUG: MYOBLOC|OTHER: PLACEBO,"Supernus Pharmaceuticals, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE3,187,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-11,2016-01,2017-01,"Loma Linda, California, 92354, United States|Los Angeles, California, 90033, United States|National City, California, 91950, United States|Aurora, Colorado, 80045, United States|Washington, District of Columbia, 20007, United States|Boca Raton, Florida, 33486, United States|Port Charlotte, Florida, 33980, United States|Carmel, Indiana, 46032, United States|Baltimore, Maryland, 21287, United States|Elkridge, Maryland, 21075, United States|Detroit, Michigan, 48334, United States|Saint Louis, Missouri, 63110, United States|Edison, New Jersey, 08818, United States|Albany, New York, 12208, United States|New York, New York, 10003, United States|Cincinnati, Ohio, 45219, United States|Tulsa, Oklahoma, 74136, United States|Port Royal, South Carolina, 29935, United States|Cordova, Tennessee, 38018, United States|Houston, Texas, 77030, United States|San Antonio, Texas, 78229, United States|Salt Lake City, Utah, 84132, United States|Kirkland, Washington, 98034, United States|Tacoma, Washington, 98409, United States|Irkutsk, Irkutsk Region, 664079, Russian Federation|Vsevolozhsk, Leningrad Region, 188643, Russian Federation|St.Petersburg, Petrodvorets, 198510, Russian Federation|Krasnoyarsk, 660037, Russian Federation|Dnipropetrovsk, 49027, Ukraine|Ivano-Frankivsk, 76008, Ukraine|Kharkiv, 61068, Ukraine|Lviv, 79010, Ukraine|Rivne, 33010, Ukraine|Uzhgorod, 88018, Ukraine"
NCT01903291,Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS,https://beta.clinicaltrials.gov/study/NCT01903291,COMPLETED,Relapsing Forms of Multiple Sclerosis,DRUG: dimethyl fumarate,Biogen,,ALL,"ADULT, OLDER_ADULT",,333,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-08,2016-02,2016-02,"Research Site, Birmingham, Alabama, 35209, United States|Research Site, Tuscon, Arizona, 85741-1196, United States|Research Site, Los Angeles, California, 90015, United States|Research Site, Sacramento, California, 95816, United States|Research Site, San Jose, California, 95124, United States|Research Site, Englewood, Colorado, 80113, United States|Research Site, Dover, Delaware, 19901, United States|Research Site, Jacksonville, Florida, 32209, United States|Research Site, Lighthouse Point, Florida, 33064, United States|Research Site, Port Charlotte, Florida, 33952, United States|Research Site, St. Petersburg, Florida, 33705, United States|Research Site, Tampa, Florida, 33612, United States|Research Site, Atlanta, Georgia, 30309, United States|Research Site, Atlanta, Georgia, 30327, United States|Research Site, Savannah, Georgia, 31405, United States|Research Site, Chicago, Illinois, 60637-1463, United States|Research Site, Evanston, Illinois, 60201, United States|Research Site, Franklin, Illinois, 37064, United States|Research Site, Indianapolis, Indiana, 46256, United States|Research Site, Des Moines, Iowa, 50314, United States|Research Site, Lenexa, Kansas, 66214-9836, United States|Research Site, Lexington, Kentucky, 40513, United States|Research Site, Louisville, Kentucky, 40207, United States|Research Site, Baton Rouge, Louisiana, 70810-1686, United States|Research Site, Annapolis, Maryland, 21401, United States|Research Site, Baltimore, Maryland, 21201, United States|Research Site, Lexington, Massachusetts, 02421, United States|Research Site, Springfield, Massachusetts, 01104, United States|Research Site, Worcester, Massachusetts, 01655, United States|Research Site, Clinton Township, Michigan, 48035, United States|Research Site, Muskegon, Michigan, 49444-3719, United States|Research Site, Golden Valley, Minnesota, 55422, United States|Research Site, Columbia, Missouri, 65201, United States|Research Site, Great Falls, Montana, 59405, United States|Research Site, Lincoln, Nebraska, 68506-2960, United States|Research Site, Lincoln, Nebraska, 68521, United States|Research Site, Omaha, Nebraska, 68198, United States|Research Site, Freehold, New Jersey, 07728, United States|Research Site, Bronx, New York, 10467, United States|Research Site, New York, New York, 10032, United States|Research Site, Patchogue, New York, 11772, United States|Research Site, Asheville, North Carolina, 28806, United States|Research Site, Hickory, North Carolina, 28602, United States|Research Site, Raleigh, North Carolina, 27607-6010, United States|Research Site, Akron, Ohio, 44302, United States|Research Site, Canton, Ohio, 44718, United States|Research Site, Centerville, Ohio, 45459, United States|Research Site, Columbus, Ohio, 43221, United States|Research Site, Medford, Oregon, 97504, United States|Research Site, Portland, Oregon, 97225, United States|Research Site, Abington, Pennsylvania, 19001, United States|Research Site, Greensburg, Pennsylvania, 15601, United States|Research Site, Pittsburgh, Pennsylvania, 15212, United States|Research Site, Knoxville, Tennessee, 37934, United States|Research Site, Round Rock, Texas, 78681, United States|Research Site, Salt Lake City, Utah, 84103, United States|Research Site, Norfolk, Virginia, 23502, United States|Research Site, Richmond, Virginia, 23226, United States|Research Site, Bellingham, Washington, 98225, United States|Research Site, Seattle, Washington, 98122, United States|Research Site, Tacoma, Washington, 98405, United States|Research Site, Neenah, Wisconsin, 54946, United States"
NCT02263339,Exercise & Brain Health in MS,https://beta.clinicaltrials.gov/study/NCT02263339,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Aerobic Exercise|BEHAVIORAL: Stretching|BEHAVIORAL: Aerobic Exercise- Healthy Subjects,Oregon Health and Science University,,ALL,"ADULT, OLDER_ADULT",NA,24,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2014-09,2016-04,2016-05-25,"Oregon Health & Science University, Portland, Oregon, 97239, United States"
NCT03591809,Combined Exercise Training in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03591809,COMPLETED,Multiple Sclerosis,OTHER: combined exercise training,Gazi University,,ALL,"ADULT, OLDER_ADULT",NA,17,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2018-09-03,2019-10-18,2019-10-21,"Gazi University, Ankara, Turkey"
NCT05576779,Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis.,https://beta.clinicaltrials.gov/study/NCT05576779,COMPLETED,Multiple Sclerosis,OTHER: Ofatunumab,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",,2101,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-12-03,2021-12-31,2021-12-31,"Novartis Investigative Site, East Hanover, New Jersey, 07936-1080, United States"
NCT04027491,Virtual Reality for Upper Limb Rehabilitation in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04027491,UNKNOWN,Multiple Sclerosis,BEHAVIORAL: Virtual Reality,University of Cagliari,Italian Multiple Sclerosis Foundation|Fondazione Don Carlo Gnocchi Onlus|Azienda Sanitaria Locale di Cagliari,ALL,"ADULT, OLDER_ADULT",NA,24,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2019-04-23,2021-06-03,2022-06-03,"Laboratorio di Biomeccanica ed Ergonomia industriale - Università degli Studi di Cagliari, Monserrato, Cagliari, 09042, Italy"
NCT00219908,Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00219908,TERMINATED,Relapsing-Remitting Multiple Sclerosis,DRUG: Mitoxantrone,Rennes University Hospital,"Bayer|Wyeth is now a wholly owned subsidiary of Pfizer|Farmades, Italy",,ADULT,PHASE2,124,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: ",1999-07,,2006-06,"Hôpital Cote de Nacre, Caen, 14033, France|Hôpital Gabriel Montpied, Clermont-Ferrand, 63003, France|CHU Henri Mondor, Creteil, 94000, France|Hôpital Général, Dijon, 21033, France|CHU Limoges, Limoges, 87042, France|Institut Catholique de Lille, Lomme, 59462, France|Pierre Weitheimer Hospital, Lyon, 69394, France|Chu Timone, Marseille, 13385, France|Centre Guy de Chauliac, Montpellier, 34295, France|CHU Hôpital Central, Nancy, 54035, France|CHU, Nice, 06000, France|CHU Pitié-Salpétrière, Paris, 75013, France|Hôpital Saint-Anne, Paris, 75014, France|Centre Fondation Rotschild, Paris, 75019, France|Tenon Hospital, Paris, 759170, France|CHU Strasbourg, Strasbourg, 67000, France|CHU Purpan, Toulouse, 31059, France|Psichiatriche dell'Università di Bari, Policlinico, Bari, 70122, Italy|Dipartimento di Scienze Neurologiche e Psichiatriche, Firenze, 50134, Italy|Hospedal Civile, Gallarate, 21013, Italy|Neuroriabilitazione dell'Università, Genova, 16132, Italy|Fondazionz SAN Raffaele del monte tabor, Milano, 20132, Italy|Clinica Neurologica Università di Torino, Torino, 10126, Italy"
NCT00064909,MR Perfusion Imaging and Hypercapnia (Increased Carbon Dioxide) to Study New Blood Vessel Formation in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00064909,COMPLETED,Multiple Sclerosis,,National Institutes of Health Clinical Center (CC),,ALL,"CHILD, ADULT, OLDER_ADULT",,50,NIH,OBSERVATIONAL,Observational Model: |Time Perspective: p,2003-07,,2006-03,"National Institutes of Health Clinical Center (CC), Bethesda, Maryland, 20892, United States"
NCT03972306,"A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT03972306,ACTIVE_NOT_RECRUITING,Multiple Sclerosis (MS),DRUG: Ocrelizumab|DRUG: Ocrelizumab|DRUG: rHuPH20,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE1,134,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2019-08-12,2023-01-27,2025-06-20,"University of Colorado; Anschutz Medical Campus Department of Neurology, Aurora, Colorado, 80045, United States|Georgetown University Medical Center, Washington, District of Columbia, 20007, United States|University of South Florida School of Medicine Morsani Center for Advanced Health Care, Tampa, Florida, 33612, United States|The NeuroMedical Clinic of Central Louisiana, Alexandria, Louisiana, 71301, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, 70121, United States|John Hopkins University School of Medicine, Baltimore, Maryland, 21287, United States|University of Massachusetts Medical School, Worcester, Massachusetts, 01655, United States|Wayne State University; Department of Neurology, Detroit, Michigan, 48201, United States|Memorial Healthcare Institute for Neurosciences and Multiple Sclerosis, Owosso, Michigan, 48867, United States|Washington Univ School of Med; Dept Neurology, Saint Louis, Missouri, 63110, United States|Columbia University Medical Center, New York, New York, 10032, United States|Cleveland Clinic Mellen Center; U10, Cleveland, Ohio, 44195, United States|UC Health Neurology, Dayton, Ohio, 45417, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, 15213, United States|Premier Neurology, Greer, South Carolina, 29650, United States|Neurology Clinic PC, Cordova, Tennessee, 38018, United States|University of Texas at Houston; Neurology, Houston, Texas, 77030, United States|Swedish Neuroscience Institute; Multiple Sclerosis Center, Seattle, Washington, 98122, United States|MultiCare Health System Institute for Research and Innovation, Tacoma, Washington, 98405, United States"
NCT05713890,Home-based Action Observation Treatment With Virtual-reality for Arm Rehabilitation in People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05713890,NOT_YET_RECRUITING,Multiple Sclerosis,OTHER: Home-based Action Observation Treatment with virtual-reality for upper limb rehabilitation|OTHER: Home-based landscape observation with virtual-reality for upper limb rehabilitation,IRCCS San Raffaele,Istituto di Neuroscienze Consiglio Nazionale delle Ricerche,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-03,2025-04,2025-07,"IRCCS San Raffaele, Milan, 20132, Italy"
NCT03928990,Assesment of Physical Activity Level of Patients With Multiple Sclerosis: From Laboratory to Real Life,https://beta.clinicaltrials.gov/study/NCT03928990,UNKNOWN,Multiple Sclerosis,DEVICE: ActiGraph accelerometer,Centre Hospitalier Universitaire de Besancon,,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2019-01-15,2021-01,2021-01,"CHU de Besançon, Besançon, 25000, France"
NCT04602390,Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04602390,RECRUITING,Multiple Sclerosis (MS)|Relapsing Remitting Multiple Sclerosis,DRUG: ANK-700|DRUG: Placebo,Anokion SA,,ALL,ADULT,PHASE1,33,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-11-06,2024-06,2024-06,"North Central Neurology, Cullman, Alabama, 35058, United States|Barrow Neurological Institute, Phoenix, Arizona, 85013, United States|UC Health Neurosciences Center, Aurora, Colorado, 80045, United States|Aqualane Clinical Research, Naples, Florida, 34105, United States|University of South Florida - Neurology, Tampa, Florida, 33612, United States|University of Kansas Lander Center on Aging/ Neurology, Kansas City, Kansas, 66103, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, 70121, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|Jefferson University Hospitals, Philadelphia, Pennsylvania, 19107, United States|First Care Research Center, Columbia, South Carolina, 29205, United States|Advanced Neurosciences Institute, Franklin, Tennessee, 37064, United States|University of Texas Southwestern, Dallas, Texas, 75390, United States|University of Texas Health Science Center, Houston, Texas, 77030, United States|MS Center of Greater Washington, Vienna, Virginia, 22180, United States|MultiCare Health System, Tacoma, Washington, 98405, United States"
NCT00343590,Whole Body Vibration Therapy in a Participant With Multiple Sclerosis Related Balance Deficits - A Case Study,https://beta.clinicaltrials.gov/study/NCT00343590,COMPLETED,Multiple Sclerosis,DEVICE: Whole Body Vibration machine,Logan College of Chiropractic,,ALL,"ADULT, OLDER_ADULT",NA,,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2006-06,2006-11,2006-11,"Logan College of Chiropractic, Chesterfield, Missouri, 63017, United States|Logan College of Chirpractic, Chesterfield, Missouri, 63017, United States"
NCT03653390,A Community Wellness Program for Adults Living With Long-term Physical Disability,https://beta.clinicaltrials.gov/study/NCT03653390,ACTIVE_NOT_RECRUITING,Physical Disability,BEHAVIORAL: EnhanceWellness for Disability (EW-D)|BEHAVIORAL: Wellness Education,University of Washington,National Institute of Nursing Research (NINR),ALL,ADULT,NA,516,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2019-01-31,2022-10-17,2024-03-31,"University of Washington, Seattle, Washington, 98195, United States"
NCT04902690,The Possible Neuroprotective Effect of Ocrelizumab Via VEGF Protein Expression in Relapsing Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT04902690,NOT_YET_RECRUITING,Multiple Sclerosis Relapse,,"IRCCS National Neurological Institute ""C. Mondino"" Foundation",,ALL,ADULT,,21,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-05-31,2024-07-31,2024-07-31,
NCT05292690,An Assistive Powered Wheelchair: Stage 2 Trial,https://beta.clinicaltrials.gov/study/NCT05292690,COMPLETED,Multiple Sclerosis|Stroke|Cystic Fibrosis|Motor Neurone Disease|Craniocerebral Trauma|Guillain-Barre Syndrome,DEVICE: Powered Wheelchair Obstacle Alerting System,East Kent Hospitals University NHS Foundation Trust,University of Kent|Sussex Community NHS Foundation Trust|KU Leuven|l'Institut supérieur de l'électronique et du numérique (ISEN) Lille,ALL,"ADULT, OLDER_ADULT",,17,OTHER_GOV,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-03-29,2021-04-01,2021-08-31,"East Kent Hospitals NHS Foundation Trust, Canterbury, Kent, CT1 3NG, United Kingdom"
NCT04893590,Adapting mHealth Technology to Improve Patient Activation,https://beta.clinicaltrials.gov/study/NCT04893590,COMPLETED,Spinal Cord Injuries|Stroke|Multiple Sclerosis,BEHAVIORAL: Fatigue self-management SMS intervention,Washington University School of Medicine,The Foundation for Barnes-Jewish Hospital,ALL,"ADULT, OLDER_ADULT",NA,27,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-05-14,2022-02-28,2022-02-28,"Washington University School of Medicine, Saint Louis, Missouri, 63108, United States"
NCT03593590,Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03593590,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,DRUG: Ocrelizumab,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",,1700,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-11-12,2025-07-26,2025-07-26,"Landesklinikum Amstetten; Abteilung für Neurologie, Amstetten, 3300, Austria|Uniklinik fuer Neurologie, Medizinische Universitaet Innsbruck; Department fuer Neurologie, Innsbruck, 6020, Austria|Kepler Universitätsklinikum GmbH - Neuromed Campus; Neurologie, Linz, 4020, Austria|Kepler Universitätskliniken GmbH - Med Campus III; Neurologie & Psychiatrie, Linz, 4021, Austria|Multiple Sklerose Zentrum, Melk, 3390, Austria|Otto Wagner Spital; Neurologisches Zentrum, Wien, 1140, Austria|Imeldaziekenhuis, Bonheiden, 2820, Belgium|AZ KLINA, Brasschaat, 2930, Belgium|UZ Brussel, Brussel, 1090, Belgium|Hospital Erasme, Bruxelles, 1070, Belgium|Cliniques Universitaires St-Luc, Bruxelles, 1200, Belgium|CHU de Charleroi, Charleroi, 6042, Belgium|UZ Antwerpen, Edegem, 2650, Belgium|CNRF - Centre Neurologique et Réadaptation Fonctionnelle, Fraiture, 4557, Belgium|Jessa Zkh (Campus Virga Jesse), Hasselt, 3500, Belgium|AZ Groeninge, Kortrijk, 8500, Belgium|CHU Tivoli, La Louvière, 7100, Belgium|CHC MontLégia, Liege, 4000, Belgium|Nationaal MS Centrum, Melsbroek, 1820, Belgium|CHU UCL Mont-Godinne, Mont-godinne, 5530, Belgium|AZ Damiaan, Oostende, 8400, Belgium|Revalidatie en MS Centrum, Overpelt, 3900, Belgium|AZ Delta (Campus Rumbeke), Roeselare, 8800, Belgium|Clinica Amo - Assistencia Medica Em Oncologia, Salvador, BA, 41950640, Brazil|Hospital de Base do Distrito Federal; Núcleo de Citopatologia e Anatomia Patológica, Brasilia, DF, 70330-150, Brazil|Instituto de Neurologia de Curitiba, Curitiba, PR, 81210-310, Brazil|Hospital Universitario Gaffree e Guinle, Rio de Janeiro, RJ, 20270-004, Brazil|CPQuali Pesquisa Clinica Ltda, Sao Paulo, SP, 01228-000, Brazil|Centro de Pesquisas Clinicas; CPCLIN, Sao Paulo, SP, 01228-200, Brazil|UMHAT 'Dr. Georgi Stranski', EAD, Pleven, 5800, Bulgaria|UMHAT Sveti Georgi Clinic of neurology, Plovdiv, 4000, Bulgaria|First MHAT; Clinic of Neurology, Sofia, 1000, Bulgaria|Shat Np Sveti Naum; 3Rd Clinic of Neurology, Sofia, 1113, Bulgaria|Multiprofile Hosp. for Active Treatment;National Cardiology Hosp., Sofia, 1309, Bulgaria|""City Clinic UMHAC"" EOOD, Sofia, 1407, Bulgaria|ACIBADEM CITY CLINIC TOKUDA HOSPITAL EAD; Clinic of Neurology and Sleep Medicine, Sofia, 1407, Bulgaria|UMHAT ""Sv. Ivan Rilski"", EAD, Sofia, 1431, Bulgaria|UMHAT Alexandrovska, EAD; Neurology, Sofia, 1431, Bulgaria|UMHAT Tsaritsa Yoanna - ISUL EAD; Clinic of Neurology, Sofia, 1527, Bulgaria|MBAL St. Marina; First Neurology Department, Varna, 9010, Bulgaria|Clinica Las Condes, Santiago, 7591046, Chile|Organizacion Sanitas Internacional, Bogota, D.C., 111321, Colombia|Fundacion ABOOD Shaio, Bogota, DC, Colombia|Centro Javeriano de Oncología, Bogota, Colombia|Fundacion Clinica Valle del Lili; Unidad de Investigaciones Clinicas, Cali, Colombia|Instituto Nacional del Cáncer Rosa Emilia Sánchez Pérez de Tavares (INCART), Santo Domingo, Dominican Republic|Clinical Research Center-Alex university; Neurology Department, Alexandria, 21561, Egypt|Faculty of Medicine-Ain Shams University; Neurology Department, Cairo, 1156 6111, Egypt|Al Azhar University Hospital, Cairo, Egypt|Ospedale San Salvatore; Clinica Neurologica - Centro Sclerosi Multipla, L'Aquila, Abruzzo, 67100, Italy|Università degli Studi della Campania Luigi Vanvitelli; Dip. Ass. Integrato Med Int-II Clinica Neur, Napoli, Campania, 80131, Italy|AOU Seconda Università degli Studi; Dip.Assistenziale Integrato Medicina Int-I Clinica Neurologica, Napoli, Campania, 80138, Italy|Arcispedale Sant'Anna; Neurochirurgia - Dipartimento Neuroscienze e Riabilitazione, Cona, Emilia-Romagna, 44124, Italy|A.O.U. di Parma; SC Neurologia, Amb. Sclerosi Multipla (malattie demielinizzanti), Parma, Emilia-Romagna, 43126, Italy|Policlinico Tor Vergata Dip. Neuroscienze-Clinica Neurologica-UOSD Sclerosi Multipla, Roma, Lazio, 00133, Italy|Azienda Ospedaliera Sant'Andrea; UOC Neurologia, Roma, Lazio, 00189, Italy|Irccs A.O.U.San Martino Ist; Dinogmi, Genova, Liguria, 16132, Italy|Presidio Ospedaliero S.O.P.A. Micone; S.C. Neurologia, Centro Sclerosi Multipla, Sestri Ponente (GE), Liguria, 16153, Italy|Ospedale S.Antonio Abate; Neurologia 2 ? Sclerosi Multipla e Recupero Neurologico, Gallarate, Lombardia, 21013, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; Unità Operativa Complessa di Neurologia, Milano, Lombardia, 20122, Italy|IRCCS Ospedale San Raffaele; Neurologia Neurofisiologia Neuroriabilitazione-Centro Sclerosi Multipla, Milano, Lombardia, 20132, Italy|Fond. Istituto Neurologico C.Besta; UO Neurologia IV - Neuroimmunologia Malattie Neuromuscolari, Milano, Lombardia, 20133, Italy|IRCCS Istituto Neurologico C. Mondino?Dip. Neurologia Neuroriabilitazione S.S. Sclerosi Multipla, Pavia, Lombardia, 27100, Italy|Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I-G.M. Lancisi-G. Salesi Di Ancona, Torrette - Ancona, Marche, 60100, Italy|IRCCS Istituto Neurologico Neuromed; Centro per lo Studio e la Cura della Sclerosi Multipla, Pozzilli, Molise, 86077, Italy|Ospedale Regina Montis Regalis; SC Neurologia, Centro Sclerosi Multipla, Mondovì (CN), Piemonte, 12084, Italy|Azienda Ospedaliero-Universitaria Consorziale Pol. di Bari; Neuroscienze e Organi di Senso, Bari, Puglia, 70124, Italy|Ospedale F. Ferrari; UO Neurologia, Centro Sclerosi Multipla, Casarano, Puglia, 73042, Italy|Ospedale Binaghi; Centro Sclerosi Multipla, Cagliari, Sardegna, 09126, Italy|AOU Policlinico V. Emanuele - P.O G. Rodolico; Clinica Neurologica, Centro Sclerosi Multipla, Catania, Sicilia, 95123, Italy|AOU Policlinico Giaccone; UOC Neurologia e Neurofisiopatologia-Amb Sclerosi Multipla, Palermo, Sicilia, 90129, Italy|AOU Senese - Presidio Ospedaliero Le Scotte; UOSA Neurologia Sperimentale, Siena, Toscana, 53100, Italy|Ibn Sina Hospital; Neurology Department, Kuwait, 10002, Kuwait|Clinical Center of Montenegro; Clinic for neurology, Podgorica, 20000, Montenegro|Amphia Ziekenhuis, Breda, 4819 EV, Netherlands|St. Antonius Ziekenhuis Nieuwegein, Nieuwegein, 3435 CM, Netherlands|Maasstadziekenhuis, Rotterdam, 3079 DZ, Netherlands|Ziekenhuis VieCuri Medisch Centrum, Venlo, 5912 BL, Netherlands|Isala, Zwolle, 8025 AB, Netherlands|Consultorio Médico Paitilla, Ciudad Panama, Panama|Hospital Central del Instituto de Previsión Social, Asunción, Paraguay|Uniwersytecki Szpital Kliniczny w Bialymstoku, Bia?ystok, 15-276, Poland|COPERNICUS Podmiot Leczniczy Sp. z o. o. Szpital im. M. Kopernika; Oddzia? Neurologiczny, Gdansk, 80-803, Poland|Szpital Specjalistyczny im. Swi?tej Rodziny w Rudnej Ma?ej k. Rzeszowa, Glogow Malopolski, 36-060, Poland|Gornoslaskie Centrum Medyczne, Katowice, 40-635, Poland|UCK im. prof. K. Gibinskiego SUM; Klinika Neurologii, Katowice, 40-752, Poland|SPZOZ Uniwersytecki Szp. Klin. nr1 im.N.Barlickiego UM;Oddzial Kliniczny Neurologii, Lodz, 90-153, Poland|SPZOZ Wojewodzki Szpital Specjalistyczny nr 3, Rybnik, 44-200, Poland|Instytut Psychiatrii i Neurologii, Warszawa, 02-957, Poland|Wojskowy Instytut Medyczny - Pa?Stwowy Instytut Badawczy, Warszawa, 04-141, Poland|SPSK nr 1; Klinika Neurologii, Zabrze, 41-800, Poland|Hospital Santo Antonio dos Capuchos; Servico de Neurologia, Lisboa, 1169-050, Portugal|Centro Hospitalar do Porto; CICAP - Unidade Clínica de Paramiloidose, Porto, 4000-436, Portugal|Hamad General Hospital; Neurology Department, Doha, 3050, Qatar|Spitalul Universitar de Urgenta Bucuresti, Bucharest, 11172, Romania|Spitalul Clinic Judetean de Urgenta Cluj-Napoca; Neurologie, Cluj-Napoca, 400012, Romania|Spitalul Clinic Judetean de Urgenta Sibiu; Neurologie, Sibiu, 550166, Romania|Spitalul Clinic Judetean de Urgenta Mures, Targu-Mures, 540136, Romania|National Center of Social Significant Disease, Sankt-peterburg, Leningrad, 197110, Russian Federation|Jusupovskaya Hospital, Moscow, Moskovskaja Oblast, 117186, Russian Federation|Regional clinical hospital named after prof. S.V. Ochapovsky, Krasnodar, 350086, Russian Federation|State Novosibirsk Regional Clinical Hospital, Novosibirsk, 630087, Russian Federation|King Abdul Aziz Medical City, King Fahd National Guard; Oncology, Riyadh, 22490, Saudi Arabia|Clinical Center of Serbia, Belgrade, 11000, Serbia|Clinical Center Kragujevac, Kragujevac, 34000, Serbia|Clinical Center Nis, NIS, 18000, Serbia|Clinical Centre of Vojvodina, Nova Sad, 21000, Serbia|Univerzitna Nemocnica - Nemocnica svateho Michala; Neurologicke oddelenie, Bratislava, 811 08, Slovakia|UN Bratislava Nemocnica Ruzinov; Neurologicka klinika, Bratislava, 826 06, Slovakia|Nemocnica akademika Ladislava Derera; Neurologicka klinika, Bratislava, 833 05, Slovakia|Univerzitna nemocnica Martin; Neurologicka klinika, Martin, 036 59, Slovakia|Ustredna vojenska nemocnica SNP Ruzomberok; Klinika neurologie, Ruzomberok, Slovakia|Fakultna nemocnica Trnava; Onkologicka klinika, Trnava, 917 75, Slovakia|Hospital Universitario de Araba; Servicio de Neurologia, Vitoria-gasteiz, Alava, 1009, Spain|Hospital General Universitario de Elche; Servicio de Neurología, Elche, Alicante, 03203, Spain|Corporació Sanitaria Parc Taulí; Servicio de Neurología, Sabadell, Barcelona, 08208, Spain|Hospital de Figueres; Servicio de Neurología, Figueres, Girona, 17600, Spain|Hospital de Donostia; Servicio de Neurologia, San Sebastian, Guipuzcoa, 20014, Spain|Complejo Hospitalario Universitario A Coruña (CHUAC); Servicio de Neurologia, Coruña, LA Coruña, 15006, Spain|Complejo Hospitalario Universitario de Santiago (CHUS) Servicio de Neurologia, Santiago de Compostela, LA Coruña, 15706, Spain|Hospital General Universitario Santa Lucia; Servicio de Neurología, Cartagena (Murcia), Murcia, 30202, Spain|Hospital Universitario Virgen de Arrixaca; Servicio de Neurología, EL Palmar (EL Palmar), Murcia, 30120, Spain|Hospital Alvaro Cunqueiro; Servicio de Neurologia, Vigo, Pontevedra, Spain|Hospital Universitario de Canarias; Servicio de Neurologia, San Cristóbal de La Laguna, Tenerife, Spain|Hospital Nuestra Señora de Candelaria; Unidad de Esclerosis Multiple, Santa Cruz de Tenerife, Tenerife, Spain|Hospital Nuestra Señora de Sonsoles; Servicio de Neurología, Avila, 05071, Spain|Hospital de la Santa Creu i Sant Pau; Servicio de Neurologia, Barcelona, 08041, Spain|Hospital Germans Trias i Pujol, Barcelona, 08916, Spain|Hospital Puerta del Mar; Sevicio de Neurologia, Cadiz, 11009, Spain|Hospital Universitario Reina Sofia; Servicio de Neurologia, Cordoba, 14004, Spain|Hospital Regional Universitario de Malaga ? Hospital General; Servicio de Neurologia, Malaga, 29010, Spain|Hospital Universitario Virgen de la Victoria; Servicio de Neurología, Malaga, 29010, Spain|Hospital Universitario Virgen Macarena; Servicio de Neurologia, Sevilla, 41009, Spain|Hospital Virgen del Rocío; Servicio de Neurología, Sevilla, 41013, Spain|Hospital Univ. Nuestra Señora de Valme; Servicio de Neurología, Sevilla, 41014, Spain|Hospital Clinico Universitario de Valencia; Servicio de Neurologia, Valencia, 46010, Spain|Hospital General Universitario de Valencia; Servicio de Neurología, Valencia, 46014, Spain|Hospital Universitario Dr. Peset; Servicio de Neurologia, Valencia, 46017, Spain|Hospital Universitari i Politecnic La Fe; Servicio de Neurología, Valencia, 46026, Spain|Hacettepe University Medical Faculty; Neurology, Ankara, 06100, Turkey|Istanbul University Istanbul School of Medicine; Neurology, Istanbul, 34093, Turkey|Istanbul Universitesi - Cerrahpasa Cerrahpasa Tip Fakultesi; Noroloji Anabilim Dali, Istanbul, 34098, Turkey|Ege University Medical Faculty, Izmir, 35100, Turkey|Kocaeli University Hospital; Department of Neurology, Kocaeli, 41380, Turkey|Mersin University Medical Faculty; Neurology, Mersin, 33079, Turkey|Ondokuz Mayis Univ. Med. Fac.; Neurology, Samsun, 55139, Turkey|Karadeniz Tecnical Uni. Med. Fac.; Neurology, Trabzon, 61080, Turkey|Sheikh Shakhbout Medical City, Abu Dhabi, 11001, United Arab Emirates|Mediclinic Parkview Hospital, Dubai-UAE, United Arab Emirates|Royal Victoria Hospital, Belfast, BT12 6BA, United Kingdom|University Hospital Coventry, Coventry, CV2 2DX, United Kingdom|Raigmore Hospital; Highland Clin Rsrch Facility, Ctr For Health Sci, Inverness, IV2 3JH, United Kingdom|Leeds General Infirmary, Leeds, LS1 3EX, United Kingdom|Lincoln County Hospital, Lincoln, LN2 5QY, United Kingdom|St George?s Hospital, London, SW17 ORE, United Kingdom|Luton General Hospital; Luton & Dunstable University Hospital, Neurology department, Luton, LU4 0DZ, United Kingdom|James Cook Hospital, Middlesbrough, TS4 3BW, United Kingdom|John Radcliffe Hospital, Oxford, OX3 9DU, United Kingdom|Derriford Hospital, Plymouth, PL6 8BT, United Kingdom|Royal Hallamshire Hospital; Neurology, Sheffield, S10 2JF, United Kingdom|Royal Stoke University Hospital, Stoke-on-Trent, ST4 6QG, United Kingdom|Sunderland Royal Hospital, Sunderland, SR4 7TP, United Kingdom|Morriston Hospital; Cardiac Center, Swansea, SA6 6NL, United Kingdom|Southmead Hospital, Westbury-on-Trym, Bristol, BS10 5NB, United Kingdom"
NCT03291756,Corevitas Multiple Sclerosis (MS) Registry,https://beta.clinicaltrials.gov/study/NCT03291756,ENROLLING_BY_INVITATION,Multiple Sclerosis,,CorEvitas,,ALL,"ADULT, OLDER_ADULT",,1000,NETWORK,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-08-10,2100-12,2100-12,"Corrona, LLC, Waltham, Massachusetts, 02451, United States"
NCT00944190,TakeCharge: Telephone Delivered Self-management Intervention for People With Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT00944190,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Self-management intervention|BEHAVIORAL: Education,University of Washington,,ALL,"ADULT, OLDER_ADULT",NA,166,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2009-10,2012-12,2013-09,"University of Washington, Seattle, Washington, 98195, United States"
NCT01925690,Development of a Motivational Intervention to Improve Treatment Adherence in MS,https://beta.clinicaltrials.gov/study/NCT01925690,COMPLETED,Relapsing-remitting Multiple Sclerosis,BEHAVIORAL: Motivational Interviewing-Cognitive Behavioral Therapy|BEHAVIORAL: Brief Education,"University of Missouri, Kansas City",National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",NA,80,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2013-02,2015-04,2015-09,"University of Missouri-Kansas City, Kansas City, Missouri, 64110, United States|Kessler Rehabillitation Institute, West Orange, New Jersey, 07052, United States"
NCT04261790,Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04261790,ACTIVE_NOT_RECRUITING,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Ocrelizumab,Johns Hopkins University,"Genentech, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE4,10,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-08-01,2023-09-01,2024-03-01,"Johns Hopkins University, Baltimore, Maryland, 21287, United States"
NCT04838990,TELEMS: Feasibility of Remote Patient Visits in MS,https://beta.clinicaltrials.gov/study/NCT04838990,COMPLETED,Multiple Sclerosis,"OTHER: EDSS|OTHER: Discussion of symptoms, Patient reported outcome (MSIS)",Medical University of Vienna,,ALL,"CHILD, ADULT, OLDER_ADULT",NA,45,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2020-11-01,2021-09-01,2021-10-01,"Medical University of Vienna, Vienna, 1090, Austria"
NCT03737097,Online Spaced Education to Improve Fall Prevention by Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03737097,UNKNOWN,Education of Patients,OTHER: Online Spaced Education|OTHER: Brochure Education,Hospital Israelita Albert Einstein,,ALL,"ADULT, OLDER_ADULT",NA,320,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2019-02-21,2019-10-15,2019-11-15,"Sociedade Benef Israelitabras Hospital Albert Einstein, São Paulo, Sao Paulo, 05652000, Brazil"
NCT04760990,A Study to Assess the Potential Impact of Disease Modifying Therapies on COVID-19 Outcomes and the Antibody Response Following an Infection With SARS-CoV-2 in Patients With Multiple Sclerosis Within the Swiss Multiple Sclerosis Cohort.,https://beta.clinicaltrials.gov/study/NCT04760990,RECRUITING,Multiple Sclerosis|COVID-19 (Severe Coronavirus Disease 2019),OTHER: data collection|OTHER: analysis of blood samples,"University Hospital, Basel, Switzerland",Swiss Multiple Sclerosis Registry,ALL,"ADULT, OLDER_ADULT",,1400,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-02-01,2023-12,2023-12,"Kantonsspital Aarau, Aarau, 5001, Switzerland|University Hospital Basel, Department of Neurology and Department of Biomedicine, Basel, 4031, Switzerland|Inselspital Bern, Bern, 3010, Switzerland|Hôpitaux Universitaires Genève, Genève, 1205, Switzerland|Lausanne University Hospital (CHUV), Lausanne, 1011, Switzerland|Ospedale Regionale di Lugano, Lugano, 6903, Switzerland|Kantonsspital St. Gallen, St. Gallen, 9007, Switzerland"
NCT00228397,Study Evaluating CCI-779 in Relapsing Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00228397,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: CCI-779,Wyeth is now a wholly owned subsidiary of Pfizer,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,221,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE|Primary Purpose: TREATMENT,2003-11,2005-11,2005-11,
NCT03276195,Studies in Patients With Tuberous Sclerosis Complex,https://beta.clinicaltrials.gov/study/NCT03276195,RECRUITING,Tuberous Sclerosis Complex,,Translational Genomics Research Institute,United States Department of Defense,ALL,"CHILD, ADULT, OLDER_ADULT",,1000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-05,2023-12,2023-12,"Translational Genomics Research Institute (TGen), Phoenix, Arizona, 85004, United States"
NCT05252195,Optimizing Detection and Prediction of Changes in Cognitive Function in Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT05252195,RECRUITING,Multiple Sclerosis,,University of Michigan,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Wayne State University|University of Washington,ALL,"ADULT, OLDER_ADULT",,250,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-05-24,2027-03,2027-03,"University of Michigan, Ann Arbor, Michigan, 48109, United States|Wayne State University, Detroit, Michigan, 48202, United States|University of Washington, Seattle, Washington, 98195, United States"
NCT03586635,Automated EDSS Score Calculation by Smartphone Application,https://beta.clinicaltrials.gov/study/NCT03586635,COMPLETED,MS CHRONIC PROGRESSIVE,OTHER: neurological exam,Centre Hospitalier Universitaire de Nice,,ALL,"ADULT, OLDER_ADULT",,105,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-12-13,2020-12-21,2021-09-03,"Nice University Hospital, Nice, 06000, France"
NCT03222596,The Impact of Exercise Training on Living Quality in Multiple Sclerosis Individuals,https://beta.clinicaltrials.gov/study/NCT03222596,COMPLETED,Multiple Sclerosis|Fatigue|Mental Status Change|Physical Disability|Physical Activity|Mental Impairment|Quality of Life|Disabilities Psychological|Disability Physical|Pain|Energy Supply; Deficiency|Motivation,BEHAVIORAL: Exercise training,University of Rijeka,,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2017-07-14,2017-08-28,2017-08-28,"Department of physiology and immunology, Medical Faculty, University of Rijeka, Rijeka, Primorsko-goranska Županija, 51000, Croatia"
NCT01623596,Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.,https://beta.clinicaltrials.gov/study/NCT01623596,COMPLETED,Relapsing Remitting Multiple Sclerosis,DRUG: Fingolimod|DRUG: Disease Modifying therapy,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE4,881,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2012-06-08,2015-07-13,2015-07-13,"Novartis Investigative Site, Cullman, Alabama, 35058, United States|Novartis Investigative Site, Phoenix, Arizona, 85004, United States|Novartis Investigative Site, Sun City, Arizona, 85351, United States|Novartis Investigative Site, Tucson, Arizona, 85741, United States|Novartis Investigative Site, Sherwood, Arkansas, 72120, United States|Novartis Investigative Site, Fullerton, California, 92835, United States|Novartis Investigative Site, Oceanside, California, 92056, United States|Novartis Investigative Site, San Francisco, California, 94117, United States|Novartis Investigative Site, Walnut Creek, California, 94598, United States|Novartis Investigative Site, Basalt, Colorado, 81621, United States|Novartis Investigative Site, Boulder, Colorado, 80301, United States|Novartis Investigative Site, Denver, Colorado, 80209, United States|Novartis Investigative Site, Denver, Colorado, 80210, United States|Novartis Investigative Site, Fort Collins, Colorado, 80528, United States|Novartis Investigative Site, Fairfield, Connecticut, 06824, United States|Novartis Investigative Site, New London, Connecticut, 06320, United States|Novartis Investigative Site, Dover, Delaware, 19901, United States|Novartis Investigative Site, Atlantis, Florida, 33462-6608, United States|Novartis Investigative Site, Bradenton, Florida, 34205, United States|Novartis Investigative Site, Delray Beach, Florida, 33445, United States|Novartis Investigative Site, Hollywood, Florida, 33021, United States|Novartis Investigative Site, Jacksonville, Florida, 32216, United States|Novartis Investigative Site, North Palm Beach, Florida, 33408, United States|Novartis Investigative Site, Plantation, Florida, 33324, United States|Novartis Investigative Site, Pompano Beach, Florida, 33060, United States|Novartis Investigative Site, Port Charlotte, Florida, 33952, United States|Novartis Investigative Site, Port Orange, Florida, 32127, United States|Novartis Investigative Site, Saint Petersburg, Florida, 33713, United States|Novartis Investigative Site, Sarasota, Florida, 34233, United States|Novartis Investigative Site, Sarasota, Florida, 34243, United States|Novartis Investigative Site, Tallahassee, Florida, 32308, United States|Novartis Investigative Site, Tampa, Florida, 33609, United States|Novartis Investigative Site, West Palm Beach, Florida, 33407, United States|Novartis Investigative Site, Atlanta, Georgia, 30312, United States|Novartis Investigative Site, Columbus, Georgia, 31904, United States|Novartis Investigative Site, Decatur, Georgia, 30083, United States|Novartis Investigative Site, Suwanee, Georgia, 30024, United States|Novartis Investigative Site, Flossmoor, Illinois, 60422, United States|Novartis Investigative Site, Northbrook, Illinois, 60062, United States|Novartis Investigative Site, Anderson, Indiana, 46011, United States|Novartis Investigative Site, Indianapolis, Indiana, 46227, United States|Novartis Investigative Site, Indianapolis, Indiana, 46256, United States|Novartis Investigative Site, Des Moines, Iowa, 50314-2611, United States|Novartis Investigative Site, Overland Park, Kansas, United States|Novartis Investigative Site, Wichita, Kansas, 67214, United States|Novartis Investigative Site, Hawesville, Kentucky, 42384, United States|Novartis Investigative Site, Lexington, Kentucky, 40504, United States|Novartis Investigative Site, Madisonville, Kentucky, 42431, United States|Novartis Investigative Site, Alexandria, Louisiana, 71301, United States|Novartis Investigative Site, Baton Rouge, Louisiana, 70809, United States|Novartis Investigative Site, New Orleans, Louisiana, 70115, United States|Novartis Investigative Site, Annapolis, Maryland, 21401, United States|Novartis Investigative Site, Fulton, Maryland, 20759, United States|Novartis Investigative Site, New Bedford, Massachusetts, 02740, United States|Novartis Investigative Site, North Dartmouth, Massachusetts, 02747, United States|Novartis Investigative Site, Springfield, Massachusetts, 01104, United States|Novartis Investigative Site, Watertown, Massachusetts, 02472, United States|Novartis Investigative Site, Worcester, Massachusetts, 01608, United States|Novartis Investigative Site, Kalamazoo, Michigan, 49007, United States|Novartis Investigative Site, Traverse City, Michigan, 49684-2340, United States|Novartis Investigative Site, Nixa, Missouri, 65714-7807, United States|Novartis Investigative Site, North Kansas City, Missouri, 64116, United States|Novartis Investigative Site, Saint Louis, Missouri, 63104, United States|Novartis Investigative Site, Las Vegas, Nevada, 89121, United States|Novartis Investigative Site, Las Vegas, Nevada, 89123, United States|Novartis Investigative Site, Las Vegas, Nevada, 89144, United States|Novartis Investigative Site, Flemington, New Jersey, 08822, United States|Novartis Investigative Site, Teaneck, New Jersey, 07666, United States|Novartis Investigative Site, Toms River, New Jersey, 08755, United States|Novartis Investigative Site, Albuquerque, New Mexico, 87108, United States|Novartis Investigative Site, Albany, New York, 12208, United States|Novartis Investigative Site, Amherst, New York, 14226, United States|Novartis Investigative Site, Bronx, New York, 10467-2490, United States|Novartis Investigative Site, Kingston, New York, 12401, United States|Novartis Investigative Site, Latham, New York, 12110, United States|Novartis Investigative Site, New York, New York, 10003, United States|Novartis Investigative Site, Patchogue, New York, 11772, United States|Novartis Investigative Site, Asheville, North Carolina, 28806, United States|Novartis Investigative Site, Charlotte, North Carolina, 28202, United States|Novartis Investigative Site, Charlotte, North Carolina, 28204, United States|Novartis Investigative Site, Greensboro, North Carolina, 27401, United States|Novartis Investigative Site, Greenville, North Carolina, 27834, United States|Novartis Investigative Site, Raleigh, North Carolina, 27607, United States|Novartis Investigative Site, Salisbury, North Carolina, 28144, United States|Novartis Investigative Site, Winston-Salem, North Carolina, 27103, United States|Novartis Investigative Site, Grand Forks, North Dakota, 58201, United States|Novartis Investigative Site, Akron, Ohio, 44320, United States|Novartis Investigative Site, Bellevue, Ohio, 44811, United States|Novartis Investigative Site, Canton, Ohio, 44718, United States|Novartis Investigative Site, Cincinnati, Ohio, 45219, United States|Novartis Investigative Site, Columbus, Ohio, 43221, United States|Novartis Investigative Site, Dayton, Ohio, 45408, United States|Novartis Investigative Site, Toledo, Ohio, 43623, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, 73104, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, 73112, United States|Novartis Investigative Site, Eugene, Oregon, 97401, United States|Novartis Investigative Site, Greensburg, Pennsylvania, 15601, United States|Novartis Investigative Site, Hershey, Pennsylvania, 17033-0850, United States|Novartis Investigative Site, Pittsburgh, Pennsylvania, 15212, United States|Novartis Investigative Site, Cranston, Rhode Island, 02920, United States|Novartis Investigative Site, Indian Land, South Carolina, 29707, United States|Novartis Investigative Site, Spartanburg, South Carolina, 29302, United States|Novartis Investigative Site, Spartanburg, South Carolina, 29307, United States|Novartis Investigative Site, Cordova, Tennessee, 38018, United States|Novartis Investigative Site, Knoxville, Tennessee, 37920, United States|Novartis Investigative Site, Nashville, Tennessee, 37205, United States|Novartis Investigative Site, Colleyville, Texas, 76034, United States|Novartis Investigative Site, Houston, Texas, 77074, United States|Novartis Investigative Site, Lubbock, Texas, 79410, United States|Novartis Investigative Site, North Richland Hills, Texas, 76180, United States|Novartis Investigative Site, Plano, Texas, 75075, United States|Novartis Investigative Site, Round Rock, Texas, 78681, United States|Novartis Investigative Site, San Antonio, Texas, 78229, United States|Novartis Investigative Site, Orem, Utah, 84058, United States|Novartis Investigative Site, Alexandria, Virginia, 22310, United States|Novartis Investigative Site, Norfolk, Virginia, 23507, United States|Novartis Investigative Site, Vienna, Virginia, 22182, United States|Novartis Investigative Site, Bothell, Washington, 98011, United States|Novartis Investigative Site, Seattle, Washington, 98101, United States|Novartis Investigative Site, Tacoma, Washington, 98405, United States|Novartis Investigative Site, Morgantown, West Virginia, 26506-9260, United States|Novartis Investigative Site, Neenah, Wisconsin, 54956, United States|Novartis Investigative Site, Guaynabo, 00968, Puerto Rico"
NCT01895335,Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients,https://beta.clinicaltrials.gov/study/NCT01895335,COMPLETED,Multiple Sclerosis,DRUG: Teriflunomide,Sanofi,,ALL,"ADULT, OLDER_ADULT",PHASE4,1001,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-06,2015-11,2015-11,"Investigational Site Number 840077, Birmingham, Alabama, 35209, United States|Investigational Site Number 840007, Cullman, Alabama, United States|Investigational Site Number 840087, Phoenix, Arizona, 85004, United States|Investigational Site Number 840114, Phoenix, Arizona, 85008, United States|Investigational Site Number 840080, Scottsdale, Arizona, 85258, United States|Investigational Site Number 840032, Tucson, Arizona, 85704, United States|Investigational Site Number 840021, Phoenix, Arkansas, United States|Investigational Site Number 840018, Fullerton, California, 92835, United States|Investigational Site Number 840037, Fullerton, California, 92835, United States|Investigational Site Number 840108, Long Beach, California, 90806, United States|Investigational Site Number 840014, Newport Beach, California, 92663, United States|Investigational Site Number 840019, Oceanside, California, 92056, United States|Investigational Site Number 840097, Boulder, Colorado, 80304, United States|Investigational Site Number 840040, Colorado Springs, Colorado, 80907, United States|Investigational Site Number 840046, Denver, Colorado, CO, United States|Investigational Site Number 840016, Englewood, Colorado, 80113, United States|Investigational Site Number 840094, Fort Collins, Colorado, 80528, United States|Investigational Site Number 840024, Bradenton, Florida, FL, United States|Investigational Site Number 840089, Clearwater, Florida, 33756, United States|Investigational Site Number 840055, Coconut Creek, Florida, 33073, United States|Investigational Site Number 840104, Hialeah, Florida, 33013, United States|Investigational Site Number 840101, Miami Lakes, Florida, 33014, United States|Investigational Site Number 840011, Ormond Beach, Florida, United States|Investigational Site Number 840059, Sarasota, Florida, 34239, United States|Investigational Site Number 840008, St. Petersburg, Florida, United States|Investigational Site Number 840081, Sunrise, Florida, 33351, United States|Investigational Site Number 840002, Atlanta, Georgia, 30318, United States|Investigational Site Number 840075, Macon, Georgia, 31210, United States|Investigational Site Number 840012, Fort Wayne, Indiana, United States|Investigational Site Number 840010, Indianapolis, Indiana, United States|Investigational Site Number 840034, Louisville, Kentucky, 40207, United States|Investigational Site Number 840047, Rockport, Maine, 04843, United States|Investigational Site Number 840107, Foxboro, Massachusetts, 02035, United States|Investigational Site Number 840030, Springfield, Massachusetts, 01104, United States|Investigational Site Number 840073, Clinton Township, Michigan, 48035, United States|Investigational Site Number 840068, Golden Valley, Minnesota, 55422, United States|Investigational Site Number 840098, Golden Valley, Minnesota, 55422, United States|Investigational Site Number 840086, Chesterfield, Missouri, 63017, United States|Investigational Site Number 840058, St. Louis, Missouri, 63110, United States|Investigational Site Number 840026, Lincoln, Nebraska, 68521, United States|Investigational Site Number 840020, Henderson, Nevada, 89012, United States|Investigational Site Number 840049, Freehold, New Jersey, 07728, United States|Investigational Site Number 840044, Toms River, New Jersey, 08755, United States|Investigational Site Number 840100, East Setauket, New York, 11733-345, United States|Investigational Site Number 840005, New York, New York, United States|Investigational Site Number 840064, NY, New York, 14203, United States|Investigational Site Number 840071, Schenectady, New York, 12308, United States|Investigational Site Number 840091, Staten Island, New York, 10306, United States|Investigational Site Number 840045, Syracuse, New York, 13202, United States|Investigational Site Number 840084, Asheville, North Carolina, 28806, United States|Investigational Site Number 840078, Charlotte, North Carolina, 28204, United States|Investigational Site Number 840042, Raliegh, North Carolina, United States|Investigational Site Number 840105, Sanford, North Carolina, United States|Investigational Site Number 840074, Wilmington, North Carolina, 28401, United States|Investigational Site Number 840090, Winston Salem, North Carolina, 27103, United States|Investigational Site Number 840041, Bismarck, North Dakota, United States|Investigational Site Number 840003, Canton, Ohio, 44718, United States|Investigational Site Number 840009, Dayton, Ohio, United States|Investigational Site Number 840053, Monaca, Pennsylvania, 15061, United States|Investigational Site Number 840056, Philadelphia, Pennsylvania, 19107, United States|Investigational Site Number 840072, Cranston, Rhode Island, 02920, United States|Investigational Site Number 840048, Nashville, Tennessee, 37215, United States|Investigational Site Number 840035, Tullahoma, Tennessee, 37388, United States|Investigational Site Number 840060, Dallas, Texas, 75246, United States|Investigational Site Number 840052, Mansfield, Texas, 76063, United States|Investigational Site Number 840028, San Antonio, Texas, 78229, United States|Investigational Site Number 840070, Henrico, Virginia, 23226, United States|Investigational Site Number 840109, Richmond, Virginia, 23298, United States|Investigational Site Number 840017, Roanoke, Virginia, 24018, United States|Investigational Site Number 840054, Vienna, Virginia, 22182, United States|Investigational Site Number 840069, Spokane, Washington, 99220-3649, United States|Investigational Site Number 840079, Morgantown, West Virginia, 26506-9180, United States|Investigational Site Number 840038, Milwaukee, Wisconsin, 53215, United States|Investigational Site Number 840112, Milwaukee, Wisconsin, United States|Investigational Site Number 840076, Neenah, Wisconsin, 54956, United States|Investigational Site Number 040-001, Linz, Austria|Investigational Site Number 040-002, Wien, Austria|Investigational Site Number 056006, Brasschaat, 2930, Belgium|Investigational Site Number 056001, Bruxelles, 1200, Belgium|Investigational Site Number 056003, Edegem, 2650, Belgium|Investigational Site Number 056002, Kortrijk, 8500, Belgium|Investigational Site Number 056007, Leuven, 3000, Belgium|Investigational Site Number 056008, Liège, 4000, Belgium|Investigational Site Number 056009, Liège, 4000, Belgium|Investigational Site Number 056005, Melsbroek, 1820, Belgium|Investigational Site Number 124006, Cambridge, N1R7L6, Canada|Investigational Site Number 124007, St. John, E2L 4L2, Canada|Investigational Site Number 152003, Concepcion, Chile|Investigational Site Number 152001, Santiago, Chile|Investigational Site Number 152005, Santiago, Chile|Investigational Site Number 246004, Hämeenlinna, 13530, Finland|Investigational Site Number 246005, Kuopio, Finland|Investigational Site Number 246006, Oulu, 90220, Finland|Investigational Site Number 246001, Turku, 20520, Finland|Investigational Site Number 246003, Turku, 20520, Finland|Investigational Site Number 250002, Agen Cedex, 47923, France|Investigational Site Number 250003, Aix En Provence, 13616, France|Investigational Site Number 250004, Albi, 81000, France|Investigational Site Number 250005, Amiens Cedex 1, 80054, France|Investigational Site Number 250006, Bayonne, 64109, France|Investigational Site Number 250007, Bordeaux, 33000, France|Investigational Site Number 250008, Caen, 14000, France|Investigational Site Number 250009, CAHORS Cedex 9, 46005, France|Investigational Site Number 250011, Chambery, 73000, France|Investigational Site Number 250012, Colmar, 68024, France|Investigational Site Number 250001, Dijon, 21000, France|Investigational Site Number 250015, GRENOBLE cedex, 38043, France|Investigational Site Number 250017, Le Mans Cedex 9, 72037, France|Investigational Site Number 250018, Lille Cedex, 59037, France|Investigational Site Number 250019, Limoges Cedex, 87000, France|Investigational Site Number 250020, Lyon Cedex 03, 69275, France|Investigational Site Number 250021, Marseille, 13008, France|Investigational Site Number 250022, Metz-Tessy, 74370, France|Investigational Site Number 250023, Montbeliard, 25200, France|Investigational Site Number 250024, MONTPELLIER Cedex 5, 34295, France|Investigational Site Number 250025, Mulhouse, 68100, France|Investigational Site Number 250026, Nancy, France|Investigational Site Number 250027, Nantes, 44093, France|Investigational Site Number 250028, Nimes, 30029, France|Investigational Site Number 250016, PARIS Cedex 13, 75013, France|Investigational Site Number 250029, PARIS Cedex 20, 75970, France|Investigational Site Number 250043, Pau, 64000, France|Investigational Site Number 250031, Quimper, 29000, France|Investigational Site Number 250032, Reims, 51100, France|Investigational Site Number 250033, Rouen, 76000, France|Investigational Site Number 250030, St Germain En Laye, 78100, France|Investigational Site Number 250035, Strasbourg, 67091, France|Investigational Site Number 250037, Toulouse, 31200, France|Investigational Site Number 250038, Tours, 37044, France|Investigational Site Number 250039, Valence Cedex 9, 26953, France|Investigational Site Number 250040, Valenciennes, 59322, France|Investigational Site Number 250013, VICHY Cedex, 03201, France|Investigational Site Number 276001, Bergisch-Gladbach, 51429, Germany|Investigational Site Number 276003, Berlin, 12099, Germany|Investigational Site Number 276004, Freiburg, 79098, Germany|Investigational Site Number 300002, Athens, 11521, Greece|Investigational Site Number 300001, Athens, 11525, Greece|Investigational Site Number 300005, Larissa, 41110, Greece|Investigational Site Number 300004, Thessaloniki, 546 36, Greece|Investigational Site Number 380008, Ancona, 60126, Italy|Investigational Site Number 380009, Bari, 70124, Italy|Investigational Site Number 380002, Gallarate (VA), 21013, Italy|Investigational Site Number 380001, Milano, 20132, Italy|Investigational Site Number 380004, Milano, 20133, Italy|Investigational Site Number 380006, Napoli, 80138, Italy|Investigational Site Number 380005, Orbassano (TO), 10043, Italy|Investigational Site Number 578002, Bergen, 5021, Norway|Investigational Site Number 578003, Namsos, 7800, Norway|Investigational Site Number 578001, Oslo, 0407, Norway|Investigational Site Number 724002, Barcelona, 08035, Spain|Investigational Site Number 724010, Córdoba, 14004, Spain|Investigational Site Number 724008, Donostia, 20014, Spain|Investigational Site Number 724001, El Palmar (MURCIA), 30120, Spain|Investigational Site Number 724004, La Coruña, 15006, Spain|Investigational Site Number 724006, Santiago de Compostela, 15706, Spain|Investigational Site Number 724007, Valencia, 46009, Spain|Investigational Site Number 724005, Valladolid, 47011, Spain|Investigational Site Number 752001, Karlstad, 65185, Sweden|Investigational Site Number 752003, Kungsbacka, 43480, Sweden|Investigational Site Number 752002, Motala, 59185, Sweden|Investigational Site Number 826-005, Birmingham, B152TH, United Kingdom|Investigational Site Number 826-003, Brighton, BN25BE, United Kingdom|Investigational Site Number 826-007, Glasgow, G116NT, United Kingdom|Investigational Site Number 826-008, Leeds, LS13EX, United Kingdom|Investigational Site Number 826-010, Leicester, LE54PW, United Kingdom|Investigational Site Number 826-009, London, SW170QT, United Kingdom|Investigational Site Number 826-001, Norwich, nr34dg, United Kingdom|Investigational Site Number 826-006, Romford, RM70AG, United Kingdom|Investigational Site Number 826-004, Salford, M68HD, United Kingdom"
NCT02280096,Efficacy and Safety of 4-aminopyridine on Cognitive Performance and Motor Function of Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02280096,COMPLETED,Multiple Sclerosis,DRUG: 4-aminopyridine|DRUG: Placebo,"Coordinación de Investigación en Salud, Mexico",,ALL,ADULT,PHASE2,24,OTHER_GOV,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-10,2016-02,2017-02,"Hospital de Especialidades, CMN Siglo XXI, Mexico City, Distrito Federal, 06725, Mexico"
NCT00835835,Lokomat Treadmill Training Effects on MS Gait,https://beta.clinicaltrials.gov/study/NCT00835835,COMPLETED,"Gait, Unsteady|Multiple Sclerosis",OTHER: Body-weight supported treadmill training +/- Lokomat assistance|OTHER: Usual Care - no active intervention,Mount Sinai Rehabilitation Hospital,,ALL,ADULT,NA,8,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2008-02,2011-10,2013-06,"Mandell Center for Multiple Sclerosis at Mt. Sinai Rehabilitation Hospital, Hartford, Connecticut, 06112, United States"
NCT03244696,Behavior and Activity Monitoring in MS,https://beta.clinicaltrials.gov/study/NCT03244696,COMPLETED,Relapsing-Remitting Multiple Sclerosis,BEHAVIORAL: Step Tracking|BEHAVIORAL: Water Tracking,Ohio State University,National Multiple Sclerosis Society,ALL,ADULT,NA,87,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-11-02,2021-06-28,2021-06-28,"Department of Psychology, The Ohio State University, Columbus, Ohio, 43210, United States"
NCT03052595,Multiple Sclerosis: The Role of Mitochondrial Dysfunction in IR Resistance,https://beta.clinicaltrials.gov/study/NCT03052595,COMPLETED,Multiple Sclerosis|Mitochondrial Alteration,DIAGNOSTIC_TEST: Oral glucose tolerance test|DIAGNOSTIC_TEST: Testing of autonomous nervous system function|DIAGNOSTIC_TEST: Stroop test,Slovak Academy of Sciences,Comenius University,ALL,ADULT,,70,OTHER_GOV,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-02-01,2023-03-31,2023-03-31,"Biomedical Center, Slovak Academy of Sciences, Institute of clinical and translational reasearch, Bratislava, 84505, Slovakia"
NCT03755167,A Follow up Study to Protocol 101/2 - Continued Treatment by IPL344 IV,https://beta.clinicaltrials.gov/study/NCT03755167,UNKNOWN,Amyotrophic Lateral Sclerosis (ALS),DRUG: IPL344,Immunity Pharma Ltd.,,ALL,"ADULT, OLDER_ADULT",PHASE2,15,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-12-09,2022-11,2022-12,"Hadassah Medical Center/Neuromuscular / EMG service and ALS / Motor Neuron Disease Clinic, Jerusalem, 91120, Israel|Hadassah Medical Center -Motor Neuron Disease Clinic, Jerusalem, Israel"
NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,https://beta.clinicaltrials.gov/study/NCT00573443,COMPLETED,Pseudobulbar Affect (PBA),DRUG: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|DRUG: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|DRUG: Placebo,Avanir Pharmaceuticals,Syneos Health,ALL,"ADULT, OLDER_ADULT",PHASE3,326,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2007-12,2009-06,2009-09,"St. Joseph's Hospital and Medical Center, Phoenix, Arizona, 85013, United States|Neuromuscular Research Center, Scottsdale, Arizona, 85258, United States|South Coast Clinical Trials, Anaheim, California, 92804, United States|UCI Medical Center, Irvine, California, 92868, United States|Center for Neurologic Study, La Jolla, California, 92103, United States|UCLA School of Medicine, Los Angeles, California, 90095, United States|The Forbes Norris MDA/ALS Research Center - California Pacific Medical Center, San Francisco, California, 94115, United States|The ALS Center at UCSF, San Francisco, California, 94117, United States|University of Colorado at Denver & Health Science Center, Aurora, Colorado, 80045, United States|Neuroscience Center, Ft. Lauderdale, Florida, 33334, United States|Mayo Clinic, Jacksonville, Florida, 32224, United States|University of Miami, Miami, Florida, 33136, United States|Suncoast Neuroscience Associates, St. Petersburg, Florida, 33701, United States|The ALS Center at Emory University, Atlanta, Georgia, 30322, United States|Neurology Specialists of Decatur of Decatur, Decatur, Georgia, 30033, United States|Northwestern University, Chicago, Illinois, 60611, United States|Consultants in Neurology, Northbrook, Illinois, 60062, United States|University of Kentucky Health Care - Dept. of Neurology, Lexington, Kentucky, 40536, United States|The John Hopkins Universitiy, Baltimore, Maryland, 21287, United States|Massachusets General Hospital, Boston, Massachusetts, 02129, United States|Baystate Medical Center, Springfield, Massachusetts, 01199, United States|University of Michigan, Ann Arbor, Michigan, 48109, United States|Henry Ford Hospital, Detroit, Michigan, 48202, United States|St.Louis University - Neuromuscular Clinic, St. Louis, Missouri, 63110, United States|Advanced Neurology Specialists, Great Falls, Montana, 59405, United States|Neurology Associates, Lincoln, Nebraska, 68506, United States|Universitiy of Nevada, Las Vegas, Nevada, 89102, United States|Upstate Clinical Research, Albany, New York, 12205, United States|Jacobs Neurological Institute, Buffalo, New York, 14203, United States|Mount Sinai Medical Center, New York, New York, 10029, United States|Neurological Institute - Columbia Presbyterian Center, New York, New York, 10032, United States|Carolinas Medical Center, Charlotte, North Carolina, 28207, United States|Duke Universitiy Medical Center, Durham, North Carolina, 27710, United States|Department of Neurology - The Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States|Ohio State Universitiy, Columbus, Ohio, 43210, United States|Oregon Health Science University, Portland, Oregon, 97239, United States|Drexel University - Department of Neurology, Philadelphia, Pennsylvania, 19107, United States|The ALS Center - Penn Neurological Institute - The University of Pennsylvania, Philadelphia, Pennsylvania, 19107, United States|Vanderbilt University, Nashville, Tennessee, 37232, United States|The Methodist Hospital - Baylor College of Medicine, Houston, Texas, 77030, United States|Department of Neuropsychiatry - Texas Tech University, Lubbock, Texas, 79430, United States|University of Texas Health Science Center, San Antonio, Texas, 78229, United States|Universitiy of Vermont, Burlington, Vermont, 05405, United States|West Virginia University, Morgantown, West Virginia, 26506, United States|Dean Foundation, Madison, Wisconsin, 53715, United States|FACENE, Buenos Aires, Ciudad de Buenos Aires, 1117ABD, Argentina|IADIN, Buenos Aires, Ciudad de Buenos Aires, C1055AAD, Argentina|Hospital Italiano, Buenos Aires, Ciudad de Buenos Aires, C1181ACH, Argentina|INEBA, Buenos Aires, Ciudad de Buenos Aires, C1192AAW, Argentina|Hospital Ramos Mejia, Buenos Aires, Ciudad de Buenos Aires, C1221ADC, Argentina|Hospital Britanico, Buenos Aires, Ciudad de Buenos Aires, C1280AEB, Argentina|Policlinico Bancario, Buenos Aires, Ciudad de Buenos Aires, C1416DRJ, Argentina|FLENI, Buenos Aires, Ciudad de Buenos Aires, C1428AQK, Argentina|Instituto Medico Rodriguez Alfici, Godoy Cruz, Mendoza, M5501AAP, Argentina|Instituto de Neurociencias Rosario, Rosario, Santa Fe, 2002KQJ, Argentina|Hospital Militar Regional de Cordoba, Cordoba, X5000HGX, Argentina|Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte, M G, 30.150-221, Brazil|Hospital da Restauração, Recife, PE, 52.010-040, Brazil|Hospital de Clínicas-UFPR, Curitiba, PR, 80.060.900, Brazil|Hospital Universitário Clementino Fraga Filho, Rio de Janeiro, RJ, 21941-913, Brazil|Hospital Moinhos de Vento, Porto Alegre, RS, 90.560.030, Brazil|Hospital das Clínicas da Faculdade de Medicina da Universidade São Paulo, Sao Paulo, SP, 05.403-000, Brazil"
NCT04416243,Feasibility of a High-intensity Interval Training Program in Persons With Multiple Sclerosis Who Have Walking Disability,https://beta.clinicaltrials.gov/study/NCT04416243,COMPLETED,Multiple Sclerosis,"BEHAVIORAL: Recumbent Stepping, High-Intensity Interval Training","University of North Texas, Denton, TX",University of Alabama at Birmingham|Berry College,ALL,"ADULT, OLDER_ADULT",NA,17,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2019-12-19,2022-12-14,2022-12-14,"University of North Texas, Denton, Texas, 76203, United States"
NCT01413243,Trichuris Suis Ova (TSO)in Recurrent Remittent Multiple Sclerosis and Clinically Isolated Syndrome,https://beta.clinicaltrials.gov/study/NCT01413243,TERMINATED,Multiple Sclerosis,DRUG: Trichuris suis ova,"Charite University, Berlin, Germany",,ALL,"ADULT, OLDER_ADULT",PHASE2,50,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2012-09,2016-12,2017-06,"Charité - Universitätsmedizin Berlin, Department of Neurology, Berlin, 10117, Germany"
NCT00965497,Escitalopram (Lexapro) for Depression MS or ALS,https://beta.clinicaltrials.gov/study/NCT00965497,COMPLETED,Major Depression|Multiple Sclerosis|Amyotrophic Lateral Sclerosis,DRUG: escitalopram,University of South Carolina,,ALL,"ADULT, OLDER_ADULT",PHASE3,13,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2009-07,2010-03,2010-03,"University of South Carolina School of Medicine, Columbia, South Carolina, 20203, United States"
NCT01667497,Does Fampridine SR Improve Cognitive Fatigue in Multiple Sclerosis Patients?,https://beta.clinicaltrials.gov/study/NCT01667497,COMPLETED,Cognitive Fatigue,DRUG: Fampridine SR|DRUG: Placebo,London Health Sciences Centre,,ALL,ADULT,PHASE2|PHASE3,60,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-09,2015-07,2015-08,"London Health Sciences Center and St. Joseph's Heathcare Center (Parkwood), London, Ontario, N6G 1W8, Canada"
NCT02912897,Trial to Assess the Safety and Feasibility of Adoptive Cell Therapy With Autologous EBV-specific Cytotoxic T Lymphocytes (CTL) in Patients With a First Clinical Episode Highly Suggestive of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02912897,RECRUITING,Multiple Sclerosis,BIOLOGICAL: Cellular therapy with EBV specific autologous CTL infusion,Nantes University Hospital,,ALL,ADULT,PHASE1,7,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-01-26,2026-11,2026-11,"University Hospital, Nantes, France"
NCT01597297,Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis.,https://beta.clinicaltrials.gov/study/NCT01597297,COMPLETED,Multiple Sclerosis,DRUG: BIIB041 (PR Fampridine)|OTHER: Placebo,Biogen,,ALL,"ADULT, OLDER_ADULT",PHASE2,132,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2012-08,2013-08,2013-08,"Research Site, Ath, Belgium|Research Site, Brugge, Belgium|Research Site, Brussels, Belgium|Research Site, Leuven, Belgium|Research Site, Yvoir, Belgium|Research Site, Halifax, Nova Scotia, Canada|Research Site, London, Ontario, Canada|Research Site, Gatineau, Quebec, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Ancona, AN, Italy|Research Site, Brescia, BS, Italy|Research Site, Empoli, FI, Italy|Research Site, Palermo, PA, Italy|Research Site, Roma, RM, Italy|Research Site, Breda, Netherlands|Research Site, Sittard-Geleen, Netherlands|Research Site, Göteborg, Sweden|Research Site, Stockholm, Sweden|Research Site, Edgbaston, Birmingham, United Kingdom|Research Site, Poole, Dorset, United Kingdom|Research Site, Swansea, Glamorgan, United Kingdom|Research Site, London, United Kingdom"
NCT04749667,Study of Mesenchymal Autologous Stem Cells as Regenerative Treatment for Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04749667,RECRUITING,Multiple Sclerosis|Progressive Multiple Sclerosis,OTHER: MSCs|DRUG: Saline,Haukeland University Hospital,"University of Bergen|University Hospital Ulm|University Hospital, Akershus|St. Olavs Hospital|University Hospital of North Norway",ALL,ADULT,PHASE1|PHASE2,18,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-08-09,2024-10-04,2025-01-04,"University hospital of North Norway, Tromsø, Troms Og Finnmark, Norway|St.Olav university hospital, Trondheim, Trøndelag, Norway|Haukeland University Hospital, Bergen, Vestland, Norway|Akershus university hospital, Lørenskog, Viken, Norway"
NCT03387267,Videofluoroscopic Swallowing Study (VFSS),https://beta.clinicaltrials.gov/study/NCT03387267,TERMINATED,Stroke|Parkinson Disease|Multiple Sclerosis|Oropharyngeal Dysphagia|Alzheimer Disease|Dementia,DEVICE: Dysphagia Detection System,Société des Produits Nestlé (SPN),Cytel Inc.|Regulatory and Clinical Research Institute Inc|Nestec Ltd.,ALL,"ADULT, OLDER_ADULT",NA,452,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: SCREENING,2017-10-24,2018-07-23,2018-07-23,"Rancho Research Institute, Rancho Los Amigos National Rehabilitation Center, Downey, California, 90242, United States|University of Colorado Denver, Aurora, Colorado, 80045, United States|Medstar Rehabilitation Hospital, Washington, District of Columbia, 20010, United States|Shirley Ryan AbilityLab, Chicago, Illinois, 60611, United States|Marionjoy Rehabilitation Hospital, Wheaton, Illinois, 60187, United States|Kentucky Clinic, Lexington, Kentucky, 40536, United States|Boston Medical Center, Boston, Massachusetts, 02118, United States|Henry Ford Health System, Detroit, Michigan, 48202, United States|New York Presbyterian/Weill Cornell Medical Center, New York, New York, 10021, United States|New York Presbyterian Hospital/Columbia University Medical Center, New York, New York, 10032, United States|The Burke Medical Research Institute, White Plains, New York, 10605, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States|Helsinki University Central Hospital, Helsinki, 00029, Finland"
NCT03422367,JASPER Early Intervention for Tuberous Sclerosis,https://beta.clinicaltrials.gov/study/NCT03422367,UNKNOWN,Tuberous Sclerosis,BEHAVIORAL: JASPER,"University of California, Los Angeles",Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Boston Children's Hospital|Massachusetts General Hospital,ALL,CHILD,NA,64,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2017-10-24,2022-06-15,2022-06-15,"University of California Los Angeles, Los Angeles, California, 90065, United States|Boston Children's Hospital, Boston, Massachusetts, 02215, United States"
NCT04132167,Supervised Perturbation Training Results in Changes in Balance and Falling in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04132167,UNKNOWN,Multiple Sclerosis,PROCEDURE: perturbation training,Suleyman Demirel University,,ALL,ADULT,NA,15,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2018-11-20,2019-10-20,2019-12-20,"Hatice Yakut, Isparta, Turkey"
NCT02598167,Participants Preferences to Disease Modifying Agents in Relapsing Remitting Multiple Sclerosis Condition,https://beta.clinicaltrials.gov/study/NCT02598167,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",,223,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-12-07,2016-02-23,2016-02-23,"Hospital Sant Joan Despi Moises Broggi; Servicio de Neurología, Sant Joan Despí, Barcelona, 08970, Spain|Hospital Universitario Marques de Valdecilla; Servicio de Neurología, Santander, Cantabria, Spain|Hospital General de Castellon; Servicio de Neurología, Castelló de la Plana, Castellon, 12004, Spain|Hospital Universitari Arnau de Vilanova de Lleida; Servicio de Neurología, Lleida, Lerida, 25198, Spain|Hospital Universitario del Sureste; Servicio de Neurologia, Arganda del Rey, Madrid, 28500, Spain|Hospital Universitario Rey Juan Carlos de Móstoles; Servicio de Neurología, Móstoles, Madrid, 28933, Spain|Hospital Quiron de Madrid; Servicio de Neurologia, Pozuelo de Alarcon, Madrid, 28223, Spain|Complejo Hospitalario Universitario de Vigo - Xeral Cies; Servicio de Neurologia, Vigo, Pontevedra, 36312, Spain|Hospital Universitario de Canarias; Servicio de Neurologia, San Cristóbal de La Laguna, Tenerife, Spain|Hospital del Mar; Servicio de Neurologia, Barcelona, 08003, Spain|Hospital Universitario Reina Sofia; Servicio de Neurologia, Cordoba, 14011, Spain|Hospital Universitari de Girona Dr. Josep Trueta; Servicio de Neurologia, Girona, 17007, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Neurologia, Madrid, 28007, Spain|Fundacion Jimenez Diaz; Servicio de Neurología, Madrid, 28040, Spain|Hospital Universitario 12 de Octubre; Servicio de Neurologia, Madrid, 28041, Spain|Hospital Clinico Universitario de Valencia; Servicio de Neurologia, Valencia, 46010, Spain|Hospital Universitario Dr. Peset; Servicio de Neurologia, Valencia, 46017, Spain|Hospital Universitario La Fe; Unidad de Esclerosis Multiple, Valencia, 46026, Spain"
NCT00928967,"Open, Multicentric, Prospective, Quality of Life Study in Multiple Sclerosis Patients",https://beta.clinicaltrials.gov/study/NCT00928967,COMPLETED,Multiple Sclerosis,"DRUG: Interferon beta-1b, (Betaseron BAY86-5046)",Bayer,,ALL,"ADULT, OLDER_ADULT",,67,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2007-05,2010-03,2010-11,"Many Locations, France"
NCT04792567,Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC),https://beta.clinicaltrials.gov/study/NCT04792567,COMPLETED,Secondary Progressive Multiple Sclerosis,DRUG: BAF312|DRUG: Baseline disease modifying therapies (DMTs),Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE4,41,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-04-19,2021-09-06,2022-08-15,"Novartis Investigative Site, Mittweida, Sachsen, 09648, Germany|Novartis Investigative Site, Bogen, 94327, Germany|Novartis Investigative Site, Chemnitz, 09117, Germany|Novartis Investigative Site, Dresden, 01307, Germany|Novartis Investigative Site, Düsseldorf, 40211, Germany|Novartis Investigative Site, Neuburg an der Donau, 86633, Germany|Novartis Investigative Site, Pforzheim, 75172, Germany|Novartis Investigative Site, Regensburg, 93059, Germany|Novartis Investigative Site, Ruelzheim, 76761, Germany|Novartis Investigative Site, Ulm, 89073, Germany"
NCT00315367,A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties,https://beta.clinicaltrials.gov/study/NCT00315367,COMPLETED,Relapsing-Remitting Multiple Sclerosis,DRUG: Donepezil HCI (drug),Neurognostics,,ALL,"ADULT, OLDER_ADULT",PHASE4,26,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE|Primary Purpose: TREATMENT,2004-09,,2007-10,"Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States"
NCT03283397,"A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in Patients With RRMS",https://beta.clinicaltrials.gov/study/NCT03283397,RECRUITING,"Multiple Sclerosis, Relapsing-Remitting",DRUG: EK-12|DRUG: INF beta-1a,Bosnalijek D.D,MonitorCRO,ALL,ADULT,PHASE3,400,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2019-03-26,2023-12-31,2024-07-01,"Kocaeli University, Faculty of Medicine, Department of Neurology, Kocaeli, Turkey"
NCT01811290,A Pilot Study Assessing the Impact of Gilenya Therapy on Bone Density Change in Relapsing Forms of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01811290,UNKNOWN,Multiple Sclerosis,,"Simnad, Virginia, M.D.",Novartis,ALL,"ADULT, OLDER_ADULT",,36,INDIV,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-01,2018-07,2018-12,"MS Center at Evergreen Health, Kirkland, Washington, 98034, United States"
NCT05031403,Development and Application of Tele-Neuro Rehabilitation System,https://beta.clinicaltrials.gov/study/NCT05031403,RECRUITING,Stroke|Multiple Sclerosis|Parkinson Disease,OTHER: Telerehabilitaton|OTHER: Home Exercise,Istanbul University - Cerrahpasa (IUC),The Scientific and Technological Research Council of Turkey,ALL,"ADULT, OLDER_ADULT",NA,114,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-04-01,2022-09-01,2022-10-01,"Istanbul University-Cerrahpasa, Istanbul, Turkey"
NCT03723356,Linking Cognitive Functioning to Multimodal Imaging in Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT03723356,TERMINATED,Multiple Sclerosis|Cognition Disorders,DIAGNOSTIC_TEST: Siemens Biograph mMR (molecular MR)|DIAGNOSTIC_TEST: fMRI|DIAGNOSTIC_TEST: Diffusion Spectrum Imaging (DSI),NYU Langone Health,,ALL,ADULT,,6,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-07-01,2021-01-09,2021-01-09,"New York University School of Medicine, New York, New York, 10016, United States"
NCT03709290,Cerebrovascular Changes in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT03709290,UNKNOWN,Multiple Sclerosis,RADIATION: mri,Assiut University,,ALL,ADULT,,50,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-10-01,2020-12-01,2021-12-31,
NCT05635890,Effect of Vestibular Rehabilitation on Trunk Kinetic and Kinematic Parameters in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05635890,COMPLETED,Vestibular Rehabilitation in MS,OTHER: Cawthorne Cooksey exercise protocol|OTHER: conventional vestibular rehabilitation,October 6 University,,ALL,ADULT,NA,30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-05-06,2022-08-10,2022-09-20,"October 6 University, El-Sheikh Zayed City, Giza, 1133, Egypt"
NCT04242056,To Study the Pathophysiological Features of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04242056,UNKNOWN,Multiple Sclerosis|Neurofilament Light Chain|Glial Fibrillary Acidic Protein,DRUG: 18F-PM-PBB3,Chang Gung Memorial Hospital,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,38,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-02-20,2020-09-30,2020-09-30,
NCT04291456,Minocycline in MS: Confirmation of Benefit,https://beta.clinicaltrials.gov/study/NCT04291456,TERMINATED,Multiple Sclerosis|Clinically Isolated Syndrome,DRUG: Minocycline 100mg,University of Calgary,"Hotchkiss Brain Institute, University of Calgary|Multiple Sclerosis Society of Canada",ALL,ADULT,PHASE3,9,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-01-31,2022-12-16,2022-12-31,"Calgary MS Clinic at Foothills Medical Centre, Calgary, Alberta, T2N 2T9, Canada"
NCT02760056,Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study,https://beta.clinicaltrials.gov/study/NCT02760056,COMPLETED,Multiple Sclerosis,DRUG: Liothyronine sodium|DRUG: Placebo,Oregon Health and Science University,,ALL,ADULT,PHASE1,15,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-06-06,2017-01-10,2017-01-10,"Oregon Health and Science University, Portland, Oregon, 97239, United States"
NCT01587690,Immune Regulation in Multiple Sclerosis: MicroRNA and Antigen-Presenting Cells,https://beta.clinicaltrials.gov/study/NCT01587690,COMPLETED,Multiple Sclerosis,,"Rutgers, The State University of New Jersey",,ALL,ADULT,,24,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-11,2013-01,2013-01,"Rutgers-RWJMS, New Brunswick, New Jersey, 08901, United States"
NCT00581997,QAX576 in Patients With Pulmonary Fibrosis Secondary to Systemic Sclerosis,https://beta.clinicaltrials.gov/study/NCT00581997,TERMINATED,Pulmonary Fibrosis Secondary to Systemic Sclerosis,DRUG: QAX576|DRUG: Placebo,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE2,8,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2007-12,2009-04,,
NCT00914290,A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00914290,COMPLETED,Spasticity|Multiple Sclerosis,DRUG: IPX056|DRUG: Baclofen IR|DRUG: Placebo IPX056|DRUG: Placebo IR,"Impax Laboratories, LLC",,ALL,"ADULT, OLDER_ADULT",PHASE2,23,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2009-04,2010-01,2010-02,"Northwest NeuroSpecialists, PLLC, Tucson, Arizona, 85741, United States|University of Colorado, Aurora, Colorado, 80045, United States|Meridien Research, Tampa, Florida, 33606, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, 46805, United States|MidAmerica Neuroscience Institute, Lenexa, Kansas, 66214, United States|QUEST Research Institute, Bingham Farms, Michigan, 48025, United States|Great Falls Cllinic, Great Falls, Montana, 59405, United States|Empire Neurology, PC, Latham, New York, 12110, United States|Winthrop University Hospital, Mineola, New York, 11501, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, 27157, United States|Central Texas Neurology Consultants, Round Rock, Texas, 78681, United States"
NCT01065090,"A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Participants With Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT01065090,COMPLETED,Exercise,,Biogen,Biogen Idec A/S,ALL,ADULT,,38,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-06,2014-01,2014-01,"Coordinating Research Site, NSW, Australia|Research Site, Odense, Denmark|Research Site, Sønderborg, Denmark|Research Site, Vejle, Denmark|Research Site, Jyväskylä, Finland|Research Site, Oulu, Finland|Research Site, Pori, Finland|Research Site, Seinäjokï, Finland|Research Site, Hamilton, New Zealand|Research Site, Drammen, Norway|Research Site, Ullevål, Norway|Research Site, Gothenburg, Sweden|Research Site, Stockholm, Sweden|Research Site, Ängelholm, Sweden"
NCT02523703,Excitotoxicity Markers and the Clinical-radiological Progression After a Demyelinating Event: a Prospective Pilot Study,https://beta.clinicaltrials.gov/study/NCT02523703,COMPLETED,Multiple Sclerosis,BIOLOGICAL: glutamate and aspartate,"University Hospital, Caen",,ALL,ADULT,NA,36,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2007-09-10,2012-02-15,2015-02-23,
NCT00799890,Sunphenon in Progressive Forms of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00799890,COMPLETED,Multiple Sclerosis,DRUG: Sunphenon EGCG|DRUG: Placebo,Friedemann Paul,TAIYO EUROPE,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,61,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2009-05,2016-03,2016-03,"Charité Universitätsmedizin Berlin (NeuroCure Clinical Research Center), Berlin, 10117, Germany"
NCT01433497,Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01433497,COMPLETED,"Multiple Sclerosis, Secondary Progressive|Multiple Sclerosis, Primary Progressive|Multiple Sclerosis, Relapse Free",DRUG: Masitinib|DRUG: Placebo,AB Science,,ALL,"ADULT, OLDER_ADULT",PHASE3,656,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-08,2019-09,2020-02,"""St. Ivan Rilski"" University Multiprofile Hospital for Active Treatment, Sofia, 1431, Bulgaria|GHICL hopital ST vincent de Paul, Lille, 59020, France|Hôpital de Gui de Chauliac, Montpellier, 34295, France|Universitätsklinikum Gießen und Marburg, Marburg, D-35033, Germany|Rehibilitation Center ""KENTAVROS"", Volos, 382 21, Greece|KO-MED Centra Kliniczne Lublin II, Lublin, 20-362, Poland|Centrul Medical Clubul Sănătăţii, Campulung, 115100, Romania|Hospital de la Santa Creu i Sant Pau, Barcelona, 08041, Spain"
NCT04130997,An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04130997,ENROLLING_BY_INVITATION,Relapsing Multiple Sclerosis (RMS),BIOLOGICAL: Ublituximab,"TG Therapeutics, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE3,1100,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2019-11-18,2027-04,2027-04,"TG Therapeutics Investigational Trial Site, Pasadena, California, 91105, United States|TG Therapeutics Investigational Trial Site, Denver, Colorado, 80045, United States|TG Therapeutics Investigational Trial Site, Miami, Florida, 33136, United States|TG Therapeutics Investigational Trial Site, Tampa, Florida, 33612, United States|TG Therapeutics Investigational Trial Site, Northbrook, Illinois, 60062, United States|TG Therapeutics Investigational Trial Site, Kansas City, Kansas, 66160, United States|TG Therapeutics Investigational Trial Site, Detroit, Michigan, 48201, United States|TG Therapeutics Investigational Trial Site, Las Vegas, Nevada, 89106, United States|TG Therapeutics Investigational Trial Site, Teaneck, New Jersey, 07666, United States|TG Therapeutics Investigational Trial Site, Albuquerque, New Mexico, 87131, United States|TG Therapeutics Investigational Trial Site, Amherst, New York, 14266, United States|TG Therapeutics Investigational Trial Site, Columbus, Ohio, 43214, United States|TG Therapeutics Investigational Trial Site, Westerville, Ohio, 43081, United States|TG Therapeutics Investigational Trial Site, Knoxville, Tennessee, 37922, United States|TG Therapeutics Investigational Trial Site, Dallas, Texas, 75246, United States|TG Therapeutics Investigational Trial Site, Frisco, Texas, 75034, United States|TG Therapeutics Investigational Trial Site, Round Rock, Texas, 78681, United States|TG Therapeutics Investigational Trial Site, San Antonio, Texas, 78258, United States|TG Therapeutics Investigational Trial Site, Seattle, Washington, 98109, United States|TG Therapeutics Investigational Trial Site, Grodno, 230017, Belarus|TG Therapeutics Investigational Trial Site, Grodno, 320017, Belarus|TG Therapeutics Investigational Trial Site, Minsk, 220114, Belarus|TG Therapeutics Investigational Trial Site, Minsk, 220116, Belarus|TG Therapeutics Investigational Trial Site, Minsk, 220226, Belarus|TG Therapeutics Investigational Trial Site, Osijek, 31000, Croatia|TG Therapeutics Investigational Trial Site, Varazdin, 42000, Croatia|TG Investigational Trial Site, Zagreb, 10000, Croatia|TG Therapeutics Investigational Trial Site, Tbilisi, 00112, Georgia|TG Therapeutics Investigational Trial Site, Tbilisi, 00114, Georgia|TG Therapeutics Investigational Trial Site, Tbilisi, 00159, Georgia|TG Therapeutics Investigational Trial Site, Tbilisi, 00160, Georgia|TG Therapeutics Investigational Trial Site, Tbilisi, 00172, Georgia|TG Therapeutics Investigational Trial Site, Tbilisi, 00179, Georgia|TG Therapeutics Investigational Trial Site, Katowice, 40-555, Poland|TG Therapeutics Investigational Trial Site, Katowice, 40-568, Poland|TG Therapeutics Investigational Trial Site, Katowice, 40-684, Poland|TG Therapeutics Investigational Trial Site, Kraków, 31-505, Poland|TG Therapeutics Investigational Trial Site, Olsztyn, 10-561, Poland|TG Therapeutics Investigational Trial Site, Poznań, 61-583, Poland|TG Therapeutics Investigational Trial Site, Warszawa, 04-141, Poland|TG Therapeutics Investigational Trial Site, Zabrze, 04-749, Poland|TG Therapeutics Investigational Trial Site, Łódź, 41-800, Poland|TG Therapeutics Investigational Trial Site, Arkhangel'sk, 163045, Russian Federation|TG Therapeutics Investigational Trial Site, Barnaul, 656045, Russian Federation|TG Therapeutics Investigational Trial Site, Bryansk, 241033, Russian Federation|TG Therapeutics Investigational Trial Site, Chelyabinsk, 454021, Russian Federation|TG Therapeutics Investigational Trial Site, Ekaterinburg, 620102, Russian Federation|TG Therapeutics Investigational Trial Site, Kemerovo, 650066, Russian Federation|TG Therapeutics Investigational Trial Site, Krasnoyarsk, 660037, Russian Federation|TG Therapeutics Investigational Trial Site, Kursk, 305007, Russian Federation|TG Therapeutics Investigational Trial Site, Moscow, 125367, Russian Federation|TG Therapeutics Investigational Trial Site, Moscow, 127015, Russian Federation|TG Therapeutics Investigational Trial Site, Nizhny Novgorod, 603155, Russian Federation|TG Therapeutics Investigational Trial Site, Novosibirsk, 630007, Russian Federation|TG Therapeutics Investigational Trial Site, Novosibirsk, 630087, Russian Federation|TG Therapeutics Investigational Trial Site, Pyatigorsk, 357538, Russian Federation|TG Therapeutics Investigational Trial Site, Saint Petersburg, 197002, Russian Federation|TG Therapeutics Investigational Trial Site, Saint Petersburg, 197110, Russian Federation|TG Therapeutics Investigational Trial Site, Saint Petersburg, 197376, Russian Federation|TG Therapeutics Investigational Trial Site, Saransk, 430032, Russian Federation|TG Therapeutics Investigational Trial Site, Smolensk, 214018, Russian Federation|TG Therapeutics Investigational Trial Site, Tomsk, 634050, Russian Federation|TG Therapeutics Investigational Trial Site, Tyumen, 625000, Russian Federation|TG Therapeutics Investigational Trial Site, Ufa, 450005, Russian Federation|TG Therapeutics Investigational Trial Site, Belgrade, 11000, Serbia|TG Therapeutics Investigational Trial Site, Kragujevac, 34000, Serbia|TG Therapeutics Investigational Trial Site, Cherkasy, 18009, Ukraine|TG Therapeutics Investigational Trial Site, Chernihiv, 14001, Ukraine|TG Therapeutics Investigational Trial Site, Chernihiv, 14029, Ukraine|TG Therapeutics Investigational Trial Site, Chernivtsi, 58002, Ukraine|TG Therapeutics Investigational Trial Site, Ivano-Frankivs'k, 76008, Ukraine|TG Therapeutics Investigational Trial Site, Kharkiv, 61058, Ukraine|TG Therapeutics Investigational Trial Site, Kharkiv, 61103, Ukraine|TG Therapeutics Investigational Trial Site, Kharkiv, 61176, Ukraine|TG Therapeutics Investigational Trial Site, Kyiv, 03037, Ukraine|TG Therapeutics Investigational Trial Site, Kyiv, 03115, Ukraine|TG Therapeutics Investigational Trial Site, Lviv, 79000, Ukraine|TG Therapeutics Investigational Trial Site, Lviv, 79010, Ukraine|TG Therapeutics Investigational Trial Site, Odesa, 65009, Ukraine|TG Therapeutics Investigational Trial Site, Poltava, 36011, Ukraine|TG Therapeutics Investigational Trial Site, Ternopil, 46027, Ukraine|TG Therapeutics Investigational Trial Site, Vinnytsya, 21005, Ukraine|TG Therapeutics Investigational Trial Site, Zaporizhia, 69065, Ukraine|TG Therapeutics Investigational Trial Site, Zaporizhia, 96900, Ukraine|TG Therapeutics Investigational Trial Site, Zhytomyr, 10002, Ukraine|TG Therapeutics Investigational Trial Site, Úzhgorod, 88018, Ukraine"
NCT05467397,Feasibility of [11C]Acetate-Positron Emission Tomography (PET) in Lymphangioleiomyomatosis and Tuberous Sclerosis Complex,https://beta.clinicaltrials.gov/study/NCT05467397,RECRUITING,Lymphangioleiomyomatosis|Tuberous Sclerosis Complex,DRUG: [11C]acetate,Brigham and Women's Hospital,Massachusetts General Hospital,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,16,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-08-30,2023-08-30,2023-12-31,"Brigham and Women's Hospital, Boston, Massachusetts, 02115, United States"
NCT02418897,Role of Neuromuscular Junction Function in Motor Fatigue in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02418897,COMPLETED,Multiple Sclerosis,,Texas Tech University Health Sciences Center,,FEMALE,"ADULT, OLDER_ADULT",,40,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-04,2016-11,2016-11,"Texas Tech University Health Sciences Center, Lubbock, Texas, 79430, United States"
NCT01592097,Exploratory Study to Assess Clinical Response to Gilenya® (Fingolimod) in Hispanics With RRMS,https://beta.clinicaltrials.gov/study/NCT01592097,COMPLETED,Multiple Sclerosis,,University of Southern California,Novartis Pharmaceuticals,ALL,"ADULT, OLDER_ADULT",,51,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-06,2018-04,2018-04,"Keck School of Medicine of the University of Southern Calfornia, Los Angeles, California, 90033, United States"
NCT02361697,DTI in Children With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02361697,UNKNOWN,"Multiple Sclerosis - Relapsing Remitting|Clinically Isolated Syndrome, CNS Demyelinating",OTHER: DTI-MRI,University Hospital Muenster,,ALL,"CHILD, ADULT",NA,15,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2014-12,2016-12,2017-12,"University Hospital Muenster, Muenster, 48149, Germany"
NCT00618267,"ATP Expression in Lymphocytes of MS Patients by Means of ""ImmuKnow®"" Assay.",https://beta.clinicaltrials.gov/study/NCT00618267,COMPLETED,Multiple Sclerosis,,Biogen,Elan Pharmaceuticals,ALL,"CHILD, ADULT, OLDER_ADULT",,100,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2008-03,2008-12,2008-12,"Brigham and Women's Hospital - Partners MS Center, Brookline, Massachusetts, 02445, United States"
NCT03458767,A Cognitive Self-Management Intervention for Persons With Multiple Sclerosis: Adapting Web-based Technology,https://beta.clinicaltrials.gov/study/NCT03458767,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Eight weekly 90-minute group educational sessions,University of Texas at Austin,,ALL,"ADULT, OLDER_ADULT",NA,16,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2017-10-09,2018-06-01,2018-06-01,"The University of Texas at Austin, Austin, Texas, 78701, United States"
NCT02209467,Balance and Falls in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02209467,COMPLETED,Multiple Sclerosis,OTHER: Group balance training,Örebro County Council,,ALL,"ADULT, OLDER_ADULT",NA,52,OTHER_GOV,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2014-08,2015-03,2015-08,"Neurorehab Mälarsjukhuset, Eskilstuna, Sweden|Physiotherapy department Gävle hospital, Gävle, Sweden|Rehab unit Karlskoga hospital, Karlskoga, Sweden|Primary Health Care, Linköping, Sweden|Nyköping hospital, Nyköping, Sweden|Rehab unit Västerås hospital, Västerås, Sweden|Physiotherapy department University hospital, Örebro, Sweden"
NCT02634307,A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1,https://beta.clinicaltrials.gov/study/NCT02634307,COMPLETED,Multiple Sclerosis,DRUG: ALKS 8700,Biogen,"Alkermes, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE3,1057,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-12-10,2021-06-01,2021-11-11,"Alkermes Investigational Site, Cullman, Alabama, 35058, United States|Alkermes Investigational Site, Phoenix, Arizona, 85004, United States|Alkermes Investigational Site, Phoenix, Arizona, 85018, United States|Alkermes Investigational Site, Phoenix, Arizona, 85032, United States|Alkermes Investigational Site, Tucson, Arizona, 85704, United States|Alkermes Investigational Site, Berkeley, California, 94705, United States|Alkermes Investigational Site, Loma Linda, California, 92354, United States|Alkermes Investigational Site, Long Beach, California, 90806, United States|Alkermes Investigational Site, San Diego, California, 92103, United States|Alkermes Investigational Site, Basalt, Colorado, 81621, United States|Alkermes Investigational Site, Centennial, Colorado, 80111, United States|Alkermes Investigational Site, Denver, Colorado, 80209, United States|Alkermes Investigational Site, Middlebury, Connecticut, 06762, United States|Alkermes Investigational Site, Stamford, Connecticut, 06905, United States|Alkermes Investigational Site, Washington, District of Columbia, 20007, United States|Alkermes Investigational Site, Atlantis, Florida, 33462, United States|Alkermes Investigational Site, Bradenton, Florida, 34209, United States|Alkermes Investigational Site, Jacksonville, Florida, 32209, United States|Alkermes Investigational Site, Maitland, Florida, 32751, United States|Alkermes Investigational Site, Naples, Florida, 34102, United States|Alkermes Investigational Site, Ormond Beach, Florida, 32174, United States|Alkermes Investigational Site, Sarasota, Florida, 34239, United States|Alkermes Investigational Site, Tampa, Florida, 33634, United States|Alkermes Investigational Site, Vero Beach, Florida, 32960, United States|Alkermes Investigational Site, Atlanta, Georgia, 30312-4201, United States|Alkermes Investigational Site, Atlanta, Georgia, 30327, United States|Alkermes Investigational Site, Atlanta, Georgia, 30342, United States|Alkermes Investigational Site, Columbus, Georgia, 31904, United States|Alkermes Investigational Site, Evanston, Illinois, 60201, United States|Alkermes Investigational Site, Indianapolis, Indiana, 46202, United States|Alkermes Investigational Site, Indianapolis, Indiana, 46260, United States|Alkermes Investigational Site, Des Moines, Iowa, 50314, United States|Alkermes Investigational Site, Overland Park, Kansas, 66213, United States|Alkermes Investigational Site, Lexington, Kentucky, 40513, United States|Alkermes Investigational Site, Alexandria, Louisiana, 71301, United States|Alkermes Investigational Site, Baton Rouge, Louisiana, 70810, United States|Alkermes Investigational Site, Detroit, Michigan, 48202, United States|Alkermes Investigational Site, Traverse City, Michigan, 49684, United States|Alkermes Investigational Site, Golden Valley, Minnesota, 55422, United States|Alkermes Investigational Site, Saint Louis, Missouri, 63104, United States|Alkermes Investigational Site, Saint Louis, Missouri, 63110, United States|Alkermes Investigational Site, Saint Louis, Missouri, 63131, United States|Alkermes Investigational Site, Albuquerque, New Mexico, 87106, United States|Alkermes Investigational Site, Patchogue, New York, 11772, United States|Alkermes Investigational Site, Plainview, New York, 11803, United States|Alkermes Investigational Site, Stony Brook, New York, 11794, United States|Alkermes Investigational Site, Syracuse, New York, 13210, United States|Alkermes Investigational Site, Charlotte, North Carolina, 28203, United States|Alkermes Investigational Site, Greensboro, North Carolina, 27405, United States|Alkermes Investigational Site, Raleigh, North Carolina, 27607, United States|Alkermes Investigational Site, Winston-Salem, North Carolina, 27103, United States|Alkermes Investigational Site, Canton, Ohio, 44718, United States|Alkermes Investigational Site, Columbus, Ohio, 43210, United States|Alkermes Investigational Site, Dayton, Ohio, 45417, United States|Alkermes Investigational Site, Oklahoma City, Oklahoma, 73104, United States|Alkermes Investigational Site, Medford, Oregon, 97504, United States|Alkermes Investigational Site, Philadelphia, Pennsylvania, 19107, United States|Alkermes Investigational Site, Charleston, South Carolina, 29406, United States|Alkermes Investigational Site, Greer, South Carolina, 29650, United States|Alkermes Investigational Site, Rock Hill, South Carolina, 29732, United States|Alkermes Investigational Site, Spartanburg, South Carolina, 29307, United States|Alkermes Investigational Site, Cordova, Tennessee, 38018, United States|Alkermes Investigational Site, Franklin, Tennessee, 37064, United States|Alkermes Investigational Site, Knoxville, Tennessee, 37922, United States|Alkermes Investigational Site, Dallas, Texas, 75231, United States|Alkermes Investigational Site, Houston, Texas, 77030, United States|Alkermes Investigational Site, Houston, Texas, 77074, United States|Alkermes Investigational Site, Lubbock, Texas, 79410, United States|Alkermes Investigational Site, Salt Lake City, Utah, 84103, United States|Alkermes Investigational Site, Newport News, Virginia, 23601, United States|Alkermes Investigational Site, Richmond, Virginia, 23228, United States|Alkermes Investigational Site, Seattle, Washington, 98101, United States|Alkermes Investigational Site, Seattle, Washington, 98122, United States|Alkermes Investigational Site, Seattle, Washington, 98133, United States|Alkermes Investigational Site, Brugge, 8000, Belgium|Alkermes Investigational Site, Fraiture, 4557, Belgium|Alkermes Investigational Site, La Louviere, 7100, Belgium|Alkermes Investigational Site, Blagoevgrad, 2700, Bulgaria|Alkermes Investigational Site, Pleven, 5800, Bulgaria|Alkermes Investigational Site, Sofia, 1309, Bulgaria|Alkermes Investigational Site, Sofia, 1606, Bulgaria|Alkermes Investigational Site, Sofia, 1797, Bulgaria|Alkermes Investigational Site, Gatineau, Quebec, J8Y 1W2, Canada|Alkermes Investigational Site, Berlin, 10713, Germany|Alkermes Investigational Site, Berlin, 12099, Germany|Alkermes Investigational Site, Dresden, 01307, Germany|Alkermes Investigational Site, Leipzig, 4103, Germany|Alkermes Investigational Site, Ulm, 89073, Germany|Alkermes Investigational Site, Ulm, 89081, Germany|Alkermes Investigational Site, Westerstede, 26655, Germany|Alkermes Investigational Site, Gdansk, 80-803, Poland|Alkermes Investigational Site, Katowice, 40-123, Poland|Alkermes Investigational Site, Katowice, 40-648, Poland|Alkermes Investigational Site, Kielce, 25-726, Poland|Alkermes Investigational Site, Krakow, 31-505, Poland|Alkermes Investigational Site, Lodz, 90-324, Poland|Alkermes Investigational Site, Lublin, 20-718, Poland|Alkermes Investigational Site, Plewiska, 62-064, Poland|Alkermes Investigational Site, Szczecin, 70-111, Poland|Alkermes Investigational Site, Krasnoyarsk, 66037, Russian Federation|Alkermes Investigational Site, Nizhniy Novgorod, 603155, Russian Federation|Alkermes Investigational Site, Belgrade, 11000, Serbia|Alkermes Investigational Site, Kragujevac, 34000, Serbia|Alkermes Investigational Site, Nis, 18000, Serbia|Alkermes Investigational Site, Barcelona, 08916, Spain|Alkermes Investigational Site, Madrid, 28905, Spain|Alkermes Investigational Site, Santa Cruz de Tenerife, 38010, Spain|Alkermes Investigational Site, Dnipro, 49005, Ukraine|Alkermes Investigational Site, Ivano-Frankivsk, 76008, Ukraine|Alkermes Investigational Site, Kharkiv, 61068, Ukraine|Alkermes Investigational Site, Kharkiv, 61103, Ukraine|Alkermes Investigational Site, Lviv, 79000, Ukraine|Alkermes Investigational Site, Odessa, 65025, Ukraine|Alkermes Investigational Site, Zaporizhzhya, 69035, Ukraine|Alkermes Investigational Site, Zaporizhzhya, 69600, Ukraine"
NCT03774407,Vaginal Estriol in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03774407,COMPLETED,Multiple Sclerosis|Neurogenic Bladder,DRUG: vaginal estriol,Texas Tech University Health Sciences Center,,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,21,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2019-06-20,2020-11-10,2020-11-29,"Texas Tech University Health Sciences Center, Lubbock, Texas, 79430, United States"
NCT04198207,The Effectiveness and Safety of Vagus Nerve Stimulation for TRE,https://beta.clinicaltrials.gov/study/NCT04198207,RECRUITING,Tuberous Sclerosis Complex|Epilepsy,,Beijing Children's Hospital,"Beijing Tiantan Hospital|The First Hospital of Jilin University|Xuanwu Hospital, Beijing|Capital Medical University|Peking University First Hospital|China-Japan Friendship Hospital|Chinese PLA General Hospital|Fourth Medical Center of PLA General Hospital|Capital Institute of Pediatrics, China|The Second Hospital of Hebei Medical University|Xijing Hospital|First Affiliated Hospital Xi'an Jiaotong University|Children's Hospital of Fudan University|RenJi Hospital|Jining Medical University|Xiamen Humanity Hospital|Xiangya Hospital of Central South University|Wuhan Medical Care Center for Women and Children|Guangdong 999 Brain Hospital|Shenzhen Children's Hospital|Xinqiao Hospital, Army Medical University|West China Hospital",ALL,"CHILD, ADULT, OLDER_ADULT",,100,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-12-10,2023-12-01,2024-02-01,"Beijing Children's Hospital, Beijing, China"
NCT04568707,Evaluation of Biological Response to SARS-COV2 (COVID-19) in Patients With Pre-existing Neurological Disease or Newly Neurological Symptoms (BIO-COCO-NEUROSCIENCES),https://beta.clinicaltrials.gov/study/NCT04568707,UNKNOWN,Covid19|Neurologic Manifestations|Psychiatric Manifestations,OTHER: blood sample,Assistance Publique - Hôpitaux de Paris,Brain & Spine Institute (ICM),ALL,"ADULT, OLDER_ADULT",NA,200,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2020-10-23,2022-10-15,2022-10-15,"Hôpital Pitié Salpétrière, Paris, 75013, France"
NCT04100343,Detection of Pattern of Some Unusual Signs and Symptoms of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04100343,UNKNOWN,Multiple Sclerosis,,Assiut University,,ALL,ADULT,,100,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-11-01,2021-12-01,2021-12-01,
NCT05622643,OFSEP Very High Definition Cohort,https://beta.clinicaltrials.gov/study/NCT05622643,RECRUITING,Multiple Sclerosis,OTHER: MRI,EDMUS Foundation,,ALL,"ADULT, OLDER_ADULT",,300,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-01-19,2026-01-01,2027-01-01,"CHU de Lyon, Lyon, France|CHU de Nancy, Nancy, France|CHU de Nîmes, Nîmes, France|CHU de Rennes, Rennes, France|CHU de Strasbourg, Strasbourg, France"
NCT05575843,Neurostatus-SMARTCARE in Comparison to Standard Neurostatus-EDSS®,https://beta.clinicaltrials.gov/study/NCT05575843,RECRUITING,Multiple Sclerosis (MS),OTHER: Neurostatus-SMARTCARE|OTHER: Standard Neurostatus-EDSS,"University Hospital, Basel, Switzerland","Novartis Pharma AG, Basel, Switzerland",ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: OTHER,2022-12-09,2024-03,2024-03,"Neurologic Clinic and Policlinic, University Hospital Basel, Basel, 4031, Switzerland|Luzerner Kantonsspital, Luzern 16, 6000, Switzerland|Reha Rheinfelden, Rheinfelden, 4310, Switzerland"
NCT01706107,Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants,https://beta.clinicaltrials.gov/study/NCT01706107,TERMINATED,Relapsing-Remitting Multiple Sclerosis,,Biogen,,ALL,"ADULT, OLDER_ADULT",,73,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-04,2017-10,2018-01,"Vancouver Island Health Authority, Victoria, British Columbia, V8R 1J8, Canada|Saint John Regional Hospital, Saint John, New Brunswick, E2L 4L2, Canada|Dalhousie MS Research Unit, Halifax, Nova Scotia, B3H 4K4, Canada|Cape Breton Regional Hospital, Sydney, Nova Scotia, B1P 1P3, Canada|London Health Sciences Centre, London, Ontario, N6A 5A5, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, M4N 3M5, Canada|Clinique Neuro-Outaouais, Gatineau, Quebec, J9J 0A5, Canada|Neuro Rive-Sud, Greenfield Park, Quebec, J4V 2J2, Canada|CHUM - Hopital Notre Dame, Montreal, Quebec, H2L 4M1, Canada|McGill University - MNI, Montreal, Quebec, H3A 2B4, Canada|CHUS - Hopital Fleurimont, Sherbrooke, Quebec, J1H 5N4, Canada"
NCT03887507,Vojta Therapy in Multiple Sclerosis.,https://beta.clinicaltrials.gov/study/NCT03887507,COMPLETED,Multiple Sclerosis|Physical Therapy,OTHER: Vojta Therapy|OTHER: Standard Program,NUMEN Foundation,Multiple Sclerosis Foundation of Madrid|Fisiovillalba Clinical center,ALL,"ADULT, OLDER_ADULT",NA,21,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2019-01-21,2019-03-28,2019-05-12,"NUMEN Foundation, Madrid, España, 28027, Spain"
NCT01749943,Validation of Hand Held Dynamometer for Assessment of Lower Limb Muscle Strength in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01749943,COMPLETED,Multiple Sclerosis,,"Brown, Theodore R., M.D., MPH",Biogen,ALL,"ADULT, OLDER_ADULT",,21,INDIV,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-07,2013-07,2013-07,"MS Center at Evergreen Hospital, Kirkland, Washington, 98034, United States"
NCT01572207,Promoting Physical Activity Behavior in Persons With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01572207,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Immediate exercise|BEHAVIORAL: Delayed exercise,Case Western Reserve University,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2011-07,2012-07,2012-07,"The Cleveland Clinic, Cleveland, Ohio, 44195, United States"
NCT02291107,Robot-assisted Gait Training in Patients With Multiple Sclerosis: Efficacy and Comparison With Traditional Methods,https://beta.clinicaltrials.gov/study/NCT02291107,UNKNOWN,Multiple Sclerosis,"DEVICE: Lokomat (Hocoma, Zurich, Switzerland)|OTHER: Conventional Physiotherapy","Habilita, Ospedale di Sarnico",,ALL,"CHILD, ADULT, OLDER_ADULT",NA,17,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-06,2015-12,2016-06,"HABILITA, Zingonia di Ciserano, Bergamo, 24040, Italy"
NCT01037907,A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS),https://beta.clinicaltrials.gov/study/NCT01037907,TERMINATED,Relapsing Remitting Multiple Sclerosis,DRUG: Pleneva TM BGC20-0134|DRUG: Placebo,Boston Scientific Corporation,,ALL,"ADULT, OLDER_ADULT",PHASE2,173,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-11,2011-12,2011-12,"University Hospital Gent, Gent, Belgium|AZ St. Jan Brugge Oostende AV., Ruddershove, Belgium|AZ ALMA, Sijsele, Belgium|CHU Amiens-Hôpital Nord-, Amiens, France|CHU Clermont Ferrand-Hôpital Gabriel Montpied-, Clermont, France|CHRU Strasbourg- Hôpital Civil-1 place de l'hôpital, Strasbourg, France|CHU Toulouse-Hôpital Purpan, Toulouse, France|Klnik Hohe Warte, Bayreuth, D-95445, Germany|Jüdisches Krankenhaus Berlin, Berlin, Germany|Universitätsklinikum Charité, Campus Mitte, Berlin, Germany|Klinikum der Ruhr-Universität Bochum, Bochum, Germany|Universitätsklinikum der Heinrich-Heine-Universität Düsseldorf, Dusseldorf, Germany|Universitätsklinikum Essen, Essen, Germany|Universitätsklinikum Magdeburg A.ö.R, Magdeburg, 39120, Germany|Klinikum Osnabrück Klinik für Neurologie, Osnabrück, 49076, Germany|Universitätsklinikum Rostock AöR, Rostock, 18147, Germany|Neurologische und psychiatrische Praxis, Stuttgart, 70191, Germany|Universitätsklinikum Ulm, Ulm, Germany|Medical University of Gdansk Ul. Nowe Ogrody 1-6, Gdansk, Poland|Upper Silezian Medical Center SAM Ul Ziolowa 45/47, Katowice, Poland|Medical University of Lodz, Lodz, Poland|Samodzielny Publiczny Szpital Kliniczny, Lublin, 20-954, Poland|State Medical University named after I.P. Pavlov, St. Petersburg, Str. L. Tolstogo 6/8, 197022, Russian Federation|City hospital # 11 Str. Dvintcev 6, Moscow, Russian Federation|Moscow regional institute of clinical research named after M.F. Vladimirsky, Moscow, Russian Federation|hospital # 33 pr. Lenina 54, Nizniy Novgorod, Novgorod, Russian Federation|City hospital # 9 Str. B. Gornaya 43, Saratov, Saratov, Russian Federation|Institute of Human Brain, str. Acad. Pavlov, St-Petersburg, St Petersburg, Russian Federation|Hospital Universitari de Girona, Girona, Avda.De Franca, S/n, 17007, Spain|Hospital Universitari Germans Trias i Pujol, Badalona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Vall'd Hebron, Barcelona, Spain|Hospital General Universitario Gregorio Marañón, Madrid, 28007, Spain|Hospital Universitario Ramón y Cajal, Madrid, 28034, Spain|Hospital Universitario Ntra Sra de la Candelaria, Santa Cruz de Tenerife, 38010, Spain"
NCT03623243,"Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients.",https://beta.clinicaltrials.gov/study/NCT03623243,COMPLETED,Multiple Sclerosis|Relapsing Multiple Sclerosis|Advancing Multiple Sclerosis,DRUG: Siponimod,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,187,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2019-02-14,2022-07-06,2022-07-06,"Novartis Investigative Site, Birmingham, Alabama, 35209, United States|Novartis Investigative Site, Cullman, Alabama, 35058, United States|Novartis Investigative Site, Tucson, Arizona, 85718, United States|Novartis Investigative Site, Fresno, California, 93710, United States|Novartis Investigative Site, Fullerton, California, 92835, United States|Novartis Investigative Site, Irvine, California, 92617, United States|Novartis Investigative Site, Colorado Springs, Colorado, 80907, United States|Novartis Investigative Site, Denver, Colorado, 80209, United States|Novartis Investigative Site, Fort Collins, Colorado, 80528, United States|Novartis Investigative Site, Boca Raton, Florida, 33487, United States|Novartis Investigative Site, Bradenton, Florida, 34205, United States|Novartis Investigative Site, Maitland, Florida, 32751, United States|Novartis Investigative Site, Miami, Florida, 33136, United States|Novartis Investigative Site, Ocala, Florida, 34471, United States|Novartis Investigative Site, Oldsmar, Florida, 34677, United States|Novartis Investigative Site, Orlando, Florida, 32806, United States|Novartis Investigative Site, Ormond Beach, Florida, 32174, United States|Novartis Investigative Site, Sarasota, Florida, 34243, United States|Novartis Investigative Site, Sunrise, Florida, 33351, United States|Novartis Investigative Site, Tampa, Florida, 33612, United States|Novartis Investigative Site, Vero Beach, Florida, 32960, United States|Novartis Investigative Site, Flossmoor, Illinois, 60422, United States|Novartis Investigative Site, Indianapolis, Indiana, 46256, United States|Novartis Investigative Site, Lexington, Kentucky, 40503, United States|Novartis Investigative Site, Lexington, Kentucky, 40509, United States|Novartis Investigative Site, Lexington, Kentucky, 40513, United States|Novartis Investigative Site, Rockville, Maryland, 20854, United States|Novartis Investigative Site, Clinton Township, Michigan, 48035, United States|Novartis Investigative Site, Saint Louis, Missouri, 63110, United States|Novartis Investigative Site, Las Vegas, Nevada, 89128, United States|Novartis Investigative Site, Hackensack, New Jersey, 07601, United States|Novartis Investigative Site, Asheville, North Carolina, 28806, United States|Novartis Investigative Site, Greensboro, North Carolina, 27405, United States|Novartis Investigative Site, Raleigh, North Carolina, 27607, United States|Novartis Investigative Site, Cincinnati, Ohio, 45219, United States|Novartis Investigative Site, Cleveland, Ohio, 44106-5028, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, 73104, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, 19141, United States|Novartis Investigative Site, Willow Grove, Pennsylvania, 19090, United States|Novartis Investigative Site, Greer, South Carolina, 29650, United States|Novartis Investigative Site, Indian Land, South Carolina, 29707, United States|Novartis Investigative Site, Cordova, Tennessee, 38018, United States|Novartis Investigative Site, Johnson City, Tennessee, 37604, United States|Novartis Investigative Site, Round Rock, Texas, 78681, United States|Novartis Investigative Site, San Antonio, Texas, 78258, United States|Novartis Investigative Site, Falls Church, Virginia, 22043, United States|Novartis Investigative Site, Kirkland, Washington, 98034, United States|Novartis Investigative Site, Seattle, Washington, 98122, United States|Novartis Investigative Site, Spokane, Washington, 99202, United States|Novartis Investigative Site, Tacoma, Washington, 98405, United States|Novartis Investigative Site, Waukesha, Wisconsin, 53188, United States|Novartis Investigative Site, Guaynabo, 00968, Puerto Rico"
NCT00981643,Effects of Meditation on Multiple Sclerosis and Peripheral Neuropathy,https://beta.clinicaltrials.gov/study/NCT00981643,COMPLETED,Multiple Sclerosis|Peripheral Neuropathy,BEHAVIORAL: Meditation instruction and practice,The Cleveland Clinic,,ALL,"CHILD, ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2009-02,2009-11,2010-12,"Cleveland Clinic, Cleveland, Ohio, 44195, United States"
NCT03752307,Safety and Tolerability of ISX (Isoxsuprine HCL) in MS Relapses,https://beta.clinicaltrials.gov/study/NCT03752307,COMPLETED,Multiple Sclerosis,DRUG: Isoxsuprine Hydrochloride|DRUG: Placebo|DRUG: Corticosteroid,University of New Mexico,,ALL,ADULT,PHASE1|PHASE2,2,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2019-02-15,2021-07-06,2021-07-06,"University of New Mexico MS Specialty Clinic, Albuquerque, New Mexico, 87106, United States"
NCT00099307,Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00099307,COMPLETED,Multiple Sclerosis,,National Institute of Neurological Disorders and Stroke (NINDS),,ALL,"ADULT, OLDER_ADULT",,94,NIH,OBSERVATIONAL,Observational Model: |Time Perspective: p,2004-12-08,,2011-09-28,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States"
NCT04746807,Barriers to Physical Activity in People With MS,https://beta.clinicaltrials.gov/study/NCT04746807,COMPLETED,Multiple Sclerosis,,University of Zurich,"Dr. Roman Gonzenbach, Kliniken Valens",ALL,"ADULT, OLDER_ADULT",,45,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-01-08,2021-11-14,2021-11-14,"Kliniken Valens, Valens, 7317, Switzerland"
NCT04697407,IL-2 Signaling and Polarization of Regulatory LBs: Involvement in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04697407,RECRUITING,Multiple Sclerosis,BIOLOGICAL: Blood sampling|BIOLOGICAL: CSF sampling,Rennes University Hospital,,ALL,"ADULT, OLDER_ADULT",NA,95,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2021-03-23,2023-09,2023-10,"CHU Rennes, Rennes, France"
NCT02488343,Profile of Adherence to Therapy and Interventions to Promote Adherence in MS,https://beta.clinicaltrials.gov/study/NCT02488343,RECRUITING,Multiple Sclerosis,BEHAVIORAL: Behavioral Intervention,Carmel Medical Center,,ALL,"ADULT, OLDER_ADULT",NA,400,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2015-08,2024-06,2024-06,"MS Clinic, Carmel Medical Center, Haifa, Israel"
NCT02137707,Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya,https://beta.clinicaltrials.gov/study/NCT02137707,COMPLETED,Multiple Sclerosis-Relapsing-Remitting,DRUG: Gilenya,McGill University,Novartis,ALL,"ADULT, OLDER_ADULT",,135,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-11,2017-11,2018-10-30,"University of British Columbia, Vancouver, British Columbia, V6T 1Z3, Canada|Dalhousie University Multiple Sclerosis Research Unit, Halifax, Nova Scotia, Canada|Ottawa General Hospital, Ottawa, Ontario, K1H 8L6, Canada|Clinique Neuro Rive-Sud, Greenfield Park, Quebec, Canada|Montreal Neurological Institute, Montreal, Quebec, H3A 2B4, Canada|Centre hospitalier de l'Universite de Montreal (CHUM), Montréal, Quebec, Canada"
NCT04548297,Clinical Factors Associated With Position Sense in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04548297,COMPLETED,Multiple Sclerosis,OTHER: Assessment,Gazi University,,ALL,"ADULT, OLDER_ADULT",,44,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-10-05,2022-05-13,2022-05-13,"Gazi University, Ankara, Turkey"
NCT04056897,Comparative Study of the Efficacy and Safety of BCD-132 With Teriflunomide and Placebo in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04056897,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,"BIOLOGICAL: BCD-132, 125 mg|DRUG: Teriflunomide|DRUG: Placebo|BIOLOGICAL: BCD-132, 500 mg",Biocad,,ALL,ADULT,PHASE2,270,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-06-07,2020-07-13,2021-12,"State Budgetary Healthcare Institution of Nizhny Novgorod region ""Regional Clinical Hospital N.A. Semashko, Nizhny Novgorod"", Nizhny Novgorod, Russian Federation"
NCT03735056,The PrEliMS Feasibility Trial,https://beta.clinicaltrials.gov/study/NCT03735056,COMPLETED,Multiple Sclerosis,OTHER: MS Nurse Support|OTHER: Peer Support,University of Nottingham,Multiple Sclerosis Society UK|Swansea University,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2018-11-30,2020-10-31,2020-10-31,"Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom"
NCT04121403,Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS),https://beta.clinicaltrials.gov/study/NCT04121403,RECRUITING,Relapsing Multiple Sclerosis|Multiple Sclerosis,BIOLOGICAL: Rituximab|DRUG: Cladribine,Oslo University Hospital,University of Oslo|Göteborg University|Sykehuset Ostfold|Sykehuset Telemark|Vestre Viken Hospital Trust|Sorlandet Hospital HF|Helse Stavanger HF|Sykehuset Innlandet HF|Sykehuset i Vestfold HF|Helse Forde|University Hospital of North Norway|St. Olavs Hospital,ALL,"ADULT, OLDER_ADULT",PHASE3,264,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2019-10-16,2024-07,2024-12,"Department of Neurology - Drammen, Vestre Viken HF, Drammen, Buskerud, 3004, Norway|Department of Neurology - Lillehammer, SI Lillehammer, Lillehammer, Oppland, 2629, Norway|Department of Neurology, Stavanger universitetssykehus, Stavanger, Rogaland, 4068, Norway|Department of Neurology - Førde, Helse Førde HF, Førde, Sogn Og Fjordane, 6807, Norway|Department of Neurology - Skien, Sykehuset Telemark, Skien, Telemark, 3710, Norway|Department of Neurology - Tromsø, University Hospital of North Norway, Tromsø, Troms, 9038, Norway|Department of Neurology - Kristiansand, Sørlandet sykehus HF, Kristiansand, Vest-Agder, 4604, Norway|Department of Neurology - Tønsberg, Sykehuset i Vestfold HF, Tønsberg, Vestfold, 3103, Norway|Department of Neurology, Oslo University Hospital, Oslo, 0424, Norway|St. Olavs Hospital, Trondheim University Hospital, Trondheim, 7006, Norway|Department of Neurology - Kalnes, Sykehuset Østfold HF, Sarpsborg, Østfold, 1714, Norway"
NCT01485003,Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants,https://beta.clinicaltrials.gov/study/NCT01485003,COMPLETED,Relapsing-Remitting Multiple Sclerosis,BIOLOGICAL: natalizumab,Biogen,,ALL,"ADULT, OLDER_ADULT",,231,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-02-07,2018-11-26,2018-11-26,"Research Site, Homewood, Alabama, 35209, United States|Research Site, Sun City, Arizona, 85351, United States|Research Site, La Jolla, California, 92037, United States|Research Site, Los Angeles, California, 90032, United States|Research Site, Aurora, Colorado, 80045, United States|Research Site, Fort Collins, Colorado, 80528, United States|Research Site, Newark, Delaware, 19713, United States|Research Site, Washington, District of Columbia, 20007, United States|Research Site, Jacksonville, Florida, 32209, United States|Research Site, Atlanta, Georgia, 30309, United States|Research Site, Chicago, Illinois, 60612, United States|Research Site, Lake Barrington, Illinois, 60010, United States|Research Site, Peoria, Illinois, 61603, United States|Research Site, Indianapolis, Indiana, 46256, United States|Research Site, Indianapolis, Indiana, 46260, United States|Research Site, Overland Park, Kansas, 66212, United States|Research Site, Louisville, Kentucky, 40207, United States|Research Site, New Orleans, Louisiana, 70121, United States|Research Site, Baltimore, Maryland, 21287, United States|Research Site, Boston, Massachusetts, 02215, United States|Research Site, Lexington, Massachusetts, 02421, United States|Research Site, Wellesley Hills, Massachusetts, 02481, United States|Research Site, Worcester, Massachusetts, 01655, United States|Research Site, East Lansing, Michigan, 48824, United States|Research Site, Lincoln, Nebraska, 68521, United States|Research Site, Freehold, New Jersey, 07728, United States|Research Site, New York, New York, 10016, United States|Research Site, New York, New York, 10021, United States|Research Site, Patchogue, New York, 11772, United States|Research Site, Plainview, New York, 11803, United States|Research Site, Staten Island, New York, 10306, United States|Research Site, Stony Brook, New York, 11794, United States|Research Site, Cincinnati, Ohio, 45219, United States|Research Site, Cleveland, Ohio, 44195, United States|Research Site, Gahanna, Ohio, 43230, United States|Research Site, Uniontown, Ohio, 44685, United States|Research Site, Portland, Oregon, 97225, United States|Research Site, Dallas, Texas, 75235, United States|Research Site, Round Rock, Texas, 78681, United States|Research Site, Salt Lake City, Utah, 84103, United States|Research Site, Newport News, Virginia, 23601, United States|Research Site, Norfolk, Virginia, 23502, United States|Research Site, Seattle, Washington, 98101, United States|Research Site, Tacoma, Washington, 98405, United States"
NCT02549703,Mitochondrial Dysfunction and Disease Progression,https://beta.clinicaltrials.gov/study/NCT02549703,COMPLETED,Clinically Isolated Syndrome|Relapsing-Remitting Multiple Sclerosis|Secondary Progressive Multiple Sclerosis|Primary Progressive Multiple Sclerosis,,Icahn School of Medicine at Mount Sinai,Columbia University|New York Stem Cell Foundation Research Institute,ALL,"ADULT, OLDER_ADULT",,47,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-09,2018-09-27,2018-09-27,"Icahn School of Medicine, New York, New York, 10029, United States"
NCT04261556,HD-tDCS to Enhance Cognitive Training in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04261556,SUSPENDED,"Multiple Sclerosis, Relapsing-Remitting",DEVICE: Real HD-tDCS + CCT|DEVICE: Sham HD-tDCS + CCT,University of Milano Bicocca,,ALL,"ADULT, OLDER_ADULT",NA,44,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-11-21,2023-12,2024-12,"University of Milano-Bicocca, Monza, 20900, Italy"
NCT05762003,Czech Pharmaco-epidemiological Study on Disease Modifying Drugs,https://beta.clinicaltrials.gov/study/NCT05762003,COMPLETED,Multiple Sclerosis,"DRUG: interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab",IMPULS Endowment Fund,,ALL,"CHILD, ADULT, OLDER_ADULT",,17478,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-01-01,2021-12-31,2021-12-31,"IMPULS Endowment Fund, Prague, 12000, Czechia"
NCT05433103,Blood Flow Restriction And Veterans With MS,https://beta.clinicaltrials.gov/study/NCT05433103,RECRUITING,Multiple Sclerosis,OTHER: Low-Load Exercise with Blood Flow Restriction|OTHER: Low-Load Exercise Control Group,VA Office of Research and Development,,ALL,"ADULT, OLDER_ADULT",NA,58,FED,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2023-01-01,2027-12-31,2027-12-31,"Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora, Colorado, 80045, United States"
NCT01039103,Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT01039103,TERMINATED,Acute Exacerbation of Remitting Relapsing Multiple Sclerosis|Clinically Isolated Syndrome,DRUG: PEG-liposomal prednisolone sodium phosphate|DRUG: Methylprednisolone,Galapagos NV,,ALL,"ADULT, OLDER_ADULT",PHASE2,15,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: ",2009-12,2011-11,2011-11,"Departement Neurologie AZ St Jan AV, Brugge, 8000, Belgium|Nationaal MS Centrum, Melsbroek, 1820, Belgium|Revalidatie & MS-centrum Overpelt, Overpelt, B-3900, Belgium|Krankenhaus Hohe Warte, Neurologische Klinik, Bayreuth, 95445, Germany|St. Josef Hospital der Ruhr, Bochum, 44791, Germany|Klinikum Rechts der Isar der technischen Universitaet Muenchen, Neurologische Klinik und Poliklinik, Muenchen, 81675, Germany|Uniwersytecki Szpital Kliniczny w Białymstoku, Białystok, 15-276, Poland|Diagnomed-Clinical Research Sp. z o.o., Katowice, 40-594, Poland"
NCT04494256,"A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation",https://beta.clinicaltrials.gov/study/NCT04494256,RECRUITING,Amyotrophic Lateral Sclerosis,DRUG: BIIB105|DRUG: Placebo,Biogen,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,98,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-09-28,2026-07-15,2026-07-15,"UCSD, La Jolla, California, 92037, United States|Stanford Neuromuscular Research Center, Palo Alto, California, 94305, United States|Georgetown University, Washington, District of Columbia, 20007-2113, United States|Mayo Clinic Florida, Jacksonville, Florida, 32224, United States|Orlando Health, Orlando, Florida, 32806, United States|The Emory Clinic, Atlanta, Georgia, 30322, United States|ALS Clinic - Department of Neurology, Neuromuscular Division, Johns Hopkins University, School of Medicine, Baltimore, Maryland, 21218, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Washington University, School of Medicine, Saint Louis, Missouri, 63110, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|University of Utah, Salt Lake City, Utah, 84132, United States|Montreal Neurological Institute-Hospital, Montreal, Quebec, H3A 2B4, Canada|A.O.U. Città della salute e della scienza di Torino, Torino, Italy|UMC Utrecht, Utrecht, 3584 CX, Netherlands"
NCT05447143,Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05447143,COMPLETED,Multiple Sclerosis|Exercise Program|Telerehabilitation|Autoimmune Disorder,OTHER: Fatigue Severity Scale|OTHER: Berg Balance Test|OTHER: Time up and go- 25 steps walking test|OTHER: Multiple Sclerosis Quality of Life|OTHER: Brief International Cognitive Assessment for MS (BICAMS)|OTHER: Beck Depression and Anxiety Scale,Muğla Sıtkı Koçman University,,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-09-30,2021-11-30,2022-06-15,"Muğla Sıtkı Koçman University, Muğla, Merkez, 48000, Turkey"
NCT03313843,Study to Assess OCT: RNFL and GCL in MS Patients,https://beta.clinicaltrials.gov/study/NCT03313843,COMPLETED,Multiple Sclerosis,,"Tampa Bay Uveitis Center, LLC",,ALL,"ADULT, OLDER_ADULT",,73,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-02-09,2020-12-17,2021-04-30,"Tampa Bay Uveitis Center, New Port Richey, Florida, 34655, United States|Tampa Bay Uveitis Center, Tampa, Florida, 33618, United States"
NCT05408767,Accelerated Brain Volume Loss in People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05408767,COMPLETED,Retrospective Study,,National MS Center Melsbroek,,ALL,"ADULT, OLDER_ADULT",,70,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-01-01,2022-01-01,2022-05-01,"Nationaal Multiple Sclerose Centrum Melsbroek, Melsbroek, Vlaams-Brabant, 1820, Belgium"
NCT05634967,Kesimpta (Ofatumumab) Pregnancy Registry,https://beta.clinicaltrials.gov/study/NCT05634967,RECRUITING,Multiple Sclerosis|Pregnancy,OTHER: Kesimpta,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",,725,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-01-05,2033-02-28,2033-02-28,"Novartis Investigative Site, La Jolla, California, 92093, United States"
NCT02490943,A Pilot Study of Warm and Cold Compress to Reduce Injection Site Erythema Due to Peginterferon-beta-1a in MS,https://beta.clinicaltrials.gov/study/NCT02490943,COMPLETED,MS (Multiple Sclerosis)|Erythema,OTHER: Warm Compress Before Injection|OTHER: Cold Compress After Injection,"Brown, Theodore R., M.D., MPH",Evergreen Healthcare,ALL,"ADULT, OLDER_ADULT",NA,28,INDIV,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2015-06,2019-01-01,2019-04-30,"Evergreen Health, Kirkland, Washington, 98034, United States"
NCT00771043,A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a,https://beta.clinicaltrials.gov/study/NCT00771043,WITHDRAWN,Relapsing-Remitting Multiple Sclerosis,DRUG: TYSABRI and AVONEX,Biogen,,ALL,ADULT,PHASE4,50,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2008-11,2009-08,2010-06,
NCT04036097,Prospective Stratification of Infectious Risks in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04036097,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,OTHER: MS-adapted AWIS questionnaire (MS-AWIS)|OTHER: infection diary (MS-AWIS diary),"University Hospital, Basel, Switzerland","Swiss Multiple Sclerosis Society|Bangerter-Rhyner Stiftung|Center for Chronic Immunodeficiency (CCI) in Freiburg, Germany",ALL,"ADULT, OLDER_ADULT",,254,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-04-10,2023-07,2023-07,"University Hospital Basel, Department of Neurology, Basel, 4031, Switzerland"
NCT03029897,E-reporting of Adverse Drug Reactions by Patients in Relapsing-remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03029897,COMPLETED,Multiple Sclerosis,OTHER: My eReport France,"University Hospital, Caen",,ALL,"ADULT, OLDER_ADULT",NA,161,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2017-05-05,2019-04-24,2019-04-24,"CHU Caen, Caen, 14000, France"
NCT00472797,Rebif New Formulation (RNF) Quality of Life (QOL) Study,https://beta.clinicaltrials.gov/study/NCT00472797,COMPLETED,Relapsing Multiple Sclerosis,DRUG: Rebif New Formulation Non Titrated|DRUG: Rebif New Formulation Titrated,EMD Serono,,ALL,ADULT,PHASE3,232,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2007-04,2009-02,2009-11,"EMD Serono, Inc., Rockland, Massachusetts, 02370, United States"
NCT03385356,Impact of Vitamin D Supplementation in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03385356,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting|Vitamin D Deficiency",DRUG: Vitamin D,University Medical Centre Maribor,Medical Faculty Maribor,ALL,ADULT,PHASE4,89,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2017-12-19,2018-04-30,2018-04-30,"University Medical Centre Maribor, Maribor, 2000, Slovenia"
NCT01701856,Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01701856,TERMINATED,Relapsing-remitting Multiple Sclerosis,DRUG: Interferon beta-1b,Claudio Gobbi,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE4,5,OTHER_GOV,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2012-09,2013-10,2013-10,"Ospedale Regionale di Lugano - Civico, Lugano, Ticino, 6903, Switzerland"
NCT03979456,RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS,https://beta.clinicaltrials.gov/study/NCT03979456,ACTIVE_NOT_RECRUITING,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Rituximab,Karolinska Institutet,,ALL,ADULT,PHASE3,200,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2018-07-04,2024-12-20,2025-06-01,"Anders Svenningsson, Danderyd, Stockholm, 18288, Sweden|South Älvsborg Hospital, Borås, Sweden|Falun Hospital, Falun, Sweden|Gävle Hospital, Gävle, Sweden|Saghlgrenska Hospital, Göteborg, Sweden|Helsingborg Hospital, Helsingborg, Sweden|Karlstad Hospital, Karlstad, Sweden|Halland Hospital Kungsbacka, Kungsbacka, Sweden|Linköping University Hospital, Linköping, Sweden|Nyköping Hospital, Nyköping, Sweden|Capio StGöran Hospital, Stockholm, Sweden|Fredrik Piehl, Stockholm, Sweden|Karolinska Hospital Huddinge, Stockholm, Sweden|Umeå University, Umeå, Sweden|Uppsala Academiska Hospital, Uppsala, Sweden|Örebro University Hospital, Örebro, Sweden|Östersund Hospital, Östersund, Sweden"
NCT00288990,A Serologic Study to Correlate Beta-IFN NAb Titers to Beta-IFN Induced Biomarker Response in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00288990,COMPLETED,Multiple Sclerosis,,Biogen,,ALL,"ADULT, OLDER_ADULT",,300,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2006-01,,2007-08,"University of Alabama - Birmingham, Birmingham, Alabama, 35294, United States|Physicians Resource Network, Cullman, Alabama, 35058, United States|Barrow Neurological Institute, Phoenix, Arizona, 85013, United States|University of California - Irvine, Irvine, California, 92697, United States|University of California San Francisco - MS Center, San Francisco, California, 94117, United States|Tampa Neurology, Tampa, Florida, 33609, United States|Northwestern University, Chicago, Illinois, 60611, United States|University of Chicago, Chicago, Illinois, 60637, United States|OSF Saint Francis Medical Center, Illinois Neurological Institute, Peoria, Illinois, 61637, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, 46805, United States|Mercy Ruan Neurology Clinic, Des Moines, Iowa, 50314, United States|Kentucky Neuroscience Research / University Neurologists, P.S.C, Louisville, Kentucky, 40202, United States|Louisiana State University Health Sciences Center, Shreveport, Louisiana, 71130, United States|University of Michigan, Ann Arbor, Michigan, 48109, United States|BJC Medical Group, St. Louis, Missouri, 63110, United States|Washington University, St. Louis, Missouri, 63110, United States|Family Health Center, White Plains, New York, 10601, United States|The Multiple Sclerosis Center at the Ohio State University, Columbus, Ohio, 43221, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, 15213, United States|Brown University / Rhode Island Hospital, Providence, Rhode Island, 02905, United States|The Baptist Hospital of East Tennessee, Knoxville, Tennessee, 37922, United States|The Advanced Neurosciences Institute, Nashville, Tennessee, 37205, United States|Vanderbilt University, Nashville, Tennessee, 37212, United States|Baylor College of Medicine - The Methodist College Multiple Sclerosis Center, Houston, Texas, 77030, United States|The University of Texas Houston, Houston, Texas, 77030, United States|Neurology Center of Fairfax, Ltd., Fairfax, Virginia, 22031, United States|University of Washington, Seattle, Washington, 98195, United States|Neurology Associates of Tacoma, Tacoma, Washington, 95405, United States"
NCT03750097,Validation of a Smartwatch in Persons With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03750097,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Comfortable walking velocity (CWV)|BEHAVIORAL: Slow walking velocity (SWV: CWV - 20%)|BEHAVIORAL: Fast walking velocity (FWV: CWV + 20%),University of Erlangen-Nürnberg,Neurological Rehabilitation Center Quellenhof|ZTM Bad Kissingen,ALL,"ADULT, OLDER_ADULT",NA,58,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2018-05-01,2018-12-15,2019-01-31,"Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Department of Sport Science and Sport, Gebbertstr. 123b, Erlangen, 91058, Germany"
NCT04548154,Proximal Resistance Training for People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04548154,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,OTHER: Proximal Resistance Training,"University of Colorado, Denver",National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),ALL,ADULT,NA,34,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-10-12,2023-06-30,2023-06-30,"University of Colorado, Aurora, Colorado, 80045, United States"
NCT03444454,Telerehabilitation in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03444454,UNKNOWN,Multiple Sclerosis,BEHAVIORAL: VRRS Khymeia|BEHAVIORAL: Usual care program|BEHAVIORAL: VRRS Khymeia plus active tDCS|BEHAVIORAL: VRRS Khymeia plus placebo tDCS,Fondazione Don Carlo Gnocchi Onlus,"IRCCS Centro Neurolesi Bonino-Pulejo, Messina (IT)|IRCCS Fondazione Istituto Neurologico Casimiro Mondino, Pavia (IT)|IRCCS San Camillo, Venezia, Italy|IRCCS San Raffaele Roma|Istituti Clinici Scientifici Maugeri SpA",ALL,"ADULT, OLDER_ADULT",NA,136,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-02-26,2018-12-31,2022-01-31,"Irccs Fondazione Don Carlo Gnocchi, Milano, MI, 20148, Italy"
NCT05516303,Pharmacogenetics of Liver Toxicity in Patients With Multiple Sclerosis Treated With Fingolimod,https://beta.clinicaltrials.gov/study/NCT05516303,RECRUITING,Multiple Sclerosis,GENETIC: Genetic polymorphism|DIAGNOSTIC_TEST: Measurement of fingolimod and fingolimod-phosphate concentrations,"University Hospital, Caen",,ALL,"ADULT, OLDER_ADULT",,65,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-06-07,2022-10-31,2022-10-31,"Caen University Hospital, Caen, 14000, France"
NCT05520554,"Development, Reliability and Validity of the Telerehabilitation Satisfaction Questionnaire- TrSQ",https://beta.clinicaltrials.gov/study/NCT05520554,ACTIVE_NOT_RECRUITING,Neurological Disease,OTHER: Development of the Telerehabilitation Satisfaction Questionnaire,Gazi University,,ALL,"ADULT, OLDER_ADULT",,60,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-08-15,2023-05-30,2023-06-30,"Gazi University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Ankara, Turkey"
NCT00238654,A Study to Evaluate Readiness to Self-inject on Adherence and Compliance to Copaxone® Therapy,https://beta.clinicaltrials.gov/study/NCT00238654,COMPLETED,Multiple Sclerosis,,"Teva Neuroscience, Inc.",,ALL,"ADULT, OLDER_ADULT",,257,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2003-05,2008-07,2008-07,
NCT01888354,Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ)Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations,https://beta.clinicaltrials.gov/study/NCT01888354,COMPLETED,Multiple Sclerosis (MS),DRUG: H.P. Acthar Gel (repository corticotropin injection),"The University of Texas Health Science Center, Houston",,ALL,ADULT,PHASE4,25,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2013-04,2014-08,2014-08,"The MS Center at the Neurology Center in Southern California, Oceanside, California, 92056, United States|The University of Texas-Houston Neurology Clinic, Houston, Texas, 77030, United States"
NCT01381354,"Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)",https://beta.clinicaltrials.gov/study/NCT01381354,COMPLETED,Multiple Sclerosis,OTHER: Progressive exercise|DEVICE: Neuromuscular electrical stimulation delivered using the electrical therapy device EMPI 300 PV|OTHER: Modified paleolithic diet|DIETARY_SUPPLEMENT: Omega 3 fatty acids|DIETARY_SUPPLEMENT: Full Spectrum vitamin|DIETARY_SUPPLEMENT: Essential - hydroxytyrosol|DIETARY_SUPPLEMENT: Maltodextrin fiber supplement|DIETARY_SUPPLEMENT: Mineral boost (magnesium)|DIETARY_SUPPLEMENT: Niacinamide|DIETARY_SUPPLEMENT: Methyl B12|DIETARY_SUPPLEMENT: Taurine|DIETARY_SUPPLEMENT: creatine|DIETARY_SUPPLEMENT: thiamine|DIETARY_SUPPLEMENT: riboflavin|DIETARY_SUPPLEMENT: N acetylcysteine|DIETARY_SUPPLEMENT: alpha lipoic acid|DIETARY_SUPPLEMENT: L acetyl carnitine|DIETARY_SUPPLEMENT: methyl folate|DIETARY_SUPPLEMENT: coenzyme Q|BEHAVIORAL: meditation|BEHAVIORAL: self massage|BEHAVIORAL: learning|DIETARY_SUPPLEMENT: Coconut oil,University of Iowa,"Direct MS Canada|DJO Incorporated|Pinnaclife Inc.|TZ Press, LLC",ALL,"ADULT, OLDER_ADULT",PHASE1,38,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2010-10,2016-02,2016-05,"Univeristy of Iowa/ VA Iowa City VA Medical Center, Iowa City, Iowa, 52246, United States"
NCT01489254,Efficacy and Safety of GTR in Comparison to Copaxone®,https://beta.clinicaltrials.gov/study/NCT01489254,COMPLETED,Multiple Sclerosis,DRUG: Glatiramer Acetate (GTR)|DRUG: Glatiramer Acetate (Copaxone®)|DRUG: Placebo,Synthon BV,,ALL,ADULT,PHASE3,794,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2011-10,2015-01,2015-01,"Synthon investigational site 112, Irvine, California, United States|Synthon investigational site 120, Port Charlotte, Florida, United States|Synthon investigational site 130, Sunrise, Florida, United States|Synthon investigational site 107, Elk Grove Village, Illinois, United States|Synthon investigational site 141, Raleigh, North Carolina, United States|Synthon investigational site 106, Cleveland, Ohio, United States|Synthon investigational site 135, Dayton, Ohio, United States|Synthon investigational site 401, Bitebsk, Belarus|Synthon investigational site 402, Gomel, Belarus|Synthon investigational site 403, Grodno, Belarus|Synthon investigational site 404, Minsk, Belarus|Synthon investigational site 407, Minsk, Belarus|Synthon investigational site 408, Minsk, Belarus|Synthon investigational site 405, Vitebsk, Belarus|Synthon investigational site 486, Banja Luka, Bosnia and Herzegovina|Synthon investigational site 487, Sarajevo, Bosnia and Herzegovina|Synthon investigational site 488, Tuzla, Bosnia and Herzegovina|Synthon investigational site 204, Pleven, Bulgaria|Synthon investigational site 207, Pleven, Bulgaria|Synthon investigational site 206, Plovdiv, Bulgaria|Synthon investigational site 202, Sofia, Bulgaria|Synthon investigational site 203, Sofia, Bulgaria|Synthon investigational site 205, Sofia, Bulgaria|Synthon investigational site 208, Sofia, Bulgaria|Synthon investigational site 201, Varna, Bulgaria|Synthon investigational site 477, Osijek, Croatia|Synthon investigational site 475, Zagreb, Croatia|Synthon investigational site 476, Zagreb, Croatia|Synthon investigational site 478, Zagreb, Croatia|Synthon investigational site 211, Brno, Czech Republic|Synthon investigational site 217, Brno, Czech Republic|Synthon investigational site 210, Olomouc, Czech Republic|Synthon investigational site 212, Ostrava, Czech Republic|Synthon investigational site 215, Praha, Czech Republic|Synthon investigational site 216, Praha, Czech Republic|Synthon investigational site 214, Teplice, Czech Republic|Synthon investigational site 297, Kohtla-Jarve, Estonia|Synthon investigational site 296, Tallinn, Estonia|Synthon investigational site 526, Tbilisi, Georgia|Synthon investigational site 527, Tbilisi, Georgia|Synthon investigational site 528, Tbilisi, Georgia|Synthon investigational site 529, Tbilisi, Georgia|Synthon investigational site 530, Tbilisi, Georgia|Synthon investigational site 227, Jena, Germany|Synthon investigational site 234, Coppito, Italy|Synthon investigational site 235, Naples, Italy|Synthon investigational site 516, Guadalajara, Mexico|Synthon investigational site 512, Mexico City, Mexico|Synthon investigational site 514, Mexico City, Mexico|Synthon investigational site 515, Morelia, Mexico|Synthon investigational site 547, Chisinau, Moldova, Republic of|Synthon investigational site 548, Chisinau, Moldova, Republic of|Synthon investigational site 549, Chisinau, Moldova, Republic of|Synthon investigational site 550, Chisinau, Moldova, Republic of|Synthon investigational site 244, Bialystok, Poland|Synthon investigational site 240, Katowice, Poland|Synthon investigational site 241, Katowice, Poland|Synthon investigational site 242, Katowice, Poland|Synthon investigational site 245, Katowice, Poland|Synthon investigational site 247, Lodz, Poland|Synthon investigational site 251, Lublin, Poland|Synthon investigational site 243, Olsztyn, Poland|Synthon investigational site 248, Poznan, Poland|Synthon investigational site 250, Szczecin, Poland|Synthon investigational site 246, Warszawa, Poland|Synthon investigational site 249, Wroclaw, Poland|Synthon investigational site 260, Bucharest, Romania|Synthon investigational site 262, Bucharest, Romania|Synthon investigational site 263, Bucharest, Romania|Synthon investigational site 264, Bucharest, Romania|Synthon investigational site 265, Bucharest, Romania|Synthon investigational site 266, Cluj-Napoca, Romania|Synthon investigational site 267, Timisoara, Romania|Synthon investigational site 438, Arkhangelsk, Russian Federation|Synthon investigational site 435, Barnaul, Russian Federation|Synthon investigational site 437, Belgorod, Russian Federation|Synthon investigational site 431, Ekaterinburg, Russian Federation|Synthon investigational site 445, Kaluga, Russian Federation|Synthon investigational site 427, Kazan, Russian Federation|Synthon investigational site 432, Kemerovo, Russian Federation|Synthon investigational site 447, Kirov, Russian Federation|Synthon investigational site 446, Lipetsk, Russian Federation|Synthon investigational site 571, Moscow, Russian Federation|Synthon investigational site 428, Nizhniy Novgorod, Russian Federation|Synthon investigational site 429, Nizhniy Novgorod, Russian Federation|Synthon investigational site 434, Novosibirsk, Russian Federation|Synthon investigational site 442, Novosibirsk, Russian Federation|Synthon investigational site 444, Penza, Russian Federation|Synthon investigational site 433, Pyatigorsk, Russian Federation|Synthon investigational site 424, Samara, Russian Federation|Synthon investigational site 420, Smolensk, Russian Federation|Synthon investigational site 421, St.Petersburg, Russian Federation|Synthon investigational site 426, St.Petersburg, Russian Federation|Synthon investigational site 430, St.Petersburg, Russian Federation|Synthon investigational site 440, St.Petersburg, Russian Federation|Synthon investigational site 422, Tomsk, Russian Federation|Synthon investigational site 441, Tver, Russian Federation|Synthon investigational site 425, Tyumen, Russian Federation|Synthon investigational site 423, Ufa, Russian Federation|Synthon investigational site 450, Belgrade, Serbia|Synthon investigational site 451, Belgrade, Serbia|Synthon investigational site 453, Kragujevac, Serbia|Synthon investigational site 452, Novi Sad, Serbia|Synthon investigational site 501, Cape Town, South Africa|Synthon investigational site 505, Durban, South Africa|Synthon investigational site 502, Pretoria, South Africa|Synthon investigational site 474, Cherkassy, Ukraine|Synthon investigational site 459, Chernihiv, Ukraine|Synthon investigational site 463, Chernivtsi, Ukraine|Synthon investigational site 458, Dnepropetrovsk, Ukraine|Synthon investigational site 472, Dnepropetrovsk, Ukraine|Synthon investigational site 464, Donetsk, Ukraine|Synthon investigational site 468, Donetsk, Ukraine|Synthon investigational site 495, Ivano-Frankivsk, Ukraine|Synthon investigational site 461, Kharkiv, Ukraine|Synthon investigational site 469, Kharkiv, Ukraine|Synthon investigational site 455, Kyiv, Ukraine|Synthon investigational site 456, Kyiv, Ukraine|Synthon investigational site 496, Kyiv, Ukraine|Synthon investigational site 473, Lutsk, Ukraine|Synthon investigational site 462, Lviv, Ukraine|Synthon investigational site 466, Lviv, Ukraine|Synthon investigational site 497, Lviv, Ukraine|Synthon investigational site 498, Mariupol, Ukraine|Synthon investigational site 457, Odessa, Ukraine|Synthon investigational site 470, Poltava, Ukraine|Synthon investigational site 471, Uzhhorod, Ukraine|Synthon investigational site 465, Vinnytsia, Ukraine|Synthon investigational site 460, Zhytomyr, Ukraine|Synthon investigational site 284, Sheffield, United Kingdom|Synthon investigational site 281, Stoke on Trent, United Kingdom|Synthon investigational site 283, Torquay, United Kingdom|Synthon investigational site 280, Truro, United Kingdom"
NCT02331654,Spinal Direct Current Stimulation Effects on Pain in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02331654,UNKNOWN,Multiple Sclerosis,OTHER: Experimental treatment|OTHER: Placebo treatment,"IRCCS National Neurological Institute ""C. Mondino"" Foundation",,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2013-11,2015-06,2016-02,"IRCCS Fondazione Istituto Neurologico Nazionale C. Mondino, Pavia, 27100, Italy"
NCT05123703,A Study To Evaluate Safety And Efficacy Of Ocrelizumab In Comparison With Fingolimod In Children And Adolescents With Relapsing-Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05123703,RECRUITING,Relapsing-Remitting Multiple Sclerosis,DRUG: Ocrelizumab|OTHER: Ocrelizumab Placebo|DRUG: Fingolimod|OTHER: Fingolimod Placebo,Hoffmann-La Roche,PPD,ALL,CHILD,PHASE3,233,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-02-04,2025-07-07,2025-11-05,"UC San Diego; ACTRI, La Jolla, California, 92037, United States|University of Colorado Denver Childrens Hospital Rocky Mountain MS Center, Aurora, Colorado, 80045, United States|Pediatric Multiple Sclerosis and Related Disorders Program at Boston Children's Hospital, Boston, Massachusetts, 02115, United States|Washington University, Pediatric MS and other Demyelinating Disease Center, Saint Louis, Missouri, 63110, United States|NYU Langone Medical Center; Laura and Isaac Perlmutter Cancer Center, New York, New York, 10016, United States|Cleveland Clinic, Mellen Center for Multiple Sclerosis, Cleveland, Ohio, 44195, United States|The Boster Center for MS, Columbus, Ohio, 43235, United States|The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States|Baylor College of Medicine/Texas Children's Hospital, Houston, Texas, 77030, United States|University of Virginia Health System, Charlottesville, Virginia, 22903, United States|Hospital de Pediatría S.A.M.I.C.- Prof. Dr. Juan P. Garrahan, Ciudad Autonoma Buenos Aires, C1249ABN, Argentina|Centro de Investigaciones Médicas Tucuman; REUMATHOLOGY, San Miguel, T4000AXL, Argentina|Royal Children's Hospital Melbourne - PIN, Parkville, Victoria, 3052, Australia|Medizinische Universität Wien; Univ.Klinik fuer Neurologie, Wien, 1090, Austria|Hôpital Universitaire des Enfants Reine Fabiola; porte 10, batiment K, Brussel, 1020, Belgium|Cliniques Universitaires St-Luc, Bruxelles, 1200, Belgium|UZ Gent, Gent, 9000, Belgium|L2 Ip - Instituto de Pesquisas Clinicas Ltda - ME, Brasilia, DF, 70200-730, Brazil|Instituto de Neurologia de Curitiba, Curitiba, PR, 81210-310, Brazil|Universidade de Caxias do Sul - Rio Grande do Sul, Caxias do Sul, RS, 95070-560, Brazil|Nucleo de Pesquisa Clinica do Rio Grande do Sul NPCR, Porto Alegre, RS, 90430-001, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, 90610-000, Brazil|CPQuali Pesquisa Clínica Sao Paulo, Sao Paulo, SP, 01228-000, Brazil|Multiprofile Hospital For Active Treatment In Neurology And Psychiatry (MHATNP) ''St. Naum"", Sofia, 1797, Bulgaria|University of Alberta Hospital, Edmonton, Alberta, T6G 1Z1, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, K1H 8L1, Canada|Centre Hospitalier Universitaire de Bicêtre, Le Kremlin-bicêtre, 94275, France|Hopital Pierre Wertheimer - Hopital Neurologique; Service de neurologie, Lyon, 69394, France|CHRU de Montpellier, Hopital Gui de Chauliac; Service de Neuropediatrie, Montpellier, 34295, France|Vestische Kinder- und Jugendklinik Datteln, Datteln, 45711, Germany|Universitätsmedizin Göttingen Georg-August-Universität; Klinik für Kinder-und Jugendmedizin_UMG, Göttingen, 37075, Germany|Universitätsklinikum Münster; Klinik für Kinder- und Jugendmedizin, Muenster, 48129, Germany|Hospital Eginition; First Department of Neurology, Athens, 115 28, Greece|Attikon University General Hospital, Chaidari, 124 62, Greece|Agios Loucas Clinic SA, Panorama, 552 36, Greece|Hippokration General Hospital; First Department of Pediatrics, Thessaloniki, 546 42, Greece|Debreceni Egyetem Klinikai Központ; Gyermekklinika, Debrecen, 4032, Hungary|Universita? G. D'Annunzio; Dipartimento di Neuroscienze, Imaging e Scienze Cliniche, Chieti, Abruzzo, 66100, Italy|A. O. U. Federico II; Dip Neuroscienze, Scienze Riproduttive ed Odontostomatologiche, Napoli, Campania, 80131, Italy|IRCCS Materno Infantile Burlo Garofolo - INCIPIT - PIN, Trieste, Friuli-Venezia Giulia, 34137, Italy|A.O. Sant'Andrea; UOC Neurologia, Dip. di Neuroscienze, Salute Mentale e Organi di Senso (NESMOS), Roma, Lazio, 00189, Italy|Irccs A.O.U.San Martino Ist; Dinogmi, Genova, Liguria, 16132, Italy|IRCCS Ospedale San Raffaele; Neurologia Neurofisiologia Neuroriabilitazione-Centro Sclerosi Multipla, Milano, Lombardia, 20132, Italy|Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuele, Catania, Sicilia, 95123, Italy|Children's Clinical University Hospital, Riga, LV-1004, Latvia|Hospital Civil Fray Antonio Alcalde, Guadalajara, Jalisco, 44280, Mexico|Grupo Médico Camino S.C., Ciudad de México, Mexico CITY (federal District), 03600, Mexico|Clinstile S.A de C.V., Mexico City, Mexico CITY (federal District), 06700, Mexico|Centro para el Desarrollo de la Medicina y de Asistencia, Culiacán Rosales, Sinaloa, 80230, Mexico|Neurociencias Estudios Clinicos S.C., Culiacán, Sinaloa, 80020, Mexico|Instituto de Investigaciones Aplicadas a la Neurociencia A.C., Durango, 34000, Mexico|FAICIC S de R.L. de C.V; FAICIC Clinical Research, Veracruz, 91900, Mexico|Instytut Centrum Zdrowia Matki Polki; Klinika Neurologii, ?ód?, 93-338, Poland|Uniwersyteckie Centrum Kliniczne; Klinika Neurologii Rozwojowej, Gda?sk, 80-952, Poland|Uniwersytecki Szpital Kliniczny w Poznaniu; Od. Kliniczny Neurologii Dzieci i M?odziezy, Pozna?, 60-355, Poland|Instytut Pomnik Centrum Zdrowia Dziecka; Klinika Neurologii i Epileptologii, Warszawa, 04-730, Poland|Hospital de Braga, Braga, 4710-243, Portugal|Centro Hospitalar e Universitário de Coimbra E.P.E.; Hospital Pediátrico, Coimbra, 3000-602, Portugal|Hospital Santo Antonio dos Capuchos; Servico de Neurologia, Lisboa, 1169-050, Portugal|Childrens University Hospital, Belgrade, 11000, Serbia|Clinic for Neurology and Psychiatry for Children and Youth, Belgrade, 11000, Serbia|Mother and Child Health Care Institute of Serbia Dr Vukan Cupic, Belgrade, 11000, Serbia|Clinic for neurology, Clinical Center Kragujevac, Kragujevac, 34000, Serbia|University Clinical Centre Nis; Clinic for Hematology, Nis, 18000, Serbia|Hospital Sant Joan De Deu, Esplugues De Llobregas, Barcelona, 08950, Spain|Hospital de Cruces; Servicio de Neurologia, Barakaldo, Vizcaya, 48903, Spain|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital Universitario de la Princesa; Servicio de Neurologia, Madrid, 28006, Spain|Hospital Universitario Ramon y Cajal, Madrid, 28034, Spain|Hospital Regional Universitario Carlos Haya; Servicio de Neurologia, Malaga, 29010, Spain|Hospital Universitario Virgen Macarena; Servicio de Neurologia, Sevilla, 41009, Spain|State Institution Institute of Neurology, Psychiatry and Narcology of NAMS of Ukraine, Kharkiv, Kharkiv Governorate, 61068, Ukraine|Communal noncommercial enterprise of Lviv Regional Council Lviv Regional Clinical Hospital, Lviv, Kharkiv Governorate, 79010, Ukraine|KZ ""Dnipropetrovska oblasna dytiacha klinichna likarnia"" DOR, Dnipropetrovsk, Tavria Okruha, 49100, Ukraine|Birmingham Children's Hospital, Birmingham, B4 6NH, United Kingdom|Great Ormond Street Hospital For Children; Neurology, London, WC1N 3JH, United Kingdom"
NCT00122954,Fish Oil for the Treatment of Depression in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00122954,COMPLETED,Multiple Sclerosis|Depression,DRUG: Fish oil concentrate|DRUG: Placebo,Oregon Health and Science University,National Center for Complementary and Integrative Health (NCCIH),ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,39,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2005-07,2009-06,2009-06,"Oregon Health and Science University, Portland, Oregon, 97239, United States"
NCT04215354,Association Between Fatigue and Balance in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04215354,COMPLETED,Multiple Sclerosis,DEVICE: Magnetic field|DEVICE: Virtual reality,Imam Abdulrahman Bin Faisal University,King AbdulAziz City for Science and Technology,ALL,ADULT,NA,95,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2014-09,2016-01,2016-05,"Imam Abdulrahman Bin Faisal University, Dammam, Eastern, 2435 Dammam 31451, Saudi Arabia"
NCT00202397,Effect of Riluzole as a Symptomatic Approach in Patients With Chronic Cerebellar Ataxia,https://beta.clinicaltrials.gov/study/NCT00202397,COMPLETED,Hereditary Ataxia|Multiple Sclerosis|Cerebellar Ataxia,DRUG: Riluzole|OTHER: placebo,S. Andrea Hospital,,ALL,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2005-06,2008-06,2008-08,"S.Andrea Hospital - University of Rome ""La Sapienza"", Rome, 00100, Italy"
NCT02525367,"Online Cognitive Training in PD, MS and Depressed Patients Treated With Electroconvulsive Therapy",https://beta.clinicaltrials.gov/study/NCT02525367,TERMINATED,Idiopathic Parkinson's Disease|Multiple Sclerosis|Elderly Post Electric Convulsive Therapy,BEHAVIORAL: Online cognitive training|BEHAVIORAL: Active control condition,"Amsterdam UMC, location VUmc",Parnassia Bavo Groep|GGZ inGeest,ALL,"ADULT, OLDER_ADULT",NA,28,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-03,2017-06,2017-07-07,"VU University Medical Center, Amsterdam, North-Holland, 1118, Netherlands"
NCT02047097,Dimethyl Fumarate (DMF) Observational Study,https://beta.clinicaltrials.gov/study/NCT02047097,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,DRUG: dimethyl fumarate,Biogen,,ALL,"ADULT, OLDER_ADULT",,5496,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-11-19,2022-10-31,2022-10-31,"Research Site, Birmingham, Alabama, 35209, United States|Research Site, Huntsville, Alabama, 35801, United States|Research Site, Gilbert, Arizona, 85234, United States|Research Site, Phoenix, Arizona, 85006, United States|Research Site, Phoenix, Arizona, 85018, United States|Research Site, Phoenix, Arizona, 85048, United States|Research Site, Scottsdale, Arizona, 85251, United States|Research Site, Tucson, Arizona, 85718, United States|Research Sites, Fullerton, California, 92835, United States|Research Site, Hanford, California, 93230, United States|Research Site, Loma Linda, California, 92354, United States|Research Site, Los Angeles, California, 90015, United States|Research Site, Los Angeles, California, 90048, United States|Research Site, Newport Beach, California, 92663, United States|Research Site, San Francisco, California, 94158, United States|Research Site, Santa Ana, California, 92704, United States|Research Site, Aurora, Colorado, 80045, United States|Research Site, Colorado Springs, Colorado, 80907, United States|Research Site, Denver, Colorado, 80210, United States|Research Site, Fort Collins, Colorado, 80528, United States|Research Site, Danbury, Connecticut, 06810-4088, United States|Research Site, Derby, Connecticut, 06418-1376, United States|Research Site, Hartford, Connecticut, 06112, United States|Research Site, Norwich, Connecticut, 06360, United States|Research Site, Dover, Delaware, 19901, United States|Research Site, Wilmington, Delaware, 19801, United States|Research Site, Washington, District of Columbia, 20007-2113, United States|Research Site, Washington, District of Columbia, 20037, United States|Research Sites, Boca Raton, Florida, 33486, United States|Research Site, Gainesville, Florida, 32610, United States|Research Site, Jacksonville, Florida, 32216, United States|Research Sites, Lighthouse Point, Florida, 33064, United States|Research Site, Maitland, Florida, 32751, United States|Research Site, Miami, Florida, 33125, United States|Research Site, Port Charlotte, Florida, 33952, United States|Research Site, Saint Petersburg, Florida, 33710, United States|Research Site, Saint Petersburg, Florida, 33713, United States|Research Site, Sarasota, Florida, 34233, United States|Research Site, Tampa, Florida, 33606, United States|Research Sites, Atlanta, Georgia, 30309, United States|Research Site, Atlanta, Georgia, 30309, United States|Research Site, Atlanta, Georgia, 30327, United States|Research Site, Augusta, Georgia, 30912, United States|Research Site, Columbus, Georgia, 31909, United States|Research Site, Savannah, Georgia, 31406, United States|Research Site, Chicago, Illinois, 60611, United States|Research Site, Chicago, Illinois, 60637, United States|Research Site, Evanston, Illinois, 60201, United States|Research Site, Herrin, Illinois, 62948-3732, United States|Research Site, Peoria, Illinois, 61603, United States|Research Site, Winfield, Illinois, 60190, United States|Research Site, Elkhart, Indiana, 46514, United States|Research Site, Indianapolis, Indiana, 46202, United States|Research Site, Des Moines, Iowa, 50309, United States|Research Site, Des Moines, Iowa, 50314, United States|Research Site, Waterloo, Iowa, 50702, United States|Research Site, Overland Park, Kansas, 66211, United States|Research Site, Overland Park, Kansas, 66212, United States|Research Site, Henderson, Kentucky, 42420, United States|Research Site, Louisville, Kentucky, 40207, United States|Research Site, Hammond, Louisiana, 70403-1475, United States|Research Site, New Orleans, Louisiana, 70121, United States|Research Site, Rockport, Maine, 04856, United States|Research Site, Baltimore, Maryland, 21201, United States|Research Site, Baltimore, Maryland, 21287, United States|Research Site, Bethesda, Maryland, 20814, United States|Research Site, Cumberland, Maryland, 21502, United States|Research Site, Glen Burnie, Maryland, 21061, United States|Research Site, Boston, Massachusetts, 02111, United States|Research Site, Boston, Massachusetts, 02135, United States|Research Site, Foxboro, Massachusetts, 02035, United States|Research Site, Jamaica Plain, Massachusetts, 02130-2075, United States|Research Site, Lexington, Massachusetts, 02421, United States|Research Site, Wellesley, Massachusetts, 02481, United States|Research Site, Worcester, Massachusetts, 01655, United States|Research Site, Ann Arbor, Michigan, 48109, United States|Research Site, East Lansing, Michigan, 48824, United States|Research Site, Farmington Hills, Michigan, 48334, United States|Research Site, West Bloomfield, Michigan, 48322, United States|Research Site, Edina, Minnesota, 55435, United States|Research Sites, Minneapolis, Minnesota, 55407-3723, United States|Research Site, Ocean Springs, Mississippi, 39564, United States|Research Site, Saint Louis, Missouri, 63110, United States|Research Site, Springfield, Missouri, 65806, United States|Research Site, Billings, Montana, 59101, United States|Research Site, Great Falls, Montana, 59405, United States|Research Sites, Lincoln, Nebraska, 68506-2960, United States|Research Site, Lincoln, Nebraska, 68521, United States|Research Site, Wahoo, Nebraska, 68066, United States|Research Site, Las Vegas, Nevada, 89106, United States|Research Site, Concord, New Hampshire, 3301, United States|Research Site, Audubon, New Jersey, 08106, United States|Research Site, Flemington, New Jersey, 08822, United States|Research Site, Hackensack, New Jersey, 07601, United States|Research Site, Livingston, New Jersey, 07039, United States|Research Site, New Brunswick, New Jersey, 08903, United States|Research Site, Newark, New Jersey, 07103, United States|Research Site, Stratford, New Jersey, 08084, United States|Research Site, Toms River, New Jersey, 08755, United States|Research Site, West Long Branch, New Jersey, 07764, United States|Research Site, Albany, New York, 12206, United States|Research Site, Cedarhurst, New York, 11516, United States|Research Site, East Meadow, New York, 11554, United States|Research Site, Kingston, New York, 12401, United States|Research Site, New York, New York, 10016, United States|Research Site, New York, New York, 10029, United States|Research Site, Patchogue, New York, 11772, United States|Research Site, Plainview, New York, 11803, United States|Research Site, Syracuse, New York, 13202, United States|Research Site, Syracuse, New York, 13210, United States|Research Site, Asheville, North Carolina, 28803, United States|Research Sites, Charlotte, North Carolina, 28204, United States|Research Site, Charlotte, North Carolina, 28226, United States|Research Site, Greensboro, North Carolina, 27405, United States|Research Site, Hendersonville, North Carolina, 28792, United States|Research Site, Pinehurst, North Carolina, 28370, United States|Research Site, Raleigh, North Carolina, 27607-6010, United States|Research Sites, Wilmington, North Carolina, 28401-7307, United States|Research Site, Winston-Salem, North Carolina, 27157, United States|Research Site, Bismarck, North Dakota, 58501, United States|Research Site, Canton, Ohio, 44735, United States|Research Site, Centerville, Ohio, 45459, United States|Research Site, Cincinnati, Ohio, 45267, United States|Research Site, Cleveland, Ohio, 44195, United States|Research Site, Columbus, Ohio, 43210, United States|Research Site, Oklahoma City, Oklahoma, 73104, United States|Research Site, Tulsa, Oklahoma, 74136, United States|Research Site, Portland, Oregon, 97225, United States|Research Site, Portland, Oregon, 97239, United States|Research Site, Abington, Pennsylvania, 19001, United States|Research Site, Allentown, Pennsylvania, 18103, United States|Research Site, Greensburg, Pennsylvania, 15601, United States|Research Site, Meadowbrook, Pennsylvania, 19046, United States|Research Site, Monroeville, Pennsylvania, 15146-3517, United States|Research Site, Natrona Heights, Pennsylvania, 15065, United States|Research Site, Philadelphia, Pennsylvania, 19107, United States|Research Site, Pittsburgh, Pennsylvania, 15212, United States|Research Site, Columbia, South Carolina, 29203, United States|Research Site, Greenville, South Carolina, 29605, United States|Research Site, Spartanburg, South Carolina, 29307, United States|Research Site, Franklin, Tennessee, 37064, United States|Research Site, Knoxville, Tennessee, 37920, United States|Research Site, Knoxville, Tennessee, 37922, United States|Research Site, Nashville, Tennessee, 37205, United States|Research Site, Nashville, Tennessee, 37232, United States|Research Site, Arlington, Texas, 76012, United States|Research Site, Colleyville, Texas, 76034, United States|Research Site, Dallas, Texas, 75246, United States|Research Site, Dallas, Texas, 75390, United States|Research Site, Houston, Texas, 77030, United States|Research Site, Norfolk, Virginia, 23502, United States|Research Site, Richmond, Virginia, 23298, United States|Research Site, Virginia Beach, Virginia, 23456, United States|Research Site, Kirkland, Washington, 98034, United States|Research Site, Seattle, Washington, 98101, United States|Research Site, Spokane, Washington, 99208, United States|Research Site, Tacoma, Washington, 98405, United States|Research Site, Tacoma, Washington, 98409, United States|Research Site, Green Bay, Wisconsin, 54301, United States|Research Site, Green Bay, Wisconsin, 54303, United States|Research Site, Green Bay, Wisconsin, 54308-8900, United States|Research Site, Green Bay, Wisconsin, 54311, United States|Research Site, La Crosse, Wisconsin, 54601-4795, United States|Research Site, Madison, Wisconsin, 53715, United States|Research Site, Milwaukee, Wisconsin, 53211, United States|Research Site, Milwaukee, Wisconsin, 53215, United States|Research Site, Neenah, Wisconsin, 54956, United States|Research Site, Waukesha, Wisconsin, 53188, United States|Research Site, Ciudad Autonoma Buenos Aires, Buenos Aires, C1181ACH, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, C1061ABD, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, C1425DKT, Argentina|Research Site, Vicente Lopez, Buenos Aires, 1602, Argentina|Research Site, Rosario, Santa Fe, S2000DFD, Argentina|Research Site, Rosario, Santa Fe, S2000, Argentina|Research Site, San Miguel de Tucuman, Tucuman, 4000, Argentina|Research Site, Ciudad Autonoma Buenos Aires, 1199, Argentina|Research Site, Ciudad Autonoma Buenos Aires, C1013AAB, Argentina|Research Site, Ciudad Autonoma Buenos Aires, C1118AAT, Argentina|Research Site, Ciudad Autonoma Buenos Aires, C1192AAW, Argentina|Research Site, Cordoba, 5000, Argentina|Research Site, Cordoba, X5004CDT, Argentina|Research Site, Guaymallén, 5519, Argentina|Research Site, Mendoza, M5502AWY, Argentina|Research Site, Salta, 4400, Argentina|Research Site, San Juan, 5400, Argentina|Research Site, Santiago del Estero, 4200, Argentina|Research Site, Camperdown, New South Wales, 2050, Australia|Research Site, Concord, New South Wales, 2139, Australia|Research Site, Kogarah, New South Wales, 2217, Australia|Research Site, Liverpool, New South Wales, 2170, Australia|Research Site, New Lambton Heights, New South Wales, 2305, Australia|Research Site, Randwick, New South Wales, 2031, Australia|Research Site, St. Leonards, New South Wales, 2065, Australia|Research Site, Sydney, New South Wales, 2109, Australia|Research Site, Westmead, New South Wales, 2145, Australia|Research Site, Auchenflower, Queensland, 4066, Australia|Research Site, Gold Coast, Queensland, 9726, Australia|Research Site, Bedford Park, South Australia, 5042, Australia|Research Site, Kent Town, South Australia, 5067, Australia|Research Site, Box Hill, Victoria, 3128, Australia|Research Site, Clayton, Victoria, 3168, Australia|Research Site, Geelong, Victoria, 3220, Australia|Research Site, Heidelberg, Victoria, 3084, Australia|Research Site, Melbourne, Victoria, 3004, Australia|Research Site, Melbourne, Victoria, 3181, Australia|Research Site, Parkville, Victoria, 3050, Australia|Research Site, Nedlands, Western Australia, 6009, Australia|Research Site, Amstetten, 3300, Austria|Research Site, Salzburg, 5020, Austria|Research Site, Vienna, 1040, Austria|Research Site, Vienna, 1180, Austria|Research Site, Calgary, Alberta, T2N 2T9, Canada|Research Site, Burnaby, British Columbia, V5H 4K7, Canada|Research Site, Victoria, British Columbia, V8R 1J8, Canada|Research Site, Moncton, New Brunswick, E1C 6Z8, Canada|Research Site, Halifax, Nova Scotia, B3H 1V7, Canada|Research Site, Sydney, Nova Scotia, B1P 1P3, Canada|Research Site, Cambridge, Ontario, N1R7L6, Canada|Research Site, London, Ontario, N6A 5A5, Canada|Research Site, Milton, Ontario, L9T 5B5, Canada|Research Site, Scarborough, Ontario, M1R 3A6, Canada|Research Site, Thunder Bay, Ontario, P7B 6V4, Canada|Research Site, Gatineau, Quebec, J8Y 1W2, Canada|Research Sites, Montreal, Quebec, H2L 4M1, Canada|Research Site, Montréal, Quebec, H2L 4M1, Canada|Research Site, Montréal, Quebec, H3A 2B4, Canada|Research Site, Regina, Saskatchewan, S4S 3R8, Canada|Research Site, Brno, 656 91, Czechia|Research Site, Hradec Kralove, 50333, Czechia|Research Site, Jihlava, 58633, Czechia|Research Site, Olomouc, 77520, Czechia|Research Site, Pardubice, 532 03, Czechia|Research Site, Praha 10, 100 34, Czechia|Research Site, Teplice, 41529, Czechia|Research Site, Aarhus C, 8200, Denmark|Research Site, Esbjerg, 6715, Denmark|Research Site, Glostrup, 2600, Denmark|Research Site, Odense C, 5000, Denmark|Research Site, Sønderborg, 6400, Denmark|Research Site, Montlucon, Allier, 03113, France|Research Site, Mulhouse Cedex, Haut Rhin, 68100, France|Research Site, Toulouse cedex 9, Haute Garonne, 31059, France|Research Site, Pringy cedex, Haute Savoie, 74374, France|Research Site, Rueil Malmaison, Hauts De Seine, 92500, France|Research Site, Dax cedex, Landes, 40107, France|Research Site, Agen cedex 09, Lot Et Garonne, 47923, France|Research Site, Perpignan, Pyrenees Orientales, 66046, France|Research Site, Bron Cedex, Rhone, 69677, France|Research Site, La Roche sur Yon, Vendee, 85925, France|Research Site, Epinal cedex, Vosges, 88021, France|Research Site, Gonesse, 95503, France|Research Site, Rambouillet, 78120, France|Research Site, Freiburg, Baden Wuerttemberg, 79098, Germany|Research Site, Heidelberg, Baden Wuerttemberg, 69120, Germany|Research Site, Heidenheim, Baden Wuerttemberg, 89518, Germany|Research Site, Ladenburg, Baden Wuerttemberg, 68526, Germany|Research Site, Mannheim, Baden Wuerttemberg, 68159, Germany|Research Site, Mannheim, Baden Wuerttemberg, 68161, Germany|Research Site, Ravensburg, Baden Wuerttemberg, 88212, Germany|Research Site, Singen, Baden Wuerttemberg, 78224, Germany|Research Site, Sinsheim, Baden Wuerttemberg, 74889, Germany|Research Site, Stuttgart, Baden Wuerttemberg, 70176, Germany|Research Site, Stuttgart, Baden Wuerttemberg, 70178, Germany|Research Site, Stuttgart, Baden Wuerttemberg, 70182, Germany|Research Site, Ulm, Baden Wuerttemberg, 89078, Germany|Research Site, Alzenau, Bavaria, 63755, Germany|Research Site, Bayreuth, Bayern, 95445, Germany|Research Site, Bogen, Bayern, 94327, Germany|Research Site, Erlangen, Bayern, 91054, Germany|Research Site, Landshut, Bayern, 84028, Germany|Research Site, Muenchen, Bayern, 81825, Germany|Research Site, Neuburg, Bayern, 86633, Germany|Research Site, Nuernberg, Bayern, 90451, Germany|Research Site, Nürnberg, Bayern, 90419, Germany|Research Site, Regensburg, Bayern, 93095, Germany|Research Site, Unterhaching, Bayern, 82008, Germany|Research Site, Wolfratshausen, Bayern, 82515, Germany|Research Site, Wuerzburg, Bayern, 97080, Germany|Research Site, Butzbach, Hessen, 35510, Germany|Research Site, Eltville, Hessen, 65343, Germany|Research Site, Erbach, Hessen, 64711, Germany|Research Site, Eschwege, Hessen, 37269, Germany|Research Site, Frankfurt, Hessen, 60313, Germany|Research Site, Frankfurt, Hessen, 60488, Germany|Research Site, Frankfurt, Hessen, 60528, Germany|Research Site, Gelnhausen, Hessen, 63571, Germany|Research Site, Giessen, Hessen, 35392, Germany|Research Site, Gladenbach, Hessen, 35075, Germany|Research Site, Kassel, Hessen, 34121, Germany|Research Site, Wiesbaden, Hessen, 65183, Germany|Research Site, Buchholz, Niedersachsen, 21244, Germany|Research Site, Gottingen, Niedersachsen, 37073, Germany|Research Site, Oldenburg, Niedersachsen, 26122, Germany|Research Site, Stade, Niedersachsen, 21682, Germany|Research Site, Aachen, Nordrhein Westfalen, 52062, Germany|Research Site, Aachen, Nordrhein Westfalen, 52078, Germany|Research Site, Bad Honnef, Nordrhein Westfalen, 53604, Germany|Research Site, Bergisch-Gladbach, Nordrhein Westfalen, 51429, Germany|Research Site, Bielefeld, Nordrhein Westfalen, 33647, Germany|Research Site, Bochum, Nordrhein Westfalen, 44789, Germany|Research Site, Bonn, Nordrhein Westfalen, 53111, Germany|Research Site, Duesseldorf, Nordrhein Westfalen, 40211, Germany|Research Site, Essen, Nordrhein Westfalen, 45138, Germany|Research Site, Hagen, Nordrhein Westfalen, 58095, Germany|Research Site, Koeln, Nordrhein Westfalen, 50935, Germany|Research Site, Köln, Nordrhein Westfalen, 51063, Germany|Research Site, Remscheid, Nordrhein Westfalen, 42853, Germany|Research Site, Siegen, Nordrhein Westfalen, 57076, Germany|Research Site, Willich, Nordrhein Westfalen, 47877, Germany|Research Site, Wuppertal, Nordrhein Westfalen, 42284, Germany|Research Site, Frankenthal, Rheinland Pfalz, 67227, Germany|Research Site, Kandel, Rheinland Pfalz, 76870, Germany|Research Site, Katzenelnbogen, Rheinland Pfalz, 56368, Germany|Research Site, Rülzheim, Rheinland Pfalz, 76761, Germany|Research Site, Trier, Rheinland Pfalz, 54292, Germany|Research Site, Halle, Sachsen Anhalt, 06120, Germany|Research Site, Magdeburg, Sachsen Anhalt, 39120, Germany|Research Site, Chemnitz, Sachsen, 09117, Germany|Research Site, Gorlitz, Sachsen, 02828, Germany|Research Site, Leipzig, Sachsen, 04103, Germany|Research Site, Leipzig, Sachsen, 04229, Germany|Research Site, Wermsdorf, Sachsen, 04779, Germany|Research Site, Kiel, Schleswig Holstein, 24105, Germany|Research Site, Eisenach, Thueringen, 99817, Germany|Research Site, Erfurt, Thueringen, 99096, Germany|Research Site, Jena, Thueringen, 07747, Germany|Research Site, Berlin, 10713, Germany|Research Site, Berlin, 10961, Germany|Research Site, Berlin, 12099, Germany|Research Site, Berlin, 12163, Germany|Research Site, Berlin, 13347, Germany|Research Site, Berlin, 13465, Germany|Research Site, Hamburg, 20249, Germany|Research Site, Hamburg, 21149, Germany|Research Site, Neusäß, 86356, Germany|Research Site, Budapest, 1086, Hungary|Research Site, Budapest, 1106, Hungary|Research Site, Budapest, 1145, Hungary|Research Site, Eger, 3300, Hungary|Research Site, Gyor, 9024, Hungary|Research Site, Miskolc, 3526, Hungary|Research Site, Szeged, 6725, Hungary|Research Site, Tatabanya, 2800, Hungary|Research Site, Zalaegerszeg, 8900, Hungary|Research Site, Dublin, D04 N2E0, Ireland|Research Site, Dublin, D09 V2N0, Ireland|Research Site, Torrette, Ancona, 60126, Italy|Research Site, Montichiari, Brescia, 25018, Italy|Research Site, Pozzilli, Isernia, 86077, Italy|Research Site, Legnano, Milano, 20025, Italy|Research Site, Fidenza, Parma, 43036, Italy|Research Site, Orbassano, Torino, 10043, Italy|Research Site, Gallarate, Varese, 21013, Italy|Research Site, Bari, 70124, Italy|Research Site, Bergamo, 24127, Italy|Research Site, Bologna, 40139, Italy|Research Site, Cagliari, 09126, Italy|Research Site, Catanzaro, 88100, Italy|Research Site, Genova, 16132, Italy|Research Site, Messina, 98125, Italy|Research Site, Milano, 20132, Italy|Research Site, Modena, 41126, Italy|Research Site, Napoli, 80131, Italy|Research Site, Palermo, 90127, Italy|Research Site, Palermo, 90146, Italy|Research Site, Parma, 43126, Italy|Research Site, Pavia, 27100, Italy|Research Site, Perugia, 06156, Italy|Research Site, Pordenone, 33170, Italy|Research Site, Reggio Emilia, 42100, Italy|Research Site, Roma, 00152, Italy|Research Site, Roma, 00161, Italy|Research Site, Roma, 00168, Italy|Research Site, Roma, 00189, Italy|Research Site, Amsterdam, 1091 AC, Netherlands|Research Site, Arnhem, 6815 AD, Netherlands|Research Site, Breda, 4818 CK, Netherlands|Research Site, Eindhoven, 5623 EJ, Netherlands|Research Site, Geldrop, 5664 EH, Netherlands|Research Site, Geleen, 6162 BG, Netherlands|Research Site, Hoorn, 1624 NP, Netherlands|Research Site, Leeuwarden, 8934 AD, Netherlands|Research Site, Leiden, 2334 CK, Netherlands|Research Site, Nieuwegein, 3435 CM, Netherlands|Research Site, Nijmegen, 6532 SZ, Netherlands|Research Site, Tilburg, 5042 AD, Netherlands|Research Site, Venlo, 5912 BL, Netherlands|Research Site, Christchurch, 8011, New Zealand|Research Site, Dunedin, 9016, New Zealand|Research Site, Hamilton, 3200, New Zealand|Research Site, Bodø, 8005, Norway|Research Site, Namsos, 7801, Norway|Research Site, Ochojec, Katowice, 40-635, Poland|Research Site, Bialystok, 15-276, Poland|Research Site, Bydgoszcz, 85-681, Poland|Research Site, Gdansk, 80-803, Poland|Research site, Glogow Malopolski, 36-060, Poland|Research Site, Grudziadz, 86-300, Poland|Research site, Katowice, 40-571, Poland|Research Site, Katowice, 40-752, Poland|Research Site, Konskie, 26-200, Poland|Research site, Konstancin-Jeziorna, 05-510, Poland|Research Site, Krakow, 31-503, Poland|Research site, Krakow, 31-637, Poland|Research Site, Lublin, 20-954, Poland|Research Site, Olsztyn, 10-561, Poland|Research Site, Poznan, 60-355, Poland|Research Site, Warszawa, 02-091, Poland|Research Site, Warszawa, 02-957, Poland|Research Site, Warszawa, 04-749, Poland|Research Site, Zabrze, 41-800, Poland|Research Site, Amadora, 2720-276, Portugal|Research Site, Braga, 4710-243, Portugal|Research Site, Guimarães, 4835-044, Portugal|Research Site, Matosinhos, 4454-509, Portugal|Research Site, Penafiel, 4560-007, Portugal|Research Site, Santarém, 2005-177, Portugal|Research Site, Viana do Castelo, 4901-858, Portugal|Research Site, Vila Nova de Gaia, 4434-502, Portugal|Research Site, Guaynabo, 00968, Puerto Rico|Research Site, San Juan, 00921, Puerto Rico|Research Site, Banska Bystrica, 97517, Slovakia|Research Site, Bratislava, 82101, Slovakia|Research Site, Bratislava, 83101, Slovakia|Research site, Martin, 03659, Slovakia|Research Site, Nitra, 95001, Slovakia|Research Site, Presov, 08081, Slovakia|Research Site, Ruzomberok, 03426, Slovakia|Research Site, Trencin, 91101, Slovakia|Research Site, Trnava, 917 75, Slovakia|Research Site, Gijon, Asturias, 33206, Spain|Research Site, Palma de Mallorca, Baleares, 07010, Spain|Research Site, Badalona, Barcelona, 08916, Spain|Research Site, L'Hospitalet de Llobregat, Barcelona, 08907, Spain|Research Site, Santander, Cantabria, 38003, Spain|Research Site, Santiago de Compostela, La Coruña, 15706, Spain|Research Site, Santa Cruz de Tenerife, Tenerife, 38010, Spain|Research Site, Alzira, Valencia, 46600, Spain|Research Site, Avila, 05004, Spain|Research Site, Cádiz, 11009, Spain|Research Site, Granada, 18014, Spain|Research Site, Huelva, 21080, Spain|Research Site, Jaén, 23007, Spain|Research Site, Madrid, 28006, Spain|Research Site, Murcia, 30008, Spain|Research Site, Pontevedra, 36071, Spain|Research Site, Bern, 3010, Switzerland|Research Site, Lausanne, CH-1011, Switzerland|Research Site, Lugano, 6900, Switzerland|Research Site, Bristol, Avon, BS10 5NB, United Kingdom|Research Site, Exeter, Devon, EX2 5DW, United Kingdom|Research Site, Plymouth, Devon, PL6 8DH, United Kingdom|Research Site, Torquay, Devon, TQ2 7AA, United Kingdom|Research Site, Salford, Greater Manchester, M6 8HD, United Kingdom|Research Site, Basingstoke, Hampshire, RG24 9NA, United Kingdom|Research Site, Southampton, Hampshire, SO16 6YD, United Kingdom|Research Site, Leicester, Leicestershire, LE5 4PW, United Kingdom|Research Site, Edinburgh, Lothian Region, EH4 2XU, United Kingdom|Research Site, Liverpool, Merseyside, L9 7LJ, United Kingdom|Research Site, Norwich, Norfolk, NR4 7UY, United Kingdom|Research Site, Nottingham, Nottinghamshire, NG7 2UH, United Kingdom|Research Site, Glasgow, Strathclyde, G51 4TF, United Kingdom|Research Site, Dundee, Tayside Region, DD1 9SY, United Kingdom|Research Site, Newcastle upon Tyne, Tyne & Wear, NE4 5PL, United Kingdom|Research Site, Birmingham, West Midlands, B15 2GB, United Kingdom|Research Site, Leeds, West Yorkshire, LS1 3EX, United Kingdom|Research Site, Belfast, BT16 0RH, United Kingdom|Research Site, Swansea, SA6 6NL, United Kingdom"
NCT02427997,VR-treadmill Combined Intervention for Enhancing Mobility and Cognitive Function in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02427997,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Treadmill training with Virtual Reality|BEHAVIORAL: Treadmill training,Tel-Aviv Sourasky Medical Center,,ALL,"ADULT, OLDER_ADULT",NA,139,OTHER_GOV,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2015-06,2022-03-31,2022-03-31,"Motor Control Research Lab at the University of Illinois Urbana-Champaign, Urbana, Illinois, 61801, United States|Tel Aviv Sourasky Medical Center, Tel Aviv, 6423906, Israel"
NCT02509897,Normobaric Hypoxic Training and Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02509897,COMPLETED,Multiple Sclerosis,OTHER: Hypoxic training|OTHER: Normoxic training,"Charite University, Berlin, Germany",,ALL,ADULT,NA,39,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE,2015-07,2017-12,2018-07,"Experimental & Clinical Research Center, Berlin, 13125, Germany"
NCT02030197,"Impact of CRISP on Self-Efficacy, Loneliness, and Depression",https://beta.clinicaltrials.gov/study/NCT02030197,COMPLETED,Multiple Sclerosis,BEHAVIORAL: CRISP Program|OTHER: Control Group,NYU Langone Health,,ALL,"ADULT, OLDER_ADULT",NA,118,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2014-02,2014-12,2014-12,"NYU MS Center, New York, New York, 10016, United States"
NCT04787497,The Effect of Extra Virgin Olive Oil in People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04787497,RECRUITING,Multiple Sclerosis,DIETARY_SUPPLEMENT: High Phenolic Extra Virgin Olive Oil,University of Cyprus,"World Olive Center for Health|Ellis-Farm, Eliama Daily Value",ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2022-05-01,2024-05,2024-11,"Private medical office, Thessaloniki, Greece"
NCT03974997,Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03974997,UNKNOWN,Multiple Sclerosis,DIAGNOSTIC_TEST: Determination of the circulating serum concentration of cytoquine TWEAK,Assistance Publique Hopitaux De Marseille,,ALL,ADULT,NA,50,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2019-09-01,2020-09-01,2021-09-01,"Assistance Publique Hopitaux de Marseille, Marseille, 13354, France"
NCT01534182,Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC),https://beta.clinicaltrials.gov/study/NCT01534182,COMPLETED,Relapsing Remitting Multiple Sclerosis,DRUG: Fingolimod|DRUG: Interferon beta - 1a (IFN)|DRUG: Glatiramer acetate (GA),Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE4,298,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2012-01,2013-06,2013-06,"Novartis Investigative Site, Arkhangelsk, Russia, 163045, Russian Federation|Novartis Investigative Site, Barnaul, 656024, Russian Federation|Novartis Investigative Site, Belgorod, 308007, Russian Federation|Novartis Investigative Site, Kazan, 420021, Russian Federation|Novartis Investigative Site, Kemerovo, 650066, Russian Federation|Novartis Investigative Site, Khanty-Mansiysk, 628012, Russian Federation|Novartis Investigative Site, Kirov, 610014, Russian Federation|Novartis Investigative Site, Krasnodar, 350086, Russian Federation|Novartis Investigative Site, Kursk, 305007, Russian Federation|Novartis Investigative Site, Moscow, 119992, Russian Federation|Novartis Investigative Site, Moscow, 127018, Russian Federation|Novartis Investigative Site, N.Novgorod, 603126, Russian Federation|Novartis Investigative Site, Nizhniy Novgorod, 603076, Russian Federation|Novartis Investigative Site, Nizhny Novgorod, 603155, Russian Federation|Novartis Investigative Site, Novosibirsk, 630087, Russian Federation|Novartis Investigative Site, Perm, 614990, Russian Federation|Novartis Investigative Site, Saransk, 430032, Russian Federation|Novartis Investigative Site, Saratov, 410030, Russian Federation|Novartis Investigative Site, Smolensk, 214019, Russian Federation|Novartis Investigative Site, St. Petersburg, 197376, Russian Federation|Novartis Investigative Site, Tomsk, 634050, Russian Federation|Novartis Investigative Site, Tumen, 625048, Russian Federation|Novartis Investigative Site, Tver, 170036, Russian Federation|Novartis Investigative Site, Ufa, 450000, Russian Federation|Novartis Investigative Site, Ulyanovsk, 432063, Russian Federation|Novartis Investigative Site, Yaroslavl, 150030, Russian Federation"
NCT00790582,A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS),https://beta.clinicaltrials.gov/study/NCT00790582,COMPLETED,Amyotrophic Lateral Sclerosis,DRUG: lithium carbonate,Forbes Norris MDA/ALS Research Center,Muscular Dystrophy Association,ALL,"ADULT, OLDER_ADULT",PHASE2,109,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2008-05,2010-03,2010-03,"Mayo Clinic, Scottsdale, Arizona, 85259, United States|UCLA Neuromuscular Research Center, Los Angeles, California, 90095, United States|UC Irvine MDA/ALS & Neuromuscular Center, Orange, California, 92868, United States|California Pacific Medical Center, San Francisco, California, 94115, United States|Kansas University Medical Center, Kansas City, Kansas, 66160, United States|Washington University Department of Neurology, Saint Louis, Missouri, 63110, United States|Providence ALS Clinic, Portland, Oregon, 97213, United States|University of Pennsylvania Neurological Institute, Philadelphia, Pennsylvania, 19107, United States|Methodist Neurological Institute, Houston, Texas, 77030, United States|University of Utah Clinical Neurosciences Center, Salt Lake City, Utah, 84132, United States"
NCT00493116,Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta,https://beta.clinicaltrials.gov/study/NCT00493116,COMPLETED,Relapsing-Remitting Multiple Sclerosis,DRUG: Interferon-beta-1a|DRUG: methylprednisolone,Biogen,,ALL,ADULT,PHASE4,20,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2003-10,2009-12,2009-12,"Coordinating Research Site, NSW, Australia|Research Site, Hamilton, New Zealand"
NCT04510220,9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04510220,RECRUITING,Relapsing Multiple Sclerosis,DRUG: Ofatumumab|DRUG: [F-18]PBR06,Brigham and Women's Hospital,Novartis,ALL,ADULT,PHASE3,10,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-09-21,2021-12-31,2021-12-31,"Partners MS Center, 60 Fenwood Road, Boston, Massachusetts, 02115, United States"
NCT03322982,Low Fat Diet for Fatigue in MS,https://beta.clinicaltrials.gov/study/NCT03322982,UNKNOWN,Multiple Sclerosis,BEHAVIORAL: Low-fat diet,Oregon Health and Science University,National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",NA,108,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: OTHER,2018-08-15,2021-09-30,2022-03-31,"Oregon Health Science University, Portland, Oregon, 97239, United States"
NCT04035720,Decision Making in Multiple Sclerosis Care Under Uncertainty,https://beta.clinicaltrials.gov/study/NCT04035720,UNKNOWN,Multiple Sclerosis,OTHER: Quantitative risk,Unity Health Toronto,Hoffmann-La Roche|University of Toronto,ALL,"ADULT, OLDER_ADULT",NA,450,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: OTHER",2019-07-06,2021-07-21,2021-12-22,"St. Michael's Hospital, Toronto, Ontario, M5B 1X2, Canada"
NCT05798520,A Study to Evaluate Safety and Efficacy of BIIB091 in Participants With Relapsing Forms of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05798520,NOT_YET_RECRUITING,Relapsing Forms of Multiple Sclerosis,DRUG: BIIB091|DRUG: DRF|DRUG: Placebo,Biogen,,ALL,ADULT,PHASE2,275,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-06-02,2026-07-06,2026-07-06,
NCT05033782,Impact of the Modifications of Environmental Exposures and Health Care Access During COVID-19 Lockdown on Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05033782,RECRUITING,Multiple Sclerosis,OTHER: questionnaire,Assistance Publique - Hôpitaux de Paris,,ALL,"ADULT, OLDER_ADULT",,1500,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-02-03,2022-11-03,2022-11-18,"Neurology Department, Hopital de la Pitié Salpêtrière, Paris, 75013, France"
NCT00004816,A Maintenance Extension of Phase I Pilot Study of Chimeric Anti-CD4 Antibody M-T412 in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00004816,COMPLETED,Multiple Sclerosis,DRUG: monoclonal antibody M-T412,National Center for Research Resources (NCRR),Stanford University,ALL,"ADULT, OLDER_ADULT",PHASE1,25,NIH,INTERVENTIONAL,Allocation: |Intervention Model: |Masking: NONE|Primary Purpose: TREATMENT,1995-07,,,
NCT05634993,Disability Level and Trunk Control in Individuals With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05634993,RECRUITING,Multiple Sclerosis,OTHER: Assessment,Hacettepe University,Bandırma Onyedi Eylül University,ALL,"ADULT, OLDER_ADULT",,100,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-06-01,2023-11-01,2023-12-01,"Melike Sumeyye Ozen, Bandırma, Balıkesir, Turkey"
NCT01651520,Prognosis Value of the Neuronal Damage in Early Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01651520,UNKNOWN,Multiple Sclerosis,DRUG: PET with 11C-Flumazenil,Assistance Publique - Hôpitaux de Paris,,ALL,ADULT,NA,60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2013-06,2019-06,2019-06,"Pitié Salpêtrière Hospital, Paris, 75013, France"
NCT01947582,The Effects of Ankle Foot Orthoses (AFOs) on Mobility in Persons With Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT01947582,COMPLETED,Multiple Sclerosis,DEVICE: Ankle foot orthosis,University of Texas Southwestern Medical Center,,ALL,ADULT,NA,2,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-10,2014-12,2014-12,"UT Southwestern Medical Center School of Health Professions, Dallas, Texas, 75223, United States"
NCT02064816,A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02064816,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Rebif®|DRUG: Rebif®,"Merck KGaA, Darmstadt, Germany",,ALL,ADULT,PHASE4,200,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2014-05-31,2016-04-30,2016-04-30,"Please contact the Merck KGaA Communication Center, Darmstadt, Germany"
NCT00040482,High Dose Chemo/Radiotherapy and Hematopoietic Stem Cell Transplant for Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00040482,COMPLETED,Multiple Sclerosis,DRUG: Cyclophosphamide|DRUG: ATG|DRUG: MESNA|PROCEDURE: Radiation therapy,Baylor College of Medicine,"The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine",ALL,ADULT,PHASE2,10,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,1999-04,,2005-08,"The Methodist Hospital, Houston, Texas, 77030, United States"
NCT02671682,Immunoadsorption vs. Plasmapheresis in the Escalation Therapy of Relapse in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02671682,COMPLETED,Multiple Sclerosis|Clinically Isolated Syndrome,PROCEDURE: Immunoadsorption|PROCEDURE: Plasmapheresis,"Albert Christian Ludolph, Prof.",,ALL,"CHILD, ADULT, OLDER_ADULT",NA,61,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2016-02-26,2019-01-03,2019-01-25,"Department of Neurology, University of Ulm, Ulm, Baden-Württemberg, 89081, Germany"
NCT02394782,Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis (ADHERQOL),https://beta.clinicaltrials.gov/study/NCT02394782,TERMINATED,"Multiple Sclerosis, Relapsing-remitting",DEVICE: RebiSmart®2.0|DEVICE: MSdialog™,"Merck KGaA, Darmstadt, Germany",,ALL,"ADULT, OLDER_ADULT",,8,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-02,2015-11,2016-03,"Please contact the Merck KGaA Communication Center, Darmstadt, Germany"
NCT03455582,Cognition Evolution and MRI Markers in PPMS Patients on 2 Years,https://beta.clinicaltrials.gov/study/NCT03455582,RECRUITING,"Multiple Sclerosis, Primary Progressive",OTHER: Clinical assessment|OTHER: Ecological evaluation|OTHER: Neuropsychological evaluation|OTHER: Psychological evaluation|DEVICE: MRI Evaluation,"University Hospital, Bordeaux",Roche Pharma AG,ALL,"ADULT, OLDER_ADULT",NA,80,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2018-09-24,2026-03,2026-03,"CHU de Bordeaux, Bordeaux, France|CHU de Limoges, Limoges, France|CHU de Poitiers, Poitiers, France"
NCT04300816,Coping and Adjusting to Living With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04300816,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,BEHAVIORAL: CBT for Uncertainty Tolerance|BEHAVIORAL: Traditional CBT,University of Washington,National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",NA,242,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2019-10-30,2022-11-10,2024-03-31,"University of Washington, Seattle, Washington, 98195, United States"
NCT03758820,Behavior Cognitive Therapy on Fatigue Impact in MS Patients,https://beta.clinicaltrials.gov/study/NCT03758820,COMPLETED,Relapsing Remitting Multiple Sclerosis|Fatigue|Cognitive Therapy,BEHAVIORAL: Behavorial Cognitive Therapy (BCT),Réseau Sep Idf Ouest,,ALL,"ADULT, OLDER_ADULT",NA,105,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2017-05-31,2020-10-15,2020-10-15,"Poissy St Germain Hospital, Poissy, 78300, France"
NCT02750982,"Laughter Therapy Effects on Mood, Stress and Self-efficacy in People With Neurological Diseases.",https://beta.clinicaltrials.gov/study/NCT02750982,COMPLETED,Alzheimer's Disease|Amyotrophic Lateral Sclerosis|Brain Injury|Huntington's Disease|Multiple Sclerosis|Parkinson's Disease|Stroke|Spinal Cord Injury,OTHER: Laughter Therapy,"Brown, Theodore R., M.D., MPH",,ALL,"ADULT, OLDER_ADULT",NA,24,INDIV,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2016-07,2018-08,2018-08,"Evergreen Healthcare, Kirkland, Washington, 98034, United States"
NCT04158063,Cognitive-motor Interference in Persons With MS,https://beta.clinicaltrials.gov/study/NCT04158063,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Dual Task Training|OTHER: Single Mobility Training,Hasselt University,Revalidatie & MS Centrum Overpelt|National MS Center Melsbroek|AZ Klina|Centre Hospitalier Universitaire de Liege|Masku Neurological Rehabilitation Centre|Tel Aviv University|Sheba Medical Center|AISM Rehabilitation Service of Genoa,ALL,"ADULT, OLDER_ADULT",NA,112,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-10-10,2018-07-01,2018-07-01,"Revalidatie & MS Centrum Overpelt, Overpelt, 3900, Belgium"
NCT00663663,Telephone Intervention for Pain Study (TIPS),https://beta.clinicaltrials.gov/study/NCT00663663,COMPLETED,Chronic Pain|Multiple Sclerosis|Amputation|Spinal Cord Injury,BEHAVIORAL: Telephone-Delivered Intervention 1|BEHAVIORAL: Telephone-Delivered Intervention 2,University of Washington,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),ALL,"ADULT, OLDER_ADULT",NA,207,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2009-09,2013-06,2013-06,"University of Washington, Seattle, Washington, 98104, United States"
NCT02317263,A Trial to Investigate the Effectiveness of Testosterone Treatment in Men With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02317263,WITHDRAWN,Multiple Sclerosis,DRUG: testosterone|DRUG: placebo gel,"University of California, Los Angeles",,MALE,ADULT,PHASE2,0,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",,2099-01,2099-01,
NCT02760082,Motivation of Patients Diagnosed With Multiple Sclerosis to Become Citizen Researchers,https://beta.clinicaltrials.gov/study/NCT02760082,UNKNOWN,Multiple Sclerosis,OTHER: Qualitative evaluation,University of Copenhagen,Danish Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",,500,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-02,2017-04,2017-04,"University of Copenhagen, Copenhagen, Denmark"
NCT04445116,Endeavor™ in Pediatric MS,https://beta.clinicaltrials.gov/study/NCT04445116,WITHDRAWN,Multiple Sclerosis,DEVICE: Action Video Game Treatment,NYU Langone Health,,ALL,"CHILD, ADULT",NA,0,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-01,2023-02-23,2023-02-23,"NYU Langone Health - Ambulatory Care Center, New York, New York, 10017, United States"
NCT04593082,Obesity and Pediatric Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04593082,RECRUITING,Multiple Sclerosis,,University of Virginia,Children's Hospital of Philadelphia,ALL,"CHILD, ADULT",,116,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-06-03,2024-09-01,2024-09-01,"Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States|University of Virginia, Charlottesville, Virginia, 22903, United States"
NCT01081782,A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01081782,COMPLETED,Multiple Sclerosis,DRUG: ONO-4641|DRUG: ONO-4641|DRUG: ONO-4641|DRUG: ONO-4641 placebo,Ono Pharma USA Inc,,ALL,ADULT,PHASE2,407,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2010-03,2011-12,2011-12,"Tucson Clinical Site 133, Tucson, Arizona, 85741, United States|Aurora Clinical Site 132, Aurora, Colorado, 80045, United States|Fort Collins Clinical Site 123, Fort Collins, Colorado, 80528, United States|Fairfield Clinical Site 110, Fairfield, Connecticut, 06824, United States|Ormond Beach Clinical Site 129, Ormond Beach, Florida, 32174, United States|Sarasota Clinical Site 116, Sarasota, Florida, 34243, United States|Sarasota Clinical Site 117, Sarasota, Florida, 34243, United States|Northbrook Clinical Site 135, Northbrook, Illinois, 60062, United States|Fort Wayne Clinical Site 111, Fort Wayne, Indiana, 46805, United States|Indianapolis Clinical Site 121, Indianapolis, Indiana, 46202, United States|Detroit Clinical Site 104, Detroit, Michigan, 48202, United States|Farmington Hills Clinical Site 126, Farmington Hills, Michigan, 48334, United States|Lebanon Clinical Site 115, Lebanon, New Hampshire, 03756, United States|Albuquerque Clinical Site 106, Albuquerque, New Mexico, 87131, United States|Rochester Clinical Site 108, Rochester, New York, 14642, United States|Charlotte Clinical Site 125, Charlotte, North Carolina, 28204, United States|HighPoint Clinical Site 128, HighPoint, North Carolina, 27265, United States|Raleigh Clinical Site 103, Raleigh, North Carolina, 27607, United States|Akron Clinical Site 112, Akron, Ohio, 44320, United States|Philadelphia Clinical Site 120, Philadelphia, Pennsylvania, 19104, United States|Knoxville Clinical Site 134, Knoxville, Tennessee, 37934, United States|Round Rock Clinical Site 107, Round Rock, Texas, 78681, United States|Seattle Clinical Site 118, Seattle, Washington, 98101, United States|Brugge Clinical Site 203, Brugge, 8000, Belgium|La Louviere Clinical Site 201, La Louviere, 7100, Belgium|Sijsele Clinical Site 202, Sijsele, 8340, Belgium|Gatineau Clinical Site 114, Gatineau, Quebec, Canada|Greenfield Park Clinical Site 109, Greenfield Park, Quebec, J4V2J2, Canada|Vancouver Clinical Site 131, British Columbia, V6T 2B5, Canada|Montreal Clinical Site 113, Quebec, H1T 2M4, Canada|Montreal Clinical Site 102, Quebec, H9X 3Z9, Canada|Olomouc Clinical Site 212, Olomouc, 775 20, Czech Republic|Ostrava Clinical Site 214, Ostrava, 702 00, Czech Republic|Pardubice Clinical Site 211, Pardubice, 532 03, Czech Republic|Praha 5 Clinical Site 213, Praha 5, 150 06, Czech Republic|Berlin Clinical Site 223, Berlin, 13347, Germany|Essen Clinical Site 222, Essen, 45147, Germany|Giessen Clinical Site 221, Giessen, 35385, Germany|Leipzig Clinical Site 229, Leipzig, 04103, Germany|Mainz Clinical Site 231, Mainz, 55101, Germany|Marburg Clinical Site 228, Marburg, 35033, Germany|Munster Clinical Site 225, Munster, 48149, Germany|Tubingen Clinical Site 226, Tubingen, 72076, Germany|Ulm Clinical Site 230, Ulm, 89081, Germany|Athens Clinical Site 243, Athens, 11529, Greece|Thessaloniki Clinical Site 245, Thessaloniki, 57010, Greece|Kanto Region Clinical Site 404, Kanto, Japan|Kanto Region Clinical Site 405, Kanto, Japan|Kanto Region Clinical Site 406, Kanto, Japan|Kanto Region Clinical Site 409, Kanto, Japan|Kinki Region Clinical Site 401, Kinki, Japan|Kinki Region Clinical Site 407, Kinki, Japan|Kinki Region Clinical Site 408, Kinki, Japan|Tohoku Region Clinical Site 403, Tohoku, Japan|Tohoku Region Clinical Site 410, Tohoku, Japan|Bialystok Clinical Site 305, Bialystok, 15-402, Poland|Czeladz Clinical Site 303, Czeladz, 41-250, Poland|Gdansk Clinical Site 302, Gdansk, 80-803, Poland|Katowice Clinical Site 309, Katowice, 40-594, Poland|Krakow Clinical Site 307, Krakow, 31-530, Poland|Lodz Clinical Site 306, Lodz, 90-153, Poland|Plewiska Clinical Site 304, Plewiska, 62-064, Poland|Warszawa Clinical Site 308, Warszawa, 04-749, Poland|Chelyabinsk Clinical Site 322, Chelyabinsk, 454136, Russian Federation|Kaluga Clinical Site 328, Kaluga, 428007, Russian Federation|Kazan Clinical Site 333, Kazan, 420103, Russian Federation|Moscow Clinical Site 332, Moscow, 107150, Russian Federation|Nizhniy Novgorod Clinical Site 321, Nizhniy Novgorod, 603155, Russian Federation|Novosibirsk Clinical Site 324, Novosibirsk, 630091, Russian Federation|Samara Clinical Site 328, Samara, 443095, Russian Federation|St. Petersburg Clinical Site 325, St. Petersburg, 428007, Russian Federation|St. Petersburg Clinical Site 327, St. Petersburg, 428007, Russian Federation|Ufa Clinical Site 326, Ufa, 450005, Russian Federation|Yaroslavl Clinical Site 331, Yaroslavl, 150030, Russian Federation|Barcelona Clinical Site 252, Barcelona, 08025, Spain|Barcelona Clinical Site 253, Barcelona, 08025, Spain|Bilbao Clinical Site 255, Bilbao, 48013, Spain|Girona Clinical Site 254, Girona, 17007, Spain|Hospitalet de Llobregat Clinical Site 251, Hospitalet de Llobregat, 08907, Spain|Sevilla Clinical Site 256, Sevilla, 41071, Spain|Dnipropetrovsk Clinical Site 341, Dnipropetrovsk, 49027, Ukraine|Donetsk Clinical Site 345, Donetsk, 83000-490, Ukraine|Kharkiv Clinical Site 346, Kharkiv, 61068, Ukraine|Kyiv Clinical Site 344, Kyiv, 03110, Ukraine|Lviv Clinical Site 343, Lviv, 79010, Ukraine|Vinnytsya Clinical Site 342, Vinnytsya, 21005, Ukraine"
NCT04413682,Telerehabilitation vs Supervised Exercises in MS,https://beta.clinicaltrials.gov/study/NCT04413682,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Structured Supervised Exercise|BEHAVIORAL: Structured telerehabilitation,Istanbul University,Istanbul University - Cerrahpasa (IUC)|Medipol University,ALL,ADULT,NA,30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2019-02-01,2020-02-10,2020-05-30,"Istanbul University-Cerrahpaşa, Istanbul, 34815, Turkey"
NCT04904016,Pilot Investigation to Evaluate FlowOx2.0™ for Experimental Treatment of Spasticity,https://beta.clinicaltrials.gov/study/NCT04904016,UNKNOWN,"Multiple Sclerosis|Spasticity, Muscle|Pain",DEVICE: FlowOx™,Otivio AS,Haukeland University Hospital,ALL,"ADULT, OLDER_ADULT",NA,10,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-05-28,2021-12,2021-12,"Neuro-SysMed, Dept. of Neurology, Haukeland University Hospital, & Dept. of Clinical Medicine, University of Bergen, Bergen, 5021, Norway"
NCT01456416,Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities,https://beta.clinicaltrials.gov/study/NCT01456416,COMPLETED,Relapsing Remitting Multiple Sclerosis,,University of Southern California,Teva Pharmaceuticals USA,ALL,ADULT,,10,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-09,2013-04,2013-04,"USC MS Comprehensive Care Center & Research Group, Los Angeles, California, 90033, United States"
NCT03961204,Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS),https://beta.clinicaltrials.gov/study/NCT03961204,COMPLETED,Multiple Sclerosis (MS),OTHER: Data Collection,"EMD Serono Research & Development Institute, Inc.","Merck KGaA, Darmstadt, Germany",ALL,"ADULT, OLDER_ADULT",PHASE4,662,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2019-08-15,2021-02-27,2021-05-13,"MS Center of Atlanta, Atlanta, Georgia, 30327, United States|Rush University Medical Center, Chicago, Illinois, 60612, United States|University of Maryland, Baltimore - Maryland Center for MS, Baltimore, Maryland, 21201, United States|Empire Neurology, PC - Empire Neurology PC, Latham, New York, 12110, United States|Sanford Neuro Health Center - Neurology, Fargo, North Dakota, 58103, United States|OMRF, Oklahoma City, Oklahoma, 73104, United States|Rowan University School of Osteopathic Medicine - Department of Medicine, Philadelphia, Pennsylvania, 19106, United States|University of Sydney, Camperdown, Australia|Barmherzige Brueder Konventspital Linz - Abteilung fuer Neurologie, Linz, Austria|Limburgs Universitair Centrum, Hasselt, Belgium|University Hospital of Liege, Seraing, Belgium|Military Medical Academy - MHAT - Pleven, Pleven, Bulgaria|MHAT - Shumen, AD, Shumen, Bulgaria|MHAT - ""National Heart Hospital"" EAD - Multiple Clinics, Sofia, Bulgaria|University Hospital ""Saint Naum"", Sofia, Bulgaria|Multiprofile Hospital for Active Treatment - Stara Zagora, Stara Zagora, Bulgaria|Burnaby Hospital Vancouver, Burnaby, Canada|Clinique Neuro-Outaouais, Gatineau, Canada|Recherche Sepmus, Inc., Greenfield Park, Canada|The Ottawa Hospital - General Campus, Ottawa, Canada|Clinical Hospital Centar Split, Split, Croatia|General Hospital Varazdin, Varaždin, Croatia|Privatni ordinace - neurologie - Nestatni zdravotnicke zarizeni, Hradec Kralove, Czechia|Fakultni nemocnice Olomouc - Neurologicka klinika, Olomouc, Czechia|Fakultni nemocnice Ostrava - Dept of Neurology, Ostrava-Poruba, Czechia|Vseobecna fakultni nemocnice v Praze - Dept of Neurologicka klinika 1.LF UK a VFN v Praze, Praha 2, Czechia|Fakultni nemocnice v Motole - Interní klinika 2. LF UK a FN Motol, Praha 5, Czechia|Krajska zdravotni, a.s. - Nemocnice Teplice, o.z. - Neurologicke oddeleni, Teplice, Czechia|Astra Team Clinic, Tallinn, Estonia|Tartu University Hospital, Tartu, Estonia|Neuro NEO Oy - NEO Research, Turku, Finland|Hopital Roger Salengro - CHU Lille - service de neurologie D, Lille, France|CHU de Nîmes - Hôpital Carémeau - Service de Neurologie, Nimes, France|CHU Rennes - Hopital Pontchaillou - Neurologie - Clinique Neurologique, Rennes cedex 09, France|Ltd. Pineo Medical Ecosystem, Tbilisi, Georgia|S. Khechinashvili University Clinic, Tbilisi, Georgia|Heinrich-Heine-Universitaet Duesseldorf - Klinik fuer Nephrologie, Duesseldorf, Germany|Diakoniekrankenhaus Henriettenstiftung GgmBH, Hanover, Germany|Klinik Und Poliklinik Fur Neurologie, Regensburg, Germany|Universitaetsmedizin Rostock - Klinik und Poliklinik fuer Neurologie, Rostock, Germany|Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari - Neurofisiopatologia, Bari, Italy|A.O.U. Policlinico V. Emanuele - Presidio Gaspare Rodolico - Clinica Neurologica I, Catania, Italy|Ospedale Clinicizzato SS. Annunziata - Centro Regionale Sclerosi Multipla, Chieti, Italy|Azienda Socio Sanitaria Territoriale della Valle Olona (presidio di Gallarate), Gallarate, Italy|Azienda Ospadaliero Universitaria San Martino - PARENT, Genova, Italy|Ospedale San Raffaele - U.O. di Neurologia, Milano, Italy|Azienda Ospedaliera Universitaria ""Federico II"" - Gastroenterologia Pediatrica, Napoli, Italy|Azienda Ospedaliero_Universitaria S. Luigi Gonzaga - Centro di Riferimento Regionale Sclerosi Multipla, Orbassano, Italy|Fondazione Istituto Neurologico Casimiro Mondino - Unità Complessa Malattie Cerebrovascolari/Stroke U, Pavia, Italy|Azienda Ospedaliera San Camillo Forlanini, Roma, Italy|Azienda Ospedaliera Universitaria Policlinico Tor Vergata - Dip. Neuroscienze-Centro per la Sclerosi Multipla, Roma, Italy|Ospedale Sant'Andrea di Roma - MS Center, Rome, Italy|National Cancer Center, Goyang-si, Korea, Republic of|Severance Hospital, Yonsei University, Seoul, Korea, Republic of|American University of Beirut Medical Center, Beirut, Lebanon|Bellevue Medical Center, Beirut, Lebanon|Hospital of Lithuanian University of Health Sciences Kaunas Clinics - Neurology Clinic, Kaunas, Lithuania|Department of Neurology, Haukeland University, Haukeland, Norway|St Olavs Hospital - PARENT, Trondheim, Norway|Szpital im. Mikołaja Kopernika - Neurology, Gdansk, Poland|Uniwersyteckie Centrum Kliniczne - Dept of Neurology, Gdansk, Poland|Prof. Dr. med. Zbigniew Stelmasiak Specjalistyczny Gabinet Neurologiczny, Lublin, Poland|Szpital Kliniczny im.Heliodora Swiecickiego Uniwersytetu Medycznego im.K. Marcinkowskiego w Poznaniu - Dept of Neurology, Poznań, Poland|Instytut Psychiatrii i Neurologii, Warszawa, Poland|Centro Hospitalar de Lisboa Central, E.P.E. - Hospital de Santo António dos Capuchos - Serviço de Neurologia, Lisboa, Portugal|SC Sana Monitoring SRL., Bucaresti, Romania|Spitalul Clinic Judetean de Urgenta Targu Mures - Sectia Clinica Neurologie I, Targu Mures, Romania|Spitalul Clinic Judetean de Urgenta ""Pius Branzeu"" Timisoara - Clinica de Neurologie II, Timisoara, Romania|SAIH ""Kemerovo Regional Clinical Hospital"" - PARENT, Kemerovo, Russian Federation|BMI ""Kursk Regional Clinical Hospital"", Kursk, Russian Federation|NHI ""Central Clinical Hospital #2 of JSC ""Russian Railways"" n.a. N.A. Semashko, Moscow, Russian Federation|SBIH of Moscow ""City Clinical Hospital # 24"" - Branch 1, Moscow, Russian Federation|SBIH of Moscow region "" Moscow Regional Scientific and Research Clinical Institute n.a. M.F. Vladimi, Moscow, Russian Federation|Medis, Nizhny Novgorod, Russian Federation|RSHI""State Novosibirsk Regional Clinical Hospital"", Novosibirsk, Russian Federation|SEIHPE ""Rostov State Medical University of MoH of RF"", Rostov-on-don, Russian Federation|LLC "" International Clinic MEDEM"", Saint-Petersburg, Russian Federation|Pavlov First Saint Petersburg State Medical University - PARENT, Saint-Petersburg, Russian Federation|SBIH ""Leningrad Regional Clinical Hospital"", Saint-Petersburg, Russian Federation|SBIH ""Samara Regional Clinical Hospital n.a. V.D. Seredavin, Samara, Russian Federation|SBEI HPE ""Saratov State Medical University n.a. V. I. Razumovskiy"" of the MoH of the RF, Saratov, Russian Federation|RSBIH ""Smolensk Regional Clinical Hospital"", Smolensk, Russian Federation|Saint-Petersburg SU on b.o. City Multifield Hospital #2 - Intensive Pulmonology and Thoracal Surgery, St. Petersburg, Russian Federation|Siberian State Medical University, Tomsk, Russian Federation|Regional Multiple Sclerosis Centre b/o CC ECM ""Neftyanik"" - Neurology, Tyumen, Russian Federation|SBHI of Yaroslavl Region ""Clinical Hospital # 8"" - Cardiology, Yaroslavl, Russian Federation|Clinical Center of Serbia, Belgrade, Serbia|Clinical Center Nis - Clinic of Neurology, Nis, Serbia|Hospital Universitario Reina Sofia, Córdoba, Spain|Hospital Universitario Nuestra Señora de la Candelaria - Servicio de Neurologia, Santa Cruz de Tenerife, Spain|Sahlgrenska Sjukhuset, Göteborg, Sweden|(CHUV), Centre Hospitalier Universitaire Vaudois - Departement des Neurosciences Cliniques, Lausanne, Switzerland|Hôpital Fattouma Bourghiba, Monastir, Tunisia|Hôpital Habib Bourguiba - Service de Neurologie, Sfax, Tunisia|Hopital Militaire de Tunis, Tunis, Tunisia|SI Institute of Neurology, Psychiatry and Narcology of NAMSU - Dept of Neuroinfections and Multiple Sclerosis, Kharkiv, Ukraine|Vinnitsa State Medical University - Neurology dept, Vinnytsia, Ukraine|Nottingham University Hospital - Division of Clinical Neurology, Nottingham, United Kingdom|Royal Hallamshire Hospital - Dept of Neurology, Sheffield, United Kingdom"
NCT04496804,Examining the Neural Effects of a Behavioral Intervention for Physical Activity in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04496804,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Behavioral Intervention for Physical Activity in MS (BIPAMS)|BEHAVIORAL: Wellness for MS (WellMS),University of Alabama at Birmingham,,ALL,ADULT,NA,24,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2020-11-02,2021-11-03,2021-11-03,"University of Alabama at Birmingham, Birmingham, Alabama, 35209, United States"
NCT01973517,High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases,https://beta.clinicaltrials.gov/study/NCT01973517,WITHDRAWN,Multiple Sclerosis,DRUG: Feraheme|DRUG: Gadolinium-based contrast,Stanford University,,ALL,"ADULT, OLDER_ADULT",,0,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-04,2018-09,2018-09,"Richard M. Lucas Center for Imaging (of Stanford University), Stanford, California, 94304, United States|Stanford Hospitals and Clinics, Stanford, California, 94305, United States"
NCT01337427,Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01337427,WITHDRAWN,Relapsing Remitting Multiple Sclerosis,DRUG: BIIB017,Johns Hopkins University,Biogen,ALL,ADULT,PHASE3,0,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2010-08,2013-08,2013-08,
NCT03967106,"RIPC on Activity, Fatigue and Gait in MS",https://beta.clinicaltrials.gov/study/NCT03967106,UNKNOWN,Multiple Sclerosis,OTHER: Ischaemic Preconditioning|OTHER: Sham,Sheffield Teaching Hospitals NHS Foundation Trust,JP Moulton Charitable Foundation,ALL,"ADULT, OLDER_ADULT",NA,92,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2019-07,2020-09,2020-09,"Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, South Yorkshire, S10 2JF, United Kingdom"
NCT00240006,A Study Comparing Shared Solutions® Plus MS Center Support Versus Shared Solutions® Alone,https://beta.clinicaltrials.gov/study/NCT00240006,COMPLETED,Multiple Sclerosis,PROCEDURE: Shared Solutions® plus MS Center v. Shared Solutions®,"Teva Neuroscience, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE4,307,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2006-01,2007-01,2007-09,
NCT04344626,Use of a Tonometer to Identify Epileptogenic Lesions During Pediatric Epilepsy Surgery,https://beta.clinicaltrials.gov/study/NCT04344626,UNKNOWN,"Epilepsy|Focal Cortical Dysplasia|Tuberous Sclerosis|Hemimegalencephaly|Polymicrogyria|Rasmussen Encephalitis|Sturge-Weber Syndrome|Gliosis|Stroke|Tumor, Brain",DEVICE: Intra-operative brain tonometry,"University of California, Los Angeles",Université de Montréal,ALL,"CHILD, ADULT, OLDER_ADULT",NA,150,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2018-07-16,2023-03,2023-03,"UCLA Mattel Children's Hospital, Los Angeles, California, 90095, United States|Sainte-Justine University Hospital, Montreal, Quebec, H3T1C5, Canada"
NCT00704626,Serum Auto-Antibodies in Neurological Diseases,https://beta.clinicaltrials.gov/study/NCT00704626,ENROLLING_BY_INVITATION,Multiple Sclerosis|Myasthenia Gravis|Transverse Myelitis,OTHER: Blood Draw|OTHER: Cheek swab,"University of California, Davis",,ALL,"ADULT, OLDER_ADULT",,120,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2002-01,2031-03,2031-03,"University of California, Davis, Sacramento, California, 95817, United States"
NCT02282826,"A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT02282826,COMPLETED,Progressive Multiple Sclerosis,DRUG: GZ402668|DRUG: placebo|DRUG: GZ402668|DRUG: placebo|DRUG: acyclovir,"Genzyme, a Sanofi Company",,ALL,"ADULT, OLDER_ADULT",PHASE1,48,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2014-10,2016-03,2016-03,"Investigational Site Number 276001, Berlin, 10117, Germany"
NCT03283826,Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03283826,ACTIVE_NOT_RECRUITING,Primary Progressive Multiple Sclerosis|Secondary Progressive Multiple Sclerosis,BIOLOGICAL: ATA188|DRUG: Placebo,Atara Biotherapeutics,,ALL,ADULT,PHASE1|PHASE2,134,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2017-10-19,2023-07,2027-09,"University of California, San Diego, La Jolla, California, 92037, United States|Kaiser Permanente MS Clinic Los Angeles, Los Angeles, California, 90027, United States|Stanford University, Palo Alto, California, 94304, United States|University of California San Francisco, San Francisco, California, 94158, United States|University of Colorado, Aurora, Colorado, 80045, United States|Advanced Neurology, Fort Collins, Colorado, 80528, United States|Neurology Associates, PA-Maitland, Maitland, Florida, 32751, United States|University of South Florida, Morsani College of Medicine, Tampa, Florida, 33612, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, 46825, United States|University of Kansas Medical Center KUMC - Multiple Sclerosis MS Center, Kansas City, Kansas, 66160, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, 70121, United States|Dragonfly Research, Wellesley, Massachusetts, 02481, United States|Washington University in St. Louis, Saint Louis, Missouri, 63110, United States|Dent Neurologic Institute, Amherst, New York, 14226, United States|Columbia University Medical Center-The Neurological Institute of New York, New York, New York, 10032, United States|University of Rochester Medical Center - URMC, Rochester, New York, 14642, United States|PMG Research of Piedmont Healthcare, Mooresville, North Carolina, 28117, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19104-5127, United States|Premier Neurology P.C., Greer, South Carolina, 29650, United States|Advanced Neurosciences Institute ANI - Franklin, Franklin, Tennessee, 37064, United States|Vanderbilt Comprehensive Multiple Sclerosis Center, Nashville, Tennessee, 37215, United States|The University of Texas Health Science Center at Houston, Houston, Texas, 77030, United States|MS Center of Greater Washington, Vienna, Virginia, 22182, United States|Inland Northwest Research LLC, Spokane, Washington, 99202, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States|Liverpool Hospital, Liverpool, New South Wales, 2170, Australia|Royal Brisbane and Women's Hospital, Brisbane, Queensland, 4029, Australia|Griffith University, School of Medicine, Southport, Queensland, 4222, Australia|Fraser Health Multiple Sclerosis Clinic, Burnaby, British Columbia, V5G 2X6, Canada|Unity Health Toronto/St. Michael's Hospital, Toronto, Ontario, M5B1W8, Canada|Recherche Sepmus Inc., Greenfield Park, Quebec, J4V2J2, Canada"
NCT03389217,Efficacy of tDCS on Pain in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03389217,RECRUITING,Multiple Sclerosis,DEVICE: Real-tDCS + rehabilitation programme|DEVICE: Sham-tDCS + rehabilitation programme,University Hospital of Ferrara,,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-12-01,2022-12-01,2023-05-01,"Ferrara University Hospital, Ferrara, 44124, Italy"
NCT01837017,Project FARMS: Fall Risk Reduction in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01837017,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Home-based Exercise,University of Illinois at Urbana-Champaign,,ALL,"ADULT, OLDER_ADULT",PHASE1,33,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2012-06,2012-12,2013-03,"University of Illinois UC, Urbana, Illinois, 61802, United States"
NCT04485104,"Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures",https://beta.clinicaltrials.gov/study/NCT04485104,RECRUITING,Seizure in Participants With Tuberous Sclerosis Complex|Seizure in Participants With Dravet Syndrome|Seizure in Participants With Lennox-Gastaut Syndrome,DRUG: GWP42003-P,Jazz Pharmaceuticals,,ALL,CHILD,PHASE3,27,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-05-19,2023-12-29,2024-12-27,"Clinical Trial Site, Little Rock, Arkansas, 72202, United States|Clinical Trial Site, Los Angeles, California, 90095, United States|Clinical Trial Site, Chicago, Illinois, 60611, United States|Clinical Trial Site, Boston, Massachusetts, 02114, United States|Clinical Trial Site, Cincinnati, Ohio, 45229, United States"
NCT02193217,A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303,https://beta.clinicaltrials.gov/study/NCT02193217,COMPLETED,Relapsing-remitting Multiple Sclerosis,DRUG: MT-1303-Low|DRUG: MT-1303-High|DRUG: Fingolimod|DRUG: Placebo,Mitsubishi Tanabe Pharma Corporation,,ALL,ADULT,PHASE1,81,INDUSTRY,INTERVENTIONAL,"Allocation: |Intervention Model: |Masking: |Primary Purpose: ",,2014-12,2015-01,"Investigational site, Leeds, United Kingdom"
NCT03954717,Pilot Study Evaluating Functional and Wellness Outcomes of the Shepherd CAN DO MS Program,https://beta.clinicaltrials.gov/study/NCT03954717,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,BEHAVIORAL: Shepherd CAN DO Program,"Shepherd Center, Atlanta GA","Genzyme, a Sanofi Company|Can Do Multiple Sclerosis",ALL,"ADULT, OLDER_ADULT",,111,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-05-14,2022-12-28,2022-12-28,"Shepherd Center, Atlanta, Georgia, 30303, United States"
NCT00436826,A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD),https://beta.clinicaltrials.gov/study/NCT00436826,COMPLETED,Multiple Sclerosis,DRUG: Cladribine|DRUG: Placebo|DRUG: Interferon-beta (IFN-beta),"EMD Serono Research & Development Institute, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE2,172,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2006-11-30,2011-09-30,2012-03-31,"Research Site, Cullman, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, Scottsdale, Arizona, United States|Research Site, Los Angeles, California, United States|Research Site, Boulder, Colorado, United States|Research Site, Fort Collins, Colorado, United States|Research Site, Tampa, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Peoria, Illinois, United States|Research Site, Boston, Massachusetts, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Newark, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Bethlehem, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Round Rock, Texas, United States|Research Site, Burlington, Vermont, United States|Research Site, Fidenza, Italy|Research Site, Milan, Italy|Research Site, Napoli, Italy|Research Site, Rome, Italy|Research Site, Arkhangelsk, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Samara, Russian Federation|Research Site, Smolensk, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Alicante, Spain|Research site, Barcelona, Spain|Research Site, Bilbao, Spain|Research Site, Madrid, Spain|Research Site, Malaga, Spain|Research Site, Santiago, Spain|Research Site, Seville, Spain"
NCT05509426,Who Benefits Most From Cognitive Rehabilitation for Multiple Sclerosis?,https://beta.clinicaltrials.gov/study/NCT05509426,RECRUITING,Multiple Sclerosis,BEHAVIORAL: Cognitive Rehabilitation,University of Nottingham,National Multiple Sclerosis Society|University of Lincoln,ALL,"ADULT, OLDER_ADULT",NA,36,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-08-15,2023-07,2023-11,"Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom"
NCT01093326,"Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT01093326,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,DRUG: Ponesimod 10 mg|DRUG: Ponesimod 20 mg|DRUG: Ponesimod 40 mg,Actelion,,ALL,ADULT,PHASE2,353,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2010-05-12,2023-09-06,2023-09-06,"Phoenix, Arizona, United States|Scottsdale, Arizona, United States|Palo Alto, California, United States|Sacramento, California, United States|Venice, Florida, United States|Indianapolis, Indiana, United States|Kansas City, Kansas, United States|Lenexa, Kansas, United States|Latham, New York, United States|Schenectady, New York, United States|Stony Brook, New York, United States|Raleigh, North Carolina, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Burlington, Vermont, United States|Kirkland, Washington, United States|Vienna, Austria|Sofia, Bulgaria|Ottawa, Ontario, Canada|Brno, Czechia|Jihlava, Czechia|Olomouc, Czechia|Ostrava-Poruba, Czechia|Praha 2, Czechia|Teplice, Czechia|Helsinki, Finland|Hyvinkää, Finland|Tampere, Finland|Turku, Finland|Montpellier Cedex 5, France|Berlin, Germany|Essen, Germany|Ulm, Germany|Budapest, Hungary|Esztergom, Hungary|Győr, Hungary|Miskolc, Hungary|Tel-Hashomer, Israel|Zerifin, Israel|Breda, Netherlands|Katowice, Poland|Poznan, Poland|Warszawa, Poland|Wroclaw, Poland|Cluj-Napoca, Romania|Timisoara, Romania|Kazan, Russian Federation|Moscow, Russian Federation|Nizhniy Novgorod, Russian Federation|Pyatigorsk, Russian Federation|Saint Petersburg, Russian Federation|Samara, Russian Federation|Saratov, Russian Federation|St. Petersburg, Russian Federation|UFA, Russian Federation|Belgrade, Serbia|Kragujevac, Serbia|Nis, Serbia|Majadahonda, Spain|Malaga, Spain|Sevilla, Spain|Göteborg, Sweden|Stockholm, Sweden|Umeå, Sweden|Lugano, Switzerland|Chernihiv, Ukraine|Dnipropetrovsk, Ukraine|Kyiv, Ukraine|Odesa, Ukraine|Bristol, United Kingdom|London, United Kingdom|Plymouth, United Kingdom"
NCT04837352,Therapeutic Adherence of Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT04837352,RECRUITING,Multiple Sclerosis,OTHER: Study of the role of sociocognitive factors,Lille Catholic University,,ALL,"ADULT, OLDER_ADULT",,153,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-11-30,2024-11-30,2024-11-30,"Hôpital Saint-Vincent de Paul, Lille, 59000, France|Hôpital Saint-Philibert, Lomme, 59462, France"
NCT02402426,Brain Health Registry: An Online Registry to Identify and Assess Subjects for Brain Research,https://beta.clinicaltrials.gov/study/NCT02402426,RECRUITING,Healthy|Neurodegenerative Disease,,"University of California, San Francisco",,ALL,"ADULT, OLDER_ADULT",,200000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-09,2030-09,2030-09,"BrainHealthRegistry.org, San Francisco, California, 94143, United States"
NCT03057652,Algorithmic-Based Evaluation and Treatment Approach for Robotic Gait Training,https://beta.clinicaltrials.gov/study/NCT03057652,RECRUITING,Complete Spinal Cord Injury|Incomplete Spinal Cord Injury|Acquired Brain Injury|Multiple Sclerosis,DEVICE: ReWalk|DEVICE: EKSO|DEVICE: REX,"The University of Texas Health Science Center, Houston",,ALL,"ADULT, OLDER_ADULT",NA,75,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2016-03,2023-12,2023-12,"TIRR Memorial Hermann, Houston, Texas, 77030, United States"
NCT04674163,Expression Profile of ERK5 and PKM2 Kinases in Neuroinflammatory Diseases.,https://beta.clinicaltrials.gov/study/NCT04674163,WITHDRAWN,"Sclerosis, Multiple|Guillain-Barre Syndrome|Inflammation",BIOLOGICAL: Blood sample and Cerebrospinal fluid (CSF) collection.,Centre Hospitalier Régional d'Orléans,Immunologie et Neurogénétique Expérimentales et Moléculaires (INEM),ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2023-01,2023-01,2023-01,
NCT02683863,Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers,https://beta.clinicaltrials.gov/study/NCT02683863,COMPLETED,Multiple Sclerosis,DRUG: BG00012 (DMF) (Tecfidera®.),Multiple Sclerosis Center of Northeastern New York,Biogen,ALL,"ADULT, OLDER_ADULT",PHASE4,20,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-08,2017-01-31,2017-01-31,"Multiple Sclerosis Center of Northeastern New York, Latham, New York, 12110, United States"
NCT03363763,Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex,https://beta.clinicaltrials.gov/study/NCT03363763,TERMINATED,Angiofibroma of Face|Tuberous Sclerosis,DRUG: Sirolimus 0.2%|DRUG: Sirolimus 0.4%|DRUG: Placebo ointment,"Aucta Pharmaceuticals, Inc",,ALL,"CHILD, ADULT",PHASE2,24,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-04-12,2023-03-24,2023-03-24,"Translational Genomics Research, Phoenix, Arizona, 85004, United States|Children's Hospital of Los Angeles, Division of Neurology, Los Angeles, California, 90027, United States|Children's Clinical Research Organization, Children's Hospital Colorado, Aurora, Colorado, 80045, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, 30329, United States|Boston Children's Hospital, Boston, Massachusetts, 02115, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States|LeBonheur Children's Hospital, Memphis, Tennessee, 38103, United States|Children's Hospital of Fudan University, Shanghai, 201102, China"
NCT01480063,An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice,https://beta.clinicaltrials.gov/study/NCT01480063,COMPLETED,Multiple Sclerosis,DRUG: Fampridine,Biogen,,ALL,"CHILD, ADULT, OLDER_ADULT",,4734,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-04-16,2019-02-08,2019-02-08,"Research Site, Ciudad Autonoma de Buanos Aires, Buenos Aires, Argentina|Research Site, Rosario, Santa Fe, Argentina|Research Site, Buenos Aires, C10161ABD, Argentina|Research Site, Cordoba, Argentina|Research Site, Salta, Argentina|Research Site, Burnaby, British Colombia, V5H 4K7, Canada|Research Site, Fredericton, New Brunswick, E3B 0C7, Canada|Research Site, Brampton, Ontario, L6W 2Z8, Canada|Reasearch Center, London, Ontario, N6A 5A5, Canada|Research Site, London, Ontario, N6A 5A5, Canada|Research Site, Ottawa, Ontario, K1H 8L6, Canada|Research Site, Brno, Czechia|Research Site, Olomouc, Czechia|Research Site, Pardubice, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 2, Czechia|Research Site, Agen cedex 09, Lot Et Garonne, 47923, France|Research Site, Rouen, Sein Maritime, 76031, France|Research Site, Bois-Guillaume, Seine-Maritime, 76230, France|Research Site, Angers, France|Research Site, Bayonne, France|Research Site, Bordeaux Cedex, France|Research Site, Bron Cedex, France|Research Site, Caen, France|Research Site, Cahors cedex 6, France|Research Site, Cergy, France|Research Site, Colmar, France|Research Site, Dax cedex, France|Research Site, Dijon Cedex, France|Research Site, Dijon, France|Research Site, Gonesse, France|Research Site, La Seyne sur Mer, France|Research Site, Le Mans cedex 09, France|Research Site, Lille cedex, France|Research Site, Limoges, France|Research Site, Lisieux, France|Research Site, Lyon, France|Research Site, Mantes La Jolie cedex, France|Research Site, Marseille, France|Research Site, Montauban, France|Research Site, Montbéliard cedex, France|Research Site, Montluçon, France|Research Site, Montpellier cedex 5, France|Research Site, Montpellier, France|Research Site, Nancy, France|Research Site, Nimes, France|Research Site, Niort Cedex, France|Research Site, Orléans, France|Research Site, Paris cedex 19, France|Research Site, Paris, France|Research Site, Poitiers cedex, France|Research Site, Pringy cedex, France|Research Site, Quimper cedex, France|Research Site, Rambouillet, France|Research Site, Roanne cedex, France|Research Site, Rouen, France|Research Site, Rueil Malmaison, France|Research Site, Saint Malo cedex, France|Research Site, Toulouse, France|Research Site, Tourcoing cedex, France|Research Site, Vichy Cedex, France|Research Site, Sindelfingen, Baden Wuerttemberg, 71034, Germany|Research Site, Karlstadt, Bayern, 97753, Germany|Research Site, Lohr Am Main, Bayern, 97816, Germany|Research Site, Muenchen, Bayern, 81825, Germany|Research Site, Neusass, Bayern, 86356, Germany|Research Site, Gottingen, Niedersachsen, 37073, Germany|Research Site, Wermsdorf, Nordsachsen, 04779, Germany|Research Site, Homburg, Saarland, 66421, Germany|Research Site, Stadtroda, Thuringia, 07646, Germany|Research Site, Abensberg, Germany|Research Site, Altenholz, Germany|Research Site, Aschaffenburg, Germany|Research Site, Bad Krozingen, Germany|Research Site, Bamberg, Germany|Research Site, Bayreuth, Germany|Research Site, Berlin, Germany|Research Site, Bochum, Germany|Research Site, Bogen, Germany|Research Site, Bonn, Germany|Research Site, Butzbach, Germany|Research Site, Eisenach, Germany|Research Site, Erbach, Germany|Research Site, Essen, Germany|Research Site, Frankfurt, Germany|Research Site, Freiburg, Germany|Research Site, Grevenbroich, Germany|Research Site, Hagen, Germany|Research Site, Hamburg, Germany|Research Site, Herford, Germany|Research Site, Itzehoe, Germany|Research Site, Kastellaun, Germany|Research Site, Landshut, Germany|Research Site, Lappersdorf, Germany|Research Site, Leipzig, Germany|Research Site, Mannheim, Germany|Research Site, Muenchen, Germany|Research Site, Neu-Ulm, Germany|Research Site, Neuburg, Germany|Research Site, Oldenburg, Germany|Research Site, Ostfildern, Germany|Research Site, Ravensburg, Germany|Research Site, Singen, Germany|Research Site, Sinsheim, Germany|Research Site, Stade, Germany|Research Site, Stuttgart, Germany|Research Site, Trier, Germany|Research Site, Ulm, Germany|Research Site, Unterhaching, Germany|Research Site, Dublin, Ireland|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Tel Aviv, Israel|Research Site, Beirut, Lebanon|Research Site, Almelo, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Arnhem, 6800 TA, Netherlands|Research Site, Blaricum, Netherlands|Research Site, Breda, Netherlands|Research Site, Dordrecht, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Emmen, Netherlands|Research Site, Enschede, Netherlands|Research Site, Gouda, Netherlands|Research Site, Groningen, Netherlands|Research Site, Heerenveen, 8441 PW, Netherlands|Research Site, Hoorn, Netherlands|Research Site, Leeuwarden, Netherlands|Research Site, Leiden, Netherlands|Research Site, Meppel, Netherlands|Research Site, Nieuwegein, Netherlands|Research Site, Nijmegen, 6500 GS, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Sittard Geleen, 6162 BG, Netherlands|Research Site, Sneek, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Venlo, Netherlands|Research Site, Vlissingen, Netherlands|Rsearch Site, Zutphen, Netherlands|Research Site, Bergen, Norway|Research Site, Molde, Norway|Research Site, Stavanger, Norway|Research Site, Amadora, Portugal|Research Site, Braga, Portugal|Research Site, Faro, Portugal|Research Site, Guimaraes, Portugal|Research Site, Lisboa, Portugal|Research Site, Loures, Portugal|Research Site, Matosinhos, Portugal|Research Site, Porto, Portugal|Research Site, Viana do Castelo, Portugal|Research Site, Palma de Mallorca, Baleares, 07010, Spain|Research Site, Getafe, Madrid, Spain|Research Site, Pamplona, Navarra, Spain|Research site, San Cristobal de La laguna, Tenerife, Spain|Site Research, Bilbao, Vizcaya, Spain|Research Site, Alicante, Spain|Research Site, Avila, Spain|Research Site, Caceres, Spain|Research Site, Cordoba, Spain|Research Site, La Coruña, Spain|Research Site, Madrid, Spain|Research Site, Málaga, Spain|Research Site, Segovia, Spain|Research Site, Valladolid, Spain|Research Site, Zaragoza, Spain|Research Site, Abu Dhabi, United Arab Emirates|Research Site, Dubai, United Arab Emirates"
NCT05403463,The Effect of Covid-19 on the Disease Course of Multiple Sclerosis :Belgian Lessons Learned From Rocky I to Rocky IV,https://beta.clinicaltrials.gov/study/NCT05403463,COMPLETED,COVID-19,,Marie D'hooghe,,ALL,"ADULT, OLDER_ADULT",,230,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-03-01,2022-06-01,2022-06-01,"Nationaal MS center, Melsbroek, Vlaams Brabant, 1820, Belgium"
NCT02544763,"A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)",https://beta.clinicaltrials.gov/study/NCT02544763,COMPLETED,Tuberous Sclerosis Complex|Seizures,DRUG: GWP42003-P|DRUG: Placebo,Jazz Pharmaceuticals,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,224,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-04-06,2019-01-22,2019-02-26,"UAB Epilepsy Center, Birmingham, Alabama, 35294, United States|Arkansas Children's Hospital, Little Rock, Arkansas, 72202, United States|UCLA-Pediatric Neurology, Los Angeles, California, 90095, United States|UCSF Benioff Children's Hospital Oakland, Oakland, California, 94609, United States|University of Colorado Denver, Aurora, Colorado, 80045, United States|Pediatric Neurology, Miami, Florida, 33155, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, 60611, United States|Mid Atlantic Epilepsy & Sleep Centre, Bethesda, Maryland, 20817, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Mayo Clinic, Rochester, Minnesota, 55905, United States|Minnesota Epilepsy Group, P.A, Saint Paul, Minnesota, 55102, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|NYU Comprehensive Epilepsy Center, New York, New York, 10016, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 27599, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, 27157, United States|Oregon Health & Science University, Portland, Oregon, 97239, United States|WellSpan Paediatric Neurology, Manchester, Pennsylvania, 17345, United States|Le Bonheur Children's Hospital, Memphis, Tennessee, 38103, United States|Texas Scottish Rite Hospital for Children, Dallas, Texas, 75104, United States|Cook Children's Health Care System, Fort Worth, Texas, 76104, United States|Paediatric Neurology, Salt Lake City, Utah, 84113, United States|University of Virginia, Charlottesville, Virginia, 22903, United States|Seattle Children's Hospital, Seattle, Washington, 98105, United States|Austin Health, Heidelberg, Australia|Royal Brisbane and Women's Hospital, Herston, Australia|The Royal Melbourne Hospital, Parkville, Australia|Sydney Children's Hospital, Randwick, Australia|Erasmus MC/Sophia Children's Hospital, Rotterdam, Netherlands|UMC Utrecht/ Wilhelmina, Kinderziekenhuis, Utrecht, Netherlands|Vitamed Gałaj I Cichomski Spółka Jawna, Bydgoszcz, Poland|Centrum Medyczne Plejady, Kraków, Poland|Wojewódzki Szpital Specjalistyczny im S. K. Wyszyńskiego SPZOZ, Lublin, Poland|Instytut ""Pomnik - Centrum Zdrowia Dziecka"", Warsaw, Poland|Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego w Warszawie, Warsaw, Poland|Centrum Neuropsychiatrii ""Neuromed"", Wrocław, Poland|Centro Médico Teknon, Barcelona, Spain|Clinical Research Unit, Barcelona, Spain|Unitat d'Epilèpsia, Barcelona, Spain|Hospital Infantil Universitario Niño Jesús, Madrid, Spain|Clinica Universidad de Navarra, Pamplona, Spain|Cardiff and Vale University Local Health Board, Cardiff, United Kingdom|Children and Young Adults' Research Unit, Cardiff, United Kingdom|NIHR Clinical Research Facility, London, United Kingdom|St George's University Hospitals NHS Foundation Trust, London, United Kingdom"
NCT03140449,Topical Rapamycin and Calcitriol for Angiofibroma of Tuberous Sclerosis,https://beta.clinicaltrials.gov/study/NCT03140449,COMPLETED,Facial Angiofibroma,DRUG: Rapamycin|DRUG: Calcitriol|DRUG: Rapamycin-calcitriol combination,National Taiwan University Hospital,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,52,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2013-09-05,2016-11-07,2017-04-25,
NCT05500963,Reducing Fatigue in People With Multiple Sclerosis by Treatment With TENS,https://beta.clinicaltrials.gov/study/NCT05500963,NOT_YET_RECRUITING,Multiple Sclerosis,DEVICE: Transcutaneous electrical nerve stimulation,"University of Colorado, Boulder",,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-04,2027-03,2028-03,
NCT04987463,Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants,https://beta.clinicaltrials.gov/study/NCT04987463,RECRUITING,Tuberous Sclerosis Complex,DRUG: Vigabatrin|DRUG: Rapamycin|DRUG: Placebo|DRUG: Placebo,Katarzyna Kotulska,,ALL,CHILD,PHASE2|PHASE3,60,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-05-07,2026-03,2026-03,"Medical University of Warsaw, Department of Pediatric Neurology, Warsaw, 02-091, Poland|Children's Memorial Health Institute, Neurology and Epileptology, Warsaw, 04-730, Poland"
NCT03698149,ECoG BMI for Motor and Speech Control,https://beta.clinicaltrials.gov/study/NCT03698149,RECRUITING,ALS|SCI - Spinal Cord Injury|Stroke|Multiple Sclerosis|Muscular Dystrophies,DEVICE: PMT/Blackrock Combination Device,"University of California, San Francisco",,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,3,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DEVICE_FEASIBILITY,2018-11-09,2025-08-15,2030-08-15,"University of California San Francisco, San Francisco, California, 94158, United States"
NCT05532163,A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS),https://beta.clinicaltrials.gov/study/NCT05532163,NOT_YET_RECRUITING,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Natalizumab,Biogen,,ALL,ADULT,PHASE4,40,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-11-01,2024-03-30,2025-02-28,
NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",https://beta.clinicaltrials.gov/study/NCT01709149,COMPLETED,Amyotrophic Lateral Sclerosis,DRUG: CK-2017357|OTHER: Placebo tablets|DRUG: Riluzole,Cytokinetics,,ALL,"ADULT, OLDER_ADULT",PHASE2,711,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-10,2014-03,2014-03,"Barrow Neurology, Phoenix, Arizona, 85013, United States|University of California, San Diego, La Jolla, California, 92093, United States|UC Irvine ALS & Neuromuscular Center, Orange, California, 92868, United States|Coordinated Clinical Research, San Diego, California, 92103, United States|California Pacific Medical Center Forbes Norris MDA/ALS Research Center, San Francisco, California, 94115, United States|Hospital for Special Care, New Britain, Connecticut, 06053, United States|The George Washington University, Washington, District of Columbia, 20037, United States|Mayo Clinic Florida Department of Neurology, Jacksonville, Florida, 32224, United States|Emory University, School of Medicine, Atlanta, Georgia, 30322, United States|Georgia Health Sciences University, Augusta, Georgia, 30912, United States|Indiana University Department of Neurology, Indianapolis, Indiana, 46202, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, 52242, United States|University of Kansas, Kansas City, Kansas, 66160, United States|Johns Hopkins University, Baltimore, Maryland, 21205, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|University of Massachusetts Medical School, Worcester, Massachusetts, 01655, United States|University of Michigan, Ann Arbor, Michigan, 48109, United States|Henry Ford Hospital, Detroit, Michigan, 48202, United States|St Mary's Healthcare, Grand Rapids, Michigan, 49503, United States|Hennepin County Medical Center - Berman Center for Research, Minneapolis, Minnesota, 55415, United States|Saint Louis University, Saint Louis, Missouri, 63104, United States|Washington University, Saint Louis, Missouri, 63110, United States|Neurology Associates, Lincoln, Nebraska, 68506, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, 03756, United States|Hospital for Special Surgery, New York, New York, 10021, United States|University of Rochester, Rochester, New York, 14642, United States|SUNY Upstate Medical University, Syracuse, New York, 13120, United States|Carolinas Medical Center Department of Neurology, Charlotte, North Carolina, 27406, United States|Duke University, Durham, North Carolina, 27705, United States|Wake Forest University, School of Medicine, Winston-Salem, North Carolina, 27157, United States|Ohio State University Department of Neurology, Columbus, Ohio, 43221, United States|Providence ALS Center, Portland, Oregon, 97213, United States|Oregon Health & Science University, Portland, Oregon, 97239, United States|Penn State Hershey Neuroscience Clinics, Hershey, Pennsylvania, 17033, United States|Drexel Neurology, Philadelphia, Pennsylvania, 19107, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19107, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, 15213, United States|Vanderbilt University Medical Center, Nashville, Tennessee, 37232, United States|Texas Neurology, Dallas, Texas, 75214, United States|Baylor College of Medicine, Houston, Texas, 77030, United States|UTHSCSA Department of Neurology, San Antonio, Texas, 78229, United States|University of Virginia, Charlottesville, Virginia, 22908, United States|West Virginia University Department of Neurology, Morgantown, West Virginia, 26506, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States|Heritage Medical Research, Calgary, Alberta, T2N 4Z6, Canada|University of Alberta Hospital, Edmonton, Alberta, B3H 3A7, Canada|University of British Columbia, Vancouver, British Columbia, V5Z 2G9, Canada|Stan Cassidy Centre for Rehabilitation, Fredericton, New Brunswick, E3B 0C7, Canada|QE II Health Sciences Centre, Halifax, Nova Scotia, B3H 3A7, Canada|McMaster University Medical Centre, Hamilton, Ontario, L8S 4K1, Canada|Queen's University : Kingston General, Kingston, Ontario, K7L 2V7, Canada|London Health Sciences, London, Ontario, N6A 5A5, Canada|Univ. of Toronto - Sunnybrook Health Sciences Centre, Toronto, Ontario, M4N 3M5, Canada|Hôpital Notre Dame (CHUM) Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, H2L4M1, Canada|Montreal Neurological Institute, Montreal, Quebec, H3A 2B4, Canada|CHU de Quebec: Hopital l'Enfant-Jesus, Quebec, G1J 1Z4, Canada|CHRU de Lille - Hôpital Roger Salengro, Lille, F-59037 LILLE cedex, France|CHU de Limoges - Hôpital Dupuytren, Limoges, 87042 LIMOGES CEDEX, France|Hôpital La Timone Adulte, Marseille, 13005, France|CHU Montepellier, Montpellier, 34295 Montpellier Cedex 5, France|Hôpital Archet 1, Nice, 06602, France|Hôpital de la Salpêtrière, Paris, Cedex 13, France|Hôpital Bretonneau, Tours, 37000, France|Charite Universitätsmedizin, Berlin, 13353, Germany|Hannover Medical School, Hannover, 30625, Germany|University of Ulm, Ulm, 89081, Germany|Trinity College, Beaumont Hospital, Dublin, 9, Ireland|Universitair Medisch Centrum Utrecht, Utrecht, 3584 CX, Netherlands|Hospital Carlos III, Madrid, 28029, Spain|Barts and the London MND & the Centre Royal London Hospital, Whitechapel, London, United Kingdom|Walton Centre for Neurology and Neurosurgery, Liverpool, L9 7LJ, United Kingdom|Kings College Hospital NHS Foundation Trust, London, SE5 8AF, United Kingdom|John Radcliffe Hospital, Oxford, OX3 9DU, United Kingdom|Plymouth Hospitals NHS Trust, Plymouth, PL6 8DH, United Kingdom|Sheffield Institute for Translational Neuroscience, Sheffield, S10 2HQ, United Kingdom"
NCT00349193,"A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod",https://beta.clinicaltrials.gov/study/NCT00349193,COMPLETED,Relapsing Remitting Multiple Sclerosis,DRUG: laquinimod 0.3|DRUG: laquinimod 0.6|OTHER: Placebo,"Teva Branded Pharmaceutical Products R&D, Inc.",,ALL,ADULT,PHASE2,306,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2005-03,2006-06,2006-08,
NCT03983720,Can Fatigability Neuromuscular Explain Chronic Fatigue in People With Multiple Sclerosis?,https://beta.clinicaltrials.gov/study/NCT03983720,RECRUITING,"Sclerosis, Multiple",OTHER: Evaluation of degree chronic fatigue.|OTHER: Questionnaires|BIOLOGICAL: Blood sample|OTHER: Cardiopulmonary evaluation|DEVICE: Capacity of muscular oxygen extraction|DEVICE: Sleep assessment|DEVICE: Metabolic fatigue|OTHER: Neuromuscular evaluation,Centre Hospitalier Universitaire de Saint Etienne,,ALL,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: DIAGNOSTIC,2020-01-21,2023-05,2023-06,"Chu Saint-Etienne, Saint-Étienne, France"
NCT00516893,Natalizumab High Titer Immunogenicity and Safety,https://beta.clinicaltrials.gov/study/NCT00516893,COMPLETED,Multiple Sclerosis,BIOLOGICAL: BG00002-E (natalizumab high titer),Biogen,Elan Pharmaceuticals,ALL,ADULT,PHASE2,113,INDUSTRY,INTERVENTIONAL,"Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: ",2006-10,2007-10,2007-12,"Research Site, Washington, District of Columbia, 20007, United States|Research Site, Maitland, Florida, 32751, United States|Research Site, Miami, Florida, 33136, United States|Research Site, Atlanta, Georgia, 30327, United States|Research Site, Farmington Hills, Michigan, 48334, United States|Research Site, Buffalo, New York, 14203, United States|Research Site, New York, New York, 10003, United States|Research Site, Charlotte, North Carolina, 28207, United States|Research Site, Philadelphia, Pennsylvania, 19104, United States|Research Site, Pittsburgh, Pennsylvania, 15212, United States|Research Site, Dallas, Texas, 75214, United States|Research site, Round Rock, Texas, 78681, United States|Research Site, Milwaukee, Wisconsin, 53215, United States"
NCT03114293,Evidence Based Patient Information and Smartphone Accelerometry to Enhance Physical Activity in MS,https://beta.clinicaltrials.gov/study/NCT03114293,UNKNOWN,"Multiple Sclerosis, Chronic Progressive",BEHAVIORAL: Smartphone App,Universitätsklinikum Hamburg-Eppendorf,,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-04-01,2017-05-30,2017-05-30,
NCT05195320,Reinventing Yourself With Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT05195320,RECRUITING,Multiple Sclerosis,BEHAVIORAL: Reinvention with MS,Kessler Foundation,Craig Hospital|University of Minnesota,ALL,"ADULT, OLDER_ADULT",NA,48,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2022-08-01,2024-09-30,2024-09-30,"Kessler Foundation, East Hanover, New Jersey, 07036, United States"
NCT05438693,"Delayed Diagnosis of Multiple Sclerosis, Treatment Initiation and Non-adherence in Upper Egypt",https://beta.clinicaltrials.gov/study/NCT05438693,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",,doaa mokhtar mahmoud,,ALL,ADULT,,80,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-06-01,2022-04-30,2022-06-01,"Assiut University, Assiut, 71511, Egypt|South valley University, Qena, 83523, Egypt"
NCT03718026,"The Reliability, Validity, and Responsiveness of the Timed 360° Turn Test in Patients With Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT03718026,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",OTHER: The timed 360° turn test,Gazi University,,ALL,"ADULT, OLDER_ADULT",,95,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-10-24,2018-11-16,2018-11-19,"Fatih Söke, Ankara, 06560, Turkey"
NCT05844826,Evaluation of the Microbiome in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05844826,NOT_YET_RECRUITING,Multiple Sclerosis,DEVICE: SIMBA Capsule,Nimble Science Ltd.,IGY Life Sciences,ALL,"ADULT, OLDER_ADULT",NA,60,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2023-06-01,2023-10-31,2023-12-01,"University of Calgary, Calgary, Alberta, T2N 1N4, Canada"
NCT02106052,Study of Exercise on Impact of Cognitive Functioning in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT02106052,UNKNOWN,Multiple Sclerosis,OTHER: Aerobic exercise|OTHER: Stretching and toning exercise,University of Washington,National Multiple Sclerosis Society,ALL,ADULT,NA,117,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2014-03,2020-05,2020-05,"University of Washington, Seattle, Washington, 98195, United States"
NCT01214317,Study of Induction Therapy With Mitoxantrone and Plasmapheresis to Treat Aggressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01214317,COMPLETED,Multiple Sclerosis,PROCEDURE: plasmapheresis,Isfahan University of Medical Sciences,,ALL,ADULT,NA,40,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2010-01,2012-01,2012-02,"Alahra hospital, Isfahan, Iran, Islamic Republic of"
NCT02389426,Transcranial Doppler in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02389426,COMPLETED,Multiple Sclerosis,DEVICE: TCD baseline|DEVICE: TCD after bosentan administration|DEVICE: NIRS baseline|DEVICE: NIRS after bosentan administration,Universitair Ziekenhuis Brussel,,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,"Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: ",2014-12,2015-03,2015-04,"Department of Neurology, Universitair Ziekenhuis (UZ) Brussel. Center for Neurosciences, Vrije Universiteit Brussel, Jette, Vlaams-Brabant, 1090, Belgium"
NCT01873417,Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States,https://beta.clinicaltrials.gov/study/NCT01873417,COMPLETED,Relapsing Forms of Multiple Sclerosis,DRUG: BG00012 (DMF),Biogen,,ALL,"ADULT, OLDER_ADULT",PHASE4,237,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-05,2013-11,2013-11,"Research Site, Cullman, Alabama, 35058, United States|Research Site, Gilbert, Arizona, 85234, United States|Research Site, Scottsdale, Arizona, 85258, United States|Research Site, Fullerton, California, 92835, United States|Research Site, Newport Beach, California, 92663, United States|Research Site, Pasadena, California, 91105, United States|Research Site, Englewood, Colorado, 80113, United States|Research Site, Fort Collins, Colorado, 80528, United States|Research Site, Danbury, Connecticut, 06810, United States|Research Site, Maitland, Florida, 32751, United States|Research Site, Naples, Florida, 34102, United States|Research Site, North Palm Beach, Florida, 33408, United States|Research Site, Port Charlotte, Florida, 33952, United States|Research Site, Sarasota, Florida, 34239, United States|Research Site, St. Petersburg, Florida, 33713, United States|Research Site, Tampa, Florida, 33609, United States|Research Site, Tampa, Florida, 33612, United States|Research Site, Atlanta, Georgia, 30327, United States|Research Site, Indianapolis, Indiana, 46256, United States|Research Site, Milford, Massachusetts, 01757, United States|Research Site, Golden Valley, Minnesota, 55422, United States|Research Site, Patchogue, New York, 11772, United States|Research Site, Charlotte, North Carolina, 28204, United States|Research Site, Greensboro, North Carolina, 27405, United States|Research Site, High Point, North Carolina, 27262, United States|Research Site, Fargo, North Dakota, 58103, United States|Research Site, Portland, Oregon, 97225, United States|Research Site, Monroeville, Pennsylvania, 15215, United States|Research Site, Cordova, Tennessee, 38018, United States|Research Site, Franklin, Tennessee, 37064, United States|Research Site, Knoxville, Tennessee, 37934, United States|Research Site, Round Rock, Texas, 78681, United States|Research Site, Salt Lake City, Utah, 84103, United States|Research Site, Richmond, Virginia, 23298, United States|Research Site, Roanoke, Virginia, 24018, United States|Research Site, Tacoma, Washington, 98405, United States|Research Site, Milwaukee, Wisconsin, 53215, United States"
NCT04292717,Deficit-specific Training in Spinal Disorders,https://beta.clinicaltrials.gov/study/NCT04292717,RECRUITING,"Spinal Cord Injuries|Multiple Sclerosis|Gait Disorders, Neurologic|Training|Neurorehabilitation",BEHAVIORAL: Gait training,University of Zurich,Swiss National Science Foundation,ALL,"ADULT, OLDER_ADULT",NA,56,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-01-01,2023-02-28,2023-02-28,"Universitätsklinik Balgrist, Zürich, 8008, Switzerland"
NCT00919217,Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms,https://beta.clinicaltrials.gov/study/NCT00919217,RECRUITING,Relapsing Remitting Multiple Sclerosis,,University of Louisville,,FEMALE,ADULT,,80,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2008-08,2023-12,2023-12,"University of Louisville (recruiting nationwide), Louisville, Kentucky, 40292, United States"
NCT00607126,Locomotor Training in Persons With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00607126,COMPLETED,Multiple Sclerosis,DEVICE: Lokomat|PROCEDURE: resistive training,"University of California, Los Angeles",National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,38,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2006-07,2009-08,2009-08,"UCLA, Los Angeles, California, 90095, United States"
NCT05218317,Evaluation of Relapse Presence in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05218317,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis Relapse",DIAGNOSTIC_TEST: in-vivo Corneal Confocal Microscopy,Marmara University,,ALL,"ADULT, OLDER_ADULT",,87,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-01-01,2021-10-01,2022-01-01,"Marmara University, Istanbul, 34899, Turkey"
NCT04933552,Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent,https://beta.clinicaltrials.gov/study/NCT04933552,RECRUITING,Multiple Sclerosis,OTHER: Siponimod,Novartis Pharmaceuticals,,FEMALE,"CHILD, ADULT, OLDER_ADULT",,867,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-12-15,2032-05-31,2032-05-31,"Novartis Investigative Site, La Jolla, California, 92093-0934, United States"
NCT04379193,Physical Therapy and Neuroactive Steroids Therapy Does Not Modulate Serum Level of Neuroactive Steroids,https://beta.clinicaltrials.gov/study/NCT04379193,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Neuroproprioceptive facilitation and inhibition physical therapy,"Charles University, Czech Republic",,ALL,"ADULT, OLDER_ADULT",NA,63,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2015-05-20,2017-05-20,2019-09-01,
NCT02986893,Pilot Diet Study for Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02986893,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Dietary Intervention|BEHAVIORAL: Non-dietary Intervention Arm,Icahn School of Medicine at Mount Sinai,,FEMALE,"ADULT, OLDER_ADULT",NA,36,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2016-11,2018-08-31,2018-08-31,"Icahn School of Medicine at Mount Sinai, New York, New York, 10029, United States"
NCT00358293,Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis (MS) Patients With Significant Spasticity,https://beta.clinicaltrials.gov/study/NCT00358293,COMPLETED,Muscle Spasticity,DRUG: Tizanidine (sublingual or oral),Teva GTC,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,20,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE|Primary Purpose: TREATMENT,2006-12,,2007-02,"Tel Aviv Sourasky Medical Center- Neurology Department, Tel Aviv, Israel"
NCT03655093,Validation of a Self-questionnaire in French on the Use of the Upper Limbs in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03655093,COMPLETED,Multiple Sclerosis,OTHER: Validation of AMSQ questionnaire,Rennes University Hospital,,ALL,"ADULT, OLDER_ADULT",,200,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-04-25,2017-07-03,2017-07-03,"Rennes University Hospital, Rennes, 35000, France"
NCT02524093,The Impact of Positive Mental Training in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02524093,COMPLETED,Multiple Sclerosis|Psychological Distress,BEHAVIORAL: Positive Mental Training|OTHER: treatment as usual,University of Edinburgh,NHS Lothian,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2016-01,2017-07,2017-07,"Anne Rowling Clinic, Edinburgh, Scotland, EH16 4SD, United Kingdom"
NCT04380220,Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04380220,UNKNOWN,Multiple Sclerosis|Relapse,DIAGNOSTIC_TEST: Blood samples and processing,Regina Elena Cancer Institute,University of Roma La Sapienza|Icahn School of Medicine at Mount Sinai,ALL,ADULT,,80,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-09-07,2020-08-31,2020-12-31,"Icahn School of Medicine at Mount Sinai, New York, New York, 10029, United States|IRCCS Regina Elena National Cancer Institute, Rome, 00144, Italy|University of Rome Sapienza, Rome, 00189, Italy"
NCT05706220,Visual Processing Speed and Objective Analysis of Ocular Movements in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05706220,ENROLLING_BY_INVITATION,Multiple Sclerosis|Clinically Isolated Syndrome|Relapsing Remitting Multiple Sclerosis|Progressive Multiple Sclerosis,DIAGNOSTIC_TEST: Eye tracking|DIAGNOSTIC_TEST: Microperimetry|DIAGNOSTIC_TEST: Optical coherence tomography (OCT)|DIAGNOSTIC_TEST: Visual processing speed test,Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA,Fundación Eugenio Rodríguez Pascual|Hospital del Río Hortega,ALL,"ADULT, OLDER_ADULT",,120,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-06-13,2023-12-31,2023-12-31,"IOBA - Universidad de Valladolid, Valladolid, 47011, Spain"
NCT05466682,RELAXaHEAD for Headache Patients (Phase II),https://beta.clinicaltrials.gov/study/NCT05466682,ACTIVE_NOT_RECRUITING,Migraine|Headache|Multiple Sclerosis|Insomnia,BEHAVIORAL: Smartphone-Based Progressive Muscle Relaxation Therapy (PMR)|BEHAVIORAL: Monitored Usual Care (MUC),NYU Langone Health,"Center for Advancing Point of Care Technologies|National Heart, Lung, and Blood Institute (NHLBI)",ALL,"ADULT, OLDER_ADULT",NA,48,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2022-06-09,2022-12-19,2023-06,"NYU Langone Health, New York, New York, 10016, United States"
NCT02239393,Safety and Efficacy of Intravenous Autologous Mesenchymal Stem Cells for MS: a Phase 2 Proof of Concept Study,https://beta.clinicaltrials.gov/study/NCT02239393,COMPLETED,Multiple Sclerosis,BIOLOGICAL: Mesenchymal Stem Cells,Ottawa Hospital Research Institute,,ALL,ADULT,PHASE2,31,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2015-06,2019-12,2019-12,"Health Sciences Centre, Winnipeg, Manitoba, R3A 1R9, Canada|Ottawa Hospital - General Campus, Ottawa, Ontario, K1H 8L6, Canada"
NCT05129293,Improving Prospective Memory Via Telehealth,https://beta.clinicaltrials.gov/study/NCT05129293,RECRUITING,Multiple Sclerosis,BEHAVIORAL: Prospective Memory Intervention|BEHAVIORAL: Educational,Saint Francis Care,,ALL,ADULT,NA,36,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-11-01,2023-06-30,2023-06-30,"Mount Sinai Rehabilitation Hospital, Hartford, Connecticut, 06112, United States"
NCT05147220,Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05147220,RECRUITING,Relapsing Multiple Sclerosis,DRUG: Remibrutinib|DRUG: Teriflunomide,Novartis Pharmaceuticals,,ALL,ADULT,PHASE3,800,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-12-16,2026-04-30,2030-10-30,"Novartis Investigative Site, Fort Smith, Arkansas, 72916, United States|Novartis Investigative Site, Berkeley, California, 94705, United States|Novartis Investigative Site, Chula Vista, California, 91910, United States|Novartis Investigative Site, Fullerton, California, 92835, United States|Novartis Investigative Site, Glendale, California, 91206, United States|Novartis Investigative Site, Boulder, Colorado, 80301, United States|Novartis Investigative Site, Newark, Delaware, 19713, United States|Novartis Investigative Site, Altamonte Springs, Florida, 32714, United States|Novartis Investigative Site, Miami, Florida, 33032, United States|Novartis Investigative Site, Miami, Florida, 33175, United States|Novartis Investigative Site, Orlando, Florida, 32806, United States|Novartis Investigative Site, Orlando, Florida, 32825, United States|Novartis Investigative Site, Ormond Beach, Florida, 32174, United States|Novartis Investigative Site, Port Charlotte, Florida, 33952, United States|Novartis Investigative Site, Seminole, Florida, 33777, United States|Novartis Investigative Site, Tampa, Florida, 33609, United States|Novartis Investigative Site, Tampa, Florida, 33612, United States|Novartis Investigative Site, Honolulu, Hawaii, 96817, United States|Novartis Investigative Site, Fort Wayne, Indiana, 46845, United States|Novartis Investigative Site, Overland Park, Kansas, 66210, United States|Novartis Investigative Site, Bethesda, Maryland, 20817, United States|Novartis Investigative Site, Lutherville, Maryland, 21093, United States|Novartis Investigative Site, Saint Louis, Missouri, 63131, United States|Novartis Investigative Site, Billings, Montana, 59101, United States|Novartis Investigative Site, Charlotte, North Carolina, 28204, United States|Novartis Investigative Site, Westerville, Ohio, 43082, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, 73104, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, 19107-5098, United States|Novartis Investigative Site, Reading, Pennsylvania, 19611, United States|Novartis Investigative Site, Summerville, South Carolina, 29485, United States|Novartis Investigative Site, Bellaire, Texas, 77401, United States|Novartis Investigative Site, Dallas, Texas, 75206, United States|Novartis Investigative Site, Dallas, Texas, 75390-9034, United States|Novartis Investigative Site, El Paso, Texas, 79912, United States|Novartis Investigative Site, McAllen, Texas, 78503, United States|Novartis Investigative Site, Salt Lake City, Utah, 84132, United States|Novartis Investigative Site, Vienna, Virginia, 22182, United States|Novartis Investigative Site, Madison, Wisconsin, 53792, United States|Novartis Investigative Site, Neenah, Wisconsin, 54956, United States|Novartis Investigative Site, Caba, Buenos Aires, C1122AAK, Argentina|Novartis Investigative Site, Capital Federal, Buenos Aires, 1424, Argentina|Novartis Investigative Site, Buenos Aires, C1012AAR, Argentina|Novartis Investigative Site, Caba, C1424BYD, Argentina|Novartis Investigative Site, Capital Federal, C1023AAB, Argentina|Novartis Investigative Site, Jette, Brussel, 1090, Belgium|Novartis Investigative Site, Antwerpen, 2018, Belgium|Novartis Investigative Site, Ath, 7800, Belgium|Novartis Investigative Site, Brugge, 8000, Belgium|Novartis Investigative Site, Lier, 2500, Belgium|Novartis Investigative Site, Melsbroek, 1820, Belgium|Novartis Investigative Site, Pleven, 5800, Bulgaria|Novartis Investigative Site, Sofia, 1113, Bulgaria|Novartis Investigative Site, Sofia, 1431, Bulgaria|Novartis Investigative Site, Santiago, Region Metropolitana, 7650568, Chile|Novartis Investigative Site, Beijing, Beijing, 100000, China|Novartis Investigative Site, Guangzhou, Guangdong, 510080, China|Novartis Investigative Site, Zhengzhou, Henan, 450052, China|Novartis Investigative Site, Changsha, Hunan, 410008, China|Novartis Investigative Site, Baotou, Inner Mongolia, 014040, China|Novartis Investigative Site, Hohhot, Inner Mongolia, 010017, China|Novartis Investigative Site, Changchun, Jilin, 130021, China|Novartis Investigative Site, Beijing, 100029, China|Novartis Investigative Site, Beijing, 100730, China|Novartis Investigative Site, Chongqing, 400016, China|Novartis Investigative Site, Tianjin, 300052, China|Novartis Investigative Site, Rijeka, HRV, 51000, Croatia|Novartis Investigative Site, Osijek, 31000, Croatia|Novartis Investigative Site, Zagreb, 10000, Croatia|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, New Delhi, Delhi, 110017, India|Novartis Investigative Site, Mumbai, Maharashtra, 400008, India|Novartis Investigative Site, Nashik, Maharashtra, 422005, India|Novartis Investigative Site, Chandigarh, Punjab, 160012, India|Novartis Investigative Site, Ludhiana, Punjab, 141008, India|Novartis Investigative Site, Hyderabad, Telangana, 500082, India|Novartis Investigative Site, Lucknow, Uttar Pradesh, 226014, India|Novartis Investigative Site, DehraDun, Uttarakhand, 248001, India|Novartis Investigative Site, Montichiari, BS, 25018, Italy|Novartis Investigative Site, Milano, MI, 20132, Italy|Novartis Investigative Site, Roma, RM, 00133, Italy|Novartis Investigative Site, Roma, RM, 00168, Italy|Novartis Investigative Site, Verona, VR, 37134, Italy|Novartis Investigative Site, Napoli, 80131, Italy|Novartis Investigative Site, Riga, LV, LV-1005, Latvia|Novartis Investigative Site, Riga, LV 1002, Latvia|Novartis Investigative Site, Seberang Jaya, Pulau Pinang, 13700, Malaysia|Novartis Investigative Site, Kuala Terengganu, Terengganu, 20400, Malaysia|Novartis Investigative Site, Kuala Lumpur, 50589, Malaysia|Novartis Investigative Site, Breda, 4818 CK, Netherlands|Novartis Investigative Site, Rotterdam, 3079 DZ, Netherlands|Novartis Investigative Site, Kielce, 25 726, Poland|Novartis Investigative Site, Lodz, 90 324, Poland|Novartis Investigative Site, Piotrkow Trybunalski, 97300, Poland|Novartis Investigative Site, Poznan, 60-693, Poland|Novartis Investigative Site, Rzeszow, 35-323, Poland|Novartis Investigative Site, Szczecin, 70111, Poland|Novartis Investigative Site, Kosice, Slovak Republic, 04066, Slovakia|Novartis Investigative Site, Bratislava, 82606, Slovakia|Novartis Investigative Site, Nitra, 94901, Slovakia|Novartis Investigative Site, Trnava, 917 75, Slovakia|Novartis Investigative Site, Cordoba, Andalucia, 14004, Spain|Novartis Investigative Site, Malaga, Andalucia, 29010, Spain|Novartis Investigative Site, Salt, Cataluna, 17190, Spain|Novartis Investigative Site, La Coruna, Galicia, 15006, Spain|Novartis Investigative Site, Getafe, Madrid, 28905, Spain|Novartis Investigative Site, El Palmar, Murcia, 30120, Spain|Novartis Investigative Site, Baracaldo, Vizcaya, 48903, Spain|Novartis Investigative Site, Barcelona, 08035, Spain|Novartis Investigative Site, Las Palmas de Gran Canaria, 35010, Spain|Novartis Investigative Site, Leon, 24080, Spain|Novartis Investigative Site, Madrid, 28034, Spain|Novartis Investigative Site, Madrid, 28040, Spain|Novartis Investigative Site, Basel, 4031, Switzerland|Novartis Investigative Site, Bern, 3010, Switzerland|Novartis Investigative Site, Winchester, Hampshire, SO21 1HU, United Kingdom"
NCT02607020,Self-Management Program Based on Physical Exercises in People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02607020,UNKNOWN,Multiple Sclerosis,OTHER: Physical exercises in an self-management setting|OTHER: Relaxation,Cliniques universitaires Saint-Luc- Université Catholique de Louvain,Hôpital Raymond Poincaré|CHU de Reims,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2015-12,2018-12,2020-01,"Cliniques universitaires Saint-Luc, Bruxelles, 1200, Belgium"
NCT02217982,Pilot Study to Assess Dimethyl Fumarate Related GI Symptom Mitigation,https://beta.clinicaltrials.gov/study/NCT02217982,TERMINATED,Relapsing Remitting Multiple Sclerosis,DRUG: Simethicone|DRUG: Loperamide|OTHER: Peanut Butter,"Rocky Mountain MS Research Group, LLC",Biogen,ALL,"ADULT, OLDER_ADULT",PHASE4,5,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2014-07,2015-06,2015-06,"Rocky Mountain MS Research Group, Salt Lake City, Utah, 84103, United States"
NCT04463316,GROWing Up With Rare GENEtic Syndromes,https://beta.clinicaltrials.gov/study/NCT04463316,RECRUITING,"Prader-Willi Syndrome|PWS-like Syndrome|Silver Russel Syndrome|Congenital Hypopituitarism|Klinefelter (XXY-)Syndrome|Congenital Adrenal Hyperplasia|XXXXY Syndrome|XXYY Syndrome|XXXX Syndrome (Tetra-X Syndrome)|Disorders of Sex Development|Turner Syndrome|46, XY DSD|Tuberous Sclerosis|Neurofibromatosis|Albright Hereditaire Osteodystrofie|Cornelia de Lange Syndrome|Saethre-Chotzen Syndrome|17p- Deletiesyndrome|VCF Syndrome|POLR3A Mutatie|Ohdo Syndrome|Jacobsen Syndrome / 11 q Syndrome|Myrhe Syndrome|CHARGE Syndrome|1q25-32 Deletie|Bardet Biedl Syndrome|Rett Syndrome|22q11 Deletion Syndrome|Allan-Herndon-Dudley Syndrome|Kallmann Syndrome|Rare Bone Disorders|Noonan Syndrome|Williams-Beuren Syndrome",DIAGNOSTIC_TEST: Retrospective file studies,dr. Laura C. G. de Graaff-Herder,,ALL,"ADULT, OLDER_ADULT",,600,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-10-01,2030-01-01,2030-01-01,"Erasmus Medical Center, Rotterdam, Zuid-Holland, 3015 GD, Netherlands"
NCT05098145,A Safety and Efficacy Study of FCR001 in Adults With Rapidly Progressive Diffuse Cutaneous Systemic Sclerosis,https://beta.clinicaltrials.gov/study/NCT05098145,ACTIVE_NOT_RECRUITING,Diffuse Cutaneous Systemic Sclerosis,BIOLOGICAL: FCR001,Talaris Therapeutics Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,18,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-11-24,2026-11,2027-02,"University of Michigan, Ann Arbor, Michigan, 48109, United States"
NCT00004645,"Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone",https://beta.clinicaltrials.gov/study/NCT00004645,UNKNOWN,Acute Disseminated Encephalomyelitis|Devic's Syndrome|Marburg's Variant of Multiple Sclerosis|Balo's Concentric Sclerosis|Acute Transverse Myelitis,PROCEDURE: Plasma exchange,National Institute of Neurological Disorders and Stroke (NINDS),Mayo Clinic,ALL,ADULT,PHASE3,22,NIH,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: |Masking: DOUBLE|Primary Purpose: TREATMENT,1995-01,,,
NCT04555863,haMSter: a Novel Smartphone Communication Tool for People With MS,https://beta.clinicaltrials.gov/study/NCT04555863,COMPLETED,M-health|Multiple Sclerosis,DEVICE: haMSter smartphone app,Medical University of Vienna,,ALL,"CHILD, ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2020-04-01,2021-04-01,2021-06-01,"Medical University of Vienna, Vienna, 1090, Austria"
NCT02493049,Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis (RRMS),https://beta.clinicaltrials.gov/study/NCT02493049,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Domperidone,University of Calgary,Alberta Innovates Health Solutions,ALL,ADULT,PHASE2,17,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2015-08,2019-02,2019-02,"Calgary MS Clinic at Foothills Medical Centre, Calgary, Alberta, T2N 2T9, Canada"
NCT03442049,Effects of Core Stability Training on Gait in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT03442049,COMPLETED,"Multiple Sclerosis|Gait Disorders, Neurologic",OTHER: Physiotherapy - Study group|OTHER: Physiotherapy - control group,Hacettepe University,,ALL,"ADULT, OLDER_ADULT",NA,68,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2015-01-01,2016-02-20,2016-05-01,
NCT04858763,MS Relapses During COVID-19 Pandemic,https://beta.clinicaltrials.gov/study/NCT04858763,UNKNOWN,Multiple Sclerosis|Covid19|Relapsing Remitting Multiple Sclerosis,OTHER: No Intervention,Nottingham University Hospitals NHS Trust,,ALL,"CHILD, ADULT, OLDER_ADULT",,340,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-05-01,2021-08-01,2021-12-01,
NCT03135249,Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03135249,COMPLETED,Multiple Sclerosis (MS),DRUG: Alemtuzumab,University of Texas Southwestern Medical Center,"Genzyme, a Sanofi Company",ALL,ADULT,PHASE4,9,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-05-01,2020-11-04,2020-11-04,"VA North Texas Health Care System, Dallas, Texas, 75216, United States|UT Southwestern Medical center, Dallas, Texas, 75390, United States"
NCT04544449,A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04544449,RECRUITING,"Multiple Sclerosis, Primary Progressive",DRUG: Fenebrutinib|DRUG: Ocrelizumab|DRUG: Placebo matched to ocrelizumab|DRUG: Placebo matched to fenebrutinib,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE3,946,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-10-26,2026-01-16,2026-12-18,"Alabama Neurology Associates, Homewood, Alabama, 35209, United States|Sutter East Bay Medical Foundation, Berkeley, California, 94705, United States|North County Neurology Associates, Carlsbad, California, 92011, United States|Fullerton Neurology and Headache Center, Fullerton, California, 92835, United States|Palo Alto Medical Foundation Research Center, Sunnyvale, California, 94086, United States|University of Colorado Denver, Aurora, Colorado, 80045, United States|Yale University School Of Medicine, New Haven, Connecticut, 06519, United States|Georgetown University Medical Center, Washington, District of Columbia, 20007, United States|Uni of Miami School of Medicine, Miami, Florida, 33136, United States|Neurological Services of Orlando, Orlando, Florida, 32806, United States|University of South Florida, Tampa, Florida, 33612, United States|Vero Beach Neurology and Research Institute, Vero Beach, Florida, 32960, United States|Josephson Wallack Munshower Neurology PC, Indianapolis, Indiana, 46256, United States|University of Kansas Medical Center, Kansas City, Kansas, 66160, United States|University of Maryland Medical Center; Department of Neurology, Baltimore, Maryland, 21201, United States|Johns Hopkins University School Of Medicine; Outpatient Center, Baltimore, Maryland, 21287, United States|Dragonfly Research, LLC, Wellesley, Massachusetts, 02481, United States|Wayne State University, Detroit, Michigan, 48201, United States|Minneapolis Clinic of Neurology, Golden Valley, Minnesota, 55422, United States|Washington University, Saint Louis, Missouri, 63128, United States|Cleveland Clinic Lou Ruvo; Center for Brain Research, Las Vegas, Nevada, 89106, United States|Hackensack U Med Ctr, Hackensack, New Jersey, 07601, United States|Barnabas Health Ambulatory Care Center, Livingston, New Jersey, 07039, United States|Jersey Shore University Medical Centre, Neptune, New Jersey, 07753, United States|Rutgers New Jersey Medical School, Newark, New Jersey, 07103, United States|Holy Name Hospital; Institute For Clinical Research, Teaneck, New Jersey, 07666, United States|Dent Neurological Institute, Amherst, New York, 14226, United States|NYU Winthrop-Huntington, NY, Huntington Station, New York, 11746, United States|Columbia University Medical Center, New York, New York, 10032, United States|University of Rochester, Rochester, New York, 14642, United States|Stony Brook University Medical Center, Stony Brook, New York, 11794, United States|SUNY Upstate Medical University, Syracuse, New York, 13210, United States|Atrium Health Neurosciences Institute ? Charlotte, Charlotte, North Carolina, 28204, United States|Neurology Associates PA, Hickory, North Carolina, 28602, United States|Raleigh Neurology Associates, Raleigh, North Carolina, 27607-6520, United States|Miami Valley Hospital South; Dayton Physician's Office, Centerville, Ohio, 45459, United States|UC Health, LLC., Cincinnati, Ohio, 45219, United States|OhioHealth Riverside Methodist Hospital; Pharmacy Services, Columbus, Ohio, 43214, United States|Providence Brain and Spine Institute, Portland, Oregon, 97225, United States|Neurology Clinic PC, Cordova, Tennessee, 38018, United States|Hope Neurology, Knoxville, Tennessee, 37922, United States|Vanderbilt University Medical Center, Nashville, Tennessee, 37212, United States|Uni of Texas Health Science Center At Houston, Houston, Texas, 77030, United States|Texas Institute for Neurological Disorders, Sherman, Texas, 75092, United States|Evergreen MS Center, Kirkland, Washington, 98034, United States|Swedish Medical Center, Seattle, Washington, 98104-1360, United States|West Virginia University, Charleston, West Virginia, 25304, United States|Medical College of Wisconsin, Inc., Milwaukee, Wisconsin, 53226-3596, United States|Centro de Especialidades Neurológicas y Rehabilitación - CENyR, Buenos Aires, C1424, Argentina|Instituto De Neurología Cognitiva - INECO, Caba, C1126AAB, Argentina|Instituto de Investigaciones Metabolicas (Idim), Ciudad Autonoma de Buenos Aires, C1012AAR, Argentina|Instituto Reumatológico Strusberg, Cordoba, X5000EDC, Argentina|Fundacion Rosarina de Neurorehabilitacion, Rosario, S2000BZL, Argentina|Centro de Investigaciones Médicas Tucuman; REUMATHOLOGY, San Miguel, T4000AXL, Argentina|Brain and Mind Research Institute, Camperdown, New South Wales, 2050, Australia|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, 2010, Australia|Liverpool Hospital, Liverpool, New South Wales, 2170, Australia|John Hunter Hospital, New Lambton, New South Wales, 2305, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, 4102, Australia|Box Hill Hospital; Department of Neurology, Box Hill, Victoria, 3128, Australia|Austin Hospital; Department of Neurology, Heidelberg, Victoria, 3084, Australia|St Vincents Hospital, Melbourne, Victoria, 3065, Australia|Royal Melbourne Hospital; Department of Neurology, Parkville, Victoria, 3050, Australia|Kepler Universitätsklinikum GmbH - Neuromed Campus; Neurologie, Linz, 4020, Austria|Medizinische Universität Wien; Univ.Klinik fuer Neurologie, Wien, 1090, Austria|Santa Casa de Misericordia; de Belo Horizonte, Belo Horizonte, MG, 30150-221, Brazil|Instituto de Neurologia de Curitiba, Curitiba, PR, 81210-310, Brazil|Hospital Universitario Gaffree e Guinle, Rio de Janeiro, RJ, 20270-004, Brazil|IMV Pesquisa Neurológica, Porto Alegre, RS, 90110-000, Brazil|Núcleo de Pesquisa do Rio Grande do Sul, Porto Alegre, RS, 90430-001, Brazil|Clinica Neurologica; Neurocirurgica de Joinville, Joinville, SC, 89202-190, Brazil|Centro de Pesquisas Clinicas; CPCLIN, Sao Paulo, SP, 01228-200, Brazil|UMHAT Dr. Georgi Stranski; 2nd Neurology Clinic, Occupational Diseases, Pleven, 5800, Bulgaria|Multiprofile Hospital for Active Treatment of Neurology and Psychiatry Sv. Naum EAD, Sofia, 1113, Bulgaria|University of Alberta Hospital, Edmonton, Alberta, T6G 1Z1, Canada|Fraser Health Authority - Fraser Health Multiple Sclerosis, Burnaby, British Columbia, V5G 2X6, Canada|University of British Columbia, Vancouver, British Columbia, V6T 1Z4, Canada|Regional health authority A vitalite health network, Moncton, New Brunswick, E1C 8X3, Canada|London Health Sciences Centre Uni Campus, London, Ontario, N6A 5A5, Canada|The Ottawa Hospital - General Campus; Department of Neurology - Multiple Sclerosis, Ottawa, Ontario, K1H 8L6, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, M4N 3M5, Canada|St. Michael's Hospital; MS Clinic, Toronto, Ontario, M5B-1W8, Canada|Clinique NeuroOutaouais, Gatineau, Quebec, J8Y 1W2, Canada|Recherche Sepmus Inc., Greenfield Park, Quebec, J4V 2J2, Canada|Montreal Neurological Institute and Hospital, Montreal, Quebec, H3A 2B4, Canada|CeCim Biocinetic, Santiago, 8331143, Chile|Clinica Alemana, Vitacura, 0, Chile|Organizacion Sanitas Internacional, Bogota, D.C., 111321, Colombia|Fundacion Clinica Valle del Lili; Unidad de Investigaciones Clinicas, Cali, Colombia|Instituto Neurologico de Colombia INDEC, Medellin, Colombia|Hjerne- og nervesygdomme, Ambulatorium, Skleroseklinikken, Aabenraa, 6200, Denmark|Aarhus Universitetshospital; Neurologisk Afd. F, Skleroseklinikken, Aarhus N, 8200, Denmark|Rigshospitalet; Neurologisk Klinik Glostrup, Glostrup, 2600, Denmark|Groupe Hospitalier Pellegrin; Service de neurochirurgie B, Bordeaux, 33076, France|Hopital Pierre Wertheimer; Neurologie D, Bron, 69677, France|CHRU de Montpellier, Hopital Gui de Chauliac; Service de Neuropediatrie, Montpellier, 34295, France|Hopital Guillaume Et Rene Laennec, Nantes, 44805, France|Hôpital Pasteur; Service de Neurologie, Nice, 06002, France|Hopital Civil de Strasbourg; Service de Neurologie, Strasbourg, 67091, France|Charite - Universitatsmedizin Berlin; Klinik fur Neurologie, Berlin, 10117, Germany|Studienzentrum für Neurologie und Psychiatrie, Böblingen, 71034, Germany|Universitätsklinikum ""Carl Gustav Carus"", Zentrum für Klinische Neurowissenschaften, Dresden, 01307, Germany|Universitätsklinikum Freiburg, Klinik für Neurologie und Neurophysiologie, Freiburg, 79106, Germany|Klinikum rechts der Isar der TU Muenchen; Neurologische Klinik und Poliklinik im Neuro-Kopf-Zentrum, München, 81675, Germany|Universitaetsklinikum Tuebingen; Abteilung Neurologie, Tuebingen, 72076, Germany|Studienzentrum Nordwest Dr med Joachim Springub Herr Wolfgang Schwarz, Westerstede, 26655, Germany|Deutsche Klinik für Diagnostik; DKD Helios Klinik Wiesbaden, Abt. Neurologie, Wiesbaden, 65191, Germany|401 Military Hospital of Athens; Neurology Department, Athens, 115 25, Greece|AHEPA Univ. General Hospital of Thessaloniki; B' Neurology Dept., Thessaloniki, 546 36, Greece|Hospital Eginition; First Department of Neurology, Αθηνα, 115 28, Greece|Clinexpert Kft., Budapest, 1033, Hungary|S-Medicon Egeszsegugyi Szolgaltato Kft., Budapest, 1138, Hungary|Jahn Ferenc Dél-Pesti Kórház, Budapest, 1204, Hungary|Markhot Ferenc Oktatokorhaz és Rendelointezet; Neurologiai és Stroke Osztaly, Eger, 3300, Hungary|Pest Megyei Flor Ferenc Korhaz, Kistarcsa, 2143, Hungary|Rambam Medical Center; Neurology Unit, Haifa, 3109601, Israel|Hadassah University Hospital - Ein Kerem, Jerusalem, 9112001, Israel|The Chaim Sheba Medical Center; Multiple Sclerosis Center, Ramat-Gan, 5262100, Israel|Tel Aviv Sourasky Medical Center; Department of Neurology, Tel Aviv, 6423906, Israel|AOU Seconda Università degli Studi; Dip.Assistenziale Integrato Medicina Int-I Clinica Neurologica, Napoli, Campania, 80138, Italy|A.O.U. di Parma; SC Neurologia, Amb. Sclerosi Multipla (malattie demielinizzanti), Parma, Emilia-Romagna, 43126, Italy|Policlinico Tor Vergata Dip. Neuroscienze-Clinica Neurologica-UOSD Sclerosi Multipla, Roma, Lazio, 00133, Italy|Irccs A.O.U.San Martino Ist; Dinogmi, Genova, Liguria, 16132, Italy|IRCCS Ospedale San Raffaele; Neurologia Neurofisiologia Neuroriabilitazione-Centro Sclerosi Multipla, Milano, Lombardia, 20132, Italy|Fond. Istituto Neurologico C.Besta; UO Neurologia IV - Neuroimmunologia Malattie Neuromuscolari, Milano, Lombardia, 20133, Italy|Ospedale Civile di Montichiari; Centro Sclerosi Multipla, Montichiari, Lombardia, 25018, Italy|IRCCS Istituto Neurologico Neuromed; Centro per lo Studio e la Cura della Sclerosi Multipla, Pozzilli, Molise, 86077, Italy|A.R.N.A.S. Civico Di Cristina Benfratelli; U.O.C. Neurologia con Stroke Unit, Palermo, Sicilia, 90127, Italy|Mexico Centre for Clinical Research, Ciudad de México, Mexico CITY (federal District), 03100, Mexico|Grupo Médico Camino S.C., Ciudad de México, Mexico CITY (federal District), 03600, Mexico|Hospital Juarez de Mexico, Ciudad de México, Mexico CITY (federal District), 07760, Mexico|Clinstile S.A de C.V., Mexico City, Mexico CITY (federal District), 06700, Mexico|Clinical Research Institute, Tlalnepantla de Baz, Mexico CITY (federal District), 54055, Mexico|University Clinic of Neurology; Movement Disorders, Skopje, 1000, North Macedonia|Hospital IV Alberto Sabogal Sologuren; Unidad de Investigacion, Bellavista, Callao 2, Peru|Clinica Internacional; Unidad De Investigacion, Lima, 15001, Peru|Instituto Nacional de Ciencias Neurológicas - Hospital Mogrovejo; Peru, Lima, Lima 01, Peru|Neurocentrum Bydgoszcz sp. z o.o, Bydgoszcz, 85-796, Poland|Care Clinic, Katowice, 40-568, Poland|Specjalistyczny Szpital Sw. Lukasza, Konskie, 26-200, Poland|Malopolskie Centrum Diagnostyczne MEDICAL Sp. z o. o., Krakow, 31-637, Poland|Centrum Neurologii Krzysztof Selmaj, Lodz, 90-324, Poland|Rejdak Konrad Indywidualna Praktyka Lekarska dr hab. Konrad Rejdak, Lublin, 20-605, Poland|Med Polonia, Pozna?, 60-693, Poland|Centrum Medyczne ""MEDYK"", Rzeszow, 35-055, Poland|Nzoz Palomed, Rzeszów, 35-232, Poland|NEURO-CARE Sp. z o.o. Sp. Komandytowa, Siemianowice ?l?skie, 41-100, Poland|Centrum Medyczne NeuroProtect, Warszawa, 01-684, Poland|Instytut Psychiatrii i Neurologii II Klinika Neurologiczna, Warszawa, 02-957, Poland|Wro Medica, Wroc?aw, 51-685, Poland|SPSK nr 1; Klinika Neurologii, Zabrze, 41-800, Poland|Hospital de Braga; Servico de Neurologia, Braga, 4710-243, Portugal|Hospital Santo Antonio dos Capuchos; Servico de Neurologia, Lisboa, 1169-050, Portugal|Hospital de Santa Maria; Servico de Neurologia, Lisboa, 1649-035, Portugal|Hospital Geral de Santo Antonio; Servico de Neurologia, Porto, 4099-001, Portugal|Hospital de Sao Joao; Servico de Neurologia, Porto, 4200-319, Portugal|San Juan MS Center, Guaynabo, 00968, Puerto Rico|FSBHI Siberian Clinical Center of the Federal Medical and Biological Agency, Krasnoyarsk, Krasnojarsk, 660037, Russian Federation|Krasnoyarsk State Medical Academy, Krasnoyarsk, Krasnojarsk, 660049, Russian Federation|National Center of Social Significant Disease, Sankt-peterburg, Leningrad, 197110, Russian Federation|Federal center of brain research and neurotechnologies, Moskva, Moskovskaja Oblast, 117997, Russian Federation|City Clinical Hospital #24; Multipal Sclerosis department, Moskva, Moskovskaja Oblast, 127015, Russian Federation|Vertebronevrologiya LLC, Kazan, Tatarstan, 420047, Russian Federation|Sverdlovsk Regional Clinical Hospital 1, Ekaterinburg, 620102, Russian Federation|Kemerovo Regional Clinical Hospital, Kemerovo, 650066, Russian Federation|Center of Cardiology and Neurology, Kirov, 610007, Russian Federation|FSBIH Siberian Regional Medical Centre of FMBA of Russia, Novosibirsk, 630007, Russian Federation|State Novosibirsk Regional Clinical Hospital, Novosibirsk, 630087, Russian Federation|Pavlov State Medical Uni ; Neurology, St Petersburg, 197022, Russian Federation|City Hospital #40 of Resort Administrative District, St. Petersburg, 197706, Russian Federation|Nebbiolo Center for Clinical Trials, Tomsk, 634009, Russian Federation|Regional Multiple Sclerosis Centre b/o CC ECM Neftyanik; Neurology, Tyumen, 625000, Russian Federation|Complejo Hospitalario Universitario A Coruña (CHUAC); Servicio de Neurologia, Coruña, LA Coruña, 15006, Spain|Hospital Universitari Arnau de Vilanova de Lleida; Servicio de Neurología, Lleida, Lerida, 25198, Spain|Hospital Quiron de Madrid; Servicio de Neurologia, Pozuelo de Alarcon, Madrid, 28223, Spain|Hospital Alvaro Cunqueiro; Servicio de Neurologia, Vigo, Pontevedra, Spain|Hospital Universitari Vall d'Hebron; Servicio de Neumo-Inmunologia, Barcelona, 08035, Spain|Hospital Puerta del Mar; Sevicio de Neurologia, Cadiz, 11009, Spain|Hospital Ramon y Cajal; Servicio de Neurologia, Madrid, 28034, Spain|Hospital Regional Universitario de Malaga ? Hospital General; Servicio de Neurologia, Malaga, 29010, Spain|Hospital Universitario Virgen Macarena; Servicio de Neurologia, Sevilla, 41009, Spain|Universitätsspital Basel; Neurologie, Basel, 4031, Switzerland|Inselspital Bern Medizin Neurologie, Bern, 3010, Switzerland|UniversitätsSpital Zürich; Klinik für Neurologie, Zürich, 8091, Switzerland|Hacettepe University Medical Faculty; Neurology, Ankara, 06100, Turkey|Istanbul Universitesi - Cerrahpasa Cerrahpasa Tip Fakultesi; Noroloji Anabilim Dali, Istanbul, 34098, Turkey|Sancaktepe Training and Research Hospital; Neurology, Istanbul, 34785, Turkey|Selcuk University Medical Faculty; Norology department, Istanbul, 42131, Turkey|Katip Celebi University Ataturk Training and Research Hospital; Neurology, Izmir, 35360, Turkey|Kocaeli University Hospital; Department of Neurology, Kocaeli, 41380, Turkey|Mersin University Medical Faculty; Neurology, Mersin, 33079, Turkey|Ondokuz Mayis Univ. Med. Fac.; Neurology, Samsun, 55139, Turkey|Karadeniz Tecnical Uni. Med. Fac.; Neurology, Trabzon, 61080, Turkey|Van Yuzuncu Yil University Hospital; Neurology, Van, 65080, Turkey|Baskent Universitesi Ankara Hastanesi; Noroloji Bolumu, Çankaya, 06490, Turkey|CNPE City Clinical Hospital #3 of Chernivtsi City Council, Chernivtsi, Chernihiv Governorate, 58022, Ukraine|MNE Lviv Territorial Medical Association Clinical Hospital for Palliative Care, Lviv, Chernihiv Governorate, 79007, Ukraine|Medical Centre of PE First Private Clinic, Zhytomir, Crimean Regional Governmenta, 10008, Ukraine|Municipal Institution Dnipropetrovsk Regional Clinical Hospital n a I I Mechnykov; Neurology dept #1, Dnipro, Katerynoslav Governorate, 49005, Ukraine|Municipal Nonprofit Enterprise of Kharkiv Regional Council Regional Clinical Hospital, Kharkiv, Kharkiv Governorate, 61058, Ukraine|Municipal Institution Zaporizhzhia Regional Clinical Hospital of Zaporizhzhia Regional Council, Zaporizhzhia, Kharkiv Governorate, 69600, Ukraine|MEDBUD, Kyiv, KIEV Governorate, 03037, Ukraine|Lviv Regional Clinical Hospital, Lviv, KIEV Governorate, 79010, Ukraine|Salutem Medical Center, Vinnytsia, KIEV Governorate, 21050, Ukraine|Medical Clinical Research Center of Medical Center LLC Health Clinic, Vinnytsia, Podolia Governorate, 21009, Ukraine|Regional Clinical Hospital; Neurology Department, Ivano-Frankivsk, 76008, Ukraine|Ams of Ukraine; Inst. of Neurology, Psychiatry & Narcology, Kharkov, 61068, Ukraine|Volyn Regional Clinical Hospital, Lutsk, 43024, Ukraine|Odesa Regional Clinical Hospital; Neurosurgery Department, Odesa, 65117, Ukraine|Queen Elizabeth University Hospital, Glasgow, G51 4TF, United Kingdom|Charing Cross Hospital, London, W6 8RF, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, NG7 2UH, United Kingdom|Derriford Hospital, Plymouth, PL6 8BT, United Kingdom|Royal Hallamshire Hospita, Sheffield, S10 2JF, United Kingdom|Morriston Hospital, Swansea, SA6 6NL, United Kingdom"
NCT00228163,Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses,https://beta.clinicaltrials.gov/study/NCT00228163,COMPLETED,Multiple Sclerosis,DRUG: teriflunomide (HMR1726),Sanofi,,ALL,"ADULT, OLDER_ADULT",PHASE2,147,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2002-01,2015-01,2015-01,"Investigational Site Number 16, Calgary, T2N 2T9, Canada|Investigational Site Number 10, Halifax, B3H 1V7, Canada|Investigational Site Number 15, London, N6A 5A5, Canada|Investigational Site Number 12, Montreal, H2L 4M1, Canada|Investigational Site Number 11, Montreal, H3A 2B4, Canada|Investigational Site Number 13, Ottawa, K1H 8L6, Canada|Investigational Site Number 18, Quebec, G1J 1Z4, Canada|Investigational Site Number 14, Toronto, M5B 1W8, Canada|Investigational Site Number 17, Vancouver, V6T 2B5, Canada|Investigational Site Number 19, Winnipeg, R3E 3N4, Canada|Investigational Site Number 24, Clermont Ferrand Cedex 1, 63003, France|Investigational Site Number 21, Lyon Cedex 03, 69394, France|Investigational Site Number 30, Marseille Cedex 5, 13385, France|Investigational Site Number 23, Montpellier Cedex 5, 34000, France|Investigational Site Number 28, Nice Cedex, 06002, France|Investigational Site Number 27, Rennes Cedex, 35033, France"
NCT03759249,Sleep Medical Treatment in MS Patients Suffering From Fatigue,https://beta.clinicaltrials.gov/study/NCT03759249,TERMINATED,Multiple Sclerosis|Fatigue,OTHER: Sleep medical treatment,"Charite University, Berlin, Germany","Genzyme, a Sanofi Company",ALL,"ADULT, OLDER_ADULT",NA,51,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2015-12-08,2021-05-31,2021-05-31,"Charité University Medicine Berlin, Berlin, 10117, Germany"
NCT03686826,Feasibility and Reliability of Multimodal Evoked Potentials,https://beta.clinicaltrials.gov/study/NCT03686826,COMPLETED,Multiple Sclerosis,PROCEDURE: Acquisition of MEP und SSEP,"University Hospital, Basel, Switzerland",,ALL,ADULT,,40,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-09-06,2017-09-15,2018-12-31,"Dep. of Neurology, Hospital of the University of Basel, Basel, 4031, Switzerland"
NCT01416363,Healthy Volunteer Study Using 3 Different Formulations of Firategrast,https://beta.clinicaltrials.gov/study/NCT01416363,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Firategrast immediate release tablet|DRUG: Firategrast modified release tablet|DRUG: Firategrast gastro-retentive solution,GlaxoSmithKline,,MALE,"ADULT, OLDER_ADULT",PHASE1,38,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2011-05-20,2011-09-17,2011-09-17,"GSK Investigational Site, Randwick, New South Wales, 2031, Australia"
NCT01424163,Dexpramipexole Japanese PK Study,https://beta.clinicaltrials.gov/study/NCT01424163,COMPLETED,Amyotrophic Lateral Sclerosis,DRUG: Single dose reduced|DRUG: Single dose standard|DRUG: Multiple Dose|DRUG: Multiple Dose,Knopp Biosciences,Biogen,ALL,ADULT,PHASE1,57,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2011-08,2012-02,2012-02,"Research Site, London, United Kingdom"
NCT05013463,Hydroxychloroquine and Indapamide in SPMS,https://beta.clinicaltrials.gov/study/NCT05013463,RECRUITING,"Multiple Sclerosis, Secondary Progressive",DRUG: Hydroxychloroquine Pill|DRUG: Indapamide Pill,University of Calgary,,ALL,ADULT,PHASE2,35,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-10-01,2023-09-01,2024-09-01,"Foothills Medical Centre, Calgary, Alberta, T2N 2T9, Canada"
NCT04948645,A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis,https://beta.clinicaltrials.gov/study/NCT04948645,ACTIVE_NOT_RECRUITING,ALS|Amyotrophic Lateral Sclerosis,DRUG: ABBV-CLS-7262|DRUG: Placebo,Calico Life Sciences LLC,AbbVie,ALL,"ADULT, OLDER_ADULT",PHASE1,31,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-09-22,2023-01-12,2025-12,"UC Irvine Health ALS and Neuromuscular Center, Irvine, California, 92868, United States|Cedars-Sinai Medical Center, Los Angeles, California, 90048, United States|Forbes Norris MDA/ALS Research and Treatment Center, San Francisco, California, 94109, United States|Mayo Clinic, Jacksonville, Florida, 32224, United States|Johns Hopkins ALS Clinical Trials Unit, Baltimore, Maryland, 21205, United States|Healey & AMG Center for ALS Research, Boston, Massachusetts, 02114, United States|Mayo Clinic, Rochester, Minnesota, 55905, United States|University of Calgary - Heritage Medical Research Clinic, Calgary, Alberta, T2V1P9, Canada|University of Alberta, Edmonton, Alberta, T6G 2G3, Canada|Stan Cassidy Centre for Rehabilitation, Fredericton, New Brunswick, E38 0C7, Canada|London Health Sciences Centre, London, Ontario, N6A585, Canada|Sunnybrook Research Institute, Toronto, Ontario, M4N 3M5, Canada|Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal, Quebec, H2L 4M1, Canada|Montreal Neurological Institute and Hospital, Montreal, Quebec, H3A 2B4, Canada"
NCT04979845,Telerehabilitation in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04979845,RECRUITING,Multiple Sclerosis,OTHER: Telerehabilitation|OTHER: Video exercise,Marmara University,,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2021-07-01,2021-12-31,2021-12-31,"Marmara University School of Medicine Department of Physical Medicine and Rehabilitation, Istanbul, 34899, Turkey"
NCT05811416,A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,https://beta.clinicaltrials.gov/study/NCT05811416,NOT_YET_RECRUITING,Relapsing-remitting Multiple Sclerosis (RRMS),,Bristol-Myers Squibb,,ALL,"ADULT, OLDER_ADULT",,200,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-05-31,2026-03-31,2026-03-31,
NCT04486716,"A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT04486716,RECRUITING,Relapsing Multiple Sclerosis,DRUG: Ofatumumab,Novartis Pharmaceuticals,,ALL,ADULT,PHASE3,100,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-10-19,2024-01-01,2024-01-01,"Novartis Investigative Site, Birmingham, Alabama, 35209, United States|Novartis Investigative Site, Phoenix, Arizona, 85018, United States|Novartis Investigative Site, Encinitas, California, 92024, United States|Novartis Investigative Site, La Jolla, California, 92037, United States|Novartis Investigative Site, Pomona, California, 91767, United States|Novartis Investigative Site, Torrance, California, 90505, United States|Novartis Investigative Site, Aurora, Colorado, 80045, United States|Novartis Investigative Site, Ormond Beach, Florida, 32174, United States|Novartis Investigative Site, Sunrise, Florida, 33351, United States|Novartis Investigative Site, Tallahassee, Florida, 32308, United States|Novartis Investigative Site, Tampa, Florida, 33612, United States|Novartis Investigative Site, Lutherville, Maryland, 21093, United States|Novartis Investigative Site, Boston, Massachusetts, 02215, United States|Novartis Investigative Site, Foxboro, Massachusetts, 02035, United States|Novartis Investigative Site, Wellesley, Massachusetts, 02481, United States|Novartis Investigative Site, Plymouth, Minnesota, 55446, United States|Novartis Investigative Site, Las Vegas, Nevada, 89106, United States|Novartis Investigative Site, Latham, New York, 12110, United States|Novartis Investigative Site, Canton, Ohio, 44718, United States|Novartis Investigative Site, Westerville, Ohio, 43082, United States|Novartis Investigative Site, Knoxville, Tennessee, 37922, United States|Novartis Investigative Site, Dallas, Texas, 75325, United States|Novartis Investigative Site, Round Rock, Texas, 78681, United States|Novartis Investigative Site, Seattle, Washington, 98122, United States|Novartis Investigative Site, Guaynabo, 00968, Puerto Rico"
NCT05684016,"Assessment of Deep Gray Matter Anatomic Changes in RRMS Patients Treated With Gilenya® With and Without Cognitive Impairment Over a 2 Year Period Using NeuroQuant, NeuroQuarc and ANAM",https://beta.clinicaltrials.gov/study/NCT05684016,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",OTHER: NeuroQuant|OTHER: Automated Neuropsychological Assessment Matrices|OTHER: EDSS|OTHER: Physical Examination,George Washington University,,ALL,ADULT,NA,75,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2013-12,2016-09,2016-12,"The George Washignton University, Washington, District of Columbia, 20037, United States"
NCT04317716,A Self-management Program to Prevent Falls in People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04317716,COMPLETED,Multiple Sclerosis,BEHAVIORAL: fall prevention program|OTHER: Brochure about falls and fall risk factors,Karolinska Institutet,Forte|The Swedish Research Council,ALL,"ADULT, OLDER_ADULT",NA,45,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2022-02-11,2022-08-17,2022-08-17,"Academic Specialist Centre of Neurology, Stockholm, Sweden|Karolinska University Hospital, Stockholm, Sweden"
NCT01112345,An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters,https://beta.clinicaltrials.gov/study/NCT01112345,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",,"Merck KGaA, Darmstadt, Germany","Merck A.E., Greece",ALL,"ADULT, OLDER_ADULT",,133,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2009-12,2012-09,2012-09,"Henry Dunant Hospital - IRB, Athens, 11526, Greece"
NCT00202982,"A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose",https://beta.clinicaltrials.gov/study/NCT00202982,COMPLETED,Relapse-Remitting Multiple Sclerosis,DRUG: glatiramer acetate 20 mg|DRUG: glatiramer acetate 40 mg,"Teva Branded Pharmaceutical Products R&D, Inc.",,ALL,ADULT,PHASE2,90,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2003-08,2005-09,2005-09,"Center for Neurologic Study, La Jolla, California, 92037, United States|North County Neurology Associates, Oceanside, California, 92056, United States|The MS Center of Atlanta, Atlanta, Georgia, United States|Consultants in Neurology, Ltd, Northbrook, Illinois, 60062, United States|Indiana University School of Medicine, Indianapolis, Indiana, 46202, United States|The Maryland Center for M.S., Baltimore, Maryland, United States|Michigan Institute of Neurological Disorders, Farmington Hills, Michigan, 48334, United States|The Minneapolis Clinic of Neurology, LTD, Golden Valley, Minnesota, 55422, United States|University of Minnesota, Minneapolis, Minnesota, 55455, United States|St. John's Mercy Medical Center, St. Louis, Missouri, 63141, United States|Clinical & Magnetic Resonance Research Ctr., Albuquerque, New Mexico, 87131, United States|MSSM - Corinne Goldsmith Dickinson Center for MS, New York, New York, 10029, United States|University of Rochester, Rochester, New York, 14642, United States|Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States|Geisinger Medical Center, Danville, Pennsylvania, 17822, United States|Allegheny Neurological Associates, Pittsburgh, Pennsylvania, 15212, United States|University of Tennessee, Memphis, Tennessee, 38163, United States|VAMC, Salt Lake City, Utah, 84148, United States|MS Hub Medical Group, Seattle, Washington, 98101, United States|Neurology & Neurosurgery, Tacoma, Washington, 98405, United States"
NCT05102682,Robotics for Mobility Rehabilitation in MS,https://beta.clinicaltrials.gov/study/NCT05102682,COMPLETED,Multiple Sclerosis|MS,OTHER: Balance exercise program using exoskeleton device,East Kent Hospitals University NHS Foundation Trust,,ALL,"ADULT, OLDER_ADULT",PHASE1,11,OTHER_GOV,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DEVICE_FEASIBILITY,2017-03-10,2017-09-12,2017-09-12,"East Kent Hospitals University NHS Trust, Canterbury, Kent, United Kingdom"
NCT01414816,Betaferon® Regulatory Post-Marketing Surveillance,https://beta.clinicaltrials.gov/study/NCT01414816,COMPLETED,Multiple Sclerosis|Clinically Isolated System,"DRUG: Interferon beta-1b (Betaseron, BAY86-5046)",Bayer,,ALL,"CHILD, ADULT, OLDER_ADULT",,355,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2008-04,2012-07,2012-07,"Many Locations, Korea, Republic of"
NCT01914016,Functional Electrical Stimulation for People With Multiple Sclerosis Who Experience Foot Drop,https://beta.clinicaltrials.gov/study/NCT01914016,COMPLETED,Multiple Sclerosis,OTHER: prolonged walk,Queen Margaret University,NHS Lothian,ALL,"ADULT, OLDER_ADULT",NA,15,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2013-09,2015-10,2015-11,"Slateford medical centre, Edinburgh, EH4 1NQ, United Kingdom"
NCT04928716,Multiple Sclerosis and Voiding Symptoms: How to Assess?,https://beta.clinicaltrials.gov/study/NCT04928716,COMPLETED,Multiple Sclerosis|Lower Urinary Tract Symptoms|Voiding Disorders,OTHER: voiding phase evaluation,Pierre and Marie Curie University,,ALL,"ADULT, OLDER_ADULT",,100,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-01-01,2020-01-01,2020-01-01,"Department of Neuro- Urology, Hôpital Tenon, Paris, 75020, France"
NCT00638027,Memantine for Spasticity in MS Patients,https://beta.clinicaltrials.gov/study/NCT00638027,COMPLETED,Multiple Sclerosis,DRUG: placebo|DRUG: memantine,University of Rochester,Forest Laboratories,ALL,"ADULT, OLDER_ADULT",PHASE4,21,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2006-07,2009-02,2009-02,"University of Rochester, Rochester, New York, 14642, United States"
NCT00067327,Treatment of Multiple Sclerosis Using Over the Counter Inosine,https://beta.clinicaltrials.gov/study/NCT00067327,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Inosine,National Center for Complementary and Integrative Health (NCCIH),,ALL,ADULT,PHASE2,30,NIH,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,2002-02,,2005-09,"Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States"
NCT05059327,"Basimglurant in Children, Adolescents, and Young Adults With TSC",https://beta.clinicaltrials.gov/study/NCT05059327,RECRUITING,Tuberous Sclerosis Complex,DRUG: Basimglurant with crossover to Placebo|DRUG: Placebo with crossover to Basimglurant,Noema Pharma AG,,ALL,"CHILD, ADULT",PHASE2,54,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-03-03,2024-03-31,2025-08-31,"David Geffen School of Medicine at UCLA (Site #: 101), Los Angeles, California, 90095, United States|Nicklaus Children's Hospital (Site # 116), Miami, Florida, 33155-3009, United States|Kennedy Krieger Institute (Site #: 110), Baltimore, Maryland, 21205, United States|Boston Children's Hospital (Site #: 102), Boston, Massachusetts, 02115-5724, United States|William Beaumont Hospital - Royal Oak (Site #: 104), Royal Oak, Michigan, 48073-6712, United States|Minnesota Epilepsy Group PA (Site #: 105), Roseville, Minnesota, 55113-1306, United States|Boston Children's Health Physicians (BCHP) (Site #: 111), Hawthorne, New York, 10532, United States|Duke Children's Hospital and Health Center (Site #: 106), Durham, North Carolina, 27705-4699, United States|Cincinnati Children's Hospital Medical Center - PIN (Site # 115), Cincinnati, Ohio, 45229-3026, United States|University Hospitals Cleveland Medical Center, Rainbow Babies and Childrens Hospital (Site #: 107), Cleveland, Ohio, 44106-1716, United States|Texas Scottish Rite Hospital For Children (Site #: 113), Dallas, Texas, 75219-3924, United States|The University of Texas Medical School at Houston (Site #: 103), Houston, Texas, 77030-3000, United States|Multicare Health System (Site #: 109), Tacoma, Washington, 98405-4048, United States|Sydney Children's Hospital (Site #: 401), Randwick, New South Wales, 2031, Australia|Queensland Children's Hospital (Site #: 402), South Brisbane, Queensland, 4101, Australia|Citi Neuro Centre (Site # 806), Hyderabad, Andhra Pradesh, 500034, India|Rainbow Children's Hospital (Site # 803), Hyderabad, Andhra Pradesh, 500034, India|All India Institute of Medical Sciences (Site # 804), New Delhi, Delhi, 110029, India|Jaslok Hospital and Research Centre (Site # 801), Mumbai, Maharashtra, 400026, India|Deenanath Mangeshkar Hospital and Research Centre (Site # 805), Pune, Maharashtra, 411006, India|Gleneagles Global Health City (Site # 802), Chennai, Tamil Nadu, 600100, India|Christian Medical College (Site # 807), Vellore, Tamil Nadu, 632004, India|Schneider Children's Medical Center of Israel - Petah Tikvah - PIN (Site #: 502), Petah Tikva, HaMerkaz, 49202, Israel|The Edmond and Lily Safra Children's Hospital (Site #: 501), Ramat Gan, Tel-Aviv, 52621, Israel|Dana Children's Hospital (Site #: 504), Tel Aviv-Yafo, Tel-Aviv, 64239, Israel|Hadassah Medical Center - PPDS (Site #: 503), Jerusalem, 91120, Israel|ASST Santi Paolo e Carlo - Azienda Universitaria-Polo Universitario San Paolo (Site # 181), Milano, Lombardia, 20142, Italy|ASST Grande Ospedale Metropolitano Niguarda - Presidio Ospedaliero Ospedale Niguarda (Site # 183), Milano, Lombardia, 20162, Italy|Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuele (Site # 182), Catania, Sicilia, 20142, Italy|Azienda Ospedaliero Universitaria A Meyer - INCIPIT - PIN (Site # 184), Firenze, Toscana, 50139, Italy|Instytut Pomnik Centrum Zdrowia Dziecka (Site # 262), Warsaw, Mazowieckie, 04-730, Poland|Centrum Medyczne Plejady (Site # 263), Kraków, 30-363, Poland|AmiCare Centrum Medyczne (Site # 261), Łódź, 91-495, Poland|Hospital Universitario Germans Trias i Pujol (Site # 194), Badalona, Barcelona, 08916, Spain|Hospital Sant Joan de Deu - PIN (Site # 192), Esplugues De Llobregat, Barcelona, 08950, Spain|Hospital Regional Universitario de Malaga - Hospital General (Site # 193), Málaga, 29010, Spain|Centro de Neurología Avanzada (Site # 191), Sevilla, 41013, Spain|Ankara Etlik Şehir Hastanesi (Site #: 903), Yenimahalle, Ankara, 06170, Turkey|Istanbul Universitesi Istanbul Tip Fakultesi Hastanesi (Site #: 905), Fatih, Istanbul, 34093, Turkey|Yeditepe University Kosuyolu Hospital (Site #: 904), Kadıköy, Istanbul, 34718, Turkey|Istanbul Egitim ve Arastirma Hastanesi (Site #: 901), Sultangazi, Istanbul, 34096, Turkey|Acibadem Altunizade Hospital (Site #: 902), Üsküdar, 34662, Turkey|Salford Royal Hospital - PPDS (Site # 304), Salford, Lancashire, M6 8HD, United Kingdom|The Royal London Hospital (Site # 302), London, London, City Of, E1 1BB, United Kingdom|St George Hospital (Site # 303), London, London, City Of, SW17 0QT, United Kingdom|Cardiff University (Site # 305), Cardiff, South Glamorgan, CF14 3UX, United Kingdom|Noahs Ark Children's Hospital (Site # 306), Cardiff, South Glamorgan, CF14 4XW, United Kingdom|Queen Elizabeth Hospital Birmingham (Site # 301), Birmingham, B15 2TH, United Kingdom"
NCT01366027,PRISM Registry: Pseudobulbar Affect Registry Series,https://beta.clinicaltrials.gov/study/NCT01366027,COMPLETED,Alzheimer's Disease|Amyotrophic Lateral Sclerosis (ALS)|Multiple Sclerosis (MS)|Parkinson's Disease|Stroke|Traumatic Brain Injury,,Avanir Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",,5290,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-05,2012-09,2012-09,"Avanir Pharmaceuticals, Aliso Viejo, California, 92656, United States"
NCT02737904,Effect of Active-Passive Trainer Cycling on Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02737904,COMPLETED,Multiple Sclerosis,OTHER: APT|OTHER: Usual care,NHS Greater Glasgow and Clyde,University of Glasgow,ALL,"ADULT, OLDER_ADULT",NA,24,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2016-08-01,2017-07-31,2017-07-31,"Physical Disability Rehabilitation Unit (PDRU), Queen Elizabeth University Hospital, Glasgow, G51 4TF, United Kingdom"
NCT00324506,Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00324506,COMPLETED,Multiple Sclerosis,DRUG: Mycophenolate Mofetil (CellCept),University of Texas Southwestern Medical Center,Aspreva Pharmaceuticals,ALL,ADULT,PHASE2,43,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2006-05,2009-06,2009-06,"Michigan Institute for Neurological Disorders (M.I.N.D.), Farmington Hills, Michigan, 48334, United States|Buffalo Neuroimaging Analysis Center (BNAC), Buffalo, New York, 14203, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, 75390, United States"
NCT02708927,"Emotional Processing, Family Life, Friendship and Social Integration in Patients With Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT02708927,COMPLETED,Multiple Sclerosis,OTHER: Clinical evaluation|OTHER: Cognitive evaluation,"University Hospital, Bordeaux",FONDATION POUR L'AIDE A LA RECHERCHE SUR LA SCLEROSE EN PLAQUES,ALL,ADULT,NA,91,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2016-03-03,2019-01-28,2019-01-28,"CHU de Bordeaux, Bordeaux, 33000, France|CHU de Dijon, Dijon, 21079, France"
NCT00654927,"Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT00654927,COMPLETED,Multiple Sclerosis,DRUG: Fampridine-SR b.i.d. (Twice Daily),Acorda Therapeutics,,ALL,"ADULT, OLDER_ADULT",PHASE3,177,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2003-11,2011-01,2011-04,"Barrow Neurology Clinic, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, 85013, United States|USC, Keck School of Medicine Health Care Consultation Center, Los Angeles, California, 90033, United States|Shepherd Center, Atlanta, Georgia, 30309, United States|University of Chicago, Chicago, Illinois, 60637, United States|Maryland Center for MS, Baltimore, Maryland, 21201, United States|The Schapiro Center for MS, Golden Valley, Minnesota, 55422, United States|Washington University School of Medicine, Div. of Rehab/Neurology, St. Louis, Missouri, 63110, United States|Gimbel MS Center at Holy Name Hospital, Teaneck, New Jersey, 07666, United States|University of Mexico, MIND Imaging Center, Albuquerque, New Mexico, 87131, United States|Maimonides MS Care Center, Brooklyn, New York, 11219, United States|Corinne Goldsmith Dickinson Center for MS, New York, New York, 10029, United States|University of Rochester, Rochester, New York, 14642, United States|SUNY Stony Brook, Stony Brook, New York, 11794, United States|CMC - Neuroscience & Spine Institute, Division of Neurology, Charlotte, North Carolina, 28207, United States|Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States|Ohio State University MS Center, Columbus, Ohio, 43221, United States|Oregon Health & Science University, MS Center of Oregon, UHS-42, Portland, Oregon, 97239, United States|Thomas Jefferson University Physicians, Philadelphia, Pennsylvania, 19107, United States|University of Texas-Houston, Houston, Texas, 77030, United States|MS Center at Evergreen, Kirkland, Washington, 98034, United States|Foothills Medical Center, Calgary, Alberta, T2N 2T9, Canada|St. Michael's Hospital, Toronto, Ontario, M5B 1WB, Canada"
NCT05321927,TENS in Persons With MS,https://beta.clinicaltrials.gov/study/NCT05321927,RECRUITING,Multiple Sclerosis,DEVICE: Trancutaneous Electrical Nerve Stimulation|OTHER: Strength training|DEVICE: Sham stimulation,University Medical Center Groningen,,ALL,"ADULT, OLDER_ADULT",NA,80,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-01-05,2023-12-31,2023-12-31,"University Medical Centre Groningen, Groningen, 9713 AW, Netherlands"
NCT02606604,Effects of Functional Electrical Stimulation Cycling Versus Cycling Only on Walking and Quality of Life in MS,https://beta.clinicaltrials.gov/study/NCT02606604,COMPLETED,Multiple Sclerosis,DEVICE: RT 300: Lower Extremity Cycling,Stony Brook University,,ALL,"ADULT, OLDER_ADULT",NA,15,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2015-11,2017-07,2017-07,"Stony Brook Univeristy, Stony Brook, New York, 11794, United States"
NCT01065727,Impact Study of 2 Therapeutic Strategy for Aggressive Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01065727,UNKNOWN,Multiple Sclerosis,OTHER: mitoxantrone - immunomodulator|OTHER: natalizumab,Rennes University Hospital,,ALL,"ADULT, OLDER_ADULT",NA,250,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH,2010-02,2016-02,2019-02,"CHU Cavale Blanche, Brest, 29609, France|CHU Rennes, Rennes, 35033, France"
NCT00423527,Levetiracetam in Central Pain in Multiple Sclerosis(MS),https://beta.clinicaltrials.gov/study/NCT00423527,COMPLETED,Multiple Sclerosis,DRUG: levetiracetam,Odense University Hospital,,ALL,"ADULT, OLDER_ADULT",PHASE4,30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2007-01,2009-01,2009-01,"Department of Neurology, Odense University Hospital, Odense C, DK-5000, Denmark"
NCT01993004,Immune Regulation in Multiple Sclerosis: The Effect of Glatiramer Acetate on MicroRNA Expression in Antigen-Presenting Cells,https://beta.clinicaltrials.gov/study/NCT01993004,COMPLETED,Multiple Sclerosis,,"Rutgers, The State University of New Jersey",,ALL,ADULT,,24,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-07,2015-12,2015-12,"Rutgers-RWJMS, New Brunswick, New Jersey, 08901, United States"
NCT02342704,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,https://beta.clinicaltrials.gov/study/NCT02342704,TERMINATED,Relapsing-Remitting Multiple Sclerosis,DRUG: natalizumab|DRUG: fingolimod,Biogen,,ALL,ADULT,PHASE4,111,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2014-11-30,2016-05-18,2016-05-18,"Research Site, Aurora, Colorado, 80045, United States|Research Site, Colorado Springs, Colorado, 80907, United States|Research Site, Port Charlotte, Florida, 33952, United States|Research Site, Atlanta, Georgia, 30327, United States|Research Site, Des Moines, Iowa, 50314, United States|Research Site, Philadelphia, Pennsylvania, 19104, United States|Research Site, Knoxville, Tennessee, 37922, United States|Research Site, Round Rock, Texas, 78681, United States|Research Site, San Antonio, Texas, 78229, United States|Research Site, Seattle, Washington, 98122, United States|Research Site, Tacoma, Washington, 98405, United States|Research Site, Milwaukee, Wisconsin, 53215, United States|Research Site, Camperdown, New South Wales, 2050, Australia|Research Site, New Lambton Heights, New South Wales, 2305, Australia|Research Site, Heidelberg, Victoria, 3084, Australia|Research Site, Brno, 625 00, Czechia|Research Site, Brno, 656 91, Czechia|Research Site, Hradec Kralove, 500 05, Czechia|Research Site, Jihlava, 58633, Czechia|Research Site, Ostrava - Poruba, 708 52, Czechia|Research Site, Pardubice, 532 03, Czechia|Research Site, Praha 5, 150 06, Czechia|Research Site, Teplice, 415 01, Czechia|Research Site, Nimes, Gard, 30029, France|Research Site, Libourne Cedex, Gironde, 33505, France|Research Site, Toulouse cedex 9, Haute Garonne, 31059, France|Research Site, Freiburg, Baden Wuerttemberg, 79106, Germany|Research Site, Erbach, Hessen, 64711, Germany|Research Site, Gianicolense, Roma, 87-00151, Italy|Research Site, Roma, 00189, Italy|Research Site, El Palmar, Murcia, 30120, Spain|Research Site, Malaga, Málaga, 29010, Spain|Research Site, Vigo, Pontevedra, 36204, Spain|Research Site, Santa Cruz de Tenerife, Tenerife, 38010, Spain|Research Site, Barcelona, 08035, Spain|Research Site, Girona, 17007, Spain|Research Site, Madrid, 28006, Spain|Research Site, Sevilla, E 41009, Spain|Research Site, Göteborg, 41345, Sweden|Research Site, Stockholm, 17176, Sweden|Research Site, London, Greater London, SE5 9NU, United Kingdom|Research Site, Glasgow, Strathclyde, G51 4TF, United Kingdom"
NCT02254304,Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™,https://beta.clinicaltrials.gov/study/NCT02254304,COMPLETED,Relapsing Multiple Sclerosis|Clinically Isolated Syndrome,DRUG: Rebif,"Merck KGaA, Darmstadt, Germany","Merck Romania SRL, an affiliate of Merck KGaA, Darmstadt, Germany",ALL,"ADULT, OLDER_ADULT",PHASE4,106,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2014-12-31,2016-08-20,2016-08-20,"Please contact the Merck KGaA Communication Center, Darmstadt, Germany"
NCT01905527,Adherence Trial With MS LifeLines ® Services,https://beta.clinicaltrials.gov/study/NCT01905527,TERMINATED,Multiple Sclerosis|Relapsing-Remitting,OTHER: Standard Services of Group A (Group A1)|OTHER: Customized Services of Group A (Group A2)|OTHER: Group B,EMD Serono,,ALL,"ADULT, OLDER_ADULT",,306,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-07,2015-01,2015-01,"Call EMD Serono Medical Information for information on recruiting sites, Boston, Massachusetts, United States"
NCT03969927,User-friendliness of a Portable Driving Simulator,https://beta.clinicaltrials.gov/study/NCT03969927,RECRUITING,Parkinson Disease|Multiple Sclerosis|Stroke,DEVICE: Low-Fidelity PDS|DEVICE: High Fidelity Fixed-Base Simulator,University of Kansas Medical Center,,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2019-08-28,2023-06-30,2023-06-30,"Abiodun Akinwuntan, Kansas City, Kansas, 66160-8500, United States"
NCT02011204,Study of Electrical Impedance Myography (EIM) in ALS,https://beta.clinicaltrials.gov/study/NCT02011204,COMPLETED,Amyotrophic Lateral Sclerosis|Motor Neuron Disease|Charcot-Marie-Tooth Disease|Multiple Sclerosis,DEVICE: Electrical impedance myography (EIM),"Skulpt, Inc.",,ALL,"ADULT, OLDER_ADULT",,106,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-11,2016-03,2016-03,"St. Joseph's Hospital & Medical Center, Phoenix, Arizona, 85013, United States|University of Miami Miller School of Medicine, Miami, Florida, 33136, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Skulpt, Inc, Boston, Massachusetts, 02210, United States|SUNY Upstate Medical University, Syracuse, New York, 13210, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, 27157, United States"
NCT03608527,Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03608527,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Voluntary-based upper limb motor rehabilitation|BEHAVIORAL: Passive upper limb mobilization,Fondazione Italiana Sclerosi Multipla,Universita degli Studi di Genova,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2013-09-09,2014-12-22,2015-03-04,
NCT04676204,Relationship Between Oral DMT Burden and Adherence in MS,https://beta.clinicaltrials.gov/study/NCT04676204,ENROLLING_BY_INVITATION,"Multiple Sclerosis|Adherence, Medication",DRUG: Cladribine|DRUG: Dimethyl fumarate|DRUG: Fingolimod|DRUG: Teriflunomide|DRUG: Ozanimod|DRUG: Diroximel fumarate,Monash University,,ALL,"ADULT, OLDER_ADULT",,323,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-09-25,2025-11-19,2026-07-11,"Monash University, Melbourne, Victoria, 3800, Australia"
NCT04908891,"A Comprehensive Assessment of Trunk, Scapula and Upper Limb in Neurological Patients. Reliability, Validity and Interrelatedness",https://beta.clinicaltrials.gov/study/NCT04908891,RECRUITING,Multiple Sclerosis|Stroke,"OTHER: Clinical Scapular protocol (ClinScaP)|OTHER: the prevalence of trunk, scapula and upper limb impairments.|OTHER: the interaction between trunk, scapula and upper limb impairments.",Hasselt University,Revalidatie & MS Centrum Overpelt|Ziekenhuis Oost-Limburg|National MS Center Melsbroek|Jessa Hospital,ALL,"ADULT, OLDER_ADULT",NA,160,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2018-12-12,2021-08-30,2021-08-30,"Ziekenhuis Oost-Limburg, Genk, 3600, Belgium|Jessa Ziekenhuis- Campus St. Ursula, Herk-de-Stad, 3540, Belgium|National MS Center Melsbroek, Melsbroek, 1820, Belgium|Noorderhart MS & Revalidatie, Overpelt, 3900, Belgium"
NCT02017808,Studying the Effects of Copaxone on Retinal Health Using Optical Tomography Over 24 Months,https://beta.clinicaltrials.gov/study/NCT02017808,COMPLETED,Multiple Sclerosis,,University at Buffalo,Teva Pharmaceuticals USA,ALL,"ADULT, OLDER_ADULT",,100,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-02,2014-12,2014-12,"Buffalo Neuroimaging Analysis Center, Buffalo, New York, 14203, United States"
NCT02652091,Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction,https://beta.clinicaltrials.gov/study/NCT02652091,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting","DRUG: Interferon beta-1b (Betaseron, BAY86-5046)|DEVICE: BETACONNECT device",Bayer,,ALL,"ADULT, OLDER_ADULT",,146,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-02-05,2017-08-11,2017-09-13,"Cullman, Alabama, 35058, United States|Boca Raton, Florida, 33428, United States|New Port Richey, Florida, 34653, United States|Tampa, Florida, 33609, United States|Atlanta, Georgia, 30309-1465, United States|Fulton, Maryland, 20759, United States|Foxboro, Massachusetts, 02035, United States|Deckerville, Michigan, 48427, United States|Saint Louis, Missouri, 63131, United States|Stratford, New Jersey, 08084, United States|Teaneck, New Jersey, 07666, United States|Staten Island, New York, 10306, United States|Medford, Oregon, 97504, United States|Medford, Oregon, United States|Bala-Cynwyd, Pennsylvania, 19004, United States|Lititz, Pennsylvania, 17543, United States|Franklin, Tennessee, 37064, United States|Memphis, Tennessee, 38104, United States|Nashville, Tennessee, 37212, United States|Lubbock, Texas, 79430, United States|Round Rock, Texas, 78681, United States|Fairfax, Virginia, 22031, United States|Virginia Beach, Virginia, United States"
NCT00942591,Atorvastatin 40 mg in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Interferon-Beta-1b,https://beta.clinicaltrials.gov/study/NCT00942591,COMPLETED,Multiple Sclerosis,DRUG: Interferon beta 1b|DRUG: Atorvastatin,"University Hospital Inselspital, Berne",PharmaPart|Laboratory: Viollier AG Spalenring 145 / 147 Postfach 4002 Basel,ALL,ADULT,PHASE2,77,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2005-05,2009-04,2009-05,"Prof. H. Mattle, Dep. of Neurology, Bern University Hospital, Bern, 3010, Switzerland"
NCT01266291,Sabril for Complex Partial Seizures in Adult Tolerability Study (TS) Patients,https://beta.clinicaltrials.gov/study/NCT01266291,TERMINATED,Complex Partial Seizures,DRUG: vigabatrin,University of Pennsylvania,H. Lundbeck A/S,ALL,"ADULT, OLDER_ADULT",PHASE4,1,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2010-08,2013-02,2013-12,"University of Pennsylvania, Philadelphia, Pennsylvania, 19103, United States"
NCT02466191,Treatment of Pendular Nystagmus in OPT,https://beta.clinicaltrials.gov/study/NCT02466191,COMPLETED,Pendular Nystagmus|Oculopalatal Tremor,DRUG: Memantine|DRUG: Gabapentin,Hospices Civils de Lyon,,ALL,"ADULT, OLDER_ADULT",PHASE4,7,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2015-06,2016-01,2016-01,"Hospices Civils de Lyon, Lyon, 69002, France"
NCT01454791,Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients Taking Glatiramer Acetate,https://beta.clinicaltrials.gov/study/NCT01454791,COMPLETED,Multiple Sclerosis,DRUG: diclofenac sodium topical gel|OTHER: Placebo,"Brown, Theodore R., M.D., MPH","Teva Neuroscience, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE4,40,INDIV,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2011-01,2013-03,2013-03,"MS Center at Evergreen Healthcare, Kirkland, Washington, 98034, United States"
NCT01842191,Efficacy of Fish Oil in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01842191,COMPLETED,Relapsing- Remitting Multiple Sclerosis,DIETARY_SUPPLEMENT: Fish Oil|DIETARY_SUPPLEMENT: Placebo,"Coordinación de Investigación en Salud, Mexico",,ALL,ADULT,PHASE4,50,OTHER_GOV,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2010-05,2011-12,2012-12,"IMSS, Specialties Hospital, Neurology Departament, Guadalajara, Jalisco, 44340, Mexico"
NCT04201691,"Effect of Manuel Therapy on Tonus, Proprioseption and Balance in Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT04201691,COMPLETED,Postural Balance|Multiple Sclerosis|Cervical Region Disorder Nos|Muscle Tonus|Proprioception,OTHER: classic rehabilitation|OTHER: classic rehabilitation+mobilization,Tuba Maden,,ALL,"ADULT, OLDER_ADULT",NA,16,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-01-07,2020-11-02,2020-12-30,"Hasan Kalyoncu University, Gaziantep, Turkey"
NCT01930708,A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes,https://beta.clinicaltrials.gov/study/NCT01930708,COMPLETED,Relapsing-Remitting Multiple Sclerosis|Multiple Sclerosis,DRUG: dimethyl fumarate,Biogen,,ALL,"ADULT, OLDER_ADULT",PHASE4,1114,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-10-31,2016-03-31,2020-01-09,"Research Site, Innsbruck, 6020, Austria|Research Site, Klagenfurt, 9026, Austria|Research Site, Linz, 4020, Austria|Research Site, Salzburg, 5020, Austria|Research Site, St. Polten, 3100, Austria|Research Site, Villach, 9500, Austria|Research Site, Wien, 1090, Austria|Research Site, Wien, 1220, Austria|Research Site, Brugge, 8000, Belgium|Research Site, Bruxelles, 1200, Belgium|Research Site, Melsbroek, 1820, Belgium|Research Site, Calgary, Alberta, T2N 2T9, Canada|Research Site, Victoria, British Columbia, V8R 1J6, Canada|Research Site, St. John's, New Brunswick, E2K 5S9, Canada|Research Site, St. John's, Newfoundland and Labrador, A1B 3V6, Canada|Research Site, Halifax, Nova Scotia, B3H 3A7, Canada|Research Site, London, Ontario, N6A 5A5, Canada|Research Site, Ottawa, Ontario, K1H 8L6, Canada|Research Site, Montreal, Quebec, H8A 2B4, Canada|Research Site, Brno, 625 00, Czechia|Research Site, Havirov, 736 00, Czechia|Research Site, Hradec Kralove, 500 05, Czechia|Research Site, Olomouc, 775 20, Czechia|Research Site, Pardubice, 532 03, Czechia|Research Site, Praha 10, 100 34, Czechia|Research Site, Praha 2, 128 08, Czechia|Research Site, Strasbourg Cedex, Bas Rhin, 67098, France|Research Site, Dijon Cedex, Cote dÝOr, 21079, France|Research Site, Besancon cedex, Doubs, 25030, France|Research Site, Nimes, Gard, 30029, France|Research Site, Bordeaux Cedex, Gironde, 33076, France|Research Site, Colmar cedex, Haut Rhin, 68024, France|Research Site, Toulouse cedex 1, Haute Garonne, 31059, France|Research Site, Limoges cedex, Haute Vienne, 87042, France|Research Site, Rennes cedex 09, Ille Et Vilaine, 35033, France|Research Site, Grenoble cedex 09, Isere, 39043, France|Research Site, Nantes cedex 1, Loire Atlantique, 44093, France|Research Site, Reims, Marne, 51092, France|Research Site, Lille Cedex, Nord, 59020, France|Research Site, Lille Cedex, Nord, 59037, France|Research Site, La Roche sur Yon, Vendee, 85025, France|Research Site, Poitiers cedex, Vienne, 86021, France|Research Site, Le Chesnay Cedex, Yvelines, 78157, France|Research Site, Nancy, 54035, France|Research Site, Rouen Cedex, 76031, France|Research Site, Budapest, 1076, Hungary|Research Site, Budapest, 1083, Hungary|Research Site, Debrecen, 4032, Hungary|Research Site, Pecs, 7623, Hungary|Research Site, Szeged, 6725, Hungary|Research Site, Veszprem, 8200, Hungary|Research Site, Ancona, 60126, Italy|Research Site, Bergamo, 24100, Italy|Research Site, Bolzano, 39100, Italy|Research Site, Castelfiorentino, 50051, Italy|Research Site, Firenze, 50139, Italy|Research Site, Genova, 16153, Italy|Research Site, Messina, 98121, Italy|Research Site, Milano, 20133, Italy|Research Site, Napoli, 80131, Italy|Research Site, Perugia, 06156, Italy|Research Site, Pozzilli, 86077, Italy|Research Site, Roma, 00135, Italy|Research Site, Roma, 00189, Italy|Research Site, Siena, 53100, Italy|Research Site, Torino, 10124, Italy|Research Site, Almada, 2801-915, Portugal|Research Site, Amadora, 2720-276, Portugal|Research Site, Guimarães, 4835-044, Portugal|Research Site, Lisboa, 1169-050, Portugal|Research Site, Lisboa, 1649-035, Portugal|Research Site, Loures, 2674-514, Portugal|Research Site, Porto, 4099-001, Portugal|Research Site, Porto, 4200-319, Portugal|Research Site, Setúbal, 2910-446, Portugal|Research Site, Bratislava, 81369, Slovakia|Research Site, Presov, 8081, Slovakia|Research Site, Ljubljana, SI-1525, Slovenia|Research Site, Maribor, 2000, Slovenia|Research Site, Majadahonda, Madrid, 28222, Spain|Research Site, Barcelona, 8035, Spain|Research Site, Bilbao, 48013, Spain|Research Site, Córdoba, 14011, Spain|Research Site, El Palmar, 30120, Spain|Research Site, Girona, 17007, Spain|Research Site, Malaga, 29010, Spain|Research Site, Sevilla, 41009, Spain|Research Site, Valencia, 46026, Spain|Research Site, Vigo, 36204, Spain|Research Site, Zaragoza, 50009, Spain"
NCT05787704,Walking and Thinking - Brain Activity During Complex Walking in People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05787704,RECRUITING,"Multiple Sclerosis|Gait Disorders, Neurologic|Neuro-Degenerative Disease|Aging",OTHER: No intervention,Karolinska Institutet,Karolinska University Hospital,ALL,"ADULT, OLDER_ADULT",,40,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-04-01,2023-12-31,2024-03-31,"Karolinska Institutet, Stockholm, Solna, 17177, Sweden"
NCT00053417,Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00053417,COMPLETED,Multiple Sclerosis,"DRUG: Placebo|DRUG: 10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP)|DRUG: 15 mg fampridine-SR (4-aminopyridine, 4-AP)|DRUG: 20 mg fampridine-SR (4-aminopyridine, 4-AP)",Acorda Therapeutics,,ALL,"ADULT, OLDER_ADULT",PHASE2,206,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2003-02,2003-12,2003-12,"Barrow Neurological Institute at St. Joseph Hospital and Medical Center, Phoenix, Arizona, 85013, United States|USC MS Comprehensive Care Center, Los Angeles, California, 90033, United States|Yale University MS Center, New Haven, Connecticut, 06510, United States|Shepherd Center, Atlanta, Georgia, 30309, United States|University of Chicago, Chicago, Illinois, 60637, United States|University of Maryland at Baltimore, Baltimore, Maryland, 21210, United States|Fairview MS Center, Minneapolis, Minnesota, 55454, United States|Washington University School of Medicine, St. Louis, Missouri, 63110, United States|Gimbel MS Center, Teaneck, New Jersey, 07666, United States|University of New Mexico, Albuquerque, New Mexico, 87131, United States|Maimonides MS Care Center, Brooklyn, New York, 11219, United States|Mt. Sinai School of Medicine - MS Center, New York, New York, 10029, United States|University of Rochester Medical School, Rochester, New York, 14642, United States|SUNY Stony Brook, Stony Brook, New York, 11794, United States|Carolinas Medical Center MS Center, Charlotte, North Carolina, 28207, United States|Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States|Ohio State University, Columbus, Ohio, 43210, United States|Oregon Health Sciences University; MS Center, Portland, Oregon, 97201, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, 19107, United States|University of Texas-Houston, Houston, Texas, 77030, United States|Swedish Medical MS Center, Seattle, Washington, 98122, United States|University of Washington School of Medicine, Seattle, Washington, 98195, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, 53792, United States|Foothills Medical Centre, Calgary, Alberta, T2N 2T9, Canada|St. Michael's Hospital, Toronto, Ontario, M5B 1WB, Canada"
NCT01144117,The Effects of Erythropoietin on Clinical Disability and Brain Pathology in Patients With Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01144117,UNKNOWN,Multiple Sclerosis (Primary or Secondary Progressive Phase).,DRUG: Erythropoietin,"Rigshospitalet, Denmark",Danish Research Centre for Magnetic Resonance,ALL,ADULT,PHASE2,56,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-11,2012-12,2013-04,"Karen Schreiber, Copenhagen, Oesterbro, DK-2100, Denmark"
NCT02264704,Exercise Intensity and Immune Function in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02264704,UNKNOWN,Multiple Sclerosis,OTHER: High intensity exericse|OTHER: Moderate intensity exericse,University of the West of Scotland,National Heatlh Service Ayrshire and Arran,ALL,ADULT,NA,63,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2014-11,2015-07,2015-07,"Douglas Grant Rehabilitation Centre, Ayrshire Central Hospital, Irvine, Ayrshire, KA12 8SS, United Kingdom"
NCT00893217,BEYOND Pilot Study,https://beta.clinicaltrials.gov/study/NCT00893217,COMPLETED,Multiple Sclerosis|Relapsing-Remitting,"DRUG: Betaseron (Interferon beta-1b, BAY86-5046)|DRUG: Betaseron (Interferon beta-1b, BAY86-5046)",Bayer,,ALL,ADULT,PHASE2,71,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2002-11,,2003-06,"Los Angeles, California, 90095, United States|Washington, District of Columbia, 20037, United States|Atlanta, Georgia, 30309-1465, United States|Chicago, Illinois, 60637-1470, United States|Kansas City, Kansas, 66160, United States|Louisville, Kentucky, 40205, United States|Ann Arbor, Michigan, 48109-0330, United States|Reno, Nevada, 89557-0035, United States|Stony Brook, New York, 11794, United States|Durham, North Carolina, 27710, United States|High Point, North Carolina, 27262, United States|Winston-Salem, North Carolina, 27157-1009, United States|Columbus, Ohio, 43210-1240, United States|Nashville, Tennessee, 37232, United States"
NCT04203017,Fecal Microbiota Transplantation After Autologous HSCT in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04203017,RECRUITING,Multiple Sclerosis,BIOLOGICAL: allogeneic fecal microbiota,St. Petersburg State Pavlov Medical University,,ALL,ADULT,PHASE1,20,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2019-06-01,2023-06-01,2024-12-01,"Pavlov First Saint-Petersburg State Medical University, Saint Petersburg, 197022, Russian Federation"
NCT01387217,GSK2018682 FTIH in Healthy Volunteers,https://beta.clinicaltrials.gov/study/NCT01387217,COMPLETED,Multiple Sclerosis,DRUG: GSK2018682|DRUG: Placebo,GlaxoSmithKline,,ALL,ADULT,PHASE1,27,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2010-05-21,2010-12-20,2010-12-20,"GSK Investigational Site, Randwick, New South Wales, 2031, Australia|GSK Investigational Site, Adelaide, South Australia, 5000, Australia"
NCT02674217,Outpatient Hematopoietic Grafting in Multiple Sclerosis Employing Autologous Peripheral Blood Stem Cells,https://beta.clinicaltrials.gov/study/NCT02674217,ENROLLING_BY_INVITATION,Multiple Sclerosis,PROCEDURE: Hematopoietic stem cell transplantation,Centro de Hematología y Medicina Interna,,ALL,"CHILD, ADULT, OLDER_ADULT",NA,1000,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-05,2025-12,2025-12,
NCT01051817,POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler,https://beta.clinicaltrials.gov/study/NCT01051817,COMPLETED,Relapsing-remitting Multiple Sclerosis|RRMS,DRUG: AIN457|DRUG: Placebo,Novartis Pharmaceuticals,,ALL,ADULT,PHASE2,73,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2009-12,2012-04,2012-04,"Novartis Investigative Site, Hradec Kralove, 500 05, Czech Republic|Novartis Investigative Site, Ostrava-Moravska Ostrava, Czech Republic|Novartis Investigative Site, Ostrava, Czech Republic|Novartis Investigative Site, Praha 10, Czech Republic|Novartis Investigative Site, Praha 2, 128 08, Czech Republic|Novartis Investigative Site, Teplice, 415 29, Czech Republic|Novartis Investigative Site, Kazan, 420021, Russian Federation|Novartis Investigative Site, Moscow, 129128, Russian Federation|Novartis Investigative Site, Nizhny Novgorod, 603155, Russian Federation|Novartis Investigative Site, Smolensk, 214019, Russian Federation|Novartis Investigative Site, Kharkiv, 61068, Ukraine|Novartis Investigative Site, Kharkiv, Ukraine|Novartis Investigative Site, Kiev, 03110, Ukraine|Novartis Investigative Site, Kiev, Ukraine|Novartis Investigative Site, Odessa, 65025, Ukraine|Novartis Investigative Site, Vinnitsya, 21005, Ukraine"
NCT02125604,Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany,https://beta.clinicaltrials.gov/study/NCT02125604,COMPLETED,Relapsing-Remitting Multiple Sclerosis,DRUG: dimethyl fumarate,Biogen,,ALL,"ADULT, OLDER_ADULT",PHASE4,214,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-06,2016-02,2016-03,"Research Site, Augsburg, Germany|Research Site, Bamburg, Germany|Research Site, Bayreuth, Germany|Research Site, Berlin, Germany|Research Site, Bochum, Germany|Research Site, Bonn, Germany|Research Site, Erbach, Germany|Research Site, Erlangen, Germany|Research Site, Freiburg, Germany|Research Site, Hamburg, Germany|Research Site, Leipzig, Germany|Research Site, Marburg, Germany|Research Site, Minden, Germany|Research Site, Mittweida, Germany|Research Site, Munchen, Germany|Research Site, Munster, Germany|Research Site, Osnabruck, Germany|Research Site, Potsdam, Germany|Research Site, Siegen, Germany"
NCT00395317,Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT00395317,COMPLETED,Multiple Sclerosis,OTHER: Placebo|DRUG: Firategrast 150 mg|DRUG: Firategrast 300 mg,GlaxoSmithKline,,ALL,"ADULT, OLDER_ADULT",PHASE2,343,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2006-12,2009-08,2010-08,"GSK Investigational Site, Camperdown, New South Wales, 2050, Australia|GSK Investigational Site, Woodville, South Australia, 5011, Australia|GSK Investigational Site, Fitzroy, Victoria, 3065, Australia|GSK Investigational Site, Parkville, Victoria, 3050, Australia|GSK Investigational Site, Graz, A-8036, Austria|GSK Investigational Site, Innsbruck, A-6020, Austria|GSK Investigational Site, London, Ontario, N6A 5C1, Canada|GSK Investigational Site, Ottawa, Ontario, K1H 8L6, Canada|GSK Investigational Site, Gatineau, Quebec, J9J 0A5, Canada|GSK Investigational Site, Greenfield Park, Quebec, J4V 2J2, Canada|GSK Investigational Site, Turku, 20100, Finland|GSK Investigational Site, Clermont Ferrand, 63003, France|GSK Investigational Site, Dijon, 21033, France|GSK Investigational Site, Lille, 59000, France|GSK Investigational Site, Marseille, 13385, France|GSK Investigational Site, Nantes, 44093, France|GSK Investigational Site, Rennes Cedex 9, 35033, France|GSK Investigational Site, Strasbourg, 67091, France|GSK Investigational Site, Neuburg / Donau, Bayern, 86633, Germany|GSK Investigational Site, Herborn, Hessen, 35745, Germany|GSK Investigational Site, Rostock, Mecklenburg-Vorpommern, 18147, Germany|GSK Investigational Site, Achim, Niedersachsen, 28832, Germany|GSK Investigational Site, Hannover, Niedersachsen, 30625, Germany|GSK Investigational Site, Bad Honnef, Nordrhein-Westfalen, 53604, Germany|GSK Investigational Site, Bielefeld, Nordrhein-Westfalen, 33647, Germany|GSK Investigational Site, Dueren, Nordrhein-Westfalen, 52349, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, 45122, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, 50767, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, 51109, Germany|GSK Investigational Site, Dresden, Sachsen, 01307, Germany|GSK Investigational Site, Leipzig, Sachsen, 04103, Germany|GSK Investigational Site, Leipzig, Sachsen, 04157, Germany|GSK Investigational Site, Berlin, 10625, Germany|GSK Investigational Site, Berlin, 10961, Germany|GSK Investigational Site, Berlin, 12167, Germany|GSK Investigational Site, Hamburg, 22087, Germany|GSK Investigational Site, Chieti, Abruzzo, 66013, Italy|GSK Investigational Site, Roma, Lazio, 00163, Italy|GSK Investigational Site, Gallarate, Lombardia, 21013, Italy|GSK Investigational Site, Milano, Lombardia, 20132, Italy|GSK Investigational Site, Siena, Toscana, 53100, Italy|GSK Investigational Site, Breda, 4818 CK, Netherlands|GSK Investigational Site, Den Bosch, 5211 RW, Netherlands|GSK Investigational Site, Eindhoven, 5623 EJ, Netherlands|GSK Investigational Site, Nieuwegein, 3435 CM, Netherlands|GSK Investigational Site, Sittard-geleen, 6162 BG, Netherlands|GSK Investigational Site, Venray, 5801 CE, Netherlands|GSK Investigational Site, Auckland, 1001, New Zealand|GSK Investigational Site, Christchurch, 8001, New Zealand|GSK Investigational Site, Wellington, 6021, New Zealand|GSK Investigational Site, Bergen, 5021, Norway|GSK Investigational Site, Drammen, 3004, Norway|GSK Investigational Site, Hamar, 2317, Norway|GSK Investigational Site, Sandnes, 4313, Norway|GSK Investigational Site, Skien, 3710, Norway|GSK Investigational Site, Gdansk, 80-299, Poland|GSK Investigational Site, Poznan, 60-479, Poland|GSK Investigational Site, Poznan, 61-298, Poland|GSK Investigational Site, Warsaw, 02-097, Poland|GSK Investigational Site, Moscow, 117049, Russian Federation|GSK Investigational Site, Moscow, 125101, Russian Federation|GSK Investigational Site, Moscow, 125367, Russian Federation|GSK Investigational Site, St-Petersburg, 194354, Russian Federation|GSK Investigational Site, St. Petersburg, 197022, Russian Federation|GSK Investigational Site, St.-Petersburg, 194291, Russian Federation|GSK Investigational Site, St.-Petersburg, 197376, Russian Federation|GSK Investigational Site, Barakaldo (Vizcaya), 48903, Spain|GSK Investigational Site, Barcelona, 08035, Spain|GSK Investigational Site, Madrid, 28007, Spain|GSK Investigational Site, Madrid, 28035, Spain|GSK Investigational Site, Madrid, 28046, Spain|GSK Investigational Site, San Sebastián, 20014, Spain|GSK Investigational Site, Sevilla, 41071, Spain|GSK Investigational Site, Valencia, 46010, Spain|GSK Investigational Site, Romford, Essex, RM7 0AG, United Kingdom|GSK Investigational Site, Hartshill, Stoke-on-Trent, ST4 7LN, United Kingdom|GSK Investigational Site, Newcastle-Upon-Tyne, NE1 4LP, United Kingdom|GSK Investigational Site, Nottingham, NG7 2UH, United Kingdom|GSK Investigational Site, Sheffield, S10 2JF, United Kingdom"
NCT01941004,Safety and Efficacy of Fingolimod in MS Patients in China,https://beta.clinicaltrials.gov/study/NCT01941004,WITHDRAWN,Multiple Sclerosis (Relapsing Remitting),DRUG: fingolimod|DRUG: Placebo (6mos) + open label fingolimod (6 mos),Novartis Pharmaceuticals,,ALL,ADULT,PHASE3,0,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2014-06,2017-05,2017-05,
NCT01404117,"A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability",https://beta.clinicaltrials.gov/study/NCT01404117,WITHDRAWN,Relapsing Multiple Sclerosis,DRUG: Laquinimod 0.6|DRUG: Laquinimod 1.2|OTHER: Glatiramer Acetate or interferon-beta+ Placebo,"Teva Branded Pharmaceutical Products R&D, Inc.",,ALL,ADULT,PHASE2,0,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2012-03,2013-12,2014-01,
NCT03339817,Description Des Troubles Respiratoires Chez Les Patients Suivis Pour Une Sclérose en Plaques (SEP) sévère,https://beta.clinicaltrials.gov/study/NCT03339817,UNKNOWN,Multiple Sclerosis|Respiration Disorders,DIAGNOSTIC_TEST: Polysomnography,"Institut National de la Santé Et de la Recherche Médicale, France",,ALL,"ADULT, OLDER_ADULT",NA,70,OTHER_GOV,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2018-01-11,2019-11-15,2020-01-10,"Département de Neurologie-Groupe Hospitalier Pitié-Salpêtrière, Paris, 75013, France"
NCT03316404,Evaluating Multiple Sclerosis Patients ShOWing A GEnomic Signature of Therapy Response,https://beta.clinicaltrials.gov/study/NCT03316404,UNKNOWN,Multiple Sclerosis|MS,,DxTerity Diagnostics,,ALL,"ADULT, OLDER_ADULT",,1500,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-11-07,2019-10-23,2019-10-23,"DxTerity Diagnostics, Compton, California, 90220, United States"
NCT02258217,Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS),https://beta.clinicaltrials.gov/study/NCT02258217,COMPLETED,Relapsing Remitting Multiple Sclerosis,DRUG: Acthar,OhioHealth,,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2014-06,2016-06-24,2016-12,"OhioHealth, Columbus, Ohio, 43214, United States"
NCT03021317,Effects of ACTHAR on Advanced MRI Surrogate Markers of Disease Activity and on Comprehensive Immune Signature During MS Relapses,https://beta.clinicaltrials.gov/study/NCT03021317,UNKNOWN,Multiple Sclerosis,DRUG: ACTHar,University of Chicago,,ALL,"ADULT, OLDER_ADULT",PHASE4,18,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2017-02,2019-05,2019-05,
NCT04806217,Nature of the Link Between Executive Functions and Theory of Mind in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04806217,NOT_YET_RECRUITING,Multiple Sclerosis,OTHER: Theory of Mind,Lille Catholic University,,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-07-01,2024-01-01,2024-01-01,
NCT04667117,A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab,https://beta.clinicaltrials.gov/study/NCT04667117,RECRUITING,Relapsing Multiple Sclerosis,BIOLOGICAL: Quadrivalent influenza vaccine|DRUG: Ofatumumab,Novartis Pharmaceuticals,,ALL,ADULT,PHASE4,66,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-01-14,2023-07-06,2023-07-06,"Novartis Investigative Site, Phoenix, Arizona, 85018, United States|Novartis Investigative Site, Sunrise, Florida, 33351, United States|Novartis Investigative Site, Saint Louis, Missouri, 63131, United States|Novartis Investigative Site, Vienna, Virginia, 22182, United States"
NCT03896217,Simvastatin in Secondary Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03896217,UNKNOWN,Secondary Progressive Multiple Sclerosis,DRUG: Simvastatin,"University College, London",National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2019-05-16,2021-01,2021-01,"Department of Neuroinflammation, UCL Institute of Neurology, London, WC1B 5EH, United Kingdom"
NCT05510817,Multiparametric Assessment to Investigate Prognostic Factors for Disease Evolution a nd Evolutionary Patterns of Cognitive Status in RRMS,https://beta.clinicaltrials.gov/study/NCT05510817,RECRUITING,"Multiple Sclerosis, Relapsing-Remitting",OTHER: Multiparametric assessment,University Hospital of Mont-Godinne,Saint-Luc University Hospital,ALL,ADULT,NA,50,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2022-06-06,2026-06-06,2026-06-06,"CHU UCL Namur site Godinne, Yvoir, Namur, Belgium"
NCT04390009,Entire-body PET Scans for Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04390009,RECRUITING,Multiple Sclerosis,DIAGNOSTIC_TEST: Entire-body PET-CT scans|DRUG: Amyvid radiopharmaceutical,Brain Health Alliance,,ALL,ADULT,EARLY_PHASE1,20,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-09-01,2023-03-31,2023-09-01,"Brain Health Alliance, Ladera Ranch, California, 92694, United States"
NCT02913209,Quantitative Fatigue and Muscle Performance in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02913209,UNKNOWN,Multiple Sclerosis|Fatigue,,Washington D.C. Veterans Affairs Medical Center,,ALL,"ADULT, OLDER_ADULT",,30,FED,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-04,2018-10,2020-12,
NCT04847609,GentleCath Air (Urinary Self-catheterization) - Pain in Female Patients With Neurological Vesico-sphincter Disorders,https://beta.clinicaltrials.gov/study/NCT04847609,WITHDRAWN,Spinal Cord Injuries|Multiple Sclerosis|Parkinsonian Disorders|Allodynia,DEVICE: GentleCath™ Air catheter,ConvaTec Inc.,ClinSearch,FEMALE,"ADULT, OLDER_ADULT",,0,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-05-31,2021-09-01,2021-10-01,
NCT04483609,SF-QUALIVEEN Turkish Validity and Reliability Study,https://beta.clinicaltrials.gov/study/NCT04483609,COMPLETED,Multiple Sclerosis,OTHER: Questionnaire administration pre test|OTHER: Questionnaire administration validation and reliability,Istanbul Aydın University,,ALL,"ADULT, OLDER_ADULT",,63,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-07-30,2020-09-30,2020-10-30,"İstanbul Üniversitesi-Cerrahpaşa, İstanbul, Turkey"
NCT01028209,Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions,https://beta.clinicaltrials.gov/study/NCT01028209,TERMINATED,Alzheimer Disease|Parkinson Disease|Multiple Sclerosis,DRUG: [18F] PBR06,Institute for Neurodegenerative Disorders,,ALL,"ADULT, OLDER_ADULT",PHASE1,12,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2009-11,2010-09-22,2010-09-22,"Institute for Neurodegenerative Disorders, New Haven, Connecticut, 06510, United States"
NCT05285891,Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05285891,RECRUITING,Multiple Sclerosis,DRUG: Ocrelizumab|DRUG: Placebo for Ocrelizumab,National Institute of Allergy and Infectious Diseases (NIAID),"Autoimmunity Centers of Excellence (ACE)|Rho Federal Systems Division, Inc.|Genentech, Inc.",ALL,ADULT,PHASE4,175,NIH,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-01-12,2028-08-01,2028-08-01,"Yale School of Medicine, New Haven, Connecticut, 06510, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, 01655, United States|University of Michigan Health System, Ann Arbor, Michigan, 48109, United States|Icahn School of Medicine at Mount Sinai, New York, New York, 10007, United States|New York University Langone Health: Multiple Sclerosis Comprehensive Care Center, New York, New York, 10016, United States|Columbia University Irving Medical Center, New York, New York, 10033, United States|University of Rochester Medical Center, Rochester, New York, 14627, United States|Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, 73104, United States|University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, 19104, United States|University of Texas Southwestern Medical Center, Dallas, Texas, 75390, United States"
NCT04882891,Holter of Movement in Patients With Multiple Sclerosis in Uncontrolled Environment.,https://beta.clinicaltrials.gov/study/NCT04882891,RECRUITING,Multiple Sclerosis,DEVICE: Actimyo,Dr. Stéphanie Delstanche,Sysnav|Centre Hospitalier Universitaire de Liege,ALL,"ADULT, OLDER_ADULT",NA,80,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-03-09,2024-02-15,2024-02-15,"Centre Hospitalier Universitaire de Liège, Liège, 4000, Belgium|CHR Citadelle, Liège, 4000, Belgium"
NCT04289909,Identification of Retinal Perivascular Inflammation in Patients With Multiple Sclerosis Using Adaptive Optics (RETIMUS),https://beta.clinicaltrials.gov/study/NCT04289909,UNKNOWN,Relapsing Remitting Multiple Sclerosis|Progressive Multiple Sclerosis|Optic Neuritis|Eye Diseases|Optic Nerve Diseases|Nervous System Diseases|Multiple Sclerosis,OTHER: Adaptive Optics Ophthalmoscopy (AOO),"Institut National de la Santé Et de la Recherche Médicale, France",Biogen,ALL,ADULT,NA,60,OTHER_GOV,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2020-03,2022-10,2022-10,"Institut du Cerveau et de la Moelle epiniere - Hopital Pitie Salpetriere, Paris, France"
NCT05474209,"Effect of Tai Chi on Balance, Mood, Cognition, and Quality of Life in Patients With Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT05474209,COMPLETED,Multiple Sclerosis,"OTHER: ""Tai-chi"" - a special program for patients with multiple sclerosis - once a week training with a Tai Chi instructor lasting 90 minutes",Comenius University,,ALL,ADULT,NA,25,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2019-01-01,2020-01-31,2022-01-31,"2nd Department of Neurology, Faculty of Medicine COMENIUS UNIVERSITY BRATISLAVA, Bratislava, Slovak Republic, 83305, Slovakia"
NCT00230204,Infections and Autoimmunity: Autobodies Screening in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00230204,UNKNOWN,Multiple Sclerosis,PROCEDURE: Serum antibodies to infectious agents using the BioPlex 2200 and complementary EIA kits,Sheba Medical Center,,ALL,ADULT,PHASE1,100,OTHER_GOV,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2005-09,,2006-04,"Multiple Sclerosis Center, Sheba Medical Center, Ramat-gan, 52621, Israel"
NCT01317004,Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change,https://beta.clinicaltrials.gov/study/NCT01317004,COMPLETED,Relapsing Remitting Multiple Sclerosis,DRUG: Fingolimod|DRUG: Standard MS DMT,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE4,61,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2011-05,2014-06,2014-06,"Novartis Investigative Site, Ancona, AN, 60126, Italy|Novartis Investigative Site, Ponderano, BI, 13900, Italy|Novartis Investigative Site, Caltanissetta, CL, 93100, Italy|Novartis Investigative Site, Cuneo, CN, 12100, Italy|Novartis Investigative Site, Como, CO, 22100, Italy|Novartis Investigative Site, Catania, CT, 95122, Italy|Novartis Investigative Site, Foggia, FG, 71100, Italy|Novartis Investigative Site, Castelfiorentino, FI, 50051, Italy|Novartis Investigative Site, Milano, MI, 20122, Italy|Novartis Investigative Site, Milano, MI, 20133, Italy|Novartis Investigative Site, San Donato Milanese, MI, 20097, Italy|Novartis Investigative Site, Modena, MO, 41100, Italy|Novartis Investigative Site, Palermo, PA, 90129, Italy|Novartis Investigative Site, Palermo, PA, 90146, Italy|Novartis Investigative Site, Pisa, PI, 56126, Italy|Novartis Investigative Site, Legnago, VR, 37045, Italy|Novartis Investigative Site, Novara, 28100, Italy"
NCT05639517,The Effect of Augmented Reality Based Telerehabilitation Application on Neuromuscular and Sensorimotor Parameters in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT05639517,NOT_YET_RECRUITING,Multiple Sclerosis,OTHER: Augmented Reality Based Telerehabilitation Application|OTHER: Training face-to-face,Ankara Yildirim Beyazıt University,,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-01-30,2024-09-30,2024-12-15,
NCT00403104,Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS),https://beta.clinicaltrials.gov/study/NCT00403104,COMPLETED,Amyotrophic Lateral Sclerosis (ALS),DRUG: ONO-2506PO|DRUG: ONO-2506PO,Ono Pharmaceutical Co. Ltd,,ALL,"ADULT, OLDER_ADULT",PHASE2,420,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2006-11,2008-12,2008-12,"L. Boltzmann Forschungsinstitut, Neurologische Abteilung, Kaiser Franz Josef Hospital, Wien, Wien, 1100, Austria|UCL Saint-Luc, Brussels, Belgium|UZ Leuven, Leuven, 3000, Belgium|Hopital Roger Salengro - Clinique Neurologique, Neurologie A, Lille Cedex, 59037, France|Hopital Duruytren, Limoges Cedex, 87042, France|Hopital de la Timone, Marseille, 13005, France|Hopital de Chauliac, Montpellier cedex 5, 34295, France|Hopital l-Archet 1, Nice cedex 3, 06202, France|Hopital LaPitie Salpetriere, Paris, 75013, France|Charite Campus Virchow, ALS Ambulanz, Berlin, 13353, Germany|Neurologische Universitatsklinik Bergmannsheil, Bochum, 44789, Germany|Poliklinik der Universitat Erlangen-Nurnberg, Neurologische Klinik, Erlangen, 91054, Germany|Martin-Luther-Universitat Halle-Wittenberg, Klinikum der Medizinischen Fakultat, Universitatsklinik und Poliklinik fur Neurologie, Halle, 06120, Germany|Medizinische Hochschule Hannover, Neurologische Klinik, Hannover, 30623, Germany|Interdisziplinares Zentrum fur Palliativmedizin, Munchen, Germany|Klinik und Poliklinik fur Neurologie der Universitat Ulm-Universitatsklinikum Ulm, Ulm, 89081, Germany|Deutsche Klinik fur Diagnostik, Fachbereich Neurologie, Wiesbaden, 65191, Germany|Dipartimento di Neurologia e Laboratorio di Neuroscienze - Universita di Milano - IRCCS - Istituto Auxologico Italiano, Milano, 20149, Italy|Divisione di Neuroriabilitazione II - Fondazione Salvatore Maugeri - IRCCS, Pavia, 27100, Italy|Dipartimento di Neuroscienze - Divisione di Neurologia II - Azienda Ospedaliera S. Giovanni Battista - Molinette, Torino, 10126, Italy|Academic Medical Centre (AMC) Amsterdam - Dept of Neurology, Amsterdam, Netherlands|University Medial Center Utrecht, Utrecht, Netherlands|Kantonsspital St. Gallen, Muskelzentrum/ALS Clinic, St. Gallen, 9007, Switzerland|Academic Neuroscience Centre, London, United Kingdom|Royal Preston Hospital, Preston, PR29HT, United Kingdom|University of Sheffield - Academic Neurology Unit, Sheffield, United Kingdom"
NCT05285904,Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study,https://beta.clinicaltrials.gov/study/NCT05285904,RECRUITING,Multiple Sclerosis,OTHER: Ofatumumab,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",,149,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-05-12,2026-12-31,2026-12-31,"Novartis Investigative Site, Baden, Aargau, 5405, Switzerland|Novartis Investigative Site, Liestal, BL, 4410, Switzerland|Novartis Investigative Site, Zuerich, CHE, 8001, Switzerland|Novartis Investigative Site, Chur, GR, 7000, Switzerland|Novartis Investigative Site, Luzern, LU, 6006, Switzerland|Novartis Investigative Site, Sargans, Saint Gallen, 7320, Switzerland|Novartis Investigative Site, Wil, SG, 9500, Switzerland|Novartis Investigative Site, Gland, Vaud, 1196, Switzerland|Novartis Investigative Site, Zug, ZG, 6300, Switzerland|Novartis Investigative Site, Zurich, ZH, 8006, Switzerland|Novartis Investigative Site, Basel, 4001, Switzerland|Novartis Investigative Site, Bern, 3010, Switzerland|Novartis Investigative Site, Lausanne, 1011, Switzerland|Novartis Investigative Site, Lugano, 6900, Switzerland|Novartis Investigative Site, Luzern, 6000, Switzerland|Novartis Investigative Site, Luzern, 6004, Switzerland|Novartis Investigative Site, Sion, 1950, Switzerland|Novartis Investigative Site, Zurich, 8091, Switzerland"
NCT01040117,Sensori-motor Integration Training in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01040117,COMPLETED,Relapsing-remitting Multiple Sclerosis,PROCEDURE: Sensory-motor Integration Training|PROCEDURE: Conventional neurorehabilitation treatment,Universita di Verona,,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,80,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-12,2011-10,2012-01,"Section of Clinical Neurology, Department Neurological, Neuropsychological, Morphological and Movement Sciences, University of Verona, Verona, Italy, Verona, 37124, Italy|S.S.O. di Riabilitazione dell'Ospedale Policlinico, Verona, 37126, Italy"
NCT01185717,JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT01185717,COMPLETED,Multiple Sclerosis,,Biogen,,ALL,"CHILD, ADULT, OLDER_ADULT",,7726,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-09,2012-05,2012-06,
NCT05435404,Qualitative Study Patient & Physician Experiences Botox COVID-19,https://beta.clinicaltrials.gov/study/NCT05435404,COMPLETED,Chronic Brain Injury|Cerebral Stroke|MS (Multiple Sclerosis),,East Kent Hospitals University NHS Foundation Trust,,ALL,"ADULT, OLDER_ADULT",,11,OTHER_GOV,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-10-08,2022-04-30,2022-04-30,"East Kent Hospitals University NHS Trust, Canterbury, Kent, CT1 3NG, United Kingdom"
NCT00552604,MUltiple Sclerosis and Extract of Cannabis (MUSEC) Study,https://beta.clinicaltrials.gov/study/NCT00552604,TERMINATED,Muscle Spasticity,DRUG: standardized cannabis extract|DRUG: Placebo,"Institut fur Klinische Forschung, Germany",Weleda AG,ALL,ADULT,PHASE3,279,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2006-06,2008-11,2008-11,"Peninsula Medical School, Plymouth, PL6 8BX, United Kingdom"
NCT03034317,NeuRx Diaphram Pacing System (DPS) Use in Amyotrophic Lateral Sclerosis (ALS),https://beta.clinicaltrials.gov/study/NCT03034317,WITHDRAWN,Amyotrophic Lateral Sclerosis,DEVICE: NeuRx DPS,Synapse Biomedical,,ALL,"ADULT, OLDER_ADULT",NA,0,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2017-02-02,2018-02-08,2018-02-12,
NCT02969304,Study of Utilization Patterns of Dimethyl Fumarate in Germany,https://beta.clinicaltrials.gov/study/NCT02969304,COMPLETED,Multiple Sclerosis,DRUG: dimethyl fumarate,Biogen,,ALL,"CHILD, ADULT, OLDER_ADULT",,930,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-12-30,2017-03-02,2017-03-02,"Research Site, Leipzig, Saxony, 04109, Germany"
NCT03520517,"Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS",https://beta.clinicaltrials.gov/study/NCT03520517,COMPLETED,"Amyotrophic Lateral Sclerosis|ALS|Lou Gehrig Disease|Lou Gehrig's Disease|Lou-Gehrigs Disease|Motor Neuron Disease, Amyotrophic Lateral Sclerosis",DRUG: BHV-0223,"Biohaven Pharmaceuticals, Inc.",Cognitive Research Corporation,ALL,"ADULT, OLDER_ADULT",PHASE1,22,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-02-02,2018-10-08,2018-10-08,"Holy Cross Neuroscience Research Institute, Fort Lauderdale, Florida, 33334, United States|Somnos/Neurology Associates Clinical Research, Lincoln, Nebraska, 68506, United States|Neurosciences Institute, Neurology - Charlotte, Charlotte, North Carolina, 28207, United States|Wesley Neurology Clinic, Cordova, Tennessee, 38018, United States|Texas Neurology, Dallas, Texas, 75214, United States"
NCT00828204,Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects,https://beta.clinicaltrials.gov/study/NCT00828204,COMPLETED,Multiple Sclerosis,DEVICE: single-use autoinjector with a prefilled liquid Avonex syringe|DEVICE: Avonex prefilled syringe via manual IM injection|DRUG: BG9418 (interferon beta-1a),Biogen,,ALL,"ADULT, OLDER_ADULT",PHASE3,95,INDUSTRY,INTERVENTIONAL,"Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: ",2009-01,2010-07,2010-10,"Research Site, Gilbert, Arizona, 85234, United States|Research Site, Phoenix, Arizona, 85018, United States|Research Site, Maitland, Florida, 32751, United States|Research Site, Atlanta, Georgia, 30327, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, 46804, United States|Research Site, Boston, Massachusetts, 2135, United States|Michigan Institute for Neurological Disorders, Farmington Hills, Michigan, 28595, United States|Research Site, Buffalo, New York, 14203, United States|Comprehensive Multiple Sclerosis Care Center, Patchogue, New York, 11772, United States|Research Site, Charlotte, North Carolina, 28207, United States|Neurology & Neuroscience Associates, Inc., Akron, Ohio, 4320, United States|Research Site, Dallas, Texas, 75214, United States|Research Site, Round Rock, Texas, 78681, United States|Research Site, Salt Lake City, Utah, 84103, United States|Research Site, Richmond, Virginia, 23298, United States|Research Site, Charleston, West Virginia, 25301, United States"
NCT01800604,Power Over Pain (POP) Study,https://beta.clinicaltrials.gov/study/NCT01800604,COMPLETED,Multiple Sclerosis|Spinal Cord Injury|Chronic Pain|Other and Unspecified Amputation Stump Complications|Muscular Dystrophies|Low Back Pain,BEHAVIORAL: Pain Self-Management Intervention #1|BEHAVIORAL: Pain Self-Management Intervention #2|BEHAVIORAL: Pain Self-Management Intervention #3|BEHAVIORAL: Pain Self-Management Intervention #4,University of Washington,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health (NIH),ALL,"ADULT, OLDER_ADULT",NA,177,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-02,2018-01,2018-01,"University of Washington, Ninth and Jefferson Building, Seattle, Washington, 98104, United States"
NCT00137904,Sleep Disorders in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00137904,UNKNOWN,Multiple Sclerosis,,Groupe Hospitalier Pitie-Salpetriere,"Institut National de la Santé Et de la Recherche Médicale, France",ALL,ADULT,,51,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,,,,"Centre d'Investigation Clinique-Hopital Pitié-Salpêtrière, Paris, 75013, France"
NCT05313204,Exercise and Pregnancy in People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05313204,RECRUITING,Multiple Sclerosis|Pregnancy,OTHER: Moderate-intensity cardiovascular exercise,University of Alberta,,FEMALE,"ADULT, OLDER_ADULT",,60,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-09-01,2023-08-01,2023-08-01,"University of Alberta, Edmonton, Alberta, T6G, Canada"
NCT01432704,Colecalciferol as an Add-on Treatment to Subcutaneously-Administered Interferon-beta-1b for Treatment of Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT01432704,COMPLETED,Multiple Sclerosis,DRUG: colecalciferol,University of Turku,Bayer,ALL,ADULT,PHASE2|PHASE3,70,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2008-03,2011-05,2011-08,
NCT03647904,The SEMS Project: Staying Employed With MS,https://beta.clinicaltrials.gov/study/NCT03647904,UNKNOWN,Multiple Sclerosis,BEHAVIORAL: SEMS Project,Kessler Foundation,,ALL,"ADULT, OLDER_ADULT",NA,16,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2017-10-01,2018-10,2018-10,"Kessler Foundation, East Hanover, New Jersey, 07936, United States"
NCT00644904,Safety Trial of High Dose Oral Vitamin D3 With Calcium in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00644904,COMPLETED,Multiple Sclerosis,DIETARY_SUPPLEMENT: Vitamin D3|DIETARY_SUPPLEMENT: Vitamin D3,University of Toronto,Direct MS-Proactive Charity|Multiple Sclerosis Society of Canada,ALL,ADULT,PHASE1|PHASE2,49,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2006-07,2008-02,2008-02,"St. Michael's Hospital, Toronto, Ontario, M5B 1W8, Canada"
NCT02852317,Urinary Markers of Detrusor Overactivity in Spina Bifida Patients,https://beta.clinicaltrials.gov/study/NCT02852317,COMPLETED,Spina Bifida|Multiple Sclerosis|Spinal Cord Injury|Overactive Bladder,,Rennes University Hospital,,ALL,"ADULT, OLDER_ADULT",,134,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-03-16,2017-03-29,2017-07-17,"Centre hospitalier universitaire de Rennes, Rennes, 35000, France"
NCT03679806,Effects Aquatic Exercises on Balance and Hand Function in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03679806,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",OTHER: Halliwick|OTHER: Aquatic Plyometric Exercises,Dokuz Eylul University,,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-05,2016-07,2016-09,"Dokuz Eylul University School of Physical Therapy and Rehabilitation, Izmir, 35330, Turkey"
NCT02019927,Electric Stimulation of the Eye to Improve Vision After Trauma,https://beta.clinicaltrials.gov/study/NCT02019927,COMPLETED,Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)|Trauma|Multiple Sclerosis (MS),DEVICE: Transcorneal Electrical Stimulation|DEVICE: Sham,Wills Eye,United States Department of Defense,ALL,"ADULT, OLDER_ADULT",NA,97,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2013-07,2017-09,2017-09,"Wills Eye Hospital, Philadelphia, Pennsylvania, 19107, United States"
NCT01134627,Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS],https://beta.clinicaltrials.gov/study/NCT01134627,TERMINATED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Minocycline|DRUG: Placebo,"Merck KGaA, Darmstadt, Germany",,ALL,ADULT,PHASE2,305,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2006-02,2011-04,2011-04,"Scleroseklinikken afsnit 2082, Copenhagen, 2100, Denmark"
NCT04304027,Exercise to Manage Fatigue in Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04304027,UNKNOWN,Multiple Sclerosis,OTHER: Tailored exercise intervention|OTHER: Standard exercise intervention,Glasgow Caledonian University,,ALL,"ADULT, OLDER_ADULT",NA,45,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2019-12-10,2020-06,2020-06,"Falkirk Community Hospital, Falkirk, FK1 5QE, United Kingdom"
NCT05269004,A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05269004,RECRUITING,Multiple Sclerosis,DRUG: Ocrelizumab,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE3,1300,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-05-03,2025-12-31,2025-12-31,"Barrow Neurological Institute, Phoenix, Arizona, 85013, United States|Arizona Neuroscience Research LLC, Phoenix, Arizona, 85032-2181, United States|MS Center of California, Laguna Hills, California, 92653, United States|Collaborative Neuroscience Research, LLC, Long Beach, California, 90806, United States|SC3 Research Group, Inc, Pasadena, California, 91105, United States|University of California San Francisco, San Francisco, California, 94117, United States|Advanced Neurosciences Research LLC, Fort Collins, Colorado, 80528, United States|University of Miami, Miami, Florida, 33136, United States|Neurological Services of Orlando, Orlando, Florida, 32806, United States|University of South Florida, Tampa, Florida, 33612, United States|Vero Beach Neurology and Research Institute, Vero Beach, Florida, 32960, United States|Atlanta Neuroscience Institute, Atlanta, Georgia, 30327, United States|Northwestern University, Chicago, Illinois, 60611-2987, United States|Indiana Univ School of Med, Indianapolis, Indiana, 46202, United States|Kansas University Medical Center, Kansas City, Kansas, 66103, United States|Wayne State University, Detroit, Michigan, 48201, United States|Henry Ford Hospital, Detroit, Michigan, 48202, United States|Michigan Institute for Neurological Disorders, Farmington Hills, Michigan, 48334, United States|Washington University, Saint Louis, Missouri, 63128, United States|Rutgers New Jersey Medical School Department of Neurology, Newark, New Jersey, 07103, United States|Holy Name Hospital, Teaneck, New Jersey, 07666, United States|University of New Mexico, Albuquerque, New Mexico, 87131, United States|Mount Sinai School of Medicine, New York, New York, 10029, United States|South Shore Neurologic Associates PC, Patchogue, New York, 11772, United States|SUNY at Stony Brook, Stony Brook, New York, 11790, United States|The Neurological Institute PA, Charlotte, North Carolina, 28204, United States|Atrium Health, Charlotte, North Carolina, 28209, United States|Neurology Associates PA, Hickory, North Carolina, 28602, United States|Raleigh Neurology Associates, Raleigh, North Carolina, 27607-6520, United States|Columbus Neuroscience, Columbus, Ohio, 43801, United States|Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, 73104, United States|Providence Neurological Specialties, Portland, Oregon, 97225, United States|Abington Neurological Associates, Abington, Pennsylvania, 19001, United States|Rhode Island Hospital, Providence, Rhode Island, 02903, United States|Neurology Clinic PC, Cordova, Tennessee, 38018, United States|Sibyl Wray MD Neurology PC, Knoxville, Tennessee, 37934, United States|Baylor College of Medicine, Houston, Texas, 77030, United States|Uni of Texas Health Science Center At Houston, Houston, Texas, 77030, United States|Bhupesh Dihenia M.D. P.A., Lubbock, Texas, 79410, United States|Central Texas Neurology Consultants, Round Rock, Texas, 78681, United States|Neurology Center of San Antonio, San Antonio, Texas, 78258, United States|University of Vermont Medical Center; Neurology, Burlington, Vermont, 05405, United States|Swedish Neuroscience Institute, Seattle, Washington, 98122, United States|MultiCare Health System Institute for Research and Innovation, Tacoma, Washington, 98405, United States|Hospital Español, Ciudad Autonoma Bs As, C1209AAB, Argentina|Fundacion Rosarina de Neurorehabilitacion, Rosario, S2000BZL, Argentina|Royal North Shore Hospital, St. Leonards, New South Wales, 2065, Australia|St Vincent's Hospital Melbourne, Fitzroy, Victoria, 3065, Australia|Medizinische Universität Innsbruck, Innsbruck, 6020, Austria|Barmherzige Brueder Konventspital, Linz, 4040, Austria|Grodno University Hospital, Grodno, Brestskaya Voblasts', 230017, Belarus|Vitebsk Regional Clinical Hospital, Vitebsk, Vitsyebskaya Voblasts', 210037, Belarus|State Institution Minsk Research and Practice Center of Surgery Transplantation and Hematology, Minsk, 2200045, Belarus|AZ Delta Campus Westlaan, Roeselare, 8800, Belgium|Sijsele ALMA Elisabeth ziekenhuis, Sijsele-Damme, 8340, Belgium|Clinica Neurológica e Neurocirúrgica de Joinville, Joinville, AP, 89202-165, Brazil|HUCFF-UFRJ - Hospital Universitário Clementino Fraga Filho Universidade Federal do Rio de Janeiro, Rio de Janeiro, BA, 21941-913, Brazil|IMV Pesquisa Neurologica Sociedade Simples Ltda, Porto Alegre, RJ, 90110-000, Brazil|Hospital Universitario Gaffree e Guinle; Neurologia, Rio de Janeiro, RJ, 20270-004, Brazil|Hospital Sao Lucas da PUCRS*X, Porto Alegre, RS, 90610-000, Brazil|HC-UFG - Hospital das Clínicas da Universidade Federal de Goiás, Campinas, SP, 13083-888, Brazil|Hospital das Clínicas da Faculdade de Medicina da UNICAMP, Campinas, SP, 13083-888, Brazil|MHAT Avis Medica OOD Department of Neurology, Pleven, 5800, Bulgaria|University First MHAT-Sofia St. Joan Krastitel EAD, Sofia, 1142, Bulgaria|National Heart Hospital EAD, Sofia, 1309, Bulgaria|Acibadem City Clinic Tokuda Hospital Ead, Sofia, 1407, Bulgaria|Military Medical Academy MHAT Sofia Department of Rheumatology; Department of Rheumatology, Sofia, 1606, Bulgaria|Calgary MS Clinic, Calgary, Alberta, T2N 2T9, Canada|University of Alberta; Northern Alberta Trials & Research Centre, Edmonton, Alberta, T6G 2C8, Canada|UBC Multiple Sclerosis & Neuromyelitis Optica NMO Clinical Trials, Vancouver, British Columbia, V6T 2B5, Canada|The Ottawa Hospital - General Campus, Ottawa, Ontario, K1H 8L6, Canada|St Michael Hospital; Hematology and Oncology, Toronto, Ontario, M5B 1W8, Canada|Clinique Neuro Outaouais, Gatineau, Quebec, J8Y 1W2, Canada|Recherche Sepmus Inc., Greenfield Park, Quebec, J4V 2J2, Canada|Montreal Neurological Institute and Hospital; Pharmacy Department, Montreal, Quebec, H3A 2B4, Canada|General Hospital Varazdin, Varazdin, 42000, Croatia|University Hospital Center Zagreb, Zagreb, 10000, Croatia|Fakultni nemocnice Brno, Brno, 613 00, Czechia|Fakultni nemocnice u sv. Anny v Brne, Brno, 656 91, Czechia|Neurospol s.r.o., Havirov, 736 00, Czechia|Fakultni nemocnice Hradec Kralove, Hradec Kralove, 500 05, Czechia|Nemocnice Jihlava, Jihlava, 586 33, Czechia|Pardubicka krajska nemocnice a.s., Pardubice, 532 03, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, 128 08, Czechia|Krajska zdravotni a.s. - Nemocnice Teplice o.z., Teplice, 415 29, Czechia|West Tallinn Central Hospital, Tallinn, 10617, Estonia|Tartu University Hospital, Tartu, 51014, Estonia|Tammer Tutka Oy, Tampere, 33200, Finland|Groupe Hospitalier Pellegrin, Bordeaux, 33000, France|Hopital Neurologique Pierre Wertheimer, Bron, 69500, France|CHU de Caen Hopital Cote de Nacre, Caen, 14033, France|CHU Hopital Gabriel Montpied, Clermont Ferrand, 63003, France|Hopital Roger Salengro Service de Neurologie, Lille, France|CHU Nancy Hôpital Central, Nancy, 54035, France|CHU Nantes Hopital Nord Laënnec; Pharmacy, Nantes, 44093, France|CHU Nice - Hôpital Pasteur 2, Nice, 06000, France|Centre Hospitalier Intercommunal de Poissy, Poissy, 78300, France|CHU Strasbourg Hôpital Hautepierre, Strasbourg, 67098, France|Charité Universitaetsmedizin Berlin - Campus Ch, Berlin, 10117, Germany|Neurologie in Bonn, Bonn, 53111, Germany|Universitaetsklinikum Carl Gustav Carus TU Dresden, Dresden, 01307, Germany|Universitaetsklinikum Duesseldorf, Dusseldorf, 40225, Germany|Zentrum fuer ambulante Neurologie, Essen, 45138, Germany|Klinikum der Johann Wolfgang Goethe-Universitaet, Frankfurt, 60590, Germany|Universitaetsklinikum Giessen und Marburg GmbH; Zytostatikaabteilung, Gießen, 35392, Germany|Universitaetsklinikum Leipzig, Leipzig, 04103, Germany|Universitaetsklinikum Muenster, Muenster, 48149, Germany|Neurozentrum Prien, Prien, 83209, Germany|Medizinische Einrichtungen des Bezirks Oberpfalz GmbH, Regensburg, 93053, Germany|NeuroPoint Gesellschaft fur vorbeugende Gesundheitspflege mbH, Ulm, 89073, Germany|Universitätsklinikum Ulm; Klinik für Neurologie, Ulm, 89081, Germany|Jahn Ferenc Del-Pesti Korhaz es Rendelointezet, Budapest, 1204, Hungary|Pecsi Tudomanyegyetem, Pecs, 7624, Hungary|Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont, Szeged, 6720, Hungary|Hadassah University Hospital - Ein Kerem, Jerusalem, 9112001, Israel|Rabin Medical Center Beilinson Campus; Gaucher Clinic Genetics Institute, Petach Tiqwa, 49100, Israel|Chaim Sheba Medical Center, Ramat Gan, 5266202, Israel|Chaim Sheba Medical Center; Neurology Department, Ramat-Gan, 5262000, Israel|Tel Aviv Sourasky Medical Center; Department of Neurology, Tel Aviv, 6423906, Israel|Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Roma, Lazio, 00133, Italy|Azienda Ospedaliera Sant'Andrea-Universitr di Roma La Sapien, Roma, Lazio, 189, Italy|Ospedale Policlinico San Martino, Genova, Liguria, 16132, Italy|Hospital San Raffaele, Milano, Lombardia, 20132, Italy|Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Lombardia, 20133, Italy|Azienda Ospedaliero Universitaria Ospedali Riuniti, Torrette Di Ancona, Marche, 60126, Italy|Fondazione Istituto G. Giglio di Cefalu, Cefalù, Sicilia, 90015, Italy|Azienda Socio Sanitaria Territoriale della Valle Olona (pres, Gallarate, Valle D?Aosta, 21013, Italy|Pauls Stradins Clinical University Hospital, R?ga, LV-1002, Latvia|Maritime Medicine Centre of Latvia Hospital of Vecmilgravis Department of Neurology, Riga, 1015, Latvia|Hospital of Lithuanian University of Health Sciences Kaunas Clinics Public Institution, Kaunas, 50009, Lithuania|Klaipeda University Hospital Public Institution, Klaipeda, 92288, Lithuania|Vilnius University Hospital Santaros Klinikos, Vilnius, 8406, Lithuania|Mexico Centre for Clinical Research, Ciudad de México, Mexico CITY (federal District), 03100, Mexico|Grupo Medico Camino, DF, Mexico CITY (federal District), Mexico|Hospital Mexico Americano, Guadalajara, Mexico CITY (federal District), 44610, Mexico|Clinical Research Institute, Tlalnepantla de Baz, Mexico CITY (federal District), 54055, Mexico|Hospital Universitario Dr Jose Eleuterio Gonzalez; Universidad Autónoma de Nuevo León, Monterrey, Nuevo LEON, 64460, Mexico|Centro de Estudios Clinicos y Especialidades Medicas S C, Monterrey, Nuevo LEON, 64620, Mexico|Hospital Angeles Culiacan, Culiacan, Sinaloa, 80020, Mexico|Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V. Aguascalientes, Aguascalientes, 20010, Mexico|Hospital Angeles Chihuahua, Chihuahua, 31238, Mexico|Haukeland Universitetssykehus, Bergen, 5053, Norway|NZOZ Vitamed, Bydgoszcz, 85-079, Poland|COPERNICUS Podmiot Leczniczy Sp z o o, Gda?sk, 80-803, Poland|M.A. LEK A.M.Maciejowscy SC., Katowice, 40-571, Poland|Specjal. Praktyka Lekarska; Prof. Grzegorz Opala, Katowice, 40-588, Poland|Zaklad Opieki Zdrowotnej w Konskich; Dzia Neurologiczny, Konskie, 26-200, Poland|Centrum Neurologii Klinicznej, Krakow, 31-505, Poland|Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie, Lublin, 20-954, Poland|Neuro-Care Gabriela Klodowska, Siemianowice ?l?skie, 41-100, Poland|Centrum Medyczne NeuroProtect, Warszawa, 01-684, Poland|Hospital Garcia de Orta; Servico de Neurologia, Almada, 2801-951, Portugal|Hospital de Braga, Braga, 4710-243, Portugal|Spitalul Universitar de Urgenta Elias; Oncologie Medicala, Bucuresti, 011461, Romania|Siberian Medical Center, Barnaul, Altaj, 656043, Russian Federation|SBIH of Republic Mordoviya ""Republican Clinical Hospital # 4"", Saransk, Mordovija, 430032, Russian Federation|FGBU FNKC FMBA of Russia, Moskva, Moskovskaja Oblast, 115682, Russian Federation|SBIH City Polyclinic 2 of the Department of Health of the City of Moscow, Moskva, Moskovskaja Oblast, 129128, Russian Federation|FSBMEI HPE ""Military Medical Academy n.a. S.M. Kirov"" of the MoD of the RF, Sankt-peterburg, Sankt Petersburg, 194044, Russian Federation|SPb SBIH ""City Multy-field Hospital # 2""; Intensive Pulmonology and Thoracal Surgery, Sankt-peterburg, Sankt Petersburg, 194354, Russian Federation|Sverdlovsk Regional Clinical Hospital 1, Yekaterinburg, Sverdlovsk, 620102, Russian Federation|SAHI ""Interregional Clinical and Diagnostic Center"", Kazan, Vologda, 420101, Russian Federation|Kirov RSBIH ""Kirov City Clinical Hospital # 1"", Kirov, 610014, Russian Federation|RSBIH ""Smolensk Regional Clinical Hospital"", Smolensk, 214018, Russian Federation|Clinical Center Kragujevac, Kragujevac, 34000, Serbia|Clinical Center Nis, NIS, 18000, Serbia|MUDr. Beata Dupejova Neurologicka ambulancia s.r.o, Banska Bystrica, 974 04, Slovakia|Univerzitna nemocnica Bratislava Nemocnica Ruzinov, Bratislava, 826 06, Slovakia|Fakultna nemocnica s poliklinikou Zilina, Zilina, 012 07, Slovakia|Complejo Hospitalario Universitario de Santiago (CHUS) Servicio de Neurologia, Santiago de Compostela, LA Coruña, 15706, Spain|Hospital Universitario Virgen Macarena, Seville, Sevilla, 41071, Spain|Hospital de Basurto Servicio de Neurologia, Bilbao, Vizcaya, 48013, Spain|Hospital Vall d'Hebron; Servicio de Neurología, Barcelona, 08035, Spain|Hospital Universitario de la Princesa; Servicio de Neurologia, Madrid, 28006, Spain|Hospital Universitario Ramon y Cajal, Madrid, 28034, Spain|Hospital Regional Universitario de Malaga, Malaga, 29010, Spain|Karolinska Universitetssjukhuset Solna Neurology, Stockholm, 113 41, Sweden|Universitaetsspital Basel, Basel, 4031, Switzerland|Ospedale Regionale di Lugano, Lugano, 6900, Switzerland|Hopital Razi, Mannouba, 2010, Tunisia|Hopital Universitaire Fattouma Bourguiba, Monastir, 5000, Tunisia|Istanbul University Cerrahpasa Medical Faculty, Istanbul, 34000, Turkey|Ondokuz Mayis Univ. Med. Fac.; Neurology, Samsun, 55139, Turkey|Institute of Neurology Psychiatry and Narcology of NAMS of Ukraine, Kharkiv, Kharkiv Governorate, 61068, Ukraine|Communal noncommercial enterprise of Lviv Regional Council Lviv Regional Clinical Hospital, Lviv, Kharkiv Governorate, 79010, Ukraine|CMPI Chernihiv Regional Hospital; Reg.Cen.for Inflam.&demyelin.dis.of the CNS, Chernihiv, KIEV Governorate, 14029, Ukraine|CE I.I.Mechnykov Dnipropetrovsk RC Hosp Dept of Neurology DSMU, Dnipro, KIEV Governorate, 49005, Ukraine|SI USSRI of Medical and Social Problems of Disabilities of MOHU, Dnipro, KIEV Governorate, 49027, Ukraine|CNE Odesa Regional Clinical Hospital of Odesa Regional Council, Odesa, KIEV Governorate, 65025, Ukraine|Royal Victoria Infirmary, Newcastle upon Tyne, NE1 4LP, United Kingdom|Morriston Hospital, Swansea, SA6 6NL, United Kingdom"
NCT01080027,"Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)",https://beta.clinicaltrials.gov/study/NCT01080027,COMPLETED,"Multiple Sclerosis, Relapsing Remitting",DRUG: Rebif® New Formulation,"Merck KGaA, Darmstadt, Germany","Merck A.E., Greece|Merck OY, Finland|Merck B.V., Netherlands|Merck A.B., Sweden|Merck, S.A., Portugal",ALL,ADULT,,254,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2008-10,2011-06,2011-06,"Neurology Clinic, General Hospital of Thessaloniki ""G. Papanikolaou"", Thessaloniki, 57010, Greece"
NCT04577404,Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS),https://beta.clinicaltrials.gov/study/NCT04577404,ACTIVE_NOT_RECRUITING,Amyotrophic Lateral Sclerosis (ALS),DRUG: MT-1186,Mitsubishi Tanabe Pharma America Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE3,140,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-10-29,2023-09,2023-09,"St. Joseph's Hospital and Medical Center (SJHMC) - Barrow Neurological Institute (BNI) - The Gregory W. Fulton ALS and Neuromuscular Disease Center, Phoenix, Arizona, 85013, United States|Neuromuscular Research Center, Phoenix, Arizona, 85028, United States|Woodland Research Northwest, Rogers, Arkansas, 72758, United States|University of Colorado Anschutz Medical Campus, Aurora, Colorado, 80045, United States|UF Health Cancer Center, Gainesville, Florida, 32610-3633, United States|Emory University - School of Medicine, Atlanta, Georgia, 30317-2819, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, 21287, United States|Neurology Associates, P.C - Lincoln, Lincoln, Nebraska, 68506-2960, United States|Wake Forest University Baptist Medical Center (WFUBMC) - The J. Paul Sticht Center on Aging and Rehabilitation, Winston-Salem, North Carolina, 27157-0001, United States|Penn State Hershey Children's Hospital, Hershey, Pennsylvania, 17025, United States|Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, 19140, United States|Alleghany General Hospital, Pittsburgh, Pennsylvania, 15212, United States|Wesley Neurology Clinic, P.C., Cordova, Tennessee, 38018, United States|Texas Neurology, PA, Dallas, Texas, 75214, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States|Heritage Medical Research Clinic - University Of Calgary, Calgary, Alberta, T2N 4Z6, Canada|University of Alberta - Walter C Mackenzie Health Sciences Centre (WCM), Edmonton, Alberta, T6G 2B7, Canada|Recherche Sepmus, Inc., Greenfield Park, Quebec, J4V 2J2, Canada|Montreal Neurological Institute and Hospital, Montreal, Quebec, H3A 2B4, Canada|CHU-Nice - Hopital Pasteur 2, Nice, Cedex 1, 06001, France|Centre Hospitalier Esquirol, Limoges, Marcland, 87025, France|Centre Hospitalier Universitaire (CHU) de Bordeaux, Bordeaux, 33400, France|Hopital Pierre Wertheimer - Hopital Neurologique, Paris, 75013, France|Deutsche Klinik fuer Diagnostik, Wiesbaden, Hessen, 65191, Germany|Medizinische Hochschule Hannover, Hannover, Lower Saxony, 30625, Germany|Ospedale San Raffaele (HSR) (Istituto Scientifico Universitario San Raffaele), Milano, Lombardia, 20132, Italy|Universita degli Studi di Torino - Centro Regionale Esperto Per La Sclerosi Laterale Amiotrofica (CRESLA), Turin, Piemonte, 10126, Italy|Fondazione Serena Onlus - Azienda Ospedaliera Niguarda Ca Granda - Centro Clinico Nemo (Neuro Muscular Omnicentre), Milan, 20162, Italy|Aichi Medical University Hospital, Nagakute-shi,, Aichi, 480-1195, Japan|National Hospital Organization Chibahigashi National Hospital, Chiba-shi, Chiba, 260-8712, Japan|Murakami Karindoh Hospital, Fukuoka-city, Fukuoka, 819-8585, Japan|Fukushima Medical University Hospital, Fukushima-shi, Fukushima, 960-1295, Japan|National Hospital Organization Hokkaido Medical Center, Sapporo-shi, Hokkaido, 063-0005, Japan|National Hospital Organization Iou National Hospital, Kanazawa-shi, Ishikawa, 920-0192, Japan|Kagawa University Hospital, Kita-gun, Kagawa, 761-0793, Japan|Kitasato University Hospital, Sagamihara-city, Kanagawa, 252-0375, Japan|Yokohama City University Hospital, Yokohama-shi, Kanagawa, 236-0004, Japan|National Hospital Organization Kumamoto Saishun Medical Center, Koshi-shi, Kumamoto, 861-1196, Japan|Tohoku University Hospital, Sendai-city, Miyagi, 980-8574, Japan|Niigata University Medical And Dental Hospital, Niigata-shi, Niigata, 951-8520, Japan|Kansai Electric Power Hospital Recruiting, Fukushima-ku, Osaka-shi, Osaka, 553-0003, Japan|National Hospital Organization Toneyama Medical Center, Toyonaka-shi, Osaka, 560-8552, Japan|Shiga University of Medical Science Hospital, Otsu-shi, Shiga, 520-2192, Japan|National Hospital Organization Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka-city, Shizuoka, 420-8688, Japan|Juntendo University Hospital, Bunkyo-ku, Tokyo, 113-8431, Japan|Tokyo Metropolitan Neurological Hospital, Fuchu-city, Tokyo, 183-0042, Japan|Toho University Omori Medical Center, Ota-ku, Tokyo, 143-8541, Japan"
NCT05391906,Intravoxel Incoherent Motion (IVIM) Magnetic Resonance Imaging in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05391906,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,OTHER: Diffusion-weighted magnetic resonance imaging,Chinese University of Hong Kong,,ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-01-30,2023-12-20,2023-12-30,"CUHK, Hong Kong, Hong Kong"
NCT02587806,A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS,https://beta.clinicaltrials.gov/study/NCT02587806,UNKNOWN,"Multiple Sclerosis, Relapsing-Remitting",BIOLOGICAL: Autologous Bone Marrow-Derived Mononuclear Stem Cells|OTHER: Liberation therapy,Novo Cellular Medicine Institute LLP,,ALL,ADULT,PHASE1|PHASE2,69,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-02,2017-02,2017-02,"Inamdar Multispecialty Hospital, Pune, Maharashtra, 411040, India|Novo Cellular Medicine Institute, San Fernando, Trinidad, Trinidad and Tobago"
NCT01202227,An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain,https://beta.clinicaltrials.gov/study/NCT01202227,COMPLETED,Spinal Cord Diseases|Spinal Cord Injuries|Neuralgia|Pain,DRUG: pregabalin,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE3,104,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2010-09,2012-03,2012-03,"Chubu Rosai Hospital, Nagoya, Aichi, Japan|Kimura Clinic, Nagoya, Aichi, Japan|Nagoya Kyoritsu Clinic, Nagoya, Aichi, Japan|Senboku Kumiai General Hospital, Daisen, Akita, Japan|Go neurosurgical clinic, Chikushi-gun, Fukuoka, Japan|Spinal Injuries Center, Iizuka, Fukuoka, Japan|Brain Attack Center Ota Memorial Hospital, Fukuyama, Hiroshima, Japan|Hokkaido Chuo Rosai Hospital Sekison Center, Bibai, Hokkaido, Japan|Hakodate Central General Hospital, Hakodate, Hokkaido, Japan|Kobe Tokushukai Hospital, Kobe, Hyogo, Japan|Aida Kinen Rehabilitation Hospital, Moriya, Ibaraki, Japan|General Hanamaki Hospital, Hanamaki, Iwate, Japan|Uchida Rehabilitation Orthopedic Clinic, Kawasaki, Kanagawa, Japan|Kumamoto Rehabilitation Hospital, Kikuchi-gun, Kumamoto, Japan|Sendai Pain Clinic, Sendai-city, Miyagi, Japan|Kohnan Hospital, Sendai, Miyagi, Japan|National Hospital Organization Niigata National Hospital, Kashiwazaki, Niigata, Japan|Nakamura Hospital, Beppu, Oita, Japan|Kitasato University Kitasato Institute Medical Center Hospital, Kitamoto, Saitama, Japan|Kamitsuga General Hospital, Kanuma, Tochigi, Japan|Juntendo University Hospital, Bunkyo-ku, Tokyo, Japan|Jukoukai hospital, Koto-ku, Tokyo, Japan|National Hospital Organization, Murayama Medical Center, Musashimurayama-shi, Tokyo, Japan|Okitama Public General Hospital, Higashiokitama-gun, Yamagata, Japan|Tokushima University Hospital, Tokushima, Japan|National Hospital Organization Yamagata Hospital, Yamagata, Japan"
NCT03751306,Aerobic Exercise and Transcranial Low Laser Therapy in Patients With Central Nervous System Injury,https://beta.clinicaltrials.gov/study/NCT03751306,UNKNOWN,"Post Stroke|Post-Traumatic Headache|Spinal Injuries|Cerebral Palsy, Spastic|Surgery|Sclerosis, Multiple|Spastic",PROCEDURE: Transcranial Photobiomodulation|PROCEDURE: Transcranial Photobiomodulation (Placebo)|PROCEDURE: Cardiorespiratory Rehabilitation,Universidade do Vale do Paraíba,,ALL,"ADULT, OLDER_ADULT",NA,90,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-01-14,2019-07-31,2020-03-05,"Universidade do Vale do Paraíba, São José Dos Campos, São Paulo, 12244-000, Brazil"
NCT01956227,Fall Risk Reduction in Multiple Sclerosis: Exercise Versus Behavior,https://beta.clinicaltrials.gov/study/NCT01956227,COMPLETED,Multiple Sclerosis|Adult Disease,BEHAVIORAL: Home-based exercise|BEHAVIORAL: Education|BEHAVIORAL: Exercise plus Education,University of Illinois at Urbana-Champaign,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,37,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2013-04,2014-09,2014-09,"University of Illinois UC, Urbana, Illinois, 61802, United States"
NCT03000127,Testosterone for Fatigue in Men With MS,https://beta.clinicaltrials.gov/study/NCT03000127,WITHDRAWN,Multiple Sclerosis,DRUG: AndroGel 1 % Topical Gel|DRUG: Placebos,"University of California, Los Angeles",Washington University School of Medicine,MALE,ADULT,PHASE2,0,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-07-01,2023-06-30,2024-01-01,"University of California, Los Angeles, Los Angeles, California, 90095, United States|Washington University, Saint Louis, Missouri, 63110, United States"
NCT00618527,Combination Therapy Using Cellcept and Rebif in RRMS,https://beta.clinicaltrials.gov/study/NCT00618527,COMPLETED,Multiple Sclerosis,DRUG: mycophenolate mofetil (Cellcept)|DRUG: human interferon beta 1a (Rebif),Aaron Boster,EMD Serono|Pfizer,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,31,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2006-08,2012-05,2012-05,"The Ohio State University Multiple Sclerosis Center, Columbus, Ohio, 43221, United States"
NCT01116427,A Cooperative Clinical Study of Abatacept in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01116427,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",BIOLOGICAL: abatacept|DRUG: Placebo,National Institute of Allergy and Infectious Diseases (NIAID),Immune Tolerance Network (ITN),ALL,"ADULT, OLDER_ADULT",PHASE2,65,NIH,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2010-09,2014-06,2015-02,"St. Josephs Hospital and Medical Center - Barrow Neurology, Phonix, Arizona, 85013, United States|Jordan Research and Education Institute (REDI): Alta Bates Summit Medical Center, Berkeley, California, 94705, United States|University of Southern California - Keck School of Medicine, Los Angeles, California, 90033, United States|Newport Beach Clinical Research Associates, Inc., Newport Beach, California, 92663, United States|University of California, Davis, Sacramento, California, 95817, United States|University of Miami, Miami, Florida, 33136, United States|South Suburban Neurology, Flossmoor, Illinois, 60422, United States|Norton Neuroscience Institute - Norton Neurology Services MS Center, Louisville, Kentucky, 40207, United States|Louisiana State University, Shreveport, Louisiana, 71130, United States|University of Maryland, Baltimore, Maryland, 21201, United States|Brigham & Women's Hospital, Boston, Massachusetts, 02115, United States|University of Minnesota, Minneapolis, Minnesota, 55414, United States|Judith Jaffe Multiple Sclerosis Center: Weill Cornell Medical College, New York, New York, 10065, United States|University of North Carolina, Chapel Hill, North Carolina, 27514, United States|Neurology Specialists, Inc., Dayton, Ohio, 45417, United States|Providence St. Vincent Medical Center, Portland, Oregon, 97225, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|The Neurology Foundation, Inc., Providence, Rhode Island, 02905, United States|Advanced Neurosciences Institute, Franklin, Tennessee, 37064, United States|Benaroya Research Institute at Virginia Mason, Seattle, Washington, 98101, United States|Ottawa Hospital Research Institute, Ottawa, Ontario, K1H 8L6, Canada"
NCT02673827,"Progressive Muscle Relaxation Effect on Sleep Quality, Depression and Stress in People With Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT02673827,COMPLETED,Multiple Sclerosis|Depression|Sleep|Stress Psychological,OTHER: Progressive muscle relaxation,Federal University of Espirito Santo,,ALL,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2014-04,2014-10,2015-07,
NCT01848327,Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01848327,COMPLETED,Relapsing Remitting MS|Secondary Progressive MS|Primary Progressive MS,DIETARY_SUPPLEMENT: Caprylic Triglyceride|DIETARY_SUPPLEMENT: Placebo,University of Miami,National Multiple Sclerosis Society|Cerecin,ALL,ADULT,NA,124,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-02,2017-12,2017-12,"University of Miami Miller School of Medicine, Miami, Florida, 33136, United States"
NCT02947906,Plantar Pressure Distribution in Patient With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02947906,UNKNOWN,Multiple Sclerosis,OTHER: No intervention,Hacettepe University,,ALL,ADULT,,70,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-10,2016-11,2016-11,
NCT04660227,Exercise Training in Pediatric-Onset Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT04660227,RECRUITING,Pediatric Multiple Sclerosis,PROCEDURE: Exercise Trainning|OTHER: Control Group,Istanbul University - Cerrahpasa (IUC),,ALL,"CHILD, ADULT",NA,20,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2020-11-23,2021-11,2022-01,"Istanbul University-Cerrahpasa, Bakırkoy, Istanbul, 34100, Turkey"
NCT03656627,Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease,https://beta.clinicaltrials.gov/study/NCT03656627,TERMINATED,Autoimmune Diseases|Non-small Cell Lung Cancer|Rheumatoid Arthritis|Psoriasis|Giant Cell Arteritis|Polymyalgia Rheumatica|Systemic Lupus Erythematosus|Crohn Disease|Multiple Sclerosis|Ulcerative Colitis,DRUG: Nivolumab,"Alliance Foundation Trials, LLC.",Bristol-Myers Squibb,ALL,"ADULT, OLDER_ADULT",PHASE1,7,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2019-06-27,2021-03-18,2021-03-18,"University of Chicago Medical Center, Chicago, Illinois, 60637, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|St. Joseph Mercy Hospital, Ann Arbor, Michigan, 48106, United States|Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, 55416, United States|Dartmouth Hitchcock Norris Cotton Cancer Center, Lebanon, New Hampshire, 03756, United States|The Ohio State University Wexner Medical Center - Thoracic Oncology Clinic, Columbus, Ohio, 43210, United States|Providence Cancer Institute Franz Clinic, Portland, Oregon, 97213, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, 15232, United States|University of Wisconsin Clinical Science Center, Madison, Wisconsin, 53792, United States"
NCT00220506,Fatigue Treatment Using Provigil,https://beta.clinicaltrials.gov/study/NCT00220506,UNKNOWN,All Multiple Sclerosis Patients,DRUG: Provigil,Sheba Medical Center,,ALL,ADULT,NA,50,OTHER_GOV,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2005-09,,2006-12,"Multiple Sclerosis Center, Tel Hashomer, Israel"
NCT02369926,Endpoint Calibration for a Phase 2 Study of Lisinopril in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02369926,UNKNOWN,"Multiple Sclerosis, Relapsing-Remitting",PROCEDURE: Multiple Sclerosis Functional Composite|PROCEDURE: Mobile Multiple Sclerosis Functional Composite,Transparency Life Sciences,,ALL,ADULT,PHASE2,20,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2014-11,2018-06,,"Icahn School of Medicine at Mount Sinai, New York, New York, 10029, United States"
NCT05571826,Effectiveness of Telerehabilitation Interventions in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05571826,RECRUITING,Multiple Sclerosis,BEHAVIORAL: telerehabilitation,Dokuz Eylul University,,ALL,"ADULT, OLDER_ADULT",,30,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-10-01,2023-10-01,2023-11-01,"Dokuz Eylul University, İzmir, Turkey"
NCT02440126,Longitudinal Analysis And Sample Collection To Evaluate PML Risk Host Markers for PML Risk Host Markers for PML Risk,https://beta.clinicaltrials.gov/study/NCT02440126,COMPLETED,Multiple Sclerosis,,"Rocky Mountain MS Research Group, LLC",Biogen,ALL,"ADULT, OLDER_ADULT",,196,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-10,2017-03,2020-07,"Rocky Mountain MS Research Group, Salt Lake City, Utah, 84103, United States"
NCT05596526,Immunogenicity of the Recombinant Zoster Vaccine in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT05596526,NOT_YET_RECRUITING,Shingles|Zoster,BIOLOGICAL: recombinant zoster vaccine,Prof Patrice Lalive,,ALL,ADULT,PHASE4,100,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-11-01,2024-11-01,2024-11-01,"University Hospitals of Geneva, Geneva,, 1205, Switzerland"
NCT04004026,3 Meter Backwards Walk Test and Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04004026,COMPLETED,"Multiple Sclerosis|Walking, Difficulty|Balance; Distorted",OTHER: Assesment,Sanko University,,ALL,ADULT,,40,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-07-01,2020-04-15,2020-06-30,"SANKO University, Gaziantep, Şehitkamil, 27090, Turkey"
NCT00391079,Sativex Versus Placebo When Added to Existing Treatment for Central Neuropathic Pain in MS,https://beta.clinicaltrials.gov/study/NCT00391079,COMPLETED,Multiple Sclerosis,DRUG: Sativex|DRUG: Placebo,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,339,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2006-09,2008-04,2008-09,"Multiple Sclerosis Program, Foothills Hospital SSB, Calgary, Alberta, T2N 2T9, Canada|MS Clinic, UBC Purdy Pavilion, Vancouver, British Columbia, V6T 2B5, Canada|Dalhousie MS Research Clinic, Halifax, Nova Scotia, B3H 1V8, Canada|London Health Sciences Centre / University Hospital, London, Ontario, N6A 5A5, Canada|Ottawa Hospital General Campus, Ottawa, Ontario, K1H 8L6, Canada|Montreal Neurological Institute, Montreal, Quebec, H3 A 2B4, Canada"
NCT03401879,Retinal Neuro-vascular Coupling in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03401879,RECRUITING,"Multiple Sclerosis, Relapsing-Remitting|Optic Neuritis",DEVICE: Dynamic Vessel Analyzer (DVA)|DEVICE: Fourier Domain Doppler Optical Coherence Tomography (FDOCT)|DEVICE: Optical coherence tomography (OCT)|DEVICE: Optical coherence tomography angiography (OCTA),Medical University of Vienna,,ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2018-02-01,2023-03,2023-03,"Department of Clinical Pharmacology, Medical University of Vienna, Vienna, 1090, Austria"
NCT05415579,Demyelinating Diseases of the Central Nervous System Registry for Patients With Traditional Chinese Medicine (DATE-TCM),https://beta.clinicaltrials.gov/study/NCT05415579,NOT_YET_RECRUITING,Demyelinating Diseases of the Central Nervous System (DDC),OTHER: Traditional Chinese medicine (TCM),"Dongzhimen Hospital, Beijing",,ALL,"ADULT, OLDER_ADULT",,2000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-06-20,2029-10-31,2030-05-31,
NCT01285479,The Gilenya Pregnancy Registry,https://beta.clinicaltrials.gov/study/NCT01285479,RECRUITING,Multiple Sclerosis,DRUG: Fingolimod,Novartis Pharmaceuticals,,FEMALE,"CHILD, ADULT, OLDER_ADULT",,500,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-10-15,2031-01-02,2031-01-02,"Novartis Investigative Site, Fort Lauderdale, Florida, 33308, United States|Novartis Investigative Site, Cambridge, Massachusetts, 02139, United States|Novartis Investigative Site, Grand Forks, North Dakota, 58201, United States|Novartis Investigative Site, Bahía Blanca, Buenos Aires, 8000, Argentina|Novartis Investigative Site, Cordoba, X5000FAL, Argentina|Novartis Investigative Site, Box Hill, Victoria, 3128, Australia|Novartis Investigative Site, Graz, 8036, Austria|Novartis Investigative Site, Linz, 4020, Austria|Novartis Investigative Site, Brasschaat, 2930, Belgium|Novartis Investigative Site, Leuven, 3000, Belgium|Novartis Investigative Site, Melsbroek, 1820, Belgium|Novartis Investigative Site, Rio de Janeiro, RJ, 21941-913, Brazil|Novartis Investigative Site, Saint-Laurent, Quebec, H4M-2P4, Canada|Novartis Investigative Site, Bogotá, Colombia|Novartis Investigative Site, Nicosia, 1683, Cyprus|Novartis Investigative Site, Ostrava-Poruba, 708 52, Czechia|Novartis Investigative Site, Aalborg, 9000, Denmark|Novartis Investigative Site, Aarhus, 8000 C, Denmark|Novartis Investigative Site, Copenhagen, DK-2100, Denmark|Novartis Investigative Site, Soenderborg, 6400, Denmark|Novartis Investigative Site, Tampere, FIN-33521, Finland|Novartis Investigative Site, Turku, 20520, Finland|Novartis Investigative Site, Bron, 69677, France|Novartis Investigative Site, Cahors, 50269, France|Novartis Investigative Site, Bochum, 44791, Germany|Novartis Investigative Site, Athens, GR, 115 25, Greece|Novartis Investigative Site, Budapest, HUN, 1204, Hungary|Novartis Investigative Site, Gyor, H-9023, Hungary|Novartis Investigative Site, Dublin 4, D04 T6F, Ireland|Novartis Investigative Site, Jerusalem, 9112001, Israel|Novartis Investigative Site, Ramat Gan, 52621, Israel|Novartis Investigative Site, Catania, CT, 95123, Italy|Novartis Investigative Site, Firenze, FI, 50134, Italy|Novartis Investigative Site, Genova, GE, 16132, Italy|Novartis Investigative Site, Milano, MI, 20132, Italy|Novartis Investigative Site, Roma, RM, 189, Italy|Novartis Investigative Site, Orbassano, TO, 10043, Italy|Novartis Investigative Site, Beirut, 1107 2020, Lebanon|Novartis Investigative Site, Mexico, Distrito Federal, 05300, Mexico|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Bergen, 5021, Norway|Novartis Investigative Site, Lubin, 20-089, Poland|Novartis Investigative Site, Warszawa, 02-957, Poland|Novartis Investigative Site, Amadora, 2720-276, Portugal|Novartis Investigative Site, Porto, 4099-001, Portugal|Novartis Investigative Site, Bucharest, 050098, Romania|Novartis Investigative Site, Moscow, 127018, Russian Federation|Novartis Investigative Site, Riyadh, SAU, 11525, Saudi Arabia|Novartis Investigative Site, Jeddah, 21499, Saudi Arabia|Novartis Investigative Site, Riyadh, 11211, Saudi Arabia|Novartis Investigative Site, Bratislava, Slovak Republic, 811 07, Slovakia|Novartis Investigative Site, Maribor, 2000, Slovenia|Novartis Investigative Site, Sevilla, Andalucia, 41071, Spain|Novartis Investigative Site, Madrid, 28222, Spain|Novartis Investigative Site, Goeteborg, 413 45, Sweden|Novartis Investigative Site, Basel, 4031, Switzerland|Novartis Investigative Site, Bern, 3010, Switzerland|Novartis Investigative Site, Lausanne, 1011, Switzerland|Novartis Investigative Site, St Gallen, 9007, Switzerland|Novartis Investigative Site, Abu Dhabi, United Arab Emirates|Novartis Investigative Site, Dubai, United Arab Emirates|Novartis Investigative Site, Newcastle upon Tyne, NE1 4LP, United Kingdom|Novartis Investigative Site, Norwich, NR1 3SR, United Kingdom|Novartis Investigative Site, Nottingham, NG7 2UH, United Kingdom"
NCT04032171,Study of Evobrutinib in Participants With RMS,https://beta.clinicaltrials.gov/study/NCT04032171,TERMINATED,Relapsing-remitting Multiple Sclerosis,DRUG: Evobrutinib|DRUG: Avonex®|DRUG: Avonex® matched Placebo|DRUG: Evobrutinib matched Placebo,"EMD Serono Research & Development Institute, Inc.","Merck KGaA, Darmstadt, Germany",ALL,ADULT,PHASE3,1,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-09-10,2020-05-20,2020-05-20,"Please Contact U.S. Medical Information, Rockland, Massachusetts, 02370, United States|Please Contact the Communication Center, Darmstadt, 64293, Germany"
NCT05081271,COVID-19 Booster Vaccination in Persons With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05081271,TERMINATED,Multiple Sclerosis,BIOLOGICAL: Homologous booster|BIOLOGICAL: Heterologous booster,Griffin Hospital,Yale-Griffin Prevention Research Center|Multiple Sclerosis Treatment Center,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,10,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-10-15,2022-05-30,2022-05-30,"Griffin Hospital, Derby, Connecticut, 06418, United States"
NCT01755871,Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01755871,TERMINATED,Relapsing Remitting Multiple Sclerosis,DRUG: Fingolimod,"Heinrich-Heine University, Duesseldorf",Novartis Pharmaceuticals,ALL,"ADULT, OLDER_ADULT",PHASE4,8,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-01,2016-01,2016-02,"Heinrich Heine Universität Düsseldorf, Düsseldorf, Nord-Rhein Westfahlen, 40225, Germany"
NCT05234671,Exercise in People With Systemic Sclerosis,https://beta.clinicaltrials.gov/study/NCT05234671,RECRUITING,Systemic Sclerosis,OTHER: Exercise programme,Sheffield Hallam University,"Leiden University|Rikshospitalet University Hospital|Karolinska Institutet|Aristotle University Of Thessaloniki|University of Campania ""Luigi Vanvitelli""",ALL,"ADULT, OLDER_ADULT",NA,180,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2021-09-01,2023-09-30,2024-02-28,"Sheffield Hallam University, Sheffield, S10 2BP, United Kingdom"
NCT04533971,The Effect of a Series of Systemic Cryotherapy Treatments on the Functional State of Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04533971,COMPLETED,Multiple Sclerosis (ICD10-G35)|Surface Electromyography|Whole-body Cryotherapy,OTHER: Whole body cryotherapy,Pomeranian Medical University Szczecin,,ALL,"ADULT, OLDER_ADULT",NA,114,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2015-04-01,2019-12-20,2019-12-20,
NCT03319771,Exercise and Learning and Memory in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03319771,TERMINATED,Multiple Sclerosis|Physical Activity|Memory Impairment|Cognitive Change,BEHAVIORAL: Treadmill Walking Exercise Training|BEHAVIORAL: Stretching-and-toning Exercise Training,University of Alabama at Birmingham,EMD Serono,ALL,ADULT,NA,14,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2018-12-01,2020-03-16,2021-01-03,"University of Alabama at Birmingham, Birmingham, Alabama, 35294-0104, United States"
NCT01056471,Autologous Mesenchymal Stem Cells From Adipose Tissue in Patients With Secondary Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01056471,COMPLETED,"Autoimmune Diseases|Immune System Diseases|Demyelinating Diseases|Nervous System Diseases|Demyelinating Autoimmune Diseases, CNS|Autoimmune Diseases of the Nervous System",OTHER: Autologous mesenchymal stem cells from adipose tissue.|OTHER: Autologous mesenchymal stem cells from adipose tissue.,Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud,Carlos III Health Institute,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2010-01,2012-06,2015-06,"Hospital Regional Universitario de Málaga, Málaga, 29010, Spain|Hospital Universitario Virgen Macarena, Sevilla, 41004, Spain"
NCT04257071,Out of Pocket Cost Communication in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT04257071,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Usual Care|BEHAVIORAL: OOP Cost Communication and Optimization,Emory University,National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",NA,61,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2020-03-03,2021-12-31,2021-12-31,"Neurology Clinic, 12 Executive Park Drive, Atlanta, Georgia, 30329, United States"
NCT00337779,Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).,https://beta.clinicaltrials.gov/study/NCT00337779,COMPLETED,Relapsing Remitting Multiple Sclerosis,DRUG: Glatiramer Acetate (GA) 40 mg|DRUG: glatiramer acetate 20 mg,"Teva Branded Pharmaceutical Products R&D, Inc.",,ALL,ADULT,PHASE3,1155,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2006-08,2008-10,2008-10,
NCT01768039,Vitamine D in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01768039,UNKNOWN,Multiple Sclerosis,DRUG: Vitamin D|DRUG: Placebo,Mazandaran University of Medical Sciences,,ALL,ADULT,PHASE3,240,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2013-03,2014-08,2014-10,"Mazandaran University of medical sciences, Sari, Mazandaran, Iran, Islamic Republic of"
NCT03610139,Longitudinal Effect of Vitamin D3 Replacement on Cognitive Performance and MRI Markers in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT03610139,RECRUITING,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting|Clinically Isolated Syndrome|Clinically Isolated Syndrome, CNS Demyelinating|Vitamin D3 Deficiency",DIETARY_SUPPLEMENT: Vitamin D3,American University of Beirut Medical Center,,ALL,"ADULT, OLDER_ADULT",NA,162,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: OTHER,2018-05-21,2022-12-31,2022-12-31,"Nehme & Therese Tohme Multiple Sclerosis Center, Beirut, 1107 2020, Lebanon"
NCT04876339,Sonification Techniques for Gait Training,https://beta.clinicaltrials.gov/study/NCT04876339,RECRUITING,Parkinson Disease|Stroke|Multiple Sclerosis,"DEVICE: Gait rehabilitation with ""sonification""|OTHER: Standard gait rehabilitation (without sonification)",Istituti Clinici Scientifici Maugeri SpA,,ALL,"CHILD, ADULT, OLDER_ADULT",NA,120,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-01-18,2023-12-31,2024-06-30,"Istituti Clinici Scientifici Maugeri IRCCS, Pavia, 27100, Italy"
NCT01895439,Safety and Efficacy Study of Autologus Bone Marrow Mesenchymal Stem Cells in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01895439,COMPLETED,Multiple Sclerosis,BIOLOGICAL: Autologous Mesenchymal Stem Cells,University of Jordan,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,13,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2012-10,2016-02,2016-02,"Cell Therapy Center, Jordan University Hospital, Amman, 11942, Jordan"
NCT00744679,A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State,https://beta.clinicaltrials.gov/study/NCT00744679,COMPLETED,Multiple Sclerosis,DRUG: Natalizumab,Biogen,Elan Pharmaceuticals,ALL,ADULT,PHASE4,20,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2008-11,2008-12,2008-12,"Research Site, Latham, New York, United States"
NCT02939079,Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT02939079,COMPLETED,Multiple Sclerosis,DRUG: Fingolimod|DIETARY_SUPPLEMENT: Fish Oil|DRUG: Placebo (for Fish Oil),Isfahan University of Medical Sciences,Shiraz University of Medical Sciences,ALL,ADULT,PHASE2|PHASE3,50,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2015-04,2016-09,2016-10,
NCT02676739,Adderall XR and Cognitive Impairment in MS,https://beta.clinicaltrials.gov/study/NCT02676739,RECRUITING,Multiple Sclerosis,DRUG: Adderall XR,Sarah Morrow,,ALL,ADULT,PHASE2|PHASE3,180,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-05-20,2023-08,2023-12,"Kaye Edmonton Clinic, Edmonton, Alberta, T6G 2G3, Canada|London Health Sciences Centre, London, Ontario, N6A 5A5, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, M4N 3M5, Canada"
NCT03603691,Study to Evaluate the Reliability and Validity of the Modified Manual Muscle Test for Persons With MS,https://beta.clinicaltrials.gov/study/NCT03603691,COMPLETED,Multiple Sclerosis,DIAGNOSTIC_TEST: Modified Manual Muscle Test|DIAGNOSTIC_TEST: BMRC manual muscle test|DIAGNOSTIC_TEST: MicroFET2 handhold dynamometer|DIAGNOSTIC_TEST: Modified Tardieu Scale|DIAGNOSTIC_TEST: Fatigue Scale for Motor and Cognitive Functions|DIAGNOSTIC_TEST: numeric rating scale Fatigue,Nanco van der Maas,"University Hospital, Basel, Switzerland|Physiotherapie Langmatten Binningen, Switzerland|Clinical Trial Unit, University Hospital Basel, Switzerland",ALL,"ADULT, OLDER_ADULT",NA,28,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: DIAGNOSTIC,2018-08-01,2018-12-15,2019-01-29,"Felix Platter Hospital, Basel, 4055, Switzerland"
NCT05092191,Cannabis as a Complementary Treatment in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05092191,RECRUITING,Multiple Sclerosis,DRUG: Cannabis oil vs placebo,Centre hospitalier de l'Université de Montréal (CHUM),Canadian Institutes of Health Research (CIHR)|Multiple Sclerosis Society of Canada,ALL,"ADULT, OLDER_ADULT",PHASE2,250,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2022-11-10,2024-03-15,2025-03-15,"CRCHUM, Montreal, Quebec, H2X 0A9, Canada"
NCT03979391,Isoelectric Focusing of Tears in Children With Radiologically Isolated or Clinically Isolated Syndrome,https://beta.clinicaltrials.gov/study/NCT03979391,RECRUITING,Clinically Isolated Syndrome|Radiologically Isolated Syndrome|Multiple Sclerosis in Children,DIAGNOSTIC_TEST: Tear collection and lumbar punction,Lille Catholic University,,ALL,"CHILD, ADULT",NA,20,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2019-09-26,2022-09-26,2024-09-01,"GHICL, Lomme, 59462, France"
NCT04982991,Single Ascending Dose Study of SAR443820 in Healthy Adult Chinese and Japanese Female and Male Participants,https://beta.clinicaltrials.gov/study/NCT04982991,COMPLETED,Multiple Sclerosis Healthy Subjects,DRUG: RIPK1 inhibitor,Sanofi,,ALL,ADULT,PHASE1,14,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2021-08-05,2021-10-11,2021-10-11,"Investigational Site Number :8260001, Harrow, London, City Of, HA1 3UJ, United Kingdom"
NCT02966808,Retrospective Observational Study About Long-term Effect of Fampridine in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02966808,UNKNOWN,Multiple Sclerosis,BEHAVIORAL: cognitive and behavioural questionnaires,Hospital General Universitario Gregorio Marañon,,ALL,"ADULT, OLDER_ADULT",,50,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-12,2021-12,2021-12,"Hospital General Universitario Gregorio Marañón, Madrid, 28007, Spain"
NCT04860791,Validation of the French Adaptation of the MSWDQ-23 Questionnaire,https://beta.clinicaltrials.gov/study/NCT04860791,RECRUITING,Multiple Sclerosis,OTHER: questionnaires,Centre Hospitalier Universitaire de Nice,,ALL,"ADULT, OLDER_ADULT",,206,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-05-10,2022-05-01,2022-05-01,"Besancon University Hospital, Besançon, 25030, France|Bordeaux university hospital, Bordeaux, 33404, France|Caen university hospital, Caen, 14033, France|Clermont Ferrand university hospital, Clermont-Ferrand, 63003, France|Gonesse hospital, Gonesse, 95503, France|Libourne hospital, Libourne, 33505, France|Lille University Hospital, Lille, 59000, France|Groupement des Hôpitaux de l'Institut Catholique de Lille, Lomme, 59462, France|Lyon University Hospital, Lyon, 69229, France|Marseille University Hospital, Marseille, 13000, France|Nancy Hospital, Nancy, 54000, France|Nimes university hospital, Nîmes, 30029, France|APHP, Paris, 75651, France|Rouen univestity hospital, Rouen, 76000, France|Saint Etienne University Hospital, Saint-Étienne, 42055, France|Strasnourg university hospital, Strasbourg, 67000, France"
NCT04154579,"Arts & Health Education to Improve Health, Resilience, and Well-Being",https://beta.clinicaltrials.gov/study/NCT04154579,TERMINATED,Hypertension|Diabetes|Obesity|COPD|CHF|High Cholesterol|Asthma|Chronic Pain|Multiple Sclerosis|Depression|Anxiety|Heart Diseases|Stroke,BEHAVIORAL: HeRe We Arts|BEHAVIORAL: HeRe We Ed,Lisa Gallagher,"National Endowment for the Arts, United States|Cuyahoga Arts and Culture|The Cleveland Clinic",ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2019-07-01,2020-06-23,2020-06-23,"Cleveland Clinic Euclid Hospital, Euclid, Ohio, 44119, United States"
NCT01881191,Th Effects of Aubagio on Brain Pathology in Multiple Sclerosis Studied Over 12 Months,https://beta.clinicaltrials.gov/study/NCT01881191,COMPLETED,Multiple Sclerosis,OTHER: MRI,University at Buffalo,,ALL,"ADULT, OLDER_ADULT",,50,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-06,2015-10,2015-10,"Buffalo Neuroimaging Analysis Center, Buffalo, New York, 14203, United States"
NCT03183791,RELAXaHEAD for Headache Patients (Phase I),https://beta.clinicaltrials.gov/study/NCT03183791,COMPLETED,Headache|Migraine|Multiple Sclerosis,BEHAVIORAL: RELAXaHEAD app|BEHAVIORAL: Monitored Usual Care (MUC),NYU Langone Health,National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",NA,402,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2017-11-01,2019-05-25,2019-05-25,"New York University School of Medicine, New York, New York, 10016, United States"
NCT00587691,Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00587691,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis, Secondary Progressive",BIOLOGICAL: Tovaxin Autologous T Cell Vaccine,"Opexa Therapeutics, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,16,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2002-07,2007-06,2008-12,"Bellaire Neurology, Bellaire, Texas, 77401, United States|Baylor College of Medicine, Houston, Texas, 77030, United States"
NCT02949908,MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT02949908,TERMINATED,Multiple Sclerosis,DRUG: Rebif,"Merck KGaA, Darmstadt, Germany","Merck B.V., Netherlands",ALL,"ADULT, OLDER_ADULT",,2,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-02-09,2017-08-25,2017-08-25,"Please Contact the Merck KGaA Communication Center, Darmstadt, 64293, Germany"
NCT05072691,Prognostic Value of Cerebrospinal Fluid Immunoglobulin Free Light Chains in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05072691,RECRUITING,Multiple Sclerosis,DIAGNOSTIC_TEST: CSF immunoglobulin (Ig) free light chains (FLC) dosage,Francis Corazza,,ALL,"ADULT, OLDER_ADULT",,100,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-07-14,2024-01-01,2024-01-01,"CHU Brugmann, Brussels, 1020, Belgium"
NCT04478591,The Wearing-off Phenomenon of Ocrelizumab in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04478591,COMPLETED,Multiple Sclerosis,OTHER: Questionnaires,"Amsterdam UMC, location VUmc",,ALL,"ADULT, OLDER_ADULT",,117,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-05-12,2021-04-01,2021-05-01,"Amsterdam UMC, location VUmc, Amsterdam, North-Holland, 1007 MB, Netherlands"
NCT05063708,Neuromuscular Electrostimulation in Multiple Sclerosis People With Dysphagia,https://beta.clinicaltrials.gov/study/NCT05063708,RECRUITING,Deglutition Disorders|Multiple Sclerosis,DEVICE: Experimental: traditional dysphagia therapy plus Neuromuscular electrostimulation|DEVICE: Sham Comparator: Traditional dysphagia therapy plus sham Neuromuscular electrostimulation,I.R.C.C.S. Fondazione Santa Lucia,,ALL,"ADULT, OLDER_ADULT",NA,136,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2021-01-21,2022-06,2023-01,"Santa Lucia foundation, Roma, Italy"
NCT00613171,Efficacy and Tolerability of STI571 (Imatinib Mesylate) for the Treatment of Fibrosis in Participants With Systemic Sclerosis,https://beta.clinicaltrials.gov/study/NCT00613171,COMPLETED,"Systemic Sclerosis, Scleroderma",DRUG: STI571,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE2,27,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2008-01-02,2010-01-13,2010-01-13,"Novartis Investigator Site, Chicago, Illinois, 60611, United States|Novartis Investigator Site, Baltimore, Maryland, 21224, United States|Novartis Investigator Site, Boston, Massachusetts, 02118, United States|Novartis Investigator Site, Erlangen, Germany|Novartis Investigator Site, Florence, Italy|Novartis Investigator Site, Zurich, Switzerland|Novartis Investigator Site, London, United Kingdom"
NCT04521439,Accurate Diagnosis of Multiple Sclerosis Using PET/MR,https://beta.clinicaltrials.gov/study/NCT04521439,COMPLETED,Multiple Sclerosis,DIAGNOSTIC_TEST: 18F-florbetapir PET+MRSI,Ruijin Hospital,,ALL,"ADULT, OLDER_ADULT",NA,49,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-02-01,2022-03-30,2022-07-30,"Shanghai Ruijin Hospital, Shanghai, 200025, China"
NCT04524039,iTBS Study for Depression in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04524039,UNKNOWN,"Multiple Sclerosis|Depression, Anxiety",DEVICE: intermittent theta burst stimulation using a MagPro X100|DEVICE: sham intermittent theta burst stimulation using a MagPro X100,"Third Affiliated Hospital, Sun Yat-Sen University",,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-12-01,2022-09-01,2022-12-31,
NCT01280539,The Effect of Transcutaneous Electrical Nerve Stimulation (TENS) in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01280539,COMPLETED,Multiple Sclerosis,DEVICE: Transcutaneous electrical nerve stimulation,Hasselt University,Provinciale Hogeschool Limburg,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-01,2012-01,2012-06,"Hasselt University (BIOMED), Diepenbeek, Limburg, 3590, Belgium"
NCT00488839,IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00488839,COMPLETED,Multiple Sclerosis,DRUG: IPX056 20 mg|DRUG: IPX056 40 mg|DRUG: Encapsulated Baclofen 20 mg|DRUG: Placebo Baclofen Tablet|DRUG: IPX056 10 mg|DRUG: IPX056 30 mg|DRUG: IPX056 35 mg|DRUG: Placebo IPX056 20 mg|DRUG: Placebo IPX056 40 mg,"Impax Laboratories, LLC",,ALL,"ADULT, OLDER_ADULT",PHASE3,173,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2007-06,2008-05,2008-05,"Northwest NeuroSpecialists, Tucson, Arizona, 85741, United States|OrthoArkansas, P. A., Little Rock, Arkansas, 72201, United States|OrthoArkansas, P.A., Little Rock, Arkansas, 72201, United States|Patricia Fodor, Colorado Springs, Colorado, 80919, United States|Sunrise Clinical Research, Hollywood, Florida, 33021, United States|Meridien Research, Tampa, Florida, 33606, United States|MS Center of Atlanta, Atlanta, Georgia, 30327, United States|OSF Saint Francis Medical Center, Peoria, Illinois, 61637, United States|Elkhardt Clinic, Elkhart, Indiana, 46514, United States|MidAmerica Neuroscience Institute, Lenexa, Kansas, 66214, United States|Springfield Neurology, Springfield, Massachusetts, 01104, United States|General Clinical Research Center 7A, Ann Arbor, Michigan, 48109, United States|Medex Healthcare Research, Inc., Saint Louis, Michigan, 63117, United States|Northern Michigan Neurology, Traverse City, Michigan, 49684, United States|Winthrop University Hospital, Mineola, New York, 11501, United States|Crozer Chester Medical Center, Upland, Pennsylvania, 19013, United States|Bhupesh Dihenia, Lubbock, Texas, 79410, United States|Integra Clinical Research, San Antonio, Texas, 78229, United States|Neurological Research Center, Bennington, Vermont, 05201, United States|Virginia Commonwealth University Medical Center, Richmond, Virginia, 23298, United States|Montreal Neurological Institute and Hospital, Montreal, Quebec, H3A 2B4, Canada|Foothills Medical Centre, MS Clinic, SSB, Calgary, t2n 2t9, Canada|West-Tallinn Central Hospital, Tallinn, 10617, Estonia|Vecmilgravis Hospital, Latvian Maritime Medicine Center, Riga, Latvia|Chernihiv Regional Hospital Department of Neurology, Chernihiv, 14029, Ukraine|Neurology and Neurosurgery Dpt., Postgraduation training faculty, Dnipropetrovsk State medical Academy, Dnipropetrovsk, 49027, Ukraine|Institue of Neruology, Psychiatry and Narcology of AMS of Ukraine, Kharkiv, 61068, Ukraine|Department of nervous system demyelization diseases of City Clinical Hospital, Kyiv, 03110, Ukraine|Odessa Regional Clinical Hospital, Odessa, 65025, Ukraine|Neurology department of Ukraine medical stomatological akademy, Poltava, 36024, Ukraine|Vinnytsya Regional Psychoneurological Hospital, Vinnytsya, 21005, Ukraine"
NCT02218879,Restoring Glutathione Synthesis With Tecfidera: An in Vivo H-MRS Single-Arm Study at 7T in Patients With RR MS,https://beta.clinicaltrials.gov/study/NCT02218879,TERMINATED,Multiple Sclerosis,DRUG: Tecfidera,Yale University,,ALL,ADULT,,7,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-08,2016-04,2016-04,"Yale University, New Haven, Connecticut, 06519, United States"
NCT04306939,Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study,https://beta.clinicaltrials.gov/study/NCT04306939,SUSPENDED,Chronic Pancreatitis|Inflammatory Bowel Diseases|Hepatitis|NASH - Nonalcoholic Steatohepatitis|Acute Pancreatitis|Rheumatoid Arthritis|Diabetes Mellitus|Dyslipidemias|Multiple Sclerosis|Irritable Bowel Syndrome|Chronic Pain|Chronic Disease|Chronic Kidney Diseases|Crohn Disease|Celiac Disease|Biliary Cirrhosis|Bile Acid Synthesis Defect|Gastritis|Cholecystitis|Cholelithiases|IPMN|Cyst Pancreas|Cystic Fibrosis|Pancreatic Exocrine Insufficiency|Diarrhea Chronic|Constipation - Functional|Constipation Chronic Idiopathic,OTHER: venipuncture|BEHAVIORAL: Questionnaires|OTHER: Additional Sample Collections,University of Pittsburgh,,ALL,"CHILD, ADULT, OLDER_ADULT",,120000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-11-01,2025-12-01,2025-12-01,"University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, 15213, United States"
NCT04356339,US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes Via the myBETAapp in Medical Care of Patients With Multiple Sclerosis Treated With BETASERON Using BETACONNECT Autoinjector,https://beta.clinicaltrials.gov/study/NCT04356339,COMPLETED,Multiple Sclerosis,"DRUG: Interferon-beta-1b (BETASERON, BAY 86-5046)",Bayer,,ALL,"ADULT, OLDER_ADULT",,100,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-11-24,2021-08-29,2021-11-11,"myBETAapp, Whippany, New Jersey, 07981, United States"
NCT04578639,Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease,https://beta.clinicaltrials.gov/study/NCT04578639,RECRUITING,Relapsing Remitting Multiple Sclerosis,DRUG: Rituximab|DRUG: Ocrelizumab,Haukeland University Hospital,"University Hospital, Akershus|Oslo University Hospital|Helse Stavanger HF|St. Olavs Hospital|University Hospital of North Norway",ALL,ADULT,PHASE3,211,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-11-02,2025-02-14,2025-02-14,"Haukeland University Hospital, Bergen, Norway|Nordlandsykehuset HF, Bodø, Norway|Vestre Viken syekhus, Drammen, Norway|Sørlandet Sykehus, Kristiansand, Norway|Molde sjukehus, Molde, Norway|Sykehuset Namsos, Namsos, Norway|Oslo University Hospital HF, Oslo, 0424, Norway|Akershus University Hospital, Oslo, 1478, Norway|Oslo University Hospital, Oslo, Norway|Sykehuset Telemark, Skien, Norway|Stavanger University Hospital HF, Stavanger, 4068, Norway|University Hospital North Norway HF, Tromsø, 9038, Norway|University Hospital North Norway, Tromsø, Norway|St. Olavs Hospital, Trondheim, 7030, Norway|Karolinska Hospital, Stockholm, Sweden"
NCT03560739,A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients,https://beta.clinicaltrials.gov/study/NCT03560739,COMPLETED,Multiple Sclerosis,COMBINATION_PRODUCT: ofatumumab with PRF|COMBINATION_PRODUCT: ofatumumab with AI,Novartis Pharmaceuticals,,ALL,ADULT,PHASE2,284,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2018-09-11,2019-08-26,2020-05-05,"Novartis Investigative Site, Fullerton, California, 92835, United States|Novartis Investigative Site, Aurora, Colorado, 80045, United States|Novartis Investigative Site, Basalt, Colorado, 81621, United States|Novartis Investigative Site, Boulder, Colorado, 80301, United States|Novartis Investigative Site, Miami, Florida, 33136, United States|Novartis Investigative Site, Tampa, Florida, 33609, United States|Novartis Investigative Site, Tampa, Florida, 33612, United States|Novartis Investigative Site, West Palm Beach, Florida, 33407, United States|Novartis Investigative Site, Indianapolis, Indiana, 46256, United States|Novartis Investigative Site, Ozark, Missouri, 65721, United States|Novartis Investigative Site, Knoxville, Tennessee, 37922, United States|Novartis Investigative Site, Round Rock, Texas, 78681, United States|Novartis Investigative Site, Sherman, Texas, 75092, United States|Novartis Investigative Site, Vienna, 1010, Austria|Novartis Investigative Site, Vienna, 1090, Austria|Novartis Investigative Site, Sofia, 1113, Bulgaria|Novartis Investigative Site, Sofia, 1309, Bulgaria|Novartis Investigative Site, Sofia, 1413, Bulgaria|Novartis Investigative Site, Sofia, 1431, Bulgaria|Novartis Investigative Site, Brno, Czech Republic, 656 91, Czechia|Novartis Investigative Site, Havirov, Czech Republic, 736 01, Czechia|Novartis Investigative Site, Teplice, Czech Republic, 415 01, Czechia|Novartis Investigative Site, Hradec Kralove, CZE, 500 05, Czechia|Novartis Investigative Site, Pardubice, 532 03, Czechia|Novartis Investigative Site, Tallinn, 10617, Estonia|Novartis Investigative Site, Tartu, 51014, Estonia|Novartis Investigative Site, Riga, LV, LV-1005, Latvia|Novartis Investigative Site, Riga, LV 1002, Latvia|Novartis Investigative Site, Riga, LV-1038, Latvia|Novartis Investigative Site, Kaunas, LTU, LT 50161, Lithuania|Novartis Investigative Site, Vilnius, LT-08661, Lithuania|Novartis Investigative Site, Kazan, 420021, Russian Federation|Novartis Investigative Site, Krasnoyarsk, 660049, Russian Federation|Novartis Investigative Site, Moscow, 127015, Russian Federation|Novartis Investigative Site, Novosibirsk, 630007, Russian Federation|Novartis Investigative Site, Saint Petersburg, 197022, Russian Federation|Novartis Investigative Site, St Petersburg, 190000, Russian Federation|Novartis Investigative Site, Barcelona, Catalunya, 08035, Spain|Novartis Investigative Site, Pozuelo de Alarcon, Madrid, 28223, Spain|Novartis Investigative Site, El Palmar, Murcia, 30120, Spain|Novartis Investigative Site, Castilleja de la cuesta, Sevilla, 41950, Spain"
NCT03869879,"Mobility Rehab, a Therapist-assisted System for Gait Rehabilitation",https://beta.clinicaltrials.gov/study/NCT03869879,UNKNOWN,"Parkinson Disease|Stroke|Multiple Sclerosis|Gait Disorders, Neurologic|Gait Disorder, Sensorimotor|Gait, Unsteady|Gait Ataxia|Gait, Stumbling|Gait, Shuffling",OTHER: Feedback-assisted physical therapy|OTHER: Traditional physical therapy,Oregon Health and Science University,NorthWest Rehabilitations Associates|APDM,ALL,"ADULT, OLDER_ADULT",NA,300,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-07-24,2021-05-30,2021-05-30,"Northwest Rehabilitation Associate, Salem, Oregon, 97302, United States"
NCT05560139,The Effect of Transcranial Direct Current Stimulation on Fatigue Among Multiple Sclerosis Patients.Patients,https://beta.clinicaltrials.gov/study/NCT05560139,NOT_YET_RECRUITING,Multiple Sclerosis,DEVICE: a-tDCS,Assiut University,,ALL,"CHILD, ADULT, OLDER_ADULT",NA,36,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-12-01,2023-05-01,2023-09-01,
NCT04777539,Comparing the Safety and Benefit of Natalizumab (Tysabri®) At-home Infusion vs At-hospital Infusion in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04777539,RECRUITING,Multiple Sclerosis (MS),OTHER: At-home natalizumab treated MS patient,Nantes University Hospital,Rennes University Hospital,ALL,"ADULT, OLDER_ADULT",,315,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-06-14,2024-03-01,2024-06-01,"Strasbourg University Hospital, Strasbourg, Bas-Rhin, 67000, France|Marseille University Hospital, Marseille, Bouches-du-Rhône, 13000, France|Brest University Hospital, Brest, Finistère, 29200, France|Quimper Hospital, Quimper, Finistère, 29000, France|Bordeaux University Hospital, Bordeaux, Gironde, 33000, France|Libourne Hospital, Libourne, Gironde, 33500, France|Toulouse University Hospital, Toulouse, Haute-Garonne, 31000, France|Limoges University Hospital, Limoges, Haute-Vienne, 87000, France|Percy Army Training Hospital, Clamart, Hauts-de-Seine, 92140, France|Montpellier University Hospital, Montpellier, Hérault, 34000, France|Rennes University Hospital, Rennes, Ille-et-Vilaine, 35000, France|Tours University Hospital, Tours, Indre-et-Loire, 37000, France|Dax Hospital, Dax, Landes, 40100, France|Nantes University Hospital, Nantes, Loire-Atlantique, 44000, France|Orléans Hospital, Orléans, Loiret, 45000, France|Lille University Hospital, Lille, Nord, 59000, France|Rouen University Hospital, Rouen, Seine-Maritime, 76000, France|Poitiers University Hospital, Poitiers, Vienne, 86000, France|Adolphe de Rothschild Ophthalmological Foundation, Paris, 75000, France|AP-HP La Pitié-Salpêtrière Hospital, Paris, 75000, France"
NCT03004079,Clinical Importance of Glucose Regulation in Relapsing MS,https://beta.clinicaltrials.gov/study/NCT03004079,UNKNOWN,Relapsing Remitting Multiple Sclerosis|Clinically Isolated Syndrome,,University of Virginia,National Multiple Sclerosis Society,ALL,ADULT,,160,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-10,2020-09,2020-09,"University of Virginia, Charlottesville, Virginia, 22903, United States"
NCT02529839,Safety and Efficacy of an Immunoablative Nonmyeloablative Conditioning Protocol for Autologous Bone Marrow Transplantation (BMT) in Patients With Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT02529839,UNKNOWN,Multiple Sclerosis,PROCEDURE: Autologous bone marrow transplantation|DRUG: Fludarabine|DRUG: Cyclophosphamide|DRUG: Alemtuzumab,Hadassah Medical Organization,,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-10,2017-10,2017-10,
NCT02012439,Comparison of the Efficacy and Mechanisms for MBCT and CT for Multiple Sclerosis (MS) Chronic Pain,https://beta.clinicaltrials.gov/study/NCT02012439,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Mindfulness Based Cognitive Therapy|BEHAVIORAL: Cognitive Therapy,University of Washington,National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,8,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2013-10,2015-04,2016-12,"UW Medicine Multiple Sclerosis Center, Seattle, Washington, 98195, United States"
NCT03638739,Exercise and Brain Health in MS,https://beta.clinicaltrials.gov/study/NCT03638739,COMPLETED,Multiple Sclerosis,OTHER: Twice-weekly exercise,McMaster University,National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",NA,10,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2018-08-01,2019-06-30,2019-09-01,"Physical Activity Centre for Excellence, Hamilton, Ontario, L8S 4K1, Canada"
NCT01034579,The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial,https://beta.clinicaltrials.gov/study/NCT01034579,COMPLETED,Relapsing Multiple Sclerosis,OTHER: Blood sampling|OTHER: Blood sampling,EMD Serono,,ALL,"ADULT, OLDER_ADULT",PHASE4,324,INDUSTRY,INTERVENTIONAL,"Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: ",2010-02,2010-11,2010-11,"Please Contact U.S. Medical Information Located in, Rockland, Massachusetts, United States"
NCT03889639,Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03889639,COMPLETED,Relapsing Multiple Sclerosis,DRUG: SAR442168|DRUG: Placebo|DRUG: Locally approved intravenous contrast medium for contrast enhanced magnetic resonance imaging (MRI),Sanofi,,ALL,ADULT,PHASE2,130,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2019-03-29,2020-01-02,2020-01-02,"Investigational Site Number 8400005, Cullman, Alabama, 35058, United States|Investigational Site Number 8400002, Maitland, Florida, 32761, United States|Investigational Site Number 8400004, Sunrise, Florida, 33351, United States|Investigational Site Number 8400009, Tampa, Florida, 33612, United States|Investigational Site Number 8400007, Savannah, Georgia, 31406, United States|Investigational Site Number 8400001, Northbrook, Illinois, 60062, United States|Investigational Site Number 8400008, Dayton, Ohio, 45417, United States|Investigational Site Number 8400006, Westerville, Ohio, 43081, United States|Investigational Site Number 8400003, Knoxville, Tennessee, 37922, United States|Investigational Site Number 1240002, Gatineau, J8Y 1W2, Canada|Investigational Site Number 1240001, Greenfield Park, J4V 2J2, Canada|Investigational Site Number 1240003, Vancouver, V6T 2B5, Canada|Investigational Site Number 2030007, Brno, 62500, Czechia|Investigational Site Number 2030004, Hradec Kralove, 50005, Czechia|Investigational Site Number 2030003, Jihlava, 58633, Czechia|Investigational Site Number 2030005, Ostrava - Poruba, 70852, Czechia|Investigational Site Number 2030006, Pardubice, 53203, Czechia|Investigational Site Number 2030001, Praha 2, 12808, Czechia|Investigational Site Number 2030002, Praha 5 - Motol, 15006, Czechia|Investigational Site Number 2330001, Tallinn, 11315, Estonia|Investigational Site Number 2500004, Nancy Cedex, 54035, France|Investigational Site Number 2500001, Nantes Cedex 1, 44093, France|Investigational Site Number 2500002, Strasbourg Cedex, 67098, France|Investigational Site Number 2500003, Toulouse Cedex 9, 31059, France|Investigational Site Number 5280001, Amsterdam, 1081 HV, Netherlands|Investigational Site Number 5280002, Sittard-Geleen, 6162 BG, Netherlands|Investigational Site Number 6430006, Kazan, 420021, Russian Federation|Investigational Site Number 6430003, Moscow, 125367, Russian Federation|Investigational Site Number 6430002, Moscow, 127015, Russian Federation|Investigational Site Number 6430001, Saint-Petersburg, 197110, Russian Federation|Investigational Site Number 6430005, St-Petersburg, 194044, Russian Federation|Investigational Site Number 6430004, St-Petersburg, 197022, Russian Federation|Investigational Site Number 6430007, Tyumen, 625000, Russian Federation|Investigational Site Number 7030001, Bratislava, 82606, Slovakia|Investigational Site Number 7030002, Martin, 03659, Slovakia|Investigational Site Number 7240006, Barakaldo, 48903, Spain|Investigational Site Number 7240002, Barcelona, 08035, Spain|Investigational Site Number 7240001, Madrid, 28007, Spain|Investigational Site Number 7240004, Murcia, 30120, Spain|Investigational Site Number 7240005, Salt, 17190, Spain|Investigational Site Number 7240003, Sevilla, 41071, Spain|Investigational Site Number 8040002, Chernivtsi, 58018, Ukraine|Investigational Site Number 8040005, Dnipro, 49005, Ukraine|Investigational Site Number 8040001, Lviv, 79010, Ukraine|Investigational Site Number 8040006, Lviv, 79013, Ukraine|Investigational Site Number 8040009, Odesa, 65025, Ukraine|Investigational Site Number 8040003, Vinnytsya, 21005, Ukraine|Investigational Site Number 8040007, Zhytomyr, 10002, Ukraine"
NCT03567239,Impact of Custom Assistive and Adaptive Technology in Rehabilitation,https://beta.clinicaltrials.gov/study/NCT03567239,UNKNOWN,Disability Physical|Brain Injuries|Stroke|Spinal Cord Injuries|Multiple Sclerosis|Paralysis,DEVICE: Using adaptive device.,Madonna Rehabilitation Hospital,,ALL,"CHILD, ADULT, OLDER_ADULT",NA,150,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2018-06-25,2020-05,2021-05,"Madonna Rehabilitation Hospitals, Lincoln, Nebraska, 68506, United States"
NCT05270239,Function Magnetic Resonance Imaging to Assess Two Therapeutic Strategies in Multiple Sclerosis (NeuroRehEM).,https://beta.clinicaltrials.gov/study/NCT05270239,RECRUITING,Multiple Sclerosis,BEHAVIORAL: N-back Cognitive Training|BEHAVIORAL: Virtual Reality Motor and Cognitive Training,Universitat Jaume I,,ALL,ADULT,NA,120,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-05-27,2023-05,2023-05,"Universitat Jaume I (ImagoBrain Research Group), Castellón De La Plana, Castellón, 12006, Spain"
NCT04498039,Reducing Symptoms of Multiple Sclerosis Using Non-invasive Neuromodulation,https://beta.clinicaltrials.gov/study/NCT04498039,COMPLETED,Multiple Sclerosis,DEVICE: Portable Neuromodulation Stimulator,"University of Wisconsin, Madison",,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: DEVICE_FEASIBILITY",2009-11,2011-05,2011-05,
NCT04405479,Resting Postural Tremor in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04405479,RECRUITING,Multiple Sclerosis,BEHAVIORAL: Examination of tremor and upper hand functions,"Charles University, Czech Republic",,ALL,"ADULT, OLDER_ADULT",,30,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-05-01,2023-10-28,2024-12-30,"Department of neurology, Prague, 100 00, Czechia|Deparment of revmatology and rehabilitation, Prague, 140 59, Czechia|Kamila Řasová, Praha, 128 00, Czechia"
NCT02283671,Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B,https://beta.clinicaltrials.gov/study/NCT02283671,COMPLETED,Multiple Sclerosis|Neuromyelitis Optica,BIOLOGICAL: Tolerogenic Dendritic cells loaded with myelin peptides,Sara Varea,,ALL,"ADULT, OLDER_ADULT",PHASE1,20,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-09,2019-07-10,2019-07-10,"Hospital Clinic of Barcelona, Barcelona, 08036, Spain"
NCT05627271,The 'Wearing Off' Effect of DMT,https://beta.clinicaltrials.gov/study/NCT05627271,RECRUITING,Multiple Sclerosis,OTHER: ocrelizumab|OTHER: natalizumab|OTHER: ofatumumab,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",,39,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-01-10,2023-05-05,2023-05-05,"Novartis Investigative Site, Basel, Switzerland"
NCT05352971,Validation of Ella Platform for Serum Nfl And GFAP Measures In Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT05352971,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,OTHER: Biomarker quantification,Centre Hospitalier Universitaire de Nīmes,,ALL,"CHILD, ADULT, OLDER_ADULT",,664,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-09-15,2023-09,2023-09,"CHU Clermont-Ferrand, Clermont-Ferrand, France|Hôpital Henri Mondor, Créteil, France|CHRU Lille, Lille, France|Hospices Civils de Lyon, Lyon, France|CHU Gui de Chauliac, Montpellier, France|CHU de Nantes,, Nantes, France|Centre Hospitalier Universitaire Pasteur 2, Nice, France|CHU de Nîmes, Nîmes, France|Hôpital Pitié-Salpêtrière, Paris, France|CHU de Strasbourg, Strasbourg, France"
NCT01891071,Lung Volume Recruitment for Lung Function and Cough Impairment in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01891071,UNKNOWN,Multiple Sclerosis,PROCEDURE: Lung volume recruitment,Ottawa Hospital Research Institute,The Ottawa Hospital,ALL,"ADULT, OLDER_ADULT",NA,35,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2013-07,2017-04,2017-04,"The Ottawa Hospital, Ottawa, Ontario, K1H 8L6, Canada|Hôpital Charles-LeMoyne, Greenfield Park, Quebec, J4V2H1, Canada"
NCT05199571,Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China,https://beta.clinicaltrials.gov/study/NCT05199571,RECRUITING,Relapsing Multiple Sclerosis,BIOLOGICAL: Ofatumumab,Novartis Pharmaceuticals,,ALL,ADULT,PHASE4,100,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-07-22,2026-05-12,2026-05-12,"Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Lanzhou, Gansu, 730030, China|Novartis Investigative Site, Guangzhou, Guangdong, 510630, China|Novartis Investigative Site, Shijiazhuang, Hebei, 050000, China|Novartis Investigative Site, Harbin, Heilongjiang, 150001, China|Novartis Investigative Site, Wuhan, Hubei, 430030, China|Novartis Investigative Site, Suzhou, Jiangsu, 215004, China|Novartis Investigative Site, Taiyuan, Shanxi, 030001, China|Novartis Investigative Site, Hangzhou, Zhejiang, 310006, China|Novartis Investigative Site, Beijing, 100034, China|Novartis Investigative Site, Guang Zhou, 510080, China|Novartis Investigative Site, Guang Zhou, 510260, China|Novartis Investigative Site, Shanghai, 200025, China|Novartis Investigative Site, Shenzhen, 518036, China|Novartis Investigative Site, Tianjin, 300052, China"
NCT01962571,"Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial",https://beta.clinicaltrials.gov/study/NCT01962571,COMPLETED,Optic Neuritis,DRUG: Erythropoietin alfa|DRUG: Placebo,"University Eye Hospital, Freiburg",German Federal Ministry of Education and Research,ALL,ADULT,PHASE3,108,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-11-25,2018-06-20,2019-11-26,"Medical Center - University of Freiburg, Eye Hospital, Freiburg, Baden-Wuerttemberg, 79106, Germany|Heidelberg University Hospital, Department of Neurooncology, Heidelberg, Baden-Wuerttemberg, 69120, Germany|Tuebingen University Hospital, Tuebingen, Baden-Wuerttemberg, 72076, Germany|University Hospital Erlangen, Erlangen, Bayern, 91054, Germany|University Hospital of Munich, Munich, Bayern, 81377, Germany|University Hospital Klinikum rechts der Isar, Munich, Munich, Bayern, 81675, Germany|University Medical Center Göttingen, Göttingen, Niedersachsen, 37075, Germany|Hannover Medical School, Hannover, Niedersachsen, 30625, Germany|Duesseldorf University Hospital, Duesseldorf, Nordrhein-Westfalen, 40225, Germany|University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Rheinland-Pfalz, 55131, Germany|University Medical Center Hamburg-Eppendorf, Hamburg, 20246, Germany"
NCT05090371,A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation,https://beta.clinicaltrials.gov/study/NCT05090371,RECRUITING,Relapsing-Remitting Multiple Sclerosis,DRUG: Ofatumumab|DRUG: Disease modifying treatment (DMT),Novartis Pharmaceuticals,,ALL,ADULT,PHASE4,150,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-03-02,2025-11-20,2025-11-20,"Novartis Investigative Site, Birmingham, Alabama, 35209, United States|Novartis Investigative Site, Cullman, Alabama, 35058, United States|Novartis Investigative Site, Phoenix, Arizona, 85032, United States|Novartis Investigative Site, Maitland, Florida, 32751, United States|Novartis Investigative Site, Orlando, Florida, 32806, United States|Novartis Investigative Site, Coeur d'Alene, Idaho, 83815, United States|Novartis Investigative Site, Lutherville, Maryland, 21093, United States|Novartis Investigative Site, Owosso, Michigan, 48867, United States|Novartis Investigative Site, Raleigh, North Carolina, 27607, United States|Novartis Investigative Site, Knoxville, Tennessee, 37922, United States|Novartis Investigative Site, Lubbock, Texas, 79410, United States|Novartis Investigative Site, Webster, Texas, 77598, United States|Novartis Investigative Site, Green Bay, Wisconsin, 54311, United States|Novartis Investigative Site, Levis, Quebec, G6W 0M5, Canada"
NCT03077971,Effectiveness of Acceptance and Commitment Therapy Self-Help for Carers of People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03077971,UNKNOWN,Carer Stress Syndrome,BEHAVIORAL: ACT Self-Help|BEHAVIORAL: ACT Self-Help with Telephone Support,University of Nottingham,,ALL,"ADULT, OLDER_ADULT",NA,24,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2016-12-01,2018-01,2018-06,"University of Nottingham, Nottingham, Nottinghamshire, NG81BB, United Kingdom"
NCT00086671,Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT00086671,COMPLETED,Multiple Sclerosis,DRUG: ABT-874/Human monoclonal antibody against IL-12|DRUG: Placebo,"AbbVie (prior sponsor, Abbott)",,ALL,ADULT,PHASE2,215,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: ",2004-04,2006-11,2006-11,"Site Reference ID/Investigator# 107, Phoenix, Arizona, 85013, United States|Site Reference ID/Investigator# 163, Sun City, Arizona, 85351, United States|Site Reference ID/Investigator# 156, Little Rock, Arkansas, 72205, United States|Site Reference ID/Investigator# 154, Irvine, California, 92618, United States|Site Reference ID/Investigator# 161, Laguna Hills, California, 92653, United States|Site Reference ID/Investigator# 84, Sacramento, California, 95817, United States|Site Reference ID/Investigator# 119, Boulder, Colorado, 80304, United States|Site Reference ID/Investigator# 111, Miami, Florida, 33136, United States|Site Reference ID/Investigator# 151, Tallahassee, Florida, 32308, United States|Site Reference ID/Investigator# 108, Atlanta, Georgia, 30309, United States|Site Reference ID/Investigator# 109, Atlanta, Georgia, 30327, United States|Site Reference ID/Investigator# 105, Northbrook, Illinois, 60062, United States|Site Reference ID/Investigator# 152, Indianapolis, Indiana, 46260, United States|Site Reference ID/Investigator# 258, Lenexa, Kansas, 66214, United States|Site Reference ID/Investigator# 261, Lexington, Kentucky, 40503, United States|Site Reference ID/Investigator# 116, Detroit, Michigan, 48201, United States|Site Reference ID/Investigator# 158, Traverse City, Michigan, 49684, United States|Site Reference ID/Investigator# 124, St. Louis, Missouri, 63110, United States|Site Reference ID/Investigator# 259, Henderson, Nevada, 89052, United States|Site Reference ID/Investigator# 153, Lebanon, New Hampshire, 03766, United States|Site Reference ID/Investigator# 110, Albany, New York, 12205, United States|Site Reference ID/Investigator# 117, Charlotte, North Carolina, 28207, United States|Site Reference ID/Investigator# 113, Columbus, Ohio, 43210, United States|Site Reference ID/Investigator# 157, Dayton, Ohio, 45409, United States|Site Reference ID/Investigator# 114, Allentown, Pennsylvania, 18103, United States|Site Reference ID/Investigator# 128, Houston, Texas, 77030, United States|Site Reference ID/Investigator# 155, Bennington, Vermont, 05201, United States|Site Reference ID/Investigator# 132, Greenfield Park, J4V 2H1, Canada|Site Reference ID/Investigator# 130, Halifax, B3H 3A7, Canada|Site Reference ID/Investigator# 82, Ottawa, K1H 8L6, Canada|Site Reference ID/Investigator# 169, Sherbrooke, J1H 5N4, Canada|Site Reference ID/Investigator# 134, Vancouver, V6T 2B5, Canada|Site Reference ID/Investigator# 149, Frankfurt, 60528, Germany|Site Reference ID/Investigator# 137, Breda, 4818 CK, Netherlands|Site Reference ID/Investigator# 148, Nieuwegein, 3435 CM, Netherlands|Site Reference ID/Investigator# 138, Nijmwegen, 6533 PA, Netherlands|Site Reference ID/Investigator# 139, Sittard, 6131 BK, Netherlands|Site Reference ID/Investigator# 159, Liverpool, L97LJ, United Kingdom|Site Reference ID/Investigator# 140, London, SE1 1UL, United Kingdom|Site Reference ID/Investigator# 142, Newcastle upon Tyne, NE1 4LP, United Kingdom|Site Reference ID/Investigator# 141, Nottingham, NG7 2UH, United Kingdom|Site Reference ID/Investigator# 144, Oxford, OX2 6HE, United Kingdom|Site Reference ID/Investigator# 143, Stoke on Trent, ST4 7LN, United Kingdom|Site Reference ID/Investigator# 160, Whitechapel, E1 1 BB, United Kingdom"
NCT00323271,Cognitive-behavior Therapy for MS-Related Chronic Pain,https://beta.clinicaltrials.gov/study/NCT00323271,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Cognitive-behavior therapy|OTHER: Interventional,US Department of Veterans Affairs,,ALL,"ADULT, OLDER_ADULT",NA,26,FED,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2006-07,2011-03,2011-03,"VA Connecticut Health Care System (West Haven), West Haven, Connecticut, 06516, United States|VA Medical Center, Jamaica Plain Campus, Boston, Massachusetts, 02130, United States"
NCT03993171,31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis.,https://beta.clinicaltrials.gov/study/NCT03993171,RECRUITING,Relapsing Remitting Multiple Sclerosis,DRUG: gold nanocrystals,Clene Nanomedicine,University of Texas Southwestern Medical Center,ALL,ADULT,PHASE2,30,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2019-12-19,2023-11,2023-12,"University of Texas Southwestern, Dallas, Texas, 75390, United States"
NCT04110171,Relationship Between the Nutritional Habits and Relapsing and Disability Rates in Patient With Multiple Sclerosis.,https://beta.clinicaltrials.gov/study/NCT04110171,UNKNOWN,Nutrition Habits in Multiple Sclerosis,,Assiut University,,ALL,ADULT,,100,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-11-01,2021-12-01,2021-12-01,
NCT04283071,Kinematic Assessment In Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04283071,COMPLETED,Multiple Sclerosis,DEVICE: Boxed infrared gross kinematic assessment tool,The Leeds Teaching Hospitals NHS Trust,University of Leeds,ALL,"ADULT, OLDER_ADULT",,57,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-11-07,2021-10-30,2021-10-30,"Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom"
NCT03269071,Neural Stem Cell Transplantation in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT03269071,COMPLETED,Progressive Multiple Sclerosis,DRUG: human fetal-derived Neural Stem Cells (hNSCs),IRCCS San Raffaele,Fondazione Italiana Sclerosi Multipla,ALL,ADULT,PHASE1,4,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2017-05-17,2021-07-31,2021-07-31,"IRCCS Ospedale San Raffaele, Milan, MI, 20132, Italy"
NCT01371071,Cohort Study of Clinically Isolated Syndrome and Early Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01371071,UNKNOWN,"Multiple Sclerosis, MS|Clinically Isolated Syndrome",,"Charite University, Berlin, Germany",,ALL,"ADULT, OLDER_ADULT",,200,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-01,2017-12,2017-12,"Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany|NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, Berlin, Germany"
NCT00370071,"Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT00370071,COMPLETED,Multiple Sclerosis,"DRUG: Interferon beta-1b (Betaseron, BAY86-5046)",Bayer,,ALL,"CHILD, ADULT",PHASE3,39,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2006-11,2008-09,2008-09,"Beijing, 100050, China|Beijing, 100730, China|Shanghai, 200040, China"
NCT03369171,Wearable Biosensor to Track and Quantify Limb Dysfunction in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT03369171,COMPLETED,Multiple Sclerosis,"DEVICE: Myo Armband (MYO,Thalamic Labs Inc, Kitchener, ON, Canada)",Nantes University Hospital,,ALL,ADULT,NA,64,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2018-01-23,2020-02-28,2020-02-28,"CHU de Nantes, Nantes, 44093, France"
NCT05131971,"A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (PD) of GSK3888130B in Healthy Participants",https://beta.clinicaltrials.gov/study/NCT05131971,RECRUITING,Multiple Sclerosis,DRUG: GSK3888130B|DRUG: Placebo,GlaxoSmithKline,,ALL,ADULT,PHASE1,70,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-11-01,2023-06-30,2023-06-30,"GSK Investigational Site, Cambridge, CB2 2GG, United Kingdom"
NCT01086371,Rhythmic Auditory Stimulation and Walking Performance in Multiple Sclerosis (MS) Patients,https://beta.clinicaltrials.gov/study/NCT01086371,WITHDRAWN,Gait Disturbance in Multiple Sclerosis Patients,OTHER: Rhythmic auditory stimulation|OTHER: Walking exercise,The Cleveland Clinic,National Institutes of Health (NIH),ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2012-01,2012-01,2012-01,"Cleveland Clinic, Cleveland, Ohio, 44195, United States"
NCT04142008,Walk With Me: a Mobile Application to Improve Walking in Persons With MS,https://beta.clinicaltrials.gov/study/NCT04142008,COMPLETED,Multiple Sclerosis,DEVICE: Walk with Me app,Hasselt University,,ALL,"ADULT, OLDER_ADULT",NA,19,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2018-09-01,2019-08-31,2019-12-31,"Hasselt University, Hasselt, 3500, Belgium"
NCT03209479,"Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) ""Prevention of Relapse of Multiple Sclerosis""",https://beta.clinicaltrials.gov/study/NCT03209479,RECRUITING,Multiple Sclerosis,DRUG: Glatiramer acetate,Takeda,,ALL,"CHILD, ADULT, OLDER_ADULT",,1000,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-11-24,2025-03-31,2025-03-31,"Takeda selected site, Tokyo, Japan"
NCT03174379,A Study to Analyze the Effect of Acupuncture on Mobility And Quality of Life in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03174379,COMPLETED,Multiple Sclerosis,PROCEDURE: Standard of Care with no acupuncture|PROCEDURE: Acupuncture,NYU Langone Health,,ALL,"ADULT, OLDER_ADULT",NA,13,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2017-06-05,2019-06-06,2019-06-06,"New York University School of Medicine, New York, New York, 10016, United States"
NCT00220779,"Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT00220779,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting","DRUG: Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified|DRUG: Albumin (Human) 25%, United States Pharmacopeia (USP)",Grifols Therapeutics LLC,,ALL,ADULT,PHASE2,128,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2002-12,2005-02,2005-02,"Barrow Neurological Institute at St. Joseph's Hospital and Medical Center, Phoenix, Arizona, 85013, United States|Northwest NeuroSpecialists, PLLC, Tucson, Arizona, 85741-3537, United States|The Mt. Sinai Medical Center, Department of Neurology, New York, New York, 10029, United States|SUNY Health Science Center at Stony Brook, Department of Neurology, Stony Brook, New York, 11794-8121, United States|Wake Forest University - School of Medicine, Winston-Salem, North Carolina, 27157, United States|Neurology Health Care Service, Fletcher Allen Health Care, Burlington, Vermont, 05401, United States|Department of Neurology, Karl-Franzens University, Graz, 8010, Austria|Foothills Hospital, Calgary, Alberta, T2N 2T9, Canada|London Health Sciences Centre, London, Ontario, N6A 5A5, Canada|The Ottawa Hospital, General Campus - Neurology Division, Ottawa, Ontario, K1H 8L6, Canada|CHUM Hospital Notre Dame, Montreal, Quebec, H2L4M1, Canada|Fakultni nemocnice Brno-Bohunice, Brno, 63900, Czech Republic|St. Anna's Teaching Hospital, Brno, 65691, Czech Republic|Všeobecná fakultní nemocnice, Prague 2, 12808, Czech Republic|Department of Neurology, Motol Teaching Hospital, Prague, 15600, Czech Republic|Medizinische Einrichtungen der Heinrich Heine Universitat, Neurologische Klinik, Dusseldorf, 40225, Germany|HELIOS Klinikum Erfurt GmbH, Klinik und Poliklinik fur Neurologie, Erfurt, 99089, Germany|Klinikum der Justus-Liebig-Universitat, Zentrum fur Neurologie und Neurochirurgie, Giessen, Germany|Universitatsklinikum Munster, Klinik und Poliklinik fur Neurologie, Munster, 48149, Germany|Klinikum Osnabrück GmbH, Osnabrück, 49076, Germany|Universitatsklinikum Ulm, Poliklinik fur Neurologie, Ulm, 89075, Germany|Klinijum der Universitat Wurzburg, Neurologische Klinik und Poliklinik, Wurzburg, Germany|Henry Dunant Hospital, Athens, 11526, Greece|Szent Imre Korhaz Neurologia, Budapest, 115, Hungary|Uzsoki Street Hospital, Budapest, H-1145, Hungary|Jahn Ferenc Delpesti Teaching Hospital, Budapest, H-1204, Hungary|Szeged University of Science, Szeged, H-5720, Hungary|Lady Davis Carmel Medical Center, Haifa, 34362, Israel|Katedra I Klinika Neurologii; Slaskiej Akademii Medycznej, Samodzielny Publiczny Centralny Szpital Kliniczny, Katowice-Ligota, 40-752, Poland|Katedra I Klinika Neurologii, Univerytetu Medycznego w Lodzi, Lodz, 90-153, Poland|Katedra I Klinika Neurologii, Lublin, 20-954, Poland|Klinika Neurologiczna, Wojskowy Instut Medyczny, Warsaw, 00-909, Poland|Fakultna menocnica Bratislava, Bratislava 2, 83-305, Slovakia|Dererova nemocnica s Poliklinikou Nerologicka Klinika, Bratislava 2, 833 05, Slovakia|Lasarette Neurologiavdeling, Lund, Sweden|Karilinska Sjukhuset, Stockholm, Sweden|University Hospital, Queens Medical Centre, Nottingham, NG7 2UH, United Kingdom"
NCT01767779,Potential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSC,https://beta.clinicaltrials.gov/study/NCT01767779,COMPLETED,Tuberous Sclerosis Complex,,University of Alabama at Birmingham,"Children's Hospital Medical Center, Cincinnati|The University of Texas Health Science Center, Houston|University of California, Los Angeles|Boston Children's Hospital",ALL,CHILD,,40,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-09,2016-12,2018-12,"University of Alabama at Birmingham, Birmingham, Alabama, 35294, United States|UCLA, Los Angeles, California, 90095, United States|Boston Children's Hospital, Boston, Massachusetts, 02115, United States|Cincinnati Children's Hospital, Cincinnati, Ohio, 45229, United States|University of Texas in Houston, Houston, Texas, 77030, United States"
NCT03600779,Application of ihMT MRI in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03600779,RECRUITING,"Sclerosis, Multiple",DEVICE: inhomogeneous Magnetisation Transfer (ihMT) sequence|DEVICE: inhomogeneous Magnetisation Transfer (ihMT) sequence at 3T,Assistance Publique Hopitaux De Marseille,,ALL,ADULT,NA,85,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2018-06-14,2023-06,2023-12,"Assistance Publique Des Hotipaux de Marseille, Marseille, Paca, 13354, France"
NCT01973491,ATX-MS-1467 in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01973491,COMPLETED,Multiple Sclerosis,DRUG: ATX-MS-1467,"Merck KGaA, Darmstadt, Germany",,ALL,"ADULT, OLDER_ADULT",PHASE2,37,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-02-28,2016-04-30,2016-04-30,"Please contact the Merck KGaA Communication Center, Darmstadt, Germany"
NCT05805839,A Study of Imaging in Demyelinating Diseases,https://beta.clinicaltrials.gov/study/NCT05805839,NOT_YET_RECRUITING,Multiple Sclerosis|Inflammatory Demyelinating Disease,DRUG: C-11 ER176 Radiotracer|DRUG: C11 Pittsburgh Compound B|DIAGNOSTIC_TEST: PET/CT scan|DIAGNOSTIC_TEST: MRI,Mayo Clinic,,ALL,"ADULT, OLDER_ADULT",PHASE2,200,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-05,2025-05,2025-05,"Mayo Clinic Minnesota, Rochester, Minnesota, 55905, United States"
NCT01244139,Safety Study of BIIB033 in Subjects With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01244139,COMPLETED,Relapsing-Remitting Multiple Sclerosis|Multiple Sclerosis,DRUG: BIIB033|DRUG: Placebo,Biogen,,ALL,ADULT,PHASE1,47,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: ",2010-10,2012-04,2012-04,"Research Site, Centennial, Colorado, United States"
NCT04221191,"Dimethyl Fumarate (DMF, Tecfidera®) Persistence in RR-MS Patients Included in the French Patient Support Program OroSEP",https://beta.clinicaltrials.gov/study/NCT04221191,RECRUITING,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Dimethyl Fumarate|OTHER: PSP,Biogen,,ALL,ADULT,,350,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-08-19,2022-09-15,2022-09-15,"Research site, Agen, 47000, France|Research Site, Agen, 47000, France|Research Site, Aix-en-Provence, 13616, France|Research Site, Albi, 81000, France|Research site, Albi, 81013, France|Research Site, Amiens, 80000, France|Research Site, Angoulême, 16000, France|Research site, Annecy, 74000, France|Research site, Antibes, 06600, France|Research Site, Antony, 92160, France|Research Site, Arras, 62000, France|Research Site, Bastia, 20600, France|Research site, Bayonne, 64100, France|Research Site, Belfort, 90000, France|Research Site, Bezannes, 51430, France|Research Site, Biarritz, 64200, France|Research Site, Bordeaux, 33000, France|Research site, Bordeaux, 33200, France|Research Site, Béziers, 34500, France|Research site, Carcassonne, 11000, France|Research Site, Challans, 85300, France|Research Site, Chatellerault, 86100, France|Research Site, Cholet, 49300, France|Research Site, Clamart, 92140, France|Research site, Cornebarrieu, 31700, France|Research Site, Créteil, 94000, France|Research site, Dax, 40100, France|Research Site, Dijon, 21000, France|Research Site, Dijon, 21000, France|Research site, Douai, 59500, France|Research Site, Eaubonne, 95600, France|Research Site, Gap, 05000, France|Research Site, Gonesse, 95500, France|Research Site, Grenoble Cedex 9, 38043, France|Research site, La Rochelle, 17000, France|Research site, La Seyne-sur-Mer, 83500, France|Research Site, Libourne, 33500, France|Research Site, Lille, 59000, France|Research Site, Lons-le-Saunier, 39016, France|Research Site, Lure, 70200, France|Research site, Lyon, 69006, France|Research Site, Melun, 77000, France|Research Site, Mont de Marsan Cedex, 40024, France|Research site, Montauban, 82000, France|Research Site, Montluçon, 03100, France|Research Site, Montpellier, 34000, France|Research Site, Montpellier, 34090, France|Research Site, Mornant, 69440, France|Research Site, Mornant, 69440, France|Research site, Muret, 31600, France|Research Site, Nice, 06000, France|Research site, Nimes, 30900, France|Research Site, Niort, 79000, France|Research Site, Nîmes, 30900, France|Research Site, Orléans, 45100, France|Research Site, Paris, 75008, France|Research Site, Paris, 75011, France|Research Site, Paris, 75014, France|Research Site, Paris, 75017, France|Research Site, Pau, 64000, France|Research Site, Perpignan, 66000, France|Research site, Pessac, 33600, France|Research site, Poissy, 78300, France|Research Site, Poitiers, 86000, France|Research Site, Quimper Cedex, 29107, France|Research Site, Rambouillet, 78120, France|Research Site, Roanne, 42300, France|Research Site, Roubaix, 59100, France|Research Site, Roubaix, 59100, France|Research Site, Saint-Quentin, 02321, France|Research Site, Soissons, 02200, France|Research site, Talence, 33400, France|Research Site, Toulon, 83000, France|Research Site, Toulon, 83000, France|Research Site, Toulouse cedex 9, 31059, France|Research Site, Tours, 37000, France|Research Site, Tours, 37000, France|Research Site, Troyes, 10000, France|Research Site, Valence, 26000, France|Research site, Vesoul Cedex, 7000, France|Research Site, Évreux, 27000, France"
NCT02346279,Responsiveness and Minimal Clinical Important Difference of the Multiple Sclerosis Questionnaire for Physiotherapists,https://beta.clinicaltrials.gov/study/NCT02346279,COMPLETED,Multiple Sclerosis,"OTHER: Questionnaires, EDSS, physical test",Institut fuer Physiotherapieforschung,Schweizer Physiotherapie Verband physioswiss|Schweizerische Multiple Sklerose Gesellschaft,ALL,"ADULT, OLDER_ADULT",,81,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-04,2013-10,2013-10,
NCT04011579,Pilates Training in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04011579,UNKNOWN,Multiple Sclerosis|Physical Activity,OTHER: MSFIT,Fondazione Italiana Sclerosi Multipla,,ALL,"ADULT, OLDER_ADULT",NA,126,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2019-09,2020-10,2020-10,
NCT04133779,Observational Study on Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04133779,COMPLETED,Multiple Sclerosis,"PROCEDURE: neurological examination, Kurtzke EDSS, Barthel scale, ecocolor-Doppler|PROCEDURE: neurological evaluation, ecocolor-Doppler|PROCEDURE: medical history, vital signs, ecocolor-Doppler",Fondazione Italiana Sclerosi Multipla,,ALL,ADULT,,1767,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-12-29,2012-05-30,2012-05-30,
NCT05735691,"High-Intensity, Dynamic-stability Gait Training in People With Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT05735691,RECRUITING,Multiple Sclerosis,PROCEDURE: High-Intensity Treadmill Training|PROCEDURE: Treadmill Training with Perturbations|PROCEDURE: Standard Treadmill Training,Marquette University,Indiana University|Medical College of Wisconsin|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),ALL,"ADULT, OLDER_ADULT",NA,150,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: TRIPLE (CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-01-01,2027-06-30,2027-06-30,"Rehabilitation Hospital of Indiana, Indianapolis, Indiana, 46254, United States|Marquette University, Milwaukee, Wisconsin, 53233, United States"
NCT02901106,Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate,https://beta.clinicaltrials.gov/study/NCT02901106,TERMINATED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Dimethyl fumarate,Fondation Ophtalmologique Adolphe de Rothschild,,ALL,"ADULT, OLDER_ADULT",PHASE4,11,NETWORK,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2017-05-23,2017-10-17,2017-10-17,"Fondation Ophtalmique Adolphe de Rothschild, Paris, 75019, France"
NCT04948606,Exploring Diroximel Fumarate Real-world Experience in Canada and Israel,https://beta.clinicaltrials.gov/study/NCT04948606,TERMINATED,Relapsing Forms of MS,DRUG: Diroximel Fumarate,Biogen,,ALL,"ADULT, OLDER_ADULT",,64,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-12-09,2023-04-14,2023-04-14,"Lady Davis Carmel Medical Center, Haifa, Israel|Hadassah Medical Center, Jerusalem, Israel|Meir Medical Center, Kfar Saba, Israel|Rabin Medical Center, Petah Tikva, Israel|Tel Aviv Sourasky Medical, Tel-Aviv, Israel|Sheba Medical Center, Tel-Hashomer, Israel"
NCT00490906,Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00490906,COMPLETED,Multiple Sclerosis|Low Bone Density,DRUG: Copaxone|DRUG: Interferon-beta 1a|DRUG: Interferon-beta 1b,"Nancy Hammond, MD","Kansas City Area Life Sciences Institute, Inc.",FEMALE,"ADULT, OLDER_ADULT",,60,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2007-06,2009-02,2012-12,"General Clinical Research Center, Kansas City, Kansas, 66160, United States|University of Kansas Medical Center, Kansas City, Kansas, 66160, United States"
NCT03369106,Mechanisms of Disease Severity in Multiple Sclerosis: an Integrative Multimodal Study,https://beta.clinicaltrials.gov/study/NCT03369106,UNKNOWN,Multiple Sclerosis,OTHER: Composite severity score calculation,"Institut National de la Santé Et de la Recherche Médicale, France",,ALL,"ADULT, OLDER_ADULT",,120,OTHER_GOV,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-12-15,2020-12-15,2022-06-15,"CIC Neurosciences Institut du Cerveau et de la Moelle Epinière, Paris, 75013, France"
NCT04735406,The MS-LINK™ Outcomes Study,https://beta.clinicaltrials.gov/study/NCT04735406,RECRUITING,Multiple Sclerosis,,"EMD Serono Research & Development Institute, Inc.",,ALL,"ADULT, OLDER_ADULT",,10000,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-03-24,2024-05-23,2024-05-23,"Alabama Neurology Associates, Birmingham, Alabama, 35209, United States|Georgetown University, Washington, District of Columbia, 20057, United States|Atlanta Neuroscience Institute, Atlanta, Georgia, 30327, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States|Memorial healthcare, Owosso, Michigan, 48867, United States|University of Nebraska medical Center, Omaha, Nebraska, 68198-7835, United States|The Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, 73104, United States|The University of Texas of Austin, Austin, Texas, 78759, United States|University of Texas Health, San Antonio, Texas, 78229, United States"
NCT00360906,Omega-3 Fatty Acid Treatment in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00360906,COMPLETED,Relapsing-Remitting Multiple Sclerosis,DRUG: Triomar™ (omega-3 fatty acids),Haukeland University Hospital,The Multiple Sclerosis National Competence Centre|The Norwegian Multiple sclerosis Society|Pronova BioPharma|Serono Nordic|Amersham Health,ALL,ADULT,PHASE2|PHASE3,100,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,2004-12,,2008-07,"Department of Neurology, Haukeland University Hospital, Bergen, N-5021, Norway"
NCT05029206,Hematopoietic Stem Cell Transplantation for Treatment of Multiple Sclerosis in Sweden,https://beta.clinicaltrials.gov/study/NCT05029206,COMPLETED,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting",PROCEDURE: Autologous hematopoietic stem cell transplantation,Uppsala University,"Karolinska University Hospital|Sahlgrenska University Hospital, Sweden|Uppsala University Hospital|Skane University Hospital|University Hospital, Linkoeping|University Hospital, Umeå|Region Örebro County",ALL,"CHILD, ADULT, OLDER_ADULT",,175,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-05-05,2022-09-30,2022-09-30,"Sahlgrenska University Hospital, Gothenburg, Sweden|Linköping University Hospital, Linköping, Sweden|Skåne University Hospital, Lund, Sweden|Danderyd Hospital, Stockholm, Sweden|Karolinska University Hospital, Stockholm, Sweden|Umeå University Hospital, Umeå, Sweden|Uppsala University Hospital, Uppsala, Sweden|Örebro University Hospital, Örebro, Sweden"
NCT01723709,The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort,https://beta.clinicaltrials.gov/study/NCT01723709,COMPLETED,Multiple Sclerosis,,Duke University,,ALL,"ADULT, OLDER_ADULT",,973,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-06,2017-05,2017-05,"Carolinas Medical Center Northeast Medical Arts Building, Concord, North Carolina, 28025, United States|Ada Jenkins Center, Davidson, North Carolina, 28036, United States|The Stedman Center on the Duke Center for Living Campus, Durham, North Carolina, 27705, United States|Kannapolis Internal Medicine, Kannapolis, North Carolina, 28081, United States|Raleigh Neurology Associates, Raleigh, North Carolina, 27607, United States"
NCT03492606,Lipid Mediators in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03492606,COMPLETED,Multiple Sclerosis,PROCEDURE: Samples,Neuromed IRCCS,,ALL,ADULT,,150,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-03-01,2020-09-09,2021-01-09,"IRCCS Neuromed, Pozzilli, Isernia, 86077, Italy"
NCT04548206,Effect of Pilates Training in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04548206,COMPLETED,Multiple Sclerosis,OTHER: Pilates training|OTHER: control,Gazi University,,ALL,"ADULT, OLDER_ADULT",NA,34,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2020-09-14,2022-07-29,2022-07-29,"Gazi University, Ankara, Turkey"
NCT00376506,A Comparison of an Implanted Neuroprosthesis With Sensory Training for Improving Airway Protection in Chronic Dysphagia,https://beta.clinicaltrials.gov/study/NCT00376506,COMPLETED,Chronic Dysphagia|Multiple Sclerosis|Parkinson Disease,DEVICE: Neurostimulation device for dysphagia|DEVICE: External vibrotactile device,National Institute of Neurological Disorders and Stroke (NINDS),,ALL,"ADULT, OLDER_ADULT",PHASE2,10,NIH,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE|Primary Purpose: TREATMENT,2006-07,2010-09,2011-01,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States"
NCT05376579,Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy,https://beta.clinicaltrials.gov/study/NCT05376579,RECRUITING,Active Secondary Progressive Multiple Sclerosis,OTHER: siponimod,Novartis Pharmaceuticals,,ALL,ADULT,,200,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-06-17,2026-06-30,2026-06-30,"Novartis Investigative Site, Ancona, AN, 60126, Italy|Novartis Investigative Site, L Aquila, AQ, 67100, Italy|Novartis Investigative Site, Bergamo, BG, 24128, Italy|Novartis Investigative Site, Bologna, BO, 40139, Italy|Novartis Investigative Site, Brescia, BS, 25123, Italy|Novartis Investigative Site, Como, CO, 22100, Italy|Novartis Investigative Site, Catanzaro, CZ, 88100, Italy|Novartis Investigative Site, Foggia, FG, 71100, Italy|Novartis Investigative Site, Genova, GE, 16132, Italy|Novartis Investigative Site, Messina, ME, 98121, Italy|Novartis Investigative Site, Milano, MI, 20132, Italy|Novartis Investigative Site, Milano, MI, 20133, Italy|Novartis Investigative Site, Palermo, PA, 90127, Italy|Novartis Investigative Site, Padova, PD, 35128, Italy|Novartis Investigative Site, Pisa, PI, 56126, Italy|Novartis Investigative Site, Pavia, PV, 27100, Italy|Novartis Investigative Site, Roma, RM, 00133, Italy|Novartis Investigative Site, Roma, RM, 00152, Italy|Novartis Investigative Site, Roma, RM, 00189, Italy|Novartis Investigative Site, Orbassano, TO, 10043, Italy|Novartis Investigative Site, Trieste, TS, 34149, Italy|Novartis Investigative Site, Vicenza, VI, 36100, Italy|Novartis Investigative Site, Napoli, 80132, Italy|Novartis Investigative Site, Napoli, 80138, Italy|Novartis Investigative Site, Novara, 28100, Italy"
NCT02896179,Virtual Reality and Robot Assisted Gait Training in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02896179,UNKNOWN,Multiple Sclerosis,DEVICE: Robot-assisted gait training group+VR|DEVICE: GEO,Universita di Verona,,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-11,2017-11,2018-11,"Azienta Ospedaliera, SSO Rehabilitation Unit, Verona, Verona, 37134, Italy"
NCT04240379,Metacognition Assessment in Patient With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04240379,COMPLETED,Multiple Sclerosis,,"University Hospital, Grenoble",University Grenoble Alps,ALL,ADULT,,80,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-06-11,2022-04-08,2022-04-08,"Chu Grenoble Alpes, Grenoble, 38043, France"
NCT01992679,Body Weight Supported Treadmill Training in Persons With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01992679,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Exercise group,University of Illinois at Urbana-Champaign,,ALL,ADULT,PHASE1|PHASE2,24,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-10,2014-09,2014-09,"University of Illinois UC, Urbana-Champaign, Illinois, 61801, United States"
NCT02736279,Impact of Tecfidera on Gut Microbiota,https://beta.clinicaltrials.gov/study/NCT02736279,UNKNOWN,Multiple Sclerosis,DRUG: Dimethyl fumarate,Virginia Simnad,Biogen,ALL,"ADULT, OLDER_ADULT",,25,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-05,2020-06,2020-12,"EvergreenHealth MS Center, Kirkland, Washington, 98034, United States"
NCT05234879,The Feasibility of Frame Running as an Exercise Option for People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05234879,RECRUITING,Multiple Sclerosis,OTHER: Frame Running,Queen Margaret University,Multiple Sclerosis Society of Great Britain,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2022-05-04,2023-06-30,2023-08-31,"Queen Margaret University, Musselburgh, East Lothian, EH21 6UU, United Kingdom"
NCT03492450,Unraveling Early Walking Dysfunction in Non-disabled MS People: Assessment and Potential Therapeutic Interventions,https://beta.clinicaltrials.gov/study/NCT03492450,UNKNOWN,Multiple Sclerosis,OTHER: Treadmill training,Fondazione Don Carlo Gnocchi Onlus,,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-05-12,2019-12,2020-06,"Fondazione Don Gnocchi Irccs, Milan, Italy"
NCT04169750,Home-based EXergames To impRove cognitivE Function in MUltiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04169750,RECRUITING,Multiple Sclerosis,BEHAVIORAL: Exergames|BEHAVIORAL: Adaptive COGNI-TRAcK|BEHAVIORAL: Sham COGNI-TRAcK,"San Camillo Hospital, Rome","Fondazione Don Carlo Gnocchi Onlus|Fondazione Italiana Sclerosi Multipla|Rehabilitation Unit 'Mons. L. Novarese' Hospital, Moncrivello (VC), IT|University of Chieti",ALL,ADULT,NA,135,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-03-01,2022-06-30,2022-09-30,"Italian MS Foundation, Genova, GE, 16149, Italy|LaRiCE Lab, Don Gnocchi Foundation IRCCS, Milano, MI, 20148, Italy|A.O. San Camillo, MS Center, Rome, RM, 00152, Italy|Dept. of Rehabilitation, M.L. Novarese, Moncrivello, VC, 13040, Italy"
NCT02208050,A Study of the Effectiveness of Fampridine in Improving Upper Limb Function in MS,https://beta.clinicaltrials.gov/study/NCT02208050,COMPLETED,Secondary Progressive Multiple Sclerosis|Primary Progressive Multiple Sclerosis,DRUG: Fampridine|DRUG: Placebo,University College Dublin,,ALL,"ADULT, OLDER_ADULT",PHASE4,64,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-02-21,2016-02-16,2016-02-16,"St Vincent's University Hospital, Dublin, Dublin 4, Ireland|St. Vincents University Hospital, Dublin, D4, Ireland"
NCT01524250,Optic Neuritis Recovery After Oral or IV Corticosteroids,https://beta.clinicaltrials.gov/study/NCT01524250,COMPLETED,Optic Neuritis,DRUG: corticosteroids|DRUG: corticosteroids,London Health Sciences Centre,The Physicians' Services Incorporated Foundation,ALL,ADULT,PHASE2|PHASE3,51,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-03,2015-05,2015-05,"London Health Sciences Center, London, Ontario, N6A 5A5, Canada|London Health Sciences Center, London, Ontario, N6G1W8, Canada"
NCT01649050,Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01649050,WITHDRAWN,Muscle Spasticity Due to Multiple Sclerosis,DRUG: BGG492|DRUG: Placebo,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE2,0,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-10,2018-03,2018-03,
NCT02117375,EMISEP : Early Spinal Cord Lesions and Late Disability in Relapsing Remitting Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT02117375,UNKNOWN,Multiple Sclerosis,DEVICE: spinal cord MRI follow-up|OTHER: clinical follow-up|OTHER: brain MRI follow-up,Rennes University Hospital,,ALL,ADULT,NA,115,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2014-01,2022-04,2022-07,"CHU Rennes, Rennes, France"
NCT04371575,Symptomatic Trigeminal Neuralgia Attributed to Multiple Sclerosis - a Prospective Study in 60 Patients,https://beta.clinicaltrials.gov/study/NCT04371575,COMPLETED,"Trigeminal Neuralgia|Multiple Sclerosis|Pain, Neuropathic",DRUG: Carbamazepine,"Stine Maarbjerg, MD PhD",,ALL,"CHILD, ADULT, OLDER_ADULT",,60,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-09-01,2019-12-31,2019-12-31,
NCT03692975,MRI Hippocampal Microstructure and Episodic Memory in Early Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03692975,COMPLETED,Multiple Sclerosis,OTHER: Clinical assessment|OTHER: Neuropsychological evaluation|OTHER: Psychological evaluation|DEVICE: MRI Evaluation,"University Hospital, Bordeaux",,ALL,ADULT,NA,84,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2019-02-12,2023-02-24,2023-02-24,"CHU de Bordeaux - service de neurologie, Bordeaux, France"
NCT01954875,Establishment of a Human Tissue Bank for Studying the Microbial Etiology of Neurodegenerative Diseases,https://beta.clinicaltrials.gov/study/NCT01954875,WITHDRAWN,Neurodegenerative Diseases|Amyotrophic Lateral Sclerosis|Multiple Sclerosis|Parkinson Disease,,Wake Forest University Health Sciences,,ALL,"ADULT, OLDER_ADULT",,0,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2009-12-02,2016-12-30,2019-07-02,"Carolinas Medical Center - Dept of Neurology, Charlotte, North Carolina, 28207, United States"
NCT01081275,Improving Hand Use in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01081275,UNKNOWN,Multiple Sclerosis,BEHAVIORAL: CI Therapy|BEHAVIORAL: CAM treatments,National Multiple Sclerosis Society,,ALL,"ADULT, OLDER_ADULT",PHASE2,66,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2010-02,2016-02,2016-03,"University of Alabama at Birmingham, Birmingham, Alabama, 35249, United States"
NCT03963375,Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03963375,RECRUITING,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting",DRUG: Cladribine,Washington University School of Medicine,EMD Serono,ALL,"ADULT, OLDER_ADULT",PHASE4,50,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2019-10-28,2025-05-30,2025-05-30,"Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, 73104, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|University of Texas Southwestern Medical Center, Dallas, Texas, 75390, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States"
NCT04289675,Multiple Sclerosis: Chi3L1 and Treatment Efficacy,https://beta.clinicaltrials.gov/study/NCT04289675,COMPLETED,Multiple Sclerosis,DRUG: Interferon-Beta,"Central Hospital, Nancy, France",,ALL,ADULT,,63,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-01-01,2019-12-01,2019-12-01,
NCT00011375,Rolipram to Treat Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00011375,COMPLETED,Multiple Sclerosis,DRUG: Rolipram,National Institute of Neurological Disorders and Stroke (NINDS),,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,52,NIH,INTERVENTIONAL,Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT,2001-02,,2004-04,"National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, 20892, United States"
NCT03306875,Impact of Brain Connectome and Personality on Cognitive Rehabilitation in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03306875,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Cognitive Training,State University of New York at Buffalo,,ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2017-11-01,2018-04-30,2018-10-20,"Jacobs Comprehensive Multiple Sclerosis Treatment and Research Center, Buffalo, New York, 14203, United States"
NCT00289159,Multimodal MRI in Multiple Sclerosis (MS): Reliability and Follow Up,https://beta.clinicaltrials.gov/study/NCT00289159,UNKNOWN,Multiple Sclerosis,,Groupe Hospitalier Pitie-Salpetriere,"Institut National de la Santé Et de la Recherche Médicale, France",ALL,ADULT,,,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,,,,
NCT05003375,Physiological Responses in Experimentally Induced Cognitive Fatigue in People With Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT05003375,RECRUITING,Multiple Sclerosis|Fatigue|Stress,BEHAVIORAL: High-challenging cognitive protocol to provoke stress and (cognitive) fatigue,KU Leuven,National MS Center Melsbroek,ALL,ADULT,,40,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-10-15,2021-08-30,2021-09-01,"KU Leuven, Department of Rehabilitation Sciences, Leuven, 3000, Belgium|National Multiple Sclerosis Center, Melsbroek, Belgium"
NCT00127075,POPART'MUS: Prevention of Post Partum Relapses With Progestin and Estradiol in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00127075,UNKNOWN,Multiple Sclerosis,DRUG: nomegestrol acetate|DRUG: estradiol|DRUG: placebo,Hospices Civils de Lyon,,FEMALE,ADULT,PHASE3,300,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2005-06,2012-04,2012-04,"Hôpital Pierre Wertheimer, Bron, 69677, France"
NCT01079975,To Identify and Evaluate the Predictive Factors for Depression in Patients Diagnosed With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01079975,COMPLETED,Multiple Sclerosis,,"Merck KGaA, Darmstadt, Germany",,ALL,"ADULT, OLDER_ADULT",,301,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2008-08,2010-10,2012-07,"Instituto de Investigacion Neurológica (Uruguay 840), Capital Federal, Buenos Aires, 1015, Argentina"
NCT03860675,Assessment of Walking-related Fatigability in Patients With Multiple Sclerosis.,https://beta.clinicaltrials.gov/study/NCT03860675,COMPLETED,Multiple Sclerosis,DIAGNOSTIC_TEST: Assessment of walking-related fatigability,Hasselt University,Revalidatie & MS Centrum Overpelt|National MS Center Melsbroek,ALL,"ADULT, OLDER_ADULT",NA,85,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2017-12-01,2018-05-31,2018-05-31,"Hasselt University, Diepenbeek, 3590, Belgium|National MS Center Melsbroek, Melsbroek, 1820, Belgium|Revalidatie & MS Centrum Overpelt, Overpelt, 3900, Belgium"
NCT01125475,A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects,https://beta.clinicaltrials.gov/study/NCT01125475,COMPLETED,Relapsing Remitting Multiple Sclerosis (RRMS),DEVICE: RebiSmart,"Merck KGaA, Darmstadt, Germany",Merck Serono Norway|Smerud Medical Research International AS,ALL,"ADULT, OLDER_ADULT",,61,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-08,2012-03,,"Sandvika Nevrosenter, Sandvika, Sandviksveien 178, N-1337, Norway"
NCT04472975,Prescription Drug Safety and Effectiveness in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04472975,COMPLETED,Multiple Sclerosis,DRUG: Exposure to one or more disease-modifying drug(s)(DMDs) used to treat MS,University of British Columbia,University of Manitoba|Dalhousie University|University of Saskatchewan|Alberta Health services|University of Alberta,ALL,"ADULT, OLDER_ADULT",,35000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,1996-01-01,2018-03-31,2018-03-31,
NCT04237675,Postoperative Relapses in MS Patients,https://beta.clinicaltrials.gov/study/NCT04237675,RECRUITING,Multiple Sclerosis Relapse|Surgery|Anesthesia,PROCEDURE: surgery and anesthesia,University of Athens,,ALL,"ADULT, OLDER_ADULT",,300,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-12-20,2027-12,2027-12,"Aretaieio Hospital, University of Athens, Athens, Attiki, 11528, Greece|Aretaieio Hospital, Athens, Greece"
NCT02738775,Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02738775,COMPLETED,Multiple Sclerosis,BIOLOGICAL: Ublituximab|DRUG: Placebo,"TG Therapeutics, Inc.",,ALL,ADULT,PHASE2,49,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2016-05-27,2017-09-27,2018-08-13,"TG Therapeutics Investigational Trial Site, Phoenix, Arizona, 85018, United States|TG Therapeutics Investigational Trial Site, Pasadena, California, 91105, United States|TG Therapeutics Investigational Trial Site, Torrance, California, 90502, United States|TG Therapeutics Investigational Trial Site, Aurora, Colorado, 80045, United States|TG Therapeutics Investigational Trial Site, Fort Collins, Colorado, 80528, United States|TG Therapeutics Investigational Trial Site, Lexington, Kentucky, 40509, United States|TG Therapeutics Investigational Trial Site, Teaneck, New Jersey, 07666, United States|TG Therapeutics Investigational Trial Site, Akron, Ohio, 44320, United States|TG Therapeutics Investigational Trial Site, Columbus, Ohio, 43201, United States|TG Therapeutics Investigational Trial Site, Knoxville, Tennessee, 37922, United States|TG Therapeutics Investigational Trial Site, Round Rock, Texas, 78681, United States|TG Therapeutics Investigational Trial Site, San Antonio, Texas, 78258, United States"
NCT02207075,Measuring Active Microglia in Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02207075,COMPLETED,Secondary Progressive Multiple Sclerosis,DRUG: [C11]PK-1195 PET scan,Weill Medical College of Cornell University,"Genzyme, a Sanofi Company",ALL,"ADULT, OLDER_ADULT",,50,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-07,2020-12,2020-12,"Weill Cornell Medical College, New York, New York, 10021, United States"
NCT05633875,Multimodal Imaging Signatures of the Biological Mechanisms Underlying Neurodegeneration in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05633875,NOT_YET_RECRUITING,Multiple Sclerosis (MS),OTHER: MRI,Assistance Publique - Hôpitaux de Paris,,ALL,"ADULT, OLDER_ADULT",,80,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2025-01-30,2025-01-30,2025-07-15,
NCT01753375,Role of Vitamin D in Reducing the Relapse Rate in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01753375,UNKNOWN,Multiple Sclerosis,DIETARY_SUPPLEMENT: Vitamin D3|DIETARY_SUPPLEMENT: Placebo,"AlJohara M AlQuaiz, M.D.",,ALL,ADULT,PHASE2,200,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2013-01,2014-07,2014-10,"Multiple Sclerosis clinic, Department of Neurology, King Khalid Hospital, Riyadh 11321, 231831, Saudi Arabia"
NCT03551275,"Dose Escalation Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 in Patients With Relapsing-Remitting Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT03551275,COMPLETED,Multiple Sclerosis,BIOLOGICAL: BCD-132,Biocad,,ALL,ADULT,PHASE1,24,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: OTHER,2018-02-22,2018-10-18,2019-03-28,"City Hospital #15, Moscow, Russian Federation|Moscow Regional Research and Clinical Institute, Moscow, Russian Federation|Scientific Center of Neurology, Moscow, Russian Federation|Pavlov First Saint Petersburg State Medical University, Saint Petersburg, 197022, Russian Federation|Institute of the Human Brain n. a. N.P. Bekhtereva Russian Academy of Sciences, Saint Petersburg, Russian Federation"
NCT03993275,Exergames Balance Program in Neurorehabilitation,https://beta.clinicaltrials.gov/study/NCT03993275,COMPLETED,Stroke|Multiple Sclerosis|Balance Disorders,DEVICE: MindMotion GO,Klinik Valens,Mindmaze SA|KU Leuven,ALL,"ADULT, OLDER_ADULT",,84,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-10-10,2020-01-15,2020-01-15,"Rehazentrum Valens, Valens, SG, 7317, Switzerland"
NCT03028675,pH-weighted MRI in Multiple Sclerosis: A Surrogate Marker of Tissue Metabolic Stress,https://beta.clinicaltrials.gov/study/NCT03028675,COMPLETED,Multiple Sclerosis,OTHER: MRI Scan,NYU Langone Health,,ALL,"ADULT, OLDER_ADULT",,4,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-05-01,2018-08-10,2018-08-10,"New York University School of Medicine, New York, New York, 10016, United States"
NCT03562975,Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus,https://beta.clinicaltrials.gov/study/NCT03562975,ACTIVE_NOT_RECRUITING,Multiple Sclerosis|Pathologic Processes|Demyelinating Diseases|Nervous System Diseases|Autoimmune Diseases|Immune System Diseases|Primary Progressive Multiple Sclerosis|Relapsing Remitting Multiple Sclerosis,DRUG: Ocrelizumab,University of South Florida,"Genentech, Inc.",ALL,"ADULT, OLDER_ADULT",,18,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-07-23,2023-02,2023-12,"Carol and Frank Morsani Center for Advanced Healthcare, Tampa, Florida, 33612, United States"
NCT03451175,Reproductibility of Cystometry in Multiple Sclerosis Patient,https://beta.clinicaltrials.gov/study/NCT03451175,COMPLETED,Lower Urinary Tract Symptoms|Cystometry|Multiple Sclerosis|Overactive Bladder|Overactive Detrusor,,Pierre and Marie Curie University,,ALL,"ADULT, OLDER_ADULT",,31,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-07-02,2017-11-01,2018-01-01,"Service de Neuro-urology, hôpital Tenon, Paris, France"
NCT01128075,Treatment Adherence When Using RebiSmart™ in Relapsing Multiple Sclerosis Subjects,https://beta.clinicaltrials.gov/study/NCT01128075,COMPLETED,Multiple Sclerosis|MS,DEVICE: RebiSmart™|DEVICE: RebiSmart™,"Merck KGaA, Darmstadt, Germany","EMD Inc., Canada",ALL,"ADULT, OLDER_ADULT",,198,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2009-08,2014-04,2014-04,"University of British Columbia, Vancouver, Canada"
NCT05748015,Definition of Autonomic Nervous System Involvement in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05748015,RECRUITING,Multiple Sclerosis,"DIAGNOSTIC_TEST: quantification of sensory and autonomic small nerve fibers by punch skin biopsy|DIAGNOSTIC_TEST: Cardiovascular Reflexes testing|OTHER: Administration of clinical scales evaluating autonomic symptoms, pain small fiber neuropathy symptoms",Istituti Clinici Scientifici Maugeri SpA,,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2021-03-04,2024-01-30,2024-03-30,"ICS Maugeri - IRCCS of Telese Terme, Telese Terme, Benevento, 82037, Italy|Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Napoli, 80131, Italy"
NCT04788615,Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS,https://beta.clinicaltrials.gov/study/NCT04788615,RECRUITING,Multiple Sclerosis,DRUG: Ofatumumab|DRUG: First line DMT,Novartis Pharmaceuticals,,ALL,ADULT,PHASE3,236,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-07-23,2024-11-15,2025-02-14,"Novartis Investigative Site, Bayonne, Bayonne Cedex, 64109, France|Novartis Investigative Site, Nantes, Cedex 1, 44093, France|Novartis Investigative Site, Amiens, 80054, France|Novartis Investigative Site, Bordeaux Cedex, 33076, France|Novartis Investigative Site, Clermont-Ferrand Cedex 1, 63003, France|Novartis Investigative Site, Creteil, 94010, France|Novartis Investigative Site, Gonesse, 95500, France|Novartis Investigative Site, Grenoble, 38042, France|Novartis Investigative Site, Lille Cedex, 59037, France|Novartis Investigative Site, Montpellier, 34295, France|Novartis Investigative Site, Nice Cedex, 06202, France|Novartis Investigative Site, Nimes, 30029, France|Novartis Investigative Site, Poissy, 78303, France|Novartis Investigative Site, Rennes Cedex, 35033, France|Novartis Investigative Site, Strasbourg, 67098, France|Novartis Investigative Site, Suresnes, 92150, France|Novartis Investigative Site, Bayreuth, 95445, Germany|Novartis Investigative Site, Berlin, 12101, Germany|Novartis Investigative Site, Bielefeld, 33647, Germany|Novartis Investigative Site, Dortmund, 44137, Germany|Novartis Investigative Site, Erbach, 64711, Germany|Novartis Investigative Site, Heidelberg, 69120, Germany|Novartis Investigative Site, Kassel, 34121, Germany|Novartis Investigative Site, Siegen, 57076, Germany|Novartis Investigative Site, Ulm, 89073, Germany|Novartis Investigative Site, Ulm, 89081, Germany|Novartis Investigative Site, Westerstede/Oldenburg, 26655, Germany|Novartis Investigative Site, Montichiari, BS, 25018, Italy|Novartis Investigative Site, Milano, MI, 20132, Italy|Novartis Investigative Site, Roma, RM, 00133, Italy|Novartis Investigative Site, Roma, RM, 00189, Italy|Novartis Investigative Site, Malaga, Andalucia, 29010, Spain|Novartis Investigative Site, Sevilla, Andalucia, 41017, Spain|Novartis Investigative Site, Salt, Cataluna, 17190, Spain|Novartis Investigative Site, Santiago de Compostela, Galicia, 15706, Spain|Novartis Investigative Site, El Palmar, Murcia, 30120, Spain|Novartis Investigative Site, Baracaldo, Vizcaya, 48903, Spain|Novartis Investigative Site, Barcelona, 08035, Spain|Novartis Investigative Site, Madrid, 28009, Spain|Novartis Investigative Site, Madrid, 28034, Spain|Novartis Investigative Site, Madrid, 28040, Spain|Novartis Investigative Site, Valencia, 46026, Spain|Novartis Investigative Site, Zaragoza, 50009, Spain|Novartis Investigative Site, Exeter, EX2 5DW, United Kingdom|Novartis Investigative Site, Glasgow, G51 4TF, United Kingdom"
NCT02555215,Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),https://beta.clinicaltrials.gov/study/NCT02555215,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: dimethyl fumarate,Biogen,,ALL,CHILD,PHASE3,20,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-02-22,2018-09-24,2018-09-24,"Research Site, Loma Linda, California, 92354, United States|Research Site, Ghent, 9000, Belgium|Research Site, Sofia, 1113, Bulgaria|Research Site, Hradec Kralove, 50333, Czechia|Research Site, Muenchen, Bayern, 80337, Germany|Research Site, Göttingen, Niedersachsen, 37075, Germany|Research Site, Kuwait City, 15462, Kuwait|Research Site, Riga, LV-1004, Latvia|Research Site, Beirut, 1107 2020, Lebanon|Research Site, Gdansk, 80-952, Poland|Research Site, Poznan, 60-355, Poland|Research Site, Ankara, 06100, Turkey"
NCT00913250,A Bioequivalence Study of Serum Free Avonex and Serum Containing Avonex in Healthy Volunteers,https://beta.clinicaltrials.gov/study/NCT00913250,COMPLETED,Multiple Sclerosis,DRUG: Serum containing Avonex|DRUG: Serum Free Avonex,Biogen,,ALL,ADULT,PHASE1,96,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE,2003-08,,2003-10,
NCT00605215,BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®),https://beta.clinicaltrials.gov/study/NCT00605215,COMPLETED,Multiple Sclerosis,DRUG: Laquinimod|DRUG: Placebo|DRUG: Avonex®,"Teva Branded Pharmaceutical Products R&D, Inc.",,ALL,ADULT,PHASE3,1331,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2008-04-24,2011-06-10,2011-06-10,"Teva Investigational Site 1267, Birmingham, Alabama, 35209, United States|Teva Investigational Site 1237, Phoenix, Arizona, 85013, United States|Teva Investigational Site 1252, Phoenix, Arizona, 85018, United States|Teva Investigational Site 1279, Phoenix, Arizona, 85018, United States|Teva Investigational Site 1276, Tucson, Arizona, 85741-3537, United States|Teva Investigational Site 1272, Pasadena, California, 91105, United States|Teva Investigational Site 1238, Sacramento, California, 95817, United States|Teva Investigational Site 1280, Aurora, Colorado, 80045, United States|Teva Investigational Site 1255, Orlando, Florida, 32806, United States|Teva Investigational Site 1282, Sarasota, Florida, 34233, United States|Teva Investigational Site 1275, Atlanta, Georgia, 30309, United States|Teva Investigational Site 1250, Peoria, Illinois, 61603, United States|Teva Investigational Site 1260, Indianapolis, Indiana, 46202, United States|Teva Investigational Site 1268, Lenexa, Kansas, 66214, United States|Teva Investigational Site 1277, New Orleans, Louisiana, 70115, United States|Teva Investigational Site 1263, Shreveport, Louisiana, 71103, United States|Teva Investigational Site 1269, Baltimore, Maryland, 21201, United States|Teva Investigational Site 1274, Grand Rapids, Michigan, 49525, United States|Teva Investigational Site 1239, Lebanon, New Hampshire, 03766, United States|Teva Investigational Site 1265, Teaneck, New Jersey, 07666, United States|Teva Investigational Site 1273, Albany, New York, 12205, United States|Teva Investigational Site 1264, Amherst, New York, 14226, United States|Teva Investigational Site 1283, Cedarhurst, New York, 11516, United States|Teva Investigational Site 1249, Raleigh, North Carolina, 27607, United States|Teva Investigational Site 1262, Winston-Salem, North Carolina, 27103, United States|Teva Investigational Site 1261, Akron, Ohio, 44320, United States|Teva Investigational Site 1241, Canton, Ohio, 44718, United States|Teva Investigational Site 1245, Cleveland, Ohio, 44195-5244, United States|Teva Investigational Site 1247, Columbus, Ohio, 43221, United States|Teva Investigational Site 1244, Portland, Oregon, 97225, United States|Teva Investigational Site 1258, Philadelphia, Pennsylvania, 19107, United States|Teva Investigational Site 1281, Nashville, Tennessee, 37205, United States|Teva Investigational Site 1284, San Antonio, Texas, 78231, United States|Teva Investigational Site 1248, Richmond, Virginia, 23298-0599, United States|Teva Investigational Site 1270, Roanoke, Virginia, 24018, United States|Teva Investigational Site 1253, Tacoma, Washington, 98405, United States|Teva Investigational Site 5914, Pleven, 5800, Bulgaria|Teva Investigational Site 5915, Pleven, 5800, Bulgaria|Teva Investigational Site 5917, Plovdiv, 4000, Bulgaria|Teva Investigational Site 4212, Ruse, 7000, Bulgaria|Teva Investigational Site 5916, Shumen, 9700, Bulgaria|Teva Investigational Site 5920, Sofia, 1000, Bulgaria|Teva Investigational Site 5907, Sofia, 1113, Bulgaria|Teva Investigational Site 5910, Sofia, 1113, Bulgaria|Teva Investigational Site 5909, Sofia, 1309, Bulgaria|Teva Investigational Site 5919, Sofia, 1407, Bulgaria|Teva Investigational Site 5906, Sofia, 1606, Bulgaria|Teva Investigational Site 5908, Sofia, 1606, Bulgaria|Teva Investigational Site 5911, Sofia, 1606, Bulgaria|Teva Investigational Site 5912, Sofia, 1606, Bulgaria|Teva Investigational Site 5918, Stara Zagora, 6000, Bulgaria|Teva Investigational Site 5913, Varna, 9010, Bulgaria|Teva Investigational Site 4211, Veliko Tarnovo, 5000, Bulgaria|Teva Investigational Site 6003, Osijek, 31 000, Croatia|Teva Investigational Site 6004, Split, 21000, Croatia|Teva Investigational Site 6005, Varazdin, 42000, Croatia|Teva Investigational Site 6001, Zagreb, 10000, Croatia|Teva Investigational Site 6002, Zagreb, 10000, Croatia|Teva Investigational Site 6006, Zagreb, 10000, Croatia|Teva Investigational Site 5422, Brno, 602 00, Czechia|Teva Investigational Site 5419, Olomouc, 779 00, Czechia|Teva Investigational Site 5418, Praha 2, 128 08, Czechia|Teva Investigational Site 5420, Praha 5- Motol, 150 06, Czechia|Teva Investigational Site 5421, Teplice, 415 29, Czechia|Teva Investigational Site 5508, Kohtla-Jarve, 31025, Estonia|Teva Investigational Site 5507, Tallinn, EE-10617, Estonia|Teva Investigational Site 5509, Tartu, EE-51014, Estonia|Teva Investigational Site 8102, Tbilisi, 0112, Georgia|Teva Investigational Site 8104, Tbilisi, 0112, Georgia|Teva Investigational Site 8103, Tbilisi, 0179, Georgia|Teva Investigational Site 6701, Bayreuth, 95445, Germany|Teva Investigational Site 6703, Berlin, 10117, Germany|Teva Investigational Site 6402, Berlin, 12203, Germany|Teva Investigational Site 6700, Berlin, 13088, Germany|Teva Investigational Site 6702, Dresden, 01307, Germany|Teva Investigational Site 6401, Hannover, 30559, Germany|Teva Investigational Site 6403, Munster, 48149, Germany|Teva Investigational Site 6400, Ulm, 89081, Germany|Teva Investigational Site 8043, Haifa, 3436212, Israel|Teva Investigational Site 8041, Jerusalem, 9112001, Israel|Teva Investigational Site 8040, Ramat Gan, 5262160, Israel|Teva Investigational Site 8042, Ramat Gan, 5262160, Israel|Teva Investigational Site 3056, Bologna, 40139, Italy|Teva Investigational Site 3062, Catania, 95122, Italy|Teva Investigational Site 3053, Cefalu, 90015, Italy|Teva Investigational Site 3054, Chieti, 66100, Italy|Teva Investigational Site 3061, Empoli, 50053, Italy|Teva Investigational Site 3049, Firenze, 50139, Italy|Teva Investigational Site 3055, Napoli, 80131, Italy|Teva Investigational Site 3048, Rome, 00133, Italy|Teva Investigational Site 3052, Rome, 00149, Italy|Teva Investigational Site 3050, Rome, 00168, Italy|Teva Investigational Site 3060, Rome, 163, Italy|Teva Investigational Site 3051, Torino, 10126, Italy|Teva Investigational Site 5708, Kaunas, 50009, Lithuania|Teva Investigational Site 5707, Siauliai, 76231, Lithuania|Teva Investigational Site 6502, Bitola, 7000, North Macedonia|Teva Investigational Site 6500, Skopje, 1000, North Macedonia|Teva Investigational Site 6501, Skopje, 1000, North Macedonia|Teva Investigational Site 5337, Bialystok, 15-402, Poland|Teva Investigational Site 5329, Gdansk, 80-803, Poland|Teva Investigational Site 5338, Gdansk, 80-952, Poland|Teva Investigational Site 6602, Gorzow Wielkopolski, 66-400, Poland|Teva Investigational Site 5333, Grodzisk Mazowiecki, 05-825, Poland|Teva Investigational Site 5339, Katowice, 40-635, Poland|Teva Investigational Site 5334, Katowice, 40-752, Poland|Teva Investigational Site 6603, Kielce, 25-736, Poland|Teva Investigational Site 4213, Konskie, 26-200, Poland|Teva Investigational Site 5332, Koscierzyna, 83-400, Poland|Teva Investigational Site 5345, Krakow, 31-826, Poland|Teva Investigational Site 5328, Lodz, 90-153, Poland|Teva Investigational Site 5330, Olsztyn, 10-560, Poland|Teva Investigational Site 5331, Szczecin, 70-215, Poland|Teva Investigational Site 5336, Warsaw, 02-957, Poland|Teva Investigational Site 5340, Warszawa, 00-909, Poland|Teva Investigational Site 5341, Warszawa, 02-097, Poland|Teva Investigational Site 5335, Wroclaw, 50-556, Poland|Teva Investigational Site 1243, Guaynabo, 00969, Puerto Rico|Teva Investigational Site 5218, Bucharest, 010825, Romania|Teva Investigational Site 5214, Bucuresti, 022328, Romania|Teva Investigational Site 5213, Bucuresti, 050098, Romania|Teva Investigational Site 5215, Cluj-Napoca, 400012, Romania|Teva Investigational Site 5217, Constanta, 900591, Romania|Teva Investigational Site 8209, Craiova, 200515, Romania|Teva Investigational Site 5216, Iasi, 700661, Romania|Teva Investigational Site 5219, Sibiu, 550245, Romania|Teva Investigational Site 5043, Barnaul, 656024, Russian Federation|Teva Investigational Site 5033, Moscow, 117152, Russian Federation|Teva Investigational Site 5032, Moscow, 117997, Russian Federation|Teva Investigational Site 5041, Moscow, 125367, Russian Federation|Teva Investigational Site 5038, Novosibirsk, 630087, Russian Federation|Teva Investigational Site 5042, Novosibirsk, 630117, Russian Federation|Teva Investigational Site 5035, Saint Petersburg, 197022, Russian Federation|Teva Investigational Site 5037, Samara, 443095, Russian Federation|Teva Investigational Site 5036, St. Petersburg, 194291, Russian Federation|Teva Investigational Site 5034, St. Petersburg, 197376, Russian Federation|Teva Investigational Site 5044, Ufa, 450007, Russian Federation|Teva Investigational Site 6200, Bratislava, 813 69, Slovakia|Teva Investigational Site 6201, Bratislava, 826 06, Slovakia|Teva Investigational Site 6202, Nitra, 949 01, Slovakia|Teva Investigational Site 6203, Zilina, 010 01, Slovakia|Teva Investigational Site 9007, Bloemfontein, 9301, South Africa|Teva Investigational Site 9001, Cape Town, 7925, South Africa|Teva Investigational Site 9004, Johannesburg, 2157, South Africa|Teva Investigational Site 9003, Johannesburg, 2193, South Africa|Teva Investigational Site 9008, Pietermaritzburg, 3201, South Africa|Teva Investigational Site 9005, Pretoria, 0041, South Africa|Teva Investigational Site 9006, Rosebank, 2196, South Africa|Teva Investigational Site 3147, Barcelona, 08035, Spain|Teva Investigational Site 3154, Figueres-Girona, 17600, Spain|Teva Investigational Site 3149, L'Hospitalet de Llobregat, 08907, Spain|Teva Investigational Site 3152, Madrid, 28041, Spain|Teva Investigational Site 3151, Malaga, 29010, Spain|Teva Investigational Site 3148, Sevilla, 41009, Spain|Teva Investigational Site 3153, Tortosa-Tarragona, 43500, Spain|Teva Investigational Site 6503, Chernihiv, 14029, Ukraine|Teva Investigational Site 5823, Chernivtsi, 58018, Ukraine|Teva Investigational Site 5811, Dnipropetrovsk, 49027, Ukraine|Teva Investigational Site 5812, Donetsk, 83003, Ukraine|Teva Investigational Site 5814, Ivano-Frankivsk, 76008, Ukraine|Teva Investigational Site 5817, Kharkiv, 61018, Ukraine|Teva Investigational Site 5818, Kharkiv, 61068, Ukraine|Teva Investigational Site 5815, Kharkiv, 61103, Ukraine|Teva Investigational Site 5822, Kyiv, 03110, Ukraine|Teva Investigational Site 5809, Lviv, 79010, Ukraine|Teva Investigational Site 5820, Odessa, 65025, Ukraine|Teva Investigational Site 5821, Poltava, 36024, Ukraine|Teva Investigational Site 5810, Vinnytsya, 21005, Ukraine|Teva Investigational Site 5819, Zaporizhzhya, 69035, Ukraine|Teva Investigational Site 5816, Zaporizhzhya, 69600, Ukraine"
NCT04510350,Investigation of Novel Immunological Biomarkers by Mass Cytometry in Patients With Early Multiple Sclerosis (CISCO),https://beta.clinicaltrials.gov/study/NCT04510350,COMPLETED,Multiple Sclerosis,OTHER: Biomarkers analysis,Rennes University Hospital,,ALL,"ADULT, OLDER_ADULT",,90,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-02-19,2022-03-02,2022-03-02,"CHU Rennes, Rennes, France"
NCT04550650,Follow-up Study of the Effectiveness of Virtual Reality Therapy in MS Patients,https://beta.clinicaltrials.gov/study/NCT04550650,COMPLETED,"Multiple Sclerosis, Chronic Progressive|Multiple Sclerosis, Primary Progressive",OTHER: Training groupe|OTHER: PNF|OTHER: Spinning grp|OTHER: Balance,Somogy Megyei Kaposi Mór Teaching Hospital,,ALL,ADULT,NA,4,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2018-04-06,2020-04-06,2020-09-01,"Somogy Megyei Kaposi Mór Oktató Kórház, Kaposvár, Somogy, 7400, Hungary"
NCT04466150,Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset,https://beta.clinicaltrials.gov/study/NCT04466150,RECRUITING,Relapsing Multiple Sclerosis|Clinically Isolated Syndrome,DRUG: Ocrelizumab,"University of California, San Francisco","Genentech, Inc.|Valhalla Foundation",ALL,ADULT,PHASE4,30,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2020-08-30,2025-12,2025-12,"University of California San Francisco, San Francisco, California, 94158, United States"
NCT05469568,Hybrid Rehabilitation Approach Through Group Exercise and Telerehabilitation in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05469568,RECRUITING,Multiple Sclerosis,OTHER: Circuit training followed by telerehabilitation|OTHER: Usual care,Brno University Hospital,,ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-07-15,2024-09-30,2024-12-20,"Michaela Sládečková, Brno, Czech Republic, 625 00, Czechia"
NCT01453868,The Effects of Aerobics Training on Balance in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01453868,UNKNOWN,"Multiple Sclerosis, Relapsing-Remitting",OTHER: Non Impact Aerobics|OTHER: Passive : lecture series,Nelson Mandela Metropolitan University,,ALL,ADULT,EARLY_PHASE1,60,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2011-10,2012-03,2012-06,"HealthZone Chiropractic Clinic, Gaylord, Michigan, 49735, United States"
NCT02335450,Theory Based Intervention Program to Support Physical Activity for Individuals With Multiple Sclerosis: a Case Series,https://beta.clinicaltrials.gov/study/NCT02335450,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Motivational Interviewing|DEVICE: Wristband physical activity monitor,Oakland University,,ALL,"ADULT, OLDER_ADULT",NA,5,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-02-12,2015-11-12,2015-11-12,"Oakland University, Rochester, Michigan, 48309, United States"
NCT04725175,Phase I Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of of PIPE-307 and Food Effect in Healthy Volunteers,https://beta.clinicaltrials.gov/study/NCT04725175,COMPLETED,Multiple Sclerosis,DRUG: PIPE-307|DRUG: Placebo oral tablet,"Pipeline Therapeutics, Inc.",,ALL,ADULT,PHASE1,70,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-02-26,2021-09-01,2021-09-01,"Linear Clinical Research, Nedlands, Western Australia, 6009, Australia"
NCT05338450,Clemastine Fumarate as Remyelinating Treatment in Internuclear Ophthalmoparesis and Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05338450,RECRUITING,Multiple Sclerosis|Internuclear Ophthalmoplegia,DRUG: Clemastine Fumarate|DRUG: Placebo,"Amsterdam UMC, location VUmc",,ALL,"ADULT, OLDER_ADULT",PHASE3,80,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-08-30,2024-05,2026-11,"Amsterdam UMC, location VUmc, Amsterdam, 1081 HV, Netherlands"
NCT02339675,Psychometric Properties Upper Limb Function Measures Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02339675,COMPLETED,Multiple Sclerosis,OTHER: conventional MS rehabilitation,Hasselt University,"Revalidatie & MS Centrum Overpelt|Charles University, Czech Republic|Danish MS Hospitals, Haslev and Ry|Fondazione Don Carlo Gnocchi Onlus|Italian Multiple Sclerosis Foundation|centrisclerosimultipla|Sheba Medical Center|Haukeland University Hospital|MS Rehabilitation Center Borne Sulinowo|University of Ljubljana|Eugenia Epalza Rehabilitation Center, Bilbao, Spain|Day General Hospital.|Shepherd Center, Atlanta GA|Queen's University|St. Louis University|De Mick|MS center Hakadal AS",ALL,"ADULT, OLDER_ADULT",NA,136,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2014-10,2016-02,2016-06,"Hasselt University, Diepenbeek, 3590, Belgium"
NCT02939859,"Use of Cellular Stromal Vascular Fraction in Multiple Sclerosis,Autoimmune, Inflammatory, Neurologic Conditions",https://beta.clinicaltrials.gov/study/NCT02939859,WITHDRAWN,Multiple Sclerosis|Autoimmune,PROCEDURE: Microcannula Harvest Adipose|DEVICE: Centricyte 1000|PROCEDURE: Sterile Normal Saline IV deployment AD-cSVF,Healeon Medical Inc,Global Alliance for Regenerative Medicine,ALL,"ADULT, OLDER_ADULT",PHASE1,0,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-12-15,2022-10,2023-10,"Regenevita LLC, Stevensville, Montana, 59870, United States|Global Alliance for Regenerative Medicine (GARM), Roatan, Hn, Honduras"
NCT02098759,"Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy - Tuberous Sclerosis Complex",https://beta.clinicaltrials.gov/study/NCT02098759,UNKNOWN,TSC|Tuberous Sclerosis Complex|Epilepsy,DEVICE: epilepsy early diagnosis protocol,Sergiusz Jozwiak,"University of Rome Tor Vergata|Institut National de la Santé Et de la Recherche Médicale, France|Vrije Universiteit Brussel|General University Hospital, Prague|Charite University, Berlin, Germany|KU Leuven|Medical University of Vienna|Rudolf Magnus Institute - University of Utrecht|Brigham and Women's Hospital",ALL,CHILD,NA,100,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: DIAGNOSTIC",2013-11,2018-10,2018-10,"Medizinische Universitaet Wien, Vienna, Austria|Vrije Universiteit Brussel, Brussels, Belgium|Katholieke Universiteit Leuven, Leuven, Belgium|Fakultni Nemocnice V Motole, Prague, Czech Republic|Institut National De La Sante et de la Recherche Medicale, Paris, France|Charite - Universitaetsmedizin Berlin, Berlin, Germany|Universita Degli Studi Di Roma Tor Vergata, Rome, Italy|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Children's Memorial Health Institute, Warsaw, Poland"
NCT02545959,Intrathecal Rituximab in Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02545959,COMPLETED,"Multiple Sclerosis, Chronic Progressive|Nervous System Diseases",DRUG: Rituximab IT|DRUG: methylprednisolone IV|DRUG: Rituximab IV,Centre Hospitalier de PAU,"University Hospital, Bordeaux",ALL,"ADULT, OLDER_ADULT",PHASE2,10,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2015-11-30,2019-02-22,2019-09-02,"Centre hospitalier F. Mitterrand (CH Pau), Pau, 64000, France"
NCT01854359,Idebenone for Primary Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01854359,COMPLETED,Multiple Sclerosis|Primary Progressive Multiple Sclerosis,DRUG: Idebenone,National Institute of Allergy and Infectious Diseases (NIAID),,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,61,NIH,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-03-12,2018-10-31,2018-10-31,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States"
NCT00101959,Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) Subjects,https://beta.clinicaltrials.gov/study/NCT00101959,WITHDRAWN,Relapsing-Remitting Multiple Sclerosis,DRUG: Rebif,EMD Serono,,ALL,ADULT,PHASE4,0,INDUSTRY,INTERVENTIONAL,Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT,2004-11,,,
NCT00424359,Ambulation Study in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00424359,COMPLETED,Multiple Sclerosis,,"Brown, Theodore R., M.D., MPH",,ALL,"ADULT, OLDER_ADULT",,40,INDIV,OBSERVATIONAL,Observational Model: |Time Perspective: p,2005-04,,2009-01,
NCT02365259,Phototherapy in Persons With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02365259,UNKNOWN,Multiple Sclerosis,DEVICE: Phototherapy,University of Illinois at Urbana-Champaign,,FEMALE,ADULT,PHASE1,20,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2015-01,2016-02,2016-02,"Exercise Neuroscience Research Laboratory, Urbana, Illinois, 61801, United States"
NCT02461459,Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC),https://beta.clinicaltrials.gov/study/NCT02461459,RECRUITING,Tuberous Sclerosis|Autism Disorder|Intellectual Disability,,Boston Children's Hospital,National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS)|Tuberous Sclerosis Alliance|National Center for Advancing Translational Sciences (NCATS)|Office of Rare Diseases (ORD)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),ALL,"CHILD, ADULT, OLDER_ADULT",,195,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-05,2024-12,2025-12,"University of Alabama at Birmingham, Birmingham, Alabama, 35294, United States|University of California at Los Angeles, Los Angeles, California, 90095, United States|Stanford University, Palo Alto, California, 94304, United States|Boston Children's Hospital, Boston, Massachusetts, 02115, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 45229, United States|University of Texas at Houston, Houston, Texas, 77030, United States"
NCT05325359,L Test in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05325359,RECRUITING,Multiple Sclerosis,BEHAVIORAL: L test,Firat University,,ALL,"ADULT, OLDER_ADULT",,50,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-02-07,2022-04-18,2022-05-09,"Fırat university, Elazığ, 23100, Turkey"
NCT00854750,Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00854750,TERMINATED,Multiple Sclerosis,DRUG: ACTHAR|DRUG: ACTHAR|DRUG: ACTHAR|DRUG: ACTHAR,Elliot Frohman,Mallinckrodt,ALL,"ADULT, OLDER_ADULT",PHASE4,1,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-05,2010-05,2010-07,"UT Southwestern Medical Center, Dallas, Texas, 75390, United States"
NCT01127750,Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients,https://beta.clinicaltrials.gov/study/NCT01127750,COMPLETED,Relapsing Multiple Sclerosis,DRUG: FTY720,Novartis,,ALL,"ADULT, OLDER_ADULT",PHASE3,2417,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2010-05,2011-10,2011-10,"Novartis Investigative Site, Box Hill, 3128, Australia|Novartis Investigative Site, Heidelberg, 3084, Australia|Novartis Investigative Site, Kogarah, 2217, Australia|Novartis Investigative Site, Liverpool, 2170, Australia|Novartis Investigative Site, Woodville South, 5011, Australia|Novartis Investigational Site, Linz, A-4020, Austria|Novartis Investigational Site, Vienna, 1010, Austria|Novartis Investigational Site, Vienna, 1090, Austria|Novartis Investigational Site, Brugge, 8000, Belgium|Novartis Investigational Site, Bruxelles, 1070, Belgium|Novartis Investigational Site, Bruxelles, 1200, Belgium|Novartis Investigational Site, Charleroi, 6000, Belgium|Novartis Investigational Site, Leuven, 3000, Belgium|Novartis Investigational Site, Melsbroek, 1820, Belgium|Novartis Investigational Site, Overpelt, 3900, Belgium|Novartis Investigational Site, Sijsele, 8340, Belgium|Novartis Investigational Site, Tinlot, 4557, Belgium|Novartis Investigational Site, Wilrijk, 2610, Belgium|Novartis Investigational Site, Montreal, H2L 4M1, Canada|Novartis Investigational Site, Quebec, G1J 1Z4, Canada|Novartis Investigational Site, Victoria, V8R 1J8, Canada|Novartis Investigational Site, Praha 2, 128 02, Czech Republic|Novartis Investigational Site, Teplice, 415 29, Czech Republic|Novartis Investigational Site, Copenhagen, 2100, Denmark|Novartis Investigational Site, Århus, DK-8000, Denmark|Novartis Investigational Site, Helsinki, 00100, Finland|Novartis Investigational Site, Turku, 20520, Finland|Novartis Investigational Site, Aachen, 52062, Germany|Novartis Investigative Site, Aachen, 52062, Germany|Novartis Investigational Site, Aalen, 73430, Germany|Novartis Investigational Site, Abensberg, 93326, Germany|Novartis Investigational Site, Achim, 28832, Germany|Novartis Investigational Site, Alzenau, 63755, Germany|Novartis Investigational Site, Aschaffenburg, 63739, Germany|Novartis Investigational Site, Attenberg, 04600, Germany|Novartis Investigational Site, Augsburg, 86156, Germany|Novartis Investigational Site, Bad Honnef, 53604, Germany|Novartis Investigational Site, Bad Krozingen, 79189, Germany|Novartis Investigative Site, Bad Mergentheim, 97980, Germany|Novartis Investigational Site, Bad Neustadt / Saale, 97616, Germany|Novartis Investigational Site, Bamberg, 96047, Germany|Novartis Investigational Site, Bamberg, 96049, Germany|Novartis Investigative Site, Bayreuth, 95445, Germany|Novartis Investigative Site, Berlin, 10117, Germany|Novartis Investigative Site, Berlin, 10178, Germany|Novartis Investigative Site, Berlin, 10625, Germany|Novartis Investigative Site, Berlin, 10713, Germany|Novartis Investigative Site, Berlin, 10785, Germany|Novartis Investigative Site, Berlin, 10961, Germany|Novartis Investigative Site, Berlin, 12103, Germany|Novartis Investigative Site, Berlin, 12163, Germany|Novartis Investigative Site, Berlin, 12351, Germany|Novarris Investigative Site, Berlin, 13088, Germany|Novartis Investigative Site, Berlin, 13347, Germany|Novartis Investigative Site, Berlin, 13439, Germany|Novartis Investigative Site, Berlin, 13507, Germany|Novartis Investigative Site, Berlin, 14163, Germany|Novartis Investigative Site, Bielefeld, 33602, Germany|Novartis Investigative Site, Bielefeld, 33617, Germany|Novartis Investigative Site, Bielefeld, 33647, Germany|Novartis Investigative Site, Boblingen, 71034, Germany|Novartis Investigational Site, Bochum, 44787, Germany|Novartis Investigative Site, Bochum, 44789, Germany|Novartis Investigational Site, Bochum, 44791, Germany|Novaratis Investigative Site, Bochum, 44892, Germany|Novartis Investigational Site, Bogen, 94327, Germany|Novartis Investigative Site, Bonn, 53105, Germany|Novartis Investigative Site, Bonn, 53117, Germany|Novartis Investigational Site, Braunschweig, 38126, Germany|Novartis Investigational Site, Buchholz, 21244, Germany|Novartis Investigational Site, Chemnitz, 09117, Germany|Novartis Investigational Site, Dillingen, 89407, Germany|Novartis Investigative Site, Dresden, 01307, Germany|Novartis Investigative Site, Düsseldorf, 40211, Germany|Novartis Investigational Site, Eisenach, 99817, Germany|Novartis Investigative Site, Emden, 26721, Germany|Novartis Investigational Site, Emmendingen, 79312, Germany|Novartis Investigative Site, Erbach, 64711, Germany|Novartis Investigational Site, Erfurt, 99089, Germany|Novartis Investigational Site, Erlangen, 91054, Germany|Novartis Investigative Site, Essen, 103949, Germany|Novartis Investigational Site, Essen, 45131, Germany|Novartis Investigative Site, Essen, 45138, Germany|Novartis Investigational Site, Frankfurt, 60488, Germany|Novartis Investigational Site, Frankfurt, 60528, Germany|Novartis Investigative Site, Freiburg, 79106, Germany|Novartis Investigational Site, Greifswald, 17487, Germany|Novartis Investigational Site, Grevenbroich, 41515, Germany|Novartis Investigative Site, Hamburg, 20099, Germany|Novartis Investigative Site, Hamburg, 20249, Germany|Novartis Investigative Site, Hamburg, 20354, Germany|Novartis Investigative Site, Hamburg, 22083, Germany|Novartis Investigational Site, Hamburg, 22087, Germany|Novartis Investigative Site, Hamburg, 22179, Germany|Novartis Investigational Site, Hamburg, 22291, Germany|Novartis Investigative Site, Hamburg, 22297, Germany|Novartis Investigative Site, Hamburg, 22523, Germany|Novartis Investigative Site, Hannover, 30161, Germany|Novartis Investigative Site, Hannover, 30559, Germany|Novartis Investigative Site, Hannover, 30625, Germany|Novartis Investigative Site, Heidelburg, 69120, Germany|Novartis Investigational Site, Herborn, 35745, Germany|Novartis Investigational Site, Herdecke, 58313, Germany|Novartis Investigational Site, Herne, 44651, Germany|Novartis Investigational Site, Homburg, 66421, Germany|Novartis Investigational Site, Itzehoe, 25524, Germany|Novartis Investigational Site, Jena, 07740, Germany|Novartis Investigational Site, Jena, 07743, Germany|Novartis Investigational Site, Kaltenkirchen, 24568, Germany|Novartis Investigative Site, Kandel, 76870, Germany|Novartis Investigational Site, Karlsruhe, 76133, Germany|Novartis Investigational Site, Karlstadt, 97753, Germany|Novartis Investigational Site, Kassel, 34121, Germany|Novartis Investigative Site, Koeln, 51109, Germany|Novartis Investigative Site, Koln, 50924, Germany|Novartis Investigative Site, Koln, 50935, Germany|Neuroscience Research of the Berkshires, Krefeld, 47805, Germany|Novartis Investigational Site, Landshut, 84028, Germany|Novartis Investigational Site, Lappersdorf, 93138, Germany|Novartis Investigational Site, Leipzig, 04275, Germany|Novartis Investigative Site, Lengerich, 49525, Germany|Novartis Investigational Site, Lohr am Main, 79816, Germany|Novartis Investigational Site, Ludwigshafen, 67059, Germany|Novartis Investigative Site, Ludwigshafen, 67063, Germany|Novartis Investigative Site, Magdeburg, 39120, Germany|Novartis Investigative Site, Mainz, 55101, Germany|Novartis Investigational Site, Mannheim, 68159, Germany|Novartis Investigational Site, Marburg, 35033, Germany|Novartis Investigational Site, Marburg, 35039, Germany|Novartis Investigational Site, Mittweida, 09648, Germany|Novartis Investigational Site, Muenchen, 80331, Germany|Novartis Investigational Site, Muenchen, 81377, Germany|Novartis Investigational Site, Muenster, 48149, Germany|Novartis Investigational Site, Munchen, 81829, Germany|Novartis Investigational Site, Mönchengladbach, 41063, Germany|Novartis Investigational Site, München, 81241, Germany|Novartis Investigational Site, München, 81675, Germany|Novartis Investigative Site, München, 81825, Germany|Novartis Investigational Site, Nagold, 72202, Germany|Novartis Investigational Site, Neu-Ulm, 89231, Germany|Novartis Investigational Site, Neuburg, 86633, Germany|Novartis Investigational Site, Neuruppin, 16816, Germany|Novartis Investigational Site, Nurnberg, 90461, Germany|Novartis Investigative Site, Oldenburg, 26122, Germany|Novartis Investigational Site, Osnabrück, 49076, Germany|Novartis Investigational Site, Ostfildern, 73760, Germany|Novartis Investigational Site, Pforzheim, 75172, Germany|Novartis Investigational Site, Potsdam, 14467, Germany|Novartis Investigational Site, Potsdam, 14471, Germany|Novartis Investigational Site, Prien, 83209, Germany|Novartis Investigational Site, Regensburg, 93053, Germany|Novartis Investigational Site, Rostock, 18147, Germany|Novartis Investigative Site, Rudersdorf, 15562, Germany|Novartis Investigational Site, Rösrath, 51503, Germany|Novartis Investigational Site, Schwarzenbruck, 90592, Germany|Novartis Investigative Site, Schwendi, 88477, Germany|Novartis Investigative Site, Siegen, 57072, Germany|Novartis Investigational Site, Sigmaringen, 72488, Germany|Novartis Investigational Site, Sinsheim, 74889, Germany|Novartis Investigative Site, Stade, 21682, Germany|Novartis Investigational Site, Stuttgart, 70176, Germany|Novartis Investigative Site, Stuttgart, 70178, Germany|Novartis Investigative Site, Stuttgart, 70182, Germany|Novartis Investigational Site, Stuttgart, 70191, Germany|Novartis Investigational Site, Teupitz, 15755, Germany|Novartis Investigational Site, Tübingen, 72076, Germany|Novartis Investigative Site, Ulm, 89073, Germany|Novartis Investigational Site, Unterhaching, 82008, Germany|Novartis Investigational Site, Wendlingen, 73240, Germany|Novartis Investigational Site, Wermsdorf, 04779, Germany|Novartis Investigational Site, Westerstede, 26655, Germany|Novartis Investigational Site, Wiesbaden, 65183, Germany|Novartis Investigative Site, Wiesbaden, 65191, Germany|Novartis Investigational Site, Wuppertal, 42283, Germany|Novartis Investigational Site, Würzburg, 97080, Germany|Novartis Investigational Site, Alexandroupolis, 68100, Greece|Novartis Investigational Site, Athens, 10675, Greece|Novartis Investigational Site, Athens, 15123, Greece|Novartis Investigational Site, Thessaloniki, 57001, Greece|Novartis Investigational Site, Thessaloniki, GR 570 10, Greece|Novartis Investigational Site, Budapest, 1083, Hungary|Novartis Investigational Site, Budapest, 1115, Hungary|Novartis Investigational Site, Budapest, 1204, Hungary|Novartis Investigational Site, Pecs, 7623, Hungary|Novartis Investigational Site, Szeged, H-6725, Hungary|Novartis Investigational Site, Cork, Ireland|Novartis Investigational Site, Dublin 4, Ireland|Novartis Investigational Site, Dublin 9, Ireland|Novartis Investigative Site, Acquaviva delle Fonti, 70021, Italy|Novartis Investigative SIte, Asti, 14100, Italy|Novartis Investigative Site, Bergamo, 24128, Italy|Novartis Investigative Site, Bologna, 40139, Italy|Novartis Investigative Site, Cagliari, 09126, Italy|Novartis Investigative Site, Catania, 95122, Italy|Novartis Investigational Site, Foggia, 71100, Italy|Novartis Investigative Site, Foggia, 71100, Italy|Novartis Investigative Site, Milano, 20132, Italy|Novartis Investigative Site, Napoli, 80131, Italy|Novartis Investigational Site, Napoli, 80132, Italy|Novartis Investigational Site, Napoli, 80138, Italy|Novartis Investigative Site, Palermo, 90146, Italy|Novartis Investigative Site, Pozzilli, 86077, Italy|Novartis Investigative Site, Ravenna, 48100, Italy|Novartis Investigational Site, Roma, 00135, Italy|Novartis Investigational Site, Roma, 00161, Italy|Novartis Investigational Site, Roma, 00168, Italy|Novartis Investigational Site, Roma, 00185, Italy|Novartis Investigative Site, Siena, 53100, Italy|Novartis Investigative Site, Udine, 33100, Italy|Novartis Investigative Site, Verona, 37134, Italy|Novartis Investigative Site, Vicenza, 36100, Italy|Novartis Investigative Site, Viterbo, 01100, Italy|Novartis Investigational Site, Amsterdam, 1061 AE, Netherlands|Novartis Investigational Site, Amsterdam, 1081 HV, Netherlands|Novartis Investigational Site, Blaricum, 1261 AN, Netherlands|Novartis Investigational Site, Breda, 4818 CK, Netherlands|Novartis Investigational Site, Enschede, 7513 ER, Netherlands|Novartis Investigational Site, Gouda, 2800 BB, Netherlands|Novartis Investigational Site, Tilburg, 5022 GC, Netherlands|Novartis Investigational Site, Lillehammer, 2609, Norway|Novartis Investigational Site, Molde, 6407, Norway|Novartis Investigational Site, Stavanger, 4868, Norway|Novartis Investigational Site, Bydgoszcz, 85-681, Poland|Novartis Investigational Site, Katowice, 40-594, Poland|Novartis Investigational Site, Lodz, 90-153, Poland|Novartis Investigational Site, Amadora, 2720-276, Portugal|Novartis Investigational Site, Coimbra, 3041-853, Portugal|Novartis Investigational Site, Lisboa, 1649-035, Portugal|Novartis Investigational Site, Porto, 4099-001, Portugal|Novartis Investigational Site, Porto, 4200-319, Portugal|Novartis Investigational Site, Ekaterinburg, 620102, Russian Federation|Novartis Investigational Site, Kazan, 420021, Russian Federation|Novartis Investigational Site, Kazan, 420097, Russian Federation|Novartis Investigational Site, Moscow, 121356, Russian Federation|Novartis Investigational Site, Moscow, 125367, Russian Federation|Novartis Investigational Site, Moscow, 127018, Russian Federation|Novartis Investigational Site, Nizhny Novgorod, 603018, Russian Federation|Novartis Investigational Site, Nizhny Novgorod, 603155, Russian Federation|Novartis Investigational Site, S.-Petersburg, 194044, Russian Federation|Novartis Investigational Site, Samara, 443095, Russian Federation|Novartis Investigational Site, Smolensk, 214019, Russian Federation|Novartis Investigational Site, St. Petersburg, 197376, Russian Federation|Novartis Investigational Site, Banska Bystrica, 975 17, Slovakia|Novartis Investigational Site, Bratislava, 82606, Slovakia|Novartis Investigational Site, Trnava, 917 75, Slovakia|Novartis Investigational Site, Barcelona, 08025, Spain|Novartis Investigational Site, Barcelona, 08036, Spain|Novartis Investigational Site, El Palmar, 30120, Spain|Novartis Investigational Site, Madrid, 28034, Spain|Novartis Investigational Site, Madrid, Spain|Novartis Investigational Site, San Sebastian, 20014, Spain|Novartis Investigational Site, Santa Cruz de Tenerife, 38009, Spain|Novartis Investigational Site, Santiago de Compostela, 15706, Spain|Novartis Investigational Site, Valencia, 46010, Spain|Novartis Investigational Site, Göteborg, 413 45, Sweden|Novartis Investigational Site, Linköping, 581 85, Sweden|Novartis Investigational Site, Umea, 901 85, Sweden|Novartis Investigational Site, Aarau, 5001, Switzerland|Novartis Investigational Site, Carouge, 1227, Switzerland|Novartis Investigational Site, Geneve, 1211, Switzerland|Novartis Investigational Site, Lausanne, 1011, Switzerland|Novartis Investigational Site, Lugano, 6900, Switzerland|Novartis Investigational Site, St. Gallen, 9007, Switzerland|Novartis Investigational Site, Zuerich, 8091, Switzerland|Novartis Investigational Site, Antalya, 07070, Turkey|Novartis Investigational Site, Gaziantep, 27070, Turkey|Novartis Investigational Site, Istanbul, 34096, Turkey|Novartis Investigational Site, Istanbul, 34098, Turkey|Novartis Investigational Site, Samsun, Turkey|Novartis Investigational Site, Trabzon, 61080, Turkey|Novartis Investigational Site, Birmingham, B15 2TH, United Kingdom|Novartis Investigational Site, Brighton, BN2 2BE, United Kingdom|Novartis Investigational Site, Dundee, United Kingdom|Novartis Investigational Site, Edinburgh, EH4 2XU, United Kingdom|Novartis Investigational Site, Essex, RM7 0BE, United Kingdom|Novartis Investigational Site, Great Yarmouth, NR31 6LA, United Kingdom|Novartis Investigational Site, Headington, OX3 9DU, United Kingdom|Novartis Investigational Site, Liverpool, L9 7LJ, United Kingdom|Novartis Investigational Site, London, SW17 0QT, United Kingdom|Novartis Investigational Site, London, W8 6RF, United Kingdom|Novartis Investigational Site, Middlesborough, TS4 3BW, United Kingdom|Novartis Investigational Site, Newcastle Upon Tyne, NE1 4LP, United Kingdom|Novartis Investigational Site, Northampton, NN1 5BD, United Kingdom|Novartis Investigational Site, Norwick, NR4 7UY, United Kingdom|Novartis Investigational Site, Poole, BH15 2JB, United Kingdom|Novartis Investigational Site, Salford, M6 8HD, United Kingdom|Novartis Investigational Site, Sheffield, S10 2JF, United Kingdom|Novartis Investigational Site, Stoke on Trent, ST4 6QG, United Kingdom|Novartis Investigational Site, Swindon, SN3 6BB, United Kingdom|Novartis Investigational Site, Truro, TR1 3LJ, United Kingdom"
NCT05357950,"A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS",https://beta.clinicaltrials.gov/study/NCT05357950,RECRUITING,Amyotrophic Lateral Sclerosis|ALS,DRUG: PrimeC|DRUG: Placebo,NeuroSense Therapeutics Ltd.,,ALL,"ADULT, OLDER_ADULT",PHASE2,69,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-05-31,2023-06,2023-10,"Tel Aviv Sourasky Medical Center, Tel Aviv, Israel"
NCT02383550,Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients - A Three Year Extension,https://beta.clinicaltrials.gov/study/NCT02383550,COMPLETED,Multiple Sclerosis,OTHER: Observational Cognitive assessments,Clinique Neuro-Outaouais,CogState Ltd.,ALL,"ADULT, OLDER_ADULT",,46,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-12,2017-08-30,2017-08-30,"Clinique Neuro-Outaouais, Gatineau, Quebec, J9J 0A5, Canada"
NCT04979650,Corticosteroid Effects on Asymptomatic Gadolinium-enhancing Lesions in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04979650,ENROLLING_BY_INVITATION,"Multiple Sclerosis, Relapsing-Remitting|Magnetic Resonance Imaging|Methylprednisolone",DRUG: Methylprednisolone succinate|DRUG: Normal saline,Mazandaran University of Medical Sciences,,ALL,ADULT,PHASE2,104,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-05-22,2023-05-22,2023-10-23,"Mazandaran University of medical sciences, Sari, Mazandaran, 4815838477, Iran, Islamic Republic of"
NCT01013350,Prospective Observational Long-term Safety Registry of Multiple Sclerosis Participants Who Have Participated in Cladribine Clinical Trials,https://beta.clinicaltrials.gov/study/NCT01013350,COMPLETED,Multiple Sclerosis,,EMD Serono,,ALL,"CHILD, ADULT, OLDER_ADULT",,1161,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2009-11-30,2018-10-25,2018-10-25,"Outcome Sciences, Inc, Cambridge, Massachusetts, 02139, United States"
NCT04428775,A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease,https://beta.clinicaltrials.gov/study/NCT04428775,TERMINATED,Amyotrophic Lateral Sclerosis,DRUG: ALZT-OP1a (cromolyn),"AZTherapies, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE2,12,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2020-09-08,2021-10-01,2021-10-01,"UCSD Altman Clinical and Translational Research Institute, La Jolla, California, 92037, United States|Mayo Clinic, Jacksonville, Florida, 32224, United States|Hospital for Special Surgery, New York, New York, 10021, United States|Columbia University Medical Center, New York, New York, 10032, United States|Wake Forest School of Medicine, Winston-Salem, North Carolina, 27157, United States|Oregon Health & Science University, Portland, Oregon, 97239, United States"
NCT00001975,Study of Skin Tumors in Tuberous Sclerosis,https://beta.clinicaltrials.gov/study/NCT00001975,RECRUITING,Tuberous Sclerosis,,"National Heart, Lung, and Blood Institute (NHLBI)",Uniformed Services University of the Health Sciences,ALL,"ADULT, OLDER_ADULT",,400,NIH,OBSERVATIONAL,Observational Model: |Time Perspective: p,2000-01-26,,,"National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States"
NCT01945359,Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover Design,https://beta.clinicaltrials.gov/study/NCT01945359,COMPLETED,Relapsing Remitting Multiple Sclerosis,,"Rocky Mountain MS Research Group, LLC",Biogen,ALL,"ADULT, OLDER_ADULT",,30,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-09,2014-09,2015-06,"Rocky Mountain MS Research Group, Salt Lake City, Utah, 84103, United States"
NCT01576354,Characterization of the Effects of Prolonged-release Fampridine on Ambulatory Function in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01576354,UNKNOWN,Multiple Sclerosis,DRUG: Prolonged-release Fampridine|DRUG: Placebo,University of Zurich,,ALL,"ADULT, OLDER_ADULT",PHASE2,70,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-03,2017-04,2017-04,"University Hospital Zurich, Division of Neurology, Zurich, ZH, 8091, Switzerland"
NCT02004054,Interest of Dynamic Measures of the Pupil in Optic Neuritis,https://beta.clinicaltrials.gov/study/NCT02004054,COMPLETED,Optic Neuritis,OTHER: measure of pupil diameter,Fondation Ophtalmologique Adolphe de Rothschild,,ALL,"ADULT, OLDER_ADULT",,30,NETWORK,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-12,2013-05,2013-05,"Fondation Ophtalmologique Adolphe de Rothschild, Paris, 75019, France"
NCT05623254,Feasibility and Effectiveness of a Mindfulness Program Delivered by Web to Patients During Hospitalization and Caregivers.,https://beta.clinicaltrials.gov/study/NCT05623254,RECRUITING,Chronic Migraine; Multiple Sclerosis; Motoneuron Disease,OTHER: no comparator - TAU (Treatment-as-usual),Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,,ALL,"ADULT, OLDER_ADULT",NA,1,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2023-01-02,2023-12-31,2023-12-31,"Fondazione IRCCS Istituto Neurologico C. Besta, Neuroalgology Unit, Milano, 20133, Italy"
NCT03230903,Physical Telerehabilitation in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03230903,COMPLETED,Multiple Sclerosis,OTHER: Home telerehabilitation|OTHER: Usual Care,Columbia University,United States Department of Defense,ALL,"ADULT, OLDER_ADULT",NA,78,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2016-10,2020-09,2020-09,"Columbia University Medical Center, New York, New York, 10032, United States"
NCT03272503,A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS),https://beta.clinicaltrials.gov/study/NCT03272503,UNKNOWN,ALS|Amyotrophic Lateral Sclerosis,DRUG: Pimozide 2mg/day (current) or 4 mg/day (study initiation)|DRUG: Placebo Oral Tablet,University of Calgary,ALS Canada|Brain Canada,ALL,"ADULT, OLDER_ADULT",PHASE2,100,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-10-27,2020-12-31,2020-12-31,"Dr. Lawrence Korngut -South Health Campus, Calgary, Alberta, T3M 1M4, Canada|Dr. Wendy Johnston - University of Alberta, Edmonton, Alberta, T6G2G3, Canada|Dr. Colleen O'Connell - Stan Cassidy Centre for Rehabilitation, Fredericton, New Brunswick, E3B 0C7, Canada|Dr. John Turnbull McMaster University/Hamilton Health Services, Hamilton, Ontario, L8N 3Z5, Canada|Dr. Christen Shoesmith - London Health Sciences Centre, London, Ontario, N6A5A5, Canada|Dr. Ariel Breiner -Ottawa Hospital Research Institute, Ottawa, Ontario, K1Y4E9, Canada|Dr. Lorne Zinman Sunnybrook Research Institute, Toronto, Ontario, M4N 3M5, Canada|Dr. Sandrine Larue - Reserche Sepmus Inc., Greenfield Park, Quebec, J4V 2J2, Canada|Dr. Genevieve Matte, Montréal, Quebec, H2L4M1, Canada"
NCT03981003,Serum Neurofilament-light Chain and GFAP Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03981003,RECRUITING,Multiple Sclerosis,DIAGNOSTIC_TEST: Blood sample,Centre Hospitalier Universitaire de Nīmes,Hospices Civils de Lyon,ALL,"CHILD, ADULT, OLDER_ADULT",,1150,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-05-22,2028-06,2028-06,"CHU d'Amiens, Amiens, France|CHU de Besancon, Besançon, France|CHU de Bordeaux, Bordeaux, France|CHU de Caen, Caen, France|CHU de Clermont Ferrand, Clermont-Ferrand, France|Hopital Henri Mondor, Créteil, France|CHU de Dijon, Dijon, France|CHU de Grenoble, Grenoble, France|CHU de Lille, Lille, France|CHU de Limoges, Limoges, France|CHU de Lyon, Lyon, France|Hopital Timone, Marseille, France|CHU de Montpellier, Montpellier, France|CHU de Nancy, Nancy, France|CHU de Nice, Nice, France|CHU de Nimes, Nîmes, 30029, France|Fondation Rothschild, Paris, France|Hopital Pitie Salpetriere, Paris, France|Hopital Saint Antoine, Paris, France|CH de Poissy, Poissy, France|CHU de Potiers, Potiers, France|CHU de Rennes, Rennes, France|CHU de Rouen, Rouen, France|CHU de Saint Etienne, Saint-Étienne, France|CHU de Strasbourg, Strasbourg, France|CHU de Toulouse, Toulouse, France|CHU de Tours, Tours, France|CHU de Martinique, Fort-de-France, Martinique"
NCT01111656,"Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b",https://beta.clinicaltrials.gov/study/NCT01111656,COMPLETED,Relapsing-remitting Multiple Sclerosis,DRUG: Interferon beta-1b group|DRUG: Interferon beta-1b/Atorvastatin group,"University Hospital Inselspital, Berne","Viollier AG, Basel, Switzerland|PharmaPart",ALL,"ADULT, OLDER_ADULT",PHASE2,28,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2007-03,2010-04,2010-04,"Department of Neurology, Bern University Hospital, and University of Bern, Bern, 3007, Switzerland"
NCT01207856,Randomised Controlled Clinical Trial of Cognitive Rehabilitation in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01207856,COMPLETED,Multiple Sclerosis|Cognitive Rehabilitation,BEHAVIORAL: specific cognitive rehabilitation|BEHAVIORAL: non specific cognitive rehabilitation|OTHER: no intervention,"University Hospital, Bordeaux",Merck Serono International SA|ARSEP foundation,ALL,ADULT,NA,65,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2011-05,2015-07,2016-02,"Service de Neurologie - Pôle des Neurosciences Cliniques, CHU de Bordeaux., Bordeaux, 3300, France"
NCT04495556,Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04495556,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,DIAGNOSTIC_TEST: MRI,The Cleveland Clinic,National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS)|University of Pennsylvania|Cedars-Sinai Medical Center,ALL,"ADULT, OLDER_ADULT",,400,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-09-11,2024-06,2024-06,"Cedars-Sinai Medical Center, Los Angeles, California, 90048, United States|University of Southern California, Los Angeles, California, 90089, United States|University of Colorado, Aurora, Colorado, 80045, United States|Yale University, New Haven, Connecticut, 06520, United States|Johns Hopkins University, Baltimore, Maryland, 21218, United States|Washington University in St. Louis, Saint Louis, Missouri, 63130, United States|Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|The University of Texas at Austin, Austin, Texas, 78759, United States|University of Vermont, Burlington, Vermont, 05405, United States|St. Michael's Hospital of Unity Health Toronto, Toronto, Ontario, M5B1W8, Canada"
NCT02255656,Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409,https://beta.clinicaltrials.gov/study/NCT02255656,COMPLETED,Relapsing Remitting Multiple Sclerosis,DRUG: alemtuzumab GZ402673,"Genzyme, a Sanofi Company",,ALL,"ADULT, OLDER_ADULT",PHASE4,1062,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-01-07,2020-07-15,2020-07-15,"Investigational Site Number 1086, Cullman, Alabama, 00000, United States|Investigational Site Number 1031, Phoenix, Arizona, 85013, United States|Investigational Site Number 1171, Phoenix, Arizona, 85018, United States|Investigational Site Number 1090, Tucson, Arizona, 85704, United States|Investigational Site Number 1040, Berkeley, California, 94705, United States|Investigational Site Number 1152, Fullerton, California, 92835, United States|Investigational Site Number 1093, Pasadena, California, 91105, United States|Investigational Site Number 1027, Fort Collins, Colorado, 80528, United States|Investigational Site Number 1078, Jacksonville, Florida, 32209, United States|Investigational Site Number 1059, Maitland, Florida, 32751, United States|Investigational Site Number 1173, Sarasota, Florida, 34239, United States|Investigational Site Number 1034, Sunrise, Florida, 33351, United States|Investigational Site Number 1005, Tampa, Florida, 33609, United States|Investigational Site Number 1049, Tampa, Florida, 33612, United States|Investigational Site Number 1008, Northbrook, Illinois, 60062, United States|Investigational Site Number 1001, Fort Wayne, Indiana, 46845, United States|Investigational Site Number 1024, Indianapolis, Indiana, 46202, United States|Investigational Site Number 1017, Des Moines, Iowa, 50314, United States|Investigational Site Number 1022, Kansas City, Kansas, 66160, United States|Investigational Site Number 1083, Lenexa, Kansas, 66214, United States|Investigational Site Number 1039, Lexington, Kentucky, 40513, United States|Investigational Site Number 1021, Louisville, Kentucky, 40202, United States|Investigational Site Number 1061, Wellesley, Massachusetts, 02481, United States|Investigational Site Number 1028, Worcester, Massachusetts, 01655, United States|Investigational Site Number 1025, Ann Arbor, Michigan, 48105-2945, United States|Investigational Site Number 1020, Detroit, Michigan, 48201, United States|Investigational Site Number 1054, Traverse City, Michigan, 49684, United States|Investigational Site Number 1084, Kansas City, Missouri, 64111, United States|Investigational Site Number 1092, Saint Louis, Missouri, 63131, United States|Investigational Site Number 1073, Teaneck, New Jersey, 07666, United States|Investigational Site Number 1014, Albuquerque, New Mexico, 87131, United States|Investigational Site Number 1081, Mineola, New York, 11501, United States|Investigational Site Number 1026, New York, New York, 10029, United States|Investigational Site Number 1160, Patchogue, New York, 11772, United States|Investigational Site Number 1015, Rochester, New York, 14642, United States|Investigational Site Number 1053, Syracuse, New York, 13202, United States|Investigational Site Number 1095, Chapel Hill, North Carolina, 27599, United States|Investigational Site Number 1082, Winston-Salem, North Carolina, 27103, United States|Investigational Site Number 1035, Cleveland, Ohio, 44195, United States|Investigational Site Number 1058, Uniontown, Ohio, 44685, United States|Investigational Site Number 1067, Oklahoma City, Oklahoma, 73104, United States|Investigational Site Number 1097, Allentown, Pennsylvania, 18103, United States|Investigational Site Number 1057, Providence, Rhode Island, 02905, United States|Investigational Site Number 1163, Cordova, Tennessee, 38018, United States|Investigational Site Number 1055, Franklin, Tennessee, 37064, United States|Investigational Site Number 1009, Knoxville, Tennessee, 37922, United States|Investigational Site Number 1042, Nashville, Tennessee, 37215, United States|Investigational Site Number 1018, Houston, Texas, 77030, United States|Investigational Site Number 1002, Round Rock, Texas, 78681, United States|Investigational Site Number 1046, San Antonio, Texas, United States|Investigational Site Number 1037, Vienna, Virginia, 22182, United States|Investigational Site Number 1068, Seattle, Washington, 98122, United States|Investigational Site Number 03208, Caba, C1061ABD, Argentina|Investigational Site Number 2013, Auchenflower, 4066, Australia|Investigational Site Number 2001, Heidelberg, 3084, Australia|Investigational Site Number 2011, Hobart, 7000, Australia|Investigational Site Number 2012, Kogarah, 2217, Australia|Investigational Site Number 2003, Melbourne, 3065, Australia|Investigational Site Number 2002, Parkville, 3050, Australia|Investigational Site Number 2005, Southport, 4215, Australia|Investigational Site Number 2009, Sydney, Australia|Investigational Site Number 2006, Westmead, 2145, Australia|Investigational Site Number 5005, Bruxelles, 1200, Belgium|Investigational Site Number 5004, Esneux, 4130, Belgium|Investigational Site Number 5001, Leuven, 3000, Belgium|Investigational Site Number 3006, Porto Alegre, 90110000, Brazil|Investigational Site Number 3002, Recife, 52010-040, Brazil|Investigational Site Number 3001, São Paulo, 01221-000, Brazil|Investigational Site Number 3003, São Paulo, 05403-000, Brazil|Investigational Site Number 1102, Calgary, T2N 2T9, Canada|Investigational Site Number 1105, Gatineau, J8Y1W2, Canada|Investigational Site Number 1104, Greenfield Park, J4V2J2, Canada|Investigational Site Number 1109, Kingston, K7L2V7, Canada|Investigational Site Number 1110, London, N6A5A5, Canada|Investigational Site Number 1101, Ottawa, K1H8L6, Canada|Investigational Site Number 1106, Vancouver, V6T1Z3, Canada|Investigational Site Number 4803, Brno, 65691, Czechia|Investigational Site Number 4804, Hradec Kralove, 50005, Czechia|Investigational Site Number 4801, Praha 2, 12808, Czechia|Investigational Site Number 4802, Teplice, 41501, Czechia|Investigational Site Number 5302, Aarhus N, 8200, Denmark|Investigational Site Number 5301, København Ø., 2100, Denmark|Investigational Site Number 4602, Berlin, 13347, Germany|Investigational Site Number 4607, Dresden, 01307, Germany|Investigational Site Number 4634, Frankfurt am Main, 60590, Germany|Investigational Site Number 4622, Hamburg, 22307, Germany|Investigational Site Number 4605, Hannover, 30625, Germany|Investigational Site Number 4609, Hennigsdorf, 16761, Germany|Investigational Site Number 4608, München, 81675, Germany|Investigational Site Number 4610, Rostock, 18147, Germany|Investigational Site Number 4613, Wermsdorf, 04779, Germany|Investigational Site Number 5501, Ramat Gan, 52621, Israel|Investigational Site Number 5505, Tel Aviv, Israel|Investigational Site Number 4112, Cagliari, 09126, Italy|Investigational Site Number 4102, Gallarate (VA), 21013, Italy|Investigational Site Number 4106, Orbassano (TO), 10043, Italy|Investigational Site Number 4110, Roma, 00189, Italy|Investigational Site Number 3105, Chihuahua, 31203, Mexico|Investigational Site Number 3102, Mexico, 14260, Mexico|Investigational Site Number 4202, Sittard-Geleen, 6162BG, Netherlands|Investigational Site Number 4902, Krakow, 31-505, Poland|Investigational Site Number 4901, Lodz, 90-324, Poland|Investigational Site Number 4903, Lublin, 20-090, Poland|Investigational Site Number 4904, Poznan, 60-355, Poland|Investigational Site Number 4905, Warszawa, 02-957, Poland|Investigational Site Number 6009, Kazan, 420097, Russian Federation|Investigational Site Number 6001, Moscow, 1217015, Russian Federation|Investigational Site Number 6005, Moscow, 1217015, Russian Federation|Investigational Site Number 6003, Moscow, Russian Federation|Investigational Site Number 6006, Nizhny Novgorod, Russian Federation|Investigational Site Number 6010, Pyatigorsk, Russian Federation|Investigational Site Number 6002, Saint-Petersburg, Russian Federation|Investigational Site Number 6004, Saint-Petersburg, Russian Federation|Investigational Site Number 6008, Saint-Petersburg, Russian Federation|Investigational Site Number 6013, Samara, Russian Federation|Investigational Site Number 6016, Ufa, Russian Federation|Investigational Site Number 4301, Barcelona, 08035, Spain|Investigational Site Number 4303, Madrid, 28040, Spain|Investigational Site Number 4305, Málaga, 29010, Spain|Investigational Site Number 4304, Sevilla, 41071, Spain|Investigational Site Number 4701, Göteborg, 41345, Sweden|Investigational Site Number 4702, Umeå, 90185, Sweden|Investigational Site Number 6102, Kharkov, Ukraine|Investigational Site Number 6104, Kiev, Ukraine|Investigational Site Number 6103, Lviv, Ukraine|Investigational Site Number 4004, Bristol, BS105NB, United Kingdom|Investigational Site Number 4001, Cambridge, CB50QQ, United Kingdom|Investigational Site Number 4005, Cardiff, CF44XN, United Kingdom|Investigational Site Number 4006, London, E12AT, United Kingdom|Investigational Site Number 4008, Salford, M68HD, United Kingdom|Investigational Site Number 4007, Sheffield, S102JF, United Kingdom"
NCT05380856,"Sacral Neuromodulation for Neurogenic Lower Urinary Tract, Bowel and Sexual Dysfunction",https://beta.clinicaltrials.gov/study/NCT05380856,RECRUITING,Neurogenic Dysfunction of the Urinary Bladder|Multiple Sclerosis|Sacral Neuromodulation|Bowel Dysfunction|Sexual Dysfunction|Quality of Life,DEVICE: Turning ON the neuromodulator|DEVICE: Turning OFF the neuromodulator,Odense University Hospital,,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-09-01,2025-01-01,2026-01-01,"Odense University Hospital, Odense, Fyn, 5000, Denmark"
NCT05364203,Interest of Immersive Virtual Reality on Stress During Botulinum Toxin Injections in Spasticity (RVTOX),https://beta.clinicaltrials.gov/study/NCT05364203,RECRUITING,Central Neurogical Impairment,DEVICE: DEEPSEN virtual reality mask,"University Hospital, Clermont-Ferrand",,ALL,"ADULT, OLDER_ADULT",NA,42,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE,2022-05-10,2023-05-30,2024-10-30,"CHU Clermont-Ferrand, Clermont-Ferrand, France"
NCT01526356,Topical Rapamycin to Erase Angiofibromas in TSC,https://beta.clinicaltrials.gov/study/NCT01526356,COMPLETED,Angiofibromas|Tuberous Sclerosis,DRUG: Placebo|DRUG: Rapamycin|DRUG: Rapamycin,"The University of Texas Health Science Center, Houston",,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,179,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-05,2014-08,2014-08,"University of Alabama at Birmingham, Birmingham, Alabama, 35294, United States|UCLA Mattel Children's Hospital, Los Angeles, California, 90095, United States|Jack & Julia Center for TSC at Oakland Children's Hospital & Research Center, Oakland, California, 94609, United States|Kennedy Krieger Institute, Baltimore, Maryland, 21205, United States|Herscot Center for Adults and Children with TSC Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Clinic Without Walls, Saint Paul, Minnesota, 55102-2697, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 45229, United States|Texas Scottish Rite Hospital, Dallas, Texas, 75219, United States|The University of Texas Medical School at Houston, Houston, Texas, 77030, United States|Sydney Children's Hospital, Sydney, New South Wales, Australia"
NCT04368403,A Study of KHK4827 in Patients With Systemic Sclerosis,https://beta.clinicaltrials.gov/study/NCT04368403,ACTIVE_NOT_RECRUITING,Systemic Sclerosis,DRUG: KHK4827,"Kyowa Kirin Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE1,8,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2017-10-06,2019-01-31,2024-02-29,"The University of Tokyo Hospital, Bunkyo-ku, Tokyo, 113-8655, Japan"
NCT01122056,Effect of Aerobic Exercise on Side Effects of Disease Modifying Therapy With Subcutaneous Interferon-b1b in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01122056,COMPLETED,Multiple Sclerosis,OTHER: Physical exercise training,University of British Columbia,"Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma",ALL,"ADULT, OLDER_ADULT",NA,128,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2010-05,2012-06-01,2012-06-01,"Vancouver Coastal Health: University of British Columbia Hospital, Vancouver, British Columbia, Canada"
NCT05402956,Aerobic Exercise in Persons With Multiple Sclerosis With Restless Legs Syndrome,https://beta.clinicaltrials.gov/study/NCT05402956,RECRUITING,Multiple Sclerosis,BEHAVIORAL: Aerobic exercise,Dokuz Eylul University,,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-05-30,2023-10,2023-12,"Dokuz Eylul University Hospital, MS Outpatient Clinic, Izmir, 35430, Turkey"
NCT02659956,Pathological Basis of MRI Signal Changes in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02659956,RECRUITING,Multiple Sclerosis,,National Institute of Neurological Disorders and Stroke (NINDS),,ALL,"ADULT, OLDER_ADULT",,200,NIH,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-04-07,2080-02-26,2080-02-26,"National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States"
NCT05077956,Sema 4A as a Marker for Inflammatory Disease in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05077956,ACTIVE_NOT_RECRUITING,Relapsing Multiple Sclerosis|Multiple Sclerosis,DIAGNOSTIC_TEST: Cerebrospinal and Blood Serum Semaphorin 4A Levels,Providence Health & Services,Milton S. Hershey Medical Center|Bristol-Myers Squibb,FEMALE,ADULT,,40,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-10-19,2023-10-25,2023-10-25,"Providence St. Vincent Medical Center, Portland, Oregon, 97225, United States"
NCT04438954,"Investigation of Fatigue, Physical Activity, Sleep Quality and Anxiety Levels",https://beta.clinicaltrials.gov/study/NCT04438954,COMPLETED,Multiple Sclerosis|Covid-19,,Ankara Yildirim Beyazıt University,,ALL,ADULT,,30,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-05-05,2020-06-05,2020-06-18,"Ankara Yıldırım Beyazıt University, Faculty of Health Sciences,Department of Physiotherapy and Rehabilitation, Ankara, Turkey"
NCT03073603,Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT03073603,COMPLETED,Multiple Sclerosis,DRUG: Discontinuation of disease modifying therapy|DRUG: Standard of Care,"University of Colorado, Denver",Patient-Centered Outcomes Research Institute|National Multiple Sclerosis Society|University of Alabama at Birmingham,ALL,"ADULT, OLDER_ADULT",PHASE4,259,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2017-04-20,2021-08-31,2021-08-31,"University of Southern California, Los Angeles, California, 90033, United States|University of Colorado Denver - Anschutz Medical Campus, Aurora, Colorado, 80045, United States|Georgetown University, Washington, District of Columbia, 20007, United States|University of Miami, Miami, Florida, 33136, United States|University of Kansas Medical Center, Kansas City, Kansas, 66103, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Washington University St. Louis, Saint Louis, Missouri, 63139, United States|NYU Langone Medical Center, New York, New York, 10016, United States|Mt. Sinai University, New York, New York, 10029, United States|University of Rochester, Rochester, New York, 14642, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|The Ohio State University, Columbus, Ohio, 43221, United States|Oregon Health and Science University, Portland, Oregon, 97239, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, 19107, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, 15213, United States|Vanderbilt University, Nashville, Tennessee, 37215, United States|University of Virginia, Charlottesville, Virginia, 22908, United States|Swedish Health Services, Seattle, Washington, 98122, United States"
NCT03735654,Multi-joint Muscle Fatigability and Gait Performance in People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03735654,UNKNOWN,"Multiple Sclerosis|Gait Disorders, Neurologic|Fatigue",,Washington D.C. Veterans Affairs Medical Center,,ALL,"ADULT, OLDER_ADULT",,35,FED,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-11-15,2020-10-01,2021-10-01,"Washington DC VA Medical Center, Washington, District of Columbia, 20422, United States"
NCT02287454,Integrative Group-based Cognitive Rehabilitation Efficacy in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02287454,COMPLETED,Multiple Sclerosis,OTHER: cognitive remediation program: REHACOP,University of Deusto,,ALL,ADULT,NA,32,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2013-01,2013-07,2013-07,"University of Deusto, Bilbao, Biskai, 48007, Spain"
NCT03332654,Stress Urinary Incontinence in Women With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03332654,COMPLETED,"Urinary Incontinence, Stress|Multiple Sclerosis",OTHER: Determine prevalence of stress urinary incontinence,Lille Catholic University,,FEMALE,"ADULT, OLDER_ADULT",,363,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-02-01,2016-01-31,2016-03-31,
NCT01226654,Quantitative Imaging and Proton Spectroscopy in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01226654,TERMINATED,Multiple Sclerosis,DEVICE: Magnetic Resonance Imaging,NYU Langone Health,National Institute of Neurological Disorders and Stroke (NINDS),ALL,"CHILD, ADULT, OLDER_ADULT",NA,69,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,1991-08,2016-04,2016-04,"NYU Langone Medical Center, New York, New York, 10016, United States"
NCT04130256,Electronic Pill Bottle Monitoring to Promote Medication Adherence for People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04130256,COMPLETED,Multiple Sclerosis,DEVICE: Electronic Pill Bottle,Massachusetts General Hospital,"National Multiple Sclerosis Society|Pillsy, Inc.",ALL,"ADULT, OLDER_ADULT",NA,85,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2019-11-15,2021-01-26,2021-01-26,"Massachusetts General Hospital, Boston, Massachusetts, 02114, United States"
NCT04948554,A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002),https://beta.clinicaltrials.gov/study/NCT04948554,RECRUITING,Systemic Sclerosis With and Without Interstitial Lung Disease,BIOLOGICAL: MK-2225|BIOLOGICAL: Placebo,"Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)",,ALL,"ADULT, OLDER_ADULT",PHASE1,48,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-03-10,2026-08-26,2026-08-26,"UCSD Altman Clinical and Translational Research Institute (Site 1013), La Jolla, California, 92037-0943, United States|Keck Medical Center ( Site 1001), Los Angeles, California, 90033, United States|Georgetown University Medical Center ( Site 1010), Washington, District of Columbia, 20007, United States|University of Florida ( Site 1002), Gainesville, Florida, 32610, United States|Central Florida Pulmonary Group ( Site 1005), Orlando, Florida, 32803, United States|University of Kansas Medical Center ( Site 1007), Kansas City, Kansas, 66160, United States|West Tennessee Research Institute ( Site 1012), Jackson, Tennessee, 38305, United States|Mount Sinai Hospital ( Site 1101), Toronto, Ontario, M5T 3L9, Canada|Kantonsspital St. Gallen (Site 1301), St Gallen, Sankt Gallen, 9000, Switzerland"
NCT01516554,Oral Testosterone for Fatigue in Male Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT01516554,TERMINATED,Multiple Sclerosis|Fatigue,DRUG: Testosterone undecanoate|DRUG: placebo,"Health Sciences Centre, Winnipeg, Manitoba",University of Manitoba|Consortium of Multiple Sclerosis Centers|Manitoba Medical Service Foundation,MALE,"ADULT, OLDER_ADULT",PHASE2,3,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-02,2014-01,2014-07,"Health Sciences Centre, Winnipeg, Manitoba, R3A1R9, Canada"
NCT05204459,MS-ResearchBiomarkerS,https://beta.clinicaltrials.gov/study/NCT05204459,RECRUITING,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis, Primary Progressive|Multiple Sclerosis, Secondary Progressive|Clinically Isolated Syndrome|Radiologically Isolated Syndrome|Neuromyelitis Optica Spectrum Disorders|Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease|Neurologic Autoimmune Disease|Neurologic Disorder|Healthy Aging",,Cedars-Sinai Medical Center,,ALL,"ADULT, OLDER_ADULT",,1000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-11-11,2041-11-11,2041-11-11,"Cedars-Sinai Medical Center, Los Angeles, California, 90048, United States"
NCT02950454,The Effect of High Intensity Interval Training on Cardiovascular Fitness in People With Progressive Multiple Sclerosis.,https://beta.clinicaltrials.gov/study/NCT02950454,COMPLETED,"Multiple Sclerosis, Progressive",OTHER: High intensity interval training|OTHER: Continuous moderate exercise,University of Glasgow,NHS Ayrshire and Arran|AKM,ALL,"ADULT, OLDER_ADULT",NA,12,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2017-01,2017-09,2017-09,"The University of Glasgow, Glasgow, G12 8LL, United Kingdom"
NCT00241254,Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00241254,COMPLETED,"Multiple Sclerosis, Chronic Progressive",DRUG: Cyclophosphamide (drug)|DRUG: Methylprednisolone (drug),"University Hospital, Bordeaux","Ministry of Health, France",ALL,"ADULT, OLDER_ADULT",PHASE3,138,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2005-12,2010-03,2012-03,"CH de la Cote Basque, Bayonne, 64109, France|CHU Besançon, Besançon, 25030, France|Hôpital Pellegrin, Département de neurologie, Bordeaux, 33076, France|CHU Caen, Caen, 14033, France|Hôpital Gabriel Montpied, Clermont Ferrand, 63003, France|AP HP Henri Mondor, Créteil, 94010, France|CHU Dijon, Dijon, 21033, France|CHU Lille Hôpital Salengro, Lille, 59037, France|CHU Limoges, Limoges, 87042, France|GHICL Hôpital St. Philibert, Lomme, 59462, France|(CHU Lyon) Hôpital neurologique, Lyon, 69394, France|Hôpital La Timone, Marseille, 13385, France|(CHR Metz-Thionville) Hôpital Notre Dame de Bon Secours, Metz, 57038, France|(CHU Montpellier), Hôpital de Gui de Chauliac, Montpellier, 34295, France|CHU Nancy Hôpital central, Nancy, 54035, France|Hôpital Guillaume et René Laënnec, Nantes, 44093, France|CHU Nice Hôpital Pasteur, Nice, 06002, France|(CHU Nîmes) Hôpital Caremeau, Nîmes, 30029, France|Fondation Rothschild, Paris, 75019, France|(AP HP) Hôpital Tenon, Paris, 75970, France|Centre Hospitalier de Pau, Pau, 64046, France|CHU de POISSY, Poissy, 78300, France|(CHU Reims) Hôpital Robert Debré, Reims, 51092, France|CHU Ponchaillou, Rennes, 35033, France|CH d'Angoulême Girac, Saint Michel, 16470, France|(CHRU Starsbourg) Hôpital civil, Strasbourg, 67091, France"
NCT03480854,The Multiple Sclerosis Continuous Quality Improvement (MSCQI) Collaborative,https://beta.clinicaltrials.gov/study/NCT03480854,COMPLETED,Multiple Sclerosis,OTHER: Quality Improvement,Dartmouth-Hitchcock Medical Center,MGH Multiple Sclerosis Clinic|University of Vermont Multiple Sclerosis Center|Neurology Associates Multiple Sclerosis Center of Greater Orlando|Concord Hospital,ALL,"ADULT, OLDER_ADULT",NA,694,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2017-07-01,2020-06-30,2020-12-31,"Neurology Associates of Greater Orlando, Maitland, Florida, 32751, United States|Massachusetts General Hospital Multiple Sclerosis Center, Boston, Massachusetts, 02114, United States|Concord Hospital, Concord, New Hampshire, 03301, United States|University of Vermont Multiple Sclerosis Center, Burlington, Vermont, 05401, United States"
NCT05615454,Effect of Bio-electromagnetic Energy Regulation Therapy on Erectile Dysfunction in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05615454,RECRUITING,"Erectile Dysfunction Due to Diseases Classified Elsewhere|Multiple Sclerosis, Relapsing-Remitting","DEVICE: bio-electromagnetic energy regulation therapy (BEMER) machine model type: B.BOX CLASSIC, model NO: 420100, 12-15 Volt, (BEMER Int.AG, Liechtenstein product).|DEVICE: placebo BEMER",Imam Abdulrahman Bin Faisal University,,MALE,ADULT,NA,50,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-02-28,2023-12-30,2024-03-30,"Ali Muteb Alshami, Dammam, 31451, Saudi Arabia|Imam Abdulrahman Bin Faisal University, Dammam, 31451, Saudi Arabia"
NCT03841903,Spinal Cord Analysis in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03841903,COMPLETED,Multiple Sclerosis,DIAGNOSTIC_TEST: spinal cord MRI,"University Hospital, Basel, Switzerland",,ALL,ADULT,,79,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-07-01,2020-03-24,2020-03-24,"Dep. of Neurology, University Hospital Basel, Basel, 4031, Switzerland"
NCT00818103,Characteristic Study on Chinese Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00818103,UNKNOWN,Multiple Sclerosis,DRUG: atorvastatin|DRUG: β-interferon|DRUG: EPO,Sun Yat-sen University,"Third Affiliated Hospital, Sun Yat-Sen University",ALL,"CHILD, ADULT, OLDER_ADULT",NA,600,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: ",2006-01,2015-01,2016-01,"Department of Neurology, The Third Affilated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, 510630, China"
NCT00441103,A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00441103,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting","DRUG: Rebif® New Formulation (IFN-beta-1a, RNF)|DRUG: Placebo|DRUG: Rebif® New Formulation (IFN-beta-1a, RNF)","Merck KGaA, Darmstadt, Germany",,ALL,ADULT,PHASE3,180,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2006-12,2008-11,2009-02,
NCT02637856,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),https://beta.clinicaltrials.gov/study/NCT02637856,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Ocrelizumab|DRUG: Ocrelizumab,"Genentech, Inc.",,ALL,ADULT,PHASE3,608,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-02-11,2019-05-03,2019-05-03,"North Central Neurology Associates, Cullman, Alabama, 35058, United States|Phoenix Neurological Associates Ltd, Phoenix, Arizona, 85006, United States|Barrow Neurological Institute, Phoenix, Arizona, 85013, United States|Territory Neurology and Research Institute, Tucson, Arizona, 85704, United States|The Research Center of Southern California, LLC, Carlsbad, California, 92011, United States|Mercy Medical Group; MS Centre Nurse, Carmichael, California, 95608, United States|Fullerton Neurology and Headache Center, Fullerton, California, 92835, United States|Scripps Health, La Jolla, California, 92037, United States|UCSF- Multiple Sclerosis Centre; Department of Neurology, San Francisco, California, CA94158, United States|Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, 90502, United States|Mountain Neurological Research Center; Roaring Fork Neurologt, P.C., Basalt, Colorado, 81621, United States|IMMUNOe Research Centers, Centennial, Colorado, 80112, United States|Colorado Neurological Institute, Englewood, Colorado, 80113, United States|Advanced Neurology of Colorado, LLC, Fort Collins, Colorado, 80528, United States|Associated Neurologists of Southern CT PC, Fairfield, Connecticut, 06824, United States|KI Health Partners, LLC; New England Institute for Clinical Research, Stamford, Connecticut, 06905, United States|Neurology Associates PA, Maitland, Florida, 32751, United States|University of Miami Miller School of Medicine; Clinical Reseach Building, Miami, Florida, 33136, United States|Neurostudies Inc, Port Charlotte, Florida, 33952, United States|Infinity Clinical Research, LLC, Sunrise, Florida, 33351, United States|Axiom Clinical Research of Florida, Tampa, Florida, 33609, United States|University of South Florida - Bradenton, Tampa, Florida, 33612, United States|Ms Center Of Atlanta, Atlanta, Georgia, 30327, United States|University of Chicago Hospital, Chicago, Illinois, 60637, United States|Consultants in Neurology Ltd, Northbrook, Illinois, 60062, United States|American Health Network Institute, LLC, Avon, Indiana, 46123, United States|Josephson Wallack Munshower Neurology PC, Indianapolis, Indiana, 46256, United States|University of Kansas Medical Center; Division of Nuclear Medicine, Kansas City, Kansas, 66160, United States|Lahey Clinic Med Ctr, Lexington, Kentucky, 02421, United States|Associates in Neurology PSC, Lexington, Kentucky, 40513, United States|Community Medical Associates Inc.; d.b.a. Norton Neurology Services MS Services, Louisville, Kentucky, 40207, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, 70121, United States|University of Maryland Medical Center; Department of Neurology, Baltimore, Maryland, 21201, United States|John Hopkins University School of Medicine, Baltimore, Maryland, 21287, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Beth Israel Deaconess Med Ctr; Neurology/MS Center, Boston, Massachusetts, 02215, United States|Dragonfly Research, LLC, Wellesley, Massachusetts, 02481, United States|UMASS Memorial Medical Center, Worcester, Massachusetts, 01655, United States|Wayne State University; Department of Neurology, Detroit, Michigan, 48201, United States|Minneapolis Clinic of Neurology, Golden Valley, Minnesota, 55422, United States|Washington University School of Medicine; Department of Neurology, Saint Louis, Missouri, 63110, United States|Cleveland Clinic Lou Ruvo; Center for Brain Research, Las Vegas, Nevada, 89106, United States|Rutgers New Jersey Medical School, Newark, New Jersey, 07103, United States|Holy Name Hospital; Institute For Clinical Research, Teaneck, New Jersey, 07666, United States|Jacobs Neurological Institute, Buffalo, New York, 14203, United States|The MS Center of Northeastern New York, Latham, New York, 12110, United States|Columbia University Medical Center, New York, New York, 10032, United States|South Shore Neurologic Associates P.C., Patchogue, New York, 11772, United States|Island Neurological Associates, P.C., Plainview, New York, 11803, United States|Raleigh Neurology Associates, Raleigh, North Carolina, 27607-6520, United States|UC Health Clinical Trials Office, Cincinnati, Ohio, 45267, United States|Cleveland Clinic Foundation; Cleveland Clinic Cancer Center/I40, Cleveland, Ohio, 44195, United States|The Ohio State University Wexner Medical Center; Department of Neurology, Columbus, Ohio, 43210, United States|Neurology Specialists, Inc, Dayton, Ohio, 45417, United States|Neurology and Neuroscience Assoc., Inc., Westerville, Ohio, 43081, United States|Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, 73104, United States|Providence Multiple Sclerosis Center, Portland, Oregon, 97225, United States|Allegheny Neurological Associates, Pittsburgh, Pennsylvania, 15212, United States|Neurology Clinic PC, Cordova, Tennessee, 38018, United States|Hope Neurology, Knoxville, Tennessee, 37922, United States|Uni of Texas Health Science Center At Houston, Houston, Texas, 77030, United States|Bhupesh Dihenia M.D. P.A., Lubbock, Texas, 79410, United States|Central Texas Neurology Consultants, Round Rock, Texas, 78681, United States|Neurology Center of San Antonio, San Antonio, Texas, 78212, United States|Rocky Mountain MS Clinic, Salt Lake City, Utah, 84103, United States|Swedish Neuroscience Institute, Seattle, Washington, 98122, United States|MultiCare Health System Institute for Research and Innovation, Tacoma, Washington, 98405, United States|Foothills Medical Centre; Centre Dept of Medical Clinical Neuroscience, Calgary, Alberta, T2N 2T9, Canada|University of Alberta; Divison of Pulmonary Medicine, Dept. of Medicine,, Edmonton, Alberta, T6C 2G3, Canada|Fraser Health Multiple Sclerosis Clinic; Burnaby Hospital Pharmacy, Burnaby, British Columbia, V5G 2X6, Canada|Horizon Health Network - Multiple Sclerosis Clinic, Saint John, New Brunswick, E2L 4L2, Canada|Dalhousie Multiple Sclerosis Research Unit, Halifax, Nova Scotia, B3H 4K4, Canada|Hamilton General Hospital, Hamilton, Ontario, L8L 2X2, Canada|The Ottawa Hospital - General Campus; Department of Neurology - Multiple Sclerosis, Ottawa, Ontario, K1H 8L6, Canada|St. Michael's Hospital MS Clinic, MS Research Centre, Toronto, Ontario, Canada|Clinique NeuroOutaouais, Gatineau, Quebec, J8Y 1W2, Canada|Recherche Sepmus, Inc., Greenfield Park, Quebec, J4V 2J2, Canada|Hopital Hotel Dieu de Levis, Levis, Quebec, G6V 3Z1, Canada|Chum Campus Notre Dame, Montreal, Quebec, H2X 0A9, Canada|McGill University; Montreal Neurological Institute; Neurological and Psychiatric, Montreal, Quebec, H3A 2B4, Canada|MS Clinic Mauricie Bois Francs, Trois Rivieres, Quebec, G8Z 3R9, Canada|CHU De Quebec Universite Laval, Quebec, G1J 1Z4, Canada"
NCT00001156,Assessment of Patients With Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT00001156,COMPLETED,Herpesviridae Infection|HTLV-I Infection|Multiple Sclerosis|Tropical Spastic Paraparesis|Vasculitis,,National Institute of Neurological Disorders and Stroke (NINDS),,ALL,"ADULT, OLDER_ADULT",,1388,NIH,OBSERVATIONAL,Observational Model: |Time Perspective: p,1976-01-23,,2010-02-01,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States"
NCT05566756,Study Evaluating Kesimpta® Treatment Effects in Patients With Relapsing Multiple Sclerosis Transitioning From Other Therapies,https://beta.clinicaltrials.gov/study/NCT05566756,RECRUITING,Multiple Sclerosis,OTHER: Ofatumumab,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",,300,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-10-28,2024-11-30,2024-11-30,"Novartis Investigative Site, Bamberg, Bavaria, 96052, Germany|Novartis Investigative Site, Essen, Nordrhein-Westfalen, 45134, Germany|Novartis Investigative Site, Alzey, 55232, Germany|Novartis Investigative Site, Bad Homburg, 61348, Germany|Novartis Investigative Site, Bayreuth, 95445, Germany|Novartis Investigative Site, Berlin, 120999, Germany|Novartis Investigative Site, Boblingen, 71032, Germany|Novartis Investigative Site, Bochum, 44787, Germany|Novartis Investigative Site, Bogen, 94327, Germany|Novartis Investigative Site, Bonn, 53111, Germany|Novartis Investigative Site, Chemnitz, 09117, Germany|Novartis Investigative Site, Düsseldorf, 40211, Germany|Novartis Investigative Site, Düsseldorf, 40625, Germany|Novartis Investigative Site, Essen, 45257, Germany|Novartis Investigative Site, Frankfurt, 60313, Germany|Novartis Investigative Site, Gelsenkirchen, 45894, Germany|Novartis Investigative Site, Gladenbach, 35075, Germany|Novartis Investigative Site, Hagen, 58095, Germany|Novartis Investigative Site, Hamburg, 20249, Germany|Novartis Investigative Site, Hannover, 30625, Germany|Novartis Investigative Site, Kaiserslautern, 67655, Germany|Novartis Investigative Site, Koln, 50935, Germany|Novartis Investigative Site, Mannheim, 66163, Germany|Novartis Investigative Site, Marburg, 35039, Germany|Novartis Investigative Site, Minden, 32423, Germany|Novartis Investigative Site, Osnabrück, 49074, Germany|Novartis Investigative Site, Pforzheim, 75172, Germany|Novartis Investigative Site, Quakenbrueck, 49610, Germany|Novartis Investigative Site, Remscheid, 42853, Germany|Novartis Investigative Site, Ruelzheim, 76761, Germany|Novartis Investigative Site, Siegen, 57076, Germany|Novartis Investigative Site, Sinsheim, 74889, Germany|Novartis Investigative Site, Stuttgart, 70174, Germany|Novartis Investigative Site, Stuttgart, 70182, Germany"
NCT05415956,"""Outwalk MS"" - Benefits of Outdoor Walking in Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT05415956,RECRUITING,Multiple Sclerosis,BEHAVIORAL: Walking exercise therapy,University of Aarhus,The Danish MS Society,ALL,"ADULT, OLDER_ADULT",NA,52,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-11-01,2022-07-31,2022-11-30,"Aarhus University, Health, Exercise Biology, Aarhus, Jutland, 8000, Denmark"
NCT03826056,Neurology Inpatient Clinical Education Trial,https://beta.clinicaltrials.gov/study/NCT03826056,COMPLETED,Myasthenia Gravis|Guillain-Barre Syndrome|Multiple Sclerosis|Seizures|Parkinsonism|Meningitis|Encephalitis|Headache|Vestibular Disorder|Spondylosis|Normal Pressure Hydrocephalus,BEHAVIORAL: Current standard discharge educational intervention|BEHAVIORAL: Personalized discharge educational intervention,Dartmouth-Hitchcock Medical Center,,ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: HEALTH_SERVICES_RESEARCH,2019-02-01,2021-12-07,2021-12-07,"Dartmouth- Hitchcock Medical Center, Lebanon, New Hampshire, 03756, United States"
NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01201356,COMPLETED,Relapsing Forms of Multiple Sclerosis,DRUG: Fingolimod,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,4125,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2010-09-13,2018-10-19,2018-10-19,"Novartis Investigative Site, Cullman, Alabama, 35058, United States|Novartis Investigative Site, Oceanside, California, 92056, United States|Novartis Investigative Site, Sacramento, California, 95817, United States|Novartis Investigative Site, San Francisco, California, 94143, United States|Novartis Investigative Site, Washington, District of Columbia, 20007, United States|Novartis Investigative Site, Jacksonville, Florida, 32209, United States|Novartis Investigative Site, Maitland, Florida, 32751, United States|Novartis Investigative Site, Miami, Florida, 33136, United States|Novartis Investigative Site, Sunrise, Florida, 33351, United States|Novartis Investigative Site, Tallahassee, Florida, 32308, United States|Novartis Investigative Site, Tampa, Florida, 33609, United States|Novartis Investigative Site, Vero Beach, Florida, 32960, United States|Novartis Investigative Site, Atlanta, Georgia, 30327, United States|Novartis Investigative Site, Kansas City, Kansas, 66160, United States|Novartis Investigative Site, Lenexa, Kansas, 66212, United States|Novartis Investigative Site, Baltimore, Maryland, 21201, United States|Novartis Investigative Site, Baltimore, Maryland, 21287, United States|Novartis Investigative Site, Kansas City, Missouri, 64111, United States|Novartis Investigative Site, Lebanon, New Hampshire, 03756, United States|Novartis Investigative Site, Albuquerque, New Mexico, 87131-0001, United States|Novartis Investigative Site, New York, New York, 10021, United States|Novartis Investigative Site, Durham, North Carolina, 27710, United States|Novartis Investigative Site, Raleigh, North Carolina, 27607, United States|Novartis Investigative Site, Toledo, Ohio, 43614, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, 73104, United States|Novartis Investigative Site, Tulsa, Oklahoma, 74136, United States|Novartis Investigative Site, Tualatin, Oregon, 97062, United States|Novartis Investigative Site, Pittsburgh, Pennsylvania, 15213, United States|Novartis Investigative Site, Bristol, Tennessee, 37620, United States|Novartis Investigative Site, Nashville, Tennessee, 37212, United States|Novartis Investigative Site, San Antonio, Texas, 78229, United States|Novartis Investigative Site, Burlington, Vermont, 05401, United States|Novartis Investigative Site, Charlottesville, Virginia, 22904, United States|Novartis Investigative Site, Seattle, Washington, 98122, United States|Novartis Investigative Site, Caba, Buenos Aires, 1425, Argentina|Novartis Investigative Site, Caba, Buenos Aires, C1181ACH, Argentina|Novartis Investigative Site, Caba, Buenos Aires, C1428AQK, Argentina|Novartis Investigative Site, Capital Federal, Buenos Aires, C1192AAW, Argentina|Novartis Investigative Site, Guaymallen, Mendoza, M5507XAD, Argentina|Novartis Investigative Site, Ciudad de Salta, Provincia De Salta, A4406BPF, Argentina|Novartis Investigative Site, Rosario, Santa Fe, 2000, Argentina|Novartis Investigative Site, San Miguel de Tucumán, Tucumán, 4000, Argentina|Novartis Investigative Site, Cordoba, X5004CDT, Argentina|Novartis Investigative Site, Salta, A4400BKZ, Argentina|Novartis Investigative Site, Camperdown, New South Wales, 2050, Australia|Novartis Investigative Site, Chatswood, New South Wales, 2067, Australia|Novartis Investigative Site, Kogarah, New South Wales, 2217, Australia|Novartis Investigative Site, Liverpool, New South Wales, 2170, Australia|Novartis Investigative Site, North Gosford, New South Wales, 2250, Australia|Novartis Investigative Site, Woodville, South Australia, 5011, Australia|Novartis Investigative Site, Box Hill, Victoria, 3128, Australia|Novartis Investigative Site, Fitzroy, Victoria, 3065, Australia|Novartis Investigative Site, Heidelberg, Victoria, 3084, Australia|Novartis Investigative Site, Parkville, Victoria, 3050, Australia|Novartis Investigative Site, Innsbruck, Tyrol, 6020, Austria|Novartis Investigative Site, Linz, A-4020, Austria|Novartis Investigative Site, Salzburg, 5020, Austria|Novartis Investigative Site, St Poelten, 3100, Austria|Novartis Investigative Site, Vienna, 1010, Austria|Novartis Investigative Site, Vienna, 1090, Austria|Novartis Investigative Site, Aalst, 9300, Belgium|Novartis Investigative Site, Brugge, 8000, Belgium|Novartis Investigative Site, Brussel, 1090, Belgium|Novartis Investigative Site, Bruxelles, 1070, Belgium|Novartis Investigative Site, Bruxelles, 1200, Belgium|Novartis Investigative Site, Charleroi, 6000, Belgium|Novartis Investigative Site, Fraiture En Condroz, 4557, Belgium|Novartis Investigative Site, Leuven, 3000, Belgium|Novartis Investigative Site, Melsbroek, 1820, Belgium|Novartis Investigative Site, Pelt, 3900, Belgium|Novartis Investigative Site, Sijsele, 8340, Belgium|Novartis Investigative Site, Sint-Truiden, 3800, Belgium|Novartis Investigative Site, Wilrijk, 2610, Belgium|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, 90610-000, Brazil|Novartis Investigative Site, Rio de Janeiro, RJ, 20270-004, Brazil|Novartis Investigative Site, Rio de Janeiro, RJ, 21941-913, Brazil|Novartis Investigative Site, Rio De Janiero, RJ, 20221-161, Brazil|Novartis Investigative Site, Porto Alegre, RS, 90020-090, Brazil|Novartis Investigative Site, Campinas, SP, 13083-970, Brazil|Novartis Investigative Site, Ribeirao Preto, SP, 14048-900, Brazil|Novartis Investigative Site, Edmonton, Alberta, T6G 2G3, Canada|Novartis Investigative Site, Burnaby, British Columbia, V5G 2X6, Canada|Novartis Investigative Site, Vancouver, British Columbia, V6T 1Z3, Canada|Novartis Investigative Site, Victoria, British Columbia, V8R 1J8, Canada|Novartis Investigative Site, Halifax, Nova Scotia, B3H 2Y9, Canada|Novartis Investigative Site, Kingston, Ontario, K7L 2V7, Canada|Novartis Investigative Site, London, Ontario, N6A 5A5, Canada|Novartis Investigative Site, Nepean, Ontario, K2G 6E2, Canada|Novartis Investigative Site, Ottawa, Ontario, K1H 8L6, Canada|Novartis Investigative Site, Toronto, Ontario, M5B 1W8, Canada|Novartis Investigative Site, Greenfield Park, Quebec, J4V 2J2, Canada|Novartis Investigative Site, Montreal, Quebec, H1T 2M4, Canada|Novartis Investigative Site, Montreal, Quebec, H2L 4M1, Canada|Novartis Investigative Site, Montreal, Quebec, H3A 2B4, Canada|Novartis Investigative Site, Sherbrooke, Quebec, J1H 5N4, Canada|Novartis Investigative Site, Regina, Saskatchewan, S4T 1A5, Canada|Novartis Investigative Site, Quebec, G1J 1Z4, Canada|Novartis Investigative Site, Brno, Czech Republic, 656 91, Czechia|Novartis Investigative Site, Olomouc, CZE, 775 20, Czechia|Novartis Investigative Site, Ostrava-Poruba, 708 00, Czechia|Novartis Investigative Site, Pardubice, 532 03, Czechia|Novartis Investigative Site, Plzen - Lochotin, 30460, Czechia|Novartis Investigative Site, Prague 5, 150 00, Czechia|Novartis Investigative Site, Praha, 12808, Czechia|Novartis Investigative Site, Rychnov nad Kneznou, 516 01, Czechia|Novartis Investigative Site, Teplice, 415 29, Czechia|Novartis Investigative Site, Aarhus, DK-8000, Denmark|Novartis Investigative Site, Copenhagen, DK-2100, Denmark|Novartis Investigative Site, Alexandria, 21131, Egypt|Novartis Investigative Site, Cairo, 11566, Egypt|Novartis Investigative Site, Cairo, Egypt|Novartis Investigative Site, Tallinn, 10617, Estonia|Novartis Investigative Site, Helsinki, 00930, Finland|Novartis Investigative Site, Seinajoki, 60220, Finland|Novartis Investigative Site, Tampere, 33100, Finland|Novartis Investigative Site, Turku, 20520, Finland|Novartis Investigative Site, Nancy, Cedex, 54035, France|Novartis Investigative Site, Bordeaux Cedex, F-33076, France|Novartis Investigative Site, Bron, 69677, France|Novartis Investigative Site, CAEN Cedex, 14033, France|Novartis Investigative Site, Clermont-Ferrand Cedex 1, 63003, France|Novartis Investigative Site, Dijon, 21034, France|Novartis Investigative Site, Lille Cedex, 59037, France|Novartis Investigative Site, Marseille cedex 05, 13385, France|Novartis Investigative Site, Montpellier, 34295, France|Novartis Investigative Site, Nice Cedex 1, 06602, France|Novartis Investigative Site, Paris Cedex 13, 75651, France|Novartis Investigative Site, Poissy, 78303, France|Novartis Investigative Site, Rennes, 35043, France|Novartis Investigative Site, St Herblain, 44800, France|Novartis Investigative Site, Strasbourg Cedex, 67091, France|Novartis Investigative Site, Toulouse cedex 9, 31059, France|Novartis Investigative Site, Ostfildern, Baden-Wuerttemberg, 73760, Germany|Novartis Investigative Site, Munich, Bavaria, 81241, Germany|Novartis Investigative Site, Regensburg, Bavaria, 93053, Germany|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, 50937, Germany|Novartis Investigative Site, Aachen, 52062, Germany|Novartis Investigative Site, Aalen, 73430, Germany|Novartis Investigative Site, Abensberg, 93326, Germany|Novartis Investigative Site, Achim, 28832, Germany|Novartis Investigative Site, Alzenau, 63755, Germany|Novartis Investigative Site, Aschaffenburg, 63739, Germany|Novartis Investigative Site, Augsburg, 86179, Germany|Novartis Investigative Site, Bad Honnef, 53604, Germany|Novartis Investigative Site, Bad Krozingen, 79189, Germany|Novartis Investigative Site, Bad Mergentheim, 97980, Germany|Novartis Investigative Site, Bad Neustadt, 97616, Germany|Novartis Investigative Site, Bamberg, 96049, Germany|Novartis Investigative Site, Bamberg, 96052, Germany|Novartis Investigative Site, Bayreuth, 95445, Germany|Novartis Investigative Site, Berlin, 10178, Germany|Novartis Investigative Site, Berlin, 10625, Germany|Novartis Investigative Site, Berlin, 10713, Germany|Novartis Investigative Site, Berlin, 10785, Germany|Novartis Investigative Site, Berlin, 120999, Germany|Novartis Investigative Site, Berlin, 12101, Germany|Novartis Investigative Site, Berlin, 12163, Germany|Novartis Investigative Site, Berlin, 12351, Germany|Novartis Investigative Site, Berlin, 13347, Germany|Novartis Investigative Site, Berlin, 13353, Germany|Novartis Investigative Site, Berlin, 13439, Germany|Novartis Investigative Site, Berlin, 13507, Germany|Novartis Investigative Site, Berlin, 14163, Germany|Novartis Investigative Site, Bielefeld, 33602, Germany|Novartis Investigative Site, Bielefeld, 33611, Germany|Novartis Investigative Site, Bielefeld, 33647, Germany|Novartis Investigative Site, Boblingen, 71032, Germany|Novartis Investigative Site, Bochum, 44787, Germany|Novartis Investigative Site, Bochum, 44789, Germany|Novartis Investigative Site, Bochum, 44892, Germany|Novartis Investigative Site, Bogen, 94327, Germany|Novartis Investigative Site, Bonn, 53111, Germany|Novartis Investigative Site, Buchholz in der Nordheide, 21244, Germany|Novartis Investigative Site, Buchholz, 21244, Germany|Novartis Investigative Site, Chemnitz, 09117, Germany|Novartis Investigative Site, Dillingen, 89407, Germany|Novartis Investigative Site, Dresden, 01307, Germany|Novartis Investigative Site, Düsseldorf, 40211, Germany|Novartis Investigative Site, Emden, 26721, Germany|Novartis Investigative Site, Emmendingen, 79312, Germany|Novartis Investigative Site, Erbach, 64711, Germany|Novartis Investigative Site, Erfurt, 99089, Germany|Novartis Investigative Site, Erlangen, 91054, Germany|Novartis Investigative Site, Essen, 45131, Germany|Novartis Investigative Site, Essen, 45147, Germany|Novartis Investigative Site, Frankfurt, 60590, Germany|Novartis Investigative Site, Freiburg, 79106, Germany|Novartis Investigative Site, Greifswald, 17475, Germany|Novartis Investigative Site, Grevenbroich, 41515, Germany|Novartis Investigative Site, Hamburg, 20099, Germany|Novartis Investigative Site, Hamburg, 20249, Germany|Novartis Investigative Site, Hamburg, 20354, Germany|Novartis Investigative Site, Hamburg, 22083, Germany|Novartis Investigative Site, Hannover, 30161, Germany|Novartis Investigative Site, Hannover, 30171, Germany|Novartis Investigative Site, Hannover, 30625, Germany|Novartis Investigative Site, Heidelberg, 69120, Germany|Novartis Investigative Site, Hennigsdorf, 16761, Germany|Novartis Investigative Site, Herborn, 35745, Germany|Novartis Investigative Site, Homburg, 66421, Germany|Novartis Investigative Site, Ibbenbueren, 49477, Germany|Novartis Investigative Site, Itzehoe, 25524, Germany|Novartis Investigative Site, Jena, 07743, Germany|Novartis Investigative Site, Kaltenkirchen, 24568, Germany|Novartis Investigative Site, Kassel, 34121, Germany|Novartis Investigative Site, Koeln, 51109, Germany|Novartis Investigative Site, Koln, 50935, Germany|Novartis Investigative Site, Krefeld, 47805, Germany|Novartis Investigative Site, Landshut, 84028, Germany|Novartis Investigative Site, Lappersdorf, 93138, Germany|Novartis Investigative Site, Leipzig, 04103, Germany|Novartis Investigative Site, Leipzig, 04275, Germany|Novartis Investigative Site, Lohr am Main, 79816, Germany|Novartis Investigative Site, Ludwigshafen, 67063, Germany|Novartis Investigative Site, Magdeburg, 39120, Germany|Novartis Investigative Site, Mainz, 55131, Germany|Novartis Investigative Site, Mannheim, 68159, Germany|Novartis Investigative Site, Marburg, 35039, Germany|Novartis Investigative Site, Muenchen, 80331, Germany|Novartis Investigative Site, Muenchen, 80377, Germany|Novartis Investigative Site, Muenchen, 81377, Germany|Novartis Investigative Site, Muenster, 48149, Germany|Novartis Investigative Site, München, 81829, Germany|Novartis Investigative Site, Nagold, 72202, Germany|Novartis Investigative Site, Neu-Ulm, 89231, Germany|Novartis Investigative Site, Neuburg an der Donau, 86633, Germany|Novartis Investigative Site, Neuruppin, 16816, Germany|Novartis Investigative Site, Oldenburg, 26122, Germany|Novartis Investigative Site, Osnabrück, 49076, Germany|Novartis Investigative Site, Pforzheim, 75172, Germany|Novartis Investigative Site, Potsdam, 14471, Germany|Novartis Investigative Site, Prien, 83209, Germany|Novartis Investigative Site, Rostock, 18057, Germany|Novartis Investigative Site, Ruelzheim, 76761, Germany|Novartis Investigative Site, Rüdersdorf, 15562, Germany|Novartis Investigative Site, Schwarzenbruck, 90592, Germany|Novartis Investigative Site, Schwendi, 88477, Germany|Novartis Investigative Site, Siegen, 57076, Germany|Novartis Investigative Site, Sinsheim, 74889, Germany|Novartis Investigative Site, Stade, 21682, Germany|Novartis Investigative Site, Stuttgart, 70174, Germany|Novartis Investigative Site, Stuttgart, 70176, Germany|Novartis Investigative Site, Stuttgart, 70178, Germany|Novartis Investigative Site, Stuttgart, 70182, Germany|Novartis Investigative Site, Teupitz, 15755, Germany|Novartis Investigative Site, Trier, 54292, Germany|Novartis Investigative Site, Tübingen, 72076, Germany|Novartis Investigative Site, Ulm, 89073, Germany|Novartis Investigative Site, Ulm, 89081, Germany|Novartis Investigative Site, Unterhaching, 82008, Germany|Novartis Investigative Site, Wendlingen, 73240, Germany|Novartis Investigative Site, Wermsdorf, 04779, Germany|Novartis Investigative Site, Wiesbaden, 65191, Germany|Novartis Investigative Site, Wuerzburg, 97080, Germany|Novartis Investigative Site, Wuppertal, 42283, Germany|Novartis Investigative Site, Würzburg, 97070, Germany|Novartis Investigative Site, Alexandroupolis, Evros, 681 00, Greece|Novartis Investigative Site, Athens, GR, 115 25, Greece|Novartis Investigative Site, Athens, GR, 115 27, Greece|Novartis Investigative Site, Thessaloniki, GR, 570 10, Greece|Novartis Investigative Site, Athens, 106 76, Greece|Novartis Investigative Site, Athens, 115 21, Greece|Novartis Investigative Site, Athens, 11526, Greece|Novartis Investigative Site, Athens, 15123, Greece|Novartis Investigative Site, Heraklion Crete, 711 10, Greece|Novartis Investigative Site, Patras, 265 00, Greece|Novartis Investigative Site, Thessaloniki, 57001, Greece|Novartis Investigative Site, Thessaloniki, GR 54636, Greece|Novartis Investigative Site, Guatemala City, 01010, Guatemala|Novartis Investigative Site, Guatemala City, 01014, Guatemala|Novartis Investigative Site, Budapest, HUN, 1204, Hungary|Novartis Investigative Site, Budapest, 1076, Hungary|Novartis Investigative Site, Budapest, 1085, Hungary|Novartis Investigative Site, Budapest, 1115, Hungary|Novartis Investigative Site, Budapest, 1145, Hungary|Novartis Investigative Site, Debrecen, 4032, Hungary|Novartis Investigative Site, Gyor, 9024, Hungary|Novartis Investigative Site, Miskolc, 3526, Hungary|Novartis Investigative Site, Pecs, 7623, Hungary|Novartis Investigative Site, Szeged, 6725, Hungary|Novartis Investigative Site, Szekesfehervar, H-8000, Hungary|Novartis Investigative Site, Veszprem, H 8200, Hungary|Novartis Investigative Site, Dublin 4, D04 T6F, Ireland|Novartis Investigative Site, Dublin, DUBLIN 9, Ireland|Novartis Investigative Site, Ashkelon, 78278, Israel|Novartis Investigative Site, Haifa, 3436212, Israel|Novartis Investigative Site, Ramat Gan, 52621, Israel|Novartis Investigative Site, Sefad, 13100, Israel|Novartis Investigative Site, Asti, AT, 14100, Italy|Novartis Investigative Site, Acquaviva delle Fonti, BA, 70021, Italy|Novartis Investigative Site, Bergamo, BG, 24127, Italy|Novartis Investigative Site, Bologna, BO, 40139, Italy|Novartis Investigative Site, Montichiari, BS, 25018, Italy|Novartis Investigative Site, Cagliari, CA, 09126, Italy|Novartis Investigative Site, Chieti, CH, 66100, Italy|Novartis Investigative Site, Catania, CT, 95122, Italy|Novartis Investigative Site, Catania, CT, 95123, Italy|Novartis Investigative Site, Cona, FE, 44100, Italy|Novartis Investigative Site, Foggia, FG, 71100, Italy|Novartis Investigative Site, Firenze, FI, 50134, Italy|Novartis Investigative Site, Genova, GE, 16132, Italy|Novartis Investigative Site, Pozzilli, IS, 86077, Italy|Novartis Investigative Site, Roma, Lazio, 00168, Italy|Novartis Investigative Site, Milano, MI, 20122, Italy|Novartis Investigative Site, Milano, MI, 20132, Italy|Novartis Investigative Site, Palermo, PA, 90146, Italy|Novartis Investigative Site, Fidenza, PR, 43036, Italy|Novartis Investigative Site, Pavia, PV, 27100, Italy|Novartis Investigative Site, Ravenna, RA, 48100, Italy|Novartis Investigative Site, Roma, RM, 00133, Italy|Novartis Investigative Site, Roma, RM, 00135, Italy|Novartis Investigative Site, Roma, RM, 00161, Italy|Novartis Investigative Site, Roma, RM, 00189, Italy|Novartis Investigative Site, Siena, SI, 53100, Italy|Novartis Investigative Site, Orbassano, TO, 10043, Italy|Novartis Investigative Site, Udine, UD, 33100, Italy|Novartis Investigative Site, Gallarate, VA, 21013, Italy|Novartis Investigative Site, Vicenza, VI, 36100, Italy|Novartis Investigative Site, Verona, VR, 37134, Italy|Novartis Investigative Site, Viterbo, VT, 01100, Italy|Novartis Investigative Site, Napoli, 80131, Italy|Novartis Investigative Site, Napoli, 80132, Italy|Novartis Investigative Site, Napoli, 80138, Italy|Novartis Investigative Site, Irbid, 22110, Jordan|Novartis Investigative Site, Gyeonggi do, Korea, 10408, Korea, Republic of|Novartis Investigative Site, Seoul, 03722, Korea, Republic of|Novartis Investigative Site, Seoul, 06351, Korea, Republic of|Novartis Investigative Site, Kuala Lumpur, Wilayah Persekutuan, 50586, Malaysia|Novartis Investigative Site, Kuala Lumpur, 59100, Malaysia|Novartis Investigative Site, Breda, CK, 4818, Netherlands|Novartis Investigative Site, Amsterdam, 1061 AE, Netherlands|Novartis Investigative Site, Amsterdam, 1081 HV, Netherlands|Novartis Investigative Site, Blaricum, 1261 AN, Netherlands|Novartis Investigative Site, Enschede, 7513 ER, Netherlands|Novartis Investigative Site, Gouda, 2803 HH, Netherlands|Novartis Investigative Site, Nieuwegein, Netherlands|Novartis Investigative Site, Nijmegen, 6525 GC, Netherlands|Novartis Investigative Site, Rotterdam, 3015 CE, Netherlands|Novartis Investigative Site, Sittard-Geleen, 6162 BG, Netherlands|Novartis Investigative Site, Tilburg, 5022 GC, Netherlands|Novartis Investigative Site, Lillehammer, 2629, Norway|Novartis Investigative Site, Molde, 6412, Norway|Novartis Investigative Site, Stavanger, 4068, Norway|Novartis Investigative Site, Panama City, 0801, Panama|Novartis Investigative Site, Panama City, Panama|Novartis Investigative Site, La Perla, Callao, 04, Peru|Novartis Investigative Site, Jesus Maria, Lima, 11, Peru|Novartis Investigative Site, San Isidro, Lima, 27, Peru|Novartis Investigative Site, Bialystok, 15-276, Poland|Novartis Investigative Site, Bialystok, 15-420, Poland|Novartis Investigative Site, Bydgoszcz, 85 681, Poland|Novartis Investigative Site, Gdansk, 80-803, Poland|Novartis Investigative Site, Katowice, 40 571, Poland|Novartis Investigative Site, Katowice, 40-648, Poland|Novartis Investigative Site, Lodz, 90 324, Poland|Novartis Investigative Site, Poznan, 60-355, Poland|Novartis Investigative Site, Warszawa, 02-097, Poland|Novartis Investigative Site, Warszawa, 02-507, Poland|Novartis Investigative Site, Warszawa, 02-957, Poland|Novartis Investigative Site, Warszawa, 04141, Poland|Novartis Investigative Site, Amadora, 2720-276, Portugal|Novartis Investigative Site, Coimbra, 3000075, Portugal|Novartis Investigative Site, Lisboa, 1150 314, Portugal|Novartis Investigative Site, Porto, 4099-001, Portugal|Novartis Investigative Site, Porto, 4200 319, Portugal|Novartis Investigative Site, Setubal, 2910-446, Portugal|Novartis Investigative Site, Bucharest, 010825, Romania|Novartis Investigative Site, Bucharest, 011461, Romania|Novartis Investigative Site, Bucharest, 050098, Romania|Novartis Investigative Site, Craiova, 200620, Romania|Novartis Investigative Site, Targu Mures, 540136, Romania|Novartis Investigative Site, Samara, Samara Region, 443095, Russian Federation|Novartis Investigative Site, Ekaterinburg, 620109, Russian Federation|Novartis Investigative Site, Kazan, 420021, Russian Federation|Novartis Investigative Site, Kazan, 420097, Russian Federation|Novartis Investigative Site, Moscow, 101990, Russian Federation|Novartis Investigative Site, Moscow, 121359, Russian Federation|Novartis Investigative Site, Moscow, 125367, Russian Federation|Novartis Investigative Site, Moscow, 127018, Russian Federation|Novartis Investigative Site, Nizhny Novgorod, 603018, Russian Federation|Novartis Investigative Site, Nizhny Novgorod, 603155, Russian Federation|Novartis Investigative Site, Saint Petersburg, 194044, Russian Federation|Novartis Investigative Site, Smolensk, 214019, Russian Federation|Novartis Investigative Site, St. Petersburg, 194291, Russian Federation|Novartis Investigative Site, St. Petersburg, 197376, Russian Federation|Novartis Investigative Site, Bratislava, Slovak Republic, 84103, Slovakia|Novartis Investigative Site, Bratislava, 813 69, Slovakia|Novartis Investigative Site, Bratislava, 826 06, Slovakia|Novartis Investigative Site, Martin, 036 59, Slovakia|Novartis Investigative Site, Trnava, 917 75, Slovakia|Novartis Investigative Site, Cape Town, 7925, South Africa|Novartis Investigative Site, Durban, South Africa|Novartis Investigative Site, Rosebank, 2196, South Africa|Novartis Investigative Site, Malaga, Andalucia, 29010, Spain|Novartis Investigative Site, Sevilla, Andalucia, 41009, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08035, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08036, Spain|Novartis Investigative Site, L Hospitalet De Llobregat, Catalunya, 08907, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, 46010, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, 46026, Spain|Novartis Investigative Site, Santiago de Compostela, Galicia, 15706, Spain|Novartis Investigative Site, Bilbao, Pais Vasco, 48013, Spain|Novartis Investigative Site, San Sebastian, Pais Vasco, 20080, Spain|Novartis Investigative Site, Barcelona, 08041, Spain|Novartis Investigative Site, Madrid, 28034, Spain|Novartis Investigative Site, Madrid, 28040, Spain|Novartis Investigative Site, Madrid, 28046, Spain|Novartis Investigative Site, Madrid, 28222, Spain|Novartis Investigative Site, Santa Cruz de Tenerife, 38009, Spain|Novartis Investigative Site, Goeteborg, 413 45, Sweden|Novartis Investigative Site, Linkoping, SE 581 85, Sweden|Novartis Investigative Site, Stockholm, 102 35, Sweden|Novartis Investigative Site, Stockholm, 14186, Sweden|Novartis Investigative Site, Umea, 901 85, Sweden|Novartis Investigative Site, Aarau, 5001, Switzerland|Novartis Investigative Site, Basel, 4031, Switzerland|Novartis Investigative Site, Carouge, 1227, Switzerland|Novartis Investigative Site, Lausanne, 1011, Switzerland|Novartis Investigative Site, Lugano, 6900, Switzerland|Novartis Investigative Site, St Gallen, 9007, Switzerland|Novartis Investigative Site, Zuerich, 8091, Switzerland|Novartis Investigative Site, Istanbul, TUR, 34098, Turkey|Novartis Investigative Site, Ankara, 06100, Turkey|Novartis Investigative Site, Ankara, 06500, Turkey|Novartis Investigative Site, Antalya, 07070, Turkey|Novartis Investigative Site, Gaziantep, 27310, Turkey|Novartis Investigative Site, Haseki / Istanbul, 34096, Turkey|Novartis Investigative Site, Istanbul, 34093, Turkey|Novartis Investigative Site, Istanbul, 34147, Turkey|Novartis Investigative Site, Istanbul, 34722, Turkey|Novartis Investigative Site, Izmir, 35040, Turkey|Novartis Investigative Site, Izmir, 35340, Turkey|Novartis Investigative Site, Mersin, 33079, Turkey|Novartis Investigative Site, Samsun, 55139, Turkey|Novartis Investigative Site, Trabzon, 61080, Turkey|Novartis Investigative Site, Yenisehir / Izmir, Turkey|Novartis Investigative Site, Truro, Cornwall, TR1 3LJ, United Kingdom|Novartis Investigative Site, Brighton, East Sussex, BN2 5BE, United Kingdom|Novartis Investigative Site, Salford, Manchester, M6 8HD, United Kingdom|Novartis Investigative Site, Headington, Oxfordshire, OX3 9DU, United Kingdom|Novartis Investigative Site, Sheffield, South Yorkshire, S10 2JF, United Kingdom|Novartis Investigative Site, Stoke on Trent, Staffordshire, ST46QG, United Kingdom|Novartis Investigative Site, Birmingham, B15 2TH, United Kingdom|Novartis Investigative Site, Bristol, BS10 5NB, United Kingdom|Novartis Investigative Site, Dundee, DD1 9SY, United Kingdom|Novartis Investigative Site, Edinburgh, EH4 2XU, United Kingdom|Novartis Investigative Site, Essex, RM7 0BE, United Kingdom|Novartis Investigative Site, Great Yarmouth, NR31 6LA, United Kingdom|Novartis Investigative Site, Liverpool, L9 7LJ, United Kingdom|Novartis Investigative Site, London, SE22 8PT, United Kingdom|Novartis Investigative Site, London, SW17 0QT, United Kingdom|Novartis Investigative Site, London, W8 6RF, United Kingdom|Novartis Investigative Site, Middlesbrough, TS4 3BW, United Kingdom|Novartis Investigative Site, Newcastle Upon Tyne, NE1 4LP, United Kingdom|Novartis Investigative Site, Northampton, NN1 5BD, United Kingdom|Novartis Investigative Site, Nottingham, NG7 2UH, United Kingdom|Novartis Investigative Site, Poole, BH15 2JB, United Kingdom|Novartis Investigative Site, Swindon, SN3 6BB, United Kingdom"
NCT00623415,Flupirtine as Oral Treatment in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00623415,TERMINATED,Relapsing Remitting Multiple Sclerosis,DRUG: Flupirtine|DRUG: Placebo,"Charite University, Berlin, Germany",Bayer,ALL,ADULT,PHASE2,30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2007-12,2012-11,2012-11,"NeuroCure Clinical Research Center, Charité Berlin, Berlin, 10117, Germany|Carl-Thiem-Clinic Cottbus, Cottbus, 03048, Germany|University of Göttingen, Department of Neurology, Göttingen, 37075, Germany|University of Ulm, Department of Neurology, Ulm, Germany"
NCT00676715,A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00676715,ACTIVE_NOT_RECRUITING,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Placebo|DRUG: Ocrelizumab|DRUG: Avonex,"Genentech, Inc.",Roche Pharma AG,ALL,ADULT,PHASE2,220,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2008-07-17,2012-03-09,2023-12-16,"Phoenix Neurological Associates Ltd, Phoenix, Arizona, 85006, United States|Barrow Neurological Institute, Phoenix, Arizona, 85013, United States|East Bay Physicians Med Group;Sutter East Bay Med Foundation, Berkeley, California, 94705, United States|University of California San Francisco, San Francisco, California, 94117, United States|Advanced Neurology of Colorado, LLC, Fort Collins, Colorado, 80528, United States|Bradenton Research Center, Bradenton, Florida, 34205, United States|MS Center of Vero Beach, Vero Beach, Florida, 32960, United States|Shepherd Center; Multiple Sclerosis Center, Atlanta, Georgia, 30309, United States|University of Chicago; Neurology, Chicago, Illinois, 60637, United States|Kansas University Medical Center, Kansas City, Kansas, 66103, United States|John Hopkins University, Baltimore, Maryland, 21205, United States|Michigan Institute for Neurological Disorders, Farmington Hills, Michigan, 48334, United States|Dartmouth-Hitchcock Medical Center; Dept of Neurology, Lebanon, New Hampshire, 03756, United States|Columbia University Medical Center; The Neurological Institute of New York, New York, New York, 10032, United States|Island Neurological Associates, P.C., Plainview, New York, 11803, United States|Suny At Stony Brook; Department Of Neurology, Stony Brook, New York, 11794, United States|The Neurological Institute PA, Charlotte, North Carolina, 28204, United States|Clinical Research of Winston Salem, Winston-Salem, North Carolina, 27103, United States|Cleveland Clinic, Cleveland, Ohio, 44106, United States|Ohio State University Med Ctr; MS Center, Columbus, Ohio, 43221, United States|Legacy Health System; Clinical Research & Tech Ctr, Tualatin, Oregon, 97062, United States|Vanderbilt University Medical Center, Nashville, Tennessee, 37212, United States|Baylor College of Medicine, Houston, Texas, 77030, United States|Integra Clinical Research, Llc, San Antonio, Texas, 78229, United States|Fletcher Allen Health Care/University of Vermont, Burlington, Vermont, 5405, United States|University of Virginia - Fontain Research Park, Charlottesville, Virginia, 22903, United States|UZ Antwerpen, Edegem, 2650, Belgium|First MHAT; Clinic of Neurology, Sofia, 1000, Bulgaria|Shat of Cardiovascular Diseases; Clinic of Neurology, Sofia, 1309, Bulgaria|ACIBADEM CITY CLINIC TOKUDA HOSPITAL EAD; Clinic of Neurology and Sleep Medicine, Sofia, 1407, Bulgaria|UMHAT Tzaritza Yoanna Sofia; CLINIC OF NEUROLOGY, Sofia, 1527, Bulgaria|CCB Medical institute, Ministry of Interior Sofia; CLINIC OF NEUROLOGY, Sofia, 1606, Bulgaria|Military Medical Academy; Neurology, Sofia, 1606, Bulgaria|Uni of British Columbia Hospital; Ms Clinical Research Group, Vancouver, British Columbia, V6T 2B5, Canada|St. Michael'S Hospital, Toronto, Ontario, M5B 1W8, Canada|McGill University; Montreal Neurological Institute; Neurological and Psychiatric, Montreal, Quebec, H3A 2B4, Canada|Fakultni Nemocnice Ostrava; Klinika hematoonkologie FNO a LF OU, Ostrava, 708 52, Czechia|Krajska Nemocnice Pardubice Neurologicka Klinika, Pardubice, 532 03, Czechia|Fakultni nemocnice Motol; Neurologicka klinika, Praha, 150 06, Czechia|Nemocnice Teplice; Neurologicke Oddeleni - Ms Centrum, Teplice, 415 29, Czechia|Aarhus Universitetshospital; Neurologisk Afd. F, Skleroseklinikken, Aarhus N, 8200, Denmark|Hopital Pellegrin-CHU de Bordeaux; Service de Neurologie, Bordeaux, 33076, France|CHU De Caen; Service De Neurologie Dejerine, Caen, 14033, France|Hopital Gabriel Montpied CHU de Clermont-Ferrand; Service de Neurologie B, Clermont-Ferrand, 63003, France|CHU De Nimes, Hopital Caremeau; Service De Neurologie Du Prof. Pierre Labauge, Nimes, 30029, France|St. Joseph-Krankenhaus, Berlin, 13088, Germany|Jüdisches Krankenhaus Berlin; Abteilung fur Neurologie, Berlin, 13347, Germany|Asklepios Klinik Nord-Heidberg; Neurologie, Hamburg, 22417, Germany|Universitatsklinikum Marburg; Zentrum für Nervenheilkunde, Klinik für Psychiatrie+Psychotherapie, Marburg, 35039, Germany|Ospedale S.Andrea-Universita di Roma; Centro Sclerosi Multipla, Roma, Lazio, 00189, Italy|Instituto Biomedico De Investigacion A.C., Aguascalientes, 20127, Mexico|Unidad de Investigacion CIMA SC, Chihuahua, 31200, Mexico|Hospital Cima Chihauhau, Chihuahua, 31328, Mexico|Hospital CIMA, Sta. Engracia, Monterrey, Nuevo León, 64060, Mexico|Spitalul Clinic Colentina; Clinica de Neurologie, Bucuresti, 020125, Romania|Spitalul Clinic Judetean de Urgenta Targu Mures; Clinica Neurologie, Targu Mures, 540136, Romania|SHI Sverdlovsk Regional Clinical Hospital #1;Neurology, Ekaterinburg, 620102, Russian Federation|LLC Research Medical Complex Vashe Zdorovie, Kazan, 4420029, Russian Federation|Central Clinical Hospital #2 N.A. Semashko OAO RJHD, Moscow, 107150, Russian Federation|Municipal City Hospital #33; Neurology, Nizhny Novgorod, 603076, Russian Federation|MRC for Oncology and Neurology; Neurology, Novosibirsk, 630090, Russian Federation|Regional Multiple Sclerosis Centre b/o CC ECM Neftyanik; Neurology, Tyumen, 625000, Russian Federation|Clinical Center of Serbia; Institute of Neurology, Belgrade, 11000, Serbia|Clinical Center Nis; Clinic for Mental Health, NIS, 18000, Serbia|Clinic of Neurology, Nova Sad, 21000, Serbia|Fakultna Nemocnica F. D. Roosevelta; Ii. Neurologicka Klinika Szu, Banska Bystrica, 975 17, Slovakia|Fakultna Nemocnica, Pracovisko Stare Mesto; Neurology, Bratislava, 813 69, Slovakia|Fakultna Nemocnica Paterua, Pracovisko Trieda Snp1 Kosice; Neurologicka Klinika, Kosice, 041 66, Slovakia|Fakultna Nemocnica Nitra; Neurologicka Klinika, Nitra, 949 01, Slovakia|Nemocnica s Poliklinikou Spisska Nova Ves, a.s., Spisska Nova Ves, 05201, Slovakia|Hospital Universitari Vall d'Hebron; Servicio de Neumo-Inmunologia, Barcelona, 08035, Spain|Hospital Clinic i Provincial; Servicio de Neurologia, Barcelona, 08036, Spain|Hospital Ramon y Cajal; Servicio de Neurologia, Madrid, 28034, Spain|Hospital Regional Universitario Carlos Haya; Servicio de Neurologia, Malaga, 29010, Spain|Hospital Universitario Virgen Macarena; Servicio de Neurologia, Sevilla, 41009, Spain|Hospital Universitario La Fe; Unidad de Esclerosis Multiple, Valencia, 46026, Spain|Universitätsspital Basel; Neurologie, Basel, 4031, Switzerland|Ams of Ukraine; Inst. of Neurology, Psychiatry & Narcology, Kharkov, 61068, Ukraine|City Clin.Hosp #4; Dept. of Neurology, Kyiv, 03110, Ukraine|Ukr.State Inst. of Med and Social Probl. Disab; Dept of Neur and Border states, Propetrovsk, 49027, Ukraine|Vin.Reg.Psych.Hosp.N.A Yuschenko O.I., Vnmu N.A. Pyrogov; Department of Nervous Diseases, Vinnytsya, 21005, Ukraine|Walton Centre NHS Foundation Trust, Neuroscience Research Centre; CLINICAL TRIALS UNIT, Liverpool, L9 7LJ, United Kingdom|Uni Hospital Queens Medical Centre; Neurology, Nottingham, NG7 2UH, United Kingdom|Royal Hallamshire Hospital; Neurology, Sheffield, S10 2JF, United Kingdom"
NCT02545868,A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02545868,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",BIOLOGICAL: 23-PPV|BIOLOGICAL: 13-PCV Booster|BIOLOGICAL: Influenza Vaccine|BIOLOGICAL: KLH|DRUG: OCR|BIOLOGICAL: TT Vaccine,Hoffmann-La Roche,,ALL,ADULT,PHASE3,102,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2015-10-27,2017-02-14,2021-10-09,"North Central Neurology Associates, Cullman, Alabama, 35058, United States|Territory Neurology and Research Institute, Tucson, Arizona, 85704, United States|Fullerton Neurology and Headache Center, Fullerton, California, 92835, United States|Scripps Clinic, La Jolla, California, 92037, United States|Neurology Associates PA, Maitland, Florida, 32751, United States|University of Miami School of Medicine; Dept. of Neurology Movement Disorder Center, Miami, Florida, 33136, United States|University of South Florida, Tampa, Florida, 33612, United States|Michigan Institute for Neurological Disorders, Farmington Hills, Michigan, 48334, United States|The Minneapolis Clinic of Neurology, Golden Valley, Minnesota, 55422, United States|Mercy Hospital St. Louis / Mercy Clinic Neurology, Chesterfield, Missouri, 63017, United States|Cleveland Clinic Lou Ruvo; Center for Brain Research, Las Vegas, Nevada, 89106, United States|University of New Mexico, Albuquerque, New Mexico, 87131, United States|Staten Island Univ Hospital, Staten Island, New York, 10306, United States|Ohio Health Research Institute Grant Medical Center, Columbus, Ohio, 43214, United States|MDH Research LLC, Westerville, Ohio, 43081, United States|Abington Neurological Associates, Abington, Pennsylvania, 19001, United States|Neurology Clinic PC, Cordova, Tennessee, 38018, United States|Central Texas Neurology Consultants, Round Rock, Texas, 78681, United States|Rocky Mountain MS Clinic, Salt Lake City, Utah, 84103, United States|Swedish Medical Center, Seattle, Washington, 98122, United States|University of Calgary, Calgary, Alberta, T2N 2T9, Canada|University of British Columbia Hospital; Division of Neurology, Vancouver, British Columbia, V6T 2B5, Canada"
NCT05209815,Safety of Exposure to Natalizumab During Pregnancy,https://beta.clinicaltrials.gov/study/NCT05209815,RECRUITING,Multiple Sclerosis,BEHAVIORAL: Questionnaire,"University Hospital, Bordeaux",Biogen,FEMALE,"ADULT, OLDER_ADULT",,212,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-06-20,2023-06,2023-06,"CHRU de Besançon - service de neurologie, Besançon, France|CHU de Bordeaux - service de neurologie, Bordeaux, France|HCL - service de neurologie, Bron, France|CH Sud Francilien - service de neurologie, Corbeil-Essonnes, France|AP-HP - Hôpital de Créteil - service de neurologie, Créteil, France|CHU de Dijon-Bourgogne, Dijon, France|CHU de Fort de France - service de neurologie, Fort-de-France, France|CHU de Grenoble-Alpes, La Tronche, France|CHRU de Lille - service de neurologie, Lille, France|CHU de Limoges - service de neurologie, Limoges, France|AP-HM - service de neurologie, Marseille, France|CHU de Montpellier - service de neurologie, Montpellier, France|CHRU de Nancy - service de neurologie, Nancy, France|CHU de Nantes - service de neurologie, Nantes, France|CHU de Nice - service de neurologie, Nice, France|CHU de Nîmes - service de neurologie, Nîmes, France|AP-HP - Hôpital La Pitié Salpétrière - service de neurologie, Paris, France|AP-HP - Hôpital Saint-Antoine - service de neurologie, Paris, France|Fondation Rothschild - service de neurologie, Paris, France|CHU de Poitiers - service de neurologie, Poitiers, France|CHU de Rennes - service de neurologie, Rennes, France|CHU de Rouen - service de neurologie, Rouen, France|CH de Saint-Denis - service de neurologie, Saint-Denis, France|CHU d'Amiens - service de neurologie, Salouël, France|CHRU de Strasbourg - service de neurologie, Strasbourg, France|CHU de Toulouse - service de neurologie, Toulouse, France|CHU de Tours - service de neurologie, Tours, France"
NCT04838015,Retrospective Study on Registry Data to Evaluate the Impact of Ocrelizumab Used in Routine Care in Patients With RRMS,https://beta.clinicaltrials.gov/study/NCT04838015,UNKNOWN,Multiple Sclerosis,,"University Hospital, Strasbourg, France",,ALL,"ADULT, OLDER_ADULT",,250,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-11-13,2021-11-13,2021-11-13,"Hautepierre Clinical Investigation Center - Strasbourg University Hospitals, Strasbourg, 67091, France"
NCT03497468,Effects of Task-oriented Training on Functional Mobility and Fatigue in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03497468,UNKNOWN,"Multiple Sclerosis, Relapsing-Remitting",OTHER: Combined exercise training|OTHER: Task-oriented training,Bezmialem Vakif University,,ALL,"ADULT, OLDER_ADULT",NA,34,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-04,2018-06-01,2018-06,
NCT03570268,Preventing Falls and Participation Restrictions in Neurological Diseases,https://beta.clinicaltrials.gov/study/NCT03570268,COMPLETED,Multiple Sclerosis|Parkinson Disease|Stroke,OTHER: Experimental Group: Education|OTHER: Control Group: Usual care,Fondazione Don Carlo Gnocchi Onlus,,ALL,"ADULT, OLDER_ADULT",NA,90,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2015-01-01,2016-12-30,2017-01-15,"Fondazione Don Gnocchi ONLUS, Milan, 20148, Italy"
NCT01628315,Assessment of Lesion Activity Analysis in the Avonex- Steroid Azathioprine (ASA) Study,https://beta.clinicaltrials.gov/study/NCT01628315,COMPLETED,"Multiple Sclerosis, Relapsing-remitting",DEVICE: MRI,University at Buffalo,"Charles University, Czech Republic|General University Hospital, Prague",ALL,ADULT,,159,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2009-03,2009-03,2014-12,"Buffalo Neuroimaging Analysis Center, Buffalo, New York, 14203, United States"
NCT03606668,Virtual Reality (VR) to Improve Quality of Life in Patients Diagnosed With Neurological Disorders,https://beta.clinicaltrials.gov/study/NCT03606668,COMPLETED,Multiple Sclerosis|Chronic Pain|Neurological Disorder,DEVICE: HTC Vive Virtual Reality (VR) system,NYU Langone Health,,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-06-20,2020-03-02,2020-03-02,"New York University School of Medicine, New York, New York, 10016, United States"
NCT01326715,Manganese-Enhanced Magnetic Resonance Imaging in Healthy Volunteers and People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01326715,COMPLETED,Multiple Sclerosis,DRUG: Mangafodipir (Teslascan),National Institute of Neurological Disorders and Stroke (NINDS),,ALL,"ADULT, OLDER_ADULT",PHASE1,17,NIH,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2013-10-17,2019-09-18,2022-09-13,"National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States"
NCT03711968,Interoception and Sense of Movement in the Patient With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03711968,COMPLETED,Multiple Sclerosis,OTHER: Rehabilitative treatment protocol,University of Roma La Sapienza,,ALL,ADULT,NA,63,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-09-13,2019-01-07,2019-03-20,"Umberto I Hospital, Rome, 00165, Italy"
NCT00146068,EARLY IFNB-1a and Simvastatin Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00146068,COMPLETED,Multiple Sclerosis,DRUG: Avonex/Zocor,University of North Carolina,,ALL,ADULT,PHASE4,30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,2004-09,2007-12,2007-12,"University of North Carolina-Chapel Hill MS clinic within the Neuroscience Hospital, Chapel Hill, North Carolina, 27599, United States"
NCT05543915,Cognitive Markers in Prodromal MS,https://beta.clinicaltrials.gov/study/NCT05543915,RECRUITING,Multiple Sclerosis,DEVICE: Active tDCS,NYU Langone Health,National Multiple Sclerosis Society,ALL,ADULT,NA,50,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2022-01-18,2024-06-18,2024-06-18,"NYU Langone Health, New York, New York, 10016, United States"
NCT00745615,"An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease",https://beta.clinicaltrials.gov/study/NCT00745615,TERMINATED,Relapsing Remitting Multiple Sclerosis,DRUG: Laquinimod|DRUG: Placebo,"Teva Pharmaceutical Industries, Ltd.",,ALL,ADULT,PHASE2,257,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2005-12-07,2017-07-23,2017-07-23,"Teva Investigational Site 382, Hradec Kralove 3, Czechia|Teva Investigational Site 380, Praha 2, Czechia|Teva Investigational Site 384, Praha 5- Motol, Czechia|Teva Investigational Site 681, Berlin, Germany|Teva Investigational Site 684, Erfurt, Germany|Teva Investigational Site 687, Hamburg, Germany|Teva Investigational Site 683, Mainz, Germany|Teva Investigational Site 686, Ulm, Germany|Teva Investigational Site 685, Wuerzburg, Germany|Teva Investigational Site 580, Debrecen, Hungary|Teva Investigational Site 581, Gyula, Hungary|Teva Investigational Site 583, Miskolc, Hungary|Teva Investigational Site 584, Veszprem, Hungary|Teva Investigational Site 981, Ramat -Gan, IL, Israel|Teva Investigational Site 982, Haifa, Israel|Teva Investigational Site 980, Jerusalem, Israel|Teva Investigational Site 483, Cagliari, Italy|Teva Investigational Site 484, Milano, Italy|Teva Investigational Site 486, Milano, Italy|Teva Investigational Site 488, Siena, Italy|Teva Investigational Site 281, Bydgoszcz, Poland|Teva Investigational Site 280, Katowice, Poland|Teva Investigational Site 285, Katowice, Poland|Teva Investigational Site 283, Lodz, Poland|Teva Investigational Site 284, Lublin, Poland|Teva Investigational Site 282, Wroclaw, Poland|Teva Investigational Site 186, Moscow, Russian Federation|Teva Investigational Site 187, Moscow, Russian Federation|Teva Investigational Site 188, Moscow, Russian Federation|Teva Investigational Site 189, Moscow, Russian Federation|Teva Investigational Site 180, Saint Petersburg, Russian Federation|Teva Investigational Site 181, St. Petersburg, Russian Federation|Teva Investigational Site 182, St. Petersburg, Russian Federation|Teva Investigational Site 184, St. Petersburg, Russian Federation|Teva Investigational Site 185, St. Petersburg, Russian Federation|Teva Investigational Site 782, Barakaldo, Spain|Teva Investigational Site 785, Barcelona, Spain|Teva Investigational Site 781, Bilbao, Spain|Teva Investigational Site 784, L'Hospitalet de Llobregat, Spain|Teva Investigational Site 780, Madrid, Spain|Teva Investigational Site 783, Sevilla, Spain|Teva Investigational Site 884, Liverpool, United Kingdom|Teva Investigational Site 882, London, United Kingdom|Teva Investigational Site 881, Sheffield, United Kingdom|Teva Investigational Site 883, Stoke on Trent, United Kingdom"
NCT01181115,Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT01181115,COMPLETED,Multiple Sclerosis,DRUG: Avonex,Biogen,,ALL,ADULT,PHASE3,60,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2010-04,2011-10,2011-10,"Research Site, Baotou, China|Research Site, Beijing, China|Research Site, Changchun, China|Research Site, Chengdu, China|Research Site, Guangzhou, China|Research Site, Hangzhou, China|Research Site, Nanchang, China|Research Site, Shanghai, China|Research Site, Taiyuan, China|Research Site, Xi'an, China"
NCT02587715,A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS,https://beta.clinicaltrials.gov/study/NCT02587715,UNKNOWN,"Multiple Sclerosis, Relapsing-Remitting",BIOLOGICAL: Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells|OTHER: Liberation therapy,Novo Cellular Medicine Institute LLP,,ALL,ADULT,PHASE1|PHASE2,69,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-02,2017-02,2017-02,"Novo Cellular Medicine Institute, San Fernando, Trinidad, Trinidad and Tobago"
NCT00321568,Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00321568,COMPLETED,Multiple Sclerosis,,National Institute of Neurological Disorders and Stroke (NINDS),,ALL,"ADULT, OLDER_ADULT",,60,NIH,OBSERVATIONAL,Observational Model: |Time Perspective: p,2006-05-01,,2011-04-19,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States"
NCT05181215,Bioequivalence Study of Bafiertam 190 mg and Vumerity® 462 mg Delayed-Release Capsules in Fasting Healthy Subjects,https://beta.clinicaltrials.gov/study/NCT05181215,COMPLETED,Relapsing Remitting Multiple Sclerosis,DRUG: Monomethyl Fumarate 190 Mg|DRUG: Diroximel Fumarate 462 mg,Banner Life Sciences LLC,,ALL,"ADULT, OLDER_ADULT",PHASE1,46,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2021-05-14,2021-08-27,2021-08-27,"BioPharma Services, Inc., Saint Louis, Missouri, 63141, United States"
NCT05322915,Therapeutic Effects of Line Dancing in People With MS,https://beta.clinicaltrials.gov/study/NCT05322915,COMPLETED,Multiple Sclerosis,OTHER: line dancing,Gazi University,Hacettepe University|Fenerbahce University,ALL,"ADULT, OLDER_ADULT",NA,31,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-06-01,2022-01-15,2022-01-15,"Hacettepe University, Ankara, Turkey"
NCT00037115,"Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.",https://beta.clinicaltrials.gov/study/NCT00037115,WITHDRAWN,Demyelinating Disorders|Multiple Sclerosis|Optic Neuritis|Myelitis|Neuritis,DRUG: interferon beta 1a|DRUG: methotrexate|DRUG: methylprednisolone,MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute,Consultants in Neurology,ALL,ADULT,PHASE4,0,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2002-05,2002-12,2002-12,"MidAmerica Neuroscience Institute, Kansas City, Missouri, 64108, United States"
NCT02019550,Rebif® Rebidose® Versus Rebiject II® Ease-of-Use,https://beta.clinicaltrials.gov/study/NCT02019550,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DEVICE: Rebif Rebidose|DEVICE: Rebiject II,EMD Serono,,ALL,"ADULT, OLDER_ADULT",PHASE4,97,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2014-03,2016-01,2016-01,"Research site, Cullman, Alabama, 35058, United States|Research Site, Tuscon, Arizona, 85718, United States|Research Site, Newport Beach, California, 92663, United States|Research site, Ft. Collins, Colorado, 80528, United States|Research Site, Dover, Delaware, 19901, United States|Research Site, Miami, Florida, 33136, United States|Research site, Sunrise, Florida, 33351, United States|Research Site, Atlanta, Georgia, 30327, United States|Research Site, Indianapolis, Indiana, 46256, United States|Research site, Foxboro, Massachusetts, 02035, United States|Research site, Golden Valley, Minnesota, 55422, United States|Research Site, Stratford, New Jersey, 08084, United States|Research Site, Patchogue, New York, 11772, United States|Research Site, Hickory, North Carolina, 28602, United States|Research Site, Winston-Salem, North Carolina, 27103, United States|Research Site, Dayton, Ohio, 45417, United States|Research Site, Oklahoma City, Oklahoma, 73104, United States|Research Site, Greensburg, Pennsylvania, 15601, United States|Research site, Spartanburg, South Carolina, 29307, United States|Research Site, Knoxville, Tennessee, 37934, United States|Research site, Mansfield, Texas, 76063, United States"
NCT01606215,Stem Cells in Rapidly Evolving Active Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01606215,COMPLETED,Multiple Sclerosis,DRUG: Mesenchymal stem cells|DRUG: Placebo,Imperial College London,,ALL,ADULT,PHASE1|PHASE2,21,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-01,2019-08,2019-08,"Imperial College Healthcare NHS Trust, London, W12 0NN, United Kingdom"
NCT01433250,"A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT01433250,COMPLETED,Multiple Sclerosis,DRUG: AIN457|DRUG: AIN457,Novartis Pharmaceuticals,,ALL,ADULT,PHASE2,39,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2012-02,2014-06,2014-06,"Novartis Investigative Site, Hradec Kralove, 500 05, Czech Republic|Novartis Investigative Site, Ostrava-Moravska Ostrava, Czech Republic|Novartis Investigative Site, Ostrava, Czech Republic|Novartis Investigative Site, Praha 2, 128 08, Czech Republic|Novartis Investigative Site, Teplice, 415 29, Czech Republic|Novartis Investigative Site, Kazan, 420021, Russian Federation|Novartis Investigative Site, Moscow, 129128, Russian Federation|Novartis Investigative Site, Nizhny Novgorod, 603155, Russian Federation|Novartis Investigative Site, Smolensk, 214019, Russian Federation|Novartis Investigative Site, Kharkiv, 61068, Ukraine|Novartis Investigative Site, Kharkiv, Ukraine|Novartis Investigative Site, Kiev, Ukraine|Novartis Investigative Site, Odessa, 65025, Ukraine|Novartis Investigative Site, Vinnitsya, 21005, Ukraine"
NCT03108950,From Clinic to Community: An Information and Communication Technology (ICT) Home-Based Exercise Training System for Translating Clinical Findings,https://beta.clinicaltrials.gov/study/NCT03108950,COMPLETED,Multiple Sclerosis|Stroke,BEHAVIORAL: Movement to Music,University of Alabama at Birmingham,Lakeshore Foundation,ALL,"ADULT, OLDER_ADULT",NA,27,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2017-02-01,2019-05-31,2019-05-31,"Lakeshore Foundation, Birmingham, Alabama, 35209, United States"
NCT04300868,Immunisation Status and Safety of Vaccines in Italian MS Patients,https://beta.clinicaltrials.gov/study/NCT04300868,RECRUITING,Multiple Sclerosis,,Monica Ulivelli,"Fondazione Italiana Sclerosi Multipla|San Luigi Gonzaga Hospital|University of Roma La Sapienza|Universita degli Studi di Catania|Universita degli Studi di Genova|San Camillo Hospital, Rome|Fondazione Policlinico Universitario Agostino Gemelli IRCCS|University of Florence|Istituto Neurologico Mediterraneo Neuromed S. R. L|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Maggiore Bellaria Hospital, Bologna|Federico II University|Ospedale San Donato|Ospedale San Giuseppe di Empoli|Ospedale Livorno|Ospedale Misericordia e Dolce|Ospedale della Misericordia|Ospedale San Jacopo|Ospedale Felice Lotti di Pontedera|Campus Bio-Medico University|Università degli Studi di Ferrara",ALL,"ADULT, OLDER_ADULT",,3000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-03-20,2023-01-31,2023-03-31,"university of Siena, Siena, SI, 53100, Italy"
NCT02797015,Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMS,https://beta.clinicaltrials.gov/study/NCT02797015,COMPLETED,Multiple Sclerosis,DRUG: RPC1063,Celgene,,ALL,ADULT,PHASE1,22,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2016-06-23,2017-10-20,2017-10-20,"Breastlink Medical Group, Inc., Long Beach, California, 90806, United States|Multiple Sclerosis Center at UCSF, San Francisco, California, 94158, United States|Raleigh Neurology Associates PA, Raleigh, North Carolina, 27607, United States|Neurology and Neuroscience Associates Inc., Akron, Ohio, 44320, United States|Hope Neurology MS Center, Knoxville, Tennessee, 37922, United States|Central Texas Neurology Consultants PA, Round Rock, Texas, 78681, United States"
NCT03110315,A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia,https://beta.clinicaltrials.gov/study/NCT03110315,COMPLETED,Multiple Sclerosis|Fatigue|Insomnia,DRUG: Suvorexant|DRUG: Placebo,"Theodore R. Brown, MD MPH",Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE4,34,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2017-03-28,2022-03-21,2022-03-21,"EvergreenHealth Multiple Sclerosis Center, Kirkland, Washington, 98034, United States"
NCT04042415,Calorie Restriction in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04042415,RECRUITING,"Multiple Sclerosis, Relapsing-Remitting|Caloric Restriction",OTHER: Caloric restriction|OTHER: Caloric restriction without cow's milk and gluten,Federico II University,Fondazione Italiana Sclerosi Multipla,ALL,ADULT,NA,120,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-14,2023-09,2023-09,"Neuromed - Istituto Neurologico Mediterraneo Pozzilli, Pozzilli, IS, 86077, Italy"
NCT04054050,Bright Light Therapy for Sleep Disturbance in People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04054050,ENROLLING_BY_INVITATION,Multiple Sclerosis,OTHER: Light therapy,Johns Hopkins University,National Institute on Minority Health and Health Disparities (NIMHD)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),ALL,"ADULT, OLDER_ADULT",NA,24,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-02-22,2024-01-30,2024-01-30,"Johns Hopkins School of Medicine, Baltimore, Maryland, 21287, United States"
NCT04295616,Additional Effect of Intrapulmonary Percussive Ventilation (IPV) on Respiration in People With Multiple Sclerosis (MS).,https://beta.clinicaltrials.gov/study/NCT04295616,TERMINATED,Multiple Sclerosis,DEVICE: Intrapulmonary percussive ventilation (IPV)|BEHAVIORAL: Active breathing training,National Multiple Sclerosis Center,National MS Center Melsbroek,ALL,"ADULT, OLDER_ADULT",NA,5,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2020-01-13,2020-07-20,2020-07-20,"National MS Center, Melsbroek, 1820, Belgium"
NCT03134716,Role of Microglia in the Pathogenesis of Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03134716,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,,Turku University Hospital,,ALL,ADULT,,35,OTHER_GOV,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-04,2023-04,2023-04,"Turku PET Centre, Turku, Finland Proper, 20520, Finland"
NCT01874145,Safety and Tolerability of Glatiramer Acetate,https://beta.clinicaltrials.gov/study/NCT01874145,COMPLETED,Relapsing-Remitting Multiple Sclerosis,DRUG: GA 20 mg/mL|DRUG: GA 40 mg/mL,"Teva Branded Pharmaceutical Products R&D, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE3,209,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2013-06,2014-04,2014-05,"Teva Investigational Site 10706, Cullman, Alabama, United States|Teva Investigational Site 10719, Gilbert, Arizona, United States|Teva Investigational Site 10720, Phoenix, Arizona, United States|Teva Investigational Site 10727, Fresno, California, United States|Teva Investigational Site 10731, Long Beach, California, United States|Teva Investigational Site 10735, Newport Beach, California, United States|Teva Investigational Site 10712, Oceanside, California, United States|Teva Investigational Site 10708, Centennial, Colorado, United States|Teva Investigational Site 10715, Maitland, Florida, United States|Teva Investigational Site 10718, Pompano Beach, Florida, United States|Teva Investigational Site 10709, St. Petersburg, Florida, United States|Teva Investigational Site 10707, Tampa, Florida, United States|Teva Investigational Site 10711, Tampa, Florida, United States|Teva Investigational Site 10710, Northbrook, Illinois, United States|Teva Investigational Site 10734, Indianapolis, Indiana, United States|Teva Investigational Site 10732, Baltimore, Maryland, United States|Teva Investigational Site 10726, Great Falls, Montana, United States|Teva Investigational Site 10702, Henderson, Nevada, United States|Teva Investigational Site 10717, Patchogue, New York, United States|Teva Investigational Site 10723, Plainview, New York, United States|Teva Investigational Site 10716, Charlotte, North Carolina, United States|Teva Investigational Site 10724, Raleigh, North Carolina, United States|Teva Investigational Site 10721, Winston-Salem, North Carolina, United States|Teva Investigational Site 10733, Bellevue, Ohio, United States|Teva Investigational Site 10703, Columbus, Ohio, United States|Teva Investigational Site 10714, Dayton, Ohio, United States|Teva Investigational Site 10704, Uniontown, Ohio, United States|Teva Investigational Site 10725, East Providence, Rhode Island, United States|Teva Investigational Site 10736, Cordova, Tennessee, United States|Teva Investigational Site 10701, Franklin, Tennessee, United States|Teva Investigational Site 10728, Nashville, Tennessee, United States|Teva Investigational Site 10729, Mansfield, Texas, United States|Teva Investigational Site 10722, Round Rock, Texas, United States|Teva Investigational Site 10699, Salt Lake City, Utah, United States|Teva Investigational Site 10700, Roanoke, Virginia, United States"
NCT02496416,Comparison of Two Physical Activity Interventions in Individuals With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02496416,RECRUITING,Multiple Sclerosis,BEHAVIORAL: Aquatic Exercise Program|BEHAVIORAL: Stretching Program,Kessler Foundation,National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2016-08,2022-12,2022-12,"Kessler Foundation, East Hanover, New Jersey, 07936, United States"
NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT03599245,RECRUITING,Multiple Sclerosis,DRUG: Ocrelizumab,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE3,1500,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-07-12,2025-02-23,2025-08-26,"Centro de Especialidades Neurológicas y Rehabilitación - CENyR, Buenos Aires, C1424, Argentina|Hospital Churruca Visca, Buenos Aires, C1437JCP, Argentina|Fundacion Rosarina de Neurorehabilitacion, Rosario, S2000BZL, Argentina|AZ Sint Jan, Brugge, 8000, Belgium|UZ Antwerpen, Edegem, 2650, Belgium|CHU Tivoli, La Louvière, 7100, Belgium|CHU Sart-Tilman, Liège, 4000, Belgium|Revalidatie en MS Centrum, Overpelt, 3900, Belgium|Instituto de Neurologia de Curitiba, Curitiba, PR, 81210-310, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, 90610-000, Brazil|Hospital das Clinicas - FMUSP, Sao Paulo, SP, 05403-900, Brazil|Shat Np Sveti Naum; 3Rd Clinic of Neurology, Sofia, 1113, Bulgaria|Multiprofile Hosp. for Active Treatment;National Cardiology Hosp., Sofia, 1309, Bulgaria|University of British Columbia, Vancouver, British Columbia, V6T 1Z4, Canada|London Health Sciences Centre Uni Campus, London, Ontario, N6A 5A5, Canada|The Ottawa Hospital - General Campus; Department of Neurology - Multiple Sclerosis, Ottawa, Ontario, K1H 8L6, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, M4N 3M5, Canada|Clinique NeuroOutaouais, Gatineau, Quebec, J8Y 1W2, Canada|Recherche Sepmus Inc., Greenfield Park, Quebec, J4V 2J2, Canada|Montreal Neurological Institute and Hospital, Montreal, Quebec, H3A 2B4, Canada|Clinical Hospital Centre Zagreb, Zagreb, 10000, Croatia|Fakultni nemocnice u sv. Anny; Neurologicka klinika, Brno, 656 91, Czechia|Nemocnice Jihlava; NEU-Neurologicke oddeleni, Jihlava, 58633, Czechia|VFN Praha Poliklinika Rs Centrum - Budova A, Prague, 12808, Czechia|Fakultni nemocnice v Motole; Neurologicka klinika 2. LF UK a FN Motol, Praha 5, 150 06, Czechia|Hjerne- og nervesygdomme, Ambulatorium, Skleroseklinikken, Aabenraa, 6200, Denmark|Aalborg Universitetshospital; Neurologisk Afdeling og Neurofysiologisk Afdeling; Skleroseamb., Aalborg, 9000, Denmark|Aarhus Universitetshospital; Neurologisk Afd. F, Skleroseklinikken, Aarhus N, 8200, Denmark|Rigshospitalet Glostrup; Neurologisk Klinik, Glostrup, 2600, Denmark|Odense Universitetshospital, Neurologisk Afdeling N; Neurologisk Ambulatorium N5; Skleroseklinikken, Odense C, 5000, Denmark|East Tallinn Central Hospital; Neurology Department, Tallinn, 10138, Estonia|West Tallinn Central Hospital, Tallinn, 10617, Estonia|Tartu University Hospital, Tartu, 51014, Estonia|Mehiläinen Neo Turku, Turku, 20520, Finland|CHU de Besancon Hopital Jean Minjoz; Service de Neurologie, Besançon, 25030, France|Groupe Hospitalier Pellegrin; Service de neurochirurgie B, Bordeaux, 33076, France|Hopital neurologique Pierre Wertheimer - CHU Lyon; Neurologie, Bron, 69677, France|Hopital Gabriel Montpied CHU de Clermont-Ferrand; Service de Neurologie B, Clermont-Ferrand, 63003, France|CH de Gonesse; Neurologie, Gonesse, 95503, France|CHU de Grenoble; Neurologie, La Tronche, 38700, France|Hopital Roger Salengro Service de Neurologie, Lille, France|CHU de la Timone - Hopital d Adultes; Service de Neurologie, Marseille, 13005, France|Hopital Gui de Chauliac; Neurologie, Montpellier, 34295, France|Hopital Central - CHU de Nancy; Service de Neurologie, Nancy, 54035, France|Hôpital Guillaume et René Laënnec; Service Neurologie, Nantes, 44805, France|Hôpital Pasteur; Service de Neurologie, Nice, 06002, France|CHU de Nîmes Hopital Caremeau; Service de Neurologie, Nimes, 30900, France|Groupe Hospitalier Pitié- Salpétrière; Service Neurologie, Paris, 75651, France|Hôpital de Poissy; Service neurologie, Poissy, 78300, France|CHU de Rouen Hopital; Service de Neurologie, Rouen, 76031, France|Höpital Hautepierre; Pediatrie1, Strasbourg, 67098, France|HIA de Toulon hôpital militaire; Neurologie, Toulon, 83041, France|Jahn Ferenc Del-Pesti Korhaz es Rendelointezet, Budapest, 1204, Hungary|VALEOMED Diagnosztikai Központ, Esztergom, 2500, Hungary|Cork University Hospital; Clinical Research Facility, Cork, Ireland|St Vincents University Hospital, Dublin 4, Ireland|Ospedale SS. Annunziata - Clinica Neurologica - Centro Sclerosi Multipla, Chieti, Abruzzo, 66013, Italy|Ospedale San Salvatore; Clinica Neurologica - Centro Sclerosi Multipla, L'Aquila, Abruzzo, 67100, Italy|A. O. U. Federico II; Dip Neuroscienze, Scienze Riproduttive ed Odontostomatologiche, Napoli, Campania, 80131, Italy|Università degli Studi della Campania Luigi Vanvitelli; Dip. Ass. Integrato Med Int-II Clinica Neur, Napoli, Campania, 80131, Italy|Ospedale Bellaria; Istituto delle Scienze Neurologiche - UO RIABILITAZIONE SCLEROSI MULTIPLA, Bologna, Emilia-Romagna, 40139, Italy|Policlinico Tor Vergata Dip. Neuroscienze-Clinica Neurologica-UOSD Sclerosi Multipla, Roma, Lazio, 00133, Italy|Ospedale S.Camillo Forlanini; UOSD Day Hospital Neurologico e Neurochirurgico, Roma, Lazio, 00152, Italy|Policlinico Universitario A. Gemelli; UOC Neurologia - Centro Sclerosi Multipla, Roma, Lazio, 00168, Italy|Azienda Ospedaliera Sant'Andrea; UOC Neurologia, Roma, Lazio, 00189, Italy|Irccs A.O.U.San Martino Ist; Dinogmi, Genova, Liguria, 16132, Italy|ASST PAPA GIOVANNI XXIII Neurologia USS Malattie Autoimmuni Centro Sclerosi Multipla, Bergamo, Lombardia, 24127, Italy|Ospedale S.Antonio Abate; Neurologia 2 ? Sclerosi Multipla e Recupero Neurologico, Gallarate, Lombardia, 21013, Italy|Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico; UOSD Malattie Neurodegenerative, Milano, Lombardia, 20122, Italy|IRCCS Ospedale San Raffaele; Neurologia Neurofisiologia Neuroriabilitazione-Centro Sclerosi Multipla, Milano, Lombardia, 20132, Italy|Fond. Istituto Neurologico C.Besta; UO Neurologia IV - Neuroimmunologia Malattie Neuromuscolari, Milano, Lombardia, 20133, Italy|Ospedale Civile di Montichiari; Centro Sclerosi Multipla, Montichiari, Lombardia, 25018, Italy|IRCCS Istituto Neurologico C. Mondino?Dip. Neurologia Neuroriabilitazione S.S. Sclerosi Multipla, Pavia, Lombardia, 27100, Italy|AOU Ospedali Riuniti Umberto I-G.M. Lancisi-G. Salesi; SOD Clinica Neurologica-Am.Sclerosi Multipla, Ancona, Marche, 60100, Italy|IRCCS Istituto Neurologico Neuromed; Centro per lo Studio e la Cura della Sclerosi Multipla, Pozzilli, Molise, 86077, Italy|Ospedale Dimiccoli Barletta; Dipartimento Testa-Collo - UO Neurologia, Barletta, Puglia, 70051, Italy|IRCCS Ospedale Casa Sollievo Della Sofferenza; SC Neurologia, San Giovanni Rotondo, Puglia, 71013, Italy|Ospedale Binaghi; Centro Sclerosi Multipla, Cagliari, Sardegna, 09126, Italy|AOU Policlinico V. Emanuele - P.O G. Rodolico; Clinica Neurologica, Centro Sclerosi Multipla, Catania, Sicilia, 95123, Italy|Fondazione Istituto S. Raffaele - Giglio; UO Neurologia, Cefalù, Sicilia, 90015, Italy|AOU Policlinico Giaccone; UOC Neurologia e Neurofisiopatologia-Amb Sclerosi Multipla, Palermo, Sicilia, 90129, Italy|AO Ospedali Riuniti Villa Sofia-Cervello;PO Villa Sofia - UO Neurologia - U.O.S. Neuroimmunologia, Palermo, Sicilia, 90146, Italy|AOU Careggi; Neurologia 1-Dip. Neuroscienze Psicologia Area Farmaco Salute del Bambino(NEUROFARBA), Firenze, Toscana, 50134, Italy|AOUC Azienda Ospedaliero-Universitaria Careggi; Neurologia 2, Firenze, Toscana, 50134, Italy|AOU Senese - Presidio Ospedaliero Le Scotte; UOSA Neurologia Sperimentale, Siena, Toscana, 53100, Italy|AO di Perugia - Ospedale S. Maria della Misericordia; Clinica Neurologica, Perugia, Umbria, 06156, Italy|Azienda Ospedaliera di Padova; Clinica Neurologica, Padova, Veneto, 35128, Italy|Policlinico G.B. Rossi; Dip. Scienze Neurologiche Biomediche - Neurologia B ? Amb. Sclerosi Multipla, Verona, Veneto, 37134, Italy|Ibn Sina Hospital; Neurology Department, Kuwait, 10002, Kuwait|Hospital General de México, Mexico City, Mexico CITY (federal District), 06726, Mexico|Hospital Angeles de Culiacán, Neurociencias Estudios Clínicos SC, Culiacán, Sinaloa, 80020, Mexico|Unidad de investigacion en salud (UIS); Neurociencias, Ciudad de México, 14050, Mexico|Jeroen Bosch Ziekenhuis, 'S Hertogenbosch, 5223 GZ, Netherlands|Amsterdam UMC Location VUMC, Amsterdam, 1081 HV, Netherlands|Amphia Ziekenhuis, Breda, 4819 EV, Netherlands|Groene Hart Ziekenhuis, Gouda, 2803 HH, Netherlands|Maasstadziekenhuis, Rotterdam, 3079 DZ, Netherlands|Zuyderland Medisch Centrum - Sittard Geleen, Sittard-Geleen, 6162 BG, Netherlands|Elisabeth-TweeSteden Ziekenhuis, Tilburg, 5042 AD, Netherlands|Haukeland universitetssykehus; Nevrologisk avdeling, Bergen, 5021, Norway|Sykehuset Buskerud HF; Nevrologisk avdeling, Drammen, 3004, Norway|Stavanger Universitetssykehus, Helse Stavanger HF, Stavanger, 4011, Norway|Neurocentrum Bydgoszcz sp. z o.o, Bydgoszcz, 85-796, Poland|COPERNICUS Podmiot Leczniczy Sp. z o. o. Szpital im. M. Kopernika; Oddzia? Neurologiczny, Gdansk, 80-803, Poland|Care Clinic, Katowice, 40-568, Poland|Malopolskie Centrum Diagnostyczne MEDICAL Sp. z o. o., Krakow, 31-637, Poland|Centrum Neurologii Krzysztof Selmaj, Lodz, 90-324, Poland|Indywidualna Praktyka Lekarska Prof. Dr Hab. N. Med. Konrad Rejdak., Lublin, 20-016, Poland|Klinika Neurologii I Wydzialu Lekarskiego WUM w Warszawie, Warszawa, 02-097, Poland|Instytut Psychiatrii i Neurologii II Klinika Neurologiczna, Warszawa, 02-957, Poland|Hospital de Braga; Servico de Neurologia, Braga, 4710-243, Portugal|HUC; Servico de Neurologia, Coimbra, 3000-075, Portugal|Hospital Beatriz Angelo; Servico de Neurologia, Loures, 2674-514, Portugal|Hospital Geral de Santo Antonio; Servico de Neurologia, Porto, 4099-001, Portugal|Univerzitna nemocnica Bratislava, Bratislava, 813 69, Slovakia|Univerzitna nemocnica Bratislava Nemocnica Ruzinov, Bratislava, 826 06, Slovakia|Fakultna nemocnica Trnava, Trnava, 917 75, Slovakia|University Medical Centre; Neurology, Ljubljana, 1000, Slovenia|University Medical Centre Maribor, Maribor, 2000, Slovenia|Hospital Universitario Central de Asturias; Servicio de Neurología, Oviedo, Asturias, Spain|Hospital Universitari de Bellvitge; Servicio de Neurologia, L'Hospitalet de Llobregat, Barcelona, 08907, Spain|Hospital General de Castellon; Servicio de Neurología, Castelló de la Plana, Castellon, 12004, Spain|Hospital Universitari de Girona Dr. Josep Trueta; Servicio de Neurologia, Salt, Girona, 17190, Spain|Complejo Hospitalario Universitario A Coruña (CHUAC); Servicio de Neurologia, Coruña, LA Coruña, 15006, Spain|Hospital Universitari Arnau de Vilanova de Lleida; Servicio de Neurología, Lleida, Lerida, 25198, Spain|Hospital Quiron de Madrid; Servicio de Neurologia, Pozuelo de Alarcon, Madrid, 28223, Spain|Hospital Universitario Virgen de Arrixaca; Servicio de Neurología, EL Palmar (EL Palmar), Murcia, 30120, Spain|Complejo Hospitalario Universitario de Vigo - Xeral Cies; Servicio de Neurologia, Vigo, Pontevedra, 36312, Spain|Hospital Vall d'Hebron; Servicio de Neurología, Barcelona, 08035, Spain|Hospital Puerta del Mar; Sevicio de Neurologia, Cadiz, 11009, Spain|Universitario de La Princesa; Servicio de Neurología, Madrid, 28006, Spain|Hospital Universitario Clínico San Carlos; Servicio de Neurología, Madrid, 28040, Spain|Hospital Universitario 12 de Octubre; Servicio de Neurologia, Madrid, 28041, Spain|Hospital Universitario La Paz; Servicio de Neurologia, Madrid, 28046, Spain|Hospital Universitario Virgen Macarena; Servicio de Neurologia, Sevilla, 41009, Spain|Hospital Clinico Universitario de Valencia; Servicio de Neurologia, Valencia, 46010, Spain|Hospital Universitario la Fe; Servicio de Neurologia, Valencia, 46026, Spain|Sahlgrenska Sjukhuset; Neurology, Göteborg, 413 45, Sweden|Centralsjukhuset; Neurologi och rehabiliteringskliniken, Karlstad, 651 85, Sweden|Centrum för Neurologi, Stockholm, 113 41, Sweden|Karolinska Universitetssjukhuset Solna Neurology, Stockholm, 113 41, Sweden|Hacettepe University Medical Faculty; Neurology, Ankara, 06100, Turkey|Gazi University Medical Faculty; Departmant of Norology, Ankara, 06500, Turkey|Mustafa Kemal Ataturk UTF; Department of norology, Hatay, 31001, Turkey|Istanbul University Istanbul School of Medicine; Neurology, Istanbul, 34093, Turkey|Istanbul Universitesi - Cerrahpasa Cerrahpasa Tip Fakultesi; Noroloji Anabilim Dali, Istanbul, 34098, Turkey|Selcuk University Medical Faculty; Norology department, Istanbul, 42131, Turkey|Ondokuz Mayis University School of Medicine; Neurology, Samsun, 55139, Turkey|Karadeniz Tecnical Uni. Med. Fac.; Neurology, Trabzon, 61080, Turkey|Royal Devon and Exeter Hospital (Wonford), Exeter, EX2 5DW, United Kingdom|Queen Elizabeth University Hospital, Glasgow, G51 4TF, United Kingdom|Raigmore Hospital, Inverness, IV2 3UV, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, LS9 7AU, United Kingdom|The Royal London Hospital, London, E1 1FR, United Kingdom|Royal Free Hospital, London, NW3 2QS, United Kingdom|St George's Hospital, London, SW17 0QT, United Kingdom|Kings College Hospital, London, SW9 8RR, United Kingdom|Charing Cross Hospital, London, W6 8RF, United Kingdom|National Hospital for Neurology and Neurosurgery,; MRC Centre for Neuromuscular Diseases, London, WC1 3BG, United Kingdom|Royal Victoria Infirmary, Newcastle upon Tyne, NE1 4LP, United Kingdom|Salford Royal NHS Foundation Trust, Salford, M6 8HD, United Kingdom|Royal Hallamshire Hospita, Sheffield, S10 2JF, United Kingdom|Morriston Hospital, Swansea, SA6 6NL, United Kingdom|Royal Cornwall Hospital, Truro, TR1 3LQ, United Kingdom"
NCT00710645,Lido Workset Study,https://beta.clinicaltrials.gov/study/NCT00710645,COMPLETED,Multiple Sclerosis,DEVICE: Lido Workset,"University of California, Davis",,ALL,"ADULT, OLDER_ADULT",,31,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2003-04,2012-06,2012-07,"University of California, Davis, Sacramento, California, 95817, United States"
NCT04856345,Running Title: Walking to Music and in Silence on a Treadmill,https://beta.clinicaltrials.gov/study/NCT04856345,UNKNOWN,Multiple Sclerosis,OTHER: Walking with music with synchronisation|OTHER: Walking with music without synchronisation|OTHER: walking without music,Hasselt University,Revalidatie & MS Centrum Overpelt,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-01-22,2022-12-31,2022-12-31,"Noorderhart Revalidatie & MS centrum, Overpelt, 3900, Belgium"
NCT05427045,A Pilot Project for Multifidus Muscle Evaluation in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05427045,RECRUITING,Multiple Sclerosis|Back Pain,OTHER: home - exercise program,University of Arkansas,,ALL,ADULT,EARLY_PHASE1,10,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-05-01,2023-05,2024-05,"University of Arkansas for Medical Sciences, Little Rock, Arkansas, 72205, United States"
NCT04929145,The Gut Microbiome in Adult Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04929145,COMPLETED,Multiple Sclerosis,,National MS Center Melsbroek,,ALL,"ADULT, OLDER_ADULT",,152,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-10-02,2019-09-16,2020-04,"Universitair Ziekenhuis Brussel, Jette, Brussel-Hoofdstedelijk-Gewest, 1090, Belgium|Nationaal Multiple Sclerose Centrum Melsbroek, Melsbroek, Vlaams-Brabant, 1820, Belgium"
NCT00270816,Interferon ß-1b Treatment by Cyclical Administration,https://beta.clinicaltrials.gov/study/NCT00270816,COMPLETED,Multiple Sclerosis,DRUG: Interferon-ß-1b|DRUG: Interferon ß-1b,S. Andrea Hospital,Italian Multiple Sclerosis Foundation,ALL,ADULT,PHASE2|PHASE3,60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2005-11,2010-08,2011-01,"Azienda Ospedaliera S. Andrea, II Facoltà di Medicina e Chirurgia, Università di Roma ""La Sapienza"", Rome, 00139, Italy"
NCT03050268,Familial Investigations of Childhood Cancer Predisposition,https://beta.clinicaltrials.gov/study/NCT03050268,RECRUITING,Acute Leukemia|Adenomatous Polyposis|Adrenocortical Carcinoma|AML|BAP1 Tumor Predisposition Syndrome|Carney Complex|Choroid Plexus Carcinoma|Constitutional Mismatch Repair Deficiency Syndrome|Diamond-Blackfan Anemia|DICER1 Syndrome|Dyskeratosis Congenita|Emberger Syndrome|Familial Acute Myeloid Leukemia|Familial Adenomatous Polyposis|Fanconi Anemia|Familial Cancer|Familial Wilms Tumor|Familial Neuroblastoma|GIST|Hereditary Breast and Ovarian Cancer|Hereditary Paraganglioma-Pheochromocytoma Syndrome|Hodgkin Lymphoma|Juvenile Polyposis|Li-Fraumeni Syndrome|Lynch Syndrome|MDS|Melanoma Syndrome|Multiple Endocrine Neoplasia Type 1|Multiple Endocrine Neoplasia Type 2|Neuroblastoma|Neurofibromatosis Type 1|Neurofibromatosis Type II|Nevoid Basal Cell Carcinoma Syndrome|Non Hodgkin Lymphoma|Noonan Syndrome and Other Rasopathy|Overgrowth Syndromes|Pancreatic Cancer|Peutz-Jeghers Syndrome|Pheochromocytoma/Paraganglioma|PTEN Hamartoma Tumor Syndrome|Retinoblastoma|Rhabdoid Tumor Predisposition Syndrome|Rhabdomyosarcoma|Rothmund-Thomson Syndrome|Tuberous Sclerosis|Von Hippel-Lindau Disease,,St. Jude Children's Research Hospital,,ALL,"CHILD, ADULT, OLDER_ADULT",,3000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-04-06,2037-03-31,2037-03-31,"St. Jude Children's Research Hospital, Memphis, Tennessee, 38105, United States"
NCT04806568,MS-NEUROPLAST: Neuroplasticity of Cortical Areas Induced by Cognitive Training in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04806568,RECRUITING,Multiple Sclerosis|Cognitive Decline,OTHER: Cognitive Training,Aristotle University Of Thessaloniki,King Fahad Medical City,ALL,ADULT,NA,150,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2020-12-01,2023-10-31,2024-06-07,"Laboratory of Medical Physics and Digital Innovation, AUTH, Thessaloníki, Central Macedonia, 54124, Greece"
NCT05715268,Wearables for the Bladder: an In-home Treatment Feasibility Pilot Study,https://beta.clinicaltrials.gov/study/NCT05715268,RECRUITING,"Multiple Sclerosis|Urinary Bladder, Overactive",DEVICE: WeB|OTHER: Standard pelvic floor physical therapy,"University of California, San Francisco",National Multiple Sclerosis Society,FEMALE,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-03-15,2023-10,2024-01,"University of California San Francisco, Weill Institute for Neurosciences, San Francisco, California, 94158, United States"
NCT01838668,An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),https://beta.clinicaltrials.gov/study/NCT01838668,COMPLETED,Relapsing-Remitting Multiple Sclerosis|Multiple Sclerosis,DRUG: Placebo|DRUG: dimethyl fumarate,Biogen,,ALL,ADULT,PHASE3,225,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2013-03-28,2015-06-16,2018-09-04,"Fakultni nemocnice u sv. Anny v Brne, Brno, 656 91, Czechia|Neurospol, s.r.o., Havirov, 736 00, Czechia|Fakultni nemocnice Hradec Kralove, Hradec Kralove, 500 05, Czechia|Privatni ordinace - neurologie, Hradec Kralove, 50003, Czechia|Nemocnice Jihlava, Jihlava, 58633, Czechia|Fakultni nemocnice Olomouc, Olomouc, 775 20, Czechia|Fakultni poliklinika VFN, Praha 2, 128 08, Czechia|Fakultni nemocnice v Motole, Praha 5, 150 06, Czechia|Krajska zdravotni, a.s. - Nemocnice Teplice, o.z., Teplice, 41529, Czechia|NHO Asahikawa Medical Center, Asahikawa-shi, 070-8644, Japan|Juntendo University Hospital, Bunkyo-ku, 113-8431, Japan|Chiba University Hospital, Chiba-shi, 260-8677, Japan|Kyushu University Hospital, Fukuoka-shi, 812-8582, Japan|Kanazawa Medical University Hospital, Kahoku-gun, 920-0293, Japan|Saitama Medical Center, Kawagoe-shi, 350-8550, Japan|Kobe University Hospital, Kobe-shi, 650-0017, Japan|National Center Hospital, NCNP, Kodaira-shi, 187-8551, Japan|Kyoto University Hospital, Kyoto-shi, 606-8507, Japan|NHO Utano Hospital, Kyoto-shi, 616-8255, Japan|Iwate Medical University Hospital, Morioka-shi, 020-8505, Japan|Niigata University Medical & Dental Hospital, Niigata-shi, 951-8520, Japan|Irino Clinic, Inc., Osaka-shi, 556-0016, Japan|Kindai University Hospital, Osakasayama-shi, 589-8511, Japan|Tokyotohokeniryokosya Ebara Hospital, Ota-ku, 145-0065, Japan|NHO Hokkaido Medical Center, Sapporo-shi, 063-0005, Japan|CEReS Sapporo Neurology Clinic, Sapporo-shi, 065-0021, Japan|Tohoku University Hospital, Sendai-shi, 980-8574, Japan|Keio University Hospital, Shinjuku-ku, 160-8582, Japan|Department of Neurosurgery, Tokyo Women's Medical University, Shinjuku-ku, 162-8666, Japan|Osaka University Hospital, Suita-shi, 565-0871, Japan|National Defense Medical College Hospital, Tokorozawa-shi, 359-8513, Japan|Ehime University Hospital, Toon-shi, 791-0295, Japan|Tsukuba University Hospital, Tsukuba-shi, 305-8576, Japan|Yamaguchi University Hospital, Ube-shi, 755-8505, Japan|Tokyo Womens Medical University Yachiyo Medical Center, Yachiyo-shi, 276-8524, Japan|Yokohama City University Hospital, Yokohama-shi, 236-0004, Japan|Yeungnam University Hospital, Daegu, 42415, Korea, Republic of|National Cancer Center, Gyeonggi-do, 10408, Korea, Republic of|Korea University Anam Hospital, Seoul, 02841, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|Copernicus Podmiot Leczniczy Sp. z o.o., Gdansk, 80-803, Poland|M.A. - LEK A.M.Maciejowscy SC., Katowice, 40-571, Poland|Nzoz Novo-Med, Katowice, 40-650, Poland|Neuro-Care Gabriela Klodowska, Katowice, 40-749, Poland|MCD Medical, Krakow, 31-637, Poland|Centrum Neurologii K. Selmaj, Lodz, 90-324, Poland|Neurologiczny NZOZ Centrum Leczenia SM, Plewiska, 62-064, Poland|NZOZ ""NEURO-KARD"", ""Ilkowski i Partnerzy"" Sp. Partn. Lek., Poznan, 61-853, Poland|Miedzyleski Szpital Specjalistyczny, Warszawa, 04-749, Poland|National Cheng Kung University Hospital, Tainan, 704, Taiwan|National Taiwan University Hospital, Taipei, 100, Taiwan|Taipei Veterans General Hospital, Taipei, 11217, Taiwan"
NCT04121468,A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04121468,RECRUITING,Multiple Sclerosis (MS),DRUG: Metformin|OTHER: Placebo,The Hospital for Sick Children,Queen's University|Ontario Institute for Regenerative Medicine|Unity Health Toronto|Stem Cell Network|Multiple Sclerosis Society of Canada,ALL,"CHILD, ADULT",PHASE1|PHASE2,30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-02-24,2023-12,2023-12,"St. Michael's Hospital, Toronto, Ontario, M5B 1W8, Canada|The Hospital for Sick Children, Toronto, Ontario, M5G 1X8, Canada"
NCT01097668,ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01097668,COMPLETED,Relapsing Remitting Multiple Sclerosis,BIOLOGICAL: ATX-MS-1467,Apitope Technology (Bristol) Ltd.,"Aptiv Solutions|ClinStar, LLC",ALL,ADULT,PHASE1,43,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2010-03,2013-07,2013-07,"Municipal Healthcare Institution ""City Clinical Hospital #3"", Department of neurology, Chelyabinsk, 454136, Russian Federation|State Medical Institution ""Republican Clinical Hospital of rehabilitation treatment of Ministry of Healthcare of Tatarstan Republic"", Republican clinicodiagnostic center of demyelinating diseases of Ministry of Healthcare of Tatarstan Republic, Kazan, 420021, Russian Federation|State Educational Institution of Higher Professional Education ""1st Moscow State Medical University n.a. I.M. Sechenov of Ministry of Healthcare and Social Development of the Russian Federation, Department of new drugs research, Moscow, 119991, Russian Federation|State Healthcare Institution 'Rostov Regional Clinical Hospital' Center of Neurology, Rostov-on-Don, 344015, Russian Federation|LLC ""International Clinic MEDEM"", Department of functional diagnostics, Saint Petersburg, 191025, Russian Federation|State Educational Institution of Higher Professional Education ""St. Petersburg State Medical University n.a. I.V. Pavlov of Roszdrav"", Department of neurology with clinic, Saint Petersburg, 197022, Russian Federation|State Healthcare Institution ""Samara Regional Clinical Hospital n.a. M.I. Kalinin"", Department of neurosurgery, Samara, 443095, Russian Federation|State Educational Institution of Higher Professional Education Saratov State Medical University, Saratov, 410012, Russian Federation|State Educational Institution of Higher Professional Education ""Smolensk State Medical Academy of Roszdrav"", Department of neurology and neurosurgery based at State Healthcare Institution ""Smolensk Regional Clinical Hospital"", Smolensk, Russian Federation|St. Petersburg State Healthcare Institution ""City multifield hospital #2"", Department of neurology #2, St Petersburg, 194354, Russian Federation|Institution of the Russian Academy of Science ""Institute of Human Brain of RAS"", Neuroimmunology Laboratory, St Petersburg, 197376, Russian Federation|North Staffordshire Royal Infirmary, Stoke on Trent, Staffordshire, ST4 7LN, United Kingdom|National Hospital for Neurology & Neurosurgery, London, WC1N 3BG, United Kingdom|Queen's Medical Centre, Nottingham, NG7 2UH, United Kingdom|Peninsula Medical School, Plymouth, PL6 8BX, United Kingdom|Royal Hallamshire Hospital, Sheffield, S10 2 JF, United Kingdom"
NCT00190268,"Efficacy of 3,4-DAP in Fatigue Associated With Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT00190268,COMPLETED,Multiple Sclerosis,"DRUG: 3,4-diaminopyridine",Assistance Publique - Hôpitaux de Paris,,ALL,ADULT,PHASE3,126,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2005-02,2008-06,2008-06,"Henri Mondor Hospital, Creteil, 94010, France|Pitié Salpetriere Hospital, Paris, 75013, France|Tenon Hospital, Paris, 75020, France|Pontchaillou Hospital, Rennes, 35000, France"
NCT01712945,Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01712945,TERMINATED,Multiple Sclerosis,DRUG: Palifermin|DRUG: Alemtuzumab,Cambridge University Hospitals NHS Foundation Trust,,ALL,"CHILD, ADULT",PHASE1|PHASE2,40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2012-06,2017-08,2017-10,"Addenbrooke's Hospital, Cambridge, Cambridgeshire, CB2 2QQ, United Kingdom"
NCT03980145,G-EO Gait Rehabilitation Training in Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03980145,COMPLETED,Progressive Multiple Sclerosis,"DEVICE: G-EO System (Reha Technology AG: Olten, Switzerland)|OTHER: Conventional Physical Therapy",Indiana University,University of Alabama at Birmingham|University of Ottawa,ALL,ADULT,NA,15,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2017-05-02,2020-03-01,2020-03-01,"Neurorehabilitation and Robotics at IU Health Neuroscience Center, Indianapolis, Indiana, 46202, United States"
NCT03847545,Muscle Strain in Multiple Sclerosis Patients Measured by Ultrasound Speckle Tracking Technique,https://beta.clinicaltrials.gov/study/NCT03847545,COMPLETED,Multiple Sclerosis,DRUG: Fampridine,University of Southern Denmark,"Odense University Hospital|Sygehus Lillebaelt|Region of Southern Denmark|The Augustinus Foundation, Denmark.|Lounkær Fonden|Fonden for scleroseramte på Fyn|The Danish Multiple Sclerosis Society|TH MAIGAARDS EFTF. FRU LILY BENTHINE LUNDS FOND AF 1. JUNI 1978|Fonden til Lægevidenskabens Fremme|Overlægeråds forskningsfond",ALL,"ADULT, OLDER_ADULT",NA,48,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-12-12,2021-10-15,2021-10-15,"University of Southern Denmark - Odense Univarsity Hospital, Odense C, 5000, Denmark"
NCT00094068,The Effect of Sildenafil Citrate (Viagra® (Registered Trademark)) on Brain Blood Flow in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT00094068,COMPLETED,Multiple Sclerosis,,National Institutes of Health Clinical Center (CC),,ALL,"CHILD, ADULT, OLDER_ADULT",,76,NIH,OBSERVATIONAL,Observational Model: |Time Perspective: p,2004-10,,2006-05,"National Institutes of Health Clinical Center (CC), Bethesda, Maryland, 20892, United States"
NCT03679468,Improving Cognition in People With Progressive Multiple Sclerosis Using Aerobic Exercise and Cognitive Rehabilitation,https://beta.clinicaltrials.gov/study/NCT03679468,ACTIVE_NOT_RECRUITING,"Multiple Sclerosis, Primary Progressive|Cognitive Impairment",OTHER: Cognitive Rehabilitation|OTHER: Sham Exercise|OTHER: Sham Cognitive Rehabilitation|OTHER: Aerobic Exercise,Sunnybrook Health Sciences Centre,"University of Florence|Fondazione Italiana Sclerosi Multipla|University College, London|Kessler Foundation|University of Alabama at Birmingham|University of Southern Denmark|Hasselt University|University of Plymouth|Universita degli Studi di Genova|Unity Health Toronto|Ospedale San Raffaele",ALL,"ADULT, OLDER_ADULT",NA,309,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: OTHER",2019-03-18,2022-06-30,2022-12-30,"Sunnybrook Health Science Center, Toronto, Ontario, M4N3M5, Canada"
NCT04075968,The Effect of Cognitive Group Exercise Combined With Physical Exercise in MS,https://beta.clinicaltrials.gov/study/NCT04075968,COMPLETED,Multiple Sclerosis,OTHER: Cognitive exercise|OTHER: Home exercise,Istanbul Physical Medicine Rehabilitation Training and Research Hospital,,ALL,"ADULT, OLDER_ADULT",,20,OTHER_GOV,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-12-01,2019-11-15,2019-12-01,"Health Sciences University Istanbul Physical Therapy and Rehabilitation Training and Research Hospital, Istanbul, 34500, Turkey"
NCT02284568,"A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo",https://beta.clinicaltrials.gov/study/NCT02284568,COMPLETED,Primary Progressive Multiple Sclerosis,DRUG: Placebo|DRUG: Laquinimod|DRUG: Placebo,"Teva Branded Pharmaceutical Products R&D, Inc.",,ALL,ADULT,PHASE2,374,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2015-01-12,2017-05-04,2017-10-01,"Teva Investigational Site 12966, Phoenix, Arizona, 85018, United States|Teva Investigational Site 12967, Newport Beach, California, 92663, United States|Teva Investigational Site 12962, San Francisco, California, 94158, United States|Teva Investigational Site 12964, Aurora, Colorado, 80045, United States|Teva Investigational Site 12973, Northbrook, Illinois, 60062, United States|Teva Investigational Site 12975, Kansas City, Kansas, 66160-7314, United States|Teva Investigational Site 12969, Lenexa, Kansas, 66214, United States|Teva Investigational Site 12977, Golden Valley, Minnesota, 55422, United States|Teva Investigational Site 13010, Golden Valley, Minnesota, 55422, United States|Teva Investigational Site 12965, Chesterfield, Missouri, 63017, United States|Teva Investigational Site 12968, Saint Louis, Missouri, 63110, United States|Teva Investigational Site 12963, New York, New York, 10016, United States|Teva Investigational Site 12971, Charlotte, North Carolina, 28207, United States|Teva Investigational Site 12976, Columbus, Ohio, 43221, United States|Teva Investigational Site 12970, Uniontown, Ohio, 44685, United States|Teva Investigational Site 11089, Calgary, AL, T2N 4Z1, Canada|Teva Investigational Site 11084, Halifax, Nova Scotia, B3H 4K4, Canada|Teva Investigational Site 11081, Ottawa, Ontario, K1H 8L6, Canada|Teva Investigational Site 11087, Toronto, Ontario, M5B-1W8, Canada|Teva Investigational Site 11082, Montreal, Quebec, H3A 2B4, Canada|Teva Investigational Site 11088, Quebec, G1J 1Z4, Canada|Teva Investigational Site 32505, Bad Mergentheim, 97980, Germany|Teva Investigational Site 32512, Bamberg, 96049, Germany|Teva Investigational Site 32510, Berlin, 10117, Germany|Teva Investigational Site 32522, Bochum, 44791, Germany|Teva Investigational Site 32509, Dresden, 01307, Germany|Teva Investigational Site 32517, Dusseldorf, 40225, Germany|Teva Investigational Site 32543, Goettigen, 37075, Germany|Teva Investigational Site 32514, Hamburg, 20099, Germany|Teva Investigational Site 32507, Hannover, 30625, Germany|Teva Investigational Site 32513, Munchen, 81675, Germany|Teva Investigational Site 32504, Munchen, D-81377, Germany|Teva Investigational Site 32516, Rostock, 18057, Germany|Teva Investigational Site 32523, Trier, 54292, Germany|Teva Investigational Site 32503, Ulm, 89081, Germany|Teva Investigational Site 32511, Wurzburg, 97080, Germany|Teva Investigational Site 30106, Cefalu, 90015, Italy|Teva Investigational Site 30110, Firenze, 50134, Italy|Teva Investigational Site 30105, Gallarate, 21013, Italy|Teva Investigational Site 30108, Genova, 16132, Italy|Teva Investigational Site 30102, Milano, 20127, Italy|Teva Investigational Site 30107, Orbassano, 10043, Italy|Teva Investigational Site 30103, Padova, 35128, Italy|Teva Investigational Site 30101, Rome, 00133, Italy|Teva Investigational Site 30104, Rome, ?00152, Italy|Teva Investigational Site 38068, Amsterdam, 1081 HV, Netherlands|Teva Investigational Site 38067, Nijmegen, 6532 SZ, Netherlands|Teva Investigational Site 38069, Sittard, 6162 BG, Netherlands|Teva Investigational Site 53262, Bialystok, 15-402, Poland|Teva Investigational Site 53250, Bydgoszcz, 85-795, Poland|Teva Investigational Site 53253, Gdansk, 80-803, Poland|Teva Investigational Site 53257, Katowice, 40-635, Poland|Teva Investigational Site 53258, Katowice, 40-684, Poland|Teva Investigational Site 53256, Katowice, 40-749, Poland|Teva Investigational Site 53255, Kielce, 25-726, Poland|Teva Investigational Site 53260, Lublin, 20-954, Poland|Teva Investigational Site 53261, Olsztyn, 10-560, Poland|Teva Investigational Site 53252, Warsaw, 02-957, Poland|Teva Investigational Site 50285, Kaluga, 248007, Russian Federation|Teva Investigational Site 50288, Kazan, 420021, Russian Federation|Teva Investigational Site 50290, Kazan, 420103, Russian Federation|Teva Investigational Site 50294, Kirov, 610006, Russian Federation|Teva Investigational Site 50292, Krasnoyarsk, 660022, Russian Federation|Teva Investigational Site 50287, Moscow, 127018, Russian Federation|Teva Investigational Site 50291, Nizhny Novgorod, 603126, Russian Federation|Teva Investigational Site 50286, Novosibirsk, 630007, Russian Federation|Teva Investigational Site 50295, Perm, 614990, Russian Federation|Teva Investigational Site 50293, Saint Petersburg, 197022, Russian Federation|Teva Investigational Site 50289, St. Petersburg, 194044, Russian Federation|Teva Investigational Site 31108, Barcelona, 08036, Spain|Teva Investigational Site 31106, Barcelona, 8035, Spain|Teva Investigational Site 31105, El Palmar, 30120, Spain|Teva Investigational Site 31111, Lleida, 25198, Spain|Teva Investigational Site 31112, Madrid, 28040, Spain|Teva Investigational Site 31192, Madrid, 28223, Spain|Teva Investigational Site 31101, Malaga, 29010, Spain|Teva Investigational Site 31104, San Sebastian, 20014, Spain|Teva Investigational Site 31102, Sevilla, 41009, Spain|Teva Investigational Site 31100, Valencia, 46026, Spain|Teva Investigational Site 58158, Dnipropetrovsk, 49005, Ukraine|Teva Investigational Site 58159, Ivano-Frankivsk, 76014, Ukraine|Teva Investigational Site 58157, Kharkiv, 61068, Ukraine|Teva Investigational Site 58160, Kyiv, ?03110, Ukraine|Teva Investigational Site 58152, Lutsk, 43005, Ukraine|Teva Investigational Site 58154, Lviv, 79010, Ukraine|Teva Investigational Site 58153, Lviv, 79044, Ukraine|Teva Investigational Site 58156, Zaporizhzhia, 69068, Ukraine|Teva Investigational Site 58150, Zaporizhzhya, 69035, Ukraine|Teva Investigational Site 58151, Zaporizhzhya, 69600, Ukraine|Teva Investigational Site 34190, Bristol, BS10 5NB, United Kingdom|Teva Investigational Site 34188, Edinburgh, EH4 2XU, United Kingdom|Teva Investigational Site 34189, Exeter, EX2 5DW, United Kingdom|Teva Investigational Site 34182, Liverpool, L9 7LJ, United Kingdom|Teva Investigational Site 34181, London, E1 2AT, United Kingdom|Teva Investigational Site 34183, Nottingham, NG7 2UH, United Kingdom|Teva Investigational Site 34184, Oxford, OX3 9DU, United Kingdom|Teva Investigational Site 34186, Plymouth, PL6 8DH, United Kingdom|Teva Investigational Site 34185, Stoke-on-Trent, ST4 6GQ, United Kingdom|Teva Investigational Site 34187, Swansea, SA6 6NL, United Kingdom"
NCT04547400,Relationship of Position Sense With Gait and Balance in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04547400,COMPLETED,Multiple Sclerosis,OTHER: assessment,Gazi University,,ALL,"ADULT, OLDER_ADULT",,40,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-10-05,2022-05-13,2022-05-13,"Gazi University, Ankara, Turkey"
NCT02141022,Computerized Exercise Training for Cognitive Remediation in Adults With Multiple Sclerosis Treated With Gilenya,https://beta.clinicaltrials.gov/study/NCT02141022,COMPLETED,Multiple Sclerosis|Cognitive Deficits|Gilenya Modifying Therapy for MS,OTHER: plasticity-based computerized cognitive remediation program|DRUG: Gileyna,Stony Brook University,Novartis,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2013-08,2014-09,2015-09,"Stony Brook University, Stony Brook, New York, 11794, United States"
NCT01444300,Dalfampridine for Imbalance in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01444300,COMPLETED,Multiple Sclerosis|Fatigue,DRUG: Dalfampridine|DRUG: Placebo,Oregon Health and Science University,Acorda Therapeutics,ALL,ADULT,PHASE2,24,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-09,2013-09,2013-09,"Oregon Health and Science University, Portland, Oregon, 97239, United States"
NCT04823000,Effects of Repeated Mesenchymal Stem Cells (MSC) in Patients With Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04823000,COMPLETED,Multiple Sclerosis,BIOLOGICAL: Mesenchymal Stem Cells (MSC),Hadassah Medical Organization,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,24,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-01-01,2016-12-01,2020-04-01,
NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00622700,COMPLETED,Multiple Sclerosis,DRUG: Teriflunomide|DRUG: Placebo,Sanofi,,ALL,ADULT,PHASE3,618,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2008-02,2012-12,2016-02,"Investigational Site Number 8965, Cullman, Alabama, 35058, United States|Investigational Site Number 8954, Phoenix, Arizona, 85013-4496, United States|Investigational Site Number 8946, Phoenix, Arizona, 85060, United States|Investigational Site Number 8962, Fort Collins, Colorado, 80528, United States|Investigational Site Number 8920, Maitland, Florida, 32761, United States|Investigational Site Number 8953, St. Petersburg, Florida, 33701, United States|Investigational Site Number 8914, Ft. Wayne, Indiana, 63104, United States|Investigational Site Number 8940, Indianapolis, Indiana, 46256, United States|Investigational Site Number 8922, Shreveport, Louisiana, 71103, United States|Investigational Site Number 8955, Grand Rapids, Michigan, 49503, United States|Investigational Site Number 8949, Traverse City, Michigan, 49684, United States|Investigational Site Number 8937, St Louis, Missouri, 63104, United States|Investigational Site Number 8951, Albuquerque, New Mexico, 87131, United States|Investigational Site Number 8925, New York, New York, 10029-6574, United States|Investigational Site Number 8941, Charlotte, North Carolina, 28204, United States|Investigational Site Number 8924, Dayton, Ohio, 45409, United States|Investigational Site Number 8905, Round Rock, Tennessee, 78681, United States|Investigational Site Number 8930, Burlington, Vermont, 05401, United States|Investigational Site Number 8963, Seattle, Washington, 98122, United States|Investigational Site Number 1405, Geelong, 3220, Australia|Investigational Site Number 1404, Heidelberg, 3081, Australia|Investigational Site Number 1407, Hobart, 7001, Australia|Investigational Site Number 1401, Parkville, 3050, Australia|Investigational Site Number 4004, Innsbruck, 6020, Austria|Investigational Site Number 4005, Linz, 4020, Austria|Investigational Site Number 4001, Wien, 1010, Austria|Investigational Site Number 5312, Pleven, 5800, Bulgaria|Investigational Site Number 5307, Sofia, 1000, Bulgaria|Investigational Site Number 5304, Sofia, 1407, Bulgaria|Investigational Site Number 5309, Sofia, 1431, Bulgaria|Investigational Site Number 5303, Sofia, 1527, Bulgaria|Investigational Site Number 5306, Sofia, 1606, Bulgaria|Investigational Site Number 5402, Greenfield Park, J4V 2J2, Canada|Investigational Site Number 5403, London, N6A 5A5, Canada|Investigational Site Number 5409, Montreal, H1T 2M4, Canada|Investigational Site Number 5401, Ottawa, K1H 8L6, Canada|Investigational Site Number 5406, Quebec, G1J 1Z4, Canada|Investigational Site Number 5408, Sherbrooke, J1H 5N4, Canada|Investigational Site Number 5410, Toronto, M4N 3M5, Canada|Investigational Site Number 5404, Toronto, M5B 1W8, Canada|Investigational Site Number 5602, Santiago, 760-0746, Chile|Investigational Site Number 5601, Santiago, Chile|Investigational Site Number 5606, Santiago, Chile|Investigational Site Number 5605, Viña Del Mar, 2520997, Chile|Investigational Site Number 5801, Brno, 65691, Czech Republic|Investigational Site Number 5803, Hradec Kralove, 50005, Czech Republic|Investigational Site Number 5804, Olomouc, 77520, Czech Republic|Investigational Site Number 5805, Ostrava - Poruba, 70852, Czech Republic|Investigational Site Number 6002, Aarhus C, 8000, Denmark|Investigational Site Number 6004, Esbjerg, 6700, Denmark|Investigational Site Number 6201, Tallinn, 10617, Estonia|Investigational Site Number 6203, Tartu, 50406, Estonia|Investigational Site Number 6405, Helsinki, 00100, Finland|Investigational Site Number 6403, Kuopio, 70210, Finland|Investigational Site Number 6401, Turku, 20100, Finland|Investigational Site Number 6611, Besancon, 25030, France|Investigational Site Number 6601, Clermont Ferrand Cedex 1, 63003, France|Investigational Site Number 6609, Lille Cedex, 59037, France|Investigational Site Number 6604, Montpellier Cedex 05, 34295, France|Investigational Site Number 6612, Nancy Cedex, 54036, France|Investigational Site Number 6605, Nantes Cedex 01, 44093, France|Investigational Site Number 6602, Nice Cedex, 06002, France|Investigational Site Number 6614, Nimes, 30029, France|Investigational Site Number 6607, Strasbourg Cedex, 67091, France|Investigational Site Number 6801, Bayreuth, 95445, Germany|Investigational Site Number 6810, Berlin, 10713, Germany|Investigational Site Number 6805, Berlin, 10785, Germany|Investigational Site Number 6807, Erbach, 64711, Germany|Investigational Site Number 6803, Essen, 45122, Germany|Investigational Site Number 6809, Hannover, 30625, Germany|Investigational Site Number 6804, Ludwigshafen, 67063, Germany|Investigational Site Number 6815, Minden, 32429, Germany|Investigational Site Number 6802, Münster, 48149, Germany|Investigational Site Number 6806, Wiesbaden, 65191, Germany|Investigational Site Number 7101, Budapest, 1076, Hungary|Investigational Site Number 7103, Budapest, 1145, Hungary|Investigational Site Number 7108, Esztergom, 2500, Hungary|Investigational Site Number 7105, Veszprém, 8200, Hungary|Investigational Site Number 7402, Klaipeda, LT-92288, Lithuania|Investigational Site Number 7403, Siauliai, LT-76231, Lithuania|Investigational Site Number 7401, Vilnius, LT-08661, Lithuania|Investigational Site Number 7501, Chihuahua, 31203, Mexico|Investigational Site Number 7502, Guadalajara, 45110, Mexico|Investigational Site Number 7709, Gdansk, 80-803, Poland|Investigational Site Number 7710, Lodz, 93-513, Poland|Investigational Site Number 7707, Warszawa 44, 04-141, Poland|Investigational Site Number 7701, Warszawa, 02-097, Poland|Investigational Site Number 7703, Warszawa, 02-957, Poland|Investigational Site Number 7803, Bucuresti, 020125, Romania|Investigational Site Number 7806, Bucuresti, 050098, Romania|Investigational Site Number 7805, Cluj-Napoca, 400012, Romania|Investigational Site Number 7807, Cluj-Napoca, 400012, Romania|Investigational Site Number 7808, Timisoara, 300736, Romania|Investigational Site Number 7907, Kazan, 420021, Russian Federation|Investigational Site Number 7909, Nizhny Novgorod, 603000, Russian Federation|Investigational Site Number 7906, Nizhny Novgorod, 603076, Russian Federation|Investigational Site Number 7904, Nizhny Novgorod, 603126, Russian Federation|Investigational Site Number 7912, Novosibirsk, 630007, Russian Federation|Investigational Site Number 7910, Rostov-On-Don, 344085, Russian Federation|Investigational Site Number 7905, Smolensk, 214019, Russian Federation|Investigational Site Number 7911, St-Petersburg, 194044, Russian Federation|Investigational Site Number 8304, Edirne, Turkey|Investigational Site Number 8309, Istanbul, 34390, Turkey|Investigational Site Number 8315, Istanbul, 34400, Turkey|Investigational Site Number 8308, Istanbul, Turkey|Investigational Site Number 8310, Istanbul, Turkey|Investigational Site Number 8312, Istanbul, Turkey|Investigational Site Number 8305, Izmir, 35100, Turkey|Investigational Site Number 8301, Izmir, 35340, Turkey|Investigational Site Number 8303, Izmir, 35380, Turkey|Investigational Site Number 8302, Izmit, 41380, Turkey|Investigational Site Number 8314, Trabzon, 61080, Turkey|Investigational Site Number 8507, Chernihiv, 14029, Ukraine|Investigational Site Number 8501, Dnipropetrovsk, 49027, Ukraine|Investigational Site Number 8511, Donets'K, 83099, Ukraine|Investigational Site Number 8506, Kharkiv, 61018, Ukraine|Investigational Site Number 8504, Kharkiv, 61178, Ukraine|Investigational Site Number 8508, Kiev, 03110, Ukraine|Investigational Site Number 8512, Lutsk, 43005, Ukraine|Investigational Site Number 8505, Lviv, 79010, Ukraine|Investigational Site Number 8510, Poltava, 36011, Ukraine|Investigational Site Number 8503, Vinnytsya, 21005, Ukraine|Investigational Site Number 8502, Zaporizhzhya, 69000, Ukraine|Investigational Site Number 8709, Liverpool, L9 7LJ, United Kingdom|Investigational Site Number 8701, London, E1 1BB, United Kingdom|Investigational Site Number 8704, London, SW17 0QT, United Kingdom|Investigational Site Number 8706, Newcastle Upon Tyne, NE1 4LP, United Kingdom|Investigational Site Number 8705, Nottingham, NG7 2UH, United Kingdom|Investigational Site Number 8708, Plymouth, PL6 5BX, United Kingdom|Investigational Site Number 8707, Salford, M6 8HD, United Kingdom|Investigational Site Number 8702, Sheffield, S10 2JF, United Kingdom"
NCT03396822,Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03396822,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,DRUG: Gadoteridol,"University of Maryland, Baltimore","Genentech, Inc.",ALL,"ADULT, OLDER_ADULT",,24,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-09-24,2023-03,2023-03,"University of Maryland School of Medicine, Baltimore, Maryland, 21201, United States"
NCT03039400,Physiotherapist-guided Home Exercise in Moderate to Severe MS,https://beta.clinicaltrials.gov/study/NCT03039400,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Physiotherapist-guided home exercise with web-based support|BEHAVIORAL: Physiotherapist-guided home exercise with standard support,University of Saskatchewan,Multiple Sclerosis Society of Canada,ALL,"ADULT, OLDER_ADULT",NA,48,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2017-03-06,2018-10-11,2018-10-11,"Department of Physical Medicine & Rehabilitation, University of Saskatchewan, Saskatoon, Saskatchewan, S7K 0M7, Canada"
NCT05098600,"The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic",https://beta.clinicaltrials.gov/study/NCT05098600,COMPLETED,"Alopecia Areata|Alopecia Totalis|Alopecia Universalis|Alopecia Areata (& Ophiasis)|Alopecia Barbae|Alopecia Diffuse|Autoimmune Diseases|Autoimmune Hyperthyroidism|Autoimmune Hypothyroidism|Diabetes Mellitus, Type 1|Ulcerative Colitis|Inflammatory Bowel Diseases|Crohn Disease|Rheumatoid Arthritis|Down Syndrome|Atopic Dermatitis|Atopic Asthma|Atopic Rhinitis|Vitiligo|Psoriasis|Ankylosing Spondylitis|Multiple Sclerosis|Lupus Erythematosus|COVID-19 Pandemic|Vaccine Reaction|Infections|Anemia, Pernicious",OTHER: Exposure of interest,Faculty Hospital Kralovske Vinohrady,,ALL,"CHILD, ADULT, OLDER_ADULT",,123,OTHER_GOV,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-10-15,2022-10-14,2022-12-20,"Teaching Hospital of Royal Vineguards, Prague, 100 00, Czechia"
NCT03091400,Recall Enhancement Through Treatment With Atomoxetine in MS (RETAIN-MS),https://beta.clinicaltrials.gov/study/NCT03091400,COMPLETED,Memory Disorders|Multiple Sclerosis,DRUG: Atomoxetine|DRUG: Placebo,Icahn School of Medicine at Mount Sinai,,ALL,ADULT,PHASE2,11,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2017-03-16,2018-06-11,2018-06-11,"Icahn School of Medicine at Mount Sinai, New York, New York, 10029, United States"
NCT00819000,Therapy Optimization in Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT00819000,COMPLETED,Multiple Sclerosis,"DRUG: Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b","Teva Neuroscience, Inc.",,ALL,"ADULT, OLDER_ADULT",,2878,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2008-12,2012-12,2013-01,"Teva Investigational Site, Swartz Creek, Michigan, United States|Teva Investigational Site, Columbus, Ohio, United States|Teva Investigational Site, Carnegie, Pennsylvania, United States"
NCT01563900,Continuous Positive Airway Pressure (CPAP) for Fatigue in Patients With Multiple Sclerosis (MS) and Obstructive Sleep Apnea (OSA),https://beta.clinicaltrials.gov/study/NCT01563900,WITHDRAWN,Fatigue|Multiple Sclerosis|Sleep Apnea,DEVICE: Auto-titration CPAP|DEVICE: Sham-CPAP,Northwestern University,,ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2012-02,2015-02,2016-02,"Northwestern UNiversity, Department of Neurology, Chicago, Illinois, 60611, United States"
NCT00245622,Autologous T Cell Vaccine (TCV) for Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00245622,COMPLETED,Relapsing-Remitting Multiple Sclerosis,BIOLOGICAL: Tovaxin Autologous T cell vaccine|BIOLOGICAL: Placebo,"Opexa Therapeutics, Inc.",,ALL,ADULT,PHASE2,150,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2006-05,2008-09,2008-09,"North Central Neurology Associates, PC, Cullman, Alabama, 35058, United States|Xenoscience - 21st Century Neurology, Phoenix, Arizona, 85013, United States|HOPE Research Institute, Phoenix, Arizona, 85050, United States|Alta Bates Summit Medical Center - East Bay Physicians Medical Group, Berkeley, California, 94705, United States|Patricia A Fodor, PC, Colorado Springs, Colorado, 80919, United States|Bradenton Neurology, Bradenton, Florida, 34205, United States|Neurological Associates, Pompano Beach, Florida, 33060, United States|Lovelace Scientific Resources, Sarasota, Florida, 34233, United States|Shepherd Center, Atlanta, Georgia, 30309, United States|Medical College of Georgia - Department of Neurology, Augusta, Georgia, 30912, United States|Consultants in Neurology, Ltd., Northbrook, Illinois, 60062, United States|Allied Physicians Inc, Fort Wayne, Indiana, 46805, United States|MidAmerica Neuroscience Institute, Lenexa, Kansas, 66214, United States|Associates in Neurology, Lexington, Kentucky, 40503, United States|University of Louisville Hospital, Louisville, Kentucky, 40202, United States|Research Nurse Specialists, Lafayette, Louisiana, 70503, United States|St Mary's of Michigan - Field Neuroscience Institute, Saginaw, Michigan, 48604, United States|Ayres & Associates Clinical Trials, Lebanon, New Hampshire, 03766, United States|Upstate Clinical Research, LLC, Albany, New York, 12205, United States|Winthrop University Hospital - Clinical Trials Unit, Mineola, New York, 11501, United States|University Hospital and Medical Center Stony Brook New York, Stony Brook, New York, 11794-8121, United States|Neurology Consultants of the Carolinas, PA, Charlotte, North Carolina, 28204, United States|Raleigh Neurology Associates, Raleigh, North Carolina, 27607, United States|Neurology & Neuroscience Associates, Inc., Akron, Ohio, 44302, United States|Neurological Research Institute, Columbus, Ohio, 43221, United States|Neurology Specialists, Inc, Dayton, Ohio, 45408, United States|Providence St. Vincent Medical Center - Northwest MS Center, Portland, Oregon, 97225, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|The Maxine Mesinger MS Clinic/Baylor College of Medicine, Houston, Texas, 77030, United States|Central Texas Neurology, Round Rock, Texas, 78681, United States|Integra Clinical Research, LLC, San Antonio, Texas, 78229, United States|MS Center at Evergreen, Kirkland, Washington, 98101, United States|Capitol Neurology, Charleston, West Virginia, 25301, United States"
NCT02744222,"Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT02744222,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",BIOLOGICAL: BCD-054 180 mcg|BIOLOGICAL: Avonex®|BIOLOGICAL: BCD-054 240 mcg|OTHER: Placebo,Biocad,,ALL,ADULT,PHASE2|PHASE3,399,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2017-08-10,2018-11-23,2020-07-06,"State Budgetary Healthcare Institution of Nizhny Novgorod region "" ""Regional Clinical Hospital N.A. Semashko, Nizhny Novgorod"", Nizhny Novgorod, Russian Federation"
NCT02410200,Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS,https://beta.clinicaltrials.gov/study/NCT02410200,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: dimethyl fumarate,Biogen,,ALL,CHILD,PHASE2,22,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-09-30,2016-09-23,2016-09-23,"Research Site, San Bernardino, California, 92408, United States|Research Site, Gent, B-9000, Belgium|Research Site, Sofia, B-1113, Bulgaria|Research Site, Hradec kralove, 500 05, Czechia|Research Site, Munchen, Bayern, 80337, Germany|Research Site, Gottingen, Niedersachsen, 37075, Germany|Research Site, Dasman, Kuwait City, 15462, Kuwait|Research Site, Riga, LV-1004, Latvia|Research Site, Beirut, 1107 2020, Lebanon|Research Site, Gdansk, 80-952, Poland|Research Site, Poznan, 60-355, Poland|Research Site, Ankara, 06100, Turkey"
NCT00395200,Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS),https://beta.clinicaltrials.gov/study/NCT00395200,COMPLETED,Multiple Sclerosis,PROCEDURE: MSC Treatment,University of Cambridge,Cambridge University Hospitals NHS Foundation Trust|Medical Research Council,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,10,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2008-07,2010-12,2010-12,"University of Cambridge Dept of Clinical Neurosciences, Cambridge, Cambridgeshire, CB2 0PY, United Kingdom|University College London Institute of Neurology, London, WC1N 3BG, United Kingdom"
NCT01466322,"A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers.",https://beta.clinicaltrials.gov/study/NCT01466322,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: GSK2018682 CD2 Capsule; GSK2018682 CD3 non-micronised Tablet; GSK2018682 CD3 micronised Tablet; GSK2018682 CD3 non-micronised Tablet in fed state,GlaxoSmithKline,,ALL,ADULT,PHASE1,16,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2010-12-22,2011-02-15,2011-02-15,"GSK Investigational Site, Herston, Queensland, 4006, Australia"
NCT05740722,Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05740722,NOT_YET_RECRUITING,Multiple Sclerosis|Progressive Multiple Sclerosis,DIETARY_SUPPLEMENT: Nicotinamid riboside|DIETARY_SUPPLEMENT: Placebo,Haukeland University Hospital,,ALL,"ADULT, OLDER_ADULT",PHASE2,300,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-03-01,2027-08-01,2027-12-30,"Haukeland University Hospital, Bergen, 5019, Norway"
NCT04977622,Gray Matter Demyelination in Primary Progressive MS at 7T,https://beta.clinicaltrials.gov/study/NCT04977622,RECRUITING,Primary Progressive Multiple Sclerosis,,Danish Research Centre for Magnetic Resonance,Scleroseforeningen|Danish Multiple Sclerosis Center,ALL,"ADULT, OLDER_ADULT",,60,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-11-30,2023-12,2024-06,"Danish Research Centre for Magnetic Resonance, Hvidovre, 2650, Denmark"
NCT01896700,Methylphenidate to Improve Balance and Walking in MS,https://beta.clinicaltrials.gov/study/NCT01896700,COMPLETED,Multiple Sclerosis,DRUG: Methylphenidate|DRUG: Placebo,Oregon Health and Science University,Portland VA Medical Center,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,24,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2013-07,2016-04,2016-04,"Portland VA Medical Center, Portland, Oregon, 97239, United States"
NCT04934800,Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS),https://beta.clinicaltrials.gov/study/NCT04934800,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,DRUG: Cladribine,"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","Merck Hellas sa., Greece, an affiliate of Merck KGaA, Darmstadt, Germany",ALL,"ADULT, OLDER_ADULT",,256,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-12-10,2024-07-29,2024-07-29,"University of Thrace, Medical School - Neurology Department, Alexandroupolis, Greece|251 General Air Force Hospital, Athens, Greece|417 NIMITS Hospital, Athens, Greece|Aeginiteion Hospital, University of Athens - A' Neurology Department, Athens, Greece|Attikon University Hospital, Athens, Greece|Evangelismos Hospital - Neurology Department, Athens, Greece|Genaral Hospital of Elefsina ""Thriasio"", Athens, Greece|General Hospital of Athens ""Evangelismos"", Athens, Greece|University of Ioannina - Neurology Department, Ioannina, Ioannina, Greece|University General Hospital of Larissa - Rheumatology Clinic, Larissa, Greece|Iatriko Palaioy Faliroy, Medical Center - Neurology Department, Paleo Faliro, Greece|University General Hospital of Patra, Patras, Greece|General Hospital of Patra ""Agios Andreas"", Patra, Greece|AHEPA General Hospital of Thessaloniki, Thessaloniki, Greece|General Hospital of Thessaloniki ""G. Papanikolaou"", Thessaloniki, Greece|Interbalkan Hospital of Thessaloniki, Thessaloniki, Greece|Papageorgiou General Hospital Thessaloniki, Thessaloniki, Greece|St Luke's Hospital, Thessaloniki, Greece|Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII) - Dipartimento di Neurologia, Bergamo, Italy|Università degli Studi G. D'Annunzio, Chieti, Italy|Azienda Ospedaliera Universitaria Arcispedale Sant'Anna - Neurologia, Cona, Italy|Azienda Socio Sanitaria Territoriale della Valle Olona (presidio di Gallarate) - Neurologia 2 - Sclerosi Multipla, Gallarate, Italy|ASL 1 Avezzano L'Aquila Sulmona- Ospedale Regionale San Salvatore - Dipartimento di Neurologia, L'Aquila, Italy|IRCCS Centro Neurolesi Bonino Pulejo - U.O. di Neurofisipatologia ed Ambulatori, Messina, Italy|Azienda Ospedaliera di Rilievo Nazionale A. Cardarelli - U.O.S. Malattie Degenerative del S.N.C., Napoli, Italy|Ospedale Maggiore della carità - Novara, Novara, Italy|Centro di Riferimento Regionale per la Sclerosi Multipla (CRESM) - SCDO Neurologia, Orbassano, Italy|Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone - Dipartimento di Neuroscienze, Palermo, Italy|Azienda Ospedaliera di Udine Ospedale S. Maria della Misericordia - UO Neurologia, Perugia, Italy|Grande Ospedale Metropolitano ""Bianchi Melacrino Morelli - Centro Regionale Epilessia, Reggio Calabria, Italy|Azienda Ospedaliera San Filippo Neri - Neurologia, Roma, Italy|Azienda Ospedaliera Universitaria Policlinico Umberto I - Università di Roma La Sapienza - Dip. di Neurologia e Psichiatria (servizio EMG), Roma, Italy|A. O. U. San Giovanni Di Dio e Ruggi D'Aragona - Struttura Complessa di Oculistica, Salerno, Italy|Azienda Ospedaliera Universitaria Integrata Verona (Ospedale Borgo Roma) - D.U.Neurologia, Verona, Italy|Vestre Viken HF Drammen Sykehus - former Sykehuset Buskerud, Drammen, Norway|Sykehuset Namsos, Namsos, Norway|Oslo Universitetssykehus HF - Ullevål, Oslo, Norway|Uniwersytecki Szpital Kliniczny w Bialymstoku - Dept of Neurology, Bialystok, Poland|Szpital Specjalistyczny im. L.Rydygiera w Krakowie - Neurology Department, Krakow, Poland|Szpital Uniwersytecki w Krakowie - Uniwersytet Jagiellonski Collegium Medicum, Krakow, Poland|Szpital Kliniczny im.Heliodora Swiecickiego Uniwersytetu Medycznego im.K. Marcinkowskiego w Poznaniu - Dept of Neurology, Poznan, Poland|Wojskowy Instytut Medyczny - Klinika Neurologiczna, Warszawa, Poland|SPZOZ Wojewodzki Szpital Specjalistyczny nr 3 w Rybniku, Zory, Poland|Centro Hospitalar de Lisboa Ocidental, E.P.E. - Hospital de Egas Moniz - Serviço de Neurologia, Lisboa, Portugal|Unidade Local de Saúde de Matosinhos, EPE (Hospital Pedro Hispano) - Serviço de Neurologia, Matosinhos, Portugal|Centro Hospitalar de São João, E.P.E. - Serviço de Neurologia, Porto, Portugal|Hospital Garcia de Orta, EPE - Serviço de Neurologia, Pragal, Portugal|Centro Hospitalar de Setubal, EPE - Hospital São Bernardo, Setúbal, Portugal|Unidade Local de Saúde do Alto Minho, EPE - Serviço de Neurologia, Viana De Castelo, Portugal|Inselspital - Universitaetsspital Bern - Neuropsychologische Rehabilitation, Neurologie, Bern, Switzerland|(CHUV), Centre Hospitalier Universitaire Vaudois - Departement des Neurosciences Cliniques, Lausanne, Switzerland|Ospedale Regionale di Lugano - Neurologia, Lugano, Switzerland|Hôpital Régional Sion-Hérens-Conthey - Neurologie, Sion, Switzerland"
NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01892722,RECRUITING,Multiple Sclerosis,DRUG: Interferon beta-1a|DRUG: Fingolimod|DRUG: Placebo capsule|DRUG: Placebo i.m. injection,Novartis Pharmaceuticals,,ALL,CHILD,PHASE3,220,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2013-07-26,2017-07-14,2028-11-02,"Novartis Investigative Site, Birmingham, Alabama, 35294, United States|Novartis Investigative Site, Little Rock, Arkansas, 72202, United States|Novartis Investigative Site, Los Angeles, California, 90027, United States|Novartis Investigative Site, San Francisco, California, 94143, United States|Novartis Investigative Site, Aurora, Colorado, 80045, United States|Novartis Investigative Site, Miami, Florida, 33136, United States|Novartis Investigative Site, Orlando, Florida, 32819, United States|Novartis Investigative Site, Tallahassee, Florida, 32308, United States|Novartis Investigative Site, Chicago, Illinois, 60611, United States|Novartis Investigative Site, Boston, Massachusetts, 02114, United States|Novartis Investigative Site, Boston, Massachusetts, 02115, United States|Novartis Investigative Site, Detroit, Michigan, 48201, United States|Novartis Investigative Site, New Brunswick, New Jersey, 08901, United States|Novartis Investigative Site, Rochester, New York, 14642, United States|Novartis Investigative Site, Stony Brook, New York, 11794, United States|Novartis Investigative Site, Chapel Hill, North Carolina, 27599-9500, United States|Novartis Investigative Site, Durham, North Carolina, 27710, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, 19104 4399, United States|Novartis Investigative Site, Greenville, South Carolina, 29607, United States|Novartis Investigative Site, San Antonio, Texas, 78229, United States|Novartis Investigative Site, Salt Lake City, Utah, 84108, United States|Novartis Investigative Site, Parkville, Victoria, 3052, Australia|Novartis Investigative Site, Vienna, 1090, Austria|Novartis Investigative Site, Minsk, 220114, Belarus|Novartis Investigative Site, Belo Horizonte, Minas Gerais, 30150 221, Brazil|Novartis Investigative Site, Rio de Janeiro, RJ, 20270-004, Brazil|Novartis Investigative Site, Sao Paulo, SP, 05403-000, Brazil|Novartis Investigative Site, Goiania, 74605 020, Brazil|Novartis Investigative Site, Sofia, 1113, Bulgaria|Novartis Investigative Site, Calgary, Alberta, T3B 6A8, Canada|Novartis Investigative Site, Ottawa, Ontario, K1H 8L1, Canada|Novartis Investigative Site, Osijek, 31000, Croatia|Novartis Investigative Site, Tallinn, 10617, Estonia|Novartis Investigative Site, Bordeaux Cedex, 33076, France|Novartis Investigative Site, Le Kremlin Bicetre, 94275, France|Novartis Investigative Site, Marseille Cedex 05, 13885, France|Novartis Investigative Site, Montpellier, 34295, France|Novartis Investigative Site, Toulouse Cedex, 31059, France|Novartis Investigative Site, Bochum, 44791, Germany|Novartis Investigative Site, Bonn, 53111, Germany|Novartis Investigative Site, Dresden, 01307, Germany|Novartis Investigative Site, Erlangen, 91054, Germany|Novartis Investigative Site, Essen, 45147, Germany|Novartis Investigative Site, Freiburg, 79106, Germany|Novartis Investigative Site, Gottingen, 37075, Germany|Novartis Investigative Site, Hamburg, 20246, Germany|Novartis Investigative Site, Muenchen, 80337, Germany|Novartis Investigative Site, Muenster, 48149, Germany|Novartis Investigative Site, Bari, BA, 70124, Italy|Novartis Investigative Site, Montichiari, BS, 25018, Italy|Novartis Investigative Site, Catania, CT, 95123, Italy|Novartis Investigative Site, Milano, MI, 20132, Italy|Novartis Investigative Site, Cefalu, PA, 90015, Italy|Novartis Investigative Site, Roma, RM, 00133, Italy|Novartis Investigative Site, Roma, RM, 00189, Italy|Novartis Investigative Site, Gallarate, VA, 21013, Italy|Novartis Investigative Site, Napoli, 80131, Italy|Novartis Investigative Site, Riga, LV-1004, Latvia|Novartis Investigative Site, Kaunas, LTU, LT 50161, Lithuania|Novartis Investigative Site, Ciudad De Mexico, D F, 06700, Mexico|Novartis Investigative Site, Mexico, Distrito Federal, 03310, Mexico|Novartis Investigative Site, Mexico, Distrito Federal, 04530, Mexico|Novartis Investigative Site, Mexico, Distrito Federal, 06720, Mexico|Novartis Investigative Site, Merida, Yucatán, 97125, Mexico|Novartis Investigative Site, Rotterdam, 3015 CN, Netherlands|Novartis Investigative Site, Lodz, 93-338, Poland|Novartis Investigative Site, Lublin, 20-093, Poland|Novartis Investigative Site, Poznan, 60-355, Poland|Novartis Investigative Site, Wroclaw, 50 420, Poland|Novartis Investigative Site, Santurce, 00912, Puerto Rico|Novartis Investigative Site, Bucuresti, 041914, Romania|Novartis Investigative Site, Kazan, 420043, Russian Federation|Novartis Investigative Site, Moscow, 119602, Russian Federation|Novartis Investigative Site, Moscow, 119991, Russian Federation|Novartis Investigative Site, Novosibirsk, 630087, Russian Federation|Novartis Investigative Site, St. Petersburg, 197110, Russian Federation|Novartis Investigative Site, Belgrade, 11000, Serbia|Novartis Investigative Site, Kragujevac, 34000, Serbia|Novartis Investigative Site, Novi Sad, 21000, Serbia|Novartis Investigative Site, Bratislava, Slovensko, 83340, Slovakia|Novartis Investigative Site, Malaga, Andalucia, 29010, Spain|Novartis Investigative Site, Sevilla, Andalucia, 41009, Spain|Novartis Investigative Site, Esplugues de Llobregat, Barcelona, 08950, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08035, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, 46010, Spain|Novartis Investigative Site, Barakaldo, Pais Vasco, 48903, Spain|Novartis Investigative Site, Vigo, Pontevedra, 36212, Spain|Novartis Investigative Site, Madrid, 28006, Spain|Novartis Investigative Site, Lund, 221 85, Sweden|Novartis Investigative Site, Konak-Izmir, Izmir, 35210, Turkey|Novartis Investigative Site, Istanbul, TUR, 34098, Turkey|Novartis Investigative Site, Ankara, 06100, Turkey|Novartis Investigative Site, Ankara, 06500, Turkey|Novartis Investigative Site, Izmir, 35340, Turkey|Novartis Investigative Site, Samsun, 55139, Turkey|Novartis Investigative Site, Cherkasy, 18000, Ukraine|Novartis Investigative Site, Dnipropetrovsk, 49027, Ukraine|Novartis Investigative Site, Kharkiv, 61068, Ukraine|Novartis Investigative Site, Kharkiv, 61091, Ukraine|Novartis Investigative Site, Kiev, 03110, Ukraine|Novartis Investigative Site, Lviv, 79010, Ukraine|Novartis Investigative Site, Odesa, 65009, Ukraine|Novartis Investigative Site, Vinnytsa, 21029, Ukraine|Novartis Investigative Site, West Midlands, Birmingham, B4 6NH, United Kingdom|Novartis Investigative Site, Edinburgh, EH9 1LF, United Kingdom|Novartis Investigative Site, London, WC1N 1EH, United Kingdom|Novartis Investigative Site, London, WC1N 3BG, United Kingdom"
NCT00432900,Brain Peripheral Benzodiazepine Receptors in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00432900,COMPLETED,Multiple Sclerosis,RADIATION: [(11)C]PBR28,National Institute of Neurological Disorders and Stroke (NINDS),,ALL,"ADULT, OLDER_ADULT",PHASE1,21,NIH,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2007-02-05,2013-05-23,2013-05-29,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States"
NCT02499900,Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®,https://beta.clinicaltrials.gov/study/NCT02499900,COMPLETED,Multiple Sclerosis,DRUG: Copaxone®,"Teva Branded Pharmaceutical Products R&D, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE4,861,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2015-08-10,2017-01-10,2017-06-02,"Teva Investigational Site 13485, Cullman, Alabama, 35058-1565, United States|Teva Investigational Site 13524, Carmichael, California, 95608, United States|Teva Investigational Site 13478, Atlanta, Georgia, 30327, United States|Teva Investigational Site 13475, Northbrook, Illinois, 60062, United States|Teva Investigational Site 13472, Foxboro, Massachusetts, 02035, United States|Teva Investigational Site 13479, Golden Valley, Minnesota, 55422, United States|Teva Investigational Site 13483, Golden Valley, Minnesota, 55422, United States|Teva Investigational Site 13487, Las Vegas, Nevada, 89106, United States|Teva Investigational Site 13470, Teaneck, New Jersey, 07666, United States|Teva Investigational Site 13482, New Hyde Park, New York, 11042, United States|Teva Investigational Site 13471, Raleigh, North Carolina, 27607, United States|Teva Investigational Site 13473, Columbus, Ohio, 43214, United States|Teva Investigational Site 13477, Uniontown, Ohio, 44685, United States|Teva Investigational Site 13481, Round Rock, Texas, 78681, United States|Teva Investigational Site 13480, Virginia Beach, Virginia, 23456, United States|Teva Investigational Site 20061, Buenos Aires, C1061ABD, Argentina|Teva Investigational Site 20062, Buenos Aires, C1280AEB, Argentina|Teva Investigational Site 20063, Rosario, S2002KQJ, Argentina|Teva Investigational Site 33040, Wien, 1010, Austria|Teva Investigational Site 37066, Bruxelles, 1200, Belgium|Teva Investigational Site 37063, Edegem, 2650, Belgium|Teva Investigational Site 60037, Rijeka, 51000, Croatia|Teva Investigational Site 60039, Slavonski Brod, 35000, Croatia|Teva Investigational Site 60034, Zagreb, 10000, Croatia|Teva Investigational Site 60035, Zagreb, 10000, Croatia|Teva Investigational Site 60036, Zagreb, 10000, Croatia|Teva Investigational Site 60040, Zagreb, 10000, Croatia|Teva Investigational Site 40014, Tampere, 33100, Finland|Teva Investigational Site 40015, Turku, 20520, Finland|Teva Investigational Site 35211, Besancon, 25030, France|Teva Investigational Site 35203, Bordeaux, 33076, France|Teva Investigational Site 35207, Bron Cedex, 69677, France|Teva Investigational Site 35210, Clermont-Ferrand, 63003, France|Teva Investigational Site 35208, Lille, 59000, France|Teva Investigational Site 35214, Lomme, 59160, France|Teva Investigational Site 35204, Nancy, 54035, France|Teva Investigational Site 35205, Nice, 6002, France|Teva Investigational Site 35206, Nimes, 30029, France|Teva Investigational Site 35212, Nimes, 30029, France|Teva Investigational Site 35213, Poissy, 78303, France|Teva Investigational Site 35202, Rennes, 35033, France|Teva Investigational Site 35201, Strasbourg, 67091, France|Teva Investigational Site 35209, Toulouse, 31059, France|Teva Investigational Site 32605, Bayreuth, 95445, Germany|Teva Investigational Site 32603, Dresden, ?01307, Germany|Teva Investigational Site 32602, Hamburg, 20249, Germany|Teva Investigational Site 32606, Rostock, 18147, Germany|Teva Investigational Site 32604, Stuttgart, 70174, Germany|Teva Investigational Site 44029, Dublin, Ireland|Teva Investigational Site 30169, Bari, 70124, Italy|Teva Investigational Site 30163, Genova, 16132, Italy|Teva Investigational Site 30165, Milano, 20122, Italy|Teva Investigational Site 30164, Milano, 20127, Italy|Teva Investigational Site 30161, Montichiari, 25018, Italy|Teva Investigational Site 30167, Naples, 80131, Italy|Teva Investigational Site 30166, Rome, ?00133, Italy|Teva Investigational Site 30162, Rome, ?00152, Italy|Teva Investigational Site 21096, DF, 03310, Mexico|Teva Investigational Site 21097, Mexico City, 14050, Mexico|Teva Investigational Site 21095, Mexico City, 14269, Mexico|Teva Investigational Site 21098, Mexico City, 3100, Mexico|Teva Investigational Site 53352, Bydgoszcz, 85-795, Poland|Teva Investigational Site 53354, Gdansk, 80-803, Poland|Teva Investigational Site 53350, Katowice, 40-635, Poland|Teva Investigational Site 53349, Kielce, 25-726, Poland|Teva Investigational Site 53353, Konskie, 26-200, Poland|Teva Investigational Site 53356, Lodz, 90-324, Poland|Teva Investigational Site 53348, Lodz, 90-549, Poland|Teva Investigational Site 53345, Lublin, 20-016, Poland|Teva Investigational Site 53355, Olsztyn, 10-560, Poland|Teva Investigational Site 53351, Rybnik, 44-200, Poland|Teva Investigational Site 53347, Rzeszow, 35-055, Poland|Teva Investigational Site 53346, Warszawa, ?00-909, Poland|Teva Investigational Site 13476, Guaynabo, 00969, Puerto Rico|Teva Investigational Site 50392, Kaluga, 248007, Russian Federation|Teva Investigational Site 50390, Kazan, 420021, Russian Federation|Teva Investigational Site 50391, Krasnoyarsk, 660049, Russian Federation|Teva Investigational Site 50387, Moscow, 125367, Russian Federation|Teva Investigational Site 50374, Moscow, 127015, Russian Federation|Teva Investigational Site 50373, Moscow, 603003, Russian Federation|Teva Investigational Site 50376, Novosibirsk, 630007, Russian Federation|Teva Investigational Site 50389, Perm, Russian Federation|Teva Investigational Site 50377, St. Petersburg, 194044, Russian Federation|Teva Investigational Site 50375, St. Petersburg, 197110, Russian Federation|Teva Investigational Site 50372, Tyumen, 625048, Russian Federation|Teva Investigational Site 50378, Yaroslavl, 150030, Russian Federation|Teva Investigational Site 31181, Burgos, 09006, Spain|Teva Investigational Site 31179, El Palmar, 30120, Spain|Teva Investigational Site 31180, Madrid, 28006, Spain|Teva Investigational Site 31177, Malaga, 29010, Spain|Teva Investigational Site 31182, Sevilla, 41009, Spain|Teva Investigational Site 31184, Sevilla, 41010, Spain|Teva Investigational Site 31178, Valencia, 46026, Spain|Teva Investigational Site 82052, Ankara, ?06100, Turkey|Teva Investigational Site 82051, Istanbul, 34098, Turkey|Teva Investigational Site 82049, Istanbul, 34250, Turkey|Teva Investigational Site 82050, Kocaeli, 41380, Turkey"
NCT02896933,Electrophysiological Study of Spatiotemporal Gait Parameters in Patients in Early Stage of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02896933,COMPLETED,Multiple Sclerosis,,Fondation Ophtalmologique Adolphe de Rothschild,,ALL,ADULT,,64,NETWORK,OBSERVATIONAL,Observational Model: |Time Perspective: p,,2015-01,,
NCT00638833,Memantine Therapy for Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00638833,TERMINATED,Multiple Sclerosis,DRUG: Memantine|DRUG: Placebo,"Clinica Universidad de Navarra, Universidad de Navarra",H. Lundbeck A/S,ALL,"ADULT, OLDER_ADULT",PHASE2,20,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2007-09,2008-03,2008-03,"Clinica Universitaria de Navarra, Pamplona, Navarra, 31008, Spain"
NCT03175133,Strength Training to Improve Gait in People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03175133,COMPLETED,Multiple Sclerosis,OTHER: Strength exercise,"University of Colorado, Denver",,ALL,"ADULT, OLDER_ADULT",NA,11,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2017-05-23,2017-11-08,2017-11-08,"University of Colorado Denver, Aurora, Colorado, 80045, United States"
NCT02696590,High Dose Oral Versus Intramuscular Vitamin D3 Supplementation In Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT02696590,COMPLETED,Relapsing Remitting Multiple Sclerosis,DIETARY_SUPPLEMENT: Vitamin D3,Isfahan University of Medical Sciences,,ALL,ADULT,NA,200,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2015-07,2015-11,2015-12,"Alzahra Hospital, Isfahan, 81745319, Iran, Islamic Republic of"
NCT01396343,Environmental and Genetic Risk Factors for Pediatric Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01396343,COMPLETED,Pediatric Multiple Sclerosis,,"University of California, San Francisco",New York University|Massachusetts General Hospital|State University of New York at Buffalo|University of Alabama at Birmingham|Mayo Clinic|Children's Hospital of Philadelphia|Boston Children's Hospital|Baylor College of Medicine|Loma Linda University|Children's Hospital Colorado|University of Texas|Ann & Robert H Lurie Children's Hospital of Chicago|Washington University School of Medicine|Children's National Med Center|Primary Children's Hospital|The Cleveland Clinic,ALL,"CHILD, ADULT",,1276,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-10,2018-04,2018-04,"Center for pediatric-onset demyelinating diseases at the Children's Hospital of Alabama, Birmingham, Birmingham, Alabama, 35294, United States|Pediatric MS Clinic, Children's Hospital, Loma Linda University, San Bernardino, California, 92408, United States|UCSF Pediatric MS Center, San Francisco, California, 94143, United States|Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado, 80045, United States|Pediatric MS Clinic, Children's National Medical Center, Washington, District of Columbia, 20010, United States|Pediatric MS Clinic, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, 60611, United States|Partners Pediatric MS Center at the Massachusetts General Hospital for Children, Boston, Massachusetts, 02114, United States|Pediatric MS Clinic, Children's Hospital Boston, Boston, Massachusetts, 02115, United States|Regional Pediatric MS Center at Mayo Clinic, Rochester, Minnesota, 55905, United States|Pediatric MS Clinic, Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|Pediatric MS Center of the Jacobs Neurological Institute, University of Buffalo, Buffalo, New York, 14203, United States|New York University Langone Medical Center, New York, New York, 10016, United States|The Cleveland Clinic, Cleveland, Ohio, 44195, United States|Pediatric MS Clinic, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States|Pediatric MS Center, University of Texas, Southwestern Medical Center, Dallas, Texas, 75390, United States|The Blue Bird Circle Clinic for MS at Texas Children's Hospital, Houston, Texas, 77030, United States|Pediatric Neurology Clinic, Primary Children's Hospital, Salt Lake City, Utah, 84113, United States"
NCT01335633,Psychometric Validation of Cognitive Endpoints,https://beta.clinicaltrials.gov/study/NCT01335633,COMPLETED,Multiple Sclerosis,,Kessler Foundation,Biogen,ALL,"ADULT, OLDER_ADULT",,60,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-03,2011-08,2011-08,"Holy Name Hospital Multiple Sclerosis Center, Teaneck, New Jersey, 07666, United States|Kessler Foundation, West Orange, New Jersey, 07052, United States|University at Buffalo, Buffalo, New York, 14203, United States|Lauren S. Caruso, White Plains, New York, 10604, United States"
NCT02687633,Early Behavioral Intervention to Improve Social Communication Function in Infants With Tuberous Sclerosis Complex,https://beta.clinicaltrials.gov/study/NCT02687633,COMPLETED,Tuberous Sclerosis Complex,BEHAVIORAL: JASPER,"University of California, Los Angeles",Boston Children's Hospital,ALL,CHILD,NA,8,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2015-09,2017-08,2017-08,"UCLA Semel Insitute, Los Angeles, California, 90095, United States"
NCT05615207,The Effect of Motor Imagery on Balance in Persons With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05615207,RECRUITING,Falls|Motor Imagery|Multiple Sclerosis|Balance|Fatigue,OTHER: Motor Imagery as compared to physical practice for balance tasks,Dominican University of New York,,ALL,"CHILD, ADULT, OLDER_ADULT",NA,10,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-01-01,2023-11-01,2023-11-01,"Dominican University New York, Orangeburg, New York, 10962, United States"
NCT05029700,The Effects of Trunk Stabilization and Aerobic Trainings in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05029700,COMPLETED,Physical Therapy,OTHER: Combined exercise training|OTHER: Aerobic training,Ankara Yildirim Beyazıt University,,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2019-06-01,2020-12-01,2021-02-01,"Ankara Yıldırım Beyazıt University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation Etlik, Ankara, Turkey, 06010, Ankara, Turkey"
NCT03954600,"A Study to Assess the Safety, Tolerability and PK of NPT520-34 in Healthy Subjects",https://beta.clinicaltrials.gov/study/NCT03954600,COMPLETED,Healthy Volunteers,DRUG: NPT520-34 (125 mg)|DRUG: Placebos (125 mg),Neuropore Therapies Inc.,Celerion,ALL,ADULT,PHASE1,49,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-05-05,2019-10-02,2019-10-09,"Celerion, Inc, Tempe, Arizona, 85283, United States"
NCT02515695,Phase I BP Interferon (IFN) Beta-001,https://beta.clinicaltrials.gov/study/NCT02515695,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Interferon beta-1a,Centre Hospitalier Universitaire Vaudois,BioPartners GmbH,ALL,ADULT,PHASE1,12,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2005-05,2005-07,2005-07,
NCT02740296,Depression and Immune Function in Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT02740296,COMPLETED,"Multiple Sclerosis|Depressive Disorder, Major",OTHER: No intervention,"Charite University, Berlin, Germany","National Multiple Sclerosis Society|Universitätsklinikum Hamburg-Eppendorf|NeuroCure Clinical Research Center, Charite, Berlin",ALL,ADULT,,104,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-11,2017-06,2017-06,"Charité - Universitätsmedizin Berlin, Berlin, 10117, Germany"
NCT01938495,Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS),https://beta.clinicaltrials.gov/study/NCT01938495,COMPLETED,Amyotrophic Lateral Sclerosis (ALS),DEVICE: NeuRx® Diaphragm Pacing System™ (DPS),Barrow Neurological Institute,ALS Association|Muscular Dystrophy Association|Synapse Biomedical,ALL,"ADULT, OLDER_ADULT",PHASE2,52,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2013-08,2017-01,2017-04,"Barrow Neurological Institute, Phoenix, Arizona, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|California Pacific Medical Center, San Diego, California, United States|Stanford University, Stanford, California, United States|Hospital for Special Care, New Britain, Connecticut, United States|Mayo Clinic Florida, Jacksonville, Florida, United States|University of Florida, Jacksonville, Jacksonville, Florida, United States|University of Iowa, Iowa City, Iowa, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Henry Ford Health Systems, Detroit, Michigan, United States|St Louis University, Saint Louis, Missouri, United States|Neurology Associates P.C., Lincoln, Nebraska, United States|Hospital for Special Surgery, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Carolinas Health Care, Charlotte, North Carolina, United States|Wake Forest University, Winston-Salem, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Providence ALS Center, Portland, Oregon, United States|Drexel University, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Texas Southwestern, Dallas, Texas, United States|University of Texas, San Antonio, Texas, United States|University of Vermont, Burlington, Vermont, United States|Virginia Mason Medical Center, Seattle, Washington, United States"
NCT02587195,A Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period,https://beta.clinicaltrials.gov/study/NCT02587195,COMPLETED,Multiple Sclerosis,DRUG: Teriflunomide,Centre Hospitalier Universitaire de Nice,,ALL,ADULT,PHASE3,5,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-12-18,2020-08-31,2021-08-31,"CHU de Besançon, Besançon, 25030, France|CHU de Lille, Lille, 59037, France|CHU de Montpellier, Montpellier, 34295, France|CHU de Nice, Nice, 06000, France|CHU de Strasbourg, Strasbourg, 67098, France"
NCT04564495,Home Based Tele-exercise for People With Chronic Neurological Impairments,https://beta.clinicaltrials.gov/study/NCT04564495,ACTIVE_NOT_RECRUITING,"Neurologic Disorder|Stroke|Spinal Cord Injuries|Cerebral Palsy|Hemiplegia|Hemiparesis|Multiple Sclerosis|Parkinson Disease|Trauma, Brain|Transverse Myelitis|Friedreich Ataxia",BEHAVIORAL: Seated exercise,Burke Medical Research Institute,,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-01-22,2023-12-31,2024-12-31,"Burke Neurological Institute, White Plains, New York, 10605, United States"
NCT00501696,"A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone",https://beta.clinicaltrials.gov/study/NCT00501696,COMPLETED,Multiple Sclerosis,DRUG: 4.5 mg Naltrexone|DRUG: Naltrexone,"University of California, San Francisco",,ALL,"ADULT, OLDER_ADULT",PHASE3,80,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2007-02,2007-11,2007-11,"MS Center UCSF, Parnassus Ave, suite #908, SAn Francisco, California, 94117, United States"
NCT00110396,Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00110396,COMPLETED,Multiple Sclerosis,BIOLOGICAL: Interferon-beta-1a FBS-free/HSA-free,EMD Serono,Pfizer,ALL,ADULT,PHASE3,260,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2005-01,2007-04,2007-04,"Local US Medical Information, Rockland, Massachusetts, 02370, United States"
NCT03740295,Impact of Ketone Bodies and Epigallocatechin Gallate in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03740295,COMPLETED,Multiple Sclerosis,DIETARY_SUPPLEMENT: Coconut oil and epigallocatechin gallate|OTHER: Placebo,Fundación Universidad Católica de Valencia San Vicente Mártir,Valencian Institute of Neurorehabilitation Foundation,ALL,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2018-10-05,2019-01-05,2019-02-05,"José Enrique de la Rubia Ortí, Valencia, 46007, Spain"
NCT04599595,Characteristics of INTESTINAL DYSFUNCTION in Patients With MULTIPLE SCLEROSIS,https://beta.clinicaltrials.gov/study/NCT04599595,COMPLETED,Multiple Sclerosis|Intestinal Dysfunction|Anal Incontinence|Microbiota,DEVICE: Peristeen (Coloplast),University Hospital of Ferrara,,ALL,"ADULT, OLDER_ADULT",,100,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-06-07,2020-04-10,2020-04-10,"Simona Ascanelli, Ferrara, 44121, Italy"
NCT00202995,Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS,https://beta.clinicaltrials.gov/study/NCT00202995,TERMINATED,Relapsing Remitting Multiple Sclerosis,DRUG: Glatiramer Acetate|DRUG: Betaseron|DRUG: Rebif,"Teva Branded Pharmaceutical Products R&D, Inc.",,ALL,ADULT,PHASE4,91,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2004-07,2007-10,2007-10,
NCT01730547,Mesenchymal Stem Cells for Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01730547,UNKNOWN,Multiple Sclerosis,BIOLOGICAL: Autologous mesenchymal stem cells,Karolinska Institutet,,ALL,ADULT,PHASE1|PHASE2,15,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-02,2015-12,2015-12,"Karolinska Institute, Karolinska University Hospital Solna, Stockholm, 171 76, Sweden"
NCT02992847,Evaluation of Potential Accumulation of Gadolinium (Dotarem and Multihance) in the French Observatory of Multiple Sclerosis (Www.Ofsep.Org/),https://beta.clinicaltrials.gov/study/NCT02992847,UNKNOWN,Multiple Sclerosis,OTHER: Unenhanced MRI,Hospices Civils de Lyon,Guerbet,ALL,"ADULT, OLDER_ADULT",,160,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-01,2017-07,2017-07,
NCT00037947,Auditory Function in Patients With and Without Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00037947,COMPLETED,Multiple Sclerosis,PROCEDURE: Hearing in Multiple Sclerosis,US Department of Veterans Affairs,,ALL,"ADULT, OLDER_ADULT",PHASE2,300,FED,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2001-10,2007-12,2007-12,"VA Medical Center, Portland, Oregon, United States"
NCT03204747,Effect of Need to Void on Gait Speed in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03204747,COMPLETED,Multiple Sclerosis|Lower Urinary Tract Symptoms|Gait,OTHER: Observational study : gait speed,Pierre and Marie Curie University,,ALL,"ADULT, OLDER_ADULT",,71,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-02-27,2017-08-31,2017-08-31,"Service de Neuro-urology, hôpital Tenon, Paris, 75020, France"
NCT05136222,Polysomnographic Titration of Non-invasive Ventilation in Motor Neurone Disease,https://beta.clinicaltrials.gov/study/NCT05136222,RECRUITING,Motor Neuron Disease / Amyotrophic Lateral Sclerosis,OTHER: Intervention polysomnography|OTHER: Sham polysomnography,University of Melbourne,"Austin Hospital, Melbourne Australia|Institute for Breathing and Sleep, Australia|Royal Prince Alfred Hospital, Sydney, Australia|Macquarie University, Australia|Macquarie Health|Western Sydney Local Health District|Flinders Medical Centre|Sir Charles Gairdner Hospital|The Prince Charles Hospital|Monash University|Motor Neurone Disease Australia|FightMND|Australian Motor Neurone Disease Registry|Calvary Bethlehem|Perron Institute for Neurological and Translational Science",ALL,"ADULT, OLDER_ADULT",NA,244,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-12-15,2026-02-28,2028-02-28,"Flinders Medical Centre, Adelaide, Australia|The Prince Charles Hospital, Brisbane, Australia|Motor Neurone Disease Australia, Canberra, Australia|Austin Health, Melbourne, Australia|Australian MND Registry, Melbourne, Australia|FightMND, Melbourne, Australia|Institute for Breathing and Sleep, Melbourne, Australia|Monash University, Melbourne, Australia|University of Melbourne, Melbourne, Australia|Sir Charles Gairdner Hospital, Perth, Australia|Macquarie University, Sydney, Australia|Royal Prince Alfred Hospital, Sydney, Australia|Westmead Hospital, Sydney, Australia"
NCT05327322,Functional Outcomes From Diets in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05327322,RECRUITING,Relapsing Remitting Multiple Sclerosis|Secondary Progressive Multiple Sclerosis,BEHAVIORAL: Glycemic load|BEHAVIORAL: Calorie restriction|BEHAVIORAL: Behavioral support,University of Alabama at Birmingham,Washington University School of Medicine|United States Department of Defense,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: OTHER,2023-03-20,2026-01-31,2026-01-31,"University of Alabama at Birmingham, Birmingham, Alabama, 35294, United States|Washington University, Saint Louis, Missouri, 63110, United States"
NCT00876447,A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00876447,COMPLETED,Overactive Bladder,BIOLOGICAL: Botulinum Toxin Type A 300U|BIOLOGICAL: Botulinum Toxin Type A 200U,Allergan,,ALL,"ADULT, OLDER_ADULT",PHASE3,397,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-01-01,2013-06-12,2013-09-04,"Middlebury, Connecticut, United States|Randwick, Australia|Innsbruck, Austria|Ghent, Belgium|Rio de Janeiro, Brazil|Victoria, British Columbia, Canada|Ostrava, Czechia|Salouel, France|Kiel, Germany|Florence, Italy|Amsterdam, Netherlands|Epsom, New Zealand|Poznan, Poland|Porto, Portugal|Moscow, Russian Federation|Singapore, Singapore|Presov, Slovakia|Pretoria, South Africa|Tenerife, Spain|Hualien, Taiwan|Kiev, Ukraine|London, United Kingdom"
NCT03977922,A Pilot Nutrition Program for Spinal Cord Injury and MS,https://beta.clinicaltrials.gov/study/NCT03977922,COMPLETED,Spinal Cord Injuries|Multiple Sclerosis,OTHER: Diet group,Brock University,,ALL,"ADULT, OLDER_ADULT",NA,6,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-02-28,2022-02-28,2022-02-28,"Brock University, Saint Catharines, Ontario, L2S 3A1, Canada"
NCT03187847,Rehabilitation in Multiple Sclerosis - Sometimes Too Much?,https://beta.clinicaltrials.gov/study/NCT03187847,COMPLETED,Multiple Sclerosis,DEVICE: Actigraph GT3X,Klinik Valens,,ALL,"ADULT, OLDER_ADULT",,28,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-08-27,2018-03-30,2018-06-04,"Kliniken Valens, Valens, 7317, Switzerland"
NCT05367947,In-phase Bilateral Exercises in People With Relapsing Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05367947,NOT_YET_RECRUITING,Multiple Sclerosis,BEHAVIORAL: In-phase Bilateral Exercises of the upper limbs,Cyprus University of Technology,The Cyprus Foundation for Muscular Dystrophy Research,ALL,"ADULT, OLDER_ADULT",NA,5,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2022-10,2023-07,2023-07,
NCT05462522,"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7303509 in Participants With Systemic Sclerosis",https://beta.clinicaltrials.gov/study/NCT05462522,RECRUITING,Systemic Sclerosis,DRUG: RO7303509|DRUG: Placebo,"Genentech, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1,100,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-01-16,2025-04-01,2025-04-01,"Medstar Georgetown University Hospital, Washington, District of Columbia, 20007, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114-2621, United States|Mayo Clinic - Cancer Center - Rochester - PPDS, Rochester, Michigan, 55905-0001, United States|Metroplex Clinical Research Centre, Dallas, Texas, 75235-6262, United States|Clinica Mayo de U.M.C.B. S.R.L, San Miguel de Tucumán, T4000IHE, Argentina|UZ Leuven, Leuven, 3000, Belgium|CHU de Liège, Liège, 4000, Belgium|Centre Hospitalier Universitaire de Grenoble - Albert Michallon, La Tronche, 38700, France|Hopital Cochin, Paris, 75014, France|CHRU Rennes, Rennes, 35000, France|Hopitaux Universitaires, Strasbourg, 67200, France|Hopital Purpan, Toulouse, 31000, France|Universitätsklinikum Carl Gustav Carus an der TU Dresden, Dresden, 01307, Germany|Rambam Medical Center - PPDS, Haifa, 3109601, Israel|Lady Davis Carmel Medical Center, Haifa, 34362, Israel|Meir Medical Center; Rheumatology Dept, Kfar Saba, 4428164, Israel|Sheba Medical Center - PPDS, Ramat-Gan, 5262000, Israel|Szpital Uniwersytecki Nr 2 im. Dr Jana Biziela w Bydgoszczy; Klinika Reumatologii, Bydgoszcz, 85-168, Poland|Szpital Specjalistyczny im. Jozefa Dietla w Krakowie, Kraków, 31-121, Poland|Zespol Poradni Specjalistycznych REUMED, Lublin, 20-607, Poland|Lecznica MAK-MED NZOZ, Nadarzyn, 05-830, Poland|Hospital Garcia de Orta, Almada, 2801-915, Portugal|The Alliance Medical Sciences Campus; University Hospital, San Juan, 00935-0001, Puerto Rico|Hospital de la Santa Creu i Sant Pau, Barcelona, 08025, Spain|Hospital Universitario Vall d Hebron, Barcelona, 08035, Spain|C.H. Regional Reina Sofia - PPDS, Cordoba, 14004, Spain|Hospital Quironsalud Infanta Luisa, Sevilla, 41010, Spain|Hospital Universitario Virgen del Rocio, Sevilla, 41013, Spain"
NCT03804047,KITAMS: Kinesio Tape and Physical Function in Persons With Multiples Sclerosis,https://beta.clinicaltrials.gov/study/NCT03804047,UNKNOWN,Multiple Sclerosis,OTHER: kinesio tape,Northern Illinois University,,ALL,ADULT,NA,24,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2019-01-01,2021-12-25,2021-12-31,"Department of Kinesiology and Physical Education. Northern Illinois University, DeKalb, Illinois, 60115, United States"
NCT03166800,MitoQ for Fatigue in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03166800,TERMINATED,Multiple Sclerosis|Fatigue,DRUG: Mitoquinone|DRUG: Mitoquinone|DRUG: Placebo,Oregon Health and Science University,MitoQ Limited|National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,9,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-09-15,2019-01-10,2019-01-10,"Oregon Health & Science University, Portland, Oregon, 97239, United States"
NCT00027300,Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00027300,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Natalizumab|DRUG: Placebo,Biogen,Elan Pharmaceuticals,ALL,ADULT,PHASE3,900,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2001-11,2004-11,2005-01,"Mayo Clinic Scottsdale, Scottsdale, Arizona, 85259, United States|East Bay Region Associates in Neurology, Berkeley, California, 94705, United States|UC Davis School of Medicine, Department of Neurology, Davis, California, 95817-2307, United States|Yale University School of Medicine, Department of Neurology, New Haven, Connecticut, 06510, United States|University of Miami School of Medicine, Department of Neurology, Miami, Florida, 33136, United States|University of Kansas Medical Center, Department of Neurology, Kansas City, Kansas, 66160, United States|Michigan Institute for Neurological Disorders, Farmington Hills, Michigan, 48335, United States|University of Nebraska Medical Center, Omaha, Nebraska, 68198, United States|Gimbel MS Center, Teaneck, New Jersey, 07666, United States|CMRRC, Albuquerque, New Mexico, 87131, United States|Oregon Health Sciences University, Department of Neurology, Portland, Oregon, 97201-3098, United States|Lehigh Valley Hospital, Neurosciences Research, Allentown, Pennsylvania, 18103, United States|Texas Neurology, Dallas, Texas, 75214, United States|University of Washington MS Research Center, Seattle, Washington, 98195, United States|Algemeen Ziekenhuis St. Jan, Brugge, 8000, Belgium|LUC- University Centre, Diepenbeek, 3590, Belgium|National MS Centrum, Melsbroek, 1820, Belgium|Vancouver Hospital and Health Sciences Center UBC Pavilion, MS Clinical Research Group, Vancouver, British Columbia, V6T 2B5, Canada|Health Services Centre, Winnipeg, Manitoba, R3A 1R9, Canada|Kingston General Hospital, Neurology, Kingston, Ontario, K7L 2V7, Canada|University Hospital, London, Ontario, N6A 5A5, Canada|Sunnybrook and Women's College and Health Science Centre, Toronto, Ontario, M4N 3M5, Canada|University of Toronto, MS Clinic, St. Michael's Hospital, Toronto, Ontario, M5B 1W8, Canada|CHVO Hull Hospital, Quebec City, Quebec, J8Y 1W7, Canada|MS Research Unit, Center for Clinical Research, Halifax, B3H 1V7, Canada|Family Medical Centre, Ottawa, K1N 5C7, Canada|Faculty Hospital Brno Bohunice, Brno, 60200, Czech Republic|Faculty Hospital St. Anne, Brno, 656 91, Czech Republic|Faculty Hospital of Hradec Kralove, Hradec Kralove, 500 05, Czech Republic|Faculty Hospital Olomouc, Olomouc, 775 20, Czech Republic|Faculty Hospital Of Ostrava Poruba, Ostrava, 70852, Czech Republic|Hospital Pardubice - Department of Neurology, Pardubice, 532 03, Czech Republic|Faculty Hospital Plzen - Clinic of Neurology, Plzen, 304 60, Czech Republic|General Teaching Hospital - Neurological Department, Prague, 2 12802, Czech Republic|Faculty Hospital Motol - Neurological Clinic, Prague, 5 105 06, Czech Republic|Hopital de la Timone, Service de Neurologie, Marseille, 13385, France|CHRU - Hopital de Pontchaillou, Service de Neurologie, Rennes, 35033, France|St. Josef-Hospital, Neurologische Klinik der Ruhruniversitat Bochum, Bochurn, 44791, Germany|Klinika Neurologii, Bydgoszcz, 85-681, Germany|Academisch Ziekenhuis VU, Amsterdam, 1081 HV, Netherlands|Institute of Neurology, Queen Square, London, WC1N 3BG, United Kingdom|The Royal London Hospital, Whitechapel, London, E1 1BB, United Kingdom|Atkin's Morely Hospital, Wimbledon, London, SW20 0NE, United Kingdom|Oldchurch Hospital, Essex, NE1 4LP, United Kingdom|Ipswich Hospital NHS Trust - Department of Clinical Neurology, Ipswich, IP4 5PD, United Kingdom|St. James University Hospital, Department of Neurology, Leeds, LS9 7TF, United Kingdom|Guy's Hospital, London, SE1 9RT, United Kingdom|King's College Hospital, London, SE5 9RS, United Kingdom|Kings College Hospital, Kings Neuroscience Center, London, SE5 9RS, United Kingdom|Royal Victoria Infirmary, Newcastle upon Tyne, NE1 4LP, United Kingdom|The Radcliffe Infirmary, University Department of Clinical Neurology, Oxford, OX2 0HE, United Kingdom|Royal Hallamshire Hospital, Sheffield, S10 2JF, United Kingdom|North Staffordshire Royal Infirmary - Neurology Department, Stoke on Trent, ST4 7LN, United Kingdom"
NCT02367222,"A Database Study to Estimate the Risk of Multiple Sclerosis Following Vaccination With Arepanrix™ in Manitoba, Canada",https://beta.clinicaltrials.gov/study/NCT02367222,COMPLETED,Multiple Sclerosis,OTHER: Exposed to Arepanrix™ Cohort|OTHER: Unexposed to Arepanrix™ Cohort,University of Manitoba,GlaxoSmithKline,ALL,"CHILD, ADULT, OLDER_ADULT",,1,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-08,2015-08,2015-12,
NCT03759522,Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.,https://beta.clinicaltrials.gov/study/NCT03759522,RECRUITING,Fibromyalgia|Chronic Fatigue Syndrome|Multiple Sclerosis|Healthy,DRUG: DPA-714 PET/MRI,University of Alabama at Birmingham,,ALL,"ADULT, OLDER_ADULT",PHASE1,120,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2019-02-03,2023-12-31,2023-12-31,"University of Alabama at Birmingham Medical Center, Birmingham, Alabama, 35294, United States"
NCT03006900,Multiple Sclerosis and Pilates,https://beta.clinicaltrials.gov/study/NCT03006900,COMPLETED,Multiple Sclerosis,OTHER: Pilates|OTHER: Massage,University of Saskatchewan,Multiple Sclerosis Society of Canada,ALL,"CHILD, ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2016-12,2017-12,2017-12,"College of Kinesiology, University of Saskatchewan, Saskatoon, Saskatchewan, S7N 5B2, Canada"
NCT02201212,Everolimus for Cancer With TSC1 or TSC2 Mutation,https://beta.clinicaltrials.gov/study/NCT02201212,COMPLETED,TSC1|TSC2|Tuberous Sclerosis Complex|MTOR,DRUG: Everolimus,Dana-Farber Cancer Institute,Novartis Pharmaceuticals,ALL,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-09,2019-06,2019-06,"Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States"
NCT04998812,A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy,https://beta.clinicaltrials.gov/study/NCT04998812,RECRUITING,Multiple Sclerosis|Clinically Isolated Syndrome,DRUG: Ocrelizumab,Hoffmann-La Roche,PPD|Laboratory Corporation of America|Illingworth Research Group,FEMALE,ADULT,PHASE4,44,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2022-04-13,2023-12-11,2024-11-18,"University of California San Francisco, San Francisco, California, 94117, United States|University Of Colorado, Aurora, Colorado, 80045, United States|Northwestern Memorial Hospital, Chicago, Illinois, 60611, United States|Brigham and Womens Hospital, Boston, Massachusetts, 02115, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|Hopital Pierre Wertheimer - Hopital Neurologique, Bron, 69677, France|Hôpital de la Pitié Salpétrière, Paris, 75013, France|St. Josef Hospital GmbH, Bochum, 44791, Germany|Universitaetsklinikum Carl Gustav Carus an der TU Dresden, Dresden, 01307, Germany|MultipEL Studies - Institut für klinische Studien, Hamburg, 22179, Germany|Hosp. Clinico San Carlos, Madrid, 28040, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, 46026, Spain|Universitätsspital Basel, Basel, 4031, Switzerland|Inselspital Bern, Bern, 3010, Switzerland|Queen Mary University of London, London, EC1M 6BQ, United Kingdom"
NCT01416155,Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01416155,COMPLETED,Relapsing-Remitting Multiple Sclerosis|Multiple Sclerosis,DRUG: natalizumab,Biogen,,ALL,"ADULT, OLDER_ADULT",PHASE2,97,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2010-10,2014-12,2014-12,"Research Site, Sapporo, Hokkaido, 060-8648, Japan|Research Site, Sapporo, Hokkaido, 063-0005, Japan|Research Site, Tsukuba, Ibaraki, 305-8576, Japan|Research Site, Morioka, Iwate, 020-8505, Japan|Research Site, Yokohama, Kanagawa, 232-0024, Japan|Research Site, Sendai, Miyagi, 980-8574, Japan|Research Site, Suita, Osaka, 565-0871, Japan|Research Site, Kawagoe, Saitama, 350-8550, Japan|Research Site, Tokorozawa, Saitama, 359-8513, Japan|Research Site, Bunkyo-ku, Tokyo, 113-8431, Japan|Research Site, Bunkyo-ku, Tokyo, 113-8519, Japan|Research Site, Kodaira, Tokyo, 187-8551, Japan|Research Site, Ota-ku, Tokyo, 145-0065, Japan|Research Site, Ube, Yamaguchi, 755-8505, Japan|Research Site, Chiba, 260-8677, Japan|Research Site, Fukuoka, 812-8582, Japan|Research Site, Hiroshima, 734-8551, Japan|Research Site, Kyoto, 604-8453, Japan|Research Site, Kyoto, 606-8507, Japan|Research Site, Kyoto, 616-8255, Japan|Research Site, Niigata, 951-8520, Japan|Research Site, Osaka, 556-0016, Japan"
NCT01235455,"Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors",https://beta.clinicaltrials.gov/study/NCT01235455,COMPLETED,Relapsing Remitting Multiple Sclerosis (RRMS)|Secondary Progressive Multiple Sclerosis (SPMS),"DRUG: Interferon beta-1b (Betaseron, BAY86-5046)",Bayer,,ALL,"ADULT, OLDER_ADULT",,10,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2007-08,,2011-05,"Many Locations, Portugal"
NCT01711255,Evaluation of Coagulation in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01711255,COMPLETED,Multiple Sclerosis,,Bastyr University,,ALL,"ADULT, OLDER_ADULT",,69,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-10,2016-05,2016-05,"Bastyr University Clinical Research Center, Kenmore, Washington, 98028, United States"
NCT01071512,Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01071512,COMPLETED,Multiple Sclerosis,DRUG: Tysabri,University of Chicago,Biogen,ALL,ADULT,NA,20,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2010-04,2016-01,2016-01,"University of Chicago, Chicago, Illinois, 60637, United States"
NCT03186612,Virtual Reality and Manual Dexterity in in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03186612,UNKNOWN,Multiple Sclerosis|Physical Activity|Upper Limb|Virtual Reality|Dexterity,BEHAVIORAL: OT+VR intervention with videogames for the upper limb (dexterity),Universidad Rey Juan Carlos,,ALL,"ADULT, OLDER_ADULT",NA,26,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2016-03-02,2017-12-02,2017-12-31,"Roberto Cano de la Cuerda, Alcorcón, Madrid, 28922, Spain"
NCT05279755,A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers,https://beta.clinicaltrials.gov/study/NCT05279755,RECRUITING,Amyotrophic Lateral Sclerosis,DRUG: prosetin|DRUG: placebo,ProJenX,Worldwide Clinical Trials,ALL,"ADULT, OLDER_ADULT",PHASE1,32,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-02-26,2022-05,2022-07,"Worldwide Clinical Trials Early Phase Services, San Antonio, Texas, 78217, United States"
NCT04279912,MR-Guided Focused Ultrasound (MRgFUS) for the Management of Tremor in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04279912,UNKNOWN,Multiple Sclerosis,DEVICE: Focused Ultrasound (MRgFUS) for the Management of Tremor in Patients With Multiple Sclerosis,Sunnybrook Health Sciences Centre,Multiple Sclerosis Society of Canada,ALL,"ADULT, OLDER_ADULT",NA,6,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DEVICE_FEASIBILITY,2020-01-16,2021-03,2021-07,"Sunnybrook Health Sciences Centre, Toronto, Ontario, M4N 3M5, Canada"
NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00420212,COMPLETED,Relapsing-Remitting Multiple Sclerosis,DRUG: BG00012|DRUG: Placebo,Biogen,,ALL,ADULT,PHASE3,1234,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2007-01,2011-02,2011-02,"Research Site, Gilbert, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, San Francisco, California, United States|Research Site, New Haven, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Vero Beach, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Evanston, Illinois, United States|Research Site, Palos Heights, Illinois, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Des Moines, Iowa, United States|Research Site, Wichita, Kansas, United States|Research Site, Lexington, Kentucky, United States|Research Site, Brighton, Massachusetts, United States|Research Site, Hopedale, Massachusetts, United States|Research Site, Lexington, Massachusetts, United States|Research Site, Springfield, Massachusetts, United States|Research Site, Worcester, Massachusetts, United States|Research Site, Farmington Hills, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Columbia, Missouri, United States|Research Site, St. Louis, Missouri, United States|Research Site, Henderson, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, Albany, New York, United States|Research Site, Staten Island, New York, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Dayton, Ohio, United States|Research Site, Erie, Pennsylvania, United States|Research Site, Hershey, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, East Providence, Rhode Island, United States|Research Site, Providence, Rhode Island, United States|Research Site, San Antonio, Texas, United States|Research Site, Newport News, Virginia, United States|Research Site, Wien, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Camperdown, New South Wales, Australia|Research Site, Chatswood, New South Wales, Australia|Research Site, Fitzroy, Australia|Research Site, Geelong, Australia|Research Site, Heidelberg, Australia|Research Site, Kogarah, Australia|Research Site, Liverpool, Australia|Research Site, Melbourne, Australia|Research Site, Newcastle, Australia|Research Site, Wien, Vienna, Austria|Research Site, Graz, Austria|Research Site, Innsbruck, Austria|Research Site, Linz, Austria|Research Site, Antwerpen, Belgium|Research Site, Brugge, Belgium|Research Site, Charleroi, Belgium|Research Site, Diepenbeek, Belgium|Research Site, Leuven, Belgium|Research Site, Lommel, Belgium|Research Site, Sijsele-Damme, Belgium|Research Site, Woluwe, Belgium|Research Site, Banja Luka, Republic of Srpksa, Bosnia and Herzegovina|Research Site, Burnaby, British Columbia, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Levis, Quebec, Canada|Research Site, Quebec City, Quebec, Canada|Research Site, Regina, Saskatchewan, Canada|Research Site, Montreal, Canada|Research Site, Zagreb, Croatia|Research Site, Brno, Czech Republic|Research Site, Jihlava, Czech Republic|Research Site, Opava, Czech Republic|Research Site, Ostrava, Czech Republic|Research Site, Plzen, Czech Republic|Research Site, Praha, Czech Republic|Research Site, Teplice, Czech Republic|Research Site, Clermont Ferrand, France|Research Site, Nice, France|Research Site, Paris, France|Research Site, Rennes, France|Research Site, Bad Neustadt-Saale, Germany|Research Site, Berlin, Germany|Research Site, Bochum, Germany|Research Site, Dusseldorf, Germany|Research Site, Essen, Germany|Research Site, Gieben, Germany|Research Site, Halle, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Leipzig, Germany|Research Site, Minden, Germany|Research Site, Munchen, Germany|Research Site, Munster, Germany|Research Site, Osnabruck, Germany|Research Site, Westerstede, Germany|Research Site, Athens, Greece|Research Site, Ioannina, Greece|Research Site, Thessaloniki, Greece|Research Site, Guatemala City, Guatemala|Research Site, Chenna, India|Research Site, Coimbatore, India|Research Site, Delhi, India|Research Site, Hyderabad, India|Research Site, Kolkata, India|Research Site, Lucknow, India|Research Site, Mangalore, India|Research Site, Mumbai, India|Research Site, New Delhi, India|Research Site, Pune, India|Research Site, Ashkelon, Israel|Research Site, Beer Yaakov, Israel|Research Site, Jerusalem, Israel|Research Site, Tel Hashomer, Israel|Research Site, Roma, Italy|Research Site, Skopje, Macedonia, The Former Yugoslav Republic of|Research Site, Guadalajara, Mexico|Research Site, Mexico City, Mexico|Research Site, San Luis Potosi, Mexico|Research Site, Chisinau, Moldova, Republic of|Research Site, Kishinev, Moldova, Republic of|Research Site, Breda, Netherlands|Research Site, Sittard, Netherlands|Research Site, Christchurch, New Zealand|Research Site, Grafton, New Zealand|Research Site, Hamilton, New Zealand|Research Site, Bialystok, Poland|Research Site, Gdansk, Poland|Research Site, Katowice, Poland|Research Site, Krakow, Poland|Research Site, Poznan, Poland|Research Site, Szczecin, Poland|Research Site, Warsaw, Poland|Research Site, Bucuresti, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Timisoara, Romania|Research Site, Belgrade, Serbia|Research Site, Kragujevac, Serbia|Research Site, Nis, Serbia|Research Site, Novi Sad, Serbia|Research Site, Bratislava, Slovakia|Research Site, Kosice, Slovakia|Research Site, Martin, Slovakia|Research Site, Cape Town, South Africa|Research Site, Durban, South Africa|Research Site, Rosebank, South Africa|Research Site, Basel, Switzerland|Research Site, St. Gallen, Switzerland|Research Site, Zurich, Switzerland|Research Site, Kharkiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lviv, Ukraine|Research Site, Odessa, Ukraine|Research Site, Poltava, Ukraine|Research Site, Zaporozhye, Ukraine|Research Site, London, United Kingdom|Research Site, Newcastle, United Kingdom|Research Site, Oxford, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Staffordshire, United Kingdom|Research Site, Vienna, Virgin Islands (U.S.)"
NCT03177655,Effect of Guided Imagery on Well-being in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03177655,COMPLETED,Multiple Sclerosis (MS),OTHER: Guided Imagery|OTHER: Journaling,"University of California, San Diego",,ALL,"CHILD, ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2012-03-01,2017-03-01,2017-03-01,"University of California, San Diego, San Diego, California, 92103, United States"
NCT04377555,Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab.,https://beta.clinicaltrials.gov/study/NCT04377555,ACTIVE_NOT_RECRUITING,"Multiple Sclerosis, Relapsing",DRUG: Ocrelizumab,"Genentech, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE4,179,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-07-30,2023-05-01,2025-08-30,"Barrow Neurological Institute, Phoenix, Arizona, 85013, United States|Center for Neurology and Spine - Phoenix - Hunt - PPDS, Phoenix, Arizona, 85032, United States|USC Keck School Of Medicine, Los Angeles, California, 90033, United States|Georgetown University Medical Center, Washington, District of Columbia, 20007, United States|Baptist Neurology - Beaches, Jacksonville Beach, Florida, 32250, United States|University of Miami Miller School of Medicine, Miami, Florida, 33136, United States|Shepherd Center Inc., Atlanta, Georgia, 30309, United States|Atlanta Neuroscience Institute, Atlanta, Georgia, 30327, United States|Rush University Medical Center, Chicago, Illinois, 60612-3244, United States|University of Chicago; Neurology, Chicago, Illinois, 60637, United States|Josephson Wallack Munshower Neurology PC, Indianapolis, Indiana, 46256, United States|University of Maryland Medical Center; Department of Neurology, Baltimore, Maryland, 21201, United States|Johns Hopkins Hospital; Neurology, Baltimore, Maryland, 21205, United States|Wayne State University; Department of Neurology, Detroit, Michigan, 48201, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States|Weill Cornell Medical College, New York, New York, 10065, United States|SUNY Upstate Medical University, Syracuse, New York, 13210, United States|Guilford Neurologic Associates, Greensboro, North Carolina, 27401, United States|UC Health, LLC., Cincinnati, Ohio, 45219, United States|Jefferson University Hospitals, Thomas Jefferson University, Philadelphia, Pennsylvania, 19107, United States|Neurology Clinic PC, Cordova, Tennessee, 38018, United States|Vanderbilt University Medical Center, Nashville, Tennessee, 37212, United States|University of Texas Southwestern Medical Center, Dallas, Texas, 75390, United States|Baylor College of Medicine Medical Center, Houston, Texas, 77030, United States|North Texas Institute of Neurology and Headache NextStage Clinical Research Clinic, Plano, Texas, 75024, United States|Multiple Sclerosis Center of Tidewater, Norfolk, Virginia, 23502, United States|Swedish Neuroscience Institute, Seattle, Washington, 98122, United States|Wheaton Franciscan Healthcare - St. Francis Outpatient Center; Center for Neurological Disorders, Milwaukee, Wisconsin, 53215, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States|Aga Khan University Hospital, Nairobi, 30270-00100, Kenya|Centro Internacional De Mercadeo, Guaynabo, 969, Puerto Rico"
NCT01834586,Anesthetic Topical Adhesive (Synera™) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications,https://beta.clinicaltrials.gov/study/NCT01834586,COMPLETED,Multiple Sclerosis,DRUG: Anesthetic Topical Adhesive Synera,"Brown, Theodore R., M.D., MPH",,ALL,"ADULT, OLDER_ADULT",PHASE4,30,INDIV,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-03,2015-03,2015-03,"MS Center at Evergreen Health, Kirkland, Washington, 98034, United States"
NCT03193086,The Effect of Alemtuzumab on the Blood-brain-barrier and the Brain's Metabolism in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT03193086,UNKNOWN,Multiple Sclerosis,DRUG: Alemtuzumab,"Glostrup University Hospital, Copenhagen","Genzyme, a Sanofi Company",ALL,ADULT,,35,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-01-01,2020-03-31,2020-03-31,"Functional Imaging Unit, Department of Clinical Physiology, Nuclear medicine and PET, Glostrup Hospital, Glostrup, Copenhagen Capital Region, 2600, Denmark"
NCT02152085,Neuromuscular Electrical Stimulation and Mobility in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02152085,COMPLETED,Multiple Sclerosis,DEVICE: Narrow pulse|DEVICE: Wide pulse,"University of Colorado, Boulder",Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),ALL,ADULT,NA,29,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-05,2017-12-31,2017-12-31,"University of Colorado, Boulder, Colorado, 80309, United States"
NCT04468919,Optimizing BCI-FIT: Brain Computer Interface - Functional Implementation Toolkit,https://beta.clinicaltrials.gov/study/NCT04468919,RECRUITING,Amyotrophic Lateral Sclerosis|Brainstem Stroke|Muscular Dystrophies|Parkinson's Disease and Parkinsonism|Multiple System Atrophy|Brain Tumor Adult|Spinal Cord Injuries|Locked-in Syndrome,BEHAVIORAL: BCI-FIT multi-modal access|BEHAVIORAL: BCI-FIT adaptive signal modeling|BEHAVIORAL: BCI-FIT active querying|BEHAVIORAL: BCI-FIT language modeling,Oregon Health and Science University,,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2022-07-15,2025-06-30,2025-06-30,"Oregon Health & Science University, Portland, Oregon, 97239, United States"
NCT04908085,Creating Satisfying Engagement in Daily Life Through Coaching for People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04908085,COMPLETED,Multiple Sclerosis|Quality of Life,BEHAVIORAL: Occupational Performance Coaching,Queen's University,,ALL,"ADULT, OLDER_ADULT",NA,31,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-10-01,2022-06-30,2022-06-30,"Queen's University, Kingston, Ontario, K7L 3N6, Canada"
NCT03552185,Depicting Neurogenic Dysphagia in Multiple Sclerosis Patients; Clinical and Endoscopic Studies,https://beta.clinicaltrials.gov/study/NCT03552185,COMPLETED,Multiple Sclerosis,,Kasr El Aini Hospital,,ALL,ADULT,,100,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-01-01,2018-06-15,2018-06-15,"Kasralainy hospital, Cairo, 11562, Egypt"
NCT04975685,Strengthening Mental Abilities With Relational Training (SMART) in Multiple Sclerosis (MS): A Feasibility Trial,https://beta.clinicaltrials.gov/study/NCT04975685,NOT_YET_RECRUITING,Multiple Sclerosis,BEHAVIORAL: SMART|BEHAVIORAL: Sham brain training (Sudoku),University of Lincoln,"University of Exeter|Nottinghamshire Healthcare NHS Trust|National University of Ireland, Maynooth|University of Nottingham",ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-10-01,2023-04-30,2023-04-30,
NCT04838886,The Effect of Telerehabilitation Based Pilates Training in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT04838886,COMPLETED,Multiple Sclerosis,OTHER: Telerehabilitation-based Pilates Exercise,Gazi University,,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-04-15,2022-05-15,2022-05-25,"Gazi University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Ankara, Turkey"
NCT01805986,Investigation of GM Pathology Using Ultra High Field (7T) MRI Scanner,https://beta.clinicaltrials.gov/study/NCT01805986,UNKNOWN,Multiple Sclerosis,,University of Nottingham,,ALL,"ADULT, OLDER_ADULT",,100,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-03,2014-02,2015-02,
NCT02506751,Open-label Study of Liothyronine in MS,https://beta.clinicaltrials.gov/study/NCT02506751,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis, Secondary Progressive|Multiple Sclerosis, Primary Progressive",DRUG: liothyronine,Johns Hopkins University,,ALL,ADULT,PHASE1,20,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-07,2017-09-18,2017-09-18,"The Johns Hopkins Hospital, Baltimore, Maryland, 21287, United States"
NCT05225012,Providing Emotional Support Around the Point of Multiple Sclerosis Diagnosis: PrEliMS 2,https://beta.clinicaltrials.gov/study/NCT05225012,RECRUITING,Multiple Sclerosis,OTHER: Acceptance and Commitment Therapy,University of Nottingham,,ALL,"ADULT, OLDER_ADULT",NA,14,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-08-12,2023-02,2023-09,"Queens Medical Hospital, Nottingham, NG7 2UH, United Kingdom"
NCT03825055,Resilience in Young Adults Newly Diagnosed With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03825055,COMPLETED,Multiple Sclerosis,,Universita di Verona,Azienda Ospedaliera Universitaria Integrata Verona|Fondazione Italiana Sclerosi Multipla|Federico II University,ALL,ADULT,,51,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-02-26,2022-03-31,2022-03-31,"Azienda Ospedaliera Universitaria Integrata Verona, Policlinico G.B. Rossi, Verona, Veneto, 37134, Italy"
NCT04944251,Regular Exercise Improves Physical Capacity and Promotes Neurotrophins in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04944251,COMPLETED,Multiple Sclerosis|Exercise Intervention|Neuro-Degenerative Disease,BEHAVIORAL: Regular Exercise,Ege University,,ALL,ADULT,NA,43,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2019-04-01,2019-12-01,2020-01-19,"Ege University, Izmir, Bornova, 35100, Turkey"
NCT05451251,Deep Brain Stimulation for Refractory Trigeminal Neuralgia With a Demyelinating Pontine Lesion,https://beta.clinicaltrials.gov/study/NCT05451251,NOT_YET_RECRUITING,Trigeminal Neuralgia,DEVICE: Deep brain stimulation,Université de Sherbrooke,,ALL,"ADULT, OLDER_ADULT",NA,6,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-10,2024-10,2025-02,
NCT01417312,Metabolic Effects of a Green Tea Extract in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT01417312,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DIETARY_SUPPLEMENT: Capsules with 160 mg Teavigo (at least 94% EGCG)|DIETARY_SUPPLEMENT: Placebo,"Charite University, Berlin, Germany",,ALL,ADULT,NA,20,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2011-07,2012-11,2013-01,"Franz-Volhard Clinical Research Center at the Experimental and Clinical Research Center, Charité University Medicine Berlin and Max Delbrueck Center for Molecular Medicine, Berlin, 13125, Germany"
NCT00257855,A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00257855,COMPLETED,Secondary Progressive Multiple Sclerosis,DRUG: Lamotrigine,University College London Hospitals,,ALL,ADULT,PHASE2,120,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,2005-11,2009-01,2009-02,"National Hospital for Neurology and Neurosurgery, London, WC1 3BG, United Kingdom"
NCT01538355,A Pilot Trial to Test the Feasibility of Prolonged Fasting and Ketogenic Diet in Relapsing-remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01538355,COMPLETED,Relapsing-Remitting Multiple Sclerosis,OTHER: Prolonged Fasting|OTHER: Ketogenic low glycemic load treatment|OTHER: Control diet,"Charite University, Berlin, Germany",,ALL,"ADULT, OLDER_ADULT",NA,48,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2012-07-30,2013-02-28,2020-06-23,"Charité-Universitätsmedizin, Berlin, 10117, Germany"
NCT00780455,Rehabilitation Study in MS Patients,https://beta.clinicaltrials.gov/study/NCT00780455,TERMINATED,"Multiple Sclerosis, Relapsing-Remitting","DRUG: Interferon beta-1b, FRP within 15 days after randomization|DRUG: Interferon beta-1b, FRP about 6 weeks after randomization",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE4,4,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2008-10,2009-09,2009-09,"Rennes, Bretagne, 35038, France|Avignon, 84025, France|Lille, 59037, France|Lomme, 59160, France|Montpellier, 34295, France|Mulhouse, 68051, France|Nimes, 30029, France|Quimper, 29000, France|Reims Cedex, 51091, France|Toulouse, 31059, France"
NCT00866112,A Randomized Exercise Trial for Wheelchair Users,https://beta.clinicaltrials.gov/study/NCT00866112,COMPLETED,Spinal Cord Injury|Multiple Sclerosis|Muscular Dystrophy|Cerebral Palsy|Spina Bifida|Amputation|Arthritis|Stroke,OTHER: Educational session to promote physical activity|OTHER: Minimal contact,University of Kansas,,ALL,"ADULT, OLDER_ADULT",NA,135,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: ",2008-05,2011-02,2012-06,"University of Kansas, Lawrence, Kansas, 66045, United States"
NCT04019912,The Novel Use of Treadmill Plus Music in MS Patients Gate Rehabilitation,https://beta.clinicaltrials.gov/study/NCT04019912,UNKNOWN,Interventional Study,OTHER: Gait Training plus music|OTHER: Traditional Gait Training,"IRCCS Centro Neurolesi ""Bonino-Pulejo""",,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-10-01,2020-03-30,2020-05,"IRCCS Neurolesi, Messina, Sicily, 98124, Italy"
NCT00278655,Hematopoietic Stem Cell Therapy for Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00278655,TERMINATED,Multiple Sclerosis,BIOLOGICAL: Hematopoietic stem cell transplantation,Northwestern University,,ALL,ADULT,PHASE1|PHASE2,21,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2003-06,2011-12,2012-05,
NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),https://beta.clinicaltrials.gov/study/NCT04458051,RECRUITING,Primary Progressive Multiple Sclerosis,DRUG: Tolebrutinib|DRUG: Placebo,Sanofi,,ALL,ADULT,PHASE3,990,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-08-13,2024-08,2024-08,"Arcadia Neurology Center-Site Number:8400070, Arcadia, California, 91006, United States|UC San Diego ACTRI-Site Number:8400101, La Jolla, California, 92037, United States|Collaborative Neuroscience Research-Site Number:8400045, Long Beach, California, 90806, United States|Multiple Sclerosis Center of California-Site Number:8400135, Newport Beach, California, 92663, United States|University of San Francisco, Sandler Neurosciences Center-Site Number:8400137, San Francisco, California, 94158, United States|Harbor UCLA-Site Number:8400088, Torrance, California, 90502, United States|University of Colorado-Site Number:8400012, Denver, Colorado, 80262, United States|Advanced Neurosciences Research-Site Number:8400025, Fort Collins, Colorado, 80528, United States|South Florida Neurology Associates-Site Number:8400029, Boca Raton, Florida, 33487, United States|University of Florida, Fixel Center for Neurology-Site Number:8400159, Gainesville, Florida, 32601, United States|Neurology Associates, PA-Site Number:8400004, Maitland, Florida, 32761, United States|University of South Florida-Site Number:8400006, Tampa, Florida, 33612, United States|Meridian Clinical Research-Site Number:8400003, Savannah, Georgia, 31406, United States|Hawaii Pacific Neuroscience-Site Number:8400103, Honolulu, Hawaii, 96817, United States|Consultants In Neurology-Site Number:8400011, Northbrook, Illinois, 60062, United States|Prairie Education and Research Cooperative-Site Number:8400071, Springfield, Illinois, 62701, United States|Methodist Hospital-Site Number:8400164, Merrillville, Indiana, 46410, United States|College Park Family Care Certer-Site Number:8400044, Overland Park, Kansas, 66212, United States|University of Kentucky-Site Number:8400106, Lexington, Kentucky, 40536, United States|Ochsner Baptist Clinical Trials Unit (CTU)-Site Number:8400107, New Orleans, Louisiana, 70121, United States|International Neurorehabilitation Institute-Site Number:8400034, Lutherville-Timonium, Maryland, 21093, United States|Tufts Medical Center-Site Number:8400072, Boston, Massachusetts, 02111, United States|Beth Israel Deaconess Medical Center-Site Number:8400143, Boston, Massachusetts, 02215, United States|University of Massachusetts-Site Number:8400014, Worcester, Massachusetts, 01655, United States|Wayne State University-Site Number:8400046, Detroit, Michigan, 48201, United States|Michigan Institute For Neurological Disorders-Site Number:8400058, Farmington Hills, Michigan, 48334, United States|The Memorial Hospital-Site Number:8400033, Owosso, Michigan, 48867, United States|Mayo Clinic-Site Number:8400111, Rochester, Minnesota, 55905, United States|Saint Luke's Hospital-Site Number:8400153, Kansas City, Missouri, 64111, United States|Sharlin Health & Neurology-Site Number:8400093, Ozark, Missouri, 65721, United States|University Of Nebraska-Site Number:8400129, Omaha, Nebraska, 68198, United States|Hackensack University Hospital-Site Number:8400047, Hackensack, New Jersey, 07601, United States|Icahn School of Medicine at Mount Sinai (Department of Endoc-Site Number:8400038, New York, New York, 10029-6501, United States|Neurology Associates of Stony Brook-Site Number:8400042, Stony Brook, New York, 11794, United States|Novant Health Multiple Sclerosis Care Center - South Park-Site Number:8400120, Charlotte, North Carolina, 28210, United States|Duke Neurological Disorders Clinic-Site Number:8400098, Durham, North Carolina, 27710, United States|Meridian Clinical Research, LLC-Site Number:8400005, Raleigh, North Carolina, 27607, United States|Wake Forest University Baptist Medical Center-Site Number:8400116, Winston-Salem, North Carolina, 27157, United States|Cleveland Clinic-Site Number:8400125, Cleveland, Ohio, 44195, United States|The Ohio State University Wexner Medical Center-Site Number:8400150, Columbus, Ohio, 43221, United States|Optimed Research, LTD-Site Number:8400147, Columbus, Ohio, 43235, United States|Providence Multiple Sclerosis Center-Site Number:8400020, Portland, Oregon, 97225, United States|Jefferson Neurology Associates-Site Number:8400016, Philadelphia, Pennsylvania, 19107, United States|Mountain View Clinical Research-Site Number:8400024, Greer, South Carolina, 29651-1817, United States|Advanced Neuroscience Center-Site Number:8400035, Franklin, Tennessee, 37064, United States|Mt Olympus Medical Research-Site Number:8400163, Katy, Texas, 77450, United States|Neurology Center of San Antonio-Site Number:8400036, San Antonio, Texas, 78258, United States|Wheaton Franciscan Healthcare-Site Number:8400022, Milwaukee, Wisconsin, 53215, United States|Medical College of Wisconsin-Site Number:8400028, Milwaukee, Wisconsin, 53226, United States|Investigational Site Number :0320002, Caba, Buenos Aires, C1012AAR, Argentina|Investigational Site Number :0320004, Caba, Buenos Aires, C1023AAB, Argentina|Investigational Site Number :0320003, Rosario, Santa Fe, 2000, Argentina|Investigational Site Number :0360005, Concord, New South Wales, 2139, Australia|Investigational Site Number :0360006, St Leonards, New South Wales, 2065, Australia|Investigational Site Number :0360003, Hobart, Tasmania, 7001, Australia|Investigational Site Number :0400004, Linz, 4021, Austria|Investigational Site Number :0400002, Wien, 1090, Austria|Investigational Site Number :1120004, Vitebsk, 210009, Belarus|Investigational Site Number :1120005, Vitebsk, 210037, Belarus|Investigational Site Number :0560009, Bruxelles, 1070, Belgium|Investigational Site Number :0560007, Bruxelles, 1200, Belgium|Investigational Site Number :0560003, Edegem, B-2650, Belgium|Investigational Site Number :0560004, Gent, 9000, Belgium|Investigational Site Number :0560006, Leuven, 3000, Belgium|Investigational Site Number :0560008, Liège, 4000, Belgium|Investigational Site Number :0560002, Mons, 7000, Belgium|Investigational Site Number :0560001, Pelt, 3900, Belgium|Investigational Site Number :1000002, Pleven, 5800, Bulgaria|Investigational Site Number :1000004, Sofia, 1113, Bulgaria|Investigational Site Number :1000008, Sofia, 1407, Bulgaria|Investigational Site Number :1000001, Sofia, 1431, Bulgaria|Investigational Site Number :1240002, Edmonton, Alberta, T6G 2C8, Canada|Investigational Site Number :1240003, Ottawa, Ontario, K1H 8L6, Canada|Investigational Site Number :1240013, Toronto, Ontario, M5B 1W8, Canada|Investigational Site Number :1240004, Montreal, Quebec, H2X 0A9, Canada|Investigational Site Number :1240015, Montreal, Quebec, H3A 2B4, Canada|Investigational Site Number :1240007, Sherbrooke, Quebec, J1H 5N4, Canada|Investigational Site Number :1240001, Quebec, G1J 1Z4, Canada|Investigational Site Number :1240021, Quebec, G1W 4R4, Canada|Investigational Site Number :1520006, Concepcion, Biobío, 4070038, Chile|Investigational Site Number :1520002, Santiago, Reg Metropolitana De Santiago, 7650568, Chile|Investigational Site Number :1520001, Santiago, Reg Metropolitana De Santiago, 8380456, Chile|Investigational Site Number :1560012, Beijing, 100053, China|Investigational Site Number :1560021, Beijing, 100700, China|Investigational Site Number :1560003, Beijing, 100730, China|Investigational Site Number :1560009, Beijing, 100730, China|Investigational Site Number :1560025, Beijing, 100730, China|Investigational Site Number :1560004, Changchun, 130021, China|Investigational Site Number :1560015, Changsha, 410008, China|Investigational Site Number :1560005, Chengdu, 610041, China|Investigational Site Number :1560035, Fuzhou, 350005, China|Investigational Site Number :1560002, Guangzhou, 510630, China|Investigational Site Number :1560027, Hohhot, 010050, China|Investigational Site Number :1560001, Shanghai, 200040, China|Investigational Site Number :1560008, Taiyuan, 030001, China|Investigational Site Number :1560020, Tianjin, 300052, China|Investigational Site Number :1560026, Wenzhou, 325000, China|Investigational Site Number :1700001, Bogota, Colombia|Investigational Site Number :1700003, Bogotá, D.C., 111321, Colombia|Investigational Site Number :1910001, Zagreb, 10000, Croatia|Investigational Site Number :1910002, Zagreb, 10000, Croatia|Investigational Site Number :2030002, Brno, 65691, Czechia|Investigational Site Number :2030004, Hradec Kralove, 50005, Czechia|Investigational Site Number :2030001, Jihlava, 58633, Czechia|Investigational Site Number :2030003, Teplice, 415 29, Czechia|Investigational Site Number :2080001, Esbjerg, 6700, Denmark|Investigational Site Number :2080005, Holstebro, 7500, Denmark|Investigational Site Number :2330001, Tallinn, 11315, Estonia|Investigational Site Number :2500011, Bron, 69500, France|Investigational Site Number :2500005, Clermont Ferrand, 63003, France|Investigational Site Number :2500015, Gonesse, 95500, France|Investigational Site Number :2500009, Lille, 59037, France|Investigational Site Number :2500006, Montpellier, 34295, France|Investigational Site Number :2500008, Nancy, 54035, France|Investigational Site Number :2500017, Nimes, 30029, France|Investigational Site Number :2500014, Paris, 75013, France|Investigational Site Number :2500007, Paris, 75019, France|Investigational Site Number :2500004, Poissy, 78300, France|Investigational Site Number :2500003, Rennes, 35033, France|Investigational Site Number :2500001, Strasbourg, 67098, France|Investigational Site Number :2500012, Toulouse, 31059, France|Investigational Site Number :2680006, Tbilisi, 0112, Georgia|Investigational Site Number :2680005, Tbilisi, 0114, Georgia|Investigational Site Number :2680003, Tbilisi, 0160, Georgia|Investigational Site Number :2680004, Tbilisi, 0172, Georgia|Investigational Site Number :2760005, Bayreuth, 95445, Germany|Investigational Site Number :2760009, Berlin, 10117, Germany|Investigational Site Number :2760015, Berlin, 10713, Germany|Investigational Site Number :2760020, Bochum, 44791, Germany|Investigational Site Number :2760001, Dresden, 01307, Germany|Investigational Site Number :2760021, Düsseldorf, 40225, Germany|Investigational Site Number :2760012, Essen, 45147, Germany|Investigational Site Number :2760002, Gießen, 35385, Germany|Investigational Site Number :2760010, Halle (Saale), 06120, Germany|Investigational Site Number :2760006, Hannover, 30625, Germany|Investigational Site Number :2760018, München, 81377, Germany|Investigational Site Number :2760008, Münster, 48149, Germany|Investigational Site Number :2760004, Rostock, 18055, Germany|Investigational Site Number :2760011, Ulm, 89081, Germany|Investigational Site Number :3000001, Athens, 115 28, Greece|Investigational Site Number :3000006, Athens, 11535, Greece|Investigational Site Number :3000002, Athens, 12462, Greece|Investigational Site Number :3000007, Athens, 15125, Greece|Investigational Site Number :3000004, Larissa, 41110, Greece|Investigational Site Number :3000003, Thessaloniki, 546 36, Greece|Investigational Site Number :3000009, Thessaloniki, 55236, Greece|Investigational Site Number :3480202, Budapest, 1145, Hungary|Investigational Site Number :3480205, Budapest, 1152, Hungary|Investigational Site Number :3480204, Kistarcsa, 2143, Hungary|Investigational Site Number :3480203, Tatabánya, 2800, Hungary|Investigational Site Number :3560007, Gurgaon, 122001, India|Investigational Site Number :3560003, Gurgaon, 122002, India|Investigational Site Number :3560004, Mangaluru, 575018, India|Investigational Site Number :3560005, New Delhi, 110029, India|Investigational Site Number :3560002, New Delhi, 110060, India|Investigational Site Number :3760002, Ashkelon, 78278, Israel|Investigational Site Number :3760008, Jerusalem, 91120, Israel|Investigational Site Number :3760001, Ramat Gan, 5265601, Israel|Investigational Site Number :3760004, Safed, 13100, Israel|Investigational Site Number :3800002, Pozzilli, Isernia, 86077, Italy|Investigational Site Number :3800007, Cagliari, 09126, Italy|Investigational Site Number :3800015, Catania, 95123, Italy|Investigational Site Number :3800018, Chieti, 66100, Italy|Investigational Site Number :3800016, Firenze, 50134, Italy|Investigational Site Number :3800001, Milano, 20132, Italy|Investigational Site Number :3800003, Napoli, 80131, Italy|Investigational Site Number :3800006, Napoli, 80131, Italy|Investigational Site Number :3800004, Padova, 35128, Italy|Investigational Site Number :3800013, Roma, 00189, Italy|Investigational Site Number :3920016, Chiba-shi, Chiba, 260-8677, Japan|Investigational Site Number :3920008, Koriyama-shi, Fukushima, 963-8052, Japan|Investigational Site Number :3920022, Morioka-shi, Iwate, 020-8505, Japan|Investigational Site Number :3920011, Kyoto-shi, Kyoto, 616-8255, Japan|Investigational Site Number :3920020, Sendai-shi, Miyagi, 980-8574, Japan|Investigational Site Number :3920005, Niigata-shi, Niigata, 951-8520, Japan|Investigational Site Number :3920004, Moriguchi-shi, Osaka, 570-8507, Japan|Investigational Site Number :3920001, Osaka-shi, Osaka, 556-0016, Japan|Investigational Site Number :3920018, Kawagoe-shi, Saitama, 350-8550, Japan|Investigational Site Number :3920014, Bunkyo-ku, Tokyo, 113-8431, Japan|Investigational Site Number :3920003, Kodaira-shi, Tokyo, 187-8551, Japan|Investigational Site Number :3920010, Ota-ku, Tokyo, 146-0065, Japan|Investigational Site Number :3920017, Shinjuku-ku, Tokyo, 160-8582, Japan|Investigational Site Number :3920015, Toyama-shi, Toyama, 930-0194, Japan|Investigational Site Number :3920009, Ube-shi, Yamaguchi, 755-8505, Japan|Investigational Site Number :3920023, Sagamihara-shi, 252-0392, Japan|Investigational Site Number :4280002, Riga, LV-1002, Latvia|Investigational Site Number :4280003, Riga, LV-1005, Latvia|Investigational Site Number :4840004, Guadalajara, Jalisco, 44670, Mexico|Investigational Site Number :4840001, Cdmx, México, 06700, Mexico|Investigational Site Number :4840005, Cdmx, México, 14050, Mexico|Investigational Site Number :4840006, Monterrey, Nuevo León, 64718, Mexico|Investigational Site Number :4840003, Veracruz, 91910, Mexico|Investigational Site Number :5280003, Breda, 4818 CK, Netherlands|Investigational Site Number :5280006, Groningen, 9728 NZ, Netherlands|Investigational Site Number :5280002, Sittard-Geleen, 6162 BG, Netherlands|Investigational Site Number :5780003, Bergen, 5021, Norway|Investigational Site Number :5780005, Tromsø, 9038, Norway|Investigational Site Number :6040004, Lima, 15084, Peru|Investigational Site Number :6160003, Bydgoszcz, Kujawsko-pomorskie, 85-796, Poland|Investigational Site Number :6160001, Lodz, Lódzkie, 90-549, Poland|Investigational Site Number :6160005, Warszawa, Mazowieckie, 01-211, Poland|Investigational Site Number :6160006, Warszawa, Mazowieckie, 01-684, Poland|Investigational Site Number :6160002, Katowice, Slaskie, 40-571, Poland|Investigational Site Number :6160007, Katowice, Slaskie, 40-684, Poland|Investigational Site Number :6160004, Katowice, Slaskie, 40-686, Poland|Investigational Site Number :6200001, Braga, 4710-243, Portugal|Investigational Site Number :6200016, Leiria, 2410-197, Portugal|Investigational Site Number :6200007, Lisboa, 1349-019, Portugal|Investigational Site Number :6200012, Lisboa, 1500-650, Portugal|Investigational Site Number :6200002, Matosinhos, 4464-513, Portugal|Investigational Site Number :6200010, Porto, 4099-001, Portugal|Investigational Site Number :6200004, Santa Maria da Feira, 4520-211, Portugal|Investigational Site Number :6420008, Bucuresti, 022328, Romania|Investigational Site Number :6420004, Campulung, 115100, Romania|Investigational Site Number :6420003, Constanta, 900123, Romania|Investigational Site Number :6420013, Oradea, 410154, Romania|Investigational Site Number :6420001, Targu Mures, 540136, Romania|Investigational Site Number :6420002, Timisoara, 300736, Romania|Investigational Site Number :6430018, Barnaul, 656024, Russian Federation|Investigational Site Number :6430022, Ekaterinburg, 620102, Russian Federation|Investigational Site Number :6430023, Kaliningrad, 236035, Russian Federation|Investigational Site Number :6430004, Kazan, 420032, Russian Federation|Investigational Site Number :6430019, Kirov, 610998, Russian Federation|Investigational Site Number :6430021, Krasnoyarsk, 660029, Russian Federation|Investigational Site Number :6430013, Moscow, 117997, Russian Federation|Investigational Site Number :6430011, Moscow, 129128, Russian Federation|Investigational Site Number :6430014, Nizhny Novgorod, 603137, Russian Federation|Investigational Site Number :6430008, Pyatigorsk, 357538, Russian Federation|Investigational Site Number :6430015, Rostov-on-Don, 344022, Russian Federation|Investigational Site Number :6430017, Saint-Petersburg, 197376, Russian Federation|Investigational Site Number :6430009, Samara, 443095, Russian Federation|Investigational Site Number :6430020, Saransk, 430032, Russian Federation|Investigational Site Number :6430007, Tyumen, 625000, Russian Federation|Investigational Site Number :6430006, Ufa, 450005, Russian Federation|Investigational Site Number :6880001, Belgrade, 11000, Serbia|Investigational Site Number :6880002, Kragujevac, 34000, Serbia|Investigational Site Number :6880004, Nis, 18000, Serbia|Investigational Site Number :7100001, Pretoria, 0041, South Africa|Investigational Site Number :7240012, La Coruña, A Coruña [La Coruña], 15006, Spain|Investigational Site Number :7240015, Santiago de Compostela, A Coruña [La Coruña], 15706, Spain|Investigational Site Number :7240007, Sevilla, Andalucia, 41009, Spain|Investigational Site Number :7240010, Barcelona, Barcelona [Barcelona], 08035, Spain|Investigational Site Number :7240013, Bilbao, Bizkaia, 48013, Spain|Investigational Site Number :7240011, Salt, Girona [Gerona], 17190, Spain|Investigational Site Number :7240016, Las Palmas de Gran Canaria, Las Palmas, 35010, Spain|Investigational Site Number :7240002, Majadahonda, Madrid, 28222, Spain|Investigational Site Number :7240001, Pozuelo De Alarcón, Madrid, 28223, Spain|Investigational Site Number :7240004, Córdoba, 14004, Spain|Investigational Site Number :7240003, Madrid, 28007, Spain|Investigational Site Number :7240005, Malaga, 29010, Spain|Investigational Site Number :7240006, Murcia, 30120, Spain|Investigational Site Number :7240014, Palma de Mallorca, 07120, Spain|Investigational Site Number :7240008, Valencia, 46026, Spain|Investigational Site Number :7520001, Göteborg, 413 45, Sweden|Investigational Site Number :7520005, Motala, 591 85, Sweden|Investigational Site Number :7560003, Aarau, 5001, Switzerland|Investigational Site Number :7560002, Bern, 3010, Switzerland|Investigational Site Number :7920009, Ankara, 06100, Turkey|Investigational Site Number :7920014, Ankara, 06500, Turkey|Investigational Site Number :7920005, Eskisehir, Turkey|Investigational Site Number :7920010, Hatay, Turkey|Investigational Site Number :7920016, Istanbul, 34093, Turkey|Investigational Site Number :7920002, Istanbul, 34303, Turkey|Investigational Site Number :7920007, Istanbul, 34785, Turkey|Investigational Site Number :7920006, Istanbul, 34896, Turkey|Investigational Site Number :7920003, Istanbul, Turkey|Investigational Site Number :7920015, Izmir, 35100, Turkey|Investigational Site Number :7920001, Izmit, 41380, Turkey|Investigational Site Number :7920011, Kutahya, 43100, Turkey|Investigational Site Number :7920012, Mersin, 33070, Turkey|Investigational Site Number :7920013, Samsun, Turkey|Investigational Site Number :7920008, Trabzon, 61080, Turkey|Investigational Site Number :8040020, Chernivtsi, 58023, Ukraine|Investigational Site Number :8040022, Ivano-Frankivsk, 76018, Ukraine|Investigational Site Number :8040012, Ivano-Frankivsk, 76493, Ukraine|Investigational Site Number :8040017, Kharkiv, 61068, Ukraine|Investigational Site Number :8040025, Kharkiv, 61068, Ukraine|Investigational Site Number :8040014, Kharkiv, 61103, Ukraine|Investigational Site Number :8040023, Kharkiv, 61103, Ukraine|Investigational Site Number :8040013, Kyiv, 02091, Ukraine|Investigational Site Number :8040015, Kyiv, 03115, Ukraine|Investigational Site Number :8040011, Lutsk, 43005, Ukraine|Investigational Site Number :8040002, Lviv, 79010, Ukraine|Investigational Site Number :8040007, Lviv, 79013, Ukraine|Investigational Site Number :8040010, Odesa, 65025, Ukraine|Investigational Site Number :8040004, Vinnytsia, 21050, Ukraine|Investigational Site Number :8040024, Vinnytsya, 21001, Ukraine|Investigational Site Number :8040008, Zhytormyr, 10002, Ukraine|Investigational Site Number :8260006, London, London, City Of, EC1M 6BQ, United Kingdom|Investigational Site Number :8260005, London, London, City Of, SW17 0QT, United Kingdom|Investigational Site Number :8260010, Swansea, Neath Port Talbot, SA6 6NL, United Kingdom|Investigational Site Number :8260012, Nottingham, Nottinghamshire, NG7 2UH, United Kingdom|Investigational Site Number :8260013, Oxford, Oxfordshire, OX3 9DU, United Kingdom|Investigational Site Number :8260001, Cardiff, Vale Of Glamorgan, The, CF4 4XY, United Kingdom|Investigational Site Number :8260019, Salford, M6 8HD, United Kingdom"
NCT04887051,The Effects of Respiratory-based Telerehabilitaion in Patients With MS,https://beta.clinicaltrials.gov/study/NCT04887051,UNKNOWN,"Multiple Sclerosis|Telerehabilitation|Compliance, Patient",OTHER: pulmonory based home exercises,Dr. Anıl Tosun,Trakya University,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-04-16,2021-06-30,2021-08-30,"Fenerbahce University, Istanbul, 34758, Turkey"
NCT04792866,3D FLAIR Versus Coronal T2-WI MRI in Detecting Optic Neuritis (FLACON),https://beta.clinicaltrials.gov/study/NCT04792866,COMPLETED,Optic Neuritis|Multiple Sclerosis|Encephalopathy,DIAGNOSTIC_TEST: Magnetic Resonance Imaging,Fondation Ophtalmologique Adolphe de Rothschild,,ALL,"ADULT, OLDER_ADULT",,1200,NETWORK,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-01-01,2020-03-01,2020-08-01,"Hôpital Fondation Adolphe de Rothschild, Paris, Ile-de-France, 75019, France"
NCT01864148,"Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex",https://beta.clinicaltrials.gov/study/NCT01864148,COMPLETED,Multiple Sclerosis,DRUG: BIIB033|OTHER: Placebo|DRUG: Avonex,Biogen,,ALL,ADULT,PHASE2,419,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2013-08,2015-12,2016-03,"North Central Neurology Assoc PC, Cullman, Alabama, 35058, United States|Phoenix Neurological Associates, Phoenix, Arizona, 85018, United States|Raleigh Neurology Associates PA, Raleigh, California, 27607-6000, United States|Stanford University Medical Center, Stanford, California, 94305, United States|Immunoe International Research Center, Centennial, Colorado, 80112, United States|Johns Hopkins Hospital, Baltimore, Maryland, 21287, United States|Michigan Institute For Neurological Disorders, Farmington Hills, Michigan, 48334, United States|Washington University, Saint Louis, Missouri, 63110, United States|Multiple Sclerosis Center of North Eastern New York, Latham, New York, 12110, United States|OMRF Multiple Sclerosis Center of Excellence, Oklahoma City, Oklahoma, 73104, United States|Swedish Medical Center, Seattle, Washington, 98122, United States|Research Site, Ottowa, Ontario, Canada|Research Site, Gatinueau, Quebec, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Levis, Quebec, Canada|Research Site, Montreal, Quebec, Canada|London Health Sciences Centre, London, N6A 5A5, Canada|Vseobecna Fakultni Nemocnice V Praze, Praha, Hlavní Mesto, 128 08, Czech Republic|Fakultni Nemocnice Hradec Kralove, Hradec Králové, Královéhradecký kraj, 500 05, Czech Republic|Nemocnice Jihlava Prispevkova Organizace, Jihlava, Vysocina, 586 33, Czech Republic|NEUROSPOL Sro, Havirov, 736 01, Czech Republic|Fakultni nemocnice v Motole, Praha 5, 150 06, Czech Republic|Krajska Zdravotni a.s. Nemocnice Teplice Oz, Teplice, Ústecký kraj, 415 29, Czech Republic|Hôpital Guillaume Et René Laënnec, Nantes, Loire-Atlantique, 44805, France|Hôpital Maison Blanche, Reims, Marne, 51092, France|Hôpital Roger Salengro, Lille, Nord, 59000, France|Hôpital Sud, Amiens, Somme, 80054, France|Hopital Gabriel Montpied, Clermont-Ferrand, 63003, France|CHRU Nancy, Nancy, 54000, France|Fondation Rothschild, Paris, 75019, France|Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ, Szeged, Csongrád, 6725, Hungary|Uzsoki Utcai Korhaz, Budapest, 1145, Hungary|Jahn Ferenc Dél-Pesti Kórház és Rendelöintézet, Budapest, 1204, Hungary|Pécsi Tudományegyetem, Pécs, 7623, Hungary|Azienda Ospedaliera Universitaria San Martino, Genova, Liguria, 16132, Italy|Ospedale San Raffaele S.r.l., Milano, Lombardia, 20127, Italy|Azienda Ospedaliera Spedali Civili di Brescia - Presidio Ospedaliero di Montichiari, Montichiari, Lombardia, 25018, Italy|Fondazione Istituto San Raffaele G. Giglio di Cefalù, Cefalù, Palermo, 90015, Italy|Azienda Ospedaliero Universitaria Policlinico-Vittorio Emanuele, Catania, Sicilia, 95123, Italy|Azienda Ospedaliera S. Antonio Abate di Gallarate, Gallarate, Varese, 21013, Italy|Erasmus MC, Rotterdam, Zuid-Holland, 3015 CE, Netherlands|Zuyderland Medisch Centrum, Sittard-Geleen, 6162 BG, Netherlands|Centrum Neurologii K. Selmaj, Lódz, Lódzkie, 93-121, Poland|Wojskowy Instytut Medyczny, Warszawa, Mazowieckie, 00-901, Poland|Novo-Med Zielinski i wsp. Sp.J., Katowice, Slaskie, 40-650, Poland|Pomorskie Centrum Traumatologii im. M. Kopernika w Gdansku, Gdansk, 80-803, Poland|Regionalny Szpital Specjalistyczny im. dr Wladyslawa Bieganskiego, Grudziądz, 86-300, Poland|M.A.- Lek A.M.Maciejowscy Spolka Cywilna, Katowice, 40-595, Poland|Gabriela Klodowska-Duda Neuro-Care NZOZ Site Management Organization, Katowice, 40-749, Poland|Neurologiczny NZOZ Centrum Leczenia SM Osrodek Badan Klinicznych Dr n. med. Hanka Hertmanowska, Plewiska, 62-064, Poland|Niepubliczny Zaklad Opieki Zdrowotnej NEURO-KARD Ilkowski i Partnerzy Spolka Partnerska Lekarzy, Poznan, 61-853, Poland|SPZOZ Wojewodzki Szpital Specjalistyczny w Rybniku, Rybnik, 44-200, Poland|EUROMEDIS Sp. z o.o., Szczecin, 70-215, Poland|Kaluga Regional Hospital, Kaluga, 248007, Russian Federation|Republican Clinical Hospital For Rehabilitation Treatment, Kazan, 420021, Russian Federation|Krasnoyarsk State Medical Academy, Krasnoyarsk, 660049, Russian Federation|Perm State Medical Academy, Perm, 614990, Russian Federation|City Center of MS Treatment based on Saint-Petersburg City Clinical Hospital #31, Saint-Petersburg, 197110, Russian Federation|Regional Clinical Hospital #3, Volgograd, 400001, Russian Federation|Clinical Center of Serbia, Belgrade, 11000, Serbia|Military Medical Academy, Belgrade, 11000, Serbia|Clinical Center Kragujevac, Kragujevac, 34000, Serbia|General Hospital Uzice, Uzice, 31000, Serbia|Hospital Universitari de Bellvitge, l Hospitalet de Llobregat, Barcelona, 8907, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Cataluña, 8035, Spain|Hospital Universitario Reina Sofia, Cordoba, Córdoba, 14008, Spain|Hospital Clinico San Carlos, Madrid, Madrid, Communidad Delaware, 28040, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, 28222, Spain|Hospital de Basurto Osakidetza, Bilbao, Vizcaya, 48013, Spain|Hospital General Carlos Haya, Malaga, 29010, Spain|Hospital Universitario Virgen Macarena, Sevilla, 41071, Spain|Queen's Medical Centre, Nottingham, Nottinghamshire, NG5 1PB, United Kingdom"
NCT05044819,Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution,https://beta.clinicaltrials.gov/study/NCT05044819,RECRUITING,Lennox Gastaut Syndrome|Dravet Syndrome|Tuberous Sclerosis Complex,DRUG: Cannabidiol,Jazz Pharmaceuticals,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE4,150,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-07-07,2027-08-01,2028-03-31,"Clinical Trial Site, Downey, California, 90242, United States|Clinical Trial Site, Long Beach, California, 90806, United States|Clinical Trial Site, Los Angeles, California, 90095-1752, United States|Clinical Trial Site, Sacramento, California, 95817, United States|Clinical Trial Site, Loxahatchee Groves, Florida, 33470, United States|Clinical Trial Site, Miami, Florida, 33136, United States|Clinical Trial Site, Miami, Florida, 33155, United States|Clinical Trial Site, Miami, Florida, 33176, United States|Clinical Trial Site, Orlando, Florida, 32806, United States|Clinical Trial Site, Tampa, Florida, 33606, United States|Clinical Trial Site, Atlanta, Georgia, 30329, United States|Clinical Trial Site, Augusta, Georgia, 30912, United States|Clinical Trial Site, Lexington, Kentucky, 40504, United States|Clinical Trial Site, Baltimore, Maryland, 21205, United States|Clinical Trial Site, Boston, Massachusetts, 02114-2743, United States|Clinical Trial Site, New Brunswick, New Jersey, 08901, United States|Clinical Trial Site, New York, New York, 10016, United States|Clinical Trial Site, Asheville, North Carolina, 28806, United States|Clinical Trial Site, Charlotte, North Carolina, 28203, United States|Clinical Trial Site, Durham, North Carolina, 27708, United States|Clinical Trial Site, Cincinnati, Ohio, 45219, United States|Clinical Trial Site, Oklahoma City, Oklahoma, 73104, United States|Clinical Trial Site, Philadelphia, Pennsylvania, 19107, United States|Clinical Trial Site, Charleston, South Carolina, 29425, United States|Clinical Trial Site, Austin, Texas, 78758, United States|Clinical Trial Site, Dallas, Texas, 75251, United States|Clinical Trial Site, Houston, Texas, 77030-3000, United States|Clinical Trial Site, Round Rock, Texas, 78681, United States|Clinical Trial Site, Henrico, Virginia, 23226, United States|Clinical Trial Site, Winchester, Virginia, 22601, United States|Clinical Trial Site, Crab Orchard, West Virginia, 25827, United States"
NCT04075266,A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04075266,RECRUITING,Multiple Sclerosis,DRUG: Ocrelizumab,Hoffmann-La Roche,,ALL,"CHILD, ADULT",PHASE2,36,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-01-09,2023-12-31,2029-12-01,"Loma Linda University health, Loma Linda, California, 92354, United States|University of California San Francisco, San Francisco, California, 94117, United States|University of Colorado Denver Childrens Hospital Rocky Mountain MS Center, Aurora, Colorado, 80045, United States|Childrens National Health Center, Washington, District of Columbia, 20010, United States|University of Louisville Physicians, Louisville, Kentucky, 40202, United States|Boston Childrens Hospital, Boston, Massachusetts, 02115, United States|Washington Universtiy school of Medicine, Saint Louis, Missouri, 63110, United States|Pediatric MS Center at New York University Langone Medical Center, New York, New York, 10016, United States|Stony Brook University Medical Center, Stony Brook, New York, 11794, United States|Akron Childrens Hospital, Akron, Ohio, 44308, United States|Cleveland Clinic, Cleveland, Ohio, 44106, United States|The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States|Ospedale Pediatrico Bambino Gesù; Divisione di Neurologia, Roma, Lazio, 00165, Italy|Azienda Ospedaliera Sant'Andrea; UOC Neurologia, Roma, Lazio, 00189, Italy|Irccs A.O.U.San Martino Ist; Dinogmi, Genova, Liguria, 16132, Italy|Ospedale S.Antonio Abate; Neurologia 2 ? Sclerosi Multipla e Recupero Neurologico, Gallarate, Lombardia, 21013, Italy|IRCCS Ospedale San Raffaele; Neurologia Neurofisiologia Neuroriabilitazione-Centro Sclerosi Multipla, Milano, Lombardia, 20132, Italy|AOU Policlinico V. Emanuele - P.O G. Rodolico; Clinica Neurologica, Centro Sclerosi Multipla, Catania, Sicilia, 95123, Italy|Clinstile S.A de C.V., Mexico City, Mexico CITY (federal District), 06700, Mexico|Instytut Centrum Zdrowia Matki Polki; Klinika Neurologii, ?ód?, 93-338, Poland|Uniwersyteckie Centrum Kliniczne; Klinika Neurologii Rozwojowej, Gda?sk, 80-952, Poland|Uniwersytecki Szpital Kliniczny w Poznaniu; Od. Kliniczny Neurologii Dzieci i M?odziezy, Pozna?, 60-355, Poland|Dzieci?cy Szpital Kliniczny im. Józefa Polikarpa Brudzi?skiego; Klinika Neurologii Dzieciecej, Warszawa, 02-091, Poland|Instytut Pomnik Centrum Zdrowia Dziecka; Klinika Neurologii i Epileptologii, Warszawa, 04-730, Poland"
NCT01228266,Mesenchymal Stem Cell Transplantation in MS,https://beta.clinicaltrials.gov/study/NCT01228266,TERMINATED,Multiple Sclerosis,BIOLOGICAL: autologous mesenchymal stem cells,Albert Saiz,Instituto de Salud Carlos III,ALL,ADULT,PHASE2,9,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2010-12,2013-06,2013-12,"Neurology Service, Hospital Clinic de barcelona, Barcelona, 08036, Spain"
NCT02222948,Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02222948,TERMINATED,Relapsing-remitting Multiple Sclerosis,DRUG: Vatelizumab|DRUG: Placebo (for Vatelizumab),"Genzyme, a Sanofi Company",,ALL,ADULT,PHASE2,112,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-09,2016-04,2016-07,"Investigational Site Number 840004, Cullman, Alabama, 35058, United States|Investigational Site Number 840009, Phoenix, Arizona, 85060, United States|Investigational Site Number 840005, Fort Collins, Colorado, 80528, United States|Investigational Site Number 840014, Washington, District of Columbia, 20037, United States|Investigational Site Number 840007, Ormond Beach, Florida, 32174, United States|Investigational Site Number 840012, Tampa, Florida, 33612, United States|Investigational Site Number 840001, Latham, New York, 12210, United States|Investigational Site Number 840015, Knoxville, Tennessee, 37922, United States|Investigational Site Number 840003, Round Rock, Texas, 78681, United States|Investigational Site Number 840016, San Antonio, Texas, 78258, United States|Investigational Site Number 840002, Salt Lake City, Utah, 84103, United States|Investigational Site Number 840008, Seattle, Washington, 98122, United States|Investigational Site Number 124001, Greenfield Park, J4V 2J2, Canada|Investigational Site Number 124002, QuebeC, Canada|Investigational Site Number 616008, Bydgoszcz, 85-079, Poland|Investigational Site Number 616007, Lodz, 90-549, Poland|Investigational Site Number 616001, Lodz, 93-121, Poland|Investigational Site Number 616004, Lublin, 20-090, Poland|Investigational Site Number 616003, Lublin, 20-718, Poland|Investigational Site Number 616002, Szczecin, 70-111, Poland|Investigational Site Number 616006, Warszawa, 02-653, Poland|Investigational Site Number 643010, Kazan, 420021, Russian Federation|Investigational Site Number 643009, Moscow, 107150, Russian Federation|Investigational Site Number 643003, Moscow, 127018, Russian Federation|Investigational Site Number 643005, Nizhniy Novgorod, 603155, Russian Federation|Investigational Site Number 643006, Nizhny Novgorod, 603076, Russian Federation|Investigational Site Number 643008, Novosibirsk, 630087, Russian Federation|Investigational Site Number 643002, St-Petersburg, 197089, Russian Federation|Investigational Site Number 643011, St-Petersburg, 197110, Russian Federation|Investigational Site Number 643001, St-Petersburg, 197376, Russian Federation|Investigational Site Number 752002, Göteborg, 416 85, Sweden|Investigational Site Number 752001, Stockholm, 171 76, Sweden"
NCT05172466,"Sensation, Motion, and Quality of Life on Natalizumab and Off Natalizumab",https://beta.clinicaltrials.gov/study/NCT05172466,WITHDRAWN,Relapsing-remitting Multiple Sclerosis (RRMS),DEVICE: BeCare application,Icahn School of Medicine at Mount Sinai,,ALL,ADULT,NA,0,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2022-10-31,2022-11-11,2022-11-11,"Mount Sinai Hospital, New York, New York, 10029, United States"
NCT04057066,Internet-based Physical Activity Promotion and Exercise Prescription for People With Multiple Sclerosis (Feasibility Study),https://beta.clinicaltrials.gov/study/NCT04057066,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Physical activity counseling|BEHAVIORAL: Exercise,University of Erlangen-Nürnberg,"Neurological Rehabilitation Center Quellenhof|ZTM Bad Kissingen|Medi train - Zentrum für Gesundheitssport, Sport- und Physiotherapie|proMX GmbH Nürnberg|motionNET systems Limited|Aktion Multiple Sklerose Erkrankter, Landesverband der DMSG in Baden-Württemberg (AMSEL) e.V.|Klinikum Würzburg Mitte GmbH",ALL,"ADULT, OLDER_ADULT",NA,26,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2019-02-28,2019-08-16,2019-08-16,"Neurological Rehabilitation Center Quellenhof, Bad Wildbad, Baden-Wuerttemberg, 75323, Germany|Klinikum Würzburg Mitte gGmbH, Würzburg, Bavaria, 97070, Germany|Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany"
NCT01656148,FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra,https://beta.clinicaltrials.gov/study/NCT01656148,COMPLETED,Multiple Sclerosis,DRUG: Fampridine-SR,University of Southern Denmark,Region of Southern Denmark|Biogen,ALL,ADULT,PHASE4,108,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-06,2014-05,2014-05,"Esbjerg Hospital, Esbjerg, 6700, Denmark|Odense University Hospital, Odense, 5000, Denmark|Sønderborg Hospital, Sønderborg, 6400, Denmark|Vejle Hospital, Vejle, 7100, Denmark"
NCT03356366,MRI Study of the Mechanisms Underlying Irreversible Disability in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03356366,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,"OTHER: MRI 3T|OTHER: MRI 1,5T|OTHER: MRI 7T",Assistance Publique Hopitaux De Marseille,,ALL,"ADULT, OLDER_ADULT",NA,70,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2017-10-02,2023-01-16,2028-12-31,"Assistance Publique - Hôpitaux de Marseille, Marseille, 13005, France"
NCT01264848,Endovascular Treatment for Chronic Cerebrospinal Venous Insufficiency (CCSVI),https://beta.clinicaltrials.gov/study/NCT01264848,COMPLETED,Multiple Sclerosis,PROCEDURE: balloon angioplasty and/or stenting|PROCEDURE: balloon angioplasty and/or stenting,"Euromedic Specialist Clinics, Poland",,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1|PHASE2,100,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2010-03,2010-10,2012-12,"Euromedic Specialist Clinics, Katowice, Poland"
NCT04997148,Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS),https://beta.clinicaltrials.gov/study/NCT04997148,ACTIVE_NOT_RECRUITING,Relapsing-Remitting Multiple Sclerosis,,"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","Merck Serono Limited, an affiliate of Merck KGaA, Darmstadt, Germany",ALL,"ADULT, OLDER_ADULT",,116,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-08-11,2023-10-15,2023-10-15,"University Hospitals Coventry and Warwickshire- Neurology, Coventry, United Kingdom|NHS Lanarkshire Health Board- Department of Neurology, Glasgow, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|University Hospitals of Leicester NHS Trust, Leicester, United Kingdom|Barking Havering and Redbridge University Hospitals NHS Trust, London, United Kingdom|University College London UCL, London, United Kingdom|Nottingham City Hospital (2655), Nottingham, United Kingdom|Salford Royal, Salford, United Kingdom"
NCT03322748,Efficacy of Lower Limb Exercises on Overactive Bladder Symptoms in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03322748,UNKNOWN,Overactive Bladder Syndrome|Multiple Sclerosis|Muscle Strain,OTHER: Usual physical therapy+ strengthening of lower limbs muscles|OTHER: Usual physical therapy,IRCCS San Raffaele,,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2018-02,2020-02,2020-02,"Prof. Giancarlo Comi, Milan, MI, 20132, Italy"
NCT00001248,Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT00001248,RECRUITING,Multiple Sclerosis,,National Institute of Neurological Disorders and Stroke (NINDS),,ALL,"ADULT, OLDER_ADULT",,2500,NIH,OBSERVATIONAL,Observational Model: |Time Perspective: p,1992-07-23,,,"National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States"
NCT00647348,Investigation of Simvastatin in Secondary Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00647348,COMPLETED,Secondary Progressive Multiple Sclerosis,DRUG: Simvastatin|DRUG: Placebo,Imperial College London,,ALL,"ADULT, OLDER_ADULT",PHASE2,140,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2008-01,2011-11,2011-11,"MRI Unit, National Society for Epilepsy, Chesham Lane, Chalfont St. Peter, Buckinghamshire, SL9 0RJ, United Kingdom|Charing Cross Hospital, Fulham Palace Road, Hammersmith, London, W6 8RF, United Kingdom|Brighton & Sussex University Hospitals NHS Trust, Eastern Road, Brighton, BN2 5BE, United Kingdom"
NCT00530348,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One",https://beta.clinicaltrials.gov/study/NCT00530348,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",BIOLOGICAL: Alemtuzumab|BIOLOGICAL: Interferon beta-1a,"Genzyme, a Sanofi Company",Bayer,ALL,ADULT,PHASE3,581,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2007-08,2011-04,2011-04,"North Central Neurology Associates, P.C., Cullman, Alabama, United States|Barrow Neurological Institute, St. Joseph's Hospital & Medical Center, Phoenix, Arizona, United States|Mayo Clinic Arizona, Scottsdale, Arizona, United States|Northwest NeuroSpecialists, PLLC, Tucson, Arizona, United States|Advanced Neurosciences Research, Fort Collins, Colorado, United States|Neurological Associates, Pompano Beach, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Idaho Falls Multiple Sclerosis Center, PLLC, Idaho Falls, Idaho, United States|Consultants in Neurology, Ltd., Northbrook, Illinois, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|MidAmerican Neuroscience Institute, Lenexa, Kansas, United States|Associates in Neurology, PSC, Lexington, Kentucky, United States|University of Louisville Research Foundation, Louisville, Kentucky, United States|Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States|UMass Memorial Medical Center, Worcester, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Wayne State University, Detroit, Michigan, United States|University of Nevada School of Medicine, Las Vegas, Nevada, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|University of New Mexico, Health Sciences Center, MS Specialty Clinic, Albuquerque, New Mexico, United States|Empire Neurology, Latham, New York, United States|Comprehensive Multiple Sclerosis Care Center at South Shore Neurologic Associates, P.C., Patchogue, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Carolinas Medical Center (CMC), Neurosciences & Spine Institute (NSSI), Charlotte, North Carolina, United States|The Ohio State University Medical Center, Multiple Sclerosis Center, Columbus, Ohio, United States|Oak Clinic for Multiple Sclerosis, Uniontown, Ohio, United States|MS Center of Oklahoma, Oklahoma City, Oklahoma, United States|Lehigh Valley Hospital Neurosciences and Pain Research, Allentown, Pennsylvania, United States|Advanced Neurosciences Institute, Franklin, Tennessee, United States|Biomedical Research Alliance of NY, LLC, Franklin, Tennessee, United States|Hope Neurology PC, Knoxville, Tennessee, United States|Baylor College of Medicine, Maxine Mesinger MS Clinic, Houston, Texas, United States|Central Texas Neurology, Round Rock, Texas, United States|Integra Clinical Research, San Antonio, Texas, United States|Neurology Center of San Antonio, San Antonio, Texas, United States|DIABAID, Buenos Aires, Argentina|The Wesley Research Institute, Auchenflower, Queensland, 4066, Australia|Griffith University School of Medicine, Southport, Queensland, Australia|The Queen Elizabeth Hospital, Woodville South, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, 7000, Australia|St Vincent's Hospital, Fitzroy, Victoria, 3065, Australia|Austin Health, Heidelberg, Victoria, 3084, Australia|Royal Melbourne Hospital, Department of Neurology, Ward 4 East, Parkville, Victoria, 3050, Australia|Concord Repatriation General Hospital, Concord, Australia|Westmead Hospital, Westmead, Australia|Hospital da Restauracao, Av Governador Agamenon Magalhaes, Recife, Pernambuco, Brazil|Hospital Sao Lucas PUC-RS, Porto Alegre, RS, Brazil|Hospital de Clínicas USP, Sao Paulo, SP, Brazil|University of Calgary and Foothills Medical Cenre, Calgary, Alberta, Canada|UBC Hospital, Vancouver, British Columbia, Canada|The Ottawa Hospital, General Campus, Ottawa, Ontario, Canada|Clinique Nuero-outaouais, Gatineau, Quebec, Canada|Clinique Neuro rive-sud, Recherche Sepmus, Inc., Greenfield park, Quebec, Canada|Clinical Hospital Centre Rijeka, Rijeka, Croatia|General Hospital Varazdin, Varazdin, Croatia|Clinical Hospital Centre ""Sestre Milosrdnice"", Zagreb, Croatia|Clinical Hospital Centre Zagreb, Zagreb, Croatia|General Hospital ""Sveti Duh"", Zagreb, Croatia|Department of Neurology, 1st Faculty of Medicine and General Teaching Hospital, Praha 2, Czech Republic|Krajska zdravotni a.s., Hospital Teplice, Teplice, Czech Republic|Hopital Purpan, Toulouse, France|Judisches Krankenhaus Berlin, Berlin, Germany|Universitätsklinik Carl Gustav Carus Dresden, Dresden, Germany|Klinikum der Goethe Universität Frankfurt, Frankfurt, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Oberhavelkliniken Hennigsdorf, Hennigsdorf, Germany|Asklepios Klinikum Brandenburg, Teupitz, Germany|Hospital Angeles del Pedregal, Camino de Santa Teresa, Mexico City, Mexico|Hospital Medica Sur CIF-BIOTEC, Mexico City, Mexico|Clinical Neurology Centre Sp. z o.o. (Ltd), Cracow, Poland|Independent Public Healthcare Facility, Norbert Barlicki University Hospital No. 1 of the Medical University of Lodz, Lodz, Poland|Independent Public Teaching Hospital No. 4 in Lublin, Lublin, Poland|Heliodor Swiecicki Teaching Hospital of the Poznan University of Medical Sciences, Poznan, Poland|Research Medical Complex ""Your Health"" Ltd, Kazan, Russian Federation|Moscow City Hospital #11, Moscow, Russian Federation|Moscow State Medical Institution City Clinical Hospital #11, Moscow, Russian Federation|Scientific Neurology Center RAMS, Moscow, Russian Federation|Municipal City Hospital #33, Nizhniy Novgorod, Russian Federation|Federal State Institution Siberian Rettitorial Medical Center under Federal Medical-Biological Agency of Russia, Novosibirsk, Russian Federation|City Clinical Hospital #2, Pyatigorsk, Russian Federation|Samara Regional Clinical Hospital n.a. Kalinin, Samara, Russian Federation|Institute of Human Brain RAS, St. Petersburg, Russian Federation|Nikolaevskaya Hospital, St. Petersburg, Russian Federation|St. Petersburg Pavlov State Medical University, St. Petersburg, Russian Federation|State Medical Institution: Republican Clinical Hospital n.a. G.G. Kuvatov, Ufa, Russian Federation|Clinical Centre Serbia, Institute for Neurology, Belgrade, Serbia|Military Medical Academy, Belgrade, Serbia|Clinical centre Kragujevac, Kragujevac, Serbia|Clinical Center Nis, Clinic for neurology, Nis, Serbia|Clinical Centre of Vojvodina, Clinic for neurology, Novi Sad, Serbia|Sahlgrenska University Hospital, Goteborg, Sweden|Chernihiv Regional Hospital, Chernihiv, Ukraine|Institute of Neurology, Psychiatry and Narcology under the Academy of Medical Sciences of Ukraine, Department of Neuroinfection and Multiple Sclerosis, Kharkiv, Ukraine|Hospoital of the Directorate of the Medical Corps within the Ukrainian Security Service, Neurology Department, Kyiv, Ukraine|Kyiv Municipal Clinical Hospital #4, Kyiv, Ukraine|Danylo Halytsky Lviv National Medical University, Lviv, Ukraine|Department Of Neurosciences, Addenbrookes Hospital, Cambridge, England, United Kingdom|Centre for Neuroscience & Trauma, Blizard Institute of Cell and Molecular Science, Barts and The London School of Medicine and Dentistry, London, England, United Kingdom|University Hospital of Wales, Cardiff, Wales, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom"
NCT05442112,Trial of eHealth Wellness Behavioral Interventions and Patient-reported Outcomes,https://beta.clinicaltrials.gov/study/NCT05442112,NOT_YET_RECRUITING,Multiple Sclerosis,BEHAVIORAL: Wellness Patient Message,Johns Hopkins University,,ALL,"ADULT, OLDER_ADULT",NA,120,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2023-05,2023-07,2023-09,
NCT01709812,Effect of an Individualized Patient Support Program on Treatment Satisfaction in Fingolimod-treated Patients With RRMS,https://beta.clinicaltrials.gov/study/NCT01709812,WITHDRAWN,Relapsing-remitting Multiple Sclerosis,OTHER: individualized patient support program|OTHER: Standard care,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE4,0,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2013-07,2013-07,2013-07,
NCT02743312,Long-Term Effects of Torso-Weighting,https://beta.clinicaltrials.gov/study/NCT02743312,COMPLETED,Multiple Sclerosis,DEVICE: Torso Weights|DEVICE: Sham Weights|DEVICE: Fitbit Flex,San Francisco State University,Samuel Merritt University,ALL,"ADULT, OLDER_ADULT",NA,5,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2015-11,2016-05,2016-06,"Samuel Merritt University, Motion Analysis Research Center, Oakland, California, 94609, United States"
NCT02798055,Bosentan Treatment of Digital Ulcers Related to Systemic Sclerosis,https://beta.clinicaltrials.gov/study/NCT02798055,COMPLETED,Systematic Sclerosis|Digital Ulcer|Scleroderma,DRUG: Bosentan group,Elpen Pharmaceutical Co. Inc.,,ALL,"ADULT, OLDER_ADULT",,148,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-09-30,2019-06-30,2019-06-30,"University Clinic, Laiko Hospital, Athens, Greece"
NCT04913012,Exercise Booster Sessions in People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04913012,RECRUITING,Multiple Sclerosis,COMBINATION_PRODUCT: Systematic aerobic training|COMBINATION_PRODUCT: Systematic resistance training|COMBINATION_PRODUCT: Aerobic training booster sessions|COMBINATION_PRODUCT: Resistance training booster sessions,University of Aarhus,Oxford Brookes University,ALL,"ADULT, OLDER_ADULT",NA,150,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-08-01,2023-06,2023-06,"Aarhus University, Aarhus, 8000, Denmark"
NCT04225312,Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04225312,ENROLLING_BY_INVITATION,Relapsing Remitting Multiple Sclerosis,DRUG: Personalized extended interval dosing of natalizumab|DRUG: Standard interval dosing,"Amsterdam UMC, location VUmc",Stichting MS Research|Innovatiefonds Zorgverzekeraars|Stichting Treatmeds,ALL,"ADULT, OLDER_ADULT",PHASE4,300,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-02-03,2025-03-01,2025-03-01,"Ziekenhuisgroep Twente hospital, Almelo, Netherlands|Flevoziekenhuis, Almere, Netherlands|Amsterdam UMC, location VUmc, Amsterdam, Netherlands|OLVG, Amsterdam, Netherlands|Rijnstate Hospital, Arnhem, Netherlands|Wilhelmina hospital Assen, Assen, Netherlands|Amphia Hospital, Breda, Netherlands|Reinier de Graaf hospital, Delft, Netherlands|Jeroen Bosch Hospital, Den Bosch, Netherlands|Slingeland Hospital, Doetinchem, Netherlands|Ommelander Hospital Groningen, Groningen, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Spaarne gasthuis hospital, Haarlem, Netherlands|Sint-Jansdal Hospital, Harderwijk, Netherlands|Medisch Centrum Leeuwarden, Leeuwarden, Netherlands|Alrijne Hospital, Leiden, Netherlands|Maasstad hospital, Maastricht, Netherlands|Canisius Wilhelmina Hospital, Nijmegen, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|Haaglanden Medical Center, The Hague, Netherlands|Elizabeth tweesteden Hospital, Tilburg, Netherlands|Diakonessenhuis, Utrecht, Netherlands|St. Antonius Hospital, Utrecht, Netherlands|Isala, Zwolle, Netherlands"
NCT00203112,Safety and Efficacy Study of Copaxone Administered in Combination With Minocycline,https://beta.clinicaltrials.gov/study/NCT00203112,COMPLETED,Relapse Remitting Multiple Sclerosis,DRUG: glatiramer acetate with minocycline|DRUG: Glatiramer acetate with placebo,"Teva Branded Pharmaceutical Products R&D, Inc.",,ALL,ADULT,PHASE2,44,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2004-06,2006-06,2006-07,
NCT03626012,"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis",https://beta.clinicaltrials.gov/study/NCT03626012,COMPLETED,Amyotrophic Lateral Sclerosis,DRUG: BIIB078|DRUG: Placebo,Biogen,,ALL,"ADULT, OLDER_ADULT",PHASE1,106,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-09-10,2021-11-17,2021-11-17,"Research Site, La Jolla, California, 92037-0886, United States|Research Site, Los Angeles, California, 90048, United States|Research Site, Palo Alto, California, 94303, United States|Research Site, Jacksonville, Florida, 32224, United States|Research Site, Miami, Florida, 33136, United States|Research Site, Atlanta, Georgia, 30322, United States|Research Site, Baltimore, Maryland, 21287, United States|Research Site, Boston, Massachusetts, 02114, United States|Research Site, Saint Louis, Missouri, 63110, United States|Research Site, Lincoln, Nebraska, 68506-2960, United States|Research Site, New York, New York, 10032, United States|Research Site, Knoxville, Tennessee, 37920, United States|Research Site, Calgary, Alberta, T2N 1N4, Canada|Research Site, Toronto, Ontario, M4N 3M5, Canada|Research Site, Montreal, Quebec, H3A 2B4, Canada|Research Site, Dublin, DUBLIN 8, Ireland|Research Site, Utrecht, 3508 GA, Netherlands|Research Site, St. Gallen, 9007, Switzerland|Research Site, London, Greater London, SE5 9RS, United Kingdom|Research Site, Sheffield, South Yorkshire, S10 2HQ, United Kingdom|Research Site, London, NW1 2PG, United Kingdom"
NCT01279655,Motor Training and White Matter in Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT01279655,TERMINATED,Multiple Sclerosis,DEVICE: tDCS|BEHAVIORAL: Bimanual Training,Hasselt University,KU Leuven|Provinciale Hogeschool Limburg,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-01,2011-12,2013-05,"Hasselt University (BIOMED), Diepenbeek, Limburg, 3590, Belgium"
NCT02495766,Autologous Mesenchymal Stromal Cells for Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02495766,COMPLETED,Relapsing-Remitting Multiple Sclerosis|Secondary Progressive Multiple Sclerosis,DRUG: XCEL-MC-ALPHA|DRUG: Placebo,Banc de Sang i Teixits,Vall d'Hebron Research Institute (VHIR),ALL,ADULT,PHASE1|PHASE2,8,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2015-05-11,2017-11-27,2018-11-15,"Hospital Vall Hebron, Barcelona, 08005, Spain"
NCT03768648,Cognition and MRI Markers in MS Patients With Aubagio® Treatment,https://beta.clinicaltrials.gov/study/NCT03768648,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",OTHER: Clinical assessment|OTHER: Ecological evaluation|OTHER: Neuropsychological evaluation|OTHER: Psychological evaluation|DEVICE: MRI Evaluation,"University Hospital, Bordeaux","Genzyme, a Sanofi Company",ALL,ADULT,NA,75,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2019-05-21,2023-02-23,2023-02-23,"CHU de Bordeaux - Service de neurologie, Bordeaux, France"
NCT02493166,Dual Task Cost in the Upper Limb in Persons With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02493166,COMPLETED,Multiple Sclerosis,OTHER: dual task cost (cognitive-motor interference),Hasselt University,"AZ Klina|University Hospital, Antwerp|private practice physician De Barsy",ALL,"ADULT, OLDER_ADULT",NA,68,OTHER,INTERVENTIONAL,"Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: ",2016-03,2016-03,2016-06,"AZ Klina, Brasschaat, 2930, Belgium|Private practice physician De Barsy, Brasschaat, 2930, Belgium|Hasselt University, Diepenbeek, 3560, Belgium|UZ Antwerp, Edegem, 2650, Belgium"
NCT02694666,Vibration Training for Preventing Falls in Healthy Population and Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02694666,ACTIVE_NOT_RECRUITING,Falls Prevention,OTHER: Controlled whole-body vibration training,Georgia State University,,ALL,"ADULT, OLDER_ADULT",NA,147,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2016-04,2023-12,2024-12,"Georgia State University, Atlanta, Georgia, 30303, United States"
NCT00688948,Alfuzosin for Voiding Dysfunction in Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT00688948,TERMINATED,Multiple Sclerosis|Bladder Dysfunction,DRUG: Alfuzosin,Nova Scotia Health Authority,Sanofi,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,20,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-11,2009-11,2009-11,"QE II Health Science Centre, Halifax Infirmary, Halifax, Nova Scotia, B3H 3A7, Canada"
NCT03464448,Mechanistic Studies of Teriflunomide in RRMS,https://beta.clinicaltrials.gov/study/NCT03464448,COMPLETED,Relapsing Remitting Multiple Sclerosis,DRUG: Teriflunomide,University of Michigan,,ALL,"ADULT, OLDER_ADULT",,30,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-04-17,2021-10-13,2021-10-13,"University of Michigan, Ann Arbor, Michigan, 48109, United States"
NCT00950248,Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS),https://beta.clinicaltrials.gov/study/NCT00950248,COMPLETED,Primary Progressive Multiple Sclerosis,DRUG: Idebenone|OTHER: placebo,National Institute of Allergy and Infectious Diseases (NIAID),,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,85,NIH,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2009-11-01,2018-04-30,2018-08-06,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States"
NCT02090348,Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate,https://beta.clinicaltrials.gov/study/NCT02090348,WITHDRAWN,Relapsing-Remitting Multiple Sclerosis|Multiple Sclerosis,DRUG: dimethyl fumarate,Biogen,,ALL,"ADULT, OLDER_ADULT",PHASE4,0,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-06,2017-10,2017-10,
NCT01207648,Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY),https://beta.clinicaltrials.gov/study/NCT01207648,COMPLETED,Multiple Sclerosis,DRUG: Rebif®,EMD Serono,,ALL,"CHILD, ADULT",,307,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-07,2011-07,2011-07,"Research Site, Birmingham, Alabama, United States|Research Site, San Francisco, California, United States|Research Site, Boston, Massachusetts, United States|Research Site, Buffalo, New York, United States|Research Site, Rochester, New York, United States|Research Site, Stoney Brook, New York, United States|Research Site, Buenos Aires, Argentina|Research Site, Toronto, Canada|Research Site, Le Kremlin Bicêtre Cedex, France|Research Site, Bari, Italy|Research Site, Catania, Italy|Research Site, Gallarate, Italy|Research Site, Milan, Italy|Research Site, Rome, Italy|Research Site, Torino, Italy|Research Site, Moscow, Russian Federation|Research Site, Tunis, Tunisia|Research Site, Maracaibo, Venezuela"
NCT03277248,Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS),https://beta.clinicaltrials.gov/study/NCT03277248,COMPLETED,Relapsing Multiple Sclerosis (RMS),BIOLOGICAL: Ublituximab|DRUG: Teriflunomide|DRUG: Oral Placebo|DRUG: IV Placebo,"TG Therapeutics, Inc.",,ALL,ADULT,PHASE3,545,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-08-25,2020-08-04,2020-11-12,"TG Therapeutics RMS Investigational Trial site, Phoenix, Arizona, 58018, United States|TG Therapeutics RMS Investigational Trial Site, Aurora, Colorado, 80045, United States|TG Therapeutics RMS Investigational Trial Site, Tampa, Florida, 33612, United States|TG Therapeutics RMS Investigational Trial Site, Lexington, Kentucky, 40513, United States|TG Therapeutics RMS Investigational Trial Site, Chesterfield, Missouri, 63017, United States|TG Therapeutics RMS Investigational Trial Site, Las Vegas, Nevada, 89106, United States|TG Therapeutics RMS Investigational Trial Site, Teaneck, New Jersey, 07666, United States|TG Therapeutics RMS Investigational Trial Site, Albuquerque, New Mexico, 87131, United States|TG Therapeutics RMS Investigational Trial Site, Patchogue, New York, 11772, United States|TG Therapeutics RMS Investigational Trial site, Columbus, Ohio, 43221, United States|TG Therapeutics RMS Investigational Trial Site, Pittsburgh, Pennsylvania, 15212, United States|TG Therapeutics RMS Investigational Trial site, San Antonio, Texas, 78258, United States|TG Therapeutics RMS Investigational Trial site, Seattle, Washington, 98122, United States"
NCT04543448,Effect of Cervical Mobilization on Balance and Plantar Pressure Distribution in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04543448,COMPLETED,Multiple Sclerosis|Muscle Spasticity|Pressure Area|Cervical Region Disorder Nos,OTHER: Traditional Rehabilitation for multiple sclerosis|OTHER: Cervical mobilization for multiple sclerosis,Hasan Kalyoncu University,,ALL,"ADULT, OLDER_ADULT",NA,12,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2019-10-02,2020-05-31,2020-08-20,"Hasan Kalyoncu University, Gaziantep, Turkey"
NCT00716066,Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases,https://beta.clinicaltrials.gov/study/NCT00716066,RECRUITING,Autoimmune Disease|Neurologic Autoimmune Disease|Autologous Transplant Autoimmune|Multiple Sclerosis Transplant|MS Stem Cell Transplant|Multiple Sclerosis Stem Cell Transplant|Stiff Person Syndrome|HCT for Neurologic Autoimmune Disorders|CIDP Transplant|Myasthenia Gravis Transplant|Autoimmune Nervous System Disorder|Central Nervous System Vasculitis|Cerebellar Degeneration|Chronic Inflammatory Demyelinating Polyneuropathy|Lambert Eaton Myasthenic Syndrome|Myasthenia Gravis|Neuromyelitis Optica|Opsoclonus Myoclonus Syndrome|Rasmussen Subacute Encephalitis,BIOLOGICAL: Anti-Thymocyte Globulin|PROCEDURE: Autologous Hematopoietic Stem Cell Transplantation|DRUG: Carmustine|DRUG: Cytarabine|DRUG: Etoposide|OTHER: Laboratory Biomarker Analysis|DRUG: Melphalan|PROCEDURE: Peripheral Blood Stem Cell Transplantation|DRUG: Prednisone|PROCEDURE: Syngeneic Bone Marrow Transplantation,Fred Hutchinson Cancer Center,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,80,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2008-06,2028-01-30,2033-06-30,"Colorado Blood Cancer Institute, Denver, Colorado, 80218, United States|Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, 98109, United States|Swedish Medical Center-First Hill, Seattle, Washington, 98122-4307, United States"
NCT03870048,tDCS to Lower Neuropathic Pain and Fatigue in People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03870048,COMPLETED,Multiple Sclerosis,DEVICE: transcranial direct current stimulation,University of Iowa,jkamholz|cdworkman,ALL,"ADULT, OLDER_ADULT",NA,6,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2019-04-15,2020-03-30,2020-03-30,"University of Iowa, Iowa City, Iowa, 52242, United States"
NCT00938366,Drug-Drug Interaction of Cladribine and Pantoprazole in Multiple Sclerosis Subjects,https://beta.clinicaltrials.gov/study/NCT00938366,COMPLETED,Multiple Sclerosis,DRUG: Cladribine|DRUG: Pantoprazole,"Merck KGaA, Darmstadt, Germany","Merck Serono S.A., Geneva",ALL,"ADULT, OLDER_ADULT",PHASE1,18,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2008-01,2009-01,2009-01,
NCT01868048,"Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis.",https://beta.clinicaltrials.gov/study/NCT01868048,WITHDRAWN,Spasticity|Multiple Sclerosis,DRUG: Sativex|DRUG: Placebo,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,0,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",,2017-06,,
NCT00206648,An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS,https://beta.clinicaltrials.gov/study/NCT00206648,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Betaferon/Betaseron|DRUG: Betaferon/Betaseron,Bayer,,ALL,ADULT,PHASE4,271,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2003-03,,2005-10,"Tucson, Arizona, 85741, United States|Berkeley, California, 94705, United States|Irvine, California, 92697, United States|Loma Linda, California, 92354, United States|Los Angeles, California, 90095-1721, United States|Sacramento, California, 95817, United States|San Jose, California, 95124, United States|Walnut Creek, California, 94596, United States|Walnut Creek, California, 94598, United States|Wilmington, Delaware, 19806, United States|Melbourne, Florida, 32940, United States|Miami, Florida, 33136, United States|Tampa, Florida, 33606, United States|Tampa, Florida, 33609, United States|Atlanta, Georgia, 30309-1465, United States|Augusta, Georgia, 30912, United States|Columbus, Georgia, 31909, United States|Savannah, Georgia, 31405, United States|Flossmoor, Illinois, 60422, United States|Springfield, Illinois, 62703, United States|Fort Wayne, Indiana, 46805, United States|Indianapolis, Indiana, 46202, United States|Des Moines, Iowa, 50314, United States|Kansas City, Kansas, 66160, United States|Shreveport, Louisiana, 71130, United States|Baltimore, Maryland, 21201, United States|Detroit, Michigan, 48201, United States|Golden Valley, Minnesota, 55422, United States|Minneapolis, Minnesota, 55455, United States|Rochester, Minnesota, 55905, United States|Kansas City, Missouri, 64108, United States|St. Louis, Missouri, 63110, United States|Reno, Nevada, 89509, United States|Albuquerque, New Mexico, 87131-5281, United States|Albany, New York, 12208, United States|Buffalo, New York, 14215, United States|Mineola, New York, 11501, United States|New York, New York, 10003, United States|Asheville, North Carolina, 28801, United States|Winston-Salem, North Carolina, 27157, United States|Dayton, Ohio, 45409, United States|Oklahoma City, Oklahoma, 73120, United States|Medford, Oregon, 97504, United States|Philadelphia, Pennsylvania, 19104, United States|Providence, Rhode Island, 02905, United States|Charleston, South Carolina, 29425, United States|Houston, Texas, 77030, United States|Fairfax, Virginia, 22031, United States|Roanoke, Virginia, 24014, United States|Seattle, Washington, 98101, United States|Tacoma, Washington, 98405, United States|Nepean, Ontario, K2G 6E2, Canada|Ottawa, Ontario, K1H 8L6, Canada"
NCT01359566,Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01359566,COMPLETED,Multiple Sclerosis,DRUG: Arbaclofen placarbil 15 mg BID|DRUG: Placebo|DRUG: Arbaclofen placarbil 30 mg BID|DRUG: Arbaclofen placarbil 45 mg BID,"XenoPort, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE3,228,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-05,2013-02,2013-02,"XenoPort Clinical Site, Phoenix, Arizona, 85004, United States|XenoPort Clinical Site, Tucson, Arizona, 85701, United States|XenoPort Clinical Site, Berkeley, California, 94705, United States|XenoPort Clinical Site, San Diego, California, 92103, United States|XenoPort Clinical Site, Denver, Colorado, 80012, United States|XenoPort Clinical Site, Port Charlotte, Florida, 33948, United States|XenoPort Clinical Site, Saint Petersburg, Florida, 33701, United States|XenoPort Clinical Site, Sarasota, Florida, 34231, United States|XenoPort Clinical Site, Tampa, Florida, 33604, United States|XenoPort Clinical Site, Lake Barrington, Illinois, 60010, United States|XenoPort Clinical Site, Indianapolis, Indiana, 46204, United States|XenoPort Clinical Site, Lenexa, Kansas, 66210, United States|XenoPort Clinical Site, Lexington, Kentucky, 40505, United States|XenoPort Clinical Site, Bingham Farms, Michigan, 48025, United States|XenoPort Clinical Site, Detroit, Michigan, 48202, United States|XenoPort Clinical Site, Toms River, New Jersey, 08753, United States|XenoPort Clinical Site, Albuquerque, New Mexico, 87102, United States|XenoPort Clinical Site, Albany, New York, 12208, United States|XenoPort Clinical Site, Patchogue, New York, 11772, United States|XenoPort Clinical Site, Plainview, New York, 11803, United States|XenoPort Clinical Site, Asheville, North Carolina, 28805, United States|XenoPort Clinical Site, Akron, Ohio, 44320, United States|XenoPort Clinical Site, Franklin, Tennessee, 37064, United States|XenoPort Clinical Site, Nashville, Tennessee, 37205, United States|XenoPort Clinical Site, San Antonio, Texas, 78206, United States|XenoPort Clinical Site, Vienna, Virginia, 22181, United States|XenoPort Clinical Site, Seattle, Washington, 98108, United States|XenoPort Clinical Site, Tacoma, Washington, 98404, United States"
NCT01918748,Effect of I-TRAVLE Training on Arm Function in MS and Chronic Stroke Patients,https://beta.clinicaltrials.gov/study/NCT01918748,UNKNOWN,Multiple Sclerosis|Paralytic Stroke,DEVICE: Haptic Master,Hasselt University,,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-07,2014-06,2014-09,"Revalidatie & MS Centrum Overpelt, Overpelt, Limburg, 3900, Belgium|Adelante Zorggroep, Hoensbroek, 6430 AB, Netherlands"
NCT04969848,Quantifying Gait Alteration in Multiple Sclerosis Using a Wearable Device,https://beta.clinicaltrials.gov/study/NCT04969848,COMPLETED,Multiple Sclerosis,OTHER: Wearable sensor,Nantes University Hospital,,ALL,ADULT,,44,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-08-18,2022-05-31,2022-05-31,"Nantes University Hospital, Nantes, Loire-Atlantique, 44093, France"
NCT00030966,Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00030966,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Natalizumab|DRUG: Placebo,Biogen,Elan Pharmaceuticals,ALL,ADULT,PHASE3,1200,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2002-01,2005-04,2005-12,"University of Alabama-Birmingham, Department of Neurology, Birmingham, Alabama, 35233, United States|Phoenix Neurological Associates, Ltd., Phoenix, Arizona, 85008, United States|University of Arkansas For Medical Sciences, Little Rock, Arkansas, 72205, United States|University of California - Irvine, Irvine, California, 92697, United States|USC MS Comprehensive Care Center, Los Angeles, California, 90033, United States|Kaiser-Permanente Medical Center, Redwood City, California, 94063, United States|MS Center at UCSF, San Francisco, California, 94117, United States|Healthsouth Rehabilitation Hospital, Colorado Springs, Colorado, 80910, United States|University of Colorado MS Center, Denver, Colorado, 80262, United States|Griffin Hospital, Derby, Connecticut, 06418, United States|Georgetown Univesity Hospital, Research Pharmacy, Washington, District of Columbia, 20007, United States|George Washington University MS Center, Washington, District of Columbia, 20037, United States|North Ridge NeuroScience Center, Ft. Lauderdale, Florida, 33334, United States|Maitland Neurology, Maitland, Florida, 32751, United States|University of Miami, Department of Neurology, Miami, Florida, 33136, United States|The Multiple Sclerosis Center of Atlanta, Atlanta, Georgia, 30327, United States|Marietta Neurological Associates, Marietta, Georgia, 30060, United States|Northwestern University, Department of Neurology, Chicago, Illinois, 60611, United States|Rush-Presbyterian St. Luke's Medical Center, Chicago, Illinois, 60612, United States|Alexian Brothers Center for Clinical Research, Elk Grove Village, Illinois, 60007, United States|Loyola Medical Center, Maywood, Illinois, 60153, United States|Consultants in Neurology Northbrook, Northbrook, Illinois, 60062, United States|Springfield Clinic Neuroscience Institute, Springfield, Illinois, 62702, United States|Indiana University Medical Center, Indianapolis, Indiana, 46202, United States|Mercy Hospital Outpatient Pharmacy, Des Moines, Iowa, 50314, United States|LSU Neurolgoy Clinic in New Orleans, New Orleans, Louisiana, 70112, United States|Maine Neurology, Scarborough, Maine, 04074-8926, United States|University of Maryland Hospital, Department of Neurology, Baltimore, Maryland, 21201, United States|Brigham and Women's Hospital, Boston, Massachusetts, 02115, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, 01655-0138, United States|Henry Ford Hospital, Detroit, Michigan, 48202-2608, United States|Michigan State University MS Clinic, East Lansing, Michigan, 48824, United States|Michigan Institute for Neurological Disorders, Farmington Hills, Michigan, 48334, United States|Noran Neurological Clinic, Minneapolis, Minnesota, 55404, United States|University of Mississippi Medical Center, Jackson, Mississippi, 39216-4505, United States|St. John's Mercy Medical Center, St. Louis, Missouri, 63141, United States|Bernard W. Gimbel MS Center, Teaneck, New Jersey, 07666, United States|Upstate Clinical Research, LLC, Albany, New York, 12205, United States|Albany Medical Center, Albany, New York, 12208, United States|Maimonides Medical Center, Division of Neurology, Brooklyn, New York, 11219, United States|Buffalo General Hospital, Department of Neurology, Buffalo, New York, 14203, United States|MS Care Center, New York, New York, 10003, United States|St. Luke's Roosevelt Hospital, MS Research & Treatment Center, New York, New York, 10019, United States|New York Hospital - Cornell Medical Center, New York, New York, 10021, United States|New York State Psychiatric Institution, New York, New York, 10032, United States|Strong Health Pharmacy Services, Rochester, New York, 14642, United States|Staten Island University Hospital, Staten Island, New York, 10305, United States|University Hospital at Stony Brook, Stony Brook, New York, 11794, United States|SUNY Upstate Medical University, Syracuse, New York, 13210, United States|MS Center at Carolinas Medical Center, Charlotte, North Carolina, 28232-2861, United States|Raleigh Neurology Associates, Raleigh, North Carolina, 27607, United States|Wake Forest University School of Medicine, Department of Neurology, Winston-Salem, North Carolina, 27157, United States|Riverhills Neurology, Cincinnati, Ohio, 45219, United States|Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States|Providence Saint Vincent Medical Center, Portland, Oregon, 97225, United States|Geisinger Medical Center, Danville, Pennsylvania, 17822, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|Greenstein Neurology Associates & MS Institute, Philadelphia, Pennsylvania, 19146, United States|Allegheny Singer Research Institute, Pittsburgh, Pennsylvania, 15212, United States|University of Pittsburgh, Department of Neurology, Pittsburgh, Pennsylvania, 15213, United States|University of Tennessee - Memphis, Memphis, Tennessee, 38163, United States|Vanderbilt Medical Center, Nashville, Tennessee, 37215, United States|Option Care Infusion, Dallas, Texas, 75226, United States|UTSW Medical School, Dallas, Texas, 75235-9036, United States|Baylor Methodist International MS Center, Houston, Texas, 77030, United States|Central Texas Neurology, Round Rock, Texas, 78681, United States|Fletcher Allen Health Care, Burlington, Vermont, 05401, United States|University of Virginia Health Sciences, Charlottesville, Virginia, 22908, United States|Neurological Associates, Inc., Richmond, Virginia, 23226, United States|Virginia Mason Medical Center, Seattle, Washington, 98111, United States|MS Research Center, Seattle, Washington, 98195, United States|St. Francis Hospital, Center for Neurological Disorders, Milwaukee, Wisconsin, 53215, United States|Universitatsklinik fur Neurologie, Graz, 8036, Austria|Universitatsklinik fur Neurologie, Innsbruck, 6020, Austria|Hopital Universitaire U.L.B. Erasme, Brussels, 1780, Belgium|Elisabeth Ziekenhuis, Sijsele, 8340, Belgium|Hopital Pellegrin Tripode, Neurologie, Bordeaux, 33076, France|Hopital neurologique Pierre Werth, Lyon, 69394, France|Judisches Krankenhaus, Berlin, 13347, Germany|Universitaetsklinikum Giessen, Oberarzt Neurologie, Giessen, 35390, Germany|Medizinische Hochschule Hannover, Neurologische Klinik, Hannover, 30625, Germany|Neurologische Abteilung, Henningsdorf, 16761, Germany|Städtische Kliniken Osnabrück, Osnabrück, 49076, Germany|Asklepios Klinik Schildautal, Seesen/Harz, 38723, Germany|Fachbereich Neurologie und Klinische Neurophysiologie, Wiesbaden, 65191, Germany|Hadassah Hebrew Uni Hospital, Department of Neurology, Jerusalem, Israel|Sheba Medical Center, MS Center, Tel Hashomer, 52621, Israel|Universita di Genova, Clinica Neurologica, Genova, 16132, Italy"
NCT04356248,Training and Energy Management Education to Improve Quality of Life in Persons With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04356248,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Endurance Training|BEHAVIORAL: Education,Klinik Valens,"German Sport University, Cologne|University of Applied Sciences and Arts of Southern Switzerland",ALL,"ADULT, OLDER_ADULT",NA,106,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2020-07-13,2022-05-11,2022-05-11,"Kliniken-Valens, Valens, Sankt Gallen, 7317, Switzerland"
NCT01489748,Canadian Avonex PEN Productivity Study,https://beta.clinicaltrials.gov/study/NCT01489748,COMPLETED,Multiple Sclerosis,,Biogen,,ALL,ADULT,,111,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-03,2014-10,2014-12,"Central Contact, Burlington, Ontario, Canada"
NCT05019248,Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine,https://beta.clinicaltrials.gov/study/NCT05019248,RECRUITING,"Multiple Sclerosis, Relapsing-Remitting|Vaccine Response Impaired",BIOLOGICAL: Most recent vaccine to seasonal influenza,"Heinrich-Heine University, Duesseldorf",,ALL,ADULT,,260,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-09-01,2021-12-31,2022-04-30,"Medical Faculty, Heinrich-Heine-University, Duesseldorf, Northrhine-Westphalia, 40225, Germany"
NCT01585766,"Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT01585766,COMPLETED,"Multiple Sclerosis, Relapsing Forms",DRUG: MEDI-551 30 MG-IV|DRUG: MEDI-551 60 MG-SC|DRUG: PLACEBO-IV-SC|DRUG: MEDI-551 100 MG-IV|DRUG: MEDI-551 300 MG-SC|DRUG: MEDI-551 600 MG-IV,MedImmune LLC,,ALL,"ADULT, OLDER_ADULT",PHASE1,56,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-04-24,2015-01-02,2016-06-20,"Research Site, Scottsdale, Arizona, United States|Research Site, Long Beach, California, United States|Research Site, Sacramento, California, United States|Research Site, Denver, Colorado, United States|Research Site, Tampa, Florida, United States|Research Site, Marlton, New Jersey, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Cordova, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Katowice, Poland|Research Site, Szczecin, Poland|Research Site, Barcelona, Spain|Research Site, Girona, Spain|Research Site, Sevilla, Spain|Research Site, Donetsk, Ukraine|Research Site, Kyiv, Ukraine"
NCT04998851,A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab,https://beta.clinicaltrials.gov/study/NCT04998851,RECRUITING,Multiple Sclerosis|Clinically Isolated Syndrome,DRUG: Ocrelizumab,Hoffmann-La Roche,PPD|Laboratory Corporation of America|Illingworth Research Group,FEMALE,ADULT,PHASE4,20,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2021-09-16,2023-07-27,2024-06-27,"University of California San Francisco, San Francisco, California, 94117, United States|University Of Colorado, Aurora, Colorado, 80045, United States|Northwestern Memorial Hospital, Chicago, Illinois, 60611, United States|Brigham and Womens Hospital, Boston, Massachusetts, 02115, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|St. Josef Hospital GmbH, Bochum, 44791, Germany|Universitaetsklinikum Carl Gustav Carus an der TU Dresden, Dresden, 01307, Germany|Hosp. Clinico San Carlos, Madrid, 28040, Spain|Queen Mary University of London, London, EC1M 6BQ, United Kingdom"
NCT05326048,Defining an Immunological Signature Related to Lesion Location in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05326048,COMPLETED,Multiple Sclerosis,OTHER: cytof analysis,Rennes University Hospital,,ALL,"ADULT, OLDER_ADULT",,60,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-03-09,2022-09-09,2022-09-09,"University hospital of Rennes, Rennes, 35000, France"
NCT01547351,Assessing Relapse in Multiple Sclerosis (ARMS) Questionnaire,https://beta.clinicaltrials.gov/study/NCT01547351,COMPLETED,Multiple Sclerosis,OTHER: ARMS Questionnaire,Mallinckrodt,,ALL,"ADULT, OLDER_ADULT",,103,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-12,2012-09,2012-09,"Tanner Center and Foundation for MS, Birmingham, Alabama, United States|Neurology Center, Oceanside, California, United States|Infinity Clinical Research, Hollywood, Florida, United States|McCare Center Neurology Services, Orlando, Florida, United States|Neurology Center of Fairfax, Fairfax, Virginia, United States"
NCT04711148,A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04711148,ACTIVE_NOT_RECRUITING,Relapsing Remitting Multiple Sclerosis,OTHER: placebo|DRUG: orelabrutinib,"Beijing InnoCare Pharma Tech Co., Ltd.",,ALL,ADULT,PHASE2,160,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-03-01,2026-02-25,2026-03-01,"Neurology Associates of Ormond Beach, Ormond Beach, Florida, 32174, United States|University of South Florida, Tampa, Florida, 33612, United States|Consultants in Neurology LTD, Northbrook, Illinois, 60062, United States|Neurology Associates, P.C., Lincoln, Nebraska, 68510, United States|Premier Neurology, P.C., Greer, South Carolina, 29650, United States|The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230022, China|Peking Union Medical College Hospital, Beijing, Beijing, 100032, China|Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, 100070, China|The First Affiliated Hospital of Chongqing Medical University, Yuzhong, Chongqing, 400016, China|Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, 430060, China|Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China|The First Hospital of Jilin University, Changchun, Jilin, 130021, China|Shengjing Hospital of China Medical University, Shengyang, Liaoning, 110004, China|Huashan Hospital, Fudan University, Shanghai, Shanghai, 200040, China|The 1st Affiliated Hospital of Shanxi Medical University, Taiyuan, Shanxi, China|The Second Affiliated Hospital of Air Force Military Medical University, Xi'an, Shanxi, 710038, China|West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310009, China|NZOZ Wielospecjalistyczna Poradnia Lekarska ""Synapsis"", Katowice, 40-123, Poland|Prywatna Praktyka Lekarska, Katowice, 40-571, Poland|Resmedica NZOZ Kielce, Kielce, 25-726, Poland|MCD Medical, Krakow, 31-637, Poland|Neuromed, Lublin, 20-954, Poland|Nzoz ""Neuro-Kard"", Poznan, 61-853, Poland|Wielospecjalistyczne Centrum Medyczne Ibismed, Zabrze, 41-807, Poland|CE I.I.Mechnykov Dnipropetrovsk RC Hosp of Dnipropetrovsk RC Dept of Neurology, Dnipro, 49005, Ukraine|Medical Center of Dnipro State Medical University, Dnipro State Medical University, Dnipro, 49027, Ukraine|SI USSRI of Medical and Social Problems of Disabilities of MOHU, Dnipro, 49027, Ukraine|CNE Regional Clinical Hospital of Ivano-Frankivsk Regional Council, Ivano-Frankivsk, 76008, Ukraine|Institute of Neurology, Psychiatry and Narcology of NAMSU, Kharkiv, 61068, Ukraine|SI Institute of Neurology, Psychiatry and Narcology of NAMSU, Kharkiv, 61068, Ukraine|CIH Kharkiv City General Practice, Kharkiv, 61172, Ukraine|Medical Center of Limited Liability Company Medbud-Clinic, Kyiv, 3110, Ukraine|CNE of Lviv Reg Council Lviv Reg Clin Hospital Dept of Neurology D.Halytskyi Lviv NMU, Lviv, 79010, Ukraine|CNE City Clinical Hospital #5 of Lviv, Lviv, 79013, Ukraine|CNE Odesa Regional Clinical Hospital of Odesa Regional Council, Odesa, 65025, Ukraine|Medical Center of Limited Liability Company Health Clinic, Medical Clinical Research Center, Vinnytsia, 21009, Ukraine|Medical Center of Limited Liability Company Medical Center Saliutem, Vinnytsia, 21050, Ukraine|Municipal Non-profit Enterprise ""City Hospital No.6"" of Zaporizhzya City Council, Zaporizhzhia, 69035, Ukraine|CNE Zaporizhzhia RCH of ZRC Dept of Neurology #1, Zaporizhzhia, 69600, Ukraine|CNE Zaporizhzhia Regional Clinical Hospital of ZRC, Zaporizhzhia, 69600, Ukraine|Medical Center of Limited Liability Company INET-09, Zaporizhzhya, 69035, Ukraine"
NCT04918251,"EEG and TMS-based Biomarkers of ALS, MS and FTD",https://beta.clinicaltrials.gov/study/NCT04918251,RECRUITING,Amyotrophic Lateral Sclerosis|Frontotemporal Dementia|Multiple Sclerosis,PROCEDURE: 128 electrode electroencephalography (EEG)|PROCEDURE: Transcranial magnetic stimulation (TMS),"University of Dublin, Trinity College","Motor Neurone Disease Association, UK|Irish Research Council, IE|Health Research Board, IE|Research Motor Neurone, IE|Thierry Latran Foundation, FR|ALS Association, USA",ALL,"ADULT, OLDER_ADULT",,400,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-09,2023-02,2023-04,"Academic Unit of Neurology, Trinity College Dublin, The University of Dublin, Dublin, Leinster, Dublin 2, Ireland"
NCT03256851,Telephone-Delivered Exercise for Multiple Sclerosis Fatigue,https://beta.clinicaltrials.gov/study/NCT03256851,COMPLETED,Multiple Sclerosis|Fatigue|Physical Activity,BEHAVIORAL: Telephone-Delivered Exercise Therapy|BEHAVIORAL: In-Person Delivered Exercise Therapy,Wayne State University,National Multiple Sclerosis Society|University of Michigan,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2017-06-01,2018-05-31,2018-07-31,"Wayne State University, Detroit, Michigan, 48201, United States"
NCT04837651,Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab,https://beta.clinicaltrials.gov/study/NCT04837651,COMPLETED,"Multiple Sclerosis|Demyelinating Autoimmune Diseases, CNS|Autoimmune Diseases of the Nervous System|Nervous System Diseases|Demyelinating Diseases|Autoimmune Diseases|Immune System Diseases|Pathologic Processes",DEVICE: Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test|DEVICE: T-Detect COVID T-cell blood test,"Dragonfly Research, LLC",,ALL,ADULT,,48,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-03-02,2021-07-01,2021-07-01,"Dragonfly Research, LLC, Wellesley, Massachusetts, 02481, United States"
NCT03198351,An Observational Study on Teriflunomide-exposed Pregnancies,https://beta.clinicaltrials.gov/study/NCT03198351,RECRUITING,Multiple Sclerosis,DRUG: Teriflunomide (HMR1726),Sanofi,,FEMALE,"CHILD, ADULT, OLDER_ADULT",,325,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-04-25,2023-07-03,2023-07-03,"University of California at San Diego-Site Number:001, San Diego, California, 92093, United States|Investigational Site Number :002, Canada, Canada"
NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00451451,COMPLETED,Relapsing-Remitting Multiple Sclerosis,DRUG: BG00012|DRUG: Placebo|DRUG: Glatiramer Acetate,Biogen,,ALL,ADULT,PHASE3,1417,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2007-06,2011-08,2011-08,"Research Site, Birmingham, Alabama, United States|Research Site, Cullman, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, La Jolla, California, United States|Research Site, Loma Linda, California, United States|Research Site, Pasadena, California, United States|Research Site, Sacramento, California, United States|Research Site, Walnut Creek, California, United States|Research Site, Boulder, Colorado, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Fort Collins, Colorado, United States|Research Site, Maitland, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Naples, Florida, United States|Research Site, Pompano Beach, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, St. Petersburg, Florida, United States|Research Site, Tallahassee, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Augusta, Georgia, United States|Research Site, Columbus, Georgia, United States|Research Site, Meridan, Idaho, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Kansas City, Kansas, United States|Research Site, Louisville, Kentucky, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Clinton Township, Michigan, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Dover, New Hampshire, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, Freehold, New Jersey, United States|Research Site, Teaneck, New Jersey, United States|Research Site, Amherst, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Cedarhurst, New York, United States|Research Site, Mineola, New York, United States|Research Site, Patchogue, New York, United States|Research Site, Plainview, New York, United States|Research Site, Staten Island, New York, United States|Research Site, Stony Brook, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Bellevue, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Edmond, Oklahoma, United States|Research Site, Eugene, Oregon, United States|Research Site, Medford, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Souderton, Pennsylvania, United States|Research Site, Cordova, Tennessee, United States|Research Site, Franklin, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Galveston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Round Rock, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Burlington, Vermont, United States|Research Site, Richmond, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, Madison, Wisconsin, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Gomel, Belarus|Research Site, Minsk, Belarus|Research Site, Vitebsk, Belarus|Research Site, Lommel, Belgium|Research Site, Sijsele-Damme, Belgium|Research Site, Woluwe, Belgium|Research Site, Tuzla, B&H Federation, Bosnia and Herzegovina|Research Site, Banja Luka, Republic Srpska, Bosnia and Herzegovina|Research Site, Sarajevo B&H Federation, Bosnia and Herzegovina|Research Site, Plovdiv, Bulgaria|Research Site, Rousse, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Edmonton, Canada|Research Site, London, Canada|Research Site, Montreal, Canada|Research Site, Osijek, Canada|Research Site, San Jose, Costa Rica|Research Site, Rijeka, Croatia|Research Site, Zagreb, Croatia|Research Site, Ostrava-Moravska, Czech Republic|Research Site, Ostrava, Czech Republic|Research Site, Praha, Czech Republic|Research Site, Kuressaare, Estonia|Research Site, Parnu, Estonia|Research Site, Tallinn, Estonia|Research Site, Tartu, Estonia|Research Site, Caen, France|Research Site, Dijon, France|Research Site, Marseille, France|Research Site, Montpellier, France|Research Site, Nancy, France|Research Site, Nimes, France|Research Site, Strasbourg, France|Research Site, Bamberg, Germany|Research Site, Bayreuth, Germany|Research Site, Berg Starnberger, Germany|Research Site, Berlin, Germany|Research Site, Dusseldorf, Germany|Research Site, Erbach, Germany|Research Site, Erlangen, Germany|Research Site, Giessen, Germany|Research Site, Halle (Saale), Germany|Research Site, Hanburg, Germany|Research Site, Heidelberg, Germany|Research Site, Koln, Germany|Research Site, Magdeburg, Germany|Research Site, Marburg, Germany|Research Site, Munchen, Germany|Research Site, Regensburg, Germany|Research Site, Schwerin, Germany|Research Site, Athens, Greece|Research Site, Larisa, Greece|Research Site, Patra, Greece|Research Site, Thessaloniki, Greece|Research Site, Ahmedabad, India|Research Site, Bangalore, India|Research Site, Calicut, India|Research Site, Chandigarh, India|Research Site, Chennai, India|Research Site, Cochin, India|Research Site, Coimbatore, India|Research Site, Kochi, India|Research Site, Kolkata, India|Research Site, Lucknow, India|Research Site, Ludhiana, India|Research Site, Mangalore, India|Research Site, Mumbai, India|Research Site, New Delhi, India|Research Site, Pune, India|Research Site, Cork, Ireland|Research Site, Dublin, Ireland|Research Site, Galway, Ireland|Research Site, Holon, Israel|Research Site, Safed, Israel|Research Site, Riga, Latvia|Research Site, Skopje, Macedonia, The Former Yugoslav Republic of|Research Site, Guadalajara, Jal, Mexico|Research Site, Morelia, Michoacan, Mexico|Research Site, Monterrey, Nuevo Leon, Mexico|Research Site, Aguascalientes, Mexico|Research Site, Guadalajara, Mexico|Research Site, Mexico DF, 10700, Mexico|Research Site, Mexico DF, Mexico|Research Site, Mexico, 14000, Mexico|Research Site, Monterray, Mexico|Research Site, Chisinau, Moldova, Republic of|Research Site, Kishinev, Moldova, Republic of|Research Site, Hamilton, New Zealand|Research Site, Bialystok, Poland|Research Site, Gdansk, Poland|Research Site, Katowice, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Poznan, Poland|Research Site, Szczecin, Poland|Research Site, Warsaw, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Guaynabo, Puerto Rico|Research Site, Bucuresti, Romania|Research Site, Iasi, Romania|Research Site, Oradea, Romania|Research Site, Tirgu Mures, Romania|Research Site, Tirgu-Mures, Romania|Research Site, Belgrade, Serbia|Research Site, Kragujevac, Serbia|Research Site, Nis, Serbia|Research Site, Novi Sad, Serbia|Research Site, Kosice, Slovakia|Research Site, Martin, Slovakia|Research Site, Barcelona, Spain|Research Site, Bilbao, Spain|Research Site, Cordoba, Spain|Research Site, Gandia, Spain|Research Site, Madrid, Spain|Research Site, Malaga, Spain|Research Site, Santiago de Compostela, Spain|Research Site, Sevilla, Spain|Research Site, Kharkiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lviv, Ukraine|Research Site, Odessa, Ukraine|Research Site, Poltava, Ukraine|Research Site, Simferopol, Ukraine|Research Site, Zaporozhye, Ukraine"
NCT01743651,Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01743651,COMPLETED,Spasticity|Multiple Sclerosis,DRUG: arbaclofen|DRUG: baclofen|DRUG: Placebo,"RVL Pharmaceuticals, Inc.",Osmotica Pharmaceutical US LLC,ALL,"ADULT, OLDER_ADULT",PHASE3,353,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-11,2014-04,2014-04,"Osmotica Study Site-138, Cullman, Alabama, 35058, United States|Osmotica Site-143, Long Beach, California, 92845, United States|Osmotica Study Site-123, Aurora, Colorado, 80045, United States|Osmotica Study Site-110, Bradenton, Florida, 34205, United States|Osmotica Study Site-142, Maitland, Florida, 32751, United States|Osmotica Study Site-119, Ormond Beach, Florida, 32174, United States|Osmotica Study Site-120, Pompano Beach, Florida, 33060, United States|Osmotica Study Site-109, Tampa, Florida, 33606, United States|Osmotica Study Site-126, Northbrook, Illinois, 60096, United States|Osmotica Study Site-108, Fort Wayne, Indiana, 46805, United States|Osmotica Study Site-116, Lenexa, Kansas, 66214, United States|Osmotica Study Site-124, Baltimore, Maryland, 21201, United States|Osmotica Study Site-136, Springfield, Massachusetts, 01104, United States|Osmotica Study Site-101, Ann Arbor, Michigan, 48104, United States|Osmotica Study Site-115, Johnson City, New York, 13790, United States|Osmotica Study Site-113, New York, New York, 10016, United States|Osmotica Study Site-141, New York, New York, 10019, United States|Osmotica Study Site-125, New York, New York, 10029, United States|Osmotica Study Site-106, Charlotte, North Carolina, 28204, United States|Osmotica Study Site-131, Cincinnati, Ohio, 45219, United States|Osmotica Study Site-127, Pittsburgh, Pennsylvania, 15212, United States|Osmotica Study Site-112, San Antonio, Texas, 78229, United States|Osmotica Study Site-133, Salt Lake City, Utah, 84103, United States|Osmotica Study Site-129, Seattle, Washington, 98122, United States|Osmotica SIte-144, Tacoma, Washington, 98405, United States|Osmotica Study Site-509, Pyatigorsk, Stavropol Krai, Russian Federation|Osmotica Study Site-510, Tonnel'nyy, Stavropol Krai, Russian Federation|Osmotica Site-511, Krasnoyarsk, Russian Federation|Osmotica Study Site-508, Krasnoyarsk, Russian Federation|Osmotica Study Site-510, Krasnoyarsk, Russian Federation|Osmotica Study Site-501, Moscow, Russian Federation|Osmotica Study Site-502, Moscow, Russian Federation|Osmotica Study Site-506, Sestroretsk, Russian Federation|Osmotica Study Site-507, St Petersburg, Russian Federation|Osmotica Study Site-503, St. Petersburg, Russian Federation|Osmotica Study Site-505, St. Petersburg, Russian Federation|Osmotica Study Site 614, Chernigov, 14001, Ukraine|Osmotica Study Site-602, Dnipropetrovsk, 49005, Ukraine|Osmotica Study Site-603, Dnipropetrovsk, 49022, Ukraine|Osmotica Study Site-609, Dnipropetrovsk, 53012, Ukraine|Osmotica Study Site-611, Donetsk, 83003, Ukraine|Osmotica Study Site-613, Ivano-Frankivsk, 76008, Ukraine|Osmotica Site-605, Kharkov, 61068, Ukraine|Osmotica Study Site-610, Kharkov, 61103, Ukraine|Osmotica Study Site-604, Kharkov, Ukraine|Osmotica Study Site-606, Lviv, Ukraine|Osmotica Study Site-608, Odessa, Ukraine|Osmotica Study Site-615, Uzhgorod, 88018, Ukraine"
NCT01049451,Pulse ACTH vs. MP for MS,https://beta.clinicaltrials.gov/study/NCT01049451,COMPLETED,Multiple Sclerosis,DRUG: ACTH|DRUG: Methylprednisolone,University of Southern California,,ALL,"ADULT, OLDER_ADULT",PHASE1,23,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2009-11,2013-06,2013-07,"USC MS Center, Los Angeles, California, 90033, United States"
NCT01144351,A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01144351,TERMINATED,Multiple Sclerosis,DRUG: ELND002|DRUG: Placebo,Elan Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE1,32,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2010-03,2012-12,,"Research Site, Berkeley, California, 94705, United States|Research Site, Fresno, California, 93710, United States|Research Site, Newport Beach, California, 92663, United States|Research Site, Aurora, Colorado, 80045, United States|Research Site, Tampa, Florida, 33609, United States|Research Site, Vero Beach, Florida, 32960, United States|Research Site, Northbrook, Illinois, 60062, United States|Research Site, Farmington Hills, Michigan, 48334, United States|Research Site, Minneapolis, Minnesota, 55404, United States|Research Site, Albuquerque, New Mexico, 87106, United States|Research Site, Raleigh, North Carolina, 27607, United States|Research Site, Cincinnati, Ohio, 45219, United States|Research Site, Uniontown, Ohio, 44685, United States|Research Site, Cordova, Tennessee, 78258, United States|Research Site, Knoxville, Tennessee, 37920, United States|Research Site, San Antonio, Texas, 78258, United States|Research Site, Salt Lake City, Utah, 84106, United States|Research Site, Calgary, Alberta, T2N 2T9, Canada|Research Site, Greenfield Park, Quebec, J4V 2J2, Canada|Research Site, Montreal, Quebec, H3A 2B4, Canada"
NCT03372187,Pilot and Feasibility Trial of a Telehealth Dietary Intervention for MS,https://beta.clinicaltrials.gov/study/NCT03372187,COMPLETED,Multiple Sclerosis,BEHAVIORAL: DIET-MS,University of Alabama at Birmingham,National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2018-03-09,2019-06-30,2019-12-31,"University of Alabama at Birmingham, Birmingham, Alabama, 35294, United States"
NCT05332951,Study of Empathy in MS,https://beta.clinicaltrials.gov/study/NCT05332951,NOT_YET_RECRUITING,Multiple Sclerosis,OTHER: Interpersonal Reactivity Index,Assistance Publique - Hôpitaux de Paris,,ALL,ADULT,,150,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-05-30,2022-08-30,2022-08-30,
NCT03046251,Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03046251,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,DRUG: Natalizumab,State University of New York at Buffalo,,FEMALE,"ADULT, OLDER_ADULT",PHASE4,30,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2015-08,2023-12,2023-12,"SUNY Buffalo, Buffalo, New York, 14203, United States"
NCT04465448,Evaluation of the Reproducibility of the Measurement of the QSM Signal (Quantitative Susceptibility Mapping),https://beta.clinicaltrials.gov/study/NCT04465448,RECRUITING,White Matter Hyperintensity|Multiple Sclerosis,OTHER: MRI,Fondation Ophtalmologique Adolphe de Rothschild,,ALL,"ADULT, OLDER_ADULT",,58,NETWORK,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-12-17,2023-06-16,2023-12-31,"Hhopital fondation adolphe de rothschild, Paris, 75019, France"
NCT05809986,Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study,https://beta.clinicaltrials.gov/study/NCT05809986,NOT_YET_RECRUITING,Relapsing Multiple Sclerosis,OTHER: Ofatumumab,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",,174,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-05-31,2026-08-30,2026-08-30,
NCT04682548,Estimating Prevalence of COVID-19 Infection and SARS-CoV-2 Antibodies in MS Patients,https://beta.clinicaltrials.gov/study/NCT04682548,COMPLETED,Multiple Sclerosis|Covid19,,NYU Langone Health,,ALL,ADULT,,920,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-01-05,2022-09-15,2022-09-15,"NYU Langone Health, New York, New York, 10016, United States"
NCT05299151,Gait Analysis in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT05299151,ENROLLING_BY_INVITATION,Multiple Sclerosis|3D Gait Analysis|Vestibular Rehabilitation,OTHER: Vestibular exercises|OTHER: Standard neurorehabilitation exercises,Istanbul Kültür University,Istanbul University - Cerrahpasa (IUC),ALL,ADULT,NA,16,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: HEALTH_SERVICES_RESEARCH,2022-06-01,2023-07-01,2023-08-31,"Istanbul University - Cerrahpaşa, Vocational School of Health Services, Istanbul, Turkey"
NCT00726648,CDP323 Biomarker Study,https://beta.clinicaltrials.gov/study/NCT00726648,COMPLETED,Relapsing Multiple Sclerosis,DRUG: CDP323|DRUG: CDP323|DRUG: CDP323|DRUG: CDP323|DRUG: Placebo,UCB Pharma,Biogen,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,71,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2008-07,2009-03,2009-03,"Tooting, London, United Kingdom|Croydon, Surrey, United Kingdom"
NCT04874051,Sensor-based Assessment and Rehabilitation of Balance in Neurological Diseases,https://beta.clinicaltrials.gov/study/NCT04874051,RECRUITING,Stroke|Multiple Sclerosis|Parkinson Disease,DEVICE: Experimental Group|OTHER: Control Group,"IRCCS San Camillo, Venezia, Italy","IRCCS San Raffaele|Istituti Clinici Scientifici Maugeri SpA|IRCCS National Neurological Institute ""C. Mondino"" Foundation|I.R.C.C.S. Fondazione Santa Lucia",ALL,"ADULT, OLDER_ADULT",NA,120,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-09-02,2023-12-31,2023-12-31,"IRCCS Fondazione Mondino, Pavia, 27100, Italy|IRCCS ICS Maugeri Spa SB, Pavia, 27100, Italy|IRCCS San Raffaele Pisana, Rom, 00163, Italy|IRCCS Fondazione Santa Lucia, Rom, 00179, Italy|San Camillo IRCCS, Venice, 30126, Italy"
NCT02011451,Safety and Brain Protection Effects of the Green Tea Extract Theaphenon 95% (95% Pure EGCG) in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02011451,WITHDRAWN,Multiple Sclerosis,DRUG: 95% Pure ECGC capsules 200mg|DRUG: Placebo Comparator:,Louisiana State University Health Sciences Center in New Orleans,National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2015-12,2017-03,2017-12,"LSU Health Sciences Center, New Orleans, Louisiana, 70112, United States"
NCT00792766,Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM),https://beta.clinicaltrials.gov/study/NCT00792766,COMPLETED,Tuberous Sclerosis|Angiolipoma,DRUG: everolimus (RAD001),"Children's Hospital Medical Center, Cincinnati",Novartis,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,20,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2008-12,2013-09,2013-09,"Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 45229, United States"
NCT03399981,Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries,https://beta.clinicaltrials.gov/study/NCT03399981,ACTIVE_NOT_RECRUITING,Progressive Multifocal Leukoencephalopathy,BIOLOGICAL: Tysabri,Biogen,,ALL,"CHILD, ADULT, OLDER_ADULT",,80327,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-01-24,2023-12-31,2023-12-31,"Research Site, Cambridge, Massachusetts, 02142, United States"
NCT00884481,Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS,https://beta.clinicaltrials.gov/study/NCT00884481,COMPLETED,Relapsing-Remitting Multiple Sclerosis|Fatigue,OTHER: Natalizumab,Biogen,,ALL,"ADULT, OLDER_ADULT",,195,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2009-03-23,2011-06-30,2011-06-30,"Research Site, Graz, Austria|Research Site, Innsbruck, Austria|Research Site, Salzburg, Austria|Research Site, Villach, Austria|Research Site, Wien, Austria|Research Site, Aarhus, Denmark|Research Site, Copenhagen, Denmark|Research Site, Odense, Denmark|Research Site, Bergen, Norway|Research Site, Bodø, Norway|Research Site, Drammen, Norway|Research Site, Førde, Norway|Research Site, Lillehammer, Norway|Research Site, Molde, Norway|Research Site, Oslo, Norway|Research Site, Danderyd, Sweden|Research Site, Göteborg, Sweden|Research Site, Helsingborg, Sweden|Research Site, Jönköping, Sweden|Research Site, Karlstad, Sweden|Research Site, Lund, Sweden|Research Site, Malmö, Sweden|Research Site, Norrköping, Sweden|Research Site, Stockholm, Sweden|Research Site, Trollhättan, Sweden|Research Site, Umeå, Sweden|Research Site, Örebro, Sweden"
NCT00355095,Safety and Efficacy Study of Erythropoietin as add-on Therapy of Methylprednisolone to Treat Acute Optic Neuritis,https://beta.clinicaltrials.gov/study/NCT00355095,COMPLETED,Optic Neuritis,DRUG: Erythropoietin,Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH,,ALL,ADULT,PHASE2,40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2006-08,2011-02,2011-07,"Department of Neurology University Hospital Goettingen, Goettingen, Niedersachsen, 37075, Germany|Department of Neurology University Homborg Hospital of the Saarland, Germany, Homburg, Saarland, 66421, Germany|University Hospital of Hamburg-Eppendorf (Institut of Neuroimmunology and Clinical MS Research (INIMS)), Hamburg, 20246, Germany"
NCT04963335,Effects of a User-centered Exergame Training on Motor and Cognitive Functions in PwMS,https://beta.clinicaltrials.gov/study/NCT04963335,RECRUITING,Multiple Sclerosis,BEHAVIORAL: Exergame Training,Eling DeBruin,,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-03-28,2021-07-31,2021-07-31,"ETH Zürich, Zürich, 8093, Switzerland"
NCT00213135,A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),https://beta.clinicaltrials.gov/study/NCT00213135,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Cladribine 5.25 mg/kg|DRUG: Cladribine 3.5 mg/kg|OTHER: Placebo,EMD Serono,,ALL,"ADULT, OLDER_ADULT",PHASE3,1326,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2005-04,2008-11,2008-11,
NCT02883335,Lorraine Registry of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02883335,RECRUITING,Multiple Sclerosis,OTHER: Observational registry,"Central Hospital, Nancy, France","Institut National de la Santé Et de la Recherche Médicale, France|University of Lorraine",ALL,"CHILD, ADULT, OLDER_ADULT",,6000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2003-05,2030-01,2030-01,"CIC 1433 Épidémiologie clinique, Inserm, Université de Lorraine, CHRU de Nancy, Nancy, 54000, France"
NCT04090996,Effects of A Dual-Task Intervention in Postural Control in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT04090996,UNKNOWN,Multiple Sclerosis,DIAGNOSTIC_TEST: Dual TAsk,"University Hospital, Limoges",,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-01-20,2022-04-20,2022-09-20,"Neurologie, Limoges, France"
NCT02059096,Analgesic Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) for Central Neuropathic Pain in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02059096,UNKNOWN,Multiple Sclerosis With Central Neuropathic Pain,DEVICE: Repetitive Transcranial Magnetic Stimulation (rTMS),"University Hospital, Clermont-Ferrand",,ALL,ADULT,PHASE3,66,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2014-01-05,2023-02,2023-02,"CHU Ambroise Paré, Boulogne-Billancourt, France|CHU de Clermont-Ferrand, Clermont-Ferrand, 63003, France|Hôpital Henri Mondor, Créteil, France"
NCT02424396,Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02424396,COMPLETED,Relapsing Remitting Multiple Sclerosis,DRUG: IL2|DRUG: Placebo,Assistance Publique - Hôpitaux de Paris,Fondation ARSEP/AFM,ALL,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2016-06-13,2019-10-11,2020-06-15,"Centre d'investigation Clinique - Pitié salpêtrière, Paris, 75013, France|Centre d'investigation clinique Biothérapie Immunologie (CIC-BTi) - Groupe Hospitalier Pitié-Salpêtrière - AP-HP, Paris, 75013, France|Département des maladies du système nerveux et Centre d'investigation clinique - Groupe Hospitalier Pitié-Salpêtrière - AP-HP, Paris, 75013, France"
NCT04603196,Prevalence and Impact of Obstructive Sleep Apnea in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04603196,RECRUITING,Multiple Sclerosis|Obstructive Sleep Apnea,,Beth Israel Deaconess Medical Center,,ALL,"ADULT, OLDER_ADULT",,800,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-06-20,2024-06-20,2024-06-20,"Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States"
NCT04821596,Study of the Mechanisms of Action of Cladribine in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04821596,UNKNOWN,Multiple Sclerosis,OTHER: biological collection,"University Hospital, Rouen",,ALL,"ADULT, OLDER_ADULT",NA,75,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2020-07-13,2021-08-13,2021-12-31,"Rouen University Hospital, Rouen, 760031, France"
NCT04832269,Effects of a Multiple Sclerosis Relapse Therapy on Offspring Neurocognitive Development and Behaviour,https://beta.clinicaltrials.gov/study/NCT04832269,RECRUITING,Multiple Sclerosis,OTHER: Exposure to methylprednisolone during pregnancy,Jena University Hospital,"Ruhr University of Bochum|Interdisciplinary Center of Clinical Research of the Medical Faculty Jena|Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany",ALL,"CHILD, ADULT",,80,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-10-19,2022-12-31,2022-12-31,"Ruhr University of Bochum, Bochum, 44791, Germany|University Hospital Jena, Jena, 07747, Germany"
NCT02326935,Multi-Center Study Safety of Adipose Derived Mesenchymal Stem Cells for the Treatment of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02326935,TERMINATED,Multiple Sclerosis,BIOLOGICAL: Autologous adipose derived mesenchymal cells,American CryoStem Corporation,,ALL,"ADULT, OLDER_ADULT",PHASE1,2,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-11,2018-05-18,2018-05-18,"The Da Vinci Center, George Town, KY1-1205, Cayman Islands"
NCT02612935,An Observational Pilot Study of Lumosity Computerized Cognitive Training in Subjects With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02612935,COMPLETED,Multiple Sclerosis (MS),DEVICE: Lumosity,"Lumos Labs, Inc.",Dignity Health,ALL,"ADULT, OLDER_ADULT",,88,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-03,2017-02,2017-02,
NCT00772525,Single Oral Doses Study of Nerispirdine on Visual Function in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00772525,COMPLETED,Multiple Sclerosis|Optic Nerve|Neuritis,DRUG: Nerispirdine|DRUG: Placebo,Sanofi,,ALL,"ADULT, OLDER_ADULT",PHASE2,31,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2008-09,2009-06,2009-06,"Sanofi-Aventis Administrave Office, Bridgewater, New Jersey, 08807, United States"
NCT03271125,Intensive Multimodal Training for Persons With MS,https://beta.clinicaltrials.gov/study/NCT03271125,COMPLETED,Rehabilitation|Multiple Sclerosis,BEHAVIORAL: Treadmill|BEHAVIORAL: Resistance,Fondazione Don Carlo Gnocchi Onlus,,ALL,"ADULT, OLDER_ADULT",NA,42,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2013-01-08,2015-05-19,,"Fondazione Don Carlo Gnocchi IRCCS, Milan, MI, 20148, Italy"
NCT01142492,A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®),https://beta.clinicaltrials.gov/study/NCT01142492,COMPLETED,Relapsing-Remitting Multiple Sclerosis,DRUG: Interferon beta-1a,"Merck KGaA, Darmstadt, Germany",,ALL,"CHILD, ADULT, OLDER_ADULT",,403,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2005-01,2008-07,2008-07,
NCT05422625,PTNS for Female Patients Suffering From Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05422625,RECRUITING,Multiple Sclerosis|Overactive Bladder,DEVICE: PTNS Treatment|DEVICE: Sham PTNS Treatment,William Beaumont Hospitals,,FEMALE,"ADULT, OLDER_ADULT",NA,34,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2023-01-09,2023-10,2023-10,"Beaumont Hospital - Royal Oak, Royal Oak, Michigan, 48073, United States"
NCT00753792,Oral Corticotherapy in Megadoses to Treat Multiple Sclerosis During Relapse,https://beta.clinicaltrials.gov/study/NCT00753792,COMPLETED,Multiple Sclerosis,DRUG: methylprednisolone|DRUG: methylprednisolone|DRUG: Placebo,Germans Trias i Pujol Hospital,,ALL,ADULT,PHASE4,49,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2008-11,2010-11,2011-01,"Germans Trias i Pujol Hospital, Badalona, Barcelona, 08916, Spain|Hospital de Figueres, Figueres, Girona, 17600, Spain|Hospital de Mataró, Barcelona, 08034, Spain|Hospital Vall d'Hebron, Barcelona, 08035, Spain|Hospital Clinic de Barcelona, Barcelona, 08036, Spain|Hospital Dr. Trueta, Girona, 17007, Spain|Hospital Arnau de Vilanova, Lleida, 25198, Spain"
NCT02869425,To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS,https://beta.clinicaltrials.gov/study/NCT02869425,WITHDRAWN,Multiple Sclerosis|Sperm,DRUG: arbaclofen ER Tablets|DRUG: Placebo for arbaclofen ER tablets,"RVL Pharmaceuticals, Inc.",Osmotica Pharmaceutical US LLC,MALE,ADULT,PHASE3,0,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: OTHER",2016-07,2018-10,2019-01,"Advance Medical Pain Management & Research Clinic, Miami, Florida, 33169, United States|Meridien Research, Tampa, Florida, 33604, United States"
NCT04248725,Telehealth Pain Self-Management for Employed Adults,https://beta.clinicaltrials.gov/study/NCT04248725,RECRUITING,"Chronic Pain|Brain Injuries, Traumatic|Multiple Sclerosis|Spinal Cord Injuries|Amputation",BEHAVIORAL: E-TIPS,University of Washington,Department of Health and Human Services,ALL,"ADULT, OLDER_ADULT",NA,200,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-03-02,2023-03-31,2023-09-01,"University of Washington, Seattle, Washington, 98104, United States"
NCT03656055,Analysis of Neurodegenerative Process Within Visual Ways In Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03656055,COMPLETED,Multiple Sclerosis,,"University Hospital, Lille",,ALL,"ADULT, OLDER_ADULT",,108,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-04-21,2018-01-03,2019-01-03,"Hôpital Roger Salengro, CHRU, Lille, France"
NCT01538225,Neurophysiological Study of Sativex in Multiple Sclerosis (MS) Spasticity,https://beta.clinicaltrials.gov/study/NCT01538225,COMPLETED,Multiple Sclerosis,DRUG: Sativex®|DRUG: Placebo,"Almirall, S.A.",,ALL,"ADULT, OLDER_ADULT",PHASE3,45,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2012-04,2013-11,2013-11,"Institute of Experimental Neurology, Milan, 20132, Italy"
NCT01780792,Examining the Effects of Video-game Exercise on Mobility and Brain Plasticity in Individuals With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01780792,COMPLETED,Multiple Sclerosis,OTHER: Dance Dance Revolution video game play,Ohio State University,,ALL,ADULT,NA,30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2011-08,2015-08,2016-12,"The Ohio State University Atwell Hall, Columbus, Ohio, 43210, United States"
NCT01699555,First-in-Human Study With GNbAC1 in Healthy Volunteers,https://beta.clinicaltrials.gov/study/NCT01699555,COMPLETED,Multiple Sclerosis,BIOLOGICAL: GNbAC1|BIOLOGICAL: GNbAC1 placebo,GeNeuro Innovation SAS,,MALE,ADULT,PHASE1,33,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-07,2012-03,2012-08,
NCT05495425,Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC,https://beta.clinicaltrials.gov/study/NCT05495425,RECRUITING,Tuberous Sclerosis Complex,DRUG: NPC-12Y gel|DRUG: NPC-12Y placebo gel,Nobelpharma,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,40,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-06-01,2023-11-30,2024-09-30,"Fujita Health University Hospital, Toyoake, Aichi, Japan|Gunma University Hospital, Maebashi, Gunma, Japan|Osaka University Hospital, Suita, Osaka, Japan|Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka, Japan|National Hospital Organization Nishi-Niigata Chuo Hospital, Niigata, Japan"
NCT02027025,Study of SPARC1103 in Subjects With Spasticity,https://beta.clinicaltrials.gov/study/NCT02027025,COMPLETED,Spasticity,DRUG: SPARC1103 low dose|DRUG: SPARC1103 high dose|DRUG: SPARC Placebo,Sun Pharma Advanced Research Company Limited,,ALL,"ADULT, OLDER_ADULT",PHASE2,142,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2014-04-21,2017-04-28,2017-04-28,"SPARC Site 4, Long Beach, California, United States|SPARC Site 6, San Diego, California, United States|SPARC Site 10, Aurora, Colorado, United States|SPARC Site 2, Jacksonville, Florida, United States|SPARC Site 7, Miami Springs, Florida, United States|SPARC Site 15, Miami, Florida, United States|SPARC Site 5, Orlando, Florida, United States|SPARC Site 13, Tampa, Florida, United States|SPARC Site 11, Kansas City, Kansas, United States|SPARC Site 3, Lenexa, Kansas, United States|SPARC Site 1, Bingham Farms, Michigan, United States|SPARC Site 14, Albuquerque, New Mexico, United States|SPARC Site 9, Charlotte, North Carolina, United States|SPARC Site 8, Cleveland, Ohio, United States|SPARC Site 12, Richland, Washington, United States|SPARC Site 18, Moscow, Russian Federation|SPARC Site 17, Nizhniy Novgorod, Russian Federation|SPARC Site 20, Samara, Russian Federation|SPARC Site 19, Smolensk, Russian Federation|SPARC Site 16, Ufa, Russian Federation|SPARC Site 22, Dnepropetrovsk, Ukraine|SPARC Site 21, Ivano-Frankivs'k, Ukraine|SPARC Site 23, L'viv, Ukraine"
NCT01718392,"Rehabilitation in Multiple Sclerosis: Influence of Exercise on Development of Insulin Resistance, Muscle Power and Aerobic Capacity",https://beta.clinicaltrials.gov/study/NCT01718392,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Training,Hasselt University,,ALL,"ADULT, OLDER_ADULT",NA,45,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2011-03,2013-03,2013-09,"REVAL, Diepenbeek, 3590, Belgium"
NCT05648292,"The Relationships Between Personal Identity, Autobiographical Memory and Future Thinking in People With Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT05648292,RECRUITING,"Multiple Sclerosis, Relapsing-Remitting|Healthy Controls",BEHAVIORAL: Neuropsychological tests and psychological questionnaires,Centre d'Investigation Clinique et Technologique 805,University Paris 8 Vincennes Saint Denis|ARSEP foundation,ALL,ADULT,,90,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-12-07,2024-12-07,2025-06-07,"Hopital Raymond Poincaré Garches, Garches, Hauts De Seine, 92380, France"
NCT02047825,Upper Limbs Intervention in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02047825,COMPLETED,Multiple Sclerosis,OTHER: Upper limbs intervention|OTHER: Usual treatment,Universidad de Granada,,ALL,"ADULT, OLDER_ADULT",NA,37,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2014-01,2015-08,2016-02,"Faculty of Health Sciences, Granada, 18071, Spain"
NCT02553525,Effects of Stimulation Patterns of Deep Brain Stimulation,https://beta.clinicaltrials.gov/study/NCT02553525,ENROLLING_BY_INVITATION,Parkinson Disease|Essential Tremor|Multiple Sclerosis,PROCEDURE: Therapeutic Stimulation Patterns|PROCEDURE: Symptogenic Stimulation Patterns,Duke University,National Institute of Neurological Disorders and Stroke (NINDS)|Emory University|University of Florida|Boston Scientific Corporation,ALL,"ADULT, OLDER_ADULT",NA,180,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE,2016-06-02,2026-09,2026-09,"University of Florida, Gainesville, Florida, 32610, United States|Emory University, Atlanta, Georgia, 30322, United States|Duke University, Durham, North Carolina, 27708, United States"
NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab,https://beta.clinicaltrials.gov/study/NCT04353492,ACTIVE_NOT_RECRUITING,Relapsing Multiple Sclerosis,BIOLOGICAL: Ofatumumab,Novartis Pharmaceuticals,,ALL,ADULT,PHASE3,564,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-07-14,2025-04-11,2025-04-11,"Novartis Investigative Site, Fullerton, California, 92835, United States|Novartis Investigative Site, Aurora, Colorado, 80045, United States|Novartis Investigative Site, Newark, Delaware, 19713, United States|Novartis Investigative Site, Hollywood, Florida, 33021, United States|Novartis Investigative Site, Maitland, Florida, 32751, United States|Novartis Investigative Site, Miami, Florida, 33032, United States|Novartis Investigative Site, Miami, Florida, 33136, United States|Novartis Investigative Site, Sarasota, Florida, 34233, United States|Novartis Investigative Site, Tampa, Florida, 33609, United States|Novartis Investigative Site, Tampa, Florida, 33612, United States|Novartis Investigative Site, West Palm Beach, Florida, 33407, United States|Novartis Investigative Site, Atlanta, Georgia, 30327, United States|Novartis Investigative Site, Suwanee, Georgia, 30024, United States|Novartis Investigative Site, Baltimore, Maryland, 21287, United States|Novartis Investigative Site, Las Vegas, Nevada, 89106, United States|Novartis Investigative Site, Albuquerque, New Mexico, 87131-0001, United States|Novartis Investigative Site, Woodmere, New York, 11598, United States|Novartis Investigative Site, Cleveland, Ohio, 44195, United States|Novartis Investigative Site, Westerville, Ohio, 43082, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, 73104, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, 19107-5098, United States|Novartis Investigative Site, Houston, Texas, 77030, United States|Novartis Investigative Site, Plano, Texas, 75024, United States|Novartis Investigative Site, Fairfax, Virginia, 22030, United States|Novartis Investigative Site, Milwaukee, Wisconsin, 53215, United States|Novartis Investigative Site, Rosario, Santa Fe, S2000BZL, Argentina|Novartis Investigative Site, Rosario, Santa Fe, S2000DSW, Argentina|Novartis Investigative Site, Buenos Aires, C1424BYD, Argentina|Novartis Investigative Site, Tucuman, 4000, Argentina|Novartis Investigative Site, New Lambton Heights, New South Wales, 2305, Australia|Novartis Investigative Site, Woolloongabba, Queensland, 4102, Australia|Novartis Investigative Site, Parkville, Victoria, 3050, Australia|Novartis Investigative Site, Linz, Oberoesterreich, A 4020, Austria|Novartis Investigative Site, Linz, 4020, Austria|Novartis Investigative Site, Vienna, 1090, Austria|Novartis Investigative Site, Wien, 1010, Austria|Novartis Investigative Site, Edegem, Antwerpen, 2650, Belgium|Novartis Investigative Site, Brugge, 8000, Belgium|Novartis Investigative Site, Bruxelles, 1200, Belgium|Novartis Investigative Site, Pleven, 5800, Bulgaria|Novartis Investigative Site, Sofia, 1113, Bulgaria|Novartis Investigative Site, Sofia, 1413, Bulgaria|Novartis Investigative Site, Sofia, 1431, Bulgaria|Novartis Investigative Site, Toronto, Ontario, M4N 3M5, Canada|Novartis Investigative Site, Brno, Czech Republic, 656 91, Czechia|Novartis Investigative Site, Havirov, Czech Republic, 736 01, Czechia|Novartis Investigative Site, Teplice, Czech Republic, 415 01, Czechia|Novartis Investigative Site, Hradec Kralove, CZE, 500 05, Czechia|Novartis Investigative Site, Praha, 12808, Czechia|Novartis Investigative Site, Tallinn, 11315, Estonia|Novartis Investigative Site, Tartu, 51014, Estonia|Novartis Investigative Site, Bielefeld, D 33647, Germany|Novartis Investigative Site, Cottbus, 03048, Germany|Novartis Investigative Site, Heidelberg, 69120, Germany|Novartis Investigative Site, Koln, 50935, Germany|Novartis Investigative Site, Leipzig, 04275, Germany|Novartis Investigative Site, Muenchen, 81377, Germany|Novartis Investigative Site, Osnabrück, 49076, Germany|Novartis Investigative Site, Potsdam, 14471, Germany|Novartis Investigative Site, Siegen, 57076, Germany|Novartis Investigative Site, Ulm, 89073, Germany|Novartis Investigative Site, Ulm, 89081, Germany|Novartis Investigative Site, Westerstede/Oldenburg, 26655, Germany|Novartis Investigative Site, Larissa, GR, 411 10, Greece|Novartis Investigative Site, Thessaloniki, 53246, Greece|Novartis Investigative Site, Thessaloniki, GR 54636, Greece|Novartis Investigative Site, Budapest, HUN, 1135, Hungary|Novartis Investigative Site, Budapest, HUN, 1204, Hungary|Novartis Investigative Site, Budapest, Komarom Esztergom, 1138, Hungary|Novartis Investigative Site, Pecs, 7623, Hungary|Novartis Investigative Site, Firenze, FI, 50134, Italy|Novartis Investigative Site, Pavia, PV, 27100, Italy|Novartis Investigative Site, Roma, RM, 00152, Italy|Novartis Investigative Site, Verona, VR, 37134, Italy|Novartis Investigative Site, Riga, LV, LV-1005, Latvia|Novartis Investigative Site, Riga, LV 1002, Latvia|Novartis Investigative Site, Ashrafieh, 166830, Lebanon|Novartis Investigative Site, Beirut, 1107 2020, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Ciudad de Mexico, Distrito Federal, 06700, Mexico|Novartis Investigative Site, Mexico, Distrito Federal, 03100, Mexico|Novartis Investigative Site, Morelia, Michoacan, 58260, Mexico|Novartis Investigative Site, Oslo, NO 0450, Norway|Novartis Investigative Site, Bydgoszcz, Woj Kujawsko-pomorskie, 85-796, Poland|Novartis Investigative Site, Katowice, 40 571, Poland|Novartis Investigative Site, Kielce, 25 726, Poland|Novartis Investigative Site, Lodz, 90-153, Poland|Novartis Investigative Site, Wroclaw, 51-685, Poland|Novartis Investigative Site, Braga, 4710243, Portugal|Novartis Investigative Site, Lisboa, 1349-019, Portugal|Novartis Investigative Site, Loures, 2674514, Portugal|Novartis Investigative Site, Porto, 4099-001, Portugal|Novartis Investigative Site, Moscow, 115516, Russian Federation|Novartis Investigative Site, Moscow, 127015, Russian Federation|Novartis Investigative Site, St Petersburg, 190000, Russian Federation|Novartis Investigative Site, Riyadh, SAU, 11525, Saudi Arabia|Novartis Investigative Site, Jeddah, 21499, Saudi Arabia|Novartis Investigative Site, Kosice, Slovak Republic, 04066, Slovakia|Novartis Investigative Site, Banska Bystrica, 975 17, Slovakia|Novartis Investigative Site, Bratislava, 813 69, Slovakia|Novartis Investigative Site, Bratislava, 82606, Slovakia|Novartis Investigative Site, Bratislava, 83305, Slovakia|Novartis Investigative Site, Nitra, 94901, Slovakia|Novartis Investigative Site, Trnava, 917 75, Slovakia|Novartis Investigative Site, Ljubljana, 1000, Slovenia|Novartis Investigative Site, Maribor, 2000, Slovenia|Novartis Investigative Site, Sevilla, Andalucia, 41009, Spain|Novartis Investigative Site, Barcelona, Cataluna, 08026, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, 46010, Spain|Novartis Investigative Site, El Palmar, Murcia, 30120, Spain|Novartis Investigative Site, Baracaldo, Vizcaya, 48903, Spain|Novartis Investigative Site, Madrid, 28040, Spain|Novartis Investigative Site, Santa Cruz de Tenerife, 38009, Spain|Novartis Investigative Site, Valencia, 46026, Spain|Novartis Investigative Site, Basel, 4031, Switzerland|Novartis Investigative Site, Sancaktepe, Istanbul, 34785, Turkey|Novartis Investigative Site, Istanbul, TUR, 34098, Turkey|Novartis Investigative Site, Izmir, 35040, Turkey|Novartis Investigative Site, Samsun, 55139, Turkey|Novartis Investigative Site, Trabzon, 61080, Turkey|Novartis Investigative Site, Cardiff, CF14 4XW, United Kingdom|Novartis Investigative Site, Swansea, United Kingdom"
NCT03710655,Evaluate Safety and Efficacy of Apitox Add-on Therapy for Improving Disability and Quality of Life in MS Patients,https://beta.clinicaltrials.gov/study/NCT03710655,UNKNOWN,Multiple Sclerosis,DRUG: Apitox - pure honeybee toxin|DRUG: Placebo,"Apimeds, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE3,468,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-04,2019-08,2019-11,
NCT01299025,Balance Training for People With Multiple Sclerosis Using Nintendo Wii Fit,https://beta.clinicaltrials.gov/study/NCT01299025,COMPLETED,Multiple Sclerosis,OTHER: Training using Nintendo Wii Fit,Örebro County Council,Uppsala-Örebro Regional Research Council|Norrbacka-Eugenia Foundation,ALL,"ADULT, OLDER_ADULT",NA,84,OTHER_GOV,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2010-09,2011-06,2011-06,"Mälarsjukhuset, Eskilstuna, 63188, Sweden|Karlstad hospital, Karlstad, Sweden|Västerås hospital, Västerås, 72189, Sweden|Family Medicine Research centre, Örebro, 70116, Sweden"
NCT05342025,Proprioceptive Neuromuscular Facilitation in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05342025,COMPLETED,Multiple Sclerosis,OTHER: PNF|OTHER: Breathing exercises,Biruni University,,ALL,ADULT,NA,34,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-05-01,2022-11-15,2023-04-01,"Biruni University, Istanbul, Turkey"
NCT01217125,Rapamycin In Angiomyolipomas In Patients With Tuberous Sclerosis,https://beta.clinicaltrials.gov/study/NCT01217125,COMPLETED,Angiomyolipoma,DRUG: Sirolimus,Fundacio Puigvert,"Ministry of Health, Spain",ALL,"CHILD, ADULT, OLDER_ADULT",PHASE4,18,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2008-10,2011-05,2011-05,
NCT03067025,"Sleep, Physical Activity and Multiple Sclerosis Symptoms in Pediatric Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT03067025,COMPLETED,Pediatric Multiple Sclerosis,DEVICE: Actigraphy,The Hospital for Sick Children,University of Alabama at Birmingham|Queen's University,ALL,"CHILD, ADULT",,50,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-03-07,2019-09-16,2019-09-16,"Hospital for Sick Children, Toronto, Ontario, M5G1X8, Canada"
NCT01090492,PF-00489791 For The Treatment Of Raynaud's,https://beta.clinicaltrials.gov/study/NCT01090492,COMPLETED,Raynaud's Disease|Peripheral Vascular Disease,DRUG: PF-00489791|DRUG: PF-00489791|DRUG: PF-00489791|DRUG: PF-00489791|DRUG: PF-00489791|DRUG: PF-00489791|DRUG: PF-00489791|DRUG: PF-00489791,Pfizer,,ALL,"ADULT, OLDER_ADULT",PHASE2,243,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2010-08-04,2011-05-31,2011-05-31,"Stanford Hospital and Outpatient Center, Redwood City, California, 94063, United States|University of Connecticut Health Center, Farmington, Connecticut, 06030-5353, United States|Georgetown University Hospital, Washington, District of Columbia, 20007, United States|Arthritis and Rheumatology of Georgia, Atlanta, Georgia, 30342, United States|Rockford Orthopedic Associates, Rockford, Illinois, 61107, United States|Diagnostic Rheumatology and Research, PC, Indianapolis, Indiana, 46227, United States|Memorial Health System, Inc. dba Memorial Medical Group Clinical Research Institute, South Bend, Indiana, 46601, United States|Johns Hopkins University - Division of Rheumatology, Baltimore, Maryland, 21224, United States|The Center for Rheumatology and Bone Research, Wheaton, Maryland, 20902, United States|Clinical Pharmacology Study Group, Worcester, Massachusetts, 01610, United States|University of Michigan, Ann Arbor, Michigan, 48106, United States|University of Michigan Health System, Ann Arbor, Michigan, 48109, United States|West Michigan Rheumatology, PLLC, Grand Rapids, Michigan, 49546, United States|Physician Research Collaboration, LLC, Lincoln, Nebraska, 68516, United States|UMDNJ - Robert Wood Johnson Medical Center Clinical Research Center, New Brunswick, New Jersey, 08903-0019, United States|The Center for Rheumatology, Albany, New York, 12206, United States|Regional Rheumatology Associates, Binghamton, New York, 13905, United States|AAIR Research Center, Rochester, New York, 14618, United States|East Penn Rheumatology Associates, PC, Bethlehem, Pennsylvania, 18015, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, 16635, United States|Rheumatic Disease Associates, Ltd., Willow Grove, Pennsylvania, 19090, United States|Metroplex Clinical Research Center, Dallas, Texas, 75231, United States|Rainier Clinical Research Center, Inc., Renton, Washington, 98057, United States|Arthritis Centre Health Sciences Centre, Winnipeg, Manitoba, R3A 1M4, Canada|St. Joseph's Health Centre, London, Ontario, N6A 4V2, Canada|Rheumatology Research Associates, Ottawa, Ontario, K1H 1A2, Canada|Sir Mortimer B. Davis, Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada|Centro Integral de Reumatologia e Inmunologia CIREI, Bogota, Cundinamarca, 0000, Colombia|Fundacion Instituto de Reumatologia Fernando Chalem, Bogota, Cundinamarca, 0000, Colombia|Idearg Sas, Bogotá, Cundinamarca, 0000, Colombia|Servimed E.U, Bucaramanga, Santander, 0000, Colombia|Medicity S.A.S, Bucaramanga, 0000, Colombia|REVMATOLOGIE s.r.o.,, Brno, 638 00, Czechia|Fakultni nemocnice Hradec Kralove, Hradec Kralove, 500 05, Czechia|Revmatologicky ustav, Praha 2, 128 50, Czechia|Dermatologisches Ambulatorium Hamburg-Alstertal, Hamburg, 22391, Germany|Semmelweis Egyetem, Ersebeszeti Klinika, Budapest, 1122, Hungary|Bacs-Kiskun Megyei Onkormanyzat Korhaza Szegedi Tudomanyegyetem AOK Oktato Korhaza, Kecskemet, 6000, Hungary|Vas Megyei Markusovszky Korhaz Nonprofit Zrt, Angiologiai Szakambulancia, Szombathely, 9700, Hungary|Seoul National University Hospital, Rheumatology, Internal Medicine, Seoul, 110-744, Korea, Republic of|Yonsei University College of Medicine, Severance Hospital, Rheumatology, Internal Medicine, Seoul, 120-752, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital/ Rheumatology, Internal Medicine, Seoul, 137-701, Korea, Republic of|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, DF, 14000, Mexico|Unidad de Investigacion en Enfermedades Cronico Degenerativas, Guadalajara, Jalisco, 44620, Mexico|Hospital Angeles. Centro Medico del Potosi, San Luis Potosi, 78200, Mexico|Slaskie Centrum Osteoporozy, Katowice, 40-084, Poland|Prywatna Praktyka Lekarska Dr Med. Pawel Hrycaj, Poznan, 61-397, Poland|Prywatna Praktyka Lekarska Prof. UM Dr hab. med. Pawel Hrycaj, Poznan, 61-397, Poland|Katedra i Klinika Dermatologii, Wenerologii i Alergologii Akademii Medycznej we Wroclawiu, Wroclaw, 50-368, Poland|Hospital Clinico Universitario Santiago de Compostela, Santiago de Compostela, A Coruña, 15706, Spain|Hospital Del Mar, Barcelona, 08003, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|CTC, Centrum för klinisk provning, Sahlgrenska Universitetssjukhuset, Goteborg, 413 45, Sweden|Reumatologkliniken Skanes Universitetssjukhus Lund, Lund, 221 85, Sweden|Karolinska Universitetssjukhuset Solna, Reumatologiska kliniken, Stockholm, 171 76, Sweden"
NCT01909492,Relaxin in Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT01909492,RECRUITING,"Multiple Sclerosis, Relapsing-Remitting",PROCEDURE: Blood Draw|PROCEDURE: Lumbar Puncture,Providence Health & Services,"Microstein, LLC",FEMALE,ADULT,,30,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-09-20,2022-09,2023-09,"Providence MS Center, Portland, Oregon, 97225, United States"
NCT04515355,Preventing Job Loss Using Acceptance and Commitment Therapy in Vocational Rehabilitation,https://beta.clinicaltrials.gov/study/NCT04515355,UNKNOWN,Multiple Sclerosis,BEHAVIORAL: Ready for MS,The Leeds Teaching Hospitals NHS Trust,,ALL,"ADULT, OLDER_ADULT",NA,92,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-08-13,2022-08-30,2022-08-30,"Leeds Teaching Hospitals NHS Trust, Leeds, West Yorkshire, LS9 7TF, United Kingdom"
NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,https://beta.clinicaltrials.gov/study/NCT01252355,TERMINATED,Multiple Sclerosis Relapse,DRUG: Teriflunomide|DRUG: Placebo (for teriflunomide)|DRUG: Interferon-beta (IFN-beta),Sanofi,,ALL,ADULT,PHASE3,534,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-01,2013-04,2013-04,"Investigational Site Number 840049, Cullman, Alabama, 35058, United States|Investigational Site Number 840005, Cordova, Alaska, 38018, United States|Investigational Site Number 840003, Phoenix, Arizona, 85060, United States|Investigational Site Number 840011, Oceanside, California, 92056, United States|Investigational Site Number 840036, Fort Collins, Colorado, 80528, United States|Investigational Site Number 840012, Maitland, Florida, 32761, United States|Investigational Site Number 840013, Ormond Beach, Florida, 32174, United States|Investigational Site Number 840055, Pompano Beach, Florida, 33060, United States|Investigational Site Number 840021, St. Petersburg, Florida, 33713, United States|Investigational Site Number 840004, Tampa, Florida, 33609-4052, United States|Investigational Site Number 840047, Tampa, Florida, 33612, United States|Investigational Site Number 840034, Chicago, Illinois, 60637, United States|Investigational Site Number 840037, Elk Grove Village, Illinois, 60007, United States|Investigational Site Number 840033, Louisville, Kentucky, 40217, United States|Investigational Site Number 840041, Baltimore, Maryland, 21201, United States|Investigational Site Number 840028, Baltimore, Maryland, 21287, United States|Investigational Site Number 840016, Clinton Township, Michigan, 48035, United States|Investigational Site Number 840031, St Louis, Missouri, 63104, United States|Investigational Site Number 840030, St Louis, Missouri, 63110, United States|Investigational Site Number 840009, Missoula, Montana, 59802, United States|Investigational Site Number 840023, Albuquerque, New Mexico, 87131, United States|Investigational Site Number 840015, New York, New York, 10029, United States|Investigational Site Number 840027, Charlotte, North Carolina, 28204, United States|Investigational Site Number 840006, Bismark, North Dakota, 58501, United States|Investigational Site Number 840007, Fargo, North Dakota, 58103, United States|Investigational Site Number 840046, Dayton, Ohio, 45409, United States|Investigational Site Number 840017, Toledo, Ohio, 43699, United States|Investigational Site Number 840043, Tulsa, Oklahoma, 74137, United States|Investigational Site Number 840002, Nashville, Tennessee, 37232, United States|Investigational Site Number 840040, Round Rock, Texas, 78681, United States|Investigational Site Number 840020, San Antonio, Texas, 78231, United States|Investigational Site Number 840032, Vienna, Virginia, 22182, United States|Investigational Site Number 032002, Argentina, 1426, Argentina|Investigational Site Number 032003, Buenos Aires, Argentina|Investigational Site Number 032004, Caba, Argentina|Investigational Site Number 036008, Bedford Park, 5042, Australia|Investigational Site Number 036005, Chatswood, 2067, Australia|Investigational Site Number 036001, Heidelberg West, 3081, Australia|Investigational Site Number 036004, Kogarah, 2217, Australia|Investigational Site Number 036010, New Lambton, 2305, Australia|Investigational Site Number 040001, Graz, 8036, Austria|Investigational Site Number 040004, Linz, 4020, Austria|Investigational Site Number 056005, Charleroi, 6000, Belgium|Investigational Site Number 056004, Gent, 9000, Belgium|Investigational Site Number 056003, Hasselt, B-3590, Belgium|Investigational Site Number 056006, La Louvière, 7100, Belgium|Investigational Site Number 056002, Leuven, 3000, Belgium|Investigational Site Number 056001, Sijsele-Damme, 8340, Belgium|Investigational Site Number 056007, Wilrijk, 2610, Belgium|Investigational Site Number 076009, Joinville, 89202-165, Brazil|Investigational Site Number 076012, Passo Fundo, 99010-180, Brazil|Investigational Site Number 076003, Porto Alegre, 90020-090, Brazil|Investigational Site Number 076007, Sao Paulo, 04024-002, Brazil|Investigational Site Number 076013, Sao Paulo, 08270-070, Brazil|Investigational Site Number 124005, Calgary, T2N 2T9, Canada|Investigational Site Number 124004, Edmonton, T6G 2G3, Canada|Investigational Site Number 124003, Gatineau, J9J 0A5, Canada|Investigational Site Number 124006, Kingston, K7L 2V7, Canada|Investigational Site Number 124007, Montreal, H3A 2B4, Canada|Investigational Site Number 124008, Ottawa, K1H 8L6, Canada|Investigational Site Number 124002, Regina, S4T 1A5, Canada|Investigational Site Number 124001, Sherbrooke, J1H 5N4, Canada|Investigational Site Number 124009, Winnipeg, R3A 1R9, Canada|Investigational Site Number 152003, Santiago, 7500710, Chile|Investigational Site Number 152004, Santiago, 838-0456, Chile|Investigational Site Number 152005, Viña Del Mar, 2570017, Chile|Investigational Site Number 170001, Barranquilla, Colombia|Investigational Site Number 170005, Bogota, Colombia|Investigational Site Number 170007, Bogota, Colombia|Investigational Site Number 170009, Medellin, Colombia|Investigational Site Number 208002, Aarhus C, 8000, Denmark|Investigational Site Number 233002, Tallinn, 10617, Estonia|Investigational Site Number 233001, Tartu, 50406, Estonia|Investigational Site Number 246003, Helsinki, 00100, Finland|Investigational Site Number 246006, Hyvinkää, 05800, Finland|Investigational Site Number 246004, Oulu, 90220, Finland|Investigational Site Number 246002, Pori, 28100, Finland|Investigational Site Number 246001, Turku, 20100, Finland|Investigational Site Number 250003, Besancon, 25030, France|Investigational Site Number 250010, Clermont Ferrand Cedex 1, 63003, France|Investigational Site Number 250002, Lyon Cedex 03, 69394, France|Investigational Site Number 250004, Montpellier Cedex 5, 34000, France|Investigational Site Number 250001, Nancy Cedex, 54036, France|Investigational Site Number 250006, Nantes Cedex 01, 44093, France|Investigational Site Number 276009, Bad Mergentheim, 97980, Germany|Investigational Site Number 276020, Bamberg, 96047, Germany|Investigational Site Number 276003, Bayreuth, 95445, Germany|Investigational Site Number 276015, Berlin, 10117, Germany|Investigational Site Number 276016, Berlin, 10713, Germany|Investigational Site Number 276021, Berlin, 12099, Germany|Investigational Site Number 276012, Bonn, 53105, Germany|Investigational Site Number 276005, Dresden, 01307, Germany|Investigational Site Number 276032, Düsseldorf, 40211, Germany|Investigational Site Number 276018, Erbach, 64711, Germany|Investigational Site Number 276004, Erlangen, 91054, Germany|Investigational Site Number 276028, Freiburg, 79098, Germany|Investigational Site Number 276006, Gießen, 35385, Germany|Investigational Site Number 276010, Hamburg, 20249, Germany|Investigational Site Number 276022, Hennigsdorf, 16761, Germany|Investigational Site Number 276024, Kassel, 34121, Germany|Investigational Site Number 276001, Leipzig, 04103, Germany|Investigational Site Number 276013, Mainz, 55131, Germany|Investigational Site Number 276023, Minden, 32429, Germany|Investigational Site Number 276002, Münster, 48149, Germany|Investigational Site Number 276031, Rostock, 18055, Germany|Investigational Site Number 276008, Wiesbaden, 65191, Germany|Investigational Site Number 276026, Wuppertal, 42283, Germany|Investigational Site Number 300002, Athens, 11527, Greece|Investigational Site Number 300001, Athens, 11535, Greece|Investigational Site Number 300003, Heraklion, 71110, Greece|Investigational Site Number 300006, Thessaloniki, 57010, Greece|Investigational Site Number 348002, Budapest, 1106, Hungary|Investigational Site Number 348006, Budapest, 1145, Hungary|Investigational Site Number 348010, Budapest, 1204, Hungary|Investigational Site Number 348009, Eger, 3300, Hungary|Investigational Site Number 348003, Esztergom, 2500, Hungary|Investigational Site Number 348001, Szeged, 6720, Hungary|Investigational Site Number 348005, Szekesfehervar, 8000, Hungary|Investigational Site Number 348007, Zalaegerszeg, 8900, Hungary|Investigational Site Number 380009, Catania, 95123, Italy|Investigational Site Number 380002, Cefalù, 90015, Italy|Investigational Site Number 380003, Fidenza, 43036, Italy|Investigational Site Number 380004, Gallarate, 21013, Italy|Investigational Site Number 380012, Montichiari, 25012, Italy|Investigational Site Number 380010, Napoli, 80131, Italy|Investigational Site Number 380011, Napoli, 80131, Italy|Investigational Site Number 380006, Padova, 35128, Italy|Investigational Site Number 380005, Roma, 00133, Italy|Investigational Site Number 380008, Roma, 00161, Italy|Investigational Site Number 380014, Verona, 37134, Italy|Investigational Site Number 410002, Goyang-Si, 410-760, Korea, Republic of|Investigational Site Number 410004, Seoul, 110-744, Korea, Republic of|Investigational Site Number 410001, Seoul, 136-705, Korea, Republic of|Investigational Site Number 440002, Kaunas, LT-50009, Lithuania|Investigational Site Number 440004, Klaipeda, LT-92288, Lithuania|Investigational Site Number 440003, Siauliai, LT-76231, Lithuania|Investigational Site Number 528001, Breda, 4818 CK, Netherlands|Investigational Site Number 528005, Nieuwegein, 3435 CM, Netherlands|Investigational Site Number 528002, Sittard-Geleen, 6162 BG, Netherlands|Investigational Site Number 528006, Venray, 5801 CE, Netherlands|Investigational Site Number 578002, Tønsberg, 3116, Norway|Investigational Site Number 620001, Amadora, 2720-276, Portugal|Investigational Site Number 620002, Coimbra, 3000-075, Portugal|Investigational Site Number 620004, Coimbra, 3041-801, Portugal|Investigational Site Number 620003, Setubal, 2910-446, Portugal|Investigational Site Number 643012, Kaluga, 248007, Russian Federation|Investigational Site Number 643007, Kazan, 420021, Russian Federation|Investigational Site Number 643001, Kemerovo, 650066, Russian Federation|Investigational Site Number 643013, Moscow, 129110, Russian Federation|Investigational Site Number 643006, Nizhny Novgorod, 603076, Russian Federation|Investigational Site Number 643004, Nizhny Novgorod, 603126, Russian Federation|Investigational Site Number 643015, Novosibirsk, 630007, Russian Federation|Investigational Site Number 643010, Rostov-On-Don, 344015, Russian Federation|Investigational Site Number 643009, Rostov-On-Don, 344022, Russian Federation|Investigational Site Number 643016, Samara, 443095, Russian Federation|Investigational Site Number 643005, Smolensk, 214019, Russian Federation|Investigational Site Number 643011, St-Petersburg, 194044, Russian Federation|Investigational Site Number 643018, St-Petersburg, 194291, Russian Federation|Investigational Site Number 643003, St-Petersburg, 194354, Russian Federation|Investigational Site Number 643017, St-Petersburg, 197089, Russian Federation|Investigational Site Number 643002, St-Petersburg, 197376, Russian Federation|Investigational Site Number 643014, Yaroslavl, 150030, Russian Federation|Investigational Site Number 703002, Martin, 03659, Slovakia|Investigational Site Number 703001, Trnava, 91775, Slovakia|Investigational Site Number 724001, Barcelona, 08035, Spain|Investigational Site Number 724002, Barcelona, 08036, Spain|Investigational Site Number 724009, Córdoba, 14004, Spain|Investigational Site Number 724003, Girona, 17007, Spain|Investigational Site Number 724004, Madrid, 28005, Spain|Investigational Site Number 724005, Madrid, 28040, Spain|Investigational Site Number 724007, Murcia, 30120, Spain|Investigational Site Number 724008, Sevilla, 41008, Spain|Investigational Site Number 752004, Göteborg, 413 45, Sweden|Investigational Site Number 752003, Stockholm, 14186, Sweden|Investigational Site Number 752001, Stockholm, 171 76, Sweden|Investigational Site Number 788002, Manouba, 2010, Tunisia|Investigational Site Number 788005, Monastir, 5000, Tunisia|Investigational Site Number 788004, Sfax, 3029, Tunisia|Investigational Site Number 788006, Tunis, 1008, Tunisia|Investigational Site Number 826008, Birmingham, B15 2TH, United Kingdom|Investigational Site Number 826005, Leeds, LS1 3EX, United Kingdom|Investigational Site Number 826006, Liverpool, L9 7LJ, United Kingdom|Investigational Site Number 826003, London, SW17 0QT, United Kingdom|Investigational Site Number 826004, Plymouth, PL6 8BX, United Kingdom|Investigational Site Number 826001, Salford, M6 8HD, United Kingdom"
NCT02418325,A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS,https://beta.clinicaltrials.gov/study/NCT02418325,TERMINATED,"Multiple Sclerosis, Relapsing-Remitting",BIOLOGICAL: Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells|OTHER: Liberation therapy,Genesis Limited,,ALL,ADULT,PHASE1|PHASE2,69,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-02,2017-02,2017-02,"Genesis Institute of Cellular Medicine, Genesis (Trinidad and Tobago) Private Limited, San Fernando, Trinidad, Trinidad and Tobago"
NCT03453125,Improving Learning in Hispanics With TBI or MS,https://beta.clinicaltrials.gov/study/NCT03453125,RECRUITING,TBI (Traumatic Brain Injury) or MS (Multiple Sclerosis),BEHAVIORAL: Spanish modified Story Memory Technique (mSMT),Kessler Foundation,"Instituto Vocacional Enrique Díaz de León A.C., Guadalajara, Mexico",ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-09-25,2022-09-30,2022-09-30,"Kessler Foundation, East Hanover, New Jersey, 07936, United States|Hospital Aita Menni, Arrasate-Mondragón, Spain"
NCT01414725,Core Stability Training in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01414725,COMPLETED,Multiple Sclerosis,OTHER: Standard Physiotherapy Exercises|OTHER: Core Stability Training|OTHER: Relaxation,University of Plymouth,,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-08,2013-07,2013-07,"Merlin Centre, Bradbury House, Hewas water, St Austell, Cornwall, PL26 7JF, United Kingdom|Devon NHS Trust, Newton Abbot, Devon, TQ12 2SL, United Kingdom|University Of Plymouth, School of Health Professions, Plymouth, Devon, PL6 9BH, United Kingdom|Tavistock Community Hospital, Spring Hill, Tavistock, Devon, PL19 8LD, United Kingdom|Lanarkshire NHS Trust, Cumbernauld, North Lanarkshire, G671BP, United Kingdom|South Tees NHS Trust, Middlesborough, South Tees, TS3BW, United Kingdom|University College London Hospital Trust, London, WC1 N3BG, United Kingdom"
NCT00472992,Pregnancy Exposure Registry for Tysabri®,https://beta.clinicaltrials.gov/study/NCT00472992,COMPLETED,Crohn's Disease|Prenatal Exposure|Multiple Sclerosis|Pregnancy,,Biogen,Elan Pharmaceuticals,FEMALE,"CHILD, ADULT, OLDER_ADULT",,376,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2007-01,2012-07,2012-07,"United BioSource Corporation, Morgantown, West Virginia, 26505, United States"
NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",https://beta.clinicaltrials.gov/study/NCT00731692,TERMINATED,Primary Progressive Multiple Sclerosis,DRUG: FTY720|DRUG: Placebo,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,970,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2008-07-28,2015-06-22,2015-06-22,"Novartis Investigative Site, Newport Beach, California, 92660, United States|Novartis Investigative Site, Sacramento, California, 95817, United States|Novartis Investigative Site, Aurora, Colorado, 80045, United States|Novartis Investigative Site, Pompano Beach, Florida, 33060, United States|Novartis Investigative Site, Tampa, Florida, 33609, United States|Novartis Investigative Site, Atlanta, Georgia, 30302, United States|Novartis Investigative Site, Chicago, Illinois, 60611, United States|Novartis Investigative Site, Chicago, Illinois, 60637, United States|Novartis Investigative Site, Kansas City, Kansas, 66160, United States|Novartis Investigative Site, Baltimore, Maryland, 21287, United States|Novartis Investigative Site, Boston, Massachusetts, 02135, United States|Novartis Investigative Site, Brookline, Massachusetts, 02445, United States|Novartis Investigative Site, Detroit, Michigan, 48201, United States|Novartis Investigative Site, Saint Louis, Missouri, 63110, United States|Novartis Investigative Site, Teaneck, New Jersey, 07666, United States|Novartis Investigative Site, Buffalo, New York, 14203, United States|Novartis Investigative Site, New York, New York, 10029, United States|Novartis Investigative Site, Rochester, New York, 14642, United States|Novartis Investigative Site, Stony Brook, New York, 11794, United States|Novartis Investigative Site, Charlotte, North Carolina, 28207, United States|Novartis Investigative Site, Durham, North Carolina, 27705, United States|Novartis Investigative Site, Cleveland, Ohio, 44195, United States|Novartis Investigative Site, Columbus, Ohio, 43221, United States|Novartis Investigative Site, Pittsburgh, Pennsylvania, 15213, United States|Novartis Investigative Site, Knoxville, Tennessee, 37934, United States|Novartis Investigative Site, Nashville, Tennessee, 37212, United States|Novartis Investigative Site, Dallas, Texas, 75390-9034, United States|Novartis Investigative Site, Houston, Texas, 77030, United States|Novartis Investigative Site, San Antonio, Texas, 78229, United States|Novartis Investigative Site, Burlington, Vermont, 05401, United States|Novartis Investigative Site, Charlottesville, Virginia, 22904, United States|Novartis Investigative Site, Seattle, Washington, 98122, United States|Novartis Investigative Site, Madison, Wisconsin, 53792, United States|Novartis Investigative Site, Camperdown, New South Wales, 2050, Australia|Novartis Investigative Site, Liverpool, New South Wales, 2170, Australia|Novartis Investigative Site, Hobart, Tasmania, 7000, Australia|Novartis Investigative Site, Box Hill, Victoria, 3128, Australia|Novartis Investigative Site, Heidelberg, Victoria, 3084, Australia|Novartis Investigative Site, Parkville, Victoria, 3050, Australia|Novartis Investigative Site, Charleroi, 6000, Belgium|Novartis Investigative Site, Edegem, 2650, Belgium|Novartis Investigative Site, Leuven, 3000, Belgium|Novartis Investigative Site, Liege, 4000, Belgium|Novartis Investigative Site, Melsbroek, 1820, Belgium|Novartis Investigative Site, Sint-Truiden, 3800, Belgium|Novartis Investigative Site, Calgary, Alberta, T2N 2T9, Canada|Novartis Investigative Site, Edmonton, Alberta, T6R 2B7, Canada|Novartis Investigative Site, Burnaby, British Columbia, V5G 2X6, Canada|Novartis Investigative Site, Vancouver, British Columbia, V6T 2B5, Canada|Novartis Investigative Site, Halifax, Nova Scotia, B3H 4K4, Canada|Novartis Investigative Site, Ottawa, Ontario, K1H 8L6, Canada|Novartis Investigative Site, Toronto, Ontario, M4N 3M5, Canada|Novartis Investigative Site, Toronto, Ontario, M5B 1W8, Canada|Novartis Investigative Site, Gatineau, Quebec, J9J 0A5, Canada|Novartis Investigative Site, Greenfield Park, Quebec, J4V 2J2, Canada|Novartis Investigative Site, Montreal, Quebec, H2L 4M1, Canada|Novartis Investigative Site, Montreal, Quebec, H3A 2B4, Canada|Novartis Investigative Site, Regina, Saskatchewan, S4T 1A5, Canada|Novartis Investigative Site, Brno, Czech Republic, 656 91, Czechia|Novartis Investigative Site, Rychnov nad Kneznou, Czech Republic, 516 01, Czechia|Novartis Investigative Site, Olomouc, CZE, 775 20, Czechia|Novartis Investigative Site, Ostrava-Poruba, 708 00, Czechia|Novartis Investigative Site, Plzen, 301 00, Czechia|Novartis Investigative Site, Praha 2, 128 08, Czechia|Novartis Investigative Site, Teplice, 415 29, Czechia|Novartis Investigative Site, Aarhus, 8000 C, Denmark|Novartis Investigative Site, Sønderborg, 6400, Denmark|Novartis Investigative Site, Helsinki, 00930, Finland|Novartis Investigative Site, Tampere, 33100, Finland|Novartis Investigative Site, Turku, 20520, Finland|Novartis Investigative Site, Bordeaux Cedex, F-33076, France|Novartis Investigative Site, Lille Cedex, 59037, France|Novartis Investigative Site, Marseille cedex 05, 13385, France|Novartis Investigative Site, Montpellier, 34295, France|Novartis Investigative Site, Nantes Cedex 1, 44093, France|Novartis Investigative Site, Paris Cedex 13, 75651, France|Novartis Investigative Site, Rennes, 35043, France|Novartis Investigative Site, Strasbourg, 67091, France|Novartis Investigative Site, Berlin, 10713, Germany|Novartis Investigative Site, Berlin, 13347, Germany|Novartis Investigative Site, Bochum, 44791, Germany|Novartis Investigative Site, Dresden, 01307, Germany|Novartis Investigative Site, Duesseldorf, D-40225, Germany|Novartis Investigative Site, Erlangen, 91054, Germany|Novartis Investigative Site, Essen, 45147, Germany|Novartis Investigative Site, Freiburg, 79106, Germany|Novartis Investigative Site, Hannover, 30625, Germany|Novartis Investigative Site, Hennigsdorf, 16761, Germany|Novartis Investigative Site, Magdeburg, 39120, Germany|Novartis Investigative Site, Muenchen, 81675, Germany|Novartis Investigative Site, Muenster, 48149, Germany|Novartis Investigative Site, Munchen, 81377, Germany|Novartis Investigative Site, Teupitz, 15755, Germany|Novartis Investigative Site, Trier, 54292, Germany|Novartis Investigative Site, Würzburg, 97080, Germany|Novartis Investigative Site, Budapest, 1076, Hungary|Novartis Investigative Site, Budapest, 1145, Hungary|Novartis Investigative Site, Debrecen, 4032, Hungary|Novartis Investigative Site, Gyor, 9024, Hungary|Novartis Investigative Site, Miskolc, 3526, Hungary|Novartis Investigative Site, Veszprem, H-8200, Hungary|Novartis Investigative Site, Bari, BA, 70124, Italy|Novartis Investigative Site, Montichiari, BS, 25018, Italy|Novartis Investigative Site, Chieti, CH, 66100, Italy|Novartis Investigative Site, Catania, CT, 95123, Italy|Novartis Investigative Site, Genova, GE, 16132, Italy|Novartis Investigative Site, Milano, MI, 20122, Italy|Novartis Investigative Site, Milano, MI, 20132, Italy|Novartis Investigative Site, Cefalù, PA, 90015, Italy|Novartis Investigative Site, Padova, PD, 35128, Italy|Novartis Investigative Site, Roma, RM, 00133, Italy|Novartis Investigative Site, Roma, RM, 00189, Italy|Novartis Investigative Site, Orbassano, TO, 10043, Italy|Novartis Investigative Site, Gallarate, VA, 21013, Italy|Novartis Investigative Site, Breda, CK, 4818, Netherlands|Novartis Investigative Site, Amsterdam, 1105 AZ, Netherlands|Novartis Investigative Site, Eindhoven, 5623 EJ, Netherlands|Novartis Investigative Site, Nieuwegein, 3435 CM, Netherlands|Novartis Investigative Site, Nijmegen, 6525 GC, Netherlands|Novartis Investigative Site, Sittard-Geleen, 6162 BG, Netherlands|Novartis Investigative Site, Lodz, 90-153, Poland|Novartis Investigative Site, Lublin, 20-954, Poland|Novartis Investigative Site, Warszawa, 02-097, Poland|Novartis Investigative Site, Warszawa, 02-957, Poland|Novartis Investigative Site, Sevilla, Andalucia, 41009, Spain|Novartis Investigative Site, Badalona, Catalunya, 08916, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08035, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08036, Spain|Novartis Investigative Site, Girona, Catalunya, 17007, Spain|Novartis Investigative Site, L'Hospitalet de Llobregat, Catalunya, 08907, Spain|Novartis Investigative Site, Lleida, Catalunya, 25198, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, 46026, Spain|Novartis Investigative Site, Majadahonda, Madrid, 28222, Spain|Novartis Investigative Site, Bilbao, Pais Vasco, 48013, Spain|Novartis Investigative Site, Madrid, 28040, Spain|Novartis Investigative Site, Madrid, 28046, Spain|Novartis Investigative Site, Goeteborg, 413 45, Sweden|Novartis Investigative Site, Stockholm, 17176, Sweden|Novartis Investigative Site, Basel, 4031, Switzerland|Novartis Investigative Site, Bern, 3010, Switzerland|Novartis Investigative Site, Lausanne, 1011, Switzerland|Novartis Investigative Site, Lugano, 6900, Switzerland|Novartis Investigative Site, Zuerich, 8091, Switzerland|Novartis Investigative Site, Ankara, 06100, Turkey|Novartis Investigative Site, Atakum / Samsun, 55139, Turkey|Novartis Investigative Site, Balcova / Izmir, 35340, Turkey|Novartis Investigative Site, Istanbul, 34093, Turkey|Novartis Investigative Site, Yenisehir / Izmir, Turkey|Novartis Investigative Site, Salford, Manchester, M6 8HD, United Kingdom|Novartis Investigative Site, Sheffield, South Yorkshire, S10 2JF, United Kingdom|Novartis Investigative Site, Bristol, BS10 5NB, United Kingdom|Novartis Investigative Site, London, EC1A 7BE, United Kingdom|Novartis Investigative Site, London, NW1 2BU, United Kingdom|Novartis Investigative Site, London, SE5 9RS, United Kingdom|Novartis Investigative Site, London, W8 6RF, United Kingdom|Novartis Investigative Site, Newcastle Upon Tyne, NE1 4LP, United Kingdom|Novartis Investigative Site, Norwich, NR4 7UY, United Kingdom"
NCT04265092,Therapeutic Benefit of Incobotulinum Toxin A for Spasticity of the Triceps Surae in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04265092,COMPLETED,Multiple Sclerosis,DRUG: Incobotulinum toxin A,Pôle Saint Hélier,,ALL,"ADULT, OLDER_ADULT",,22,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-01,2014-03,2019-01,
NCT04936555,The Effect of Self-Acupressure Application on Functional Composite and Quality of Life in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT04936555,COMPLETED,Multiple Sclerosis,OTHER: Self-Acupressure,Istanbul Sabahattin Zaim University,,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2021-05-01,2021-06-01,2021-07-15,"Istanbul Sabahattin Zain Universitiy, Istanbul, State, 34303, Turkey"
NCT05789225,Evaluation of a Self-management Program to Prevent Falls in People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05789225,NOT_YET_RECRUITING,Multiple Sclerosis,BEHAVIORAL: Fall prevention program|OTHER: Brochure,Karolinska Institutet,,ALL,"ADULT, OLDER_ADULT",NA,208,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2023-11-01,2024-12-31,2024-12-31,
NCT00014755,"Phase I Pilot Study of Total-Body Irradiation, Anti-Thymocyte Globulin and Cyclophosphamide Followed By Syngeneic or Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT00014755,COMPLETED,Multiple Sclerosis,DRUG: anti-thymocyte globulin|DRUG: cyclophosphamide|DRUG: filgrastim|DRUG: prednisone|PROCEDURE: peripheral blood stem cell transplantation|PROCEDURE: irradiation,Fred Hutchinson Cancer Center,,ALL,ADULT,PHASE1,35,OTHER,INTERVENTIONAL,Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT,1997-12,,,"City of Hope National Medical Center, Duarte, California, 91010, United States|University of Colorado Cancer Center, Denver, Colorado, 80262, United States|Washington University Barnard Cancer Center, Saint Louis, Missouri, 63110, United States|University of Nebraska Medical Center, Omaha, Nebraska, 68198-3330, United States|Duke University Medical Center, Durham, North Carolina, 27710, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, 98109, United States"
NCT01149525,Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01149525,COMPLETED,Multiple Sclerosis,DRUG: L-Carnitine|DRUG: Placebo,"University Hospital, Bordeaux",,ALL,"ADULT, OLDER_ADULT",PHASE3,59,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2010-06,2013-03,2013-07,"University Hospital, Hospital Pellegrin, Bordeaux, 33076, France|University Hospital, Fort de France, 97261, France|University Hospital, Hospital Dupuytren, Limoges, 87042, France|University Hospital, Hospital Central, Nancy, 54034, France|University Hospital, Hospital Laënnec, Nantes, 44093, France|University Hospital, Hospital Pasteur, Nice, 06000, France"
NCT05227092,3D OPTIMIZED WMN MPRAGE Increased Detection of Focal Spinal Cord Lesion in Multiple Sclerosis (WHINUME),https://beta.clinicaltrials.gov/study/NCT05227092,NOT_YET_RECRUITING,Multiple Sclerosis,DEVICE: 3D OPTIMIZED WMN MPRAGE,"University Hospital, Bordeaux",,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-06-01,2024-05-01,2024-05-01,"CHU de Bordeaux, Bordeaux, France"
NCT00598455,Tuberous Sclerosis Complex Natural History Study: Renal Manifestations,https://beta.clinicaltrials.gov/study/NCT00598455,COMPLETED,Tuberous Sclerosis Complex,,"Children's Hospital Medical Center, Cincinnati","Loma Linda University|Massachusetts General Hospital|Boston Children's Hospital|University of Alabama at Birmingham|University of Pennsylvania|Connecticut Children's Medical Center|The University of Texas Health Science Center, Houston",ALL,"CHILD, ADULT, OLDER_ADULT",,450,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2008-02,2013-09,2013-09,"Cincinnati Children's, Cincinnati, Ohio, 45229, United States"
NCT01420055,Fingolimod -Response According to Coping - Evaluation,https://beta.clinicaltrials.gov/study/NCT01420055,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: fingolimod,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE4,189,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-08,2013-06,2013-06,"Novartis Investigative Site, Agen Cedex 9, 47923, France|Novartis Investigative Site, Amiens Cedex 1, 80054, France|Novartis Investigative Site, Angers Cedex 1, 49033, France|Novartis Investigative Site, Auxerre, 89000, France|Novartis Investigative Site, Avignon, 84000, France|Novartis Investigative Site, Bayonne, 64109, France|Novartis Investigative Site, Beziers, 34525, France|Novartis Investigative Site, Bobigny Cedex, 93009, France|Novartis Investigative Site, Brest, 29240, France|Novartis Investigative Site, Calais, 62107, France|Novartis Investigative Site, Castelnau-le-Lez, 34170, France|Novartis Investigative Site, Chambray les Tours, 37175, France|Novartis Investigative Site, Cherbourg, 50100, France|Novartis Investigative Site, Clermont-Ferrand Cedex 1, 63003, France|Novartis Investigative Site, Créteil, 94010, France|Novartis Investigative Site, Dijon, 21034, France|Novartis Investigative Site, Epinal, 88021, France|Novartis Investigative Site, Grenoble Cedex 9, 38042, France|Novartis Investigative Site, Hagueneau, 67500, France|Novartis Investigative Site, La Rochelle cedex 1, 17019, France|Novartis Investigative Site, La Seyne sur mer, 83500, France|Novartis Investigative Site, Le Kremlin Bicetre, 94275, France|Novartis Investigative Site, Le Mans Cedex 09, 72037, France|Novartis Investigative Site, Limoges, France|Novartis Investigative Site, Lyon, 69275, France|Novartis Investigative Site, Marseille, 13008, France|Novartis Investigative Site, Marseille, 13012, France|Novartis Investigative Site, Metz, 57085, France|Novartis Investigative Site, Montpellier, 34000, France|Novartis Investigative Site, Montpellier, 34295, France|Novartis Investigative Site, Nimes, 32900, France|Novartis Investigative Site, Orsay, 91401, France|Novartis Investigative Site, Paris, 75005, France|Novartis Investigative Site, Poitiers, 86021, France|Novartis Investigative Site, Pontoise, F-95300, France|Novartis Investigative Site, Reims, 51092, France|Novartis Investigative Site, Rennes Cedex, 35033, France|Novartis Investigative Site, Roanne, 42328, France|Novartis Investigative Site, Saint Aubin sur Scie, 76550, France|Novartis Investigative Site, Saint Jean, 31243, France|Novartis Investigative Site, Sainte Foy les Lyon, 69110, France|Novartis Investigative Site, Saumur, 49400, France|Novartis Investigative Site, Strasbourg Cedex, 67091, France|Novartis Investigative Site, Talant, 21240, France|Novartis Investigative Site, Toulouse, 31059, France|Novartis Investigative Site, Tourcoing, 59200, France|Novartis Investigative Site, Tours Cedex, 37044, France"
NCT02661555,Aerobic Exercise and Brain Health in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02661555,COMPLETED,Multiple Sclerosis|Brain Atrophy|Cognitive Impairment,OTHER: Aerobic exercise,University of Aarhus,Jascha fund|Knud and Edith Eriksens memorial fund|University of Southern Denmark|Augustinus fund|Masku Neurological Center,ALL,ADULT,NA,86,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2016-01,2018-08,2019-05,"Sport Science, Department of Public Health, Aarhus University, Aarhus, Aarhus C, 8000, Denmark"
NCT03737825,Computerized Cognitive Training in MS,https://beta.clinicaltrials.gov/study/NCT03737825,ACTIVE_NOT_RECRUITING,Multiple Sclerosis|Cognitive Decline,DEVICE: Computerized gaming rehabilitation Program 1|DEVICE: Computerized gaming rehabilitation Program 2,"University of California, San Francisco",,ALL,ADULT,NA,40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-04-25,2023-12,2023-12,"Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, 94158, United States|Lausanne University Hospital (CHUV), Lausanne, 1005, Switzerland"
NCT02142192,Natalizumab Subcutaneous Immunogenicity and Safety Study,https://beta.clinicaltrials.gov/study/NCT02142192,TERMINATED,Relapsing Multiple Sclerosis,DRUG: natalizumab,Biogen,,ALL,"ADULT, OLDER_ADULT",PHASE2,2,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-12,2016-11,2016-11,"Research Site, Leuven, 3000, Belgium|Research Site, Liege, 4000, Belgium"
NCT00552955,Effect of Fasting on the Size of Abdominal Lymphatic Tumors in Women,https://beta.clinicaltrials.gov/study/NCT00552955,COMPLETED,Lymphangioleiomyomas|Tuberous Sclerosis|Lymphangioleiomyomatosis,,"National Heart, Lung, and Blood Institute (NHLBI)",,FEMALE,"ADULT, OLDER_ADULT",,35,NIH,OBSERVATIONAL,Observational Model: |Time Perspective: p,2007-10-26,,2016-03-21,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States"
NCT03041025,Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis,https://beta.clinicaltrials.gov/study/NCT03041025,COMPLETED,"Scleroderma, Systemic",DRUG: GSK2330811|DRUG: Placebo,GlaxoSmithKline,,ALL,"ADULT, OLDER_ADULT",PHASE2,35,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2017-06-05,2020-07-07,2020-07-07,"GSK Investigational Site, Los Angeles, California, 90045, United States|GSK Investigational Site, Stanford, California, 94304, United States|GSK Investigational Site, Chicago, Illinois, 60611, United States|GSK Investigational Site, Baltimore, Maryland, 21224, United States|GSK Investigational Site, Boston, Massachusetts, 02118, United States|GSK Investigational Site, Ann Arbor, Michigan, 48109, United States|GSK Investigational Site, Toronto, Ontario, M5T 3L9, Canada|GSK Investigational Site, Nijmegen, 6525 GA, Netherlands|GSK Investigational Site, Salford, Greater Manchester, M6 8HD, United Kingdom|GSK Investigational Site, Liverpool, Merseyside, L9 7AL, United Kingdom|GSK Investigational Site, Birmingham, B15 2TH, United Kingdom|GSK Investigational Site, Dundee, DD1 9SY, United Kingdom|GSK Investigational Site, Leeds, LS7 4SA, United Kingdom|GSK Investigational Site, London, NW3 2QG, United Kingdom"
NCT01706055,Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE),https://beta.clinicaltrials.gov/study/NCT01706055,COMPLETED,Multiple Sclerosis,"BIOLOGICAL: Interferon beta-1b (Betaseron, BAY86-5046)",Bayer,,ALL,"ADULT, OLDER_ADULT",,629,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-09,2015-09,2016-03,"Many Locations, Poland"
NCT03451955,The Effect of a Gluten Free Diet on the Permeability of the Blood Brain Barrier in Patients With CIS,https://beta.clinicaltrials.gov/study/NCT03451955,COMPLETED,Optic Neuritis|Multiple Sclerosis|Clinically Isolated Syndrome,OTHER: Gluten-free diet,University of Copenhagen,"Rigshospitalet, Denmark",ALL,ADULT,NA,103,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2018-01-19,2022-06-07,2022-06-16,"University of Copenhagen, Copenhagen, Frederiksberg, 1958, Denmark|Rigshopitalet, Glostrup, 2600, Denmark"
NCT05196425,Expression of PARP-1 in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT05196425,RECRUITING,Multiple Sclerosis,GENETIC: Blood sampling,Sohag University,,ALL,ADULT,NA,80,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: DIAGNOSTIC,2021-08-01,2022-03,2022-04,"Elshimaa A.Mateen, Sohag, 82511, Egypt"
NCT04855825,Investigating the Effects of Wearable Robotic Exoskeleton for Improving Mobility and Cognition in Persons With MS,https://beta.clinicaltrials.gov/study/NCT04855825,RECRUITING,"Multiple Sclerosis|Gait Disorders, Neurologic|Motility Disorder|Cognitive Impairment",DEVICE: Robotic Exoskeleton Rehabilitation|OTHER: Conventional Gait Therapy,Kessler Foundation,Kessler Institute for Rehabilitation,ALL,"ADULT, OLDER_ADULT",NA,10,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2017-10-05,2022-12-30,2022-12-30,"Kessler Foundation, West Orange, New Jersey, 07052, United States"
NCT04202055,Immunologic Biomarker Profile of Cerebrospinal Fluid,https://beta.clinicaltrials.gov/study/NCT04202055,COMPLETED,Multiple Sclerosis|Neuromyelitis Optica,OTHER: Biomarker analysis,Centre Hospitalier Universitaire de Nīmes,,ALL,"CHILD, ADULT, OLDER_ADULT",,165,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-01-02,2019-08-31,2019-08-31,"CHU de Nimes, Nîmes, 30029, France"
NCT04497025,Conventional Vestibular Training Versus Immersive Virtual Reality- Based Vestibular in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04497025,NOT_YET_RECRUITING,Multiple Sclerosis|Vestibular Disease|Dizziness|Balance Disorders|Fatigue|Quality of Life|Usability|Cybersickness,OTHER: Immersive Virtual-based vestibular rehabilitation|OTHER: Conventional vestibular rehabilitation protocol,Maria Jesus Casuso-Holgado,,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2024-01,2025-12,2025-12,"Universidad de Sevilla, Sevilla, 41004, Spain"
NCT04937725,Reading Problems Associated With Central Nervous System (CNS) Pathologies.,https://beta.clinicaltrials.gov/study/NCT04937725,COMPLETED,"Injury Brain|Eye Abnormalities|Multiple Sclerosis|Parkinson Disease|Ataxia, Cerebellar",DIAGNOSTIC_TEST: eye tracking,Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA,Hospital Clínico Universitario de Valladolid|Hospital del Río Hortega,ALL,"ADULT, OLDER_ADULT",,75,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-06-01,2022-11-01,2022-11-30,"IOBA - Universidad de Valladolid, Valladolid, 47011, Spain"
NCT05691192,Cognitive Reserve-building Activities in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05691192,RECRUITING,Multiple Sclerosis,BEHAVIORAL: Cognitive Leisure Activities,"Rigshospitalet, Denmark",University of Copenhagen,ALL,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-12-01,2023-12-01,2024-07-01,"Danish Multiple Sclerosis Center, Copenhagen University Hospital, Rigshospitalet-Glostrup, Glostrup, 2600, Denmark"
NCT03737812,A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03737812,COMPLETED,Multiple Sclerosis (MS),DRUG: elezanumab|DRUG: placebo,AbbVie,,ALL,"ADULT, OLDER_ADULT",PHASE2,123,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2019-02-27,2021-01-15,2021-08-30,"St. Josephs Hospital and Med Center /ID# 202809, Phoenix, Arizona, 85013, United States|Sutter East Bay Medical Foundation-Jordon Research and Education Dev. Inst. /ID# 202448, Berkeley, California, 94705-2017, United States|The Research Center of Southern California /ID# 202802, Carlsbad, California, 92011-4213, United States|Vladimir Royter MD /ID# 202483, Hanford, California, 93230-5787, United States|Stanford MS Center /ID# 202445, Palo Alto, California, 94304-1416, United States|UC Davis Health-Neurological Surgery /ID# 202485, Sacramento, California, 95817-2307, United States|UCSF School of Medicine - Neurology /ID# 203194, San Francisco, California, 94143-0003, United States|University of Colorado School of Medicine, Dept of Neurology /ID# 202807, Aurora, Colorado, 80045-2527, United States|Advanced Neurosciences Research, LLC /ID# 203072, Fort Collins, Colorado, 80528, United States|Rowe Neurology Institute /ID# 202744, Lenexa, Kansas, 66214, United States|Duplicate_Parexel International /ID# 202747, Baltimore, Maryland, 21225, United States|International Neurorehabilitation Institute /ID# 213333, Lutherville, Maryland, 21093-6016, United States|Michigan Institute for Neurological Disorders (MIND) /ID# 202470, Farmington Hills, Michigan, 48334, United States|Memorial Neurological Institute and Center for Multiple Sclerosis /ID# 206327, Owosso, Michigan, 48867-2116, United States|Ridgeview Specialty Clinic Chaska - Neurology /ID# 204384, Chaska, Minnesota, 55318-4551, United States|Washington University School of Medicine /ID# 202899, Saint Louis, Missouri, 63110-1010, United States|The MS Center for Innovations in Care at Missouri Baptist Medical Center /ID# 205432, Saint Louis, Missouri, 63131-2322, United States|Cleveland Clinic Lou Ruvo Cent /ID# 204744, Las Vegas, Nevada, 89106-0100, United States|Oklahoma Med Res. Foundation /ID# 203442, Oklahoma City, Oklahoma, 73104, United States|Providence Neurological Specialties - West /ID# 203193, Portland, Oregon, 97225-6646, United States|Advanced Neurosciences Institute /ID# 204555, Franklin, Tennessee, 37064, United States|KCA Neurology - Franklin /ID# 202912, Franklin, Tennessee, 37067-5914, United States|Neurology Consultants of Dallas - LBJ Fwy /ID# 203102, Dallas, Texas, 75243-1188, United States|Central Texas Neurology Consul /ID# 203108, Round Rock, Texas, 78681, United States|Integrated Neurology Services /ID# 202743, Alexandria, Virginia, 22310, United States|Evergreen Neuroscience Institute /ID# 204205, Kirkland, Washington, 98034-3029, United States|Virginia Mason - Seattle Orthapedics /ID# 205439, Seattle, Washington, 98101, United States|Swedish MS Center /ID# 202904, Seattle, Washington, 98122-5698, United States|West Virginia Univ School Med /ID# 202849, Morgantown, West Virginia, 26506, United States|Froedtert Memorial Lutheran Hospital /ID# 202618, Milwaukee, Wisconsin, 53226-3522, United States|University of British Columbia - MS & NMO Clinical Trials Group, Djavad Mowafagh /ID# 203536, Vancouver, British Columbia, V6T 1Z3, Canada|Duplicate_London Health Sciences Centre - University Hospital /ID# 203538, London, Ontario, N6A 5A5, Canada|The Ottawa Hospital /ID# 203058, Ottawa, Ontario, K1H 8L6, Canada|Unity Health Toronto - St. Michael's Hospital /ID# 206213, Toronto, Ontario, M5B 1W8, Canada|Recherche Sepmus Inc. /ID# 212852, Greenfield Park, Quebec, J4V 2J2, Canada|Crchum /Id# 203869, Montreal, Quebec, H2X 0A9, Canada|Montreal Neurological Institut /ID# 203868, Montreal, Quebec, H3A 2B4, Canada"
NCT05528666,Risk Perception in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05528666,COMPLETED,Multiple Sclerosis,OTHER: High Efficacy Therapy (HET)|OTHER: Non High Efficacy Therapy (Non-HET),Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",,4361,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-09-09,2021-09-17,2021-09-17,"Novartis Investigative Site, East Hanover, New Jersey, 07936-1080, United States"
NCT04782466,ATOMIC (Active Teens Multiple Sclerosis) Physical Activity Research Program,https://beta.clinicaltrials.gov/study/NCT04782466,RECRUITING,Pediatric Multiple Sclerosis,BEHAVIORAL: Physical Activity (PA) Intervention|BEHAVIORAL: Waitlist attention-control,The Hospital for Sick Children,Children's Hospital of Philadelphia|University of Alabama at Birmingham|Queen's University|National Multiple Sclerosis Society,ALL,"CHILD, ADULT",NA,56,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2020-12-01,2023-09,2023-09,"The University of Alabama at Birmingham, Birmingham, Alabama, 35294, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States|The Hospital for Sick Children, Toronto, Ontario, M5G 1X8, Canada"
NCT00513448,Promoting Physical Activity for Persons With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00513448,COMPLETED,Multiple Sclerosis,OTHER: Group wellness intervention|OTHER: Individualized physical rehabilitation,University of Minnesota,Agency for Healthcare Research and Quality (AHRQ),ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2005-04,,2005-11,"University of Minnesota, Minneapolis, Minnesota, 55455, United States"
NCT05544448,"In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases",https://beta.clinicaltrials.gov/study/NCT05544448,NOT_YET_RECRUITING,Autoimmune Diseases|Inflammatory Disease|Acquired Bone Marrow Aplasia|Systemic Lupus Erythematosus|Multiple Sclerosis|Gvhd|Rheumatoid Arthritis|Autoimmune Thyroiditis|Vitiligo|Alopecia|Atopic Dermatitis,OTHER: Blood sample taken at a single time point,Assistance Publique - Hôpitaux de Paris,,ALL,"ADULT, OLDER_ADULT",NA,90,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2022-10-15,2023-04-15,2023-04-15,
NCT02310048,Comparative Oral Bioavailability Study of MT-1303,https://beta.clinicaltrials.gov/study/NCT02310048,COMPLETED,Relapsing-remitting Multiple Sclerosis,DRUG: MT-1303-FormA|DRUG: MT-1303-FormB,Mitsubishi Tanabe Pharma Corporation,,MALE,ADULT,PHASE1,34,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2014-11,2015-03,2015-03,"Investigational site, Leeds, United Kingdom"
NCT02287948,Wii FIT Balance Board to Recording Balance Parameters in Multiple Sclerosis Subjects,https://beta.clinicaltrials.gov/study/NCT02287948,COMPLETED,Postural Balance|Multiple Sclerosis,DEVICE: Nintendo Wii Fit Balance Board,University Hospital of Ferrara,,ALL,"ADULT, OLDER_ADULT",,40,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-09,2015-12,2016-01,"Ferrara University Hospital, Ferrara, 44124, Italy"
NCT05283551,Famciclovir in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05283551,RECRUITING,Multiple Sclerosis,DRUG: Famciclovir,Queen Mary University of London,,ALL,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2020-11-25,2023-11-25,2023-11-25,"Royal London Hospital, Barts Health NHS Trust, London, E1 1BB, United Kingdom"
NCT05760651,Awareness of Osteoporosis in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT05760651,NOT_YET_RECRUITING,Multiple Sclerosis|Osteoporosis|Osteoporosis Risk,OTHER: Patient Participation Form,Uskudar State Hospital,,ALL,"ADULT, OLDER_ADULT",,400,OTHER_GOV,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-04-01,2023-07-01,2023-10-01,
NCT00411619,Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex,https://beta.clinicaltrials.gov/study/NCT00411619,COMPLETED,Tuberous Sclerosis|Subependymal Giant Cell Astrocytoma,DRUG: Everolimus,"Children's Hospital Medical Center, Cincinnati",Novartis,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1|PHASE2,28,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-01,2014-01,2014-01,"Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 45229, United States"
NCT00492466,Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies,https://beta.clinicaltrials.gov/study/NCT00492466,COMPLETED,Relapsing-Remitting Multiple Sclerosis,DRUG: Interferon-beta-1a|DRUG: methylprednisolone,Biogen,,ALL,ADULT,PHASE4,14,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2003-03,2006-08,2006-08,"Coordinating Research Site, Turku, Finland"
NCT01310166,Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01310166,COMPLETED,Relapsing-remitting Multiple Sclerosis,DRUG: Fingolimod,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE4,447,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2011-02,2012-07,2012-07,"Novartis Investigative Site, Ostfildern, Baden-Wuerttemberg, 73760, Germany|Novartis Investigative Site, Aalen, 73430, Germany|Novartis Investigative Site, Abensberg, 93326, Germany|Novartis Investigative Site, Altenholz-Stift, 24161, Germany|Novartis Investigative Site, Alzenau, 63755, Germany|Novartis Investigative Site, Andernach, 56626, Germany|Novartis Investigative Site, Aschaffenburg, 63739, Germany|Novartis Investigative Site, Bad Mergentheim, 97980, Germany|Novartis Investigative Site, Bamberg, 96052, Germany|Novartis Investigative Site, Berg, 82335, Germany|Novartis Investigative Site, Berlin, 10437, Germany|Novartis Investigative Site, Berlin, 10713, Germany|Novartis Investigative Site, Berlin, 12165, Germany|Novartis Investigative Site, Berlin, 13347, Germany|Novartis Investigative Site, Bielefeld, 33611, Germany|Novartis Investigative Site, Bochum, 44787, Germany|Novartis Investigative Site, Bochum, 44789, Germany|Novartis Investigative Site, Bochum, 44791, Germany|Novartis Investigative Site, Bremen, 28755, Germany|Novartis Investigative Site, Böblingen, 71032, Germany|Novartis Investigative Site, Celle, 29223, Germany|Novartis Investigative Site, Dortmund, 44135, Germany|Novartis Investigative Site, Dresden, 01307, Germany|Novartis Investigative Site, Düsseldorf, 40225, Germany|Novartis Investigative Site, Erbach, 64711, Germany|Novartis Investigative Site, Erlangen, 91054, Germany|Novartis Investigative Site, Frankfurt, 60313, Germany|Novartis Investigative Site, Fulda, 36043, Germany|Novartis Investigative Site, Grevenbroich, 41515, Germany|Novartis Investigative Site, Göttingen, 37073, Germany|Novartis Investigative Site, Hamburg, 20249, Germany|Novartis Investigative Site, Hamburg, 22083, Germany|Novartis Investigative Site, Hennigsdorf, 16761, Germany|Novartis Investigative Site, Jena, 07740, Germany|Novartis Investigative Site, Kastellaun, 56288, Germany|Novartis Investigative Site, Kiel, 24105, Germany|Novartis Investigative Site, Klingenmünster, 76889, Germany|Novartis Investigative Site, Krefeld, 47800, Germany|Novartis Investigative Site, Lappersdorf, 93138, Germany|Novartis Investigative Site, Leipzig, 04157, Germany|Novartis Investigative Site, Leipzig, 04299, Germany|Novartis Investigative Site, Leverkusen, 51375, Germany|Novartis Investigative Site, Merzig, 66663, Germany|Novartis Investigative Site, Mönchengladbach, 41239, Germany|Novartis Investigative Site, München, 81829, Germany|Novartis Investigative Site, Neuburg, 86633, Germany|Novartis Investigative Site, Osnabrück, 49076, Germany|Novartis Investigative Site, Regensburg, 93053, Germany|Novartis Investigative Site, Schwendi, 88477, Germany|Novartis Investigative Site, Siegen, 57076, Germany|Novartis Investigative Site, Singen, 78224, Germany|Novartis Investigative Site, Stade, 21682, Germany|Novartis Investigative Site, Stadtroda, 07646, Germany|Novartis Investigative Site, Stuttgart, 70178, Germany|Novartis Investigative Site, Troisdorf, 53844, Germany|Novartis Investigative Site, Tübingen, 72076, Germany|Novartis Investigative Site, Ulm, 89073, Germany|Novartis Investigative Site, Unterhaching, 82008, Germany|Novartis Investigative Site, Wermsdorf, 04779, Germany|Novartis Investigative Site, Wolfenbüttel, 38300, Germany"
NCT03033355,Central Nervous System Changes Following BotulinumtoxinA Injection in the Bladder,https://beta.clinicaltrials.gov/study/NCT03033355,COMPLETED,"Multiple Sclerosis|Lower Urinary Tract Symptoms|Neurogenic Bladder|Detrusor, Overactive|Urge Incontinence",DRUG: Intradetrusor injection of Botulinum Toxin-A,"Rose Khavari, M.D.",The Methodist Hospital Research Institute,FEMALE,"ADULT, OLDER_ADULT",,28,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-02,2019-03,2019-03,"Houston Methodist Hospital, Houston, Texas, 77030, United States"
NCT04100525,Intervention for Employed Women With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04100525,UNKNOWN,Multiple Sclerosis,BEHAVIORAL: Neuropsychological testing intervention plus follow up,"Holy Name Medical Center, Inc.",Women United in Philanthropy (WUIP),FEMALE,ADULT,NA,89,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2016-04,2020-02,2022-01,
NCT02104492,Effects of a 12-week Respiratory Muscles Training Program in Persons With Relapsing- Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02104492,UNKNOWN,Relapsing-remitting Multiple Sclerosis,OTHER: a 12-week Respiratory Muscles Training Program (RMTP)|OTHER: Active Comparator,University of Malaga,,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2014-03,2015-03,2015-03,"University of Málaga, Málaga, Spain"
NCT04676555,Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04676555,COMPLETED,Relapsing Forms of Multiple Sclerosis,DRUG: Ocrelizumab|DRUG: Ofatumumab,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",,2,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-05-11,2021-10-21,2021-10-21,"Novartis Investigative Site, Lutherville, Maryland, 21093, United States|Novartis Investigative Site, Parkville, Victoria, 3050, Australia"
NCT01633112,MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone,https://beta.clinicaltrials.gov/study/NCT01633112,TERMINATED,Relapsing-remitting Multiple Sclerosis (RRMS),DRUG: fingolimod|DRUG: glatiramer acetate,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,1064,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-08-09,2018-04-30,2018-04-30,"Novartis Investigative Site, Cullman, Alabama, 35058, United States|Novartis Investigative Site, Phoenix, Arizona, 85004, United States|Novartis Investigative Site, Phoenix, Arizona, 85013, United States|Novartis Investigative Site, Phoenix, Arizona, 85018, United States|Novartis Investigative Site, Tucson, Arizona, 85741, United States|Novartis Investigative Site, Los Angeles, California, 90089, United States|Novartis Investigative Site, Sacramento, California, 95817, United States|Novartis Investigative Site, Aurora, Colorado, 80045, United States|Novartis Investigative Site, Boulder, Colorado, 80304, United States|Novartis Investigative Site, Denver, Colorado, 80220, United States|Novartis Investigative Site, Fort Collins, Colorado, 80528, United States|Novartis Investigative Site, Loveland, Colorado, 80538, United States|Novartis Investigative Site, Fairfield, Connecticut, 06824, United States|Novartis Investigative Site, Newark, Delaware, 19713, United States|Novartis Investigative Site, Washington, District of Columbia, 20007, United States|Novartis Investigative Site, Jacksonville, Florida, 32209, United States|Novartis Investigative Site, Maitland, Florida, 32751, United States|Novartis Investigative Site, Naples, Florida, 34119, United States|Novartis Investigative Site, New Port Richey, Florida, 34653, United States|Novartis Investigative Site, Orlando, Florida, 32806, United States|Novartis Investigative Site, Ormond Beach, Florida, 32174, United States|Novartis Investigative Site, Pompano Beach, Florida, 33060, United States|Novartis Investigative Site, Ponte Vedra Beach, Florida, 32082-4627, United States|Novartis Investigative Site, Port Charlotte, Florida, 33952, United States|Novartis Investigative Site, Sarasota, Florida, 34243, United States|Novartis Investigative Site, Tallahassee, Florida, 32308, United States|Novartis Investigative Site, Tampa, Florida, 33609, United States|Novartis Investigative Site, Vero Beach, Florida, 32960, United States|Novartis Investigative Site, West Palm Beach, Florida, 33407, United States|Novartis Investigative Site, Atlanta, Georgia, 30327, United States|Novartis Investigative Site, Elk Grove Village, Illinois, 60007, United States|Novartis Investigative Site, Evanston, Illinois, 60201, United States|Novartis Investigative Site, Flossmoor, Illinois, 60422, United States|Novartis Investigative Site, Northbrook, Illinois, 60062, United States|Novartis Investigative Site, Indianapolis, Indiana, 46202, United States|Novartis Investigative Site, Indianapolis, Indiana, 46256, United States|Novartis Investigative Site, West Des Moines, Iowa, 50314, United States|Novartis Investigative Site, Kansas City, Kansas, 66160, United States|Novartis Investigative Site, Lenexa, Kansas, 66212, United States|Novartis Investigative Site, Louisville, Kentucky, 40207, United States|Novartis Investigative Site, Hammond, Louisiana, 70403, United States|Novartis Investigative Site, New Orleans, Louisiana, 70121, United States|Novartis Investigative Site, Baltimore, Maryland, 21201, United States|Novartis Investigative Site, Boston, Massachusetts, 02215, United States|Novartis Investigative Site, Springfield, Massachusetts, 01104, United States|Novartis Investigative Site, Detroit, Michigan, 48201, United States|Novartis Investigative Site, Detroit, Michigan, 48202, United States|Novartis Investigative Site, Farmington Hills, Michigan, 48334, United States|Novartis Investigative Site, Grand Rapids, Michigan, 49503, United States|Novartis Investigative Site, Traverse City, Michigan, 49684-2340, United States|Novartis Investigative Site, Kansas City, Missouri, 64111, United States|Novartis Investigative Site, Saint Louis, Missouri, 63104, United States|Novartis Investigative Site, Saint Louis, Missouri, 63131, United States|Novartis Investigative Site, Saint Louis, Missouri, 63141, United States|Novartis Investigative Site, Great Falls, Montana, 59405, United States|Novartis Investigative Site, Las Vegas, Nevada, 89106, United States|Novartis Investigative Site, Freehold, New Jersey, 07728, United States|Novartis Investigative Site, Newark, New Jersey, 07103, United States|Novartis Investigative Site, Teaneck, New Jersey, 07666, United States|Novartis Investigative Site, Albuquerque, New Mexico, 87131, United States|Novartis Investigative Site, Albany, New York, 12208, United States|Novartis Investigative Site, Amherst, New York, 14226, United States|Novartis Investigative Site, Buffalo, New York, 14203, United States|Novartis Investigative Site, Patchogue, New York, 11772, United States|Novartis Investigative Site, Rochester, New York, 14642, United States|Novartis Investigative Site, Stony Brook, New York, 11794, United States|Novartis Investigative Site, Syracuse, New York, 13210, United States|Novartis Investigative Site, Chapel Hill, North Carolina, 27599-9500, United States|Novartis Investigative Site, Charlotte, North Carolina, 28204, United States|Novartis Investigative Site, Winston-Salem, North Carolina, 27157, United States|Novartis Investigative Site, Akron, Ohio, 44320, United States|Novartis Investigative Site, Bellevue, Ohio, 44811, United States|Novartis Investigative Site, Columbus, Ohio, 43210, United States|Novartis Investigative Site, Columbus, Ohio, 43221, United States|Novartis Investigative Site, Dayton, Ohio, 45408, United States|Novartis Investigative Site, Toledo, Ohio, 43614, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, 73104, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, 73112, United States|Novartis Investigative Site, Tulsa, Oklahoma, 74137, United States|Novartis Investigative Site, Portland, Oregon, 97225, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, 19141, United States|Novartis Investigative Site, Spartanburg, South Carolina, 29302, United States|Novartis Investigative Site, Cordova, Tennessee, 38018, United States|Novartis Investigative Site, Knoxville, Tennessee, 37934, United States|Novartis Investigative Site, Nashville, Tennessee, 37204, United States|Novartis Investigative Site, Nashville, Tennessee, 37205, United States|Novartis Investigative Site, Dallas, Texas, 75214, United States|Novartis Investigative Site, Houston, Texas, 77030, United States|Novartis Investigative Site, Round Rock, Texas, 78681, United States|Novartis Investigative Site, San Antonio, Texas, 78258, United States|Novartis Investigative Site, Sherman, Texas, 75092, United States|Novartis Investigative Site, Salt Lake City, Utah, 84103, United States|Novartis Investigative Site, Alexandria, Virginia, 22310, United States|Novartis Investigative Site, Charlottesville, Virginia, 22903, United States|Novartis Investigative Site, Norfolk, Virginia, 23507, United States|Novartis Investigative Site, Richmond, Virginia, 23226, United States|Novartis Investigative Site, Roanoke, Virginia, 24018, United States|Novartis Investigative Site, Issaquah, Washington, 98029, United States|Novartis Investigative Site, Seattle, Washington, 98101, United States|Novartis Investigative Site, Seattle, Washington, 98122-4379, United States|Novartis Investigative Site, Milwaukee, Wisconsin, 53215, United States|Novartis Investigative Site, Caba, Buenos Aires, C1437JCP, Argentina|Novartis Investigative Site, Buenos aires, C1015ABR, Argentina|Novartis Investigative Site, Belo Horizonte, Minas Gerais, 30150 221, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, 90610-000, Brazil|Novartis Investigative Site, Joinville, Santa Catarina, 89202-165, Brazil|Novartis Investigative Site, São Paulo, SP, 08270-070, Brazil|Novartis Investigative Site, Campina Grande do Sul, 83430 000, Brazil|Novartis Investigative Site, Goiania, 74605 020, Brazil|Novartis Investigative Site, Passo Fundo, 99010-080, Brazil|Novartis Investigative Site, Rio de Janeiro, 22610-350, Brazil|Novartis Investigative Site, Sao Paulo, 05651-901, Brazil|Novartis Investigative Site, Edmonton, Alberta, T6R 2B7, Canada|Novartis Investigative Site, Burnaby, British Columbia, V5G 2X6, Canada|Novartis Investigative Site, Halifax, Nova Scotia, B3H 4K4, Canada|Novartis Investigative Site, Ottawa, Ontario, K1H 8L6, Canada|Novartis Investigative Site, Chicoutimi, Quebec, G7H 5H6, Canada|Novartis Investigative Site, Montreal, Quebec, H1T 2M4, Canada|Novartis Investigative Site, Montreal, Quebec, H3A 2B4, Canada|Novartis Investigative Site, Santiago, 8380815, Chile|Novartis Investigative Site, Santiago, PISO 1, Chile|Novartis Investigative Site, Mexico, Distrito Federal, 03310, Mexico|Novartis Investigative Site, Tlalnepantla, Edo De Mexico, 54055, Mexico|Novartis Investigative Site, Monterrey, Nuevo León, 64000, Mexico|Novartis Investigative Site, San Luis Potosi, San Luis Potosí, 78240, Mexico|Novartis Investigative Site, Aguascalientes, 20127, Mexico|Novartis Investigative Site, Chihuahua, 31000, Mexico|Novartis Investigative Site, Chihuahua, 31203, Mexico|Novartis Investigative Site, Monterrey, 64460, Mexico|Novartis Investigative Site, Guaynabo, 00968, Puerto Rico"
NCT01836055,Imaging Multiple Sclerosis Lesions Using Magnevist and Gadavist,https://beta.clinicaltrials.gov/study/NCT01836055,TERMINATED,Multiple Sclerosis,,Wayne State University,,ALL,ADULT,,19,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-01,2014-01,2014-02,"Wayne State University, Detroit, Michigan, 48201, United States"
NCT05523466,Effect of Acupuncture on Heart Rate Variability in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05523466,NOT_YET_RECRUITING,Multiple Sclerosis,OTHER: Acupuncture Active|OTHER: Acupuncture Sham,University of Sao Paulo,,ALL,ADULT,NA,40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-12,2023-07,2023-12,
NCT00291148,Neuropathic Pain Assessment Comparing Pregabalin and Paroxetine in Management of MS-induced Neuropathic Pain,https://beta.clinicaltrials.gov/study/NCT00291148,COMPLETED,Neuropathic Pain|Multiple Sclerosis,DRUG: paroxetine|DRUG: pregabalin,University of Manitoba,,ALL,"ADULT, OLDER_ADULT",PHASE3,75,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2006-03,2012-07,2012-07,"Multiple Sclerosis Clinic, Health Sciences Centre, Winnipeg, Manitoba, R3T 2N2, Canada"
NCT00776048,Validation of an Obstacle Course Used in Patients With Muscle Tightness,https://beta.clinicaltrials.gov/study/NCT00776048,UNKNOWN,Stroke|Traumatic Brain Injury|Multiple Sclerosis|Spasticity|Healthy Controls,,Kessler Foundation,,ALL,"ADULT, OLDER_ADULT",,40,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2007-01,2009-12,2009-12,"KesslerMRREC, West Orange, New Jersey, 07052, United States"
NCT01289912,Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC),https://beta.clinicaltrials.gov/study/NCT01289912,COMPLETED,Tuberous Sclerosis Complex,DRUG: RAD001|DRUG: Placebo,Mustafa Sahin,Tuberous Sclerosis Alliance|Autism Speaks|Novartis Pharmaceuticals|Seizure Tracker LLC,ALL,"CHILD, ADULT",PHASE2,52,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2011-01,2014-12,2014-12,"Boston Children's Hospital, Boston, Massachusetts, 02115, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 45229, United States"
NCT03561155,Robot-assisted Arm Training in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03561155,COMPLETED,Multiple Sclerosis|Rehabilitation,DEVICE: Robot assisted treatment (Amadeo®)|OTHER: Conventional treatment,Universita di Verona,,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2014-11,2017-09-01,2018-05-01,"UOC Neurorehabilitation, Verona, 37134, Italy"
NCT04789551,T Cell Profiling in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04789551,NOT_YET_RECRUITING,Multiple Sclerosis,OTHER: Blood Sample,Boston Children's Hospital,,ALL,"CHILD, ADULT",,40,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-06-01,2024-07-01,2024-12-01,"Boston Children's Hopsital, Boston, Massachusetts, 02115, United States"
NCT01591551,NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness,https://beta.clinicaltrials.gov/study/NCT01591551,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Natalizumab (Tysabri),"Cornerstone Health Care, PA",Biogen,ALL,"ADULT, OLDER_ADULT",PHASE4,37,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2012-03,2013-08,2013-08,"South Shore Neurologic Associates, Patchogue, New York, 11772, United States|Cornerstone Neurology, High Point, North Carolina, 27262, United States|Providence Brain Institute, Portland, Oregon, 97225, United States"
NCT04550455,A Prospective Biomarker Study in Active SPMS Subjects Treated With Cladribine Tablets,https://beta.clinicaltrials.gov/study/NCT04550455,RECRUITING,Multiple Sclerosis,DRUG: Cladribine Tablets,"Keith Edwards, M.D.",EMD Serono,ALL,"ADULT, OLDER_ADULT",PHASE4,30,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-16,2024-12,2025-12,"Multiple Sclerosis Center of Northeastern New York, P.C., Latham, New York, 12110, United States"
NCT05232825,"A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT05232825,RECRUITING,Relapsing Multiple Sclerosis|Primary Progressive Multiple Sclerosis,DRUG: Ocrelizumab IV|DRUG: Ocrelizumab SC|DRUG: Methylprednisolone IV|DRUG: Diphenhydramine IV|DRUG: Dexamethasone given orally|DRUG: Desloratadine given orally,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE3,234,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-05-03,2023-03-10,2025-04-01,"University of South Florida, Tampa, Florida, 33612, United States|The NeuroMedical Clinic of Central Louisiana, Alexandria, Louisiana, 71301, United States|Johns Hopkins Hospital; Neurology, Baltimore, Maryland, 21205, United States|Memorial Healthcare Institute for Neurosciences and Multiple Sclerosis, Owosso, Michigan, 48867, United States|Neurology Associates PA, Hickory, North Carolina, 28602, United States|UC Health Neurology, Dayton, Ohio, 45417, United States|Premier Neurology, Greer, South Carolina, 29650, United States|Neurology Clinic PC, Cordova, Tennessee, 38018, United States|Concord Repatriation General Hospital, Concord, New South Wales, 2139, Australia|Royal North Shore Hospital; Department of Neurology, St Leonards, New South Wales, 2065, Australia|The Memorial Hospital, North Adelaide, South Australia, 5006, Australia|Clinica Amo - Assistencia Medica Em Oncologia, Salvador, BA, 41950640, Brazil|CEDOES - Diagnóstico e Pesquisa, Vitoria, ES, 29055-450, Brazil|Hospital Santa Marcelina; AME - Ambulatório de Especialidades Médicas, Sao Paulo, SP, 08270-070, Brazil|Memorial University of Newfoundland (MUN) - Faculty of Medicine - St. Clare's Mercy Hospital (SCM), St. John's, Newfoundland and Labrador, A1B 3V6, Canada|CIUSSS de l?Estrie-CHUS/Hopital de Granby, Granby, Quebec, J2G 1T7, Canada|Fakultni nemocnice u sv. Anny; Neurologicka klinika, Brno, 656 91, Czechia|Charles University, Medical faculty, Hradec Kralove ;Department of Neurology, Hradec Králové, 500 05, Czechia|Nemocnice Jihlava; NEU-Neurologicke oddeleni, Jihlava, 58633, Czechia|Fakultni nemocnice Ostrava; MS centrum, Ostrava-Poruba, 708 52, Czechia|Pardubicka Krajska Nemocnice; Department of Neurology, Pardubice, 532 03, Czechia|Fakultni poliklinika VFN; RS centrum, Praha 2, 128 08, Czechia|Institut neuropsychiatricke pece (INEP), Praha 8, 186 00, Czechia|Fakultni nemocnice Motol; Neurologicka klinika, Praha, 150 06, Czechia|Krajska zdravotni a.s Nemocnice Teplice o.z.; RS centrum, Teplice, 415 01, Czechia|Ch De Calais; Hopital De Jour, Calais Cedex, 62107, France|Hôpital General - Service de neurologie; Service de neurologie, Dijon Cedex, 21079, France|A. O. U. Federico II; Dip Neuroscienze, Scienze Riproduttive ed Odontostomatologiche, Napoli, Campania, 80131, Italy|Policlinico Tor Vergata Dip. Neuroscienze-Clinica Neurologica-UOSD Sclerosi Multipla, Roma, Lazio, 00133, Italy|Azienda Ospedaliera Sant'Andrea; UOC Neurologia, Roma, Lazio, 00189, Italy|Irccs A.O.U.San Martino Ist; Dinogmi, Genova, Liguria, 16132, Italy|IRCCS Ospedale San Raffaele; Neurologia Neurofisiologia Neuroriabilitazione-Centro Sclerosi Multipla, Milano, Lombardia, 20132, Italy|Ospedale Civile di Montichiari; Centro Sclerosi Multipla, Montichiari, Lombardia, 25018, Italy|IRCCS Istituto Neurologico Neuromed; Centro per lo Studio e la Cura della Sclerosi Multipla, Pozzilli, Molise, 86077, Italy|Optimal Clinical Trials, Auckland, 1010, New Zealand|Hawkes Bay Hospital, Hastings, 4120, New Zealand|Neurocentrum Bydgoszcz sp. z o.o, Bydgoszcz, 85-796, Poland|Care Clinic, Katowice, 40-568, Poland|Centrum Neurologii Krzysztof Selmaj, Lodz, 90-324, Poland|Przychodnia EuroMediCare, Wroc?aw, 50-220, Poland|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, 28222, Spain|Hospital Universitario Virgen Macarena, Seville, Sevilla, 41071, Spain|Complejo Hospitalario Nuestra Señora de la Candelaria; Servicio de Neurologia, Santa Cruz De Tenerife, Tenerife, 38010, Spain|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital Universitario Reina Sofia; Servicio de Neurologia, Cordoba, 14004, Spain|Hospital Regional Universitario de Malaga ? Hospital General; Servicio de Neurologia, Malaga, 29010, Spain|Hacettepe University Medical Faculty; Neurology, Ankara, 06100, Turkey|Bakirkoy State Mental Hospital, Istanbul, 34000, Turkey|Istanbul Universitesi - Cerrahpasa Cerrahpasa Tip Fakultesi; Noroloji Anabilim Dali, Istanbul, 34098, Turkey|Katip Celebi University Ataturk Training and Research Hospital; Neurology, Izmir, 35360, Turkey|Kocaeli University Hospital; Department of Neurology, Kocaeli, 41380, Turkey|Kutahya Saglik Bilimleri Universitesi; Noroloji, Merkez, 43100, Turkey|Namik Kemal Universitesi Sagli Uygulama ve Arastirma Hastanesi; Noroloji, Süleymanpa?a, 59100, Turkey"
NCT03927092,Reliability and Validity of the Turkish Version of the Multiple Sclerosis Knowledge Questionnaire,https://beta.clinicaltrials.gov/study/NCT03927092,COMPLETED,Multiple Sclerosis,OTHER: Multiple Sclerosis Knowledge Questionnaire,Ege University,,ALL,"ADULT, OLDER_ADULT",,58,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-05,2016-05,2016-05,
NCT03201692,Improving Dynamic Balance and Gait Adaptability Using Treadmill Training,https://beta.clinicaltrials.gov/study/NCT03201692,UNKNOWN,Multiple Sclerosis|Stroke|Parkinson Disease,DEVICE: Virtual Reality Treadmill Training|DEVICE: Treadmill training,Fondazione Don Carlo Gnocchi Onlus,,ALL,"ADULT, OLDER_ADULT",NA,48,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2017-07-01,2019-04-10,2019-04-10,"Don Gnocchi Foundation, Milan, 20148, Italy"
NCT00176592,"Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI",https://beta.clinicaltrials.gov/study/NCT00176592,COMPLETED,Multiple Sclerosis,DRUG: Betaseron|DRUG: Copaxone,University of Medicine and Dentistry of New Jersey,,ALL,ADULT,PHASE4,75,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2003-01,2007-01,2007-01,"New Jersey Medical School, Newark, New Jersey, 07103, United States"
NCT04651725,Effectiveness of Hippotherapy Simulator in PwMS,https://beta.clinicaltrials.gov/study/NCT04651725,COMPLETED,Multiple Sclerosis|Exercise,OTHER: Exercises,Uşak University,,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2020-11-01,2022-04-15,2022-04-15,"University of Usak, Uşak, 64200, Turkey"
NCT03963492,Intermittent vs Continuous Walking in People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03963492,SUSPENDED,Multiple Sclerosis,OTHER: Walking,"Rutgers, The State University of New Jersey","Mount Sinai Rehabilitation Hospital|City University of New York, School of Public Health",ALL,"ADULT, OLDER_ADULT",NA,24,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2019-07-01,2023-02-28,2023-02-28,"Mandell Center for Multiple Sclerosis - Mount Sinai Rehabilitation Hospital, Hartford, Connecticut, 06112, United States"
NCT00457730,A Study to Test the Use of Duloxetine for Pain in MS,https://beta.clinicaltrials.gov/study/NCT00457730,COMPLETED,Multiple Sclerosis,DRUG: Duloxetine|DRUG: Placebo,"Brown, Theodore R., M.D., MPH",Eli Lilly and Company,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,38,INDIV,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2007-01,2012-08,2012-08,"Evergreen Healthcare, Kirkland, Washington, 98034, United States"
NCT05757830,PURO - PUlmonary Rehabilitation With O-RAGT Platform,https://beta.clinicaltrials.gov/study/NCT05757830,RECRUITING,Multiple Sclerosis|Spinal Cord Injury|Stroke|Traumatic Brain Damage,DEVICE: UANGO suite exoskeleton,Fondazione Don Carlo Gnocchi Onlus,Roessingh Research and Development|Hospital Nacional de Parapléjicos de Toledo|Lithuanian University of Health Sciences,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2022-12-23,2023-03-31,2023-03-31,"Fondazione Don Carlo Gnocchi, Milan, MI, 20162, Italy|Lithuanian University of Health Sciences, Kaunas, LT-50161, Lithuania|Roessingh Research and Development, Enschede, AH, 7522, Netherlands|Hospital Nacional de Parapléjicos de Toledo, Toledo, 45071, Spain"
NCT01099930,Autologous Stem Cell Transplant for Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01099930,COMPLETED,Multiple Sclerosis,"OTHER: immuno-ablation and autologous CD34 selected hematopoietic stem cell transplantation (HSCT),|OTHER: Standard Therapy",Ottawa Hospital Research Institute,Multiple Sclerosis Scientific Research Foundation,ALL,ADULT,PHASE2,24,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2001-08,2012-11,2016-06,"Ottawa Hospital Research Institute, Ottawa, Ontario, K1H 8L6, Canada"
NCT02269930,Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers,https://beta.clinicaltrials.gov/study/NCT02269930,COMPLETED,Multiple Sclerosis,DRUG: peginterferon beta-1a|DRUG: Rebif,Biogen,,ALL,ADULT,PHASE1,30,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2014-10,2014-12,2014-12,"Research Site, Evansville, Indiana, 47710, United States"
NCT03900221,French Registry for Monitoring Pregnancies for Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03900221,RECRUITING,"Sclerosis, Multiple|Neuromyelitis Optica Spectrum Disorder|Myelin Oligodendrocyte Glycoprotein (MOG)-Antibody Related Disorders|Pregnancy Abnormal",OTHER: No intervention,Hospices Civils de Lyon,,ALL,"CHILD, ADULT, OLDER_ADULT",,1000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-08-12,2030-08-12,2030-08-12,"Chu D'Amiens, Amiens, 80054, France|Hopital Jean Minjoz, Besançon, 25030, France|Hopital Pellegrin, Bordeaux, 33076, France|Hôpital Neurologique Pierre Wertheimer, Bron, 69677, France|Hopital Cote de Nacre, Caen, 14033, France|Hopital Gabriel Montpied, Clermont-Ferrand, 63003, France|Centre Hospitalier Sud Francilien, Corbeil-Essonnes, 91100, France|Hopital Henri Mondor, Créteil, 94010, France|Hopital Du Bocage, Dijon, 21079, France|Chu de Grenoble, Grenoble, 38043, France|Centre Hospitalier de Versailles Hôpital Andre Mignot, Le Chesnay, 78157, France|Chru de Lille, Lille, 59037, France|Hopital Dupuytren, Limoges, 87042, France|Hopital Timone Adultes, Marseille, 13385, France|Hopital Gui de Chauliac, Montpellier, 34295, France|Hôpital Central, Nancy, 54035, France|Hopital Pasteur, Nice, 06001, France|Hopital Caremeau, Nîmes, 30029, France|Fondation Rotschild, Paris, 75019, France|Hopital Saint Antoine, Paris, 75570, France|Hopital Pitie Salpetriere, Paris, 75651, France|Chi Poissy Saint Germain En Laye, Poissy, 78303, France|Chr La Miletrie, Poitiers, 86021, France|Hopital Rene Dubos, Pontoise, 95300, France|Hopital de La Maison Blanche, Reims, 51092, France|Hopital Pontchaillou, Rennes, 35033, France|Hôpital Charles-Nicolle, Rouen, 76000, France|Centre Hospitalier de Saint-Denis, Saint-Denis, 93200, France|Hopital G. Et R. Laennec, Saint-Herblain, 44800, France|Hopital Nord, Saint-Priest-en-Jarez, 42277, France|Hopital Hautepierre, Strasbourg, 67098, France|Hopital Purpan, Toulouse, 31059, France|Chru de Tours Hopital Bretonneau, Tours, 37044, France|Hopital P. Zobda-Quitman, Fort-de-France, 97200, Martinique"
NCT03166930,Evaluation of a Spasticity Management Program for People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03166930,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Spasticity Take Control|BEHAVIORAL: Stretching for People with MS: An Illustrated Manual,VA Office of Research and Development,Oregon Health and Science University,ALL,"ADULT, OLDER_ADULT",NA,231,FED,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2018-01-01,2021-07-30,2022-01-31,"VA Portland Health Care System, Portland, OR, Portland, Oregon, 97239, United States"
NCT03281330,Effect of Motor Entrainment to Auditory Cues and Music During Walking on Quality of Movement and Perceived Fatigue in Persons With Multiple Sclerosis (PwMS),https://beta.clinicaltrials.gov/study/NCT03281330,COMPLETED,Multiple Sclerosis,BEHAVIORAL: auditory cues and music during walking,Hasselt University,University Ghent|Revalidatie & MS Centrum Overpelt|National MS Center Melsbroek,ALL,"ADULT, OLDER_ADULT",,60,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-02-01,2018-05-30,2018-06-30,"University of Ghent, Gent, Belgium|Nationaal Multiple Sclerose Center, Melsbroek, Belgium|Revalidatie & MS Centrum Overpelt, Overpelt, Belgium"
NCT03768830,"Impact of Exercise on ""Invisible"" Symptoms and Quality of Life in Multiple Sclerosis Individuals",https://beta.clinicaltrials.gov/study/NCT03768830,COMPLETED,Multiple Sclerosis|Quality of Life|Motivation|Pain|Headache|Migraine|Anxiety Disorders|Depressive Disorder|Sleep Disorder|Insomnia|Physical Disability|Fatigue,BEHAVIORAL: Exercise training,University of Rijeka,,ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2018-10-01,2019-02-05,2019-02-05,"University of Rijeka, Faculty of Medicine, Department of Physiology, Immunology and Pathophysiology, Rijeka, 51000, Croatia"
NCT01108887,"An Observational Study for the Assessment of Adherence, Effectiveness and Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart™.",https://beta.clinicaltrials.gov/study/NCT01108887,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",,"Merck KGaA, Darmstadt, Germany","Merck Serono S.A., Geneva",ALL,"ADULT, OLDER_ADULT",,912,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2009-09,2013-01,2013-01,"Merck Serono Observational Site, Breda, Netherlands"
NCT05732285,A Pilot Randomized Controlled Trial: CoINTEGRATE,https://beta.clinicaltrials.gov/study/NCT05732285,RECRUITING,Neurocognitive Disorders|Cognitive Dysfunction|Traumatic Brain Injury|Multiple Sclerosis|Mild Cognitive Impairment,BEHAVIORAL: CRT|BEHAVIORAL: CBT|BEHAVIORAL: Modifiable lifestyle factors|BEHAVIORAL: Usual care Psychoeducation,University of Michigan,,ALL,"ADULT, OLDER_ADULT",NA,56,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (CARE_PROVIDER)|Primary Purpose: TREATMENT,2023-06-01,2025-03-01,2025-03-30,"University of Michigan, Ann Arbor, Michigan, 48109, United States"
NCT05340985,Investigating the Effects of Hydroxyvitamin D3 on Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05340985,NOT_YET_RECRUITING,"Multiple Sclerosis, Relapsing-Remitting|Adult ALL|Vitamin D3 Deficiency",DIETARY_SUPPLEMENT: 25(OH)D3|DIETARY_SUPPLEMENT: vitamin D3,Tehran University of Medical Sciences,Boston University,ALL,ADULT,PHASE4,54,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE,2022-07,2023-06,2023-12,
NCT01847287,A Longitudinal Study of Brain Atrophy in MS Patients Over 5 Years,https://beta.clinicaltrials.gov/study/NCT01847287,COMPLETED,Multiple Sclerosis,,University at Buffalo,,ALL,"ADULT, OLDER_ADULT",,60,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-05,2013-02,2013-02,"Buffalo Neuroimaging Analysis Center, Buffalo, New York, 14203, United States"
NCT02136485,Mindfulness-based Stress Reduction in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02136485,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Mindfulness-based stress reduction (MBSR)|OTHER: waiting list control,NHS Greater Glasgow and Clyde,University of Glasgow,ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-06-02,2016-08-31,2016-08-31,"NHS Centre for Integrative Care, Glasgow, G12 0XP, United Kingdom"
NCT01578785,"An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)",https://beta.clinicaltrials.gov/study/NCT01578785,TERMINATED,Relapsing-Remitting Multiple Sclerosis,DRUG: Glatiramer Acetate|DRUG: Placebo,"Teva Branded Pharmaceutical Products R&D, Inc.",,ALL,ADULT,PHASE3,178,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2012-03,2012-10,2012-11,"Teva Investigational Site 10192, Cullman, Alabama, United States|Teva Investigational Site 10204, Fresno, California, United States|Teva Investigational Site 10201, La Jolla, California, United States|Teva Investigational Site 10196, Centennial, Colorado, United States|Teva Investigational Site 10184, Miami, Florida, United States|Teva Investigational Site 10180, Sarasota, Florida, United States|Teva Investigational Site 10197, Sarasota, Florida, United States|Teva Investigational Site 10190, Tampa, Florida, United States|Teva Investigational Site 10207, Tampa, Florida, United States|Teva Investigational Site 10199, Vero Beach, Florida, United States|Teva Investigational Site 10181, Chicago, Illinois, United States|Teva Investigational Site 10202, Northbrook, Illinois, United States|Teva Investigational Site 10188, Patchogue, New York, United States|Teva Investigational Site 10198, Charlotte, North Carolina, United States|Teva Investigational Site 10203, Hickory, North Carolina, United States|Teva Investigational Site 10209, Hickory, North Carolina, United States|Teva Investigational Site 10212, Raleigh, North Carolina, United States|Teva Investigational Site 10215, Winston Salem, North Carolina, United States|Teva Investigational Site 10213, Winston-Salem, North Carolina, United States|Teva Investigational Site 10194, Akron, Ohio, United States|Teva Investigational Site 10191, Dayton, Ohio, United States|Teva Investigational Site 10200, Uniontown, Ohio, United States|Teva Investigational Site 10206, Cordova, Tennessee, United States|Teva Investigational Site 10214, Cordova, Tennessee, United States|Teva Investigational Site 10186, Nashville, Tennessee, United States|Teva Investigational Site 67001, Tirana, Albania|Teva Investigational Site 68007, Gomel, Belarus|Teva Investigational Site 68004, Grodno, Belarus|Teva Investigational Site 68003, Minsk, Belarus|Teva Investigational Site 68005, Minsk, Belarus|Teva Investigational Site 68006, Minsk, Belarus|Teva Investigational Site 68001, Vitebsk, Belarus|Teva Investigational Site 68002, Vitebsk, Belarus|Teva Investigational Site 69004, Bihac, Bosnia and Herzegovina|Teva Investigational Site 69002, Mostar, Bosnia and Herzegovina|Teva Investigational Site 69001, Sarajevo, Bosnia and Herzegovina|Teva Investigational Site 69003, Tuzla, Bosnia and Herzegovina|Teva Investigational Site 59020, Blagoevgrad, Bulgaria|Teva Investigational Site 59018, Pleven, Bulgaria|Teva Investigational Site 59019, Pleven, Bulgaria|Teva Investigational Site 59025, Pleven, Bulgaria|Teva Investigational Site 59024, Ruse, Bulgaria|Teva Investigational Site 59023, Shumen, Bulgaria|Teva Investigational Site 59006, Sofia, Bulgaria|Teva Investigational Site 59007, Sofia, Bulgaria|Teva Investigational Site 59008, Sofia, Bulgaria|Teva Investigational Site 59009, Sofia, Bulgaria|Teva Investigational Site 59010, Sofia, Bulgaria|Teva Investigational Site 59011, Sofia, Bulgaria|Teva Investigational Site 59012, Sofia, Bulgaria|Teva Investigational Site 59014, Sofia, Bulgaria|Teva Investigational Site 59015, Sofia, Bulgaria|Teva Investigational Site 59016, Sofia, Bulgaria|Teva Investigational Site 59017, Sofia, Bulgaria|Teva Investigational Site 59021, Sofia, Bulgaria|Teva Investigational Site 59026, Sofia, Bulgaria|Teva Investigational Site 59022, Stara Zagora, Bulgaria|Teva Investigational Site 59013, Varna, Bulgaria|Teva Investigational Site 59027, Veliko Tarnovo, Bulgaria|Teva Investigational Site 59028, Veliko Tarnovo, Bulgaria|Teva Investigational Site 60003, Osijek, Croatia|Teva Investigational Site 60005, Varazdin, Croatia|Teva Investigational Site 60001, Zagreb, Croatia|Teva Investigational Site 60002, Zagreb, Croatia|Teva Investigational Site 60004, Zagreb, Croatia|Teva Investigational Site 60006, Zagreb, Croatia|Teva Investigational Site 60007, Zagreb, Croatia|Teva Investigational Site 55004, Paernu, Estonia|Teva Investigational Site 55003, Tallinn, Estonia|Teva Investigational Site 81001, Tbilisi, Georgia|Teva Investigational Site 81002, Tbilisi, Georgia|Teva Investigational Site 81003, Tbilisi, Georgia|Teva Investigational Site 81004, Tbilisi, Georgia|Teva Investigational Site 81005, Tbilisi, Georgia|Teva Investigational Site 63017, Athens, Greece|Teva Investigational Site 63021, Athens, Greece|Teva Investigational Site 63020, Melissia, Greece|Teva Investigational Site 63018, Thessaloniki, Greece|Teva Investigational Site 63019, Thessaloniki, Greece|Teva Investigational Site 56004, Riga, Latvia|Teva Investigational Site 65005, Shtip, Macedonia, The Former Yugoslav Republic of|Teva Investigational Site 65001, Skopje, Macedonia, The Former Yugoslav Republic of|Teva Investigational Site 65002, Skopje, Macedonia, The Former Yugoslav Republic of|Teva Investigational Site 65003, Skopje, Macedonia, The Former Yugoslav Republic of|Teva Investigational Site 65006, Strumica, Macedonia, The Former Yugoslav Republic of|Teva Investigational Site 65004, Tetovo, Macedonia, The Former Yugoslav Republic of|Teva Investigational Site 21023, Estado de Mexico, Mexico|Teva Investigational Site 21021, Guadalajara, JALISCO, Mexico|Teva Investigational Site 21022, Mexico City, DISTRITO FEDERAL, Mexico|Teva Investigational Site 21025, Monterrey, Mexico|Teva Investigational Site 21020, Morelia, MICHOACAN, Mexico|Teva Investigational Site 21024, San Luís Potosí, Mexico|Teva Investigational Site 70001, Chisinau, Moldova, Republic of|Teva Investigational Site 70002, Chisinau, Moldova, Republic of|Teva Investigational Site 70003, Chisinau, Moldova, Republic of|Teva Investigational Site 70004, Chisinau, Moldova, Republic of|Teva Investigational Site 66001, Podgorica, Montenegro|Teva Investigational Site 53033, Bialystok, Poland|Teva Investigational Site 53020, Czestochowa, Poland|Teva Investigational Site 53023, Gdansk, Poland|Teva Investigational Site 53024, Gdansk, Poland|Teva Investigational Site 53031, Grodzisk Mazowiecki, Poland|Teva Investigational Site 53032, Grodzisk Mazowiecki, Poland|Teva Investigational Site 53021, Katowice, Poland|Teva Investigational Site 53019, Kielce, Poland|Teva Investigational Site 53028, Konstancin-Jeziorna, Poland|Teva Investigational Site 53037, Koscierzyna, Poland|Teva Investigational Site 53018, Lodz, Poland|Teva Investigational Site 53027, Lublin, Poland|Teva Investigational Site 53036, Olsztyn, Poland|Teva Investigational Site 53030, Poznan / Plewiska, Poland|Teva Investigational Site 53034, Poznan, Poland|Teva Investigational Site 53025, Szczecin, Poland|Teva Investigational Site 53026, Szczecin, Poland|Teva Investigational Site 53022, Warsaw, Poland|Teva Investigational Site 53029, Warszawa, Poland|Teva Investigational Site 52010, Bucuresti, Romania|Teva Investigational Site 52012, Bucuresti, Romania|Teva Investigational Site 52015, Cluj-Napoca, Romania|Teva Investigational Site 52016, Cluj-Napoca, Romania|Teva Investigational Site 52017, Constanta, Romania|Teva Investigational Site 52018, Constanta, Romania|Teva Investigational Site 52014, Iasi, Romania|Teva Investigational Site 52021, Oradea, Romania|Teva Investigational Site 52011, Piatra-Neamt, Romania|Teva Investigational Site 52013, Sibiu, Romania|Teva Investigational Site 52020, Targu-Mures, Romania|Teva Investigational Site 52019, Timisoara, Romania|Teva Investigational Site 50023, Barnaul, Russian Federation|Teva Investigational Site 50021, Chelyabinsk, Russian Federation|Teva Investigational Site 50025, Kazan, Russian Federation|Teva Investigational Site 50039, Krasnodar, Russian Federation|Teva Investigational Site 50022, Moscow, Russian Federation|Teva Investigational Site 50034, Moscow, Russian Federation|Teva Investigational Site 50035, Moscow, Russian Federation|Teva Investigational Site 50036, Moscow, Russian Federation|Teva Investigational Site 50020, Nizhny Novgorod, Russian Federation|Teva Investigational Site 50024, Nizhny Novgorod, Russian Federation|Teva Investigational Site 50123, Nizhny Novgorod, Russian Federation|Teva Investigational Site 50027, Novosibirsk, Russian Federation|Teva Investigational Site 50019, Perm, Russian Federation|Teva Investigational Site 50038, Rostov-on-Don, Russian Federation|Teva Investigational Site 50032, Saint Petersburg, Russian Federation|Teva Investigational Site 50030, Samara, Russian Federation|Teva Investigational Site 50037, Saratov, Russian Federation|Teva Investigational Site 50028, Smolensk, Russian Federation|Teva Investigational Site 50029, St. Petersburg, Russian Federation|Teva Investigational Site 50031, Tyumen, Russian Federation|Teva Investigational Site 50026, Ufa, Russian Federation|Teva Investigational Site 50040, Volgograd, Russian Federation|Teva Investigational Site 50033, Yaroslavl, Russian Federation|Teva Investigational Site 61002, Belgrade, Serbia|Teva Investigational Site 61005, Belgrade, Serbia|Teva Investigational Site 61001, Kragujevac, Serbia|Teva Investigational Site 61003, Nis, Serbia|Teva Investigational Site 58022, Chernihiv, Ukraine|Teva Investigational Site 58030, Donetsk, Ukraine|Teva Investigational Site 58020, Ivano-Frankivsk, Ukraine|Teva Investigational Site 58028, Kharkiv, Ukraine|Teva Investigational Site 58023, Kyiv, Ukraine|Teva Investigational Site 58025, Kyiv, Ukraine|Teva Investigational Site 58018, Lviv, Ukraine|Teva Investigational Site 58021, Odessa, Ukraine|Teva Investigational Site 58029, Poltava, Ukraine|Teva Investigational Site 58032, Simferopol, AR Crimea, Ukraine|Teva Investigational Site 58031, Uzhgorod, Ukraine|Teva Investigational Site 58027, Vinnytsya, Ukraine|Teva Investigational Site 58019, Zaporizhzhya, Ukraine|Teva Investigational Site 58024, Zaporizhzhya, Ukraine"
NCT05526287,Effects of Dual-Task Training in People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05526287,RECRUITING,Multiple Sclerosis,OTHER: Dual-Task Training|OTHER: Home Exercise Program,Ege University,,ALL,"ADULT, OLDER_ADULT",NA,26,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-11-01,2023-04-01,2023-08-15,"Ege University Faculty of Health Sciences, İzmir, Karsıyaka, 35575, Turkey"
NCT03949387,Functional Electrical Stimulation Cycling for Managing Mobility Disability in People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03949387,RECRUITING,Multiple Sclerosis,OTHER: FES Cycling Exercise|OTHER: Passive Leg Cycling,University of Ottawa,The Ottawa Hospital|Multiple Sclerosis Society of Canada,ALL,ADULT,NA,40,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2019-10-16,2023-08,2023-12,"University of Ottawa, Ottawa, Ontario, K1N 6N5, Canada"
NCT05414487,Effects of Ofatumumab Treatment on Immune Cells and Meningeal Lymphatic Drainage in Patients With Demyelinating Diseases,https://beta.clinicaltrials.gov/study/NCT05414487,RECRUITING,Multiple Sclerosis|Neuromyelitis Optica Spectrum Disorder|Demyelinating Diseases of the Central Nervous System,DRUG: Ofatumumab,Tianjin Medical University General Hospital,,ALL,"ADULT, OLDER_ADULT",,34,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-10-15,2023-12-01,2024-06-01,"Tianjin Medical University General Hospital, Tianjin, Tianjin, 300052, China"
NCT02601885,A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02601885,COMPLETED,Multiple Sclerosis,DRUG: ABT-555|OTHER: Placebo,AbbVie,,ALL,ADULT,PHASE1,20,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2016-10-18,2018-04-20,2018-04-20,"Compass Research LLC, Orlando, Florida, 32806, United States|Rowe Neurology Institute, Lenexa, Kansas, 66214, United States|Parexel International, Baltimore, Maryland, 21225, United States|MIND, Farmington Hills, Michigan, 48334, United States|Duke Univ Med Ctr, Durham, North Carolina, 27710, United States|Tri-State Mountain Neurology, Johnson City, Tennessee, 37604, United States|Clinical Trial Network, Houston, Texas, 77074, United States|Integrated Neurology Services, Alexandria, Virginia, 22310, United States"
NCT00725985,Oral Cladribine in Early Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT00725985,COMPLETED,Multiple Sclerosis,DRUG: Cladribine|DRUG: Placebo|DRUG: Rebif® new formulation (RNF),"EMD Serono Research & Development Institute, Inc.",,ALL,ADULT,PHASE3,617,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2008-12-31,2011-07-31,2012-04-30,"Hope Research Institute Medical Plaza LLC Desert Hills, Phoenix, Arizona, United States|Multiple Sclerosis Center Drive, Neurology Suite 701, Newport Beach, California, United States|University of Colorado at Denver Health Sciences, Denver, Colorado, United States|Fort Collins Neurology, Fort Collins, Colorado, United States|MS Center of Brevard MIMA Centry Research Associates, Melbourne, Florida, United States|University of South Florida, Tampa, Florida, United States|MS Center of Atlanta, Atlanta, Georgia, United States|Bruce Hughes West Building, Des Moines, Iowa, United States|Michigan Neurology Associates, Clinton Township, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Dennis Dietrich, Great Falls, Montana, United States|University of Medicine and Dentistry of New Jersey School of Neurology, Stratford, New Jersey, United States|Upstate Clinical Research LLC 3, Albany, New York, United States|Neurological Specialists of Long Island, Great Neck, New York, United States|Multiple Sclerosis Center of Northeastern NY, New York, New York, United States|Comprehensive MS Care Clinic at South Shore Multiple Sclerosis, Patchogue, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Meritcare Neuroscience Center Neurology, Fargo, North Dakota, United States|University of Cincinnati, Cincinnati, Ohio, United States|MS Center of Oklahoma, Oklahoma City, Oklahoma, United States|Neurology and Sleep Medicine, Bethlehem, Pennsylvania, United States|Swedish Medical Center Cherry Hill, Seattle, Washington, United States|Neurology & Neurological Association of Tacoma, Tacoma, Washington, United States|Instituto Medico Rodriguez Alfici, Godoy Cruz, Argentina|Fundacion Rosarina de Neurorehabilitacion, Rosario, Argentina|Krankenhaus der Barmherzigen Brüder, Linz, Austria|Algemeen Ziekenhuis St Jan, Brugge, Belgium|Cliniques Universitaires St-Luc, Brussels, Belgium|Hopital Erasme, Bruxelles, Belgium|CHU de Liege - Domaine Universitaire du Sart Tilman,, Liège, Belgium|Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina|Military Medical Academy- Sofia (MMA), Pleven, Bulgaria|MBAL Rousse AD 1st, Rousse, Bulgaria|Central Clinic Hospital, Sofia, Bulgaria|Military Medical Academy, Sofia, Bulgaria|National Heart Hospital, Sofia, Bulgaria|Second MHAT, Sofia, Bulgaria|Tokuda Hospital, Sofia, Bulgaria|University Hospital St Naum, Sofia, Bulgaria|Medical Centre Centromed 2000, Veliko Tarnovo, Bulgaria|Ottawa General Hospital, Ottawa, Canada|General Hospital Varazdin, Varazdin, Croatia|University Hospital Zagreb, Zagreb, Croatia|Faculty Hospital Brno, Brno, Czechia|Neurological dept of Faculty, Hradec Kralove, Czechia|Fakultní nemocnice s poliklinikou Ostrava, Ostrava, Czechia|Faculty Hospital Motol, Prague, Czechia|Klinika Vseobecne, Prague, Czechia|Nemocnice Teplice, Teplice, Czechia|East Tallinn Central Hospital, Tallinn, Estonia|West Tallinn Central Hospital, Tallinn, Estonia|HUS Hyvinkaa Central Hospital, Hyvinkaa, Finland|OYKS Neurologian Klinikka, Oulu, Finland|Neurologian Klinikka Seinajoen Keskussairaala, Seinajoki, Finland|Tampere University Hospital, Tampere, Finland|Turun Yliopistollinen Keskussairaala Rakennus 3 1, Turku, Finland|CHU de Lille, Lille Cedex, France|CHU de Nantes, Nantes, France|American Memorial Hospital, Reims Cedex, France|David Tatishvili Medical Center, Tbilisi, Georgia|Medical Center Health, Tbilisi, Georgia|S. Khechinashvili Tbilisi State Medical University, Tbilisi, Georgia|Universitaetsklinikum und Medizinische Fakultaet Heidelberg, Heidelberg, Germany|Philipps-Universitaet Marburg, Marburg, Germany|M S Ramaiah Medical College Hospital, Bangalore, Karnataka, India|St.John's Medical College and Hospital, Bangalore, Karnataka, India|Amrita Institute of Medical Sciences and Research, Kochi, Kerala, India|Kovai Medical Centre and Hospital, Coimbatore, India|Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India|Mallikatta Neuro and Research Centre, Mangalore, India|Ospedale Regionale Torrette, Ancona, Italy|Università de Bari, Bari, Italy|Ospedale Binaghi Centro Sclerosi Multipla, Cagliari, Italy|Azienda Ospedaliera Garibaldi, Catania, Italy|Dipartimento di Neuroscienze, Catania, Italy|Università G. D'Annunzio, Chieti, Italy|Ospedale San Antonio Abate, Gallarate, Italy|Universita degli Studi di Genova, Genova, Italy|Ospedale e casa di riposo P. Richiedei, Gussago, Italy|Ospedale San Raffaele, Milano, Italy|Dipartimento di Scienze Neurologiche, Napoli, Italy|Azienda Sanitaria Ospedaliera San Luigi Gonzaga, Orbassano, Italy|Villa Sofia Hospital Azienda Ospedaliera Villa Sofia P.zza Salerno e Resuttana 1, Palermo, Italy|Istituto Neurologico C. Mondino, Pavia, Italy|Azienda Ospedaliera S. Camillo Forlanini, Roma, Italy|Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Roma, Italy|Università di Roma La Sapienza, Roma, Italy|National Cancer Center, Department of Neurology,, Gyeonggi-do, Korea, Republic of|Department of Neurology, 50 Ilwon-dong, Gangnam-gu, Seoul, Korea, Republic of|Department of Neurology, Asan Medical Center, 388-1 Pungnap 2-dong, Songpa-gu, Seoul, Korea, Republic of|Seoul National University Hospital, Department of Neurology, Seoul, Korea, Republic of|Yonsei University Medical Center, Department of Neurology, Yonsei University Medical Center, Seoul, Korea, Republic of|American University of Beirut, Beirut, Lebanon|Clinic of Neurology ""Klinicki Centar"", Skopje, North Macedonia|Helse Bergen HF Kvinneklinikken Haukeland Universitetssykehus Jonas, Bergen, Norway|Regionsykehuset I Trondheim, Nevrologisk avd., Trondheim, Norway|10 Wojskowy Szpital Kliniczny, Bydgoszcz, Poland|Wojewodzki Szpital Specjalistyczny im. M. Kopernika, Gdansk, Poland|Niepubliczny Zespol Opieki Zdrowotnej, Krakow, Poland|Medical Academy of Lodz, Lodz, Poland|Panstwowy Szpital Kliniczny, Lublin, Poland|Wojewodzki Szpital Specjalistyczny Oddział Neurologii z Pododdziałem Udarowym, Olsztyn, Poland|Medical Academy, Poznan, Poland|Medical Academy II, Warsaw, Poland|Medical Academy, Warsaw, Poland|Hospital Fernando da Fonseca, Amadora, Portugal|Hospitais da Universidade de Coimbra, Coimbra, Portugal|Hospital de Santa Maria, Lisboa, Portugal|Centro Hospitalar de Coimbra, S. Martinho Do Bispo, Portugal|""Dr. Carol Davilla"" Military Clinical Hospital, Bucharest, Romania|Centrul Medical SANA, Bucharest, Romania|Spitalul Clinic Judetean Mures, Targu-Mures, Romania|County Hospital Timisoara, Timisoara, Romania|Municipal Healthcare Institution ""City Clinical Hospital #3"", Chelyabinsk, Russian Federation|State Healthcare Institution ""Sverdlovsk Regional Clinical Hospital #1"", Ekaterinburg, Russian Federation|State Healthcare Institution ""Kaluga Regional Hospital"", Kaluga, Russian Federation|State Medical Institution ""Republican Rehabilitation Clinic of Tatarstan Ministry of Health"", Kazan, Russian Federation|State Healthcare Institution ""Kemerovo Regional Clinical Hospital"", Kemerovo, Russian Federation|State Medical Institution "" Jursk Regional Clinical Hospital"", Kursk, Russian Federation|Moscow State Healthcare Institution City Clinical Hospital #11, Moscow, Russian Federation|Non-State Healthcare Institution ""Central Clinical Hospital #2 named after N.A. Semasko of Russian Railways"", Moscow, Russian Federation|State Educational Institute of Higher Professional Education ""I.M. Sechenov Moscow Medical Academy of Roszdrav"" Russia based on A. Ya. Kozhevnikov Nervous Disease Clinic, Moscow, Russian Federation|Municipal Treatment Prophylactic Institution ""City Hospital #33"", Nizhny Novgorod, Russian Federation|Federal State Institution "" Siberian Reginal Medical Center of Roszdarv"", Novosibirsk, Russian Federation|State institution Science Research Institute Clinical and Experimental Lymphology of Russian Academy of Medical Sciences, Novosibirsk, Russian Federation|State Educational Institute of Higher Professional Education ""Rostov State Medical University of Roszdrav"", Rostov-on-Don, Russian Federation|State Healthcare Institution ""Rostov Region Clinical Hospital"", Rostov-on-Don, Russian Federation|State Educational Institution of Higher Professional Education ""Military Medical Academy named after S. M. Korov of Dept of Defense of Russian Federation based on Clinic of Neurology of State Institution, Saint-Petersburg, Russian Federation|State Educational Institution of Higher Professional Education ""Samara State Medical University of Roszdrav"" on State Healthcare Institution ""Samara Regional Clinical Hospital named after M. I. Kalinin"", Samara, Russian Federation|State Educational Institution of Higher Professional Education ""Saratov State Medical University of Roszdrav"" based on Clincial Hosptial #3 of Saratov State Medical University, Saratov, Russian Federation|Regional State Healthcare Institution ""State Smolensk Region Clinical Hospital"", Smolensk, Russian Federation|Institute of Human Brain of Russian Academy of Science Dept. of Multiple Sclerosis, St Petersburg, Russian Federation|International Clinic and Hospital, Neurology, St Petersburg, Russian Federation|St. Petersburg State Healthcare Institution ""Multifield City Hospital #2"", St. Petersburg, Russian Federation|State Educational Institution of Higher Professional Education ""Siberian State Medical University of Roszdrav"", Tomsk, Russian Federation|Closed joint-stock society Medical sanitary unit ""Nephtaynik"" based the hospital, Tyumen, Russian Federation|Vladimir Regional State Healthcare Institution ""Regional Clinical Hospital"", Vladimir, Russian Federation|Municipal Healthcare Institution ""Yaroslavi Clinical Hospital #8"", Yaroslavl, Russian Federation|Clinical Centre of Serbia, Belgrade, Serbia|Hospital for Prevention and Treatment of Cerebro-Vascular Diseases, Belgrade, Serbia|Clinical Centre Niš, Niš, Serbia|National Neuroscience Institute (TTSH Campus), Singapore, Singapore|Hospital Reina Sofia Cordoba, Cordoba, Spain|Hospital Universitario Nuestra Senora de la Candelaria, Sta. Cruz de Tenerife, Spain|Sahlgrenskasjukhuset, Goteborg, Sweden|Karolinska University Hospital, Stockholm, Sweden|Umea University Hospital, Umea, Sweden|Taipei Veterans, Taipei, Taiwan|Chang Gung Medical Foundation- Linkou Branch No5, Taoyuan, Taiwan|Srinagarind Hospital, Khon Kaen, Thailand|Dokuz Eylul University, Izmir, Turkey|Ondokuz Mayis Universitesi, Samsun, Turkey|State Established ""Institute of Neurology, Psychiatry and Narcology of the AMS of Ukraine"", Depart of Neurinfections and Multiple Sclorosis, Kharkiv, Ukraine|Institue for Clinical Radiology of the State Establishment ""Research Centre for Radiation Medicine of the AMS of Ukraino"" Depart of Radiation Psychoneurology, Kiev, Ukraine|Vinnylsia Regional Psychoneurological Hosptial Named After O. I Yushchenko, Neurological Depart, Vinnytsia National Medical University Named After M. I. Pirogov, Chair of Neurology, Vinnitsa, Ukraine|Rashid Hospital, Dubai, United Arab Emirates|Kings College London, London, United Kingdom"
NCT00594087,Eszopiclone for Improving Sleep in Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT00594087,COMPLETED,Relapsing Remitting Multiple Sclerosis|Sleep Initiation and Maintenance Disorders|Fatigue,DRUG: eszopiclone|OTHER: placebo,University of Vermont,,ALL,ADULT,NA,30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2006-12,2008-05,2008-06,"University of Vermont, Burlington, Vermont, 05401, United States"
NCT01808885,Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta.,https://beta.clinicaltrials.gov/study/NCT01808885,COMPLETED,Relapsing Remitting Multiple Sclerosis,DRUG: olesoxime (TRO19622)|DRUG: placebo,Hoffmann-La Roche,Hôpital de la Timone|SGS S.A.|STRAGEN Services,ALL,"ADULT, OLDER_ADULT",PHASE1,44,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-04,2014-01,2014-01,"Timone University Hospital, Neurology Department, UMR CRMBM CNRS 6612, Marseille, 13385, France|CHU Reims, Maison Blanche Hospital, Neurology Department & University of Reims, Reims, 51092, France|CHU Pontchaillou, Neurology Department, Rennes, 35033, France"
NCT03783585,Feasibility of Web-based CBT-I Intervention in Individuals With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03783585,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Cognitive behavioral therapy for insomnia|BEHAVIORAL: Cognitive behavioral therapy for insomnia + biweekly support,University of Kansas Medical Center,,ALL,"ADULT, OLDER_ADULT",NA,44,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2018-10-01,2019-08-20,2019-08-20,"Catherine Siengsukon, Kansas City, Kansas, 66160, United States"
NCT04503187,Motor Skill Acquisition Between Individuals With Neurological Disorders and Healthy Individuals,https://beta.clinicaltrials.gov/study/NCT04503187,RECRUITING,Stroke|Multiple Sclerosis,BEHAVIORAL: Visuomotor leg reaching task,Texas Woman's University,,ALL,"ADULT, OLDER_ADULT",,130,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-04-04,2023-12-31,2024-12-31,"Texas Woman's University, Houston, Texas, 77030, United States"
NCT02814487,MSFC Versus DAM. A Smartphone Application for Multiple Sclerosis Self-assessment.,https://beta.clinicaltrials.gov/study/NCT02814487,COMPLETED,Multiple Sclerosis,,Ad scientiam,Roche Pharma AG,ALL,"ADULT, OLDER_ADULT",,30,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-12,2016-09,2016-09,
NCT02649985,Microglial Activation Positron Emission Tomography (PET) Brain Imaging in Multiple Sclerosis and Alzheimer's Disease,https://beta.clinicaltrials.gov/study/NCT02649985,UNKNOWN,Multiple Sclerosis|Alzheimer's Disease,DRUG: [F-18]PBR06|DRUG: [C-11]PBR28,Brigham and Women's Hospital,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,105,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2016-05-02,2021-12-31,2021-12-31,"Partners MS Center, 60 Fenwood Road, Boston, Massachusetts, 02115, United States"
NCT02131285,Stabilometric Assessment of Balance Recovery in Persons With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02131285,COMPLETED,Multiple Sclerosis,OTHER: Sensory training,Fondazione Don Carlo Gnocchi Onlus,,ALL,"ADULT, OLDER_ADULT",NA,53,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2005-01,2007-09,2007-09,"Fondazione Don Gnocchi ONLUS, Milan, 20148, Italy"
NCT04367285,Sensor-based Technology for Upper Limb Rehabilitation,https://beta.clinicaltrials.gov/study/NCT04367285,COMPLETED,Multiple Sclerosis,OTHER: Sensor-based Training|OTHER: Upper limb motor training,I.R.C.C.S. Fondazione Santa Lucia,,ALL,"ADULT, OLDER_ADULT",NA,35,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2017-03-01,2019-11-04,2020-01-31,"Marco Tramontano, Rome, 00179, Italy"
NCT03653585,Cortical Lesions in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03653585,COMPLETED,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis, Secondary Progressive",,Danish Research Centre for Magnetic Resonance,Scleroseforeningen|Danish Multiple Sclerosis Center,ALL,"ADULT, OLDER_ADULT",,80,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-09-04,2020-09-03,2020-09-03,"Danish Research Centre for Magnetic Resonance, Hvidovre, 2650, Denmark"
NCT01024985,Evaluation of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Oct,https://beta.clinicaltrials.gov/study/NCT01024985,UNKNOWN,Multiple Sclerosis|Neuromyelitis Optica,,University of Sao Paulo,,ALL,"CHILD, ADULT",,40,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2009-09,2010-12,2011-12,"Hospital Das Clinicas Medical School of University of Sao Paulo, Sao Paulo, 05403-000, Brazil"
NCT00618085,Motor Imagery Practice in Neurological Rehabilitation,https://beta.clinicaltrials.gov/study/NCT00618085,COMPLETED,Stroke|Brain Injury|Multiple Sclerosis,BEHAVIORAL: Motor imagery practice|OTHER: Standard physiotherapy and occupational therapy,Nuffield Orthopaedic Centre NHS Trust,Oxford Brookes University,ALL,"ADULT, OLDER_ADULT",PHASE2,50,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2008-02,2009-04,2009-04,"Oxford Centre for Enablement, Oxford, OX3 7LD, United Kingdom"
NCT01498887,Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy,https://beta.clinicaltrials.gov/study/NCT01498887,COMPLETED,Relapsing Remitting Multiple Sclerosis,DRUG: Fingolimod (FTY720),Novartis Pharmaceuticals,,ALL,ADULT,PHASE4,347,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2011-12-24,2015-12-26,2015-12-26,"Novartis Investigative Site, East Gosford, New South Wales, 2250, Australia|Novartis Investigative Site, Kanwal, New South Wales, 2259, Australia|Novartis Investigative Site, Liverpool, New South Wales, 2170, Australia|Novartis Investigative Site, New Lambton Heights, New South Wales, 2305, Australia|Novartis Investigative Site, Sydney, New South Wales, 2050, Australia|Novartis Investigative Site, Auchenflower, Queensland, 4066, Australia|Novartis Investigative Site, Adelaide, South Australia, Australia|Novartis Investigative Site, Box Hill, Victoria, 3128, Australia|Novartis Investigative Site, Fitzroy, Victoria, 3011, Australia|Novartis Investigative Site, Melbourne, Victoria, 3000, Australia|Novartis Investigative Site, Parkville, Victoria, 3050, Australia|Novartis Investigative Site, Nedlands, Western Australia, 6009, Australia|Novartis Investigative Site, Bedford Park, SA 5042, Australia|Novartis Investigative Site, Brisbane Queensland, 4029, Australia|Novartis Investigative Site, Geelong VIC, 3220, Australia|Novartis Investigative Site, Ferrol, A Coruna, 15405, Spain|Novartis Investigative Site, Córdoba, Andalucia, 14004, Spain|Novartis Investigative Site, Granada, Andalucia, 18012, Spain|Novartis Investigative Site, Malaga, Andalucia, 29010, Spain|Novartis Investigative Site, Sevilla, Andalucia, 41009, Spain|Novartis Investigative Site, Sevilla, Andalucia, 41014, Spain|Novartis Investigative Site, Oviedo, Asturias, 33006, Spain|Novartis Investigative Site, Santander, Cantabria, 39008, Spain|Novartis Investigative Site, Albacete, Castilla La Mancha, 02006, Spain|Novartis Investigative Site, Valladolid, Castilla Y Leon, 47011, Spain|Novartis Investigative Site, Leon, Castilla Y León, 24080, Spain|Novartis Investigative Site, Badalona, Catalunya, 08916, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08035, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08036, Spain|Novartis Investigative Site, Tarragona, Cataluña, 43007, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, 46010, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, 46017, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, 46026, Spain|Novartis Investigative Site, La Coruna, Galicia, 15006, Spain|Novartis Investigative Site, Palma De Mallorca, Islas Baleares, 07120, Spain|Novartis Investigative Site, Las Palmas de Gran Canaria, Las Palmas De G.C, 35010, Spain|Novartis Investigative Site, Pamplona, Navarra, 31008, Spain|Novartis Investigative Site, Barakaldo, Pais Vasco, 48903, Spain|Novartis Investigative Site, Bilbao, Pais Vasco, 48013, Spain|Novartis Investigative Site, Barcelona, 08041, Spain|Novartis Investigative Site, Las Palmas de Gran Canaria, 35016, Spain|Novartis Investigative Site, Madrid, 28006, Spain|Novartis Investigative Site, Madrid, 28007, Spain|Novartis Investigative Site, Madrid, 28034, Spain|Novartis Investigative Site, Madrid, 28040, Spain|Novartis Investigative Site, Madrid, 28041, Spain|Novartis Investigative Site, Santa Cruz de Tenerife, 38009, Spain"
NCT02290587,Study of Social Cognition by Morphological and Functional Imaging in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT02290587,COMPLETED,Multiple Sclerosis,OTHER: Brain MRI - Clinical and cognitive evaluation|DEVICE: MRI,"University Hospital, Bordeaux",La Ligue Française Contre la Sclérose en Plaques,ALL,ADULT,NA,35,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2015-11,2017-03,2017-03,"CHU de Bordeaux, Bordeaux, 33000, France"
NCT02241785,Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies,https://beta.clinicaltrials.gov/study/NCT02241785,TERMINATED,Relapsing Multiple Sclerosis,DRUG: natalizumab,Biogen,,ALL,ADULT,PHASE4,47,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-09-30,2016-05-02,2016-05-02,"Research Site, Fullerton, California, 92835, United States|Research Site, Aurora, Colorado, 80045, United States|Research Site, Des Moines, Iowa, 50314, United States|Research Site, Saint Louis, Missouri, 63110, United States|Research Site, Plainview, New York, 11803, United States|Research Site, Raleigh, North Carolina, 27607-6010, United States|Research Site, Akron, Ohio, 44320, United States|Research Site, Cleveland, Ohio, 44195, United States|Research Site, Knoxville, Tennessee, 37922, United States|Research Site, Round Rock, Texas, 78681, United States|Research Site, Tacoma, Washington, 98405, United States"
NCT01556685,"MATRIX: Measuring Neutralizing Antibodies in the Patients Treated With Interferon Beta 1a IM, in Mexico and Colombia",https://beta.clinicaltrials.gov/study/NCT01556685,COMPLETED,Multiple Sclerosis,OTHER: clinical and neurological evaluation|OTHER: Blood Sample|GENETIC: Blood Sample,Biogen,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE4,180,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: |Masking: |Primary Purpose: TREATMENT,2011-03,2011-10,,"Research Site, Bogota, Colombia|Research Site, Leon, Guanajuato, Mexico"
NCT04943887,CONNECT Trial of eSupport Online Health-coach Moderated Support Groups for Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04943887,COMPLETED,Multiple Sclerosis,BEHAVIORAL: eSupport Health Weekly Group Sessions for PwMS,eSupport Health,,ALL,"ADULT, OLDER_ADULT",NA,52,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2021-08-01,2022-06-01,2022-06-01,"eSupport Health, New York, New York, 10018, United States"
NCT02679885,Teriflunomide Male Transmission Study,https://beta.clinicaltrials.gov/study/NCT02679885,COMPLETED,Multiple Sclerosis,,Griffin Hospital,,ALL,ADULT,,20,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-10,2018-08,2018-09,"Multiple Sclerosis Treatment Center at Griffin Hospital, Derby, Connecticut, 06418, United States"
NCT05446285,Multiple Sclerosis Outcome Determination Evaluating Real Differences After TimE,https://beta.clinicaltrials.gov/study/NCT05446285,ENROLLING_BY_INVITATION,Relapsing Remitting Multiple Sclerosis,OTHER: Clinical assessment,NHS Greater Glasgow and Clyde,Biogen,ALL,"CHILD, ADULT, OLDER_ADULT",,245,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-02-07,2023-08,2023-08,"Clinical Research Facility, Glasgow, G51 4TF, United Kingdom"
NCT00837785,A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS,https://beta.clinicaltrials.gov/study/NCT00837785,COMPLETED,Relapsing Remitting Multiple Sclerosis,DRUG: BG00012|DRUG: BG00012,Biogen,,ALL,ADULT,PHASE1,48,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2009-02-28,2009-10-31,2009-10-31,"Research Site, Berlin, Germany"
NCT02542787,Study of VSN16R for the Treatment of Spasticity in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02542787,COMPLETED,Spasticity in People With Multiple Sclerosis,DRUG: VSN16R|OTHER: Placebo,Canbex Therapeutics Ltd,,ALL,"ADULT, OLDER_ADULT",PHASE2,160,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2015-08,2017-10,2017-10,"The Neuroscience Research Centre, The Walton Centre NHS Foundation Trust, Liverpool, L9 7LJ, United Kingdom|The Royal London Hospital, London, E1 1BB, United Kingdom|The National Hospital for Neurology and Neurosurgery, London, WC1N 3BG, United Kingdom|Royal Hallamshire Hospital, Sheffield Teaching Hospital NHS Foundation Trust, Sheffield, S10 2JFS, United Kingdom"
NCT04009187,A Wheelchair Propulsion Training Program,https://beta.clinicaltrials.gov/study/NCT04009187,COMPLETED,Spinal Cord Injuries|Multiple Sclerosis|Amputation|Spina Bifida,BEHAVIORAL: In-person wheelchair propulsion training program|BEHAVIORAL: 30-minute education session,Washington University School of Medicine,,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2018-03-27,2019-10-22,2019-10-22,"Washington University School of Medicine, Saint Louis, Missouri, 63108, United States"
NCT03806387,Physical and Cognitive Performance During the Two First Years of Lemtrada Treatment,https://beta.clinicaltrials.gov/study/NCT03806387,UNKNOWN,Multiple Sclerosis,DRUG: Alemtuzumab,University of Aarhus,"Genzyme, a Sanofi Company",ALL,"ADULT, OLDER_ADULT",,60,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-03-01,2019-04-30,2021-04-30,"Aarhus University, Health, Section for Sport Science, Aarhus, Jutland, 8000, Denmark"
NCT02313285,A Long-term Follow-up Study Of Multiple Sclerosis Patients Who Participated In Genzyme-sponsored Studies of GZ402668,https://beta.clinicaltrials.gov/study/NCT02313285,COMPLETED,Progressive Multiple Sclerosis,,"Genzyme, a Sanofi Company",,ALL,"ADULT, OLDER_ADULT",,64,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-01-12,2022-04-20,2022-04-20,"Investigational Site Number 276001, Berlin, 10117, Germany"
NCT03696485,Study to Assess the Safety and Efficacy of an IT Administration of SCM-010 in SPMS,https://beta.clinicaltrials.gov/study/NCT03696485,NOT_YET_RECRUITING,Secondary Progressive Multiple Sclerosis (SPMS),BIOLOGICAL: SCM-010,Stem Cell Medicine Ltd.,,ALL,ADULT,PHASE1|PHASE2,12,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-02-01,2024-02-01,2024-02-01,"Tel Aviv Medical Center, Tel Aviv, Israel"
NCT04024085,Time to be Ready to Void: a New Tool to Assess the Time Needed to Perform Micturition in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04024085,COMPLETED,"Gait Disorders, Neurologic|Urinary Incontinence, Urge|Multiple Sclerosis",OTHER: completion of the test created Time to be Ready to Void,Gérard Amarenco,,ALL,"ADULT, OLDER_ADULT",,70,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-03-13,2019-07-31,2019-07-31,"department of Neuro-Urology, Hôpital Tenon, Paris, 75020, France"
NCT03177785,Testing a Resilience Intervention for Individuals Aging With Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT03177785,COMPLETED,Multiple Sclerosis,BEHAVIORAL: EverydayMatters,University of Washington,,ALL,"ADULT, OLDER_ADULT",NA,31,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2016-08-04,2016-12-31,2016-12-31,
NCT04267185,A Dyadic Approach for Promoting Physical Activity Among People With MS and Their Support Partners,https://beta.clinicaltrials.gov/study/NCT04267185,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,BEHAVIORAL: Physical Activity Together for PwMS and their CGs (PAT-MS),University of Ottawa,The Ottawa Hospital|Consortium of Multiple Sclerosis Centers|Queen's University,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-02-04,2022-12-31,2023-12-31,"University of Ottawa, Ottawa, Ontario, K1N 6N5, Canada"
NCT01018485,The Efficacy of Botulinum Toxin in Disabling Multiple Sclerosis (MS) Tremor,https://beta.clinicaltrials.gov/study/NCT01018485,COMPLETED,Multiple Sclerosis|Tremor,DRUG: Botulinum Toxin Type A,Melbourne Health,Eastern Health,ALL,"ADULT, OLDER_ADULT",PHASE3,30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2008-10,2010-02,2010-06,"Melbourne Health, Melbourne, Victoria, 3050, Australia"
NCT03540485,Safety and Efficacy of Melatonin in Patients With Multiple Progressive Primary Sclerosis,https://beta.clinicaltrials.gov/study/NCT03540485,RECRUITING,"Sclerosis, Multiple|Autoimmune Diseases of the Nervous System|Nervous System Diseases|Autoimmune Diseases",DRUG: Melatonin|OTHER: Placebo,Fundación Pública Andaluza para la gestión de la Investigación en Sevilla,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,50,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2019-11-29,2024-07,2024-12,"Virgen Macarena Hospital, Seville, 41009, Spain|Virgen del Rocio University Hospital, Seville, 41013, Spain|Hospital Vithas Nisa Sevilla, Seville, 41950, Spain"
NCT02937285,"National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Phase of Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT02937285,COMPLETED,Multiple Sclerosis,DRUG: Interferon beta 1a|DRUG: Mitoxantrone,Rennes University Hospital,,ALL,ADULT,PHASE3,35,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2010-12-06,2020-05-28,2020-05-28,"CHU Rennes, Rennes, France"
NCT00616187,Atorvastatin in Relapsing-Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00616187,COMPLETED,Relapsing Remitting Multiple Sclerosis,DRUG: interferon beta treatment to add-on atorvastatin treatment|DRUG: untreated to atorvastatin treatment,"Charite University, Berlin, Germany",German Research Foundation|German Federal Ministry of Education and Research|Pfizer,ALL,ADULT,PHASE2,41,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2003-10,2007-06,,
NCT02807285,Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02807285,NO_LONGER_AVAILABLE,Multiple Sclerosis,DRUG: Ocrelizumab,"Genentech, Inc.",,ALL,ADULT,,,INDUSTRY,EXPANDED_ACCESS,,,,,"Phoenix Neurological Associates Ltd, Phoenix, Arizona, 85006, United States|Territory Neurology and Research Institute, Tucson, Arizona, 85704, United States|Mercy Medical Group; MS Centre Nurse, Carmichael, California, 95608, United States|Scripps Clinic, La Jolla, California, 92037, United States|MS Center of Southern California, Newport Beach, California, 92663, United States|Stanford University, Palo Alto, California, 94304, United States|Neuro-Therapeutics Inc., Pasadena, California, 91105, United States|UCSF- Multiple Sclerosis Centre; Department of Neurology, San Francisco, California, 94158, United States|University Of Colorado, Aurora, Colorado, 80045, United States|Advanced Neurology of Colorado, LLC, Fort Collins, Colorado, 80528, United States|Associated Neurologists of Southern CT PC, Fairfield, Connecticut, 06824, United States|Neurology Associates, Norwich, Connecticut, 06360, United States|University of Miami Miller School of Medicine; Clinical Reseach Building, Miami, Florida, 33136, United States|Neurological Services of Orlando, Orlando, Florida, 32806, United States|Infinity Clinical Research, LLC, Sunrise, Florida, 33351, United States|University of South Florida, Tampa, Florida, 33612, United States|MS Center of Vero Beach, Vero Beach, Florida, 32960, United States|Consultants in Neurology Ltd, Northbrook, Illinois, 60062, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, 46805, United States|Indiana University, Indianapolis, Indiana, 46202, United States|University of Kansas Medical Center, Kansas City, Kansas, 66160, United States|Norton Neurology Services, Louisville, Kentucky, 40207, United States|Steward St. Elizabeth's Medical Center, Boston, Massachusetts, 02135, United States|Wayne State Uni /Detroit Medical Center, Detroit, Michigan, 48201, United States|Henry Ford Health System, Detroit, Michigan, 48202, United States|Michigan Institute for Neurological Disorders, Farmington Hills, Michigan, 48334, United States|The Minneapolis Clinic of Neurology, Golden Valley, Minnesota, 55422, United States|Washington University, Saint Louis, Missouri, 63110, United States|University of Nebraska Medical Center, Omaha, Nebraska, 68198-9450, United States|Rutgers New Jersey Medical School, Newark, New Jersey, 07103, United States|Holy Name Hospital, Teaneck, New Jersey, 07666, United States|Icahn School of Medicine at Mount Sinai, New York, New York, 10029, United States|South Shore Neurologic Associates P.C., Patchogue, New York, 11772, United States|Stony Brook University Medical Center, Stony Brook, New York, 11794, United States|Carolinas Healthcare System, Charlotte, North Carolina, 28208, United States|Raleigh Neurology Associates, Raleigh, North Carolina, 27607-6520, United States|University of Cincinnati, Cincinnati, Ohio, 45203-0542, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|The Ohio State University Wexner Medical Center; Department of Neurology, Columbus, Ohio, 43210, United States|Neurology and Neuroscience Assoc., Inc., Westerville, Ohio, 43081, United States|Oklahoma Medical Research Foundation; MS Center of Excellence, Oklahoma City, Oklahoma, 73104, United States|Providence Multiple Sclerosis Center, Portland, Oregon, 97225, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, 15213, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, 19090, United States|The Neurology Foundation, Inc., Providence, Rhode Island, 02905, United States|Sibyl Wray MD Neurology PC, Knoxville, Tennessee, 37934, United States|Advanced Neurosciences Institute, Nashville, Tennessee, 37205, United States|University Of Texas Health Science Center Houston, Houston, Texas, 77030, United States|Central Texas Neurology Consultants, Round Rock, Texas, 78681, United States|Neurology Center of San Antonio, San Antonio, Texas, 78212, United States|University of Vermont, Burlington, Vermont, 05401, United States|Neurological Associates Inc; Clinical Research, Richmond, Virginia, 23236, United States|Swedish Neuroscience Institute; Multiple Sclerosis Center, Seattle, Washington, 98122, United States|Multicare Neuroscience Center of Washington, Tacoma, Washington, 98405, United States|Columbia St. Mary's Hospital System, Milwaukee, Wisconsin, 53211, United States"
NCT00000147,Longitudinal Optic Neuritis Study (LONS),https://beta.clinicaltrials.gov/study/NCT00000147,UNKNOWN,Multiple Sclerosis|Optic Neuritis,DRUG: Methylprednisolone|DRUG: Prednisone,National Eye Institute (NEI),,ALL,ADULT,NA,,NIH,INTERVENTIONAL,Allocation: |Intervention Model: |Masking: SINGLE|Primary Purpose: TREATMENT,1988-07,,,"University of Arkansas, Little Rock, Arkansas, United States|California Pacific Medical Center, San Francisco, California, United States|Georgetown University, Washington, District of Columbia, United States|University of Florida, Gainesville, Florida, United States|University of Illinois, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|Johns Hopkins University, Baltimore, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|Michigan State University, East Lansing, Michigan, United States|New York University, New York, New York, United States|Duke University, Durham, North Carolina, United States|Devers Eye Institute, Portland, Oregon, United States|Wills Eye Hospital, Philadelphia, Pennsylvania, United States|Baylor College of Medicine, Houston, Texas, United States|Swedish Medical Center, Seattle, Washington, United States"
NCT00211887,Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx,https://beta.clinicaltrials.gov/study/NCT00211887,COMPLETED,Relapsing Remitting Multiple Sclerosis,DRUG: Interferon beta 1-a|DRUG: glatiramer acetate|OTHER: placebo,Fred Lublin,National Institute of Neurological Disorders and Stroke (NINDS),ALL,ADULT,PHASE3,1008,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2005-01,2012-04,2013-03,"University of Alabama - Birmingham, Birmingham, Alabama, United States|Barrow Neurology Clinic, Phoenix, Arizona, United States|Mayo Clinic - Scottsdale, Scottsdale, Arizona, United States|Northwest Neurospecialists PLLC, Tucson, Arizona, 85741, United States|Sutter East Bay Medical Group, Berkeley, California, United States|Neurology Center North Orange County, La Habra, California, United States|VA West Los Angeles Healthcare Center, Los Angeles, California, United States|University of California - Davis Medical Center, Sacramento, California, 95817, United States|Alpine Clinical Research Center, Boulder, Colorado, United States|Patricia Fodor P.C., Colorado Springs, Colorado, United States|University of Colorado Health Sciences Center, Denver, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Neurology Associates, PA, Maitland, Florida, United States|University of Miami - Neurology, Miami, Florida, 33124, United States|MS Center of Atlanta, Atlanta, Georgia, United States|Shepherd Center, Atlanta, Georgia, United States|Northwest University, Chicago, Illinois, United States|Consultants in Neurology - Multiple Sclerosis Center, Northbrook, Illinois, United States|University of Illinois College of Medicine, Peoria, Illinois, United States|Ruan Neurology Clinic and Research Center, Des Moines, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Maryland Center for MS, Baltimore, Maryland, United States|Tufts-New England Medical Center, Boston, Massachusetts, United States|University of Massachusetts Memorial Medical Center, Boston, Massachusetts, United States|Lahey Clinic, Burlington, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|Michigan State University, East Lansing, Michigan, United States|Minneapolis Clinic - MS Center, Golden Valley, Minnesota, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|St. Louis University - St. Louis VA, St. Louis, Missouri, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Northern Rockies MS Center, Billings, Montana, United States|Dartmouth Medical School, Lebanon, New Hampshire, United States|CentraState Medical Center, Freehold, New Jersey, United States|University of New Mexico, Albuquerque, New Mexico, United States|Neuro Associates of Albany, PC, Albany, New York, 12208, United States|Albany Medical College, Albany, New York, United States|The Jacobs Neurological Institute, Buffalo, New York, United States|Winthrop Neurology Faculty Practice, Mineola, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, 10029, United States|Columbia University Medical Center, New York, New York, 10032, United States|NYU Hospital For Joint Diseases, New York, New York, United States|South Shore Neurologic Associates Inc., Patchogue, New York, United States|University of Rochester, Rochester, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|CMC-Neuroscience & Spine Institute, Division of Neurology, MS Center, Charlotte, North Carolina, United States|Meritcare Neuroscience, Fargo, North Dakota, United States|NeuroCare Center, Inc., Canton, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Neurology Specialists, Dayton, Ohio, 45415, United States|Medical College Of Ohio, Toledo, Ohio, United States|Oak Clinic for Multiple Sclerosis, Uniontown, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Allegheny MS Treatment Center, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor College of Medicine, Houston, Texas, United States|University of Texas - Houston, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Neurological Research Center, Inc., Bennington, Vermont, United States|Fletcher Allen Health Care, Burlington, Vermont, United States|Neurological Associates, Inc., Richmond, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|MS Center at Evergreen, Seattle, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Regional MS Center at St. Luke's Medical Center, Milwaukee, Wisconsin, United States|Foothills Medical Centre, Calgary, Alberta, Canada|Capital Health and the University of Alberta, Edmonton, Alberta, Canada|Ottawa Hospital, Ottawa, Ontario, Canada|St. Michael's Hospital-Multiple Sclerosis Research Center, Toronto, Ontario, Canada"
NCT04793087,Post-COntrast 3D SE T1 Versus Coronal SE T1-WI MRI in Detecting Optic Neuritis (COCON),https://beta.clinicaltrials.gov/study/NCT04793087,COMPLETED,Optic Neuritis|Multiple Sclerosis,DIAGNOSTIC_TEST: Magnetic Resonance Imaging,Fondation Ophtalmologique Adolphe de Rothschild,,ALL,"ADULT, OLDER_ADULT",,1200,NETWORK,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-01-01,2018-01-01,2020-08-30,"Hôpital Fondation Adolphe de Rothschild, Paris, Ile-de-France, 75019, France"
NCT00852722,Low Fat Diet and Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00852722,COMPLETED,Multiple Sclerosis,OTHER: Low fat study diet,Oregon Health and Science University,,ALL,"ADULT, OLDER_ADULT",PHASE1,61,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2009-02,2014-07,2014-07,"Oregon Health and Science University, Portland, Oregon, 97239, United States"
NCT00483847,TYGRIS - ROW: TYSABRI Global Observational Program in Safety - Rest of World,https://beta.clinicaltrials.gov/study/NCT00483847,COMPLETED,Multiple Sclerosis,,Biogen,,ALL,"CHILD, ADULT, OLDER_ADULT",,4296,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2006-09,2014-11,2014-11,"There are multiple sites throughout Europe in this clinical trial. Contact Advanced Medical Services (AMS)., Mannheim, D-68167, Germany"
NCT05660187,VIRtual Versus UsuAL In-office Care for Multiple Sclerosis (VIRTUAL-MS),https://beta.clinicaltrials.gov/study/NCT05660187,RECRUITING,Multiple Sclerosis,OTHER: Multiple Sclerosis Clinical Care Delivery via telehealth|OTHER: Multiple Sclerosis Clinical Care Delivery via standard in clinic visits,The Cleveland Clinic,"University of California, San Francisco|University of Washington",ALL,"ADULT, OLDER_ADULT",NA,120,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH,2023-03-31,2027-06,2027-06,"University of California San Francisco, San Francisco, California, 94158, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States"
NCT03803800,Periodized Rehabilitation and Beta-alanine Supplementation in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03803800,COMPLETED,Multiple Sclerosis,"OTHER: Classic, progressive endurance training|OTHER: Periodized exercise training|DIETARY_SUPPLEMENT: beta-alanine",Hasselt University,,ALL,"ADULT, OLDER_ADULT",NA,31,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2019-01-09,2019-12-01,2019-12-09,"Hasselt University, Diepenbeek, Limburg, 3590, Belgium"
NCT00220922,A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Using Alcohol Wipes Prior to Daily Injections of Copaxone®.,https://beta.clinicaltrials.gov/study/NCT00220922,COMPLETED,Multiple Sclerosis,PROCEDURE: Alcohol Wipes vs. No Alcohol Wipes,"Teva Neuroscience, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE4,50,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: PREVENTION,2004-08,2005-10,2006-02,
NCT03647722,Assessing the Induction of Long-term Immune Regulation Following Treatment With Lemtrada® (Alemtuzumab).,https://beta.clinicaltrials.gov/study/NCT03647722,TERMINATED,Multiple Sclerosis,OTHER: Assessment of leukocyte function.,University of Southern California,,ALL,"ADULT, OLDER_ADULT",,97,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-11-02,2020-11-01,2020-11-30,"University of Southern California, Department of Neurology, Los Angeles, California, 90033, United States"
NCT05816122,MS-DETECT: Early Detection of Multiple Sclerosis Progression With MSCopilot®,https://beta.clinicaltrials.gov/study/NCT05816122,NOT_YET_RECRUITING,Multiple Sclerosis,DEVICE: MSCopilot® mobile application,Ad scientiam,,ALL,"ADULT, OLDER_ADULT",NA,243,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2023-06-30,2026-03-31,2026-03-31,"Oklahoma Medical Research Foundation,, Oklahoma City, Oklahoma, 73104, United States|St. Michael's Hospital, Toronto, Canada|University Hospital of Southern Denmark, Esbjerg, Denmark|Hôpital Roger Salengro, Lille, France|Universitätsklinikum Carl Gustav Carus, Dresden, Germany|IRCCS Ospedale San Raffaele, Milan, Italy|University Hospital San Carlos, Madrid, Spain"
NCT04699747,Investigating the Utility of Demyelination Tracer [18F]3F4AP in Controls and Multiple Sclerosis Subjects,https://beta.clinicaltrials.gov/study/NCT04699747,RECRUITING,Multiple Sclerosis,DRUG: F-18 3F4AP,Massachusetts General Hospital,,ALL,"ADULT, OLDER_ADULT",PHASE1,60,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2021-03-25,2024-11-30,2024-11-30,"Massachusetts General Hospital, Boston, Massachusetts, 02114, United States"
NCT03662347,Patient Acceptable Symptomatic State and Minimal Clinically Important Difference of the Fatigue in Multiple Sclerosis (SeDiF_SEP),https://beta.clinicaltrials.gov/study/NCT03662347,UNKNOWN,Multiple Sclerosis,,"Central Hospital, Nancy, France",,ALL,"ADULT, OLDER_ADULT",,2100,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-03-19,2022-03,2022-03,"CIC 1433 Épidémiologie clinique, Inserm, CHRU de Nancy, Université de Lorraine, Vandoeuvre Les Nancy, 54511, France"
NCT02016222,Tear Analysis in the Diagnosis of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02016222,COMPLETED,Primary Progressive Multiple Sclerosis,PROCEDURE: tears sampling,Lille Catholic University,Bayer,ALL,"ADULT, OLDER_ADULT",NA,80,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2011-04,2016-03,2016-03,"Centre hospitalier universitaire (CHU), Nice, Nice, Alpes Maritimes, 06003, France|Groupement des Hôpitaux de l'Institut Catholique de Lille (GHICL), Lille, Nord, 59000, France|Centre hospitaliere universitaire, Bordeaux, 33404, France|Centre hospitalier universitaire, Caen, 14033, France|Centre hospitalier régional universitaire, Clermont-Ferrand, 63003, France|Centre hospitalier universitaire, Dijon, 21079, France|Centre hospitalier régional universitaire, Lille, 59037, France|Hospices civils de Lyon, Lyon, 69229, France|Assistance Publique - Hôpitaux de Marseille, Marseille, 13354, France|Centre hospitalier universitaire, Nancy, 54035, France|Centre hospitalier universitaire, Nimes, 30029, France|Centre hospitalier intercommunal, Poissy, 78303, France|Centre hospitalier régional universtaire, Strasbourg, 67091, France"
NCT05124522,A Health Action Process Approach Online Intervention for People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05124522,RECRUITING,Multiple Sclerosis,BEHAVIORAL: MSPA eClass,University of Illinois at Urbana-Champaign,,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-10-25,2024-06-30,2024-12-31,"University of Illinois Urbana-Champaign, Champaign, Illinois, 61820, United States"
NCT01738347,"Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS).",https://beta.clinicaltrials.gov/study/NCT01738347,COMPLETED,Relapsing-remitting Multiple Sclerosis (rrMS),DRUG: Arm 1 - GEH120714 (18F) Injection,GE Healthcare,Centre for Probe Development and Commercialization,ALL,ADULT,PHASE1,30,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2013-04,2016-05,2016-05,"St. Joseph Healthcare, Hamilton, Ontario, Canada"
NCT04742400,"Tolebrutinib, a Brain-penetrant Bruton s Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT04742400,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,DRUG: tolebrutinib 60mg|DRUG: tolebrutinib 120mg,National Institute of Neurological Disorders and Stroke (NINDS),,ALL,"ADULT, OLDER_ADULT",PHASE2,11,NIH,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-04-15,2025-12-31,2025-12-31,"National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States"
NCT01610687,A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01610687,COMPLETED,Multiple Sclerosis|Spasticity,DRUG: GW-1000-02,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,137,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2001-07,2005-02,2005-02,"Rivermead Rehabilitation Centre, Oxford, OX3 7LD, United Kingdom"
NCT03157830,Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab,https://beta.clinicaltrials.gov/study/NCT03157830,COMPLETED,Relapsing Remitting Multiple Sclerosis,,Providence Health & Services,"Genentech, Inc.",ALL,"ADULT, OLDER_ADULT",,34,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-06-01,2021-10-10,2021-12-31,"RWJBarnabas Health, Livingston, New Jersey, 07039, United States|Providence MS Center, Portland, Oregon, 97225, United States|Kadlec Neuroscience Center, Richland, Washington, 99352, United States|Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, Washington, 98122, United States|Providence Multiple Sclerosis Center, Spokane, Washington, 99208, United States"
NCT04528121,Effect of CoDuSe Balance Training and Step Square Exercises on Risk of Fall in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04528121,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",OTHER: CoDuSe balance training and step square exercises|OTHER: conventional balance training,Lama Saad El-Din Mahmoud,,ALL,ADULT,NA,52,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-15,2020-12-30,2020-12-30,"October 6 University, Giza, El-Sheikh Zayed City Giza 1133 Egypt, Egypt"
NCT00203021,Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness,https://beta.clinicaltrials.gov/study/NCT00203021,COMPLETED,Relapsing-Remitting Multiple Sclerosis,DRUG: Glatiramer acetate,"Teva Branded Pharmaceutical Products R&D, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE4,208,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,1994-03-26,2018-02-28,2018-02-28,"Teva Investigational Site 009, Los Angeles, California, 90033, United States|Teva Investigational Site 004, Los Angeles, California, 90095-7077, United States|Teva Investigational Site 008, New Haven, Connecticut, 06520-8018, United States|Teva Investigational Site 005, Baltimore, Maryland, 21201, United States|Teva Investigational Site 003, Detroit, Michigan, 48201, United States|Teva Investigational Site 002, Albuquerque, New Mexico, 87131, United States|Teva Investigational Site 007, Rochester, New York, 14642, United States|Teva Investigational Site 001, Philadelphia, Pennsylvania, 19104, United States|Teva Investigational Site 010, Houston, Texas, 77030, United States|Teva Investigational Site 006, Salt Lake City, Utah, 84148, United States|Teva Investigational Site 011, Madison, Wisconsin, 53719, United States"
NCT02606630,[11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 555 in Subjects With Relapsing Forms of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02606630,TERMINATED,Multiple Sclerosis,DRUG: ABT-555,AbbVie,,ALL,ADULT,PHASE1,4,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-10,2015-12,2015-12,"Site Reference ID/Investigator# 141463, London, SW17 ORE, United Kingdom|Site Reference ID/Investigator# 141461, Whitechapel, E1 2AT, United Kingdom"
NCT04106830,Clinical and Imaging Patterns of Neuroinflammation Diseases in China (CLUE),https://beta.clinicaltrials.gov/study/NCT04106830,RECRUITING,NMO Spectrum Disorder|MRI|Multiple Sclerosis,DRUG: Intravenous steroid,Beijing Tiantan Hospital,,ALL,"CHILD, ADULT, OLDER_ADULT",,1000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-01-01,2022-12-31,2025-12-31,"Beijing Tiantan Hospital, Beijing, Beijing, 100053, China"
NCT05561621,Prediction of Non-motor Symptoms in Fully Ambulatory MS Patients Using Vocal Biomarkers,https://beta.clinicaltrials.gov/study/NCT05561621,RECRUITING,Multiple Sclerosis,OTHER: Voice analysis,"University Hospital Inselspital, Berne",AUDEERING GMBH|Biogen,ALL,ADULT,,70,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-07-15,2023-08-15,2023-12-31,"Inselspital University Hospital Bern, Bern, 3010, Switzerland"
NCT04450030,Immunoadsorption Versus High-dose Intravenous Corticosteroids in Relapsing Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04450030,UNKNOWN,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Methyl Prednisolonate|PROCEDURE: Immunoadsorption,University Hospital Muenster,,ALL,"ADULT, OLDER_ADULT",,204,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-08-01,2020-09-05,2020-12-31,"Department of Neurology with Institute of Translational Neurology, University Hospital Muenster, Muenster, Northrhine-Westphalia, 48149, Germany"
NCT00591721,Teleconference Fatigue Management for People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00591721,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Energy conservation education,University of Illinois at Chicago,,ALL,"ADULT, OLDER_ADULT",NA,190,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2007-11,2010-02,2010-02,"University of Illinois at Chicago, Chicago, Illinois, 60612, United States"
NCT05210621,LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB,https://beta.clinicaltrials.gov/study/NCT05210621,RECRUITING,Multiple Sclerosis,DRUG: Ocrelizumab,Centre Hospitalier Universitaire de Nice,,ALL,"ADULT, OLDER_ADULT",PHASE3,89,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-03-08,2026-02-24,2029-02-24,"Amiens University Hospital, Amiens, 80051, France|Bayonne Hospital, Bayonne, 64100, France|Bordeaux University Hospital, Bordeaux, 33076, France|Caen University Hospital, Caen, 14033, France|Clermont ferrand University Hospital, Clermont-Ferrand, 63003, France|Lille University Hospital, Lille, 59037, France|Lyon University Hospital, Lyon, 69677, France|Marseille Univesity Hospital, Marseille, 13385, France|Montpellier University Hospital, Montpellier, 34295, France|Nancy University Hospital, Nancy, 54000, France|Nantes University hospital, Nantes, 42055, France|Nice University Hospital, Nice, 06000, France|Nimes University Hospital, Nîmes, 30900, France|Rennes University Hospital, Rennes, 35033, France|Strasbourg University Hospital, Strasbourg, 67000, France"
NCT01470521,Worms for Immune Regulation of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01470521,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",BIOLOGICAL: Hookworm larvae|BIOLOGICAL: Placebo,University of Nottingham,National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",PHASE2,72,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-12,2016-01,2016-01,"University of Nottingham, Nottingham, Nottinghamshire, NG7 2UH, United Kingdom"
NCT00127530,Study of Oral Fampridine-SR in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00127530,COMPLETED,Multiple Sclerosis,DRUG: Fampridine-SR|DRUG: Placebo,Acorda Therapeutics,,ALL,"ADULT, OLDER_ADULT",PHASE3,300,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2005-05,2006-06,2006-09,"University of Alabama, Birmingham, Alabama, 35233, United States|Barrow Neurology Clinic, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, 85013, United States|USC, Keck School of Medicine, Los Angeles, California, 90033, United States|UC Davis, Sacramento, California, 95817, United States|University of Colorado Health Sciences Center, Denver, Colorado, 80262, United States|Multiple Sclerosis Treatment Center, Derby, Connecticut, 06418, United States|Shepard Center, Atlanta, Georgia, 30309, United States|University of Chicago, Chicago, Illinois, 60637, United States|Indiana University MS Center, Indianapolis, Indiana, 46202, United States|Maryland Center for MS, Baltimore, Maryland, 21201, United States|Wayne State University, Department of Neurology, Detroit, Michigan, 48201, United States|The Schapiro Center for MS, Golden Valley, Minnesota, 55422, United States|Washington University SOM, Saint Louis, Missouri, 63110, United States|Gimbel MS Center at Holy Name Hospital, Teaneck, New Jersey, 07666, United States|University of Mexico, MIND Imaging Center, Albuquerque, New Mexico, 87131, United States|Maimonides Medical Center, Brooklyn, New York, 11220, United States|Corinne Goldsmith Dickinson Center for MS, New York, New York, 10029, United States|University of Rochester, Rochester, New York, 14642, United States|SUNY - Stony Brook, Stony Brook, New York, 11794, United States|Carolinas Healthcare System, Charlotte, North Carolina, 28207, United States|Cleveland Clinical Foundation, Cleveland, Ohio, 44095, United States|Ohio State University MS Center, Columbus, Ohio, 43221, United States|Oregon Health & Science University, MS Center of Oregon, UHS-42, Portland, Oregon, 97239, United States|Thomas Jefferson University Physicians, Philadelphia, Pennsylvania, 19107, United States|Allegheny General Hospital, Allegheny Neurological Associates, Pittsburgh, Pennsylvania, 15212, United States|University of Texas - Houston, Houston, Texas, 77030, United States|Neurological Research Center, Inc., Bennington, Vermont, 05201, United States|Fletcher Allen Health Care, Burlington, Vermont, 05401, United States|MS Hub Medical Group, Seattle, Washington, 98101, United States|University of Washington, MS Research Center, Seattle, Washington, 98195, United States|Foothills Medical Center, Calgary, Alberta, T2N 2T9, Canada|University of British Columbia, Vancouver Coastal Health Research Institute, Vancouver, British Columbia, V6T 2B5, Canada|QEII Health Sciences Centre, Nova Scotia Rehabilitation Centre Site, Halifax, Nova Scotia, B3H 4K4, Canada|Ottawa Hospital General Campus, Ottawa, Ontario, K1H 8L6, Canada"
NCT01647321,Functional Electrical Stimulation for Individuals With Secondary Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01647321,COMPLETED,Secondary Progressive Multiple Sclerosis,BEHAVIORAL: Active cycling|BEHAVIORAL: Passive cycling,Johns Hopkins University,"Hugo W. Moser Research Institute at Kennedy Krieger, Inc.",ALL,"ADULT, OLDER_ADULT",NA,16,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2012-07,2019-10,2019-10,"Johns Hopkins / Kennedy Krieger Institute, Baltimore, Maryland, 21205, United States"
NCT05029830,Assessment of Quality of Life and Psychological Problems in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05029830,COMPLETED,Multiple Sclerosis Acute and Progressive,COMBINATION_PRODUCT: investigations like MRI..,Assiut University,,ALL,ADULT,,70,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-09-01,2022-09-01,2022-10-30,"Samah, Assuit, Egypt"
NCT01578330,"A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720",https://beta.clinicaltrials.gov/study/NCT01578330,COMPLETED,Multiple Sclerosis|Relapsing-Remitting,DRUG: Fingolimod,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE4,42,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2012-10,2015-04,2015-04,"Novartis Investigative Site, Altunizade, 34662, Turkey|Novartis Investigative Site, Ankara, 06100, Turkey|Novartis Investigative Site, Ankara, 06500, Turkey|Novartis Investigative Site, Atakum / Samsun, 55139, Turkey|Novartis Investigative Site, Bursa, 16059, Turkey|Novartis Investigative Site, Fatih / Istanbul, 34098, Turkey|Novartis Investigative Site, Izmir, 35040, Turkey|Novartis Investigative Site, Kocaeli, 41380, Turkey|Novartis Investigative Site, Mecidiyekoy/Istanbul, 34394, Turkey|Novartis Investigative Site, Trabzon, 61080, Turkey|Novartis Investigative Site, Uskudar / Istanbul, 34668, Turkey"
NCT02390830,Falls Prevention and Balance Rehabilitation in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02390830,COMPLETED,Multiple Sclerosis,OTHER: Falls Prevention|OTHER: Reduction of limitations at body function and activity levels,Fondazione Don Carlo Gnocchi Onlus,,,"CHILD, ADULT, OLDER_ADULT",NA,119,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2011-03,2013-10,2013-10,
NCT04667130,Preventive Program in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04667130,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Preventive Complex Program for Newly Diagnosed People With Multiple Sclerosis,Kamila Řasová,,ALL,"ADULT, OLDER_ADULT",NA,17,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2017-10-01,2019-10-01,2019-10-01,"Kamila Řasová, Praha, 128 00, Czechia"
NCT05834855,Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS,https://beta.clinicaltrials.gov/study/NCT05834855,RECRUITING,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting|Demyelinating Autoimmune Diseases, CNS|Autoimmune Diseases of the Nervous System|Nervous System Diseases|Demyelinating Diseases",DRUG: Rituximab,"Amsterdam UMC, location VUmc",Stichting Treatmeds,ALL,"ADULT, OLDER_ADULT",PHASE3,200,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-04,2027-05,2027-05,"Amsterdam UMC, location VUmc, Amsterdam, 1081 HV, Netherlands"
NCT00870155,A Study for Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00870155,TERMINATED,Secondary Progressive Multiple Sclerosis,DRUG: dirucotide,Eli Lilly and Company,BioMS Technology Corp.,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,546,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-02,2009-09,2009-09,"St. Michaels Hospital, Toronto, Ontario, M5B 1W8, Canada|Copenhagen University Hospital, Kobenhavn, 2100, Denmark|West Tallinn Central Hospital, Tallinn, 10617, Estonia|Terveystalo Turku Kuvantaminen, Turku, 20101, Finland|Heinrich Heine Universitaets, Duesseldorf, North Rhine Westphalia, 40225, Germany|Vecmilgravis Hospital, Riga, 1015, Latvia|Maaslandziekenhuis, Sittard, 6131BK, Netherlands|Hospital Duran I Reynals, Barcelona, 08907, Spain|Karolinska Universitetssjukhus, Stockholm, 14186, Sweden|Walton Hospital, Liverpool, L97LJ, United Kingdom"
NCT01384825,Observational Study of the Prevalence of CCSVI in Multiple Sclerosis and in Other Neurodegenerative Diseases,https://beta.clinicaltrials.gov/study/NCT01384825,COMPLETED,Multiple Sclerosis|Neurodegenerative Diseases,,Fondazione Italiana Sclerosi Multipla,"Opera CRO, a TIGERMED Group Company",ALL,ADULT,,200,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-12,2012-09,2012-10,"Azienda Ospedali Riuniti - Div. di Neurologia - Centro Studi Sclerosi Multipla, Ancona, 60126, Italy|Università di Bari - Ospedale Consorziale Policlinico - Dip. Scienze Neurologiche e Psichiatriche, Bari, 70124, Italy|Azienda USL Città di Bologna - Distretto Santo Stefano Savena - Centro Sclerosi Multipla, Bologna, 40141, Italy|Azienda Ospedaliera Spedali Civili Presidio Montichiari - Centro Studi Sclerosi Multipla, Brescia, 25012, Italy|Università degli Studi di Cagliari - Centro Sclerosi Multipla - Ospedale Binaghi, Cagliari, 09126, Italy|Azienda Ospedaliera ""Garibaldi"" - U.O. Neurologia, Catania, 95122, Italy|Azienda Ospedaliera Universitaria ""Policlinico Vittorio Emanuele"" - Istituto Scienze Neurologiche, Catania, 95123, Italy|Istituto San Raffaele Giuseppe Giglio - Centro Sclerosi Multipla, Cefalù, 90015, Italy|Ospedale Universitario G. D'Annunzio - Centro Sclerosi Multipla, Chieti, 66013, Italy|Azienda Ospedaliera San Giuseppe - Centro Scl. Multipla - U.O. Neurologia, Empoli, 50053, Italy|Università degli Studi di Ferrara Arcispedale Sant'Anna - Clinica Neurologica, Ferrara, 44100, Italy|Università degli Studi di Ferrara Arcispedale Sant'Anna - Istituto di Clinica Neurologica, Ferrara, 44100, Italy|Azienda Ospedaliero Universitaria Careggi - Centro di Riferimento Regionale per la Sclerosi Multipla, Firenze, 50134, Italy|Azienda Ospedaliero Universitaria Careggi - Centro Sclerosi Multipla, Firenze, 50134, Italy|Azienda Ospedaliera Universitaria Ospedali Riuniti - Centro Sclerosi Multipla, Foggia, 71122, Italy|Ospedale S. Antonio Abate - Centro Studi Sclerosi Multipla, Gallarate, 21013, Italy|Azienda Ospedaliera Universitaria San Martino, Genova, 16132, Italy|Ospedale S. Andrea - Divisione di Neurologia, La Spezia, 19124, Italy|Ospedale Tappeiner - Div. Neurologica, Merano, 39012, Italy|IRCCS Centro Studi Neurolesi ""Bonino Pulejo"" di Messina, Messina, 98121, Italy|Azienda Ospedaliera Universitaria ""G. Martino"" - Dipartimento Neuroscienze Psichiatria e Anestesiologia, Messina, 98125, Italy|Università degli Studi di Milano - Dipartimento di Neurologia - Ospedale S. Raffaele - Via Olgettina , 60, Milano, 20132, Italy|Fondazione Ist. Neurologico Besta - Centro Sclerosi Multipla, Milano, 20133, Italy|Fondazione Don Carlo Gnocchi, IRCCS Santa Maria Nascente - Unità Operativa Sclerosi Multipla, Milano, 20148, Italy|Ospedale Niguarda Cà Granda - Centro Sclerosi Multipla, Milano, 20162, Italy|Università Federico II - Clinica Neurologica II, Napoli, 80131, Italy|Azienda Ospedaliera S. Luigi - Centro Sclerosi Multipla - Divisione Universitaria di Neurologia, Orbassano, 10043, Italy|Policlinico Az. Ospedaliera - Clinica Neurologica I, Padova, 35128, Italy|Università degli Studi di Palermo - Istituto di Neuropsichiatria - A.O.U.P. ""P. Giaccone"", Palermo, 90129, Italy|Azienda Ospedaliera Villa Sofia C.T.O. - Neurologia Padiglione Geriatrico, Palermo, 90146, Italy|Istituto Neurologico C. Mondino - Divisione di Neurologia, Pavia, 27100, Italy|Arciospedale S. Maria Nuova - Centro Studi Sclerosi Multipla, Reggio Emilia, 42100, Italy|Università Tor Vergata - Clinica Neurologica - Dipartimento di Neuroscienze, Roma, 00133, Italy|Ospedale Sant'Andrea - Neurologia e Centro Neurologico Terapie Sperimentali, Roma, 00189, Italy|Università di Sassari - Clinica Neurologica, Sassari, 07100, Italy|Università degli Studi di Siena - Dip. di Neuroscienze - Sez. Neurologia, Siena, 53100, Italy|Università degli Studi di Siena - Dip. di Neuroscienze - U.O. Neurologia e Malattie Neurometaboliche, Siena, 53100, Italy|Azienda Ospedaliera Universitaria S. Giovanni Battista - Centro Sclerosi Multipla - Dipartimento di Neuroscienze, Torino, 10126, Italy|Azienda Ospedaliera ""Ca Foncello"" - Dipartimento di Neuroscienze - U.O. Neurologia, Treviso, 31100, Italy|Ospedale di Cattinara - Istituto Clinica Neurologica, Trieste, 34149, Italy|Ospedale S. Bortolo - Divisione di Neurologia - Centro Sclerosi Multipla, Vicenza, 36100, Italy|Azienda Sanitaria Provinciale di Ragusa Ospedale ""R. Guzzardi"" - U.O.C. Neurologia e Neurofisiopatologia, Stroke Unit, Vittoria, 97019, Italy|Opera Contract Research Organization SRL, Timisoara, Timis, 300209, Romania"
NCT04002492,Effects of a Weight Based Training Program on MS Patients,https://beta.clinicaltrials.gov/study/NCT04002492,UNKNOWN,Multiple Sclerosis,BEHAVIORAL: Bodyweight training,"Holy Name Medical Center, Inc.",Biogen,ALL,ADULT,NA,25,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2019-07-01,2019-11,2019-12,"Holy Name Medical Center, Teaneck, New Jersey, 07666, United States"
NCT01707992,"The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)",https://beta.clinicaltrials.gov/study/NCT01707992,COMPLETED,Multiple Sclerosis,DRUG: Laquinimod|DRUG: Placebo,"Teva Branded Pharmaceutical Products R&D, Inc.",,ALL,ADULT,PHASE3,2199,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-02-20,2015-04-13,2017-07-04,"Teva Investigational Site 10329, Cullman, Alabama, 35058, United States|Teva Investigational Site 10349, Sun City, Arizona, 85351, United States|Teva Investigational Site 10342, Tucson, Arizona, 85741-3537, United States|Teva Investigational Site 10310, Fresno, California, 93710, United States|Teva Investigational Site 10307, Aurora, Colorado, 80045, United States|Teva Investigational Site 10334, Centennial, Colorado, 80112, United States|Teva Investigational Site 10332, Fort Collins, Colorado, 80528, United States|Teva Investigational Site 10316, Coral Gables, Florida, 33146, United States|Teva Investigational Site 10341, Saint Petersburg, Florida, 33701, United States|Teva Investigational Site 10308, Sarasota, Florida, 34233, United States|Teva Investigational Site 10315, Sunrise, Florida, 33351, United States|Teva Investigational Site 10323, Tampa, Florida, 33606, United States|Teva Investigational Site 10350, Chicago, Illinois, 60612, United States|Teva Investigational Site 10345, Evanston, Illinois, 60201, United States|Teva Investigational Site 10343, Northbrook, Illinois, 60062, United States|Teva Investigational Site 10339, Fort Wayne, Indiana, 46805, United States|Teva Investigational Site 10348, Lenexa, Kansas, 66214, United States|Teva Investigational Site 10338, Boston, Massachusetts, 02215, United States|Teva Investigational Site 10346, Advance, North Carolina, 27006, United States|Teva Investigational Site 10347, Winston-Salem, North Carolina, 27157, United States|Teva Investigational Site 10309, Bellevue, Ohio, 44811, United States|Teva Investigational Site 10317, Columbus, Ohio, 43221, United States|Teva Investigational Site 10325, Dayton, Ohio, 45417, United States|Teva Investigational Site 10340, Hershey, Pennsylvania, 17033-0850, United States|Teva Investigational Site 10331, Philadelphia, Pennsylvania, 19104, United States|Teva Investigational Site 10313, Cordova, Tennessee, 38018, United States|Teva Investigational Site 10324, Franklin, Tennessee, 37064, United States|Teva Investigational Site 10318, Nashville, Tennessee, 37205, United States|Teva Investigational Site 10319, Salt Lake City, Utah, 84103, United States|Teva Investigational Site 10330, Newport News, Virginia, 23601, United States|Teva Investigational Site 10311, Roanoke, Virginia, 24018, United States|Teva Investigational Site 10335, Seattle, Washington, 98122, United States|Teva Investigational Site 33013, Innsbruck, A-6020, Austria|Teva Investigational Site 33014, Linz, 4020, Austria|Teva Investigational Site 33016, Wien, 1010, Austria|Teva Investigational Site 33015, Wien, 1090, Austria|Teva Investigational Site 68010, Gomel, 246029, Belarus|Teva Investigational Site 68013, Grodno, 230027, Belarus|Teva Investigational Site 68012, Minsk, 220026, Belarus|Teva Investigational Site 68009, Minsk, 220114, Belarus|Teva Investigational Site 68008, Minsk, 220116, Belarus|Teva Investigational Site 68011, Vitebsk, 210023, Belarus|Teva Investigational Site 37023, Charleroi, 6000, Belgium|Teva Investigational Site 37024, Sijsele, 8340, Belgium|Teva Investigational Site 69008, Mostar, 88000, Bosnia and Herzegovina|Teva Investigational Site 69006, Sarajevo, 71000, Bosnia and Herzegovina|Teva Investigational Site 69009, Tuzla, 75000, Bosnia and Herzegovina|Teva Investigational Site 59039, Pleven, 5800, Bulgaria|Teva Investigational Site 59040, Pleven, 5800, Bulgaria|Teva Investigational Site 59060, Pleven, 5800, Bulgaria|Teva Investigational Site 59062, Plovdiv, 4002, Bulgaria|Teva Investigational Site 59061, Ruse, 7003, Bulgaria|Teva Investigational Site 59055, Shumen, 9700, Bulgaria|Teva Investigational Site 59048, Sofia, 1113, Bulgaria|Teva Investigational Site 59052, Sofia, 1113, Bulgaria|Teva Investigational Site 59057, Sofia, 1113, Bulgaria|Teva Investigational Site 59050, Sofia, 1142, Bulgaria|Teva Investigational Site 59044, Sofia, 1309, Bulgaria|Teva Investigational Site 59063, Sofia, 1407, Bulgaria|Teva Investigational Site 59038, Sofia, 1431, Bulgaria|Teva Investigational Site 59043, Sofia, 1431, Bulgaria|Teva Investigational Site 59058, Sofia, 1431, Bulgaria|Teva Investigational Site 59041, Sofia, 1527, Bulgaria|Teva Investigational Site 59042, Sofia, 1606, Bulgaria|Teva Investigational Site 59054, Sofia, 1606, Bulgaria|Teva Investigational Site 59059, Sofia, 1606, Bulgaria|Teva Investigational Site 59045, Sofia, 1750, Bulgaria|Teva Investigational Site 59049, Stara Zagora, 6003, Bulgaria|Teva Investigational Site 59046, Varna, 9010, Bulgaria|Teva Investigational Site 59051, Veliko Tarnovo, 5000, Bulgaria|Teva Investigational Site 59053, Veliko Tarnovo, 5100, Bulgaria|Teva Investigational Site 11013, Edmonton, Alberta, T6G 1Z1, Canada|Teva Investigational Site 11014, Burnaby, British Columbia, V5G 2X6, Canada|Teva Investigational Site 11015, Ottawa, K1H 8L6, Canada|Teva Investigational Site 11016, Saskatoon, S7K 0M7, Canada|Teva Investigational Site 60010, Osijek, 31 000, Croatia|Teva Investigational Site 60011, Varazdin, 42000, Croatia|Teva Investigational Site 60009, Zagreb, 10000, Croatia|Teva Investigational Site 54042, Brno, 602 00, Czechia|Teva Investigational Site 54043, Havirov, 736 01, Czechia|Teva Investigational Site 54047, Hradec Kralove 3, 50003, Czechia|Teva Investigational Site 54046, Jihlava, 58633, Czechia|Teva Investigational Site 54044, Olomouc, 779 00, Czechia|Teva Investigational Site 54045, Ostrava, 702 00, Czechia|Teva Investigational Site 54049, Praha 10, 100 31, Czechia|Teva Investigational Site 54041, Praha, 104 00, Czechia|Teva Investigational Site 54048, Teplice, 415 29, Czechia|Teva Investigational Site 55005, Parnu, 80010, Estonia|Teva Investigational Site 55008, Tallinn, EE-10138, Estonia|Teva Investigational Site 55006, Tallinn, EE-10617, Estonia|Teva Investigational Site 55007, Tartu, EE-51014, Estonia|Teva Investigational Site 35075, Clermont-Ferrand Cedex 1, 63003, France|Teva Investigational Site 35077, Dijon, France|Teva Investigational Site 35073, Lille, 59000, France|Teva Investigational Site 35076, Lyon cedex 04, 69317, France|Teva Investigational Site 35079, Nimes, 30029, France|Teva Investigational Site 81018, Tbilisi, 0112, Georgia|Teva Investigational Site 81014, Tbilisi, 0141, Georgia|Teva Investigational Site 81015, Tbilisi, 0179, Georgia|Teva Investigational Site 81019, Tbilisi, 0179, Georgia|Teva Investigational Site 81017, Tbilisi, 0186, Georgia|Teva Investigational Site 81016, Tbilisi, 0194, Georgia|Teva Investigational Site 32199, Bad Mergentheim, 97980, Germany|Teva Investigational Site 32195, Berg, 82335, Germany|Teva Investigational Site 32200, Berlin, 10117, Germany|Teva Investigational Site 32186, Berlin, 10437, Germany|Teva Investigational Site 32176, Berlin, 10625, Germany|Teva Investigational Site 32174, Berlin, 10713, Germany|Teva Investigational Site 32198, Berlin, 12163, Germany|Teva Investigational Site 32177, Bochum, 44791, Germany|Teva Investigational Site 32193, Dresden, 01307, Germany|Teva Investigational Site 32184, Erbach, 64711, Germany|Teva Investigational Site 32189, Erfurt, 99089, Germany|Teva Investigational Site 32203, Giessen, 35385, Germany|Teva Investigational Site 32202, Goettigen, 37075, Germany|Teva Investigational Site 32196, Halle (Saale), 06120, Germany|Teva Investigational Site 32181, Hamburg, 20246, Germany|Teva Investigational Site 32179, Hamburg, 22083, Germany|Teva Investigational Site 32182, Hannover, 30171, Germany|Teva Investigational Site 32175, Ibbenburen, 49477, Germany|Teva Investigational Site 32201, Jena, 07743, Germany|Teva Investigational Site 32183, Koln, 50935, Germany|Teva Investigational Site 32190, Leipzig, 4103, Germany|Teva Investigational Site 32185, Magdeburg, 39120, Germany|Teva Investigational Site 32191, Rostock, 18147, Germany|Teva Investigational Site 32194, Teupitz, 15755, Germany|Teva Investigational Site 32173, Ulm, 89081, Germany|Teva Investigational Site 32197, Wermsdorf, 04773, Germany|Teva Investigational Site 32188, Westerstede, 26655, Germany|Teva Investigational Site 63027, Athens, 115 28, Greece|Teva Investigational Site 63024, Athens, 11525, Greece|Teva Investigational Site 63029, Chaidari, 12462, Greece|Teva Investigational Site 63026, Heraklion, 71110, Greece|Teva Investigational Site 63030, Larisa, 41110, Greece|Teva Investigational Site 63025, Thessaloniki, 54636, Greece|Teva Investigational Site 63028, Thessaloniki, 57010, Greece|Teva Investigational Site 51046, Budapest, 1134, Hungary|Teva Investigational Site 51043, Debrecen, 4043, Hungary|Teva Investigational Site 51045, Eger, H-3300, Hungary|Teva Investigational Site 51044, Kaposvar, H-7400, Hungary|Teva Investigational Site 80023, Haifa, 31096, Israel|Teva Investigational Site 80024, Haifa, 31096, Israel|Teva Investigational Site 80020, Ramat Gan, 5262160, Israel|Teva Investigational Site 80021, Tel Aviv, 64239, Israel|Teva Investigational Site 30037, Bologna, 40139, Italy|Teva Investigational Site 30031, Castelfiorentino, 50051, Italy|Teva Investigational Site 30030, Cefalu, 90015, Italy|Teva Investigational Site 30032, Chieti, 66100, Italy|Teva Investigational Site 30024, Firenze, 50139, Italy|Teva Investigational Site 30029, Gallarate, 21013, Italy|Teva Investigational Site 30023, Milano, 20132, Italy|Teva Investigational Site 30039, Milano, 20133, Italy|Teva Investigational Site 30034, Napoli, 80131, Italy|Teva Investigational Site 30027, Palermo, 90146, Italy|Teva Investigational Site 30028, Rome, 00149, Italy|Teva Investigational Site 30025, Rome, 00163, Italy|Teva Investigational Site 30026, Rome, 00168, Italy|Teva Investigational Site 30035, Rome, 00178, Italy|Teva Investigational Site 30040, Verona, 37134, Italy|Teva Investigational Site 87001, Goyang-si, 410-769, Korea, Republic of|Teva Investigational Site 87003, Seoul, 03080, Korea, Republic of|Teva Investigational Site 87002, Seoul, 138-736, Korea, Republic of|Teva Investigational Site 56006, Riga, 1038, Latvia|Teva Investigational Site 56005, Riga, LV-1005, Latvia|Teva Investigational Site 70006, Chisinau, 2001, Moldova, Republic of|Teva Investigational Site 70005, Chisinau, 2024, Moldova, Republic of|Teva Investigational Site 70008, Chisinau, 2028, Moldova, Republic of|Teva Investigational Site 66002, Podgorica, 20000, Montenegro|Teva Investigational Site 65010, Skopje, 1000, North Macedonia|Teva Investigational Site 65011, Skopje, 1000, North Macedonia|Teva Investigational Site 65012, Skopje, 1000, North Macedonia|Teva Investigational Site 53066, Bialystok, 15-276, Poland|Teva Investigational Site 53071, Bialystok, 15-402, Poland|Teva Investigational Site 53085, Bydgoszcz, 85-654, Poland|Teva Investigational Site 53084, Czestochowa, 42-280, Poland|Teva Investigational Site 53069, Gdansk, 80-299, Poland|Teva Investigational Site 53083, Gdansk, 80-546, Poland|Teva Investigational Site 53067, Gdansk, 80-803, Poland|Teva Investigational Site 53078, Grodzisk Mazowiecki, 05-825, Poland|Teva Investigational Site 53080, Katowice, 40-555, Poland|Teva Investigational Site 53081, Katowice, 40-650, Poland|Teva Investigational Site 53073, Katowice, 40-684, Poland|Teva Investigational Site 53070, Katowice, 40-749, Poland|Teva Investigational Site 53074, Katowice, 40-752, Poland|Teva Investigational Site 53064, Konskie, 26-200, Poland|Teva Investigational Site 53065, Konstancin-Jeziorna, 05-510, Poland|Teva Investigational Site 53072, Koscierzyna, 83-400, Poland|Teva Investigational Site 53063, Lodz, 90-324, Poland|Teva Investigational Site 53079, Olsztyn, 10-560, Poland|Teva Investigational Site 53068, Plewiska, 62-064, Poland|Teva Investigational Site 53076, Szczecin, 70-111, Poland|Teva Investigational Site 52045, Balotesti, 77015, Romania|Teva Investigational Site 52041, Bucharest, 012071, Romania|Teva Investigational Site 52050, Bucuresti, 020125, Romania|Teva Investigational Site 52037, Bucuresti, 022328, Romania|Teva Investigational Site 52034, Bucuresti, 050098, Romania|Teva Investigational Site 52040, Cluj-Napoca, 400006, Romania|Teva Investigational Site 52036, Cluj-Napoca, 400437, Romania|Teva Investigational Site 52038, Constanta, 900123, Romania|Teva Investigational Site 52044, Constanta, 900591, Romania|Teva Investigational Site 52048, Craiova, 200473, Romania|Teva Investigational Site 52049, Hunedoara, 331057, Romania|Teva Investigational Site 52042, Iasi, 700661, Romania|Teva Investigational Site 52039, Oradea, 410108, Romania|Teva Investigational Site 52047, Piatra-Neamt, 610136, Romania|Teva Investigational Site 52046, Sibiu, 550245, Romania|Teva Investigational Site 52035, Targu Mures, Romania|Teva Investigational Site 52043, Timisoara, 100182, Romania|Teva Investigational Site 50130, Barnaul, 656024, Russian Federation|Teva Investigational Site 50129, Chelyabinsk, 454021, Russian Federation|Teva Investigational Site 50208, Kazan, 420021, Russian Federation|Teva Investigational Site 50148, Kemerovo, 650061, Russian Federation|Teva Investigational Site 50144, Krasnodar, 350012, Russian Federation|Teva Investigational Site 50147, Moscow, 119021, Russian Federation|Teva Investigational Site 50124, Moscow, 127015, Russian Federation|Teva Investigational Site 50133, Moscow, 129110, Russian Federation|Teva Investigational Site 50146, Moscow, 129128, Russian Federation|Teva Investigational Site 50141, Nizhny Novgorod, 603076, Russian Federation|Teva Investigational Site 50128, Nizhny Novgorod, 603155, Russian Federation|Teva Investigational Site 50131, Nizhny Novgorod, 603155, Russian Federation|Teva Investigational Site 50127, Perm, 614990, Russian Federation|Teva Investigational Site 50143, Rostov-on-Don, 344015, Russian Federation|Teva Investigational Site 50149, Rostov-on-Don, 344022, Russian Federation|Teva Investigational Site 50126, Saint Petersburg, 191186, Russian Federation|Teva Investigational Site 50140, Saint Petersburg, 197022, Russian Federation|Teva Investigational Site 50138, Samara, 443095, Russian Federation|Teva Investigational Site 50135, Saratov, 410054, Russian Federation|Teva Investigational Site 50136, Smolensk, 214018, Russian Federation|Teva Investigational Site 50137, St. Petersburg, 194354, Russian Federation|Teva Investigational Site 50125, Tomsk, 634050, Russian Federation|Teva Investigational Site 50139, Tyumen, 625000, Russian Federation|Teva Investigational Site 50134, Ufa, 450007, Russian Federation|Teva Investigational Site 50132, Volgograd, 400138, Russian Federation|Teva Investigational Site 50142, Yaroslavl, 150030, Russian Federation|Teva Investigational Site 61025, Belgrade, 11000, Serbia|Teva Investigational Site 61027, Belgrade, 11000, Serbia|Teva Investigational Site 61024, Belgrade, 11080, Serbia|Teva Investigational Site 61018, Cacak, 32000, Serbia|Teva Investigational Site 61015, Kragujevac, 34000, Serbia|Teva Investigational Site 61014, Nis, 18000, Serbia|Teva Investigational Site 61019, Sombor, 25000, Serbia|Teva Investigational Site 61016, Subotica, 24000, Serbia|Teva Investigational Site 61017, Uzice, 31000, Serbia|Teva Investigational Site 61022, Valjevo, 14000, Serbia|Teva Investigational Site 61026, Vrbas, 21460, Serbia|Teva Investigational Site 61021, Zrenjanin, 23000, Serbia|Teva Investigational Site 62012, Hlohovec, 92001, Slovakia|Teva Investigational Site 62013, Trnava, 917 75, Slovakia|Teva Investigational Site 31035, Barcelona, 08025, Spain|Teva Investigational Site 31030, Barcelona, 08035, Spain|Teva Investigational Site 31031, Getafe, 28905, Spain|Teva Investigational Site 31036, L'Hospitalet de Llobregat, 08907, Spain|Teva Investigational Site 31032, Madrid, 28040, Spain|Teva Investigational Site 31034, Madrid, 28046, Spain|Teva Investigational Site 31033, Navarro, 31008, Spain|Teva Investigational Site 31039, Oviedo, 33011, Spain|Teva Investigational Site 31037, Salt, 17190, Spain|Teva Investigational Site 58087, Chernihiv, 14001, Ukraine|Teva Investigational Site 58083, Chernivtsi, 58018, Ukraine|Teva Investigational Site 58077, Dnipropetrovsk, 49044, Ukraine|Teva Investigational Site 58088, Ivano-Frankivsk, 76008, Ukraine|Teva Investigational Site 58076, Ivano-Frankivsk, Ukraine|Teva Investigational Site 58116, Kharkiv, 61068, Ukraine|Teva Investigational Site 58084, Kharkiv, 61103, Ukraine|Teva Investigational Site 58089, Kiev, 04112, Ukraine|Teva Investigational Site 58073, Kyiv, 01601, Ukraine|Teva Investigational Site 58078, Kyiv, 03110, Ukraine|Teva Investigational Site 58081, Kyiv, 03115, Ukraine|Teva Investigational Site 58115, Lviv, 79013, Ukraine|Teva Investigational Site 58086, Lviv, 79059, Ukraine|Teva Investigational Site 58074, Odesa, 65025, Ukraine|Teva Investigational Site 58085, Odessa, 65014, Ukraine|Teva Investigational Site 58082, Poltava, 36024, Ukraine|Teva Investigational Site 58080, Simferopol, 95000, Ukraine|Teva Investigational Site 58072, Vinnytsya, 21005, Ukraine|Teva Investigational Site 58079, Zaporizhzhya, 69035, Ukraine|Teva Investigational Site 58075, Zaporizhzhya, 69600, Ukraine|Teva Investigational Site 34015, Glasgow, G51 4TF, United Kingdom|Teva Investigational Site 34011, Liverpool, B0T 1K0, United Kingdom|Teva Investigational Site 34010, Liverpool, L9 7LJ, United Kingdom|Teva Investigational Site 34019, London, E1 1BB, United Kingdom|Teva Investigational Site 34016, Salford, M6 8HD, United Kingdom|Teva Investigational Site 34017, Sheffield, S10 2JF, United Kingdom|Teva Investigational Site 34013, Stoke-on-Trent, ST4 6QG, United Kingdom"
NCT03138525,Immune Profiling During Ocrelizumab Treatment in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03138525,COMPLETED,Multiple Sclerosis|Healthy,OTHER: Blood sampling (MS)|OTHER: Blood sampling (controls),Brigham and Women's Hospital,"Genentech, Inc.",ALL,ADULT,,161,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-06-20,2019-12-20,2019-12-20,"Brigham and Women's Hospital, Boston, Massachusetts, 02115, United States"
NCT02424825,Rouxbe Pilot for MS,https://beta.clinicaltrials.gov/study/NCT02424825,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Cooking Course,Oregon Health and Science University,Rouxbe Cooking School,ALL,"ADULT, OLDER_ADULT",NA,15,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-02,2015-05,2015-05,"Oregon Health & Science University Multiple Sclerosis Center., Portland, Oregon, 97239, United States"
NCT04918225,Motor Asymmetry in Progressive Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT04918225,RECRUITING,"Multiple Sclerosis, Primary Progressive|Multiple Sclerosis, Secondary Progressive",RADIATION: Magnetic Resonance Imaging|DIAGNOSTIC_TEST: Neurological examination|DIAGNOSTIC_TEST: Multiple Sclerosis Functional Composite|DIAGNOSTIC_TEST: Physiotherapist examination,Rennes University Hospital,,ALL,ADULT,,60,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-11-03,2026-05,2026-05,"Hôpital de la Timone, AP-HM, Marseille, 13385, France|CHU de Rennes - Hôpital Pontchaillou, Rennes, 35033, France"
NCT04873492,From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04873492,RECRUITING,Multiple Sclerosis,OTHER: Biological sample collection,Nantes University Hospital,,ALL,"ADULT, OLDER_ADULT",NA,130,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2022-01-24,2023-07-24,2025-07-24,"Nantes University Hospital, Nantes, Loire-Atlantique, 44093, France"
NCT04369092,Myotonometer Analyses of Muscles in Multiple Sclerosis Patients With Dysphagia,https://beta.clinicaltrials.gov/study/NCT04369092,COMPLETED,Multiple Sclerosis|Dysphagia|Swallowing Disorder|Deglutition Disorders|Muscle Tonus,OTHER: DYMUS,Tuba Maden,,ALL,"ADULT, OLDER_ADULT",NA,28,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2019-10-02,2019-12-28,2020-01-30,"Hasan Kalyoncu University, Gaziantep, Turkey"
NCT00656825,Tolerability and Bioavailability of the P144 Peptide Inhibitor of TGF-β1 After Topical Administration in Healthy Volunteers,https://beta.clinicaltrials.gov/study/NCT00656825,COMPLETED,Healthy,DRUG: P144 cream|DRUG: P144 cream|DRUG: P144 cream|DRUG: Placebo,ISDIN,Digna Biotech S.L.,ALL,ADULT,PHASE1,36,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: ",2007-03,2007-06,2007-06,"Hospital Universitario Puerta de Hierro, Madrid, 28035, Spain|Clínica Universitaria de Navarra, Pamplona, 31008, Spain"
NCT02335892,PROFILE - Evaluation of QoL and PRO Outcomes in Patients Taking Fingolimod,https://beta.clinicaltrials.gov/study/NCT02335892,COMPLETED,Relapsing Remitting Multiple Sclerosis,,Novartis Pharmaceuticals,,ALL,ADULT,,114,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-11-11,2017-02-01,2017-02-01,"Novartis Investigative Site, Truro, Cornwall, TR1 3LJ, United Kingdom|Novartis Investigative Site, Swansea, England, SA6 6NL, United Kingdom|Novartis Investigative Site, Romford, Essex, RM7 0AG, United Kingdom|Novartis Investigative Site, Basingstoke, Hampshire, RG24 9NA, United Kingdom|Novartis Investigative Site, Edinburgh, EH16 4SA, United Kingdom|Novartis Investigative Site, Glasgow, G51 4TF, United Kingdom|Novartis Investigative Site, Leicester, LE5 4PW, United Kingdom|Novartis Investigative Site, Liverpool, L9 7LT, United Kingdom|Novartis Investigative Site, London, E1 1BB, United Kingdom|Novartis Investigative Site, London, SW17 0QT, United Kingdom|Novartis Investigative Site, London, W6 8RF, United Kingdom|Novartis Investigative Site, London, WC1N 3BG, United Kingdom|Novartis Investigative Site, Norwich, NR4 7UY, United Kingdom|Novartis Investigative Site, Nottingham, NG5 1PB, United Kingdom"
NCT05604092,"Lesion Load and Location in Relation to Cognition, Fatigue and Physical Disability in RRMS",https://beta.clinicaltrials.gov/study/NCT05604092,COMPLETED,Relapsing Remitting Multiple Sclerosis,"DIAGNOSTIC_TEST: VolBrain, a fully automated platform to generate the volumetric data (lesion count, volume and location as well as different atrophy measures)|OTHER: Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)",Assiut University,,ALL,"CHILD, ADULT, OLDER_ADULT",,63,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-03-01,2022-08-31,2022-09-30,"Eman Khedr, Assiut, 11517, Egypt"
NCT00280592,Cranberry for Prevention of Urinary Tract Infections in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT00280592,COMPLETED,Multiple Sclerosis|Urinary Tract Infections|Bladder Dysfunction,DRUG: Cranberry|DRUG: Placebo,Rennes University Hospital,"Pierre Fabre Laboratories|Ministry of Health, France",ALL,"ADULT, OLDER_ADULT",PHASE3,171,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2006-01,2008-03,2008-10,"Unité de Médecine Physique et Réadaptation - CHU Jean Minjoz, Besançon, 25030, France|Service de Médecine Physique et Réadaptation - Hôpital Pellegrin, Bordeaux, 33076, France|Service de Médecine Physique et Réadaptation - Hôpital Raymond Poincaré, Garches, 92380, France|Consultations maladies infectieuses et tropicales, Hôpital Raymond Poincaré, Garches, France|Médecine Physique et Réadaptation - Groupe Hospitalier de l'institut Catholique de Lille - Hôpital Saint Philibert, Lomme, 59160, France|Rééducation Neurologique et Explorations Périnéales - Hôpital Rothschild, Paris, 75571, France|Centre Mutualiste de Rééducation et de Réadaptation Fonctionnelles de KERPAPE, Ploemeur, 56275, France|Service de Médecine Physique et Réadaptation - Hôpital Pontchaillou, Rennes, 35033, France|Centre de Médecine Physique et Réadaptation Notre Dame de Lourdes, Rennes, 35043, France|Service de médecine physique et réadapation Hopital de Rangueil, Toulouse, 31059, France"
NCT04530955,Transitioning to a Valve-Gated Intrathecal Drug Delivery System (IDDS),https://beta.clinicaltrials.gov/study/NCT04530955,RECRUITING,"Injuries, Spinal Cord|CVA (Cerebrovascular Accident)|Traumatic Brain Injury|MS (Multiple Sclerosis)|Muscle Spasticity|Cerebral Palsy, Spastic",DEVICE: Prometra II Programmable Pump - Flowonix Medical,Culicchia Neurological Clinic,Flowonix Medical,ALL,"ADULT, OLDER_ADULT",NA,92,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2020-09-24,2022-12,2023-06,"Culicchia Neurological Clinic, Marrero, Louisiana, 70072, United States"
NCT01220830,Cytotron® Delivered Rotational Field Quantum Nuclear Magnetic Resonance Therapy for Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01220830,UNKNOWN,Multiple Sclerosis,DEVICE: Cytotron,"The Centre for Advanced Research & Development, India",,ALL,ADULT,PHASE2,40,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2010-09,2011-12,2011-12,"Centre for Advanced Research and Development, Bangalore, Karnataka, 560 049, India"
NCT00200655,Safety and Efficacy of Pravastatin in Relapsing-remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00200655,COMPLETED,Relapsing-remitting Multiple Sclerosis,DRUG: Pravastatin|DRUG: Placebo,Nantes University Hospital,,ALL,ADULT,PHASE3,40,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,2004-12,,2007-11,"Nantes University Hospital, Nantes, 44093, France"
NCT05671055,CogMS - A Real-world Study Into Cognitive Impairment in People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05671055,RECRUITING,Multiple Sclerosis,OTHER: Custom study version of icompanion app,icometrix,Bristol-Myers Squibb,ALL,"ADULT, OLDER_ADULT",,300,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-01-07,2023-08-01,2023-08-01,"Brain Health Center of the Rockies, Fort Collins, Colorado, 80528, United States|Dent Neurologic Institute, Buffalo, New York, 14226, United States|The Boster Center for Multiple Sclerosis, Columbus, Ohio, 43235, United States|Texas Neurology, Dallas, Texas, 75206, United States|GZA Antwerpen, Antwerpen, 2018, Belgium|Imelda Ziekenhuis, Bonheiden, 2820, Belgium|AZ Sint-Jan Brugge, Brugge, 8000, Belgium|UZ Brussel, Jette, 1090, Belgium|University of Greifswald, Greifswald, 17489, Germany"
NCT04798651,Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04798651,RECRUITING,Multiple Sclerosis|Clinically Isolated Syndrome,BIOLOGICAL: blood sample|BIOLOGICAL: cerebro-spinal fluid,"University Hospital, Bordeaux",University of Bordeaux,ALL,"ADULT, OLDER_ADULT",NA,150,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2021-09-30,2026-09,2026-09,"CHU de Bordeaux - service de neurologie, Bordeaux, France"
NCT05470751,GentleCath™ Air for Men Intermittent Catheter With FeelClean™ Technology,https://beta.clinicaltrials.gov/study/NCT05470751,NOT_YET_RECRUITING,Bladder Outlet Obstruction|Multiple Sclerosis|Cauda Equina Syndrome|Enlarged Prostate With Lower Urinary Tract Symptoms|Parkinson Disease|Lower Urinary Tract Symptoms|Detrusor Underactivity|Spinal Cord Injuries,DEVICE: Intermittent self-catheterisation,ConvaTec Inc.,,MALE,"ADULT, OLDER_ADULT",,165,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-01,2023-02,2023-05,
NCT04183751,"The Relationship Between Kinesiophobia, Physical Activity, Balance and Fear of Fall in MS Patients",https://beta.clinicaltrials.gov/study/NCT04183751,UNKNOWN,Multiple Sclerosis,OTHER: scale study,Marmara University,,ALL,"ADULT, OLDER_ADULT",,40,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-04-21,2020-12-21,2021-07,"Marmara University, Istanbul, 34000, Turkey"
NCT03566251,"Core Stability, Trunk Position Sense, Balance and Functional Mobility in Patients With Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT03566251,COMPLETED,Physical Therapy,OTHER: Balance|OTHER: Functional mobility|OTHER: Core stability|OTHER: Trunk position sense,Ankara Yildirim Beyazıt University,,ALL,"ADULT, OLDER_ADULT",NA,74,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: SCREENING,2016-05-01,2017-01-01,2017-02-01,"Ankara Yıldırım Beyazıt University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation Etlik, Ankara, Turkey, 06010, Ankara, Turkey"
NCT04388592,The Effect of Nurse Practitioner (NP-led) Care Upon Mood in People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04388592,COMPLETED,Multiple Sclerosis|Nurse's Role,OTHER: Nurse Practitioner (NP) Led Care Arm,University of Alberta,University Hospital Foundation,ALL,"ADULT, OLDER_ADULT",NA,248,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2017-04-01,2019-04-30,2019-11-30,"University of Alberta, Edmonton, Alberta, T6G 2R3, Canada"
NCT02634931,Long-term Trial of Topical Sirolimus to Angiofibroma in Patient With Tuberous Sclerosis Complex,https://beta.clinicaltrials.gov/study/NCT02634931,COMPLETED,Tuberous Sclerosis|Angiofibroma|Hypomelanotic Macule|Plaque,DRUG: NPC-12G gel,Nobelpharma,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,94,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-12,2018-10,2018-10,"Graduate School of Medicine, Osaka University, Suita, Osaka, 565-0871, Japan"
NCT01318421,A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01318421,TERMINATED,Multiple Sclerosis,DRUG: ELND002,Elan Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE1,12,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2010-12,2012-12,,
NCT04496531,Efficacy of PoNS in Reducing Symptoms of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04496531,COMPLETED,Multiple Sclerosis,DEVICE: Portable Neuromodulation Stimulator,Helius Medical Inc,McGill University,ALL,ADULT,NA,14,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-12,2016-08,2016-08,
NCT05491031,MRI Biomarkers Predictive of Disability Progression in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05491031,NOT_YET_RECRUITING,Multiple Sclerosis|Magnetic Resonance Spectroscopy,OTHER: magnetic resonance spectroscopy,Poitiers University Hospital,,ALL,"ADULT, OLDER_ADULT",NA,250,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2023-04-24,2028-01-01,2028-05-01,
NCT00630721,Characterization of Interferon Beta -1b-Induced Tolerizing Effect in Dendritic Cells,https://beta.clinicaltrials.gov/study/NCT00630721,COMPLETED,Multiple Sclerosis,OTHER: IFNbeta-1b,"University of North Carolina, Chapel Hill",,ALL,ADULT,NA,56,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2007-09,2010-05-15,2011-03-15,"University of North Carolina, Chapel Hill, North Carolina, 27599, United States"
NCT02994121,Prospective Investigation of Multiple Sclerosis in the Three Rivers Region,https://beta.clinicaltrials.gov/study/NCT02994121,RECRUITING,Multiple Sclerosis,,University of Pittsburgh,,ALL,"CHILD, ADULT, OLDER_ADULT",,7500,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-12,2047-01,2047-01,"University of Pittsburgh, Pittsburgh, Pennsylvania, 15260, United States"
NCT05385731,MUSCLE - Nordic Walking in MUltiple SCLErosis,https://beta.clinicaltrials.gov/study/NCT05385731,NOT_YET_RECRUITING,"Multiple Sclerosis, Chronic Progressive|Multiple Sclerosis|Multiple Sclerosis, Primary Progressive|Multiple Sclerosis, Secondary Progressive",OTHER: Nordic Walking (NWG)|OTHER: Free Walking (FWG)|OTHER: Health Education (HEG),Leonardo A. Peyré-Tartaruga,Aline Nogueira Haas|Flávia Gomes Martinez,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-08-02,2022-12-30,2024-12-30,"Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande Do Sul, 90690-200, Brazil"
NCT02084121,Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis (Compassionate Use),https://beta.clinicaltrials.gov/study/NCT02084121,NO_LONGER_AVAILABLE,Metachromatic Leukodystrophy,BIOLOGICAL: Enriched Hematopoetic Stem Cell Infusion,Talaris Therapeutics Inc.,Duke University,MALE,"CHILD, ADULT, OLDER_ADULT",,,INDUSTRY,EXPANDED_ACCESS,,,,,"Duke University, Durham, North Carolina, 27705, United States"
NCT00922831,Progression of Cognitive and Physical Symptoms in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00922831,WITHDRAWN,Multiple Sclerosis,,MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute,"University of Missouri, Kansas City",ALL,"ADULT, OLDER_ADULT",,0,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2008-08,2013-08,2013-08,
NCT02266121,Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02266121,TERMINATED,Relapsing Remitting Multiple Sclerosis|Secondary-progressive Multiple Sclerosis|Cognitive Deficits|Motor Deficits,DEVICE: tDCS,University Hospital of Mont-Godinne,Université Catholique de Louvain|Teva Pharmaceuticals USA,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-10,2023-05-08,2023-05-08,"Department of Neurology, CHU Dinant Godinne UcL Namur, Yvoir, Namur, B-5530, Belgium"
NCT05388331,RIS International Cohort,https://beta.clinicaltrials.gov/study/NCT05388331,RECRUITING,Multiple Sclerosis|Radiologically Isolated Syndrome,OTHER: No intervention,Centre Hospitalier Universitaire de Nice,,ALL,"CHILD, ADULT, OLDER_ADULT",,1000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-04-15,2023-04-15,2029-04-15,"Nice University Hospital, Nice, 06000, France"
NCT03164031,Feasibility and Acceptability of Orthotic Shorts for People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03164031,COMPLETED,Multiple Sclerosis,DEVICE: Close-fitting orthotic shorts|DEVICE: Looser fitting shorts,Sheffield Hallam University,Sheffield Teaching Hospitals NHS Foundation Trust,ALL,"ADULT, OLDER_ADULT",NA,16,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2018-01-10,2019-05-30,2019-05-30,"Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, South Yorkshire, S10 2JF, United Kingdom"
NCT04032431,Upper Limb Telerehabilitation With Virtual Reality in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04032431,UNKNOWN,Multiple Sclerosis,BEHAVIORAL: Telerehab VR intervention,University of Cagliari,Azienda Sanitaria Locale di Cagliari|Tel Aviv University,ALL,ADULT,NA,24,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-12-01,2021-09-01,2022-09-01,"The Multiple Sclerosis Center, Sheba Medical Center, Tel HaShomer, Israel|Laboratorio di Biomeccanica ed Ergonomia industriale - Università degli Studi di Cagliari, Monserrato, Cagliari, 09042, Italy"
NCT01185821,"Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT01185821,COMPLETED,Relapsing Remitting Multiple Sclerosis,DRUG: BAF312,Novartis Pharmaceuticals,,ALL,ADULT,PHASE2,185,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2010-08-30,2016-10-10,2016-10-10,"Novartis Investigative Site, Miami, Florida, 33136, United States|Novartis Investigative Site, Pompano Beach, Florida, 33060, United States|Novartis Investigative Site, Tallahassee, Florida, 32308, United States|Novartis Investigative Site, Chicago, Illinois, 60637, United States|Novartis Investigative Site, Grand Rapids, Michigan, 49525, United States|Novartis Investigative Site, Akron, Ohio, 44320, United States|Novartis Investigative Site, Greenville, South Carolina, 29607, United States|Novartis Investigative Site, Seattle, Washington, 98122, United States|Novartis Investigative Site, Ottawa, Ontario, K1H 8L6, Canada|Novartis Investigative Site, Gatineau, Quebec, J9J 0A5, Canada|Novartis Investigative Site, Greenfield Park, Quebec, J4V 2J2, Canada|Novartis Investigative Site, Helsinki, 00930, Finland|Novartis Investigative Site, Tampere, FIN-33520, Finland|Novartis Investigative Site, Dresden, 01307, Germany|Novartis Investigative Site, Ibbenbueren, 49477, Germany|Novartis Investigative Site, Muenchen, 81675, Germany|Novartis Investigative Site, Muenster, 48149, Germany|Novartis Investigative Site, Budapest, 1076, Hungary|Novartis Investigative Site, Budapest, 1145, Hungary|Novartis Investigative Site, Debrecen, 4032, Hungary|Novartis Investigative Site, Veszprem, H-8200, Hungary|Novartis Investigative Site, Montichiari, BS, 25018, Italy|Novartis Investigative Site, Chieti, CH, 66100, Italy|Novartis Investigative Site, Roma, RM, 00133, Italy|Novartis Investigative Site, Roma, RM, 00152, Italy|Novartis Investigative Site, Bergen, 5021, Norway|Novartis Investigative Site, Oslo, 0424, Norway|Novartis Investigative Site, Lodz, 90-324, Poland|Novartis Investigative Site, Lublin, 20-954, Poland|Novartis Investigative Site, Warszawa, 02-957, Poland|Novartis Investigative Site, Kazan, 420103, Russian Federation|Novartis Investigative Site, Moscow, 125367, Russian Federation|Novartis Investigative Site, Moscow, 127018, Russian Federation|Novartis Investigative Site, Saint Petersburg, 197022, Russian Federation|Novartis Investigative Site, Saint-Petersburg, 194044, Russian Federation|Novartis Investigative Site, Sevilla, Andalucia, 41009, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08035, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, 46026, Spain|Novartis Investigative Site, Basel, 4031, Switzerland|Novartis Investigative Site, Lugano, 6900, Switzerland|Novartis Investigative Site, Zuerich, 8091, Switzerland|Novartis Investigative Site, Ankara, 06100, Turkey|Novartis Investigative Site, Haseki / Istanbul, 34096, Turkey|Novartis Investigative Site, Istanbul, 34093, Turkey|Novartis Investigative Site, Izmir, 35340, Turkey|Novartis Investigative Site, Kocaeli, 41380, Turkey"
NCT04650321,Home Based Infusions for Ocrelizumab,https://beta.clinicaltrials.gov/study/NCT04650321,RECRUITING,Multiple Sclerosis,DRUG: Ocrelizumab at home,"University of Colorado, Denver","Genentech, Inc.",ALL,ADULT,PHASE4,110,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-03-01,2021-08-31,2021-08-31,"Amerita, Centennial, Colorado, 80112, United States"
NCT05826431,Cubii for Exercise in People With MS,https://beta.clinicaltrials.gov/study/NCT05826431,NOT_YET_RECRUITING,"Multiple Sclerosis|Fatigue|Activity, Motor|Quality of Life",DEVICE: Cubii elliptical,University of Washington,,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-04-19,2023-08-31,2023-12-31,
NCT02021162,Effects of Gilenya (Fingolimod) on Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02021162,COMPLETED,Multiple Sclerosis|Healthy,,University at Buffalo,Novartis,ALL,ADULT,,50,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-11,2018-09,2018-10,"Buffalo Neuroimaging Analysis Center, Buffalo, New York, 14203, United States"
NCT02784210,Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques,https://beta.clinicaltrials.gov/study/NCT02784210,RECRUITING,Multiple Sclerosis,DRUG: Methylprednisolone|DRUG: Prednisone,National Institute of Neurological Disorders and Stroke (NINDS),,ALL,"ADULT, OLDER_ADULT",PHASE2,30,NIH,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2016-10-05,2024-12-31,2024-12-31,"National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States"
NCT04387110,Ocrelizumab in Breastmilk,https://beta.clinicaltrials.gov/study/NCT04387110,COMPLETED,Multiple Sclerosis|Clinically Isolated Syndrome,DRUG: Ocrelizumab,"University of California, San Francisco","Genentech, Inc.",FEMALE,ADULT,,30,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-08-07,2022-03-01,2022-03-01,"University of California, San Francisco, San Francisco, California, 94158, United States"
NCT02044510,Urodynamic and Clinical Efficacy of Mirabegron for Neurogenic Bladder Patients,https://beta.clinicaltrials.gov/study/NCT02044510,TERMINATED,"Urinary Bladder, Neurogenic",DRUG: Mirabegron|DRUG: Placebo,Lawson Health Research Institute,,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,32,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-07,2018-01,2018-02,"Rehabiliation Center, Health Sciences Center, Winnipeg, Manitoba, R3A 1M4, Canada|Kingston General Hospital and Hotel Dieu Hospital (Queens University), Kingston, Ontario, K7L 5G2, Canada|Western University, London, Ontario, N6A 4V2, Canada|University of Ottawa, Ottawa, Ontario, K1Y 4E9, Canada|Toronto Western Hospital, Toronto, Ontario, M5T 2S8, Canada"
NCT05380362,Prospective Randomized Endovascular Therapy in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05380362,COMPLETED,Multiple Sclerosis,OTHER: Venous Angioplasty|OTHER: Sham Angioplasty,University at Buffalo,Volcano Corporation,ALL,"ADULT, OLDER_ADULT",PHASE1,30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2010-06,2013-04,2013-04,"Gates Circle Hospital, Buffalo, New York, 14209, United States"
NCT00913510,Efficacy of Clean Intermittent Catheterization (CIC) in Multiple Sclerosis (MS) Patients With Bladder Dysfunction,https://beta.clinicaltrials.gov/study/NCT00913510,TERMINATED,Bladder Dysfunction|Multiple Sclerosis,DEVICE: CIC using LoFric Primo|DRUG: Anticholinergic medication,Wellspect HealthCare,,ALL,"ADULT, OLDER_ADULT",NA,24,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2009-12,2012-05,2012-05,"Centre Hospitalier Universitaire de Liège Ourthe Ambléve, Esneux, 4130, Belgium|UZ Gasthuisberg, Leuven, 3000, Belgium|St. Hedwig Hospital, Department of Urology, Berlin, 10115, Germany|UMC ST Radboud Nijmegen, Department of Urology, Nijmegen, 6500 HB, Netherlands|University College of London, Institute of Neurology, London, WC1N 3BG, United Kingdom"
NCT01883310,Task-oriented Circuit Training Combined With Cerebellar tDCS in Multiple Sclerosis Subjects,https://beta.clinicaltrials.gov/study/NCT01883310,COMPLETED,Multiple Sclerosis Subjects,DEVICE: sham tDCS + TOCT|DEVICE: real tDCS +TOCT,University Hospital of Ferrara,,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2017-02-01,2017-07-01,2017-11-01,"Ferrara University Hospital, Ferrara, 44124, Italy"
NCT03113162,Reduced-intensity Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03113162,UNKNOWN,Multiple Sclerosis,BIOLOGICAL: Autologous Hematopoietic Stem Cell|DRUG: BEAM Regimen,Makati Medical Center,,ALL,ADULT,PHASE1,15,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-05-29,2020-05-29,2022-05-29,"Makati Medical Center, Makati, 1229, Philippines"
NCT04933110,Investigation of Hand Functions and Related Parameters in People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04933110,NOT_YET_RECRUITING,Multiple Sclerosis,,Uğur OVACIK,Istanbul University - Cerrahpasa (IUC),ALL,"ADULT, OLDER_ADULT",,90,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-07-05,2021-09-06,2021-09-20,
NCT04126772,Multimodal Imaging of MS Reveals the Smoldering Inflammation,https://beta.clinicaltrials.gov/study/NCT04126772,RECRUITING,Multiple Sclerosis,,Turku University Hospital,,ALL,"ADULT, OLDER_ADULT",,40,OTHER_GOV,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-02-27,2023-06,2023-09,"Turku PET Centre, Turku, Finland Proper, 20520, Finland"
NCT02486562,iConquerMS™ - A Patient-Powered Research Network for Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02486562,RECRUITING,Multiple Sclerosis,,Accelerated Cure Project for Multiple Sclerosis,Patient-Centered Outcomes Research Institute|Ogilvy|Arizona State University,ALL,"ADULT, OLDER_ADULT",,20000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-11,2026-10,2036-10,"Accelerated Cure Project, Waltham, Massachusetts, 02451, United States"
NCT00972062,Herbal Therapy for Subcutaneous Injection Site Reactions in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00972062,COMPLETED,Multiple Sclerosis,OTHER: Bach's Rescue Remedy Cream|OTHER: Placebo Cream,"University of North Carolina, Charlotte","Teva Branded Pharmaceutical Products R&D, Inc.",ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2009-06,2009-12,2010-03,"University of North Carolina at Charlotte, Charlotte, North Carolina, 28223, United States"
NCT03429062,Comparison of Two Community Based Exercise Protocols in People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03429062,WITHDRAWN,Multiple Sclerosis,OTHER: Personal training exercises,Texas Woman's University,,ALL,"ADULT, OLDER_ADULT",,0,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-02-13,2019-02-13,2019-02-13,"MINDSET Fitness and Yoga, Fort Worth, Texas, 76117, United States"
NCT05121662,COVID-19 Vaccine Biomarker Study in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05121662,RECRUITING,Multiple Sclerosis|COVID-19,,Columbia University,Novartis,ALL,"ADULT, OLDER_ADULT",,100,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-07-29,2023-07-29,2023-07-29,"Columbia University Irving Medical Center, New York, New York, 10032, United States"
NCT03651362,Linking Optic Nerve MRI and the Retinal Axonal Loss After Optic Neuritis,https://beta.clinicaltrials.gov/study/NCT03651362,UNKNOWN,Optic Neuritis,,"University Hospital, Lille",,ALL,"ADULT, OLDER_ADULT",,50,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-02,2019-02,2019-02,"Hôpital Roger Salengro, CHRU de Lille, Lille, France"
NCT00276172,Open-Label Natalizumab Safety Extension Study,https://beta.clinicaltrials.gov/study/NCT00276172,COMPLETED,Multiple Sclerosis,DRUG: Natalizumab,Biogen,,ALL,"ADULT, OLDER_ADULT",PHASE3,1615,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2003-12,2005-10,2006-01,"Performed at only C-1801, C-1802, and C-1803 sites globally. No general public enrollment. Biogen Idec is located in, Cambridge, Massachusetts, 02142, United States"
NCT01768910,Supraspinal Control of Lower Urinary Tract Function in Healthy Controls and Patients With Bladder Dysfunction,https://beta.clinicaltrials.gov/study/NCT01768910,COMPLETED,Neurogenic Lower Urinary Tract Dysfunction|Multiple Sclerosis|Overactive Bladder|Spinal Cord Injury,OTHER: fMRI|OTHER: bladder filling|OTHER: bladder cooling|OTHER: additional post-treatment fMRI scan,University of Zurich,Swiss National Science Foundation|Balgrist University Hospital,ALL,ADULT,NA,91,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2011-12,2015-07-17,2018-12,"Neuro-Urology, Spinal Cord Injury Center & Research, University of Zürich, Balgrist University Hospital, Zürich, 8008, Switzerland|University Hospital Zürich, Zürich, 8008, Switzerland"
NCT00463710,Effect of Interferon Beta-1a (Avonex®) on Changes of Non-conventional MRI Measures in Patients With MS,https://beta.clinicaltrials.gov/study/NCT00463710,COMPLETED,Multiple Sclerosis,DRUG: Avonex® monotherapy (6.0 MIU administered i.m. each week),State University of New York at Buffalo,Biogen,ALL,"ADULT, OLDER_ADULT",,150,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2005-06,,2006-09,"The Jacobs Neurological Institute, Buffalo, New York, 14127, United States"
NCT03404388,Brain and Behavioral Influences on Motor Skill Learning in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03404388,ENROLLING_BY_INVITATION,Multiple Sclerosis,BEHAVIORAL: Balance Training,Wayne State University,,ALL,"ADULT, OLDER_ADULT",NA,150,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2020-04-01,2025-01-31,2025-03-31,"Wayne State University, Detroit, Michigan, 48201, United States"
NCT04688788,Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04688788,RECRUITING,Relapsing Remitting Multiple Sclerosis|Secondary Progressive Multiple Sclerosis|Primary Progressive Multiple Sclerosis,DRUG: Rituximab|DRUG: Ocrelizumab|DRUG: Fexofenadine|DRUG: Paracetamol|DRUG: Methylprednisolone,"Rigshospitalet, Denmark","Odense University Hospital|Aarhus University Hospital|Aalborg University Hospital|Herlev Hospital|Hillerod Hospital, Denmark|Zealand University Hospital|Kolding Sygehus|Regional Hospital Holstebro|Hvidovre University Hospital|Hospital of South West Jutland, Esbjerg, Denmark|GCP unit, Copenhagen University Hospital|GCP-unit at Aarhus University Hospital, Aarhus, Denmark|Hospital of Southern Jutland, Sønderborg, Denmark|Hospital of Central Denmark Region, Viborg, Denmark|Danske Regioner",ALL,"ADULT, OLDER_ADULT",PHASE3,594,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-04-28,2025-04-28,2028-04-28,"Danish Multiple Sclerosis Center, Rigshospitalet, Glostrup, Copenhagen, 2600, Denmark|Department of Neurology, Aalborg University Hospital, Aalborg, 9000, Denmark|Department of Neurology, Aarhus University Hospital, Aarhus, 8200, Denmark|Department of Neurology, Hospital of South West Jutland, Esbjerg, Esbjerg, 6700, Denmark|Department of Neurology, Herlev Hospital, Herlev, 2730, Denmark|Department of Neurology, Nordsjællands Hospital i Hillerød, Hillerød, 3400, Denmark|Department of Neurology, Regionshospitalet Holstebro, Holstebro, 7500, Denmark|Department of Neurology, Kolding Hospital, Kolding, 6000, Denmark|Department of Neurology, Odense University Hospital, Odense, 5000, Denmark|Department of Neurology, Sjællands Universitetshospital, Roskilde, Roskilde, 4000, Denmark|Department of Neurology, Hospital of Southern Jutland, Sønderborg, Sønderborg, 6400, Denmark|Department of neurology, Regionshospitalet Viborg, Viborg, 8800, Denmark"
NCT02086188,Study of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02086188,COMPLETED,Multiple Sclerosis,DRUG: Mirabegron|DRUG: Placebo,"Theodore R. Brown, MD MPH",Astellas Pharma Inc,ALL,"ADULT, OLDER_ADULT",PHASE4,28,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2014-05,2019-04,2019-06,"EvergreenHealth MS Center, Kirkland, Washington, 98034, United States"
NCT03584672,"The Reliability, Validity, and Responsiveness of the Static Balance Test in Patients With Multiple Sclerosis.",https://beta.clinicaltrials.gov/study/NCT03584672,UNKNOWN,Multiple Sclerosis,OTHER: Static Balance Test|OTHER: Berg Balance Scale|OTHER: Timed Up an Go Test|OTHER: Four Square Step Test|OTHER: Functional Reach Test|OTHER: One-leg Stance Test,Gazi University,,ALL,"ADULT, OLDER_ADULT",,30,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-08-05,2018-08-20,2018-08-30,
NCT01392872,Cognitive Disability and Quality of Life of Patients Suffering From Multiple Sclerosis and Treatment With Immunosuppressant,https://beta.clinicaltrials.gov/study/NCT01392872,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",OTHER: Neuropsychological assessment,"University Hospital, Clermont-Ferrand","University Hospital, Bordeaux|University Hospital, Caen|University Hospital, Marseille|Dr Remy MORELLO - CHU de Caen",ALL,"ADULT, OLDER_ADULT",NA,48,OTHER,INTERVENTIONAL,"Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: ",2009-11,2016-01,2016-01,"CHU Clermont-Ferrand, Clermont-Ferrand, 63003, France"
NCT01737372,A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01737372,COMPLETED,Multiple Sclerosis|Secondary Progressive Multiple Sclerosis|Clinically Isolated Syndrome,,"John F. Foley, MD","Genzyme, a Sanofi Company",ALL,"ADULT, OLDER_ADULT",,49,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-11,2016-10,2016-10,"Rocky Mountain MS Clinic, Salt Lake City, Utah, 84103, United States"
NCT00853762,"Atacicept in Multiple Sclerosis Extension Study, Phase II",https://beta.clinicaltrials.gov/study/NCT00853762,TERMINATED,Relapsing Multiple Sclerosis,DRUG: Atacicept 25 mg|DRUG: Atacicept 75 mg|DRUG: Atacicept 150 mg|DRUG: Atacicept 150 mg,EMD Serono,"Merck KGaA, Darmstadt, Germany",ALL,ADULT,PHASE2,74,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-03,2009-09,2011-02,"Research Site, Phoenix, Arizona, United States|Research Site, Northbrook, Illinois, United States|Research Site, East Lansing, Michigan, United States|Research Site, Cleveland,, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Box Hill VIC, Australia|Research Site, Fitzroy, Australia|Research Site, New Lambton, Australia|Research Site, Woodville, Australia|Research Site, Diepenbeek, Belgium|Research Site, Sijsele, Belgium|Research Site, Calgary, Alberta, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Brno, Czech Republic|Research Site, Hradec Králové, Czech Republic|Research Site, Caen, France|Research Site, Saint-Herblain, France|Research Site, Bochum, Germany|Research Site, Düsseldorf, Germany|Research Site, Beyrouth, Lebanon|Research Site, Kaunas, Lithuania|Research Site, Breda, Netherlands|Research Site, Nieuwegein, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Winston Salem, New Caledonia|Research Site, Ekaterinburg, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Samara, Russian Federation|Research Site, Vladimir, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Malaga, Spain|Research Site, Stockholm, Sweden|Research Site, Basel, Switzerland|Research Site, Innsbruck, Switzerland|Research Site, Zürich, Switzerland|Research Site, Kharkiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Odessa, Ukraine|Research Site, Uzhgorod, Ukraine|Research Site, London, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Stoke on Trent, United Kingdom"
NCT01424462,Healthy Volunteer Pilot Study Using 3 Types of Modified Release Formulations of Firategrast to Investigate How Quickly Absorption From the Digestive System Takes Place.,https://beta.clinicaltrials.gov/study/NCT01424462,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: A|DRUG: B|DRUG: C|DRUG: D,GlaxoSmithKline,,ALL,"ADULT, OLDER_ADULT",PHASE1,20,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2010-04-19,2010-07-06,2010-07-06,"GSK Investigational Site, Randwick, New South Wales, 2031, Australia"
NCT03963310,Optical Coherence Tomography and Optic Neuritis Not Related to Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03963310,RECRUITING,Optic Neuritis,,Fondation Ophtalmologique Adolphe de Rothschild,,ALL,"ADULT, OLDER_ADULT",,60,NETWORK,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-09-14,2024-09-14,2024-09-14,"Fondation A. de Rothschild, Paris, 75019, France"
NCT02522962,Innovative Physiotherapy and Coordination of Care for People With MS: a RCT and a Qualitative Study,https://beta.clinicaltrials.gov/study/NCT02522962,UNKNOWN,Multiple Sclerosis,BEHAVIORAL: GroupCoreSIT|BEHAVIORAL: Standard care,Nordlandssykehuset HF,Helse Nord|University of Tromso|University Hospital of North Norway|Hasselt University|University of Memphis,ALL,"ADULT, OLDER_ADULT",NA,80,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2015-09,2016-09,2019-12,"Physiotherapy department, Nordlandssykehuset HF, Bodø, Norway"
NCT03424538,"The Effect of Neurorehabilitation Therapy on Postural Control, Mobility and Quality of Life in Multiple Sclerosis Patients",https://beta.clinicaltrials.gov/study/NCT03424538,COMPLETED,"Multiple Sclerosis, Chronic Progressive|Multiple Sclerosis, Primary Progressive",OTHER: Neurorehabilitation|OTHER: Physiotherapy,Somogy Megyei Kaposi Mór Teaching Hospital,University Medical Center Groningen,ALL,ADULT,NA,2,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2018-02-05,2018-04-16,2018-06-10,"Somogy Megyei Kaposi Mór Teaching Hospital, Kaposvár, Somogy, 7400, Hungary"
NCT00333138,Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00333138,COMPLETED,Multiple Sclerosis,DRUG: FTY720|DRUG: Placebo,Novartis,,ALL,ADULT,PHASE2,281,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2003-05,2011-04,2011-04,"Novartis Investigational site, Montreal, Canada|Novartis Investigational site, Ottawa, Canada|Novartis Investigational site, Toronto, Canada|Novartis Investigational site, Vancouver, Canada|Novartis Investigational site, Copenhagen, Denmark|Novartis Investigational site, Helsinki, Finland|Novartis Investigational site, Turku, Finland|Novartis Investigational site, Lille, France|Novartis Investigational site, Marseille, France|Novartis Investigational site, Schwendi, Germany|Novartis Investigational site, Wurzburg, Germany|Novartis Investigational site, Gallarate, Italy|Novartis Investigational site, Genova, Italy|Novartis Investigational site, Milano, Italy|Novartis Investigational site, Roma, Italy|Novartis Investigational site, Warszawa, Poland|Novartis Investigational site, Coimbra, Portugal|Novartis Investigational site, Lisboa, Portugal|Novartis Investigational site, Barcelona, Spain|Novartis Investigational site, Madrid, Spain|Novartis Investigational site, Malaga, Spain|Novartis Investigational site, Sevilla, Spain|Novartis Investigational site, Valencia, Spain|Novartis Investigational site, Basel, Switzerland|Novartis Investigational site, Zurich, Switzerland|Novartis Investigational site, Newcastle upon Tyne, United Kingdom"
NCT00861172,"Longitudinal (Weekly) Follow-up of Active Plaques in Multiple Sclerosis With 3 Teslas Multi-modality MRI Using Diffusion, Perfusion, Venography and Proton Spectroscopy",https://beta.clinicaltrials.gov/study/NCT00861172,COMPLETED,Lesions|Multiple Sclerosis,PROCEDURE: 3T MR scanner,Hospices Civils de Lyon,,ALL,ADULT,NA,6,OTHER,INTERVENTIONAL,"Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: ",2009-02,2012-07,2012-07,"Services de Neurologie A et Service de Neuroradiologie, Pôle transversal d'imagerie, Hôpital Neurologique, BRON Cedex, 69677, France"
NCT01436838,"China Betaferon Adherence, Coping and Nurse Support Study",https://beta.clinicaltrials.gov/study/NCT01436838,COMPLETED,"Multiple Sclerosis, Chronic Progressive","DRUG: Interferon beta-1b (Betaseron, BAY86-5046)",Bayer,,ALL,"ADULT, OLDER_ADULT",,110,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-03,2015-09,2015-12,"Many locations, China"
NCT03689972,"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration",https://beta.clinicaltrials.gov/study/NCT03689972,ACTIVE_NOT_RECRUITING,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Natalizumab,Biogen,,ALL,ADULT,PHASE3,500,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2018-12-26,2023-01-31,2023-07-28,"Research Site, Cullman, Alabama, 35058, United States|Research Site, Homewood, Alabama, 35209, United States|Research Site, Irvine, California, 92697, United States|Research Site, La Jolla, California, 92037, United States|Research Site, Newport Beach, California, 92663, United States|Research Site, Palo Alto, California, 94304, United States|Research Site, Aurora, Colorado, 80045, United States|Research Site, Fort Collins, Colorado, 80528, United States|Research Site, Fairfield, Connecticut, 06824, United States|Research Site, Miami, Florida, 33136, United States|Research Site, Sunrise, Florida, 33351, United States|Research Site, Tampa, Florida, 33612, United States|Research Site, Atlanta, Georgia, 30309, United States|Research Site, Atlanta, Georgia, 30327, United States|Research Site, Chicago, Illinois, 60611, United States|Research Site, Glenview, Illinois, 60026, United States|Research Site, Overland Park, Kansas, 66212, United States|Research Site, Boston, Massachusetts, 02215, United States|Research Site, Foxboro, Massachusetts, 02035, United States|Research Site, Lexington, Massachusetts, 02421, United States|Research Site, Wellesley, Massachusetts, 02481, United States|Research Site, Farmington Hills, Michigan, 48334, United States|Research Site, Owosso, Michigan, 48867, United States|Research Site, Golden Valley, Minnesota, 55422, United States|Research Site, Saint Louis, Missouri, 63110, United States|Research Site, Las Vegas, Nevada, 89101, United States|Research Site, Livingston, New Jersey, 07039, United States|Research Site, Teaneck, New Jersey, 07666, United States|Research Site, New York, New York, 10016, United States|Research Site, New York, New York, 10029, United States|Research Site, New York, New York, 10032, United States|Research Site, Patchogue, New York, 11772, United States|Research Site, Raleigh, North Carolina, 27607-6010, United States|Research Site, Winston-Salem, North Carolina, 27157, United States|Research Site, Cleveland, Ohio, 44195, United States|Research Site, Dayton, Ohio, 45417, United States|Research Site, Dayton, Ohio, 45459, United States|Research Site, Portland, Oregon, 97225, United States|Research Site, Philadelphia, Pennsylvania, 19107, United States|Research Site, Pittsburgh, Pennsylvania, 15213, United States|Research Site, Knoxville, Tennessee, 37934, United States|Research Site, Nashville, Tennessee, 37215, United States|Research Site, Round Rock, Texas, 78681, United States|Research Site, Salt Lake City, Utah, 84103, United States|Research Site, Charlottesville, Virginia, 22903, United States|Research Site, Vienna, Virginia, 22182, United States|Research Site, Seattle, Washington, 98101, United States|Research Site, Milwaukee, Wisconsin, 53215, United States|Research Site, St Leonards, New South Wales, 2065, Australia|Research Site, Sydney, New South Wales, 2050, Australia|Research Site, Box Hill, Victoria, 3128, Australia|Research Site, Melbourne, Victoria, 3004, Australia|Research Site, Parkville, Victoria, 3050, Australia|Research Site, Bruxelles, 1070, Belgium|Research Site, Bruxelles, 1200, Belgium|Research Site, Edegem, 2650, Belgium|Research Site, La Louvière, 7100, Belgium|Research Site, Toronto, Ontario, M5B 1W8, Canada|Research Site, Gatineau, Quebec, J8Y 1W2, Canada|Research Site, Greenfield Park, Quebec, J4V 2J2, Canada|Research Site, Montreal, Quebec, H2X 0A9, Canada|Research Site, Montreal, Quebec, H3A 3B4, Canada|Research Site, Bordeaux, 33076, France|Reseach Site, Caen, 14033, France|Research Site, Lille, 59037, France|Research Site, Nice, 06002, France|Research Site, Saint Herblain, 44800, France|Research Site, Strasbourg, 67091, France|Research Site, Bamberg, 96052, Germany|Research Site, Berlin, 10117, Germany|Research Site, Bochum, 44791, Germany|Research Site, Erbach, 64711, Germany|Research Site, Essen, 45147, Germany|Research Site, Freiburg, 79106, Germany|Research Site, Marburg, 35043, Germany|Research Site, Muenster, 48149, Germany|Research Site, Munich, 81675, Germany|Research Site, Stuttgart, 70182, Germany|Research Site, Ramat Gan, 52363, Israel|Research Site, Catania, 95123, Italy|Research Site, Cefalù, 90015, Italy|Research Site, Milano, 20123, Italy|Research Site, Napoli, 80131, Italy|Research Site, Pozzilli, 86077, Italy|Research Site, Breda, 4818 CK, Netherlands|Research Site, Nieuwegein, 3435 CM, Netherlands|Research Site, Sittard, 6162 BG, Netherlands|Research Site, Lleida, Catalonia, 25198, Spain|Research Site, El Palmar, Murcia, 30120, Spain|Research Site, Madrid, 28034, Spain|Research Site, Malaga, 29010, Spain|Research Site, Sevilla, 41009, Spain|Research Site, London, W6 8RF, United Kingdom|Research Site, Nottingham, NG7 2UH, United Kingdom|Research Site, Salford, M6 8HD, United Kingdom|Research Site, Sheffield, S10 2JF, United Kingdom|Research Site, Swansea, SA6 6NL, United Kingdom"
NCT02638038,This is a Randomized Study Comparing Two Doses of INT131 ( 3 mg and 1 mg) Administered Orally (PO) Daily (QD) Versus Placebo 1 Tablet PO QD in Subjects With Treatment-naïve RRMS for ≤ 3 Years,https://beta.clinicaltrials.gov/study/NCT02638038,COMPLETED,"Multiple Sclerosis, Relapsing Remitting",DRUG: INT131,"InteKrin Therapeutics, Inc.",,ALL,ADULT,PHASE2,228,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2015-02,2016-12-12,2016-12-12,
NCT03968172,Interactive Web Platform for EmPOWERment in Early Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03968172,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,BEHAVIORAL: EBBC programme|BEHAVIORAL: Control group programme,Universitätsklinikum Hamburg-Eppendorf,"Charite University, Berlin, Germany|University of Cologne|University Medical Center Goettingen|Heinrich-Heine University, Duesseldorf|Gaia AG|BKK Dachverband e.V.|Deutsche Multiple Sklerose Gesellschaft (DMSG)|Deutsche Multiple Sklerose Gesellschaft (DMSG) Landesverband Berlin e.V.",ALL,"ADULT, OLDER_ADULT",NA,234,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2019-07-01,2023-03-31,2023-03-31,"Universitätsklinikum Hamburg-Eppendorf, Hamburg, 20246, Germany"
NCT05171972,Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment,https://beta.clinicaltrials.gov/study/NCT05171972,RECRUITING,Relapsing Remitting Multiple Sclerosis,DRUG: Ofatumumab,University of Southern California,Novartis Pharmaceuticals,ALL,"ADULT, OLDER_ADULT",,40,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-01-29,2023-06,2023-12,"University of Southern California, Los Angeles, California, 90089, United States"
NCT02776072,Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS),https://beta.clinicaltrials.gov/study/NCT02776072,COMPLETED,Multiple Sclerosis,,Biogen,,ALL,"ADULT, OLDER_ADULT",,2978,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-05,2016-12,2016-12,"Research Site, Homewood, Alabama, 35209, United States|Research Site, Gilbert, Arizona, 85234, United States|Research Site, Hanford, California, 93230, United States|Research Site, Modesto, California, 95355, United States|Research Site, Santa Ana, California, 92704, United States|Research Site, Aurora, Colorado, 80045, United States|Research Site, Danbury, Connecticut, 06810, United States|Research Site, Hartford, Connecticut, 6112, United States|Research Site, Jacksonville, Florida, 32256, United States|Research Site, Port Orange, Florida, 32127, United States|Research Site, Savannah, Georgia, 31406, United States|Research Site, Avon, Indiana, 46123, United States|Research Site, Franklin, Indiana, 46131, United States|Research Site, Muncie, Indiana, 47304, United States|Research Site, Overland Park, Kansas, 66212, United States|Research Site, Boston, Massachusetts, 02135, United States|Research Site, Boston, Massachusetts, 02215, United States|Research Site, Wellesley, Massachusetts, 02481, United States|Research Site, Golden Valley, Minnesota, 55422, United States|Research Site, Amherst, New York, 14226, United States|Research Site, New Hyde park, New York, 11042, United States|Research Site, New York, New York, 10019, United States|Research Site, Patchogue, New York, 11772, United States|Research Site, Raleigh, North Carolina, 27607-6010, United States|Research Site, Cleveland, Ohio, 44195, United States|Research Site, Columbus, Ohio, 43210, United States|Research Site, Columbus, Ohio, 43221, United States|Research Site, Medford, Oregon, 97504, United States|Research Site, Portland, Oregon, 97225, United States|Research Site, Philadelphia, Pennsylvania, 19107, United States|Research Site, Pittsburgh, Pennsylvania, 15212, United States|Research Site, Dallas, Texas, 75246, United States|Research Site, Houston, Texas, 77018, United States|Research Site, Mansfield, Texas, 76063, United States|Research Site, Round Rock, Texas, 78681, United States|Research Site, Salt Lake City, Utah, 84103, United States|Research Site, Norfolk, Virginia, 23502, United States|Research Site, Tacoma, Washington, 98405, United States|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, C1061ABD, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, C1425DKT, Argentina|Research Site, Rosario, Santa Fe, 2000, Argentina|Research Site, Rosario, Santa Fe, S20000, Argentina|Research Site, Ciudad Autonoma Buenos Aires, C1428AQK, Argentina|Research Site, Cordoba, X5000JHQ, Argentina|Research Site, Salta, 4400, Argentina|Research Site, New Lambton Heights, New South Wales, 2305, Australia|Research Site, Box Hill, Victoria, 3128, Australia|Research Site, Heidelberg, Victoria, 3084, Australia|Research Site, Melbourne, Victoria, 3050, Australia|Research Site, Burnaby, British Columbia, V5H 4K7, Canada|Research Site, St. John, New Brunswick, E2L4L2, Canada|Research Site, Halifax, Nova Scotia, B3H4K4, Canada|Research Site, Cambridge, Ontario, N1R7L6, Canada|Research Site, Guelph, Ontario, N1H 4J4, Canada|Research Site, Chicoutimi, Quebec, G7H 5H6, Canada|Research Site, Gatineau, Quebec, J9J 0A5, Canada|Research Site, Greenfield Park, Quebec, J4V 2J2, Canada|Research Site, Osijek, 31000, Croatia|Research Site, Varazdin, 42000, Croatia|Research Site, Brno, 656 91, Czech Republic|Research Site, Hradec Kralove, 500 05, Czech Republic|Research Site, Hradec Kralove, 50003, Czech Republic|Research Site, Jihlava, 58633, Czech Republic|Research Site, Olomouc, 775 20, Czech Republic|Research Site, Ostrava-Poruba, 70800, Czech Republic|Research Site, Pardubice, 532 03, Czech Republic|Research Site, Prague 5, 150 06, Czech Republic|Research Site, Teplice, 41501, Czech Republic|Research Site, Libourne Cedex, Gironde, 33505, France|Research Site, Toulouse cedex 9, Haute Garonne, 31059, France|Research Site, Le Mans cedex 9, Sarthe, 72037, France|Research Site, Le Chesnay Cedex, Yvelines, 78157, France|Research Site, Freiburg, Baden Wuerttemberg, 79098, Germany|Research Site, Pforzheim, Baden Wuerttemberg, 75172, Germany|Research Site, Stuttgart, Baden Wuerttemberg, 70182, Germany|Research Site, Bamberg, Bayern, 96052, Germany|Research Site, Potsdam, Brandenburg, 14471, Germany|Research Site, Kassel, Hessen, 34121, Germany|Research Site, Oldenburg, Niedersachsen, 26122, Germany|Research Site, Osnabrueck, Niedersachsen, 49076, Germany|Research Site, Stade, Niedersachsen, 21682, Germany|Research Site, Bochum, Nordrhein Westfalen, 44787, Germany|Research Site, Düsseldorf, Nordrhein Westfalen, 40211, Germany|Research Site, Gelsenkirchen, Nordrhein Westfalen, 45879, Germany|Research Site, Hagen, Nordrhein Westfalen, 58095, Germany|Research Site, Siegen, Nordrhein Westfalen, 57076, Germany|Research Site, Sprockhoevel, Nordrhein Westfalen, 45549, Germany|Research Site, Kandel, Rheinland Pfalz, 76870, Germany|Research Site, St. Ingbert, Saarland, 66386, Germany|Research Site, Leipzig, Sachsen, 04229, Germany|Research Site, Kiel, Schleswig Holstein, 24105, Germany|Research Site, Berlin, 10961, Germany|Research Site, Berlin, 12099, Germany|Research Site, Hamburg, 20249, Germany|Research Site, Budapest, 1083, Hungary|Research Site, Debrecen, 4032, Hungary|Research Site, Eger, 3300, Hungary|Research Site, Esztergom, 2500, Hungary|Research Site, Kecskemet, 6000, Hungary|Research Site, Nyiregyhaza, 4400, Hungary|Research Site, Cagliari, 09126, Italy|Research Site, Catania, 95123, Italy|Research Site, Napoli, 80131, Italy|Research Site, Napoli, 80138, Italy|Research Site, Badalona, Barcelona, 08916, Spain|Research Site, Santiago de Compostela, La Coruña, 15706, Spain|Research Site, Vigo, Pontevedra, 36312, Spain|Research Site, Alicante, 03010, Spain|Research Site, Cordoba, 14011, Spain|Research Site, Madrid, 28007, Spain|Research Site, Malaga, 29010, Spain|Research Site, Sevilla, 41071, Spain|Research Site, Lausanne, CH-1011, Switzerland|Research Site, Lugano, 6903, Switzerland|Research Site, Truro, Cornwall, TR1 3LJ, United Kingdom|Research Site, Exeter, Devon, EX2 5DW, United Kingdom|Research Site, Chelmsford, Essex, CM1 7ET, United Kingdom|Research Site, Romford, Essex, RM7 0AG, United Kingdom|Research Site, London, Greater London, SW17 0QT, United Kingdom|Research Site, Glasgow, Strathclyde, G51 4TF, United Kingdom|Research Site, Chertsey, Surrey, KT16 0PZ, United Kingdom"
NCT05730738,Dalfampridine in Egyptian Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05730738,RECRUITING,Multiple Sclerosis,"DRUG: Dalfampridine ER, 10 Mg Oral Tablet, Extended Release|DRUG: Placebo",Ain Shams University,,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-06-01,2023-12-01,2024-12-01,"Ain Shams Univeristy, Cairo, 11591, Egypt"
NCT00078338,Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00078338,COMPLETED,Relapsing-remitting Multiple Sclerosis,DRUG: Rebif®|DRUG: Copaxone®,EMD Serono,Pfizer,ALL,ADULT,PHASE4,764,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2004-02-16,2006-11-28,2006-11-28,"University of Alabama at Birmingham, Birmingham, Alabama, 35249, United States|Barrow Neurology Clinics, Phoenix, Arizona, 85013, United States|Northwest NeuroSpecialists, Tucson, Arizona, 85741, United States|University of California, Davis, Sacramento, California, 95817, United States|Kaiser Permanente Neurology, San Diego, California, 92102, United States|Advanced Neurology of Colorado, LLC, Fort Collins, Colorado, 80528, United States|The MS Treatment Center at Griffin Hospital, Derby, Connecticut, 06418, United States|Associated Neurologists of Southern Connecticut, P.C., Fairfield, Connecticut, 06824, United States|Neurological Center of South Florida, Miami, Florida, 33176, United States|Harbourside Medical Plaza, Tampa, Florida, 33606, United States|Shepherd Center, Atlanta, Georgia, 30309, United States|University Chicago Hospitals, Chicago, Illinois, 60619, United States|Consultants In Neurology, Ltd., Northbrook, Illinois, 60062, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, 46805, United States|University of Maryland MD Center for MS, Baltimore, Maryland, 21201, United States|University Of Michigan, Ann Arbor, Michigan, 48109, United States|Wayne State University, Detroit, Michigan, 48201, United States|Henry Ford Hospital Dept of Neurology, Detroit, Michigan, 48202, United States|The Minneapolis Clinic of Neurology, Golden Valley, Minnesota, 55422, United States|University of Minnesota Medical School, Dept of Neurology, Minneapolis, Minnesota, 55455, United States|Nevada Neurological Consultants, Henderson, Nevada, 89052, United States|Albany Medical College Dept of Neurology MC-70, Albany, New York, 12208, United States|Neurology University of Rochester, Rochester, New York, 14642, United States|SUNY At Stony Brook U Hospital - Department of Neurology, Stony Brook, New York, 11794, United States|SUNY Upstate Medical University Dept of Neurology, Syracuse, New York, 13210, United States|MS Center/CHS, Charlotte, North Carolina, 28207, United States|Wake Forest Univ. Health Sciences, Winston-Salem, North Carolina, 27157, United States|Ohio State University, Columbus, Ohio, 43210, United States|Oak Clinic for Multiple Sclerosis, Uniontown, Ohio, 44685, United States|Medford Neurological and Spine Clinic, Medford, Oregon, 97504, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|Thomas Jefferson University Physicians Dept of Neurology, Philadelphia, Pennsylvania, 19107, United States|Baptist West Hospital, Knoxville, Tennessee, 37922, United States|University of Texas-Houston, Houston, Texas, 77030, United States|Central Texas Neurology, Round Rock, Texas, 78681, United States|Neurology Health Care Service / Fletcher Allen Health Care, Burlington, Vermont, 05401, United States|Neurology Center of Fairfax, Fairfax, Virginia, 22031, United States|Blue Ridge Research Center, Roanoke, Virginia, 24014, United States|Minor & James Medical, PLLC, Seattle, Washington, 98104, United States|CAMC Institute, Charleston, West Virginia, 25304, United States|Center for Neurological Disorders, Milwaukee, Wisconsin, 53215, United States|Servicio de Neurologia, Buenos Aires, 1221, Argentina|Departmento Enfermedades Desmielinizantes, Buenos Aires, 1428, Argentina|Servicio de Neurologia Departmento Enfermedades Desmielinizantes, Buenos Aires, C118ACH, Argentina|Seccion Neurolgia Instituto INEBA, Buenos Aires, C1192AAW, Argentina|Fundacion Rosarina de Neurorehabilitacion, Rosario, CP 2000, Argentina|Dept Neurologia Sanatorio Britanico de Rosario, Rosario, Argentina|OO Landes-Nervenklinik, Linz, 4020, Austria|Campus Ribeirao Preto Faculdade de Medicina de Sao Paolo, Riberao Preto-SP, 14048-900, Brazil|Dept of Neurology CHU Timone, Marseille, 13385, France|Hopital Pontchaillou, Rennes cedex, 35033, France|Dept of Neurology Johannes Gutenberg University, Mainz, 55131, Germany|Dept of Neurology Universitatsklinikum Munster, Munster, 48149, Germany|Dept of Neurological and Psychiatric Sciences University of Bari, Bari, 70124, Italy|Dept of Neurosciences Oftamology and Genetics Univ of Genoa, Genoa, 16132, Italy|Dept Neurology Ospedale San Raffaele, Milan, Italy|Dept of Neurological Sciences University La Sapienza Rome, Rome, 00185, Italy|Academisch Ziekenhuis Vrije Universiteit, Amsterdam, 1081, Netherlands|MS Center Nijmegen, Nijmegen, 6533 PA, Netherlands|City Clinical Hospital No 83, Moscow, 115682, Russian Federation|Dept Of Neurology and Neurosurgery, Russian State Med Univ, Moscow, 117049, Russian Federation|State Instituion Central Clinical Milatary Hospital, Moscow, 123182, Russian Federation|Scientific Research Center of Neurology Russian MOH, Moscow, 125367, Russian Federation|Department of Neurology City Hospital #33, Nizhniy Novgorod, 603076, Russian Federation|Institute of Clinical Immunology RAMS, Novosibirsk, 630099, Russian Federation|Military Medical Academy, Saint-Petersburg, 194044, Russian Federation|Dept of Neurology St Petersburg State Medical University, St Petersburg, 197022, Russian Federation|Dept of MS Institute for Human Brain of R.A.Sci, St Petersburg, 197376, Russian Federation|Dept of Neurology Medical Clinic of Russian MoH, St Petersburg, Russian Federation|Chair of Nuerological Diseases and Medical Genetics, Yaroslavl, 150030, Russian Federation|Neuroinmunologia Clinica Hospital Vall d'Hebron, Barcelona, 08035, Spain|Servicio de Neurologia Hospital Bellvitge, Hospitalet de Llobregat, 08907, Spain|Neurologia Hospital Carlos Haya, Malaga, 29010, Spain|Unidad de EM Neurologia Hospital Virgen Macarena, Sevilla, 41009, Spain|Dept Of Neurology, Zurich, 8091, Switzerland|Department of Neurology, Whitechapel, London, E1 1BB, United Kingdom|Department Of Neurology Royal London Hospital, London, E1 1BB, United Kingdom|Royal Victoria Infirmary, Newcastle upon Tyne, NE1 4LP, United Kingdom|Div of Clinical Neurology B Floor Medical School Univ Hospital, Nottingham, NG7 2UH, United Kingdom|Division of Clinical Neurology Medical School Universtity Hopsital, Nottingham, NG7 2UH, United Kingdom"
NCT04807738,Virtual Reality in Physical Therapy in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04807738,RECRUITING,Multiple Sclerosis,"DEVICE: Neuroproprioceptive ""facilitation and inhibition"" in virtual reality|OTHER: Neuroproprioceptive ""facilitation and inhibition""","Charles University, Czech Republic",,ALL,ADULT,NA,110,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2021-04-01,2025-04,2025-07,"Department of neurology, Prague, 100 00, Czechia|Deparment of revmatology and rehabilitation, Prague, 140 59, Czechia"
NCT03471338,Neuropsychological Management of Multiple Sclerosis: Benefits of a Computerised Semi-autonomous At-home Cognitive Rehabilitation Programme,https://beta.clinicaltrials.gov/study/NCT03471338,RECRUITING,Relapsing Remitting Multiple Sclerosis|Secondary Progressive Multiple Sclerosis,BEHAVIORAL: Cognitive rehabilitation|BEHAVIORAL: Standard Psychological care,"University Hospital, Caen",,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: OTHER,2017-10-31,2023-06-30,2023-06-30,"University Hospital of Caen, Caen, Calvados, 14000, France"
NCT04415372,Macromolecular Imaging of White and Gray Matter Pathology in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04415372,RECRUITING,Multiple Sclerosis|MS,DIAGNOSTIC_TEST: MRI|DIAGNOSTIC_TEST: Neuropsychological Testing,"University of Wisconsin, Madison",National Institute for Biomedical Imaging and Bioengineering (NIBIB),ALL,ADULT,,75,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-11-19,2025-04,2027-04,"University of Wisconsin, Madison, Madison, Wisconsin, 53705, United States"
NCT01610310,Peginterferon Beta-1a (BIIB017) Autoinjector Pharmacokinetic Study in Healthy Volunteers,https://beta.clinicaltrials.gov/study/NCT01610310,COMPLETED,Healthy|Multiple Sclerosis,DEVICE: BIIB017 (peginterferon beta-1a) Pre-filled syringe (PFS)|DEVICE: BIIB017 (peginterferon beta-1a) Autoinjector,Biogen,,ALL,ADULT,PHASE1,55,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2012-06,2012-10,2012-10,"Research Site, St. Paul, Minnesota, United States"
NCT03853746,Short-term B-cell Depletion in Relapsing Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03853746,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,DRUG: Ocrelizumab,Johns Hopkins University,National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",PHASE4,10,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2019-04-01,2024-03,2024-08,"Johns Hopkins University, Baltimore, Maryland, 21287, United States"
NCT02490046,D-mannose for the Prevention of UTIs in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02490046,UNKNOWN,Multiple Sclerosis|Recurrent Urinary Tract Infections,DIETARY_SUPPLEMENT: D Mannose,"University College, London",UCLH,ALL,"ADULT, OLDER_ADULT",PHASE1,20,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2015-02,2015-10,2015-11,"The National Hospital for Neurology and Neurosurgery, London, WC1N 3BG, United Kingdom"
NCT01497262,Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01497262,COMPLETED,Multiple Sclerosis,DRUG: Fingolimod,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,162,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2012-02,2014-04,2014-04,"Novartis Investigative Site, Caba, Buenos Aires, 1425, Argentina|Novartis Investigative Site, Guaymallen, Mendoza, M5507XAD, Argentina|Novartis Investigative Site, San Miguel de Tucuman, Tucumán, T4000DPB, Argentina|Novartis Investigative Site, San Miguel de Tucumán, Tucumán, 4000, Argentina|Novartis Investigative Site, Cordoba, X5004CDT, Argentina|Novartis Investigative Site, Salta, A4400ANG, Argentina|Novartis Investigative Site, Salta, A4400BKZ, Argentina|Novartis Investigative Site, Rio de Janeiro, RJ, 20270-004, Brazil|Novartis Investigative Site, Rio de Janeiro, RJ, 21941-590, Brazil|Novartis Investigative Site, Porto Alegre, RS, 90610-000, Brazil|Novartis Investigative Site, Barranquilla, Atlantico, Colombia|Novartis Investigative Site, Bogotá, Cundinamarca, 110111, Colombia|Novartis Investigative Site, Bogotá, 00000, Colombia|Novartis Investigative Site, Bogotá, Colombia|Novartis Investigative Site, Cali, Colombia|Novartis Investigative Site, Amman, 11942, Jordan|Novartis Investigative Site, Irbid, 22110, Jordan|Novartis Investigative Site, Kuala Lumpur, 50586, Malaysia|Novartis Investigative Site, Kuala Lumpur, 59100, Malaysia|Novartis Investigative Site, Penang, 10990, Malaysia|Novartis Investigative Site, Mexico, Distrito Federal, 06700, Mexico|Novartis Investigative Site, México, Distrito Federal, 10700, Mexico|Novartis Investigative Site, Monterrey, Nuevo León, 64060, Mexico|Novartis Investigative Site, San Nicolas De Los Garza, Nuevo León, 66480, Mexico|Novartis Investigative Site, San Luis Potosí, 78240, Mexico|Novartis Investigative Site, Panama City, Panamá, Panama|Novartis Investigative Site, La Perla, Callao, 04, Peru|Novartis Investigative Site, Jesus Maria, Lima, 11, Peru|Novartis Investigative Site, San Isidro, Lima, 27, Peru"
NCT02247310,BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon,https://beta.clinicaltrials.gov/study/NCT02247310,COMPLETED,"Multiple Sclerosis, Relapsing Remitting","DRUG: Interferon beta-1b (Betaferon®, BAY 86-5046)|DEVICE: BETACONNECT",Bayer,,ALL,"CHILD, ADULT, OLDER_ADULT",,498,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-10-20,2016-07-19,2016-11-08,"Many locations, Austria|Many locations, Belgium|Many Locations, Bosnia and Herzegovina|Many locations, Croatia|Many Locations, Czechia|Many locations, France|Many locations, Greece|Many locations, Hungary|Many locations, Italy|Many locations, Spain|Many locations, Switzerland"
NCT02296346,Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02296346,TERMINATED,Secondary Progressive Multiple Sclerosis,DRUG: SoluMedrol|DEVICE: Extracorporeal Photopheresis,University of Utah,Mallinckrodt,ALL,"ADULT, OLDER_ADULT",NA,13,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-10,2017-06-13,2018-05-10,"University of Michigan Health Systems, Ann Arbor, Michigan, 48109, United States"
NCT01713946,A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures,https://beta.clinicaltrials.gov/study/NCT01713946,COMPLETED,Tuberous Sclerosis Complex-associated Refractory Seizures,DRUG: RAD001|DRUG: Placebo|DRUG: Antiepileptic drug (1 to 3 only)|DRUG: open label RAD001 (only used for post-extension phase),Novartis Pharmaceuticals,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,366,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-04-29,2017-10-25,2017-10-25,"University of Alabama at Birmingham SC, Birmingham, Alabama, 35294, United States|TGen/APNNA, Phoenix, Arizona, 85012, United States|University of California at Los Angeles SC, Los Angeles, California, 90095, United States|Children's Hospital Oakland SC, Oakland, California, 94609, United States|Children's Hospital of Orange County SC, Orange, California, 92868-3874, United States|Rady Children's Hospital SC, San Diego, California, 92123, United States|Children's Hospital Colorado, Aurora, Colorado, 80045, United States|Connecticut Childrens Medical Center SC, Hartford, Connecticut, 06106, United States|University of Chicago SC - 2, Chicago, Illinois, 60637, United States|Kennedy Krieger Institute SC, Baltimore, Maryland, 21205, United States|Children's Hospital Boston SC, Boston, Massachusetts, 02115, United States|Minnesota Epilepsy Group - PA SC, Saint Paul, Minnesota, 55102-2383, United States|Washington University School of Medicine SC-2, Saint Louis, Missouri, 63110, United States|Morristown Memorial Hospital SC-2, Morristown, New Jersey, 07962, United States|New York University Medical Center SC-3, New York, New York, 10016, United States|Cincinnati Children's Hospital Medical Center SC, Cincinnati, Ohio, 45229-3039, United States|Oregon Health and Science University SC - 3, Portland, Oregon, 97239, United States|Children's Hospital of Philadelphia SC, Philadelphia, Pennsylvania, 19104-4399, United States|LeBonheur Childrens Medical Group SC, Memphis, Tennessee, 38103, United States|Texas Scottish Rite Hospital for Children Texas Scottish, Dallas, Texas, 75219, United States|Texas Children s Hospital SC, Houston, Texas, 77030, United States|The University of Texas Medical School-Houston SC, Houston, Texas, 77030, United States|Novartis Investigative Site, Caba, Buenos Aires, C1428AQK, Argentina|Novartis Investigative Site, Cordoba, X5000JJS, Argentina|Novartis Investigative Site, Randwick, New South Wales, 2031, Australia|Novartis Investigative Site, Parkville, Victoria, 3052, Australia|Novartis Investigative Site, Perth, Western Australia, 6840, Australia|Novartis Investigative Site, Jette, Brussel, 1090, Belgium|Novartis Investigative Site, Bruxelles, 1070, Belgium|Novartis Investigative Site, Bruxelles, 1200, Belgium|Novartis Investigative Site, Gent, 9000, Belgium|Novartis Investigative Site, Leuven, 3000, Belgium|Novartis Investigative Site, Vancouver, British Columbia, V6H 3V4, Canada|Novartis Investigative Site, Montreal, Quebec, H3T 1C5, Canada|Novartis Investigative Site, Cali, Valle Del Cauca, Colombia|Novartis Investigative Site, Bogotá, Colombia|Novartis Investigative Site, Medellín, Colombia|Novartis Investigative Site, Aarhus, 8000 C, Denmark|Novartis Investigative Site, Amiens Cedex 1, 80054, France|Novartis Investigative Site, Angers cedex 09, 49933, France|Novartis Investigative Site, Bron Cedex, 69677, France|Novartis Investigative Site, Lille Cedex, 59037, France|Novartis Investigative Site, Marseille, 13385, France|Novartis Investigative Site, Strasbourg Cedex, F-67098, France|Novartis Investigative Site, Berlin, 12351, Germany|Novartis Investigative Site, Bielefeld, 33617, Germany|Novartis Investigative Site, Kehl-Kork, 77694, Germany|Novartis Investigative Site, Kiel, 24105, Germany|Novartis Investigative Site, Ioannina, GR, 455 00, Greece|Novartis Investigative Site, Athens, 15236, Greece|Novartis Investigative Site, Budapest, 1145, Hungary|Novartis Investigative Site, Kaposvar, 7400, Hungary|Novartis Investigative Site, Nyiregyhaza, 4400, Hungary|Novartis Investigative Site, Dublin, 12, Ireland|Novartis Investigative Site, Bari, BA, 70124, Italy|Novartis Investigative Site, Bologna, BO, 40133, Italy|Novartis Investigative Site, Catania, CT, 95100, Italy|Novartis Investigative Site, Genova, GE, 16147, Italy|Novartis Investigative Site, Milano, MI, 20142, Italy|Novartis Investigative Site, Pavia, PV, 27100, Italy|Novartis Investigative Site, Roma, RM, 00161, Italy|Novartis Investigative Site, Siena, SI, 53100, Italy|Novartis Investigative Site, Okayama-city, Okayama, 700-8558, Japan|Novartis Investigative Site, Izumi-city, Osaka, 594-1101, Japan|Novartis Investigative Site, Suita-city, Osaka, 565 0871, Japan|Novartis Investigative Site, Shizuoka-city, Shizuoka, 420-8688, Japan|Novartis Investigative Site, Setagaya-ku, Tokyo, 157-8535, Japan|Novartis Investigative Site, Osaka, 534-0021, Japan|Novartis Investigative Site, Seoul, Korea, 03080, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, 05505, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, 06351, Korea, Republic of|Novartis Investigative Site, Seoul, 03722, Korea, Republic of|Novartis Investigative Site, Guadalajara, Jalisco, 44280, Mexico|Novartis Investigative Site, Heeze, 5591 VE, Netherlands|Novartis Investigative Site, Rotterdam, 3015 CN, Netherlands|Novartis Investigative Site, Utrecht, 3584CX, Netherlands|Novartis Investigative Site, Oslo, 0424, Norway|Novartis Investigative Site, Warszawa, 04 730, Poland|Novartis Investigative Site, Samara, Samara Region, 443095, Russian Federation|Novartis Investigative Site, Voronezh, Voronezh Region, 394024, Russian Federation|Novartis Investigative Site, Moscow, 119991, Russian Federation|Novartis Investigative Site, Moscow, 127412, Russian Federation|Novartis Investigative Site, Sevilla, Andalucía, 41013, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08035, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, 46026, Spain|Novartis Investigative Site, San Sebastian, Pais Vasco, 20080, Spain|Novartis Investigative Site, Madrid, 28009, Spain|Novartis Investigative Site, Tainan, Taiwan ROC, 70421, Taiwan|Novartis Investigative Site, Kaohsiung City, 83301, Taiwan|Novartis Investigative Site, Taipei, 10002, Taiwan|Novartis Investigative Site, Bangkok, 10330, Thailand|Novartis Investigative Site, Bangkok, 10400, Thailand|Novartis Investigative Site, Bangkok, 10700, Thailand|Novartis Investigative Site, Ankara, 06100, Turkey|Novartis Investigative Site, Ankara, 06500, Turkey|Novartis Investigative Site, Istanbul, 34093, Turkey|Novartis Investigative Site, Birmingham, B15 2WB, United Kingdom|Novartis Investigative Site, Buckinghamshire, SL9 0RJ, United Kingdom|Novartis Investigative Site, Cambridge, CB2 2QQ, United Kingdom|Novartis Investigative Site, Liverpool, L12 2AP, United Kingdom|Novartis Investigative Site, London, SW17 0QT, United Kingdom|Novartis Investigative Site, London, WC1N 3JH, United Kingdom|Novartis Investigative Site, Sheffield, S10 2TH, United Kingdom|Novartis Investigative Site, York, YO31 7EX, United Kingdom"
NCT00785473,Can Vitamin D Supplementation Prevent Bone Loss in Persons With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00785473,COMPLETED,"Multiple Sclerosis, Osteoporosis",DIETARY_SUPPLEMENT: cholecalciferol|DIETARY_SUPPLEMENT: calcium carbonate,University Hospital of North Norway,,ALL,ADULT,PHASE4,80,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2008-01,2010-04,2010-04,"University Hospital of North Norway, Tromsø, 9038, Norway"
NCT04131673,MS and NMOSD in African-Americans,https://beta.clinicaltrials.gov/study/NCT04131673,WITHDRAWN,Multiple Sclerosis|Neuromyelitis Optica,,Jagannadha R Avasarala,,ALL,"ADULT, OLDER_ADULT",,0,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-07-05,2023-12-31,2023-12-31,"University of Kentucky, Lexington, Kentucky, 40536, United States"
NCT03219073,Transcranial Direct Current Stimulation to Lower Neuropathic Pain in People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03219073,TERMINATED,Multiple Sclerosis|Neuropathic Pain,DEVICE: Active tDCS using tDCS device|DEVICE: SHAM tDCS using tDCS device,Thorsten Rudroff,,ALL,"ADULT, OLDER_ADULT",NA,1,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2018-02-01,2018-06-16,2018-07-01,"University of Colorado Denver, Aurora, Colorado, 80045, United States"
NCT03134573,Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study,https://beta.clinicaltrials.gov/study/NCT03134573,COMPLETED,Multiple Sclerosis,"DRUG: Interferon beta-1b (Betaferon, BAY86-5046)|DEVICE: Betaconnect auto-injector|DEVICE: myBETAapp",Bayer,,ALL,"ADULT, OLDER_ADULT",,96,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-09-15,2018-05-09,2018-05-09,"Many locations, Multiple Locations, Germany"
NCT04000373,Pilot Study of Powered Exoskeleton Use for Gait Rehabilitation in Individuals With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04000373,COMPLETED,"Multiple Sclerosis|Gait Disorders, Neurologic",DEVICE: Ekso GT™ exoskeleton,The Cleveland Clinic,,ALL,"ADULT, OLDER_ADULT",NA,5,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2019-07-23,2020-01-09,2020-01-09,"Cleveland Clinic Neurological Institute Mellen Center, Cleveland, Ohio, 44195, United States"
NCT03801473,Comparison of Robot-Assisted Gait Training and Conventional Therapy in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT03801473,COMPLETED,Multiple Sclerosis,OTHER: robot assisted gait therapy|OTHER: Conventional rehabilitation,"Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey",,ALL,"ADULT, OLDER_ADULT",NA,42,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-02-04,2020-03-01,2020-03-01,"Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey"
NCT04567264,"Wireless, Implantable Tibial Nerve Stimulator System for the Treatment of Refractory Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT04567264,ACTIVE_NOT_RECRUITING,"Multiple Sclerosis, Relapsing-Remitting","DEVICE: StimRouter®, Self-activated and self-controlled neuromodulation device (Bioness Inc, CE0086).",Chiara Zecca,ABREOC,ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-08-26,2022-06-30,2022-06-30,"Ospedale Regionale di Lugano, Neurocenter of Southern Switzerland, Lugano, Ticino, 6903, Switzerland"
NCT02305264,Imaging of Intracerebral Inflammation in MS,https://beta.clinicaltrials.gov/study/NCT02305264,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis, Secondary Progressive|Multiple Sclerosis, Primary Progressive",DRUG: 18F-DPA-714 and 18F-FDG,Assistance Publique - Hôpitaux de Paris,,ALL,"ADULT, OLDER_ADULT",NA,61,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2012-03-19,2018-09-10,2018-09-10,"Saint Antoine Hospital, Paris, 75012, France|Pitie Salpetriere Hospital, Paris, 75013, France"
NCT02133664,Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02133664,COMPLETED,Multiple Sclerosis|Cognition,DRUG: lipoic acid and omega-3 fatty acids|DRUG: Placebo,Oregon Health and Science University,National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,54,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-06,2016-05,2016-05,"Oregon Health and Science University, Portland, Oregon, 97239, United States"
NCT03122873,Quantitation of McArdle's Sign and Evaluation of Specificity for Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03122873,COMPLETED,Multiple Sclerosis,,Mayo Clinic,,ALL,"ADULT, OLDER_ADULT",,125,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-02-01,2017-06-30,2017-06-30,"Mayo Clinic, Rochester, Minnesota, 55905, United States"
NCT01717664,Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS),https://beta.clinicaltrials.gov/study/NCT01717664,COMPLETED,Relapsing Remitting Multiple Sclerosis,DRUG: RHB-104,RedHill Biopharma Limited,,ALL,"ADULT, OLDER_ADULT",PHASE2,18,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-06,2015-12,2016-07,"RedHill MS Clinical Trial Site 002, Tel Aviv, Israel|RedHill MS Clinical Trials Site 001, Zefat (Safed), Israel"
NCT03108573,Improved Detection of Multiple Sclerosis Plaques in Inversion Recovery by Optimization of Sequence Parameters,https://beta.clinicaltrials.gov/study/NCT03108573,COMPLETED,Multiple Sclerosis,,Fondation Ophtalmologique Adolphe de Rothschild,,ALL,"ADULT, OLDER_ADULT",,27,NETWORK,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-12-12,2013-07-31,2013-07-31,
NCT01080573,Rebif Compliance Support Program - Assessing Needs in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01080573,COMPLETED,Multiple Sclerosis,,"Merck KGaA, Darmstadt, Germany",,ALL,"CHILD, ADULT, OLDER_ADULT",,1257,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2007-01,2011-04,2011-04,"Bupa Home Healthcare, Harlow, Essex, CM19 5GU, United Kingdom"
NCT00457964,RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM,https://beta.clinicaltrials.gov/study/NCT00457964,COMPLETED,Tuberous Sclerosis|Lymphangioleiomyomatosis,DRUG: RAD001,"Children's Hospital Medical Center, Cincinnati",Novartis Pharmaceuticals,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,36,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2005-08,2013-07,2013-07,"Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 45229, United States"
NCT03653273,Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years (STOP-I-SEP),https://beta.clinicaltrials.gov/study/NCT03653273,RECRUITING,Multiple Sclerosis,OTHER: DMT withdrawal|DRUG: DMT continuation,Rennes University Hospital,,ALL,"ADULT, OLDER_ADULT",PHASE3,250,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2019-01-24,2026-07,2028-01,"CHU Angers, Angers, France|CHU Brest, Brest, France|CHU Clermont-Ferrand, Clermont-Ferrand, France|Hôpital Henri Mondor, Créteil, France|CHU Dijon, Dijon, France|CHU Grenoble, Grenoble, France|CHU Lille, Lille, France|Hôpital Saint Vincent de Paul, Lille, France|Hospices Civils Lyon, Lyon, France|AP-HM, Marseille, France|CHU Montpellier, Montpellier, France|CHU Nancy, Nancy, France|CHU Nantes, Nantes, France|CHU Nice, Nice, France|CHU de Nîmes, Nîmes, France|AP-HP (La Pitié Salpêtrière), Paris, France|Fondation de Rothschild, Paris, France|CH Poissy, Poissy, France|CHU Poitiers, Poitiers, France|CH Quimper, Quimper, France|CHU Rennes, Rennes, France|CHU Strasbourg, Strasbourg, France|CHU Tours, Tours, France"
NCT05456464,Fatigue and Sleep Quality in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT05456464,RECRUITING,Multiple Sclerosis,OTHER: Reiki,Istanbul Sabahattin Zaim University,,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2022-06-01,2022-08-08,2022-09-30,"Istanbul Sabahattin Zaim University, Faculty of Health Sciences, Istanbul, Güneydoğu Anadolu Bölgesi, 340340, Turkey"
NCT01712373,Ginseng in Treatment of Fatigue in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01712373,COMPLETED,Fatigue,DRUG: Ginseng|DRUG: Placebo,Isfahan University of Medical Sciences,,ALL,ADULT,PHASE2,60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2010-12,2011-04,2011-04,"Al-zahra university hospital, Isfahan, 7007, Iran, Islamic Republic of"
NCT03232073,"Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT03232073,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,DRUG: Ponesimod,Actelion,,ALL,"ADULT, OLDER_ADULT",PHASE3,877,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2017-07-05,2024-01-18,2024-01-18,"The Research Center of Southern California, LLC, Carlsbad, California, 92011, United States|The Neurology Group, Pomona, California, 91767, United States|Mountain View Clinical Research, Denver, Colorado, 80209, United States|Neurology Associates of Ormond Beach, Ormond Beach, Florida, 32174, United States|University of South Florida, Tampa, Florida, 33612, United States|Josephson Wallack Munshower Neurology, PC, Indianapolis, Indiana, 46256, United States|Raleigh Neurology Associates, Raleigh, North Carolina, 27607, United States|Ohio Health, Columbus, Ohio, 43214, United States|Advanced Neurosciences Institute, Franklin, Tennessee, 37064, United States|Grodno University Hospital, Grodno, 230017, Belarus|Minsk City Clinical Hospital 5, Minsk, 220026, Belarus|Republican Scientific Clinical Centre, Minsk, 220114, Belarus|Vitebsk Regional Diagnostic Center, Vitebsk, 210023, Belarus|Vitebsk Regional Clinical Hospital, Vitebsk, 210037, Belarus|University Clinicl Center Sarajevo, Sarajevo, 71000, Bosnia and Herzegovina|UMHAT Sveti Georgi, Plovdiv, 4002, Bulgaria|Multiprofile Hospital for Active Treatment in Neurology and Psychiatry Sveti Naum, Sofia, 1113, Bulgaria|Multiprofile Hospital For Active Treatment National Cardiology Hospital, Ead, Sofia, 1309, Bulgaria|Acibadem City Clinic Tokuda Hospital, Sofia, 1407, Bulgaria|St Ivan Rilski University Multiprofile Hospital For Active Treatment, Sofia, 1431, Bulgaria|University Multiprofile Hospital for Active Treatment Alexandrovska EAD, Sofia, 1431, Bulgaria|Military Medical Academy, Multiprofile Hospital for Active Treatment -Sofia, Sofia, 1606, Bulgaria|University of Alberta, Edmonton, Alberta, T6G 1Z1, Canada|Royal Jubilee Hospital, Victoria, British Columbia, V8R 1J8, Canada|Ottawa Hospital, Ottawa, Ontario, K1H 8L6, Canada|Recherche Sepmus Inc., Greenfield Park, Quebec, J4V 2J2, Canada|Ch Osijek, Osijek, 31000, Croatia|University Hospital Center Zagreb, Zagreb, 10000, Croatia|Fakultní nemocnici Brno, Brno, 65691, Czechia|Fakultni nemocnice Hradec Kralove, Hradec Králové, 500 05, Czechia|Nemocnice Jihlava, Jihlava, 586 33, Czechia|Fakultni nemocnice Ostrava, Ostrava-Poruba, 708 52, Czechia|Pardubicka krajska nemocnice a.s., Pardubice, 532 03, Czechia|Vseobecna Fakultní Nemocnice, Praha 2, 128 08, Czechia|FN Motol, Praha 5, 150 06, Czechia|Krajska zdravotni, a.s. - Nemocnice Teplice, o.z., Teplice, 415 29, Czechia|Suomen Terveystalo Tampere, Tampere, 33100, Finland|Mehilainen NEO, Turku, 20520, Finland|Hôpital Pellegrin CHU Bordeaux, Bordeaux cedex, 33076, France|CHU Clermont-Ferrand - Hopital Gabriel Montpied, Clermont Ferrand Cedex 1, 63003, France|Hôpital Nord Laennec - CHU NANTES, Nantes Cedex 1, 44093, France|Hopital PASTEUR, Nice, 6000, France|Nouvel Hôpital Civil, Strasbourg CEDEX, 67091, France|LTD 'Aversi Clinic', T'bilisi, 0160, Georgia|P. Sarajishvili Institute of Neurology, Tbilisi, 112, Georgia|Pineo Medical Ecosystem Ltd, Tbilisi, 114, Georgia|S.Khechinashvili University Hospital, Tbilisi, 179, Georgia|Curatio, Jsc, Tbilisi, 186, Georgia|Universitätsklinikum Carl-Gustav-Carus Dresden, Dresden, 1307, Germany|Helios Klinikum Erfurt, Erfurt, 99089, Germany|Panakeia - Arzneimittelforschung GmbH, Leipzig, 04275, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, 55131, Germany|401 Military Hospital, Athens, 115 25, Greece|Naval Hospital of Athens, Athens, 11521, Greece|Medical Center of Athens, Marousi, 15125, Greece|Uzsoki Utcai Korhaz, Budapest, 1145, Hungary|Jahn Ferenc Del-pesti Korhaz es Rendelointezet, Budapest, 1204, Hungary|Valeomed EGÉSZSÉGÜGYI KÖZPONT, Esztergom, 2500, Hungary|Petz Aladar Megyei Oktato Korhaz, Győr, 9023, Hungary|Pest Megyei Flor Ferenc Korhaz, Kistarcsa, 2143, Hungary|Barzilai Medical Center, Ashkelon, 7830604, Israel|Rambam Medical Center, Haifa, 3109601, Israel|Hadassah Medical Center, Jerusalem, 9112001, Israel|Ziv Medical Center, Safed, 1304300, Israel|Ospedale San Salvatore, L' Aquila, 67100, Italy|Azienda Ospedaliera Sant Andrea, Roma, 189, Italy|Pauls Stradins Clinical University Hospital, Riga, 1002, Latvia|Latvias Juras medicinas centrs Ltd, Riga, 1015, Latvia|Rīgas Austrumu klīniskā universitātes slimnīca, Riga, LV-1038, Latvia|Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Kaunas, LT50161, Lithuania|VsI Respublikine Siauliu ligonine, V., Šiauliai, 76231, Lithuania|Unidad de Investigacion En Salud, Chihuahua, 31203, Mexico|CRI Centro Regiomontano de Investigacion SC, Nuevo Leon, 64060, Mexico|Neurocentrum Bydgoszcz Sp Z O O, Bydgoszcz, 85-796, Poland|Copernicus Podmiot Leczniczy Sp. z o.o, Gdansk, 80-803, Poland|NeuroCentrum. Centrum Terapii SM, Katowice, 40-571, Poland|NEURO-MEDIC Janusz Zbrojkiewicz Poradnia Wielospecjalistyczna, Katowice, 40-686, Poland|Centrum Kompleksowej Rehabilitacji, Konstancin-Jeziorna, 05-510, Poland|Centrum Opieki Zdrowotnej Orkan-Med, Ksawerow, 95-054, Poland|Indywidualna Praktyka Lekarska Prof. Konrad Rejdak, Lublin, 20-015, Poland|Szpital Kliniczny im. Heliodora Swiecickiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Po, Poznan, 60-355, Poland|Clinical Research Center sp. z o.o MEDIC-R s.k., Poznan, 61-731, Poland|NZOZ NEURO-KARD Ilkowski i Partnerzy Sp. Partnerska Lekarzy, Poznan, 61-853, Poland|WroMedica I.Bielicka, A.Strzałkowska s.c., Wrocław, 51-685, Poland|Hospital de Braga, Braga, 4710-243, Portugal|Hospitais da universidade de Coimbra, Coimbra, 3000-075, Portugal|Hosp. Cuf Descobertas, Lisboa, 1998-018, Portugal|H. Santo António - Centro Hospitalar do Porto, Porto, 4099-001, Portugal|Spitalul Universitar de Urgenta Militar Central 'Dr. Carol Davila', Bucuresti, 10825, Romania|Institutul Clinic Fundeni, Bucuresti, 22328, Romania|Spitalul Universitar de Urgenta Bucuresti, Bucuresti, 50098, Romania|Spitalul Clinic Judetean de Urgenta 'Pius Brinzeu', Timisoara, 300723, Romania|Barnaul Territorial Clinical Hospital, Barnaul, Altai Krai, 656024, Russian Federation|St. Joseph Belgorod Regional Hospital, Belgorod, 308007, Russian Federation|Bryansk Regional Hospital #1, Bryansk, 241033, Russian Federation|Sverdlovsk Region Clinical Hospital #1, Ekaterinburg, 620102, Russian Federation|Research Medical Center Your Health, Kazan, 420097, Russian Federation|Federal State Budgetary Institution, Krasnoyarsk, 660037, Russian Federation|State Budgetary Healthcare Institution Kursk Region Kursk Regional Clinical Hospital, Kursk, 305007, Russian Federation|Clinical City Hospital #1, Moscow, 117049, Russian Federation|State Health Care Institution Of Moscow, Moscow, 127015, Russian Federation|Central Clinical Hospital N.A.Semashko, Moscow, 129128, Russian Federation|Municipal Clinical Hospital # 3, Nizhniy Novgorod, 603155, Russian Federation|Siberian District Medical Center of Federal Medical-Biological Agency, Novosibirsk, 630007, Russian Federation|Federal Scientific Clinical Center of Physico-Chemical Medicine, Odintsovo, 143000, Russian Federation|Perm State Medical Academy n.a. E. A. Vagner, Perm, 614990, Russian Federation|City Clinical Hospital # 2, Pyatigorsk, 357538, Russian Federation|Pavlov First Saint Petersburg State Medical University, Saint Petersburg, 197022, Russian Federation|State Healthcare Institution Samara Regional Clinical Hospital named after V.D.Seredavin, Samara, 443095, Russian Federation|Smolensk Regional Clinical Hospital, Smolensk, 214018, Russian Federation|Municipal Multi-Specialty Hospital # 2, St. Petersburg, 194354, Russian Federation|City Clinical Hospital #31, St. Petersburg, 197110, Russian Federation|Institute of Human Brain Ras, St. Petersburg, 197376, Russian Federation|City Hospital# 40, St.Petersburg, 197706, Russian Federation|Siberian State Medical University, Tomsk, 634050, Russian Federation|Tver Regional Clinical Hospital, Tver, 170036, Russian Federation|GUZ Novgorod Regional Clinical Hospital, Velikiy Novgorod, 214018, Russian Federation|Yaroslavl Clinical Hospital #8, Yaroslavl, 150003, Russian Federation|Clinical Hospital Center Zvezdara, Belgrade, 11000, Serbia|Vojnomedicinska Akademija, Belgrade, 11000, Serbia|University Clinical Center Kragujevac, Kragujevac, 34000, Serbia|University Clinical Center NIS, Nis, 18000, Serbia|Hospital del Mar, Barcelona, 8003, Spain|Hospital Vall d'Hebron, Barcelona, 8035, Spain|Hospital Clinic I Provincial, Barcelona, 8036, Spain|Hospital Universitario de La Princesa, Madrid, 28006, Spain|Hospital Regional Universitario de Malaga, Malaga, 29010, Spain|Hospital Universitario Virgen Macarena, Sevilla, 41009, Spain|Hospital Vithas Nisa Sevilla, Sevilla, 41950, Spain|Sahlgrenska Universitetsjukhuset, Göteborg, 413 45, Sweden|Centrum för Neurologi, Stockholm, 113 65, Sweden|Karadeniz Teknik University Medical Faculty, Trabzon, 61080, Turkey|Public Non-profit Enterprise: Chernihiv City Hospital #4 under Chernihiv City Council, Chernihiv, 14001, Ukraine|Municipal health care institution Chernihiv Regional Hospital, Chernihiv, 14029, Ukraine|Ivano-Frankivsk Regional Clinical Hospital, Ivano-Frankivsk, 76018, Ukraine|Limited Liability Company 'Neuro Global', Ivano-Frankivsk, 76493, Ukraine|Kharkiv Railway Clinical Hospital N1 Of Brance 'Health Center', Kharkiv, 61103, Ukraine|Kharkiv Postgrad Academy, Dept of Neurology #1 At Hosp #7, Kharkiv, 61176, Ukraine|National Research Center for Radiation Medicine, Kyiv, 3115, Ukraine|Public Non-Profit Enterprise: Lviv City Clinical Hospital #5, Lviv, 79000, Ukraine|Lviv Clinical Regional Hospital, Lviv, 79010, Ukraine|Odessa National Medical University, Odesa, 65009, Ukraine|ME 'Poltava Regional Clinical Hospital n.a. M.V. Sklifosovsky of the Poltava Regional Council', Poltava, 36024, Ukraine|Mnce 'Ternopil Regional Clinical Psychoneurology Hospital' of Trb, Ternopil, 46027, Ukraine|Public Institution Vinnitsa O.I. Yuschenko Regional Neuropsychiatric Hospital, Vinnytsia, 21005, Ukraine|O.F. Herbachevskyi Regional Clinical Hospital, Zhytomyr, 10008, Ukraine|Royal Preston Hospital, Preston, PR2 9HT, United Kingdom|Salford Royal NHS Foundation Trust, Salford, M6 8HD, United Kingdom"
NCT01535664,"An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)",https://beta.clinicaltrials.gov/study/NCT01535664,COMPLETED,Multiple Sclerosis,OTHER: Withdrawal of dalfampridine-ER 10mg,Acorda Therapeutics,"Prometrika, LLC|BCS Consulting, Inc.",ALL,"ADULT, OLDER_ADULT",,20,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-01,2012-05,2012-06,"OMRF Multiple Sclerosis Center of Excellence, Oklahoma City, Oklahoma, 73104, United States"
NCT03094364,Video Game-based Therapy for Arm Weakness In Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03094364,COMPLETED,Primary Progressive Multiple Sclerosis|Hemiparesis,BEHAVIORAL: Gaming CI Therapy,"University of Massachusetts, Lowell",Ohio State University,ALL,"ADULT, OLDER_ADULT",NA,31,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2015-11,2018-10-31,2018-10-31,"The Ohio State University, 2154 Dodd Hall, Columbus, Ohio, 43210, United States"
NCT03233646,OCTA in Mild Cognitive Impairment and Alzheimer's Disease,https://beta.clinicaltrials.gov/study/NCT03233646,RECRUITING,Alzheimer Disease|Mild Cognitive Impairment|Retinal Vascular|Parkinson Disease|Multiple Sclerosis|Huntington Disease|Neuro-Degenerative Disease,DEVICE: Retinal Imaging,Duke University,University of Edinburgh,ALL,"ADULT, OLDER_ADULT",NA,1000,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2017-07-20,2023-12-31,2025-12-31,"Duke University Medical Center, Durham, North Carolina, 27705, United States"
NCT05088473,Diagnosic and Pronostic Values of Kappa and Lambda Free Light Chains in Central Nervous System Inflammatory Diseases,https://beta.clinicaltrials.gov/study/NCT05088473,COMPLETED,Central Nervous System Diseases|Multiple Sclerosis,OTHER: Biological collection,Centre Hospitalier Universitaire de Nice,,ALL,"CHILD, ADULT, OLDER_ADULT",,1500,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-10-15,2021-10-31,2021-10-31,"Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France|Centre Hospitalier Universitaire de Dijon, Dijon, France|Centre Hospitalier Universitaire de Grenoble, Grenoble, France|Centre Hospitalier Universitaire de Lille, Lille, France|Assistance Publique des Hôpitaux de Marseille, Marseille, France|Centre Hospitalier Universitaire de Montpellier, Montpellier, France|Centre Hospitalier Universitaire de Nantes, Nantes, France|Centre Hospitalier Universitaire de Nice, Nice, France|Centre Hospitalier Universitaire de Nîmes, Nîmes, France|Assistance Publique des Hôpitaux de Paris, Paris, France|Centre Hospitalier Universitaire de Saint-Etienne, Saint-Étienne, France|Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France|Centre Hospitalier Universitaire de Toulouse, Toulouse, France|Centre Hospitalier Régional et Universaitaire de Tours, Tours, France"
NCT02277964,Disease Control in RRMS Transferring Treatment From Natalizumab to Fingolimod,https://beta.clinicaltrials.gov/study/NCT02277964,COMPLETED,Relapsing Remitting Multiple Sclerosis,,"University Hospital, Basel, Switzerland",Novartis,ALL,"ADULT, OLDER_ADULT",,25,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-03,2016-08,2016-08,"University Hospital Basel, Switzerland, Basel, 4031, Switzerland"
NCT04131764,Diagnosis of ON With or Without MS or NMOSD,https://beta.clinicaltrials.gov/study/NCT04131764,TERMINATED,Multiple Sclerosis|Neuromyelitis Optica Spectrum Disorder Attack|Neuromyelitis Optica Spectrum Disorder Relapse|Neuromyelitis Optica Spectrum Disorder Progression|Optic Neuritis,"DIAGNOSTIC_TEST: Reflex (Brightlamp Inc., Purdue University)",Jagannadha R Avasarala,,ALL,"ADULT, OLDER_ADULT",,112,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-10-04,2022-09-06,2022-09-06,"University of Kentucky, Lexington, Kentucky, 40536, United States"
NCT02544373,CPAP to Treat Cognitive Dysfunction in MS,https://beta.clinicaltrials.gov/study/NCT02544373,COMPLETED,Multiple Sclerosis,DEVICE: PAP therapy,University of Michigan,National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",NA,135,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2015-11-12,2021-06-25,2021-06-25,"University of Michigan Medical Center, Ann Arbor, Michigan, 48109, United States"
NCT01067573,The Role of Serum Leptin Levels in Multiple Sclerosis Disease Activity While on Interferon Beta 1a (Rebif) Treatment,https://beta.clinicaltrials.gov/study/NCT01067573,COMPLETED,Multiple Sclerosis,,University of South Florida,EMD Serono,ALL,ADULT,,20,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2009-12,,2011-07,"USF Health, Tampa, Florida, 33612, United States"
NCT03817073,Assessing Fatiguability of Tongue Muscles in MS,https://beta.clinicaltrials.gov/study/NCT03817073,UNKNOWN,Muscle Weakness|Fatigue|Multiple Sclerosis|Deglutition Disorders|Exertion; Excess,DEVICE: Iowa Oral Performance Instrument (IOPI),Thomas More Kempen,Revalidatie & MS Centrum Overpelt,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2019-03-01,2021-07-01,2021-07-01,"Thomas More University College of Applied Sciences, Antwerp, Antwerpen, 2018, Belgium"
NCT04833673,"The Effects of Relaxation Techniques on Pain, Fatigue and Kinesiophobia in Multiple Sclerosis Patients: A Three Arms Randomized Trial",https://beta.clinicaltrials.gov/study/NCT04833673,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting|Pain, Chronic|Fatigue Syndrome, Chronic|Kinesiophobia",BEHAVIORAL: PMR: Progressive Muscle Relaxation|BEHAVIORAL: BRT:Benson Relaxation Technique,Hacettepe University,,ALL,"ADULT, OLDER_ADULT",NA,80,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-06-22,2020-12-30,2021-03-15,"Hacettepe University, Ankara, None Selected, 06100, Turkey"
NCT03607773,Mindfulness for Newly Diagnosed Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03607773,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Mindfulness Behavioural Intervention (MBI) group,Sarah Morrow,Lawson Health Research Institute,ALL,ADULT,NA,26,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-09-19,2020-01-20,2020-01-20,"London Health Sciences Center, London, Ontario, N6A5A5, Canada"
NCT04022473,Study to Compare GI Tolerability Following Oral Administration of Bafiertam™ or Tecfidera to Healthy Volunteers,https://beta.clinicaltrials.gov/study/NCT04022473,COMPLETED,Multiple Sclerosis,DRUG: Bafiertam|DRUG: Tecfidera,Banner Life Sciences LLC,,ALL,"ADULT, OLDER_ADULT",PHASE1,210,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2019-07-07,2019-10-19,2019-10-19,"BioPharma Services, Inc., Columbia, Missouri, 65201, United States"
NCT03632473,Validation of Multimodal Evoked Potentials (mmEP) for Predicting Disease Progression in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03632473,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,DIAGNOSTIC_TEST: multimodal evoked potentials (mmEP),"University Hospital, Basel, Switzerland",,ALL,"ADULT, OLDER_ADULT",,29,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-03-12,2024-04,2024-07,"Dep. of Neurology, Hospital of the University of Basel, Basel, 4031, Switzerland|Hopitaux universitaires de Genève, Geneva, Switzerland|Neurocenter of Southern Switzerland, Ospedale Regionale di Lugano, Lugano, 6903, Switzerland"
NCT02043964,Tear Analysis by Isoelectric Focusing in Clinically Isolated Syndrome as Multiple Sclerosis Criterion,https://beta.clinicaltrials.gov/study/NCT02043964,UNKNOWN,Clinically Isolated Syndrome|Multiple Sclerosis,PROCEDURE: tears and cerebrospinal fluid sampling,Lille Catholic University,,ALL,"ADULT, OLDER_ADULT",NA,165,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2012-10,2018-06,2018-12,"Centre Hospitalier Universitaire de Bordeaux, Bordeaux, 33300, France|Centre Hospitalier Universitaire Caen, Caen, 14000, France|Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, 63000, France|Centre Hospitalier Universitaire de Dijon, Dijon, 21000, France|Centre Hospitalier Régional Universitaire de Lille, Lille, 59000, France|Groupe Hospitalier de l'Institut Catholique de Lille, Lomme, 59 462, France|Centre Hospitalier Universitaire de Lyon, Lyon, 69000, France|Hopital de la Timone, Marseille, 13000, France|Universitaire de Nancy, Nancy, 54100, France|Centre Hospitalier Universitaire de Nantes, Nantes, 44200, France|Centre Hospitalier Universitaire de Nice, Nice, 6200, France|Centre Hospitalier Intercommunal Poissy-St-Germain, Poissy, 78300, France|Centre Hospitalier Univetrsitaire de Rouen, Rouen, 76100, France|Centre Hospitalier Régional Universitaire de Strasbourg, Strasbourg, 67100, France|Centre Hospitalier de Valenciennes, Valenciennes, 59300, France"
NCT02391064,Validation of Brief Computerized Cognitive Assessment in Multiple Sclerosis (BCCAMS),https://beta.clinicaltrials.gov/study/NCT02391064,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Cognitive evaluation|BEHAVIORAL: Expanded Disability Status Scale (EDSS) score,"University Hospital, Bordeaux",Bayer,ALL,ADULT,NA,421,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2015-02-17,2018-02-18,2018-02-18,"CHU de Bordeaux, Bordeaux, 33000, France|CHU de Caen, Caen, 14033, France|CHU de Clermont-Ferrand, Clermont-Ferrand, 63003, France|Hôpital du Bocage, Dijon, 21079, France|CH de Dunkerque, Dunkerque, 59385, France|Centre Hospitalier Saint Vincent de Paul, Lille, 59020, France|Hôpital Roger Salengro, Lille, France|CHU de Marseille, Marseille, 13385, France|CHU Montpellier, Montpellier, 34295, France|CHU de Nancy, Nancy, 54035, France|CHU de Nice, Nice, 06002, France|Hôpital Tenon, Paris, 75970, France|Hôpital de Poissy Saint Germain, Poissy, 78303, France|CHU de Reims, Reims, 51092, France|CHU de Strasbourg, Strasbourg, 67200, France"
NCT00203073,A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.,https://beta.clinicaltrials.gov/study/NCT00203073,COMPLETED,Relapsing Remitting Multiple Sclerosis,"DRUG: glatiramer acetate 20 mg|DRUG: glatiramer acetate 20 mg, with mitoxantrone","Teva Branded Pharmaceutical Products R&D, Inc.",,ALL,ADULT,PHASE2,40,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2003-06,2005-01,2005-04,
NCT05374473,An Online Lifestyle Modification Course for People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05374473,RECRUITING,Multiple Sclerosis,BEHAVIORAL: Lifestyle modification|BEHAVIORAL: Standard-care,University of Melbourne,,ALL,"ADULT, OLDER_ADULT",NA,1054,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2022-06-24,2024-12,2024-12,"The University of Melbourne, Melbourne, Victoria, 3010, Australia"
NCT04091464,TRAIN-BW: Backward Walking Training in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04091464,RECRUITING,"Multiple Sclerosis|Gait Disorders, Neurologic|Accidental Fall",BEHAVIORAL: Backward Walking Training|BEHAVIORAL: Forward Walking Training,Wayne State University,,ALL,"ADULT, OLDER_ADULT",NA,90,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-01-01,2025-01-31,2025-06-30,"Wayne State University, Detroit, Michigan, 48201, United States"
NCT03807973,Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes.,https://beta.clinicaltrials.gov/study/NCT03807973,RECRUITING,Fibromyalgia|Chronic Fatigue Syndrome|Multiple Sclerosis|Healthy,DRUG: [Zr-89]Oxine-labeled leukocytes PET/MRI,University of Alabama at Birmingham,,ALL,"ADULT, OLDER_ADULT",PHASE1,120,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-10-05,2024-10-05,2025-10-05,"UAB, Birmingham, Alabama, 35294, United States"
NCT01417273,Impact of Vitamin A on Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT01417273,UNKNOWN,Relapsing Remitting Multiple Sclerosis,DIETARY_SUPPLEMENT: vitamin A|DRUG: Drug: placebo,Tehran University of Medical Sciences,,ALL,ADULT,PHASE4,100,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2010-02,2013-02,2013-08,"Tehran University of Medical Sciences,, Tehran, School of Public Health, Iran, Islamic Republic of"
NCT00612872,Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects,https://beta.clinicaltrials.gov/study/NCT00612872,TERMINATED,Parkinson Disease|Alzheimer Disease|Healthy Controls|Multiple Sclerosis,DRUG: [123I]CLINDE,Institute for Neurodegenerative Disorders,,ALL,ADULT,PHASE1,46,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2008-01,2009-11-01,2009-11-01,"Institute for Neurodegenerative Disorders, New Haven, Connecticut, 06510, United States"
NCT02301572,Aggressive Onset Multiple Sclerosis: A Practical Definition and Study of Its Clinical Course,https://beta.clinicaltrials.gov/study/NCT02301572,COMPLETED,Multiple Sclerosis,,Weill Medical College of Cornell University,"Genzyme, a Sanofi Company",ALL,"CHILD, ADULT, OLDER_ADULT",,750,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-08,2016-07,2016-08,"Weill Cornell Medical College, New York, New York, 10021, United States"
NCT05334472,A Survey to Evaluate Early Experience From Patient and Care Partner on Injection and Device for KESIMPTA® Indicated for Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05334472,COMPLETED,Multiple Sclerosis,OTHER: Kesimpta,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",,100,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-11-24,2023-02-15,2023-02-15,"Novartis Investigative Site, East Hanover, New Jersey, 07936, United States"
NCT01450072,Prospective Randomized Endovascular Therapy in Multiple Sclerosis - PREMiSE,https://beta.clinicaltrials.gov/study/NCT01450072,COMPLETED,Multiple Sclerosis,DEVICE: Selective Venography followed by therapeutic balloon angioplasty|OTHER: Control arm,University at Buffalo Neurosurgery,,ALL,"ADULT, OLDER_ADULT",PHASE2,20,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2010-06,2011-12,2012-12,"University at Buffalo Neurosurgery, Buffalo, New York, 14209, United States"
NCT04066972,Vigorous Cool Room Treadmill Training,https://beta.clinicaltrials.gov/study/NCT04066972,COMPLETED,"Multiple Sclerosis|Rehabilitation|Gait Disorders, Neurologic|Neuronal Plasticity",OTHER: Body-weight supported treadmill training in a room cooled to 16°C,Memorial University of Newfoundland,,ALL,"ADULT, OLDER_ADULT",NA,10,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-07-10,2019-07-09,2019-07-09,"Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, A1A 1E5, Canada"
NCT00781872,Mesenchymal Stem Cells for the Treatment of MS,https://beta.clinicaltrials.gov/study/NCT00781872,COMPLETED,Multiple Sclerosis,BIOLOGICAL: Injection of autologous bone marrow derived mesenchymal stem cells,Hadassah Medical Organization,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,24,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2006-10,2009-12,2009-12,
NCT00126672,RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS,https://beta.clinicaltrials.gov/study/NCT00126672,COMPLETED,Nonmalignant Neoplasm|Tuberous Sclerosis|Lymphangioleimyomatosis|Kidney Angiomyolipoma,DRUG: Rapamycin,Dana-Farber Cancer Institute,National Cancer Institute (NCI)|Wyeth is now a wholly owned subsidiary of Pfizer|Tuberous Sclerosis Alliance,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,36,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2005-12-20,2010-04,2010-04,"Loma Linda University School of Medicine, Loma Linda, California, 92350, United States|Connecticut Children's Medical Center, Hartford, Connecticut, 06106, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|New York University Medical Center, New York, New York, 10016, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 45229-3039, United States|University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, 19104, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, 75390, United States"
NCT02315872,ACTH for Fatigue in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT02315872,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: ACTH|DRUG: Placebo,Providence Health & Services,Mallinckrodt,ALL,"ADULT, OLDER_ADULT",PHASE3,8,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2015-05-22,2017-06-20,2018-12-13,"North Central Neurology Associates, PC, Cullman, Alabama, 35058, United States|Providence Medical Group - Medford Neurology, Medford, Oregon, 97504, United States|Providence St. Vincent Medical Center, Portland, Oregon, 97225, United States|Swedish Medical Center, Seattle, Washington, 98122, United States|MultiCare Health System -- Institute for Research and Innovation, Tacoma, Washington, 98405, United States"
NCT00818038,A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function,https://beta.clinicaltrials.gov/study/NCT00818038,COMPLETED,Relapsing-Remitting Multiple Sclerosis,DRUG: BG0002 (natalizumab),Biogen,,ALL,"ADULT, OLDER_ADULT",,30,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2009-03,2011-03,2011-03,
NCT04796272,Role of Individualized Versus Traditional Exercise in Combating Fatigue,https://beta.clinicaltrials.gov/study/NCT04796272,RECRUITING,Multiple Sclerosis,OTHER: Adapted and individualized physical training program|OTHER: traditional training program,Centre Hospitalier Universitaire de Saint Etienne,,ALL,"ADULT, OLDER_ADULT",NA,38,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-04-02,2023-10-30,2024-01-30,"CHU de Saint-Etienne, Saint-Étienne, France"
NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01795872,COMPLETED,Multiple Sclerosis,PROCEDURE: Several diagnostic procedures,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE4,278,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-09,2014-04,2014-06,"Graz, Steiermark, 8036, Austria|Innsbruck, 6020, Austria|Bruxelles - Brussel, 1200, Belgium|Gent, 9000, Belgium|Leuven, 3000, Belgium|Liege, 4000, Belgium|Calgary, Alberta, T2N 2T9, Canada|London, Ontario, N6A 5A5, Canada|Ottawa, Ontario, K1H 8L6, Canada|Montreal, Quebec, H2L 4M1, Canada|Brno, 625 00, Czech Republic|Hradec Kralove, 500 05, Czech Republic|Ostrava-Poruba, 708 52, Czech Republic|Praha 2, 121 11, Czech Republic|Glostrup, DK-2600, Denmark|Oulu, 90029, Finland|Seinäjoki, Finland|Tampere, 33521, Finland|Turku, 20100, Finland|Bordeaux, 33000, France|Clermont ferrand, 63003, France|Dijon, 21033, France|Lille, 59037, France|Nice, 06200, France|Rennes, 35033, France|Toulouse, 31059, France|Ulm, Baden-Württemberg, 89075, Germany|München, Bayern, 81377, Germany|Regensburg, Bayern, 93053, Germany|Würzburg, Bayern, 97080, Germany|Hennigsdorf, Brandenburg, 16761, Germany|Gießen, Hessen, 35392, Germany|Marburg, Hessen, 35039, Germany|Offenbach, Hessen, 63069, Germany|Greifswald, Mecklenburg-Vorpommern, 17475, Germany|Göttingen, Niedersachsen, 37099, Germany|Düsseldorf, Nordrhein-Westfalen, 40225, Germany|Köln, Nordrhein-Westfalen, 50931, Germany|Mainz, Rheinland-Pfalz, 55101, Germany|Halle, Sachsen-Anhalt, 06120, Germany|Erfurt, Thüringen, 99089, Germany|Münster, 48149, Germany|Budapest, 1076, Hungary|Budapest, 1145, Hungary|Debrecen, 4012, Hungary|Szeged, 6720, Hungary|Jerusalem, Israel|Tel Hashomer, 5262000, Israel|Orbassano, Torino, 10043, Italy|Gallarate, 21013, Italy|Milano, 20132, Italy|Padova, 35128, Italy|Pavia, 27100, Italy|Torino, 10126, Italy|Sittard, 6131 BK, Netherlands|Bergen, 5021, Norway|Bydgoszcz, 85-681, Poland|Krakow, 30-503, Poland|Lodz, 90-153, Poland|Lublin, 20-090, Poland|Wroclaw, 50420, Poland|Coimbra, 3030-075, Portugal|Ljubljana, 1525, Slovenia|Sevilla, Andalucía, 41071, Spain|L'Hospitalet de Llobregat, Barcelona, 08907, Spain|Barcelona, 08035, Spain|Barcelona, 08036, Spain|Madrid, 28040, Spain|Málaga, 29010, Spain|Valencia, 46026, Spain|Göteborg, 413 45, Sweden|Basel, Basel-Stadt, 4031, Switzerland|St. Gallen, Sankt Gallen, 9007, Switzerland|Bern, 3010, Switzerland|Sheffield, South Yorkshire, S10 2JF, United Kingdom|Aberdeen, AB25 2ZN, United Kingdom|Dundee, DD1 9SY, United Kingdom"
NCT02419638,Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS,https://beta.clinicaltrials.gov/study/NCT02419638,WITHDRAWN,Multiple Sclerosis,DRUG: Rebif (IFN β-1a subcutaneous three times per week)|DRUG: Tecifdera (dimethyl fumarate),Brigham and Women's Hospital,EMD Serono,ALL,"ADULT, OLDER_ADULT",,0,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-05,2015-12,2016-02,"Partners MS Center, 1 Brookline Place Suite 225, Brookline, Massachusetts, 02445, United States"
NCT05162638,Immune Profiles in Multiple Sclerosis (MS) Patients and Healthy Volunteers Through Thoracic Duct Cannulation,https://beta.clinicaltrials.gov/study/NCT05162638,ENROLLING_BY_INVITATION,Multiple Sclerosis|Healthy,PROCEDURE: thoracic duct cannulation,University of Pennsylvania,Novartis Pharmaceuticals|Novartis Institutes for BioMedical Research,ALL,ADULT,NA,24,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2022-04-19,2026-01,2027-01,"University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States"
NCT05201638,"Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT05201638,RECRUITING,"Multiple Sclerosis, Relapsing-Remitting",DRUG: IMU-838 tablets|DRUG: Placebo matching IMU-838 tablets,Immunic AG,,ALL,ADULT,PHASE3,1050,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-01-12,2024-10,2032-10,"Neuro of Central Florida, Altamonte Springs, Florida, 32714, United States|Healthcare Innovations, Coral Springs, Florida, 33067, United States|Homestead Associates, Miami, Florida, 33032, United States|Premier Clinical Research, Miami, Florida, 33122, United States|Baptist Health Lexington, Nicholasville, Kentucky, 40356, United States|Boston Clinical Trials, Boston, Massachusetts, 02131, United States|Heratsi Hospital Complex 1, Yerevan, 0025, Armenia|Erebouni Medical Center, Yerevan, 0087, Armenia|Cantonal Hospital Bihac Dr. Irfan Ljubijankic, Bihać, 77000, Bosnia and Herzegovina|University Clinical Center of Sarajevo, Sarajevo, 71000, Bosnia and Herzegovina|University Clinical Center Sarajevo, Sarajevo, 71000, Bosnia and Herzegovina|University Clinical Center Tuzla, Tuzla, 75000, Bosnia and Herzegovina|Astra Clinic, Tallinn, Estonia|Fortis Memorial Research Institute, Gurugramam, 122002, India|Dr Ram Manohar Lohia Institute of Medical Sciences, Lucknow, 226010, India|All India Institute of Medical Sciences, New Delhi, 110029, India|SRI Guru Ram Das Institute of Medical Sciences and Research, Punjabi Bagh, 143006, India|DKS PGI, Raipur, 492001, India|NZOZ Wielospecjalistyczna Poradnia Lekarska ""Synapsis"", Katowice, 40123, Poland|Neuro-Medic Janusz Zbrojkiewicz, Katowice, 40686, Poland|NZOZ Neuromed, Lublin, 20-064, Poland|Instytut Zdrowia Boczarska, Oświęcim, 32-600, Poland|NZOZ Hertmanowskiej, Plewiska, 62-064, Poland|NZOZ Neuro-Kard, Poznań, 61-853, Poland|Centrum Medyczne NeuroProtect, Warsaw, 01684, Poland|Spitalul clinic CF Constanta, Constanţa, 900123, Romania|Asociatia Comunitatea Oamenilor, Craiova, 200157, Romania|Clubul Sanatatii SRL, Câmpulung, 115100, Romania|Aria Clinic SRL, Sibiu, 550052, Romania|Neuro Therapy, Timişoara, 300425, Romania|Spit Jud Branzeu TIM Neuro, Timişoara, 300723, Romania|Klinicko bolnicki centar Dr Dragisa Misovic - Dedinje, Belgrade, 11000, Serbia|Klinicko bolnicki centar Zvezdara, Belgrade, 11000, Serbia|Opsta bolnica Medicinski sistem Beograd, Belgrade, 11000, Serbia|Vojnomedicinska akademija, Belgrade, 11000, Serbia|Univerzitetski Klinicki centar Kragujevac, Kragujevac, 34000, Serbia|Univerzitetski Klinicki centar Nis, Niš, 18000, Serbia|General Hospital Uzice, Užice, 31000, Serbia|Klinicko Bolnicki centar Zemun, Zemun, 11080, Serbia|Opsta bolnica Djordje Jovanovic Zrenjanin, Zrenjanin, 23000, Serbia|Acibadem Adana Hospital, Adana, 01130, Turkey|Adana Baskent Hospital, Adana, 01250, Turkey|Baskent University Ankara Hospital, Ankara, 06490, Turkey|Bezmialem Vakif University Hospital, Istanbul, 34093, Turkey|T.C. Ministry of Health Istanbul Haseki Training and Research Hospital, Istanbul, 34250, Turkey|Sancaktepe Sehit Prof.Dr. Ilhan Varank Training and Research Hospital, Istanbul, 34785, Turkey|Marmara University Pendik Training and Research Hospital, Istanbul, 34899, Turkey|Kocaeli University Research and Application Hospital, Kocaeli, 41000, Turkey|T.C. Ministry of Health Kutahya Provincial Directorate of Health Kutahya University of Health Sciences Evliya Celebi Training and Research Hospital, Kütahya, 43100, Turkey|Manisa Celal Bayar University Hafsa Sultan Hospital, Manisa, 45030, Turkey|19 Mayis University Medical Faculty Hospital Health Application and Research Center, Samsun, 55200, Turkey|Zonguldak Bulent Ecevit University Health Practice and Research Hospital, Zonguldak, 67000, Turkey|MS Diagnosis Treatment Center, Cherkasy, Ukraine|Chernihiv City Hospital 4, Chernihiv, Ukraine|Dnipro City Hospital 6, Dnipro, Ukraine|1 Private Clinic Medical Center, Kyiv, Ukraine|Dopomoga Plus medical center, Kyiv, Ukraine|Volyn Reg Clin Hospital, Luts'k, 43005, Ukraine|Lviv Regional Central Hospital, Lviv, 79010, Ukraine|5 City Clin Hospital, Lviv, 79013, Ukraine|City Clinical Hospital 2, Rivne, Ukraine|Sumy Reg Clinical Hospital, Sumy, Ukraine|Salutem, Vinnytsia, 21018, Ukraine|LCC Medical center INET-09, Zaporizhzhya, 69001, Ukraine|Zaporizhia Med, Zaporizhzhya, Ukraine|Zaporizhia Regional Clinic Hospital, Zaporizhzhya, Ukraine|Zaporizhzhya City Hospital 6, Zaporizhzhya, Ukraine|Zaporizhzhya Hospital 9, Zaporizhzhya, Ukraine"
NCT01216072,"A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT01216072,COMPLETED,Relapsing Forms of Multiple Sclerosis,DRUG: Fingolimod|DRUG: Standard MS DMTs,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE4,1053,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2010-08,2012-08,2012-08,"Novartis Investigative Site, Birmingham, Alabama, 35209, United States|Novartis Investigative Site, Cullman, Alabama, 35058, United States|Novartis Investigative Site, Phoenix, Arizona, 85004, United States|Novartis Investigative Site, Phoenix, Arizona, 85006, United States|Novartis Investigative Site, Phoenix, Arizona, 85013, United States|Novartis Investigative Site, Phoenix, Arizona, 85032, United States|Novartis Investigative Site, Tucson, Arizona, 85741, United States|Novartis Investigative Site, Anaheim, California, 92801, United States|Novartis Investigative Site, Berkeley, California, 94705, United States|Novartis Investigative Site, Fresno, California, 93710, United States|Novartis Investigative Site, Fullerton, California, 92835, United States|Novartis Investigative Site, La Habra, California, 90631, United States|Novartis Investigative Site, Loma Linda, California, 92354, United States|Novartis Investigative Site, Newport Beach, California, 92660, United States|Novartis Investigative Site, Oceanside, California, 92056, United States|Novartis Investigative Site, Sacramento, California, 95817, United States|Novartis Investigative Site, Walnut Creek, California, 94598, United States|Novartis Investigative Site, Boulder, Colorado, 80304, United States|Novartis Investigative Site, Colorado Springs, Colorado, 80920, United States|Novartis Investigative Site, Fort Collins, Colorado, 80528, United States|Novartis Investigative Site, Fairfield, Connecticut, 06824, United States|Novartis Investigative Site, New London, Connecticut, 06320, United States|Novartis Investigative Site, Stratford, Connecticut, 06615, United States|Novartis Investigative Site, Dover, Delaware, 19901, United States|Novartis Investigative Site, Newark, Delaware, 19713, United States|Novartis Investigative Site, Atlantis, Florida, 33462-6608, United States|Novartis Investigative Site, Bradenton, Florida, 32405, United States|Novartis Investigative Site, Doral, Florida, 33166, United States|Novartis Investigative Site, Fort Lauderdale, Florida, 33308, United States|Novartis Investigative Site, Hollywood, Florida, 33021, United States|Novartis Investigative Site, Jacksonville, Florida, 32209, United States|Novartis Investigative Site, Jacksonville, Florida, 32216, United States|Novartis Investigative Site, Lighthouse Point, Florida, 33064, United States|Novartis Investigative Site, Maitland, Florida, 32751, United States|Novartis Investigative Site, Miami, Florida, 33015, United States|Novartis Investigative Site, Miami, Florida, 33133, United States|Novartis Investigative Site, Pompano Beach, Florida, 33060, United States|Novartis Investigative Site, Ponte Vedra Beach, Florida, 32082-4627, United States|Novartis Investigative Site, Port Orange, Florida, 32127, United States|Novartis Investigative Site, Sarasota, Florida, 34243, United States|Novartis Investigative Site, St. Petersburg, Florida, 33713, United States|Novartis Investigative Site, Sunrise, Florida, 33351, United States|Novartis Investigative Site, Tallahassee, Florida, 32308, United States|Novartis Investigative Site, Tampa, Florida, 33609, United States|Novartis Investigative Site, Tampa, Florida, 33612, United States|Novartis Investigative Site, Vero Beach, Florida, 32960, United States|Novartis Investigative Site, West Palm Beach, Florida, 33407, United States|Novartis Investigative Site, Atlanta, Georgia, 30302, United States|Novartis Investigative Site, Atlanta, Georgia, 30309, United States|Novartis Investigative Site, Columbus, Georgia, 31901, United States|Novartis Investigative Site, Decatur, Georgia, 30083, United States|Novartis Investigative Site, Idaho Falls, Idaho, 83402, United States|Novartis Investigative Site, Elk Grove Village, Illinois, 60007, United States|Novartis Investigative Site, Evanston, Illinois, 60201, United States|Novartis Investigative Site, Flossmoor, Illinois, 60422, United States|Novartis Investigative Site, Northbrook, Illinois, 60062, United States|Novartis Investigative Site, Anderson, Indiana, 46011, United States|Novartis Investigative Site, Indianapolis, Indiana, 46202-5111, United States|Novartis Investigative Site, Indianapolis, Indiana, 46256, United States|Novartis Investigative Site, Merrillville, Indiana, 46410, United States|Novartis Investigative Site, Valparaiso, Indiana, 46383, United States|Novartis Investigative Site, Des Moines, Iowa, 50314-2611, United States|Novartis Investigative Site, Lenexa, Kansas, 66214, United States|Novartis Investigative Site, Baton Rouge, Louisiana, 70809, United States|Novartis Investigative Site, Destrehan, Louisiana, 70047, United States|Novartis Investigative Site, Hammond, Louisiana, 70403, United States|Novartis Investigative Site, Metairie, Louisiana, 70001, United States|Novartis Investigative Site, Shreveport, Louisiana, 71101, United States|Novartis Investigative Site, Shreveport, Louisiana, 71130, United States|Novartis Investigative Site, Baltimore, Maryland, 21201, United States|Novartis Investigative Site, Bethesda, Maryland, 20814, United States|Novartis Investigative Site, Boston, Massachusetts, 02135, United States|Novartis Investigative Site, Springfield, Massachusetts, 01104, United States|Novartis Investigative Site, Worcester, Massachusetts, 01608, United States|Novartis Investigative Site, Worcester, Massachusetts, 01665, United States|Novartis Investigative Site, Detroit, Michigan, 48201, United States|Novartis Investigative Site, Grand Rapids, Michigan, 49503, United States|Novartis Investigative Site, Kalamazoo, Michigan, 49007, United States|Novartis Investigative Site, Southfield, Michigan, 48034, United States|Novartis Investigative Site, Bolivar, Missouri, 65613, United States|Novartis Investigative Site, Kansas City, Missouri, 64111, United States|Novartis Investigative Site, Kansas City, Missouri, 64132, United States|Novartis Investigative Site, Nixa, Missouri, 65714-7807, United States|Novartis Investigative Site, North Kansas City, Missouri, 64116, United States|Novartis Investigative Site, St. Louis, Missouri, 63104, United States|Novartis Investigative Site, Billings, Montana, 59102, United States|Novartis Investigative Site, Freehold, New Jersey, 07728, United States|Novartis Investigative Site, Somerset, New Jersey, 08873, United States|Novartis Investigative Site, Teaneck, New Jersey, 07666, United States|Novartis Investigative Site, Toms River, New Jersey, 08755, United States|Novartis Investigative Site, Amherst, New York, 14226, United States|Novartis Investigative Site, Latham, New York, 12110, United States|Novartis Investigative Site, New York, New York, 10023, United States|Novartis Investigative Site, Patchogue, New York, 11772, United States|Novartis Investigative Site, Plainview, New York, 11803, United States|Novartis Investigative Site, Asheville, North Carolina, 28806, United States|Novartis Investigative Site, Burlington, North Carolina, 27215, United States|Novartis Investigative Site, Charlotte, North Carolina, 28204, United States|Novartis Investigative Site, Charlotte, North Carolina, 28207, United States|Novartis Investigative Site, Greensboro, North Carolina, 27401, United States|Novartis Investigative Site, Greenville, North Carolina, 27834, United States|Novartis Investigative Site, Raleigh, North Carolina, 27607, United States|Novartis Investigative Site, Salisbury, North Carolina, 28144, United States|Novartis Investigative Site, Wilmington, North Carolina, 28401, United States|Novartis Investigative Site, Winston-Salem, North Carolina, 27103, United States|Novartis Investigative Site, Akron, Ohio, 44320, United States|Novartis Investigative Site, Bellevue, Ohio, 44811, United States|Novartis Investigative Site, Canton, Ohio, 44718, United States|Novartis Investigative Site, Cincinnati, Ohio, 45219, United States|Novartis Investigative Site, Columbus, Ohio, 43221, United States|Novartis Investigative Site, Uniontown, Ohio, 44685, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, 73112, United States|Novartis Investigative Site, Corvallis, Oregon, 97330, United States|Novartis Investigative Site, Eugene, Oregon, 97401, United States|Novartis Investigative Site, Medford, Oregon, 97504, United States|Novartis Investigative Site, Portland, Oregon, 97223, United States|Novartis Investigative Site, Monroeville, Pennsylvania, 15146, United States|Novartis Investigative Site, Rumford, Rhode Island, 02916, United States|Novartis Investigative Site, Beufort, South Carolina, 29902, United States|Novartis Investigative Site, Columbia, Tennessee, 38401, United States|Novartis Investigative Site, Cordova, Tennessee, 38018, United States|Novartis Investigative Site, Knoxville, Tennessee, 37934, United States|Novartis Investigative Site, Nashville, Tennessee, 37205, United States|Novartis Investigative Site, Austin, Texas, 78756, United States|Novartis Investigative Site, Colleyville, Texas, 76034, United States|Novartis Investigative Site, Dallas, Texas, 75204, United States|Novartis Investigative Site, Houston, Texas, 77025, United States|Novartis Investigative Site, Lubbock, Texas, 79410, United States|Novartis Investigative Site, Plano, Texas, 75075, United States|Novartis Investigative Site, Round Rock, Texas, 78681, United States|Novartis Investigative Site, San Antonio, Texas, 78229, United States|Novartis Investigative Site, San Antonio, Texas, 78258, United States|Novartis Investigative Site, Sherman, Texas, 75092, United States|Novartis Investigative Site, Salt Lake City, Utah, 84103, United States|Novartis Investigative Site, Newport News, Virginia, 23606, United States|Novartis Investigative Site, Richmond, Virginia, 23226, United States|Novartis Investigative Site, Roanoke, Virginia, 24014, United States|Novartis Investigative Site, Vienna, Virginia, 22182, United States|Novartis Investigative Site, Kirkland, Washington, 98034, United States|Novartis Investigative Site, Seattle, Washington, 98122, United States|Novartis Investigative Site, Seattle, Washington, 98144, United States|Novartis Investigative Site, Morgantown, West Virginia, 26506-9260, United States|Novartis Investigative Site, Calgary, Alberta, T2N 2T9, Canada|Novartis Investigative Site, Nepean, Ontario, K2G 6E2, Canada|Novartis Investigative Site, Ottawa, Ontario, K1H 8L6, Canada|Novartis Investigative Site, Greenfield Park, Quebec, J4V 2J2, Canada|Novartis Investigative Site, Montreal, Quebec, H1T 2M4, Canada|Novartis Investigative Site, Montreal, Quebec, H3A 2B4, Canada|Novartis Investigative Site, Guaynabo, 00969, Puerto Rico"
NCT02048072,Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS,https://beta.clinicaltrials.gov/study/NCT02048072,COMPLETED,Multiple Sclerosis|Autonomic Nervous System Dysfunction,DRUG: Gilenya,Jochen Vehoff,,ALL,ADULT,PHASE4,33,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2013-07,2015-06,2015-06,"Cantonal Hospital St. Gallen, St. Gallen, SG, 9000, Switzerland"
NCT03944538,Physical Activity Intervention for Improving Vascular Comorbidity Risk in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03944538,RECRUITING,Multiple Sclerosis,BEHAVIORAL: Lifestyle Physical Activity|BEHAVIORAL: General Wellness,University of Ottawa,University of Illinois at Chicago|National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",NA,48,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: OTHER,2019-07-21,2023-07,2023-12,"University of Ottawa, Ottawa, Ontario, K1N 6N5, Canada"
NCT01405872,"Persistence, Adherence, Quality of Life, and Treatment Satisfaction With Avonex® PEN™.",https://beta.clinicaltrials.gov/study/NCT01405872,COMPLETED,Multiple Sclerosis,OTHER: AVONEX PEN,Biogen,,ALL,"CHILD, ADULT, OLDER_ADULT",,270,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-09,2013-09,2013-09,"Research Site, Glostrup, Denmark|Research Site, Holstebro, Denmark|Research Site, Naestved, Denmark|Research Site, Amiens, France|Research Site, Clermont Ferrand, France|Research Site, Créteil, France|Research Site, Nancy, France|Research Site, Rouen, France|Research Site, Strasbourg, France|Research Site, Aachen, Germany|Research Site, Bamberg, Germany|Research Site, Berlin, Germany|Research Site, Dresden, Germany|Research Site, Eisenach, Germany|Research Site, Erbach, Germany|Research Site, Freiburg, Germany|Research Site, Hamburg, Germany|Research Site, Heidenheim, Germany|Research Site, Herford, Germany|Research Site, Itzehoe, Germany|Research Site, Kastellaun, Germany|Research Site, München, Germany|Research Site, Nagold, Germany|Research Site, Potsdam, Germany|Research Site, Regensburg, Germany|Research Site, Rottweil, Germany|Research Site, Ruedersdorf, Germany|Research Site, Schwendi, Germany|Research Site, Siegen, Germany|Research Site, Sinsheim, Germany|Research Site, Stade, Germany|Research Site, Weil am Rhein, Germany|Research Site, Weisbaden, Germany|Research Site, Wolfratshausen, Germany|Research Site, Eindhoven, Netherlands|Research Site, Heerlen, Netherlands|Research Site, Hertogenbosch, Netherlands|Research Site, Leeuwarden, Netherlands|Research Site, Sittard, Netherlands|Research Site, Bergen, Norway|Research Site, Drammem, Norway|Research Site, Førde, Norway|Research Site, Molde, Norway|Research Site, Tønsberg, Norway|Research Site, Amadora, Portugal|Research Site, Kosice, Slovakia|Research Site, Helsingborg, Sweden|Research Site, Karlstad, Sweden|Research Site, Linköping, Sweden|Research Site, Norrköping, Sweden|Research Site, Skövde, Sweden|Research Site, Stockholm, Sweden|Research Site, Trollhättan, Sweden|Research Site, Lugano, Switzerland|Research Site, Luzern, Switzerland|Research Site, Sion, Switzerland|Research Site, St. Gallen, Switzerland|Research Site, Dundee, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Hammersmith, United Kingdom|Research Site, Haywards Heath, United Kingdom|Research Site, Irvine, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, Sheffield, United Kingdom"
NCT00766272,Lokomat Training Effects on MS Gait Abnormalities,https://beta.clinicaltrials.gov/study/NCT00766272,TERMINATED,Multiple Sclerosis,DEVICE: Lokomat,US Department of Veterans Affairs,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,20,FED,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2008-06,2008-06,2008-06,"Providence VA Medical Center, Providence, Rhode Island, 02908-4799, United States"
NCT01026272,Novel Immune Markers in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01026272,UNKNOWN,Multiple Sclerosis,,University of Washington,,ALL,ADULT,,120,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-01,2011-01,2011-05,"University of Washington, Seattle, Washington, 98028, United States|University of Washington, Seattle, Washington, 98195, United States"
NCT02726672,Fatigue and Inspiratory Muscles Training in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02726672,TERMINATED,Multiple Sclerosis,DEVICE: respiratory rehabilitation using Powerbreathe,Lille Catholic University,,ALL,"ADULT, OLDER_ADULT",NA,46,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2016-02,2018-05,2018-11,"Hospital Group of the Catholic Institute of Lille, Lomme, 59462, France"
NCT05534672,Placebo Controlled Study to Assess the Efficacy and Safety of Rapamycin in Drug Resistant Epilepsy Associated With Tuberous Sclerosis Complex,https://beta.clinicaltrials.gov/study/NCT05534672,NOT_YET_RECRUITING,Tuberous Sclerosis Complex,OTHER: Rapamycin|OTHER: Placebo,Katarzyna Kotulska,,ALL,"CHILD, ADULT",PHASE3,200,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-09,2027-06,2027-06,"Medical University of Lodz, Lodz, 90-419, Poland|Children's Memorial Health Institute, Neurology and Epileptology, Warsaw, 04-730, Poland"
NCT02660138,Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1,https://beta.clinicaltrials.gov/study/NCT02660138,TERMINATED,Urinary Incontinence|Overactive Bladder,BIOLOGICAL: Botulinum toxin type A|BIOLOGICAL: Botulinum toxin type A|DRUG: Placebo|DRUG: Placebo,Ipsen,,ALL,"ADULT, OLDER_ADULT",PHASE3,227,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2016-03,2018-11-09,2019-02-14,"UAB School of Medicine Spain Rehabilitation Center (SRC), Birmingham, Alabama, 35249, United States|Urological Associates of Southern Arizona, P.C., Tucson, Arizona, 85715-3808, United States|Atlantic Urology Medical Group, Long Beach, California, 90806, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, 90089, United States|UC Davis Medical Center, Sacramento, California, 95817-2307, United States|University of Colorado Denver, Aurora, Colorado, 80045-2527, United States|Women's Health Specialty Care, Farmington, Connecticut, 06032-1933, United States|Gousse Urology - The Bladder Heath and Reconstructive Urology Institute, Miramar, Florida, 33029-5593, United States|The Iowa Clinic, PC, West Des Moines, Iowa, 50266, United States|Chesapeake Urology Associates, PA, Owings Mills, Maryland, 21117, United States|University of Michigan Hospital, Ann Arbor, Michigan, 48109, United States|Weill Cornell Medical College, Denville, New Jersey, 07834, United States|Delaware Valley Urology,IIC, Voorhees, New Jersey, 08043, United States|Urology Group of New Mexico, PC, Albuquerque, New Mexico, 87109, United States|Montefiore Medical Center, Bronx, New York, 10461, United States|New York University Langone Medical Center and School of Medicine, New York, New York, 10016, United States|New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, 10065, United States|Advanced Urology Centers of New York, Plainview, New York, 11783, United States|University of North Carolina School of Medicine, Chapel Hill, North Carolina, 27599, United States|Levine Cancer Institute, Charlotte, North Carolina, 28207, United States|Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, 44106, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|Lancaster Urology, Lancaster, Pennsylvania, 17601, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, 19107, United States|Medical University of South Carolina (MUSC), Charleston, South Carolina, 29425, United States|Vanderbilt University Medical Center, Nashville, Tennessee, 37232, United States|Urology Clinics of North Texas, Dallas, Texas, 75231, United States|Houston Methodist Hospital, Houston, Texas, 77030, United States|Lahey Hospital & Medical Center, Burlington, Vermont, 01805-0001, United States|Urology of Virginia, PLLC, Virginia Beach, Virginia, 23462-1815, United States|Integrity Medical Research, Mountlake Terrace, Washington, 98043, United States|Medical College of Wisconsin - Freodert Hospital, Milwaukee, Wisconsin, 53226, United States|CHUS - Hôpital Fleurimont, Sherbrooke, 02114-2621, Canada|Sunnybrook Health Sciences Centre, Toronto, 02115-6110, Canada|UBC Hospital - Koerner Pavilion, Vancouver, V6T 2B5, Canada|Spinal Cord Research Centre, University of Manitoba, Winnipeg, R3A 1M4, Canada|Fakultní Nemocnice Brno, Brno, 62500, Czechia|Karlovarska krajska nemocnice, a.s., Karlovy Vary, 360 01, Czechia|Krajská Nemocnice Liberec, a.s., Liberec, 46063, Czechia|Uromedical Center s.r.o., Olomouc, 77900, Czechia|Fakultní nemocnice Královské Vinohrady, Praha 10, 100 34, Czechia|Všeobecná fakultní nemocnice v Praze, Praha 2, 12808, Czechia|Fakultní Nemocnice v Motole, Praha 5, 15006, Czechia|Thomayerova nemocnice, Praha, 14059, Czechia|Urologicka Ordinace s.r.o., Sternberk, 785 01, Czechia|Azienda Ospedaliero-Universitaria Careggi - Dipartimento Di Neuro-Urologia, Firenze, 50134, Italy|Farmacia Istituto Ospedaliero ICOT ""Marco Pasquali"", Latina, 04100, Italy|Azienda Ospedaliera di Perugia - Ospedale Santa Maria della Misericordia, Perugia, 06132, Italy|Viale Oxford, 81, Roma, 00133, Italy|Ospedale ""Bolognini"" di Seriate, Seriate, 24068, Italy|Azienda Ospedaliera di Perugia - Ospedale Santa Maria della Misericordia, Udine, 33100, Italy|88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea, Republic of|Samsung Medical Center, Seoul, 6351, Korea, Republic of|Ulsan University Hospital (UUH), Ulsan, 44033, Korea, Republic of|VU University Medical Center, Amsterdam, 1081 HV, Netherlands|Radboud UMC, Nijmegen, 6525 GA, Netherlands|Erasmus MC, Rotterdam, 3015 CE, Netherlands|Wojewódzki Szpital Zespolony w Elblągu, Elblag, 82-300, Poland|Nzoz Neuro-Medic Poradnia Wielospecjalistyczna, Katowice, 40-752, Poland|NZOZ Heureka, Piaseczno, 05-500, Poland|Szpital Kliniczny Dzieciątka Jezus w Warszawie, Warszawa, 02-005, Poland|EuroMediCare Szpital Specjalistyczny z Przychodnią we Wrocławiu, Wroclaw, 54-144, Poland|Hospital de Braga, Braga, 4700-001, Portugal|Centro Hospitalar do Alto Ave, EPE, Guimarães, 4835-044, Portugal|British Hospital, Lisboa, 1600-209, Portugal|Centro Hospitalar do Porto, EPE - Hospital Geral de Santo António, Porto, 4099-001, Portugal|Centro Hospitalar de São João, EPE - Hospital de São João, Porto, 4200-319, Portugal|Gnosis Evomed, Bucharest, 031864, Romania|Spitalul Clinic Colentina, Bucharest, 20125, Romania|Spitalul Clinic Fundeni Bucureşti, Bucharest, 22328, Romania|Hifu Terramed Conformal S.R.L, Bucharest, 31864, Romania|Spitalul Clinic Judeţean Mureş, Târgu-Mureş, 540103, Romania|Ankara Üniversitesi Tıp Fakültesi, Ankara, 6100, Turkey|Medipol Mega University Hospital, Bagcilar, 34200, Turkey|Uludag Universitesi Tip Fakultesi, Uroloji Anabilim Dali, Gorukle, Bursa, 16059, Turkey|Marmara Üniversitesi Eğitim ve Araştırma Hastanesi, Istanbul, 34670, Turkey|Istanbul Medeniyet Universitesi Goztepe Egitim ve Arastirma Hastanesi Merdivenköy Mah, Istanbul, 34732, Turkey|Erciyes Üniversitesi Tıp Fakültesi, Kayseri, 38039, Turkey|Kocaeli Üniversitesi Tıp Fakültesi, Kocaeli, 41380, Turkey|Celal Bayar Universitesi Hafsa Sultan Hastanesi, Manisa, 45040, Turkey|Ondokuz Mayıs Üniversitesi Tıp Fakültesi, Samsun, 55139, Turkey"
NCT02307838,Long-term Follow-up of Fingolimod Phase II Study Patients,https://beta.clinicaltrials.gov/study/NCT02307838,COMPLETED,"Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis",OTHER: Assessments arm,Novartis Pharmaceuticals,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE4,177,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2014-06,2015-12,2015-12,"Novartis Investigative Site, Ottawa, Ontario, K1H 8L6, Canada|Novartis Investigative Site, Toronto, Ontario, M5B 1N9, Canada|Novartis Investigative Site, Montreal, Quebec, H2L 4M1, Canada|Novartis Investigative Site, Montreal, Quebec, H3A 2B4, Canada|Novartis Investigative Site, Copenhagen, DK-2100, Denmark|Novartis Investigative Site, Glostrup, DK-2600, Denmark|Novartis Investigative Site, Lille, 59037, France|Novartis Investigative Site, Marseille, 13385, France|Novartis Investigative Site, Würzburg, 97080, Germany|Novartis Investigative Site, Genova, GE, 16132, Italy|Novartis Investigative Site, Milano, MI, 20132, Italy|Novartis Investigative Site, Roma, RM, 00189, Italy|Novartis Investigative Site, Gallarate, VA, 21013, Italy|Novartis Investigative Site, Warszawa, 02-097, Poland|Novartis Investigative Site, Warszawa, 02-957, Poland|Novartis Investigative Site, Coimbra, 3000-075, Portugal|Novartis Investigative Site, Lisboa, 1150-314, Portugal|Novartis Investigative Site, Malaga, Andalucia, 29010, Spain|Novartis Investigative Site, Sevilla, Andalucia, 41009, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08035, Spain|Novartis Investigative Site, L'Hospitalet de Llobregat, Catalunya, 08907, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, 46026, Spain|Novartis Investigative Site, Madrid, 28040, Spain|Novartis Investigative Site, Basel, 4031, Switzerland|Novartis Investigative Site, Zuerich, 8091, Switzerland|Novartis Investigative Site, Newcastle Upon Tyne, NE1 4LP, United Kingdom"
NCT05165238,Impact Program for Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05165238,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,BEHAVIORAL: Impact of four week coaching program on dietary habits,University of Alabama at Birmingham,,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2022-01-10,2023-06,2023-06,"UAB, Birmingham, Alabama, 35094, United States"
NCT04191772,The Impact of Training on Sitting Time and Brain Volumes in Multiple Sclerosis.,https://beta.clinicaltrials.gov/study/NCT04191772,COMPLETED,Multiple Sclerosis,"OTHER: Periodized, home-based running program",Hasselt University,,ALL,"ADULT, OLDER_ADULT",NA,156,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-01-15,2021-06-30,2021-06-30,"Hasselt University, Diepenbeek, Limburg, 3590, Belgium"
NCT02764372,Telerehabilitation Upper Extremity for Neurological Disorders,https://beta.clinicaltrials.gov/study/NCT02764372,COMPLETED,Multiple Sclerosis|Stroke,BEHAVIORAL: Serious games|BEHAVIORAL: Exergames,Fondazione Don Carlo Gnocchi Onlus,University of Bremen,ALL,"ADULT, OLDER_ADULT",PHASE1,20,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2015-07,2016-03,2016-04,
NCT01232738,Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS),https://beta.clinicaltrials.gov/study/NCT01232738,COMPLETED,Amyotrophic Lateral Sclerosis (ALS),DRUG: rasagiline,"Yunxia Wang, MD",Western ALS Study Group,ALL,"ADULT, OLDER_ADULT",PHASE2,36,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-12,2013-05,2013-05,"Phoenix Neurological Institute, Phoenix, Arizona, 85018, United States|California Pacific Medical Center, San Francisco, California, 94118, United States|University of Iowa, Iowa City, Iowa, 52242, United States|University Of Kansas Medical Center, Kansas City, Kansas, 66160, United States|University of Minnesota, Minneapolis, Minnesota, 55414, United States|University of Nebraska Medical Center, Omaha, Nebraska, 68198, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|University of Tennessee, Memphis, Tennessee, 38104, United States|The Methodist Hospital System, Houston, Texas, 77030, United States|McGill University, Montreal, Quebec, H3A 2B4, Canada"
NCT02411838,Calorie Restriction in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT02411838,COMPLETED,Multiple Sclerosis,OTHER: Calorie restriction,Washington University School of Medicine,,ALL,ADULT,NA,17,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2014-02,2016-12,2017-06,"Washington University in St Louis, Saint Louis, Missouri, 63110, United States"
NCT04538872,Learning Strategies for Improving Dual Task Performance in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04538872,COMPLETED,Multiple Sclerosis,BEHAVIORAL: StraDiMS implicit|BEHAVIORAL: StraDiMs explicit,Hasselt University,National MS Center Melsbroek|Revalidatie & MS Centrum Overpelt,ALL,"ADULT, OLDER_ADULT",NA,37,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2020-09-01,2021-04-30,2021-04-30,"Noorderhart, Overpelt, 3900, Belgium|National MS Center Melsbroek, Steenokkerzeel, 1820, Belgium"
NCT00489489,Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00489489,COMPLETED,Multiple Sclerosis,DRUG: Teriflunomide|DRUG: Placebo (for Teriflunomide)|DRUG: Interferon-β,Sanofi,,ALL,ADULT,PHASE2,118,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2007-05,2009-06,2009-06,"Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, 08807, United States|Sanofi-Aventis Administrative Office, Laval, Canada|Sanofi-Aventis Administrative Office, Berlin, Germany|Sanofi-Aventis Administrative Office, Milan, Italy|Sanofi-Aventis Administrative Office, Barcelona, Spain"
NCT04285346,Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B),https://beta.clinicaltrials.gov/study/NCT04285346,COMPLETED,Tuberous Sclerosis,DRUG: Ganaxolone,Marinus Pharmaceuticals,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,23,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-04-08,2021-06-25,2022-08-30,"Marinus Research Site, Los Angeles, California, 90095, United States|Marinus Research Site, Palo Alto, California, 94304, United States|Marinus Research Site, Boston, Massachusetts, 02115, United States|Marinus Research Site, Livingston, New Jersey, 07039, United States|Marinus Research Site, Durham, North Carolina, 27710, United States|Marinus Research Site, Cincinnati, Ohio, 45229, United States|Marinus Research Site, Houston, Texas, 77030, United States"
NCT03878810,Exergaming in Persons With Multiple Sclerosis With Restless Legs Syndrome,https://beta.clinicaltrials.gov/study/NCT03878810,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Exergaming,Dokuz Eylul University,,ALL,"ADULT, OLDER_ADULT",NA,65,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2019-03-29,2021-09-15,2021-12-15,"MS Outpatient Clinic, Dokuz Eylul University Hospital, Izmir, 35430, Turkey"
NCT04688710,Use of Audio Recordings of Self-Hypnosis and Meditation for Fatigue Management in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04688710,RECRUITING,Multiple Sclerosis|Fatigue,BEHAVIORAL: Self-Hypnosis (HYP)|BEHAVIORAL: Mindfulness Meditation (MM),University of Washington,National Multiple Sclerosis Society|The University of Queensland,ALL,"ADULT, OLDER_ADULT",NA,333,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-04-30,2023-12-31,2024-03-31,"UW Medicine Multiple Sclerosis Center, Seattle, Washington, 98133, United States"
NCT02142946,Quantified Balance Measures During Stance and Gait: Multiple Sclerosis Patients. A Longitudinal Clinical Study,https://beta.clinicaltrials.gov/study/NCT02142946,RECRUITING,Balance Control,,"University Hospital, Basel, Switzerland",,ALL,"ADULT, OLDER_ADULT",,300,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-04,2023-06,2023-12,"Lab for Exp Otoneurology, University Hospital Basel, Basel, CH-4031, Switzerland"
NCT03387046,A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS),https://beta.clinicaltrials.gov/study/NCT03387046,TERMINATED,"Multiple Sclerosis, Relapsing-Remitting",DIETARY_SUPPLEMENT: D-aspartate|DRUG: Placebo|BIOLOGICAL: IFN beta-1a|DRUG: Methylprednisolone,"Merck KGaA, Darmstadt, Germany",,ALL,ADULT,PHASE2,7,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2018-03-26,2019-01-11,2019-01-11,"Ospedale Binaghi, Università di Cagliari,ASL 8, Cagliari, Italy|Ospedale Clinicizzato SS. Annunziata, Chieti, Italy|Azienda Socio Sanitaria Territoriale della Valle Olona (presidio di Gallarate), Gallarate, Italy|Azienda Ospedaliero Universitaria San Martino, Genova, Italy|Ospedale P.A.Micone, Genova, Italy|Ospedale San Raffaele, Milano, Italy|A.O.U. Federico II, Napoli, Italy|Azienda Ospedaliera di Rilievo Nazionale A. CardarelliAzienda Ospedaliera di Rilievo Nazionale A. Cardarelli, Napoli, Italy|Seconda Università degli Studi di Napoli, Napoli, Italy|Azienda Ospedaliera di Padova, Padova, Italy|I.R.C.C.S. Neuromed-Istituto Neurologico Mediterraneo, Pozzilli, Italy|Azienda Ospedaliera San Camillo Forlanini, Roma, Italy|Azienda Ospedaliera Sant'Andrea-Università di Roma La Sapienza, Roma, Italy|Policlinico Universitario Agostino Gemelli, Roma, Italy|Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Rome, Italy|Ospedale S. Paolo, Savona, Italy|Azienda Ospedaliero Universitaria Ospedali Riuniti, Torrette Di Ancona, Italy"
NCT00147446,Stress Management for Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00147446,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Individual Stress Management|OTHER: Wait List Control,Northwestern University,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),ALL,"ADULT, OLDER_ADULT",PHASE2,121,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2005-05,2009-01,2009-01,"UCSF Behavioral Medicine Research Center, San Francisco, California, 94121, United States|Northwestern University, Department of Preventive Medicine, Chicago, Illinois, 60611, United States|MS Center at Evergreen Medical Center, Kirkland, Washington, 98034, United States"
NCT03049046,CC100: Phase 1 Multiple-Dose Safety and Tolerability in Subjects With ALS,https://beta.clinicaltrials.gov/study/NCT03049046,UNKNOWN,Amyotrophic Lateral Sclerosis,DRUG: CC100|DRUG: Placebos,"Chemigen, LLC",,ALL,ADULT,PHASE1,21,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2017-04-07,2018-01-30,2018-03-30,"Indiana University, IU Health Physicians Neurology, Indianapolis, Indiana, 46202, United States"
NCT04338646,Is the Severity of Urinary Disorders Related to Falls in People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04338646,COMPLETED,Fall|Multiple Sclerosis|Lower Urinary Tract Symptoms,OTHER: Clinical tests,Gérard Amarenco,,ALL,"ADULT, OLDER_ADULT",,150,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-07-01,2020-04-15,2020-04-30,"department of Neuro-Urology, Hôpital Tenon, Paris, 75020, France"
NCT04979546,Using Patient-Reported Outcomes To Improve the Care of People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04979546,RECRUITING,Multiple Sclerosis|Anxiety|Depression|Patient Satisfaction,OTHER: Intensive Use of Patient Reported Outcome Measures and Open PROM Availability to Treating Neurologist|OTHER: Conservative Use of Patient Reported Outcome Measures and Blinded PROM Availability to Treating Neurologist,University of Alberta,University Hospital Foundation,ALL,"ADULT, OLDER_ADULT",NA,356,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2021-11-04,2023-10-15,2024-10-15,"University of Alberta, Edmonton, Alberta, T6G 2R3, Canada"
NCT00043264,Antibiotic Treatment Trial Directed Against Chlamydia Pneumonia in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00043264,COMPLETED,Multiple Sclerosis,DRUG: Rifampin|DRUG: Azithromycin,National Center for Research Resources (NCRR),National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",PHASE2,40,NIH,INTERVENTIONAL,Allocation: |Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,,,,"University of Texas Medical School, Houston, Texas, 77030, United States"
NCT04338061,Study of Evobrutinib in Participants With RMS (evolutionRMS 2),https://beta.clinicaltrials.gov/study/NCT04338061,ACTIVE_NOT_RECRUITING,Relapsing Multiple Sclerosis,DRUG: Evobrutinib|DRUG: Placebo (match to Teriflunomide)|DRUG: Teriflunomide|DRUG: Placebo (match to Evobrutinib),"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","EMD Serono Research & Development Institute, Inc.",ALL,ADULT,PHASE3,1124,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-07-02,2023-09-04,2026-06-26,"Research Site 752, Cullman, Alabama, 35058, United States|Research Site 741, Scottsdale, Arizona, 85258, United States|Research Site 704, Tucson, Arizona, 85710, United States|Research Site 751, Hanford, California, 93230, United States|Research Site 737, West Hollywood, California, 90048, United States|Research Site 759, Colorado Springs, Colorado, 80907, United States|Research Site 725, Fort Collins, Colorado, 80528, United States|Research Site 746, Altamonte Springs, Florida, 32714, United States|Research Site 718, Jacksonville, Florida, 32209, United States|Research Site 702, Naples, Florida, 34105, United States|Research Site 740, Orlando, Florida, 32806, United States|Research Site 726, Port Charlotte, Florida, 33952, United States|Research Site 719, Sarasota, Florida, 34243, United States|Research Site 743, Tampa, Florida, 33612, United States|Research Site 707, Tampa, Florida, 33634, United States|Research Site 732, Vero Beach, Florida, 32960, United States|Research Site 705, Weeki Wachee, Florida, 34607, United States|Research Site 753, West Palm Beach, Florida, 33407, United States|Research Site 742, Honolulu, Hawaii, 96817, United States|Research Site 715, Evanston, Illinois, 60201, United States|Research Site 714, Fort Wayne, Indiana, 46804, United States|Research Site 744, Lafayette, Indiana, 47904, United States|Research Site 717, Overland Park, Kansas, 66212, United States|Research Site 735, Nicholasville, Kentucky, 40356, United States|Research Site 706, Scarborough, Maine, 04074, United States|Research Site 738, Detroit, Michigan, 48202, United States|Research Site 723, Saint Louis, Missouri, 63128, United States|Research Site 724, Amherst, New York, 14226, United States|Research Site 736, Asheville, North Carolina, 28006, United States|Research Site 712, Chapel Hill, North Carolina, 27599, United States|Research Site 728, Winston-Salem, North Carolina, 27157, United States|Research Site 711, Canton, Ohio, 44735, United States|Research Site 757, Columbus, Ohio, 43214, United States|Research Site 734, Dayton, Ohio, 45459, United States|Research Site 748, Philadelphia, Pennsylvania, 19107, United States|Research Site 703, San Antonio, Texas, 78258, United States|Research Site 721, Norfolk, Virginia, 23502, United States|Research Site 144, Gomel, Belarus|Research Site 143, Grodno, Belarus|Research Site 142, Minsk, Belarus|Research Site 141, Vitebsk, Belarus|Research Site 145, Vitebsk, Belarus|Research Site 603, Belo Horizonte, Brazil|Research Site 599, Curitiba, Brazil|Research Site 604, Goiânia, Brazil|Research Site 600, Joinville, Brazil|Research Site 614, Passo Fundo, Brazil|Research Site 591, Porto Alegre, Brazil|Research Site 594, Porto Alegre, Brazil|Research Site 596, Porto Alegre, Brazil|Research Site 609, Vitória, Brazil|Research Site 155, Blagoevgrad, Bulgaria|Research Site 156, Dupnitsa, Bulgaria|Research Site 157, Pleven, Bulgaria|Research Site 801, Pleven, Bulgaria|Research Site 804, Pleven, Bulgaria|Research Site 805, Plovdiv, Bulgaria|Research Site 151, Sofia, Bulgaria|Research Site 152, Sofia, Bulgaria|Research Site 153, Sofia, Bulgaria|Research Site 158, Sofia, Bulgaria|Research Site 159, Sofia, Bulgaria|Research Site 160, Sofia, Bulgaria|Research Site 802, Sofia, Bulgaria|Research Site 803, Sofia, Bulgaria|Research Site 808, Sofia, Bulgaria|Research Site 154, Veliko Tarnovo, Bulgaria|Research Site 106, Burnaby, Canada|Research Site 107, London, Canada|Research Site 105, Montreal, Canada|Research Site 101, Ottawa, Canada|Research Site 455, Bordeaux Cedex, France|Research Site 459, Brest cedex 2, France|Reserach Site 451, Clermont Ferrand Cedex, France|Research Site 458, Limoges cedex, France|Research Site 456, Nimes, France|Research Site 453, Paris, France|Research Site 457, Pringy cedex, France|Research Site 452, Strasbourg cedex, France|Research Site 454, Tours cedex 9, France|Research Site 172, Augsburg, Germany|Research Site 177, Berlin, Germany|Research Site 180, Berlin, Germany|Research Site 178, Bonn, Germany|Research Site 184, Dresden, Germany|Research Site 174, Hamburg, Germany|Research Site 182, Heidelberg, Germany|Research Site 179, Koeln, Germany|Research Site 181, Leipzig, Germany|Research Site 173, Mainz, Germany|Research Site 176, Minden, Germany|Research Site 171, Regensburg, Germany|Research Site 183, Rostock, Germany|Research Site 175, Tuebingen, Germany|Research Site 194, Athens, Greece|Research Site 196, Athens, Greece|Research Site 197, Athens, Greece|Research Site 201, Athens, Greece|Research Site 202, Athens, Greece|Research Site 205, Athens, Greece|Research Site 207, Athens, Greece|Reserach Site 206, Athens, Greece|Research Site 198, Heraklion, Greece|Research Site 204, Ioannina, Greece|Research Site 192, Larissa, Greece|Research Site 199, Marousi, Greece|Research Site 191, Patras, Greece|Research Site 203, Patra, Greece|Research Site 195, Thessaloniki, Greece|Research Site 445, Ahmedabad, India|Research Site 444, Bangalore, India|Research Site 443, Mangalore, India|Research Site 442, New Delhi, India|Research Site 218, Bari, Italy|Research Site 216, Catania, Italy|Research Site 214, Cefalù, Italy|Research Site 219, Firenze, Italy|Research Site 221, Milano, Italy|Research Site 211, Napoli, Italy|Research Site 215, Napoli, Italy|Research Site 220, Orbassano, Italy|Research Site 217, Palermo, Italy|Research Site 212, Pozzilli, Italy|Research Site 213, Roma, Italy|Research Site 222, Roma, Italy|Research Site 231, Riga, Latvia|Research Site 232, Riga, Latvia|Research Site 233, Riga, Latvia|Research site 241, Kaunas, Lithuania|Research site 244, Klaipeda, Lithuania|Research site 243, Siauliai, Lithuania|Research site 242, Vilnius, Lithuania|Research Site 551, Kuala Lumpur, Malaysia|Research Site 554, Kuala Lumpur, Malaysia|Research Site 556, Kuala Lumpur, Malaysia|Research Site 552, Kuching, Malaysia|Research Site 553, Seberang Jaya, Malaysia|Research Site 251, Chisinau, Moldova, Republic of|Research Site 252, Chisinau, Moldova, Republic of|Research Site 481, Bergen, Norway|Research site 483, Drammen, Norway|Research Site 482, Namsos, Norway|Research Site 562, Baguio City, Philippines|Research Site 561, Cebu City, Philippines|Reserach Site 267, Bydgoszcz, Poland|Reserach Site 268, Bydgoszcz, Poland|Research site 274, Katowice-Ochojec, Poland|Research Site 273, Katowice, Poland|Research site 846, Katowice, Poland|Research Site 276, Krakow, Poland|Research Site 263, Lodz, Poland|Research Site 266, Nowa Sol, Poland|Research Site 270, Poznan, Poland|Research Site 262, Rzeszow, Poland|Research Site 265, Siemianowice, Poland|Research Site 271, Szczecin, Poland|Research Site 264, Warszawa, Poland|Research Site 277, Warszawa, Poland|Reserach Site 275, Warszawa, Poland|Research Site 261, Zabrze, Poland|Research Site 278, Zamosc, Poland|Research Site 272, Łódź, Poland|Research Site 293, Aveiro, Portugal|Research Site 282, Braga, Portugal|Research Site 289, Coimbra, Portugal|Research Site 281, Lisboa, Portugal|Research Site 283, Lisboa, Portugal|Research Site 287, Lisboa, Portugal|Research SIte 284, Matosinhos, Portugal|Research Site 292, Porto, Portugal|Research Site 288, Pragal, Portugal|Research Site 291, Santa Maria da Feira, Portugal|Research Site 286, Torres Vedras, Portugal|Research Site 791, Guaynabo, Puerto Rico|Research Site 314, Brasov, Romania|Research Site 307, București, Romania|Research Site 309, Caracal, Romania|Research Site 302, Targu Mures, Romania|Research Site 325, Kazan, Russian Federation|Research Site 329, Kazan, Russian Federation|Research Site 323, Kemerovo, Russian Federation|Research Site 344, Kirov, Russian Federation|Research Site 340, Krasnodar, Russian Federation|Research Site 334, Krasnoyarsk, Russian Federation|Research Site 341, Moscow, Russian Federation|Research Site 343, Moscow, Russian Federation|Research Site 345, Moscow, Russian Federation|Research Site 332, Nizhniy Novgorod, Russian Federation|Research Site 327, Novosibirsk, Russian Federation|Research Site 330, Novosibirsk, Russian Federation|Research Site 331, Novosibirsk, Russian Federation|Research Site 335, Novosibirsk, Russian Federation|Research Site 328, Rostov-on-Don, Russian Federation|Research Site 346, Saint Petersburg, Russian Federation|Research Site 324, Saint-Petersburg, Russian Federation|Research Site 338, Saint-Petersburg, Russian Federation|Research Site 339, Saint-Petersburg, Russian Federation|Research Site 342, Saint-Petersburg, Russian Federation|Research Site 326, Saransk, Russian Federation|Research Site 321, Sestroretsk, Russian Federation|Research Site 337, Tyumen, Russian Federation|Research Site 493, Riyadh, Saudi Arabia|Research Site 571, Singapore, Singapore|Research site 572, Singapore, Singapore|Research Site 351, Banska Bystrica, Slovakia|Research Site 352, Bratislava, Slovakia|Research Site 353, Bratislava, Slovakia|Research Site 354, Bratislava, Slovakia|Research Site 356, Bratislava, Slovakia|Research Site 359, Dubnica nad Vahom, Slovakia|Research Site 358, Trencin, Slovakia|Research Site 357, Trnava, Slovakia|Research Site 373, Celje, Slovenia|Research Site 372, Ljubljana, Slovenia|Research Site 371, Maribor, Slovenia|Research Site 501, Cape Town, South Africa|Research Site 502, Cape Town, South Africa|Research Site 503, Cape Town, South Africa|Research Site 504, Pretoria, South Africa|Research Site 384, Alcorcon, Spain|Research Site 391, Barakaldo, Spain|Research Site 390, Barcelona, Spain|Research Site 382, Cordoba, Spain|Research Site 389, El Palmar, Spain|Research Site 388, Madrid, Spain|Research Site 392, Majadahonda, Spain|Research Site 383, Malaga, Spain|Research Site 387, Sevilla, Spain|Research Site 385, Valencia, Spain|Research Site 386, Valencia, Spain|Research Site 381, Vigo, Spain|Research Site 512, Göteborg, Sweden|Research site 514, Malmö, Sweden|Research Site 511, Stockholm, Sweden|Research Site 513, Uppsala, Sweden|Research Site 404, Aarau, Switzerland|Research Site 402, Bern, Switzerland|Research Site 403, Lugano, Switzerland|Research Site 583, Bangkoknoi, Thailand|Research Site 582, Muang, Thailand|Research Site 538, Ankara, Turkey|Research Site 544, Ankara, Turkey|Research Site 531, Istanbul, Turkey|Research Site 534, Istanbul, Turkey|Research Site 536, Istanbul, Turkey|Research Site 541, Istanbul, Turkey|Research Site 543, Istanbul, Turkey|Research Site 539, Izmir, Turkey|Research Site 533, Kocaeli, Turkey|Research Site 537, Konya, Turkey|Research Site 540, Mersin, Turkey|Research Site 535, Samsun, Turkey|Research Site 532, Trabzon, Turkey|Research Site 415, Chernihiv, Ukraine|Research Site 417, Chernihiv, Ukraine|Research Site 414, Dnipro, Ukraine|Research Site 416, Dnipro, Ukraine|Research Site 420, Dnipro, Ukraine|Research Site 413, Ivano-Frankivsk, Ukraine|Research Site 624, Kharkiv, Ukraine|Research Site 632, Kharkiv, Ukraine|Research Site 633, Kharkiv, Ukraine|Research Site 419, Kherson, Ukraine|Research Site 411, Kyiv, Ukraine|Research Site 418, Kyiv, Ukraine|Research Site 629, Lutsk, Ukraine|Research Site 627, Lviv, Ukraine|Research Site 622, Poltava, Ukraine|Research Site 625, Rivne, Ukraine|Research Site 628, Ternopil, Ukraine|Research Site 630, Uzhgorod, Ukraine|Research Site 623, Vinnytsia, Ukraine|Research Site 412, Zaporizhzhia, Ukraine|Research Site 621, Zaporizhzhia, Ukraine|Research Site 631, Zaporizhzhia, Ukraine|Research Site 626, Zhytomyr, Ukraine"
NCT01684761,Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01684761,COMPLETED,Autoimmune Diseases of the Nervous System|Multiple Sclerosis|Secondary Progressive Multiple Sclerosis|Disease Progression|Brain Atrophy,BIOLOGICAL: Tcelna|BIOLOGICAL: Placebo,"Opexa Therapeutics, Inc.",,ALL,ADULT,PHASE2,183,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-08,2016-10,2016-10,"HOPE Research Institute, Phoenix, Arizona, 85050, United States|Northwest NeuroSpecialists, LLC, Tucson, Arizona, 85741, United States|Alta Bates Summit Medical Center, The Research and Education Development Institute, Berkeley, California, 94705, United States|Neurology Associates, P.A., Maitland, Florida, 32751, United States|University of Miami, Miami, Florida, 33136, United States|Collier Neurologic Specialists, LLC, Naples, Florida, 34102, United States|Neurological Services of Orlando, Orlando, Florida, 32806, United States|Meridien Research, Tampa, Florida, 33606, United States|Vero Beach Neurology, Vero Beach, Florida, 32960, United States|Shepherd Center, Atlanta, Georgia, 30309, United States|Consultants In Neurology, Ltd., Northbrook, Illinois, 60062, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, 46804, United States|Josephson Wallack Munshower Neurology, PC, Indianapolis, Indiana, 46256, United States|University of Kansas Medical Center, Kansas City, Kansas, 66160, United States|Associates in Neurology, Lexington, Kentucky, 40503, United States|Saint Elizabeth's Medical Center, Boston, Massachusetts, 02135, United States|Island Neurological Assoicates, PC, Plainview, New York, 11803, United States|University Hospital and Medical Center Stony Brook New York, Stony Brook, New York, 11794-8121, United States|The Neurological Institute, PA, Charlotte, North Carolina, 28204, United States|Carolinas Medical Center Neurology, Charlotte, North Carolina, 28207, United States|PMG Research of Charlotte, Charlotte, North Carolina, 28209, United States|Neurology Specialists, Inc, Dayton, Ohio, 45408, United States|Providence Medical Group - Medford, Medford, Oregon, 97504, United States|Providence St. Vincent Medical Center - Northwest MS Center, Portland, Oregon, 97225, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|The Maxine Mesinger MS Clinic/Baylor College of Medicine, Houston, Texas, 77030, United States|Central Texas Neurology, Round Rock, Texas, 78681, United States|Integra Clinical Research, LLC, San Antonio, Texas, 78229, United States|Fletcher Allen Health Care - Neurology Service, Burlington, Vermont, 05401, United States|Hampton Roads Neurology, Newport News, Virginia, 23601, United States|Neurological Associates, Inc, Richmond, Virginia, 23226, United States|Swedish Neuroscience Institute, Issaquah, Washington, 98029, United States|Swedish Neuroscience Institute, Seattle, Washington, 98122, United States|University of Ottawa, Ottawa, Ontario, K1H 8L6, Canada|Recherche Sepmus Inc., Greenfield Park, Quebec, J4V 2J2, Canada|Montreal Neurological Institute and Hospital, Montreal, Quebec, H3A 2B4, Canada"
NCT00317564,Betaseron Pregnancy Registry,https://beta.clinicaltrials.gov/study/NCT00317564,COMPLETED,Birth Defects|Pregnancy Complications|Multiple Sclerosis,,Syneos Health,Bayer,FEMALE,"CHILD, ADULT, OLDER_ADULT",,113,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2006-04,2012-04,2012-06,"INC Research, Wilmington, North Carolina, 28405, United States"
NCT05049161,A Long-term Extension of Study GNC-401,https://beta.clinicaltrials.gov/study/NCT05049161,TERMINATED,Multiple Sclerosis,DRUG: Temelimab 18 mg/kg|DRUG: Temelimab 36mg/kg|DRUG: Temelimab 54 mg/kg,GeNeuro Innovation SAS,,ALL,ADULT,PHASE2,33,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-08-27,2022-05-18,2022-05-18,"Center for Neurology, Academic Specialist Center, Stockholm, 113 65, Sweden"
NCT02740361,Online Program to Reduce Depression in MS,https://beta.clinicaltrials.gov/study/NCT02740361,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,"BEHAVIORAL: Deprexis, DeprexisPlus","Charite University, Berlin, Germany","National Multiple Sclerosis Society|Universitätsklinikum Hamburg-Eppendorf|Cedars-Sinai Medical Center|University of Missouri, Kansas City|Penn State University|King's College London|University Medical Center Goettingen|NeuroCure Clinical Research Center, Charite, Berlin",ALL,"ADULT, OLDER_ADULT",NA,400,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2017-02-15,2021-01-30,2021-12-31,"Cedars-Sinai Medical Center, Los Angeles, California, 90048, United States|University of Missouri, Kansas City, Kansas City, Kansas, 66103, United States|Penn State University, State College, Pennsylvania, 16801, United States|Charité University, Berlin, 10117, Germany|Universitätsklinikum Hamburg-Eppendorf, Hamburg, 20246, Germany"
NCT03805061,Effects of Aerobic and Isokinetic Exercise in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03805061,COMPLETED,Multiple Sclerosis,OTHER: 'aerobic exercise'|DEVICE: 'isokinetic exercise',Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization,,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2008-04-30,2008-10-30,2008-11-01,
NCT05755061,WEBCAMS: Walking Exercise for Brain and Cognition in Adults With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05755061,RECRUITING,Multiple Sclerosis|Relapsing-remitting Multiple Sclerosis,BEHAVIORAL: GEMS Plus|BEHAVIORAL: GEMS,Kessler Foundation,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1,32,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-02-01,2024-05-31,2024-07-31,"Kessler Foundation, West Orange, New Jersey, 07052, United States"
NCT02104661,Protective Role of Oxcarbazepine in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02104661,COMPLETED,Multiple Sclerosis,DRUG: Oxcarbazepine|DRUG: Placebo,Queen Mary University of London,"National Multiple Sclerosis Society|Novartis Pharmaceuticals|Barts & The London NHS Trust|University College, London|Royal Free Hospital NHS Foundation Trust|Mid and South Essex NHS Foundation Trust|St George's Healthcare NHS Trust|Barnet and Chase Farm Hospitals NHS Trust",ALL,ADULT,PHASE2,30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-10,2018-01-31,2018-01-31,"Barts Health NHS Trust, London, E1 1BB, United Kingdom"
NCT00534261,Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a?,https://beta.clinicaltrials.gov/study/NCT00534261,COMPLETED,Relapsing Remitting Multiple Sclerosis,DRUG: Interferon beta-1a,Biogen,,ALL,"ADULT, OLDER_ADULT",PHASE4,284,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,1999-11,,2004-02,"Coordinating Research Site, Sijsele-Damme, 8340, Belgium|Coordinating Research Site, Esch-Sur-Alzette, 4011, Luxembourg|Coordinating Research Site, Glasgow, Scotland, United Kingdom"
NCT04379661,SUNLIGHT Study: Online Support Groups for MS to Address COVID-19,https://beta.clinicaltrials.gov/study/NCT04379661,COMPLETED,MS (Multiple Sclerosis)|COVID-19|Support Groups,BEHAVIORAL: Online support Group,Columbia University,,ALL,"ADULT, OLDER_ADULT",NA,32,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-05-07,2020-07-07,2020-08-31,"Columbia University Medical Center, New York, New York, 10032, United States"
NCT03322761,Early Exercise Efforts in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03322761,COMPLETED,Multiple Sclerosis,COMBINATION_PRODUCT: Systematic exercise training|BEHAVIORAL: Educational program,University of Aarhus,University of Southern Denmark|Region of Southern Denmark,ALL,ADULT,NA,84,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2018-04-01,2021-12-31,2021-12-31,"Section for Sport Science, Department of Public Health, University of Aarhus, Aarhus, 8000, Denmark"
NCT03207464,Molecular Imaging of Norepinephrine Transporter (NET) Using [C-11]Methylreboxetine PET in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03207464,UNKNOWN,Multiple Sclerosis,DRUG: [C-11]Methylreboxetine,Brigham and Women's Hospital,,ALL,ADULT,PHASE1|PHASE2,19,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2017-10-10,2021-12-31,2021-12-31,"Partners MS Center, 60 Fenwood Road, Boston, Massachusetts, 02115, United States"
NCT02142764,Preliminary Study for Selective Detection of the CD8+ Myelin Specific T Cell in the Blood of Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT02142764,COMPLETED,Multiple Sclerosis,BIOLOGICAL: Blood samples|BIOLOGICAL: Blood samples,"University Hospital, Bordeaux",Merck Serono International SA|ADERA,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,"Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: ",2014-11,2016-02,2016-02,"Service de Neurologie - Tripode - Hôpital Pellegrin, Bordeaux, 33076, France"
NCT02775110,Natalizumab Temporary Discontinuation Study,https://beta.clinicaltrials.gov/study/NCT02775110,COMPLETED,Multiple Sclerosis,OTHER: Natalizumab discontinuation,University at Buffalo,,ALL,"ADULT, OLDER_ADULT",PHASE4,50,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2012-11,2014-03,2014-03,"Buffalo Neuroimaging Analysis Center, Buffalo, New York, 14203, United States|Jacobs Neurological Institute, Buffalo, New York, 14203, United States"
NCT00711646,A Study of Sativex® for Relief of Spasticity in Subjects With Multiple Sclerosis.,https://beta.clinicaltrials.gov/study/NCT00711646,COMPLETED,Spasticity|Multiple Sclerosis,DRUG: Sativex®|DRUG: Placebo,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,189,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2002-06,2004-03,2004-03,"Royal Berkshire Hospital, Reading, Oxfordshire, RG1 5AN, United Kingdom"
NCT04548310,Muscle Fatigue in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04548310,COMPLETED,Multiple Sclerosis,OTHER: Muscles Fatigue,Gazi University,,ALL,"ADULT, OLDER_ADULT",,36,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-09-14,2022-05-27,2022-05-27,"Gazi University, Ankara, Turkey"
NCT00062972,Improving Memory in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00062972,WITHDRAWN,Multiple Sclerosis,DRUG: donepezil|DRUG: glucose,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),U.S. Department of Education,ALL,ADULT,PHASE3,0,NIH,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,1999-09,,2002-08,"University Hospital and Medical Center, Stony Brook, New York, 11794-8121, United States"
NCT03995810,Oral Carnosine for Neuromuscular Performance in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03995810,COMPLETED,Multiple Sclerosis,"DIETARY_SUPPLEMENT: Carnosine, capsulle, 2 g/day, 8 weeks","University of Novi Sad, Faculty of Sport and Physical Education",CarnoMed,ALL,"ADULT, OLDER_ADULT",NA,3,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2019-06-15,2019-11-01,2019-12-01,"Applied Bioenergetics Lab at Faculty of Sport and PE, Novi Sad, Vojvodina, 21000, Serbia"
NCT04952246,Clinical Isolation Syndrome of Spinal Cord and Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04952246,RECRUITING,Clinical Isolation Syndrome of Spinal Cord|Multiple Sclerosis,,Peking University Third Hospital,,ALL,"CHILD, ADULT, OLDER_ADULT",,150,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-01-01,2020-11-30,2023-11-30,"Peking University Third Hospital, Beijin, China"
NCT03887546,Inspiratory Muscle Training in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03887546,UNKNOWN,Multiple Sclerosis,DEVICE: Inspiratory muscle trainer|PROCEDURE: Respiratory exercise,University of Salamanca,,ALL,"ADULT, OLDER_ADULT",NA,67,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2019-04-23,2019-07-24,2019-09-15,
NCT02623946,Motor Evoked Potentials as a Biomarker in Alemtuzumab Treated Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT02623946,COMPLETED,Multiple Sclerosis,,Clinique Neuro-Outaouais,CogState Ltd.,ALL,"ADULT, OLDER_ADULT",,10,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-11,2020-12-09,2021-02,"Clinique Neuro-Outaouais, Gatineau, Quebec, J8Y 1W2, Canada"
NCT01364246,Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica,https://beta.clinicaltrials.gov/study/NCT01364246,UNKNOWN,Progressive Multiple Sclerosis|Neuromyelitis Optica.,BIOLOGICAL: human umbilical cord mesenchymal stem cells,"Shenzhen Beike Bio-Technology Co., Ltd.",The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|The Affiliated Nanjing Brain Hospital of Nanjing University Medical School|Nanjing University Medical College Affiliated Wuxi Second Hospital|Xuzhou Medical University|The Second Hospital of Nanjing Medical University,ALL,ADULT,PHASE1|PHASE2,20,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2010-01,2013-03,2014-12,"Nanjing University Medical College Affiliated Drum Tower Hospital, Nanjing, Jiangsu, China"
NCT03787446,PET Study in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03787446,UNKNOWN,Multiple Sclerosis,,University of British Columbia,Hoffmann-La Roche,ALL,ADULT,,9,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-03-26,2020-03,2020-09,"UBC MS & NMO Clinical Trials Group, Vancouver, British Columbia, V6T1Z3, Canada"
NCT02436746,The Cognitive Variability in NF1 and TSC Monozygotic Twins,https://beta.clinicaltrials.gov/study/NCT02436746,UNKNOWN,Neurofibromatosis Type I|Tuberous Sclerosis Complex,,Erasmus Medical Center,,ALL,"CHILD, ADULT, OLDER_ADULT",,116,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-04,2017-04,2017-04,"Erasmus MC, Rotterdam, 3000 CA, Netherlands"
NCT03051646,Aspirin as a Pre-Treatment for Exercise in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03051646,COMPLETED,Fatigue|Overheating,"DRUG: Acetylsalicylic acid at 1st visit, then Placebo at 2nd visit|DRUG: Placebo at 1st visit, then Acetylsalicylic acid at 2nd visit",Columbia University,National Multiple Sclerosis Society,ALL,ADULT,EARLY_PHASE1,12,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2017-01-13,2017-05-10,2017-05-10,"Columbia University Medical Center, MS Center, New York, New York, 10032, United States"
NCT03434873,Effect of Motor Cortex Versus Sacral Magnetic Stimulation in Multiple Sclerosis Patients With Urinary Tract Dysfunction,https://beta.clinicaltrials.gov/study/NCT03434873,COMPLETED,Multiple Sclerosis|Lower Urinary Tract Symptoms,OTHER: magnetic stimulation,Cairo University,,ALL,ADULT,NA,40,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2014-10,2015-04,2015-04,
NCT02726373,Comparison of Intermittent vs. Continuous Walking in MS,https://beta.clinicaltrials.gov/study/NCT02726373,COMPLETED,"Multiple Sclerosis, Endurance",OTHER: type of walking,Hunter College of City University of New York,,ALL,"ADULT, OLDER_ADULT",NA,12,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2013-01,2014-12,2014-12,
NCT00381264,Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00381264,COMPLETED,Multiple Sclerosis,DRUG: Cesamet™ (nabilone),"NEMA Research, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE4,23,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2006-09,2007-10,2007-10,"South Florida Medical Research, Aventura, Florida, 33180, United States|Sunrise Clinical Research, Inc., Hollywood, Florida, 33021, United States|Naples Anesthesia and Pain Associates, Naples, Florida, 34108, United States|Lazlo Mate, MD, West Palm Beach, Florida, 33407, United States"
NCT00298662,Combination Therapy of Betaseron-Prograf in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00298662,UNKNOWN,Multiple Sclerosis,DRUG: Interferon beta-1b and Tacrolimus,Clinique de sclérose en plaques et neuromusculaire de l'Outaouais,,ALL,ADULT,PHASE2,30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2003-02,,2006-09,"Clinique de sclérose en plaques et neuromusculaire, Gatineau, Quebec, J8Y 1W7, Canada"
NCT05002062,"Efficacy of Cognitive Behavioral Therapy on Fatigue, Cognition and Inflammatory Biomarkers in MS Patients",https://beta.clinicaltrials.gov/study/NCT05002062,COMPLETED,Multiple Sclerosis,"DEVICE: ""RehaCom"" computer-based cognitive training in addition to Conventional physical therapy program|OTHER: Conventional physical therapy program",Cairo University,,ALL,ADULT,NA,40,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2020-12-21,2021-05-18,2021-06-07,"Faculty of physical therapy, Cairo University, Giza, Dokki, 11432, Egypt"
NCT04705610,"Social Cognition in Multiple Sclerosis, From a Study of Eye Movement and Gaze Strategies Using Video-oculography",https://beta.clinicaltrials.gov/study/NCT04705610,COMPLETED,Multiple Sclerosis (MS)|Multiple Sclerosis (MS) Relapsing Remitting|Multiple Sclerosis (MS) Primary Progressive|Multiple Sclerosis (MS) Secondary Progressive|Radiologically Isolated Syndrome|Clinically Isolated Syndrome|Healthy,OTHER: Video-oculography / Social cognition tasks / Neuropsychological evaluations,Association de Recherche Bibliographique pour les Neurosciences,Centre Hospitalier Universitaire de Nice|Centre Hospitalier Princesse Grace,ALL,"ADULT, OLDER_ADULT",NA,76,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2017-05-23,2019-06-26,2019-06-26,"Centre Mémoire / Centre de Gérontologie Clinique Rainier III / Princess Grace Hospital, Monaco, 98000, Monaco"
NCT03222973,Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT03222973,TERMINATED,Multiple Sclerosis,DRUG: BIIB033 (opicinumab)|DRUG: Placebo,Biogen,,ALL,ADULT,PHASE2,263,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-11-15,2021-02-12,2021-02-12,"Research Site, Cullman, Alabama, 35058, United States|Research Site, Gilbert, Arizona, 85234, United States|Research Site, Berkeley, California, 94705, United States|Research Site, Long Beach, California, 90806, United States|Research Site, Newport Beach, California, 92663, United States|Research Site, Orange, California, 92868, United States|Research Site, Centennial, Colorado, 80112, United States|Research Site, Fort Collins, Colorado, 80528, United States|Research Site, Stamford, Connecticut, 06905, United States|Research Site, Washington, District of Columbia, 20007, United States|Research Site, Sunrise, Florida, 33351, United States|Research Site, Tampa, Florida, 33612, United States|Research Site, Atlanta, Georgia, 30309, United States|Research Site, Chicago, Illinois, 60612, United States|Research Site, Chicago, Illinois, 60637, United States|Research Site, Overland Park, Kansas, 66212, United States|Research Site, Lexington, Kentucky, 40513, United States|Research Site, Baltimore, Maryland, 21287, United States|Research Site, Boston, Massachusetts, 02114, United States|Research Site, Boston, Massachusetts, 02215, United States|Research Site, Lexington, Massachusetts, 01805, United States|Research Site, Wellesley, Massachusetts, 02481, United States|Research Site, Farmington Hills, Michigan, 48334, United States|Research Site, Minneapolis, Minnesota, 55422, United States|Research Site, Saint Louis, Missouri, 63110, United States|Research Site, Saint Louis, Missouri, 63131, United States|Research Site, Las Vegas, Nevada, 89106, United States|Research Site, Freehold, New Jersey, 07728, United States|Research Site, Teaneck, New Jersey, 07666, United States|Research Site, Latham, New York, 12110, United States|Research Site, New York, New York, 10021, United States|Research Site, Patchogue, New York, 11772, United States|Research Site, Rochester, New York, 14642, United States|Research Site, Stony Brook, New York, 11794, United States|Research Site, Durham, North Carolina, 27710, United States|Research Site, Raleigh, North Carolina, 27607, United States|Research Site, Columbus, Ohio, 43214, United States|Research Site, Dayton, Ohio, 45417, United States|Research Site, Oklahoma City, Oklahoma, 73104, United States|Research Site, Portland, Oregon, 97225, United States|Research Site, Pittsburgh, Pennsylvania, 15213, United States|Research Site, Willow Grove, Pennsylvania, 19090, United States|Research Site, Knoxville, Tennessee, 37922, United States|Research Site, Memphis, Tennessee, 38018, United States|Research Site, Dallas, Texas, 75390-8806, United States|Research Site, Houston, Texas, 77030, United States|Research Site, Round Rock, Texas, 78681, United States|Research Site, Orem, Utah, 84058, United States|Research Site, Salt Lake City, Utah, 84103, United States|Research Site, Seattle, Washington, 98122, United States|Research Site, Seattle, Washington, 98133, United States|Research Site, Box Hill, Victoria, 3128, Australia|Research Site, Clayton, Victoria, 3168, Australia|Research Site, Heidelberg, Victoria, 3084, Australia|Research Site, Melbourne, Victoria, 3004, Australia|Research Site, Parkville, Victoria, 3050, Australia|Research Site, New Lambton Heights, NS 2305, Australia|Research Site, Westmead, 2145, Australia|Research Site, Brugge, 8000, Belgium|Research Site, Bruxelles, 1090, Belgium|Research Site, Bruxelles, 1200, Belgium|Research Site, Gent, 9000, Belgium|Research Site, La Louvière, 7100, Belgium|Research Site, Leuven, 3000, Belgium|Research Site, Roeselare, 8800, Belgium|Research Site, Edmonton, Alberta, T6G 1Z1, Canada|Research Site, Vancouver, British Columbia, V6T 1Z3, Canada|Research Site, Victoria, British Columbia, V8R 1J8, Canada|Research Site, Ottawa, Ontario, K1H8L6, Canada|Research Site, Toronto, Ontario, M5B1W8, Canada|Research Site, Gatineau, Quebec, J8Y 1W2, Canada|Research Site, Longueuil, Quebec, J4V2J2, Canada|Research Site, Montreal, Quebec, H3A 2B4, Canada|Research Site, Brno, 65691, Czechia|Research Site, Brno, 66491, Czechia|Research Site, Hradec Kralove, 50005, Czechia|Research Site, Jihlava, 58601, Czechia|Research Site, Pardubice, 53203, Czechia|Research Site, Praha 2, 12808, Czechia|Research Site, Strasbourg Cedex, Bas Rhin, 67098, France|Research Site, Nimes, Gard, 30029, France|Research Site, Bordeaux, Gironde, 33076, France|Research Site, Toulouse, Haute Garonne, 31059, France|Research Site, Montpellier, Herault, 34295, France|Research Site, Nantes Cedex 1, Loire Atlantique, 44093, France|Research Site, Lille, Nord, 59000, France|Research Site, Clermont-Ferrand, Puy De Dome, 63003, France|Research Site, Bron Cedex, Rhone, 69500, France|Research Site, Amiens Cedex 1, Somme, 80054, France|Research Site, Paris, 75013, France|Research Site, Freiburg, Baden Wuerttemberg, 79106, Germany|Research Site, Tuebingen, Baden Wuerttemberg, 72076, Germany|Research Site, Ulm, Baden Wuerttemberg, 89081, Germany|Research Site, Muenchen, Bavaria, 81675, Germany|Research Site, Bochum, North Rhine-Westphalia, 44791, Germany|Research Site, Duesseldorf, North Rhine-Westphalia, 40225, Germany|Research Site, Trier, Rhineland-Palatinate, 54292, Germany|Research Site, Dresden, Saxony, 1307, Germany|Research Site, Berlin, 10117, Germany|Research Site, Muenster, 48149, Germany|Research Site, Budapest, 1135, Hungary|Research Site, Budapest, 1145, Hungary|Research Site, Budapest, H-1204, Hungary|Research Site, Esztergom, 2500, Hungary|Research Site, Kistarcsa, 2143, Hungary|Research Site, Pecs, 7623, Hungary|Research Site, Ramat Gan, 5262000, Israel|Research Site, Montichiari, Brescia, 25018, Italy|Research Site, Pozzilli, Isernia, 86077, Italy|Research Site, Cefalù, Palermo, 90015, Italy|Research Site, Genova, 16132, Italy|Research Site, Messina, 98124, Italy|Research Site, Milano, 20132, Italy|Research Site, Milano, 20133, Italy|Research Site, Napoli, 80055, Italy|Research Site, Napoli, 80131, Italy|Research Site, Napoli, 80138, Italy|Research Site, Pisa, 56126, Italy|Research Site, Roma, 185, Italy|Research Site, Verona, 37134, Italy|Research Site, Geleen, 6162 AP, Netherlands|Research Site, Bydgoszcz, 85-795, Poland|Research Site, Gdansk, 80-803, Poland|Research Site, Katowice, 40-571, Poland|Research Site, Katowice, 40-650, Poland|Research Site, Krakow, 31-637, Poland|Research Site, Lodz, 90-324, Poland|Research Site, Lublin, 20-954, Poland|Research Site, Szczecin, 70-111, Poland|Research Site, Warszawa, 04-749, Poland|Research Site, Zabrze, 41-800, Poland|Research Site, Salt, Girona, 17190, Spain|Research Site, Majadahonda, Madrid, 28222, Spain|Research Site, Barakaldo, Vizcaya, 48903, Spain|Research Site, Barcelona, 08907, Spain|Research Site, Barcelona, 8035, Spain|Research Site, Barcelona, 8036, Spain|Research Site, Cordoba, 14004, Spain|Research Site, Madrid, 28006, Spain|Research Site, Sevilla, 41009, Spain|Research Site, Aarau, 5001, Switzerland|Research Site, Basel, 4031, Switzerland|Research Site, Bern, 3010, Switzerland|Research Site, Lugano, 6903, Switzerland|Research Site, Zurich, 8091, Switzerland|Research Site, Exeter, Devon, EX2 5DW, United Kingdom|Research Site, Plymouth, Devon, PL6 8DH, United Kingdom|Research Site, London, Greater London, SE5 9RS, United Kingdom|Research Site, London, Greater London, W6 8RF, United Kingdom|Research Site, Salford, Greater Manchester, M6 8HD, United Kingdom|Research Site, Liverpool, Merseyside, L9 7LJ, United Kingdom|Research Site, Nottingham, Nottinghamshire, NG7 2UH, United Kingdom|Research Site, Oxford, Oxfordshire, OX3 9DU, United Kingdom|Research Site, Glasgow, Strathclyde, G51 4TF, United Kingdom|Research Site, Newcastle Upon Tyne, Tyne & Wear, NE1 4LP, United Kingdom|Research Site, Leeds, West Yorkshire, LS1 3EX, United Kingdom|Research Site, Brighton, BN2 5BE, United Kingdom|Research Site, Sheffield, S10 2JF, United Kingdom|Research Site, Swansea, SA6 6NL, United Kingdom"
NCT02159573,"Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)",https://beta.clinicaltrials.gov/study/NCT02159573,COMPLETED,Relapsing-Remitting Multiple Sclerosis,BIOLOGICAL: natalizumab|DRUG: dimethyl fumarate,Biogen,,ALL,"ADULT, OLDER_ADULT",,530,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-07,2015-01,2015-01,"Research Site, Birmingham, Alabama, United States|Research Site, Cullman, Alabama, United States|Research Site, Gilbert, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Aurora, Colorado, United States|Research Site, Centennial, Colorado, United States|Research Site, Washington, District of Columbia, United States|Research Site, Jacksonville Beach, Florida, United States|Research Site, Palm Bay, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Athens, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Idaho Falls, Idaho, United States|Research Site, Chicago, Illinois, United States|Research Site, Peoria, Illinois, United States|Research Site, Baton Rouge, Louisiana, United States|Research Site, Glen Burnie, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Farmington Hills, Michigan, United States|Research Site, Golden Valley, Minnesota, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Teaneck, New Jersey, United States|Research Site, Amherst, New York, United States|Research Site, East Meadow, New York, United States|Research Site, New York, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Columbus, Ohio, United States|Research Site, Gahanna, Ohio, United States|Research Site, Uniontown, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Portland, Oregon, United States|Research Site, Altoona, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Newport News, Virginia, United States|Research Site, Norfolk, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Madison, Wisconsin, United States|Research Site, Milwaukee, Wisconsin, United States"
NCT04573673,Transcutaneous Tibial Neuro-stimulation to Improve Voiding Dysfunction in Multiple Sclerosis.,https://beta.clinicaltrials.gov/study/NCT04573673,RECRUITING,Multiple Sclerosis|Lower Urinary Tract Symptoms,DEVICE: PTNS de verum|DEVICE: PTNS placebo,"University Hospital, Lille",,ALL,"ADULT, OLDER_ADULT",NA,68,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-12-01,2024-04,2024-04,"Hop Claude Huriez Chu Lille, Lille, 59037, France"
NCT03277261,Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 ),https://beta.clinicaltrials.gov/study/NCT03277261,COMPLETED,Relapsing Multiple Sclerosis (RMS),BIOLOGICAL: Ublituximab|DRUG: Teriflunomide|DRUG: Oral Placebo|DRUG: IV Placebo,"TG Therapeutics, Inc.",,ALL,ADULT,PHASE3,549,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-09-19,2020-07-23,2020-11-06,"TG Therapeutics RMS Investigational Trial Site, Carlsbad, California, 92001, United States|TG Therapeutics RMS Investigational Trial Site, Long Beach, California, 90808, United States|TG Therapeutics RMS Investigational Trial Site, Pasadena, California, 91105, United States|TG Therapeutics RMS Investigational Trial Site, Stanford, California, 94305, United States|TG Therapeutics RMS Investigational Trial Site, Miami, Florida, 33136, United States|TG Therapeutics RMS Investigational Trial Site, Northbrook, Illinois, 60062, United States|TG Therapeutics RMS Investigational Trial Site, Kansas City, Kansas, 66160, United States|TG Therapeutics RMS Investigational Trial Site, Detroit, Michigan, 48201, United States|TG Therapeutics RMS Investigational Trial Site, Amherst, New York, 14226, United States|TG Therapeutics RMS Investigational Trial Site, Westerville, Ohio, 43081, United States|TG Therapeutics RMS Investigational Trial Site, Franklin, Tennessee, 37064, United States|TG Therapeutics RMS Investigational Trial Site, Knoxville, Tennessee, 37922, United States|TG Therapeutics RMS Investigational Trial Site, Dallas, Texas, 75246, United States|TG Therapeutics RMS Investigational Site, Round Rock, Texas, 78681, United States"
NCT04625153,RC18 in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II Trial,https://beta.clinicaltrials.gov/study/NCT04625153,RECRUITING,"Multiple Sclerosis, Relapsing-Remitting",BIOLOGICAL: RC18 160mg|BIOLOGICAL: RC18 240mg,"RemeGen Co., Ltd.",,ALL,ADULT,PHASE2,18,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-06-02,2022-04,2022-11,"the Third Affiliated Hospital,Sun Yat-Sen University, Guangzhou, Guangdong, China"
NCT03886753,Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products,https://beta.clinicaltrials.gov/study/NCT03886753,TERMINATED,"ALS|Autism Spectrum Disorder|Cancer|Spasticity, Muscle|Dyskinetic Syndrome|Epilepsy|Glaucoma|Huntington Disease|Inflammatory Bowel Disease (IBD)|Multiple Sclerosis|Neuropathy|Opioid Use|Parkinson Disease|HIV/AIDS|Ptsd|Intractable Pain|Sickle Cell Disease|Terminal Illness",OTHER: Registry|OTHER: PK microsampling of blood,Children's Hospital of Philadelphia,Ilera Healthcare,ALL,"CHILD, ADULT, OLDER_ADULT",,10,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-05-15,2020-06-30,2020-06-30,"Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States"
NCT02588053,Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)?,https://beta.clinicaltrials.gov/study/NCT02588053,COMPLETED,Multiple Sclerosis,,"University of Colorado, Denver",,ALL,ADULT,,85,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-07,2018-12,2019-01,"University of Colorado Anschutz, Aurora, Colorado, 80045, United States"
NCT04142853,"Underlying Causes and Related Factors, and Rehabilitation Approaches",https://beta.clinicaltrials.gov/study/NCT04142853,COMPLETED,Multiple Sclerosis,OTHER: Training intervention + Dance intervention,Hasselt University,University of Liege,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2019-03-01,2019-12-31,2019-12-31,"Hasselt University, Hasselt, 3500, Belgium|Centre Hospitalier Universitaire de Liège, Liège, 4000, Belgium"
NCT00912860,Immunogenicity and Safety Study of Serum-Free Avonex,https://beta.clinicaltrials.gov/study/NCT00912860,COMPLETED,Multiple Sclerosis,DRUG: Interferon beta-1a,Biogen,,ALL,ADULT,PHASE2,155,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2003-01,2004-12,2005-01,
NCT03568760,Finding the Right Words in Neurogenic Communication Disorders,https://beta.clinicaltrials.gov/study/NCT03568760,COMPLETED,Anomia|Stroke|Aphasia|Parkinson Disease|Multiple Sclerosis,BEHAVIORAL: Semantic feature analysis|BEHAVIORAL: Comprehension training,Göteborg University,The Swedish Research Council|Swedish Council for Working Life and Social Research,ALL,"ADULT, OLDER_ADULT",NA,17,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2016-01-01,2021-12-31,2021-12-31,"University of Gothenburg, Gothenburg, Västra Göraland, 405 30, Sweden"
NCT02006160,Effects of Dalfampridine on Cognition in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02006160,COMPLETED,Multiple Sclerosis,DRUG: dalfampridine|DRUG: placebo,State University of New York at Buffalo,,ALL,ADULT,PHASE2|PHASE3,61,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-12,2016-02,2016-02,"Buffalo General Hospital, Buffalo, New York, 14203, United States"
NCT04819360,Botulinum Toxin A vs Anticholinergic Treatment of Neurogenic Overactive Bladder in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04819360,RECRUITING,"Urinary Bladder, Neurogenic|Multiple Sclerosis",DRUG: VESIcare 10Mg Tablet|DRUG: Botox 100 UNT Injection,Brigitte Schürch,Centre Hospitalier Universitaire Vaudois,ALL,"ADULT, OLDER_ADULT",PHASE4,46,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-06-01,2022-11-30,2023-01-31,"Centre Hospitalier Universitaire Vaudois, Lausanne, 1011, Switzerland"
NCT04082260,Signatures of Immune Reprogramming in Anti-CD52 Therapy of MS: Markers for Risk Stratification and Treatment Response,https://beta.clinicaltrials.gov/study/NCT04082260,UNKNOWN,Multiple Sclerosis,DRUG: Alemtuzumab Injection [Lemtrada],University Hospital Muenster,,ALL,"ADULT, OLDER_ADULT",,150,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-01,2022-01,2022-01,"Department of Neurology, Münster, NRW, 48149, Germany"
NCT00986960,Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT00986960,WITHDRAWN,Multiple Sclerosis,DRUG: repository corticotropin injection|DRUG: Saline,University at Buffalo,,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2009-12,2010-09,2010-12,"University at Buffalo, Buffalo General Hospital, Buffalo, New York, 14203, United States"
NCT01371760,BRAVE-DREAMS (BRAin VEnous DRainage Exploited Against Multiple Sclerosis),https://beta.clinicaltrials.gov/study/NCT01371760,COMPLETED,Multiple Sclerosis|Venous Insufficiency,PROCEDURE: Venous PTA|OTHER: Catheter Venography,S. Anna Hospital,Regione Emilia-Romagna,ALL,"ADULT, OLDER_ADULT",NA,212,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-08,2014-12,2015-12,"S. Anna Hospital, Ferrara, Fe, 44100, Italy|S. Anna Hospital, University of Ferrara, Ferrara, Italy, Ferrara, 44100, Italy"
NCT05009160,DreaMS - Validation Study 1,https://beta.clinicaltrials.gov/study/NCT05009160,RECRUITING,Multiple Sclerosis,DEVICE: dreaMS App R2.1,Research Center for Clinical Neuroimmunology and Neuroscience Basel,"Healios AG|University Hospital, Basel, Switzerland|University of Basel|Innosuisse - Swiss Innovation Agency|Novartis Pharmaceuticals|Hoffmann-La Roche",ALL,"ADULT, OLDER_ADULT",,450,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-03-30,2025-04,2025-04,"MS Center, Department of Neurology University Hospital Basel, Basel, Switzerland"
NCT04931953,Feasibility of Neuromodulation With Connectivity-Guided iTBS for Cognitive Impairment in MS,https://beta.clinicaltrials.gov/study/NCT04931953,NOT_YET_RECRUITING,Multiple Sclerosis|Cognitive Impairment,OTHER: Intermittent theta burst stimulation (iTBS)|OTHER: Sham Intermittent theta burst stimulation (iTBS),University of Nottingham,,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2022-06-01,2023-08,2023-12,
NCT02301260,Speed of Processing Training to Improve Cognition in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02301260,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Speed of Processing Training (SPT)|BEHAVIORAL: Placebo Control,Kessler Foundation,National Multiple Sclerosis Society,ALL,ADULT,NA,100,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-04,2020-02,2020-02,"Kessler Foundation, West Orange, New Jersey, 07052, United States"
NCT00087529,A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00087529,COMPLETED,Multiple Sclerosis,DRUG: placebo|DRUG: rituximab,"Genentech, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,439,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2004-06,2007-10,,
NCT05539729,Vancomycin Study in Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT05539729,RECRUITING,Multiple Sclerosis,DRUG: Vancomycin|DRUG: Placebo,Icahn School of Medicine at Mount Sinai,Doris Duke Charitable Foundation,ALL,ADULT,PHASE1,40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-02-08,2024-03,2024-09,"Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai, New York, New York, 10029, United States"
NCT00915460,Open-Label Safety Extension Study of Avonex,https://beta.clinicaltrials.gov/study/NCT00915460,COMPLETED,Multiple Sclerosis,DRUG: Interferon beta-1a (Avonex),Biogen,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE4,408,INDUSTRY,INTERVENTIONAL,"Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: ",1999-09,2003-06,2003-07,
NCT00344253,"Randomized, Controlled Trial to Test the Efficacy of Interferon Beta in the Treatment of Intermediate Uveitis",https://beta.clinicaltrials.gov/study/NCT00344253,COMPLETED,"Uveitis, Intermediate|Macular Edema|Multiple Sclerosis",DRUG: Interferon beta|DRUG: Methotrexate,Heidelberg University,Serono GmbH,ALL,"ADULT, OLDER_ADULT",PHASE3,19,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2006-03,2011-03,2012-01,"Interdisciplinary Uveitis Center, University of Heidelberg, Heidelberg, 69120, Germany"
NCT00097760,Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00097760,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Natalizumab|DRUG: Natalizumab|DRUG: Placebo,Biogen,Elan Pharmaceuticals,ALL,ADULT,PHASE2,110,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2003-06,2004-03,2004-03,
NCT02717429,Cognitive and Emotion Regulation Training in MS,https://beta.clinicaltrials.gov/study/NCT02717429,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Mindfulness Meditation|BEHAVIORAL: Computerized Cognitive Training,Ohio State University,,ALL,ADULT,NA,62,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2015-10,2017-05-14,2017-05-14,"Department of Psychology, The Ohio State University, Columbus, Ohio, 43210, United States"
NCT03239860,Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an Open Label Long-term Safety Study in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03239860,TERMINATED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: GNbAC1 Monoclonal Antibody,GeNeuro SA,Les Laboratoires Servier|Worldwide Clinical Trials|Institut de Recherches Internationales Servier,ALL,ADULT,PHASE2,220,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-06-06,2018-11-14,2018-11-14,"Hospital, Sofia, Bulgaria|Hospital, Zagreb, Croatia|Hospital, Jihlava, Czechia|Hospital, Tallinn, Estonia|Hospital, Berlin, Germany|Hospital, Budapest, Hungary|Hospital, Rome, Italy|Hospital, Warsaw, Poland|Hospital, Moscow, Russian Federation|Hospital, Belgrade, Serbia|Hospital, Barcelona, Spain|Hospital, Kharkiv, Ukraine"
NCT03255460,The Relationship Between Fatigue and Physical Activity Level in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03255460,COMPLETED,Multiple Sclerosis,,Gazi University,,ALL,"ADULT, OLDER_ADULT",,70,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-03-27,2018-07-04,2018-07-04,"Gazi University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Ankara, Turkey"
NCT02046629,A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese Volunteers,https://beta.clinicaltrials.gov/study/NCT02046629,COMPLETED,Multiple Sclerosis,DRUG: Teriflunomide HMR1726|DRUG: cholestyramine,Sanofi,,ALL,ADULT,PHASE1,12,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2014-05,2014-07,2014-07,"Investigational Site Number 156001, Shanghai, 200025, China"
NCT04441229,Mobile Attentional Bias Modification Training in Pediatric MS,https://beta.clinicaltrials.gov/study/NCT04441229,COMPLETED,Pediatric Multiple Sclerosis,BEHAVIORAL: ABMT mobile application,NYU Langone Health,,ALL,"CHILD, ADULT",NA,37,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-06-12,2021-03-25,2021-03-26,"NYU Langone Health, New York, New York, 10016, United States"
NCT04210960,Correlation of Serum Lactate and Activity of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04210960,UNKNOWN,Multiple Sclerosis,RADIATION: Magentic resonanace imaging|RADIATION: Magentic resonanace spectroscopy,Mansoura University Hospital,,ALL,"ADULT, OLDER_ADULT",,80,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-12-23,2020-05-01,2020-06-01,"Mansoura University Hospital, Mansoura, Dakahlia, 35516, Egypt"
NCT03282760,Safety Study of Human Neural Stem Cells Injections for Secondary Progressive Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT03282760,COMPLETED,Secondary-progressive Multiple Sclerosis,BIOLOGICAL: Human Neural Stem Cells,Casa Sollievo della Sofferenza IRCCS,Associazione Revert ONLUS|Neurocenter of Southern Switzerland|Fondazione Cellule Staminali,ALL,ADULT,PHASE1,24,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2017-09-09,2021-05-29,2021-05-29,"Casa Sollievo della Sofferenza - IRCCS, San Giovanni Rotondo, Foggia, 71013, Italy|Azienda Ospedaliera Santa Maria di Terni, Terni, 05100, Italy|Neurocentro della Svizzera Italiana, Istituto di Neurosienze cliniche della svizzera italiana, Centro sclerosi Multipla, Lugano, 6900, Switzerland"
NCT00006060,Diagnostic Study of Quantitative Imaging and Spectroscopy in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00006060,UNKNOWN,Multiple Sclerosis,DRUG: standard gadolinium contrast,National Center for Research Resources (NCRR),University of Pennsylvania,ALL,"ADULT, OLDER_ADULT",,100,NIH,OBSERVATIONAL,Observational Model: |Time Perspective: p,1999-04,,,"New York University Medical Center, New York, New York, 10016, United States"
NCT04281160,Patient Centered Outcomes Analysis for MS Using a Mobile Application,https://beta.clinicaltrials.gov/study/NCT04281160,ENROLLING_BY_INVITATION,Multiple Sclerosis,DEVICE: BeCare Mobile App,BeCare Link LLC,Weill Medical College of Cornell University,ALL,"ADULT, OLDER_ADULT",,60,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-02-19,2023-09-01,2023-09-01,"Weill Cornell Medical College, New York, New York, 10065, United States"
NCT04452760,"Effects of Ten-Weeks Progressive Resistance Training on Neuromuscular Performance, Mobility, Heart Rate Variability and Sleep Quality in Persons With Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT04452760,COMPLETED,Multiple Sclerosis,OTHER: Physical exercise|OTHER: Testing sessions,Universidad Católica San Antonio de Murcia,,ALL,"ADULT, OLDER_ADULT",NA,36,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-07-15,2020-10-01,2020-10-05,"Universidad Católica San Antonio, Murcia, 30107, Spain"
NCT05704361,"A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous RO7121932 in Participants With Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT05704361,RECRUITING,Multiple Sclerosis,DRUG: RO7121932,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE1,63,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-08-11,2025-01-31,2025-01-31,"Stanford University Medical Center; Stanford Neuroscience Health Center, Stanford, California, 94305, United States|Yale University Multiple Sclerosis Center, New Haven, Connecticut, 06473, United States|University of South Florida, Tampa, Florida, 33612, United States|University of Massachusetts Medical School, Worcester, Massachusetts, 01655, United States|UC Health, LLC., Cincinnati, Ohio, 45219, United States|UZ Gent, Gent, 9000, Belgium|Universitätsklinikum ""Carl Gustav Carus""; MS Center Dresden, Dresden, 01307, Germany|Universitätsmedizin Göttingen Georg-August-Universität; Klinik für Neurologie, Göttingen, 37075, Germany|Klinikum rechts der Isar der TU Muenchen; Neurologische Klinik und Poliklinik im Neuro-Kopf-Zentrum, München, 81675, Germany|Universitätsklinikum Münster Klinik u. Poliklinik f. Neurologie, Münster, 48149, Germany|Hadassah University Hospital - Ein Kerem, Jerusalem, 9112001, Israel|Tel Aviv Sourasky Medical Center; Department of Neurology, Tel Aviv, 6423906, Israel|IRCCS Ospedale San Raffaele; Neurologia Neurofisiologia Neuroriabilitazione-Centro Sclerosi Multipla, Milano, Lombardia, 20132, Italy|Fond. Istituto Neurologico C.Besta; UO Neurologia IV - Neuroimmunologia Malattie Neuromuscolari, Milano, Lombardia, 20133, Italy|Uniwersyteckie Centrum Kliniczne; Osrodek Badan Wczesnych Faz, Gda?sk, 80-214, Poland|Regionalny Szpital Specjalistyczny im. W. Bieganskiego; Oddzial Neurologiczny, Grudzi?dz, 86-300, Poland|MedPolonia, Poznan, 60-693, Poland|Osrodek Badan Klinicznych Euromedis, Szczecin, 70-111, Poland|Instytut Psychiatrii i Neurologii II Klinika Neurologiczna, Warszawa, 02-957, Poland|Hospital de Braga; Centro Clínico Académico (Piso 1, Ala E), Braga, 4710-243, Portugal"
NCT01765361,Assessment of Ocrelizumab (OCR) Treatment Effects on Functional Impairment of MS Patients Enrolled in the Phase III Orchestra Programme Using Multimodal Evoked Potentials (EP) and Highresolution Electroencephalography (EEG),https://beta.clinicaltrials.gov/study/NCT01765361,COMPLETED,Multiple Sclerosis,,"University Hospital, Basel, Switzerland",,ALL,"ADULT, OLDER_ADULT",,16,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-09,2015-01,2017-01,"Dep. Neurology, Hospital of the University of Basel, Basel, 4031, Switzerland"
NCT01981161,Difference in Efficacy of Natalizumab Versus Fingolimod for the Treatment of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01981161,COMPLETED,Multiple Sclerosis,PROCEDURE: biological samples and clinical data,"University Hospital, Toulouse",European Commission,ALL,ADULT,,307,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-11-19,2018-06-20,2018-11-30,"CHU Besançon, Besancon, 25000, France|CHU Bordeaux, Bordeaux, 33 000, France|CHU Caen, Caen, 14033, France|Chu Lille, Lille, 59037, France|Chu La Timone, Marseille, 13385, France|CHU Nancy, Nancy, 54035, France|CHU Nantes, Nantes, 44093, France|CHU Nice, Nice, 06002, France|CHU Nîmes, Nimes, 30029, France|CHRU Strasbourg, Strasbourg, 67098, France|Université de Muenter, Munster, Germany|Hôpital Vall D'Hebron, Barcelone, Spain"
NCT03186664,The Role of SAtivex® in Robotic-Rehabilitation,https://beta.clinicaltrials.gov/study/NCT03186664,COMPLETED,Rehabilitation,DEVICE: Lokomat training|DRUG: Sativex,"IRCCS Centro Neurolesi ""Bonino-Pulejo""",,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2016-12-28,2017-12,2018-06,"IRCCS Centro Neurolesi Bonino-Pulejo"", Messina, Sicily, 98123, Italy"
NCT01883661,Safety and Efficacy of BMMNC in Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT01883661,UNKNOWN,Multiple Sclerosis,BIOLOGICAL: BMMNC,"Chaitanya Hospital, Pune",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,15,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-06,2016-11,2016-12,"Chaitanya Hospital, Pune,, Maharashtra, 411009, India"
NCT02259361,Efficacy of Dalfampridine on Upper Extremity Function in Patients With MS,https://beta.clinicaltrials.gov/study/NCT02259361,UNKNOWN,Multiple Sclerosis,DRUG: Sustained-release oral dalfampridine|DRUG: Placebo,Sheba Medical Center,,ALL,"ADULT, OLDER_ADULT",PHASE4,30,OTHER_GOV,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-11,2014-11,2014-11,"Multiple Sclerosis Center, Tel-hashomer, Ramat-gan, Israel"
NCT04217564,Nutritional Counselling for Patients at Kasr AlAiny Multiple Sclerosis Clinic: an Intervention Study,https://beta.clinicaltrials.gov/study/NCT04217564,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Nutritional counselling,Cairo University,,ALL,"ADULT, OLDER_ADULT",NA,120,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-01-01,2020-03-18,2020-06-30,"Faculty of medicine, Cairo University, Cairo, 11731, Egypt"
NCT02670161,Quality Improvement and Practice Based Research in Neurology Using the EMR,https://beta.clinicaltrials.gov/study/NCT02670161,ENROLLING_BY_INVITATION,Brain Tumors|Epilepsy|Migraine|Mild Cognitive Impairment|Concussion|Multiple Sclerosis|Neuropathy|Parkinson's|Restless Legs Syndrome|Stroke,"DRUG: Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)",NorthShore University HealthSystem,,ALL,"ADULT, OLDER_ADULT",PHASE4,3300,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2016-05,2024-12,2025-12,
NCT02253264,A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT02253264,COMPLETED,Primary Progressive Multiple Sclerosis|Secondary Progressive Multiple Sclerosis,DRUG: Rituximab,Johns Hopkins University,,ALL,"ADULT, OLDER_ADULT",PHASE1,8,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-11,2017-08,2017-08,"The Johns Hopkins Hospital, Baltimore, Maryland, 21287, United States"
NCT03368664,"A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT",https://beta.clinicaltrials.gov/study/NCT03368664,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,DRUG: Alemtuzumab GZ402673|DRUG: Glatiramer acetate|DRUG: Beta-Interferon|DRUG: Methylprednisolone|DRUG: Ranitidine|DRUG: Ceterizine|DRUG: Dexchlorpheniramine|DRUG: Paracetamol|DRUG: Acyclovir|DRUG: Prednisolone|DRUG: Diphenydramine|DRUG: Other H1 antagonist|DRUG: Other H1 antagonist,"Genzyme, a Sanofi Company",,ALL,"CHILD, ADULT",PHASE3,16,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2017-10-24,2021-05-04,2025-12,"Investigational Site Number :0400001, Wien, 1090, Austria|Investigational Site Number :0560001, Gent, 9000, Belgium|Investigational Site Number :2500001, Le Kremlin Bicetre, 94270, France|Investigational Site Number :2500002, Strasbourg, 67091, France|Investigational Site Number :3800005, Cagliari, 09126, Italy|Investigational Site Number :3800001, Milano, 20132, Italy|Investigational Site Number :3800004, Napoli, 80131, Italy|Investigational Site Number :5280001, Rotterdam, 3015 CN, Netherlands|Investigational Site Number :6160003, Lodz, Lódzkie, 93-338, Poland|Investigational Site Number :6160002, Poznan, Wielkopolskie, 60-355, Poland|Investigational Site Number :6160001, Warszawa, 04-730, Poland|Investigational Site Number :6200001, Coimbra, 3000-075, Portugal|Investigational Site Number :6430001, Moscow, 119602, Russian Federation|Investigational Site Number :6430004, Moscow, 129110, Russian Federation|Investigational Site Number :6430005, Saint-Petersburg, 197022, Russian Federation|Investigational Site Number :6430002, St-Petersburg, 197110, Russian Federation|Investigational Site Number :7920002, Ankara, 06100, Turkey|Investigational Site Number :7920001, Ankara, 06500, Turkey|Investigational Site Number :7920003, Istanbul, 34390, Turkey|Investigational Site Number :7920004, Istanbul, Turkey|Investigational Site Number :8260002, London, London, City Of, WC1N 3JH, United Kingdom"
NCT03621761,"Cognitive Behavioral Therapy, Modafinil, or Both for Multiple Sclerosis Fatigue",https://beta.clinicaltrials.gov/study/NCT03621761,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Telephone-based Cognitive Behavioral Therapy|DRUG: Modafinil,University of Michigan,University of Washington|Patient-Centered Outcomes Research Institute|National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",PHASE4,343,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2018-11-15,2021-08-24,2021-11-30,"The University of Michigan, Ann Arbor, Michigan, 48109, United States|The University of Washington, Seattle, Washington, 98195, United States"
NCT02232061,"Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks",https://beta.clinicaltrials.gov/study/NCT02232061,COMPLETED,Multiple Sclerosis,DRUG: Fingolimod,Novartis Pharmaceuticals,,ALL,ADULT,PHASE4,6,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2014-09-29,2020-01-24,2020-01-24,"Novartis Investigative Site, Gent, 9000, Belgium|Novartis Investigative Site, Hasselt, 3500, Belgium|Novartis Investigative Site, Ravensburg, 88212, Germany|Novartis Investigative Site, Napoli, 80131, Italy"
NCT02398461,An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse,https://beta.clinicaltrials.gov/study/NCT02398461,COMPLETED,"Multiple Sclerosis, Acute Relapsing",DRUG: rHIgM22|DRUG: Placebo,Acorda Therapeutics,PRA Health Sciences,ALL,"ADULT, OLDER_ADULT",PHASE1,27,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2015-04,2017-09,2017-09-21,"Acorda Site #12, Long Beach, California, 90806, United States|Acorda Site #3, Sacramento, California, 95817, United States|Acorda Site #7, San Francisco, California, 94158, United States|Acorda Site #11, Aurora, Colorado, 80045, United States|Acorda Site #16, Centennial, Colorado, 80112, United States|Acorda Site #22, Chicago, Illinois, 60612, United States|Acorda Site #14, Saint Louis, Missouri, 63131, United States|Acorda Site #19, Teaneck, New Jersey, 07666, United States|Acorda Site #10, Rochester, New York, 14642, United States|Acorda Site #18, Dallas, Texas, 75390-8508, United States|Acorda Site #2, Seattle, Washington, 98101, United States|Acorda Site #6, Seattle, Washington, 98122, United States"
NCT01743664,The Efficacy of EMDR in Patients With PTSD in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01743664,UNKNOWN,Posttraumatic Stress Disorders|Multiple Sclerosis,BEHAVIORAL: EMDR|BEHAVIORAL: Relaxation,San Luigi Gonzaga Hospital,Fondazione Italiana Sclerosi Multipla,ALL,"ADULT, OLDER_ADULT",PHASE3,60,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2010-05,2013-03,2014-02,"San Luigi Gonzaga University Hospital, Orbassano, Torino, 10043, Italy"
NCT01453764,Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01453764,WITHDRAWN,Multiple Sclerosis|Autoimmune Diseases|Autoimmune Diseases of the Nervous System|Nervous System Diseases,PROCEDURE: Harvesting and Implantation of SVF,Ageless Regenerative Institute,,ALL,"ADULT, OLDER_ADULT",NA,0,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-04,2018-12,2019-04,"Ageless Regenerative Institute LLC, Aventura, Florida, 33180, United States"
NCT04540861,Managed Access Program (MAP) for Patients Diagnosed With Secondary Progressive Multiple Sclerosis With Active Disease,https://beta.clinicaltrials.gov/study/NCT04540861,AVAILABLE,Multiple Sclerosis,DRUG: Siponimod,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",,,INDUSTRY,EXPANDED_ACCESS,,,,,
NCT05002764,Thalamic Nuclei Volumes in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05002764,RECRUITING,Multiple Sclerosis,,"University Hospital, Bordeaux","Institut National de la Santé Et de la Recherche Médicale, France",ALL,"ADULT, OLDER_ADULT",,2000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-07-01,2023-07-01,2023-07-01,"CHU Bordeaux, Bordeaux, 33 076, France"
NCT04022564,"Incidence, and Survival Medical Expenditure of Patients With Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT04022564,UNKNOWN,Neurologic Signs and Symptoms,,Chun-Ming Liao,,ALL,"CHILD, ADULT, OLDER_ADULT",,2000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-07-15,2020-05-20,2020-05-20,"Genetic and Rare Disease Center, Taichung, 404, Taiwan"
NCT05296161,B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05296161,RECRUITING,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Ocrelizumab,"Amsterdam UMC, location VUmc",,ALL,ADULT,PHASE4,296,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-04-20,2024-04,2026-03,"Amsterdam UMC, location VU, Amsterdam, Noord-Holland, 1081 HV, Netherlands"
NCT02157064,Outcomes Data of Adipose Stem Cells to Treat Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02157064,UNKNOWN,Multiple Sclerosis,,StemGenex,,ALL,"ADULT, OLDER_ADULT",,221,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-05,2019-05,2019-05,"StemGenex, San Diego, California, 92121, United States"
NCT03096977,Use of the Nine Holes Peg Test in Multiple Sclerosis: Participation of Elementary Neurological Components in the Functional Evaluation of Manual Dexterity,https://beta.clinicaltrials.gov/study/NCT03096977,COMPLETED,Multiple Sclerosis,DIAGNOSTIC_TEST: Scale for the assessment and rating of ataxia (SARA)|DEVICE: JAMAR hand dynamometer|DEVICE: Vibratory sensibility testing|DEVICE: Sermes and Weinstein test|DEVICE: Weber test,Brugmann University Hospital,,ALL,ADULT,NA,30,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2017-03-15,2019-01-30,2019-01-30,"CHU Brugmann, Brussel, 1020, Belgium"
NCT02677077,Clinical Disease Activity With Long Term Natalizumab Treatment,https://beta.clinicaltrials.gov/study/NCT02677077,COMPLETED,Relapsing-Remitting Multiple Sclerosis,DRUG: natalizumab,Biogen,,ALL,"ADULT, OLDER_ADULT",,277,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-12-31,2016-08-18,2016-08-18,"Research Site 1, Brussels, Belgium|Research Site 2, Brussels, Belgium|Research Site, Overpelt, Belgium|Research Site, Prague, Czechia"
NCT03375177,Multiple Sclerosis Registry in Argentina (RelevarEM),https://beta.clinicaltrials.gov/study/NCT03375177,RECRUITING,Multiple Sclerosis,OTHER: Natural history of disease,Hospital Italiano de Buenos Aires,,ALL,"CHILD, ADULT, OLDER_ADULT",,4000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-03-25,2021-07-16,2024-06-23,"Hospital Italiano de Buenos Aires, Buenos Aires, 1411, Argentina"
NCT01703429,Complementary and Alternative Care in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01703429,RECRUITING,Multiple Sclerosis,,Bastyr University,,ALL,"ADULT, OLDER_ADULT",,1000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-06,2030-06,2030-06,"Bastyr University Clinical Research Center, Kenmore, Washington, 98028, United States"
NCT00888277,Bayer/Cognitive Assessments With Multiple Sclerosis Subjects,https://beta.clinicaltrials.gov/study/NCT00888277,COMPLETED,"Multiple Sclerosis, Relapsing-remitting|Multiple Sclerosis, Secondary Progressive",,University of Louisville,"Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma",ALL,ADULT,,74,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2009-05,2009-12,2010-01,"University of Louisville, Louisville, Kentucky, 40202, United States"
NCT00035529,A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00035529,TERMINATED,Multiple Sclerosis,DRUG: Placebo|DRUG: BMS 188667 (Abatacept)|DRUG: BMS 188667 (Abatacept),Bristol-Myers Squibb,,ALL,ADULT,PHASE2,,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2001-11,2003-12,2003-12,"Local Institution, New Haven, Connecticut, United States|Local Institution, Louisville, Kentucky, United States|Local Institution, Worcester, Massachusetts, United States|Local Institution, Newark, New Jersey, United States|Local Institution, New York, New York, United States|Local Institution, Charlotte, North Carolina, United States|Local Institution, Philadelphia, Pennsylvania, United States|Local Institution, Dallas, Texas, United States|Local Institution, Burlington, Vermont, United States|Local Institution, Madison, Wisconsin, United States"
NCT02225977,Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya.,https://beta.clinicaltrials.gov/study/NCT02225977,COMPLETED,Multiple Sclerosis,DRUG: Gilenya,University of Southern California,,ALL,"ADULT, OLDER_ADULT",,125,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-07-31,2016-12-31,2017-04-30,"University of Southern California, Department of Neurology, Los Angeles, California, 90033, United States"
NCT04074629,Novel Nanosensor Array for Detection of Volatile Biomarkers From Skin in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04074629,COMPLETED,Multiple Sclerosis,"DIAGNOSTIC_TEST: Diagnosis, skin volatile organic compounds (VOCs)",Carmel Medical Center,"Technion, Israel Institute of Technology",ALL,"ADULT, OLDER_ADULT",NA,107,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2019-12-16,2022-05-23,2022-08-02,"Ariel Miller, Haifa, 34362, Israel"
NCT04034277,Lee Silverman Voice Treatment Versus Standard Speech Therapy Versus Control in Hypophonia Rehabilitation in MS,https://beta.clinicaltrials.gov/study/NCT04034277,UNKNOWN,Multiple Sclerosis,OTHER: Lee Silverman Voice Therapy|OTHER: Conventional Treatment,Fondazione Don Carlo Gnocchi Onlus,,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2018-01-15,2019-09-30,2020-03-30,"Fondazione Don Gnocchi Irccs, Milan, Italy"
NCT03577977,Betaferon Use in Children and Adolescents With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03577977,COMPLETED,Multiple Sclerosis,"DRUG: Interferon beta-1b (Betaseron, Betaferon, BAY86-5046)",Bayer,,ALL,"CHILD, ADULT",,70,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2008-06-01,2009-04-15,2009-04-15,"Multiple Locations, Russian Federation"
NCT00382629,BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00382629,COMPLETED,Relapsing Remitting Multiple Sclerosis,DRUG: BHT-3009 0.5 mg|DRUG: BHT-3009 1.5 mg|DRUG: Placebo,Bayhill Therapeutics,,ALL,ADULT,PHASE2,252,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,2006-02,,2007-06,
NCT04768777,Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04768777,ACTIVE_NOT_RECRUITING,"Multiple Sclerosis, Relapsing-Remitting|Sexual Dysfunction",BEHAVIORAL: Behavioural intervention for physical activity for multiple sclerosis (BIPAMS),University of Alabama at Birmingham,National Multiple Sclerosis Society,FEMALE,ADULT,NA,30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-06-01,2022-05-01,2023-12-31,"University of Alabama at Birmingham, Birmingham, Alabama, 35243, United States"
NCT01796860,Effectiveness of Ankle Foot Orthoses on Gait in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01796860,TERMINATED,Multiple Sclerosis,OTHER: AFO,University of Texas Southwestern Medical Center,,ALL,ADULT,NA,10,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2012-09,2013-08,2013-08,"University of Texas Southwestern Medical Center, School of Health Professions, Dallas, Texas, 75390, United States"
NCT02636829,Validation of Self-administered Questionnaire for Assessing Calcium Intake in Patients With Multiple Sclerosis or Chronic Inflammatory Arthritis,https://beta.clinicaltrials.gov/study/NCT02636829,COMPLETED,Multiple Sclerosis|Rheumatoid Arthritis,OTHER: QALCIMUM questionnaire|OTHER: Determination of calcium intake by a dietician interview,Centre Hospitalier Universitaire de Nīmes,,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2016-03,2016-08,2016-08,"CHRU de Nîmes - Hôpital Universitaire Carémeau, Nîmes Cedex 09, 30029, France"
NCT02307877,"Comparison of Brain Atrophy Rates, Cognition, and Patient-Reported Outcomes in MS Patients Using Long-term Fingolimod and Glatiramer Acetate",https://beta.clinicaltrials.gov/study/NCT02307877,COMPLETED,Multiple Sclerosis,,"University of Colorado, Denver",,ALL,ADULT,,157,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-09,2018-05,2018-05,"University of Colorado Hospital, Aurora, Colorado, 80045, United States"
NCT04095377,Development of Automated Analysis to Electroencephelogram (EEG) Data in Patients Treated at the Sagol Hyperbaric Medicine and Research Center at the Years 2017-2019.,https://beta.clinicaltrials.gov/study/NCT04095377,COMPLETED,"Healthy|CVA|Hemorrhage|TBI (Traumatic Brain Injury)|Concussion, Brain|Fibromyalgia|ABD|Adhd|Dementia|Mci|Cognitive Impairment|Cognitive Decline|MS (Multiple Sclerosis)","OTHER: No intervention, this is a retrospective study.",QuantalX Neuroscience,,ALL,"ADULT, OLDER_ADULT",,875,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-03-24,2022-02-14,2022-02-14,"Asaf-Harophe, Rishon LeZion, 70300, Israel"
NCT05347277,CSF Free Kappa Light Chain for The Diagnosis of Demyelinating Disorders,https://beta.clinicaltrials.gov/study/NCT05347277,COMPLETED,Multiple Sclerosis,DIAGNOSTIC_TEST: Kappa Free Light Chain (K-FLC),Aga Khan University,,ALL,"CHILD, ADULT, OLDER_ADULT",,60,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-06-01,2021-08-31,2021-08-31,"Clinical Chemistry, Sopari wala building, Karachi, Sindh, 74800, Pakistan"
NCT02914964,Dietary Approaches to Treat Multiple Sclerosis-Related Fatigue Study,https://beta.clinicaltrials.gov/study/NCT02914964,ACTIVE_NOT_RECRUITING,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting",BEHAVIORAL: Swank Diet|BEHAVIORAL: Wahls Elimination Diet,Terry L. Wahls,National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2016-08,2020-01-26,2025-01-26,"University of Iowa Hospitals and Clinics, Iowa City, Iowa, 52242, United States"
NCT00273364,Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study,https://beta.clinicaltrials.gov/study/NCT00273364,COMPLETED,Multiple Sclerosis,PROCEDURE: Hematopoietic Stem Cell Therapy|DRUG: Standard treatment with a conventional drug,Northwestern University,Uppsala University|Sheffield Teaching Hospitals NHS Foundation Trust|University of Sao Paulo,ALL,ADULT,PHASE2,110,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2005-11-16,2017-01-05,2019-08-30,"Northwestern University, Feinberg School of Medicine, Chicago, Illinois, 60611, United States"
NCT04552561,My MS Toolkit + Coaching: A Guided Web-based Symptom Self-Management Program for People With MS,https://beta.clinicaltrials.gov/study/NCT04552561,COMPLETED,Multiple Sclerosis,BEHAVIORAL: My MS Toolkit,University of Michigan,,ALL,"ADULT, OLDER_ADULT",NA,5,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2020-10-19,2021-01-18,2021-01-18,"The University of Michigan, Ann Arbor, Michigan, 48109, United States"
NCT04239664,Acceptance Based Telephone Support When Transitioning to SPMS,https://beta.clinicaltrials.gov/study/NCT04239664,COMPLETED,Secondary Progressive Multiple Sclerosis,OTHER: Acceptance Based Telephone Support (ABS+UC),University of Nottingham,Nottingham University Hospitals NHS Trust,ALL,"ADULT, OLDER_ADULT",NA,14,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2019-09-09,2020-03-20,2020-03-20,"Queens Medical Centre, Nottingham, Nottingham, Nottinghamshire, NG7 2UH, United Kingdom"
NCT01199861,Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT01199861,COMPLETED,Relapsing Multiple Sclerosis,DRUG: Fingolimod|DRUG: Placebo|BIOLOGICAL: Seasonal influenza vaccine|BIOLOGICAL: Tetanus toxoid vaccine,Novartis,,ALL,ADULT,PHASE3,138,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2010-08,2011-05,2011-05,"Novartis Investigative Site, Aalst, 9300, Belgium|Novartis Investigative Site, Bruxelles, 1200, Belgium|Novartis Investigative Site, Leuven, 3000, Belgium|Novartis Investigative Site, Liege, 4000, Belgium|Novartis Investigative Site, Wilrijk, 2610, Belgium|Novartis Investigative Site, Nepean, Ontario, K2G 6E2, Canada|Novartis Investigative Site, Montreal, Quebec, H3A 2B4, Canada|Novartis Investigative Site, Sherbrooke, JiH 5N4, Canada|Novartis Investigative Site, Seinajoki, 60220, Finland|Novartis Investigative Site, Turku, 20100, Finland|Novartis Investigative Site, Caen, 14033, France|Novartis Investigative Site, Rennes, 35043, France|Novartis Investigative Site, St Herblain, 44800, France|Novartis Investigative Site, Toulouse, 31059, France|Novartis Investigative Site, Guatemala City, 01010, Guatemala|Novartis Investigative Site, Guatemala City, 01014, Guatemala|Novartis Investigative Site, Katowice, 40-594, Poland|Novartis Investigative Site, Lodz, 90-153, Poland|Novartis Investigative Site, Madrid, 28029, Spain|Novartis Investigative Site, Madrid, 28040, Spain|Novartis Investigative Site, Sevilla, 41009, Spain|Novartis Investigative Site, Valencia, 46009, Spain|Novartis Investigational Site, Basel, 4031, Switzerland|Novartis Investigative Site, Nottingham, NG7 2UH, United Kingdom|Novartis Investigative Site, Stoke-on-Trent, ST4 7LN, United Kingdom"
NCT03705364,Fall Prevention Program for Non-ambulatory Wheeled Mobility Device Users Living With MS,https://beta.clinicaltrials.gov/study/NCT03705364,UNKNOWN,Multiple Sclerosis,OTHER: Fall Management program,University of Illinois at Urbana-Champaign,,ALL,"ADULT, OLDER_ADULT",NA,120,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: PREVENTION,2018-03-01,2020-01-01,2020-01-01,"The Shepherd Center, Atlanta, Georgia, 30309, United States|UIC, Chicago, Illinois, 60607, United States|UIUC, Urbana, Illinois, 61801, United States"
NCT05229861,The Influence of HIIT Versus MCT on Cardiorespiratory Fitness in PPMS,https://beta.clinicaltrials.gov/study/NCT05229861,RECRUITING,Primary Progressive Multiple Sclerosis|Exercise|Cardiorespiratory Fitness,BEHAVIORAL: HIIT|BEHAVIORAL: MCT,Klinik Valens,"Technische Universität Dortmund, Germany",ALL,"ADULT, OLDER_ADULT",NA,61,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-05-10,2024-02-29,2024-02-29,"Klinik Valens, Valens rehabilitation clinic, Valens, Sankt Gallen, 7317, Switzerland"
NCT03574961,E-Support Groups in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03574961,COMPLETED,Multiple Sclerosis,BEHAVIORAL: e-Support group|BEHAVIORAL: e-Journaling placebo,Columbia University,National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2018-05-10,2019-04-30,2019-06-30,"Columbia University Medical Center (MS Center), New York, New York, 10032, United States"
NCT00109161,"Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT00109161,COMPLETED,Multiple Sclerosis,DRUG: Daclizumab (Anti-CD25 Humanized Monoclonal Antibody),"PDL BioPharma, Inc.",,ALL,ADULT,PHASE2,270,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,2005-04,,2006-10,"St. Joseph's Hospital and Medical Center, Phoenix, Arizona, 85013, United States|Mayo Clinic, Scottsdale, Arizona, 85013, United States|Sutter East Bay Medical Foundation, Berkeley, California, 94705, United States|Neurology Associates, P.A., Maitland, Florida, 32751, United States|The Multiple Sclerosis Center of Atlanta, Atlanta, Georgia, 30327, United States|Consultants in Neurology, Northbrook, Illinois, 60062, United States|KUMC Neurology, Kansas City, Kansas, 66160, United States|Louisiana State University Health Sciences Center, Shreveport,, Louisiana, 71103, United States|Maryland Center for MS, Baltimore, Maryland, 21201, United States|Wayne State University MS Center, Detroit, Michigan, 48201, United States|Michigan State University, East Lansing, Michigan, 48824, United States|Michigan Medical P.C. Neurology, Grand Rapids, Michigan, 49525, United States|St. Louis University Hospital, St. Louis, Missouri, 63110, United States|MS Center at Dartmouth, Lebanon, New Hampshire, 03756, United States|Gimble MS Center, Teaneck, New Jersey, 07666, United States|Upstate Clinical Research, Albany, New York, 12205, United States|Albany Medical Center, Albany, New York, 12208, United States|Winthrop University Hospital, Mineola, New York, 11501, United States|Hospital for Joint Diseases, MS Care Center, New York, New York, 10003, United States|University of Rochester Medical Center, Rochester, New York, 14642, United States|MS Center/CMC Meyers Park, Charlotte, North Carolina, 28207, United States|Raleigh Neurology Associates, Raleigh, North Carolina, 27607, United States|University of Cincinnati, Cincinnati, Ohio, 45219, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|The MS Center at Texas Neurology, Dallas, Texas, 75214, United States|Central Texas Neurology, Round Rock, Texas, 78681, United States|University of Utah CAMT, Salt Lake City, Utah, 84108, United States|MS Hub Medical Group, Seattle, Washington, 98101, United States|Rockwood Clinic, PS, Spokane, Washington, 99202, United States|Wenatchee Valley Medical Center, Wenatchee, Washington, 98801, United States|Foothills Medical Centre-MS Research Program, Calgary, Alberta, T2N 2T9, Canada|University of Alberta, Edmonton, Alberta, T6G-2C8, Canada|Health Sciences Center, Winnipeg, Manitoba, R3A 1R9, Canada|London Health Sciences Centre, London, Ontario, N6A 5A5, Canada|Clinique SEP/NM, Gatineau, Quebec, PQ J8Y 1W7, Canada|Montreal Neurological Institute, Montreal, Quebec, H3A 2B4, Canada"
NCT02391961,Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02391961,COMPLETED,Multiple Sclerosis|Internuclear Ophthalmoplegia|Fatigue,DRUG: Dalfampridine|DRUG: Placebo,VA Office of Research and Development,,ALL,"ADULT, OLDER_ADULT",PHASE2,23,FED,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2015-04-01,2019-01-31,2019-03-31,"Louis Stokes VA Medical Center, Cleveland, OH, Cleveland, Ohio, 44106, United States"
NCT02508961,WEB-Based Physiotherapy for People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02508961,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Exercise,University of Glasgow,National Heatlh Service Ayrshire and Arran|NHS Lothian|University of Plymouth|University Hospital Plymouth NHS Trust,ALL,"ADULT, OLDER_ADULT",NA,90,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2015-01,2016-12,2016-12,"Anne Rowling Regenerative Neurology Clinic, Edinburgh, EH16 4SB, United Kingdom|Douglas Grant Rehabilitation Centre, Irvine, KA128SS, United Kingdom|University of Plymouth, Plymouth, PL6 8BH, United Kingdom"
NCT03544177,Effects of Low-intensity Interval Walking With Blood Flow Restriction on Functional Capacity in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03544177,COMPLETED,Multiple Sclerosis,OTHER: BFR-Walking|OTHER: Conventional therapy,University Hospital of Ferrara,,ALL,"ADULT, OLDER_ADULT",NA,24,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2018-05-21,2019-09-30,2019-12-30,"University Hospital of Ferrara, Ferrara, 44124, Italy"
NCT00493077,Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy,https://beta.clinicaltrials.gov/study/NCT00493077,COMPLETED,Multiple Sclerosis,DRUG: low immunogenic interferon-beta-1a,Biogen,,ALL,ADULT,PHASE4,3,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2004-05,2006-05,2006-05,"Research Site, Goteborg, 416 85, Sweden|Coordinating Research Site, Huddinge, Sweden|Research Site, Joenkoeping, 551 85, Sweden|Research Site, Karlstad, 651 85, Sweden|Research Site, Stockholm, 141 86, Sweden"
NCT00095329,"Treating Multiple Sclerosis With Sirolimus, an Immune System Suppressor",https://beta.clinicaltrials.gov/study/NCT00095329,TERMINATED,Multiple Sclerosis (MS) - Relapsing-remitting,BIOLOGICAL: sirolimus,National Institute of Allergy and Infectious Diseases (NIAID),Autoimmunity Centers of Excellence,ALL,ADULT,PHASE1|PHASE2,14,NIH,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2003-05,2005-03,2005-03,"Center for Neurological Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, 02115, United States"
NCT04048577,A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab,https://beta.clinicaltrials.gov/study/NCT04048577,RECRUITING,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting",DRUG: Dosing Interruption of Natalizumab,"Berkovich, Regina MD, PhD Inc.",Biogen|Cedars-Sinai Medical Center,ALL,"ADULT, OLDER_ADULT",PHASE4,10,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2019-07-03,2021-11-01,2021-12-01,"Regina Berkovich MD, PhD Inc., West Hollywood, California, 90048, United States"
NCT04880577,Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04880577,WITHDRAWN,"Multiple Sclerosis, Relapsing-Remitting|Fatigue",DRUG: TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY]|DRUG: Placebo,Massachusetts General Hospital,Gilead Sciences,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-09-15,2024-02-14,2025-02-14,"Massachusetts General Hospital, Boston, Massachusetts, 02114, United States"
NCT00915577,Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex Syringe,https://beta.clinicaltrials.gov/study/NCT00915577,COMPLETED,Multiple Sclerosis,DRUG: Interferon beta-1a|DEVICE: Single-use autoinjector,Biogen,,ALL,"ADULT, OLDER_ADULT",PHASE3,74,INDUSTRY,INTERVENTIONAL,"Allocation: |Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: ",2005-08,2006-04,2006-04,
NCT01198977,Telehealth-Based Exercise Program to Treat Fatigue in MS,https://beta.clinicaltrials.gov/study/NCT01198977,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Brief telephone-based counseling|OTHER: Education counseling,VA Office of Research and Development,,ALL,"ADULT, OLDER_ADULT",NA,64,FED,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2009-10,2015-09,2016-12,"VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington, 98108, United States"
NCT02489877,Comparison Between Clinical and MRI Multiple Sclerosis Activity and Expression of Human Endogenous Retrovirus Type W and Herpesvirus,https://beta.clinicaltrials.gov/study/NCT02489877,UNKNOWN,Multiple Sclerosis,,Faculdade de Ciências Médicas da Santa Casa de São Paulo,University of Sao Paulo,ALL,"CHILD, ADULT, OLDER_ADULT",,84,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-07,2016-07,2017-07,
NCT03368677,Effect of Teriflunomide Treatment on Microglial Activation in an MS Patient Cohort at Risk of Progression,https://beta.clinicaltrials.gov/study/NCT03368677,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,,Turku University Hospital,,ALL,ADULT,,26,OTHER_GOV,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-12-01,2023-12,2024-11,"Turku PET Centre, Turku, Finland Proper, 20520, Finland"
NCT05179577,A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05179577,NOT_YET_RECRUITING,Spasticity,DRUG: Arbaclofen|DRUG: Placebo,"RVL Pharmaceuticals, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE3,442,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-06,2024-06,2024-09,
NCT00242177,Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability,https://beta.clinicaltrials.gov/study/NCT00242177,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: ACTOS (Pioglitazone),University of Illinois at Chicago,"Takeda Pharmaceuticals North America, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE1,30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,2003-10,,2005-10,"University of Illinois at Chicago, Chicago, Illinois, 60612, United States"
NCT01911377,Botulinum Toxin Type A for Treating Allodynic Pain in SCI and MS,https://beta.clinicaltrials.gov/study/NCT01911377,TERMINATED,Neuropathic Pain|Allodynia,DRUG: Botulinum Toxin Type A|DRUG: Normal Saline for Injection,University of Manitoba,Allergan,ALL,"ADULT, OLDER_ADULT",PHASE2,12,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-10,2015-05,2015-08,"WRHA Health Sciences Centre Rehabilitation Hospital, Winnipeg, Manitoba, R3A IM4, Canada"
NCT01024777,Safety and Immunologic Effect of Low Dose Versus High Dose Vitamin D3 in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01024777,COMPLETED,Multiple Sclerosis|Vitamin D Deficiency,DRUG: Cholecalciferol|DRUG: Cholecalciferol,Johns Hopkins University,,ALL,ADULT,PHASE1,40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2010-03,2013-01,2013-01,"Johns Hopkins University, Baltimore, Maryland, 21287, United States"
NCT02874677,A Reeducation Program to Effort to Improve the Walking of Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT02874677,UNKNOWN,Multiple Sclerosis,OTHER: Effort reeducation program,Lille Catholic University,,ALL,"ADULT, OLDER_ADULT",NA,88,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2017-12-07,2020-05,2020-05,"Centre Hospitalier Universitaire d'Amiens, Amiens, Nord Pas-de-Calais, 80000, France|Centre Jacques Calvé, Berck, Nord Pas-de-Calais, 62600, France|Centre Hospitalier Régional Universitaire de Lille, Lille, Nord Pas-de-Calais, 59000, France|Groupement des Hôpitaux de l'Institut Catholique de Lille, Lille, Nord Pas-de-Calais, 59000, France"
NCT02835677,Integrating Caregiver Support Into MS Care,https://beta.clinicaltrials.gov/study/NCT02835677,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Behavioral,VA Office of Research and Development,Memphis VA Medical Center,ALL,"ADULT, OLDER_ADULT",NA,25,FED,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-09-07,2018-04-09,2018-06-30,"Memphis VA Medical Center, Memphis, TN, Memphis, Tennessee, 38104, United States"
NCT05839977,The Effect of Telerehabilitation on Balance in People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05839977,RECRUITING,Telerehabilitation,OTHER: Individual telerehabilitation|OTHER: Home exercises based on videos,"Charles University, Czech Republic",,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-03-01,2025-10,2025-12,"Center for Demyelinating Disease (RS Center), First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Karlovo Náměstí 32, 121 21, Czechia|Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Karlovo Náměstí 32, 121 21, Czechia"
NCT02907177,Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®),https://beta.clinicaltrials.gov/study/NCT02907177,TERMINATED,Multiple Sclerosis,DRUG: Ponesimod|OTHER: Placebo,Actelion,,ALL,ADULT,PHASE3,136,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-03-30,2020-03-26,2020-03-26,"UAB Dpt of Neurology, Birmingham, Alabama, 35233, United States|Neuro-Pain Medical Center, Fresno, California, 93710, United States|SC3 Research - Pasadena, Pasadena, California, 91105, United States|Care Access Research - Santa Clarita, Santa Clarita, California, 91321, United States|Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, 90502, United States|University of Colorado Hospital, Aurora, Colorado, 80045, United States|Mountain View Clinical Research, Inc, Denver, Colorado, 80209, United States|Associated Neurologists, Danbury, Connecticut, 06810, United States|Bradenton Research Center, Bradenton, Florida, 34205, United States|Neurology Associates - MS Center of Greater Orlando, Maitland, Florida, 32751, United States|Neurology Assoc of Ormond Beach - CNS Trials, Ormond Beach, Florida, 32174, United States|Suncoast Neuroscience Associates, Inc, Saint Petersburg, Florida, 33713, United States|The MS Center of Vero Beach, Vero Beach, Florida, 32960, United States|Fort Wayne Neurological Center - North Office, Fort Wayne, Indiana, 46825, United States|University of Kansas Med Center, Kansas City, Kansas, 66160, United States|MidAmerica Neuroscience Research Foundation/Rowe Neurology, Lenexa, Kansas, 66214, United States|Henry Ford Health System - Neurology, Detroit, Michigan, 48202, United States|Univ of New Mexico - Health Sciences Center, Albuquerque, New Mexico, 87131, United States|NYU Langone Medical Center - MS Comprehensive Care Center, New York, New York, 10016, United States|Riverhills Healthcare, Inc., Cincinnati, Ohio, 45212, United States|OhioHealth Research Institute, Columbus, Ohio, 43214, United States|Neurology and Neuromuscular Center, Oklahoma City, Oklahoma, 73102, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|Thomas Jefferson University Hospital - Dpt Neurology MS Center, Philadelphia, Pennsylvania, 19107, United States|Advanced Neuroscience Institute, Franklin, Tennessee, 37064, United States|Neurology Center of San Antonio, San Antonio, Texas, 78258, United States|Austin Health - Neuro-Immunology Clinical Research, Education and Support Service, Heidelberg, Victoria, 3084, Australia|MS Ambulanz Maida, Wien, 1010, Austria|Medizinische Universität Wien, Universitätsklinik für Neurologie, Wien, 1090, Austria|Hospital universitair Brussels_neurology department, Brussels, 1090, Belgium|Hospital - Universitair Gent __Neurology Department, Gent, 9000, Belgium|Hospital - Revalidatie & MS Centrum Overpelt_Neurology Department, Overpelt, 3900, Belgium|""Multiprofile Hospital for Active Treatment of Neurology and Psychiatry - Sveti Naum"" EAD - Neurology Clinic for Movement Disorders, Sofia, 1113, Bulgaria|""University Multiprofile Hospital for Active Treatment - Alexandrovska"" EAD, Neurology Clinic, Sofia, 1431, Bulgaria|University Multiprofile Hospital for Active Treatment ""Sv. Ivan Rilski"" EAD, Neurology Clinic, Sofia, 1431, Bulgaria|University of Alberta, Edmonton, T6G 1Z1, Canada|Fakultní nemocnice u sv. Anny Brno, RS Centrum, Brno, 656 91, Czechia|Fakultní nemocnice Hradec Králové, Neurologická klinika, Hradec Králové, 500 05, Czechia|Nemocnice Jihlava, Neurologické oddělení, Jihlava, 586 33, Czechia|Pardubicka krajska nemocnice, MS Centrum, Pardubice, 532 03, Czechia|Krajská zdravotní a.s. - Nemonice Teplice o.z., RS Centrum, Teplice, 415 29, Czechia|Aalborg Universitetshospital, Skleroseklinikken Neurologisk afdelning, Aalborg, 9000, Denmark|Glostrup Hospital, Neurologisk afdelning, Glostrup, 2600, Denmark|Hôpital Avicenne, Service de Neurologie, Bobigny, 93000, France|Hosp Gabriel Montpied, Dept Neurology, Clermont Ferrand, 63003, France|Centre Hospitalier Sud Francilien - Service de Neurologie, Corbeil-Essonnes, 91100, France|CHU de Dijon - Hôpital François Miterrand, Service de Neurologie, Dijon, 21079, France|CHRU de Lille - Hôpital Roger Salengro, Service de Neurologie, Lille, 59037, France|Hopital Gui de Chauliac - CHU Montpellier, Montpellier, 34295, France|Hôpital Central - CHU Nancy, Département Neurologie, Nancy, 54035, France|Hôpital Universitaire Carémeau, Service de Neurologie, Nimes, 30029, France|CHI POISSY-Saint Germay en Laye_Service de Neurologie et Réeducation, Poissy, 78303, France|Hosp Pontchaillou, Dept Cardiology, Rennes, 35033, France|Hosp Charles Nicolle Dept Neurology, Rouen, 76000, France|Zentrum für klinische Forschung Dr. med. Irma Schöll, Bad Homburg, 61348, Germany|Neurologische Klinik und Poliklinik - Universitätsklinikum Carl Gustav Carus, Zentrum für klinische Neurowissenschaften, Dresden, 01307, Germany|Helios Klinikum Erfurt, Erfurt, 99089, Germany|Universitätsklinikum Giessen Klinik und Poliklinik für Neurologie, Giessen, 35385, Germany|Universitätsmedizin Greifswald - Körperschaft des öffentlichen Rechts - Klinik und Poliklinik für Neurologie, Greifswald, 17475, Germany|Medizinische Hochschule Hannover, Neurologie, Hannover, 30625, Germany|AFL Arzneimittelforschung Leipzig GmbH, Leipzig, 04107, Germany|Universitätsklinikum Münster, Klinik für Allgemeine Neurologie, Münster, 48149, Germany|Medizinzentrum Siegerland Weidenau, Siegen, 57076, Germany|NeuroPoint GmbH, Gesellschaft für vorbeugende Gesundheitspflege, Ulm, 89073, Germany|Gemeinschaftspraxis Dr. med. Joachim Springub / Wolfgang Schwarz, Studienzentrum Nord-West (Study Center), Westerstede, 26655, Germany|Naval Hospital of Athens - Neurology Dpt, Athens, 11521, Greece|401 Military Hospital of Athens - Neurology Dept, Athens, 11525, Greece|Aeginition Hospital - Neurology Department, Athens, 11528, Greece|Medical Center of Athens - Neurology Dpt, Marousi, 15125, Greece|General Hospital of Thessaloniki, Thessaloniki, 57010, Greece|Uzsoki utcai Kórház, Neurológiai Osztály, Budapest, 1145, Hungary|Valeomed EGÉSZSÉGÜGYI KÖZPONT, Esztergom, 2500, Hungary|Pest Megyei Flór Ferenc Kórház, Neurológia és Stroke ambulancia, Kistarcsa, 2143, Hungary|Fondazione Istituto San Raffaele , Unità Operativa di Neurologia, Cefalù, 90015, Italy|Università degli Studi di Firenze - Azienda Ospedaliero Universitaria Careggi - CTO - SOD Neurologia 2, Firenze, 50139, Italy|AOU San Martino di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DINOGMI), Genova, 16132, Italy|Istituto Neurologico Carlo Besta, UOC Neurologia 4, Neuroimmunologia e Malattie Neuromuscolari, Centro Sclerosi Multipla, Milano, 20133, Italy|Azienda Ospedaliera Universitaria (AOU) ""Federico II"" - Centro Regionale Per la Sclerosi Multipla c/o Clinica Neurologica II - Dipartimento di Scienze, Napoli, 80131, Italy|AOU Università degli Studi della Campania L. Vanvitelli - I° Policlinico - DAI di Medicina Interna e Specialistica CS, Centro Sclerosi Multipla, Napoli, 80138, Italy|Azienda Ospedaliero Universitaria San Luigi Gonzaga - Centro Sclerosi Multipla CRESM, Orbassano, 10043, Italy|IRCCS NEUROMED - Istituto Neurologico Mediterraneo - Unità Operativa di Neurologia I, Pozzilli, 86077, Italy|Azienda Ospedaliera S. Andrea di Roma - Unità Operativa Complessa di Neurologia, Roma, 00189, Italy|Azienda Ospedaliera Universitaria Senese - Dipartimento di Scienze Neurologiche e neurosensoriali - UOSA Neurologia Sperimentale, Siena, 53100, Italy|Unidad de Investigacion en Salud de Chihuahua SC, Médica Sur, Unidad de Neurociencias, Tlalpan, DF, 14050, Mexico|Desarrollo Ético en Investigación Clínica S.C ., Guadalajara, Jalisco, 44500, Mexico|Axis Heilsa S. de R.L. de C.V. (Althian), Nuevo Leon, Monterrey, 64060, Mexico|Unidad de Investigación de Salud en Chihuahua, Chihuahua, 31203, Mexico|Uniwersytecki Szpital Kliniczny w Bialymstoku, Klinika Neurologii i Oddziat Udarowy, Bialystok, 15-276, Poland|B&B Robert Bonek, Pawel Bochniak S.C, Bydgoszcz, 85-795, Poland|COPERNICUS - Podmiot Leczniczy Sp. z o.o., Gdansk, 80-803, Poland|Centrum Terapii SM, Katowice, 40-571, Poland|Neuro-Medic Janusz Zbrojkiewicz Poradnia Weilospecjalistyczna, Katowice, 40-752, Poland|Centrum Kompleksowej Rehabilitacji, Konstancin-Jeziorna, 05-510, Poland|Centrum Opieki Zdrowotnej Orkan - Med., Ksawerów, 95-054, Poland|Instytut Psychiatrii i Neurologii, II Klinika Neurologiczna, Warszawa, 02-957, Poland|WroMedica, J. Bielicka A. Strzałkowska SC, Wroclaw, 51-685, Poland|Centro Hospitalar de Lisboa Central, Lisboa, 1169-050, Portugal|Hospital de Santa Maria - Neurology Department, Lisboa, 1649-035, Portugal|Centro Hospitalar de São João, E.P.E. - Hospital de São João - Neurology Department, Porto, 4200-319, Portugal|State Budgetary Healthcare Institution Regional Clinical Hospital No 3, Chelyabinsk, 454021, Russian Federation|Center of Professional Therapy, LLC, Krasnodar, 350051, Russian Federation|Moscow State Budgetary Healthcare Institution Filatov City Clinical Hospital No.15 of Moscow Health Department, Moscow, 111539, Russian Federation|Neuro-Clinic, LLC, Moscow, 117186, Russian Federation|Moscow State Budgetary Healthcare Institution Pirogov City Clinical Hospital No. 1 of Moscow Health Department, Moscow, 119049, Russian Federation|Moscow State Budgetary Healthcare Institution City Clinical Hospital No. 24 of Moscow Health Department, Moscow, 127015, Russian Federation|Hospital Santa Creu I Sant Pau - Neurology Dpt, Barcelona, 08041, Spain|Hosp Virgen de la Arrixaca, Neurology, El Palmar, 30120, Spain|Hosp Gregorio Marañón, Neurology, Madrid, 28007, Spain|Hospital Clinico San Carlos, Neurology, Madrid, 28040, Spain|Hospital Santa Caterina - Neurology Department, Salt, 17190, Spain|Complejo Hospitalario Universitario de Santiago de Compostela (CHUS) - Neurology Department 2, Santiago de Compostela, 15703, Spain|Hospital Universitario Virgen Macarena - Neurofisiology Department, Sevilla, 41009, Spain|Centro de Neurologia Avanzada, Neurology, Sevilla, 41013, Spain|Univeritätsspital Basel Neurologie, Neurologische Klinik und Poliklinik, Basel, 4031, Switzerland|Ospedale Regionale di Lugano - Civico e Italiano, Neurologia, Lugano, Lugano, 6903, Switzerland|Queen Square MS Centre / NMR research Unit UCL Institute of Neurology, London, WC1N 3BG, United Kingdom|Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, OX3 9DU, United Kingdom|Royal Hallamshire Hospital, Sheffield, S10 2JF, United Kingdom|University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, ST4 6QG, United Kingdom"
NCT04448977,Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI,https://beta.clinicaltrials.gov/study/NCT04448977,RECRUITING,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Ocrevus,Kessler Foundation,Hackensack Meridian Health,ALL,ADULT,,60,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-05-06,2023-07,2023-07,"Kessler Foundation, West Orange, New Jersey, 07052, United States"
NCT03935529,Behavioural Activation for Low Mood in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03935529,COMPLETED,Depression|Secondary-progressive Multiple Sclerosis,BEHAVIORAL: Behavioural Activation,University of Lincoln,Nottingham University Hospitals NHS Trust,ALL,"ADULT, OLDER_ADULT",NA,10,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2019-03-04,2019-06-30,2019-06-30,"Nottingham University Hospitals - Queens Medical Centre, Nottingham, United Kingdom"
NCT05236777,TOPIK Study: A Study to Report Progressive Multifocal Leukoencephalopathy and Other Serious Opportunistic Infections in Natalizumab Treated Participants,https://beta.clinicaltrials.gov/study/NCT05236777,RECRUITING,Multiple Sclerosis,DRUG: Natalizumab,Biogen,"Association for Functional Rehabilitation, Recreation and Applied Kinesiology Impulse",ALL,"CHILD, ADULT, OLDER_ADULT",,600,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-01-01,2023-04-30,2025-04-30,"Fakultní nemocnice Brno, Brno, Czechia|Fakultní nemocnice u sv. Anny v Brně, Brno, Czechia|Fakultní nemocnice Hradec Králové, Hradec Králové, Czechia|Nemocnice Jihlava, Jihlava, Czechia|Fakultní nemocnice Olomouc, Olomouc, Czechia|Fakultní nemocnice v Ostravě, Ostrava, Czechia|Nemocnice Pardubického kraje, Pardubice, Czechia|Fakultní nemocnice v Plzni, Pilsen, Czechia|Fakultní nemocnice Královské Vinohrady v Praze, Prague, Czechia|Fakultní nemocniceMotol v Praze, Prague, Czechia|Fakultní Thomayerova nemocnice v Praze v Krči, Prague, Czechia|Všeobecná fakultní nemocnice v Praze, Prague, Czechia|Nemocnice Teplice, Teplice, Czechia|Krajská nemocnice T. Bati ve Zlíně, Zlín, Czechia|Nemocnice České Budějovice, České Budějovice, Czechia"
NCT00937677,Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study,https://beta.clinicaltrials.gov/study/NCT00937677,COMPLETED,Multiple Sclerosis,DRUG: Tysabri,University at Buffalo,Biogen,ALL,"ADULT, OLDER_ADULT",,85,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2007-11,2009-12,2010-11,"Jacobs Neurological Institute, Buffalo, New York, 14203, United States"
NCT04480853,Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04480853,RECRUITING,Multiple Sclerosis,DRUG: Fingolimod,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE4,30,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-10-12,2025-02-28,2025-02-28,"Novartis Investigative Site, Kaoshiung, 83301, Taiwan|Novartis Investigative Site, Taichung, 40705, Taiwan|Novartis Investigative Site, Tainan, 70403, Taiwan|Novartis Investigative Site, Taipei, 10002, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taoyuan, 33305, Taiwan"
NCT05382195,Clinical Correlates of Psychiatric Comorbidities in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05382195,NOT_YET_RECRUITING,Patients With Multiple Sclerosis,OTHER: hospital anxiety and depression scale,Sohag University,,ALL,"CHILD, ADULT, OLDER_ADULT",,100,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-06-01,2023-02-01,2023-02-01,"Sohag University Hospital, Sohag, Egypt"
NCT04391023,Cerebellar tDCS and Balance Training in PwMS,https://beta.clinicaltrials.gov/study/NCT04391023,RECRUITING,Multiple Sclerosis,DEVICE: Sham Transcranial Direct Current Stimulation (tDCS)|BEHAVIORAL: Balance Training|DEVICE: 2 mA Transcranial Direct Current Stimulation|DEVICE: 4 mA Transcranial Direct Current Stimulation,University of Iowa,,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-09-26,2023-05-15,2023-07-15,"University of Iowa, Iowa City, Iowa, 52242, United States"
NCT03854123,"Multiple Sclerosis in the Elderly: Epidemiology, Clinical and MRI Characteristics",https://beta.clinicaltrials.gov/study/NCT03854123,COMPLETED,Multiple Sclerosis,,"University Hospital, Bordeaux",Observatoire Français de la sclérose en plaques (OFSEP)|Novartis,ALL,OLDER_ADULT,,159,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-09-21,2020-09-23,2020-09-23,"CHU de Bordeaux - Pellegrin - service de neurologie, Bordeaux, France|Hôpital neurologique - Pierre Wertheimer, Bron, France|CHU de Rennes - service de neurologie, Rennes, France"
NCT01667484,Adderall XR and Processing Speed in Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT01667484,COMPLETED,Impaired Processing Speed|Cognitive Impairment|Multiple Sclerosis,DRUG: Adderall XR 5mg|DRUG: Adderall XR 10 mg|DRUG: Placebo,London Health Sciences Centre,,ALL,ADULT,PHASE2|PHASE3,70,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-09,2013-02,2015-02,"London Health Sciences Center and St. Joseph's Heathcare Center (Parkwood), London, Ontario, N6G 1W8, Canada"
NCT03257358,A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod,https://beta.clinicaltrials.gov/study/NCT03257358,COMPLETED,Relapsing Multiple Sclerosis,DRUG: Fingolimod,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE4,382,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2017-09-19,2019-03-05,2019-06-28,"Novartis Investigative Site, Birmingham, Alabama, 35209, United States|Novartis Investigative Site, Cullman, Alabama, 35058, United States|Novartis Investigative Site, Tucson, Arizona, 85718, United States|Novartis Investigative Site, Berkeley, California, 94705, United States|Novartis Investigative Site, Sacramento, California, 95817, United States|Novartis Investigative Site, Colorado Springs, Colorado, 80907, United States|Novartis Investigative Site, Louisville, Colorado, 80027, United States|Novartis Investigative Site, Boca Raton, Florida, 33482, United States|Novartis Investigative Site, Boca Raton, Florida, 33487, United States|Novartis Investigative Site, Jacksonville, Florida, 32209, United States|Novartis Investigative Site, Miami, Florida, 33136, United States|Novartis Investigative Site, Ocala, Florida, 34471, United States|Novartis Investigative Site, Port Charlotte, Florida, 33952, United States|Novartis Investigative Site, Sarasota, Florida, 34243, United States|Novartis Investigative Site, Sunrise, Florida, 33351, United States|Novartis Investigative Site, Vero Beach, Florida, 32960, United States|Novartis Investigative Site, Savannah, Georgia, 31406, United States|Novartis Investigative Site, Suwanee, Georgia, 30024, United States|Novartis Investigative Site, Flossmoor, Illinois, 60422, United States|Novartis Investigative Site, Kansas City, Kansas, 66160, United States|Novartis Investigative Site, Louisville, Kentucky, 40202, United States|Novartis Investigative Site, Louisville, Kentucky, 40207, United States|Novartis Investigative Site, Lutherville, Maryland, 21093, United States|Novartis Investigative Site, Foxboro, Massachusetts, 02035, United States|Novartis Investigative Site, Lexington, Massachusetts, 02421, United States|Novartis Investigative Site, Wellesley, Massachusetts, 02481, United States|Novartis Investigative Site, Ann Arbor, Michigan, 48109, United States|Novartis Investigative Site, Owosso, Michigan, 48867, United States|Novartis Investigative Site, Golden Valley, Minnesota, 55422, United States|Novartis Investigative Site, Kansas City, Missouri, 64111, United States|Novartis Investigative Site, Saint Louis, Missouri, 63131, United States|Novartis Investigative Site, Las Vegas, Nevada, 89106, United States|Novartis Investigative Site, Fair Lawn, New Jersey, 07410, United States|Novartis Investigative Site, Livingston, New Jersey, 07039, United States|Novartis Investigative Site, Patchogue, New York, 11772, United States|Novartis Investigative Site, Plainview, New York, 11803, United States|Novartis Investigative Site, Asheville, North Carolina, 28806, United States|Novartis Investigative Site, Charlotte, North Carolina, 28207, United States|Novartis Investigative Site, Mooresville, North Carolina, 28117, United States|Novartis Investigative Site, Raleigh, North Carolina, 27607, United States|Novartis Investigative Site, Winston-Salem, North Carolina, 27103, United States|Novartis Investigative Site, Cleveland, Ohio, 44195, United States|Novartis Investigative Site, Dayton, Ohio, 45408, United States|Novartis Investigative Site, Toledo, Ohio, 43623, United States|Novartis Investigative Site, Westerville, Ohio, 43081, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, 73102, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, 73104, United States|Novartis Investigative Site, Portland, Oregon, 97225, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, 19140, United States|Novartis Investigative Site, Greer, South Carolina, 29650, United States|Novartis Investigative Site, Mount Pleasant, South Carolina, 29464, United States|Novartis Investigative Site, Port Royal, South Carolina, 29935, United States|Novartis Investigative Site, Knoxville, Tennessee, 37922, United States|Novartis Investigative Site, Nashville, Tennessee, 37215, United States|Novartis Investigative Site, Dallas, Texas, 75246, United States|Novartis Investigative Site, San Antonio, Texas, 78258, United States|Novartis Investigative Site, Falls Church, Virginia, 22043, United States|Novartis Investigative Site, Vienna, Virginia, 22182, United States|Novartis Investigative Site, Kirkland, Washington, 98034, United States|Novartis Investigative Site, Seattle, Washington, 98122, United States|Novartis Investigative Site, Spokane, Washington, 99202, United States|Novartis Investigative Site, Tacoma, Washington, 98405, United States|Novartis Investigative Site, Huntington, West Virginia, 25701, United States|Novartis Investigative Site, Green Bay, Wisconsin, 54311, United States|Novartis Investigative Site, Milwaukee, Wisconsin, 53215, United States|Novartis Investigative Site, Neenah, Wisconsin, 54956, United States"
NCT00112723,Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,https://beta.clinicaltrials.gov/study/NCT00112723,TERMINATED,Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Lymphocyte Predominant Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Multiple Myeloma|Splenic Marginal Zone Lymphoma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma|Waldenström Macroglobulinemia,DRUG: alvocidib,National Cancer Institute (NCI),,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,46,NIH,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2005-12,2011-02,2015-11,"Ohio State University Medical Center, Columbus, Ohio, 43210, United States"
NCT01070823,JC-Virus (JCV) Antibody Program,https://beta.clinicaltrials.gov/study/NCT01070823,COMPLETED,Multiple Sclerosis,DRUG: Tysabri® (natalizumab),Biogen,"United BioSource, LLC|Elan Pharmaceuticals",ALL,"CHILD, ADULT, OLDER_ADULT",,1096,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-03,2012-06,2012-06,"Research Site, Aurora, Colorado, 80045, United States|Research Site, Atlanta, Georgia, 30327, United States|Research Site, Cullman, Georgia, 35058, United States|Research Site, Barrington, Illinois, 60010, United States|Research Site, Brighton, Massachusetts, 2135, United States|Research Site, Farmington Hills, Michigan, 48334, United States|Research Site, Raleigh, North Carolina, 27607, United States|Research Site, Portland, Oregon, 97225, United States|Research Site, Round Rock, Texas, 78681, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Milwaukee, Wisconsin, 53215, United States"
NCT05697523,Multiple Sclerosis and Respiratory and Functional Capacity,https://beta.clinicaltrials.gov/study/NCT05697523,COMPLETED,Multiple Sclerosis,"OTHER: Expanded Disability Status Scale, pulmonary function test, International Physical Activity Questionnaire - Short Form, 6 minute walk test",Nigde Omer Halisdemir University,Pamukkale University,ALL,ADULT,,80,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-01-01,2021-01-01,2021-01-01,"Pamukkale University, Denizli, 20200, Turkey"
NCT04743284,Tele-Assessment and Face-to-Face Evaluation of Balance in MS,https://beta.clinicaltrials.gov/study/NCT04743284,COMPLETED,Multiple Sclerosis,,Istanbul University - Cerrahpasa (IUC),,ALL,"ADULT, OLDER_ADULT",,40,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-03-05,2022-01-16,2022-03-07,"Istanbul University Cerrahpasa, Faculty of Health Science, Istanbul, Turkey"
NCT04465084,Assessment of Language Disorders in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT04465084,COMPLETED,Sclerosis|Language Disorders,OTHER: Case|OTHER: Withness,Fondation Ophtalmologique Adolphe de Rothschild,Groupe Hospitalier Pitie-Salpetriere|Saint Antoine University Hospital,ALL,ADULT,NA,142,NETWORK,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2020-08-17,2020-08-17,2022-07-08,"Antoine GUEGUEN, Paris, France"
NCT03735823,IL-11 in the Development of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03735823,RECRUITING,Multiple Sclerosis,"OTHER: No intervention, just collect blood samples and CSF samples",Thomas Jefferson University,,ALL,"ADULT, OLDER_ADULT",,96,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-06-01,2023-05-31,2023-05-31,"Thomas Jefferson University, Philadelphia, Pennsylvania, 19446, United States"
NCT00202384,Gene Expression in MS Patients Before and During Treatment With Interferon-beta,https://beta.clinicaltrials.gov/study/NCT00202384,TERMINATED,Multiple Sclerosis,,S. Andrea Hospital,,ALL,ADULT,,600,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2004-11,2011-01,2011-01,"Azienda Ospedaliera S. Andrea, II Facoltà di Medicina e Chirurgia, Università di Roma ""La Sapienza"", Rome, 00100, Italy"
NCT04869358,Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab,https://beta.clinicaltrials.gov/study/NCT04869358,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,DRUG: Ofatumumab,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE4,34,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-05-27,2022-05-10,2023-06-21,"Novartis Investigative Site, Berlin, 13353, Germany|Novartis Investigative Site, Bielefeld, D 33647, Germany|Novartis Investigative Site, Dresden, 01307, Germany|Novartis Investigative Site, Erbach, 64711, Germany|Novartis Investigative Site, Siegen, 57076, Germany|Novartis Investigative Site, Unterhaching, 82008, Germany"
NCT03001284,Multiple Sclerosis Produces Cardiovascular Subclinical Dysfunction,https://beta.clinicaltrials.gov/study/NCT03001284,UNKNOWN,Multiple Sclerosis,OTHER: NO intervention,Carol Davila University of Medicine and Pharmacy,,ALL,"ADULT, OLDER_ADULT",,103,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-10,2016-12,2016-12,
NCT00879658,"Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT00879658,COMPLETED,Relapsing-remitting Multiple Sclerosis,DRUG: BAF312|DRUG: Placebo,Novartis Pharmaceuticals,,ALL,ADULT,PHASE2,297,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-03-30,2011-05-04,2011-05-04,"Novartis Investigative Site, Cullman, Alabama, 35058, United States|Novartis Investigative Site, San Francisco, California, 94143, United States|Novartis Investigative Site, Centennial, Colorado, 80112, United States|Novartis Investigative Site, Miami, Florida, 33136, United States|Novartis Investigative Site, Pompano Beach, Florida, 33060, United States|Novartis Investigative Site, Tallahassee, Florida, 32308, United States|Novartis Investigative Site, Tampa, Florida, 33609, United States|Novartis Investigative Site, Chicago, Illinois, 60637, United States|Novartis Investigative Site, Elk Grove Village, Illinois, 60007, United States|Novartis Investigative Site, Grand Rapids, Michigan, 49525, United States|Novartis Investigative Site, Raleigh, North Carolina, 27607, United States|Novartis Investigative Site, Akron, Ohio, 44320, United States|Novartis Investigative Site, Pittsburgh, Pennsylvania, 15213, United States|Novartis Investigative Site, Greenville, South Carolina, 29607, United States|Novartis Investigative Site, Seattle, Washington, 98122, United States|Novartis Investigative Site, Milwaukee, Wisconsin, 53215, United States|Novartis Investigative Site, Vancouver, British Columbia, V6T 1Z3, Canada|Novartis Investigative Site, Ottawa, Ontario, K1H 8L6, Canada|Novartis Investigative Site, Gatineau, Quebec, J9J 0A5, Canada|Novartis Investigative Site, Greenfield Park, Quebec, J4V 2J2, Canada|Novartis Investigative Site, Montreal, Quebec, H3A 2B4, Canada|Novartis Investigative Site, Helsinki, 00930, Finland|Novartis Investigative Site, Tampere, FIN-33520, Finland|Novartis Investigative Site, Turku, 20520, Finland|Novartis Investigative Site, Berlin, 10713, Germany|Novartis Investigative Site, Berlin, 13439, Germany|Novartis Investigative Site, Dresden, 01307, Germany|Novartis Investigative Site, Freiburg, 79106, Germany|Novartis Investigative Site, Leipzig, 04103, Germany|Novartis Investigative Site, Lengerich, 49525, Germany|Novartis Investigative Site, Muenchen, 81675, Germany|Novartis Investigative Site, Muenster, 48149, Germany|Novartis Investigative Site, Wiesbaden, 65191, Germany|Novartis Investigative Site, Budapest, 1076, Hungary|Novartis Investigative Site, Budapest, 1145, Hungary|Novartis Investigative Site, Debrecen, 4032, Hungary|Novartis Investigative Site, Veszprem, H-8200, Hungary|Novartis Investigative Site, Montichiari, BS, 25018, Italy|Novartis Investigative Site, Chieti, CH, 66100, Italy|Novartis Investigative Site, Milano, MI, 20132, Italy|Novartis Investigative Site, Roma, RM, 00133, Italy|Novartis Investigative Site, Roma, RM, 00152, Italy|Novartis Investigative Site, Roma, RM, 00189, Italy|Novartis Investigative Site, Bergen, 5021, Norway|Novartis Investigative Site, Drammen, 3004, Norway|Novartis Investigative Site, Oslo, 0424, Norway|Novartis Investigative Site, Lodz, 90-153, Poland|Novartis Investigative Site, Lublin, 20-954, Poland|Novartis Investigative Site, Warszawa, 02-957, Poland|Novartis Investigative Site, Kazan, 420103, Russian Federation|Novartis Investigative Site, Moscow, 101990, Russian Federation|Novartis Investigative Site, Moscow, 119049, Russian Federation|Novartis Investigative Site, Moscow, 121359, Russian Federation|Novartis Investigative Site, Moscow, 125367, Russian Federation|Novartis Investigative Site, Moscow, 127018, Russian Federation|Novartis Investigative Site, Moscow, 129110, Russian Federation|Novartis Investigative Site, Saint Petersburg, 197022, Russian Federation|Novartis Investigative Site, St. Petersburg, 190013, Russian Federation|Novartis Investigative Site, Sevilla, Andalucia, 41009, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08035, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, 46026, Spain|Novartis Investigative Site, Bilbao, Pais Vasco, 48013, Spain|Novartis Investigative Site, Madrid, 28040, Spain|Novartis Investigative Site, Basel, 4031, Switzerland|Novartis Investigative Site, Bern, 3010, Switzerland|Novartis Investigative Site, Lugano, 6900, Switzerland|Novartis Investigative Site, Zuerich, 8091, Switzerland|Novartis Investigative Site, Ankara, 06100, Turkey|Novartis Investigative Site, Haseki / Istanbul, 34096, Turkey|Novartis Investigative Site, Istanbul, 34093, Turkey|Novartis Investigative Site, Izmir, 35340, Turkey|Novartis Investigative Site, Kocaeli, 41380, Turkey"
NCT02960984,Neurorehabilitation on Upper Limb and on Fatigue in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02960984,UNKNOWN,Multiple Sclerosis,OTHER: Task Oriented rehabilitation and aerobic training,Fondazione Don Carlo Gnocchi Onlus,University of Genova,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2016-11,2017-12,,"Fondazione Don Gnocchi ONLUS, Milan, 20148, Italy"
NCT00077584,Efficacy and Safety of Oral Bosentan on Healing/Prevention of Digital (Finger) Ulcers in Patients With Scleroderma,https://beta.clinicaltrials.gov/study/NCT00077584,COMPLETED,Digital Ulcers|Systemic Sclerosis,DRUG: Bosentan 62.5 mg|DRUG: Bosentan 125 mg|DRUG: Placebo,Actelion,,ALL,"ADULT, OLDER_ADULT",PHASE3,188,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2003-10,2005-03,2005-05,"Barri Fessler, MD, Birmingham, Alabama, 35249-7201, United States|Daniel Furst, MD, Los Angeles, California, 90095-1670, United States|David Collier, MD, Aurora, Colorado, 80010, United States|Naomi Rothfield, MD, Farmington, Connecticut, 06030-1310, United States|Michael Ellman, MD, Chicago, Illinois, 60637, United States|Mittie Doyle, MD, New Orleans, Louisiana, 70112, United States|Frederick Wigley, MD, Baltimore, Maryland, 21224, United States|Joseph Korn, MD, Boston, Massachusetts, 02118-2394, United States|Richard Martin, MD, Grand Rapids, Michigan, 49503, United States|Thomas Osborn, MD, Rochester, Minnesota, 55905, United States|Vivien Hsu, MD, New Brunswick, New Jersey, 08903, United States|Lee Shapiro, MD, Albany, New York, 12206, United States|Avram Goldberg, MD, Manhasset, New York, 11030, United States|Bashar Kahaleh, MD, Toledo, Ohio, 43614, United States|Chris Derk, MD, Philadelphia, Pennsylvania, 19107, United States|Thomas Medsger, MD, Pittsburgh, Pennsylvania, 15261, United States|Edwin Smith, MD, Charleston, South Carolina, 29425, United States|Maureen Mayes, MD, Houston, Texas, 77030, United States|Jerry Molitor, MD, Seattle, Washington, 98101, United States|Howard Kenney, MD, Spokane, Washington, 99204, United States|Mary Ellen Csuka, MD, Milwaukee, Wisconsin, 53211, United States|Janet Pope, MD, London, Ontario, N6A 4V2, Canada|Peter Lee, MD, Toronto, Ontario, M5G 1X5, Canada|Eric Rich, MD, Montreal, Quebec, H2L 4M1, Canada|Murray Baron, MD, Montreal, Quebec, H3T1E2, Canada"
NCT02294058,Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT02294058,COMPLETED,Multiple Sclerosis,DRUG: Ozanimod|DRUG: Interferon beta-1a|DRUG: Placebo to ozanimod|DRUG: Placebo to interferon beta-1a,Celgene,,ALL,ADULT,PHASE3,1346,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-12-03,2016-12-22,2016-12-22,"Xenosciences Inc, Phoenix, Arizona, 85004, United States|St Josephs Hospital and Medical Center, Phoenix, Arizona, 85013, United States|Northwest Neuro Specialists PLLC, Tucson, Arizona, 85712, United States|Alta Bates Summit Medical Center, Berkeley, California, 94705, United States|Collaborative Neuroscience Network Inc, Long Beach, California, 90806, United States|University of California Davis Medical Center, Sacramento, California, 95817, United States|Multiple Sclerosis Center at UCSF, San Francisco, California, 94158, United States|Denver Neurological Clinic, Denver, Colorado, 80210, United States|Neurology Associates PA, Maitland, Florida, 32751, United States|Neurology Associates of Ormond Beach, Ormond Beach, Florida, 32174, United States|Infinity Clinical Research LLC, Pompano Beach, Florida, 33060, United States|Neurostudies Inc, Port Charlotte, Florida, 33952, United States|Roskamp Institute, Sarasota, Florida, 34243, United States|Axiom Clinical Research of Florida, Tampa, Florida, 33609, United States|Meridien Research, Tampa, Florida, 33634, United States|West Georgia Sleep Disorder Center and Neurology Associates, Douglasville, Georgia, 30134, United States|Consultants In Neurology, Northbrook, Illinois, 60062, United States|University of Kansas Medical Center, Kansas City, Kansas, 66160, United States|MidAmerica Neuroscience Research Foundation, Lenexa, Kansas, 66214, United States|Associates In Neurology, Lexington, Kentucky, 40513, United States|Norton Healthcare, Louisville, Kentucky, 40207, United States|Henry Ford Health System, Detroit, Michigan, 48202, United States|Michigan State University, East Lansing, Michigan, 48824, United States|Minneapolis Clinic of Neurology, Golden Valley, Minnesota, 55422, United States|Washington University, Saint Louis, Missouri, 63110, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, 89106, United States|Neurology Specialists of Monmouth County PA, West Long Branch, New Jersey, 07764, United States|Neuro Medical Care Associates PLLC, Johnson City, New York, 13790, United States|Raleigh Neurology Associates PA, Raleigh, North Carolina, 27607, United States|Neurology and Neuroscience Associates Inc., Akron, Ohio, 44320, United States|Neurological Research Institute Inc, Columbus, Ohio, 43221, United States|Providence Multiple Sclerosis Center, Portland, Oregon, 97225, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|Hope Neurology MS Center, Knoxville, Tennessee, 37922, United States|University of Texas Health Science Center at Houston, Houston, Texas, 77030, United States|Bhupesh Dihenia MD PA, Lubbock, Texas, 79410, United States|EvergreenHealth, Kirkland, Washington, 98034, United States|The Polyclinic, Seattle, Washington, 98104, United States|Neurology of Neurosurgery Associates of Tacoma, Tacoma, Washington, 98405, United States|Center for Neurological Disorders, Milwaukee, Wisconsin, 53215, United States|Grodno Clinical Regional Hospital, Grodno, 230017, Belarus|Minsk Municipal Clinical Hospital 5, Minsk, 220026, Belarus|Republican Scientific and Practical Centre of Neurology and Neurosurgery, Minsk, 220114, Belarus|Minsk City Clinical Hospital 9, Minsk, 220116, Belarus|Vitebsk Regional Diagnostic Centre, Vitebsk, 210023, Belarus|Vitebsk Regional Clinical Hospital, Vitebsk, 210037, Belarus|Clinical Center Banja Luka, Banja Luka, 51000, Bosnia and Herzegovina|Clinical Center University of Sarajevo, Sarajevo, 71000, Bosnia and Herzegovina|University Clinical Center Tuzla, Tuzla, 75000, Bosnia and Herzegovina|Military Medical Academy HBAT, Pleven, 5800, Bulgaria|Multiprofile Hospital for Active Treatment of Neurology and Psychiatry Sv Naum EAD, Sofia, 1113, Bulgaria|Multiprofile Hospital for Active Treatment National Cardiology Hospital EAD, Sofia, 1309, Bulgaria|Multiprofile Hospital for Active Treatment Tokuda Hospital Sofia, Sofia, 1407, Bulgaria|University Multiprofile Hospital for Active Treatment Aleksandrovska EAD, Sofia, 1431, Bulgaria|University Multiprofile Hospital for Active Treatment Sveti Ivan Rilski EAD, Sofia, 1431, Bulgaria|University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna ISUL EAD, Sofia, 1527, Bulgaria|Military Medical Academy - MHAT, Sofia, 1606, Bulgaria|Multiprofile Hospital for Active Treatment Sveta Marina EAD, Varna, 9010, Bulgaria|Clinique Neuro Outaouais, Gatineau, Quebec, J9J 0A5, Canada|Clinical Hospital Osijek, Osijek, 31000, Croatia|General Hospital Varazdin, Varazdin, 42000, Croatia|Clinical Hospital Center Zagreb, Zagreb, 10000, Croatia|Clinical Hospital Dubrava, Zagreb, 10000, Croatia|Clinical Hospital Sestre Milosrdnice, Zagreb, 10000, Croatia|Clinical Hospital Sveti duh, Zagreb, 10000, Croatia|University Hospital Brno, Brno, 625 00, Czechia|Fakultni nemocnice u sv Anny v Brne, Brno, 656 91, Czechia|Private Neurological Practice Radomir Talab MD, Hradec Kralove, 500 05, Czechia|University Hospital Hradec Kralove, Hradec Kralove, 500 05, Czechia|Nemocnice Jihlava prispevkova organizace, Jihlava, 586 33, Czechia|Fakultni Nemocnice Olomouc, Olomouc, 775 20, Czechia|Vseobecna Fakultni Nemocnice v Praze, Praha 2, 128 21, Czechia|Krajska zdravotni as Nemocnice Teplice oz, Teplice, 415 29, Czechia|East Tallinn Central Hospital, Tallinn, 10138, Estonia|West Tallinn Central Hospital, Tallinn, 10617, Estonia|Tartu University Hospital, Tartu, EE-51014, Estonia|Aversi Clinic LTD, Tbilisi, 0160, Georgia|Khechinashvili University Hospital, Tbilisi, 179, Georgia|LTD MediClubGeorgia, Tbilisi, ¿0112, Georgia|Sarajishvili Institute of Neurology, Tbilisi, ¿0112, Georgia|Curatio JSC, Tbilisi, ¿0186, Georgia|Ltd DEKA, Tbilisi, ¿0186, Georgia|Praxis Dr. Wilfried Luer, Berlin, 12163, Germany|St. Joseph Krankenhaus Berlin, Berlin, 13088, Germany|Asklepios Fachklinikum Teupitz, Brandenburg, 15755, Germany|Universitatsklinikum Carl Gustav Carus an der TU Dresden, Dresden, 01307, Germany|Heinrich Heine Universitat Dusseldorf, Düsseldorf, 40225, Germany|DataMed GmbH, Köln, 50935, Germany|Universitatsklinikum Leipzig, Leipzig, 04103, Germany|Klinikum der Stadt Ludwigshafen gGmbH, Ludwigshafen am Rhein, 67063, Germany|Klinikum der Philipps Universitat Marburg, Marburg, 35043, Germany|St. Josefs-Krankenhaus Potsdam-Sanssouci GmbH, Potsdam, 14471, Germany|Krankenhaus der Barmherzigen Brueder, Trier, 54292, Germany|NeuroPoint Akademie, Ulm, 89079, Germany|Kenezy Gyula Korhaz es Rendelointezet, Debrecen, 4043, Hungary|Pest Megyei Flor Ferenc Korhaz, Kistarcsa, 2143, Hungary|Latvian Maritime Medicine Centre, Riga, LV-1015, Latvia|Riga East Clinical University Hospital clinic Gailezers, Riga, LV-1038, Latvia|Pauls Stradins Clinical University Hospital, Riga, LV1002, Latvia|Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Kaunas, LT-50009, Lithuania|Klaipeda University Hospital, Klaipeda, LT-5808, Lithuania|IMSP Institutul de Medicina Urgenta, Chisinau, 2004, Moldova, Republic of|Municipal Clinical Hospital Sf Arhanghel Mihail, Chisinau, 2005, Moldova, Republic of|Institutul de Neurologie si Neurochirurgie, Chisinau, 2028, Moldova, Republic of|Zuyderland Medisch Centrum, Sittard-Geleen, 6162 BG, Netherlands|Auckland City Hospital, Auckland, 1023, New Zealand|Christchurch Hospital, Christchurch, 8011, New Zealand|Waikato Hospital, Hamilton, 2001, New Zealand|B&B Robert Bonek, Pawel Bochniak, Spolka Cywilna, Bydgoszcz, 85-795, Poland|Powiatowy Zespol Zakladow Opieki Zdrowotnej Szpital w Czeladzi, Czeladz, 41-250, Poland|Copernicus Podmiot Leczniczy Sp. z o.o., Gdansk, 80-803, Poland|Akson Clinical Research Maciejowski Bielecki Sp. Jawna, Jaroslaw, 37-500, Poland|Niepubliczny Zaklad Opieki Zdrowotnej NEURO-MEDIC, Katowice, 40-555, Poland|M.A.- Lek A.M.Maciejowscy Spolka Cywilna, Katowice, 40-595, Poland|Novo-Med Zielinski i wsp. Sp.J., Katowice, 40-650, Poland|NEURO- CARE Site Management Organization Gabriela Klodowska-Duda, Katowice, 40-749, Poland|RESMEDICA Spolka z o.o., Kielce, 25-726, Poland|Niepubliczny Zespol Leczniczo-Rehabilitacyjny Centrum Kompleksowej Rehabilitacji, Konstancin Jeziorna, 05-510, Poland|NZOZ NEUROMED M. I M. Nastaj Spolka Partnerska, Lublin, 20-059, Poland|Wojewodzki Szpital Specjalistyczny im Stefana Kardynala Wyszynskiego, Lublin, 20-718, Poland|Centrum Neurologii Krzysztof Selmaj, Lódzkie, 90-324, Poland|Samodzielny Publiczny Centralny Szpital Kliniczny, Mazowieckie, 02-097, Poland|Neurologiczny NZOZ Centrum Leczenia SM Osrodek Badan Klinicznych Dr n med Hanka Hertmanowska, Plewiska, 62-064, Poland|Niepubliczny Zaklad Opieki Zdrowotnej KENDRON, Podlaskie, 15-402, Poland|Indywidualna Specjalistyczna Praktyka Lekarska dr nmed Monika Lyczak, Pomorskie, 80-299, Poland|Niepubliczny Zaklad Opieki Zdrowotnej NEUROKARD Ilkowski i Partnerzy Spolka Partnerska Lekarzy, Poznan, 61-853, Poland|SPZOZ Wojewodzki Szpital Specjalistyczny nr 3 w Rybniku, Rybnik, 44-200, Poland|Centrum Medyczne Medyk, Rzeszow, 35-055, Poland|Indywidualna Specjalistyczna Praktyka Lekarska Zbigniew Cebulski, Warminsko-mazurskie, 10-443, Poland|Szpital Czerniakowski Samodzielny Publiczny Zaklad Opieki Zdrowotnej, Warsaw, 00-739, Poland|Centrum Medyczne NeuroProtect, Warszawa, 01-697, Poland|Instytut Psychiatrii i Neurologii, Warszawa, 02-957, Poland|Centrum Medyczne doktorA, Warszawa, 05-077, Poland|Hospital Garcia de Orta, Almada, 2805-267, Portugal|Hospital de Braga, Braga, 4710-243, Portugal|Centro Hospitalar E Universitario de Coimbra EPE, Coimbra, 3000-075, Portugal|Hospital Beatriz Angelo, Loures, 2674-514, Portugal|Campus Neurologico Senior, Torres Vedras, 2560-280, Portugal|Fundeni Clinical Institute, Bucharest, 022328, Romania|Colentina Clinical Hospital, Bucharest, 20125, Romania|Cluj Clinical County Hospital, Cluj Napoca, 400012, Romania|Cai Ferate Clinical Hospital, Constanta, 900123, Romania|Sibiu Emergency County Clinical Hospital, Sibiu, 550166, Romania|Timisoara Emergency County Clinical Hospital, Timisoara, 300736, Romania|Arkhangelsk Regional Clinical Hospital, Arkhangelsk, 163045, Russian Federation|Regional Clinical Hospital, Barnaul, 656024, Russian Federation|Belgorod Regional Clinical Hospital, Belgorod, 308007, Russian Federation|Bryansk Regional Hospital 1, Bryansk, 241033, Russian Federation|Chelyabinsk City Clinical Hospital 3, Chelyabinsk, 454136, Russian Federation|Sverdlovsk Regional Clinical Hospital 1, Ekaterinburg, 620102, Russian Federation|Research Medical Complex Vashe Zdorovie, Kazan, 420097, Russian Federation|Kemerovo Regional Clinical Hospital, Kemerovo, 650066, Russian Federation|Regional Clinical Hospital, Khanty-mansiysk, 628012, Russian Federation|Kirov City Clinical Hospital 1, Kirov, 610014, Russian Federation|Krasnoyarsk State Medical Academy, Krasnoyarsk, 660022, Russian Federation|Kursk Regional Clinical Hospital, Kursk, 305007, Russian Federation|Central Clinical Hospital 2 na NA Semashko OAO RZhD, Moscow, 107150, Russian Federation|City Clinical Hospital 24, Moscow, 117997, Russian Federation|City Clinical Hospital 1 na NIPirogov, Moscow, 119049, Russian Federation|Research Center of Neurology of RAMS, Moscow, 125367, Russian Federation|City Clinical Hospital 11, Moscow, 127018, Russian Federation|Nizhniy Novgorod City Hospital 33, Nizhny Novgorod, 603076, Russian Federation|City Clinical Hospital 3 Nizhniy Novgorod Geriatrics Centre, Nizhny Novgorod, 603155, Russian Federation|Siberian Regional Medical Center, Novosibirsk, 630007, Russian Federation|Novosibirsk State Medical University, Novosibirsk, 630087, Russian Federation|Penza Regional Clinical Hospital na NN Burdenko, Penza, 440026, Russian Federation|Perm State Medical Academy, Perm, 614045, Russian Federation|Republican Hospital na VA Baranov, Petrozavodsk, 185019, Russian Federation|Pyatigorsk City Hospital 2, Pyatigorsk, 357538, Russian Federation|Rostov Regional Clinical Hospital, Rostov on Don, 344015, Russian Federation|Samara Regional Clinical Hospital named after MI Kalinin, Samara, 443095, Russian Federation|Smolensk State Medical Academy, Smolensk, 214018, Russian Federation|City Hospital 31, St. Petersburg, 194354, Russian Federation|City Hospital Nikolaevskaya Bolnitsa, St. Petersburg, 194354, Russian Federation|St. Petersburg Multi Field City Hospital 2, St. Petersburg, 194354, Russian Federation|First St Petersburg State Medical University na IP Pavlov, St. Petersburg, 197022, Russian Federation|Institute of Human Brain RAN, St. Petersburg, 197376, Russian Federation|City Clinical Hospital 40, St. Petersburg, 197706, Russian Federation|Siberian State Medical University, Tomsk, 634050, Russian Federation|Regional State Budget Institution of Healthcare Tver Regional Clinical Hospital, Tver, 125170, Russian Federation|Neftyanik Medical and Sanitary Unit, Tyumen, 625000, Russian Federation|Kuvatov Republican Clinical Hospital, Ufa, 450005, Russian Federation|Yaroslavl Clinical Hospital 8, Yaroslavl, 150030, Russian Federation|Clinical Center of Serbia, Belgrade, 11000, Serbia|Clinical Hospital Centar Zvezdara, Belgrade, 11000, Serbia|Military Medical Academy, Belgrade, 11000, Serbia|Clinical Hospital Centre Zemun, Belgrade, 11080, Serbia|Clinical Center Kragujevac, Kragujevac, 34000, Serbia|Clinical Center Nis, Nis, 18000, Serbia|Hospital Universitario Vall D hebron, Barcelona, 08035, Spain|Hospital Arnau de Vilanova, Lleida, 25198, Spain|Complejo Hospitalario de Navarra, Pamplona/ Navarra, 31008, Spain|Hospital Moises Broggi, Sant Joan Despí, 08970, Spain|Hospital Clinico Universitario de Valencia, Valencia, 46010, Spain|Sahlgrenska Universitetssjukhuset, Goteborg, SE-41345, Sweden|Karolinska Universitetssjukhuset Solna, Stockholm, SE-17176, Sweden|MI Cherkasy Regional Hospital of Cherkasy Regional Council, Cherkasy, 18009, Ukraine|Hospital 4 of Chernihiv City Council, Chernihiv, 14001, Ukraine|Municipal Treatment and Preventive Institution Chernihiv Regional Clinical Hospital, Chernihiv, 14029, Ukraine|Municipal Institution Chernivtsi Regional Psychiatric Hospital, Chernivtsi, 58018, Ukraine|Municipal Institution Dnipropetrovsk Regional Clinical Hospital na I.I. Mechnykov, Dnipropetrovsk, 49027, Ukraine|Ivano Frankivsk City Clinical Hospital 1, Ivano Frankivsk, 76000, Ukraine|Regional Clinical Hospital., Ivano Frankivsk, 76008, Ukraine|State Treatment and Prevention Institution Central Clinical Hospital of Ukrzaliznytsya, Kharkiv, 61018, Ukraine|Regional Clinical Hospital Center for Emergency Medical Care and Disaster Medicine, Kharkiv, 61022, Ukraine|Municipal Institution of Health Care Kharkiv Clinical City Hospital 7, Kharkiv, 61176, Ukraine|National Research Center for Radiation Medicine, Institute of Clinical Radiology, Kyiv, 03115, Ukraine|Kyiv City Clinical Hospital 4, Kyiv, 3110, Ukraine|Volyn Regional Clinical Hospital, Lutsk, 43024, Ukraine|Lviv Regional Clinical Hospital, Lviv, 79010, Ukraine|Municipal City Clinical Hospital 5, Lviv, 79044, Ukraine|Center for Reconstructive and Rehabilitation Medicine University Clinic of ONMedU, Odesa, 65009, Ukraine|Municipal Institution Odesa Regional Clinical Hospital, Odesa, 65025, Ukraine|Regional Clinical Hospital na NV Sklifosovskyi, Poltava, 36024, Ukraine|Regional Clinical Center of Neurosurgery and Neurology, Uzhhorod, 88018, Ukraine|Municipal Institution Vinnytsia Regional Psychoneurological Hospital na OI Yushchenko, Vinnytsia, 21005, Ukraine|Municipal Institution City Clinical Hospital 2, Zaporizhya, 6972, Ukraine|Municipal Institution 6th City Clinical Hospital of Zaporizhzhia City Council, Zaporizhzhia, 69035, Ukraine|Municipal Institution Zaporizhzhia, Zaporizhzhia, 69600, Ukraine|Regional Clinical Hospital na OFHerbachevskyi of Zhytomyr Regional Council, Zhytomyr, 10008, Ukraine|University Hospital of Wales, Cardiff, CF14 4XW, United Kingdom|Raigmore Hospital, Inverness, IV2 3UJ, United Kingdom|Kings College Hospital, London, SE5 9RS, United Kingdom|Royal Hallamshire Hospital Sheffield Teaching Hospitals NHS Trust, Sheffield, S10 2JF, United Kingdom"
NCT01658384,Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT01658384,COMPLETED,Multiple Sclerosis,,Clinique Neuro-Outaouais,CogState Ltd.,ALL,"ADULT, OLDER_ADULT",,63,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-09,2015-02,2015-03,"Clinique Neuro-Outaouais, Gatineau, Quebec, J9J 0A5, Canada"
NCT00464958,One Year Extension Study To Protocol C2/5/TZ:MS-05,https://beta.clinicaltrials.gov/study/NCT00464958,TERMINATED,Spasticity|Multiple Sclerosis,DRUG: sublingual tizanidine 12 mg,Teva GTC,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,10,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2008-01,2008-12,2008-12,"Tel Aviv Sourasky Medical Center, Tel Aviv, 64239, Israel"
NCT04280484,Acute Intermittent Hypoxia in Persons With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04280484,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",OTHER: Intermittent Hypoxia|OTHER: Sham Hypoxia,Shirley Ryan AbilityLab,Edward Hines Jr. VA Hospital,ALL,"ADULT, OLDER_ADULT",NA,10,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2018-06-18,2019-10-10,2019-12-30,"Shirley Ryan AbilityLab, Chicago, Illinois, 60611, United States"
NCT05685784,Multiple Sclerosis Prediction and Monitoring of Progression Study,https://beta.clinicaltrials.gov/study/NCT05685784,RECRUITING,Progressive Multiple Sclerosis,DEVICE: Bytelfies kit - sensor dot,"University Hospital, Ghent",University Ghent|Byteflies,ALL,ADULT,NA,70,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-03-01,2025-12-12,2025-12-12,"University Hospital Ghent, Ghent, Oost-Vlaanderen, 9000, Belgium"
NCT01206023,Applications of Nanotechnology in Multiple Sclerosis by Respiratory Samples,https://beta.clinicaltrials.gov/study/NCT01206023,COMPLETED,Multiple Sclerosis,OTHER: NA-NOSE artificial olfactory system,Carmel Medical Center,"Technion, Israel Institute of Technology",ALL,ADULT,,71,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-11,2011-11,2012-11,"MS Clinic, Carmel Medical Center, Haifa, 34362, Israel|MS Clinic, Carmel Medical Center, Haifa, Israel"
NCT05848323,Prospective Case Series to Refine Standalone Cognitive Behavioral Therapy Components for Multiple Sclerosis Fatigue,https://beta.clinicaltrials.gov/study/NCT05848323,NOT_YET_RECRUITING,Multiple Sclerosis|Fatigue,BEHAVIORAL: 4-week Relaxation Training|BEHAVIORAL: 4-week Behavioral Activation|BEHAVIORAL: 4-week Cognitive Therapy,University of Washington,,ALL,"ADULT, OLDER_ADULT",NA,21,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-08-01,2024-04-30,2024-04-30,
NCT05131984,Ocrelizumab Access by Socio-Economic Status,https://beta.clinicaltrials.gov/study/NCT05131984,NOT_YET_RECRUITING,Multiple Sclerosis,DRUG: Ocrelizumab,Brigham and Women's Hospital,"Genentech, Inc.|Boston Medical Center",ALL,"ADULT, OLDER_ADULT",,600,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-11-15,2022-07-01,2022-10-01,"Brigham and Women's Hospital, Boston, Massachusetts, 02115, United States"
NCT01555684,Functional Changes Following Percutaneous Venoplasty in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT01555684,WITHDRAWN,Multiple Sclerosis|Chronic Cerebrospinal Venous Insufficiency,PROCEDURE: percutaneous venoplasty to alleviate chronic cerebrospinal venous insufficiency,University of Stirling,,ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2012-04,2012-11,2012-12,"University of Stirling, Stirling, FK94LA, United Kingdom"
NCT05053984,Ultrasound-Guided Percutaneous Neuromodulation in Spasticity,https://beta.clinicaltrials.gov/study/NCT05053984,NOT_YET_RECRUITING,Multiple Sclerosis,PROCEDURE: Percutaneous Echoguided Neuromodulation,Hospital Universitario de Canarias,,ALL,ADULT,NA,30,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-11-02,2022-01-31,2022-06-30,"UICEC, La Laguna, S/C De Tenerife, 38320, Spain"
NCT00914758,Comparison of Campath and Rebif Treatment on Cognition in Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT00914758,UNKNOWN,Relapsing Remitting Multiple Sclerosis,,Washington Neuropsychology Research Group,"Genzyme, a Sanofi Company",ALL,ADULT,,1,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2009-03,2011-10,2011-12,"The Research and Education Institute of Alta Bates Summit Medical Center, Berkely, California, 94705, United States|Associates In Neurology. PSC, Lexington, Kentucky, 40513, United States|Springfield Neurology Associates, LLC, Springfield, Massachusetts, 01104, United States|Dartmouth Medical School/Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, 03756, United States|Multiple Sclerosis Center of NE New York, Empire Neurology, PC, Latham, New York, 12110, United States|Multiple Sclerosis Center, University of Rochester Medical Center, Rochester, New York, 14642, United States|MS Center of Greater Washington, Vienna, Virginia, 22180, United States"
NCT04586023,Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS),https://beta.clinicaltrials.gov/study/NCT04586023,RECRUITING,Relapsing Multiple Sclerosis,DRUG: Fenebrutinib|DRUG: Teriflunomide|DRUG: Placebo,Hoffmann-La Roche,,ALL,ADULT,PHASE3,736,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-03-24,2025-10-02,2025-11-27,"North Central Neurology Associates, Cullman, Alabama, 35058, United States|Xenoscience, Phoenix, Arizona, 85004, United States|Stanford University Medical Center; Stanford Neuroscience Health Center, Stanford, California, 94305, United States|Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance, California, 90502, United States|KI Health Partners, LLC; New England Institute for Clinical Research, Stamford, Connecticut, 06905, United States|Georgetown University Medical Center, Washington, District of Columbia, 20007, United States|SFM Clinical Research, LLC, Boca Raton, Florida, 33487, United States|University of South Florida, Tampa, Florida, 33612, United States|Atlanta Neuroscience Institute, Atlanta, Georgia, 30327, United States|American Health Network Institute, LLC, Avon, Indiana, 46123, United States|University of Kansas Medical Center, Kansas City, Kansas, 66160, United States|Neuro Institute of New England P.C.; Research, Foxboro, Massachusetts, 02035, United States|Wayne State University; Department of Neurology, Detroit, Michigan, 48201, United States|Memorial Healthcare Institute for Neurosciences and Multiple Sclerosis, Owosso, Michigan, 48867, United States|Guilford Neurologic Research, Greensboro, North Carolina, 27405, United States|NeuroScience Research Center, Canton, Ohio, 44718, United States|University of Cincinnati; Department of Neurology, Cincinnati, Ohio, 45219, United States|Providence Neurological Specialties, Portland, Oregon, 97225, United States|Geisinger Medical Center, Danville, Pennsylvania, 17822, United States|Allegheny Neurological Associates, Pittsburgh, Pennsylvania, 15212, United States|Hope Neurology, Knoxville, Tennessee, 37922, United States|Baylor College of Medicine, Houston, Texas, 77030, United States|Central Texas Neurology Consultants, Round Rock, Texas, 78681, United States|Integrated Neurology Services PLLC, Falls Church, Virginia, 22043, United States|Medical College of Wisconsin, Inc., Milwaukee, Wisconsin, 53226-3596, United States|Kepler Universitätskliniken GmbH - Med Campus III; Neurologie & Psychiatrie, Linz, 4021, Austria|Medizinische Universität Wien; Univ.Klinik fuer Neurologie, Wien, 1090, Austria|L2 Ip Instituto de Pesquisas Clinicas Ltda ME; Centro Medico Hospitalar, Brasilia, DF, 70200-730, Brazil|Santa Casa de Misericordia; de Belo Horizonte, Belo Horizonte, MG, 30150-221, Brazil|Instituto de Neurologia de Curitiba, Curitiba, PR, 81210-310, Brazil|Hospital Universitario Clementino Fraga Filho - UFRJ, Rio de Janeiro, RJ, 21941-913, Brazil|IMV Pesquisa Neurológica, Porto Alegre, RS, 90110-000, Brazil|Núcleo de Pesquisa do Rio Grande do Sul, Porto Alegre, RS, 90430-001, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, 90610-000, Brazil|Clinica Neurologica; Neurocirurgica de Joinville, Joinville, SC, 89202-190, Brazil|Hospital das Clinicas - UNICAMP, Campinas, SP, 13083-887, Brazil|Praxis Pesquisa Médica, Santo Andre, SP, 09090-790, Brazil|CEMEC - Centro Multidisciplinar de Estudos Clínicos, Sao Bernardo Do Campo, SP, 09715-090, Brazil|Centro de Pesquisas Clinicas; CPCLIN, Sao Paulo, SP, 01228-200, Brazil|Jordy Sinapse Medicina LTDA ME, Sao Paulo, SP, 04515-000, Brazil|Hospital Santa Marcelina; AME - Ambulatório de Especialidades Médicas, Sao Paulo, SP, 08270-070, Brazil|UMHAT Dr. Georgi Stranski; 2nd Neurology Clinic, Occupational Diseases, Pleven, 5800, Bulgaria|MHATNP Sveti Naum EAD, Sofia, 1113, Bulgaria|University of Alberta Hospital, Edmonton, Alberta, T6G 1Z1, Canada|The Ottawa Hospital - General Campus; Department of Neurology - Multiple Sclerosis, Ottawa, Ontario, K1H 8L6, Canada|CIUSSS du Saguenay Lac-Saint-Jean, Chicoutimi Hospital, Chicoutimi, Quebec, G7H 5H6, Canada|Recherche Sepmus Inc., Greenfield Park, Quebec, J4V 2J2, Canada|MUCH - Montreal Neurological Institute & Hospital, Montreal, Quebec, H3A 2B4, Canada|CHU de Québec, Quebec City, Quebec, G1J 1Z4, Canada|Hjerne- og nervesygdomme, Ambulatorium, Skleroseklinikken, Aabenraa, 6200, Denmark|Aalborg Universitetshospital; Neurologisk Afdeling og Neurofysiologisk Afdeling; Skleroseamb., Aalborg, 9000, Denmark|Sydvestjysk Sygehus Esbjerg; Neurologisk Afd., Skleroseklinikken, Esbjerg, 6700, Denmark|Rigshospitalet; Neurologisk Klinik Glostrup, Glostrup, 2600, Denmark|Hopital Pellegrin-CHU de Bordeaux; Service de Neurologie, Bordeaux, 33076, France|Hopital Gabriel Montpied CHU de Clermont-Ferrand; Service de Neurologie B, Clermont-Ferrand, 63003, France|Hopital européen de Marseille; Neurologie, Marseille, 13003, France|Hopital Gui de Chauliac; Neurologie, Montpellier, 34295, France|Hôpital Pasteur; Service de Neurologie, Nice, 06002, France|Hôpital Charles Nicolle; Service de Neurologie, Rouen, 76031, France|CHU toulouse - Hôpital Purpan; Departement de Neurologie, Toulouse, 31059, France|University General Hospital of Larisa; Neurology Clinic, Larisa, 411 10, Greece|AHEPA Univ. General Hospital of Thessaloniki; B' Neurology Dept., Thessaloniki, 546 36, Greece|Hospital Eginition; First Department of Neurology, Αθηνα, 115 28, Greece|University General Hospital of Ioannina; Neurology Clinic, Ιωαννινα, 455 00, Greece|Nucare, Ciudad Guatemala, 01015, Guatemala|Nucare, Ciudad Guatemala, 01015, Guatemala|Sir Gangaram Hospital, NEW Delhi Delhi, Delhi, 110060, India|Zydus Hospital; Department of Neuro Sciences, Ahmadabad CITY, Gujarat, 380054, India|Sahyadri Superspeciality Hospital, Pune City, Maharashtra, 411006, India|Deenanath Mangeshkar Hospital & Research Centre, Pune, Maharashtra, 411004, India|Christian Medical College and Hospital, Ludhiana, Punjab, 141008, India|Fortis Escorts Hospital, Jaipur, Rajasthan, 302017, India|SRM Institute of Medical Sciences, Vadapalani, Tamil NADU, 600026, India|Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India|Seth G.S Medical College K.E.M Hospital, Mumbai, 400012, India|Universita? G. D'Annunzio; Dipartimento di Neuroscienze, Imaging e Scienze Cliniche, Chieti, Abruzzo, 66100, Italy|A. O. U. Federico II; Dip Neuroscienze, Scienze Riproduttive ed Odontostomatologiche, Napoli, Campania, 80131, Italy|Ospedale S.Camillo Forlanini; UOSD Day Hospital Neurologico e Neurochirurgico, Roma, Lazio, 00152, Italy|Policlinico Universitario A. Gemelli; UOC Neurologia - Centro Sclerosi Multipla, Roma, Lazio, 00168, Italy|NCL Institute Neuroscience, Roma, Lazio, 00178, Italy|Irccs A.O.U.San Martino Ist; Dinogmi, Genova, Liguria, 16132, Italy|Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico; UOSD Malattie Neurodegenerative, Milano, Lombardia, 20122, Italy|Fond. Istituto Neurologico C.Besta; UO Neurologia IV - Neuroimmunologia Malattie Neuromuscolari, Milano, Lombardia, 20133, Italy|Ospedale Civile di Montichiari; Centro Sclerosi Multipla, Montichiari, Lombardia, 25018, Italy|IRCCS Istituto Neurologico C. Mondino?Dip. Neurologia Neuroriabilitazione S.S. Sclerosi Multipla, Pavia, Lombardia, 27100, Italy|IRCCS Istituto Neurologico Neuromed; Centro per lo Studio e la Cura della Sclerosi Multipla, Pozzilli, Molise, 86077, Italy|Azienda Ospedaliero-Universitaria Consorziale Pol. di Bari; Neuroscienze e Organi di Senso, Bari, Puglia, 70124, Italy|Ospedale Binaghi; Centro Sclerosi Multipla, Cagliari, Sardegna, 09126, Italy|AOU Policlinico Giaccone; UOC Neurologia e Neurofisiopatologia-Amb Sclerosi Multipla, Palermo, Sicilia, 90129, Italy|Keimyung University Dongsan Medical Center, Daegu, 41931, Korea, Republic of|National Cancer Center, Goyang-si, 10408, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Samsung Medical Center, Seoul, 135-710, Korea, Republic of|Mexico Centre for Clinical Research, Ciudad de México, Mexico CITY (federal District), 03100, Mexico|Grupo Médico Camino S.C., Ciudad de México, Mexico CITY (federal District), 03600, Mexico|Clinstile S.A de C.V., Mexico City, Mexico CITY (federal District), 06700, Mexico|Unidad de Investigación en Salud; Psiquiatria, Chihuahua, 31203, Mexico|Unidad de investigacion en salud (UIS); Neurociencias, Ciudad de México, 14050, Mexico|NZOZ Vitamed, Bydgoszcz, 85-079, Poland|Neurocentrum Bydgoszcz sp. z o.o, Bydgoszcz, 85-796, Poland|COPERNICUS Podmiot Leczniczy Sp. z o. o. Szpital im. M. Kopernika; Oddzia? Neurologiczny, Gdansk, 80-803, Poland|Gornoslaskie Centrum Medyczne, Katowice, 40-635, Poland|RESMEDICA Spolka z o.o., Kielce, 25-726, Poland|Centrum Neurologii Klinicznej, Krakow, 31-505, Poland|Malopolskie Centrum Diagnostyczne MEDICAL Sp. z o. o., Krakow, 31-637, Poland|MT Medic Krosno, Krosno, 38-400, Poland|Centrum Neurologii Krzysztof Selmaj, Lodz, 90-324, Poland|Indywidualna Praktyka Lekarska Prof. Dr Hab. N. Med. Konrad Rejdak., Lublin, 20-016, Poland|Wojewodzki Szpital Specjalistyczny, Olsztyn, 10-561, Poland|Instytut Zdrowia Dr Boczarska-Jedynak Sp. z o.o. Sp. k., Oswiecim, 32-600, Poland|Neurologiczny Niepubliczny ZOZ Centrum Leczenia SM Osrodek Bada? Klinicznych, Plewiska, 62-064, Poland|NZOZ NEURO-KARD Ilkowski i Partnerzy Sp. Partn. Lek, Pozna?, 61-853, Poland|MedPolonia, Poznan, 60-693, Poland|Wojewódzki Szpital Specjalistyczny Nr 3, Rybnik, 44-200, Poland|Klinika Neurologii I Wydzialu Lekarskiego WUM w Warszawie, Warszawa, 02-097, Poland|Instytut Psychiatrii i Neurologii II Klinika Neurologiczna, Warszawa, 02-957, Poland|Przychodnia EuroMediCare, Wroc?aw, 50-220, Poland|Wro Medica, Wroc?aw, 51-685, Poland|IBISMED Wielospecjalistyczne Centrum Medyczne, Zabrze, 41-800, Poland|San Juan MS Center, Guaynabo, 00968, Puerto Rico|FSBHI Siberian Clinical Center of the Federal Medical and Biological Agency, Krasnoyarsk, Krasnojarsk, 660037, Russian Federation|Krasnoyarsk State Medical Academy, Krasnoyarsk, Krasnojarsk, 660049, Russian Federation|National Center of Social Significant Disease, Sankt-peterburg, Leningrad, 197110, Russian Federation|Federal center of brain research and neurotechnologies, Moskva, Moskovskaja Oblast, 117997, Russian Federation|Regional clinical hospital named after prof. S.V. Ochapovsky, Krasnodar, 350086, Russian Federation|Regional Clinical Hospital N.A. Semashko; Neurology, Nizhny Novgorod, 603126, Russian Federation|State Novosibirsk Regional Clinical Hospital, Novosibirsk, 630087, Russian Federation|Nebbiolo Center for Clinical Trials, Tomsk, 634009, Russian Federation|Regional Multiple Sclerosis Centre b/o CC ECM Neftyanik; Neurology, Tyumen, 625000, Russian Federation|Hacettepe University Medical Faculty; Neurology, Ankara, 06100, Turkey|Gazi University Medical Faculty; Departmant of Norology, Ankara, 06500, Turkey|Bakirkoy State Mental Hospital, Istanbul, 34000, Turkey|Istanbul Universitesi - Cerrahpasa Cerrahpasa Tip Fakultesi; Noroloji Anabilim Dali, Istanbul, 34098, Turkey|Sancaktepe Training and Research Hospital; Neurology, Istanbul, 34785, Turkey|Selcuk University Medical Faculty; Norology department, Istanbul, 42131, Turkey|Katip Celebi University Ataturk Training and Research Hospital; Neurology, Izmir, 35360, Turkey|Kocaeli University Hospital; Department of Neurology, Kocaeli, 41380, Turkey|Ege Üniversitesi Tip Fakültesi, Lzmir, 35100, Turkey|Mersin University Medical Faculty; Neurology, Mersin, 33079, Turkey|Ondokuz Mayis University School of Medicine; Neurology, Samsun, 55139, Turkey|Karadeniz Tecnical Uni. Med. Fac.; Neurology, Trabzon, 61080, Turkey|Van Yuzuncu Yil University Hospital; Neurology, Van, 65080, Turkey|Baskent Universitesi Ankara Hastanesi; Noroloji Bolumu, Çankaya, 06490, Turkey|Salford Royal NHS Foundation Trust, Salford, M6 8HD, United Kingdom|Recognition Health, Winchester, SO21 1HU, United Kingdom"
NCT03941184,Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity,https://beta.clinicaltrials.gov/study/NCT03941184,COMPLETED,"SCAD|Addison Disease|Ankylosing Spondylitis|Antiphospholipid Antibody Syndrome|Celiac Disease|Crohn Disease|Dermatomyositis|Polymyositis|Guillain-Barre Syndrome|Hepatitis, Autoimmune|Graves Disease|Hashimoto Thyroiditis|Multiple Sclerosis|Myasthenia Gravis|Pernicious Anemia|Polymyalgia Rheumatica|Primary Biliary Cirrhosis|Psoriasis|Rheumatoid Arthritis|Systemic Sclerosis|Sjögren Syndrome|Systemic Lupus Erythematosus|Takayasu Arteritis|Type 1 Diabetes Mellitus|Ulcerative Colitis|Uveitis|Vasculitis|Vitiligo|Raynaud",,Mayo Clinic,,ALL,"ADULT, OLDER_ADULT",,114,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,1995-01-01,2020-11-10,2020-11-10,"Mayo Clinic, Rochester, Minnesota, 55905, United States"
NCT00981084,Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT00981084,COMPLETED,Multiple Sclerosis,DRUG: armodafinil,"University of Missouri, Kansas City",University of Kansas,ALL,ADULT,PHASE2|PHASE3,33,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-09,2011-04,2011-04,"University of Kansas Medical Center, Kansas City, Kansas, 66160, United States"
NCT02996084,MS PATHS Normative Sub-Study,https://beta.clinicaltrials.gov/study/NCT02996084,COMPLETED,Healthy Volunteer,,Biogen,,ALL,ADULT,,246,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-12-12,2022-12-31,2022-12-31,"Johns Hopkins University, Baltimore, Maryland, 21287, United States|Washington University, Saint Louis, Missouri, 63110, United States|University of Rochester Medical Center, Rochester, New York, 14642, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States|University Hospital Carl Gustav Carus Dresden, Dresden, Germany|Multiple Sclerosis Centre of Catalonia (Cemcat) Vall d'Hebron Hospital, Barcelona, Spain"
NCT02419378,Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential,https://beta.clinicaltrials.gov/study/NCT02419378,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Alemtuzumab,University Hospital Muenster,"Genzyme, a Sanofi Company",ALL,ADULT,PHASE4,15,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2015-06,2020-07,2020-11,"Universitätsklinikum Münster, Klinik für Allgemeine Neurologie, Münster, 48149, Germany"
NCT02647502,A Pilot Study of Intermittent Calorie Restriction in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02647502,COMPLETED,Relapsing Remitting Multiple Sclerosis,OTHER: Diet,Johns Hopkins University,,ALL,ADULT,NA,36,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2015-12,2017-06,2017-06,"Johns Hopkins University, Baltimore, Maryland, 21287, United States"
NCT00248378,Short-Term Effects of Medicinal Cannabis Therapy on Spasticity in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00248378,COMPLETED,Multiple Sclerosis,DRUG: Smoked Cannabis,Center for Medicinal Cannabis Research,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE|Primary Purpose: TREATMENT,2001-09,,2005-03,"UC San Diego Medical Center, San Diego, California, 92093, United States"
NCT02282878,The Effect of Dietary Salt Intake on Immune Function in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02282878,COMPLETED,Multiple Sclerosis,DIETARY_SUPPLEMENT: High/Low Sodium Diet,Yale University,,ALL,ADULT,NA,14,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2014-09,2018-12-19,2019-12-08,"Yale MS Center, New Haven, Connecticut, 06519, United States"
NCT05175378,Adherence to Mediterranean Diet and Cardiovascular Health in Multiple Sclerosis Female Patients: a Case Control Study,https://beta.clinicaltrials.gov/study/NCT05175378,COMPLETED,Multiple Sclerosis,OTHER: Lifestyle intervention,"Iaso Maternity Hospital, Athens, Greece",Harokopio University|G.Gennimatas General Hospital,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE",2020-12-01,2021-02-28,2021-03-12,"Iaso Hospital, Athens, Greece"
NCT04748302,Impaired Glucose Tolerance and Cognition in MS,https://beta.clinicaltrials.gov/study/NCT04748302,TERMINATED,Multiple Sclerosis,,University of Virginia,,ALL,ADULT,,7,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-01-06,2020-04-01,2020-04-01,"University of Virginia, Charlottesville, Virginia, 22903, United States"
NCT00642902,A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS),https://beta.clinicaltrials.gov/study/NCT00642902,TERMINATED,Relapsing Multiple Sclerosis,DRUG: Atacicept|DRUG: Atacicept|DRUG: Atacicept|DRUG: Placebo matched to atacicept,EMD Serono,,ALL,ADULT,PHASE2,255,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2008-04,2009-09,2009-09,"Research Site, Phoenix, Arizona, United States|Research Site, Atlanta, Georgia, United States|Research Site, Northbrook, Illinois, United States|Research Site, East Lansing, Michigan, United States|Research Site, Dartmouth, New Hampshire, United States|Research Site, Cleveland, Ohio, United States|Philadelphia, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Box Hill, Australia|Research Site, Fitzroy, Australia|Research Site, New Lambton, Australia|Research Site, Woodville, Australia|Research Site, Innsbruck, Austria|Research Site, Diepenbeek, Belgium|Research Site, Sijsele, Belgium|Research Site, Calgary, Alberta, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Ontario, Canada|Research Site, Brno, Czech Republic|Research Site, Hradec Kralove, Czech Republic|Research Site, Olomouc, Czech Republic|Research Site, Caen, France|Research Site, Saint-Herblain, France|Research Site, Bochum, Germany|Research Site, Dusseldorf, Germany|Research Site, Beirut, Lebanon|Research Site, Beyrouth, Lebanon|Research Site, Kaunas, Lithuania|Research Site, Breda, Netherlands|Research Site, Nieuwegein, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Dnipropetrovsk, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Samara, Russian Federation|Research Site, Vladimir, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Malaga, Spain|Research Site, Stockholm, Sweden|Research Site, Basel, Switzerland|Research Site, Kharkiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Odessa, Ukraine|Research Site, Uzhgorod, Ukraine|Research Site, London, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Stoke on Trent, United Kingdom"
NCT02583594,A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02583594,COMPLETED,Progressive Multiple Sclerosis,DRUG: Acyclovir|DRUG: Methylprednisolone|DRUG: alemtuzumab GZ402673|DRUG: alemtuzumab GZ402673|DRUG: Paracetamol|DRUG: Loratadine|DRUG: Ceterizine|DRUG: Dexchlorpheniramine,"Genzyme, a Sanofi Company",,ALL,"ADULT, OLDER_ADULT",PHASE1,24,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2015-12-06,2016-03,2021-03-01,"Investigational Site Number 724001, Barcelona, 08035, Spain"
NCT03344094,Mechanism of Action of Ocrelizumab in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03344094,UNKNOWN,Multiple Sclerosis|Immune System Diseases,DRUG: ocrelizumab,University of Chicago,,ALL,"ADULT, OLDER_ADULT",,30,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-10-12,2018-12-31,2019-12-31,"University of Chicago, Chicago, Illinois, 60637, United States"
NCT05161494,Gait in Rare Diseases,https://beta.clinicaltrials.gov/study/NCT05161494,RECRUITING,Tuberous Sclerosis|STXBP1 Encephalopathy With Epilepsy,,Universiteit Antwerpen,"University Hospital, Antwerp",ALL,"CHILD, ADULT",,70,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-01-25,2023-12,2024-02,"University of Antwerp, Antwerp, 2160, Belgium"
NCT05061953,Development of a Novel Functional Eye-Tracking Software Application for Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05061953,RECRUITING,Multiple Sclerosis,DEVICE: Eye-Tracking,Innodem Neurosciences,Novartis Pharmaceuticals,ALL,"ADULT, OLDER_ADULT",,168,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-10-18,2027-10-18,2027-10-18,"The Neuro, Montreal, Quebec, H3A 2B4, Canada|Genge Partners, Inc., Montreal, Quebec, H4A 3T4, Canada"
NCT03457753,Riluzole Oral Soluble Film Safety and Tolerability in Amyotrophic Lateral Sclerosis,https://beta.clinicaltrials.gov/study/NCT03457753,WITHDRAWN,ALS,DRUG: Riluzole Oral Soluble Film,Aquestive Therapeutics,Inventiv Health|Covance,ALL,"ADULT, OLDER_ADULT",PHASE2,0,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2018-03-01,2018-03-27,2018-03-27,"Texas Neurology, P.A., Dallas, Texas, 75214, United States"
NCT01080053,"Sexual Dysfunction, Disability and Quality of Life in Patients With Multiple Sclerosis (MS)",https://beta.clinicaltrials.gov/study/NCT01080053,COMPLETED,"Multiple Sclerosis, Relapsing Remitting",,"Merck KGaA, Darmstadt, Germany",Merck Quimica Argentina S.A.I.C,ALL,"ADULT, OLDER_ADULT",,306,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2008-11,2013-05,2013-05,"Dr. Norma Deri, Buenos Aires, Argentina"
NCT05562453,Performance and Long-term Safety of FlowOx2.0™ in Patients With Multiple Sclerosis - Impact on Spasticity and Pain,https://beta.clinicaltrials.gov/study/NCT05562453,RECRUITING,"Multiple Sclerosis|Spasticity, Muscle|Pain, Chronic",DEVICE: FlowOx 2.0|DEVICE: FlowOx2.0 (Sham),Otivio AS,,ALL,"ADULT, OLDER_ADULT",NA,60,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-10-04,2023-06-30,2023-06-30,"NeuroCentrum (Centrum för Neurologi), Stockholm, 113 65, Sweden"
NCT03134794,Medical Education for Better Multiple Sclerosis Outcomes,https://beta.clinicaltrials.gov/study/NCT03134794,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Educational intervention applying the traffic light system (TLS),Unity Health Toronto,Roche Pharma AG,ALL,"ADULT, OLDER_ADULT",NA,90,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE",2017-03-22,2018-10-30,2018-10-30,"INEBA, Buenos Aires, Ciudad De Buenos Aires, 1642, Argentina|St Michael's Hospital, Toronto, Ontario, M5C 1R6, Canada|Clinica Las Condes, Santiago, Chile|Espacio GV30, Madrid, Spain"
NCT03362294,Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMS,https://beta.clinicaltrials.gov/study/NCT03362294,RECRUITING,Primary Progressive Multiple Sclerosis,DRUG: GA Depot 40mg once monthly|DRUG: GA Depot 25mg once monthly,Mapi Pharma Ltd.,,ALL,"ADULT, OLDER_ADULT",PHASE2,30,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2017-12-11,2023-12,2023-12,"Mapi Pharma Research site 09, Haifa, Israel|Mapi Pharma Research site 07, Jerusalem, Israel|Mapi Pharma Research site 08, Petah tikva, Israel|Mapi Pharma Research site 06, Rehovot, Israel|Mapi Pharma Research site 01, Tel Aviv, Israel|Mapi Pharma Research site 20, Chisinau, Moldova, Republic of|Mapi Pharma Research site 22, Chisinau, Moldova, Republic of"
NCT01971294,Lower Urinary Tract Symptoms in Systemic Sclerosis,https://beta.clinicaltrials.gov/study/NCT01971294,COMPLETED,Urinary Symptoms|Systemic Sclerosis,,"University Hospital, Geneva","University Hospital, Paris|Azienda Ospedaliera di Padova|Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia",ALL,"ADULT, OLDER_ADULT",,334,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-10,2015-10,2022-10,"Hôpital Cochin, Paris, 75014, France|Azienda Ospedaliera Spedali Civili di Brescia, Brescia, 25124, Italy|Azienda Ospedaliera di Padova, Padova, 35121, Italy|Universtiy Hospital, Geneva, Geneva, 1205, Switzerland"
NCT04758494,Quality of Life Assessment Between Stroke and Multiple Sclerosis Patients of the Same Age Range,https://beta.clinicaltrials.gov/study/NCT04758494,COMPLETED,Stroke|Multiple Sclerosis|Quality of Life|Depression|Mental Health Disorder,OTHER: Questionnaire,Hellenic Red Cross Hospital,G.Gennimatas General Hospital,ALL,ADULT,,172,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-11-11,2020-11-10,2020-11-10,"Department of Vascular Surgery, Hellenic Red Cross Hospital, Athens, 11526, Greece"
NCT03797378,"Movement-2-Music: Lakeshore Examination of Activity, Disability, and Exercise Response Study",https://beta.clinicaltrials.gov/study/NCT03797378,RECRUITING,Spinal Cord Injuries|Traumatic Brain Injury|Spina Bifida|Cerebral Palsy|Stroke|Parkinson Disease|Multiple Sclerosis,OTHER: eM2M,University of Alabama at Birmingham,Lakeshore Foundation|YMCA of Greater Birmingham,ALL,"ADULT, OLDER_ADULT",NA,108,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: OTHER,2019-08-09,2023-05-31,2023-09-30,"UAB Research Collaborative, Birmingham, Alabama, 35209, United States"
NCT03938558,Art for MS - Controlled Trial,https://beta.clinicaltrials.gov/study/NCT03938558,COMPLETED,Multiple Sclerosis|Fatigue,OTHER: MS-Dance|OTHER: MS-Art,Hasselt University,,ALL,"ADULT, OLDER_ADULT",NA,17,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2018-08-28,2019-04-19,2019-04-19,"Hasselt University, Hasselt, 3500, Belgium"
NCT04984278,Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04984278,TERMINATED,Spasticity With Multiple Sclerosis,DRUG: Nabiximols|DRUG: Placebo,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,56,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-08-16,2022-11-11,2022-11-11,"Mountain View Clinical Research, Denver, Colorado, 80209, United States|Collier Neurologic Specialists, Naples, Florida, 34105, United States|University of South Florida, Tampa, Florida, 33613, United States|Consultants in Neurology - Northbrook, Chicago, Illinois, 60062, United States|Premier Neurology Research, PC, Greer, South Carolina, 29650, United States|Neurology Clinic-Cordova, Cordova, Tennessee, 38018, United States|NeuropsychiatrieHK, Choceň, 565 01, Czechia|NeuropsychiatrieHK, Hradec Králové, 503 41, Czechia|Krajská Zdravotní - Nemocnice Teplice, Teplice, 415 29, Czechia|Centrum Medyczne Neuromed - Ośrodek Badań Klinicznych, Bydgoszcz, Kujawsko-Pomorskie, 85-163, Poland|Indywidualna Praktyka Lekarska Dr Hab Konrad Rejdak, Lublin, Lubelskie, 20-016, Poland|Małopolskie Centrum Kliniczne, Kraków, Malopolskie, 30-149, Poland|Instytut Zdrowia dr Boczarska-Jedynak, Oświęcim, Malopolskie, 32-600, Poland|Centrum Medyczne Pratia - Warszawa, Warszawa, Mazowieckie, 01-868, Poland|Szpital Wolski im dr. Anny Gostyńskiej Samodzielny Publiczny Zakład Opieki Zdrowotnej, Warszawa, Mazowieckie, Poland|MA-LEK A.M. Maciejowscy S.C. Centrum Terapii SM, Katowice, Slaskie, 40-571, Poland|DENDRYT Centrum Medyczne, Katowice, Slaskie, 40-684, Poland|Neuro-Medic Janusz Zbrojkiewicz, Katowice, Slaskie, 40-686, Poland|Wielospecjalistyczne Centrum Medyczne Ibismed, Zabrze, Slaskie, 41-800, Poland|RESMEDICA Poradnia Neurologiczna, Kielce, Swietokrzyskie, 25-726, Poland|Niepubliczny Zakład Opieki Zdrowotnej NEURO - KARD, Poznań, Wielkopolskie, 61-853, Poland|Hospital Universitario de Getafe, Getafe, Madrid, 289005, Spain|Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, 8003, Spain|Hospital Universitario Ramón y Cajal, Madrid, 28034, Spain|Hospital Vithas Nisa Sevilla, Sevilla, 41009, Spain|Panthera Biopartners - North London, North London, England, EN1 1LJ, United Kingdom|ReCognition Health - Plymouth, Plymouth, England, PL6 8BT, United Kingdom|Panthera Biopartners - Preston, Preston, England, PR2 9QB, United Kingdom|Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, England, S10 2JF, United Kingdom|NHS Highland, Inverness, Scotland, IV2 3UJ, United Kingdom"
NCT04599023,Assessing the Feasibility of the MSPT Device in Routine Clinical Practice in the Swiss Healthcare System,https://beta.clinicaltrials.gov/study/NCT04599023,TERMINATED,Multiple Sclerosis|Clinically Isolated Syndrome,DEVICE: MSPT,"University Hospital Inselspital, Berne",Biogen,ALL,"ADULT, OLDER_ADULT",,182,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-10-16,2022-08-31,2022-08-31,"Inselspital Bern, Ambulantes Neurozentrum, Bern, 3010, Switzerland"
NCT03315923,Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT03315923,COMPLETED,Secondary Progressive Multiple Sclerosis,DRUG: Rituximab|DRUG: Glatiramer Acetate,Isfahan University of Medical Sciences,,ALL,ADULT,PHASE2|PHASE3,84,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2017-12-01,2019-02-01,2019-03-01,"Kashani Hospital, Isfahan, 8174673461, Iran, Islamic Republic of"
NCT00202423,Use of Cannabinoids in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00202423,UNKNOWN,Multiple Sclerosis,DRUG: Sativex,S. Andrea Hospital,University of Roma La Sapienza,ALL,ADULT,PHASE2,20,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE|Primary Purpose: TREATMENT,2005-07,,,"Department of Neurology- University of Rome la Sapienza, Rome, 00185, Italy"
NCT00411723,Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00411723,UNKNOWN,"Multiple Sclerosis, Chronic Progressive|Multiple Sclerosis, Relapsing-Remitting",DRUG: RTL1000 (recombinant T cell receptor ligand)|DRUG: RTL1000 Placebo,Artielle ImmunoTherapeutics,,ALL,"ADULT, OLDER_ADULT",PHASE1,34,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2006-12,2009-02,2009-05,"Yale Center for MS Treatment and Research, New Haven, Connecticut, 06510, United States|Indiana University, Dept. of Neurology, Indianapolis, Indiana, 46202, United States|University of Kansas Medical Center, Landon Center on Aging, Kansas City, Kansas, 66160, United States|University of Maryland School of Medicine, Baltimore, Maryland, 21201, United States|MS Center of Oregon Health & Science University, Portland, Oregon, 97239, United States|MS Center at Evergreen, Kirkland, Washington, 98034, United States"
NCT04856384,Effect of Variance on Error Correction During Coupling,https://beta.clinicaltrials.gov/study/NCT04856384,UNKNOWN,Multiple Sclerosis|Progressive Multiple Sclerosis,OTHER: synchronisation abilities,Hasselt University,National MS Center Melsbroek|Revalidatie & MS Centrum Overpelt,ALL,"ADULT, OLDER_ADULT",NA,80,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2021-02-01,2022-12-31,2022-12-31,"National MS Center Melsbroek, Melsbroek, 1820, Belgium|Noorderhart Revalidatie & MS centrum, Overpelt, 3900, Belgium"
NCT03508284,Dual-Task Performance in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03508284,COMPLETED,Multiple Sclerosis,,Gazi University,,ALL,"ADULT, OLDER_ADULT",,60,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-06-18,2019-05-16,2019-05-18,"Gazi University, Ankara, Turkey"
NCT00467584,Aspirin for Treatment of Multiple Sclerosis-Related Fatigue,https://beta.clinicaltrials.gov/study/NCT00467584,TERMINATED,Multiple Sclerosis|Fatigue,DRUG: High Dose Aspirin (1300 mg/day)|DRUG: Low Dose Aspirin (162 mg/day)|DRUG: Placebo,Mayo Clinic,National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",PHASE3,62,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2007-07,2013-09,2013-09,"Mayo Clinic, Scottsdale, Arizona, 85259, United States"
NCT02870023,How Does Strength Training and Balance Training Affect Gait Function and Fatigue in Patients With Multiple Sclerosis?,https://beta.clinicaltrials.gov/study/NCT02870023,COMPLETED,Multiple Sclerosis,OTHER: Balance training|OTHER: Strength training,University of Aarhus,"VIA University College|TrygFonden, Denmark|Fondazione Don Carlo Gnocchi Onlus",ALL,"ADULT, OLDER_ADULT",NA,71,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2016-06,2018-12,2018-12,"Department of Public Health - Sport Science, Aarhus, 8000, Denmark"
NCT01333358,Evaluating Alemtuzumab as a Treatment in Stabilizing Neurocognitive Function In Relapsing Remitting Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT01333358,UNKNOWN,Multiple Sclerosis,DRUG: Alemtuzumab,Central Texas Neurology Consultants,"Genzyme, a Sanofi Company",ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,30,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-05,2013-12,2014-03,
NCT00752778,Magnetic Resonance Imaging (MRI) Follow-up of Macrophagic Infiltration in MS Patients Treated With Tysabri,https://beta.clinicaltrials.gov/study/NCT00752778,TERMINATED,Multiple Sclerosis,OTHER: pet-scan FDG-F18,"University Hospital, Strasbourg, France",Biogen,ALL,"ADULT, OLDER_ADULT",PHASE4,8,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2008-12,2011-03,2011-03,"Service de Neurologie, Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, 37091, France|Service de Médecine Nucléaire, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, 67098, France|Service de Radiologie 2, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, 67098, France"
NCT04032158,Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS),https://beta.clinicaltrials.gov/study/NCT04032158,TERMINATED,Relapsing-remitting Multiple Sclerosis,DRUG: Evobrutinib|DRUG: Avonex®|DRUG: Avonex® matched Placebo|DRUG: Evobrutinib matched Placebo,"EMD Serono Research & Development Institute, Inc.","Merck KGaA, Darmstadt, Germany",ALL,ADULT,PHASE3,3,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-08-26,2020-04-16,2020-04-16,"Please Contact U.S. Medical Information, Rockland, Massachusetts, 02370, United States|Please Contact the Communication Center, Darmstadt, 64293, Germany"
NCT02485223,Single Test to ARrive at MS Diagnosis. Using a Single MRI Brain Scan to Help Diagnose Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02485223,UNKNOWN,Multiple Sclerosis,,University of Nottingham,,ALL,"ADULT, OLDER_ADULT",,60,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-05,2016-05,2017-05,"Clinical Neurology, Division of Clinical Neuroscience, University of Nottingham, UK, Nottingham, Nottinghamshire, NG7 2UH, United Kingdom"
NCT04431323,Intervention for Young Adults With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04431323,COMPLETED,Multiple Sclerosis,BEHAVIORAL: ESPRIMO,Azienda Ospedaliera Universitaria Integrata Verona,,ALL,ADULT,NA,53,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-05-13,2022-07-30,2022-10-30,"Azienda Ospedaliera Universitaria Integrata Verona, Policlinico G.B. Rossi, Verona, Veneto, 37134, Italy"
NCT01492023,The Effects of Attention Retraining in MS,https://beta.clinicaltrials.gov/study/NCT01492023,COMPLETED,Multiple Sclerosis,BEHAVIORAL: neuropsychological rehabilitation,Finnish MS Society,"Social Insurance Institution, Finland|Tampere University Hospital|Seinajoki Central Hospital",ALL,ADULT,,97,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-11,2012-04,2012-05,"Masku Neurological Rehabilitation Centre, Masku, 212521, Finland|Seinajoki Central Hospital, Seinäjoki, 60220, Finland|Tampere University Hospital, Tampere, Finland"
NCT05083923,A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS),https://beta.clinicaltrials.gov/study/NCT05083923,RECRUITING,Relapsing Forms of Multiple Sclerosis,DRUG: Diroximel fumarate,Biogen,,ALL,"ADULT, OLDER_ADULT",PHASE3,100,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-11-18,2024-07-15,2024-07-15,"Research Site, Tianjin, 300052, China|Research Site, Asahikawa-shi, 070-8644, Japan|Research Site, Bunkyo-ku, 113-8431, Japan|Research Site, Chiba-City, 260-8677, Japan|Research Site, Fukuoka-shi, 814-0180, Japan|Research Site, Kawagoe-shi, 350-8550, Japan|Research Site, Kitakyushu-shi, 807-8555, Japan|Research Site, Kodaira, 187-8551, Japan|Research Site, Koriyama-shi, 963-8052, Japan|Research Site, Moriguchi-shi, 570-8507, Japan|Research Site, Morioka-shi, 020-8505, Japan|Research Site, Niigata-shi, 951-8510, Japan|Research Site, Obihiro-City, 080-0024, Japan|Research Site, Ota-ku, 145-0065, Japan|Research Site, Sapporo-shi, 063-0005, Japan|Research Site, Sendai City, 980-8574, Japan|Research Site, Sendai City, 983-8512, Japan|Research Site, Shinjukuku, 162-8666, Japan|Research Site, Toon, 791-0295, Japan|Research Site, Tsukuba-shi, 305-8576, Japan|Research Site, Ube City, 755-8505, Japan|Research Site, Wakayama City, 641-8510, Japan|Research Site, Yachiyo-City, 276-8524, Japan|Research Site, Yokohama-shi, 236-0004, Japan"
NCT05177523,Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05177523,RECRUITING,Multiple Sclerosis (MS)|Relapsing-remitting Multiple Sclerosis (RRMS)|Secondary-progressive Multiple Sclerosis (SPMS)|Primary Progressive Multiple Sclerosis (PPMS),DIAGNOSTIC_TEST: MRI|OTHER: Neurocognitive examination for healthy subjects|OTHER: blood sampling,"University Hospital, Basel, Switzerland",Swiss National Science Foundation,ALL,"ADULT, OLDER_ADULT",,300,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-09-04,2024-09,2024-09,"University Hospital Basel, Department of Neurology, Basel, 4031, Switzerland"
NCT05658484,A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China,https://beta.clinicaltrials.gov/study/NCT05658484,NOT_YET_RECRUITING,Multiple Sclerosis,DRUG: Dimethyl fumarate,Biogen,,ALL,"ADULT, OLDER_ADULT",PHASE4,60,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-05-14,2025-04-16,2025-04-30,
NCT02782858,Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS,https://beta.clinicaltrials.gov/study/NCT02782858,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: GNbAC1|DRUG: Placebo,GeNeuro SA,Les Laboratoires Servier (LLS)|Institut de Recherches Internationales Servier|Worldwide Clinical Trials,ALL,ADULT,PHASE2,270,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-04,2017-08,2017-12,"Sofia, Bulgaria|Zagreb, Croatia|Jihlava, Czechia|Tallinn, Estonia|Berlin, Germany|Budapest, Hungary|Roma, Italy|Warsaw, Poland|Moscow, Russian Federation|Belgrade, Serbia|Barcelona, Spain|Kharkiv, Ukraine"
NCT01451723,Safety and Neuroprotective Effects of Polyphenon E in MS; Phase II,https://beta.clinicaltrials.gov/study/NCT01451723,TERMINATED,Multiple Sclerosis,DRUG: Polyphenon E|OTHER: Placebo,Louisiana State University Health Sciences Center in New Orleans,National Center for Complementary and Integrative Health (NCCIH),ALL,ADULT,PHASE2,11,OTHER,INTERVENTIONAL,"Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-07,2013-02,2013-02,"LSu Health Sciences Center, New Orleans, Louisiana, 70112, United States"
NCT02377323,Real-Life Outcomes of Multiple Sclerosis Treatment With Rebif,https://beta.clinicaltrials.gov/study/NCT02377323,COMPLETED,Multiple Sclerosis,OTHER: MACFIMS|OTHER: MSQoL-54,Centre hospitalier de l'Université de Montréal (CHUM),EMD Serono Canada Inc.,ALL,"ADULT, OLDER_ADULT",NA,296,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2014-01,2015-05,2016-12,"CHUM, Montréal, Quebec, H2L 4M1, Canada"
NCT00695084,Constraint-Induced (CI) Movement Therapy for Progressive Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT00695084,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Constraint-Induced Movement Therapy,National Multiple Sclerosis Society,,ALL,"ADULT, OLDER_ADULT",PHASE1,7,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-03,2008-04,2008-04,"University of Alabama at Birmingham, Birmingham, Alabama, 35249, United States"
NCT02410278,Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera,https://beta.clinicaltrials.gov/study/NCT02410278,COMPLETED,Multiple Sclerosis,DRUG: dimethyl fumarate|DRUG: montelukast|DRUG: Placebo,Biogen,,ALL,"ADULT, OLDER_ADULT",PHASE4,102,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2015-03-12,2017-02-16,2017-04-27,"Research Site, Jonesboro, Arkansas, 72401, United States|Research Site, Carmichael, California, 95608, United States|Research Site, La Jolla, California, 92037, United States|Research Site, La Mesa, California, 91942, United States|Research Site, Pomona, California, 91767, United States|Research Site, Simi Valley, California, 93065, United States|Research Site, Aurora, Colorado, 80045, United States|Research Site, Colorado Springs, Colorado, 80907, United States|Research Site, Fairfield, Connecticut, 06824, United States|Research Site, Washington, District of Columbia, 20057, United States|Research Site, Jacksonville, Florida, 32216, United States|Research Site, Naples, Florida, 34102, United States|Research Site, Ormond Beach, Florida, 32174-3102, United States|Research Site, Sunrise, Florida, 33351, United States|Research Site, Rome, Georgia, 30165-1625, United States|Research Site, Smyrna, Georgia, 30269, United States|Research Site, Chicago, Illinois, 60612, United States|Research Site, Flossmoor, Illinois, 60422, United States|Research Site, Indianapolis, Indiana, 46256, United States|Research Site, Louisville, Kentucky, 40207, United States|Research Site, Scarborough, Maine, 04074, United States|Research Site, Farmington Hills, Michigan, 48334, United States|Research Site, Chesterfield, Missouri, 63017, United States|Research Site, Kansas City, Missouri, 64111, United States|Research Site, Saint Louis, Missouri, 63104, United States|Research Site, Freehold, New Jersey, 07728, United States|Research Site, Amherst, New York, 14226, United States|Research Site, New York, New York, 10029, United States|Research Site, Patchogue, New York, 11772, United States|Research Site, Hendersonville, North Carolina, 28792, United States|Research Site, Raleigh, North Carolina, 27607-6010, United States|Research Site, Sanford, North Carolina, 27330, United States|Research Site, Winston-Salem, North Carolina, 27103, United States|Research Site, Dayton, Ohio, 45417, United States|Research Site, Dayton, Ohio, 45459, United States|Research Site, Uniontown, Ohio, 44685, United States|Research Site, Oklahoma City, Oklahoma, 73109, United States|Research Site, Portland, Oregon, 97225, United States|Research Site, Tualatin, Oregon, 97062, United States|Research Site, Dickson City, Pennsylvania, 18519, United States|Research Site, Greensburg, Pennsylvania, 15601, United States|Research Site, Hershey, Pennsylvania, 17033, United States|Research Site, Wilkes-Barre, Pennsylvania, 18711, United States|Research Site, Nashville, Tennessee, 37215, United States|Research Site, Dallas, Texas, 75214, United States|Research Site, Round Rock, Texas, 78681, United States|Research Site, Alexandria, Virginia, 22310, United States|Research Site, Newport News, Virginia, 23601, United States|Research Site, Seattle, Washington, 98122, United States|Research Site, Madison, Wisconsin, 53705, United States"
NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03523858,ACTIVE_NOT_RECRUITING,Progressive Multiple Sclerosis (PMS),DRUG: Ocrelizumab,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE3,927,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-05-28,2026-01-15,2026-12-04,"MS Center of California, Laguna Hills, California, 92653, United States|SC3 Research Group, Inc, Pasadena, California, 91105, United States|University of California San Francisco, San Francisco, California, 94117, United States|Yale University Multiple Sclerosis Center, New Haven, Connecticut, 06473, United States|University of South Florida, Tampa, Florida, 33612, United States|University of Chicago; Neurology/MC 2030, Chicago, Illinois, 60637-1470, United States|Massachusetts General Hospital; Neurological Clinical Research Institute (NCRI), Boston, Massachusetts, 02114, United States|The Elliot Lewis Center, Wellesley, Massachusetts, 02481, United States|Wayne State University School of Medicine, Detroit, Michigan, 48210, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|The MS Center of Northeastern New York, Latham, New York, 12110, United States|University of Cincinnati; Department of Neurology, Cincinnati, Ohio, 45219, United States|Cleveland Clinic Mellen Center; U10, Cleveland, Ohio, 44195, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|Neurology Clinic PC, Cordova, Tennessee, 38018, United States|Central Texas Neurology Consultants, Round Rock, Texas, 78681, United States|Neurology Center of San Antonio, San Antonio, Texas, 78258, United States|Swedish Multiple Sclerosis Center, Seattle, Washington, 98122, United States|University Clinical Center of the Republic of Srpska; Neurology Clinic, Banja Luka, 78000, Bosnia and Herzegovina|University Hospital Mostar; Neurology Clinic, Mostar, 88000, Bosnia and Herzegovina|Clinical Center University of Sarajevo; Neurology clinic, Sarajevo, 71000, Bosnia and Herzegovina|University Clinical Center Tuzla; Neurology, Tuzla, 75000, Bosnia and Herzegovina|Instituto de Neurologia de Curitiba, Curitiba, PR, 81210-310, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, 90610-000, Brazil|Hospital das Clínicas Faculdades Médicas de Ribeirão Preto, Ribeirao Preto, SP, 14051-140, Brazil|Hospital das Clinicas - FMUSP_X; Neurologia, Sao Paulo, SP, 05403-000, Brazil|Fraser Health Authority - Fraser Health Multiple Sclerosis, Burnaby, British Columbia, V5G 2X6, Canada|University of British Columbia Hospital; Division of Neurology, Vancouver, British Columbia, V6T 2B5, Canada|London Health Sciences Centre Uni Campus, London, Ontario, N6A 5A5, Canada|St. Michael'S Hospital, Toronto, Ontario, M5B 1W8, Canada|Recherche Sepmus Inc., Greenfield Park, Quebec, J4V 2J2, Canada|Hospital Notre-Dame du Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, H2L 4M1, Canada|Saskatoon City Hospital; Neurology, Saskatoon, Saskatchewan, S7K 0M7, Canada|Organizacion Sanitas Internacional, Bogota, D.C., 111321, Colombia|Fundacion Clinica Valle del Lili; Unidad de Investigaciones Clinicas, Cali, Colombia|Hospital Clínica Biblica, San José, 10101, Costa Rica|Nemocnice Jihlava; NEU-Neurologicke oddeleni, Jihlava, 58633, Czechia|Fakultní Nemocnice Olomouc; Neurologicka Klinika, Olomouc, 779 00, Czechia|Fakultni nemocnice Ostrava; MS centrum, Ostrava-Poruba, 708 52, Czechia|Vseobecna fakultni nemocnice v Praze; MS Centrum, Neurologicka klinika, Praha 2, 128 08, Czechia|Hjerne- og nervesygdomme, Ambulatorium, Skleroseklinikken, Aabenraa, 6200, Denmark|Aarhus Universitetshospital; Neurologisk Afd. F, Skleroseklinikken, Aarhus N, 8200, Denmark|Rigshospitalet; Neurologisk Klinik Glostrup, Glostrup, 2600, Denmark|Rigshospitalet; Skleroseklinikken - Glostrup, Glostrup, 2600, Denmark|Clinical Research Center-Alex university; Neurology Department, Alexandria, 21561, Egypt|Ain Shams University Hospital; Clinical Research Center (MASRI-CRC), Cairo, 11566, Egypt|CHU Amiens Hopital Sud; Neurologie, Amiens Cedex1, 80054, France|CHIC Cote Basque Bayonne; Neurologie, Bayonne Cedex, 64109, France|Groupe Hospitalier Pellegrin; Service de Neurologie - 3ème étage, Bordeaux, 33076, France|Hopital neurologique Pierre Wertheimer - CHU Lyon; Neurologie, Bron, 69677, France|CHU De Caen; Service De Neurologie Dejerine, Caen, 14033, France|Hopital Gabriel Montpied CHU de Clermont-Ferrand; Service de Neurologie B, Clermont-Ferrand, 63003, France|Hopital B Roger Salengro; Neurologie C, Lille, 59037, France|CHU de la Timone - Hopital d Adultes; Service de Neurologie, Marseille, 13005, France|Hopital Gui de Chauliac; Neurologie, Montpellier, 34295, France|CHRU Nancy; Service de neurologie, Nancy, 54035, France|Hopital Nord Laennec, Nantes, 44093, France|Hôpital Pasteur; Service de Neurologie, Nice, 06002, France|Groupe Hospitalo-Universitaire Caremeau; Service Neurologie, Nimes, 30029, France|Centre Hospitalier Universitaire de Rennes, Rennes, 35033, France|Hopital Civil de Strasbourg; Service de Neurologie, Strasbourg, 67091, France|Universitätsklinikum ""Carl Gustav Carus"", Zentrum für Klinische Neurowissenschaften, Dresden, 01307, Germany|Universitätsmedizin Greifswald; Klinik und Poliklinik für Neurologie, Greifswald, 17475, Germany|NeuroConcept AG C/O mind mvz GmbH, Stuttgart, 70182, Germany|NeuroPoint, Gesellschaft für vorbeugende Gesundheitspflege mbH, Ulm, 89073, Germany|Studienzentrum Nordwest, Dr. med. Joachim Springub / Herr Wolfgang Schwarz, Westerstede, 26655, Germany|Deutsche Klinik für Diagnostik; DKD Helios Klinik Wiesbaden, Abt. Neurologie, Wiesbaden, 65191, Germany|Nucare, Ciudad Guatemala, 01015, Guatemala|Semmelweis Egyetem AOK; Neurologiai Klinika, Budapest, 1083, Hungary|VALEOMED Diagnosztikai Központ, Esztergom, 2500, Hungary|Jósa András Oktatókórház, Nyíregyháza, 4400, Hungary|Pécsi Tudományegyetem, Klinikai Központ Neurológiai Klinika; Klinikai Központ Neurológiai Klinika, Pécs, 7623, Hungary|Cork University Hospital, Cork, Ireland|Beaumont Hospital; Clinical Research and Education Centre, Smurfit Building, Dublin, 9, Ireland|St Vincents University Hospital; Carew House-Neurology Department, Dublin, Dublin 4, Ireland|A. O. U. Federico II; Dip Neuroscienze, Scienze Riproduttive ed Odontostomatologiche, Napoli, Campania, 80131, Italy|Università degli Studi della Campania Luigi Vanvitelli; Dip. Ass. Integrato Med Int-II Clinica Neur, Napoli, Campania, 80131, Italy|Università degli studi della Campania Luigi Vanvitelli; Dip.Ass Int Med Int-I Clinica Neurologica, Napoli, Campania, 80138, Italy|Ospedale Cattinara; Amb Studio Sclerosi Multipla, Clinica Neurlogica, Trieste, Friuli-Venezia Giulia, 34149, Italy|Policlinico Tor Vergata Dip. Neuroscienze-Clinica Neurologica-UOSD Sclerosi Multipla, Roma, Lazio, 00133, Italy|Policlinico Universitario A. Gemelli; UOC Neurologia - Centro Sclerosi Multipla, Roma, Lazio, 00168, Italy|A.O. Sant'Andrea; UOC Neurologia, Dip. di Neuroscienze, Salute Mentale e Organi di Senso (NESMOS), Roma, Lazio, 00189, Italy|Azienda Ospedaliera Sant'Andrea; UOC Neurologia, Roma, Lazio, 00189, Italy|Irccs A.O.U.San Martino Ist; Dinogmi, Genova, Liguria, 16132, Italy|IRCCS Ospedale San Raffaele; Neurologia Neurofisiologia Neuroriabilitazione-Centro Sclerosi Multipla, Milano, Lombardia, 20132, Italy|Fond. Istituto Neurologico C.Besta; UO Neurologia IV - Neuroimmunologia Malattie Neuromuscolari, Milano, Lombardia, 20133, Italy|IRCCS Istituto Neurologico C. Mondino?Dip. Neurologia Neuroriabilitazione S.S. Sclerosi Multipla, Pavia, Lombardia, 27100, Italy|IRCCS Istituto Neurologico Neuromed; Centro per lo Studio e la Cura della Sclerosi Multipla, Pozzilli, Molise, 86077, Italy|Azienda Sanitaria Ospedaliera S. Luigi Gonzaga; Centro Regionale Sclerosi Multipla - Neurologia II, Orbassano, Piemonte, 10043, Italy|AOU Città della Salute e della Scienza; Neurologia 1, Torino, Piemonte, 10126, Italy|Azienda Ospedaliero Universitaria Consorziale Policlinico di; Scienze Neurologiche, Bari, Puglia, 70124, Italy|Ospedale Binaghi; Centro Sclerosi Multipla, Cagliari, Sardegna, 09126, Italy|AOU Policlinico V. Emanuele - P.O G. Rodolico; Clinica Neurologica, Centro Sclerosi Multipla, Catania, Sicilia, 95123, Italy|AOUC Azienda Ospedaliero-Universitaria Careggi; Neurologia 2, Firenze, Toscana, 50134, Italy|Policlinico G.B. Rossi; Dip. Scienze Neurologiche Biomediche - Neurologia B ? Amb. Sclerosi Multipla, Verona, Veneto, 37134, Italy|American University of Beirut - Medical Center, Beirut, 1107 2020, Lebanon|Lebanese American University Medical Center- Rizk Hospial, Beirut, 1132 8811, Lebanon|Grupo Medico de Investigacion Clinica Multidisciplinaria, Mexico City, Mexico CITY (federal District), 03100, Mexico|Clinstile S.A de C.V., Mexico City, Mexico CITY (federal District), 06700, Mexico|Hospital General de Mexico, Mexico, Tlaxcala, 06726, Mexico|Unidad de investigacion en salud (UIS); Neurociencias, Ciudad de México, 14050, Mexico|Centre Hospitalier Universitaire Hassan II, FES, 30000, Morocco|Hopital Cheikh Zaid, Rabat, 10000, Morocco|Hopital Militaire d'Instruction Mohamed V, Rabat, 10100, Morocco|Amphia Ziekenhuis, Breda, 4819 EV, Netherlands|Catharina ziekenhuis, Eindhoven, 5623 EJ, Netherlands|Maasstadziekenhuis, Rotterdam, 3079 DZ, Netherlands|Zuyderland Medisch Centrum - Sittard Geleen, Sittard-Geleen, 6162 BG, Netherlands|Consultorios Médicos PaItilla, Panama City, 0816 03075, Panama|Uniwersytecki Szpital Kliniczny w Bialymstoku, Bia?ystok, 15-276, Poland|Szpital Uniwersytecki w Krakowie; Oddzia? kliniczny Neurologii, Kraków, 31-503, Poland|Centrum Neurologii Krzysztof Selmaj, Lodz, 90-324, Poland|SP Swiecickiego UM Marcinkowskiego; Od. Klin. Neurologii z podod. Udarowym, Pozna?, 60-355, Poland|Centrum Medyczne ""MEDYK"", Rzeszow, 35-055, Poland|Wojskowy Instytut Medyczny - Pa?Stwowy Instytut Badawczy, Warszawa, 04-141, Poland|SPSK nr 1; Klinika Neurologii, Zabrze, 41-800, Poland|National Center of Social Significant Disease, Sankt-peterburg, Leningrad, 197110, Russian Federation|Jusupovskaya Hospital, Moscow, Moskovskaja Oblast, 117186, Russian Federation|Scientific Neurology Center; Neurological department #6?, Moscow, Moskovskaja Oblast, 125367, Russian Federation|City Clinical Hospital #24; Multipal Sclerosis department, Moskva, Moskovskaja Oblast, 127015, Russian Federation|Vladimirskiy Regional Scientific Research Inst., Moscow, 129110, Russian Federation|Hospital Universitario Virgen de Arrixaca; Servicio de Neurología, EL Palmar (EL Palmar), Murcia, 30120, Spain|Hospital Vall d'Hebron; Servicio de Neurología, Barcelona, 08035, Spain|Hospital Universitario la Fe; Servicio de Neurologia, Valencia, 46026, Spain|Cleveland Clinic Abu Dhabi, Abu Dhabi, 112412, United Arab Emirates|Rashid hospital, Dubai, 4545, United Arab Emirates"
NCT05701423,A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Participants,https://beta.clinicaltrials.gov/study/NCT05701423,RECRUITING,Multiple Sclerosis,DRUG: Natalizumab,Biogen,,ALL,"ADULT, OLDER_ADULT",,100,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-02-08,2024-07-01,2024-07-01,"Klinik für Neurologie, Universitätsklinikum Düsseldorf, Düsseldorf, 40225, Germany"
NCT04528784,Feasibility Study of Transcutaneous Tibial Nerve Stimulation for Urinary Symptoms in People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04528784,COMPLETED,"Bladder Dysfunction|Neurogenic Bladder Dysfunction|Urinary Incontinence|Urinary Bladder, Overactive|Urinary Incontinence, Urge|Nocturia|Urinary Frequency More Than Once at Night|Lower Urinary Tract Symptoms|Multiple Sclerosis|Urinary Bladder, Neurogenic",DEVICE: Transcutaneous tibial nerve stimulation,University of Limerick,,ALL,"ADULT, OLDER_ADULT",NA,23,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-10-14,2021-03-12,2021-03-12,"University of Limerick, Limerick, LK, Ireland"
NCT04822623,Imaging Evaluation of Central Nervous Autoimmune Diseases,https://beta.clinicaltrials.gov/study/NCT04822623,UNKNOWN,MS (Multiple Sclerosis)|NMO Spectrum Disorder,DIAGNOSTIC_TEST: MRI,Qilu Hospital of Shandong University,,ALL,"ADULT, OLDER_ADULT",,300,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-05-01,2021-12-31,2022-07-01,
NCT00142402,Modafinil in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00142402,COMPLETED,Multiple Sclerosis,DRUG: Modafinil,Kessler Foundation,National Multiple Sclerosis Society,ALL,ADULT,NA,20,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE|Primary Purpose: TREATMENT,2003-06,2006-09,2006-09,"Kessler Foundation, West Orange, New Jersey, 07052, United States"
NCT01274702,Visual Reconstitution Therapy After Optic Neuritis,https://beta.clinicaltrials.gov/study/NCT01274702,COMPLETED,Optic Neuritis|Multiple Sclerosis,OTHER: Visual Reconstitutions Therapy|OTHER: Saccadic Eye Movement Training,Friedemann Paul,"Beuth Hochschule für Technik Berlin|NovaVision AG, Zentrum für Sehtherapie",ALL,"ADULT, OLDER_ADULT",PHASE2,25,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2010-05,2013-03,2013-03,"NeuroCure Clinical Reserach Center, Charité Universitaetsmedizin, Berlin, 10117, Germany"
NCT04496830,SPINCOMS Biomarker Study,https://beta.clinicaltrials.gov/study/NCT04496830,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,DEVICE: SOMAscan,Washington University School of Medicine,"National Institute of Allergy and Infectious Diseases (NIAID)|University of Colorado, Denver|University of Ottawa|Montana State University",ALL,"ADULT, OLDER_ADULT",NA,160,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-06-15,2023-12-01,2024-03-01,"Washington University in St Louis, Saint Louis, Missouri, 63110, United States"
NCT00239655,A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED),https://beta.clinicaltrials.gov/study/NCT00239655,TERMINATED,Relapsing-Remitting Multiple Sclerosis,DRUG: MK0812,Merck Sharp & Dohme LLC,,ALL,ADULT,PHASE2,120,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2004-08,2005-12,2006-01,
NCT01890655,Extension Study of MT-1303,https://beta.clinicaltrials.gov/study/NCT01890655,COMPLETED,Relapsing-remitting Multiple Sclerosis,DRUG: MT-1303-Low|DRUG: MT-1303-Middle|DRUG: MT-1303-High,Mitsubishi Tanabe Pharma Corporation,,ALL,ADULT,PHASE2,367,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-08,2016-03,2016-03,"Research Site, City name, Belgium|Research Site, City name, Bulgaria|Research Site, City name, Canada|Research Site, City name, Croatia|Research Site, City name, Czech Republic|Research Site, City name, Finland|Research Site, City name, Germany|Research Site, City name, Hungary|Research Site, City name, Italy|Research Site, City name, Lithuania|Research Site, City name, Poland|Research Site, City name, Russian Federation|Research Site, City name, Serbia|Research Site, City name, Spain|Research Site, City name, Turkey|Research Site, City name, Ukraine|Research Site, City name, United Kingdom"
NCT04185792,"Polish Translation and Validation of NBSS, Qualiveen and SF-Qualiveen",https://beta.clinicaltrials.gov/study/NCT04185792,COMPLETED,Spinal Cord Injuries|Multiple Sclerosis,"DIAGNOSTIC_TEST: NBSS, Qualiveen and SF-Qualiveen",Jagiellonian University,"Piotr Chlosta, Full-time Professor, University Hospital, Cracow, Poland",ALL,"ADULT, OLDER_ADULT",,200,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-01-01,2020-09-18,2020-09-18,"Department of Urology Jagiellonian University, Kraków, Malopolska, 31-531, Poland"
NCT00649792,"Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial",https://beta.clinicaltrials.gov/study/NCT00649792,COMPLETED,Multiple Sclerosis,DRUG: Fampridine-SR,Acorda Therapeutics,,ALL,"ADULT, OLDER_ADULT",PHASE3,214,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-08,2011-01,2011-04,"Barrow Neurology Clinic, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, 85013, United States|HOPE Research Institute, Phoenix, Arizona, 85050, United States|Neurological Associates, Fayetteville, Arkansas, 72703, United States|Alta Bates Summit Medical Center - Research and Education Institute, Berkeley, California, 94705, United States|USC, Keck School of Medicine Health Care Consultation Center, Los Angeles, California, 90033, United States|UC Davis, Sacramento, California, 95817, United States|Yale University MS Center, New Haven, Connecticut, 06510, United States|Shepherd Center, Atlanta, Georgia, 30309, United States|University of Chicago, Chicago, Illinois, 60637, United States|Consultants in Neurology, Ltd., Northbrook, Illinois, 60062, United States|Indiana University MS Center, Indianapolis, Indiana, 46202, United States|Associates in Neurology, PSC, Lexington, Kentucky, 40503, United States|Maryland Center for MS, Baltimore, Maryland, 21201, United States|Lahey Clinic, Lexington, Massachusetts, 02421, United States|Wayne State University, Department of Neurology, Detroit, Michigan, 48201, United States|The Schapiro Center for MS, Golden Valley, Minnesota, 55422, United States|Washington University School of Medicine, St. Louis, Missouri, 63110, United States|Advanced Neurology Specialists, Great Falls, Montana, 59405, United States|UMDNJ, Newark, New Jersey, 07103, United States|Gimbel MS Center at Holy Name Hospital, Teaneck, New Jersey, 07666, United States|Jacobs Neurological Institute Buffalo General Hospital, Buffalo, New York, 14203, United States|Corinne Goldsmith Dickinson Center for MS, New York, New York, 10029, United States|Columbia University Multiple Sclerosis Clinical Care Center, New York, New York, 10032, United States|University of Rochester, Rochester, New York, 14642, United States|SUNY Stony Brook, Stony Brook, New York, 11794, United States|CMC - Neuroscience & Spine Institute, Division of Neurology, Charlotte, North Carolina, 28207, United States|Raleigh Neurology Associates, Raleigh, North Carolina, 27607, United States|Wake Forest University, Dept of Neurology, M.S. Research, Winston-Salem, North Carolina, 27157, United States|The Center for Neurological Services, Bismarck, North Dakota, 58501, United States|Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States|Ohio State University MS Center, Columbus, Ohio, 43221, United States|Oregon Health & Science University, MS Center of Oregon, UHS-42, Portland, Oregon, 97239, United States|Thomas Jefferson University Physicians, Philadelphia, Pennsylvania, 19107, United States|Neurological Research Center, Inc., Bennington, Vermont, 05201, United States|Fletcher Allen Health Care, Burlington, Vermont, 05401, United States|MS Center at Evergreen, Kirkland, Washington, 98034, United States|CAMC Health Education & Research Institute, Charleston, West Virginia, 25304, United States|Center for Neurological Disorders of Aurora, St. Luke's Medical Center, Milwaukee, Wisconsin, 53215, United States|Foothills Medical Center, Calgary, Alberta, T2N 2T9, Canada|University of British Columbia, Vancouver Coastal Health Research Institute, Vancouver, British Columbia, V6T 2B5, Canada|River Valley Health c/o Stan Cassidy Centre for Rehabilitation, Fredericton, New Brunswick, E3B 0C7, Canada|QEII Health Sciences Centre, Nova Scotia Rehabilitation Centre Site, Halifax, Nova Scotia, B3H 4K4, Canada"
NCT00424788,A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT00424788,COMPLETED,Relapsing Forms of Multiple Sclerosis,PROCEDURE: Plasma exchange|DRUG: natalizumab treatment,Biogen,,ALL,ADULT,EARLY_PHASE1,12,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-01,2007-10,2007-10,"Cleveland Clinic Mellen Center for MS, Cleveland, Ohio, 44195, United States|Center for Neurological Disorders, Aurora Health Care, Milwaukee, Wisconsin, 53201-0342, United States"
NCT01181089,Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS),https://beta.clinicaltrials.gov/study/NCT01181089,WITHDRAWN,Secondary Progressive Multiple Sclerosis,BIOLOGICAL: Placebo|BIOLOGICAL: Baminercept,Biogen,,ALL,ADULT,PHASE1|PHASE2,0,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2010-09,,,
NCT04212689,Virtual Reality Approach in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04212689,UNKNOWN,Rehabilitation|Multiple Sclerosis,DEVICE: Game Based Virtual Reality Exercises|OTHER: Conventional Physiotherapy and Rehabilitation,Marmara University,,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-01-20,2021-06-01,2021-06-01,"Cadde Tıp Merkezi - Cadde Medical Center, Istanbul, Turkey"
NCT05345288,Effect of Computerized Cognitive Training in Persons With MS,https://beta.clinicaltrials.gov/study/NCT05345288,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DEVICE: BrainHQ cognitive training|DEVICE: BrainHQ control games,University of Nebraska,,ALL,ADULT,NA,53,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2022-06-28,2022-10-21,2022-10-21,"University of Nebraska Medical Center, Omaha, Nebraska, 68198, United States"
NCT02517788,Phase I BP Interferon (IFN) Beta-004,https://beta.clinicaltrials.gov/study/NCT02517788,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Interferon beta-1a HSA-free biosimilar|DRUG: Interferon beta-1a HSA+ biosimilar|DRUG: Interferon beta-1a original,Centre Hospitalier Universitaire Vaudois,BioPartners GmbH,ALL,ADULT,PHASE1,24,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2006-05,2006-07,2006-07,
NCT04459988,Mechanistic Study of Ocrevus,https://beta.clinicaltrials.gov/study/NCT04459988,RECRUITING,Multiple Sclerosis,DRUG: Ocrelizumab,University of Michigan,,ALL,"ADULT, OLDER_ADULT",,35,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-07-01,2023-07,2023-07,"University of Michigan, Ann Arbor, Michigan, 48109, United States"
NCT01259388,A Pilot Study of Lithium in Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01259388,COMPLETED,Multiple Sclerosis,DRUG: Lithium Carbonate,VA Office of Research and Development,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,23,FED,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2011-05,2015-08,2015-12,"Birmingham VA Medical Center, Birmingham, AL, Birmingham, Alabama, 35233, United States|Kirklin Clinic, Birmingham, Alabama, 35233, United States"
NCT01450488,Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01450488,COMPLETED,Multiple Sclerosis,DRUG: masitinib|DRUG: masitinib,AB Science,,ALL,ADULT,PHASE2,35,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2005-06,2007-07,2010-01,
NCT00039988,Treatment of Multiple Sclerosis With Copaxone and Albuterol,https://beta.clinicaltrials.gov/study/NCT00039988,COMPLETED,Autoimmune Diseases|Multiple Sclerosis,DRUG: Glatiramer acetate|DRUG: Albuterol|DRUG: Albuterol placebo,National Institute of Allergy and Infectious Diseases (NIAID),Autoimmunity Centers of Excellence,ALL,ADULT,NA,40,NIH,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2001-11,2006-03,2007-11,"Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts, 02115, United States"
NCT03999788,miR-142-3p as Potential Biomarker of Synaptopathy in MS,https://beta.clinicaltrials.gov/study/NCT03999788,RECRUITING,Multiple Sclerosis|Spasticity,PROCEDURE: lumbar puncture and blood withdrawal|PROCEDURE: Intermittent theta burst stimulation (iTBS) therapeutic protocol for spasticity,Neuromed IRCCS,,ALL,"ADULT, OLDER_ADULT",NA,1000,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2019-12-10,2023-12-28,2025-12-28,"IRCCS Neuromed, Pozzilli, Isernia, 86077, Italy"
NCT05290688,Cellular microRNA Signatures in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05290688,NOT_YET_RECRUITING,"Multiple Sclerosis, Relapsing-Remitting",GENETIC: 50 ml blodd sampling,Institut Pasteur,Höpital La Pitié-Salpêtrière,ALL,ADULT,NA,20,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2022-09-15,2024-09-15,2024-09-15,"Hôpital La Pitié - Salpêtrière, Paris, 75013, France"
NCT03824938,Aspirin for Exercise in Multiple Sclerosis (ASPIRE),https://beta.clinicaltrials.gov/study/NCT03824938,COMPLETED,Multiple Sclerosis,DRUG: Aspirin 650mg Oral Capsule|DRUG: Acetaminophen Tablet 650mg|OTHER: Placebo,Columbia University,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),ALL,"ADULT, OLDER_ADULT",PHASE3,60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2019-04-30,2022-02-28,2022-02-28,"Columbia University Irving Medical Center, New York, New York, 10032, United States"
NCT00097188,A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00097188,COMPLETED,Multiple Sclerosis,DRUG: rituximab,"Genentech, Inc.",,ALL,ADULT,PHASE2,104,INDUSTRY,INTERVENTIONAL,Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT,2004-12,,2006-12,"Phoenix Neurological Associates, Phoenix, Arizona, 85006, United States|Loma Linda University, Loma Linda, California, 92354, United States|Sutter Gould Medical Foundation, Modesto, California, 95355, United States|University Of California At Davis, Sacramento, California, 95817, United States|Neurological Research Institute Of East Bay, Walnut Creek, California, 94596, United States|Neurology Associates, P.A., Maitland, Florida, 32751, United States|Multiple Sclerosis Center of Brevard, Melbourne, Florida, 32940, United States|Neurological Services Of Orlando, Orlando, Florida, 32806, United States|Neurological Associates, Pompano Beach, Florida, 33060, United States|MS Center of Vero Beach, Vero Beach, Florida, 32960, United States|MS Center Of Atlanta, Atlanta, Georgia, 30327, United States|Medical College of Georgia, Augusta, Georgia, 30912, United States|University Of Kansas Medical Center, Kansas City, Kansas, 66160, United States|Kentucky Neuroscience Research, Louisville, Kentucky, 40202, United States|University of Maryland Hospital MS Center, Baltimore, Maryland, 21201, United States|Michigan Institute For Neurological Disorders, Farmington Hills, Michigan, 48334, United States|Deaconess Billings Clinical Research Division, Billings, Montana, 59101, United States|Albany Medical Center, Albany, New York, 12208, United States|Meritcare Neuroscience Clinic, Fargo, North Dakota, 58103, United States|Neurology and Neuroscience Assoc.,INC, Akron, Ohio, 44302, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States|The Ohio State University, Columbus, Ohio, 43221, United States|Geisinger Medical Center, Danville, Pennsylvania, 17822, United States|University Of Pennsylvania Medical Center, Philadelphia, Pennsylvania, 19104, United States|Neurology Specialists of Dallas, PA, Dallas, Texas, 75231, United States|Maxine Mesinger MS Clinic/ Baylor College of Medicine, Houston, Texas, 77030, United States|Neurology Clinic of San Antonio, San Antonio, Texas, 78229, United States|Virginia Mason Medical Center, Seattle, Washington, 98101, United States|Holy Family MS Center, Spokane, Washington, 99208, United States|Neurology and Neurosurgery Associates of Tacoma, Inc., P.S., Tacoma, Washington, 98405, United States|St. Luke's Medical Center/Center for Neurological Disorders, Milwaukee, Wisconsin, 53215, United States"
NCT02339688,Psychometric Properties Mobility Measures MS,https://beta.clinicaltrials.gov/study/NCT02339688,COMPLETED,Multiple Sclerosis,OTHER: conventional MS rehabilitation,Hasselt University,"Dept Neurological Rehabilitation Reha Zentrum Münster Gröben|National MS Center Melsbroek|Revalidatie & MS Centrum Overpelt|De Mick|Charles University, Czech Republic|Danish MS Hospitals, Haslev and Ry|Masku Neurological Rehabilitation Center|Quellenhof|Fondazione Don Carlo Gnocchi Onlus|Italian Multiple Sclerosis Foundation|Sheba Medical Center|MS-Senteret Hakadal|Haukeland University Hospital|MS Rehabilitation Center Borne Sulinowo|Clinical center Belgrado|Eugenia Epalza Rehabilitation Center, Bilbao, Spain|Cleveland Mellen MS Center|University of Colorado - Anschutz Medical Campus|Queen's University|Shepherd Center Atlanta|St. Louis University",ALL,"ADULT, OLDER_ADULT",NA,254,OTHER,INTERVENTIONAL,"Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: ",2014-10,2015-12,2016-06,"Hasselt University, Diepenbeek, 3590, Belgium"
NCT02815878,Enhance Wellness for Individuals With Long-Term Physical Disabilities,https://beta.clinicaltrials.gov/study/NCT02815878,COMPLETED,Multiple Sclerosis|Muscular Dystrophy|Post-polio Syndrome|Spinal Cord Injury,BEHAVIORAL: Enhance Wellness,University of Washington,,ALL,"ADULT, OLDER_ADULT",NA,240,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2014-05-12,2017-11,2017-11,"University of Washington, Seattle, Washington, 98195, United States"
NCT01774123,Optical Coherence Tomography in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT01774123,COMPLETED,Multiple Sclerosis|Optic Neuritis,,The Cleveland Clinic,,ALL,"ADULT, OLDER_ADULT",,78,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-08,2013-06,2013-06,"Cole Eye Institute, Cleveland, Ohio, 44195, United States"
NCT04125823,Video Game-based Physical Activity Training in People With Multiple Sclerosis During Relapse Treatment,https://beta.clinicaltrials.gov/study/NCT04125823,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Video game-based physical activity training|BEHAVIORAL: Conventional physiotherapy program,Dokuz Eylul University,,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2019-10-23,2022-01-15,2022-02-15,"Dokuz Eylul University Hospital, Neurology Department, Izmir, 35430, Turkey"
NCT02664623,Personalized Nutrition Advice for Optimizing Dietary Calcium Intake in MS Patients,https://beta.clinicaltrials.gov/study/NCT02664623,COMPLETED,Multiple Sclerosis,PROCEDURE: Individual dietary consultations|PROCEDURE: Dietary advice sheet,Centre Hospitalier Universitaire de Nīmes,,ALL,"ADULT, OLDER_ADULT",NA,182,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2016-07-13,2020-01-06,2020-01-06,"CH d'Alès, Alès, 30103, France|CHRU de Nîmes - Hôpital Universitaire Carémeau, Nîmes Cedex 09, 30029, France"
NCT00510523,Whole Body Vibration Therapy in Participants With MS Related Balance Deficits,https://beta.clinicaltrials.gov/study/NCT00510523,COMPLETED,Multiple Sclerosis,DEVICE: Whole Body Vibration machine,Logan College of Chiropractic,,ALL,"ADULT, OLDER_ADULT",NA,80,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE|Primary Purpose: TREATMENT,2006-10,,2007-11,"Logan University, College of Chiropractic, Chesterfield, Missouri, 63017, United States|Logan University, College of Chirpractic, Chesterfield, Missouri, 63017, United States"
NCT04771858,Digital Gait Analysis in the Home Environment of Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04771858,RECRUITING,Multiple Sclerosis,,Medical Valley Digital Health Application Center GmbH,Celgene Corporation|NeuroSys GmbH|Fraunhofer Institute for Integrated Circuits IIS|Portabiles HealthCare Technologies GmbH|University of Regensburg,ALL,"ADULT, OLDER_ADULT",,70,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-03-09,2023-02,2023-02,"Department of Neurology, University of Regensburg, Regensburg, Bavaria, 93053, Germany"
NCT01257958,Vitamin D Pilot Study in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01257958,COMPLETED,Relapsing Remitting Multiple Sclerosis,DRUG: 19 nor vitamin d,"University of Wisconsin, Madison",,ALL,ADULT,PHASE1,,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: |Primary Purpose: TREATMENT,1998-02,2000-02,2000-06,"UW-Madison, Madison, Wisconsin, 53792, United States"
NCT03822858,Expanded Access to Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03822858,NO_LONGER_AVAILABLE,Multiple Sclerosis,DRUG: Intrathecal MSC-NP injection,Tisch Multiple Sclerosis Research Center of New York,,ALL,"ADULT, OLDER_ADULT",,,OTHER,EXPANDED_ACCESS,,,,,"Tisch MS Research Center of New York, New York, New York, 10019, United States"
NCT02048358,"Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients",https://beta.clinicaltrials.gov/study/NCT02048358,TERMINATED,Healthy Volunteers|Multiple Sclerosis,DRUG: 2B3-201|DRUG: Placebo|DRUG: Methylprednisolone hemisuccinate,BBB-Therapeutics B.V.,,ALL,"ADULT, OLDER_ADULT",PHASE1,47,INDUSTRY,INTERVENTIONAL,"Allocation: |Intervention Model: |Masking: |Primary Purpose: ",2013-11,2015-01,2015-02,"VUmc, PET and neurology clinical research unit, Amsterdam, Noord-Holland, 1081 HV, Netherlands|Centre for Human Drug Research (CHDR), Leiden, 2333 CH, Netherlands"
NCT03179423,Clinical Trial Assessing the GNbAC1 in Patients With Onset of Type 1 Diabetes Within 4 Years,https://beta.clinicaltrials.gov/study/NCT03179423,COMPLETED,Diabetes Mellitus Type 1,DRUG: GNbAC1|DRUG: Placebo,GeNeuro Australia PTY Ltd,Southern Star Research Pty Ltd.,ALL,ADULT,PHASE2,64,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-06-14,2018-09-01,2019-05-07,"Macquarie University Hospital, Macquarie University, New South Wales, Australia|AIM Centre, Merewether, New South Wales, Australia|Northern Sydney Local Health District - Royal North Shore Hospital, St Leonards, New South Wales, Australia|Ipswich Research Centre, Ipswich, Queensland, Australia|Mater Misericordiae Ltd and Mater Medical Research Institute Limited, South Brisbane, Queensland, Australia|Gold Coast Hospital and Health Service, Southport, Queensland, Australia|Southern Adelaide Local Health Network - Repatriation General Hospital, Adelaide, South Australia, Australia|Northern Adelaide Local Health Network Incorporated, operating as Lyell McEwin Hospital, Elizabeth Vale, South Australia, Australia|Eastern Health, Box Hill, Victoria, Australia|St Vincent's Hospital (Melbourne) Limited, Fitzroy, Victoria, Australia|Barwon Health - University of Geelong, Geelong, Victoria, Australia|Heidelberg Repatriation Hospital, Heidelberg, Victoria, Australia|Keogh Institute of Medical Research, Nedlands, Western Australia, Australia"
NCT02959658,Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02959658,COMPLETED,Primary Progressive Multiple Sclerosis,DRUG: Dimethyl fumarate|DRUG: Placebo,"Rigshospitalet, Denmark",Biogen,ALL,"ADULT, OLDER_ADULT",PHASE2,54,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-12,2019-12-21,2020-12-09,"Danish Multiple Sclerosis Center, Department of neurology, Copenhagen, 2100, Denmark"
NCT01424423,NOGO-A in Multiple Sclerosis FTIH,https://beta.clinicaltrials.gov/study/NCT01424423,TERMINATED,Multiple Sclerosis,DRUG: Placebo|DRUG: GSK1223249,GlaxoSmithKline,,ALL,ADULT,PHASE1,3,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2010-02-11,2010-08-26,2010-08-26,"GSK Investigational Site, Heidelberg, Victoria, VIC 3084, Australia"
NCT02846558,A Pragmatic Trial of Dietary Programs in People With Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT02846558,COMPLETED,Multiple Sclerosis,OTHER: Frequent Patient Interaction|BEHAVIORAL: Timing Restriction|DEVICE: LoseIt! Smartphone Application,Johns Hopkins University,,ALL,"ADULT, OLDER_ADULT",NA,54,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2016-08,2017-06,2017-07,
NCT05103358,Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1),https://beta.clinicaltrials.gov/study/NCT05103358,RECRUITING,"Tumor|Tumor, Solid|Metastasis|Metastatic Cancer|Cancer|Cancer Metastatic|Tumors|Neoplasms|Neoplasm Metastasis|Solid Tumor|Advanced Solid Tumor|Advanced Cancer|Malignant Solid Tumor|Malignant Solid Neoplasm|Malignant Neoplasm|Malignant Tumor|TSC|TSC1|TSC2|Metastatic Solid Tumor|Metastatic Neoplasm",DRUG: nab-sirolimus,"Aadi Bioscience, Inc.",,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,120,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-02-15,2024-12-31,2025-12-31,"Southern Cancer Center, Mobile, Alabama, 36607, United States|Arizona Oncology Associates, Prescott Valley, Arizona, 86314, United States|City of Hope, Duarte, California, 91010, United States|St. Joseph Heritage Health - Fullerton, Fullerton, California, 92835, United States|MemorialCare, Long Beach, California, 90806, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, 90033, United States|UCLA - Jonsson Comprehensive Cancer Center, Los Angeles, California, 90095, United States|St Joseph Health Napa, Napa, California, 94558, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, 92663, United States|Sharp HealthCare, San Diego, California, 92123, United States|UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, 94115, United States|Ridley-Tree Cancer Center, Santa Barbara, California, 93105, United States|Sarcoma Oncology Research Center, Santa Monica, California, 90403, United States|St. Joes - Santa Rosa, Santa Rosa, California, 95403, United States|Stanford Cancer Center, Stanford, California, 94305, United States|The Oncology Institute of Hope & Innovation, Whittier, California, 90602, United States|Rocky Mountain Cancer Centers (Williams St), Denver, Colorado, 80218, United States|Hartford Healthcare, Hartford, Connecticut, 06102, United States|Eastern Connecticut Hematology and Oncology, Norwich, Connecticut, 06360, United States|Holy Cross, Fort Lauderdale, Florida, 33308, United States|Florida Cancer Specialists South Division, Fort Myers, Florida, 33901, United States|Cancer Specialists of North Florida, Jacksonville, Florida, 32256, United States|Ocala, Ocala, Florida, 34474, United States|Florida Cancer Specialists and Research Institute - North Division, Saint Petersburg, Florida, 33705, United States|Florida Cancer Specialists - East, West Palm Beach, Florida, 33401, United States|University Cancer & Blood Center, Athens, Georgia, 30607, United States|Hawaii Cancer Center, Honolulu, Hawaii, 96813, United States|Urology of Indiana, Carmel, Indiana, 46032, United States|Fort Wayne, Fort Wayne, Indiana, 46845, United States|Goshen Health, Goshen, Indiana, 46526, United States|Community Health Network, Indianapolis, Indiana, 46250, United States|Beacon Health System, South Bend, Indiana, 46601, United States|Pontchartrain, Hammond, Louisiana, 70403, United States|American Oncology Partners of Maryland PA (Center for Cancer & Blood Disorders), Bethesda, Maryland, 20817, United States|The Center for Cancer and Blood Disorders - Maryland, Bethesda, Maryland, 20817, United States|Frederick Health, Frederick, Maryland, 21702, United States|Maryland Oncology Hematology, Rockville, Maryland, 20850, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Southcoast, Fairhaven, Massachusetts, 02719, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, 48201, United States|Sparrow Health, Lansing, Michigan, 48912, United States|Central Care Cancer Center, Bolivar, Missouri, 65613, United States|Mosaic Life Care, Saint Joseph, Missouri, 64507, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|Oncology Hematology Associates, Springfield, Missouri, 65807, United States|Nebraska Cancer Specialists, Grand Island, Nebraska, 68803, United States|OptumCare Cancer Care-Parent, Las Vegas, Nevada, 89102, United States|New Jersey Cancer Care and Blood Disorders, Belleville, New Jersey, 07109, United States|Englewood Hospital and Medical Center, Englewood, New Jersey, 07631, United States|Summit Medical Group - NJ, Florham Park, New Jersey, 07932, United States|Atlantic Health System - Morristown Medical Center, Morristown, New Jersey, 07960, United States|Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, United States|David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Southeastern, Goldsboro, North Carolina, 27534, United States|Aultman Medical Group, Canton, Ohio, 44708, United States|Good Samaritan Hospital TriHealth, Cincinnati, Ohio, 45220, United States|TriHealth, Cincinnati, Ohio, 45220, United States|University of Cincinnati (UC) - Cancer Institute, Cincinnati, Ohio, 45627, United States|Fred Hutchinson - University Hospitals Cleveland Medical Center - Rainbow Babies, Cleveland, Ohio, 44106, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|OhioHealth, Columbus, Ohio, 43214, United States|The Toledo Clinic, Toledo, Ohio, 43623, United States|Oklahoma State University (OSU) - Stephenson Cancer Center, Oklahoma City, Oklahoma, 73104, United States|Oklahoma Cancer Specialist, Tulsa, Oklahoma, 74146, United States|Gettysburg, Gettysburg, Pennsylvania, 17325, United States|Cancer Care Associates of York - Parent, York, Pennsylvania, 17403, United States|Prisma Health Cancer Institute, Greenville, South Carolina, 29605, United States|Avera Cancer Institute, Sioux Falls, South Dakota, 57105, United States|Sanford Health, Sioux Falls, South Dakota, 57117, United States|Baptist Cancer Center, Memphis, Tennessee, 38120, United States|Sarah Cannon and HCA Research Institute, Nashville, Tennessee, 37203, United States|Mary Crowley Cancer Research, Dallas, Texas, 75230, United States|Texas Oncology-El Paso, El Paso, Texas, 79915, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|Oncology Consultants, Houston, Texas, 77030, United States|Lumi Research, Kingwood, Texas, 77339, United States|South Texas Accelerated Research Therapeutics (START), San Antonio, Texas, 78229, United States|Community Cancer Trials of Utah, Ogden, Utah, 84405, United States|Utah Cancer Specialists, Salt Lake City, Utah, 84106, United States|Virginia Cancer Specialists, Fairfax, Virginia, 22031, United States|Hematology Oncology Associates of Fredericksburg, Fredericksburg, Virginia, 22408, United States|Virginia Cancer Institute, Richmond, Virginia, 23230, United States|Virginia Urology, Richmond, Virginia, 23235, United States|University of Washington Cancer Consortium, Seattle, Washington, 98109, United States|Northwest Medical Specialties, Tacoma, Washington, 98405, United States|ThedaCare, Appleton, Wisconsin, 54911, United States|University of Wisconsin - Carbone Cancer Center, Madison, Wisconsin, 53705, United States|Pan American Center for Oncology Trials, LLC, San Juan, 00935, Puerto Rico"
NCT03919058,Sit Less or Exercise More: Impact on Cardiometabolic Health in MS,https://beta.clinicaltrials.gov/study/NCT03919058,COMPLETED,Multiple Sclerosis,OTHER: Baseline activity (control regime)|OTHER: Increased sitting time (sit regime)|OTHER: Non-exercise physical activity (sit less regime)|OTHER: Structured exercise (exercise regime),Hasselt University,,ALL,"ADULT, OLDER_ADULT",NA,28,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2019-04-13,2021-04-30,2021-04-30,"Hasselt University, Diepenbeek, Limburg, 3590, Belgium"
NCT01954823,Use of an Electronic Diary by People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01954823,UNKNOWN,Multiple Sclerosis,DEVICE: e-diary,Carmel Medical Center,,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2015-09,2016-10,2016-12,"Carmel Medical Center, Haifa, 34362, Israel"
NCT05269628,Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype,https://beta.clinicaltrials.gov/study/NCT05269628,RECRUITING,Multiple Sclerosis|Sleep|Pain,DRUG: Cannabidiol (CBD)|DRUG: Tetrahydrocannabinol (THC)|DRUG: Placebo CBD|DRUG: Placebo THC,"Tiffany J. Braley, MD, MS",National Center for Complementary and Integrative Health (NCCIH),ALL,"ADULT, OLDER_ADULT",PHASE2,166,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2022-03-25,2026-06,2026-06,"University of Michigan, Ann Arbor, Michigan, 48109, United States"
NCT05503628,A Measurement Study of TIS-modNV and AccuGait Force Platform in People With MS,https://beta.clinicaltrials.gov/study/NCT05503628,NOT_YET_RECRUITING,Multiple Sclerosis,,Nordlandssykehuset HF,Nord University|Helse Nord,ALL,"ADULT, OLDER_ADULT",,60,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-08-15,2023-01-01,2023-01-01,"Nordland Hospital Trust, Bodø, 8000, Norway"
NCT05663541,Validity and Reliability of Lower Extremity Position Test in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05663541,ACTIVE_NOT_RECRUITING,Multiple Sclerosis|Sensory Impairments|Proprioceptive Disorders|Validity|Reliability,DIAGNOSTIC_TEST: Lower extremity position test,Pamukkale University,,ALL,"ADULT, OLDER_ADULT",,90,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-10-24,2023-06,2023-07,"Romatem Bursa Fizik Tedavi ve Rehabilitasyon Hastanesi, Bursa, Turkey"
NCT04038541,Prebiotic vs Probiotic in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04038541,RECRUITING,Multiple Sclerosis|Clinically Isolated Syndrome (CIS),DIETARY_SUPPLEMENT: Prebiotics (Prebiotin Prebiotic Fiber Stick Pac)|DIETARY_SUPPLEMENT: Probiotics (Visbiome®),Columbia University,National Multiple Sclerosis Society|Exegi Pharma,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER,2020-03-11,2023-12,2023-12,"Columbia University Irving Medical Center, New York, New York, 10032, United States|University of Pittsburg, Pittsburgh, Pennsylvania, 15260, United States"
NCT00784836,Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients,https://beta.clinicaltrials.gov/study/NCT00784836,TERMINATED,Multiple Sclerosis,DRUG: BG9418 (interferon beta 1-a),Biogen,,ALL,ADULT,PHASE3,3,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2008-10,2009-02,2009-02,"Henry Ford Hospital, Detroit, Michigan, 48202, United States|MS Center at Texas Neurology, Dallas, Texas, 75214, United States"
NCT00978536,"A Monocenter, Cross-sectional Study to Compare Different Type of Cognitive Impairment in Multiple Sclerosis Patients and Cerebrospinal Fluid Biomarkers (Beta Amyloid, Total Tau Protein and Tau-phosphorylated Protein).",https://beta.clinicaltrials.gov/study/NCT00978536,TERMINATED,Disseminated Sclerosis,OTHER: Cognitive impairment of multiple sclerosis,Nantes University Hospital,,ALL,"CHILD, ADULT, OLDER_ADULT",NA,29,OTHER,INTERVENTIONAL,"Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: ",2009-02,2011-11,2011-11,"CHU de Nantes, Nantes, 44093, France"
NCT01947036,T and B Cell Responses in Autoimmune Diseases,https://beta.clinicaltrials.gov/study/NCT01947036,TERMINATED,"Type 1 Diabetes Mellitus|Multiple Sclerosis|Arthritis, Rheumatoid|Crohn's Disease|Psoriasis",,National Institute of Allergy and Infectious Diseases (NIAID),Autoimmunity Centers of Excellence,ALL,"CHILD, ADULT",,68,NIH,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-01,2015-10,2015-10,"Yale University, New Haven, Connecticut, 06511, United States|Emory University, Atlanta, Georgia, 30322, United States|Feinstein Institute for Medical Research, Manhasset, New York, 11030, United States|University of Rochester, Rochester, New York, 14642, United States|Oklahoma Medical Research Foundation, Oklahoma City,, Oklahoma, 73104, United States|Baylor Institute of Immunology Research - Clinical Rheumatology, Dallas, Texas, 75204, United States"
NCT05826028,Mayzent (Siponimod) Onboarding of Secondary Progressive Multiple Sclerosis (SPMS) Patients With MSGo,https://beta.clinicaltrials.gov/study/NCT05826028,COMPLETED,Secondary Progressive Multiple Sclerosis,,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",,368,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-07-09,2022-04-20,2022-04-20,"Novartis Investigational Site, Camperdown, New South Wales, 2050, Australia|Novartis Investigational Site, St Leonards, New South Wales, 2065, Australia"
NCT00338741,Rebif® Pregnancy Registry,https://beta.clinicaltrials.gov/study/NCT00338741,COMPLETED,Multiple Sclerosis,,EMD Serono,Pfizer,FEMALE,"ADULT, OLDER_ADULT",,36,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2002-12,2007-10,2008-02,"Local Medical Information Office, Rockland, Massachusetts, 02370, United States"
NCT03364036,Evaluation of the Onset of Action in Highly Active MS (MAGNIFY),https://beta.clinicaltrials.gov/study/NCT03364036,COMPLETED,Multiple Sclerosis,DRUG: Mavenclad®,"Merck KGaA, Darmstadt, Germany",,ALL,"ADULT, OLDER_ADULT",PHASE4,270,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-05-28,2020-05-05,2022-02-21,"Liverpool Hospital, Sydney, New South Wales, 2170, Australia|John Hunter Hospital, Hunter Region Mail Centre, 2310-2305, Australia|Perron Institute - Neurology, Nedlands, 6009, Australia|The Alfred Hospital, Prahran, 3181, Australia|Klagenfurt1, Klagenfurt am Wörthersee, 9020, Austria|Paracelsus Medical University Salzburg, Salzburg, 5020, Austria|MS Clinical Trials Group, Vancouver, British Columbia, V6T 1Z3, Canada|UB - State University of New York, London, Ontario, N6A 5A5, Canada|University of Alberta, Edmonton, T6G 2G3, Canada|Montreal Neurological Hospital, Montreal, H3A 2B4, Canada|Nemocnice Pardubickeho kraje, a.s. Pardubicka nemocnice, Pardubice, Pardubický Kraj, 532 03, Czechia|Fakultni nemocnice Brno, Brno-Bohunice, 630 00, Czechia|Fakultni nemocnice u sv. Anny v Brne, Brno, 65691, Czechia|FN Hradec Kralove, Chocen, 56501, Czechia|Fakultni nemocnice v Motole, Praha 5, 15006, Czechia|Helsinki University Central Hospital, Helsinki, Finland|FinnMedi Oy vastaanotto - Finn-Medi 3, Tampere, 33520, Finland|Turku University Hospital, Turku, 20521, Finland|CHU de Pontchaillou, Rennes cedex 09, Ille Et Vilaine, 35033, France|CHRU de Lille, Lille cedex, 59037, France|CHU Nice - Hôpital Pasteur, NICE Cedex 1, 06002, France|CHU Nîmes, Nimes Cedex, 30029, France|CHU Montpellier-Nîmes - Hôpital Caremeau, Nimes, 30004, France|CHU de Poissy, Poissy Cedex, 78303, France|Hôpital Civil, Strasbourg, 67091, France|Universitätsklinikum Bonn, Bonn, 53105, Germany|Universitätsklinikum Carl Gustav Carus, Dresden, 01307, Germany|Neuro Centrum Science GmbH, Erbach, Germany|Universitätsklinikum Essen, Essen, Germany|Neurologische Praxis Eppendorf, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, 30625, Germany|Universitätsklinikum Leipzig, Leipzig, 04103, Germany|Universitätsklinikum Münster, Munster, 48149, Germany|Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpo, Szeged, 6701, Hungary|Barzilai Medical Center, Ashkelon, 78306, Israel|Rambam MC, Haifa, 31096, Israel|The Chaim Sheba Medical Center, Tel-Hashomer, 52621, Israel|Policlinico Universitario SS Annunziata, Chieti, Italy|Seconda Univesità degli Studi di Napoli, AOU, Napoli, 80131, Italy|IRCSS Neuromed Istituto Neurologico Mediterraneo, Roma, 133, Italy|Universita di SIENA, Siena, 53100, Italy|Indywidualna Praktyka Lekarska Prof. Konrad Rejdak, Lublin, Lubelskie, 20-954, Poland|Samodzielny Publiczny Szpital Kliniczny nr 7 SUM, Katowice, 40-662, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1 im. Prof. Stanislawa Szyszko SUM w Katowicach, Zabrze, 41-800, Poland|Hospital de Cruces, Baracaldo Vizcaya, Vizcaya, 48903, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Madrid, 28035, Spain|Hospital Clinico San Carlos, Madrid, 28046, Spain|Hospital Vithas NISA Sevilla, Sevilla, 41009, Spain|Hospital La Fe, Valencia, 46009, Spain|Sahlgrenska Universitetssjukhus, Göteborg, 416 85, Sweden|Akademiskt Specialist Centrum - Centrum för Neurologi, plan 5, Stockholm, 171 76, Sweden|University Hospital of Wales, Cardiff, Wales, CF14 4XN, United Kingdom|Queen Elizabeth Hospital, Birmingham, B15 2TH, United Kingdom|Sheffield Teaching Hospitals Sheffield, Sheffield, SI0 2JF, United Kingdom"
NCT01780441,Early Biomarkers of Autism in Infants With Tuberous Sclerosis Complex (TSC),https://beta.clinicaltrials.gov/study/NCT01780441,COMPLETED,Tuberous Sclerosis Complex,,Boston Children's Hospital,National Institute of Neurological Disorders and Stroke (NINDS)|Tuberous Sclerosis Alliance,ALL,CHILD,,166,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-01,2019-12,2020-12,"University of Alabama at Birmingham, Birmingham, Alabama, 35294, United States|University of California at Los Angeles, Los Angeles, California, 90095, United States|Boston Children's Hospital, Boston, Massachusetts, 02115, United States|Cincinnati Children's Hospital, Cincinnati, Ohio, 45229, United States|University of Texas at Houston, Houston, Texas, 77030, United States"
NCT01718678,Effect of Melatonin on Multiple Sclerosis Related Fatigue,https://beta.clinicaltrials.gov/study/NCT01718678,COMPLETED,Fatigue,DRUG: Melatonin|DRUG: Placebo,Isfahan University of Medical Sciences,,ALL,ADULT,PHASE2,44,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2012-05,2012-10,2012-10,"Al-zahra university hospital, Isfahan, 7007, Iran, Islamic Republic of"
NCT02686684,Tecfidera Diffusion Tensor Imaging,https://beta.clinicaltrials.gov/study/NCT02686684,COMPLETED,"Multiple Sclerosis, Dimethyl Fumarate, Diffusion Tensor Imaging Magnetic Resonance Imaging",DRUG: Dimethyl fumarate,University at Buffalo,,ALL,"ADULT, OLDER_ADULT",,115,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-11,2016-10,2016-10,
NCT00640328,Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients,https://beta.clinicaltrials.gov/study/NCT00640328,COMPLETED,Multiple Sclerosis,DRUG: Ofatumumab 100|DRUG: Ofatumumab 300|DRUG: Ofatumumab 700|DRUG: Placebo,GlaxoSmithKline,,ALL,ADULT,PHASE2,38,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2008-05,2010-05,2011-10,
NCT00276341,Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00276341,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: EGb 761® (Tanakan®),Ipsen,,ALL,"ADULT, OLDER_ADULT",PHASE3,240,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,2003-08,,,"Centre Hospitalier du Pays d'Aix, Aix en Provence, 13616, France|Hôpital Nord - CHU d'Amiens, Amiens, 80054, France|Hôpital J. Minjoz, Besancon, 25030, France|CHU de Bordeaux, Bordeaux, 33076, France|Groupe Hospitalier Pellegrin, Bordeaux, 33076, France|Hôpital de la cavale Blanche, Brest, 29609, France|Hôpital Neurologique, Bron, 69500, France|Hopital Nord, Cebazat, 63118, France|CHU Hôpital Gabriel Montpied, Clermont-Ferrand, 63003, France|Hôpital Civil de Colmar, Colmar, 68024, France|Hôpital Henri Mondor, Creteil, 94010, France|14 bis Rue du Chapeau Rouge, Dijon, 21000, France|CHG Dijon, Dijon, 21033, France|Centre Hospitalier, Gonesse, 95503, France|Hôpital Universitaire Dupuytren, Limoges, 87042, France|Centre Hospitalier François, Mantes La Jolie, 78200, France|Hôpital Saint Joseph, Marseille, 13008, France|Hôpital Gui de Chauliac, Montpellier, 34295, France|Hôpital Central, Nancy, 54035, France|Hôpital Guillaume et Réne, Nantes, 44093, France|Hôpital Pasteur, Nice, 06002, France|Hôpital Léopold Bellan, Paris, 75014, France|Hôpital Saint Joseph, Paris, 75014, France|Centre Hospitalier René Dubos, Pontoise, 95303, France|Hôpital Laënnec, Quimper, 29107, France|CHU de Reims - Hôpital Maison Blanche, Reims, 51092, France|CHU Hôpital de Pontchaillou, Rennes, 35033, France|Hôpital Charles Nicolle, Rouen, 76031, France|Cabinet Médical, Rouen, 76100, France|Hôpital Delafontaine, Saint Denis, 93205, France"
NCT01006941,Trichuris Suis Ova Therapy for Relapsing Multiple Sclerosis - a Safety Study,https://beta.clinicaltrials.gov/study/NCT01006941,COMPLETED,Relapsing Multiple Sclerosis,BIOLOGICAL: Trichuris suis ova,"Rigshospitalet, Denmark","University of Copenhagen|Statens Serum Institut|Copenhagen University Hospital, Hvidovre|OvaMed GmbH",ALL,ADULT,PHASE2,10,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2010-05,2011-01,2011-09,"Danish Multiple Sclerosis Center, Rigshospitalet, Copenhagen, 2100, Denmark"
NCT02511028,"In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance Imaging",https://beta.clinicaltrials.gov/study/NCT02511028,COMPLETED,Multiple Sclerosis,DRUG: Ferumoxytol,National Institute of Neurological Disorders and Stroke (NINDS),National Institutes of Health Clinical Center (CC),ALL,"ADULT, OLDER_ADULT",PHASE1,14,NIH,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2015-11-27,2018-08-01,2019-01-29,"National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States"
NCT04711941,A ToM Training for People With Multiple Sclerosis: an Efficacy Study.,https://beta.clinicaltrials.gov/study/NCT04711941,UNKNOWN,Multiple Sclerosis,BEHAVIORAL: Rehabilitation training,Fondazione Don Carlo Gnocchi Onlus,,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-02-01,2021-05,2021-09,"IRCCS Fondazione Don Carlo Gnocchi, Milan, Italy"
NCT03574428,Single Ascending Doses Study With GNbAC1 in Healthy Male Volunteers,https://beta.clinicaltrials.gov/study/NCT03574428,COMPLETED,Multiple Sclerosis,DRUG: GNbAC1|OTHER: GNbAC1 Placebo,GeNeuro Australia PTY Ltd,,MALE,ADULT,PHASE1,24,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-05-08,2018-11-02,2018-11-02,"Scientia Clinical Research Ltd, Sydney, New South Wales, 2031, Australia"
NCT03493841,Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03493841,COMPLETED,Multiple Sclerosis|Progressive Multiple Sclerosis|Secondary Progressive Multiple Sclerosis|Primary Progressive Multiple Sclerosis,DRUG: Alpha Lipoic Acid,Rebecca Spain,,ALL,"ADULT, OLDER_ADULT",PHASE1,20,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-06-08,2019-01-25,2019-01-25,"Oregon Health & Science University, Portland, Oregon, 97239, United States"
NCT05369741,"TIME™ at Home Feasibility Study: Evaluation of a Virtually Delivered, Community-based, Task-oriented Exercise Program",https://beta.clinicaltrials.gov/study/NCT05369741,RECRUITING,Mobility Limitation|Balance Impairment,OTHER: TIME™ at Home,University of Toronto,"March of Dimes, Canada",ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-01-22,2022-07-31,2022-07-31,"March of Dimes Canada (Halifax), Halifax, Nova Scotia, B3L 2C2, Canada|March of Dimes Canada (Toronto), Toronto, Ontario, M5S 1W8, Canada"
NCT05265728,"A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT05265728,RECRUITING,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Natalizumab,Biogen,,ALL,"ADULT, OLDER_ADULT",PHASE3,20,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-04-26,2023-04-26,2024-05-27,"Juntendo University Hospital, Bunkyo-ku, 113-8431, Japan|Chiba University Hospital, Chiba-shi, 260-8677, Japan|St.Marianna University Hospital, Kawasaki-shi, 216-8511, Japan|National Center of Neurology and Psychiatry, Kodaira-shi, 187-8551, Japan|Kansai Medical University Medical Center, Moriguchi-shi, 570-8507, Japan|Tokyo Metropolitan Hospital Organization Tokyo Metropolitan Ebara Hospital, Ota-ku, 145-0065, Japan|The Kitasato Institute Kitasato University Hospital, Sagamihara-shi, 252-0375, Japan|National Hospital Organization Hokkaido Medical Center, Sapporo-shi, 063-0005, Japan|Tohoku Medical and Pharmaceutical University Hospital, Sendai-shi, 983-8512, Japan|Osaka University Hospital, Suita-shi, 565-0871, Japan|University of Tsukuba Hospital, Tsukuba-shi, 305-8576, Japan|Tokyo Women's Medical University Yachiyo Medical Center, Yachiyo-shi, 276-8524, Japan"
NCT01272128,Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL Study,https://beta.clinicaltrials.gov/study/NCT01272128,COMPLETED,Multiple Sclerosis,DRUG: Interferon beta-1a,Biogen,,ALL,"ADULT, OLDER_ADULT",,100,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-12,2014-09,2015-09,"Research Site, Bonheiden, Antwerp, 2820, Belgium|Research Site, Middelheim, Antwerp, 2020, Belgium|Research Site, Ottignies, Brabant Wallon, 1340, Belgium|Research Site, Woluwe, Bruxelles, 1200, Belgium|Research Site, Aalst, East Flanders, 9300, Belgium|Research Site, St Niklaas, East Flanders, 9100, Belgium|Research Site, Tielt, East Flanders, 8700, Belgium|Research Site, Baudour, Hainaut, 7331, Belgium|Research Site, Charleroi, Hainaut, 6000, Belgium|Research Site, Charleroi, Hainaut, 6042, Belgium|Research Site, La Louvière, Hainaut, 7100, Belgium|Research Site, Tournai, Hainaut, 7500, Belgium|Research Site, Hasselt, Limburg, 3500, Belgium|Research Site, Verviers, Liège, 4800, Belgium|Research Site, Libramont, Luxembourg, 6800, Belgium|Research Site, Sijsele, West Flanders, 8340, Belgium|Research Site, Liège, 4000, Belgium"
NCT03606460,A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS),https://beta.clinicaltrials.gov/study/NCT03606460,COMPLETED,Multiple Sclerosis,DRUG: Ocrelizumab Dose 1|DRUG: Ocrelizumab Dose 2 and Dose 3,"Genentech, Inc.",,ALL,ADULT,PHASE3,141,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-09-14,2019-05-31,2019-05-31,"University of Colorado; Anschutz Medical Campus Department of Neurology, Aurora, Colorado, 80045, United States|Dragonfly Research, LLC, Wellesley, Massachusetts, 02481, United States|Cleveland Clinic Fndn, Cleveland, Ohio, 44195, United States|Ohio Health Research Institute Grant Medical Center, Columbus, Ohio, 43215, United States|Oklahoma Medical Research Foundation; MS Center of Excellence, Oklahoma City, Oklahoma, 73104, United States"
NCT05641532,Physical Activity in Persons Newly Diagnosed With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05641532,ACTIVE_NOT_RECRUITING,Multiple Sclerosis (MS),BEHAVIORAL: Physical activity behavioral intervention in persons newly diagnosed with MS,University of Alabama at Birmingham,,ALL,"ADULT, OLDER_ADULT",NA,16,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2023-01-17,2023-08,2023-12,"University of Alabama at Birmingham, Birmingham, Alabama, 35205, United States"
NCT05199402,Clinical Trial Data Set Re-use With Statistical Methodologies Tailored for Clinical Trials in Rare Diseases,https://beta.clinicaltrials.gov/study/NCT05199402,RECRUITING,Tuberous Sclerosis|Epilepsy,,Imagine Institute,RWTH Aachen University|Ruhr University of Bochum|Medical University of Warsaw,ALL,CHILD,,35,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-07-01,2022-03-31,2023-10-01,"Rima Nabbout, Paris, 75015, France"
NCT05654818,Peripheral Immunological Effects of High-dose Vitamin D Treatment in Healthy Subjects,https://beta.clinicaltrials.gov/study/NCT05654818,RECRUITING,Vitamin d Deficiency,DRUG: Vitamin D|DRUG: Placebo,Centre Hospitalier Universitaire de Nīmes,,ALL,"ADULT, OLDER_ADULT",NA,56,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2023-04-13,2024-07,2024-07,"CHU de Nîmes, Nîmes, France"
NCT03736902,Views on Physical Activity Following a Relapse in People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03736902,COMPLETED,Multiple Sclerosis,OTHER: Qualitative semi structured interview,"City, University of London",University College London Hospitals,ALL,"ADULT, OLDER_ADULT",,15,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-11-13,2019-05-14,2019-09-30,"University College London Hospitals, London, Greater London, WC1N 3BG, United Kingdom"
NCT05563402,"""Evaluation of Usability and Safety of the Self-balancing Walking System Atalante in Patients With Multiple Sclerosis""",https://beta.clinicaltrials.gov/study/NCT05563402,RECRUITING,Multiple Sclerosis|Ataxia|Paraplegia,DEVICE: Atalante,Multiple Sclerosis Center of Catalonia,,ALL,"CHILD, ADULT, OLDER_ADULT",NA,15,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-09-20,2022-12-20,2023-03-30,"Centre d'Esclerosi Mútiple de Catalunya (Cemcat) - Barcelona, Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain"
NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02792218,COMPLETED,Relapsing Multiple Sclerosis,DRUG: Ofatumumab subcutaneous injection|DRUG: Teriflunomide-matching placebo capsules|DRUG: Teriflunomide capsule|DRUG: Matching placebo of ofatumumab subcutaneous injections,Novartis Pharmaceuticals,,ALL,ADULT,PHASE3,930,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-09-20,2019-07-05,2020-07-20,"Novartis Investigative Site, Phoenix, Arizona, 85013, United States|Novartis Investigative Site, Berkeley, California, 94705, United States|Novartis Investigative Site, Fullerton, California, 92835, United States|Novartis Investigative Site, Sacramento, California, 95817, United States|Novartis Investigative Site, Washington, District of Columbia, 20007, United States|Novartis Investigative Site, Atlantis, Florida, 33462-6608, United States|Novartis Investigative Site, Delray Beach, Florida, 33445, United States|Novartis Investigative Site, Hollywood, Florida, 33021, United States|Novartis Investigative Site, Loxahatchee Groves, Florida, 33470, United States|Novartis Investigative Site, Miami, Florida, 33032, United States|Novartis Investigative Site, Miami, Florida, 33136, United States|Novartis Investigative Site, Naples, Florida, 34102, United States|Novartis Investigative Site, North Palm Beach, Florida, 33408, United States|Novartis Investigative Site, Pensacola, Florida, 32514, United States|Novartis Investigative Site, Port Charlotte, Florida, 33952, United States|Novartis Investigative Site, Sunrise, Florida, 33351, United States|Novartis Investigative Site, Vero Beach, Florida, 32960, United States|Novartis Investigative Site, West Palm Beach, Florida, 33407, United States|Novartis Investigative Site, Savannah, Georgia, 31406, United States|Novartis Investigative Site, Honolulu, Hawaii, 96817, United States|Novartis Investigative Site, Chicago, Illinois, 60612, United States|Novartis Investigative Site, Northbrook, Illinois, 60062, United States|Novartis Investigative Site, Indianapolis, Indiana, 46202, United States|Novartis Investigative Site, Des Moines, Iowa, 50314-2611, United States|Novartis Investigative Site, Kansas City, Kansas, 66160, United States|Novartis Investigative Site, Overland Park, Kansas, 66210, United States|Novartis Investigative Site, Alexandria, Louisiana, 71301, United States|Novartis Investigative Site, Baton Rouge, Louisiana, 70810, United States|Novartis Investigative Site, Clinton Township, Michigan, 48035, United States|Novartis Investigative Site, Detroit, Michigan, 48201, United States|Novartis Investigative Site, Golden Valley, Minnesota, 55422, United States|Novartis Investigative Site, Chesterfield, Missouri, 63017, United States|Novartis Investigative Site, Ozark, Missouri, 65721, United States|Novartis Investigative Site, Saint Louis, Missouri, 63110, United States|Novartis Investigative Site, Las Vegas, Nevada, 89106, United States|Novartis Investigative Site, Latham, New York, 12110, United States|Novartis Investigative Site, Charlotte, North Carolina, 28204, United States|Novartis Investigative Site, Raleigh, North Carolina, 27607, United States|Novartis Investigative Site, Winston-Salem, North Carolina, 27103, United States|Novartis Investigative Site, Winston-Salem, North Carolina, 27157, United States|Novartis Investigative Site, Cleveland, Ohio, 44195, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, 73104, United States|Novartis Investigative Site, Spartanburg, South Carolina, 29303, United States|Novartis Investigative Site, Johnson City, Tennessee, 37604, United States|Novartis Investigative Site, Knoxville, Tennessee, 37920, United States|Novartis Investigative Site, Dallas, Texas, 75246, United States|Novartis Investigative Site, El Paso, Texas, 79935, United States|Novartis Investigative Site, Houston, Texas, 77074, United States|Novartis Investigative Site, Round Rock, Texas, 78681, United States|Novartis Investigative Site, San Antonio, Texas, 78229, United States|Novartis Investigative Site, San Antonio, Texas, 78258, United States|Novartis Investigative Site, Virginia Beach, Virginia, 23456, United States|Novartis Investigative Site, Green Bay, Wisconsin, 54311, United States|Novartis Investigative Site, Madison, Wisconsin, 53792, United States|Novartis Investigative Site, Milwaukee, Wisconsin, 53215, United States|Novartis Investigative Site, Neenah, Wisconsin, 54956, United States|Novartis Investigative Site, Rosario, Santa Fe, S2000BZL, Argentina|Novartis Investigative Site, Buenos Aires, 1061, Argentina|Novartis Investigative Site, Cordoba, X5004CDT, Argentina|Novartis Investigative Site, New Lambton Heights, New South Wales, 2305, Australia|Novartis Investigative Site, St Leonards, New South Wales, 2065, Australia|Novartis Investigative Site, Brasschaat, 2930, Belgium|Novartis Investigative Site, Brugge, 8000, Belgium|Novartis Investigative Site, Liege, 4000, Belgium|Novartis Investigative Site, Pelt, 3900, Belgium|Novartis Investigative Site, Plovdiv, 4002, Bulgaria|Novartis Investigative Site, Sofia, 1309, Bulgaria|Novartis Investigative Site, Sofia, 1431, Bulgaria|Novartis Investigative Site, Vancouver, British Columbia, V6T 1Z3, Canada|Novartis Investigative Site, Gatineau, Quebec, J9J 0A5, Canada|Novartis Investigative Site, Montreal, Quebec, H3A 2B4, Canada|Novartis Investigative Site, Quebec, G1J 1Z4, Canada|Novartis Investigative Site, Rijeka, HRV, 51000, Croatia|Novartis Investigative Site, Zagreb, 10000, Croatia|Novartis Investigative Site, Praha 4 Krc, Czech Republic, 140 59, Czechia|Novartis Investigative Site, Hradec Kralove, CZE, 500 05, Czechia|Novartis Investigative Site, Olomouc, CZE, 775 20, Czechia|Novartis Investigative Site, JIhlava, 586 01, Czechia|Novartis Investigative Site, Pardubice, 532 03, Czechia|Novartis Investigative Site, Praha 5, 150 06, Czechia|Novartis Investigative Site, Aarhus, 8000, Denmark|Novartis Investigative Site, Copenhagen, DK-2100, Denmark|Novartis Investigative Site, Odense C, 5000, Denmark|Novartis Investigative Site, Tallinn, 10617, Estonia|Novartis Investigative Site, Tartu, 51014, Estonia|Novartis Investigative Site, Nancy, Cedex, 54035, France|Novartis Investigative Site, Lille Cedex, 59037, France|Novartis Investigative Site, Nantes Cedex 1, 44093, France|Novartis Investigative Site, Nimes Cedex, 30029, France|Novartis Investigative Site, Barsinghausen, 30890, Germany|Novartis Investigative Site, Bayreuth, 95445, Germany|Novartis Investigative Site, Bielefeld, D 33647, Germany|Novartis Investigative Site, Hamburg, 20249, Germany|Novartis Investigative Site, Marburg, 35043, Germany|Novartis Investigative Site, Muenchen, 80377, Germany|Novartis Investigative Site, Muenchen, 81377, Germany|Novartis Investigative Site, Neuburg an der Donau, 86633, Germany|Novartis Investigative Site, Potsdam, 14471, Germany|Novartis Investigative Site, Ulm, 89073, Germany|Novartis Investigative Site, Wiesbaden, 65191, Germany|Novartis Investigative Site, Athens, GR, 115 25, Greece|Novartis Investigative Site, Athens, 115 28, Greece|Novartis Investigative Site, Thessaloniki, GR 54636, Greece|Novartis Investigative Site, Budapest, HUN, 1135, Hungary|Novartis Investigative Site, Budapest, 1106, Hungary|Novartis Investigative Site, Kistarcsa, 2143, Hungary|Novartis Investigative Site, Szeged, 6725, Hungary|Novartis Investigative Site, New Delhi, Delhi, 110017, India|Novartis Investigative Site, Bangalore, Karnataka, 560054, India|Novartis Investigative Site, Kochi, Kerala, 682 026, India|Novartis Investigative Site, Chandigarh, Punjab, 160012, India|Novartis Investigative Site, Kolkata, West Bengal, 700068, India|Novartis Investigative Site, Mangalore, 575018, India|Novartis Investigative Site, Ashkelon, 78278, Israel|Novartis Investigative Site, Haifa, 310 9601, Israel|Novartis Investigative Site, Sefad, 13100, Israel|Novartis Investigative Site, Tel Aviv, 6423906, Israel|Novartis Investigative Site, Milano, MI, 20132, Italy|Novartis Investigative Site, Roma, RM, 00189, Italy|Novartis Investigative Site, Gallarate, VA, 21013, Italy|Novartis Investigative Site, Napoli, 80131, Italy|Novartis Investigative Site, Mexico, Distrito Federal, 03100, Mexico|Novartis Investigative Site, Sittard-Geleen, BG, 6162 BG, Netherlands|Novartis Investigative Site, Amsterdam, 1081 HV, Netherlands|Novartis Investigative Site, Rotterdam, 3015 CE, Netherlands|Novartis Investigative Site, Bydgoszcz, 85-796, Poland|Novartis Investigative Site, Gdansk, 80 952, Poland|Novartis Investigative Site, Gdansk, 80-462, Poland|Novartis Investigative Site, Gdansk, 80-803, Poland|Novartis Investigative Site, Katowice, 40 571, Poland|Novartis Investigative Site, Kielce, 25 726, Poland|Novartis Investigative Site, Lodz, 90 324, Poland|Novartis Investigative Site, Guaynabo, 00968, Puerto Rico|Novartis Investigative Site, Kemerovo, 650066, Russian Federation|Novartis Investigative Site, Moscow, 125367, Russian Federation|Novartis Investigative Site, Nizhny Novgorod, 603155, Russian Federation|Novartis Investigative Site, Novosibirsk, 630007, Russian Federation|Novartis Investigative Site, Saint Petersburg, 194044, Russian Federation|Novartis Investigative Site, Saransk, 430032, Russian Federation|Novartis Investigative Site, Sestroretsk, 197706, Russian Federation|Novartis Investigative Site, Tyumen, 625000, Russian Federation|Novartis Investigative Site, Banska Bystrica, 97517, Slovakia|Novartis Investigative Site, Bratislava, 82606, Slovakia|Novartis Investigative Site, Bratislava, 83305, Slovakia|Novartis Investigative Site, Nitra, 94901, Slovakia|Novartis Investigative Site, Trnava, 917 75, Slovakia|Novartis Investigative Site, Cadiz, Andalucia, 11009, Spain|Novartis Investigative Site, Barcelona, Cataluna, 08026, Spain|Novartis Investigative Site, Barcelona, Cataluna, 08036, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08035, Spain|Novartis Investigative Site, L Hospitalet De Llobregat, Catalunya, 08907, Spain|Novartis Investigative Site, Salt, Cataluña, 17190, Spain|Novartis Investigative Site, El Palmar, Murcia, 30120, Spain|Novartis Investigative Site, Barcelona, 08003, Spain|Novartis Investigative Site, Valencia, 46026, Spain|Novartis Investigative Site, Goeteborg, 413 45, Sweden|Novartis Investigative Site, Stockholm, 102 35, Sweden|Novartis Investigative Site, Basel, 4031, Switzerland|Novartis Investigative Site, Khon Kaen, THA, 40002, Thailand|Novartis Investigative Site, Istanbul, 34147, Turkey|Novartis Investigative Site, Izmir, 35040, Turkey|Novartis Investigative Site, Kocaeli, 41380, Turkey|Novartis Investigative Site, Samsun, 55139, Turkey|Novartis Investigative Site, Headington, Oxfordshire, OX3 9DU, United Kingdom|Novartis Investigative Site, Glasgow, G51 4TF, United Kingdom|Novartis Investigative Site, London, E1 1BB, United Kingdom"
NCT00947232,Motivational Interviewing to Increase Physical Activity to Treat Depression in People Aging With MS or SCI,https://beta.clinicaltrials.gov/study/NCT00947232,COMPLETED,Multiple Sclerosis|Spinal Cord Injury,BEHAVIORAL: Motivational interviewing|BEHAVIORAL: Education,University of Washington,,ALL,"ADULT, OLDER_ADULT",NA,123,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2009-10,2012-12,2013-03,"University of Washington, Seattle, Washington, 98195, United States"
NCT01994018,Correlation Between Relapses in Multiple Sclerosis (MS) and Vitamin D Intake,https://beta.clinicaltrials.gov/study/NCT01994018,COMPLETED,Multiple Sclerosis,,OSF Healthcare System,,ALL,"ADULT, OLDER_ADULT",,100,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-11,2014-06,2014-06,"OSF Saint Francis Medical Center, Peoria, Illinois, 61637, United States"
NCT02428218,Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS),https://beta.clinicaltrials.gov/study/NCT02428218,WITHDRAWN,Relapsing-Remitting Multiple Sclerosis|Relapsing Forms of Multiple Sclerosis,DRUG: dimethyl fumarate|DRUG: Placebo,Biogen,,ALL,CHILD,PHASE3,0,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2016-05,2027-01,2027-01,
NCT01490502,Vitamin D Supplementation in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01490502,COMPLETED,Relapsing Remitting Multiple Sclerosis,DRUG: Vitamin D3,Johns Hopkins University,"Oregon Health and Science University|University of California, San Francisco|Washington University School of Medicine|Icahn School of Medicine at Mount Sinai|University of Pennsylvania|Yale University|The Cleveland Clinic|University of Rochester|Stanford University|University of Virginia|Swedish Medical Center|Anne Arundel Health System Research Institute|Columbia University|University of Massachusetts, Worcester|Dignity Health",ALL,ADULT,PHASE3,172,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-03,2021-05-15,2021-05-15,"Dignity Health Medical Foundation, Carmichael, California, United States|University of California, San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|Yale University, New Haven, Connecticut, United States|Anne Arundel Health System Research Institute, Annapolis, Maryland, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|University of Massachusetts, Worcester, Massachusetts, United States|Washington University St. Louis, Saint Louis, Missouri, United States|Columbia University, New York, New York, 10032, United States|Mount Sinai School of Medicine, New York, New York, United States|University of Rochester, Rochester, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Oregon Health Sciences University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Virginia, Charlottesville, Virginia, United States|Swedish Medical Center, Seattle, Washington, United States"
NCT04895202,Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional Study,https://beta.clinicaltrials.gov/study/NCT04895202,RECRUITING,Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity,OTHER: Siponimod,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",,60,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-11-19,2025-08-25,2025-08-25,"Novartis Investigative Site, Baden, Aargau, 5405, Switzerland|Novartis Investigative Site, Valens, CH, 7317, Switzerland|Novartis Investigative Site, Zug, ZG, 6300, Switzerland|Novartis Investigative Site, Zurich, ZH, 8006, Switzerland|Novartis Investigative Site, Basel, 4031, Switzerland|Novartis Investigative Site, Bern, 3010, Switzerland|Novartis Investigative Site, Lugano, 6900, Switzerland|Novartis Investigative Site, Luzern, 6004, Switzerland|Novartis Investigative Site, Winterthur, 8400, Switzerland"
NCT04539002,Aerobic Exercise for Remyelination in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04539002,RECRUITING,"Multiple Sclerosis|Sclerosis|Demyelinating Diseases|Autoimmune Diseases of the Nervous System|Nervous System Diseases|Demyelinating Autoimmune Diseases, CNS|Exercise",BEHAVIORAL: Aerobic exercise|BEHAVIORAL: Education Group Control,Oregon Health and Science University,"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Portland VA Medical Center|Oregon Clinical and Translational Research Institute|Myelin Repair Foundation|EMD Serono|Medical Research Foundation, Oregon",ALL,ADULT,PHASE1|PHASE2,60,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-04-29,2025-11-03,2026-03-09,"Oregon Health & Science University, Portland, Oregon, 97239, United States"
NCT03691077,Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714,https://beta.clinicaltrials.gov/study/NCT03691077,UNKNOWN,Multiple Sclerosis|Relapse|Primary Progressive Multiple Sclerosis,DRUG: Ocrelizumab,Assistance Publique - Hôpitaux de Paris,Roche Pharma AG|Institut du Cerveau et de la Moelle épinière,ALL,ADULT,PHASE3,51,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-11-11,2022-05,2022-09,"Hôpital Saint-Antoine - Service de Neurologie, Paris, 75651, France"
NCT05057338,"Functions, Physical Activity and Employment for Individuals With MS: A Pilot Feasibility Study",https://beta.clinicaltrials.gov/study/NCT05057338,ENROLLING_BY_INVITATION,Multiple Sclerosis,BEHAVIORAL: CoreDISTparticipation|BEHAVIORAL: Standard care,Nordlandssykehuset HF,Nord University|Hasselt University|Helse Nord,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-08-27,2021-12-31,2022-08-30,"Bodø Municipality, Bodø, Norway|Physiotherapy department, Nordlandssykehuset HF, Bodø, Norway"
NCT00071838,Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00071838,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Daclizumab,National Institute of Neurological Disorders and Stroke (NINDS),,ALL,"ADULT, OLDER_ADULT",PHASE2,16,NIH,INTERVENTIONAL,Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT,2003-10-30,2007-10-04,2011-08-16,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States"
NCT03342638,Maximizing Outcome of Multiple Sclerosis Transplantation,https://beta.clinicaltrials.gov/study/NCT03342638,TERMINATED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Cyclophosphamide|DRUG: Mesna|DRUG: rATG|DRUG: Methylprednisolone|DRUG: G-CSF|BIOLOGICAL: IVIg|BIOLOGICAL: Autologous Stem Cells,Northwestern University,,ALL,ADULT,PHASE3,66,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2017-11-08,2019-07-23,2019-10-09,"Northwestern University, Chicago, Illinois, 60611, United States"
NCT04545372,Aerobic Exercises for Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04545372,COMPLETED,"Multiple Sclerosis, Primary Progressive",OTHER: aerobic exercise,South Valley University,,ALL,ADULT,NA,30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2015-02-02,2018-08-04,2020-08-06,"South Valley University, Faculty of Physical Therapy, Qina,, 83523, Egypt"
NCT03502772,Clinical Pilates Training for Persons With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03502772,COMPLETED,Multiple Sclerosis,OTHER: Pilates exercises|OTHER: Home exercise program,Dokuz Eylul University,Izmir Katip Celebi University,ALL,"ADULT, OLDER_ADULT",NA,42,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2017-04-03,2017-12-29,2017-12-29,"Dokuz Eylul University Hospital, MS Outpatient Clinic, İzmir, 35430, Turkey"
NCT03111394,Study of myMS in Participants With a Diagnosis of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03111394,COMPLETED,Multiple Sclerosis,,University of Southern California,,ALL,"ADULT, OLDER_ADULT",,200,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-04-17,2021-11-25,2021-11-25,"Aimslab@Usc.Edu, Los Angeles, California, 90033, United States"
NCT04925778,Observational Study in Patients With Relapsing-Remitting Multiple Sclerosis Switched to Bafiertam® From Dimethyl Fumarate,https://beta.clinicaltrials.gov/study/NCT04925778,WITHDRAWN,Relapsing Remitting Multiple Sclerosis,DRUG: monomethyl fumarate,Banner Life Sciences LLC,,ALL,"ADULT, OLDER_ADULT",,0,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-06-30,2022-08-30,2022-09-29,
NCT04618978,Periodic Leg Movements' Diagnosis in Spinal Cord Injury: Actigraphy as an Alternative for Polysomnography?,https://beta.clinicaltrials.gov/study/NCT04618978,RECRUITING,Spinal Cord Injuries|Periodic Limb Movement Disorder,PROCEDURE: PSG and actigraphy recording,Assistance Publique - Hôpitaux de Paris,,ALL,"ADULT, OLDER_ADULT",NA,160,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-02-25,2023-12,2023-12,"Physiologie, explorations fonctionnelles - Unité des pathologies du sommeil, Hôpital Raymond Poincaré, APHP, Garches, 92380, France"
NCT02184494,Blood Lactate Concentrations With and Without Exercise in Parkinson's Disease and Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT02184494,COMPLETED,Parkinson's Disease|Multiple Sclerosis,"DEVICE: pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)",Florida State University,,ALL,"ADULT, OLDER_ADULT",NA,34,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2014-08,2014-11,2014-12,"Fitness and Wellness Center, Tallahassee, Florida, 32306, United States|Balance Disorders Clinic, Tallahassee, Florida, 32308, United States"
NCT03335618,Coaching and Activity Tracking in Multiple Sclerosis - A Pilot Study,https://beta.clinicaltrials.gov/study/NCT03335618,COMPLETED,Multiple Sclerosis,OTHER: Activity Monitoring and Symptom Coaching|OTHER: Passive Activity Monitoring,"University of California, San Francisco",,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2017-10-01,2019-08-01,2020-03-23,"University of California, San Francisco, San Francisco, California, 94158, United States"
NCT02408718,Assistive Device Training in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02408718,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Assistive Device Training,Portland VA Medical Center,Oregon Health and Science University,ALL,"ADULT, OLDER_ADULT",NA,40,FED,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2015-07,2016-09,2016-09,"VA Portland Health Care System, Portland, Oregon, 97239, United States"
NCT00229502,Cognitive Effects of Immunomodulatory Drugs in MS,https://beta.clinicaltrials.gov/study/NCT00229502,COMPLETED,Multiple Sclerosis,,"Sharon Lynch, MD",EMD Serono,ALL,ADULT,,96,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2005-09,2011-09,2011-12,"University of Kansas Medical Center, Kansas City, Kansas, 66160, United States"
NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,https://beta.clinicaltrials.gov/study/NCT00099502,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting","DRUG: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|DRUG: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|DRUG: Copaxone",Bayer,,ALL,ADULT,PHASE3,2244,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2003-11,,2007-08,"Birmingham, Alabama, 35294, United States|Cullman, Alabama, 35058, United States|Phoenix, Arizona, 85013, United States|Tucson, Arizona, 85741-3537, United States|Berkeley, California, 94705, United States|La Jolla, California, 92037, United States|Sacramento, California, 95817, United States|San Francisco, California, 94117, United States|Englewood, Colorado, 80110, United States|Fort Collins, Colorado, 80528, United States|Wilmington, Delaware, 19806, United States|Washington, District of Columbia, 20037, United States|Miami, Florida, 33125, United States|Tampa, Florida, 33606-3508, United States|Tampa, Florida, 33609, United States|Atlanta, Georgia, 30309-1465, United States|Augusta, Georgia, 30912, United States|Chicago, Illinois, 60637-1470, United States|Fort Wayne, Indiana, 46805, United States|Indianapolis, Indiana, 46202, United States|Des Moines, Iowa, 50314, United States|Kansas City, Kansas, 66160, United States|Lexington, Kentucky, 40536, United States|Louisville, Kentucky, 40202, United States|Shreveport, Louisiana, 71130, United States|Detroit, Michigan, 48202, United States|Duluth, Minnesota, 55805-1984, United States|St. Louis, Missouri, 63110, United States|Henderson, Nevada, 89052, United States|Reno, Nevada, 89557-0035, United States|Lebanon, New Hampshire, 03756-0001, United States|New Brunswick, New Jersey, 08901, United States|Albuquerque, New Mexico, 87131, United States|Albany, New York, 12208, United States|Mineola, New York, 11501-3987, United States|Rochester, New York, 14642, United States|Stony Brook, New York, 11794, United States|Charlotte, North Carolina, 28203, United States|Durham, North Carolina, 27710, United States|High Point, North Carolina, 27262, United States|Winston-Salem, North Carolina, 27157-1009, United States|Cincinnati, Ohio, 45219, United States|Columbus, Ohio, 43210-1240, United States|Tualatin, Oregon, 97062, United States|Philadelphia, Pennsylvania, 19104, United States|Philadelphia, Pennsylvania, 19107, United States|Pittsburgh, Pennsylvania, 15213-2592, United States|Providence, Rhode Island, 02905, United States|Charleston, South Carolina, 29425, United States|Nashville, Tennessee, 37205, United States|Houston, Texas, 77030, United States|San Antonio, Texas, 78229, United States|Fairfax, Virginia, 22031, United States|Seattle, Washington, 98101, United States|Tacoma, Washington, 98405, United States|Marshfield, Wisconsin, 54449, United States|Milwaukee, Wisconsin, 53215, United States|Buenos Aires, Capital Federal, C1117ABE, Argentina|Buenos Aires, Capital Federal, C1280AEB, Argentina|Rosario, Santa Fe, S2000CVB, Argentina|Rosario, Santa Fe, S2000ZBL, Argentina|Buenos Aires, C1416CRJ, Argentina|Cordoba, X5000HGX, Argentina|Gosford, New South Wales, 2250, Australia|Kogarah, New South Wales, 2217, Australia|Liverpool, New South Wales, 2170, Australia|Melbourne, Victoria, 3065, Australia|Parkville, Victoria, 3050, Australia|Nedlands, Western Australia, 6009, Australia|St. Pölten, Niederösterreich, 3100, Austria|Graz, Steiermark, 8036, Austria|Innsbruck, Tirol, 6020, Austria|Linz, 4020, Austria|Bruxelles - Brussel, 1090, Belgium|Leuven, 3000, Belgium|Melsbroek, 1820, Belgium|Curitiba, Parana, 80060-900, Brazil|Recife, PE, 52010-040, Brazil|Rio de Janeiro, RJ, 21949 900, Brazil|Porto Alegre, RS, Brazil|Campinas, Sao Paulo, 13081- 970, Brazil|Sao Paulo, SP, 05403-900, Brazil|Sao Pulo, SP, 05651-901, Brazil|Sao Paulo, 04039, Brazil|Calgary, Alberta, T2N 2T9, Canada|Vancouver, British Columbia, V6T 2B5, Canada|Winnipeg, Manitoba, R3A 1R9, Canada|Halifax, Nova Scotia, B3H 3A7, Canada|London, Ontario, N6A 5A5, Canada|Mississauga, Ontario, L5B 1B8, Canada|Nepean, Ontario, K2G 6E2, Canada|Ottawa, Ontario, K1H 8L6, Canada|Toronto, Ontario, M5C 2T2, Canada|Greenfield Park, Quebec, J4V 2H1, Canada|Hull, Quebec, J8Y 1W7, Canada|Montreal, Quebec, H2L 4M1, Canada|Montreal, Quebec, H3A 2B4, Canada|Aarhus C, 8000, Denmark|Oulu, Finland|Tampere, 33521, Finland|Rennes, Bretagne, 35038, France|Bordeaux, Gironde, 33076, France|Caen, F-14033, France|Clermont ferrand, 63003, France|Dijon, 21033, France|Lille, 59037, France|Lyon, 69003, France|Nancy, 54035, France|Nantes, 44805, France|Nice, 06000, France|Nimes, 30029, France|Toulouse, 31059, France|Heidelberg, Baden-Württemberg, 69112, Germany|Bayreuth, Bayern, 95445, Germany|Regensburg, Bayern, 93053, Germany|Hennigsdorf, Brandenburg, 16761, Germany|Gießen, Hessen, 35392, Germany|Marburg, Hessen, 35043, Germany|Offenbach, Hessen, 63069, Germany|Greifswald, Mecklenburg-Vorpommern, 17489, Germany|Göttingen, Niedersachsen, 37075, Germany|Hannover, Niedersachsen, 30171, Germany|Hannover, Niedersachsen, 30625, Germany|Düsseldorf, Nordrhein-Westfalen, 40225, Germany|Essen, Nordrhein-Westfalen, 45177, Germany|Münster, Nordrhein-Westfalen, 48149, Germany|Asbach, Rheinland-Pfalz, 53567, Germany|Halle, Sachsen-Anhalt, 06120, Germany|Dresden, Sachsen, 01307, Germany|Leipzig, Sachsen, 04129, Germany|Berlin, 13347, Germany|Berlin, 13578, Germany|Hamburg, 20099, Germany|Hamburg, 20251, Germany|Athens, Attica, 11527, Greece|Athens, 15127, Greece|Thessaloniki, 546 36, Greece|Budapest, 1076, Hungary|Budapest, 1145, Hungary|Györ, 9024, Hungary|Miskolc, 3526, Hungary|Pecs, 7623, Hungary|Zalaegerszeg, 8900, Hungary|Dublin, Dublin 24, Ireland|Cork, Ireland|Dublin, 7, Ireland|Dublin, 9, Ireland|Dublin, DUBLIN 4, Ireland|Ashkelon, 78306, Israel|Haifa, 31048, Israel|Haifa, 34362, Israel|Jerusalem, 91120, Israel|Petach Tikva, 49100, Israel|Tel Hashomer, 52621, Israel|Tel-Aviv, 64239, Israel|Zerifin, 70300, Israel|Bari, BA, 70122, Italy|Firenze, FI, 50134, Italy|Milano, MI, 20132, Italy|Padova, PD, 35128, Italy|Roma, RO, 00189, Italy|Orbassano, TO, 10043, Italy|Riga, LV-1015, Latvia|Nijmegen, Gelderland, 6533 PA, Netherlands|Breda, 4819 EV, Netherlands|Sittard, 6131 BK, Netherlands|Bergen, N-5021, Norway|Gdansk, 80-803, Poland|Katowice, 40752, Poland|Lodz, 90-153, Poland|Poznan, 60-355, Poland|Warszawa, 02-097, Poland|Warszawa, 02957, Poland|Wroclaw, 50-417, Poland|Moscow, 117049, Russian Federation|Moscow, 119048, Russian Federation|Moskva, 123367, Russian Federation|Moskva, 127018, Russian Federation|Moskva, 129110, Russian Federation|Nizhny Novogorod, 603076, Russian Federation|Novosibirsk, 630007, Russian Federation|Sankt-Peterburg, 194044, Russian Federation|Sankt-Peterburg, 197376, Russian Federation|St. Petersburg, 197022, Russian Federation|Yaroslavl, 150039, Russian Federation|Ljubljana, 1000, Slovenia|Maribor, 2000, Slovenia|L'Hospitalet de Llobregat, Barcelona, 08907, Spain|Málaga, 29010, Spain|Sevilla, 41071, Spain|Helsingborg, 25278, Sweden|Stockholm, 182 88, Sweden|Uppsala, 75185, Sweden|Bern, 3010, Switzerland|St. Gallen, 9007, Switzerland|Donetsk, 83003, Ukraine|Kharkiv, 61068, Ukraine|Kiev, 03110, Ukraine|Lviv, 79000, Ukraine"
NCT00179478,Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00179478,COMPLETED,Multiple Sclerosis|Optic Neuritis|Transverse Myelitis|Acute Brainstem/Cerebellar Syndrome,DRUG: interferon beta 1a 30 ug IM once weekly,Beth Israel Deaconess Medical Center,Biogen,ALL,"ADULT, OLDER_ADULT",PHASE4,155,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2001-02,2009-03,2009-03,"MS Treatment Center at Griffin Hospital, Derby, Connecticut, 06418, United States|Jaeb Center for Health Research, Tampa, Florida, 33647, United States|MS Center of Atlanta, Atlanta, Georgia, 30327, United States|Beta Research, Inc, Elk Grove, Illinois, 60007, United States|University of Iowa College of Medicine, Iowa City, Iowa, 52242, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States|Michigan State University, East Lansing, Michigan, 48824, United States|St. Louis University Health Sciences Center, Saint Louis, Missouri, 63110, United States|Jacobs Neurological Institute, Buffalo, New York, 14203, United States|University of Rochester, Rochester, New York, 14642, United States|Carolinas Medical Center - MS Center, Charlotte, North Carolina, 28207, United States|Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States|The Ohio State University, Columbus, Ohio, 43210, United States|The Neurology Group, Norristown, Pennsylvania, 19401, United States|Univeristy of Pennsylvania Medical Center, Philadelphia, Pennsylvania, 19104, United States|Allegheny Neurological Associates, Pittsburgh, Pennsylvania, 15212, United States|Univeristy of Texas Houston Health Science Center, Houston, Texas, 77030, United States|Virginia Commonwealth University/Medical College of Virginia, Richmond, Virginia, 23219, United States|Neurological Associates, Inc., Richmond, Virginia, 23230, United States|Marshfield Clinic, Marshfield, Wisconsin, 54449, United States|Vancouver Hospital Health Sciences Centre, Vancouver, British Columbia, V6T 2B5, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, B3H 1V7, Canada|Ottawa General Hospital, Ottawa, Ontario, K1H 8L6, Canada|University of Toronto - St. Michael's Hospital, Toronto, Ontario, M5B 1W8, Canada|Hospital Notre Dame, Montreal, Quebec, H2l 4M1, Canada|Montreal Neurological Institute, Montreal, Quebec, H3A 2B4, Canada"
NCT03190902,Cognitive Impairment in Pediatric Onset Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03190902,COMPLETED,Pediatric Onset Multiple Sclerosis|ADHD Predominantly Inattentive Type,BEHAVIORAL: Attention Processing Training program (APT)|BEHAVIORAL: nonspecific computer training (n-ST),Pietro Iaffaldano,,ALL,CHILD,NA,36,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2015-09-15,2016-04-30,2016-04-30,
NCT00037102,Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00037102,COMPLETED,Multiple Sclerosis,DRUG: interferon beta 1a|DRUG: methotrexate,MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute,Consultants in Neurology|Biogen,ALL,ADULT,PHASE4,16,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2001-07,2003-12,2003-12,
NCT02200718,"A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT02200718,NOT_YET_RECRUITING,Multiple Sclerosis,BIOLOGICAL: NeuroVax|BIOLOGICAL: IFA Incomplete Freund's Adjuvant,"Immune Response BioPharma, Inc.",,ALL,CHILD,PHASE1,12,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-12-31,2024-11-09,2024-11-09,"CRO, San Diego, California, 92129, United States"
NCT02082002,Multidimensional Assessment of Fatigue in Multiple Sclerosis- Observational Study - Ticino,https://beta.clinicaltrials.gov/study/NCT02082002,COMPLETED,Multiple Sclerosis,,Claudio Gobbi,Swiss Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",,93,OTHER_GOV,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-11,2018-12-21,2018-12-21,"Ospedale Regionale di Lugano - Civico, Lugano, Ticino, 6903, Switzerland"
NCT04002102,Open-Label Placebos to Treat Fatigue in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04002102,COMPLETED,Multiple Sclerosis|Fatigue,OTHER: OLP treatment|OTHER: Usual care|OTHER: Expectancy Group,University of Alabama at Birmingham,,ALL,"ADULT, OLDER_ADULT",NA,48,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2020-02-17,2022-01-19,2022-01-19,"Tanner Foundation, Birmingham, Alabama, 35209, United States|University of Alabama at Birmingham, Birmingham, Alabama, 35294, United States"
NCT02618902,"A ""Negative""Dendritic Cell-based Vaccine for the Treatment of Multiple Sclerosis: a First-in-human Clinical Trial",https://beta.clinicaltrials.gov/study/NCT02618902,UNKNOWN,Multiple Sclerosis,BIOLOGICAL: tolerogenic dendritic cells (tolDC),"University Hospital, Antwerp",,ALL,ADULT,PHASE1,9,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2017-05-30,2021-11-30,2021-12-31,"Antwerp University Hospital, Edegem, 2650, Belgium"
NCT01462318,An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01462318,COMPLETED,Relapsing-Remitting Multiple Sclerosis,DRUG: Midazolam|OTHER: Caffeine|DRUG: S-warfarin|OTHER: Vitamin K|DRUG: Omeprazole|DRUG: Dextromethorphan|BIOLOGICAL: BIIB019 (Daclizumab),Biogen,,ALL,"ADULT, OLDER_ADULT",PHASE3,133,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2011-11,2016-01,2016-01,"Research Site, Centennial, Colorado, 80112, United States|Research Site, Washington, District of Columbia, 20057, United States|Research Site, Lake Barrington, Illinois, 60010, United States|Research Site, Lexington, Kentucky, 40513, United States|Research Site, Farmington Hills, Michigan, 48334, United States|Research Site, Dayton, Ohio, 45417, United States|Research Site, Franklin, Tennessee, 37064, United States|Research Site, Brno, 65691, Czech Republic|Research Site, Jihlava, 58633, Czech Republic|Research Site, Ostrava, 70852, Czech Republic|Research Site, Pardubice, 53203, Czech Republic|Research Site, Teplice, 41501, Czech Republic|Research Site, Veszprem, Korhazu 1, 8200, Hungary|Research Site, Budapest, 1134, Hungary|Research Site, Debrecen, 4031, Hungary|Research Site, Esztergom, 2500, Hungary|Research Site, Szekesfehervar, Hungary|Research Site, Katowice, Poland|Research Site, Krakow, 31-501, Poland"
NCT03164018,"Fampridine in MS Patients: A Cognition, Fatigue, Depression and Quality of Life Analysis",https://beta.clinicaltrials.gov/study/NCT03164018,COMPLETED,Multiple Sclerosis,DRUG: Fampridine,Genesis Pharma CNS & Specialty,,ALL,"ADULT, OLDER_ADULT",,111,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-03-07,2018-12-15,2018-12-15,"Αiginitio hospital, Athens, Attika, 11528, Greece"
NCT05859802,Effects of Physical Therapy and Dalfampridine on Functional Mobility in Non Ambulatory Persons With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05859802,COMPLETED,Multiple Sclerosis,DRUG: Dalfampridine Pill|DRUG: Placebo,D'Youville College,Acorda Therapeutics|University at Buffalo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,35,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2011-07-13,2015-03-03,2016-01-09,
NCT05777902,Multidimensional Integrated Assessment to Test the Efficacy and Response to Ozanimod in Multiple Sclerosis.,https://beta.clinicaltrials.gov/study/NCT05777902,RECRUITING,Multiple Sclerosis,DRUG: Ozanimod Oral Capsule,I.R.C.C.S. Fondazione Santa Lucia,,ALL,ADULT,PHASE4,30,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-01-31,2025-01-31,2025-01-31,"IRCCS Fondazione Santa Lucia, Roma, RM, 00179, Italy"
NCT04909502,"Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT04909502,SUSPENDED,Relapsing Forms of Multiple Sclerosis,DRUG: EHP-101 25 mg OD|DRUG: EHP-101 25 mg BID|DRUG: EHP-101 50 mg OD|DRUG: EHP-101 50 mg BID,Emerald Health Pharmaceuticals,,ALL,ADULT,PHASE2,50,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-10-19,2023-12,2024-04,"North Central Neurology Associates, Cullman, Alabama, 35058, United States|Fullerton Neurology and Headache Center, Fullerton, California, 92835, United States|Accel Research Sites - Brain and Spine Institute of Port Orange, Port Orange, Florida, 32127, United States|St. Vincent's Hospital, Melbourne, Victoria, 3065, Australia"
NCT00559702,Safety Study of Natalizumab to Treat Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT00559702,COMPLETED,Relapsing-Remitting Multiple Sclerosis|Secondary Progressive Multiple Sclerosis,DRUG: natalizumab|OTHER: standard of care,Biogen,Elan Pharmaceuticals,ALL,"ADULT, OLDER_ADULT",PHASE1,76,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2007-10,2011-11,2011-11,"Research Site, Phoenix, Arizona, 85006, United States|Research Site, Scottsdale, Arizona, 85259, United States|Research Site, Berkeley, California, 94705, United States|Research Site, Centennial, Colorado, 80112, United States|Research Site, Maitland, Florida, 32751, United States|Research Site, Vero Beach, Florida, 32960, United States|Research Site, Peoria, Illinois, 61637, United States|Research Site, Farmington Hills, Michigan, 48334, United States|Research Site, Buffalo, New York, 14203, United States|Research Site, Dallas, Texas, 75214, United States|Research Site, Round Rock, Texas, 78681, United States|Research Site, Vienna, Virginia, 22182, United States"
NCT01879202,Methylphenidate as Treatment Option of Fatigue in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01879202,UNKNOWN,Multiple Sclerosis|Fatigue,DRUG: Methylphenidate modified release|DRUG: Maltodextrin,Medical University of Vienna,,ALL,"ADULT, OLDER_ADULT",PHASE2,96,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-12,2017-02,2017-02,"Medical University of Vienna, Department of Neurology, Vienna, 1090, Austria"
NCT00959218,Efficacy and Safety of the Pain Relieving Effect of Dronabinol in Central Neuropathic Pain Related to Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00959218,COMPLETED,Central Neuropathic Pain in Multiple Sclerosis,DRUG: Dronabinol|DRUG: Placebo,Bionorica Research GmbH,,ALL,"ADULT, OLDER_ADULT",PHASE3,240,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2007-06,2010-03,2010-04,"Maerkische Kliniken GmbH, Klinikum Luedenscheid, Akademisches Lehrkrankenhaus der Universitaet Bonn, Klinik fuer Neurologie, Luedenscheid, 58515, Germany"
NCT03799718,Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MS,https://beta.clinicaltrials.gov/study/NCT03799718,COMPLETED,"Multiple Sclerosis, Chronic Progressive",BIOLOGICAL: NurOwn (MSC-NTF cells),Brainstorm-Cell Therapeutics,,ALL,"ADULT, OLDER_ADULT",PHASE2,23,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2019-03-13,2021-03-11,2021-03-30,"University of Southern California, Los Angeles, California, 90033, United States|Stanford University School of Medicine, Redwood City, California, 94305, United States|The Mount Sinai Hospital, New York, New York, 10029, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States"
NCT04926818,Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04926818,RECRUITING,Multiple Sclerosis (MS),DRUG: Fingolimod|DRUG: Ofatumumab|DRUG: Siponimod|OTHER: Fingolimod placebo|OTHER: Siponimod placebo|OTHER: Ofatumumab placebo,Novartis Pharmaceuticals,,ALL,CHILD,PHASE3,180,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-10-05,2026-08-04,2029-06-01,"Novartis Investigative Site, Little Rock, Arkansas, 72202, United States|Novartis Investigative Site, Los Angeles, California, 90027, United States|Novartis Investigative Site, San Diego, California, 92103, United States|Novartis Investigative Site, Tampa, Florida, 33609, United States|Novartis Investigative Site, Atlanta, Georgia, 30329, United States|Novartis Investigative Site, Portland, Oregon, 97225, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, 19104 4399, United States|Novartis Investigative Site, Salt Lake City, Utah, 84132, United States|Novartis Investigative Site, Milwaukee, Wisconsin, 53226, United States|Novartis Investigative Site, Parkville, Victoria, 3052, Australia|Novartis Investigative Site, Vienna, 1090, Austria|Novartis Investigative Site, Esneux, 4130, Belgium|Novartis Investigative Site, Gent, 9000, Belgium|Novartis Investigative Site, Curitiba, PR, 81210-310, Brazil|Novartis Investigative Site, Porto Alegre, RS, 90430-001, Brazil|Novartis Investigative Site, Toronto, Ontario, M5G 1X8, Canada|Novartis Investigative Site, Montreal, Quebec, H3A 2B4, Canada|Novartis Investigative Site, Montreal, Quebec, H3T 1C5, Canada|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Zagreb, Croatia|Novartis Investigative Site, Tallinn, 11315, Estonia|Novartis Investigative Site, Le Kremlin Bicetre, 94275, France|Novartis Investigative Site, Montpellier, 34295, France|Novartis Investigative Site, Strasbourg, 67098, France|Novartis Investigative Site, Bochum, 44791, Germany|Novartis Investigative Site, Erlangen, 91054, Germany|Novartis Investigative Site, Freiburg, 79106, Germany|Novartis Investigative Site, Gottingen, 37075, Germany|Novartis Investigative Site, Guatemala, 01015, Guatemala|Novartis Investigative Site, New Delhi, Delhi, 110 060, India|Novartis Investigative Site, New Delhi, Delhi, 110017, India|Novartis Investigative Site, Lucknow, Uttar Pradesh, 226014, India|Novartis Investigative Site, Kolkata, West Bengal, 700017, India|Novartis Investigative Site, Petach-Tikva, 49202, Israel|Novartis Investigative Site, Milano, MI, 20132, Italy|Novartis Investigative Site, Roma, RM, 00165, Italy|Novartis Investigative Site, Napoli, 80131, Italy|Novartis Investigative Site, Riga, LV-1004, Latvia|Novartis Investigative Site, Ciudad de Mexico, Distrito Federal, 06700, Mexico|Novartis Investigative Site, Chihuahua, 31203, Mexico|Novartis Investigative Site, Gdansk, 80 952, Poland|Novartis Investigative Site, Lodz, 93-338, Poland|Novartis Investigative Site, Poznan, 60-355, Poland|Novartis Investigative Site, Warsaw, 04 730, Poland|Novartis Investigative Site, Coimbra, 3000-602, Portugal|Novartis Investigative Site, Lisboa, 1169-050, Portugal|Novartis Investigative Site, St Petersburg, 190000, Russian Federation|Novartis Investigative Site, Bratislava, 833 40, Slovakia|Novartis Investigative Site, Sevilla, Andalucia, 41009, Spain|Novartis Investigative Site, Baracaldo, Vizcaya, 48903, Spain|Novartis Investigative Site, Kaohsiung City, 83301, Taiwan|Novartis Investigative Site, Taipei, 10002, Taiwan|Novartis Investigative Site, Istanbul, TUR, 34098, Turkey|Novartis Investigative Site, Izmir, 35340, Turkey|Novartis Investigative Site, Kocaeli, 41380, Turkey|Novartis Investigative Site, Samsun, 55139, Turkey"
NCT02463318,The Effect of Melatonin on Gene Expression and Activity of the Sirt1 and Its Target Genes Catalase and MnSOD in Multiple Sclerosis Patients and Healthy Subjects,https://beta.clinicaltrials.gov/study/NCT02463318,COMPLETED,Multiple Sclerosis|Oxidative Stress,DRUG: Melatonin|OTHER: Hydrogen peroxide,Tehran University of Medical Sciences,,FEMALE,ADULT,NA,34,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2012-09,2015-06,2015-09,"Solaleh Emamgholipour, Tehran, Iran, Islamic Republic of"
NCT03561402,Biomarkers and Disease Activity in Patients Treated With Teriflunomide (Aubagio),https://beta.clinicaltrials.gov/study/NCT03561402,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Teriflunomide,McGill University,,ALL,ADULT,,24,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-12-01,2020-12-30,2020-12-30,"Department of Pathology, Montréal, Quebec, H3A 2B4, Canada"
NCT01939002,Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017),https://beta.clinicaltrials.gov/study/NCT01939002,COMPLETED,Relapsing Multiple Sclerosis,DRUG: BIIB017|DRUG: naproxen,Biogen,,ALL,"ADULT, OLDER_ADULT",PHASE3,251,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2013-11,2015-10,2015-11,"Research Site, Gilbert, Arizona, 85234, United States|Research Site, Phoenix, Arizona, 85004, United States|Research Site, Phoenix, Arizona, 85018, United States|Research Site, Tucson, Arizona, 85704, United States|Research Site, Boulder, Colorado, 80301, United States|Research Site, Fort Collins, Colorado, 80528, United States|Research Site, Dover, Delaware, 19901, United States|Research Site, Newark, Delaware, 19713, United States|Research Site, Jacksonville, Florida, 32209, United States|Research Site, Melbourne, Florida, 32901, United States|Research Site, Tampa, Florida, 33609, United States|Research Site, Atlanta, Georgia, 30327, United States|Research Site, Kansas City, Kansas, 66160, United States|Research Site, Lexington, Kentucky, 40513, United States|Research Site, Louisville, Kentucky, 40207, United States|Research Site, Boston, Massachusetts, 02135, United States|Research Site, Lexington, Massachusetts, 02421, United States|Research Site, Worcester, Massachusetts, 01655, United States|Research Site, Detroit, Michigan, 48202, United States|Research Site, Chesterfield, Missouri, 63017, United States|Research Site, St. Louis, Missouri, 63110, United States|Research Site, Great Falls, Montana, 59405, United States|Research Site, Lincoln, Nebraska, 68521, United States|Research Site, Latham, New York, 12110, United States|Research Site, Plainview, New York, 11803, United States|Research Site, Asheville, North Carolina, 28806, United States|Research Site, Akron, Ohio, 44320, United States|Research Site, Dayton, Ohio, 45417, United States|Research Site, Uniontown, Ohio, 44685, United States|Research Site, Oklahoma City, Oklahoma, 73104, United States|Research Site, Portland, Oregon, 97225, United States|Research Site, Greenville, South Carolina, 29607, United States|Research Site, Franklin, Tennessee, 37064, United States|Research Site, Knoxville, Tennessee, 37934, United States|Research Site, Salt Lake City, Utah, 84103, United States|Research Site, Newport News, Virginia, 23601, United States|Research Site, Roanoke, Virginia, 24018, United States|Research Site, Spokane, Washington, 99202, United States"
NCT04691102,Predictive Indices of Independent Activity of Daily-living in Neurorehabilitation,https://beta.clinicaltrials.gov/study/NCT04691102,RECRUITING,Stroke|Brain Injuries|Mild Cognitive Impairment|Parkinson Disease|Multiple Sclerosis,,I.R.C.C.S. Fondazione Santa Lucia,,ALL,"CHILD, ADULT, OLDER_ADULT",,120,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-05-01,2023-06-30,2023-10-01,"Santa Lucia Foundation I.R.C.C.S., Roma, Rm, 00179, Italy"
NCT05439902,Efficacy of Alpha-blockers (Tamsulosin) in the Treatment of Symptomatic Dysuria in Multiple Sclerosis in Women,https://beta.clinicaltrials.gov/study/NCT05439902,RECRUITING,Multiple Sclerosis|Dysuria|Lower Urinary Tract Symptoms|Voiding Dysfunction|Urinary Retention,DRUG: Tamsulosin|DRUG: Placebo,Centre Hospitalier Universitaire de Nīmes,,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-10-05,2024-03,2024-03,"CHU de Nîmes, Nîmes, France"
NCT01085318,Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial,https://beta.clinicaltrials.gov/study/NCT01085318,COMPLETED,Multiple Sclerosis,DRUG: Rebif,EMD Serono,,ALL,"ADULT, OLDER_ADULT",PHASE4,38,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2010-06-30,2012-02-29,2012-03-31,"EMD Serono, Inc., Rockland, Massachusetts, 02370, United States"
NCT01933802,Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01933802,COMPLETED,Multiple Sclerosis,BIOLOGICAL: intrathecal administration of autologous MSC-NP,Tisch Multiple Sclerosis Research Center of New York,,ALL,"ADULT, OLDER_ADULT",PHASE1,20,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-04,2016-12,2017-03,"Tisch MS Research Center of New York, New York, New York, 10019, United States"
NCT01968902,Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT01968902,COMPLETED,Muscle Spasticity|Multiple Sclerosis,BIOLOGICAL: incabotulinumtoxinA|BIOLOGICAL: Placebo,Multiple Sclerosis Center of Northeastern New York,"Merz North America, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE4,27,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2013-11,2016-01-27,2016-12-31,"Multiple Sclerosis Center of Northeastern New York, Latham, New York, 12110, United States"
NCT03933202,A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2),https://beta.clinicaltrials.gov/study/NCT03933202,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,DRUG: Cladribine Tablets,"EMD Serono Research & Development Institute, Inc.","Merck KGaA, Darmstadt, Germany",ALL,"ADULT, OLDER_ADULT",,295,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-07-22,2024-11-15,2026-11-15,"North Central Neurology Associates, P.C., Cullman, Alabama, 35058, United States|University of South Alabama, Mobile, Alabama, 36693, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, 72205, United States|Fullerton Neurology and Headache Center, Fullerton, California, 92835, United States|Regina Berkovich MD PhD INC, West Hollywood, California, 90048, United States|Colorado Springs Neurological Associates, PC - Neurology, Colorado Springs, Colorado, 80907, United States|Advanced Neurosciences Research, LLC, Fort Collins, Colorado, 80528, United States|Associated Neurologists of Southern Connecticut, PC, Fairfield, Connecticut, 06824, United States|Neurology Associates, P. A., Maitland, Florida, 32751, United States|Orlando Health Multiple Sclerosis Comprehensive Care Center - Downtown Orlando, Orlando, Florida, 32806, United States|Axiom Clinical Research of Florida, Tampa, Florida, 33609, United States|University of South Florida, Tampa, Florida, 33612, United States|Northwest Neurology Ltd, Rolling Meadows, Illinois, 60008, United States|Prairie Education & Research, Springfield, Illinois, 62702, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, 46804, United States|College Park Family Care Center, Overland Park, Kansas, 66212, United States|Northern Light Comprehensive Multiple Sclerosis Care Center, Bangor, Maine, 04401, United States|Neurological Clinical Research Institute, Boston, Massachusetts, 02114, United States|Neuro Institute of New England P.C., Foxboro, Massachusetts, 02035, United States|The Elliot Lewis Center for Multiple Sclerosis Care, Wellesley, Massachusetts, 02481, United States|UMASS - Neurology, Worcester, Massachusetts, 01655, United States|Wayne State University (WSU) - Multiple Sclerosis Treatment and Clinical Research Center (MS Center) - Department of Neurology, Detroit, Michigan, 48201, United States|Detroit Clinical Research Center, PC, Farmington Hills, Michigan, 48334, United States|Memorial Healthcare, Owosso, Michigan, 48867, United States|Minneapolis Clinic of Neurology - Neurology, Golden Valley, Minnesota, 55422, United States|Neurology Center of Las Vegas, Las Vegas, Nevada, 89128, United States|DENT Neurologic Institute, Amherst, New York, 14226, United States|The Trustee of Columbia University in the City of New York, New York, New York, 10032, United States|The Charlotte-Mecklenburg Hospital Authority - Carolinas Healthcare System, Charlotte, North Carolina, 28203, United States|Guilford Neurologic Associates, Greensboro, North Carolina, 27405, United States|Raleigh Neurology Associates, Raleigh, North Carolina, 27607-6010, United States|Insight Neuroscience LLC, Bellevue, Ohio, 44811, United States|Dayton Center for Neurological Disorders, Dayton, Ohio, 45459, United States|Providence Neurological Specialties, Portland, Oregon, 97225, United States|Premier Neurology Research, P.C., Greer, South Carolina, 29650, United States|Neurology, PC, Knoxville, Tennessee, 37922, United States|Vanderbilt University Medical Center, Nashville, Tennessee, 37232, United States|Northwest Houston Neurology, Cypress, Texas, 77429, United States|DHR Health Neurology Institute Neuroimmunology and Multiple Sclerosis, McAllen, Texas, 78503, United States|Central Texas Neurology Consultants, Round Rock, Texas, 78681, United States|Neurology Center of San Antonio, San Antonio, Texas, 78258, United States|Integrated Neurology Services - Dr. Simon Fishman's Office, Alexandria, Virginia, 22310, United States|Blacksburg Neurology, PC, Christiansburg, Virginia, 24073, United States|Meridian Clinical Research (Neurology), Norfolk, Virginia, 23502, United States|Neurological Associates, Richmond, Virginia, 23226, United States|Multiple Sclerosis Center of Greater Washington, Vienna, Virginia, 22182, United States|Sentara Ambulatory Care Center, Virginia Beach, Virginia, 23456, United States|MS Center of Evergreen, Kirkland, Washington, 98034, United States|MultiCare Health System Institute for Research and Innovation - MultiCare Health System Institute for Research and, Spokane, Washington, 99202, United States|MultiCare Health System Institute for Research and Innovation - MultiCare Health System Institute for Research, Tacoma, Washington, 98405, United States|Ascension St. Francis Center for Neurological Disorders, S.C., Milwaukee, Wisconsin, 53215, United States|The Medical College of Wisconsin - Endocrinology, Milwaukee, Wisconsin, 53226, United States|Neuroscience Group of Northeast Wisconsin - DUPLICATE, Neenah, Wisconsin, 54956, United States"
NCT00811902,"Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT00811902,COMPLETED,Multiple Sclerosis,DRUG: Nerispirdine|DRUG: placebo,Sanofi,,ALL,"ADULT, OLDER_ADULT",PHASE2,405,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2008-12,2010-03,2010-03,"Sanofi-aventis Administrative Office, Bridgewater, New Jersey, 08807, United States|Sanofi-aventis Administrative Office, Laval, Canada|Sanofi-aventis Administrative Office, Helsinki, Finland|Sanofi-Aventis Administrative Office, Paris, France|Sanofi-aventis Administrative Office, Berlin, Germany|Sanofi-Aventis Administrative Office, Lysaker, Norway|Sanofi-aventis Administrative Office, Barcelona, Spain"
NCT03408093,Study of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1b,https://beta.clinicaltrials.gov/study/NCT03408093,COMPLETED,Multiple Sclerosis,"DRUG: Interferon beta-1b (Betaseron, BAY86-5046)",Bayer,,ALL,"ADULT, OLDER_ADULT",,120,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2009-02-03,2010-03-30,2010-03-30,
NCT00220493,Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) Patients,https://beta.clinicaltrials.gov/study/NCT00220493,UNKNOWN,"Relapsing Remitting Multiple Sclerosis|Multiple Sclerosis, Chronic Progressive",DRUG: Ritalin,Sheba Medical Center,,ALL,"ADULT, OLDER_ADULT",PHASE1,80,OTHER_GOV,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: ECT,2003-06,,2005-06,"Multiple Sclerosis Center, Ramat Gan, 52621, Israel"
NCT00588393,FolateScan in Autoimmune Disease,https://beta.clinicaltrials.gov/study/NCT00588393,COMPLETED,Rheumatoid Arthritis|Osteoarthritis|Multiple Sclerosis|Crohn's Disease|Systemic Lupus Erythematosus,DRUG: FolateScan (Technetium Tc 99mEC20),Mayo Clinic,Endocyte,ALL,"ADULT, OLDER_ADULT",PHASE2,75,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2006-09,2007-12,2007-12,"Mayo Clinic, Rochester, Minnesota, 55905, United States"
NCT01110993,An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF),https://beta.clinicaltrials.gov/study/NCT01110993,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",,"Merck KGaA, Darmstadt, Germany",,ALL,"ADULT, OLDER_ADULT",,65,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-11,2013-09,2013-09,"Medical University, Department of Neurology, Lublin, Poland"
NCT05319093,Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT05319093,NOT_YET_RECRUITING,Fatigue|Multiple Sclerosis,DRUG: Ozanimod,Brigham and Women's Hospital,Bristol-Myers Squibb,ALL,"ADULT, OLDER_ADULT",,40,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-04,2023-07,2023-12,
NCT00595920,Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00595920,TERMINATED,"Multiple Sclerosis, Relapsing-Remitting|Clinically Isolated Syndrome",BIOLOGICAL: Tovaxin,"Opexa Therapeutics, Inc.",,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,116,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-11,2008-12,2008-12,"North Central Neurology Associates, PC, Cullman, Alabama, 35058, United States|Xenoscience - 21st Century Neurology, Phoenix, Arizona, 85013, United States|HOPE Research Institute, Phoenix, Arizona, 85050, United States|Alta Bates Summit Medical Center - East Bay Physicians Medical Group, Berkeley, California, 94705, United States|Patricia A Fodor, PC, Colorado Springs, Colorado, 80919, United States|Bradenton Neurology, Bradenton, Florida, 34205, United States|Neurological Associates, Pompano Beach, Florida, 33060, United States|Medical College of Georgia - Department of Neurology, Augusta, Georgia, 30912, United States|Consultants in Neurology, Ltd., Northbrook, Illinois, 60062, United States|Allied Physicians Inc, Fort Wayne, Indiana, 46805, United States|MidAmerica Neuroscience Institute, Lenexa, Kansas, 66214, United States|Associates in Neurology, Lexington, Kentucky, 40503, United States|St Mary's of Michigan - Field Neuroscience Institute, Saginaw, Michigan, 48604, United States|Ayres & Associates Clinical Trials, Lebanon, New Hampshire, 03766, United States|Upstate Clinical Research, LLC, Albany, New York, 12205, United States|Winthrop University Hospital - Clinical Trials Unit, Mineola, New York, 11501, United States|Neurology Consultants of the Carolinas, PA, Charlotte, North Carolina, 28204, United States|Raleigh Neurology Associates, Raleigh, North Carolina, 27607, United States|Neurology & Neuroscience Associates, Inc., Akron, Ohio, 44302, United States|Neurological Research Institute, Columbus, Ohio, 43221, United States|Neurology Specialists, Inc, Dayton, Ohio, 45408, United States|Providence St. Vincent Medical Center - Northwest MS Center, Portland, Oregon, 97225, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|The Maxine Mesinger MS Clinic/Baylor College of Medicine, Houston, Texas, 77030, United States|Central Texas Neurology, Round Rock, Texas, 78681, United States|Integra Clinical Research, LLC, San Antonio, Texas, 78229, United States|MS Center at Evergreen, Kirkland, Washington, 98101, United States"
NCT01167426,Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients,https://beta.clinicaltrials.gov/study/NCT01167426,COMPLETED,Multiple Sclerosis,DRUG: Glatiramer Acetate 20 mg/0.5 mL|DRUG: Glatiramer acetate 20 mg/0.5 mL,"Teva Neuroscience, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE3,148,INDUSTRY,INTERVENTIONAL,"Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: ",2010-07,2010-11,2010-12,
NCT00261326,Simvastatin Treatment of Patients With Acute Optic Neuritis,https://beta.clinicaltrials.gov/study/NCT00261326,UNKNOWN,Optic Neuritis|Multiple Sclerosis,DRUG: simvastatin|DRUG: placebo,"Glostrup University Hospital, Copenhagen",Alpharma ApS,ALL,ADULT,PHASE3,64,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2006-09,2010-01,2011-05,"The clinic of the research for optic neuritis and MS, The Dpt. of Neurology at Glostrup Hospital, Glostrup, DK-2600, Denmark"
NCT04702763,Eye Movements Recording Using a Smartphone: Comparison to Standard Video-oculography in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04702763,COMPLETED,Multiple Sclerosis,OTHER: Eye-Tracker®T2 + e-VOG|OTHER: e-VOG + Eye-Tracker®T2,Association de Recherche Bibliographique pour les Neurosciences,Centre Hospitalier Princesse Grace|Centre Hospitalier Universitaire de Nice,ALL,"ADULT, OLDER_ADULT",,30,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-10-08,2021-10-30,2021-10-30,"Centre Mémoire / Centre de Gérontologie Clinique Rainier III / Princess Grace Hospital, Monaco, 98000, Monaco"
NCT01628393,Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT01628393,COMPLETED,Relapsing Multiple Sclerosis,DRUG: Ozanimod|DRUG: Placebo,Celgene,,ALL,ADULT,PHASE2|PHASE3,258,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-09-18,2014-04-13,2016-05-11,"Alta Bates Summit Medical Center, Berkeley, California, 94705, United States|Neuro Pain Medical Center, Fresno, California, 93710, United States|University of California Davis Medical Center, Sacramento, California, 95817, United States|The Neurological Institute PA, Charlotte, North Carolina, 28204, United States|Neurology and Neuroscience Associates Inc., Akron, Ohio, 44320, United States|The Polyclinic, Seattle, Washington, 98104, United States|Cliniques Universitaires St-Luc, Brussels, 1200, Belgium|Centre Hospitalier Chretien Clinique Saint Joseph, Montegnee, 4420, Belgium|Clinique Saint-Pierre, Ottignies, 1340, Belgium|University Multiprofile Hospital for Active Treatment Sv Ivan Rilski EAD, Sofia, 1431, Bulgaria|Sarajishvili Institute of Neurology, Tbilisi, 0112, Georgia|LTD MediClubGeorgia, Tbilisi, 0160, Georgia|Khechinashvili University Hospital, Tbilisi, 0179, Georgia|Evaggelismos General Hospital, Athens, 10676, Greece|401 Military Hospital of Athens, Athens, 11525, Greece|Georgios Papanikolaou General Hospital of Thessaloniki, Thessaloniki, 57010, Greece|Vaszary Kolos Korhaz, Esztergom, 2500, Hungary|Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuele, Cantania, 95123, Italy|Powiatowy Zespol Zakladow Opieki Zdrowotnej Szpital w Czeladzi, Czeladz, 41-250, Poland|Regionalny Szpital Specjalistyczny im. dr Wladyslawa Bieganskiego, Grudziadz, 86-300, Poland|Novo-Med Zielinski i wsp. Sp.J., Katowice, 40-650, Poland|NEURO- CARE Site Management Organization Gabriela Klodowska-Duda, Katowice, 40-749, Poland|NEURO MEDIC Janusz Zbrojkiewicz, Katowice, 40-752, Poland|RESMEDICA Spolka z o.o., Kielce, 25-726, Poland|Centrum Kompleksowej Rehabilitacji Sp.z.o.o. Szpital Wielospecjalistyczny, Konstancin Jeziorna, 05-510, Poland|Prof. dr med. Zbigniew Stelmasiak Specjalistyczny Gabinet Neurologiczny, Lublin, 20-718, Poland|Centrum Neurologii Krzysztof Selmaj, Lódzkie, 90-324, Poland|Wojewodzki Szpital Specjalistyczny, Olsztyn, 10-561, Poland|Neurologiczny NZOZ Centrum Leczenia SM Osrodek Badan Klinicznych Dr n med Hanka Hertmanowska, Plewiska, 62-064, Poland|Niepubliczny Zaklad Opieki Zdrowotnej KENDRON, Podlaskie, 15-402, Poland|Niepubliczny Zaklad Opieki Zdrowotnej NEUROKARD Ilkowski i Partnerzy Spolka Partnerska Lekarzy, Poznan, 61-853, Poland|EUROMEDIS Sp. z.o.o., Szczecin, 70-111, Poland|Indywidualna Specjalistyczna Praktyka Lekarska Zbigniew Cebulski, Warminsko-mazurskie, 10-443, Poland|Szpital Czerniakowski Samodzielny Publiczny Zaklad Opieki Zdrowotnej, Warsaw, 00-739, Poland|Centralny Szpital Kliniczny MSWIA, Warsaw, 02-507, Poland|Wojskowy Instytut Medyczny, Warszawa, 00-909, Poland|Instytut Psychiatrii i Neurologii, Warszawa, 02-957, Poland|Health Club Medical Center S.R.L., Campulung, 115100, Romania|Rehabilitation Clinical Hospital, Cluj-Napoca, 400347, Romania|Colentina Clinical Hospital, Napoca, 400001, Romania|Timisoara Emergency County Clinical Hospital, Timisoara, 300736, Romania|Republican Clinical Hospital for Rehabilitation Treatment, Kazan, 420021, Russian Federation|Research Medical Complex Vashe Zdorovie, Kazan, 420097, Russian Federation|City Clinical Hospital 4, Saransk, 430032, Russian Federation|Clinical Center of Serbia, Belgrade, 11000, Serbia|Clinical Hospital Centar Zvezdara, Belgrade, 11000, Serbia|Military Medical Academy, Belgrade, 11000, Serbia|Clinical Hospital Centre Zemun, Belgrade, 11080, Serbia|Clinical Center Kragujevac, Kragujevac, 34000, Serbia|Hospital Donostia, San Sebastian, 20014, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, 46026, Spain|Municipal Medical & Preventive Institution Chernigiv Regional Clinical Hospital, Chernigiv, 14033, Ukraine|Municipal Institution Dnipropetrovsk Regional Clinical Hospital na I.I. Mechnykov, Dnipropetrovsk, 49027, Ukraine|Regional Clinical Hospital, Ivano Frankivsk, 76008, Ukraine|State Treatment and Prevention Institution Central Clinical Hospital of Ukrzaliznytsya, Kharkiv, 61103, Ukraine|Municipal Institution of Kyiv Regional Council Kyiv Regional Clinical Hospital, Kyiv, 04107, Ukraine|Volyn Regional Clinical Hospital, Lutsk, 43024, Ukraine|Municipal Institution Vinnytsya Regional Psychoneurological Hospital na OI Yushchenko, Vinnytsya, 21005, Ukraine"
NCT04355663,"Neuroproprioceptive ""Facilitation, Inhibition"" and Brain Plasticity",https://beta.clinicaltrials.gov/study/NCT04355663,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Motor program activating therapy|BEHAVIORAL: Vojta's reflex locomotion|BEHAVIORAL: Functional electric stimulation,"Charles University, Czech Republic",,ALL,"ADULT, OLDER_ADULT",NA,92,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2015-05-20,2017-05-20,2019-08-01,
NCT01435993,Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01435993,TERMINATED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: GSK1223249|OTHER: Saline placebo,GlaxoSmithKline,,ALL,ADULT,PHASE1,3,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2011-09-08,2012-01-23,2012-01-23,"GSK Investigational Site, Verona, Veneto, 37134, Italy|GSK Investigational Site, Lørenskog, 1478, Norway"
NCT01767493,Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients,https://beta.clinicaltrials.gov/study/NCT01767493,COMPLETED,Multiple Sclerosis,DRUG: [18F]Florbetapir PET imaging,Institute for Neurodegenerative Disorders,Biogen,ALL,ADULT,PHASE4,19,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2012-11,2013-11,2013-11,"Institute for Neurodegenerative Disorders, New Haven, Connecticut, 06510, United States"
NCT01455220,The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01455220,COMPLETED,Multiple Sclerosis,DRUG: Tysabri ® (Natalizumab),University of South Florida,,ALL,ADULT,NA,45,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2011-01,2014-10,2014-10,"University of South Florida, Frank and Carol Morsani Center, Tampa, Florida, 33612, United States"
NCT00239993,A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone®,https://beta.clinicaltrials.gov/study/NCT00239993,COMPLETED,Multiple Sclerosis,DRUG: glatiramer acetate|PROCEDURE: Warm compress prior to injection of glatiramer acetate,"Teva Neuroscience, Inc.",,ALL,ADULT,PHASE4,50,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: PREVENTION,2005-08,2005-12,2006-02,"Fullerton Neurology & Headache Center, Fullerton, California, United States|Neurological Center of South Florida, Miami, Florida, United States|Springfield Neurology Associates, Springfield, Massachusetts, United States|Multiple Sclerosis Care Center, Brooklyn, New York, United States|Advanced Neurosciences Institute, Nashville, Tennessee, United States|Virginia Beach Neurology, Virginia Beach, Virginia, United States"
NCT01641120,Assessing Tolerability of Avonex Intramuscular Injections,https://beta.clinicaltrials.gov/study/NCT01641120,COMPLETED,Multiple Sclerosis,DRUG: Avonex,Saint Francis Care,Biogen,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2012-05,2014-02,2014-02,"The Mandell Center for Multiple Sclerosis, Hartford, Connecticut, 06112, United States"
NCT00536120,The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00536120,COMPLETED,Multiple Sclerosis,BIOLOGICAL: BG00002 (natalizumab)|BIOLOGICAL: keyhole limpet hemocyanin (KLH)|BIOLOGICAL: tetanus diphtheria toxoid vaccine (Td),Biogen,,ALL,ADULT,PHASE4,60,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: ",2008-01,2009-11,2009-12,"Research Site 1, Fullerton, California, 92835, United States|Research Site, Centennial, Colorado, 80112, United States|Research site, Farmington Hills, Michigan, 48334, United States|Research Site, Patchogue, New York, 11772, United States|Research Site 3, Charlotte, North Carolina, 28207, United States|Research Site 5, Oklahoma City, Oklahoma, 73130, United States|Research Site, Franklin, Tennessee, 37064, United States|Research Site, Dallas, Texas, 75214, United States|Research Site 2, Seattle, Washington, 98122, United States|Research Site 4, Charleston, West Virginia, 25301, United States"
NCT02100020,Implementing Physical Activity Guidelines for Adults With MS,https://beta.clinicaltrials.gov/study/NCT02100020,COMPLETED,Multiple Sclerosis,OTHER: Direct Referral to physical activity,McMaster University,,ALL,ADULT,NA,94,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2014-05,2018-03-31,2018-03-31,"McMaster University, Physical Activity Centre for Excellence, Hamilton, Ontario, L8S 4K1, Canada|Queens University, Kingston, Ontario, K7L 3N6, Canada"
NCT01659593,Evaluation of the Efficiency of a Cognitive Remedial Program (PROCOG-SEP) Designed for Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT01659593,UNKNOWN,Cognitive Disorders|Multiple Sclerosis,OTHER: procog|OTHER: Placebo,"Central Hospital, Nancy, France","University Hospital, Strasbourg, France|Centre Hospitalier Universitaire Dijon|Centre Hospitalier Universitaire de Besancon",ALL,ADULT,NA,140,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-09,2016-09,2018-06,"University hospital Nancy, Nancy, 54000, France"
NCT01954693,A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous Sclerosis,https://beta.clinicaltrials.gov/study/NCT01954693,UNKNOWN,Tuberous Sclerosis,DRUG: Placebo|DRUG: Everolimus (RAD001),Cardiff University,Novartis,ALL,"CHILD, ADULT",PHASE2,48,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-06,2018-08-06,2018-08-06,"Cardiff University, Cardiff, CF14 4YS, United Kingdom"
NCT03933020,Impact of Physical Activity on Cognitive Outcomes in Youth With Pediatric-Onset Multiple Sclerosis (POMS),https://beta.clinicaltrials.gov/study/NCT03933020,TERMINATED,Pediatric Onset Multiple Sclerosis (POMS),DEVICE: VR active video game intervention|BEHAVIORAL: Educational session|BEHAVIORAL: Standard Management of Physical Activity,"The University of Texas Health Science Center, Houston",Microsoft Houston,ALL,"CHILD, ADULT",NA,2,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2019-05-10,2019-05-31,2019-05-31,"The University of Texas Health Science Center,Houston, Houston, Texas, 77030, United States"
NCT05682963,Efficacy of Square- Stepping Exercises in Individuals With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05682963,RECRUITING,Multiple Sclerosis,OTHER: Square Step Exercises Program|OTHER: Home Exercise Program,Pamukkale University,,ALL,ADULT,NA,34,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-03-28,2025-12-30,2026-01-01,"Pamukkale University Denizli Health Services Vocational School of Higher Education, Denizli, Centre, 20160, Turkey"
NCT01943526,Ireland Natalizumab (TYSABRI) Observational Program,https://beta.clinicaltrials.gov/study/NCT01943526,COMPLETED,Relapsing-Remitting Multiple Sclerosis,BIOLOGICAL: natalizumab,Biogen,,ALL,"CHILD, ADULT, OLDER_ADULT",,191,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-11-30,2017-12-31,2017-12-31,"Research site, Cork, County Cork, Ireland|Research site, Dublin, County Dublin, Ireland|Research site, Galway, County Galway, Ireland|Research site, Tralee, County Kerry, Ireland|Research site, Sligo, County Sligo, Ireland"
NCT01652352,Experimental Evaluation of Wheelchair-Mounted Robotic Arms,https://beta.clinicaltrials.gov/study/NCT01652352,COMPLETED,Spinal Cord Injury|Cerebral Palsy|Multiple Sclerosis,,University of South Florida,U.S. National Science Foundation,ALL,ADULT,,20,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-08,2011-07,2011-07,"Rehabilitation Robotics and Prosthetics Testbed, Tampa, Florida, 33620, United States"
NCT04063852,PTNS on Urinary and Global Quality of Life in MS Patients,https://beta.clinicaltrials.gov/study/NCT04063852,COMPLETED,Multiple Sclerosis|Lower Urinary Tract Symptoms|Neurogenic Bladder|Overactive Bladder|Urinary Incontinence|Urinary Urge Incontinence,,University of Michigan,Society for Urodynamics & Female Urology (SUFU) Research Foundation,ALL,"ADULT, OLDER_ADULT",,23,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-02-27,2022-11-27,2022-11-27,"University of Michigan, Ann Arbor, Michigan, 48109, United States"
NCT01448252,T Cell Vaccination in Patients With Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01448252,COMPLETED,Multiple Sclerosis,BIOLOGICAL: multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides)|BIOLOGICAL: T cell vaccination,Hadassah Medical Organization,,ALL,ADULT,PHASE1|PHASE2,30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2002-05,2008-09,2009-03,"Dept of Neurology,Hadassah ein-Kerem, Jerusalem, 91120, Israel"
NCT01592552,"A Biospecimen and Clinical Data Study on Patients With Alzheimer's, Multiple Sclerosis, Parkinson's, and Huntington's, for Drug & Biomarker Discovery",https://beta.clinicaltrials.gov/study/NCT01592552,COMPLETED,Alzheimer's Disease|Multiple Sclerosis|Parkinson's Disease|Huntington's Disease|Amyotrophic Lateral Sclerosis (ALS),,Sanguine Biosciences,,ALL,"ADULT, OLDER_ADULT",,20,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-11,2015-03,2015-03,"Sanguine Biosciences, Sherman Oaks, California, 91403, United States"
NCT04267926,MitoQ for Fatigue in Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT04267926,RECRUITING,Multiple Sclerosis|Fatigue,DRUG: 20 mg MitoQ|DRUG: Placebo|DRUG: 40mg of MitoQ,VA Office of Research and Development,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,60,FED,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-04-01,2023-10-01,2024-03-31,"VA Portland Health Care System, Portland, OR, Portland, Oregon, 97207-2964, United States"
NCT03066752,Cognitive Dysfunction in MS: Using Altered Brain Oscillation to Link Molecular Mechanisms With Clinical Outcomes,https://beta.clinicaltrials.gov/study/NCT03066752,COMPLETED,Pediatric Multiple Sclerosis,,The Hospital for Sick Children,,ALL,"CHILD, ADULT",,20,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-03-27,2017-11-24,2017-11-24,"Hospital for Sick Children, Toronto, Ontario, M5G1X8, Canada"
NCT03983252,Effect of Alemtuzumab on Microglial Activation Positron Emission Tomography (PET) in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03983252,NOT_YET_RECRUITING,Multiple Sclerosis,DRUG: [F-18]PBR06,Brigham and Women's Hospital,"Genzyme, a Sanofi Company",ALL,ADULT,PHASE1|PHASE2,10,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2019-07,2024-05-01,2024-05-01,"Partners MS Center, 60 Fenwood Road, Boston, Massachusetts, 02115, United States"
NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT00404352,COMPLETED,Multiple Sclerosis,DRUG: RNF|DRUG: RNF|DRUG: Placebo,"Merck KGaA, Darmstadt, Germany",,ALL,ADULT,PHASE3,517,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2006-11,2010-08,2011-07,"Research Site, Mendoza, Argentina|Research Site, Sydney, Australia|Research Site, Graz, Austria|Research Site, Innsbruck, Austria|Research Site, B-Leuven, Belgium|Research Site, Brugge, Belgium|Research Site, Pleven, Bulgaria|Research Site, Rousse, Bulgaria|Research Site, Shumen, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Montreal, Quebec, Canada|Research Site, Ontario, Canada|Research Site, Victoria British Columbia, Canada|Research Site, Karlovac, Croatia|Research Site, Osijek, Croatia|Research Site, Rijeka, Croatia|Research Site, Split, Croatia|Research Site, Zagreb, Croatia|Research Site, Hradec Kralove, Czech Republic|Research Site, Olomouc, Czech Republic|Research Site, Prague, Czech Republic|Research Site, Tallinn, Estonia|Research Site, Tartu, Estonia|Research Site, OYS, Finland|Research Site, Vantaa, Finland|Research Site, Paris, France|Research Site, Poissy Cedex, France|Research Site, Hannover, Germany|Research Site, Henningsdorf, Germany|Research Site, Munich, Germany|Research Site, Athens, Greece|Research Site, Ness Ziona, Israel|Research Site, Safed, Israel|Research Site, Tel-Hashomer, Israel|Research Site, Catania, Italy|Research Site, Milano, Italy|Research Site, Padova, Italy|Research Site, Roma, Italy|Research Site, Riga, Latvia|Research Site, Beirut, Lebanon|Research Site, Rabat, Morocco|Research Site, Bialystok, Poland|Research Site, Lodz, Poland|Research Site, Warsaw, Poland|Research Site, Wroclaw, Poland|Research Site, Lisboa, Portugal|Research Site, Bucharest, Romania|Research Site, Iasi, Romania|Research Site, Targu-Mures, Romania|Research Site, Timisoara, Romania|Research Site, Ekaterinburg, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Samara, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Riyadh, Saudi Arabia|Research Site, Belgrade, Serbia|Research Site, Nis, Serbia|Research Site, Presov, Slovakia|Research Site, Barcelona, Spain|Research Site, Bilbao, Spain|Research Site, Madrid, Spain|Research Site, Sevilla, Spain|Research Site, Istanbul, Turkey"
NCT05177952,Low-Load Blood Flow Restriction on Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05177952,RECRUITING,Training Study|Multiple Sclerosis|Blood Flow Restriction,OTHER: Blood Flow Restriction|OTHER: Standard of Care,University of Central Florida,AdventHealth,FEMALE,ADULT,NA,30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-01-01,2022-12-31,2022-12-31,"University of Central Florida, Orlando, Florida, 32816, United States"
NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,https://beta.clinicaltrials.gov/study/NCT03870763,TERMINATED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Dimethyl Fumarate|DRUG: Peginterferon Beta-1a|DRUG: Placebo,Biogen,,ALL,CHILD,PHASE3,11,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-03-19,2022-07-21,2022-07-21,"Research Site, Raleigh, North Carolina, 27607, United States|Research Site, Medellín, Colombia|Research Site, Tallinn, 11315, Estonia|Research Site, Budapest, 1083, Hungary|Research Site, Ar-Ramtha, Jordan|Research Site, Seoul, 06351, Korea, Republic of|Research Site, Petaling Jaya, Malaysia|Research Site, Seberang Jaya, Malaysia|Research Site, Guadalajara, Mexico|Research Site, Morelia, Mexico|Research Site, Santa Cruz, Mexico|Research Site, Dammam, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, Taipei, 10002, Taiwan|Research Site, Taoyuan, 333, Taiwan|Research Site, Bangkok, Thailand|Research Site, Manouba, Tunisia|Research Site, Monastir, Tunisia|Research Site, Sfax, Tunisia|Research Site, Tunis, Tunisia|Research Site, Ankara, Turkey|Research Site, Izmir, Turkey|Research Site, Samsun, Turkey"
NCT05754593,"Study of Ovarian Reserve Concerning Patients With Multiple Sclerosis (MS), Compared to a Control Group",https://beta.clinicaltrials.gov/study/NCT05754593,NOT_YET_RECRUITING,Multiple Sclerosis,BIOLOGICAL: Anti-Mullerian hormone (AMH) level|OTHER: Antral follicle count (AFC)|OTHER: Clinical assessment,"University Hospital, Bordeaux",,FEMALE,ADULT,NA,160,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-04,2025-04,2025-04,"CHU de Bordeaux - service de neurologie, Bordeaux, France"
NCT04042363,Effect of Transorbital Electrical STIMulation of Optic Nerve on Remyelination After an Acute Optic Neuritis,https://beta.clinicaltrials.gov/study/NCT04042363,UNKNOWN,Multiple Sclerosis|Optic Neuritis,DEVICE: Transorbital electrical stimulation (Eyetronic Next Wave 1.1)|DEVICE: Transorbital electrical stimulation (Eyetronic Next Wave 1.1) - Sham stimulation,Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts,Fondation ARSEP|APHP,ALL,ADULT,NA,45,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-07-10,2021-07,2022-07,"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, Paris, 75012, France|Institut du Cerveau et de la Moelle epiniere - Hopital Pitie Salpetriere, Paris, France"
NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00134563,COMPLETED,Multiple Sclerosis,DRUG: Teriflunomide|DRUG: Placebo (for teriflunomide),Sanofi,,ALL,ADULT,PHASE3,1088,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2004-09,2010-07,2010-07,"Sanofi-Aventis, Bridgewater, New Jersey, 08807, United States|Sanofi-Aventis Austria, Vienna, Austria|sanofi-aventis, Canada, Laval, Canada|Sanofi-Aventis, Santiago de Chile, Chile|Sanofi-Aventis Administrative Office, Praha, Czech Republic|sanofi-aventis Denmark, Horsholm, Denmark|Sanofi-Aventis Administrative Office, Tallinn, Estonia|sanofi-aventis Finland, Helsinki, Finland|sanofi-aventis France, Paris, France|Sanofi-Aventis Deutschland GmbH, Berlin, Germany|Sanofi-Aventis, Milano, Italy|Sanofi-Aventis, Gouda, Netherlands|Sanofi-Aventis, Lysaker, Norway|sanofi-aventis Poland, Warszawa, Poland|Sanofi-Aventis, Porto Salvo, Portugal|Sanofi-Aventis, Moscow, Russian Federation|Sanofi-Aventis, Bromma, Sweden|Sanofi-Aventis Switzerland, Geneva, Switzerland|sanofi-aventis Turkey, Istanbul, Turkey|Sanofi-Aventis Administrative Office, Kiev, Ukraine|sanofi-aventis UK, Guildford, Surrey, United Kingdom"
NCT01766063,"Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on Betaferon",https://beta.clinicaltrials.gov/study/NCT01766063,COMPLETED,Multiple Sclerosis,"DRUG: Interferon beta-1b (Betaferon, BAY 86-5046)",Bayer,,ALL,"ADULT, OLDER_ADULT",,138,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-12-06,2017-01-09,2017-03-14,"Multiple Locations, Germany"
NCT01451593,Neuroprotection With Phenytoin in Optic Neuritis,https://beta.clinicaltrials.gov/study/NCT01451593,COMPLETED,Optic Neuritis|Multiple Sclerosis,DRUG: Phenytoin|DRUG: Placebo,"University College, London",National Multiple Sclerosis Society|Multiple Sclerosis Society of Great Britain and Northern Ireland,ALL,ADULT,PHASE2,92,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-11,2014-12,2015-03,"National Hospital for Neurology and Neurosurgery, London, WC1 3BG, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom"
NCT00232193,Safety/Effectiveness of Adding Monthly Dexamethasone to Weekly Avonex for MS,https://beta.clinicaltrials.gov/study/NCT00232193,COMPLETED,Relapsing-remitting Multiple Sclerosis|Clinically Isolated Syndrome,,Providence Multiple Sclerosis Center,Biogen,ALL,ADULT,,40,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2003-12,2008-12,2010-08,"Providence MS Center, Portland, Oregon, 97225, United States"
NCT01632293,Evaluating Intervention Responsiveness in People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01632293,COMPLETED,Multiple Sclerosis,BEHAVIORAL: progressive resistance training,"Hugo W. Moser Research Institute at Kennedy Krieger, Inc.",National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2012-04,2015-09,2015-09,"Motion Analysis Lab, Baltimore, Maryland, 21205, United States"
NCT01900093,Evaluation of the Response to Acthar Gel Therapy in Patients Who Failed Intravenous Methylprednisolone (IVMP) for MS Relapses,https://beta.clinicaltrials.gov/study/NCT01900093,UNKNOWN,Multiple Sclerosis,DRUG: Acthar Gel,Aaron Miller,Mallinckrodt,ALL,"ADULT, OLDER_ADULT",NA,10,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-07,2018-03,2018-03,"Icahn School of Medicine at Mount Sinai, New York, New York, 10029, United States"
NCT01932593,Repeat Infusion of Autologous Bone Marrow Cells in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01932593,COMPLETED,Multiple Sclerosis,PROCEDURE: Infusion of autologous bone marrow,North Bristol NHS Trust,Sir Halley Stewart Trust,ALL,"ADULT, OLDER_ADULT",NA,4,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2014-01-31,2017-09-01,2018-08-20,"North Bristol NHS Trust, Bristol, Avon, BS10 5NB, United Kingdom"
NCT04386863,Taxonomy of Neurorehabilitation Treatments and Outcome Measures: a Multicentre Italian Study,https://beta.clinicaltrials.gov/study/NCT04386863,COMPLETED,Multiple Sclerosis|Stroke|Parkinson Disease,,Fondazione Don Carlo Gnocchi Onlus,"IRCCS San Camillo, Venezia, Italy|Universita degli Studi di Genova|AIAS di Milano Onlus|Ospedale San Carlo Borromeo|Azienda Universitaria Integrata Giuliano Isontina, Trieste, Italy|Presidio Ospedaliero San Camillo di Torino|Ospedali Riuniti Ancona|Istituto Don Orione, Pescara, Italy",ALL,"ADULT, OLDER_ADULT",,204,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-06-22,2022-07-07,2022-07-22,"Universita degli Studi di Genova, Genova, 16126, Italy|Fondazione Don Gnocchi ONLUS, Milan, 20148, Italy|Ospedale San Carlo Borromeo, Milan, 20153, Italy|AIAS di Milano Onlus, Milan, 20156, Italy|Ospedale San Giovanni Battista ACISMOM, Roma, 00148, Italy|Università degli studi di Trieste, Trieste, 34127, Italy|IRCCS San Camillo, Venice, 30126, Italy"
NCT02308579,Centralized Reading Assessment of Chronic CerebroSpinal Venous Insufficiency (CCSVI) in Patients With Multiple Sclerosis and Other Neurological Diseases,https://beta.clinicaltrials.gov/study/NCT02308579,COMPLETED,Clinically Isolated Syndrome (CIS)|Multiple Sclerosis (MS)|Other Neurological Disorders (OND)|Healthy (HC),,University at Buffalo,University of Pavia,ALL,"CHILD, ADULT, OLDER_ADULT",,499,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-07,2015-03,2015-03,
NCT02170779,Developing and Testing a Comprehensive MS Spasticity Management Program,https://beta.clinicaltrials.gov/study/NCT02170779,COMPLETED,Multiple Sclerosis|Spasticity,BEHAVIORAL: Spasticity: Take Control|OTHER: Usual care,VA Office of Research and Development,Oregon Health and Science University,ALL,"ADULT, OLDER_ADULT",PHASE2,40,FED,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2015-10,2016-05,2016-06,"VA Portland Health Care System, Portland, OR, Portland, Oregon, 97239, United States"
NCT00457808,Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM,https://beta.clinicaltrials.gov/study/NCT00457808,COMPLETED,Tuberous Sclerosis|Lymphangioleiomyomatosis,"DRUG: Rapamycin, sirolimus","Children's Hospital Medical Center, Cincinnati",The LAM Foundation|Tuberous Sclerosis Alliance,ALL,"ADULT, OLDER_ADULT",PHASE2,25,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2002-12,,2006-03,"Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, 45229-3039, United States"
NCT04294979,Exercise Therapy in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04294979,UNKNOWN,Multiple Sclerosis,OTHER: Physical Therapy,IRCCS San Raffaele,Neuromed IRCCS,ALL,"ADULT, OLDER_ADULT",NA,44,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-02-01,2021-09-01,2023-02-01,"IRCCS San Raffele Pisana, Roma, RM, 00166, Italy"
NCT03863379,Sarcopenic Obesity in Neurodisabilities,https://beta.clinicaltrials.gov/study/NCT03863379,COMPLETED,Sarcopenic Obesity|Spinal Cord Injuries|Stroke|Multiple Sclerosis|Traumatic Brain Injury,DIAGNOSTIC_TEST: whole body DXA,"Dionyssiotis, Yannis, M.D.",University of Athens|University of Patras,ALL,"ADULT, OLDER_ADULT",,150,INDIV,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-05-02,2021-06-15,2022-05-15,"National Rehabilitation Center EKA, Ilion, Athens, 13122, Greece"
NCT01328379,Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01328379,COMPLETED,Multiple Sclerosis,DRUG: Dalfampridine-ER 5mg|DRUG: Dalfampridine-ER 10mg|OTHER: Placebo,Acorda Therapeutics,,ALL,"ADULT, OLDER_ADULT",PHASE3,430,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-03,2012-04,2012-07,"North Central Neurology Associates, PC, Cullman, Alabama, United States|Phoenix Neurological Associates, Ltd, Phoenix, Arizona, United States|Arizona Neurological Institute, Sun City, Arizona, United States|Clinical Research Advantage Inc., Tempe, Arizona, United States|Sutter East Bay Physicians Medical Foundation, Berkeley, California, United States|Neuro-Pain Medical Center, Inc., Fresno, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Collaborative NeuroScience Network, Inc., Long Beach, California, United States|University of California Davis Medical Center, Sacramento, California, United States|Mount Sinai Rehabilitation Hospital, Hartford, Connecticut, United States|Georgetown University Hospital, Washington, District of Columbia, United States|Neurology Associates, PA, Maitland, Florida, United States|University of Miami School of Medicine, Dept. of Neurology, Miami, Florida, United States|Neurological Associates, Pompano Beach, Florida, United States|Neurologique Foundation, Inc., Ponte Vedra, Florida, United States|Suncoast Neuroscience Associates, Inc., Saint Petersburg, Florida, United States|Negroski, Sutherland and Hanes Neurology, Sarasota, Florida, United States|Tallahassee Neurological Clinic, PA, Tallahassee, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|The Multiple Sclerosis Center of Vero Beach, Vero Beach, Florida, United States|Sheperd Center, Inc., Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Consultants in Neurology Ltd., Northbrook, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|Josephson Wallack Munshower Neurology, PC, Indianapolis, Indiana, United States|Methodist Plaza Specialty, Des Moines, Iowa, United States|Ruan Neurology Clinic and Research Center, Des Moines, Iowa, United States|The University of Kansas Medical Center, Kansas City, Kansas, United States|Associates in Neurology, PSC, Lexington, Kentucky, United States|University of Maryland, Maryland Center for Multiple Sclerosis, Baltimore, Maryland, United States|Lahey Clinic, Lexington, Massachusetts, United States|Springfield Neurology Associates, LLC, Springfield, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|Advanced Neurology Specialists, Great Falls, Montana, United States|Veterans Administration Sierra Neveda Health Care System, Reno, Nevada, United States|Upstate Clinical Research, LLC, Albany, New York, United States|NYU Langone Medical Center MS Comprehensive Care Center, New York, New York, United States|Comprehensive Multiple Sclerosis Care Center at South Shore Neurologic Associates, Patchogue, New York, United States|Island Neurological Associates, PC, Plainview, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|PMG Research of Charlotte, Charlotte, North Carolina, United States|The Neurological Institute, PA, Charlotte, North Carolina, United States|PMG Research of Hickory, LLC, Hickory, North Carolina, United States|Raleigh Neurology Associates, Raleigh, North Carolina, United States|PMG Research of Winston-Salem, Winston-Salem, North Carolina, United States|Altru Health System Clinic, Grand Forks, North Dakota, United States|Northern Ohio Neuroscience, LLC, Bellevue, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Neurological Research Institute, Columbus, Ohio, United States|Ohio State University, Columbus, Columbus, Ohio, United States|Neurology Specialists, Inc., Dayton, Ohio, United States|OMRF Multiple Sclerosis Center of Excellence, Oklahoma City, Oklahoma, United States|Oregon Health and Science University, Portland, Oregon, United States|Providence Multiple Sclerosis Center, Portland, Oregon, United States|The Pennsylvania State University, Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University School of Medicine, Philadelphia, Pennsylvania, United States|The Neurology Foundation, Inc., Providence, Rhode Island, United States|Wesley Neurology Clinic, PC, Cordova, Tennessee, United States|Advanced Neurosciences Institute, Franklin, Tennessee, United States|Sibyl E. Wray, MD, Neurology, PC, Knoxville, Tennessee, United States|Texas Neurology, PA, Dallas, Texas, United States|Kelsey-Seybold Clinic, Houston, Texas, United States|Maxine Mesinger Multiple Sclerosis Clinic; Baylor College of Medicine, Houston, Texas, United States|Fletcher Allen Health Care, Burlington, Vermont, United States|Hampton Roads Neurology, Newport News, Virginia, United States|Neurological Associates, Richmond, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Swedish Neuroscience Institute, Seattle, Washington, United States|Aurora Saint Luke's Medical Center, Milwaukee, Wisconsin, United States"
NCT03945006,"Balance, Trunk Impairment and Fear of Falling in Multiple Sclerosis Patients With Incontinence",https://beta.clinicaltrials.gov/study/NCT03945006,COMPLETED,Multiple Sclerosis|Physical Therapy|Incontinence,OTHER: Incontinence Severity|OTHER: Balance|OTHER: Trunk impairment|OTHER: Fear of falling,Ankara Yildirim Beyazıt University,,ALL,ADULT,,36,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-03-25,2019-04-20,2019-04-30,"Ankara Yıldırım Beyazıt University, Faculty of Health Sciences,Department of Physiotherapy and Rehabilitation, Ankara, Esenboğa, 06970, Turkey"
NCT02257606,Robot-assisted Training of the Upper Limb in Persons With Multiple Sclerosis: an Randomized Controlled Trial,https://beta.clinicaltrials.gov/study/NCT02257606,COMPLETED,Multiple Sclerosis,OTHER: I-TRAVLE training,Hasselt University,Revalidatie & MS Centrum Overpelt|Expertise Centre for digital Media|tUL|iMinds|Interreg,ALL,"ADULT, OLDER_ADULT",NA,17,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2011-07,2011-09,2011-09,
NCT05362006,"Exopulse Mollii Suit, Spasticity & Tissue Oxygenation",https://beta.clinicaltrials.gov/study/NCT05362006,RECRUITING,Multiple Sclerosis,DEVICE: Exopulse Mollii Suit|DEVICE: Exopulse Mollii suit (sham),Institut De La Colonne Vertebrale Et Des Neurosciences,,ALL,"ADULT, OLDER_ADULT",NA,34,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-03-01,2023-03,2023-04,"Hopital Henri Mondor, Créteil, 94010, France"
NCT05482906,Common and Specific Information From Neuroimaging and Smartphone,https://beta.clinicaltrials.gov/study/NCT05482906,RECRUITING,Multiple Sclerosis,OTHER: eGait,Nantes University Hospital,Rennes University Hospital,ALL,"ADULT, OLDER_ADULT",,100,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-04-03,2025-04-01,2025-04-01,"Nantes University Hospital, Nantes, Loire-Atlantique, 44093, France"
NCT00670449,An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00670449,COMPLETED,Multiple Sclerosis,DRUG: Fingolimod,Novartis,Mitsubishi Tanabe Pharma Corporation,ALL,ADULT,PHASE2,143,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2008-04,2012-04,2012-04,"Novartis Investigative Site, Chiba, 276-8524, Japan|Novartis Investigative Site, Ehime, 791-0295, Japan|Novartis Investigative Site, Fukuoka, 807-8555, Japan|Novartis Investigative Site, Gunma, 371-8511, Japan|Novartis Investigative Site, Hyogo, 650-0017, Japan|Novartis Investigative Site, Ibaraki, 305-8576, Japan|Novartis Investigative Site, Kanagawa, 259-1193, Japan|Novartis Investigative Site, Kyoto, 604-8453, Japan|Novartis Investigative Site, Kyoto, 616-8255, Japan|Novartis Investigative Site, Morioka, 020-8505, Japan|Novartis Investigative Site, Niigata, 951-8520, Japan|Novartis Investigative Site, Osaka, 556-0016, Japan|Novartis Investigative Site, Osaka, 589-8511, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Sapporo, 060-8648, Japan|Novartis Investigative Site, Tochigi, 329-0498, Japan|Novartis Investigative Site, Tokyo, 113-8519, Japan|Novartis Investigative Site, Tokyo, 145-0065, Japan|Novartis Investigative Site, Tokyo, 162-8666, Japan|Novartis Investigative Site, Wakayama, 641-8510, Japan"
NCT01742052,Dose-finding Study of MT-1303,https://beta.clinicaltrials.gov/study/NCT01742052,COMPLETED,Relapsing-remitting Multiple Sclerosis,DRUG: MT-1303-Low|DRUG: MT-1303-Middle|DRUG: MT-1303-High|DRUG: Placebo,Mitsubishi Tanabe Pharma Corporation,,ALL,ADULT,PHASE2,415,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-01,2014-07,2014-10,"Research Site, Brussels, Belgium|Research Site, Sofia, Bulgaria|Research Site, Edmonton, Canada|Research Site, Zagreb, Croatia|Research Site, Praha, Czech Republic|Research Site, Vantaa, Finland|Research Site, Berlin, Germany|Research Site, Budapest, Hungary|Research Site, Roma, Italy|Research Site, Kaunas, Lithuania|Research Site, Katowice, Poland|Research Site, Moscow, Russian Federation|Research Site, Belgrade, Serbia|Research Site, Madrid, Spain|Research Site, Basel, Switzerland|Research Site, Kozyatagi, Istanbul, Turkey|Research Site, Kiev, Ukraine|Research Site, London, United Kingdom"
NCT01906684,Comprehensive Analysis of Relapse in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01906684,UNKNOWN,Multiple Sclerosis,DRUG: Acthar Gel,Tanner Foundation for Multiple Sclerosis,Mallinckrodt|Auburn University MRI Research Center|iReportoire Inc,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-08,2014-01,2015-01,"Tanner Center for MS, Birmingham, Alabama, 35209, United States"
NCT03826628,Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex,https://beta.clinicaltrials.gov/study/NCT03826628,COMPLETED,Facial Angiofibroma|Tuberous Sclerosis,DRUG: rapamycin|DRUG: placebo,Dermatology Specialties Limited Partnership,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2|PHASE3,107,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-07-28,2022-07-12,2022-07-12,"Phoenix Children's Hospital, Phoenix, Arizona, 85016, United States|University of California San Diego, La Jolla, California, 92037, United States|All Children's Research Institute, Saint Petersburg, Florida, 33701, United States|Spectrum Health, Grand Rapids, Michigan, 49503, United States|Mayo Clinic, Rochester, Minnesota, 55905, United States|University of Virginia, Charlottesville, Virginia, 22903, United States|Children's Health Queensland, Brisbane, Queensland, 4101, Australia|Fakultni nemocnice Brno, Brno, 5HG9+4W, Czechia|Bethesda Children's Hospital of the Hungarian Reformed Church, Budapest, G39Q+49, Hungary|University of Pécs, Pécs, H-7624, Hungary|Canterbury District Health Board, Christchurch, Canterbury, 8011, New Zealand|Clinic of Neurology and Psychiatry for Children and Youth, Belgrade, 11000, Serbia|Clinical Center of Serbia, Belgrade, 11000, Serbia|Narodný ústav detských chorȏb, Bratislava, 83340, Slovakia|Clinica Universidad de Navarra, Pamplona, Navarra, 31008, Spain|Clínica Universidad de Navarra, Madrid, 28007, Spain|National Taiwan University Hospital, Taipei, Taiwan"
NCT00367484,Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00367484,COMPLETED,Relapsing Remitting Multiple Sclerosis,BIOLOGICAL: Rebif® (clone 484-39),"Merck KGaA, Darmstadt, Germany",,ALL,ADULT,PHASE4,460,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2004-05,2006-01,2006-01,
NCT00984984,Efficacy and Safety of Methylprednisolone Per os Versus IV for the Treatment of Multiple Sclerosis (MS) Relapses,https://beta.clinicaltrials.gov/study/NCT00984984,UNKNOWN,"Multiple Sclerosis, Relapsing-Remitting",DRUG: methylprednisolone PO|DRUG: methylprednisolone IV,Rennes University Hospital,,ALL,ADULT,PHASE3,200,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2008-03,2013-06,2014-06,"Hôpital des Armées, Brest, 29249, France|CHU Cavale Blanche, Brest, 29609, France|Centre Hospitalier de Vendée, La Roche sur Yon, 85000, France|Centre Hospitalier de Lannion, Lannion, 22300, France|Centre hospitalier Bretagne Sud, Lorient, 56100, France|CHU Laennec, Nantes, 44000, France|Hôpital La pitié Salpétriere, Paris, 75651 cedex 13, France|Centre Hospitalier de Pontivy, Pontivy, 56300, France|CH de Cornouaille, Quimper, 29000, France|Hôpital de Cornouaille, Quimper, 29000, France|Rennes University Hospital, Rennes, 35033, France|Hopital Yves Le Foll, Saint Brieuc, 22023, France|CH Saint Malo, Saint Malo, 35400, France|Centre Hospitalier Bretagne Atlantique, Vannes, 56000, France"
NCT04796584,Efficacy of COVID-19 Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication,https://beta.clinicaltrials.gov/study/NCT04796584,TERMINATED,Multiple Sclerosis,OTHER: Analysis of cell-mediated and antibody-mediated immunity to SARS-CoV-2 virus,Providence Health & Services,,ALL,"ADULT, OLDER_ADULT",,20,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-07-11,2022-10-04,2022-10-25,"Providence Neurological Specialties West, Portland, Oregon, 97225, United States"
NCT00050778,"A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT00050778,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",BIOLOGICAL: Interferon beta-1a|BIOLOGICAL: Alemtuzumab 12 mg|BIOLOGICAL: Alemtuzumab 24 mg,"Genzyme, a Sanofi Company",Bayer,ALL,ADULT,PHASE2,334,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2002-12,2007-09,2010-01,"Mayo Clinic Scottsdale Arizona, Scottsdale, Arizona, 85259, United States|Clinical Trials, Inc, Little Rock, Arkansas, 72205, United States|East Bay Physicians Medical Group, Berkeley, California, 94705, United States|Nerve Pro Research, Irvine, California, 92618, United States|Neuro-Therapeutics, Inc., Pasadena, California, 91105, United States|Neurological Research Institute of the East Bay, Walnut Creek, California, 938-1343, United States|Neurologic Research Institute/Mile High Research Center, Denver, Colorado, 80218, United States|Neurological Service of Orlando, Orlando, Florida, 32806, United States|Neurological Associates/ Research Dept., Pompano Beach, Florida, 33060, United States|Neurology Clinical Research, Inc., Sunrise, Florida, 3335-6637, United States|Axiom Clinical Research of Florida, Tampa, Florida, 33609, United States|Medical Research and Health Education, Columbus, Georgia, 31909, United States|Consultants in Neurology, Ltd, Northbrook, Illinois, 60062, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, 46805, United States|Associate in Neurology, Lexington, Kentucky, 40503, United States|University of Maryland -Maryland Center for MS, Baltimore, Maryland, 21201, United States|Wayne State University Department of Neurology, Detroit, Michigan, 48201, United States|Michigan Institute for Neurological Disorders, Farmington Hills, Michigan, 48334, United States|Michigan Medical P.C. Neurology, Grand Rapids, Michigan, 49525, United States|Mayo Clinic Rochester Department of Neurology, Rochester, Minnesota, 55905, United States|Nevada Neurological Consultants, Ltd., Las Vegas, Nevada, 89102, United States|University Hospital an Medical Center, Stony Brook, New York, 11794, United States|ALL-Trials Clinical Research, LLC, Winston-Salem, North Carolina, 27103, United States|Neurological Associates of Tulsa, Inc, Tulsa, Oklahoma, 74137, United States|Neurosciencies and Pain Research, Allentown, Pennsylvania, 18103-6296, United States|Neurology, PC, Knoxville, Tennessee, 37934, United States|Baylor College of Medicine, Houston, Texas, United States|Dallas Neurological Associate, Richardson, Texas, 75080, United States|Central Texas Neurology Consultants PA, Round Rock, Texas, 78681, United States|Integra Clinical Research, LLC, San Antonio, Texas, 78231, United States|Neurology Center of San Antonio, San Antonio, Texas, 78258, United States|Department of Neurology, University Hospital ""Osijek"", Osijek, Croatia|Department of Neurology, Clinical Hospital Centre ""Rijeka"", Rijeka, Croatia|Department of Neurology, Clinical Hospital Centre ""Zagreb"", Zagreb, Croatia|Department of Neurology, General Hospital ""Sveti Duh"", Zagreb, Croatia|Department of Neurology, University Hopsital ""Sestre Milosrdnice"", Zagreb, Croatia|Centrum Neurologii Klinicznej, Krakow, Poland|Samodzielny Publiczny Zakład Opieki Zdrowotnej, Lodz, Poland|Klinika Neurologii, Lublin, Poland|Oddzial Kliniczny Neurologii, Poznan, Poland|Instytut Psychiatrii i Neurologii, Warszawa, Poland|Katedra i Klinika Neurologii, Warszawa, Poland|Russian State Medical University, Moscow, 117437, Russian Federation|Neurology Scientific Center RAMS, Moscow, 125367, Russian Federation|Moscow City Hospital #11, Moscow, Russian Federation|Moscow City Hospital #61, Moscow, Russian Federation|Institute of Human brain RAS, St. Petersburg, 197376, Russian Federation|St. Petersburg State Pavlov Medical University, St. Petersburg, Russian Federation|Addenbrooke's Hospital, Cambridge, England, United Kingdom"
NCT01250678,Neurocognitive Changes in Patients With Remitting Relapsing Multiple Sclerosis Treated With Natalizumab,https://beta.clinicaltrials.gov/study/NCT01250678,UNKNOWN,Multiple Sclerosis|Cognitive Impairment,,Cantonal Hospital of St. Gallen,Biogen,ALL,ADULT,,50,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-01,2014-01,2014-06,"Cantonal Hospital of Saint Gallen, Saint Gallen, 9007, Switzerland"
NCT03931278,Sonification Embodied Associations,https://beta.clinicaltrials.gov/study/NCT03931278,COMPLETED,Multiple Sclerosis,OTHER: learning and recall of a sequence of body movements,Hasselt University,University Ghent|Revalidatie & MS Centrum Overpelt|National MS Center Melsbroek,ALL,"ADULT, OLDER_ADULT",NA,62,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2018-12-18,2020-01-24,2020-01-24,"University Ghent, Ghent, 9000, Belgium|National MS Center Melsbroek, Melsbroek, 1820, Belgium|Revalidatie en MS Centrum Overpelt, Overpelt, 3900, Belgium"
NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),https://beta.clinicaltrials.gov/study/NCT04410978,ACTIVE_NOT_RECRUITING,Relapsing Multiple Sclerosis,DRUG: Tolebrutinib|DRUG: Teriflunomide HMR1726|DRUG: Placebo to match Tolebrutinib|DRUG: Placebo to match Teriflunomide,Sanofi,,ALL,ADULT,PHASE3,900,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-06-30,2023-09-06,2023-09-06,"University of Alabama MS Center-Site Number:8400013, Birmingham, Alabama, 35233, United States|University of San Francisco, Sandler Neurosciences Center-Site Number:8400137, San Francisco, California, 94158, United States|University of Colorado-Site Number:8400012, Aurora, Colorado, 80045, United States|Georgetown University Medical Center-Site Number:8400119, Washington, District of Columbia, 20007, United States|Beth Israel Deaconess Medical Center-Site Number:8400064, Fort Myers, Florida, 33919, United States|Axiom Clinical Research of Florida-Site Number:8400001, Tampa, Florida, 33609-4052, United States|University of South Florida-Site Number:8400006, Tampa, Florida, 33612, United States|Meridian Clinical Research-Site Number:8400003, Savannah, Georgia, 31406, United States|Consultants In Neurology-Site Number:8400011, Northbrook, Illinois, 60062, United States|Tufts Medical Center-Site Number:8400072, Boston, Massachusetts, 02111, United States|Michigan Institute For Neurological Disorders-Site Number:8400058, Farmington Hills, Michigan, 48334, United States|The Memorial Hospital-Site Number:8400033, Owosso, Michigan, 48867, United States|Sharlin Health & Neurology-Site Number:8400093, Ozark, Missouri, 65721, United States|Missouri Baptist Medical Center-Site Number:8400019, Saint Louis, Missouri, 63131, United States|Meridian Clinical Research, LLC-Site Number:8400005, Raleigh, North Carolina, 27607, United States|Wake Forest University Baptist Medical Center-Site Number:8400116, Winston-Salem, North Carolina, 27157, United States|The Ohio State University Wexner Medical Center-Site Number:8400150, Columbus, Ohio, 43221, United States|Optimed Research, LTD-Site Number:8400147, Columbus, Ohio, 43235, United States|Columbus Neuroscience-Site Number:8400010, Westerville, Ohio, 40382, United States|Oklahoma Medical Research Foundation-Site Number:8400018, Oklahoma City, Oklahoma, 73104, United States|Providence Multiple Sclerosis Center-Site Number:8400020, Portland, Oregon, 97225, United States|University of Texas Southwestern Medical Center-Site Number:8400077, Dallas, Texas, 75390, United States|Multiple Sclerosis Center, Swedish Neuroscience Institute-Site Number:8400121, Seattle, Washington, 98122, United States|Investigational Site Number :0400004, Linz, 4021, Austria|Investigational Site Number :1120005, Vitebsk, 210009, Belarus|Investigational Site Number :1120004, Vitebsk, 210037, Belarus|Investigational Site Number :1000002, Pleven, 5800, Bulgaria|Investigational Site Number :1000005, Plovdiv, 4000, Bulgaria|Investigational Site Number :1000004, Sofia, 1113, Bulgaria|Investigational Site Number :1000008, Sofia, 1407, Bulgaria|Investigational Site Number :1000001, Sofia, 1431, Bulgaria|Investigational Site Number :1000006, Sofia, 1431, Bulgaria|Investigational Site Number :1000009, Sofia, 1680, Bulgaria|Investigational Site Number :1240016, Vancouver, British Columbia, V6T 2B5, Canada|Investigational Site Number :1240003, Ottawa, Ontario, K1H 8L6, Canada|Investigational Site Number :1240013, Toronto, Ontario, M5B 1W8, Canada|Investigational Site Number :1240006, Gatineau, Quebec, J8Y 1W2, Canada|Investigational Site Number :1560022, Baotou, 014010, China|Investigational Site Number :1560006, Beijing, 100034, China|Investigational Site Number :1560010, Beijing, 100050, China|Investigational Site Number :1560012, Beijing, 100053, China|Investigational Site Number :1560023, Beijing, 100191, China|Investigational Site Number :1560001, Beijing, 100730, China|Investigational Site Number :1560009, Beijing, 100730, China|Investigational Site Number :1560025, Beijing, 100730, China|Investigational Site Number :1560021, Beijing, 100853, China|Investigational Site Number :1560004, Changchun, 130021, China|Investigational Site Number :1560015, Changsha, 410008, China|Investigational Site Number :1560005, Chengdu, 610041, China|Investigational Site Number :1560019, Chongqing, 400016, China|Investigational Site Number :1560035, Fuzhou, 350005, China|Investigational Site Number :1560016, Guangzhou, 510080, China|Investigational Site Number :1560028, Guangzhou, 510515, China|Investigational Site Number :1560002, Guangzhou, 510630, China|Investigational Site Number :1560027, Hohhot, 010050, China|Investigational Site Number :1560044, Nanjing, 210008, China|Investigational Site Number :1560042, Nanjing, 210029, China|Investigational Site Number :1560003, Shanghai, 200040, China|Investigational Site Number :1560018, Shenyang, 110004, China|Investigational Site Number :1560014, Shijiazhuang, 050000, China|Investigational Site Number :1560008, Taiyuan, 030001, China|Investigational Site Number :1560020, Tianjin, 300052, China|Investigational Site Number :1560011, Wuhan, 430030, China|Investigational Site Number :1560017, Xi'an, 710038, China|Investigational Site Number :1560033, Yinchuan, 750004, China|Investigational Site Number :2030004, Hradec Kralove, 50005, Czechia|Investigational Site Number :2030009, Pardubice, 53203, Czechia|Investigational Site Number :2030003, Teplice, 415 29, Czechia|Investigational Site Number :2030007, Zlin, 76275, Czechia|Investigational Site Number :2080001, Esbjerg, 6700, Denmark|Investigational Site Number :2080005, Holstebro, 7500, Denmark|Investigational Site Number :2330001, Tallinn, 11315, Estonia|Investigational Site Number :2330002, Tartu, 50406, Estonia|Investigational Site Number :2460003, Helsinki, 00180, Finland|Investigational Site Number :2460001, Tampere, 33520, Finland|Investigational Site Number :2460002, Turku, 20520, Finland|Investigational Site Number :2760001, Dresden, 01307, Germany|Investigational Site Number :2760019, Düsseldorf, 40225, Germany|Investigational Site Number :2760016, Hamburg, 22179, Germany|Investigational Site Number :2760008, Münster, 48149, Germany|Investigational Site Number :2760004, Rostock, 18055, Germany|Investigational Site Number :2760011, Ulm, 89081, Germany|Investigational Site Number :3800002, Pozzilli, Isernia, 86077, Italy|Investigational Site Number :3800007, Orbassano, Torino, 10043, Italy|Investigational Site Number :3800011, Bergamo, 24127, Italy|Investigational Site Number :3800015, Catania, 95123, Italy|Investigational Site Number :3800012, Firenze, 50134, Italy|Investigational Site Number :3800014, Genova, 16132, Italy|Investigational Site Number :3800001, Milano, 20132, Italy|Investigational Site Number :3800010, Milano, 20133, Italy|Investigational Site Number :3800003, Napoli, 80131, Italy|Investigational Site Number :3800006, Napoli, 80131, Italy|Investigational Site Number :3800008, Pavia, 27100, Italy|Investigational Site Number :3800005, Roma, 00152, Italy|Investigational Site Number :3800009, Roma, 00168, Italy|Investigational Site Number :3800013, Roma, 00189, Italy|Investigational Site Number :3920016, Chiba-shi, Chiba, 260-8677, Japan|Investigational Site Number :3920008, Koriyama-shi, Fukushima, 963-8052, Japan|Investigational Site Number :3920012, Tsukuba-shi, Ibaraki, 305-0005, Japan|Investigational Site Number :3920022, Morioka-shi, Iwate, 020-8505, Japan|Investigational Site Number :3920005, Niigata-shi, Niigata, 951-8520, Japan|Investigational Site Number :3920004, Moriguchi-shi, Osaka, 570-8507, Japan|Investigational Site Number :3920001, Osaka-shi, Osaka, 556-0016, Japan|Investigational Site Number :3920018, Kawagoe-shi, Saitama, 350-8550, Japan|Investigational Site Number :3920014, Bunkyo-ku, Tokyo, 113-8431, Japan|Investigational Site Number :3920003, Kodaira-shi, Tokyo, 187-8551, Japan|Investigational Site Number :3920010, Ota-ku, Tokyo, 146-0065, Japan|Investigational Site Number :3920013, Shinjuku-ku, Tokyo, 162-8666, Japan|Investigational Site Number :3920009, Ube-shi, Yamaguchi, 755-8505, Japan|Investigational Site Number :3920023, Sagamihara-shi, 252-0392, Japan|Investigational Site Number :4400003, Kaunas, 50161, Lithuania|Investigational Site Number :4400002, Klaipeda, 92288, Lithuania|Investigational Site Number :4400004, Siauliai, LT-76231, Lithuania|Investigational Site Number :4400001, Vilnius, 08661, Lithuania|Investigational Site Number :4840002, Mexico, 03100, Mexico|Investigational Site Number :4840001, Mexico, 06700, Mexico|Investigational Site Number :4840003, Veracruz, 91910, Mexico|Investigational Site Number :6160003, Bydgoszcz, Kujawsko-pomorskie, 85-796, Poland|Investigational Site Number :6160005, Warszawa, Mazowieckie, 01-211, Poland|Investigational Site Number :6160006, Warszawa, Mazowieckie, 01-684, Poland|Investigational Site Number :6160009, Glogow Mlp., Podkarpackie, 36-060, Poland|Investigational Site Number :6160002, Katowice, Slaskie, 40-571, Poland|Investigational Site Number :6160004, Katowice, Slaskie, 40-686, Poland|Investigational Site Number :6160008, Plewiska, Wielkopolskie, 62-064, Poland|Investigational Site Number :6160001, Lodz, 90-549, Poland|Investigational Site Number :6420015, Brasov, 500283, Romania|Investigational Site Number :6420008, Bucuresti, 022328, Romania|Investigational Site Number :6420004, Campulung, 115100, Romania|Investigational Site Number :6420003, Constanta, 900123, Romania|Investigational Site Number :6420010, Oradea, 410169, Romania|Investigational Site Number :6420005, Sibiu, 550052, Romania|Investigational Site Number :6420001, Targu Mures, 540136, Romania|Investigational Site Number :6420002, Timisoara, 300736, Romania|Investigational Site Number :6430014, Krasnoyarsk, 660029, Russian Federation|Investigational Site Number :6430002, Moscow, 125367, Russian Federation|Investigational Site Number :6430008, Moscow, 129128, Russian Federation|Investigational Site Number :6430011, Nizhny Novgorod, 603137, Russian Federation|Investigational Site Number :6430003, Nizhny Novgorod, 603155, Russian Federation|Investigational Site Number :6430007, Pyatigorsk, 357538, Russian Federation|Investigational Site Number :6430012, Rostov-on-Don, 344022, Russian Federation|Investigational Site Number :6430005, Samara, 443095, Russian Federation|Investigational Site Number :6430009, Smolensk, 214018, Russian Federation|Investigational Site Number :6430001, St-Petersburg, 194044, Russian Federation|Investigational Site Number :6430006, Tyumen, 625000, Russian Federation|Investigational Site Number :6430004, Ufa, 450005, Russian Federation|Investigational Site Number :7240003, Sevilla, Andalucia, 41009, Spain|Investigational Site Number :7240009, Barcelona, Barcelona [Barcelona], 08035, Spain|Investigational Site Number :7240001, Pozuelo De Alarcón, Madrid, 28223, Spain|Investigational Site Number :7240008, Donostia, Pais Vasco, 20014, Spain|Investigational Site Number :7240004, Córdoba, 14004, Spain|Investigational Site Number :7240006, Murcia, 30120, Spain|Investigational Site Number :7240005, Málaga, 29010, Spain|Investigational Site Number :7240007, Valencia, 46026, Spain|Investigational Site Number :7520001, Göteborg, 413 45, Sweden|Investigational Site Number :7520002, Stockholm, 113 65, Sweden|Investigational Site Number :1580007, Hsinchu City, 30059, Taiwan|Investigational Site Number :1580005, Kaohsiung, 833, Taiwan|Investigational Site Number :1580003, Taichung, 402, Taiwan|Investigational Site Number :1580002, Taipei, 112, Taiwan|Investigational Site Number :1580006, Taoyuang, 333, Taiwan|Investigational Site Number :7920005, Eskisehir, Turkey|Investigational Site Number :7920011, Hatay, Turkey|Investigational Site Number :7920002, Istanbul, 34098, Turkey|Investigational Site Number :7920009, Istanbul, 34688, Turkey|Investigational Site Number :7920007, Istanbul, 34785, Turkey|Investigational Site Number :7920003, Istanbul, Turkey|Investigational Site Number :7920008, Izmir, 35100, Turkey|Investigational Site Number :7920010, Izmir, Turkey|Investigational Site Number :7920001, Kocaeli, 41380, Turkey|Investigational Site Number :7920006, Mersin, 33070, Turkey|Investigational Site Number :8040011, Ivano-Frankivsk, 76493, Ukraine|Investigational Site Number :8040016, Kharkiv, 61068, Ukraine|Investigational Site Number :8040013, Kharkiv, 61103, Ukraine|Investigational Site Number :8040008, Kherson, 73000, Ukraine|Investigational Site Number :8040014, Kyiv, 03115, Ukraine|Investigational Site Number :8040010, Lutsk, 43005, Ukraine|Investigational Site Number :8040001, Lviv, 79010, Ukraine|Investigational Site Number :8040009, Odesa, 65025, Ukraine"
NCT01142518,An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone,https://beta.clinicaltrials.gov/study/NCT01142518,COMPLETED,Relapsing-Remitting Multiple Sclerosis,DRUG: Interferon beta 1a,"Merck KGaA, Darmstadt, Germany",,ALL,"CHILD, ADULT, OLDER_ADULT",,86,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2005-07,2009-03,2009-03,
NCT05177718,Natalizumab and Chronic Inflammation,https://beta.clinicaltrials.gov/study/NCT05177718,RECRUITING,Multiple Sclerosis,DRUG: Natalizumab 300 MG in 15 ML Injection,Vanderbilt University Medical Center,Biogen,ALL,"ADULT, OLDER_ADULT",PHASE4,36,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-09-16,2024-12-31,2025-12-31,"Vanderbilt University Medical Center, Nashville, Tennessee, 37215, United States"
NCT02858778,Timing of Acute Palliative Care Consultation in Critically Ill Patients,https://beta.clinicaltrials.gov/study/NCT02858778,UNKNOWN,Multiple Organ Failure|End Stage Cardiac Failure|End Stage Chronic Obstructive Airways Disease|Chronic Kidney Disease Stage 5|Hepatic Encephalopathy|Sepsis|Dementia|Multiple Sclerosis|Parkinson's Disease|In-Hospital Cardiac Arrest|Solid Organ Cancer,OTHER: Early order of palliative care consultation,Wayne State University,Blue Cross Blue Shield of Michigan Foundation,ALL,OLDER_ADULT,NA,120,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2016-06,2017-01,,"Detroit Medical Center Detroit Receiving Hospital, Detroit, Michigan, 48201, United States|Detroit Medical Center Sinai Grace Hospital, Detroit, Michigan, 48235, United States"
NCT05010902,Pregnancy Cohort in Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT05010902,RECRUITING,Multiple Sclerosis (MS)|Clinically Isolated Syndrome (CIS),,"Charite University, Berlin, Germany",,FEMALE,ADULT,,100,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-01-01,2025-12-31,2026-12-31,"Charité Universitätsmedizin Berlin, Berlin, 13125, Germany"
NCT05462678,Memory Rehabilitation Strategies in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05462678,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Cognitive Rehabilitation|BEHAVIORAL: Combined Rehabilitation|BEHAVIORAL: Motor Rehabilitation,I.R.C.C.S. Fondazione Santa Lucia,,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2018-09-01,2021-04-20,2021-11-20,"Santa Lucia Foundation I.R.C.C.S., Roma, Rm, 00179, Italy|I.R.C.C.S. ""Santa Lucia"" Foundation, Rome, 00149, Italy"
NCT01166178,Zoledronic Acid in MS-patients With Osteoporosis,https://beta.clinicaltrials.gov/study/NCT01166178,TERMINATED,Osteoporosis|Multiple Sclerosis,DRUG: Zoledronic Acid|DRUG: Placebo|DIETARY_SUPPLEMENT: Calcium and Vitamin D combination,Novartis,,ALL,"ADULT, OLDER_ADULT",PHASE3,29,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2010-10,2012-06,2012-06,"Novartis Investigative Site, Bamberg, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bochum, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Kassel, Germany|Novartis investigative site, Leipzig, Germany|Novartis Investigative Site, Leverkusen, Germany|Novartis investigative site, Ludwigshafen, Germany|Novartis investigative site, Magdeburg, Germany|Novartis investigative site, Muenchen, Germany|Novartis investigative site, Numbrecht, Germany|Novartis investigative site, Oldenburg, Germany|Novartis Investigative Site, Siegen, Germany|Novartis investigative site, Stade, Germany"
NCT03539094,Intermittent Fasting in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03539094,COMPLETED,Relapsing Remitting Multiple Sclerosis,OTHER: Intermittent fasting,Washington University School of Medicine,,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2018-01-01,2022-01-20,2022-01-20,"Washington University in St Louis, Saint Louis, Missouri, 63110, United States"
NCT04885894,An Examination of Cognitive Fatigue Using Functional Neuroimaging,https://beta.clinicaltrials.gov/study/NCT04885894,NOT_YET_RECRUITING,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Zeposia,Kessler Foundation,Celgene|Hackensack Meridian Health|St. Barnabas Medical Center,ALL,ADULT,,60,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-09,2023-08,2023-08,"Kessler Foundation, West Orange, New Jersey, 07052, United States"
NCT01212094,Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe),https://beta.clinicaltrials.gov/study/NCT01212094,TERMINATED,Multiple Sclerosis,DRUG: Rituximab|OTHER: normal saline,National Institute of Neurological Disorders and Stroke (NINDS),,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,44,NIH,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2010-09,2015-12,2015-12,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States"
NCT05496894,A Study of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05496894,WITHDRAWN,Relapsing Multiple Sclerosis,DRUG: Mitoxantrone Hydrochloride Liposome Injection,"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.",,ALL,ADULT,PHASE2,0,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-08,2022-11-08,2022-11-08,"Xuanwu Hospital Capital Medical University, Beijing, Beijing, 100000, China"
NCT01442194,Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies,https://beta.clinicaltrials.gov/study/NCT01442194,COMPLETED,Multiple Sclerosis,DRUG: other disease-modifying therapy|DRUG: Fingolimod,Novartis Pharmaceuticals,,ALL,"CHILD, ADULT, OLDER_ADULT",,3076,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-08-01,2020-07-10,2020-07-10,"Novartis Investigative Site, Birmingham, Alabama, 35209, United States|Novartis Investigative Site, Birmingham, Alabama, 35233-0271, United States|Novartis Investigative Site, Birmingham, Alabama, 35235, United States|Novartis Investigative Site, Cullman, Alabama, 35058, United States|Novartis Investigative Site, Mobile, Alabama, 36617, United States|Novartis Investigative Site, Phoenix, Arizona, 85013, United States|Novartis Investigative Site, Sottsdale, Arizona, 85258, United States|Novartis Investigative Site, Tucson, Arizona, 85718, United States|Novartis Investigative Site, Bakersfield, California, 93311, United States|Novartis Investigative Site, Banning, California, 92220, United States|Novartis Investigative Site, Burbank, California, 91505, United States|Novartis Investigative Site, Fresno, California, 93710, United States|Novartis Investigative Site, Fullerton, California, 92835, United States|Novartis Investigative Site, Huntington Beach, California, 92649, United States|Novartis Investigative Site, Irvine, California, 92618, United States|Novartis Investigative Site, Loma Linda, California, 92354, United States|Novartis Investigative Site, Los Angeles, California, 90073, United States|Novartis Investigative Site, Newport Beach, California, 92660, United States|Novartis Investigative Site, Oceanside, California, 92056, United States|Novartis Investigative Site, Placentia, California, 92870, United States|Novartis Investigative Site, Pomona, California, 91767, United States|Novartis Investigative Site, Redding, California, 96001, United States|Novartis Investigative Site, Santa Monica, California, 90404, United States|Novartis Investigative Site, Temecula, California, 92591, United States|Novartis Investigative Site, Aurora, Colorado, 80045, United States|Novartis Investigative Site, Basalt, Colorado, 81621, United States|Novartis Investigative Site, Colorado Springs, Colorado, 80907, United States|Novartis Investigative Site, Denver, Colorado, 80210, United States|Novartis Investigative Site, Fort Collins, Colorado, 80524, United States|Novartis Investigative Site, Louisville, Colorado, 80027, United States|Novartis Investigative Site, Parker, Colorado, 80138, United States|Novartis Investigative Site, Fairfield, Connecticut, 06824, United States|Novartis Investigative Site, Hartford, Connecticut, 6112, United States|Novartis Investigative Site, Waterbury, Connecticut, 06708, United States|Novartis Investigative Site, Dover, Delaware, 19901, United States|Novartis Investigative Site, Newark, Delaware, 19713, United States|Novartis Investigative Site, Washington, District of Columbia, 20007, United States|Novartis Investigative Site, Washington, District of Columbia, 20037, United States|Novartis Investigative Site, Bradenton, Florida, 34205, United States|Novartis Investigative Site, Clermont, Florida, 34711, United States|Novartis Investigative Site, Delray Beach, Florida, 33445, United States|Novartis Investigative Site, Doral, Florida, 33136, United States|Novartis Investigative Site, Hollywood, Florida, 33021, United States|Novartis Investigative Site, Jupiter, Florida, 33458, United States|Novartis Investigative Site, Maitland, Florida, 32751, United States|Novartis Investigative Site, Miami, Florida, 33032, United States|Novartis Investigative Site, Miami, Florida, 33144, United States|Novartis Investigative Site, Miami, Florida, 33155, United States|Novartis Investigative Site, Naples, Florida, 34102, United States|Novartis Investigative Site, Orlando, Florida, 32806, United States|Novartis Investigative Site, Ormond Beach, Florida, 32174, United States|Novartis Investigative Site, Panama City, Florida, 32405, United States|Novartis Investigative Site, Port Charlotte, Florida, 33952, United States|Novartis Investigative Site, Sarasota, Florida, 34233, United States|Novartis Investigative Site, Wellington, Florida, 33414, United States|Novartis Investigative Site, West Palm Beach, Florida, 33407, United States|Novartis Investigative Site, Weston, Florida, 33331, United States|Novartis Investigative Site, Atlanta, Georgia, 30309, United States|Novartis Investigative Site, Atlanta, Georgia, 30327, United States|Novartis Investigative Site, Augusta, Georgia, 30912, United States|Novartis Investigative Site, Macon, Georgia, 31210, United States|Novartis Investigative Site, Suwanee, Georgia, 30024, United States|Novartis Investigative Site, Arlington Heights, Illinois, 60004, United States|Novartis Investigative Site, Carbondale, Illinois, 62901, United States|Novartis Investigative Site, Flossmoor, Illinois, 60422, United States|Novartis Investigative Site, Marywood, Illinois, 60153, United States|Novartis Investigative Site, Peoria, Illinois, 61637, United States|Novartis Investigative Site, Anderson, Indiana, 46011, United States|Novartis Investigative Site, Indianapolis, Indiana, 46227, United States|Novartis Investigative Site, Indianapolis, Indiana, 46256, United States|Novartis Investigative Site, Lafayette, Indiana, 47905, United States|Novartis Investigative Site, Merrillville, Indiana, 46410, United States|Novartis Investigative Site, Des Moines, Iowa, 50314-2611, United States|Novartis Investigative Site, Kansas City, Kansas, 66160, United States|Novartis Investigative Site, Lenexa, Kansas, 66212, United States|Novartis Investigative Site, Overland Park, Kansas, 66210, United States|Novartis Investigative Site, Topeka, Kansas, 66606, United States|Novartis Investigative Site, Lexington, Kentucky, 40503, United States|Novartis Investigative Site, Lexington, Kentucky, 40513, United States|Novartis Investigative Site, Louisville, Kentucky, 40202, United States|Novartis Investigative Site, Hammond, Louisiana, 70403, United States|Novartis Investigative Site, Auburn, Maine, 04210, United States|Novartis Investigative Site, Bangor, Maine, 04401, United States|Novartis Investigative Site, Baltimore, Maryland, 21201, United States|Novartis Investigative Site, Baltimore, Maryland, 21209, United States|Novartis Investigative Site, Baltimore, Maryland, 21212, United States|Novartis Investigative Site, Bethesda, Maryland, 20814, United States|Novartis Investigative Site, Charlotte Hall, Maryland, 20622, United States|Novartis Investigative Site, Hagerstown, Maryland, 21741, United States|Novartis Investigative Site, Lutherville, Maryland, 21093, United States|Novartis Investigative Site, Waldorf, Maryland, 20603, United States|Novartis Investigative Site, Boston, Massachusetts, 02135, United States|Novartis Investigative Site, Boston, Massachusetts, 02215, United States|Novartis Investigative Site, Foxboro, Massachusetts, 02035, United States|Novartis Investigative Site, Springfield, Massachusetts, 01104, United States|Novartis Investigative Site, Wellesley, Massachusetts, 02481, United States|Novartis Investigative Site, Worcester, Massachusetts, 01608, United States|Novartis Investigative Site, Caro, Michigan, 48723, United States|Novartis Investigative Site, Detroit, Michigan, 48201, United States|Novartis Investigative Site, Jackson, Michigan, 49201, United States|Novartis Investigative Site, Owosso, Michigan, 48867, United States|Novartis Investigative Site, Rochester Hills, Michigan, 48301, United States|Novartis Investigative Site, Southfield, Michigan, 48034, United States|Novartis Investigative Site, Traverse City, Michigan, 49684-2340, United States|Novartis Investigative Site, Edina, Minnesota, 55435, United States|Novartis Investigative Site, Golden Valley, Minnesota, 55422, United States|Novartis Investigative Site, Saint Louis, Missouri, 63104, United States|Novartis Investigative Site, Saint Louis, Missouri, 63128, United States|Novartis Investigative Site, Saint Peters, Missouri, 63303, United States|Novartis Investigative Site, Springfield, Missouri, 65807, United States|Novartis Investigative Site, Great Falls, Montana, 59405, United States|Novartis Investigative Site, Hastings, Nebraska, 68901, United States|Novartis Investigative Site, Omaha, Nebraska, 68198-2045, United States|Novartis Investigative Site, Las Vegas, Nevada, 89106, United States|Novartis Investigative Site, Lebanon, New Hampshire, 03756, United States|Novartis Investigative Site, Fair Lawn, New Jersey, 07410, United States|Novartis Investigative Site, Livingston, New Jersey, 07039, United States|Novartis Investigative Site, Somerset, New Jersey, 08873, United States|Novartis Investigative Site, West Long Branch, New Jersey, 07764, United States|Novartis Investigative Site, Albany, New York, 12208, United States|Novartis Investigative Site, Amherst, New York, 14226, United States|Novartis Investigative Site, Bronx, New York, 10467, United States|Novartis Investigative Site, Brooklyn, New York, 11220, United States|Novartis Investigative Site, Cedarhurst, New York, 11516, United States|Novartis Investigative Site, Johnson City, New York, 13790, United States|Novartis Investigative Site, Kingston, New York, 12401, United States|Novartis Investigative Site, Lake Success, New York, 11042, United States|Novartis Investigative Site, New York, New York, 10003, United States|Novartis Investigative Site, Patchogue, New York, 11772, United States|Novartis Investigative Site, Plainview, New York, 11803, United States|Novartis Investigative Site, Poughkeepsie, New York, 12601, United States|Novartis Investigative Site, Staten Island, New York, 10306, United States|Novartis Investigative Site, Syracuse, New York, 13210, United States|Novartis Investigative Site, Asheville, North Carolina, 28805, United States|Novartis Investigative Site, Asheville, North Carolina, 28806, United States|Novartis Investigative Site, Chapel Hill, North Carolina, 27599-9500, United States|Novartis Investigative Site, Charlotte, North Carolina, 28202, United States|Novartis Investigative Site, Charlotte, North Carolina, 28204, United States|Novartis Investigative Site, Durham, North Carolina, 27710, United States|Novartis Investigative Site, Hickory, North Carolina, 28602, United States|Novartis Investigative Site, Raleigh, North Carolina, 27607, United States|Novartis Investigative Site, Sanford, North Carolina, 27330, United States|Novartis Investigative Site, Wilmington, North Carolina, 28401, United States|Novartis Investigative Site, Bismarck, North Dakota, 58501, United States|Novartis Investigative Site, Bellevue, Ohio, 44811, United States|Novartis Investigative Site, Centerville, Ohio, 45459, United States|Novartis Investigative Site, Cincinnati, Ohio, 45219, United States|Novartis Investigative Site, Columbus, Ohio, 43210, United States|Novartis Investigative Site, Columbus, Ohio, 43221, United States|Novartis Investigative Site, Dayton, Ohio, 45408, United States|Novartis Investigative Site, Toledo, Ohio, 43614, United States|Novartis Investigative Site, Toledo, Ohio, 43623, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, 73102, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, 73104, United States|Novartis Investigative Site, Portland, Oregon, 97225, United States|Novartis Investigative Site, Springfield, Oregon, 97477, United States|Novartis Investigative Site, Greensburg, Pennsylvania, 15601, United States|Novartis Investigative Site, Meadowbrook, Pennsylvania, 19046, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, 19107-5098, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, 19107, United States|Novartis Investigative Site, Pittsburgh, Pennsylvania, 15243, United States|Novartis Investigative Site, Willow Grove, Pennsylvania, 19090, United States|Novartis Investigative Site, Beaufort, South Carolina, 29902, United States|Novartis Investigative Site, Camden, South Carolina, 29020, United States|Novartis Investigative Site, Charleston, South Carolina, 29406, United States|Novartis Investigative Site, Greer, South Carolina, 29650, United States|Novartis Investigative Site, Indian Land, South Carolina, 29707, United States|Novartis Investigative Site, Mount Pleasant, South Carolina, 29464, United States|Novartis Investigative Site, Spartanburg, South Carolina, 29303, United States|Novartis Investigative Site, Spartanburg, South Carolina, 29307, United States|Novartis Investigative Site, Knoxville, Tennessee, 37922, United States|Novartis Investigative Site, Nashville, Tennessee, 37205, United States|Novartis Investigative Site, Nashville, Tennessee, 37212, United States|Novartis Investigative Site, Brownwood, Texas, 76801, United States|Novartis Investigative Site, Dallas, Texas, 75214, United States|Novartis Investigative Site, Dallas, Texas, 75390, United States|Novartis Investigative Site, Houston, Texas, 77005, United States|Novartis Investigative Site, Houston, Texas, 77025, United States|Novartis Investigative Site, Kingwood, Texas, 77339, United States|Novartis Investigative Site, Mansfield, Texas, 76063, United States|Novartis Investigative Site, San Antonio, Texas, 78229, United States|Novartis Investigative Site, Stafford, Texas, 77477, United States|Novartis Investigative Site, Sugar Land, Texas, 77479, United States|Novartis Investigative Site, Provo, Utah, 84604, United States|Novartis Investigative Site, Salt Lake City, Utah, 84103, United States|Novartis Investigative Site, Salt Lake City, Utah, 84132, United States|Novartis Investigative Site, Alexandria, Virginia, 22310, United States|Novartis Investigative Site, Arlington, Virginia, 22205, United States|Novartis Investigative Site, Charlottesville, Virginia, 22911, United States|Novartis Investigative Site, McLean, Virginia, 22101, United States|Novartis Investigative Site, Newport News, Virginia, 23601, United States|Novartis Investigative Site, Norfolk, Virginia, 23507, United States|Novartis Investigative Site, Richmond, Virginia, 23228, United States|Novartis Investigative Site, Richmond, Virginia, 23924, United States|Novartis Investigative Site, Vienna, Virginia, 22182, United States|Novartis Investigative Site, Winchester, Virginia, 22601, United States|Novartis Investigative Site, Richland, Washington, 99352, United States|Novartis Investigative Site, Spokane, Washington, 99208, United States|Novartis Investigative Site, Tacoma, Washington, 98405, United States|Novartis Investigative Site, Wenatchee, Washington, 98801, United States|Novartis Investigative Site, Beckley, West Virginia, 25801, United States|Novartis Investigative Site, Huntington, West Virginia, 25701, United States|Novartis Investigative Site, Green Bay, Wisconsin, 54311, United States|Novartis Investigative Site, Milwaukee, Wisconsin, 53211, United States|Novartis Investigative Site, Monroe, Wisconsin, 53566, United States|Novartis Investigative Site, Neenah, Wisconsin, 54956, United States|Novartis Investigative Site, Wisconsin Rapids, Wisconsin, 54495, United States|Novartis Investigative Site, Casper, Wyoming, 82601, United States|Novartis Investigative Site, Jenin, Buenos Aires, 6000, Argentina|Novartis Investigative Site, San Miguel de Tucuman, Tucuman, T4000DPB, Argentina|Novartis Investigative Site, Buenos Aires, 1061, Argentina|Novartis Investigative Site, Ciudad Autonoma de Bs As, Argentina|Novartis Investigative Site, Cordoba, X5004CDT, Argentina|Novartis Investigative Site, Salta, A4400BKZ, Argentina|Novartis Investigative Site, Kogarah, New South Wales, 2217, Australia|Novartis Investigative Site, Box Hill, Victoria, 3128, Australia|Novartis Investigative Site, Melbourne, Victoria, 3004, Australia|Novartis Investigative Site, Parkville, Victoria, 3050, Australia|Novartis Investigative Site, Edmonton, Alberta, T6G 2G3, Canada|Novartis Investigative Site, Saint John, New Brunswick, E2L 4L2, Canada|Novartis Investigative Site, Halifax, Nova Scotia, B3H 4K4, Canada|Novartis Investigative Site, Guelph, Ontario, N1H 4J4, Canada|Novartis Investigative Site, Kingston, Ontario, K7L 2V7, Canada|Novartis Investigative Site, Ottawa, Ontario, K1H 8L6, Canada|Novartis Investigative Site, St. Catharine's, Ontario, L2R 2P7, Canada|Novartis Investigative Site, Chicoutimi, Quebec, G7H 5H6, Canada|Novartis Investigative Site, Montreal, Quebec, H1T 2M4, Canada|Novartis Investigative Site, Montreal, Quebec, H2L 4M1, Canada|Novartis Investigative Site, Montreal, Quebec, H3A 2B4, Canada|Novartis Investigative Site, Montreal, Quebec, H3T 1E2, Canada|Novartis Investigative Site, Trois Rivieres, Quebec, G8Z 3R9, Canada|Novartis Investigative Site, Santiago, PISO 1, Chile|Novartis Investigative Site, Guadalajara, Jalisco, 44130, Mexico|Novartis Investigative Site, Culiacan, MEX, 80020, Mexico|Novartis Investigative Site, Monterrey, Nuevo León, 64710, Mexico|Novartis Investigative Site, Distrito Federal, 10700, Mexico|Novartis Investigative Site, Guaynabo, 00968, Puerto Rico|Novartis Investigative Site, San Juan, 00935, Puerto Rico"
NCT03247894,Obstetric Anesthesia and Analgesia and Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03247894,COMPLETED,Multiple Sclerosis,OTHER: Data search,Brno University Hospital,Masaryk University,FEMALE,"ADULT, OLDER_ADULT",,70,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-08-01,2017-07-31,2017-08-01,"Brno University Hospital, Brno, Czechia, 62500, 62500, Czechia"
NCT05560880,High Intensity Interval Gait Training in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05560880,RECRUITING,Multiple Sclerosis,BEHAVIORAL: High Intensity Interval Gait training|BEHAVIORAL: Moderate Intensity Interval gait training,Hunter College of City University of New York,,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-09-01,2023-12-31,2023-12-31,"Hunter College, New York, New York, 11238, United States"
NCT00871780,"A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients",https://beta.clinicaltrials.gov/study/NCT00871780,COMPLETED,Relapsing Remitting Multiple Sclerosis (RRMS),DRUG: BG00002 (natalizumab),Biogen,Elan Pharmaceuticals,ALL,ADULT,PHASE4,224,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2009-08,2012-07,2012-07,"Biogen Idec Investigative Site, Liege, Belgium|Biogen Idec Investigative Site, Puebla, Mexico|Biogen Idec Investigative Site, Bialystok, Poland|Biogen Idec Investigative Site, Bydgoszcz, Poland|Biogen Idec Investigative Site, Lotz, Poland|Biogen Idec Investigative Site, Poznan, Poland|Biogen Idec Investigative Site, Warszawa, Poland|Biogen Idec Investigative Site, Bucharest, Romania|Biogen Idec Investigative Site, Mures, Romania|Biogen Idec Investigative Site, Riyadh, Saudi Arabia|Biogen Idec Investigative Site, Dnipropetrovsk, Ukraine|Biogen Idec Investigative Site, Kharkiv, Ukraine|Biogen Idec Investigative Site, Kyiv, Ukraine|Biogen Idec Investigative Site, Lviv, Ukraine|Biogen Idec Investigative Site, Simferopol, Ukraine"
NCT01647880,MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study),https://beta.clinicaltrials.gov/study/NCT01647880,TERMINATED,Multiple Sclerosis,DRUG: Verum arm receiving Gilenya®|DRUG: Active Comparator receiving Extavia®,"Charite University, Berlin, Germany","NeuroCure Clinical Research Center, Charite, Berlin",ALL,ADULT,PHASE2|PHASE3,15,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2013-07,2016-04,2016-04,"Charité-Universitätsmedizin Berlin, Berlin, Germany|Sankt Josefs Krankenhaus Potsdam Neurologie, Potsdam, Germany"
NCT02967380,"Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases",https://beta.clinicaltrials.gov/study/NCT02967380,TERMINATED,Adult Anaplastic (Malignant) Meningioma|Adult Anaplastic Astrocytoma|Adult Anaplastic Ependymoma|Adult Anaplastic Oligodendroglioma|Adult Brain Stem Glioma|Adult Choroid Plexus Neoplasm|Adult Diffuse Astrocytoma|Adult Ependymoblastoma|Adult Ependymoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Grade II Meningioma|Adult Medulloblastoma|Adult Mixed Glioma|Adult Oligodendroglioma|Adult Papillary Meningioma|Adult Pineal Gland Astrocytoma|Adult Pineoblastoma|Adult Primary Melanocytic Lesion of Meninges|Adult Supratentorial Primitive Neuroectodermal Tumor|Malignant Adult Intracranial Hemangiopericytoma|Metastatic Malignant Neoplasm in the Brain|Multiple Sclerosis|Recurrent Adult Brain Neoplasm,PROCEDURE: Dynamic Contrast-Enhanced Magnetic Resonance Imaging|DRUG: Gadobenate Dimeglumine|DRUG: Gadobutrol|RADIATION: Gadopentetate Dimeglumine,University of Southern California,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",NA,14,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2011-12-14,2014-10-14,2015-10-14,"USC / Norris Comprehensive Cancer Center, Los Angeles, California, 90033, United States"
NCT05012241,The Reliability of the Nine Hole Peg Test in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05012241,ACTIVE_NOT_RECRUITING,Motor Activity,DIAGNOSTIC_TEST: Nine Hole Peg Test,"Charles University, Czech Republic",,ALL,"ADULT, OLDER_ADULT",,33,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-09-01,2022-02-28,2023-01-31,"Center for Demyelinating Disease (MS center), Department of Neurology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Praha, Czechia|Department of Rehabilitation Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Praha, Czechia"
NCT05820334,Multiple Sclerosis and Fatigue Assessment,https://beta.clinicaltrials.gov/study/NCT05820334,RECRUITING,Multiple Sclerosis,,Asli Celik,Gazi University,ALL,"ADULT, OLDER_ADULT",,54,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-04-01,2024-12-01,2024-12-01,"Gazi University, Ankara, 06490, Turkey"
NCT02805634,Correlation Between the 'Nine Holes Peg Test' Performance and the Triple Stimulation Technique Within a Group a Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02805634,COMPLETED,Multiple Sclerosis,OTHER: Nine Hole Test|DEVICE: Triple Stimulation Technique,Brugmann University Hospital,,ALL,ADULT,NA,30,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2016-02-09,2019-01-30,2019-01-30,"CHU Brugmann, Brussels, 1020, Belgium"
NCT04892134,"Evaluation of Clinical, Morphologic and Biochemical Markers in Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT04892134,RECRUITING,Multiple Sclerosis,OTHER: blood sample,Medical University of Graz,,ALL,"ADULT, OLDER_ADULT",,500,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-10-03,2024-10-31,2025-10-31,"Medical University of Graz, Graz, Styria, 8010, Austria"
NCT01339234,Supported Treadmill Training for Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01339234,COMPLETED,Multiple Sclerosis,OTHER: Body-weight supported treadmill training,"Hicks, Audrey, Ph.D.",Multiple Sclerosis Society of Canada,ALL,ADULT,NA,6,INDIV,INTERVENTIONAL,"Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: ",2008-04,2009-06,2009-06,"McMaster University (Centre for Health Promotion and Rehabilitation)/Hamilton Health Sciences, Hamilton, Ontario, L8S 4K1, Canada"
NCT01414634,"Establish Tolerance In MS With Peptide-Coupled, Peripheral Blood Mononuclear Cells",https://beta.clinicaltrials.gov/study/NCT01414634,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",BIOLOGICAL: ETIMS,Universitätsklinikum Hamburg-Eppendorf,,ALL,ADULT,PHASE1|PHASE2,9,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2010-02,2012-10,2012-10,
NCT00001934,Zenapax to Treat Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00001934,COMPLETED,Multiple Sclerosis,DRUG: Zenapax,National Institute of Neurological Disorders and Stroke (NINDS),,ALL,"ADULT, OLDER_ADULT",PHASE2,22,NIH,INTERVENTIONAL,Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT,1999-09,2005-08,2008-09,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States"
NCT00355134,Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00355134,COMPLETED,Multiple Sclerosis,DRUG: Fingolimod|DRUG: Placebo,Novartis,,ALL,ADULT,PHASE3,1083,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2006-06,2011-06,2011-08,"University of Alabama Birmingham, Birmingham, Alabama, 35249, United States|North Central Neurology Associates, PC, Cullman, Alabama, 35058, United States|University of South Alabama - Dept of Neurology, Mobile, Alabama, 36693, United States|Barrow Neurology Clinic, Phoenix, Arizona, 85013, United States|Research and Education Institute of Alta Bates Summit Medical Center, Berkeley, California, 94705, United States|University of California - Irvine, Deptarment of Neurology, Irvine, California, 92697, United States|Cedars Sinai Medical Center, Los Angeles, California, 90048, United States|The Neurology Center, Oceanside, California, 92056, United States|Neuro-Therapeutics, Inc., Pasadena, California, 91105, United States|UC Davis Medical Center, Sacramento, California, 95817, United States|Multiple Sclerosis Center at UCSF, San Francisco, California, 94117, United States|University of Colorado, Denver, Colorado, 80262, United States|Associated Neurologists, PC, Danbury, Connecticut, 06810, United States|Associated Neurologists of Southern CT, P.C., Fairfield, Connecticut, 06824, United States|Yale University - Yale Multiple Sclerosis Center, New Haven, Connecticut, 06510, United States|Georgetown University Hospital - Dept of Neurology, Washington, District of Columbia, 20007, United States|Sunrise Clinical Research, Inc., Hollywood, Florida, 33021, United States|University of Florida Health Sciences Center/Shands Jacksonville, Jacksonville, Florida, 32209, United States|Neurology Associates, PA, Maitland, Florida, 32751, United States|University of Miami, Department of Neurology, Miami, Florida, 33136, United States|Neurological Associates, Pompano Beach, Florida, 33060, United States|Roskamp Institute, Clinical Trials Division, Sarasota, Florida, 34243, United States|Neurology Clinical Research, Inc, Sunrise, Florida, 33351, United States|AMO Corporation, Tallahassee, Florida, 32308, United States|Axiom Clinical Research of Florida, Tampa, Florida, 33609, United States|The MS Center of Vero Beach, Vero Beach, Florida, 32960, United States|MS Center of Atlanta, Atlanta, Georgia, 30327, United States|Medical College of Georgia, Augusta, Georgia, 30912, United States|Northwestern University Medical School - Dept of Neurology, Chicago, Illinois, 60611, United States|Rush University Medical Center Department of Neurological Sciences, Chicago, Illinois, 60612, United States|University of Chicago - Dept of Neurology, Chicago, Illinois, 60637, United States|Alexian Brothers Neurosciences Research, Elk Grove Village, Illinois, 60007, United States|South Suburban Neurology, Flossmoor, Illinois, 60402, United States|Neurologic Associates, Ltd., Palos Heights, Illinois, 60453, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, 46805, United States|Indiana University Medical Center, Indianapolis, Indiana, 46202, United States|Ruan Neurology Clinical Research Center, Des Moines, Iowa, 50314, United States|University of Kansas Medical Center, Kansas City, Kansas, 66160, United States|Mid America Neuroscience Institute, Lenexa, Kansas, 66214, United States|Kentucky Research Associates, Louisville, Kentucky, 40202, United States|University of Maryland, Baltimore, Maryland, 21201, United States|Johns Hopkins MS Center, Baltimore, Maryland, 21287, United States|Caritas St. Elizabeth's Medical Center, Brighton, Massachusetts, 02135, United States|Newton Wesley Hospital, Newton, Massachusetts, 02462, United States|Springfield Neurology, Springfield, Massachusetts, 01104, United States|UMass Memorial Medical Center, Worchester, Massachusetts, 01605, United States|University of Michigan Mulitiple Sclerosis Clinic, Ann Arbor, Michigan, 48109, United States|Wayne State University MS Clinic, Detroit, Michigan, 48201, United States|Henry Ford Hospital, Department of Neurology, Detroit, Michigan, 48202, United States|Michigan State University MS Clinic, East Lansing, Michigan, 48824, United States|Michigan Medical, P.C., Grand Rapids, Michigan, 49525, United States|Michigan Neurology Associates, PC, St. Clair Shores, Michigan, 48080, United States|St. Luke's Hospital - Mid-America Brain and Stroke Institute, Kansas City, Missouri, 64111, United States|The MS Center for Innovation in Care, St. Louis, Missouri, 63110, United States|Institute for Neurosciences, Reno, Nevada, 85902, United States|Multiple Sclerosis Center, Lebanon, New Hampshire, 03756, United States|Gimbel Multiple Sclerosis Center at Holy Name Hospital, Teaneck, New Jersey, 07666, United States|University of New Mexico Health Science Center, Albuquerque, New Mexico, 87131, United States|Empire Neurology, PC, Latham, New York, 12110, United States|NYU Hospital for Joint Diseases, New York, New York, 10003, United States|Cornell University - NY Presbyterian Hospital, New York, New York, 10021, United States|Mount Sinai School of Medicine, New York, New York, 10029, United States|Island Neurological Associates, PC, Plainview, New York, 11803, United States|University of Rochester Medical Center, Rochester, New York, 14642, United States|Alpha Neurology, Staten Island, New York, 10306, United States|SUNY Stony Brook, Stony Brook, New York, 11794, United States|SUNY Upstate Medical University, Syracuse, New York, 13210, United States|UNC - Chapel Hill Neuroscience Hospital, Chapel Hill, North Carolina, 27599, United States|Duke University Medical Center, Durham, North Carolina, 27705, United States|Raleigh Neurology Associates, Raleigh, North Carolina, 27607, United States|Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, 27157, United States|Neurology & Neuroscience Associates, Inc., Akron, Ohio, 44302, United States|Northern Ohio Neuroscience, LLC., Bellevue, Ohio, 44811, United States|NeuroCare Center, Inc, Canton, Ohio, 44718, United States|River Hills Health Care, Cincinnati, Ohio, 45219, United States|Ohio State University, Columbus, Ohio, 48221, United States|University of Toledo Health Science Campus, Toledo, Ohio, 43614, United States|Oak Clinic, Uniontown, Ohio, 44685, United States|MS Center of Oklahoma, Mercy Neuroscience Institute, Oklahoma City, Oklahoma, 73120, United States|Neurologial Associates of Tulsa, Tulsa, Oklahoma, 74137, United States|Oregon Neurology, Tualatin, Oregon, 97062, United States|University of Pennsylvania, Department of Neurology, Philadelphia, Pennsylvania, 19104, United States|Thomas Jefferson University Hospital, Department of Neurology, Philadelphia, Pennsylvania, 19107, United States|Allegheny Neurological Associates, Pittsburgh, Pennsylvania, 15212, United States|University of Pittsburgh - Dept of Neurology, Pittsburgh, Pennsylvania, 15213, United States|Absher Neurology, Greenville, South Carolina, 29615, United States|Mountain Empire Neurological Associates, PC, Bristol, Tennessee, 37620, United States|Advanced Neurosciences Institute, Nashville, Tennessee, 37205, United States|Vanderbilt Stallworth Rehabilitation Hospital, Nashville, Tennessee, 37212, United States|University of Texas - Houston Medical School, Houston, Texas, 77030, United States|Investigational Site - Private Practice, Lubbock, Texas, 79410, United States|Integra Clinical Research, LLC, San Antonio, Texas, 78231, United States|Neurology Health Care Service - Fletcher Allen Hospital, Burlington, Vermont, 05401, United States|University of Virginia - Fontaine Adult Neurology, Charlottesville, Virginia, 22903, United States|Virginia Mason Multiple Sclerosis Center, Seattle, Washington, 98111, United States|Seattle Neuroscience Institute at Swedish Medical Center, Seattle, Washington, 98122, United States|University Health Associates - West Virgina University, Morgantown, West Virginia, 26506, United States|Dean Foundation, Madison, Wisconsin, 53715, United States|University of Wisconsin Medical School, Madison, Wisconsin, 53792, United States|St. Luke's Medical Center, Milwaukee, Wisconsin, 53215, United States|Novartis Investigative Site, North Gosford, New South Wales, Australia|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Ottawa, Ontario, Canada|Novartis Investigative Site, Greenfield Park, Quebec, Canada|Novartis Investigative Site, Bialystok, Poland|Novartis Investigative Site, Warsaw, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Targu Mures, Romania|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Yenisehir/Izmir, Turkey|Novartis Investigative Site, Bristol, United Kingdom"
NCT01774201,Respiratory Function and Walking Capacity in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01774201,COMPLETED,"Multiple Sclerosis|Respiratory; Disorder, Functional, Impaired|Difficulty Walking",OTHER: Breathing exercises,Region Örebro County,Örebro County Council,ALL,"CHILD, ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2012-09,2014-12,2014-12,
NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01064401,COMPLETED,Relapsing-Remitting Multiple Sclerosis,BIOLOGICAL: BIIB019 (Daclizumab High Yield Process)|DRUG: Interferon beta-1a Placebo|BIOLOGICAL: Interferon beta-1a|DRUG: Daclizumab High Yield Process Placebo,Biogen,AbbVie,ALL,ADULT,PHASE3,1841,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2010-05,2014-03,2014-07,"Research Site, Gilbert, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, La Jolla, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Naples, Florida, United States|Research Site, Pompano Beach, Florida, United States|Research Site, St. Petersburg, Florida, United States|Research Site, Sunrise, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Evanston, Illinois, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Des Moines, Iowa, United States|Research Site, Kansas City, Kansas, United States|Research Site, Lexington, Kentucky, United States|Research Site, Baltimore, Maryland, United States|Research Site, Springfield, Massachusetts, United States|Research Site, Worchester, Massachusetts, United States|Research Site, Clinton Township, Michigan, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, New Brunswick, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Buffalo, New York, United States|Research Site, Latham, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Winston Salem, North Carolina, United States|Research Site, Medford, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Allentown, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburg, Pennsylvania, United States|Research Site, Providence, Rhode Island, United States|Research Site, Franklin, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Burlington, Vermont, United States|Research Site, Kirkland, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Godoy Cruz, Mendoza, Argentina|Research Site, Rosario, Santa Fe, Argentina|Research Site, Camperdown, New South Wales, Australia|Research Site, New Lambton Heights, New South Wales, Australia|Research Site, Auchenflower, Queensland, Australia|Research Site, Woodville, South Australia, Australia|Research Site, Fitzroy, Victoria, Australia|Research Site, Heidelberg West, Victoria, Australia|Research Site, Belo Horizonte, Bahia, Brazil|Research Site, Brasilia, Distrito Federal, Brazil|Research Site, Recife, Pernambuco, Brazil|Research Site, Porto Alegre, Rio Grande, Brazil|Research Site, Sao Paulo, Rio Grande, Brazil|Research Site, Campinas, Sao Paulo, Brazil|Research Site, Ribeirão Preto, Sao Paulo, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Saint John, Newfoundland and Labrador, Canada|Research Site, London, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Gatineau, Quebec, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Montréal, Quebec, Canada|Research Site, Regina, Saskatchewan, Canada|Research Site, Brno, Jihocesky Kraj, Czech Republic|Research Site, Jihlava, Kraj Vysocina, Czech Republic|Research Site, Olomouc, Olomoucký kraj, Czech Republic|Research Site, Praha 10, Praha, Czech Republic|Research Site, Praha 2, Praha, Czech Republic|Research Site, Havirov, Severomoravksy Krav, Czech Republic|Research Site, Brno, Czech Republic|Research Site, Hradec Kralove, Czech Republic|Research Site, Jihlava, Czech Republic|Research Site, Ostrava, Czech Republic|Research Site, Pardubice, Czech Republic|Research Site, Copenhagen, Denmark|Research Site, Glostrup, Denmark|Research Site, Odense C, Denmark|Research Site, Århus, Denmark|Research Site, Tampere, Western Finalnd, Finland|Research Site, Helsinki, Finland|Research Site, Oulu, Finland|Research Site, Seinäjoki, Finland|Research Site, Turku, Finland|Research Site, Strasbourg, Alsace, France|Research Site, Caen Cedex 5, Basse-normandie, France|Research Site, Bobigny, Ile-de-france, France|Research Site, Paris Cedex 5, Ile-de-france, France|Research Site, Paris, Ile-de-france, France|Research Site, Amiens, Picardie, France|Research Site, Nice, Provence Alpes Cote D'azur, France|Research Site, Lyon, Rhone-alpes, France|Research Site, Bourdeaux, France|Research Site, Dijon, France|Research Site, Lille, France|Research Site, Lomme, France|Research Site, Marseille Cedex 9, France|Research Site, Nancy, France|Research Site, Toulouse Cedex 3, France|Research Site, Tbilisi, Georgia|Research Site, Freiburg, Baden-wuerttemberg, Germany|Research Site, Bad Mergentheim, Baden-Wurttemberg, Germany|Research Site, Bamberg, Bayern, Germany|Research Site, Bayreuth, Bayern, Germany|Research Site, München, Bayern, Germany|Research Site, Neuburg an der Donau, Bayern, Germany|Research Site, Marburg, Hessen, Germany|Research Site, Essen, Nordrhein Westfalen, Germany|Research Site, Koln, Nordrhein Westfalen, Germany|Research Site, Munster, Nordrhein-Westfalen, Germany|Research Site, Trier, Rheinland-Pfalz, Germany|Research Site, Dresden, Sachsen, Germany|Research Site, Berlin, Germany|Research Site, Hamburg, Germany|Research Site, Tübingen, Germany|Research Site, Athens, Attica, Greece|Research Site, Heraklion, Crete, Greece|Research Site, Thessaloniki, Macedoni, Greece|Research Site, Székesfehérvár, Fejer, Hungary|Research Site, Gyor, Gyor-moson-sopron, Hungary|Research Site, Budapest, Hungary|Research Site, Esztergom, Hungary|Research Site, Miskolc, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Veszprém, Hungary|Research Site, Hyderabad, Andhra Pradesh, India|Research Site, Delhi, Dwivdee, India|Research Site, Bangalore, Karnataka, India|Research Site, Trivandrum, Kerala, India|Research Site, Mumbai, Maharashtra, India|Research Site, Nagpur, Maharashtra, India|Research Site, New Delhi, India|Research Site, Dublin, Ireland|Research Site, Ashkelon, Ashqelon, Israel|Research Site, Tzrifin, Beer Yaakov, Israel|Research Site, Petach Tikva, Petah Tiqwa, Israel|Research Site, Beer-Sheva, Israel|Research Site, Haifa, Israel|Research Site, Kfar Saba, Israel|Research Site, Tzfat, Israel|Research Site, Cefalù, PA, Italy|Research Site, Orbassano, Torino, Italy|Research Site, Bari, Italy|Research Site, Cagliari, Italy|Research Site, Catania, Italy|Research Site, Firenze, Italy|Research Site, Genova, Italy|Research Site, Milano, Italy|Research Site, Padova, Italy|Research Site, Roma, Italy|Research Site, Mexico, Distrito Federal, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Chisinau, Moldova, Republic of|Research Site, Lublin, Dolnoslaskie, Poland|Research Site, Bydgoszcz, Kujawsko-pomorskie, Poland|Research Site, Grudziadz, Kujawsko-pomorskie, Poland|Research Site, Lódz, Lodzkie, Poland|Research Site, Kraków, Malopolskie, Poland|Research Site, Warszawa, Mazowieckie, Poland|Research Site, Bialystok, Podlaskie, Poland|Research Site, Gdansk, Pomorskie, Poland|Research Site, Katowice, Slaskie, Poland|Research Site, Kielce, Swietokrzycie, Poland|Research Site, Olsztyn, Warminsko-mazurskie, Poland|Research Site, Poznan, Wielkopolskie, Poland|Research Site, Szczecin, Zachodniopomorskie, Poland|Research Site, Bydgoszczas, Poland|Research Site, Plewiska, Poland|Research Site, Bucurest, Bucuresti, Romania|Research Site, Cluj-Napoca, Cluj, Romania|Research Site, Timisoara, Timis, Romania|Research Site, Iasi, Romania|Research Site, Târgu Mures, Romania|Research Site, Kazan, Povolje-Tatarstan, Russian Federation|Research Site, Ekaterinburg, Ural, Russian Federation|Research Site, Yaroslavl, Yaroslavlr, Russian Federation|Research Site, Chelyabinsk, Russian Federation|Research Site, Kaluga, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Krasnoyarsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Smolensk, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Tumen, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Belgrade, Serbia|Research Site, Kragujevac, Serbia|Research Site, Nis, Serbia|Research Site, Novi Sad, Serbia|Research Site, L´Hospitalet de Llobregat, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Cordoba, Spain|Research Site, Girona, Spain|Research Site, Madrid, Spain|Research Site, Sevilla, Spain|Research Site, Göteborg, Sweden|Research Site, Linköping, Sweden|Research Site, Malmö, Sweden|Research Site, Stockholm, Sweden|Research Site, Basel, Switzerland|Research Site, Lugano, Switzerland|Research Site, Dnepropetrovsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kyviv, Ukraine|Research Site, Odessa, Ukraine|Research Site, Poltava, Ukraine|Research Site, Vinnitsa, Ukraine|Research Site, Zaporozhye, Ukraine|Research Site, Brighton, United Kingdom|Research Site, Bristol, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, London, United Kingdom|Research Site, New Castle Upon Tyne, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Romford, United Kingdom|Research Site, Salford, United Kingdom|Research Site, Sheffield, United Kingdom"
NCT00342134,Immunological Mechanisms of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00342134,COMPLETED,Multiple Sclerosis,PROCEDURE: Stem Cell Transplanataion,National Institute of Neurological Disorders and Stroke (NINDS),,ALL,"ADULT, OLDER_ADULT",PHASE2,34,NIH,INTERVENTIONAL,Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT,2002-05-01,2011-05-04,2011-05-04,"Northwestern University, Chicago, Illinois, 60611, United States|Johns Hopkins University, Baltimore, Maryland, 21205, United States"
NCT04002934,Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04002934,RECRUITING,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting",DRUG: Bazedoxifene Acetate,"Riley Bove, MD",,FEMALE,"ADULT, OLDER_ADULT",PHASE2,50,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-09-10,2024-02-15,2024-08-31,"Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, 94158, United States"
NCT04694534,"Remediation Program Via a ""Serious Game"" for the Cognitive Functions of Multiple Sclerosis Patients",https://beta.clinicaltrials.gov/study/NCT04694534,RECRUITING,Multiple Sclerosis|Memory|Learning,DIAGNOSTIC_TEST: Serious game|DIAGNOSTIC_TEST: Usual HAS care,Lille Catholic University,,ALL,"ADULT, OLDER_ADULT",NA,150,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: DIAGNOSTIC,2021-10-08,2024-03-01,2024-03-01,"CH d'Arras, Arras, Nord Pas De Calais, 62000, France|CHRU, Lille, Nord Pas De Calais, 59000, France|Saint Vincent hospital, Lille, Nord Pas De Calais, 59000, France|Saint-Philibert hospital, Lomme, Nord, 59462, France|Charles Nicolle Hospital, Rouen, Normandie, 76000, France|CHU Amiens-Picardie, Amiens, Picardie, 80000, France"
NCT01356134,Vascular Fundus Changes in Patients With High Probability of Chronic Cerebrospinal Venous Insufficiency (CCSVI),https://beta.clinicaltrials.gov/study/NCT01356134,COMPLETED,Ehlers-Danlos Syndrome|Multiple Sclerosis,,Genetic Disease Investigators,"Optos, PLC",ALL,"CHILD, ADULT, OLDER_ADULT",,60,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-05,2015-04,2015-04,"Total Eye Care, Colleyville, Texas, 76034, United States"
NCT01031901,Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1),https://beta.clinicaltrials.gov/study/NCT01031901,COMPLETED,Tuberous Sclerosis|Neurofibromatoses|Angiofibroma|Neurofibroma,DRUG: Skincerity|DRUG: Skincerity plus sirolimus/rapamycin|DRUG: Skinercity plus sirolimus/rapamycin,"The University of Texas Health Science Center, Houston",Society for Pediatric Dermatology,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1,52,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-12,2011-02,2011-06,"The University of Texas Health Science Center, Houston, Texas, 77030, United States"
NCT04834401,Effect of Disease Modifying Therapy on Antibody Response to COVID19 Vaccination in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04834401,COMPLETED,Multiple Sclerosis|Covid19,,St. Barnabas Medical Center,,ALL,"ADULT, OLDER_ADULT",,45,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-03-22,2022-05-17,2022-05-17,"Saint Barnabas Medical Center, Livingston, New Jersey, 07039, United States"
NCT00151801,Safety and Tolerability of Interferon-Beta-1a and Estroprogestins Association in MS Patients,https://beta.clinicaltrials.gov/study/NCT00151801,UNKNOWN,Multiple Sclerosis,DRUG: estroprogestins|DRUG: interferon-beta 1a,S. Andrea Hospital,,FEMALE,ADULT,PHASE2,200,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE|Primary Purpose: TREATMENT,2002-05,,2008-12,"Department of Neurology - University of Rome La Sapienza, Rome, 00100, Italy"
NCT00210301,Combination Therapy (Provigil + Avonex) to Treat Cognitive Problems in MS,https://beta.clinicaltrials.gov/study/NCT00210301,UNKNOWN,Relapsing-Remitting Multiple Sclerosis,DRUG: Provigil (modafinil),Institute for Clinical Research,,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE|Primary Purpose: TREATMENT,2003-01,,,"Veterans Affairs Medical Center, Washington, District of Columbia, 20422, United States"
NCT04639401,Auditory-motor Coupling in Multiple Sclerosis With Cerebellar Lesions,https://beta.clinicaltrials.gov/study/NCT04639401,UNKNOWN,Multiple Sclerosis|Cerebral Lesion,OTHER: motor entrainment to auditory cues and music during walking on quality of movement,Hasselt University,National MS Center Melsbroek|Revalidatie & MS Centrum Overpelt,ALL,"ADULT, OLDER_ADULT",NA,8,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2020-11-09,2022-12-31,2022-12-31,"National MS Center Melsbroek, Melsbroek, Belgium|Noorderhart Revalidatie & MS centrum, Overpelt, 3900, Belgium"
NCT05605951,Acute Optic Neuritis Network: an International Study That Invesitages Subjects With a First-ever Episode of Acute Inflammation of the Optic Nerve,https://beta.clinicaltrials.gov/study/NCT05605951,RECRUITING,Demyelinating Diseases|Multiple Sclerosis|Neuromyelitis Optica Spectrum Disorder Attack|Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease|Optic Neuritis,OTHER: non-interventional study,"Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecul",,ALL,"ADULT, OLDER_ADULT",,200,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-08-15,2025-12-31,2025-12-31,"University of Colorado School of Medicine, Aurora, Colorado, 80045, United States|Harvard Medical School, Boston, Massachusetts, 02115, United States|Departments of Neurology and Ophthalmology, Mayo Clinic, Rochester, Minnesota, 55902, United States|Hospital Aleman, Buenos Aires, Argentina|Department of Neurology, Concord Hospital, Faculty of Medicine and Health, Sydney, Australia|University of Botswana, Gaborone, Botswana|Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil|Del Rosario University, Bogotá, Colombia|Department of Ophthalmology, Oftlamo-Sanitas Eye Institute, School of Medicine, Fundación Universitaria Sanitas, Bogotá, Colombia|Pontificia Universidad Javeriana, Bogotá, Colombia|Department of Neurology, Slagelse, Institute for Health Research, University of Southern Denmark, Odense, Denmark|(MIRCEM) Lyon Civil Hospices, France, Lyon, France|Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin, Germany, Department of Neurology, Berlin, Germany|Institute for Clinical Neuroimmunology, LMU Clinic of Ludwig-Maximilians Universität in Munich, Munich, Germany|Nitte University, Karnataka, Mangalore, India|Hadassah Hebrew University, Jerusalem, Israel|Sackler School of Medicine and Rabin Medical Center, Tel Aviv, Israel|University of Bologna, Bologna, Italy|University of Verona, Verona, Italy|Fukushima Medical University School of Medicine, Fukushima, Japan|National Cancer Center, Seúl University, Seúl, Korea, Republic of|University of Barcelona, Barcelona, Spain|Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain|University Hospitals of Birmingham, Birmingham, United Kingdom|Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, United Kingdom|University Teaching Hospital in Lusaka, Lusaka, Zambia"
NCT00666887,Minocycline in Clinically Isolated Syndromes (CIS),https://beta.clinicaltrials.gov/study/NCT00666887,COMPLETED,Clinically Isolated Syndromes|Early Single Relapse of Multiple Sclerosis,DRUG: Minocycline|DRUG: Placebo,Dr. Luanne Metz,Multiple Sclerosis Society of Canada,ALL,ADULT,PHASE3,142,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2009-01,2014-12,2015-07,"University of Calgary, Calgary Health Region, Calgary, Alberta, T2N 4N1, Canada|University of Alberta, Edmonton, Alberta, T6G 2G3, Canada|Fraser Health Multiple Sclerosis Clinic, Burnaby, British Columbia, V5G 2X6, Canada|UBC Hospital, Vancouver, British Columbia, V6T 2B5, Canada|MS Research Unit, Health Sciences Centre, Winnipeg, Manitoba, R3A 1R9, Canada|Dalhousie MS Research Unit, Halifax, Nova Scotia, B3H 1V7, Canada|MS Clinic, London Health Sciences Centre, London, Ontario, N6A 5A5, Canada|The Ottawa Hospital, Multiple Sclerosis Research Clinic, Ottawa, Ontario, K1H 8L6, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, M4N 3M5, Canada|Clinique Neuro Rive-Sud, Greenfield Park, Quebec, J4V2J2, Canada|CHUM Notre-Dame, Montreal, Quebec, H2L 4M1, Canada|CHAUQ Enfant-Jesus, Quebec City, Quebec, G1J 1Z4, Canada"
NCT04121221,"A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS",https://beta.clinicaltrials.gov/study/NCT04121221,ACTIVE_NOT_RECRUITING,"Multiple Sclerosis, Relapsing-Remitting",DRUG: GA Depot|OTHER: Placebo,Mapi Pharma Ltd.,,ALL,ADULT,PHASE3,1016,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-09-19,2022-06-15,2023-06,"Mapi Pharma Research site 08, Birmingham, Alabama, 35209, United States|Mapi Pharma Research site 11, Cullman, Alabama, 35058, United States|Mapi Pharma Research site 15, Pasadena, California, 91105, United States|Mapi Pharma Research site 14, Denver, Colorado, 80209, United States|Mapi Pharma Research site 12, Washington, District of Columbia, 20007, United States|Mapi Pharma Research site 17, Homestead, Florida, 33032, United States|Mapi Pharma Research site 09, Miami, Florida, 33136, United States|Mapi Pharma Research site 01, Northbrook, Illinois, 60062, United States|Mapi Pharma Research site 02, Detroit, Michigan, 48201, United States|Mapi Pharma Research site 13, Westerville, Ohio, 43081, United States|Mapi Pharma Research site 04, Round Rock, Texas, 78681, United States|Mapi Pharma Research site 02, Gomel, Belarus|Mapi Pharma Research site 04, Minsk, Belarus|Mapi Pharma Research site 05, Minsk, Belarus|Mapi Pharma Research site 06, Minsk, Belarus|Mapi Pharma Research site 01, Vitebsk, Belarus|Mapi Pharma Research site 07, Vitebsk, Belarus|Mapi Pharma Research site 04, Banja Luka, Bosnia and Herzegovina|Mapi Pharma Research site 06, Bihać, Bosnia and Herzegovina|Mapi Pharma Research site 01, Sarajevo, Bosnia and Herzegovina|Mapi Pharma Research site 03, Tuzla, Bosnia and Herzegovina|Mapi Pharma Research site 14, Haskovo, Bulgaria|Mapi Pharma Research site 10, Pazardzhik, Bulgaria|Mapi Pharma Research site 01, Pleven, Bulgaria|Mapi Pharma Research site 02, Pleven, Bulgaria|Mapi Pharma Research site 03, Pleven, Bulgaria|Mapi Pharma Research site 07, Pleven, Bulgaria|Mapi Pharma Research site 12, Plovdiv, Bulgaria|Mapi Pharma Research site 18, Rousse, Bulgaria|Mapi Pharma Research site 04, Sofia, Bulgaria|Mapi Pharma Research site 05, Sofia, Bulgaria|Mapi Pharma Research site 06, Sofia, Bulgaria|Mapi Pharma Research site 08, Sofia, Bulgaria|Mapi Pharma Research site 11, Sofia, Bulgaria|Mapi Pharma Research site 13, Sofia, Bulgaria|Mapi Pharma Research site 15, Sofia, Bulgaria|Mapi Pharma Research site 16, Sofia, Bulgaria|Mapi Pharma Research site 19, Sofia, Bulgaria|Mapi Pharma Research site 09, Veliko Tarnovo, Bulgaria|Mapi Pharma Research site 17, Vratsa, Bulgaria|Mapi Pharma Research site 01, Tallinn, Estonia|Mapi Pharma Research site 01, Tbilisi, Georgia|Mapi Pharma Research site 02, Tbilisi, Georgia|Mapi Pharma Research site 03, Tbilisi, Georgia|Mapi Pharma Research site 04, Tbilisi, Georgia|Mapi Pharma Research site 05, Tbilisi, Georgia|Mapi Pharma Research site 06, Tbilisi, Georgia|Mapi Pharma Research site 07, Tbilisi, Georgia|Mapi Pharma Research site 08, Tbilisi, Georgia|Mapi Pharma Research site 09, Tbilisi, Georgia|Mapi Pharma Research site 01, Safed, Israel|Mapi Pharma Research site 02, Tel Aviv, Israel|Mapi Pharma Research site 01, Chisinau, Moldova, Republic of|Mapi Pharma Research site 02, Chisinau, Moldova, Republic of|Mapi Pharma Research site 29, Barnaul, Russian Federation|Mapi Pharma Research site 27, Bryansk, Russian Federation|Mapi Pharma Research site 23, Chelyabinsk, Russian Federation|Mapi Pharma Research site 01, Kazan, Russian Federation|Mapi Pharma Research site 19, Kemerovo, Russian Federation|Mapi Pharma Research site 24, Krasnodar, Russian Federation|Mapi Pharma Research site 03, Moscow, Russian Federation|Mapi Pharma Research site 13, Moscow, Russian Federation|Mapi Pharma Research site 14, Moscow, Russian Federation|Mapi Pharma Research site 21, Moscow, Russian Federation|Mapi Pharma Research site 25, Moscow, Russian Federation|Mapi Pharma Research site 28, Moscow, Russian Federation|Mapi Pharma Research site 10, Nizhniy Novgorod, Russian Federation|Mapi Pharma Research site 02, Nizhny Novgorod, Russian Federation|Mapi Pharma Research site 07, Nizhny Novgorod, Russian Federation|Mapi Pharma Research site 11, Novosibirsk, Russian Federation|Mapi Pharma Research site 06, Perm, Russian Federation|Mapi Pharma Research site 22, Pyatigorsk, Russian Federation|Mapi Pharma Research site 08, Rostov-Na-Donu, Russian Federation|Mapi Pharma Research site 09, Saint Petersburg, Russian Federation|Mapi Pharma Research site 18, Saint Petersburg, Russian Federation|Mapi Pharma Research site 20, Saint Petersburg, Russian Federation|Mapi Pharma Research site 05, Samara, Russian Federation|Mapi Pharma Research site 26, Saransk, Russian Federation|Mapi Pharma Research site 15, Smolensk, Russian Federation|Mapi Pharma Research site 16, Tyumen, Russian Federation|Mapi Pharma Research site 04, Ufa, Russian Federation|Mapi Pharma Research site 17, Ulyanovsk, Russian Federation|Mapi Pharma Research site 32, Cherkasy, Ukraine|Mapi Pharma Research site 06, Chernihiv, Ukraine|Mapi Pharma Research site 11, Chernivtsi, Ukraine|Mapi Pharma Research site 03, Dnipropetrovs'k, Ukraine|Mapi Pharma Research site 04, Dnipropetrovs'k, Ukraine|Mapi Pharma Research site 24, Dnipro, Ukraine|Mapi Pharma Research site 18, Ivano-Frankivs'k, Ukraine|Mapi Pharma Research site 26, Ivano-Frankivs'k, Ukraine|Mapi Pharma Research site 27, Ivano-Frankivs'k, Ukraine|Mapi Pharma Research site 09, Kharkiv, Ukraine|Mapi Pharma Research site 10, Kharkiv, Ukraine|Mapi Pharma Research site 08, Kherson, Ukraine|Mapi Pharma Research site 21, Kyiv, Ukraine|Mapi Pharma Research site 25, Kyiv, Ukraine|Mapi Pharma Research site 28, Kyiv, Ukraine|Mapi Pharma Research site 29, Kyiv, Ukraine|Mapi Pharma Research site 17, Luts'k, Ukraine|Mapi Pharma Research site 12, Lviv, Ukraine|Mapi Pharma Research site 13, Lviv, Ukraine|Mapi Pharma Research site 23, Lviv, Ukraine|Mapi Pharma Research site 05, Odesa, Ukraine|Mapi Pharma Research site 14, Poltava, Ukraine|Mapi Pharma Research site 34, Ternopil', Ukraine|Mapi Pharma Research site 16, Vinnitsa, Ukraine|Mapi Pharma Research site 01, Zaporizhzhya, Ukraine|Mapi Pharma Research site 02, Zaporizhzhya, Ukraine|Mapi Pharma Research site 07, Zaporizhzhya, Ukraine|Mapi Pharma Research site 20, Zaporizhzhya, Ukraine|Mapi Pharma Research site 33, Zhytomyr, Ukraine|Mapi Pharma Research site 31, Úzhgorod, Ukraine"
NCT01740830,The Effect of Anodal tDCS on Motor Learning in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01740830,COMPLETED,Anodal tDCS|Recruitment Curves,DEVICE: Transcranial Direct Current Stimulation (tDCS) (Neuroconn DC-stimulator),Hasselt University,,ALL,"ADULT, OLDER_ADULT",NA,31,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-06,2012-10,2012-10,
NCT04115930,"Correlation Between Daily Physical Activity and Disability, Fatigue, Cognition and Quality of Life in MS Patients",https://beta.clinicaltrials.gov/study/NCT04115930,COMPLETED,Relapsing Remitting Multiple Sclerosis|Fatigue|Quality of Life|Physical Activity,DEVICE: Physical Activity measurement:,University of Eastern Finland,,ALL,ADULT,,61,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-05-16,2019-06-13,2019-06-13,"Joensuu, Joensuu, Finland|Jyväskylä, Jyväskylä, Finland|University of Eastern Finland, Kuopio, Finland|Oulu, Oulu, Finland"
NCT01067521,"A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo",https://beta.clinicaltrials.gov/study/NCT01067521,COMPLETED,Relapsing Remitting Multiple Sclerosis,DRUG: Glatiramer acetate (GA)|DRUG: Placebo,"Teva Branded Pharmaceutical Products R&D, Inc.",,ALL,ADULT,PHASE3,1404,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2010-06-22,2012-05-08,2017-05-12,"Teva Investigational Site 1332, Birmingham, Alabama, 35209, United States|Teva Investigational Site 1327, Gilbert, Arizona, 85234, United States|Teva Investigational Site 1311, Phoenix, Arizona, 85004, United States|Teva Investigational Site 1326, Fullerton, California, 92835, United States|Teva Investigational Site 1335, La Jolla, California, 92037, United States|Teva Investigational Site 1297, Aurora, Colorado, 80045, United States|Teva Investigational Site 1344, Boulder, Colorado, 80304, United States|Teva Investigational Site 1315, Centennial, Colorado, 80112, United States|Teva Investigational Site 1350, Fort Collins, Colorado, 80528, United States|Teva Investigational Site 1345, Miami, Florida, 33136, United States|Teva Investigational Site 1336, Naples, Florida, 34102, United States|Teva Investigational Site 1347, Pompano Beach, Florida, 33060, United States|Teva Investigational Site 1319, Ponte Vedra, Florida, 32082, United States|Teva Investigational Site 1298, Sarasota, Florida, 34233, United States|Teva Investigational Site 1316, Sarasota, Florida, 34239, United States|Teva Investigational Site 1340, Tampa, Florida, 33606, United States|Teva Investigational Site 1317, Vero Beach, Florida, 32960, United States|Teva Investigational Site 1303, Northbrook, Illinois, 60062, United States|Teva Investigational Site 1334, Lenexa, Kansas, 66214, United States|Teva Investigational Site 1302, Lexington, Kentucky, 40513, United States|Teva Investigational Site 1322, Shreveport, Louisiana, 71103, United States|Teva Investigational Site 1306, Detroit, Michigan, 48201, United States|Teva Investigational Site 1329, Akron, Ohio, 44320, United States|Teva Investigational Site 1349, Columbus, Ohio, 43221, United States|Teva Investigational Site 1313, Dayton, Ohio, 45417, United States|Teva Investigational Site 1318, Uniontown, Ohio, 44685, United States|Teva Investigational Site 1341, Oklahoma City, Oklahoma, 73104, United States|Teva Investigational Site 1310, Nashville, Tennessee, 37205, United States|Teva Investigational Site 1321, Lubbock, Texas, 79410, United States|Teva Investigational Site 1337, Round Rock, Texas, 78681, United States|Teva Investigational Site 1301, San Antonio, Texas, 78231, United States|Teva Investigational Site 1346, San Antonio, Texas, 78258, United States|Teva Investigational Site 1343, Salt Lake City, Utah, 84106, United States|Teva Investigational Site 1338, Richmond, Virginia, 23298-0599, United States|Teva Investigational Site 1339, Roanoke, Virginia, 24018, United States|Teva Investigational Site 1300, Vienna, Virginia, 22182, United States|Teva Investigational Site 1323, Kirkland, Washington, 98034, United States|Teva Investigational Site 5940, Blagoevgrad, 2700, Bulgaria|Teva Investigational Site 5931, Pleven, 5800, Bulgaria|Teva Investigational Site 5932, Pleven, 5800, Bulgaria|Teva Investigational Site 5933, Plovdiv, 4000, Bulgaria|Teva Investigational Site 5936, Ruse, 7000, Bulgaria|Teva Investigational Site 5935, Shumen, 9700, Bulgaria|Teva Investigational Site 5939, Sofia, 1000, Bulgaria|Teva Investigational Site 5921, Sofia, 1113, Bulgaria|Teva Investigational Site 5922, Sofia, 1113, Bulgaria|Teva Investigational Site 5926, Sofia, 1309, Bulgaria|Teva Investigational Site 5938, Sofia, 1407, Bulgaria|Teva Investigational Site 5924, Sofia, 1431, Bulgaria|Teva Investigational Site 5927, Sofia, 15257, Bulgaria|Teva Investigational Site 5923, Sofia, 1606, Bulgaria|Teva Investigational Site 5925, Sofia, 1606, Bulgaria|Teva Investigational Site 5928, Sofia, 1606, Bulgaria|Teva Investigational Site 5929, Sofia, 1606, Bulgaria|Teva Investigational Site 5934, Stara Zagora, 6000, Bulgaria|Teva Investigational Site 5930, Varna, 9010, Bulgaria|Teva Investigational Site 5937, Veliko Tarnovo, 5000, Bulgaria|Teva Investigational Site 6011, Osijek, 31 000, Croatia|Teva Investigational Site 6009, Zagreb, 10000, Croatia|Teva Investigational Site 6010, Zagreb, 10000, Croatia|Teva Investigational Site 6012, Zagreb, 10000, Croatia|Teva Investigational Site 6013, Zagreb, 10000, Croatia|Teva Investigational Site 5433, Olomouc, 779 00, Czechia|Teva Investigational Site 5434, Ostrava - poruba, 708 52, Czechia|Teva Investigational Site 5432, Prague 10, 100 31, Czechia|Teva Investigational Site 5435, Teplice, 415 29, Czechia|Teva Investigational Site 5513, Kohtla-Jarve, 31025, Estonia|Teva Investigational Site 5510, Tallinn, EE-10617, Estonia|Teva Investigational Site 5512, Tartu, EE-51014, Estonia|Teva Investigational Site 8110, Tbilisi, 0112, Georgia|Teva Investigational Site 8111, Tbilisi, 0179, Georgia|Teva Investigational Site 3268, Bad Wildbad, 75323, Germany|Teva Investigational Site 3272, Bayreuth, 95445, Germany|Teva Investigational Site 3262, Berlin, 10117, Germany|Teva Investigational Site 3276, Berlin, 12203, Germany|Teva Investigational Site 3271, Bonn, 53117, Germany|Teva Investigational Site 3265, Dresden, 01307, Germany|Teva Investigational Site 3267, Duesseldorf, 40211, Germany|Teva Investigational Site 3263, Erbach, 64711, Germany|Teva Investigational Site 3269, Hamburg, 22179, Germany|Teva Investigational Site 3266, Hannover, 30171, Germany|Teva Investigational Site 3270, Herborn, 35745, Germany|Teva Investigational Site 3273, Kaltenkirchen, 24568, Germany|Teva Investigational Site 3275, Marburg, 35043, Germany|Teva Investigational Site 3261, Munster, 48149, Germany|Teva Investigational Site 3264, Ulm, 89081, Germany|Teva Investigational Site 5127, Budapest, H-1115, Hungary|Teva Investigational Site 5129, Debrecen, 4043, Hungary|Teva Investigational Site 5130, Eger, H-3300, Hungary|Teva Investigational Site 5132, Esztergom, H-2500, Hungary|Teva Investigational Site 5131, Gyor, H-9023, Hungary|Teva Investigational Site 5128, Kaposvar, H-7400, Hungary|Teva Investigational Site 5133, Veszprem, H-8200, Hungary|Teva Investigational Site 8052, Ramat Gan, 5262160, Israel|Teva Investigational Site 3089, Bologna, 40139, Italy|Teva Investigational Site 3084, Cefalu, 90015, Italy|Teva Investigational Site 3092, Cosenza, 87100, Italy|Teva Investigational Site 3080, Milano, 20148, Italy|Teva Investigational Site 3086, Rome, 00144, Italy|Teva Investigational Site 5710, Kaunas, 50009, Lithuania|Teva Investigational Site 5712, Siauliai, 76231, Lithuania|Teva Investigational Site 5711, Vilnius, LT-08661, Lithuania|Teva Investigational Site 5374, Czestochowa, 42-200, Poland|Teva Investigational Site 5377, Elblag, 82-300, Poland|Teva Investigational Site 5381, Gdansk, 80-299, Poland|Teva Investigational Site 5380, Gdansk, 80-803, Poland|Teva Investigational Site 5376, Gorzow Wielkopolski, 66-400, Poland|Teva Investigational Site 5372, Grodzisk Mazowiecki, 05-825, Poland|Teva Investigational Site 5375, Katowice, 40-684, Poland|Teva Investigational Site 5368, Katowice, 40-752, Poland|Teva Investigational Site 5379, Kielce, 25-726, Poland|Teva Investigational Site 5382, Konskie, 26-200, Poland|Teva Investigational Site 5369, Koscierzyna, 83-400, Poland|Teva Investigational Site 5378, Krakow, 31-826, Poland|Teva Investigational Site 5366, Lodz, 90-153, Poland|Teva Investigational Site 5373, Olsztyn, 10-560, Poland|Teva Investigational Site 5384, Poznan, 60-355, Poland|Teva Investigational Site 5371, Szczecin, 70-111, Poland|Teva Investigational Site 5367, Warszawa, 02-097, Poland|Teva Investigational Site 5370, Wroclaw, 50-556, Poland|Teva Investigational Site 5233, Balotesti, 077015, Romania|Teva Investigational Site 5222, Bucharest, 010825, Romania|Teva Investigational Site 5221, Bucuresti, 022328, Romania|Teva Investigational Site 5220, Bucuresti, 050098, Romania|Teva Investigational Site 5227, Cluj-Napoca, 400006, Romania|Teva Investigational Site 5230, Cluj-Napoca, 400437, Romania|Teva Investigational Site 5225, Constanta, 900123, Romania|Teva Investigational Site 5226, Constanta, 900591, Romania|Teva Investigational Site 5232, Craiova, 200515, Romania|Teva Investigational Site 5231, Iasi, 700661, Romania|Teva Investigational Site 5223, Piatra-Neamt, 610136, Romania|Teva Investigational Site 5228, Sibiu, 550245, Romania|Teva Investigational Site 5229, Targu-Mures, 540136, Romania|Teva Investigational Site 5224, Timisoara, 300736, Romania|Teva Investigational Site 5063, Barnaul, 656024, Russian Federation|Teva Investigational Site 5059, Ekaterinburg, 620102, Russian Federation|Teva Investigational Site 5068, Irkutsk, 664079, Russian Federation|Teva Investigational Site 5067, Krasnoyarsk, 660022, Russian Federation|Teva Investigational Site 5052, Moscow, 127015, Russian Federation|Teva Investigational Site 5057, Nizhny Novgorod, 603126, Russian Federation|Teva Investigational Site 5062, Novosibirsk, 630087, Russian Federation|Teva Investigational Site 5060, Perm, 614990, Russian Federation|Teva Investigational Site 5053, Saint Petersburg, 197022, Russian Federation|Teva Investigational Site 5058, Samara, 443095, Russian Federation|Teva Investigational Site 5064, Smolensk, 214018, Russian Federation|Teva Investigational Site 5056, St. Petersburg, 194044, Russian Federation|Teva Investigational Site 5055, St. Petersburg, 194354, Russian Federation|Teva Investigational Site 5054, St. Petersburg, 197376, Russian Federation|Teva Investigational Site 5066, Tomsk, 634050, Russian Federation|Teva Investigational Site 5061, Ufa, 450007, Russian Federation|Teva Investigational Site 5065, Yaroslavl, 150030, Russian Federation|Teva Investigational Site 9020, Johannesburg, 2157, South Africa|Teva Investigational Site 9019, Johannesburg, 2193, South Africa|Teva Investigational Site 9022, Pietermaritzburg, 3201, South Africa|Teva Investigational Site 9025, Pretoria, 0002, South Africa|Teva Investigational Site 9018, Pretoria, 0041, South Africa|Teva Investigational Site 9021, Rosebank, 2196, South Africa|Teva Investigational Site 9024, Umhlanga, 4320, South Africa|Teva Investigational Site 5835, Chernihiv, 14029, Ukraine|Teva Investigational Site 5834, Chernivtsi, 58018, Ukraine|Teva Investigational Site 5827, Dnipropetrovsk, 49027, Ukraine|Teva Investigational Site 5828, Donetsk, 83003, Ukraine|Teva Investigational Site 5829, Ivano-Frankivsk, 76008, Ukraine|Teva Investigational Site 5830, Kharkiv, 61018, Ukraine|Teva Investigational Site 5833, Kyiv, 03110, Ukraine|Teva Investigational Site 5836, Kyiv, 03115, Ukraine|Teva Investigational Site 5825, Lviv, 79010, Ukraine|Teva Investigational Site 5839, Odesa, 65014, Ukraine|Teva Investigational Site 5832, Poltava, 36024, Ukraine|Teva Investigational Site 5838, Simferopol, 295017, Ukraine|Teva Investigational Site 5837, Uzhgorod, 88018, Ukraine|Teva Investigational Site 5826, Vinnytsya, 21005, Ukraine|Teva Investigational Site 5831, Zaporizhzhya, 69600, Ukraine|Teva Investigational Site 3439, Nottingham, NG7 2UH, United Kingdom|Teva Investigational Site 3438, Salford, M6 8HD, United Kingdom|Teva Investigational Site 3440, Sheffield, S10 2JF, United Kingdom"
NCT05752630,"Physical Activity, Sedentary Behaviour and Cardiometabolic Health in Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT05752630,RECRUITING,"Multiple Sclerosis, Relapsing-Remitting",,Hasselt University,,ALL,ADULT,,50,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-01-30,2024-01-20,2024-01-20,"Hasselt University, Diepenbeek, Limburg, 3590, Belgium"
NCT03423121,A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03423121,COMPLETED,Progressive Multiple Sclerosis,DRUG: Tauroursodeoxycholic Acid|DRUG: Placebo oral capsule,Johns Hopkins University,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,59,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2018-06-19,2022-04-28,2022-07-05,"Johns Hopkins University, Baltimore, Maryland, 21287, United States"
NCT02166021,Clinical Efficacy of Autologous Mesenchymal Bone Marrow Stem Cells in Active & Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02166021,COMPLETED,Multiple Sclerosis (MS),BIOLOGICAL: Mesenchymal stem cells,Dimitrios Karussis,,ALL,"ADULT, OLDER_ADULT",PHASE2,48,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2015-01-29,2018-06-15,2018-12-24,"Hadassah Medical Organization, Jerusalem, 91120, Israel"
NCT05003388,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for MS,https://beta.clinicaltrials.gov/study/NCT05003388,RECRUITING,Multiple Sclerosis,BIOLOGICAL: AlloRx,The Foundation for Orthopaedics and Regenerative Medicine,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1,15,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-06-26,2025-10,2025-10,"Medical Surgical Associates Center, St. John's, Antigua and Barbuda|Center for Investigation in Tissue Engineering and Cellular Therapy, Buenos Aires, Argentina|Medyca Bosques, San Pedro Garza García, N.L, Mexico"
NCT01714089,Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01714089,WITHDRAWN,Relapsing Remitting Multiple Sclerosis,DRUG: RNS60 125 ml|DRUG: RNS60 250 ml|DRUG: Interferon beta 1a,Revalesio Corporation,,ALL,ADULT,PHASE2,0,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",,,,"Mt. Sinai School of Medicine, New York, New York, 10029, United States"
NCT04079088,Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS),https://beta.clinicaltrials.gov/study/NCT04079088,NOT_YET_RECRUITING,Relapsing Multiple Sclerosis,DRUG: Placebo|DRUG: BIIB061|BIOLOGICAL: Interferon-beta1|DRUG: Glatiramer acetate,Biogen,,ALL,ADULT,PHASE2,300,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-06-30,2024-09-18,2024-09-18,
NCT05248438,Study of Gynecological Follow-up Concerning Women With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05248438,RECRUITING,Multiple Sclerosis,BEHAVIORAL: Questionnaire,"University Hospital, Bordeaux",Merck Sharp & Dohme LLC,FEMALE,ADULT,,250,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-05-11,2023-05,2023-05,"CHU de Bordeaux - service de neurologie, Bordeaux, France"
NCT03910738,TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03910738,RECRUITING,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection|DRUG: Placebo 4 mL Solution for Injection|PROCEDURE: MRI|BEHAVIORAL: Assessment of impact of MS on cognition; quality of life; fatigue; anxiety/depression and work and activities|BEHAVIORAL: Assessment of disability,"University Hospital, Strasbourg, France",Bayer|Fédération Hospitalo-Universitaire NEUROGENYCS,MALE,ADULT,PHASE2,40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-10-29,2023-05,2023-05,"CHU de Besançon, Besançon, 25000, France|CHU Nancy, Nancy, 54000, France|Hôpital Pitié-Salpêtrière, Paris, 75013, France|CHU de Rennes/Pontchaillou, Rennes, 35000, France|CHRU de Strasbourg, Strasbourg, 67000, France"
NCT00681538,"A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)",https://beta.clinicaltrials.gov/study/NCT00681538,COMPLETED,Spasticity|Multiple Sclerosis,DRUG: Sativex®|DRUG: Placebo,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,572,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2008-01,2009-01,2009-01,"Department of Neurology, Northampton General Hospital, Cliftonville, Northampton, NN1 5BD, United Kingdom"
NCT00997438,Defining the Anti-inflammatory Role of Lipoic Acid in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00997438,COMPLETED,Multiple Sclerosis,DIETARY_SUPPLEMENT: Lipoic Acid,Portland VA Medical Center,Oregon Health and Science University,ALL,"ADULT, OLDER_ADULT",PHASE1,69,FED,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2010-08,2013-12,2013-12,"Oregon Health & Science University, Portland, Oregon, 97239, United States|Portland VA Medical Center, Portland, Oregon, 97239, United States"
NCT05357638,Physical Training for People With Parkinson's Disease and Multiple Sclerosis: Effect on Mind and Body,https://beta.clinicaltrials.gov/study/NCT05357638,RECRUITING,Parkinson Disease|Multiple Sclerosis,BEHAVIORAL: High Intensity Interval Training (HIIT)|BEHAVIORAL: Continuous Aerobic Training (CAT)|BEHAVIORAL: Movement Advice,"Amsterdam UMC, location VUmc",Netherlands Brain Foundation,ALL,"ADULT, OLDER_ADULT",NA,48,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-05-02,2025-05-02,2025-11-02,"Amsterdam UMC, location VU medical center, Amsterdam, Noord-Holland, 1081HZ, Netherlands"
NCT04626921,"A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT04626921,ACTIVE_NOT_RECRUITING,Relapsing Multiple Sclerosis,DRUG: CNM-Au8,Clene Nanomedicine,George Clinical,ALL,ADULT,PHASE2|PHASE3,150,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-10-22,2024-06,2024-08,"Sydney Brain Mind Centre, Camperdown, New South Wales, 2050, Australia|John Hunter Hospital, New Lambton Heights, New South Wales, 2305, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, 4102, Australia|Menzies Institute for Medical Research, Hobart, TAZ, 7000, Australia|The Alfred Centre Department of Neuroscience, Melbourne, Victoria, 3004, Australia"
NCT02665221,"Single Center, Open Label, Study of Preparation H on Erythema in Relapsing MS Patients Treated With PLEGRIDY",https://beta.clinicaltrials.gov/study/NCT02665221,TERMINATED,Multiple Sclerosis,OTHER: No Treatment Arm|DRUG: Topical Preparation H arm,NYU Langone Health,,ALL,"ADULT, OLDER_ADULT",PHASE4,30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2015-07,2016-09,2016-09,"New York University School of Medicine, New York, New York, 10016, United States"
NCT04239521,"The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata",https://beta.clinicaltrials.gov/study/NCT04239521,COMPLETED,Alopecia Areata|Depressive Episode|Recurrent Depressive Disorder|Anxiety Disorders|Atopic Dermatitis|Allergic Rhinitis|Asthma|Crohn Disease|Ulcerative Colitis|Pernicious Anemia|Type 1 Diabetes|Hashimoto Thyroiditis|Graves Disease|Rheumatoid Arthritis|Psoriatic Arthritis|Ankylosing Spondylitis|Systemic Lupus Erythematosus|Polymyalgia Rheumatica|Sjogren's Syndrome|Psoriasis|Vitiligo|Multiple Sclerosis|Celiac Disease|Upper Respiratory Tract Infection|Influenza|Lower Resp Tract Infection|Acute Bronchitis|Pneumonia|Gastrointestinal Infection|Skin Infection|Urinary Tract Infections|Genital Infection|Herpes Zoster|Herpes Simplex|Infection|Infection Viral,OTHER: Exposure of interest (studies 2 & 3).,Momentum Data,Pfizer|University of Surrey|University of Oxford,ALL,"CHILD, ADULT, OLDER_ADULT",,51955,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-10-01,2022-03-31,2022-11-28,"Momentum Data Ltd, London, WC1X 8QT, United Kingdom"
NCT04667221,Cognitive Improvement Through tDCS for Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04667221,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,DEVICE: Active transcranial direct current stimulation|DEVICE: Sham transcranial direct current stimulation,University Medicine Greifswald,,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-12-08,2023-12-31,2023-12-31,"University Medicine Greifswald, Greifswald, 17489, Germany"
NCT00954421,Use of Two Deep Brain Stimulation (DBS) Electrodes to Treat Post-Traumatic Tremor,https://beta.clinicaltrials.gov/study/NCT00954421,COMPLETED,Multiple Sclerosis,DEVICE: Deep Brain Stimulation,University of Florida,National Institute of Neurological Disorders and Stroke (NINDS)|Medtronic,ALL,"ADULT, OLDER_ADULT",NA,16,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2006-11,2012-06,2013-12,"University of Florida, Gainesville, Florida, 32610, United States"
NCT02459821,Effects of GE-O System on Gait Impairments in Multiple Sclerosis Subjects,https://beta.clinicaltrials.gov/study/NCT02459821,UNKNOWN,Multiple Sclerosis,OTHER: GE-O SYSTEM|OTHER: Conventional training,Universita di Verona,,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2015-05,2016-09,2016-12,"Azienta Ospedaliera, SSO Rehabilitation Unit, Verona, Verona, Italy, Verona, 37134, Italy|prof. Smania Nicola, Verona, 37134, Italy"
NCT01118130,Pharmacogenomics of Drug Safety in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01118130,RECRUITING,Multiple Sclerosis,,University of British Columbia,Canadian Institutes of Health Research (CIHR)|Canada Foundation for Innovation|Genome Canada|British Columbia Clinical Genomics Network,ALL,"ADULT, OLDER_ADULT",,300,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-06,2024-05,2024-05,"MS Clinic UBC Hospital, Vancouver, British Columbia, V6T 2B5, Canada|Winnipeg Health Sciences Centre, Winnipeg, Manitoba, Canada|Dalhousie MS Research Unit, Halifax, Nova Scotia, Canada|London Health Sciences Centre MS clinic, London, Ontario, Canada|Hôpital Notre-Dame MS clinic, Montréal, Quebec, Canada"
NCT00306592,Natalizumab Re-Initiation of Dosing,https://beta.clinicaltrials.gov/study/NCT00306592,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",BIOLOGICAL: BG00002 (natalizumab),Biogen,Elan Pharmaceuticals,ALL,"ADULT, OLDER_ADULT",PHASE3,404,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2006-03,2007-12,2008-02,"Research Site, Birmingham, Alabama, 35233, United States|Research Site, Phoenix, Arizona, 85006, United States|Research Site, Scottsdale, Arizona, 85259, United States|Research Site, Little Rock, Arkansas, 72205, United States|Research Site, Berkeley, California, 94705, United States|Research Site, Los Angeles, California, 90033, United States|Research Site, Redwood City, California, 94063, United States|Research Site, Sacramento, California, 95817, United States|Research Site, San Francisco, California, 94117, United States|Research Site, Colorado Springs, Colorado, 80919, United States|Research Site, New Haven, Connecticut, 06510, United States|Research Site, Washington, District of Columbia, 20007, United States|Research Site, Maitland, Florida, 32751, United States|Research Site, Miami, Florida, 33136, United States|Research Site, Pompano Beach, Florida, 33060, United States|Research Site, Atlanta, Georgia, 30327, United States|Research Site, Arlington, Illinois, 60007, United States|Research Site, Chicago, Illinois, 60612, United States|Research Site, Chicago, Illinois, 60637, United States|Research Site, Northbrook, Illinois, 60062, United States|Research Site, Des Moines, Iowa, 50314, United States|Research Site, Kansas City, Kansas, 66160, United States|Research Site, Baltimore, Maryland, 21201, United States|Research Site, Worcester, Massachusetts, 01655, United States|Research Site, East Lansing, Michigan, 48824, United States|Research Site, Farmington Hills, Michigan, 48334, United States|Research Site, Teaneck, New Jersey, 07666, United States|Research Site, Albuquerque, New Mexico, 87131, United States|Research Site, Albany, New York, 12208, United States|Research Site, Buffalo, New York, 14203, United States|Research Site, Great Neck, New York, 10019, United States|Research Site, New York, New York, 10003, United States|Research Site, New York, New York, 10319, United States|Research Site, Staten Island, New York, 10305, United States|Research Site, Syracuse, New York, 13202, United States|Research Site, Charlotte, North Carolina, 28207, United States|Research Site, Raleigh, North Carolina, 27607, United States|Research Site, Fargo, North Dakota, 58103, United States|Research Site, Cincinnati, Ohio, 45219, United States|Research Site, Cleveland, Ohio, 44195, United States|Research Site, Portland, Oregon, 97225, United States|Research Site, Allentown, Pennsylvania, 18103, United States|Research Site, Philadelphia, Pennsylvania, 19104, United States|Research Site, Philadelphia, Pennsylvania, 19146, United States|Research Site, Pittsburgh, Pennsylvania, 15212, United States|Research Site, Pittsburgh, Pennsylvania, 15213, United States|Research Site, Memphis, Tennessee, 38163, United States|Research Site, Nashville, Tennessee, 37215, United States|Research Site, Dallas, Texas, 75214, United States|Research Site, Round Rock, Texas, 78681, United States|Research Site, Burlington, Vermont, 05401, United States|Research Site, Charlottesville, Virginia, 22903, United States|Research Site, Milwaukee, Wisconsin, 53215, United States|Research Site, Vancouver, British Columbia, V6T2B5, Canada|Research Site, Halifax, Nova Scotia, B3H1V7, Canada|Research Site, Kingston, Ontario, K7L2V7, Canada|Research Site, London, Ontario, N6A5A5, Canada|Research Center, New York, Ontario, M4N 3M5, Canada|Research Site, Ottawa, Ontario, K2G6E2, Canada|Research Site, Toronto, Ontario, M5B1W8, Canada|Research Site, Gatineau, Quebec, J8Y1W7, Canada|Research Site, Greenfield Park, Quebec, J4V2H1, Canada|Research Site, Montreal, Quebec, H3A2B4, Canada"
NCT00292253,Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis Subjects,https://beta.clinicaltrials.gov/study/NCT00292253,COMPLETED,"Multiple Sclerosis, Relapsing-remitting",DEVICE: Rebif® via Rebiject™Mini|DEVICE: Rebif® via manual injections,EMD Serono,Merck Serono International SA,ALL,"ADULT, OLDER_ADULT",PHASE3,1883,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2001-01,2002-12,2002-12,
NCT05359653,Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy,https://beta.clinicaltrials.gov/study/NCT05359653,NOT_YET_RECRUITING,"Multiple Sclerosis (MS)|Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis, Primary Progressive|Multiple Sclerosis, Chronic Progressive|Multiple Sclerosis Relapse|Multiple Sclerosis Brain Lesion|Multiple Sclerosis Benign",DRUG: Clemastine Fumarate|DRUG: Placebo,"University of California, San Francisco",United States Department of Defense,ALL,ADULT,PHASE1|PHASE2,74,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-06-01,2025-06-01,2025-06-01,"Sandler Neurosciences Building, Neurological Clinical Research Unit, San Francisco, California, 94107, United States"
NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT00882453,COMPLETED,Multiple Sclerosis,"DRUG: Interferon beta-1b (Betaseron, BAY86-5046)",Bayer,,ALL,"ADULT, OLDER_ADULT",,1739,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2006-08,2011-03,2011-03,"Many Locations, Australia|Many Locations, Austria|Many Locations, Bahrain|Many Locations, Belgium|Many Locations, Canada|Many Locations, Colombia|Many Locations, Czech Republic|Many Locations, Denmark|Many Locations, Egypt|Many Locations, France|Many Locations, Germany|Many Locations, Greece|Many Locations, Indonesia|Many Locations, Israel|Many Locations, Italy|Many Locations, Jordan|Many Locations, Kazakhstan|Many Locations, Korea, Republic of|Many Locations, Kuwait|Many Locations, Lebanon|Many Locations, Mexico|Many Locations, Netherlands|Many Locations, Norway|Many Locations, Oman|Many Locations, Portugal|Many Locations, Slovenia|Many Locations, Spain|Many Locations, Sweden|Many Locations, Switzerland|Many Locations, Taiwan|Many Locations, Thailand|Many Locations, United Arab Emirates|Many Locations, United Kingdom"
NCT00414453,Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00414453,TERMINATED,Neuropathic Pain|Chronic Pain|Multiple Sclerosis,DRUG: Lidocaine patch 5%|DRUG: Extended-release oxycodone|DRUG: Placebo extended-release oxycodone pills|DRUG: Placebo lidocaine patches,University of Rochester,Endo Pharmaceuticals,ALL,"ADULT, OLDER_ADULT",PHASE4,19,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2007-01,2011-08,2011-08,"University of Rochester Medical Center, Rochester, New York, 14642, United States"
NCT04123353,Scan-Rescan Sub-Study of MS PATHS,https://beta.clinicaltrials.gov/study/NCT04123353,COMPLETED,Multiple Sclerosis,,Biogen,,ALL,ADULT,,30,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-02-11,2017-05-09,2017-05-09,"Research Site, Baltimore, Maryland, 21205, United States|Research Site, New York, New York, 10016, United States|Research Site, Cleveland, Ohio, 44195, United States"
NCT04619953,Cognitive-motor Dual Task Training in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04619953,RECRUITING,Multiple Sclerosis|Cognitive Impairment|Motor Disorders,OTHER: Dynamic Postural Stability Training|OTHER: Cognitive-Motor Training|OTHER: Conventional Therapy,I.R.C.C.S. Fondazione Santa Lucia,,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-11-09,2022-05-01,2022-10-01,"Marco Tramontano, Roma, 00179, Italy"
NCT05840653,The Effect of Hope Placement Program on Dıagnosed Wıth MS,https://beta.clinicaltrials.gov/study/NCT05840653,NOT_YET_RECRUITING,Multiple Sclerosis,OTHER: psychotherapeutic intervention,Ondokuz Mayıs University,,ALL,"ADULT, OLDER_ADULT",NA,80,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH",2023-05-01,2023-06-01,2023-12-01,"SAMSUN, Samsun, 55000, Turkey"
NCT03847753,Exploring the Comorbidity Between Mental Disorders and General Medical Conditions,https://beta.clinicaltrials.gov/study/NCT03847753,COMPLETED,"Organic, Including Symptomatic, Mental Disorders|Substance Use|Schizophrenia|Mood [Affective] Disorders|Neurotic, Stress-related and Somatoform Disorders|Eating Disorder|Disorders of Adult Personality and Behavior|Mental Retardation|Disorder of Psychological Development|Behavioural Disorder|Hypertension|Dyslipidemias|Ischemic Heart Disease|Atrial Fibrillation|Heart Failure|Peripheral Occlusive Disease|Stroke|Diabetes Mellitus|Thyroid Disorder|Gout|Chronic Pulmonary Disease|Allergy|Chronic Gastritis|Chronic Liver Disease|Inflammatory Bowel Diseases|Diverticular Disease of Large Intestine|Chronic Kidney Diseases|Prostate Disorders|Connective Tissue Disorder|Osteoporosis|Pain|HIV/AIDS|Anemia|Cancer|Vision Disorders|Hearing Disorders|Migraine|Epilepsy|Parkinson Disease|Multiple Sclerosis|Neuropathy",OTHER: Organic Disorders|OTHER: Substance Use Disorders|OTHER: Schizophrenia Disorders|OTHER: Mood disorders|OTHER: Neurotic disorders|OTHER: Eating Disorders|OTHER: Personality Disorders|OTHER: Intellectual Disorders|OTHER: Developmental Disorders|OTHER: Behavioral Disorders,University of Aarhus,,ALL,"CHILD, ADULT, OLDER_ADULT",,5940299,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2000-01-01,2016-12-31,2020-01-31,
NCT03555253,Resilience-Based Program for Support Partners of Persons With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03555253,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Resilience-Based Program for Support Partners of PwMS,Healios Inc.,"Genentech, Inc.",ALL,"ADULT, OLDER_ADULT",NA,62,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2018-05-23,2019-03-31,2019-03-31,"Healios, Inc., Flemington, New Jersey, 08822, United States"
NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),https://beta.clinicaltrials.gov/study/NCT02283853,ACTIVE_NOT_RECRUITING,Relapsing-Remitting Multiple Sclerosis,DRUG: dimethyl fumarate|DRUG: Interferon β-1a,Biogen,,ALL,CHILD,PHASE3,156,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2014-08-28,2025-09-08,2025-09-08,"Research Site, Boston, Massachusetts, 02115, United States|Research Site, Charlottesville, Virginia, 22903, United States|Research Site, Brussels, 1020, Belgium|Research Site, Gent, 9000, Belgium|Research Site, Sofia, 1113, Bulgaria|Research Site, Calgary, T3B 6A8, Canada|Research Site, Brno, 656 91, Czechia|Research Site, Hradec Kralove, 500 05, Czechia|Research Site, Jihlava, 58633, Czechia|Research Site, Ostrava - Poruba, 708 52, Czechia|Research Site, København, 2100, Denmark|Research Site, Odense, 5000, Denmark|Research Site, Århus C, 8000, Denmark|Research Site, Strasbourg, Bas Rhin, 67098, France|Research Site, Dijon Cedex, Cote dÝOr, 21033, France|Research Site, Rennes cedex 09, Ille Et Vilaine, 35033, France|Research Site, Bron Cedex, Rhone, 69677, France|Research Site, Amiens Cedex 1, Somme, 80054, France|Research Site, Vandoeuvre les Nancy, Vandoeuvre Les Nancy Cedex, 54511, France|Research Site, Clermont Ferrand, 63003, France|Research Site, Le Kremlin Bicêtre, 94275, France|Research Site, Lille Cedex, 59037, France|Research Site, Marseille, 13385, France|Research Site, Montpellier, 34295, France|Research Site, Augsburg, Bayern, 86156, Germany|Researh Site, Bochum, 44791, Germany|Research Site, Muenchen, 80337, Germany|Research Site, Budapest, 1083, Hungary|Research Site, Budapest, 1089, Hungary|Research Site, Jerusalem, 91120, Israel|Research Site, Petach-Tikva, 4920235, Israel|Resaerch Site, Ramat-Gan, 52621, Israel|Research Site, Gallarate, Varese, 21013, Italy|Research Site, Bari, 70124, Italy|Research Site, Genova, 16132, Italy|Research Site, Milano, 20132, Italy|Research Site, Napoli, 80131, Italy|Research Site, Padova, 35128, Italy|Research Site, Palermo, 90127, Italy|Research Site, Rome, 00165, Italy|Research Site, Rome, 00189, Italy|Research Site, Kuwait, Shuwaikh, 73767, Kuwait|Research Site, Bialystok, 15-274, Poland|Research Site, Gdansk, 80-952, Poland|Research Site, Lodz, 93-338, Poland|Research Site, Poznan, 60-355, Poland|Research Site, Warsaw, 04-730/20, Poland|Research Site, Belgrade, 11000, Serbia|Research Site, Belgrade, 11070, Serbia|Resaerch Site, Kragujevac, 34000, Serbia|Research Site, Barcelona, 8036, Spain|Resaeach Site, Cordoba, 14011, Spain|Research Site, Madrid, 28850, Spain|Resaerch Site, Sevilla, 41009, Spain|Research Site, Göteborg, 41345, Sweden|Research Site, Stockholm, 17176, Sweden|Research Site, Ankara, 06100, Turkey|Research Site, Antalya, 07070, Turkey|Research Site, London, Greater London, SE1 7EH, United Kingdom|Research Site, London, Greater London, WC1N 3JH, United Kingdom|Research Site, Birmingham, West Midlands, B4 6NH, United Kingdom|Research Site, London, WC1N 3BG, United Kingdom"
NCT01142453,An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) Patients,https://beta.clinicaltrials.gov/study/NCT01142453,COMPLETED,Relapsing-Remitting Multiple Sclerosis,DRUG: Interferon beta 1a,"Merck KGaA, Darmstadt, Germany",Gesellschaft für Therapieforschung mbH,ALL,"CHILD, ADULT, OLDER_ADULT",,231,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2005-05,2008-06,2008-06,
NCT04972929,Effects of Chiropractic Care on Cytokine Levels in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04972929,RECRUITING,"Multiple Sclerosis, Relapsing-Remitting",OTHER: Spinal Manipulation|OTHER: Sham Spinal Manipulation,University of Alabama at Birmingham,,ALL,ADULT,NA,24,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-12-15,2023-12-30,2023-12-30,"University of Alabama at Birmingham, Birmingham, Alabama, 35294, United States"
NCT05073731,Telerehabilitation-based Upper Extremity Training in People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05073731,RECRUITING,Multiple Sclerosis,OTHER: Telerehabilitation-based Upper Extremity Training,Dokuz Eylul University,,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-12-15,2022-09-30,2022-10-28,"School of Physical Therapy and Rehabilitation, Dokuz Eylül University, Izmir, Turkey"
NCT05758831,RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.,https://beta.clinicaltrials.gov/study/NCT05758831,NOT_YET_RECRUITING,Multiple Sclerosis|Relapsing-remitting Multiple Sclerosis,DRUG: Perfusion of treatment Rituximab|DRUG: Perfusion of treatment Ocrelizumab,Rennes University Hospital,,ALL,ADULT,PHASE3,386,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-02-28,2030-03-31,2030-05-01,"Hospices Civils de Lyon Hôpital Neurologique Pierre Wertheimer, Lyon, Bron, 69677, France|CHRU de Brest - Hôpital la Cavale Blanche, Brest, 29609, France|Centre Hospitalier Universitaire de Caen, Caen, 14033, France|Centre Hospitalier de Pontoise - GHT NOVO, Cergy-Pontoise, 95300, France|Hôpital Gabriel Montpieds, Clermont-Ferrand, 63003, France|Centre hospitalier de Gonnesse, Gonesse, 95503, France|Groupe Hospitalier de l'Institut Catholique de Lille, Lille, 59160, France|Centre Hospitalier Universitaire de Limoges, Limoges, 87042, France|AP-HM - Hôpital la Timone, Marseille, 13385, France|CHRU de Montpellier - Hôpital Gui de Chauliac, Montpellier, 34295, France|Centre Hospitalier Régional de Nancy, Nancy, 54035, France|CHU de Nantes -Hôpital Nord Laennec, Nantes, 44800, France|CHU de Nice - Hôpital Pasteur 2, Nice, 06002, France|CHU de Nîmes - Hôpital Caremeau, Nîmes, 30029, France|AP-HP Höpital la Pitié-Salpétrière, Paris, 75010, France|Groupe Hospitalier Universitaire Henri Mondor, Paris, 94000, France|Hôpital Saint-Germain, Poissy, 78303, France|Centre Hospitalier de Cornouaille, Quimper, 29107, France|Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, Rennes, 35000, France|CHU de Rouen - Hôpital Charles Nicolle, Rouen, 76038, France|CHRU de Strasbourg - Hôpital Hautpierre, Strasbourg, 67200, France|Hôpital Foch, Suresnes, 92150, France|CHU de Toulouse - Bâtiment Pierre Paul Riquet, Toulouse, 31059, France"
NCT00429442,Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00429442,WITHDRAWN,Relapsing Remitting Multiple Sclerosis,DRUG: Simvastatin|DRUG: placebo,Anna Tsakiri,Sanofi,ALL,ADULT,PHASE3,0,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2008-03,,2011-03,"Department of Neurology, Glostrup University Hospital, Glostrup, 2600, Denmark"
NCT00883142,Functional and Physiological Responses to Lokomat Therapy (Pilot Study),https://beta.clinicaltrials.gov/study/NCT00883142,COMPLETED,Spinal Cord Injuries|Multiple Sclerosis|Stroke,,US Department of Veterans Affairs,,ALL,"ADULT, OLDER_ADULT",,27,FED,OBSERVATIONAL,Observational Model: |Time Perspective: p,2006-10,2012-08,2013-03,"VA Medical Center, Bronx, Bronx, New York, 10468, United States"
NCT01929642,Rapalogues for Autism Phenotype in TSC: A Feasibility Study,https://beta.clinicaltrials.gov/study/NCT01929642,COMPLETED,Tuberous Sclerosis Complex|Self-injury|Autism,DRUG: Sirolimus|DRUG: Everolimus,"Hugo W. Moser Research Institute at Kennedy Krieger, Inc.",,ALL,"CHILD, ADULT",PHASE2,3,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-07,2016-07,2016-08,"Kennedy Krieger Institute, Baltimore, Maryland, 21205, United States"
NCT01627938,Study to Evaluate the Reduction of Cardiac Problems in Multiple Sclerosis Patients With Mitoxantrone and Dexrazoxane in Combination,https://beta.clinicaltrials.gov/study/NCT01627938,UNKNOWN,Multiple Sclerosis,DRUG: Dexrazoxane (DRZ) plus Mitoxantrone (MX)|DRUG: Placebo plus Mitoxantrone (MX),PD Dr. Andrew Chan,,ALL,ADULT,PHASE2,50,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-04,2015-04,2016-04,"Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, 44791, Germany"
NCT00845338,Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity,https://beta.clinicaltrials.gov/study/NCT00845338,TERMINATED,Multiple Sclerosis|Overactive Detrusor,DRUG: Darifenacin (BAY79-4998),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,7,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-02,2007-10,2007-10,"Emmendingen, Baden-Württemberg, 79312, Germany|Heidelberg, Baden-Württemberg, 69112, Germany|Lahr, Baden-Württemberg, 77933, Germany|Tübingen, Baden-Württemberg, 72076, Germany|Villingen-Schwenningen, Baden-Württemberg, 78054, Germany|Planegg, Bayern, 82152, Germany|Oberursel, Hessen, 61440, Germany|Herne, Nordrhein-Westfalen, 44627, Germany|Mönchengladbach, Nordrhein-Westfalen, 41063, Germany|Mülheim, Nordrhein-Westfalen, 45468, Germany|Mainz, Rheinland-Pfalz, 55131, Germany|Halle, Sachsen-Anhalt, 06112, Germany|Bad Berka, Thüringen, 99437, Germany|Berlin, 10115, Germany|Hamburg, 20246, Germany"
NCT05017038,The Role of Social and Territorial Inequalities in the Management and Prognosis of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05017038,RECRUITING,Multiple Sclerosis|Social and Territorial Inequalities,,"Central Hospital, Nancy, France",,ALL,"ADULT, OLDER_ADULT",,2000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-03-03,2023-03-03,2023-06-30,"Service de Neurologie et Maladies inflammatoires du Système nerveux central, Bordeaux, 33000, France|Service de Neurologie, Clermont-ferrand, 63000, France|Service de Neurologie, Nancy, 54000, France|Pôle Neurosciences, Rennes, 35000, France|CIC 1433 Épidémiologie CliniqueInserm, CHRU, Université de Lorraine, Vandœuvre-les-Nancy, 54511, France"
NCT05084638,"Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.",https://beta.clinicaltrials.gov/study/NCT05084638,RECRUITING,Relapse Remitting Multiple Sclerosis,DRUG: Ofatumumab,Novartis Pharmaceuticals,,ALL,ADULT,PHASE4,168,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-01-25,2025-02-21,2026-06-22,"Novartis Investigative Site, Chandler, Arizona, 85226, United States|Novartis Investigative Site, Phoenix, Arizona, 85032, United States|Novartis Investigative Site, Altamonte Springs, Florida, 32714, United States|Novartis Investigative Site, Maitland, Florida, 32751, United States|Novartis Investigative Site, Orlando, Florida, 32806, United States|Novartis Investigative Site, Orlando, Florida, 32825, United States|Novartis Investigative Site, Tallahassee, Florida, 32308, United States|Novartis Investigative Site, Alexandria, Louisiana, 71301, United States|Novartis Investigative Site, Detroit, Michigan, 48202, United States|Novartis Investigative Site, North Massapequa, New York, 11758, United States|Novartis Investigative Site, Dayton, Ohio, 45408, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, 73104, United States|Novartis Investigative Site, Knoxville, Tennessee, 37922, United States|Novartis Investigative Site, Dallas, Texas, 75390-9034, United States|Novartis Investigative Site, Houston, Texas, 77030, United States|Novartis Investigative Site, San Antonio, Texas, 78258, United States|Novartis Investigative Site, Guaynabo, 00968, Puerto Rico"
NCT04966338,Efficacy and Safety of Xacrel® (Ocrelizumab) in Participants With Relapsing Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04966338,COMPLETED,Multiple Sclerosis|Relapsing-Remitting,"BIOLOGICAL: Ocrelizumab (CinnaGen, Iran)|BIOLOGICAL: Ocrelizumab (Roche, Switzerland)",Cinnagen,,ALL,ADULT,PHASE3,170,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-08-19,2020-11-09,2021-10-01,"Qaem International Hospital, Rasht, Guilan, Iran, Islamic Republic of|Qaem Hospital, Mashhad, Khorasan Razavi, Iran, Islamic Republic of|Golestan Hospital, Ahvaz, Khozestan, Iran, Islamic Republic of|Bouali Hospital, MS Clinic, Sari, Mazandaran, Iran, Islamic Republic of|Sina Hospital, Hamadān, Iran, Islamic Republic of|Ayatollah Kashani Hospital, MS Clinic, Isfahan, Iran, Islamic Republic of|Imam Reza Hospital, Kermanshah, Iran, Islamic Republic of|Shafa Hospital, Kerman, Iran, Islamic Republic of|Dr. Nikseresht's office, Shiraz, Iran, Islamic Republic of|Namazi Hospital, Shiraz, Iran, Islamic Republic of|Imam Reza Hospital Department of Neurology, Tabriz, Iran, Islamic Republic of|Amir Alam Hospital, Tehran, Iran, Islamic Republic of|Imam Hossein Hospital, MS Clinic, Tehran, Iran, Islamic Republic of|Imam Khomeini Hospital, Tehran, Iran, Islamic Republic of|Sina Hospital, MS Research Center, Tehran, Iran, Islamic Republic of"
NCT01097538,Study of Alternative Exercise Therapies for Progressive Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT01097538,COMPLETED,Multiple Sclerosis,OTHER: Body-weight supported treadmill training|OTHER: Total body recumbent stepper training,"Hicks, Audrey, Ph.D.",,ALL,ADULT,NA,10,INDIV,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: ",2010-04,2011-06,2011-08,"Centre for Health Promotion and Rehabilitation, McMaster University, Hamilton, Ontario, L8S 4K1, Canada"
NCT02472938,Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02472938,WITHDRAWN,Relapsing Remitting Multiple Sclerosis,DRUG: dimethyl fumarate|OTHER: Placebo,Biogen,GB Pharma Services & Consulting s.r.l.,ALL,ADULT,PHASE4,0,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2015-07,2019-07,2020-07,
NCT00988988,The Effects of Ethyl-Alpha-Guanido-Methyl Ethanoate on Skin Reactions From Glatiramer Acetate Injections,https://beta.clinicaltrials.gov/study/NCT00988988,WITHDRAWN,Multiple Sclerosis,DRUG: AGEE cream|DRUG: 1% Steroid Cream|DRUG: topical placebo cream with no active ingredients,University of Nebraska,"Teva Branded Pharmaceutical Products R&D, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE4,0,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2010-02,2010-11,2010-12,"University of Nebraska Medical Center, Omaha, Nebraska, 68198-5330, United States"
NCT02034188,Feasibility Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02034188,COMPLETED,Multiple Sclerosis,BIOLOGICAL: Umbilical cord mesenchymal stem cells,Translational Biosciences,,ALL,ADULT,PHASE1|PHASE2,20,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-01,2016-03,2016-03,"Stem Cell Institute, Panama City, Panama"
NCT02428231,Tecfidera Slow-Titration Study,https://beta.clinicaltrials.gov/study/NCT02428231,TERMINATED,Multiple Sclerosis,DRUG: dimethyl fumarate,Biogen,,ALL,"ADULT, OLDER_ADULT",PHASE3,62,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2015-04,2015-12,2016-01,"Research Site, Gilbert, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Long Beach, California, United States|Research Site, Miami, Florida, United States|Research Site, Avon, Indiana, United States|Research Site, Franklin, Indiana, United States|Research Site, Overland Park, Kansas, United States|Research Site, Lewiston, Maine, United States|Research Site, Asheville, North Carolina, United States|Research Site, Cary, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Dallas, Texas, United States|Research Site, Wenatchee, Washington, United States|Research Site, Leuven, Belgium|Research Site, Wilrijk, Belgium|Research Site, Prague, Czech Republic|Research Site, Merano, Bolzano, Italy|Research Site, Montichiari, Italy"
NCT03148938,Digitalization of Neurofunctional Tests Via a Mobile Application DAMS for Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT03148938,COMPLETED,Multiple Sclerosis,OTHER: Digital Assessment on mobile,Ad scientiam,,ALL,ADULT,NA,222,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: OTHER,2017-10-02,2018-07-30,2018-08-29,"Hôpital le Bocage, Dijon, France|Hôpital Saint-Phllibert, Lille, France|Hôpital La Timone Adulte, Marseille, France|Hôpital Gui de Chauliac, Montpellier, France|Hôpital Pasteur, Nice, France|Hôpital Pitié Salpêtrière, Paris, France|Hôpital Maison Blanche, Reims, France|Hôpital Saint Hélier, Rennes, France|Hôpital Charles Nicolle, Rouen, France|Hôpital Hautepierre, Strasbourg, France"
NCT00228228,TCV -01-002: T-Cell Vaccination in the Treatment of Probable Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00228228,UNKNOWN,Multiple Sclerosis,BIOLOGICAL: T cell vaccination,Sheba Medical Center,,ALL,"CHILD, ADULT",PHASE3,80,OTHER_GOV,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,2002-05,,2006-12,"Sheba Medical Center, Ramat Gan, 52621, Israel"
NCT04228328,Validity and Reliability of the 6-minute Walk Test Over a Distance of 6 Metres in People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04228328,COMPLETED,Multiple Sclerosis,DIAGNOSTIC_TEST: The 6-minutes Walk Test,Haute Ecole de Santé Vaud,University of Applied Sciences of Western Switzerland,ALL,"ADULT, OLDER_ADULT",,21,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-03-03,2020-11-05,2020-11-05,"Haute Ecole de Santé Vaud, Lausanne, VD, 1011, Switzerland"
NCT04891341,Investigation of the Effects of Technology Supported Different Physiotherapy Approaches on Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04891341,COMPLETED,Multiple Sclerosis,OTHER: Technology Supported Task-Oriented Circuit Training|OTHER: Home-based Telerehabilitation,Hacettepe University,,ALL,ADULT,NA,34,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-02-16,2022-07-16,2022-07-17,"Mert Doğan, Ankara, Altındağ, 06100, Turkey"
NCT04125628,Exercise on Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT04125628,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Exercise with cooling|BEHAVIORAL: Exercise without cooling,Petros Dinas,,ALL,"CHILD, ADULT, OLDER_ADULT",NA,10,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: PREVENTION",2019-06-01,2019-06-25,2019-06-25,"FAME Lab, Department of Exercise Science, University of Thessaly, Tríkala, Thessaly, 42100, Greece"
NCT05134441,"Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT05134441,RECRUITING,Multiple Sclerosis,DRUG: IMU-838 tablets|DRUG: Placebo matching IMU-838 tablets,Immunic AG,,ALL,ADULT,PHASE3,1050,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-11-18,2024-09,2032-09,"Xenoscience, Inc., 21st Century Neurology, Phoenix, Arizona, 85004, United States|Bradenton Research Center, Bradenton, Florida, 34205, United States|Reliant Medical Research, LLC, Miami, Florida, 33165, United States|Collier Neurologic Specialists, Naples, Florida, 34105, United States|Neurology Associates of Ormond Beach, Ormond Beach, Florida, 32174, United States|Consultants in Neurology, Ltd, Northbrook, Illinois, 60062, United States|Klinika Mjekesore Nuova, Neurology Clinic, Tirana, 1005, Albania|MHAT Puls AD, Blagoevgrad, 2700, Bulgaria|MHAT ""Heart and Brain"", EAD, Burgas, 8000, Bulgaria|MC Exacta Medica OOD, Pleven, 5800, Bulgaria|MHAT Avis Medica, Pleven, 5800, Bulgaria|UMHAT Dr.Georgi Stranski EAD, Pleven, 5800, Bulgaria|Heart and Brain University Hospital, Pleven, Bulgaria|MC Vita 1, Pleven, Bulgaria|UMHAT Sveti Georgi, Plovdiv, 4002, Bulgaria|CCB Medical Institute Ministry of Interior, Sofia, 1000, Bulgaria|Diagnostic and Consultative Center Neoclinic, Sofia, 1000, Bulgaria|UMHAT ""Sveti Ivan Rilski"" EAD, Sofia, 1000, Bulgaria|MHATNP ""Sveti Naum"", EAD, Sofia, 1113, Bulgaria|MHATNPsy Sveti Naum EAD, Sofia, 1113, Bulgaria|UMHAT ""Alexandrovska"" EAD, Sofia, 1431, Bulgaria|UMHAT ""Alexandrovska"", Sofia, 1431, Bulgaria|Military Medical Academy MHAT, Sofia, 1606, Bulgaria|MHAT ""Sveta Sofia"" EOOD, Sofia, 1618, Bulgaria|Military Medical Academy, Sofia, Bulgaria|UMHATEM N.Pirogov, Sofia, Bulgaria|1st Uni Clinic of Tbilisi LEPL, Tbilisi, 0141, Georgia|Eristavi Experimental Center, Tbilisi, Georgia|J.S.C. Curatio Clinic, Tbilisi, Georgia|Katsiashvili Emergency Center, Tbilisi, Georgia|Khechinashvili University Hospital, Tbilisi, Georgia|LTD Aversi Clinic, Tbilisi, Georgia|MediClub Georgia LLC, Tbilisi, Georgia|Pineo Medical Ecosystem LTD, Tbilisi, Georgia|Sarajishvili Neurology Institute, Tbilisi, Georgia|Kanoria Hospital & Research Centre, Gandhinagar, 382428, India|Mallikatte, Kadri, Mangalore, 575002, India|Sir Ganga Ram Hospital, New Delhi, 110060, India|Ruby Hospital, Pune, 411001, India|Indira Gandhi Medical College & Hospital, Shimla, 171001, India|Institute of Medical Sciences Banaras Hindu University,IMS BHU Varanasi, Varanasi, 221005, India|Lietuvos Sveikatos Mokslu Universitetas - Kauno Klinikos, Kaunas, 50161, Lithuania|Klaipedos Universitetine Ligonine - Klaipedos Issetines Sklerozes Centra, Klaipėda, 92288, Lithuania|Neurociencias Estudios Clínicos S.C, Culiacán, 80020, Mexico|Instituto Jalisciense de Metabolismo, SC, Guadalajara, 44670, Mexico|Cliditer S.A de C.V, Mexico City, 06700, Mexico|Unidad de Investigación en Salud de Chihuahua S.C., Mexico City, 14050, Mexico|Centro de Morelia, Morelia, 58000, Mexico|Sociedad de Metabolismo y Corazon, S.C., Veracruz, 91900, Mexico|Instititute of Emergency Medicine, Chisinau, Moldova, Republic of|Medico-Sanitary Public Institution, Institute of Neurology and Neurosurgery ""Diomid Gherman"", Chisinau, Moldova, Republic of|The Diomid Gherman Institute of Neurology and Neurosurgery, Chisinau, Moldova, Republic of|Hospital ""8 mi Septemvri"", Skopje, North Macedonia|University Clinic of Neurology, Skopje, North Macedonia|Regional Clinical Hospital, Ivano-Frankivs'k, 76008, Ukraine|Neuro Global, LLC, Ivano-Frankivs'k, 76493, Ukraine|""Medbud"", Kyiv, 3037, Ukraine|SMART medical center, Kyiv, 4212, Ukraine|Ternopil Psycho-Neuro Hospital, Ternopil', 46027, Ukraine"
NCT02890641,Genetic and Electrophysiologic Study in Focal Drug-resistant Epilepsies,https://beta.clinicaltrials.gov/study/NCT02890641,RECRUITING,Refractory Focal Epilepsy|Focal Cortical Dysplasia|Hemimegalencephaly|Tuberous Sclerosis|Mild Malformation of Cortical Development With Oligodendroglial Hyperplasia in Epilepsy (MOGHE),"GENETIC: Sampling of blood, frozen resected tissues, and cerebrospinal fluid (CSF)",Fondation Ophtalmologique Adolphe de Rothschild,,ALL,"CHILD, ADULT",,450,NETWORK,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-12-12,2030-12,2030-12,"Fondation Ophtalmologique Adolphe de Rothschld, Paris, 75019, France"
NCT05366036,A Study for Tecfidera (Dimethyl Fumarate) Capsules in Korean Participants With Relapsing-Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05366036,COMPLETED,"Multiple Sclerosis, Relapsing-remitting",OTHER: No Intervention,Eisai Korea Inc.,,ALL,ADULT,,172,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-06-14,2022-01-14,2022-01-14,"Site #20, Cheonan, Chungcheongnam-do, Korea, Republic of|Site #15, Ansan, Gyeonggi-do, Korea, Republic of|Site #08, Bucheon, Gyeonggi-do, Korea, Republic of|Site #09, Goyang, Gyeonggi-do, Korea, Republic of|Site #14, Goyang, Gyeonggi-do, Korea, Republic of|Site #23, Changwon, Gyeongsangnam-do, Korea, Republic of|Site #13, Jinju, Gyeongsangnam-do, Korea, Republic of|Site #02, Busan, Korea, Republic of|Site #16, Busan, Korea, Republic of|Site #01, Daegu, Korea, Republic of|Site #17, Daegu, Korea, Republic of|Site #07, Daejeon, Korea, Republic of|Site #03, Kwangju, Korea, Republic of|Site #04, Seoul, Korea, Republic of|Site #06, Seoul, Korea, Republic of|Site #11, Seoul, Korea, Republic of|Site #12, Seoul, Korea, Republic of|Site #18, Seoul, Korea, Republic of|Site #19, Seoul, Korea, Republic of|Site #21, Seoul, Korea, Republic of"
NCT01695434,A Longitudinal Study of Effect of Copaxone in RRMS Over 24 Months,https://beta.clinicaltrials.gov/study/NCT01695434,COMPLETED,Multiple Sclerosis,OTHER: MRI,University at Buffalo,,ALL,"ADULT, OLDER_ADULT",,60,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-06,2013-02,2013-02,"Buffalo Neuroimaging Analysis Center, Buffalo, New York, 14203, United States"
NCT01599234,A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01599234,COMPLETED,Multiple Sclerosis,DRUG: Sativex|DRUG: Placebo,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,337,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2005-03,2005-12,2005-12,"The Royal Berkshire and Battle Hospitals NHS Trust, Reading, RG1 5AN, United Kingdom"
NCT00789828,Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1),https://beta.clinicaltrials.gov/study/NCT00789828,COMPLETED,Tuberous Sclerosis|Subependymal Giant Cell Astrocytoma,DRUG: Everolimus|DRUG: Placebo,Novartis Pharmaceuticals,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,117,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-08,2011-03,2014-10,"University of Alabama at Birmingham, Birmingham, Alabama, 35294, United States|Barrow Tuberous Sclerosis Center, Phoenix, Arizona, 85013, United States|University of California at Los Angeles, Los Angeles, California, 90048, United States|Children's Hospital Oakland Hematology/Oncology Dept, Oakland, California, 94609-1809, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, 30342, United States|University of CHicago Comer Children's Hospital, Chicago, Illinois, 60637-1470, United States|Massachusetts General Hospital Mass General, Boston, Massachusetts, 02114, United States|Children's Hospital Boston SC-1, Boston, Massachusetts, 02115, United States|Minnesota Epilepsy Group - PA, St. Paul, Minnesota, 55102-2383, United States|Cincinnati Children's Hospital Medical Center Cincinnati Children's Hosp, Cincinnati, Ohio, 45229-3039, United States|Texas Scottish Rite Hospital for Children, Dallas, Texas, 75219, United States|Children's Regional Outpatients Center SC, Fairfax, Virginia, 22031, United States|Novartis Investigative Site, Randwick, New South Wales, 2130, Australia|Novartis Investigative Site, Brussel, 1090, Belgium|Novartis Investigative Site, Toronto, Ontario, M5G 1X8, Canada|Novartis Investigative Site, Quebec, H3T IC5, Canada|Novartis Investigative Site, Berlin, 13353, Germany|Novartis Investigative Site, Heidelberg, 69120, Germany|Novartis Investigative Site, Genova, GE, 16147, Italy|Novartis Investigative Site, Roma, 00137, Italy|Novartis Investigative Site, Utrecht, 3584CX, Netherlands|Novartis Investigative Site, Warszawa, 04-730, Poland|Novartis Investigative Site, Moscow, 127412, Russian Federation|Novartis Investigative Site, Bristol, BS1 3NU, United Kingdom"
NCT01705236,A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®,https://beta.clinicaltrials.gov/study/NCT01705236,COMPLETED,Relapsing Remitting Multiple Sclerosis RRMS,DRUG: Fingolimod,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE4,87,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2012-08-20,2019-02-18,2019-02-18,"Novartis Investigative Site, Bochum, 44791, Germany|Novartis Investigative Site, Bonn, 53105, Germany|Novartis Investigative Site, Dresden, 01307, Germany|Novartis Investigative Site, Duesseldorf, 40225, Germany|Novartis Investigative Site, Hannover, 30625, Germany|Novartis Investigative Site, Heidelberg, 69120, Germany|Novartis Investigative Site, Leipzig, 04103, Germany|Novartis Investigative Site, Rostock, 18057, Germany|Novartis Investigative Site, Ulm, 89081, Germany|Novartis Investigative Site, Zuerich, 8091, Switzerland"
NCT02628834,Acute Effect of Fascial Mobilization on Gait in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02628834,UNKNOWN,Multiple Sclerosis,OTHER: Fascial mobilization|OTHER: Stretching Exercise,Hacettepe University,,ALL,ADULT,NA,20,OTHER,INTERVENTIONAL,"Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2015-12,2016-11,2016-12,
NCT05219201,Effectiveness of Cryotherapy on the Fatigue of Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05219201,RECRUITING,Multiple Sclerosis,DEVICE: partial-body cryotherapy chamber session,Fondation Ildys,Lille Catholic University,ALL,"ADULT, OLDER_ADULT",NA,80,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-09-12,2023-03,2027-06,"Centre de Perharidy, Roscoff, France"
NCT04906928,Evaluation of New MRI Sequences Including 3D-FGAPSIR for the Optimization of Inflammatory Spinal Cord Lesions Research,https://beta.clinicaltrials.gov/study/NCT04906928,NOT_YET_RECRUITING,Spinal Cord Injuries,DEVICE: MRI,Fondation Ophtalmologique Adolphe de Rothschild,,ALL,"ADULT, OLDER_ADULT",,200,NETWORK,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-06-01,2024-06,2024-08,"Fondation Ophtalmologique Adolphe de Rothschild (FOR), Paris, 75019, France"
NCT01143441,Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT01143441,COMPLETED,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting",BIOLOGICAL: DAC-HYP,National Institute of Neurological Disorders and Stroke (NINDS),,ALL,ADULT,PHASE1,48,NIH,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2010-05-13,2017-08-11,2017-08-11,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States"
NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",https://beta.clinicaltrials.gov/study/NCT04544436,RECRUITING,Multiple Sclerosis,DRUG: Ocrelizumab|DRUG: Ocrelizumab|DRUG: Antihistamine|DRUG: Methylprednisolone,Hoffmann-La Roche,,ALL,ADULT,PHASE3,865,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-11-26,2025-07-18,2029-03-30,"North Central Neurology Associates, Cullman, Alabama, 35058, United States|Alabama Neurology Associates, Homewood, Alabama, 35209, United States|21st Century Neurology, Phoenix, Arizona, 85004, United States|North County Neurology Associates, Carlsbad, California, 92011, United States|University of California Davis Medical Center, Sacramento, California, 95817, United States|Stanford University Medical Center; Stanford Neuroscience Health Center, Stanford, California, 94305, United States|Collaborative Neuroscience Network Inc., Torrance, California, 90502, United States|Mountain Neurological Research Center; Roaring Fork Neurologt, P.C., Basalt, Colorado, 81621, United States|Colorado Neurological Institute, Englewood, Colorado, 80113, United States|Advanced Neurology of Colorado, LLC, Fort Collins, Colorado, 80528, United States|SFM Clinical Research, LLC, Boca Raton, Florida, 33487, United States|MS and Neuromuscular Center of Excellence, Clearwater, Florida, 33761, United States|Neurology Associates, PA; Research Department, Maitland, Florida, 32751, United States|University of South Florida, Tampa, Florida, 33612, United States|Shepherd Center Inc., Atlanta, Georgia, 30309, United States|Consultants in Neurology Ltd, Northbrook, Illinois, 60062, United States|American Health Network Institute, LLC, Avon, Indiana, 46123, United States|University of Kansas Medical Center, Kansas City, Kansas, 66160, United States|The NeuroMedical Clinic of Central Louisiana, Alexandria, Louisiana, 71301, United States|Maine Medical Center, Scarborough, Maine, 04074, United States|Massachusetts General Hospital., Boston, Massachusetts, 02114, United States|Dragonfly Research, LLC, Wellesley, Massachusetts, 02481, United States|Wayne State University; Department of Neurology, Detroit, Michigan, 48201, United States|Henry Ford Health System, Detroit, Michigan, 48202, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|Cleveland Clinic Lou Ruvo; Center for Brain Research, Las Vegas, Nevada, 89106, United States|Dent Neurological Institute, Amherst, New York, 14226, United States|Stony Brook University Medical Center, Stony Brook, New York, 11794, United States|UC Health Neurology, Dayton, Ohio, 45417, United States|Oklahoma Medical Research Foundation; MS Center of Excellence, Oklahoma City, Oklahoma, 73104, United States|Abington Neurological Associates, Abington, Pennsylvania, 19001, United States|Tri-State Mountain Neurology, Johnson City, Tennessee, 37604, United States|Hope Neurology, Knoxville, Tennessee, 37922, United States|Bhupesh Dihenia M.D. P.A., Lubbock, Texas, 79410, United States|Central Texas Neurology Consultants, Round Rock, Texas, 78681, United States|Neurology Center of San Antonio, San Antonio, Texas, 78258, United States|Evergreen MS Center, Kirkland, Washington, 98034, United States|Centro de Especialidades Neurológicas y Rehabilitación - CENyR, Buenos Aires, C1424, Argentina|CEMIC, Buenos Aires, C1431FWO, Argentina|Centro de Investigaciones Médicas Tucuman; REUMATHOLOGY, San Miguel, T4000AXL, Argentina|Concord Repatriation General Hospital, Concord, New South Wales, 2139, Australia|Specialists on College; Neurology, Kent Town, South Australia, 5067, Australia|Austin Hospital; Department of Neurology, Heidelberg, Victoria, 3084, Australia|Hospital Erasme, Bruxelles, 1070, Belgium|CHU Tivoli, La Louvière, 7100, Belgium|Revalidatie en MS Centrum, Overpelt, 3900, Belgium|Instituto de Neurologia de Curitiba, Curitiba, PR, 81210-310, Brazil|IMV Pesquisa Neurológica, Porto Alegre, RS, 90110-000, Brazil|Clinica Neurologica; Neurocirurgica de Joinville, Joinville, SC, 89202-190, Brazil|CPQuali Pesquisa Clinica Ltda, Sao Paulo, SP, 01228-000, Brazil|Hospital das Clinicas - FMUSP, Sao Paulo, SP, 05403-900, Brazil|Foothills Medical Centre; Centre Dept of Medical Clinical Neuroscience, Calgary, Alberta, T2N 2T9, Canada|University of Alberta Hospital, Edmonton, Alberta, T6G 1Z1, Canada|Fraser Health Authority - Fraser Health Multiple Sclerosis, Burnaby, British Columbia, V5G 2X6, Canada|University of British Columbia, Vancouver, British Columbia, V6T 1Z4, Canada|The Ottawa Hospital - General Campus; Department of Neurology - Multiple Sclerosis, Ottawa, Ontario, K1H 8L6, Canada|St. Michael'S Hospital, Toronto, Ontario, M5B 1W8, Canada|Recherche Sepmus Inc., Greenfield Park, Quebec, J4V 2J2, Canada|Chum Campus Notre Dame, Montreal, Quebec, H2X 0A9, Canada|Centre Hospitalier Affilie Universitaire de Quebec - Hopital de L'Enfant Jesus, Quebec City, Quebec, G1J 1Z4, Canada|Hotel-Dieu de Levis, Quebec, G1W 4R4, Canada|Fakultni nemocnice u sv. Anny; Neurologicka klinika, Brno, 656 91, Czechia|Charles University, Medical faculty, Hradec Kralove ;Department of Neurology, Hradec Králové, 500 05, Czechia|Nemocnice Jihlava; NEU-Neurologicke oddeleni, Jihlava, 58633, Czechia|Krajska Nemocnice Pardubice Neurologicka Klinika, Pardubice, 532 03, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, 12808, Czechia|Fakultni nemocnice Motol; Neurologicka klinika, Praha, 150 06, Czechia|Nemocnice Teplice; Neurologicke Oddeleni - Ms Centrum, Teplice, 415 29, Czechia|Rigshospitalet Glostrup; Neurologisk Klinik, Glostrup, 2600, Denmark|CHU de Besancon Hopital Jean Minjoz; Service de Neurologie, Besançon, 25030, France|Groupe Hospitalier Pellegrin; Service de Neurologie - 3ème étage, Bordeaux, 33076, France|CHU Brest Hopital La Cavale Blanche; Neurologie, Brest, 29609, France|Hopital Cote De Nacre; Unite Neurologie Generale, Caen, 14033, France|CHU Hopital Gabriel Montpied; Service de Neurologie, Clermont Ferrand, 63003, France|CH St Vincent de Paul, Lille, 59000, France|Hôpital Charles Nicolle; Service de Neurologie, Rouen, 76031, France|Charite - Universitätsmedizin Berlin, Berlin, 12203, Germany|St. Josef-Hospital, Klinik für Neurologie, Bochum, 44791, Germany|Gesundheitszentrum St. Johannes Hospital; Neurolog. Gemeinschaftspraxis Dres. Schmidt, Neudecker etc, Bonn, 53111, Germany|Studienzentrum für Neurologie und Psychiatrie, Böblingen, 71034, Germany|Universitätsklinikum ""Carl Gustav Carus"", Zentrum für Klinische Neurowissenschaften, Dresden, 01307, Germany|Gemeinschaftspraxis für Neurologie; Dr. Katrin Schulte, Dr. Nils Richter, Dr. Margarete Capito, Düsseldorf, 40211, Germany|Krankenhaus Martha-Maria Hallo-Dölau, Klinik für Neurologie, Halle (Saale), 06120, Germany|Medizinische Hochschule Hannover, Klinik für Neurologie, Hannover, 30625, Germany|Universitätsklinikum Jena, Klinik für Neurologie, Jena, 07747, Germany|Neurologische Gemeinschaftspraxis Kassel und Vellmar, Ch. Lassek, Dres. Ammerbach, Fetzer, M. Fische, Kassel, 34121, Germany|Universitätsklinikum Schleswig-Holstein; Klinik für Neurologie, Kiel, 24105, Germany|Universität Leipzig; Innere Medizin, Neurologie, Dermatologie, Leipzig, 04103, Germany|PANAKEIA - Arzneimittelforschung Leipzig GmbH, Leipzig, 04275, Germany|Universitaetsklinikum Marburg; Klinik fuer Neurologie, Marburg, 35043, Germany|Krankenhaus der Barmherzigen Brüder Trier; Neurologie, Neurophysiol. neurolog.Reha/Schlaganfalleinh, Trier, 54292, Germany|Universitätsklinikum Tübingen, Zentrum für Neurologie, Tübingen, 72076, Germany|Universitätsklinikum Ulm; Klinik für Neurologie, Ulm, 89081, Germany|Neuropraxis München Süd, Unterhaching, 82008, Germany|Deutsche Klinik für Diagnostik; DKD Helios Klinik Wiesbaden, Abt. Neurologie, Wiesbaden, 65191, Germany|401 Military Hospital of Athens; Neurology Department, Athens, 115 25, Greece|University General Hospital of Ioannina; Neurology Clinic, Ioannina, 455 00, Greece|University General Hospital of Larisa; Neurology Clinic, Larisa, 411 10, Greece|AHEPA Univ. General Hospital of Thessaloniki; B' Neurology Dept., Thessaloniki, 546 36, Greece|Bajcsy-Zsilinszky Hospital, Budapest, 1106, Hungary|S-Medicon Egeszsegugyi Szolgaltato Kft., Budapest, 1138, Hungary|UNO Medical Trials Kft., Budapest, 1152, Hungary|Somogy Megyei Kaposi Mor Oktato Korhaz; Department of Neurology, Kaposvár, 7400, Hungary|Barzilai Medical Center; Neurology Department, Ashkelon, 7830604, Israel|Rambam Medical Center; Neurology Unit, Haifa, 3109601, Israel|Hadassah University Hospital - Ein Kerem, Jerusalem, 9112001, Israel|The Chaim Sheba Medical Center; Multiple Sclerosis Center, Ramat-Gan, 5262100, Israel|Tel Aviv Sourasky Medical Center; Department of Neurology, Tel Aviv, 6423906, Israel|Universita? G. D'Annunzio; Dipartimento di Neuroscienze, Imaging e Scienze Cliniche, Chieti, Abruzzo, 66100, Italy|AOU Seconda Università degli Studi; Dip. Assistenziale Integrato Medicina Int-II Clinica Neurologica, Napoli, Campania, 80131, Italy|AOU Seconda Università degli Studi; Dip.Assistenziale Integrato Medicina Int-I Clinica Neurologica, Napoli, Campania, 80138, Italy|Policlinico Tor Vergata Dip. Neuroscienze-Clinica Neurologica-UOSD Sclerosi Multipla, Roma, Lazio, 00133, Italy|NCL Institute Neuroscience, Roma, Lazio, 00178, Italy|Policlinico Umberto I; Centro Sclerosi Multipla DAI Neuroscienze e Salute Mentale, Roma, Lazio, 00185, Italy|Fondazione IRCCS CA GRANDA Ospedale Maggiore Policlinico; Centro Dino Ferrari, Div. di Neurologia, Milano, Lombardia, 20122, Italy|Fond. Istituto Neurologico C.Besta; UO Neurologia IV - Neuroimmunologia Malattie Neuromuscolari, Milano, Lombardia, 20133, Italy|IRCCS Istituto Neurologico Neuromed; Centro per lo Studio e la Cura della Sclerosi Multipla, Pozzilli, Molise, 86077, Italy|A.O. Universitaria S. Luigi Gonzaga Di Orbassano, Orbassano, Piemonte, 10043, Italy|Azienda Ospedaliero-Universitaria Consorziale Pol. di Bari; Neuroscienze e Organi di Senso, Bari, Puglia, 70124, Italy|Grupo Médico Camino S.C., Ciudad de México, Mexico CITY (federal District), 03600, Mexico|Clinstile S.A de C.V., Mexico City, Mexico CITY (federal District), 06700, Mexico|Clinical Research Institute, Tlalnepantla de Baz, Mexico CITY (federal District), 54055, Mexico|Neurociencias Prisma, A.C, San Luis Potosí, SAN LUIS Potosi, 78216, Mexico|Neurociencias Estudios Clinicos S.C., Culiacán, Sinaloa, 80020, Mexico|Centro de Investigacion Medico Biologico y Terapia Avanzada, S.C., Guadalajara, 44130, Mexico|Zuyderland Medisch Centrum - Sittard Geleen, Sittard-Geleen, 6162 BG, Netherlands|Hospital Nacional Carlos Alberto Seguin Escobedo, Arequipa, 54, Peru|Hospital IV Alberto Sabogal Sologuren; Unidad de Investigacion, Bellavista, Callao 2, Peru|Clinica Internacional; Unidad De Investigacion, Lima, 15001, Peru|Hospital Nacional Dos de Mayo; Unidad de Investigacion de Neurologia, Lima, 15003, Peru|Instituto Nacional de Ciencias Neurológicas - Hospital Mogrovejo; Peru, Lima, Lima 01, Peru|Hospital Maria Auxiliadora, Lima, Lima 29, Peru|Clinica Sanchez Ferrer, Trujillo, 13009, Peru|Neurocentrum Bydgoszcz sp. z o.o, Bydgoszcz, 85-796, Poland|COPERNICUS Podmiot Leczniczy Sp. z o. o. Szpital im. M. Kopernika; Oddzia? Neurologiczny, Gdansk, 80-803, Poland|MA-LEK Clinical Sp. Z o.o., Katowice, 40-595, Poland|SPZOZ Uniwersytecki Szp. Klin. nr1 im.N.Barlickiego UM;Oddzial Kliniczny Neurologii, Lodz, 90-153, Poland|Centrum Neurologii Krzysztof Selmaj, Lodz, 90-324, Poland|Indywidualna Praktyka Lekarska Prof. Dr Hab. N. Med. Konrad Rejdak., Lublin, 20-016, Poland|Neurologiczny Niepubliczny ZOZ Centrum Leczenia SM Osrodek Bada? Klinicznych, Plewiska, 62-064, Poland|EMC Instytut Medyczny SA, Pozna?, 60-309, Poland|Nzoz Palomed, Rzeszów, 35-232, Poland|Osrodek Badan Klinicznych Euromedis, Szczecin, 70-111, Poland|Centrum Medyczne NeuroProtect, Warszawa, 01-684, Poland|Klinika Neurologii I Wydzialu Lekarskiego WUM w Warszawie, Warszawa, 02-097, Poland|Instytut Psychiatrii i Neurologii II Klinika Neurologiczna, Warszawa, 02-957, Poland|Wojskowy Instytut Medyczny - Pa?Stwowy Instytut Badawczy, Warszawa, 04-141, Poland|Hospital de Braga; Centro Clínico Académico (Piso 1, Ala E), Braga, 4710-243, Portugal|Centro Hospitalar de Lisboa Ocidental - Hospital Egas Moniz; Neurologia, Lisboa, 1349-019, Portugal|Hospital de Santa Maria; Servico de Neurologia, Lisboa, 1649-035, Portugal|Hospital Beatriz Angelo; Servico de Neurologia, Loures, 2674-514, Portugal|FSBHI Siberian Clinical Center of the Federal Medical and Biological Agency, Krasnoyarsk, Krasnojarsk, 660037, Russian Federation|National Center of Social Significant Disease, Sankt-peterburg, Leningrad, 197110, Russian Federation|Neiro Clinica LLC, Moscow, Moskovskaja Oblast, 117186, Russian Federation|Research Center of Neurology of RAMS, Moscow, Moskovskaja Oblast, 125367, Russian Federation|Federal center of brain research and neurotechnologies, Moskva, Moskovskaja Oblast, 117997, Russian Federation|City Clinical Hospital #24; Multipal Sclerosis department, Moskva, Moskovskaja Oblast, 127015, Russian Federation|N.P. Bechtereva Institute of the Human Brain, Sankt-petersburg, Sankt Petersburg, 197376, Russian Federation|City Hospital #40 of Kurortniy Administrative District, St. Petersburg, Sankt Petersburg, 197706, Russian Federation|Vertebronevrologiya LLC, Kazan, Tatarstan, 420047, Russian Federation|KSMU Interregional Clinical Diagnostic Centre, Kazan, Tatarstan, 420101, Russian Federation|Ulyanovsk Regional Clinical Hospital, Ulyanovsk, Uljanovsk, 432063, Russian Federation|State institution of health care - Territorial Clinical Hospital, Barnaul, 656024, Russian Federation|SHI Sverdlovsk Regional Clinical Hospital #1;Neurology, Ekaterinburg, 620102, Russian Federation|NSHI ?Central Clinical Hospital #2 of JSC ""Russian Railways"" n.a. N.A. Semashko?, Moscow, 129128, Russian Federation|Saratov State Medical University of RosZdrav; Neurology, Saratov, 410012, Russian Federation|Nebbiolo Center for Clinical Trials, Tomsk, 634009, Russian Federation|Complejo Hospitalario Universitario A Coruña (CHUAC); Servicio de Neurologia, Coruña, LA Coruña, 15006, Spain|Hospital Quiron de Madrid; Servicio de Neurologia, Pozuelo de Alarcon, Madrid, 28223, Spain|Hospital Alvaro Cunqueiro; Servicio de Neurologia, Vigo, Pontevedra, Spain|Hospital Universitari Vall d'Hebron; Servicio de Neumo-Inmunologia, Barcelona, 08035, Spain|Hospital Puerta del Mar; Sevicio de Neurologia, Cadiz, 11009, Spain|Hospital Regional Universitario de Malaga ? Hospital General; Servicio de Neurologia, Malaga, 29010, Spain|Kantonsspital Aarau AG Medizin Neurologie; Neurologie, Aarau, 5001, Switzerland|Universitätsspital Basel Medizin Neurologie; Neurologische Poliklinik, Basel, 4031, Switzerland|Inselspital Bern Medizin Neurologie; Neurologische Poliklinik, Bern, 3010, Switzerland|Ospedale Regionale di Lugano - Civico; Neurologia, Lugano, 6903, Switzerland|Gazi University Medical Faculty, Ankara, 06500, Turkey|Istanbul University Istanbul Medical Faculty; Neurology, Istanbul, 34093, Turkey|Istanbul Universitesi - Cerrahpasa Cerrahpasa Tip Fakultesi; Noroloji Anabilim Dali, Istanbul, 34098, Turkey|Sancaktepe Training and Research Hospital; Neurology, Istanbul, 34785, Turkey|Selcuk University Medical Faculty; Norology department, Istanbul, 42131, Turkey|Kocaeli University Hospital; Department of Neurology, Kocaeli, 41380, Turkey|Ege Üniversitesi Tip Fakültesi, Lzmir, 35100, Turkey|Mersin University Medical Faculty; Neurology, Mersin, 33079, Turkey|Ondokuz Mayis University School of Medicine; Neurology, Samsun, 55139, Turkey|Karadeniz Tecnical Uni. Med. Fac.; Neurology, Trabzon, 61080, Turkey|Medical Center Dopomoga Plus, Kyiv, Chernihiv Governorate, 02123, Ukraine|Municipal Non-profit Enterprise Zaporizhzhya Regional Hospital Zaporizhzhya Regional Council, Zaporizhzhia, Katerynoslav Governorate, 69600, Ukraine|Zaporizhia City Multispecialty Clinical Hospital #9, Zaporizhzhye, Katerynoslav Governorate, 69063, Ukraine|Municipal Nonprofit Enterprise of Kharkiv Regional Council Regional Clinical Hospital, Kharkiv, Kharkiv Governorate, 61058, Ukraine|Medical Center of Private Execution First Private Clinic, Kyiv, KIEV Governorate, 03037, Ukraine|Lvivska oblasna tsentralna likarnia, Lviv, KIEV Governorate, 79010, Ukraine|Miska Klinichna Likarnia ?16, Dnipropetrovsk, Tavria Okruha, 49100, Ukraine|Municipal Institution Cherkasy Regional Hospital of Cherkasy Regional Council, Cherkasy, 18009, Ukraine|Mun.Med.Proph.Inst.?Chernihiv Reg.Hosp.?; Neurology Department, Chernihiv, 14029, Ukraine|Bukovinsky SMU RMI Chernivtsi RCH, Chernivtsi, 58013, Ukraine|Regional Clinical Hospital; Neurology Department, Ivano-Frankivsk, 76008, Ukraine|St.In.Inst. of Neurol.Psych.and Narcol.of the AMSU; Dept. of Neuroinfection and Multiply Sclerosis, Kharkov, 61068, Ukraine|The Royal London Hospital, London, E1 1FR, United Kingdom|National Hospital for Neurology and Neurosurgery,; MRC Centre for Neuromuscular Diseases, London, WC1 3BG, United Kingdom|University of Nottingham, Nottingham, NG7 2UH, United Kingdom|Derriford Hospital, Plymouth, PL6 8BT, United Kingdom"
NCT03723434,Physiology of Interregional Connectivity in the Human Brain,https://beta.clinicaltrials.gov/study/NCT03723434,UNKNOWN,Healthy|Stroke|Traumatic Brain Injury|Multiple Sclerosis,DEVICE: Single-pulse transcranial magnetic stimulation (spTMS)|DEVICE: Paired associative stimulation (PAS)|DEVICE: Repetitive transcranial magnetic stimulation (rTMS),Shirley Ryan AbilityLab,Northwestern University,ALL,"ADULT, OLDER_ADULT",NA,76,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2017-05-31,2020-11,2020-11,"Shirley Ryan AbilityLab, Chicago, Illinois, 60611, United States"
NCT02047734,Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02047734,COMPLETED,Relapsing Multiple Sclerosis,DRUG: Ozanimod|DRUG: Ozanimod placebo|DRUG: Interferon beta-1a|DRUG: Interferon beta-1a placebo,Celgene,,ALL,ADULT,PHASE3,1320,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-12-03,2017-03-27,2017-04-13,"Receptos Study Site 115, Phoenix, Arizona, 85004, United States|Xenoscience, Phoenix, Arizona, 85004, United States|Receptos Study Site 118, Phoenix, Arizona, 85013, United States|Saint Josephs Hosptial and Medical Center, Phoenix, Arizona, 85013, United States|Territory Neurology and Research Institute, Tucson, Arizona, 85704, United States|Receptos Study Site 119, Tucson, Arizona, 85741, United States|Alta Bates Summit Medical Center, Berkeley, California, 94705, United States|Receptos Study Site 110, Berkeley, California, 94705, United States|Receptos Study Site 122, Long Beach, California, 90806, United States|Receptos Study Site 112, Sacramento, California, 95817, United States|University of California Davis Medical Center, Sacramento, California, 95817, United States|Multiple Sclerosis Center at UCSF, San Francisco, California, 94158, United States|Receptos Study Site 120, San Francisco, California, 94158, United States|Denver Neurological Research LLC, Denver, Colorado, 80210, United States|Receptos Study Site 127, Denver, Colorado, 80210, United States|Neurology Associates PA, Maitland, Florida, 32751, United States|Receptos Study Site 114, Maitland, Florida, 32751, United States|Receptos Study Site 124, Pompano Beach, Florida, 33060, United States|Neurostudies Inc, Port Charlotte, Florida, 33952, United States|Receptos Study Site 123, Port Charlotte, Florida, 33952, United States|Infinity Clinical Research LLC, Sunrise, Florida, 33351, United States|West Georgia Sleep Disorder Center and Neurology Associates, Douglasville, Georgia, 30134, United States|Consultants In Neurology, Northbrook, Illinois, 60062, United States|Receptos Study Site 113, Northbrook, Illinois, 60062, United States|Receptos Study Site 121, Saint Louis, Missouri, 63110, United States|Washington University, Saint Louis, Missouri, 63110, United States|Receptos Study Site 101, Charlotte, North Carolina, 28204, United States|The Neurological Institute PA, Charlotte, North Carolina, 28204, United States|Neurology and Neuroscience Associates Inc., Akron, Ohio, 44320, United States|Receptos Study Site 107, Akron, Ohio, 44320, United States|Receptos Study Site 104, Cleveland, Ohio, 44195, United States|Receptos Study Site 109, Philadelphia, Pennsylvania, 19104, United States|Receptos Study Site 102, Seattle, Washington, 98104, United States|The Polyclinic, Seattle, Washington, 98104, United States|Receptos Study Site 125, Tacoma, Washington, 98405, United States|Gomel Regional Clinical Hospital, Gomel, 246029, Belarus|Receptos Study Site 904, Gomel, 246029, Belarus|Grodno Clinical Regional Hospital, Grodno, 230017, Belarus|Receptos Study Site 907, Grodno, 230017, Belarus|Minsk Municipal Clinical Hospital 5, Minsk, 220026, Belarus|Receptos Study Site 902, Minsk, 220026, Belarus|Receptos Study Site 901, Minsk, 220114, Belarus|Republican Scientific and Practical Centre of Neurology and Neurosurgery, Minsk, 220114, Belarus|Minsk City Clinical Hospital 9, Minsk, 220116, Belarus|Receptos Study Site 903, Minsk, 220116, Belarus|Receptos Study Site 905, Vitebsk, 210023, Belarus|Vitebsk Regional Diagnostic Centre, Vitebsk, 210023, Belarus|Receptos Study Site 906, Vitebsk, 210037, Belarus|AZ Sint-Jan AV Brugge, Brugge, 8000, Belgium|Receptos Study Site 256, Brugge, 8000, Belgium|Receptos Study Site 255, Brussels, 1200, Belgium|Cliniques Universitaires St Luc, Bruxelles, 1200, Belgium|Centre Hospitalier Chretien Clinique Saint Joseph, Montegnee, 4420, Belgium|Receptos Study Site 252, Montegnée, 4420, Belgium|Clinique Saint Pierre, Ottignies, 1340, Belgium|Receptos Study Site 254, Ottignies, 1340, Belgium|Clinical Center University of Sarajevo, Sarajevo, 71000, Bosnia and Herzegovina|Receptos Study Site 911, Sarajevo, 71000, Bosnia and Herzegovina|Multiprofile Hospital for Active Treatment of Neurology and Psychiatry Sv Naum EAD, Sofia, 1113, Bulgaria|Receptos Study Site 453, Sofia, 1113, Bulgaria|Receptos Study Site 454, Sofia, 1113, Bulgaria|Receptos Study Site 452, Sofia, 1309, Bulgaria|Multiprofile Hospital for Active Treatment Tokuda Hospital Sofia, Sofia, 1407, Bulgaria|Receptos Study Site 456, Sofia, 1407, Bulgaria|Receptos Study Site 457, Sofia, 1431, Bulgaria|University Multiprofile Hospital for Active Treatment Aleksandrovska EAD, Sofia, 1431, Bulgaria|University Multiprofile Hospital for Active Treatment Sv Ivan Rilski EAD, Sofia, 1431, Bulgaria|Receptos Study Site 451, Sofia, 1527, Bulgaria|University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna ISUL EAD, Sofia, 1527, Bulgaria|Receptos Study Site 455, Sofia, 1606, Bulgaria|University of Alberta MS Clinic, Edmonton, Alberta, T6G 2G3, Canada|Receptos Study Site 154, Edmonton, Alberta, T6G2B7, Canada|Clinical Hospital Center Osijek, Osijek, 31000, Croatia|Receptos Study Site 923, Osijek, 31000, Croatia|Receptos Study Site 921, Zagreb, 10 000, Croatia|Receptos Study Site 922, Zagreb, 10 000, Croatia|Receptos Study Site 924, Zagreb, 10 000, Croatia|Clinical Hospital Center ""Sestre milosrdnice"", Clinic of Internal Diseases, Zagreb, 10000, Croatia|Clinical Hospital Centre Zagreb, Zagreb, 10000, Croatia|Clinical Hospital Sveti duh, Zagreb, 10000, Croatia|Receptos Study Site 301, Tbilisi, 0112, Georgia|LTD MediClubGeorgia, Tbilisi, 0160, Georgia|Receptos Study Site 302, Tbilisi, 0160, Georgia|Khechinashvili University Hospital, Tbilisi, 0179, Georgia|Receptos Study Site 303, Tbilisi, 0179, Georgia|Sarajishvili Institute of Neurology, Tbilisi, 112, Georgia|Evaggelismos General Hospital, Athens, 10676, Greece|Receptos Study Site 552, Athens, 10676, Greece|Receptos Study Site 554, Athens, 10676, Greece|Navy Hospital of Athens, Athens, 115 21, Greece|Receptos Study Site 553, Athens, 11521, Greece|401 Military Hospital of Athens, Athens, 11525, Greece|Receptos Study Site 551, Athens, 11525, Greece|AHEPA University General Hospital of Thessaloniki, Thessaloniki, 546 36, Greece|Receptos Study Site 557, Thessaloniki, 54636, Greece|Georgios Papanikolaou General Hospital of Thessaloniki, Thessaloniki, 57010, Greece|Receptos Study Site 555, Thessaloniki, 57010, Greece|Receptos Study Site 352, Budapest, 1145, Hungary|Uzsoki Utcai Korhaz, Budapest, 1145, Hungary|Jahn Ferenc DelPesti Korhaz es Rendelointezet, Budapest, 1204, Hungary|Receptos Study Site 356, Budapest, 1204, Hungary|Receptos Study Site 354, Esztergom, 2500, Hungary|Vaszary Kolos Korhaz, Esztergom, 2500, Hungary|Pest Megyei Flor Ferenc Korhaz, Kistarcsa, 2143, Hungary|Receptos Study Site 358, Kistarcsa, 2143, Hungary|SzabolcsSzatmarBereg Megyei Korhazak es Egyetemi Oktatokorhaz, Nyiregyhaza, 4400, Hungary|Receptos Study Site 351, Nyíregyháza, 4400, Hungary|Receptos Study Site 355, Szekesfehervar, 8000, Hungary|Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuele, Catania, 95123, Italy|Receptos Study Site 654, Catania, 95123, Italy|Fondazione Istituto San Raffaele G Giglio di Cefalu, Cefalu, 90015, Italy|Receptos Study Site 653, Cefalù, 90015, Italy|Receptos Study Site 655, Milano, 20122, Italy|Receptos Study Site 652, Milano, 20132, Italy|Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan, 20122, Italy|Presidio Ospedaliero di Montichiari, Montichiari, 25018, Italy|Receptos Study Site 659, Montichiari, 25018, Italy|Receptos Study Site 656, Napoli, Italy|Receptos Study Site 658, Pavia, 27100, Italy|Fondazione PTV Policlinico Tor Vergata, Roma, 00133, Italy|Receptos Study Site 651, Roma, 00133, Italy|Azienda Ospedaliera Universitaria Senese, Siena, 53100, Italy|Receptos Study Site 657, Siena, 53100, Italy|IMSP Institutul de Medicina Urgenta, Chisinau, 2004, Moldova, Republic of|Receptos Study Site 932, Chisinau, 2004, Moldova, Republic of|Institutul de Neurologie si Neurochirurgie, Chisinau, 2028, Moldova, Republic of|Receptos Study Site 931, Chisinau, 2028, Moldova, Republic of|Receptos Study Site 933, Chisinau, 2028, Moldova, Republic of|Receptos Study Site 401, Bialystok, 15-402, Poland|Receptos Study Site 423, Bydgoszcz, 85-654, Poland|Specjalistyczna Praktyka Lekarska Lek Med Robert Bonek, Bydgoszcz, 85-654, Poland|Powiatowy Zespol Zakladow Opieki Zdrowotnej Szpital w Czeladzi, Czeladz, 41-250, Poland|Receptos Study Site 406, Czeladz, 41-250, Poland|Receptos Study Site 405, Gdansk, 80-083, Poland|Receptos Study Site 425, Gdansk, 80-299, Poland|Copernicus PL Sp. z. o.o., Gdansk, 80-803, Poland|NEUROMEDIC Janusz Zbrojkiewicz, Katowice, 40-555, Poland|MA LEK AM Maciejowscy SC Centrum Terapii SM, Katowice, 40-595, Poland|Receptos Study Site 427, Katowice, 40-595, Poland|NovoMed Zielinski i Wspolnicy Spolka Jawna, Katowice, 40-650, Poland|Receptos Study Site 426, Katowice, 40-650, Poland|NEUROCARE Site Management Organization Gabriela KlodowskaDuda, Katowice, 40-749, Poland|Receptos Study Site 407, Katowice, 40-749, Poland|Receptos Study Site 417, Katowice, 40-752, Poland|Receptos Study Site 424, Kielce, 25-726, Poland|RESMEDICA Spolka z o.o., Kielce, 25-726, Poland|Centrum Kompleksowej Rehabilitacji Sp.z.o.o. Szpital Wielospecjalistyczny, Konstancin Jeziorna, 05-510, Poland|Receptos Study Site 404, Konstancin-Jeziorna, 05-510, Poland|Krakowska Akademia Neurologii Sp. z. o.o., Krakow, 31-305, Poland|Receptos Study Site 414, Krakow, 31-305, Poland|Centrum Neurologii Krzysztof Selmaj, Lodz, 93-121, Poland|Receptos Study Site 411, Lodz, 93-121, Poland|Prof. dr med. Zbigniew Stelmasiak Specjalistyczny Gabinet Neurologiczny, Lublin, 20-718, Poland|Receptos Study Site 412, Lublin, 20-718, Poland|Receptos Study Site 420, Lublin, 20-718, Poland|Wojewodzki Szpital Specjalistyczny im Stefana Kardynala Wyszynskiego, Lublin, 20-718, Poland|Receptos Study Site 402, Olsztyn, 10-443, Poland|Receptos Study Site 415, Olsztyn, 10-561, Poland|Wojewodzki Szpital Specjalistyczny, Olsztyn, 10-561, Poland|Neurologiczny NZOZ Centrum Leczenia SM Osrodek Badan Klinicznych Dr n med Hanka Hertmanowska, Plewiska, 62-064, Poland|Receptos Study Site 421, Plewiska, 62-064, Poland|Niepubliczny Zaklad Opieki Zdrowotnej KENDRON, Podlaskie, 15-402, Poland|Indywidualna Specjalistyczna Praktyka Lekarska dr nmed Monika Lyczak, Pomorskie, 80-299, Poland|Receptos Study Site 408, Poznan, 60-355, Poland|Szpital Kliniczny im HSwiecickiego Uniwersytetu Medycznego im Karola Marcinkowskiego w Poznaniu, Poznan, 60-355, Poland|Niepubliczny Zaklad Opieki Zdrowotnej NEUROKARD Ilkowski i Partnerzy Spolka Partnerska Lekarzy, Poznan, 61-853, Poland|Receptos Study Site 418, Poznan, 61-853, Poland|EUROMEDIS Sp. z.o.o., Szczecin, 70-111, Poland|Receptos Study Site 419, Szczecin, 70-111, Poland|Indywidualna Specjalistyczna Praktyka Lekarska Zbigniew Cebulski, Warminsko-mazurskie, 10-443, Poland|Szpital Czerniakowski Samodzielny Publiczny Zaklad Opieki Zdrowotnej, Warsaw, 00-739, Poland|Receptos Study Site 410, Warszawa, 00-739, Poland|Centrum Medyczne NeuroProtect, Warszawa, 01-697, Poland|Receptos Study Site 428, Warszawa, 01-697, Poland|Centralny Szpital Kliniczny MSW w Warszawie, Warszawa, 02-507, Poland|Receptos Study Site 422, Warszawa, 02-507, Poland|Instytut Psychiatrii i Neurologii, Warszawa, 02-957, Poland|Receptos Study Site 403, Warszawa, 02-957, Poland|Receptos Study Site 413, Warszawa, 04-141, Poland|Wojskowy Instytut Medyczny, Warszawa, 04-141, Poland|Clinical Hospital of Psychiatry and Neurology Brasov, Brasov, 500123, Romania|Receptos Study Site 503, Brasov, 500123, Romania|Health Club Medical Center S.R.L., Campulung, 115100, Romania|Receptos Study Site 502, Campulung, 115100, Romania|Receptos Study Site 501, Cluj-Napoca, 400347, Romania|Rehabilitation Clinical Hospital, Cluj-Napoca, 400347, Romania|Receptos Study Site 505, Sibiu, 550166, Romania|Sibiu Emergency County Clinical Hospital, Sibiu, 550166, Romania|Receptos Study Site 506, Timisoara, 300736, Romania|Timisoara Emergency County Clinical Hospital, Timisoara, 300736, Romania|Chelyabinsk City Clinical Hospital 3, Chelyabinsk, 454136, Russian Federation|Receptos Study Site 701, Chelyabinsk, 454136, Russian Federation|Receptos Study Site 704, Kazan, 420021, Russian Federation|Republican Clinical Hospital for Rehabilitation Treatment, Kazan, 420021, Russian Federation|Receptos Study Site 713, Kazan, 420101, Russian Federation|Research Medical Complex Vashe Zdorovie, Kazan, 420101, Russian Federation|Central Clinical Hospital 2 na NA Semashko OAO RZhD, Moscow, 107150, Russian Federation|Receptos Study Site 712, Moscow, 107150, Russian Federation|City Clinical Hospital 1 na NIPirogov, Moscow, 119049, Russian Federation|Receptos Study Site 709, Moscow, 119049, Russian Federation|City neurology center Sibneuromed LLC, Novosibirsk, 630091, Russian Federation|Receptos Study Site 703, Novosibirsk, 630091, Russian Federation|Perm State Medical Academy, Perm, 614990, Russian Federation|Receptos Study Site 710, Perm, 614990, Russian Federation|Receptos Study Site 716, Samara, 443095, Russian Federation|Samara Regional Clinical Hospital named after MI Kalinin, Samara, 443095, Russian Federation|City Clinical Hospital 4, Saransk, 430032, Russian Federation|Receptos Study Site 715, Saransk, 430032, Russian Federation|Receptos Study Site 714, Saratov, 410012, Russian Federation|Saratov State Medical University, Saratov, 410054, Russian Federation|Receptos Study Site 707, Smolensk, 214018, Russian Federation|Smolensk State Medical Academy, Smolensk, 214018, Russian Federation|Receptos Study Site 708, St. Petersburg, 194044, Russian Federation|Russian Medical Military Academy na SMKirov, St. Petersburg, 194044, Russian Federation|Receptos Study Site 717, Tyumen, 625000, Russian Federation|Neftyanik Medical and Sanitary Unit, Tyumen, 625048, Russian Federation|Receptos Study Site 711, Yaroslavl, 150030, Russian Federation|Yaroslavl Clinical Hospital 8, Yaroslavl, 150030, Russian Federation|Clinical Center of Serbia, Belgrade, 11000, Serbia|Clinical Hospital Centar Zvezdara, Belgrade, 11000, Serbia|Military Medical Academy, Belgrade, 11000, Serbia|Receptos Study Site 602, Belgrade, 11000, Serbia|Receptos Study Site 603, Belgrade, 11000, Serbia|Receptos Study Site 604, Belgrade, 11000, Serbia|Clinical Hospital Centre Zemun, Belgrade, 11080, Serbia|Receptos Study Site 601, Belgrade, 11080, Serbia|Clinical Center Kragujevac, Kragujevac, 34000, Serbia|Receptos Study Site 605, Kragujevac, 34000, Serbia|University Hospital Bratislava - Hospital ak. L. Derera, II Neurology Clinic, Bratislava, 833 05, Slovakia|Receptos Study Site 946, Bratislava, 83305, Slovakia|Receptos Study Site 942, Lucenec, 984 01, Slovakia|Receptos Study Site 945, Trnava, 917 75, Slovakia|Receptos Study Site 956, KwaZulu-Natal, 4321, South Africa|Neurology Practice, Pretoria, 0040, South Africa|Receptos Study Site 953, Pretoria, 0041, South Africa|Receptos Study Site 755, Sevilla, Andalucía, 41009, Spain|Receptos Study Site 763, Santa Cruz de Tenerife, Canarias, 38010, Spain|Receptos Study Site 756, Barcelona, Cataluña, 08003, Spain|Receptos Study Site 760, Girona, Cataluña, 17007, Spain|Receptos Study Site 762, Alicante, Comunidad Valenciana, 03010, Spain|Receptos Study Site 752, Valencia, Comunidad Valenciana, 46026, Spain|Receptos Study Site 761, Bilbao, País Vasco, 48013, Spain|Receptos Study Site 759, San Sebastián, País Vasco, 20014, Spain|Hospital General Universitario de Alicante, Alicante, 03010, Spain|Hospital del Mar, Barcelona, 08003, Spain|Receptos Study Site 758, Barcelona, 08035, Spain|Hospital Universitario Vall D hebron, Barcelona, 28040, Spain|Organizacion Sanitaria Integrada Bilbao Basurto, Bilbao, 48013, Spain|Hospital Universitari de Girona Dr Josep Trueta, Girona, 17007, Spain|Hospital Universitario de la Princesa, Madrid, 28006, Spain|Receptos Study Site 757, Madrid, 28006, Spain|Receptos Study Site 751, Madrid, 28040, Spain|Receptos Study Site 754, Majadahonda (Madrid), 28222, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, 28222, Spain|Hospital Universitario Vírgen Macarena, Sevilla, 41009, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, 46026, Spain|Municipal Medical & Preventive Institution Chernigiv Regional Clinical Hospital, Chernigiv, 14033, Ukraine|Receptos Study Site 805, Chernihiv, 14033, Ukraine|Municipal Institution Chernivtsi Regional Psychiatric Hospital, Chernivtsi, 58018, Ukraine|Receptos Study Site 813, Chernivtsi, 58018, Ukraine|Municipal Institution Dnipropetrovsk Regional Clinical Hospital na I.I. Mechnykov, Dnipropetrovsk, 49027, Ukraine|Receptos Study Site 802, Dnipropetrovsk, 49027, Ukraine|State Institution Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine, Dnipropetrovsk, 49027, Ukraine|Receptos Study Site 815, Dnipropetrovsk, 49095, Ukraine|Regional Clinical Hospital, Ivano Frankivsk, 76008, Ukraine|Receptos Study Site 801, Ivano-Frankivsk, 76008, Ukraine|Receptos Study Site 814, Kharkiv, 61103, Ukraine|State Treatment and Prevention Institution Central Clinical Hospital of Ukrzaliznytsya, Kharkiv, 61103, Ukraine|Municipal Institution Kherson City Clinical Hospital, Kherson, 73000, Ukraine|Receptos Study Site 811, Kherson, 73003, Ukraine|Receptos Study Site 818, Kyiv, 03110, Ukraine|Municipal Institution of Kyiv Regional Council Kyiv Regional Clinical Hospital, Kyiv, 04107, Ukraine|Receptos Study Site 803, Kyiv, 04107, Ukraine|Kyiv City Clinical Hospital 4, Kyiv, 3110, Ukraine|Municipal Institution Lutsk City Clinical Hospital, Lutsk, 43024, Ukraine|Receptos Study Site 816, Lutsk, 43024, Ukraine|Receptos Study Site 817, Lutsk, 43024, Ukraine|Volyn Regional Clinical Hospital, Lutsk, 43024, Ukraine|Lviv Regional Clinical Hospital, Lviv, 79010, Ukraine|Receptos Study Site 812, Lviv, 79010, Ukraine|Center for Reconstructive and Rehabilitation Medicine University Clinic of ONMedU, Odesa, 65009, Ukraine|Receptos Study Site 810, Odesa, 65009, Ukraine|Municipal Institution Odesa Regional Clinical Hospital, Odesa, 65025, Ukraine|Receptos Study Site 804, Odesa, 65025, Ukraine|Municipal Institution Vinnytsya Regional Psychoneurological Hospital na OI Yushchenko, Vinnytsya, 21005, Ukraine|Receptos Study Site 809, Vinnytsya, 21005, Ukraine|Municipal Institution City Clinical Hospital 6, Zaporizhzhya, 69035, Ukraine|Receptos Study Site 806, Zaporizhzhya, 69035, Ukraine|Royal Sussex County Hospital, Brighton East Sussex, BN2 5BE, United Kingdom|Receptos Study Site 965, Brighton, BN2 5BE, United Kingdom|Raigmore Hospital, Inverness, IV2 3UJ, United Kingdom|Receptos Study Site 963, Inverness, IV2 3UJ, United Kingdom|Kings College Hospital, London, SE5 9RS, United Kingdom|Receptos Study Site 961, London, SE5 9RS, United Kingdom|National Hospital for Neurology and Neurosurgery, London, WC1N 3BG, United Kingdom|Receptos Study Site 967, London, WC1N 3BG, United Kingdom|Receptos Study Site 966, Romford, RM7 0AG, United Kingdom|Receptos Study Site 964, Sheffield, S10 2JF, United Kingdom|Royal Hallamshire Hospital Sheffield Teaching Hospitals NHS Trust, Sheffield, S10 2JF, United Kingdom"
NCT05323734,Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy,https://beta.clinicaltrials.gov/study/NCT05323734,RECRUITING,Tuberous Sclerosis Complex,DRUG: Ganaxalone|DRUG: Placebo,Marinus Pharmaceuticals,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,162,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-04-01,2024-01-01,2025-02-01,"Barrow Neurological Institute at Phoenix Children's Hospital, Phoenix, Arizona, 85106, United States|Arkansas Children's Research Institute, Little Rock, Arkansas, 72202, United States|UCLA Mattel Children's Hospital, TSC Center, Los Angeles, California, 90095, United States|Children's Hospital of Orange County, Orange, California, 92868, United States|Childrens Hospital Colorado, Aurora, Colorado, 80045, United States|Nemours Children's Hospital - Delaware Valley, Wilmington, Delaware, 19803, United States|University of Florida Gainesville, Gainesville, Florida, 32608, United States|NW FL Clinical Research Group, LLC, Gulf Breeze, Florida, 32561, United States|Nicklaus Children's Hospital, Miami, Florida, 33155, United States|Orlando Health, Orlando, Florida, 32806, United States|Comprehensive Neurology Clinic, Orlando, Florida, 32825, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, 30329, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, 60611, United States|Mid Atlantic Epilepsy & Sleep Center, Bethesda, Maryland, 20817, United States|Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, 02115, United States|Children's Hospital of Michigan Central Michigan University, Detroit, Michigan, 48201, United States|Mayo Clinic - Rochester, Rochester, Minnesota, 55905, United States|University of Missouri Child Health, Columbia, Missouri, 65201, United States|Children's Mercy Hosptial, Kansas City, Missouri, 64108, United States|TSC Clinic at Northeast Regional Epilepsy Group, Hackensack, New Jersey, 07601, United States|Institute of Neurology and Neurosurgery at Saint Barnabas, Livingston, New Jersey, 07039, United States|University of Rochester Medical Center, Rochester, New York, 14642, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 27599, United States|Atrium Health/Levine Children's Hospital, Charlotte, North Carolina, 28207, United States|Duke University Medical Center, Durham, North Carolina, 27712, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 45229, United States|Penn State Children's Hospital, Hershey, Pennsylvania, 17033, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States|Medical University of South Carolina, Charleston, South Carolina, 29425, United States|Le Bonheur Children's Hospital, Memphis, Tennessee, 38103, United States|Child Neurology Consultants of Austin (CNCA), Austin, Texas, 78757, United States|University of Texas Southwestern Medical Center, Dallas, Texas, 75207, United States|McGovern Medical School at the University of Texas Health Science Center, Houston, Texas, 77030, United States|University of Utah Health Care-Pediatric Neurology, Salt Lake City, Utah, 84108, United States|Seattle Children's Hospital, Seattle, Washington, 98105, United States|Hôtel Dieu de Montréal - CHUM, Montreal, H2X 0C2, Canada|CHU Sainte-Justine, Montréal, H3T 1C5, Canada|The Hospital for Sick Children, Toronto, M5G 1X8, Canada|Toronto Western Hospital, Toronto, M5T 2S8, Canada|BC Children's Hospital, Vancouver, V6H 3V4, Canada|University Hospital of Lyon, Bron, 69229, France|University Hospital of Lille, Lille, 59037, France|Robert-Debré Hospital, Paris, 75019, France|Hôpital de la Pitié-Salpêtrière, Paris, 75651, France|University Hospital of Rennes, Rennes, 35700, France|University of Strasbourg, Strasbourg, 67084, France|Epilepsie-Zentrum Bethel - Krankenhaus Mara, Bielefeld, 33617, Germany|University Hospital Bonn, Bonn, 53127, Germany|ZNN - Epilepsiezentrum Frankfurt am Main, Frankfurt, 60528, Germany|Universitäts Krankenhaus Freiburg, Freiburg, 79106, Germany|Gemeinschaftskrankenhaus Herdecke, Herdecke, 58313, Germany|Epilepsiezentrum Kleinwachau gGmbH, Radeberg, 01454, Germany|Soroka University Medical Center, Beer-Sheva, 8410100, Israel|Hadassah Medical Center, Jerusalem, 9112991, Israel|Schneider Children´s Medical Center, Petah Tikva, 4920235, Israel|Sheba Medical Center, Tel Hashomer, 52621, Israel|Tel-Aviv Sourasky Medical Center, Tel-Aviv, 64239, Israel|Department of Neurology and Sense Organs, AOU Policlinico di Bari, Bari, 1170124, Italy|Azienda Ospedaliero-Universitaria Meyer, Firenze, 50139, Italy|Pediatric Neurology and Muscular Diseases Unit - University of Genoa, Genova, 16147, Italy|Children's Hospital Bambino Gesù, Rome, 00165, Italy|Policlinico Umberto I, Rome, 00185, Italy|Hospital de la Santa Creu i Sant Pau, Barcelona, 08025, Spain|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital Sant Joan de Déu, Barcelona, 08950, Spain|Hospital Infantil Universitario Niño Jesús, Madrid, 28009, Spain|Hospital Ruber International, Madrid, 28034, Spain|Hospital Regional Universitario de Málaga, Málaga, 29010, Spain|Hospital Universitario y Politécnico La Fe, Valencia, 46026, Spain|Royal Aberdeen Children's Hospital, NHS Grampian, Aberdeen, AB25 2ZG, United Kingdom|Bristol Royal Hospital for Children, Bristol, BS2 8AE, United Kingdom|Leeds General Infirmary, Leeds, LS1 3EX, United Kingdom|NHS acute tertiary referral centre, John Radcliffe Hospital, Oxford, OX3 9DU, United Kingdom|Salford Royal Hospital, Salford, M6 8HD, United Kingdom|Sheffield Children's Hospital, Sheffield, S10 2TH, United Kingdom"
NCT00017628,Phase I Study of High-Dose Cyclophosphamide and Total Body Irradiation With T Lymphocyte-Depleted Autologous Peripheral Blood Stem Cell or Bone Marrow Rescue in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00017628,COMPLETED,Multiple Sclerosis,DRUG: cyclophosphamide|DRUG: filgrastim|DRUG: methylprednisolone|PROCEDURE: Autologous Stem Cell Transplantation,Northwestern Memorial Hospital,,ALL,"CHILD, ADULT",PHASE1,20,OTHER,INTERVENTIONAL,Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT,2001-04,,,"Northwestern Memorial Hospital, Chicago, Illinois, 60611, United States|Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, 60612, United States"
NCT05131828,"CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying Therapy",https://beta.clinicaltrials.gov/study/NCT05131828,RECRUITING,Multiple Sclerosis,DRUG: Metformin and clemastine in combination|DRUG: Placebo,Cambridge University Hospitals NHS Foundation Trust,University of Cambridge,ALL,ADULT,PHASE2,50,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-03-08,2023-10,2023-10,"Addenbrooke's Hospital, Cambridge, United Kingdom"
NCT01547234,Observational Study for Assessment of the Effect of Fampyra on the Manual Function of Persons With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01547234,COMPLETED,Multiple Sclerosis,,Carmel Medical Center,,ALL,"ADULT, OLDER_ADULT",,47,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-02,2014-12,2014-12,"Multiple Sclerosis Center Carmel Medical Center, Haifa, Israel"
NCT02146534,Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients,https://beta.clinicaltrials.gov/study/NCT02146534,COMPLETED,Multiple Sclerosis,DRUG: extended release fampridine|DRUG: Placebo,Clinique Neuro-Outaouais,CogState Ltd.,ALL,"ADULT, OLDER_ADULT",PHASE4,44,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-12,2016-01,2016-01,"Clinique Neuro-Outaouais, Gatineau, Quebec, J9J 0A5, Canada"
NCT02388334,Impact of Multiple Sclerosis From the Viewpoint of the Caregivers,https://beta.clinicaltrials.gov/study/NCT02388334,UNKNOWN,Multiple Sclerosis,OTHER: to develop a standardized questionnaire,Rennes University Hospital,"Ministry of Health, France|Nantes University Hospital|University Hospital, Angers|Central Hospital, Nancy, France|University Hospital, Strasbourg|University Hospital, Marseille|University Hospital, Clermont-Ferrand",ALL,"ADULT, OLDER_ADULT",,730,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-03,2015-12,2017-06,
NCT03161028,Lipoic Acid for Progressive Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT03161028,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,DRUG: Lipoic acid|DRUG: Placebo,VA Office of Research and Development,,ALL,"ADULT, OLDER_ADULT",PHASE2,115,FED,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-07-01,2023-12-31,2024-06-30,"University of Alabama at Birmingham, Birmingham, Alabama, 35294, United States|University of Colorado, Aurora, Colorado, 80045, United States|Washington DC VA Medical Center, Washington, DC, Washington, District of Columbia, 20422, United States|VA Portland Health Care System, Portland, OR, Portland, Oregon, 97207-2964, United States|VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas, Texas, 75216, United States|University of Utah, Salt Lake City, Utah, 84148, United States|VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City, Utah, 84148, United States|University of Vermont, Burlington, Vermont, 05401, United States|VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington, 98108, United States|Swedish Medical Center, Seattle, Washington, 98122, United States|Ottawa Hospital Research Institute, Ottawa, Ontario, K1Y 4E9, Canada"
NCT03375541,Drug Risk Aversion Calculator Use to Facilitate MS Patient Self-efficacy,https://beta.clinicaltrials.gov/study/NCT03375541,WITHDRAWN,Multiple Sclerosis,OTHER: Risk Aversion Calculator,Duke University,,ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2018-03,2019-03,2019-03,
NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),https://beta.clinicaltrials.gov/study/NCT04411641,ACTIVE_NOT_RECRUITING,Secondary Progressive Multiple Sclerosis,DRUG: Tolebrutinib|DRUG: Placebo to match Tolebrutinib,Sanofi,,ALL,ADULT,PHASE3,1131,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-09-24,2024-08,2024-08,"University of Alabama MS Center-Site Number:8400013, Birmingham, Alabama, 35233, United States|Center for Neurology and Spine-Site Number:8400089, Phoenix, Arizona, 84018, United States|Arcadia Neurology Center-Site Number:8400070, Arcadia, California, 91006, United States|UC San Diego ACTRI-Site Number:8400101, La Jolla, California, 92037, United States|Collaborative Neuroscience Research-Site Number:8400045, Long Beach, California, 90806, United States|Multiple Sclerosis Center-Site Number:8400143, Los Angeles, California, 90033, United States|University of San Francisco, Sandler Neurosciences Center-Site Number:8400137, San Francisco, California, 94158, United States|Harbor UCLA-Site Number:8400088, Torrance, California, 90502, United States|Regina Berkovich, MD, PhD-Site Number:8400059, West Hollywood, California, 90048, United States|Mountain Neurological Research Center, Inc.-Site Number:8400128, Basalt, Colorado, 81621, United States|University of Colorado-Site Number:8400012, Denver, Colorado, 80262, United States|Advanced Neurosciences Research-Site Number:8400025, Fort Collins, Colorado, 80528, United States|South Florida Neurology Associates-Site Number:8400029, Boca Raton, Florida, 33487, United States|Neurology Associates, PA-Site Number:8400004, Maitland, Florida, 32761, United States|Aqualane Clinical Research-Site Number:8400027, Naples, Florida, 34105, United States|Axiom Clinical Research of Florida-Site Number:8400001, Tampa, Florida, 33609-4052, United States|University of South Florida-Site Number:8400006, Tampa, Florida, 33612, United States|Meridian Clinical Research-Site Number:8400003, Savannah, Georgia, 31406, United States|Consultants In Neurology-Site Number:8400011, Northbrook, Illinois, 60062, United States|University of Kansas Medical Center-Site Number:8400023, Kansas City, Kansas, 66160-7321, United States|CHI Saint Joseph Medical Group Neurology-Site Number:8400110, Lexington, Kentucky, 40509, United States|Tufts Medical Center-Site Number:8400072, Boston, Massachusetts, 02111, United States|University of Massachusetts-Site Number:8400014, Worcester, Massachusetts, 01655, United States|Wayne State University-Site Number:8400046, Detroit, Michigan, 48201, United States|The Memorial Hospital-Site Number:8400033, Owosso, Michigan, 48867, United States|Minneapolis Clinic of Neurology-Site Number:8400051, Minneapolis, Minnesota, 55422, United States|Mayo Clinic-Site Number:8400111, Rochester, Minnesota, 55905, United States|Missouri Baptist Medical Center-Site Number:8400019, Saint Louis, Missouri, 63131, United States|Lou Ruvo Center for Brain Health-Site Number:8400117, Las Vegas, Nevada, 89106, United States|Holy Name Hospital-Site Number:8400104, Teaneck, New Jersey, 07666, United States|University of New Mexico-Site Number:8400032, Albuquerque, New Mexico, 87131, United States|Icahn School of Medicine at Mount Sinai (Department of Endoc-Site Number:8400038, New York, New York, 10029-6501, United States|Neurology Associates of Stony Brook-Site Number:8400042, Stony Brook, New York, 11794, United States|Meridian Clinical Research, LLC-Site Number:8400005, Raleigh, North Carolina, 27607, United States|Sanford Brain & Spine Center-Site Number:8400126, Fargo, North Dakota, 58103, United States|University Hospitals CMC-Site Number:8400083, Cleveland, Ohio, 44106, United States|Cleveland Clinic-Site Number:8400125, Cleveland, Ohio, 44195, United States|Optimed Research, LTD-Site Number:8400147, Columbus, Ohio, 43235, United States|Neurology Specialists-Site Number:8400002, Dayton, Ohio, 45417, United States|Columbus Neuroscience-Site Number:8400010, Westerville, Ohio, 40382, United States|Providence Multiple Sclerosis Center-Site Number:8400020, Portland, Oregon, 97225, United States|Perelman Center for Advanced Medicine-Site Number:8400142, Philadelphia, Pennsylvania, 19104, United States|Jefferson Neurology Associates-Site Number:8400016, Philadelphia, Pennsylvania, 19107, United States|Premier Neurology-Site Number:8400069, Greer, South Carolina, 29650, United States|Mountain View Clinical Research-Site Number:8400024, Greer, South Carolina, 29651-1817, United States|Neurology Clinic, PC-Site Number:8400087, Cordova, Tennessee, 38018, United States|Advanced Neuroscience Center-Site Number:8400035, Franklin, Tennessee, 37064, United States|Baylor College of Medicine-Site Number:8400136, Houston, Texas, 77030, United States|Neurology Center of San Antonio-Site Number:8400036, San Antonio, Texas, 78258, United States|University Of Vermont College Of Medicine-Site Number:8400130, Burlington, Vermont, 05401, United States|Medical College of Wisconsin-Site Number:8400028, Milwaukee, Wisconsin, 53226, United States|Investigational Site Number :0320002, Capital Federal, Buenos Aires, 1012, Argentina|Investigational Site Number :0320001, Caba, Ciudad De Buenos Aires, C1061, Argentina|Investigational Site Number :0320007, Buenos Aires, 1860, Argentina|Investigational Site Number :0320006, Córdoba, 5000, Argentina|Investigational Site Number :0320005, San Miguel de Tucuman, T4000AXL, Argentina|Investigational Site Number :0360003, Woolloongabba, Queensland, 4102, Australia|Investigational Site Number :0360002, Kent Town, South Australia, Australia|Investigational Site Number :0360004, Hobart, Tasmania, 7001, Australia|Investigational Site Number :0360001, Fitzroy, Victoria, 3065, Australia|Investigational Site Number :0360006, Heidelberg West, Victoria, 3081, Australia|Investigational Site Number :0400003, Innsbruck, 6020, Austria|Investigational Site Number :0400001, Linz, 4020, Austria|Investigational Site Number :0400004, Linz, 4021, Austria|Investigational Site Number :0400002, Wien, 1090, Austria|Investigational Site Number :1120004, Vitebsk, 210009, Belarus|Investigational Site Number :1120005, Vitebsk, 210037, Belarus|Investigational Site Number :0560007, Bruxelles, 1200, Belgium|Investigational Site Number :0560003, Edegem, B-2650, Belgium|Investigational Site Number :0560006, Leuven, 3000, Belgium|Investigational Site Number :0560008, Liège, 4000, Belgium|Investigational Site Number :0560002, Mons, 7000, Belgium|Investigational Site Number :0560001, Pelt, 3900, Belgium|Investigational Site Number :1000002, Pleven, 5800, Bulgaria|Investigational Site Number :1000005, Plovdiv, 4000, Bulgaria|Investigational Site Number :1000004, Sofia, 1113, Bulgaria|Investigational Site Number :1000008, Sofia, 1407, Bulgaria|Investigational Site Number :1000001, Sofia, 1431, Bulgaria|Investigational Site Number :1000006, Sofia, 1431, Bulgaria|Investigational Site Number :1000009, Sofia, 1680, Bulgaria|Investigational Site Number :1240017, Burnaby, British Columbia, V5G 2X6, Canada|Investigational Site Number :1240011, Halifax, Nova Scotia, B3H 1V7, Canada|Investigational Site Number :1240003, Ottawa, Ontario, K1H 8L6, Canada|Investigational Site Number :1240008, Toronto, Ontario, M4N 3M5, Canada|Investigational Site Number :1240006, Gatineau, Quebec, J8Y 1W2, Canada|Investigational Site Number :1240005, Greenfield Park, Quebec, J4V 2J2, Canada|Investigational Site Number :1240004, Montreal, Quebec, H2X 0A9, Canada|Investigational Site Number :1240015, Montreal, Quebec, H3A 2B4, Canada|Investigational Site Number :1240007, Sherbrooke, Quebec, J1H 5N4, Canada|Investigational Site Number :1240021, Quebec, G1W 4R4, Canada|Investigational Site Number :1560006, Beijing, 100034, China|Investigational Site Number :1560012, Beijing, 100053, China|Investigational Site Number :1560021, Beijing, 100700, China|Investigational Site Number :1560003, Beijing, 100730, China|Investigational Site Number :1560009, Beijing, 100730, China|Investigational Site Number :1560004, Changchun, 130021, China|Investigational Site Number :1560015, Changsha, 410008, China|Investigational Site Number :1560005, Chengdu, 610041, China|Investigational Site Number :1560019, Chongqing, 400016, China|Investigational Site Number :1560035, Fuzhou, 350005, China|Investigational Site Number :1560001, Guangzhou, 510630, China|Investigational Site Number :1560007, Hangzhou, 310009, China|Investigational Site Number :1560014, Shijiazhuang, 050000, China|Investigational Site Number :1560008, Taiyuan, 030001, China|Investigational Site Number :1560017, Xi'an, 710038, China|Investigational Site Number :2030002, Brno, 65691, Czechia|Investigational Site Number :2030004, Hradec Kralove, 50005, Czechia|Investigational Site Number :2030001, Jihlava, 58633, Czechia|Investigational Site Number :2030010, Ostrava - Poruba, 70852, Czechia|Investigational Site Number :2030005, Praha 2, 12808, Czechia|Investigational Site Number :2030003, Teplice, 415 29, Czechia|Investigational Site Number :2080001, Esbjerg, 6700, Denmark|Investigational Site Number :2080005, Holstebro, 7500, Denmark|Investigational Site Number :2080004, Odense, 5000, Denmark|Investigational Site Number :2460003, Helsinki, 00180, Finland|Investigational Site Number :2460001, Tampere, 33520, Finland|Investigational Site Number :2460002, Turku, 20520, Finland|Investigational Site Number :2500011, Bron, 69500, France|Investigational Site Number :2500005, Clermont Ferrand, 63003, France|Investigational Site Number :2500015, Gonesse, 95500, France|Investigational Site Number :2500009, Lille, 59037, France|Investigational Site Number :2500006, Montpellier, 34295, France|Investigational Site Number :2500008, Nancy, 54035, France|Investigational Site Number :2500010, Nantes, 44093, France|Investigational Site Number :2500017, Nimes, 30029, France|Investigational Site Number :2500016, Paris, 75012, France|Investigational Site Number :2500014, Paris, 75013, France|Investigational Site Number :2500007, Paris, 75019, France|Investigational Site Number :2500003, Rennes, 35033, France|Investigational Site Number :2500001, Strasbourg, 67098, France|Investigational Site Number :2500012, Toulouse, 31059, France|Investigational Site Number :2760005, Bayreuth, 95445, Germany|Investigational Site Number :2760009, Berlin, 10117, Germany|Investigational Site Number :2760001, Dresden, 01307, Germany|Investigational Site Number :2760012, Essen, 45147, Germany|Investigational Site Number :2760002, Gießen, 35385, Germany|Investigational Site Number :2760010, Halle (Saale), 06120, Germany|Investigational Site Number :2760006, Hannover, 30625, Germany|Investigational Site Number :2760008, Münster, 48149, Germany|Investigational Site Number :2760004, Rostock, 18055, Germany|Investigational Site Number :2760011, Ulm, 89081, Germany|Investigational Site Number :3000001, Athens, 115 28, Greece|Investigational Site Number :3000006, Athens, 11535, Greece|Investigational Site Number :3000002, Athens, 12462, Greece|Investigational Site Number :3000007, Athens, 15125, Greece|Investigational Site Number :3000004, Larissa, 41110, Greece|Investigational Site Number :3000003, Thessaloniki, 546 36, Greece|Investigational Site Number :3000005, Thessaloniki, 57010, Greece|Investigational Site Number :3480008, Budapest, 1135, Hungary|Investigational Site Number :3480004, Budapest, 1145, Hungary|Investigational Site Number :3480007, Budapest, 1152, Hungary|Investigational Site Number :3480002, Pécs, 7623, Hungary|Investigational Site Number :3480001, Szeged, 6725, Hungary|Investigational Site Number :3480006, Tatabánya, 2800, Hungary|Investigational Site Number :3560007, Gurgaon, 122001, India|Investigational Site Number :3560003, Gurgaon, 122002, India|Investigational Site Number :3560005, India, India|Investigational Site Number :3560004, Mangaluru, 575018, India|Investigational Site Number :3560006, New Delhi, 110029, India|Investigational Site Number :3560002, New Delhi, 110060, India|Investigational Site Number :3760002, Ashkelon, 78278, Israel|Investigational Site Number :3760003, Haifa, 31096, Israel|Investigational Site Number :3760008, Jerusalem, 91120, Israel|Investigational Site Number :3760001, Tel HaShomer, 52621, Israel|Investigational Site Number :3760004, Zefat, 13100, Israel|Investigational Site Number :3800011, Bergamo, 24127, Italy|Investigational Site Number :3800007, Cagliari, 09126, Italy|Investigational Site Number :3800012, Firenze, 50134, Italy|Investigational Site Number :3800016, Firenze, 50141, Italy|Investigational Site Number :3800014, Genova, 16132, Italy|Investigational Site Number :3800013, L'Aquila, 67010, Italy|Investigational Site Number :3800004, Milano, 20122, Italy|Investigational Site Number :3800001, Milano, 20132, Italy|Investigational Site Number :3800010, Milano, 20133, Italy|Investigational Site Number :3800008, Pavia, 27100, Italy|Investigational Site Number :3800005, Roma, 00152, Italy|Investigational Site Number :3800009, Roma, 00168, Italy|Investigational Site Number :3920016, Chiba-shi, Chiba, 260-8677, Japan|Investigational Site Number :3920022, Morioka-shi, Iwate, 020-8505, Japan|Investigational Site Number :3920011, Kyoto-shi, Kyoto, 616-8255, Japan|Investigational Site Number :3920020, Sendai-shi, Miyagi, 980-8574, Japan|Investigational Site Number :3920005, Niigata-shi, Niigata, 951-8520, Japan|Investigational Site Number :3920004, Moriguchi-shi, Osaka, 570-8507, Japan|Investigational Site Number :3920001, Osaka-shi, Osaka, 556-0016, Japan|Investigational Site Number :3920018, Kawagoe-shi, Saitama, 350-8550, Japan|Investigational Site Number :3920003, Kodaira-shi, Tokyo, 187-8551, Japan|Investigational Site Number :3920010, Ota-ku, Tokyo, 146-0065, Japan|Investigational Site Number :3920009, Ube-shi, Yamaguchi, 755-8505, Japan|Investigational Site Number :3920023, Sagamihara-shi, 252-0392, Japan|Investigational Site Number :4400003, Kaunas, 50161, Lithuania|Investigational Site Number :4400002, Klaipeda, 92288, Lithuania|Investigational Site Number :4400001, Vilnius, 08661, Lithuania|Investigational Site Number :5280001, Amsterdam, 1081 GN, Netherlands|Investigational Site Number :5280003, Breda, 4818 CK, Netherlands|Investigational Site Number :5280006, Groningen, 9728 NZ, Netherlands|Investigational Site Number :5280002, Sittard-Geleen, 6162 BG, Netherlands|Investigational Site Number :5780003, Bergen, 5021, Norway|Investigational Site Number :5780002, Namsos, 7800, Norway|Investigational Site Number :5780001, Oslo, 0450, Norway|Investigational Site Number :6160003, Bydgoszcz, Kujawsko-pomorskie, 85-796, Poland|Investigational Site Number :6160005, Warszawa, Mazowieckie, 01-211, Poland|Investigational Site Number :6160006, Warszawa, Mazowieckie, 01-684, Poland|Investigational Site Number :6160002, Katowice, Slaskie, 40-571, Poland|Investigational Site Number :6160007, Katowice, Slaskie, 40-684, Poland|Investigational Site Number :6160004, Katowice, Slaskie, 40-686, Poland|Investigational Site Number :6160008, Plewiska, Wielkopolskie, 62-064, Poland|Investigational Site Number :6160001, Lodz, 90-549, Poland|Investigational Site Number :6160012, Lublin, 20-016, Poland|Investigational Site Number :6160011, Zabrze, 41-800, Poland|Investigational Site Number :6200001, Braga, 4710-243, Portugal|Investigational Site Number :6200011, Lisboa, 1162-050, Portugal|Investigational Site Number :6200007, Lisboa, 1349-019, Portugal|Investigational Site Number :6200006, Lisboa, 1649-035, Portugal|Investigational Site Number :6200002, Matosinhos, 4464-513, Portugal|Investigational Site Number :6200010, Porto, 4099-001, Portugal|Investigational Site Number :6420008, Bucuresti, 022328, Romania|Investigational Site Number :6420004, Campulung, 115100, Romania|Investigational Site Number :6420006, Cluj-Napoca, 400012, Romania|Investigational Site Number :6420003, Constanta, 900123, Romania|Investigational Site Number :6420013, Oradea, 410154, Romania|Investigational Site Number :6420005, Sibiu, 550052, Romania|Investigational Site Number :6420001, Targu Mures, 540136, Romania|Investigational Site Number :6420002, Timisoara, 300736, Romania|Investigational Site Number :6430018, Barnaul, 656024, Russian Federation|Investigational Site Number :6430023, Ekaterinburg, 620102, Russian Federation|Investigational Site Number :6430025, Kaliningrad, 236035, Russian Federation|Investigational Site Number :6430003, Kazan, 420021, Russian Federation|Investigational Site Number :6430022, Kemerovo, 650099, Russian Federation|Investigational Site Number :6430017, Kirov, 610998, Russian Federation|Investigational Site Number :6430024, Krasnoyarsk, 660029, Russian Federation|Investigational Site Number :6430020, Moscow, 117997, Russian Federation|Investigational Site Number :6430002, Moscow, 125367, Russian Federation|Investigational Site Number :6430013, Moscow, 127015, Russian Federation|Investigational Site Number :6430001, Moscow, 129110, Russian Federation|Investigational Site Number :6430008, Moscow, 129128, Russian Federation|Investigational Site Number :6430021, Nizhny Novgorod, 603137, Russian Federation|Investigational Site Number :6430006, Nizhny Novgorod, 603155, Russian Federation|Investigational Site Number :6430005, Novosibirsk, 630087, Russian Federation|Investigational Site Number :6430026, Perm, 614990, Russian Federation|Investigational Site Number :6430007, Pyatigorsk, 357538, Russian Federation|Investigational Site Number :6430016, Rostov-on-Don, 344022, Russian Federation|Investigational Site Number :6430004, Saint-Petersburg, 197110, Russian Federation|Investigational Site Number :6430009, Samara, 443095, Russian Federation|Investigational Site Number :6430019, Saransk, 430032, Russian Federation|Investigational Site Number :6430014, Smolensk, 214018, Russian Federation|Investigational Site Number :6430011, St-Petersburg, 197022, Russian Federation|Investigational Site Number :6430012, Tyumen, 625000, Russian Federation|Investigational Site Number :6430010, Ufa, 450005, Russian Federation|Investigational Site Number :7240007, Sevilla, Andalucia, 41009, Spain|Investigational Site Number :7240013, Barcelona, Barcelona [Barcelona], 08035, Spain|Investigational Site Number :7240016, Barcelona, Barcelona [Barcelona], 08036, Spain|Investigational Site Number :7240014, Salt, Girona [Gerona], 17190, Spain|Investigational Site Number :7240017, Las Palmas de Gran Canaria, Las Palmas, 35010, Spain|Investigational Site Number :7240004, Majadahonda, Madrid, 28222, Spain|Investigational Site Number :7240001, Pozuelo De Alarcón, Madrid, 28223, Spain|Investigational Site Number :7240012, Donostia, Pais Vasco, 20014, Spain|Investigational Site Number :7240008, Córdoba, 14004, Spain|Investigational Site Number :7240015, Lleida, 25198, Spain|Investigational Site Number :7240005, Madrid, 28007, Spain|Investigational Site Number :7240002, Madrid, 28034, Spain|Investigational Site Number :7240003, Madrid, 28040, Spain|Investigational Site Number :7240010, Murcia, 30120, Spain|Investigational Site Number :7240009, Málaga, 29010, Spain|Investigational Site Number :7240011, Valencia, 46026, Spain|Investigational Site Number :7920005, Eskisehir, Turkey|Investigational Site Number :7920010, Hatay, Turkey|Investigational Site Number :7920002, Istanbul, 34098, Turkey|Investigational Site Number :7920009, Istanbul, 34688, Turkey|Investigational Site Number :7920007, Istanbul, 34785, Turkey|Investigational Site Number :7920006, Istanbul, 34896, Turkey|Investigational Site Number :7920003, Istanbul, Turkey|Investigational Site Number :7920013, Izmir, 35100, Turkey|Investigational Site Number :7920001, Izmit, 41380, Turkey|Investigational Site Number :7920011, Kütahya, 43100, Turkey|Investigational Site Number :7920012, Mersin, 33070, Turkey|Investigational Site Number :7920008, Trabzon, 61080, Turkey|Investigational Site Number :8040008, Chernivtsi, 58000, Ukraine|Investigational Site Number :8040016, Chernivtsi, 58023, Ukraine|Investigational Site Number :8040003, Dnipro, 49005, Ukraine|Investigational Site Number :8040010, Ivano-Frankivsk, 76018, Ukraine|Investigational Site Number :8040007, Kharkiv, 61068, Ukraine|Investigational Site Number :8040011, Kharkiv, 61103, Ukraine|Investigational Site Number :8040012, Kharkiv, 61103, Ukraine|Investigational Site Number :8040013, Kyiv, 03115, Ukraine|Investigational Site Number :8040005, Lutsk, 43005, Ukraine|Investigational Site Number :8040009, Lviv, 79010, Ukraine|Investigational Site Number :8040004, Lviv, 79013, Ukraine|Investigational Site Number :8040002, Odesa, 65025, Ukraine|Investigational Site Number :8040006, Vinnytsia, 21050, Ukraine|Investigational Site Number :8040014, Zhytomyr, 10002, Ukraine|Investigational Site Number :8260003, Exeter, Devon, EX2 5DW, United Kingdom|Investigational Site Number :8260008, Plymouth, Devon, PL6 8DH, United Kingdom|Investigational Site Number :8260010, Swansea, Neath Port Talbot, SA6 6NL, United Kingdom|Investigational Site Number :8260012, Nottingham, Nottinghamshire, NG7 2UH, United Kingdom|Investigational Site Number :8260013, Oxford, Oxfordshire, OX3 9DZ, United Kingdom|Investigational Site Number :8260009, Bristol, BS10 5NB, United Kingdom|Investigational Site Number :8260001, Cardiff, CF4 4XY, United Kingdom|Investigational Site Number :8260005, London, SW17 0RE, United Kingdom|Investigational Site Number :8260018, London, W6 8RF, United Kingdom|Investigational Site Number :8260014, Newcastle Upon Tyne, NE1 4LP, United Kingdom|Investigational Site Number :8260019, Salford, M6 8HD, United Kingdom"
NCT01864941,Interventional Clinical Trial for CCSVI in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT01864941,COMPLETED,Multiple Sclerosis,PROCEDURE: Catheter venography with balloon venoplasty|DEVICE: Catheter venography with balloon venoplasty and balloon,University of British Columbia,Canadian Institutes of Health Research (CIHR)|Multiple Sclerosis Society of Canada,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,104,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-05,2017-08-01,2017-08-01,"Vancouver Coastal Health - University of British Columbia Hospital, Vancouver, British Columbia, V6T 2B5, Canada|University of Manitoba Health Sciences Centre, Winnipeg, Manitoba, R3A 1R9, Canada|Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, H2L 4M1, Canada|CHU de Québec - Hôpital de l'Enfant-Jésus, Quebec City, Quebec, G1J 1Z4, Canada"
NCT00694941,"A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)",https://beta.clinicaltrials.gov/study/NCT00694941,COMPLETED,Amyotrophic Lateral Sclerosis (ALS),DRUG: ONO-2506PO,Ono Pharmaceutical Co. Ltd,,ALL,"ADULT, OLDER_ADULT",PHASE2,15,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2008-06,2008-12,,"Prof. Maloteaux, UCL Saint-Luc, Brussels, Belgium|Prof. Wim Robberecht, UZ Leuven, Leuven, Belgium|Prof. Alain Destee, Hopital Roger Salengro - Clinique Neurologique, Neurologie A, Lille Cedex, France|Prof. Philippe Couratier, Hopital Duruytren, Limoges Cedex, France|Prof. Jan Pouget, Hopital de la Timone, Marseille, France|Prof. William Camu, Hopital de Chauliac, Montpellier cedex 5, France|Prof. Claude Desnuelle, Hopital 1-Archet 1, Nice cedex 3, France|Prof. Vincent Meininger, Hopital LaPitie Salpetriere, Paris, France|Dr. Thomas Meyer, Charite Campus Virchow, ALS Ambulanz, Berlin, Germany|Prof. Torsten Grehl, Neurologische Ambulanz Universitatsklinik Bergmannsheil, Bochum, Germany|Professor Dieter Heuss, Poliklinik der Universitat Erlangen-Nurnberg, Neurologische Klinik, Erlangen, Germany|Prof. Stephan Zierz, Martin Luther Universitat Halle-Wittenberg, Klinikum der Medizinischen Fakultat, Universitatsklinik und Poliklinik fur Neurologie, Halle, Germany|Prof. Reinhard Dengler, Medizinische Hochschule Hannover, Neurologische Klinik, Hannover, Germany|Prof Gian Domenico Borasio, Interdisziplinares Zentrum fur Palliativmedizin, Munchen, Germany|Prof. Albert Ludolph, Klinik und Poliklinikfur Neurologie der Universitat Ulm-Univeritatsklinikum Ulm, Ulm, Germany|Dr. Berthold Schrank, Deutsche Klinik fur Diagnostik, Fachbereich Neurologie, Wiesbarden, Germany|Prof. Vincenzo Silani, Dipartimento di Neurologia e Laboratorio di Neuroscienze - Universita di Milano - IRCCS - Istituto Auxologico Italiano, Milano, Italy|Dr. Gabriele Mora, Divisione di Neuroriabilitazione II - Fondazione Salvatore Maugeri - IRCCS, Pavia, Italy|Prof. Adriano Chio, Dipartimento di Neuroscienze - Divisione di Neurologia II - Azienda Ospedaliera S. Giovanni Battista - Molinette, Torino, Italy|Prof Marianne de Visser, Academic Medical Centre (AMC) Amsterdam - Dept of Neurology, Amsterdam, Netherlands|Prof. Leonard H Van Den Berg, University Medical Center Utrecht, Utrecht, Netherlands|Dr. Markus Weber, Kantonsspital St. Gallen, Muskelzentrum/ALS Clinic, St. Gallen, Switzerland|Prof. Nigel Leigh, Academic Neuroscience Centre, London, United Kingdom|Prof. Douglas Mitchell, Royal Preston Hospital, Preston, United Kingdom|Dr. Chris McDermott, Royal Hallamshire Hospital, Sheffield, United Kingdom"
NCT04635436,Efficacy of Split Gait in the Treatment of Dynamic Asymmetries in Subjects With Pathologic Claudication,https://beta.clinicaltrials.gov/study/NCT04635436,RECRUITING,Multiple Sclerosis|Poststroke/CVA Hemiparesis|Parkinson Disease|Amputation|Knee Impairment,OTHER: Pathologic group,Istituto Auxologico Italiano,,ALL,"ADULT, OLDER_ADULT",,20,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-02-05,2022-12-31,2022-12-31,"Istituto Auxologico Italiano, Milan, MI, 20121, Italy"
NCT03846336,"Upper Extremity Function, Shoulder Position Sense and Disability Level İn Patients With Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT03846336,COMPLETED,Physical Therapy|Upper Extremity Function|Position Sense,OTHER: Upper extremity function|OTHER: Shoulder position sense,Ankara Yildirim Beyazıt University,,ALL,ADULT,NA,41,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: SCREENING,2018-06-01,2018-07-01,2018-09-01,"Ankara Yıldırım Beyazıt University, Faculty of Health Sciences,Department of Physiotherapy and Rehabilitation, Ankara, Esenboğa, 06970, Turkey"
NCT04879628,Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04879628,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,DRUG: SAR441344 IV|DRUG: placebo IV|DRUG: SAR441344 SC|DRUG: placebo SC|DRUG: MRI contrast-enhancing preparations,Sanofi,,ALL,ADULT,PHASE2,129,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-06-07,2022-09-21,2025-04-03,"Investigational Site Number :8400007, Phoenix, Arizona, 85032, United States|Investigational Site Number :8400001, Tampa, Florida, 33612, United States|Investigational Site Number :8400004, Charlotte, North Carolina, 28204, United States|Investigational Site Number :8400002, Philadelphia, Pennsylvania, 19107, United States|Investigational Site Number :8400003, Milwaukee, Wisconsin, 53215, United States|Investigational Site Number :8400006, Milwaukee, Wisconsin, 53226, United States|Investigational Site Number :1000002, Pleven, 5800, Bulgaria|Investigational Site Number :1000003, Sofia, 1113, Bulgaria|Investigational Site Number :1000001, Sofia, 1407, Bulgaria|Investigational Site Number :1240001, Gatineau, Quebec, J8Y 1W2, Canada|Investigational Site Number :2030003, Brno, 65691, Czechia|Investigational Site Number :2030002, Hradec Kralove, 50005, Czechia|Investigational Site Number :2030001, Jihlava, 58633, Czechia|Investigational Site Number :2030005, Ostrava - Poruba, 70852, Czechia|Investigational Site Number :2030004, Teplice, 415 29, Czechia|Investigational Site Number :2500007, Ars-Laquenexy, 57085, France|Investigational Site Number :2500003, Caen, 14033, France|Investigational Site Number :2500006, Calais, 62107, France|Investigational Site Number :2500002, Dijon, 21079, France|Investigational Site Number :2500004, Marseille, 13003, France|Investigational Site Number :2760003, Dresden, 01307, Germany|Investigational Site Number :2760001, Gießen, 35385, Germany|Investigational Site Number :2760012, Leipzig, 04103, Germany|Investigational Site Number :2760004, Münster, 48149, Germany|Investigational Site Number :2760011, Sande, 26452, Germany|Investigational Site Number :2760005, Würzburg, 97070, Germany|Investigational Site Number :6430002, Kazan, 420021, Russian Federation|Investigational Site Number :6430007, Moscow, 117556, Russian Federation|Investigational Site Number :6430006, Moscow, 117997, Russian Federation|Investigational Site Number :6430001, Moscow, 127015, Russian Federation|Investigational Site Number :6430004, Saint-Petersburg, 197110, Russian Federation|Investigational Site Number :6430003, St-Petersburg, 194044, Russian Federation|Investigational Site Number :6430005, St-Petersburg, 197022, Russian Federation|Investigational Site Number :6430008, Tyumen, 625000, Russian Federation|Investigational Site Number :7240004, Barcelona, Barcelona [Barcelona], 08035, Spain|Investigational Site Number :7240003, Pamplona, Navarra, 31008, Spain|Investigational Site Number :7240002, Vigo, Pontevedra [Pontevedra], 36312, Spain|Investigational Site Number :7920004, Eskisehir, Turkey|Investigational Site Number :7920003, Istanbul, Turkey|Investigational Site Number :7920001, Izmit, 41380, Turkey|Investigational Site Number :7920002, Mersin, 33070, Turkey|Investigational Site Number :8040006, Dnipro, 49005, Ukraine|Investigational Site Number :8040010, Dnipro, 49069, Ukraine|Investigational Site Number :8040008, Ivano-Frankivsk, 76493, Ukraine|Investigational Site Number :8040002, Kharkiv, 61103, Ukraine|Investigational Site Number :8040004, Lviv, 79013, Ukraine|Investigational Site Number :8040003, Odesa, 65025, Ukraine|Investigational Site Number :8040005, Vinnytsia, 21050, Ukraine"
NCT02275741,Study to Investigate the Immune Response and Safety of Prophylactic Vaccines in Patients Treated for Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02275741,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting","BIOLOGICAL: prophylactic vaccine (tetanus, diphtheria, pertussis, poliomyelitis, influenza, hepatitis A, hepatitis B, tick-borne encephalitis, meningococcal, pneumococcal)",Dr. med. Micha Loebermann,,ALL,"ADULT, OLDER_ADULT",,226,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2009-10,2015-09,2016-11,"University of Rostock, Rostock, 18057, Germany"
NCT01679041,High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior Treatment,https://beta.clinicaltrials.gov/study/NCT01679041,TERMINATED,Multiple Sclerosis,DRUG: Alemtuzumab|DRUG: Fludarabine|DRUG: Cyclophosphamide,Seah Lim M.D.,,ALL,ADULT,PHASE2,1,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2012-11,2013-11,2013-11,"Amarillo Diagnostic Clinic, Amarillo, Texas, 79106, United States|Dr Ruby Saulog, Amarillo, Texas, 79106, United States|Texas Oncology, Amarillo, Texas, 79106, United States"
NCT04604041,Biomarkers in Relapsing-Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04604041,RECRUITING,Multiple Sclerosis|Relapsing Remitting Multiple Sclerosis,"DIAGNOSTIC_TEST: 1. Clinical testing; 2. Neurophysiological examination (TMS, EMNG); 3. Psychomotor examination; 4. Neuropsychological evaluation; 5. Flow cytometry; 6. ELISA","University of Split, School of Medicine",University Hospital of Split,ALL,"ADULT, OLDER_ADULT",,50,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-11-23,2023-02,2024-02,"University of Split School of Medicine, Split, 21000, Croatia"
NCT05767736,A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT05767736,NOT_YET_RECRUITING,Multiple Sclerosis,DRUG: Diroximel Fumarate|DRUG: Dimethyl Fumarate|DRUG: Disease-Modifying Therapies (DMTs),Biogen,,ALL,"ADULT, OLDER_ADULT",,10500,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-06-04,2028-02-02,2028-02-02,
NCT00340834,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase,https://beta.clinicaltrials.gov/study/NCT00340834,COMPLETED,Multiple Sclerosis,DRUG: Fingolimod 1.25 mg|DRUG: Fingolimod 0.5 mg|DRUG: Interferon β-1a 30 µg,Novartis,,ALL,ADULT,PHASE3,1292,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2006-05,2011-07,2011-07,"North Central Neurology Associates, PC, 1809 Kress Street, Cullman, Alabama, 35058, United States|Barrow Neurological Institute, Phoenix, Arizona, 85013, United States|The Neurology Center, 3907 Waring Road, Suite 3, Oceanside, California, 92056, United States|Associated Neurologists, PC, 69 Sand Pit Road, Suite 300, Danbury, Connecticut, 06810, United States|Associated Neurologists of Southern CT, PC, 75 Kings Highway Cutoff, Fairfield, Connecticut, 06824, United States|Yale University Multiple Sclerosis Center, New Haven, Connecticut, 06510, United States|University of Florida Health Science Center, Jacksonville, Florida, 32209, United States|Neurology Associates, PA, 301 N. Maitland Avenue, Suite A1, Maitland, Florida, 32751, United States|University of Miami, Department of Neurology, Miami, Florida, 33136, United States|Neurological Associates, Pompano Beach, Florida, 33060, United States|Roskamp Institute, 2040 Whitfield Ave., Sarasota, Florida, 34243, United States|AMO Corporation, Tallahassee, Florida, 32308, United States|Axiom Clinical Research of Florida, 2919 Swann Avenue, Suite 401, Tampa, Florida, 33609, United States|University of South Florida, Department of Neurology, Tampa, Florida, 33612, United States|The MS Center of Vero Beach, Vero Beach, Florida, 32960, United States|University of Kansas Medical Center, Kansas City, Kansas, 66160, United States|Mid America Neuroscience Institute, 8550 Marshall Drive, Suite 100, Lenexa, Kansas, 66214, United States|University Physician Group, #1 Barnes-Jewish Hospital Plaza, Suite 16304, Saint Louis, Missouri, 63110, United States|Neuroscience and Spine Center, Charlotte, North Carolina, 28207, United States|Raleigh Neurology Associates, 1540 Sunday Drive, Raleigh, North Carolina, 27607, United States|Neurology & Neuroscience Associates, Inc, Akron, Ohio, 44302, United States|Northern Ohio Neuroscience, LLC, Bellevue, Ohio, 44811, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|Oregon Neurology, Tualatin, Oregon, 97062, United States|University of Pittsburgh, Department of Neurology, Pittsburgh, Pennsylvania, 15213, United States|Absher Neurology, 274-A Commonwealth Drive, Greenville, South Carolina, 29615, United States|Mountain Empire Neurological Associates, PC, 3183 West State Street, Suite 1201, Bristol, Tennessee, 37620, United States|Advanced Neurosciences Institute, Franklin, Tennessee, 37064, United States|Baylor College of Medicine, Houston, Texas, 77030, United States|Private Practice, 3815 23rd Street, Lubbock, Texas, 79410, United States|Integra Clinical Research, 4242 Medical Drive, Suite 6100, San Antonio, Texas, 78229, United States|Swedish Neuroscience Institute, Seattle, Washington, 98122, United States|Rockwood Clinic, P.S., Spokane, Washington, 99202, United States|West Virginia University Health Associates, Morgantown, West Virginia, 26506, United States|Center for Neurological Disorders - Aurora St. Luke's Med Center, Milwaukee, Wisconsin, 53215, United States|Ineba, Guarda Vieja 4435, Capital Federal, Buenos Aires, 1428, Argentina|Fundacion Rosarina de Neurorehabilitacion, Rosario, Santa Fe, 2000, Argentina|Instituto de Neurociencias de Rosario, Rosario, Santa Fe, 2000, Argentina|Hospital Italiano de Buenos Aires, Buenos Aires, C118ACK, Argentina|Fundacion Lenox Cordoba, Cordoba, 5000, Argentina|Hospital J. M. Ramos Mejia, General Urquiza 609, Buenos Aires, C1221ADC, Argentina|FLENI, Montaneses 2325, Buenos Aires, C1428AQK, Argentina|Strategic Health Evaluators, Chatswood, New South Wales, 2067, Australia|Royal Prince Alfred Hospital, Department of Medicine, Level, Missenden R, Camperdown, New South Wales, 2050, Australia|Liverpool Hospital, Neurology Department, Health Services Building, 4th Floor, Goulburn and Campbell Street, Liverpool, New South Wales, 2170, Australia|Gosford Private Hospital, North Gosford, New South Wales, 2250, Australia|St George Private Hospital, Suite 7E, Level 5, South Street, Kogarah, New South Wales, 2217, Australia|Box Hill Hopsital, Level 3, 16 Arnold Street, Box Hill, Victoria, 3128, Australia|Royal Melbourne Hospital, Suite 30, Grattan St., Parkbville, Victoria, 3050, Australia|Landesklinikum St. Poelten, Probst-Ruehrer-Str. 4, St. Poelten, Sankt Poelten, 3100, Austria|Landes-Narvenklinik Wagner-Jauregg, Abteilung fuer Neurologie, Linz, A-4020, Austria|Universitätsklinik f. Neurologie Innsbruck, Anichstrasse 35, Innsbruck, 6020, Austria|Landes-Nervenklinik Christian Doppler Klinik, Ignaz Harrerstr. 79 , Salzburg, A-5020, Austria|Evangel.Krankenh./Wien-Waehring Außenstelle, Vienna, 1010, Austria|Univ.-Klinik fuer Neurologie AKH, Vienna, 1090, Austria|Cliniques Universitaires Saint Luc, Avenue Hippocrate 10, Bruxelles, 1200, Belgium|UZ Brussel, Laarbeeklaan 101, Brussels, 1090, Belgium|Nationaal Multiple Sclerose Centrum v.z.w, Melsbroek, 1820, Belgium|Regionaal Ziekenhuis Sint-Trudo - Campus Sint-Jozef, Sint-Truiden, 3800, Belgium|Hospital Sao Rafael, Salvador, BA, 41256 900, Brazil|Hospital das Clincas - UNICAMP, Campinas, SP, 13083-970, Brazil|Hospital das Clinicas da FMRPUSP, Ribeirao Preto, SP, 48000-900, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, RS 90020-090, Brazil|Hospital dos Servidores do Estado, Rio de Janeiro, RJ 20221-903, Brazil|Hospital Universitario Gaffree e Guinle, Rio de Janeiro, RJ 20270-004, Brazil|Fraser Health MS Clinic, Burnaby Hospital, 3935 Kincaid Street, Vancouver, British Columbia, V56 2X6, Canada|UBC MS Research, 2211 Westbrook Mall, Vancouver, British Columbia, V6T 2B5, Canada|Nepean Medical Centre, 1 Centrepointe Drive, Suite 407, Ottawa, Ontario, K2G 6E2, Canada|St. Michael's Hospital, Chief, Division of Neurology, 30 Bond Street,Suite 3007 - Shuter Wing, Toronto, Ontario, M5B 1W8, Canada|Centre Hospitalier Universitaire de Sherbrooke, 3001 12th Avenue North, Fleurimont, Quebec, J1H 5N4, Canada|Charles Lemoyne Hospital, Greenfield Park, Quebec, J4V 2H1, Canada|CHUM - Hopital Notre-Dame, Montreal, Quebec, H2L 4M1, Canada|Montreal Neurological Institute, 3801 University Street, Montreal, Quebec, H3A 2B4, Canada|The Ottawa General Hospital, 501 Smyth Rd., Ottawa, K1H 8L6, Canada|Private Clinic, 48 Sidi Gaber St., Alexandria, Egypt|35, Dokki St., Apt. 4, Cairo, Egypt|Al Azhar University, 11 Talaat Harb St, Fourth Floor, Apt 18, Cairo, Egypt|Private Clinic, 35 Dokki St., Apt. 4, Cairo, Egypt|Private Clinic, 7 Batal Ahmed Abdelaziz St Abdeen, Cairo, Egypt|Hopital La Timone Cpcet, Rue Jean Moulin, Marseille, 13385, France|Hopital Central, 29 Avenue du Marechal de Lattre de Tassigny, Nancy, 54035, France|Hôpital Pellegrin, Place Amélie Raba Léon, Bordeaux Cedex, 33076, France|Hopital De Purpan, Place du Dr. Baylac, Toulouse Cedex, 31059, France|Centre Hospitalier de Poissy, 10 rue du Champ Gaillard, Poissy, 78303, France|Hoppital Pasteur, Archet II, 30 avenue de la Voie, Romaine, 06602, France|Investigational Site, Bamberg, 96049, Germany|Investigational Site, Berlin, 10713, Germany|Investigational Site, Berlin, 13439, Germany|Investigational Site, Bremen, 28177, Germany|Investigational Site, Buchholz, 21244, Germany|Investigational Site, Dresden, 01307, Germany|Investigational Site, Dusseldorf, 40225, Germany|Investigational Site, Erbach/Odenwald, 64711, Germany|Investigational Site, Essen, 45122, Germany|Investigational Site, Freiburg, 79106, Germany|Investigational Site, Greifswald, 17475, Germany|Investigational Site, Hamburg, 66421, Germany|Investigational Site, Hannover, 30623, Germany|Investigational Site, Heidelberg, 69120, Germany|Investigational Site, Hennigsdorf, 16761, Germany|Investigational Site, Koeln, 51109, Germany|Investigational Site, Lengerich, 49525, Germany|Investigational Site, Mainz, 55131, Germany|Investigational Site, Muenchen, 80331, Germany|Investigational Site, Munchen, 81675, Germany|Investigational Site, Potsdam, 14471, Germany|Investigational Site, Teupitz, 15755, Germany|Investigational Site, Trier, 54292, Germany|Investigational Site, Tubingen, 72076, Germany|Investigational Site, Ulm, 89073, Germany|Investigational Site, Ulm, 89075, Germany|Investigational Site, Wermsdorf, 04779, Germany|Investigational Site, Wurzburg, 97070, Germany|Univ. Hospital of Heraklion, Voutes, Heraklion, Crete, GR 71001, Greece|Errikos Dinan General Hospital, 107 Mesogion Ave., Athens, 11526, Greece|General Hospital of Athens G. Gennimatas, 154 Mesogeion Ave., Athens, G-156 69, Greece|Metropolitan Hospital, Ethnarchou Makariou 6 & Eleftheriou Venizelou 1, Athens, GR 18547, Greece|General University Hospital of Patra-RIO, Patra - RIO, GR- 26500, Greece|Ahepa University General Hospital of Thessaloniki, 1 Stilp. Kyriakidi Str., Thessaloniki, GR 54636, Greece|Debreceni Egyetem Orvos es Egszstd. Centr., Debrecen, 4012, Hungary|Petz Aladár Megyei Oktató Kórház, Györ, 9024, Hungary|Veszprem Megyei Csolnoky Ferenc Korhaz, Korhaz u. 1, Veszprem, H-8200, Hungary|Pecsi Tudomanyegyetem Neurologiai Klinika, Pecs, 7623, Hungary|Peterfy Sandor u. Hospital, Neurology, u. 8-20m, Budapest, 1076, Hungary|Uzsoki korhaz, Uzsoki u. 29., Budapest, 1145, Hungary|Azienda Sanitaria Osp. S. Luigi, Gonzaga, Orbassano, TO 10043, Italy|Ospedale S. Antonio Abate, via Pastori, 4, Gallarate, VA, 21013, Italy|Presidio Ospedaliero Roberto Binaghi, Cagliari, CA 09126, Italy|Azienda Ospedaliera Universitaria Arcispedale Sant'Anna, Ferrara, FE 44100, Italy|Presidio Ospedaliero di Vaio Fidenza, Fidenza, PR 43036, Italy|Osp. Magg. Pol. Mangiagalli e Regina Elena - Fond. IRCCS, Milano, MI 20122, Italy|Az. Osp. Niguarda Ca' Granda, Milano, MI 20162, Italy|Presidio Ospedaliero di Montichiari, Montichiari, BS 25018, Italy|IRCCS Neurologico C. Mondino, Pavia, PV 27100, Italy|Az. Osp. Ospedale Consorziale e Policlinico, piazza Giulio Cesare, 11 Bari, 70124, Italy|Az. Osp. Ospedale S. Martino - Università degli Studi, via Antonio De Toni, 5, Genova, 16132, Italy|Ist. Neurol. Mediterraneo Neuromed, Via Atinense, 18, Pozzilli, 86077, Italy|Ospedali Riuniti Umberto I - GM Lancisi - G.Salesi, via Conca, 71, Torrette di Ancona, 60020, Italy|Osp. Clinicizzato Colle dell'Ara - Università G. D'Annunzio, via dei Vestini, 5 Chieti, 66100, Italy|Azienda Ospedaliera Sant'Andrea - Università La Sapienza, Via di Grottarossa, 1035/1039, Roma, 00189, Italy|Azienda Ospedaliera di Padova - Università degli Studi, Via Giustiniani, 2, Padova, 35128, Italy|Az. Osp. Universitaria Policlinico Tor Vergata, via Montpellier, 1, Roma, 00133, Italy|Ospedale San Raffaele - IRCCS, via Olgettina, 48/60, Milano, 20132, Italy|Policlinico - Università degli Studi Federico II, via Pansini, 5, Napoli, 80131, Italy|Istituto di Scienze Neurologiche Università di Catania, via Santa Sofia, 78, Catania, 95123, Italy|Ospedale Bellaria Maggiore, via Toscana Nazionale, 17/19, Bologna, 40139, Italy|Azienda Ospedaliera Careggi - Università degli Studi, Viale Giovan Battista Morgagni, 85, Firenze, 50134, Italy|National Cancer Center, 809 Madu 1-dong, Ilsan-gu, Kyunggi, Goyang, 411-764, Korea, Republic of|Samsung Medical Center, Seoul, Korea, 135-710, Korea, Republic of|Yonsei Univ. Med. Center,Severance Hospital, 134 Shinchon-dong, Suedaemoon-ku, Seoul, 135-230, Korea, Republic of|Kyung Pook National University Hospital, Taegu, 700-721, Korea, Republic of|Hospital Fernando Fonseca, Amadora, 2720-276, Portugal|Hospitais da Universidade de Coimbra, Av. Dr. Bissaya Barreto, Coimbra, 3000-075, Portugal|Hospital Sto. António dos, Capuchos, Portugal|Hospital de São João, Porto, 4200-319, Portugal|Hospital de S. Bernardo, Rua Camilo Castelo Branco, Setubal, 2910-446, Portugal|Complejo Hospitalario Carlos Haya, Avda. Carlos Haya, s/n, Málaga, 29010, Spain|Hospital Universitario Virgen Macarena, Avenida Dr. Fedriani, 3, Sevilla, 41009, Spain|Ciutat Sanitaria I, Universitaria De Bellvitge, c/o Feixa Llarga, Hospitalet de Llobregat, Barcelona, 08907, Spain|Hospital de Basurto, Bilbao, 48013, Spain|Hospital Clinico San Carlos, C/ Dr. Martin Lagos, s/n, Madrid, 28040, Spain|Unitat de Neuroimmunologia Clinica, Hospital Vall d'Hebron, EUI-planta 2, Pg. Vall d'Hebron 119-29, Barcelona, 08035, Spain|Puerta de Huerro Univeristy Hospital, San Martin de Porres, 4, Madrid, 28035, Spain|Hospital Universitario La Fe., Valencia, 46009, Spain|Universitätsspital Zuerich, Neurologische Klinik, Frauenklinikstrasse 26, Zuerich, 8091, Switzerland|Universitätsspital Basel, Neurochirugishen Poliklinik, Petersgraben 4, Basel, 4031, Switzerland|Novartis, Investigational Site, United Kingdom|Charing Cross Hospital, London, W8 6RF, United Kingdom|The Walton Centre for Neurology and Neurosurgery, Lower Lane, Fazakerly, Liverpool, L9 7LJ, United Kingdom|Norfolk & Norwich University Hospital, Norwick, NR4 7UY, United Kingdom"
NCT04145934,A Randomized Controlled Trial of a Multicomponent Walking Aid Program for People With MS,https://beta.clinicaltrials.gov/study/NCT04145934,COMPLETED,Multiple Sclerosis,BEHAVIORAL: ADSTEP,Oregon Health and Science University,Portland VA Medical Center,ALL,"ADULT, OLDER_ADULT",NA,78,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2020-02-06,2023-01-26,2023-01-26,"Oregon Health and Science University, Portland, Oregon, 97239, United States"
NCT05783934,Demyelination and Remyelination in Multiple Sclerosis (MS) Detected by Brain Amyloid PET-CT,https://beta.clinicaltrials.gov/study/NCT05783934,RECRUITING,Multiple Sclerosis,DIAGNOSTIC_TEST: 18F-florbetaben PET/CT,Istituti Clinici Scientifici Maugeri SpA,,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2021-07-27,2024-12,2024-12,"ICS Maugeri SpA SB IRCCS, Pavia, PV, 27100, Italy"
NCT00220428,T-Cell Vaccination in Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT00220428,UNKNOWN,Multiple Sclerosis,BIOLOGICAL: T-Cell Vaccination,Sheba Medical Center,,ALL,"CHILD, ADULT",PHASE1|PHASE2,20,OTHER_GOV,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: ECT,1998-07,,2007-12,"Multiple Sclerosis Center, Ramat Gan, Israel"
NCT04466228,Non-invasive Transcranial Electrical Stimulation in MS,https://beta.clinicaltrials.gov/study/NCT04466228,COMPLETED,Multiple Sclerosis|Cognitive Impairment,DEVICE: non-invasive transcranial electrical stimulation,"University of California, San Francisco",,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-10-16,2022-08-23,2022-08-23,"UCSF Sandler Neurosciences Center, San Francisco, California, 94158, United States"
NCT04578041,TRPMS to Improve Mobility and Depression in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04578041,NOT_YET_RECRUITING,Multiple Sclerosis,DEVICE: TRPMS (Transcranial Rotating Permanent Magnet Stimulation)|OTHER: Aerobic Exercise Program|OTHER: Computerized CT (Cognitive Training),NYU Langone Health,,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-01-01,2024-10-31,2024-10-31,
NCT02641041,"Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants",https://beta.clinicaltrials.gov/study/NCT02641041,COMPLETED,Central Nervous System (CNS) Demyelinating Disease|Multiple Sclerosis,BIOLOGICAL: BIIB033|OTHER: Placebo,Biogen,,ALL,ADULT,PHASE1,24,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2016-02,2016-09,2016-09,"Research Site, Leeds, West Yorkshire, LS2 9LH, United Kingdom"
NCT01805336,Assessment of Attentional and Executive Disorders in Multiple Sclerosis Using Techniques of Virtual Reality,https://beta.clinicaltrials.gov/study/NCT01805336,COMPLETED,Relapsing-Remitting Multiple Sclerosis,"OTHER: Assessment of attentional functions by traditional tests|OTHER: Assessment of attentional functions by virtual reality tests|OTHER: Assessment of executive functions by traditional tests|OTHER: Assessment of executive functions by virtual reality test|OTHER: Evaluation of cognitive complaint, fatigue, anxiety and depression","University Hospital, Caen",,ALL,ADULT,NA,60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: OTHER,2013-03-28,2020-07-09,2020-07-09,"Department of Neurologie, Caen Hospital University, Caen, Basse-Normandie, 14033, France|Inserm Unit 1075 Comete, Caen Hospital University, Caen, Basse-Normandie, 14033, France"
NCT03525834,Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.,https://beta.clinicaltrials.gov/study/NCT03525834,COMPLETED,Renal Angiomyolipoma,DRUG: Everolimus,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE4,40,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-11-09,2020-09-25,2020-09-25,"Novartis Investigative Site, Wuhan, Hubei, 430030, China|Novartis Investigative Site, Shanghai, Shanghai, 200032, China|Novartis Investigative Site, Chengdu, Sichuan, 610041, China|Novartis Investigative Site, Beijing, 100028, China|Novartis Investigative Site, Beijing, 100730, China"
NCT01776034,Health Promotion and Wellness Program for Adults With Disabling Conditions,https://beta.clinicaltrials.gov/study/NCT01776034,COMPLETED,Stroke|Multiple Sclerosis|Rheumatoid Arthritis,BEHAVIORAL: SystemCHANGE Group Lifestyle counseling|BEHAVIORAL: Phone Lifestyle Counseling,Case Western Reserve University,American Heart Association|National Institutes of Health (NIH),ALL,"ADULT, OLDER_ADULT",NA,66,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2013-01,2016-12,2016-12,"Case Western Reserve University, Cleveland, Ohio, 44106, United States"
NCT04387734,Effects of Ocrevus in Relapsing Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04387734,RECRUITING,Relapsing Multiple Sclerosis,DRUG: Ocrelizumab|DRUG: Platform,Georgia State University,Multiple Sclerosis Center of Atlanta,ALL,"ADULT, OLDER_ADULT",PHASE4,60,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-02-05,2023-09,2025-09,"Georgia State University, Atlanta, Georgia, 30303, United States|Multiple Sclerosis Center of Atlanta, Atlanta, Georgia, 30327, United States"
NCT02474134,Comparison Study of PF530 and Betaferon in Healthy Subjects,https://beta.clinicaltrials.gov/study/NCT02474134,COMPLETED,Multiple Sclerosis,"DRUG: Interferon beta-1b (PF530, Betaferon)","Pfenex, Inc",,ALL,ADULT,PHASE1,12,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2015-03,2015-10,2015-10,"CMAX, Adelaide, South Australia, 5000, Australia"
NCT01117090,Measuring Signatures in the Fluid Surrounding the Spinal Cord in Patients Who Have Problems With Intrathecal Drug Delivery,https://beta.clinicaltrials.gov/study/NCT01117090,COMPLETED,Cerebral Palsy|Multiple Sclerosis|Traumatic Brain Injury|Spinal Cord Injury,,MedtronicNeuro,,ALL,"CHILD, ADULT, OLDER_ADULT",,47,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-06,2012-09,2012-12,"Goodman Campbell Brain and Spine, Indianapolis, Indiana, 46202, United States|Moss Rehab, Philadelphia, Pennsylvania, 19027, United States"
NCT02290990,"Efficacy Study of ""Imaginative Distention"", a Self Managed Tool to Cope With Fatigue,Insomnia and Stress in pw Insomnia and pw MS",https://beta.clinicaltrials.gov/study/NCT02290990,COMPLETED,Multiple Sclerosis,"BEHAVIORAL: ""Imaginative Distention"" technique",Niguarda Hospital,,ALL,"ADULT, OLDER_ADULT",NA,144,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2014-09,2015-10,2016-12,"Azienda ospedaliera Ospedale Niguarda Ca' Granda, Milano, 20162, Italy"
NCT00676156,A Study of the Pharmacokinetics and Immunologic Effects of Lipoic Acid in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00676156,COMPLETED,Multiple Sclerosis,DRUG: oral lipoic acid (LA)|DRUG: lipoic acid (LA) with fish oil and LA without fish oil|DRUG: R lipoic acid,Oregon Health and Science University,National Center for Complementary and Integrative Health (NCCIH),ALL,"ADULT, OLDER_ADULT",PHASE1,40,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2005-12,2008-02,2008-11,"Oregon Health and Science University Multiple Sclerosis Dept., Portland, Oregon, 97239, United States"
NCT03668990,"Feasability, Validty and Reliability of Inertial Sensors",https://beta.clinicaltrials.gov/study/NCT03668990,COMPLETED,Multiple Sclerosis|CVA,"OTHER: IMUs (Xsens, MVN Studio)",Hasselt University,Revalidatie & MS Centrum Overpelt|Jessa Hospital,ALL,"ADULT, OLDER_ADULT",NA,18,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2017-10-01,2018-05-31,2018-05-31,"Jessa Ziekenhuis, Hasselt, B-3500, Belgium|Revalidatie & MS Centrum Overpelt, Overpelt, 3900, Belgium"
NCT02061397,Safety of Simvastatin in LAM and TSC,https://beta.clinicaltrials.gov/study/NCT02061397,COMPLETED,Lymphangioleiomyomatosis|Tuberous Sclerosis Complex,DRUG: Simvastatin|DRUG: Sirolimus Oral Product|DRUG: Everolimus Oral Product,University of Pennsylvania,The LAM Foundation,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,10,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-03,2019-12-13,2019-12-13,"University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States"
NCT05658497,Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate),https://beta.clinicaltrials.gov/study/NCT05658497,NOT_YET_RECRUITING,Multiple Sclerosis,DRUG: Diroximel Fumarate|DRUG: Avonex|BIOLOGICAL: Tysabri|DRUG: Dimethyl Fumarate,Biogen,,FEMALE,"CHILD, ADULT, OLDER_ADULT",,454,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-07-30,2032-07-06,2032-07-06,
NCT02408367,Intensity Depended Impacts on Cognitive Functions in Persons With Multiple Sclerosis - a Pilot Study,https://beta.clinicaltrials.gov/study/NCT02408367,UNKNOWN,Multiple Sclerosis,BEHAVIORAL: Exercise|BEHAVIORAL: Relaxation,Jens Bansi,,ALL,"ADULT, OLDER_ADULT",,20,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-02,2015-05,2015-05,"Kliniken-Valens, Valens, Sankt Gallen, 7317, Switzerland"
NCT01499667,Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod,https://beta.clinicaltrials.gov/study/NCT01499667,TERMINATED,Relapsing Remitting Multiple Sclerosis (RRMS),DRUG: Fingolimod|DRUG: Placebo,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,142,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-09,2012-11,2012-11,"Novartis Investigative Site, Box Hill, Victoria, 3128, Australia|Novartis Investigative Site, Heidelberg, Victoria, 3084, Australia|Novartis Investigative Site, Vienna, 1010, Austria|Novartis Investigative Site, Prague 5, 150 00, Czech Republic|Novartis Investigative Site, Praha 2, 128 08, Czech Republic|Novartis Investigative Site, Teplice, 415 29, Czech Republic|Novartis Investigative Site, Helsinki, 00100, Finland|Novartis Investigative Site, Ostfildern, Baden-Wuerttemberg, 73760, Germany|Novartis Investigative Site, Bad Mergentheim, 97980, Germany|Novartis Investigative Site, Berlin, 10713, Germany|Novartis Investigative Site, Berlin, 12163, Germany|Novartis Investigative Site, Bielefeld, 33647, Germany|Novartis Investigative Site, Bochum, 44791, Germany|Novartis Investigative Site, Celle, 29223, Germany|Novartis Investigative Site, Erbach, 64711, Germany|Novartis Investigative Site, Erfurt, 99089, Germany|Novartis Investigative Site, Hamburg, 22083, Germany|Novartis Investigative Site, Itzehoe, 25524, Germany|Novartis Investigative Site, Kandel, 76870, Germany|Novartis Investigative Site, Krefeld, 47805, Germany|Novartis Investigative Site, Leipzig, 04275, Germany|Novartis Investigative Site, Münster, 48149, Germany|Novartis Investigative Site, Neuburg, 86633, Germany|Novartis Investigative Site, Neuruppin, 16816, Germany|Novartis Investigative Site, Rüdersdorf, 15562, Germany|Novartis Investigative Site, Siegen, 57076, Germany|Novartis Investigative Site, Ulm, 89073, Germany|Novartis Investigative Site, Athens, GR, 115 25, Greece|Novartis Investigative Site, Ioannina, GR, 455 00, Greece|Novartis Investigative Site, Thessaloniki, GR, 570 10, Greece|Novartis Investigative Site, Athens, GR 151 25, Greece|Novartis Investigative Site, Athens, GR-106 76, Greece|Novartis Investigative Site, Budapest, 1074, Hungary|Novartis Investigative Site, Budapest, 1085, Hungary|Novartis Investigative Site, Ashkelon, 78278, Israel|Novartis Investigative Site, Jerusalem, 91120, Israel|Novartis Investigative Site, Milano, MI, 20132, Italy|Novartis Investigative Site, Cefalù, PA, 90015, Italy|Novartis Investigative Site, Málaga, Andalucia, 29010, Spain|Novartis Investigative Site, Sevilla, Andalucia, 41009, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08035, Spain|Novartis Investigative Site, Barcelona, 08025, Spain|Novartis Investigative Site, Madrid, 28046, Spain|Novartis Investigative Site, Basel, 4031, Switzerland"
NCT04874597,Investigation of the Effect of Ocrelizumab on Peripheral Lymphocyte Immunophenotypes With Suppressive Capacity in MS,https://beta.clinicaltrials.gov/study/NCT04874597,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,DRUG: Ocrelizumab,Dr Recai Turkoglu,Health Sciences University Istanbul Haydarpaşa Numune Training and Research Hospital,ALL,"ADULT, OLDER_ADULT",,30,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-11-15,2023-11,2023-11,"Health Sciences University Istanbul Haydarpaşa Numune Training and Research Hospital, Neurology Department, Istanbul, Uskudar, 34668, Turkey"
NCT04633967,Observational Study of a Novel Peri Infusion Regimen on the Infusion Associated Reactions With Alemtuzumab Infusion in Patients With Multiple Sclerosis in a Canadian Clinical Setting.,https://beta.clinicaltrials.gov/study/NCT04633967,UNKNOWN,Frequency of Infusion Reactions in Novel Versus Standard Protocol in Multiple Sclerosis,DRUG: Alemtuzumab Injection,Maritime Neurology,,ALL,"ADULT, OLDER_ADULT",,30,NETWORK,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-05-15,2020-12-30,2021-02-28,"Maritime Neurology, Halifax, Nova Scotia, B3R1V9, Canada"
NCT04815967,Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity,https://beta.clinicaltrials.gov/study/NCT04815967,ACTIVE_NOT_RECRUITING,Spasticity|Cerebrovascular Accident|Multiple Sclerosis|Traumatic Brain Injury|Cervical Spinal Cord Injury|Cerebral Palsy,DRUG: Phase 2; Low Dose MYOBLOC|DRUG: Phase 2; High Dose MYOBLOC|DRUG: Phase 2; Placebo|DRUG: Phase 3; MYOBLOC|DRUG: Phase 3; Placebo,"Supernus Pharmaceuticals, Inc.",Solstice Neurosciences,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,272,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-11-16,2023-07-01,2024-07-01,"Rancho Research Institute, Downey, California, 90242, United States|New England Institute for Clinical Research, Stamford, Connecticut, 06905, United States|Nova Clinical Research, LLC, Bradenton, Florida, 34209, United States|Idaho Physical Medicine and Rehabilitation, Boise, Idaho, 83706, United States|Coastal Neurology, Port Royal, South Carolina, 29935, United States|Vanderbilt University Medical Center, Nashville, Tennessee, 37232, United States|University of Texas Southwestern Medical Center, Dallas, Texas, 75390, United States|Fakultní nemocnice Brno, Neurologická klinika FN Brno (University Hospital Brno, Department of Neurology), Brno, Czechia|Centrum pro intervenční terapii motorických poruch, Neurologická klinika, Univerzita Karlova Katerinska, Prague, Czechia"
NCT00445367,Biobank For MS And Other Demyelinating Diseases,https://beta.clinicaltrials.gov/study/NCT00445367,ACTIVE_NOT_RECRUITING,Multiple Sclerosis|Transverse Myelitis|Neuromyelitis Optica|Acute Disseminated Encephalomyelitis|Optic Neuritis,,Accelerated Cure Project for Multiple Sclerosis,,ALL,"CHILD, ADULT, OLDER_ADULT",,3226,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2006-05,2026-10,2036-10,"Barrow Neurological Institute, Phoenix, Arizona, 85013, United States|Stanford University, Stanford, California, 94305, United States|The Rocky Mountain MS Center at Anschutz Medical Campus at UC Denver, Aurora, Colorado, 80045, United States|Shepherd Center, Atlanta, Georgia, 30309, United States|Johns Hopkins, Baltimore, Maryland, 21287, United States|Beth Israel Deaconess, Boston, Massachusetts, 02215, United States|University of Massachusetts Medical School, Worcester, Massachusetts, 01605, United States|Multiple Sclerosis Research Center of New York, New York, New York, 10019, United States|The Ohio State University, Columbus, Ohio, 43210, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, 76051, United States"
NCT05438147,Effects of a CT-100 DiNaMo Component on Cognitive Functioning and Mood Symptoms,https://beta.clinicaltrials.gov/study/NCT05438147,COMPLETED,Multiple Sclerosis|Mild Cognitive Impairment|Cancer,OTHER: CT-100 DiNaMo|OTHER: Care-as-Usual,"Click Therapeutics, Inc.",,ALL,"ADULT, OLDER_ADULT",NA,114,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2022-05-13,2022-09-06,2022-09-06,"Click Therapeutics, New York, New York, 10013, United States"
NCT01964547,A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT01964547,COMPLETED,Multiple Sclerosis|Spasticity,DRUG: Sativex|DRUG: Placebo,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE4,121,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-01,2013-05,2013-05,"MS Centre, Charles University, Prague, 128 08, Czechia"
NCT03796247,Alexithymia Frequency and Interhemispheric Transfer in Patients With a First Demyelinating Event,https://beta.clinicaltrials.gov/study/NCT03796247,COMPLETED,Multiple Sclerosis,,"University Hospital, Lille",,ALL,ADULT,,57,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-05-02,2016-05,2016-05,"Hôpital Roger Salengro, CHRU de Lille, Lille, France"
NCT04601233,Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04601233,NOT_YET_RECRUITING,Multiple Sclerosis|Erectile Dysfunction|Testosterone Deficiency,DRUG: XYOSTED 75 milligram (mg) in 0.5 ML Auto-Injector,Tulane University,Louisiana State University Health Sciences Center in New Orleans|Antares Pharma Inc.,MALE,"ADULT, OLDER_ADULT",PHASE4,20,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-12,2024-08,2024-08,"LSU Health Multispecilaity Clinics, New Orleans, Louisiana, 70112, United States"
NCT02885233,Evaluation of a Web-Based Fall Prevention Program on People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02885233,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Free From Falls Online|BEHAVIORAL: Waitlist Control,Oregon Health and Science University,University of Alabama at Birmingham,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2017-02-15,2018-01-25,2018-01-25,"Oregon Health Sciences University, Portland, Oregon, 97239, United States"
NCT02596633,A RCT of Telephone-supported ACT in MS,https://beta.clinicaltrials.gov/study/NCT02596633,UNKNOWN,Multiple Sclerosis,BEHAVIORAL: Telephone-support Acceptance and Commitment Therapy (ACT),University of Nottingham,,ALL,"ADULT, OLDER_ADULT",PHASE3,30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2015-01,2016-03,2016-04,
NCT05516537,"Examining the Effects of a Remotely-delivered, Racially-tailored Exercise Training Program for Immediate and Sustained Improvements in Walking Dysfunction, Symptoms, and Health-related Quality of Life (HRQOL) Among African-Americans With Multiple Sclerosis (MS) Residing in Rural Environments.",https://beta.clinicaltrials.gov/study/NCT05516537,RECRUITING,Multiple Sclerosis,BEHAVIORAL: Guidelines for Exercise in Multiple Sclerosis (GEMS)|BEHAVIORAL: FLEX Stretching and Toning Program,University of Illinois at Chicago,University of Alabama at Birmingham|Bristol-Myers Squibb,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2022-09-02,2024-08,2025-08,"University of Illinois at Chicago, Chicago, Illinois, 60612, United States"
NCT04112537,Dermatologic Patterns of Tuberous Sclerosis Patients and Somatic Mutation Relationship,https://beta.clinicaltrials.gov/study/NCT04112537,UNKNOWN,Tuberous Sclerosis Complex,,"University Hospital, Montpellier",,ALL,"CHILD, ADULT, OLDER_ADULT",,90,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-03-01,2019-12-30,2020-12-30,"Uh Montpellier, Montpellier, 34295, France"
NCT01764737,"Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS",https://beta.clinicaltrials.gov/study/NCT01764737,COMPLETED,Multiple Sclerosis,DRUG: VX15/2503|DRUG: Placebo,Vaccinex Inc.,PRA Health Sciences,ALL,ADULT,PHASE1,50,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-12,2014-11,2014-11,"North Central Neurology Associates, PC, Cullman, Alabama, 35058, United States|University of Colorado Hospital, Aschutz Inpatient Pavilion, Aurora, Colorado, 80045, United States|Indiana University Health Neuroscience Center, Indianapolis, Indiana, 46202, United States|University of Kansas Medical Center, Kansas City, Kansas, 66160, United States|Wayne State University - University Health Center, Detroit, Michigan, 48201, United States|MS Center of Northeastern NY/Empire Neurology, Latham, New York, 12110, United States|University of Rochester Medical Center, Rochester, New York, 14642, United States|The Neurological Institute, PA, Charlotte, North Carolina, 28204, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States|Swedish Medical Center, Seattle, Washington, 98122, United States"
NCT05320237,Immersive Virtual Reality for Upper Limb Rehabilitation in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05320237,RECRUITING,Multiple Sclerosis,OTHER: Immersive Virtual Reality Intervention,Glasgow Caledonian University,"MS Society, UK|NHS Lanarkshire",ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-06-26,2023-01,2023-01,"Amy Webster, Glasgow, Scotland, G4 0BA, United Kingdom"
NCT01606137,A Study of the Long-term Safety of Sativex Use,https://beta.clinicaltrials.gov/study/NCT01606137,COMPLETED,Multiple Sclerosis|Spasticity|Pain,DRUG: GW-1000-02,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,507,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2002-02,2004-12,2004-12,"Gartnavel General Hospital, Glasgow, G12 0YN, United Kingdom"
NCT04804787,Emotions in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04804787,RECRUITING,Multiple Sclerosis,DIAGNOSTIC_TEST: Carrying out a tests and questionnaires battery,Lille Catholic University,,ALL,ADULT,NA,100,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-06-23,2023-06-23,2023-06-23,"Hôpital Saint-Vincent de Paul, Lille, 59000, France"
NCT04756687,Real World Analysis on Lymphocyte Reconstitution After Lymphopenia in Participants Treated by Tecfidera,https://beta.clinicaltrials.gov/study/NCT04756687,COMPLETED,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting",DRUG: Dimethyl fumarate,Biogen,,ALL,"ADULT, OLDER_ADULT",,1507,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-03-10,2021-06-15,2021-06-15,"Research Site, Amiens, France|Research Site, Besançon, France|Research Site, Bordeaux, France|Research Site, Brest, France|Research Site, Caen, France|Research Site, Clermont-Ferrand, France|Research Site, Dijon, France|Research Site, Grenoble, France|Research Site, Lille, France|Research Site, Limoges, France|Research Site, Lyon, France|Research Site, Marseille, France|Research Site, Montpellier, France|Research Site, Nancy, France|Research Site, Nantes, France|Research Site, Nice, France|Research Site, Nîmes, France|Research Site, Poitiers, France|Research Site, Rennes, France|Research Site, Rouen, France|Research Site, Saint-Etienne, France|Research Site, Strasbourg, France|Research Site, Toulouse, France|Research Site, Tours, France|Research Site, Île-de-France - Bicêtre, France|Research Site, Île-de-France - Créteil, France|Research Site, Île-de-France - Poissy St-Germain, France|Research Site, Île-de-France - Pontoise, France|Research Site, Île-de-France - Rothschild, France|Research Site, Île-de-France - Saint-Antoine, France|Research Site, Île-de-France - Saint-Denis, France|Research Site, Île-de-France - Salpêtrière, France"
NCT02688985,Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS),https://beta.clinicaltrials.gov/study/NCT02688985,ACTIVE_NOT_RECRUITING,"Relapsing Multiple Sclerorsis|Multiple Sclerosis, Primary Progressive",DRUG: Ocrelizumab|PROCEDURE: Lumbar Puncture|DRUG: Methyloprednisolone|DRUG: Antihistamine,"Genentech, Inc.",,ALL,ADULT,PHASE3,132,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2016-04-29,2023-07-30,2023-07-30,"Stanford University, Palo Alto, California, 94303, United States|University of California at San Francisco, San Francisco, California, 94115, United States|University Of Colorado, Aurora, Colorado, 80045, United States|Yale University School of Medicine ; Pulmonary & Critical Care, New Haven, Connecticut, 06510, United States|University of Massachusetts Medical School, Worcester, Massachusetts, 01655, United States|Washington University; Wash Uni. Sch. Of Med, Saint Louis, Missouri, 63110, United States|Empire Neurology, PC, Latham, New York, 12210, United States|Weill Cornell MC-NY Presbyter; Dept. of Neurology/Neuroscience, Judith Jaffe Multiple Sclerosis Ctr, New York, New York, 63110, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 27599, United States|Ohio State University, Columbus, Ohio, 43210, United States|Oklahoma Medical Research Foundation; MS Center of Excellence, Oklahoma City, Oklahoma, 73104, United States|University of Texas Southwestern Medical Center, Dallas, Texas, 75390, United States|University of British Columbia Hospital Site; Djavad Mowafaghian Centre for Brain Health, Vancouver, British Columbia, V6T 1Z3, Canada|McGill University; Montreal Neurological Institute; Neurological and Psychiatric, Montreal, Quebec, H3A 2B4, Canada|Universitätsklinikum ""Carl Gustav Carus"" der Technischen Universität Dresden, Dresden, 01307, Germany|Universitätsmedizin Göttingen Georg-August-Universität, Göttingen, 37075, Germany|Karolinska Universitetssjukhuset, Solna, Stockholm, 113 41, Sweden"
NCT05835622,Clinical Investigation of the Quality of Life Benefit of Using a Home Walking Exoskeleton for a Population of Multiple Sclerosis Patients.,https://beta.clinicaltrials.gov/study/NCT05835622,NOT_YET_RECRUITING,Multiple Sclerosis,DEVICE: Keeogo|OTHER: adviced home practice,Pôle Saint Hélier,,ALL,"ADULT, OLDER_ADULT",NA,28,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-05-02,2026-02,2026-02-02,"Hospices Civils de Lyon - Hôpital Henry Gabrielle, Saint Genis Laval, Auvergne-Rhône-Alpes, 69230, France|Pôle Saint Hélier, Rennes, Bretagne, 35000, France|Hôpital Saint Philibert-Groupement des Hôpitaux de l'Institut Catholique de Lille, Lomme, Hauts-de-France, 59160, France|Centre de rééducation Fonctionnelle Propara-Montpellier, Montpellier, Occitanie, 34090, France|CHU Angers- SSR Les Capucins, Angers, Pays De La Loire, 49103, France|CHU Nantes site de Saint Jacques, Nantes, Pays De La Loire, 44093, France"
NCT04057222,Effect of Need to Void on Rectal Sensory Function in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04057222,COMPLETED,Multiple Sclerosis|Anorectal Disorders|Bladder Dysfunction,OTHER: No intervention,Gérard Amarenco,,ALL,"ADULT, OLDER_ADULT",,30,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-07-26,2019-09-06,2019-09-06,"department of Neuro-Urology, Hôpital Tenon, Paris, 70020, France"
NCT05718947,Ultra-high-field Brain MRI in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05718947,NOT_YET_RECRUITING,Multiple Sclerosis,"DIAGNOSTIC_TEST: Brain MRI (3T, 7T, 9.4T)",Zuyderland Medisch Centrum,Scannexus,ALL,"ADULT, OLDER_ADULT",,10,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-03-01,2023-12-31,2023-12-31,"Zuyderland MC, Geleen, Limburg, 6162BG, Netherlands"
NCT03778333,Mesenchymal Stem Cells for Progressive Multiple Sclerosis_Sweden,https://beta.clinicaltrials.gov/study/NCT03778333,COMPLETED,Autologous Mesenchymal Stem Cells|Multiple Sclerosis,BIOLOGICAL: Autologous mesenchymal stem cells,Karolinska Institutet,,ALL,"ADULT, OLDER_ADULT",PHASE1,7,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2012-12-01,2016-12,2016-12-31,"Karolinska Institute, Karolinska University Hospital Solna, Stockholm, 171 76, Sweden|Karolinska Institute, Karolinska University Hospital, Stockholm, 17176, Sweden"
NCT01915433,Wahls Paleo Diet and Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01915433,COMPLETED,Multiple Sclerosis,OTHER: Wahls Paleo Plus|OTHER: Wahls Diet,Terry L. Wahls,,ALL,"ADULT, OLDER_ADULT",NA,15,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2013-07,2014-02,2016-11,"Univeristy of Iowa, Iowa City, Iowa, 52240, United States|Univeristy of Iowa, Iowa City, Iowa, 52246, United States"
NCT01977287,Walking With FES or AFO in People With MS With Foot Drop,https://beta.clinicaltrials.gov/study/NCT01977287,COMPLETED,Multiple Sclerosis|Foot Drop,DEVICE: Functional Electrical Stimulation|DEVICE: Ankle Foot Orthosis,Queen Margaret University,Multiple Sclerosis Society UK|NHS Lothian,ALL,"ADULT, OLDER_ADULT",,18,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-06,2016-03,2016-03,"Queen Margaret University, Musselburgh, East Lothian, EH21 6UU, United Kingdom"
NCT03268187,Biofeedback-based Relaxation Training or Self-alert Training to Alleviate Fatigue in Multiple Sclerosis Patients.,https://beta.clinicaltrials.gov/study/NCT03268187,COMPLETED,Fatigue|Multiple Sclerosis,DEVICE: Biofeedback|BEHAVIORAL: Self-Alert Training|BEHAVIORAL: Relaxation Training,Rehazentrum Wilhelmshaven,,ALL,"CHILD, ADULT, OLDER_ADULT",NA,61,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2017-07-17,2018-06-09,2018-10-18,"Rehazentrum Wilhelmshaven, Wilhelmshaven, Lower Saxony, 26382, Germany"
NCT04129736,Teriflunomide Concentration in Serum and Cerebrospinal Fluid From Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04129736,COMPLETED,"Multiple Sclerosis, Pharmacokinetics",DRUG: Teriflunomide 14 MG,Jan Lycke,,ALL,"ADULT, OLDER_ADULT",PHASE4,12,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2019-10-10,2021-03-31,2021-06-30,"MS Centre, Gothenburg, Vastra Gotaland, 41345, Sweden"
NCT00076934,Safety of RG2077 in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00076934,COMPLETED,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting",DRUG: RG2077 (CTLA4-IgG4m),National Institute of Allergy and Infectious Diseases (NIAID),Immune Tolerance Network (ITN)|Repligen Corporation,ALL,ADULT,PHASE1,20,NIH,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2003-01,,2006-02,"Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts, 02115, United States"
NCT02716701,Exercise in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02716701,TERMINATED,Multiple Sclerosis,BEHAVIORAL: Exercise Group|OTHER: Control Group|OTHER: wristband activity tracker,University of Minnesota,,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2016-01,2020-08-12,2020-08-13,"VA Medical Center, Minneapolis, Minnesota, 55417, United States"
NCT02269436,A follow-on Study to Assess Long-term Safety and Tolerability of i.c.v Administration of sNN0029 in Patients With ALS,https://beta.clinicaltrials.gov/study/NCT02269436,TERMINATED,Amyotrophic Lateral Sclerosis,DRUG: sNN0029 infusion solution,Newron Sweden AB,,ALL,"ADULT, OLDER_ADULT",PHASE1,11,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-01,2015-10,2015-10,"Philip Van Damme, Leuven, B-3000, Belgium|Leonard van den Berg, Utrecht, NL-3508, Netherlands"
NCT02870634,Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND,https://beta.clinicaltrials.gov/study/NCT02870634,COMPLETED,Amyotrophic Lateral Sclerosis|Motor Neuron Disease,DRUG: Cu(II)ATSM,Collaborative Medicinal Development Pty Limited,,ALL,"ADULT, OLDER_ADULT",PHASE1,50,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-11-16,2019-10-30,2020-01-30,"Macquarie University, Sydenham, New South Wales, 2109, Australia|Calvary Health Care Bethlehem, Caulfield, Victoria, 3162, Australia"
NCT01846234,Sodium Intake in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01846234,COMPLETED,Multiple Sclerosis,,Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia,,ALL,ADULT,,132,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-11,2013-07,2013-07,"FLENI, Buenos Aires, 1428, Argentina"
NCT01767701,Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01767701,COMPLETED,Relapsing Remitting Multiple Sclerosis,DRUG: Raltegravir,Queen Mary University of London,Merck Sharp & Dohme LLC,ALL,ADULT,PHASE2,23,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-04,2014-09,2014-09,"The Royal London Hospital, London, E1 2AT, United Kingdom"
NCT05587101,Neurogenic Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05587101,RECRUITING,Multiple Sclerosis|Neurogenic Bladder,DIAGNOSTIC_TEST: Urodynamic Study (Filling cystometry and pressure-flow study)|DIAGNOSTIC_TEST: Questionnaires|DIAGNOSTIC_TEST: Uroflowmetry,Koç University,,ALL,"ADULT, OLDER_ADULT",,30,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-10-19,2024-01-01,2024-06-01,"Koç University, Istanbul, 34010, Turkey"
NCT00843128,The Effectiveness of Locomotor Therapy Using Robot-Driven Gait Orthosis System in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT00843128,COMPLETED,Multiple Sclerosis,DEVICE: robot-assisted gait training (RAGT)|DEVICE: conventional walking training (CWT),Hadassah Medical Organization,,ALL,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2009-03,2010-08,2010-08,"Hadassah University Hospital, Jerusalem, 91240, Israel"
NCT01380041,Cytokine in Cerebrospinal Fluid (CSF) From Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT01380041,TERMINATED,Multiple Sclerosis,,"University Hospital, Montpellier",,ALL,"ADULT, OLDER_ADULT",,101,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-06,2011-06,2013-06,"CHU Montpellier, Montpellier, 34295, France"
NCT00317941,Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif,https://beta.clinicaltrials.gov/study/NCT00317941,COMPLETED,Relapsing-remitting Multiple Sclerosis,DRUG: Betaferon/Betaseron|DRUG: Rebif|DRUG: Betaferon/Betaseron,Bayer,,ALL,ADULT,PHASE4,220,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2006-03,2008-04,2008-04,"Aix en Provence, 13616, France|Alkirch, France|Annecy Cedex, 74011, France|Aurillac, 15000, France|Belfort, France|Blaye, France|Bordeaux, 33000, France|Boulogne sur Mer, 62321, France|Brest Cedex, France|Brive La Gaillarde, 19100, France|Carcassonne, France|Castelnau le Lez, 34170, France|ChamaliÃ¿res, France|Champigny sur Marne, France|Colmar, France|Corbeil Essones Cedex, France|CrÃ©teil, 94000, France|Dijon, France|Dreux, France|Dunkerque, 59140, France|Elbeuf, France|Evreux Cedex, 27023, France|Evry, France|La Seyne sur Mer, 83500, France|Le Mans Cedex, France|Le Mans, 72000, France|Libourne Cedex, 33505, France|Lille, France|Lomme Cedex, France|Lyon, France|Marseille, 13006, France|Montpellier Cedex 5, France|Montpellier, France|Nancy Cedex, France|Nancy, 54000, France|Nantes, 44000, France|Nice, France|Nimes Cedex 9, 30900, France|Paris, France|Pau, France|Perpignan, 66000, France|Poissy, France|Quimper Cedex, France|Quimper, 29000, France|Quimper, France|Reims, France|Rennes, France|Rouen, France|Rueil Malmaison, France|Saint Herblain, 44800, France|Saint Quentin, France|St Etienne, France|St LÃ¿, 50000, France|St Omer, 62505, France|Strasbourg, France|Toulouse, 31400, France|Tourcoing, France|Trelaze, France|Vendome, France|Vesoul, 70000, France|Vichy, France"
NCT02876536,Effect of Transcutaneous Electrical Nerve Stimulation on Cognition in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT02876536,UNKNOWN,Multiple Sclerosis|Cognitive Disorders,DEVICE: TENS,Isfahan University of Medical Sciences,,ALL,"CHILD, ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2016-06,2016-08,2016-09,"Alzahra Hospital, Isfahan, Iran, Islamic Republic of"
NCT03849001,Impact of Acute Leg Cycling at Various Intensities on RLS Severity in Persons With MS,https://beta.clinicaltrials.gov/study/NCT03849001,WITHDRAWN,Multiple Sclerosis|Restless Legs Syndrome,BEHAVIORAL: Exercise Conditions|BEHAVIORAL: Exercise Conditions|BEHAVIORAL: Exercise Conditions|BEHAVIORAL: Exercise Conditions,University of Alabama at Birmingham,,ALL,ADULT,NA,0,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2019-09-01,2019-09-01,2019-09-01,
NCT03172741,The Effects of Different Medical Marijuana Strains on Motor and Cognitive Function in People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03172741,WITHDRAWN,Multiple Sclerosis,DRUG: Medical Marijuana|DRUG: Placebo,Colorado State University,,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,0,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2017-01,2018-01,2018-01,
NCT03362541,A Multi-Site Trial of MS INFoRm (Fatigue Management Resource),https://beta.clinicaltrials.gov/study/NCT03362541,COMPLETED,Multiple Sclerosis,BEHAVIORAL: MS INFoRm|BEHAVIORAL: Usual Care Control Group,Dr. Marcia Finlayson,University of Alberta|University of Calgary,ALL,"ADULT, OLDER_ADULT",NA,161,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-01-30,2021-06-15,2021-06-15,"University of Calgary, Calgary, Alberta, T2N 4N1, Canada|University of Alberta, Edmonton, Alberta, T6G 2G3, Canada|Queen's University, Kingston, Ontario, K7L 3N6, Canada"
NCT00704834,Gene Expression Profiles in Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT00704834,COMPLETED,Multiple Sclerosis,OTHER: Blood Draw,"University of California, Davis",,ALL,"ADULT, OLDER_ADULT",,46,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2006-03,2017-07-05,2017-07-05,"University of California, Davis, Sacramento, California, 95817, United States"
NCT05828901,Predicting Disease Activity and Rebound Risk in MS Patients Treated With Sphingosine-1-phosphate Receptor Modulators (S1PRM),https://beta.clinicaltrials.gov/study/NCT05828901,RECRUITING,Multiple Sclerosis,OTHER: S1PR analysis on immune cells,"University Hospital Inselspital, Berne",,ALL,"ADULT, OLDER_ADULT",,60,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-03-27,2026-03,2027-03,"Neurology department, Bern, 3010, Switzerland"
NCT04930380,Description of Adherence to the Main Preventive Health Campaigns of Persons With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04930380,RECRUITING,Multiple Sclerosis,OTHER: phone interview,University of Siena,,ALL,"ADULT, OLDER_ADULT",,1250,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-04-01,2023-02-28,2023-03-30,"University of Ferrara, Ferrara, FE, Italy|University of Siena, Sena, SI, 53100, Italy|AOU San Luigi Gonzaga, Orbassano, TO, Italy|Aulss3- Ospedale dell'Angelo, Mestre, VE, Italy|Università di Cagliari, Cagliari, Italy|Università di Catania, Catania, Italy|Ospedale Murri, Fermo, Italy|Fondazione Italiana Sclerosi Multipla, Genova, Italy|Università degli Studi di Milano Statale, Milan, Italy|Università degli Studi di Palermo, Palermo, Italy|IRCCS Neuromed, Pozzilli, Italy|Università La Sapienza, Roma, Italy"
NCT04175834,Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab,https://beta.clinicaltrials.gov/study/NCT04175834,ACTIVE_NOT_RECRUITING,Multiple Sclerosis|Infusion Reaction,DRUG: antihistamine,Providence Health & Services,"Genentech, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE3,52,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-02-05,2023-01,2024-06,"Providence Neurological Specialties West, Portland, Oregon, 97225, United States"
NCT02346734,Physical Telerehabilitation in Veterans With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02346734,COMPLETED,Multiple Sclerosis,DEVICE: Multiple Sclerosis Home Automated Telemanagement (MS HAT) system,University of Maryland,Baltimore VA Medical Center,ALL,"ADULT, OLDER_ADULT",NA,74,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2012-07,2017-04-06,2017-04-06,"University of Maryland, Baltimore, Maryland, 21201, United States"
NCT01918501,Testing Mitochondria Activity and Blood Lipid Content of Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT01918501,UNKNOWN,Multiple Sclerosis,PROCEDURE: Blood testing,Ziv Hospital,,ALL,ADULT,NA,120,OTHER_GOV,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2013-08,2015-07,2015-07,"ZIV Medical Center, Safed, 13100, Israel"
NCT01080001,"A Observational, Prospective Study to Assess the Impact of Fatigue in the Quality of Life of Patients With Multiple Sclerosis in Argentina",https://beta.clinicaltrials.gov/study/NCT01080001,COMPLETED,"Multiple Sclerosis, Relapsing-remitting",,"Merck KGaA, Darmstadt, Germany",,ALL,ADULT,,71,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2008-08,2010-12,2012-11,"Hospital Fernandez de Buenos Aires, Capital federal, Buenos Aires, Argentina"
NCT03087136,A Multicenter Observational Study to Evaluate Pediatric Multiple Sclerosis in Brazil,https://beta.clinicaltrials.gov/study/NCT03087136,UNKNOWN,Multiple Sclerosis,DIAGNOSTIC_TEST: anti-aquaporin-4 antibody|DIAGNOSTIC_TEST: anti-myelin oligodendrocyte glycoprotein,Pontificia Universidade Católica do Rio Grande do Sul,Teva Pharmaceuticals USA,ALL,"CHILD, ADULT",,100,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-03-01,2019-03-31,2021-03-31,"Universidade Federal de Uberlândia, Uberlandia, MG, 38405320, Brazil|Hospital da Restauração de Recife, Recife, PE, 50110900, Brazil|Instituto de Neurologia de Curitiba, Curitiba, PR, 81210310, Brazil|Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro, RJ, 22290255, Brazil|Santa Casa de Misericordia de Porto Alegre, Porto Alegre, RS, 90020090, Brazil|Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, RS, 9061000, Brazil|Hospital das Clinicas da Faculdade de Medicina de Ribeirão Preto / Universidade de São Paulo, Ribeirao Preto, SP, 65470000, Brazil|Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, SP, 05403010, Brazil"
NCT03999034,XO as a Screening Test of Cognitive Impairment in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03999034,UNKNOWN,"Sclerosis, Multiple|Cognitive Dysfunction",DIAGNOSTIC_TEST: questionnaire completion,"University Hospital, Clermont-Ferrand",Merck Santé SAS,ALL,"ADULT, OLDER_ADULT",NA,540,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2019-07-08,2020-09-08,2020-10-08,"CHU Clermont-Ferrand, Clermont-Ferrand, 63000, France"
NCT00112034,"AVONEX® Combination Trial - ""ACT""",https://beta.clinicaltrials.gov/study/NCT00112034,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Methotrexate|DRUG: IV methylprednisolone,Biogen,,ALL,ADULT,PHASE4,350,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: DOUBLE|Primary Purpose: ",2003-06,2006-06,2007-05,"MS Academic Coordinating Center, Cleveland, Ohio, 44195, United States"
NCT02988401,Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02988401,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis, Secondary Progressive|Multiple Sclerosis, Primary Progressive",DRUG: Insulin|DRUG: Placebo (Sterile diluent),Johns Hopkins University,United States Department of Defense,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,105,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-12-01,2021-12-17,2021-12-17,"Johns Hopkins University School of Medicine, Baltimore, Maryland, 21287, United States"
NCT00223301,Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00223301,COMPLETED,Multiple Sclerosis,DRUG: Mycophenolate Mofetil (cellcept),University of Texas Southwestern Medical Center,Roche Pharma AG|Biogen,ALL,ADULT,PHASE2|PHASE3,24,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: DOUBLE|Primary Purpose: TREATMENT,2004-07,2007-03,2007-03,"University of Texas Southwestern Medical Center, Dallas, Texas, 75390-8806, United States"
NCT05402501,Lifestyle Intervention for Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05402501,RECRUITING,Multiple Sclerosis,"BEHAVIORAL: Lifestyle intervention program ""Leef! met MS""","Amsterdam UMC, location VUmc","National MS Foundation, The Netherlands|Voeding Leeft",ALL,"ADULT, OLDER_ADULT",,900,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-04-15,2024-11,2024-11,"Amsterdam UMC, location VUmc, Amsterdam, Noord-Holland, 1081 HV, Netherlands"
NCT03856801,Acute Effects of Whole-body Vibration Training in Hypoxia and Normoxia in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT03856801,COMPLETED,Multiple Sclerosis,OTHER: Exercise,Universidad Católica San Antonio de Murcia,,ALL,"ADULT, OLDER_ADULT",NA,13,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2018-06-15,2018-07-30,2018-08-30,"Universidad Católica San Antonio, Murcia, 30107, Spain"
NCT01950234,ACTH in Progressive Forms of MS,https://beta.clinicaltrials.gov/study/NCT01950234,TERMINATED,Secondary Progressive Multiple Sclerosis|Primary Progressive Multiple Sclerosis|Progressive Relapsing Multiple Sclerosis,DRUG: ACTH|DRUG: Placebo,University of Minnesota,Mallinckrodt,ALL,"ADULT, OLDER_ADULT",PHASE2,59,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-04-17,2022-12-31,2022-12-31,"Clinical Neuroscience Research Unit, University of Minnesota, Minneapolis, Minnesota, 55414, United States|Sanford Clinic Neuroscience, Fargo, North Dakota, 58103, United States|Wheaton Franciscan Healthcare - St Francis Center for Neurological Disorders, Milwaukee, Wisconsin, 53215, United States"
NCT02611401,Efficacy of MBI for Depressive Symptoms in Patients With MS,https://beta.clinicaltrials.gov/study/NCT02611401,COMPLETED,Multiple Sclerosis|Depression,BEHAVIORAL: Mindfulness|BEHAVIORAL: Psychoeducation,"University of Turin, Italy",Fondazione Italiana Sclerosi Multipla,ALL,"ADULT, OLDER_ADULT",NA,88,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-05,2016-12,2017-05,"Clinical and Biological Sciences Department, Orbassano, Turin, 10043, Italy"
NCT05426980,Artificial Intelligence in Predicting Progression in Multiple Sclerosis Study,https://beta.clinicaltrials.gov/study/NCT05426980,RECRUITING,Multiple Sclerosis|Multiple Sclerosis Lesion|Multiple Sclerosis Brain Lesion,,University of Ljubljana,Novartis|General and Teaching Hospital Celje|University Medical Centre Ljubljana|University Medical Centre Maribor|General Hospital Izola,ALL,"ADULT, OLDER_ADULT",,1200,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-12-13,2023-06-30,2023-06-30,"University medical center Ljubljana, Ljubljana, Osrednjeslovenska, 1000, Slovenia|General and teaching hospital Celje, Celje, 3000, Slovenia|General hospital Izola, Izola, Slovenia|University medical center Maribor, Maribor, 2000, Slovenia"
NCT03206034,Stylistic Memory Enhancement,https://beta.clinicaltrials.gov/study/NCT03206034,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Stylistic Memory Enhancement,Kessler Foundation,,ALL,ADULT,NA,20,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-03-01,2015-12-31,2015-12-31,
NCT01333501,Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms,https://beta.clinicaltrials.gov/study/NCT01333501,COMPLETED,Multiple Sclerosis,DRUG: Fingolimod|DRUG: Interferon beta 1b,Novartis Pharmaceuticals,,ALL,ADULT,PHASE4,151,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2011-05,2015-09,2015-09,"Novartis Investigative Site, Alzenau, 63755, Germany|Novartis Investigative Site, Bamberg, 96049, Germany|Novartis Investigative Site, Leipzig, 04103, Germany|Novartis Investigative Site, Würzburg, 97080, Germany|Novartis Investigative Site, Ancona, AN, 60126, Italy|Novartis Investigative Site, Bari, BA, 70124, Italy|Novartis Investigative Site, Bergamo, BG, 24128, Italy|Novartis Investigative Site, Montichiari, BS, 25018, Italy|Novartis Investigative Site, Chieti, CH, 66100, Italy|Novartis Investigative Site, Catania, CT, 95122, Italy|Novartis Investigative Site, Catania, CT, 95123, Italy|Novartis Investigative Site, Firenze, FI, 50134, Italy|Novartis Investigative Site, Genova, GE, 16132, Italy|Novartis Investigative Site, Pozzilli, IS, 86077, Italy|Novartis Investigative Site, Messina, ME, 98121, Italy|Novartis Investigative Site, Milano, MI, 20122, Italy|Novartis Investigative Site, Milano, MI, 20132, Italy|Novartis Investigative Site, Cefalù, PA, 90015, Italy|Novartis Investigative Site, Pavia, PV, 27100, Italy|Novartis Investigative Site, Roma, RM, 00133, Italy|Novartis Investigative Site, Roma, RM, 00161, Italy|Novartis Investigative Site, Roma, RM, 00179, Italy|Novartis Investigative Site, Roma, RM, 00189, Italy|Novartis Investigative Site, Gallarate, VA, 21013, Italy|Novartis Investigative Site, Napoli, 80131, Italy|Novartis Investigative Site, Napoli, 80138, Italy"
NCT01440101,"Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)",https://beta.clinicaltrials.gov/study/NCT01440101,COMPLETED,Multiple Sclerosis,DRUG: Natalizumab (BG00002)|DRUG: Placebo,Biogen,,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,106,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2010-11,2012-08,2012-08,"Research Site, Chiba, Japan|Research Site, Fukuoka, Japan|Research Site, Hiroshima, Japan|Research Site, Kawagoe, Japan|Research Site, Kyoto, Japan|Research Site, Morioka, Japan|Research Site, Niigata, Japan|Research Site, Osaka, Japan|Research Site, Otaku, Japan|Research Site, Sapporo, Japan|Research Site, Sendai, Japan|Research Site, Suita, Japan|Research Site, Tokorozawa, Japan|Research Site, Tokyo, Japan|Research Site, Tsukuba, Japan|Research Site, Ube, Japan|Research Site, Yokohama, Japan"
NCT00674141,Nasal Administration of Dexamethasone for Multiple Sclerosis (MS) Treatment,https://beta.clinicaltrials.gov/study/NCT00674141,WITHDRAWN,MS Patient With Relpasing Remitting Attacks,DRUG: Dexamethasone soduim phosphate,Hadassah Medical Organization,,ALL,"ADULT, OLDER_ADULT",PHASE1,10,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2008-07,2008-12,2009-01,"Hadassah Medical Organization, Jerusalem, 91120, Israel"
NCT03155334,Understanding Evaluation of Patient Information Sheets by User Testing Method,https://beta.clinicaltrials.gov/study/NCT03155334,UNKNOWN,MS (Multiple Sclerosis),OTHER: PIS User Testing,Fondazione Italiana Sclerosi Multipla,"Opera CRO, a TIGERMED Group Company",ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2017-01-31,2018-02-20,2018-12-30,"Fondazione Italiana Sclerosi Multipla (FISM), Genova, Liguria, Italy|Opera Contract Research Organization SRL, Timisoara, Timis, 300209, Romania"
NCT05028634,Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy,https://beta.clinicaltrials.gov/study/NCT05028634,RECRUITING,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting","BIOLOGICAL: Tetanus, diphtheria, and acellular pertussis vaccine|BIOLOGICAL: Pneumococcal polysaccharide vaccine|BIOLOGICAL: Seasonal influenza vaccine",Celgene,,ALL,"ADULT, OLDER_ADULT",PHASE3,60,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-10-27,2024-01-31,2024-01-31,"Stanford University, Palo Alto, California, 94304, United States|Colorado Springs Neurological Associates, Colorado Springs, Colorado, 80907, United States|Hartford Healthcare CT, Southington, Connecticut, 06489, United States|University of Florida Health, Gainesville, Florida, 32610, United States|Neurostudies Inc, Port Charlotte, Florida, 33952, United States|Accel Research Sites - Brain and Spine Institute of Port Orange - ERN - PPDS, Port Orange, Florida, 32127, United States|University of Chicago Medicine, Chicago, Illinois, 60637, United States|Consultants In Neurology, Northbrook, Illinois, 60062, United States|University Of Kansas Medical Center, Kansas City, Kansas, 66205, United States|CPFCC Neurology Research Dept., Overland Park, Kansas, 66212, United States|Neuromedical Clinic of Central LA, Alexandria, Louisiana, 71301, United States|Neurology Center of New England P.C., Foxboro, Massachusetts, 02035, United States|Michigan State University MS Clinic, East Lansing, Michigan, 48824, United States|Shapiro Center for MS at the Minneapolis Clinic of Neurology, Minneapolis, Minnesota, 55422, United States|Neurology Associates PC, Lincoln, Nebraska, 68506, United States|Jersey Shore MS Center, Neptune, New Jersey, 07753, United States|Holy Name Hospital, Teaneck, New Jersey, 07666, United States|South Shore Neurology Associates, Inc, Patchogue, New York, 11772, United States|Asheville Neurology Specialists PA, Asheville, North Carolina, 28806, United States|Lake Norman Neurology, Mooresville, North Carolina, 28117, United States|NeuroScience Research Center, LLC, Canton, Ohio, 44718, United States|Velocity Clinical Research - Cleveland - ERN - PPDS, Cleveland, Ohio, 44122, United States|Thomas Jefferson University - Clinical Research Institute, Philadelphia, Pennsylvania, 19107, United States|Sanford Health, Sioux Falls, South Dakota, 57104, United States|Hope Neurology MS Center, Knoxville, Tennessee, 37922, United States|Central Texas Neurology Consultants PA, Round Rock, Texas, 78681, United States|MultiCare Institute for Research and Innovation, Tacoma, Washington, 98405, United States|Vaught Neurological Services, PLLC, Crab Orchard, West Virginia, 25827, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States|Local Institution - 200, Bochum, 44791, Germany|Local Institution - 201, Dresden, 01307, Germany|Local Institution - 206, Mannheim, 68163, Germany|Local Institution - 204, Rostock, 18147, Germany"
NCT00674934,Far Infrared Irradiation for Managing and Treating Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT00674934,UNKNOWN,Multiple Sclerosis,RADIATION: Far Infrared Radiation (5μm to 20μm wavelength),GAAD Medical Research Institute Inc.,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1,5,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2008-05,2010-05,2010-06,"The Centre for Incurable Diseases, Toronto, Ontario, M4V 1L5, Canada"
NCT01851434,Natural History of Optic Neuritis,https://beta.clinicaltrials.gov/study/NCT01851434,TERMINATED,Multiple Sclerosis,,National Institute of Neurological Disorders and Stroke (NINDS),National Eye Institute (NEI),ALL,ADULT,,8,NIH,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-03-20,2014-09-05,2017-10-26,"National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States|University of Utah, Salt Lake City, Utah, 84112, United States|Hadassah Hospital/Hebrew University Medical Center, Jerusalem, Israel"
NCT05585541,Teleassessment in Ataxic Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05585541,RECRUITING,Ataxia|Multiple Sclerosis,,Hacettepe University,,ALL,ADULT,,50,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-10-24,2023-06-30,2023-08-31,"Hacettepe University, Ankara, Turkey"
NCT00574041,How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose,https://beta.clinicaltrials.gov/study/NCT00574041,TERMINATED,Relapsing Remitting Multiple Sclerosis,DRUG: Interferon beta-1a,Biogen,,ALL,"ADULT, OLDER_ADULT",PHASE4,19,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2007-06,2008-02,2008-02,"Coordinating Research Site, Malvern, Victoria, 3144, Australia"
NCT00484536,"Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323",https://beta.clinicaltrials.gov/study/NCT00484536,TERMINATED,Multiple Sclerosis,DRUG: CDP323|DRUG: placebo|DRUG: CDP323,UCB Pharma,Biogen,ALL,ADULT,PHASE2,232,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2007-05,2009-11,2010-07,"Cullman, Alabama, United States|Phoenix, Arizona, United States|Tucson, Arizona, United States|Springs, Colorado, United States|Washington, District of Columbia, United States|Maitland, Florida, United States|Atlanta, Georgia, United States|Northbrook, Illinois, United States|Fort Wayne, Indiana, United States|Kansas City, Kansas, United States|Lenexa, Kansas, United States|Lexington, Kentucky, United States|Louisville, Kentucky, United States|Farmington Hills, Michigan, United States|Charlotte, North Carolina, United States|Columbus, Ohio, United States|Providence, Rhode Island, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Kirkland, Washington, United States|Charleston, West Virginia, United States|Milwaukee, Wisconsin, United States|Diepenbeek, Belgium|Gent, Belgium|Melsbroek, Belgium|Overpelt, Belgium|Sijsele, Belgium|Sint-Truiden, Belgium|London, Ontario, Canada|Ottawa, Ontario, Canada|Gatineau, Quebec, Canada|Greenfield Park, Quebec, Canada|Sherbrooke, Quebec, Canada|Oulu, Finland|Tampere, Finland|Turku, Finland|Besancon, France|Clermont-Ferrand, France|Lyon Cedex 03, France|Rennes, France|Strasbourg, France|Bayreuth, Germany|Berlin, Germany|Giessen, Germany|Hamburg, Germany|Marburg, Germany|Rostock, Germany|Ulm, Germany|Wiesbaden, Germany|Budapest, Hungary|Gyor, Hungary|Nyiregyhaza, Hungary|Pecs, Hungary|Amsterdam, Netherlands|Breda, Netherlands|Nieuwegein, Netherlands|Nijmegen, Netherlands|Barcelona, Spain|Bilbao, Spain|Girona, Spain|Madrid, Spain|Malaga, Spain|Oviedo, Spain|Santa Cruz de Tenerife, Spain|Sevilla, Spain|Goteborg, Sweden|Umea, Sweden|Hartshill, United Kingdom|Newcastle, United Kingdom|Nottingham, United Kingdom|Sheffield, United Kingdom"
NCT04286828,"Position Sense, Balance, and Dual Task Performance at the Menstrual Cycle in Females With Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT04286828,COMPLETED,Multiple Sclerosis|Neurologic Symptoms|Menstrual Cycle,OTHER: Position Sense|OTHER: Balance|OTHER: Dual Task Performance,Ankara Yildirim Beyazıt University,,FEMALE,ADULT,,27,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-03-25,2019-10-20,2019-11-26,"Ankara Yıldırım Beyazıt University, Faculty of Health Sciences,Department of Physiotherapy and Rehabilitation, Ankara, Esenboğa, 06970, Turkey"
NCT02076841,Tolerability and Quality of Life Study in Participants Who Switched to Avonex Pen,https://beta.clinicaltrials.gov/study/NCT02076841,COMPLETED,Relapsing-Remitting Multiple Sclerosis|Clinical Isolated Syndrome (CIS)|Multiple Sclerosis,DEVICE: interferon beta-1a,Biogen,,ALL,"ADULT, OLDER_ADULT",,40,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-07,2016-02,2016-10,"Research Site, Brno, Czech Republic|Research Site, Hradec Králové, Czech Republic|Research Site, Jihlava, Czech Republic|Research Site, Plzeň, Czech Republic|Research Site, Praha, Czech Republic|Research Site, Teplice, Czech Republic|Research Site, Bienne, Switzerland|Research Site, Langenthal, Switzerland|Research Site, Lugano, Switzerland|Research Site, Sion, Switzerland|Research Site, Wil, Switzerland"
NCT03151941,Respiratory Monitoring of Intrathecal Baclofen- a Feasibility Study,https://beta.clinicaltrials.gov/study/NCT03151941,COMPLETED,Intrathecal Baclofen|Multiple Sclerosis|Respiratory System|Cerebral Palsy,,Solent NHS Trust,,ALL,"ADULT, OLDER_ADULT",,15,OTHER_GOV,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-03-06,2017-08-31,2017-08-31,"Solent NHS Trust, Portsmouth, Hampshire, United Kingdom"
NCT04964336,An Observational Study to Investigate the Role of B Cells in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04964336,RECRUITING,Multiple Sclerosis,OTHER: Analysis of B cells,University of Oslo,,ALL,"ADULT, OLDER_ADULT",,40,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-02-05,2024-12,2024-12,"Akershus University Hospital, Lørenskog, Norway|Oslo University Hospital, Oslo, Norway"
NCT02714036,A Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS),https://beta.clinicaltrials.gov/study/NCT02714036,COMPLETED,Amyotrophic Lateral Sclerosis,DRUG: ibudilast,MediciNova,Massachusetts General Hospital|South Shore Neurologic Associates,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,35,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-05-06,2019-12-31,2020-06-30,"Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|South Shore Neurologic Associates, P.C., Patchogue, New York, 11772, United States"
NCT00364936,Development and Evaluation of a New Palliative Care Service for People Severely Affected With Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT00364936,COMPLETED,Multiple Sclerosis,PROCEDURE: Palliative care service,King's College London,National Multiple Sclerosis Society,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1|PHASE2,52,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2004-03,,2006-12,"King's College Hospital, London, SE5 9RJ, United Kingdom"
NCT03878836,Follow-up of Persons With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03878836,UNKNOWN,Multiple Sclerosis,OTHER: Routine assessments,Dokuz Eylul University,,ALL,"ADULT, OLDER_ADULT",,118,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-10-01,2021-08-01,2021-08-01,"Dokuz Eylul University Hospital, MS Outpatient Clinic, Izmir, 35430, Turkey"
NCT03769636,Changes in Physical Activity in All Day Life in People With MS Before and After Rehabilitation,https://beta.clinicaltrials.gov/study/NCT03769636,UNKNOWN,Rehabilitation,DEVICE: GaitUp Physilog 5,Klinik Valens,,ALL,"ADULT, OLDER_ADULT",,30,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-01-01,2019-06,2019-10,"Klinik Valens, Valens, St.Gallen, 7313, Switzerland"
NCT01051128,Continuous Intrathecal Baclofen Infusion for Chronic Spasticity,https://beta.clinicaltrials.gov/study/NCT01051128,WITHDRAWN,Spasticity,DEVICE: Prometra Programmable Implantable Pump System,Flowonix Medical,,ALL,"ADULT, OLDER_ADULT",PHASE3,0,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2010-01,2010-06,2010-12,
NCT00260741,Cannabis for Spasticity in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00260741,TERMINATED,Multiple Sclerosis,DRUG: Smoked Cannabis,Center for Medicinal Cannabis Research,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,2003-03,,2006-01,"UC Davis Medical Center, Sacramento, California, 95817, United States"
NCT01070836,JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab,https://beta.clinicaltrials.gov/study/NCT01070836,COMPLETED,Relapsing Multiple Sclerosis,DRUG: natalizumab,Biogen,,ALL,"CHILD, ADULT, OLDER_ADULT",,35895,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-03,2015-11,2015-11,"Research Site, Birmingham, Alabama, 35209, United States|Research Site, Birmingham, Alabama, 35233, United States|Research Site, Cullman, Alabama, 35058, United States|Research Site, Tucaloosa, Alabama, 35406, United States|Research Site, Anchorage, Alaska, 99508, United States|Research Site, Flagstaff, Arizona, 86001, United States|Research Site, Gilbert, Arizona, 85234, United States|Research Site, Phoenix, Arizona, 85004, United States|Research Site, Phoenix, Arizona, 85013, United States|Research Site, Phoenix, Arizona, 85018, United States|Research Site, Phoenix, Arizona, 85032, United States|Research Site, Scottsdale, Arizona, 85258, United States|Research Site, Tucson, Arizona, 85718, United States|Research Site, Tucson, Arizona, 85741, United States|Research Site, Fayetteville, Arkansas, 72703, United States|Research Site, Little Rock, Arkansas, 72205, United States|Research Site, Sherwood, Arkansas, 72120, United States|Research Site, Auburn, California, 95602, United States|Research Site, Berkeley, California, 94705, United States|Research Site, Carmel, California, 93923, United States|Research Site, Carmichael, California, 95608, United States|Research Site, Fountain Valley, California, 92708, United States|Research Site, Fresno, California, 93701, United States|Research Site, Fresno, California, 93720, United States|Research Site, Fullerton, California, 92835, United States|Research Site, La Jolla, California, 92037, United States|Research Site, Loma Linda, California, 92354, United States|Research Site, Los Alamitos, California, 90720, United States|Research Site, Los Angeles, California, 90033, United States|Research Site, Los Angeles, California, 90073, United States|Research Site, Marina Del Rey, California, 90292, United States|Research Site, Modesto, California, 95355, United States|Research Site, Newport Beach, California, 92663, United States|Research Site, Northridge, California, 91328, United States|Research Site, Palo Alto, California, 94301, United States|Research Site, Pasadena, California, 91101, United States|Research Site, Pasadena, California, 91105, United States|Research Site, Redding, California, 96001, United States|Research Site, Sacramento, California, 95816, United States|Research Site, San Diego, California, 82117, United States|Research Site, San Francisco, California, 94109, United States|Research Site, San Francisco, California, 94115, United States|Research Site, San Francisco, California, 94117, United States|Research Site, Santa Barbara, California, 93105, United States|Research Site, St. Helena, California, 94574, United States|Research Site, Stanford, California, 94305, United States|Research Site, Stockton, California, 95204, United States|Research Site, Thousand Oaks, California, 91360, United States|Research Site, Tracy, California, 95376, United States|Research Site, Arvada, Colorado, 80002, United States|Research Site, Aurora, Colorado, 80045, United States|Research Site, Basalt, Colorado, 81621, United States|Research Site, Centennial, Colorado, 80112, United States|Research Site, Colorado Springs, Colorado, 80907, United States|Research Site, Colorado Springs, Colorado, 80920, United States|Research Site, Denver, Colorado, 80205, United States|Research Site, Fort Collins, Colorado, 80525, United States|Research Site, Fort Collins, Colorado, 80528, United States|Research Site, Greeley, Colorado, 80631, United States|Research Site, Parker, Colorado, 80138, United States|Research Site, Pueblo, Colorado, 81004, United States|Research Site, Danbury, Connecticut, 06810, United States|Research Site, Derby, Connecticut, 06418, United States|Research Site, Fairfield, Connecticut, 06824, United States|Research Site, Hartford, Connecticut, 06105, United States|Research Site, Hartford, Connecticut, 06112, United States|Research Site, New Haven, Connecticut, 06510, United States|Research Site, New London, Connecticut, 06320, United States|Research Site, Norwich, Connecticut, 06360, United States|Research Site, Dover, Delaware, 19901, United States|Research Site, Newark, Delaware, 19713, United States|Research Site, Washington, District of Columbia, 20007, United States|Research Site, Washington, District of Columbia, 20037, United States|Research Site, Bradenton, Florida, 34205, United States|Research Site, Clearwater, Florida, 33756, United States|Research Site, Fort Lauderdale, Florida, 33308, United States|Research Site, Fort Walton Beach, Florida, 32547, United States|Research Site, Gainesville, Florida, 32607, United States|Research Site, Hollywood, Florida, 33021, United States|Research Site, Jacksonville Beach, Florida, 32250, United States|Research Site, Jacksonville, Florida, 32209, United States|Research Site, Lighthouse Point, Florida, 33064, United States|Research Site, Maitland, Florida, 32751, United States|Research Site, Melbourne, Florida, 32901, United States|Research Site, Miami, Florida, 33133, United States|Research Site, Miami, Florida, 33136, United States|Research Site, Naples, Florida, 34102, United States|Research Site, Ocala, Florida, 34471, United States|Research Site, Orange Park, Florida, 32073, United States|Research Site, Orlando, Florida, 32806, United States|Research Site, Ormond Beach, Florida, 32174, United States|Research Site, Palm Bay, Florida, 32905, United States|Research Site, Palm Beach Gardens, Florida, 33410, United States|Research Site, Pompano Beach, Florida, 33060, United States|Research Site, Ponte Vedra Beach, Florida, 32082, United States|Research Site, Port Charlotte, Florida, 33952, United States|Research Site, Sarasota, Florida, 34239, United States|Research Site, Sarasota, Florida, 34243, United States|Research Site, St. Petersburg, Florida, 33705, United States|Research Site, St. Petersburg, Florida, 33713, United States|Research Site, Sunrise, Florida, 33351, United States|Research Site, Tallahassee, Florida, 32308, United States|Research Site, Tampa, Florida, 33609, United States|Research Site, Tampa, Florida, 33612, United States|Research Site, Vero Beach, Florida, 32960, United States|Research Site, Winter Haven, Florida, 33880, United States|Research Site, Winter Park, Florida, 32792, United States|Research Site, Athens, Georgia, 30606, United States|Research Site, Atlanta, Georgia, 30309, United States|Research Site, Atlanta, Georgia, 30312, United States|Research Site, Atlanta, Georgia, 30322, United States|Research Site, Atlanta, Georgia, 30327, United States|Research Site, Columbus, Georgia, 31909, United States|Research Site, Johns Creek, Georgia, 30097, United States|Research Site, Macon, Georgia, 31210, United States|Research Site, Savannah, Georgia, 31406, United States|Research Site, Snellville, Georgia, 30078, United States|Research Site, Honolulu, Hawaii, 96813, United States|Research Site, Boise, Idaho, 83706, United States|Research Site, Idaho Falls, Idaho, 83404, United States|Research Site, Meridian, Idaho, 83642, United States|Research Site, Nampa, Idaho, 83687, United States|Research Site, Bloomington, Illinois, 61701, United States|Research Site, Bloomington, Illinois, 61704, United States|Research Site, Champaign, Illinois, 61820, United States|Research Site, Chicago, Illinois, 60611, United States|Research Site, Chicago, Illinois, 60612, United States|Research Site, Chicago, Illinois, 60616, United States|Research Site, Chicago, Illinois, 60637, United States|Research Site, Elk Grove Village, Illinois, 60007, United States|Research Site, Elmhurst, Illinois, 60126, United States|Research Site, Evanston, Illinois, 60201, United States|Research Site, Flossmoor, Illinois, 60422, United States|Research Site, Herrin, Illinois, 62948, United States|Research Site, Lake Barrington, Illinois, 60010, United States|Research Site, Lombard, Illinois, 60148, United States|Research Site, Melrose Park, Illinois, 60160, United States|Research Site, Niles, Illinois, 60714, United States|Research Site, North Aurora, Illinois, 60542, United States|Research Site, Palos Heights, Illinois, 60463, United States|Research Site, Peoria, Illinois, 61606, United States|Research Site, St. Charles, Illinois, 60175, United States|Research Site, Anderson, Indiana, 46016, United States|Research Site, Bloomington, Indiana, 47403, United States|Research Site, Elkhart, Indiana, 46514, United States|Research Site, Evansville, Indiana, 47715, United States|Research Site, Fort Wayne, Indiana, 76845, United States|Research Site, Indianapolis, Indiana, 46256, United States|Research Site, Indianapolis, Indiana, 46260, United States|Research Site, Lafayette, Indiana, 47905, United States|Research Site, Merrillville, Indiana, 46410, United States|Research Site, Mishawaka, Indiana, 46545, United States|Research Site, Valparaiso, Indiana, 46383, United States|Research Site, Ames, Iowa, 80010, United States|Research Site, Des Moines, Iowa, 50309, United States|Research Site, Des Moines, Iowa, 50314, United States|Research Site, Iowa City, Iowa, 52242, United States|Research Site, West Burlington, Iowa, 52655, United States|Research Site, Hays, Kansas, 67601, United States|Research Site, Kansas City, Kansas, 66160, United States|Research Site, Lenexa, Kansas, 66214, United States|Research Site, Overland Park, Kansas, 66212, United States|Research Site, Topeka, Kansas, 66606, United States|Research Site, Wichita, Kansas, 67206, United States|Research Site, Wichita, Kansas, 67208, United States|Research Site, Wichita, Kansas, 67214, United States|Research Site, Lexington, Kentucky, 40513, United States|Research Site, Lexington, Kentucky, 40536, United States|Research Site, Louisville, Kentucky, 40207, United States|Research Site, Paducah, Kentucky, 42003, United States|Research Site, Alexandria, Louisiana, 71301, United States|Research Site, Baton Rouge, Louisiana, 70809, United States|Research Site, Baton Rouge, Louisiana, 70810, United States|Research Site, Lacombe, Louisiana, 70445, United States|Research Site, Lafayette, Louisiana, 70506, United States|Research Site, New Orleans, Louisiana, 70112, United States|Research Site, New Orleans, Louisiana, 70115, United States|Research Site, Shreveport, Louisiana, 71103, United States|Research Site, Belfast, Maine, 04915, United States|Research Site, Lewiston, Maine, 04240, United States|Research Site, Scarborough, Maine, 04074, United States|Research Site, Westbrook, Maine, 04092, United States|Research Site, Annapolis, Maryland, 21401, United States|Research Site, Baltimore, Maryland, 21201, United States|Research Site, Baltimore, Maryland, 21287, United States|Research Site, Bethesda, Maryland, 20814, United States|Research Site, Frederick, Maryland, 21702, United States|Research Site, Hagerstown, Maryland, 21742, United States|Research Site, Attleboro, Massachusetts, 02703, United States|Research Site, Boston, Massachusetts, 02111, United States|Research Site, Boston, Massachusetts, 02135, United States|Research Site, Boston, Massachusetts, 02215, United States|Research Site, Brookline, Massachusetts, 02445, United States|Research Site, Burlington, Massachusetts, 01805, United States|Research Site, Milford, Massachusetts, 01757, United States|Research Site, Peabody, Massachusetts, 01960, United States|Research Site, Springfield, Massachusetts, 01104, United States|Research Site, Worcester, Massachusetts, 01605, United States|Research Site, Ann Arbor, Michigan, 48109, United States|Research Site, Bingham Farms, Michigan, 48025, United States|Research Site, Cinton Township, Michigan, 48035, United States|Research Site, Detroit, Michigan, 48201, United States|Research Site, Detroit, Michigan, 48202, United States|Research Site, East Lansing, Michigan, 48824, United States|Research Site, Farmington Hills, Michigan, 48334, United States|Research Site, Grand Rapids, Michigan, 49525, United States|Research Site, Kalamazoo, Michigan, 49007, United States|Research Site, Kalamazoo, Michigan, 49048, United States|Research Site, Midland, Michigan, 48640, United States|Research Site, Muskegon, Michigan, 49444, United States|Research Site, Rochester Hills, Michigan, 48307, United States|Research Site, Roseville, Michigan, 48066, United States|Research Site, Saginaw, Michigan, 48604, United States|Research Site, Southfield, Michigan, 48034, United States|Research Site, Traverse City, Michigan, 49684, United States|Research Site, West Bloomfield, Michigan, 48322, United States|Research Site, Woodhaven, Michigan, 48183, United States|Research Site, Golden Valley, Minnesota, 55422, United States|Research Site, Minneapolis, Minnesota, 55404, United States|Research Site, Minneapolis, Minnesota, 55414, United States|Research Site, Rochester, Minnesota, 55905, United States|Research Site, Greenwood, Mississippi, 38930, United States|Research Site, Hattiesburg, Mississippi, 39401, United States|Research Site, Tupelo, Mississippi, 38801, United States|Research Site, Kansas City, Missouri, 64111, United States|Research Site, Nixa, Missouri, 65714, United States|Research Site, Springfield, Missouri, 65807, United States|Research Site, St. Louis, Missouri, 63104, United States|Research Site, St. Louis, Missouri, 63110, United States|Research Site, St. Louis, Missouri, 63131, United States|Research Site, St. Louis, Missouri, 63141, United States|Research Site, Washington, Missouri, 63090, United States|Research Site, Billings, Montana, 59101, United States|Research Site, Great Falls, Montana, 59405, United States|Research Site, Missoula, Montana, 59802, United States|Research Site, Hastings, Nebraska, 68901, United States|Research Site, Lincoln, Nebraska, 68521, United States|Research Site, Norfolk, Nebraska, 68701, United States|Research Site, North Platte, Nebraska, 69101, United States|Research Site, Omaha, Nebraska, 68131, United States|Research Site, Omaha, Nebraska, 68198, United States|Research Site, Scottsbluff, Nebraska, 69361, United States|Research Site, Las Vegas, Nevada, 89102, United States|Research Site, Reno, Nevada, 89502, United States|Research Site, Reno, Nevada, 89509, United States|Research Site, Lebanon, New Hampshire, 03766, United States|Research Site, Bayonne, New Jersey, 07002, United States|Research Site, Denville, New Jersey, 07834, United States|Research Site, Edison, New Jersey, 08820, United States|Research Site, Flemington, New Jersey, 08822, United States|Research Site, Freehold, New Jersey, 07728, United States|Research Site, Lawrenceville, New Jersey, 08648, United States|Research Site, Livingston, New Jersey, 07039, United States|Research Site, New Brunswick, New Jersey, 08901, United States|Research Site, Newark, New Jersey, 07103, United States|Research Site, Paterson, New Jersey, 07503, United States|Research Site, Stratford, New Jersey, 08084, United States|Research Site, Teaneck, New Jersey, 07666, United States|Research Site, West Long Branch, New Jersey, 07764, United States|Research Site, Alburquerque, New Mexico, 87106, United States|Research Site, Albany, New York, 12205, United States|Research Site, Albany, New York, 12206, United States|Research Site, Albany, New York, 12208, United States|Research Site, Amherst, New York, 14226, United States|Research Site, Bay Shore, New York, 11706, United States|Research Site, Brooklyn, New York, 11215, United States|Research Site, Brooklyn, New York, 11219, United States|Research Site, Brooklyn, New York, 11220, United States|Research Site, Buffalo, New York, 14203, United States|Research Site, Camillus, New York, 13031, United States|Research Site, Cedarhurst, New York, 11516, United States|Research Site, Corning, New York, 14830, United States|Research Site, East Meadow, New York, 11554, United States|Research Site, East Syracuse, New York, 13057, United States|Research Site, Flushing, New York, 11365, United States|Research Site, Fresh Meadows, New York, 11365, United States|Research Site, Great Neck, New York, 11021, United States|Research Site, Kingston, New York, 12401, United States|Research Site, Lake Success, New York, 11042, United States|Research Site, Latham, New York, 12110, United States|Research Site, Mineola, New York, 11501, United States|Research Site, Mount Kisco, New York, 10549, United States|Research Site, New Hyde Park, New York, 11040, United States|Research Site, New York, New York, 10016, United States|Research Site, New York, New York, 10019, United States|Research Site, New York, New York, 10022, United States|Research Site, New York, New York, 10029, United States|Research Site, New York, New York, 10065, United States|Research Site, Newark, New York, 14513, United States|Research Site, Patchogue, New York, 11772, United States|Research Site, Plainview, New York, 11803, United States|Research Site, Poughkeepsie, New York, 12601, United States|Research Site, Rochester, New York, 14608, United States|Research Site, Rochester, New York, 14623, United States|Research Site, Rochester, New York, 14626, United States|Research Site, Rochester, New York, 14642, United States|Research Site, Rye Brook, New York, 10573, United States|Research Site, Schenectady, New York, 12308, United States|Research Site, Staten Island, New York, 10306, United States|Research Site, Stony Brook, New York, 11794, United States|Research Site, Syracuse, New York, 13210, United States|Research Site, West Seneca, New York, 14224, United States|Research Site, White Plains, New York, 10604, United States|Research Site, Williamsville, New York, 14221, United States|Research Site, Woodmere, New York, 11598, United States|Research Site, Advance, North Carolina, 27006, United States|Research Site, Asheville, North Carolina, 28806, United States|Research Site, Boone, North Carolina, 28607, United States|Research Site, Chapel Hill, North Carolina, 27599, United States|Research Site, Charlotte, North Carolina, 28203, United States|Research Site, Charlotte, North Carolina, 28204, United States|Research Site, Charlotte, North Carolina, 28207, United States|Research Site, Concord, North Carolina, 28025, United States|Research Site, Durham, North Carolina, 37710, United States|Research Site, Greensboro, North Carolina, 27405, United States|Research Site, Greenville, North Carolina, 27834, United States|Research Site, Hendersonville, North Carolina, 28792, United States|Research Site, Henderson, North Carolina, 27536, United States|Research Site, High Point, North Carolina, 27262, United States|Research Site, Mooresville, North Carolina, 28117, United States|Research Site, Pinehurst, North Carolina, 28374, United States|Research Site, Raleigh, North Carolina, 27607, United States|Research Site, Salisbury, North Carolina, 28144, United States|Research Site, Wilmington, North Carolina, 28401, United States|Research Site, Winston Salem, North Carolina, 27103, United States|Research Site, Bismarck, North Dakota, 58501, United States|Research Site, Fargo, North Dakota, 58103, United States|Research Site, Grand Forks, North Dakota, 58201, United States|Research Site, Akron, Ohio, 44320, United States|Research Site, Bellevue, Ohio, 44811, United States|Research Site, Canton, Ohio, 44718, United States|Research Site, Cincinnati, Ohio, 45219, United States|Research Site, Cleveland, Ohio, 44119, United States|Research Site, Cleveland, Ohio, 44195, United States|Research Site, Columbus, Ohio, 43210, United States|Research Site, Columbus, Ohio, 43221, United States|Research Site, Dayton, Ohio, 45417, United States|Research Site, Franklin, Ohio, 45005, United States|Research Site, Gahanna, Ohio, 43230, United States|Research Site, Newark, Ohio, 43055, United States|Research Site, Toledo, Ohio, 43617, United States|Research Site, Toledo, Ohio, 43623, United States|Research Site, Uniontown, Ohio, 44685, United States|Research Site, Youngstown, Ohio, 44504, United States|Research Site, Zanesville, Ohio, 43701, United States|Research Site, Oklahoma City, Oklahoma, 73104, United States|Research Site, Tulsa, Oklahoma, 74137, United States|Research Site, Bend, Oregon, 97701, United States|Research Site, Clackamas, Oregon, 97015, United States|Research Site, Corvallis, Oregon, 97330, United States|Research Site, Medford, Oregon, 97504, United States|Research Site, Portland, Oregon, 97225, United States|Research Site, Portland, Oregon, 97239, United States|Research Site, Roseburg, Oregon, 97471, United States|Research Site, Tulatin, Oregon, 97034, United States|Research Site, Abington, Pennsylvania, 19001, United States|Research Site, Allentown, Pennsylvania, 18103, United States|Research Site, Allentown, Pennsylvania, 18104, United States|Research Site, Altoona, Pennsylvania, 16602, United States|Research Site, Bethlehem, Pennsylvania, 18015, United States|Research Site, Brackenridge, Pennsylvania, 15014, United States|Research Site, Collegeville, Pennsylvania, 19426, United States|Research Site, Danville, Pennsylvania, 17822, United States|Research Site, Duncansville, Pennsylvania, 16635, United States|Research Site, Erie, Pennsylvania, 16507, United States|Research Site, Greensburg, Pennsylvania, 15601, United States|Research Site, Harrisburg, Pennsylvania, 17111, United States|Research Site, Hershey, Pennsylvania, 17033, United States|Research Site, Johnstown, Pennsylvania, 15904, United States|Research Site, Lititz, Pennsylvania, 17543, United States|Research Site, Meadowbrook, Pennsylvania, 19046, United States|Research Site, Monaca, Pennsylvania, 15061, United States|Research Site, Monroeville, Pennsylvania, 15146, United States|Research Site, Paoli, Pennsylvania, 19301, United States|Research Site, Philadelphia, Pennsylvania, 19104, United States|Research Site, Philadelphia, Pennsylvania, 19107, United States|Research Site, Philadelphia, Pennsylvania, 19124, United States|Research Site, Pittsburgh, Pennsylvania, 15206, United States|Research Site, Pittsburgh, Pennsylvania, 15212, United States|Research Site, Sellersville, Pennsylvania, 18960, United States|Research Site, Tarentum, Pennsylvania, 15084, United States|Research Site, Upland, Pennsylvania, 19013, United States|Research Site, Washington, Pennsylvania, 15301, United States|Research Site, West Reading, Pennsylvania, 19611, United States|Research Site, York, Pennsylvania, 17402, United States|Research Site, East Providence, Rhode Island, 02914, United States|Research Site, Providence, Rhode Island, 02903, United States|Research Site, Columbia, South Carolina, 29203, United States|Research Site, Greenville, South Carolina, 29605, United States|Research Site, Mount Pleasant, South Carolina, 29464, United States|Research Site, Port Royal, South Carolina, 29935, United States|Research Site, Spartanburg, South Carolina, 29302, United States|Research Site, Spartanburg, South Carolina, 29307, United States|Research Site, Sioux Falls, South Dakota, 57104, United States|Research Site, Sioux Falls, South Dakota, 57105, United States|Research Site, Bartlett, Tennessee, 38134, United States|Research Site, Chattanooga, Tennessee, 37403, United States|Research Site, Chattanooga, Tennessee, 37404, United States|Research Site, Columbia, Tennessee, 38401, United States|Research Site, Franklin, Tennessee, 37064, United States|Research Site, Knoxville, Tennessee, 37923, United States|Research Site, Knoxville, Tennessee, 37934, United States|Research Site, Nashville, Tennessee, 37205, United States|Research Site, Nashville, Tennessee, 73215, United States|Research Site, Amarillo, Texas, 79106, United States|Research Site, Arlington, Texas, 76012, United States|Research Site, Austin, Texas, 78705, United States|Research Site, Bedford, Texas, 76021, United States|Research Site, Colleyville, Texas, 76034, United States|Research Site, Dallas, Texas, 75214, United States|Research Site, Dallas, Texas, 75243, United States|Research Site, Dallas, Texas, 75390, United States|Research Site, Houston, Texas, 77024, United States|Research Site, Houston, Texas, 77030, United States|Research Site, Kerrville, Texas, 78028, United States|Research Site, Mansfield, Texas, 76063, United States|Research Site, Round Rock, Texas, 78681, United States|Research Site, San Antonio, Texas, 78229, United States|Research Site, San Antonio, Texas, 78231, United States|Research Site, San Antonio, Texas, 78258, United States|Research Site, Wichita Falls, Texas, 79301, United States|Research Site, Ivins, Utah, 84738, United States|Research Site, Provo, Utah, 84604, United States|Research Site, Salt Lake City, Utah, 84103, United States|Research Site, Salt Lake City, Utah, 84108, United States|Research Site, Salt Lake City, Utah, 84124, United States|Research Site, Washington Terrace, Utah, 84405, United States|Research Site, Burlington, Vermont, 05401, United States|Research Site, Alexandria, Virginia, 22304, United States|Research Site, Alexandria, Virginia, 22310, United States|Research Site, Carrollton, Virginia, 23314, United States|Research Site, Centreville, Virginia, 20120, United States|Research Site, Charlottesville, Virginia, 22903, United States|Research Site, Christiansburg, Virginia, 24073, United States|Research Site, Fairfax, Virginia, 22031, United States|Research Site, Fredericksburg, Virginia, 22401, United States|Research Site, McLean, Virginia, 22101, United States|Research Site, Newport News, Virginia, 23601, United States|Research Site, Norfolk, Virginia, 23502, United States|Research Site, Norfolk, Virginia, 23507, United States|Research Site, Richmond, Virginia, 23226, United States|Research Site, Roanoke, Virginia, 24018, United States|Research Site, Stafford, Virginia, 22556, United States|Research Site, Vienna, Virginia, 22182, United States|Research Site, Winchester, Virginia, 22601, United States|Research Site, Auburn, Washington, 98001, United States|Research Site, Bellingham, Washington, 98225, United States|Research Site, Burien, Washington, 98166, United States|Research Site, Federal Way, Washington, 98003, United States|Research Site, Kirkland, Washington, 98034, United States|Research Site, Mount Vernon, Washington, 98274, United States|Research Site, Renton, Washington, 98055, United States|Research Site, Richland, Washington, 99352, United States|Research Site, Seattle, Washington, 98101, United States|Research Site, Seattle, Washington, 98122, United States|Research Site, Seattle, Washington, 98195, United States|Research Site, Silverdale, Washington, 98383, United States|Research Site, Spokane, Washington, 99202, United States|Research Site, Spokane, Washington, 99204, United States|Research Site, Spokane, Washington, 99208, United States|Research Site, Tacoma, Washington, 98405, United States|Research Site, Wenatchee, Washington, 98801, United States|Research Site, Huntington, West Virginia, 25702, United States|Research Site, Point Pleasant, West Virginia, 25550, United States|Research Site, Green Bay, Wisconsin, 54301, United States|Research Site, Green Bay, Wisconsin, 54308, United States|Research Site, La Crosse, Wisconsin, 54601, United States|Research Site, Madison, Wisconsin, 53715, United States|Research Site, Milwaukee, Wisconsin, 53215, United States|Research Site, Milwaukee, Wisconsin, 53226, United States|Research Site, Neenah, Wisconsin, 54956, United States|Research Site, Waukesha, Wisconsin, 53188, United States|Research Site, Cheyenne, Wyoming, 82001, United States|Research Site, Arecibo, 00612, Puerto Rico|Research Site, Bayamon, 00961, Puerto Rico|Research Site, Guaynabo, 00968, Puerto Rico|Research Site, Mayaguez, 00680, Puerto Rico|Research Site, Ponce, 00717, Puerto Rico"
NCT05064436,"A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT05064436,RECRUITING,Multiple Sclerosis (MS),DRUG: 11C-BMS-986196,Bristol-Myers Squibb,,ALL,ADULT,PHASE1,14,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-12-10,2023-07-23,2023-07-23,"University Of Michigan, Ann Arbor, Michigan, 48109, United States|Local Institution - 0002, London, W12 0HS, United Kingdom"
NCT05688436,A Study to Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate,https://beta.clinicaltrials.gov/study/NCT05688436,RECRUITING,Multiple Sclerosis,DRUG: Diroximel Fumarate|BIOLOGICAL: Alemtuzumab|DRUG: Fingolimod|DRUG: Glatiramer acetate|BIOLOGICAL: Interferon beta|BIOLOGICAL: Natalizumab|BIOLOGICAL: Ocrelizumab|BIOLOGICAL: Peginterferon beta-1a|DRUG: Siponimod,Biogen,,FEMALE,ADULT,,825,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-09-24,2031-01-17,2031-01-17,"OptumInsight, Eden Prairie, Minnesota, 55344-2503, United States"
NCT01507636,Occupational Therapy in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01507636,COMPLETED,Multiple Sclerosis|Apraxia,OTHER: Occupational Therapy|OTHER: Physical therapy,"University Hospital Inselspital, Berne",,ALL,ADULT,NA,40,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2012-01,2012-12,2012-12,"Department of Neurology, Bern university Hospital, Bern, 3010, Switzerland"
NCT03976128,Endurance and Walking Training by Nordic Walking in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03976128,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Nordic Walking Training|BEHAVIORAL: Conventional endurance training,Multiple Sclerosis Center of Catalonia,,ALL,"ADULT, OLDER_ADULT",NA,66,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2016-09,2019-06,2020-03,"Multiple Sclerosis Center of Catalonia, Barcelona, 08035, Spain"
NCT05598736,"Performance and Long-term Safety of FlowOx2.0™, Multiple Sclerosis, Spasticity and Pain",https://beta.clinicaltrials.gov/study/NCT05598736,ENROLLING_BY_INVITATION,"Multiple Sclerosis|Spasticity, Muscle|Pain",DEVICE: FlowOx 2.0,Otivio AS,,ALL,"ADULT, OLDER_ADULT",NA,60,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-11-04,2023-06-30,2023-12-31,"Dept. of Neurology Haukeland Univ. Hospital & Dept. of Clin. Med., Univ. of Bergen, Bergen, Norway, Bergen, 5839, Norway"
NCT03817424,"A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis",https://beta.clinicaltrials.gov/study/NCT03817424,COMPLETED,Systemic Lupus Erythematosus|Cutaneous Lupus Erythematosus|Sjogren's Syndrome|Systemic Sclerosis|Polymyositis|Dermatomyositis,DRUG: VIB7734|DRUG: Placebo,Viela Bio,,ALL,"ADULT, OLDER_ADULT",PHASE1,31,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2018-12-13,2020-07-20,2020-07-20,"Viela Bio Investigative Site, Anniston, Alabama, 36201, United States|Viela Bio Investigative Site, Birmingham, Alabama, 35294, United States|Viela Bio Investigative Site, Los Angeles, California, 90022, United States|Viela Bio Investigative Site, Upland, California, 91786, United States|Viela Bio Investigative Site, Danbury, Connecticut, 06810, United States|Viela Bio Investigative Site, Fort Lauderdale, Florida, 33309, United States|Viela Bio Investigative Site, Hialeah, Florida, 33016, United States|Viela Bio Investigative Site, Jacksonville, Florida, 32216, United States|Viela Bio Investigative Site, Miami Lakes, Florida, 33014, United States|Viela Bio Investigative Site, Saint Petersburg, Florida, 33710, United States|Viela Bio Investigative Site, Lawrenceville, Georgia, 30046, United States|Viela Bio Investigative Site, Great Neck, New York, 11021, United States|Viela Bio Investigative Site, Charlotte, North Carolina, 28204, United States|Viela Bio Investigative Site, Durham, North Carolina, 27713, United States|Viela Bio Investigative Site, Duncansville, Pennsylvania, 16635, United States|Viela Bio Investigative Site, Philadelphia, Pennsylvania, 19104, United States|Viela Bio Investigative Site, Memphis, Tennessee, 38119, United States|Viela Bio Investigative Site, Allen, Texas, 75013, United States|Viela Bio Investigative Site, Mesquite, Texas, 75150, United States|Viela Bio Investigative Site, Białystok, Poland|Viela Bio Investigative Site, Bydgoszcz, Poland|Viela Bio Investigative Site, Kraków, Poland|Viela Bio Investigative Site, Poznań, Poland|Viela Bio Investigative Site, Rzeszów, Poland|Viela Bio Investigative Site, Warsaw, Poland|Viela Bio Investigative Site, Wrocław, Poland|Viela Bio Investigative Site, Barcelona, Spain|Viela Bio Investigative Site, Bilbao, Spain|Viela Bio Investigative Site, Madrid, Spain|Viela Bio Investigative Site, Sevilla, Spain"
NCT01838824,Applying Speed of Processing Training to Individuals With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01838824,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Speed of Processing Training,Kessler Foundation,National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",NA,38,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2011-11,2020-03,2021-12,"Kessler Foundation, West Orange, New Jersey, 07052, United States"
NCT02654340,Biomarkers for Tuberous Sclerosis Complex (BioTuScCom),https://beta.clinicaltrials.gov/study/NCT02654340,TERMINATED,Hypomelanotic Macules|Facial Angiofibroma|Shagreen Patches|Ungual Fibromas|Cortical Dysplasia|Cardiac Rhabdomyoma|Lymphangioleiomyomatosis|Renal Angiomyolipoma|Subependymal Giant Cell Astrocytoma,,CENTOGENE GmbH Rostock,,ALL,"CHILD, ADULT",,20,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-08-01,2022-12-30,2022-12-30,"University Hospital Center Mother Teresa, Tirana, 10001, Albania|Department of Pediatrics, Alexandria University Children's Hospital, Alexandria, 21131, Egypt|Departmnet of Molecular and Medical Genetics, Tbilisi State Medical University, Tbilisi, 0177, Georgia|Department of Pediatric Genetics, Amrita Institute of Medical Sciences & Research Centre, Cochin, Kerala, 682041, India|Rare diseases coordinating centre, Vilnius University Hospital Santaros klinikos, Vilnius, Lithuania|Departmnet of Pediatric Gastroenterology and Hepatology, The Children's Hospital and Institute of Child Health, Lahore, 54600, Pakistan|Emergency Hospital for Children ""Louis Turcanu"", Timişoara, 300011, Romania|Lady Ridgeway Hospital for Children, Colombo, 00800, Sri Lanka"
NCT04276324,"Effects of Ten-Weeks Power Training on Neuromuscular Performance, Heart Rate Variability, Sleep Quality and Mobility in Persons With Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT04276324,COMPLETED,Multiple Sclerosis,OTHER: Resistance training|OTHER: Testing sessions,Universidad Católica San Antonio de Murcia,,ALL,ADULT,NA,36,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-03-10,2020-06-15,2020-10-15,"Universidad Católica San Antonio, Murcia, 30107, Spain"
NCT01758224,Expiratory Muscle Conditioning in Multiple Sclerosis Using Magnetic Stimulation,https://beta.clinicaltrials.gov/study/NCT01758224,COMPLETED,Multiple Sclerosis,OTHER: Functional Magnetic Stimulation|OTHER: Resistive Expiratory Muscle Training,The Cleveland Clinic,United States Department of Defense,ALL,"ADULT, OLDER_ADULT",NA,4,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2012-09,2015-09,2015-09,"Cleveland Clinic, Cleveland, Ohio, 44195, United States"
NCT00047580,Comparison of Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex® (Tizanidine Hydrochloride Tablets) Taken While in the Fed State (Just After a Meal) and in the Fasted State (Before a Meal) in Patients With Moderate to Severe Spasticity.,https://beta.clinicaltrials.gov/study/NCT00047580,COMPLETED,Multiple Sclerosis|Muscle Spasticity|Spinal Cord Injury|Stroke,DRUG: tizanidine hydrochloride capsule,Elan Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,120,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: |Masking: NONE|Primary Purpose: TREATMENT,2002-06,,2002-09,"Radiant Research, Tucson, Arizona, 85710, United States|The Neurology Center, Encinitas, California, 92024, United States|Northridge Neurological Center, Northridge, California, 91325, United States|The Neurology Center, Oceanside, California, 92056, United States|Neurology Medical Group of Diablo Valley, Walnut Creek, California, 94598, United States|Colorado Neurology Movement Disorders Center, Englewood, Colorado, 80110, United States|Yale Center for MS Treatment and Research, New Haven, Connecticut, 06510, United States|Neurology Clinic Research Institution, Plantation, Florida, 33324, United States|Axiom Clinical Research, Tampa, Florida, 33609, United States|Comprehensive Neurology Specialists, PC, Atlanta, Georgia, 30338, United States|Neurotrials Research, Inc., Atlanta, Georgia, 30342, United States|Springfield Clinic Neuroscience Institute, Springfield, Illinois, 62702, United States|The Minneapolis Clinic of Neurology, Ltd., Minneapolis, Minnesota, 55422, United States|Neurological Associates of Tulsa, Inc., Tulsa, Oklahoma, 74136-8327, United States|Medford Neurological and Spine Clinic, Medford, Oregon, 97504-8456, United States|Sargent Rehabilitation Center, Warwick, Rhode Island, 02818, United States"
NCT03703180,Vision Assessment With the Quick Contrast Sensitivity Function (qCSF) Method in Healthy Controls and MS,https://beta.clinicaltrials.gov/study/NCT03703180,UNKNOWN,Multiple Sclerosis,,Universitätsklinikum Hamburg-Eppendorf,,ALL,"ADULT, OLDER_ADULT",,200,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-01-29,2021-02,2021-02,"Institute of Neuroimmunology and MS, Hamburg, 20246, Germany"
NCT05054140,"Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT05054140,RECRUITING,Multiple Sclerosis,DRUG: IMU-838|DRUG: Placebo matching IMU-838,Immunic AG,,ALL,"ADULT, OLDER_ADULT",PHASE2,450,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-09-30,2024-04-05,2024-07-28,"Los Angeles County Harbor UCLA, Medical Center and Lundquist Institute, Torrance, California, 90504, United States|Dr. Sonia Kalirao, Coral Springs, Florida, 33067, United States|Collier Neurologic Specialists, Naples, Florida, 34105, United States|Prof. James Scott, Ormond Beach, Florida, 32174, United States|Shepherd Center, Atlanta, Georgia, 30309, United States|Consultants in Neurology, Ltd., Northbrook, Illinois, 60062, United States|Prof. George Katsamakis, Rolling Meadows, Illinois, 60008, United States|Dr. Daniel Becker, Lutherville, Maryland, 21093, United States|Dr. Mirela Cerghet, Detroit, Michigan, 48202, United States|University of New Mexico (UNM), MS Specialty Clinic, Albuquerque, New Mexico, 87106, United States|MHAT Pulse, Blagoevgrad, 2700, Bulgaria|MHAT""Heart and Brain"" EAD, Burgas, Bulgaria|Dr. Maya Danovska, Pleven, 5800, Bulgaria|Dr. Plamen Bozhinov, Pleven, 5804, Bulgaria|UMHAT Pulmed, Plovdiv, Bulgaria|Dr. Rositsa Krasteva, Ruse, 7003, Bulgaria|Dr. Nikolay Georgiev, Shumen, 9700, Bulgaria|MHAT Shumen, Shumen, 9705, Bulgaria|Dr. Ivan Milanov, Sofia, 1113, Bulgaria|MHAT Lyulin, Sofia, 1336, Bulgaria|Dr. Rosen Ikonomov, Sofia, 1408, Bulgaria|Dr. Penko Shotekov, Sofia, 1431, Bulgaria|UMHAT Alexandrovska, Sofia, 1431, Bulgaria|Dr. Kana Prinova, Sofia, 1606, Bulgaria|Dr. Kosta Kostov, Sofia, 1606, Bulgaria|MHAT Sveta Sofia, Sofia, Bulgaria|UMHATSM N.I.Pirogov, Sofia, Bulgaria|UMHAT Prof. Stoyan Kirkovich, Stara Zagora, Bulgaria|Dr. Ara Kaprelyan, Varna, 9010, Bulgaria|Montreal Neurological Inst., Montréal, H3A 2B4, Canada|The Ottawa Hospital Research Institute, Ottawa, K1H 8L6, Canada|The University Hospital Brno, Brno, Czechia|Fakultni nemocnice, Hradec Králové, Czechia|Nemocniční lékárna, Prague, Czechia|Klinikum Bayreuth GmbH, Bayreuth, 95445, Germany|Klinik und Poliklinik für Neurologie, Universitätsklinikum Dresden, Dresden, 01307, Germany|Neuro Centrum Science GmbH, Erbach, Germany|Universitätsklinikum Hamburg Eppendorf, Hamburg, 20251, Germany|Datamed GmbH, Köln, 50935, Germany|Klinikum rechts der Isar, München, Germany|Universitätsklinikum Münster, Klinik für Neurologie, Münster, 48149, Germany|Dr. Stanislav Groppa, Chisinau, 2004, Moldova, Republic of|Dr. Mihail Gavriliuc, Chisinau, 2028, Moldova, Republic of|Dr. Olesea Odainic, Chisinau, 2028, Moldova, Republic of|Dr. Eva Strijibis, Amsterdam, 1081BT, Netherlands|Alrijne ziekenhuis, Leiderdorp, Netherlands|Dr. Ana Doneva Skopje 1000, Skopje, 1000, North Macedonia|Dr. Milcho Demerdziev, Skopje, 1000, North Macedonia|Dr. Tatjana Boshkova, Skopje, 1000, North Macedonia|Dr. Robert Bonek, Bydgoszcz, 85-796, Poland|Dr. Maciej Maciejowski, Katowice, 40-571, Poland|Dr. Janusz Zbrojkiewicz, Katowice, 40-686, Poland|Dr. Elzbieta Jasinska, Kielce, 25-726, Poland|Indywidualna Praktyka Lekarska Prof. Rejdak, Lublin, 20-016, Poland|Dr. Marcin Nastaj, Lublin, 20-640, Poland|Instytut Zdrowia, Oświęcim, Poland|Dr. Justyna Hryniewicz, Plewiska, 62-064, Poland|Clinical Research Center, Poznań, Poland|EMC PL Certus, Poznań, Poland|NZOZ ""Neuro-kard"", Poznań, Poland|Dr. Marcin Ratajczak, Szczecin, 70-111, Poland|Provita Poliklinika, Warsaw, Poland|Warszawska Klinika, Warsaw, Poland|EMC Instytut Medyczny, Wrocław, Poland|Dr. Cristina Panea, Bucharest, 11461, Romania|Dr. Adriana Dulamea, Bucharest, 22328, Romania|Dr. Lacramioara Perju-Dumbrava, Cluj-Napoca, 400013, Romania|Dr. Ana Maria Ionescu, Constanta, 900123, Romania|Dr. Steliana Halmagean, Timisoara, 300425, Romania|Clinical Hospital Center Zemun, Belgrade, Serbia|Military Medical Academy, Belgrade, Serbia|Klinicki Centar Kragujevac, Kragujevac, 34000, Serbia|University Clinical Center Nis, Niš, Serbia|Clinical center of Vojvodina, Novi Sad, Serbia|Chernivtsi Medical Hospital, Chernivtsi, Ukraine|Dr. Olena Moroz, Dnipro, 49000, Ukraine|Dr. Pavlo Khaitov, Dnipro, 49128, Ukraine|Dr. Tamara Mishchenko, Kharkiv, 61068, Ukraine|Dr. Hanna Hostieva, Kherson, 73003, Ukraine|Dr. Oleksandr Doroschenko, Krykhivtsi, 76493, Ukraine|Dr. Larysa Sokolova, Kyiv, 03037, Ukraine|Dr. Galusha, Kyiv, 04106, Ukraine|Dr. Olga Shulga, Lutsk, 43005, Ukraine|Dr.Tetyana Nehrych, Lviv, 79010, Ukraine|Dr. Svitlana Skhrobot, Ternopil, 46024, Ukraine|Dr. Sergii Moskovko, Vinnytsya, 21050, Ukraine|Dr. Nataliya Tomakh, Zaporizhzhya, 69035, Ukraine|Dr. Nataliia Buchakchyska, Zaporizhzhya, 69600, Ukraine"
NCT01366040,Avonex PEN Satisfaction and Patients Experience Clinical Trial,https://beta.clinicaltrials.gov/study/NCT01366040,COMPLETED,Multiple Sclerosis,,Biogen,,ALL,"ADULT, OLDER_ADULT",,89,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-06,2012-05,2012-05,"Foothills Medical Center, Calgary, Alberta, T2N 2T9, Canada|Saint John Regional Hospital, Saint John, New Brunswick, E2L 4L2, Canada|MUN Hospital, St. John's, Newfoundland and Labrador, Newfoundland and Labrador, A1B 3V6, Canada|Dalhousie MS Research Unit, Halifax, Nova Scotia, B3H 4K4, Canada|Norfolk Medical Clinic, Guelph, Ontario, N1H 4J4, Canada|London Health Sciences Centre, London, Ontario, N6A 5A5, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, M4N 3M5, Canada|Clinique Neuro-Outaouais, Gatineau, Quebec, J9J 0A5, Canada|Neuro Rive-Sud, Greenfield Park, Quebec, J4V 2J2, Canada|IRDPQ, Quebec City, Quebec, G1M 2S8, Canada"
NCT01199640,Study of the Safety and Efficacy of MLN1202 in Patients in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01199640,COMPLETED,Multiple Sclerosis,DRUG: MLN1202,"Millennium Pharmaceuticals, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE2,50,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2005-05,2007-07,2007-10,
NCT00246324,Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00246324,COMPLETED,Multiple Sclerosis,"DRUG: Interferon beta 1a, oral doxycycline",Louisiana State University Health Sciences Center Shreveport,Biogen,ALL,ADULT,PHASE4,16,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2003-12,2009-08,2009-10,"LSU Health Sciences Center Shreveport, Shreveport, Louisiana, 71103, United States"
NCT01874340,Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01874340,TERMINATED,Multiple Sclerosis,DRUG: Placebo|DRUG: AIN457,Novartis Pharmaceuticals,,ALL,ADULT,PHASE2,28,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-06,2014-04,2014-04,"Novartis Investigative Site, Brugge, 8000, Belgium|Novartis Investigative Site, JIhlava, 586 33, Czech Republic|Novartis Investigative Site, St Herblain, 44800, France|Novartis Investigative Site, Roma, RM, 00133, Italy|Novartis Investigative Site, Osaka-city, Osaka, 556-0016, Japan|Novartis Investigative Site, Lodz, 93-121, Poland|Novartis Investigative Site, Poznan, 60-355, Poland|Novartis Investigative Site, Moscow, 127018, Russian Federation|Novartis Investigative Site, Saint-Petersburg, 194044, Russian Federation|Novartis Investigative Site, Barcelona, Catalunya, 08035, Spain|Novartis Investigative Site, Bilbao, Pais Vasco, 48013, Spain|Novartis Investigative Site, Stockholm, 17176, Sweden|Novartis Investigative Site, Atakum / Samsun, 55139, Turkey"
NCT05116540,Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05116540,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,BIOLOGICAL: HB-adMSCs|DRUG: Placebo,Hope Biosciences Stem Cell Research Foundation,,ALL,"ADULT, OLDER_ADULT",PHASE2,24,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-11-24,2023-11-22,2023-11-22,"Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, 77478, United States"
NCT02882724,"Changes in Speed, Endurance and Balance in Women Patients With Multiple Sclerosis After 4 & 8 Weeks of Aquatic Exercise Training",https://beta.clinicaltrials.gov/study/NCT02882724,COMPLETED,Multiple Sclerosis|Aquatic|Exercise,BEHAVIORAL: Exercise|BEHAVIORAL: Control,University of Isfahan,,FEMALE,ADULT,PHASE1,32,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-01,2016-04,,
NCT00666224,Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome,https://beta.clinicaltrials.gov/study/NCT00666224,COMPLETED,Multiple Sclerosis,DRUG: Glatiramer Acetate (DB)|DRUG: Placebo|DRUG: Glatiramer Acetate (OL),"Teva Branded Pharmaceutical Products R&D, Inc.",,ALL,ADULT,PHASE3,481,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2004-01,2007-10,2010-06,
NCT04574024,HFP (High-Fiber Supplement) in MS (Multiple Sclerosis),https://beta.clinicaltrials.gov/study/NCT04574024,ENROLLING_BY_INVITATION,Multiple Sclerosis,DRUG: NBT-NM108 (60 g/day)|OTHER: NBT-NM108 (0 g/day),"Suhayl Dhib-Jalbut, MD",,ALL,ADULT,PHASE1|PHASE2,50,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2021-11-16,2022-09-30,2023-09-30,"Robert Wood Johnson University Hospital, New Brunswick, New Jersey, 08901, United States"
NCT05208840,A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05208840,NOT_YET_RECRUITING,Multiple Sclerosis,DRUG: Ocrelizumab,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE4,50,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-02-14,2025-01-31,2026-01-31,"City Clinical Hospital #24; Multipal Sclerosis department, Moskva, Moskovskaja Oblast, 127015, Russian Federation|National Center of Socially Significant Diseases, Saint-Petersburg, Sankt Petersburg, 197110, Russian Federation"
NCT03490240,Project BIPAMS: Behavioral Intervention for Physical Activity in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03490240,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,BEHAVIORAL: BIPAMS|BEHAVIORAL: WELLMS,University of Alabama at Birmingham,National Multiple Sclerosis Society,ALL,ADULT,NA,280,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2018-03-01,2023-03-01,2023-12-31,"Exercise Neuroscience Research Lab, Birmingham, Alabama, 35233, United States"
NCT00870740,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00870740,COMPLETED,Relapsing-Remitting Multiple Sclerosis,BIOLOGICAL: BIIB019 (Daclizumab High Yield Process)|DRUG: Placebo,Biogen,AbbVie,ALL,ADULT,PHASE2,517,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-02,2012-05,2012-10,"Research Site, Brno, Czech Republic|Research Site, Hraddec Kralove, Czech Republic|Research Site, Olomouc, Czech Republic|Research Site, Plzen, Czech Republic|Research Site, Prague, Czech Republic|Research Site, Teplice, Czech Republic|Research Site, Bayreuth, Germany|Research Site, Erlangen, Germany|Research Site, Marburg, Germany|Research Site, Osnabruck, Germany|Research Site, Regensburg, Germany|Research Site, Rostock, Germany|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Esztergom, Hungary|Research Site, Gyor, Hungary|Research Site, Kecskemet, Hungary|Research Site, Miskolc, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Siofok, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Andra-Pradeash, India|Research Site, Bangalore, India|Research Site, Jaipur, India|Research Site, Kolkata, India|Research Site, Mumbai, India|Research Site, Visakhapatnam, India|Research Site, Bialystok, Poland|Research Site, Gdansk, Poland|Research Site, Katowice, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Warsaw, Poland|Research Site, Warszawa, Poland|Research Site, Kazan, Russian Federation|Research Site, Krasnoyarsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Samara, Russian Federation|Research Site, Smolensk, Russian Federation|Research Site, St Petersburg, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Yaroskavl, Russian Federation|Research Site, Chernivtsi, Ukraine|Research Site, Dnipropetrovsk, Ukraine|Research Site, Donetsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kiev, Ukraine|Research Site, Lviv, Ukraine|Research Site, Poltava, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Zaporozhye, Ukraine|Research Site, Devon, United Kingdom|Research Site, London, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Stoke-on-Trent, United Kingdom"
NCT03735524,Exercise-based Therapy for Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT03735524,UNKNOWN,Multiple Sclerosis,OTHER: Exercise,Neuromed IRCCS,,ALL,"ADULT, OLDER_ADULT",NA,35,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2019-05,2020-11,2021-05,"IRCCS Neuromed, Pozzilli, Isernia, 86077, Italy"
NCT05546424,EMRESERVA to Enhance Cognitive Reserve in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05546424,RECRUITING,Cognitive Change,BEHAVIORAL: EMRESERVA,Fundación Pública Andaluza para la gestión de la Investigación en Sevilla,,ALL,ADULT,,58,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-05-19,2023-10-30,2023-10-30,"Fundación Pública Andaluza para la gestión de la Investigación en Salud de Sevilla (FISEVI), Sevilla, Andalucía, 41013, Spain"
NCT03254680,Turmeric as Treatment in Epilepsy,https://beta.clinicaltrials.gov/study/NCT03254680,WITHDRAWN,Epilepsy|Dravet Syndrome|Lennox-Gastaut Syndrome|Tuberous Sclerosis|Focal Seizures,DIETARY_SUPPLEMENT: Turmeric,NYU Langone Health,,ALL,"CHILD, ADULT, OLDER_ADULT",NA,0,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-03,2018-11,2018-11,"New York University School of Medicine, New York, New York, 10016, United States"
NCT03205280,Clinical Decision Support System (CADIMS) for MS Diagnostic,https://beta.clinicaltrials.gov/study/NCT03205280,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",,Rennes University Hospital,Association Neuro-Bretagne|Institut National de Recherche en Informatique et en Automatique|Groupement de Coopération Sanitaire e-Santé Bretagne|Institut de Recherche Technologique b<>com,ALL,"ADULT, OLDER_ADULT",,200,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-10-11,2022-12-07,2022-12-07,"Centre Hospitalier Bretagne Sud, Lorient, 56322, France|Centre Hospitalier Universitaire de Rennes, Rennes, 35000, France|Centre Hospitalier, Rennes, 35500, France|Centre d'imagerie médicale de la découverte, Saint-Malo, 35400, France|Centre Hospitalier Bretagne Atlantique, Vannes, 56017, France"
NCT01080040,To Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT01080040,COMPLETED,"Multiple Sclerosis, Relapsing Remitting",,"Merck KGaA, Darmstadt, Germany",,ALL,ADULT,,150,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2008-08,2013-03,2013-03,"Fundación Rosarina de Neurorehabilitación, Rosario, Argentina"
NCT04073940,Exploration of Brain Changes Due to a Targeted Ballet Program in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04073940,UNKNOWN,"Multiple Sclerosis, Relapsing-Remitting",BEHAVIORAL: Targeted Ballet Program,University of Illinois at Urbana-Champaign,,ALL,ADULT,NA,30,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2019-08-29,2021-01-15,2021-01-15,"University of Illinois at Urbana-Champaign, Champaign, Illinois, 61820, United States"
NCT02486640,Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon,https://beta.clinicaltrials.gov/study/NCT02486640,COMPLETED,Multiple Sclerosis,"DRUG: Interferon beta-1b (Betaferon, BAY86-5046)|DEVICE: Betaconnect Autoinjector",Bayer,,ALL,"ADULT, OLDER_ADULT",,162,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-09-08,2019-10-31,2020-01-16,"Multiple Locations, Germany"
NCT04178980,Role of Simvastatin in Relapsing-Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04178980,UNKNOWN,Simvastatin Multiple Sclerosis,DRUG: Simvastatin in relapsing remitting multiple sclerosis,Assiut University,,ALL,"ADULT, OLDER_ADULT",PHASE1,60,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2020-01-01,2022-01-01,2022-03-01,
NCT03677440,Exercise Training Effects on Cognition and Brain Function in Multiple Sclerosis: Project EXACT,https://beta.clinicaltrials.gov/study/NCT03677440,RECRUITING,Multiple Sclerosis|Cognitive Impairment,BEHAVIORAL: Treadmill Walking Exercise Training|BEHAVIORAL: Stretching-and-Toning Exercise Training,Kessler Foundation,National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),ALL,"ADULT, OLDER_ADULT",NA,88,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-02-05,2023-08-30,2023-09-30,"Kessler Foundation, West Orange, New Jersey, 07052, United States"
NCT01457924,Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01457924,COMPLETED,Multiple Sclerosis,DRUG: Ofatumumab 3mg|DRUG: Ofatumumab 30mg|DRUG: Ofatumumab 60mg|DRUG: Placebo,GlaxoSmithKline,,ALL,ADULT,PHASE2,232,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-11-01,2013-08-23,2015-06-10,"GSK Investigational Site, Cullman, Alabama, 35058, United States|GSK Investigational Site, Fullerton, California, 92835, United States|GSK Investigational Site, Fairfield, Connecticut, 06824, United States|GSK Investigational Site, Miami, Florida, 33136, United States|GSK Investigational Site, Sunrise, Florida, 33351, United States|GSK Investigational Site, Tampa, Florida, 33612, United States|GSK Investigational Site, West Palm Beach, Florida, 33407, United States|GSK Investigational Site, Atlanta, Georgia, 30327, United States|GSK Investigational Site, Northbrook, Illinois, 60062, United States|GSK Investigational Site, Fort Wayne, Indiana, 46805, United States|GSK Investigational Site, Grand Rapids, Michigan, 49503, United States|GSK Investigational Site, Oklahoma City, Oklahoma, 73104, United States|GSK Investigational Site, Philadelphia, Pennsylvania, 19107, United States|GSK Investigational Site, Nashville, Tennessee, 37204, United States|GSK Investigational Site, Round Rock, Texas, 78681, United States|GSK Investigational Site, Seattle, Washington, 98122, United States|GSK Investigational Site, Sofia, 1000, Bulgaria|GSK Investigational Site, Sofia, 1113, Bulgaria|GSK Investigational Site, Sofia, 1309, Bulgaria|GSK Investigational Site, Sofia, 1431, Bulgaria|GSK Investigational Site, Edmonton, Alberta, T6G 1Z1, Canada|GSK Investigational Site, Montreal, Quebec, H3A 2B4, Canada|GSK Investigational Site, Brno, 625 00, Czechia|GSK Investigational Site, Brno, 656 91, Czechia|GSK Investigational Site, Jihlava, 586 33, Czechia|GSK Investigational Site, Olomouc, 775 20, Czechia|GSK Investigational Site, Teplice, 415 29, Czechia|GSK Investigational Site, Koebenhavn Ø, 2100, Denmark|GSK Investigational Site, Alzenau, Bayern, 63755, Germany|GSK Investigational Site, Achim, Niedersachsen, 28832, Germany|GSK Investigational Site, Hannover, Niedersachsen, 30625, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, 44791, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, 50935, Germany|GSK Investigational Site, Leipzig, Sachsen, 04103, Germany|GSK Investigational Site, Berlin, 10961, Germany|GSK Investigational Site, Berlin, 12163, Germany|GSK Investigational Site, Hamburg, 22087, Germany|GSK Investigational Site, Modena, Emilia-Romagna, 41126, Italy|GSK Investigational Site, Verona, Veneto, 37134, Italy|GSK Investigational Site, Sittard-geleen, 6162 BG, Netherlands|GSK Investigational Site, Venray, 5801 CE, Netherlands|GSK Investigational Site, Hamar, 2317, Norway|GSK Investigational Site, Kazan, 420021, Russian Federation|GSK Investigational Site, Moscow, 107150, Russian Federation|GSK Investigational Site, Moscow, 119049, Russian Federation|GSK Investigational Site, Moscow, 127018, Russian Federation|GSK Investigational Site, N. Novgorod, 603126, Russian Federation|GSK Investigational Site, Smolensk, 214018, Russian Federation|GSK Investigational Site, St. Petersburg, 197022, Russian Federation|GSK Investigational Site, St.Petersburg, 194291, Russian Federation|GSK Investigational Site, Baracaldo/Vizcaya, 48903, Spain|GSK Investigational Site, Barcelona, 08035, Spain|GSK Investigational Site, Barcelona, 08907, Spain|GSK Investigational Site, Castellón, 12004, Spain|GSK Investigational Site, Córdoba, 14001, Spain|GSK Investigational Site, Girona, 17007, Spain|GSK Investigational Site, Madrid, 28034, Spain|GSK Investigational Site, Madrid, 28040, Spain|GSK Investigational Site, Madrid, 28046, Spain|GSK Investigational Site, Malaga, 29010, Spain|GSK Investigational Site, Sevilla, 41071, Spain"
NCT04116424,VIGIP-SEP2: Evaluation of the Impact of the Training of Patients by a Nurse on the Adverse Drug Reaction Reporting by RRMS Patient Via a Mobile Application: Randomized Real-life Study,https://beta.clinicaltrials.gov/study/NCT04116424,UNKNOWN,Multiple Sclerosis,OTHER: nurse training of the patient|OTHER: neurologist accompaniement,"University Hospital, Caen",,ALL,"ADULT, OLDER_ADULT",NA,46,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-01,2021-01,2021-04,
NCT03888924,Bacille Calmette-Guérin (BCG) Vaccine In Radiologically Isolated Syndrome (RIS),https://beta.clinicaltrials.gov/study/NCT03888924,RECRUITING,Multiple Sclerosis,DRUG: Bacille Calmette-Guerin vaccine|DRUG: Placebo,S. Andrea Hospital,,ALL,"ADULT, OLDER_ADULT",PHASE2,100,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2019-06-17,2023-07-01,2023-10-01,"Center for Experimental Neurological Therapies (CENTERS), S. Andrea Hospital, Faculty of Medicine and Psychology, ""Sapienza"" University of Rome, Rome, 00139, Italy"
NCT04988880,Territorial Implementation and Evaluation of a Multiple Sclerosis Expert Patient Program,https://beta.clinicaltrials.gov/study/NCT04988880,ACTIVE_NOT_RECRUITING,Multiple Sclerosis|Quality of Life|Patient Empowerment|Patient Activation|Fatigue|Peer Group,OTHER: Multiple Sclerosis Expert Patient Program of Catalonia,Hospital Universitari Vall d'Hebron Research Institute,,ALL,"ADULT, OLDER_ADULT",NA,152,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-11-01,2023-12-31,2024-07-31,"Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, 08916, Spain|Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Barcelona Hospital Campus, Barcelona, 08035, Spain|Center for Neuroimmunology. Advanced Imaging in Neuroimmunological Diseases lab (ImaginEM). Hospital Clinic Barcelona, Barcelona, 08036, Spain|Unitat de Neuroimmunologia i Esclerosi Múltiple, Girona, 17007, Spain|Hospital Universitari Arnau de Vilanova Lleida; Institut de Recerca Biomèdica de Lleida (IRBLleida), Lleida, 25198, Spain|Hospital Universitari de Tarragona Joan XXIII; Salut Sant Joan de Reus - Baix Camp; Fundació Esclerosi Múltiple - Mas Sabater, Tarragona, 43005, Spain"
NCT05503524,Finding Patterns In Clinical Study Experiences of Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT05503524,NOT_YET_RECRUITING,Multiple Sclerosis,,Power Life Sciences Inc.,,ALL,"ADULT, OLDER_ADULT",,500,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-09,2024-09,2025-09,
NCT05747040,Pain in Neurorehabilitation Through Wearable Devices: an Exploratory Study,https://beta.clinicaltrials.gov/study/NCT05747040,RECRUITING,Pain|Multiple Sclerosis,DIAGNOSTIC_TEST: monitoring,Azienda Usl di Bologna,,ALL,"ADULT, OLDER_ADULT",NA,15,OTHER_GOV,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-02-01,2023-10-01,2023-10-01,"Irccs - Istituto Delle Scienze Neurologiche, Bologna, 40139, Italy"
NCT05277740,Implementation of a Novel Functional Eye-Tracking Biomarker for Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05277740,RECRUITING,Clinically Isolated Syndrome|Relapsing Remitting Multiple Sclerosis,DEVICE: Eye-tracking,McGill University,Innodem Neurosciences,ALL,"ADULT, OLDER_ADULT",,120,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-09-01,2024-07,2024-07,"Montreal Neurological Institute and Hospital, Montréal, Quebec, H3A 2B4, Canada"
NCT03779724,Isokinetic Exercises in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03779724,COMPLETED,Multiple Sclerosis,OTHER: exercises,Aksaray University Training and Research Hospital,,ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2015-07-29,2016-07-29,2016-07-29,"Aksaray University Training and Research Hospital, Aksaray, Turkey|Ankara Training and Researc Hospital, Health Sciences University, Ankara, Turkey"
NCT02227524,Trekking Poles to Aid Multiple Sclerosis Gait Impairment,https://beta.clinicaltrials.gov/study/NCT02227524,COMPLETED,Multiple Sclerosis,OTHER: No device|DEVICE: Single-point cane (SPC)|DEVICE: Four-point cane (FPC)|DEVICE: Trekking pole (TP).,Rowan University,,ALL,ADULT,NA,29,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: OTHER,2014-04,2019-03-07,2019-03-07,"Rowan University School of Osteopathic Medicine, Stratford, New Jersey, 08084, United States"
NCT02369224,Multicenter Validation of The Evergreen Myometric Strength Test for Lower Extremities (EMST-LE) in Multiple Sclerosis: Protocol for Strength Testing and Reliability Characteristics,https://beta.clinicaltrials.gov/study/NCT02369224,COMPLETED,Multiple Sclerosis,,"Brown, Theodore R., M.D., MPH",Biogen,ALL,"ADULT, OLDER_ADULT",,27,INDIV,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-01,2016-02,2016-02,"MS Center at Evergreen Health, Kirkland, Washington, 98034, United States"
NCT05123924,Respiratory Functions in Pediatric-Onset Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05123924,RECRUITING,Pediatric-onset Multiple Sclerosis,"OTHER: Evaluation of respiratory capacity, respiratory muscle strength and fatigue",Istanbul University - Cerrahpasa (IUC),,ALL,"CHILD, ADULT",,46,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-10-29,2022-06,2022-07,"Istanbul University-Cerrahpasa, Istanbul, Bakırköy, 34100, Turkey"
NCT01356940,A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01356940,COMPLETED,Multiple Sclerosis,DRUG: dalfampridine ER|DRUG: placebo,"Brown, Theodore R., M.D., MPH",Acorda Therapeutics,ALL,"ADULT, OLDER_ADULT",PHASE4,43,INDIV,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2010-11,2013-04,2013-04,"MS Center at Evergreen, Kirkland, Washington, 98034, United States"
NCT01450124,"Safety, Tolerability And Mechanism Of Action Of Boswellic Acids (BA) In Multiple Sclerosis (SABA)",https://beta.clinicaltrials.gov/study/NCT01450124,COMPLETED,Relapsing Remitting Multiple Sclerosis,DRUG: Boswellic acids (BOSWELAN),Universitätsklinikum Hamburg-Eppendorf,,ALL,"ADULT, OLDER_ADULT",PHASE2,29,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-09,2014-12,2014-12,"NeuroCure Clinical Research Center (NCRC), Berlin, 10117, Germany|University Medical Centre Hamburg-Eppendorf, Hamburg, 20246, Germany"
NCT02236624,Aerobic Exercise and Flu-like Symptoms Following Interferon Beta 1a Injections in Patients With Multiple Sclerosis?,https://beta.clinicaltrials.gov/study/NCT02236624,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Aerobic exercise,University of Aarhus,Aarhus University Hospital|MS-Clinic of Southern Jutland|MS-Clinic Viborg|MS-Clinic Odense|Biogen,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2014-03,2016-02,2016-04,"Sport Science, Department of Public Health, Aarhus University, Aarhus, Aarhus C, 8000, Denmark"
NCT03093324,A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2,https://beta.clinicaltrials.gov/study/NCT03093324,COMPLETED,Relapsing Remitting Multiple Sclerosis,DRUG: ALKS 8700|DRUG: Dimethyl Fumarate,Biogen,"Alkermes, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE3,506,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-03-15,2019-06-27,2019-06-27,"Alkermes Investigational Site, Cullman, Alabama, 35058, United States|Alkermes Investigational Site, Phoenix, Arizona, 85004, United States|Alkermes Investigational Site, Tucson, Arizona, 85704, United States|Alkermes Investigational Site, Long Beach, California, 90806, United States|Alkermes Investigational Site, San Diego, California, 92103, United States|Alkermes Investigational Site, Basalt, Colorado, 81621, United States|Alkermes Investigational Site, Centennial, Colorado, 80112, United States|Alkermes Investigational Site, Denver, Colorado, 80209, United States|Alkermes Investigational Site, Middlebury, Connecticut, 06762, United States|Alkermes Investigational Site, Stamford, Connecticut, 06905, United States|Alkermes Investigational Site, Washington, District of Columbia, 20007, United States|Alkermes Investigational Site, Atlantis, Florida, 33462, United States|Alkermes Investigational Site, Bradenton, Florida, 34209, United States|Alkermes Investigational Site, Maitland, Florida, 32751, United States|Alkermes Investigational Site, Naples, Florida, 34105, United States|Alkermes Investigational Site, Ormond Beach, Florida, 32174, United States|Alkermes Investigational Site, Sarasota, Florida, 34233, United States|Alkermes Investigational Site, Tampa, Florida, 33634, United States|Alkermes Investigational Site, Vero Beach, Florida, 32960, United States|Alkermes Investigational Site, Atlanta, Georgia, 30312, United States|Alkermes Investigational Site, Atlanta, Georgia, 30327, United States|Alkermes Investigational Site, Atlanta, Georgia, 30342, United States|Alkermes Investigational Site, Columbus, Georgia, 31904, United States|Alkermes Investigational Site, Evanston, Illinois, 60201, United States|Alkermes Investigational Site, Des Moines, Iowa, 50314, United States|Alkermes Investigational Site, Lenexa, Kansas, 66214, United States|Alkermes Investigational Site, Alexandria, Louisiana, 71301, United States|Alkermes Investigational Site, Detroit, Michigan, 48202, United States|Alkermes Investigational Site, Golden Valley, Minnesota, 55422, United States|Alkermes Investigational Site, Saint Louis, Missouri, 63104, United States|Alkermes Investigational Site, Saint Louis, Missouri, 63110, United States|Alkermes Investigational Site, Saint Louis, Missouri, 63131, United States|Alkermes Investigational Site, Albuquerque, New Mexico, 87106, United States|Alkermes Investigational Site, Patchogue, New York, 11772, United States|Alkermes Investigational Site, Stony Brook, New York, 11794, United States|Alkermes Investigational Site, Syracuse, New York, 13210, United States|Alkermes Investigational Site, Charlotte, North Carolina, 28203, United States|Alkermes Investigational Site, Greensboro, North Carolina, 27405, United States|Alkermes Investigational Site, Winston-Salem, North Carolina, 27103, United States|Alkermes Investigational Site, Canton, Ohio, 44718, United States|Alkermes Investigational Site, Columbus, Ohio, 43221, United States|Alkermes Investigational Site, Dayton, Ohio, 45417, United States|Alkermes Investigational Site, Oklahoma City, Oklahoma, 73104, United States|Alkermes Investigational Site, Charleston, South Carolina, 29406, United States|Alkermes Investigational Site, Greer, South Carolina, 29650, United States|Alkermes Investigational Site, Indian Land, South Carolina, 29707, United States|Alkermes Investigational Site, Spartanburg, South Carolina, 29307, United States|Alkermes Investigational Site, Franklin, Tennessee, 37064, United States|Alkermes Investigational Site, Knoxville, Tennessee, 37922, United States|Alkermes Investigational Site, Dallas, Texas, 75231, United States|Alkermes Investigational Site, Houston, Texas, 77030, United States|Alkermes Investigational Site, Houston, Texas, 77074, United States|Alkermes Investigational Site, Newport News, Virginia, 23601, United States|Alkermes Investigational Site, Richmond, Virginia, 23226, United States|Alkermes Investigational Site, Seattle, Washington, 98101, United States|Alkermes Investigational Site, Seattle, Washington, 98122, United States|Alkermes Investigational Site, Seattle, Washington, 98133, United States|Alkermes Investigational Site, Dresden, Germany|Alkermes Investigational Site, Leipzig, Germany|Alkermes Investigational Site, Ulm, Germany|Alkermes Investigational Site, Westerstede, Germany|Alkermes Investigational Site, Gdańsk, 80-803, Poland|Alkermes Investigational Site, Katowice, 40-123, Poland|Alkermes Investigational Site, Kielce, 25-726, Poland|Alkermes Investigational Site, Lodz, 90-324, Poland|Alkermes Investigational Site, Plewiska, 62-064, Poland|Alkermes Investigational Site, Szczecin, 70-111, Poland"
NCT05857280,"EXOPULSE Mollii Suit, Motor Function & Multiple Sclerosis (EXOSEP 2)",https://beta.clinicaltrials.gov/study/NCT05857280,RECRUITING,"Sclerosis, Multiple|MS (Multiple Sclerosis)|Spasticity, Muscle|Spastic",DEVICE: EXOPULSE Mollii Suit Stimulation,Sheikh Shakhbout Medical City,,ALL,"ADULT, OLDER_ADULT",NA,36,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-03-21,2023-12-31,2024-04-15,"SSMC, Abu Dhabi, United Arab Emirates"
NCT04673240,CLINICAL EFFECT OF BOTULINUM TOXIN TYPE A IN TREATMENT OF SPASTICITY,https://beta.clinicaltrials.gov/study/NCT04673240,UNKNOWN,Spasticity|Brain Injuries|Spinal Cord Injuries|Multiple Sclerosis,DRUG: Botulinum toxin type A injection,"Università degli Studi del Piemonte Orientale ""Amedeo Avogadro""",Ipsen|Azienda Ospedaliero Universitaria Maggiore della Carita|SIRN,ALL,"ADULT, OLDER_ADULT",,70,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-03-29,2021-12-31,2022-06-30,"Azienda Ospedaliero Universitaria Maggiore della Carità, Novara, 28100, Italy"
NCT02325440,Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya,https://beta.clinicaltrials.gov/study/NCT02325440,UNKNOWN,Relapsing Remitting Multiple Sclerosis,DRUG: Fingolimod|DRUG: Natalizumab,University Hospital Muenster,Novartis,ALL,"ADULT, OLDER_ADULT",PHASE4,15,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-03,2016-04,2016-04,"Universitaetsklinikum Muenster, Department of Neurology, Muenster, 48149, Germany"
NCT05344040,Remote Exercise Effects on Cognitive Processing Speed in Multiple Sclerosis: A Pilot Trial,https://beta.clinicaltrials.gov/study/NCT05344040,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Remotely Delivered and Supported Aerobic Walking Exercise Training|BEHAVIORAL: Remotely Delivered and Supported Stretching and Toning Exercise Training,Kessler Foundation,,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,25,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-05-25,2022-12-01,2022-12-01,"Kessler Foundation, West Orange, New Jersey, 07052, United States"
NCT00217295,A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00217295,UNKNOWN,Multiple Sclerosis,DRUG: Avonex and Topamax,Multiple Sclerosis Institute,,ALL,ADULT,PHASE2,30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,2004-04,,2007-12,"Multiple Sclerosis Institute, Philadelphia, Pennsylvania, 19146, United States"
NCT01005095,The Effects of Interferon Beta Combined With Vitamin D on Relapsing Remitting Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT01005095,TERMINATED,MULTIPLE SCLEROSIS,DIETARY_SUPPLEMENT: Vitamin D3|DIETARY_SUPPLEMENT: Vitamin D3,Carmel Medical Center,,ALL,"ADULT, OLDER_ADULT",PHASE4,45,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2010-10,2012-04,2012-04,"MS Clinic, Carmel Medical Center, Haifa, Israel"
NCT02408380,Analysis of a Biomarker Signature in Patients With Multiple Sclerosis (MS) Treated With Gilenya (FTY720),https://beta.clinicaltrials.gov/study/NCT02408380,UNKNOWN,Multiple Sclerosis,,McGill University,Novartis Pharmaceuticals,ALL,"ADULT, OLDER_ADULT",,216,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-09,2015-09,2015-12,"McGill University, Montreal, Quebec, H3A 2B4, Canada"
NCT04532944,The Energetic Origin of Neurodegeneration in MS,https://beta.clinicaltrials.gov/study/NCT04532944,NOT_YET_RECRUITING,Multiple Sclerosis,DIAGNOSTIC_TEST: imaging of energy dysfunction,"Institut National de la Santé Et de la Recherche Médicale, France",,ALL,ADULT,NA,55,OTHER_GOV,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2020-09-15,2022-09-15,2024-03-15,
NCT01744444,Treatment of Pendular Nystagmus With Gabapentin and Memantine in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01744444,COMPLETED,Pendular Nystagmus Patients With Multiple Sclerosis,DRUG: Memantine|DRUG: Gabapentin,Hospices Civils de Lyon,,ALL,"ADULT, OLDER_ADULT",PHASE2,10,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2012-11,2013-07,2013-07,"Hôpital Neurologique Unité de Neuro-Ophtalmologie, Bron, 69677, France"
NCT02746744,RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis.,https://beta.clinicaltrials.gov/study/NCT02746744,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Rituximab|DRUG: Dimethyl fumarate|DRUG: Sodium Chloride solution,Anders Svenningsson,,ALL,ADULT,PHASE3,200,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2016-05,2021-07,2021-08,"South Älvsborg Hospital, Borås, Sweden|Falun Hospital, Falun, Sweden|Gävle Hospital, Gävle, Sweden|Saghlgrenska Hospital, Göteborg, Sweden|Helsingborg Hospital, Helsingborg, Sweden|Karlstad Hospital, Karlstad, Sweden|Halland Hospital Kungsbacka, Kungsbacka, Sweden|Linköping University Hospital, Linköping, Sweden|Nyköping Hospital, Nyköping, Sweden|Capio StGöran Hospital, Stockholm, Sweden|Danderyd hospital, Stockholm, Sweden|Fredrik Piehl, Stockholm, Sweden|Karolinska Hospital Huddinge, Stockholm, Sweden|Umeå University, Umeå, Sweden|Uppsala Academiska Hospital, Uppsala, Sweden|Örebro University Hospital, Örebro, Sweden|Östersund Hospital, Östersund, Sweden"
NCT04053374,Regulation of Lipid Metabolism in Autoimmune Disease: Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04053374,UNKNOWN,Multiple Sclerosis,OTHER: Blood sampling,"University College, London",University College London Hospitals,ALL,"ADULT, OLDER_ADULT",,275,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-09-01,2020-06,2020-06,"University College London Hospitals NHS Foundation Trust, London, NW1 2BU, United Kingdom|National Hospital for Neurology and Neurosurgery, London, WC1N 3BG, United Kingdom"
NCT02290444,Effects of Acthar on Recovery From Cognitive Relapses in MS,https://beta.clinicaltrials.gov/study/NCT02290444,COMPLETED,Multiple Sclerosis,DRUG: Adrenocorticotropic Hormone,State University of New York at Buffalo,,ALL,"ADULT, OLDER_ADULT",PHASE3,64,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2013-08,2018-11-01,2018-11-01,"University at Buffalo-State University of New York, Department of Neurology, Buffalo General Hospital, Buffalo, New York, 14203, United States"
NCT02073474,An Observational Post-Marketing Safety Registry of Sativex®,https://beta.clinicaltrials.gov/study/NCT02073474,COMPLETED,Multiple Sclerosis|Diabetes|Cancer|Neuropathic Pain,DRUG: Sativex®,Jazz Pharmaceuticals,,ALL,"CHILD, ADULT, OLDER_ADULT",,978,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-02,2015-01,2015-01,
NCT04607174,Voluntary Activation During Isokinetic Contractions in Subjects With Neuromotor Disorders,https://beta.clinicaltrials.gov/study/NCT04607174,RECRUITING,Multiple Sclerosis|Poststroke/CVA Hemiparesis|Parkinson Disease|Knee Impairment,OTHER: Pathologic group,Istituto Auxologico Italiano,,ALL,"ADULT, OLDER_ADULT",,20,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-10-07,2022-12-31,2022-12-31,"Istituto Auxologico Italiano, Milan, MI, 20121, Italy"
NCT00621374,Management of Pain in Persons With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00621374,COMPLETED,Multiple Sclerosis|Pain,BEHAVIORAL: Cognitive Behavioral Therapy (CBT) +Hypnosis (HYP)|BEHAVIORAL: Cognitive Behavioral Therapy (CBT)|BEHAVIORAL: Self-Hypnosis Training (HYP)|BEHAVIORAL: Education Control (CONT),University of Washington,National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",NA,22,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2008-02,2009-06,2009-06,"University of Washington, Seattle, Washington, 98195, United States"
NCT05344469,A NIS Evaluating Injectable Treatments in Patients With Relapsing Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05344469,RECRUITING,Relapsing Multiple Sclerosis,OTHER: ofatumumab|OTHER: glatiramer acetate|OTHER: interferon β1,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",,800,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-05-10,2025-10-17,2025-10-17,"Novartis Investigative Site, Schwaebisch, Baden-Wuerttemberg, 74523, Germany|Novartis Investigative Site, Bamberg, Bavaria, 96052, Germany|Novartis Investigative Site, Munich, Bavaria, 81241, Germany|Novartis Investigative Site, Untermeiting, Bayern, 86836, Germany|Novartis Investigative Site, Falkensee, Brandenburg, 14612, Germany|Novartis Investigative Site, Schwetzingen, BW, 68723, Germany|Novartis Investigative Site, Hannover, Lower Saxony, 30161, Germany|Novartis Investigative Site, Hannover, Lower Saxony, 30449, Germany|Novartis Investigative Site, Wildeshausen, Lower Saxony, 27793, Germany|Novartis Investigative Site, Essen, Nordrhein-Westfalen, 45134, Germany|Novartis Investigative Site, Oer-Erkenschwick, Northrhine Westfalia, 50996, Germany|Novartis Investigative Site, Muenster, Northwest, 48165, Germany|Novartis Investigative Site, Altmark, Sachsen-Anhalt, 39629, Germany|Novartis Investigative Site, Altenburg, 04600, Germany|Novartis Investigative Site, Altenholz, 24161, Germany|Novartis Investigative Site, Alzey, 55232, Germany|Novartis Investigative Site, Bad Homburg, 61348, Germany|Novartis Investigative Site, Bamberg, 96047, Germany|Novartis Investigative Site, Bayreuth, 95445, Germany|Novartis Investigative Site, Bergneustadt, 51702, Germany|Novartis Investigative Site, Berlin, 10437, Germany|Novartis Investigative Site, Berlin, 10713, Germany|Novartis Investigative Site, Berlin, 120999, Germany|Novartis Investigative Site, Berlin, 12351, Germany|Novartis Investigative Site, Berlin, 13357, Germany|Novartis Investigative Site, Berlin, 14169, Germany|Novartis Investigative Site, Boblingen, 71032, Germany|Novartis Investigative Site, Bochum, 44787, Germany|Novartis Investigative Site, Bonn, 53111, Germany|Novartis Investigative Site, Bremen, 28195, Germany|Novartis Investigative Site, Chemnitz, 09117, Germany|Novartis Investigative Site, Dessau, 06846, Germany|Novartis Investigative Site, Dillingen, 89407, Germany|Novartis Investigative Site, Dortmund, 44135, Germany|Novartis Investigative Site, Dresden, 01067, Germany|Novartis Investigative Site, Dresden, 01307, Germany|Novartis Investigative Site, Duisburg, 47138, Germany|Novartis Investigative Site, Düsseldorf, 40211, Germany|Novartis Investigative Site, Düsseldorf, 40625, Germany|Novartis Investigative Site, Erbach, 64711, Germany|Novartis Investigative Site, Essen, 45138, Germany|Novartis Investigative Site, Essen, 45257, Germany|Novartis Investigative Site, Frankfurt, 60313, Germany|Novartis Investigative Site, Frankfurt, 65929, Germany|Novartis Investigative Site, Fulda, 36037, Germany|Novartis Investigative Site, Gelsenkirchen, 45894, Germany|Novartis Investigative Site, Giessen, 35392, Germany|Novartis Investigative Site, Gladenbach, 35075, Germany|Novartis Investigative Site, Hagen, 58095, Germany|Novartis Investigative Site, Hamburg, 20249, Germany|Novartis Investigative Site, Hamburg, 22179, Germany|Novartis Investigative Site, Hannover, 30625, Germany|Novartis Investigative Site, Ingelheim, 55218, Germany|Novartis Investigative Site, Itzehoe, 25524, Germany|Novartis Investigative Site, Kaiserslautern, 67655, Germany|Novartis Investigative Site, Koln, 50935, Germany|Novartis Investigative Site, Köln, 51063, Germany|Novartis Investigative Site, Leipzig, 04103, Germany|Novartis Investigative Site, Luenen, 44534, Germany|Novartis Investigative Site, Mannheim, 66163, Germany|Novartis Investigative Site, Marburg, 35037, Germany|Novartis Investigative Site, Marburg, 35043, Germany|Novartis Investigative Site, Mettmann, 40822, Germany|Novartis Investigative Site, Minden, 32429, Germany|Novartis Investigative Site, Muenchen, 81675, Germany|Novartis Investigative Site, Muenster, 48149, Germany|Novartis Investigative Site, Mühlhausen, 99974, Germany|Novartis Investigative Site, München, 81829, Germany|Novartis Investigative Site, Neuburg an der Donau, 86633, Germany|Novartis Investigative Site, Neuruppin, 16816, Germany|Novartis Investigative Site, Nuernberg, 90491, Germany|Novartis Investigative Site, Osnabrück, 49074, Germany|Novartis Investigative Site, Pforzheim, 75172, Germany|Novartis Investigative Site, Potsdam, 14471, Germany|Novartis Investigative Site, Regensburg, 93059, Germany|Novartis Investigative Site, Remscheid, 42853, Germany|Novartis Investigative Site, Rostock, 18057, Germany|Novartis Investigative Site, Ruedersdorf, 15562, Germany|Novartis Investigative Site, Ruelzheim, 76761, Germany|Novartis Investigative Site, Saalouis, 66740, Germany|Novartis Investigative Site, Siegen, 57076, Germany|Novartis Investigative Site, Stuttgart, 70174, Germany|Novartis Investigative Site, Stuttgart, 70176, Germany|Novartis Investigative Site, Stuttgart, 70182, Germany|Novartis Investigative Site, Unterhaching, 82008, Germany|Novartis Investigative Site, Wolfratshausen, 82515, Germany"
NCT02008669,Evaluation of Nutritional Status and Fatigue in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02008669,COMPLETED,Multiple Sclerosis,PROCEDURE: Blood sampling|OTHER: Gustatory sensitivity test using Taste strips|OTHER: Questionnaires,Lille Catholic University,,ALL,"ADULT, OLDER_ADULT",,360,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-11,2017-06-09,2017-06-09,"Centre Hospitalier Universitaire de Caen, Caen, Basse-Normandie, 14033, France|Centre Hospitalier d'Arras, Arras, Nord Pas-de-Calais, 62022, France|Centre Hospitalier de Boulogne, Hôpital Duchenne, Boulogne sur Mer, Nord Pas-de-Calais, 62200, France|Centre Hospitalier de Calais, Calais, Nord Pas-de-Calais, 62100, France|Groupement des Hôpitaux de l'Institut Catholique de Lille, Lille, Nord Pas-de-Calais, 59000, France|Centre Hospitalier Régional Universitaire de Lille, Lille, Nord Pas-de-Calais, 59037, France|Centre Hospitalier de Sambre-Avenois, Maubeuge, Nord Pas-de-Calais, 59600, France|Centre Hélène Borel, Raimbeaucourt, Nord Pas-de-Calais, 59283, France|Centre Hospitalier Dron de Tourcoing, Tourcoing, Nord Pas-de-Calais, 59208, France|Centre Hospitalier de Valenciennes, Valenciennes, Nord Pas-de-Calais, 59322, France|Centre Hospitalier de Douai, Douai, Nord-Pas De Calais, 59507, France|Centre Hospitalier Universitaire d'Amiens, Amiens, Picardie, 80054, France"
NCT04847596,A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab,https://beta.clinicaltrials.gov/study/NCT04847596,COMPLETED,Relapsing Multiple Sclerosis,OTHER: Ofatumumab|OTHER: Covid-19 vaccine,Novartis Pharmaceuticals,,ALL,ADULT,,25,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-05-21,2022-02-18,2022-02-18,"Novartis Investigative Site, Phoenix, Arizona, 85018, United States|Novartis Investigative Site, Owosso, Michigan, 48867, United States|Novartis Investigative Site, Saint Louis, Missouri, 63131, United States|Novartis Investigative Site, Plainview, New York, 11803, United States|Novartis Investigative Site, Guaynabo, 00968, Puerto Rico"
NCT02452996,Safety Study of GNbAC1 Monoclonal Antibody in Healthy Male Volunteers,https://beta.clinicaltrials.gov/study/NCT02452996,COMPLETED,Healthy Volunteers,DRUG: GNbAC1,GeNeuro Innovation SAS,,MALE,ADULT,PHASE1,21,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: |Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2015-04,2015-08,2015-08,"PAREXEL Early Phase Clinical Unit, Berlin, 14050, Germany"
NCT03217396,Biomarkers of Synaptic Damage in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03217396,RECRUITING,Multiple Sclerosis|Parkinson Disease|Amyotrophic Lateral Sclerosis|Alzheimer Disease,PROCEDURE: lumbar puncture,Neuromed IRCCS,IRCCS Multimedica,ALL,"ADULT, OLDER_ADULT",,300,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-11-22,2026-09-01,2027-09-30,"IRCCS Neuromed, Pozzilli, Isernia, 86077, Italy"
NCT04117035,"A Personalised Radiosurgery Procedure for People With Trigeminal Neuralgia to Improve Pain, Quality of Life and Reduce Complications",https://beta.clinicaltrials.gov/study/NCT04117035,RECRUITING,Trigeminal Neuralgia|Multiple Sclerosis|Pain,PROCEDURE: Gamma Knife Radiosurgery (GKRS) personalised procedure|PROCEDURE: GKRS standard care,University of Leeds,,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-11-01,2022-08-31,2022-12-31,"Sheffield royal hallamshire hospital, Sheffield, United Kingdom"
NCT05423769,"Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in Egypt",https://beta.clinicaltrials.gov/study/NCT05423769,ACTIVE_NOT_RECRUITING,Relapsing-Remitting Multiple Sclerosis,DRUG: Fingolimod,Hikma Pharmaceuticals LLC,,ALL,"ADULT, OLDER_ADULT",,30,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-01-19,2023-10,2023-10,"Neuropsychiatry department, Faculty of Medicine, Alexandria University Hospitals, Hadra University Hospital, Alexandria, Egypt|Faculty of medicine Ain shams Research Institute-Clinical Research Center (MASRI-CRC), Cairo, Egypt"
NCT03564496,Assessment of tDCS-Induced Neuronal Responses in Multiple Sclerosis (MS) With Advanced MRI,https://beta.clinicaltrials.gov/study/NCT03564496,RECRUITING,Multiple Sclerosis,OTHER: Active tDCS|OTHER: Sham (placebo) stimulation,NYU Langone Health,,ALL,"ADULT, OLDER_ADULT",NA,72,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2018-07-09,2023-12-01,2023-12-01,"New York University School of Medicine, New York, New York, 10016, United States"
NCT04783935,Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension),https://beta.clinicaltrials.gov/study/NCT04783935,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,DRUG: Mavenclad®,"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany",,ALL,"ADULT, OLDER_ADULT",PHASE4,219,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2021-03-10,2024-02-09,2024-02-09,"Liverpool Hospital, Liverpool, Australia|John Hunter Hospital, New Lambton, Australia|Klinikum Klagenfurt, Klagenfurt, Austria|Paracelsus Medical University Salzburg, Salzburg, Austria|University of Alberta, Edmonton, Canada|Children's Hospital, London Health Sciences Centre- Pediatrics, London, Canada|Montreal Neurological Hospital, Montreal, Canada|MS Clinical Trials Group, Vancouver, Canada|Fakultni nemocnice Brno, Brno, Czechia|Fakultni nemocnice u sv. Anny v Brne, Brno, Czechia|FN Hradec Kralove, Hradec Kralove, Czechia|Nemocnice Pardubickeho kraje, a.s. Pardubicka nemocnice, Pardubice, Czechia|Fakultni nemocnice v Motole, Praha 5, Czechia|Tampere University Hospital, Tampere, Finland|Turku University Hospital, Turku, Finland|CHU de Montpellier Hôpital Gui de Chauliac- Département de Neurologie, Montpellier, France|CHU Nice - Hôpital Pasteur, Nice, France|CHU Nîmes, Nimes, France|CHU de Poissy, Poissy Cedex, France|CHU de Pontchaillou, Rennes Cedex 9, France|Hôpital Civil, Strasbourg Cedex, France|Universitätsklinikum Carl Gustav Carus, Dresden, Germany|Universitätsklinikum Essen, Essen, Germany|Neurologische Praxis Eppendorf, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Klinik und Poliklinik fur Neurologie, Leipzig, Germany|Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpo, Szeged, Hungary|Barzilai Medical Center, Ashkelon, Israel|Rambam MC, Haifa, Israel|Sheba Medical Centre, Tel-Hashomer, Israel|Università ""G. D'Annunzio"" Chieti-Pescara Ospedale Cliniciz, Chieti, Italy|Dipartimento di internistica clinica e sperimentale ""Flaviano Magrassi""Università degli studi della Campania ""Luigi Vanvitelli"", Napoli, Italy|IRCSS Neuromed Istituto Neurologico Mediterraneo, Pozzilli, Italy|Samodzielny Publiczny Szpital Kliniczny nr 7 SUM, Katowice, Poland|Indywidualna Praktyka Lekarska Prof. Konrad Rejdak, Lublin, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1 im. Prof. Stanislawa Szyszko SUM w Katowicach, Zabrze, Poland|Hospital de Cruces, Baracaldo, Spain|Hospital Vithas NISA Sevilla, Castilleja de la Cuesta, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain|Hospital La Fe, Valencia, Spain|Sahlgrenska Universitetssjukhus, Göteborg, Sweden|Akademiskt Specialist Centrum - Centrum för Neurologi,, Stockholm, Sweden|Queen Elizabeth Hospital, Birmingham, United Kingdom|University Hospital of Wales, Cardiff, United Kingdom|Sheffield Teaching Hospitals Sheffield, Sheffield, United Kingdom"
NCT00813969,Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS,https://beta.clinicaltrials.gov/study/NCT00813969,COMPLETED,Relapsing-Remitting Multiple Sclerosis|Secondary Progressive Multiple Sclerosis|Progressive Relapsing Multiple Sclerosis,BIOLOGICAL: Autologous mesenchymal stem cell transplantation,The Cleveland Clinic,University Hospitals Cleveland Medical Center,ALL,ADULT,PHASE1,24,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-03,2014-01,2014-05,"Cleveland Clinic Mellen Center, Cleveland, Ohio, 44195, United States"
NCT00001669,A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients,https://beta.clinicaltrials.gov/study/NCT00001669,COMPLETED,Multiple Sclerosis,DRUG: rhIGF-1 (CEP-151),National Institute of Neurological Disorders and Stroke (NINDS),,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,15,NIH,INTERVENTIONAL,Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT,1997-07,,2000-04,"National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, 20892, United States"
NCT03183869,Fecal Microbial Transplantation in Relapsing Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT03183869,TERMINATED,Autoimmune Diseases|Relapsing Multiple Sclerosis,DRUG: Fecal microbiota,Lawson Health Research Institute,,ALL,"ADULT, OLDER_ADULT",PHASE2,14,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2017-08-24,2018-11-19,2019-01-25,"London Health Sciences Centre, University Hospital, London, Ontario, N6A 5A5, Canada"
NCT02461069,Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02461069,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Dimethyl fumarate,University Hospital Muenster,Biogen,ALL,ADULT,PHASE4,67,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2015-05-06,2018-01-24,2018-05-07,"Neurologisches Studienzentrum Dr. Schmidt/Dr. Neudecker/ Dr. Viehbahn/Dr. Kronenberger, Bonn, 53111, Germany|Neurologische Gemeinschaftspraxis im Bienenkorbhaus, Frankfurt am Main, 60313, Germany|Neurologische Univ.-Klinik, Heidelberg, 69120, Germany|Klinik und Poliklinik für Neurologie, Universitätsklinikum Mainz, Mainz, 55131, Germany|University Hospital Muenster, Department of Neurology, Muenster, 48149, Germany|MVZ-Neurologie Klinikum Osnabrück GmbH, Osnabrück, 49076, Germany"
NCT01863069,"Avonex®: Safety, Blood Levels and Effects",https://beta.clinicaltrials.gov/study/NCT01863069,COMPLETED,Multiple Sclerosis (MS),DRUG: Interferon beta 1a|DRUG: (IM) AVONEX®,Trio Medicines Ltd.,Biogen,ALL,ADULT,PHASE1,77,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: |Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2001-01,2001-10,2001-10,"Hammersmith Medicines Research, London, NW10 7EW, United Kingdom"
NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01194570,COMPLETED,"Multiple Sclerosis, Primary Progressive",DRUG: Ocrelizumab|OTHER: Placebo,Hoffmann-La Roche,,ALL,ADULT,PHASE3,735,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2011-03-02,2015-07-23,2022-12-31,"Phoenix Neurological Associates Ltd, Phoenix, Arizona, 85006, United States|Barrow Neurology Clinic, Phoenix, Arizona, 85013, United States|Mayo Clinic- Scottsdale, Scottsdale, Arizona, 85259, United States|Arizona Neuroscience Research, LLC, Phoenix, Arkansas, 85032-2181, United States|Sutter East Bay Medical Foundation, Berkeley, California, 94705, United States|MS Center of Southern California, Newport Beach, California, 92663, United States|Univ of CA Davis Med Ctr; Neurology, Sacramento, California, 95817, United States|Univ of CA San Francisco; Department of Neurology, San Francisco, California, 94143, United States|University of Colorado; Anschutz Medical Campus Department of Neurology, Aurora, Colorado, 80045, United States|University of Miami School of Medicine; Dept. of Neurology Movement Disorder Center, Miami, Florida, 33136, United States|Vero Beach Neurology and Research Institute, Vero Beach, Florida, 32960, United States|University of Kansas Medical Center, Kansas City, Kansas, 66160, United States|MidAmerica Neuroscience Institute, Prairie Village, Kansas, 66206, United States|Wayne State University; Department of Neurology, Detroit, Michigan, 48201, United States|Henry Ford Health System; Neurology & Neurosurgery, Detroit, Michigan, 48202, United States|Michigan Institute for Neurological Disorders, Farmington Hills, Michigan, 48334, United States|University of Minnesota; Clin. Neuro Research Unit, Minneapolis, Minnesota, 55414, United States|Washington University School of Medicine; Department of Neurology, Saint Louis, Missouri, 63110, United States|Holy Name Hospital, Teaneck, New Jersey, 07666, United States|University of New Mexico; MS Specialty Clinic, Albuquerque, New Mexico, 87131, United States|Winthrop University Hospital, Mineola, New York, 11501, United States|Weill Medical College of Cornell University; Judith Jaffe MS Ctr, New York, New York, 10021, United States|Mount Sinai School of Medicine; Neurology, New York, New York, 10029, United States|Comprehensive MS Care Center at South Shore Neurologic Assoc., Patchogue, New York, 11772, United States|Neurology Assoc of Stony Brook, Stony Brook, New York, 11794, United States|Carolinas Medical Center; Ms Center, Charlotte, North Carolina, 28207, United States|Raleigh Neurology Associates, Raleigh, North Carolina, 27607-6520, United States|The Ohio State University Wexner Medical Center; Department of Neurology, Columbus, Ohio, 43221, United States|Oklahoma Medical Research Foundation; MS Center of Excellence, Oklahoma City, Oklahoma, 73104, United States|Trustees of the University of Pennsylvania; Neurology, Philadelphia, Pennsylvania, 19104, United States|The Neurology Foundation, Inc., Providence, Rhode Island, 02905, United States|Neurology Clinic PC, Cordova, Tennessee, 38018, United States|University of Texas Southwestern, Dallas, Texas, 75390-8897, United States|Maxine Mesinger MS Clinic/Baylor College of Medicine; Neurology, Houston, Texas, 77030, United States|Neurological Associates, Inc., Richmond, Virginia, 23229, United States|Swedish Neuroscience Institute; Multiple Sclerosis Center, Seattle, Washington, 98122, United States|Royal Hobart Hospital, Hobart, Tasmania, 7000, Australia|St Vincent's Hospital Melbourne; Clinical Neuroscience and Neurological Research, Fitzroy, Victoria, 3065, Australia|Uniklinik fuer Neurologie, Medizinische Universitaet Innsbruck; Department fuer Neurologie, Innsbruck, 6020, Austria|Kepler Universitätsklinikum GmbH - Neuromed Campus; Neurologie, Linz, 4020, Austria|Kepler Universitätskliniken GmbH - Med Campus III; Neurologie & Psychiatrie, Linz, 4021, Austria|Christian-Doppler-Klinik - Universitätsklinikum; Universitätskliniik für Neurologie, Salzburg, 5020, Austria|Medizinische Universitat Wien Medical University of Vienna, Wien, 1090, Austria|CHU Tivoli, La Louvière, 7100, Belgium|AZ Alma vzw (Sijsele), Sijsele, 8340, Belgium|Hospital das Clinicas - UFG;Reumatologia, Goiania, GO, 74653-050, Brazil|Santa Casa de Misericordia; de Belo Horizonte, Belo Horizonte, MG, 30150-221, Brazil|Hospital Universitario Clementino Fraga Filho - UFRJ, Rio de Janeiro, RJ, 21941-913, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, 90610-000, Brazil|Shat Np Sveti Naum; 3Rd Clinic of Neurology, Sofia, 1113, Bulgaria|Multiprofile Hosp. for Active Treatment;National Cardiology Hosp., Sofia, 1309, Bulgaria|Foothills Medical Centre, Calgary, Alberta, T2N 2T9, Canada|University of British Columbia UBC Hospital; Multiple Sclerosis (MS) Clinic - Vancouver, Vancouver, British Columbia, V6T 1Z3, Canada|Health Sciences Centre, Winnipeg, Manitoba, R8A 1R9, Canada|The Ottawa Hospital - General Campus, Ottawa, Ontario, K1H 8L6, Canada|St. Michael'S Hospital, Toronto, Ontario, M5B 1W8, Canada|Recherche Sepmus Inc., Greenfield Park, Quebec, J4V 2J2, Canada|Montreal Neurological Institute and Hospital, Montreal, Quebec, H3A 2B4, Canada|Fakultni nemocnice Brno; Interni kardiologicka klinika, Brno, 625 00, Czechia|Vseobecna fakultni nemocnice v Praze; MS Centrum, Neurologicka klinika, Praha 2, 128 08, Czechia|Krajska zdravotni, a. s. ? Nemocnice Teplice, o. z.; Neurologicke oddeleni, Teplice, 415 29, Czechia|Helsingin yliopistollinen keskussairaala, Helsinki, 00290, Finland|Tampereen yliopisto; Kliinisen lääketieteen laitos, Neurologian yksikkö, Tampere, 33520, Finland|Turku University Central Hospital; Pharmacy, Turku, 20520, Finland|Groupe Hospitalier Pellegrin; Service de neurochirurgie B, Bordeaux, 33076, France|Hopital Neurologique et Neurochirurgical Pierre Wertheimer; Service de Neurologie A, Bron, 69677, France|Hopital Cote De Nacre; Unite Neurologie Generale, Caen, 14033, France|Hopital Gabriel Montpied CHU de Clermont-Ferrand; Service de Neurologie B, Clermont-Ferrand, 63003, France|Hopital Roger Salengro Service de Neurologie, Lille, France|CHU de la Timone - Hopital d Adultes; Service de Neurologie, Marseille, 13005, France|Hopital Gui de Chauliac; Neurologie, Montpellier, 34295, France|CHRU Nancy; Service de neurologie, Nancy, 54035, France|Hôpital Guillaume et René Laënnec; Service Neurologie, Nantes, 44805, France|Hôpital Pasteur; Service de Neurologie, Nice, 06002, France|Groupe Hospitalo-Universitaire Caremeau; Service Neurologie, Nimes, 30029, France|Fondation Rothschild; Service de Neurologie, Paris, 75019, France|Groupe Hospitalier Pitié- Salpétrière; Service Neurologie, Paris, 75651, France|Hôpital de Poissy; Service neurologie, Poissy, 78300, France|Hôpital Maison Blanche; Service de Neurologie, Reims, 51092, France|Chu De Strasbourg; Hopital Civil, Strasbourg, 67091, France|Hopital Purpan; Fédération de neurologie, Toulouse, 31059, France|Klinikum Bayreuth GmbH; Neurologische Klinik, Bayreuth, 95445, Germany|Marianne-Strauß-Klinik; Behandlung Kempfen für Multip Sklero Kranke gemeinnütz GmbH, Berg, 82335, Germany|Charite - Universitatsmedizin Berlin; Klinik fur Neurologie, Berlin, 10117, Germany|Jüdisches Krankenhaus Berlin; Abteilung fur Neurologie, Berlin, 13347, Germany|Berufsgenossenschaftliches Uni-Klinikum Bergmannsheil GmbH, Bochum, 44789, Germany|Universitätsklinikum ""Carl Gustav Carus""; Klinik und Poliklinik für Neurologie, Dresden, 01307, Germany|Heinrich Heine Universität Düsseldorf; Neurologische Klinik, Düsseldorf, 40225, Germany|Klinikum Joh.Wolfg.Goethe-UNI Senckenbergisches Institut für Neuroonkologie, Frankfurt am Main, 60528, Germany|Universitätsklinikum Gießen und Marburg GmbH; Neurologie, Gießen, 35392, Germany|Universitaetsklinikum Heidelberg, Heidelberg, 69120, Germany|Kliniken der Stadt Koln gGmbH, Koln, 51109, Germany|Universität Leipzig; Innere Medizin, Neurologie, Dermatologie, Leipzig, 04103, Germany|Klinikum rechts der Isar der Technischen Universität München, Munchen, 81675, Germany|Universitatsklinikum Munster, Münster, 48149, Germany|Medizinische Einrichtungen des Bezirks Oberpfalz GmbH; Neurologie, Regensburg, 93053, Germany|Universitätsklinikum Tübingen, Zentrum für Neurologie, Tübingen, 72076, Germany|Universitätsklinikum Ulm; Klinik für Neurologie, Ulm, 89081, Germany|DKD Helios Klinik (Deutsche Klinik für Diagnostik GmbH), Wiesbaden, 65191, Germany|401 Military Hospital of Athens; Neurology Department, Athens, 115 25, Greece|AHEPA Univ. General Hospital of Thessaloniki; B' Neurology Dept., Thessaloniki, 546 36, Greece|Georgios Papanikolaou General Hosp. of Thessaloniki, Thessaloniki, 57010, Greece|Fövárosi Önkormányzat uzsoki utcai Kórház, Budapest, 1145, Hungary|Jahn Ferenc Del-Pesti Korhaz es Rendelointezet, Budapest, 1204, Hungary|Vaszary Kolos Korhaz; Neurology, Esztergom, 2500, Hungary|Pécsi Tudományegyetem, Pécs, 7623, Hungary|Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ; Neurológiai Klinika, Szeged, 6725, Hungary|Veszprém Megyei Csolnoky Ferenc Kórház; Reumatológia, Veszprem, 8200, Hungary|Barzilai Medical Center; Neurology Department, Ashkelon, 7830604, Israel|Hadassah University Hospital Ein Kerem; Neurology Department, Jerusalem, 91120, Israel|Rabin Medical Center; Multiple Sclerosis Clinic, Petach Tikva, 49100, Israel|The Chaim Sheba Medical Center; Multiple Sclerosis Center, Ramat-Gan, 5262100, Israel|Medical Center Ziv Safed; Neurology Department, Safed, 13100, Israel|Tel Aviv Sourasky Medical Center; Department of Neurology, Tel Aviv, 6423906, Israel|A.O. Universitaria S. Martino Di Genova, Genova, Liguria, 16132, Italy|Hospital San Raffaele, Milano, Lombardia, 20132, Italy|Azienda Sanitaria Ospedaliera S. Luigi Gonzaga; Centro Regionale Sclerosi Multipla - Neurologia II, Orbassano, Piemonte, 10043, Italy|Ospedale Binaghi; Centro Sclerosi Multipla, Cagliari, Sardegna, 09126, Italy|Hospital of Lithuanian University of Health. Sciences Kaunas Clinics, Kaunas, 50009, Lithuania|Klaipeda University Hospital Public Institution, Klaipeda, 92288, Lithuania|Siauliai Hospital, Siauliai, 76231, Lithuania|Instituto Biomedico De Investigacion A.C., Aguascalientes, 20127, Mexico|Instituto Nacional de Neurologia y Neurocirugia, Mexico City, 14390, Mexico|Eleccion Salud SC, Mexico, 03600, Mexico|Centro de Estudios Clinicos y Espec. Med. SC, Monterrey, 64620, Mexico|Erasmus MC; Afdeling Neurologie, Rotterdam, 3015 GD, Netherlands|Zuyderland Medisch Centrum - Sittard Geleen, Sittard-Geleen, 6162 BG, Netherlands|Waikato Hospital; Neurology, Hamilton, 3240, New Zealand|Wellington Hospital; Department of Neurology, Wellington, 6021, New Zealand|Oslo universitetssykehus HF, Ullevål; Nevrologisk avdeling, Oslo, 0407, Norway|Hospital IV Alberto Sabogal Sologuren; Unidad de Investigacion, Bellavista, Callao 2, Peru|Clinica Anglo Americana, Lima, 18, Peru|Hospital Nacional Dos de Mayo - Centro de Investigacion en Oncología, Lima, Lima 1, Peru|Niepubliczny Zaklad Opieki Zdrowotnej KENDRON ; Poradnia Neurologiczna, Bialystok, 15-402, Poland|Akson - Clinical Research Maciejowski - Bielecki Sp. Jawna, Jaroslaw, 37-500, Poland|Diagnomed Clinical Research Sp. z o.o., Katowice, 40-594, Poland|Niepubliczny Zaklad Opieki Zdrowotnej; Neuro-Medic, Katowice, 40-686, Poland|Zespol Opieki Zdrowotnej w Konskich; Oddzial Neurologiczny, Konskie, 26-200, Poland|SPZOZ Uni. Szpital Kliniczny nr 1 im. Norberta Barlickiego Uni. Medycznego w Lodzi ; Neurologii, Lodz, 90-153, Poland|Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie; Klinika Neurochirurgii i Neurochirurgii Dzi, Lublin, 20-954, Poland|Hospital Garcia de Orta; Servico de Neurologia, Almada, 2801-951, Portugal|Hospital Prof. Dr. Fernando Fonseca; Servico de Neurologia, Amadora, 2720-276, Portugal|HUC; Servico de Neurologia, Coimbra, 3000-075, Portugal|Hospital Geral; Servico de Neurologia, Coimbra, 3041-801, Portugal|Hospital de Santa Maria; Servico de Neurologia, Lisboa, 1649-035, Portugal|Hospital Geral de Santo Antonio; Servico de Neurologia, Porto, 4099-001, Portugal|Elias Emergency University Hospital Neurology Dept; Neurology Department, Bucharest, 011461, Romania|SC Clubul Sanatatii SRL, Campulung, 115100, Romania|Spitalul Clinic Judetean de Urgenta Targu Mures; Clinica Neurologie, Targu Mures, 540136, Romania|Timisoara Emergency County Clinical Hospital, Timi?oara, 300595, Romania|Research Medical Complex ""Vashe Zdorovie""; Neurology Department, Kazan, 420103, Russian Federation|Hospital Universitari de Girona Dr. Josep Trueta; Servicio de Neurologia, Salt, Girona, 17190, Spain|Hospital Donostia, San Sebastian, Guipuzcoa, 20014, Spain|Complejo Hospitalario Universitario de Santiago (CHUS) ; Intermedios y Urgencias Pediatricas, Santiago de Compostela, LA Coruña, 15706, Spain|Hospital de Basurto Servicio de Neurologia, Bilbao, Vizcaya, 48013, Spain|Hospital General Univ. de Alicante, Alicante, 03010, Spain|Hospital del Mar; Servicio de Neurologia, Barcelona, 08003, Spain|Hospital Universitari Vall d'Hebron; Servicio de Neumo-Inmunologia, Barcelona, 08035, Spain|Hospital Clinic i Provincial; Servicio de Neurologia, Barcelona, 08036, Spain|Hospital de la Santa Creu i Sant Pau; Servicio de Neurologia, Barcelona, 08041, Spain|Universitario de La Princesa; Servicio de Neurología, Madrid, 28006, Spain|Hospital Ramon y Cajal; Servicio de Neurologia, Madrid, 28034, Spain|Hospital Universitario Clínico San Carlos; Servicio de Neurología, Madrid, 28040, Spain|Hospital Regional Universitario Carlos Haya; Servicio de Neurologia, Malaga, 29010, Spain|Hospital Universitario Virgen Macarena; Servicio de Neurologia, Sevilla, 41009, Spain|Universitätsspital Basel; Neurologie, Basel, 4031, Switzerland|Ospedale Regionale di Lugano - Civico; Neurologia, Lugano, 6903, Switzerland|CNPE City Clinical Hospital #3 of Chernivtsi City Council, Chernivtsi, Chernihiv Governorate, 58022, Ukraine|Municipal Non-profit Enterprise Odessa Regional Clinical Hospital of Odessa Regional Council, Odesa, Kherson Governorate, 65025, Ukraine|Municipal Non-profit Enterprise of Kyiv Regional Council Kyiv Regional Clinical Hospital, Kyiv, KIEV Governorate, 04107, Ukraine|Ukrainian State Inst. of Med. and Social Problems of Disability; Neuro, Dnipropetrovsk, 49027, Ukraine|Dnipropetrovsk State Medical Academy; Dept of Neurology, Dnipropetrovsk, 49044, Ukraine|Kh. Med. Ac. of P.-Gr. Ed.; Cl. Cen. Hosp. of UkrZal.; 3rd Dept. Neurology, Kharkiv, 61176, Ukraine|Ams of Ukraine; Inst. of Neurology, Psychiatry & Narcology, Kharkov, 61068, Ukraine|Kyiv City Clinical Hospital #4 MAHC of Kyiv; Chair of Neurology, Kyiv, 03110, Ukraine|Volyn Regional Clinical Hospital, Lutsk, 43024, Ukraine|Lviv Regional Clinical Hospital; Department of Neurology, Lviv, 79010, Ukraine|Vinnytsya National Med. Uni. n.a. M.I. Pyrohov; Dept. of Neurology #3, Vinnytsya, 21018, Ukraine|Walton Centre NHS Foundation Trust, Neuroscience Research Centre; CLINICAL TRIALS UNIT, Liverpool, L9 7LJ, United Kingdom|Barts and the London NHS Trust, London, E1 2ES, United Kingdom|Kings College Hospital; Neurology, London, SE5 9RS, United Kingdom|Royal Victoria Infirmary; Neurology Dept., Newcastle Upon Tyne, NE1 4LP, United Kingdom|Uni Hospital Queens Medical Centre; Neurology, Nottingham, NG7 2UH, United Kingdom|Indiana University Medical Center; Department of Neurology, Indianapolis, 46202, Uruguay"
NCT02308670,Evaluate the Effect of Switching From Daily Injections of 20mg Glatiramer Acetate (GA) to 40mg GA Three Times a Week in Subjects With Relapsing-remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02308670,COMPLETED,Multiple Sclerosis,,University at Buffalo,Teva Pharmaceuticals USA,ALL,"ADULT, OLDER_ADULT",,150,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-07,2016-10,2016-10,"Buffalo Neuroimaging Analysis Center, Buffalo, New York, 14203, United States"
NCT05604170,Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy,https://beta.clinicaltrials.gov/study/NCT05604170,ENROLLING_BY_INVITATION,Tuberous Sclerosis Complex,DRUG: Ganaxolone,Marinus Pharmaceuticals,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,169,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-05-16,2024-12-31,2024-12-31,"Barrow Neurological Institute at Phoenix Children's Hospital, Phoenix, Arizona, 85016, United States|Arkansas Children's Research Institute, Little Rock, Arkansas, 72202, United States|UCLA Mattel Children's Hospital, TSC Center, Los Angeles, California, 90095, United States|Children's Hospital Colorado, Aurora, Colorado, 80045, United States|Mid-Atlantic Epilepsy & Sleep Center, Bethesda, Maryland, 20817, United States|Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, 02115, United States|Children's Hospital of Michigan Central Michigan University, Detroit, Michigan, 48201, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 27599, United States|Atrium Health/Levine Children's Hospital, Charlotte, North Carolina, 28207, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 45229, United States|Medical University of South Carolina, Charleston, South Carolina, 29425, United States|Le Bonheur Children's Hospital, Memphis, Tennessee, 38103, United States|Child Neurology Consultants of Austin (CNCA), Austin, Texas, 78757, United States|McGovern Medical School at the University of Texas Health Science Center, Houston, Texas, 77030, United States"
NCT02759211,Pilot Trial of Backwards Walking in Persons With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02759211,UNKNOWN,Multiple Sclerosis,OTHER: Backwards Walking|OTHER: Forwards Walking,Mount Sinai Rehabilitation Hospital,National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",NA,16,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2016-04,2018-02,2018-02,"Mandell Center for Multiple Sclerosis at the Mount Sinai Rehabilitation Hospital, Hartford, Connecticut, 06112, United States"
NCT02234713,Adherence in Pediatric Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02234713,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Motivational Interview|OTHER: Video Attention Control,The Hospital for Sick Children,"National Multiple Sclerosis Society|Loma Linda University|University of Pittsburgh|Children's Hospital of Philadelphia|Boston Children's Hospital|Baylor College of Medicine|University of Alabama at Birmingham|Mayo Clinic|University of Colorado, Denver|University of California, San Francisco|Washington University School of Medicine|Alberta Children's Hospital|The Cleveland Clinic|DeltaQuest Foundation",ALL,"CHILD, ADULT",NA,71,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: OTHER,2013-01,2016-07,2016-09,"University of Alabama, Birmingham, Alabama, 35294, United States|Loma Linda University, Loma Linda, California, 92354, United States|The Regents of the University of California, San Francisco, San Francisco, California, 94143, United States|University of Colorado at Denver, Denver, Colorado, 80202, United States|Boston Children's Hospital, Boston, Massachusetts, 02115, United States|Mayo Clinic, Rochester, Minnesota, 55905, United States|Washington University, Saint Louis, Missouri, 63130, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, 15213, United States|Baylor College of Medicine, Houston, Texas, 77030, United States|Alberta Children's Hospital, Calgary, Alberta, T3B 6A8, Canada|The Hospital for Sick Children, Toronto, Ontario, M5G 1X8, Canada"
NCT05266469,Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf,https://beta.clinicaltrials.gov/study/NCT05266469,RECRUITING,Relapsing Multiple Sclerosis,OTHER: Ofatumumab|OTHER: Ocrelizumab,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",,240,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-07-26,2024-07-30,2024-07-30,"Novartis Investigative Site, Muscat, 112, Oman|Novartis Investigative Site, Abu Dhabi, 51900, United Arab Emirates|Novartis Investigative Site, Abu Dhabi, United Arab Emirates|Novartis Investigative Site, Dubai, United Arab Emirates"
NCT01884935,PK and PD Study of Natalizumab in Pediatric Subjects With RRMS,https://beta.clinicaltrials.gov/study/NCT01884935,COMPLETED,Relapsing-Remitting Multiple Sclerosis,BIOLOGICAL: Natalizumab,Biogen,,ALL,CHILD,PHASE1,13,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-07,2014-09,2014-09,"Research Site, Cefalu, Italy|Research Site, Gallarate, Italy|Research Site, Milan, Italy|Research Site, Padua, Italy|Research Site, Rome, Italy"
NCT02273635,"Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS",https://beta.clinicaltrials.gov/study/NCT02273635,UNKNOWN,"Primary Progressive Multiple Sclerosis|Multiple Sclerosis, Secondary Progressive",DRUG: Andrographolides|DRUG: placebo,Innobioscience SpA,Pontificia Universidad Catolica de Chile|University of Chile|Universidad Austral de Chile,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,68,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-09,2016-11,2017-04,"Multiple Sclerosis Centre, Pontificia Universidad Catolica de Chile, Santiago, Metropolitana, 8330033, Chile"
NCT03091569,Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy,https://beta.clinicaltrials.gov/study/NCT03091569,COMPLETED,Relapsing-Remitting Multiple Sclerosis,OTHER: Vitamin K Cream|OTHER: Placebo Cream,Biogen,,ALL,"ADULT, OLDER_ADULT",PHASE4,23,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE",2017-03-10,2018-01-27,2018-01-27,"Research Site, Napoli, 80131, Italy"
NCT00206635,Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00206635,COMPLETED,Multiple Sclerosis,"DRUG: Interferon beta-1b (Betaseron, BAY86-5046)",Bayer,,ALL,"ADULT, OLDER_ADULT",,432,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2005-01,,2005-12,"Many Locations, Alabama, United States|Many Locations, Arizona, United States|Many Locations, California, United States|Many Locations, Illinois, United States|Many Locations, Maryland, United States|Many Locations, Pennsylvania, United States|Many Locations, British Columbia, Canada|Many Locations, Ontario, Canada|Many Locations, Quebec, Canada"
NCT01228396,AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01228396,UNKNOWN,Secondary Progressive Multiple Sclerosis,DRUG: Hyperimmune caprine serum against HIV lysate,Daval International Limited,,ALL,"ADULT, OLDER_ADULT",PHASE2,20,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-05,2011-05,2012-03,"Royal Free Hospital Hampstead NHS Trust, London, NW3 2QG, United Kingdom"
NCT05258396,Exploring Cortical Remyelination in Children With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05258396,NOT_YET_RECRUITING,Children With Multiple Sclerosis,OTHER: MRI without injection of contrast product,Assistance Publique - Hôpitaux de Paris,,ALL,"CHILD, ADULT",NA,30,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2022-04-15,2025-05-15,2025-05-15,
NCT02921035,Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS),https://beta.clinicaltrials.gov/study/NCT02921035,COMPLETED,Relapsing Multiple Sclerosis (RMS),DRUG: Rebif (Interferon beta-1a),"Merck KGaA, Darmstadt, Germany",Merck Serono Middle East FZ LLC,ALL,ADULT,,594,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-06-30,2020-07-27,2020-07-27,"Research site, Alger, Algeria|Research site, Annaba, Algeria|Research site, Blida, Algeria|Research site, Oran, Algeria|Research site, Setif, Algeria|Research site, Tizi Ouzou, Algeria|Research site, Mendoza, Argentina|Research site, Rosario, Argentina|Research site, Tucuman, Argentina|Research site, Manamah, Bahrain|Research site, Sofia, Bulgaria|Research site, Alexandria, Egypt|Research site 1, Cairo, Egypt|Research site 2, Cairo, Egypt|Research site, Mansoura, Egypt|Research site 1, Budapest, Hungary|Research site 2, Budapest, Hungary|Research site 3, Budapest, Hungary|Research site, Esztergom, Hungary|Research site, Isfahan, Iran, Islamic Republic of|Research site, Tehran, Iran, Islamic Republic of|Research site 2, Seoul, Korea, Republic of|Research site, Kuwait, Kuwait|Research site 1, Beirut, Lebanon|Research site 2, Beirut, Lebanon|Research site, Casablanca, Morocco|Research site, Fés, Morocco|Research site, Marrakech, Morocco|Research site 1, Rabat, Morocco|Research site 2, Rabat, Morocco|Research site 3, Rabat, Morocco|Research site, Gdańsk, Poland|Research site, Katowice, Poland|Research site, Lublin, Poland|Research site, Rybnik, Poland|Research site, Warszawa, Poland|Research site, Łódź, Poland|Research site, Dammam, Saudi Arabia|Research site, Jeddah, Saudi Arabia|Research site, Khober, Saudi Arabia|Research site, Riyadh, Saudi Arabia"
NCT03191669,Vaccine Exposure in Patients With MS,https://beta.clinicaltrials.gov/study/NCT03191669,COMPLETED,Multiple Sclerosis,OTHER: Auto-questionnaire,Hospices Civils de Lyon,,ALL,"ADULT, OLDER_ADULT",,335,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-06-26,2017-07-07,2017-07-07,"Hôpital Neurologique Pierre Wertheimer, Bron, 69500, France|Service de Neurologie - Hôpital G. Montpied, Clermont-Ferrand, 63003, France|Service de Neurologie - CHU de Grenoble, Grenoble, 38043, France|Service de Neurologie - Hôpital Saint Joseph Saint Luc, Lyon, 69007, France|Cabinet de Neurologie - Clinique de la Sauvegarde, Lyon, 69009, France|Service de Neurologie - Hôpital Nord - CHU St Etienne, Saint-Étienne, 42055, France"
NCT05046535,The Effect of Cigarette Smoke on Sleep Quality and Physical Activity in People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05046535,RECRUITING,Multiple Sclerosis,BEHAVIORAL: Sleep quality and physical activity|GENETIC: Nicotine dependence|DIAGNOSTIC_TEST: Nicotine and cotinine serum levels|BEHAVIORAL: Smoking,University of Jordan,,ALL,"ADULT, OLDER_ADULT",,80,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-09-01,2022-08,2022-12-15,"Cell Therapy Center, Amman, Jordan"
NCT02139696,Sphingosine-1 Phosphate -Receptor Targeting and Microglial Activation,https://beta.clinicaltrials.gov/study/NCT02139696,COMPLETED,Multiple Sclerosis,RADIATION: PET and MRI,Turku University Hospital,,ALL,ADULT,,10,OTHER_GOV,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-09,2015-01,2016-10,"Turku University Hospital, Turku, 20520, Finland"
NCT01667796,Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health,https://beta.clinicaltrials.gov/study/NCT01667796,COMPLETED,"Multiple Sclerosis, Relapsing-remitting",DIETARY_SUPPLEMENT: Vitamin D3,Johns Hopkins University,"University of California, San Francisco|National Multiple Sclerosis Society",FEMALE,ADULT,NA,57,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2010-11,2014-03,2014-03,"University of California, San Francisco, San Francisco, California, 94143, United States|Johns Hopkins University, Baltimore, Maryland, 21287, United States"
NCT02234869,Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy,https://beta.clinicaltrials.gov/study/NCT02234869,WITHDRAWN,Relapsing Multiple Sclerosis,DRUG: Interferon Beta|DRUG: BIIB017 (Peginterferon beta-1a),Biogen,,ALL,"ADULT, OLDER_ADULT",PHASE4,0,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2014-10,2017-02,2018-03,
NCT05301335,Transformation of Dormant Spinal Networks to Mitigate Symptoms of Neurogenic Bladder,https://beta.clinicaltrials.gov/study/NCT05301335,RECRUITING,Neurogenic Bladder|Spinal Cord Injuries|Stroke|Multiple Sclerosis,DEVICE: SCONE,SpineX Inc.,"Rancho Los Amigos National Rehabilitation Center|Wake Forest University Health Sciences|MedStar National Rehabilitation Network|University of California, San Diego|Craig Hospital|Columbia University|Institute of Brain and Spine",ALL,"ADULT, OLDER_ADULT",NA,130,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2022-05-25,2024-04-01,2024-04-01,"Rancho Research Institute, Downey, California, 90242, United States|Univ of California, San Diego, San Diego, California, 92093, United States|Craig Hospital, Denver, Colorado, 80113, United States|Medstar National Rehab, Washington, District of Columbia, 20010, United States|Insitute of Brain and Spine, New Delhi, India"
NCT00348296,Efficacy and Safety Study of GB-0998 for Treatment of Systemic Sclerosis,https://beta.clinicaltrials.gov/study/NCT00348296,COMPLETED,"Scleroderma, Systemic",DRUG: High-dose intravenous immunoglobulin (Venoglobulin-IH),Benesis Corporation,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,60,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,2006-07,2009-07,2009-07,"Nagasaki University, Nagasaki, 852-8501, Japan"
NCT00678496,Cognitive Behavioural Therapy Software for the Treatment of Depression in People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00678496,COMPLETED,Depression|Multiple Sclerosis,OTHER: CBT Software|OTHER: Treatment as usual,University of Sheffield,Sheffield Teaching Hospitals NHS Foundation Trust|Walton Centre NHS Foundation Trust,ALL,"ADULT, OLDER_ADULT",NA,24,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2008-10,2010-01-31,2010-01-31,"Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, South Yorkshire, S10 3TG, United Kingdom"
NCT01272596,Evaluation of Sloan-Charts for Assessment of Disease Progress in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01272596,COMPLETED,Multiple Sclerosis,,"Charite University, Berlin, Germany",Novartis Germany GmbH,ALL,"ADULT, OLDER_ADULT",,100,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2009-12,2013-11,2013-11,"NeuroCure Clinical Reserach Center, Charité Universitaetsmedizin, Berlin, 10117, Germany"
NCT02274935,Cognitive Motor Interference Rehabilitation in Persons With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02274935,COMPLETED,Multiple Sclerosis,OTHER: Exercise,University of Illinois at Urbana-Champaign,,ALL,ADULT,NA,20,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH,2014-10,2016-07,2016-09,"Motor control research lab, Urbana, Illinois, 61801, United States"
NCT05853835,"First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug;LPX-TI641",https://beta.clinicaltrials.gov/study/NCT05853835,NOT_YET_RECRUITING,Autoimmune Diseases|Multiple Sclerosis,DRUG: LPX-TI641,LAPIX Therapeutics Inc.,,ALL,ADULT,PHASE1,60,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-06-30,2023-12-15,2024-03-01,"Triumpharma, Amman, 11941, Jordan"
NCT03101735,Study to Assess Resource Utilization and Quality of Life of Patients With RRMS Treated With Tecfidera in Greece,https://beta.clinicaltrials.gov/study/NCT03101735,COMPLETED,RRMS,DRUG: Dimethyl Fumarate (DMF),Genesis Pharma CNS & Specialty,,ALL,"ADULT, OLDER_ADULT",,455,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-09-23,2020-04-23,2020-04-23,"University General Hospital AHEPA (B'), Thessaloniki, 54636, Greece"
NCT04113135,The Utilization of Yoga as a Therapeutic Tool to Promote Physical Activity Behavior Change and Improved Postural Control in Individuals With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04113135,WITHDRAWN,Multiple Sclerosis,OTHER: Yoga|OTHER: Control,Winston Salem State University,Appalachian State University,ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-01-01,2020-12-31,2020-12-31,"Winston Salem State University, Winston-Salem, North Carolina, 27110, United States"
NCT02571335,Impacts of Different Training Modes (Intense Versus Ordinary) on the Immune System and Memory Functions in pwMS,https://beta.clinicaltrials.gov/study/NCT02571335,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Intensive Training|BEHAVIORAL: Normal Training,Klinik Valens,"German Sport University, Cologne",ALL,"ADULT, OLDER_ADULT",NA,65,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE,2015-09,2016-08,2016-08,"Kliniken-Valens, Valens, Sankt Gallen, 7317, Switzerland"
NCT02845635,MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02845635,COMPLETED,Multiple Sclerosis,OTHER: Personal history of multiple sclerosis,Duke University,,ALL,"ADULT, OLDER_ADULT",,2200,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-09-29,2021-07-28,2021-07-28,"Duke University Medical Center, Durham, North Carolina, 27710, United States"
NCT02580435,Deciphering the Role of the Gut Microbiota in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02580435,UNKNOWN,Multiple Sclerosis,,Sheba Medical Center,Weizmann Institute of Science,ALL,"ADULT, OLDER_ADULT",,520,OTHER_GOV,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-12,2020-12,2021-12,
NCT00902135,"Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)",https://beta.clinicaltrials.gov/study/NCT00902135,COMPLETED,Relapsing-Remitting Multiple Sclerosis,"DRUG: Interferon beta-1b (Betaseron, BAY86-5046)|DRUG: Interferon beta-1b (Betaseron, BAY86-5046)|DRUG: Interferon beta-1b (Betaseron, BAY86-5046)",Bayer,,ALL,"ADULT, OLDER_ADULT",,702,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2009-05,2013-12,2014-08,"Many Locations, Germany"
NCT02525874,Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).,https://beta.clinicaltrials.gov/study/NCT02525874,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis",DRUG: dimethyl fumarate,Biogen,,ALL,"ADULT, OLDER_ADULT",PHASE3,218,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-08-11,2017-04-24,2018-04-23,"Research Site, Gilbert, Arizona, 85234, United States|Research Site, Long Beach, California, 90806, United States|Research Site, Ocala, Florida, 34471, United States|Research Site, Oldsmar, Florida, 34677, United States|Research Site, Tampa, Florida, 33609, United States|Research Site, Tampa, Florida, 33612, United States|Research Site, Atlanta, Georgia, 30342, United States|Research Site, Overland Park, Kansas, 66212, United States|Research Site, Baltimore, Maryland, 33612, United States|Research Site, Traverse City, Michigan, 49684, United States|Research Site, Raleigh, North Carolina, 27607, United States|Research Site, Spartanburg, South Carolina, 29307, United States|Research Site, San Antonio, Texas, 78258, United States|Research Site, Salt Lake City, Utah, 84103, United States|Research Site, Tacoma, Washington, 98405, United States|Research Site, La Louviere, Hainaut, 7100, Belgium|Research Site, Brugge, West-Vlaanderen, 8000, Belgium|Research Site, Brasschaat, 2930, Belgium|Research Site, Plaven, 5800, Bulgaria|Research Site, Pleven, 5800, Bulgaria|Research Site, Sofia, 1113, Bulgaria|Research Site, Sofia, 1606, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Kuwait City, 00001, Kuwait|Research Site, Kaunas, LT-50009, Lithuania|Research Site, Klaipeda, 92288, Lithuania|Research Site, Vilnius, LT-08661, Lithuania|Research Site, Bydgoszcz, 85-795, Poland|Research Site, Katowice, 40-595, Poland|Research Site, Katowice, 40-650, Poland|Research Site, Lodz, 90-324, Poland|Research Site, Plewiska, 62-064, Poland|Research Site, Szczecin, 70-215, Poland|Research Site, Umuttepe, Kocaeli, 41380, Turkey"
NCT00480181,Efficacy and Safety Evaluation of Nabilone as Adjunctive Therapy to Gabapentin for the Management of Neuropathic Pain in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00480181,COMPLETED,Neuropathic Pain|Multiple Sclerosis,DRUG: nabilone|OTHER: placebo,University of Manitoba,"Bausch Health Americas, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE4,50,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2007-06,2012-07,2012-07,"Health Sciences Centre Multiple Sclerosis Clinic, Winnipeg, Manitoba, R3A 1R9, Canada"
NCT01592474,Evaluation of Brain Atrophy in CIS Patients on Avonex,https://beta.clinicaltrials.gov/study/NCT01592474,COMPLETED,Multiple Sclerosis,,University at Buffalo,"Biogen|Jacobs Neurological Institute|Charles University, Czech Republic",ALL,ADULT,,180,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2005-10,2011-08,2012-06,
NCT00812474,Regional Cortical Cerebral Quantitative MRI Perfusion Correlation Neurocognition in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00812474,COMPLETED,Multiple Sclerosis,,Sunnybrook Health Sciences Centre,Unity Health Toronto|The Physicians' Services Incorporated Foundation,ALL,"CHILD, ADULT, OLDER_ADULT",,60,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2008-12,2009-06,2015-11,
NCT02894281,Pupillometry Dynamic Measures in Patients Without Ocular or Neurological Disease,https://beta.clinicaltrials.gov/study/NCT02894281,COMPLETED,Optic Neuritis,DEVICE: pupillary light reflex,Fondation Ophtalmologique Adolphe de Rothschild,,ALL,"ADULT, OLDER_ADULT",,22,NETWORK,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-06,2017-06-30,2017-06-30,"Fondation Ophtalmologique A. de Rothschild, Paris, 75019, France"
NCT04562376,High-intensity Resistance Training in People With Multiple Sclerosis Experiencing Fatigue,https://beta.clinicaltrials.gov/study/NCT04562376,COMPLETED,Multiple Sclerosis|Fatigue|Exercise Therapy|Resistance Training|Cytokines,OTHER: High-intensity resistance training|OTHER: Low frequency of high-intensity resistance training,Karolinska Institutet,Neuro+,ALL,"ADULT, OLDER_ADULT",NA,73,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-08-20,2021-06-28,2022-06-30,"Academic Specialist Center, , Stockholm Health Services, Region Stockholm, Stockholm, 11365, Sweden"
NCT05349474,Metformin Treatment in Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05349474,RECRUITING,Secondary Progressive Multiple Sclerosis|Primary Progressive Multiple Sclerosis,"DRUG: Metformin 500 Mg Oral Tablet, up to 4 tablets a day|DRUG: Placebo oral tablet identical to metformin, up to 4 tablets a day","University of California, Los Angeles",,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,44,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-04-26,2025-05-26,2026-05-26,"University of California, Los Angeles, Los Angeles, California, 90095, United States"
NCT01339676,Colecalciferol as an Add-on Treatment to Interferon-beta-1b for Treatment of Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT01339676,UNKNOWN,Multiple Sclerosis,DRUG: Colecalciferol|DRUG: Placebo capsules,University of Turku,,ALL,ADULT,PHASE4,70,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2008-03,2011-05,2011-06,"Turku University Hospital, Turku, FIN-20521, Finland"
NCT01628276,Brain Functional Connectivity Changes Following Cognitive Rehabilitation in Multiple Sclerosis: an fMRI Study,https://beta.clinicaltrials.gov/study/NCT01628276,COMPLETED,MS (Multiple Sclerosis),BEHAVIORAL: Cog Rehab,"Sina Hospital, Iran",,ALL,ADULT,NA,45,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: ",2012-07,2013-09,2013-10,"Sina Hospital, Tehran, Iran, Islamic Republic of"
NCT05792176,Ukulele Playing to Improve Cognition in People With Multiple Sclerosis: A Feasibility Study,https://beta.clinicaltrials.gov/study/NCT05792176,RECRUITING,"Multiple Sclerosis|Pathologic Processes|Demyelinating Autoimmune Diseases, CNS|Autoimmune Diseases of the Nervous System|Nervous System Diseases|Demyelinating Diseases|Autoimmune Diseases|Immune System Diseases",BEHAVIORAL: Music Training Intervention|BEHAVIORAL: Music Listening,University of Texas at Austin,,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2023-03-27,2024-03-01,2024-08-01,"University of Texas at Austin, Austin, Texas, 78712, United States"
NCT03951181,Life-Style Exercise and Activity Package for People Living With Progressive MS,https://beta.clinicaltrials.gov/study/NCT03951181,COMPLETED,Multiple Sclerosis,BEHAVIORAL: LEAP-MS,Cardiff University,,ALL,"ADULT, OLDER_ADULT",NA,21,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-08-13,2021-04-19,2021-04-19,"Centre for Trials Research, Cardiff, CF144YS, United Kingdom"
NCT04580381,Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort,https://beta.clinicaltrials.gov/study/NCT04580381,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Natalizumab Injection [Tysabri],"University Hospital, Caen",Biogen,ALL,"ADULT, OLDER_ADULT",,500,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-09-01,2021-10-01,2021-10-30,"Department of Neurology, CHU Bobigny-Avicenne, Bobigny, 93000, France|Department of Neurology, CHU de Caen, Caen, 14000, France|Department of Neurology, Percy Military Hospital, Clamart, 92140, France|Department of Neurology, CHU Nice, Nice, 06000, France|Department of Neurology, CHU Toulouse Purpan, Toulouse, 31300, France"
NCT00001781,"Safety, Tolerability, and Effectiveness of CGP77116 in Patients With Multiple Sclerosis (MS)",https://beta.clinicaltrials.gov/study/NCT00001781,COMPLETED,Multiple Sclerosis,DRUG: CGP 77116,National Institute of Neurological Disorders and Stroke (NINDS),,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,25,NIH,INTERVENTIONAL,Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT,1998-02,,2002-03,"National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, 20892, United States"
NCT02579681,Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012,https://beta.clinicaltrials.gov/study/NCT02579681,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: dimethyl fumarate,Biogen,,ALL,"ADULT, OLDER_ADULT",PHASE3,221,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-04-30,2016-12-21,2016-12-21,"Research site, Bari, Italy|Research site, Cagliari, Italy|Research site, Catania, Italy|Research site, Cefalu, Italy|Research site, Chieti, Italy|Research site, Ferrara, Italy|Research site, Fidenza, Italy|Research site, Firenze, Italy|Research site, Gallarate, Italy|Research site, Genova, Italy|Research site, L'aquila, Italy|Research site, Milano, Italy|Research site, Napoli, Italy|Research site, Orbassano, Italy|Research site, Padova, Italy|Research site, Palermo, Italy|Research site, Pavia, Italy|Research site, Roma, Italy"
NCT02466074,Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02466074,TERMINATED,Multiple Sclerosis,DRUG: Acetazolamide|DRUG: Placebo,"The University of Texas Health Science Center, Houston",,ALL,ADULT,PHASE2,5,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-08-17,2022-02-07,2022-02-07,"UTHealth, Houston, Texas, 77030, United States"
NCT01838174,A Trial of Neuroprotection With ACTH in Acute Optic Neuritis,https://beta.clinicaltrials.gov/study/NCT01838174,TERMINATED,Multiple Sclerosis,DRUG: ACTHAR Gel (ACTH)|DRUG: IV methylprednisolone (steroids),"University of Colorado, Denver",Mallinckrodt|University of Pennsylvania,ALL,ADULT,PHASE4,37,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2013-05,2022-01-13,2022-01-13,"University of Colorado Denver, Aurora, Colorado, 80045, United States|University of Pennsylvania Scheie Eye Institute, Philadelphia, Pennsylvania, 19104, United States"
NCT01979081,Detecting and Addressing Preclinical Disability,https://beta.clinicaltrials.gov/study/NCT01979081,COMPLETED,Back Pain|Coronary Artery Disease|Chronic Obstructive Pulmonary Disease|Diabetes|Hypertension|Multiple Sclerosis|Osteoporosis|Osteoarthritis|Rheumatoid Arthritis|Stroke,OTHER: Tailored advice from a physiotherapist and/or an occupational therapist through the myOSCAR patient portal,McMaster University,,ALL,"ADULT, OLDER_ADULT",,148,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-01,2017-06,2017-12,"Stonechurch Family Health Centre, Hamilton, Ontario, L8W 3L2, Canada"
NCT03983681,Evaluation of a Theory-Driven Manualized Approach to Improving New Learning and Memory in MS,https://beta.clinicaltrials.gov/study/NCT03983681,RECRUITING,Multiple Sclerosis,BEHAVIORAL: Strategy-Based Training to Enhance Memory (STEM)|BEHAVIORAL: Placebo control exercises,Kessler Foundation,,ALL,ADULT,NA,120,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2019-09-26,2024-02-15,2024-03-31,"Kessler Foundation, East Hanover, New Jersey, 07936, United States|Kessler Rehabilitation Center, Marlton, New Jersey, 08053, United States"
NCT02318576,Computerized Cognition Testing and Cognitive Motor Interference in MS,https://beta.clinicaltrials.gov/study/NCT02318576,COMPLETED,Multiple Sclerosis,OTHER: Cognitive Training,University of Illinois at Urbana-Champaign,,ALL,"ADULT, OLDER_ADULT",NA,29,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: ",2015-03,2016-03,2016-03,"Motor control research lab, Urbana, Illinois, 61801, United States"
NCT02904876,Evaluation of Early Changes Visible to the Diffusion MRI in Response to Two Years of Treatment With Tysabri in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02904876,TERMINATED,Multiple Sclerosis,RADIATION: Diffusion Magnetic Resonance Imaging at 6 months,"University Hospital, Strasbourg, France",,ALL,"ADULT, OLDER_ADULT",PHASE4,70,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2015-03,2019-12,2020-05,"Service de Neurologie Hôpital de Hautepierre, Strasbourg, Alsace, France"
NCT00464074,Evaluation of Natalizumab for thE Relief of MS Associated FatiGue,https://beta.clinicaltrials.gov/study/NCT00464074,COMPLETED,Multiple Sclerosis,,Biogen,Elan Pharmaceuticals,ALL,ADULT,,200,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2007-09,2010-07,2010-07,"Research Site, Phoenix, Arizona, 85006, United States|Research Site, Fresno, California, 93720, United States|Research Site, Atlanta, Georgia, 30327, United States|Research Site, Idaho Falls, Idaho, 83404, United States|Research Site, Evanston, Illinois, 60201, United States|Research Site, Lake Barrington, Illinois, 60010, United States|Research Site, Indianapolis, Indiana, 46256, United States|Research Site, West Des Moines, Iowa, 50314, United States|Research Site, Lexington, Kentucky, 40503, United States|Research Site, Louisville, Kentucky, 40202, United States|Research Site, Boston, Massachusetts, 02135, United States|Research Site, Lexington, Massachusetts, 2421, United States|Research Site, Farmington Hills, Michigan, 48334, United States|Research Site, Buffalo, New York, 14203, United States|Research Site, New York, New York, 10003-3804, United States|Research Site, Patchogue, New York, 11772, United States|Research Site, Chapel Hill, North Carolina, 27599, United States|Research Site, High Point, North Carolina, 27262, United States|Research Site, Raleigh, North Carolina, 27607, United States|Research Site, Portland, Oregon, 97225, United States|Research Site, Anderson, South Carolina, 29621, United States|Research Site, Franklin, Tennessee, 37064, United States|Research Site, Knoxville, Tennessee, 37934, United States|Research Site, Nashville, Tennessee, 37205, United States|Research Site, Nashville, Tennessee, 37212, United States|Research Site, Salt Lake City, Utah, 84103, United States|Research Site, Salt Lake City, Utah, 84108, United States|Research Site, Seattle, Washington, 98195-6097, United States|Research Site, Charleston, West Virginia, 25301, United States|Research Site, Waukesha, Wisconsin, 53188, United States|Research Site, Guaynabo, 00969, Puerto Rico"
NCT04148781,Fampridine-SR and Optic Neuritis Recovery,https://beta.clinicaltrials.gov/study/NCT04148781,RECRUITING,Optic Neuritis,DRUG: Fampridine SR,Courtney Casserly,,ALL,ADULT,EARLY_PHASE1,20,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-03-22,2023-12,2024-01,"London Health Sciences Centre, London, Ontario, N6A 5A5, Canada"
NCT03418376,Carnosine Loading and Periodized Training in MS and HC,https://beta.clinicaltrials.gov/study/NCT03418376,COMPLETED,Multiple Sclerosis|Exercise Therapy|Dietary Supplement,DIETARY_SUPPLEMENT: Beta-alanine supplementation|OTHER: Exercise intervention,Hasselt University,,ALL,"ADULT, OLDER_ADULT",NA,45,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2017-02-01,2017-10-30,2017-12-30,"Hasselt University, Diepenbeek, Limburg, 3590, Belgium"
NCT04941781,PET Study to Determine the Relationship Between Plasma Concentrations and Muscarinic Type 1 Receptor (M1AChR) Occupancy of PIPE-307 in Healthy Volunteers,https://beta.clinicaltrials.gov/study/NCT04941781,COMPLETED,Multiple Sclerosis,DRUG: PIPE-307,"Pipeline Therapeutics, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1,6,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-09-01,2021-11-10,2021-11-10,"Hammersmith Medicines Research, London, United Kingdom"
NCT01044576,Patient Research Cohort: Rapidly Evolving Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01044576,COMPLETED,Relapsing-remitting Multiple Sclerosis|Secondary Progressive Multiple Sclerosis,,Imperial College London,"Medical Research Council|Imperial College Healthcare NHS Trust|University College, London|Queen Mary University of London|GlaxoSmithKline|University of Cambridge",ALL,"ADULT, OLDER_ADULT",,200,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-01,2012-11,2012-11,"Imperial College NHS Trust, London, United Kingdom"
NCT02427776,A Trial for Evaluating Both Safety and Preliminary Efficacy of a Single Infusion of Stimulated Autologous CD4+T Cells in Patients With Relapsing- Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02427776,TERMINATED,"Multiple Sclerosis, Relapsing-Remitting",BIOLOGICAL: Autologous CD4+T cells stimulated and expanded ex vivo by a MOG peptide modified by the introduction of a thioreductase motif into the flanking residues of the T cell epitope,Imcyse SA,,ALL,ADULT,PHASE1|PHASE2,2,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-01,2016-08,2016-08,"Cliniques universitaires Saint-Luc, Bruxelles, 1200, Belgium|University Hospital Leuven (Gasthuisberg), Leuven, 3000, Belgium|University Hospital of Liège, Liège, 4000, Belgium"
NCT01480076,Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01480076,COMPLETED,Multiple Sclerosis,DRUG: Fampridine,Biogen,,ALL,"ADULT, OLDER_ADULT",PHASE4,901,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2012-02,2013-07,2013-08,"Research Site, Concord, New South Wales, Australia|Research Site, Kogarah, New South Wales, Australia|Research Site, Liverpool, New South Wales, Australia|Research Site, New Lambton Heights, New South Wales, Australia|Research Site, Auchenflower, Queensland, Australia|Research Site, Box Hill, Victoria, Australia|Research Site, Clayton, Victoria, Australia|Research Site, Fitzroy, Victoria, Australia|Research Site, Heidelberg, Victoria, Australia|Research Site, Brasschaat, Belgium|Research Site, Brussels, Belgium|Research Site, Diepenbeek, Belgium|Research Site, Fraiture-en-Condroz, Belgium|Research Site, Gent, Belgium|Research Site, Liege, Belgium|Research Site, Melsbroek, Belgium|Research Site, Overpelt, Belgium|Research Site, Sijsele-Damme, Belgium|Research Site, Wilrijk, Belgium|Research Site, Copenhagen, Denmark|Research Site, Nice, Alpes-Maritimes, France|Research Site, Strasbourg, Bas-Rhin, France|Research Site, Caen, Calvados, France|Research Site, Bordeaux Cedex, Gironde 5, France|Research Site, Rennes, Ille-et-Vilaine, France|Research Site, Nantes, Loire-Atlantique 6, France|Research Site, Reims, Marne, France|Research Site, Clemont-Ferrand, Rhone, France|Research Site, Paris, Seine-Saint-Denis 14, France|Research Site, Amiens, Somme, France|Research Site, Paris, France|Research Site, Heidenheim, Bad Wuerttemberg, Germany|Research Site, Kassel, Hessen, Germany|Research Site, Oldenburg, Niedersachsen, Germany|Research Site, Muenster, Nordrhein-Westfalen, Germany|Research Site, Berlin, Germany|Research Site, Erbach, Germany|Research Site, Hamburg, Germany|Research Site, Jena, Germany|Research Site, Osnabrueck, Germany|Research Site, Schwendi, Germany|Research Site, Bari, Italy|Research Site, Firenze, Italy|Research Site, Milano, Italy|Research Site, Padova, Italy|Research Site, Roma, Italy|Research Site, Eindhoven, Netherlands|Research Site, Hoorn, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Amadora, Portugal|Research Site, Coimbra, Portugal|Research Site, Lisboa, Portugal|Research Site, Porto, Portugal|Research Site, Salford, Greater Manchester, United Kingdom|Research Site, Nottingham, Northamptonshire, United Kingdom|Research Site, Glasgow, Stirlingshire, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, London, United Kingdom"
NCT01596881,Using Optical Coherence Tomography to Capture Retinal Microvascular Changes Associated With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01596881,COMPLETED,Multiple Sclerosis,,Oregon Health and Science University,,ALL,"ADULT, OLDER_ADULT",,101,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-04,2017-02-08,2017-02-08,"Oregon Health & Science University, Portland, Oregon, 97239, United States"
NCT00342381,Fatigue in Multiple Sclerosis: Evaluated With 3 MRI and Transcranial Magnetic Stimulation,https://beta.clinicaltrials.gov/study/NCT00342381,COMPLETED,Multiple Sclerosis|Fatigue,"DRUG: 3,4-diaminopyridine|DRUG: Placebo",University of Aarhus,The Danish Multiple Sclerosis Society,ALL,ADULT,PHASE2,120,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2006-06,,2007-12,"Aarhus University Hospital, Department of Neurology, Aarhus, 8000, Denmark"
NCT01279876,Melatonin in Relapsing-Remitting Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT01279876,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Melatonin,Tehran University of Medical Sciences,,ALL,ADULT,PHASE2,25,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2010-10,2014-01,2014-02,"Iranian Center for Neurological Researches, Imam Khomeini Hospital, Tehran, Iran, Islamic Republic of"
NCT01378676,A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS),https://beta.clinicaltrials.gov/study/NCT01378676,COMPLETED,Amyotrophic Lateral Sclerosis,DRUG: Placebo (Part A)|DRUG: CK-2017357 (Part A)|DRUG: CK-2017357 (Part A)|DRUG: CK-2017357 (Part A)|DRUG: Riluzole 50 MG (Part B)|DRUG: Placebo (Part B)|DRUG: CK-2017357 (Part B)|DRUG: CK-2017357 (Part B)|DRUG: CK-2017357 (Part B),Cytokinetics,,ALL,"ADULT, OLDER_ADULT",PHASE2,49,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-06,2012-03,2012-03,"California Pacific Medical Center, San Francisco, California, 94115, United States|Mayo Florida, Jacksonville, Florida, 32224, United States|University of Kansas, Kansas City, Kansas, 06053, United States|Johns Hopkins Hospital, Baltimore, Maryland, 21287, United States|Columbia University Medical Center, New York, New York, 10032, United States|SUNY Upstate Medical Center, Syracuse, New York, 13210, United States|Carolinas Neuromuscular ALS-MND Center, Charlotte, North Carolina, 28207, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, 17033, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, 19107, United States"
NCT02887781,Clinical Presentation and Renal Outcome of Patients With Tuberous Sclerosis Complex and/or Renal Angiomyolipoma in the Great West Region of France,https://beta.clinicaltrials.gov/study/NCT02887781,UNKNOWN,Tuberous Sclerosis Complex,,"University Hospital, Brest",,ALL,"CHILD, ADULT, OLDER_ADULT",,150,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-08-13,2020-12-31,2020-12-31,"CHU Brest, Brest, 29200, France|CHU Rennes, Rennes, 35033, France"
NCT04746976,Study of Diroximel Fumarate in the Real-World Setting,https://beta.clinicaltrials.gov/study/NCT04746976,RECRUITING,Relapsing Forms of MS,DRUG: Diroximel Fumarate,Biogen,,ALL,"ADULT, OLDER_ADULT",,200,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-03-01,2024-09-01,2024-09-01,"University of Calfornia San Diego, La Jolla, California, 92093, United States|Regina Berkovich MD Phd Inc, West Hollywood, California, 90048, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, 20007, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States|Michigan Institute for Neurological Disorders (MIND), Farmington, Michigan, 48071, United States|Memorial Healthcare, Owosso, Michigan, 48867, United States|St. Luke's Neurology, Kansas City, Missouri, 64111, United States|MS Center at St Barnabas, Livingston, New Jersey, 07052, United States|Multiple Sclerosis Center JSUMC, Neptune, New Jersey, 07753, United States|Jacobs School of Medicine and Biomedical Sciences, Buffalo, New York, 14202, United States|Guilford Neurological, Greensboro, North Carolina, 27405, United States|Toledo Clinic, Toledo, Ohio, 43623, United States|Providence Brain and Spine Institute, Portland, Oregon, 97225, United States|Hope Neurology, Knoxville, Tennessee, 37922, United States|Riverside Neurology Specialists, Newport News, Virginia, 23601, United States|Providence Medical Research Center, Spokane, Washington, 99204, United States"
NCT03839381,"Turkish Version of Mini-BESTest, Validity and Reliability for Adult Participants With Sensoriomotor Impairments",https://beta.clinicaltrials.gov/study/NCT03839381,UNKNOWN,"Parkinson Disease|Multiple Sclerosis|Trauma, Brain",,T.C. ORDU ÜNİVERSİTESİ,,ALL,"ADULT, OLDER_ADULT",,50,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-03-04,2019-11-29,2019-12-04,
NCT01403376,Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide,https://beta.clinicaltrials.gov/study/NCT01403376,COMPLETED,Multiple Sclerosis,DRUG: teriflunomide|DRUG: Interferon-β-1|BIOLOGICAL: Influenza vaccine,Sanofi,,ALL,ADULT,PHASE2,128,INDUSTRY,INTERVENTIONAL,"Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: ",2011-09,2012-01,2012-01,"Investigational Site Number 040001, Wien, 1010, Austria|Investigational Site Number 124005, Calgary, T2N 2T9, Canada|Investigational Site Number 124003, Greenfield Park, J4V 2J2, Canada|Investigational Site Number 124002, London, N6A 5A5, Canada|Investigational Site Number 124007, Montreal, H3A 2B4, Canada|Investigational Site Number 124008, Ottawa, K1H 8L6, Canada|Investigational Site Number 124001, Quebec, G1J 1Z4, Canada|Investigational Site Number 124009, Toronto, M5B 1W8, Canada|Investigational Site Number 276003, Berlin, 10785, Germany|Investigational Site Number 276001, Essen, 45122, Germany|Investigational Site Number 276002, Münster, 48149, Germany|Investigational Site Number 643002, Nizhny Novgorod, 603076, Russian Federation|Investigational Site Number 804002, Ivano-Frankovsk, 76008, Ukraine|Investigational Site Number 804001, Kharkiv, 61018, Ukraine"
NCT04198181,The Effectiveness and Safety of Resective Epilepsy Surgery for TRE,https://beta.clinicaltrials.gov/study/NCT04198181,RECRUITING,Tuberous Sclerosis Complex|Epilepsy,,Beijing Children's Hospital,"Beijing Tiantan Hospital|The First Hospital of Jilin University|Xuanwu Hospital, Beijing|Capital Medical University|Peking University First Hospital|China-Japan Friendship Hospital|Chinese PLA General Hospital|Fourth Medical Center of PLA General Hospital|Capital Institute of Pediatrics, China|The Second Hospital of Hebei Medical University|Xijing Hospital|First Affiliated Hospital Xi'an Jiaotong University|Children's Hospital of Fudan University|RenJi Hospital|Jining Medical University|Xiamen Humanity Hospital|Xiangya Hospital of Central South University|Wuhan Medical Care Center for Women and Children|Guangdong 999 Brain Hospital|Shenzhen Children's Hospital|Xinqiao Hospital, Army Medical University|West China Hospital",ALL,"CHILD, ADULT, OLDER_ADULT",,200,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-12-12,2023-12-01,2024-02-01,"Beijing Children's Hospital, Beijing, Beijing, 100045, China"
NCT03708276,My MS Toolkit: a Symptom Self-management Program for Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03708276,COMPLETED,Multiple Sclerosis,OTHER: My MS Toolkit,University of Michigan,United States Department of Defense,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2019-02-26,2019-09-25,2019-09-25,"University of Michigan, Ann Arbor, Michigan, 48109, United States"
NCT03535298,Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS,https://beta.clinicaltrials.gov/study/NCT03535298,RECRUITING,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Early Highly Effective Therapies Group|DRUG: Escalation Therapies Group,The Cleveland Clinic,University of Nottingham,ALL,ADULT,PHASE4,800,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2019-01-03,2025-12-31,2026-09,"University of Colorado-Anschutz Medical Campus, Aurora, Colorado, 80045, United States|University of Minnesota, Minneapolis, Minnesota, 55455, United States|Mayo Clinic, Rochester, Minnesota, 55902, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, 89106, United States|University of Buffalo, Buffalo, New York, 14202, United States|University Rochester Medical Center, Rochester, New York, 14642, United States|University of Cincinnati, Cincinnati, Ohio, 45267, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|Ohio Health, Columbus, Ohio, 43214, United States|UT-Austin, Austin, Texas, 78712, United States|Baylor College of Medicine, Houston, Houston, Texas, 77030, United States|UTHealth-Houston, Houston, Texas, 77030, United States|University of Virginia, Charlottesville, Virginia, 22903, United States|Virginia Commonwealth University, Richmond, Virginia, 23284, United States|University of Wisconsin-Madison, Madison, Wisconsin, 53705, United States|University Hospitals Coventry and Warwickshire, Coventry, England, CV2 2DX, United Kingdom|Frimley Park, Frimley, England, GU16 7UJ, United Kingdom|The Leeds Teaching Hospitals NHS Trust, Leeds General Infirmary, Leeds, England, LS1 3EX, United Kingdom|University Hospitals Leicester, Leicester, England, LE1 5WW, United Kingdom|Imperial College Healthcare NHS Trust, Charing Cross Hospital, London, England, W6 8RF, United Kingdom|University College London Hospitals NHS Foundation Trust, University College Hospital, London, England, WC1N 3BG, United Kingdom|Salford Royal NHS Foundation Trust, Salford Hospital, Manchester, England, M6 8HD, United Kingdom|Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, England, OX3 9DU, United Kingdom|University Hospitals Plymouth NHS Trust, Derriford Hospital, Plymouth, England, PL6 8DH, United Kingdom|Sheffield Teaching Hospitals, Sheffield, England, S5 7AT, United Kingdom|University Hospitals of North Midlands, Stoke, England, ST4 6QG, United Kingdom|Royal Infirmary of Edinburgh, Edinburgh, Scotland, EH16 4SA, United Kingdom|Cardiff and Vale University Local Health Board, University Hospital of Wales, Cardiff, Wales, CF14 4XW, United Kingdom|Aneurin Bevan Local Health Board Headquarters, Royal Gwent Hospital, Newport, Wales, NP19 0BH, United Kingdom|Swansea Bay University Local Health Board, Morriston Hospital, Swansea, Wales, SA6 6NL, United Kingdom|Nottingham University Hospitals NHS Trust, Queens Medical Centre, Nottingham, NG7 2UH, United Kingdom"
NCT02040298,Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02040298,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Clemastine|DRUG: Placebo,"University of California, San Francisco",,ALL,ADULT,PHASE2,50,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-01,2015-09,2016-04,"UCSF Multiple Sclerosis Center, San Francisco, California, 94518, United States"
NCT05529498,High Intensity Interval Gait Training in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05529498,RECRUITING,"Multiple Sclerosis,Gait, Exercise",BEHAVIORAL: Moderate paced continuous gait training|BEHAVIORAL: High Intensity Interval gait training,City University of New York,,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-09-02,2023-12-31,2023-12-31,"Hunter College, New York, New York, 11238, United States"
NCT02644044,Intrathecal Methotrexate for Progressive Multiple Sclerosis: An Open Label Single Arm Study,https://beta.clinicaltrials.gov/study/NCT02644044,UNKNOWN,To Evaluate the Effect of Therapy With IT MTX on the Disease Course of Patients With Progressive MS,DRUG: Intrathecal methotrexate,Tel-Aviv Sourasky Medical Center,,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,30,OTHER_GOV,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-01,2017-12,2018-01,
NCT04203498,Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04203498,TERMINATED,Multiple Sclerosis (MS),DRUG: Nabiximols|DRUG: Placebo,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,238,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-10-01,2023-02-10,2023-02-27,"University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, 35233, United States|Neurostudies - Port Charlotte, Port Charlotte, Florida, 33952, United States|Tallahassee Neurological Clinic, Tallahassee, Florida, 32308, United States|University of South Florida, Tampa, Florida, 33613, United States|Accel Research Sites - Enterprise, Tampa, Florida, 33634, United States|Shepherd Center, Atlanta, Georgia, 30309, United States|Consultants in Neurology - Northbrook, Northbrook, Illinois, 60062, United States|American Health Network of Indiana, Avon, Indiana, 46123, United States|Ochsner Medical Center, New Orleans, Louisiana, 70121, United States|The Multiple Sclerosis Center For Innovations In Care, Saint Louis, Missouri, 63131, United States|Raleigh Neurology Associates - Raleigh Location, Raleigh, North Carolina, 27607, United States|University of Cincinnati (UC) Health, Dayton, Ohio, 45417, United States|Abington Neurological Associates, Abington, Pennsylvania, 19001, United States|Neurology Clinic - Cordova, Cordova, Tennessee, 38018, United States|Hope Neurology, Knoxville, Tennessee, 37922, United States|University of Texas Southwestern Medical Center, Dallas, Texas, 75390, United States|Central Texas Neurology Consultants, Round Rock, Texas, 78681, United States|Poliklinika Choceň, Choceň, Pardubice, 565 01, Czechia|Neurologie Taláb Radomír Doc. MUDr., CSc, Hradec Králové, 500 03, Czechia|Nemocnice Jihlava, Jihlava, 586 01, Czechia|Fakultní Nemocnice Královské Vinohrady, Praha 10, 100 34, Czechia|Krajská Zdravotní - Nemocnice Teplice, Teplice, 415 29, Czechia|Wromedica Centrum Zdrowia, Wrocław, Dolnoslaskie, 51-685, Poland|Centrum Medyczne Neuromed - Ośrodek Badań Klinicznych, Bydgoszcz, Kujawsko-Pomorskie, 85-163, Poland|Centrum Medyczne Neuroprotect, Warszawa, Mazowieckie, 01-684, Poland|Centrum Medyczne Pratia - Warszawa, Warszawa, Mazowieckie, 01-868, Poland|Neuro-Medic Janusz Zbrojkiewicz, Katowice, Slaskie, 40-555, Poland|Wielospecjalistyczne Centrum Medyczne Ibismed, Zabrze, Slaskie, 41-800, Poland|RESMEDICA Poradnia Neurologiczna, Kielce, Swietokrzyskie, 25-726, Poland|Niepubliczny Zakład Opieki Zdrowotnej NEURO - KARD, Poznań, Wielkopolskie, 61-853, Poland|Centrum Medyczne Oporów, Lublin, 20-855, Poland|Neurologiczny NZOZ Centrum Leczenia SM Ośrodek Badań Klinicznych im. dr n. med. Hanki Hertmanowskiej Witosław Cieślak, Plewiska, 62-064, Poland|Wromedica Centrum Zdrowia, Wrocław, 51-685, Poland|SP ZOZ Uniwersytecki Szpital Kliniczny Nr 1 im. Norberta Barlickiego w Łodzi, Łódź, 90-001, Poland|Spitalul Municipal Caracal, Caracal, 235200, Romania|Spitalul Clinic Cai Ferate Constanta, Constanţa, 900123, Romania|Centrul Medical Clubul Sanatatii, Câmpulung, 115100, Romania|Spitalul Municipal Sf. Dr. Cosma si Damian Radauti, Rădăuți, 725400, Romania|Barts Health NHS Trust, London, England, E1 1BB, United Kingdom"
NCT04707144,Performance Evaluation of a 3D PSIR Sequence in MRI at 1.5T,https://beta.clinicaltrials.gov/study/NCT04707144,RECRUITING,Multiple Sclerosis,DEVICE: MRI 1.5 tesla,Fondation Ophtalmologique Adolphe de Rothschild,,ALL,"ADULT, OLDER_ADULT",,100,NETWORK,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-05-06,2023-05,2023-05,"CHU DE Bordeaux, Bordeaux, 33000, France|Chu de Clermont-Ferrand, Clermont-ferrand, 63000, France|Chu de Lille, Lille, 59000, France|CHU de LYON, Lyon, 69002, France|Hôpital privé des Peupliers, Paris, 75013, France|Fondation Ophtalmologique Adolphe de Rothschild (FOR), Paris, 75019, France"
NCT03353974,Video Games Therapy on Balance and Cognitive Functions in Mild to Moderate Impaired Multiple Sclerosis Patients.,https://beta.clinicaltrials.gov/study/NCT03353974,RECRUITING,Multiple Sclerosis,DEVICE: Video game therapy|DEVICE: Balance platform therapy,University Hospital of Ferrara,,ALL,ADULT,NA,48,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2017-12-01,2022-10-01,2022-10-01,"Sofia Straudi, Ferrara, Emilia Romagna, 44124, Italy|Ferrara University Hospital, Ferrara, 44124, Italy"
NCT02980640,Swiss Multiple Sclerosis Registry,https://beta.clinicaltrials.gov/study/NCT02980640,RECRUITING,Multiple Sclerosis,,Swiss Multiple Sclerosis Registry,"University of Zurich, Epidemiology, Biostatistics and Prevention Institute|Schweizerische Multiple Sklerose Gesellschaft",ALL,"ADULT, OLDER_ADULT",,10000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-06,2041-06,2041-06,"University of Zurich; Epidemiology, Biostatistics & Prevention Institute, Zurich, 8001, Switzerland"
NCT04906057,The Therapeutic Effects of Forced Aerobic Exercise in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04906057,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,BEHAVIORAL: Forced Aerobic Exercise (FE)|BEHAVIORAL: Voluntary Aerobic Exercise (VE),The Cleveland Clinic,,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-07-06,2023-12-01,2023-12-01,"Cleveland Clinic Main Campus, Cleveland, Ohio, 44195, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States"
NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",https://beta.clinicaltrials.gov/study/NCT03160898,COMPLETED,Amyotrophic Lateral Sclerosis,DRUG: Reldesemtiv|DRUG: Placebo,Cytokinetics,Astellas Pharma Inc,ALL,"ADULT, OLDER_ADULT",PHASE2,458,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-07-24,2019-03-07,2019-03-07,"St. Joseph's Hospital and Medical Center - Barrow Neurological Clinics, Phoenix, Arizona, 85013, United States|Cedars-Sinai Medical Center, Los Angeles, California, 90048, United States|University of California Irvine, Orange, California, 92868, United States|Forbes Norris MDA/ALS Research Center, San Francisco, California, 94115, United States|Stanford Hospital and Clinics, Stanford, California, 94305, United States|University of Colorado Hospital Anschutz Outpatient Pavilion, Aurora, Colorado, 80045, United States|Hospital for Special Care, New Britain, Connecticut, 06053, United States|George Washington University Medical Faculty Associates, Washington, District of Columbia, 20037, United States|University of Florida, Gainesville, Florida, 32610, United States|Mayo Clinic, Jacksonville, Florida, 32224, United States|Carol & Frank Morsani Center for Advanced Healthcare - University of South Florida, Tampa, Florida, 33612, United States|Emory Clinic, Atlanta, Georgia, 30322, United States|Duchossois Center for Advanced Medicine, Chicago, Illinois, 60637, United States|IU Health Neuroscience Center of Excellence, Indianapolis, Indiana, 46202, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, 52242, United States|University of Kansas Medical Center, Kansas City, Kansas, 66160, United States|Johns Hopkins University - Outpatient Center, Baltimore, Maryland, 21287, United States|University of Massachusetts Memorial Medical Center/University of Massachusetts Medical School, Worcester, Massachusetts, 01655, United States|Michigan Medicine, Ann Arbor, Michigan, 48109, United States|Henry Ford Health System, Detroit, Michigan, 48202, United States|Hennepin County Medical Center, Minneapolis, Minnesota, 55415, United States|Mayo Clinic, Rochester, Minnesota, 55905, United States|Saint Louis University, Department of Neurology, Saint Louis, Missouri, 63104, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|Neurology Associates, P.C., Lincoln, Nebraska, 68506, United States|Hospital For Special Surgery, New York, New York, 10021, United States|Neurological Institute, Columbia University Medical Center, New York, New York, 10032, United States|SUNY Upstate Medical University, Syracuse, New York, 13210, United States|Neurosciences Institute, Neurology - Charlotte, Charlotte, North Carolina, 28207, United States|Duke Neurological Disorders Clinic, Durham, North Carolina, 27705, United States|Wake Forest School of Medicine, Winston-Salem, North Carolina, 27157, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, 43210, United States|Providence Brain and Spine Institute ALS Center, Portland, Oregon, 97213, United States|Oregon Health & Science University, Portland, Oregon, 97239, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, 17033, United States|Temple University School of Medicine, Philadelphia, Pennsylvania, 19140, United States|Vanderbilt University Medical Center - Clinical Research Center, Nashville, Tennessee, 37232, United States|Texas Neurology, Dallas, Texas, 75214, United States|Houston Methodist Hospital, Houston, Texas, 77030, United States|UTHSCSA Medical Arts and Research Center, San Antonio, Texas, 78229, United States|University of Vermont Medical Center, Burlington, Vermont, 05405, United States|University of Virginia Health System, Charlottesville, Virginia, 22908, United States|VCU Health - Ambulatory Care Center (ACC), Richmond, Virginia, 23298, United States|University of Washington Medical Center, Seattle, Washington, 98195, United States|West Virginia University, Dept. of Neurology, Morgantown, West Virginia, 26506-9180, United States|Froedtert Memorial Lutheran Hospital, Milwaukee, Wisconsin, 53226, United States|Brain and Mind Centre, The University of Sydney, Camperdown, New South Wales, 2050, Australia|Department of Neurology, Westmead Hospital, Westmead, New South Wales, 2145, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, 4029, Australia|Flinders Medical Centre, Bedford Park, South Australia, 5042, Australia|The Perron Institute for Neurological and Translation Science, Nedlands, Western Australia, 6009, Australia|University of Calgary, Heritage Medical Research Center, Calgary, Alberta, T2N 4Z6, Canada|Edmonton Kaye Clinic, Edmonton, Alberta, T6GT 1Z1, Canada|McMaster University Medical Centre, Hamilton, Ontario, L8N 3Z5, Canada|London Health Sciences Centre University Hospital, London, Ontario, N6A 5A5, Canada|Sunnybrook Health Science Centre, Toronto, Ontario, M4N 3M5, Canada|Montreal Neurological Institute and Hospital, Montreal, Quebec, H3A 2B4, Canada|Centre de recherche du Centre Hospitalier de l'Universite de Montreal, Montréal, Quebec, H2X 0A9, Canada|Saskatoon City Hospital, Saskatoon, Saskatchewan, S7H 0G9, Canada|CHU de Quebec-Universite Laval, Hopital de l'Enfant Jesus, Quebec, G1J 1Z4, Canada|Beaumont Hospital, Dublin, Dublin 9, Ireland|University Medical Center Utrecht, Utrecht, 3584 CX, Netherlands|Hospital San Rafael Servicio de Neurologia, Madrid, 28016, Spain"
NCT02664324,MSPT Device Usability Study,https://beta.clinicaltrials.gov/study/NCT02664324,COMPLETED,Multiple Sclerosis,,Biogen,,ALL,"ADULT, OLDER_ADULT",,60,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-03,2016-04,2016-04,"Research Site, Baltimore, Maryland, 21287, United States|Research Site, New York, New York, 10016, United States|Research Site, Cleveland, Ohio, 44195, United States"
NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01247324,COMPLETED,Relapsing Multiple Sclerosis,DRUG: Interferon beta-1a|DRUG: Ocrelizumab-matching placebo|DRUG: Ocrelizumab|DRUG: Interferon beta-1a-matching placebo,Hoffmann-La Roche,,ALL,ADULT,PHASE3,821,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-08-31,2015-04-02,2022-12-31,"21st Century Neurology, Phoenix, Arizona, 85004, United States|Mercy Medical Group, Carmichael, California, 95608, United States|Scripps Clinic, La Jolla, California, 92037, United States|MS Center of California, Laguna Hills, California, 92653, United States|Southern California Permanente Medical Group, Los Angeles, California, 90027, United States|Neuro-Therapeutics Inc., Pasadena, California, 91105, United States|University of California at San Francisco, San Francisco, California, 94115, United States|Health First Physicians Inc., Melbourne, Florida, 32901, United States|Mercy Research Institute, Miami, Florida, 33133, United States|Miami Research Associates, South Miami, Florida, 33143, United States|Axiom Clinical Research of Florida, Tampa, Florida, 33609, United States|University of South Florida, Tampa, Florida, 33612, United States|Shepherd Center Inc., Atlanta, Georgia, 30309, United States|Emory University; Department of Neurology, Atlanta, Georgia, 30322, United States|NeuroTrials Research, Inc., Atlanta, Georgia, 30342, United States|Northwestern University; Dept. of Neurology, Chicago, Illinois, 60611, United States|Consultants in Neurology Ltd, Northbrook, Illinois, 60062, United States|American Health Network Institute, LLC, Avon, Indiana, 46123, United States|Massachusetts General Hospital., Boston, Massachusetts, 2114, United States|Michigan Neurology Associates P.C., Clinton Township, Michigan, 48035, United States|Michigan Institute for Neurological Disorders, Farmington Hills, Michigan, 48334, United States|The Minneapolis Clinic of Neurology, Golden Valley, Minnesota, 55422, United States|Washington University; Wash Uni. Sch. Of Med, Saint Louis, Missouri, 63110, United States|The MS Center for Innovations In Care, Saint Louis, Missouri, 63131, United States|University of Nebraska Medical Center, Omaha, Nebraska, 68198-0600, United States|University of New Mexico, Albuquerque, New Mexico, 87131, United States|The MS Center; Advance Neurology and Pain, Advance, North Carolina, 27006, United States|Atrium Health Neurosciences Institute ? Charlotte, Charlotte, North Carolina, 28204, United States|OnSite Clinical Solutions LLC, Charlotte, North Carolina, 28277, United States|Neurology Associates PA, Hickory, North Carolina, 28602, United States|University Neurology Inc., Cincinnati, Ohio, 45219, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, 43212, United States|Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, 73104, United States|Providence Neurological Specialties, Portland, Oregon, 97225, United States|Albert Einstein Medical Center; Depatment of Neurosensory sciences, Philadelphia, Pennsylvania, 19141, United States|Magee-Woman's Hospital, Pittsburgh, Pennsylvania, 15213, United States|Uni of Texas Health Science Center At Houston, Houston, Texas, 77030, United States|Bhupesh Dihenia M.D. P.A., Lubbock, Texas, 79410, United States|Uni of Vermont Medical Center;, Burlington, Vermont, 05405, United States|Multicare Research Institute; Multicare Neuroscience Center of Washington, Tacoma, Washington, 98405, United States|Instituto centenario, Buenos Aires, C1204AAD, Argentina|Hospital Español, Ciudad Autonoma Bs As, C1209AAB, Argentina|Fundacion Rosarina de Neurorehabilitacion, Rosario, S2000BZL, Argentina|Royal North Shore Hospital; Department of Neurology, St Leonards, New South Wales, 2065, Australia|Barmherzige Brueder Konventspital, Linz, 4040, Austria|AZ Sint Jan, Brugge, 8000, Belgium|Cliniques Universitaires Saint-Luc; Neurology, Bruxelles, 1200, Belgium|AZ Delta (Campus Rumbeke), Roeselare, 8800, Belgium|Hospital das Clinicas - UFG;Reumatologia, Goiania, GO, 74653-050, Brazil|IMV Pesquisa Neurológica, Porto Alegre, RS, 90110-000, Brazil|Clinica Neurologica; Neurocirurgica de Joinville, Joinville, SC, 89202-190, Brazil|MHAT Avis Medica; Neurology Department, Pleven, 5800, Bulgaria|First MHAT; Clinic of Neurology, Sofia, 1000, Bulgaria|MHATNP Sv.Naum EAD; Clinic in neurology diseases for movement disorders, Sofia, 1113, Bulgaria|ACIBADEM CITY CLINIC TOKUDA HOSPITAL EAD; Clinic of Neurology and Sleep Medicine, Sofia, 1407, Bulgaria|Military Medical Academy; Neurology, Sofia, 1606, Bulgaria|Hospital Carlos Van Buren, Valparaiso, 2340000, Chile|Fakultni nemocnice u sv. Anny; Neurologicka klinika, Brno, 656 91, Czechia|Fakultni nemocnice Hradec Kralove, Hradec Kralove, 500 05, Czechia|Nemocnice Jihlava; NEU-Neurologicke oddeleni, Jihlava, 58633, Czechia|Krajska Nemocnice Pardubice Neurologicka Klinika, Pardubice, 532 03, Czechia|VFN Praha Poliklinika Rs Centrum - Budova A, Prague, 12808, Czechia|Krajska zdravotni, a. s. ? Nemocnice Teplice, o. z.; Neurologicke oddeleni, Teplice, 415 29, Czechia|West Tallinn Central Hospital, Tallinn, 10617, Estonia|Tartu University Hospital, Tartu, 51014, Estonia|FinnMedi Oy, Tampere, 33520, Finland|Groupe Hospitalier Pellegrin, Bordeaux, 33000, France|CHU Hopital Gabriel Montpied; Service de Neurologie, Clermont Ferrand, 63003, France|Hopital Central; Neurologie, Nancy, 54035, France|CHU de Nîmes Hopital Caremeau; Service de Neurologie, Nimes, 30900, France|Hopital Hautepierre - CHU Strasbourg; Service de Neurologie, Strasbourg, 67098, France|Charité Universitaetsmedizin Berlin, Campus Charité Mitte, Berlin, 10117, Germany|Universitätsklinikum ""Carl Gustav Carus""; MS Center Dresden, Dresden, 01307, Germany|Asklepiosklinik Barmbek; Abteilung Neurologie, Hamburg, 22291, Germany|Diakoniekrankenhaus Henriettenstiftung gGMBH; Klinik für Neurologie und klinische Neurophysiologie, Hannover, 30171, Germany|Universitaetsklinikum Mainz - PS; Klinik und Poliklinik fuer Neurologie, Mainz, 55131, Germany|Praxis Dr. med. Mathias Niedhammer, Facharzt für Neurologie, Oldenburg, 26122, Germany|Neurozentrum Prien Elisabeth Hans-Thümmler Stefan Braune, Prien, 83209, Germany|Universitätsklinikum Rostock, Zentrum für Nervenheilkunde; Klinik und Poliklinik für Neurologie, Rostock, 18147, Germany|Universitätsklinikum Tübingen, Zentrum für Neurologie, Tübingen, 72076, Germany|Studienzentrum Nordwest, Dr. med. Joachim Springub / Herr Wolfgang Schwarz, Westerstede, 26655, Germany|Semmelweis Egyetem AOK; Neurologiai Klinika, Budapest, 1083, Hungary|Fovarosi Onkormanyzat Jahn Ferenc Del-Pesti, Budapest, 1204, Hungary|Szent Borbala Korhaz; Neurology, Tatabánya, 2800, Hungary|Chaim Sheba Medical Center; Neurology Department, Ramat-Gan, 5262000, Israel|Azienda Ospedaliera Sant'Andrea, Roma, Lazio, 00189, Italy|Irccs Ospedale San Raffaele, Milano, Lombardia, 20132, Italy|Azienda Socio Sanitaria Territoriale della Valle Olona (pres, Gallarate, Valle D?Aosta, 21013, Italy|Azienda Ospedaliera di Padova; Clinica Neurologica, Padova, Veneto, 35128, Italy|Maritime Medicine Centre of Latvia Hospital of Vecmilgravis Department of Neurology, Riga, 1015, Latvia|P. Stradins Clinical University Hospital; Neurology, Riga, LV-1002, Latvia|Kaunas Medical University Hospital, Kaunas, 50009, Lithuania|Klaipeda University Hospital Public Institution, Klaipeda, 92288, Lithuania|Vilnius University Hospital Santariskiu Clinic, Vilnius, 08661, Lithuania|Grupo Médico Camino S.C., Ciudad de México, Mexico CITY (federal District), 03600, Mexico|Hospital Universitario Dr Jose Eleuterio Gonzalez; Universidad Autónoma de Nuevo León, Monterrey, 64460, Mexico|St. Antonius Ziekenhuis Nieuwegein, Nieuwegein, 3435 CM, Netherlands|Policlinico Especializado en Neurologia, Callao, 04, Peru|Clinica Anglo Americana, Lima, 18, Peru|Hospital Nacional Dos de Mayo, Lima, Peru|Clinica Centenario Peruano Japonesa; Neurology, Pueblo Libre, Lima 21, Peru|COPERNICUS Podmiot Leczniczy Sp. z o. o. Szpital im. M. Kopernika; Oddzia? Neurologiczny, Gdansk, 80-803, Poland|Specjal. Praktyka Lekarska; Prof. Grzegorz Opala, Katowice, 40-588, Poland|MA-LEK Clinical Sp. Z o.o., Katowice, 40-595, Poland|Neurologiczny NZOZ Centrum Leczenia SM; Osrodek Badan Klinicznych, Plewiska, 62-064, Poland|Hospital de Braga; Servico de Neurologia, Braga, 4710-243, Portugal|Sverdlovsk Regional Clinical Hospital 1, Ekaterinburg, 620102, Russian Federation|Kemerovo Regional Clinical Hospital, Kemerovo, 650066, Russian Federation|Central Clinical Hospital #2 N.A. Semashko OAO RJHD, Moscow, 107150, Russian Federation|FGBU FNKC FMBA of Russia, Moscow, 115682, Russian Federation|FSBIH Siberian Regional Medical Centre of FMBA of Russia, Novosibirsk, 630007, Russian Federation|MRC for Oncology and Neurology Biotherapy, Novosibirsk, 630090, Russian Federation|Samara State Medical University, Samara, 443099, Russian Federation|Reg. SI of Health Care Smolensk Regional Clinical Hospital, Smolensk, 214018, Russian Federation|MMA of Ministry of Defense of Russia named after S.M. Kirov, St. Petersburg, 194044, Russian Federation|St.-Peterburg State institution of health care City multifield hospital #2, St. Petersburg, 194354, Russian Federation|Regional Multiple Sclerosis Centre b/o CC ECM ""Neftyanik"", Tyumen, 625000, Russian Federation|Military Medical Academy, Belgrade, 11040, Serbia|Clinical Center Kragujevac, Kragujevac, 34000, Serbia|Clinical Center Nis, NIS, 18000, Serbia|FNsP Bratislava - Nemocnica Stare mesto, Bratislava, 813 69, Slovakia|FNsP Bratislava, Nemocnica Ruzinov, Bratislava, 826 06, Slovakia|Univerzitna nemocnica Bratislava Nemocnica sv. Cyrila a Metoda; Nemocnicna lekaren, Bratislava, 851 07, Slovakia|Fakultna nemocnica s poliklinikou Zilina, Zilina, 012 07, Slovakia|Dr CC Coetzee Inc, Durban, 4319, South Africa|Complejo Hospitalario Nuestra Señora de la Candelaria; Servicio de Neurologia, Santa Cruz De Tenerife, Tenerife, 38010, Spain|Hospital de Basurto, Bilbao, Vizcaya, 48013, Spain|Hospital Universitario Puerta De Hierro Majadahonda; Servicio de Neurología, Madrid, 28222, Spain|Hospital Universitario Virgen Macarena, Sevilla, 41009, Spain|Universitätsspital Basel Medizin Neurologie; Neurologische Poliklinik, Basel, 4031, Switzerland|Ospedale Regionale Lugano Civico Medizin Neurologie; Neurologia, Lugano, 6900, Switzerland|Hopital Razi, Mannouba, 2010, Tunisia|Hopital Universitaire Fattouma Bourguiba, Monastir, 5000, Tunisia|Hopital Charles Nicolle, Tunis, 1006, Tunisia|MMPIDon.Reg.Cl.&Ter.Med.Com.Neur.Dept.DNMU n.a.M.Gorkiy; Ch. of Nervous Diseases and Med. Genetics, Donetsk, 83099, Ukraine|St.In.Inst. of Neurol.Psych.and Narcol.of the AMSU; Dept. of Neuroinfection and Multiply Sclerosis, Kharkov, 61068, Ukraine|Kyiv City Cl.Hosp.#4 Depart.of Neurology #2NMU; Department of Neurology, Kyiv, 03110, Ukraine|Lviv Regional Clinical Hospital; Department of Neurology, Lviv, 79010, Ukraine|Vin.Reg.Psych.Hosp.N.A Yuschenko O.I., Vnmu N.A. Pyrogov; Department of Nervous Diseases, Vinnytsya, 21005, Ukraine|Walton Centre NHS Foundation Trust, Neuroscience Research Centre; CLINICAL TRIALS UNIT, Liverpool, L9 7LJ, United Kingdom|Royal London Hospital; Neurology, London, E1 1BD, United Kingdom"
NCT03526224,Teriflunomide Tecfidera LMCE,https://beta.clinicaltrials.gov/study/NCT03526224,COMPLETED,Tecfidera|Teriflunomide,DRUG: Dimethyl Fumarate|DRUG: Teriflunomide,University at Buffalo,,ALL,"ADULT, OLDER_ADULT",,120,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-06-14,2019-07-10,2019-07-10,"Buffalo Neuroimaging Analysis Center, Buffalo, New York, 14203, United States"
NCT02474940,MS Symptom Management Study,https://beta.clinicaltrials.gov/study/NCT02474940,COMPLETED,Multiple Sclerosis|Chronic Pain|Fatigue,BEHAVIORAL: Intervention #1|BEHAVIORAL: Intervention #2|BEHAVIORAL: Intervention #3,University of Washington,National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",NA,37,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2015-06,2016-11,2016-11,"University of Washington, Ninth and Jefferson Building, Seattle, Washington, 98104, United States"
NCT03345940,Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03345940,TERMINATED,Relapsing Remitting Multiple Sclerosis,DRUG: Fingolimod|DRUG: Dimethyl Fumarate,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,Patient-Centered Outcomes Research Institute|Universita degli Studi di Genova,ALL,"ADULT, OLDER_ADULT",PHASE4,55,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2017-04-30,2019-10-30,2019-10-30,"Fondazione IRCCS Istituto Neurologico C. Besta, Neuroimmunology Unit, Milan, 20133, Italy"
NCT01156298,Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neurological Surveillance,https://beta.clinicaltrials.gov/study/NCT01156298,TERMINATED,Multiple Sclerosis,,Biogen,,ALL,"ADULT, OLDER_ADULT",,383,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-06,2016-12,2017-03,"Research Site, Buffalo, New York, 14203, United States"
NCT01330498,"Longitudinal Pharmacokinetic, Pharmacodynamic, Immunological, and Biochemical",https://beta.clinicaltrials.gov/study/NCT01330498,COMPLETED,Multiple Sclerosis,,"John F. Foley, MD",Biogen,ALL,"ADULT, OLDER_ADULT",,229,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-04,2011-08,2011-08,"Rocky Mountain Multiple Sclerosis Clinic, Salt Lake City, Utah, 84103, United States"
NCT02519244,Wearable Lower Extremity Exoskeleton to Promote Walking in Persons With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02519244,COMPLETED,Multiple Sclerosis,DEVICE: Ekso® (Wearable lower limb exoskeleton),"The University of Texas Health Science Center, Houston",National Multiple Sclerosis Society|Texas Woman's University,ALL,"ADULT, OLDER_ADULT",NA,11,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2015-05,2017-02-06,2017-02-06,"TIRR Memorial Hermann, Houston, Texas, 77030, United States"
NCT03373344,Remediation of Emotional Processing Deficits in MS,https://beta.clinicaltrials.gov/study/NCT03373344,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Emotional Processing Training|BEHAVIORAL: Placebo control exercises,Kessler Foundation,,ALL,"ADULT, OLDER_ADULT",NA,39,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-11,2020-03,2020-03,"Kessler Foundation, East Hanover, New Jersey, 07936, United States"
NCT04016844,tDCS and Glucose Uptake in Leg Muscles,https://beta.clinicaltrials.gov/study/NCT04016844,COMPLETED,Multiple Sclerosis,DEVICE: transcranial direct current stimulation or SHAM,University of Iowa,,ALL,"ADULT, OLDER_ADULT",NA,4,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2019-12-06,2020-10-01,2020-10-01,"University of Iowa, Iowa City, Iowa, 52242, United States"
NCT02220244,Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02220244,UNKNOWN,Multiple Sclerosis,DRUG: MD1003 100mg capsule,MedDay Pharmaceuticals SA,,ALL,"ADULT, OLDER_ADULT",PHASE3,105,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-10,2015-12,2018-01,"Hopital Pellegrin, Bordeaux, 33000, France|Hopital de la cote de Nacre, Caen, 14000, France|Hopital Gabriel Montpied, Clermont Ferrand, 63000, France|Hopital general du Bocage, Dijon, 21000, France|CHRU de Lille, Lille, 59000, France|Hopital Pierre Wertheimer, Lyon, 69000, France|Hopital de la Timone, Marseille, 13000, France|Hopital Gui de Chauliac, Montpellier, 34000, France|Hopital Central, Nancy, 54000, France|Hopital Nord Laennec, Nantes, 44000, France|Hopital Pasteur, Nice, 06000, France|Centre hospitalier national d'ophtalmologie des Quinze Vingts, Paris, 75012, France|Groupe hospitalier la Pitie-Salpetriere, Paris, 75013, France|Fondation Rothschild, Paris, 75019, France|Centre hospitalier Intercommunal Poissy/Saint-Germain-en-Laye, Poissy, 78300, France|Hopital Maison Blanche, Reims, 51000, France|Hopital Pontchaillou, Rennes, 35000, France|Hopital de Hautepierre, Strasbourg, 67000, France|Hopital Purpan, Toulouse, 31000, France|UCL Institute of Neurology, London, WC1N 3BG, United Kingdom"
NCT01034644,Pharmacogenetic Trial and Long-term Follow-up of the PRISMS Trial (PRISMS-15),https://beta.clinicaltrials.gov/study/NCT01034644,COMPLETED,Multiple Sclerosis,,"Merck KGaA, Darmstadt, Germany",,ALL,"ADULT, OLDER_ADULT",,290,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-03,2010-11,2011-01,"Please call/email Central Contact for Recruiting Information in, Geneva, Switzerland"
NCT02907281,Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02907281,COMPLETED,Multiple Sclerosis|RRMS,OTHER: Observational,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",,414,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-05-29,2017-07-24,2017-07-24,"Novartis Investigative Site, San Francisco, California, 94143-0359, United States|Novartis Investigative Site, Torrance, California, 90509-2004, United States|Novartis Investigative Site, Iowa City, Iowa, 52242, United States|Novartis Investigative Site, Baltimore, Maryland, 21287, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, 19104-4283, United States|Novartis Investigative Site, Camperdown, New South Wales, 2050, Australia|Novartis Investigative Site, Parkville,, Victoria, 3065, Australia|Novartis Investigative Site, Calgary, Alberta, T2N 4Z1, Canada|Novartis Investigative Site, Greenfield Park, Quebec, J4V 2J2, Canada|Novartis Investigative Site, Praha 2, 128 08, Czechia|Novartis Investigative Site, Copenhagen, DK-2100, Denmark|Novartis Investigative Site, Berlin, 10117, Germany|Novartis Investigative Site, Magdeburg, 39120, Germany|Novartis Investigative Site, Cagliari, CA, 09126, Italy|Novartis Investigative Site, Milano, MI, 20132, Italy|Novartis Investigative Site, Bari, 70124, Italy|Novartis Investigative Site, Genova, 16132, Italy|Novartis Investigative Site, Montichiari, 25018, Italy|Novartis Investigative Site, Padova, 35128, Italy|Novartis Investigative Site, Roma, 189, Italy|Novartis Investigative Site, Amsterdam, 1081, Netherlands|Novartis Investigative Site, Lodz, Lódzkie, 90-153, Poland|Novartis Investigative Site, Barcelona, Catalunya, 08035, Spain|Novartis Investigative Site, Barcelona, Cataluña, 8036, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, 46026, Spain|Novartis Investigative Site, Madrid, 28040, Spain|Novartis Investigative Site, Zürich, 8091, Switzerland|Novartis Investigative Site, London, EC1V 2PD, United Kingdom"
NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01416181,TERMINATED,Secondary Progressive Multiple Sclerosis,DRUG: natalizumab|DRUG: Placebo,Biogen,,ALL,ADULT,PHASE3,889,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2011-09-13,2015-07-28,2016-04-13,"Research Site, Phoenix, Arizona, 85013, United States|Research Site, Tucson, Arizona, 85741, United States|Research Site, Fullerton, California, 92835, United States|Research Site, Los Angeles, California, 90027, United States|Research Site, Aurora, Colorado, 80045, United States|Research Site, Tampa, Florida, 33612, United States|Research Site, Chicago, Illinois, 60637, United States|Research Site, Lake Barrington, Illinois, 60010, United States|Research Site, Peoria, Illinois, 61606, United States|Research Site, Indianapolis, Indiana, 46202, United States|Research Site, Indianapolis, Indiana, 46256, United States|Research Site, Kansas City, Kansas, 66160, United States|Research Site, Lexington, Kentucky, 40513, United States|Research Site, Lexington, Kentucky, 40536, United States|Research Site, Baltimore, Maryland, 21287, United States|Research Site, Burlington, Massachusetts, 01805, United States|Research Site, Omaha, Nebraska, 68198, United States|Research Site, Lebanon, New Hampshire, 03756, United States|Research Site, Teaneck, New Jersey, 07666, United States|Research Site, Latham, New York, 12110, United States|Research Site, New York, New York, 10029, United States|Research Site, Advance, North Carolina, 27006, United States|Research Site, Charlotte, North Carolina, 28207, United States|Research Site, Raleigh, North Carolina, 27607, United States|Research Site, Akron, Ohio, 44320, United States|Research Site, Uniontown, Ohio, 44685, United States|Research Site, Oklahoma City, Oklahoma, 73104, United States|Research Site, Clackamas, Oregon, 97015, United States|Research Site, Portland, Oregon, 97225, United States|Research Site, Portland, Oregon, 97239, United States|Research Site, Nashville, Tennessee, 37215, United States|Research Site, Charlottesville, Virginia, 22903, United States|Research Site, Seattle, Washington, 98101, United States|Research Site, Green Bay, Wisconsin, 54311, United States|Research Site, Milwaukee, Wisconsin, 53215, United States|Research Site, La Louviere, 7100, Belgium|Research Site, Melsbroek, 1820, Belgium|Research Site, Overpelt, 3900, Belgium|Research Site, Calgary, Alberta, T2N 2T9, Canada|Research Site, Edmonton, Alberta, T6G 2G3, Canada|Research Site, Vancouver, British Columbia, V6T 1Z3, Canada|Research Site, Halifax, Nova Scotia, B3H 4K4, Canada|Research Site, Kingston, Ontario, K7L 2V7, Canada|Research Site, London, Ontario, N6A 5A5, Canada|Research Site, Ottawa, Ontario, K1H 8L6, Canada|Research Site, Toronto, Ontario, M4N 3M5, Canada|Research Site, Gatineau, Quebec, J9J 0A5, Canada|Research Site, Greenfield Park, Quebec, J4V 2J2, Canada|Research Site, Montreal, Quebec, H2L 4M1, Canada|Research Site, Montreal, Quebec, H3A 2B4, Canada|Research Site, Hradec Kralove, Bohemia, 50005, Czechia|Research Site, Brno, 65691, Czechia|Research Site, Olomouc, 77520, Czechia|Research Site, Praha, 12111, Czechia|Research Site, Arthus C, 8000, Denmark|Research Site, Esbjerg, 6700, Denmark|Research Site, Glostrup, 2600, Denmark|Research Site, København Ø, 2100, Denmark|Research Site, Odense, 5000, Denmark|Research Site, Jyväskylä, 40620, Finland|Research Site, Tampere, 33520, Finland|Research Site, Turku, 20520, Finland|Research Site, Nice, Alpes Maritimes, 06002, France|Research Site, Marseille cedex 5, Bouches-du-Rhône, 13385, France|Research Site, Nantes, Loire Atlantique, 44093, France|Research Site, Nancy, Meurthe et Moselle, 54035, France|Research Site, Lille Cedex, Nord, 59000, France|Research Site, Bron cedex, Rhone, 69677, France|Research Site, Salouel, Somme, 80054, France|Research Site, Bordeaux, 33076, France|Research Site, Bad Wilbad, Baden Wuerttemberg, 75323, Germany|Research Site, Tuebingen, Baden Wuerttemberg, 72076, Germany|Research Site, Bad Mergentheim, Baden-Wuerttemberg, 97980, Germany|Research Site, Muenchen, Bayern, 81377, Germany|Research Site, Muenchen, Bayern, 81675, Germany|Research Site, Hennigsdorf, Brandenburg, 16761, Germany|Research Site, Teupitz, Brandenburg, 15755, Germany|Research Site, Kassel, Hessen, 34121, Germany|Research Site, Duesseldorf, Nordrhein Westfalen, 40225, Germany|Research Site, Muenster, Nordrhein Westfalen, 48149, Germany|Research Site, Dresden, Sachsen, 01307, Germany|Research Site, Dublin, D4, Ireland|Research Site, Dublin, D9, Ireland|Research Site, Jerusalem, 91120, Israel|Research Site, Ramat Gan, 52621, Israel|Research Site, Baggiovara, Modena, 41100, Italy|Research Site, Cefalu, Palermo, 90015, Italy|Research Site, Gallarate, Varese, 21013, Italy|Research Site, Bari, 70124, Italy|Research Site, Florence, 50134, Italy|Research Site, Genova, 16132, Italy|Research Site, Milano, 20122, Italy|Research Site, Milano, 20132, Italy|Research Site, Naples, 80138, Italy|Research Site, Napoli, 80131, Italy|Research Site, Palermo, 90146, Italy|Research Site, Pavia, 27100, Italy|Research Site, Rome, 00176, Italy|Research Site, Rome, 00189, Italy|Research Site, Amsterdam, 1081 HV, Netherlands|Research Site, Breda, 4800 RK, Netherlands|Research Site, Hertogenbosch, 5223 GZ, Netherlands|Research Site, Hoorn, 1624 NP, Netherlands|Research Site, Nieuwegein, 3430 EM, Netherlands|Research Site, Sittard-Geleen, 6130 MB, Netherlands|Research Site, Bialystok, 15-276, Poland|Research Site, Gdansk, 80-803, Poland|Research Site, Katowice, 40-595, Poland|Research Site, Katowice, 40-635, Poland|Research Site, Katowice, 40-749, Poland|Research Site, Krakow, 31-505, Poland|Research Site, Lodz, 90-324, Poland|Research Site, Lublin, 20-954, Poland|Research Site, Olsztyn, 10-561, Poland|Research Site, Plewiska, 62-064, Poland|Research Site, Poznan, 61-853, Poland|Research Site, Szczecin, 70-111, Poland|Research Site, Warszawa-Miedzylesie, 04-749, Poland|Research Site, Warszawa, 01-697, Poland|Research Site, Warszawa, 02-097, Poland|Research Site, Warszawa, 04-141, Poland|Research Site, Wroclaw, 50-556, Poland|Research Site, Belgorod, 308007, Russian Federation|Research Site, Kazan, 420021, Russian Federation|Research Site, Kazan, 420097, Russian Federation|Research Site, Moscow, 127015, Russian Federation|Research Site, St. Petersburg, 197110, Russian Federation|Research Site, Tyumen, 625000, Russian Federation|Research Site, Barcelona, 08035, Spain|Research Site, Barcelona, 08036, Spain|Research Site, Barcelona, 08041, Spain|Research Site, El Palmar, 30120, Spain|Research Site, Madrid, 28034, Spain|Research Site, Madrid, 28040, Spain|Research Site, Majadahonda, 28222, Spain|Research Site, Málaga, 29010, Spain|Research Site, Santa Cruz de Tenerife, 38010, Spain|Research Site, Sevilla, 41009, Spain|Research Site, Göteborg, 41345, Sweden|Research Site, Stockholm, 14186, Sweden|Research Site, Stockholm, 17176, Sweden|Research Site, Stockholm, 18288, Sweden|Research Site, Umeå, 90185, Sweden|Research Site, Örebro, 70185, Sweden|Research Site, Irvine, Ayrshire, KA12 8SS, United Kingdom|Research Site, Edgbaston, Birmingham, B15 2TH, United Kingdom|Research Site, Exeter, Devon, EX2 5DW, United Kingdom|Research Site, Plymouth, Devon, PL6 8BX, United Kingdom|Research Site, London, Greater London, E1 2AT, United Kingdom|Research Site, London, Greater London, SE5 9RS, United Kingdom|Research Site, Hammersmith, London, W6 8RF, United Kingdom|Research Site, Edinburgh, Lothian Region, EH4 2XU, United Kingdom|Research Site, Salford, Manchester, M6 8HD, United Kingdom|Research Site, Liverpool, Merseyside, L9 7LJ, United Kingdom|Research Site, Norwich, Norfolk, NR4 7UY, United Kingdom|Research Site, Nottingham, Nottinghamshire, NG7 2UH, United Kingdom|Research Site, Morriston, Swansea, SA6 6NL, United Kingdom|Research Site, Newcastle, Tyne, NE1 4LP, United Kingdom|Research Site, Brighton, BN2 5BE, United Kingdom|Research Site, London, WC1N 3BG, United Kingdom|Research Site, Sheffield, S10 2JF, United Kingdom"
NCT01101776,Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.,https://beta.clinicaltrials.gov/study/NCT01101776,COMPLETED,Multiple Sclerosis,DRUG: Interferon beta-1a (Rebif),"Merck KGaA, Darmstadt, Germany",Merck Serono Australia Pty Ltd,ALL,"ADULT, OLDER_ADULT",,49,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-01,2013-04,2013-04,"Merck Serono Research Site, Bruce, Australian Capital Territory, 2617, Australia|Merck Serono Research Site, Burwood, New South Wales, 2134, Australia|Merck Serono Research Site, Chatswood, New South Wales, 2067, Australia|Merck Serono Research Site, Orange, New South Wales, 2800, Australia|Merck Serono Research Site, Rozelle, New South Wales, 2039, Australia|Merck Serono Research Site, Woollongong, New South Wales, 2500, Australia|Merck Serono Research Site, Adelaide, South Australia, 5000, Australia|Merck Serono Research Site, Adelaide, South Australia, 5067, Australia|Merck Serono Research Site, Box Hill, Victoria, 3128, Australia|Merck Serono Research Site, Clayton, Victoria, 3168, Australia|Merck Serono Research Site, Fitzroy, Victoria, 3065, Australia|Merck Serono Research Site, Footscray, Victoria, 3011, Australia|Merck Serono Research Site, Geelong, Victoria, 3220, Australia|Merck Serono Research Site, Heidelberg, Victoria, 3084, Australia|Merck Serono Research Site, Nedlands, Western Australia, 6009, Australia|Merck Serono Research Site, Perth, Western Australia, 6151, Australia"
NCT03659981,Grey Matter Damage at the Earliest Phase of Multiple Sclerosis : a Longitudinal 7T MRI Study,https://beta.clinicaltrials.gov/study/NCT03659981,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,OTHER: MRI 7T,Assistance Publique Hopitaux De Marseille,,ALL,ADULT,NA,30,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2018-11-13,2022-05-19,2024-05-18,"Assistance Publique Des Hopitaux de Marseille, Marseille, Paca, 13354, France"
NCT04408274,Remediation of Emotional Deficits in Multiple Sclerosis and Traumatic Brain Injury,https://beta.clinicaltrials.gov/study/NCT04408274,COMPLETED,Multiple Sclerosis|Traumatic Brain Injury,BEHAVIORAL: Emotional Processing Training|BEHAVIORAL: Placebo Control,Kessler Foundation,,ALL,"ADULT, OLDER_ADULT",NA,29,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-05,2017-08,2017-08,"Kessler Foundation, East Hanover, New Jersey, 07936, United States"
NCT05650281,Silent Progression Activity Monitoring - SPAM Study,https://beta.clinicaltrials.gov/study/NCT05650281,NOT_YET_RECRUITING,Multiple Sclerosis,OTHER: NO INTERVENTION,Centre Hospitalier Universitaire de Nice,,ALL,"CHILD, ADULT, OLDER_ADULT",,100,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-01-01,2023-03-31,2023-03-31,"CHU de Nice, Nice, France"
NCT01023074,Effects of Training on Central Auditory Function in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01023074,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Auditory training|OTHER: MS: Control Activity,VA Office of Research and Development,Oregon Health and Science University,ALL,"ADULT, OLDER_ADULT",NA,52,FED,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2007-10,2011-06,2011-06,"VA Portland Health Care System, Portland, OR, Portland, Oregon, 97239, United States"
NCT05156281,Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS),https://beta.clinicaltrials.gov/study/NCT05156281,RECRUITING,Relapsing Multiple Sclerosis,DRUG: Remibrutinib|DRUG: Teriflunomide,Novartis Pharmaceuticals,,ALL,ADULT,PHASE3,800,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-12-13,2026-04-30,2030-10-30,"Novartis Investigative Site, Hanford, California, 93230, United States|Novartis Investigative Site, Aurora, Colorado, 80045, United States|Novartis Investigative Site, Bradenton, Florida, 34209, United States|Novartis Investigative Site, Hollywood, Florida, 33021, United States|Novartis Investigative Site, Maitland, Florida, 32751, United States|Novartis Investigative Site, Miami, Florida, 33136, United States|Novartis Investigative Site, Naples, Florida, 34102, United States|Novartis Investigative Site, Pembroke Pines, Florida, 33024, United States|Novartis Investigative Site, Pensacola, Florida, 32514, United States|Novartis Investigative Site, Port Orange, Florida, 32127, United States|Novartis Investigative Site, Vero Beach, Florida, 32960, United States|Novartis Investigative Site, Suwanee, Georgia, 30024, United States|Novartis Investigative Site, Merrillville, Indiana, 46410, United States|Novartis Investigative Site, Kansas City, Kansas, 66160, United States|Novartis Investigative Site, New Orleans, Louisiana, 70121, United States|Novartis Investigative Site, Columbus, Ohio, 43235, United States|Novartis Investigative Site, Dayton, Ohio, 45408, United States|Novartis Investigative Site, Greer, South Carolina, 29650, United States|Novartis Investigative Site, El Paso, Texas, 79935, United States|Novartis Investigative Site, Houston, Texas, 77094, United States|Novartis Investigative Site, San Antonio, Texas, 78229, United States|Novartis Investigative Site, Seattle, Washington, 98133, United States|Novartis Investigative Site, Crab Orchard, West Virginia, 25827, United States|Novartis Investigative Site, Bombal, Mendoza, M5500DXO, Argentina|Novartis Investigative Site, Rosario, Santa Fe, S2000BZL, Argentina|Novartis Investigative Site, Buenos Aires, C1012AAR, Argentina|Novartis Investigative Site, Curitiba, PR, 81210-310, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, 90035-001, Brazil|Novartis Investigative Site, Porto Alegre, RS, 90110-000, Brazil|Novartis Investigative Site, Porto Alegre, RS, 90430-001, Brazil|Novartis Investigative Site, Joinville, Santa Catarina, 89202-165, Brazil|Novartis Investigative Site, Plovdiv, 4002, Bulgaria|Novartis Investigative Site, Sofia, 1309, Bulgaria|Novartis Investigative Site, Sofia, 1407, Bulgaria|Novartis Investigative Site, Sofia, 1413, Bulgaria|Novartis Investigative Site, Greenfield Park, Quebec, J4V 2J2, Canada|Novartis Investigative Site, Levis, Quebec, G6W 0M5, Canada|Novartis Investigative Site, Fuzhou, Fujian, 350025, China|Novartis Investigative Site, Wuhan, Hubei, 430060, China|Novartis Investigative Site, Hangzhou, Zhejiang, 310016, China|Novartis Investigative Site, Wenzhou, Zhejiang, 325000, China|Novartis Investigative Site, Shanghai, 200040, China|Novartis Investigative Site, Split, HRV, 21000, Croatia|Novartis Investigative Site, Vukovar, 32000, Croatia|Novartis Investigative Site, Zagreb, 10000, Croatia|Novartis Investigative Site, Nantes, Cedex 1, 44093, France|Novartis Investigative Site, Toulon Cedex 9, Val De Marne, 83800, France|Novartis Investigative Site, CAEN Cedex, 14033, France|Novartis Investigative Site, Clermont-Ferrand Cedex 1, 63003, France|Novartis Investigative Site, Gonesse, 95500, France|Novartis Investigative Site, Grenoble, 38042, France|Novartis Investigative Site, Lille Cedex, 59037, France|Novartis Investigative Site, Lille, 59000, France|Novartis Investigative Site, Nice Cedex, 06202, France|Novartis Investigative Site, Nimes, 30029, France|Novartis Investigative Site, Suresnes, 92150, France|Novartis Investigative Site, Toulouse Cedex 9, 31059, France|Novartis Investigative Site, Ioannina, GR, 455 00, Greece|Novartis Investigative Site, Larissa, GR, 411 10, Greece|Novartis Investigative Site, Amyntaio, 53246, Greece|Novartis Investigative Site, Athens, 115 28, Greece|Novartis Investigative Site, Pune, Maharashtra, 411013, India|Novartis Investigative Site, Amritsar, Punjab, 143006, India|Novartis Investigative Site, Hyderabad, Telangana, 500082, India|Novartis Investigative Site, Kolkata, West Bengal, 700017, India|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Pozzilli, IS, 86077, Italy|Novartis Investigative Site, Pavia, PV, 27100, Italy|Novartis Investigative Site, Fukuoka city, Fukuoka, 812-8582, Japan|Novartis Investigative Site, Nishinomiya, Hyogo, 663 8501, Japan|Novartis Investigative Site, Chiba, 260 8677, Japan|Novartis Investigative Site, Ciudad de Mexico, Distrito Federal, 06700, Mexico|Novartis Investigative Site, Chihuahua, 31203, Mexico|Novartis Investigative Site, Ciudad De Mexico, 14050, Mexico|Novartis Investigative Site, Queretaro, 76070, Mexico|Novartis Investigative Site, Katowice, 40 571, Poland|Novartis Investigative Site, Zabrze, 41-800, Poland|Novartis Investigative Site, Matosinhos, Porto, 4454509, Portugal|Novartis Investigative Site, Braga, 4710243, Portugal|Novartis Investigative Site, Lisboa, 1600190, Portugal|Novartis Investigative Site, Guaynabo, 00968, Puerto Rico|Novartis Investigative Site, Banska Bystrica, 974 04, Slovakia|Novartis Investigative Site, Banska Bystrica, 975 17, Slovakia|Novartis Investigative Site, Bratislava, 83305, Slovakia|Novartis Investigative Site, Celje, 3000, Slovenia|Novartis Investigative Site, Ljubljana, 1000, Slovenia|Novartis Investigative Site, Maribor, 2000, Slovenia|Novartis Investigative Site, Sevilla, Andalucia, 41009, Spain|Novartis Investigative Site, Gijon, Asturias, 33394, Spain|Novartis Investigative Site, Hospitalet de Llobregat, Barcelona, 08907, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08003, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, 46017, Spain|Novartis Investigative Site, Santiago de Compostela, Galicia, 15706, Spain|Novartis Investigative Site, Torrejon de Ardoz, Madrid, 28850, Spain|Novartis Investigative Site, Vitoria-Gasteiz, País Vasco, 01009, Spain|Novartis Investigative Site, Madrid, 28009, Spain|Novartis Investigative Site, Madrid, 28040, Spain|Novartis Investigative Site, Valencia, 46026, Spain|Novartis Investigative Site, Stockholm, 102 35, Sweden|Novartis Investigative Site, Stockholm, 141 86, Sweden|Novartis Investigative Site, Sancaktepe, Istanbul, 34785, Turkey|Novartis Investigative Site, Istanbul, 34093, Turkey|Novartis Investigative Site, Izmir, 35620, Turkey|Novartis Investigative Site, Kocaeli, 41380, Turkey|Novartis Investigative Site, Samsun, 55139, Turkey"
NCT05496881,Exercise and Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05496881,RECRUITING,Progressive Multiple Sclerosis,OTHER: Exercise Group 1|OTHER: Exercise Group 2|OTHER: Exercise Group 3,University of Regina,First Steps Wellness Centre|Saskatchewan Health Research Foundation|University of Saskatchewan,ALL,"ADULT, OLDER_ADULT",NA,69,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2022-06-15,2024-03-31,2024-10-31,"University of Regina, Regina, Saskatchewan, S4S5N6, Canada"
NCT01829776,Pilot Study of Free From Falls Program in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01829776,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Educational intervention,Oregon Health and Science University,,ALL,"ADULT, OLDER_ADULT",NA,13,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2013-04,2014-09,2014-09,"Oregon Health and Science University and Portland VA Medical Center, Portland, Oregon, 97239, United States"
NCT04707976,Comparing Transanal Irrigation With Navina Smart vs. Standard Bowel Care in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04707976,RECRUITING,Neurogenic Bowel (Disorder)|Fecal Constipation|Fecal Incontinence|Multiple Sclerosis,DEVICE: Navina Smart|OTHER: Standard Bowel Care,Wellspect HealthCare,,ALL,"ADULT, OLDER_ADULT",NA,92,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-12-01,2023-07,2023-07,"Aarhus University Hospital, Aarhus, Denmark|Hospital Tenon Service de Neuro-urologie et d'Explorations Périnéales, Paris, 75020, France|La Fé University Hospital, Valencia, 46026, Spain|Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, 1011, Switzerland|University College London Hospital, London, United Kingdom"
NCT05297474,Structural and Functional Impairment of Multiple Organs in Patients With Systemic Sclerosis: A MR Imaging Study,https://beta.clinicaltrials.gov/study/NCT05297474,RECRUITING,Systemic Sclerosis|Multisystem Disorder,OTHER: MRI,Tsinghua University,Peking Union Medical College Hospital,ALL,"ADULT, OLDER_ADULT",,95,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-07-01,2022-07-01,2022-12-01,"Huilin He, Beijing, 100032, China|China Center for Biomedical Imaging Research, Department of Biomedical Engineering, Tsinghua University, Beijing, 100084, China"
NCT05377476,Investigation of the Effects of Motor Imagery and Action Observation Training in Individuals With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05377476,RECRUITING,Multiple Sclerosis,OTHER: Motor Imagery training|OTHER: Action Observation training|OTHER: standard rehabilitation,Hacettepe University,Bandırma Onyedi Eylül University,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-06-01,2024-05-01,2024-06-01,"Hacettepe University, Ankara, Turkey"
NCT00529581,A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00529581,COMPLETED,Cognition Disorders|Multiple Sclerosis,DRUG: C105,"Cognition Pharmaceuticals, LLC",,ALL,"ADULT, OLDER_ADULT",PHASE2,150,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2006-11,2008-03,2008-04,"Saint Joseph's Hospital, Barrow Neurology Clinics, Phoenix, Arizona, 85013, United States|Northwest Neuro Specialists, PLLC, Tuscon, Arizona, 85741, United States|Research Center for Clinical Studies West, Lancaster, California, 93534, United States|Loma Linda University, Department of Neurology, Loma Linda, California, 92354, United States|Associated Neurologists, P.C., Danbury, Connecticut, 06810, United States|Associated Neurologist of Southern Connecticut, PC, Fairfield, Connecticut, 06824, United States|Yale University MS Center, New Haven, Connecticut, 06510, United States|Neurology Associates, PA, Maitland, Florida, 32751, United States|Lovelace Scientific Resources, Sarasota, Florida, 34233, United States|Roskamp Institute, Sarasota, Florida, 34243, United States|Suncoast Neuroscience Associates, Inc., St. Petersburg, Florida, 33701, United States|Axiom Clinical Research of Florida, Tampa, Florida, 33609, United States|Shepard Center, Atlanta, Georgia, 30309, United States|University of Kansas Medical Center, Department of Neurology, Kansas City, Kansas, 66160, United States|MidAmerica Neuroscience Institute, Lenexa, Kansas, 66214, United States|University of Kentucky, Lexington, Kentucky, 40536, United States|Henry Ford Health System, Department of Neurology, Detroit, Michigan, 48202, United States|Northern Michigan Neurology, Traverse City, Michigan, 49684, United States|The Jacobs Neurological Institute, Buffalo, New York, 14203, United States|Raleigh Neurology Associates, Raleigh, North Carolina, 17607, United States|MeritCare Neuroscience Clinic, Fargo, North Dakota, 58103, United States|Neurology & Neuroscience Associates, Inc., Akron, Ohio, 44302, United States|Riverhills Healthcare, Inc, Cincinnati, Ohio, 45242, United States|The Neurology Foundation, Inc., Providence, Rhode Island, 02905, United States|Baylor College of Medicine, Houston, Texas, 77030, United States|Central Texas Neurology, Round Rock, Texas, 78681, United States|Integra Clinical Research, San Antonio, Texas, 78229, United States|University of Virginia, Department of Neurology, Charlottesville, Virginia, 22908, United States|Neurological Associates, Inc, Richmond, Virginia, 23230, United States|Capitol Neurology, Charleston, West Virginia, 25301, United States"
NCT05357781,Immunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)?,https://beta.clinicaltrials.gov/study/NCT05357781,RECRUITING,Hypogammaglobulinemia|Multiple Sclerosis|Fatigue,DIAGNOSTIC_TEST: Laboratory test,"University Hospital Inselspital, Berne",,ALL,"ADULT, OLDER_ADULT",,106,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-07-01,2023-11-30,2024-01-01,"University Hospital of Bern Inselspital, Bern, BE, 3010, Switzerland"
NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00751881,COMPLETED,Multiple Sclerosis,DRUG: Placebo|DRUG: Teriflunomide,Sanofi,,ALL,ADULT,PHASE3,1169,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2008-08,2012-04,2015-08,"Sanofi-Aventis Investigational Site Number 840041, Phoenix, Arizona, 85060, United States|Sanofi-Aventis Investigational Site Number 840084, Tucson, Arizona, 85741-3537, United States|Sanofi-Aventis Investigational Site Number 840008, Loma Linda, California, 92354, United States|Sanofi-Aventis Investigational Site Number 840034, Modesto, California, 95355, United States|Sanofi-Aventis Investigational Site Number 840090, Fort Collins, Colorado, 80528, United States|Sanofi-Aventis Investigational Site Number 840011, Fairfield, Connecticut, 06430, United States|Sanofi-Aventis Investigational Site Number 840013, Maitland, Florida, 32761, United States|Sanofi-Aventis Investigational Site Number 840083, Ocala, Florida, 34474, United States|Sanofi-Aventis Investigational Site Number 840086, Ormond Beach, Florida, 32174, United States|Sanofi-Aventis Investigational Site Number 840025, Sarasota, Florida, 34239, United States|Sanofi-Aventis Investigational Site Number 840015, St. Petersburg, Florida, 33606, United States|Sanofi-Aventis Investigational Site Number 840033, Sunrise, Florida, 33351, United States|Sanofi-Aventis Investigational Site Number 840063, Elk Grove Village, Illinois, 60007, United States|Sanofi-Aventis Investigational Site Number 840064, Flossmoor, Illinois, 60402, United States|Sanofi-Aventis Investigational Site Number 840039, Ft Wayne, Indiana, 46804, United States|Sanofi-Aventis Investigational Site Number 840012, Indianapolis, Indiana, 46256, United States|Sanofi-Aventis Investigational Site Number 840016, Des Moines, Iowa, 50314, United States|Sanofi-Aventis Investigational Site Number 840069, Clinton Township, Michigan, 48035, United States|Sanofi-Aventis Investigational Site Number 840075, Grand Rapids, Michigan, 49503, United States|Sanofi-Aventis Investigational Site Number 840061, Traverse City, Michigan, 49684, United States|Sanofi-Aventis Investigational Site Number 840076, Minneapolis, Minnesota, 55455, United States|Sanofi-Aventis Investigational Site Number 840079, Tupelo, Mississippi, 38801, United States|Sanofi-Aventis Investigational Site Number 840088, St. Louis, Missouri, 63131, United States|Sanofi-Aventis Investigational Site Number 840060, Syracuse, New York, 13210, United States|Sanofi-Aventis Investigational Site Number 840029, Charlotte, North Carolina, 28204, United States|Sanofi-Aventis Investigational Site Number 840074, Bismarck, North Dakota, 58501, United States|Sanofi-Aventis Investigational Site Number 840026, Cincinnati, Ohio, 45219, United States|Sanofi-Aventis Investigational Site Number 840078, Dayton, Ohio, 45409, United States|Sanofi-Aventis Investigational Site Number 840066, Tulsa, Oklahoma, 74137, United States|Sanofi-Aventis Investigational Site Number 840024, Portland, Oregon, 97225, United States|Sanofi-Aventis Investigational Site Number 840073, Philadelphia, Pennsylvania, 19102, United States|Sanofi-Aventis Investigational Site Number 840022, Philadelphia, Pennsylvania, 19107, United States|Sanofi-Aventis Investigational Site Number 840068, Greenville, South Carolina, 29615, United States|Sanofi-Aventis Investigational Site Number 840071, Cordova, Tennessee, 38018, United States|Sanofi-Aventis Investigational Site Number 840036, Nashville, Tennessee, 37232, United States|Sanofi-Aventis Investigational Site Number 840007, San Antonio, Texas, 78229, United States|Sanofi-Aventis Investigational Site Number 840006, Bennington, Vermont, 05201, United States|Sanofi-Aventis Investigational Site Number 840089, Seattle, Washington, 98122, United States|Sanofi-Aventis Investigational Site Number 840020, Charleston, West Virginia, 25301, United States|Sanofi-Aventis Investigational Site Number 036005, Bedford Park, 5042, Australia|Sanofi-Aventis Investigational Site Number 036006, Chatswood, 2067, Australia|Sanofi-Aventis Investigational Site Number 036003, Fitzroy, 3065, Australia|Sanofi-Aventis Investigational Site Number 036004, Geelong, 3220, Australia|Sanofi-Aventis Investigational Site Number 036008, Heidelberg, 3084, Australia|Sanofi-Aventis Investigational Site Number 036002, New Lambton, 2305, Australia|Sanofi-Aventis Investigational Site Number 036001, Sydney, 2050, Australia|Sanofi-Aventis Investigational Site Number 040001, Wien, 1010, Austria|Sanofi-Aventis Investigational Site Number 112105, Grodno, Belarus|Sanofi-Aventis Investigational Site Number 112102, Minsk, 220226, Belarus|Sanofi-Aventis Investigational Site Number 112101, Minsk, Belarus|Sanofi-Aventis Investigational Site Number 112104, Minsk, Belarus|Sanofi-Aventis Investigational Site Number 112103, Vitebsk, Belarus|Sanofi-Aventis Investigational Site Number 056004, Brugge, 8000, Belgium|Sanofi-Aventis Investigational Site Number 056002, Leuven, 3000, Belgium|Sanofi-Aventis Investigational Site Number 056001, Melsbroek, Belgium|Sanofi-Aventis Investigational Site Number 056003, Sijsele-Damme, Belgium|Sanofi-Aventis Investigational Site Number 124004, Gatineau, J9J 0A5, Canada|Sanofi-Aventis Investigational Site Number 124002, Kingston, K7L 2V7, Canada|Sanofi-Aventis Investigational Site Number 124007, Montreal, H1T 2M4, Canada|Sanofi-Aventis Investigational Site Number 124008, Ottawa, K2G 6E2, Canada|Sanofi-Aventis Investigational Site Number 124001, Quebec, G1J 1Z4, Canada|Sanofi-Aventis Investigational Site Number 124003, Regina, S4T 1A5, Canada|Sanofi-Aventis Investigational Site Number 124006, Saint John, E2L 3L6, Canada|Sanofi-Aventis Investigational Site Number 152006, Santiago, Chile|Sanofi-Aventis Investigational Site Number 152007, Santiago, Chile|Sanofi-Aventis Investigational Site Number 152002, Viña Del Mar, Chile|Sanofi-Aventis Investigational Site Number 156023, Baotou, 014010, China|Sanofi-Aventis Investigational Site Number 156031, Beijing, 100034, China|Sanofi-Aventis Investigational Site Number 156006, Beijing, 100050, China|Sanofi-Aventis Investigational Site Number 156010, Beijing, 100050, China|Sanofi-Aventis Investigational Site Number 156005, Beijing, 100053, China|Sanofi-Aventis Investigational Site Number 156032, Beijing, 100068, China|Sanofi-Aventis Investigational Site Number 156024, Beijing, 100088, China|Sanofi-Aventis Investigational Site Number 156030, Beijing, 100191, China|Sanofi-Aventis Investigational Site Number 156001, Beijing, 100730, China|Sanofi-Aventis Investigational Site Number 156008, Beijing, 100853, China|Sanofi-Aventis Investigational Site Number 156007, Changchun, 130021, China|Sanofi-Aventis Investigational Site Number 156002, Chengdu, 610041, China|Sanofi-Aventis Investigational Site Number 156025, Guangzhou, 510260, China|Sanofi-Aventis Investigational Site Number 156012, Guangzhou, 510630, China|Sanofi-Aventis Investigational Site Number 156027, Haikou, 570102, China|Sanofi-Aventis Investigational Site Number 156021, Hangzhou, 310016, China|Sanofi-Aventis Investigational Site Number 156033, Jinan, 250033, China|Sanofi-Aventis Investigational Site Number 156034, Nanjing, 210008, China|Sanofi-Aventis Investigational Site Number 156011, Nanjing, 210029, China|Sanofi-Aventis Investigational Site Number 156019, Qingdao, 266003, China|Sanofi-Aventis Investigational Site Number 156029, Shanghai, 200003, China|Sanofi-Aventis Investigational Site Number 156016, Shanghai, 200040, China|Sanofi-Aventis Investigational Site Number 156009, Shenyang, 110001, China|Sanofi-Aventis Investigational Site Number 156022, Shijiazhuang, 050051, China|Sanofi-Aventis Investigational Site Number 156018, Suzhou, 215006, China|Sanofi-Aventis Investigational Site Number 156028, Taiyuan, 030001, China|Sanofi-Aventis Investigational Site Number 156003, Tianjin, 300052, China|Sanofi-Aventis Investigational Site Number 156035, Tianjin, 300211, China|Sanofi-Aventis Investigational Site Number 156017, Wenzhou, 325000, China|Sanofi-Aventis Investigational Site Number 156004, Wuhan, 430030, China|Sanofi-Aventis Investigational Site Number 156014, Xi'An, 710032, China|Sanofi-Aventis Investigational Site Number 156015, Xi'An, 710061, China|Sanofi-Aventis Investigational Site Number 203001, Brno, 65691, Czech Republic|Sanofi-Aventis Investigational Site Number 203002, Ostrava - Poruba, 70852, Czech Republic|Sanofi-Aventis Investigational Site Number 203004, Teplice, 415 29, Czech Republic|Sanofi-Aventis Investigational Site Number 233002, Tallinn, 10617, Estonia|Sanofi-Aventis Investigational Site Number 233001, Tartu, 50406, Estonia|Sanofi-Aventis Investigational Site Number 250005, Besancon, 25030, France|Sanofi-Aventis Investigational Site Number 250008, Dijon Cedex, 21033, France|Sanofi-Aventis Investigational Site Number 250001, Lyon Cedex 03, 69394, France|Sanofi-Aventis Investigational Site Number 250007, Nantes Cedex 01, 44093, France|Sanofi-Aventis Investigational Site Number 250006, Nice Cedex, 06002, France|Sanofi-Aventis Investigational Site Number 250002, Nimes, 30029, France|Sanofi-Aventis Investigational Site Number 250003, Poissy, 78300, France|Sanofi-Aventis Investigational Site Number 276010, Bamberg, 96047, Germany|Sanofi-Aventis Investigational Site Number 276003, Bayreuth, 95445, Germany|Sanofi-Aventis Investigational Site Number 276005, Berlin, 10713, Germany|Sanofi-Aventis Investigational Site Number 276001, Erlangen, 91054, Germany|Sanofi-Aventis Investigational Site Number 276006, Gießen, 35385, Germany|Sanofi-Aventis Investigational Site Number 276004, Hannover, 30625, Germany|Sanofi-Aventis Investigational Site Number 276007, Leipzig, 04157, Germany|Sanofi-Aventis Investigational Site Number 276009, Magdeburg, 39120, Germany|Sanofi-Aventis Investigational Site Number 276002, Wiesbaden, 65191, Germany|Sanofi-Aventis Investigational Site Number 300001, Athens, 11527, Greece|Sanofi-Aventis Investigational Site Number 300006, Thessaloniki, 57010, Greece|Sanofi-Aventis Investigational Site Number 484005, Monterrey, 64460, Mexico|Sanofi-Aventis Investigational Site Number 484003, México, 06726, Mexico|Sanofi-Aventis Investigational Site Number 528003, 'S Hertogenbosch, 5211 NL, Netherlands|Sanofi-Aventis Investigational Site Number 528001, Breda, 4818 CK, Netherlands|Sanofi-Aventis Investigational Site Number 528002, Groesbeek, 6561 KE, Netherlands|Sanofi-Aventis Investigational Site Number 528004, Nieuwegein, 3435 CM, Netherlands|Sanofi-Aventis Investigational Site Number 528006, Sittard-Geleen, 6162 BG, Netherlands|Sanofi-Aventis Investigational Site Number 608004, Cebu City, Philippines|Sanofi-Aventis Investigational Site Number 608002, Makati City, 1229, Philippines|Sanofi-Aventis Investigational Site Number 608001, Manila, Philippines|Sanofi-Aventis Investigational Site Number 608003, Quezon City, 1102, Philippines|Sanofi-Aventis Investigational Site Number 616002, Gdansk, 80-803, Poland|Sanofi-Aventis Investigational Site Number 616005, Lodz, 90-549, Poland|Sanofi-Aventis Investigational Site Number 616001, Lublin, 20-718, Poland|Sanofi-Aventis Investigational Site Number 616004, Szczecin, 70-215, Poland|Sanofi-Aventis Investigational Site Number 616003, Warszawa 44, 04-141, Poland|Sanofi-Aventis Investigational Site Number 642006, Bacau, 600114, Romania|Sanofi-Aventis Investigational Site Number 642005, Brasov, 500123, Romania|Sanofi-Aventis Investigational Site Number 642001, Bucuresti, 010584, Romania|Sanofi-Aventis Investigational Site Number 642007, Oradea, 410154, Romania|Sanofi-Aventis Investigational Site Number 703003, Bratislava 2, 82606, Slovakia|Sanofi-Aventis Investigational Site Number 703005, Bratislava 2, 82606, Slovakia|Sanofi-Aventis Investigational Site Number 703001, Martin, 03659, Slovakia|Sanofi-Aventis Investigational Site Number 703006, Presov, 08181, Slovakia|Sanofi-Aventis Investigational Site Number 724001, Barcelona, 08035, Spain|Sanofi-Aventis Investigational Site Number 724007, Getafe, 28905, Spain|Sanofi-Aventis Investigational Site Number 724002, Girona, 17007, Spain|Sanofi-Aventis Investigational Site Number 724004, Madrid, 28040, Spain|Sanofi-Aventis Investigational Site Number 724003, Sevilla, 41071, Spain|Sanofi-Aventis Investigational Site Number 752002, Stockholm, 141 86, Sweden|Sanofi-Aventis Investigational Site Number 752001, Stockholm, 171 76, Sweden|Sanofi-Aventis Investigational Site Number 752003, Stockholm, 182 88, Sweden|Sanofi-Aventis Investigational Site Number 764002, Bangkok-Noi, 10700, Thailand|Sanofi-Aventis Investigational Site Number 764001, Bangkok, 10330, Thailand|Sanofi-Aventis Investigational Site Number 788003, Manouba, 2010, Tunisia|Sanofi-Aventis Investigational Site Number 788004, Sfax, 3029, Tunisia|Sanofi-Aventis Investigational Site Number 788002, Tunis, 1006, Tunisia|Sanofi-Aventis Investigational Site Number 788001, Tunis, 1007, Tunisia|Sanofi-Aventis Investigational Site Number 792011, Edirne, Turkey|Sanofi-Aventis Investigational Site Number 792009, Istanbul, 34147, Turkey|Sanofi-Aventis Investigational Site Number 792001, Istanbul, 34390, Turkey|Sanofi-Aventis Investigational Site Number 792007, Istanbul, Turkey|Sanofi-Aventis Investigational Site Number 792010, Istanbul, Turkey|Sanofi-Aventis Investigational Site Number 792012, Izmir, 35380, Turkey|Sanofi-Aventis Investigational Site Number 792002, Kocaeli, 41380, Turkey|Sanofi-Aventis Investigational Site Number 792003, Manisa, Turkey|Sanofi-Aventis Investigational Site Number 792005, Samsun, Turkey|Sanofi-Aventis Investigational Site Number 792004, Trabzon, 61080, Turkey|Sanofi-Aventis Investigational Site Number 804101, Chernihiv, 14025, Ukraine|Sanofi-Aventis Investigational Site Number 804103, Dnipropetrovsk, 49027, Ukraine|Sanofi-Aventis Investigational Site Number 804107, Donetsk, 83003, Ukraine|Sanofi-Aventis Investigational Site Number 804117, Donetsk, 83099, Ukraine|Sanofi-Aventis Investigational Site Number 804119, Ivano-Frankovsk, 76008, Ukraine|Sanofi-Aventis Investigational Site Number 804102, Kharkiv, 61018, Ukraine|Sanofi-Aventis Investigational Site Number 804109, Kharkov, 61068, Ukraine|Sanofi-Aventis Investigational Site Number 804115, Kiev, 04050, Ukraine|Sanofi-Aventis Investigational Site Number 804116, Kiev, 04112, Ukraine|Sanofi-Aventis Investigational Site Number 804108, Kiev, Ukraine|Sanofi-Aventis Investigational Site Number 804111, Lutsk, 43005, Ukraine|Sanofi-Aventis Investigational Site Number 804124, Lutsk, 43024, Ukraine|Sanofi-Aventis Investigational Site Number 804114, Lviv, 79010, Ukraine|Sanofi-Aventis Investigational Site Number 804121, Lviv, 79010, Ukraine|Sanofi-Aventis Investigational Site Number 804120, Poltava, 36011, Ukraine|Sanofi-Aventis Investigational Site Number 804105, Vinnytsya, 21005, Ukraine|Sanofi-Aventis Investigational Site Number 804118, Zaporizhya, 69035, Ukraine|Sanofi-Aventis Investigational Site Number 804104, Zaporizhzhia, 69600, Ukraine|Sanofi-Aventis Investigational Site Number 804122, Zaporozhye, 69000, Ukraine|Sanofi-Aventis Investigational Site Number 826002, Edinburgh, EH4 2XU, United Kingdom|Sanofi-Aventis Investigational Site Number 826004, Haywards Heath, RH16 4EX, United Kingdom|Sanofi-Aventis Investigational Site Number 826001, Irvine, KA12 8SS, United Kingdom|Sanofi-Aventis Investigational Site Number 826003, Leeds, LS1 3EX, United Kingdom|Sanofi-Aventis Investigational Site Number 826005, Salford, M6 8HD, United Kingdom"
NCT05724901,At-Home Gait Assessment,https://beta.clinicaltrials.gov/study/NCT05724901,RECRUITING,Multiple Sclerosis,,NYU Langone Health,United States Department of Defense,ALL,"ADULT, OLDER_ADULT",,30,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-11-15,2024-04-15,2024-04-15,"NYU Langone Health, New York, New York, 10016, United States"
NCT03032601,Physiological Effects of N-Acetyl Cysteine in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03032601,ENROLLING_BY_INVITATION,Multiple Sclerosis,DIETARY_SUPPLEMENT: N-acetyl Cysteine,Thomas Jefferson University,,ALL,"ADULT, OLDER_ADULT",NA,55,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2017-01-05,2025-01-05,2025-01-05,"Thomas Jefferson University, Philadelphia, Pennsylvania, 19107, United States"
NCT01236534,Lubiprostone in Patients With Multiple Sclerosis Associated Constipation,https://beta.clinicaltrials.gov/study/NCT01236534,COMPLETED,Multiple Sclerosis|Constipation,DRUG: Lubiprostone|DRUG: Placebo,University of Rochester,Takeda,ALL,"ADULT, OLDER_ADULT",PHASE4,21,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2010-11,2012-01,2012-04,"University of Rochester, Rochester, New York, 14642, United States"
NCT05808101,Gut Microbiome and Depression,https://beta.clinicaltrials.gov/study/NCT05808101,RECRUITING,Multiple Sclerosis|Depression,OTHER: Neuro-QoL T-score determination,Washington University School of Medicine,University of Connecticut|University of Texas,ALL,"ADULT, OLDER_ADULT",,120,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-01-27,2023-10,2024-10,"Washington University in St Louis, Saint Louis, Missouri, 63110, United States"
NCT01601080,"An Observational, Retrospective, UK & Ireland Audit of Patient Adherence to Rebif® Injections Using the RebiSmart™ Injection Device",https://beta.clinicaltrials.gov/study/NCT01601080,COMPLETED,Relapsing Multiple Sclerosis,,"Merck KGaA, Darmstadt, Germany","Merck Serono Limited, UK",ALL,"CHILD, ADULT, OLDER_ADULT",,230,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-04,2012-10,,"Please contact the, Merck KGaA Communication Center for recruiting locations, United Kingdom"
NCT04674280,Observational Study in Multiple Sclerosis Patients Treated With Autologous Hematopoietic Stem Cell Transplantation,https://beta.clinicaltrials.gov/study/NCT04674280,NOT_YET_RECRUITING,Multiple Sclerosis,PROCEDURE: aHSCT,European Society for Blood and Marrow Transplantation,,ALL,"ADULT, OLDER_ADULT",,50,NETWORK,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-01,2025-01,2025-01,
NCT03045380,Effect of Video Game Based Physical Activity Training in Persons With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03045380,COMPLETED,Multiple Sclerosis,OTHER: Game based physical activity training|OTHER: Conventional physiotherapy,Dokuz Eylul University,,ALL,ADULT,NA,60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2016-11,2017-06,2017-06,"School of Physical Therapy and Rehabilitation, Dokuz Eylül University, Izmir, Turkey"
NCT04695080,ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04695080,RECRUITING,Advanced Multiple Sclerosis|Progressive Multiple Sclerosis,DRUG: Cladribine (MAVENCLAD®)|DRUG: Placebo,Queen Mary University of London,"National Institute for Health Research, United Kingdom|Merck Serono Limited, UK|Multiple Sclerosis Society of Great Britain & Northern Ireland|National Multiple Sclerosis Society|Barts & The London NHS Trust",ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,200,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-06-25,2024-12-31,2026-12-31,"Queens University Belfast (Belfast Health and Social Care Trust), Belfast, BT12 6BA, United Kingdom|University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, Birmingham, B15 2TH, United Kingdom|Cardiff University Hospital, Cardiff, CF14 4XW, United Kingdom|University Hospitals of Coventry and Warwickshire NHS Trust, Coventry, CV2 2DX, United Kingdom|Anne Rowling Clinic, University of Edinburgh, Edinburgh, EH16 4SB, United Kingdom|Queen Elizabeth University Hospital Glasgow, Glasgow, G51 4TF, United Kingdom|University Hospital Hairmyres, NHS Lanarkshire, Glasgow, G75 8RG, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, LS1 3EX, United Kingdom|Walton Centre NHS Trust, Liverpool, L9 7LJ, United Kingdom|Royal London Hospital, London, E1 1FR, United Kingdom|Royal Free London NHS Foundation Trust, London, NW3 2QG, United Kingdom|Queen's Hospital (Havering and Redbridge University Hospitals NHS Trust), London, RM7 0AG, United Kingdom|Lewisham and Greenwich NHS Trust, London, SE13 6LH, United Kingdom|St George's University Hospitals NHS Foundation Trust, London, SW17 0RE, United Kingdom|Luton and Dunstable Hospital, Luton, LU4 0DZ, United Kingdom|Salford Royal Hospital NHS Trust, Manchester, M6 8HD, United Kingdom|Aneurin Bevan University Health Board, Newport, NP20 2UB, United Kingdom|Nottingham University Hospital (Nottingham University Hospitals NHS Trust), Nottingham, NG7 2UH, United Kingdom|University Hospitals Plymouth NHS Trust, Plymouth, PL6 8DH, United Kingdom|Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, S10 2JF, United Kingdom|University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, ST4 6QG, United Kingdom|Morriston Hospital, Swansea, Swansea, SA6 6NL, United Kingdom"
NCT03850301,Validation of the 18 kiloDalton Translocator Protein (TSPO) as a Novel Neuroimmunodulatory Target,https://beta.clinicaltrials.gov/study/NCT03850301,RECRUITING,Multiple Sclerosis,DRUG: XBD173|DRUG: Etifoxine,Imperial College London,,ALL,"ADULT, OLDER_ADULT",NA,44,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: OTHER,2018-04-01,2022-12-31,2022-12-31,"Imperial College Healthcare NHS Trust, London, England, W12 0NN, United Kingdom"
NCT01357980,Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01357980,COMPLETED,Detrusor Muscle Hyperactivity,BIOLOGICAL: Botulinum toxin type A|DRUG: Placebo,Ipsen,,ALL,"ADULT, OLDER_ADULT",PHASE2,47,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-05,2013-03,2013-03,"Faculty Hospital Motol, Praha, Czechia|THOMAYER Faculty Hospital, Praha, Czechia|Hopital Raymond Poincaré, Garches, France|Hopital HURIET, Lille, France|Hôpital Lyon Sud -Hospices Civils de Lyon, Lyon, France|Hopital de la conception, Marseille, France|CHU Hotel Dieu, Nantes, France|Groupe Hospitalier La Pitié Salpetriere, Paris, France|Hopital Tenon, Paris, France|CMRRF Kerpape, Ploemeur, France|CHU Rouen - Hopital Charles Nicolle, Rouen, France|Nouvel Hopital civil de Strasbourg, Strasbourg, France|CHU Toulouse - Hopital Rangueil, Toulouse, France|Universitätsklinik Kiel, Kiel, Germany|Städtisches Klinikum Neunkirchen, Neunkirchen, Germany|Ospedale Careggi, Firenze, Italy|NZOZ Centrum Medyczne Mazovia, Warszawa, Poland"
NCT00289978,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00289978,COMPLETED,Relapsing-remitting Multiple Sclerosis,DRUG: Fingolimod 1.25 mg|DRUG: Fingolimod 0.5 mg|DRUG: Placebo,Novartis,,ALL,ADULT,PHASE3,1272,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2006-01,2009-07,2009-07,"The Queen Elizabeth Hospital, Woodville South, South Australia, 5011, Australia|North Gosford Private Hospital, Burrabil Avenue, Suite 17, Gosford, NSW 2250, Australia|Strategic Health Evaluators, Chatswood, 2067, Australia|St Vincent's Hospital Melbourne, Department of Clinical Neurosciences, Fitzroy, 3065 VIC, Australia|Austin Health, Department of Neurology, Heidelberg, 3084, Australia|Algemeen Ziekenhuis St. Jan, Department of Neurology, Ruddershove 10, Brugge, 8000, Belgium|Erasme Hospital, Route de Lennik 808, Brussels, 1070, Belgium|CHU Charleroi, Hôpital Civil, Boulevard Paul Janson 92, Charleroi, 6000, Belgium|University Hospital Gasthuisberg, Department Neurology, Herestraat 49, Leuven, 3000, Belgium|AZ Alma, Department of Neurology & Rehab-Umit, Gentsesteenweg 132, Sijsele, 8340, Belgium|Regionaal Ziekenhuis, St.Trudo, Diestersteenweg 100,, St.Truiden, 3800, Belgium|MS Klinik, Boemerangstraat 2, Overpelt, 3900, Belgium|National Multiple Sclerose Centrum v.z.w, Vanheylenstraat 16, Melsbroek, 1820, Belgium|University of British Columbia, ME498 2211 Wesbrook Mall, Vancouver, British Columbia, V6T 2B5, Canada|DMSRU - Capital Health, Halifax, Nova Scotia, Canada|Kingston General Hospital, MS Clinic, Connell 7, 76 Stuart Street, Kingston, Ontario, K7L 2V7, Canada|Nepean Medical Center, Ottawa, Ontario, K2G 6E2, Canada|St. Michael's Hospital, Toronto, Ontario, M5B 1W8, Canada|Clinical Trials Office,, Trillium Health Center, 00 Queesway West, Mississauga, Ontario, L5B 1B8, Canada|Hopital Maisonneuve-Rosemont, Recherche Clinique de Neurologie, Montreal, Quebec, H1T 2M4, Canada|University of Saskatchewan, Regina, Saskatchewan, S4T 1A5, Canada|Military Hospital of Brno, Department of Neurology, Zabrdovicka 3, Brno, 63600, Czech Republic|Faculty Hospital St. Anne, First Department of Neurology, Pekarska 53, Brno, 65691, Czech Republic|Faculty Hospital, Department of Neurology, I.P. Paulova 6, Olomouc, 77520, Czech Republic|Hospital of Pardubice, Department of Neurology, Kyjevska 44, Pardubice, 53203, Czech Republic|Faculty Hospital, Department of Neurology, Alej Svobody 80, Plzeň, 3046, Czech Republic|Faculty Hospital Motol, MS Center, Department of Neurology, V Uvalu 84, Prague 5, 15006, Czech Republic|Vseobecna fakultni nemocnice, MS Centrum, Neurologicka klinika, Karlovo namesti 32, Praha 2, 12808, Czech Republic|Neurologicka klinika, Fakultni nemocnice, Kralovske Vinohrady, Srobarova 50, Praha, 10034, Czech Republic|MS Centrum, Neurology Department of Hospital Teplice, Duchcovska 53, Teplice, 41529, Czech Republic|Centrum neurologicke pece, Jiraskova 1389, Rychnov nad Kneznou, 51601, Czech Republic|Facultní Nemocnice Spoliklinikou Ostrava, Neurology Department, Ostrava, 70852, Czech Republic|Helsinki Headache Center Postitalon Lääkäriasema, Mannnerheiminaukio 1 B 2 Floor, Helsinki, 0100, Finland|Finnish Special Neurology Center Ltd., Brahenkatu 11 D,, Turku, 20100, Finland|Suomen Terveystalo/ Päänsärkykeskus, Tampere, Hämeenkatu 18, 6th fl., Tampere, 33200, Finland|Turku University Hospital, Neurology Department 799, Kiinanmyllynkatu 11- 14, Turku, 20520, Finland|Hyvinkään sairaala, Neurologian poliklinikka, Sairaalankatu 1, Hyvinkää, 05850, Finland|CHU La Timone, Service Neurologie, Boulevard Jean Moulin, Marsielle Cedex 5, 13385, France|Investigational Site, Berlin, 10117, Germany|Investigational Site, Berlin, 13347, Germany|Investigational Site, Dusseldorf, 40225, Germany|Investigational Site, Giessen, 35385, Germany|Investigational Site, Hamburg, 20099, Germany|Investigational Site, Hamburg, 20246, Germany|Investigational Site, Leipzig, 04103, Germany|Investigational Site, Magdeburg, 39120, Germany|Investigational Site, Munchen, 80331, Germany|Investigational Site, Munchen, 81377, Germany|Investigational Site, Munster, 48149, Germany|Investigational Site, Regensburg, 93053, Germany|Investigational Site, Seesen/Harz, 38723, Germany|Investigational Site, Stuttgart, 70191, Germany|Investigational Site, Tubingen, 72076, Germany|Investigational Site, Wurzburg, 97080, Germany|Athens Naval Hospital, Neurology Department, Athens, 11521, Greece|Neurology Department Athens General Hospital, G. Gennimatas, Mesogeion 154 Ave., Athens, 11527, Greece|1st IKA Papadimitriou Neurology Dept, Terma Zaimi, Melissia-Athens, 15127, Greece|University General Hospital of Thessaloniki ""AHEPA"", B' University Department of Neurology, Thessaloniki, 54636, Greece|Barzilai Medical Center, Ashkelon, 78306, Israel|Carmel Medical Center, Haifa, 34362, Israel|Sieff Medical Center, Safed, 13100, Israel|Sheba - Medical Center, Tel Hashomer, Ramat-Gan,, 52621, Israel|Kaunas University Hospital Department of Neurology, Eiveniu 2, Kaunas, LY-50009, Lithuania|Academisch Ziekenhuis VU, De Boelelaan 1118, Amsterdam, 1081, Netherlands|St. Antonius Ziekenhuis, Postbus 2500, Nieuwegein, 3430 EM, Netherlands|Multiple Clerosis Center Nijmegen, Heiweg 97, Nyimegen, 6533, Netherlands|Erasmus MC, Dr. Molewaterplein 40, Rotterdam, 3015 GD, Netherlands|Sint Elisabeth Ziekenhuis, Hilvarenbeekse Weg 60, Tilburg, 5022, Netherlands|Maaslandziekenhuis Sittard, Walramstraat 23, BK Sittard, 6131, Netherlands|Samodzielny Publiczny Szpital Kliniczny, Klinika Neurologii, Ul. Marii Skłodowskiej-Curie 24 A, Bialystok, 15-276, Poland|Niezalezny Zespol Opieki Zdrowotnej Kendron, Ul. Swietego Mikolaja 1/8, Bialystok, 15-420, Poland|Oddzial Neurologiczny i Leczenia Udarow, Mozgu, Nowe Ogrody 1/6, Gdańsk, 80-803, Poland|Katedra i Klinika Neurologii Slaskiej Akademii Medycznej, ul. Medykow 14, Katowice, 40-752, Poland|Univ. Med. Sci. Poznan, Katedra i Klinika Neurologii,, Department of Neurology, ul. Przybyszewskiego 49, Poznan, 60-355, Poland|CSK MSWiA Hospital, Department of Neurology, Wołoska 137, Warsaw, 02-507, Poland|Jadwiga Kruszewska-Ozimska, Instytut Psychiatrii i Neurologii, II Klinika Neurologii, ul. Sobieskiego 1/9, Warsaw, 02-957, Poland|Centralny Szpital Kliniczny, Klinika Neurologii, MSWiAw Warszawie, Woloska 137, Warszawa, 00-909, Poland|Katedra i Klinika Neurologii Centralny Szpital Kliniczny AM w Warszawie, ul. Banacha 1A, Warszawa, 01-097, Poland|Medical University of Lodz, Lodz, Poland|Interregional Clinical Diagnistic Center, Neurology Department, Kazan, 420111, Russian Federation|Central Clinical Hospital of Medical Center of Administration of President of Russian Federation, Moscow, 121356, Russian Federation|Moscow Regional Research Clinical Institue, Moscow, 129110, Russian Federation|GUZ ""Central Medical Sanitary Department #122 of Federal Medical-Biological agency"", Neurology department, St-Petersburg, Russian Federation|Military Medical Academy, Neurology Department, St. Petersburg, 194044, Russian Federation|II. Neurologická klinika Fakultná nemocnica s poliklinikou Bratislava pracovisko Kramáre, Limbová 5, Bratislava, 833 05, Slovakia|Neurologická klinika, Martinská fakultná nemocnica, Kollárova 2, Martin, 03659, Slovakia|I. Neurologická klinika, Fakultná nemocnica s poliklinikou Bratislava pracovisko Staré mesto, Mickiewiczova 13, Bratislava, 813 69, Slovakia|Neurologické oddelenie, Nemocnica s poliklinikou Žilina, ul.V. Spanyola 43, Žilina, 012 07, Slovakia|Umhlanga Hospital, Umhlanga, KZN, 4319, South Africa|Division of Neurology, Groote Schuur Hospital, E 8-74, Groote Schuur Hospital, Observatory Cape Town, 7925, South Africa|Private Neurologist (Morningside Medi-Clinic), Suite C, Block C, Rochester Place, Sandton, 2196, South Africa|MS Centrum, Forskningsenhet, SU/Östra CKÖ plan 0, Gothenburg, 41345, Sweden|Karolinska University Hospital Huddinge, Department Of Neurology R54, Stockholm, 14186, Sweden|Karolinska University Hospital, Department of Medicine, Neuroimmunology unit, CMM L8:04, Stockholm, 171 76, Sweden|Kantonsspital Basel, Policlinic, Neurology-Neurosurgical, Petersgraben 4, Basel, 4031, Switzerland|Centre Hospitalier, Universitaire Vaudois Policlinique de Neurologie, Rue du Bugnon, Lausanne, 1011, Switzerland|UniversitätsSpital Zürich, Neurologische Klinik, Frauenklinikstr. 26, Zurich, 8091, Switzerland|Hacettepe Universiti Hospitals, Department of Neurology, Ankara, Turkey|Gazi University, Medical Faculty Neurology Department, Besevler Ankara, 06500, Turkey|EGE University, Medical Faculty Hospital Neurolgy Department, Bornova Izmir, 35100, Turkey|Istanbul University, Istanbul Faculty of Medicine, Departement of Neurology, Capa Istanbul, 34093, Turkey|Istanbul University, Cerrahpasa School of Medicine, Department of Neurology, Cerrahpasa Istanbul, 34098, Turkey|Gaziantep University School of Medicine, Neurology Department, Gaziantep, 27070, Turkey|Uludag University Faculty of Medche, Tip Fakultesi, Noroloji ABD, Görükle / Bursa, Turkey|Tepecik Training and Research, Hospital Neurology Service, 35120 Gaziler Cad. Izmir, Turkey|Dokuz University Medical Faculty, Neurology Department, Inciralti, Izmir, 35340, Turkey|Bakirkoy Ruh ve Sinir Hastaliklari Hastanesi, Istanbul, 34147, Turkey|Mersin Universitesi Tip Fakultesi Hastanesi, Noroloji ABD, Mersin, 33079, Turkey|T.C. Saglik Bakanligi Goztepe Egitim ve Arastirma Hastanesi, Noroloji Klinigi, Göztepe Istanbul, 34722, Turkey|King's College Hospital, Trials office Academie Neuroscience Center, P041 Institute of Psychiatry, Denmark Hill, London, SES 8AF, United Kingdom|Queens Medical Centre, Division of Clinical Neurology Medical School, Nottingham, NG7 24H, United Kingdom|Royal Hallamshire Hospital, Glossop Road, Sheffield, S102JF, United Kingdom|St. George's Hospital, Neurology Dept. Atkinson Morley Wing, Backshaw Road, London, Tooting London SW17 0QT, United Kingdom|Frenchay Hospital, Department of Neurology, Beckspool Road, Bristol, BS16 1LE, United Kingdom|Royal Victoria Infirmary, Queen Victoria Road, Newcastle-upon-Tyne, NE1 4LP, United Kingdom"
NCT00469378,Study Of White Blood Cells In The Cerebrospinal Fluid And Blood Of Patients With Relapsing Forms Of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00469378,COMPLETED,Multiple Sclerosis,DRUG: firategrast,GlaxoSmithKline,,ALL,"ADULT, OLDER_ADULT",PHASE2,46,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-07,2009-05,2010-02,"GSK Investigational Site, Bruxelles, 1070, Belgium|GSK Investigational Site, Bruxelles, 1200, Belgium|GSK Investigational Site, Olomouc, 775 20, Czech Republic|GSK Investigational Site, Praha 2, 120 00, Czech Republic|GSK Investigational Site, Glostrup, DK-2600, Denmark|GSK Investigational Site, Koebenhavn Ø, 2100, Denmark|GSK Investigational Site, Lørenskog, 1478, Norway|GSK Investigational Site, Göteborg, SE-416 85, Sweden|GSK Investigational Site, Stockholm, SE-171 76, Sweden|GSK Investigational Site, Umeå, SE-901 85, Sweden"
NCT04145284,Quantitative Magnetic Resonance Imaging (MRI) Sub-Study of MS PATHS,https://beta.clinicaltrials.gov/study/NCT04145284,COMPLETED,Multiple Sclerosis,,Biogen,,ALL,"CHILD, ADULT, OLDER_ADULT",,6,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-04-30,2020-04-30,2020-04-30,"Research Site, Cleveland, Ohio, 44195, United States|Research Site, Dresden, Saxony, 01307, Germany"
NCT01866878,Rehabilitation Protocol for Disorders on Hand Sensitivity in Multiple Sclerosis Patients.,https://beta.clinicaltrials.gov/study/NCT01866878,COMPLETED,Multiple Sclerosis,DEVICE: equipment rehabilitation stereognosis|DEVICE: TENS,Centre Hospitalier Universitaire de Nice,,ALL,"ADULT, OLDER_ADULT",NA,10,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2013-07-30,2015-07-28,2015-07-28,"Hôpital Pasteur, Nice, 06000, France"
NCT01853423,Tuberous Sclerosis Complex: Facial Angiofibroma Skin Cream,https://beta.clinicaltrials.gov/study/NCT01853423,COMPLETED,Facial Angiofibroma,DRUG: Rapamune,Le Bonheur Children's Hospital,Pfizer|University of Tennessee,ALL,"CHILD, ADULT",PHASE1,11,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-10,2016-05,2016-07,"LeBonheur Children's Hospital, Memphis, Tennessee, 38103, United States"
NCT05112484,Therapeutic Monitoring of Drugs Used in the Treatment of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05112484,NOT_YET_RECRUITING,Multiple Sclerosis,DIAGNOSTIC_TEST: Measurement of concentrations of orally-used DMDs|DIAGNOSTIC_TEST: Genetic testing|DIAGNOSTIC_TEST: Parameters for routine use of DMDs|OTHER: Side effects of orally used DMDs,University Hospital Ostrava,University of Ostrava,ALL,"ADULT, OLDER_ADULT",,600,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-02-01,2025-11,2026-05,"University of Ostrava, Ostrava, Moravian-Silesian Region, 70300, Czechia|University Hospital Ostrava, Ostrava, Moravian-Silesian Region, 70852, Czechia"
NCT01953523,"Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions",https://beta.clinicaltrials.gov/study/NCT01953523,COMPLETED,Neurodegenerative Diseases|Osteoarthritis|Erectile Dysfunction|Autoimmune Diseases|Cardiomyopathies|Emphysema,PROCEDURE: Administration of autologous adipose derived SVF,Elliot Lander,,ALL,"CHILD, ADULT, OLDER_ADULT",NA,3000,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-09-02,2016-12-31,2017-01-01,"California Stem Cell Treatment Center, Rancho Mirage, California, 92270, United States"
NCT03137602,ATOMIC (Active Teens With MultIple sClerosis) Teens: A Feasibility Study,https://beta.clinicaltrials.gov/study/NCT03137602,COMPLETED,Pediatric Multiple Sclerosis,DEVICE: ATOMIC mobile app,The Hospital for Sick Children,University of Alabama at Birmingham|Queen's University,ALL,"CHILD, ADULT",NA,14,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2018-03-07,2019-09-30,2019-09-30,"Hospital for Sick Children, Toronto, Ontario, M5G1X8, Canada"
NCT02065284,Effects of a Home Based Walking Program Using Rhythmic Auditory Stimulation in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02065284,COMPLETED,Multiple Sclerosis|Ambulation Difficulty,OTHER: Rhythmic Auditory Stimulation (RAS),The Cleveland Clinic,The Kelvin and Eleanor Smith Foundation,ALL,"ADULT, OLDER_ADULT",NA,32,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2014-02,2015-09,2015-11,"Cleveland Clinic Neurological Institute Mellen Center, Cleveland, Ohio, 44195, United States"
NCT04944784,A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS),https://beta.clinicaltrials.gov/study/NCT04944784,TERMINATED,Amyotrophic Lateral Sclerosis,DRUG: Reldesemtiv|DRUG: Placebo,Cytokinetics,,ALL,"ADULT, OLDER_ADULT",PHASE3,486,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-08-16,2023-03-31,2023-03-31,"St. Joseph's Hospital & Medical Center - Barrow Neurological Institute, Phoenix, Arizona, 85013, United States|Cedars-Sinai Medical Center, Los Angeles, California, 90048, United States|University of California Irvine - ALS & Neuromuscular Center, Orange, California, 92868, United States|California Pacific Medical Center - Forbes Norris MDA/ALS Research Center, San Francisco, California, 94109, United States|Stanford Hospital and Clinics, Stanford, California, 94305, United States|University of Colorado Hospital Anschutz Outpatient Pavilion, Aurora, Colorado, 80045, United States|GW Medical Faculty Associates, Washington, District of Columbia, 20037, United States|University of Florida Jacksonville, Jacksonville, Florida, 32209, United States|Mayo Clinic Florida, Jacksonville, Florida, 32224, United States|University of South Florida - Carol and Frank Morsani Center for Advanced Health Care, Tampa, Florida, 33612, United States|Duchossois Center for Advanced Medicine, Chicago, Illinois, 60637, United States|Indiana University, Indianapolis, Indiana, 46202, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, 52242, United States|The University of Kansas Medical Center, Kansas City, Kansas, 66160, United States|Johns Hopkins Outpatient Center, Baltimore, Maryland, 21287, United States|Massachusetts General Hospital - Neurological Clinical Research Institute, Boston, Massachusetts, 02114, United States|University of Massachusetts Memorial Medical Center/Medical School, Worcester, Massachusetts, 01655, United States|Michigan Medicine, Ann Arbor, Michigan, 48109, United States|Henry Ford Health System, Detroit, Michigan, 48202, United States|Washington University School of Medicine - Center for Advance Medicine, Saint Louis, Missouri, 63108, United States|Neurology Associates, PC, Lincoln, Nebraska, 68506, United States|Hospital for Special Surgery, New York, New York, 10021, United States|Columbia University Medical Center, New York, New York, 10032, United States|University of Rochester Medical Center, Rochester, New York, 14642, United States|SUNY Upstate Medical University, Syracuse, New York, 13210, United States|Atrium Health Neuroscience Institute - Charlotte, Charlotte, North Carolina, 28207, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|Providence ALS Center, Portland, Oregon, 97213, United States|Oregon Health and Science University, Portland, Oregon, 97239, United States|Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, 17033, United States|Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, 19140, United States|Vanderbilt University Medical Center - Clinical Research Center, Nashville, Tennessee, 37232, United States|Texas Neurology, P.A., Dallas, Texas, 75206, United States|University of Vermont Medical Center, Burlington, Vermont, 05401, United States|VCU Neuroscience Orthopaedic and Wellness Center (NOW), Henrico, Virginia, 23233, United States|Froedtert Hospital, Milwaukee, Wisconsin, 53226, United States|Brain and Mind Centre, Camperdown, New South Wales, 2050, Australia|Concord Repatriation General Hospital, Concord, New South Wales, 2139, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, 4029, Australia|Flinders Medical Centre, Bedford Park, South Australia, 5042, Australia|The Perron Institute, Nedlands, Western Australia, 6009, Australia|UZ Leuven Gasthuisberg, Department of Neurology, Leuven, 3000, Belgium|University of Calgary - Heritage Medical Research Clinic, Calgary, Alberta, T2N 4Z6, Canada|University of Alberta, Edmonton, Alberta, T6G 2B7, Canada|Stan Cassidy Centre for Rehabilitation, Fredericton, New Brunswick, E3B 0C7, Canada|McMaster University Medical Centre, Hamilton, Ontario, L8N 3Z5, Canada|London Health Sciences Centre, London, Ontario, N6A 5A5, Canada|Ottawa Hospital Research Institute - Civic Campus, Ottawa, Ontario, K1Y 4E9, Canada|Sunnybrook Research Institute, Toronto, Ontario, M4N 3M5, Canada|Centre de recherche du CHUM, Montréal, Quebec, H2X 0A9, Canada|McGill University, Montreal Neurological Institute & Hospital, Montréal, Quebec, H3A 2B4, Canada|CHU de Quebec-Université Laval, Québec, Quebec, G1J 1Z4, Canada|Saskatoon City Hospital, Saskatoon, Saskatchewan, S7K 0M7, Canada|Deparment of Neurology Bispebjerg University Hospital, Copenhagen, 2400, Denmark|CRC SLA de Lyon, Bron, 69677, France|CHRU de Lille Hopital Roger Salengro, Lille, 59037, France|CHU de Limoges - Hopital Dupuytren, Limoges, 87 042, France|CHU de la Timone, Marseille, 13005, France|CHU de Nice - Hôpital Pasteur 2, Nice, 06 001, France|Hopital La Pitie Salpetriere, Paris, 75013, France|CHRU de Tours, Hopital Bretonneau, Clinical Research Center, Tours, 37044, France|Charité - Universitätsmedizin Berlin, Berlin, 13353, Germany|Universitatsklinikum Bonn, Bonn, 53127, Germany|Medical School Hannover - Department of Neurology, Hanover, 30625, Germany|Universitatsklinikum Jena, Jena, 07747, Germany|Universitätsklinikum Schleswig Holstein, Lübeck, 23538, Germany|Universitatsklinikum Ulm, Ulm, 89081, Germany|RSCI Education and Research Centre, Beaumont Hospital, Beaumont, Dublin, 9, Ireland|Instituti Clinici Scientifici Maugeri, Milano, 20138, Italy|Ospedale San Luca, Milan, 20149, Italy|Centro Clinical Nemo - Fondazione Serena Onlus, Milan, 20162, Italy|AOU Città della Salute e Scienza (Molinette),, Turin, 10126, Italy|UMC Utrecht, Department of Neurology, ALS Center, Utrecht, 3584 CX, Netherlands|City Clinic Research, Warsaw, 02-473, Poland|Centro Hospitalar Universitario Lisboa Norte, Department of Neurology, Lisboa, 1649-035, Portugal|Hospital Universitari de Bellvitge, Barcelona, 08907, Spain|Hospital Universitario Basurto, Bilbao, 48013, Spain|Hospital San Rafael, Madrid, 28016, Spain|Hospital Universitari i Politecnic La Fe, Valencia, 46026, Spain|Neurologimottagningen Skane University Hospital, Malmö, 21428, Sweden|Studieenheten Akademiskt Specialistcentrum, Sabbatsberg Hospital, Stockholm, 11361, Sweden|Muskelzentrum/ALS Clinic, Saint Gallen, 9007, Switzerland|The Walton Centre NHS Foundation Trust, Liverpool, L9 7LJ, United Kingdom|Maurice Wohl Clinical Neuroscience Institute, London, SE5 9RX, United Kingdom"
NCT05168384,Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05168384,RECRUITING,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis, Secondary Progressive",COMBINATION_PRODUCT: Extracorporeal Photopheresis|COMBINATION_PRODUCT: MS standard of care,Abu Dhabi Stem Cells Center,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,45,OTHER_GOV,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-03-26,2023-10,2024-04,"Abu Dhabi Stem Cells Center, Abu Dhabi, 4600, United Arab Emirates"
NCT00428584,RNF and Betaseron® Tolerability Study,https://beta.clinicaltrials.gov/study/NCT00428584,COMPLETED,Relapsing Remitting Multiple Sclerosis (RRMS),DRUG: New Formulation of rebif - human interferon beta-1a|DRUG: Interferon beta -1b,EMD Serono,Pfizer,ALL,ADULT,PHASE3,129,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2006-12,2007-11,2009-09,"EMD Serono Med Info, Rockland, Massachusetts, 02370, United States"
NCT01931644,"At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions",https://beta.clinicaltrials.gov/study/NCT01931644,RECRUITING,All Diagnosed Health Conditions|ADD/ADHD|Alopecia Areata|Ankylosing Spondylitis|Asthma|Atopic Dermatitis Eczema|Beta Thalassemia|Bipolar Disorder|Breast Cancer|Celiac Disease|Cervical Cancer|Chronic Inflammatory Demyelinating Polyneuropathy|Chronic Kidney Diseases|Chronic Obstructive Pulmonary Disease|Colon Cancer|Colorectal Cancer|Crohn's Disease|Cystic Fibrosis|Depression|Diabetes Mellitus|Duchenne Muscular Dystrophy|Endometriosis|Epilepsy|Facioscapulohumeral Muscular Dystrophy|G6PD Deficiency|General Anxiety Disorder|Hepatitis B|Hereditary Hemorrhagic Telangiectasia|HIV/AIDS|Human Papilloma Virus|Huntington's Disease|Idiopathic Thrombocytopenic Purpura|Insomnia|Kidney Cancer|Leukemia|Lung Cancer|Lupus Nephritis|Lymphoma|Melanoma|Multiple Myeloma|Multiple Sclerosis|Myositis|Myotonic Dystrophy|Ovarian Cancer|Pancreatic Cancer|Parkinson's Disease|Polycystic Kidney Diseases|Prostate Cancer|Psoriasis|Psoriatic Arthritis|Rosacea|Scleroderma|Sickle Cell Anemia|Sickle Cell Trait|Sjogren's Syndrome|Skin Cancer|Spinal Muscular Atrophy|Systemic Lupus Erythematosus|Thrombotic Thrombocytopenic Purpura|Trisomy 21|Ulcerative Colitis,,Sanguine Biosciences,,ALL,"ADULT, OLDER_ADULT",,20000,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-07,2025-08,2040-12,"Sanguine Biosciences, Los Angeles, California, 91403, United States"
NCT04993274,Sensitivity of Motor Assessment in MS - a Prospective Cohort Study,https://beta.clinicaltrials.gov/study/NCT04993274,ACTIVE_NOT_RECRUITING,"Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis, Secondary Progressive|Multiple Sclerosis, Chronic Progressive",DIAGNOSTIC_TEST: PASS-MS,Friedemann Paul,Roche Pharma AG,ALL,"ADULT, OLDER_ADULT",,100,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-02-20,2022-11,2022-11,"Experimental and Clinical Research Center, Studienambulanz Neuroimmunologie am Standort NCRC, Campus Mitte,Charité - Universitätsmedizin Berlin, Berlin, 10117, Germany"
NCT04325074,Mental Practice and Manipulative Skills Training in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04325074,COMPLETED,Multiple Sclerosis,OTHER: Mental practice|OTHER: Mental practice + skill training|OTHER: Control group,Cristina García-Bravo,,ALL,ADULT,NA,40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2015-09-15,2015-11,2016-06,
NCT04843774,Vaccine-generated Immunity in Ocrelizumab-treated Patients: Longitudinal Assessments (VIOLA),https://beta.clinicaltrials.gov/study/NCT04843774,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,DRUG: SARS-COV-2 mRNA Vaccine,NYU Langone Health,,ALL,"ADULT, OLDER_ADULT",,64,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-04-20,2023-06-30,2023-10-14,"University of Colorado, Denver (UCD), Denver, Colorado, 80204, United States|NYU Langone Health Multiple Sclerosis Comprehensive Care Center (NYULH MSCCC), New York, New York, 10016, United States"
NCT03548974,Internet-based MOTOmed Exercise to Reduce Spasticity and Improve Physical Function in Persons With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03548974,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Treatment group 1|BEHAVIORAL: Treatment group 2,University of Erlangen-Nürnberg,Fa. Reck MOTOmed,ALL,"ADULT, OLDER_ADULT",NA,57,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2015-01,2015-10,2015-10,
NCT00103974,Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00103974,COMPLETED,Multiple Sclerosis,BIOLOGICAL: BHT-3009-01,Bayhill Therapeutics,,ALL,"ADULT, OLDER_ADULT",PHASE1,30,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE|Primary Purpose: TREATMENT,2004-07,,2007-03,"Barrow Neurology Clinics, Phoenix, Arizona, 85013, United States|USC, LAC & USC Medical Center, Los Angeles, California, 90033, United States|University of British Columbia, MS Research, Vancouver, British Columbia, V6T 2B5, Canada|Montreal Neurological Institute, Clinical Research Unit and MS clinic, Montreal, Quebec, H3A 2B4, Canada"
NCT04230174,Effect of Ocrelizumab on Neuroinflammation in Multiple Sclerosis as Measured by 11C-PBR28 MR-PET Imaging of Microglia Activation,https://beta.clinicaltrials.gov/study/NCT04230174,UNKNOWN,Multiple Sclerosis,DRUG: 11C-PBR28,Massachusetts General Hospital,"Genentech, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE4,24,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-02,2022-01,2022-07,
NCT00599274,Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00599274,COMPLETED,Multiple Sclerosis,DRUG: Interferon beta-1a|DRUG: Interferon beta-1a,Biogen,,ALL,ADULT,,136,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2002-08,,2003-05,"Research Site, Los Angeles, California, United States|Research Site, Walnut Creek, California, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Worcester, Massachusetts, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Columbus, Ohio, United States|Research Site, Edmonds, Washington, United States|Research Site, Milwaukee, Wisconsin, United States|Coordinating Research Site, Woodville, Australia|Coordinating Research Site, Linz, Austria|Coordinating Research Site, Halifax, Nova Scotia, Canada"
NCT05778474,Mechanical Determinants of Upper Limbs Oscillation During Gait,https://beta.clinicaltrials.gov/study/NCT05778474,RECRUITING,Multiple Sclerosis|Poststroke/CVA Hemiparesis|Parkinson Disease|Cerebral Palsy|Amputation,OTHER: Healthy subjects|OTHER: Pathologic group,Istituto Auxologico Italiano,,ALL,"ADULT, OLDER_ADULT",NA,25,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-05-27,2023-12,2024-04,"Istituto Auxologico Italiano, Milan, 20145, Italy"
NCT02137044,Multiple Sclerosis-Collaborative Approach to Rehabilitation Effectiveness Study,https://beta.clinicaltrials.gov/study/NCT02137044,COMPLETED,Multiple Sclerosis|Pain|Depression,BEHAVIORAL: Collaborative Care (CC),University of Washington,Patient-Centered Outcomes Research Institute,ALL,"ADULT, OLDER_ADULT",NA,195,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2014-07,2017-04,2017-04,"University of Washington- Harborview Medical Center, Seattle, Washington, 98104, United States|University of Washington Medicine MS Center, Seattle, Washington, 98133, United States|University of Washington-Health Sciences Building, Seattle, Washington, 98195, United States"
NCT02898974,Medical Marijuana and Its Effects on Motor Function in People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02898974,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Medical Marijuana,Colorado State University,"William R. Shaffer, M.D.",ALL,ADULT,,22,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-09,2017-10,2017-10,"Department of Health and Exercise Science, Fort Collins, Colorado, 80523, United States"
NCT04047628,Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS),https://beta.clinicaltrials.gov/study/NCT04047628,RECRUITING,Relapsing Multiple Sclerosis|Relapsing Remitting Multiple Sclerosis|Secondary Progressive Multiple Sclerosis,PROCEDURE: Autologous Hematopoietic Stem Cell Transplantation|BIOLOGICAL: Best Available Therapy (BAT),National Institute of Allergy and Infectious Diseases (NIAID),"Immune Tolerance Network (ITN)|Blood and Marrow Transplant Clinical Trials Network|PPD|Rho Federal Systems Division, Inc.",ALL,ADULT,PHASE3,156,NIH,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2019-12-19,2026-10,2029-10,"Stanford Multiple Sclerosis Center, Palo Alto, California, 94304, United States|Rocky Mountain Multiple Sclerosis Center, University of Colorado School of Medicine, Aurora, Colorado, 80045, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, 01655, United States|University of Minnesota Multiple Sclerosis Center, Minneapolis, Minnesota, 55455, United States|Mayo Clinic, Rochester, Minnesota, 55905, United States|John L. Trotter Multiple Sclerosis Center, Washington University School of Medicine in St. Louis, Saint Louis, Missouri, 63110, United States|Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Siinai, New York, New York, 10029, United States|Rochester Multiple Sclerosis Center, University of Rochester, Rochester, New York, 14620, United States|Duke University Medical Center, Durham, North Carolina, 27710, United States|University of Cincinnati (UC) Waddell Center for Multiple Sclerosis, Cincinnati, Ohio, 45219, United States|Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, Ohio, 44195, United States|Multiple Sclerosis Center, Oregon Health & Science University, Portland, Oregon, 97239, United States|Penn Comprehensive MS Center, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|University of Texas Southwestern Medical Center: Division of Multiple Sclerosis and Neuroimmunology, Dallas, Texas, 75390, United States|Maxine Mesigner Multiple Sclerosis Comprehensive Care Center, Baylor College of Medicine Medical Center, Houston, Texas, 77030, United States|Virginia Commonwealth University Multiple Sclerosis Treatment and Research Center, Richmond, Virginia, 23219, United States|Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, 98109, United States|Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, Washington, 98122, United States|Multiple Sclerosis Center at Northwest Hospital, Seattle, Washington, 98133, United States|Imperial College Healthcare NHS Trust, London, W12 0NN, United Kingdom"
NCT03827928,LoveYourBrain Yoga for Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03827928,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Yoga/meditation,Dartmouth-Hitchcock Medical Center,,ALL,"ADULT, OLDER_ADULT",NA,15,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2019-07-01,2019-12-30,2019-12-30,"Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, 03756, United States"
NCT01157728,Early Cognitive Impairment in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01157728,COMPLETED,Multiple Sclerosis|Cognitive Impairment,,Assistance Publique - Hôpitaux de Paris,ARSEP (Association pour la Recherche sur la Sclerose en Plaques)|JNLF (Journées de Neurologie de Langue Française),ALL,ADULT,,69,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2008-05,2010-12,2010-12,"Pitie salpêtrière Hospital, PAris, 75013, France"
NCT00398528,An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00398528,TERMINATED,Relapsing-Remitting Multiple Sclerosis,"DRUG: Glatiramer acetate, (Copaxone®)|DRUG: IFN-β-1a, (Avonex®)",Neurognostics,,ALL,"ADULT, OLDER_ADULT",,48,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2006-09,,2007-11,"University of Southern California, Los Angeles, California, 90033, United States|Minor & James Medical, Seattle, Washington, 98104, United States|University of Wisconsin - Madison, Madison, Wisconsin, 53792, United States|Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, 53215, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States"
NCT02433028,Swiss Multiple Sclerosis Cohort-Study,https://beta.clinicaltrials.gov/study/NCT02433028,RECRUITING,Multiple Sclerosis,,"University Hospital, Basel, Switzerland","Cantonal Hospital of Aarau, Switzerland|Cantonal Hospital of St. Gallen|University Hospital Inselspital, Berne|Regional Hospital Lugano (EOC), Switzerland|University Hospital, Geneva|University of Lausanne Hospitals|National Multiple Sclerosis Society",ALL,"CHILD, ADULT, OLDER_ADULT",,1200,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-06,2042-01,2042-01,"Cantonal Hospital Aarau, Aarau, AG, 5001, Switzerland|University Hospital Berne, Berne, BE, 3010, Switzerland|University Hospital Basel, Basel, BS, 4031, Switzerland|University Hospital Geneva, Geneva, GE, 1211, Switzerland|Cantonal Hospital St. Gallen, St. Gallen, SG, 9007, Switzerland|Regional Hospital Lugano, Lugano, TI, 6900, Switzerland|University Hospital Lausanne, Lausanne, VD, 1011, Switzerland|Univeristy Hospital Zürich, Zürich, Switzerland"
NCT03915028,Thermal Cures in the Treatment of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03915028,UNKNOWN,Multiple Sclerosis,OTHER: Spa therapy,Association Francaise pour la Recherche Thermale,,ALL,"ADULT, OLDER_ADULT",NA,200,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2019-05-23,2021-05,2021-08,"Département de Médecine Physique et de Réadaptation, Hopital LAPEYRONIE, Montpellier, 34295, France"
NCT01710228,Alternative Treatment Paradigm for Natalizumab Trial,https://beta.clinicaltrials.gov/study/NCT01710228,WITHDRAWN,Multiple Sclerosis (MS),DRUG: methylprednisolone,University of Texas Southwestern Medical Center,"Teva Branded Pharmaceutical Products R&D, Inc.|The University of Texas Health Science Center, Houston|University of Alabama at Birmingham|Charite University, Berlin, Germany",ALL,ADULT,PHASE2,0,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-07,2013-12,2013-12,"UT Southwestern Medical Center, Dallas, Texas, 75390, United States"
NCT02591901,Preventing UTIs in Chronic Neurogenic Bladder Dysfunction (Mix Methods),https://beta.clinicaltrials.gov/study/NCT02591901,COMPLETED,UTI|Neurogenic Bladder|Antibiotic Resistance,DRUG: Uro vaxom|OTHER: Placebo comparator,Buckinghamshire Healthcare NHS Trust,"National Institute for Health Research, United Kingdom|Oxford Clinical Trials Research Unit",ALL,"ADULT, OLDER_ADULT",PHASE2,48,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2018-04-06,2019-08-02,2019-09-21,"Stoke Mandeville Hospital, Aylesbury, Buckinghamshire, HP21 8AL, United Kingdom|Oxford Centre for Enablement, Oxford, Oxfordshire, United Kingdom"
NCT03825601,PET With [18F]Flumazenil as an Index of Neurodegeneration in MS,https://beta.clinicaltrials.gov/study/NCT03825601,UNKNOWN,Multiple Sclerosis|Relapsing-Remitting Multiple Sclerosis,DIAGNOSTIC_TEST: PET with [11C]Flumazenil,"Institut National de la Santé Et de la Recherche Médicale, France",,ALL,ADULT,NA,45,OTHER_GOV,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2019-02-01,2021-04-01,2021-04-01,
NCT00168701,Efficacy and Safety of BG00012 in MS,https://beta.clinicaltrials.gov/study/NCT00168701,COMPLETED,Multiple Sclerosis,DRUG: BG00012,Biogen,,ALL,ADULT,PHASE2,260,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,2004-10,,2006-03,"Faculty Hospital St. Anne, Bmo, 656 91, Czech Republic|Faculty Hospital, Hradec Kralove, 500 05, Czech Republic|Hospital of Pardubice, Pardupice, 532 03, Czech Republic|Faculty Hospital of Plzen, Plzen, 304 60, Czech Republic|General Teaching Hospital, Prague, 128 02, Czech Republic|Bochum am St. Josef-Hospital, Bochum, 44791, Germany|Heinrich-Heine-Universitat, Dusseldorf, 40225, Germany|George-August-Universitat Goettigen, Goettigen, 37073, Germany|Uzsoki Hospital, Budapest, 1145, Hungary|University of Debrecen, Debrecen, 4012, Hungary|Petz Aladar County Hospital, Gyor, 9024, Hungary|VUMC, Amsterdam, 1081 HV, Netherlands|Academic Hospital Rotterdam, Rotterdam, 3015 GD, Netherlands|SamodzielnyPubliczny Szpital Kliniczny, Bialystok, 15-276, Poland|Niesalezny Zespol Opieki Zdrowognej, Bialystok, 15-420, Poland|10 Wojskowy Szpital Kliniczny z Poliklinika, Bydgoszcz, 85-681, Poland|Wojewodzki Szpital Specjalistczny, Gdansk, 80-803, Poland|Slaskiej Akademii Medycznej, Katowice-Ligota, 41-741, Poland|Szpital Uniwersytecki w Krakowie, Krakow, 31-503, Poland|Panstwowy Szpital Kliniczny, Lodz, 90-153, Poland|Samodzielny Publiczny Centralny Szpital, Warszawa, 01-097, Poland|Moscow, 1153682, Russian Federation|Moscow, 123182, Russian Federation|Moscow, 123367, Russian Federation|Moscow, 127018, Russian Federation|Novgorod, 603076, Russian Federation|Novosibirsk, 630075, Russian Federation|St. Petersburg, 194044, Russian Federation|St. Petersburg, 194291, Russian Federation|St. Petersburg, 197022, Russian Federation|St. Petersburg, 197376, Russian Federation|MS Centrum, Molndal, 431 80, Sweden|Karolinska University Hospital, Stockholm, 141 86, Sweden|Karolinska University Hospital, Stockholm, 171 76, Sweden|Kantonsspital Basel, Basel, CH 4.31, Switzerland|Hacettepe Unisersitesi, Ankara, 6100, Turkey|Istanbul University, Istanbul, 34303, Turkey|University of Instanbul, Istanbul, TR-34390, Turkey|Multiple Sclerosis Reseach Clinic, London, SE1 9RT, United Kingdom|Institute of Neurology, London, WC1N 3BG, United Kingdom|Royal Hampshire Hospital, Sheffield, S10 2JF, United Kingdom|University Hospital of North Staffordshire, Stoke-on-Trent, ST4 7LN, United Kingdom"
NCT04973501,Functional Disorders of the Musculoskeletal System in People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04973501,COMPLETED,Multiple Sclerosis|Rehabilitation|Musculoskeletal Complication,BEHAVIORAL: Manual physiotherapeutic correction (MFK) Method|BEHAVIORAL: Dynamic Neuromuscular Stabilization (DNS) Method,"Charles University, Czech Republic",,ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-05,2018-05,2020-12,
NCT01075880,Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif®,https://beta.clinicaltrials.gov/study/NCT01075880,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Rebif (Interferon beta-1a),"Merck KGaA, Darmstadt, Germany","Merck spol.s.r.o., Czech Republic",ALL,"ADULT, OLDER_ADULT",,300,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2009-05,2013-06,2013-06,"Neurologicka klinika FNBB, Brno, Czech Republic|Neurologicka klinika, Fakultní nemocnice U Sv. Anny, Brno, Czech Republic|Neurologicke oddeleni KN., Ceske Budejovice, Czech Republic|Neurologicka klinika Fakultní nemocnice, Hradec Kralove, Czech Republic|Neurologicka klinika Fakultní nemocnice, Motol, Czech Republic|Neurologicka klinika, Fakultní nemocnice, Olomouc, Czech Republic|Neurologicka klinika Fakultní nemocnice, Ostrava, Czech Republic|Neurologicke oddeleni KN, Pardubice, Czech Republic|Neurologicka klinika Fakultní nemocnice, Plzeň, Czech Republic|Neurologicka klinika FNKV, Praha, Czech Republic|Neurologicka klinika, Fakultní Thomayerovy nemocnice, Praha, Czech Republic|Neurologicke oddeleni NsP, Teplice, Czech Republic|Neurologicke oddeleni, Baťova nemocnice, Zlín, Czech Republic"
NCT05658601,A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS),https://beta.clinicaltrials.gov/study/NCT05658601,NOT_YET_RECRUITING,"Multiple Sclerosis, Relapsing-Remitting",,Bristol-Myers Squibb,,ALL,ADULT,,180,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-12-28,2024-11-15,2024-11-15,
NCT01419301,Mindfulness Based Stress Reduction in Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT01419301,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Mindfulness based stress reduction (MBSR),Stony Brook University,Teva Pharmaceuticals USA,ALL,"ADULT, OLDER_ADULT",NA,31,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE,2011-05,2013-04,2014-11,"Stony Brook University, Stony Brook, New York, 11786-8121, United States"
NCT01285401,Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment,https://beta.clinicaltrials.gov/study/NCT01285401,COMPLETED,Relapsing-Remitting Multiple Sclerosis,DRUG: VigantOL oil plus interferon beta-1a (Rebif)|DRUG: Placebo plus interferon beta-1a (Rebif)|BIOLOGICAL: Interferon beta-1a (Rebif®) alone,"Merck KGaA, Darmstadt, Germany",,ALL,ADULT,PHASE2,260,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2011-02,2015-04,2015-05,"Research Site, Vienna, Austria|Research Site, Esbjerg, Denmark|Research Site, Glostrup, Denmark|Research Site, Sønderborg, Denmark|Research Site, Vejle, Denmark|Research Site, Viborg, Denmark|Research Site, Tallinn, Estonia|Research Site, Helsinki, Finland|Research Site, Turku, Finland|Research Site, Bad Neustadt / Saale, Germany|Research Site, Bamberg, Germany|Research Site, Berlin, Germany|Research Site, Erlangen, Germany|Research Site, Freiburg, Germany|Research Site, Hannover, Germany|Research Site, Köln, Germany|Research Site, Münster, Germany|Research Site, Regensburg, Germany|Research Site, Rostock, Germany|Research Site, Cefalu, Italy|Research Site, Riga, Latvia|Research Site, Kaunas, Lithuania|Research Site, Amsterdam, Netherlands|Research Site, Gouda, Netherlands|Research Site, Nieuwegein, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Sittard, Netherlands|Research Site, Bergen, Norway|Research Site, Lørenskog, Norway|Research Site, Tromsø, Norway|Research Site, Amadora, Portugal|Research Site, Lisboa, Portugal|Research Site, Porto, Portugal|Research Site, Bern, Switzerland|Research Site, Lausanne, Switzerland|Research Site, Lugano, Switzerland|Research Site, St. Gallen, Switzerland|Research Site, Zurich, Switzerland"
NCT03154801,Early Detection and Paramedical Care of Sexual Difficulties in Nervous System Diseases: Example of Multiple Sclerosis and Brain Tumors (NEUROSEX),https://beta.clinicaltrials.gov/study/NCT03154801,ACTIVE_NOT_RECRUITING,Low Grade Glioma of Brain|Multiple Sclerosis|Sexual Dysfunctions,OTHER: Paramedical care,Assistance Publique - Hôpitaux de Paris,,ALL,"ADULT, OLDER_ADULT",NA,54,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2017-07-26,2022-01-26,2022-07-26,"Groupe Hospitalier Pitie Salpetriere, Paris, 75013, France"
NCT03500328,Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial,https://beta.clinicaltrials.gov/study/NCT03500328,RECRUITING,"Multiple Sclerosis, Relapsing-Remitting",OTHER: Early Aggressive Therapy or Traditional Therapy,Johns Hopkins University,Patient-Centered Outcomes Research Institute,ALL,ADULT,NA,900,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2018-05-02,2025-08-01,2025-08-01,"University of Alabama at Birmingham, Birmingham, Alabama, 35233, United States|The University of South Alabama, Mobile, Alabama, 36604, United States|St. Joseph's Hospital & Medical Center - Barrow Neurological Institute, Phoenix, Arizona, 85013, United States|CommonSpirit Health Research Institute, Carmichael, California, 95608, United States|Cedars-Sinai Medical Center, Los Angeles, California, 90048, United States|University of California, Los Angeles, Los Angeles, California, 90095, United States|University of California, San Diego, San Diego, California, 92037, United States|University of California, San Francisco, San Francisco, California, 94158, United States|Christiana Care Health Services, Inc., Newark, Delaware, 19713, United States|Georgetown University, Washington, District of Columbia, 20007, United States|University of Florida, Gainesville, Florida, 32611, United States|University of Miami, Miami, Florida, 33136, United States|University of South Florida Health, Tampa, Florida, 33612, United States|Rush University Medical Center, Chicago, Illinois, 60612, United States|The University of Kansas Medical Center (KUMC), Kansas City, Kansas, 66160, United States|University of Louisville, Louisville, Kentucky, 40202, United States|Norton Neurology MS Services, Louisville, Kentucky, 40207, United States|University of Maryland, Baltimore, Baltimore, Maryland, 21201, United States|The Johns Hopkins Hospital, Baltimore, Maryland, 21287, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|University of Massachusetts Medical School, Worcester, Massachusetts, 01655, United States|University of Michigan, Ann Arbor, Michigan, 48109, United States|Wayne State University, Detroit, Michigan, 48201, United States|Mayo Clinic, Rochester, Minnesota, 55905, United States|Billings Clinic, Billings, Montana, 59101, United States|Advanced Neurology Specialists, Great Falls, Montana, 59405, United States|University of Nebraska Medical Center, Omaha, Nebraska, 68198, United States|Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States|RWJBarnabas Health Multiple Sclerosis Comprehensive Care Center, Livingston, New Jersey, 07039, United States|New York University School of Medicine, New York, New York, 10016, United States|Icahn School of Medicine at Mount Sinai, New York, New York, 10029, United States|Columbia University Medical Center, New York, New York, 10032, United States|University of Rochester Medical Center, Rochester, New York, 14642, United States|Stony Brook University, Stony Brook, New York, 11794-8121, United States|Novant Health Neurology and Sleep, Charlotte, North Carolina, 28207, United States|University of Cincinnati, Cincinnati, Ohio, 45219, United States|OhioHealth Research Institute, Columbus, Ohio, 43214, United States|Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, 73104, United States|Providence Health and Services - Oregon, Portland, Oregon, 97225, United States|Geisinger Clinic, Danville, Pennsylvania, 17822, United States|Allegheny Health Network Research Institute, Pittsburgh, Pennsylvania, 15212, United States|Vanderbilt Comprehensive MS Center, Nashville, Tennessee, 37215, United States|Baylor Scott and White Health, Dallas, Texas, 75246, United States|The University of Texas Southwestern Medical Center, Dallas, Texas, 75390-8806, United States|Central Texas Neurology Consultants, Round Rock, Texas, 78681, United States|University of Utah, Salt Lake City, Utah, 84108, United States|The University of Vermont and State Agricultural College, Burlington, Vermont, 05405, United States|Blacksburg Neurology, Christiansburg, Virginia, 24073, United States|Neurology Consultants of Tidewater, Norfolk, Virginia, 23502, United States|Swedish Health Services, Seattle, Washington, 98122, United States|University of Washington, Seattle, Washington, 98133, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States"
NCT02860494,Topical Everolimus in Patients With Tuberous Sclerosis Complex,https://beta.clinicaltrials.gov/study/NCT02860494,WITHDRAWN,Facial Angiofibromas,DRUG: Everolimus|DRUG: Placebo,Hospices Civils de Lyon,,ALL,CHILD,PHASE2|PHASE3,0,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-12,2023-12,2024-12,"Hopital Femme Mère Enfant, Bron, France"
NCT03505294,The Effect of Task-Oriented Training in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03505294,COMPLETED,Multiple Sclerosis,OTHER: Task-oriented training,Gazi University,,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2018-06-18,2018-11-30,2018-12-24,"Gazi University, Ankara, Turkey"
NCT04634994,Novel Assessment of Synaptic Density in Progressive MS,https://beta.clinicaltrials.gov/study/NCT04634994,RECRUITING,Primary Progressive Multiple Sclerosis|Secondary Progressive Multiple Sclerosis|Relapsing Multiple Sclerosis|Multiple Sclerosis,DRUG: [F-18]SDM-8,Brigham and Women's Hospital,Massachusetts General Hospital,ALL,ADULT,EARLY_PHASE1,30,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-08,2022-08,2022-08,"Brigham and Women's Hospital, Boston, Massachusetts, 02115, United States"
NCT01071694,QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea,https://beta.clinicaltrials.gov/study/NCT01071694,WITHDRAWN,"Multiple Sclerosis, Relapsing-Remitting","DRUG: Interferon beta 1-b (Betaferon/Betaseron, BAY86-5046)",Bayer,,ALL,"ADULT, OLDER_ADULT",,0,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-01,2012-12,2012-12,"Many locations, Korea, Republic of"
NCT02804594,A Study of Oxidative Pathways in MS Fatigue,https://beta.clinicaltrials.gov/study/NCT02804594,COMPLETED,Progressive Multiple Sclerosis|Fatigue,DRUG: N-acetyl cysteine|DRUG: Placebo,"University of California, San Francisco",,ALL,"ADULT, OLDER_ADULT",PHASE2,15,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2016-10-01,2018-06-01,2018-06-01,"University of California San Francisco, San Francisco, California, 94158, United States"
NCT02695394,Emotional Processing in Multiple Sclerosis / Clinically Isolated Syndrome: A Neuropsychological fMRI-study,https://beta.clinicaltrials.gov/study/NCT02695394,COMPLETED,Multiple Sclerosis (MS)|Clinically Isolated Syndrome (CIS),,"Charite University, Berlin, Germany","NeuroCure Clinical Research Center, Charite, Berlin",ALL,"ADULT, OLDER_ADULT",,60,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-02,2016-12,2016-12,"Charité Unversitätsmedizin Berlin; NeuroCure Clinical Research Center NCRC, Berlin, 10117, Germany"
NCT04403594,Functional Intermuscular Reduction of Spasticity,https://beta.clinicaltrials.gov/study/NCT04403594,COMPLETED,Multiple Sclerosis,OTHER: dry needling,University of Oklahoma,Oklahoma Medical Research Foundation,ALL,ADULT,,16,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-08-19,2021-04-01,2021-04-18,"Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, 73104, United States"
NCT01854294,GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS),https://beta.clinicaltrials.gov/study/NCT01854294,COMPLETED,Amyotrophic Lateral Sclerosis,DRUG: GM604|DRUG: Placebo comparator,"Genervon Biopharmaceuticals, LLC",Columbia University|Massachusetts General Hospital,ALL,"ADULT, OLDER_ADULT",PHASE2,12,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-08,2014-04,2014-07,"Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Columbia Medical Center NY, New York, New York, 10032, United States"
NCT02352194,Physical Capacity and Rehabilitation of Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02352194,UNKNOWN,Multiple Sclerosis (MS),OTHER: Rehabilitation,Assistance Publique - Hôpitaux de Paris,,ALL,"ADULT, OLDER_ADULT",,60,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-07,2015-07,2015-10,"Raymond Poincaré Hospital, Garches, 92380, France"
NCT03308994,Impact of the Arrival on the French Market of New First Line Oral Treatments on the Delay Between MS Onset and First Disease Modifying Treatment (DMTs) Administration,https://beta.clinicaltrials.gov/study/NCT03308994,COMPLETED,C10.114.375.500,OTHER: Delay between MS onset and introduction of first line DMT|OTHER: EDI,"University Hospital, Caen","Genzyme, a Sanofi Company|Ligue contre le cancer, France",ALL,"CHILD, ADULT, OLDER_ADULT",,650,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-11-01,2019-12-31,2019-12-31,"Groupement des Hôpitaux de l'Institut Catholique de Lille (HICL), Lille, Hauts-de-France, 59020, France|University Hospital of Lille, Lille, Hauts-de-France, 59037, France|University Hospital Center of Caen, Caen, Normandie, 14033, France|University Hospital of Rouen, Rouen, Normandie, 76031, France"
NCT00638196,Placebo vs. Linoleic Acid Controlled Assessment of Treatment Efficacy in MS,https://beta.clinicaltrials.gov/study/NCT00638196,TERMINATED,Multiple Sclerosis,DRUG: Linoleic Acid/Oleic Acid,University of Rochester,,ALL,"ADULT, OLDER_ADULT",PHASE1,9,OTHER,INTERVENTIONAL,Allocation: |Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2008-03,2012-09,2012-09,"University of Rochester, Rochester, New York, 14642, United States"
NCT00947895,Efficacy Study of Adrenocorticotropin Hormone to Treat Multiple Sclerosis (MS) Relapses After Sub-responding to an Initial 3 Day Course of Intravenous (IV) Methylprednisolone,https://beta.clinicaltrials.gov/study/NCT00947895,TERMINATED,Multiple Sclerosis,DRUG: Methylprednisolone|DRUG: ACTH|OTHER: IV placebo|OTHER: IM placebo,"Neurologique Foundation, Inc.",Mallinckrodt,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-10,2011-01,2011-01,"Neurologique Foundation, Inc., Ponte Vedra, Florida, 32082, United States"
NCT00678795,A Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00678795,COMPLETED,Detrusor Overactivity|Multiple Sclerosis,DRUG: Sativex®|DRUG: Placebo,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,135,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2002-08,2005-10,2005-10,"Division of Clinical Neurology, Queen's Medical Centre, Nottingham, Notts, NG7 2UH, United Kingdom"
NCT01610713,An Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01610713,COMPLETED,Multiple Sclerosis,DRUG: GW-1000-02,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,154,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2001-05,2002-07,2002-07,"Rivermead Rehabilitation Centre, Oxford, United Kingdom"
NCT01978574,Intellectual Enrichment to Build Cognitive Reserve in MS,https://beta.clinicaltrials.gov/study/NCT01978574,COMPLETED,Cognitive Impairment in Multiple Sclerosis,BEHAVIORAL: Intellectual Enrichment daily activities|BEHAVIORAL: Intellectual Enrichment documentary videos,Kessler Foundation,National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",NA,9,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-06-01,2014-06-01,2014-06-01,"Kessler Foundation, West Orange, New Jersey, 07052, United States"
NCT03117881,Tele-Exercise and Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03117881,COMPLETED,Multiple Sclerosis,BEHAVIORAL: DirectCAM|BEHAVIORAL: TeleCAM|BEHAVIORAL: rDirectCAM,University of Alabama at Birmingham,"Patient-Centered Outcomes Research Institute|Alabama Neurology Associates, PC|Lakeshore Foundation",ALL,"ADULT, OLDER_ADULT",NA,912,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2018-01-08,2021-10-30,2022-10-30,"Upstream Rehabilitation Inc., Athens, Alabama, 35613, United States|Upstream Rehabilitation Inc., Bessemer, Alabama, 35022, United States|Tanner Foundation, Birmingham, Alabama, 35209, United States|Upstream Rehabilitation Inc., Calera, Alabama, 35040, United States|Upstream Rehabilitation Inc., Cullman, Alabama, 35058, United States|Southeast Alabama Medical Center Rehabilitation Services, Dothan, Alabama, 36301, United States|Gulf Coast Therapy, Fairhope, Alabama, 36532, United States|Gulf Coast Therapy, Foley, Alabama, 36536, United States|Encore Rehabilitation, Fort Payne, Alabama, 35967, United States|Upstream Rehabilitation Inc., Gadsden, Alabama, 35906, United States|Therapy Achievements, Huntsville, Alabama, 35801, United States|Upstream Rehabilitation Inc., Jacksonville, Alabama, 36265, United States|Upstream Rehabilitation Inc., Jasper, Alabama, 35501, United States|Gulf Coast Therapy, Mobile, Alabama, 36607, United States|Montgomery East Physical Therapy, Montgomery, Alabama, 36117, United States|Upstream Rehabilitation Inc., Muscle Shoals, Alabama, 35674, United States|Encore Rehabilitation, Phenix City, Alabama, 36867, United States|Upstream Rehabilitation Inc., Tuscaloosa, Alabama, 35046, United States|Cornerstone Rehabilitation, Batesville, Mississippi, 38668, United States|Upstream Rehabilitation Inc., Byram, Mississippi, 39272, United States|Upstream Rehabilitation Inc., Canton, Mississippi, 39046, United States|Upstream Rehabilitation Inc., Columbus, Mississippi, 39702, United States|Upstrem Rehabilitation, Forest, Mississippi, 39074, United States|Upstream Rehabilitation Inc., Fulton, Mississippi, 38843, United States|River City Rehabilitation, Greenville, Mississippi, 38703, United States|Encore Rehabilitation, Grenada, Mississippi, 38901, United States|Upstream Rehabilitation Inc., Hattiesburg, Mississippi, 39402, United States|Methodist Rehabilitation Center, Jackson, Mississippi, 39216, United States|Encore Rehabilitation, Ocean Springs, Mississippi, 39564, United States|North Sunflower Medical Center, Ruleville, Mississippi, 38771, United States|Cornerstone Rehabilitation, Southaven, Mississippi, 38671, United States|Upstream Rehabilitation Inc., Starkville, Mississippi, 39759, United States|Upstream Rehabilitation Inc., Tupelo, Mississippi, 38801, United States|Cornerstone Rehabilitation, Water Valley, Mississippi, 38965, United States|Upstream Rehabilitation Inc., Bristol, Tennessee, 37620, United States|Upstream Rehabilitation Inc., Cool Springs, Tennessee, 37067, United States|Upstream Rehabilitation Inc., Gordonsville, Tennessee, 38563, United States|Upstream Rehabilitation Inc., Knoxville, Tennessee, 37931, United States|Upstream Rehabilitation Inc., Newport, Tennessee, 37821, United States|Upstream Rehabilitation Inc., Winchester, Tennessee, 37398, United States"
NCT03756974,BX-1 in Spasticity Due to Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03756974,COMPLETED,Spasticity Due to Multiple Sclerosis,DRUG: BX-1|DRUG: Placebo,Bionorica SE,,ALL,"ADULT, OLDER_ADULT",PHASE3,397,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-02-18,2021-03-30,2021-03-30,"Investigative Site, Choceň, 56501, Czechia|Investigative Site, Havířov, 73601, Czechia|Investigative Site, Hradec Králové, 50003, Czechia|Investigative site, Hradec Králové, 50341, Czechia|Investigative Site, Olomouc, 77520, Czechia|Investigative Site, Plzen, 31200, Czechia|Investigative Site, Praha, 10034, Czechia|Investigative Site, Praha, 12808, Czechia|Investigative Site, Praha, 14059, Czechia|Investigative Site, Praha, 18600, Czechia|Investigative Site, Teplice, 41529, Czechia|Investigative Site, Freiburg, 79106, Germany|Investigative Site, Ulm, 89073, Germany|Investigative Site, Budapest, 1024, Hungary|Investigative Site, Budapest, 1116, Hungary|Investigative Site, Budapest, 1145, Hungary|Investigative Site, Debrecen, 4031, Hungary|Investigative Site, Győr, 9024, Hungary|Investigative Site, Miskolc, 3526, Hungary|Investigative Site, Szeged, 6725, Hungary|Investigative Site, Szolnok, 5000, Hungary|Investigative Site, Tatabánya, 2800, Hungary|Investigative Site, Bydgoszcz, 85-065, Poland|Investigative Site, Częstochowa, 42-280, Poland|Investigative Site, Katowice, 40-555, Poland|Investigative Site, Katowice, 40-588, Poland|Investigative Site, Katowice, 40-611, Poland|Investigative Site, Katowice, 40-650, Poland|Investigative Site, Kraków, 30-539, Poland|Investigative Site, Plewiska, 62-064, Poland|Investigative Site, Poznań, 61-853, Poland|Investigative Site, Warszawa, 00-874, Poland|Investigative Site, Warszawa, 01-684, Poland|Investigative Site, Barcelona, 08003, Spain|Investigative Site, Barcelona, 08025, Spain|Investigative Site, Hospitalet de Llobregat, 08907, Spain|Investigative Site, Madrid, 28034, Spain|Investigative Site, Málaga, 29010, Spain|Investigative Site, Salt, 17190, Spain|Investigative Site, Valencia, 46026, Spain"
NCT04061681,Efficacy of BIPAMS for Restless Legs Syndrome in Adults With Multiple Sclerosis: A Pilot Study,https://beta.clinicaltrials.gov/study/NCT04061681,COMPLETED,Multiple Sclerosis|Restless Legs Syndrome,BEHAVIORAL: Behavioral Intervention (BIPAMS),University of Alabama at Birmingham,,ALL,"ADULT, OLDER_ADULT",NA,15,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-01-01,2020-11-23,2020-11-23,"University of Alabama at Birmingham, Birmingham, Alabama, 35294, United States"
NCT02952911,Monitoring of Multiple Sclerosis (MS) Participants With the Use of Digital Technology (Smartphones and Smartwatches) - A Feasibility Study,https://beta.clinicaltrials.gov/study/NCT02952911,COMPLETED,Multiple Sclerosis,DEVICE: Smartphone and Smartwatch,Hoffmann-La Roche,,ALL,ADULT,NA,100,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2016-11-28,2018-05-04,2018-05-04,"UCSF- Multiple Sclerosis Centre; Department of Neurology, San Francisco, California, CA94158, United States|Hospital Vall d'Hebron; Servicio de Neurología, Barcelona, 08035, Spain"
NCT02519413,Tecfidera Lymphocyte Chart Review,https://beta.clinicaltrials.gov/study/NCT02519413,COMPLETED,Multiple Sclerosis,DRUG: dimethyl fumarate,Biogen,,ALL,"ADULT, OLDER_ADULT",,483,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-07,2016-02,2016-02,"Research site, Homewood, Alabama, 35209, United States|Research Site, Newport Beach, California, 92663, United States|Research Site, Atlanta, Georgia, 30309, United States|Research Site, Buffalo, New York, 14203, United States|Research Site, Patchogue, New York, 11772, United States|Research Site, Huntersville, North Carolina, 28078, United States|Research Site, Philadelphia, Pennsylvania, 19125, United States|Research Site, Seattle, Washington, 98101, United States|Research Site, Seattle, Washington, 98104, United States|Research Site, Milwaukee, Wisconsin, 53215, United States"
NCT04355611,Epidemiological Characteristics of COVID-19 in Patients With MS or NMO,https://beta.clinicaltrials.gov/study/NCT04355611,UNKNOWN,Multiple Sclerosis|NMO Spectrum Disorder|COVID-19,OTHER: Evaluation of the epidemiological characteristics of coronavirus infection (SARS-CoV-2),Assistance Publique - Hôpitaux de Paris,,ALL,"CHILD, ADULT, OLDER_ADULT",,2000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-04-20,2022-04-20,2022-04-20,"Hôpital Pitié Salpétrière, Paris, 75013, France"
NCT00477113,TYSABRI Global Observational Program in Safety,https://beta.clinicaltrials.gov/study/NCT00477113,COMPLETED,Multiple Sclerosis,,Biogen,,ALL,"CHILD, ADULT, OLDER_ADULT",,2207,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2007-01,2015-05,2015-05,"There may be mulitple sites in this clinical trial. Contact United BioSource Corporation, Kansas City, Missouri, 64111, United States"
NCT05298670,Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT05298670,RECRUITING,Multiple Sclerosis,DRUG: MetFORMIN 1000 Mg Oral Tablet|DRUG: Interferon beta-1a,German University in Cairo,,ALL,ADULT,PHASE2,80,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-02-01,2023-02-28,2023-03-28,"Nasser Institute for Research and Treatment, Cairo, Egypt"
NCT05543213,The Effects of Action Observation Therapy (AOT) on Balance and Gait in Patients With Multiple Sclerosis.,https://beta.clinicaltrials.gov/study/NCT05543213,NOT_YET_RECRUITING,Multiple Sclerosis,BEHAVIORAL: Action Observation Therapy,Shiraz University of Medical Sciences,,ALL,ADULT,NA,28,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-01-01,2023-04-01,2023-07-01,"School of Rehabilitation Sciences, Shiraz, Fars, 7194733669, Iran, Islamic Republic of"
NCT04595513,Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants,https://beta.clinicaltrials.gov/study/NCT04595513,COMPLETED,Tuberous Sclerosis Complex|Epilepsy,DRUG: TAVT-18 (sirolimus),"Children's Hospital Medical Center, Cincinnati",,ALL,CHILD,PHASE1|PHASE2,5,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2020-09-08,2022-12-15,2022-12-15,"Cincinnati Children's Hospital, Cincinnati, Ohio, 45229, United States"
NCT04014413,Safety and Efficacy of Fecal Microbiota Transplantation,https://beta.clinicaltrials.gov/study/NCT04014413,RECRUITING,Crohn Disease|Ulcerative Colitis|Celiac Disease|Irritable Bowel Syndrome|Functional Dysphonia|Constipation|Clostridium Difficile Infection|Diabetes Mellitus|Obesity|Multidrug -Resistant Infection|Hepatic Encephalopathy|Multiple Sclerosis|Pseudo-Obstruction|Carbapenem-Resistant Enterobacteriaceae Infection|Vancomycin Resistant Enterococci Infection|Multiple Organ Dysfunction Syndrome|Dysbiotic Bowel Syndrome|MRSA Enteritis|Pseudomembranous Enterocolitis|Alopecia|Autism|Graft-versus-host Disease|Idiopathic Thrombocytopenic Purpura|Atopy or Allergy|Liver Disease|Alcohol Dependence|Psoriatic Arthropathy,PROCEDURE: Fecal Microbiota Transplantation,Chinese University of Hong Kong,,ALL,"CHILD, ADULT, OLDER_ADULT",NA,450,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2019-07-15,2023-10-31,2024-10-31,"The Chinese University of Hong Kong, Hong Kong, Shatin, 000000, Hong Kong"
NCT03729713,Computerized Cognitive Rehabilitation in MS Patients,https://beta.clinicaltrials.gov/study/NCT03729713,RECRUITING,Multiple Sclerosis|Cognitive Impairment,OTHER: Computerized cognitive rehabilitation|OTHER: Sham placebo,"Rutgers, The State University of New Jersey",Horizon Blue Cross Blue Shield of New Jersey,ALL,"ADULT, OLDER_ADULT",NA,80,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-04-21,2023-05,2024-05,"Robert Wood Johnson Medical School, New Brunswick, New Jersey, 08091, United States"
NCT02652013,Evaluation and Neural Basis of Communication in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02652013,COMPLETED,Multiple Sclerosis|Social Cognition|Neuropsychology|Psychological Therory|Theory of Mind,OTHER: cognitive evaluation,Pôle Saint Hélier,"Rennes University Hospital|University Hospital, Angers|Université Européenne de Bretagne",ALL,"ADULT, OLDER_ADULT",NA,76,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2015-12,2019-12,2020-01,"Pôle Saint Hélier, Rennes, Bretagne, 35000, France"
NCT03975413,Fecal Microbiota Transplantation (FMT) in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03975413,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",OTHER: Fecal Microbiota Transplantation (FMT),Rush University Medical Center,,ALL,"ADULT, OLDER_ADULT",,1,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-09-25,2020-04-01,2020-05-01,"Rush University Medical Center, Chicago, Illinois, 60612, United States"
NCT04667013,"A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of TBN",https://beta.clinicaltrials.gov/study/NCT04667013,NOT_YET_RECRUITING,Healthy,DRUG: Tetramethylpyrazine nitrone (TBN) tablet / Placebo,"Guangzhou Magpie Pharmaceuticals Co., Ltd.",,ALL,ADULT,PHASE1,16,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-12-15,2024-06-30,2024-08-30,
NCT02675413,Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS,https://beta.clinicaltrials.gov/study/NCT02675413,WITHDRAWN,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting",DRUG: Dimethyl Fumarate,Washington University School of Medicine,Biogen,ALL,"ADULT, OLDER_ADULT",PHASE4,0,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2016-04,2016-04,2016-04,"Washington University (John L. Trotter MS Center), St. Louis, Missouri, 63110, United States|Swedish Neuroscience Institute, Seattle, Washington, 98122, United States"
NCT03951974,A Social Emotion Regulation Intervention in MS,https://beta.clinicaltrials.gov/study/NCT03951974,UNKNOWN,Multiple Sclerosis|Emotional Disturbances,BEHAVIORAL: Social Emotion Regulation Strategy Development|BEHAVIORAL: Control,Kessler Foundation,,ALL,"ADULT, OLDER_ADULT",NA,42,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2019-07-09,2021-07-09,2021-07-09,"Kessler Foundation, East Hanover, New Jersey, 07936, United States"
NCT00137176,EARLY IFNb-1a and Atorvastatin Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00137176,COMPLETED,Multiple Sclerosis,DRUG: Rebif,"University of North Carolina, Chapel Hill",,ALL,ADULT,NA,30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: ",2004-10,2007-10,2008-10,"University of North Carolina-Chapel Hill MS Clinic Within the Neuroscience Hospital, Chapel Hill, North Carolina, 27599, United States"
NCT05441488,Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05441488,RECRUITING,Progressive Multiple Sclerosis,DRUG: Placebo|DRUG: Masitinib (4.5),AB Science,,ALL,"ADULT, OLDER_ADULT",PHASE3,800,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-06-28,2025-12,2025-12,"Service de Neurologie Hôpital Henri-Mondor, Créteil, France|Hôpital Roger Salengro, Lille, France|Hôpital Pasteur - CHU de Nice, Nice, France|Centre Hospitalier Universitaire Nimes - Service de Neurologie, Nîmes, France|Centre hospitalier intercommunal de Poissy-Saint-Germain-en-Laye, Poissy, France|Le Centre hospitalier universitaire de Poitiers, Poitiers, France|Centre Hospitalier Universitaire de Rouen, Rouen, France|Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France|Centre Hospitalier Universitaire Toulouse, Toulouse, France|Athens Naval Hospital, Athens, Greece|Eginition Hospital, Athens University Medical School, Athens, Greece|General University Hospital of Larissa, Larissa, Greece|AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloníki, Greece|Private Clinic ELPIS, Volos, Greece|Azienda Ospedaliero Universitaria Policlinico ""G.Rodolico -San Marco"", Catania, Italy|Nzoz Neuro-Medic, Katowice, Poland|NOVI-MED, Ksawerów, Poland|NZOZ Neuro-Med, Lublin, Poland|Generała Jarosława Dąbrowskiego, Oświęcim, Poland|NZOZ Neuro-Kard, Poznań, Poland|Clinical Best Solutions, Warsaw, Poland|Centrum Neurologii Krzysztof Selmaj, Łódź, Poland|State Budgetary Institution of Health of the City of Moscow City Polyclinic #2, Moscow, Russian Federation|Perm Regional Clinical Hospital, Perm, Russian Federation|City Hospital No. 40 Kurortny District, Saint Petersburg, Russian Federation|LLC ""Center of socially significant diseases"", Saint Petersburg, Russian Federation|Hospital del Mar, Barcelona, Spain|Hospital Universitario de Cruces, Bilbao, Spain|Gregorio Marañón General University Hospital, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario y Politécnico La Fe, Valencia, Spain|Sahlgrenska University Hospital, Gothenburg, Sweden|Centrum för neurologi, Stockholm, Sweden|Lviv Regional Clinical Hospital, Lviv, Ukraine|Rivne Regional Specialized Dispensary for Radiation Protection of the Population Municipal Enterprise, Rivne, Ukraine|Communal Non-Profit Enterprise ""Ternopil Regional Clinical Psychoneurological Hospital"" of Ternopil Regional Council, Department of Neurology #1, Ternopil, Ukraine|Salutem Medical Center, Vinnytsia, Ukraine"
NCT00393588,Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00393588,COMPLETED,Multiple Sclerosis,,National Institute of Neurological Disorders and Stroke (NINDS),,ALL,ADULT,,50,NIH,OBSERVATIONAL,Observational Model: |Time Perspective: p,2006-10-26,,2011-09-29,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States"
NCT05269888,Covid-19 Vaccine Immune Response in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05269888,RECRUITING,Multiple Sclerosis,OTHER: Blood Test 1|OTHER: Blood Test 2,University Hospitals of North Midlands NHS Trust,,ALL,"ADULT, OLDER_ADULT",,240,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-02-16,2022-06-30,2023-04-30,"University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, St4 6QG, United Kingdom"
NCT04943289,Intrathecal Administration of DUOC-01 in Adults With Primary Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04943289,RECRUITING,Primary Progressive Multiple Sclerosis,BIOLOGICAL: DUOC-01,"Joanne Kurtzberg, MD",,ALL,"ADULT, OLDER_ADULT",PHASE1,20,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-01-24,2024-08-30,2024-08-30,"Duke University Medical Center, Durham, North Carolina, 27705, United States"
NCT00139789,"A Multicenter, Open-label Randomized Crossover Trial to Assess Subject Preference for Kemstro™ Compared to Conventional Baclofen Tablets in Subjects With Stable Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT00139789,COMPLETED,Multiple Sclerosis,DRUG: Kemstro,UCB Pharma,,ALL,"ADULT, OLDER_ADULT",PHASE3,60,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2005-01,2005-04,2005-04,"Schwarz, Milwaukee, Wisconsin, United States"
NCT03508089,Exploration of Microcirculatory Alteration and Endothelial Dysfunction by Adaptive Optics in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03508089,UNKNOWN,"Sclerosis, Multiple",OTHER: Ocular fundus on patient with Multiple Sclerosis|OTHER: Ocular Fundus on voluntary person,Versailles Hospital,,ALL,ADULT,NA,60,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2017-08-22,2017-10-26,2018-06-30,"CH de Versailles, Le Chesnay, France"
NCT04185688,The Reliability and Validity of the Functional Reach Test in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04185688,COMPLETED,Multiple Sclerosis,OTHER: Functional Reach Test,Gazi University,,ALL,"ADULT, OLDER_ADULT",,79,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-12-06,2020-02-07,2020-02-07,"Fatih Söke, Ankara, 06560, Turkey"
NCT01037088,Effects of Vaporized Marijuana on Neuropathic Pain,https://beta.clinicaltrials.gov/study/NCT01037088,COMPLETED,Neuropathic Pain|Reflex Sympathetic Dystrophy|Peripheral Neuropathy|Post-herpetic Neuralgia|Spinal Cord Injury|Multiple Sclerosis,DRUG: Mild dose cannabis|DRUG: Low dose cannabis|DRUG: Cannabis,"University of California, Davis",Center for Medicinal Cannabis Research|VA Northern California Health Care System,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,44,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-12,2012-11,2012-11,"CTSC Clinical Research Center, Sacramento VA Medical Center, Sacramento, California, 95817, United States"
NCT02543788,CHRONIC OPTIC NEUROPATHY IN MULTIPLE SCLEROSIS,https://beta.clinicaltrials.gov/study/NCT02543788,COMPLETED,Chronic Optic Neuropathy in Multiple Sclerosis,"PROCEDURE: • Neuro-Ophthalmological examination, Visual Acuity, Fundus, Visual Field, Color Vision, OCT, EDSS • NEI-VFQ 25 and the 10-item • VEPs, p-ERG and mf-ERG",Hospices Civils de Lyon,Fondation pour la Recherche Médicale,ALL,"ADULT, OLDER_ADULT",NA,39,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2014-09,2016-08,2016-08,"Unité de Neuro-Ophtalmologie - Hôpital Neurologique - HOSPICES CIVILS DE LYON, France, Bron, 69677, France"
NCT05312138,Multiple Sclerosis and Overactive Bladder Treatment,https://beta.clinicaltrials.gov/study/NCT05312138,ENROLLING_BY_INVITATION,Neurogenic Bladder Dysfunction,DEVICE: Repetitive Transcranial Magnetic Stimulation|DEVICE: Transcutaneous Posterior Tibial Nerve Stimulation,Istanbul Medipol University Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,16,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-06-08,2022-10,2022-12,"Istanbul Medipol Mega University Hospital, Istanbul, Turkey"
NCT01863888,Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01863888,COMPLETED,Multiple Sclerosis,DRUG: teriflunomide HMR1726|DRUG: cholestyramine|DRUG: charcoal,Sanofi,,ALL,ADULT,PHASE3,70,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2013-10,2015-01,2015-01,"Investigational Site Number 056001, Brussels, 1070, Belgium|Investigational Site Number 056002, Overpelt, 3900, Belgium|Investigational Site Number 056003, Sijsele-Damme, 8340, Belgium|Investigational Site Number 276-003, Bad Mergentheim, 97980, Germany|Investigational Site Number 276-004, Hannover, 30625, Germany|Investigational Site Number 276-005, Marburg, 35043, Germany|Investigational Site Number 276-007, Mönchengladbach, 41061, Germany|Investigational Site Number 276-001, Münster, 48149, Germany|Investigational Site Number 276-002, Ulm, 89073, Germany|Investigational Site Number 528001, Sittard-Geleen, 6162BG, Netherlands"
NCT03109288,"Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)",https://beta.clinicaltrials.gov/study/NCT03109288,RECRUITING,Multiple Sclerosis,DRUG: Pioglitazone|DRUG: clemastine fumarate|DRUG: Dantrolene|DRUG: Pirfenidone,National Institute of Allergy and Infectious Diseases (NIAID),,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,250,NIH,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,2017-08-11,2025-01-01,2029-01-01,"National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States"
NCT05671588,"Cardiovascular Fitness of Patients With Multiple Sclerosis, Effect of Exercise on Fatigue and Depression",https://beta.clinicaltrials.gov/study/NCT05671588,RECRUITING,Multiple Sclerosis,PROCEDURE: Controlled combined exercise group|PROCEDURE: Conventional rehabilitation,University Hospital Ostrava,,ALL,ADULT,NA,70,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2022-05-01,2025-06-30,2025-12-31,"University Hospital Ostrava, Ostrava, Moravian-Silesian Region, 708 52, Czechia"
NCT00325988,Biomarkers in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00325988,COMPLETED,Multiple Sclerosis,,National Institute of Neurological Disorders and Stroke (NINDS),,ALL,ADULT,,858,NIH,OBSERVATIONAL,Observational Model: |Time Perspective: p,2004-12-17,,2014-02-03,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States"
NCT03873389,Ocrelizumab Effects on the Metabolome in MS,https://beta.clinicaltrials.gov/study/NCT03873389,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,DRUG: Ocrelizumab,Johns Hopkins University,"Genentech, Inc.",ALL,"ADULT, OLDER_ADULT",,25,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-06-12,2023-06,2023-06,"Johns Hopkins University, Baltimore, Maryland, 21287, United States"
NCT04458688,Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04458688,RECRUITING,"Multiple Sclerosis, Relapsing-Remitting",OTHER: Observation of Ocrelizumab as Treatment in RRMS Patients,Wayne State University,,ALL,ADULT,,80,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-11-20,2025-07,2030-12,"Wayne State University, Detroit, Michigan, 48201, United States"
NCT04115488,Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®,https://beta.clinicaltrials.gov/study/NCT04115488,COMPLETED,Relapsing-Remitting Multiple Sclerosis (RRMS),BIOLOGICAL: Intravenous (IV) infusions,Polpharma Biologics S.A.,,ALL,ADULT,PHASE3,265,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-10-01,2021-08-23,2022-02-07,"Grodno Regional Clinical Hospital, Grodno, 230017, Belarus|Minsk City Clinical Hospital #5, Minsk, 220026, Belarus|Republican Research and Development Center for Neurology and Neurosurgery, Minsk, 220114, Belarus|Minsk Scientific and Practical Center of Surgery, Transplantology and Hematology, Minsk, 220116, Belarus|Vitebsk Regional Diagnostic Center, Vitebsk, 210023, Belarus|Vitebsk Regional Clinical Hospital, Vitebsk, 210037, Belarus|Clinical Hospital Center Osijek, Clinic of Neurology, Osijek, 31000, Croatia|Clinical Hospital Center Split, Clinic of Neurology, Split, 21000, Croatia|University Hospital Centre Zagreb, Clinic of Neurology, Zagreb, 10000, Croatia|P. Sarajishvili Institute of Neurology, LTD, Tbilisi, 0112, Georgia|LTD Saint Michael Archangel Multifunctional Clinical Hospital, Tbilisi, 0159, Georgia|Malkhaz Katsiashvili Multiprofile Emergency Medicine Center, Tbilisi, 0172, Georgia|LTD S.Khechinashvili University Hospital, Tbilisi, 0179, Georgia|LTD Aversi Clinic, Tbilisi, Georgia|Pineo Medical Ecosystem, Tbilisi, Georgia|Institute for Emergency Medicine, Department of Neurology, Chisinau, 2004, Moldova, Republic of|Institute for Emergency Medicine, Department of Neurology, Chisinau, 2028, Moldova, Republic of|National Institute of Neurology and Neurosurgery, Vascular Neurology Department, Chisinau, 2028, Moldova, Republic of|COPERNICUS Podmiot Leczniczy Sp. z o.o N. Copernicus Hospital, Department of Neurology, Gdansk, Pomerania, 80-803, Poland|Neuro-Medic, Katowice, 40-555, Poland|Neurology Center Krzysztof Selmaj, Lodz, 90-324, Poland|Provincial Specialist Hospital in Olsztyn, Department of Neurology, Olsztyn, 10-561, Poland|MED-Polonia, Sp. z o.o. (LLC), Poznan, Poland|NeuroProtect Medical Center, Warszawa, 01-684, Poland|Clinical Center of Serbia, Clinic of Neurology, Belgrade, 11000, Serbia|Clinical Hospital Center Zemun, Department of Neurology, Belgrade, 11080, Serbia|Clinical Center Kragujevac, Clinic of Neurology, Kragujevac, 34000, Serbia|Clinical Center of Vojvodina, Clinic of Neurology, Novi Sad, 21000, Serbia|Cherkasy Regional Hospital of Cherkasy Oblast Council, Cherkasy, Ukraine|Dnipropetrovsk I.I. Mechnykov Regional Clinical Hospital, Dnipro, Ukraine|Ivano-Frankivsk City Clinical Hospital #1, Ivano-Frankivs'k, Ukraine|Regional Clinical Hospital, Ivano-Frankivs'k, Ukraine|City Clinical Hospital #7, Kharkiv, Ukraine|Institute of Neurology, Psychiatry and Narcology, Kharkiv, Ukraine|Kharkiv Railway Clinical Hospital, Kharkiv, Ukraine|Kyiv City Clinical Hospital, Kyiv, Ukraine|Medical Center of First Private Clinic, Kyiv, Ukraine|National Research Center for Radiation Medicine, Kyiv, Ukraine|Communal Noncommercial Enterprise of Lviv Regional Council Lviv Regional Clinical Hospital, Lviv, Ukraine|Lviv City Clinical Hospital #5, Lviv, Ukraine|Center for Reconstructive and Restorative Medicine (University Clinic), Odesa, Ukraine|Sklifosovskyi Regional Clinical Hospital, Poltava, Ukraine|Ternopil Regional Clinical Psychonevrological Hospital, Ternopil', Ukraine|Vinnytsia O.I. Yushchenko Regional Psychoneurology Hospital, Vinnytsia, Ukraine|Clinical Hospital No. 9 under Zaporizhia City Council, Zaporizhia, Ukraine|City Clinical Hospital #2, Zaporizhzhya, Ukraine|Zaporizhia Regional Clinical Hospital, Zaporizhzhya, Ukraine|O.F. Herbachevskyi Regional Clinical Hospital, Zhytomyr, 10008, Ukraine"
NCT01225289,Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT01225289,COMPLETED,Relapsing Remitting Multiple Sclerosis,DIETARY_SUPPLEMENT: Vitamin A|DRUG: Placebo,Tehran University of Medical Sciences,,ALL,ADULT,PHASE4,36,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-10,2013-12,2014-01,"Tehran University of Medical Sciences, School of Public Health Tehran, Tehran, Iran, Islamic Republic o, Tehran, Iran, Islamic Republic of|Tehran University of Medical Sciences, School of Public Health, Tehran, Iran, Islamic Republic of"
NCT03360188,Pediatric Onset Multiple Sclerosis in Egyptians,https://beta.clinicaltrials.gov/study/NCT03360188,COMPLETED,Multiple Sclerosis in Children,,Cairo University,,ALL,"CHILD, ADULT",,237,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-06,2015-12,2015-12,
NCT05776888,Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years,https://beta.clinicaltrials.gov/study/NCT05776888,NOT_YET_RECRUITING,Relapsing Multiple Sclerosis,OTHER: Ofatumumab,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",,100,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-05-31,2026-08-31,2026-08-31,
NCT02753088,Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02753088,COMPLETED,Relapsing-remitting Multiple Sclerosis,DRUG: BCD-063|DRUG: Copaxone-Teva|DRUG: Placebo,Biocad,,ALL,ADULT,PHASE3,158,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2013-10,2015-11,2015-11,
NCT00235989,Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00235989,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting","DRUG: Interferon beta 1b (Betaseron, BAY86-5046)|DRUG: Interferon beta 1b (Betaseron, BAY86-5046)|DRUG: Interferon beta 1b (Betaseron, BAY86-5046)|DRUG: Interferon beta 1b (Betaseron, BAY86-5046)",Bayer,,ALL,ADULT,PHASE2,63,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2003-06,2008-01,2008-01,"Los Angeles, California, 90095-1721, United States|San Francisco, California, 94117, United States|Washington, District of Columbia, 20037, United States|Atlanta, Georgia, 30309-1465, United States|Chicago, Illinois, 60637, United States|Kansas City, Kansas, 66160, United States|Louisville, Kentucky, 40202, United States|Ann Arbor, Michigan, 48109-0022, United States|Ann Arbor, Michigan, 48109, United States|Reno, Nevada, 89509, United States|Stony Brook, New York, 11794, United States|Durham, North Carolina, 27710, United States|High Point, North Carolina, 27262, United States|Winston-Salem, North Carolina, 27157, United States|Columbus, Ohio, 43221, United States|Nashville, Tennessee, 37212, United States|Nashville, Tennessee, 37232, United States"
NCT02686788,TMP001 in Relapsing-remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02686788,COMPLETED,Remitting-Relapsing Multiple Sclerosis,DRUG: TMP001,Dr. Frank Behrens,SocraMetrics GmbH,ALL,ADULT,PHASE2,9,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-08,2018-04,2018-04,"UKT, Universitätsklinikum Tübingen, Tübingen, Baden-Würtemberg, 72076, Germany|Goethe-Universität Frankfurt am Main, Frankfurt am Main, Hessen, 60528, Germany|Universitätsklinikum Münster, Klinik für Allgemeine Neurologie, Münster, Nordrhein-Westfalen, 48149, Germany|Charite- Universitätsmedizin Berlin (Campus Mitte) NeuroCure Clinical Research Center NCRC AG Klinische Neuroimmunologie, Berlin, 10177, Germany|Universitätsklinikum Heidelberg Neurologische Klinik, Heidelberg, 69120, Germany"
NCT04942938,Impact of Direct Current Electrical Stimulation on Spasticity Levels and Functional Muscle Use in MS,https://beta.clinicaltrials.gov/study/NCT04942938,COMPLETED,Multiple Sclerosis,DEVICE: Neubie,Centura Health,NeuFit - Neurological Fitness and Education,ALL,"ADULT, OLDER_ADULT",NA,6,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-06-20,2022-07-05,2022-07-05,"Centura Health at Home, Littleton, Colorado, 80027, United States"
NCT01723631,Analyze the Myelin-TRAP as Diagnostic Tool in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01723631,TERMINATED,Multiple Sclerosis,DEVICE: Trap Myelin Test,Nantes University Hospital,"Institut National de la Santé Et de la Recherche Médicale, France",FEMALE,ADULT,NA,189,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2012-04,2014-12,2015-10,"University Hospital of Bordeaux, Bordeaux, France|Hopital neurologigue Pierre Wertheimer, Bron, France|University Hospital of clermont Ferrand, Clermont Ferrand, France|University Hospital of Lille, Lille, France|University Hospital of Marseille, Marseille, France|University Hospital of Montpellier, Montpellier, France|University Hospital of Nantes, Nantes, France|University Hospital of Nice, Nice, France|University Hospital of Rennes, Rennes, France|University Hospital of Strasbourg, Strasbourg, France|University Hospital of Toulouse, Toulouse, France"
NCT02792231,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.,https://beta.clinicaltrials.gov/study/NCT02792231,COMPLETED,Relapsing Multiple Scelrosis,DRUG: Ofatumumab subcutaneous injection|DRUG: Teriflunomide-matching placebo capsules|DRUG: Teriflunomide capsule|DRUG: Matching placebo of ofatumumab subcutaneous injections,Novartis Pharmaceuticals,,ALL,ADULT,PHASE3,955,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-08-26,2019-07-10,2020-10-22,"Novartis Investigative Site, Birmingham, Alabama, 35233-0271, United States|Novartis Investigative Site, Cullman, Alabama, 35058, United States|Novartis Investigative Site, Tucson, Arizona, 85704, United States|Novartis Investigative Site, Aurora, Colorado, 80045, United States|Novartis Investigative Site, Basalt, Colorado, 81621, United States|Novartis Investigative Site, Boulder, Colorado, 80301, United States|Novartis Investigative Site, Centennial, Colorado, 80112, United States|Novartis Investigative Site, Colorado Springs, Colorado, 80907, United States|Novartis Investigative Site, Denver, Colorado, 80210, United States|Novartis Investigative Site, Fort Collins, Colorado, 80528, United States|Novartis Investigative Site, Fort Collins, Colorado, 907-280528, United States|Novartis Investigative Site, Fairfield, Connecticut, 06824, United States|Novartis Investigative Site, Newark, Delaware, 19713, United States|Novartis Investigative Site, Bradenton, Florida, 34205, United States|Novartis Investigative Site, Gainesville, Florida, 32611, United States|Novartis Investigative Site, Maitland, Florida, 32751, United States|Novartis Investigative Site, Ocala, Florida, 34471, United States|Novartis Investigative Site, Oldsmar, Florida, 34677, United States|Novartis Investigative Site, Ormond Beach, Florida, 32174, United States|Novartis Investigative Site, Palm Coast, Florida, 32164, United States|Novartis Investigative Site, Saint Petersburg, Florida, 33713, United States|Novartis Investigative Site, Sarasota, Florida, 34243, United States|Novartis Investigative Site, Tallahassee, Florida, 32312, United States|Novartis Investigative Site, Tampa, Florida, 33603, United States|Novartis Investigative Site, Tampa, Florida, 33609, United States|Novartis Investigative Site, Tampa, Florida, 33612, United States|Novartis Investigative Site, Suwanee, Georgia, 30024, United States|Novartis Investigative Site, Anderson, Indiana, 46011, United States|Novartis Investigative Site, Indianapolis, Indiana, 46256, United States|Novartis Investigative Site, Wellesley, Massachusetts, 02481, United States|Novartis Investigative Site, Detroit, Michigan, 48202, United States|Novartis Investigative Site, Golden Valley, Minnesota, 55422, United States|Novartis Investigative Site, Billings, Montana, 59101, United States|Novartis Investigative Site, Great Falls, Montana, 59405, United States|Novartis Investigative Site, Albuquerque, New Mexico, 87131-0001, United States|Novartis Investigative Site, Asheville, North Carolina, 28806, United States|Novartis Investigative Site, Charlotte, North Carolina, 28202, United States|Novartis Investigative Site, Greensboro, North Carolina, 27405, United States|Novartis Investigative Site, Akron, Ohio, 44320, United States|Novartis Investigative Site, Columbus, Ohio, 43214, United States|Novartis Investigative Site, Columbus, Ohio, 43221, United States|Novartis Investigative Site, Westerville, Ohio, 43081, United States|Novartis Investigative Site, Portland, Oregon, 97225, United States|Novartis Investigative Site, Pittsburgh, Pennsylvania, 15212, United States|Novartis Investigative Site, Willow Grove, Pennsylvania, 19090, United States|Novartis Investigative Site, Greer, South Carolina, 29650, United States|Novartis Investigative Site, Cordova, Tennessee, 38018, United States|Novartis Investigative Site, Knoxville, Tennessee, 37922, United States|Novartis Investigative Site, Nashville, Tennessee, 37205, United States|Novartis Investigative Site, Greenville, Texas, 75401, United States|Novartis Investigative Site, Lubbock, Texas, 79410, United States|Novartis Investigative Site, Sherman, Texas, 75092, United States|Novartis Investigative Site, Orem, Utah, 84058, United States|Novartis Investigative Site, Salt Lake City, Utah, 84103, United States|Novartis Investigative Site, Salt Lake City, Utah, 84132, United States|Novartis Investigative Site, Kirkland, Washington, 98034, United States|Novartis Investigative Site, Seattle, Washington, 98122, United States|Novartis Investigative Site, Tacoma, Washington, 98405, United States|Novartis Investigative Site, Waukesha, Wisconsin, 53188, United States|Novartis Investigative Site, Caba, Buenos Aires, C1428AQK, Argentina|Novartis Investigative Site, Rosario, Santa Fe, S2000DSW, Argentina|Novartis Investigative Site, Tucuman, 4000, Argentina|Novartis Investigative Site, Liverpool, New South Wales, 2170, Australia|Novartis Investigative Site, Vienna, 1090, Austria|Novartis Investigative Site, Wien, 1010, Austria|Novartis Investigative Site, Edegem, Antwerpen, 2650, Belgium|Novartis Investigative Site, Aalst, 9300, Belgium|Novartis Investigative Site, Bruxelles, 1200, Belgium|Novartis Investigative Site, Gent, 9000, Belgium|Novartis Investigative Site, Sofia, 1113, Bulgaria|Novartis Investigative Site, Sofia, 1413, Bulgaria|Novartis Investigative Site, London, Ontario, N6A 5A5, Canada|Novartis Investigative Site, Ottawa, Ontario, K1H 8L6, Canada|Novartis Investigative Site, Toronto, Ontario, M4N 3M5, Canada|Novartis Investigative Site, Greenfield Park, Quebec, J4V 2J2, Canada|Novartis Investigative Site, Osijek, 31000, Croatia|Novartis Investigative Site, Zagreb, 10000, Croatia|Novartis Investigative Site, Brno, Czech Republic, 656 91, Czechia|Novartis Investigative Site, Havirov, Czech Republic, 736 01, Czechia|Novartis Investigative Site, Teplice, Czech Republic, 415 01, Czechia|Novartis Investigative Site, Ostrava-Poruba, 708 52, Czechia|Novartis Investigative Site, Praha 10, 100 34, Czechia|Novartis Investigative Site, Tampere, 33100, Finland|Novartis Investigative Site, Turku, 20520, Finland|Novartis Investigative Site, Nice, Cedex1, 06001, France|Novartis Investigative Site, Bordeaux Cedex, 33076, France|Novartis Investigative Site, Clermont-Ferrand, 63000, France|Novartis Investigative Site, Montpellier, 34295, France|Novartis Investigative Site, Paris Cedex 13, 75651, France|Novartis Investigative Site, Rennes Cedex, 35033, France|Novartis Investigative Site, Strasbourg, 67098, France|Novartis Investigative Site, Bochum, 44791, Germany|Novartis Investigative Site, Dresden, 01307, Germany|Novartis Investigative Site, Essen, 45147, Germany|Novartis Investigative Site, Hamburg, 22179, Germany|Novartis Investigative Site, Hannover, 30625, Germany|Novartis Investigative Site, Heidelberg, 69120, Germany|Novartis Investigative Site, Homburg, 66421, Germany|Novartis Investigative Site, Koln, 50935, Germany|Novartis Investigative Site, Leipzig, 04103, Germany|Novartis Investigative Site, Leipzig, 04107, Germany|Novartis Investigative Site, Minden, 32429, Germany|Novartis Investigative Site, Siegen, 57076, Germany|Novartis Investigative Site, Ulm, 89081, Germany|Novartis Investigative Site, Unterhaching, 82008, Germany|Novartis Investigative Site, Budapest, HUN, 1204, Hungary|Novartis Investigative Site, Esztergom, HUN, 2500, Hungary|Novartis Investigative Site, Hyderabad, Andhra Pradesh, 500018, India|Novartis Investigative Site, New Delhi, Delhi, 110 060, India|Novartis Investigative Site, Mumbai, Maharashtra, 400008, India|Novartis Investigative Site, Mumbai, Maharashtra, 400012, India|Novartis Investigative Site, Pune, Maharashtra, 411004, India|Novartis Investigative Site, Ludhiana, Punjab, 141008, India|Novartis Investigative Site, Mumbai, 400016, India|Novartis Investigative Site, Padova, PD, 35128, Italy|Novartis Investigative Site, Roma, RM, 00133, Italy|Novartis Investigative Site, Genova, 16132, Italy|Novartis Investigative Site, Milano, 20133, Italy|Novartis Investigative Site, Napoli, 80138, Italy|Novartis Investigative Site, Rome, 00178, Italy|Novartis Investigative Site, Riga, LV, LV-1005, Latvia|Novartis Investigative Site, Riga, LV 1002, Latvia|Novartis Investigative Site, Riga, LV-1038, Latvia|Novartis Investigative Site, Kaunas, LTU, LT 50161, Lithuania|Novartis Investigative Site, Vilnius, LT-08661, Lithuania|Novartis Investigative Site, Chihuahua, 31238, Mexico|Novartis Investigative Site, Drammen, 1086, Norway|Novartis Investigative Site, Cercado De Lima, Lima, 01, Peru|Novartis Investigative Site, San Isidro, Lima, 27, Peru|Novartis Investigative Site, Lima, LIMA 13, Peru|Novartis Investigative Site, Glogow, 36-060, Poland|Novartis Investigative Site, Rzeszow, 35 055, Poland|Novartis Investigative Site, Warszawa, 02 957, Poland|Novartis Investigative Site, Wroclaw, 51-685, Poland|Novartis Investigative Site, Zabrze, 41-800, Poland|Novartis Investigative Site, Matosinhos, Porto, 4454509, Portugal|Novartis Investigative Site, Amadora, 2720-276, Portugal|Novartis Investigative Site, Braga, 4710243, Portugal|Novartis Investigative Site, Coimbra, 3000-075, Portugal|Novartis Investigative Site, Lisboa, 1169-050, Portugal|Novartis Investigative Site, Lisboa, 1500 650, Portugal|Novartis Investigative Site, Lisboa, 1600190, Portugal|Novartis Investigative Site, Loures, 2674514, Portugal|Novartis Investigative Site, Porto, 4000001, Portugal|Novartis Investigative Site, Santa Maria da Feira, 4520 211, Portugal|Novartis Investigative Site, Ekaterinburg, 620109, Russian Federation|Novartis Investigative Site, Kazan, 420021, Russian Federation|Novartis Investigative Site, Krasnoyarsk, 660049, Russian Federation|Novartis Investigative Site, Moscow, 127015, Russian Federation|Novartis Investigative Site, Nizhny Novgorod, 603137, Russian Federation|Novartis Investigative Site, Novosibirsk, 630087, Russian Federation|Novartis Investigative Site, Saint Petersburg, 197022, Russian Federation|Novartis Investigative Site, St. Petersburg, 197110, Russian Federation|Novartis Investigative Site, St. Petersburg, 197376, Russian Federation|Novartis Investigative Site, Bratislava, 813 69, Slovakia|Novartis Investigative Site, Martin, 036 59, Slovakia|Novartis Investigative Site, Ruzomberok, 03426, Slovakia|Novartis Investigative Site, Pretoria, 0041, South Africa|Novartis Investigative Site, Rosebank, 2196, South Africa|Novartis Investigative Site, Malaga, Andalucia, 29010, Spain|Novartis Investigative Site, Sevilla, Andalucia, 41017, Spain|Novartis Investigative Site, Pozuelo de Alarcon, Madrid, 28223, Spain|Novartis Investigative Site, Baracaldo, Vizcaya, 48903, Spain|Novartis Investigative Site, Madrid, 28006, Spain|Novartis Investigative Site, Madrid, 28034, Spain|Novartis Investigative Site, Madrid, 28040, Spain|Novartis Investigative Site, Madrid, 28222, Spain|Novartis Investigative Site, San Sebastian, 20014, Spain|Novartis Investigative Site, Lugano, 6900, Switzerland|Novartis Investigative Site, Tainan, 70403, Taiwan|Novartis Investigative Site, Haseki / Istanbul, 34096, Turkey|Novartis Investigative Site, Izmir, 35340, Turkey|Novartis Investigative Site, Mersin, 33079, Turkey|Novartis Investigative Site, Trabzon, 61080, Turkey|Novartis Investigative Site, Luton, Beds, LU4 0DZ, United Kingdom|Novartis Investigative Site, Sheffield, South Yorkshire, S10 2JF, United Kingdom|Novartis Investigative Site, London, SE5 9RS, United Kingdom|Novartis Investigative Site, London, SW17 0QT, United Kingdom"
NCT04565431,Examining Effects of Tysabri on Cognitive Fatigue Using fMRI,https://beta.clinicaltrials.gov/study/NCT04565431,RECRUITING,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Tysabri,Kessler Foundation,St. Barnabas Medical Center,ALL,ADULT,,25,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-03-19,2023-07,2023-07,"Kessler Foundation, West Orange, New Jersey, 07052, United States"
NCT05335031,"A Study Investigating the Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany for Participants With Relapsing-remitting Multiple Sclerosis Treated With Ozanimod (Zeposia®)",https://beta.clinicaltrials.gov/study/NCT05335031,RECRUITING,"Multiple Sclerosis, Relapsing-Remitting",,Bristol-Myers Squibb,,ALL,"ADULT, OLDER_ADULT",,1300,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-03-03,2029-03-31,2029-11-30,"Universitätsklinikum Dresden, MS Ambulanz, Dresden, Saxony, 01307, Germany"
NCT00097331,Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00097331,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: SB683699,GlaxoSmithKline,,ALL,"ADULT, OLDER_ADULT",PHASE2,261,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,2004-09,2006-07,2006-07,"GSK Investigational Site, Bruxelles, 1200, Belgium|GSK Investigational Site, Fraiture en Condroz, 4557, Belgium|GSK Investigational Site, Hamburg, 20099, Germany|GSK Investigational Site, Hamburg, 22087, Germany|GSK Investigational Site, Polanki 117, 80-308, Poland|GSK Investigational Site, Poznan, 60-479, Poland|GSK Investigational Site, Warszawa, 02-957, Poland|GSK Investigational Site, Moscow, 117049, Russian Federation|GSK Investigational Site, Moscow, 125367, Russian Federation|GSK Investigational Site, St. Petersburg, 197022, Russian Federation|GSK Investigational Site, Malaga, 29010, Spain"
NCT02421731,Robot-assisted Gait Training on Mobility in Severely Disabled Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT02421731,COMPLETED,Multiple Sclerosis,DEVICE: Robot-assisted gait training|OTHER: Conventional therapy,University Hospital of Ferrara,Regione Emilia-Romagna|Università degli Studi di Ferrara,ALL,"ADULT, OLDER_ADULT",NA,72,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2014-02,2018-02,2018-02,"Ferrara University Hospital, Ferrara, Italy"
NCT01802931,GSK239512 DDI Study,https://beta.clinicaltrials.gov/study/NCT01802931,COMPLETED,Multiple Sclerosis,DRUG: GSK239512|DRUG: ketoconazole,GlaxoSmithKline,,MALE,ADULT,PHASE1,22,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2013-01-07,2013-04-15,2013-04-15,"GSK Investigational Site, Randwick, New South Wales, 2031, Australia"
NCT02087631,Safety and Tolerability of Quetiapine in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02087631,COMPLETED,Multiple Sclerosis,DRUG: Extended-release quetiapine fumarate,University of Calgary,Multiple Sclerosis Society of Canada,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,14,OTHER,INTERVENTIONAL,Allocation: |Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2014-12,2019-07,2019-07,"MS Clinic, Foothills Medical Centre, Calgary, Alberta, T2N 2T9, Canada"
NCT02454465,Evaluation of an Acceptance and Commitment Therapy Group for Adjustment Difficulties in Neurological Conditions,https://beta.clinicaltrials.gov/study/NCT02454465,COMPLETED,Brain Injuries|Multiple Sclerosis|Parkinson Disease|Stroke,OTHER: Acceptance and Commitment Therapy group,University of Hertfordshire,,ALL,"ADULT, OLDER_ADULT",NA,26,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2015-07,2016-02,2016-09,"Jacketts Field, Abbots Langley, WD50PA, United Kingdom"
NCT02889965,The French Multiple Sclerosis Registry,https://beta.clinicaltrials.gov/study/NCT02889965,UNKNOWN,Multiple Sclerosis|Neuromyelitis Optica Spectrum Disorders,,Hospices Civils de Lyon,,ALL,"CHILD, ADULT, OLDER_ADULT",,54000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-01,2019-12,2019-12,"Hospices Civils de Lyon / Hopital Neurologique Pierre Wertheimer, Bron, 69500, France"
NCT04468165,"Effectiveness and Safety of Generic Delayed-Release Dimethyl Fumarate (Sclera® or Marovarex ®, Hikma) in Routine Medical Practice in the Treatment of Relapsing-Remitting Multiple Sclerosis in MENA Region",https://beta.clinicaltrials.gov/study/NCT04468165,ACTIVE_NOT_RECRUITING,Relapsing Remitting Multiple Sclerosis,DRUG: Dimethyl Fumarate (DMF),Hikma Pharmaceuticals LLC,,ALL,"ADULT, OLDER_ADULT",,155,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-02-23,2023-07,2023-07,"CHU Frantz FANON, Blida, Algeria|Nedir Mohamed Hospital, Tizi Ouzou, Algeria|New University Hospital, Alexandria, Egypt|Demerdash hospital (Ain Shams University), Cairo, Egypt|Private Clinic, Cairo, Egypt|King Abdullah University Hospital (KAUH), Ar Ramtha, Jordan"
NCT00475865,Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00475865,COMPLETED,Multiple Sclerosis,DRUG: Teriflunomide|DRUG: Placebo (for teriflunomide)|DRUG: Glatiramer Acetate (GA),Sanofi,,ALL,ADULT,PHASE2,123,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2007-04,2009-10,2009-10,"Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, 08807, United States|Sanofi-Aventis Administrative Office, Vienna, Austria|Sanofi-Aventis Administrative Office, Laval, Canada|Sanofi-Aventis Administrative Office, Berlin, Germany|Sanofi-Aventis Administrative Office, Milan, Italy|Sanofi-Aventis Administrative Office, Guildford, United Kingdom"
NCT02330965,Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02330965,COMPLETED,Secondary Progressive Multiple Sclerosis,PROCEDURE: Blood Draw|PROCEDURE: CSF collection by lumbar puncture (Optional),National Institute of Allergy and Infectious Diseases (NIAID),Autoimmunity Centers of Excellence|Novartis Pharmaceuticals,ALL,ADULT,,36,NIH,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-12,2017-07-12,2017-07-12,"Jordan Research & Education Institute: Sutter Alta Bates Summit, Berkeley, California, 94705, United States|University of Southern California, Los Angeles, California, 90033, United States|University of California, Davis, Sacramento, California, 95817, United States|University of Colorado, Aurora, Colorado, 80045, United States|University of Michigan Health System -Multiple Sclerosis Center, Ann Arbor, Michigan, 48109, United States|Henry Ford Health System, Detroit, Michigan, 48202, United States|Minneapolis Clinic of Neurology, Golden Valley, Minnesota, 55422, United States|University of New Mexico: Health Sciences Center, Albuquerque, New Mexico, 87131, United States|South Shore Neurologic Associates - Multiple Sclerosis Care Center, Patchogue, New York, 11772, United States|Carolinas Medical Center (CMC), Charlotte, North Carolina, 28207, United States|Cleveland Clinic: Mellen Center for Multiple Sclerosis, Cleveland, Ohio, 44195, United States|Providence Multiple Sclerosis Center, Portland, Oregon, 97225, United States|Swedish Neuroscience Institute, Seattle, Washington, 98122, United States"
NCT05393765,The Effect of an Interactive Web-based Program in the Management of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05393765,RECRUITING,Multiple Sclerosis,BEHAVIORAL: Yönetebilirim,Selcuk University,,ALL,"ADULT, OLDER_ADULT",NA,76,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2022-06-13,2022-09-01,2023-06-01,"Selcuk University, Selçuklu, Konya, Turkey"
NCT04940065,Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen,https://beta.clinicaltrials.gov/study/NCT04940065,ACTIVE_NOT_RECRUITING,Relapsing-remitting Multiple Sclerosis|Active Secondary Progressive Multiple Sclerosis,OTHER: Kesimpta,Novartis Pharmaceuticals,,ALL,"CHILD, ADULT, OLDER_ADULT",,331,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-06-30,2026-07-31,2026-07-31,"Novartis Investigative Site, Ichinomiya, Aichi, 491-0041, Japan|Novartis Investigative Site, Nagakute-city, Aichi, 480-1195, Japan|Novartis Investigative Site, Nagoya-city, Aichi, 467-8602, Japan|Novartis Investigative Site, Nagoya, Aichi, 453-0815, Japan|Novartis Investigative Site, Nagoya, Aichi, 457 8510, Japan|Novartis Investigative Site, Tokoname, Aichi, 479-0868, Japan|Novartis Investigative Site, Toyohashi, Aichi, 441-8570, Japan|Novartis Investigative Site, Hachinohe, Aomori, 031-0011, Japan|Novartis Investigative Site, Hachinohe, Aomori, 039-1104, Japan|Novartis Investigative Site, Hirosaki, Aomori, 036 8563, Japan|Novartis Investigative Site, Ichikawa, Chiba, 272-8513, Japan|Novartis Investigative Site, Narita, Chiba, 286-8523, Japan|Novartis Investigative Site, Yachiyo-city, Chiba, 276-8524, Japan|Novartis Investigative Site, Toon-city, Ehime, 791-0295, Japan|Novartis Investigative Site, Fukuoka city, Fukuoka, 812-8582, Japan|Novartis Investigative Site, Fukuoka-city, Fukuoka, 810-0001, Japan|Novartis Investigative Site, Iizuka-city, Fukuoka, 820-8505, Japan|Novartis Investigative Site, Kitakyushu-city, Fukuoka, 802-8555, Japan|Novartis Investigative Site, Kurume city, Fukuoka, 830-0011, Japan|Novartis Investigative Site, Omuta, Fukuoka, 836-8566, Japan|Novartis Investigative Site, Gifu-city, Gifu, 501-1194, Japan|Novartis Investigative Site, Maebashi city, Gunma, 371 8511, Japan|Novartis Investigative Site, Maebashi, Gunma, 371-0847, Japan|Novartis Investigative Site, Fukuyama, Hiroshima, 720-0825, Japan|Novartis Investigative Site, Hiroshima-city, Hiroshima, 734-8530, Japan|Novartis Investigative Site, Asahikawa, Hokkaido, 070-8530, Japan|Novartis Investigative Site, Hakodate, Hokkaido, 041-0821, Japan|Novartis Investigative Site, Sapporo city, Hokkaido, 060 8648, Japan|Novartis Investigative Site, Sapporo city, Hokkaido, 063-0005, Japan|Novartis Investigative Site, Sapporo-city, Hokkaido, 060-8543, Japan|Novartis Investigative Site, Sapporo, Hokkaido, 065-0021, Japan|Novartis Investigative Site, Sunagawa, Hokkaido, 073-0196, Japan|Novartis Investigative Site, Kobe-city, Hyogo, 650-0047, Japan|Novartis Investigative Site, Kobe-shi, Hyogo, 650-0017, Japan|Novartis Investigative Site, Mito-city, Ibaraki, 310-0011, Japan|Novartis Investigative Site, Tsuchiura, Ibaraki, 300-0028, Japan|Novartis Investigative Site, Ichinoseki, Iwate, 021-0871, Japan|Novartis Investigative Site, Ichinoseki, Iwate, 029-0192, Japan|Novartis Investigative Site, Morioka, Iwate, 020-8505, Japan|Novartis Investigative Site, Kagoshima city, Kagoshima, 890 8520, Japan|Novartis Investigative Site, Kanoya, Kagoshima, 893-0023, Japan|Novartis Investigative Site, Kawasaki-city, Kanagawa, 216-8511, Japan|Novartis Investigative Site, Sagamihara-city, Kanagawa, 252-0375, Japan|Novartis Investigative Site, Yokohama city, Kanagawa, 232 0024, Japan|Novartis Investigative Site, Yokohama-city, Kanagawa, 227-8501, Japan|Novartis Investigative Site, Yokohama-city, Kanagawa, 236-0004, Japan|Novartis Investigative Site, Yokohama, Kanagawa, 247-8581, Japan|Novartis Investigative Site, Nankoku city, Kochi, 783 8505, Japan|Novartis Investigative Site, Kyoto-city, Kyoto, 600-8558, Japan|Novartis Investigative Site, Kyoto-city, Kyoto, 602-8566, Japan|Novartis Investigative Site, Kyoto-city, Kyoto, 616-8255, Japan|Novartis Investigative Site, Kesennuma, Miyagi, 988-0085, Japan|Novartis Investigative Site, Sendai city, Miyagi, 980 8574, Japan|Novartis Investigative Site, Sendai city, Miyagi, 983 8512, Japan|Novartis Investigative Site, Nagano-city, Nagano, 380-8582, Japan|Novartis Investigative Site, Nagano-city, Nagano, 381-8551, Japan|Novartis Investigative Site, Sasebo-city, Nagasaki, 857-1165, Japan|Novartis Investigative Site, Kashihara city, Nara, 634 8522, Japan|Novartis Investigative Site, Tenri, Nara, 632-8552, Japan|Novartis Investigative Site, Niigata-city, Niigata, 950-1197, Japan|Novartis Investigative Site, Kurashiki-city, Okayama, 710-0826, Japan|Novartis Investigative Site, Okayama-city, Okayama, 700-8558, Japan|Novartis Investigative Site, Fujiidera, Osaka, 583-0014, Japan|Novartis Investigative Site, Moriguchi, Osaka, 570-8507, Japan|Novartis Investigative Site, Osaka Sayama, Osaka, 589 8511, Japan|Novartis Investigative Site, Osaka-city, Osaka, 530-8480, Japan|Novartis Investigative Site, Osaka-city, Osaka, 543-8555, Japan|Novartis Investigative Site, Osaka-city, Osaka, 558-8558, Japan|Novartis Investigative Site, Sakai, Osaka, 592-8555, Japan|Novartis Investigative Site, Suita, Osaka, 565 0871, Japan|Novartis Investigative Site, Kawagoe, Saitama, 350 8550, Japan|Novartis Investigative Site, Koshigaya-city, Saitama, 343-8555, Japan|Novartis Investigative Site, Wako-city, Saitama, 351-0102, Japan|Novartis Investigative Site, Ohtsu-city, Shiga, 520-2192, Japan|Novartis Investigative Site, Omihachiman, Shiga, 523-0082, Japan|Novartis Investigative Site, Izumo-city, Shimane, 693 8501, Japan|Novartis Investigative Site, Hamamatsu-city, Shizuoka, 431-3192, Japan|Novartis Investigative Site, Oyama, Tochigi, 323-0827, Japan|Novartis Investigative Site, Shimotsuga Gun, Tochigi, 321-0293, Japan|Novartis Investigative Site, Shimotsuke, Tochigi, 329-0403, Japan|Novartis Investigative Site, Bunkyo ku, Tokyo, 113 8655, Japan|Novartis Investigative Site, Bunkyo ku, Tokyo, 113-8431, Japan|Novartis Investigative Site, Edogawa, Tokyo, 134-0086, Japan|Novartis Investigative Site, Fuchu, Tokyo, 183-0042, Japan|Novartis Investigative Site, Kiyose-city, Tokyo, 204-8585, Japan|Novartis Investigative Site, Minato-ku, Tokyo, 105-8471, Japan|Novartis Investigative Site, Nakano, Tokyo, 164-8607, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, 160 8582, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, 160-0023, Japan|Novartis Investigative Site, Toyama-city, Toyama, 930-0194, Japan|Novartis Investigative Site, Wakayama-city, Wakayama, 641-8510, Japan|Novartis Investigative Site, Kudamatsu, Yamaguchi, 744-0075, Japan|Novartis Investigative Site, Shunan-city, Yamaguchi, 745-8522, Japan|Novartis Investigative Site, Ube, Yamaguchi, 755-8505, Japan|Novartis Investigative Site, Aomori, 030 8553, Japan|Novartis Investigative Site, Chiba, 260 8677, Japan|Novartis Investigative Site, Kagoshima, 890-8760, Japan|Novartis Investigative Site, Kyoto, 606 8507, Japan|Novartis Investigative Site, Niigata, 951 8520, Japan|Novartis Investigative Site, Oita, 870-8511, Japan|Novartis Investigative Site, Osaka, 545-8586, Japan|Novartis Investigative Site, Osaka, 556-0015, Japan|Novartis Investigative Site, Saitama, 330-8553, Japan"
NCT02592265,Measuring Consequences of Disability for Patients With Multiple Sclerosis and Caregivers on Economic Burden,https://beta.clinicaltrials.gov/study/NCT02592265,COMPLETED,Multiple Sclerosis|Physical Disability|Economic Burden|Social Interaction|Capability|Quality of Life,,Lille Catholic University,"Université de Lille|Région Nord-Pas de Calais, France|La Ligue Française Contre la Sclérose en Plaques|Novartis",ALL,"ADULT, OLDER_ADULT",,233,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-10,2015-08,2016-06,
NCT03355365,Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03355365,COMPLETED,Multiple Sclerosis,BIOLOGICAL: Intrathecal MSC-NP injection|OTHER: Intrathecal saline injection,Tisch Multiple Sclerosis Research Center of New York,,ALL,"ADULT, OLDER_ADULT",PHASE2,54,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-09-21,2023-02-09,2023-04-17,"Tisch MS Research Center of New York, New York, New York, 10019, United States"
NCT02575365,Effect of Fingolimod on Neurodegeneration,https://beta.clinicaltrials.gov/study/NCT02575365,TERMINATED,Cognition|Brain Volume Loss,"DRUG: 0,5 mg Fingolimod",Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE4,4,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-02-16,2017-01-27,2017-01-27,"Novartis Investigative Site, Bursa, 16059, Turkey|Novartis Investigative Site, Kocaeli, 41380, Turkey|Novartis Investigative Site, Kutahya, 43000, Turkey"
NCT01354665,Depression and Fatigue in MS Patients Treated With Betaferon.,https://beta.clinicaltrials.gov/study/NCT01354665,COMPLETED,Multiple Sclerosis,"BIOLOGICAL: Interferon beta-1b (Betaferon, BAY86-5046)",Bayer,,ALL,"ADULT, OLDER_ADULT",,567,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-05,2013-06,2013-06,"Many Locations, Poland"
NCT04429789,Waking Hypnosis in the Treatment of MS-related Fatigue,https://beta.clinicaltrials.gov/study/NCT04429789,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Active-Alert Hypnosis|BEHAVIORAL: Traditional Hypnosis,University of Washington,National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",NA,32,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-05-27,2021-03-31,2021-03-31,"University of Washington, Seattle, Washington, 98104, United States"
NCT02614989,MRI Guided Focused Ultrasound for Tremor in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02614989,UNKNOWN,Multiple Sclerosis,PROCEDURE: MRI guided focused ultrasound thalamotomy,Rambam Health Care Campus,,ALL,"ADULT, OLDER_ADULT",NA,15,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-01,2017-12,2018-12,
NCT02468765,Depression and Facial Identity Recognition Abilities in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02468765,UNKNOWN,Multiple Sclerosis|Depression,OTHER: Neuropsychological and emotional evaluation with monitoring,Lille Catholic University,,ALL,ADULT,,90,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-05,2016-12,2017-04,"Hôpital Saint Vincent de Paul (GHICL), Lille, Nord Pas De Calais, 59000, France"
NCT04410965,Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 Weeks,https://beta.clinicaltrials.gov/study/NCT04410965,COMPLETED,Multiple Sclerosis,DRUG: TERIFLUNOMIDE,Sanofi,,ALL,ADULT,PHASE4,82,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-05-20,2021-07-12,2021-07-12,"Investigational Site Number, China, China"
NCT04969562,"The Effect of Emotional Freedom Technique on Depression, Anxiety and Distress of Individuals With Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT04969562,COMPLETED,Multiple Sclerosis|Anxiety|Depressive Symptoms|Psychiatric Nursing,BEHAVIORAL: Emotional Freedom Technique,Dokuz Eylul University,,ALL,"ADULT, OLDER_ADULT",NA,36,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2020-08-01,2021-10-30,2021-10-30,"Dokuz Eylul University, Izmir, Turkey"
NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),https://beta.clinicaltrials.gov/study/NCT03085810,ACTIVE_NOT_RECRUITING,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Ocrelizumab,Hoffmann-La Roche,,ALL,ADULT,PHASE3,1239,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2017-03-24,2024-08-15,2024-08-15,"University of California Irvine, Irvine, California, 92697, United States|Palo Alto Medical Foundation Research Center, Sunnyvale, California, 94086, United States|University of Colorado Denver, Aurora, Colorado, 80045, United States|Advanced Neurology of Colorado, LLC, Fort Collins, Colorado, 80528, United States|KI Health Partners, LLC; New England Institute for Clinical Research, Stamford, Connecticut, 06905, United States|Georgetown University Medical Center, Washington, District of Columbia, 20007, United States|University of South Florida - Bradenton, Tampa, Florida, 33612, United States|Shepherd Center Inc., Atlanta, Georgia, 30309, United States|College Park Family Care Ctr, Overland Park, Kansas, 66212, United States|The NeuroMedical Center, Baton Rouge, Louisiana, 70810, United States|Maine Medical Center, Scarborough, Maine, 04074, United States|University of Maryland Medical Center; Department of Neurology, Baltimore, Maryland, 21201, United States|Neurology Center of New England, Foxboro, Massachusetts, 02035, United States|Dragonfly Research, LLC, Wellesley, Massachusetts, 02481, United States|Minneapolis Clinic of Neurology, Golden Valley, Minnesota, 55422, United States|Cleveland Clinic Lou Ruvo; Center for Brain Research, Las Vegas, Nevada, 89106, United States|Columbia University Medical Center, New York, New York, 10032, United States|Island Neurological Associates, P.C., Plainview, New York, 11803, United States|Neurology Associates PA, Hickory, North Carolina, 28602, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, 27157, United States|Cleveland Clinic Foundation; Cleveland Clinic Cancer Center/I40, Cleveland, Ohio, 44195, United States|Neurology Specialists, Inc, Dayton, Ohio, 45417, United States|Vanderbilt University Medical Center, Nashville, Tennessee, 37212, United States|Kane Hall Barry Neurology, Bedford, Texas, 76021, United States|MultiCare Health System Institute for Research and Innovation, Tacoma, Washington, 98405, United States|Wheaton Franciscan Healthcare - St. Francis Outpatient Center; Center for Neurological Disorders, Milwaukee, Wisconsin, 53215, United States|Centro de Especialidades Neurológicas y Rehabilitación - CENyR, Buenos Aires, C1424, Argentina|Hospital Churruca Visca, Buenos Aires, C1437JCP, Argentina|Fundacion Rosarina de Neurorehabilitacion, Rosario, S2000BZL, Argentina|Brain and Mind Centre, Camperdown, New South Wales, 2050, Australia|Liverpool Hospital, Liverpool, New South Wales, 2170, Australia|John Hunter Hospital, New Lambton, New South Wales, 2305, Australia|Royal North Shore Hospital; Department of Neurology, St Leonards, New South Wales, 2065, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, 4102, Australia|Box Hill Hospital; Department of Neurology, Box Hill, Victoria, 3128, Australia|Austin Hospital; Department of Neurology, Heidelberg, Victoria, 3084, Australia|Royal Melbourne Hospital; Department of Neurology, Parkville, Victoria, 3050, Australia|Perron Institute for Neurological and Translational Science, Nedlands, Western Australia, 6009, Australia|Medizinische Universität Graz; Universitätsklinik für Neurologie, Graz, 8036, Austria|Uniklinik fuer Neurologie, Medizinische Universitaet Innsbruck; Department fuer Neurologie, Innsbruck, 6020, Austria|Christian-Doppler-Klinik - Universitätsklinikum; Universitätskliniik für Neurologie, Salzburg, 5020, Austria|Medizinische Universität Wien; Univ.Klinik fuer Neurologie, Wien, 1090, Austria|AZ Sint Jan, Brugge, 8000, Belgium|UZ Brussel, Brussel, 1090, Belgium|Cliniques Universitaires St-Luc, Bruxelles, 1200, Belgium|UZ Antwerpen, Edegem, 2650, Belgium|CHU Tivoli, La Louvière, 7100, Belgium|CHU Sart-Tilman, Liège, 4000, Belgium|Revalidatie en MS Centrum, Overpelt, 3900, Belgium|Hospital das Clinicas - UFMG, Belo Horizonte, MG, 31270-901, Brazil|Instituto de Neurologia de Curitiba, Curitiba, PR, 81210-310, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, 90610-000, Brazil|Hospital das Clinicas - FMUSP, Sao Paulo, SP, 05403-900, Brazil|Shat Np Sveti Naum; 3Rd Clinic of Neurology, Sofia, 1113, Bulgaria|Multiprofile Hosp. for Active Treatment;National Cardiology Hosp., Sofia, 1309, Bulgaria|UMHAT Alexandrovska, EAD; Neurology, Sofia, 1431, Bulgaria|UBC Hospital; Div of Neurology, Dept of Medicine, Vancouver, British Columbia, V6T 1Z3, Canada|London Health Sciences Centre Uni Campus, London, Ontario, N6A 5A5, Canada|Ottawa Hospital Research Institute, Ottawa, Ontario, K1Y 4E9, Canada|Sunnybrook Health Science Centre, Toronto, Ontario, M4N 3M5, Canada|Clinique NeuroOutaouais, Gatineau, Quebec, J8Y 1W2, Canada|Recherche Sepmus Inc., Greenfield Park, Quebec, J4V 2J2, Canada|Montreal Neurological Institute and Hospital, Montreal, Quebec, H3A 2B4, Canada|Clinical Hospital Centre Zagreb, Zagreb, 10000, Croatia|Aalborg Universitetshospital; Neurologisk Afdeling og Neurofysiologisk Afdeling; Skleroseamb., Aalborg, 9000, Denmark|Aarhus Universitetshospital; Neurologisk Afd. F, Skleroseklinikken, Aarhus N, 8200, Denmark|Rigshospitalet; Neurologisk Klinik Glostrup, Glostrup, 2600, Denmark|CHU de Besancon Hopital Jean Minjoz; Service de Neurologie, Besançon, 25030, France|Hopital Pellegrin-CHU de Bordeaux; Service de Neurologie, Bordeaux, 33076, France|Hopital Pierre Wertheimer; Neurologie D, Bron, 69677, France|CHU de Caen Hopital Cote de Nacre, Caen, 14033, France|CHU Hopital Gabriel Montpied; Service de Neurologie, Clermont Ferrand, 63003, France|CH de Gonesse; Neurologie, Gonesse, 95503, France|CHU de Grenoble; Neurologie, La Tronche, 38700, France|Hopital Gui de Chauliac; Neurologie, Montpellier, 34295, France|Hopital Central - CHU de Nancy; Service de Neurologie, Nancy, 54035, France|Hôpital Guillaume et René Laënnec; Service Neurologie, Nantes, 44805, France|Hôpital Pasteur; Service de Neurologie, Nice, 06002, France|CHU de Nîmes Hopital Caremeau; Service de Neurologie, Nimes, 30900, France|Hôpital de Poissy; Service neurologie, Poissy, 78300, France|Centre Hospitalier Universitaire de Rennes, Rennes, 35033, France|CHU de Rouen Hopital; Service de Neurologie, Rouen, 76031, France|CHU de Strasbourg, Strasbourg, 67098, France|Hopital Foch; Neurologie, Suresnes, 92151, France|HIA de Toulon hôpital militaire; Neurologie, Toulon, 83041, France|CHU toulouse - Hôpital Purpan; Departement de Neurologie, Toulouse, 31059, France|CHRU - Hôpital Bretonneau; Neurologie, Tours, 37000, France|Praxis Dr.med. Sylvia Menck, Fachärztin für Neurologie und Psychiatrie, Barsinghausen, 30890, Germany|Jüdisches Krankenhaus Berlin; Abteilung fur Neurologie, Berlin, 13347, Germany|St. Josef-Hospital, Klinik für Neurologie, Bochum, 44791, Germany|Studienzentrum für Neurologie und Psychiatrie, Böblingen, 71034, Germany|Universitätsklinikum ""Carl Gustav Carus"", Zentrum für Klinische Neurowissenschaften, Dresden, 01307, Germany|Universitätsklinikum Düsseldorf; Klinik für Neurologie, Düsseldorf, 40225, Germany|NeuroCentrum Odenwald; Dres. Reifschneider, Unsorg, Ries, Schumann, Hoffmann, Knoblich, Erbach/Odenwald, 64711, Germany|Universitätsklinikum Essen (AöR); Klinik für Neurologie, Essen, 45147, Germany|MultipEL Studies - Institut für klinische Studien, Hamburg, 22179, Germany|Universitaetsklinikum Heidelberg, Heidelberg, 69120, Germany|Neurologische Gemeinschaftspraxis Kassel und Vellmar, Ch. Lassek, Dres. Ammerbach, Fetzer, M. Fische, Kassel, 34121, Germany|Uniklinik Schleswig-Holstein; Neuroimmunologie, Institut für Klinische Chemie + Klinik f. Neurologie, Kiel, 24105, Germany|Universitaetsklinikum Marburg; Klinik fuer Neurologie, Marburg, 35043, Germany|Klinikum rechts der Isar der TU Muenchen; Neurologische Klinik und Poliklinik im Neuro-Kopf-Zentrum, München, 81675, Germany|Universitätsklinikum Münster; Klinik und Poliklinik für Neurologie, Münster, 48149, Germany|Praxis Dr. med. Bergmann, Neuburg, 86633, Germany|Asklepios Kliniken Schildautal Seesen; Klinik für Neurologie, Seesen, 38723, Germany|Universitätsklinikum Tübingen, Zentrum für Neurologie, Tübingen, 72076, Germany|Semmelweis Egyetem AOK; Neurologiai Klinika, Budapest, 1083, Hungary|Uzsoki Utcai Korhaz, Budapest, 1145, Hungary|Jahn Ferenc Dél-Pesti Kórház, Budapest, 1204, Hungary|VALEOMED Diagnosztikai Központ, Esztergom, 2500, Hungary|Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ; Neurológiai Klinika, Szeged, 6725, Hungary|A.O.U. Mater Domin; U.O. NEUROLOGIA, Catanzaro, Calabria, 88100, Italy|A. O. U. Federico II; Dip Neuroscienze, Scienze Riproduttive ed Odontostomatologiche, Napoli, Campania, 80131, Italy|Università degli Studi della Campania Luigi Vanvitelli; Dip. Ass. Integrato Med Int-II Clinica Neur, Napoli, Campania, 80131, Italy|Ospedale Cattinara; Amb Studio Sclerosi Multipla, Clinica Neurlogica, Trieste, Friuli-Venezia Giulia, 34149, Italy|Policlinico Tor Vergata Dip. Neuroscienze-Clinica Neurologica-UOSD Sclerosi Multipla, Roma, Lazio, 00133, Italy|Azienda Ospedaliera Sant'Andrea; UOC Neurologia, Roma, Lazio, 00189, Italy|Irccs A.O.U.San Martino Ist; Dinogmi, Genova, Liguria, 16132, Italy|IRCCS Ospedale San Raffaele; Neurologia Neurofisiologia Neuroriabilitazione-Centro Sclerosi Multipla, Milano, Lombardia, 20132, Italy|Fond. Istituto Neurologico C.Besta; UO Neurologia IV - Neuroimmunologia Malattie Neuromuscolari, Milano, Lombardia, 20133, Italy|Ospedale Civile di Montichiari; Centro Sclerosi Multipla, Montichiari, Lombardia, 25018, Italy|IRCCS Istituto Neurologico Neuromed; Centro per lo Studio e la Cura della Sclerosi Multipla, Pozzilli, Molise, 86077, Italy|AOU Policlinico V. Emanuele - P.O G. Rodolico; Clinica Neurologica, Centro Sclerosi Multipla, Catania, Sicilia, 95123, Italy|AO Ospedali Riuniti Villa Sofia-Cervello;PO Villa Sofia - UO Neurologia - U.O.S. Neuroimmunologia, Palermo, Sicilia, 90146, Italy|AOU Careggi; Neurologia 1-Dip. Neuroscienze Psicologia Area Farmaco Salute del Bambino(NEUROFARBA), Firenze, Toscana, 50134, Italy|Ospedale Misericordia USL9 di Grosseto; U.O. Neurologia, Grosseto, Toscana, 58100, Italy|Ospedale Le Scotte; Clinica Neurologica e Malattie Neurometaboliche, Siena, Toscana, 53100, Italy|Ibn Sina Hospital; Neurology Department, Kuwait, 10002, Kuwait|American University of Beirut - Medical Center, Beirut, 1107 2020, Lebanon|Neurociencias Estudios Clinicos S.C., Culiacán, Sinaloa, 80020, Mexico|Hospital General de Mexico, Mexico, Tlaxcala, 06726, Mexico|Unidad de investigacion en salud (UIS); Neurociencias, Ciudad de México, 14050, Mexico|Jeroen Bosch Ziekenhuis, 'S Hertogenbosch, 5223 GZ, Netherlands|VU Medisch Centrum; Afdeling Neurologie, Amsterdam, 1081 HV, Netherlands|Groene Hart Ziekenhuis, Gouda, 2803 HH, Netherlands|Zuyderland Medisch Centrum - Sittard Geleen, Sittard-Geleen, 6162 BG, Netherlands|Akershus universitetssykehus HF; Nevroklinikken S203, Lørenskog, 1478, Norway|Stavanger Universitetssykehus, Helse Stavanger HF, Stavanger, 4011, Norway|Neurocentrum Bydgoszcz sp. z o.o, Bydgoszcz, 85-796, Poland|COPERNICUS Podmiot Leczniczy Sp. z o. o. Szpital im. M. Kopernika; Oddzia? Neurologiczny, Gdansk, 80-803, Poland|Care Clinic, Katowice, 40-568, Poland|Malopolskie Centrum Diagnostyczne MEDICAL Sp. z o. o., Krakow, 31-637, Poland|Centrum Neurologii Krzysztof Selmaj, Lodz, 90-324, Poland|Indywidualna Praktyka Lekarska Prof. Dr Hab. N. Med. Konrad Rejdak., Lublin, 20-016, Poland|Klinika Neurologii I Wydzialu Lekarskiego WUM w Warszawie, Warszawa, 02-097, Poland|Instytut Psychiatrii i Neurologii II Klinika Neurologiczna, Warszawa, 02-957, Poland|Hospital Garcia de Orta; Servico de Neurologia, Almada, 2801-951, Portugal|Hospital de Braga; Servico de Neurologia, Braga, 4710-243, Portugal|HUC; Servico de Neurologia, Coimbra, 3000-075, Portugal|Hospital Beatriz Angelo; Servico de Neurologia, Loures, 2674-514, Portugal|Hospital Geral de Santo Antonio; Servico de Neurologia, Porto, 4099-001, Portugal|Spitalul Universitar de Urgenta Bucuresti, Bucharest, 11172, Romania|Spitalul Clinic Judetean Sibiu, Sibiu, 550245, Romania|Spitalul Clinic Judetean de Urgenta Mures, Targu-Mures, 540136, Romania|Univerzitna nemocnica Bratislava, Nemocnica Staré Mesto; I. Neurologická klinika LF UK a UNB, Bratislava, 813 69, Slovakia|UN Bratislava Nemocnica Ruzinov; Neurologicka klinika, Bratislava, 826 06, Slovakia|GB NeuroPRAKTIK, s.r.o, Nitra, 949 11, Slovakia|Fakultna nemocnica Trnava; Onkologicka klinika, Trnava, 917 75, Slovakia|University Medical Centre; Neurology, Ljubljana, 1000, Slovenia|University Medical Centre Maribor, Maribor, 2000, Slovenia|Complejo Hospitalario Nuestra Señora de la Candelaria; Servicio de Neurologia, Santa Cruz De Tenerife, Tenerife, 38010, Spain|Hospital de Cruces; Servicio de Neurologia, Barakaldo, Vizcaya, 48903, Spain|Hospital General Universitario de Alicante; Servicio de Neurología, Alicante, 03010, Spain|Hospital del Mar; Servicio de Neurologia, Barcelona, 08003, Spain|Hospital Vall d'Hebron; Servicio de Neurología, Barcelona, 08035, Spain|Hospital Universitario Puerta De Hierro Majadahonda; Servicio de Neurología, Madrid, 28222, Spain|Hospital General Universitario Morales Meseguer; Servicio de Neurología, Murcia, 30008, Spain|Sahlgrenska Sjukhuset; Neurology, Göteborg, 413 45, Sweden|Centralsjukhuset; Neurologi och rehabiliteringskliniken, Karlstad, 651 85, Sweden|Centrum för Neurologi, Stockholm, 113 41, Sweden|Universitätsspital Basel; Neurologie, Basel, 4031, Switzerland|Inselspital Bern Medizin Neurologie; Neurologische Poliklinik, Bern, 3010, Switzerland|Ospedale Regionale di Lugano - Civico; Neurologia, Lugano, 6903, Switzerland|Luzerner Kantonsspital Luzern Medizin Neurologie, Luzern, 6004, Switzerland|Kantonsspital; Neurologische Klinik, St. Gallen, 9007, Switzerland|Hacettepe University Medical Faculty; Neurology, Ankara, 06100, Turkey|Gazi University Medical Faculty; Departmant of Norology, Ankara, 06500, Turkey|Mustafa Kemal Ataturk UTF; Department of norology, Hatay, 31001, Turkey|Istanbul University Istanbul Medical Faculty; Neurology, Istanbul, 34093, Turkey|Istanbul Universitesi - Cerrahpasa Cerrahpasa Tip Fakultesi; Noroloji Anabilim Dali, Istanbul, 34098, Turkey|Istanbul Bilim Universty Medical Fac., Istanbul, 34394, Turkey|Selcuk University Medical Faculty; Norology department, Istanbul, 42131, Turkey|Ondokuz Mayis Univ. Med. Fac.; Neurology, Samsun, 55139, Turkey|Karadeniz Tecnical Uni. Med. Fac.; Neurology, Trabzon, 61080, Turkey|Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, United Kingdom|Queen Elizabeth University Hospital, Glasgow, G51 4TF, United Kingdom|Royal Free Hospital, London, NW3 2QS, United Kingdom|King'S College Hospital, London, SE5 9RS, United Kingdom|Charing Cross Hospital, London, W6 8RF, United Kingdom|National Hospital for Neurology and Neurosurgery,; MRC Centre for Neuromuscular Diseases, London, WC1 3BG, United Kingdom|Royal Victoria Infirmary, Newcastle upon Tyne, NE1 4LP, United Kingdom|Derriford Hospital, Plymouth, PL6 8BT, United Kingdom|Salford Royal NHS Foundation Trust, Salford, M6 8HD, United Kingdom|Abertawe and Bro Morgannwg NHS Trust; Clinical Researdh Institute, Swansea, SA6 6NL, United Kingdom"
NCT03574610,Brain Targets in Patients With Bladder Emptying Difficulties,https://beta.clinicaltrials.gov/study/NCT03574610,ACTIVE_NOT_RECRUITING,Neurogenic Bladder|Multiple Sclerosis|Voiding Dysfunction,DEVICE: Transcranial Rotating Permanent Magnet Stimulator (TRPMS),The Methodist Hospital Research Institute,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),ALL,"ADULT, OLDER_ADULT",NA,10,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-07-01,2021-04-26,2022-07-31,"Houston Methodist Hospital, Houston, Texas, 77030, United States"
NCT04578262,Epley Manoeuvre in Participants With Multiple Sclerosis Diagnosed From Benign Paroxysmal Positional Vertigo,https://beta.clinicaltrials.gov/study/NCT04578262,UNKNOWN,Benign Paroxysmal Positional Vertigo|Multiple Sclerosis,PROCEDURE: Epley Manoeuvre|PROCEDURE: Sham Manoeuvre,University of Seville,,ALL,"ADULT, OLDER_ADULT",NA,80,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-11-01,2022-02,2022-03,
NCT05418010,"Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)",https://beta.clinicaltrials.gov/study/NCT05418010,RECRUITING,Multiple Sclerosis|Clinically Isolated Syndrome of Demyelination,DRUG: Tysabri Injectable Product|DRUG: Placebo,Queen Mary University of London,Biogen|UCL Queen Square Institute of Neurology|Moorfields Eye Hospital NHS Foundation Trust|Barts & The London NHS Trust,ALL,ADULT,PHASE2,40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-12-01,2024-05-31,2024-05-31,"Royal London Hospital, London, E1 1FR, United Kingdom"
NCT04186910,In Clinic Physical Activity in Persons With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04186910,UNKNOWN,Rehabilitation|Multiple Sclerosis,BEHAVIORAL: Control group|BEHAVIORAL: Feedback group,Fondazione Don Carlo Gnocchi Onlus,,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2019-07-01,2020-07,2020-09,"Fondazione Don Carlo Gnocchi IRCCS, Milan, 20148, Italy"
NCT00202410,Efficacy of Anti-Tubercular Vaccination in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00202410,COMPLETED,Multiple Sclerosis,BIOLOGICAL: Bacille of Calmette-Guerin|OTHER: placebo,S. Andrea Hospital,Italian Multiple Sclerosis Foundation|Istituto Superiore di Sanità,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,80,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2001-11,2007-09,2008-04,"Department of Neurology - University of Rome La Sapienza, Rome, Roma, 00100, Italy"
NCT01970410,MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV,https://beta.clinicaltrials.gov/study/NCT01970410,COMPLETED,Multiple Sclerosis,DRUG: teriflunomide,Providence Health & Services,Multiple Sclerosis Center of Northeastern New York,ALL,ADULT,PHASE4,55,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-10,2021-04-30,2022-02-14,"Phoenix Neurological Associates, Ltd, Phoenix, Arizona, 85018, United States|Multiple Sclerosis Center of Northeastern New York, Latham, New York, 12110, United States|Providence Multiple Sclerosis Center, Portland, Oregon, 97225, United States"
NCT04586010,A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS),https://beta.clinicaltrials.gov/study/NCT04586010,RECRUITING,Relapsing Multiple Sclerosis,DRUG: Fenebrutinib|DRUG: Teriflunomide|DRUG: Placebo,Hoffmann-La Roche,,ALL,ADULT,PHASE3,736,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-03-17,2025-10-02,2025-11-27,"University of Alabama Birmingham, Birmingham, Alabama, 35233, United States|Alabama Neurology Associates, Homewood, Alabama, 35209, United States|Center for Neurology and Spine - Phoenix - Hunt - PPDS, Phoenix, Arizona, 85032, United States|North County Neurology Associates, Carlsbad, California, 92011, United States|University of California Irvine, Irvine, California, 92697, United States|SC3 Research Group, Inc, Pasadena, California, 91105, United States|University of Colorado Denver, Aurora, Colorado, 80045, United States|Mountain Neurological Research Center; Roaring Fork Neurologt, P.C., Basalt, Colorado, 81621, United States|Mountain View Clinical Research, Denver, Colorado, 80209, United States|Advanced Neurology of Colorado, LLC, Fort Collins, Colorado, 80528, United States|Neurology Associates, PA; Research Department, Maitland, Florida, 32751, United States|Elite Clinical Research, Miami, Florida, 33144, United States|Axiom Clinical Research of Florida, Tampa, Florida, 33609, United States|NorthShore University HealthSystem, Highland Park, Illinois, 60035, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, 46805, United States|The NeuroMedical Center, Baton Rouge, Louisiana, 70810, United States|Johns Hopkins University School Of Medicine; Outpatient Center, Baltimore, Maryland, 21287, United States|University of Massachusetts Medical School, Worcester, Massachusetts, 01655, United States|Henry Ford Health System, Detroit, Michigan, 48202, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|Rutgers New Jersey Medical School, Newark, New Jersey, 07103, United States|Holy Name Hospital; Institute For Clinical Research, Teaneck, New Jersey, 07666, United States|University of New Mexico; MS Specialty Clinic, Albuquerque, New Mexico, 87131, United States|St. Lawrence Health System, Canton, New York, 13617, United States|Miami Valley Hospital South; Dayton Physician's Office, Centerville, Ohio, 45459, United States|OhioHealth, Columbus, Ohio, 43214, United States|The Boster Center for MS, Columbus, Ohio, 43235, United States|MDH Research LLC, Westerville, Ohio, 43082, United States|Oklahoma Medical Research Foundation; MS Center of Excellence, Oklahoma City, Oklahoma, 73104, United States|St. Luke's University Health network, Bethlehem, Pennsylvania, 18015, United States|Premier Neurology, Greer, South Carolina, 29650, United States|Neurology Clinic PC, Cordova, Tennessee, 38018, United States|New Orleans Center for Clinical Research, Knoxville, Tennessee, 37920, United States|North Texas Institute of Neurology and Headache NextStage Clinical Research Clinic, Plano, Texas, 75024, United States|Texas Institute for Neurological Disorders, Sherman, Texas, 75092, United States|Blacksburg Neurology, PC, Christiansburg, Virginia, 24073, United States|Multiple Sclerosis Center of Greater Washington, Vienna, Virginia, 22182, United States|Evergreen MS Center, Kirkland, Washington, 98034, United States|MultiCare Health System Institute for Research and Innovation, Tacoma, Washington, 98405, United States|Wheaton Franciscan Healthcare - St. Francis Outpatient Center; Center for Neurological Disorders, Milwaukee, Wisconsin, 53215, United States|Fundación Faicep, Buenos Aires, C1122AAK, Argentina|Centro de Especialidades Neurológicas y Rehabilitación - CENyR, Buenos Aires, C1424, Argentina|NeuroSite, Ciudad Autonoma Buenos Aires, C1405CBA, Argentina|Instituto de Investigaciones Metabolicas (Idim), Ciudad Autonoma de Buenos Aires, C1012AAR, Argentina|Diagnostico Medico Oroño, Rosario, S2000CTC, Argentina|Cer San Juan, San Juan, J5400CEP, Argentina|Centro de Investigaciones Médicas Tucuman; REUMATHOLOGY, San Miguel, T4000AXL, Argentina|Peking University First Hospital, Beijing City, 100034, China|Beijing Tiantan Hospital,Capital Medical University, Beijing City, 100050, China|the First Hospital of Jilin University, Changchun, 130021, China|Xiangya Hospital Central South University, Changsha City, 410008, China|West China Hospital, Sichuan University, Chengdu, 610041, China|The First Affiliated Hospital, Chongqing Medical University, Chongqing, 400016, China|The First Affiliated Hospital of Sun Yat-sen University, Guangzhou City, 510080, China|The second Affiliated Hospital of Guangzhou Medical University, Guangzhou City, 510260, China|The affiliated Hospital of Guiyang Medical College, Guiyang, China|The First People?s Hospital of Yunnan Province, Kunming City, 650021, China|Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China|The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, China|The First Affiliated Hospital of Soochow University; Neurology department, Suzhou City, 215031, China|1st Affiliated Hospital of Shanxi Medical University, Taiyuan City, 030000, China|Tianjin Medical University General Hospital, Tianjin, 300052, China|Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan City, 430030, China|Tangdu Hospital, The Fourth Military Medical University; Neurology Department, Xi'an City, 710038, China|NeuroINC, Santiago de los Caballeros, 51000, Dominican Republic|Hospital Padre Billini, Santo Domingo, 10210, Dominican Republic|Helsinki University Central Hospital; Department of Neurology, Helsinki, 00290, Finland|Terveystalo Oulu, Oulu, 90100, Finland|Jüdisches Krankenhaus Berlin; Abteilung fur Neurologie, Berlin, 13347, Germany|Studienzentrum für Neurologie und Psychiatrie, Böblingen, 71034, Germany|Universitätsklinikum ""Carl Gustav Carus"", Zentrum für Klinische Neurowissenschaften, Dresden, 01307, Germany|Universitätsklinikum Gießen und Marburg GmbH; Neurologie, Gießen, 35392, Germany|Uniklinik Schleswig-Holstein; Neuroimmunologie, Institut für Klinische Chemie + Klinik f. Neurologie, Kiel, 24105, Germany|Universitätsklinikum Münster; Klinik und Poliklinik für Neurologie, Münster, 48149, Germany|Nordwest-Krankenhaus Sanderbusch gGMBH; Neurologische Klinik, Sande, 26452, Germany|Praxis Dr. med. Andreas Kowalik, Arzt für Neurologie und Psychiatrie, Stuttgart, 70174, Germany|Universitätsklinikum Tübingen, Zentrum für Neurologie, Tübingen, 72076, Germany|Universitätsklinikum Ulm; Klinik für Neurologie, Ulm, 89081, Germany|Studienzentrum Nordwest, Dr. med. Joachim Springub / Herr Wolfgang Schwarz, Westerstede, 26655, Germany|Pamela Youde Nethersole Eastern Hospital; Department of Medicine, Hong Kong, Hong Kong|Queen Mary Hospital; Department of Medicine, Division of Neurology, Hong Kong, Hong Kong|Prince of Wales Hospital; Division of Neurology, Department of Medicine and Therapeutics, Shatin, New Territories, Hong Kong|Clinexpert Kft., Budapest, 1033, Hungary|S-Medicon Egeszsegugyi Szolgaltato Kft., Budapest, 1138, Hungary|Markhot Ferenc Oktatokorhaz és Rendelointezet; Neurologiai és Stroke Osztaly, Eger, 3300, Hungary|Pest Megyei Flor Ferenc Korhaz, Kistarcsa, 2143, Hungary|Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ; Neurológiai Klinika, Szeged, 6725, Hungary|Ospedale San Salvatore; Clinica Neurologica - Centro Sclerosi Multipla, L'Aquila, Abruzzo, 67100, Italy|AOU Seconda Università degli Studi; Dip. Assistenziale Integrato Medicina Int-II Clinica Neurologica, Napoli, Campania, 80131, Italy|AOU Policlinico - Università L. Vanvitelli; D.A.I. di Medicina Interna e Specialistica, Napoli, Campania, 80138, Italy|A.O.U. di Parma; SC Neurologia, Amb. Sclerosi Multipla (malattie demielinizzanti), Parma, Emilia-Romagna, 43126, Italy|Policlinico Tor Vergata Dip. Neuroscienze-Clinica Neurologica-UOSD Sclerosi Multipla, Roma, Lazio, 00133, Italy|Policlinico Umberto I; Centro Sclerosi Multipla DAI Neuroscienze e Salute Mentale, Roma, Lazio, 00185, Italy|Azienda Ospedaliera Sant'Andrea; UOC Neurologia, Roma, Lazio, 00189, Italy|ASST PAPA GIOVANNI XXIII Neurologia USS Malattie Autoimmuni Centro Sclerosi Multipla, Bergamo, Lombardia, 24127, Italy|Ospedale S.Antonio Abate; Neurologia 2 ? Sclerosi Multipla e Recupero Neurologico, Gallarate, Lombardia, 21013, Italy|IRCCS Ospedale San Raffaele; Neurologia Neurofisiologia Neuroriabilitazione-Centro Sclerosi Multipla, Milano, Lombardia, 20132, Italy|Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I-G.M. Lancisi-G. Salesi Di Ancona, Torrette - Ancona, Marche, 60100, Italy|Ospedale Regina Montis Regalis; SC Neurologia, Centro Sclerosi Multipla, Mondovì (CN), Piemonte, 12084, Italy|AO.U. Policlinico Riuniti Foggia; Neurologia Univ.-Centro intradip. malattie demielinizzanti, Foggia, Puglia, 71100, Italy|AOU Policlinico V. Emanuele - P.O G. Rodolico; Clinica Neurologica, Centro Sclerosi Multipla, Catania, Sicilia, 95123, Italy|AOUC Azienda Ospedaliero-Universitaria Careggi; Neurologia 2, Firenze, Toscana, 50134, Italy|AOU Senese - Presidio Ospedaliero Le Scotte; UOSA Neurologia Sperimentale, Siena, Toscana, 53100, Italy|Azienda Ospedaliera di Padova; Clinica Neurologica, Padova, Veneto, 35128, Italy|Clinical Research Institute Saltillo, Saltillo, Coahuila, 25020, Mexico|Health Pharma Professional Research, Cdmx, Mexico CITY (federal District), 03100, Mexico|Grupo Medico de Investigacion Clinica Multidisciplinaria, Mexico City, Mexico CITY (federal District), 03100, Mexico|Neurociencias Estudios Clinicos S.C., Culiacán, Sinaloa, 80020, Mexico|Hospital General de Mexico, Mexico, Tlaxcala, 06726, Mexico|Zuyderland Medisch Centrum - Sittard Geleen, Sittard-Geleen, 6162 BG, Netherlands|PHO General City Hospital 8th September Center for dialysis, Skopje, 1000, North Macedonia|University Clinic for Neurology - Skopje, Skopje, 1000, North Macedonia|Clinical Hospital Stip, Stip, 2000, North Macedonia|Hospital IV Alberto Sabogal Sologuren; Unidad de Investigacion, Bellavista, Callao 2, Peru|HOSPITAL NACIONAL GUILLERMO ALMENARA IRIGOYEN; Unidad de Investigacion en Neurologia, La Victoria, Lima, Lima 13, Peru|Hospital Nacional Dos de Mayo; Unidad de Investigacion de Neurologia, Lima, 15003, Peru|Clinica Internacional Sede Lima, LIma, Lima 01, Peru|ASOCIACION CIVIL PORLASALUD; Unidad de Investigación, Miraflores, 15046, Peru|Clinica Centenario Peruano Japonesa; Neurology, Pueblo Libre, Lima 21, Peru|Neurocentrum Bydgoszcz sp. z o.o, Bydgoszcz, 85-796, Poland|Neurocentrum Bydgoszcz sp. z o.o, Bydgoszcz, 85-796, Poland|Care Clinic, Katowice, 40-568, Poland|MT Medic Krosno, Krosno, 38-400, Poland|Centrum Neurologii Krzysztof Selmaj, Lodz, 90-324, Poland|Neurologiczny Niepubliczny ZOZ Centrum Leczenia SM Osrodek Bada? Klinicznych, Plewiska, 62-064, Poland|Clinical Research Center Sp. z o.o. MEDIC-R Spó?ka Komandytowa, Pozna?, 61-731, Poland|MedPolonia, Poznan, 60-693, Poland|Instytut Psychiatrii i Neurologii II Klinika Neurologiczna, Warszawa, 02-957, Poland|IBISMED Wielospecjalistyczne Centrum Medyczne, Zabrze, 41-800, Poland|Hospital de Braga; Centro Clínico Académico (Piso 1, Ala E), Braga, 4710-243, Portugal|HUC; Servico de Neurologia, Coimbra, 3000-075, Portugal|Hospital Santo Antonio dos Capuchos; Servico de Neurologia, Lisboa, 1169-050, Portugal|Hospital da Luz; Neurologia, Lisboa, 1500-650, Portugal|Hospital de Santa Maria; Servico de Neurologia, Lisboa, 1649-035, Portugal|Hospital Beatriz Angelo; Servico de Neurologia, Loures, 2674-514, Portugal|Hospital Geral de Santo Antonio; Servico de Neurologia, Porto, 4099-001, Portugal|Hospital de Sao Joao; Servico de Neurologia, Porto, 4200-319, Portugal|Centro Hospitalar Entre o Douro e Vouga E.P.E. - Hospital de São Sebastião; Servilo de Neurologia, Santa Maria Da Feira, 4520-211, Portugal|Regional State Budgetary Institution of Healthcare ""Regional Clinical Hospital"", Barnaul, Altaj, 656024, Russian Federation|N.P. Bechtereva Institute of the Human Brain, Sankt-petersburg, Sankt Petersburg, 197376, Russian Federation|Ulyanovsk Regional Clinical Hospital, Ulyanovsk, Uljanovsk, 432063, Russian Federation|SHI Sverdlovsk Regional Clinical Hospital #1;Neurology, Ekaterinburg, 620102, Russian Federation|Center of Cardiology and Neurology, Kirov, 610007, Russian Federation|FSBIH Siberian Regional Medical Centre of FMBA of Russia, Novosibirsk, 630007, Russian Federation|Leningrad Regional Clinical Hospital, St Petersburg, 194291, Russian Federation|Pavlov State Medical Uni ; Neurology, St Petersburg, 197022, Russian Federation|Republican clinical hospital named after G.G. Kuvatov, UFA, 450005, Russian Federation|Hospital Universitari de Bellvitge; Servicio de Neurologia, L'Hospitalet de Llobregat, Barcelona, 08907, Spain|Hospital Quiron de Madrid; Servicio de Neurologia, Pozuelo de Alarcon, Madrid, 28223, Spain|Hospital Universitario Virgen de Arrixaca; Servicio de Neurología, EL Palmar (EL Palmar), Murcia, 30120, Spain|Hospital Alvaro Cunqueiro; Servicio de Neurologia, Vigo, Pontevedra, Spain|Hospital Universitari Vall d'Hebron; Servicio de Neumo-Inmunologia, Barcelona, 08035, Spain|Hospital Universitario de la Princesa; Servicio de Neurologia, Madrid, 28006, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Neurologia, Madrid, 28007, Spain|Hospital Ramon y Cajal; Servicio de Neurologia, Madrid, 28034, Spain|Fundacion Jimenez Diaz; Servicio de Neurología, Madrid, 28040, Spain|Hospital Regional Universitario de Malaga ? Hospital General; Servicio de Neurologia, Malaga, 29010, Spain|Hospital Universitario Virgen Macarena; Servicio de Neurologia, Sevilla, 41009, Spain|Inselspital Bern Medizin Neurologie; Neurologische Poliklinik, Bern, 3010, Switzerland|Ospedale Regionale di Lugano - Civico; Neurologia, Lugano, 6903, Switzerland|China Medical University Hospital; Neurology, North Dist., 40447, Taiwan|National Taiwan University Hospital; Neurology, Taipei, 100, Taiwan|Chang Gung Memorial Foundation - Linkou - Neurology, Taoyuan, 333, Taiwan|Medical Center Dopomoga Plus, Kyiv, Chernihiv Governorate, 02123, Ukraine|MNE Lviv Territorial Medical Association Clinical Hospital for Palliative Care, Lviv, Chernihiv Governorate, 79007, Ukraine|Municipal Institution Dnipropetrovsk Regional Clinical Hospital n a I I Mechnykov; Neurology dept #1, Dnipro, Katerynoslav Governorate, 49005, Ukraine|Municipal Non-profit Enterprise Zaporizhzhya Regional Hospital Zaporizhzhya Regional Council, Zaporizhzhia, Katerynoslav Governorate, 69600, Ukraine|Zaporizhia City Multispecialty Clinical Hospital #9, Zaporizhzhye, Katerynoslav Governorate, 69063, Ukraine|Medical Center of Private Execution First Private Clinic, Kyiv, KIEV Governorate, 03037, Ukraine|Salutem Medical Center, Vinnytsia, KIEV Governorate, 21050, Ukraine|Medical Clinical Research Center of Medical Center LLC Health Clinic, Vinnytsia, Podolia Governorate, 21009, Ukraine|Miska Klinichna Likarnia ?16, Dnipropetrovsk, Tavria Okruha, 49100, Ukraine|Ams of Ukraine; Inst. of Neurology, Psychiatry & Narcology, Kharkov, 61068, Ukraine|Lviv Regional Clinical Hospital; Department of Neurology, Lviv, 79010, Ukraine|Odesa Regional Clinical Hospital; Neurosurgery Department, Odesa, 65117, Ukraine"
NCT04171310,Study of Excretion Balance and Pharmacokinetics of [14C]-SAR442168 in Healthy Male Subjects,https://beta.clinicaltrials.gov/study/NCT04171310,COMPLETED,Multiple Sclerosis,DRUG: SAR442168,Sanofi,,MALE,"ADULT, OLDER_ADULT",PHASE1,6,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2019-11-13,2019-12-30,2019-12-30,"Investigational Site Number 8260001, Nottingham, United Kingdom"
NCT01440062,Efficacy of Vitamin D Supplementation in Multiple Sclerosis (EVIDIMS),https://beta.clinicaltrials.gov/study/NCT01440062,TERMINATED,Multiple Sclerosis,DRUG: Verum arm receiving Vitamin D oil|DRUG: low dose arm receiving neutral oil and 400 IU/g of Vitamin D every second day,"Charite University, Berlin, Germany","NeuroCure Clinical Research Center, Charite, Berlin",ALL,"ADULT, OLDER_ADULT",PHASE2,55,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2011-12,2017-06,2017-06,"Kliniken für Neurologie Teupitz/Lübben, Asklepios Fachkliniken Brandenburg GmbH, Teupitz, Brandenburg, Germany|Charité - Universitätsmedizin Berlin, Berlin, 10117, Germany|Neurologische Praxis, Berlin, Germany|Neurologisches Facharztzentrum, Berlin, Germany|Krankenhaus Martha-Maria Halle-Dölau gGmbH, Halle, Germany|Sankt Josefs Krankenhaus Potsdam Neurologie, Potsdam, Germany"
NCT02880553,"Disability, Perceived Social Support and Quality of Life in Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT02880553,COMPLETED,Multiple Sclerosis,,Fondation Ophtalmologique Adolphe de Rothschild,,ALL,"ADULT, OLDER_ADULT",,150,NETWORK,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-08-23,2017-03-09,2017-03-09,"casa di cura de San Pellegrino, San Pellegrino, Italy"
NCT02047760,Neuroretinal Biomarkers in Neurodegenerative Diseases,https://beta.clinicaltrials.gov/study/NCT02047760,COMPLETED,Multiple Sclerosis,,University of Edinburgh,,ALL,"ADULT, OLDER_ADULT",,80,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-03,2016-02,2016-02,"Anne Rowling Regenerative Neurology Clinic, Edinburgh, EH16 4SB, United Kingdom"
NCT02777060,Exploring the Effectiveness of Sensor-based Balance Training on Patient Outcome Measures,https://beta.clinicaltrials.gov/study/NCT02777060,UNKNOWN,Diabetes|Cancer|Multiple Sclerosis|Arthritis|Parkinson's Disease|Cognitive Disorders|Brain Injury|Stroke,PROCEDURE: Exergame|PROCEDURE: Home based balance training,University of Arizona,,ALL,"ADULT, OLDER_ADULT",NA,200,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2014-09,2016-12,2017-08,"University of Arizona, Tucson, Arizona, 85724, United States"
NCT01752660,Exercise in Severely Disabled Patients With MS,https://beta.clinicaltrials.gov/study/NCT01752660,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Endurance training|BEHAVIORAL: Standard care,University of Aarhus,"The Danish MS Society|Danish MS Hospitals, Haslev and Ry|Aarhus University Hospital",ALL,"ADULT, OLDER_ADULT",PHASE1,12,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2012-10,2013-02,2013-07,"MS Hospital in Ry, Ry, Jylland, 8680, Denmark"
NCT01804660,Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Normal Population,https://beta.clinicaltrials.gov/study/NCT01804660,COMPLETED,Multiple Sclerosis,OTHER: No study treatments administered,GeNeuro Innovation SAS,,ALL,ADULT,,25,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-10,2013-11,2013-12,"Etablissement Français du Sang Rhône Alpes - 1 route de Taninges, Annemasse, 74100, France"
NCT05058729,MS PATHS COVID-19 Questionnaire Data Linkage Sub-Study,https://beta.clinicaltrials.gov/study/NCT05058729,COMPLETED,Multiple Sclerosis (MS),,Biogen,,ALL,"CHILD, ADULT, OLDER_ADULT",,1507,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-12-07,2021-10-08,2021-10-08,"Research Site, Baltimore, Maryland, 21287, United States|Research Site, Saint Louis, Missouri, 63110, United States|Research Site, Las Vegas, Nevada, 89106, United States|Research Site, New York, New York, 10016, United States|Research Site, Cleveland, Ohio, 44195, United States|Research Site, Columbus, Ohio, 44195, United States"
NCT03153553,"Ischemic Preconditioning, Exercise Tolerance and Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT03153553,UNKNOWN,Multiple Sclerosis,OTHER: Ischemic Preconditioning|OTHER: Sham Intervention,Sheffield Teaching Hospitals NHS Foundation Trust,,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2017-04-05,2019-12-31,2019-12-31,"Royal Hallamshire Hospital, Sheffield, South Yorkshire, S10 2JF, United Kingdom"
NCT00682929,Cannabis for Spasticity in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00682929,TERMINATED,Multiple Sclerosis,DRUG: Inhaled Cannabis|DRUG: Oral THC|DRUG: Oral Placebo|DRUG: Inhaled placebo,"University of California, Davis",National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,41,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2004-04-14,2011-08-17,2011-08-17,"University of California Davis Medical Center, Sacramento, California, 95817, United States"
NCT03047460,Feasibility and Reliability of Multimodal Evoked Potentials in an International Multicenter Setting,https://beta.clinicaltrials.gov/study/NCT03047460,COMPLETED,Multiple Sclerosis,OTHER: multimodal evoked potentials,Clinique Neuro-Outaouais,,ALL,ADULT,,14,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-04,2018-01,2018-01,"Clinique Neuro-Outaouais, Gatineau, Quebec, J9J 0A5, Canada"
NCT01512329,Pacing Activity Self-management for Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01512329,COMPLETED,Multiple Sclerosis,BEHAVIORAL: pacing|BEHAVIORAL: relaxation,Vrije Universiteit Brussel,"University Hospital, Antwerp|Universiteit Antwerpen|Artesis University College, Antwerp",ALL,"ADULT, OLDER_ADULT",PHASE2,31,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-10,2014-02,2014-10,"Nationaal Multiple Sclerosis Centrum, Melsbroek, Belgium"
NCT03126760,Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS),https://beta.clinicaltrials.gov/study/NCT03126760,TERMINATED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Acthar Gel|DRUG: Placebo,Mallinckrodt ARD LLC,,ALL,"ADULT, OLDER_ADULT",PHASE4,35,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2017-05-22,2020-07-14,2020-07-14,"Stanford University Medical Center, Palo Alto, California, 94304, United States|Advanced Neurosciences Research LLC, Fort Collins, Colorado, 80528, United States|University of South Florida, Bradenton, Florida, 34205, United States|Neurology Associates, P. A., Maitland, Florida, 32751, United States|University of Miami - Miller School of Medicine, Miami, Florida, 33136, United States|Tallahassee Neurological Clinic, PA, Tallahassee, Florida, 32308, United States|Multiple Sclerosis Center of Atlanta, Atlanta, Georgia, 30327, United States|Meridian Clinical Research LLC, Savannah, Georgia, 31405, United States|Consultants in Neurology LTD, Northbrook, Illinois, 60062, United States|OSF Healthcare System Saint Francis Medical Center, Peoria, Illinois, 61603, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, 46804, United States|University of Kansas Medical Center Research Institute, Inc., Kansas City, Kansas, 66160, United States|Wayne State University (WSU) - Multiple Sclerosis Treatment and Clinical Research Center (MS Center), Detroit, Michigan, 97205, United States|University of New Mexico, Albuquerque, New Mexico, 87131, United States|University of Buffalo, Buffalo, New York, 14215, United States|Wake Forest University School of Medicine, Winston-Salem, North Carolina, 27157, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States|University of Cincinnati Physicians Company, LLC, Dayton, Ohio, 45417, United States|Northern Ohio Neuroscience, LLC, Sandusky, Ohio, 44870, United States|Texas Neurology, PA, Dallas, Texas, 75214, United States|Neurology Center of San Antonio, San Antonio, Texas, 78258, United States|MultiCare Neuroscience Center of WA, Tacoma, Washington, 98405, United States"
NCT01776060,Serial Collection of Primary Progressive Multiple Sclerosis Participants in the MURDOCK Study,https://beta.clinicaltrials.gov/study/NCT01776060,COMPLETED,Primary Progressive Multiple Sclerosis,OTHER: generation of 'omic markers of disease progression,Duke University,,ALL,"ADULT, OLDER_ADULT",,28,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-01,2020-09-21,2020-09-21,"NE Neurology, Concord, North Carolina, 28025, United States|The Stedman Center on the Duke Center for Living Campus, Durham, North Carolina, 27705, United States|Raleigh Neurology Associates, Raleigh, North Carolina, 27607, United States"
NCT03646929,Motor Evoked Potentials With Modified Facilitation Technique,https://beta.clinicaltrials.gov/study/NCT03646929,COMPLETED,Multiple Sclerosis,DIAGNOSTIC_TEST: MEP using standard facilitation technique|DIAGNOSTIC_TEST: MEP using modified facilitation technique,"University Hospital, Basel, Switzerland",,ALL,"ADULT, OLDER_ADULT",NA,81,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2017-12-20,2019-01-15,2019-01-15,"Dep. of Neurology and Clinical Neurophysiology , Hospital of the University of Basel, Basel, 4031, Switzerland"
NCT02869360,Correlation Between PET and Advanced MRI in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02869360,COMPLETED,Multiple Sclerosis,,University of British Columbia,Teva Pharmaceuticals USA,ALL,ADULT,,14,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-10,2019-10-02,2019-10-02,"MS Clinical Trials Group - UBC, Vancouver, British Columbia, V6T 1Z3, Canada"
NCT05777629,"Determination of Compliance to Mediterranean Diet, Impacts on Walking and Quality of Life in Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT05777629,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,,University of Gaziantep,,ALL,"ADULT, OLDER_ADULT",,103,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-02-28,2023-05-30,2023-06-01,"UGaziantep, Gaziantep, Turkey"
NCT02471560,Tecfidera and the Gut Microbiota,https://beta.clinicaltrials.gov/study/NCT02471560,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: dimethyl fumarate|DRUG: injectable MS DMT,Biogen,,ALL,"ADULT, OLDER_ADULT",PHASE4,36,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2015-11-06,2017-06-12,2017-06-12,"Research site, Drammen, 3019, Norway|Research site, Haukeland, 5021, Norway|Research Site, Lillehammer, 2609, Norway|Research site, Lørenskog, 1478, Norway|Research site, Molde, 6412, Norway|Research site, Oslo, 0450, Norway|Research site, Stavanger, 4011, Norway"
NCT01518660,Multiple Sclerosis and Progressive Resistance Training,https://beta.clinicaltrials.gov/study/NCT01518660,COMPLETED,Multiple Sclerosis (Relapsing Remitting),BEHAVIORAL: Training,University of Aarhus,Aarhus University Hospital|Biogen,ALL,ADULT,NA,35,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2012-02,2014-01,2014-01,"MS Clinic, Department of Neurology, Aarhus University Hospital, Aarhus C, 8000, Denmark|Sport Science, Aarhus University, Aarhus C, 8000, Denmark"
NCT02430532,BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02430532,TERMINATED,"Multiple Sclerosis, Secondary Progressive",DRUG: dimethyl fumarate|OTHER: Placebo,Biogen,,ALL,ADULT,PHASE3,58,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2015-05,2016-01,2016-01,"Research Site, Long Beach, California, 90806, United States|Research Site, San Francisco, California, 94143, United States|Research Site, Tampa, Florida, 33634, United States|Research Site, Vero Beach, Florida, 32960, United States|Research Site, Charlotte, North Carolina, 28207, United States|Research Site, Willow Grove, Pennsylvania, 19001, United States|Research Site, Round Rock, Texas, 78681, United States|Research Site, Bruxelles, 1200, Belgium|Research Site, Brno, 656 91, Czech Republic|Research Site, Hradec Kralove, 500 05, Czech Republic|Research Site, Sittard-Geleen, 6162 BG, Netherlands|Research Site, Gdansk, 80-803, Poland|Research Site, Katowice, Poland|Research Site, Krakow, 31-505, Poland|Research Site, Lodz, 93-121, Poland|Research Site, Plewiska, 62-064, Poland|Research Site, Poznan, 61-853, Poland|Research Site, Banska Bystrica, 97404, Slovakia"
NCT04413032,DreaMS - Digital Biomarkers for Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04413032,COMPLETED,Multiple Sclerosis,DEVICE: DreaMS,Research Center for Clinical Neuroimmunology and Neuroscience Basel,,ALL,"ADULT, OLDER_ADULT",NA,62,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2020-10-05,2021-02-26,2021-02-26,"RC2NB, Basel, 4031, Switzerland"
NCT02283918,Observational Study to Establish Patient-Matched Population Norms for the Multiple Sclerosis Cognition Assessment Battery,https://beta.clinicaltrials.gov/study/NCT02283918,COMPLETED,Healthy,,Biogen,,ALL,ADULT,,467,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-11,2015-08,2015-08,"Research Site, Thornton, Colorado, 80233, United States|Research site, Decatur, Georgia, 30033, United States|Research Site, Latham, New York, 12110, United States|Research Site, Akron, Ohio, 44320, United States|Research site, Marseille Cedex 5, Bouches-du-Rhône, 13385, France|Research site, Bordeaux, Gironde, 33076, France|Research site, Milano, 20162, Italy|Research site, Roma, 179, Italy"
NCT04687332,IA or PE - What is the Best Treatment Option of Steroid Refractory Neurological Autoimmune Diseases,https://beta.clinicaltrials.gov/study/NCT04687332,COMPLETED,Neurological Autoimmune Diseases,"OTHER: Apheresis therapy by Octo Nova Technology (DIAMED, Cologne, Germany)",University Medical Center Mainz,,ALL,"ADULT, OLDER_ADULT",NA,32,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2016-06-01,2019-09-15,2019-12-01,"UNIVERSITÄTSMEDIZIN der Johannes Gutenberg-Universität Mainz I. Medizinische Klinik und Poliklinik, Mainz, Rheinland-Pfalz, 55130, Germany"
NCT00754832,American Ginseng Treatment for Multiple Sclerosis Related Fatigue,https://beta.clinicaltrials.gov/study/NCT00754832,COMPLETED,Multiple Sclerosis,DRUG: American ginseng extract HT-1001|DRUG: placebo,Oregon Health and Science University,National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",PHASE2,56,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2005-09,2008-09,2011-03,"Oregon Health & Science University, Portland, Oregon, 97239, United States"
NCT00856518,Expiratory Muscle Training for Persons With Neurodegenerative Disease,https://beta.clinicaltrials.gov/study/NCT00856518,COMPLETED,Parkinson's Disease|Multiple Sclerosis,DEVICE: EMST|DEVICE: Sham,VA Office of Research and Development,University of Florida,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,42,FED,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-03,2014-08,2014-08,"North Florida/South Georgia Veterans Health System, Gainesville, FL, Gainesville, Florida, 32608, United States"
NCT05051618,Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05051618,RECRUITING,Multiple Sclerosis|Major Depressive Disorder,BEHAVIORAL: POWER-MS|BEHAVIORAL: FLEX-MS,University of Illinois at Chicago,Congressionally Directed Medical Research Programs,ALL,ADULT,NA,146,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-04-01,2025-03-31,2025-03-31,"University of Illinois at Chicago, Chicago, Illinois, 60612, United States"
NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,https://beta.clinicaltrials.gov/study/NCT00297232,TERMINATED,Relapsing-Remitting Multiple Sclerosis,DRUG: Natalizumab,Biogen,,ALL,"ADULT, OLDER_ADULT",PHASE3,1094,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2006-03,2014-04,2014-04,"Research Site, Camperdown, 2050, Australia|Research Site, Heidelberg, 3084, Australia|Research Site, Parkville, 3050, Australia|Research Site, Brugge, 8000, Belgium|Research Site, Brussels, 1070, Belgium|Research Site, Charleroi, 6000, Belgium|Research Site, Diepenbeek, 3590, Belgium|Research Site, Melsbroek, 1820, Belgium|Research Site, Sijsele, 8340, Belgium|Research Site, Vancouver, British Columbia, V6T 2B5, Canada|Research Site, Halifax, Nova Scotia, B3H IV7, Canada|Research Site, Kingston, Ontario, K7L 2V7, Canada|Research Site, London, Ontario, N6A5A5, Canada|Research Site, New York, Ontario, M4N 3M5, Canada|Research Site, Ottawa, Ontario, K2G6E2, Canada|Research Site, Toronto, Ontario, M5B 1W8, Canada|Research Site, Gatineau, Quebec, J8Y 1W7, Canada|Research Site, Greenfield Park, Quebec, J4V 2H1, Canada|Research Site, Montreal, Quebec, H3A2B4, Canada|Research Site, Brno, 625 00, Czech Republic|Research Site, Brno, 656 91, Czech Republic|Research Site, Hradec Kralove, 500 05, Czech Republic|Research Site, Olomouc, 775 20, Czech Republic|Research Site, Ostrava, 708 52, Czech Republic|Research Site, Pardubice, 532 03, Czech Republic|Research Site, Plzen, 323 00, Czech Republic|Research Site, Praha 2, 12000, Czech Republic|Research Site, Praha 5, 150 06, Czech Republic|Research Site, Aarhus C, 8000, Denmark|Research Site, Esbjerg, 6700, Denmark|Research Site, Kobenhavn, 2100, Denmark|Research Site, Helsinki, 00290, Finland|Research Site, Tampere, 33520, Finland|Research Site, Turku, 20100, Finland|Research Site, Besancon, 25030, France|Research Site, Bordeaux, 33076, France|Research Site, Clermont-Ferrand, 63003, France|Research Site, Creteil, 94101, France|Research Site, Dijon, 21033, France|Research Site, Lille, 59037, France|Research Site, Lyon, 69677, France|Research Site, Marseille, 13385, France|Research Site, Nancy, 54035, France|Research Site, Paris, 75019, France|Research Site, Paris, 75651, France|Research Site, Rennes, 35033, France|Research Site, Strasbourg, 67091, France|Research Site, Toulouse, 31059, France|Research Site, Berlin, 13347, Germany|Research Site, Essen, 45122, Germany|Research Site, Gießen, 35385, Germany|Research Site, Hannover, 30625, Germany|Research Site, Hennigsdorf, 16761, Germany|Research Site, München, 81377, Germany|Research Site, Offenbach, 63069, Germany|Research Site, Osnabrück, 49076, Germany|Research Site, Regensburg, 93053, Germany|Research Site, Rostock, 18147, Germany|Research Site, Athens, 11527, Greece|Research Site, Budapest, 1021, Hungary|Research Site, Budapest, 1115, Hungary|Research Site, Budapest, 1145, Hungary|Research Site, Budapest, 1204, Hungary|Research Site, Debrecen, 4012, Hungary|Research Site, Debrecen, 4031, Hungary|Research Site, Gyor, 9000, Hungary|Research Site, Nyiregyhaza, 4400, Hungary|Research Site, Szekesfehervar, 8000, Hungary|Research Site, Dublin, 4, Ireland|Research Site, Jerusalem, 91120, Israel|Research Site, Tel Hashomer, 52621, Israel|Research Site, Bari, 70124, Italy|Research Site, Genova, 16132, Italy|Research Site, Milano, 20132, Italy|Research Site, Roma, 00185, Italy|Research Site, Amsterdam, 1081HV, Netherlands|Research Site, Breda, 4818 CK, Netherlands|Research Site, Hertogenbosch, 5211 NL, Netherlands|Research Site, Nieuwegein, 3435 CM, Netherlands|Research Site, Nijmegen, 6533 PA, Netherlands|Research Site, Rotterdam, 3015 GD, Netherlands|Research Site, Auckland, 1023, New Zealand|Research Site, Christchurch, 8011, New Zealand|Research Site, Białystok, 15-402, Poland|Research Site, Białystok, 15-420, Poland|Research Site, Bydgoszcz, 85-681, Poland|Research Site, Gdańsk, 80-803, Poland|Research Site, Katowice, 40-752, Poland|Research Site, Kraków, 31-530, Poland|Research Site, Lodz, 90-153, Poland|Research Site, Lublin, 20-954, Poland|Research Site, Warsaw, 02-957, Poland|Research Site, Warszawa, 02-097, Poland|Research Site, Barcelona, 08035, Spain|Research Site, Barcelona, 08907, Spain|Research Site, Málaga, 29010, Spain|Research Site, Goteborg, 41685, Sweden|Research Site, Stockholm, 141 86, Sweden|Research Site, Stockholm, 17176, Sweden|Research Site, Basel, 4031, Switzerland|Research Site, Ankara, 06100, Turkey|Research Site, Istanbul, 34303, Turkey|Research Site, Istanbul, 34390, Turkey|Research Site, Essex, RM7 0AG, United Kingdom|Research Site, Liverpool, L9 7AJ, United Kingdom|Research Site, London, E1 1BB, United Kingdom|Research Site, London, SE5 9RF, United Kingdom|Research Site, London, SW17 0QT, United Kingdom|Research Site, Newcastle Upon Tyne, NE14LP, United Kingdom|Research Site, Oxford, OX3 9DU, United Kingdom|Research Site, Sheffield, S10 2JF, United Kingdom|Research Site, Stoke on Trent, ST4 7LN, United Kingdom"
NCT04563832,Self-administered Hyperinsufflation Chest on the Risk of Low Respiratory Infection in Patients With Multiple Sclerosis With Sputum Capacity Deficit,https://beta.clinicaltrials.gov/study/NCT04563832,UNKNOWN,Multiple Sclerosis,OTHER: Standardized respiratory management program|OTHER: CoughAssist,Assistance Publique - Hôpitaux de Paris,,ALL,"ADULT, OLDER_ADULT",NA,84,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-11-25,2022-10,2022-10,"Hôpital Raymond Poincaré, Garches, Haut De Seine, 92380, France"
NCT05286632,KidneYou - Innovative Digital Therapy,https://beta.clinicaltrials.gov/study/NCT05286632,RECRUITING,Chronic Kidney Diseases|Diabetes|Arterial Hypertension|Chronic Glomerulonephritis|Cystic Kidney Diseases|Polycystic Kidney|Nephronophthisis|Cortical Cystic Disease|Cystic Diseases|Tuberous Sclerosis|Albuminuria|Treatment Adherence|Treatment Adherence and Compliance,DEVICE: KidneYou APP,Advice Pharma Group srl,,ALL,"ADULT, OLDER_ADULT",NA,210,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-07-18,2024-01,2024-01,"U.O. Nefrologia, Bari, Italy"
NCT01844232,"One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity",https://beta.clinicaltrials.gov/study/NCT01844232,COMPLETED,Multiple Sclerosis|Spasticity,DRUG: arbaclofen,"RVL Pharmaceuticals, Inc.",Osmotica Pharmaceutical US LLC,ALL,"ADULT, OLDER_ADULT",PHASE3,150,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2013-04,2014-12,2015-01,"Osmotica Study Site-154, Gilbert, Arizona, 85234, United States|Osmotica Study Site-158, Phoenix, Arizona, 85032, United States|Osmotica Study Site-165, Pasadena, California, 91105, United States|Osmotica Study Site-164, Torrance, California, 90505, United States|Osomtica Study Site-164, Torrance, California, 90505, United States|Osmotica Study Site-173, Bradenton, Florida, 34205, United States|Osmotica Study Site-178, Pompano Beach, Florida, 33060, United States|Osmotica Study Site-170, Tampa, Florida, 33606, United States|Osmotica Study Site-179, Northbrook, Illinois, 60096, United States|Osmotica Study Site-174, Lenexa, Kansas, 66214, United States|Osmotica Study Site-175, Ann Arbor, Michigan, 48104, United States|Osmotica Study Site-161, Plainview, New York, 11803, United States|Osmotica Study Site-151, Charlotte, North Carolina, 28203, United States|Osmotica Study Site-157, High Point, North Carolina, 27262, United States|Osmotica Study Site-155, Raleigh, North Carolina, 27607, United States|Osmotica Study Site-152, Wilmington, North Carolina, 28401, United States|Osmotica Study Site-156, Dayton, Ohio, 45417, United States|Osmotica Study Site-163, Philadelphia, Pennsylvania, 19107, United States|Osmotica Study Site-162, Franklin, Tennessee, 37064, United States|Osmotica Study Site-171, San Antonio, Texas, 78229, United States|Osmotica Study Site-166, Vienna, Virginia, 22182, United States|Osmotica Study Site-554, Krasnoyarsk, 660022, Russian Federation|Osmotica Study Site-552, Krasnoyarsk, Russian Federation|Osmotica Study Site-557, Moscow, 107150, Russian Federation|Osmotica Study Site-556, Moscow, 127018, Russian Federation|Osmotica Study Site-553, Pyatigorsk, Russian Federation|Osmotica Study Site-560, Sestroretsk, 197706, Russian Federation|Osmotica Study Site-551, St. Petersburg, 190000, Russian Federation|Osmotica Study Site-555, Tonnel'nyy, 357034, Russian Federation|Osmotica Study Site-653, Dnipropetrovsk, 49022, Ukraine|Osmotica Study Site-655, Dnipropetrovsk, 53012, Ukraine|Osmotica Study Site-651, Donetsk, 83003, Ukraine|Osmotica Study Site-654, Kharkov, 61103, Ukraine|Osmotica Study Site-656, Lviv, 79010, Ukraine|Osmotica Study Site-657, Poltava, 36011, Ukraine"
NCT03237832,A Phase 1 Study of ARN-6039,https://beta.clinicaltrials.gov/study/NCT03237832,COMPLETED,Multiple Sclerosis,DRUG: ARN-6039|OTHER: Placebo,Arrien Pharmaceuticals,Worldwide Clinical Trials,ALL,ADULT,PHASE1,60,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH",2016-05-16,2016-10-06,2017-02,
NCT00532532,Safety and Preliminary Effectiveness of AV650 in Patients With Spasticity Associated With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00532532,TERMINATED,Muscle Spasticity,DRUG: tolperisone HCl|DRUG: tolperisone HCl|DRUG: tolperisone HCl,Avigen,,ALL,"ADULT, OLDER_ADULT",PHASE2,150,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2007-09,2008-09,2008-11,"Annes University Hospital, Brno, 65691, Czech Republic|University Hospital Hradec Kralove, Hradec Kralove, 50005, Czech Republic|University Hospital Plzen, Plzen, 30460, Czech Republic|University Hospital Motol, Praha, 15006, Czech Republic|Facharzt fur Neurologie, Bad Saarow, 15526, Germany|Facharztin fur Neurologie und Psychiatrie, Berlin, 12555, Germany|Facharzt fur Neurologie und Psychiatrie, Berlin, 13053, Germany|Private practice, Berlin, D-13156, Germany|Neurological practice, Bochum, 44805, Germany|Neuro-Consil GmbH, Dusseldorf, 40212, Germany|X-pert-med GmbH, Graefelfing, 82166, Germany|Asklepios Klinik Nord-Heidberg, Hamburg, D022417, Germany|Neurological practice, Koln, 50767, Germany|City Hospital #33, Nizhniy Novgorod, 603076, Russian Federation|Regional Clinical Hospital named Semashko, Nizhniy Novgorod, 603126, Russian Federation|Institute of Human Brain, St. Petersburg, 194291, Russian Federation|Leningrad Regional Clinical Hospital, St. Petersburg, 197376, Russian Federation|Nikolaevskaya Hospital, Complex Rehabilitation Department, St. Petersburg, 198510, Russian Federation|Clinical Center of Serbia Institute of Neurology, Belgrade, 11000, Serbia|Clinical Center Nis Clinic of Neurology, Nis, 18000, Serbia|Ivano-Frankivsk Regional Clinical Hospital, Ivano-Frankivsk, 76008, Ukraine|Central Clinical Hospital Ukrzalinznytsi (Dept. Neur. No. 1), Kharkiv, 61018, Ukraine|Central Clinical Hospital Ukrzalinznytsi (Dept. Neur. No. 3), Kharkiv, 61018, Ukraine|Institute of Neurology, Psychiatry and Narcology of AMS of Ukraine, Kharkiv, 61068, Ukraine|Institute of Clinical Radiology of the Scientific Centre of Radiation Medicine of the AMS of Ukraine, Kyiv, 03115, Ukraine|Odesa Regional Psychoneurological Dispensary, Odesa, 65014, Ukraine|M.O.Semashko Republican Clinical Hospital, Simferopol, 95017, Ukraine|Uzhgorod Regional Centre of Neurosurgery and Neurology, Uzhorod, 88018, Ukraine"
NCT04640818,Safety and Efficacy of Cladribine Therapy After Anti CD20 Therapy,https://beta.clinicaltrials.gov/study/NCT04640818,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,DRUG: Cladribine Oral Tablet|DRUG: Rituximab|DRUG: Ocrelizumab,Claudio Gobbi,Merck AG Switzerland,ALL,"ADULT, OLDER_ADULT",,45,OTHER_GOV,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-12-17,2022-10-31,2022-10-31,"Neurocenter of Southern Switzerland, Ospedale Regionale di Lugano, Lugano, Ticino, 6903, Switzerland"
NCT00240032,A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®.,https://beta.clinicaltrials.gov/study/NCT00240032,COMPLETED,Multiple Sclerosis,DRUG: glatiramer acetate injection with oral cetirizine hydrochloride|DRUG: glatiramer acetate with placebo,"Teva Branded Pharmaceutical Products R&D, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE4,80,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2004-10,2006-06,2006-07,
NCT03569618,Digital Cognition in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03569618,COMPLETED,Multiple Sclerosis|Cognitive Decline,DEVICE: Tablet-based Game,"University of California, San Francisco","Akili Interactive Labs, Inc.",ALL,"ADULT, OLDER_ADULT",NA,44,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-04-01,2018-11-01,2019-01-15,"University of California San Francisco, San Francisco, California, 94158, United States"
NCT05078177,Safety and Efficacy of Intrathecal Rituximab in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05078177,RECRUITING,Multiple Sclerosis,DRUG: Rituximab,St. Petersburg State Pavlov Medical University,,ALL,"ADULT, OLDER_ADULT",PHASE1,40,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-12-21,2022-12-21,2024-12-21,"First Pavlov State Medical University of St. Petersburg, Saint Petersburg, 197022, Russian Federation"
NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT03958877,RECRUITING,"Multiple Sclerosis, Relapsing-Remitting",DRUG: BIIB017 (peginterferon beta-1a)|DRUG: Interferon beta type 1a,Biogen,,ALL,"CHILD, ADULT",PHASE3,142,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2019-10-18,2029-11-05,2029-11-05,"UC San Diego Health, San Diego, California, 92121, United States|UNC Hospitals, Chapel Hill, North Carolina, 27514, United States|Meridian Clinical Research, Norfolk, Virginia, 23502, United States|Hospital Italiano de Buenos Aires, Ciudad Autonoma de Buenos Aires, Buenos Aires, C1181ACH, Argentina|Royal Children's Hospital, Parkville, Victoria, 3052, Australia|Universitair Ziekenhuis Gent, Gent, East Flanders, 9000, Belgium|Clinique CHC MontLégia, Liege, Wallonia, 4000, Belgium|MHATNP ""Sv.Naum"", EAD, Sofia, 1113, Bulgaria|University Hospital Centre Split, Split, Dalmatia, 21000, Croatia|Children's Hospital Zagreb, Zagreb, 10000, Croatia|Clinical Hospital 'Sestre Milosrdnice', Zagreb, 10000, Croatia|University Hospital Centre Zagreb, Zagreb, 10000, Croatia|Fakultni nemocnice Hradec Kralove, Hradec Kralove, 50333, Czechia|CHU Strasbourg - Hôpital Hautepierre, Strasbourg, Bas Rhin, 67098, France|Hopital Purpan, Toulouse cedex 9, Haute Garonne, 31059, France|Hopital Gui de Chauliac, Montpellier, Herault, 34295, France|Hopital Roger Salengro - CHU Lille, Lille, Nord, 59037, France|Hôpital Bicêtre, Le Kremlin Bicêtre cedex, Val De Marne, 94275, France|Universitaetsklinikum Freiburg, Freiburg, Baden Wuerttemberg, 79106, Germany|Universitaetsmedizin Goettingen, Gottingen, Niedersachsen, 37075, Germany|St. Josef-Hospital Universitaetsklinikum, Bochum, Nordrhein Westfalen, 44791, Germany|Charité - Campus Virchow-Klinikum, Berlin, 13353, Germany|General Hospital of Larissa, Larissa, Thessaly, 41110, Greece|IASO Children's Hospital, Marousi, 15123, Greece|General Hospital of Thessaloniki 'Hippokration', Thessaloniki, 54642, Greece|Pecsi Tudomanyegyetem, Pecs, Baranya, 7623, Hungary|Debreceni Egyetem, Debrecen, Hajdú-Bihar, 4032, Hungary|Semmelweis Egyetem AOK, Budapest, 1083, Hungary|Hadassah University Hospital - Ein Kerem, Jerusalem, Levant, 9112001, Israel|Schneider Children's Medical Center, Petach-Tikva, Tel Aviv, 4920235, Israel|Azienda Ospedaliera Universitaria- Università degli Studi della Campania ""Luigi Vanvitelli"", Napoli, Campania, 80138, Italy|Azienda Ospedaliero Universitaria Ospedale Pediatrico Meyer, Firenze, 50139, Italy|Azienda Ospedaliera Universitaria 'Federico II', Napoli, 80131, Italy|Ibn Sina Hospital, Shuwaikh, 12345, Kuwait|Centro Hospitalar e Universitário Lisboa Norte E.P.E., Lisboa, Lisbon, 1649-035, Portugal|Hospital Beatriz Ângelo, Loures, Lisbon, 2674-514, Portugal|Hospital de Braga, Braga, Minho, 4710-243, Portugal|Centro Hospitalar e Universitário de Coimbra E.P.E. - Hospital Pediátrico, Coimbra, 3000-602, Portugal|Centro Hospitalar do Porto, E.P.E. - Hospital de Santo António, Porto, 4099-001, Portugal|SBEI HPE 'Bashkir State Medical University' of the MoH of the RF, Ufa, Bashkortostan, 450077, Russian Federation|FSBI ""Federal Siberian Scientific-Clinical Center of FMBA"", Krasnoyarsk, Krasnoyarsk Krai, 660037, Russian Federation|LLC National center for socially significan disease, St. Petersburg, Leningrad, 197110, Russian Federation|Nebbiolo LLC, Tomsk, Oblast, 634009, Russian Federation|SAIH 'Kemerovo Regional Clinical Hospital', Kemerovo, Siberia, 650066, Russian Federation|RSBIH 'Belgorod Regional Clinical Hospital of Saint Ioasaf', Belgorod, 308007, Russian Federation|SBHI, Moscow, 119602, Russian Federation|SBIH of Moscow region ""Moscow Regional Scientific & Research, Moscow, 129110, Russian Federation|SBEI HPE 'Rostov State Medical University' of the MoH of the RF, Rostov-on-Don, 344022, Russian Federation|State Budgetary Institution of Healthcare of Yaroslavl region 'Clinical Hospital # 2', Yaroslavl, 150000, Russian Federation|King Faisal Specialist Hospital & Research Center, Jeddah, Makkah, 40047, Saudi Arabia|King Saud University, Riyadh, 11472, Saudi Arabia|Clinic of Neurology and Psychiatry for Children and Youth, Belgrade, Balkans, 11000, Serbia|University Children's Hospital, Belgrade, Balkans, 11000, Serbia|Mother and Child Health Care Institute of Serbia ''Dr Vukan Cupic'', Belgrade, Balkans, 11070, Serbia|Narodny ustav detskych chorob, Bratislava, 83340, Slovakia|Hospital Sant Joan de Deu, Esplugues de Llobregat, Barcelona, 08950, Spain|Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, 30120, Spain|Hospital Universitario Reina Sofia, Cordoba, 14004, Spain|Hospital Universitario Ramon y Cajal, Madrid, 28034, Spain|Hopital Razi, Manouba, Mannouba, 2010, Tunisia|Hôpital Fattouma Bourghiba, Monastir, 5000, Tunisia|Hôpital Habib Bourguiba, Sfax, 3029, Tunisia|Gazi University Medical Faculty Clinical Research Unit, Ankara, 06500, Turkey|Akdeniz University Medical Faculty, Antalya, 07059, Turkey|Izmir Dr. Behcet Uz Cocuk Hastaliklari ve Cerrahisi Egitim ve Arastirma Hastanesi, Izmir, 35210, Turkey|Ondokuz Mayis Univ. Med. Fac., Samsun, 55139, Turkey"
NCT01435694,Robot-assisted Gait Training in Multiple Sclerosis Subjects,https://beta.clinicaltrials.gov/study/NCT01435694,COMPLETED,Multiple Sclerosis,"BEHAVIORAL: Lokomat (Hocoma, Switzerland)|BEHAVIORAL: Conventional Therapy",University Hospital of Ferrara,"Azienda Ospedaliero, Universitaria Pisana",ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2011-04,2013-06,2013-06,"Physical Medicine and Rehabilitation Department, Ferrara, 44100, Italy"
NCT00151294,The Efficacy and Safety of Escitalopram for Depression in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00151294,TERMINATED,Depression|Multiple Sclerosis,DRUG: escitalopram oxalate antidepressant,Weill Medical College of Cornell University,Forest Laboratories,ALL,"ADULT, OLDER_ADULT",PHASE4,20,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,2004-11,,2006-10,"NewYork Presbyterian Hospital, White Plains, New York, 10605, United States"
NCT03004794,Characteristics and Predictors of Progression of an Egyptian Multiple Sclerosis Cohort,https://beta.clinicaltrials.gov/study/NCT03004794,COMPLETED,Multiple Sclerosis,OTHER: medical records review,Cairo University,,ALL,"CHILD, ADULT",,1581,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-06,2016-08,2016-08,
NCT04719494,Dynamic Balance Training in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04719494,COMPLETED,Multiple Sclerosis,OTHER: Dynamic balance walking training,Marquette University,Greater Milwaukee Foundation,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2017-01-01,2019-05-31,2020-08-31,
NCT04114994,Longitudinal Cognitive Assessment by BoCA,https://beta.clinicaltrials.gov/study/NCT04114994,RECRUITING,Alzheimer Disease|Mild Cognitive Impairment|Vascular Dementia|Frontotemporal Dementia|Parkinson Disease|Multiple Sclerosis|TBI,DIAGNOSTIC_TEST: Boston Cognitive Assessment (BoCA),Alzheimer's Light LLC,,ALL,"ADULT, OLDER_ADULT",,10000,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-10-01,2029-10-01,2029-10-01,"Andrey Vyshedskiy, Miami, Florida, 33156, United States"
NCT01307332,Advanced MRI Measures of Repair in Alemtuzumab Treated Patients,https://beta.clinicaltrials.gov/study/NCT01307332,COMPLETED,Relapsing Remitting Multiple Sclerosis,DRUG: MabCampath-1h,University of British Columbia,"Genzyme, a Sanofi Company",ALL,ADULT,PHASE3,27,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-03,2018-09-28,2018-09-28,"University of British Columbia Hospital, Vancouver, British Columbia, V6T 2B5, Canada"
NCT04530318,Dendritic Cells Therapy Combined With Immunomodulatory Treatment in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04530318,RECRUITING,Relapsing-Remitting Multiple Sclerosis,OTHER: Autologous peripheral blood differentiated adult tolerogenic dendritic cells expanded|OTHER: Placebo,Judit Pich,,ALL,"ADULT, OLDER_ADULT",PHASE2,45,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-01-27,2024-10,2024-10,"Hospital Moisés Broggi, Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital Clínic de Barcelona, Barcelona, 08036, Spain|Hospital de Sant Pau, Barcelona, Spain|Hospital del Mar, Barcelona, Spain"
NCT02538094,tDCS and Cognition in Adults With Multiple Sclerosis or Encephalitis,https://beta.clinicaltrials.gov/study/NCT02538094,COMPLETED,Multiple Sclerosis|Encephalitis,DEVICE: Sham Transcranial direct current stimulation|DEVICE: Anodal Transcranial direct current stimulation,Johns Hopkins University,,ALL,"ADULT, OLDER_ADULT",NA,7,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2014-09,2019-06-30,2019-06-30,"Johns Hopkins East Baltimore Campus; Medical Psychiatry department, Baltimore, Maryland, 21287, United States"
NCT04097418,Aerobic Training Effects on Motor and Cognitive Performances in MS: an Exploratory Study With Structural and Functional MRI,https://beta.clinicaltrials.gov/study/NCT04097418,RECRUITING,Multiple Sclerosis,BEHAVIORAL: Aerobic training compared to conventional motor training,IRCCS San Raffaele,,ALL,"ADULT, OLDER_ADULT",NA,80,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2015-06-13,2024-12-31,2024-12-31,"IRCCS San Raffaele, Milan, 20132, Italy"
NCT03693118,Influence of Cognitive Function Software Therapy on the Improvement of Manual Skills in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT03693118,TERMINATED,Multiple Sclerosis,"BEHAVIORAL: Reh1,Reh2",Pomeranian Medical University Szczecin,,ALL,"ADULT, OLDER_ADULT",NA,86,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2018-01-13,2018-04-20,2018-05-30,"Departmen of Neurology, Szczecin, Unii Lubelskiej, 71-228, Poland"
NCT02045732,A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT02045732,TERMINATED,Multiple Sclerosis,BIOLOGICAL: PF-06342674 0.25 mg/kg|BIOLOGICAL: Placebo|BIOLOGICAL: PF-06342674 1.5 mg/kg|BIOLOGICAL: PF-06342674 6.0 mg/kg,Pfizer,,ALL,ADULT,PHASE1,4,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2014-09,2015-10,2015-10,"Albany Advanced Imaging, Albany, New York, 12205, United States|Fallon Wellness Pharmacy, Latham, New York, 12110, United States|Northeast Eye Center, Latham, New York, 12110, United States|The MS Center of Northeastern New York, Latham, New York, 12110, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|Retina Vitreous Center, Edmond, Oklahoma, 73013, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, 73112, United States|Radiology Associates (X-ray facility only), Oklahoma City, Oklahoma, 73112, United States"
NCT02219932,Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02219932,COMPLETED,Multiple Sclerosis,DRUG: fampridine|DRUG: Placebo,Biogen,,ALL,"ADULT, OLDER_ADULT",PHASE3,646,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2014-09,2016-02,2016-02,"Research site, Cullman, Alabama, 35058, United States|Research site, Phoenix, Arizona, 85013, United States|Research site, San Diego, California, 92108, United States|Research site, Bradenton, Florida, 34205, United States|Research Site, Orlando, Florida, 32806, United States|Research site, Tampa, Florida, 33612, United States|Research site, Tampa, Florida, 33634, United States|Research site, West Palm Beach, Florida, 33407, United States|Research site, Lexington, Kentucky, 40513, United States|Research site, New Bedford, Massachusetts, 02740, United States|Research site, Detroit, Michigan, 48201, United States|Research site, Chesterfield, Missouri, 63017, United States|Research site, Rochester, New York, 14642, United States|Research site, Charlotte, North Carolina, 28207, United States|Research site, Charlotte, North Carolina, 28210, United States|Research site, Columbus, Ohio, 43210, United States|Research site, Roanoke, Virginia, 24018, United States|Research site, Pleven, 5800, Bulgaria|Research site, Plovdiv, 4002, Bulgaria|Research site, Sofia, 1113, Bulgaria|Research site, Sofia, 1142, Bulgaria|Research Site, Sofia, 1407, Bulgaria|Research site, Sofia, 1431, Bulgaria|Research site, Sofia, 1606, Bulgaria|Research Site, Sofia, 1797, Bulgaria|Research site, Brno, 62500, Czech Republic|Research site, Brno, 65691, Czech Republic|Research site, Chocen, 56501, Czech Republic|Research site, Havirov, 73601, Czech Republic|Research site, Jihlava, 58633, Czech Republic|Research site, Pardubice, 53203, Czech Republic|Research site, Praha 2, 12808, Czech Republic|Research site, Praha 5, 15006, Czech Republic|Research site, Teplice, 41501, Czech Republic|Research site, Helsinki, 00100, Finland|Research site, Oulu, 90220, Finland|Research site, Tampere, 33520, Finland|Research site, Turku, 20520, Finland|Research Site, Gallarate, Italy|Research site, Messina, 98121, Italy|Research site, Milano, 20133, Italy|Research site, Napoli, 80138, Italy|Research site, Rome, 00189, Italy|Research site, Kaunas, 50009, Lithuania|Research site, Klaipeda, 92288, Lithuania|Research site, Vilnius, 08661, Lithuania|Research Site, Breda, 4818, Netherlands|Research Site, s-Hertogenbosch, 5223, Netherlands|Research Site, Sittard-Geleen, 6162, Netherlands|Research Site, Bialystok, 15-276, Poland|Research site, Gdansk, 80-803, Poland|Research site, Grudziadz, 86-300, Poland|Research Site, Katowice, 40-595, Poland|Research Site, Katowice, 40-749, Poland|Research site, Katowice, 40-752, Poland|Research Site, Kielce, 25-726, Poland|Research site, Krakow, 31-505, Poland|Research site, Krakow, 31-637, Poland|Research site, Lodz, 90-324, Poland|Research site, Olsztyn, 10-561, Poland|Research site, Plewiska, 62064, Poland|Research site, Rzeszow, 35055, Poland|Research site, Warsaw, 00-669, Poland|Research site, Warsaw, 01-697, Poland|Research site, Warsaw, 04-749, Poland|Research Site, Kazan, 420021, Russian Federation|Research site, Kemerovo, 650066, Russian Federation|Research site, Krasnoyarsk, 660037, Russian Federation|Research Site, Moscow, 127015, Russian Federation|Research site, Moscow, 129128, Russian Federation|Research Site, Nizhny Novgorod, 60155, Russian Federation|Research site, Belgrade, 11000, Serbia|Research site, Kragujevac, 34000, Serbia|Research site, Nis, 18000, Serbia|Research site, Exeter, Devon, EX2 5DW, United Kingdom|Research site, Plymouth, Devon, PL6 8DH, United Kingdom|Research site, Romford, Essex, RM7 0AG, United Kingdom|Research site, Salford, Greater Manchester, M6 8HD, United Kingdom|Research site, Norwich, Norfolk, NR4 7UY, United Kingdom|Research site, Glasgow, Scotland, G51 4TF, United Kingdom|Research site, Chertsey, Surrey, KT16 0PZ, United Kingdom|Research site, Cardiff, Swansea, SA6 6NL, United Kingdom|Research site, Birmingham, West Midlands, B15 2WB, United Kingdom|Research site, London, E1 2AT, United Kingdom|Research site, London, NW3 2QG, United Kingdom|Research site, London, WC1N 3BG, United Kingdom|Research site, Nottingham, NG7 2UH, United Kingdom"
NCT00050232,Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT00050232,COMPLETED,Multiple Sclerosis,DRUG: AVP-923,Avanir Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,96,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: DOUBLE|Primary Purpose: TREATMENT,2002-12,2004-06,2004-06,"Barrow Neurological Institute, Phoenix, Arizona, 85013, United States|George Washington University Medical Faculty Associates, Washington, District of Columbia, 20037, United States|Neurological Associates, Ft. Lauderdale, Florida, 33334, United States|Neurology & Headache Specialist of Atlanta, L.L.C., Decatur, Georgia, 30033, United States|Radiant Research Alexian Brothers, Elk Grove Village, Illinois, 60007, United States|Consultants in Neurology LTD, Northbrook, Illinois, 60062, United States|Advanced Neurology Specialists, Great Falls, Montana, 59405, United States|Neurological Associates, P.C., Lincoln, Nebraska, 68506, United States|Upstate Clinical Research, Albany, New York, 12205, United States|DENT Neurologic Group L.L.P., Amherst, New York, 14266, United States|Hospital for Joint Diseases - MS Care Center, New York, New York, 10003, United States|Institute for Human Performance, Syracuse, New York, 13210, United States|Raleigh Neurology Associates, P.A., Raleigh, North Carolina, 27607, United States|NeuroCare Center, Inc., Canton, Ohio, 44718, United States|Leheigh Valley Neurosciences and Pain Research Center, Allentown, Pennsylvania, 18103, United States|Westmorland Neurology, Greensburg, Pennsylvania, 15601, United States|Neurological Associates of Delaware Valley, Upland, Pennsylvania, 19013, United States|FACH-UHC Department of Neurological Services, Burlington, Vermont, 05401, United States|Swedish Medical Center, Seattle, Washington, 98122, United States|Neurology and Neurosurgery Associates of Tacoma, Tacoma, Washington, 98405, United States"
NCT01198132,A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly,https://beta.clinicaltrials.gov/study/NCT01198132,COMPLETED,Multiple Sclerosis,DIETARY_SUPPLEMENT: Cholecalciferol (Vitamin D3)|DIETARY_SUPPLEMENT: Placebo|DRUG: Rebif,"Merck KGaA, Darmstadt, Germany","Merck Serono S.A.S, France",ALL,"ADULT, OLDER_ADULT",PHASE2,129,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE",2009-11,2015-03,2015-11,"CHU Hôpital Gui de Chauliac Service de Neurologie B, Montpellier, France"
NCT01541618,A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01541618,COMPLETED,Relapsing Remitting Multiple Sclerosis,OTHER: MSDX Complex-1 Biomarker test,"MSDx, Inc.",,ALL,"ADULT, OLDER_ADULT",,15,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-01,2012-07,2012-07,"Northwest NeuroSpecialists, PLLC, Tucson, Arizona, 85741, United States"
NCT03319732,A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS,https://beta.clinicaltrials.gov/study/NCT03319732,COMPLETED,"Multiple Sclerosis|Spasticity, Muscle",DRUG: Arbaclofen,"RVL Pharmaceuticals, Inc.",Osmotica Pharmaceutical US LLC,ALL,"ADULT, OLDER_ADULT",PHASE3,323,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-04-03,2020-01-27,2020-06-11,"Neuro Pain Medical Center, Fresno, California, 93710, United States"
NCT05420532,Designing Virtual Reality-based Software for People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05420532,RECRUITING,Multiple Sclerosis,OTHER: Exergaming,Yuzuncu Yıl University,Dokuz Eylul University,ALL,"ADULT, OLDER_ADULT",NA,15,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-01-30,2023-07-15,2023-08-30,"Dokuz Eylul University, İzmir, Turkey"
NCT01815632,Assessment of Bone Marrow-derived Cellular Therapy in Progressive Multiple Sclerosis (ACTiMuS),https://beta.clinicaltrials.gov/study/NCT01815632,UNKNOWN,Progressive Multiple Sclerosis,OTHER: Early infusion of autologous marrow|OTHER: Late infusion of autologous marrow,North Bristol NHS Trust,Bristol Royal Hospital for Children|University of Bristol|University of Nottingham|NHS Blood and Transplant|Kenneth and Claudia Silverman Family Foundation|Multiple Sclerosis Trust|Medical Research Council|Rosetrees Trust|Catholic Bishops of England and Wales|Friends of Frenchay,ALL,"ADULT, OLDER_ADULT",PHASE2,80,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-01,2019-10,2019-10,"Southmead Hospital, Bristol, BS10 5NB, United Kingdom"
NCT04028232,Influence of Socio-Economic Factor on Net Survival in Patients With Multiple Sclerosis in France ( ECOVIMUS).,https://beta.clinicaltrials.gov/study/NCT04028232,UNKNOWN,C10.114.375.500,,"University Hospital, Caen",Ecole des Hautes Etudes en Santé Publique|Hospices Civils de Lyon,ALL,"CHILD, ADULT, OLDER_ADULT",,30000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-07-10,2020-04-30,2020-12-31,"University Hospital Center of CAEN, Caen, Normandy, 14033, France|University Hospital of Besancon, Besançon, France|University Hospital of Bordeaux, Bordeaux, France|University Hospital Centre of Caen, Caen, France|University Hospital of Clermont Ferrand, Clermont-Ferrand, France|University Hospital of Dijon, Dijon, France|University Hospital of Lille, Lille, France|University Hospital of Lyon, Lyon, France|University Hospital of Marseille, Marseille, France|University Hospital of Montpellier, Montpellier, France|University Hospital of Nancy, Nancy, France|University Hospital of Nantes, Nantes, France|University Hospital of Nice, Nice, France|University hospital Centre of Nîmes, Nîmes, France|University Hospital of Rennes, Rennes, France|University Hospital Centre of Saint-Etienne, Saint-Étienne, France|University Hospital of Strasbourg, Strasbourg, France|University Hospital Centre of Toulouse, Toulouse, France"
NCT05147532,Remyelination in Multiple Sclerosis: a PET-MR Longitudinal Study Investigating Individual Profiles of Myelin Repair and the Contribution of Neuroinflammation,https://beta.clinicaltrials.gov/study/NCT05147532,NOT_YET_RECRUITING,Multiple Sclerosis|Inflammatory Disease,PROCEDURE: PET-MRI with [18F]-Florbetaben and PET-MRI with [18F]-DPA-714,Assistance Publique - Hôpitaux de Paris,,ALL,ADULT,NA,80,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2022-01,2023-10,2024-05,
NCT03706118,Physiologic Volume and Atrophy of Brain and Spinal Cord Measured by Magnetic Resonance Imaging,https://beta.clinicaltrials.gov/study/NCT03706118,UNKNOWN,Cognitive Change|Atrophy Brain|Atrophy; Spinal Cord|Multiple Sclerosis,OTHER: Magnetic resonance imaging,Dana Horakova,,ALL,ADULT,NA,102,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2018-03-15,2018-09-14,2021-11-01,"Dpt of Neurology, Charles University and General University Hospital in Prague, Prague, 12000, Czechia"
NCT04875832,EMDR for Depressed People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04875832,UNKNOWN,Multiple Sclerosis|Depression,BEHAVIORAL: Eye Movement Desensitization and Reprocessing - EMDR,Fondazione Don Carlo Gnocchi Onlus,EMDR Europe|Catholic University of the Sacred Heart,ALL,"ADULT, OLDER_ADULT",NA,15,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-05,2022-08,2022-11,
NCT02297932,Physical Activity in Multiple Sclerosis (MS): A Novel Approach to Study Outcomes,https://beta.clinicaltrials.gov/study/NCT02297932,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Strength training|BEHAVIORAL: Stretching,Kessler Foundation,University of Illinois at Urbana-Champaign,ALL,ADULT,NA,18,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2014-11,2016-06,2016-06,"Kessler Foundation, West Orange, New Jersey, 07052, United States"
NCT00001532,Role of Genetic Factors in the Development of Lung Disease,https://beta.clinicaltrials.gov/study/NCT00001532,RECRUITING,Cystic Fibrosis|Pulmonary Fibrosis|Tuberous Sclerosis|Asthma|Pulmonary Sarcoidosis,,"National Heart, Lung, and Blood Institute (NHLBI)",Suburban Hospital,ALL,"CHILD, ADULT, OLDER_ADULT",,3500,NIH,OBSERVATIONAL,Observational Model: |Time Perspective: p,1996-09-13,,,"National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States"
NCT01871818,A Trial to Compare the Effectiveness of Two Rehabilitation Programs for Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT01871818,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Combined program|BEHAVIORAL: Physiotherapy in private practice,Assistance Publique - Hôpitaux de Paris,,ALL,"ADULT, OLDER_ADULT",NA,240,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-05,2017-04,2017-10,"Physical medicine and rehabilation Department, Hôpital RAYMOND POINCARE, Garches, Hauts DE Seine, 92380, France"
NCT04175418,The Effects of Two Different Types of Exercise Programs to Increase Physical Activity in Patients With MS,https://beta.clinicaltrials.gov/study/NCT04175418,UNKNOWN,Multiple Sclerosis,OTHER: Supervised Exercise Program|OTHER: Online Education Program,Istanbul University - Cerrahpasa (IUC),"Prof.Dr.Mazhar Osman Mental Health and Psychiatric Diseases Education, Research Hospital",ALL,ADULT,NA,30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2019-10-14,2020-06,2020-09,"Istanbul University-Cerrahpasa, Istanbul, 34000, Turkey"
NCT03660618,"LSFG-SKIN, Laser Speckle Flowgraphy",https://beta.clinicaltrials.gov/study/NCT03660618,TERMINATED,Hypertension|Heart Failure|Vascular Ischemia|Burns|Chemotherapy Effect|Radiation Injuries|Uveitis|Scleritis|Multiple Sclerosis|Autonomic Neuropathy|Stroke|Intracranial Hemorrhages|TIA|Migraine|Headache|Pain,DEVICE: laser speckle flowgraphy,Randy Kardon,,ALL,"ADULT, OLDER_ADULT",NA,1,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2017-05-23,2019-03-02,2019-03-02,"University of Iowa Department of Ophthalmology, Iowa City, Iowa, 52242, United States"
NCT01324232,Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01324232,COMPLETED,Central Neuropathic Pain|Multiple Sclerosis,DRUG: AVP-923-45|DRUG: AVP-923-30|DRUG: AVP-923-20|DRUG: Placebo,Avanir Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE2,209,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-09-08,2013-09-26,2013-09-26,"North Central Neurology Associates PC, Cullman, Alabama, 35058, United States|St. Joseph's Hospital Medical Center, Phoenix, Arizona, 85013, United States|Alta Bates Summit Medical Center, Berkeley, California, 94705, United States|University of California, Irvine, Orange, California, 92868, United States|Coordinated Clinical Research, San Diego, California, 92103, United States|University of California, San Francisco, San Francisco, California, 94158, United States|University of Colorado, Aurora, Colorado, 80045, United States|Neurology Associates, PA, Maitland, Florida, 32751, United States|Collier Neurologic Specialists, Naples, Florida, 34102, United States|Laszlo J. Mate, MD, North Palm Beach, Florida, 33408, United States|Neurology Associates of Ormond Beach, Ormond Beach, Florida, 32174, United States|Neurological Associates, Pompano Beach, Florida, 33060, United States|Neurologique Foundation, Ponte Vedra Beach, Florida, 32082-4040, United States|Suncoast Neuroscience Associates, Inc., Saint Petersburg, Florida, 33713, United States|University of South Florida, Tampa, Florida, 33612, United States|Geodyssey Research, LLC, Vero Beach, Florida, 32960, United States|Shepard Center, Atlanta, Georgia, 30309, United States|Rush-Presbyterian St. Luke's Medical Center, Chicago, Illinois, 60612, United States|Consultants in Neurology, Northbrook, Illinois, 60062, United States|Josephson Wallack Munshower Neurology, P.C., Indianapolis, Indiana, 46256, United States|MidAmerica Neuroscience Institute, Lenexa, Kansas, 66214, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, 21287, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States|Michigan Neurology Associates, P.C., Clinton Township, Michigan, 48035, United States|Wayne State University, Detroit, Michigan, 48201, United States|Henry Ford Health System, Detroit, Michigan, 48202, United States|Advanced Neurology Specialists, Great Falls, Montana, 59405, United States|Neurology Associates PC, Lincoln, Nebraska, 68506, United States|Albany Medical Center Hospital, Albany, New York, 12208, United States|NYU-Hospital for Joint Diseases, New York, New York, 10003, United States|University of Rochester, Rochester, New York, 14642, United States|SUNY at Stony Brook, Stony Brook, New York, 11794, United States|Carolinas Medical Center, Charlotte, North Carolina, 28207, United States|Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States|Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, 73104, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, 19107, United States|Geisinger Health System, Wilkes-Barre, Pennsylvania, 18711, United States|Advanced Neurosciences Institute, Franklin, Tennessee, 37064, United States|Baylor College of Medicine, Houston, Texas, 77030, United States|Rocky Mountain MS Clinic, Salt Lake City, Utah, 84103, United States|Neurological Associates, Henrico, Virginia, 23226, United States|MS Center of Greater Washington, Vienna, Virginia, 22182, United States|Swedish Medical Center, Seattle, Washington, 98122, United States|MultiCare Health System, Tacoma, Washington, 98405, United States|Instituto de Neurologia Cognitiva, Ciudad Autonoma de Buenos Aires, Buenos Aires, C1126AAB, Argentina|Hospital Britanico de Buenos Aires, Ciudad Autonoma de Buenos Aires, Buenos Aires, C1280AEB, Argentina|Hospital Italiano, Ciudad Autónoma de Buenos Aires, Buenos Aires, C1181ACH, Argentina|Instituto Argentino de Investigacion Neurologica, Ciudad de Buenos Aires, Buenos Aires, C1015ABR, Argentina|Hospital Churruca-Visca, Buenos Aires, C1437JCH, Argentina|Fundación Argentina Contra las Enfermedades Neurológicas del Envejecimiento - FACENE, Buenos Aires, CP1117ABD, Argentina|Medeos - Centro de Medicina Integral e Investigación Clínica, Ciudad Autonoma de Buenos Aires, Argentina|Instituto de Neurología y Neurorrehabilitación del Litoral, Santa Fe, Argentina|Fakultni nemocnice u sv. Anny v Brne, Brno, Czechia|Fakultni nemocnice Hradec Kralove, Hradec Kralove, 500 0, Czechia|Nemocnice Jihlava, prispevkova organizace, Jihlava, 586 33, Czechia|Fakultni Nemocnice Ostrava, Ostrava, 708 52, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, 128 21, Czechia|Szpital Powiatowy w Czeladzi, Czeladz, 41-250, Poland|Pomorskie Centrum Traumatologii im. M. Kopernika w Gdansku, Gdansk, 80-803, Poland|Diagnomed Clinical Research Sp. z.o.o., Katowice, 40-594, Poland|Niepubliczny Zaklad Opieki Zdrowotnej NEURO-MEDIC, Katowice, 40-752, Poland|Niepubliczny Zaklad Opieki Zdrowotnej PROFILAKTYKA, Katowice, Poland|Zespol Opieki Zdrowotnej w Konskich, Konskie, 26-200, Poland|Specjalistyczny Gabinet Neurologiczny, Plewiska, 62-064, Poland|Niepubliczny Zaklad Opieki Zdrowotnej NEURO-KARD Ilkowski i Partnerzy Spolka Partnerska Lekarzy, Poznan, 61-289, Poland|Osrodek Badan Klinicznych Indywidualnej Specjalistycznej Praktyki Lekarskiej, Szczecin, 70-215, Poland|Hospital del Mar, Barcelona, Cataluña, 08003, Spain|Hospital Vall D´Hebron, Barcelona, Cataluña, 08035, Spain|Hospital Universitari de Girona Dr. Josep Trueta, Girona, Cataluña, 17007, Spain|Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, 30120, Spain|Hospital Univ. Nuestra Sra. De La Candelaria, Santa Cruz De Tenerife, 38010, Spain|Hospital Universitario Vírgen Macarena, Sevilla, 41009, Spain"
NCT05519553,Peer Support Impact on Therapeutic Adherence in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05519553,NOT_YET_RECRUITING,"Multiple Sclerosis, Relapsing-remitting",OTHER: Peer support,Nantes University Hospital,,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2022-11-01,2024-03-01,2026-03-01,
NCT04231253,MUltiple Sclerosis : T Cell / B Cell Exploration,https://beta.clinicaltrials.gov/study/NCT04231253,COMPLETED,Multiple Sclerosis,,Rennes University Hospital,,ALL,"ADULT, OLDER_ADULT",,90,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-02-25,2021-10-31,2021-10-31,"Rennes University Hospital, Rennes, 35033, France"
NCT00930553,An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab,https://beta.clinicaltrials.gov/study/NCT00930553,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",BIOLOGICAL: alemtuzumab,"Genzyme, a Sanofi Company",Bayer,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,1314,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2009-08,2016-02,2016-02,"North Central Neurology Associates, P.C., Cullman, Alabama, United States|HOPE Research Institute, Phoenix, Arizona, United States|St. Joseph's Hospital and Medical Center Barrow Neurology Clinics - Barrow Neurological Institute, Phoenix, Arizona, United States|Mayo Clinic Arizona (Scottsdale), Scottsdale, Arizona, United States|Northwest NeuroSpecialists, PLLC, Tucson, Arizona, United States|East Bay Physicians Medical Group/ Sutter East Bay Medical Foundation, Berkeley, California, United States|Neurology Center North Orange County, La Habra, California, United States|University of Southern California Keck School of Medicine/University of Southern California LAC & USC Medical Center, Los Angeles, California, United States|Neuro-Therapeutics, Inc., Pasadena, California, United States|Stanford University Medical Center, Stanford, California, United States|University of Colorado Health Science Center - Aurora, Aurora, Colorado, United States|Advanced Neurology of Colorado, Fort Collins, Colorado, United States|Yale MS Research Center, New Haven, Connecticut, United States|The George Washington University Medical Faculty Associates, Washington, D.C., District of Columbia, United States|University of Florida Neuroscience Institute, Jacksonville, Florida, United States|Neurology Associates, P.A., Maitland, Florida, United States|Neurological Associates, Pompano Beach, Florida, United States|Negroski, Stein, Sutherland and Hanes Neurology, Sarasota, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|University of South Florida College of Medicine, Tampa, Florida, United States|Emory University Department of Neurology, Atlanta, Georgia, United States|Shepherd Center Multiple Sclerosis Institute, Atlanta, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Consultants in Neurology, LTD, Northbrook, Illinois, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, United States|Indiana University Multiple Sclerosis Center, Indianapolis, Indiana, United States|Iowa Health Physicians, Des Moines, Iowa, United States|Ruan Neurology Clinic and Clinical Research Center, Mercy Medical Center, Des Moines, Iowa, United States|University of Kansas Medical Center, Department of Neurology, Kansas City, Kansas, United States|MidAmerica Neuroscience Institute, Lenexa, Kansas, United States|Associates in Neurology, P.S.C., Lexington, Kentucky, United States|Kentucky Neuroscience Research, Louisville, Kentucky, United States|University of Maryland, Maryland Center for MS, Baltimore, Maryland, United States|The MS Center at St. Elizabeth's, Boston, Massachusetts, United States|UMass Memorial Medical Center, Worcester, Massachusetts, United States|University of Michigan Medical School, Ann Arbor, Michigan, United States|Michigan Neurology Association, Clinton, Michigan, United States|Wayne State University, The School of Medicine, Department of Neurology, Detroit, Michigan, United States|Spectrum Health Medical Group, Neurology/Michigan Medical P.C., West Michigan MS Clinic, Grand Rapids, Michigan, United States|Northern Michigan Neurology, Traverse City, Michigan, United States|Saint Luke's Brain & Stroke Institute, Kansas City, Missouri, United States|Renown Institute for Neurosciences, Reno, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|MS Center at Holy Name Hospital, Teaneck, New Jersey, United States|University of New Mexico, Dept. of Neurology, Albuquerque, New Mexico, United States|Empire Neurology P.C., Latham, New York, United States|Winthrop University Hospital Multiple Sclerosis Treatment Center, Mineola, New York, United States|MS Care Center at NYUMC and HJD, New York, New York, United States|The Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai, New York, New York, United States|South Shore Neurologic Associates, P.C., Patchogue, New York, United States|Rochester Multiple Sclerosis Center, Rochester, New York, United States|SUNY Upstate Medical University, Department of Neurology, Syracuse, New York, United States|The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Wake Forest University Health Science Department of Neurology, Winston-Salem, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Oak Clinic for Multiple Sclerosis, Uniontown, Ohio, United States|OMRF Multiple Sclerosis Center of Excellence, Oklahoma City, Oklahoma, United States|Lehigh Valley Hospital Neurosciences and Pain Research, Allentown, Pennsylvania, United States|Rhode Island Hospital MS Center - The Neurology Foundation, Inc, Providence, Rhode Island, United States|Neurology Clinic PC, Cordova, Tennessee, United States|Advanced Neurosciences Institute, Franklin, Tennessee, United States|Hope Neurology, Knoxville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor College of Medicine, Maxine Mesinger MS Clinic, Houston, Texas, United States|Central Texas Neurology Consultants, Round Rock, Texas, United States|Integra Clinical Research, San Antonio, Texas, United States|Neurology Center of San Antonio, San Antonio, Texas, United States|MS Center of Greater Washington, Vienna, Virginia, United States|Swedish Medical MS Center, Seattle, Washington, United States|DIABAID, Buenos Aires, Argentina|Concord Repatriation General Hospital, Concord, New South Wales, Australia|Southern Neurology, Kogarah, New South Wales, Australia|Liverpool Hospital, Liverpool, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Gold Coast Hospital, Southport, Queensland, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|St. Vincent's Hospital, Fitzroy, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|The Wesley Research Institute, Auchenflower QLD, Australia|The Queen Elizabeth Hospital, Woodville, SA, Australia|AKH Wien-Universitätskliniken für Neurologie, Vienna, Austria|Cliniques Universitaires Saint-luc, Brussel, Belgium|CHU Ourthe Amblève, Esneux, Belgium|University Hospital Leuven, Campus Gasthuisberg, Leuven, Belgium|Hospital Mae de Deus, Porto Alegre, Brazil|Hospital da Restauração, Neurology department, Recife, PE, Brazil|Irmandade da Santa Casa de Misericórdio de São Paulo, Neurology department, São Paulo, SP, Brazil|Hospital das Clínicas da Faculdade de Medicina da USP, Neurology department, São Paulo,SP, Brazil|University of Calgary, Department of Neurology, Calgary, Alberta, Canada|Kingston General Hospital MS Clinic, Kingston, Ontario, Canada|Clinique Neuro-Outaouais, Gatineau, Quebec, Canada|Recherche Sepmus, Inc., Greenfield Park, Quebec, Canada|Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada|London Health Sciences Centre - University Hospital, London, ON, Canada|The Ottawa Hospital - MS Research, Ottawa, Ontario, Canada|University of British Columbia, Vancouver, BC, Canada|Clinical Hospital Osijek, Osijek, Croatia|Clinical Hospital Centre Rijeka, Rijeka, Croatia|General Hospital Varazdin, Department for Neurology, Varazdin, Croatia|Clinical Hospital Centre ""Sestre Milosrdnice"", Zagreb, Croatia|Clinical Hospital Centre Zagreb, Zagreb, Croatia|Clinical Hospital Sveti Duh, Zagreb, Croatia|St. Anne's University Hospital Brno, Brno, Czechia|University Hospital Hradec Králové, Hradec Kralove, Czechia|General Hospital, 128 21 Praha 2, Prague, Czechia|Hospital Teplice, Neurology Department, MS centrum, Teplice, Czechia|Rigshospitalet Department of Neurology, Copenhagen, Denmark|Aarhus Sygehus, Århus C, Denmark|Hôpital Général, Dijon Cedex, France|Groupe Hospitalier Pitié-Salpêtrière, Fédération de Maladies du System Nerveux Central, Paris Cedex 13, France|CHU Pontchaillou, Rennes Cedex 9, France|Hôpital Civil, Strasbourg Cedex, France|CHU de Toulouse, Hôpital Purpan, Toulouse Cedex 9, France|Klinik und Poliklinik für Neurologie, Universitätsklinikum Bonn, Bonn, DE, Germany|Jüdisches Krankenhaus Berlin, Berlin-Mitte, Germany|Universitätsklinik Carl Gustav Carus Dresden, Dresden, Germany|Klinikum der JW Goethe Universität, Frankfurt am Main, Germany|Asklepios Klinik Barmbek, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Oberhavel Klinicum GmbH - Krankenhaus Hennigsdorf, Hennigsdorf, Germany|Klinikum Ingolstadt, Ingolstadt, Germany|Klinikum rechts der Isar, München, Germany|Medizinische Fakultät der Universität Rostock,Zentrum für Nervenheilkunde, Rostock, Germany|Universitätsklinikum Ulm, Klinik für Neurologie im RKU, Ulm, Germany|Fachkrankenhaus Hubertusburg GmbH, Klinik für Neurologie und Neurologische Intensivmedizin, Wermsdorf, Germany|Hadassah Medical Center Ein Karem, Ein Karem, Jerusalem, Israel|Sheba Medical Center, Ramat Gan, Israel|Sourasky Tel Aviv Medical Center, Tel Aviv, Israel|Università di Cagliari, Cagliari, Italy|Ospedale S. Antonio Abate di Gallarate, Gallarate (Varese), Italy|Ospedale S. Luigi Gonzaga, Orbassano (TO), Italy|Universita Degli Studi di Roma ""La Sapienza"", Roma, Italy|Unidad de Investigación en Salud, Chihuahua, CHH, Mexico|Medica Sur, Mexico City, DFE, Mexico|Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands|Orbis Medisch Concern, Sittard-Geleen, Netherlands|Centrum Neurologii Klinicznej Sp. Zo.o., Krakow, Poland|Samodzielny Publiczny ZOZ, Uniwersytecki Szpital Kliniczny Nr1 im. Norberta Barlickiego, Lodz, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie, Lublin, Poland|Szpital Kliniczny im. Heliodora Swiecickiego Uniwersytetu Med. im. Karola Marcinkowskiego w Poznaniu, Poznan, Poland|Institute of Psychiatry and Neurology/Instytut Psychiatrii i Neurologii, Warsaw, Poland|Research Medical Complex ""Your Health"" Ltd, Kazan, Russian Federation|Moscow State Public Medical Institution Clinical Hospital #11, Neurology Department, Moscow, Russian Federation|Neurology Research Center under the Russian Academy of Medical Sciences, Moscow, Russian Federation|Russian State Medical University, Department of Neurology and Neurosurgery, Moscow, Russian Federation|Municipal Treatment and Prevention Institution, City Hospital #33, Nizhny Novgorod, Russian Federation|Federal State Public Medical Institution: Siberian District Medical Center under the Federal Agency, Novosibirsk, Russian Federation|Municipal Public Medical Institution: City Hospital #2 of Pyatigorsk, Neurology Department, Pyatigorsk, Russian Federation|Samara Regional Clinical Hospital n.a. Kalinin, Samara, Russian Federation|Institute of Human Brain RAS, Laboratory of Neuroimmunology, St. Petersburg, Russian Federation|St Petersburg State Pavlov Medical University, Dept of Neurology and Neurosurgery with a Hospital, St. Petersburg, Russian Federation|St. Petersburg General Hospital #2, Neurology Department #2, St. Petersburg, Russian Federation|St. Petersburg State Public Medical Institution: Nikolayevskaya Hospital, St. Petersburg, Russian Federation|State Public Medical Institution: Republican Clinical Hospital n.a. G.G. Kuvatov, Ufa, Russian Federation|Clinical Centre Serbia, Institute of Neurology,Dr.Subotica 6,Belgrade, Belgrade, Serbia|Military Medical Academy, Institute of Neurology, Belgrade, Serbia|Clinical Centre Kragujevac, Clinic of Neurology, Kragujevac, Serbia|Clinical Centre Nis, Clinic of Neurology, Nis, Serbia|Clinical Centre Vojvodina, Novi Sad, Serbia|Hospital Universitario Vall d' Hebron, Barcelona, Spain|Hospital Clínico Universitario San Carlos, Madrid, Spain|Hospital Carlos Haya, Neurology Service, Málaga, Spain|Hospital Virgen Macarena, Seville, Spain|SU/Östra sjukhuset, Göteborg, Sweden|Norrlands Universitets sjukhus, Umeå, Sweden|Institute of Neurology, Psychiatry and Narcology under the AMS of Ukraine, Dep of Neuroinfection& MS, Kharkov, Ukraine|Hospital of Directorate of the Medical Corps within the Ukrainian Security Service, Neurology Dept., Kiev-21, Ukraine|Kiev Municipal Clinical Hospital #4, Department of Demyelinating Diseases of the Nervous System, Kiev, Ukraine|Lviv National Medical University n.a. Danylo Galytsky, Department of Neurology, Lviv, Ukraine|Frenchay Hospital, Bristol, United Kingdom|Addenbrookes Hospital, Cambridge, United Kingdom|University Hospital of Wales, Dept of Neurology, Cardiff, United Kingdom|Royal London Hospital, London, United Kingdom|Salford Royal NHS Foundation Trust, Salford, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom"
NCT00405353,Testosterone Treatment for Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00405353,COMPLETED,Multiple Sclerosis,DRUG: Androgel 10 grams of gel containing 100 mg of testosterone,"University of California, Los Angeles",National Multiple Sclerosis Society,MALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,10,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2002-04,2007-03,2007-03,"University of California, Los Angeles, Los Angeles, California, 90095, United States"
NCT01567553,The Inflammatory Process and the Medical Imaging in Patients With an Inflammatory Disease of the Central Nervous System.,https://beta.clinicaltrials.gov/study/NCT01567553,TERMINATED,Multiple Sclerosis (MS)|Inflammatory Disease,OTHER: USPIO MRI - Gadolinium MRI,Rennes University Hospital,Bayer,ALL,ADULT,,37,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2009-04,2014-06,2015-06,"La Timone University Hospital (APHM), Marseille, 13385, France|La Pitie-Salpaetriere Hospital (APHP), Paris, 75013, France|Maison Blanche Hospital, Reims, 51092, France|Rennes University Hospital, Rennes, 35000, France|Purpan Hospital, Toulouse, 31059, France"
NCT04255953,Development of a Telehealth Obesity Intervention for Patients With MS: Modifying Diet and Exercise in MS,https://beta.clinicaltrials.gov/study/NCT04255953,ACTIVE_NOT_RECRUITING,Multiple Sclerosis|Obesity,BEHAVIORAL: behavioral telehealth|OTHER: Treatment as Usual,Jared Bruce,National Multiple Sclerosis Society|University of Kansas Medical Center|Children's Mercy Hospital Kansas City,ALL,"ADULT, OLDER_ADULT",NA,70,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-08-01,2024-10,2024-10,"University of Missouri-Kansas City, Kansas City, Missouri, 64110, United States"
NCT05663853,An Observational Biomarker Study in Multiple Sclerosis (MS) Patients,https://beta.clinicaltrials.gov/study/NCT05663853,RECRUITING,"Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis, Primary Progressive|Multiple Sclerosis, Secondary Progressive",,LAPIX Therapeutics Inc.,,ALL,"ADULT, OLDER_ADULT",,200,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-03-28,2023-10-01,2024-01-01,"The Johns Hopkins University, Baltimore, Maryland, 21205, United States|MedStar Health, Chevy Chase, Maryland, 20815, United States|Corinne Goldsmith Dickinson Center for MS, New York, New York, 10029, United States|Mellen Center, Cleveland, Ohio, 44195, United States"
NCT04252053,The Effects of Pilates-Based Core Stabilization Training in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04252053,COMPLETED,Multiple Sclerosis,OTHER: Pilates Based Core Stabilization Training|OTHER: Home based exercise,Istanbul University - Cerrahpasa (IUC),,ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2020-02-06,2021-01-03,2021-01-03,"Istanbul University-Cerrahpasa, Istanbul, 34147, Turkey"
NCT00872053,Effect of Robot-assisted Training on Foot Drop in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00872053,COMPLETED,MS (Multiple Sclerosis),DEVICE: Anklebot|DEVICE: Lokomat,US Department of Veterans Affairs,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,18,FED,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2009-02,2009-12,2010-01,"Providence VA Medical Center, Providence, Rhode Island, 02908-4799, United States"
NCT00094172,Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00094172,COMPLETED,Multiple Sclerosis,DRUG: Atorvastatin|DRUG: Placebo,National Institute of Allergy and Infectious Diseases (NIAID),Immune Tolerance Network (ITN),ALL,ADULT,PHASE2,82,NIH,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2005-05,2009-05,2009-05,"Barrow Neurological Institute, Phoenix, Arizona, 85013, United States|Keck School of Medicine, Los Angeles, California, 90033, United States|University of California, San Francisco, San Francisco, California, 94143, United States|Yale MS Research Center, New Haven, Connecticut, 06510, United States|Johns Hopkins, Baltimore, Maryland, 21287, United States|Washington University Multiple Sclerosis Center, St Louis, Missouri, 63110, United States|Jacobs Neurological Institute, Buffalo, New York, 14203, United States|Mount Sinai School of Medicine, New York, New York, 10029, United States|University of Rochester, Rochester, New York, 14642, United States|Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States|Oregon Health Sciences University, Portland, Oregon, 97201, United States|University of Texas Southwestern Medical Center, Dallas, Texas, 75930, United States|Virginia Mason MS Center, Seattle, Washington, 98111, United States|Montreal Neurological Institute, Montreal, Quebec, H3A 2B4, Canada"
NCT05247372,The Effect of Iyengar Yoga Practice on Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05247372,ACTIVE_NOT_RECRUITING,"Multiple Sclerosis, Iyenagar Yoga, Yoga, EDSS",OTHER: The effect of Iyengar yoga practice on patients with multiple sclerosis,"University Hospital, Motol",,FEMALE,"ADULT, OLDER_ADULT",NA,5,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-06-25,2022-06-30,2022-06-30,"University Hospital Motol, Prague, Czech Republic, 15006, Czechia"
NCT01074346,Tolerability of Rebif® (Interferon-beta 1-A) Therapy in Korean Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01074346,COMPLETED,Multiple Sclerosis,DRUG: Interferon-β-1a,"Merck KGaA, Darmstadt, Germany",,ALL,"CHILD, ADULT, OLDER_ADULT",,60,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2008-08,2011-11,2011-11,"Samsung Medical Center, Seoul, 50 Ilwon-dong, Gangnam-gu, Korea, Republic of"
NCT04153773,OCT and Early Cognitive Impairment in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04153773,COMPLETED,Multiple Sclerosis,DIAGNOSTIC_TEST: OCT,Mansoura University Hospital,,ALL,ADULT,,90,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-08-01,2019-06-01,2019-09-01,"Mansoura University Hospital, Mansoura, Dakahlia, 35516, Egypt"
NCT03782246,MBCT and CBT for Chronic Pain in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03782246,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,BEHAVIORAL: MBCT|BEHAVIORAL: CBT,University of Washington,National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",NA,273,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2018-11-28,2022-08-01,2022-08-01,"UW Medicine Multiple Sclerosis Center, Seattle, Washington, 98195, United States"
NCT00000146,Optic Neuritis Treatment Trial (ONTT),https://beta.clinicaltrials.gov/study/NCT00000146,UNKNOWN,Multiple Sclerosis|Optic Neuritis,DRUG: Methylprednisolone|DRUG: Prednisone,National Eye Institute (NEI),,ALL,ADULT,PHASE3,,NIH,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: |Masking: SINGLE|Primary Purpose: TREATMENT,1988-07,,,"University of Arkansas, Little Rock, Arkansas, United States|California Pacific Medical Center, San Francisco, California, United States|Georgetown University, Washington, District of Columbia, United States|University of Florida, Gainesville, Florida, United States|University of Illinois, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|Johns Hopkins University, Baltimore, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|Michigan State University, East Lansing, Michigan, United States|New York University, New York, New York, United States|Duke University, Durham, North Carolina, United States|Devers Eye Institute, Portland, Oregon, United States|Wills Eye Hospital, Philadelphia, Pennsylvania, United States|Baylor College of Medicine, Houston, Texas, United States|Swedish Medical Center, Seattle, Washington, United States"
NCT02314585,Fall Risk Reduction in Multiple Sclerosis (FIRMS),https://beta.clinicaltrials.gov/study/NCT02314585,UNKNOWN,Multiple Sclerosis,OTHER: Exercise|OTHER: Education,University of Illinois at Urbana-Champaign,,ALL,ADULT,NA,100,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: ",2014-12,2018-01,2018-01,"Motor control research lab, Urbana, Illinois, 61801, United States"
NCT02583386,Comprehensive Fall Prevention and Detection in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02583386,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Free From Falls fall prevention program|OTHER: Electronic Fall Detector,Portland VA Medical Center,Oregon Health and Science University,ALL,"ADULT, OLDER_ADULT",NA,96,FED,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2016-04,2019-10,2019-10,"VA Portland Health Care System, Portland, Oregon, 97239, United States"
NCT01337986,Ampyra for Optic Neuritis in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01337986,COMPLETED,Multiple Sclerosis|Optic Neuritis,DRUG: Dalfampridine/Placebo|DRUG: Placebo/Dalfampridine,Washington University School of Medicine,Acorda Therapeutics,ALL,ADULT,PHASE2|PHASE3,53,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2011-05,2013-12,2013-12,"Washington University (John L. Trotter MS Center), Saint Louis, Missouri, 63110, United States"
NCT05110586,"Electrical Stimulations on Pain, Functional Capacity and Quality of Life in Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT05110586,COMPLETED,Multiple Sclerosis,OTHER: Electrotherapy,Kahramanmaras Sutcu Imam University,,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-05-01,2022-08-15,2022-08-30,"Kahramanmaraş Sutcu Imam University, Kahramanmaraş, Turkey"
NCT01601119,Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients,https://beta.clinicaltrials.gov/study/NCT01601119,COMPLETED,Relapsing Multiple Sclerosis,DRUG: Rebif|OTHER: Other: Disease modifying therapies (DMT),"Merck KGaA, Darmstadt, Germany","Merck Serono Limited, UK",ALL,"ADULT, OLDER_ADULT",,545,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-01,2014-07,2014-07,"Please contact the, Merck KGaA Communication Center for locations, United Kingdom"
NCT04192786,Local Vibration in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT04192786,UNKNOWN,Multiple Sclerosis,OTHER: Standard physiotherapy program+50 Hz local vibration|OTHER: Standard physiotherapy program+100 Hz local vibration|OTHER: Standard physiotherapy program,Hacettepe University,,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2019-12-15,2020-11,2020-12,"Hacettepe University, Faculty of Physical Therapy and Rehabilitation, Ankara, Altındağ, 06100, Turkey"
NCT02212886,"Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMS",https://beta.clinicaltrials.gov/study/NCT02212886,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,DRUG: GA Depot 80 mg|DRUG: GA Depot 40 mg,Mapi Pharma Ltd.,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,25,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2014-10,2017-05,2024-11,"Barzilai Medical Center, Ashkelon, Israel|Rambam Medical Center, Haifa, Israel|TASMC, Tel Aviv, Israel"
NCT03586986,Risk Factors in Early Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03586986,RECRUITING,Multiple Sclerosis|Magnetic Resonance Imaging|Biomarkers|Clinically Isolated Syndrome|Radiologically Isolated Syndrome,DIAGNOSTIC_TEST: Brain MRI,"University of Colorado, Denver",Colorado School of Public Health,ALL,ADULT,,300,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-07-26,2024-05,2024-05,"University of Colorado Anschutz Medical Campus, Aurora, Colorado, 80045, United States"
NCT04996186,Symptoms and Treatment Assessment of Ano-Rectal Disorders in Multiple Sclerosis Patients : STAR-Q,https://beta.clinicaltrials.gov/study/NCT04996186,COMPLETED,Multiple Sclerosis|Constipation|Fecal Incontinence,OTHER: Clinical interviews,Pierre and Marie Curie University,,ALL,"ADULT, OLDER_ADULT",,200,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-06-01,2020-07-01,2021-04-30,"Department of Neuro- Urology, Hôpital Tenon, Paris, 75020, France"
NCT04863586,COVID-19 and Multiple Sclerosis Disease Modifying Therapies,https://beta.clinicaltrials.gov/study/NCT04863586,UNKNOWN,Covid19|Multiple Sclerosis,,Nottingham University Hospitals NHS Trust,,ALL,"ADULT, OLDER_ADULT",,14240,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-04-01,2021-10-31,2022-05-31,"Nottingham University Hospitals NHS Trust, Nottingham, Nottinghamshire, NG7 2UH, United Kingdom"
NCT01698086,Vestibular Rehabilitation for Persons With Multiple Sclerosis: Who Benefits the Most? (MSVR3trial),https://beta.clinicaltrials.gov/study/NCT01698086,COMPLETED,Multiple Sclerosis|Balance|Fatigue|Eye Movement,OTHER: Vestibular rehabilitation: balance and eye movement exercises,"University of Colorado, Denver",National Multiple Sclerosis Society,ALL,ADULT,NA,88,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2012-10,2018-08,2018-08,"University of Colorado Anschutz Medical Campus/University of Colorado Denver, Aurora, Colorado, 80045, United States"
NCT03718819,Effects of Exercises in MS on Postural Control With Dual Task,https://beta.clinicaltrials.gov/study/NCT03718819,UNKNOWN,Multiple Sclerosis,OTHER: exercise,Dokuz Eylul University,,ALL,"ADULT, OLDER_ADULT",NA,13,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-03-01,2018-11-30,2018-11-30,"Dokuz Eylül University, School of Physical Therapy and Rehabilitation, İzmir, Balçova, 35330, Turkey"
NCT00869986,A Study for Patients With Relapsing Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00869986,COMPLETED,Relapsing Remitting Multiple Sclerosis,DRUG: dirucotide|DRUG: placebo,Eli Lilly and Company,BioMS Technology Corp.,ALL,ADULT,PHASE2|PHASE3,218,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2006-11,2009-09,2009-09,"Military Medical Academy, Sofia, Bulgaria|Silesian Medical School, Katowice, Poland|Clinical City Hospital No. 11, Moscow, Russian Federation|Clinical Center of Serbia, Belgrade, Serbia|FNsP J A Reimana, Presov, Slovakia|Vinnitsa State Medical University, Vinnitsa, Ukraine"
NCT05630547,A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05630547,RECRUITING,Multiple Sclerosis,DRUG: SAR443820|OTHER: Placebo,Sanofi,,ALL,ADULT,PHASE2,168,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-12-19,2025-08-27,2025-08-27,"Investigational Site Number :0560001, Bruxelles, BE-1200, Belgium|Investigational Site Number :1240002, Ottawa, Ontario, K1H 8L6, Canada|Investigational Site Number :1240001, Gatineau, Quebec, J8Y 1W2, Canada|Investigational Site Number :1240003, Levis, Quebec, G6W 0M5, Canada|Investigational Site Number :1560003, Chengdu, 610041, China|Investigational Site Number :1560002, Shanghai, 200040, China|Investigational Site Number :1560004, Xi'an, 710038, China|Investigational Site Number :2500004, Caen, 14033, France|Investigational Site Number :2500002, Nice, 06001, France|Investigational Site Number :2500001, Paris, 75013, France|Investigational Site Number :2500003, Strasbourg, 67098, France|Investigational Site Number :3800001, Pozzilli, Isernia, 86077, Italy|Investigational Site Number :6160002, Katowice, Slaskie, 40-571, Poland|Investigational Site Number :6160005, Katowice, Slaskie, 40-686, Poland|Investigational Site Number :6160004, Plewiska, Wielkopolskie, 62-064, Poland|Investigational Site Number :7240002, Sevilla, Andalucia, 41009, Spain|Investigational Site Number :7240001, Barcelona, Barcelona [Barcelona], 08035, Spain|Investigational Site Number :7240004, Madrid, Comunidad De Madrid, 28007, Spain|Investigational Site Number :7240003, Madrid, Madrid, Comunidad De, 28040, Spain|Investigational Site Number :7240006, Madrid, 28034, Spain|Investigational Site Number :7240005, Murcia, 30120, Spain"
NCT02471222,Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment,https://beta.clinicaltrials.gov/study/NCT02471222,COMPLETED,Walking Impairment|Multiple Sclerosis,DRUG: ADS-5102|OTHER: Placebo,"Adamas Pharmaceuticals, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE2,60,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2015-05,2016-06,2016-06,"Phoenix, Arizona, 85018, United States|Aurora, Colorado, 80045, United States|Sarasota, Florida, 34239, United States|Atlanta, Georgia, 30309, United States|Northbrook, Illinois, 60062, United States|Rochester, Minnesota, 55905, United States|Lincoln, Nebraska, 68506, United States|Albuquerque, New Mexico, 87131, United States|Patchogue, New York, 11772, United States|Raleigh, North Carolina, 27607, United States|Cleveland, Ohio, 44195, United States|Oklahoma City, Oklahoma, 73104, United States|Franklin, Tennessee, 37064, United States|Dallas, Texas, 75214, United States|Kirkland, Washington, 11772, United States"
NCT03000647,Guided Versus Non-guided Pelvic Floor Exercises for Urinary Incontinence in Relapsing-Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03000647,COMPLETED,Relapsing-Remitting Multiple Sclerosis|Urinary Incontinence,PROCEDURE: Pelvic floor exercises guided by a physiotherapist|PROCEDURE: Non guided pelvic floor exercises,Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz,Universidad Rey Juan Carlos,ALL,"ADULT, OLDER_ADULT",NA,48,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2015-10,2016-10,2016-10,"Hospital General de Villalba, Villalba, Madrid, 28400, Spain"
NCT00331747,Gait Evaluation in Multiple Sclerosis Patients Treated With Glatiramer Acetate,https://beta.clinicaltrials.gov/study/NCT00331747,UNKNOWN,Multiple Sclerosis,DRUG: Glatiramer acetate,Sheba Medical Center,,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER_GOV,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2006-05,,,"Multiple Sclerosis Center, Sheba Medical Center, Tel Hashomer, 52621, Israel"
NCT00203047,Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate,https://beta.clinicaltrials.gov/study/NCT00203047,TERMINATED,Relapsing Remitting Multiple Sclerosis,DRUG: Glatiramer Acetate|DRUG: Placebo|DRUG: Prednisone,"Teva Branded Pharmaceutical Products R&D, Inc.",,ALL,ADULT,PHASE4,414,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2005-01,2009-05,2009-05,
NCT05611047,Telerehabilitation of Multidomain Cognitive Impairment in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05611047,RECRUITING,Multiple Sclerosis,OTHER: Clinical assessment|OTHER: Classical cognitive evaluation of several domains:|OTHER: Ecological evaluation|BEHAVIORAL: Patent reported outcomes (PRO's)|OTHER: Telerehabilitation : active procedure|OTHER: Telerehabilitation : comparator procedure,"University Hospital, Bordeaux",Celgene,ALL,ADULT,NA,150,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-02-21,2025-02,2025-02,"CHU de Bordeaux - Service de neurologie, Bordeaux, France|CHU de Clermont-Ferrand - Service de neurologie, Clermont-Ferrand, France|CHU de Dijon-Bourgogne - Service de neurologie, Dijon, France|CH de Dunkerque - Service de neurologie, Dunkerque, France|Hôpital Saint Vincent de Paul - Service de neurologie, Lille, France|CHU de Montpellier - Service de neurologie, Montpellier, France|CHI Hôpital de Poissy Saint Germain en Laye - Service de neurologie, Poissy, France"
NCT00790400,Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM),https://beta.clinicaltrials.gov/study/NCT00790400,COMPLETED,Tuberous Sclerosis Complex (TSC)|Lymphangioleiomyomatosis (LAM),DRUG: Everolimus (RAD001)|DRUG: Everolimus Placebo,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,118,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-04,2011-06,2015-11,"University of Alabama at Birmingham, Birmingham, Alabama, 35294, United States|Barrow Tuberous Sclerosis Center, Phoenix, Arizona, 85013, United States|Massachusetts General Hospital Massachussetts General Hospita, Boston, Massachusetts, 02114, United States|Minnesota Epilepsy Group, St. Paul, Minnesota, 55102-2383, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 45229-3039, United States|LeBonheur Childrens Medical Group SC-2, Memphis, Tennessee, 38103, United States|Novartis Investigative Site, Torono, Ontario, M5G 2C4, Canada|Novartis Investigative Site, Lyon, 69003, France|Novartis Investigative Site, Berlin, 10098, Germany|Novartis Investigative Site, München, 80336, Germany|Novartis Investigative Site, Siena, SI, 53100, Italy|Novartis Investigative Site, Torino, TO, 10126, Italy|Novartis Investigative Site, Roma, 00137, Italy|Novartis Investigative Site, Sapporo-city, Hokkaido, 060-8648, Japan|Novartis Investigative Site, Suita-city, Osaka, 565-0871, Japan|Novartis Investigative Site, Yamagata, 990-9585, Japan|Novartis Investigative Site, Utrecht, 3584CX, Netherlands|Novartis Investigative Site, Warszawa, 01138, Poland|Novartis Investigative Site, Warszawa, 04-730, Poland|Novartis Investigative Site, Moscow, 127412, Russian Federation|Novartis Investigative Site, Barcelona, Catalunya, 08025, Spain|Novartis Investigative Site, Brighton, East Sussex, BN2 5BE, United Kingdom|Novartis Investigative Site, Craigavon, Northern Ireland, BT63 5QQ, United Kingdom|Novartis Investigative Site, Cardiff, Wales, CF14 4XN, United Kingdom|Novartis Investigative Site, London, SW17 0QT, United Kingdom"
NCT02896647,3D Phase Sensitive Inversion Recuperation MRI to Detect and Characterize Multiple Sclerosis Spinal Cord Lesions,https://beta.clinicaltrials.gov/study/NCT02896647,TERMINATED,Multiple Sclerosis,,Fondation Ophtalmologique Adolphe de Rothschild,,ALL,"ADULT, OLDER_ADULT",,60,NETWORK,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-12-14,2018-09,2018-09,"Fondation A De Rothschild, Paris, 75019, France"
NCT01728922,Dose-related Effects of Vitamin D3 on Immune Responses in Patients With Clinically Isolated Syndrome,https://beta.clinicaltrials.gov/study/NCT01728922,COMPLETED,Clinically Isolated Syndrome|Multiple Sclerosis,DIETARY_SUPPLEMENT: 5000IU vitamin D|DIETARY_SUPPLEMENT: 10000IU vitamin D|OTHER: Placebo,University College Dublin,"University of Dublin, Trinity College|St Vincent's University Hospital, Ireland",ALL,ADULT,PHASE1|PHASE2,64,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-11-06,2015-06-05,2016-06-05,"St Vincent's University Hospital, Dublin, Dublin 4, Ireland"
NCT02403947,MEsenchymal StEm Cells for Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02403947,TERMINATED,Multiple Sclerosis,DRUG: Mesenchymal stem cells|DRUG: Suspension media,"University Hospital, Toulouse",,ALL,ADULT,PHASE1|PHASE2,1,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2015-02,2017-12,2017-12,"Purpan Hospital, Toulouse, 31059, France"
NCT01804647,Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Patients With Multiple Sclerosis Disease,https://beta.clinicaltrials.gov/study/NCT01804647,COMPLETED,Multiple Sclerosis (MS)|Relapsing-Remitting MS|Primary Progressive MS|Secondary Progressive MS|Clinically Isolated Syndrome (CIS),OTHER: No study treatments administered - blood draws only,GeNeuro Innovation SAS,,ALL,ADULT,,58,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-11,2015-02,2015-02,"Hospices civils de Lyon - Service de Neurologie A - 59 Boulevard Pinel, Bron cedex, 69677, France|CHU Timone - Service de Neurologie et CRMBM CNRS 7339 - 264, rue Saint Pierre, Marseille Cedex 5, 13385, France|Hospital Universitari and Research Institute Vall d'Hebron - Servicio de Neuroimunologia de Nuestro Centro - Pg. Vall d'Hebron 119-129, Barcelona, Cataluna, 08035, Spain|Centre Hospitalier Universitaire Vaudois - Dpt of Clinical Neurosciences - Neurology /Batiment 10-131 - Rue du Bugnon 46 -, Lausanne, CH-1011, Switzerland"
NCT03213522,Comparison of Craniosacral Therapy vs Pelvic Floor Physical Therapy,https://beta.clinicaltrials.gov/study/NCT03213522,UNKNOWN,Multiple Sclerosis|Bladder Dysfunction|Urinary Incontinence|Overactive Bladder,PROCEDURE: Pelvic Floor Physical Therapy|PROCEDURE: Craniosacral Therapy,CentraState Medical Center,,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2017-04-10,2018-04-09,2018-04-09,"CentraState Medical Center, Freehold, New Jersey, 07728, United States"
NCT04655222,Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program,https://beta.clinicaltrials.gov/study/NCT04655222,COMPLETED,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting",DRUG: Interferon Beta Therapy,Biogen,,FEMALE,"ADULT, OLDER_ADULT",,470,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-04-30,2021-10-15,2021-10-15,"Research Site, Göttingen, Germany"
NCT03784547,Real-world Data of Ocrelizumab in Multiple Sclerosis in LATAM,https://beta.clinicaltrials.gov/study/NCT03784547,UNKNOWN,Multiple Sclerosis,DRUG: Ocrelizumab,Hospital Italiano de Buenos Aires,,ALL,"CHILD, ADULT, OLDER_ADULT",,100,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-02-01,2019-08-01,2019-09-01,"Juan Ignacio Rojas, Buenos Aires, 1453, Argentina|Juan Ignacio Rojas, Buenos Aires, 1453, Argentina|Juan Ignacio Rojas, Buenos Aires, 1453, Argentina|Edgard Carnero, Buenos Aires, Argentina"
NCT04657666,Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04657666,COMPLETED,Spasticity in Participants With Multiple Sclerosis,DRUG: Nabiximols|DRUG: Placebo,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,68,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-12-21,2022-05-04,2022-05-10,"Clinical Trial Site, Choceň, 565 01, Czechia|Clinical Trial Site, Bydgoszcz, Kujawsko-Pomorskie, 85-163, Poland|Clinical Trial Site 1, Kraków, Malopolskie, 30-539, Poland|Clinical Trial Site, Oswiecim, Malopolskie, 32-600, Poland|Clinical Trial Site 2, Warszawa, Mazowieckie, 01-211, Poland|Clinical Trial Site 1, Warszawa, Mazowieckie, 01-868, Poland|Clinical Trial Site, Gdansk, Pomorskie, 80-803, Poland|Clinical Trial Site, Chorzow, Slaskie, 41-500, Poland|Clinical Trial Site 3, Katowice, Slaskie, 40-123, Poland|Clinical Trial Site 1, Katowice, Slaskie, 40-571, Poland|Clinical Trial Site 2, Katowice, Slaskie, 40-684, Poland|Clinical Trial Site, Kielce, Swietokrzyskie, 25-726, Poland|Clinical Trial Site 2, Poznan, Wielkopolskie, 61-853, Poland|Clinical Trial Site 1, Poznan, Wielkopolskie, 62-064, Poland|Clinical Trial Site, Kraków, 30-149, Poland|Clinical Trial Site, Zabrze, 41-800, Poland"
NCT01074619,Study on Cognitive Disorders of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01074619,COMPLETED,Multiple Sclerosis,DRUG: Memantine|DRUG: Placebo,"University Hospital, Caen","Ministry of Health, France|H. Lundbeck A/S",ALL,ADULT,PHASE3,90,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2005-09,2011-03,2011-11,"CHU Caen, Caen, 14033, France"
NCT03005119,"Evaluation of the Safety, Tolerability, and Efficacy of Orally Administered PTL201 in MS Patients With Spasticity-related Symptoms",https://beta.clinicaltrials.gov/study/NCT03005119,UNKNOWN,Multiple Sclerosis,DRUG: PTL201|DRUG: Placebo Oral Capsule,"PhytoTech Therapeutics, Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE2,70,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2018-03-01,2018-12,2018-12,"Sheba medical center, Tel Hashomer, Ramat gan, Israel"
NCT04952766,Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults,https://beta.clinicaltrials.gov/study/NCT04952766,COMPLETED,Kidney Transplant|Myeloma|Cancer|Hematologic Malignancy|Multiple Sclerosis|Hypergammaglobulinemia|Malignant Tumor|Hiv|Diabetes Type 2,BIOLOGICAL: Biological samples,Centre Hospitalier Régional d'Orléans,,ALL,"ADULT, OLDER_ADULT",PHASE4,196,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2021-03-26,2022-02-06,2022-02-06,"CHR d'Orleans - Service Maladies Infectieuses, Orléans, 45067, France"
NCT01077466,Natalizumab Treatment of Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01077466,COMPLETED,Primary Progressive Multiple Sclerosis|Secondary Progressive Multiple Sclerosis,DRUG: Natalizumab,"Rigshospitalet, Denmark","Copenhagen University Hospital, Hvidovre|Biogen|University of Copenhagen|Signifikans ApS",ALL,ADULT,PHASE2,24,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2010-03,2012-01,2012-01,"Danish Multiple Sclerosis Center, Section 2082, Rigshospitalet, Copenhagen, 2100, Denmark"
NCT04354519,The United Kingdom Multiple Sclerosis Register Covid-19 Substudy,https://beta.clinicaltrials.gov/study/NCT04354519,UNKNOWN,Multiple Sclerosis|COVID-19,,Swansea University,,ALL,"ADULT, OLDER_ADULT",,3000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-03-14,2022-07-14,2022-07-14,"Swansea Univeristy, Swansea, SA28PP, United Kingdom"
NCT03150966,The Immunomodulatory Effects of Oral Nanocurcumin in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT03150966,COMPLETED,Multiple Sclerosis,DRUG: Nanocurcumin|DRUG: Placebo,Tabriz University of Medical Sciences,,ALL,"ADULT, OLDER_ADULT",PHASE2,41,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2016-06-08,2017-08-10,2017-11-07,"Drug Applied Research Center, Tabriz, Iran, Tabriz, Iran, Islamic Republic of"
NCT00420719,Motor-Point Stimulation for Conditioning the Diaphragm of Patients With Amyotrophic Lateral Sclerosis (ALS),https://beta.clinicaltrials.gov/study/NCT00420719,UNKNOWN,Amyotrophic Lateral Sclerosis (ALS),DEVICE: Intramuscular diaphragm electrodes,Synapse Biomedical,University Hospitals Cleveland Medical Center|Johns Hopkins University|Stanford University,ALL,"ADULT, OLDER_ADULT",NA,100,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2004-10,2009-10,2009-10,"Forbes Norris - California Pacific Medical Center (CPMC), San Francisco, California, 94115, United States|Stanford University Medical Center, Stanford, California, 94305, United States|Mayo Clinic, Jacksonville, Florida, 32224, United States|Johns Hopkins University, Baltimore, Maryland, 21287, United States|Henry Ford Health System, Detroit, Michigan, 48202-2689, United States|University Hospitals Of Cleveland, Cleveland, Ohio, 44106, United States|The Methodist Hospital, Houston, Texas, 77030, United States|Groupe Hospitalier Pitie-Salpetriere, Paris, France"
NCT01057719,Climate Influence on Physiotherapy in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01057719,COMPLETED,Multiple Sclerosis,OTHER: Physiotherapy,Haukeland University Hospital,"Oslo University Hospital|University Hospital, Akershus|University of Bergen",ALL,ADULT,NA,60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2006-06,2008-05,2008-05,"Haukeland University Hospital, Bergen, 5021, Norway"
NCT03193866,COMparison Between All immunoTherapies for Multiple Sclerosis.,https://beta.clinicaltrials.gov/study/NCT03193866,ACTIVE_NOT_RECRUITING,Relapsing-remitting Multiple Sclerosis,DRUG: Rituximab,Karolinska Institutet,Patient-Centered Outcomes Research Institute|Kaiser Foundation Research Institute,ALL,"ADULT, OLDER_ADULT",,3526,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-06-02,2022-12-31,2022-12-31,"Fredrik Piehl, Stockholm, Sweden"
NCT04979819,The Validity and Reliability of the Upper Extremity Exercise Testing (UULEX) in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04979819,RECRUITING,Multiple Sclerosis,OTHER: Upper extremity endurance test (UULEX),Marmara University,,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2021-07-01,2021-10-31,2021-10-31,"Marmara University School of Medicine Department of Physical Medicine and Rehabilitation, Istanbul, 34899, Turkey"
NCT00292266,A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT00292266,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Rebif®|DRUG: Avonex®,EMD Serono,Merck Serono International SA,ALL,ADULT,PHASE3,677,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,1999-11,2002-06,2002-06,
NCT02386566,Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With Natalizumab,https://beta.clinicaltrials.gov/study/NCT02386566,COMPLETED,Multiple Sclerosis,DRUG: natalizumab,Biogen,,ALL,"ADULT, OLDER_ADULT",,48,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-03-20,2018-01-28,2018-01-28,"Research Site, Aarau, Switzerland|Research Site, Basel, Switzerland|Research Site, Bern, Switzerland|Research Site, Lugano, Switzerland|Research site - private practice, Luzern, Switzerland|Research Site, Wohlen, Switzerland|Research Site, Zurich, Switzerland"
NCT00836719,Safety of Polyphenon E in Multiple Sclerosis Pilot Study,https://beta.clinicaltrials.gov/study/NCT00836719,COMPLETED,Multiple Sclerosis,DRUG: Polyphenon E,Louisiana State University Health Sciences Center in New Orleans,National Center for Complementary and Integrative Health (NCCIH),ALL,"ADULT, OLDER_ADULT",PHASE1,10,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2009-02,2010-11,2010-11,"Louisiana Health Sciences Center New Orleans, New Orleans, Louisiana, 70112, United States"
NCT02687919,Evaluation of a Modified Paleolithic Dietary Intervention in the Treatment of Relapsing-Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02687919,COMPLETED,"Multiple Sclerosis, Relapsing-remitting",OTHER: Modified Paleo diet,Amanda Irish,,ALL,ADULT,NA,31,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2012-10,2014-09,2014-10,"University of Iowa, Iowa City, Iowa, 52241, United States"
NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,https://beta.clinicaltrials.gov/study/NCT01332019,COMPLETED,Relapsing Multiple Sclerosis,DRUG: peginterferon beta-1a,Biogen,,ALL,"ADULT, OLDER_ADULT",PHASE3,1077,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2011-04,2015-10,2015-10,"Research Site, Atlanta, Georgia, 30327, United States|Research Site, Lexington, Kentucky, 40513, United States|Research Site, Baltimore, Maryland, 21287, United States|Research Site, Raleigh, North Carolina, 27607 6520, United States|Research Site, Akron, Ohio, 44320, United States|Research Site, Cleveland, Ohio, 44195, United States|Research Site, Franklin, Tennessee, 37205, United States|Research Site, Sint-Truiden, 3800, Belgium|Research Site, Plovdiv, 4002, Bulgaria|Research Site, Sofia, 1113, Bulgaria|Research Site, Sofia, 1309, Bulgaria|Research Site, Sofia, 1407, Bulgaria|Research Site, Sofia, 1431, Bulgaria|Research Site, Sofia, 1606, Bulgaria|Research Site, London, Ontario, N6A 5A5, Canada|Research Site, Montreal, Quebec, H2L 4M1, Canada|Research Site, Santiago, 8207257, Chile|Research Site, Barranquilla, Colombia|Research Site, Bogota, Colombia|Research Site, Zagreb, Croatia|Research Site, Brno, 625 00, Czech Republic|Research Site, Havffov, 73601, Czech Republic|Research Site, Olomouc, 775 20, Czech Republic|Research Site, Ostrava-Vitkovice, 703 00, Czech Republic|Research Site, Ostrava, 708 52, Czech Republic|Research Site, Praha 5, 150 06, Czech Republic|Research Site, Praha, 128 08, Czech Republic|Research Site, Teplice, 415 29, Czech Republic|Research Site, Parnu, EE 80010, Estonia|Research Site, Tallinn, EE 10617, Estonia|Research Site, Tartu, EE 51014, Estonia|Research Site, Amiens, 80054, France|Research Site, Bouches-du-Rhone, 13385, France|Research Site, Clermont-Ferrand, 63003, France|Research Site, Nice, 6002, France|Research Site, Tbilisi, 0112, Georgia|Research Site, Tbilisi, 112, Georgia|Research Site, Tbilisi, 179, Georgia|Research Site, Tbilisi, 186, Georgia|Research Site, Bayreuth, 95445, Germany|Research Site, Berlin, 10713, Germany|Research Site, Erbach, 64711, Germany|Research Site, Hannover, 30559, Germany|Research Site, Koln, 50935, Germany|Research Site, Leipzig, 4103, Germany|Research Site, Marberg, 35043, Germany|Research Site, Prien, 83209, Germany|Research Site, Ulm, 89079, Germany|Research Site, Westerstede, 26655, Germany|Research Site, Athens, 11521, Greece|Research Site, Athens, 11525, Greece|Research Site, Thessaloniki, 57010, Greece|Research Site, Ahmedabad, Gujarat, 380006, India|Research Site, Rajkot, Gujarat, 360001, India|Research Site, Indore, Madhyr Pradesh, 452018, India|Research Site, Mumbai, Maharashtra, 400026, India|Research Site, Nagpur, Maharashtra, 440010, India|Research Site, Pune, Maharashtra, 411004, India|Research Site, Pune, Maharashtra, 411030, India|Research Site, Amritsar, Punjab, 143001, India|Research Site, Coimbatore, Tamil Nadu, 641014, India|Research Site, Kolkata, West Bengal, 700068, India|Research Site, Bangalore, 560017, India|Research Site, Chennai, 600017, India|Research Site, Mangalore, 575018, India|Research Site, Navi Mumbai, 400703, India|Research Site, New Delhi, 110029, India|Research Site, New Delhi, 110060, India|Research Site, Saket, 110017, India|Research Site, Riga, LV1005, Latvia|Research Site, Aguascalientes, 20127, Mexico|Research Site, Chihuahua, 31203, Mexico|Research Site, Heroes de Padierna, 10700, Mexico|Research Site, Mexico City, 3600, Mexico|Research Site, Monterrey, 64710, Mexico|Research Site, Breda, 4818 CK, Netherlands|Research Site, Nieuwegein, 3435 CM, Netherlands|Research Site, Auckland, New Zealand|Research Site, Christchurch, New Zealand|Research Site, Dunedin, New Zealand|Research Site, Lima, Lima01, Peru|Research Site, Lima, Lima1, Peru|Research Site, Lima, Lima21, Peru|Research Site, San Isidro, Lima27, Peru|Research Site, Bialystok, 15276, Poland|Research Site, Bialystok, 15402, Poland|Research Site, Bydgoszcz, 85618, Poland|Research Site, Gdansk, 80299, Poland|Research Site, Gdansk, 80803, Poland|Research Site, Gdansk, 80952, Poland|Research Site, Katowice, 40594, Poland|Research Site, Katowice, 40662, Poland|Research Site, Katowice, 40749, Poland|Research Site, Katowice, 40752, Poland|Research Site, Konskie, 26200, Poland|Research Site, Krakow, 31505, Poland|Research Site, Krakow, 31637, Poland|Research Site, Krakow, 31826, Poland|Research Site, Lodz, 90153, Poland|Research Site, Lublin, 20718, Poland|Research Site, Lublin, 20954, Poland|Research Site, Olsztyn, 10082, Poland|Research Site, Plewiska, 62064, Poland|Research Site, Poznan, 60355, Poland|Research Site, Poznan, 61289, Poland|Research Site, Szczecin, 70111, Poland|Research Site, Szczecin, 71252, Poland|Research Site, Warszawa, 00851, Poland|Research Site, Warszawa, 04141, Poland|Research Site, Warszawa, 04749, Poland|Research Site, Wroclaw, 50556, Poland|Research Site, Brasov, 500123, Romania|Research Site, Bucharest, 50098, Romania|Research Site, Campulung, 115100, Romania|Research Site, Sibiu, 550166, Romania|Research Site, Targu Mures, 540136, Romania|Research Site, Kaluga, 248007, Russian Federation|Research Site, Kazan, 420021, Russian Federation|Research Site, Kransodar, 350012, Russian Federation|Research Site, Kursk, 305007, Russian Federation|Research Site, Moscow, 107150, Russian Federation|Research Site, Moscow, 119021, Russian Federation|Research Site, Novosibirsk, 630007, Russian Federation|Research Site, Perm, 614990, Russian Federation|Research Site, Rostov-on-Don, Russian Federation|Research Site, Smolensk, Russian Federation|Research Site, Ufa, 450005, Russian Federation|Research Site, Belgrade, 11000, Serbia|Research Site, Kragujevac, 34000, Serbia|Research Site, Nis, 18000, Serbia|Research Site, Cordoba, 14008, Spain|Research Site, Madrid, 28041, Spain|Research Site, Madrid, 28046, Spain|Research Site, Malaga, 29010, Spain|Research Site, Seville, 41009, Spain|Research Site, Chernivtsi, 58018, Ukraine|Research Site, Dnipropetrovsk, 49027, Ukraine|Research Site, Donetsk, 83099, Ukraine|Research Site, Kharkiv, 61068, Ukraine|Research Site, Kharkiv, 61103, Ukraine|Research Site, Kyiv, 3110, Ukraine|Research Site, Kyiv, 4107, Ukraine|Research Site, Odesa, 65025, Ukraine|Research Site, Poltava, 26011, Ukraine|Research Site, Simferopol, 95017, Ukraine|Research Site, Ternopil, 46027, Ukraine|Research Site, Vinnytsya, 21005, Ukraine|Research Site, London, E11BB, United Kingdom|Research Site, Manchester, M68HD, United Kingdom|Research Site, Nottingham, NG72UH, United Kingdom|Research Site, Sheffield, S108JF, United Kingdom"
NCT03757819,Transcranial Direct Current Stimulation and Walking in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03757819,COMPLETED,Transcranial Direct Current Stimulation,DEVICE: tDCS|DEVICE: SHAM,Thorsten Rudroff,,ALL,"ADULT, OLDER_ADULT",NA,12,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2019-02-25,2019-07-07,2019-07-07,"University of Iowa, Iowa City, Iowa, 52242, United States"
NCT01070719,"Pharmacokinetic, Immunological and Biochemical Sample Collection and Analysis of a Tysabri Patient Cohort",https://beta.clinicaltrials.gov/study/NCT01070719,COMPLETED,Multiple Sclerosis|Relapse,,"John F. Foley, MD",Biogen,ALL,"ADULT, OLDER_ADULT",,270,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-02,2010-05,2010-05,"Rocky Mountain Multiple Sclerosis Clinic, Salt Lake City, Utah, 84103, United States"
NCT05661266,Investigating Eye-Movement Biomarkers of Disease Severity and Cognition in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05661266,NOT_YET_RECRUITING,Multiple Sclerosis,DEVICE: Eye-Tracking,Innodem Neurosciences,,ALL,"ADULT, OLDER_ADULT",,120,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-04,2025-04,2025-04,"Genge Partners, Inc., Montreal, Quebec, H4A 3T4, Canada"
NCT02772666,Novel Portable Diagnostic Device for Automatic Detection of Relative Afferent Pupillary Defect,https://beta.clinicaltrials.gov/study/NCT02772666,COMPLETED,Multiple Sclerosis|Glaucoma,DEVICE: O-Glass|OTHER: Swinging Flashlight Test,Mashhad University of Medical Sciences,,ALL,ADULT,NA,44,OTHER,INTERVENTIONAL,"Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: DIAGNOSTIC",2015-12,2016-05,2016-06,
NCT03856619,To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03856619,COMPLETED,Relapsing Multiple Sclerosis,DRUG: TERIFLUNOMIDE HMR1726,Sanofi,,ALL,"ADULT, OLDER_ADULT",PHASE4,121,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2019-03-27,2022-05-13,2022-05-13,"Investigational Site Number :024, Ahmedabad, 380054, India|Investigational Site Number :017, Bengaluru, 560054, India|Investigational Site Number :001, Chandigarh, 160012, India|Investigational Site Number :023, Coimbatore, India|Investigational Site Number :007, Gurgaon, 122001, India|Investigational Site Number :026, Gurgaon, India|Investigational Site Number :005, Kochi, 682041, India|Investigational Site Number :006, Kolkata, 700068, India|Investigational Site Number :011, Lucknow, 226003, India|Investigational Site Number :020, Ludhiana, 141001, India|Investigational Site Number :018, Nashik, 422001, India|Investigational Site Number :025, New Delhi, India|Investigational Site Number :014, Pune, 411004, India|Investigational Site Number :022, Thiruvananthapuram, 695011, India"
NCT03691766,Photobiomodulation Therapy in Persons With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03691766,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",OTHER: Photobiomodulation Therapy|OTHER: Placebo,Marquette University,"University of Wisconsin, Milwaukee",ALL,ADULT,NA,21,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2018-04-30,2019-09-23,2019-09-23,"Marquette University, Milwaukee, Wisconsin, 53201-1881, United States"
NCT05635266,A Single-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives,https://beta.clinicaltrials.gov/study/NCT05635266,RECRUITING,Age-Related Macular Degeneration|Allergies|Alpha-Gal Syndrome|Alzheimer Disease|Amyloidosis|Ankylosing Spondylitis|Arthritis|Alopecia Areata|Asthma|Atopic Dermatitis|Autism|Autoimmune Hepatitis|Behcet's Disease|Beta-Thalassemia|Cancer|Celiac Disease|Kidney Diseases|COPD|Crohn Disease|Cystic Fibrosis|Diabetes|Dravet Syndrome|DMD|Fibromyalgia|Graves Disease|Thyroid Diseases|Hepatitis|Hidradenitis Suppurativa|ITP|Leukemia|ALS|Lupus or SLE|Lymphoma|Multiple Sclerosis|Myasthenia Gravis|Heart Diseases|Parkinson Disease|Pemphigus Vulgaris|Cirrhosis|Psoriasis|Schizophrenia|Scleroderma|Sickle Cell Disease|Stroke|Ulcerative Colitis|Vasculitis|Vitiligo,DIAGNOSTIC_TEST: Specimen sample,Sanguine Biosciences,,ALL,"ADULT, OLDER_ADULT",,20000,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-10-26,2023-10,2023-10,"Sanguine Biosciences, Waltham, Massachusetts, 02451, United States"
NCT01817166,Efficacy of Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of MS After a Clinically Isolated Syndrome,https://beta.clinicaltrials.gov/study/NCT01817166,COMPLETED,Multiple Sclerosis,DRUG: Vitamin D|DRUG: Placebo|OTHER: Imaging|BIOLOGICAL: Lumbar puncture|BIOLOGICAL: Blood sampling|BIOLOGICAL: Urine samples,Centre Hospitalier Universitaire de Nīmes,,ALL,ADULT,PHASE3,316,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2013-07-16,2023-01-04,2023-01-04,"CHU d'Amiens - Hôpital Nord, Amiens Cedex 1, 80054, France|CHU de Lyon - Hôpital Pierre Wertheimer, Bron, 69677, France|CHU de Caen - Hôpital Côte de Nacre, Caen Cedex 9, 14033, France|CHU de Clermont Ferrand - Hôpital Gabriel-Montpied, Clermont Ferrand, 63003, France|CH Sud Francilien, Corbeil-Essonnes, 91100, France|Clinique des Cèdres - Capio, Cornebarrieu, 31700, France|CHU de Dijon, Dijon, 21079, France|CHU de Martinique - Hôpital Pierre Zobda-Quitman, Fort-de-France, 97261, France|CHU de Grenoble - Hôpital A Michallon, Grenoble, 38043, France|CHRU de Lille - Hôpital Roger Salengro, Lille, 59037, France|CHU de Limoges - Hôpital Dupuytren, Limoges, 87042, France|Groupe Hospitalier de l'Institut Catholique de Lille, Lomme Cedex, 59462, France|CHU de Montpellier - Hôpital Gui de Chauliac, Montpellier, 34295, France|CHU de Nancy - Hôpital Central, Nancy, 54035, France|CHU de Nantes - Hôtel-Dieu, Nantes, 44093, France|CHU de Nice - Hôpital Pasteur, Nice, 06002, France|CHU de Nîmes - Hôpital Universitaire Carémeau, Nîmes Cedex 9, 30029, France|APHP - Hôpital Saint-Antoine, Paris Cedex 12, 75571, France|MAILLART Elisabeth - La Pitié Salpétrière, Paris, 75013, France|Fondation Ophtalmologique Adolphe Rothschild, Paris, 75019, France|CH de Pau, Pau, 64000, France|CH de Perpignan - Hôpital Saint Jean, Perpignan, 66046, France|CH de Cornouaille - Site Quimper - Hôpital Laennec, Quimper, 29107, France|CHU de Reims - Hôpital Maison Blanche, Reims, 51092, France|CHU de Rennes - Hôpital PontChaillou, Rennes, 35033, France|CHU de Rouen - Hôpital Charles Nicolle, Rouen, 76031, France|CH de Poissy - Saint-Germain-en-Laye, Saint-Germain-en-Laye, 78100, France|CH de Saumur, Saumur Cedex, 49403, France|CHRU de Strasbourg - Hôpital Civil, Strasbourg Cedex, 67091, France|CHRU de Toulouse - Hôpital Purpan, Toulouse Cedex 9, 31059, France|CHRU de Tours - Hôpital Bretonneau, Tours, 37044, France|CH de Versailles - Hôpital Mignot, Versailles, 78000, France|CH de Vichy - Jacques Larin, Vichy, 03207, France"
NCT03846219,MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS),https://beta.clinicaltrials.gov/study/NCT03846219,ACTIVE_NOT_RECRUITING,Relapsing-Remitting Multiple Sclerosis (RRMS),DRUG: IMU-838 (30 mg/day)|DRUG: IMU-838 (45 mg/day)|DRUG: Placebo|DRUG: IMU-838 (10 mg/day),Immunic AG,,ALL,ADULT,PHASE2,210,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-01-28,2020-04-24,2029-12,"MHAT Pulse AD, Department of Neurology Diseases, Blagoevgrad, 2700, Bulgaria|UMHAT ""Dr.Georgi Stranski"" EAD Pleven Department of Professional Diseases, Pleven, 5800, Bulgaria|MHAT ""Heart and brain"" EAD Pleven Department of Neurology Diseases, Pleven, 5804, Bulgaria|UMHAT "" Kaspela"" EOOD, Department of Neurology Diseases, Plovdiv, 4001, Bulgaria|UMHAT ""Kanev Ruse"", Department of General and Vascular Neurology, Ruse, 7002, Bulgaria|MHATNP ""Sveti Naum"" EAD, Neurology Clinic for Movement Disorders, First Department of Neurology Diseases, Sofia, 1113, Bulgaria|MHATNPsy ""Sveti Naum"" EAD, Intensive Therapy Clinic Of Neurology Diseases, Sofia, 1113, Bulgaria|DCC ""Neoclinic"" EAD, Cabinet Neurology Diseases, Sofia, 1408, Bulgaria|UMHAT ""Alexandrovska"" EAD, Clinic of Neurology Diseases, Department of Inherited Degenerative and Immunoinflamatori Diseases at Peripheral Nervous System, Sofia, 1431, Bulgaria|UMHAT ""Sveti Ivan Rilski"" EAD Sofia Clinic of Neurological Diseases, Sofia, 1431, Bulgaria|UMHAT""Alexandrovska""EAD, Department of Degenerative and Immunoinflamatory Disease of the Central Nervous System, Sofia, 1431, Bulgaria|Central Clinical Base-Medical Institute - Ministry of Interior, Neurology Clinic, Sofia, 1606, Bulgaria|Military Medical Academy - Sofia, Clinic of Neurology Diseases, Sofia, 1606, Bulgaria|Military Medical Academy, Clinic of Functional Diagnostics of Nevous System, Sofia, 1606, Bulgaria|UMHAT "" Sveta Marina EAD, First Neurology Clinic, Varna, 9010, Bulgaria|Nasz Lekarz Ośrodek Badań Klinicznych, Bydgoszcz, 85-065, Poland|Specjalistyczna Praktyka Lekarska Paweł Bochniak, Bydgoszcz, 85-796, Poland|Indywidualna Praktyka Lekarska Prof. Konrad Rejdak, Lublin, 20-016, Poland|BioResearch Group Sp. Z o.o, Nadarzyn, 05-830, Poland|Centrum Medyczne NeuroProtect, Warszawa, 01-684, Poland|S.C. Sana Monitoring Srl, Bucharest, 011025, Romania|Spitalul Universitar Elias Bucharesti, Bucharest, 011461, Romania|S.C. Quantum Medical Center Srl, Bucharest, 012071, Romania|Spitalul Clinic Colentina Bucharest, Neurologie 2, Bucharest, 020125, Romania|Spitalul Clinic Cai Ferate Constanta, Constanta, 900123, Romania|Chernihiv Regional Hospital, Department of Neurology, Chernihiv, 14029, Ukraine|Dnipropetrovsk Municipal Hospital #5, Neurological Department of the inflammatory and demyelinating diseases of CNS, Dnipro, 49000, Ukraine|Ukrainian State Research Institute of Medical and Social Problems of Disability of MOH of Ukraine, Dnipro, 49027, Ukraine|Regional Clinical Hospital, Department of vascular Neurology, Ivano-Frankivsk, 76000, Ukraine|Kharkiv Regional Clinical Hospital, Department of Neurology, Kharkiv, 61000, Ukraine|Institute of Neurology, Psychiatry and Narcology NAMSU, Kharkiv, 61068, Ukraine|Kyiv City Clinical Hospital #4, Department of Neurology, Kyiv, 03110, Ukraine|Volyn Regional Clinical Hospital, Department of Neurology, Lutsk, 43005, Ukraine|Poltava Regional Clinical Hospital n.a. Sklifosovskyi, Department of Neurology, Poltava, 36011, Ukraine|Regional Clinical Centre of Neurosurgery and Neurology, Department #2, Uzhgorod, 88018, Ukraine|Vinnytsya Regional Psychoneurology Hospital n.a. Yushchenko, Department of Neurology #3, Vinnytsya, 21005, Ukraine|City Clinical Hospital #2, Department of Neurology, Zaporizhzhya, 69068, Ukraine|Zaporizhzhya Regional Clinical Hospital, Department of Neurology #1, Zaporizhzhya, 69600, Ukraine"
NCT04990219,A Study of Lu AG06466 for the Treatment of Spasticity in Participants With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04990219,TERMINATED,Multiple Sclerosis,DRUG: Lu AG06466|DRUG: Placebo,H. Lundbeck A/S,,ALL,"ADULT, OLDER_ADULT",PHASE1,37,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-09-27,2023-01-19,2023-01-31,"Mountain View Clinical Research, Denver, Colorado, 80209, United States|Johns Hopkins University, Baltimore, Maryland, 21287, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|Wake Research - Clinical Research Center of Nevada, Las Vegas, Nevada, 89106, United States|Universitätsklinikum Düsseldorf, Dusseldorf NRW, 40225, Germany|Neurostimulation Center for Movement Disorders, Mainz, 55131, Germany|Center of Neurology, Hertie Institute for Clinical Brain Research, Tubingen, 72076, Germany"
NCT03461419,Use of Stromal Vascular Fraction in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03461419,SUSPENDED,Multiple Sclerosis|Autoimmune,PROCEDURE: Microcannula Harvest Adipose Stroma|DEVICE: Centricyte 1000|PROCEDURE: Sterile Normal Saline IV Deployment of cSVF,Healeon Medical Inc,Global Alliance for Regenerative Medicine,ALL,"ADULT, OLDER_ADULT",NA,100,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2019-08-01,2024-01-01,2024-12-15,"Robert W. Alexander, MD, FICS, LLC, Stevensville, Montana, 59870, United States|Global Alliance of Regenerative Medicine (GARM) International, Roatan, Hn, Honduras, Honduras"
NCT02889419,Benefits Evaluation of Selfia® Adapted Underwear for MS Patients Performing Self-catheterization,https://beta.clinicaltrials.gov/study/NCT02889419,WITHDRAWN,Multiple Sclerosis,DEVICE: Evaluation of underwear Selfia®,Lille Catholic University,,ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2017-01,2020-06,2020-06,"Groupement des Hôpitaux de l'Institut Catholique de Lille, Lomme, Nord Pas-de-Calais, 59462, France|Clinique Saint-Augustin, Bordeaux, 33076, France|Hôpital Swynghedauw - CHRU de Lille, Lille, 59037, France|Cabinet médical de Neurologie, Lyon, 69006, France|Hôpital Saint-Jacques - CHU Nantes, Nantes, 44093, France|Pôle MPR Saint Hélier, Rennes, 35043, France"
NCT04498286,COVID-19 and SARS-CoV-2 Antibodies in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT04498286,COMPLETED,Multiple Sclerosis,DIAGNOSTIC_TEST: Testing of SARS-CoV-2 antibodies,Zoé van Kempen,,ALL,"ADULT, OLDER_ADULT",,546,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-08-08,2021-10-31,2021-10-31,"VU medical center, Amsterdam, Netherlands"
NCT02446886,Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS,https://beta.clinicaltrials.gov/study/NCT02446886,TERMINATED,Multiple Sclerosis,DRUG: Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®),Weill Medical College of Cornell University,Mallinckrodt,ALL,"ADULT, OLDER_ADULT",PHASE4,15,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2016-06,2020-03,2020-06,"Weill Cornell Medicine, New York, New York, 10021, United States"
NCT02141386,Computerized Cognitive Exercise Training Treatment for Adults With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02141386,UNKNOWN,Multiple Sclerosis,"OTHER: PACR (Plasticity-based, Adaptive, Computerized Cognitive Remediation)",Stony Brook University,National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",NA,136,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-09,2015-09,,"Stony Brook University, Stony Brook, New York, 11794, United States"
NCT01089686,Study To Evaluate Treating Chronic Cerebrospinal Venous Insufficiency (CCSVI) in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT01089686,TERMINATED,Multiple Sclerosis,PROCEDURE: Venoplasty|PROCEDURE: Sham procedure (non-treatment),"Manish Mehta, MD","Center for Vascular Awareness, Albany, New York",ALL,"ADULT, OLDER_ADULT",NA,2,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: DIAGNOSTIC",2010-08,2012-10,2012-10,"The Vascular Group, PLLC, The Vascular Health Pavillion, Albany, New York, 12205, United States"
NCT05185986,Investigating the Home-based RCTs of Pilates Exercises and Cognitive Rehabilitation Exercises for Executive Functions and Anxiety in MS.,https://beta.clinicaltrials.gov/study/NCT05185986,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Home-Based Pilates exercise|OTHER: Home-based Cognitive Rehabilitation|OTHER: waiting list group,Arak University of Medical Sciences,Pardis Specialized Wellness Institute,ALL,"ADULT, OLDER_ADULT",NA,51,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2021-12-20,2022-02-28,2022-03-07,"MS society of Isfahan, Isfahan, 83, Iran, Islamic Republic of"
NCT05070286,Lifestyle Weight Management Program: Interviews and Stakeholder Meetings.,https://beta.clinicaltrials.gov/study/NCT05070286,RECRUITING,Multiple Sclerosis|Neuromyelitis Optica,BEHAVIORAL: Observational Study.,Oxford Brookes University,Great Ormond Street Hospital for Children NHS Foundation Trust|Guy's and St Thomas' NHS Foundation Trust|Oxford University Hospitals NHS Trust,ALL,"CHILD, ADULT",,45,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-01-01,2022-12-31,2022-12-31,"John Radcliffe Hospital, Oxford, Oxfordshire, OX3 9DU, United Kingdom"
NCT02364986,Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02364986,UNKNOWN,Relapsing-remitting Multiple Sclerosis,DRUG: Rebif®|DRUG: Avonex,PD Dr. Marcus Müller,"BfARM, Bonn|DZNE, Bonn",ALL,"ADULT, OLDER_ADULT",PHASE1,50,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-01,2017-01,2017-01,"Department of Neurology, Bonn, 53105, Germany|Phase I Unit, Bonn, 53105, Germany"
NCT03512886,The Effect of Multiple-Task Training in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03512886,COMPLETED,Multiple Sclerosis,OTHER: Multi-task training|OTHER: Single task training,Gazi University,,ALL,"ADULT, OLDER_ADULT",NA,39,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2018-06-18,2019-07-04,2019-07-25,"Gazi University, Ankara, Turkey"
NCT04681586,Bright Light Therapy as Possible Treatment Option for MS-Fatigue,https://beta.clinicaltrials.gov/study/NCT04681586,UNKNOWN,Multiple Sclerosis|Fatigue,DEVICE: bright light therapy|DEVICE: dim red light,Medical University of Vienna,National Bank of Austria,ALL,"ADULT, OLDER_ADULT",NA,36,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2019-12-01,2021-09,2022-01,"Medical University of Vienna, Vienna, 1090, Austria"
NCT00069186,Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis,https://beta.clinicaltrials.gov/study/NCT00069186,UNKNOWN,Amyotrophic Lateral Sclerosis (ALS),DRUG: Creatine Monohydrate,The Avicena Group,,ALL,"ADULT, OLDER_ADULT",PHASE3,107,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,2003-06,,2005-04,"University of California, San Francisco, San Francisco, California, 94115, United States|University of Kansas, Kansas City, Kansas, 66160, United States|University of New Mexico, Albuquerque, New Mexico, 87131, United States|Carolinas Medical Center, Charlotte, North Carolina, 28203-5812, United States|Duke University Medical Center, Durham, North Carolina, 27705, United States|Oregon Health Sciences University, Portland, Oregon, 97239, United States|University of Texas Health Science Center, San Antonio, Texas, 48284-7883, United States|University of Virginia Health System, Charlottesville, Virginia, 22908, United States"
NCT05252585,A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML),https://beta.clinicaltrials.gov/study/NCT05252585,RECRUITING,Renal Angiomyolipoma,DRUG: Everolimus,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE4,10,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-05-01,2024-09-30,2025-07-19,"Novartis Investigative Site, Taichung, Taiwan ROC, 40201, Taiwan|Novartis Investigative Site, Kuei Shan Chiang, Taoyuan Taiwan ROC, 33305, Taiwan|Novartis Investigative Site, Taipei, 10002, Taiwan"
NCT05705986,Immunoregulatory Effect of Microparticle Delivered STING Agonist in the Control of Experimental Autoimmune Encephalomyelitis (EAE) and Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT05705986,RECRUITING,Relapse Remitting Multiple Sclerosis,OTHER: Blood Draw,Thomas Jefferson University,,ALL,ADULT,,40,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-02-26,2024-05,2024-05,"Thomas Jefferson University, Philadelphia, Pennsylvania, 19107, United States"
NCT00203086,A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00203086,COMPLETED,Relapsing Remitting Multiple Sclerosis,,"Teva Branded Pharmaceutical Products R&D, Inc.",,ALL,ADULT,,30,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2005-10,2009-10,2009-12,
NCT01816100,The Effect of Exercise on Strength and Mobility and Corresponding CNS Plasticity in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT01816100,COMPLETED,Multiple Sclerosis,OTHER: specifically design 6 month resistance training program|BEHAVIORAL: 6 months weight resistance and balance program,University of Nebraska,Biogen,ALL,"ADULT, OLDER_ADULT",NA,6,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2013-04,2015-09,2015-09,"UNMC, Omaha, Nebraska, 68198, United States"
NCT05081700,A Systems Approach to Understanding Disease Processes in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05081700,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,DRUG: All patients in the study will be treated with ocrelizumab,Providence Health & Services,"Institute for Systems Biology|Genentech, Inc.",ALL,ADULT,,14,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-05-11,2023-08,2023-08,"Providence Neurological Specialties West, Portland, Oregon, 97225, United States|Swedish Medical Center Multiple Sclerosis Center, Seattle, Washington, 98122, United States"
NCT01639300,Safety Study of GNbAC1 in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT01639300,COMPLETED,Multiple Sclerosis,BIOLOGICAL: GNbAC1|BIOLOGICAL: GNbAC1 placebo,GeNeuro Innovation SAS,,ALL,"ADULT, OLDER_ADULT",PHASE2,10,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2012-07,2014-04,2014-04,"University Hospital Basel, Basel, 4031, Switzerland|Hopitaux Universitaires de Genève - HUG, Geneva, 1211, Switzerland"
NCT03836300,Parent-Infant Inter(X)Action Intervention (PIXI),https://beta.clinicaltrials.gov/study/NCT03836300,ENROLLING_BY_INVITATION,Fragile X Syndrome|Angelman Syndrome|Prader-Willi Syndrome|Dup15Q Syndrome|Duchenne Muscular Dystrophy|Phelan-McDermid Syndrome|Rett Syndrome|Smith Magenis Syndrome|Williams Syndrome|Turner Syndrome|Klinefelter Syndrome|Chromosome 22q11.2 Deletion Syndrome|Tuberous Sclerosis|Down Syndrome,BEHAVIORAL: Parent-Infant Inter(X)action Intervention (PIXI),RTI International,"University of North Carolina, Chapel Hill",ALL,"CHILD, ADULT, OLDER_ADULT",NA,120,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-11-30,2024-12-31,2025-06-30,"RTI International, Research Triangle Park, North Carolina, 27709, United States"
NCT05124600,An Individualized-health eLibrary App for People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05124600,RECRUITING,Multiple Sclerosis,DEVICE: SavvyHealth,University of Illinois at Urbana-Champaign,,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2021-10-25,2023-08-31,2024-08-31,"University of Illinois Urbana-Champaign, Champaign, Illinois, 61820, United States"
NCT01918800,A Randomized Trial of Two Formal Group Programs for Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01918800,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Fatigue: Take control|BEHAVIORAL: MS: Take Control,VA Office of Research and Development,Oregon Health and Science University,ALL,"ADULT, OLDER_ADULT",NA,282,FED,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2013-03-28,2015-12-30,2015-12-30,"North Florida/South Georgia Veterans Health System, Gainesville, FL, Gainesville, Florida, 32608, United States|Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD, Baltimore, Maryland, 21201, United States|VA Portland Health Care System, Portland, OR, Portland, Oregon, 97239, United States|VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington, 98108, United States"
NCT03477500,"RCT Comparing Autologous Hematopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab in MS",https://beta.clinicaltrials.gov/study/NCT03477500,RECRUITING,Multiple Sclerosis,DRUG: Cyclophosphamide and ATG|DRUG: Alemtuzumab|DRUG: Cladribine Pill|DRUG: Ocrelizumab,Haukeland University Hospital,,ALL,ADULT,PHASE3,100,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2018-03-21,2025-12-21,2026-03-21,"Rigshospitalet, Copenhagen, Denmark|VUmc, Amsterdam, Netherlands|Haukeland University Hospital, Bergen, Norway|Akershus University Hospital, Oslo, Norway|University Hospital of North Norway, Tromsø, Norway|St. Olav's University Hospital, Trondheim, Norway|Sahlgrenska University Hospital, Gothenburg, Sweden|Akademiska sjukhuset, Uppsala, Sweden"
NCT04964700,Analysis of MS Patients Who Have Had Greater Than 60 Infusions of Natalizumab,https://beta.clinicaltrials.gov/study/NCT04964700,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,DRUG: Natalizumab,Multiple Sclerosis Center of Northeastern New York,,ALL,"ADULT, OLDER_ADULT",,42,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-05-06,2022-04-01,2022-06-01,"Multiple Sclerosis Center of Northeastern New York, P.C., Latham, New York, 12110, United States"
NCT01413100,Scleroderma Treatment With Autologous Transplant (STAT) Study,https://beta.clinicaltrials.gov/study/NCT01413100,ACTIVE_NOT_RECRUITING,Systemic Scleroderma,BIOLOGICAL: Anti-Thymocyte Globulin|PROCEDURE: Autologous Hematopoietic Stem Cell Transplantation|DRUG: Cyclophosphamide|BIOLOGICAL: Filgrastim|OTHER: Laboratory Biomarker Analysis|DRUG: Mycophenolate Mofetil|PROCEDURE: Peripheral Blood Stem Cell Transplantation|DRUG: Plerixafor|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,21,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-09-15,2025-01-31,2025-01-31,"City of Hope Comprehensive Cancer Center, Duarte, California, 91010, United States|UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, 90095, United States|University of Colorado, Denver, Colorado, 80217-3364, United States|Colorado Blood Cancer Institute, Denver, Colorado, 80218, United States|Boston Medical Center, Boston, Massachusetts, 02118, United States|Boston University School of Medicine, Boston, Massachusetts, 02118, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, 48109, United States|Duke University Medical Center, Durham, North Carolina, 27710, United States|M D Anderson Cancer Center, Houston, Texas, 77030, United States|The University of Texas Health Science Center, Houston, Houston, Texas, 77030, United States|Seattle Children's Hospital, Seattle, Washington, 98105, United States|Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, 98109, United States"
NCT01610700,An Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT01610700,COMPLETED,Multiple Sclerosis,DRUG: GW-1000-02|DRUG: Placebo,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,160,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2001-05,2002-07,2002-07,"Rivermead Rehabilitation Centre, Oxford, OX3 7LD, United Kingdom"
NCT04881422,"Sport, Rehabilitation and Nutrition in Multiple Sclerosis: The LINUS Project",https://beta.clinicaltrials.gov/study/NCT04881422,UNKNOWN,Multiple Sclerosis,BEHAVIORAL: B-HIPE (Brief High Impact Preparatory Experience),Fondazione Don Carlo Gnocchi Onlus,,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-07-15,2021-12-31,2022-06-30,"IRCCS Fondazione Don Carlo Gnocchi, Milan, Italy"
NCT03652519,High-intensity Training and Its Effects on Neuroplasticity,https://beta.clinicaltrials.gov/study/NCT03652519,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Exercise Training,Klinik Valens,"German Sport University, Cologne",ALL,"ADULT, OLDER_ADULT",NA,72,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2018-11-21,2019-11-11,2019-11-11,"Kliniken-Valens, Valens, Sankt Gallen, 7317, Switzerland"
NCT04030819,Effectiveness of a Schema Therapy on Anxiety in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04030819,UNKNOWN,Anxiety,BEHAVIORAL: schema therapy,Paris Nanterre University,Isfahan University of Medical Sciences,ALL,"ADULT, OLDER_ADULT",NA,106,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2018-12-20,2019-06-18,2019-12-15,"university Paris Nanterre, Paris, 75, France"
NCT00168766,Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS,https://beta.clinicaltrials.gov/study/NCT00168766,COMPLETED,Relapsing-remitting Multiple Sclerosis,DRUG: Interferon-beta-1a (Avonex) plus methylprednisolone,Biogen,,ALL,ADULT,PHASE4,345,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2003-01,2008-11,2008-11,"CUB Hôpital Erasme, Bruxelles, Belgium|Coordinating Research Site, Copenhagen, Denmark|Rigshospitalet, Skleroseklinikken, Denmark|Tampereen yliopistollinen sairaala - Neurologian klinikka, Tampere, Finland|Stichting MS Centrum, Nijemegen, Netherlands|Ullevål Universitetssykehus, Oslo, Norway|Neurologkliniken, Stockholm, Sweden|Kantonspital, St. Gallen, Switzerland|Queens Medical Centre - Division of Neurology, Nottingham, Ng72uh, United Kingdom"
NCT02252666,Exploring the Use of Non-invasive Neuromodulation Combined With Exercise in People With Advanced Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT02252666,COMPLETED,Multiple Sclerosis,DEVICE: Neuromodulation Rehabilitation,"University of Wisconsin, Madison",,ALL,"ADULT, OLDER_ADULT",NA,6,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-03,2017-01,2017-06-28,"TCNL, 455 Science Drive, Suite 165, Madison, Wisconsin, 53711, United States"
NCT00940719,Vitamin D3 Supplementation and the T Cell Compartment in Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT00940719,COMPLETED,Multiple Sclerosis,DIETARY_SUPPLEMENT: vitamin D3,Maastricht University Medical Center,Orbis Medical Centre,ALL,"ADULT, OLDER_ADULT",NA,15,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2009-08,2010-03,2010-07,"Orbis Medical Center, Sittard, 6130MD, Netherlands"
NCT00913666,Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers,https://beta.clinicaltrials.gov/study/NCT00913666,COMPLETED,Multiple Sclerosis,DRUG: Interferon beta-1a (Avonex),Biogen,,ALL,"ADULT, OLDER_ADULT",PHASE4,121,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE,2002-11,,2004-11,
NCT01142466,A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone,https://beta.clinicaltrials.gov/study/NCT01142466,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: Interferon beta-1a (Rebif),"Merck KGaA, Darmstadt, Germany",Gesellschaft für Therapieforschung mbH,ALL,ADULT,PHASE4,30,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2005-12,2009-12,2010-01,
NCT01047319,"A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT01047319,TERMINATED,Relapsing Multiple Sclerosis,DRUG: Laquinimod,"Teva Branded Pharmaceutical Products R&D, Inc.",,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,1047,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2010-05-27,2017-06-30,2017-06-30,"Teva Investigational Site 1267, Homewood, Alabama, 35209, United States|Teva Investigational Site 1237, Phoenix, Arizona, 85013, United States|Teva Investigational Site 1279, Phoenix, Arizona, 85018, United States|Teva Investigational Site 1276, Tucson, Arizona, 85704, United States|Teva Investigational Site 1272, Pasadena, California, 91105, United States|Teva Investigational Site 1238, Sacramento, California, 95817, United States|Teva Investigational Site 1280, Aurora, Colorado, 80045, United States|Teva Investigational Site 1282, Sarasota, Florida, 34233, United States|Teva Investigational Site 1275, Atlanta, Georgia, 30309, United States|Teva Investigational Site 1250, Peoria, Illinois, 61603, United States|Teva Investigational Site 1260, Indianapolis, Indiana, 46202, United States|Teva Investigational Site 1263, Shreveport, Louisiana, 71103, United States|Teva Investigational Site 1269, Baltimore, Maryland, 21201, United States|Teva Investigational Site 1273, Albany, New York, 12205, United States|Teva Investigational Site 1264, Amherst, New York, 14226, United States|Teva Investigational Site 1261, Akron, Ohio, 44320, United States|Teva Investigational Site 1245, Cleveland, Ohio, 44195-5244, United States|Teva Investigational Site 1247, Columbus, Ohio, 43221, United States|Teva Investigational Site 1244, Portland, Oregon, 97225, United States|Teva Investigational Site 1281, Nashville, Tennessee, 37205, United States|Teva Investigational Site 1270, Roanoke, Virginia, 24018, United States|Teva Investigational Site 1253, Tacoma, Washington, 98405, United States|Teva Investigational Site 5914, Pleven, 5800, Bulgaria|Teva Investigational Site 5915, Pleven, 5800, Bulgaria|Teva Investigational Site 5917, Plovdiv, 4000, Bulgaria|Teva Investigational Site 4212, Ruse, 7000, Bulgaria|Teva Investigational Site 5916, Shumen, 9700, Bulgaria|Teva Investigational Site 5920, Sofia, 1000, Bulgaria|Teva Investigational Site 5907, Sofia, 1113, Bulgaria|Teva Investigational Site 5910, Sofia, 1113, Bulgaria|Teva Investigational Site 5909, Sofia, 1309, Bulgaria|Teva Investigational Site 5919, Sofia, 1407, Bulgaria|Teva Investigational Site 5906, Sofia, 1606, Bulgaria|Teva Investigational Site 5908, Sofia, 1606, Bulgaria|Teva Investigational Site 5911, Sofia, 1606, Bulgaria|Teva Investigational Site 5912, Sofia, 1606, Bulgaria|Teva Investigational Site 5918, Stara Zagora, 6000, Bulgaria|Teva Investigational Site 5913, Varna, 9010, Bulgaria|Teva Investigational Site 4211, Veliko Tarnovo, 5000, Bulgaria|Teva Investigational Site 6003, Osijek, 31 000, Croatia|Teva Investigational Site 6005, Varazdin, 42000, Croatia|Teva Investigational Site 6001, Zagreb, 10000, Croatia|Teva Investigational Site 6002, Zagreb, 10000, Croatia|Teva Investigational Site 6006, Zagreb, 10000, Croatia|Teva Investigational Site 5419, Olomouc, 779 00, Czechia|Teva Investigational Site 5418, Praha 2, 128 08, Czechia|Teva Investigational Site 5420, Praha 5- Motol, 150 06, Czechia|Teva Investigational Site 5421, Teplice, 415 29, Czechia|Teva Investigational Site 5508, Kohtla-Jarve, 31025, Estonia|Teva Investigational Site 5507, Tallinn, EE-10617, Estonia|Teva Investigational Site 5509, Tartu, EE-51014, Estonia|Teva Investigational Site 8102, Tbilisi, 0112, Georgia|Teva Investigational Site 8104, Tbilisi, 0112, Georgia|Teva Investigational Site 8103, Tbilisi, 0179, Georgia|Teva Investigational Site 6703, Berlin, 10117, Germany|Teva Investigational Site 6402, Berlin, 12203, Germany|Teva Investigational Site 6400, Ulm, 89081, Germany|Teva Investigational Site 8041, Jerusalem, 9112001, Israel|Teva Investigational Site 8040, Ramat Gan, 5262160, Israel|Teva Investigational Site 3056, Bologna, 40139, Italy|Teva Investigational Site 3053, Cefalu, 90015, Italy|Teva Investigational Site 3054, Chieti, 66100, Italy|Teva Investigational Site 3061, Empoli, 50053, Italy|Teva Investigational Site 3049, Firenze, 50139, Italy|Teva Investigational Site 3055, Napoli, 80131, Italy|Teva Investigational Site 3048, Rome, 00133, Italy|Teva Investigational Site 3052, Rome, 00149, Italy|Teva Investigational Site 3050, Rome, 00168, Italy|Teva Investigational Site 5708, Kaunas, 50009, Lithuania|Teva Investigational Site 5707, Siauliai, 76231, Lithuania|Teva Investigational Site 6500, Skopje, 1000, North Macedonia|Teva Investigational Site 6501, Skopje, 1000, North Macedonia|Teva Investigational Site 6502, Skopje, 1000, North Macedonia|Teva Investigational Site 5337, Bialystok, 15-402, Poland|Teva Investigational Site 5329, Gdansk, 80-803, Poland|Teva Investigational Site 5338, Gdansk, 80-952, Poland|Teva Investigational Site 6602, Gorzow Wielkopolski, 66-400, Poland|Teva Investigational Site 5333, Grodzisk Mazowiecki, 05-825, Poland|Teva Investigational Site 5334, Katowice, 40-650, Poland|Teva Investigational Site 5339, Katowice, 40-684, Poland|Teva Investigational Site 6603, Kielce, 25-726, Poland|Teva Investigational Site 4213, Konskie, 26-200, Poland|Teva Investigational Site 5332, Koscierzyna, 83-400, Poland|Teva Investigational Site 5345, Krakow, 31-826, Poland|Teva Investigational Site 5328, Lodz, 90-153, Poland|Teva Investigational Site 5330, Olsztyn, 10-560, Poland|Teva Investigational Site 5331, Szczecin, 70-111, Poland|Teva Investigational Site 5336, Warsaw, 02-957, Poland|Teva Investigational Site 5340, Warszawa, 00-909, Poland|Teva Investigational Site 5341, Warszawa, 02-097, Poland|Teva Investigational Site 5335, Wroclaw, 50-556, Poland|Teva Investigational Site 5235, Balotesti, 077015, Romania|Teva Investigational Site 5218, Bucharest, 010825, Romania|Teva Investigational Site 5214, Bucuresti, 022328, Romania|Teva Investigational Site 5213, Bucuresti, 050098, Romania|Teva Investigational Site 5215, Cluj-Napoca, 400012, Romania|Teva Investigational Site 5217, Constanta, 900591, Romania|Teva Investigational Site 8209, Craiova, 200515, Romania|Teva Investigational Site 5216, Iasi, 700661, Romania|Teva Investigational Site 5219, Sibiu, 550245, Romania|Teva Investigational Site 5043, Barnaul, 656024, Russian Federation|Teva Investigational Site 5033, Moscow, 117152, Russian Federation|Teva Investigational Site 5041, Moscow, 125367, Russian Federation|Teva Investigational Site 5032, Moscow, 127015, Russian Federation|Teva Investigational Site 5038, Novosibirsk, 630087, Russian Federation|Teva Investigational Site 5042, Novosibirsk, 630117, Russian Federation|Teva Investigational Site 5035, Saint Petersburg, 197022, Russian Federation|Teva Investigational Site 5037, Samara, 443095, Russian Federation|Teva Investigational Site 5036, St. Petersburg, 194291, Russian Federation|Teva Investigational Site 5034, St. Petersburg, 197376, Russian Federation|Teva Investigational Site 5044, Ufa, 450007, Russian Federation|Teva Investigational Site 6200, Bratislava, 813 69, Slovakia|Teva Investigational Site 6201, Bratislava, 826 06, Slovakia|Teva Investigational Site 6202, Nitra, 949 01, Slovakia|Teva Investigational Site 6203, Zilina, 010 01, Slovakia|Teva Investigational Site 9007, Bloemfontein, 9301, South Africa|Teva Investigational Site 9001, Cape Town, 7925, South Africa|Teva Investigational Site 9004, Johannesburg, 2157, South Africa|Teva Investigational Site 9003, Parktown- Johannesburg, 2193, South Africa|Teva Investigational Site 9008, Pietermaritzburg, 3201, South Africa|Teva Investigational Site 9005, Pretoria, 0041, South Africa|Teva Investigational Site 9006, Rosebank, 2196, South Africa|Teva Investigational Site 3147, Barcelona, 08035, Spain|Teva Investigational Site 3154, Figueres-Girona, 17600, Spain|Teva Investigational Site 3149, L'Hospitalet de Llobregat, 08907, Spain|Teva Investigational Site 3152, Madrid, 28041, Spain|Teva Investigational Site 3151, Malaga, 29010, Spain|Teva Investigational Site 3148, Sevilla, 41009, Spain|Teva Investigational Site 3153, Tortosa-Tarragona, 43500, Spain|Teva Investigational Site 6503, Chernihiv, 14029, Ukraine|Teva Investigational Site 5823, Chernivtsi, 58018, Ukraine|Teva Investigational Site 5811, Dnipropetrovsk, 49027, Ukraine|Teva Investigational Site 5812, Donetsk, 83003, Ukraine|Teva Investigational Site 5814, Ivano-Frankivsk, 76008, Ukraine|Teva Investigational Site 5817, Kharkiv, 61018, Ukraine|Teva Investigational Site 5818, Kharkiv, 61068, Ukraine|Teva Investigational Site 5815, Kharkiv, 61103, Ukraine|Teva Investigational Site 5822, Kyiv, 03110, Ukraine|Teva Investigational Site 5809, Lviv, 79010, Ukraine|Teva Investigational Site 5820, Odessa, 65025, Ukraine|Teva Investigational Site 5821, Poltava, 36024, Ukraine|Teva Investigational Site 5810, Vinnytsya, 21005, Ukraine|Teva Investigational Site 5819, Zaporizhzhya, 69035, Ukraine|Teva Investigational Site 5816, Zaporizhzhya, 69600, Ukraine"
NCT01917019,A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01917019,COMPLETED,"Multiple Sclerosis, Remittent Progressive|Multiple Sclerosis, Primary Progressive|Relapsing-Remitting Multiple Sclerosis|Secondary Progressive Multiple Sclerosis|Multiple Sclerosis",DRUG: Placebo|DRUG: BIIB041 (fampridine),Biogen,,ALL,"ADULT, OLDER_ADULT",PHASE3,101,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-08,2015-10,2017-03,"Research Site, Bunkyo-ku, Japan|Research Site, Chiba-shi, Japan|Research Site, Fuchu, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Kawagoe-shi, Japan|Research Site, Kodaira-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Morioka, Japan|Research Site, Niigata, Japan|Research Site, Obihiro, Japan|Research Site, Osaka, Japan|Research Site, Ota-ku, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sendai, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Suita-shi, Japan|Research Site, Toon-shi, Japan|Research Site, Ube-shi, Japan|Research Site, Yachiyo-shi, Japan"
NCT03798366,A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis,https://beta.clinicaltrials.gov/study/NCT03798366,COMPLETED,Systemic Sclerosis,DRUG: GLPG1690|DRUG: Placebo,Galapagos NV,,ALL,"ADULT, OLDER_ADULT",PHASE2,33,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-01-14,2020-05-21,2020-06-22,"Pacific Arthritis Care Center, Los Angeles, California, 90045, United States|UCLA Rheumatology, Los Angeles, California, 90095, United States|RASF Clinical Research Center, Boca Raton, Florida, 33486, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|University of Michigan, Ann Arbor, Michigan, 48109, United States|Metroplex Clinical Research Center, Dallas, Texas, 75231, United States|UT Physicians Center for Autoimmunity, Houston, Texas, 77030, United States|UZ Gent, Gent, 9000, Belgium|UZ Leuven, Leuven, 3000, Belgium|Charité - Universitätsmedizin Berlin, Berlin, 10117, Germany|Universitätsklinikum Frankfurt, Frankfurt, 60590, Germany|Azienda Ospedaliero, Firenze, 50439, Italy|Ospedale San Raffaele S.r.l. - PPDS, Milano, 20132, Italy|Hospital Universitario Vall d'Hebron - PPDS, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Nuestra Señora de Valme, Sevilla, Spain|University Hospital Aintree, Liverpool, L9 7AL, United Kingdom|Royal Free Hospital, London, NW32QG, United Kingdom"
NCT00267319,FOCUS Fatigue Outcome in Copaxone USers,https://beta.clinicaltrials.gov/study/NCT00267319,COMPLETED,Multiple Sclerosis,DRUG: Glatiramer acetate,Sanofi,,ALL,"ADULT, OLDER_ADULT",PHASE4,111,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2003-06,2006-10,,"Sanofi-Aventis, Praha, Czech Republic"
NCT02711566,Robot-based Rehabilitation of Upper Limb Impairment in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02711566,COMPLETED,Multiple Sclerosis,DEVICE: Physioassistant: Haptic training|DEVICE: Physioassistant: Sensorimotor training,Fondazione Don Carlo Gnocchi Onlus,University of Genova|Azienda Sanitaria Locale 3 Genovese,ALL,"ADULT, OLDER_ADULT",NA,41,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2010-01,2011-07,2011-12,
NCT01411514,Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01411514,TERMINATED,Multiple Sclerosis,DRUG: Prednisone|DRUG: Placebo,Claudio Gobbi,"Ente Ospedaliero Cantonale, Ticino, Switzerland",ALL,"ADULT, OLDER_ADULT",PHASE4,27,OTHER_GOV,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2011-08,2015-01,2015-01,"Osepdale Civico, Lugano, Ticino, 6903, Switzerland"
NCT05433714,Figure of 8 Walk Test in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05433714,COMPLETED,Multiple Sclerosis,OTHER: Assesment,Kahramanmaras Sutcu Imam University,,ALL,"ADULT, OLDER_ADULT",,50,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-08-01,2022-10-01,2022-10-06,"Kahramanmaraş Sutcu Imam University, Kahramanmaraş, Turkey"
NCT04244214,Pilot Study for the Evaluation of the More Stamina in Persons With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04244214,UNKNOWN,"Multiple Sclerosis|Fatigue|Chronic Conditions, Multiple",OTHER: More Stamina,Hospital Italiano de Buenos Aires,University of Oulu|University of Seville|Klinik Valens|Hospitales Nisa,ALL,"ADULT, OLDER_ADULT",,60,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-08-21,2020-10-01,2020-11-01,
NCT04220814,Evaluation of the Impact of Lesions of the Motor and Proprioceptive Brain and Pan-medullary Pathways on Their Clinically and Electrophysiologically Assessed Function in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04220814,RECRUITING,"Multiple Sclerosis, Relapsing-Remitting",RADIATION: MRI|OTHER: Electrophysiology,Rennes University Hospital,,ALL,"ADULT, OLDER_ADULT",NA,90,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2020-11-03,2024-05-28,2024-12-31,"AP-HM Timone, Marseille, France|CHU Rennes, Rennes, France"
NCT05641714,The Reliability and Validity of the L-test in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05641714,COMPLETED,Multiple Sclerosis,OTHER: L test|OTHER: Timed Up and Go test|OTHER: 10 meter walk test|OTHER: Six Minute Walk Test|OTHER: The timed 360° turn test,Gazi University,,ALL,"ADULT, OLDER_ADULT",,68,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-12-15,2023-01-16,2023-01-16,"Gazi University, Ankara, Turkey"
NCT02710214,A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02710214,COMPLETED,Menopause|Multiple Sclerosis,DRUG: Tissue Selective Estrogen Complex|DRUG: Placebo,"University of California, San Francisco",National Multiple Sclerosis Society,FEMALE,ADULT,PHASE2,24,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-02,2019-04-24,2019-04-24,"University of California, San Francisco, San Francisco, California, 94158, United States"
NCT03508414,Nutritional Approaches in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03508414,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,BEHAVIORAL: ketogenic diet|BEHAVIORAL: Intermittent therapeutical fasting|BEHAVIORAL: Active comparator,"Charite University, Berlin, Germany",,ALL,"ADULT, OLDER_ADULT",NA,111,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: OTHER,2017-04-11,2021-12-01,2021-12-01,"Charité - Universitätsmedizin Berlin, Berlin, 10117, Germany"
NCT02747914,Repetitive Transcranial Magnetic Stimulation for Lower Limb Spasticity in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT02747914,RECRUITING,Multiple Sclerosis,DEVICE: Transcranial magnetic stimulation|OTHER: Conventional exercise,University of Belgrade,,ALL,"CHILD, ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-01-25,2022-12,2023-12,"Clinic for rehabilitation dr Miroslav Zotovic Faculty of Medicine University of Belgrade, Belgrade, 11000, Serbia"
NCT05450237,Psychometric Evaluation in Patients With Brain Damage During Neuroinflammation (NeuroPsyc),https://beta.clinicaltrials.gov/study/NCT05450237,ENROLLING_BY_INVITATION,Multiple Sclerosis|Epilepsy|Parkinson Disease|Dementia|Stroke,BEHAVIORAL: Psychometric Evaluations,Neuromed IRCCS,,ALL,"ADULT, OLDER_ADULT",,500,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-05-18,2022-05-18,2025-06-01,"Ircss Neuromed, Pozzilli, Isernia, 86077, Italy"
NCT03499314,A Pilot Trial of Remotely-Supervised Transcranial Direct Current Stimulation (RS-tDCS) to Enhance Motor Learning in Progressive Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT03499314,COMPLETED,Multiple Sclerosis,DEVICE: Active RS-tDCS +At-Home Manual Dexterity Training|DEVICE: Sham RS-tDCS +At-Home Manual Dexterity Training|OTHER: Manual dexterity training,NYU Langone Health,,ALL,"ADULT, OLDER_ADULT",NA,65,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2018-04-15,2020-11-30,2020-11-30,"New York University School of Medicine, New York, New York, 10016, United States"
NCT02035514,Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02035514,COMPLETED,Relapsing Remitting Multiple Sclerosis (RRMS),BIOLOGICAL: Bone marrow autologous mesenchymal stem cells transplantation,Germans Trias i Pujol Hospital,"Ministerio de Sanidad, Servicios Sociales e Igualdad",ALL,ADULT,PHASE1|PHASE2,9,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2013-12,2016-07,2016-07,"Germans Trias i Pujol Hospital, Badalona, Barcelona, 08916, Spain"
NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),https://beta.clinicaltrials.gov/study/NCT02861014,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",BIOLOGICAL: Ocrelizumab,Hoffmann-La Roche,,ALL,ADULT,PHASE3,681,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-09-09,2019-10-25,2020-12-15,"St George Hospital, Kogarah, New South Wales, New South Wales, 2217, Australia|Hospital Erasme, Bruxelles, 1070, Belgium|Cliniques Universitaires St-Luc, Bruxelles, 1200, Belgium|UZ Antwerpen, Edegem, 2650, Belgium|UZ Gent, Gent, 9000, Belgium|CHU Tivoli, La Louvière, 7100, Belgium|UZ Leuven Gasthuisberg, Leuven, 3000, Belgium|Nationaal MS Centrum, Melsbroek, 1820, Belgium|Revalidatie en MS Centrum, Overpelt, 3900, Belgium|Fakultni nemocnice u sv. Anny; Neurologicka klinika, Brno, 656 91, Czechia|Nemocnice Jihlava; NEU-Neurologicke oddeleni, Jihlava, 58633, Czechia|VFN Praha Poliklinika Rs Centrum - Budova A, Prague, 12808, Czechia|Fakultni nemocnice Motol; Neurologicka klinika, Praha, 150 06, Czechia|Aarhus Universitetshospital, Neurologisk Afd. F, Skleroseklinikken, Aarhus N, 8200, Denmark|Rigshospitalet Glostrup; Neurologisk Klinik, Glostrup, 2600, Denmark|Odense Universitetshospital, Neurologisk Afdeling N, Odense C, 5000, Denmark|Sydjysk Skleroseklinik - Sønderborg, Sønderborg, 6400, Denmark|East Tallinn Central Hospital; Neurology Department, Tallinn, 10138, Estonia|West Tallinn Central Hospital, Tallinn, 10617, Estonia|Tartu University Hospital, Tartu, 51014, Estonia|Terveystalo Tampere, Tampere, 33100, Finland|Mehiläinen Neo Turku, Turku, 20520, Finland|CHU de Besancon Hopital Jean Minjoz; Service de Neurologie, Besançon, 25030, France|Groupe Hospitalier Pellegrin; Service de neurochirurgie B, Bordeaux, 33076, France|Hopital Neurologique et Neurochirurgical Pierre Wertheimer; Service de Neurologie A, Bron, 69677, France|Hopital Gabriel Montpied CHU de Clermont-Ferrand; Service de Neurologie B, Clermont-Ferrand, 63003, France|Hopital Roger Salengro; Service de Neurologie, Lille, France|CHU de la Timone - Hopital d Adultes; Service de Neurologie, Marseille, 13005, France|Hopital Gui de Chauliac; Neurologie, Montpellier, 34295, France|Hôpital Guillaume et René Laënnec; Service Neurologie, Nantes, 44805, France|Hôpital Pasteur; Service de Neurologie, Nice, 06002, France|Fondation Rothschild; Service de Neurologie, Paris, 75019, France|Groupe Hospitalier Pitié- Salpétrière; Service Neurologie, Paris, 75651, France|Hôpital Maison Blanche; Service de Neurologie, Reims, 51092, France|Hôpitaux Universitaires de strasbourg - hôpital civil, Strasbourg, 67091, France|CHU toulouse - Hôpital Purpan; Departement de Neurologie, Toulouse, 31059, France|CHRU - Hôpital Bretonneau; Neurologie, Tours, 37000, France|Klinikum Augsburg, Neurologische Klinik und klinische Neurophysiologie, Augsburg, 86156, Germany|Marianne-Strauß-Klinik; Behandlung Kempfen für Multip Sklero Kranke gemeinnütz GmbH, Berg, 82335, Germany|Charite - Universitatsmedizin Berlin; Klinik fur Neurologie, Berlin, 10117, Germany|Praxis Dr. Said Masri, Berlin, 12099, Germany|Gemeinschaftspraxis Dr.med. Reinhard Ehret/Dr. med Wolfram von Pannwitz, Berlin, 12163, Germany|Jüdisches Krankenhaus Berlin; Abteilung fur Neurologie, Berlin, 13347, Germany|St. Josef-Hospital, Klinik für Neurologie, Bochum, 44791, Germany|Gesundheitszentrum St. Johannes Hospital; Neurolog. Gemeinschaftspraxis Dres. Schmidt, Neudecker etc, Bonn, 53111, Germany|PNP Buchholz, Praxis für Neurologie - Psychiatrie, Dres. Dee/Gößling/Hoge, Buchholz, 21244, Germany|Studienzentrum für Neurologie und Psychiatrie, Böblingen, 71034, Germany|Universitätsklinikum ""Carl Gustav Carus"", Zentrum für Klinische Neurowissenschaften, Dresden, 01307, Germany|Gemeinschaftspraxis für Neurologie; Dr. Katrin Schulte, Dr. Nils Richter, Dr. Margarete Capito, Düsseldorf, 40211, Germany|NeuroCentrum Odenwald; Dres. Reifschneider, Unsorg, Ries, Schumann, Hoffmann, Knoblich, Erbach/Odenwald, 64711, Germany|Universitaetsklinikum Frankfurt; Klinik für Neurologie, Frankfurt, 60528, Germany|Universitätsklinikum Freiburg, Klinik für Neurologie und Neurophysiologie, Freiburg, 79106, Germany|Universiätsklinikum Hamburg-Eppendorf , Multiple Sklerose Tagesklinik u. Ambulanz Neurol. Poliklinik, Hamburg, 20246, Germany|Neurologische Praxisgemeinschaft Hamburger-Straße; Dres. Müller-Habich/Emrich/Vogt, Hamburg, 22083, Germany|MultipEL Studies - Institut für klinische Studien, Hamburg, 22179, Germany|Henriettenstiftung Hannover; Klinik fuer Neurologie und Klinische Neurophysiologie, Hannover, 30171, Germany|Neurologische Klinik, Universitätsklinikum Heidelberg, Heidelberg, 69120, Germany|Oberhavel Kliniken GmbH, Klinik Hennigsdorf, Neurologie, Hennigsdorf, 16761, Germany|Neurozentrum am Klosterforst in Itzehoe, Itzehoe, 25524, Germany|Neurologische Gemeinschaftspraxis Kassel und Vellmar, Ch. Lassek, Dres. Ammerbach, Fetzer, M. Fische, Kassel, 34121, Germany|PANAKEIA - Arzneimittelforschung Leipzig GmbH, Leipzig, 04275, Germany|Universitätsklinikum Magdeburg,Otto-von-Guericke-Universität A.ö.R., Klinik für Neurologie, Magdeburg, 39120, Germany|Universitaetsklinikum Mainz - PS; Klinik und Poliklinik fuer Neurologie, Mainz, 55131, Germany|Universitaetsklinikum Marburg; Klinik fuer Neurologie, Marburg, 35043, Germany|Max-Planck-Institut für Psychiatrie, München, 80804, Germany|Klinikum Grosshadern der LMU; Neuroimmunologie II, München, 81377, Germany|Klinikum rechts der Isar der TU Muenchen; Neurologische Klinik und Poliklinik im Neuro-Kopf-Zentrum, München, 81675, Germany|Universitätsklinikum Münster; Klinik und Poliklinik für Neurologie, Münster, 48149, Germany|Ruppiner Kliniken, Hochschulklinikum der Medizinischen Hochschule Brandenburg, Klinik für Neurologie, Neuruppin, 16816, Germany|AMEOS Klinikum Oldenburg, Klinik für Neurologie und Neurophysiologie, Oldenburg in Holstein, 23758, Germany|St. Josefs-Krankenhaus, Klinik für Neurologie, Potsdam, 14471, Germany|NeuroConcept AG C/O mind mvz GmbH, Stuttgart, 70182, Germany|Universitätsklinikum Tübingen, Zentrum für Neurologie, Tübingen, 72076, Germany|NeuroPoint, Gesellschaft für vorbeugende Gesundheitspflege mbH, Ulm, 89073, Germany|Studienzentrum Nordwest, Dr. med. Joachim Springub / Herr Wolfgang Schwarz, Westerstede, 26655, Germany|Cork University Hospital; Clinical Research Facility, Cork, Ireland|St Vincents University Hospital, Dublin 4, Ireland|Beaumont Hospital, Dublin, 9, Ireland|Ospedale SS. Annunziata - Clinica Neurologica - Centro Sclerosi Multipla, Chieti, Abruzzo, 66013, Italy|Ospedale San Salvatore; Clinica Neurologica - Centro Sclerosi Multipla, L'Aquila, Abruzzo, 67100, Italy|A. O. U. Federico II; Dip Neuroscienze, Scienze Riproduttive ed Odontostomatologiche, Napoli, Campania, 80131, Italy|Università degli Studi della Campania Luigi Vanvitelli; Dip. Ass. Integrato Med Int-II Clinica Neur, Napoli, Campania, 80131, Italy|Ospedale Bellaria; Istituto delle Scienze Neurologiche - UO RIABILITAZIONE SCLEROSI MULTIPLA, Bologna, Emilia-Romagna, 40139, Italy|Policlinico Tor Vergata Dip. Neuroscienze-Clinica Neurologica-UOSD Sclerosi Multipla, Roma, Lazio, 00133, Italy|Ospedale S.Camillo Forlanini; UOSD Day Hospital Neurologico e Neurochirurgico, Roma, Lazio, 00152, Italy|Policlinico Universitario A. Gemelli; UOC Neurologia - Centro Sclerosi Multipla, Roma, Lazio, 00168, Italy|Azienda Ospedaliera Sant'Andrea; UOC Neurologia, Roma, Lazio, 00189, Italy|Irccs A.O.U.San Martino Ist; Dinogmi, Genova, Liguria, 16132, Italy|ASST PAPA GIOVANNI XXIII Neurologia USS Malattie Autoimmuni Centro Sclerosi Multipla, Bergamo, Lombardia, 24127, Italy|Ospedale S.Antonio Abate; Neurologia 2 - Sclerosi Multipla e Recupero Neurologico, Gallarate, Lombardia, 21013, Italy|Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico; UOSD Malattie Neurodegenerative, Milano, Lombardia, 20122, Italy|IRCCS Ospedale San Raffaele; Neurologia Neurofisiologia Neuroriabilitazione-Centro Sclerosi Multipla, Milano, Lombardia, 20132, Italy|Fond. Istituto Neurologico C.Besta; UO Neurologia IV - Neuroimmunologia Malattie Neuromuscolari, Milano, Lombardia, 20133, Italy|Ospedale Civile di Montichiari; Centro Sclerosi Multipla, Montichiari, Lombardia, 25018, Italy|IRCCS Istituto Neurologico C. Mondino-Dip. Neurologia Neuroriabilitazione S.S. Sclerosi Multipla, Pavia, Lombardia, 27100, Italy|AOU Ospedali Riuniti Umberto I-G.M. Lancisi-G. Salesi; SOD Clinica Neurologica-Am.Sclerosi Multipla, Ancona, Marche, 60100, Italy|IRCCS Istituto Neurologico Neuromed; Centro per lo Studio e la Cura della Sclerosi Multipla, Pozzilli, Molise, 86077, Italy|Ospedale Dimiccoli Barletta; Dipartimento Testa-Collo - UO Neurologia, Barletta, Puglia, 70051, Italy|IRCCS Ospedale Casa Sollievo Della Sofferenza; SC Neurologia, San Giovanni Rotondo, Puglia, 71013, Italy|Ospedale Binaghi; Centro Sclerosi Multipla, Cagliari, Sardegna, 09126, Italy|AOU Policlinico V. Emanuele - P.O G. Rodolico; Clinica Neurologica, Centro Sclerosi Multipla, Catania, Sicilia, 95123, Italy|Fondazione Istituto S. Raffaele - Giglio; UO Neurologia, Cefalù, Sicilia, 90015, Italy|AOU Policlinico Giaccone; UOC Neurologia e Neurofisiopatologia-Amb Sclerosi Multipla, Palermo, Sicilia, 90129, Italy|AO Ospedali Riuniti Villa Sofia-Cervello;PO Villa Sofia - UO Neurologia - U.O.S. Neuroimmunologia, Palermo, Sicilia, 90146, Italy|AOU Careggi; Neurologia 1-Dip. Neuroscienze Psicologia Area Farmaco Salute del Bambino(NEUROFARBA), Firenze, Toscana, 50134, Italy|AOUC Azienda Ospedaliero-Universitaria Careggi; Neurologia 2, Firenze, Toscana, 50134, Italy|AOU Senese - Presidio Ospedaliero Le Scotte; UOSA Neurologia Sperimentale, Siena, Toscana, 53100, Italy|AO di Perugia - Ospedale S. Maria della Misericordia; Clinica Neurologica, Perugia, Umbria, 06156, Italy|Azienda Ospedaliera di Padova; Clinica Neurologica, Padova, Veneto, 35128, Italy|Policlinico G.B. Rossi; Dip. Scienze Neurologiche Biomediche - Neurologia B - Amb. Sclerosi Multipla, Verona, Veneto, 37134, Italy|Amphia Ziekenhuis, Breda, 4819 EV, Netherlands|St. Antonius Ziekenhuis Nieuwegein, Nieuwegein, 3435 CM, Netherlands|Maasstadziekenhuis, Rotterdam, 3079 DZ, Netherlands|Zuyderland Medisch Centrum - Sittard Geleen, Sittard-Geleen, 6162 BG, Netherlands|Sint Elizabeth Ziekenhuis, Tilburg, 5042 AD, Netherlands|Haukeland Universitetssykehus, Bergen, 5021, Norway|Sykehuset Buskerud HF; Nevrologisk avdeling, Drammen, 3004, Norway|Hospital Universitario Central de Asturias; Servicio de Neurología, Oviedo, Asturias, Spain|Hospital Universitari de Bellvitge; Servicio de Neurologia, L'Hospitalet de Llobregat, Barcelona, 08907, Spain|Hospital General de Castellon; Servicio de Neurología, Castelló de la Plana, Castellon, 12004, Spain|Hospital Universitari de Girona Dr. Josep Trueta; Servicio de Neurologia, Salt, Girona, 17190, Spain|Complejo Hospitalario Universitario A Coruña (CHUAC); Servicio de Neurologia, Coruña, LA Coruña, 15006, Spain|Hospital Universitari Arnau de Vilanova de Lleida; Servicio de Neurología, Lleida, Lerida, 25198, Spain|Hospital Quiron de Madrid; Servicio de Neurologia, Pozuelo de Alarcon, Madrid, 28223, Spain|Complejo Hospitalario Universitario de Vigo - Xeral Cies; Servicio de Neurologia, Vigo, Pontevedra, 36312, Spain|Hospital del Mar; Servicio de Neurologia, Barcelona, 08003, Spain|Hospital Vall d'Hebron; Servicio de Neurología, Barcelona, 08035, Spain|Hospital Puerta del Mar; Sevicio de Neurologia, Cadiz, 11009, Spain|Universitario de La Princesa; Servicio de Neurología, Madrid, 28006, Spain|Hospital Universitario Clínico San Carlos; Servicio de Neurología, Madrid, 28040, Spain|Hospital Universitario 12 de Octubre; Servicio de Neurologia, Madrid, 28041, Spain|Hospital Universitario La Paz; Servicio de Neurologia, Madrid, 28046, Spain|Hospital Universitario Virgen de Arrixaca; Servicio de Neurología, Murcia, Spain|Hospital Universitario Virgen Macarena; Servicio de Neurologia, Sevilla, 41009, Spain|Hospital Clinico Universitario de Valencia; Servicio de Neurologia, Valencia, 46010, Spain|Hospital Universitario la Fe; Servicio de Neurologia, Valencia, 46026, Spain|Sahlgrenska Sjukhuset; Neurology, Göteborg, 413 45, Sweden|Länssjukhuset Ryhov; Medicinkliniken / Neurologmottagningen, Jönköping, 55185, Sweden|Centrum för Neurologi, Stockholm, 113 41, Sweden|Universitätsspital Basel Medizin Neurologie; Neurologische Poliklinik, Basel, 4031, Switzerland|CHUV Lausanne Méd.Neurologie, Lausanne, 1011, Switzerland|Hacettepe University Medical Faculty; Neurology, Ankara, 06100, Turkey|Istanbul Uni Istanbul Medical Faculty, Istanbul, 34093, Turkey|Istanbul Universitesi - Cerrahpasa Cerrahpasa Tip Fakultesi; Noroloji Anabilim Dali, Istanbul, 34098, Turkey|Ege University Medical Faculty, Izmir, 35100, Turkey|Kocaeli University Hospital; Department of Neurology, Kocaeli, 41380, Turkey|Mersin University Medical Faculty; Neurology, Mersin, 33079, Turkey|Ondokuz Mayis Univ. Med. Fac.; Neurology, Samsun, 55139, Turkey|Karadeniz Tecnical Uni. Med. Fac.; Neurology, Trabzon, 61080, Turkey|New Queen Elizabeth Hospital Birmingham, Birmingham, B15 2WB, United Kingdom|Western General Hospital, Edinburgh, EH4 2XU, United Kingdom|Royal Devon and Exeter Hospital (Wonford), Exeter, EX2 5DW, United Kingdom|Queen Elizabeth University Hospital, Glasgow, G51 4TF, United Kingdom|Raigmore Hospital, Inverness, IV2 3UV, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, LS9 7AU, United Kingdom|The Royal London Hospital, London, E1 1FR, United Kingdom|Kings College Hospital, London, SW9 8RR, United Kingdom|Charing Cross Hospital, London, W6 8RF, United Kingdom|Royal Victoria Infirmary, Newcastle upon Tyne, NE1 4LP, United Kingdom|Salford Royal NHS Foundation Trust, Salford, M6 8HD, United Kingdom|Royal Hallamshire Hospita, Sheffield, S10 2JF, United Kingdom|Morriston Hospital, Swansea, SA6 6NL, United Kingdom|Royal Cornwall Hospital, Truro, TR1 3LQ, United Kingdom"
NCT05644522,Nomad P-KAFO Study,https://beta.clinicaltrials.gov/study/NCT05644522,NOT_YET_RECRUITING,Cerebrovascular Accident|Post-polio Syndrome|Spinal Cord Injuries|Multiple Sclerosis|Muscular Dystrophy|Paralysis,"DEVICE: Indego Nomad® Powered Knee-Ankle-Foot Orthosis (P-KAFO) (Parker Hannifin Corp., Cleveland, OH)",Shirley Ryan AbilityLab,,ALL,"ADULT, OLDER_ADULT",NA,36,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2023-06,2027-12,2027-12,"Shirley Ryan AbilityLab, Chicago, Illinois, 60611, United States"
NCT00334100,Treadmill Training in Chronic MS: Efficacy and Cost-effectiveness,https://beta.clinicaltrials.gov/study/NCT00334100,WITHDRAWN,Multiple Sclerosis,BEHAVIORAL: Exercise,US Department of Veterans Affairs,,ALL,"CHILD, ADULT, OLDER_ADULT",NA,0,FED,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2006-04,2011-09,2014-12,"VA Maryland Health Care System, Baltimore, Baltimore, Maryland, 21201, United States"
NCT04756700,Validation of DigiCog and Konectom Tools to Support Digitalized Clinical Assessment in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04756700,COMPLETED,Multiple Sclerosis,DIAGNOSTIC_TEST: DigiCog (BCCAMS app)|DIAGNOSTIC_TEST: Konectom Application,Biogen,,ALL,ADULT,NA,158,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-10-12,2022-07-26,2022-07-26,"Research Site, Bordeaux, 33000, France"
NCT05378100,Ketamine for Multiple Sclerosis Fatigue,https://beta.clinicaltrials.gov/study/NCT05378100,RECRUITING,Multiple Sclerosis Fatigue,DRUG: Ketamine|DRUG: Midazolam,Johns Hopkins University,United States Department of Defense,ALL,"ADULT, OLDER_ADULT",PHASE2,110,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-01-01,2025-12-01,2026-03-01,"Johns Hopkins University, Baltimore, Maryland, 21287, United States"
NCT01491100,Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01491100,COMPLETED,Multiple Sclerosis,"DRUG: Interferon beta-1b (Betaseron, BAY86-5046)",Bayer,,ALL,"CHILD, ADULT, OLDER_ADULT",,1085,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-04-30,2016-12-22,2017-04-05,"Multiple Locations, Albania|Multiple Locations, Algeria|Multiple Locations, Argentina|Multiple Locations, Belgium|Multiple Locations, Czechia|Multiple Locations, Egypt|Multiple Locations, France|Multiple Locations, Germany|Multiple Locations, Greece|Multiple Locations, Hungary|Multiple Locations, Israel|Multiple Locations, Kazakhstan|Multiple Locations, Netherlands|Multiple Locations, Portugal|Multiple Locations, Saudi Arabia|Multiple Locations, Tunisia|Multiple Locations, Turkey"
NCT01353547,Genes and Environment in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01353547,RECRUITING,Multiple Sclerosis,,Columbia University,University of Pittsburgh|Brigham and Women's Hospital,ALL,"ADULT, OLDER_ADULT",,5000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-10-01,2040-10,2040-10,"National Institute of Neurological Disorders and Stroke, Bethesda, Maryland, 15213, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Brigham and Women's Hospital, Boston, Massachusetts, 02115, United States|Columbia University Irving Center, New York, New York, 10032, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, 15213, United States"
NCT04338022,Study of Evobrutinib in Participants With RMS (evolutionRMS 1),https://beta.clinicaltrials.gov/study/NCT04338022,ACTIVE_NOT_RECRUITING,Relapsing Multiple Sclerosis,DRUG: Evobrutinib|DRUG: Placebo (match to Teriflunomide)|DRUG: Teriflunomide|DRUG: Placebo (match to Evobrutinib),"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","EMD Serono Research & Development Institute, Inc.",ALL,ADULT,PHASE3,1124,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-06-12,2023-09-04,2026-06-26,"Research Site 629, Mobile, Alabama, 36693-7003, United States|Research Site 614, Phoenix, Arizona, 85013, United States|Research Site 677, Phoenix, Arizona, 85018, United States|Research Site 642, Long Beach, California, 90806, United States|Research Site 644, Pasadena, California, 91105, United States|Research Site 672, San Diego, California, 92121, United States|Research Site 634, Stamford, Connecticut, 06905, United States|Research Site 656, Washington, District of Columbia, 20007, United States|Research Site 616, Boca Raton, Florida, 33428, United States|Research Site 625, Maitland, Florida, 32751, United States|Research Site 617, Miami, Florida, 33136, United States|Research Site 643, Ormond Beach, Florida, 32174, United States|Research site 645, Saint Petersburg, Florida, 33713, United States|Research Site 652, Tallahassee, Florida, 32308, United States|Research Site 621, Elk Grove Village, Illinois, 60007, United States|Research Site 649, Northbrook, Illinois, 60062, United States|Research Site 675, Peoria, Illinois, 61637, United States|Research Site 628, Rolling Meadows, Illinois, 60008, United States|Research Site 624, Indianapolis, Indiana, 46256, United States|Research Site 632, Kansas City, Kansas, 66160, United States|Research Site 653, New Orleans, Louisiana, 70115, United States|Research Site 623, Baltimore, Maryland, 21201, United States|Research Site 633, Boston, Massachusetts, 02114, United States|Research Site 639, Foxboro, Massachusetts, 02035, United States|Research Site 635, Lawrence, Massachusetts, 01843, United States|Research Site 636, Worcester, Massachusetts, 01655, United States|Research Site 613, Detroit, Michigan, 48201, United States|Research Site 612, Farmington Hills, Michigan, 48334, United States|Research Site 638, Saint Louis, Missouri, 63110, United States|Research Site 664, Saint Louis, Missouri, 63131, United States|Research Site 668, Omaha, Nebraska, 68130, United States|Research Site 626, Las Vegas, Nevada, 89106, United States|Research Site 667, Audubon, New Jersey, 08106, United States|Research Site 620, Patchogue, New York, 11772, United States|Research Site 663, Akron, Ohio, 44320, United States|Research Site 630, Toledo, Ohio, 43614-2598, United States|Research Site 611, Oklahoma City, Oklahoma, 73104, United States|Research Site 641, Oklahoma City, Oklahoma, 73104, United States|Research Site 615, Springfield, Oregon, 97477, United States|Research Site 647, Willow Grove, Pennsylvania, 19090, United States|Research Site 648, Knoxville, Tennessee, 37922, United States|Research Site 627, Nashville, Tennessee, 37205, United States|Research Site 637, Nashville, Tennessee, 37215, United States|Research Site 662, Dallas, Texas, 75214, United States|Research Site 631, Houston, Texas, 77030, United States|Research Site 650, Lubbock, Texas, 79410, United States|Research Site 619, Round Rock, Texas, 78681, United States|Research Site 676, Layton, Utah, 84041, United States|Research Site 673, Alexandria, Virginia, 22310, United States|Research Site 654, Virginia Beach, Virginia, 23456, United States|Research Site 651, Milwaukee, Wisconsin, 53226-3596, United States|Research Site 566, Ciudad Autonoma Buenos Aires, Argentina|Research Site 567, Ciudad Autonoma Buenos Aires, Argentina|Research Site 574, Ciudad Autonoma Buenos Aires, Argentina|Research Site 579, Ciudad Autonoma Buenos Aires, Argentina|Research Site 561, Ciudad Autonoma de Buenos Aires, Argentina|Research Site 562, Ciudad Autonoma de Buenos Aires, Argentina|Research Site 577, Ciudad Autonoma de Buenos Aires, Argentina|Research Site 564, Cordoba, Argentina|Research Site 568, Godoy Cruz, Argentina|Research Site 576, Guaymallen, Argentina|Research Site 565, Rosario, Argentina|Research Site 569, Rosario, Argentina|Research Site 571, Salta, Argentina|Research Site 572, San Juan, Argentina|Research Site 563, San Miguel de Tucuman, Argentina|Research Site 104, Auchenflower, Australia|Research Site 107, Concord, Australia|Research Site 109, Hobart, Australia|Research Site 101, Liverpool, Australia|Research Site 102, New Lambton Heights, Australia|Research Site 103, St Leonards, Australia|Research Site 151, Innsbruck, Austria|Research Site 156, Linz, Austria|Research Site 154, Salzburg, Austria|Research Site 153, Vienna, Austria|Research Site 474, Bruxelles, Belgium|Research Site 475, Bruxelles, Belgium|Research Site 473, Kortrijk, Belgium|Research Site 471, La Louvière, Belgium|Research Site 472, Liège, Belgium|Research Site 478, Overpelt, Belgium|Research Site 476, Roeselare, Belgium|Research Site 161, Bihac, Bosnia and Herzegovina|Research Site 163, Mostar, Bosnia and Herzegovina|Research Site 162, Sarajevo, Bosnia and Herzegovina|Research Site 171, Pleven, Bulgaria|Research Site 174, Pleven, Bulgaria|Reasearch Site 175, Plovdiv, Bulgaria|Research Site 177, Plovdiv, Bulgaria|Research Site 172, Sofia, Bulgaria|Research Site 173, Sofia, Bulgaria|Research Site 176, Sofia, Bulgaria|Research Site 178, Sofia, Bulgaria|Research Site 179, Sofia, Bulgaria|Research Site 180, Sofia, Bulgaria|Research Site 126, Greenfield Park, Canada|Research Site 125, Levis, Canada|Research Site 128, Moncton, Canada|Research Site 129, Montreal, Canada|Research Site 124, Toronto, Canada|Research Site 591, Barranquilla, Colombia|Research Site 597, Barranquilla, Colombia|Research Site 592, Medellin, Colombia|Research Site 600, Medellin, Colombia|Research Site 193, Osijek, Croatia|Research Site 197, Rijeka, Croatia|Research Site 195, Varazdin, Croatia|Research Site 192, Zagreb, Croatia|Research Site 194, Zagreb, Croatia|Research Site 212, Brno, Czechia|Research Site 218, Brno, Czechia|Research Site 219, Hradec Kralove, Czechia|Research Site 222, Hradec Kralove, Czechia|Research Site 211, Jihlava, Czechia|Research Site 223, Ostrava, Czechia|Research Site 215, Pardubice, Czechia|Research Site 216, Plzen-Bory, Czechia|Research Site 217, Praha 10, Czechia|Research Site 220, Praha 2, Czechia|Research Site 213, Praha 4 - Krc, Czechia|Research Site 224, Praha 5, Czechia|Research Site 231, Tallinn, Estonia|Research Site 232, Tartu, Estonia|Research Site 491, Turku, Finland|Research Site 510, Bron cedex, France|Research Site 509, Caen cedex 9, France|Research Site 502, Grenoble cedex 09, France|Research Site 504, Lille cedex, France|Research Site 508, Lille, France|Reserach Site 505, Montpellier, France|Research Site 511, Nantes cedex 1, France|Research Site 506, Nice Cedex 1, France|Research Site 507, Rennes cedex 09, France|Research Site 501, Rouen Cedex, France|Research Site 503, Toulouse cedex 9, France|Research Site 241, Tbilisi, Georgia|Research Site 242, Tbilisi, Georgia|Research Site 243, Tbilisi, Georgia|Research Site 244, Tbilisi, Georgia|Research Site 245, Tbilisi, Georgia|Research Site 246, Tbilisi, Georgia|Research Site 247, Tbilisi, Georgia|Research Site 248, Tbilisi, Georgia|Research Site 249, Tbilisi, Georgia|Research Site 250, Tbilisi, Georgia|Research Site 265, Bamberg, Germany|Research Site 267, Bayreuth, Germany|Research Site 271, Berlin, Germany|Research Site 264, Bochum, Germany|Research Site 274, Bonn, Germany|Research Site 270, Erbach, Germany|Research Site 268, Essen, Germany|Research Site 263, Frankfurt, Germany|Research Site 275, Hannover, Germany|Research Site 272, Mannheim, Germany|Research Site 262, Muenchen, Germany|Research Site 266, Muenster, Germany|Research Site 261, Potsdam, Germany|Research Site 273, Siegen, Germany|Research Site 269, Ulm, Germany|Research Site 700, Hong Kong, Hong Kong|Research Site 704, Hongkong, Hong Kong|Research Site 701, Shatin, Hong Kong|Research Site 282, Budapest, Hungary|Research Site 285, Budapest, Hungary|Research Site 286, Budapest, Hungary|Research Site 288, Budapest, Hungary|Research Site 290, Budapest, Hungary|Research Site 281, Kistarcsa, Hungary|Research Site 284, Pecs, Hungary|Research Site 289, Tatabanya, Hungary|Research Site 291, Vac, Hungary|Research Site 457, Hyderabad, India|Research Site 456, Nashik, India|Research Site 451, New Delhi, India|Research Site 303, Ashkelon, Israel|Research Site 305, Jerusalem, Israel|Research Site 307, Petah Tikva, Israel|Research Site 308, Ramat Gan, Israel|Research Site 301, Rechovot, Israel|Research Site 304, Safed, Israel|Research Site 319, Bologna, Italy|Research Site 321, Chieti, Italy|Research Site 322, Genova, Italy|Research Site 320, Messina, Italy|Research Site 315, Milano, Italy|Research Site 314, Montichiari, Italy|Research Site 316, Napoli, Italy|Research Site 317, Napoli, Italy|Research Site 311, Reggio Calabria, Italy|Research Site 318, Roma, Italy|Research Site 312, Salerno, Italy|Research Site 313, Verona, Italy|Research Site 462, Goyang-si, Korea, Republic of|Research Site 461, Seoul, Korea, Republic of|Research Site 463, Seoul, Korea, Republic of|Research Site 464, Seoul, Korea, Republic of|Research Site 465, Seoul, Korea, Republic of|Research Site 466, Seoul, Korea, Republic of|Research Site 467, Seoul, Korea, Republic of|Research Site 133, Aguascalientes, Mexico|Research Site 134, Culiacan, Mexico|Research Site 534, Hoorn, Netherlands|Research Site 531, Nieuwegein, Netherlands|Research Site 535, Rotterdam, Netherlands|Research Site 532, Sittard-Geleen, Netherlands|Research Site 332, Bydgoszcz, Poland|Research Site 335, Gdansk, Poland|Research Site 336, Katowice, Poland|Research Site 340, Knurow, Poland|Research Site 339, Lodz, Poland|Research Site 337, Lublin, Poland|Research Site 331, Oswiecim, Poland|Research Site 338, Rzeszów, Poland|Research Site 341, Warszawa, Poland|Research Site 342, Warszawa, Poland|Research Site 365, Barnaul, Russian Federation|Research Site 368, Ekaterinburg, Russian Federation|Research Site 355, Kaluga, Russian Federation|Research Site 358, Kazan, Russian Federation|Research Site 354, Kirov, Russian Federation|Research Site 363, Krasnoyarsk, Russian Federation|Research Site 353, Moscow, Russian Federation|Research Site 359, Moscow, Russian Federation|Research Site 352, Nizhniy Novgorod, Russian Federation|Research Site 367, Perm, Russian Federation|Research Site 362, Pyatigorsk, Russian Federation|Research Site 369, Saint-Petersburg, Russian Federation|Research Site 360, Saratov, Russian Federation|Research Site 361, Smolensk, Russian Federation|Research Site 356, St.Petersburg, Russian Federation|Research Site 370, Tomsk, Russian Federation|Research Site 351, Ufa, Russian Federation|Research Site 357, Ulyanovsk, Russian Federation|Research Site 366, Yaroslavl, Russian Federation|Research Site 382, Belgrade, Serbia|Research Site 383, Belgrade, Serbia|Research Site 385, Belgrade, Serbia|Research Site 389, Kragujevac, Serbia|Research Site 390, Nis, Serbia|Research Site 388, Novi Sad, Serbia|Research Site 384, Uzice, Serbia|Research Site 381, Valjevo, Serbia|Research Site 406, Barcelona, Spain|Research Site 407, Barcelona, Spain|Research Site 405, Cadiz, Spain|Research Site 401, Lleida, Spain|Research Site 403, Madrid, Spain|Research Site 408, Madrid, Spain|Research Site 409, Madrid, Spain|Research Site 411, Pozuelo de Alarcon, Spain|Research Site 410, Salt, Spain|Research Site 402, San Sebastian, Spain|Research Site 404, Sevilla, Spain|Research site 713, Kaohsiung, Taiwan|Research Site 711, Taichung, Taiwan|Research site 714, Taipei, Taiwan|Research site 715, Taipei, Taiwan|Research Site 432, Chernivtsi, Ukraine|Research Site 425, Kharkiv, Ukraine|Research Site 429, Kharkiv, Ukraine|Research Site 430, Kharkiv, Ukraine|Research Site 435, Kharkiv, Ukraine|Research Site 436, Kharkiv, Ukraine|Research Site 437, Kharkiv, Ukraine|Research Site 422, Kropyvnytskyi, Ukraine|Research Site 438, Kyiv, Ukraine|Research Site 426, Lviv, Ukraine|Research Site 424, Odesa, Ukraine|Research Site 423, Poltava, Ukraine|Research Site 427, Sumy, Ukraine|Research Site 431, Vinnytsia, Ukraine|Research Site 421, Zaporizhzhia, Ukraine|Research Site 428, Zaporizhzhia, Ukraine|Research Site 544, Exeter, United Kingdom|Research Site 549, Glasgow, United Kingdom|Research Site 552, Newcastle, United Kingdom|Research Site 547, Swansea, United Kingdom"
NCT03718247,Utilization of the Ketogenic Diet in Patient With Relapsing Remitting MS,https://beta.clinicaltrials.gov/study/NCT03718247,COMPLETED,Relapsing Remitting Multiple Sclerosis,OTHER: Modified Atkins diet,University of Virginia,,ALL,"CHILD, ADULT",,45,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-10-31,2021-06-21,2021-07-01,"University of Virginia, Charlottesville, Virginia, 22903, United States"
NCT03594487,Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03594487,ACTIVE_NOT_RECRUITING,Relapsing Remitting Multiple Sclerosis,DRUG: FMP30 Donor Stool|PROCEDURE: Fecal Microbiota Transplantation (FMT) of FMP30 Donor Stool|OTHER: Observational Control,Jeffrey Gelfand,,ALL,ADULT,PHASE1,30,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2018-11-16,2023-01-31,2023-01-31,"UCSF Multiple Sclerosis Center, San Francisco, California, 94158, United States"
NCT01615887,Study of Lisdexamfetamine Sulfate to Treat Cognitive Dysfunction in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01615887,COMPLETED,Multiple Sclerosis,DRUG: lisdexamfetamine sulfate|DRUG: placebo,State University of New York at Buffalo,,ALL,ADULT,PHASE2,63,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2009-11,2011-08,2011-08,"Kaleida Health, Jacobs Neurological Institute, Buffalo, New York, 14203, United States"
NCT03944447,Outcomes Mandate National Integration With Cannabis as Medicine,https://beta.clinicaltrials.gov/study/NCT03944447,RECRUITING,Chronic Pain|Chronic Pain Syndrome|Chronic Pain Due to Injury|Chronic Pain Due to Trauma|Fibromyalgia|Seizures|Hepatitis C|Cancer|Crohn Disease|HIV/AIDS|Multiple Sclerosis|Traumatic Brain Injury|Sickle Cell Disease|Post Traumatic Stress Disorder|Tourette Syndrome|Ulcerative Colitis|Glaucoma|Epilepsy|Inflammatory Bowel Diseases|Parkinson Disease|Amyotrophic Lateral Sclerosis|Chronic Traumatic Encephalopathy|Anxiety|Depression|Insomnia|Autism|Opioid-use Disorder|Bipolar Disorder|Covid19|SARS-CoV Infection|COVID-19|Corona Virus Infection|Coronavirus,"DRUG: Cannabis, Medical|DEVICE: RYAH-Medtech Inhaler","OMNI Medical Services, LLC",OMNI Medical Services Inc,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,200000,NETWORK,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2018-12-01,2025-12-31,2025-12-31,"OMNI Medical Services, Boca Raton, Florida, 33433, United States|OMNI Medical Services, Bradenton, Florida, 34209, United States|OMNI Medical Services, Fort Lauderdale, Florida, 33308, United States|OMNI Medical Services, Fort Myers, Florida, 34135, United States|OMNI Medical Services, Gainesville, Florida, 36201, United States|OMNI Medical Services, Merritt Island, Florida, 32952, United States|OMNI Medical Services, Miami, Florida, 33137, United States|OMNI Medical Services, Ocoee, Florida, 34761, United States|OMNI Medical Services, Pensacola, Florida, 32505, United States|OMNI Medical Services, Pompano Beach, Florida, 33060, United States|OMNI Medical Services, Tampa, Florida, 33614, United States|OMNI Medical Services, Wesley Chapel, Florida, 33544, United States|OMNI Medical Services, Beechwood, Ohio, 44122, United States|OMNI Medical Services, Bowling Green, Ohio, 43402, United States|OMNI Medical Services, Sandusky, Ohio, 44870, United States|OMNI Medical Services, Toledo, Ohio, 43604, United States|OMNI Medical Services, Toledo, Ohio, 43611, United States"
NCT05505383,"The Effect of Backward Walking Training on Balance, Gait and Functional Mobility in Patients With Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT05505383,RECRUITING,Multiple Sclerosis,OTHER: Exercise training,Saglik Bilimleri Universitesi,Ankara University,ALL,"ADULT, OLDER_ADULT",NA,22,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2022-08-18,2022-11-20,2022-12-20,"Ankara University, Ankara, Turkey|Ankara University, Ankara, Turkey"
NCT01745783,"Mesenchymal Cells From Autologous Bone Marrow, Administered Intravenously in Patients Diagnosed With Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT01745783,COMPLETED,Multiple Sclerosis,OTHER: Bone marrow mesenchymal stem cells autologous|OTHER: Placebo comparator,Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud,Iniciativa Andaluza en Terapias Avanzadas,ALL,ADULT,PHASE1|PHASE2,26,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-01,2020-06-30,2020-06-30,"University Hospital Reina Sofia, Córdoba, 14004, Spain|University Regional Hospital Carlos Haya, Málaga, 29010, Spain|University Hospital Virgen Macarena, Sevilla, 41009, Spain"
NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01412333,COMPLETED,Relapsing Multiple Sclerosis,DRUG: Interferon beta-1a|DRUG: Ocrelizumab-matching placebo|DRUG: Ocrelizumab|DRUG: Interferon beta-1a-matching placebo,Hoffmann-La Roche,,ALL,ADULT,PHASE3,835,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-09-20,2015-05-12,2022-12-30,"Hope Research Institute, Phoenix, Arizona, 85050, United States|HonorHealth Neurology, Scottsdale, Arizona, 85251, United States|Territory Neurology and Research Institute, Tucson, Arizona, 85704, United States|Collaborative Neuroscience Research, LLC, Long Beach, California, 90806, United States|Stanford University Medical Center, Palo Alto, California, 94304, United States|University of Colorado, Denver, Colorado, 80262, United States|Advanced Neurosciences Research LLC, Fort Collins, Colorado, 80528, United States|Associated Neurologists of Southern CT PC, Fairfield, Connecticut, 06824, United States|Infinity Clinical Research, Hollywood, Florida, 33024, United States|University of Miami; Dept. of Neurology MS Center, Miami, Florida, 33136, United States|Neurological Services of Orlando, Orlando, Florida, 32806, United States|Lovelace Scientific Resources, Sarasota, Florida, 34292, United States|University of South Florida, Tampa, Florida, 33612, United States|Atlanta Neuroscience Institute, Atlanta, Georgia, 30327, United States|Josephson Wallack Munshower Neurology PC, Indianapolis, Indiana, 46256, United States|University of Kansas Medical Center, Kansas City, Kansas, 66160, United States|MidAmerica Neuroscience Institute, Prairie Village, Kansas, 66206, United States|Associates in Neurology PSC, Lexington, Kentucky, 40513, United States|Dragonfly Research, LLC, Wellesley, Massachusetts, 02481, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, 01655, United States|University of Michigan Health System, Ann Arbor, Michigan, 48109-0666, United States|Wayne State University; Department of Neurology, Detroit, Michigan, 48201, United States|The Minneapolis Clinic of Neurology, Golden Valley, Minnesota, 55422, United States|Rutgers New Jersey Medical School, Newark, New Jersey, 07103, United States|Holy Name Hospital, Teaneck, New Jersey, 07666, United States|MS Comprehensive Care Center, Teaneck, New Jersey, 07666, United States|Shore Neurology, Toms River, New Jersey, 08755, United States|Empire Neurology, PC, Latham, New York, 12210, United States|Weill Cornell MC-NY Presbyter; Dept. of Neurology/Neuroscience, Judith Jaffe Multiple Sclerosis Ctr, New York, New York, 63110, United States|South Shore Neurologic Associates P.C., Patchogue, New York, 11772, United States|University of Rochester Medical Center, Rochester, New York, 14642, United States|SUNY at Stony Brook, Stony Brook, New York, 11790, United States|The Neurological Institute PA, Charlotte, North Carolina, 28204, United States|Neurology Associates PA, Hickory, North Carolina, 28602, United States|Raleigh Neurology Associates, Raleigh, North Carolina, 27607-6520, United States|Columbus Neuroscience, Columbus, Ohio, 43801, United States|Abington Neurological Associates, Abington, Pennsylvania, 19001, United States|Absher Neurology PA, Greenville, South Carolina, 29607, United States|Neurology Clinic PC, Cordova, Tennessee, 38018, United States|Sibyl Wray MD Neurology PC, Knoxville, Tennessee, 37934, United States|Advanced Neurosciences Institute, Nashville, Tennessee, 37205, United States|University of Texas Southwestern Medical Center, Dallas, Texas, 75390, United States|Baylor College of Medicine, Houston, Texas, 77030, United States|Bhupesh Dihenia M.D. P.A., Lubbock, Texas, 79410, United States|Central Texas Neurology Consultants, Round Rock, Texas, 78681, United States|Integra Clinical Research, Llc, San Antonio, Texas, 78229, United States|Neurology Center of San Antonio, San Antonio, Texas, 78258, United States|Swedish Neuroscience Institute, Seattle, Washington, 98122, United States|ALPI-Inst. de Rehabilitacion Marcelo Fitte, Buenos Aires, C1425BWO, Argentina|STAT Research S.A., Ciudad de Buenos Airesa, C1013AAB, Argentina|Grodno State Medical University, Grodno, 230017, Belarus|City Clinical Hospital #9, Minsk, 220116, Belarus|Vitebsk; Regional Diagnostic Center, Vitebsk, 210023, Belarus|Vitebsk Regional Clinical Hospital, Vitebsk, 210032, Belarus|UZ Antwerpen, Edegem, 2650, Belgium|University Clinic Ctr Sarajevo, Sarajevo, 71 000, Bosnia and Herzegovina|Uni Hospital Center Tuzla, Tuzla, 75000, Bosnia and Herzegovina|Santa Casa de Misericordia; de Belo Horizonte, Belo Horizonte, MG, 30150-221, Brazil|Hospital Universitario Gaffree e Guinle, Rio de Janeiro, RJ, 20270-004, Brazil|Hospital das Clinicas - UNICAMP, Campinas, SP, 13083-887, Brazil|MHATNP Sv.Naum EAD; Clinic for intensive treatment of neurology diseases, Sofia, 1113, Bulgaria|Fifth MHAT-Sofia AD; Neuro Dept with Vascular Unit, Sofia, 1233, Bulgaria|MHAT National Cardiology Hospital, EAD; Neurology, Sofia, 1309, Bulgaria|UMHAT Alexandrovska, EAD; Neurology, Sofia, 1431, Bulgaria|Multiple Sclerosis Clinic, Calgary, Alberta, T2N 2T9, Canada|University of Alberta; Northern Alberta Trials & Research Centre, Edmonton, Alberta, T6G 2C8, Canada|Vancouver Hospital - UBC Hospital Site, Vancouver, British Columbia, V6Z 1Y6, Canada|The Ottawa Hospital - General Campus, Ottawa, Ontario, K1H 8L6, Canada|Clinique NeuroOutaouais, Gatineau, Quebec, J8Y 1W2, Canada|Recherche Sepmus Inc., Greenfield Park, Quebec, J4V 2J2, Canada|Montreal Neurological Institute and Hospital, Montreal, Quebec, H3A 2B4, Canada|Hôpital Maisonneuve - Rosemont; Recherche Clinique de Neurologie, Montréal, Quebec, H1T 2M4, Canada|General Hospital Pula, Pula, 52100, Croatia|General Hospital Varazdin, Varazdin, 42000, Croatia|Clinical Hospital Centre Zagreb;Clinic for Neurology, Zagreb, 10000, Croatia|Uni Hospital Centre Dubrava, Zagreb, 10000, Croatia|Fakultni nemocnice Brno, Brno, 613 00, Czechia|Neurospol s.r.o., Havirov, 736 00, Czechia|Pardubicka Krajska Nemocnice; Department of Neurology, Pardubice, 532 03, Czechia|Krajska zdravotni, a. s. ? Nemocnice Teplice, o. z.; Neurologicke oddeleni, Teplice, 415 29, Czechia|Hopital Neurologique Pierre Wertheimer, Bron, 69500, France|Hôpital General - Service de neurologie; Service de neurologie, Dijon Cedex, 21079, France|Hôpital Saint Philibert, Lommé, 59462, France|Groupe Hospitalier Pitie-Salpetriere, Paris, 75651, France|Hôpital Maison Blanche; Service de Neurologie, Reims, 51092, France|CHU toulouse - Hôpital Purpan; Departement de Neurologie, Toulouse, 31059, France|Sankt Gertrauden Krankenhaus; Neurologisches Facharztzentrum, Berlin, 10713, Germany|Neurologische Praxis Bonn, Bonn, 53117, Germany|Universitätsklinikum Düsseldorf; Klinik für Neurologie, Düsseldorf, 40225, Germany|Zentrum fuer ambulante Neurologie, Essen, 45138, Germany|Universitaetsklinikum Frankfurt; Klinik für Neurologie, Frankfurt, 60528, Germany|Universitaetsklinikum Heidelberg, Heidelberg, 69120, Germany|Ratsapotheke Mittweida, Mittweida, 09648, Germany|Klinikum Grosshadern der LMU, Muenchen, 81377, Germany|Klinikum rechts der Isar der TU Muenchen; Neurologische Klinik und Poliklinik im Neuro-Kopf-Zentrum, München, 81675, Germany|Neurologische Gemeinschaftspraxis Dr. Lang, Prof. Schreiber, Dr. Krauß, Dr. Kornhuber, Ulm, 89073, Germany|St Vincents University Hospital, Dublin 4, Ireland|Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Roma, Lazio, 00133, Italy|Policlinico Universitario Agostino Gemelli, Roma, Lazio, 00168, Italy|A.O. Universitaria S. Martino Di Genova, Genova, Liguria, 16132, Italy|Fondazione IRCCS Istituto Neurologico Carlo Besta; Farmacia Interna, Milano, Lombardia, 20133, Italy|Ospedale Civile di Montichiari; Centro Sclerosi Multipla, Montichiari, Lombardia, 25018, Italy|Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I-G.M. Lancisi-G. Salesi Di Ancona, Torrette - Ancona, Marche, 60100, Italy|Ospedale degli Infermi, Ponderano, Piemonte, 13875, Italy|Ospedale Generale Regionale F. Miulli, Acquaviva delle Fonti, Puglia, 70021, Italy|Ospedale Casa Sollievo Della Sofferenza IRCCS, San Giovanni Rotondo, Puglia, 71013, Italy|Fond. Ist. S. Raffaele - giglio, Cefalu, Sicilia, 90015, Italy|Mexico Centre for Clinical Research, Ciudad de México, Mexico CITY (federal District), 03100, Mexico|Clinical Research Institute, Tlalnepantla de Baz, Mexico CITY (federal District), 54055, Mexico|Instituto Biomedico De Investigacion A.C., Aguascalientes, 20127, Mexico|Hospital CIMA Chihuahua; Centro de Investigación Clínicatorre de Consultoriospiso 4, Chihuahua, 31238, Mexico|Hospital Angeles Culiacan; Neurociencias, Culiacan, 80020, Mexico|Hospital Mexico Americano SC; Departamento de Electroencefalografía, Guadalajara, 44620, Mexico|Haukeland Universitetssykehus, Bergen, 5053, Norway|Vitamed, Bydgoszcz, 85-021, Poland|MA-LEK Clinical Sp. Z o.o., Katowice, 40-595, Poland|Krakowska Akademia Neurologii Sp z o.o. Centrum Neurologii K, Krakow, 31-505, Poland|SPZOZ Uniwersytecki Szp. Klin. nr1 im.N.Barlickiego UM;Oddzial Kliniczny Neurologii, Lodz, 90-153, Poland|Centrum Neurologii Krzysztof Selmaj, Lodz, 90-324, Poland|Samodz.Publi.Szpital Kliniczny; nr 4 w Lublinie, Lublin, 20-954, Poland|Wojewodzki Specjalistyczny Szpital w Olsztynie; Oddzial Neurologiczny z Pododdzialem Udarowym, Olsztyn, 10-561, Poland|Neuro-Care Gabriela Klodowska, Siemianowice ?l?skie, 41-100, Poland|mMED Maciej Czarnecki, Warszawa, 01-684, Poland|State institution of health care - Territorial Clinical Hospital, Barnaul, 656024, Russian Federation|State autonomous institution of healthcare Inter-regional clinical and diagnostic center, Kazan, 420101, Russian Federation|Kirov City Clinical Hospital #1; Neurology Department, Kirov, 610014, Russian Federation|SBHI of Nizhny Novgorod region City Clinical Hospital #3; neurology department, Nizniy Novgorod, 603155, Russian Federation|Perm SMA n.a. academ. E.A. Vagner, Perm, 614990, Russian Federation|City Clinical Hospital#2, Pyatigorsk, 357538, Russian Federation|St. Petersburg State Medical University n.a. I.P. Pavlov; Hematology, transfusiology and transplanta, Saint-Petersburg, 197022, Russian Federation|Saratov State Medical University of RosZdrav; Neurology, Saratov, 410012, Russian Federation|MUDr. Beata Dupejova Neurologicka ambulancia s.r.o, Banska Bystrica, 974 04, Slovakia|Fakultna Nemocnica Roosevelta, Banska Bystrica, 975 17, Slovakia|Vseobecna nemocnica s poliklinikou Levoca a.s., Levoca, 054 01, Slovakia|Institut Catala d?Oncologia Hospital Germans Trias i Pujol, Badalona, Barcelona, 08916, Spain|Hospital Universitari de Bellvitge; Servicio de Neurologia, L'Hospitalet de Llobregat, Barcelona, 08907, Spain|Hospital General Univ. de Alicante, Alicante, 03010, Spain|Hospital del Mar, Barcelona, 08003, Spain|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital Universitari de Girona Dr Josep Trueta, Girona, 17007, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Neurologia, Madrid, 28007, Spain|Hospital Universitario Clinico San Carlos, Madrid, 28040, Spain|Hospital Regional Universitario de Malaga, Malaga, 29010, Spain|Hospital Clinico Universitario de Valencia; Servicio de Neurologia, Valencia, 46010, Spain|Sahlgrenska Sjukhuset; Neurology, Göteborg, 413 45, Sweden|Karolinska Universitetssjukhuset Solna Neurology, Stockholm, 113 41, Sweden|Karolinska Universitetssjukhuset Huddinge, Stockholm, 171 64, Sweden|Norrlands Universitetssjukhus, Umeå, 901 85, Sweden|Hacettepe University Medical Faculty; Neurology, Ankara, 06100, Turkey|Haseki Training and Research Hospital, Istanbul, 34096, Turkey|Istanbul Universitesi - Cerrahpasa Cerrahpasa Tip Fakultesi; Noroloji Anabilim Dali, Istanbul, 34098, Turkey|Istanbul Bilim Universty Medical Fac., Istanbul, 34394, Turkey|Ege University Medical Faculty, Izmir, 35100, Turkey|Kocaeli University Medical Faculty, Kocaeli, 41380, Turkey|Ondokuz Mayis Univ. Med. Fac.; Neurology, Samsun, 55139, Turkey|Karadeniz Tecnical Uni. Med. Fac.; Neurology, Trabzon, 61080, Turkey|Mun.Med.Proph.Inst.?Chernihiv Reg.Hosp.?; Neurology Department, Chernihiv, 14029, Ukraine|City Clinical Hospital #4, Dnipropetrovsk, 49102, Ukraine|State Institution V.K. Gusak Institute of Urgent and Recover; Dep of Reconstructive Angioneurology a, Donetsk, 83045, Ukraine|Road Clinical Hospital of Donetsk Station; Neurology Department, Donetsk, 83114, Ukraine|Regional Clinical Hospital; Neurology Department, Ivano-Frankivsk, 76008, Ukraine|Royal Devon and Exeter Hospital (Wonford), Exeter, EX2 5DW, United Kingdom|Kings College Hospital; Neurosciences Clinical Trials Office, London, SE5 9NT, United Kingdom|City General Hospital; Department of Neurology, Stoke on Trent, ST4 6QG, United Kingdom|Morriston Hospital, Swansea, SA6 6NL, United Kingdom"
NCT01071083,Treatment Interruption of Natalizumab,https://beta.clinicaltrials.gov/study/NCT01071083,COMPLETED,Relapsing Remitting Multiple Sclerosis,DRUG: natalizumab|DRUG: interferon beta 1-a|DRUG: methylprednisolone|OTHER: IV placebo|DRUG: glatiramer acetate,Biogen,Elan Pharmaceuticals,ALL,ADULT,PHASE2,175,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2010-03,2011-11,2011-11,"Research Site, Cullman, Alabama, 35058, United States|Research Site, San Francisco, California, 94117, United States|Research Site, Fort Collins, Colorado, United States|Research Site, Pompano Beach, Florida, 33060, United States|Research Site, Atlanta, Georgia, 30309, United States|Research Site, Atlanta, Georgia, 30327, United States|Research Site, Chicago, Illinois, 60612, United States|Research Site, Lake Barrington, Illinois, 60010, United States|Research Site, Des Moines, Iowa, 50314, United States|Research Site, Boston, Massachusetts, 2135, United States|Research Site, Boston, Massachusetts, 2215, United States|Research Site, Buffalo, New York, 14203, United States|Research Site, Latham, New York, 12110, United States|Research Site, Patchogue, New York, 11772, United States|Research Site, Charlotte, North Carolina, 28207, United States|Research Site, Raleigh, North Carolina, 27607, United States|Research Site, Cleveland, Ohio, 44195, United States|Research Site, Uniontown, Ohio, United States|Research Site, Salt Lake City, Utah, 84103, United States|Research Site, Seattle, Washington, 98111, United States|Research Site, Freiburg, Baden-Wuerttemberg, 79106, Germany|Research Site, Munchen, Bayern, 81675, Germany|Research Site, Hennigsdorf, Brandenburg, 16761, Germany|Research Site, Marburg, Hessen, 35039, Germany|Research Site, Bochum, Nordrhein-Westfalen, 44791, Germany|Research Site, Dresden, Sachsen, 1307, Germany|Research Site, Hamburg, 20246, Germany|Research Site, L´Hospitalet de Llobregat, Barcelona, 8907, Spain|Research Site, Málaga, Malaga, 29010, Spain|Research Site, El Palmar, Murcia, 30120, Spain|Research Site, Barcelona, 8035, Spain|Research Site, Valencia, 46009, Spain|Research Site, Valencia, 46010, Spain"
NCT01103583,Hydroxyurea in Primary Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01103583,TERMINATED,Multiple Sclerosis,DRUG: Hydroxyurea|OTHER: placebo,S. Andrea Hospital,,ALL,ADULT,PHASE2|PHASE3,33,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2011-07,2013-12,,"Centre for Experimental Neurological Therapies (CENTERS), Tor Vergata University Hospital, Rome, 00133, Italy|Centre for Experimental Neurological Therapies (CENTERS), S.Andrea Hospital, Rome, 00189, Italy"
NCT01142583,A Canadian Study Assessing the Utility of the Treatment Optimization Recommendations in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01142583,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",,"Merck KGaA, Darmstadt, Germany",,ALL,ADULT,,192,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2006-07,2009-08,2009-08,
NCT00675883,COMPliance With Avonex® PS in Patients With Relapsing-Remitting MS,https://beta.clinicaltrials.gov/study/NCT00675883,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",,Biogen,,ALL,"ADULT, OLDER_ADULT",,1000,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2008-05,2011-12,2011-12,"University Hospital, London Health Sciences Centre, London, Ontario, Canada"
NCT04326283,"Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)",https://beta.clinicaltrials.gov/study/NCT04326283,TERMINATED,Amyotrophic Lateral Sclerosis,DRUG: Trametinib (0.5 mg)|DRUG: Trametinib (1 mg)|DRUG: Riluzole (100 mg),Genuv Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,23,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-04-02,2023-04-28,2023-04-28,"Inje University Busan Paik Hospital, Busan, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of"
NCT00166283,Improving New Learning and Memory in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00166283,COMPLETED,Multiple Sclerosis,BEHAVIORAL: memory retraining exercises|BEHAVIORAL: placebo control memory exercises,Kessler Foundation,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),ALL,"ADULT, OLDER_ADULT",NA,88,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2005-02,2011-12,2011-12,"Kessler Foundation Research Center, West Orange, New Jersey, 07052, United States"
NCT02893683,Paris Visual Learning Test: a New French Task for Assess Visual Learning and Memory to Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT02893683,COMPLETED,Multiple Sclerosis,OTHER: Paris Visual Learning Test,Fondation Ophtalmologique Adolphe de Rothschild,,ALL,"ADULT, OLDER_ADULT",,50,NETWORK,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-12-19,2017-05-15,2017-05-15,"Fondation Ophtalmologique Adolphe de Rothschild, Paris, 75019, France"
NCT00785083,A Study of the Effect of FTY720 on Pulmonary Function in Patients With Moderate Asthma,https://beta.clinicaltrials.gov/study/NCT00785083,COMPLETED,Asthma,DRUG: FTY720|DRUG: Placebo,Novartis,,ALL,"ADULT, OLDER_ADULT",PHASE2,36,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2008-09,2009-02,,"Novartis Investigator Site, Manchester, United Kingdom"
NCT04754542,Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS): Extension of the DISCOMS Study,https://beta.clinicaltrials.gov/study/NCT04754542,COMPLETED,Multiple Sclerosis,,"University of Colorado, Denver",EMD Serono|National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",,81,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-05-18,2022-11-30,2022-11-30,"University of Colorado Denver, Aurora, Colorado, 80045, United States|University of Kansas Medical Center, Kansas City, Kansas, 66160, United States|New York University, New York, New York, 10003, United States|Mount Sinai, New York, New York, 10029, United States|University of Rochester, Rochester, New York, 14627, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, 15260, United States|Vanderbilt University, Nashville, Tennessee, 37235, United States|University of Virginia, Charlottesville, Virginia, 22904, United States|Swedish, Seattle, Washington, 98122, United States"
NCT03302442,Comparison of Oral Molecules Preventing Relapses in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03302442,COMPLETED,Relapsing-remitting Multiple Sclerosis,OTHER: Non interventional study,Nantes University Hospital,,ALL,"CHILD, ADULT, OLDER_ADULT",,3000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-05-01,2017-08-01,2017-10-01,"Nantes University Hospital, Nantes, 44093, France"
NCT00702065,"A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment",https://beta.clinicaltrials.gov/study/NCT00702065,COMPLETED,Multiple Sclerosis,,EMD Serono,,ALL,"ADULT, OLDER_ADULT",,599,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2007-11,2010-10,2010-10,"Research Site, Phoenix, Arizona, United States|Research Site, Las Vegas, Nevada, United States|Reseach site, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Camperdown, Australia|Research Site, Melbourne, Australia|Research Site, New Lambton Heights, Australia|Research Site, Victoria, Australia|Research Site, Graz, Austria|Research Site, Linz, Austria|Research Site, Wien, Austria|Research Site, Lomme, France|Research Site, Marseille, France|Research Site, Bad Wildbad, Germany|Research Site, Bochum, Germany|Research Site, München, Germany|Research Site, Afula, Israel|Research Site, Ashkelon, Israel|Research Site, Haifa, Israel|Research Site, Holon, Israel|Research Site, Brindisi, Italy|Research Site, Centro Bologna, Italy|Research Site, Firenze, Italy|Research Site, Modena, Italy|Research Site, Palermo, Italy|Research Site, Lorenskog, Norway|Reseach Site, Malaga, Spain|Research Site, Izmir, Turkey|Research Site, Glasgow, United Kingdom|Research Site, Nottingham, United Kingdom"
NCT01730131,Natural History Study of Progressive Multifocal Leukoencephalopathy (PML),https://beta.clinicaltrials.gov/study/NCT01730131,RECRUITING,Progressive Multifocal Leukoencephalopathy,,National Institute of Neurological Disorders and Stroke (NINDS),,ALL,"CHILD, ADULT, OLDER_ADULT",,700,NIH,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-11-08,2027-01-01,,"National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States"
NCT01746342,Sleep Apnea in Multiple Sclerosis Positive Airway Pressure Trial,https://beta.clinicaltrials.gov/study/NCT01746342,COMPLETED,Obstructive Sleep Apnea-hypopnea in Multiple Sclerosis Patients,DEVICE: Effective continuous positive airway pressure (CPAP)|DEVICE: Sham continuous positive airway pressure (CPAP),McGill University,Multiple Sclerosis Society of Canada (Primary funding agency)|Centre hospitalier de l'Université de Montréal (CHUM)|Philips Respironics|VitalAire Incorporated (Respiratory Therapist time),ALL,"ADULT, OLDER_ADULT",NA,49,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-02,2018-11-30,2018-11-30,"McGill University Health Centre, Montreal, Quebec, H3A 1A1, Canada"
NCT03326765,Characterizing Sleep Disorders in Children and Adults With Tuberous Sclerosis Complex (TSC),https://beta.clinicaltrials.gov/study/NCT03326765,UNKNOWN,Sleep Disorder,OTHER: Questionnaires|PROCEDURE: electroencephalogram (EEG)|PROCEDURE: polysomnography|PROCEDURE: Actigraphy,Universitair Ziekenhuis Brussel,,ALL,"CHILD, ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2017-09-27,2019-11-01,2019-11-30,"Universitair Ziekenhuis Brussel, Jette, Vlaams Brabant, 1090, Belgium"
NCT00799942,Open-lable Extension Study on Safety and Efficacy of Neramexane to Treat Congenital and Acquired Nystagmus,https://beta.clinicaltrials.gov/study/NCT00799942,TERMINATED,"Nystagmus, Congenital|Nystagmus, Acquired|Multiple Sclerosis",DRUG: Neramexane mesylate,Merz Pharmaceuticals GmbH,,ALL,"ADULT, OLDER_ADULT",PHASE2,48,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2009-05,,,"University of Leicester, Leicester Royal Infirmary, Ophthalmology Group, Leicester, LE2 7LX, United Kingdom"
NCT03655431,Home Exercise Telerehabiliation for MS,https://beta.clinicaltrials.gov/study/NCT03655431,COMPLETED,Multiple Sclerosis,OTHER: Telerehabilitation|OTHER: Standard treatment,Shane.Chanpimol,,ALL,"ADULT, OLDER_ADULT",NA,10,FED,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-10-01,2019-10-01,2021-01-01,"Washington DC VAMC, Washington, District of Columbia, 20422, United States"
NCT03706131,The Effect of Cervical Mobilization on Balance and Spasticity in Multiple Sclerosis Individuals,https://beta.clinicaltrials.gov/study/NCT03706131,COMPLETED,Multiple Sclerosis|Balance; Distorted,OTHER: cervical mobilisation,Hacettepe University,,ALL,"ADULT, OLDER_ADULT",NA,36,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-04-01,2021-04-30,2021-04-30,"Hacettepe University, Ankara, Turkey"
NCT00010842,Natural Antioxidants in the Treatment of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00010842,COMPLETED,Multiple Sclerosis,DRUG: Ginkgo biloba|DRUG: Alpha-lipoic acid|DRUG: Vitamin E/Selenium|DRUG: Essential fatty acids,National Center for Complementary and Integrative Health (NCCIH),,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1|PHASE2,,NIH,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: |Masking: |Primary Purpose: TREATMENT,1999-09,,2004-12,"Oregon Health Sciences University, Portland, Oregon, 97207, United States"
NCT02781142,Motor Imagery Training in Persons With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02781142,COMPLETED,Multiple Sclerosis,OTHER: Motor imagery training,Dokuz Eylul University,,ALL,"ADULT, OLDER_ADULT",NA,70,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2016-05,2017-10,2017-11,"Dokuz Eylul University Hospital, MS Outpatient Clinic, Izmir, 35430, Turkey|Dokuz Eylul University, School of Physical Therapy and Rehabilitation, Izmir, 35430, Turkey"
NCT03595631,Neurodynamic Interventions for Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03595631,COMPLETED,Multiple Sclerosis,OTHER: Physical Therapy|OTHER: Physical Therapy plus Neurodynamic,Universidad Rey Juan Carlos,,ALL,"ADULT, OLDER_ADULT",NA,32,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-07-26,2018-09-15,2018-10-04,"César Fernández-de-las-Peñas, Alcorcon, Madrid, 28922, Spain"
NCT03808142,PROmyBETAappGame: a Study to Learn More About the Medication Usage & Patient Reported Outcomes Via the myBETAapp and to Find Out More About the Usage of Game Principles and Game Design Elements (Gamification) in Medical Care of Patients With Multiple Sclerosis Treated With Betaferon,https://beta.clinicaltrials.gov/study/NCT03808142,COMPLETED,Multiple Sclerosis,"OTHER: myBETAapp|OTHER: PEAK|DRUG: Betaferon, BAY86-5046|DEVICE: BETACONNECT",Bayer,,ALL,"ADULT, OLDER_ADULT",,79,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-02-20,2020-04-20,2020-09-02,"Many locations, Multiple Locations, Germany"
NCT05017142,Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD),https://beta.clinicaltrials.gov/study/NCT05017142,RECRUITING,"Optic Neuritis|Transverse Myelitis|Acute Disseminated Encephalomyelitis|Multiple Sclerosis|Neuromyelitis Optica Spectrum Disorder|Anti-NMDAR Encephalitis|Anti-GAD65 Associated Autoimmune Encephalitis|Anti-AMPAR-1/2 Associated Autoimmune Encephalitis|Anti-Lgi-1 Associated Autoimmune Encephalitis|Anti-CASPR-2 Associated Autoimmune Encephalitis|Anti-GABAR-1/2 Associated Autoimmune Encephalitis|Onconeuronal Antibody (Hu, Ri, Yo, Amphiphysin, CRMP-5, Ma-1, Ma-2, SOX-1) Associated Autoimmune Encephalitis|Hashimoto Encephalitis|CNS Vasculitis|CNS Sarcoidosis|CNS Lupus|Rasmussen Encephalitis",,University of Bern,"Schweizerische Multiple Sklerose Gesellschaft|University Hospital Inselspital, Berne|Roche Pharma (Switzerland) Ltd|Novartis",ALL,"CHILD, ADULT, OLDER_ADULT",,500,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-04-14,2071-01-01,2071-01-01,"Kantonsspital Aarau, Aarau, Aargau, 5001, Switzerland|Kantonsspital Graubünden, Chur, Graubünden, 7000, Switzerland|Children's Hospital of Eastern Switzerland, St.Gallen, Saint Gallen, 9000, Switzerland|Pediatric Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Ticino, 6500, Switzerland|University Children's Hospital Lausanne (CHUV), Lausanne, Vaud, 1011, Switzerland|Kinderspital Winterthur, Winterthur, Zurich, 8400, Switzerland|University Children's Hospital Basel, UKBB, Basel, 4031, Switzerland|University Children's Hospital, Inselspital Bern, Bern, 3010, Switzerland|Institute of Social and Preventive Medicine, University of Bern, Bern, 3012, Switzerland|University Hospitals of Geneva (HUG), Geneva, 1211, Switzerland|Luzerner Kantonsspital, Luzern, 6000, Switzerland|University Children's Hospital Zurich, Zurich, 8032, Switzerland"
NCT02851342,GTA-MEG as a Biomarker for Cognition in MS,https://beta.clinicaltrials.gov/study/NCT02851342,COMPLETED,Multiple Sclerosis,,Universitair Ziekenhuis Brussel,,ALL,ADULT,,159,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-04,2018-01,2019-01,"National MS Center Melsbroek, Melsbroek, Vlaams Brabant, 1820, Belgium"
NCT02739542,Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS),https://beta.clinicaltrials.gov/study/NCT02739542,COMPLETED,Multiple Sclerosis (MS),DRUG: Tecfidera|DRUG: Placebo,University of Texas Southwestern Medical Center,Biogen,ALL,"ADULT, OLDER_ADULT",PHASE4,87,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-03-19,2021-03-31,2021-03-31,"Keck School of Medicine - USC - Department of Neurology, Los Angeles, California, 90089, United States|Johns Hopkins University - Neurology, Baltimore, Maryland, 21287, United States|Mayo Clinic Department of Neurology, Rochester, Minnesota, 55905, United States|Washington University Department of Neurology, Saint Louis, Missouri, 63110, United States|Cleveland Clinic - Lou Ruvo Center for Brain Health, Las Vegas, Nevada, 89106, United States|MS Clinical Care and Research Center, Dept of Neurology, Columbia University, New York, New York, 10032, United States|Oklahoma Medical Research Foundation, MS Center of Excellence, Oklahoma City, Oklahoma, 73104, United States|MS Treatment Center of Dallas, Dallas, Texas, 75246, United States|UT Southwestern Medical Center, Dallas, Texas, 75390-8806, United States|Swedish Medical Center, Seattle, Washington, 98122, United States|MultiCare Institute for Research and Innovation, Tacoma, Washington, 98405, United States"
NCT03619642,"Reliability, Validity and Clinical Utility of a Robotic Assessment for Proprioception",https://beta.clinicaltrials.gov/study/NCT03619642,COMPLETED,Neurological Diseases or Conditions|Sensory Disorders|Multiple Sclerosis|Stroke,OTHER: Robotic assessment of finger proprioception,Hasselt University,Jessa Hospital|Revalidatie & MS Centrum Overpelt,ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2017-12-15,2018-05-31,2018-05-31,"Jessa Ziekenhuis, Hasselt, 3590, Belgium|Revalidatie & MS Centrum Overpelt, Overpelt, Belgium"
NCT00989742,Doxycycline In Lymphangioleiomyomatosis (LAM),https://beta.clinicaltrials.gov/study/NCT00989742,COMPLETED,Lymphangioleiomyomatosis|Tuberous Sclerosis,DRUG: Doxycycline|DRUG: Placebo,University of Nottingham,,FEMALE,"ADULT, OLDER_ADULT",PHASE4,24,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2009-07,2013-01,2013-01,"Nottingham University Hospitals, Nottingham, NG7 2UH, United Kingdom"
NCT05286242,Evaluating the Immune Response to COVID19 Vaccination in Immunodeficient Patients,https://beta.clinicaltrials.gov/study/NCT05286242,ACTIVE_NOT_RECRUITING,Multiple Sclerosis|Autoimmune Blistering Disease|B-Cell Deficiency,BIOLOGICAL: COVID19 vaccine,Yale University,National Institute of Allergy and Infectious Diseases (NIAID)|Robert Leet and Clara Guthrie Patterson Trust,ALL,"ADULT, OLDER_ADULT",,400,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-02-10,2024-05-31,2024-06-30,"Yale University, New Haven, Connecticut, 06520, United States"
NCT01036165,"A Multicenter, Open-label, RebiSmart™ Autoinjector Ease of Use Study",https://beta.clinicaltrials.gov/study/NCT01036165,COMPLETED,Multiple Sclerosis,DEVICE: RebiSmart™,EMD Serono,,ALL,"ADULT, OLDER_ADULT",PHASE3,103,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2010-01,2010-08,2010-08,"EMD Serono, Inc., Rockland, Massachusetts, 02370, United States"
NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,https://beta.clinicaltrials.gov/study/NCT01797965,TERMINATED,Relapsing-Remitting Multiple Sclerosis|Multiple Sclerosis,DRUG: BIIB019 (Daclizumab),Biogen,AbbVie,ALL,"ADULT, OLDER_ADULT",PHASE3,1501,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-02-15,2018-09-24,2018-09-24,"Research Site, Phoenix, Arizona, 85013, United States|Research Site, Phoenix, Arizona, 85050, United States|Research Site, Tucson, Arizona, 85704, United States|Research Site, Little Rock, Arkansas, 72205, United States|Research Site, La Jolla, California, 92037, United States|Research Site, Aurora, Colorado, 80045, United States|Research Site, Centennial, Colorado, 80112, United States|Research Site, Naples, Florida, 34102, United States|Research Site, Pompano Beach, Florida, 33060, United States|Research Site, Atlanta, Georgia, 30327, United States|Research Site, Fort Wayne, Indiana, 46804, United States|Research Site, Indianapolis, Indiana, 46202, United States|Research Site, Kansas City, Kansas, 66160, United States|Research Site, Lexington, Kentucky, 40503, United States|Research Site, Wellesley, Massachusetts, 02481, United States|Research Site, Worcester, Massachusetts, 01605, United States|Research Site, Farmington Hills, Michigan, 48334, United States|Research Site, Lebanon, New Hampshire, 03756, United States|Research Site, Albuquerque, New Mexico, 87131, United States|Research Site, Buffalo, New York, 14203, United States|Research Site, Latham, New York, 12110, United States|Research Site, New York, New York, 10016, United States|Research Site, New York, New York, 10065, United States|Research Site, Rochester, New York, 14642, United States|Research Site, Charlotte, North Carolina, 28207, United States|Research Site, Raleigh, North Carolina, 27607, United States|Research Site, Winston-Salem, North Carolina, 27103, United States|Research Site, Dayton, Ohio, 45408, United States|Research Site, Medford, Oregon, 97504, United States|Research Site, Portland, Oregon, 97225, United States|Research Site, Allentown, Pennsylvania, 18103, United States|Research Site, Pittsburgh, Pennsylvania, 15213, United States|Research Site, Cordova, Tennessee, 38018, United States|Research Site, Franklin, Tennessee, 37064, United States|Research Site, Knoxville, Tennessee, 37922, United States|Research Site, Round Rock, Texas, 78681, United States|Research Site, Henrico, Virginia, 23226, United States|Research Site, Tacoma, Washington, 98405, United States|Research Site, Milwaukee, Wisconsin, 53215, United States|Research Site, Ciudad Autónoma de Buenos Aires, Buenos Aires, C1015ABR, Argentina|Research Site, Ciudad Autónoma de Buenos Aires, Buenos Aires, C1061ABD, Argentina|Research Site, Godoy Cruz, Mendoza, M5501, Argentina|Research Site, Rosario, Santa Fe, S2000BZL, Argentina|Research Site, Auchenflower, Queensland, 4066, Australia|Research Site, Heidelberg, Victoria, 3084, Australia|Research Site, Belo Horizonte, Minas Gerais, 30150-221, Brazil|Research Site, Recife, Pernambuco, 52010-040, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, 90035-001, Brazil|Research Site, Campinas, São Paulo, 13083-888, Brazil|Research Site, Ribeirão Preto, São Paulo, 14049-900, Brazil|Research Site, Rio de Janeiro, 20270-004, Brazil|Research Site, Rio De Janeiro, 21941-590, Brazil|Research Site, Vancouver, British Columbia, V6T 2B5, Canada|Research Site, Saint Johns, Newfoundland and Labrador, A1B 3V6, Canada|Research Site, London, Ontario, N6A 5A5, Canada|Research Site, Ottawa, Ontario, K1H 8L6, Canada|Research Site, Gatineau, Quebec, J9J 0A5, Canada|Research Site, Greenfield Park, Quebec, J4V 2J2, Canada|Research Site, Brno, Jihomoravský Kraj, 625 00, Czechia|Research Site, Brno, Jihomoravský Kraj, 656 91, Czechia|Research Site, Jihlava, Kray Vysocina, 586 33, Czechia|Research Site, Ostrava, Moravskoslezský Kraj, 708 52, Czechia|Research Site, Pardubice, Pardubický Kraj, 532 03, Czechia|Research Site, Praha 10, Praha, 100 34, Czechia|Research Site, Praha 2, Praha, 128 08, Czechia|Research Site, Olomouc, Severomoravsky Kraj, 775 20, Czechia|Research Site, Hradec Kralove, 500 03, Czechia|Research Site, Praha 5, 150 06, Czechia|Research Site, Teplice, Ústecký Kraj, 415 29, Czechia|Research Site, Copenhagen, 2100, Denmark|Research Site, Glostrup, 2600, Denmark|Research Site, Odense C, 5000, Denmark|Research Site, Strasbourg, Bas-Rhin, 67091, France|Research Site, Marseille, Bouches-du-Rhône, 13385, France|Research Site, Caen, Calvados, 14033, France|Research Site, Bordeaux, Gironde, 33076, France|Research Site, Toulouse, Haute-Garonne, 31059, France|Research Site, Bobigny, Ile-de-France, 93009, France|Research Site, Nancy, Meurthe-et-Moselle, 54000, France|Research Site, Lille, Nord, 59037, France|Research Site, Amiens Cedex 1, 80054, France|Research Site, Paris, 75019, France|Research Site, Tbilisi, 0179, Georgia|Research Site, Bad Mergentheim, Baden-Württemberg, 97980, Germany|Research Site, Freiburg, Baden-Württemberg, 79106, Germany|Research Site, Bayreuth, Bayern, 95445, Germany|Research Site, Erlangen, Bayern, 91054, Germany|Research Site, München, Bayern, 81675, Germany|Research Site, Marburg, Hessen, 35043, Germany|Research Site, Rostock, Mecklenburg-Vorpommern, 18147, Germany|Research Site, Dresden, Sachsen, 01307, Germany|Research Site, Bamberg, 96052, Germany|Research Site, Athens, Attiki, 11525, Greece|Research Site, Thessaloniki, Macedonia, 57010, Greece|Research Site, Athens, 115 21, Greece|Research Site, Thessaloniki, 546 36, Greece|Research Site, Miskolc, Borsod-Abaúj-Zemplén, 3533, Hungary|Research Site, Kecskemét, Bács-Kiskun, 6000, Hungary|Research Site, Székesfehérvár, Fejer, 8000, Hungary|Research Site, Balatonfüred, 8230, Hungary|Research Site, Budapest, 1125, Hungary|Research Site, Budapest, 1134, Hungary|Research Site, Budapest, 1145, Hungary|Research Site, Budapest, 1204, Hungary|Research Site, Debrecen, 4043, Hungary|Research Site, Esztergom, 2500, Hungary|Research Site, Gyor, 9024, Hungary|Research Site, Miskolc, 3526, Hungary|Research Site, Nyíregyháza, 4400, Hungary|Research Site, Hyderabad, Andhra Pradesh, 500082, India|Research Site, Bangalore, Karnataka, 560054, India|Research Site, Trivandrum, Kerala, 695011, India|Research Site, Mumbai, Maharashtra, 400016, India|Research Site, Gurgaon, 122002, India|Research Site, Dublin, DU04, Ireland|Research Site, Dublin, DU09, Ireland|Research Site, Ashkelon, 78278, Israel|Research Site, Haifa, 31096, Israel|Research Site, Petah Tikva, 49100, Israel|Research Site, Safed, 13100, Israel|Research Site, Genova, Liguria, 16132, Italy|Research Site, Milano, Lombardia, 20127, Italy|Research Site, Padova, Veneto, 35128, Italy|Research Site, Catania, 95123, Italy|Research Site, Cefalù, 90015, Italy|Research Site, Roma, 00133, Italy|Research Site, Roma, 00189, Italy|Research Site, Distrito Federal, 03310, Mexico|Research Site, Distrito Federal, 06700, Mexico|Research Site, Chisinau, MD 2001, Moldova, Republic of|Research Site, Chisinau, MD 2028, Moldova, Republic of|Research Site, Bydgoszcz, Kujawsko-pomorskie, 85-681, Poland|Research Site, Lublin, Lubelskie, 20-954, Poland|Research Site, Lodz, Lódzkie, 90-324, Poland|Research Site, Kraków, Malopolskie, 31-505, Poland|Research Site, Kraków, Malopolskie, 31-637, Poland|Research Site, Warszawa, Mazowieckie, 00-901, Poland|Research Site, Warszawa, Mazowieckie, 02-097, Poland|Research Site, Warszawa, Mazowieckie, 02-507, Poland|Research Site, Warszawa, Mazowieckie, 02-957, Poland|Research Site, Warszawa, Mazowieckie, 04-749, Poland|Research Site, Bialystok, Podlaskie, 15-276, Poland|Research Site, Bialystok, Podlaskie, 15-402, Poland|Research Site, Gdansk, Pomorskie, 80-299, Poland|Research Site, Gdansk, Pomorskie, 80-952, Poland|Research Site, Katowice, Slaskie, 40-595, Poland|Research Site, Katowice, Slaskie, 40-650, Poland|Research Site, Katowice, Slaskie, 40-752, Poland|Research Site, Kielce, Swietokrzyskie, 25-726, Poland|Research Site, Olsztyn, Warminsko-mazurskie, 10-443, Poland|Research Site, Plewiska, Wielkopolskie, 62-064, Poland|Research Site, Poznan, Wielkopolskie, 60-355, Poland|Research Site, Poznan, Wielkopolskie, 60-631, Poland|Research Site, Poznan, Wielkopolskie, 61-853, Poland|Research Site, Szczecin, Zachodniopomorskie, 70-111, Poland|Research Site, Szczecin, Zachodniopomorskie, 71-252, Poland|Research Site, Gdansk, 80-803, Poland|Research Site, Grudziadz, 86-300, Poland|Research Site, Katowice, 40-684, Poland|Research Site, Katowice, 40-749, Poland|Research Site, Olsztyn, 10-561, Poland|Research Site, Cluj- Napoca, Cluj, 400012, Romania|Research Site, Târgu Mures, Mures, 540136, Romania|Research Site, Timisoara, Timis, 300736, Romania|Research Site, Bucharest, 011461, Romania|Research Site, Iasi, 700656, Romania|Research Site, Yaroslavl, Yaroslavlr, 150030, Russian Federation|Research Site, Kazan, 420021, Russian Federation|Research Site, Kemerovo, 650066, Russian Federation|Research Site, Krasnoyarsk, 660022, Russian Federation|Research Site, Moscow, 127018, Russian Federation|Research Site, Moscow, 129128, Russian Federation|Research Site, Nizhny Novgorod, 603005, Russian Federation|Research Site, Nizhny Novgorod, 603155, Russian Federation|Research Site, Novosibirsk, 630087, Russian Federation|Research Site, Omsk, 644043, Russian Federation|Research Site, Perm, 614990, Russian Federation|Research Site, Samara, 443095, Russian Federation|Research Site, Smolensk, 214018, Russian Federation|Research Site, St. Petersburg, 194044, Russian Federation|Research Site, St. Petersburg, 194291, Russian Federation|Research Site, St. Petersburg, 197376, Russian Federation|Research Site, Tyumen, 625000, Russian Federation|Research Site, Ufa, 450005, Russian Federation|Research Site, Belgrade, 11000, Serbia|Research Site, Kragujevac, 34000, Serbia|Research Site, Nis, 18000, Serbia|Research Site, Novi Sad, 21000, Serbia|Research Site, Badalona, Barcelona, 08035, Spain|Research Site, Cordoba, Córdoba, 14008, Spain|Research Site, Madrid, Madrid, Communidad Delaware, 28040, Spain|Research Site, Girona, 17007, Spain|Research Site, l'Hospitalet de Llobregat, 08907, Spain|Research Site, Sevilla, 41071, Spain|Research Site, Malmö, Skane, 205 02, Sweden|Research Site, Stockholm, Sodermanlands Lan, 141 86, Sweden|Research Site, Stockholm, Sodermanlands Lan, 182 88, Sweden|Research Site, Göteborg, Vastra Gotalands Lan, 413 45, Sweden|Research Site, Stockholm, 171 76, Sweden|Research Site, Basel, Basel-Stadt (de), 4031, Switzerland|Research Site, Chernivtsi, Chernivets'ka Oblast, 58018, Ukraine|Research Site, Dnipropetrovsk, Dnipropetrovs'ka Oblast', 49027, Ukraine|Research Site, Donetsk, Donets'ka Oblast', 83003, Ukraine|Research Site, Kharkiv, Kharkivs'ka Oblast', 61068, Ukraine|Research Site, Kyiv, Kyïv, 02125, Ukraine|Research Site, Kyiv, Kyïv, 03110, Ukraine|Research Site, Kyiv, Kyïv, 04060, Ukraine|Research Site, Odesa, Odes'ka Oblast, 65025, Ukraine|Research Site, Poltava, Poltavs'ka Oblast, 36011, Ukraine|Research Site, Vinnytsia, Vinnyts'ka Oblast', 21005, Ukraine|Research Site, Zaporizhzhia, Zaporiz'ka Oblast', 69035, Ukraine|Research Site, Zaporizhzhia, Zaporizhia Oblast, 69600, Ukraine|Research Site, Kharkiv, 61103, Ukraine|Research Site, Plymouth, Devon, PL6 8BX, United Kingdom|Research Site, Edinburgh, Edinburgh, City Of, EH4 2XU, United Kingdom|Research Site, Brighton, BN2 5BE, United Kingdom|Research Site, London, E1 2AT, United Kingdom|Research Site, London, SE5 9RS, United Kingdom|Research Site, London, W6 8RF, United Kingdom|Research Site, London, WC1N 3BG, United Kingdom|Research Site, Nottingham, NG7 2UH, United Kingdom|Research Site, Sheffield, S10 2JF, United Kingdom"
NCT02301442,Step it Up: An Exercise and Behaviour Change Programme for People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02301442,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Exercise + behaviour change intervention|BEHAVIORAL: Exercise + control education,University of Limerick,,ALL,"ADULT, OLDER_ADULT",NA,65,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-09,2016-02,2016-02,"Department of Clinical Therapies, University of Limerick, Limerick, Munster, Ireland"
NCT03756142,Biomechanical Characterization of the Locomotion in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT03756142,UNKNOWN,Multiple Sclerosis,DIAGNOSTIC_TEST: Motion Analysis,Lille Catholic University,"Laboratoire d'Automatique, de Mécanique et d'Informatique Industrielles et Humaines",ALL,"ADULT, OLDER_ADULT",,80,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-11-06,2020-11-05,2020-11-05,"Hôpital Saint-Philibert, Lomme, 59000, France"
NCT05106465,A Sub-Study to Explore Association Patterns Between Digital Outcome Assessments From the Konectom™ Platform and Magnetic Resonance Imaging (MRI) Measures of Brain Tissue Damage,https://beta.clinicaltrials.gov/study/NCT05106465,RECRUITING,Multiple Sclerosis (MS),DEVICE: Konectom platform,Biogen,,ALL,"ADULT, OLDER_ADULT",,500,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-12-15,2023-12-27,2023-12-27,"Research Site, Dresden, 01307, Germany"
NCT03917589,Preventive Use of COrticosteroids During the Post-Partum in Relapsing MS Patients (COPP-MS),https://beta.clinicaltrials.gov/study/NCT03917589,COMPLETED,Multiple Sclerosis,,Rennes University Hospital,,FEMALE,"CHILD, ADULT",,350,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-06-20,2020-05-18,2020-05-18,"Hôpital LAENNEC, Saint Herblain, Nantes, 44800, France|CHU Lyon, Lyon, France|Hôpital Pasteur 2 - CHU Nice, Nice, 06000, France|CHU Rennes, Rennes, 35033, France|CHU Strasbourg, Strasbourg, 67098, France"
NCT03934489,Emotion Regulation Skills Training for Individuals With MS and Their Support Partners,https://beta.clinicaltrials.gov/study/NCT03934489,COMPLETED,Multiple Sclerosis,BEHAVIORAL: PERSIST|BEHAVIORAL: Facilitated Peer Support,Johns Hopkins University,National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-01-07,2021-03-15,2021-03-15,"Johns Hopkins University, Baltimore, Maryland, 21205, United States"
NCT02466165,Multiple Sclerosis: Associated Cardiometabolic Risks and Impact of Exercise Therapy,https://beta.clinicaltrials.gov/study/NCT02466165,COMPLETED,Multiple Sclerosis|Healthy Controls,BEHAVIORAL: Physical exercise,Bert Op't Eijnde,,ALL,"ADULT, OLDER_ADULT",NA,80,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-02,2015-08,2015-12,"REVAL, Diepenbeek, 3590, Belgium|Jessa hospital, Hasselt, 3500, Belgium"
NCT03266965,Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach,https://beta.clinicaltrials.gov/study/NCT03266965,COMPLETED,Multiple Sclerosis,DRUG: Carbidopa|DIETARY_SUPPLEMENT: L-Histidine,University of Miami,United States Department of Defense,ALL,ADULT,PHASE1,18,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-03-23,2020-08-07,2020-08-07,"University of Miami, Miami, Florida, 33136, United States"
NCT02559765,"Access, Use and Opinions of Physiotherapy and Rehabilitation Services of People With Progressive MS in the UK.",https://beta.clinicaltrials.gov/study/NCT02559765,COMPLETED,Progressive Multiple Sclerosis,,University of Glasgow,NHS Ayrshire and Arran|AKM,ALL,"ADULT, OLDER_ADULT",,1298,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-08,2015-11,2015-11,"The University of Glasgow, Glasgow, G12 8LL, United Kingdom"
NCT03486665,Characterization of White Blood Cells Sub-populations From Multiple Sclerosis Patients.,https://beta.clinicaltrials.gov/study/NCT03486665,UNKNOWN,Multiple Sclerosis,OTHER: Blood Sampling|OTHER: CSF Sampling,Bioimmunate,,ALL,"ADULT, OLDER_ADULT",,60,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-04-24,2018-09,2020-03,"Hadassah Medical Center, Jerusalem, Israel"
NCT01281189,Phase 3 Study of Dexpramipexole in ALS,https://beta.clinicaltrials.gov/study/NCT01281189,COMPLETED,Amyotrophic Lateral Sclerosis,DRUG: Dexpramipexole|DRUG: Placebo,Knopp Biosciences,,ALL,"ADULT, OLDER_ADULT",PHASE3,942,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-03,2012-11,2012-11,"Barrow Neurological Institute - St. Joseph's Hospital, Phoenix, Arizona, 85013, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, 72205, United States|University of California at San Francisco - Fresno, Fresno, California, 93701, United States|University of California, Irvine, Orange, California, 92868, United States|University of California, Davis, Sacramento, California, 95817, United States|California Pacific Medical Center, San Francisco, California, 94115, United States|Hospital for Special Care, New Britain, Connecticut, 06053, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, 32224, United States|University of Miami Miller School of Medicine, Miami, Florida, 33136, United States|University of South Florida Medical Center, Tampa, Florida, 33612, United States|Emory University, Atlanta, Georgia, 30322, United States|Northwestern University, Chicago, Illinois, 60611, United States|Indiana University, Indianapolis, Indiana, 46202, United States|University of Iowa, Iowa City, Iowa, 52242, United States|University of Kansas Medical Center, Kansas City, Kansas, 66160, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, 21287, United States|Massachusetts General Hospital, Charlestown, Massachusetts, 02129, United States|St. Mary's Health Care, Grand Rapids, Michigan, 49503, United States|Hennepin County Medical Center, Minneapolis, Minnesota, 55404, United States|Mayo Clinic - Rochester, Rochester, Minnesota, 55905, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|Neurology Associates, P.C., Lincoln, Nebraska, 68506, United States|University of Nevada School of Medicine, Las Vegas, Nevada, 89102, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, 03756, United States|Columbia University, New York, New York, 10032, United States|Research Foundation of the State University of New York, Syracuse, New York, 12201, United States|Carolinas Medical Center, Charlotte, North Carolina, 28207, United States|Duke University Medical Center, Durham, North Carolina, 27705, United States|Wake Forest University, Winston-Salem, North Carolina, 27157, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States|Ohio State University, Columbus, Ohio, 43210, United States|Providence ALS Center, Portland, Oregon, 97213, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, 17033, United States|ALS Center at Penn, Philadelphia, Pennsylvania, 19107, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, 19129, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, 15213, United States|Vanderbilt University Medical Center, Nashville, Tennessee, 37232, United States|Texas Neurology, Dallas, Texas, 75214, United States|Methodist Neurological Institute, Houston, Texas, 77030, United States|University of Texas Health Sciences Center, San Antonio, Texas, 78229, United States|University of Utah, Salt Lake City, Utah, 84132, United States|University of Virginia Health System, Charlottesville, Virginia, 22908, United States|University of Washington, Seattle, Washington, 98195, United States|Prince of Wales Hospital, Randwick, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, 2145, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, 4029, Australia|Calvary Health Care Bethlehem, Melbourne, Victoria, 3121, Australia|AZ St-Lucas, Gent, 9000, Belgium|UZ Leuven, Leuven, 3000, Belgium|Univ of Calgary / Foothills MC, Calgary, Alberta, T2V 1P9, Canada|CHUM - Hopital Notre Dame, Montreal, Quebec, H2L 4M1, Canada|Mcgill University, Montreal, Quebec, H3A 2B4, Canada|London Health Sciences Centre, London, Canada|Sunnybrook and Women's College and Health Sciences Centre, Toronto, M4N 3M5, Canada|University of British Columbia, Vancouver, Canada|CHRU de Lille - Hôpital Roger Salengro, Lille, 59037, France|CHU de Limoges - Hôpital Dupuytren, Limoges, France|Centre Hospitalier La Timone, Marseille, France|CHU Gui de Chauliac, Montpellier, 34295, France|CHU de Nice - Hôpital de l'Archet 1, Nice, France|Hôpital La Pitié Salpétrière, Paris, 75013, France|Charité - Universitätsmedizin Berlin, Berlin, Germany|Bergmannsheil Gmbh, Bochum, Germany|Medizinische Hochschule Hannover (MHH), Hannover, Germany|Universitätsklinikum Jena, Jena, Germany|University of Ulm, RKU, Ulm, Germany|Beaumont Hospital, Dublin, Dublin 9, Ireland|Academisch Medisch Centrum, Amsterdam, 1105 AZ, Netherlands|UMC St. Radboud, Nijmegen, 6525 GA, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, 3584 CX, Netherlands|Hospital Universitario de Bellvitge, Barcelona, 8907, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital La Paz, Madrid, 28046, Spain|Hospital Carlos III, Madrid, Spain|Sahlgrenska Universitetssjukhuset, Göteborg, 41345, Sweden|Karolinska Universitetssjukhuset, Solna, Stockholm, 17176, Sweden|Queen Elizabeth Hospital, Birmingham, B15 2TH, United Kingdom|Walton Centre for Neurology & Neurosurgery, Liverpool, L9 7LJ, United Kingdom|Kings College Hospital NHS Foundation Trust, London, SE5 8AF, United Kingdom|Newcastle University Hospital - Clinical Ageing Research Unit, Newcastle, NE4 5PL, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom|Sheffield Institute for Transnational Neuroscience, Sheffield, S10 2HQ, United Kingdom"
NCT04953689,Technology-assisted Conscientiousness Therapy for People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04953689,RECRUITING,Multiple Sclerosis,BEHAVIORAL: Conscientiousness Coach,State University of New York at Buffalo,,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-10-19,2023-12-30,2023-12-30,"Conventus Building, Buffalo, New York, 14203, United States"
NCT04122989,Validation of a Shared Decision-Making Tool for Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04122989,COMPLETED,Multiple Sclerosis,OTHER: MS-SUPPORT,Shared Decision Making Resources,EMD Serono|Multiple Sclerosis Association of America,ALL,"ADULT, OLDER_ADULT",NA,501,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (CARE_PROVIDER)|Primary Purpose: HEALTH_SERVICES_RESEARCH,2019-11-12,2020-10-26,2021-12-23,"Shared Decision Making Resources, Georgetown, Maine, 04548, United States"
NCT04121065,Role of ADA SNPs in Subjects With Relapsing Multiple Sclerosis (RMS),https://beta.clinicaltrials.gov/study/NCT04121065,RECRUITING,Relapsing Multiple Sclerosis,PROCEDURE: Blood withdrawal,Neuromed IRCCS,,ALL,"ADULT, OLDER_ADULT",,150,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-09-07,2023-06,2025-06,"IRCCS Neuromed, Pozzilli, Isernia, 86077, Italy"
NCT02587065,Plegridy Satisfaction Study in Participants,https://beta.clinicaltrials.gov/study/NCT02587065,COMPLETED,Relapsing-Remitting Multiple Sclerosis (RRMS),DRUG: peginterferon beta-1a,Biogen,,ALL,"ADULT, OLDER_ADULT",PHASE4,193,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-02-03,2017-10-02,2017-12-21,"Research Site, Arezzo, 52100, Italy|Research Site, Bari, 70124, Italy|Research Site, Cagliari, 09126, Italy|Research Site, Cefalù, 90015, Italy|Research Site, Chieti, 66100, Italy|Research Site, Como, 22100, Italy|Research Site, Fidenza, 43036, Italy|Research Site, Foligno, 06034, Italy|Research Site, Gallarate, 21013, Italy|Research Site, Genova, 16132, Italy|Research Site, L'Aquila, 67100, Italy|Research Site, Messina, 98125, Italy|Research Site, Milano, 20132, Italy|Research Site, Milano, 20133, Italy|Research Site, Modena, 41126, Italy|Research Site, Mondovì, 12084, Italy|research Site, Napoli, 80131, Italy|Research Site, Napoli, 80137, Italy|Research Site, Orbassano, 10043, Italy|Research Site, Ozieri, 07014, Italy|Research Site, Palermo, 90129, Italy|Research Site, Palermo, 90146, Italy|Research Site, Pavia, 27100, Italy|Research Site, Pietra Ligure, 17027, Italy|Research Site, Pozzilli, 86077, Italy|Research Site, Reggio Calabria, 89100, Italy|Research Site, Roma, 00152, Italy|Research Site, Roma, 00168, Italy|Research Site, Roma, 00189, Italy|Research Site, Torino, 10126, Italy"
NCT04367389,Internet-based Physical Activity Promotion and Exercise Prescription for People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04367389,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Physical activity promotion|BEHAVIORAL: Exercise,University of Erlangen-Nürnberg,"Neurological Rehabilitation Center Quellenhof|ZTM Bad Kissingen|Medi train - Zentrum für Gesundheitssport, Sport- und Physiotherapie|proMX GmbH Nürnberg|motionNET systems Limited|Aktion Multiple Sklerose Erkrankter, Landesverband der DMSG in Baden-Württemberg (AMSEL) e.V.|Klinikum Würzburg Mitte GmbH",ALL,"ADULT, OLDER_ADULT",NA,62,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER,2019-10-01,2020-07-30,2020-07-30,"Neurological Rehabilitation Center Quellenhof, Bad Wildbad, 75323, Germany|Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, 91058, Germany|Kliniken Schmieder Konstanz, Konstanz, 78464, Germany|Facharztpraxis für Neurologie und Psychiatrie Dr. med Wolfgang Mattes und Andreas Stockert, Pforzheim, 75172, Germany|Fachklinik für Neurologie Dietenbronn GmbH, Schwendi, 88477, Germany|E/M/S/A - Zentrum für Neurologie/Psychiatrie/Neuroradiologie, Singen, 78224, Germany|Klinikum Stuttgart Katharinenhospital, Stuttgart, 70174, Germany|Neurologisch-Psychiatrische Praxis Dr. Weber, Stuttgart, 70178, Germany|Klinikum Würzburg Mitte gGmbH, Würzburg, 97070, Germany"
NCT03369665,Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS),https://beta.clinicaltrials.gov/study/NCT03369665,COMPLETED,Multiple Sclerosis,DRUG: Mavenclad®,"Merck KGaA, Darmstadt, Germany",,ALL,"ADULT, OLDER_ADULT",PHASE4,485,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-06-20,2021-11-12,2021-11-12,"Kepler Universitätsklinikum, Linz, 4021, Austria|Paracelsus Medical University Salzburg, Salzburg, Austria|Eva Maida, Wien, Austria|Cliniques Univ. St.-Luc, Brussels, 1200, Belgium|UZ Antwerpen, Edegem, 2650, Belgium|Clinique Saint Pierre, Ottignies, 1340, Belgium|FN u sv. Anny Brno, Brno, 65691, Czechia|FN Hradec Kralove, Chocen, 56501, Czechia|Nemocnice Jihlava, p.o., Jihlava, 586 33, Czechia|Fakultni nemocnice Olomouc, Olomouc, 779 00, Czechia|Fakultni nemocnice Ostrava (11573), Ostrava, 70852, Czechia|Faculty Hospital Kralovske Vinohrad, Praha 10, 100 34, Czechia|Vseobecna fakultni nemocnice v Praze (11163), Praha 2, 128 08, Czechia|Nemocnice Teplice, Teplice, 415 29, Czechia|Aalborg Hospital, Aalborg, 9100, Denmark|Glostrup University Hospital, Glostrup, DK-2600, Denmark|Odense Univeristy Hospital, Odense, Denmark|Matthias Kant, Sønderborg, 6400, Denmark|Helsinki University Central Hospital, Helsinki, 290, Finland|Helsinki University Central Hospital, Helsinki, Finland|Terveystalo Mikkeli, Mikkeli, 50100, Finland|Neo Research, Neuro NEO Oy, Turku, Finland|Centre hospitalier de la Côte Basque - Saint Léon, Bayonne, 64100, France|Hopital Pellegrin, Bordeaux Cedex, 33076, France|University Hospital of Caen, Caen, 14033, France|CHRU de Lille, Lille, 59037, France|Groupe Hospitalier de l'Institut Catholique de Lille - Centre Hospitalier Saint Philibert, Lomme, France|CHU de Nantes, Nantes Cedex 01, 44093, France|Centre Hospitalier de Gonesse, Paris, 75013, France|Hôpital de la Pitié-Salpétrière, Paris, 75013, France|CHU de Poissy, Poissy Cedex, 78303, France|CHU Hopital Gabriel Montpied, Puy-de-Dome, 63003, France|Centre Universitaire de Rouen, Rouen, 76031, France|Hopital Pierre-Paul Riquet - Neurologie, Toulouse, 31059, France|CHU Tours - Hôpital Bretonneau, Tours Cedex, 37044, France|Hos. Errikos Dynan, Athens, 11526, Greece|401 Army Hospital, Athens, 11527, Greece|Athens Medical Centre, Athens, 11527, Greece|Semmelweis Egyetem AOK, Budapest, 1083, Hungary|Uzsoki Utcai Korhaz, Budapest, 1145, Hungary|Jahn Ferenc Dél-Pesti Kórház és Rendelőintézet, Budapest, 1204, Hungary|University of Debrecen, Debrecen, 4032, Hungary|VALEOMED Kft, Esztergom, 2500, Hungary|Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókór, Nyiregyhaza, 4403, Hungary|A.O.U. Ospedali Riuniti Umberto I, Ancona, Italy|Ospedale Binaghi, Università di Cagliari,ASL 8 - Centro Sclerosi Multipla, Cagliari, 09126, Italy|Policlinico di Catania, Catania, 95125, Italy|Ospedale San Raffaele Giglio, Cefalù, 90015, Italy|Ospedale San Raffaele, IRCCS, Milano, 20127, Italy|Instituto Nazionale Neurologico ""Carlo Besta"", Milano, 20133, Italy|A.O. Universitaria Federico II, Napoli, 80131, Italy|Seconda Univesità degli Studi di Napoli, AOU, Napoli, Italy|Villa Sofia Hospital, Palermo, 90146, Italy|Azienda Ospedaliera S. Camillo Forlanini (8025), Roma, 00152, Italy|Azienda Ospedaliera Sant'Andrea Università La Sapienza, Roma, 00189, Italy|Neurological Center Of Latium, Roma, 00189, Italy|Policlinico Tor Vergata, Roma, Italy|Hospital of Lithuanian University of Health Sciences Kaunas, Kaunas, 50161, Lithuania|Klaipedos Ligonine, Kaunas, 50161, Lithuania|Vilnius University Hospital Santariskiu Clinics, Vilnius, 8661, Lithuania|Zuyderland, Sittard-Geleen, 6131 BG, Netherlands|Drammen Hospital, Drammen, 3004, Norway|COPERNICUS Podmiot Leczn. Sp z o.o., Gdansk, 80-803, Poland|M.A. - LEK A.M.Maciejowscy SC., Katowice, 40-571, Poland|Uniwersytecki Szpital Kliniczny nr 1 i.m. Norberta Barlickie, Lodz, 90-153, Poland|Centrum Medyczne Medyk, Lublin, 20-954, Poland|Indywidualna Praktyka Lekarska Prof. Konrad Rejdak, Lublin, 20-954, Poland|Instytut Psychiatrii i Neurologii, Warszawa, 02-957, Poland|Centrum Neurologii K. Selmaj, Łódź, 90-153, Poland|Hospital de Braga, Braga, 4710-243, Portugal|Centro Hospitalar do Porto E.P.E. Hospital de Santo António, Porto, 4099-001, Portugal|Univerzitna nemocnica Bratislava, Bratislava, 813 69, Slovakia|Univerzitna nemocnica Martin, Martin, 036 01, Slovakia|Fakultna nemocnica Nitra, Nitra, 950 01, Slovakia|Fakultna nemocnica Trnava, Trnava, 917 75, Slovakia|C.A.U. de León - H. de León, León, 24071, Spain|Hospital Arnau de Vilanova, Lérida, 25198, Spain|Hospital General Universitario Gregorio Marañón (5030), Madrid, 28007, Spain|H. U. Quirónsalud Madrid, Madrid, 28040, Spain|Hospital Universitario de Getafe, Madrid, 28905, Spain|Hospital Virgen de la Arrixaca, Murcia, 30120, Spain|Hospital de Sant Joan Despí Moisès Broggi, Sant Joan Despí, 08970, Spain|Hospital Universitario Nuestra Senora de la Candelaria (4776), Santa Cruz De Tenerfie, 38010, Spain|Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, 15706, Spain|Hospital Universitario Virgen del Rocio - Servicio de Oncologia, Sevilla, 41013, Spain|Karlstad Hospital (8232), Karlstad, 651 86, Sweden|Motala Hospital (11119), Motala, 59185, Sweden|Institute of Neurological Sciences, Glasgow, G51 4TF, United Kingdom|Institute of Neurological Sciences, Glasgow, United Kingdom|GM LCRN - Great Manchester Local Clinical Research Network, Manchester, M13 9WL, United Kingdom|The Newcastle Hospitals NHS Foundation Trust, Newcastle Upon Tyne, NE1 4LP, United Kingdom|Morriston Hospital (4232), Swansea West Glamorgan, SA6 6NL, United Kingdom"
NCT03185065,"Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT03185065,COMPLETED,Fatigue in Multiple Sclerosis,DRUG: Amantadine|DRUG: Modafinil|DRUG: Methylphenidate|DRUG: Placebos,Johns Hopkins University,Patient-Centered Outcomes Research Institute,ALL,"ADULT, OLDER_ADULT",PHASE3,141,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-10-04,2019-11-21,2019-11-21,"University of California San Francisco, San Francisco, California, 94158, United States|Johns Hopkins University, Baltimore, Maryland, 21287, United States"
NCT03370965,Optic Neuritis Differential Diagnosis Study,https://beta.clinicaltrials.gov/study/NCT03370965,RECRUITING,Optic Neuritis|Neuromyelitis Optica|Multiple Sclerosis,DIAGNOSTIC_TEST: Neuro-ophtalmology examination,University Hospital Center of Martinique,University Hospital Center of Guadeloupe|Hospital Center of Cayenne (French Guyana),ALL,"ADULT, OLDER_ADULT",NA,150,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2019-06-07,2024-06,2025-06,"CHU of Martinique, Fort-de-France, 97261, France"
NCT03501342,"Effects of Immersive Virtual Reality on Balance, Mobility, and Fatigue in Patients With Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT03501342,COMPLETED,Multiple Sclerosis,OTHER: Virtual reality group|OTHER: Dynamic Balance Training,Gazi University,,ALL,"ADULT, OLDER_ADULT",NA,39,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2018-04-09,2018-09-01,2018-09-01,"Gazi University, Ankara, Turkey"
NCT01106365,Repetitive Deep Transcranial Magnetic Stimulation in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01106365,COMPLETED,Multiple Sclerosis,DEVICE: H-coil (Repetitive deep transcranial magnetic stimulation),"Charite University, Berlin, Germany",Brainsway,ALL,"ADULT, OLDER_ADULT",NA,36,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2010-02,2012-12,2012-12,"Charite University Berlin (NeuroCure Clinical Research Center NCRC), Berlin, 10117, Germany"
NCT01250665,Study Comparing Corpus Callosum Atrophy as a Marker of Later Development of Cognitive Impairment in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01250665,UNKNOWN,Multiple Sclerosis|Cognitive Impairment,,Cantonal Hospital of St. Gallen,Bayer,ALL,ADULT,,65,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-01,2011-06,2011-06,"Cantonal Hospital of Saint Gallen, Saint Gallen, 9007, Switzerland"
NCT05811689,Trabecular Bone Score in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05811689,COMPLETED,Multiple Sclerosis|Endocrine System Diseases|Neurologic Disorder,DIAGNOSTIC_TEST: sm tbs group,"IRCCS Centro Neurolesi ""Bonino-Pulejo""",,ALL,"ADULT, OLDER_ADULT",,300,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-02-14,2021-08-20,2023-02-15,"IRCCS Centro Neurolesi Bonino Pulejo, Messina, 98149, Italy"
NCT00001465,Study of the Disease Process of Lymphangioleiomyomatosis,https://beta.clinicaltrials.gov/study/NCT00001465,RECRUITING,Lung Disease|Pneumothorax|Tuberous Sclerosis|Lymphangioleiomyomatosis,DEVICE: Toshibia Aquilion One CT,"National Heart, Lung, and Blood Institute (NHLBI)",,ALL,"CHILD, ADULT, OLDER_ADULT",,2000,NIH,OBSERVATIONAL,Observational Model: |Time Perspective: p,1995-12-18,,,"National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States"
NCT01783665,The Effect of Aerobic Exercise on Cognitive Function and Sleep Quality in Individuals With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01783665,COMPLETED,Multiple Sclerosis,OTHER: aerobic exercise|OTHER: home exercise program,"Catherine Siengsukon, PT, PhD",,ALL,"ADULT, OLDER_ADULT",NA,28,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2012-08,2015-12,2015-12,"University of Kansas Medical Center, Kansas City, Kansas, 66160, United States"
NCT03887065,Magnetic Resonance Imaging Study of JM-4 in Multiple Sclerosis/Clinically Patients,https://beta.clinicaltrials.gov/study/NCT03887065,UNKNOWN,Multiple Sclerosis,DRUG: JM-4,"Cook, Stuart, MD",,ALL,ADULT,EARLY_PHASE1,15,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2019-06-15,2019-12-15,2020-03-15,
NCT03636789,Evaluation of the Prevalence of Oculomotor Disorders in Patients With Radiologically Isolated Syndrome,https://beta.clinicaltrials.gov/study/NCT03636789,COMPLETED,Radiologically Isolated Syndrome (RIS)|Multiple Sclerosis,OTHER: Neurological consultation,Centre Hospitalier Universitaire de Nīmes,,ALL,ADULT,NA,61,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2018-10-26,2021-10-21,2021-11-05,"Hôpital Neurologique Pierre Wertheimer, Bron, France|Hôpital Guy de Chauliac, Montpellier, France|Nice University Hospital, Nice, France|Nimes University Hospital, Nîmes, France|Pitié Salpêtrière University Hospital (APHP), Paris, France|Toulouse University Hospital, Toulouse, France"
NCT03500289,Ketamine for Treatment of MS Fatigue,https://beta.clinicaltrials.gov/study/NCT03500289,COMPLETED,Multiple Sclerosis|Fatigue,DRUG: Ketamine|DRUG: Midazolam,Johns Hopkins University,National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,18,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2018-08-10,2019-08-30,2019-08-30,"Johns Hopkins University, Baltimore, Maryland, 21287, United States"
NCT02032589,Testing the Efficacy of Self-Generation Treatment Protocol,https://beta.clinicaltrials.gov/study/NCT02032589,UNKNOWN,Multiple Sclerosis,BEHAVIORAL: Self-generation treatment,Kessler Foundation,National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-01,2014-12,2014-12,"Kessler Foundation, West Orange, New Jersey, 07052, United States"
NCT05112289,A Study to Evaluate White Matter Hyperintensities in Migraine,https://beta.clinicaltrials.gov/study/NCT05112289,RECRUITING,Migraine|Small Vessel Ischemic Disease|Multiple Sclerosis,DIAGNOSTIC_TEST: Brain Neuroimaging,Mayo Clinic,,FEMALE,ADULT,NA,50,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-08-16,2023-08-16,2023-08-16,"Mayo Clinic in Arizona, Phoenix, Arizona, 85054, United States"
NCT04035889,Melatonin for Sleep in MS,https://beta.clinicaltrials.gov/study/NCT04035889,COMPLETED,Multiple Sclerosis,DIETARY_SUPPLEMENT: Melatonin|DIETARY_SUPPLEMENT: Placebo,"University of California, San Francisco",,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-09-23,2020-11-17,2020-11-17,"University of California, San Francisco, San Francisco, California, 94158, United States"
NCT05355389,Cognitive-motor Telerehabilitation in MS,https://beta.clinicaltrials.gov/study/NCT05355389,RECRUITING,Multiple Sclerosis,BEHAVIORAL: Cognitive training|BEHAVIORAL: Motor training,Universitair Ziekenhuis Brussel,National MS Center Melsbroek|Research Foundation Flanders,ALL,"ADULT, OLDER_ADULT",NA,90,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-09-01,2024-05,2025-05,"Universitair Ziekenhuis Brussel, Brussel, Belgium|National MS Center Melsbroek, Melsbroek, Belgium"
NCT03757065,Cell Surface Marker Expression in Autoimmune Diseases,https://beta.clinicaltrials.gov/study/NCT03757065,COMPLETED,Systemic Lupus Erythematosus|Sjogren's Syndrome|Multiple Sclerosis|Systemic Sclerosis|Crohn's Disease|Ulcerative Colitis|Inflammatory Myositis,,"Alpine Immune Sciences, Inc.",,ALL,"ADULT, OLDER_ADULT",,14,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-06-12,2019-10-25,2019-10-25,"GI Research Institute, Vancouver, British Columbia, V6Z 2K5, Canada|Mary Pack Arthritis Center, Vancouver, Canada"
NCT03216889,Cognitive Behavioral Therapy for Insomnia to Address Insomnia Symptoms in People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03216889,COMPLETED,Insomnia,BEHAVIORAL: Cognitive Behavioral Therapy for Insomnia|BEHAVIORAL: Control,University of Kansas Medical Center,National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",NA,43,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2017-06-29,2019-08-15,2019-08-15,"University of Kansas Medical Center, Kansas City, Kansas, 66160, United States"
NCT00490789,Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM,https://beta.clinicaltrials.gov/study/NCT00490789,UNKNOWN,Tuberous Sclerosis|Lymphangioleiomyomatosis,DRUG: sirolimus,Cardiff University,University of Nottingham|St Georges Hospital Medical School|Royal Sussex County Hospital|The Tuberous Sclerosis Association|Wyeth is now a wholly owned subsidiary of Pfizer,ALL,"ADULT, OLDER_ADULT",PHASE2,14,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2005-10,2009-09,2009-09,"University Hospital of Wales, Cardiff, Wales, CF14 4XN, United Kingdom|Royal Sussex County Hospital, Brighton, BN2 5BE, United Kingdom|City Hospital, Nottingham, NG5 1PB, United Kingdom"
NCT04837365,Impact of Neuropsychological Disorders in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04837365,RECRUITING,Multiple Sclerosis,OTHER: Three dimensional gait analysis with eyetracking,Lille Catholic University,,ALL,ADULT,NA,20,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-05-21,2023-02,2023-06,"St Vincent hospital - neurological service, Lille, France|St Philibert hospital - Neurologial service, Lomme, France|St Philibert hospital - Physical Medicine and Rehabilitation, Lomme, France"
NCT00492765,Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00492765,COMPLETED,Multiple Sclerosis,DRUG: Interferon-beta-1a|DRUG: Simvastatin|DRUG: Placebo,Biogen,,ALL,ADULT,PHASE4,380,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2006-02,2010-04,2010-04,"Coordinating Research Site, Copenhagen, Denmark"
NCT01006265,"Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT01006265,COMPLETED,Multiple Sclerosis,DRUG: ACT-128800 Dose 1|DRUG: Placebo|DRUG: ACT-128800 Dose 2|DRUG: ACT-128800 Dose 3,Actelion,,ALL,ADULT,PHASE2,464,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-10-01,2011-06-01,2011-07-01,"Clinical Investigative Site 3132, Scottsdale, Arizona, 85259, United States|Clinical Investigative Site 3100, Tucson, Arizona, 85741, United States|Clinical Investigative Site 3115, Sacramento, California, 95817, United States|Clinical Investigative Site 3117, Stanford, California, 94305, United States|Clinical Invesigative Site 3116, Sarasota, Florida, 34233, United States|Clinical Investigative Site 3101, Indianapolis, Indiana, 46202, United States|Clinical Investigative Site 3105, Kansas City, Kansas, 66160, United States|Clinical Investigative Site 3107, Lenexa, Kansas, 66214, United States|Clinical Investigative Site 3118, Baltimore, Maryland, 21201, United States|Clinical Investigative Site 3133, Worcester, Massachusetts, 01605, United States|Clinical Investigator 3136, Saint Louis, Missouri, 63100, United States|Clinical Investigative Site # 3135, Newark, New Jersey, 07103, United States|Clinical Investigative Site 3129, Latham, New York, 12110, United States|Clinical Investigative Site # 3128, New York, New York, 10032, United States|Clinical Investigative Site 3127, Schenectady, New York, 12308, United States|Clinical Investigative Site 3120, Stony Brook, New York, 11794, United States|Clinical Investigative Site 3119, Raleigh, North Carolina, 27607, United States|Clinical Investigator 3126, Akron, Ohio, 44320, United States|Clinical Investigative Site 3113, Cincinnati, Ohio, 45219, United States|Clinical Investigative Site 3130, Columbus, Ohio, 43221, United States|Clinical Investigator 3104, Portland, Oregon, 97225, United States|Clinical Investigative Site 3125, Philadelphia, Pennsylvania, 19107, United States|Clinical Investigative Site 3112, Burlington, Vermont, 05401, United States|Clinical Investigative Site 3111, Richmond, Virginia, 23298, United States|Clinical Investigative Site 3102, Kirkland, Washington, 98034, United States|Clinical Investigative Site # 1001, Fitzroy, 3065, Australia|Clinical Investigative Site 1000, Westmead, 2145, Australia|Clinical Investigative Site 1102, Amstetten, 3300, Austria|Clinical Investigative Site 1100, St Polten, 3100, Austria|Clinical Investigative Site 1101, Vienna, 1090, Austria|Clinical Investigative Site 1201, La Louviere, 7100, Belgium|Clinical Investigative Site # 1205, Liege, 4000, Belgium|Clinical Investigative Site 1204, Ottignies, 1340, Belgium|Clinical Investigative Site 1203, Sijsele-Damme, 8340, Belgium|Clinical Investigative Site 1302, Sofia, 1309, Bulgaria|Clinical Investigative Site 1301, Sofia, 1431, Bulgaria|Clinical Investigative Site 1303, Varna, 9010, Bulgaria|Clinical Investigative Site 1304, Varna, 9010, Bulgaria|Clinical Investigative Site 1401, Burbaby, British Columbia, V5G 2X6, Canada|Clinical Investigative Site # 1401, Burnaby, V5G 2X6, Canada|Clinical Investigative Site 1400, Ottawa, K1H 8L6, Canada|Clinical Investigative Site 1502, Brno, 656 91, Czechia|Clinical Investigative Site 1506, Jihlava, 586 33, Czechia|Clinical Investigative Site 1504, Olomouc, 775 20, Czechia|Clinical Investigative Site 1501, Ostrava-Poruba, 70852, Czechia|Clinical Investigative Site 1500, Praha, 128 08, Czechia|Clinical Investigative Site 1503, Teplice, Czechia|Clinical Investigative Site 1600, Helsinki, 00100, Finland|Clinical Investigative Site 1601, Hyvinkaa, 05800, Finland|Clinical Investigative Site 1603, Tampere, 33520, Finland|Clinical Investigative Site 1602, Turku, 20100, Finland|Clinical Investigative Site 1701, Montpellier Cedex, 34295, France|Clinical Investigative Site # 1806, Bayreuth, 95445, Germany|Clinical Investigative 1807, Berlin, 10117, Germany|Clinical Investigative Site 1803, Berlin, 13347, Germany|Clinical Investigative site 1800, Dusseldorf, 40225, Germany|Clinical Investigative Site 1802, Essen, 45147, Germany|Clinical Investigative Site 1805, Homburg/Saar, 66421, Germany|Clinical Investigative Site 1804, Ulm, 89081, Germany|Clinical Investigative Site 1905, Budapest, 1134, Hungary|Clinical Investigative Site # 1904, Budapest, H-1115, Hungary|Clinical Investigative Site 1908, Budapest, H-1145, Hungary|Clinical Investigative Site 1902, Gyor, 11-9024, Hungary|Clinical Investigative Site 1900, Petofi, 2500, Hungary|Clinical Investigative Site 1901, Szentpeteri-Kapu, 3526, Hungary|Clinical Investigative Site 2000, Ashkelon, 78278, Israel|Clinical Investigative Site 2003, Tel-Aviv, 64239, Israel|Clinical Investigative Site 2001, Tel-Hashomer, 52621, Israel|Clinical Investigative Site 2002, Zerifin, 70300, Israel|Clinical Investigative Site 2101, Gallarte, 21013, Italy|Clinical Investigative Site 2104, Genova, 16132, Italy|Clinical Investigative Site # 2106, Milan, 20132, Italy|Clinical Investigative Site 2102, Padova, 35128, Italy|Clinical Investigative Site 2103, Roma, 00189, Italy|Clinical Investigative Site 2105, Siena, 53100, Italy|Clinical Investigative Site 2203, Breda, 4818, Netherlands|Clinical Investigative Site 2202, Nijmegen, 6533, Netherlands|Clinical Investigative Site 2201, Sittard-Geleen, 6162, Netherlands|Clinical Investigative Site 2305, Katowice, 47-752, Poland|Clinical Investigative Site 2303, Poznan, 60-355, Poland|Clinical Investigative Site 2304, Warsaw, 02-957, Poland|Clinical Investigative Site 2302, Wroclaw, 50-044, Poland|Clinical Investigative Site 2400, Bucuresti, 022903, Romania|Clinical Investigative Site 2401, Cluj-Napoca, 428063, Romania|Clinical Investigative Site 2402, Timisoara, 300736, Romania|Clinical Investigative Site # 3202, Moscow, 127018, Russian Federation|Clinical Investigative Site # 3203, Nizhniy Novgorod, 603155, Russian Federation|Clinical Investigative Site # 3206, Pyatigorsk, 357538, Russian Federation|Clinical Investigative Site # 3201, Samara, 443095, Russian Federation|Clinical Investigative Site 3209, Saratov, 410030, Russian Federation|Clinical Investigative Site # 3204, St. Petersburg, 194354, Russian Federation|Clinical Investigative Site 3201, St. Petersburg, 197022, Russian Federation|Clinical Investigative Site 3200, St. Petersburg, 197376, Russian Federation|Clinical Investigative Site 3208, Ufa, 450005, Russian Federation|Clinical Investigative Site 2501, Belgrade, 11000, Serbia|Clinical Investigative Site 2503, Kragujevac, 34000, Serbia|Clinical Investigative Site 2502, Nis, 18000, Serbia|Clinical Investigative Site 2706, Barcelona, 08035, Spain|Clinical Investigative Site 2702, Madrid, 28040, Spain|Clinical Investigative Site 2705, Madrid, 28222, Spain|Clinical Investigative Site 2701, Malaga, 29010, Spain|Clinical Investigative Site 2700, Sevilla, 41009, Spain|Clinical Investigative Site 2704, Valencia, 46009, Spain|Clinical Investigative Site 2802, Goteburg, 41345, Sweden|Clinical Investigative Site 2800, Stockholm, 17176, Sweden|Clinical Investigative Site 2801, Umed, 90185, Sweden|Clinical Investigative Site 2901, Lugano, CH-6900, Switzerland|Clinical Investigative Site 2900, St Gallen, CH-9007, Switzerland|Clinical Investigative Site 3302, Chernihiv, 14029, Ukraine|Clinical Investigative Site 3303, Dnipropetrovsk, 49044, Ukraine|Clinical Investigative Site 3300, Kyiv, 03110, Ukraine|Clinical Investigative Site 3304, Odesa, 65000, Ukraine|Clinical Investigative Site 3003, Bristol, BS16 1LE, United Kingdom|Clinical Investigative Site 3004, Devon, PL6 SBX, United Kingdom|Clinical Investigative Site 3002, London, SE5 9RS, United Kingdom"
NCT04857489,Deficient T Regulatory Cell (Treg) Function in Patients With Relapsing Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04857489,RECRUITING,Relapse Remitting Multiple Sclerosis,,Thomas Jefferson University,,ALL,ADULT,,80,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-06-01,2023-06,2023-06,"Thomas Jefferson University, Philadelphia, Pennsylvania, 19107, United States"
NCT05541965,The Effect of Reflexology and Pelvic Floor Muscle Exercises (Kegel) on Urinary Incontinence in MS Patients,https://beta.clinicaltrials.gov/study/NCT05541965,RECRUITING,Multiple Sclerosis|Reflexology|Urinary Incontinence,OTHER: Reflexology and kegel exercises,Ondokuz Mayıs University,,FEMALE,"ADULT, OLDER_ADULT",NA,15,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2020-05-01,2022-09-30,2022-09-30,"Afitap ÖZDELİKARA, Samsun, 55200, Turkey"
NCT03551665,Protective Stepping & MS,https://beta.clinicaltrials.gov/study/NCT03551665,RECRUITING,Multiple Sclerosis,BEHAVIORAL: Protective step training,VA Office of Research and Development,Arizona State University,ALL,"ADULT, OLDER_ADULT",NA,51,FED,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2019-02-22,2023-09-01,2023-09-01,"Phoenix VA Health Care System, Phoenix, AZ, Phoenix, Arizona, 85012, United States"
NCT01802489,Amiloride Clinical Trial In Optic Neuritis,https://beta.clinicaltrials.gov/study/NCT01802489,COMPLETED,Optic Neuritis|Multiple Sclerosis,DRUG: Amiloride|DRUG: Placebo,University of Oxford,Multiple Sclerosis Society of Great Britain and Northern Ireland,ALL,ADULT,PHASE2,46,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-02,2015-11,2015-11,"John Radcliffe Hospital, Oxford, OX3 9DU, United Kingdom"
NCT02635789,Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC),https://beta.clinicaltrials.gov/study/NCT02635789,COMPLETED,Tuberous Sclerosis|Angiofibroma|Hypomelanotic Macule|Plaque,DRUG: NPC-12G gel|DRUG: Placebo gel,Nobelpharma,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,62,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2015-12,2016-10,2016-10,"Graduate School of Medicine, Osaka University, Suita, Osaka, 565-0871, Japan"
NCT04408742,"Relationship Between Pain, Anxiety and Fatigue and Knee Position Sense, Balance and Dual Task Performance During Menstrual Cycle in Females With Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT04408742,COMPLETED,Multiple Sclerosis|Menstrual Pain|Anxiety|Fatigue|Neurologic Symptoms,OTHER: pain|OTHER: fatigue|OTHER: anxiety|OTHER: position sense|OTHER: balance|OTHER: dual task performance,Ankara Yildirim Beyazıt University,,FEMALE,ADULT,,14,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-04-15,2019-10-20,2019-12-11,"Ankara Yıldırım Beyazıt University, Faculty of Health Sciences,Department of Physiotherapy and Rehabilitation, Ankara, Esenboğa, 06970, Turkey"
NCT00629642,Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00629642,COMPLETED,Multiple Sclerosis|Neurogenic Bladder|Spinal Cord Diseases,DRUG: Solifenacin Succinate|DRUG: Solifenacin Succinate|DRUG: Oxybutynin Hydrochloride|DRUG: Placebo,Astellas Pharma Inc,,ALL,"ADULT, OLDER_ADULT",PHASE4,249,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2008-03-14,2011-01-28,2011-01-28,"Brisbane, Australia|Melbourne, Australia|Perth, Australia|Randwick, Australia|Antwerpen, Belgium|Esneux, Belgium|Fraiture-en-Condroz, Belgium|Gent, Belgium|Leuven, Belgium|Melsbroek, Belgium|Brno, Czechia|Ceske Budejovice, Czechia|Prague, Czechia|Caen, France|Garches, France|Paris, France|Ploemeur, France|Berlin, Germany|Hagenow, Germany|Heidelberg, Germany|Kiel, Germany|Nyiregyhaza, Hungary|Sopron, Hungary|Szeged, Hungary|Firenze, Italy|Milan, Italy|Rome, Italy|Torino, Italy|Apeldoorn, Netherlands|Eindhoven, Netherlands|Nijmegen, Netherlands|St. Petersburg, 190089, Russian Federation|St. Petersburg, 196084, Russian Federation|San Juan de Alicante, Alicante, Spain|Badalona, Barcelona, Spain|Getafe, Madrid, Spain|La Coruna, Spain|Cardiff, United Kingdom|Newcastle Upon Tyne, United Kingdom"
NCT05075642,Multicenter Observational Study for the Evaluation in Clinical Practice of Urinary Disorders in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05075642,NOT_YET_RECRUITING,"Multiple Sclerosis|Urinary Bladder, Neurogenic",OTHER: Initial management of the urinary disorder/s identified during the screening phase,ASP 7 Ragusa,,ALL,"ADULT, OLDER_ADULT",,214,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-11,2023-05,2023-07,"Multiple Sclerosis Center of ASP 7 Ragusa, Vittoria, Ragusa, 97019, Italy"
NCT02980042,Safety of Switching From Rituximab to Ocrelizumab in MS Patients,https://beta.clinicaltrials.gov/study/NCT02980042,COMPLETED,Multiple Sclerosis,DRUG: Ocrelizumab|DRUG: Rituximab,"University of Colorado, Denver",,ALL,"ADULT, OLDER_ADULT",PHASE3,200,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2017-01-01,2019-03-06,2019-03-06,"University of Colorado Hospital, Aurora, Colorado, 80045, United States"
NCT01982942,"Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT01982942,COMPLETED,"Multiple Sclerosis, Primary Progressive|Multiple Sclerosis, Secondary Progressive",DRUG: ibudilast|DRUG: Placebo oral capsule,MediciNova,National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS)|National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",PHASE2,255,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2013-11,2017-05,2017-12,"University of Alabama at Birmingham, Birmingham, Alabama, 35294, United States|University of California Davis, Davis, California, 95817, United States|University of California Los Angeles, Los Angeles, California, 90095, United States|University of Colorado Denver, Denver, Colorado, 80045, United States|University of Miami Miller School of Medicine, Miami, Florida, 33136, United States|Emory University, Atlanta, Georgia, 30322, United States|Northwestern University, Evanston, Illinois, 60208, United States|University of Kansas Medical Center, Kansas City, Kansas, 66160, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Brigham and Women's Hospital, Boston, Massachusetts, 02445, United States|Washington University School of Medicine in St Louis, Saint Louis, Missouri, 63110, United States|Montefiore Medical Center, Bronx, New York, 10467, United States|University at Buffalo, The State University of New York, Buffalo, New York, 14260, United States|Cornell Medical College, New York, New York, 10021, United States|Columbia University Medical Center, New York, New York, 10032, United States|University of Rochester, Rochester, New York, 14627, United States|University at Stony Brook, The State University of New York, Stony Brook, New York, 11794, United States|University at Upstate, The State University of New York, Syracuse, New York, 13210, United States|University of Cincinnati, Department of Neurology, Cincinnati, Ohio, 45267, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|Ohio State University, Columbus, Ohio, 43210, United States|Oregon Health and Science University, Portland, Oregon, 97239, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, 15261, United States|Vanderbilt University, Nashville, Tennessee, 37235, United States|University of Texas Southwestern Medical Center, Dallas, Texas, 75390, United States|University of Utah, Salt Lake City, Utah, 84112, United States|University of Virginia Charlottesville, Charlottesville, Virginia, 22904, United States|Swedish Medical Center - Seattle, Seattle, Washington, 98122, United States"
NCT02601131,Post-transfusion Platelet Count,https://beta.clinicaltrials.gov/study/NCT02601131,COMPLETED,Leukemia|Multiple Sclerosis,BIOLOGICAL: Platelet transfusion,Region Skane,,ALL,"ADULT, OLDER_ADULT",,80,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-02,2016-09,2016-09,"Region Skåne, Lund, 22185, Sweden"
NCT04062331,Transcranial Magnetic Stimulation (TMS) in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04062331,UNKNOWN,Multiple Sclerosis,DEVICE: Transcranial Magnetic Stimulation (TMS)|DRUG: Placebos,Maimónides Biomedical Research Institute of Córdoba,Isaac Tunez-Fiñana|Eduardo Agüera-Morales,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1|PHASE2,90,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-10-01,2021-10-01,2022-10-01,
NCT04762342,Exercise and Neuroprotection in Older Persons With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04762342,RECRUITING,"Multiple Sclerosis|Sclerosis|Demyelinating Autoimmune Diseases, CNS|Autoimmune Diseases of the Nervous System|Demyelinating Diseases|Healthy Aging|Aging",OTHER: Resistance training (Power training),University of Aarhus,University of Southern Denmark|University of Copenhagen,ALL,"ADULT, OLDER_ADULT",NA,120,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-12-07,2024-03,2024-03,"Exercise Biology, Department of Public Health, Aarhus University, Aarhus, 8000, Denmark"
NCT05482542,Optimal Conditioning Regimen for Autologous Transplantation of Relapsing Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05482542,RECRUITING,"Multiple Sclerosis, Relapsing-Remitting",OTHER: Autologous hematopoietic stem cell transplantation|DRUG: Cyclophosphamide/ATG|DRUG: Cyclophosphamide/Rituximab,Scripps Health,,ALL,ADULT,NA,200,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-01-01,2027-07-01,2027-07-01,"Scripps Green Hospital, La Jolla, California, 92037, United States"
NCT02833142,"Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes",https://beta.clinicaltrials.gov/study/NCT02833142,COMPLETED,Multiple Sclerosis|Acute Optic Neuritis,DRUG: BIIB033 (opicinumab),Biogen,,ALL,ADULT,PHASE1,28,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2016-07,2016-11,2016-11,"Research Site, Madison, Wisconsin, 53704, United States"
NCT00841321,Trial of Ginkgo as a Treatment for Cognitive Problems in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00841321,COMPLETED,"Multiple Sclerosis|Cognitive Ability, General",DRUG: Ginkgo biloba|DRUG: Placebo,US Department of Veterans Affairs,,ALL,"ADULT, OLDER_ADULT",PHASE2,120,FED,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-01,2010-11,2010-12,"Portland VA Medical Center, Portland, OR, Portland, Oregon, 97239, United States|VA Puget Sound Health Care System, Seattle, Seattle, Washington, 98108, United States"
NCT04334031,Deployment o the Multidisciplinary Prospective Cohort Imminent,https://beta.clinicaltrials.gov/study/NCT04334031,RECRUITING,Chronic Inflammatory Disease|Angioedema|Severe Asthma|Lupus|Atopic Dermatitis|Psoriatic Arthritis|Multiple Sclerosis|Systemic Sclerosis|Behçet Disease,GENETIC: Biobanking with genetic analysis|OTHER: SF-12 questionnaire,"University Hospital, Lille",FHU IMMINeNT|FHU PRECISE: Projet Fédératif Hospitalo-Universitaire PREcision health in Complex Immune-mediated inflammatory diseaSEs|Fond de dotation de la Société Française de Dermatologie (SFD),ALL,"ADULT, OLDER_ADULT",NA,2200,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-07-20,2031-07,2031-07,"Hop Claude Huriez Chu Lille, Lille, 59037, France"
NCT03498131,Melatonin in Patients With Multiple Sclerosis (MS).,https://beta.clinicaltrials.gov/study/NCT03498131,ACTIVE_NOT_RECRUITING,Relapsing Remitting Multiple Sclerosis,DRUG: 3 mg Melatonin|DRUG: 5 mg Melatonin,Providence Health & Services,,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-05-09,2022-09,2022-12,"Providence MS Center, Portland, Oregon, 97225, United States"
NCT05571631,Effect of Arm Ergometer Exercise Training on Upper Extremity Function in People With Multiple Sclerosis.,https://beta.clinicaltrials.gov/study/NCT05571631,NOT_YET_RECRUITING,Multiple Sclerosis,OTHER: exercise,Dokuz Eylul University,,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-10-15,2024-09-15,2024-11-15,
NCT03243721,Gilenya's Impact on Cognitive Function and Thalamic Volumes,https://beta.clinicaltrials.gov/study/NCT03243721,COMPLETED,Multiple Sclerosis,DIAGNOSTIC_TEST: 7T MRI|DIAGNOSTIC_TEST: Neurocognitive testing,The Cleveland Clinic,Novartis Pharmaceuticals,ALL,ADULT,NA,20,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2017-10-20,2019-11-12,2019-11-12,"Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States"
NCT04786821,Acceptability of Exoskeleton Assisted Walking for Persons With Mobility Issues Due to Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04786821,UNKNOWN,"Multiple Sclerosis|Pathologic Processes|Sclerosis|Autoimmune Diseases of the Nervous System|Demyelinating Autoimmune Diseases, CNS|Autoimmune Diseases",BEHAVIORAL: Standard Exercise Training|DEVICE: Phoenix Exoskeleton suit,Sheffield Teaching Hospitals NHS Foundation Trust,,ALL,"ADULT, OLDER_ADULT",NA,24,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2021-09,2022-03,2022-09,
NCT05374031,Multiple Sclerosis Intimacy and Sexuality Questionnaire,https://beta.clinicaltrials.gov/study/NCT05374031,COMPLETED,Multiple Sclerosis|Sexual Dysfunction|Questionnaires,OTHER: descriptive study,Bozok University,,FEMALE,ADULT,,130,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-08-12,2021-12-10,2022-03-10,"Yozgat Bozok University, Yozgat, 66000, Turkey"
NCT02987621,Can Transcranial Direct Current Stimulation Improve Ambulation and Fatigue Resistance in People With MS?,https://beta.clinicaltrials.gov/study/NCT02987621,COMPLETED,Multiple Sclerosis,DEVICE: tDCS,Colorado State University,,ALL,ADULT,NA,14,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE,2016-11,2018-06,2018-06,"Department of Health and Exercise Science, Fort Collins, Colorado, 80523, United States"
NCT02205489,Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA,https://beta.clinicaltrials.gov/study/NCT02205489,COMPLETED,Relapsing-remitting Multiple Sclerosis,DRUG: Alemtuzumab GZ402673|DRUG: cetirizine|DRUG: ranitidine|DRUG: methylprednisolone|DRUG: methylprednisolone|DRUG: aciclovir|DRUG: esomeprazole|DRUG: ibuprofen|DRUG: paracetamol,"Genzyme, a Sanofi Company",,ALL,"ADULT, OLDER_ADULT",PHASE4,58,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-10,2016-04,2016-04,"Investigational Site Number 056002, Brugge, 8000, Belgium|Investigational Site Number 056001, Brussels, 1070, Belgium|Investigational Site Number 250009, Dijon, 21000, France|Investigational Site Number 250005, Lille Cedex, 59037, France|Investigational Site Number 250001, Lyon Bron, 69677, France|Investigational Site Number 250006, Nancy, France|Investigational Site Number 250010, Nantes, 44093, France|Investigational Site Number 250007, Nimes, 30029, France|Investigational Site Number 250008, PARIS Cedex 20, 75970, France|Investigational Site Number 250004, RENNES Cedex 9, 35033, France|Investigational Site Number 250003, Strasbourg Cedex 2, 67098, France|Investigational Site Number 250002, Toulouse, 31200, France|Investigational Site Number 528001, Breda, 4818CK, Netherlands|Investigational Site Number 528002, Rotterdam, 3079DZ, Netherlands|Investigational Site Number 724001, Barcelona, 08035, Spain|Investigational Site Number 724005, Bilbao, 48013, Spain|Investigational Site Number 724002, Madrid, 28040, Spain|Investigational Site Number 724006, Málaga, 29010, Spain|Investigational Site Number 724003, Sevilla, 41071, Spain|Investigational Site Number 724004, Valencia, 46009, Spain"
NCT04844489,Study of the Humoral Response to SARS-CoV-2 Variants and of the Cellular Response After Vaccination Against COVID-19 in Immunocompromised People,https://beta.clinicaltrials.gov/study/NCT04844489,COMPLETED,Autoimmune or Autoinflammatory Diseases|HIV|Multiple Sclerosis|Solid Tumors or Cancers|Solid Organ Transplant,OTHER: Blood samples for the study of the humoral response to SARS-CoV-2 variants and of the cellular response after vaccination against COVID-19,Assistance Publique - Hôpitaux de Paris,,ALL,"ADULT, OLDER_ADULT",NA,377,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2021-04-16,2022-11-24,2022-12-31,"Hospital Pitié-Salpêtrière - AP-HP, Paris, 75013, France"
NCT02769689,Methylprednisolone During the Switch Between Natalizumab and Fingolimod,https://beta.clinicaltrials.gov/study/NCT02769689,RECRUITING,Multiple Sclerosis,DRUG: Methylprednisolone|DRUG: Placebo|DRUG: natalizumab (NTZ)|DRUG: fingolimob (FTY),"University Hospital, Clermont-Ferrand",,ALL,"ADULT, OLDER_ADULT",PHASE4,56,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2019-06-12,2024-06-20,2024-07-20,"CHU Clermont-Ferrand, Clermont-Ferrand, 63003, France"
NCT04888689,Holter of Movement in Patients With Multiple Sclerosis in Controlled Environment.,https://beta.clinicaltrials.gov/study/NCT04888689,UNKNOWN,Multiple Sclerosis,DEVICE: Actimyo°|DEVICE: IMU,Dr. Stéphanie Delstanche,Sysnav|Centre Hospitalier Universitaire de Liege,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-02-04,2022-02-04,2022-02-04,"Centre Hospitalier Régional de la Citadelle, Liège, 4000, Belgium|Laboratoire d'Analyse du Mouvement Humain, Liège, 4000, Belgium"
NCT01604265,A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01604265,COMPLETED,Multiple Sclerosis|Neuropathic Pain,DRUG: Placebo|DRUG: Sativex,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,66,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2002-03,2002-08,2002-08,"Walton Centre for Neurology and Neurosurgery, Liverpool, L9 7LJ, United Kingdom"
NCT01235221,Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.,https://beta.clinicaltrials.gov/study/NCT01235221,COMPLETED,Multiple Sclerosis,DRUG: BIIB041 (Fampridine-SR),Biogen,Acorda Therapeutics,ALL,"ADULT, OLDER_ADULT",PHASE3,38,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2010-12,2012-06,2012-06,"Foothills Medical Center, Calgary, Alberta, Canada|University of British Columbia, Vancouver, British Columbia, Canada|River Valley Health, Fredericton, New Brunswick, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|Ottawa Hospital General Campus, Ottawa, Ontario, Canada"
NCT03290131,A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS,https://beta.clinicaltrials.gov/study/NCT03290131,COMPLETED,"Multiple Sclerosis|Spasticity, Muscle",DRUG: Arbaclofen|DRUG: Placebo,"RVL Pharmaceuticals, Inc.",Osmotica Pharmaceutical US LLC,ALL,"ADULT, OLDER_ADULT",PHASE3,536,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2018-01-28,2018-12-03,2019-01-02,"Grodno Regional Clinical Hospital, Grodno, Belarus|Minsk City Clinical Hospital #5, Minsk, Belarus|Minsk Scientific and Practical Center of Surgery, Transplantology and Hematology, Minsk, Belarus|Republican Research and Development Center for Neurology and Neurosurgery, Minsk, Belarus|Vitebsk Regional Diagnostic Center, Vitebsk, Belarus|University Clinical Centre of the Republic of Srpska, Clinic of Neurology, Banja Luka, Bosnia and Herzegovina|University Clinical Hospital Mostar, Clinic of Neurology, Mostar, Bosnia and Herzegovina|Multiprofile Hospital for Active Treatment - Pleven within the structure of Military Medical Academy, Sofia, Pleven, Bulgaria|University Multiprofile Hospital for Active Treatment ""Dr. Georgi Stranski"", Pleven, Clinic of Neurological Diseases, Pleven, Bulgaria|Medical Center ""Rusemed"" EOOD, Ruse, Bulgaria|Multiprofile Hospital for Active Treatment ""ACIBADEM City Clinic Tokuda Hospital"", Sofia, Neurology and Sleep Medicine Clinic, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment of Neurology and Psychiatry ""Sveti Naum"", Sofia, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment ""Sveti Ivan Rilski"", Sofia, Clinic of Neurology Diseases, Sofia, Bulgaria|Clinical Hospital Center Osijek, Clinic of Neurology, Osijek, Croatia|Clinical Hospital Center Rijeka, Department of Neurology, Rijeka, Croatia|General Hospital Varazdin, Department of Neurology, Varaždin, Croatia|Clinical Hospital Dubrava, Department of Neurology, Zagreb, Croatia|Institute for Emergency Medicine, Chisinau, Moldova, Republic of|National Institute of Neurology and Neurosurgery, Chisinau, Moldova, Republic of|Dendryt Medical Center, Katowice, Poland|Neuro-Medic, Katowice, Poland|Medical Practice Professor K. Rejdak, Lublin, Poland|MED-Polonia, Sp. z o.o. (LLC), Poznań, Poland|""MEDYK"" Stanislaw Mazur Sp. z o.o. (LLC) Medical Centre, Rzeszów, Poland|NeuroProtect Medical Center, Warsaw, Poland|Neurology Center Krzysztof Selmaj, Łódź, Poland|Clinical Center of Serbia, Belgrade, Serbia|Clinical Hospital Center Zemun, Department of Neurology, Belgrade, Serbia|Clinical Hospital Center Zvezdara, Belgrade, Serbia|Clinical Center Kragujevac, Kragujevac, Serbia"
NCT03597451,The Effects of Muscles Strength on Physical Performance in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03597451,COMPLETED,Multiple Sclerosis,,Gazi University,,ALL,"ADULT, OLDER_ADULT",,87,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-08-13,2020-02-28,2020-03-06,"Gazi University, Ankara, Turkey"
NCT01569451,Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate,https://beta.clinicaltrials.gov/study/NCT01569451,COMPLETED,Multiple Sclerosis,DRUG: Rituximab|DRUG: Glatiramer Acetate|OTHER: Placebo,"University of Colorado, Denver","Rocky Mountain MS Research Group, LLC",ALL,ADULT,PHASE2,53,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-02,2015-05,2015-05,"University of Colorado Hospital, Aurora, Colorado, 80045, United States"
NCT01141751,An Observational Study Comparing Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) in Relapsing Multiple Sclerosis (RMS) Patients on Long-term Rebif® Therapy,https://beta.clinicaltrials.gov/study/NCT01141751,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",,"Merck KGaA, Darmstadt, Germany",,ALL,"CHILD, ADULT, OLDER_ADULT",,334,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2005-09,2011-06,2011-06,
NCT03737851,A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03737851,COMPLETED,Multiple Sclerosis (MS),DRUG: elezanumab|DRUG: placebo,AbbVie,,ALL,"ADULT, OLDER_ADULT",PHASE2,208,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2018-12-11,2021-01-07,2021-09-09,"University of Alabama at Birmingham - Main /ID# 204618, Birmingham, Alabama, 35233, United States|St. Josephs Hospital and Med Center /ID# 204197, Phoenix, Arizona, 85013, United States|Sutter East Bay Medical Foundation-Jordon Research and Education Dev. Inst. /ID# 204249, Berkeley, California, 94705-2017, United States|The Research Center of Southern California /ID# 204269, Carlsbad, California, 92011-4213, United States|Vladimir Royter MD /ID# 204392, Hanford, California, 93230-5787, United States|UC Irvine Health /ID# 205728, Irvine, California, 92697, United States|Stanford MS Center /ID# 204283, Palo Alto, California, 94304-1416, United States|UC Davis Health-Neurological Surgery /ID# 204188, Sacramento, California, 95817-2307, United States|UCSF School of Medicine - Neurology /ID# 204251, San Francisco, California, 94143-0003, United States|University of Colorado School of Medicine, Dept of Neurology /ID# 204250, Aurora, Colorado, 80045-2527, United States|Advanced Neurosciences Research, LLC /ID# 204289, Fort Collins, Colorado, 80528, United States|The University of Chicago Medical Center /ID# 205319, Chicago, Illinois, 60637-1443, United States|Indiana Univ School Medicine /ID# 204891, Indianapolis, Indiana, 46202, United States|Rowe Neurology Institute /ID# 204391, Lenexa, Kansas, 66214, United States|The NeuroMedical Center /ID# 204253, Baton Rouge, Louisiana, 70810, United States|Ochsner Medical Center /ID# 204189, New Orleans, Louisiana, 70121-2429, United States|Duplicate_Parexel International /ID# 204273, Baltimore, Maryland, 21225, United States|International Neurorehabilitation Institute /ID# 213332, Lutherville, Maryland, 21093-6016, United States|Mass General Hospital /ID# 204279, Boston, Massachusetts, 02114-4724, United States|Michigan Institute for Neurological Disorders (MIND) /ID# 204194, Farmington Hills, Michigan, 48334, United States|Memorial Neurological Institute and Center for Multiple Sclerosis /ID# 206328, Owosso, Michigan, 48867-2116, United States|Ridgeview Specialty Clinic Chaska - Neurology /ID# 204383, Chaska, Minnesota, 55318-4551, United States|Washington University School of Medicine /ID# 204388, Saint Louis, Missouri, 63110-1010, United States|The MS Center for Innovations in Care at Missouri Baptist Medical Center /ID# 205433, Saint Louis, Missouri, 63131-2322, United States|Cleveland Clinic Lou Ruvo Cent /ID# 204745, Las Vegas, Nevada, 89106-0100, United States|Oklahoma Med Res. Foundation /ID# 204389, Oklahoma City, Oklahoma, 73104, United States|Providence Neurological Specialties - West /ID# 204248, Portland, Oregon, 97225-6646, United States|Thomas Jefferson University /ID# 204281, Philadelphia, Pennsylvania, 19107, United States|Advanced Neurosciences Institute /ID# 204557, Franklin, Tennessee, 37064, United States|KCA Neurology - Franklin /ID# 204208, Franklin, Tennessee, 37067-5914, United States|Tri-State Mountain Neurology /ID# 204252, Johnson City, Tennessee, 37604, United States|Neurology Consultants of Dallas - LBJ Fwy /ID# 204398, Dallas, Texas, 75243-1188, United States|UT HSC Multiple Sclerosis Research Group - Houston /ID# 206418, Houston, Texas, 77030-1501, United States|Dr. Bhupesh Dihenia, MD, PA /ID# 207839, Lubbock, Texas, 79410, United States|Central Texas Neurology Consul /ID# 204268, Round Rock, Texas, 78681, United States|Integrated Neurology Services /ID# 204261, Alexandria, Virginia, 22310, United States|Evergreen Neuroscience Institute /ID# 204203, Kirkland, Washington, 98034-3029, United States|Virginia Mason - Seattle Orthapedics /ID# 205440, Seattle, Washington, 98101, United States|Swedish MS Center /ID# 204198, Seattle, Washington, 98122-5698, United States|University of Washington Medicine MS Center /ID# 205852, Seattle, Washington, 98133-8400, United States|West Virginia Univ School Med /ID# 204292, Morgantown, West Virginia, 26506, United States|Froedtert Memorial Lutheran Hospital /ID# 204202, Milwaukee, Wisconsin, 53226-3522, United States|University of British Columbia - MS & NMO Clinical Trials Group, Djavad Mowafagh /ID# 204841, Vancouver, British Columbia, V6T 1Z3, Canada|Duplicate_London Health Sciences Centre - University Hospital /ID# 204848, London, Ontario, N6A 5A5, Canada|The Ottawa Hospital /ID# 204842, Ottawa, Ontario, K1H 8L6, Canada|Unity Health Toronto - St. Michael's Hospital /ID# 206214, Toronto, Ontario, M5B 1W8, Canada|Recherche Sepmus Inc. /ID# 212851, Greenfield Park, Quebec, J4V 2J2, Canada|Crchum /Id# 204844, Montreal, Quebec, H2X 0A9, Canada|Montreal Neurological Institut /ID# 204843, Montreal, Quebec, H3A 2B4, Canada"
NCT02823951,"Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®",https://beta.clinicaltrials.gov/study/NCT02823951,COMPLETED,Relapsing-remitting Multiple Sclerosis,DRUG: Rebif|DRUG: Tecfidera,IMS HEALTH GmbH & Co. OHG,EMD Serono,ALL,ADULT,,479,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-02,2017-04,2018-02,"Alabama Neurology Associates, Birmingham, Alabama, 35209, United States|Colorado Springs Neurological Associates, Colorado Springs, Colorado, 80907, United States|Savannah Neurology Specialists, Savannah, Georgia, 31406, United States|Northshore University, Evanston, Illinois, 60201, United States|OSF Multi-specialty Group d/b/a Illinois Neurological Institute, Peoria, Illinois, 61637, United States|St Elizabeths/ Dragonfly Research, Brighton, Massachusetts, 02135, United States|Lahey Clinic, Burlington, Massachusetts, 01805, United States|Minneapolis Clinic of Neurology, Golden Valley, Minnesota, 55422, United States|Washington university, Saint Louis, Missouri, 63110, United States|University of Nebraska Medical Center, Lincoln, Nebraska, 68588, United States|University of Buffalo Clinical and Translational research Center, Buffalo, New York, 14203, United States|Neurological Associates of Long Island, Lake Success, New York, 11042, United States|Onsite Clinical Solutions, Charlotte, North Carolina, 28277, United States|Raleigh Neurology Associates, Raleigh, North Carolina, 27607, United States|Dayton Center for Neurological Disorders, Centerville, Ohio, 45459, United States|Oak Clinic-Multiple Sclerosis, Uniontown, Ohio, 44685, United States|Providence St. Vincent Medical Center, Portland, Oregon, 97228, United States|The university of Texas Health Science Center at San Antonio, San Antonio, Texas, 78229, United States|University of Vermont, Burlington, Vermont, 05405, United States|Blacksburg Neurology, Christiansburg, Virginia, 24073, United States|MultiCare Health System, Tacoma, Washington, 98405, United States|Neuroscience Group, Neenah, Wisconsin, 54956, United States|Centre Hospitalier de l'Universite de Montreal, Montréal, Quebec, H2X 0A9, Canada"
NCT01626248,Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active Control,https://beta.clinicaltrials.gov/study/NCT01626248,COMPLETED,Multiple Sclerosis,,"John F. Foley, MD",Biogen|Elan Pharmaceuticals,ALL,"ADULT, OLDER_ADULT",,164,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-07,2013-03,2013-04,"Rocky Mountain MS Clinic, Salt Lake City, Utah, 84103, United States"
NCT03744351,B Cell Differentiation in MS,https://beta.clinicaltrials.gov/study/NCT03744351,RECRUITING,Multiple Sclerosis,OTHER: Biological Samples|OTHER: Biological Samples|OTHER: Biological Samples|OTHER: Biological Samples,Rennes University Hospital,,ALL,"ADULT, OLDER_ADULT",NA,170,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2019-02-25,2024-02,2024-02,"Rennes University Hospital, Rennes, 35033, France"
NCT05242731,Telemonitoring and Connected Care Applied to Multiple Sclerose,https://beta.clinicaltrials.gov/study/NCT05242731,RECRUITING,Multiple Sclerosis,"DEVICE: MSmonitor, a self-management/education program with e-health interventions|DEVICE: Video calling program ""Better-close""|DEVICE: Researchmanager program",Isala,,ALL,"ADULT, OLDER_ADULT",NA,208,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-04-29,2024-04-29,2025-12-31,"University Medical Center Groningen, Groningen, Nederland, 9713AV, Netherlands|University of Maastricht, Maastricht, Nederland, 6200MD, Netherlands|MS4research Institute, Nijmegen, Nederland, 6522KJ, Netherlands|Isala, Zwolle, Nederland, 7943KA, Netherlands"
NCT00390221,Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00390221,COMPLETED,Relapsing-Remitting Multiple Sclerosis,BIOLOGICAL: BIIB019 (Daclizumab High Yield Process)|DRUG: Placebo,Biogen,AbbVie,ALL,ADULT,PHASE2,621,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2008-02,2011-05,2011-08,"Research Site, Brno, Czech Republic|Research Site, Olomouc, Czech Republic|Research Site, Plzen, Czech Republic|Research Site, Teplice, Czech Republic|Research Site, Erlangen, Germany|Research Site, Marburg, Germany|Research Site, Osnabrueck, Germany|Research Site, Regensburg, Germany|Research Site, Rostock, Germany|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Esztergom, Hungary|Research Site, Gyor, Hungary|Research Site, Kecskemet, Hungary|Research Site, Miskolc, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Siofok, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Andra-Pradeash, India|Research Site, Bangalore, India|Research Site, Chennai, India|Research Site, Kolkata, India|Research Site, Mumbai, India|Research Site, Rajasthan, India|Research Site, Visakhapatnam, India|Research Site, Bialystok, Poland|Research Site, Gdansk, Poland|Research Site, Katowice, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Warsaw, Poland|Research Site, Warszawa, Poland|Research Site, Kazan, Russian Federation|Research Site, Krasnoyarsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Samara, Russian Federation|Research Site, Smolensk, Russian Federation|Research Site, St Petersburg, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Chernivtsi, Ukraine|Research Site, Dnipropetrovsk, Ukraine|Research Site, Donetsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kiev, Ukraine|Research Site, Lviv, Ukraine|Research Site, Poltava, Ukraine|Research Site, Zaporozhye, Ukraine|Research Site, London, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Plymouth, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Stoke-on-Trent, United Kingdom"
NCT01302431,Nurse-Led Manualized Telephone Support Intervention,https://beta.clinicaltrials.gov/study/NCT01302431,COMPLETED,Multiple Sclerosis,OTHER: Manualised nurse-led telephone support,"University of Dublin, Trinity College",,ALL,"ADULT, OLDER_ADULT",NA,71,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2011-04,2013-10,2014-03,"Site 1, Dublin, 24, Ireland|Dublin, Ireland"
NCT02688231,Task-oriented Upper Limb Training in MS,https://beta.clinicaltrials.gov/study/NCT02688231,COMPLETED,Multiple Sclerosis,OTHER: Task-oriented upper limb training|OTHER: Control intervention,Hasselt University,,ALL,"ADULT, OLDER_ADULT",NA,21,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-01,2018-03,2018-03,"Revalidatie en MS centrum, Overpelt, Limburg, 3900, Belgium|Hasselt University, Diepenbeek, 3560, Belgium"
NCT03138421,Central Pain Study for ABX-1431,https://beta.clinicaltrials.gov/study/NCT03138421,COMPLETED,Neuromyelitis Optica Spectrum Disorder|Transverse Myelitis|Multiple Sclerosis|Longitudinally Extensive Transverse Myelitis,DRUG: ABX-1431 HCl|DRUG: Placebo,Abide Therapeutics,,ALL,"ADULT, OLDER_ADULT",PHASE1,9,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-08-01,2018-07-23,2018-07-24,"The Walton Centre, Liverpool, L97LJ, United Kingdom|Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, United Kingdom"
NCT02301247,Treating New Learning and Memory Deficits in Progressive Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT02301247,COMPLETED,"Multiple Sclerosis, Progressive|Cognition - Other|Memory Impairment",BEHAVIORAL: Memory retraining exercises|BEHAVIORAL: Placebo control memory exercises,Kessler Foundation,International Progressive MS Alliance,ALL,ADULT,NA,32,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2014-11,2017-04-02,2017-04-02,"Kessler Foundation, West Orange, New Jersey, 07052, United States"
NCT03360487,Effect of Photobiomodulation Treatment in Individuals With Multiple Sclerosis:,https://beta.clinicaltrials.gov/study/NCT03360487,UNKNOWN,Multiple Sclerosis,RADIATION: Photobiomodulation in the sublingual region|RADIATION: Photobiomodulation in the spinal cord|RADIATION: Photobiomodulation in the radial artery,University of Nove de Julho,,ALL,ADULT,PHASE2,34,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-01-01,2018-12-31,2019-02-28,"UNINOVE, São Paulo, SP, 01504-001, Brazil"
NCT00118547,Health Behavior Change in Chronic Disease Management,https://beta.clinicaltrials.gov/study/NCT00118547,COMPLETED,Multiple Sclerosis,BEHAVIORAL: In home monitoring with feedback,US Department of Veterans Affairs,,ALL,"ADULT, OLDER_ADULT",NA,20,FED,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2005-09,2007-09,2007-09,"VA Puget Sound Health Care System, Seattle, Seattle, Washington, 98108, United States"
NCT01465087,Nanotechnology for Detection of Multiple Sclerosis Compared to Autoimmune and Neurological Diseases by Exhaled Samples,https://beta.clinicaltrials.gov/study/NCT01465087,COMPLETED,Multiple Sclerosis,OTHER: NA-NOSE artificial olfactory system,Carmel Medical Center,"Technion, Israel Institute of Technology",ALL,"ADULT, OLDER_ADULT",NA,314,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2011-12,2014-02,2015-01,"Multiple Sclerosis Clinic, Carmel Medical Center, Haifa, Israel"
NCT03357887,Prognostic Value of Three New Biomarkers of Multiple Sclerosis in Patients With Radiologically Isolated Syndrome,https://beta.clinicaltrials.gov/study/NCT03357887,COMPLETED,Multiple Sclerosis|Radiologically Isolated Syndrome,OTHER: Analysis of cerebrospinal fluid and serum,Centre Hospitalier Universitaire de Nīmes,,ALL,"CHILD, ADULT, OLDER_ADULT",,100,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-07-01,2018-12-31,2018-12-31,"CHU Nimes, Nîmes, 30029, France"
NCT04283747,Rituximab-Induced Hypogammaglobulinemia in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04283747,UNKNOWN,Multiple Sclerosis|Hypogammaglobulinemia,DIAGNOSTIC_TEST: Serum immunoglobulin titer,Mazandaran University of Medical Sciences,,ALL,"ADULT, OLDER_ADULT",,170,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-02-28,2022-10,2022-12,"Bu Ali Sina hospital, Sari, Iran, Islamic Republic of"
NCT04080687,Effect of Ankle-foot Orthoses on Balance Confidence,https://beta.clinicaltrials.gov/study/NCT04080687,COMPLETED,Peripheral Nerve Disease|Peripheral Nerve Injury Lower Limb|Poliomyelitis|Cerebral Palsy|Multiple Sclerosis,DEVICE: Ankle-foot orthosis,"University Rehabilitation Institute, Republic of Slovenia",,ALL,"ADULT, OLDER_ADULT",,150,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-02-06,2021-02-12,2021-02-12,"University Rehabilitation Institute, Republic of Slovenia, Ljubljana, 1000, Slovenia"
NCT01219647,Exercise as a Strategy to Treat Cognitive Dysfunction in Persons With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01219647,COMPLETED,Multiple Sclerosis,BEHAVIORAL: exercise|BEHAVIORAL: stretching,"University of California, Los Angeles","California State University, Northridge",ALL,ADULT,PHASE1|PHASE2,35,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2010-07,2014-08,2014-08,"UCalifornia at Los Angeles, Los Angeles, California, 90095, United States|CAl State University at Northridge, Northridge, California, 91330, United States"
NCT04860947,"Assessment of NfL and GFAP Levels, Atrophy of the Macula GCC by OCT and Whole Brain Atrophy by MRI to Predict Evolution of Neurological Disability in MS Patients",https://beta.clinicaltrials.gov/study/NCT04860947,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,DIAGNOSTIC_TEST: Brain MRI|DIAGNOSTIC_TEST: Spinal Cord MRI|DIAGNOSTIC_TEST: Retinal imaging,Centre Hospitalier Universitaire de Nīmes,Institut de Recherches en Biothérapie,ALL,"ADULT, OLDER_ADULT",,200,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-06-25,2026-06,2026-06,"CHU de Nimes, Nîmes, 30029, France"
NCT01611987,The Role of Exercise in Modifying Outcomes for People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01611987,UNKNOWN,Multiple Sclerosis,OTHER: MStep|OTHER: General guideline approach,McGill University,,ALL,"ADULT, OLDER_ADULT",NA,240,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2012-09,2017-12,2018-12,"Sunnybrook Hospital, Toronto, Ontario, M4N 3M5, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Toronto Rehabiliation Institute, Toronto, Ontario, Canada|CHUM, Montreal, Quebec, Canada|Muhc - Mnh, Montreal, Quebec, Canada"
NCT03200899,Computer Assisted Cognitive Rehabilitation for Persons With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03200899,UNKNOWN,Multiple Sclerosis,BEHAVIORAL: MAPSS-MS|OTHER: Usual Care plus computer games,University of Texas at Austin,,ALL,ADULT,NA,220,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2014-01,2017-11,2018-06,"The University of Texas at Austin, Austin, Texas, 78701, United States"
NCT03550170,Fatigue Management Programs for People With MS,https://beta.clinicaltrials.gov/study/NCT03550170,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,"BEHAVIORAL: Teleconference|BEHAVIORAL: Internet|BEHAVIORAL: 1-to-1, in-person",Case Western Reserve University,"Patient-Centered Outcomes Research Institute|University of Illinois at Chicago|University of Minnesota|Queen's University, Kingston, Ontario|Dalhousie University|The Cleveland Clinic",ALL,"ADULT, OLDER_ADULT",NA,582,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2019-03-01,2023-04-28,2024-06-30,"University of Illinois at Chicago, Chicago, Illinois, 60612, United States|University of Minnesota, Minneapolis, Minnesota, 55455, United States|Case Western Reserve University, Cleveland, Ohio, 44106, United States"
NCT03838770,tDCS for the Management of Multiple Sclerosis Related Fatigue,https://beta.clinicaltrials.gov/study/NCT03838770,COMPLETED,Multiple Sclerosis,DEVICE: Active tDCS|DEVICE: sham tDCS,NYU Langone Health,National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",NA,122,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2019-04-04,2021-06-30,2021-06-30,"NYU Langone Health, New York, New York, 10016, United States"
NCT04233970,Development and Evaluation of a Web-based Programme on Relapse Management for People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04233970,ACTIVE_NOT_RECRUITING,"Multiple Sclerosis, Relapsing-Remitting",BEHAVIORAL: web-based intervention programme|BEHAVIORAL: web-based information material offered via the same platform (broca®) in addition to usual care,Universitätsklinikum Hamburg-Eppendorf,"University of Cologne|University Medical Center Goettingen|Heinrich-Heine University, Duesseldorf|Gaia AG|Deutsche Multiple Sklerose Gesellschaft (DMSG), Bundesverband e.V.|MS-Stiftung Trier|BBK Dachverband e.V.",ALL,"ADULT, OLDER_ADULT",NA,160,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2020-02-17,2023-03-31,2023-03-31,"Universitätsklinikum Hamburg-Eppendorf, Hamburg, 20246, Germany"
NCT01303770,Development and Evaluation of a Cognitive Rehabilitation Program for Persons With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01303770,UNKNOWN,Multiple Sclerosis|Cognitive Impairment,BEHAVIORAL: Self-management cognitive rehabilitation group intervention|BEHAVIORAL: Control intervention,Tel Aviv University,,ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2011-02,2014-12,2014-12,"Rabin Medical Center, Multiple Sclerosis Clinic, Petah Tikva, 49100, Israel"
NCT02403570,Rotating Frame Relaxation Imaging in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02403570,COMPLETED,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis, Chronic Progressive",OTHER: Brain MRI,Turku University Hospital,,ALL,"ADULT, OLDER_ADULT",,21,OTHER_GOV,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-02,2016-12-31,2016-12-31,"Division of Clinical Neurosciences, Turku University Hospital, Turku, FI-20520, Finland"
NCT04705870,Comparison of the Performance of an Optimized 3D EPI SWI Sequence and a Non-EPI QSM SWI Sequence in Detecting the Central Vein Sign in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04705870,RECRUITING,Multiple Sclerosis,DEVICE: cerebral MRI,Fondation Ophtalmologique Adolphe de Rothschild,,ALL,"ADULT, OLDER_ADULT",,60,NETWORK,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-06-02,2023-06,2023-06,"Hhopital fondation adolphe de rothschild, Paris, 75019, France"
NCT03262870,Gut Microbiota and Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03262870,UNKNOWN,Multiple Sclerosis,,Assiut University,,ALL,ADULT,,40,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-01-04,2019-01-04,2020-01-04,
NCT04288011,Validation of the BeCare Multiple Sclerosis Assessment App,https://beta.clinicaltrials.gov/study/NCT04288011,ENROLLING_BY_INVITATION,Multiple Sclerosis,,BeCare Link LLC,Yale University,ALL,"ADULT, OLDER_ADULT",,30,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-02-26,2022-12-20,2023-02-20,"Yale University School of Medicine, New Haven, Connecticut, 06520, United States"
NCT01407211,"Impact of Vitamin A on Gene Expression, in Multiple Sclerosis Patient",https://beta.clinicaltrials.gov/study/NCT01407211,UNKNOWN,Relapsing Remitting Multiple Sclerosis,DIETARY_SUPPLEMENT: vitamin A,Tehran University of Medical Sciences,,ALL,ADULT,PHASE4,30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-04,2013-04,2013-09,"Tehran University of Medical Sciences, School of Public Health, Tehran, Iran, Islamic Republic of"
NCT02090413,Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02090413,COMPLETED,Relapsing-Remitting Multiple Sclerosis,DRUG: dimethyl fumarate|DRUG: acetylsalicylic acid|DRUG: ASA-Placebo,Biogen,,ALL,"ADULT, OLDER_ADULT",PHASE4,241,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2014-05,2015-02,2015-11,"Research Site, Cork, Ireland|Research Site, Dublin, Dublin 4, Ireland|Research Site, Dublin, Dublin 7, Ireland|Research Site, Dublin, Dublin 9, Ireland|Research Site, Basingstoke, RG24 9NA, United Kingdom|Research Site, Birmingham, B15 2TH, United Kingdom|Research Site, Cardiff, CF14 4XW, United Kingdom|Research Site, Edinburgh, EHA 2XU, United Kingdom|Research Site, Exeter, EX2 5DW, United Kingdom|Research Site, Glasgow, G51 4TH, United Kingdom|Research Site, Leicester, LE5 4PW, United Kingdom|Research Site, Liverpool, L9 7LJ, United Kingdom|Research Site, London, SE5 9RS, United Kingdom|Research Site, London, SW17 0QT, United Kingdom|Research Site, London, WC1N 3BG, United Kingdom|Research Site, Newcastle upon Tyne, NE1 4LP, United Kingdom|Research Site, Norwich, NR4 7UY, United Kingdom|Research Site, Nottingham, NG7 2UH, United Kingdom|Research Site, Plymouth, PL6 8BX, United Kingdom|Research Site, Salford, M6 8HD, United Kingdom|Research Site, Swansea, SA6 6NL, United Kingdom"
NCT01772199,Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01772199,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: GSK239512|DRUG: Placebo,GlaxoSmithKline,,ALL,ADULT,PHASE2,131,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-02,2014-09,2014-09,"GSK Investigational Site, Sofia, 1113, Bulgaria|GSK Investigational Site, Sofia, 1309, Bulgaria|GSK Investigational Site, Sofia, 1431, Bulgaria|GSK Investigational Site, Calgary, Alberta, T2N 2T9, Canada|GSK Investigational Site, Edmonton, Alberta, T6G 1Z1, Canada|GSK Investigational Site, Ottawa, Ontario, K1H 8L6, Canada|GSK Investigational Site, Gatineau, Quebec, J9J 0A5, Canada|GSK Investigational Site, Montreal, Quebec, H3A 2B4, Canada|GSK Investigational Site, Jihlava, 586 33, Czech Republic|GSK Investigational Site, Olomouc, 775 20, Czech Republic|GSK Investigational Site, Teplice, 415 29, Czech Republic|GSK Investigational Site, Ulm, Baden-Wuerttemberg, 89073, Germany|GSK Investigational Site, Alzenau, Bayern, 63755, Germany|GSK Investigational Site, Unterhaching, Bayern, 82008, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, 50935, Germany|GSK Investigational Site, Muenster, Nordrhein-Westfalen, 48149, Germany|GSK Investigational Site, Dresden, Sachsen, 01069, Germany|GSK Investigational Site, Leipzig, Sachsen, 04103, Germany|GSK Investigational Site, Berlin, 10961, Germany|GSK Investigational Site, Berlin, 12163, Germany|GSK Investigational Site, Hamburg, 20249, Germany|GSK Investigational Site, Hamburg, 22083, Germany|GSK Investigational Site, Barcelona, 08035, Spain|GSK Investigational Site, Barcelona, 08036, Spain|GSK Investigational Site, Madrid, 28034, Spain|GSK Investigational Site, Madrid, 28040, Spain|GSK Investigational Site, Madrid, 28046, Spain|GSK Investigational Site, Majadahonda (Madrid), 28222, Spain|GSK Investigational Site, Malaga, 29010, Spain|GSK Investigational Site, Sevilla, 41009, Spain|GSK Investigational Site, Stockholm, SE-141 86, Sweden|GSK Investigational Site, Donetsk, 83099, Ukraine|GSK Investigational Site, Ivano-Frankivsk, 76008, Ukraine|GSK Investigational Site, Kharkiv, 61068, Ukraine|GSK Investigational Site, Kyiv, 04107, Ukraine|GSK Investigational Site, Lutsk, 43005, Ukraine|GSK Investigational Site, Lviv, 79010, Ukraine|GSK Investigational Site, Poltava, 36024, Ukraine|GSK Investigational Site, Vinnitsa, 21005, Ukraine|GSK Investigational Site, London, NW1 2BU, United Kingdom|GSK Investigational Site, London, SE5 9RS, United Kingdom|GSK Investigational Site, Romford, RM7 0AG, United Kingdom|GSK Investigational Site, Sheffield, S10 2JF, United Kingdom"
NCT03674099,Imatinib for Multiple Sclerosis (MS) Relapses,https://beta.clinicaltrials.gov/study/NCT03674099,RECRUITING,Multiple Sclerosis,DRUG: Imatinib Mesylate|DRUG: Methylprednisolone,Tomas Olsson,The Swedish Research Council,ALL,ADULT,PHASE2,200,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2018-10-01,2022-12-31,2023-07-30,"Rigshospitalet, Copenhagen, 2100, Denmark|Hamburg-Eppendorf, Hamburg, 20246, Germany|UKSH Campus Kiel, Kiel, 24105, Germany|Uniklinik Köln, Köln, 50937, Germany|Haukeland sjukhus, Bergen, 5021, Norway|Akershus University Hospital, Lørenskog, 1478, Norway|Rikshospitalet, Oslo, Oslo, 0372, Norway|Ullevåls sjukhus, Oslo, 0424, Norway|Karolinska Universityhospital, Huddinge, Huddinge, Stockholm, 14186, Sweden|Neurology Sahlgrenska Hospital, Göteborg, 41345, Sweden|Linköping University Hospital, Linköping, 58185, Sweden|Akademiskt specialistcentrum, Stockholm, 11341, Sweden|Karolinska Universitetssjukhuset, Solna, Stockholm, 17176, Sweden|Uppsala University Hospital, Uppsala, 75185, Sweden"
NCT04570670,Comparative Bioavailability of BAFIERTAM™ (Monomethyl Fumarate) and Tecfidera® (Dimethyl Fumarate) in Healthy Subjects,https://beta.clinicaltrials.gov/study/NCT04570670,COMPLETED,Relapsing Remitting Multiple Sclerosis,DRUG: monomethyl fumarate 190 mg|DRUG: dimethyl fumarate 240 mg,Banner Life Sciences LLC,,ALL,ADULT,PHASE1,50,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2017-01-06,2017-02-17,2017-02-17,
NCT04753411,The 3-Meter Backward Walk Test in Individuals With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04753411,UNKNOWN,Reliability and Validity,,Firat University,,ALL,"ADULT, OLDER_ADULT",,50,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-02-05,2021-04-04,2021-05-04,
NCT01156311,BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01156311,COMPLETED,Relapsing-Remitting Multiple Sclerosis|Multiple Sclerosis,DRUG: dimethyl fumarate,Biogen,,ALL,ADULT,PHASE2,108,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2010-06,2012-03,2012-03,"Research Site, Gilbert, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Danbury, Connecticut, United States|Research Site, Atlanta, Georgia, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Golden Valley, Minnesota, United States|Research Site, Teaneck, New Jersey, United States|Research Site, Patchogue, New York, United States|Research Site, Cleveland, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Portland, Oregon, United States|Research Site, Cordova, Tennessee, United States|Research Site, Franklin, Tennessee, United States|Research Site, Milwaukee, Wisconsin, United States"
NCT01271699,Prevalence of Fabry Disease in a Defined Population at Risk - Patients Formerly Diagnosed With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01271699,COMPLETED,Multiple Sclerosis,,CENTOGENE GmbH Rostock,,ALL,ADULT,,250,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-01,2019-12-01,2019-12-01,
NCT01031199,Evaluation of the Positron Emission Tomography (PET) Tracer ZK 6032924 in Patients With Multiple Sclerosis Compared to Healthy Volunteers,https://beta.clinicaltrials.gov/study/NCT01031199,COMPLETED,Positron-Emission Tomography|Multiple Sclerosis,DRUG: F-18 FEDAA1106 (BAY85-8101)|DRUG: F-18 FEDAA1106 (BAY85-8101),Bayer,,ALL,ADULT,PHASE1,16,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2009-01,2009-12,2009-12,"Heidelberg, Victoria, 3084, Australia|Stockholm, 171 76, Sweden"
NCT03796611,Phenotypic and Functional Study of 4BL B Cells in Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT03796611,UNKNOWN,Multiple Sclerosis,,"University Hospital, Lille",,ALL,ADULT,,172,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-12,2022-10,2022-10,
NCT05075499,Immune Response to COVID-19 Vaccine in Multiple Sclerosis Patients Treated With Teriflunomide and Alemtuzumab,https://beta.clinicaltrials.gov/study/NCT05075499,RECRUITING,Multiple Sclerosis,BIOLOGICAL: COVID-19 vaccination,Sheba Medical Center,Sanofi,ALL,"ADULT, OLDER_ADULT",NA,70,OTHER_GOV,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2021-03-20,2021-12,2022-09,"Sheba Medical Center, Ramat Gan, 52621, Israel"
NCT05460299,Telko for Balance and Gait Rehabilitation for People With MS,https://beta.clinicaltrials.gov/study/NCT05460299,NOT_YET_RECRUITING,Multiple Sclerosis,COMBINATION_PRODUCT: Telko plus conventional physical therapy (CPT),Anas Radi Hassan Alashram,,ALL,"ADULT, OLDER_ADULT",NA,24,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-05-04,2023-07-16,2023-07-20,"Isra University, Amman, 11199, Jordan"
NCT01195870,Assessment of Patient Use of a New Device: RebiSmart,https://beta.clinicaltrials.gov/study/NCT01195870,COMPLETED,Multiple Sclerosis,,"Merck KGaA, Darmstadt, Germany","Merck Serono Limited, UK",ALL,"ADULT, OLDER_ADULT",,63,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2009-07,2010-09,2010-10,
NCT03552211,Evaluation of the Incidence of Relapses in Patients With Biotin-treated Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03552211,UNKNOWN,Progressive Multiple Sclerosis,DRUG: biotin|OTHER: propensity score,"University Hospital, Clermont-Ferrand",OFSEP (Observatoire Français de la Sclérose en Plaques)|SFSEP (Société Francophone de la Sclérose en Plaques)|MedDay Pharmaceuticals SA,ALL,"ADULT, OLDER_ADULT",,3000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-05-30,2019-02-01,2019-04-30,"CHU Clermont-FERRAND, Clermont-Ferrand, 63003, France"
NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,https://beta.clinicaltrials.gov/study/NCT00185211,COMPLETED,Multiple Sclerosis,"DRUG: Interferon beta-1b (Betaseron, BAY86-5046)|DRUG: Interferon beta-1b (Betaseron, BAY86-5046)",Bayer,,ALL,ADULT,PHASE3,468,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2002-08,2008-05,2008-05,"Graz, 8036, Austria|Innsbruck, 6020, Austria|Wien, 1090, Austria|Bruxelles, 1200, Belgium|Gent, 9000, Belgium|Leuven, 3000, Belgium|Liège 1, 4000, Belgium|Calgary, Alberta, T2N 2T9, Canada|Vancouver, British Columbia, V6T 2B5, Canada|London, Ontario, N6A 5A5, Canada|Ottawa, Ontario, K1H 8L6, Canada|Toronto, Ontario, M5B 1W8, Canada|Montreal, Quebec, H2L 4M1, Canada|Brno, 63900, Czech Republic|Hradec Kralove, 50005, Czech Republic|Ostrava, 70852, Czech Republic|Plzen, 30460, Czech Republic|Prag, 10034, Czech Republic|Prag, 12808, Czech Republic|Glostrup, 2600, Denmark|Helsinki, 00100, Finland|Kuopio, 70210, Finland|Oulu, 90029, Finland|Seinäjoki, 60220, Finland|Tampere, 33521, Finland|Turku, 20100, Finland|Rennes, Bretagne, 35038, France|Bordeaux, Gironde, 33076, France|Clermont ferrand, 63003, France|Dijon, 21033, France|Lille, 59037, France|Nancy, 54035, France|Nice, 06000, France|Paris, 75019, France|Toulouse, 31059, France|Ulm, Baden-Württemberg, 89081, Germany|München, Bayern, 81377, Germany|Regensburg, Bayern, 93053, Germany|Würzburg, Bayern, 97080, Germany|Hennigsdorf, Brandenburg, 16761, Germany|Gießen, Hessen, 35392, Germany|Marburg, Hessen, 35039, Germany|Offenbach, Hessen, 63069, Germany|Greifswald, Mecklenburg-Vorpommern, 17475, Germany|Braunschweig, Niedersachsen, 38126, Germany|Göttingen, Niedersachsen, 37099, Germany|Düsseldorf, Nordrhein-Westfalen, 40225, Germany|Düsseldorf, Nordrhein-Westfalen, 40479, Germany|Köln, Nordrhein-Westfalen, 50931, Germany|Münster, Nordrhein-Westfalen, 48149, Germany|Mainz, Rheinland-Pfalz, 55101, Germany|Homburg, Saarland, 66424, Germany|Halle, Sachsen-Anhalt, 06120, Germany|Magdeburg, Sachsen-Anhalt, 39120, Germany|Erfurt, Thüringen, 99089, Germany|Berlin, 12200, Germany|Berlin, 13585, Germany|Szeged, Csongrad, 6720, Hungary|Budapest, 1076, Hungary|Budapest, 1145, Hungary|Budapest, 1204, Hungary|Debrecen, 4032, Hungary|Haifa, 34362, Israel|Tel Hashomer, 52621, Israel|Gallarate, Varese, 21013, Italy|Milano, 20132, Italy|Padova, 35128, Italy|Pavia, 27100, Italy|Torino, 10126, Italy|Sittard, 6131 BK, Netherlands|Tilburg, 5022 GC, Netherlands|Bergen, N-5021, Norway|Bydgoszcz, 85681, Poland|Krakow, 31503, Poland|Lodz, 90153, Poland|Lublin, 20090, Poland|Wroclaw, 50420, Poland|Coimbra, 3000, Portugal|Lubljana, 1525, Slovenia|Hospitalet de Llobregat, Barcelona, 08907, Spain|Barakaldo, Vizcaya, 48903, Spain|Barcelona, 08035, Spain|Barcelona, 08036, Spain|Madrid, 28040, Spain|Malaga, 29010, Spain|Sevilla, 41071, Spain|Valencia, 46026, Spain|Göteborg, 41685, Sweden|Basel, Basel-Stadt, 4031, Switzerland|St. Gallen, 9007, Switzerland|Dundee, Scotland, DD1 9SY, United Kingdom|Aberdeen, AB25 2ZN, United Kingdom|London, W6 8RF, United Kingdom|Sheffield, S10 2JF, United Kingdom"
NCT00156676,Restoration of Walking in Multiple Sclerosis Using Treadmill Training.,https://beta.clinicaltrials.gov/study/NCT00156676,COMPLETED,Multiple Sclerosis,DEVICE: Body-weight supported treadmill|DEVICE: Lokomat|DEVICE: Body-weight supported treadmill|DEVICE: Lokomat,US Department of Veterans Affairs,,ALL,"ADULT, OLDER_ADULT",NA,30,FED,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2004-09,2007-09,2007-09,"Providence VA Medical Center, Providence, Rhode Island, 02908-4799, United States"
NCT02965170,Validation of a Laboratory Test Measuring Natalizumab (Tysabri®) Serum Levels in MS,https://beta.clinicaltrials.gov/study/NCT02965170,COMPLETED,Multiple Sclerosis,,"Rocky Mountain MS Research Group, LLC",Abreos Biosciences,ALL,"ADULT, OLDER_ADULT",,109,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-10,2017-12,2018-05,"Rocky Mountain MS Clinic, Salt Lake City, Utah, 84103, United States"
NCT00492570,GER-009-06-AVX Early Therapy in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00492570,COMPLETED,Relapsing-Remitting Multiple Sclerosis,,Biogen,,ALL,"CHILD, ADULT, OLDER_ADULT",,230,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2006-04,2007-10,2008-12,
NCT03069170,Autologous Bone Marrow Derived Stem Cells for the Treatment of Multiple Sclerosis.,https://beta.clinicaltrials.gov/study/NCT03069170,UNKNOWN,Multiple Sclerosis,BIOLOGICAL: Stem Cell Transplantation,Stem Cells Arabia,,ALL,"ADULT, OLDER_ADULT",PHASE1,50,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-07,2020-09,2021-01,"Stem Cells Arabia, Amman, 11953, Jordan"
NCT04389970,Time Restricted Eating Outcomes in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04389970,COMPLETED,"Multiple Sclerosis|Diet, Healthy",BEHAVIORAL: Time Restricted Feeding,University of Alabama at Birmingham,,ALL,"ADULT, OLDER_ADULT",NA,12,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-10-01,2021-07-30,2021-07-30,"University of Alabama at Birmingham, Birmingham, Alabama, 35294, United States"
NCT03284970,Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes,https://beta.clinicaltrials.gov/study/NCT03284970,COMPLETED,Relapsing-Remitting Multiple Sclerosis,,"EMD Serono Research & Development Institute, Inc.","Merck KGaA, Darmstadt, Germany",ALL,"ADULT, OLDER_ADULT",,34,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-08-23,2018-05-11,2018-05-11,"Neurology Center of New England, Foxboro, Massachusetts, 02035, United States"
NCT05182411,Validity and Reliability of Turkish Version Leg Activity Measure,https://beta.clinicaltrials.gov/study/NCT05182411,COMPLETED,Spinal Cord Injuries|Multiple Sclerosis|Stroke,OTHER: assessment,Kahramanmaras Sutcu Imam University,,ALL,"ADULT, OLDER_ADULT",,50,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-06-30,2022-07-30,2022-08-05,"Kahramanmaraş Sutcu Imam University, Kahramanmaraş, Turkey"
NCT05057676,Autoimmune Intervention Mastery Course Study,https://beta.clinicaltrials.gov/study/NCT05057676,ACTIVE_NOT_RECRUITING,Multiple Sclerosis|Clinically Isolated Syndrome,BEHAVIORAL: Immediate Autoimmune Intervention Mastery Course (AIM)|BEHAVIORAL: Immediate Question and Answer sessions. (AIM Q and A sessions)|BEHAVIORAL: Delayed Autoimmune Intervention Mastery Course (delayed AIM course)|BEHAVIORAL: Delayed AIM Question and Answer sessions,Terry L. Wahls,,ALL,"ADULT, OLDER_ADULT",NA,80,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE,2021-12-01,2023-12-01,2023-12-01,"Univeristy of Iowa, Iowa City, Iowa, 52246, United States"
NCT02280876,Efficacy Study of Andrographis Paniculata Purified Standardized Extract (ApE) in Patients With Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT02280876,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: 1 - Andrographis paniculata p/st extract|DRUG: 2 - Excipients,Universidad Austral de Chile,Comisión Nacional de Investigación Científica y Tecnológica|University of Chile,ALL,ADULT,PHASE1|PHASE2,30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2012-01,2015-02,2015-05,"Hospital Regional, Valdivia, Los Ríos, 5090000, Chile"
NCT05676099,TSC Biosample Repository and Natural History Database,https://beta.clinicaltrials.gov/study/NCT05676099,RECRUITING,Tuberous Sclerosis|Lymphangioleiomyomatosis,PROCEDURE: Phlebotomy|PROCEDURE: Buccal (cheek) swab|GENETIC: Genetic Testing|OTHER: Tissue donation after routine clinical procedure,National Tuberous Sclerosis Association,,ALL,"CHILD, ADULT, OLDER_ADULT",,5000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-01,2050-12,2050-12,"University of Alabama Birmingham, Birmingham, Alabama, United States|Loma Linda University Children's Hospital, Loma Linda, California, United States|University of California Los Angeles, Los Angeles, California, 90095, United States|Jack & Julia Center for TSC, Oakland Children's Hospital and Research Center, Oakland, California, United States|The Children's Hospital, Denver, Colorado, United States|Nicklaus Children's Hospital, Miami, Florida, United States|Chicago Comer Children's Hospital Neurogenetic Clinic, University of Chicago, Chicago, Illinois, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|TSC Alliance, Silver Spring, Maryland, 20910, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Minnesota Epilepsy Group, Roseville, Minnesota, United States|Washington University in St. Louis, Saint Louis, Missouri, 63110, United States|New York University Medical Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States|Le Bonheur Children's Hospital, Memphis, Tennessee, United States|Texas Scottish Rite Hospital for Children, Dallas, Texas, United States|Memorial Hermann-Texas Medical Center (University of Texas Houston), Houston, Texas, United States|Children's National Medical Center, Fairfax, Virginia, United States|Centre Hospitalier de L'Université de Montréal (Chum), Montréal, Canada|Sainte-Justine Université de Montréal, Montréal, Canada"
NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",https://beta.clinicaltrials.gov/study/NCT01963611,TERMINATED,Relapsing Remitting Multiple Sclerosis,DRUG: Plovamer acetate 0.5 milligram (mg)|DRUG: Copaxone 20 mg|DRUG: Plovamer acetate 3 mg|DRUG: Plovamer acetate 10 mg|DRUG: Plovamer acetate 20 mg,EMD Serono,,ALL,ADULT,PHASE2,255,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2013-10,2015-03,2015-03,"Research site, Redding, California, 96001, United States|Research site, San Diego, California, 92117, United States|Research site, San Diego, California, 92128, United States|Research site, Fairfield, Connecticut, 06824, United States|Research site, Dover, Delaware, 19901, United States|Research site, Miami, Florida, 33136, United States|Research site, Naples, Florida, 34102, United States|Research site, Pompano Beach, Florida, 33060, United States|Research site, Sarasota, Florida, 34233, United States|Research site, Sunrise, Florida, 33351, United States|Research site, Columbus, Georgia, 31909, United States|Research site, Rome, Georgia, 30165, United States|Research site, Elk Grove Village, Illinois, 60007, United States|Research site, Indianapolis, Indiana, 46256, United States|Research site, Baltimore, Maryland, 21287, United States|Research site, New Bedford, Massachusetts, 02740, United States|Research site, Worcester, Massachusetts, 01655, United States|Research site, Detroit, Michigan, 48202-2689, United States|Research Site, Detroit, Michigan, 97205, United States|Research site, Golden Valley, Minnesota, 55422, United States|Research site, St Louis, Missouri, 63110, United States|Research site, Plainview, New York, 11803, United States|Research site, Charlotte, North Carolina, 28209, United States|Research site, Hickory, North Carolina, 28602, United States|Research site, Matthews, North Carolina, 28105, United States|Research site, Raleigh, North Carolina, 27607-6010, United States|Research site, Wilmington, North Carolina, 28401, United States|Research site, Cincinnati, Ohio, 45206, United States|Research site, Dayton, Ohio, 45417, United States|Research site, Willow Grove, Pennsylvania, 19090, United States|Research site, Nashville, Tennessee, 37205, United States|Research Site, Round Rock, Texas, 78681, United States|Research Site, San Antonio, Texas, 78258, United States|Research site, Roanoke, Virginia, 24018, United States|Research site, Tacoma, Washington, 98405, United States|Research site, Blagoevgrad, Bulgaria|Research site, Dupnitsa, Bulgaria|Research site, Sofia, Bulgaria|Research site, Osijek, Croatia|Research site, Varazdin, Croatia|Research site, Zagreb, Croatia|Research site, Brno, Czech Republic|Research site, Havirov, Czech Republic|Research site, Hradec Kralove, Czech Republic|Research site, Jihlava, Czech Republic|Research site, Olomouc, Czech Republic|Research site, Praha, Czech Republic|Research site, Kuopio, Finland|Research site, Oulu, Finland|Research site, Turku, Finland|Research site, Athens, Greece|Research site, Thessaloniki, Greece|Research site, Budapest, Hungary|Research site, Debrecen, Hungary|Research site, Esztergom, Hungary|Research site, Miskolc, Hungary|Research site, Castelfiorentino, Italy|Research site, Catania, Italy|Research site, Cefalù, Italy|Research site, Milano, Italy|Research site, Modena, Italy|Research site, Montichiari, Italy|Research site, Parma, Italy|Research site, Roma, Italy|Research site, Cuautitlan Izcalli, Mexico|Research site, Leon, Mexico|Research site, Mexico City, Mexico|Research site, Mexico, Mexico|Research site, Monterrey, Mexico|Research site, Morelia, Mexico|Research site, Tlalnepantla, Mexico|Research site, Gdansk, Poland|Research site, Katowice, Poland|Research site, Lodz, Poland|Research site, Olsztyn, Poland|Research site, Poznan, Poland|Research site, Rzeszow, Poland|Research site, Warsaw, Poland|Research site, Warszawa, Poland|Research site, Ekaterinburg, Russian Federation|Research site, Krasnoyarsk, Russian Federation|Research site, Kursk, Russian Federation|Research site, Moscow, Russian Federation|Research site, Nizhniy Novgorod, Russian Federation|Research site, Novosibirsk, Russian Federation|Research site, Rostov-on-Don, Russian Federation|Research site, Saransk, Russian Federation|Research site, St Petersburg, Russian Federation|Research site, St. Petersburg, Russian Federation|Research site, Ufa, Russian Federation|Research site, Belgrade, Serbia|Research site, Kragujevac, Serbia|Research site, Nis, Serbia|Research site, Cape Town, South Africa|Research site, Durban, South Africa|Research site, Pretoria, South Africa|Research site, Aranjuez, Spain|Research site, Córdoba, Spain|Research site, Madrid, Spain|Research site, Mostoles, Spain|Research site, Santander, Spain|Research site, Zaragoza, Spain|Research site, Diyarbakir, Turkey|Research site, Edirne, Turkey|Research site, Istanbul, Turkey|Research site, Kocaeli, Turkey|Research site, Mersin, Turkey|Research site, Samsun, Turkey|Research site, Dnipropetrovsk, Ukraine|Research site, Ivano-Frankivsk, Ukraine|Research site, Kyiv, Ukraine|Research site, Lutsk, Ukraine|Research site, Simferopol, Ukraine|Research site, Vinnytsia, Ukraine|Research site, Zaporizhzhia, Ukraine|Research site, Exeter, United Kingdom|Research site, Hull, United Kingdom|Research site, Sheffield, United Kingdom|Research site, Southampton, United Kingdom|Research site, Stoke on Trent, United Kingdom"
NCT02306811,Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839,https://beta.clinicaltrials.gov/study/NCT02306811,TERMINATED,Relapsing-remitting Multiple Sclerosis,DRUG: Vatelizumab,"Genzyme, a Sanofi Company",,ALL,"ADULT, OLDER_ADULT",PHASE2,62,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2015-02,2016-04,2016-07,"Investigational Site Number 840004, Cullman, Alabama, 35058, United States|Investigational Site Number 840005, Fort Collins, Colorado, 80528, United States|Investigational Site Number 840007, Ormond Beach, Florida, 32174, United States|Investigational Site Number 840001, Latham, New York, 12210, United States|Investigational Site Number 840003, Round Rock, Texas, 78681, United States|Investigational Site Number 840016, San Antonio, Texas, 78258, United States|Investigational Site Number 124001, Greenfield Park, J4V 2J2, Canada|Investigational Site Number 616001, Lodz, 93-121, Poland|Investigational Site Number 616004, Lublin, 20-090, Poland|Investigational Site Number 616003, Lublin, 20-718, Poland|Investigational Site Number 616002, Szczecin, 70-215, Poland|Investigational Site Number 643010, Kazan, 420021, Russian Federation|Investigational Site Number 643009, Moscow, 107150, Russian Federation|Investigational Site Number 643005, Nizhniy Novgorod, 603155, Russian Federation|Investigational Site Number 643006, Nizhny Novgorod, 603076, Russian Federation|Investigational Site Number 643008, Novosibirsk, 630087, Russian Federation|Investigational Site Number 643002, St-Petersburg, 197089, Russian Federation|Investigational Site Number 643001, St-Petersburg, 197376, Russian Federation"
NCT05811013,Effects of Transcranial Static Magnetic Field Stimulation (tSMS) in Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05811013,NOT_YET_RECRUITING,Progressive Multiple Sclerosis,DEVICE: Transcranial static magnetic field stimulation (tSMS)|DEVICE: Sham Transcranial static magnetic field stimulation (tSMS),Neuromed IRCCS,,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-05-03,2026-04-03,2026-04-03,
NCT02848976,Re-training to Effort (RE) According to the Severity of Multiple Sclerosis: Preliminary Assessments Based on Fatigue and Quality of Life,https://beta.clinicaltrials.gov/study/NCT02848976,COMPLETED,Multiple Sclerosis,OTHER: Re-training to effort (RE),Nantes University Hospital,,ALL,"CHILD, ADULT, OLDER_ADULT",,32,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2009-01,2010-04,2010-05,"University Hospital, Nantes, France"
NCT03381170,An Extension of the TG1101-RMS201 Trial,https://beta.clinicaltrials.gov/study/NCT03381170,COMPLETED,Relapsing Remitting Multiple Sclerosis,BIOLOGICAL: Ublituximab,"TG Therapeutics, Inc.",,ALL,ADULT,PHASE2,48,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2017-06-01,2022-11-11,2022-11-11,"TG Therapeutics Investigational Trial Site, Pasadena, California, 91105, United States|TG Therapeutics Investigational Trial Site, Aurora, Colorado, 80045, United States|TG Therapeutics Investigational Trial Site, Lexington, Kentucky, 40513, United States|TG Therapeutics Investigational Trial Site, Columbus, Ohio, 43210, United States|TG Therapeutics Investigational Trial Site, Westerville, Ohio, 43081, United States|TG Therapeutics Investigational Trial Site, Knoxville, Tennessee, 37922, United States|TG Therapeutics Investigational Trial Site, Round Rock, Texas, 78681, United States|TG Therapeutics Investigational Trial Site, San Antonio, Texas, 78258, United States"
NCT05323370,"Lymphangioleiomyomatosis, a Study on Cathepsin K",https://beta.clinicaltrials.gov/study/NCT05323370,COMPLETED,Lymphangioleiomyomatosis|Tuberous Sclerosis Complex,OTHER: 24h urine|OTHER: urine sample,"University Hospital, Tours",,FEMALE,"ADULT, OLDER_ADULT",,19,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-05-31,2022-10-30,2022-10-30,"University hospital, Tours, 37044, France"
NCT03536299,Measurement and Training of Dual-Task of Gait in Persons With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03536299,UNKNOWN,"Multiple Sclerosis|Gait Disorders, Neurologic|Cognitive Impairment",OTHER: Dual-task gait|OTHER: Single-task gait,Texas Woman's University,"TIRR Memorial Hermann|The University of Texas Health Science Center, Houston",ALL,"ADULT, OLDER_ADULT",NA,80,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2018-05-31,2020-05-31,2020-05-31,"Texas Woman's University Institute of Health Sciences - Houston Center, Houston, Texas, 77030, United States|TIRR Memorial Hermann Adult and Pediatric Outpatient Rehabilitation at the Kirby Glen Center, Houston, Texas, 77030, United States"
NCT03637699,A Positive Psychology Intervention for Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03637699,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Positive Psychology,Brigham and Women's Hospital,Consortium of Multiple Sclerosis Centers|Massachusetts General Hospital,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2018-03-12,2019-04-09,2019-04-09,"Brigham and Women's Hospital, Boston, Massachusetts, 02115, United States"
NCT03387670,Multiple Sclerosis-Simvastatin Trial 2,https://beta.clinicaltrials.gov/study/NCT03387670,ACTIVE_NOT_RECRUITING,Secondary Progressive Multiple Sclerosis (SPMS),DRUG: Simvastatin|DRUG: Placebo,"University College, London",University of Edinburgh|Queen Mary University of London|London School of Hygiene and Tropical Medicine|University of Leeds|The Leeds Teaching Hospitals NHS Trust|Imperial College Healthcare NHS Trust,ALL,"ADULT, OLDER_ADULT",PHASE3,964,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-03-28,2024-08-31,2024-08-31,"Belfast City Hospital, Belfast, BT9 7AB, United Kingdom|Royal Sussex County Hospital, Brighton, BN2 5BE, United Kingdom|Addenbrooke's Hospital, Cambridge, CB2 0QQ, United Kingdom|University Hospital of Wales, Cardiff, CF14 4XW, United Kingdom|The Anne Rowling Regenerative Neurology Clinic, Edinburgh, EH16 4SB, United Kingdom|Royal Devon and Exeter Hospital, Exeter, EX2 5DW, United Kingdom|The Queen Elizabeth University Hospital, Glasgow, G51 4TF, United Kingdom|Leeds General Infirmary, Leeds, LS1 3EX, United Kingdom|The Leeds Teaching Hospital, Leeds, LS1 3EX, United Kingdom|The Walton Centre NHS Foundation Trust, Liverpool, L9 7LJ, United Kingdom|Queen's Hospital, Barking, Havering and Redbridge University Hospitals, London, RM7 0AG, United Kingdom|King's College Hopsital, London, SE5 8EF, United Kingdom|Charing Cross Hospital, London, W6 8RF, United Kingdom|University College London Hospital, London, WC1N 3BG, United Kingdom|Salford Royal Hospital, Manchester, M6 8HD, United Kingdom|Royal Victoria Infirmary, Newcastle Upon Tyne, NE1 4LP, United Kingdom|Nottingham Teaching Hospitals, Nottingham, NG5 1PB, United Kingdom|Queen's Medical Centre, Nottingham, NG7 2UH, United Kingdom|John Radcliffe Hospital, Oxford, OX3 9DU, United Kingdom|Derriford Hospital, Plymouth, PL6 8BH, United Kingdom|Poole Hospital, Poole, BH15 2JB, United Kingdom|Royal Hallamshire Hospital, Sheffield, S10 2JF, United Kingdom|University Hospital of North Staffordshire, Stoke-on-Trent, ST4 6QG, United Kingdom|Morriston & Neath Port Talbot Hospitals (Abertawe Bro Morgannwg University Local Health Board), Swansea, United Kingdom"
NCT00381576,Multiple Sclerosis and Heavy Progressive Resistance Training,https://beta.clinicaltrials.gov/study/NCT00381576,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Resistance training,University of Aarhus,Sonderborg Hospital|The Danish Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",NA,36,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: ",2006-11,2008-03,2008-06,"MS Clinic, Department of Neurology, Aarhus University Hospital, Aarhus, 8000, Denmark|Department of Sports Science, University of Aarhus, Aarhus, 8200, Denmark"
NCT05783999,Muscle Vibration and Fatigue in Patients With MS,https://beta.clinicaltrials.gov/study/NCT05783999,RECRUITING,Multiple Sclerosis,DEVICE: vibra plus,"IRCCS Centro Neurolesi ""Bonino-Pulejo""",,ALL,ADULT,NA,20,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-10-28,2024-06-30,2024-06-30,"Irccs Neurolesi Centro Bonino Pulejo, Messina, Sicily, 98121, Italy"
NCT03671499,A Study for Testing Text Messaging and Newsletter as a Strategy for Interrupting Sedentary Behavior,https://beta.clinicaltrials.gov/study/NCT03671499,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Social Cognitive Theory based text messages,University of Alabama at Birmingham,Consortium of Multiple Sclerosis Centers,ALL,ADULT,NA,30,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2018-03-27,2019-06-05,2019-10-25,"University of Alabama Birmingham, Birmingham, Alabama, 35209, United States"
NCT04302870,Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial,https://beta.clinicaltrials.gov/study/NCT04302870,RECRUITING,"Motor Neuron Disease, Amyotrophic Lateral Sclerosis",DRUG: Memantine Hydrochloride Oral Solution|DRUG: Trazodone Hydrochloride oral solution|DRUG: Placebo oral solution|DRUG: Amantadine Hydrochloride Oral Solution,University of Edinburgh,"University College, London|University of Warwick|NHS Lothian",ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,800,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-02-27,2026-09,2026-12,"Southern Health and Social Care Trust, Craigavon Area Hospital, Portadown, County Armagh, BT63 5QQ, United Kingdom|Aberdeen Royal Infirmary, Aberdeen, United Kingdom|University Hospitals of Birmingham NHS Foundation Trust, Birmingham, B15 2TH, United Kingdom|West Suffolk NHS Foundation Trust, Bury Saint Edmunds, IP33 2QZ, United Kingdom|Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, United Kingdom|Cardiff and Vale University Local Health Board, Cardiff, CF14 4XW, United Kingdom|Clinical Research Centre , Ninewells Hospital, Dundee, United Kingdom|Anne Rowling Regenerative Neurology Clinic, Edinburgh, EH16 4SB, United Kingdom|Royal Devon and Exeter Hospital, Exeter, United Kingdom|Queen Elizabeth University Hospital Clinical Research Facility, Glasgow, United Kingdom|NHS Highland Clinical Research Facility, Raigmore Hospital, Inverness, United Kingdom|East Suffolk and North Essex NHS Foundation Trust, Ipswich, CO4 5JL, United Kingdom|Royal London Hospital, London, E1 1FR, United Kingdom|St George's University Hospitals NHS Foundation Trust, London, SW17 0QT, United Kingdom|Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, NE7 7DN, United Kingdom|Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, NR4 7UY, United Kingdom|University Hospitals of Dorset NHS Trust, Poole, United Kingdom|Clinical Research Facility Salford Royal NHS Foundation Trust, Salford, United Kingdom|Clinical Research Facility University Hospital Southampton, Southampton, United Kingdom"
NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00906399,COMPLETED,Relapsing Multiple Sclerosis,DRUG: BIIB017 (peginterferon beta-1a)|DRUG: Placebo,Biogen,,ALL,"ADULT, OLDER_ADULT",PHASE3,1516,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-06,2012-10,2013-10,"Research Site, Phoenix, Arizona, 85013, United States|Research Site, Ponte Vedra Beach, Florida, 32082 4040, United States|Research Site, Atlanta, Georgia, 30327, United States|Research Site, Des Moines, Iowa, 50314, United States|Research Site, Lexington, Kentucky, 40513, United States|Research Site, Baltimore, Maryland, 21287, United States|Research Site, Teaneck, New Jersey, 07666, United States|Research Site, Raleigh, North Carolina, 27607 6520, United States|Research Site, Akron, Ohio, 44320, United States|Research Site, Cleveland, Ohio, 44195, United States|Research Site, Franklin, Tennessee, 37064, United States|Research Site, Round Rock, Texas, 78681, United States|Research Site, 'Sint-Truiden, 3800, Belgium|Research Site, Bruxelles, 1200, Belgium|Research Site, Plovdiv, 4002, Bulgaria|Research Site, Sofia, 1113, Bulgaria|Research Site, Sofia, 1309, Bulgaria|Research Site, Sofia, 1407, Bulgaria|Research Site, Sofia, 1431, Bulgaria|Research Site, Sofia, 1527, Bulgaria|Research Site, Sofia, 1606, Bulgaria|Research Site, London, Ontario, N6A 5A5, Canada|Research Site, Montreal, Quebec, H2L4M1, Canada|Research Site, Santiago, 8207257, Chile|Research Site, Barranquilla, Atlantico, Colombia|Research Site, Bogota, Cundinamarca, Colombia|Research Site, Bogota, Colombia|Research Site, Osijek, 31000, Croatia|Research Site, Zagreb, 10000, Croatia|Research Site, Brno, 62500, Czech Republic|Research Site, Olomouc, 77520, Czech Republic|Research Site, Ostrava - Vitkovice, 70200, Czech Republic|Research Site, Ostrava-Poruba, 70300, Czech Republic|Research Site, Ostrava, 70852, Czech Republic|Research Site, Praha 2, 12808, Czech Republic|Research Site, Praha 5, 15006, Czech Republic|Research Site, Teplice, 41529, Czech Republic|Research Site, Parnu, EE 80010, Estonia|Research Site, Tallinn, EE 10617, Estonia|Research Site, Tartu, EE 51014, Estonia|Research Site, Amiens, 80054, France|Research Site, Clermont-Ferrand, 63003, France|Research Site, Lyon, 69394, France|Research Site, Marseille, 13385, France|Research Site, Nice, 6002, France|Research Site, Tbilisi, 112, Georgia|Research Site, Tbilisi, 141, Georgia|Research Site, Tbilisi, 179, Georgia|Research Site, Tbilisi, 186, Georgia|Research Site, Bayreuth, 95445, Germany|Research Site, Berlin, 10713, Germany|Research Site, Berlin, 14163, Germany|Research Site, Bochum, 44791, Germany|Research Site, Erbach, 64711, Germany|Research Site, Erlangen, 91054, Germany|Research Site, Hamburg, 20099, Germany|Research Site, Hannover, 30559, Germany|Research Site, Koln, 50935, Germany|Research Site, Leipzig, 04103, Germany|Research Site, Marburg, 35043, Germany|Research Site, Munchen, 80331, Germany|Research Site, Munster, 48149, Germany|Research Site, Prien, 83209, Germany|Research Site, Ulm, 89079, Germany|Research Site, Westerstede, 26655, Germany|Research Site, Athens, 11521, Greece|Research Site, Athens, 11525, Greece|Research Site, Thessaloniki, 57010, Greece|Research Site, New Delhi, Delhi, 110029, India|Research Site, New Delhi, Delhi, 110060, India|Research Site, Saket, Delhi, 110017, India|Research Site, Ahmedabad, Gujarat, 380006, India|Research Site, Rajkot, Gujarat, 360001, India|Research Site, Bangalore, Karnataka, 560043, India|Research Site, Indore, Madhyr Pradesh, 452018, India|Research Site, Mumbai, Maharashtra, 400026, India|Research Site, Nagpur, Maharashtra, 440010, India|Research Site, Nasik, Maharashtra, 422004, India|Research Site, Pune, Maharashtra, 411004, India|Research Site, Pune, Maharashtra, 411030, India|Research Site, Amritsar, Punjab, 143001, India|Research Site, Jaipur, Rajasthan, 302004, India|Research Site, Chennai, Tamil Nadu, 600017, India|Research Site, Coimbatore, Tamil Nadu, 641014, India|Research Site, Kolkata, West Bengal, 700068, India|Research Site, Bangalore, 560017, India|Research Site, Mangalore, 575018, India|Research Site, Navi Mumbai, 400703, India|Research Site, Nehru Nagar, 110065, India|Research Site, Riga, LV 1005, Latvia|Research Site, Aquas Calientes, 20127, Mexico|Research Site, Chihuahua, 31203, Mexico|Research Site, Mexico City, 10700, Mexico|Research Site, Mexico DF, 03310, Mexico|Research Site, Monterrey, Nuevo Leon, 64710, Mexico|Research Site, Tijuana, Baja California, 22320, Mexico|Research Site, Breda, 4818CK, Netherlands|Research Site, Nieuwegein, 3435CM, Netherlands|Research Site, Auckland, 1023, New Zealand|Research Site, Christchurch, New Zealand|Research Site, Dunedin, New Zealand|Research Site, Lima, Lima 01, Peru|Research Site, Lima, Lima 1, Peru|Research Site, Lima, Lima 21, Peru|Research Site, San Isidro, Lima 27, Peru|Research Site, Bialystok, 15276, Poland|Research Site, Bialystok, 15402, Poland|Research Site, Bydgoszcz, 85681, Poland|Research Site, Gdansk, 80299, Poland|Research Site, Gdansk, 80803, Poland|Research Site, Gdansk, 80952, Poland|Research Site, Katowice, 40650, Poland|Research Site, Katowice, 40662, Poland|Research Site, Katowice, 40684, Poland|Research Site, Konskie, 26200, Poland|Research Site, Krakow, 31505, Poland|Research Site, Krakow, 31637, Poland|Research Site, Krakow, 31826, Poland|Research Site, Lodz, 90153, Poland|Research Site, Lublin, 20718, Poland|Research Site, Lublin, 20954, Poland|Research Site, Olsztyn, 10082, Poland|Research Site, Plewiska, 62064, Poland|Research Site, Poznan, 60355, Poland|Research Site, Poznan, 61853, Poland|Research Site, Szczecin, 70215, Poland|Research Site, Szczecin, 71252, Poland|Research Site, Warsawa, 00851, Poland|Research Site, Warsawa, 02957, Poland|Research Site, Warsawa, 04141, Poland|Research Site, Warsawa, 04749, Poland|Research Site, Wroclaw, 50556, Poland|Research Site, Zabrze, 41800, Poland|Research Site, Brasov, 500123, Romania|Research Site, Bucharest, 50098, Romania|Research Site, Campulung, 115100, Romania|Research Site, Iasi, 700656, Romania|Research Site, Sibiu, 550166, Romania|Research Site, Targu Mures, 540136, Romania|Research Site, Chelyabinsk, 454136, Russian Federation|Research Site, Kaluga, 248007, Russian Federation|Research Site, Kazan, 420021, Russian Federation|Research Site, Krasnodar, 350012, Russian Federation|Research Site, Kursk, 305007, Russian Federation|Research Site, Moscow, 107150, Russian Federation|Research Site, Moscow, 119021, Russian Federation|Research Site, Moscow, 125367, Russian Federation|Research Site, Moscow, 127018, Russian Federation|Research Site, Novosibirsk, 630007, Russian Federation|Research Site, Perm, 614990, Russian Federation|Research Site, Rostov-on-Don, 344015, Russian Federation|Research Site, Smolensk, 214018, Russian Federation|Research Site, Tomsk, 634050, Russian Federation|Research Site, Ufa, 450005, Russian Federation|Research Site, Belgrade, 11000, Serbia|Research Site, Kragujevac, 34000, Serbia|Research Site, Nis, 18000, Serbia|Research Site, Cordoba, 14008, Spain|Research Site, Madrid, 28041, Spain|Research Site, Madrid, 28046, Spain|Research Site, Malaga, 29010, Spain|Research Site, Sevilla, 41071, Spain|Research Site, Chernivtsi, 58018, Ukraine|Research Site, Dnipropetrovsk, 49027, Ukraine|Research Site, Donetsk, 83099, Ukraine|Research Site, Kharkiv, 61068, Ukraine|Research Site, Kharkiv, 61103, Ukraine|Research Site, Kyiv, 3110, Ukraine|Research Site, Kyiv, 4107, Ukraine|Research Site, Odesa, 65025, Ukraine|Research Site, Poltava, 26011, Ukraine|Research Site, Simferopol, 95017, Ukraine|Research Site, Ternopil, 46027, Ukraine|Research Site, Vinnytsya, 21005, Ukraine|Research Site, London, E1 1BB, United Kingdom|Research Site, Nottingham, NG7 2UH, United Kingdom|Research Site, Salford, M6 8HD, United Kingdom|Research Site, Sheffield, S10 2JF, United Kingdom"
NCT03345199,Effects of Inspiratory Muscle Training in Persons With Advanced Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03345199,COMPLETED,Multiple Sclerosis,OTHER: Inspiratory Muscle Trainer (IMT),University of Michigan,National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",NA,38,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2017-10-28,2018-12-31,2019-04-01,"The Boston Home, Boston, Massachusetts, 02124, United States|University of Michigan-Flint, Flint, Michigan, 48502, United States"
NCT04699370,The Added Value of Cognition-targeted Exercise Versus Symptom-targeted Exercise for Multiple Sclerosis Fatigue,https://beta.clinicaltrials.gov/study/NCT04699370,COMPLETED,Physical and Rehabilitation Medicine,OTHER: cognition-targeted exercise|BEHAVIORAL: Cognitive behavioral therapy|OTHER: Standardized physical therapy,Cairo University,,ALL,ADULT,NA,60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-01-01,2021-02-20,2021-06-04,"Cairo University, Giza, 12613, Egypt"
NCT01294176,Lipoic Acid as a Treatment for Acute Optic Neuritis,https://beta.clinicaltrials.gov/study/NCT01294176,COMPLETED,Optic Neuritis,DRUG: Lipoic Acid,Oregon Health and Science University,,ALL,"ADULT, OLDER_ADULT",PHASE1,31,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-01,2016-11,2016-11,"Oregon Health & Science University, Portland, Oregon, 97239, United States"
NCT02799199,Fingolimod Real World Experience: the French Grand-Est Cohort,https://beta.clinicaltrials.gov/study/NCT02799199,COMPLETED,Multiple Sclerosis,,CHU de Reims,,ALL,"ADULT, OLDER_ADULT",,1014,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-09,2015-10,2015-10,
NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",https://beta.clinicaltrials.gov/study/NCT04548999,RECRUITING,Multiple Sclerosis,DRUG: Ocrelizumab|DRUG: Ocrelizumab|DRUG: Antihistamine|DRUG: Methylprednisolone,Hoffmann-La Roche,,ALL,ADULT,PHASE3,699,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-12-03,2025-12-25,2029-09-06,"Alabama Neurology Associates, Homewood, Alabama, 35209, United States|21st Century Neurology, Phoenix, Arizona, 85004, United States|Center for Neurosciences, Tucson, Arizona, 85718, United States|University of California Irvine, Irvine, California, 92697, United States|SC3 Research Group, Inc, Pasadena, California, 91105, United States|University of California Davis Health System; Department of Neurology, Sacramento, California, 95817, United States|Stanford University Medical Center; Stanford Neuroscience Health Center, Stanford, California, 94305, United States|Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance, California, 90502, United States|University of Colorado Denver, Aurora, Colorado, 80045, United States|Mountain Neurological Research Center; Roaring Fork Neurologt, P.C., Basalt, Colorado, 81621, United States|Colorado Neurological Institute, Englewood, Colorado, 80113, United States|Advanced Neurosciences Research LLC, Fort Collins, Colorado, 80528, United States|KI Health Partners, LLC; New England Institute for Clinical Research, Stamford, Connecticut, 06905, United States|SFM Clinical Research, LLC, Boca Raton, Florida, 33487, United States|MS and Neuromuscular Center of Excellence, Clearwater, Florida, 33761, United States|Elite Clinical Research, Miami, Florida, 33144, United States|Infinity Clinical Research, LLC, Sunrise, Florida, 33351, United States|Axiom Clinical Research of Florida, Tampa, Florida, 33609, United States|University of South Florida, Tampa, Florida, 33612, United States|University of Chicago Hospital, Chicago, Illinois, 60637, United States|Baptist Health Lexington, Nicholasville, Kentucky, 40356, United States|Maine Medical Center, Scarborough, Maine, 04074, United States|International Neurorehabilitation Institute, Lutherville, Maryland, 21093, United States|Massachusetts General Hospital., Boston, Massachusetts, 02114, United States|Neuro Institute of New England P.C.; Research, Foxboro, Massachusetts, 02035, United States|Dragonfly Research, LLC, Wellesley, Massachusetts, 02481, United States|University of Massachusetts Medical School, Worcester, Massachusetts, 01655, United States|Michigan Institute for Neurological Disorders, Farmington Hills, Michigan, 48334, United States|Memorial Healthcare Institute for Neurosciences and Multiple Sclerosis, Owosso, Michigan, 48867, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|The MS Center for Innovations In Care, Saint Louis, Missouri, 63131, United States|Jersey Shore University Medical Centre, Neptune, New Jersey, 07753, United States|Northwell Health, Great Neck, New York, 11021, United States|Lenox Hill Hospital, New York, New York, 10075, United States|Atrium Health Neurosciences Institute ? Charlotte, Charlotte, North Carolina, 28204, United States|University of Cincinnati; Department of Neurology, Cincinnati, Ohio, 45219, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|OhioHealth Research Institute, Columbus, Ohio, 43214, United States|Premier Neurology, Greer, South Carolina, 29650, United States|Neurology Clinic PC, Cordova, Tennessee, 38018, United States|Wesley Neurology Clinic, Cordova, Tennessee, 38018, United States|New Orleans Center for Clinical Research, Knoxville, Tennessee, 37920, United States|Advanced Neurosciences Institute, Nashville, Tennessee, 37205, United States|University of Texas Southwestern Medical Center, Dallas, Texas, 75390, United States|Baylor College of Medicine, Houston, Texas, 77030, United States|Neurology Center of San Antonio, San Antonio, Texas, 78258, United States|Texas Institute for Neurological Disorders, Sherman, Texas, 75092, United States|Meridian Clinical Research, Norfolk, Virginia, 23502, United States|Wheaton Franciscan Healthcare - St. Francis Outpatient Center; Center for Neurological Disorders, Milwaukee, Wisconsin, 53215, United States|Centro de Especialidades Neurológicas y Rehabilitación - CENyR, Buenos Aires, C1424, Argentina|CEMIC Saavedra, Buenos Aires, C1431FWO, Argentina|INECO; Neurociencias, Rosario, S2000QGB, Argentina|CH EpiCURA Site Ath, Ath, 7800, Belgium|Revalidatie en MS Centrum, Overpelt, 3900, Belgium|L2 Ip Instituto de Pesquisas Clinicas Ltda ME; Centro Medico Hospitalar, Brasilia, DF, 70200-730, Brazil|Hospital das Clinicas - UFG, Goiania, GO, 74605-020, Brazil|Instituto de Neurologia de Curitiba, Curitiba, PR, 81210-310, Brazil|Instituto Méderi de Pesquisa e Saúde, Passo Fundo, RS, 99010-120, Brazil|Hospital Moinhos de Vento, Porto Alegre, RS, 90035-000, Brazil|IMV Pesquisa Neurológica, Porto Alegre, RS, 90110-000, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, 90610-000, Brazil|Clinica Neurologica; Neurocirurgica de Joinville, Joinville, SC, 89202-190, Brazil|Hospital das Clinicas - UNICAMP, Campinas, SP, 13083-887, Brazil|Praxis Pesquisa Médica, Santo Andre, SP, 09090-790, Brazil|CPQuali Pesquisa Clinica Ltda, Sao Paulo, SP, 01228-000, Brazil|Hospital das Clinicas - FMUSP, Sao Paulo, SP, 05403-900, Brazil|UMHAT Dr. Georgi Stranski; 2nd Neurology Clinic, Occupational Diseases, Pleven, 5800, Bulgaria|MHATNP Sveti Naum EAD, Sofia, 1113, Bulgaria|University of British Columbia, Vancouver, British Columbia, V6T 1Z4, Canada|CIUSSS du Saguenay Lac-Saint-Jean, Chicoutimi Hospital, Chicoutimi, Quebec, G7H 5H6, Canada|Chum Campus Notre Dame, Montreal, Quebec, H2X 0A9, Canada|MUCH - Montreal Neurological Institute & Hospital, Montreal, Quebec, H3A 2B4, Canada|Hotel-Dieu de Levis, Quebec, G1W 4R4, Canada|Fakultni nemocnice u sv. Anny; Neurologicka klinika, Brno, 656 91, Czechia|Fakultni nemocnice Ostrava; MS centrum, Ostrava-Poruba, 708 52, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, 12808, Czechia|Aalborg Universitetshospital; Neurologisk Afdeling og Neurofysiologisk Afdeling; Skleroseamb., Aalborg, 9000, Denmark|Rigshospitalet Glostrup; Neurologisk Klinik, Glostrup, 2600, Denmark|Odense Universitetshospital, Neurologisk Afdeling N; Neurologisk Ambulatorium N5; Skleroseklinikken, Odense C, 5000, Denmark|CHU de Besancon Hopital Jean Minjoz; Service de Neurologie, Besançon, 25030, France|CHU Brest Hopital La Cavale Blanche; Neurologie, Brest, 29609, France|Hopital Pierre Wertheimer; Neurologie D, Bron, 69677, France|Hopital Cote De Nacre; Unite Neurologie Generale, Caen, 14033, France|CHU Hopital Gabriel Montpied; Service de Neurologie, Clermont Ferrand, 63003, France|CH St Vincent de Paul, Lille, 59000, France|Hopital Central - CHU de Nancy; Service de Neurologie, Nancy, 54035, France|Hopital Hautepierre - CHU Strasbourg; Service de Neurologie, Strasbourg, 67098, France|Gesundheitszentrum St. Johannes Hospital; Neurolog. Gemeinschaftspraxis Dres. Schmidt, Neudecker etc, Bonn, 53111, Germany|Universitätsklinikum ""Carl Gustav Carus"", Zentrum für Klinische Neurowissenschaften, Dresden, 01307, Germany|Universitätsmedizin Greifswald; Klinik und Poliklinik für Neurologie, Greifswald, 17475, Germany|Universitätsmedizin Göttingen Georg-August-Universität, Göttingen, 37075, Germany|Krankenhaus Martha-Maria Hallo-Dölau, Klinik für Neurologie, Halle (Saale), 06120, Germany|Medizinische Hochschule Hannover, Klinik für Neurologie, Hannover, 30625, Germany|Universitätsklinikum Jena, Klinik für Neurologie, Jena, 07747, Germany|Universitätsklinikum Schleswig-Holstein; Klinik für Neurologie, Kiel, 24105, Germany|Universität Leipzig; Innere Medizin, Neurologie, Dermatologie, Leipzig, 04103, Germany|Universitaetsklinikum Marburg; Klinik fuer Neurologie, Marburg, 35043, Germany|Universitätsklinikum Münster; Klinik und Poliklinik für Neurologie, Münster, 48149, Germany|Praxis Dr. med. Bergmann, Neuburg, 86633, Germany|Neurozentrum Stuttgart Mitte Sophienstraße; Neurologische Gemeinschaftspraxis, Stuttgart, 70178, Germany|Krankenhaus der Barmherzigen Brüder Trier; Neurologie, Neurophysiol. neurolog.Reha/Schlaganfalleinh, Trier, 54292, Germany|Universitätsklinikum Tübingen, Zentrum für Neurologie, Tübingen, 72076, Germany|Universitätsklinikum Ulm; Klinik für Neurologie, Ulm, 89081, Germany|Deutsche Klinik für Diagnostik; DKD Helios Klinik Wiesbaden, Abt. Neurologie, Wiesbaden, 65191, Germany|401 Military Hospital of Athens; Neurology Department, Athens, 115 25, Greece|Hospital Eginition; First Department of Neurology, Athens, 115 28, Greece|University General Hospital of Larisa; Neurology Clinic, Larisa, 411 10, Greece|AHEPA Univ. General Hospital of Thessaloniki; B' Neurology Dept., Thessaloniki, 546 36, Greece|Orszagos Mentalis, Ideggyogyaszati es Idegsebeszeti Intezet; Neurology, Budapest, 1145, Hungary|UNO Medical Trials Kft., Budapest, 1152, Hungary|Petz Aladar Megyei Oktato Korhaz; Neurologiai Osztaly, Gyor, 9024, Hungary|Somogy Megyei Kaposi Mor Oktato Korhaz; Department of Neurology, Kaposvár, 7400, Hungary|Pest Megyei Flor Ferenc Korhaz; Neurology and Stroke Ambulance, Kistarcsa, 2143, Hungary|A. O. U. Federico II; Dip Neuroscienze, Scienze Riproduttive ed Odontostomatologiche, Napoli, Campania, 80131, Italy|AOU Seconda Università degli Studi; Dip.Assistenziale Integrato Medicina Int-I Clinica Neurologica, Napoli, Campania, 80138, Italy|Ospedale S.Camillo Forlanini; UOSD Day Hospital Neurologico e Neurochirurgico, Roma, Lazio, 00152, Italy|Azienda Ospedaliera Sant'Andrea; UOC Neurologia, Roma, Lazio, 00189, Italy|ASST PAPA GIOVANNI XXIII Neurologia USS Malattie Autoimmuni Centro Sclerosi Multipla, Bergamo, Lombardia, 24127, Italy|Ospedale S.Antonio Abate; Neurologia 2 ? Sclerosi Multipla e Recupero Neurologico, Gallarate, Lombardia, 21013, Italy|IRCCS Ospedale San Raffaele; Neurologia Neurofisiologia Neuroriabilitazione-Centro Sclerosi Multipla, Milano, Lombardia, 20132, Italy|IRCCS Istituto Neurologico C. Mondino?Dip. Neurologia Neuroriabilitazione S.S. Sclerosi Multipla, Pavia, Lombardia, 27100, Italy|AOU Città della Salute e della Scienza; Neurologia 1, Torino, Piemonte, 10126, Italy|Ospedale Binaghi; Centro Sclerosi Multipla, Cagliari, Sardegna, 09126, Italy|AOU Senese; UOC Clinica Neurologica e Malattie neurometaboliche, Siena, Toscana, 53100, Italy|Grupo Médico Camino S.C., Ciudad de México, Mexico CITY (federal District), 03600, Mexico|Clinstile S.A de C.V., Mexico City, Mexico CITY (federal District), 06700, Mexico|Neurociencias Prisma, A.C, San Luis Potosí, SAN LUIS Potosi, 78216, Mexico|Centro de Investigacion Medico Biologico y Terapia Avanzada, S.C., Guadalajara, 44130, Mexico|Hospital Nacional Guillermo Almenara Irigoyen, La Victoria, Lima, Lima 13, Peru|Hospital Nacional Dos de Mayo; Unidad de Investigacion de Neurologia, Lima, 15003, Peru|Instituto Nacional de Ciencias Neurológicas - Hospital Mogrovejo; Peru, Lima, Lima 01, Peru|Clinica Sanchez Ferrer, Trujillo, 13009, Peru|Neurocentrum Bydgoszcz sp. z o.o, Bydgoszcz, 85-796, Poland|COPERNICUS Podmiot Leczniczy Sp. z o. o. Szpital im. M. Kopernika; Oddzia? Neurologiczny, Gdansk, 80-803, Poland|MA-LEK Clinical Sp. Z o.o., Katowice, 40-595, Poland|Specjalistyczny Szpital Sw. Lukasza, Konskie, 26-200, Poland|Szpital Specjalistyczny im. Rydygiera w Krakowie; Oddzial Neurologii i Udarow Mozgu, Krakow, 31-637, Poland|Centrum Neurologii Krzysztof Selmaj, Lodz, 90-324, Poland|Indywidualna Praktyka Lekarska Prof. Dr Hab. N. Med. Konrad Rejdak., Lublin, 20-016, Poland|Wojewodzki Szpital Specjalistyczny, Olsztyn, 10-561, Poland|Instytut Zdrowia Dr Boczarska-Jedynak Sp. z o.o. Sp. k., Oswiecim, 32-600, Poland|Neurologiczny Niepubliczny ZOZ Centrum Leczenia SM Osrodek Bada? Klinicznych, Plewiska, 62-064, Poland|EMC Instytut Medyczny SA, Pozna?, 60-309, Poland|Wojewódzki Szpital Specjalistyczny Nr 3, Rybnik, 44-200, Poland|Nzoz Palomed, Rzeszów, 35-232, Poland|NEURO-CARE Sp. z o.o. Sp. Komandytowa, Siemianowice ?l?skie, 41-100, Poland|Osrodek Badan Klinicznych Euromedis, Szczecin, 70-111, Poland|Centrum Medyczne NeuroProtect, Warszawa, 01-684, Poland|Instytut Psychiatrii i Neurologii II Klinika Neurologiczna, Warszawa, 02-957, Poland|Wojskowy Instytut Medyczny - Pa?Stwowy Instytut Badawczy, Warszawa, 04-141, Poland|Hospital Garcia de Orta; Servico de Neurologia, Almada, 2801-951, Portugal|Hospital de Braga; Centro Clínico Académico (Piso 1, Ala E), Braga, 4710-243, Portugal|Hospital Santo Antonio dos Capuchos; Servico de Neurologia, Lisboa, 1169-050, Portugal|Centro Hospitalar de Lisboa Ocidental - Hospital Egas Moniz; Neurologia, Lisboa, 1349-019, Portugal|Hospital Geral de Santo Antonio; Servico de Neurologia, Porto, 4099-001, Portugal|Centro Hospitalar de Setubal, EPE - Hospital São Bernardo; Serviço de Neurologia, Setúbal, 2910-446, Portugal|San Juan MS Center, Guaynabo, 00968, Puerto Rico|FSBHI Siberian Clinical Center of the Federal Medical and Biological Agency, Krasnoyarsk, Krasnojarsk, 660037, Russian Federation|Krasnoyarsk State Medical Academy, Krasnoyarsk, Krasnojarsk, 660049, Russian Federation|National Center of Social Significant Disease, Sankt-peterburg, Leningrad, 197110, Russian Federation|Research Center of Neurology of RAMS, Moscow, Moskovskaja Oblast, 125367, Russian Federation|Federal center of brain research and neurotechnologies, Moskva, Moskovskaja Oblast, 117997, Russian Federation|City Clinical Hospital #24; Multipal Sclerosis department, Moskva, Moskovskaja Oblast, 127015, Russian Federation|N.P. Bechtereva Institute of the Human Brain, Sankt-petersburg, Sankt Petersburg, 197376, Russian Federation|City Hospital #40 of Kurortniy Administrative District, St. Petersburg, Sankt Petersburg, 197706, Russian Federation|Vertebronevrologiya LLC, Kazan, Tatarstan, 420047, Russian Federation|Ulyanovsk Regional Clinical Hospital, Ulyanovsk, Uljanovsk, 432063, Russian Federation|SHI Sverdlovsk Regional Clinical Hospital #1;Neurology, Ekaterinburg, 620102, Russian Federation|Center of Cardiology and Neurology, Kirov, 610007, Russian Federation|Regional clinical hospital named after prof. S.V. Ochapovsky, Krasnodar, 350086, Russian Federation|FSBIH Siberian Regional Medical Centre of FMBA of Russia, Novosibirsk, 630007, Russian Federation|Perm SMA n.a. academ. E.A. Vagner, Perm, 614990, Russian Federation|Leningrad Regional Clinical Hospital, St Petersburg, 194291, Russian Federation|SBEI of HPE ?Bashkir State Medical University? of MoH RF, Ufa, 450000, Russian Federation|Hospital Quiron de Madrid; Servicio de Neurologia, Pozuelo de Alarcon, Madrid, 28223, Spain|Hospital Universitario Virgen de Arrixaca; Servicio de Neurología, EL Palmar (EL Palmar), Murcia, 30120, Spain|Hospital Universitari Vall d'Hebron; Servicio de Neumo-Inmunologia, Barcelona, 08035, Spain|Hospital Universitario Puerta De Hierro Majadahonda; Servicio de Neurología, Madrid, 28222, Spain|Kantonsspital Aarau AG Medizin Neurologie; Neurologie, Aarau, 5001, Switzerland|Inselspital Bern Medizin Neurologie; Neurologische Poliklinik, Bern, 3010, Switzerland|Ospedale Regionale di Lugano - Civico; Neurologia, Lugano, 6903, Switzerland|Gazi University Medical Faculty, Ankara, 06500, Turkey|Haseki Training and Research Hospital; Department of Neurology, Istanbul, 34096, Turkey|Istanbul Universitesi - Cerrahpasa Cerrahpasa Tip Fakultesi; Noroloji Anabilim Dali, Istanbul, 34098, Turkey|Sancaktepe Training and Research Hospital; Neurology, Istanbul, 34785, Turkey|Selcuk University Medical Faculty; Norology department, Istanbul, 42131, Turkey|Erciyes Universitesi; Pediatric Neurology, Kayseri, 38039, Turkey|Kocaeli University Hospital; Department of Neurology, Kocaeli, 41380, Turkey|Ege Üniversitesi Tip Fakültesi, Lzmir, 35100, Turkey|Cumhuriyet Universitesi Tip Fakultesi; Noroloji Bolumu, Merkez, 58060, Turkey|Mersin University Medical Faculty; Neurology, Mersin, 33079, Turkey|Ondokuz Mayis University School of Medicine; Neurology, Samsun, 55139, Turkey|Baskent Universitesi Ankara Hastanesi; Noroloji Bolumu, Çankaya, 06490, Turkey|Medical Center Dopomoga Plus, Kyiv, Chernihiv Governorate, 02123, Ukraine|Municipal Non-profit Enterprise Zaporizhzhya Regional Hospital Zaporizhzhya Regional Council, Zaporizhzhia, Katerynoslav Governorate, 69600, Ukraine|Municipal Nonprofit Enterprise of Kharkiv Regional Council Regional Clinical Hospital, Kharkiv, Kharkiv Governorate, 61058, Ukraine|State Institution Institute of Neurology, Psychiatry and Narcology of NAMS of Ukraine, Kharkiv, Kharkiv Governorate, 61068, Ukraine|Medical Center of Private Execution First Private Clinic, Kyiv, KIEV Governorate, 03037, Ukraine|Lvivska oblasna tsentralna likarnia, Lviv, KIEV Governorate, 79010, Ukraine|Medical Clinical Research Center of Medical Center LLC Health Clinic, Vinnytsia, Podolia Governorate, 21009, Ukraine|Sumy Regional Clinical Hospital, Sumy, Polissya Okruha, 40031, Ukraine|Miska Klinichna Likarnia ?16, Dnipropetrovsk, Tavria Okruha, 49100, Ukraine|Municipal Institution Cherkasy Regional Hospital of Cherkasy Regional Council, Cherkasy, 18009, Ukraine|Regional Clinical Hospital; Neurology Department, Ivano-Frankivsk, 76008, Ukraine|St.In.Inst. of Neurol.Psych.and Narcol.of the AMSU; Dept. of Neuroinfection and Multiply Sclerosis, Kharkov, 61068, Ukraine|Volyn Regional Clinical Hospital, Lutsk, 43024, Ukraine|University Hospital of Wales, Cardiff, CF14 4XW, United Kingdom|Charing Cross Hospital, London, W6 8RF, United Kingdom|National Hospital for Neurology and Neurosurgery,; MRC Centre for Neuromuscular Diseases, London, WC1 3BG, United Kingdom|Royal Victoria Infirmary, Newcastle upon Tyne, NE1 4LP, United Kingdom|University of Nottingham, Nottingham, NG7 2UH, United Kingdom|Derriford Hospital, Plymouth, PL6 8BT, United Kingdom"
NCT03436199,Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment,https://beta.clinicaltrials.gov/study/NCT03436199,COMPLETED,Walking Impairment|Multiple Sclerosis,"DRUG: ADS-5102, 137 mg|DRUG: ADS-5102, 274 mg|OTHER: Placebo","Adamas Pharmaceuticals, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE3,558,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-03-29,2019-12-10,2019-12-10,"Adamas Clinical Site, Cullman, Alabama, 35058, United States|Adamas Clinical Site, Phoenix, Arizona, 85032, United States|Adamas Clinical Site, Scottsdale, Arizona, 85251, United States|Adamas Clinical Site, Tucson, Arizona, 85704, United States|Adamas Clinical Site, Carlsbad, California, 92011, United States|Adamas Clinical Site, Fresno, California, 93710, United States|Adamas Clinical Site, Fullerton, California, 92835, United States|Adamas Clinical Site, Long Beach, California, 90806, United States|Adamas Clinical Site, Newport Beach, California, 92663, United States|Adamas Clinical Site, Sacramento, California, 95817, United States|Adamas Clinical Site, Aurora, Colorado, 80045, United States|Adamas Clinical Site, Colorado Springs, Colorado, 80907, United States|Adamas Clinical Site, Denver, Colorado, 80209, United States|Adamas Clinical Site, Fort Collins, Colorado, 80528, United States|Adamas Clinical Site, Fairfield, Connecticut, 06824, United States|Adamas Clinical Site, New London, Connecticut, 06320, United States|Adamas Clinical Site, Washington, District of Columbia, 20007, United States|Adamas Clinical Site, Maitland, Florida, 32751, United States|Adamas Clinical Site, Miami, Florida, 33136, United States|Adamas Clinical Site, Naples, Florida, 34105, United States|Adamas Clinical Site, Orlando, Florida, 32806, United States|Adamas Clinical Site, Ormond Beach, Florida, 32174, United States|Adamas Clinical Site, Palm Coast, Florida, 32164, United States|Adamas Clinical Site, Port Charlotte, Florida, 33952, United States|Adamas Clinical Site, Sarasota, Florida, 34233, United States|Adamas Clinical Site, Tampa, Florida, 33609, United States|Adamas Clinical Site, Vero Beach, Florida, 32960, United States|Adamas Clinical Site, Atlanta, Georgia, 30309, United States|Adamas Clinical Site, Savannah, Georgia, 31406, United States|Adamas Clinical Site, Northbrook, Illinois, 60062, United States|Adamas Clinical Site, Indianapolis, Indiana, 46256, United States|Adamas Clinical Site, Kansas City, Kansas, 66160, United States|Adamas Clinical Site, Lenexa, Kansas, 66214, United States|Adamas Clinical Site, Overland Park, Kansas, 66212, United States|Adamas Clinical Site, Foxboro, Massachusetts, 02035, United States|Adamas Clinical Site, Lexington, Massachusetts, 02421, United States|Admas Clinical Site, Detroit, Michigan, 48201, United States|Adamas Clinical Site, Farmington Hills, Michigan, 48334, United States|Adamas Clinical Site, Golden Valley, Minnesota, 55422, United States|Adamas Clinical Site, Kansas City, Missouri, 64111, United States|Adamas Clinical Site, Saint Louis, Missouri, 63110, United States|Adamas Clinical Site, Great Falls, Montana, 59405, United States|Adamas Clinical Site, Lincoln, Nebraska, 68506, United States|Adamas Clinical Site, Omaha, Nebraska, 68198, United States|Adamas Clinical Site, Las Vegas, Nevada, 89016, United States|Adamas Clinical Site, Albuquerque, New Mexico, 87131, United States|Adamas Clinical Site, Amherst, New York, 14226, United States|Adamas Clinical Site, Lake Success, New York, 11042, United States|Adamas Clinical Site, New York, New York, 10029, United States|Adamas Clinical Site, Patchogue, New York, 11772, United States|Adamas Clinical Site, Plainview, New York, 11803, United States|Adamas Clinical Site, Rochester, New York, 14642, United States|Adamas Clinical Site, Staten Island, New York, 10306, United States|Adamas Clinical Site, Charlotte, North Carolina, 28207, United States|Adamas Clinical Site, Raleigh, North Carolina, 27607, United States|Adamas Clinical Site, Centerville, Ohio, 45459, United States|Adamas Clinical Site, Cleveland, Ohio, 44195, United States|Adamas Clinical Site, Columbus, Ohio, 43214, United States|Adamas Clinical Site, Oklahoma City, Oklahoma, 73104, United States|Adamas Clinical Site, Portland, Oregon, 97225, United States|Adamas Clinical Site, Philadelphia, Pennsylvania, 19140, United States|Adamas Clinical Site, Charleston, South Carolina, 29406, United States|Adamas Clinical Site, Greer, South Carolina, 29650, United States|Adamas Clinical Site, Indian Land, South Carolina, 29707, United States|Adamas Clinical Site, Spartanburg, South Carolina, 29307, United States|Adamas Clinical Site, Cordova, Tennessee, 38018, United States|Adamas Clinical Site, Franklin, Tennessee, 37064, United States|Adamas Clinical Site, Johnson City, Tennessee, 37604, United States|Adamas Clinical Site, Houston, Texas, 77030, United States|Adamas Clinical Site, Houston, Texas, 77074, United States|Adamas Clinical Site, Round Rock, Texas, 78681, United States|Adamas Clinical Site, Salt Lake City, Utah, 84103, United States|Adamas Clinical Site, Newport News, Virginia, 23601, United States|Adamas Clinical Site, Norfolk, Virginia, 23502, United States|Adamas Clinical Site, Kirkland, Washington, 98034, United States|Adamas Clinical Site, Seattle, Washington, 98101, United States|Adamas Clinical Site, Seattle, Washington, 98122, United States|Adamas Clinical Site, Milwaukee, Wisconsin, 53215, United States|Adamas Clinical Site, Edmonton, Alberta, T6R 2B7, Canada|Adamas Clinical Site, Lethbridge, Alberta, T1J 0N9, Canada|Adamas Clinical Site, Burnaby, British Columbia, V5G 2X6, Canada|Adamas Clinical Site, Greenfield Park, Quebec, J4V 2J2, Canada|Adamas Clinical Site, Montréal, Quebec, H3A 2B4, Canada|Adamas Clinical Site, Quebec City, Quebec, G1J 1Z4, Canada"
NCT00882999,A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS),https://beta.clinicaltrials.gov/study/NCT00882999,COMPLETED,Relapsing-Remitting Multiple Sclerosis,DRUG: LY2127399|DRUG: Placebo,Eli Lilly and Company,,ALL,ADULT,PHASE2,245,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2009-04,2011-02,2012-06,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Phoenix, Arizona, 85013, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tucson, Arizona, 85741, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fullerton, California, 92835, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Denver, Colorado, 80220, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Naples, Florida, 34102, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Plantation, Florida, 33324, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sarasota, Florida, 34239, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Northbrook, Illinois, 60062, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, 46202, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kansas City, Kansas, 66160, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lexington, Kentucky, 40513, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Biddeford, Maine, 04005, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Farmington Hills, Michigan, 48334, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toms River, New Jersey, 08755, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Schenectady, New York, 12308, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charlotte, North Carolina, 28207, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Raleigh, North Carolina, 27607, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Akron, Ohio, 44320, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Green, Ohio, 44685, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greensburg, Pennsylvania, 15601, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greenville, South Carolina, 29615, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Franklin, Tennessee, 37064, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Memphis, Tennessee, 38120, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lubbock, Texas, 79410, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Round Rock, Texas, 78681, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Newport News, Virginia, 23601, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roanoke, Virginia, 24018, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sofia, 1407, Bulgaria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brno, 62500, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pardubice, 500 05, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Prague, 140 59, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Caen, 14033, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montpellier, 34295, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nimes, 30900, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Strasbourg, 67091, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, 13156, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ulm, 89075, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Budapest, 1095, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gyor, 9023, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gyula, 5700, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tel Hashomer, 52621, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gdansk, 80-952, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gliwice, 44-100, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Grodzisk Mazowiecki, 05-825, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Krakow-Nowa Huta, PL-31-826, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lodz, 90-549, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lublin, 20-090, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Targu Mures, 540136, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kazan, 4420029, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kemerovo, 650066, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moscow, 119435, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Belgrade, 11000, Serbia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nis, 18000, Serbia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bratislava, 833 05, Slovakia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kosice, 04011, Slovakia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Spisska Nova Ves, 05201, Slovakia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zilina, 01001, Slovakia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dnepropetrovsk, 49027, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Donetsk, 83037, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ivano-Frankivsk, 76008, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kharkiv, 61000, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vinnytsya, 21005, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zaporizhzhya, 69057, Ukraine"
NCT03369470,App Based Dexterity Training in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03369470,COMPLETED,Multiple Sclerosis,BEHAVIORAL: App Dexterity|BEHAVIORAL: Theraband,Luzerner Kantonsspital,"University Hospital Inselspital, Berne",ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2017-12-01,2021-08-01,2021-08-30,"Luzerner Kantonsspital, Luzern, 6000, Switzerland"
NCT04868370,Validation of a Novel Instrument Task for Assessing Upper Limb,https://beta.clinicaltrials.gov/study/NCT04868370,RECRUITING,Assessment of Arm and Hand Sensorimotor Functions in Multiple Sclerosis Subjects,OTHER: Assessment of the upper limb (VPIT + PPIT),Swiss Federal Institute of Technology,"Kliniken Valens, Rehazentrum Valens, Taminaplatz 1, 7317 Valens",ALL,"ADULT, OLDER_ADULT",,85,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-05-05,2023-04,2023-04,"Rehazentrum Valens, Valens, Saint Gallen, 7317, Switzerland"
NCT05437276,A Therapeutic Experience Program (TEP) Study for Improvement of Gait in People With Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT05437276,RECRUITING,Gait Impairment Due to Mild/Moderate Multiple Sclerosis (MS),DEVICE: PoNS®,Helius Medical Inc,,ALL,"ADULT, OLDER_ADULT",,50,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-07-01,2023-12,2024-07,"Shepherd Center, Atlanta, Georgia, 30309, United States|MGH Institute of Health Professions, Boston, Massachusetts, 02129, United States|Neurology Center of New England, P.C., Foxboro, Massachusetts, 02035, United States|NYU Langone Health, NYU Grossman School of Medicine, New York, New York, 10016, United States|Oregon Health and Science university (OHSU), Portland, Oregon, 97239, United States"
NCT00498199,"Visual Impairment, Oscillopsia and Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT00498199,TERMINATED,Multiple Sclerosis,PROCEDURE: visual tests,Hospices Civils de Lyon,,ALL,"ADULT, OLDER_ADULT",,100,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2007-04,,,"Caroline Tilikete, Lyon, 69677, France"
NCT02198599,Mobility Enhancing Nursing Intervention,https://beta.clinicaltrials.gov/study/NCT02198599,COMPLETED,Stroke|Multiple Sclerosis,PROCEDURE: Mobility-enhancing-nursing intervention,Zurich University of Applied Sciences,Swiss National Science Foundation,ALL,"ADULT, OLDER_ADULT",NA,140,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2011-03,2013-04,2013-04,"Zurich University of Applied Sciences, Winterthur, Zurich, 8401, Switzerland"
NCT04252599,Upper Airway Function and Cardiorespiratory Performance in Impair Trunk Motor Control Multiple Sclerosis Patients.,https://beta.clinicaltrials.gov/study/NCT04252599,UNKNOWN,Multiple Sclerosis,,Universidad de Granada,,ALL,"ADULT, OLDER_ADULT",,60,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-11-20,2019-12-02,2020-01-24,"Faculty of Healthy Sciences, Granada, 18016, Spain"
NCT01930799,Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns,https://beta.clinicaltrials.gov/study/NCT01930799,COMPLETED,Multiple Sclerosis|Urinary Bladder Diseases,BEHAVIORAL: Systematic Screening and Education Regimen,Allergan,,ALL,"ADULT, OLDER_ADULT",PHASE4,120,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2013-08,2015-03,2015-03,"Fresno, California, United States"
NCT03347370,A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03347370,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting",DRUG: SC Peginterferon beta-1a|DRUG: SC interferon beta-1a|DRUG: SC interferon beta-1b,Biogen,AMS Advanced Medical Services GmbH,ALL,"ADULT, OLDER_ADULT",,626,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-11-27,2019-07-31,2019-07-31,"Research Site, Göttingen, 37073, Germany"
NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT00835770,COMPLETED,Relapsing-Remitting Multiple Sclerosis,DRUG: dimethyl fumarate|DRUG: Placebo,Biogen,,ALL,ADULT,PHASE3,1736,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-02-03,2019-11-08,2019-11-08,"Research Site, Birmingham, Alabama, 35294, United States|Research Site, Huntsville, Alabama, 35801, United States|research Site, Mesa, Arizona, 85206, United States|Research Site, Phoenix, Arizona, 85013, United States|Research Site, Loma Linda, California, 92354, United States|Research Site, Boulder, Colorado, 80304, United States|Research Site, Fort Collins, Colorado, 80528, United States|Research Site, North Haven, Connecticut, 06473, United States|Research Site, Washington, District of Columbia, 20007, United States|Research Site, Maitland, Florida, 32751, United States|Research Site, Miami, Florida, 33136, United States|Research Site, Naples, Florida, 34102, United States|Research Site, Sarasota, Florida, 34239, United States|Research Site, Tampa, Florida, 33612, United States|Research Site, Atlanta, Georgia, 30309, United States|Research Site, Atlanta, Georgia, 30327, United States|Research Site, Evanston, Illinois, 60201, United States|Research Site, Fort Wayne, Indiana, 46845, United States|Research Site, Kansas City, Kansas, 66160, United States|Research Site, Wichita, Kansas, 67206, United States|Research Site, Shreveport, Louisiana, 71103, United States|Research Site, Baltimore, Maryland, 21201, United States|Research Site, Boston, Massachusetts, 02135, United States|Research Site, Boston, Massachusetts, 02215, United States|Research Site, Farmington Hills, Michigan, 48334, United States|Research Site, Minneapolis, Minnesota, 55414, United States|Research Site, Chesterfield, Missouri, 63017, United States|Research Site, Saint Louis, Missouri, 63104, United States|Research Site, Albany, New York, 12206, United States|Research Site, Amherst, New York, 14226, United States|Research Site, Buffalo, New York, 14203, United States|Research Site, Patchogue, New York, 11772, United States|Research Site, Charlotte, North Carolina, 28204, United States|Research Site, Raleigh, North Carolina, 27607, United States|Research Site, Bellevue, Ohio, 44811, United States|Research Site, Cleveland, Ohio, 44195, United States|Research Site, Columbus, Ohio, 43221, United States|Research Site, Dayton, Ohio, 45417, United States|Research Site, Medford, Oregon, 97504, United States|Research Site, Portland, Oregon, 97225, United States|Research Site, Philadelphia, Pennsylvania, 19104, United States|Research Site, Philadelphia, Pennsylvania, 19140, United States|Research Site, Pittsburgh, Pennsylvania, 15213, United States|Research Site, Rumford, Rhode Island, 02916, United States|Research Site, Cordova, Tennessee, 38018, United States|Research Site, Knoxville, Tennessee, 37922, United States|Research Site, Houston, Texas, 77030, United States|Research Site, Newport News, Virginia, 23601, United States|Research Site, Issaquah, Washington, 98029, United States|Research Site, Madison, Wisconsin, 53792, United States|Research Site, Kogarah, New South Wales, 2217, Australia|Research Site, New Lambton Heights, New South Wales, 2305, Australia|Research Site, Melbourne, Victoria, 3084, Australia|Research Site, Box Hill, 3128, Australia|Research Site, Chatswood, 2067, Australia|Research Site, Fitzroy, 3065, Australia|Research Site, Geelong, 3220, Australia|Research Site, Sydney, 2000, Australia|Research Site, Graz, 8036, Austria|Research Site, Linz, 4021, Austria|Research Site, Vienna, 1090, Austria|Research Site, Belarus, Gomel, 246029, Belarus|Research Site, Belarus, Vitebsk, 210023, Belarus|Research Site, Minsk, 220114, Belarus|Research Site, Minsk, 220116, Belarus|Research Site, Antwerpen, 2020, Belgium|Research Site, Brugge, 8000, Belgium|Research Site, Brussels, 1200, Belgium|Research Site, Charleroi, 6000, Belgium|Research Site, Damme, 8340, Belgium|Research Site, Diepenbeek, 3590, Belgium|Research Site, Hechtel-Eksel, 3940, Belgium|Research Site, Leuven, 3000, Belgium|Research Site, Lodelinsart, 6042, Belgium|Research Site, Sint-Truiden, 3800, Belgium|Research Site, Tuzla, 75000, Bosnia and Herzegovina|Research Site, Ruse, 7002, Bulgaria|Research Site, Sofia, 1113, Bulgaria|Research Site, Sofia, 1309, Bulgaria|Research Site, Sofia, 1431, Bulgaria|Research Site, Lévis, Quebec, G6V 3Z1, Canada|Research Site, Edmonton, T6G 2G3, Canada|Research Site, London, N6A 5A5, Canada|Research Site, Montreal, H3A 2B4, Canada|Research Site, Nova Scotia, B3H 4K4, Canada|Research Site, Ottawa, K2G 6E2, Canada|Research Site, Regina, S4T 7T1, Canada|Research Site, Zagreb, 10000, Croatia|Research Site, Brno, 656 91, Czechia|Research Site, Jihlava, 586 33, Czechia|Research Site, Moravska Ostrava, 702 00, Czechia|Research Site, Olomouc, 775 20, Czechia|Research Site, Opava, 746 01, Czechia|Research Site, Ostrava - Vítkovice, 70300, Czechia|Research Site, Prague, 128 08, Czechia|Research Site, Prague, 150 06, Czechia|Research Site, Teplice, 415 01, Czechia|Research Site, Parnu, 80010, Estonia|Research Site, Tallinn, 10138, Estonia|Research Site, Tallinn, 10617, Estonia|Research Site, Tartu, 51014, Estonia|Research Site, Amiens, 80054, France|Research Site, Caen, 14033, France|Research Site, Clermont-Ferrand, 63003, France|Research Site, Dijon, 21033, France|Research Site, Lille, 59037, France|Research Site, Lyon, 69394, France|Research Site, Marseille, 13385, France|Research Site, Montpellier, 34090, France|Research Site, Nancy, 54035, France|Research Site, Nice, 06002, France|Research Site, Paris, 75019, France|Research Site, Rennes, 35033, France|Research Site, Strasbourg, 67000, France|Research Site, Berg, Bavaria, 82335, Germany|Research Site, Steinfurt, Ibbenbueren, 49477, Germany|Research Site, Bayreuth, 95445, Germany|Research Site, Berlin, 10437, Germany|Research Site, Berlin, 10625, Germany|Research Site, Berlin, 10961, Germany|Research Site, Berlin, 12099, Germany|Research Site, Berlin, 12163, Germany|Research Site, Berlin, 13347, Germany|Research Site, Bochum, 44791, Germany|Research Site, Dresden, 01307, Germany|Research Site, Dusseldorf, 40212, Germany|Research Site, Erbach, 64711, Germany|Research Site, Erlangen, 91054, Germany|Research Site, Essen, 45257, Germany|Research Site, Halle, 06120, Germany|Research Site, Hamburg, 20099, Germany|Research Site, Hamburg, 20246, Germany|Research Site, Hamburg, 22083, Germany|Research Site, Hannover, 30171, Germany|Research Site, Hannover, 30625, Germany|Research Site, Koeln, 50935, Germany|Research Site, Leipzig, 04103, Germany|Research Site, Magdeburg, 39120, Germany|Research Site, Marburg, 35043, Germany|Research Site, Minden, 32429, Germany|Research Site, Munich (München), 81675, Germany|Research Site, Münster, 48149, Germany|Research Site, Osnabrück, 49076, Germany|Research Site, Regensburg, 93053, Germany|Research Site, Westerstede, 26655, Germany|Research Site, Athens, 11527, Greece|Research Site, Thessaloniki, 54636, Greece|Research Site, Thessaloniki, 57010, Greece|Research Site, Ahmedabad, 380006, India|Research Site, Bangalore, 560054, India|Research Site, Chandigarh, 160012, India|Research Site, Hyderabad, 500082, India|Research Site, Kolkata, 700054, India|Research Site, Kolkata, 700068, India|Research Site, Ludhiana, 141001, India|Research Site, Ludhiana, 141008, India|Research Site, Mangalore, 575002, India|Research Site, Mumbai, 400054, India|Research Site, New Delhi, 110017, India|Research Site, New Delhi, 110029, India|Research Site, New Delhi, 110060, India|Research Site, Pune, 411001, India|Research Site, Pune, 411004, India|Research Site, Dublin, DUBLIN 4, Ireland|Research Site, Ashkelon, 78278, Israel|Research Site, Jerusalem, 9112001, Israel|Research Site, Safed, 13100, Israel|Research Site, Roma, 00189, Italy|Research Site, Riga, LV-1015, Latvia|Research Site, Guadalajara, 44610, Mexico|Research Site, Mexico, 03310, Mexico|Research Site, Mexico, 06700, Mexico|Research Site, Mexico, 06720, Mexico|Research Site, Morelia, 58000, Mexico|Research Site, San Luis Potosi, 78240, Mexico|Research Site, Chisinau, 2001, Moldova, Republic of|Research Site, Chisinau, 2028, Moldova, Republic of|Research Site, Breda, 4818 CK, Netherlands|Research Site, Geleen, 6162 BG, Netherlands|Research Site, Auckland, 1023, New Zealand|Research Site, Christchurch, 8011, New Zealand|Research Site, Hamilton, 3204, New Zealand|Research Site, Skopje, 1000, North Macedonia|Research Site, Bialystok, 15-276, Poland|Research Site, Bialystok, 15-402, Poland|Research Site, Gdansk, 80-299, Poland|Research Site, Gdansk, 80-803, Poland|Research Site, Gdansk, 80-952, Poland|Research Site, Katowice, 40-594, Poland|Research Site, Katowice, 40-752, Poland|Research Site, Krakow, 31-505, Poland|Research Site, Lublin, 20-954, Poland|Research Site, Lódz, 90-153, Poland|Research Site, Olsztyn, 10-561, Poland|Research Site, Plewiska, 62-064, Poland|Research Site, Poznan, 60-355, Poland|Research Site, Poznan, 60-539, Poland|Research Site, Szczecin, 70-215, Poland|Research Site, Szczecin, 71-252, Poland|Research Site, Warszawa, 02-097, Poland|Research Site, Warszawa, 02-507, Poland|Research Site, Warszawa, 02-957, Poland|Research Site, Wroclaw, 50-556, Poland|Research Site, Guaynabo, 00968, Puerto Rico|Research Site, Bucuresti, 011464, Romania|Research Site, Bucuresti, 020125, Romania|Research Site, Bucuresti, 022104, Romania|Research Site, Bucuresti, 050098, Romania|Research Site, Cluj-Napoca, 400012, Romania|Research Site, Timisoara, 300736, Romania|Research Site, Târgu Mures, 540136, Romania|Research Site, Belgrade, 11000, Serbia|Research Site, Kragujevac, 34000, Serbia|Research Site, Nis, 18000, Serbia|Research Site, Novi Sad, 21000, Serbia|Research Site, Bratislava, 81369, Slovakia|Research Site, Bratislava, 82606, Slovakia|Research Site, Martin, 03659, Slovakia|Research Site, Cape Town, 7925, South Africa|Research Site, Durban, 4001, South Africa|Research Site, Barcelona, 08035, Spain|Research Site, Córdoba, 14011, Spain|Research Site, Madrid, 28040, Spain|Research Site, Malaga, 29010, Spain|Research Site, Sevilla, 41009, Spain|Research Site, Basel, 4031, Switzerland|Research Site, St. Gallen, 9007, Switzerland|Research Site, Zurich, 8091, Switzerland|Research Site, Ivano-Frankivsk, 76018, Ukraine|Research Site, Kharkiv, 61068, Ukraine|Research Site, Kharkiv, 61103, Ukraine|Research Site, Kyiv, 03110, Ukraine|Research Site, Kyiv, 04112, Ukraine|Research Site, Lviv, 79010, Ukraine|Research Site, Odessa, 65117, Ukraine|Research Site, Poltava, 36011, Ukraine|Research Site, Vinnytsia, 21005, Ukraine|Research Site, Zaporizhzhia, 69600, Ukraine|Research Site, London, E1 2EF, United Kingdom|Research Site, London, E1 4AT, United Kingdom|Research Site, London, SE5 9NT, United Kingdom|Research Site, London, W6 8RF, United Kingdom|Research Site, Newcastle upon Tyne, NE1 4HH, United Kingdom|Research Site, Oxford, OX3 9DU, United Kingdom|Research Site, Sheffield, S10 2JF, United Kingdom|Research Site, Stoke on Trent, ST4 6QG, United Kingdom"
NCT05326711,Effects of Telerehabilitation-Based Motor Imagery Training on Pain in People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05326711,RECRUITING,Multiple Sclerosis|Pain,BEHAVIORAL: Telerehabilitation-based motor imagery training,Dokuz Eylul University,Izmir Katip Celebi University,ALL,"ADULT, OLDER_ADULT",NA,32,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-04-11,2023-05-11,2023-08-11,"Dokuz Eylul University Hospital, MS Outpatient Clinic, Izmir, Inciralti, 35340, Turkey|Dokuz Eylul University Hospital, MS Outpatient Clinic, Izmir, 35430, Turkey"
NCT04314076,Rhythmic Auditory Stimulation & Gait Training,https://beta.clinicaltrials.gov/study/NCT04314076,COMPLETED,"Multiple Sclerosis|Gait Disorders, Neurologic",OTHER: Rhythmic auditory stimulation|OTHER: Gait Training,The Cleveland Clinic,"Consortium of Multiple Sclerosis Centers|MedRhythms, Inc.",ALL,"ADULT, OLDER_ADULT",NA,24,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: OTHER,2020-06-08,2022-11-07,2022-11-07,"Cleveland Clinic, Cleveland, Ohio, 44195, United States"
NCT05197699,Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2)-Related Multiple Sclerosis (MS) Vaccination Study,https://beta.clinicaltrials.gov/study/NCT05197699,RECRUITING,Multiple Sclerosis (MS),,Biogen,,ALL,"ADULT, OLDER_ADULT",,200,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-07-01,2023-12-01,2023-12-01,"Multiple Sklerose Zentrum, Bamberg, Germany|St. Josef Hospital, Klinikum der Ruhr-Universität Bochum, Bochum, Germany|Universitätsklinikum Erlangen, Neurologische Klinik, Erlangen, Germany|Universitätsklinik Freiburg, Neurologie, Freiburg, Germany|Klinik für Neurologie, Haar, Germany|UKE Hamburg, Klinik und Poliklinik für Neurologie, Hamburg, Germany|Univ.-Klinikum Heidelberg, Neurologische Klinik, Heidelberg, Germany|Klinik und Poliklinik für Neurologie, Leipzig, Germany|Klinik und Poliklinik für Neurologie, Munich, Germany|Universitätsklinikum Tübingen, Neurologie, Tübingen, Germany|Neuropraxis München Süd, Unterhaching, Germany|DKD Helios Klinik, Neurologie, Wiesbaden, Germany"
NCT05776511,Diagnostic Value of eVOG,https://beta.clinicaltrials.gov/study/NCT05776511,RECRUITING,Multiple Sclerosis|Radiologically Isolated Syndrome|White Matter Lesions,PROCEDURE: eVOG,Centre Hospitalier Universitaire de Nice,,ALL,"ADULT, OLDER_ADULT",NA,150,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2023-04-07,2025-04-01,2026-04-01,"Nice University Hospital, Nice, 06000, France"
NCT05142111,Pilot Study on EEG and Behavioral Effects of Two Different Treatments on Sexual Life,https://beta.clinicaltrials.gov/study/NCT05142111,RECRUITING,Multiple Sclerosis|Spinal Cord Injuries,BEHAVIORAL: Therapy,"IRCCS San Camillo, Venezia, Italy",,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2021-04-01,2023-03-31,2023-03-31,"IRCCS San Camillo, Venice, 30126, Italy"
NCT00313976,"Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)",https://beta.clinicaltrials.gov/study/NCT00313976,WITHDRAWN,Multiple Sclerosis,"DRUG: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|DRUG: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,0,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",,,,"ask Contact, Denmark|Copenhagen, DK-2100, Denmark|Hillerød, DK-3400, Denmark|Holstebro, DK-7500, Denmark|Stockholm, 11281, Sweden|Stockholm, 14186, Sweden|Stockholm, 171 76, Sweden"
NCT01606176,A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin,https://beta.clinicaltrials.gov/study/NCT01606176,COMPLETED,Pain|Multiple Sclerosis,DRUG: GW-1000-02|DRUG: Placebo,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,70,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2002-03,2002-08,2002-08,"James Paget Hospital, Norfolk, NR31 6LA, United Kingdom"
NCT02970370,"Demographics, Clinical and Paraclinical Characteristics of Multiple Sclerosis in Egypt",https://beta.clinicaltrials.gov/study/NCT02970370,COMPLETED,Multiple Sclerosis,OTHER: no intervention,Cairo University,,ALL,"CHILD, ADULT, OLDER_ADULT",,2752,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-12,2016-07,,
NCT02789670,Analysis of the Distribution of Regulatory B Cells in Blood of Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT02789670,COMPLETED,Multiple Sclerosis|Systemic Sclerosis,OTHER: Blood sample collection,"University Hospital, Lille",,ALL,"ADULT, OLDER_ADULT",,137,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-07,2021-04,2021-04,"CHRU de Lille, Lille, 59037, France"
NCT01377870,Evaluation of Autologous Mesenchymal Stem Cell Transplantation (Effects and Side Effects) in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01377870,COMPLETED,Multiple Sclerosis,BIOLOGICAL: intravenous injection of mesenchymal stem cells|BIOLOGICAL: injection of cell free media,Royan Institute,,ALL,ADULT,PHASE1|PHASE2,22,OTHER_GOV,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2011-12,2014-03,2014-04,"Royan Institute, Tehran, Iran, Islamic Republic of"
NCT02568111,Brimonidine Tartrate for the Treatment of Injection Related Erythema,https://beta.clinicaltrials.gov/study/NCT02568111,WITHDRAWN,Relapsing-Remitting Multiple Sclerosis (RRMS),DRUG: peginterferon beta-1a|DRUG: brimonidine tartrate|DRUG: Vehicle Gel,Biogen,,ALL,"ADULT, OLDER_ADULT",PHASE4,0,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE",2016-02,2016-08,2016-08,
NCT04595799,Use of a Smartphone Application to Predict the Prognosis in Patients With Newly Diagnosed Multiple Sclerosis.,https://beta.clinicaltrials.gov/study/NCT04595799,RECRUITING,Multiple Sclerosis,,Centre Hospitalier Universitaire de Nice,,ALL,ADULT,,100,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-11-09,2022-11-09,2025-11-09,"Lille University Hospital, Lille, 59037, France|LYON Civil Hospital, Lyon, 69000, France|Montpellier university hospital, Montpellier, 34295, France|Nice University Hospital, Nice, 06000, France|Nimes University Hospital, Nîmes, 30900, France|Paris University Hospital - la pitié salpétriere, Paris, 75013, France|Rennes University Hospital, Rennes, 35033, France|Rouen University hospital, Rouen, 76031, France|Strasbourg University Hospital, Strasbourg, 67000, France|Toulouse university hospital, Toulouse, 31059, France"
NCT05154370,China National Registry of CNS Inflammatory Demyelinating Diseases,https://beta.clinicaltrials.gov/study/NCT05154370,RECRUITING,Multiple Sclerosis|NMO Spectrum Disorder|Clinically Isolated Syndrome|CNS Demyelinating Autoimmune Diseases|Acute Disseminated Encephalomyelitis,DRUG: Intravenous steroid,Beijing Tiantan Hospital,,ALL,"CHILD, ADULT, OLDER_ADULT",,10000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-12-15,2026-11-01,2026-11-01,"Beijing Tiantan Hospital, Beijing, Beijing, 100069, China"
NCT02099370,Adherence to Treatment With Tecfidera™ in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT02099370,COMPLETED,Multiple Sclerosis,,University of South Florida,Biogen,ALL,"ADULT, OLDER_ADULT",,34,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-03,2016-01,2016-01,"USF Carol and Frank Morsani Center for Advanced Healthcare, Tampa, Florida, 33612, United States"
NCT02442570,A Study to Evaluate Safety and Efficacy of DC-TAB in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02442570,COMPLETED,Multiple Sclerosis,BIOLOGICAL: recombinant human alpha B-crystallin|OTHER: Placebo comparator,Delta Crystallon BV,,ALL,ADULT,PHASE2,32,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-09,2014-06,2015-02,"Sveti Naum Hospital, Sofia, 1113, Bulgaria|National Cardiology Hopsital, Sofia, 1309, Bulgaria|Tokuda Hospital Sofia, Sofia, 1407, Bulgaria|Aleksandrovska Hospital, Sofia, 1431, Bulgaria|Military Medical Academy, Sofia, 1431, Bulgaria"
NCT01564511,Effects of Electromechanical Gait Trainer in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01564511,COMPLETED,Relapsing-Remitting Multiple Sclerosis,DEVICE: Gait trainer treatment|OTHER: Conventional treatment,Universita di Verona,,ALL,ADULT,NA,50,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2011-11,2012-02,2012-12,"S.S.O. di Riabilitazione dell'Ospedale Policlinico, Verona, 37124, Italy"
NCT01854957,MEsenchymal StEm Cells for Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01854957,UNKNOWN,Multiple Sclerosis,BIOLOGICAL: Autologous Mesenchymal Stem Cells,Antonio Uccelli,Azienda Ospedaliera Universitaria Integrata Verona|Ospedale San Raffaele,ALL,ADULT,PHASE1|PHASE2,20,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-07,2014-07,2014-09,"University of Genova, Genova, 16132, Italy"
NCT01112657,An Observational Study on the Progression of Clinically Isolated Syndrome to Multiple Sclerosis Over a 2-year Period,https://beta.clinicaltrials.gov/study/NCT01112657,COMPLETED,Multiple Sclerosis,,"Merck KGaA, Darmstadt, Germany",,ALL,"CHILD, ADULT",,154,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2008-11,2014-10,2014-10,"Kaohsiung Medical University, Chung-Ho Memorial Hospital, Kaohsiung, 807, Taiwan|Chang-Gung Memorial Hospital - Kaohsiung Branch, Kaohsiung, 833, Taiwan|China Medical University Hospital, Taichung, 404, Taiwan|National Taiwan University Hospital, Taipei, 100, Taiwan|Taipei Veterans General Hospital, Taipei, 201, Taiwan|Chang-Gung Memorial Hospital - Linkou Branch, Taoyuan, 333, Taiwan"
NCT01084798,A Retrospective Study to Understand the Clinical Management of Subjects With Multiple Sclerosis at a Site in Taiwan Over the Last 10 Years,https://beta.clinicaltrials.gov/study/NCT01084798,COMPLETED,Multiple Sclerosis,,"Merck KGaA, Darmstadt, Germany",,ALL,"CHILD, ADULT, OLDER_ADULT",,123,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2008-08,2008-12,2009-11,"Chang-Gung Memorial Hospital, Taoyuan county, 333, Taiwan"
NCT00336557,Determine Impact of Multiple NAb Tests on Treatment Compared to Usual Care of MS Patients on High-dose IFN Therapy,https://beta.clinicaltrials.gov/study/NCT00336557,COMPLETED,Multiple Sclerosis,PROCEDURE: NAbs testing,"Teva Branded Pharmaceutical Products R&D, Inc.",,ALL,"ADULT, OLDER_ADULT",,1230,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2006-07,2009-04,2009-07,"Phoenix Neurological Associates, LTD, Phoenix, Arizona, 85006, United States|East Bay Physicians Medical Group, Berkley, California, 94705, United States|Neuro-Pain Medical Center, Fresno, California, 93710, United States|Fullerton Neurology and Headache Center, Fullerton, California, 92835, United States|University of Southern California, Los Angeles, California, 90033, United States|University of California, Davis, Sacramento, California, 95817, United States|Neurology Clinic of Marin, San Anselmo, California, 94960, United States|Colorado Springs Neurological Associates, PC, Colorado Springs, Colorado, 80910, United States|Colorado Neurosurgery, Engelwood, Colorado, 80113, United States|The Emery Neuroscience Center, Ft. Lauderdale, Florida, 33308, United States|Neurology Associates, PA, Maitland, Florida, 32751, United States|Collier Neurologic Specialitsts, Naples, Florida, 34102, United States|Axiom Clinical Research of Florida, Tampa, Florida, 33609, United States|University of South Florida, Tampa, Florida, 33612, United States|Medical College of Georgia Augusta MS Center, Augusta, Georgia, 30912, United States|Carle Clinic Association, Urbana, Illinois, 61801, United States|Neurology Associates, Hopedale, Massachusetts, 01747, United States|Lahey Clinic, Lexinton, Massachusetts, 02124, United States|South Shores Neurology Associates, INC, South Weymouth, Massachusetts, 02190, United States|Michigan Neurology Associates, St Clair Shores, Michigan, 48080, United States|Mankato Clinic, Mankato, Minnesota, 56001, United States|Columbia Center for Neurology and MS, Columbia, Missouri, 65201, United States|St John's Mercy Medical Center, St Louis, Missouri, 63141, United States|Advanced Neurology Specialist, Great Falls, Montana, 59405, United States|Creighton University Department of Neurology, Bellvue, Nebraska, 68123, United States|The Neuroscience Center of Northern NJ, Morristown, New Jersey, 07960, United States|Neurology Associates of Albany, P.C., Albany, New York, 12208, United States|NYU Hospital for Join Diseases, MS Center, New York, New York, 10003, United States|Comprehensive MS Care Clinic at South Shore Neurology, Patchogue, New York, 11772, United States|Rochester Multiple Sclerosis Center, Rochester, New York, 14642, United States|Asheville Neurology Specialist, PA, Asheville, North Carolina, 28806, United States|East Carolina Neurology, Greenville, North Carolina, 27834, United States|Alliance for Neuro Research, LLC Absher Neurology, Greenville, North Carolina, 29615, United States|Raleigh Neurology Associates, Raleigh, North Carolina, 27607, United States|Central Carolina Neurology & Sleep, Salisbury, North Carolina, 28144, United States|NeuroCare Center, Canton, Ohio, 44718, United States|Neurology Specialists, Inc, Dayton, Ohio, 45408, United States|Oak Clinic, Uniontown, Ohio, 44685, United States|Medford Neurological Clinic,Inc, Medford, Oregon, 97504, United States|Abington Neurological Associates, Abington, Pennsylvania, 19001, United States|Neurology Associates of Monroe County, East Stroudsburg, Pennsylvania, 18301, United States|North Shore Clinical Associates, Erie, Pennsylvania, 16507, United States|NeuroHealth, INC, Warwick, Rhode Island, 02886, United States|Mid-South Physicians, Germantown, Tennessee, 38138, United States|Central Texas Neurology, Round Rock, Texas, 78681, United States|Neurology Center of San Antonio, P.A., San Antonio, Texas, 78212, United States|Neurology Center of San Antonio, San Antonio, Texas, 78232, United States|Rocky Mountain Multiple Sclerosis Clinic, Salt Lake City, Utah, 84103, United States|Dean Health System, Madison, Wisconsin, 53715, United States"
NCT02391298,An Online Self-Guided Meditation Course for Individuals With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02391298,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Mindfulness Meditation,Haley Duncanson,Suffolk University,ALL,"ADULT, OLDER_ADULT",NA,26,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-12,2016-05,2016-05,"Suffolk University, Boston, Massachusetts, 02114, United States"
NCT05245344,Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study,https://beta.clinicaltrials.gov/study/NCT05245344,NOT_YET_RECRUITING,Relapsing-Remitting Multiple Sclerosis (RRMS)|Neuromyelitis Optica|Healthy,PROCEDURE: Peripheral blood withdrawal,Neuromed IRCCS,University of Rome Tor Vergata,ALL,ADULT,,154,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-04-01,2023-06-30,2023-10-31,"IRCCS INM-Neuromed, Pozzilli, Isernia, 86077, Italy|IRCCS Ospedale Policlinico San Martino, Genova, Italy|Centre for Experimental Neurological Therapies (CENTERS), Department of Neurosciences, Mental Health and Sensory Organs, Sapienza University of Rome, Roma, Italy"
NCT01791244,A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device,https://beta.clinicaltrials.gov/study/NCT01791244,COMPLETED,Multiple Sclerosis|Relapsing-Remitting,DRUG: Rebif®,"Merck KGaA, Darmstadt, Germany",,ALL,"ADULT, OLDER_ADULT",PHASE4,93,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2013-02-28,2016-02-29,2016-02-29,"Please contact the Merck Communications Service for Recruiting locations, Darmstadt, Germany|Research site, Angered, Sweden|Research Site, Danderyd, Sweden|Research Site, Eksjö, Sweden|Research Site, Gävle, Sweden|Research Site, Karlstad, Sweden|Research Site, KS Huddinge, Sweden|Research Site, Linköping, Sweden|Research Site, Malmö/Lund, Sweden|Research Site, Motala, Sweden|Research Site, Skövde, Sweden|Research Site, Trollhättan, Sweden|Research site, Ängelholm, Sweden|Research Site, Örnsköldsvik, Sweden"
NCT01399957,Responsiveness to Dalfampridine-ER Treatment Among Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT01399957,COMPLETED,Multiple Sclerosis,,Mount Sinai Rehabilitation Hospital,Brown University|Acorda Therapeutics,ALL,"ADULT, OLDER_ADULT",,52,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-08,2014-09,2015-09,"Mandell Center for Multiple Sclerosis at the Mount Sinai Rehabilitation Hospital, Hartford, Connecticut, 06112, United States"
NCT00439257,"Costs, Quality of Life and Functional Outcomes in Veterans Treated for Multiple Sclerosis With Beta-Interferon l-B (Betaseron)",https://beta.clinicaltrials.gov/study/NCT00439257,COMPLETED,Multiple Sclerosis,,US Department of Veterans Affairs,,ALL,"CHILD, ADULT, OLDER_ADULT",,124,FED,OBSERVATIONAL,Observational Model: |Time Perspective: p,,,2000-06,"VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven, Connecticut, 06516, United States"
NCT05821257,Arm Swing During Walking in Early Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05821257,ACTIVE_NOT_RECRUITING,"Multiple Sclerosis|Upper Extremity Problem|Gait Disorders, Neurologic",OTHER: Evaluation of the arm swing during gait|OTHER: Functional Tests,Istanbul University - Cerrahpasa (IUC),,ALL,"ADULT, OLDER_ADULT",,28,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-12-01,2023-05,2023-06,"Istanbul University-Cerrahpaşa, Istanbul, Turkey"
NCT01865357,Prospective Longitudinal 1-year Study of the Correlation Between Cognitive Functioning in Patients With Clinically Isolated Syndrome Suggestive of Multiple Sclerosis and Disconnection in the Brain Assessed by MRI,https://beta.clinicaltrials.gov/study/NCT01865357,COMPLETED,Clinically Isolated Demyelinating Syndromes|Multiple Sclerosis|Cognitive Deficiencies|Brain MRI,OTHER: Brain MRI - Clinical and cognitive evaluation|OTHER: Eye movement,"University Hospital, Bordeaux",TEVA laboratories,ALL,"ADULT, OLDER_ADULT",NA,117,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2012-08-24,2016-12-01,2016-12-01,"CHU de Bordeaux, Bordeaux, 33000, France"
NCT05155644,Safety of Therapeutic Step-down in Neuromyelitis Optica,https://beta.clinicaltrials.gov/study/NCT05155644,COMPLETED,Neuromyelitis Optica,,"University Hospital, Strasbourg, France",,ALL,"ADULT, OLDER_ADULT",,947,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-08-01,2021-11-30,2021-12-31,"Service de Neurologie - Hôpitaux Universitaires de Strasbourg, Strasbourg, 67091, France"
NCT00937157,Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA),https://beta.clinicaltrials.gov/study/NCT00937157,COMPLETED,Multiple Sclerosis,DRUG: Copaxone,University at Buffalo,"Teva Neuroscience, Inc.",ALL,"ADULT, OLDER_ADULT",NA,12,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2007-09,2010-07,2011-04,"Jacobs Neurological Institute, Buffalo, New York, 14203, United States"
NCT02010398,Effects of the Cross-Training in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02010398,COMPLETED,Multiple Sclerosis|Weakness|Fatigue,OTHER: Cross-Training healthy subjects|OTHER: Cross-Training multiple sclerosis|OTHER: Standard-training multiple sclerosis,Università degli Studi di Sassari,,ALL,"ADULT, OLDER_ADULT",NA,45,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-07,2017-03-27,2017-03-27,"Department of Biomedical Sciences- University of Sassari, Sassari, Sassari (SS), 07100, Italy|Department of Clinical and Experimental Medicine, University of Sassari, Sassari, 07100, Italy|Department of Surgery, Microsurgery and Medical-Surgical Specialties, Sassari, 07100, Italy"
NCT04266444,Functional Exercise in Virtual Environment for Persons With Multiple Sclerosis or Parkinson's Disease,https://beta.clinicaltrials.gov/study/NCT04266444,COMPLETED,Parkinson Disease|Multiple Sclerosis,DEVICE: Exergaming in virtual environment,"University Rehabilitation Institute, Republic of Slovenia",,ALL,"ADULT, OLDER_ADULT",NA,108,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-02-06,2021-09-29,2021-09-29,"University Rehabilitation Institute, Republic of Slovenia, Ljubljana, 1000, Slovenia"
NCT03893344,STAT4 in Multiple Sclerosis by PCR and Flow Cytometry,https://beta.clinicaltrials.gov/study/NCT03893344,COMPLETED,Multiple Sclerosis,DIAGNOSTIC_TEST: detection of STAT4 gene,Assiut University,,ALL,"CHILD, ADULT, OLDER_ADULT",,104,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-09-20,2020-05-20,2020-05-22,"Assiut University Hospital, Assiut, 71111, Egypt"
NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),https://beta.clinicaltrials.gov/study/NCT01665144,ACTIVE_NOT_RECRUITING,Secondary Progressive Multiple Sclerosis,DRUG: BAF312|DRUG: Placebo,Novartis Pharmaceuticals,,ALL,ADULT,PHASE3,1652,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2012-12-20,2016-04-29,2024-03-01,"Novartis Investigative Site, Phoenix, Arizona, 85032, United States|Novartis Investigative Site, Berkeley, California, 94705, United States|Novartis Investigative Site, Los Angeles, California, 90033, United States|Novartis Investigative Site, Oceanside, California, 92056, United States|Novartis Investigative Site, Sacramento, California, 95817, United States|Novartis Investigative Site, Aurora, Colorado, 80045, United States|Novartis Investigative Site, Basalt, Colorado, 81621, United States|Novartis Investigative Site, Boulder, Colorado, 80301, United States|Novartis Investigative Site, Colorado Springs, Colorado, 80907, United States|Novartis Investigative Site, Englewood, Colorado, 80113, United States|Novartis Investigative Site, Fairfield, Connecticut, 06824, United States|Novartis Investigative Site, Delray Beach, Florida, 33445, United States|Novartis Investigative Site, Jacksonville, Florida, 32209, United States|Novartis Investigative Site, Maitland, Florida, 32751, United States|Novartis Investigative Site, Ormond Beach, Florida, 32174, United States|Novartis Investigative Site, Port Charlotte, Florida, 33952, United States|Novartis Investigative Site, Sunrise, Florida, 33351, United States|Novartis Investigative Site, Tampa, Florida, 33609, United States|Novartis Investigative Site, Tampa, Florida, 33612, United States|Novartis Investigative Site, Vero Beach, Florida, 32960, United States|Novartis Investigative Site, Chicago, Illinois, 60612, United States|Novartis Investigative Site, Evanston, Illinois, 60201, United States|Novartis Investigative Site, Flossmoor, Illinois, 60422, United States|Novartis Investigative Site, Lenexa, Kansas, 66212, United States|Novartis Investigative Site, Baltimore, Maryland, 21287, United States|Novartis Investigative Site, Ann Arbor, Michigan, 48109, United States|Novartis Investigative Site, Detroit, Michigan, 48201, United States|Novartis Investigative Site, Detroit, Michigan, 48202, United States|Novartis Investigative Site, Golden Valley, Minnesota, 55422, United States|Novartis Investigative Site, Saint Louis, Missouri, 63131, United States|Novartis Investigative Site, Las Vegas, Nevada, 89106, United States|Novartis Investigative Site, Lebanon, New Hampshire, 03756, United States|Novartis Investigative Site, Freehold, New Jersey, 07728, United States|Novartis Investigative Site, Albuquerque, New Mexico, 87131-0001, United States|Novartis Investigative Site, New York, New York, 10017, United States|Novartis Investigative Site, New York, New York, 10029, United States|Novartis Investigative Site, Patchogue, New York, 11772, United States|Novartis Investigative Site, Stony Brook, New York, 11794, United States|Novartis Investigative Site, Charlotte, North Carolina, 28207, United States|Novartis Investigative Site, Akron, Ohio, 44320, United States|Novartis Investigative Site, Dayton, Ohio, 45408, United States|Novartis Investigative Site, Portland, Oregon, 97225, United States|Novartis Investigative Site, Springfield, Oregon, 97477, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, 19104, United States|Novartis Investigative Site, Providence, Rhode Island, 02905, United States|Novartis Investigative Site, Dallas, Texas, 75216, United States|Novartis Investigative Site, Lubbock, Texas, 79410, United States|Novartis Investigative Site, San Antonio, Texas, 78258, United States|Novartis Investigative Site, Burlington, Vermont, 05401, United States|Novartis Investigative Site, Seattle, Washington, 98101, United States|Novartis Investigative Site, Seattle, Washington, 98122, United States|Novartis Investigative Site, Milwaukee, Wisconsin, 53215, United States|Novartis Investigative Site, Caba, Buenos Aires, 1425, Argentina|Novartis Investigative Site, Caba, Buenos Aires, C1181ACH, Argentina|Novartis Investigative Site, Caba, Buenos Aires, C1428AQK, Argentina|Novartis Investigative Site, Capital Federal, Buenos Aires, 1424, Argentina|Novartis Investigative Site, Buenos Aires, 1061, Argentina|Novartis Investigative Site, Cordoba, X5000FAL, Argentina|Novartis Investigative Site, Camperdown, New South Wales, 2050, Australia|Novartis Investigative Site, Kogarah, New South Wales, 2217, Australia|Novartis Investigative Site, Liverpool, New South Wales, 2170, Australia|Novartis Investigative Site, Heidelberg, Victoria, 3084, Australia|Novartis Investigative Site, Parkville, Victoria, 3050, Australia|Novartis Investigative Site, Klagenfurt, 9020, Austria|Novartis Investigative Site, Vienna, 1090, Austria|Novartis Investigative Site, Wien, 1010, Austria|Novartis Investigative Site, Edegem, Antwerpen, 2650, Belgium|Novartis Investigative Site, Brugge, 8000, Belgium|Novartis Investigative Site, Bruxelles, 1070, Belgium|Novartis Investigative Site, Fraiture En Condroz, 4557, Belgium|Novartis Investigative Site, Gent, 9000, Belgium|Novartis Investigative Site, Leuven, 3000, Belgium|Novartis Investigative Site, Pelt, 3900, Belgium|Novartis Investigative Site, Sijsele, 8340, Belgium|Novartis Investigative Site, Sofia, 1113, Bulgaria|Novartis Investigative Site, Sofia, 1413, Bulgaria|Novartis Investigative Site, Sofia, 1431, Bulgaria|Novartis Investigative Site, Varna, 9010, Bulgaria|Novartis Investigative Site, Calgary, Alberta, T2N 2T9, Canada|Novartis Investigative Site, Edmonton, Alberta, T6G 2G3, Canada|Novartis Investigative Site, Burnaby, British Columbia, V5G 2X6, Canada|Novartis Investigative Site, Halifax, Nova Scotia, B3H 4K4, Canada|Novartis Investigative Site, Kingston, Ontario, K7L 2V7, Canada|Novartis Investigative Site, Ottawa, Ontario, K1H 8L6, Canada|Novartis Investigative Site, Toronto, Ontario, M4N 3M5, Canada|Novartis Investigative Site, Greenfield Park, Quebec, J4V 2J2, Canada|Novartis Investigative Site, Montreal, Quebec, H2X 0A9, Canada|Novartis Investigative Site, Montreal, Quebec, H3A 2B4, Canada|Novartis Investigative Site, Beijing, Beijing, 100034, China|Novartis Investigative Site, Beijing, Beijing, 100730, China|Novartis Investigative Site, Changchun, Jilin, 130021, China|Novartis Investigative Site, Taiyuan, Shanxi, 030001, China|Novartis Investigative Site, Xi'an, Shanxi, 710038, China|Novartis Investigative Site, Chengdu, Sichuan, 610041, China|Novartis Investigative Site, Beijing, 100028, China|Novartis Investigative Site, Beijing, 100730, China|Novartis Investigative Site, Shanghai, 200040, China|Novartis Investigative Site, Brno, Czech Rep., 625 00, Czechia|Novartis Investigative Site, Teplice, Czech Republic, 415 01, Czechia|Novartis Investigative Site, JIhlava, 586 01, Czechia|Novartis Investigative Site, Prague 5, 150 00, Czechia|Novartis Investigative Site, Praha, 12808, Czechia|Novartis Investigative Site, Tallinn, 10138, Estonia|Novartis Investigative Site, Tallinn, 10617, Estonia|Novartis Investigative Site, Nancy, Cedex, 54035, France|Novartis Investigative Site, Bordeaux Cedex, 33076, France|Novartis Investigative Site, CAEN Cedex, 14033, France|Novartis Investigative Site, Lille Cedex, 59037, France|Novartis Investigative Site, Marseille Cedex 05, 13885, France|Novartis Investigative Site, Montpellier, 34295, France|Novartis Investigative Site, Nimes, 30029, France|Novartis Investigative Site, Paris Cedex 13, 75651, France|Novartis Investigative Site, Rennes, 35043, France|Novartis Investigative Site, St Herblain, 44800, France|Novartis Investigative Site, Strasbourg, 67091, France|Novartis Investigative Site, Regensburg, Bavaria, 93053, Germany|Novartis Investigative Site, Aschaffenburg, 63739, Germany|Novartis Investigative Site, Bad Mergentheim, 97980, Germany|Novartis Investigative Site, Bayreuth, 95445, Germany|Novartis Investigative Site, Berg, 82335, Germany|Novartis Investigative Site, Berlin, 10713, Germany|Novartis Investigative Site, Berlin, 13347, Germany|Novartis Investigative Site, Bielefeld, 33647, Germany|Novartis Investigative Site, Boblingen, 71032, Germany|Novartis Investigative Site, Bochum, 44791, Germany|Novartis Investigative Site, Bonn, 53111, Germany|Novartis Investigative Site, Dresden, 01307, Germany|Novartis Investigative Site, Erbach, 64711, Germany|Novartis Investigative Site, Erlangen, 91054, Germany|Novartis Investigative Site, Frankfurt, 60313, Germany|Novartis Investigative Site, Freiburg, 79106, Germany|Novartis Investigative Site, Hamburg, 20249, Germany|Novartis Investigative Site, Hamburg, 22083, Germany|Novartis Investigative Site, Hannover, 30171, Germany|Novartis Investigative Site, Hannover, 30625, Germany|Novartis Investigative Site, Heidelberg, 69120, Germany|Novartis Investigative Site, Homburg, 66421, Germany|Novartis Investigative Site, Itzehoe, 25524, Germany|Novartis Investigative Site, Jena, 07740, Germany|Novartis Investigative Site, Kassel, 34121, Germany|Novartis Investigative Site, Leipzig, 04103, Germany|Novartis Investigative Site, Leipzig, 04107, Germany|Novartis Investigative Site, Muenchen, 80377, Germany|Novartis Investigative Site, Muenster, 48149, Germany|Novartis Investigative Site, Neuburg an der Donau, 86633, Germany|Novartis Investigative Site, Oldenburg, 26122, Germany|Novartis Investigative Site, Potsdam, 14471, Germany|Novartis Investigative Site, Prien, 83209, Germany|Novartis Investigative Site, Rostock, 18057, Germany|Novartis Investigative Site, Schwendi, 88477, Germany|Novartis Investigative Site, Siegen, 57076, Germany|Novartis Investigative Site, Stade, 21682, Germany|Novartis Investigative Site, Stadtroda, 07646, Germany|Novartis Investigative Site, Teupitz, 15755, Germany|Novartis Investigative Site, Ulm, 89073, Germany|Novartis Investigative Site, Ulm, 89081, Germany|Novartis Investigative Site, Unterhaching, 82008, Germany|Novartis Investigative Site, Wiesbaden, 65191, Germany|Novartis Investigative Site, Athens, 106 76, Greece|Novartis Investigative Site, Heraklion Crete, 711 10, Greece|Novartis Investigative Site, Thessaloniki, GR 54636, Greece|Novartis Investigative Site, Budapest, HUN, 1135, Hungary|Novartis Investigative Site, Budapest, HUN, 1145, Hungary|Novartis Investigative Site, Budapest, HUN, 1204, Hungary|Novartis Investigative Site, Esztergom, HUN, 2500, Hungary|Novartis Investigative Site, Balassagyarmat, 2660, Hungary|Novartis Investigative Site, Budapest, 1085, Hungary|Novartis Investigative Site, Budapest, 1106, Hungary|Novartis Investigative Site, Eger, H-3300, Hungary|Novartis Investigative Site, Miskolc, 3526, Hungary|Novartis Investigative Site, Nyiregyhaza, 4400, Hungary|Novartis Investigative Site, Veszprem, H 8200, Hungary|Novartis Investigative Site, Dublin 9, D9, Ireland|Novartis Investigative Site, Dublin 4, D04 T6F, Ireland|Novartis Investigative Site, Jerusalem, 9112001, Israel|Novartis Investigative Site, Ramat Gan, 52621, Israel|Novartis Investigative Site, Genova, GE, 16132, Italy|Novartis Investigative Site, Milano, MI, 20122, Italy|Novartis Investigative Site, Milano, MI, 20132, Italy|Novartis Investigative Site, Cefalu, PA, 90015, Italy|Novartis Investigative Site, Roma, RM, 00133, Italy|Novartis Investigative Site, Roma, RM, 00152, Italy|Novartis Investigative Site, Roma, RM, 00161, Italy|Novartis Investigative Site, Roma, RM, 00168, Italy|Novartis Investigative Site, Roma, RM, 00179, Italy|Novartis Investigative Site, Napoli, 80131, Italy|Novartis Investigative Site, Toon-city, Ehime, 791-0295, Japan|Novartis Investigative Site, Asahikawa-city, Hokkaido, 070-8644, Japan|Novartis Investigative Site, Morioka, Iwate, 020-8505, Japan|Novartis Investigative Site, Kyoto-city, Kyoto, 616-8147, Japan|Novartis Investigative Site, Suita, Osaka, 565 0871, Japan|Novartis Investigative Site, Kawagoe, Saitama, 350 8550, Japan|Novartis Investigative Site, Tokorozawa city, Saitama, 359 8513, Japan|Novartis Investigative Site, Kodaira, Tokyo, 187-8551, Japan|Novartis Investigative Site, Ota-ku, Tokyo, 145-0065, Japan|Novartis Investigative Site, Shinjuku ku, Tokyo, 162 8666, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, 160 8582, Japan|Novartis Investigative Site, Aomori, 030 8553, Japan|Novartis Investigative Site, Chiba, 260 8677, Japan|Novartis Investigative Site, Osaka, 556-0016, Japan|Novartis Investigative Site, Riga, LV, LV-1005, Latvia|Novartis Investigative Site, Riga, LV 1002, Latvia|Novartis Investigative Site, Riga, LV-1038, Latvia|Novartis Investigative Site, Kaunas, LTU, LT 50161, Lithuania|Novartis Investigative Site, Klaipeda, LT-92288, Lithuania|Novartis Investigative Site, Vilnius, LT-08661, Lithuania|Novartis Investigative Site, Breda, CK, 4818 CK, Netherlands|Novartis Investigative Site, Amsterdam, 1105 AZ, Netherlands|Novartis Investigative Site, Eindhoven, 5623 EJ, Netherlands|Novartis Investigative Site, Hoorn, 1624 NP, Netherlands|Novartis Investigative Site, Sittard-Geleen, 6162 BG, Netherlands|Novartis Investigative Site, Tilburg, 5022 GC, Netherlands|Novartis Investigative Site, Grudziadz, 86 300, Poland|Novartis Investigative Site, Katowice, 40 571, Poland|Novartis Investigative Site, Kielce, 25 726, Poland|Novartis Investigative Site, Konskie, 26 200, Poland|Novartis Investigative Site, Krakow, 31-637, Poland|Novartis Investigative Site, Lodz, 90 324, Poland|Novartis Investigative Site, Poznan, 60-355, Poland|Novartis Investigative Site, Warszawa, 02-957, Poland|Novartis Investigative Site, Amadora, 2720-276, Portugal|Novartis Investigative Site, Braga, 4710243, Portugal|Novartis Investigative Site, Coimbra, 3000 075, Portugal|Novartis Investigative Site, Lisboa, 1600190, Portugal|Novartis Investigative Site, Porto, 4099-001, Portugal|Novartis Investigative Site, Constanta, Jud. Constanta, 900591, Romania|Novartis Investigative Site, Bucharest, 020125, Romania|Novartis Investigative Site, Bucharest, 050098, Romania|Novartis Investigative Site, Suceava, 727525, Romania|Novartis Investigative Site, Targu Mures, 540136, Romania|Novartis Investigative Site, Timisoara, 300736, Romania|Novartis Investigative Site, Barnaul, 656024, Russian Federation|Novartis Investigative Site, Kazan, 420043, Russian Federation|Novartis Investigative Site, Moscow, 119049, Russian Federation|Novartis Investigative Site, Moscow, 127018, Russian Federation|Novartis Investigative Site, Novosibirsk, 630007, Russian Federation|Novartis Investigative Site, Saint Petersburg, 194044, Russian Federation|Novartis Investigative Site, St. Petersburg, 197110, Russian Federation|Novartis Investigative Site, St. Petersburg, 197376, Russian Federation|Novartis Investigative Site, Ufa, 450000, Russian Federation|Novartis Investigative Site, Banska Bystrica, 97517, Slovakia|Novartis Investigative Site, Bratislava, 813 69, Slovakia|Novartis Investigative Site, Bratislava, 826 06, Slovakia|Novartis Investigative Site, Martin, 036 59, Slovakia|Novartis Investigative Site, Nitra, 94911, Slovakia|Novartis Investigative Site, Presov, 081 81, Slovakia|Novartis Investigative Site, Trencin, 91171, Slovakia|Novartis Investigative Site, Trnava, 917 75, Slovakia|Novartis Investigative Site, Malaga, Andalucia, 29010, Spain|Novartis Investigative Site, Sevilla, Andalucia, 41009, Spain|Novartis Investigative Site, Barcelona, Cataluna, 08026, Spain|Novartis Investigative Site, Badalona, Catalunya, 08916, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08003, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08035, Spain|Novartis Investigative Site, L Hospitalet De Llobregat, Catalunya, 08907, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, 46010, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, 46026, Spain|Novartis Investigative Site, El Palmar, Murcia, 30120, Spain|Novartis Investigative Site, Bilbao, Pais Vasco, 48013, Spain|Novartis Investigative Site, San Sebastian, Pais Vasco, 20080, Spain|Novartis Investigative Site, Madrid, 28040, Spain|Novartis Investigative Site, Madrid, 28222, Spain|Novartis Investigative Site, Goeteborg, 413 45, Sweden|Novartis Investigative Site, Stockholm, 102 35, Sweden|Novartis Investigative Site, Stockholm, 10235, Sweden|Novartis Investigative Site, Aarau, CH, 5001, Switzerland|Novartis Investigative Site, Basel, 4031, Switzerland|Novartis Investigative Site, Lausanne, 1011, Switzerland|Novartis Investigative Site, Lugano, 6900, Switzerland|Novartis Investigative Site, Luzern, 6000, Switzerland|Novartis Investigative Site, St Gallen, 9007, Switzerland|Novartis Investigative Site, Zuerich, 8091, Switzerland|Novartis Investigative Site, Istanbul, TUR, 34098, Turkey|Novartis Investigative Site, Altunizade, 34662, Turkey|Novartis Investigative Site, Haseki / Istanbul, 34096, Turkey|Novartis Investigative Site, Kocaeli, 41380, Turkey|Novartis Investigative Site, Mecidiyekoy/Istanbul, 34394, Turkey|Novartis Investigative Site, Samsun, 55139, Turkey|Novartis Investigative Site, Trabzon, 61080, Turkey|Novartis Investigative Site, Salford, Manchester, M6 8HD, United Kingdom|Novartis Investigative Site, Headington, Oxfordshire, OX3 9DU, United Kingdom|Novartis Investigative Site, Sheffield, South Yorkshire, S10 2JF, United Kingdom|Novartis Investigative Site, Bristol, BS10 5NB, United Kingdom|Novartis Investigative Site, Glasgow, G51 4TF, United Kingdom|Novartis Investigative Site, Leeds, LS1 3EX, United Kingdom|Novartis Investigative Site, Leicester, LE5 4PW, United Kingdom|Novartis Investigative Site, London, EC1A 7BE, United Kingdom|Novartis Investigative Site, London, W8 6RF, United Kingdom|Novartis Investigative Site, Newcastle Upon Tyne, NE1 4LP, United Kingdom"
NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,https://beta.clinicaltrials.gov/study/NCT00787657,COMPLETED,Relapsing Remitting Multiple Sclerosis (RRMS),"DRUG: Interferon beta-1b (Betaseron, BAY86-5046)",Bayer,,ALL,"CHILD, ADULT, OLDER_ADULT",,1723,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2008-06,2013-09,2014-10,"Many Locations, Argentina|Many Locations, Bahrain|Many Locations, Belgium|Many Locations, Bosnia and Herzegovina|Many Locations, Canada|Many Locations, China|Many Locations, Colombia|Many Locations, Czech Republic|Many Locations, Egypt|Many Locations, Estonia|Many Locations, France|Many Locations, Germany|Many Locations, Iran, Islamic Republic of|Many Locations, Israel|Many Locations, Italy|Many Locations, Jordan|Many Locations, Korea, Republic of|Many Locations, Kuwait|Many Locations, Lebanon|Many Locations, Libyan Arab Jamahiriya|Many Locations, Mexico|Many Locations, Netherlands|Many Locations, New Zealand|Many Locations, Norway|Many Locations, Pakistan|Many Locations, Portugal|Many Locations, Saudi Arabia|Many Locations, Singapore|Many Locations, Slovakia|Many Locations, Slovenia|Many Locations, Sweden|Many Locations, Syrian Arab Republic|Many Locations, Taiwan|Many Locations, United Arab Emirates|Many Locations, United Kingdom|Many Locations, Venezuela"
NCT04877457,Ocrelizumab for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease.,https://beta.clinicaltrials.gov/study/NCT04877457,RECRUITING,Radiologically Isolated Syndrome|Multiple Sclerosis,DRUG: Ocrelizumab|OTHER: Placebo,Yale University,"Genentech, Inc.",ALL,ADULT,PHASE4,100,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-02-15,2028-07,2028-07,"USC, Keck School of Medicine, Los Angeles, California, 90033, United States|Yale University, North Haven, Connecticut, 06473, United States|Georgetown University, Washington, District of Columbia, 20007, United States|University of South Florida Morsani Center, Tampa, Florida, 33612, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|The Elliot Lewis Center for Multiple Sclerosis Care, Wellesley, Massachusetts, 02481, United States|Washington University- St. Louis, Saint Louis, Missouri, 63110, United States|Cleveland Clinic- Lou Ruvo Center for Brain Health, Las Vegas, Nevada, 89106, United States|Icahn School of Medicine at Mount Sinai, New York, New York, 10029, United States|Northwell, New York, New York, 10075, United States|Cleveland Clinic Melen Center, Cleveland, Ohio, 44195, United States|The Boster Center for Multiple Sclerosis, Columbus, Ohio, 43235, United States|Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, 73104, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|University of Utah, Salt Lake City, Utah, 84108, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States"
NCT01705457,Impact of Vitamin A on RAR Gene Expression in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01705457,UNKNOWN,Relapsing Remitting Multiple Sclerosis,DRUG: Dietary Supplement: vitamin A|DRUG: placebo,Tehran University of Medical Sciences,,ALL,ADULT,PHASE4,20,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2010-02,2013-02,2013-08,"Tehran University of Medical Sciences,, Tehran, Iran, Islamic Republic of"
NCT00910598,Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT00910598,UNKNOWN,Multiple Sclerosis,DRUG: glatiramer acetate,Amphia Hospital,Sanofi|TEVA Pharmachemie,ALL,ADULT,PHASE4,60,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2009-09,2012-06,2012-06,"Amphia Ziekenhuis, Breda, 4818 CK, Netherlands|Maasland Ziekenhuis, Sittard, Netherlands"
NCT00493298,Tysabri Observational Program,https://beta.clinicaltrials.gov/study/NCT00493298,ACTIVE_NOT_RECRUITING,Relapsing-Remitting Multiple Sclerosis,DRUG: Tysabri,Biogen,,ALL,"ADULT, OLDER_ADULT",,6620,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2007-06-29,2029-01-03,2029-01-03,"Research Site, Buenos Aires, 8000, Argentina|Research Site, Buenos Aires, C1061ABD, Argentina|Research Site, Buenos Aires, C1118AAT, Argentina|Research Site, Buenos Aires, C1428AQK, Argentina|Research Site, Caba, C1015ABR, Argentina|Research Site, Cordoba, X5014HYR, Argentina|Research site, Santa Fe, S2000BZL, Argentina|Research site, Camperdown, New South Wales, 2050, Australia|Research site, Liverpool, New South Wales, 2170, Australia|Research site, New Lambton Heights, New South Wales, 2305, Australia|Research Site, St. Leonards, New South Wales, 2065, Australia|Research Site, Auchenflower, Queensland, 4066, Australia|Research site, Gold Coast, Queensland, 9726, Australia|Research site, Adelaide, South Australia, 5042, Australia|Research Site, North Adelaide, South Australia, 5006, Australia|Research site, Box Hill, Victoria, 3128, Australia|Research site, Fitzroy, Victoria, 3065, Australia|Research site, Heidelberg, Victoria, 3084, Australia|Research Site, Melbourne, Victoria, 3004, Australia|Research site, Parkville, Victoria, 3050, Australia|Research site, Nedlands, Western Australia, 6009, Australia|Research site, Aalst, 9300, Belgium|Research site, Antwerpen, 2020, Belgium|Research site, Bocholt, 3950, Belgium|Research site, Brasschaat, 2930, Belgium|Research site, Brugge, 8000, Belgium|Research site, Brussel (Jette), 1090, Belgium|Research site, Brussel, 1000, Belgium|Research site, Brussel, 1180, Belgium|Research site, Bruxelles (Anderlecht), 1070, Belgium|Research site, Charleroi, 6000, Belgium|Research Site, Charleroi, B-6042, Belgium|Research site, Edegem, 2650, Belgium|Research site, Fraiture, 4557, Belgium|Research site, Genk, 3600, Belgium|Research site, Gent, 9000, Belgium|Research site, Hasselt, 3500, Belgium|Research site, Kortrijk, 8500, Belgium|Research site, La Louviere, 7100, Belgium|Research site, Leuven, 3000, Belgium|Research site, Libramont, 6800, Belgium|Research site, Liège, 4000, Belgium|Research site, Malmedy, 4960, Belgium|Research site, Melsbroek, 1820, Belgium|Research site, Oostende, 8400, Belgium|Research site, Ottignies, 1340, Belgium|Research Site, Overpelt, 3900, Belgium|Research site, Sijsele, 8340, Belgium|Research site, Tournai, 7500, Belgium|Research site, Wilrijk, 2610, Belgium|Research site, Woluwe-Saint-Lambert, 1200, Belgium|Research Site, Belo Horizonte, 30130-090, Brazil|Research Site, Botucatu, 18618-687, Brazil|Research Site, Rio de Janeiro, 21941-590, Brazil|Research Site, Sao Paulo, 05402-000, Brazil|Research Site, Sao Paulo, 2151-1233, Brazil|Research site, Edmonton, Alberta, T5H 4B9, Canada|Research site, Burnaby, British Columbia, V5G2X6, Canada|Research Site, Vancouver, British Columbia, V6T 2B5, Canada|Research site, Winnipeg, Manitoba, R3E0T5, Canada|Research site, Saint John, New Brunswick, E2L 4L2, Canada|Research site, Halifax, Nova Scotia, B3HIV7, Canada|Research site, Bracebridge, Ontario, P1L 1R1, Canada|Research site, Guelph, Ontario, N1H4J4, Canada|Research site, Hamilton, Ontario, L8L5G4, Canada|Research site, Hamilton, Ontario, L8N 1T8, Canada|Research site, London, Ontario, N6A5A5, Canada|Research site, Milton, Ontario, L9T 7H3, Canada|Research site, Thunder Bay, Ontario, P7B7C7, Canada|Research site, Toronto, Ontario, M5B 1W8, Canada|Research site, Gatineau, Quebec, J8Y 1W2, Canada|Research site, Greenfield Park, Quebec, J4V 2J2, Canada|Research site, Montreal, Quebec, H3A 2B4, Canada|Research site, Montréal, Quebec, H2X OA9, Canada|Research site, Regina, Saskatchewan, S4S3K8, Canada|Research site, Brno, 62500, Czechia|Research site, Brno, 65691, Czechia|Research site, Ceské Budejovice, 37087, Czechia|Research site, Hradec Kralové, 50005, Czechia|Research site, Jihlava, 58633, Czechia|Research site, Olomouc, 77520, Czechia|Research site, Ostrava, 70852, Czechia|Research site, Pardubice, 53203, Czechia|Research site, Plzen, 30460, Czechia|Research site, Prague 10, 10034, Czechia|Research site, Prague 4, 14200, Czechia|Research site, Prague, 12808, Czechia|Research site, Praha 5, 15006, Czechia|Research site, Teplice, 41528, Czechia|Research Site, Teplice, 41529, Czechia|Research site, Zlín, 76275, Czechia|Research site, Helsinki, 00029, Finland|Research site, Jyväskylä, 40620, Finland|Research site, Kuopio, 70211, Finland|Research site, Pori, 28500, Finland|Research site, Seinäjoki, 60220, Finland|Research site, Tampere, 33521, Finland|Research site, Turku, 20521, Finland|Research site, Agen Cedex 9, 47923, France|Research site, Aix En Provence Cedex 1, 13100, France|Research site, Alencon Cedex, 61014, France|Research site, Angouleme, 16000, France|Research site ,1 Allée du Château- Dr Wagner, Ars-Laquenexy, 57245, France|Research site, Auxerre Cedex, 89011, France|Research site, Avranches Cedex, 50300, France|Research site, Bayonne Cedex, 64100, France|Research site, Beauvais Cedex, 60000, France|Research site, Belfort Cedex, 90000, France|Research site, Bethune Cedex, 62408, France|Research site, Beuvry, 62660, France|Research site, Boulogne sur mer cedex, 62321, France|Research site, Calais Cedex, 62107, France|Research site, Castelnau Le Lez Cedex, 34171, France|Research site, Castres Cedex, 81108, France|Research site, Chambery Cedex, 73000, France|Research site, Chambery cedex, 73011, France|Research site, Colmar Cedex, 68024, France|Research site, Compiegne Cedex, 60321, France|Research site, Dieppe, 76200, France|Research site, Dreux Cedex, 28107, France|Research site, Dunkerque cedex 1, 59385, France|Research site, Epinal cedex, 88021, France|Research site, Haguenau cedex, 67501, France|Research site, La Rochelle Cedex 1, 17000, France|Research site 177, rue de Versailles- Dr Servan, Le Chesnay Cedex, 78157, France|Research site, Le Chesnay Cedex, 78157, France|Research site, Le Coudray, 28630, France|Research site, Le Havre, 76600, France|Research site, Le Mans, 72037, France|Research site, Lille, 59000, France|Research site, Lisieux Cedex, 14100, France|Research site, Lomme Cedex, 59462, France|Research site, Mantes La Jolie Cedex, 78201, France|Research site, Maubeuge Cedex, 59600, France|Research site, Metz Cedex 01, 57038, France|Research site, Metz Tessy, 74370, France|Research site, Mont De Marsan Cedex, 40024, France|Research site, Montauban Cedex, 82000, France|Research site, Montlucon, 03100, France|Research site, Montpellier, 34080, France|Research site, Montpellier, 34264, France|Research site, Mulhouse Cedex, 68100, France|Research site, Nice Cedex 2, 06105, France|Research site, Paris cedex 14, 75674, France|Research site, Paris, 75020, France|Research site, Pau Cedex, 64000, France|Research site, PAU, 64000, France|Research site, Quimper Cedex, 29000, France|Research site, Reims, 51100, France|Research site, Sarreguemines, 57200, France|Research site, Saumur Cedex, 49400, France|Research site, St Aubin Sur Scie, 76550, France|Research site, St Malo Cedex, 35400, France|Research site, Talant, 21240, France|Research site, Tarbes Cedex 9, 65013, France|Research site, Tarbes, 65013, France|Research site, Tourcoing Cedex, 59200, France|Research site, Trappes, 78190, France|Research site, Trelaze, 49800, France|Research site, Trélazé, 49800, France|Research site, Valenciennes Cedex, 59322, France|Research site, Vesoul Cedex, 70014, France|Research site, Vichy cedex, 3201, France|Research site, Évreux, 27015, France|Research site, Abensberg, 93326, Germany|Research site, Andernach, 56626, Germany|Research Site, Arnsdorf, 01477, Germany|Research site, Asperg, 71679, Germany|Research site, Augsburg, 86156, Germany|Research site, Bad Hersfeld, 36088, Germany|Research site, Bad Honnef, 53604, Germany|Research Site, Bad Kissingen, 97688, Germany|Research site, Bad Mergentheim, 97980, Germany|Research site, Bad Reichenhall, 83435, Germany|Research site, Bamberg, 96049, Germany|Research site, Berlin-Tegel, 13507, Germany|Research site, Berlin, 10017, Germany|Research site, Berlin, 10437, Germany|Research site, Berlin, 10785, Germany|Research site, Berlin, 10969, Germany|Research site, Berlin, 12057, Germany|Research site, Berlin, 12099, Germany|Research site, Berlin, 12203, Germany|Research site, Berlin, 13347, Germany|Research site, Berlin, 13439, Germany|Research site, Berlin, 14163, Germany|Research site, Bielefeld, 33602, Germany|Research site, Bielefeld, 33647, Germany|Research site, Bochum, 44791, Germany|Research site, Bogen, 94327, Germany|Research site, Bonn, 53111, Germany|Research site, Bruchsal, 76646, Germany|Research site, Buchholz, 21244, Germany|Research site, Celle, 29223, Germany|Research site, Chemnitz, 09117, Germany|Research site, Dillingen, 66763, Germany|Research site, Dresden, 01067, Germany|Research site, Duisburg, 47169, Germany|Research site, Düren, 52351, Germany|Research site, Düsseldorf, 40211, Germany|Research site, Düsseldorf, 40225, Germany|Research site, Eisenach, 99817, Germany|Research site, Emden, 26721, Germany|Research site, Emmendingen, 79312, Germany|Research site, Erbach, 64711, Germany|Research site, Erlangen, 91054, Germany|Research site, Essen, 45122, Germany|Research site, Essen, 45138, Germany|Research site, Essen, 45257, Germany|Research site, Falkenstein, 61462, Germany|Research site, Frankfurt, 60325, Germany|Research site, Freiburg, 79106, Germany|Research site, Greifswald, 17489, Germany|Research site, Görlitz, 02828, Germany|Research site, Göttingen, 37073, Germany|Research site, Halle, 06120, Germany|Research site, Hamburg, 20249, Germany|Research site, Hamburg, 20354, Germany|Research site, Hamburg, 22179, Germany|Research site, Heidelberg, 69120, Germany|Research site, Herford, 32052, Germany|Research site, Itzehoe, 25524, Germany|Research site, Jena, 07740, Germany|Research site, Kaiserslautern, 67655, Germany|Research site, Kaltenkirchen, 24568, Germany|Research site, Kandel, 76870, Germany|Research site, Kassel, 34121, Germany|Research site, Kastellaun, 56288, Germany|Research site, Kirchberg, 08107, Germany|Research site, Kirchheim unter Teck, 73230, Germany|Research Site, Kreuzau, 52372, Germany|Research site, Köln, 50924, Germany|Research site, Köln, 50996, Germany|Research site, Ladenburg, 68526, Germany|Research site, Leipzig, 041579, Germany|Research site, Leipzig, 04275, Germany|Research site, Lengerich, 49525, Germany|Research site, Ludwigshafen, 67059, Germany|Research site, Lüdenscheid, 58511, Germany|Research site, Lüdenscheid, 58515, Germany|Research site, Lüneburg, 21335, Germany|Research site, Magdeburg, 39120, Germany|Research site, Mannheim, 68158, Germany|Research site, Mannheim, 68161, Germany|Research site, Marburg, 35043, Germany|Research site, München, 80331, Germany|Research site, München, 80333, Germany|Research site, München, 81479, Germany|Research site, München, 81675, Germany|Research site, München, 81825, Germany|Research site, Münster, 48149, Germany|Research site, Neuburg, 86633, Germany|Research site, Neukirchen-Vluyn, 47506, Germany|Research site, Neuruppin, 16816, Germany|Research site, Nürnberg, 90419, Germany|Research site, Nürnberg, 90451, Germany|Research site, Nürnberg, 90461, Germany|Research site, Oldenburg, 26121, Germany|Research site, Oldenburg, 26127, Germany|Research site, Olpe, 57462, Germany|Research site, Osnabrück, 49074, Germany|Research site, Osnabrück, 49076, Germany|Research site, Osnabrück, 49078, Germany|Research site, Paderborn, 33098, Germany|Research site, Potsdam, 14471, Germany|Research site, Regensburg, 93053, Germany|Research site, Remscheid, 42853, Germany|Research site, Rüdersdorf, 15562, Germany|Research Site, Rülzheim, 76761, Germany|Research site, Schlüchtern, 36381, Germany|Research site, Schorndorf, 73614, Germany|Research site, Schwaebisch, 74523, Germany|Research site, Siegen, 57076, Germany|Research site, Sinsheim, 74889, Germany|Research site, Stade, 21682, Germany|Research site, Stadtroda, 07646, Germany|Research site, Stuttgart, 70176, Germany|Research site, Stuttgart, 70182, Germany|Research site, Teupitz, 15755, Germany|Research site, Trier, 54282, Germany|Research site, Troisdorf, 53844, Germany|Research site, Ulm, 89073, Germany|Research site, Ulm, 89077, Germany|Research site, Ulm, 89081, Germany|Research site, Unterhaching, 82008, Germany|Research site, Wasserburg, 83512, Germany|Research site, Weimar, 99425, Germany|Research site, Weinheim, 69469, Germany|Research site, Wermsdorf, 04779, Germany|Research site, Wernigerode, 38855, Germany|Research site, Wiesbaden, 65185, Germany|Research site, Wolfenbüttel, 38300, Germany|Research site, Wolfratshausen, 82515, Germany|Research site, Würzburg, 97080, Germany|Research site, Zwickau, 08058, Germany|Research site, Heraklion, Crete, 71201, Greece|Research Site, Alexandroupoli, 68100, Greece|Research site, Athens, 10676, Greece|Research site, Athens, 11521, Greece|Research site, Athens, 11524, Greece|Research site, Athens, 11525, Greece|Research site, Athens, 11526, Greece|Research site, Ioannina, 45500, Greece|Research site, Patras, 26504, Greece|Research site, Patras, 26535, Greece|Research site, Thessaloniki, 54636, Greece|Research site, Thessaloniki, 56429, Greece|Research site, Thessaloniki, 57010, Greece|Research site, Bari, 70121, Italy|Research site, Bergamo, 24126, Italy|Research site, Cagliari, 09100, Italy|Research site, Cefalù, 90015, Italy|Research site, Chieti, 66013, Italy|Research site, Cuneo, 11100, Italy|Research site, Fidenza, 43036, Italy|Research site, Firenze, 50134, Italy|Research site, Foggia, 71100, Italy|Research site, Gallarate, 21013, Italy|Research site, Milano, 20122, Italy|Research site, Milano, 20133, Italy|Research site, Napoli, 80131, Italy|Research site, Orbassano, 10043, Italy|Research site, Roma, 00144, Italy|Research site, Roma, 00152, Italy|Research site, Roma, 00185, Italy|Research site, Zapopan, Jalisco, 45150, Mexico|Research site, Monterrey, Nuevo León, 64060, Mexico|Research site, Monterrey, Nuevo León, 64380, Mexico|Research site, Aguascalientes, 20230, Mexico|Research site, Estado de México, 52763, Mexico|Research Site, Leon, 37150, Mexico|Research site, Mexico City, 01030, Mexico|Research site, Mexico City, 05300, Mexico|Research site, Mexico City, 06700, Mexico|Research site, Mexico City, 06760, Mexico|Research site, Mexico City, 09220, Mexico|Research Site, Mexico city, 14260, Mexico|Research site, Puebla, 72540, Mexico|Research Site, Puebla, 91919, Mexico|Research Site, San Luis Potosi, 78399, Mexico|Research Site, Almelo, 7600 SZ, Netherlands|Research site, Blaricum, 1261 AN, Netherlands|Research site, Breda, 4818 CK, Netherlands|Research site, Den Haag, 2566 MJ, Netherlands|Research site, Eindhoven, 5602 ZA, Netherlands|Research site, Geldrop, 5664 EH, Netherlands|Research site, Gouda, 2803 HH, Netherlands|Research site, Heerenveen, 8441 PW, Netherlands|Research site, Heerlen, 6419 PC, Netherlands|Research site, Helmond, 5700 AB, Netherlands|Research site, Hengelo, 7550 AM, Netherlands|Research site, Hoorn, 1624 NP, Netherlands|Research site, Leeuwarden, 8934 AD, Netherlands|Research Site, Meppel, 7943 SM, Netherlands|Research site, Nieuwegein, 3430 EM, Netherlands|Research site, Nijmegen, 6500 GS, Netherlands|Research site, Roermond, 6043 CV, Netherlands|Research site, Rotterdam, 3079 DZ, Netherlands|Research site, s Hertogenbosch, 5223 GZ, Netherlands|Research site, Sittard-Geleen, 6162 BG, Netherlands|Research site, Tilburg, 5022 GC, Netherlands|Research site, Venray, 5801 CE, Netherlands|Research site, Woerden, 3447 GN, Netherlands|Research Site, Zwolle, 8011 JW, Netherlands|Research site, Bergen, 5021, Norway|Research site, Bodo, 8092, Norway|Research site, Drammen, 3004, Norway|Research site, Forde, 6812, Norway|Research Site, Fredrikstad, 1603, Norway|Research site, Haugesund, 5504, Norway|Research site, Lillehammer, 2629, Norway|Research site, Lørenskog, 1478, Norway|Research site, Molde, 6407, Norway|Research site, Namsos, 7800, Norway|Research site, Oslo, 0027, Norway|Research Site, Oslo, 0407, Norway|Research Site, Skien, 3710, Norway|Research site, Stavanger, 4095, Norway|Research Site, Tromso, 9038, Norway|Research site, Trondheim, 7006, Norway|Research site, Tønsberg, 3103, Norway|Research site, Aveiro, 3810-095, Portugal|Research site, Beja, 7801-849, Portugal|Research site, Evora, 7000-811, Portugal|Research site, Funchal, 9000, Portugal|Research site, Lisboa, 1349-019, Portugal|Research site, Lisboa, 1649-035, Portugal|Research site, Porto, 4200 - 319, Portugal|Research site, Setubal, 2910-446, Portugal|Research Site, Banská Bystrica, 975 17, Slovakia|Research Site, Bratislava, 813 69, Slovakia|Research Site, Bratislava, 826 06, Slovakia|Research site, Bratislava, 833 05, Slovakia|Research site, Kosice, 041 66, Slovakia|Research site, Nitra, 949 01, Slovakia|Research site, Avila, 05071, Spain|Research site, Badalona, 08916, Spain|Research site, Barcelona, 08003, Spain|Research site, Barcelona, 08907, Spain|Research site, Girona, 17007, Spain|Research site, Langreo, 33920, Spain|Research site, Logroño, 26006, Spain|Research site, Palma de Mallorca, 07014, Spain|Research site, Ponferrada, 24411, Spain|Research site, San Sebastian, 20014, Spain|Research site, Tarragona, 43003, Spain|Research site, Tarragona, 43500, Spain|Research site, Vitoria, 01009, Spain|Research site, Edgbaston, Birmingham, B15 2TH, United Kingdom|Research site, Canterbury, Kent, CT1 3NG, United Kingdom|Research site, Hammersmith, London, W6 8RF, United Kingdom|Research site, Salford, Manchester, M6 8HD, United Kingdom|Research site, Belfast, BT16 1RH, United Kingdom|Research site, Brighton, BN2 5BE, United Kingdom|Research site, Bristol, BS16 1LE, United Kingdom|Research site, Coventry, CV2 2DX, United Kingdom|Research site, Exeter, EX25DW, United Kingdom|Research site, Liverpool, L9 7LJ, United Kingdom|Research site, Middlesborough, TS4 3BW, United Kingdom|Research site, Newcastle Upon Tyne, NE1 4LP, United Kingdom|Research site, Nottingham, NG7 2UH, United Kingdom|Research site, Stoke on Trent, ST4 6QG, United Kingdom"
NCT00715598,Cognitive Testing for the Pain Quality Assessment Scale (PQAS),https://beta.clinicaltrials.gov/study/NCT00715598,COMPLETED,Pain|Spinal Cord Injuries|Multiple Sclerosis,,University of Washington,Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",,213,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2008-06,2010-06,2010-08,"University of Washington, Seattle, Washington, 98195, United States"
NCT02004444,JC Virus Reactivation in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02004444,COMPLETED,Progressive Multifocal Leukoencephalopathy|Multiple Sclerosis,,Beth Israel Deaconess Medical Center,National Multiple Sclerosis Society|Biogen,ALL,"ADULT, OLDER_ADULT",,50,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-10,2016-01,2016-01,"Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02115, United States"
NCT00004744,"Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT00004744,COMPLETED,Multiple Sclerosis,DRUG: immune globulin,National Institute of Neurological Disorders and Stroke (NINDS),Mayo Clinic,ALL,ADULT,PHASE3,76,NIH,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: |Masking: DOUBLE|Primary Purpose: TREATMENT,1993-02,1998-09,,
NCT02913157,Hydroxychloroquine in Primary Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02913157,COMPLETED,"Multiple Sclerosis, Primary Progressive",DRUG: Hydroxychloroquine,University of Calgary,,ALL,"ADULT, OLDER_ADULT",PHASE2,35,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-11,2021-06,2021-06,"MS Clinic Foothills Medical Centre, Calgary, Alberta, T2N2T9, Canada"
NCT03603457,OFSEP High Definition Cohort,https://beta.clinicaltrials.gov/study/NCT03603457,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,,EDMUS Foundation,,ALL,"CHILD, ADULT, OLDER_ADULT",,2900,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-07-10,2025-12,2026-12,"CHU d'Amiens, Amiens, France|CHU de Besançon, Besançon, France|CHU de Bordeaux, Bordeaux, France|CHU de Caen, Caen, France|CHU de Clermont-Ferrand, Clermont-Ferrand, France|CHU de Créteil, Créteil, France|CHU de Dijon, Dijon, France|CHU de Grenoble, Grenoble, France|CHU de Lille, Lille, France|CHU de Limoges, Limoges, France|CHU de Lyon, Lyon, France|CHU de Marseille, Marseille, France|CHU de Montpellier, Montpellier, France|CHU de Nancy, Nancy, France|CHU de Nantes, Nantes, France|CHU de Nice, Nice, France|CHU de Nîmes, Nîmes, France|CHU Pitié-Salpétrière, Paris, France|CHU Saint-Antoine, Paris, France|Fondation Rothschild, Paris, France|CHI de Poissy-Saint-Germain-en-Laye, Poissy, France|CHU de Poitiers, Poitiers, France|CHU de Rennes, Rennes, France|CHU de Strasbourg, Strasbourg, France|CHU de Toulouse, Toulouse, France|CHU de Tours, Tours, France|CHU de Fort-de-France, Fort-de-France, Martinique"
NCT04518657,Internet-Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04518657,RECRUITING,Multiple Sclerosis,BEHAVIORAL: Behavioral Intervention for Physical Activity in MS (BIPAMS)|BEHAVIORAL: Wellness for MS (WellMS),University of Illinois at Chicago,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),ALL,"ADULT, OLDER_ADULT",NA,280,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2023-03-01,2024-10-31,2025-07-31,"University of Illinois at Chicago, Chicago, Illinois, 60612, United States"
NCT01986998,Study to Compare the Clinical and Radiological Efficacy of 625 mg Versus 1250 mg of Oral Methylprednisolone in Patients With Multiple Sclerosis in Relapse,https://beta.clinicaltrials.gov/study/NCT01986998,COMPLETED,Multiple Sclerosis,DRUG: Methylprednisolone 1250 mg/24h x3 days|DRUG: Oral Methylprednisolone 625 mg/24h x3 days,Germans Trias i Pujol Hospital,,ALL,ADULT,PHASE4,49,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-10,2016-02,2016-03,"Hospital Universitari Germans Trias I Pujol de, Badalona, Barcelona, 08916, Spain|Hospital Del Mar, Barcelona, 08003, Spain|Hospital de Mataró, Barcelona, 08034, Spain|Hospital Clinic I Provincial de Barcelona, Barcelona, 08036, Spain|Hospital de Sant Joan Despí Moisés Broggi, Barcelona, Spain|Hospital Universitari de Girona Dr. Josep Trueta, Girona, 17007, Spain|Hospital Universitari Arnau de Vilanova de Lleida, Lleida, 25198, Spain|Hospital de Sant Pau I Santa Tecla, Tarragona, Spain"
NCT04878211,A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab,https://beta.clinicaltrials.gov/study/NCT04878211,RECRUITING,Relapsing Multiple Sclerosis (RMS),DRUG: Ofatumumab|BIOLOGICAL: mRNA COVID-19 vaccine|DRUG: interferon or glatiramer acetate,Novartis Pharmaceuticals,,ALL,ADULT,PHASE4,88,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-06-10,2024-01-22,2024-01-22,"Novartis Investigative Site, Phoenix, Arizona, 85032, United States|Novartis Investigative Site, Sunrise, Florida, 33351, United States|Novartis Investigative Site, Saint Louis, Missouri, 63131, United States|Novartis Investigative Site, Charlotte, North Carolina, 28204, United States|Novartis Investigative Site, Knoxville, Tennessee, 37922, United States"
NCT02521311,Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER),https://beta.clinicaltrials.gov/study/NCT02521311,RECRUITING,Optic Neuritis,DRUG: Clemastine|DRUG: Placebo,"University of California, San Francisco",Moorfields Eye Hospital NHS Foundation Trust,ALL,ADULT,PHASE2,90,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-02-28,2024-08,2024-08,"University of California San Francisco, San Francisco, California, 94158, United States"
NCT05005013,A Teleheath tDCS Approach to Decrease Cannabis Use,https://beta.clinicaltrials.gov/study/NCT05005013,RECRUITING,Cannabis Use Disorder|Multiple Sclerosis,OTHER: Transcranial Direct Current Stimulation (tDCS)|OTHER: Sham - Transcranial Direct Current Stimulation (tDCS)|OTHER: Mindfulness,NYU Langone Health,,FEMALE,"ADULT, OLDER_ADULT",NA,46,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-08-13,2024-02-29,2024-02-29,"NYU Langone Health, New York, New York, 10017, United States"
NCT05374811,"The Relationship of Neuropathic Pain With Incontinence, Disability and Life Quality in Multiple Sclerosis Patients",https://beta.clinicaltrials.gov/study/NCT05374811,RECRUITING,"Multiple Sclerosis|Disabilities Multiple|Quality of Life|Incontinence, Urinary|Incontinence Bowel|Neuropathic Pain",OTHER: Neuropathic Pain,Istanbul University - Cerrahpasa (IUC),,ALL,"ADULT, OLDER_ADULT",,138,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-04-15,2022-11-15,2022-11-15,"Istanbul University- Cerrahpasa, Istanbul, Turkey"
NCT04006613,Effects of a Circuit Training on Balance in Persons With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04006613,UNKNOWN,Multiple Sclerosis,OTHER: Circuit Training|OTHER: Usual Care,Fondazione Don Carlo Gnocchi Onlus,,ALL,"ADULT, OLDER_ADULT",NA,52,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2019-02-26,2020-08,2020-09,"Fondazione Don Carlo Gnocchi Onlus, Milan, 20148, Italy"
NCT04832399,Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants,https://beta.clinicaltrials.gov/study/NCT04832399,ACTIVE_NOT_RECRUITING,Relapsing Remitting Multiple Sclerosis,DRUG: Natalizumab,Biogen,,ALL,ADULT,,60,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-11-12,2023-08-31,2023-08-31,"Research Site, Amadora, 2720-276, Portugal|Research Site, Angra do Heroismo, 9700-049, Portugal|Research Site, Aveiro, 3810-164, Portugal|Research Site, Braga, 4710-243, Portugal|Research Site, Coimbra, 3004-561, Portugal|Research Site, Faro, 8000-386, Portugal|Research Site, Funchal, 9000-177, Portugal|Research Site, Guimaraes, 4835-044, Portugal|Research Site, Leiria, 2410-197, Portugal|Research Site, Lisboa, 1649-028, Portugal|Research Site, Loures, 2674-514, Portugal|Research Site, Matosinhos, 4450-021, Portugal|Research Site, Penafiel, 4564-007, Portugal|Research Site, Porto, 4200-319, Portugal|Research Site, Santa Maria da Feira, 4520-220, Portugal|Research Site, Setubal, 2910-446, Portugal|Research Site, Viana do Castelo, 4904-858, Portugal|Research Site, Vila Nova de Gaia, 4434-502, Portugal"
NCT00203099,Safety and Efficacy Study of Copaxone Administered in Combination With N-Acetylcysteine,https://beta.clinicaltrials.gov/study/NCT00203099,COMPLETED,Relapse Remitting Multiple Sclerosis,"DRUG: Glatiramer Acetate, N-Acetylcysteine","Teva Branded Pharmaceutical Products R&D, Inc.",,ALL,ADULT,PHASE2,18,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2004-12,2006-08,2008-06,
NCT02518776,Influence of Emotional Disorders and Executive on the Components Retrograde and Anterograde Episodic Memory in MS,https://beta.clinicaltrials.gov/study/NCT02518776,UNKNOWN,Multiple Sclerosis,BEHAVIORAL: Neuropsychological tests,"University Hospital, Caen",,ALL,ADULT,NA,80,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2010-06,2016-07,,"Department of Neurologie, Caen Hospital University, Caen, Basse-Normandie, 14033, France"
NCT04369976,Short Arm Human Centrifuge Therapeutic Training and Rehabilitation (GRACER1),https://beta.clinicaltrials.gov/study/NCT04369976,RECRUITING,"Multiple Sclerosis|Stroke|Pulmonary Disease, Chronic Obstructive|Aged",DEVICE: ARTIFICIAL GRAVITY COMBINED WITH EXERCISE,Greek Aerospace Medical Association and Space Research,,ALL,"CHILD, ADULT, OLDER_ADULT",NA,105,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2020-02-01,2021-03-01,2022-08-01,"Euromedica-Arogi Rehabilitation Center, Thessaloniki, FW, 54210, Greece"
NCT00430599,The Effect of Levetiracetam (Keppra) on the Treatment of Tremor in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00430599,COMPLETED,Multiple Sclerosis,,Newcastle-upon-Tyne Hospitals NHS Trust,,ALL,ADULT,,20,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2007-02,,2009-09,"Sir James Spence Institute, Royal Victoria Infirmary, Newcastle, Tyne and Wear, NE1 4LP, United Kingdom"
NCT05409599,The Effects of Vestibular Exercise and Cervical Stabilization Exercise Training on Balance and Gait in MS Patients,https://beta.clinicaltrials.gov/study/NCT05409599,RECRUITING,Multiple Sclerosis|Vestibular|Exercises,OTHER: Exercises,Sanko University,,ALL,"ADULT, OLDER_ADULT",NA,36,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2021-10-01,2023-01-25,2023-02-01,"Sanko University, Gaziantep, Şehitkamil, 27500, Turkey"
NCT04201470,Serum Neurofilaments and GFAP in Atypical Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04201470,COMPLETED,Relapsing Remitting Multiple Sclerosis|Progressive Multiple Sclerosis|Controls|Multiple Sclerosis,OTHER: Blood withdrawal|OTHER: MRI|OTHER: Neurologic / neuropsychologic tests - Patients|OTHER: Neurologic / neuropsychologic tests - Controls,"University Hospital, Montpellier",,ALL,"ADULT, OLDER_ADULT",NA,58,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2019-12-09,2022-05-23,2022-05-23,"CHU Montpellier, Montpellier, 34000, France"
NCT05080270,Feasibility Study of Tolerogenic Fibroblasts in Patients With Refractory Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05080270,COMPLETED,"Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis",BIOLOGICAL: Tolerogenic Fibroblasts,FibroBiologics,,ALL,ADULT,EARLY_PHASE1,5,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-09-21,2021-06-08,2021-06-08,"Servicios Medicos UCC, S.C., Tijuana, Baja California, 22504, Mexico"
NCT00423111,Correlation Between Cognitive Functions and MRI in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00423111,UNKNOWN,Multiple Sclerosis,,Sheba Medical Center,,ALL,"ADULT, OLDER_ADULT",,100,OTHER_GOV,OBSERVATIONAL,Observational Model: |Time Perspective: p,2007-02,,2009-02,"Sheba Medical Center, Ramat Gan, 52621, Israel"
NCT01514370,Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a,https://beta.clinicaltrials.gov/study/NCT01514370,COMPLETED,Multiple Sclerosis,DRUG: IFN beta 1a 44 mcg TIW|DRUG: Curcumin|DRUG: Placebo,"Merck KGaA, Darmstadt, Germany","Merck Serono S.P.A., Italy",ALL,ADULT,PHASE2,80,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2012-04-30,2016-03-31,2016-03-31,"Investigational Site, Naples, 80131, Italy"
NCT05351411,Exercise on Contactin-1 and Contactin-2 Level in Persons With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05351411,COMPLETED,Relapsing Remitting Multiple Sclerosis,OTHER,Firat University,,ALL,"ADULT, OLDER_ADULT",,60,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-11-01,2022-01-03,2022-03-04,"Fırat university, Elazığ, 23100, Turkey"
NCT04928313,Safety and Effectiveness of Cinnomer® (Glatiramer Acetate) in Multiple Sclerosis (MS) Treatment in Iran,https://beta.clinicaltrials.gov/study/NCT04928313,COMPLETED,Relapsing Multiple Sclerosis,DRUG: Glatiramer Acetate,Cinnagen,,ALL,ADULT,,368,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-04-12,2020-02-17,2020-02-17,
NCT03906370,Capillary Dysfunction and CD46-immunoreceptor (CD46) Type in MS,https://beta.clinicaltrials.gov/study/NCT03906370,COMPLETED,Multiple Sclerosis,DIAGNOSTIC_TEST: Diagnostic criteria for MS,University of Aarhus,,ALL,"ADULT, OLDER_ADULT",,83,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-12-01,2021-05-01,2021-05-01,"Department of Neurology, Aarhus, Denmark"
NCT00468611,Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00468611,TERMINATED,"Multiple Sclerosis, Secondary Progressive",DRUG: MBP8298,BioMS Technology Corp.,,ALL,"ADULT, OLDER_ADULT",PHASE3,510,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2007-06,2009-07,2009-09,
NCT00473213,Optimizing IFN Beta - 1B Dose,https://beta.clinicaltrials.gov/study/NCT00473213,COMPLETED,Multiple Sclerosis,DRUG: Interferon Beta 1,"University of Turin, Italy",Dimensione Ricerca s.r.l.,ALL,ADULT,PHASE3,217,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE|Primary Purpose: TREATMENT,1999-09,,2004-02,
NCT04260711,Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS).,https://beta.clinicaltrials.gov/study/NCT04260711,RECRUITING,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis, Secondary Progressive",DRUG: DMT,"Amsterdam UMC, location VUmc",,ALL,"ADULT, OLDER_ADULT",NA,130,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-07-01,2023-08-01,2024-01-01,"Amsterdam UMC, Amsterdam, Netherlands"
NCT02833311,e-Mobile Tablet for People With Chronic Conditions,https://beta.clinicaltrials.gov/study/NCT02833311,COMPLETED,Fibromyalgia|Multiple Sclerosis|Osteoarthritis|Sjögren's Syndrome|Parkinson's Disease,BEHAVIORAL: Computer Tablet Group|BEHAVIORAL: Paper and Pencil Group|BEHAVIORAL: Contact Control Group,Case Western Reserve University,,ALL,"ADULT, OLDER_ADULT",NA,46,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2013-11,2016-04,2016-04,"Case Western Reserve University, Cleveland, Ohio, 44106, United States"
NCT02228213,Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02228213,COMPLETED,Secondary Progressive Multiple Sclerosis,BIOLOGICAL: MIS416|DRUG: Saline,Innate Immunotherapeutics,Syneos Health,ALL,"ADULT, OLDER_ADULT",PHASE2,93,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-10,2017-05,2017-06,"The Wesley-St. Andrew's Research Institute, Brisbane, Queensland, 4066, Australia|PARC Clinical Research, Adelaide, South Australia, 5000, Australia|Nucleus Network - Centre for Clinical Studies, Melbourne, Victoria, 3004, Australia|Western Australian Neuroscience Research Institute, Perth, Western Australia, 6009, Australia|Neurodegenerative Disorders Research, West Perth, Western Australia, 6005, Australia|Optimal Clinical Trials, Auckland, 1010, New Zealand|P3 Research, Wellington, 6021, New Zealand"
NCT01020370,Exploratory Study to Investigate the Reparative and Regenerative Potential of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients Participating in the CARE MS I and MS II Studies,https://beta.clinicaltrials.gov/study/NCT01020370,COMPLETED,Multiple Sclerosis,,Wayne State University,,ALL,"ADULT, OLDER_ADULT",,,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,,,,
NCT01188811,Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT01188811,COMPLETED,"Multiple Sclerosis, Chronic Progressive",DRUG: lipoic acid|DRUG: Placebo,VA Office of Research and Development,Oregon Health and Science University,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,54,FED,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2010-10,2015-08,2015-08,"VA Portland Health Care System, Portland, OR, Portland, Oregon, 97239, United States"
NCT04490044,Under and Over Rehabilitation Study,https://beta.clinicaltrials.gov/study/NCT04490044,COMPLETED,Multiple Sclerosis,OTHER: Under & Over rehabilitation tool,Queen Mary University of London,Roche Pharma AG|Barts & The London NHS Trust,ALL,"ADULT, OLDER_ADULT",NA,120,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: OTHER,2020-09-01,2022-04-01,2022-05-01,"Queen Mary University of London, London, EC1M 6BQ, United Kingdom"
NCT04287244,Transcutaneous Direct Current Stimulation of the Spinal Cord for Treatment of Spasticity in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04287244,UNKNOWN,Spastic Parapareses,DEVICE: Transcutaneous Spinal Direct Current Stimulation,Lebanese American University,,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-03,2022-02,2022-05,
NCT03092544,Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients,https://beta.clinicaltrials.gov/study/NCT03092544,UNKNOWN,Multiple Sclerosis,DRUG: dimethyl fumarate,Multiple Sclerosis Center of Northeastern New York,Icahn School of Medicine at Mount Sinai|Biogen,ALL,"ADULT, OLDER_ADULT",PHASE4,57,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2015-02,2018-12,2018-12,"Multiple Sclerosis Center of Northeastern New York, Latham, New York, 12110, United States"
NCT03766698,Muscle Architecture of Lower Extremity In Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03766698,COMPLETED,Multiple Sclerosis,,Sanko University,,ALL,ADULT,,35,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-12-18,2020-01-18,2020-02-15,"Sanko University, Gaziantep, Turkey"
NCT04369898,Combined Sensitivity and Specificity of Cortical Lesions and Central Vein Sign for MS Diagnosis and Differential Diagnosis,https://beta.clinicaltrials.gov/study/NCT04369898,RECRUITING,Multiple Sclerosis),OTHER: Image analysis/ Central vein detection|OTHER: Image analysis/ Automatic cortical lesion detection,"University Hospital, Basel, Switzerland",,ALL,"CHILD, ADULT, OLDER_ADULT",,500,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-06-01,2024-12,2024-12,"Translational Imaging in Neurology, University Hospital Basel, Basel, 4031, Switzerland"
NCT03136744,Reducing Sedentary Behaviour: A Novel Opportunity for Managing Comorbidity in MS?,https://beta.clinicaltrials.gov/study/NCT03136744,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Sit Less with MS,University of Alberta,Alberta Innovates Health Solutions,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2018-02-03,2019-06-12,2019-12-31,"University of Alberta, Edmonton, Alberta, T6G 2G4, Canada"
NCT05449574,Sensory Integration Disorders in Patients With MS Including Disease Advancement and Relapses in the Last Year,https://beta.clinicaltrials.gov/study/NCT05449574,COMPLETED,Multiple Sclerosis,DIAGNOSTIC_TEST: Scale for the Assessment of Sensory Integration in Adults,Pomeranian Medical University Szczecin,,ALL,ADULT,,2,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-01-20,2022-05-25,2022-06-27,"Departmen of Neurology, Szczecin, Unii Lubelskiej, 71-228, Poland"
NCT05351957,Dry Needling for Treating Spasticity in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05351957,COMPLETED,Multiple Sclerosis,PROCEDURE: Dry needling,Hospital Universitario de Canarias,,ALL,ADULT,NA,10,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-02-18,2020-04-20,2020-09-22,"Hospital Universitario de Canarias, La Laguna, Santa Cruz De Tenerife, 38320, Spain"
NCT01195857,Assessment of Subject Use of the Rebiject II Injection Device According to Nurse Examination of Subject Accuracy in 10 Steps as a Dummy Demonstration,https://beta.clinicaltrials.gov/study/NCT01195857,COMPLETED,Multiple Sclerosis,,"Merck KGaA, Darmstadt, Germany","Merck Serono Limited, UK",ALL,"ADULT, OLDER_ADULT",,100,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2009-01,2009-09,2009-09,
NCT03198598,Effects of Yoga Practice in Multiple Sclerosis Patients: a Multidimensional Approach,https://beta.clinicaltrials.gov/study/NCT03198598,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,BEHAVIORAL: Iyengar Yoga|BEHAVIORAL: Yoga app,Hospital Israelita Albert Einstein,,ALL,ADULT,NA,130,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2017-06-19,2022-12-26,2022-12-26,"Hospital Israelita Albert Einstein, Sao Paulo, 05652901, Brazil"
NCT05385744,"An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT05385744,RECRUITING,Multiple Sclerosis,BIOLOGICAL: BCD-132|DRUG: Teriflunomide,Biocad,,ALL,ADULT,PHASE3,336,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-04-05,2023-03,2024-03,"State Budgetary Healthcare Institution of the Moscow Region M.F. Vladimirsky Moscow Regional Research and Clinical Institute, Moscow, 129110, Russian Federation"
NCT03745144,Effects of Cladribine Tablets on the PK of Microgynon®,https://beta.clinicaltrials.gov/study/NCT03745144,COMPLETED,Relapsing Multiple Sclerosis (RMS),DRUG: Cladribine|DRUG: Placebo|DRUG: Microgynon®,"Merck KGaA, Darmstadt, Germany",,FEMALE,ADULT,PHASE1,24,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: OTHER",2019-01-17,2022-09-02,2022-09-16,"St. Josef und St. Elisabeth Hospital gGmbH, Bochum, Germany|Nuvisan GmbH, Neu-Ulm, Germany|M.A. - LEK A.M.Maciejowscy SC., Katowice, Poland|BioResearch Group Sp. z o. o, Nadarzyn, Poland|IKARDIA Hospital Cardiology, Nałęczów, Poland|BioVirtus Research Site Sp, Otwock, Poland|MTZ Clinical Research Sp. z o.o., Warszawa, Poland"
NCT05797740,Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA),https://beta.clinicaltrials.gov/study/NCT05797740,NOT_YET_RECRUITING,Multiple Sclerosis,DRUG: Mavenclad,"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany",,ALL,"ADULT, OLDER_ADULT",,360,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-05-26,2028-08-11,2028-08-11,"UCL Saint Luc, Bruxelles, Belgium|UZ Antwerpen, Edegem, Belgium|AZ Groeninge vzw, Kortrijk, Belgium|CHU Sart Tilman, Liege 1, Belgium|FN u sv. Anny Brno, Brno, Czechia|FN Hradec Králové, Hradec Kralove, Czechia|Fakultni nemocnice Ostrava, Ostrava, Czechia|Nemocnice Teplice, Teplice, Czechia|University of Thrace, Medical School - Neurology Department, Alexandroupoli, Alexandroupoli, Greece|251 General Air Force Hospital, Athens, Greece|Aiginiteio' Hospital, Athens, Greece|Attikon, Athens, Greece|General Miliary Hospital of Athens ""401"", Athens, Greece|General Oncology Hospital ""Agioi Anargyroi"", Athens, Greece|University Hospital of Larissa, Larissa, Greece|General Hospital ""Agios Andreas"", Patras, Greece|University of Patras, Patras, Greece|AHEPA University Hospital of Thessaloniki, Thessaloniki, Greece|General Hospital of Athens G.Gennimatas, Thessaloniki, Greece|Interbalkan Hospital of Thessaloniki, Thessaloniki, Greece|Papageorgiou General Hospital Thessaloniki, Thessaloniki, Greece|St Luke's Clinic, Thessaloniki, Greece|Zuyderland, Sittard-Geleen, Netherlands|Uniwersytecki Szpital Kliniczny w Bialymstoku, Bialystok, Poland|Medical Academy Neurology Clinic, Poznan, Poland|Szpital Kliniczny Nr 1 Pomorskiego Uniwersytetu Medycznego w Szczecinie, Szczecin, Poland|Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal|Centro Hospitalar Lisboa Norte Hospital de Santa Maria, Lisboa, Portugal|Centro Hospitalar Universitário Lisboa Central - Hospital dos Capuchos, Lisbon, Portugal|Centro Hospitalar de São João E. P. E., Porto, Portugal"
NCT02849457,Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex,https://beta.clinicaltrials.gov/study/NCT02849457,COMPLETED,Tuberous Sclerosis Complex,DRUG: Vigabatrin|DRUG: Placebo,Martina Bebin,National Institute of Neurological Disorders and Stroke (NINDS),ALL,CHILD,PHASE2,84,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2016-12,2023-04-26,2023-05-05,"University of Alabama at Birmingham, Birmingham, Alabama, 35233, United States|University of California, Los Angeles, Los Angeles, California, 90095, United States|Stanford University, Palo Alto, California, 94304, United States|Children's National Medical Center, Washington, District of Columbia, 20010, United States|Boston Children's Hospital, Boston, Massachusetts, 02215, United States|Beaumont Children's Hospital, Royal Oak, Michigan, 48073, United States|Minnesota Epilepsy Group, PA, Saint Paul, Minnesota, 55102, United States|Washington University in St. Louis, Saint Louis, Missouri, 63110, United States|Duke University, Durham, North Carolina, 37710, United States|Cincinnati's Children Hospital Medical Center, Cincinnati, Ohio, 45229, United States|The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States|University of Texas Health Science Center at Houston, Houston, Texas, 77054, United States|Seattle Children's Hospital, Seattle, Washington, 98105, United States"
NCT03784898,Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada,https://beta.clinicaltrials.gov/study/NCT03784898,COMPLETED,Multiple Sclerosis,OTHER: Blood draw for future biomarker analysis,"Genzyme, a Sanofi Company",,ALL,"ADULT, OLDER_ADULT",PHASE4,13,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2019-02-08,2019-12-11,2019-12-11,"Investigational Site Number 8400001, Los Angeles, California, 90094, United States"
NCT03753698,"Wireless, Implantable Tibial Nerve Stimulator System (eCoin™) for the Treatment of Refractory Lower Urinary Tract Symptoms in Patients With MS",https://beta.clinicaltrials.gov/study/NCT03753698,WITHDRAWN,Multiple Sclerosis,DEVICE: eCoin,Chiara Zecca,,ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-07-01,2022-12-31,2022-12-31,"Ospedale Regionale di Lugano, Neurocenter of Southern Switzerland, Lugano, Ticino, 6903, Switzerland"
NCT02421744,A Task-oriented Circuit Training in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02421744,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Task Oriented Circuit Training|BEHAVIORAL: Delayed Onset TOCT,University Hospital of Ferrara,,ALL,"ADULT, OLDER_ADULT",NA,35,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2015-03,2018-10,2018-10,"Ferrara University Hospital, Ferrara, Italy|Azienda Ospedaliera Universitaria Pisana, Pisa, Italy"
NCT04236544,Patient Experiences of Multiple Sclerosis (PExMS),https://beta.clinicaltrials.gov/study/NCT04236544,NOT_YET_RECRUITING,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting|Patient Engagement|Self Efficacy",BEHAVIORAL: PExMS and DECIMS-Wiki|BEHAVIORAL: DECIMS-Wiki,Universitätsklinikum Hamburg-Eppendorf,"Marianne-Strauss-Klinik, Berg, Germany|Gesundheitszentrum St. Johannes Hospital, Bonn, Germany|University Hospital Cologne, Cologne, Germany|Rechts der Isar Hospital, Munich, Germany|University Medical Center Schleswig-Holstein, Kiel, Germany",ALL,"ADULT, OLDER_ADULT",NA,55,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2024-01-01,2025-12-31,2025-12-31,
NCT02425644,Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02425644,COMPLETED,Multiple Sclerosis,DRUG: ponesimod|DRUG: teriflunomide,Actelion,,ALL,ADULT,PHASE3,1133,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2015-06-04,2019-05-16,2019-05-16,"Investigator Site 8045, Carlsbad, California, 92011, United States|Investigator Site 8311, Pomona, California, 91767, United States|Investigator Site 8036, Denver, Colorado, 80209, United States|Investigator Site 8065, Ormond Beach, Florida, 32174, United States|Investigator Site 8018, Tampa, Florida, 33612, United States|Investigator Site 8013, Indianapolis, Indiana, 46256, United States|Investigator Site 8040, Raleigh, North Carolina, 27607, United States|Investigator Site 8006, Columbus, Ohio, 43214, United States|Investigator Site 8015, Franklin, Tennessee, 37064, United States|Investigator Site 8042, Orem, Utah, 84058, United States|Investigator Site 3605, Grodno, 230017, Belarus|Investigator Site 3603, Minsk, 220026, Belarus|Investigator Site 3602, Minsk, 220114, Belarus|Investigator Site 3606, Vitebsk, 210023, Belarus|Investigator Site 3604, Vitebsk, 210037, Belarus|Investigator Site 9104, Sarajevo, 71000, Bosnia and Herzegovina|Investigator Site 2709, Plovdiv, 4002, Bulgaria|Investigator Site 2711, Sofia, 1113, Bulgaria|Investigator Site 2702, Sofia, 1309, Bulgaria|Investigator Site 2707, Sofia, 1407, Bulgaria|Investigator Site 2701, Sofia, 1431, Bulgaria|Investigator Site 2708, Sofia, 1431, Bulgaria|Investigator Site 2703, Sofia, 1606, Bulgaria|Investigator Site 8102, Edmonton, Alberta, T6G 1Z1, Canada|Investigator Site 8120, Victoria, British Columbia, V8R 1J8, Canada|Investigator Site 8101, Ottawa, Ontario, K1H 8L6, Canada|Investigator Site 8113, Greenfield Park, Quebec, J4V 2J2, Canada|Investigator Site 2506, Osijek, 31000, Croatia|Investigator Site 2502, Zagreb, 10000, Croatia|Investigator Site 2508, Zagreb, 10000, Croatia|Investigator Site 2509, Zagreb, 10000, Croatia|Investigator Site 3009, Brno, 625 00, Czechia|Investigator Site 3003, Brno, 656 91, Czechia|Investigator Site 3010, Hradec Králové, 500 05, Czechia|Investigator Site 3006, Jihlava, 586 33, Czechia|Investigator Site 3002, Ostrava-Poruba, 708 52, Czechia|Investigator Site 3007, Pardubice, 532 03, Czechia|Investigator Site 3001, Praha 2, 128 08, Czechia|Investigator Site 3008, Praha 5, 150 06, Czechia|Investigator Site 3004, Teplice, 415 29, Czechia|Investigator Site 2212, Tampere, 33100, Finland|Investigator Site 2202, Turku, 20520, Finland|Investigator Site 1713, Bordeaux Cedex, 33076, France|Investigator Site 1703, Clermont Ferrand Cedex 1, 63003, France|Investigator Site 1715, Nantes Cedex 1, 44093, France|Investigator Site 1706, Nice Cedex 1, 06002, France|Investigator Site 1705, Strasbourg Cedex, 67091, France|Investigator Site 3905, Tbilisi, 0112, Georgia|Investigator Site 3904, Tbilisi, 0160, Georgia|Investigator Site 3903, Tbilisi, 0179, Georgia|Investigator Site 3906, Tbilisi, 0179, Georgia|Investigator Site 3902, Tbilisi, 0194, Georgia|Investigator Site 1113, Dresden, 01307, Germany|Investigator Site 1107, Erfurt, 99089, Germany|Investigator Site 1109, Leipzig, 04107, Germany|Investigator Site 1104, Mainz, 55131, Germany|Investigator Site 1102, Ulm, 89081, Germany|Investigator Site 1303, Athens, 11521, Greece|Investigator Site 1301, Athens, 11525, Greece|Investigator Site 1307, Athens, 15125, Greece|Investigator Site 2903, Budapest, 1145, Hungary|Investigator Site 2905, Budapest, 1204, Hungary|Investigator Site 2910, Esztergom, 2500, Hungary|Investigator Site 2902, Gyor, 9023, Hungary|Investigator Site 2909, Kistarcsa, 2143, Hungary|Investigator Site 4005, Ashkelon, 7830604, Israel|Investigator Site 4004, Haifa, 3109601, Israel|Investigator Site 4006, Jerusalem, 9112001, Israel|Investigator Site 4010, Zfat, 13100, Israel|Investigator Site 1403, Cefalu, 90015, Italy|Investigator Site 1409, Genova, 16132, Italy|Investigator Site 1413, L'Aquila, 67100, Italy|Investigator Site 1405, Roma, 00189, Italy|Investigator Site 3401, Riga, 1015, Latvia|Investigator Site 3402, Riga, LV-1002, Latvia|Investigator Site 3403, Riga, LV-1038, Latvia|Investigator Site 3502, Kaunas, 50161, Lithuania|Investigator Site 3503, Klaipeda, 92288, Lithuania|Investigator Site 3504, Siauliai, 76231, Lithuania|Investigator Site 7410, Chihuahua, 31203, Mexico|Investigator Site 7409, Monterrey, 64710, Mexico|Investigator Site 3219, Bialystok, 15-270, Poland|Investigator Site 3215, Bydgoszcz, 85-795, Poland|Investigator Site 3208, Gdansk, 80-803, Poland|Investigator Site 3217, Katowice, 40-595, Poland|Investigator Site 3203, Katowice, 40-752, Poland|Investigator Site 3205, Konstancin-Jeziorna, 05-510, Poland|Investigator Site 3216, Ksawerow, 95-054, Poland|Investigator Site 3220, Lublin, 20-015, Poland|Investigator Site 3202, Poznan, 60-355, Poland|Investigator Site 3214, Poznan, 60-848, Poland|Investigator Site 3207, Poznan, 61-853, Poland|Investigator Site 3213, Wroclaw, 51-685, Poland|Investigator Site 1602, Amadora, 2720 276, Portugal|Investigator Site 1605, Braga, 4710-243, Portugal|Investigator Site 1603, Coimbra, 3000-075, Portugal|Investigator Site 1604, Porto, 4099-001, Portugal|Investigator Site 2807, Bucuresti, 010825, Romania|Investigator Site 2811, Bucuresti, 022903, Romania|Investigator Site 2804, Bucuresti, 050098, Romania|Investigator Site 2802, Timisoara, 300723, Romania|Investigator Site 3821, Barnaul, Altai Krai, 656024, Russian Federation|Investigator Site 3818, Belgorod, 308007, Russian Federation|Investigator Site 3837, Bryansk, 241033, Russian Federation|Investigator Site 3836, Ekaterinburg, 620102, Russian Federation|Investigator Site 3811, Kazan, 420029, Russian Federation|Investigator Site 3822, Kemerovo, 650066, Russian Federation|Investigator Site 3814, Krasnoyarsk, 660037, Russian Federation|Investigator Site 3823, Kursk, 305007, Russian Federation|Investigator Site 3831, Moscow, 119049, Russian Federation|Investigator Site 3803, Moscow, 127015, Russian Federation|Investigator Site 3840, Moscow, 127015, Russian Federation|Investigator Site 3810, Moscow, 129128, Russian Federation|Investigator Site 3802, Nizhniy Novgorod, 603155, Russian Federation|Investigator Site 3834, Nizhny Novgorod, 603076, Russian Federation|Investigator Site 3835, Novgorod, 173008, Russian Federation|Investigator Site 3829, Novosibirsk, 630007, Russian Federation|Investigator Site 3839, Perm, 614990, Russian Federation|Investigator Site 3812, Pyatigorsk, 357538, Russian Federation|Investigator Site 3813, Saint Petersburg, 197110, Russian Federation|Investigator Site 3805, Samara, 443095, Russian Federation|Investigator Site 3825, Smolensk, 214019, Russian Federation|Investigator Site 3808, St. Petersburg, 194354, Russian Federation|Investigator Site 3833, St. Petersburg, 197022, Russian Federation|Investigator Site 3807, St. Petersburg, 197376, Russian Federation|Investigator Site 3815, St. Petersburg, 197706, Russian Federation|Investigator Site 3801, Tomsk, 634050, Russian Federation|Investigator Site 3819, Tver, 170026, Russian Federation|Investigator Site 3842, Yaroslavl, 150030, Russian Federation|Investigator Site 2601, Belgrade, 11000, Serbia|Investigator Site 2606, Belgrade, 11000, Serbia|Investigator Site 2607, Belgrade, 11080, Serbia|Investigator Site 2603, Kragujevac, 34000, Serbia|Investigator Site 2602, Nis, 18000, Serbia|Investigator Site 1509, Barcelona, 08003, Spain|Investigator Site 1505, Barcelona, 08035, Spain|Investigator Site 1504, Barcelona, 08036, Spain|Investigator Site 1502, Madrid, 28006, Spain|Investigator Site 1501, Malaga, 29010, Spain|Investigator Site 1506, Sevilla, 41009, Spain|Investigator Site 2103, Goteborg, 413 45, Sweden|Investigator Site 2110, Stockholm, 141 86, Sweden|Investigator Site 2101, Stockholm, 171 76, Sweden|Investigator Site 9004, Trabzon, 61080, Turkey|Investigator Site 3714, Chernihiv, 14001, Ukraine|Investigator Site 3701, Chernihiv, 14029, Ukraine|Investigator Site 3713, Ivano-Frankivsk, 76008, Ukraine|Investigator Site 3711, Ivano-Frankivsk, 76018, Ukraine|Investigator Site 3723, Kharkiv, 61103, Ukraine|Investigator Site 3724, Kharkiv, 61176, Ukraine|Investigator Site 3716, Kyiv, 03115, Ukraine|Investigator Site 3715, Lviv, 79000, Ukraine|Investigator Site 3721, Lviv, 79010, Ukraine|Investigator Site 3703, Odessa, 65009, Ukraine|Investigator Site 3717, Poltava, 36011, Ukraine|Investigator Site 3730, Ternopil, 46027, Ukraine|Investigator Site 3718, Vinnytsia, 21005, Ukraine|Investigator Site 3722, Zaporizhia, 69000, Ukraine|Investigator Site 3725, Zhytomyr, 10008, Ukraine|Investigator Site 2015, Glasgow, G51 4TF, United Kingdom|Investigator Site 2021, Lancashire, PR2 9HT, United Kingdom|Investigator Site 2003, Salford, M6 8HD, United Kingdom"
NCT02504840,Natural History of Multiple Sclerosis and Its Mimickers,https://beta.clinicaltrials.gov/study/NCT02504840,COMPLETED,Neurologic Disorders|Healthy Volunteers|Multiple Sclerosis,,National Institute of Neurological Disorders and Stroke (NINDS),,ALL,"ADULT, OLDER_ADULT",,104,NIH,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-07-23,2020-03-05,2020-03-05,"National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States"
NCT04767698,Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04767698,TERMINATED,Multiple Sclerosis,DRUG: Belimumab|DRUG: Short-course Ocrelizumab|DRUG: Continued Ocrelizumab,Johns Hopkins University,GlaxoSmithKline,ALL,"ADULT, OLDER_ADULT",PHASE2,4,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-10-01,2022-05-10,2022-05-10,"Johns Hopkins University, Baltimore, Maryland, 21287, United States"
NCT04066244,Study of Safety and of the Mechanism of BLZ945 in ALS Patients,https://beta.clinicaltrials.gov/study/NCT04066244,RECRUITING,Amyotrophic Lateral Sclerosis,DRUG: BLZ945,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE2,56,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2019-12-30,2025-03-27,2026-05-08,"Novartis Investigative Site, New Haven, Connecticut, 06520-8048, United States|Novartis Investigative Site, Boston, Massachusetts, 02114, United States|Novartis Investigative Site, New York, New York, 10032, United States|Novartis Investigative Site, Turku, 20520, Finland|Novartis Investigative Site, Stockholm, 14186, Sweden"
NCT04956744,"A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT04956744,RECRUITING,Multiple Sclerosis,BIOLOGICAL: IMS001,ImStem Biotechnology,"Rho, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE1,30,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-08-31,2027-12,2027-12,"Shepherd Center, Atlanta, Georgia, 30309, United States|UMass Memorial Medical Center, Worcester, Massachusetts, 01605, United States|Rocky Mountain MS Clinic, Salt Lake City, Utah, 84103, United States"
NCT02830074,Treatment of Sleep-disordered Breathing in Patients With SCI,https://beta.clinicaltrials.gov/study/NCT02830074,COMPLETED,Spinal Cord Injury|Sleep-disordered Breathing|Spinal Cord Disease|Multiple Sclerosis,BEHAVIORAL: Best practices PAP + patient Education +ongoing Support and Training|BEHAVIORAL: Sleep Education,VA Office of Research and Development,,ALL,"ADULT, OLDER_ADULT",NA,73,FED,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-05-01,2019-09-30,2020-03-30,"John D. Dingell VA Medical Center, Detroit, MI, Detroit, Michigan, 48201, United States"
NCT04925557,Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04925557,RECRUITING,Secondary-progressive Multiple Sclerosis,DRUG: Mayzent|DRUG: Ocrevus,State University of New York at Buffalo,,ALL,ADULT,PHASE4,60,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-09-27,2025-04-30,2025-04-30,"University at Buffalo, Buffalo General Hospital, Buffalo, New York, 14203, United States"
NCT02286557,Testing the Effects of Methylphenidate on Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02286557,UNKNOWN,Fatigue in Multiple Sclerosis,DRUG: Methelphenidate|DRUG: Placebo,Kessler Foundation,,ALL,"ADULT, OLDER_ADULT",PHASE2,36,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-10,2015-09,2015-09,
NCT03594357,Cognitive Functions in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03594357,COMPLETED,Multiple Sclerosis,,Gazi University,,ALL,"ADULT, OLDER_ADULT",,137,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-09-03,2018-12-21,2018-12-24,"Gazi University, Ankara, Turkey"
NCT04448444,Brain Activity Changes Following Neuroproprioceptive Physiotherapy in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04448444,COMPLETED,Neuronal Plasticity|Multiple Sclerosis|Rehabilitation,BEHAVIORAL: Motor Program Activating Therapy|BEHAVIORAL: Vojta reflex locomotion,"Charles University, Czech Republic",,ALL,"ADULT, OLDER_ADULT",NA,87,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2015-05,2017-05-15,2019-11-10,
NCT00765544,Targeted Lower Extremity Joint Training,https://beta.clinicaltrials.gov/study/NCT00765544,TERMINATED,Multiple Sclerosis,DEVICE: Anklebot|DEVICE: Lokomat,US Department of Veterans Affairs,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,10,FED,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2008-09,2008-09,2008-09,"Providence VA Medical Center, Providence, Rhode Island, 02908-4799, United States"
NCT01281657,Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program,https://beta.clinicaltrials.gov/study/NCT01281657,COMPLETED,Multiple Sclerosis,DRUG: fingolimod,Novartis,,ALL,"ADULT, OLDER_ADULT",,64,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-02,2012-07,2012-07,"North Central Neurology Associates, PC, Cullman, Alabama, 35058, United States|The Research & Education Inst. of Alta Bates Summit Med. Grp, Berkeley, California, 94705, United States|Neuro-Therapeutics, Inc., Pasadena, California, 91105, United States|University of California San Francisco, San Francisco, California, 94117, United States|Yale Multiple Sclerosis Center, New Haven, Connecticut, 06510, United States|Georgetown University/Lombardi Cancer Center, Washington, District of Columbia, 20007, United States|Sunrise Clinical Research, Inc., Hollywood, Florida, 33021, United States|University of Florida, Jacksonville, Florida, 32209, United States|University of Miami, Miami, Florida, 33136, United States|Neurological Associates, Pompano Beach, Florida, 33060, United States|Neurology Clinical Research, Inc., Sunrise, Florida, 33351, United States|AMO Corporation, Tallahassee, Florida, 32308, United States|MS Center of Vero Beach, Vero Beach, Florida, 32960, United States|South Suburban Neurology, Flossmoor, Illinois, 60422, United States|Neurologic Associates, LTD, Palos Heights, Illinois, 60463, United States|Mercy Ruan Neurology Clinic Res Ct., Des Moines, Iowa, 50314, United States|University of Kansas Medical Center, Kansas City, Kansas, 66160, United States|Mid America Neuroscience Institute, Lenexa, Kansas, 66214, United States|University of Maryland, Baltimore, Maryland, 21201, United States|Johns Hopkins MS Center, Baltimore, Maryland, 21287, United States|Caritas St. Elizabeth's Hospital, Boston, Massachusetts, 02135, United States|Springfield Neurology Associates, LLC, Springfield, Massachusetts, 01104, United States|Spectrum Health Medical Group, Neurology, Grand Rapids, Michigan, 49525, United States|Saint Luke's Hospital, Kansas City, Missouri, 64111, United States|The MS Center for Innovation in Care, St. Louis, Missouri, 63131, United States|University of New Mexico Health Science Center, Albuquerque, New Mexico, 87131, United States|Mount Sinai School of Medicine, New York, New York, 10029, United States|Island Neurological Associates, Plainview, New York, 11803, United States|SUNY - Stony Brook University, Stony Brook, New York, 11794, United States|University of Toledo Health Science Campus, Toledo, Ohio, 43614, United States|MS Center of Oklahoma, Oklahoma City, Oklahoma, 73120, United States|Neurological Associates of Tulsa, Inc, Tulsa, Oklahoma, 74137, United States|University of Pennsylvania Health System, Philadelphia, Pennsylvania, 19104, United States|Thomas Jerfferson University Hospital, Philadelphia, Pennsylvania, 19107, United States|Vanderbilt University, Nashville, Tennessee, 37204, United States|University of Texas Medical School, Houston, Texas, 77030, United States|Integra Clinical Research, San Antonio, Texas, 78231, United States|University of Virginia Health System, Charlottesville, Virginia, 22903, United States|Swedish Neuroscience Institute, Seattle, Washington, 98122, United States|Dean Foundation, Madison, Wisconsin, 53715, United States|University of Wisconsin Madison, Madison, Wisconsin, 53792, United States|St. Luke's Medical Center, Milwaukee, Wisconsin, 53215, United States|Novartis Investigative Site, Burnaby, British Columbia, V5G 2X6, Canada|Novartis Investigative Site, Vancouver, British Columbia, V6T 2B5, Canada|Novartis Investigative Site, Victoria, British Columbia, V8R 1J8, Canada|Novartis Investigative Site, Halifax, Nova Scotia, B3H 4K4, Canada|Novartis Investigative Site, Kingston, Ontario, K7L 2V7, Canada|Novartis Investigative Site, London, Ontario, N6A 5A5, Canada|Novartis Investigative Site, Nepean, Ontario, K2G 6E2, Canada|Novartis Investigative Site, Ottawa, Ontario, K1H 8L6, Canada|Novartis Investigative Site, Toronto, Ontario, M5B 1W8, Canada|Novartis Investigative Site, Greenfield Park, Quebec, J4V 2J2, Canada|Novartis Investigative Site, Montreal, Quebec, H1T 2M4, Canada|Novartis Investigative Site, Montreal, Quebec, H2L 4M1, Canada|Novartis Investigative Site, Montreal, Quebec, H3A 2B4, Canada|Novartis Investigative Site, Sherbrooke, Quebec, J1H 5N4, Canada|Novartis Investigative Site, Regina, Saskatchewan, S4T 1A5, Canada|Novartis Investigative Site, Quebec, G1J 1Z4, Canada"
NCT00010998,Yoga: Effect on Attention in Aging & Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00010998,COMPLETED,Multiple Sclerosis,PROCEDURE: Yoga,National Center for Complementary and Integrative Health (NCCIH),,ALL,OLDER_ADULT,PHASE2,,NIH,INTERVENTIONAL,Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT,1999-09,,2004-12,"Oregon Health Sciences University/Neurology, Portland, Oregon, 97201, United States"
NCT03410498,The Effects of FES in a Variety of Walking Conditions in People With MS,https://beta.clinicaltrials.gov/study/NCT03410498,RECRUITING,Multiple Sclerosis,OTHER: Incremental shuttle walk test,Queen Margaret University,,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2018-08-01,2022-12-29,2022-12-29,"Queen Margeret University, Musselburgh, EH21 6UU, United Kingdom"
NCT02848898,The Effects of Focal Vibration on Spasticity in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT02848898,UNKNOWN,Multiple Sclerosis,DEVICE: Equistasi|OTHER: Placebo,Federico II University,,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2016-08,2017-05,2017-07,"Prof. Giuseppe Orefice, Naples, Campania, 81025, Italy"
NCT03336424,Urinary Disorders in Patients With Multiple Sclerosis: Invasive Vs Non-invasive Investigations.,https://beta.clinicaltrials.gov/study/NCT03336424,UNKNOWN,"Multiple Sclerosis|Urinary Bladder, Neurogenic|Urodynamics",DIAGNOSTIC_TEST: Non-invasive investigations|DIAGNOSTIC_TEST: Invasive investigations,Saint-Joseph University,,ALL,"CHILD, ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2017-10-01,2019-08,2019-10,"Saint Joseph University, Beyrouth, Lebanon"
NCT04720898,LUNA-EMG to Enhance Motor Functions in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04720898,RECRUITING,Multiple Sclerosis,DEVICE: LUNA-EMG,University of Liege,"Jean-François Kaux, MD PhD|Frank Houlmont",ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-03-01,2024-01-01,2024-01-01,"CNRF, Tinlot, Liege, 4557, Belgium"
NCT04546698,5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04546698,COMPLETED,"Multiple Sclerosis, Acute Relapsing|Multiple Sclerosis",OTHER: blood sampling,Centre Hospitalier Régional d'Orléans,National Scientific Research Centre,ALL,ADULT,,78,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-09-07,2021-07-19,2021-07-19,"CHR Orléans, Orléans, 45067, France"
NCT02121444,"BAY86-5046 (Betaseron), Non Interventional Studies",https://beta.clinicaltrials.gov/study/NCT02121444,COMPLETED,Multiple Sclerosis,"DRUG: Interferon beta-1b (Betaferon, BAY 86-5046)|DEVICE: BETACONNECT auto-injector.",Bayer,,ALL,"ADULT, OLDER_ADULT",,151,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-06-23,2016-03-09,2016-06-01,"Many Locations, Germany"
NCT04211740,Phase II Clinical Trial of OCH-NCNP1,https://beta.clinicaltrials.gov/study/NCT04211740,ACTIVE_NOT_RECRUITING,"Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis, Secondary Progressive",DRUG: OCH-NCNP1|DRUG: Placebo,"National Center of Neurology and Psychiatry, Japan",,ALL,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-12-06,2023-05-31,2023-05-31,"National Center of Neurology and Psychiatry, Tokyo, 187-8551, Japan"
NCT01142557,An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01142557,COMPLETED,Multiple Sclerosis,DRUG: Interferon beta-1a (Rebif),"Merck KGaA, Darmstadt, Germany",Gesellschaft für Therapieforschung mbH,ALL,"CHILD, ADULT, OLDER_ADULT",,522,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2004-06,2005-11,2005-11,"Merck Serono GmbH, Darmstadt, 64289, Germany"
NCT03567057,A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment,https://beta.clinicaltrials.gov/study/NCT03567057,COMPLETED,Multiple Sclerosis|Walking Impairment,"DRUG: ADS-5102, 274 mg","Adamas Pharmaceuticals, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE3,424,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-07-18,2020-11-17,2021-04-18,"Adamas Clinical Site, Cullman, Alabama, 35058, United States|Adamas Clinical Site, Phoenix, Arizona, 85018, United States|Adamas Clinical Site, Phoenix, Arizona, 85032, United States|Adamas Clinical Site, Tucson, Arizona, 85704, United States|Adamas Clinical Site, Carlsbad, California, 92011, United States|Adamas Clinical Site, Fresno, California, 93710, United States|Adamas Clinical Site, Fullerton, California, 92835, United States|Adamas Clinical Site, Long Beach, California, 90806, United States|Adamas Clinical Site, Newport Beach, California, 92663, United States|Adamas Clinical Site, Sacramento, California, 95817, United States|Adamas Clinical Site, Aurora, Colorado, 80045, United States|Adamas Clinical Site, Colorado Springs, Colorado, 80907, United States|Adamas Clinical Site, Denver, Colorado, 800209, United States|Adamas Clinical Site, Fort Collins, Colorado, 80528, United States|Adamas Clinical Site, Fairfield, Connecticut, 06824, United States|Adamas Clinical Site, New London, Connecticut, 06320, United States|Adamas Clinical Site, Washington, District of Columbia, 20007, United States|Adamas Clinical Site, Maitland, Florida, 32751, United States|Adamas Clinical Site, Miami, Florida, 33136, United States|Adamas Clinical Site, Miami, Florida, 33176, United States|Adamas Clinical Site, Naples, Florida, 34105, United States|Adamas Clinical Site, Orlando, Florida, 32806, United States|Adamas Clinical Site, Ormond Beach, Florida, 32174, United States|Adamas Clinical Site, Palm Coast, Florida, 32164, United States|Adamas Clinical Site, Port Charlotte, Florida, 33952, United States|Adamas Clinical Site, Saint Petersburg, Florida, 33713, United States|Adamas Clinical Site, Sarasota, Florida, 34233, United States|Adamas Clinical Site, Tampa, Florida, 33609, United States|Adamas Clinical Site, Vero Beach, Florida, 32960, United States|Adamas Clinical Site, Atlanta, Georgia, 30309, United States|Adamas Clinical Site, Savannah, Georgia, 31406, United States|Adamas Clinical Site, Northbrook, Illinois, 60062, United States|Adamas Clinical Site, Indianapolis, Indiana, 46256, United States|Adamas Clinical Site, Kansas City, Kansas, 66103, United States|Adamas Clinical Site, Lenexa, Kansas, 66214, United States|Adamas Clinical Site, Overland Park, Kansas, 66212, United States|Adamas Clinical Site, Burlington, Massachusetts, 01805, United States|Adamas Clinical Site, Foxboro, Massachusetts, 02035, United States|Adamas Clinical Site, Worcester, Massachusetts, 01655, United States|Adamas Clinical Site, Detroit, Michigan, 42801, United States|Adamas Clinical Site, Farmington Hills, Michigan, 48334, United States|Adamas Clinical Site, Golden Valley, Minnesota, 55422, United States|Adamas Clinical Site, Kansas City, Missouri, 64111, United States|Adamas Clinical Site, Saint Louis, Missouri, 63110, United States|Adamas Clinical Site, Great Falls, Montana, 59405, United States|Adamas Clinical Site, Lincoln, Nebraska, 68506, United States|Adamas Clinical Site, Omaha, Nebraska, 68105, United States|Adamas Clinical Site, Las Vegas, Nevada, 89106, United States|Adamas Clinical Site, Albuquerque, New Mexico, 87106, United States|Adamas Clinical Site, Amherst, New York, 14226, United States|Adamas Clinical Site, Lake Success, New York, 11042, United States|Adamas Clinical Site, New York, New York, 10029, United States|Adamas Clinical Site, Patchogue, New York, 11772, United States|Adamas Clinical Site, Plainview, New York, 11803, United States|Adamas Clinical Site, Rochester, New York, 14642, United States|Adamas Clinical Site, Staten Island, New York, 10306, United States|Adamas Clinical Site, Charlotte, North Carolina, 28204, United States|Adamas Clinical Site, Raleigh, North Carolina, 27607, United States|Adamas Clinical Site, Centerville, Ohio, 45459, United States|Adamas Clinical Site, Cleveland, Ohio, 44195, United States|Adamas Clinical Site, Columbus, Ohio, 43214, United States|Adamas Clinical Site, Oklahoma City, Oklahoma, 73104, United States|Adamas Clinical Site, Portland, Oregon, 97213, United States|Adamas Clinical Site, Philadelphia, Pennsylvania, 19140, United States|Adamas Clinical Site, Charleston, South Carolina, 29406, United States|Adamas Clinical Site, Greer, South Carolina, 29650, United States|Adamas Clinical Site, Rock Hill, South Carolina, 29732, United States|Adamas Clinical Site, Spartanburg, South Carolina, 29307, United States|Adamas Clinical Site, Cordova, Tennessee, 38018, United States|Adamas Clinical Site, Franklin, Tennessee, 37064, United States|Adamas Clinical Site, Johnson City, Tennessee, 37604, United States|Adamas Clinical Site, Houston, Texas, 77030, United States|Adamas Clinical Site, Houston, Texas, 77074, United States|Adamas Clinical Site, Lubbock, Texas, 79410, United States|Adamas Clinical Site, Round Rock, Texas, 78681, United States|Adamas Clinical Site, Salt Lake City, Utah, 84103, United States|Adamas Clinical Site, Newport News, Virginia, 23601, United States|Adamas Clinical Site, Norfolk, Virginia, 23502, United States|Adamas Clinical Site, Kirkland, Washington, 98034, United States|Adamas Clinical Site, Seattle, Washington, 98122, United States|Adamas Clinical Site, Seattle, Washington, 98191, United States|Adamas Clinical Site, Milwaukee, Wisconsin, 53215, United States|Adamas Clinical Site, Edmonton, Alberta, T6G 2G3, Canada|Adamas Clinical Site, Lethbridge, Alberta, T1J 0N9, Canada|Adamas Clinical Site, Burnaby, Brithis Columbia, V5G 2X6, Canada|Adamas Clinical Site, Vancouver, British Columbia, V6T 2B5, Canada|Adamas Clinical Site, Hamilton, Ontario, L8L 2X2, Canada|Adamas Clinical Site, London, Ontario, N6A 5A5, Canada|Adamas Clinical Site, Ottawa, Ontario, K1H 8L6, Canada|Adamas Clinical Site, Greenfield Park, Quebec, J4V 2J2, Canada|Adamas Clinical Site, Montréal, Quebec, H3A 2B4, Canada|Adamas Clinical Site, Québec City, Quebec, G1J 1Z4, Canada"
NCT04144257,Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue,https://beta.clinicaltrials.gov/study/NCT04144257,RECRUITING,Multiple Sclerosis,DRUG: [F-18]PBR06|DRUG: [C-11]Methylreboxetine,Brigham and Women's Hospital,U.S. Army Medical Research Acquisition Activity,ALL,ADULT,PHASE1|PHASE2,12,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-03-12,2021-09-30,2021-09-30,"Partners MS Center, 60 Fenwood Road, Boston, Massachusetts, 02115, United States"
NCT05182398,Validity and Reliability of the Modified Four Square Step Test in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT05182398,NOT_YET_RECRUITING,Multiple Sclerosis,OTHER: Assesment,Kahramanmaras Sutcu Imam University,,ALL,"ADULT, OLDER_ADULT",,50,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-05-15,2022-07-15,2022-08-15,
NCT01490840,Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01490840,TERMINATED,Fatigue in Multiple Sclerosis,OTHER: Physical exercise,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE4,178,INDUSTRY,INTERVENTIONAL,Allocation: |Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2011-11,2014-07,2014-07,"Novartis Investigative Site, Aachen, 52062, Germany|Novartis Investigative Site, Alzenau, 63755, Germany|Novartis Investigative Site, Aschaffenburg, 63739, Germany|Novartis Investigative Site, Bad Mergentheim, 97980, Germany|Novartis Investigative Site, Bamberg, 96052, Germany|Novartis Investigative Site, Bayreuth, 95445, Germany|Novartis Investigative Site, Berlin, 10437, Germany|Novartis Investigative Site, Berlin, 10625, Germany|Novartis Investigative Site, Berlin, 10691, Germany|Novartis Investigative Site, Berlin, 12587, Germany|Novartis Investigative Site, Berlin, 13347, Germany|Novartis Investigative Site, Bielefeld, 33647, Germany|Novartis Investigative Site, Bochum, 44787, Germany|Novartis Investigative Site, Böblingen, 71032, Germany|Novartis Investigative Site, Dortmund, 44135, Germany|Novartis Investigative Site, Erbach, 64711, Germany|Novartis Investigative Site, Erlangen, 91054, Germany|Novartis Investigative Site, Frankfurt, 65929, Germany|Novartis Investigative Site, Hamburg, 22179, Germany|Novartis Investigative Site, Heidelberg, 69120, Germany|Novartis Investigative Site, Jena, 07740, Germany|Novartis Investigative Site, Kassel, 34121, Germany|Novartis Investigative Site, Leipzig, 04299, Germany|Novartis Investigative Site, Potsdam, 14471, Germany|Novartis Investigative Site, Prien, 83209, Germany|Novartis Investigative Site, Regensburg, 93053, Germany|Novartis Investigative Site, Siegen, 57076, Germany|Novartis Investigative Site, Sinsheim, 74889, Germany|Novartis Investigative Site, Stuttgart, 70174, Germany|Novartis Investigative Site, Stuttgart, 70178, Germany|Novartis Investigative Site, Teupitz, 15755, Germany|Novartis Investigative Site, Unterhaching, 82008, Germany"
NCT04721340,The Minnesota Manual Dexterity Test As A Measure Of Hand Function in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04721340,COMPLETED,Multiple Sclerosis,OTHER: Test Group|OTHER: Control Grup,Istanbul Aydın University,,ALL,"ADULT, OLDER_ADULT",,80,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-02-02,2021-05-02,2021-05-16,"Istanbul Aydin University, Istanbul, Küçükçekmece, Turkey"
NCT03368157,PREG-MS: New England MS Pregnancy Registry,https://beta.clinicaltrials.gov/study/NCT03368157,RECRUITING,Multiple Sclerosis|Pregnancy Related,,Brigham and Women's Hospital,,FEMALE,"CHILD, ADULT, OLDER_ADULT",,500,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-04-07,2022-07-07,2022-12-07,"Brigham and Women's Hospital, Boston, Massachusetts, 02115, United States"
NCT02373098,Fingolimod Effect on Cytokine and Chemokine Levels,https://beta.clinicaltrials.gov/study/NCT02373098,COMPLETED,Relapsing Remitting Multiple Sclerosis,DRUG: Fingolimod 0.5 mg,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE4,126,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-03-31,2017-01-18,2017-01-18,"Novartis Investigative Site, Mecidiyekoy, Istanbul, 34394, Turkey|Novartis Investigative Site, Uskudar, Istanbul, 34668, Turkey|Novartis Investigative Site, Istanbul, 34093, Turkey"
NCT02442557,Safety and Dose-finding Study of DC-TAB in Healthy Subjects,https://beta.clinicaltrials.gov/study/NCT02442557,COMPLETED,Multiple Sclerosis,BIOLOGICAL: recombinant human alpha B-crystallin|OTHER: placebo comparator,Delta Crystallon BV,,ALL,ADULT,PHASE1,76,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-12,2010-10,2011-07,"Kendle International, Utrecht, 3584CJ, Netherlands"
NCT03521557,Gaze and Postural Stability in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03521557,COMPLETED,Multiple Sclerosis|Vertigo|Dizziness|Falls Injury,BEHAVIORAL: Gaze and Postural Stability|BEHAVIORAL: Standard Care Control,University of Utah,National Multiple Sclerosis Society|Arizona State University|Johns Hopkins University,ALL,"ADULT, OLDER_ADULT",NA,42,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2018-05-29,2020-06-30,2020-09-30,"University of Utah, Salt Lake City, Utah, 84108, United States"
NCT02118298,Allocentric Memory in MS and Resting State Functional MRI,https://beta.clinicaltrials.gov/study/NCT02118298,COMPLETED,Multiple Sclerosis,,Yale University,,ALL,ADULT,,120,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-04,2016-04,2016-04,"Yale University, New Haven, Connecticut, 06520, United States"
NCT00223457,Factors That Influence Compliance With Disease-Modifying Therapy in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00223457,COMPLETED,Multiple Sclerosis,BEHAVIORAL: Factors that influence compliance,University of Texas Southwestern Medical Center,Biogen,ALL,"ADULT, OLDER_ADULT",,1040,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2004-04,,2005-09,"UT Southwestern Medical Center, Dallas, Texas, 75390, United States"
NCT01585298,STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START),https://beta.clinicaltrials.gov/study/NCT01585298,COMPLETED,Multiple Sclerosis,DRUG: FTY720,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE4,6998,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2012-04-29,2016-12-12,2016-12-12,"Novartis Investigative Site, Ostfildern, Baden-Wuerttemberg, 73760, Germany|Novartis Investigative Site, Munich, Bavaria, 81241, Germany|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, 50937, Germany|Novartis Investigative Site, Flensburg, Schleswig Holstein, 24939, Germany|Novartis Investigative Site, Aachen, 52062, Germany|Novartis Investigative Site, Aachen, 52074, Germany|Novartis Investigative Site, Aalen-Wasseralfingen, 73433, Germany|Novartis Investigative Site, Aalen, 73430, Germany|Novartis Investigative Site, Abensberg, 93326, Germany|Novartis Investigative Site, Achim, 28832, Germany|Novartis Investigative Site, Aichach, 86551, Germany|Novartis Investigative Site, Altenburg, 04600, Germany|Novartis Investigative Site, Altenholz-Stift, 24161, Germany|Novartis Investigative Site, Alzenau, 63755, Germany|Novartis Investigative Site, Andernach, 56626, Germany|Novartis Investigative Site, Asbach, 53567, Germany|Novartis Investigative Site, Aschaffenburg, 63739, Germany|Novartis Investigative Site, Augsburg, 86179, Germany|Novartis Investigative Site, Bad Berka, 99437, Germany|Novartis Investigative Site, Bad Hersfeld, 36251, Germany|Novartis Investigative Site, Bad Homburg, 61348, Germany|Novartis Investigative Site, Bad Honnef, 53604, Germany|Novartis Investigative Site, Bad Krozingen, 79189, Germany|Novartis Investigative Site, Bad Mergentheim, 97980, Germany|Novartis Investigative Site, Bad Saarow, 15526, Germany|Novartis Investigative Site, Bad Wildbad, 75323, Germany|Novartis Investigative Site, Bamberg, 96052, Germany|Novartis Investigative Site, Bayreuth, 95445, Germany|Novartis Investigative Site, Bergisch Gladbach, 51429, Germany|Novartis Investigative Site, Berg, 82335, Germany|Novartis Investigative Site, Berlin, 10178, Germany|Novartis Investigative Site, Berlin, 10365, Germany|Novartis Investigative Site, Berlin, 10437, Germany|Novartis Investigative Site, Berlin, 10713, Germany|Novartis Investigative Site, Berlin, 120999, Germany|Novartis Investigative Site, Berlin, 12101, Germany|Novartis Investigative Site, Berlin, 12163, Germany|Novartis Investigative Site, Berlin, 12351, Germany|Novartis Investigative Site, Berlin, 12587, Germany|Novartis Investigative Site, Berlin, 12621, Germany|Novartis Investigative Site, Berlin, 13347, Germany|Novartis Investigative Site, Berlin, 13353, Germany|Novartis Investigative Site, Berlin, 13465, Germany|Novartis Investigative Site, Berlin, 13507, Germany|Novartis Investigative Site, Berlin, 14059, Germany|Novartis Investigative Site, Berlin, 14163, Germany|Novartis Investigative Site, Berlin, 14169, Germany|Novartis Investigative Site, Bielefeld, 33602, Germany|Novartis Investigative Site, Bielefeld, 33647, Germany|Novartis Investigative Site, Boblingen, 71032, Germany|Novartis Investigative Site, Bochum, 44787, Germany|Novartis Investigative Site, Bochum, 44789, Germany|Novartis Investigative Site, Bochum, 44791, Germany|Novartis Investigative Site, Bochum, 44795, Germany|Novartis Investigative Site, Bochum, 44869, Germany|Novartis Investigative Site, Bogen, 94327, Germany|Novartis Investigative Site, Bonn, 53111, Germany|Novartis Investigative Site, Borna, 04552, Germany|Novartis Investigative Site, Bottrop, 46236, Germany|Novartis Investigative Site, Braunschweig, 38100, Germany|Novartis Investigative Site, Braunschweig, 38114, Germany|Novartis Investigative Site, Bremen, 28755, Germany|Novartis Investigative Site, Bruchsal, 76646, Germany|Novartis Investigative Site, Buchholz in der Nordheide, 21244, Germany|Novartis Investigative Site, Buchholz, 21244, Germany|Novartis Investigative Site, Butzbach, 35510, Germany|Novartis Investigative Site, Celle, 29223, Germany|Novartis Investigative Site, Chemnitz, 09117, Germany|Novartis Investigative Site, Delbrueck, 33129, Germany|Novartis Investigative Site, Dessau, 06846, Germany|Novartis Investigative Site, Dillingen, 66763, Germany|Novartis Investigative Site, Dillingen, 89407, Germany|Novartis Investigative Site, Dortmund, 44135, Germany|Novartis Investigative Site, Dortmund, 44137, Germany|Novartis Investigative Site, Dresden, 01067, Germany|Novartis Investigative Site, Dresden, 01307, Germany|Novartis Investigative Site, Duesseldorf, 40225, Germany|Novartis Investigative Site, Duesseldorf, 40479, Germany|Novartis Investigative Site, Düren, 52351, Germany|Novartis Investigative Site, Düsseldorf, 40211, Germany|Novartis Investigative Site, Düsseldorf, 40625, Germany|Novartis Investigative Site, Eberswalde, 16225, Germany|Novartis Investigative Site, Eisenach, 99817, Germany|Novartis Investigative Site, Eltville, 65343, Germany|Novartis Investigative Site, Emden, 26721, Germany|Novartis Investigative Site, Emmendingen, 79312, Germany|Novartis Investigative Site, Erbach, 64711, Germany|Novartis Investigative Site, Erfurt, 99089, Germany|Novartis Investigative Site, Erfurt, 99096, Germany|Novartis Investigative Site, Erlangen, 91054, Germany|Novartis Investigative Site, Eschwege, 37269, Germany|Novartis Investigative Site, Essen, 45131, Germany|Novartis Investigative Site, Essen, 45138, Germany|Novartis Investigative Site, Essen, 45147, Germany|Novartis Investigative Site, Essen, 45257, Germany|Novartis Investigative Site, Frankfurt am Main, 60313, Germany|Novartis Investigative Site, Frankfurt am Main, 60594, Germany|Novartis Investigative Site, Frankfurt, 60313, Germany|Novartis Investigative Site, Frankfurt, 60590, Germany|Novartis Investigative Site, Freiburg, 79098, Germany|Novartis Investigative Site, Freiburg, 79106, Germany|Novartis Investigative Site, Friedrichshafen, 88048, Germany|Novartis Investigative Site, Fulda, 36037, Germany|Novartis Investigative Site, Fulda, 36043, Germany|Novartis Investigative Site, Geldern, 47608, Germany|Novartis Investigative Site, Gelnhausen, 63571, Germany|Novartis Investigative Site, Gelsenkirchen, 45879, Germany|Novartis Investigative Site, Gilching, 82205, Germany|Novartis Investigative Site, Gladenbach, 35075, Germany|Novartis Investigative Site, Gottingen, 37075, Germany|Novartis Investigative Site, Greifswald, 17475, Germany|Novartis Investigative Site, Grevenbroich, 41515, Germany|Novartis Investigative Site, Griesheim, 64347, Germany|Novartis Investigative Site, Guetersloh, 33332, Germany|Novartis Investigative Site, Gummersbach, 51643, Germany|Novartis Investigative Site, Göttingen, 37073, Germany|Novartis Investigative Site, Haar, 85540, Germany|Novartis Investigative Site, Hagen, 58095, Germany|Novartis Investigative Site, Halle (Saale), 06120, Germany|Novartis Investigative Site, Halle S, 06120, Germany|Novartis Investigative Site, Hamburg, 20099, Germany|Novartis Investigative Site, Hamburg, 20249, Germany|Novartis Investigative Site, Hamburg, 20354, Germany|Novartis Investigative Site, Hamburg, 22083, Germany|Novartis Investigative Site, Hamburg, 22179, Germany|Novartis Investigative Site, Hamburg, 22297, Germany|Novartis Investigative Site, Hamburg, 22523, Germany|Novartis Investigative Site, Hannover, 30161, Germany|Novartis Investigative Site, Hannover, 30171, Germany|Novartis Investigative Site, Hannover, 30625, Germany|Novartis Investigative Site, Heidelberg, 69120, Germany|Novartis Investigative Site, Heidenheim, 89518, Germany|Novartis Investigative Site, Herdecke, 58313, Germany|Novartis Investigative Site, Herford, 32049, Germany|Novartis Investigative Site, Herford, 32052, Germany|Novartis Investigative Site, Hildesheim, 31134, Germany|Novartis Investigative Site, Homburg, 66421, Germany|Novartis Investigative Site, Hoppegarten, 15366, Germany|Novartis Investigative Site, Ibbenbueren, 49477, Germany|Novartis Investigative Site, Idar-Oberstein, 55743, Germany|Novartis Investigative Site, Isselburg-Anholt, 46419, Germany|Novartis Investigative Site, Itzehoe, 25524, Germany|Novartis Investigative Site, Jena, 07740, Germany|Novartis Investigative Site, Jena, 07743, Germany|Novartis Investigative Site, Juelich, 52428, Germany|Novartis Investigative Site, Kaiserslautern, 67655, Germany|Novartis Investigative Site, Kaltenkirchen, 24568, Germany|Novartis Investigative Site, Kandel, 76870, Germany|Novartis Investigative Site, Karlstadt, 97753, Germany|Novartis Investigative Site, Kassel, 34121, Germany|Novartis Investigative Site, Kiel, 24105, Germany|Novartis Investigative Site, Klingenmünster, 76889, Germany|Novartis Investigative Site, Koeln-Longerich, 50737, Germany|Novartis Investigative Site, Koeln, 51109, Germany|Novartis Investigative Site, Koln, 50935, Germany|Novartis Investigative Site, Korbach, 34497, Germany|Novartis Investigative Site, Krefeld, 47800, Germany|Novartis Investigative Site, Krefeld, 47805, Germany|Novartis Investigative Site, Köln, 50674, Germany|Novartis Investigative Site, Königsbrück, 01936, Germany|Novartis Investigative Site, Landshut, 84028, Germany|Novartis Investigative Site, Lappersdorf, 93138, Germany|Novartis Investigative Site, Leipzig, 04103, Germany|Novartis Investigative Site, Leipzig, 04157, Germany|Novartis Investigative Site, Leipzig, 04275, Germany|Novartis Investigative Site, Leipzig, 04299, Germany|Novartis Investigative Site, Leverkusen, 51375, Germany|Novartis Investigative Site, Lohr am Main, 79816, Germany|Novartis Investigative Site, Lubeck, 23538, Germany|Novartis Investigative Site, Ludwigshafen, 67059, Germany|Novartis Investigative Site, Ludwigshafen, 67063, Germany|Novartis Investigative Site, Luenen, 44534, Germany|Novartis Investigative Site, Luneburg, 21335, Germany|Novartis Investigative Site, Lutherstadt Eisleben, 06295, Germany|Novartis Investigative Site, Magdeburg, 39104, Germany|Novartis Investigative Site, Magdeburg, 39120, Germany|Novartis Investigative Site, Mannheim, 66163, Germany|Novartis Investigative Site, Mannheim, 68159, Germany|Novartis Investigative Site, Mannheim, 68161, Germany|Novartis Investigative Site, Marburg, 35039, Germany|Novartis Investigative Site, Meisenheim, 55590, Germany|Novartis Investigative Site, Minden, 32423, Germany|Novartis Investigative Site, Minden, 32429, Germany|Novartis Investigative Site, Mittweida, 09648, Germany|Novartis Investigative Site, Mosbach, 74821, Germany|Novartis Investigative Site, Muenchen, 80331, Germany|Novartis Investigative Site, Muenchen, 81675, Germany|Novartis Investigative Site, Muenster, 48149, Germany|Novartis Investigative Site, Mönchengladbach, 41063, Germany|Novartis Investigative Site, Mönchengladbach, 41239, Germany|Novartis Investigative Site, Mülheim, 45481, Germany|Novartis Investigative Site, München, 81829, Germany|Novartis Investigative Site, Münster, 48147, Germany|Novartis Investigative Site, Nagold, 72202, Germany|Novartis Investigative Site, Naumburg, 06618, Germany|Novartis Investigative Site, Neu-Ulm, 89231, Germany|Novartis Investigative Site, Neuburg an der Donau, 86633, Germany|Novartis Investigative Site, Neuruppin, 16816, Germany|Novartis Investigative Site, Neusaess, 86356, Germany|Novartis Investigative Site, Neustadt An Der Weinstraße, 67433, Germany|Novartis Investigative Site, Nordhausen, 99734, Germany|Novartis Investigative Site, Nürnberg, 90461, Germany|Novartis Investigative Site, Offenbach, 63069, Germany|Novartis Investigative Site, Oldenburg I. Holstein, 23758, Germany|Novartis Investigative Site, Oldenburg, 26122, Germany|Novartis Investigative Site, Osnabrueck, 49076, Germany|Novartis Investigative Site, Osnabrück, 49074, Germany|Novartis Investigative Site, Osnabrück, 49076, Germany|Novartis Investigative Site, Osnabrück, 49078, Germany|Novartis Investigative Site, Paderborn, 33098, Germany|Novartis Investigative Site, Papenburg, 26871, Germany|Novartis Investigative Site, Pforzheim, 75172, Germany|Novartis Investigative Site, Potsdam, 14471, Germany|Novartis Investigative Site, Prien, 83209, Germany|Novartis Investigative Site, Quakenbrueck, 49610, Germany|Novartis Investigative Site, Querfurt, 06268, Germany|Novartis Investigative Site, Ravensburg, 88212, Germany|Novartis Investigative Site, Recklinghausen, 45657, Germany|Novartis Investigative Site, Regensburg, 93059, Germany|Novartis Investigative Site, Remscheid, 42853, Germany|Novartis Investigative Site, Rostock, 18057, Germany|Novartis Investigative Site, Rüdersdorf, 15562, Germany|Novartis Investigative Site, Saarbruecken, 66113, Germany|Novartis Investigative Site, Saint Ingbert, 66386, Germany|Novartis Investigative Site, Sande, 26452, Germany|Novartis Investigative Site, Schwalmstadt-Treysa, 34613, Germany|Novartis Investigative Site, Schwerin, 19057, Germany|Novartis Investigative Site, Siegen, 57076, Germany|Novartis Investigative Site, Singen, 78224, Germany|Novartis Investigative Site, Sinsheim, 74889, Germany|Novartis Investigative Site, Solingen, 42719, Germany|Novartis Investigative Site, Stade, 21682, Germany|Novartis Investigative Site, Stadtroda, 07646, Germany|Novartis Investigative Site, Stralsund, 18439, Germany|Novartis Investigative Site, Stuttgart, 70174, Germany|Novartis Investigative Site, Stuttgart, 70176, Germany|Novartis Investigative Site, Stuttgart, 70178, Germany|Novartis Investigative Site, Stuttgart, 70182, Germany|Novartis Investigative Site, Telgte, 48291, Germany|Novartis Investigative Site, Teupitz, 15755, Germany|Novartis Investigative Site, Troisdorf, 53844, Germany|Novartis Investigative Site, Tübingen, 72076, Germany|Novartis Investigative Site, Ulm, 89073, Germany|Novartis Investigative Site, Ulm, 89081, Germany|Novartis Investigative Site, Unterhaching, 82008, Germany|Novartis Investigative Site, Wasserburg, 83512, Germany|Novartis Investigative Site, Wendlingen, 73240, Germany|Novartis Investigative Site, Wermsdorf, 04779, Germany|Novartis Investigative Site, Westerstede/Oldenburg, 26655, Germany|Novartis Investigative Site, Westerstede, 26655, Germany|Novartis Investigative Site, Wiesbaden, 65183, Germany|Novartis Investigative Site, Wiesbaden, 65191, Germany|Novartis Investigative Site, Wolfratshausen, 82515, Germany|Novartis Investigative Site, Wuppertal, 42103, Germany|Novartis Investigative Site, Wuppertal, 42283, Germany|Novartis Investigative Site, Würzburg, 97070, Germany|Novartis Investigative Site, Würzburg, 97080, Germany|Novartis Investigative Site, Zwickau, 08060, Germany|Novartis Investigative Site, Öhringen, 74613, Germany"
NCT01975298,A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS),https://beta.clinicaltrials.gov/study/NCT01975298,WITHDRAWN,Relapsing Remitting Multiple Sclerosis,DRUG: Laquinimod|DRUG: Avonex®,"Teva Branded Pharmaceutical Products R&D, Inc.",,ALL,ADULT,PHASE3,0,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2014-01,2014-03,2014-03,
NCT04057898,Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS,https://beta.clinicaltrials.gov/study/NCT04057898,RECRUITING,Amyotrophic Lateral Sclerosis,DRUG: MN-166|DRUG: placebo,MediciNova,,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,230,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-05-28,2023-12,2024-12,"University of California, Orange, California, 92868, United States|Mayo Clinic, Jacksonville, Florida, 32224, United States|Augusta University, Augusta, Georgia, 30912, United States|Indiana University IU Health Neuroscience Center, Indianapolis, Indiana, 46202, United States|University of Kansas Medical Center, Kansas City, Kansas, 66160, United States|Johns Hopkins University, Baltimore, Maryland, 21287, United States|Hennepin Healthcare Research Institute, Minneapolis, Minnesota, 55415, United States|Mayo Clinic / Rochester, Rochester, Minnesota, 55905, United States|Hospital for Special Surgery, New York, New York, 10021, United States|SUNY Upstate Medical University, Syracuse, New York, 13210, United States|Atrium Health Neurosciences Institute, Charlotte, North Carolina, 28207, United States|Duke University, Durham, North Carolina, 27705, United States|Providence Brain and Spine Institute, Portland, Oregon, 97213, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, 18103, United States|Allegheny Health Network, Allegheny Neurological Associates, Pittsburgh, Pennsylvania, 15212, United States|University of Virginia Health System, Charlottesville, Virginia, 22908, United States|Swedish Neuroscience Institute, Seattle, Washington, 98122, United States|University of Alberta Hospital, Edmonton, Alberta, T6G 2G3, Canada|McMaster University Medical Center, Hamilton, Ontario, L8N 3Z5, Canada|Sunnybrook Research Institute, Toronto, Ontario, M4N 3M5, Canada|Montreal Neurological Institute and Hospital, Montreal, Quebec, H3A 2B4, Canada|Clinique Maladies Neuromusculaire, Sherbrooke, Quebec, J1H 5N4, Canada|University of Saskatchewan - Sastakoon Hospital, Saskatoon, Saskatchwean, S7K 0M7, Canada|Hopital de L'Enfant-Jesus, CHU de Quebec-Universite Laval, Quebec, G1J 1Z4, Canada"
NCT00873340,Physical Disability in Patients Treated With Betaferon,https://beta.clinicaltrials.gov/study/NCT00873340,COMPLETED,Multiple Sclerosis,"DRUG: Interferon-1beta (Betaseron, BAY86-5046)",Bayer,,ALL,"ADULT, OLDER_ADULT",,83,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2007-10,2011-01,2011-01,"Many Locations, Colombia"
NCT02260557,Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis,https://beta.clinicaltrials.gov/study/NCT02260557,COMPLETED,Raynaud's Phenomenon Secondary to Systemic Sclerosis,DRUG: Selexipag|DRUG: Placebo,Actelion,,ALL,"ADULT, OLDER_ADULT",PHASE2,74,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-10,2015-04,2015-06,"Investigator Site, Grenoble cedex, 38043, France|Investigator Site, Lille Cedex, 59037, France|Investigator Site, Nantes Cedex 1, 44093, France|Investigator Site, Paris, 75679, France|Investigator Site, Strasbourg, 67200, France|Investigator Site, Bad Nauheim, 61231, Germany|Investigator Site, Berlin, 10117, Germany|Investigator Site, Erlangen, 91054, Germany|Investigator Site, Koln, 50937, Germany|Investigator Site, Magdeburg, 39120, Germany|Investigator Site, Mainz, 55131, Germany|Investigator Site, Bath, BA11RL, United Kingdom|Investigator Site, Leeds, LS74SA, United Kingdom|Investigator Site, Liverpool, L97AL, United Kingdom|Investigator Site, London, NW32QG, United Kingdom|Investigator Site, Salford, M55AP, United Kingdom"
NCT03438357,Evaluation of an Automatic Segmentation Software (Pixyl.Neuro) to Track Lesions in Multiple Sclerosis Patients Via Cerebral MRI,https://beta.clinicaltrials.gov/study/NCT03438357,COMPLETED,Multiple Sclerosis|Clinically Isolated Syndrome,OTHER: Analysis of cerebral MRI with automatic segmentation software,Centre Hospitalier Universitaire de Nīmes,Roche Pharma AG,ALL,ADULT,,200,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-01-02,2022-07-06,2022-07-06,"CHU Nimes, Nîmes, 30029, France"
NCT05781113,A Novel Wearable Digital Biomarker for Detecting Changes in Multiple Sclerosis (MS) Condition,https://beta.clinicaltrials.gov/study/NCT05781113,NOT_YET_RECRUITING,Multiple Sclerosis,,Celestra Health Systems,University of Ottawa|The Ottawa Hospital,ALL,ADULT,,90,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-07-01,2024-03-01,2024-09-01,
NCT04843813,Effects of Lutein Supplementation on Cognition and MPOD in Multiple Sclerosis Patients-,https://beta.clinicaltrials.gov/study/NCT04843813,UNKNOWN,Multiple Sclerosis,DIETARY_SUPPLEMENT: Lutein|DIETARY_SUPPLEMENT: Placebo,University of Illinois at Urbana-Champaign,"Division of Nutritional Sciences, University of Illinois at Urbana-Champaign|National Institutes of Health Rehabilitation Research Resource to Enhance Clinical Trials (REACT)",ALL,ADULT,NA,60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2021-03-26,2023-03,2023-03,"University of Illinois at Urbana-Champaign, Urbana, Illinois, 61801, United States"
NCT04148313,A Pilot Study to Explore the Role of Gut Flora in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04148313,RECRUITING,Multiple Sclerosis|MS,OTHER: No Intervention,ProgenaBiome,,ALL,"CHILD, ADULT, OLDER_ADULT",,100,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-03-02,2023-03,2023-07,"ProgenaBiome, Ventura, California, 93003, United States"
NCT02580669,Study by Magnetic Resonance Imaging in the Progressive Forms of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT02580669,TERMINATED,"Progressive Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting",OTHER: Neuropsychological assessment|OTHER: Neurologic consultation|OTHER: MRIs (with vasoreactivity testing),"University Hospital, Montpellier","Genzyme, a Sanofi Company",ALL,ADULT,NA,70,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2014-06-16,2017-02-13,2017-02-13,"Hopital Gui de Chauliac -Service de Neurologie, Montpellier, 34295, France"
NCT04024969,DiagnosE Using the Central veIn SIgn,https://beta.clinicaltrials.gov/study/NCT04024969,UNKNOWN,Multiple Sclerosis,DIAGNOSTIC_TEST: T2* MRI|DIAGNOSTIC_TEST: Lumbar puncture to test for presence of unmatched oligoclonal bands,Nottingham University Hospitals NHS Trust,,ALL,"ADULT, OLDER_ADULT",,115,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-11-06,2022-05,2022-11,"Cardiff & Vale University Lhb, Cardiff, United Kingdom|Barts Health Nhs Trust, London, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Oxford University Hospitals Nhs Foundation Trust, Oxford, United Kingdom"
NCT04182269,Reliability and Validity of the Glittre Activities of Daily Living Test in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT04182269,COMPLETED,Multiple Sclerosis,OTHER: Measurement of functional exercise capacity,Hacettepe University,,ALL,"ADULT, OLDER_ADULT",,51,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-10-01,2019-10-15,2020-08-04,"Hacettepe University, Ankara, Turkey"
NCT03585569,""" Treating MS Patients With Lower Extremity Spasticity Using Dysport""",https://beta.clinicaltrials.gov/study/NCT03585569,UNKNOWN,"Multiple Sclerosis|Spasticity, Muscle",BIOLOGICAL: Abobotulinumtoxin A,Neurology Center of New England P.C.,Ipsen,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,30,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-05-01,2019-05,2020-05,"Neurology Center of New England P.C., Foxboro, Massachusetts, 02035, United States"
NCT03049969,Cognitive Remediation Augmented With Transcranial Direct Current Stimulation (tDCS),https://beta.clinicaltrials.gov/study/NCT03049969,COMPLETED,Multiple Sclerosis|Neurological Disorder,DEVICE: tDCS stimulation,NYU Langone Health,,ALL,"ADULT, OLDER_ADULT",NA,15,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2017-02-07,2023-03-26,2023-03-26,"New York University Medical Center, New York, New York, 10016, United States"
NCT04772495,miRNA Biomarkers in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04772495,COMPLETED,Multiple Sclerosis|miRNA|Epigenetic|Biomarker,GENETIC: miRNA,University of Gaziantep,,ALL,"ADULT, OLDER_ADULT",,69,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-05,2017-05,2017-07,
NCT00079495,Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients With Relapsing Multiple Sclerosis (MS),https://beta.clinicaltrials.gov/study/NCT00079495,COMPLETED,Multiple Sclerosis,DRUG: NBI-5788,Neurocrine Biosciences,Immune Tolerance Network (ITN),ALL,ADULT,PHASE2,150,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,2003-07,,2005-04,
NCT00811395,Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00811395,COMPLETED,Multiple Sclerosis,DRUG: Teriflunomide|DRUG: Placebo (for teriflunomide)|DRUG: Interferon-β [IFN-β]|DRUG: Glatiramer Acetate [GA],Sanofi,,ALL,ADULT,PHASE2,182,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2007-10,2010-04,2010-04,"Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, 08807, United States|Sanofi-Aventis Administrative Office, Wien, Austria|Sanofi-Aventis Administrative Office, Laval, Canada|Sanofi-Aventis Administrative Office, Berlin, Germany|Sanofi-Aventis Administrative Office, Milano, Italy|Sanofi-Aventis Administrative Office, Barcelona, Spain|Sanofi-Aventis Administrative Office, Guildford, United Kingdom"
NCT01539395,A Cross-Sectional Study of MSDx Complex 1 as a Marker for Active Disease in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01539395,WITHDRAWN,Multiple Sclerosis,OTHER: MSDx Complex-1 Biomarker Test,"MSDx, Inc.",,ALL,"ADULT, OLDER_ADULT",,0,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-01,2012-04,2012-07,"Northwest NeuroSpecialists, PLLC, Tucson, Arizona, 85741, United States"
NCT01073813,Neuroprotection and Repair in Optic Neuritis,https://beta.clinicaltrials.gov/study/NCT01073813,TERMINATED,Multiple Sclerosis|Optic Neuritis,DRUG: Minocycline,University of Calgary,Neuroscience Canada,ALL,ADULT,PHASE2,6,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2010-02,2011-12,2013-01,
NCT00764413,Chronotherapy in Acute Multiple Sclerosis (MS) Attack,https://beta.clinicaltrials.gov/study/NCT00764413,TERMINATED,Multiple Sclerosis,DRUG: methylprednisolone|DRUG: Sodium chlorid,Sykehuset Innlandet HF,,ALL,"ADULT, OLDER_ADULT",NA,57,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-04,2012-07,2012-07,"Innlandet Hosptal Trust-Lillehammer, Neurological Department, Lillehammer, Oppland, 2609, Norway"
NCT02104011,Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers,https://beta.clinicaltrials.gov/study/NCT02104011,COMPLETED,Renal Angiomyolipomas|Tuberous Sclerosis,DRUG: Propranolol,"University Hospital, Bordeaux",,ALL,"ADULT, OLDER_ADULT",PHASE2,2,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-05-22,2017-11-22,2017-11-22,"Nephrology department, Bordeaux, France"
NCT05209113,Development and Evaluation of the Self-management Module in Patients With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05209113,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,OTHER: Education,Hacettepe University,,ALL,"ADULT, OLDER_ADULT",NA,200,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2020-09-15,2021-12-15,2022-09-15,"Hacettepe University, Ankara, Sihhiye, 06100, Turkey"
NCT05141669,Impact of Fingolimod Adherence on Outcomes,https://beta.clinicaltrials.gov/study/NCT05141669,COMPLETED,Multiple Sclerosis,DRUG: Fingolimod,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",,694,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-05-18,2020-11-20,2020-11-20,"Novartis Investigational Site, East Hanover, New Jersey, 07936-1080, United States"
NCT01790269,Monitoring Natural Killer Cells in Multiple Sclerosis Patients Treated With Fingolimod,https://beta.clinicaltrials.gov/study/NCT01790269,TERMINATED,Relapsing-Remitting Multiple Sclerosis,,"Charite University, Berlin, Germany",Dr. Carmen Infante-Duarte,ALL,ADULT,,21,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-09,2018-08,2018-08,"Charité Universitätsmedizin Berlin, Berlin, 10117, Germany"
NCT04776213,Cognition and HRQoL in Adults With Highly-active RMS in Year 3 and 4 After Initial Mavenclad® Dose (CLARIFY MS Extension),https://beta.clinicaltrials.gov/study/NCT04776213,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,DRUG: Mavenclad®,"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany",,ALL,"ADULT, OLDER_ADULT",PHASE4,280,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2021-02-23,2023-09-11,2023-09-11,"Eva Maida, Vienna, Austria|FN u sv. Anny Brno, Brno, Czechia|FN Hradec Králové, Hradec Kralove, Czechia|Nemocnice Jihlava, p.o., Jihlava, Czechia|Fakultni nemocnice Olomouc, Olomouc, Czechia|Fakultni nemocnice Ostrava, Ostrava, Czechia|Faculty Hospital Kralovske Vinohrady, Praha 10, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia|Nemocnice Teplice, Teplice, Czechia|Glostrup Sygehus, Glostrup, Denmark|Odense Univeristy Hospital, Odense, Denmark|Centre hospitalier de la Côte Basque - Saint Léon, Bayonne, France|Pellegrin, Bordeaux, France|CHU de la Côte de Nacre, Caen, France|Centre Hospitalier de Gonesse, Gonesse, France|CHRU de Lille Hôpital Roger Salengro, Lille, France|CHU Hôpital Nord Laennec, Nantes Cedex 01, France|Hôpital de la Pitié-Salpétrière, Paris Cédex 13, France|CHU de Poissy, Poissy Cedex, France|Centre Universitaire de Rouen, Rouen Cedex, France|CHU Tours - Hôpital Bretonneau, Tours Cedex, France|Jahn Ferenc Dél-Pesti Kórház és Rendelőintézet, Budapest, Hungary|Semmelweis University II, Budapest, Hungary|Uzsoki Utcai Korhaz, Budapest, Hungary|Debreceni Egyetem Orvos- és Egészségtudományi Centrum, Debrecen, Hungary|Valeomed Kft, Esztergom, Hungary|Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókór, Nyíregyháza, Hungary|A.O.U. Ospedali Riuniti Umberto, Ancona, Italy|University of Cagliari, Cagliari, Italy|PO G.Rodolico, AOU Policlinico-Vittorio Emanuele Catania, Catania, Italy|Ospedale San Raffaele Giglio, Cefalù, Italy|Instituto Nazionale Neurologico ""Carlo Besta"", Milano, Italy|Ospedale San Raffaele, IRCCS, Milano, Italy|A.O. Universitaria Federico II, Napoli, Italy|Policlinico Università della Campania L. Vanvitelli, Napoli, Italy|A.O. Ospedali Riuniti Villa Sofia-Cervello U.O. Endocrinolog, Palermo, Italy|Azienda Ospedaliera S. Camillo Forlanini, Roma, Italy|Neurological Center of Latium, Roma, Italy|Ospedale Sant'Andrea Neurologia - Università La Sapienza, Roma, Italy|Policlinico Tor Vergata, Roma, Italy|Zuyderland, Sittard-Geleen, Netherlands|COPERNICUS Podmiot Leczn. Sp z o.o., Gdansk, Poland|M.A.-Lek A.M. Maciejowscy S.C. Centrum Terapii SM, Katowice, Poland|Centrum Neurologii Krzysztof Selmaj, Lodz, Poland|Uniwersytecki Szpital Kliniczny nr 1 i.m. Norberta Barlickie, Lodz, Poland|Indywidualna Praktyka Lekarska Prof. Konrad Rejdak, Lublin, Poland|Centrum Medyczne Medyk, Rzeszow, Poland|Instytut Psychiatrii i Neurologii - Dept of Neurology II, Warszawa, Poland|Neuropoint s.r.o, Bratislava, Slovakia|Univerzitna nemocnica Martin, Martin, Slovakia|Fakultna nemocnica Nitra, Nitra, Slovakia|Fakultna nemocnica Trnava, Trnava, Slovakia|Hospital Universitario de Getafe, Getafe, Spain|C.A.U. de León - H. de León, León, Spain|Hospital Arnau de Vilanova, Lleida, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Virgen de la Arrixaca, Murcia, Spain|Hospital de Sant Joan Despí Moisès Broggi, Sant Joan Despí, Spain|Hospital Universitario Nuestra Senora de la Candelaria, Santa Cruz de Tenerife, Spain|Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain"
NCT03403413,Muscle Vibration in MS to Improve Walking,https://beta.clinicaltrials.gov/study/NCT03403413,TERMINATED,Multiple Sclerosis,DEVICE: muscle vibration during walking,VA Office of Research and Development,,ALL,"ADULT, OLDER_ADULT",NA,5,FED,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DEVICE_FEASIBILITY,2017-01-01,2018-12-31,2018-12-31,"Louis Stokes VA Medical Center, Cleveland, OH, Cleveland, Ohio, 44106, United States"
NCT03862313,Repetitive Transorbital Alternating Current Stimulation in Acute Autoimmune Optic Neuritis,https://beta.clinicaltrials.gov/study/NCT03862313,TERMINATED,Acute Autoimmune Inflammatory Optic Neuritis,DEVICE: active-rtACS treatment|DEVICE: sham-rtACS treatment,University of Zurich,"University Hospital, Zürich|Swiss MS Society|Data Management, Clinical Trials Center, Zurich, Switzerland",ALL,ADULT,NA,2,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2019-10-14,2019-12-27,2019-12-27,"Department of Neurology and Department of Ophthalmology, University Hospital Zurich, Zurich, 8091, Switzerland"
NCT05432713,A Study of LP-168 in Healthy Volunteers,https://beta.clinicaltrials.gov/study/NCT05432713,COMPLETED,Multiple Sclerosis|NMO Spectrum Disorder,DRUG: LP-168 tablet|DRUG: LP-168 Placebo tablet,Guangzhou Lupeng Pharmaceutical Company LTD.,,ALL,ADULT,PHASE1,70,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-05-14,2022-11-20,2022-12-28,"The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310009, China"
NCT04530669,The Effect of High Tone Power Therapy on Fatigue and Functional Outcomes in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT04530669,COMPLETED,Multiple Sclerosis,DEVICE: High Tone Power Therapy|OTHER: exercise program,Lama Saad El-Din Mahmoud,,ALL,ADULT,NA,40,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-01,2020-10-15,2020-12-30,"Kasr Al-Ainy MS clinic, Neurology department, Cairo University hospitals., Al Jīzah, Select State, Egypt"
NCT01076595,"Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years Period",https://beta.clinicaltrials.gov/study/NCT01076595,COMPLETED,Multiple Sclerosis,"DRUG: Interferon beta-1b (Betaseron, BAY86-5046)",Bayer,,ALL,"ADULT, OLDER_ADULT",,73,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-05,2013-11,2014-07,"Many Locations, France"
NCT00548769,Firategrast (SB683699) Surface Area Study in Multiple Sclerosis Patients,https://beta.clinicaltrials.gov/study/NCT00548769,COMPLETED,Multiple Sclerosis,DRUG: Formulation A|DRUG: Formulation B|DRUG: Formulation C|DRUG: Formulation D,GlaxoSmithKline,,ALL,"ADULT, OLDER_ADULT",PHASE1,37,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2007-04-21,2007-11-26,2007-11-26,"GSK Investigational Site, Praha 5, 150 18, Czechia|GSK Investigational Site, Berlin, 10117, Germany|GSK Investigational Site, Grodzisk Mazowiecki, 05-825, Poland|GSK Investigational Site, Poznan, 60-479, Poland"
NCT05119569,A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS),https://beta.clinicaltrials.gov/study/NCT05119569,ACTIVE_NOT_RECRUITING,Relapsing Multiple Sclerosis,DRUG: Fenebrutinib|DRUG: Placebo,Hoffmann-La Roche,,ALL,ADULT,PHASE2,109,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-03-01,2023-03-29,2026-12-02,"Fullerton Neurology and Headache Center, Fullerton, California, 92835, United States|Cleveland Clinic Lou Ruvo; Center for Brain Research, Las Vegas, Nevada, 89106, United States|University Clinical Centre of the Republic of Srpska, Banja Luka, 78000, Bosnia and Herzegovina|Clinical Hospital Center Rijeka - PPDS, Rijeka, 51000, Croatia|General Hospital Varazdin, Varazdin, 42000, Croatia|Klinicki bolnicki centar Zagreb, Zagreb, 10000, Croatia|Poliklinika Solmed, Zagreb, 10000, Croatia|Fakultni nemocnice u sv. Anny v Brne, Brno, 656 91, Czechia|Fakultni nemocnice Hradec Kralove, Hradec Kralove, 500 05, Czechia|Nemocnice Jihlava, Jihlava, 586 33, Czechia|Univerzita Karlova v Praze a Vseobecna fakultni nemocnice v Praze - 1; Lekarska Fakulta - I, Prague 2, 128 08, Czechia|Clinical Center of Serbia, Belgrade, 11000, Serbia|Military Medical Academy, Belgrade, 11040, Serbia|Clinical center Kragujevac, Kragujevac, 34000, Serbia|Clinical Center Nis, NIS, 18000, Serbia|Clinical Hospital Centre Zemun, Zemun, 11080, Serbia|Univerzitna nemocnica Bratislava, Bratislava, 813 69, Slovakia"
NCT03250169,Neurofilaments for NEDA Assessing in MS,https://beta.clinicaltrials.gov/study/NCT03250169,TERMINATED,Multiple Sclerosis,DRUG: Alemtuzumab,Queen Mary University of London,,ALL,ADULT,,21,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-08-01,2022-01-28,2022-01-28,"Queen Mary University of London, London, England, E1 2AT, United Kingdom"
NCT03356769,Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex,https://beta.clinicaltrials.gov/study/NCT03356769,UNKNOWN,Tuberous Sclerosis Complex|Aspirin|Epilepsy|Cognitive Decline|Skin Lesions,DRUG: Aspirin|DRUG: AED|DRUG: Placebo,Peking Union Medical College Hospital,Shijiazhuang Yiling Pharmaceutical Co. Ltd,ALL,"CHILD, ADULT",PHASE2,98,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-11-20,2021-11-20,2021-11-20,"Department of Neurology, Peking Union Medical College Hospital, Beijing, Beijing, 100005, China"
NCT05451069,"Neurofilament Light Chain ,Chitinase-3 Like-1 Proteins and Plasmacytoid Dendritic Cells in Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT05451069,NOT_YET_RECRUITING,Multiple Sclerosis,"DIAGNOSTIC_TEST: Neurofilament Light Chain ,Chitinase-3 Like-1 Protein Levels and Tolerogenic plasmacytoid Dendritic Cells",Assiut University,,ALL,ADULT,,42,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-10-01,2024-07-25,2025-07-27,
NCT02323269,Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve),https://beta.clinicaltrials.gov/study/NCT02323269,TERMINATED,"Multiple Sclerosis, Relapsing-Remitting|Relapsing-Remitting Multiple Sclerosis",DRUG: dimethyl fumarate,Biogen,,ALL,"ADULT, OLDER_ADULT",,24,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-05,2016-03,2016-03,"Research Site, Edmonton, Alberta, T6G 2G3, Canada|Research Site, Burnaby, British Columbia, V5G 2X6, Canada|Research Site, St. John, New Brunswick, E2L 4L2, Canada|Research Site, St. John's, Newfoundland and Labrador, A1B 3V6, Canada|Research Site, Halifax, Nova Scotia, B3H 4K4, Canada|Research Site, Sydney, Nova Scotia, B1P 1P3, Canada|Research Site, Cambridge, Ontario, N1R 7L6, Canada|Research Site, London, Ontario, N6A 5A5, Canada|Research Site, Gatineau, Quebec, J9J 0A5, Canada|Research Site, Montreal, Quebec, H3A 2B4, Canada"
NCT01621269,ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon,https://beta.clinicaltrials.gov/study/NCT01621269,WITHDRAWN,Multiple Sclerosis,DRUG: Fingolimod,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE4,0,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-06,2014-06,2014-06,
NCT05417269,IMCY-0141 Safety and Efficacy in Multiple Sclerosis - ISEMIS Study,https://beta.clinicaltrials.gov/study/NCT05417269,RECRUITING,"Multiple Sclerosis, Relapsing-Remitting",DRUG: IMCY-0141|DRUG: Placebo|DRUG: Dimethyl Fumarate,Imcyse SA,,ALL,ADULT,PHASE1|PHASE2,150,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-04-12,2025-05-23,2025-12-31,"Republican Clinical Hospital, ARENSIA Exploratory Medicine, Chisinau, MD-2025, Moldova, Republic of"
NCT03025269,Ocrelizumab Effects on Physiological and Cognitive Changes in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03025269,COMPLETED,Multiple Sclerosis,DRUG: Ocrelizumab,University at Buffalo,,ALL,ADULT,,30,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-11-15,2022-01-08,2022-01-08,"Jacobs Institute, Buffalo, New York, 14203, United States"
NCT01487096,Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses,https://beta.clinicaltrials.gov/study/NCT01487096,COMPLETED,Multiple Sclerosis,DRUG: Teriflunomide|DRUG: Placebo (placebo for teriflunomide),Sanofi,,ALL,"ADULT, OLDER_ADULT",PHASE2,179,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2001-04,2003-03,2003-03,"Canada, Toronto, Ontario, Canada|sanofi-aventis France, Lyon, France"
NCT03949296,Mindfulness Meditation in Treating Insomnia in Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT03949296,COMPLETED,Insomnia Chronic|Multiple Sclerosis,BEHAVIORAL: Mindfulness Intervention|BEHAVIORAL: Sleep Hygiene,Griffin Hospital,Yale-Griffin Prevention Research Center|Yale University- Stress Center,ALL,"ADULT, OLDER_ADULT",NA,49,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2017-12-11,2019-12-16,2019-12-16,"Yale-Griffin Prevention Research Center, Derby, Connecticut, 06418, United States"
NCT01617395,Relating Genetic and Environmental Risk Scores to Multiple Sclerosis Susceptibility,https://beta.clinicaltrials.gov/study/NCT01617395,COMPLETED,Multiple Sclerosis,,National Institute of Neurological Disorders and Stroke (NINDS),,ALL,"ADULT, OLDER_ADULT",,181,NIH,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-08-15,,,"National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States"
NCT02230969,Plegridy Observational Program,https://beta.clinicaltrials.gov/study/NCT02230969,COMPLETED,Relapsing Forms of Multiple Sclerosis,DRUG: peginterferon beta-1a,Biogen,,ALL,"ADULT, OLDER_ADULT",,1208,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-11-12,2022-01-20,2022-01-20,"Research Site, Homewood, Alabama, 35209, United States|Research Site, Gilbert, Arizona, 85234, United States|Research Site, Scottsdale, Arizona, 85258, United States|Research Site, Berkeley, California, 94705, United States|Research Site, California City, California, 93449, United States|Research Site, Hanford, California, 93230, United States|Research Site, Orange, California, 92868, United States|Research Site, Basalt, Colorado, 81621, United States|Research Site, Colorado Springs, Colorado, 80907, United States|Research Site, Washington, District of Columbia, 20007, United States|Research Site, Washington, District of Columbia, 20037, United States|Research Site, Delray Beach, Florida, 33445, United States|Research Site, Atlanta, Georgia, 30327, United States|Research Site, Schaumburg, Illinois, 60173, United States|Research Site, Indianapolis, Indiana, 46256, United States|Research Site, Des Moines, Iowa, 50314, United States|Research Site, Iowa City, Iowa, 52242, United States|Research Site, Louisville, Kentucky, 40207, United States|Research Site, New Orleans, Louisiana, 70121, United States|Research Site, Scarborough, Maine, 04074, United States|Research Site, Boston, Massachusetts, 02215, United States|Research Site, Lexington, Massachusetts, 02421, United States|Research Site, Worcester, Massachusetts, 01655, United States|Research Site, Southfield, Michigan, 48034, United States|Research Site, Golden Valley, Minnesota, 55422, United States|Research Site, Saint Louis, Missouri, 63131, United States|Research Site, Great Falls, Montana, 59405, United States|Research Site, Lebanon, New Hampshire, 03756, United States|Research Site, Freehold, New Jersey, 07728, United States|Research Site, Albuquerque, New Mexico, 87131, United States|Research Site, Buffalo, New York, 14203, United States|Research Site, New Hyde Park, New York, 11042, United States|Research Site, New York, New York, 10016, United States|Research Site, Staten Island, New York, 10306, United States|Research Site, Charlotte, North Carolina, 28203, United States|Research Site, Hickory, North Carolina, 28602, United States|Research Site, Raleigh, North Carolina, 27607, United States|Research Site, Dayton, Ohio, 45417, United States|Research Site, Dayton, Ohio, 45459, United States|Research Site, Oklahoma City, Oklahoma, 73104, United States|Research Site, Oklahoma City, Oklahoma, 73112, United States|Research Site, Portland, Oregon, 97225, United States|Research Site, Pittsburgh, Pennsylvania, 15212, United States|Research Site, Port Royal, South Carolina, 29935, United States|Research Site, Knoxville, Tennessee, 37934, United States|Research Site, Bedford, Texas, 76021, United States|Research Site, Salt Lake City, Utah, 84103, United States|Research Site, Richmond, Virginia, 23298, United States|Research Site, Virginia Beach, Virginia, 23456, United States|Research Site, Milwaukee, Wisconsin, 53215, United States|Research Site, Camperdown, New South Wales, 2050, Australia|Research Site, New Lambton Heights, New South Wales, 2305, Australia|Research Site, Auchenflower, Queensland, 4066, Australia|Research Site, Bedford Park, South Australia, 5042, Australia|Research Site, Fitzroy, Victoria, 3065, Australia|Research Site, Heidelberg, Victoria, 3084, Australia|Research Site, Linz, 4021, Austria|Research Site, Vienna, 1180, Austria|Research Site, Calgary, Alberta, T2N2T9, Canada|Research Site, Saint John, New Brunswick, E2K 5S9, Canada|Research Site, Halifax, Nova Scotia, B3H4K4, Canada|Research Site, Sydney, Nova Scotia, B1P 1P3, Canada|Research Site, Barrie, Ontario, L4M5K3, Canada|Research Site, Cambridge, Ontario, N1R7L6, Canada|Research Site, Toronto, Ontario, M4N 3M5, Canada|Research Site, Gatineau, Quebec, J9J 0A5, Canada|Research Site, Esbjerg, 6700, Denmark|Research site, Glostrup, 2600, Denmark|Research Site, Sonderborg, 6400, Denmark|Research Site, Nimes, Gard, 30029, France|Research Site, Toulouse cedex 9, Haute Garonne, 31093, France|Research Site, Montpellier, Herault, 34295, France|Research Site, Rennes cedex 09, Ille Et Vilaine, 35033, France|Research Site, Saint Malo cedex, Ille Et Vilaine, 35403, France|Research Site, Le Mans cedex 9, Sarthe, 72037, France|Research Site, La Seyne sur Mer, Var, 83500, France|Research Site, Poitiers cedex, Vienne, 86021, France|Research Site, Mantes La Jolie cedex, Yvelines, 78201, France|Research Site, Gonesse, 95503, France|Research Site, Aalen, Baden Wuerttemberg, 73433, Germany|Research Site, Freiburg, Baden Wuerttemberg, 79098, Germany|Research Site, Heidenheim, Baden Wuerttemberg, 89518, Germany|Research Site, Ladenburg, Baden Wuerttemberg, 68526, Germany|Research Site, Pforzheim, Baden Wuerttemberg, 75172, Germany|Research Site, Stuttgart, Baden Wuerttemberg, 70182, Germany|Research Site, Bamberg, Bayern, 96052, Germany|Research Site, Muenchen, Bayern, 81825, Germany|Research Site, Regensburg, Bayern, 93053, Germany|Research Site, Regensburg, Bayern, 93095, Germany|Research Site, Ruedersdorf, Brandenburg, 15562, Germany|Research Site, Bad Homburg, Hessen, 61348, Germany|Research Site, Butzbach, Hessen, 35510, Germany|Research Site, Frankfurt, Hessen, 60313, Germany|Research Site, Gelnhausen, Hessen, 63571, Germany|Research Site, Kassel, Hessen, 34121, Germany|Research Site, Gottingen, Niedersachsen, 37073, Germany|Research Site, Sande, Niedersachsen, 26452, Germany|Research Site, Stade, Niedersachsen, 21682, Germany|Research Site, Aachen, Nordrhein Westfalen, 52062, Germany|Research Site, Bonn, Nordrhein Westfalen, 53127, Germany|Research Site, Duesseldorf, Nordrhein Westfalen, 40211, Germany|Research Site, Koeln, Nordrhein Westfalen, 50935, Germany|Research Site, Siegen, Nordrhein Westfalen, 57076, Germany|Research Site, Kandel, Rheinland Pfalz, 76870, Germany|Research Site, Ludwigshafen, Rheinland Pfalz, 67059, Germany|Research Site, Chemnitz, Sachsen, 09117, Germany|Research Site, Leipzig, Sachsen, 04229, Germany|Research Site, Itzehoe, Schleswig Holstein, 25524, Germany|Research Site, Kiel, Schleswig Holstein, 24105, Germany|Research Site, Altenburg, Thueringen, 04600, Germany|Research Site, Erfurt, Thueringen, 99096, Germany|Research Site, Jena, Thueringen, 07747, Germany|Research Site, Stadtroda, Thueringen, 07646, Germany|Research Site, Berlin, 10713, Germany|Research Site, Berlin, 12099, Germany|Research Site, Berlin, 14169, Germany|Research Site, Hamburg, 20249, Germany|Research Site, Hamburg, 22179, Germany|Research Site, Dublin, DUBLIN 4, Ireland|Research Site, Bergamo, 24127, Italy|Research Site, Cagliari, 09126, Italy|Research Site, Catanzaro, 88100, Italy|Research Site, Firenze, 50134, Italy|Research Site, Genova, 16153, Italy|Research Site, Messina, 98121, Italy|Research Site, Milano, 20133, Italy|Research Site, Napoli, 80138, Italy|Research Site, Roma, 00133, Italy|Research Site, Roma, 00152, Italy|Research Site, Roma, 00189, Italy|Research Site, Blaricum, 1261 AN, Netherlands|Research Site, Breda, 4818 CK, Netherlands|Research Site, Hoorn, 1624 NP, Netherlands|Research Site, Guimarães, 4835-044, Portugal|Research Site, Setúbal, 2910-446, Portugal|Research Site, Cadiz, 11009, Spain|Research Site, Cordoba, 14011, Spain|Research Site, Málaga, 29010, Spain|Research Site, Sevilla, 41014, Spain|Research Site, Sevilla, 41071, Spain|Research Site, Aarau, 5001, Switzerland|Research Site, Basel, 4031, Switzerland|Research Site, Bern, 3010, Switzerland|Research Site, Luzern, 6000, Switzerland|Research Site, Irvine, Ayrshire, KA128SS, United Kingdom|Research Site, Truro, Cornwall, TR13LJ, United Kingdom|Research Site, London, Greater London, NW3 2QG, United Kingdom|Research Site, Salford, Greater Manchester, M6 8HD, United Kingdom|Research Site, Inverness, Highland Region, IV2 3UJ, United Kingdom|Research Site, Leicester, Leicestershire, LE5 4 PW, United Kingdom|Research Site, Glasgow, Strathclyde, G51 4TF, United Kingdom|Research Site, Swansea, SA6 6NL, United Kingdom"
NCT03684369,Improving Mobility and Reducing Fatigue in People With Multiple Sclerosis by Electrical Stimulation Therapy,https://beta.clinicaltrials.gov/study/NCT03684369,WITHDRAWN,Multiple Sclerosis,DEVICE: Transcutaneous electrical nerve stimulation,"University of Colorado, Boulder","University of Colorado, Denver|Colorado State University",ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-07,2024-12,2025-06,
NCT05834335,Protection Against Severe Coronavirus Disease 2019 in Patients With Multiple Sclerosis Stratified According to Disease Modifying Treatment,https://beta.clinicaltrials.gov/study/NCT05834335,COMPLETED,Multiple Sclerosis,,National MS Center Melsbroek,,ALL,"CHILD, ADULT, OLDER_ADULT",,400,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-03-01,2022-12-01,2023-04-01,"Nationaal MS center, Melsbroek, Vlaams Brabant, 1820, Belgium"
NCT00819195,Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT00819195,COMPLETED,Multiple Sclerosis,DRUG: Glatiramer acetate,"University of California, San Francisco","National Multiple Sclerosis Society|Teva Neuroscience, Inc.",ALL,ADULT,,17,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2008-12,2012-09,2012-09,"UCSF Multiple Sclerosis Center, San Francisco, California, 94143, United States"
NCT01993095,FlexToBa for People With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01993095,COMPLETED,Multiple Sclerosis,"BEHAVIORAL: Home-based, DVD-delivered physical activity|BEHAVIORAL: Behavioral: Usual care/Wait list",University of Illinois at Urbana-Champaign,National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2013-10,2014-09,2014-09,"University of Illinois at Urbana-Champaign, Urbana, Illinois, 61801, United States"
NCT05787795,Identifying and Characterizing Preclinical MS,https://beta.clinicaltrials.gov/study/NCT05787795,RECRUITING,Multiple Sclerosis,OTHER: biological samples,Yale University,Roche-Genentech,ALL,"ADULT, OLDER_ADULT",,1000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-06-21,2027-06-30,2028-06-30,"Yale University, North Haven, Connecticut, 06473, United States"
NCT01111435,A Prospective Study of Spasticity in Individuals With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01111435,UNKNOWN,Spasticity,,"Fraser, Cira, Ph.D., RN, ACNS-BC",,ALL,"ADULT, OLDER_ADULT",,110,INDIV,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-04,2012-09,2012-12,"Shared Solutions Call Center, Kansas City, Missouri, 64131, United States"
NCT02749396,EPID Multiple Sclerosis Pregnancy Study,https://beta.clinicaltrials.gov/study/NCT02749396,COMPLETED,Multiple Sclerosis,"DRUG: Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG|DRUG: Extavia (interferon beta-1b), Novartis Pharma AG|DRUG: Rebif (interferon beta-1a), Merck Serono Europe Ltd|DRUG: Plegridy (peginterferon beta-1a), Biogen Idec Ltd|DRUG: Avonex (interferon beta-1a), Biogen Idec Ltd|DRUG: MSDMDs other than Betaseron (Interferon beta-1b, BAY86-5046)|OTHER: No MSDMDs therapy (control)",Bayer,EPID Research|Biogen|Merck Serono Europe Ltd|Novartis Pharmaceuticals,FEMALE,"CHILD, ADULT, OLDER_ADULT",,2089,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-05-02,2018-08-14,2018-08-14,"Many locations, Multiple Locations, Finland"
NCT03268096,"Disability, MRI Lesions and Thickness of Retinal Fibers: Evaluation 15 Years After a First Episode of Demyelination",https://beta.clinicaltrials.gov/study/NCT03268096,COMPLETED,"Multiple Sclerosis|Pathologic Processes|Tomography, Optical Coherence|Magnetic Resonance Imaging|Prognosis",DEVICE: Cerebral MRI and Optical Coherence Tomography,Fondation Ophtalmologique Adolphe de Rothschild,,ALL,"CHILD, ADULT, OLDER_ADULT",,182,NETWORK,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-05-03,2021-11-03,2021-11-03,"Fondation Ophtalmologique A. de Rothschild, Paris, France"
NCT03624296,Characterization of Cortical Injury in Early MS Patients: a 7T MRI Study,https://beta.clinicaltrials.gov/study/NCT03624296,UNKNOWN,Multiple Sclerosis (MS),DEVICE: MRI 7T|OTHER: TEST EDSS|OTHER: TEST MSFC,Assistance Publique Hopitaux De Marseille,,ALL,ADULT,NA,30,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2018-10,2019-10,2020-03,"Assistance Publique Hopitaux de Marseille, Marseille, 13354, France"
NCT01845896,"Influence of High Intensity Exercise on Insulin Resistance, Muscle Contractile Properties, Aerobic Capacity and Body Composition in Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT01845896,COMPLETED,Multiple Sclerosis|Healthy Controls,BEHAVIORAL: Training,Bert Op't Eijnde,,ALL,"ADULT, OLDER_ADULT",NA,34,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2013-03,2014-03,2014-03,"Reval, Diepenbeek, 3590, Belgium"
NCT00461396,"Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron",https://beta.clinicaltrials.gov/study/NCT00461396,COMPLETED,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting","DRUG: Interferon-1beta (Betaseron, BAY86-5046)",Bayer,,ALL,ADULT,,104,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2007-05,2009-06,2009-11,"Many Locations, Alabama, United States|Many Locations, Arizona, United States|Many Locations, Delaware, United States|Many Locations, District of Columbia, United States|Many Locations, Florida, United States|Many Locations, Georgia, United States|Many Locations, Illinois, United States|Many Locations, Iowa, United States|Many Locations, Louisiana, United States|Many Locations, Maine, United States|Many Locations, Minnesota, United States|Many Locations, Missouri, United States|Many Locations, New Jersey, United States|Many Locations, New York, United States|Many Locations, North Carolina, United States|Many Locations, Ohio, United States|Many Locations, Pennsylvania, United States|Many Locations, Tennessee, United States|Many Locations, West Virginia, United States"
NCT05387395,COVID-19 on Disease Activity in Radiologically Isolated Syndrome Cohort,https://beta.clinicaltrials.gov/study/NCT05387395,COMPLETED,Multiple Sclerosis|COVID-19,OTHER: NO intervention,Centre Hospitalier Universitaire de Nice,,ALL,"ADULT, OLDER_ADULT",,217,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-05-31,2022-07-01,2022-07-01,"Nice University Hospital, Nice, 06000, France"
NCT03920995,Multi-center Database Registry to Study Thalamus Changes Using AI in MS,https://beta.clinicaltrials.gov/study/NCT03920995,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,,University at Buffalo,Celgene,ALL,"ADULT, OLDER_ADULT",,1000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-05-13,2023-12-31,2023-12-31,"University at Buffalo, Buffalo, New York, 14203, United States"
NCT02451696,A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD,https://beta.clinicaltrials.gov/study/NCT02451696,COMPLETED,Epilepsy|Tuberous Sclerosis Complex|Focal Cortical Dysplasia,DRUG: Everolimus,NYU Langone Health,,ALL,"CHILD, ADULT",PHASE2,15,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2014-01,2017-12-08,2017-12-28,"New York University Langone Medical Center, New York, New York, 10016, United States"
NCT01191996,Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT01191996,COMPLETED,Secondary Progressive Multiple Sclerosis|Primary Progressive Multiple Sclerosis,BIOLOGICAL: MIS416,Innate Immunotherapeutics,Primorus Clinical Trials|National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,34,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2010-08,2012-06,2012-11,"Primorus Clinical Trials, 40 Stewart Street, Christchurch, Canterbury, 8011, New Zealand"
NCT03826095,"Respiratory Functions, Trunk Control and Mobility Evaluation in Multiple Sclerosis",https://beta.clinicaltrials.gov/study/NCT03826095,COMPLETED,Physical Therapy,,Hacettepe University,KARMUTLU|MATUNCER|EÇKÜTÜKÇÜ,ALL,"ADULT, OLDER_ADULT",,60,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-02-04,2019-07-26,2019-08-02,"Hacettepe University, Ankara, Turkey"
NCT05341895,Kinesiotape on Balance in With Multiple Sclerosis,https://beta.clinicaltrials.gov/study/NCT05341895,RECRUITING,Individuals With Multiple Sclerosis|With Ataxia Symptoms|No Secondary Disease Affecting Balance,OTHER: Kinesiotape,Firat University,,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER,2021-11-22,2022-04-22,2022-05-06,"Furkan Bilek, Elazığ, 23100, Turkey|Fırat university, Elazığ, 23100, Turkey"
NCT03458169,LEAP a New Overground Body Weight Support Robot: Usability Trial,https://beta.clinicaltrials.gov/study/NCT03458169,COMPLETED,Spinal Cord Injuries|Cerebral Palsy|Parkinson Disease|Multiple Sclerosis|Stroke|People With Impaired Lower Extremity Function,DEVICE: Therapist LEAP session feedback|DEVICE: Participant LEAP session feedback|DEVICE: LEAP risk control validation,Clinique Romande de Readaptation,,ALL,"CHILD, ADULT, OLDER_ADULT",NA,43,NETWORK,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2018-01-01,2018-04-30,2018-04-30,"Clinique Romande de Réadaptation (CRR), SUVAcare, Sion, Valais, 1951, Switzerland"
